Medicare Program: Changes to Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems and Quality Reporting Programs, 58818-59179 [2018-24243]

Download as PDF 58818 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Medicare & Medicaid Services 42 CFR Parts 416 and 419 [CMS–1695–FC] RIN 0938–AT30 Medicare Program: Changes to Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems and Quality Reporting Programs Centers for Medicare & Medicaid Services (CMS), HHS. ACTION: Final rule with comment period. AGENCY: This final rule with comment period revises the Medicare hospital outpatient prospective payment system (OPPS) and the Medicare ambulatory surgical center (ASC) payment system for CY 2019 to implement changes arising from our continuing experience with these systems. In this final rule with comment period, we describe the changes to the amounts and factors used to determine the payment rates for Medicare services paid under the OPPS and those paid under the ASC payment system. In addition, this final rule with comment period updates and refines the requirements for the Hospital Outpatient Quality Reporting (OQR) Program and the ASC Quality Reporting (ASCQR) Program. In addition, we are updating the Hospital Consumer Assessment of Healthcare Providers and Systems (HCAHPS) Survey measure under the Hospital Inpatient Quality Reporting (IQR) Program by removing the Communication about Pain questions; and retaining two measures that were proposed for removal, the Catheter-Associated Urinary Tract Infection (CAUTI) Outcome Measure and Central Line-Associated Bloodstream Infection (CLABSI) Outcome Measure, in the PPS-Exempt Cancer Hospital Quality Reporting (PCHQR) Program beginning with the FY 2021 program year. DATES: Effective date: This final rule with comment period is effective on January 1, 2019. Comment period: To be assured consideration, comments on the payment classifications assigned to the interim APC assignments and/or status indicators of new or replacement Level II HCPCS codes in this final rule with comment period must be received at one of the addresses provided in the khammond on DSK30JT082PROD with RULES2 SUMMARY: VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 ADDRESSES section no later than 5 p.m. EST on December 3, 2018. ADDRESSES: In commenting, please refer to file code CMS–1695–FC when commenting on the issues in this final rule with comment period. Because of staff and resource limitations, we cannot accept comments by facsimile (FAX) transmission. Comments, including mass comment submissions, must be submitted in one of the following three ways (please choose only one of the ways listed): 1. Electronically. You may (and we encourage you to) submit electronic comments on this regulation to https:// www.regulations.gov. Follow the instructions under the ‘‘submit a comment’’ tab. 2. By regular mail. You may mail written comments to the following address ONLY: Centers for Medicare & Medicaid Services, Department of Health and Human Services, Attention: CMS– 1695–FC, P.O. Box 8013, Baltimore, MD 21244–1850. Please allow sufficient time for mailed comments to be received before the close of the comment period. 3. By express or overnight mail. You may send written comments via express or overnight mail to the following address ONLY: Centers for Medicare & Medicaid Services, Department of Health and Human Services, Attention: CMS– 1695–FC, Mail Stop C4–26–05, 7500 Security Boulevard, Baltimore, MD 21244–1850. b. For delivery in Baltimore, MD— Centers for Medicare & Medicaid Services, Department of Health and Human Services, 7500 Security Boulevard, Baltimore, MD 21244– 1850. For information on viewing public comments, we refer readers to the beginning of the SUPPLEMENTARY INFORMATION section. FOR FURTHER INFORMATION CONTACT: 340B Drug Payment Policy to Nonexcepted Off-Campus Departments of a Hospital, contact Juan Cortes via email Juan.Cortes@cms.hhs.gov or at 410–786–4325. Advisory Panel on Hospital Outpatient Payment (HOP Panel), contact the HOP Panel mailbox at APCPanel@cms.hhs.gov. Ambulatory Surgical Center (ASC) Payment System, contact Scott Talaga via email Scott.Talaga@cms.hhs.gov or at 410–786–4142. Ambulatory Surgical Center Quality Reporting (ASCQR) Program Administration, Validation, and PO 00000 Frm 00002 Fmt 4701 Sfmt 4700 Reconsideration Issues, contact Anita Bhatia via email Anita.Bhatia@ cms.hhs.gov or at 410–786–7236. Ambulatory Surgical Center Quality Reporting (ASCQR) Program Measures, contact Vinitha Meyyur via email Vinitha.Meyyur@cms.hhs.gov or at 410– 786–8819. Blood and Blood Products, contact Josh McFeeters via email Joshua.McFeeters@cms.hhs.gov or at 410–786–9732. Cancer Hospital Payments, contact Scott Talaga via email Scott.Talaga@ cms.hhs.gov or at 410–786–4142. CMS Web Posting of the OPPS and ASC Payment Files, contact Chuck Braver via email Chuck.Braver@ cms.hhs.gov or at 410–786–6719. CPT Codes, contact Marjorie Baldo via email Marjorie.Baldo@cms.hhs.gov or at 410–786–4617. Collecting Data on Services Furnished in Off-Campus Provider-Based Emergency Departments, contact Twi Jackson via email Twi.Jackson@ cms.hhs.gov or at 410–786–1159. Control for Unnecessary Increases in Volume of Outpatient Services, contact Elise Barringer via email Elise.Barringer@cms.hhs.gov or at 410– 786–9222. Composite APCs (Low Dose Brachytherapy and Multiple Imaging), contact Elise Barringer via email Elise.Barringer@cms.hhs.gov or at 410– 786–9222. Comprehensive APCs (C–APCs), contact Lela Strong-Holloway via email Lela.Strong@cms.hhs.gov or at 410–786– 3213. Expansion of Clinical Families of Services at Excepted Off-Campus Departments of a Provider, contact Juan Cortes via email Juan.Cortes@ cms.hhs.gov or at 410–786–4325. Hospital Outpatient Quality Reporting (OQR) Program Administration, Validation, and Reconsideration Issues, contact Anita Bhatia via email Anita.Bhatia@cms.hhs.gov or at 410– 786–7236. Hospital Outpatient Quality Reporting (OQR) Program Measures, contact Vinitha Meyyur via email Vinitha.Meyyur@cms.hhs.gov or at 410– 786–8819. Hospital Outpatient Visits (Emergency Department Visits and Critical Care Visits), contact Twi Jackson via email Twi.Jackson@cms.hhs.gov or at 410– 786–1159. Inpatient Only (IPO) Procedures List, contact Lela Strong-Holloway via email Lela.Strong@cms.hhs.gov or at 410–786– 3213. New Technology Intraocular Lenses (NTIOLs), contact Scott Talaga via email E:\FR\FM\21NOR2.SGM 21NOR2 khammond on DSK30JT082PROD with RULES2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations Scott.Talaga@cms.hhs.gov or at 410– 786–4142. No Cost/Full Credit and Partial Credit Devices, contact Twi Jackson via email Twi.Jackson@cms.hhs.gov or at 410– 786–1159. OPPS Brachytherapy, contact Scott Talaga via email Scott.Talaga@ cms.hhs.gov or at 410–786–4142. OPPS Data (APC Weights, Conversion Factor, Copayments, Cost-to-Charge Ratios (CCRs), Data Claims, Geometric Mean Calculation, Outlier Payments, and Wage Index), contact Erick Chuang via email Erick.Chuang@cms.hhs.gov or at 410–786–1816, Steven Johnson via email Steven.Johnson@cms.hhs.gov or at 410–786–3332, or Scott Talaga via email Scott.Talaga@cms.hhs.gov or at 410– 786–4142. OPPS Drugs, Radiopharmaceuticals, Biologicals, and Biosimilar Products, contact Josh McFeeters via email Joshua.McFeeters@cms.hhs.gov or at 410–786–9732. OPPS New Technology Procedures/ Services, contact the New Technology APC email at NewTechAPCapplications@ cms.hhs.gov. OPPS Exceptions to the 2 Times Rule, contact Marjorie Baldo via email Marjorie.Baldo@cms.hhs.gov or at 410– 786–4617. OPPS Packaged Items/Services, contact Lela Strong-Holloway via email Lela.Strong@cms.hhs.gov or at 410–786– 3213. OPPS Pass-Through Devices, contact the Device Pass-Through email at DevicePTapplications@cms.hhs.gov. OPPS Status Indicators (SI) and Comment Indicators (CI), contact Marina Kushnirova via email Marina.Kushnirova@cms.hhs.gov or at 410–786–2682. Partial Hospitalization Program (PHP) and Community Mental Health Center (CMHC) Issues, contact the PHP Payment Policy Mailbox at PHPPaymentPolicy@cms.hhs.gov. PPS-Exempt Cancer Hospital Quality Reporting (PCHQR) Program measures, contact Nekeshia McInnis via email Nekeshia.McInnis@cms.hhs.gov. Rural Hospital Payments, contact Josh McFeeters via email Joshua.McFeeters@ cms.hhs.gov or at 410–786–9732. Skin Substitutes, contact Josh McFeeters via email Joshua.McFeeters@ cms.hhs.gov or at 410–786–9732. All Other Issues Related to Hospital Outpatient and Ambulatory Surgical Center Payments Not Previously Identified, contact Marjorie Baldo via email Marjorie.Baldo@cms.hhs.gov or at 410–786–4617. SUPPLEMENTARY INFORMATION: Inspection of Public Comments: All comments VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 received before the close of the comment period are available for viewing by the public, including any personally identifiable or confidential business information that is included in a comment. We post all comments received before the close of the comment period on the following website as soon as possible after they have been received: https:// www.regulations.gov/. Follow the search instructions on that website to view public comments. Electronic Access This Federal Register document is also available from the Federal Register online database through Federal Digital System (FDsys), a service of the U.S. Government Publishing Office. This database can be accessed via the internet at https://www.gpo.gov/fdsys/. Addenda Available Only Through the Internet on the CMS Website In the past, a majority of the Addenda referred to in our OPPS/ASC proposed and final rules were published in the Federal Register as part of the annual rulemakings. However, beginning with the CY 2012 OPPS/ASC proposed rule, all of the Addenda no longer appear in the Federal Register as part of the annual OPPS/ASC proposed and final rules to decrease administrative burden and reduce costs associated with publishing lengthy tables. Instead, these Addenda are published and available only on the CMS website. The Addenda relating to the OPPS are available at: https://www.cms.gov/Medicare/ Medicare-Fee-for-Service-Payment/ HospitalOutpatientPPS/. The Addenda relating to the ASC payment system are available at: https:// www.cms.gov/Medicare/Medicare-Feefor-Service-Payment/ HospitalOutpatientPPS/. Current Procedural Terminology (CPT) Copyright Notice Throughout this final rule with comment period, we use CPT codes and descriptions to refer to a variety of services. We note that CPT codes and descriptions are copyright 2018 American Medical Association. All Rights Reserved. CPT is a registered trademark of the American Medical Association (AMA). Applicable Federal Acquisition Regulations (FAR) and Defense Federal Acquisition Regulations (DFAR) apply. Table of Contents I. Summary and Background A. Executive Summary of This Document B. Legislative and Regulatory Authority for the Hospital OPPS PO 00000 Frm 00003 Fmt 4701 Sfmt 4700 58819 C. Excluded OPPS Services and Hospitals D. Prior Rulemaking E. Advisory Panel on Hospital Outpatient Payment (the HOP Panel or the Panel) F. Public Comments Received in Response to the CY 2019 OPPS/ASC Proposed Rule G. Public Comments Received in Response to the CY 2018 OPPS/ASC Final Rule With Comment Period II. Updates Affecting OPPS Payments A. Recalibration of APC Relative Payment Weights B. Conversion Factor Update C. Wage Index Changes D. Statewide Average Default Cost-toCharge Ratios (CCRs) E. Adjustment for Rural Sole Community Hospitals (SCHs) and Essential Access Community Hospitals (EACHs) Under Section 1833(t)(13)(B) of the Act F. Payment Adjustment for Certain Cancer Hospitals for CY 2019 G. Hospital Outpatient Outlier Payments H. Calculation of an Adjusted Medicare Payment From the National Unadjusted Medicare Payment I. Beneficiary Copayments III. OPPS Ambulatory Payment Classification (APC) Group Policies A. OPPS Treatment of New CPT and Level II HCPCS Codes B. OPPS Changes—Variations Within APCs C. New Technology APCs D. OPPS APC-Specific Policies IV. OPPS Payment for Devices A. Pass-Through Payments for Devices B. Device-Intensive Procedures V. OPPS Payment Changes for Drugs, Biologicals, and Radiopharmaceuticals A. OPPS Transitional Pass-Through Payment for Additional Costs of Drugs, Biologicals, and Radiopharmaceuticals B. OPPS Payment for Drugs, Biologicals, and Radiopharmaceuticals Without PassThrough Payment Status VI. Estimate of OPPS Transitional PassThrough Spending for Drugs, Biologicals, Radiopharmaceuticals, and Devices A. Background B. Estimate of Pass-Through Spending VII. OPPS Payment for Hospital Outpatient Visits and Critical Care Services VIII. Payment for Partial Hospitalization Services A. Background B. PHP APC Update for CY 2019 C. Outlier Policy for CMHCs D. Proposed Update to PHP Allowable HCPCS Codes IX. Procedures That Will Be Paid Only as Inpatient Procedures A. Background B. Changes to the Inpatient Only (IPO) List X. Nonrecurring Policy Changes A. Collecting Data on Services Furnished in Off-Campus Provider-Based Emergency Departments B. Method To Control Unnecessary Increases in the Volume of Outpatient Services C. Application of the 340B Drug Payment Policy to Nonexcepted Off-Campus Departments of a Hospital D. Expansion of Clinical Families of Services at Excepted Off-Campus Departments of a Provider E:\FR\FM\21NOR2.SGM 21NOR2 khammond on DSK30JT082PROD with RULES2 58820 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations XI. CY 2019 OPPS Payment Status and Comment Indicators A. CY 2019 OPPS Payment Status Indicator Definitions B. CY 2019 Comment Indicator Definitions XII. Updates to the Ambulatory Surgical Center (ASC) Payment System A. Background B. Treatment of New and Revised Codes C. Update to the List of ASC Covered Surgical Procedures and Covered Ancillary Services D. ASC Payment for Covered Surgical Procedures and Covered Ancillary Services E. New Technology Intraocular Lenses (NTIOLs) F. ASC Payment and Comment Indicators G. Calculation of the ASC Payment Rates and the ASC Conversion Factor XIII. Requirements for the Hospital Outpatient Quality Reporting (OQR) Program A. Background B. Hospital OQR Program Quality Measures C. Administrative Requirements D. Form, Manner, and Timing of Data Submitted for the Hospital OQR Program E. Payment Reduction for Hospitals That Fail To Meet the Hospital OQR Program Requirements for the CY 2019 Payment Determination XIV. Requirements for the Ambulatory Surgical Center Quality Reporting (ASCQR) Program A. Background B. ASCQR Program Quality Measures C. Administrative Requirements D. Form, Manner, and Timing of Data Submitted for the ASCQR Program E. Payment Reduction for ASCs That Fail To Meet the ASCQR Program Requirements XV. Comments Received in Response to Requests for Information (RFIs) A. Comments Received in Response to Request for Information on Promoting Interoperability and Electronic Health Care Information Exchange Through Possible Revisions to the CMS Patient Health and Safety Requirements for Hospitals and Other MedicareParticipating and Medicaid-Participating Providers and Suppliers B. Comments Received in Response to Request for Information on Price Transparency: Improving Beneficiary Access to Provider and Supplier Charge Information C. Comments Received in Response to Request for Information on Leveraging the Authority for the Competitive Acquisition Program (CAP) for Part B Drugs and Biologicals for a Potential CMS Innovation Center Model XVI. Additional Hospital Inpatient Quality Reporting (IQR) Program Policies XVII. Additional PPS-Exempt Cancer Hospital Quality Reporting (PCHQR) Program Policies A. Background B. Retention and Removal of Previously Finalized Quality Measures for PCHs Beginning With the FY 2021 Program Year VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 C. Public Display Requirements XVIII. Files Available to the Public via the Internet XIX. Collection of Information Requirements A. Statutory Requirement for Solicitation of Comments B. ICRs for the Hospital OQR Program C. ICRs for the ASCQR Program D. ICRs for the Update to the HCAHPS Survey Measure in the Hospital IQR Program E. Total Reduction in Burden Hours and in Costs XX. Response to Comments XXI. Economic Analyses A. Statement of Need B. Overall Impact for the Provisions of This Final Rule With Comment Period C. Detailed Economic Analyses D. Effects of the Update to the HCAHPS Survey Measure in the Hospital IQR Program E. Effects of Requirements for the PPSExempt Cancer Hospital Quality Reporting (PCHQR) Program F. Regulatory Review Costs G. Regulatory Flexibility Act (RFA) Analysis H. Unfunded Mandates Reform Act Analysis I. Reducing Regulation and Controlling Regulatory Costs J. Conclusion XXII. Federalism Analysis Regulation Text I. Summary and Background A. Executive Summary of This Document 1. Purpose In this final rule with comment period, we are updating the payment policies and payment rates for services furnished to Medicare beneficiaries in hospital outpatient departments (HOPDs) and ambulatory surgical centers (ASCs), beginning January 1, 2019. Section 1833(t) of the Social Security Act (the Act) requires us to annually review and update the payment rates for services payable under the Hospital Outpatient Prospective Payment System (OPPS). Specifically, section 1833(t)(9)(A) of the Act requires the Secretary to review certain components of the OPPS not less often than annually, and to revise the groups, relative payment weights, and the wage and other adjustments that take into account changes in medical practices, changes in technologies, and the addition of new services, new cost data, and other relevant information and factors. In addition, under section 1833(i) of the Act, we annually review and update the ASC payment rates. This final rule with comment period also includes additional policy changes made in accordance with our experience with the OPPS and the ASC payment system. We describe these and various PO 00000 Frm 00004 Fmt 4701 Sfmt 4700 other statutory authorities in the relevant sections of this final rule with comment period. In addition, this final rule with comment period updates and refines the requirements for the Hospital Outpatient Quality Reporting (OQR) Program and the ASC Quality Reporting (ASCQR) Program. In this final rule with comment period, two quality reporting policies that impact inpatient hospitals are updated due to their time sensitivity. In the Hospital IQR Program, we are updating the HCAHPS Survey measure by removing the Communication about Pain questions from the HCAHPS Survey, which are used to assess patients’ experiences of care, effective with October 2019 discharges for the FY 2021 payment determination and subsequent years. This policy addresses public health concerns about opioid overprescribing through patient pain management questions that were recommended for removal in the President’s Commission on Combating Drug Addiction and the Opioid Crisis report. In addition, we are finalizing that we will not publicly report any data collected from the Communication Abut Pain questions—a modification from what we proposed. We also are retaining two measures that we proposed for removal in the PCHQR Program beginning with the FY 2021 program year, the Catheter-Associated Urinary Tract Infection (CAUTI) Outcome Measure and Central Line-Associated Bloodstream Infection (CLABSI) Outcome Measure. This policy impacts infection measurement and public reporting for PPS-exempt cancer hospitals and was deferred to this rule from the CY 2019 IPPS/LTCH PPS final rule published in August 2018. 2. Improving Patient Outcomes and Reducing Burden Through Meaningful Measures Regulatory reform and reducing regulatory burden are high priorities for CMS. To reduce the regulatory burden on the healthcare industry, lower health care costs, and enhance patient care, in October 2017, we launched the Meaningful Measures Initiative.1 This initiative is one component of our agency-wide Patients Over Paperwork Initiative,2 which is aimed at evaluating and streamlining regulations with a goal 1 Meaningful Measures web page: https:// www.cms.gov/Medicare/Quality-Initiatives-PatientAssessment-Instruments/QualityInitiativesGenInfo/ MMF/General-info-Sub-Page.html. 2 Remarks by Administrator Seema Verma at the Health Care Payment Learning and Action Network (LAN) Fall Summit, as prepared for delivery on October 30, 2017. Available at: https:// www.cms.gov/Newsroom/MediaReleaseDatabase/ Fact-sheets/2017-Fact-Sheet-items/2017-10-30.html. E:\FR\FM\21NOR2.SGM 21NOR2 58821 • Significant opportunity for improvement; • Address measure needs for population based payment through alternative payment models; and • Align across programs and/or with other payers. In order to achieve these objectives, we have identified 19 Meaningful Measures areas and mapped them to six overarching quality priorities, as shown in the table below. to reduce unnecessary cost and burden, increase efficiencies, and improve beneficiary experience. The Meaningful Measures Initiative is aimed at identifying the highest priority areas for quality measurement and quality improvement in order to assess the core quality of care issues that are most vital to advancing our work to improve patient outcomes. The Meaningful Measures Initiative represents a new approach to quality measures that fosters operational efficiencies, and will reduce costs including, collection and reporting burden, while producing quality measurement that is more focused on meaningful outcomes. The Meaningful Measures framework has the following objectives: • Address high-impact measure areas that safeguard public health; • Patient-centered and meaningful to patients; • Outcome-based where possible; • Fulfill each program’s statutory requirements; • Minimize the level of burden for health care providers; BILLING CODE 4120–01–P BILLING CODE 4120–01–C We believe that the Meaningful Measures Initiative will improve outcomes for patients, their families, and health care providers while reducing burden and costs for clinicians and providers as well as promoting operational efficiencies. We received numerous comments from stakeholders regarding the Meaningful Measures Initiative and the impact of its implementation in CMS’ quality programs. Many of these comments pertained to specific program proposals, and are discussed in the appropriate program-specific sections of this final rule with comment period. However, commenters also provided insights and recommendations for the ongoing development of the Meaningful Measures Initiative generally, including: ensuring transparency in public reporting and usability of publicly reported data; evaluating the benefit of individual measures to patients via use in quality programs weighed against the burden to providers of collecting and By including Meaningful Measures in our programs, we believe that we can also address the following cross-cutting measure criteria: • Eliminating disparities; • Tracking measurable outcomes and impact; • Safeguarding public health; • Achieving cost savings; • Improving access for rural communities; and • Reducing burden. VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 PO 00000 Frm 00005 Fmt 4701 Sfmt 4700 E:\FR\FM\21NOR2.SGM 21NOR2 ER21NO18.000</GPH> khammond on DSK30JT082PROD with RULES2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations 58822 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations khammond on DSK30JT082PROD with RULES2 reporting that measure data; and identifying additional opportunities for alignment across CMS quality programs. We look forward to continuing to work with stakeholders to refine and further implement the Meaningful Measures Initiative, and will take commenters’ insights and recommendations into account moving forward. 3. Summary of the Major Provisions • OPPS Update: For CY 2019, we are increasing the payment rates under the OPPS by an outpatient department (OPD) fee schedule increase factor of 1.35 percent. This increase factor is based on the final hospital inpatient market basket percentage increase of 2.9 percent for inpatient services paid under the hospital inpatient prospective payment system (IPPS), minus the multifactor productivity (MFP) adjustment of 0.8 percentage point, and minus a 0.75 percentage point adjustment required by the Affordable Care Act. Based on this update, we estimate that total payments to OPPS providers (including beneficiary costsharing and estimated changes in enrollment, utilization, and case-mix) for CY 2019 will be approximately $74.1 billion, an increase of approximately $5.8 billion compared to estimated CY 2018 OPPS payments. We are continuing to implement the statutory 2.0 percentage point reduction in payments for hospitals failing to meet the hospital outpatient quality reporting requirements, by applying a reporting factor of 0.980 to the OPPS payments and copayments for all applicable services. • Comprehensive APCs: For CY 2019, we are creating three new comprehensive APCs (C–APCs). These new C–APCs include ears, nose, and throat (ENT) and vascular procedures. This increases the total number of C– APCs to 65. • Changes to the Inpatient Only List: For CY 2019, we are removing four procedures from the inpatient only list and adding one procedure to the list. • Method to Control Unnecessary Increases in Volume of Outpatient Services: To the extent that similar services are safely provided in more than one setting, it is not prudent for the OPPS to pay more for such services because that leads to an unnecessary increase in the number of those services provided in the OPPS setting. We believe that capping the OPPS payment at the Physician Fee Schedule (PFS)equivalent rate is an effective method to control the volume of the unnecessary increases in certain services because the payment differential that is driving the site-of-service decision will be removed. VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 In particular, we believe this method of capping payment will control unnecessary volume increases both in terms of numbers of covered outpatient department services furnished and costs of those services. Therefore, as we proposed, we are using our authority under section 1833(t)(2)(F) of the Act to apply an amount equal to the sitespecific PFS payment rate for nonexcepted items and services furnished by a nonexcepted off-campus provider-based department (PBD) of a hospital (the PFS payment rate) for the clinic visit service, as described by HCPCS code G0463, when provided at an off-campus PBD excepted from section 1833(t)(21) of the Act. We will be phasing in the application of the reduction in payment for code G0463 in this setting over 2 years. In CY 2019, the payment reduction will be transitioned by applying 50 percent of the total reduction in payment that would apply if these departments were paid the sitespecific PFS rate for the clinic visit service. In other words, these departments will be paid 70 percent of the OPPS rate for the clinic visit service in CY 2019. In CY 2020 and subsequent years, these departments will be paid the site-specific PFS rate for the clinic visit service. That is, these departments will be paid 40 percent of the OPPS rate for the clinic visit in CY 2020 and subsequent years. In addition to this proposal, we solicited public comments on how to expand the application of the Secretary’s statutory authority under section 1833(t)(2)(F) of the Act to additional items and services paid under the OPPS that may represent unnecessary increases in OPD utilization. The public comment we received will be considered for future rulemaking. • Expansion of Clinical Families of Services at Excepted Off-Campus Provider-Based Departments (PBDs) of a Hospital: For CY 2019, we proposed that if an excepted off-campus PBD furnished items and services from a clinical family of services from which it did not furnish items and services (and subsequently bill for those items and services) during a baseline period, services from the new clinical family of services would not be covered OPD services. Instead, services in the new clinical family of services would be paid under the PFS. While we are not finalizing this proposal at this time, we intend to monitor the expansion of services in excepted off-campus PBDs. • Application of 340B Drug Payment Policy to Nonexcepted Off-Campus Provider-Based Departments of a Hospital: For CY 2019, as we proposed, we are paying the average sales price PO 00000 Frm 00006 Fmt 4701 Sfmt 4700 (ASP) minus 22.5 percent under the PFS for separately payable 340B-acquired drugs furnished by nonexcepted, offcampus provider-based departments (PBDs) of a hospital. This is consistent with the payment methodology adopted in CY 2018 for 340B-acquired drugs furnished in hospital departments paid under the OPPS. • Payment Policy for Biosimilar Biological Products without PassThrough Status That Are Acquired under the 340B Program: For CY 2019, we are making payment for nonpassthrough biosimilars acquired under the 340B program at ASP minus 22.5 percent of the biosimilar’s own ASP rather than ASP minus 22.5 percent of the reference product’s ASP. • Payment of Drugs, Biologicals, and Radiopharmaceuticals If Average Sales Price (ASP) Data Are Not Available: For CY 2019, we are making payment for separately payable drugs and biologicals that do not have pass-through payment status and are not acquired under the 340B Program at wholesale acquisition cost (WAC)+3 percent instead of WAC+6 percent if ASP data are not available. If WAC data are not available for a drug or biological product, we are continuing our policy to pay for separately payable drugs and biologicals at 95 percent of the average wholesale price (AWP). Drugs and biologicals that are acquired under the 340B Program will continue to be paid at ASP minus 22.5 percent, WAC minus 22.5 percent, or 69.46 percent of AWP, as applicable. • Device-Intensive Procedure Criteria: For CY 2019, we are modifying the device-intensive criteria to allow procedures that involve single-use devices, regardless of whether or not they remain in the body after the conclusion of the procedure, to qualify as device-intensive procedures. We also are allowing procedures with a device offset percentage of greater than 30 percent to qualify as device-intensive procedures. • Device Pass-Through Payment Applications: For CY 2019, we evaluated seven applications for device pass-through payments and based on public comments received, we are approving one of these applications for device pass-through payment status. • New Technology APC Payment for Extremely Low-Volume Procedures: For CY 2019 and future years, we are establishing a different payment methodology for services assigned to New Technology APCs with fewer than 100 claims using our equitable adjustment authority under section 1833(t)(2)(E) of the Act. We will use a ‘‘smoothing methodology’’ based on multiple years of claims data to E:\FR\FM\21NOR2.SGM 21NOR2 khammond on DSK30JT082PROD with RULES2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations establish a more stable rate for services assigned to New Technology APCs with fewer than 100 claims per year under the OPPS. Under this policy, we will calculate the geometric mean costs, the median costs, and the arithmetic mean costs for these procedures and adopt through our annual rulemaking the most appropriate payment rate for the service using one of these methodologies. We will use this approach to establish a payment rate for each low-volume service both for purposes of assigning the service to a New Technology APC and to a clinical APC at the conclusion of payment for the service through a New Technology APC. In addition, we are excluding services assigned to New Technology APCs from bundling into C–APC procedures. • Cancer Hospital Payment Adjustment: For CY 2019, we are continuing to provide additional payments to cancer hospitals so that the cancer hospital’s payment-to-cost ratio (PCR) after the additional payments is equal to the weighted average PCR for the other OPPS hospitals using the most recently submitted or settled cost report data. However, section 16002(b) of the 21st Century Cures Act requires that this weighted average PCR be reduced by 1.0 percentage point. Based on the data and the required 1.0 percentage point reduction, we are providing that a target PCR of 0.88 will be used to determine the CY 2019 cancer hospital payment adjustment to be paid at cost report settlement. That is, the payment adjustments will be the additional payments needed to result in a PCR equal to 0.88 for each cancer hospital. • Rural Adjustment: For 2019 and subsequent years, we are continuing the 7.1 percent adjustment to OPPS payments for certain rural SCHs, including essential access community hospitals (EACHs). We intend to continue the 7.1 percent adjustment for future years in the absence of data to suggest a different percentage adjustment should apply. • Ambulatory Surgical Center (ASC) Payment Update: For CYs 2019 through 2023, we are updating the ASC payment system using the hospital market basket update instead of the CPI–U. However, during this 5-year period, we intend to examine whether such adjustment leads to a migration of services from other settings to the ASC setting. Using the hospital market basket methodology, for CY 2019, we are increasing payment rates under the ASC payment system by 2.1 percent for ASCs that meet the quality reporting requirements under the ASCQR Program. This increase is based on a hospital market basket percentage increase of 2.9 percent VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 minus a MFP adjustment required by the Affordable Care Act of 0.8 percentage point. Based on this update, we estimate that total payments to ASCs (including beneficiary cost-sharing and estimated changes in enrollment, utilization, and case-mix) for CY 2019 will be approximately $4.85 billion, an increase of approximately $200 million compared to estimated CY 2018 Medicare payments to ASCs. We note that the CY 2019 ASC payment update, under our prior policy, would have been 1.8 percent, based on a projected CPI–U update of 2.6 percent minus a MFP adjustment required by the Affordable Care Act of 0.8 percentage point. In addition, we will continue to assess the feasibility of collaborating with stakeholders to collect ASC cost data in a minimally burdensome manner for future policy development. • Changes to the List of ASC Covered Surgical Procedures: For CY 2019, we are revising our definition of ‘‘surgery’’ in the ASC payment system to account for certain ‘‘surgery-like’’ procedures that are assigned codes outside the Current Procedural Terminology (CPT) surgical range. In addition, as we proposed, we are adding 12 cardiac catheterization procedures, and, in response to public comments, an additional 5 related procedures to the ASC covered procedures list. At this time, we are not finalizing our proposal to establish an additional review of recently added procedures to the ASC covered procedures list. • Payment for Non-Opioid Pain Management Therapy: For CY 2019, in response to the recommendation from the President’s Commission on Combating Drug Addiction and the Opioid Crisis, we are changing the packaging policy for certain drugs when administered in the ASC setting and providing separate payment for nonopioid pain management drugs that function as a supply when used in a surgical procedure when the procedure is performed in an ASC. • Hospital Outpatient Quality Reporting (OQR) Program: For the Hospital OQR Program, we are making changes effective with this final rule with comment period and for the CY 2019, CY 2020, and CY 2021 payment determinations and subsequent years. Effective on the effective date of this final rule with comment period, we are codifying several previously established policies: to retain measures from a previous year’s Hospital OQR Program measure set for subsequent years’ measure sets at 42 CFR 419.46(h)(1); to use the rulemaking process to remove a measure for circumstances for which we PO 00000 Frm 00007 Fmt 4701 Sfmt 4700 58823 do not believe that continued use of a measure raises specific patient safety concerns at 42 CFR 419.46(h)(3); and to immediately remove measures as a result of patient safety concerns at 42 CFR 419.46(h)(2). Effective on the effective date of this final rule with comment period, we also are updating measure removal Factor 7; adding a new removal Factor 8; and codifying our measure removal policies and factors. We also are providing clarification of our criteria for ‘‘topped-out’’ measures. These changes align the Hospital OQR Program measure removal factors with those used in the ASCQR Program. Beginning with CY 2019, we are updating the frequency with which we will release a Hospital OQR Program Specifications Manual, such that it will occur every 12 months—a modification from what we proposed. For the CY 2020 payment determination and subsequent years, we are updating the participation status requirements by removing the Notice of Participation (NOP) form; extending the reporting period for the OP–32: Facility Seven-Day Risk-Standardized Hospital Visit Rate after Outpatient Colonoscopy measure to 3 years; and removing the OP–27: Influenza Vaccination Coverage Among Healthcare Personnel measure. Beginning with the CY 2021 payment determination and subsequent years, we are removing the following seven measures: OP–5: Median Time to ECG; OP–9: Mammography Follow-up Rates; OP–11: Thorax CT Use of Contrast Material; OP–12: The Ability for Providers with HIT to Receive Laboratory Data Electronically Directly into Their Qualified/Certified EHR System as Discrete Searchable Data; OP– 14: Simultaneous Use of Brain Computed Tomography (CT) and Sinus CT; OP–17: Tracking Clinical Results between Visits; and OP–30: Endoscopy/ Polyp Surveillance: Colonoscopy Interval for Patients with a History of Adenomatous Polyps—Avoidance of Inappropriate Use. We are not finalizing our proposals to remove the OP–29 or OP–31 measures. • Ambulatory Surgical Center Quality Reporting (ASCQR) Program: For the ASCQR Program, we are making changes in policies effective with this final rule with comment period and for the CY 2019, CY 2020, and CY 2021 payment determinations and subsequent years. Effective on the effective date of this final rule with comment period, we are removing one measure removal factor; adding two new measure removal factors; and updating the regulations to better reflect our measure removal policies. We also are making one clarification to measure removal Factor E:\FR\FM\21NOR2.SGM 21NOR2 58824 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations 1. These changes align the ASCQR Program measure removal factors with those used in the Hospital OQR Program. Beginning with the CY 2020 payment determination and subsequent years, we are extending the reporting period for the ASC–12: Facility Seven-Day RiskStandardized Hospital Visit Rate after Outpatient Colonoscopy measure to 3 years; and removing the ASC–8: Influenza Vaccination Coverage Among Healthcare Personnel measure. Beginning with the CY 2021 payment determination and subsequent years, we are removing the ASC–10: Endoscopy/ Polyp Surveillance: Colonoscopy Interval for Patients with a History of Adenomatous Polyps—Avoidance of Inappropriate Use measure. We are not finalizing our proposals to remove the following measures: ASC–9: Endoscopy/ Polyp Surveillance Follow-up Interval for Normal Colonoscopy in Average Risk Patients and ASC–11: Cataracts— Improvement in Patient’s Visual Function within 90 Days Following Cataract Surgery. We also are not finalizing our proposals to remove the following measures: ASC–1: Patient Burn; ASC–2: Patient Fall; ASC–3: Wrong Site, Wrong Side, Wrong Patient, Wrong Procedure, Wrong Implant; and ASC–4: All-Cause Hospital Transfer/ Admission, but are retaining these measures in the ASCQR Program and suspending data collection for them until further action in rulemaking with the goal of revising the measures. • Hospital Inpatient Quality Reporting (IQR) Program Update: In this final rule with comment period, we are finalizing a modification of our proposals to update the HCAHPS Survey measure by finalizing the removal of the Communication About Pain questions from the HCAHPS Survey for the Hospital IQR Program, effective with October 2019 discharges for the FY 2021 payment determination and subsequent years. In addition, instead of publicly reporting the data from October 2020 until October 2022 and then subsequently discontinuing reporting as proposed, we are finalizing that we will not publicly report any data collected from the Communication About Pain questions. khammond on DSK30JT082PROD with RULES2 4. Summary of Costs and Benefits In sections XXI. and XXII. of this CY 2019 OPPS/ASC final rule with comment period, we set forth a detailed analysis of the regulatory and Federalism impacts that the changes will have on affected entities and beneficiaries. Key estimated impacts are described below. VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 a. Impacts of All OPPS Changes Table 62 in section XXI. of this final rule with comment period displays the distributional impact of all the OPPS changes on various groups of hospitals and CMHCs for CY 2019 compared to all estimated OPPS payments in CY 2018. We estimate that the policies in this final rule with comment period will result in a 0.6 percent overall increase in OPPS payments to providers. We estimate that total OPPS payments for CY 2019, including beneficiary costsharing, to the approximately 3,840 facilities paid under the OPPS (including general acute care hospitals, children’s hospitals, cancer hospitals, and CMHCs) will increase by approximately $360 million compared to CY 2018 payments, excluding our estimated changes in enrollment, utilization, and case-mix. We estimated the isolated impact of our OPPS policies on CMHCs because CMHCs are only paid for partial hospitalization services under the OPPS. Continuing the provider-specific structure we adopted beginning in CY 2011, and basing payment fully on the type of provider furnishing the service, we estimate a 15.1 percent decrease in CY 2019 payments to CMHCs relative to their CY 2018 payments. b. Impacts of the Updated Wage Indexes We estimate that our update of the wage indexes based on the FY 2019 IPPS final rule wage indexes will result in no estimated payment change for urban hospitals under the OPPS and an estimated decrease of 0.2 percent for rural hospitals. These wage indexes include the continued implementation of the OMB labor market area delineations based on 2010 Decennial Census data, with updates, as discussed in section II.C. of this final rule with comment period. c. Impacts of the Rural Adjustment and the Cancer Hospital Payment Adjustment There are no significant impacts of our CY 2019 payment policies for hospitals that are eligible for the rural adjustment or for the cancer hospital payment adjustment. We are not making any change in policies for determining the rural hospital payment adjustments. While we are implementing the required reduction to the cancer hospital payment adjustment required by section 16002 of the 21st Century Cures Act for CY 2019, the target payment-to-cost ratio (PCR) for CY 2019 remains the same as in CY 2018 and therefore does not impact the budget neutrality adjustments. PO 00000 Frm 00008 Fmt 4701 Sfmt 4700 d. Impacts of the OPD Fee Schedule Increase Factor For the CY 2019 OPPS/ASC, we are establishing an OPD fee schedule increase factor of 1.35 percent and applying that increase factor to the conversion factor for CY 2019. As a result of the OPD fee schedule increase factor and other budget neutrality adjustments, we estimate that rural and urban hospitals will experience an increase of approximately 1.4 percent for urban hospitals and 1.3 percent for rural hospitals. Classifying hospitals by teaching status, we estimate nonteaching hospitals will experience an increase of 1.4 percent, minor teaching hospitals will experience an increase of 1.3 percent, and major teaching hospitals will experience an increase of 1.5 percent. We also classified hospitals by the type of ownership. We estimate that hospitals with voluntary ownership, hospitals with proprietary ownership, and hospitals with government ownership will all experience an increase of 1.4 percent in payments. e. Impacts of the Policy To Control for Unnecessary Increases in the Volume of Outpatient Services In section X.B. of this CY 2019 OPPS/ ASC final rule with comment period, we discuss our CY 2019 proposal and finalized policies to control for unnecessary increases in the volume of outpatient service by paying for clinic visits furnished at an off-campus PBD of a hospital at a PFS-equivalent rate under the OPPS rather than at the standard OPPS rate. As a result of this finalized policy, we estimated decreases of 0.6 percent to urban hospitals, and estimated decreases of 0.6 percent to rural hospitals, with the estimated effect for individual groups of hospitals depending on the volume of clinic visits provided at the hospitals’ off-campus PBDs. f. Impacts of the ASC Payment Update For impact purposes, the surgical procedures on the ASC list of covered procedures are aggregated into surgical specialty groups using CPT and HCPCS code range definitions. The percentage change in estimated total payments by specialty groups under the CY 2019 payment rates, compared to estimated CY 2018 payment rates, generally ranges between an increase of 1 and 3 percent, depending on the service, with some exceptions. We estimate the impact of applying the hospital market basket update to ASC payment rates will increase payments by $80 million under the ASC payment system in CY 2019, E:\FR\FM\21NOR2.SGM 21NOR2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations compared to an increase of $60 million if we had applied an update based on CPI–U. khammond on DSK30JT082PROD with RULES2 c. Impact of the Changes to the Hospital OQR Program Across 3,300 hospitals participating in the Hospital OQR Program, we estimate that our requirements will result in the following changes to costs and burdens related to information collection for the Hospital OQR Program compared to previously adopted requirements: (1) No change in the total collection of information burden or costs for the CY 2020 payment determination; (2) a total collection of information burden reduction of 681,735 hours and a total collection of information cost reduction of approximately $24.9 million for the CY 2021 payment determination due to the removal of four measures: OP–5, OP–12, OP–17, and OP–30. Further, we anticipate that the removal of a total of eight measures will result in a reduction in costs unrelated to information collection. For example, it may be costly for health care providers to track the confidential feedback, preview reports, and publicly reported information on a measure where we use the measure in more than one program. Also, when measures are in multiple programs, maintaining the specifications for those measures, as well as the tools we need to collect, validate, analyze, and publicly report the measure data may result in costs to CMS. In addition, beneficiaries may find it confusing to see public reporting on the same measure in different programs. d. Impact of the Changes to the ASCQR Program Across 3,937 ASCs participating in the ASCQR Program, we estimate that our requirements will result in the following changes to costs and burdens related to information collection for the ASCQR Program, compared to previously adopted requirements: (1) No change in the total collection of information burden or costs for the CY 2020 payment determination; (2) a total collection of information burden reduction of 62,008 hours and a total collection of information cost reduction of approximately $2,268,244 for the CY 2021 payment determination due to the removal of ASC–10. Further, we anticipate that the removal of ASC–10 will result in a reduction in costs unrelated to information collection. For example, it may be costly for health care providers to track the confidential feedback, preview reports, and publicly reported information on a measure where we use VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 the measure in more than one program. Also, when measures are in multiple programs, maintaining the specifications for those measures as well as the tools we need to collect, analyze, and publicly report the measure data may result in costs to CMS. In addition, beneficiaries may find it confusing to see public reporting on the same measure in different programs. B. Legislative and Regulatory Authority for the Hospital OPPS When Title XVIII of the Social Security Act was enacted, Medicare payment for hospital outpatient services was based on hospital-specific costs. In an effort to ensure that Medicare and its beneficiaries pay appropriately for services and to encourage more efficient delivery of care, the Congress mandated replacement of the reasonable costbased payment methodology with a prospective payment system (PPS). The Balanced Budget Act of 1997 (BBA) (Pub. L. 105–33) added section 1833(t) to the Act, authorizing implementation of a PPS for hospital outpatient services. The OPPS was first implemented for services furnished on or after August 1, 2000. Implementing regulations for the OPPS are located at 42 CFR parts 410 and 419. The Medicare, Medicaid, and SCHIP Balanced Budget Refinement Act of 1999 (BBRA) (Pub. L. 106–113) made major changes in the hospital OPPS. The following Acts made additional changes to the OPPS: the Medicare, Medicaid, and SCHIP Benefits Improvement and Protection Act of 2000 (BIPA) (Pub. L. 106–554); the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (MMA) (Pub. L. 108–173); the Deficit Reduction Act of 2005 (DRA) (Pub. L. 109–171), enacted on February 8, 2006; the Medicare Improvements and Extension Act under Division B of Title I of the Tax Relief and Health Care Act of 2006 (MIEA–TRHCA) (Pub. L. 109–432), enacted on December 20, 2006; the Medicare, Medicaid, and SCHIP Extension Act of 2007 (MMSEA) (Pub. L. 110–173), enacted on December 29, 2007; the Medicare Improvements for Patients and Providers Act of 2008 (MIPPA) (Pub. L. 110–275), enacted on July 15, 2008; the Patient Protection and Affordable Care Act (Pub. L. 111–148), enacted on March 23, 2010, as amended by the Health Care and Education Reconciliation Act of 2010 (Pub. L. 111– 152), enacted on March 30, 2010 (these two public laws are collectively known as the Affordable Care Act); the Medicare and Medicaid Extenders Act of 2010 (MMEA, Pub. L. 111–309); the Temporary Payroll Tax Cut PO 00000 Frm 00009 Fmt 4701 Sfmt 4700 58825 Continuation Act of 2011 (TPTCCA, Pub. L. 112–78), enacted on December 23, 2011; the Middle Class Tax Relief and Job Creation Act of 2012 (MCTRJCA, Pub. L. 112–96), enacted on February 22, 2012; the American Taxpayer Relief Act of 2012 (Pub. L. 112–240), enacted January 2, 2013; the Pathway for SGR Reform Act of 2013 (Pub. L. 113–67) enacted on December 26, 2013; the Protecting Access to Medicare Act of 2014 (PAMA, Pub. L. 113–93), enacted on March 27, 2014; the Medicare Access and CHIP Reauthorization Act (MACRA) of 2015 (Pub. L. 114–10), enacted April 16, 2015; the Bipartisan Budget Act of 2015 (Pub. L. 114–74), enacted November 2, 2015; the Consolidated Appropriations Act, 2016 (Pub. L. 114–113), enacted on December 18, 2015, the 21st Century Cures Act (Pub. L. 114–255), enacted on December 13, 2016, the Consolidated Appropriations Act, 2018 (Pub. L. 115– 141), enacted on March 23, 2018, and the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act (Pub. L. 115–271), enacted on October 24, 2018. Under the OPPS, we generally pay for hospital Part B services on a rate-perservice basis that varies according to the APC group to which the service is assigned. We use the Healthcare Common Procedure Coding System (HCPCS) (which includes certain Current Procedural Terminology (CPT) codes) to identify and group the services within each APC. The OPPS includes payment for most hospital outpatient services, except those identified in section I.C. of this final rule with comment period. Section 1833(t)(1)(B) of the Act provides for payment under the OPPS for hospital outpatient services designated by the Secretary (which includes partial hospitalization services furnished by CMHCs), and certain inpatient hospital services that are paid under Medicare Part B. The OPPS rate is an unadjusted national payment amount that includes the Medicare payment and the beneficiary copayment. This rate is divided into a labor-related amount and a nonlabor-related amount. The laborrelated amount is adjusted for area wage differences using the hospital inpatient wage index value for the locality in which the hospital or CMHC is located. All services and items within an APC group are comparable clinically and with respect to resource use (section 1833(t)(2)(B) of the Act). In accordance with section 1833(t)(2)(B) of the Act, subject to certain exceptions, items and services within an APC group cannot be considered comparable with respect to E:\FR\FM\21NOR2.SGM 21NOR2 58826 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations khammond on DSK30JT082PROD with RULES2 the use of resources if the highest median cost (or mean cost, if elected by the Secretary) for an item or service in the APC group is more than 2 times greater than the lowest median cost (or mean cost, if elected by the Secretary) for an item or service within the same APC group (referred to as the ‘‘2 times rule’’). In implementing this provision, we generally use the cost of the item or service assigned to an APC group. For new technology items and services, special payments under the OPPS may be made in one of two ways. Section 1833(t)(6) of the Act provides for temporary additional payments, which we refer to as ‘‘transitional passthrough payments,’’ for at least 2 but not more than 3 years for certain drugs, biological agents, brachytherapy devices used for the treatment of cancer, and categories of other medical devices. For new technology services that are not eligible for transitional pass-through payments, and for which we lack sufficient clinical information and cost data to appropriately assign them to a clinical APC group, we have established special APC groups based on costs, which we refer to as New Technology APCs. These New Technology APCs are designated by cost bands which allow us to provide appropriate and consistent payment for designated new procedures that are not yet reflected in our claims data. Similar to pass-through payments, an assignment to a New Technology APC is temporary; that is, we retain a service within a New Technology APC until we acquire sufficient data to assign it to a clinically appropriate APC group. C. Excluded OPPS Services and Hospitals Section 1833(t)(1)(B)(i) of the Act authorizes the Secretary to designate the hospital outpatient services that are paid under the OPPS. While most hospital outpatient services are payable under the OPPS, section 1833(t)(1)(B)(iv) of the Act excludes payment for ambulance, physical and occupational therapy, and speechlanguage pathology services, for which payment is made under a fee schedule. It also excludes screening mammography, diagnostic mammography, and effective January 1, 2011, an annual wellness visit providing personalized prevention plan services. The Secretary exercises the authority granted under the statute to also exclude from the OPPS certain services that are paid under fee schedules or other payment systems. Such excluded services include, for example, the professional services of physicians and nonphysician practitioners paid under the Medicare Physician Fee Schedule VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 (MPFS); certain laboratory services paid under the Clinical Laboratory Fee Schedule (CLFS); services for beneficiaries with end-stage renal disease (ESRD) that are paid under the ESRD prospective payment system; and services and procedures that require an inpatient stay that are paid under the hospital IPPS. In addition, section 1833(t)(1)(B)(v) of the Act does not include applicable items and services (as defined in subparagraph (A) of paragraph (21)) that are furnished on or after January 1, 2017 by an off-campus outpatient department of a provider (as defined in subparagraph (B) of paragraph (21). We set forth the services that are excluded from payment under the OPPS in regulations at 42 CFR 419.22. Under § 419.20(b) of the regulations, we specify the types of hospitals that are excluded from payment under the OPPS. These excluded hospitals include: • Critical access hospitals (CAHs); • Hospitals located in Maryland and paid under the Maryland All-Payer Model; • Hospitals located outside of the 50 States, the District of Columbia, and Puerto Rico; and • Indian Health Service (IHS) hospitals. D. Prior Rulemaking On April 7, 2000, we published in the Federal Register a final rule with comment period (65 FR 18434) to implement a prospective payment system for hospital outpatient services. The hospital OPPS was first implemented for services furnished on or after August 1, 2000. Section 1833(t)(9)(A) of the Act requires the Secretary to review certain components of the OPPS, not less often than annually, and to revise the groups, relative payment weights, and the wage and other adjustments that take into account changes in medical practices, changes in technologies, and the addition of new services, new cost data, and other relevant information and factors. Since initially implementing the OPPS, we have published final rules in the Federal Register annually to implement statutory requirements and changes arising from our continuing experience with this system. These rules can be viewed on the CMS website at: https://www.cms.gov/Medicare/ Medicare-Fee-for-Service-Payment/ HospitalOutpatientPPS/HospitalOutpatient-Regulations-andNotices.html. PO 00000 Frm 00010 Fmt 4701 Sfmt 4700 E. Advisory Panel on Hospital Outpatient Payment (the HOP Panel or the Panel) 1. Authority of the Panel Section 1833(t)(9)(A) of the Act, as amended by section 201(h) of Pub. L. 106–113, and redesignated by section 202(a)(2) of Pub. L. 106–113, requires that we consult with an external advisory panel of experts to annually review the clinical integrity of the payment groups and their weights under the OPPS. In CY 2000, based on section 1833(t)(9)(A) of the Act, the Secretary established the Advisory Panel on Ambulatory Payment Classification Groups (APC Panel) to fulfill this requirement. In CY 2011, based on section 222 of the Public Health Service Act, which gives discretionary authority to the Secretary to convene advisory councils and committees, the Secretary expanded the panel’s scope to include the supervision of hospital outpatient therapeutic services in addition to the APC groups and weights. To reflect this new role of the panel, the Secretary changed the panel’s name to the Advisory Panel on Hospital Outpatient Payment (the HOP Panel or the Panel). The HOP Panel is not restricted to using data compiled by CMS, and in conducting its review, it may use data collected or developed by organizations outside the Department. 2. Establishment of the Panel On November 21, 2000, the Secretary signed the initial charter establishing the Panel, and, at that time, named the APC Panel. This expert panel is composed of appropriate representatives of providers (currently employed fulltime, not as consultants, in their respective areas of expertise) who review clinical data and advise CMS about the clinical integrity of the APC groups and their payment weights. Since CY 2012, the Panel also is charged with advising the Secretary on the appropriate level of supervision for individual hospital outpatient therapeutic services. The Panel is technical in nature, and it is governed by the provisions of the Federal Advisory Committee Act (FACA). The current charter specifies, among other requirements, that the Panel— • May advise on the clinical integrity of Ambulatory Payment Classification (APC) groups and their associated weights; • May advise on the appropriate supervision level for hospital outpatient services; • Continues to be technical in nature; • Is governed by the provisions of the FACA; E:\FR\FM\21NOR2.SGM 21NOR2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations khammond on DSK30JT082PROD with RULES2 • Has a Designated Federal Official (DFO); and • Is chaired by a Federal Official designated by the Secretary. The Panel’s charter was amended on November 15, 2011, renaming the Panel and expanding the Panel’s authority to include supervision of hospital outpatient therapeutic services and to add critical access hospital (CAH) representation to its membership. The Panel’s charter was also amended on November 6, 2014 (80 FR 23009), and the number of members was revised from up to 19 to up to 15 members. The Panel’s current charter was approved on November 21, 2016, for a 2-year period (81 FR 94378). The current Panel membership and other information pertaining to the Panel, including its charter, Federal Register notices, membership, meeting dates, agenda topics, and meeting reports, can be viewed on the CMS website at: https://www.cms.gov/ Regulations-and-Guidance/Guidance/ FACA/AdvisoryPanelon AmbulatoryPayment ClassificationGroups.html. 3. Panel Meetings and Organizational Structure The Panel has held many meetings, with the last meeting taking place on August 20, 2018. Prior to each meeting, we publish a notice in the Federal Register to announce the meeting and, when necessary, to solicit nominations for Panel membership, to announce new members and to announce any other changes of which the public should be aware. Beginning in CY 2017, we have transitioned to one meeting per year (81 FR 31941). Further information on the 2018 summer meeting can be found in the meeting notice titled ‘‘Medicare Program: Announcement of the Advisory Panel on Hospital Outpatient Payment (the Panel) Meeting on August 20–21, 2018’’ (83 FR 19785). In addition, the Panel has established an operational structure that, in part, currently includes the use of three subcommittees to facilitate its required review process. The three current subcommittees include the following: • APC Groups and Status Indicator Assignments Subcommittee, which advises the Panel on the appropriate status indicators to be assigned to HCPCS codes, including but not limited to whether a HCPCS code or a category of codes should be packaged or separately paid, as well as the appropriate APC assignment of HCPCS codes regarding services for which separate payment is made; • Data Subcommittee, which is responsible for studying the data issues VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 confronting the Panel and for recommending options for resolving them; and • Visits and Observation Subcommittee, which reviews and makes recommendations to the Panel on all technical issues pertaining to observation services and hospital outpatient visits paid under the OPPS. Each of these subcommittees was established by a majority vote from the full Panel during a scheduled Panel meeting, and the Panel recommended at the August 20, 2018 meeting that the subcommittees continue. We accepted this recommendation. Discussions of the other recommendations made by the Panel at the August 20, 2018 Panel meeting, namely CPT codes and a comprehensive APC for autologous hematopoietic stem cell transplantation, OPPS payment for outpatient clinic visits and restrictions to service line expansions, and packaging policies, were discussed in the CY 2019 OPPS/ASC proposed rule (83 FR 37138 through 37143) or are included in the sections of this final rule with comment period that are specific to each recommendation. For discussions of earlier Panel meetings and recommendations, we refer readers to previously published OPPS/ASC proposed and final rules, the CMS website mentioned earlier in this section, and the FACA database at https://facadatabase.gov. F. Public Comments Received in Response to the CY 2019 OPPS/ASC Proposed Rule We received over 2,990 timely pieces of correspondence on the CY 2019 OPPS/ASC proposed rule that appeared in the Federal Register on July 31, 2018 (83 FR 37046). We note that we received some public comments that were outside the scope of the CY 2019 OPPS/ ASC proposed rule. Out-of-scope public comments are not addressed in this CY 2019 OPPS/ASC final rule with comment period. Summaries of those public comments that are within the scope of the proposed rule and our responses are set forth in the various sections of this final rule with comment period under the appropriate headings. G. Public Comments Received on the CY 2018 OPPS/ASC Final Rule With Comment Period We received over 125 timely pieces of correspondence on the CY 2018 OPPS/ ASC final rule with comment period that appeared in the Federal Register on December 14, 2017 (82 FR 59216), some of which contained comments on the interim APC assignments and/or status indicators of new or replacement Level PO 00000 Frm 00011 Fmt 4701 Sfmt 4700 58827 II HCPCS codes (identified with comment indicator ‘‘NI’’ in OPPS Addendum B, ASC Addendum AA, and ASC Addendum BB to that final rule). Summaries of the public comments are set forth in the CY 2019 proposed rule and this final rule with comment period under the appropriate subject matter headings. II. Updates Affecting OPPS Payments A. Recalibration of APC Relative Payment Weights 1. Database Construction a. Database Source and Methodology Section 1833(t)(9)(A) of the Act requires that the Secretary review not less often than annually and revise the relative payment weights for APCs. In the April 7, 2000 OPPS final rule with comment period (65 FR 18482), we explained in detail how we calculated the relative payment weights that were implemented on August 1, 2000 for each APC group. In the CY 2019 OPPS/ASC proposed rule (83 FR 37055), for CY 2019, we proposed to recalibrate the APC relative payment weights for services furnished on or after January 1, 2019, and before January 1, 2020 (CY 2019), using the same basic methodology that we described in the CY 2018 OPPS/ASC final rule with comment period (82 FR 52367 through 52370), using updated CY 2017 claims data. That is, as we proposed, we recalibrate the relative payment weights for each APC based on claims and cost report data for hospital outpatient department (HOPD) services, using the most recent available data to construct a database for calculating APC group weights. For the purpose of recalibrating the APC relative payment weights for CY 2019, we began with approximately 163 million final action claims (claims for which all disputes and adjustments have been resolved and payment has been made) for HOPD services furnished on or after January 1, 2017, and before January 1, 2018, before applying our exclusionary criteria and other methodological adjustments. After the application of those data processing changes, we used approximately 86 million final action claims to develop the proposed CY 2019 OPPS payment weights. For exact numbers of claims used and additional details on the claims accounting process, we refer readers to the claims accounting narrative under supporting documentation for the CY 2019 OPPS/ ASC proposed rule on the CMS website at: https://www.cms.gov/Medicare/ E:\FR\FM\21NOR2.SGM 21NOR2 khammond on DSK30JT082PROD with RULES2 58828 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations Medicare-Fee-for-Service-Payment/ Hospital>OutpatientPPS/. Addendum N to the proposed rule (which is available via the internet on the CMS website) included the proposed list of bypass codes for CY 2019. The proposed list of bypass codes contained codes that were reported on claims for services in CY 2017 and, therefore, included codes that were in effect in CY 2017 and used for billing, but were deleted for CY 2018. We retained these deleted bypass codes on the proposed CY 2019 bypass list because these codes existed in CY 2017 and were covered OPD services in that period, and CY 2017 claims data were used to calculate CY 2019 payment rates. Keeping these deleted bypass codes on the bypass list potentially allows us to create more ‘‘pseudo’’ single procedure claims for ratesetting purposes. ‘‘Overlap bypass codes’’ that are members of the proposed multiple imaging composite APCs were identified by asterisks (*) in the third column of Addendum N to the proposed rule. HCPCS codes that we proposed to add for CY 2019 were identified by asterisks (*) in the fourth column of Addendum N. In the CY 2019 OPPS/ASC proposed rule, we did not propose to remove any codes from the CY 2019 bypass list. We did not receive any public comments on our general proposal to recalibrate the relative payment weights for each APC based on claims and cost report data for HOPD services or on our proposed bypass code process. Therefore, we are adopting as final the proposed ‘‘pseudo’’ single claims process and the final CY 2019 bypass list of 169 HCPCS codes, as displayed in Addendum N to this final rule with comment period (which is available via the internet on the CMS website). For this final rule with comment period, for purposes of recalibrating the final APC relative payment weights for CY 2019, we used approximately 91 million final action claims (claims for which all disputes and adjustments have been resolved and payment has been made) for HOPD services furnished on or after January 1, 2017 and before January 1, 2018. For exact numbers of claims used and additional details on the claims accounting process, we refer readers to the claims accounting narrative under supporting documentation for this CY 2019 OPPS/ASC final rule with comment period on the CMS website at: https://www.cms.gov/Medicare/ Medicare-Fee-for-Service-Payment/ HospitalOutpatientPPS/. VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 b. Calculation and Use of Cost-to-Charge Ratios (CCRs) For CY 2019, in the CY 2019 OPPS/ ASC proposed rule (83 FR 37055), we proposed to continue to use the hospital-specific overall ancillary and departmental cost-to-charge ratios (CCRs) to convert charges to estimated costs through application of a revenue code-to-cost center crosswalk. To calculate the APC costs on which the CY 2019 APC payment rates are based, we calculated hospital-specific overall ancillary CCRs and hospital-specific departmental CCRs for each hospital for which we had CY 2017 claims data by comparing these claims data to the most recently available hospital cost reports, which, in most cases, are from CY 2016. For the proposed CY 2019 OPPS payment rates, we used the set of claims processed during CY 2017. We applied the hospital-specific CCR to the hospital’s charges at the most detailed level possible, based on a revenue codeto-cost center crosswalk that contains a hierarchy of CCRs used to estimate costs from charges for each revenue code. That crosswalk is available for review and continuous comment on the CMS website at: https://www.cms.gov/ Medicare/Medicare-Fee-for-ServicePayment/HospitalOutpatientPPS/ index.html. To ensure the completeness of the revenue code-to-cost center crosswalk, we reviewed changes to the list of revenue codes for CY 2017 (the year of claims data we used to calculate the proposed CY 2019 OPPS payment rates) and found that the National Uniform Billing Committee (NUBC) did not add any new revenue codes to the NUBC 2017 Data Specifications Manual. In accordance with our longstanding policy, we calculate CCRs for the standard and nonstandard cost centers accepted by the electronic cost report database. In general, the most detailed level at which we calculate CCRs is the hospital-specific departmental level. For a discussion of the hospital-specific overall ancillary CCR calculation, we refer readers to the CY 2007 OPPS/ASC final rule with comment period (71 FR 67983 through 67985). The calculation of blood costs is a longstanding exception (since the CY 2005 OPPS) to this general methodology for calculation of CCRs used for converting charges to costs on each claim. This exception is discussed in detail in the CY 2007 OPPS/ASC final rule with comment period and discussed further in section II.A.2.a.(1) of the proposed rule and this final rule with comment period. In the CY 2014 OPPS/ASC final rule with comment period (78 FR 74840 PO 00000 Frm 00012 Fmt 4701 Sfmt 4700 through 74847), we finalized our policy of creating new cost centers and distinct CCRs for implantable devices, magnetic resonance imaging (MRIs), computed tomography (CT) scans, and cardiac catheterization. However, in response to the CY 2014 OPPS/ASC proposed rule, commenters reported that some hospitals currently use an imprecise ‘‘square feet’’ allocation methodology for the costs of large moveable equipment like CT scan and MRI machines. They indicated that while CMS recommended using two alternative allocation methods, ‘‘direct assignment’’ or ‘‘dollar value,’’ as a more accurate methodology for directly assigning equipment costs, industry analysis suggested that approximately only half of the reported cost centers for CT scans and MRIs rely on these preferred methodologies. In response to concerns from commenters, we finalized a policy for the CY 2014 OPPS to remove claims from providers that use a cost allocation method of ‘‘square feet’’ to calculate CCRs used to estimate costs associated with the APCs for CT and MRI (78 FR 74847). Further, we finalized a transitional policy to estimate the imaging APC relative payment weights using only CT and MRI cost data from providers that do not use ‘‘square feet’’ as the cost allocation statistic. We provided that this finalized policy would sunset in 4 years to provide a sufficient time for hospitals to transition to a more accurate cost allocation method and for the related data to be available for ratesetting purposes (78 FR 74847). Therefore, beginning CY 2018, with the sunset of the transition policy, we would estimate the imaging APC relative payment weights using cost data from all providers, regardless of the cost allocation statistic employed. However, in the CY 2018 OPPS/ASC final rule with comment period (82 FR 59228 and 59229), we finalized a policy to extend the transition policy for 1 additional year and continued to remove claims from providers that use a cost allocation method of ‘‘square feet’’ to calculate CT and MRI CCRs for the CY 2018 OPPS. As we discussed in the CY 2018 OPPS/ASC final rule with comment period (82 FR 59228), some stakeholders have raised concerns regarding using claims from all providers to calculate CT and MRI CCRs, regardless of the cost allocations statistic employed (78 FR 74840 through 74847). Stakeholders noted that providers continue to use the ‘‘square feet’’ cost allocation method and that including claims from such providers would cause significant E:\FR\FM\21NOR2.SGM 21NOR2 that report CT and MRI standard cost centers using ‘‘square feet’’ as the cost allocation method by extracting HCRIS data on Worksheet B–1. Table 2 below provides statistical values based on the Our analysis shows that since the CY 2014 OPPS in which we established the transition policy, the number of valid MRI CCRs has increased by 17.5 percent to 2,177 providers and the number of valid CT CCRs has increased by 15.1 percent to 2,251 providers. However, as shown in Table 1 above, nearly all imaging APCs would see an increase in payment rates for CY 2019 if claims from providers that report using the ‘‘square feet’’ cost allocation method were removed. This can be attributed to the generally lower CCR values from providers that use a cost allocation method of ‘‘square feet’’ as shown in Table 2 above. In response to provider concerns and to provide added flexibility for hospitals to improve their cost allocation methods, for the CY 2019 OPPS, in the CY 2019 OPPS/ASC proposed rule (83 FR 37056), we proposed to extend our transition policy and remove claims VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 PO 00000 Frm 00013 Fmt 4701 Sfmt 4700 CT and MRI standard cost center CCRs using the different cost allocation methods. BILLING CODE 4120–01–P from providers that use a cost allocation method of ‘‘square feet’’ to calculate CCRs used to estimate costs with the APCs for CT and MRI identified in Table 2 above. We stated in the proposed rule that this proposed extension would mean that CMS would now be providing 6 years for providers to transition from a ‘‘square feet’’ cost allocation method to another cost allocation method. We stated in the proposed rule that we do not believe E:\FR\FM\21NOR2.SGM 21NOR2 ER21NO18.002</GPH> reductions in the imaging APC payment rates. Table 1 below demonstrates the relative effect on imaging APC payments after removing cost data for providers 58829 ER21NO18.001</GPH> khammond on DSK30JT082PROD with RULES2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations khammond on DSK30JT082PROD with RULES2 another extension in CY 2020 will be warranted and expect to determine the imaging APC relative payment weights for CY 2020 using cost data from all providers, regardless of the cost allocation method employed. Comment: Some commenters supported CMS’ proposal to extend its transition policy an additional year and determine imaging APC relative payment weights for CY 2020 using cost data from all providers. Response: We thank the commenters for their support. Comment: Some commenters recommended that CMS discontinue the use of CT and MRI cost centers for developing CT and MRI CCRs and use a single diagnostic radiology CCR instead. One commenter suggested that CCRs for CT and MRI are inaccurate, too low, and equalize the payment rates for advanced and nonadvanced imaging. This commenter also noted that if CMS were to use CCRs from all cost allocation methods, including ‘‘square feet,’’ such a change would impact technical payments under the Medicare Physician Fee Schedule because OPPS payments for imaging services would fall below the technical payments for such services under the Medicare Physician Fee Schedule and would require a reduction as required by section 1848(b)(4) of the Act. Further, the commenter noted that a significant number of CT and MRI CCRs are close to zero. The commenter VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 suggested that this probably reflects that the costs of the equipment and dedicated space for these services are likely spread across to other departments of hospitals. The commenter also suggested that hospitals have standard accounting practices for high-cost moveable equipment and that it would be burdensome and inconsistent to apply a different standard for costs associated with CT and MRI. Response: We appreciate the comments regarding the use of standard CT and MRI cost center CCRs. As we stated in prior rulemaking, we recognize the concerns with regard to the application of the CT and MRI standard cost center CCRs and their use in OPPS ratesetting in lieu of the previously used single diagnostic radiology CCR. As compared to the IPPS, there is greater sensitivity to the cost allocation method being used on the cost report forms for these relatively new standard imaging cost centers under the OPPS due to the limited size of the OPPS payment bundles and because the OPPS applies the CCRs at the departmental level for cost estimation purposes. However, we note that since the time we initially established the transition policy in the OPPS, we have made changes toward making the OPPS more of a prospective payment system, including greater packaging and the development of the comprehensive APCs. As we have made changes to package a greater number of PO 00000 Frm 00014 Fmt 4701 Sfmt 4725 items and services with imaging payments under the OPPS, and CT and MRI procedures are not solely based on the CCR applied to each procedure, we believe there is less sensitivity to imaging payments that is attributable to the cost allocation method being used on the cost report forms. Table 3 and Table 4 below display the largest and smallest CT and MRI CCRs based on the cost allocation method, respectively. Specifically, Tables 3 and 4 display the minimum, 5th percentile, 10th percentile, 90th percentile, 95th percentile, and maximum CCRs based on the cost allocation method. While we note that there are differences in CT and MRI CCR values by the cost allocation method, we also note that the CT CCR distributions and MRI CCR distributions are largely similar across the cost allocation method. As stated in past rulemaking, we also note that our current trimming methodology excludes CCRs that are +/¥3 standard deviations from the geometric mean. While we acknowledge the commenter’s concern that a number of CCRs, particular those CT CCRs from hospitals that use a cost allocation method of ‘‘square feet,’’ are below 0.0100, we do not believe it would be appropriate to modify our standard trimming methodology because it is not our general policy to judge the accuracy of hospital charging and hospital cost reporting practices for purposes of ratesetting. E:\FR\FM\21NOR2.SGM 21NOR2 ER21NO18.003</GPH> 58830 khammond on DSK30JT082PROD with RULES2 BILLING CODE 4120–01–C In addition, as we stated in the CY 2014 OPPS/ASC final rule with comment period (78 FR 74845), we have noted the potential impact the CT and MRI CCRs may have on other payment systems. We understand that payment reductions for imaging services under the OPPS could have significant payment impacts under the Physician Fee Schedule where the technical component payment for many imaging services is capped at the OPPS payment amount. We will continue to monitor OPPS imaging payments in the future and consider the potential impacts of payment changes to other payment systems. Over the past several years, we have encouraged hospitals to use more precise cost reporting methods through cost reporting instructions and communication with Medicare contractors regarding the approval of hospitals’ request to switch from the square feet statistical allocation method. While we have not seen a substantial decline in the number of hospitals that use the square feet cost allocation method, and we acknowledge that there are costs and challenges with transitioning to a different accounting method for CT and MRI costs, we continue to believe that adopting CT and MRI cost center CCRs fosters more specific cost reporting and improves the data contained in the electronic cost report data files and, therefore, the accuracy of our cost estimation process for the OPPS relative weights. Therefore, for CY 2019, after consideration of the public comments we received, for CY 2019, we are finalizing our proposal to extend our transition policy for 1 additional year and continue to remove claims from providers that use a ‘‘square feet’’ cost allocation method to calculate CT and MRI CCRs for the CY 2019 OPPS. VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 2. Data Development Process and Calculation of Costs Used for Ratesetting In this section of this final rule with comment period, we discuss the use of claims to calculate the OPPS payment rates for CY 2019. The Hospital OPPS page on the CMS website on which this final rule is posted (https:// www.cms.gov/Medicare/Medicare-Feefor-Service-Payment/Hospital OutpatientPPS/) provides an accounting of claims used in the development of the final payment rates. That accounting provides additional detail regarding the number of claims derived at each stage of the process. In addition, below in this section we discuss the file of claims that comprises the data set that is available upon payment of an administrative fee under a CMS data use agreement. The CMS website, https://www.cms.gov/Medicare/ Medicare-Fee-for-Service-Payment/ HospitalOutpatientPPS/, includes information about obtaining the ‘‘OPPS Limited Data Set,’’ which now includes the additional variables previously available only in the OPPS Identifiable Data Set, including ICD–10– CM diagnosis codes and revenue code payment amounts. This file is derived from the CY 2017 claims that were used to calculate the final payment rates for this CY 2019 OPPS/ASC final rule with comment period. Previously, the OPPS established the scaled relative weights, on which payments are based using APC median costs, a process described in the CY 2012 OPPS/ASC final rule with comment period (76 FR 74188). However, as discussed in more detail in section II.A.2.f. of the CY 2013 OPPS/ ASC final rule with comment period (77 FR 68259 through 68271), we finalized the use of geometric mean costs to calculate the relative weights on which the CY 2013 OPPS payment rates were based. While this policy changed the cost metric on which the relative PO 00000 Frm 00015 Fmt 4701 Sfmt 4700 58831 payments are based, the data process in general remained the same, under the methodologies that we used to obtain appropriate claims data and accurate cost information in determining estimated service cost. In the CY 2019 OPPS/ASC proposed rule (83 FR 37057), we proposed to continue to use geometric mean costs to calculate the relative weights on which the CY 2019 OPPS payment rates are based. Comment: One commenter believed that revenue code 0815 (Allogeneic Stem Cell Acquisition Services) was inadvertently excluded from the packaged revenue code list for use in the OPPS ratesetting. The commenter stated that this would primarily have an impact on APC 5244 (Level 4 Blood Product Exchange and Related Services) which would potentially include those packaged costs. The commenter requested that CMS include revenue code 0815 on the packaged revenue code list in order to be consistent with the C–APC ratesetting approach from prior years. Response: We thank the commenter for bringing this omission to our attention. As discussed in the CY 2018 OPPS/ASC final rule with comment period (81 FR 79586), beginning in CY 2017, we would include the revenue code for purposes of identifying costs associated with stem cell transplants. We agree that the revenue code was inadvertently not included on the packaged revenue code list and therefore have included it in this final rule with comment period for the CY 2019 OPPS ratesetting. After consideration of the public comment on the proposed process we received, we are adding revenue code 0815 to the packaged revenue code list and are finalizing our proposed methodology for calculating geometric mean costs for purposes of creating relative payment weights and subsequent APC payment rates for the CY 2019 OPPS. For more information E:\FR\FM\21NOR2.SGM 21NOR2 ER21NO18.004</GPH> Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations khammond on DSK30JT082PROD with RULES2 58832 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations regarding the stem cell transplants, we refer readers to section II.A.2.b. of this final rule with comment period. We used the methodology described in sections II.A.2.a. through II.A.2.c. of this final rule with comment period to calculate the costs we used to establish the relative payment weights used in calculating the OPPS payment rates for CY 2019 shown in Addenda A and B to this final rule with comment period (which are available via the internet on the CMS website). We refer readers to section II.A.4. of this final rule with comment period for a discussion of the conversion of APC costs to scaled payment weights. We note that this is the first year in which claims data containing lines with the modifier ‘‘PN’’ are available, which indicate nonexcepted items and services furnished and billed by off-campus provider-based departments (PBDs) of hospitals. Because nonexcepted services are not paid under the OPPS, in the CY 2019 OPPS/ASC proposed rule (83 FR 37057), we proposed to remove those claim lines reported with modifier ‘‘PN’’ from the claims data used in ratesetting for the CY 2019 OPPS and subsequent years. Comment: One commenter requested that CMS not finalize the removal of claims with modifier ‘‘PN’’ from the CY 2019 OPPS and future ratesetting. The commenter believed that this could result in unfair adjustments against hospital outpatient departments with large off-campus PBD presence and that CMS should perform ratesetting with and without the modifier in CY 2020 and continue to gather stakeholder input until the impact of removing those lines is fully understood. Response: While we generally attempt to obtain more information from the claims and cost data available to us, we do so to obtain accurate cost information for OPPS services. As discussed in the proposed rule, we do not believe that lines with modifier ‘‘PN’’ should be included as part of the OPPS ratesetting process because they are paid under the otherwise applicable payment system, rather than the OPPS (83 FR 37056 and 37057). We note that the impact of removing these modifier ‘‘PN’’ lines has only a nominal effect on the APC geometric mean costs due to the relatively low number of claims reported with modifier ‘‘PN’’. After consideration of the public comment we received, we are finalizing the policy of removing lines with the ‘‘PN’’ modifier as proposed. For details of the claims process used in this final rule with comment period, we refer readers to the claims accounting narrative under supporting VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 documentation for this CY 2019 OPPS/ ASC final rule with comment period on the CMS website at: https:// www.cms.gov/Medicare/Medicare-Feefor-Service-Payment/Hospital OutpatientPPS/. a. Calculation of Single Procedure APC Criteria-Based Costs (1) Blood and Blood Products (a) Methodology Since the implementation of the OPPS in August 2000, we have made separate payments for blood and blood products through APCs rather than packaging payment for them into payments for the procedures with which they are administered. Hospital payments for the costs of blood and blood products, as well as for the costs of collecting, processing, and storing blood and blood products, are made through the OPPS payments for specific blood product APCs. In the CY 2019 OPPS/ASC proposed rule (83 FR 37057 through 37058), we proposed to continue to establish payment rates for blood and blood products using our blood-specific CCR methodology, which utilizes actual or simulated CCRs from the most recently available hospital cost reports to convert hospital charges for blood and blood products to costs. This methodology has been our standard ratesetting methodology for blood and blood products since CY 2005. It was developed in response to data analysis indicating that there was a significant difference in CCRs for those hospitals with and without blood-specific cost centers, and past public comments indicating that the former OPPS policy of defaulting to the overall hospital CCR for hospitals not reporting a bloodspecific cost center often resulted in an underestimation of the true hospital costs for blood and blood products. Specifically, in order to address the differences in CCRs and to better reflect hospitals’ costs, we proposed to continue to simulate blood CCRs for each hospital that does not report a blood cost center by calculating the ratio of the blood-specific CCRs to hospitals’ overall CCRs for those hospitals that do report costs and charges for blood cost centers. We also proposed to apply this mean ratio to the overall CCRs of hospitals not reporting costs and charges for blood cost centers on their cost reports in order to simulate bloodspecific CCRs for those hospitals. We proposed to calculate the costs upon which the proposed CY 2019 payment rates for blood and blood products are based using the actual blood-specific CCR for hospitals that reported costs PO 00000 Frm 00016 Fmt 4701 Sfmt 4700 and charges for a blood cost center and a hospital-specific, simulated bloodspecific CCR for hospitals that did not report costs and charges for a blood cost center. We continue to believe that the hospital-specific, simulated bloodspecific, CCR methodology better responds to the absence of a bloodspecific CCR for a hospital than alternative methodologies, such as defaulting to the overall hospital CCR or applying an average blood-specific CCR across hospitals. Because this methodology takes into account the unique charging and cost accounting structure of each hospital, we believe that it yields more accurate estimated costs for these products. We stated in the proposed rule that we continue to believe that this methodology in CY 2019 would result in costs for blood and blood products that appropriately reflect the relative estimated costs of these products for hospitals without blood cost centers and, therefore, for these blood products in general. We note that, as discussed in section II.A.2.b. of the CY 2018 OPPS/ASC final rule with comment period (82 FR 59234 through 59239), we defined a comprehensive APC (C–APC) as a classification for the provision of a primary service and all adjunctive services provided to support the delivery of the primary service. Under this policy, we include the costs of blood and blood products when calculating the overall costs of these C–APCs. In the CY 2019 OPPS/ASC proposed rule (83 FR 37057 through 37058), we proposed to continue to apply the blood-specific CCR methodology described in this section when calculating the costs of the blood and blood products that appear on claims with services assigned to the C–APCs. Because the costs of blood and blood products would be reflected in the overall costs of the C–APCs (and, as a result, in the payment rates of the C–APCs), we proposed to not make separate payments for blood and blood products when they appear on the same claims as services assigned to the C–APCs (we refer readers to the CY 2015 OPPS/ASC final rule with comment period (79 FR 66796)). We also referred readers to Addendum B to the CY 2019 OPPS/ASC proposed rule (which is available via the internet on the CMS website) for the proposed CY 2019 payment rates for blood and blood products (which are identified with status indicator ‘‘R’’). For a more detailed discussion of the blood-specific CCR methodology, we refer readers to the CY 2005 OPPS proposed rule (69 FR 50524 through E:\FR\FM\21NOR2.SGM 21NOR2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations khammond on DSK30JT082PROD with RULES2 50525). For a full history of OPPS payment for blood and blood products, we refer readers to the CY 2008 OPPS/ ASC final rule with comment period (72 FR 66807 through 66810). We did not receive any public comments for these proposals. Therefore, we are finalizing our proposals, without modification, to continue to apply the blood-specific CCR methodology described in this section when calculating the costs of the blood and blood products that appear on claims with services assigned to the C–APCs and to not make separate payments for blood and blood products when they appear on the same claims as services assigned to the C–APCs for CY 2019. (b) Pathogen-Reduced Platelets Payment Rate In the CY 2016 OPPS/ASC final rule with comment period (80 FR 70322 through 70323), we reiterated that we calculate payment rates for blood and blood products using our blood-specific CCR methodology, which utilizes actual or simulated CCRs from the most recently available hospital cost reports to convert hospital charges for blood and blood products to costs. Because HCPCS code P9072 (Platelets, pheresis, pathogen reduced or rapid bacterial tested, each unit), the predecessor code to HCPCS code P9073 (Platelets, pheresis, pathogen-reduced, each unit), was new for CY 2016, there were no claims data available on the charges and costs for this blood product upon which to apply our blood-specific CCR methodology. Therefore, we established an interim payment rate for HCPCS code P9072 based on a crosswalk to existing blood product HCPCS code P9037 (Platelets, pheresis, leukocytes reduced, irradiated, each unit), which we believed provided the best proxy for the costs of the new blood product. In addition, we stated that once we had claims data for HCPCS code P9072, we would calculate its payment rate using the claims data that should be available for the code beginning in CY 2018, which is our practice for other blood product HCPCS codes for which claims data have been available for 2 years. We stated in the CY 2018 OPPS/ASC final rule with comment period (82 FR 59232) that, although our standard practice for new codes involves using claims data to set payment rates once claims data become available, we were concerned that there may have been confusion among the provider community about the services that HCPCS code P9072 described. That is, as early as 2016, there were discussions about changing the descriptor for VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 HCPCS code P9072 to include the phrase ‘‘or rapid bacterial tested’’, which is a less costly technology than pathogen reduction. In addition, effective January 2017, the code descriptor for HCPCS code P9072 was changed to describe rapid bacterial testing of platelets and, effective July 1, 2017, the descriptor for the temporary successor code for HCPCS code P9072 (HCPCS code Q9988) was changed again back to the original descriptor for HCPCS code P9072 that was in place for 2016. Based on the ongoing discussions involving changes to the original HCPCS code P9072 established in CY 2016, we believed that claims from CY 2016 for pathogen reduced platelets may have potentially reflected certain claims for rapid bacterial testing of platelets. Therefore, we decided to continue to crosswalk the payment amount for services described by HCPCS code P9073 to the payment amount for services described by HCPCS P9037 for CY 2018 (82 FR 59232), as had been done previously, to determine the payment rate for services described by HCPCS code P9072. In the CY 2019 OPPS/ASC proposed rule (83 FR 37058), for CY 2019, we discussed that we had reviewed the CY 2017 claims data for the two predecessor codes to HCPCS code P9073 (HCPCS codes P9072 and Q9988), along with the claims data for the CY 2017 temporary code for pathogen test for platelets (HCPCS code Q9987), which describes rapid bacterial testing of platelets. We found that there were over 2,200 claims billed with either HCPCS code P9072 or Q9988. Accordingly, we believe that there are a sufficient number of claims to use to calculate a payment rate for HCPCS code P9073 for CY 2019. We also performed checks to estimate the share of claims that may have been billed for rapid bacterial testing of platelets as compared to the share of claims that may have been billed for pathogen-reduced, pheresis platelets (based on when HCPCS code P9072 was an active procedure code from January 1, 2017 to June 30, 2017). First, we found that the geometric mean cost for pathogen-reduced, pheresis platelets, as reported by HCPCS code Q9988 when billed separately from rapid bacterial testing of platelets, was $453.87, and that over 1,200 claims were billed for services described by HCPCS code Q9988. Next, we found that the geometric mean cost for rapid bacterial testing of platelets, as reported by HCPCS code Q9987 on claims, was $33.44, and there were 59 claims reported for services described by PO 00000 Frm 00017 Fmt 4701 Sfmt 4700 58833 HCPCS code Q9987, of which 3 were separately paid. These findings imply that almost all of the claims billed for services reported with HCPCS code P9072 were for pathogen-reduced, pheresis platelets. In addition, the geometric mean cost for services described by HCPCS code P9072, which may contain rapid bacterial testing of platelets claims, was $468.11, which is higher than the geometric mean cost for services described by HCPCS code Q9988 of $453.87, which should not have contained claims for rapid bacterial testing of platelets. Because the geometric mean for services described by HCPCS code Q9987 is only $33.44, it would be expected that if a significant share of claims billed for services described by HCPCS code P9072 were for the rapid bacterial testing of platelets, the geometric mean cost for services described by HCPCS code P9072 would be lower than the geometric mean cost for services described by HCPCS code Q9988. Instead, we found that the geometric mean cost for services described by HCPCS code Q9988 is higher than the geometric mean cost for services described by HCPCS code P9072. Based on our analysis of claims data, we stated in the CY 2019 OPPS/ASC proposed rule that we believed there were sufficient claims available to establish a payment rate for pathogenreduced pheresis platelets without using a crosswalk. Therefore, we proposed to calculate the payment rate for services described by HCPCS code P9073 in CY 2019 and in subsequent years using claims payment history, which is the standard methodology used by the OPPS for HCPCS and CPT codes with at least 2 years of claims history. We referred readers to Addendum B of the proposed rule for the proposed payment rate for services described by HCPCS code P9073 reportable under the OPPS. Addendum B is available via the internet on the CMS website. Comment: Several commenters opposed the proposal to use claims history to calculate the payment rate for services described by HCPCS code P9073. Instead, the commenters requested that CMS calculate the payment rate for services described by HCPCS code P9072 based on a crosswalk to existing blood product HCPCS code P9037 through either CY 2019 or CY 2020. The commenters stated that the acquisition cost for pathogen-reduced platelets is over $600, which is substantially higher than the proposed payment rate for services described by HCPCS code P9073 found in Addendum B to the proposed rule E:\FR\FM\21NOR2.SGM 21NOR2 khammond on DSK30JT082PROD with RULES2 58834 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations and closer to the payment rate for services described by HCPCS code P9073. Some commenters indicated that the cost for pathogen-reduced platelets is higher than the cost of leukocytes reduced and irradiated platelets, the product covered by HCPCS code P9073, the crosswalked code. Several of the commenters believed the claim costs for pathogen-reduced platelets were lower than actual costs because of coding errors by providers, providers who did not use pathogen-reduced platelets billing the service, and confusion over whether to use the hospital CCR or the blood center CCR to report charges for pathogen-reduced platelets. One commenter also stated that a provider that billed several claims for pathogenreduced platelets believed that CMS assigned an unusually low CCR to its claims, leading the provider to report lower than actual costs for the service. Response: We appreciate the concerns of the commenters. Pathogen-reduced platelets (HCPCS code P9073) are a relatively new service. As we noted in the CY 2019 OPPS/ASC proposed rule (83 FR 37058), there were many changes to the procedure code billed for pathogen-reduced platelets, as well as with the services covered by the procedure codes for pathogen-reduced platelets and the code descriptors. We had concerns that all of these coding changes could lead to billing confusion. The comments we received from providers, stakeholder groups, and the developer of the pathogen-reduced technology support that there indeed may have been confusion about billing that has led to aberrancies in the data we have available for ratesetting. After consideration of the public comments we received, we are not finalizing our proposal to calculate the payment rate for services described by HCPCS code P9073 in CY 2019 using claims payment history. Instead, for CY 2019 (that is, for one more year), we are establishing the payment rate for services described by HCPCS code P9073 by performing a crosswalk from the payment amount for services described by HCPCS code P9073 to the payment amount for services described by HCPCS P9037. We refer readers to Addendum B to this final rule with comment period for the final payment rate for services described by HCPCS code P9073 reportable under the OPPS. Addendum B is available via the internet on the CMS website. (2) Brachytherapy Sources Section 1833(t)(2)(H) of the Act mandates the creation of additional groups of covered OPD services that classify devices of brachytherapy VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 consisting of a seed or seeds (or radioactive source) (‘‘brachytherapy sources’’) separately from other services or groups of services. The statute provides certain criteria for the additional groups. For the history of OPPS payment for brachytherapy sources, we refer readers to prior OPPS final rules, such as the CY 2012 OPPS/ ASC final rule with comment period (77 FR 68240 through 68241). As we have stated in prior OPPS updates, we believe that adopting the general OPPS prospective payment methodology for brachytherapy sources is appropriate for a number of reasons (77 FR 68240). The general OPPS methodology uses costs based on claims data to set the relative payment weights for hospital outpatient services. This payment methodology results in more consistent, predictable, and equitable payment amounts per source across hospitals by averaging the extremely high and low values, in contrast to payment based on hospitals’ charges adjusted to costs. We believe that the OPPS methodology, as opposed to payment based on hospitals’ charges adjusted to cost, also would provide hospitals with incentives for efficiency in the provision of brachytherapy services to Medicare beneficiaries. Moreover, this approach is consistent with our payment methodology for the vast majority of items and services paid under the OPPS. We refer readers to the CY 2016 OPPS/ASC final rule with comment period (80 FR 70323 through 70325) for further discussion of the history of OPPS payment for brachytherapy sources. In the CY 2019 OPPS/ASC proposed rule (83 FR 37059), for CY 2019, we proposed to use the costs derived from CY 2017 claims data to set the proposed CY 2019 payment rates for brachytherapy sources because CY 2017 is the same year of data we proposed to use to set the proposed payment rates for most other items and services that would be paid under the CY 2019 OPPS. We proposed to base the payment rates for brachytherapy sources on the geometric mean unit costs for each source, consistent with the methodology that we proposed for other items and services paid under the OPPS, as discussed in section II.A.2. of the proposed rule. We also proposed to continue the other payment policies for brachytherapy sources that we finalized and first implemented in the CY 2010 OPPS/ASC final rule with comment period (74 FR 60537). We proposed to pay for the stranded and nonstranded not otherwise specified (NOS) codes, HCPCS codes C2698 (Brachytherapy source, stranded, not otherwise PO 00000 Frm 00018 Fmt 4701 Sfmt 4700 specified, per source) and C2699 (Brachytherapy source, non-stranded, not otherwise specified, per source), at a rate equal to the lowest stranded or nonstranded prospective payment rate for such sources, respectively, on a per source basis (as opposed to, for example, a per mCi), which is based on the policy we established in the CY 2008 OPPS/ASC final rule with comment period (72 FR 66785). We also proposed to continue the policy we first implemented in the CY 2010 OPPS/ASC final rule with comment period (74 FR 60537) regarding payment for new brachytherapy sources for which we have no claims data, based on the same reasons we discussed in the CY 2008 OPPS/ASC final rule with comment period (72 FR 66786; which was delayed until January 1, 2010 by section 142 of Pub. L. 110–275). Specifically, this policy is intended to enable us to assign new HCPCS codes for new brachytherapy sources to their own APCs, with prospective payment rates set based on our consideration of external data and other relevant information regarding the expected costs of the sources to hospitals. The proposed CY 2019 payment rates for brachytherapy sources were included in Addendum B to the proposed rule (which is available via the internet on the CMS website) and were identified with status indicator ‘‘U’’. For CY 2019, we proposed to continue to assign status indicator ‘‘U’’ (Brachytherapy Sources, Paid under OPPS; separate APC payment) to HCPCS code C2645 (Brachytherapy planar source, palladium-103, per square millimeter) and to use external data (invoice prices) and other relevant information to establish the proposed APC payment rate for HCPCS code C2645. Specifically, we proposed to set the payment rate at $4.69 per mm2, the same rate that was in effect for CYs 2017 and 2018. We note that, for CY 2019, we proposed to assign status indicator ‘‘E2’’ (Items and Services for Which Pricing Information and Claims Data Are Not Available) to HCPCS code C2644 (Brachytherapy cesium-131 chloride) because this code was not reported on CY 2017 claims. Therefore, we were unable to calculate a proposed payment rate based on the general OPPS ratesetting methodology described earlier. Although HCPCS code C2644 became effective July 1, 2014, there are no CY 2017 claims reporting this code. Therefore, we proposed to assign new proposed status indicator ‘‘E2’’ to HCPCS code C2644 in the CY 2019 OPPS. E:\FR\FM\21NOR2.SGM 21NOR2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations khammond on DSK30JT082PROD with RULES2 Comment: One commenter expressed concern regarding CMS’ policy to establish prospective payment rates for brachytherapy sources using the general OPPS methodology, which uses costs based on claims data to set the relative payment weights for hospital outpatient services. The commenter stated that, as a result of use of these cost data from claims, payments for low-volume brachytherapy sources have fluctuated significantly under the OPPS. Response: As we stated in the CY 2012 OPPS/ASC final rule with comment period (76 FR 74161) when we established a prospective payment for VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 brachytherapy sources, the OPPS relies on the concept of averaging, where the payment may be more or less than the estimated cost of providing a service for a particular patient; however, with the exception of outlier cases, we believe that such a prospective payment is adequate to ensure access to appropriate care. We acknowledge that payment for brachytherapy sources based on geometric mean costs from a small set of claims may be more variable on a year-to-year basis when compared to geometric mean costs for brachytherapy sources from a larger claims set. However, as illustrated in Table 5 PO 00000 Frm 00019 Fmt 4701 Sfmt 4700 58835 below, we believe that payment for currently payable brachytherapy sources has been relatively consistent over the years and that a prospective payment for brachytherapy sources based on geometric mean costs is appropriate and provides hospitals with the greatest incentives for efficiency in furnishing brachytherapy treatment. For CY 2019 OPPS payment rates for the brachytherapy sources listed in Table 5, we refer readers to Addendum B of this final rule with comment period (which is available via the internet on the CMS website). BILLING CODE 4120–01–P E:\FR\FM\21NOR2.SGM 21NOR2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations khammond on DSK30JT082PROD with RULES2 BILLING CODE 4120–01–C After consideration of the public comments we received, we are finalizing our proposal to continue to set the payment rates for brachytherapy sources using our established prospective payment methodology. We also are finalizing our proposal to assign status indicator ‘‘U’’ (Brachytherapy Sources, Paid under OPPS; separate APC payment) to HCPCS code C2645 (Brachytherapy planar source, palladium-103, per square millimeter) VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 and to use external data (invoice prices) and other relevant information to establish the APC payment rate for HCPCS code C2645 for CY 2019. Lastly, because we were unable to calculate a payment rate for HCPCS code C2644 (Brachytherapy cesium-131 chloride) based on the general OPPS ratesetting methodology, we are finalizing our proposal to assign HCPCS code C2644 status indicator ‘‘E2’’ (Items and Services for Which Pricing PO 00000 Frm 00020 Fmt 4701 Sfmt 4700 Information and Claims Data Are Not Available) for CY 2019. The final CY 2019 payment rates for brachytherapy sources are included in Addendum B to this final rule with comment period (which is available via the internet on the CMS website) and are identified with status indicator ‘‘U’’. We continue to invite hospitals and other parties to submit recommendations to us for new codes to describe new brachytherapy sources. Such recommendations should be E:\FR\FM\21NOR2.SGM 21NOR2 ER21NO18.005</GPH> 58836 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations directed to the Division of Outpatient Care, Mail Stop C4–01–26, Centers for Medicare and Medicaid Services, 7500 Security Boulevard, Baltimore, MD 21244. We will continue to add new brachytherapy source codes and descriptors to our systems for payment on a quarterly basis. b. Comprehensive APCs (C–APCs) for CY 2019 khammond on DSK30JT082PROD with RULES2 (1) Background In the CY 2014 OPPS/ASC final rule with comment period (78 FR 74861 through 74910), we finalized a comprehensive payment policy that packages payment for adjunctive and secondary items, services, and procedures into the most costly primary procedure under the OPPS at the claim level. The policy was finalized in CY 2014, but the effective date was delayed until January 1, 2015, to allow additional time for further analysis, opportunity for public comment, and systems preparation. The comprehensive APC (C–APC) policy was implemented effective January 1, 2015, with modifications and clarifications in response to public comments received regarding specific provisions of the C–APC policy (79 FR 66798 through 66810). A C–APC is defined as a classification for the provision of a primary service and all adjunctive services provided to support the delivery of the primary service. We established C–APCs as a category broadly for OPPS payment and implemented 25 C–APCs beginning in CY 2015 (79 FR 66809 through 66810). In the CY 2016 OPPS/ASC final rule with comment period (80 FR 70332), we finalized 10 additional C–APCs to be paid under the existing C–APC payment policy and added one additional level to both the Orthopedic Surgery and Vascular Procedures clinical families, which increased the total number of C– APCs to 37 for CY 2016. In the CY 2017 OPPS/ASC final rule with comment period (81 FR 79584 through 79585), we finalized another 25 C–APCs for a total of 62 C–APCs. In the CY 2018 OPPS/ ASC final rule with comment period, we did not change the total number of C– APCs from 62. Under this policy, we designate a service described by a HCPCS code assigned to a C–APC as the primary service when the service is identified by OPPS status indicator ‘‘J1’’. When such a primary service is reported on a hospital outpatient claim, taking into consideration the few exceptions that are discussed below, we make payment for all other items and services reported on the hospital outpatient claim as VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 being integral, ancillary, supportive, dependent, and adjunctive to the primary service (hereinafter collectively referred to as ‘‘adjunctive services’’) and representing components of a complete comprehensive service (78 FR 74865 and 79 FR 66799). Payments for adjunctive services are packaged into the payments for the primary services. This results in a single prospective payment for each of the primary, comprehensive services based on the costs of all reported services at the claim level. Services excluded from the C–APC policy under the OPPS include services that are not covered OPD services, services that cannot by statute be paid for under the OPPS, and services that are required by statute to be separately paid. This includes certain mammography and ambulance services that are not covered OPD services in accordance with section 1833(t)(1)(B)(iv) of the Act; brachytherapy seeds, which also are required by statute to receive separate payment under section 1833(t)(2)(H) of the Act; pass-through payment drugs and devices, which also require separate payment under section 1833(t)(6) of the Act; self-administered drugs (SADs) that are not otherwise packaged as supplies because they are not covered under Medicare Part B under section 1861(s)(2)(B) of the Act; and certain preventive services (78 FR 74865 and 79 FR 66800 through 66801). A list of services excluded from the C–APC policy is included in Addendum J to this final rule with comment period (which is available via the internet on the CMS website). The C–APC policy payment methodology set forth in the CY 2014 OPPS/ASC final rule with comment period for the C–APCs and modified and implemented beginning in CY 2015 is summarized as follows (78 FR 74887 and 79 FR 66800): Basic Methodology. As stated in the CY 2015 OPPS/ASC final rule with comment period, we define the C–APC payment policy as including all covered OPD services on a hospital outpatient claim reporting a primary service that is assigned to status indicator ‘‘J1’’, excluding services that are not covered OPD services or that cannot by statute be paid for under the OPPS. Services and procedures described by HCPCS codes assigned to status indicator ‘‘J1’’ are assigned to C–APCs based on our usual APC assignment methodology by evaluating the geometric mean costs of the primary service claims to establish resource similarity and the clinical characteristics of each procedure to PO 00000 Frm 00021 Fmt 4701 Sfmt 4700 58837 establish clinical similarity within each APC. In the CY 2016 OPPS/ASC final rule with comment period, we expanded the C–APC payment methodology to qualifying extended assessment and management encounters through the ‘‘Comprehensive Observation Services’’ C–APC (C–APC 8011). Services within this APC are assigned status indicator ‘‘J2’’. Specifically, we make a payment through C–APC 8011 for a claim that: • Does not contain a procedure described by a HCPCS code to which we have assigned status indicator ‘‘T’’ that is reported with a date of service on the same day or 1 day earlier than the date of service associated with services described by HCPCS code G0378; • Contains 8 or more units of services described by HCPCS code G0378 (Hospital observation services, per hour); • Contains services provided on the same date of service or 1 day before the date of service for HCPCS code G0378 that are described by one of the following codes: HCPCS code G0379 (Direct admission of patient for hospital observation care) on the same date of service as HCPCS code G0378; CPT code 99281 (Emergency department visit for the evaluation and management of a patient (Level 1)); CPT code 99282 (Emergency department visit for the evaluation and management of a patient (Level 2)); CPT code 99283 (Emergency department visit for the evaluation and management of a patient (Level 3)); CPT code 99284 (Emergency department visit for the evaluation and management of a patient (Level 4)); CPT code 99285 (Emergency department visit for the evaluation and management of a patient (Level 5)) or HCPCS code G0380 (Type B emergency department visit (Level 1)); HCPCS code G0381 (Type B emergency department visit (Level 2)); HCPCS code G0382 (Type B emergency department visit (Level 3)); HCPCS code G0383 (Type B emergency department visit (Level 4)); HCPCS code G0384 (Type B emergency department visit (Level 5)); CPT code 99291 (Critical care, evaluation and management of the critically ill or critically injured patient; first 30–74 minutes); or HCPCS code G0463 (Hospital outpatient clinic visit for assessment and management of a patient); and • Does not contain services described by a HCPCS code to which we have assigned status indicator ‘‘J1’’. The assignment of status indicator ‘‘J2’’ to a specific combination of services performed in combination with each other allows for all other OPPS payable services and items reported on the claim (excluding services that are E:\FR\FM\21NOR2.SGM 21NOR2 khammond on DSK30JT082PROD with RULES2 58838 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations not covered OPD services or that cannot by statute be paid for under the OPPS) to be deemed adjunctive services representing components of a comprehensive service and resulting in a single prospective payment for the comprehensive service based on the costs of all reported services on the claim (80 FR 70333 through 70336). Services included under the C–APC payment packaging policy, that is, services that are typically adjunctive to the primary service and provided during the delivery of the comprehensive service, include diagnostic procedures, laboratory tests, and other diagnostic tests and treatments that assist in the delivery of the primary procedure; visits and evaluations performed in association with the procedure; uncoded services and supplies used during the service; durable medical equipment as well as prosthetic and orthotic items and supplies when provided as part of the outpatient service; and any other components reported by HCPCS codes that represent services that are provided during the complete comprehensive service (78 FR 74865 and 79 FR 66800). In addition, payment for hospital outpatient department services that are similar to therapy services and delivered either by therapists or nontherapists is included as part of the payment for the packaged complete comprehensive service. These services that are provided during the perioperative period are adjunctive services and are deemed not to be therapy services as described in section 1834(k) of the Act, regardless of whether the services are delivered by therapists or other nontherapist health care workers. We have previously noted that therapy services are those provided by therapists under a plan of care in accordance with section 1835(a)(2)(C) and section 1835(a)(2)(D) of the Act and are paid for under section 1834(k) of the Act, subject to annual therapy caps as applicable (78 FR 74867 and 79 FR 66800). However, certain other services similar to therapy services are considered and paid for as hospital outpatient department services. Payment for these nontherapy outpatient department services that are reported with therapy codes and provided with a comprehensive service is included in the payment for the packaged complete comprehensive service. We note that these services, even though they are reported with therapy codes, are hospital outpatient department services and not therapy services. Therefore, the requirement for functional reporting under the regulations at 42 CFR 410.59(a)(4) and VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 42 CFR 410.60(a)(4) does not apply. We refer readers to the July 2016 OPPS Change Request 9658 (Transmittal 3523) for further instructions on reporting these services in the context of a C–APC service. Items included in the packaged payment provided in conjunction with the primary service also include all drugs, biologicals, and radiopharmaceuticals, regardless of cost, except those drugs with pass-through payment status and SADs, unless they function as packaged supplies (78 FR 74868 through 74869 and 74909 and 79 FR 66800). We refer readers to Section 50.2M, Chapter 15, of the Medicare Benefit Policy Manual for a description of our policy on SADs treated as hospital outpatient supplies, including lists of SADs that function as supplies and those that do not function as supplies. We define each hospital outpatient claim reporting a single unit of a single primary service assigned to status indicator ‘‘J1’’ as a single ‘‘J1’’ unit procedure claim (78 FR 74871 and 79 FR 66801). Line item charges for services included on the C–APC claim are converted to line item costs, which are then summed to develop the estimated APC costs. These claims are then assigned one unit of the service with status indicator ‘‘J1’’ and later used to develop the geometric mean costs for the C–APC relative payment weights. (We note that we use the term ‘‘comprehensive’’ to describe the geometric mean cost of a claim reporting ‘‘J1’’ service(s) or the geometric mean cost of a C–APC, inclusive of all of the items and services included in the C–APC service payment bundle.) Charges for services that would otherwise be separately payable are added to the charges for the primary service. This process differs from our traditional cost accounting methodology only in that all such services on the claim are packaged (except certain services as described above). We apply our standard data trims, which exclude claims with extremely high primary units or extreme costs. The comprehensive geometric mean costs are used to establish resource similarity and, along with clinical similarity, dictate the assignment of the primary services to the C–APCs. We establish a ranking of each primary service (single unit only) to be assigned to status indicator ‘‘J1’’ according to its comprehensive geometric mean costs. For the minority of claims reporting more than one primary service assigned to status indicator ‘‘J1’’ or units thereof, we identify one ‘‘J1’’ service as the primary service for the claim based on PO 00000 Frm 00022 Fmt 4701 Sfmt 4700 our cost-based ranking of primary services. We then assign these multiple ‘‘J1’’ procedure claims to the C–APC to which the service designated as the primary service is assigned. If the reported ‘‘J1’’ services on a claim map to different C–APCs, we designate the ‘‘J1’’ service assigned to the C–APC with the highest comprehensive geometric mean cost as the primary service for that claim. If the reported multiple ‘‘J1’’ services on a claim map to the same C–APC, we designate the most costly service (at the HCPCS code level) as the primary service for that claim. This process results in initial assignments of claims for the primary services assigned to status indicator ‘‘J1’’ to the most appropriate C–APCs based on both single and multiple procedure claims reporting these services and clinical and resource homogeneity. Complexity Adjustments. We use complexity adjustments to provide increased payment for certain comprehensive services. We apply a complexity adjustment by promoting qualifying paired ‘‘J1’’ service code combinations or paired code combinations of ‘‘J1’’ services and certain add-on codes (as described further below) from the originating C–APC (the C–APC to which the designated primary service is first assigned) to the next higher paying C–APC in the same clinical family of C–APCs. We apply this type of complexity adjustment when the paired code combination represents a complex, costly form or version of the primary service according to the following criteria: • Frequency of 25 or more claims reporting the code combination (frequency threshold); and • Violation of the 2 times rule in the originating C–APC (cost threshold). These criteria identify paired code combinations that occur commonly and exhibit materially greater resource requirements than the primary service. The CY 2017 OPPS/ASC final rule with comment period (81 FR 79582) included a revision to the complexity adjustment eligibility criteria. Specifically, we finalized a policy to discontinue the requirement that a code combination (that qualifies for a complexity adjustment by satisfying the frequency and cost criteria thresholds described above) also not create a 2 times rule violation in the higher level or receiving APC. After designating a single primary service for a claim, we evaluate that service in combination with each of the other procedure codes reported on the claim assigned to status indicator ‘‘J1’’ (or certain add-on codes) to determine if E:\FR\FM\21NOR2.SGM 21NOR2 khammond on DSK30JT082PROD with RULES2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations there are paired code combinations that meet the complexity adjustment criteria. For a new HCPCS code, we determine initial C–APC assignment and qualification for a complexity adjustment using the best available information, crosswalking the new HCPCS code to a predecessor code(s) when appropriate. Once we have determined that a particular code combination of ‘‘J1’’ services (or combinations of ‘‘J1’’ services reported in conjunction with certain add-on codes) represents a complex version of the primary service because it is sufficiently costly, frequent, and a subset of the primary comprehensive service overall according to the criteria described above, we promote the claim including the complex version of the primary service as described by the code combination to the next higher cost C– APC within the clinical family, unless the primary service is already assigned to the highest cost APC within the C– APC clinical family or assigned to the only C–APC in a clinical family. We do not create new APCs with a comprehensive geometric mean cost that is higher than the highest geometric mean cost (or only) C–APC in a clinical family just to accommodate potential complexity adjustments. Therefore, the highest payment for any claim including a code combination for services assigned to a C–APC would be the highest paying C–APC in the clinical family (79 FR 66802). We package payment for all add-on codes into the payment for the C–APC. However, certain primary service addon combinations may qualify for a complexity adjustment. As noted in the CY 2016 OPPS/ASC final rule with comment period (80 FR 70331), all addon codes that can be appropriately reported in combination with a base code that describes a primary ‘‘J1’’ service are evaluated for a complexity adjustment. To determine which combinations of primary service codes reported in conjunction with an add-on code may qualify for a complexity adjustment for CY 2019, in the CY 2019 OPPS/ASC proposed rule (83 FR 37061), we proposed to apply the frequency and cost criteria thresholds discussed above, testing claims reporting one unit of a single primary service assigned to status VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 indicator ‘‘J1’’ and any number of units of a single add-on code for the primary ‘‘J1’’ service. If the frequency and cost criteria thresholds for a complexity adjustment are met and reassignment to the next higher cost APC in the clinical family is appropriate (based on meeting the criteria outlined above), we make a complexity adjustment for the code combination; that is, we reassign the primary service code reported in conjunction with the add-on code to the next higher cost C–APC within the same clinical family of C–APCs. As previously stated, we package payment for add-on codes into the C–APC payment rate. If any add-on code reported in conjunction with the ‘‘J1’’ primary service code does not qualify for a complexity adjustment, payment for the add-on service continues to be packaged into the payment for the primary service and is not reassigned to the next higher cost C–APC. We listed the complexity adjustments proposed for ‘‘J1’’ and add-on code combinations for CY 2019, along with all of the other proposed complexity adjustments, in Addendum J to the CY 2019 OPPS/ASC proposed rule (which is available via the internet on the CMS website). Addendum J to the proposed rule included the cost statistics for each code combination that would qualify for a complexity adjustment (including primary code and add-on code combinations). Addendum J to the proposed rule also contained summary cost statistics for each of the paired code combinations that describe a complex code combination that would qualify for a complexity adjustment and were proposed to be reassigned to the next higher cost C–APC within the clinical family. The combined statistics for all proposed reassigned complex code combinations were represented by an alphanumeric code with the first 4 digits of the designated primary service followed by a letter. For example, the proposed geometric mean cost listed in Addendum J for the code combination described by complexity adjustment assignment 3320R, which is assigned to C–APC 5224 (Level 4 Pacemaker and Similar Procedures), includes all paired code combinations that were proposed to be reassigned to C–APC 5224 when CPT code 33208 is the primary code. Providing the information contained in Addendum J to the proposed rule PO 00000 Frm 00023 Fmt 4701 Sfmt 4700 58839 allowed stakeholders the opportunity to better assess the impact associated with the proposed reassignment of claims with each of the paired code combinations eligible for a complexity adjustment. Comment: Several commenters requested that CMS alter the C–APC complexity adjustment eligibility criteria to allow additional code combinations to qualify for complexity adjustments. The commenters requested that CMS consider clusters of ‘‘J1’’ and add-on codes, rather than only code pairs, and also consider code combinations of ‘‘J1’’ codes and devices such as drug-coated balloons and drugeluting stents. The commenters also requested that CMS eliminate the 25claim frequency threshold. Another commenter requested that CMS consider patient complexity and procedures assigned to status indicator ‘‘S’’ or ‘‘T’’ when evaluating procedures for a complexity adjustment. One commenter suggested that procedures initially eligible for a complexity adjustment by meeting the applicable requirements in a year maintain that complexity adjustment for a total period of 3 years, regardless of whether they continue to meet the criteria after the first year. In terms of payment for complexity adjustments, one commenter requested that CMS promote the qualifying code combination to two APC levels higher than the originating APC rather than to the next higher paying C–APC. Another commenter suggested that CMS pay the geometric mean cost of the highest ranking procedure in the qualifying code combination at 100 percent, and then each secondary procedure at 50 percent of the geometric mean cost of the secondary procedure. Other commenters also requested an explanation of how the geometric mean costs of the code combinations evaluated for complexity adjustments are calculated, stating that the geometric mean cost of certain code combinations represented in Addendum J were lower than the geometric mean costs of the primary service when the service is billed without an additional ‘‘J1’’ or ‘‘J1’’ add-on procedure. Commenters also requested that CMS establish complexity adjustments for the specific code combinations listed in Table 6 below. BILLING CODE 4120–01–P E:\FR\FM\21NOR2.SGM 21NOR2 58840 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations Primary "Jl" HCPCS Code 22551 (Arthrodesis, anterior interbody, including disc space preparation, discectomy, osteophytectomy and decompression of spinal cord and/or nerve roots; cervical below c2) khammond on DSK30JT082PROD with RULES2 28297 (Correction, hallux valgus (bunionectomy), with sesamoidectomy, when performed; with first metatarsal and medial cuneiform joint arthrodesis, any method) 28297 (Correction, hallux valgus (bunionectomy), with sesamoidectomy, when performed; with first metatarsal and medial cuneiform joint arthrodesis, any method) 28740 (Arthrodesis, midtarsal or tarsometatarsal, single joint) 28740 (Arthrodesis, midtarsal or tarsometatarsal, single joint) VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 PO 00000 5115 Requested Complexity Adjusted APC Assignment 5116 5114 5115 28285 (Correction, hammertoe (eg, interphalangeal fusion, partial or total phalangectomy)) 5114 5115 20900 ((Bone graft, any donor area; minor or small (eg, dowel or button)) 5114 5115 28292 (Correction, hallux valgus (bunionectomy), with sesamoidectomy, when performed; with resection of proximal phalanx base, when performed, any method) 5114 5115 Secondary "Jl" or Addon HCPCS Code 22552 (Arthrodesis, anterior interbody, including disc space preparation, discectomy, osteophytectomy and decompression of spinal cord and/or nerve roots; cervical below c2, each additional interspace (list separately in addition to code for separate procedure) 20900 (Bone graft, any donor area; minor or small (eg, dowel or button)) Frm 00024 Fmt 4701 Sfmt 4725 Primary APC Assignment E:\FR\FM\21NOR2.SGM 21NOR2 ER21NO18.006</GPH> TABLE 6.-C-APC COMPLEXITY ADJUSTMENTS REQUESTED BY COMMENTERS Primary "Jl" HCPCS Code khammond on DSK30JT082PROD with RULES2 28740 (Arthrodesis, midtarsal or tarsometatarsal, single joint) 31276 (Nasal/sinus endoscopy, surgical, with frontal sinus exploration, including removal of tissue from frontal sinus, when performed) 31288 (Nasal/sinus endoscopy, surgical, with sphenoidotomy; with removal of tissue from the sphenoid sinus) 31296 (Nasal/sinus endoscopy, surgical; with dilation of frontal sinus ostium (eg, balloon dilation) 52214 (Cystourethroscopy, with fulguration (including cryosurgery or laser surgery) of trigone, bladder neck, prostatic fossa, urethra, or periurethral glands) 52234 (Cystourethroscopy, with fulguration (including cryosurgery or laser surgery) and/or resection of; small bladder tumor( s) (0.5 up to 2.0 em)) VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 PO 00000 3 8220 (Diagnostic bone marrow; aspiration( s)) 5114 Requested Complexity Adjusted APC Assignment 5115 31255 (Nasal/sinus endoscopy, surgical with ethmoidectomy; total (anterior and posterior)) 5155 N/A 31255 (Nasal/sinus endoscopy, surgical with ethmoidectomy; total (anterior and posterior)) 5155 N/A 31297 (Nasal/sinus endoscopy, surgical; with dilation of sphenoid sinus ostium (eg, balloon dilation) C9738 (Adjunctive blue light cystoscopy with fluorescent imaging agent (list separately in addition to code for primary procedure)) 5155 N/A 5373 5374 C9738 (Adjunctive blue light cystoscopy with fluorescent imaging agent (list separately in addition to code for primary procedure) 5374 5375 Secondary "Jl" or Addon HCPCS Code Frm 00025 Fmt 4701 Sfmt 4725 Primary APC Assignment E:\FR\FM\21NOR2.SGM 21NOR2 58841 ER21NO18.007</GPH> Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations khammond on DSK30JT082PROD with RULES2 BILLING CODE 4120–01–C Response: We appreciate these comments. However, at this time, we do not believe changes to the C–APC complexity adjustment criteria are necessary or that we should make exceptions to the criteria to allow claims with the code combinations suggested by the commenters to receive complexity adjustments. As stated previously (81 FR 79582), we continue to believe that the complexity adjustment criteria, which require a frequency of 25 or more claims reporting a code combination and a violation of the 2 times rule in the originating C–APC in order to receive payment in the next higher cost C–APC within the clinical family, are adequate to determine if a combination of procedures represents a complex, costly subset of the primary service. If a code combination meets these criteria, the combination receives payment at the next higher cost C–APC. Code combinations that do not meet these criteria receive the C–APC payment rate associated with the primary ‘‘J1’’ service. A minimum of 25 claims is already very low for a national payment system. Lowering the minimum of 25 claims further could lead to unnecessary complexity adjustments for service combinations that are rarely performed. The complexity adjustment cost threshold compares the code combinations to the lowest costsignificant procedure assigned to the APC. If the cost of the code combination does not exceed twice the cost of the lowest cost-significant procedure within VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 the APC, no complexity adjustment is made. Lowering or eliminating this threshold could remove so many claims from the accounting for the primary ‘‘J1’’ service that the geometric mean costs attributed to the primary procedure could be skewed. With regard to the specific complexity adjustments requested by commenters listed in Table 6 above, we note that we did not propose that claims with these code combinations would receive complexity adjustments because they did not meet the cost and frequency criteria for the adjustment. Therefore, we do not believe it is appropriate to change the complexity adjustment criteria at this time, and because the suggested code combinations do not meet the existing criteria, we do not believe it is appropriate to establish complexity adjustments for these code combinations at this time. Regarding the request for a code combination that qualified for a complexity adjustment in a year to continue to qualify for the adjustment for the next 2 years for a total period of 3 years, we note that we evaluate code combinations each year against our complexity adjustment criteria using the latest available data. At this time, we do not believe it is necessary to expand the ability for code combinations to meet the complexity adjustment criteria in this manner because we believe that the existing criteria that were already established sufficiently reflect those combinations of procedures that are commonly billed together and are costly enough to merit a complexity PO 00000 Frm 00026 Fmt 4701 Sfmt 4700 adjustment. Further, we believe that code combinations should be evaluated each year to determine if they meet the criteria based on the latest hospital billing and utilization data. We also do not believe that it is necessary to provide payment for claims including qualifying code combinations at two APC levels higher than the originating APC or for CMS to pay based on the geometric mean cost of the highest ranking procedure in the qualifying code combination at 100 percent, and then each secondary procedure based on 50 percent of the geometric mean cost of the secondary procedure. We believe that payment at the next higher paying C–APC is adequate for code combinations that exhibit materially greater resource requirements than the primary service and that, in many cases, paying the rate assigned to two levels higher may lead to a significant overpayment. As mentioned previously, we do not create new APCs with a comprehensive geometric mean cost that is higher than the highest geometric mean cost (or only) C–APC in a clinical family just to accommodate potential complexity adjustments. The highest payment for any claim including a code combination for services assigned to a C–APC would be the highest paying C– APC in the clinical family (79 FR 66802). Therefore, a policy to pay for claims with qualifying code combinations at two C–APC levels higher than the originating APC is not always feasible. Likewise, while paying 100 percent of the highest ranking procedure and paying 50 percent of the E:\FR\FM\21NOR2.SGM 21NOR2 ER21NO18.008</GPH> 58842 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations khammond on DSK30JT082PROD with RULES2 secondary procedure is the established payment policy under the multiple procedure payment reduction policy that applies to services assigned to status indicator ‘‘T,’’ we continue to believe that the established C–APC complexity adjustment policy is appropriate for services assigned to status indicator ‘‘J1’’ or ‘‘J2’’, and we do not believe that it should be replaced with a multiple procedure payment reduction payment methodology. In response to the request for an explanation of the cost statistics for the paired ‘‘J1’’ code combinations or paired code combinations of ‘‘J1’’ services and certain add-on codes evaluated for complexity adjustments, the geometric mean costs of these code combinations shown in Addendum J are calculated using only claims that include these code pairings. As stated previously, the cost of the code combination must exceed twice the cost of the lowest costsignificant procedure within the APC in order for the combination to qualify for a complexity adjustment. Lastly, as stated in the CY 2018 OPPS/ ASC final rule with comment period (82 FR 59238), we do not believe that it is necessary to adjust the complexity adjustment criteria to allow claims that include a drug or device code, more than two ‘‘J1’’ procedures, or procedures performed at certain hospitals to qualify for a complexity adjustment. As mentioned earlier, we believe the current criteria are adequate to determine if a combination of procedures represents a complex, costly subset of the primary service. After consideration of the public comments we received on the proposed complexity adjustment policy, we are finalizing the C–APC complexity adjustment policy for CY 2019, as proposed, without modification. (2) Additional C–APCs for CY 2019 For CY 2019 and subsequent years, in the CY 2019 OPPS/ASC proposed rule (83 FR 37062), we proposed to continue to apply the C–APC payment policy methodology made effective in CY 2015 and updated with the implementation of status indicator ‘‘J2’’ in CY 2016. We refer readers to the CY 2017 OPPS/ASC final rule with comment period (81 FR 79583) for a discussion of the C–APC payment policy methodology and revisions. Each year, in accordance with section 1833(t)(9)(A) of the Act, we review and revise the services within each APC group and the APC assignments under the OPPS. As a result of our annual review of the services and the APC assignments under the OPPS, in the proposed rule (83 FR 37062), we VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 proposed to add three C–APCs under the existing C–APC payment policy beginning in CY 2019: Proposed C–APC 5163 (Level 3 ENT Procedures); proposed C–APC 5183 (Level 3 Vascular Procedures); and proposed C–APC 5184 (Level 4 Vascular Procedures). These APCs were selected to be included in this proposal because, similar to other C–APCs, these APCs include primary, comprehensive services, such as major surgical procedures, that are typically reported with other ancillary and adjunctive services. Also, similar to other APCs that have been converted to C–APCs, there are higher APC levels within the clinical family or related clinical family of these APCs that have previously been assigned to a C–APC. Table 3 of the proposed rule listed the proposed C–APCs for CY 2019. All C– APCs were displayed in Addendum J to the proposed rule (which is available via the internet on the CMS website). Addendum J to the proposed rule also contained all of the data related to the C–APC payment policy methodology, including the list of proposed complexity adjustments and other information. Comment: Several commenters supported the proposals. Other commenters, including device manufacturer associations, expressed ongoing concerns that the C–APC payment rates may not adequately reflect the costs associated with the services and requested that CMS not establish any additional C–APCs. These commenters also requested that CMS provide an analysis of the impact of the C–APC policy on affected procedures. Response: We appreciate the commenters’ responses. We continue to believe that the proposed C–APCs for CY 2019 are appropriate to be added to the existing C–APC payment policy. We also note that, in the CY 2018 OPPS/ ASC final rule with comment period (82 FR 59246), we conducted an analysis of the effects of the C–APC policy. The analysis looked at data from CY 2016 OPPS/ASC final rule with comment period, the CY 2017 OPPS/ASC final rule with comment period, and the CY 2018 OPPS/ASC proposed rule, which involved claims data from CY 2014 (before C–APCs became effective) to CY 2016. We looked at separately payable codes that were then assigned to C– APCs and, overall, we observed an increase in claim line frequency, units billed, and Medicare payment for those procedures, which suggest that the C– APC payment policy did not adversely affect access to care or reduce payments to hospitals. Comment: Several commenters requested that CMS discontinue the C– PO 00000 Frm 00027 Fmt 4701 Sfmt 4700 58843 APC payment policy for several brachytherapy insertion procedures and single session stereotactic radiosurgery procedures, stating concerns that the C– APC methodology does not account for the complexity of delivering radiation therapy and fails to capture appropriately coded claims. The commenters also requested that CMS continue to make separate payments for the 10 planning and preparation codes related to stereotactic radiosurgery (SRS) and include the HCPCS code for IMRT planning (77301) on the list of planning and preparation codes, stating that the service has become more common in single fraction radiosurgery treatment planning. Response: At this time, we do not believe that it is necessary to discontinue the C–APCs that include brachytherapy insertion procedures and single session SRS procedures. We continue to believe that the C–APC policy is appropriately applied to these surgical procedures for the reasons cited when this policy was first adopted and note that the commenters did not provide any empirical evidence to support their claims that the existing C– APC policy does not adequately pay for these procedures. Also, we will continue in CY 2019 to pay separately for the 10 planning and preparation services (HCPCS codes 70551, 70552, 70553, 77011, 77014, 77280, 77285, 77290, 77295, and 77336) adjunctive to the delivery of the SRS treatment using either the Cobalt-60-based or LINAC based technology when furnished to a beneficiary within 1 month of the SRS treatment for CY 2019 (82 FR 59242 and 59243). Comment: Several commenters representing stem cell transplant organizations requested that CMS also establish a new C–APC for autologous stem cell transplants for CY 2019. These commenters stated that the C–APC methodology will allow CMS to better capture the costs of additional services, such as laboratory tests, provided with the autologous transplant. The Advisory Panel on Hospital Outpatient Payment (HOP Panel) also recommended that CMS study the appropriateness of creating a comprehensive APC for autologous hematopoietic stem cell transplantation. Response: We appreciate these comments and may consider the creation of a C–APC for autologous stem cell transplants for future rulemaking as recommended by the HOP Panel. Comment: Two manufacturers of drugs used in ocular procedures requested that CMS discontinue the C– APC payment policy for existing C– APCs that include procedures involving E:\FR\FM\21NOR2.SGM 21NOR2 58844 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations khammond on DSK30JT082PROD with RULES2 their drugs and instead provide separate payment for the drugs. The manufacturer commenters, as well as several physicians, believed that the C– APC packaging policy, which packages payment for certain drugs that are adjunctive to the primary service, results in underpayment for the drugs. Response: We continue to believe that the procedures assigned to the proposed C–APCs, including the procedures involving the drugs used in ocular procedures mentioned by the commenters, are appropriately paid through a comprehensive APC and the costs of drugs (as well as other items or services furnished with the procedures) are reflected in hospital billing, and VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 therefore the rates that are established for the ocular procedures. As stated in the CY 2017 OPPS/ASC final rule with comment period (81 FR 79584), procedures assigned to C–APCs are primary services (mostly major surgical procedures) that are typically the focus of the hospital outpatient stay. In addition, with regard to the packaging of the drugs based on the C–APC policy, as stated in previous rules (78 FR 74868 through 74869 and 74909 and 79 FR 66800), items included in the packaged payment provided with the primary ‘‘J1’’ service include all drugs, biologicals, and radiopharmaceuticals payable under the OPPS, regardless of PO 00000 Frm 00028 Fmt 4701 Sfmt 4700 cost, except those drugs with passthrough payment status. After consideration of the public comments we received, we are finalizing the proposed C–APCs for CY 2019. Table 7 below lists the final C– APCs for CY 2019. All C–APCs are displayed in Addendum J to this final rule with comment period (which is available via the internet on the CMS website). Addendum J to this final rule with comment period also contains all of the data related to the C–APC payment policy methodology, including the list of complexity adjustments and other information for CY 2019. BILLING CODE 4120–01–P E:\FR\FM\21NOR2.SGM 21NOR2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations 58845 TABLE 7.-CY 2019 C-APCs 5072 5073 5091 5092 5093 5094 khammond on DSK30JT082PROD with RULES2 5112 5113 5114 5115 5116 5153 5154 5155 5163 5164 5165 5166 5183 5184 5191 5192 5193 5194 5200 5211 5212 5213 5222 5223 5224 5231 VerDate Sep<11>2014 20:42 Nov 20, 2018 Level2 Excision/Biopsy/Incision and Drainage Level 3 Excision/Biopsy/Incision and Drainage Levell Breast/Lymphatic Surgery and Related Procedures Level2 Breast/Lymphatic Surgery and Related Procedures Level3 Breast/Lymphatic Surgery and Related Procedures Level4 Breast/Lymphatic Surgery and Related Procedures Level 2 Musculoskeletal Procedures Level 3 Musculoskeletal Procedures Level 4 Musculoskeletal Procedures Level 5 Musculoskeletal Procedures Level 6 Musculoskeletal Procedures Level 3 Airway Endoscopy Level 4 Airway Endoscopy Level 5 Airway Endoscopy Level 3 ENT Procedures Level 4 ENT Procedures Level 5 ENT Procedures Cochlear Implant Procedure Level 3 Vascular Procedures Level 4 Vascular Procedures Level 1 Endovascular Procedures Level 2 Endovascular Procedures Level 3 Endovascular Procedures Level 4 Endovascular Procedures Implantation Wireless PA Pressure Monitor Level 1 Electrophysiologic Procedures Level 2 Electrophysiologic Procedures Level 3 Electrophysiologic Procedures Level 2 Pacemaker and Similar Procedures Level 3 Pacemaker and Similar Procedures Level 4 Pacemaker and Similar Procedures Levell ICD and Similar Procedures Jkt 247001 PO 00000 Frm 00029 Fmt 4701 Sfmt 4725 E:\FR\FM\21NOR2.SGM Clinical Family EBIDX EBIDX BREAS New C-APC BREAS BREAS BREAS ORTHO ORTHO ORTHO ORTHO ORTHO AENDO AENDO AENDO ENTXX ENTXX ENTXX COCHL VASCX VASCX EVASC EVASC EVASC EVASC WPMXX EPHYS EPHYS EPHYS AICDP AICDP AICDP AICDP 21NOR2 * * * ER21NO18.009</GPH> CY 2019 APC Group Title C-APC 58846 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations C-APC 5232 5244 5302 5303 5313 5331 5341 5361 5362 5373 5374 5375 5376 5377 5414 5415 5416 5431 5432 5462 5463 5464 5471 5491 5492 5493 5494 5495 5503 5504 5627 5881 8011 CY 2019 APC Group Title Level2 ICD and Similar Procedures Level 4 Blood Product Exchange and Related Services Level 2 Upper GI Procedures Level3 Upper GI Procedures Level3 Lower GI Procedures Complex GI Procedures Abdominal/Peritoneal/Biliary and Related Procedures Level 1 Laparoscopy and Related Services Level 2 Laparoscopy and Related Services Level 3 Urology and Related Services Level 4 Urology and Related Services Level 5 Urology and Related Services Level 6 Urology and Related Services Level 7 Urology and Related Services Level 4 Gynecologic Procedures Level 5 Gynecologic Procedures Level 6 Gynecologic Procedures Levell Nerve Procedures Level2 Nerve Procedures Level 2 N eurostimulator and Related Procedures Level 3 N eurostimulator and Related Procedures Level 4 N eurostimulator and Related Procedures Implantation of Drug Infusion Device Level 1 Intraocular Procedures Level 2 Intraocular Procedures Level 3 Intraocular Procedures Level 4 Intraocular Procedures Level 5 Intraocular Procedures Level3 Extraocular, Repair, and Plastic Eye Procedures Level4 Extraocular, Repair, and Plastic Eye Procedures Level 7 Radiation Therapy Ancillary Outpatient Services When Patient Dies Comprehensive Observation Services Clinical Family AICDP New C-APC SCTXX GIXXX GIXXX GIXXX GIXXX GIXXX LAP XX LAP XX UROXX UROXX UROXX UROXX UROXX GYNXX GYNXX GYNXX NERVE NERVE NSTIM NSTIM NSTIM PUMPS INEYE INEYE INEYE INEYE INEYE EXEYE EXEYE RADTX N/A N/A AENDO = Airway Endoscopy AICDP = Automatic Implantable Cardiac Defibrillators, Pacemakers, and Related Devices. VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 PO 00000 Frm 00030 Fmt 4701 Sfmt 4725 E:\FR\FM\21NOR2.SGM 21NOR2 ER21NO18.010</GPH> khammond on DSK30JT082PROD with RULES2 C-APC Clinical Family Descriptor Key: Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations khammond on DSK30JT082PROD with RULES2 (3) Exclusion of Procedures Assigned to New Technology APCs From the C–APC Policy Services that are assigned to New Technology APCs are typically new procedures that do not have sufficient claims history to establish an accurate payment for the procedures. Beginning in CY 2002, we retain services within New Technology APC groups until we gather sufficient claims data to enable us to assign the service to an appropriate clinical APC. This policy allows us to move a service from a New Technology APC in less than 2 years if sufficient data are available. It also allows us to retain a service in a New Technology APC for more than 2 years if sufficient data upon which to base a decision for reassignment have not been collected (82 FR 59277). The C–APC payment policy packages payment for adjunctive and secondary items, services, and procedures into the most costly primary procedure under the OPPS at the claim level. When a procedure assigned to a New Technology APC is included on the claim with a primary procedure, identified by OPPS status indicator ‘‘J1’’, payment for the new technology service is typically packaged into the payment for the primary procedure. Because the new technology service is not separately paid in this scenario, the overall number of single claims available to determine an appropriate clinical APC for the new service is reduced. This is contrary to the objective of the New Technology APC payment policy, which is to gather sufficient claims data to enable us to VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 assign the service to an appropriate clinical APC. For example, for CY 2017, there were seven claims generated for HCPCS code 0100T (Placement of a subconjunctival retinal prosthesis receiver and pulse generator, and implantation of intraocular retinal electrode array, with vitrectomy), which involves the use of the Argus® II Retinal Prosthesis System. However, several of these claims were not available for ratesetting because HCPCS code 0100T was reported with a ‘‘J1’’ procedure and, therefore, payment was packaged into the associated C– APC payment. If these services had been separately paid under the OPPS, there would be at least two additional single claims available for ratesetting. As mentioned previously, the purpose of the new technology APC policy is to ensure that there are sufficient claims data for new services, which is particularly important for services with a low volume such as procedures described by HCPCS code 0100T. Another concern is the costs reported for the claims when payment is not packaged for a new technology procedure may not be representative of all of the services included on a claim that is generated, which may also affect our ability to assign the new service to the most appropriate clinical APC. To address this issue and help ensure that there is sufficient claims data for services assigned to New Technology APCs, in the CY 2019 OPPS/ASC proposed rule (83 FR 37063), we proposed to exclude payment for any procedure that is assigned to a New Technology APC (APCs 1491 through 1599 and APCs 1901 through 1908) from being packaged when included on a PO 00000 Frm 00031 Fmt 4701 Sfmt 4700 claim with a ‘‘J1’’ service assigned to a C–APC. This issue is also addressed in section III.C.3.b. of the proposed rule and this final rule with comment period. Comment: Numerous commenters supported the proposal. Response: We appreciate the commenters’ support. After consideration of the public comments we received, we are finalizing the proposal, without modification, to exclude payment for any procedure that is assigned to a New Technology APC (APCs 1491 through 1599 and APCs 1901 through 1908) from being packaged when included on a claim with a ‘‘J1’’ service assigned to a C–APC. c. Calculation of Composite APC Criteria-Based Costs As discussed in the CY 2008 OPPS/ ASC final rule with comment period (72 FR 66613), we believe it is important that the OPPS enhance incentives for hospitals to provide necessary, high quality care as efficiently as possible. For CY 2008, we developed composite APCs to provide a single payment for groups of services that are typically performed together during a single clinical encounter and that result in the provision of a complete service. Combining payment for multiple, independent services into a single OPPS payment in this way enables hospitals to manage their resources with maximum flexibility by monitoring and adjusting the volume and efficiency of services themselves. An additional advantage to the composite APC model is that we can use data from correctly coded multiple procedure claims to E:\FR\FM\21NOR2.SGM 21NOR2 ER21NO18.011</GPH> BILLING CODE 4120–01–C 58847 58848 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations khammond on DSK30JT082PROD with RULES2 calculate payment rates for the specified combinations of services, rather than relying upon single procedure claims which may be low in volume and/or incorrectly coded. Under the OPPS, we currently have composite policies for mental health services and multiple imaging services. (We note that, in the CY 2018 OPPS/ASC final rule with comment period, we finalized a policy to delete the composite APC 8001 (LDR Prostate Brachytherapy Composite) for CY 2018 and subsequent years.) We refer readers to the CY 2008 OPPS/ASC final rule with comment period (72 FR 66611 through 66614 and 66650 through 66652) for a full discussion of the development of the composite APC methodology, and the CY 2012 OPPS/ ASC final rule with comment period (76 FR 74163) and the CY 2018 OPPS/ASC final rule with comment period (82 FR 59241 through 59242 and 59246 through 52950) for more recent background. In the CY 2019 OPPS/ASC proposed rule (83 FR 37064), for CY 2019 and subsequent years, we proposed to continue our composite APC payment policies for mental health services and multiple imaging services, as discussed below. In addition, as discussed in section II.A.2.b.(3) and II.A.2.c. of the CY 2018 OPPS/ASC proposed rule and final rule with comment period (82 FR 33577 through 33578 and 59241 through 59242 and 59246, respectively), in the CY 2019 proposed rule, we proposed to continue to assign CPT code 55875 (Transperineal placement of needles or catheters into prostate for interstitial radioelement application, with or without cystoscopy) to status indicator ‘‘J1’’ and to continue to assign the services described by CPT code 55875 to C–APC 5375 (Level 5 Urology and Related Services) for CY 2019. We did not receive any public comments on these proposed assignments. Therefore, for CY 2019, we are continuing to assign CPT code 55875 to status indicator ‘‘J1’’ and to assign services described by CPT code 55875 to C–APC 5375. (1) Mental Health Services Composite APC In the CY 2019 OPPS/ASC proposed rule (83 FR 37064), we proposed to continue our longstanding policy of limiting the aggregate payment for specified less resource-intensive mental health services furnished on the same date to the payment for a day of partial hospitalization services provided by a hospital, which we consider to be the most resource intensive of all outpatient mental health services. We refer readers to the April 7, 2000 OPPS final rule with comment period (65 FR 18452 through 18455) for the initial discussion VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 of this longstanding policy and the CY 2012 OPPS/ASC final rule with comment period (76 FR 74168) for more recent background. In the CY 2017 OPPS/ASC final rule with comment period (81 FR 79588 through 79589), we finalized a policy to combine the existing Level 1 and Level 2 hospital-based PHP APCs into a single hospital-based PHP APC, and thereby discontinue APCs 5861 (Level 1 Partial Hospitalization (3 services) for HospitalBased PHPs) and 5862 (Level 2 Partial Hospitalization (4 or more services) for Hospital-Based PHPs) and replace them with APC 5863 (Partial Hospitalization (3 or more services per day)). In the CY 2018 OPPS/ASC proposed rule and final rule with comment period (82 FR 33580 through 33581 and 59246 through 59247, respectively), we proposed and finalized the policy for CY 2018 and subsequent years that, when the aggregate payment for specified mental health services provided by one hospital to a single beneficiary on a single date of service, based on the payment rates associated with the APCs for the individual services, exceeds the maximum per diem payment rate for partial hospitalization services provided by a hospital, those specified mental health services will be paid through composite APC 8010 (Mental Health Services Composite). In addition, we set the payment rate for composite APC 8010 for CY 2018 at the same payment rate that will be paid for APC 5863, which is the maximum partial hospitalization per diem payment rate for a hospital, and finalized a policy that the hospital will continue to be paid the payment rate for composite APC 8010. Under this policy, the I/OCE will continue to determine whether to pay for these specified mental health services individually, or to make a single payment at the same payment rate established for APC 5863 for all of the specified mental health services furnished by the hospital on that single date of service. We continue to believe that the costs associated with administering a partial hospitalization program at a hospital represent the most resource intensive of all outpatient mental health services. Therefore, we do not believe that we should pay more for mental health services under the OPPS than the highest partial hospitalization per diem payment rate for hospitals. In the CY 2019 OPPS/ASC proposed rule (83 FR 37064), for CY 2019, we proposed that when the aggregate payment for specified mental health services provided by one hospital to a single beneficiary on a single date of service, based on the payment rates PO 00000 Frm 00032 Fmt 4701 Sfmt 4700 associated with the APCs for the individual services, exceeds the maximum per diem payment rate for partial hospitalization services provided by a hospital, those specified mental health services would be paid through composite APC 8010 for CY 2019. In addition, we proposed to set the proposed payment rate for composite APC 8010 at the same payment rate that we proposed for APC 5863, which is the maximum partial hospitalization per diem payment rate for a hospital, and that the hospital continue to be paid the proposed payment rate for composite APC 8010. Comment: One commenter supported equalizing payments between the outpatient APC rate and the PHP per diem rate. The commenter also supported the increase in the proposed CY 2019 payment rates from the CY 2018 payment rates. Response: We appreciate the commenter’s support. After consideration of the public comment we received, we are finalizing our CY 2019 proposal, without modification, that when the aggregate payment for specified mental health services provided by one hospital to a single beneficiary on a single date of service, based on the payment rates associated with the APCs for the individual services, exceeds the maximum per diem payment rate for partial hospitalization services provided by a hospital, those specified mental health services will be paid through composite APC 8010 for CY 2019. In addition, we are finalizing our CY 2019 proposal, without modification, to set the payment rate for composite APC 8010 at the same payment rate as APC 5863, which is the maximum partial hospitalization per diem payment rate for a hospital, and that the hospital continue to be paid the payment rate for composite APC 8010. (2) Multiple Imaging Composite APCs (APCs 8004, 8005, 8006, 8007, and 8008) Effective January 1, 2009, we provide a single payment each time a hospital submits a claim for more than one imaging procedure within an imaging family on the same date of service, in order to reflect and promote the efficiencies hospitals can achieve when performing multiple imaging procedures during a single session (73 FR 41448 through 41450). We utilize three imaging families based on imaging modality for purposes of this methodology: (1) Ultrasound; (2) computed tomography (CT) and computed tomographic angiography (CTA); and (3) magnetic resonance E:\FR\FM\21NOR2.SGM 21NOR2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations khammond on DSK30JT082PROD with RULES2 imaging (MRI) and magnetic resonance angiography (MRA). The HCPCS codes subject to the multiple imaging composite policy and their respective families are listed in Table 12 of the CY 2014 OPPS/ASC final rule with comment period (78 FR 74920 through 74924). While there are three imaging families, there are five multiple imaging composite APCs due to the statutory requirement under section 1833(t)(2)(G) of the Act that we differentiate payment for OPPS imaging services provided with and without contrast. While the ultrasound procedures included under the policy do not involve contrast, both CT/CTA and MRI/MRA scans can be provided either with or without contrast. The five multiple imaging composite APCs established in CY 2009 are: • APC 8004 (Ultrasound Composite); • APC 8005 (CT and CTA without Contrast Composite); • APC 8006 (CT and CTA with Contrast Composite); • APC 8007 (MRI and MRA without Contrast Composite); and • APC 8008 (MRI and MRA with Contrast Composite). We define the single imaging session for the ‘‘with contrast’’ composite APCs as having at least one or more imaging procedures from the same family performed with contrast on the same date of service. For example, if the hospital performs an MRI without contrast during the same session as at least one other MRI with contrast, the hospital will receive payment based on the payment rate for APC 8008, the ‘‘with contrast’’ composite APC. We make a single payment for those imaging procedures that qualify for payment based on the composite APC payment rate, which includes any packaged services furnished on the same date of service. The standard (noncomposite) APC assignments continue to apply for single imaging procedures and multiple imaging VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 procedures performed across families. For a full discussion of the development of the multiple imaging composite APC methodology, we refer readers to the CY 2009 OPPS/ASC final rule with comment period (73 FR 68559 through 68569). In the CY 2019 OPPS/ASC proposed rule (83 FR 37065), we proposed, for CY 2019 and subsequent years, to continue to pay for all multiple imaging procedures within an imaging family performed on the same date of service using the multiple imaging composite APC payment methodology. We stated that we continue to believe that this policy would reflect and promote the efficiencies hospitals can achieve when performing multiple imaging procedures during a single session. The proposed CY 2019 payment rates for the five multiple imaging composite APCs (APCs 8004, 8005, 8006, 8007, and 8008) were based on proposed geometric mean costs calculated from a partial year of CY 2017 claims available for the CY 2019 OPPS/ASC proposed rule that qualified for composite payment under the current policy (that is, those claims reporting more than one procedure within the same family on a single date of service). To calculate the proposed geometric mean costs, we used the same methodology that we have used to calculate the geometric mean costs for these composite APCs since CY 2014, as described in the CY 2014 OPPS/ASC final rule with comment period (78 FR 74918). The imaging HCPCS codes referred to as ‘‘overlap bypass codes’’ that we removed from the bypass list for purposes of calculating the proposed multiple imaging composite APC geometric mean costs, in accordance with our established methodology as stated in the CY 2014 OPPS/ASC final rule with comment period (78 FR 74918), were identified by asterisks in Addendum N to the CY 2019 OPPS/ASC proposed rule (which is available via the internet on the CMS website) and PO 00000 Frm 00033 Fmt 4701 Sfmt 4700 58849 were discussed in more detail in section II.A.1.b. of the CY 2019 OPPS/ASC proposed rule. For the CY 2019 OPPS/ASC proposed rule, we were able to identify approximately 638,902 ‘‘single session’’ claims out of an estimated 1.7 million potential claims for payment through composite APCs from our ratesetting claims data, which represents approximately 37 percent of all eligible claims, to calculate the proposed CY 2019 geometric mean costs for the multiple imaging composite APCs. Table 4 of the CY 2019 OPPS/ASC proposed rule listed the proposed HCPCS codes that would be subject to the multiple imaging composite APC policy and their respective families and approximate composite APC proposed geometric mean costs for CY 2019. We did not receive any public comments on these proposals. However, in the CY 2019 OPPS/ASC proposed rule (83 FR 37065), we inadvertently omitted the new CPT codes that will be effective January 1, 2019 from Table 4. We did include these codes in Addendum M to the proposed rule (which was available via the internet on the CMS website). Therefore, new Category I CPT codes that will be effective January 1, 2019 are flagged with comment indicator ‘‘NI’’ in Addendum M to this CY 2019 OPPS/ ASC final rule with comment period to indicate that we have assigned the codes an interim APC assignment for CY 2019. We are inviting public comments in this CY 2019 OPPS/ASC final rule with comment period on the interim APC assignments and payment rates for the new codes in Addendum M that will be finalized in the CY 2020 OPPS/ASC final rule with comment period. Table 8 below lists the HCPCS codes that will be subject to the multiple imaging composite APC policy and their respective families and approximate composite APC final geometric mean costs for CY 2019. BILLING CODE 4120–01–P E:\FR\FM\21NOR2.SGM 21NOR2 58850 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations TABLE 8.-0PPS IMAGING FAMILIES AND MULTIPLE IMAGING PROCEDURE COMPOSITE APCs Family 1- Ultrasound CY 2019 APC 8004 (Ultrasound Composite) CY 2019 Approximate APC Geometric Mean Cost = $302 76700 76705 76770 76776 76831 76856 76857 76981 76982 Us exam, abdom, complete Echo exam of abdomen Us exam abdo back wall, comp Us exam k transpl w/Doppler Echo exam, uterus Us exam, pelvic, complete Us exam, pelvic, limited Us parenchyma Use 1st target lesion Family 2 - CT and CTA with and without Contrast 70450 70480 70486 70490 71250 72125 72128 72131 72192 73200 73700 74150 74261 Ct head/brain w/o dye Ct orbit/ear/fossa w/o dye Ct maxillofacial w/o dye Ct soft tissue neck w/o dye Ct thorax w/o dye Ct neck spine w/o dye Ct chest spine w/o dye Ct lumbar spine w/o dye Ct pelvis w/o dye Ct upper extremity w/o dye Ct lower extremity w/o dye Ct abdomen w/o dye Ct colonography, w/o dye 74176 Ct angio abd & pelvis CY 2019 Approximate APC Geometric Mean Cost = $485 Ct maxillofacial w/dye Ct head/brain w/dye Ct head/brain w/o & w/dye Ct orbit/ear/fossa w/dye Ct orbit/ear/fossa w/o & w/dye khammond on DSK30JT082PROD with RULES2 CY 2019 APC 8006 (CT and CTA with Contrast Composite) 70487 70460 70470 70481 70482 VerDate Sep<11>2014 20:42 Nov 20, 2018 CY 2019 Approximate APC Geometric Mean Cost = $267 Jkt 247001 PO 00000 Frm 00034 Fmt 4701 Sfmt 4725 E:\FR\FM\21NOR2.SGM 21NOR2 ER21NO18.012</GPH> CY 2019 APC 8005 (CT and CTA without Contrast Composite)* Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations 58851 70488 Ct maxillofacial w/o & w/dye 70491 Ct soft tissue neck w/dye 70492 Ct sft tsue nck w/o & w/dye 70496 Ct angiography, head 70498 Ct angiography, neck Ct thorax w/dye 71260 71270 Ct thorax w/o & w/dye 71275 Ct angiography, chest Ct neck spine w/dye 72126 72127 Ct neck spine w/o & w/dye 72129 Ct chest spine w/dye 72130 Ct chest spine w/o & w/dye Ct lumbar spine w/dye 72132 72133 Ct lumbar spine w/o & w/dye 72191 Ct angiograph pelv w/o & w/dye 72193 Ct pelvis w/dye 72194 Ct pelvis w/o & w/dye 73201 Ct upper extremity w/dye 73202 Ct uppr extremity w/o & w/dye 73206 Ct angio upr extrm w/o & w/dye 73701 Ct lower extremity w/dye 73702 Ct lwr extremity w/o & w/dye Ct angio lwr extr w/o & w/dye 73706 74160 Ct abdomen w/dye 74170 Ct abdomen w/o & w/dye Ct angio abdom w/o & w/dye 74175 74262 Ct colonography, w/dye Ct angio abdominal arteries 75635 74177 Ct angio abd & pelv w/contrast 74178 Ct angio abd & pelv 1+ regns * If a "without contrast" CT or CTA procedure is performed during the same session as a "with contrast" CT or CTA procedure, the I/OCE assigns the procedure to APC 8006 rather than APC 8005. Family 3 - MRI and MRA with and without Contrast 70336 70540 70544 VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 PO 00000 CY 2019 Approximate APC Geometric Mean Cost = $549 Magnetic image, jaw joint Mri orbit/face/neck w/o dye Mr angiography head w/o dye Frm 00035 Fmt 4701 Sfmt 4725 E:\FR\FM\21NOR2.SGM 21NOR2 ER21NO18.013</GPH> khammond on DSK30JT082PROD with RULES2 CY 2019 APC 8007 (MRI and MRA without Contrast Composite)* Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations 70547 70551 70554 71550 72141 72146 72148 72195 73218 73221 73718 73721 74181 75557 75559 76391 77046 77047 C8901 C8910 C8913 C8919 C8932 C8935 CY 2019 APC 8008 (MRI and MRA with Contrast Composite) 70549 70542 70543 70545 70546 70547 70548 70552 70553 71551 71552 72142 72147 VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 PO 00000 Frm 00036 Fmt 4701 Mr angiography neck w/o dye Mri brain w/o dye Fmri brain by tech Mri chest w/o dye Mri neck spine w/o dye Mri chest spine w/o dye Mri lumbar spine w/o dye Mri pelvis w/o dye Mri upper extremity w/o dye Mri joint upr extrem w/o dye Mri lower extremity w/o dye Mri jnt oflwr extre w/o dye Mri abdomen w/o dye Cardiac mri for morph Cardiac mri w/stress img Mr elastography Mri breast c- unilateral Mri breast c- bilateral MRA w/o cont, abd MRA w/o cont, chest MRA w/o cont, lwr ext MRA w/o cont, pelvis MRA, w/o dye, spinal canal MRA, w/o dye, upper extr CY 2019 Approximate APC Geometric Mean Cost = $863 Mr angiograph neck w/o & w/dye Mri orbit/face/neck w/dye Mri orbt/fac/nck w/o & w/dye Mr angiography head w/dye Mr angiograph head w/o & w/dye Mr angiography neck w/o dye Mr angiography neck w/dye Mri brain w/dye Mri brain w/o & w/dye Mri chest w/dye Mri chest w/o & w/dye Mri neck spine w/dye Mri chest spine w/dye Sfmt 4725 E:\FR\FM\21NOR2.SGM 21NOR2 ER21NO18.014</GPH> khammond on DSK30JT082PROD with RULES2 58852 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations 58853 BILLING CODE 4120–01–C 3. Changes to Packaged Items and Services a. Background and Rationale for Packaging in the OPPS Like other prospective payment systems, the OPPS relies on the concept VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 PO 00000 Frm 00037 Fmt 4701 Sfmt 4700 of averaging to establish a payment rate for services. The payment may be more or less than the estimated cost of providing a specific service or a bundle of specific services for a particular patient. The OPPS packages payments E:\FR\FM\21NOR2.SGM 21NOR2 ER21NO18.015</GPH> khammond on DSK30JT082PROD with RULES2 72149 Mri lumbar spine w/dye 72156 Mri neck spine w/o & w/dye 72157 Mri chest spine w/o & w/dye 72158 Mri lumbar spine w/o & w/dye 72196 Mri pelvis w/dye Mri pelvis w/o & w/dye 72197 73219 Mri upper extremity w/dye 73220 Mri uppr extremity w/o & w/dye Mri joint upr extrem w/dye 73222 73223 Mri joint upr extr w/o & w/dye 73719 Mri lower extremity w/dye 73720 Mri lwr extremity w/o & w/dye Mri joint oflwr extr w/dye 73722 73723 Mri joint lwr extr w/o & w/dye 74182 Mri abdomen w/dye 74183 Mri abdomen w/o & w/dye 75561 Cardiac mri for morph w/dye Card mri w/stress img & dye 75563 C8900 MRA w/cont, abd C8902 MRA w/o fol w/cont, abd MRI w/cont, breast, uni C8903 C8905 MRI w/o fol w/cont, brst, un C8906 MRI w/cont, breast, bi MRI w/o fol w/cont, breast, C8908 MRA w/cont, chest C8909 C8911 MRA w/o fol w/cont, chest C8912 MRA w/cont, lwr ext C8914 MRA w/o fol w/cont, lwr ext C8918 MRA w/cont, pelvis C8920 MRA w/o fol w/cont, pelvis C8931 MRA, w/dye, spinal canal MRA, w/o&w/dye, spinal canal C8933 C8934 MRA, w/dye, upper extremity MRA, w/o&w/dye, upper extr C8936 * If a "without contrast" MRI or MRA procedure is performed during the same session as a "with contrast" MRI or MRA procedure, the IIOCE assigns the procedure to APC 8008 rather than APC 8007. khammond on DSK30JT082PROD with RULES2 58854 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations for multiple interrelated items and services into a single payment to create incentives for hospitals to furnish services most efficiently and to manage their resources with maximum flexibility. Our packaging policies support our strategic goal of using larger payment bundles in the OPPS to maximize hospitals’ incentives to provide care in the most efficient manner. For example, where there are a variety of devices, drugs, items, and supplies that could be used to furnish a service, some of which are more costly than others, packaging encourages hospitals to use the most cost-efficient item that meets the patient’s needs, rather than to routinely use a more expensive item, which often occurs if separate payment is provided for the item. Packaging also encourages hospitals to effectively negotiate with manufacturers and suppliers to reduce the purchase price of items and services or to explore alternative group purchasing arrangements, thereby encouraging the most economical health care delivery. Similarly, packaging encourages hospitals to establish protocols that ensure that necessary services are furnished, while scrutinizing the services ordered by practitioners to maximize the efficient use of hospital resources. Packaging payments into larger payment bundles promotes the predictability and accuracy of payment for services over time. Finally, packaging may reduce the importance of refining service-specific payment because packaged payments include costs associated with higher cost cases requiring many ancillary items and services and lower cost cases requiring fewer ancillary items and services. Because packaging encourages efficiency and is an essential component of a prospective payment system, packaging payments for items and services that are typically integral, ancillary, supportive, dependent, or adjunctive to a primary service has been a fundamental part of the OPPS since its implementation in August 2000. For an extensive discussion of the history and background of the OPPS packaging policy, we refer readers to the CY 2000 OPPS final rule (65 FR 18434), the CY 2008 OPPS/ASC final rule with comment period (72 FR 66580), the CY 2014 OPPS/ASC final rule with comment period (78 FR 74925), the CY 2015 OPPS/ASC final rule with comment period (79 FR 66817), the CY 2016 OPPS/ASC final rule with comment period (80 FR 70343), the CY 2017 OPPS/ASC final rule with comment period (81 FR 79592), and the VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 CY 2018 OPPS/ASC final rule with comment period (82 FR 59250). As we continue to develop larger payment groups that more broadly reflect services provided in an encounter or episode of care, we have expanded the OPPS packaging policies. Most, but not necessarily all, categories of items and services currently packaged in the OPPS are listed in 42 CFR 419.2(b). Our overarching goal is to make payments for all services under the OPPS more consistent with those of a prospective payment system and less like those of a per-service fee schedule, which pays separately for each coded item. As a part of this effort, we have continued to examine the payment for items and services provided under the OPPS to determine which OPPS services can be packaged to further achieve the objective of advancing the OPPS toward a more prospective payment system. For CY 2019, we examined the items and services currently provided under the OPPS, reviewing categories of integral, ancillary, supportive, dependent, or adjunctive items and services for which we believe payment would be appropriately packaged into payment of the primary service that they support. Specifically, we examined the HCPCS code definitions (including CPT code descriptors) and outpatient hospital billing patterns to determine whether there were categories of codes for which packaging would be appropriate according to existing OPPS packaging policies or a logical expansion of those existing OPPS packaging policies. In the CY 2019 OPPS/ASC proposed rule (83 37067 through 37071), for CY 2019, we proposed to conditionally package the costs of selected newly identified ancillary services into payment with a primary service where we believe that the packaged item or service is integral, ancillary, supportive, dependent, or adjunctive to the provision of care that was reported by the primary service HCPCS code. Below we discuss the proposed and finalized changes to the packaging policies beginning in CY 2019. b. CY 2019 Packaging Policy for NonOpioid Pain Management Treatments In the CY 2018 OPPS/ASC proposed rule (82 FR 33588), within the framework of existing packaging categories, such as drugs that function as supplies in a surgical procedure or diagnostic test or procedure, we requested stakeholder feedback on common clinical scenarios involving currently packaged items and services described by HCPCS codes that stakeholders believe should not be PO 00000 Frm 00038 Fmt 4701 Sfmt 4700 packaged under the OPPS. We also expressed interest in stakeholder feedback on common clinical scenarios involving separately payable HCPCS codes for which payment would be most appropriately packaged under the OPPS. Commenters expressed a variety of views on packaging under the OPPS. In the CY 2018 OPPS/ASC final rule with comment period, we summarized the comments received in response to our request (82 FR 59255). The comments ranged from requests to unpackage most items and services that are either conditionally or unconditionally packaged under the OPPS, including drugs and devices, to specific requests for separate payment for a specific drug or device. We stated in the CY 2018 OPPS/ASC final rule with comment period that CMS would continue to explore and evaluate packaging policies under the OPPS and consider these policies in future rulemaking. In addition to stakeholder feedback regarding OPPS packaging policies, the President’s Commission on Combating Drug Addiction and the Opioid Crisis (the Commission) recently recommended that CMS examine payment policies for certain drugs that function as a supply, specifically nonopioid pain management treatments. The Commission was established in 2017 to study ways to combat and treat drug abuse, addiction, and the opioid crisis. The Commission’s report 3 included a recommendation for CMS to ‘‘. . . review and modify ratesetting policies that discourage the use of nonopioid treatments for pain, such as certain bundled payments that make alternative treatment options cost prohibitive for hospitals and doctors, particularly those options for treating immediate postsurgical pain. . . .’’ 4 With respect to the packaging policy, the Commission’s report states that ‘‘. . . the current CMS payment policy for ‘supplies’ related to surgical procedures creates unintended incentives to prescribe opioid medications to patients for postsurgical pain instead of administering nonopioid pain medications. Under current policies, CMS provides one all-inclusive bundled payment to hospitals for all ‘surgical supplies,’ which includes hospital-administered drug products intended to manage patients’ postsurgical pain. This policy results in the hospitals receiving the same fixed fee from Medicare whether the surgeon 3 President’s Commission on Combating Drug Addiction and the Opioid Crisis, Report (2017). Available at: https://www.whitehouse.gov/sites/ whitehouse.gov/files/images/Final_Report_Draft_ 11-1-2017.pdf. 4 Ibid, at page 57, Recommendation 19. E:\FR\FM\21NOR2.SGM 21NOR2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations administers a non-opioid medication or not.’’ 5 HHS also presented an Opioid Strategy in April 2017 6 that aims in part to support cutting-edge research and advance the practice of pain management. On October 26, 2017, the opioid crisis was declared a national public health emergency under Federal law 7 and this determination was renewed on April 20, 2018.8 As discussed in the CY 2019 OPPS/ ASC proposed rule (83 FR 37068 through 37071), in response to stakeholder comments on the CY 2018 OPPS/ASC proposed rule and in light of the recommendations regarding payment policies for certain drugs, we recently evaluated the impact of our packaging policy for drugs that function as a supply when used in a surgical procedure on the utilization of these drugs in both the hospital outpatient department and the ASC setting. Currently, as noted above, drugs that function as a supply are packaged under the OPPS and the ASC payment system, regardless of the costs of the drugs. The costs associated with packaged drugs that function as a supply are included in the ratesetting methodology for the surgical procedures with which they are billed and the payment rate for the associated procedure reflects the costs of the packaged drugs and other packaged items and services to the extent they are billed with the procedure. In our evaluation, we used currently available data to analyze the utilization patterns associated with specific drugs that function as a supply over a 5-year time period (CYs 2013 through 2017) to determine whether this packaging policy has reduced the use of these drugs. If the packaging policy discouraged the use of drugs that function as a supply or impeded access to these products, we would expect to see a significant decline in utilization of these drugs over time, although we note that a decline in utilization could also reflect other factors, such as the availability of alternative products. We did not observe significant declines in the total number of units used in the hospital outpatient department for a majority of the drugs included in our analysis. khammond on DSK30JT082PROD with RULES2 5 Ibid. 6 Available at: https://www.hhs.gov/about/ leadership/secretary/speeches/2017-speeches/ secretary-price-announces-hhs-strategy-for-fightingopioid-crisis/. 7 Available at: https://www.hhs.gov/about/news/ 2017/10/26/hhs-acting-secretary-declares-publichealth-emergency-address-national-opioidcrisis.html. 8 Available at: https://www.phe.gov/emergency/ news/healthactions/phe/Pages/default.aspx. VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 In fact, under the OPPS, we observed the opposite effect for several drugs that function as a supply, including Exparel (HCPCS code C9290). Exparel is a liposome injection of bupivacaine, an amide local anesthetic, indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. In 2011, Exparel was approved by the FDA for administration into the postsurgical site to provide postsurgical analgesia.9 Exparel had pass-through payment status from CYs 2012 through 2014 and was separately paid under both the OPPS and the ASC payment system during this 3-year period. Beginning in CY 2015, Exparel was packaged as a surgical supply under both the OPPS and the ASC payment system. Exparel is currently the only non-opioid pain management drug that is packaged as a drug that functions as a supply when used in a surgical procedure under the OPPS and the ASC payment system. From CYs 2013 through 2017, there was an overall increase in the OPPS Medicare utilization of Exparel of approximately 229 percent (from 2.3 million units to 7.7 million units) during this 5-year time period. The total number of claims reporting Exparel increased by 222 percent (from 10,609 claims to 34,183 claims) over this time period. This increase in utilization continued, even after the 3-year drug pass-through payment period ended for this product in 2014, with 18 percent overall growth in the total number of units used from CYs 2015 through 2017 (from 6.5 million units to 7.7 million units). The number of claims reporting Exparel increased by 21 percent during this time period (from 28,166 claims to 34,183 claims). Thus, we have not found evidence to support the notion that the OPPS packaging policy has had an unintended consequence of discouraging the use of non-opioid treatment for postsurgical pain management in the hospital outpatient department. Therefore, based on this data analysis, we stated in the CY 2019 OPPS/ASC proposed rule that we did not believe that changes were necessary under the OPPS for the packaged drug policy for drugs that function as a surgical supply when used in a surgical procedure in this setting at this time. In terms of Exparel in particular, we have received several requests to pay separately for the drug rather than packaging payment for it as a surgical supply. In the CY 2015 OPPS/ASC final rule with comment period (79 FR 66874 and 66875), in response to comments 9 Available at: https://www.accessdata.fda.gov/ drugsatfda_docs/label/2011/022496s000lbl.pdf. PO 00000 Frm 00039 Fmt 4701 Sfmt 4700 58855 from stakeholders requesting separate payment for Exparel, we stated that we considered Exparel to be a drug that functions as a surgical supply because it is indicated for the alleviation of postoperative pain. We also stated that we consider all items related to the surgical outcome and provided during the hospital stay in which the surgery is performed, including postsurgical pain management drugs, to be part of the surgery for purposes of our drug and biological surgical supply packaging policy. In the CY 2018 OPPS/ASC final rule with comment period (82 FR 59345), we reiterated our position with regard to payment for Exparel, stating that we believed that payment for this drug is appropriately packaged with the primary surgical procedure. In addition, we have reviewed recently available literature with respect to Exparel, including a briefing document 10 submitted for the FDA Advisory Committee Meeting held February 14– 15, 2018, by the manufacturer of Exparel that notes that ‘‘. . . Bupivacaine, the active pharmaceutical ingredient in Exparel, is a local anesthetic that has been used for infiltration/field block and peripheral nerve block for decades’’ and that ‘‘since its approval, Exparel has been used extensively, with an estimated 3.5 million patient exposures in the US.’’ 11 On April 6, 2018, the FDA approved Exparel’s new indication for use as an interscalene brachial plexus nerve block to produce postsurgical regional analgesia.12 Therefore, we also stated in the CY 2019 OPPS/ASC proposed rule that, based on our review of currently available OPPS Medicare claims data and public information from the manufacturer of the drug, we did not believe that the OPPS packaging policy had discouraged the use of Exparel for either of the drug’s indications. Accordingly, we continue to believe it is appropriate to package payment for Exparel as we do with other postsurgical pain management drugs when it is furnished in a hospital outpatient department. However, we invited public comments on whether separate payment would nonetheless further incentivize appropriate use of Exparel in the hospital outpatient setting and peerreviewed evidence that such increased utilization would lead to a decrease in 10 Food and Drug Administration, Meeting of the Anesthetic and Analgesic Drug Products Advisory Committee Briefing Document (2018). Available at: https://www.fda.gov/downloads/ AdvisoryCommittees/CommitteesMeetingMaterials/ Drugs/AnestheticAndAnalgesicDrugProducts AdvisoryCommittee/UCM596314.pdf. 11 Ibid, page 9. 12 Available at: https://www.accessdata.fda.gov/ drugsatfda_docs/label/2018/022496s009lbledt.pdf. E:\FR\FM\21NOR2.SGM 21NOR2 khammond on DSK30JT082PROD with RULES2 58856 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations opioid use and addiction among Medicare beneficiaries. Comment: Several commenters, including hospital associations, medical specialty societies, and drug manufacturers, requested that CMS pay separately for Exparel in the hospital outpatient setting. Some of these commenters noted that Exparel is used more frequently in this setting and the use of non-opioid pain management treatments should also be encouraged in the hospital outpatient department. The manufacturer of Exparel, Pacira Pharmaceuticals, stated that since the drug became packaged in 2015, utilization of the drug in the hospital outpatient department has remained flat while the opioid crisis has continued to worsen. The manufacturer suggested that, to address the opioid crisis among Medicare beneficiaries, CMS should promote ‘‘increased penetration of nonopioid therapies in the HOPD setting— or in other words, higher rates of usage of non-opioid treatments for the same number of surgical procedures.’’ Response: While these commenters advocated paying separately for Exparel in the hospital outpatient setting, we do not believe that there is sufficient evidence that non-opioid pain management drugs should be paid separately in the hospital outpatient setting at this time. The commenters submitted some peer-reviewed studies, discussed in further detail below, that showed that the use of Exparel could lead to a decrease in opioid use in the treatment of acute post-surgical pain among Medicare beneficiaries. However, the commenters did not provide evidence that the OPPS packaging policy for Exparel (or other non-opioid drugs) creates a barrier to use of Exparel in the hospital setting. Further, while we received some public comments suggesting that, as a result of using Exparel in the OPPS setting, providers may prescribe fewer opioids for Medicare beneficiaries, we do not believe that the OPPS payment policy presents a barrier to use of Exparel or affects the likelihood that providers may prescribe fewer opioids in the HOPD setting. Several drugs are packaged under the OPPS and payment for such drugs is included in the payment for the associated primary procedure. We were not persuaded by the anecdotal information supplied by commenters suggesting that some providers avoid use of non-opioid alternatives (including Exparel) solely because of the OPPS packaged payment policy. Finally, while the rate of growth for Exparel use in the HOPD setting has declined over recent years, such trend might be expected because absolute VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 utilization tends to be smaller in the initial period when a drug first comes available on the U.S. market. Additionally, we observed that the total number of providers billing for Exparel under the OPPS has increased each year from 2012 to 2017. Therefore, we do not believe that the current OPPS payment methodology for Exparel and other nonopioid pain management drugs presents a barrier to their use. In addition, higher use in the hospital outpatient setting not only supports the notion that the packaged payment for Exparel is not causing an access to care issue, but also that the payment rate for primary procedures in the HOPD using Exparel adequately reflects the cost of the drug. That is, because Exparel is commonly used and billed under the OPPS, the APC rates for the primary procedures reflect such utilization. Therefore, the higher utilization in the OPPS setting should mitigate the need for separate payment. We remind readers that the OPPS is a prospective payment system, not a cost-based system and, by design, is based on a system of averages whereby payment for certain cases may exceed the costs incurred, while for others, it may not. As stated earlier in this section, the OPPS packages payments for multiple interrelated items and services into a single payment to create incentives for hospitals to furnish services most efficiently and to manage their resources with maximum flexibility. Our packaging policies support our strategic goal of using larger payment bundles in the OPPS to maximize hospitals’ incentives to provide care in the most efficient manner. We will continue to analyze the evidence and monitor utilization of non-opioid alternatives in the OPD and ASC settings for potential future rulemaking. We also stated in the proposed rule that, although we found increases in utilization for Exparel when it is paid under the OPPS, we did notice different effects on Exparel utilization when examining the effects of our packaging policy under the ASC payment system. In particular, during the same 5-year period of CYs 2013 through 2017, the total number of units of Exparel used in the ASC setting decreased by 25 percent (from 98,160 total units to 73,595 total units) and the total number of claims reporting Exparel decreased by 16 percent (from 527 claims to 441 claims). In the ASC setting, after the passthrough payment period ended for Exparel at the end of CY 2014, the total number of units of Exparel used decreased by 70 percent (from 244,757 units to 73,595 units) between CYs 2015 and 2017. The total number of claims PO 00000 Frm 00040 Fmt 4701 Sfmt 4700 reporting Exparel also decreased during this time period by 62 percent (from 1,190 claims to 441 claims). However, there was an increase of 238 percent (from 98,160 total units to 331,348 total units) in the total number of units of Exparel used in the ASC setting during the time period of CYs 2013 and 2014 when the drug received pass-through payments, indicating that the payment rate of ASP+6 percent for Exparel may have had an impact on its usage in the ASC setting. The total number of claims reporting Exparel also increased during this time period from 527 total claims to 1,540 total claims, an increase of 192 percent. While several variables may contribute to this difference in utilization and claims reporting between the hospital outpatient department and the ASC setting, one potential explanation is that, in comparison to hospital outpatient departments, ASCs tend to provide specialized care and a more limited range of services. Also, ASCs are paid, in aggregate, approximately 55 percent of the OPPS rate. Therefore, fluctuations in payment rates for specific services may impact these providers more acutely than hospital outpatient departments, and therefore, ASCs may be less likely to choose to furnish non-opioid postsurgical pain management treatments, which are typically more expensive than opioids, as a result. Another possible contributing factor is that ASCs do not typically report packaged items and services and, accordingly, our analysis may be undercounting the number of Exparel units utilized in the ASC setting. In light of the results of our evaluation of packaging policies under the OPPS and the ASC payment system, which showed decreased utilization for certain drugs that function as a supply in the ASC setting in comparison to the hospital outpatient department setting, as well as the Commission’s recommendation to examine payment policies for non-opioid pain management drugs that function as a supply, we stated in the proposed rule that we believe a change in how we pay for non-opioid pain management drugs that function as surgical supplies may be warranted. In particular, we stated that we believe it may be appropriate to pay separately for evidence-based nonopioid pain management drugs that function as a supply in a surgical procedure in the ASC setting to address the decreased utilization of these drugs and to encourage use of these types of drugs rather than prescription opioids. Therefore, we proposed in section XII.D.3. of the CY 2019 OPPS/ASC E:\FR\FM\21NOR2.SGM 21NOR2 khammond on DSK30JT082PROD with RULES2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations proposed rule to unpackage and pay separately for the cost of non-opioid pain management drugs that function as surgical supplies when they are furnished in the ASC setting for CY 2019 (83 FR 37065). We have stated previously (82 FR 59250) that our packaging policies are designed to support our strategic goal of using larger payment bundles in the OPPS to maximize hospitals’ incentives to provide care in the most efficient manner. The packaging policies established under the OPPS also typically apply when services are provided in the ASC setting, and the policies have the same strategic goals in both settings. While the CY 2019 proposal is a departure from our current ASC packaging policy for drugs (specifically, non-opioid pain management drugs) that function as a supply when used in a surgical procedure, we stated in the proposed rule that we believe that the proposed change will incentivize the use of nonopioid pain management drugs and is responsive to the Commission’s recommendation to examine payment policies for non-opioid pain management drugs that function as a supply, with the overall goal of combating the current opioid addiction crisis. As previously noted, a discussion of the CY 2019 proposal for payment of non-opioid pain management drugs in the ASC setting was presented in further detail in section XII.D.3. of the proposed rule, and we refer readers to section XII.D.3. of this CY 2019 OPPS/ASC final rule with comment period for further discussion of the final policy for CY 2019. We also stated in the CY 2019 OPPS/ASC proposed rule that we were interested in peer-reviewed evidence that demonstrates that use of non-opioid alternatives, such as Exparel, furnished in the outpatient setting actually does lead to a decrease in prescription opioid use and addiction and invited public comments containing evidence that demonstrate whether and how such non-opioid alternatives affect prescription opioid use during or after an outpatient visit or procedure. Comment: Several commenters, including individual stakeholders, hospital and physician groups, national medical associations, drug rehabilitation specialists, device manufacturers, and groups representing the pharmaceutical industry, supported the proposal to unpackage and pay separately for the cost of non-opioid pain management drugs that function as surgical supplies, such as Exparel, in the ASC setting for CY 2019. These commenters believed that packaged payment for non-opioid alternatives presents a barrier to care VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 and that separate payment for nonopioid pain management drugs would be an appropriate response to the opioid drug abuse epidemic. Other commenters, including MedPAC, did not support this proposal and stated that the policy was counter to the OPPS packaging policies created to encourage efficiencies and could set a precedent for unpackaging services. One commenter stated that Exparel is more costly, but not more effective than bupivacaine, a less costly non-opioid alternative. Other commenters expressed concerns that the proposal may have the unintended consequence of limiting access to opioid prescriptions for beneficiaries for whom an opioid prescription would be appropriate. The commenters noted that some non-opioid pain management treatments may pose other risks for patients and patient safety. Response: This comment and other comments specific to packaging under the ASC payment system are addressed in section XII.D.3. of this final rule with comment period. In addition, as noted in section XII.D.3. of the proposed rule (83 FR 37065 through 37068), we sought comments on whether the proposed policy would decrease the dose, duration, and/or number of opioid prescriptions beneficiaries receive during and following an outpatient visit or procedure (especially for beneficiaries at high-risk for opioid addiction) as well as whether there are other non-opioid pain management alternatives that would have similar effects and may warrant separate payment. For example, we stated we were interested in identifying whether single post-surgical analgesic injections, such as Exparel, or other non-opioid drugs or devices that are used during an outpatient visit or procedure are associated with decreased opioid prescriptions and/or reduced cases of associated opioid addiction following such an outpatient visit or procedure. We also requested comments that provide evidence (such as published peer-reviewed literature) we could use to determine whether these products help to deter or avoid prescription opioid use and addiction as well as evidence that the current packaged payment for such non-opioid alternatives presents a barrier to access to care and, therefore, warrants separate payment under either or both the OPPS and the ASC payment system. We stated that any evidence demonstrating the reduction or avoidance of prescription opioids would be the criterion we use to determine whether separate payment is warranted for CY 2019. We also stated PO 00000 Frm 00041 Fmt 4701 Sfmt 4700 58857 that if evidence changes over time, we would consider whether a reexamination of any policy adopted in the final rule would be necessary. Comment: With regard to whether the proposed policy would decrease the dose, duration, and/or number of opioid prescriptions beneficiaries receive during and following an outpatient visit or procedure and supportive evidence of these reductions, one commenter, the manufacturer of Exparel, submitted studies that claimed that the use of Exparel by Medicare patients undergoing total knee replacement procedures reduced prescription opioid consumption by 90 percent compared to the control group measured at 48 hours post-surgery.13 The manufacturer submitted additional studies claiming statistically significant reductions in opioid use with the use of Exparel for various surgeries, including laparotomy, shoulder replacement, and breast reconstruction. Several commenters identified other non-opioid pain management drugs that they believe decrease the dose, duration, and/or number of opioid prescriptions beneficiaries receive during and following an outpatient visit or procedure (especially for beneficiaries at high-risk for opioid addiction) and may warrant separate payment for CY 2019. Commenters from the makers of other packaged non-opioid pain management drugs, including a non-opioid intrathecal infusion drug indicated for the management of severe chronic pain, submitted supporting studies which claimed that the drug reduced opioid use in patients with chronic pain. Several commenters, from hospitals, hospital associations, and clinical specialty organizations, requested separate payment for IV acetaminophen, IV ibuprofen, and epidural steroid injections. In addition, one commenter, the manufacturer of a non-opioid analgesic containing bupivacaine hcl not currently approved by FDA, requested clarification regarding whether the proposal would also apply to this drug once it receives FDA approval. Several commenters requested separate payment for a drug that treats postoperative pain after cataract surgery, currently has drug pass-through payment status, and therefore is not packaged under the OPPS or the ASC payment system. The commenters requested that CMS explicitly state that this drug will also be paid for separately in the ASC setting after pass-through 13 Michael A. Mont et al., Local Infiltration Analgesia With Liposomal Bupivacaine Improves Pain Scores and Reduces Opioid Use After Total Knee Arthroplasty: Results of a Randomized Controlled Trial. J. of Arthroplasty (2018). E:\FR\FM\21NOR2.SGM 21NOR2 khammond on DSK30JT082PROD with RULES2 58858 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations payment status ends for the drug in 2020. Lastly, one commenter, the makers of a diagnostic drug that is not a non-opioid, requested separate payment. Response: We appreciate these comments. After reviewing the studies provided by the commenters, we continue to believe the separate payment is appropriate for Exparel in the ASC setting. At this time, we have not found compelling evidence for other non-opioid pain management drugs described above to warrant separate payment under the ASC payment system for CY 2019. Also, with regard to the requests for CMS to confirm that the proposed policy would also apply in the future to certain non-opioid pain management drugs, we reiterate that the proposed policy is for CY 2019 and is applicable to non-opioid pain management drugs that are currently packaged under the policy for drugs that function as a surgical supply when used in the ASC setting, which currently is only Exparel. To the extent that other non-opioid pain management drugs become available on the U.S. market in 2019, this policy would also apply to those drugs. As noted above, we stated in the proposed rule that we were interested in comments regarding other non-opioid treatments besides Exparel that might be affected by our OPPS and ASC packaging policies, including alternative, non-opioid pain management treatments, such as devices or therapy services that are not currently separable payable. We stated that we were specifically interested in comments regarding whether CMS should consider separate payment for items and services for which payment is currently packaged under the OPPS and the ASC payment system that are effective non-opioid alternatives as well as evidence that demonstrates such items and services lead to a decrease in prescription opioid use and/or addiction during or after an outpatient visit or procedure in order to determine whether separate payment may be warranted. As previously stated, we intended to examine the evidence submitted to determine whether to adopt a final policy in this final rule with comment period that incentivizes use of non-opioid alternative items and services that have evidence to demonstrate an associated decrease in prescription opioid use and/or addiction following an outpatient visit or procedure. We stated that some examples of evidence that may be relevant could include an indication on the product’s FDA label or studies published in peer-reviewed literature VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 that such product aids in the management of acute or chronic pain and is an evidence-based non-opioid alternative for acute and/or chronic pain management. We indicated in the proposed rule that we also were interested in evidence relating to products that have shown clinical improvement over other alternatives, such as a device that has been shown to provide a substantial clinical benefit over the standard of care for pain management. We stated that this could include, for example, spinal cord stimulators used to treat chronic pain, such as the devices described by HCPCS codes C1822 (Generator, neurostimulator (implantable), high frequency, with rechargeable battery and charging system), C1820 (Generator, neurostimulator (implantable), with rechargeable battery and charging system), and C1767 (Generator, neurostimulator (implantable), nonrechargeable) which are primarily assigned to APCs 5463 and 5464 (Levels 3 and 4 Neurostimulator and Related Procedures) with proposed CY 2019 payment rates of $18,718 and $27,662, respectively, that have received passthrough payment status as well as other similar devices. Currently, all devices are packaged under the OPPS and the ASC payment system unless they have pass-through payment status. However, we stated in the proposed rule that, in light of the Commission’s recommendation to review and modify ratesetting policies that discourage the use of non-opioid treatments for pain, we were interested in comments from stakeholders regarding whether, similar to the goals of the proposed payment policy for nonopioid pain management drugs that function as a supply when used in a surgical procedure, a policy of providing separate payment (rather than packaged payment) for these products, indefinitely or for a specified period of time, would also incentivize the use of alternative non-opioid pain management treatments and improve access to non-opioid alternatives, particularly for innovative and lowvolume items and services. We also stated that we were interested in comments regarding whether we should provide separate payment for non-opioid pain management treatments or products using a mechanism such as an equitable payment adjustment under our authority at section 1833(t)(2)(E) of the Act, which states that the Secretary shall establish, in a budget neutral manner, other adjustments as determined to be necessary to ensure equitable payments. For example, we stated in the proposed rule that we were PO 00000 Frm 00042 Fmt 4701 Sfmt 4700 considering whether an equitable payment adjustment in the form of an add-on payment for APCs that use a non-opioid pain management drug, device, or service would be appropriate. We indicated that, to the extent that commenters provided evidence to support this approach, we would consider adopting a final policy in this final rule with comment period, which could include regulatory changes that would allow for an exception to the packaging of certain nonpass-through devices that represent non-opioid alternatives for acute or chronic pain that have evidence to demonstrate that their use leads to a decrease in opioid prescriptions and/or opioid abuse or misuse during or after an outpatient visit or procedure to effectuate such change. Comment: Several commenters, manufacturers of spinal cord stimulators (SCS), stated that separate payment was also warranted for these devices because they provide an alternative treatment option to opioids for patients with chronic, leg, or back pain. One of the manufacturers of a high-frequency SCS device provided supporting studies which claimed that patients treated with their device reported a statistically significant average decrease in opioid use compared to the control group.14 This commenter also submitted data that showed a decline in the mean daily dosage of opioid medication taken and that fewer patients were relying on opioids at all to manage their pain when they used the manufacturer’s device.15 Another commenter, a SCS manufacturer, stated that there are few peer-reviewed studies that evaluate opioid elimination and/or reduction following SCS and that there is a need for more population-based research with opioid reduction or elimination as a study endpoint. However, this commenter believed that current studies suggest that opioid use may be reduced following SCS therapy. Commenters representing various stakeholders requested separate payments for various non-opioid pain management treatments, such as 14 Kapural L, Yu C, Doust MW, Gliner BE, Vallejo R, Sitzman BT, Amirdelfan K, Morgan DM, Brown LL, Yearwood TL, Bundschu R, Burton AW, Yang T, Benyamin R, Burgher AH. Novel 10-kHz highfrequency therapy (HF10 therapy) is superior to traditional low-frequency spinal cord stimulation for the treatment of chronic back and leg pain: The SENZA–RCT randomized controlled trial, Anesthesiology. 2015 Oct;123(4):851–60. 15 Al-Kaisy A, Van Buyten JP, Smet I, Palmisani S, Pang D, Smith T. Sustained effectiveness of 10 kHz high-frequency spinal cord stimulation for patients with chronic, low back pain: 24-month results of a prospective multicenter study. Pain Med. 2014 Mar; 15(3):347–54. E:\FR\FM\21NOR2.SGM 21NOR2 khammond on DSK30JT082PROD with RULES2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations continuous nerve blocks (including a disposable elastomeric pump that delivers non-opioid local anesthetic to a surgical site or nerve), cooled thermal radiofrequency ablation for nonsurgical, chronic nerve pain, and physical therapy services. These commenters, including national hospital associations, recommended that while ‘‘certainly not a solution to the opioid epidemic, unpackaging appropriate non-opioid therapies, like Exparel, is a low-cost tactic that could change long-standing practice patterns without major negative consequences.’’ This same commenter suggested that Medicare consider separate payment for Polar ice devices for postoperative pain relief after knee procedures. The commenter also noted that therapeutic massage, topically applied THC oil, acupuncture, and dry needling procedures are very effective therapies for relief of both postoperative pain and long-term and chronic pain. Commenters suggested various mechanisms through which separate payment or a higher-paying APC assignment for the primary service could be made. Commenters offered reports, studies, and anecdotal evidence of varying degrees to support why the items or services about which they were writing offered an alternative to or reduction of the need for opioid prescriptions. Response: We appreciate the detailed responses to our solicitation for comments on this topic. We plan to take these comments and suggestions into consideration for future rulemaking. We agree that providing incentives to avoid and/or reduce opioid prescriptions may be one of several strategies for addressing the opioid epidemic. To the extent that the items and services mentioned by the commenters are effective alternatives to opioid prescriptions, we encourage providers to use them when medically necessary. We note that some of the items and services mentioned by commenters are not covered by Medicare, and we do not intend to establish payment for noncovered items and services. We look forward to working with stakeholders as we further consider suggested refinements to the OPPS and the ASC payment system that will encourage use of medically necessary items and services that have demonstrated efficacy in decreasing opioid prescriptions and/ or opioid abuse or misuse during or after an outpatient visit or procedure. Comment: One commenter suggested that CMS provide separate payment for HCPCS code A4306 (Disposable drug delivery system, flow rate of less than 50 ml per hour) in the hospital outpatient department setting and the VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 ASC setting following a post-surgery procedure. This commenter explained that if a patient needs additional pain relief 3 to 5 days post-surgery, a facility cannot receive payment for providing a replacement disposable drug delivery system (HCPCS code A4306) unless the entire continuous nerve block procedure is performed. This commenter believed that CMS should allow for HCPCS code A4306 to be dispensed to the patient as long as the patient is in pain, the pump is empty, and the delivery catheters are still in place. The commenter believed that the drug delivery system should incentivize the continued use of nonopioid alternatives when needed. In addition, several commenters stated that CMS should use an equitable payment adjustment under our authority at section 1833(t)(2)(E) of the Act to establish add-on payments for packaged devices used as non-opioid alternatives. Response: We appreciate the commenter’s suggestion. We acknowledge that use of these items may help in the reduction of opioid use postoperatively. However, we note that packaged payment of such an item does not prevent the use of these items. We remind readers that payment for packaged items is included in the payment for the primary service. We share the commenter’s concern about the need to reduce opioid use and will take the commenter’s suggestion into consideration for future rulemaking. After reviewing the non-opioid pain management alternatives suggested by the commenters as well as the studies and other data provided to support the request for separate payment, we have not determined that separate payment is warranted at this time for any of the non-opioid pain management alternatives discussed above. We also invited public comments on whether a reorganization of the APC structure for procedures involving nonopioid products or establishing more granular APC groupings for specific procedure and device combinations to ensure that the payment rate for such services is aligned with the resources associated with procedures involving specific devices would better achieve our goal of incentivizing increased use of non-opioid alternatives, with the aim of reducing opioid use and subsequent addiction. For example, we stated we would consider finalizing a policy to establish new APCs for procedures involving non-opioid pain management packaged items or services if such APCs would better recognize the resources involved in furnishing such items and services and decrease or eliminate the need for prescription opioids. In addition, given the general desire to PO 00000 Frm 00043 Fmt 4701 Sfmt 4700 58859 encourage provider efficiency through creating larger bundles of care and packaging items and services that are integral, ancillary, supportive, dependent, or adjunctive to a primary service, we also invited comments on how such alternative payment structures would continue to balance the goals of incentivizing provider efficiencies with encouraging the use of non-opioid alternatives to pain management. Furthermore, because patients may receive opioid prescriptions following receipt of a non-opioid drug or implantation of a device, we stated that we were interested in identifying any cost implications for the patient and the Medicare program caused by this potential change in policy. We also stated that the implications of incentivizing use of non-opioid pain management drugs available for postsurgical acute pain relief during or after an outpatient visit or procedure are of interest. The goal is to encourage appropriate use of such non-opioid alternatives. As previously stated, this comment solicitation is also discussed in section XII.D.3. of this final rule with comment period relating to the ASC payment system. Comment: Regarding APC reorganization, one commenter suggested that CMS restructure the twolevel Nerve Procedure APCs (5431 and 5432) to provide more payment granularity for the procedures included in the APCs by creating a third level. Response: This comment is addressed in section III.D.17. of this final rule with comment period. As stated in that section, we believe that the current twolevel APCs for the Nerve Procedures provide an appropriate distinction between the resource costs at each level and provide clinical homogeneity. We will continue to review this APC structure to determine if additional granularity is necessary for this APC family in future rulemaking. In addition, we believe that more analysis of such groupings is necessary before adopting such change. In addition, in the proposed rule, we invited the public to submit ideas on regulatory, subregulatory, policy, practice, and procedural changes to help prevent opioid use disorders and improve access to treatment under the Medicare program. We stated that we were interested in identifying barriers that may inhibit access to non-opioid alternatives for pain treatment and management or access to opioid use disorder treatment, including those barriers related to payment methodologies or coverage. In addition, consistent with our ‘‘Patients Over E:\FR\FM\21NOR2.SGM 21NOR2 58860 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations khammond on DSK30JT082PROD with RULES2 Paperwork’’ Initiative, we stated that we were interested in suggestions to improve existing requirements in order to more effectively address the opioid epidemic. Comment: Several commenters addressed payment barriers that may inhibit access to non-opioid pain management treatments previously discussed throughout this section. With regard to barriers related to payment methodologies or coverage, one commenter, a clinical specialty society, suggested that CMS support multimodal pain management and enhanced recovery after surgery (ERAS) and encourage patient access to certified registered nurse anesthetist (CRNA) pain management. One commenter also suggested that CMS reduce cost-sharing and eliminate the need for prior authorization for non-opioid pain management strategies. Response: We appreciate the various, insightful comments we received from stakeholders regarding barriers that may inhibit access to non-opioid alternatives for pain treatment and management in order to more effectively address the opioid epidemic. Many of these comments have been previously addressed throughout this section. After consideration of the public comments that we received, we are finalizing the proposed policy, without modification, to unpackage and pay separately at ASP+6 percent for the cost of non-opioid pain management drugs that function as surgical supplies when they are furnished in the ASC setting for CY 2019. We will continue to analyze the issue of access to non-opioid alternatives in the OPD and the ASC settings as we implement section 6082 of the Substance Use–Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act (Pub. L. 115–271 enacted on October 24, 2018. This policy is also discussed in section XII.D.3 of this final rule with comment period. 4. Calculation of OPPS Scaled Payment Weights We established a policy in the CY 2013 OPPS/ASC final rule with comment period (77 FR 68283) of using geometric mean-based APC costs to calculate relative payment weights under the OPPS. In the CY 2018 OPPS/ ASC final rule with comment period (82 FR 59255 through 59256), we applied this policy and calculated the relative payment weights for each APC for CY 2018 that were shown in Addenda A and B to that final rule with comment period (which were made available via the internet on the CMS website) using VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 the APC costs discussed in sections II.A.1. and II.A.2. of that final rule with comment period. For CY 2019, as we did for CY 2018, in the CY 2019 OPPS/ ASC proposed rule (83 FR 37071), we proposed to continue to apply the policy established in CY 2013 and calculate relative payment weights for each APC for CY 2019 using geometric mean-based APC costs. For CY 2012 and CY 2013, outpatient clinic visits were assigned to one of five levels of clinic visit APCs, with APC 0606 representing a mid-level clinic visit. In the CY 2014 OPPS/ASC final rule with comment period (78 FR 75036 through 75043), we finalized a policy that created alphanumeric HCPCS code G0463 (Hospital outpatient clinic visit for assessment and management of a patient), representing any and all clinic visits under the OPPS. HCPCS code G0463 was assigned to APC 0634 (Hospital Clinic Visits). We also finalized a policy to use CY 2012 claims data to develop the CY 2014 OPPS payment rates for HCPCS code G0463 based on the total geometric mean cost of the levels one through five CPT E/M codes for clinic visits previously recognized under the OPPS (CPT codes 99201 through 99205 and 99211 through 99215). In addition, we finalized a policy to no longer recognize a distinction between new and established patient clinic visits. For CY 2016, we deleted APC 0634 and reassigned the outpatient clinic visit HCPCS code G0463 to APC 5012 (Level 2 Examinations and Related Services) (80 FR 70372). For CY 2019, as we did for CY 2018, we proposed to continue to standardize all of the relative payment weights to APC 5012. We believe that standardizing relative payment weights to the geometric mean of the APC to which HCPCS code G0463 is assigned maintains consistency in calculating unscaled weights that represent the cost of some of the most frequently provided OPPS services. For CY 2019, as we did for CY 2018, we proposed to assign APC 5012 a relative payment weight of 1.00 and to divide the geometric mean cost of each APC by the geometric mean cost for APC 5012 to derive the unscaled relative payment weight for each APC. The choice of the APC on which to standardize the relative payment weights does not affect payments made under the OPPS because we scale the weights for budget neutrality. We did not receive any public comments on our proposal to continue to use the geometric mean cost of APC 5012 to standardize relative payment weights for CY 2019. Therefore, we are finalizing our proposal and assigning PO 00000 Frm 00044 Fmt 4701 Sfmt 4700 APC 5012 the relative payment weight of 1.00, and using the relative payment weight for APC 5012 to derive the unscaled relative payment weight for each APC for CY 2019. We note that, in section X.B. of the OPPS/ASC proposed rule (83 FR 37137 through 37138) and of this final rule with comment period, we discuss our CY 2019 proposal and established final policy to control for unnecessary increases in the volume of covered outpatient department services by paying for clinic visits furnished at excepted off-campus provider-based department (PBD) at an amount of 70 percent of the OPPS rate for a clinic visit service in CY 2019, rather than at the standard OPPS rate. While the volume associated with these visits is included in the impact model, and thus used in calculating the weight scalar, the proposal and final policy have only a negligible effect on the scalar. Specifically, under the proposed and final policy, there is no change to the relativity of the OPPS payment weights because the adjustment is made at the payment level rather than in the cost modeling. Further, under our proposed and final policy, the savings that will result from the change in payments for these clinic visits will not be budget neutral. Therefore, the impact of the proposed and final policy will generally not be reflected in the budget neutrality adjustments, whether the adjustment is to the OPPS relative weights or to the OPPS conversion factor. We refer readers to section X.B. of this CY 2019 OPPS/ASC final rule with comment period for further discussion of this final policy. Section 1833(t)(9)(B) of the Act requires that APC reclassification and recalibration changes, wage index changes, and other adjustments be made in a budget neutral manner. Budget neutrality ensures that the estimated aggregate weight under the OPPS for CY 2019 is neither greater than nor less than the estimated aggregate weight that would have been made without the changes. To comply with this requirement concerning the APC changes, in the CY 2019 OPPS/ASC proposed rule (83 FR 37071 through 37072), we proposed to compare the estimated aggregate weight using the CY 2018 scaled relative payment weights to the estimated aggregate weight using the proposed CY 2019 unscaled relative payment weights. For CY 2018, we multiplied the CY 2018 scaled APC relative payment weight applicable to a service paid under the OPPS by the volume of that service from CY 2017 claims to calculate the total relative payment weight for E:\FR\FM\21NOR2.SGM 21NOR2 khammond on DSK30JT082PROD with RULES2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations each service. We then added together the total relative payment weight for each of these services in order to calculate an estimated aggregate weight for the year. For CY 2019, we proposed to apply the same process using the estimated CY 2019 unscaled relative payment weights rather than scaled relative payment weights. We proposed to calculate the weight scalar by dividing the CY 2018 estimated aggregate weight by the unscaled CY 2019 estimated aggregate weight. For a detailed discussion of the weight scalar calculation, we refer readers to the OPPS claims accounting document available on the CMS website at: https://www.cms.gov/Medicare/ Medicare-Fee-for-Service-Payment/ HospitalOutpatientPPS/. Click on the CY 2019 OPPS final rule link and open the claims accounting document link at the bottom of the page. We proposed to compare the estimated unscaled relative payment weights in CY 2019 to the estimated total relative payment weights in CY 2018 using CY 2017 claims data, holding all other components of the payment system constant to isolate changes in total weight. Based on this comparison, we proposed to adjust the calculated CY 2019 unscaled relative payment weights for purposes of budget neutrality. We proposed to adjust the estimated CY 2019 unscaled relative payment weights by multiplying them by a proposed weight scalar of 1.4553 to ensure that the proposed CY 2019 relative payment weights are scaled to be budget neutral. The proposed CY 2019 relative payment weights listed in Addenda A and B to the proposed rule (which are available via the internet on the CMS website) were scaled and incorporated the recalibration adjustments discussed in sections II.A.1. and II.A.2. of the proposed rule. Section 1833(t)(14) of the Act provides the payment rates for certain SCODs. Section 1833(t)(14)(H) of the Act provides that additional expenditures resulting from this paragraph shall not be taken into account in establishing the conversion factor, weighting, and other adjustment factors for 2004 and 2005 under paragraph (9), but shall be taken into account for subsequent years. Therefore, the cost of those SCODs (as discussed in section V.B.2. of this final rule with comment period) is included in the budget neutrality calculations for the CY 2019 OPPS. We did not receive any public comments on the proposed weight scalar calculation. Therefore, we are finalizing our proposal to use the calculation process described in the VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 proposed rule, without modification, for CY 2019. Using updated final rule claims data, we are updating the estimated CY 2019 unscaled relative payment weights by multiplying them by a weight scalar of 1.4574 to ensure that the final CY 2019 relative payment weights are scaled to be budget neutral. The final CY 2019 relative payments weights listed in Addenda A and B to this final rule with comment period (which are available via the internet on the CMS website) were scaled and incorporate the recalibration adjustments discussed in sections II.A.1. and II.A.2. of this final rule with comment period. B. Conversion Factor Update Section 1833(t)(3)(C)(ii) of the Act requires the Secretary to update the conversion factor used to determine the payment rates under the OPPS on an annual basis by applying the OPD fee schedule increase factor. For purposes of section 1833(t)(3)(C)(iv) of the Act, subject to sections 1833(t)(17) and 1833(t)(3)(F) of the Act, the OPD fee schedule increase factor is equal to the hospital inpatient market basket percentage increase applicable to hospital discharges under section 1886(b)(3)(B)(iii) of the Act. As stated in the CY 2019 OPPS/ASC proposed rule, in the FY 2019 IPPS/LTCH PPS proposed rule (83 FR 20381), consistent with current law, based on IHS Global, Inc.’s fourth quarter 2017 forecast of the FY 2019 market basket increase, the proposed FY 2019 IPPS market basket update was 2.8 percent. However, sections 1833(t)(3)(F) and 1833(t)(3)(G)(v) of the Act, as added by section 3401(i) of the Patient Protection and Affordable Care Act of 2010 (Pub. L. 111–148) and as amended by section 10319(g) of that law and further amended by section 1105(e) of the Health Care and Education Reconciliation Act of 2010 (Pub. L. 111– 152), provide adjustments to the OPD fee schedule increase factor for CY 2019. Specifically, section 1833(t)(3)(F)(i) of the Act requires that, for 2012 and subsequent years, the OPD fee schedule increase factor under subparagraph (C)(iv) be reduced by the productivity adjustment described in section 1886(b)(3)(B)(xi)(II) of the Act. Section 1886(b)(3)(B)(xi)(II) of the Act defines the productivity adjustment as equal to the 10-year moving average of changes in annual economy-wide, private nonfarm business multifactor productivity (MFP) (as projected by the Secretary for the 10-year period ending with the applicable fiscal year, year, cost reporting period, or other annual period) (the ‘‘MFP adjustment’’). In the PO 00000 Frm 00045 Fmt 4701 Sfmt 4700 58861 FY 2012 IPPS/LTCH PPS final rule (76 FR 51689 through 51692), we finalized our methodology for calculating and applying the MFP adjustment, and then revised this methodology as discussed in the FY 2016 IPPS/LTCH PPS final rule (80 FR 49509). In the CY 2019 OPPS/ASC proposed rule (83 FR 37072), the proposed MFP adjustment for FY 2019 was 0.8 percentage point. In the CY 2019 OPPS/ASC proposed rule (83 FR 37072), we proposed that if more recent data became subsequently available after the publication of the proposed rule (for example, a more recent estimate of the market basket increase and the MFP adjustment), we would use such updated data, if appropriate, to determine the CY 2019 market basket update and the MFP adjustment, which are components in calculating the OPD fee schedule increase factor under sections 1833(t)(3)(C)(iv) and 1833(t)(3)(F) of the Act, in this CY 2019 OPPS/ASC final rule with comment period. In addition, section 1833(t)(3)(F)(ii) of the Act requires that, for each of years 2010 through 2019, the OPD fee schedule increase factor under section 1833(t)(3)(C)(iv) of the Act be reduced by the adjustment described in section 1833(t)(3)(G) of the Act. For CY 2019, section 1833(t)(3)(G)(v) of the Act provides a 0.75 percentage point reduction to the OPD fee schedule increase factor under section 1833(t)(3)(C)(iv) of the Act. Therefore, in accordance with sections 1833(t)(3)(F)(ii) and 1833(t)(3)(G)(v) of the Act, in the CY 2019 OPPS/ASC proposed rule, we proposed to apply a 0.75 percentage point reduction to the OPD fee schedule increase factor for CY 2019. We note that section 1833(t)(3)(F) of the Act provides that application of this subparagraph may result in the OPD fee schedule increase factor under section 1833(t)(3)(C)(iv) of the Act being less than 0.0 percent for a year, and may result in OPPS payment rates being less than rates for the preceding year. As described in further detail below, we are applying an OPD fee schedule increase factor of 1.35 percent for the CY 2019 OPPS (which is 2.9 percent, the final estimate of the hospital inpatient market basket percentage increase, less the final 0.8 percentage point MFP adjustment, and less the 0.75 percentage point additional adjustment). Hospitals that fail to meet the Hospital OQR Program reporting requirements are subject to an additional reduction of 2.0 percentage points from the OPD fee schedule increase factor adjustment to the conversion factor that would be used to E:\FR\FM\21NOR2.SGM 21NOR2 khammond on DSK30JT082PROD with RULES2 58862 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations calculate the OPPS payment rates for their services, as required by section 1833(t)(17) of the Act. For further discussion of the Hospital OQR Program, we refer readers to section XIII. of this final rule with comment period. In the CY 2019 OPPS/ASC proposed rule, we proposed to amend 42 CFR 419.32(b)(1)(iv)(B) by adding a new paragraph (10) to reflect the requirement in section 1833(t)(3)(F)(i) of the Act that, for CY 2019, we reduce the OPD fee schedule increase factor by the MFP adjustment as determined by CMS, and to reflect the requirement in section 1833(t)(3)(G)(v) of the Act, as required by section 1833(t)(3)(F)(ii) of the Act, that we reduce the OPD fee schedule increase factor by an additional 0.75 percentage point for CY 2019. To set the OPPS conversion factor for the CY 2019 OPPS/ASC proposed rule, we proposed to increase the CY 2018 conversion factor of $78.636 by 1.25 percent (83 FR 37073). In accordance with section 1833(t)(9)(B) of the Act, we proposed further to adjust the conversion factor for CY 2019 to ensure that any revisions made to the wage index and rural adjustment were made on a budget neutral basis. We proposed to calculate an overall budget neutrality factor of 1.0004 for wage index changes by comparing proposed total estimated payments from our simulation model using the proposed FY 2019 IPPS wage indexes to those payments using the FY 2018 IPPS wage indexes, as adopted on a calendar year basis for the OPPS. For the CY 2019 OPPS/ASC proposed rule, we proposed to maintain the current rural adjustment policy, as discussed in section II.E. of the proposed rule and this final rule with comment period. Therefore, the proposed budget neutrality factor for the rural adjustment was 1.0000. For the CY 2019 OPPS/ASC proposed rule, we proposed to continue previously established policies for implementing the cancer hospital payment adjustment described in section 1833(t)(18) of the Act, as discussed in section II.F. of the proposed rule and this final rule with comment period. We proposed to calculate a CY 2019 budget neutrality adjustment factor for the cancer hospital payment adjustment by comparing estimated total CY 2019 payments under section 1833(t) of the Act, including the proposed CY 2019 cancer hospital payment adjustment, to estimated CY 2019 total payments using the CY 2018 final cancer hospital payment adjustment as required under section 1833(t)(18)(B) of the Act. The CY 2019 proposed estimated payments applying VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 the proposed CY 2019 cancer hospital payment adjustment were the same as estimated payments applying the CY 2018 final cancer hospital payment adjustment. Therefore, we proposed to apply a budget neutrality adjustment factor of 1.0000 to the conversion factor for the cancer hospital payment adjustment. In accordance with section 16002(b) of the 21st Century Cures Act, we stated in the proposed rule that we are applying a budget neutrality factor calculated as if the proposed cancer hospital adjustment target payment-tocost ratio was 0.89, not the 0.88 target payment-to-cost ratio we are applying as stated in section II.F. of the proposed rule. For the CY 2019 OPPS/ASC proposed rule, we estimated that proposed passthrough spending for drugs, biologicals, and devices for CY 2019 would equal approximately $126.7 million, which represented 0.17 percent of total projected CY 2019 OPPS spending. Therefore, the proposed conversion factor would be adjusted by the difference between the 0.04 percent estimate of pass-through spending for CY 2018 and the 0.17 percent estimate of proposed pass-through spending for CY 2019, resulting in a proposed decrease for CY 2019 of 0.13 percent. Proposed estimated payments for outliers would remain at 1.0 percent of total OPPS payments for CY 2019. We estimated for the proposed rule that outlier payments would be 1.02 percent of total OPPS payments in CY 2018; the 1.00 percent for proposed outlier payments in CY 2019 would constitute a 0.02 percent increase in payment in CY 2019 relative to CY 2018. For the CY 2019 OPPS/ASC proposed rule, we also proposed that hospitals that fail to meet the reporting requirements of the Hospital OQR Program would continue to be subject to a further reduction of 2.0 percentage points to the OPD fee schedule increase factor. For hospitals that fail to meet the requirements of the Hospital OQR Program, we proposed to make all other adjustments discussed above, but use a reduced OPD fee schedule update factor of -0.75 percent (that is, the proposed OPD fee schedule increase factor of 1.25 percent further reduced by 2.0 percentage points). This would result in a proposed reduced conversion factor for CY 2019 of $77.955 for hospitals that fail to meet the Hospital OQR Program requirements (a difference of -1.591 in the conversion factor relative to hospitals that met the requirements). In summary, for CY 2019, we proposed to amend § 419.32(b)(1)(iv)(B) by adding a new paragraph (10) to reflect the reductions to the OPD fee PO 00000 Frm 00046 Fmt 4701 Sfmt 4700 schedule increase factor that are required for CY 2019 to satisfy the statutory requirements of sections 1833(t)(3)(F) and (t)(3)(G)(v) of the Act. We proposed to use a reduced conversion factor of $77.955 in the calculation of payments for hospitals that fail to meet the Hospital OQR Program requirements (a difference of -1.591 in the conversion factor relative to hospitals that met the requirements). For CY 2019, we proposed to use a conversion factor of $79.546 in the calculation of the national unadjusted payment rates for those items and services for which payment rates are calculated using geometric mean costs; that is, the proposed OPD fee schedule increase factor of 1.25 percent for CY 2019, the required proposed wage index budget neutrality adjustment of approximately 1.0004, the proposed cancer hospital payment adjustment of 1.0000, and the proposed adjustment of -0.13 percentage point of projected OPPS spending for the difference in pass-through spending that resulted in a proposed conversion factor for CY 2019 of $79.546. We invited public comments on these proposals. However, we did not receive any public comments. Therefore, we are finalizing these proposals without modification. For CY 2019, we proposed to continue previously established policies for implementing the cancer hospital payment adjustment described in section 1833(t)(18) of the Act (discussed in section II.F. of this final rule with comment period). Based on the final rule updated data used in calculating the cancer hospital payment adjustment in section II.F. of this final rule with comment period, the target payment-to-cost ratio for the cancer hospital payment adjustment, which was 0.88 for CY 2018, is 0.88 for CY 2019. As a result, we are applying a budget neutrality adjustment factor of 1.0000 to the conversion factor for the cancer hospital payment adjustment. As a result of these finalized policies, the OPD fee schedule increase factor for the CY 2019 OPPS is 1.35 percent (which reflects the 2.9 percent final estimate of the hospital inpatient market basket percentage increase, less the final 0.8 percentage point MFP adjustment, and less the 0.75 percentage point additional adjustment). For CY 2019, we are using a conversion factor of $79.490 in the calculation of the national unadjusted payment rates for those items and services for which payment rates are calculated using geometric mean costs; that is, the OPD fee schedule increase factor of 1.35 percent for CY 2019, the required wage index budget neutrality adjustment of E:\FR\FM\21NOR2.SGM 21NOR2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations khammond on DSK30JT082PROD with RULES2 approximately 0.9984, and the adjustment of -0.10 percentage point of projected OPPS spending for the difference in pass-through spending that results in a conversion factor for CY 2019 of $79.490. C. Wage Index Changes Section 1833(t)(2)(D) of the Act requires the Secretary to determine a wage adjustment factor to adjust the portion of payment and coinsurance attributable to labor-related costs for relative differences in labor and laborrelated costs across geographic regions in a budget neutral manner (codified at 42 CFR 419.43(a)). This portion of the OPPS payment rate is called the OPPS labor-related share. Budget neutrality is discussed in section II.B. of this final rule with comment period. The OPPS labor-related share is 60 percent of the national OPPS payment. This labor-related share is based on a regression analysis that determined that, for all hospitals, approximately 60 percent of the costs of services paid under the OPPS were attributable to wage costs. We confirmed that this labor-related share for outpatient services is appropriate during our regression analysis for the payment adjustment for rural hospitals in the CY 2006 OPPS final rule with comment period (70 FR 68553). In the CY 2019 OPPS/ASC proposed rule (83 FR 37073), we proposed to continue this policy for the CY 2019 OPPS. We refer readers to section II.H. of this final rule with comment period for a description and an example of how the wage index for a particular hospital is used to determine payment for the hospital. We did not receive any public comments on this proposal. Therefore, for the reasons discussed above and in the CY 2019 OPPS/ASC proposed rule (83 FR 37073), we are finalizing our proposal, without modification, to continue this policy as discussed above for the CY 2019 OPPS. As discussed in the claims accounting narrative included with the supporting documentation for this final rule with comment period (which is available via the internet on the CMS website), for estimating APC costs, we standardize 60 percent of estimated claims costs for geographic area wage variation using the same FY 2019 pre-reclassified wage index that the IPPS uses to standardize costs. This standardization process removes the effects of differences in area wage levels from the determination of a national unadjusted OPPS payment rate and copayment amount. Under 42 CFR 419.41(c)(1) and 419.43(c) (published in the OPPS April 7, 2000 final rule with comment period VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 (65 FR 18495 and 18545)), the OPPS adopted the final fiscal year IPPS postreclassified wage index as the calendar year wage index for adjusting the OPPS standard payment amounts for labor market differences. Therefore, the wage index that applies to a particular acute care, short-stay hospital under the IPPS also applies to that hospital under the OPPS. As initially explained in the September 8, 1998 OPPS proposed rule (63 FR 47576), we believe that using the IPPS wage index as the source of an adjustment factor for the OPPS is reasonable and logical, given the inseparable, subordinate status of the HOPD within the hospital overall. In accordance with section 1886(d)(3)(E) of the Act, the IPPS wage index is updated annually. The Affordable Care Act contained several provisions affecting the wage index. These provisions were discussed in the CY 2012 OPPS/ASC final rule with comment period (76 FR 74191). Section 10324 of the Affordable Care Act added section 1886(d)(3)(E)(iii)(II) to the Act, which defines a frontier State and amended section 1833(t) of the Act to add paragraph (19), which requires a frontier State wage index floor of 1.00 in certain cases, and states that the frontier State floor shall not be applied in a budget neutral manner. We codified these requirements at § 419.43(c)(2) and (c)(3) of our regulations. For the CY 2019 OPPS, we proposed to implement this provision in the same manner as we have since CY 2011. Under this policy, the frontier State hospitals would receive a wage index of 1.00 if the otherwise applicable wage index (including reclassification, the rural floor, and rural floor budget neutrality) is less than 1.00 (as discussed below and in the CY 2019 OPPS/ASC proposed rule (83 FR 37074 through 37076), we proposed not to extend the imputed floor under the OPPS for CY 2019 and subsequent years, consistent with our proposal in the FY 2019 IPPS/ LTCH PPS proposed rule (83 FR 20362 and 20363) not to extend the imputed floor under the IPPS for FY 2019 and subsequent fiscal years). Because the HOPD receives a wage index based on the geographic location of the specific inpatient hospital with which it is associated, we stated that the frontier State wage index adjustment applicable for the inpatient hospital also would apply for any associated HOPD. In the CY 2019 OPPS/ASC proposed rule (83 FR 37074), we referred readers to the FY 2011 through FY 2018 IPPS/LTCH PPS final rules for discussions regarding this provision, including our methodology for identifying which areas meet the PO 00000 Frm 00047 Fmt 4701 Sfmt 4700 58863 definition of ‘‘frontier States’’ as provided for in section 1886(d)(3)(E)(iii)(II) of the Act: For FY 2011, 75 FR 50160 through 50161; for FY 2012, 76 FR 51793, 51795, and 51825; for FY 2013, 77 FR 53369 through 53370; for FY 2014, 78 FR 50590 through 50591; for FY 2015, 79 FR 49971; for FY 2016, 80 FR 49498; for FY 2017, 81 FR 56922; and for FY 2018, 82 FR 38142. We did not receive any public comments on this proposal. Therefore, for the reasons discussed above and in the CY 2019 OPPS/ASC proposed rule (83 FR 37074), we are finalizing our proposal to implement the frontier State floor under the OPPS in the same manner as we have since CY 2011. In addition to the changes required by the Affordable Care Act, we note that the FY 2019 IPPS wage indexes continue to reflect a number of adjustments implemented over the past few years, including, but not limited to, reclassification of hospitals to different geographic areas, the rural floor provisions, an adjustment for occupational mix, and an adjustment to the wage index based on commuting patterns of employees (the out-migration adjustment). We refer readers to the FY 2019 IPPS/LTCH PPS proposed rule (83 FR 20353 through 20377) and final rule (83 FR 41362 through 41390) for a detailed discussion of all proposed and final changes to the FY 2019 IPPS wage indexes. We note that, in the FY 2019 IPPS/LTCH PPS proposed rule (83 FR 20362 through 20363), we proposed not to apply the imputed floor to the IPPS wage index computations for FY 2019 and subsequent fiscal years. Consistent with this, we proposed in the CY 2019 OPPS/ASC proposed rule (83 FR 37074) not to extend the imputed floor policy under the OPPS beyond December 31, 2018 (the date the imputed floor policy is set to expire under the OPPS). In the FY 2019 IPPS/LTCH PPS final rule (83 FR 41376 through 41380), we finalized our proposal to not extend the imputed floor policy under the IPPS. We refer readers to the FY 2019 IPPS/LTCH PPS final rule (83 FR 41376 through 41380) for a detailed discussion of our rationale for discontinuing the imputed floor under the IPPS. Summarized below are the comments we received regarding our proposal to discontinue the imputed floor under the OPPS, along with our response. Comment: Several commenters agreed with the proposal not to extend the imputed floor policy under the OPPS beyond December 31, 2018. Response: We appreciate the commenters’ support. E:\FR\FM\21NOR2.SGM 21NOR2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations After consideration of the public comments we received, for the reasons discussed above and in the CY 2019 OPPS/ASC proposed rule (83 FR 37074), consistent with the FY 2019 IPPS/LTCH PPS final rule, we are finalizing our proposal not to extend the imputed floor policy under the OPPS beyond December 31, 2018. As discussed in the FY 2015 IPPS/ LTCH PPS final rule (79 FR 49951 through 49963) and in each subsequent IPPS/LTCH PPS final rule, including the FY 2019 IPPS/LTCH PPS final rule (83 FR 41362 through 41363), the Office of Management and Budget (OMB) issued revisions to the labor market area delineations on February 28, 2013 (based on 2010 Decennial Census data), that included a number of significant changes such as new Core Based Statistical Areas (CBSAs), urban counties that became rural, rural counties that became urban, and existing CBSAs that were split apart (OMB Bulletin 13–01). This bulletin can be found at: https:// obamawhitehouse.archives.gov/sites/ default/files/omb/bulletins/2013/b1301.pdf. In the FY 2015 IPPS/LTCH PPS final rule (79 FR 49950 through 49985), for purposes of the IPPS, we adopted the use of the OMB statistical area delineations contained in OMB Bulletin No. 13–01, effective October 1, 2014. For purposes of the OPPS, in the CY 2015 OPPS/ASC final rule with comment period (79 FR 66826 through 66828), we adopted the use of the OMB statistical area delineations contained in OMB Bulletin No. 13–01, effective January 1, 2015, beginning with the CY 2015 OPPS wage indexes. In the FY 2017 IPPS/LTCH PPS final rule (81 FR 56913), we adopted revisions to statistical areas contained in OMB Bulletin No. 15–01, issued on July 15, 2015, which provided updates to and superseded OMB Bulletin No. 13–01 that was issued on February 28, 2013. For purposes of the OPPS, in the CY 2017 OPPS/ASC final rule with comment period (81 FR 79598), we adopted the revisions to the OMB statistical area delineations contained in OMB Bulletin No. 15–01, effective January 1, 2017, beginning with the CY 2017 OPPS wage indexes. We believe that it is important for the OPPS to use the latest labor market area delineations available as soon as is reasonably possible in order to maintain a more accurate and up-to-date payment system that reflects the reality of population shifts and labor market conditions. On August 15, 2017, OMB issued OMB Bulletin No. 17–01, which provided updates to and superseded OMB Bulletin No. 15–01 that was issued on July 15, 2015. The attachments to OMB Bulletin No. 17–01 provide detailed information on the update to the statistical areas since July 15, 2015, and are based on the application of the 2010 Standards for Delineating Metropolitan and Micropolitan Statistical Areas to Census Bureau population estimates for July 1, 2014 and July 1, 2015. In OMB Bulletin No. 17–01, OMB announced that one Micropolitan Statistical Area now qualifies as a Metropolitan Statistical Area. The new urban CBSA is as follows: • Twin Falls, Idaho (CBSA 46300). This CBSA is comprised of the principal city of Twin Falls, Idaho in Jerome County, Idaho and Twin Falls County, Idaho. The OMB Bulletin No. 17–01 is available on the OMB website at https:// www.whitehouse.gov/sites/ whitehouse.gov/files/omb/bulletins/ 2017/b-17-01.pdf. In the FY 2019 IPPS/ LTCH PPS proposed rule (83 FR 20354), we noted that we did not have sufficient time to include this change in the computation of the proposed FY 2019 IPPS wage index, ratesetting, and Tables 2 and 3 associated with the FY 2019 IPPS/LTCH PPS proposed rule. We stated that this new CBSA may affect the IPPS budget neutrality factors and wage indexes, depending on whether the area is eligible for the rural floor and the impact of the overall payments of the hospital located in this new CBSA. As we did in the FY 2019 IPPS/LTCH PPS proposed rule (83 FR 20354), in the CY 2019 OPPS/ASC proposed rule (83 FR 37075), we provided an estimate of this new area’s wage index based on the average hourly wages for new CBSA 46300 and the national average hourly wages from the wage data for the proposed FY 2019 IPPS wage index (described in section III.B. of the preamble of the FY 2019 IPPS/LTCH PPS proposed rule). Currently, provider 130002 is the only hospital located in Twin Falls County, Idaho, and there are no hospitals located in Jerome County, Idaho. Thus, the proposed wage index for CBSA 46300 was calculated using the average hourly wage data for one provider (provider 130002). In the CY 2019 OPPS/ASC proposed rule (83 FR 37075), we provided the proposed FY 2019 IPPS unadjusted and occupational mix adjusted national average hourly wages and the estimated CBSA average hourly wages. Taking the estimated average hourly wage of new CBSA 46300 and dividing by the proposed national average hourly wage resulted in the estimated wage indexes shown in the table in the proposed rule (83 FR 37075), which is also provided below. As we stated in the FY 2019 IPPS/ LTCH PPS final rule (83 FR 41363), for the FY 2019 IPPS wage indexes, we used the OMB delineations that were adopted beginning with FY 2015 to calculate the area wage indexes, with updates as reflected in OMB Bulletin Nos. 13–01, 15–01, and 17–01, and incorporated the revision from OMB Bulletin No. 17–01 in the final FY 2019 IPPS wage index, ratesetting, and tables. Similarly, in the CY 2019 OPPS/ASC proposed rule (82 FR 37075), for the proposed CY 2019 OPPS wage indexes, we proposed to use the OMB VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 PO 00000 Frm 00048 Fmt 4701 Sfmt 4700 E:\FR\FM\21NOR2.SGM 21NOR2 ER21NO18.016</GPH> khammond on DSK30JT082PROD with RULES2 58864 khammond on DSK30JT082PROD with RULES2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations delineations that were adopted beginning with CY 2015 to calculate the area wage indexes, with updates as reflected in OMB Bulletin Nos. 13–01, 15–01, and 17–01, and stated that we would incorporate the revision from OMB Bulletin No. 17–01 in the final CY 2019 OPPS wage index, ratesetting, and tables. We did not receive any public comments on our proposals. Accordingly, for the reasons discussed above and in the CY 2019 OPPS/ASC proposed rule (83 FR 37074 through 37075), we are finalizing the proposal, without modification, to use the OMB delineations that were adopted beginning with CY 2015 to calculate the area wage indexes, with updates as reflected in OMB Bulletin Nos. 13–01, 15–01, and 17–01, and have incorporated the revision from OMB Bulletin No. 17–01 in the final CY 2019 OPPS wage index, ratesetting, and tables. CBSAs are made up of one or more constituent counties. Each CBSA and constituent county has its own unique identifying codes. The FY 2018 IPPS/ LTCH PPS final rule (82 FR 38130) discussed the two different lists of codes to identify counties: Social Security Administration (SSA) codes and Federal Information Processing Standard (FIPS) codes. Historically, CMS listed and used SSA and FIPS county codes to identify and crosswalk counties to CBSA codes for purposes of the IPPS and OPPS wage indexes. However, the SSA county codes are no longer being maintained and updated, although the FIPS codes continue to be maintained by the U.S. Census Bureau. The Census Bureau’s most current statistical area information is derived from ongoing census data received since 2010; the most recent data are from 2015. In the FY 2018 IPPS/LTCH PPS final rule (82 FR 38130), for purposes of crosswalking counties to CBSAs for the IPPS wage index, we finalized our proposal to discontinue the use of the SSA county codes and begin using only the FIPS county codes. Similarly, for the purposes of crosswalking counties to CBSAs for the OPPS wage index, in the CY 2018 OPPS/ASC final rule with comment period (82 FR 59260), we finalized our proposal to discontinue the use of SSA county codes and begin using only the FIPS county codes for the purposes of crosswalking counties to CBSAs for the OPPS wage index. The Census Bureau maintains a complete list of changes to counties or county equivalent entities on the website at: https://www.census.gov/geo/ reference/county-changes.html. In our transition to using only FIPS codes for VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 counties for the IPPS wage index, in the FY 2018 IPPS/LTCH PPS final rule (82 FR 38130), we updated the FIPS codes used for crosswalking counties to CBSAs for the IPPS wage index effective October 1, 2017, to incorporate changes to the counties or county equivalent entities included in the Census Bureau’s most recent list. We included these updates to calculate the area IPPS wage indexes in a manner that is generally consistent with the CBSA-based methodologies finalized in the FY 2005 IPPS final rule and the FY 2015 IPPS/ LTCH PPS final rule. In the CY 2018 OPPS/ASC final rule with comment period (82 FR 59261), we finalized our proposal to implement these FIPS code updates for the OPPS wage index effective January 1, 2018, beginning with the CY 2018 OPPS wage indexes. In the CY 2019 OPPS/ASC proposed rule (83 FR 37075), we proposed to use the FY 2019 hospital IPPS postreclassified wage index for urban and rural areas as the wage index for the OPPS to determine the wage adjustments for both the OPPS payment rate and the copayment standardized amount for CY 2019. Therefore, we stated in the proposed rule that any adjustments for the FY 2019 IPPS postreclassified wage index would be reflected in the final CY 2019 OPPS wage index. (We refer readers to the FY 2019 IPPS/LTCH PPS proposed rule (83 FR 20353 through 20377) and final rule (83 FR 41362 through 41390), and the proposed and final FY 2019 hospital wage index files posted on the CMS website.) We stated in the CY 2019 OPPS/ASC proposed rule (83 FR 37075) that we believe that using the IPPS wage index as the source of an adjustment factor for the OPPS is reasonable and logical, given the inseparable, subordinate status of the HOPD within the hospital overall. Summarized below are the comments we received regarding this proposal, along with our response. Comment: Several commenters opposed applying a budget neutrality adjustment for the rural floor under the OPPS on a national basis. The commenters believed applying budget neutrality on a national basis disadvantages hospitals in most States while benefiting hospitals in a few States that have taken advantage of the system where a rural hospital has a wage index higher than most or all urban hospitals in a State. The commenters stated that rural floor budget neutrality currently requires all wage indexes for hospitals throughout the Nation to be reduced. However, the commenters added, hospitals in those States that have higher wage indexes PO 00000 Frm 00049 Fmt 4701 Sfmt 4700 58865 because of the rural floor are not substantially affected by the wage index reductions. One of the commenters supported calculating rural floor budget neutrality under the OPPS for each individual State. Response: We appreciate these comments. As we stated in the CY 2018 OPPS/ASC final rule with comment period (82 FR 59259), we acknowledge that the application of the wage index and applicable wage index adjustments to OPPS payment rates may create distributional payment variations, especially within a budget neutral system. However, we continue to believe it is reasonable and appropriate to continue the current policy of applying budget neutrality for the rural floor under the OPPS on a national basis, consistent with the IPPS. We believe that hospital inpatient and outpatient departments are subject to the same labor cost environment, and therefore, the wage index and any applicable wage index adjustments (including the rural floor and rural floor budget neutrality) should be applied in the same manner under the IPPS and OPPS. Furthermore, we believe that applying the rural floor and rural floor budget neutrality in the same manner under the IPPS and OPPS is reasonable and logical, given the inseparable, subordinate status of the HOPD within the hospital overall. In addition, we believe the application of different wage indexes and wage index adjustments under the IPPS and OPPS would add a level of administrative complexity that is overly burdensome and unnecessary. Therefore, we are continuing the current policy of applying budget neutrality for the rural floor under the OPPS on a national basis, consistent with the IPPS. After consideration of the public comments we received, for the reasons discussed above and in the CY 2019 OPPS/ASC proposed rule (83 FR 37075), we are finalizing our proposal, without modification, to use the FY 2019 hospital IPPS post-reclassified wage index for urban and rural areas as the wage index for the OPPS to determine the wage adjustments for both the OPPS payment rate and the copayment standardized amount for CY 2019. Therefore, any adjustments for the FY 2019 IPPS post-reclassified wage index are reflected in the final CY 2019 OPPS wage index. As stated earlier, we continue to believe that using the final fiscal year IPPS post-reclassified wage index, inclusive of any adjustments, as the wage index for the OPPS to determine the wage adjustments for both the OPPS payment rate and the copayment standardized amount is reasonable and logical, given the E:\FR\FM\21NOR2.SGM 21NOR2 khammond on DSK30JT082PROD with RULES2 58866 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations inseparable, subordinate status of the HOPD within the hospital overall. Hospitals that are paid under the OPPS, but not under the IPPS, do not have an assigned hospital wage index under the IPPS. Therefore, for non-IPPS hospitals paid under the OPPS, it is our longstanding policy to assign the wage index that would be applicable if the hospital were paid under the IPPS, based on its geographic location and any applicable wage index adjustments. In the CY 2019 OPPS/ASC proposed rule (83 FR 37075), we proposed to continue this policy for CY 2019, and included a brief summary of the major proposed FY 2019 IPPS wage index policies and adjustments that we proposed to apply to these hospitals under the OPPS for CY 2019, which we have summarized below. We invited public comments on these proposals. We refer readers to the FY 2019 IPPS/LTCH PPS final rule (83 FR 41362 through 41390) for a detailed discussion of the changes to the FY 2019 IPPS wage indexes. It has been our longstanding policy to allow non-IPPS hospitals paid under the OPPS to qualify for the out-migration adjustment if they are located in a section 505 out-migration county (section 505 of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (MMA)). Applying this adjustment is consistent with our policy of adopting IPPS wage index policies for hospitals paid under the OPPS. We note that, because nonIPPS hospitals cannot reclassify, they are eligible for the out-migration wage adjustment if they are located in a section 505 out-migration county. This is the same out-migration adjustment policy that applies if the hospital were paid under the IPPS. For CY 2019, we proposed to continue our policy of allowing non-IPPS hospitals paid under the OPPS to qualify for the outmigration adjustment if they are located in a section 505 out-migration county (section 505 of the MMA). We did not receive any public comments on these proposals. Therefore, for the reasons discussed above and in the CY 2019 OPPS/ASC proposed rule (83 FR 37075 through 37076), we are finalizing these proposals without modification. As stated earlier, in the FY 2015 IPPS/ LTCH PPS final rule, we adopted the OMB labor market area delineations issued by OMB in OMB Bulletin No. 13–01 on February 28, 2013, based on standards published on June 28, 2010 (75 FR 37246 through 37252) and the 2010 Census data to delineate labor market areas for purposes of the IPPS wage index. For IPPS wage index purposes, for hospitals that were located VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 in urban CBSAs in FY 2014 but were designated as rural under these revised OMB labor market area delineations, we generally assigned them the urban wage index value of the CBSA in which they were physically located for FY 2014 for a period of 3 fiscal years (79 FR 49957 through 49960). To be consistent, we applied the same policy to hospitals paid under the OPPS but not under the IPPS so that such hospitals maintained the wage index of the CBSA in which they were physically located for FY 2014 for 3 calendar years (until December 31, 2017). Because this 3-year transition ended at the end of CY 2017, it was not applied beginning in CY 2018. In addition, in the FY 2019 IPPS/ LTCH PPS proposed rule (83 FR 20362 through 20363), we proposed not to extend the imputed floor policy under the IPPS for FY 2019 and subsequent fiscal years, and in the FY 2019 IPPS/ LTCH PPS final rule (83 FR 41376 through 41380), we finalized this proposal. Similarly, in the CY 2019 OPPS/ASC proposed rule, we proposed not to extend the imputed floor policy under the OPPS beyond December 31, 2018 (the date the policy is set to expire). The comments we received on this proposal, along with our response, are summarized above. As discussed earlier, consistent with the FY 2019 IPPS/LTCH PPS final rule, in this CY 2019 OPPS/ASC final rule with comment period, we are finalizing our proposal not to extend the imputed floor policy under the OPPS beyond December 31, 2018. For CMHCs, for CY 2019, we proposed to continue to calculate the wage index by using the postreclassification IPPS wage index based on the CBSA where the CMHC is located. As with OPPS hospitals and for the same reasons, for CMHCs previously located in urban CBSAs that were designated as rural under the revised OMB labor market area delineations in OMB Bulletin No. 13–01, we finalized a policy to maintain the urban wage index value of the CBSA in which they were physically located for CY 2014 for 3 calendar years (until December 31, 2017). Because this 3-year transition ended at the end of CY 2017, it was not applied beginning in CY 2018. We proposed that the wage index that would apply to CMHCs for CY 2019 would include the rural floor adjustment, but would not include the imputed floor adjustment because, as discussed above, we proposed to not extend the imputed floor policy beyond December 31, 2018. Also, we proposed that the wage index that would apply to CMHCs would not include the out- PO 00000 Frm 00050 Fmt 4701 Sfmt 4700 migration adjustment because that adjustment only applies to hospitals. We did not receive any public comments on these proposals. Therefore, for the reasons discussed above and in the CY 2019 OPPS/ASC proposed rule (83 FR 37076), we are finalizing these proposals without modification. Table 2 associated with the FY 2019 IPPS/LTCH PPS final rule (available via the internet on the CMS website at: https://www.cms.gov/Medicare/ Medicare-Fee-for-Service-Payment/ AcuteInpatientPPS/) identifies counties eligible for the outmigration adjustment and IPPS hospitals that will receive the adjustment for FY 2019. We are including the out-migration adjustment information from Table 2 associated with the FY 2019 IPPS/LTCH PPS final rule as Addendum L to this final rule with comment period with the addition of non-IPPS hospitals that will receive the section 505 out-migration adjustment under the CY 2019 OPPS. Addendum L is available via the internet on the CMS website. We refer readers to the CMS website for the OPPS at: https://www.cms.gov/Medicare/ Medicare-Fee-for-Service-Payment/ HospitalOutpatientPPS/. At this link, readers will find a link to the final FY 2019 IPPS wage index tables and Addendum L. D. Statewide Average Default Cost-toCharge Ratios (CCRs) In addition to using CCRs to estimate costs from charges on claims for ratesetting, CMS uses overall hospitalspecific CCRs calculated from the hospital’s most recent cost report to determine outlier payments, payments for pass-through devices, and monthly interim transitional corridor payments under the OPPS during the PPS year. MACs cannot calculate a CCR for some hospitals because there is no cost report available. For these hospitals, CMS uses the statewide average default CCRs to determine the payments mentioned earlier until a hospital’s MAC is able to calculate the hospital’s actual CCR from its most recently submitted Medicare cost report. These hospitals include, but are not limited to, hospitals that are new, hospitals that have not accepted assignment of an existing hospital’s provider agreement, and hospitals that have not yet submitted a cost report. CMS also uses the statewide average default CCRs to determine payments for hospitals that appear to have a biased CCR (that is, the CCR falls outside the predetermined ceiling threshold for a valid CCR) or for hospitals in which the most recent cost report reflects an all- E:\FR\FM\21NOR2.SGM 21NOR2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations khammond on DSK30JT082PROD with RULES2 inclusive rate status (Medicare Claims Processing Manual (Pub. 100–04), Chapter 4, Section 10.11). In the CY 2019 OPPS/ASC proposed rule (83 FR 37076), we proposed to update the default ratios for CY 2019 using the most recent cost report data. We discussed our policy for using default CCRs, including setting the ceiling threshold for a valid CCR, in the CY 2009 OPPS/ASC final rule with comment period (73 FR 68594 through 68599) in the context of our adoption of an outlier reconciliation policy for cost VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 reports beginning on or after January 1, 2009. For detail on our process for calculating the statewide average CCRs, we referred readers to the CY 2019 OPPS proposed rule Claims Accounting Narrative that is posted on the CMS website. Table 5 published in the proposed rule (83 FR 37076 through 37078) listed the proposed statewide average default CCRs for OPPS services furnished on or after January 1, 2019, based on proposed rule data. We did not receive any public comments on our proposal to use PO 00000 Frm 00051 Fmt 4701 Sfmt 4700 58867 statewide average default CCRs if a MAC cannot calculate a CCR for a hospital and to use these CCRs to adjust charges to costs on claims data for setting the final CY 2019 OPPS relative payment weights. Therefore, we are finalizing our proposal without modification. Table 9 below lists the statewide average default CCRs for OPPS services furnished on or after January 1, 2019, based on final rule data. BILLING CODE 4120–01–P E:\FR\FM\21NOR2.SGM 21NOR2 58868 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations TABLE 9.-CY 2019 STATEWIDE AVERAGE CCRs Urban/Rural khammond on DSK30JT082PROD with RULES2 ALASKA ALASKA ALABAMA ALABAMA ARKANSAS ARKANSAS ARIZONA ARIZONA CALIFORNIA CALIFORNIA COLORADO COLORADO CONNECTICUT CONNECTICUT DISTRICT OF COLUMBIA DELAWARE FLORIDA FLORIDA GEORGIA GEORGIA HAWAII HAWAII IOWA IOWA IDAHO IDAHO ILLINOIS ILLINOIS INDIANA INDIANA KANSAS VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 Previous Default CCR(CY2018 OPPS Final Rule) RURAL URBAN RURAL URBAN RURAL URBAN RURAL URBAN RURAL URBAN RURAL URBAN RURAL URBAN 0.655 0.219 0.185 0.153 0.194 0.195 0.245 0.161 0.180 0.188 0.344 0.198 0.323 0.248 0.659 0.218 0.190 0.155 0.186 0.200 0.232 0.160 0.181 0.193 0.346 0.204 0.324 0.249 URBAN URBAN RURAL URBAN RURAL URBAN RURAL URBAN RURAL URBAN RURAL URBAN RURAL URBAN RURAL URBAN RURAL 0.268 0.266 0.169 0.134 0.225 0.195 0.340 0.320 0.285 0.240 0.418 0.344 0.206 0.211 0.250 0.209 0.258 0.279 0.295 0.158 0.138 0.222 0.198 0.332 0.322 0.296 0.254 0.339 0.369 0.214 0.208 0.299 0.213 0.264 PO 00000 Frm 00052 Fmt 4701 Sfmt 4725 E:\FR\FM\21NOR2.SGM 21NOR2 ER21NO18.017</GPH> State CY 2019 Default CCR Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations U rban!Rural KANSAS KENTUCKY KENTUCKY LOUISIANA LOUISIANA MASSACHUSETTS MASSACHUSETTS MAINE MAINE MARYLAND MARYLAND MICHIGAN MICHIGAN MINNESOTA MINNESOTA MISSOURI MISSOURI MISSISSIPPI MISSISSIPPI MONTANA MONTANA NORTH CAROLINA NORTH CAROLINA NORTH DAKOTA NORTH DAKOTA NEBRASKA NEBRASKA NEW HAMPSHIRE NEW HAMPSHIRE NEW JERSEY NEW MEXICO NEW MEXICO NEVADA NEVADA NEW YORK NEW YORK VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 CY 2019 Default CCR URBAN RURAL URBAN RURAL URBAN RURAL URBAN RURAL URBAN RURAL URBAN RURAL URBAN RURAL URBAN RURAL URBAN RURAL URBAN RURAL URBAN RURAL URBAN RURAL URBAN RURAL URBAN RURAL URBAN URBAN RURAL URBAN RURAL URBAN RURAL URBAN PO 00000 Frm 00053 Previous Default CCR(CY2018 OPPS Final Rule) 0.187 0.175 0.189 0.212 0.191 0.322 0.336 0.395 0.373 0.253 0.226 0.297 0.312 0.364 0.306 0.213 0.244 0.209 0.160 0.476 0.334 0.200 0.211 0.326 0.375 0.293 0.238 0.309 0.259 0.198 0.205 0.274 0.163 0.125 0.303 0.268 Fmt 4701 Sfmt 4725 E:\FR\FM\21NOR2.SGM 0.199 0.184 0.187 0.212 0.195 0.322 0.348 0.419 0.422 0.258 0.227 0.302 0.318 0.379 0.302 0.220 0.240 0.213 0.160 0.486 0.350 0.206 0.212 0.366 0.369 0.313 0.233 0.307 0.255 0.200 0.224 0.284 0.175 0.114 0.299 0.303 21NOR2 ER21NO18.018</GPH> khammond on DSK30JT082PROD with RULES2 State 58869 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations State U rban!Rural OHIO OHIO OKLAHOMA OKLAHOMA OREGON OREGON PENNSYLVANIA PENNSYLVANIA PUERTO RICO RHODE ISLAND SOUTH CAROLINA SOUTH CAROLINA SOUTH DAKOTA SOUTH DAKOTA TENNESSEE TENNESSEE TEXAS TEXAS UTAH UTAH VIRGINIA VIRGINIA VERMONT VERMONT WASHINGTON WASHINGTON WISCONSIN WISCONSIN WEST VIRGINIA WEST VIRGINIA WYOMING WYOMING RURAL URBAN RURAL URBAN RURAL URBAN RURAL URBAN URBAN URBAN RURAL URBAN RURAL URBAN RURAL URBAN RURAL URBAN RURAL URBAN RURAL URBAN RURAL URBAN RURAL URBAN RURAL URBAN RURAL URBAN RURAL URBAN khammond on DSK30JT082PROD with RULES2 BILLING CODE 4120–01–C E. Adjustment for Rural Sole Community Hospitals (SCHs) and Essential Access Community Hospitals (EACHs) Under Section 1833(t)(13)(B) of the Act for CY 2019 In the CY 2006 OPPS final rule with comment period (70 FR 68556), we finalized a payment increase for rural VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 CY 2019 Default CCR 0.268 0.250 0.213 0.172 0.267 0.326 0.262 0.177 0.555 0.277 0.167 0.184 0.346 0.237 0.169 0.179 0.210 0.167 0.298 0.318 0.183 0.210 0.414 0.397 0.261 0.326 0.348 0.314 0.257 0.276 0.401 0.325 sole community hospitals (SCHs) of 7.1 percent for all services and procedures paid under the OPPS, excluding drugs, biologicals, brachytherapy sources, and devices paid under the pass-through payment policy, in accordance with section 1833(t)(13)(B) of the Act, as added by section 411 of the Medicare Prescription Drug, Improvement, and PO 00000 Frm 00054 Previous Default CCR(CY2018 OPPS Final Rule) Fmt 4701 Sfmt 4700 0.280 0.203 0.215 0.169 0.290 0.336 0.267 0.173 0.577 0.276 0.170 0.191 0.391 0.242 0.173 0.174 0.205 0.168 0.391 0.304 0.177 0.215 0.393 0.378 0.256 0.323 0.348 0.308 0.253 0.297 0.407 0.327 Modernization Act of 2003 (MMA) (Pub. L. 108–173). Section 1833(t)(13) of the Act provided the Secretary the authority to make an adjustment to OPPS payments for rural hospitals, effective January 1, 2006, if justified by a study of the difference in costs by APC between hospitals in rural areas and hospitals in urban areas. Our analysis E:\FR\FM\21NOR2.SGM 21NOR2 ER21NO18.019</GPH> 58870 khammond on DSK30JT082PROD with RULES2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations showed a difference in costs for rural SCHs. Therefore, for the CY 2006 OPPS, we finalized a payment adjustment for rural SCHs of 7.1 percent for all services and procedures paid under the OPPS, excluding separately payable drugs and biologicals, brachytherapy sources, and devices paid under the pass-through payment policy, in accordance with section 1833(t)(13)(B) of the Act. In the CY 2007 OPPS/ASC final rule with comment period (71 FR 68010 and 68227), for purposes of receiving this rural adjustment, we revised § 419.43(g) of the regulations to clarify that essential access community hospitals (EACHs) also are eligible to receive the rural SCH adjustment, assuming these entities otherwise meet the rural adjustment criteria. Currently, two hospitals are classified as EACHs, and as of CY 1998, under section 4201(c) of Pub. L. 105–33, a hospital can no longer become newly classified as an EACH. This adjustment for rural SCHs is budget neutral and applied before calculating outlier payments and copayments. We stated in the CY 2006 OPPS final rule with comment period (70 FR 68560) that we would not reestablish the adjustment amount on an annual basis, but we may review the adjustment in the future and, if appropriate, would revise the adjustment. We provided the same 7.1 percent adjustment to rural SCHs, including EACHs, again in CYs 2008 through 2018. Further, in the CY 2009 OPPS/ASC final rule with comment period (73 FR 68590), we updated the regulations at § 419.43(g)(4) to specify, in general terms, that items paid at charges adjusted to costs by application of a hospital-specific CCR are excluded from the 7.1 percent payment adjustment. In the CY 2019 OPPS/ASC proposed rule (83 FR 37078), for the CY 2019 OPPS, we proposed to continue the current policy of a 7.1 percent payment adjustment that is done in a budget neutral manner for rural SCHs, including EACHs, for all services and procedures paid under the OPPS, excluding separately payable drugs and biologicals, devices paid under the passthrough payment policy, and items paid at charges reduced to costs. We invited public comment on our proposal. In addition, we proposed to maintain this 7.1 percent payment adjustment for the years after CY 2019 until we identify data in the future that would support a change to this payment adjustment. We invited public comments on our proposal. Comment: Several commenters supported the proposal to continue the 7.1 percent payment adjustment for VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 rural SCHs, including EACHs, for all services and procedures paid under the OPPS, excluding separately payable drugs and biologicals, devices paid under the pass-through payment policy, and items paid at charges reduced to costs. A few commenters explicitly supported the part of the proposal that would allow the adjustment to continue after CY 2019 until CMS identifies data that would cause CMS to reassess the adjustment. These commenters approved of having more certainty about whether the rural SCH adjustment would be in effect on an ongoing basis, because it would help hospitals covered by the adjustment improve their budget forecasting based on expected revenues. Response: We appreciate the commenters’ support. Comment: One commenter suggested that CMS further examine whether the payment adjustment for rural SCHs, including EACHs, should continue to be 7.1 percent. The commenter noted the rate of the payment adjustment was based on data analyses that are more than 10 years old. Response: While the data for the initial analyses are more than 10 years old, we periodically review the calculations used to generate the rural SCHs and EACHs adjustment. For any given year, the level of increased costs experienced by rural SCH and EACH may be higher or lower than the current 7.1 percent adjustment. Since being established in CY 2008, we believe the payment increase of 7.1 percent has continued to reasonably reflect the increased costs that rural SCHs and EACHs face when providing outpatient hospital services based on regression analyses performed on the claims data. Comment: Some commenters requested that CMS expand the payment adjustment for rural SCHs and EACHs to additional types of hospitals. One commenter requested that the payment adjustment apply to include urban SCHs because, according to the commenter, urban SCHs care for patient populations similar to rural SCHs and EACHs, face similar financial challenges to rural SCHs and EACHs, and act as safety net providers for rural areas despite their designation as urban providers. Another commenter requested that the payment adjustment also apply to Medicaredependent hospitals (MDHs) because, according to the commenter, these hospitals face similar financial challenges to rural SCHs and EACHs, and MDHs play a similar safety net role to rural SCHs and EACHs, especially for Medicare. One commenter requested that payment rates for OPPS services for all rural hospitals be increased to reduce financial vulnerability for rural PO 00000 Frm 00055 Fmt 4701 Sfmt 4700 58871 hospitals related to the high share of Medicare and Medicaid beneficiaries they serve. Response: We thank the commenters for their comments. However, the analysis we did to compare costs of urban providers to those of rural providers did not support an add-on adjustment for providers other than rural SCHs and EACHs, and our followup analyses performed in recent years have not shown differences in costs for all services for any of the additional types of providers mentioned by the commenters. Accordingly, we do not believe we currently have a basis to expand the payment adjustment to any other providers other than rural SCHs and EACHs. After consideration of the public comments we received, we are implementing our proposals, without modification, to continue the current policy of a 7.1 percent payment adjustment that is done in a budget neutral manner for rural SCHs, including EACHs, for all services and procedures paid under the OPPS, excluding separately payable drugs and biologicals, devices paid under the passthrough payment policy, and items paid at charges reduced to costs. In addition, we will maintain this 7.1 percent payment adjustment for the years after CY 2019 until our data support a change to this payment adjustment. F. Payment Adjustment for Certain Cancer Hospitals for CY 2019 1. Background Since the inception of the OPPS, which was authorized by the Balanced Budget Act of 1997 (BBA) (Pub. L. 105– 33), Medicare has paid the 11 hospitals that meet the criteria for cancer hospitals identified in section 1886(d)(1)(B)(v) of the Act under the OPPS for covered outpatient hospital services. These cancer hospitals are exempted from payment under the IPPS. With the Medicare, Medicaid and SCHIP Balanced Budget Refinement Act of 1999 (Pub. L. 106–113), Congress established section 1833(t)(7) of the Act, ‘‘Transitional Adjustment to Limit Decline in Payment,’’ to determine OPPS payments to cancer and children’s hospitals based on their pre-BBA payment amount (often referred to as ‘‘held harmless’’). As required under section 1833(t)(7)(D)(ii) of the Act, a cancer hospital receives the full amount of the difference between payments for covered outpatient services under the OPPS and a ‘‘pre-BBA amount.’’ That is, cancer hospitals are permanently held harmless to their ‘‘pre-BBA amount,’’ E:\FR\FM\21NOR2.SGM 21NOR2 khammond on DSK30JT082PROD with RULES2 58872 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations and they receive transitional outpatient payments (TOPs) or hold harmless payments to ensure that they do not receive a payment that is lower in amount under the OPPS than the payment amount they would have received before implementation of the OPPS, as set forth in section 1833(t)(7)(F) of the Act. The ‘‘pre-BBA amount’’ is the product of the hospital’s reasonable costs for covered outpatient services occurring in the current year and the base payment-to-cost ratio (PCR) for the hospital defined in section 1833(t)(7)(F)(ii) of the Act. The ‘‘preBBA amount’’ and the determination of the base PCR are defined at 42 CFR 419.70(f). TOPs are calculated on Worksheet E, Part B, of the Hospital Cost Report or the Hospital Health Care Complex Cost Report (Form CMS–2552– 96 or Form CMS–2552–10, respectively), as applicable each year. Section 1833(t)(7)(I) of the Act exempts TOPs from budget neutrality calculations. Section 3138 of the Affordable Care Act amended section 1833(t) of the Act by adding a new paragraph (18), which instructs the Secretary to conduct a study to determine if, under the OPPS, outpatient costs incurred by cancer hospitals described in section 1886(d)(1)(B)(v) of the Act with respect to APC groups exceed outpatient costs incurred by other hospitals furnishing services under section 1833(t) of the Act, as determined appropriate by the Secretary. Section 1833(t)(18)(A) of the Act requires the Secretary to take into consideration the cost of drugs and biologicals incurred by cancer hospitals and other hospitals. Section 1833(t)(18)(B) of the Act provides that, if the Secretary determines that cancer hospitals’ costs are higher than those of other hospitals, the Secretary shall provide an appropriate adjustment under section 1833(t)(2)(E) of the Act to reflect these higher costs. In 2011, after conducting the study required by section 1833(t)(18)(A) of the Act, we determined that outpatient costs incurred by the 11 specified cancer hospitals were greater than the costs incurred by other OPPS hospitals. For a complete discussion regarding the cancer hospital cost study, we refer readers to the CY 2012 OPPS/ASC final rule with comment period (76 FR 74200 through 74201). Based on these findings, we finalized a policy to provide a payment adjustment to the 11 specified cancer hospitals that reflects their higher outpatient costs, as discussed in the CY 2012 OPPS/ASC final rule with comment period (76 FR 74202 through 74206). Specifically, we adopted a VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 policy to provide additional payments to the cancer hospitals so that each cancer hospital’s final PCR for services provided in a given calendar year is equal to the weighted average PCR (which we refer to as the ‘‘target PCR’’) for other hospitals paid under the OPPS. The target PCR is set in advance of the calendar year and is calculated using the most recently submitted or settled cost report data that are available at the time of final rulemaking for the calendar year. The amount of the payment adjustment is made on an aggregate basis at cost report settlement. We note that the changes made by section 1833(t)(18) of the Act do not affect the existing statutory provisions that provide for TOPs for cancer hospitals. The TOPs are assessed, as usual, after all payments, including the cancer hospital payment adjustment, have been made for a cost reporting period. For CYs 2012 and 2013, the target PCR for purposes of the cancer hospital payment adjustment was 0.91. For CY 2014, the target PCR for purposes of the cancer hospital payment adjustment was 0.89. For CY 2015, the target PCR was 0.90. For CY 2016, the target PCR was 0.92, as discussed in the CY 2016 OPPS/ASC final rule with comment period (80 FR 70362 through 70363). For CY 2017, the target PCR was 0.91, as discussed in the CY 2017 OPPS/ASC final rule with comment period (81 FR 79603 through 79604). For CY 2018, the target PCR was 0.88, as discussed in the CY 2018 OPPS/ ASC final rule with comment period (82 FR 59265 through 59266). 2. Policy for CY 2019 Section 16002(b) of the 21st Century Cures Act (Pub. L. 114–255) amended section 1833(t)(18) of the Act by adding subparagraph (C), which requires that in applying 42 CFR 419.43(i) (that is, the payment adjustment for certain cancer hospitals) for services furnished on or after January 1, 2018, the target PCR adjustment be reduced by 1.0 percentage point less than what would otherwise apply. Section 16002(b) also provides that, in addition to the percentage reduction, the Secretary may consider making an additional percentage point reduction to the target PCR that takes into account payment rates for applicable items and services described under section 1833(t)(21)(C) of the Act for hospitals that are not cancer hospitals described under section 1886(d)(1)(B)(v) of the Act. Further, in making any budget neutrality adjustment under section 1833(t) of the Act, the Secretary shall not take into account the reduced expenditures that result from PO 00000 Frm 00056 Fmt 4701 Sfmt 4700 application of section 1833(t)(18)(C) of the Act. In the CY 2019 OPPS/ASC proposed rule (83 FR 37079), for CY 2019, we proposed to provide additional payments to the 11 specified cancer hospitals so that each cancer hospital’s final PCR is equal to the weighted average PCR (or ‘‘target PCR’’) for the other OPPS hospitals using the most recent submitted or settled cost report data that were available at the time of the development of the proposed rule, reduced by 1.0 percentage point, to comply with section 16002(b) of the 21st Century Cures Act. We invited public comment on our proposal. We did not propose an additional reduction beyond the 1.0 percentage point reduction required by section 16002(b) for CY 2019. To calculate the proposed CY 2019 target PCR, we used the same extract of cost report data from HCRIS, as discussed in section II.A. of the proposed rule and this final rule with comment period, used to estimate costs for the CY 2019 OPPS. Using these cost report data, we included data from Worksheet E, Part B, for each hospital, using data from each hospital’s most recent cost report, whether as submitted or settled. We then limited the dataset to the hospitals with CY 2017 claims data that we used to model the impact of the proposed CY 2019 APC relative payment weights (3,676 hospitals) because it is appropriate to use the same set of hospitals that are being used to calibrate the modeled CY 2019 OPPS. The cost report data for the hospitals in this dataset were from cost report periods with fiscal year ends ranging from 2014 to 2017. We then removed the cost report data of the 43 hospitals located in Puerto Rico from our dataset because we did not believe their cost structure reflected the costs of most hospitals paid under the OPPS, and, therefore, their inclusion may bias the calculation of hospital-weighted statistics. We also removed the cost report data of 18 hospitals because these hospitals had cost report data that were not complete (missing aggregate OPPS payments, missing aggregate cost data, or missing both), so that all cost reports in the study would have both the payment and cost data necessary to calculate a PCR for each hospital, leading to a proposed analytic file of 3,615 hospitals with cost report data. Using this smaller dataset of cost report data, we estimated that, on average, the OPPS payments to other hospitals furnishing services under the OPPS were approximately 89 percent of reasonable cost (weighted average PCR of 0.89). Therefore, after applying the E:\FR\FM\21NOR2.SGM 21NOR2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 report data for the hospitals in the dataset were from cost report periods with fiscal year ends ranging from 2010 to 2018. We then removed the cost report data of the 46 hospitals located in Puerto Rico from our dataset because we do not believe that their cost structure reflects the costs of most hospitals paid under the OPPS and, therefore, their inclusion may bias the calculation of hospital-weighted statistics. We also removed the cost report data of 22 hospitals because these hospitals had cost report data that were not complete (missing aggregate OPPS payments, missing aggregate cost data, or missing both), so that all cost reports in the study would have both the payment and cost data necessary to calculate a PCR for each hospital, leading to an analytic file of 3,628 hospitals with cost report data. Using this smaller dataset of cost report data, we estimated a target PCR of 0.89. Therefore, after applying the 1.0 percentage point reduction as required by section 16002(b) of the 21st Century PO 00000 Frm 00057 Fmt 4701 Sfmt 4725 Cures Act, we are finalizing that the payment amount associated with the cancer hospital payment adjustment to be determined at cost report settlement will be the additional payment needed to result in a PCR equal to 0.88 for each cancer hospital. Table 10 below shows the estimated percentage increase in OPPS payments to each cancer hospital for CY 2019, due to the cancer hospital payment adjustment policy. The actual amount of the CY 2019 cancer hospital payment adjustment for each cancer hospital will be determined at cost report settlement and will depend on each hospital’s CY 2019 payments and costs. We note that the requirements contained in section 1833(t)(18) of the Act do not affect the existing statutory provisions that provide for TOPs for cancer hospitals. The TOPs will be assessed, as usual, after all payments, including the cancer hospital payment adjustment, have been made for a cost reporting period. BILLING CODE 4120–01–P E:\FR\FM\21NOR2.SGM 21NOR2 ER21NO18.020</GPH> khammond on DSK30JT082PROD with RULES2 1.0 percentage point reduction, as required by section 16002(b) of the 21st Century Cures Act, we proposed that the payment amount associated with the cancer hospital payment adjustment to be determined at cost report settlement would be the additional payment needed to result in a proposed target PCR equal to 0.88 for each cancer hospital. We did not receive any public comments on our proposals. Therefore, we are finalizing our proposed cancer hospital payment adjustment methodology without modification. For this final rule with comment period, we are using the most recent cost report data through June 30, 2018 to update the adjustment. This update yields a target PCR of 0.89. We limited the dataset to the hospitals with CY 2017 claims data that we used to model the impact of the CY 2019 APC relative payment weights (3,696 hospitals) because it is appropriate to use the same set of hospitals that we are using to calibrate the modeled CY 2019 OPPS. The cost 58873 58874 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations BILLING CODE 4120–01–C G. Hospital Outpatient Outlier Payments khammond on DSK30JT082PROD with RULES2 1. Background The OPPS provides outlier payments to hospitals to help mitigate the financial risk associated with high-cost and complex procedures, where a very costly service could present a hospital with significant financial loss. As explained in the CY 2015 OPPS/ASC final rule with comment period (79 FR 66832 through 66834), we set our projected target for aggregate outlier payments at 1.0 percent of the estimated aggregate total payments under the OPPS for the prospective year. Outlier payments are provided on a service-byservice basis when the cost of a service exceeds the APC payment amount multiplier threshold (the APC payment amount multiplied by a certain amount) as well as the APC payment amount plus a fixed-dollar amount threshold (the APC payment plus a certain amount of dollars). In CY 2018, the outlier threshold was met when the hospital’s cost of furnishing a service exceeded 1.75 times (the multiplier threshold) the APC payment amount and exceeded the APC payment amount plus $4,150 (the fixed-dollar amount threshold) (82 FR 59267 through 59268). If the cost of a service exceeds both the multiplier threshold and the fixed-dollar threshold, the outlier payment is calculated as 50 percent of the amount by which the cost of furnishing the service exceeds 1.75 times the APC payment amount. Beginning with CY 2009 payments, outlier payments are subject to a reconciliation process similar to the IPPS outlier reconciliation process for cost reports, as discussed in the CY 2009 OPPS/ASC final rule with comment period (73 FR 68594 through 68599). It has been our policy to report the actual amount of outlier payments as a percent of total spending in the claims being used to model the OPPS. Our estimate of total outlier payments as a percent of total CY 2017 OPPS payments, using CY 2017 claims available for the CY 2019 OPPS/ASC proposed rule (83 FR 37080 through 37081), was approximately 1.0 percent of the total aggregated OPPS payments. Therefore, for CY 2017, we estimated that we paid the outlier target of 1.0 percent of total aggregated OPPS payments. Using an updated claims dataset for this CY 2019 OPPS final rule with comment period, we estimate that we paid approximately 1.12 percent of the total aggregated OPPS payments in outliers for CY 2017. VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 For the CY 2019 OPPS/ASC proposed rule, using CY 2017 claims data and CY 2018 payment rates, we estimate that the aggregate outlier payments for CY 2018 would be approximately 1.02 percent of the total CY 2018 OPPS payments. We provided estimated CY 2019 outlier payments for hospitals and CMHCs with claims included in the claims data that we used to model impacts in the Hospital-Specific Impacts—Provider-Specific Data file on the CMS website at: https:// www.cms.gov/Medicare/Medicare-Feefor-Service-Payment/ HospitalOutpatientPPS/. 2. Outlier Calculation for CY 2019 In the CY 2019 OPPS/ASC proposed rule (83 FR 37080 through 37081), for CY 2019, we proposed to continue our policy of estimating outlier payments to be 1.0 percent of the estimated aggregate total payments under the OPPS. We proposed that a portion of that 1.0 percent, an amount equal to less than 0.01 percent of outlier payments (or 0.0001 percent of total OPPS payments), would be allocated to CMHCs for PHP outlier payments. This is the amount of estimated outlier payments that would result from the proposed CMHC outlier threshold as a proportion of total estimated OPPS outlier payments. As discussed in section VIII.C. of the CY 2019 OPPS/ASC proposed rule (83 FR 37134 through 37136), we proposed to continue our longstanding policy that if a CMHC’s cost for partial hospitalization services, paid under APC 5853 (Partial Hospitalization for CMHCs), exceeds 3.40 times the payment rate for proposed APC 5853, the outlier payment would be calculated as 50 percent of the amount by which the cost exceeds 3.40 times the proposed APC 5853 payment rate. For further discussion of CMHC outlier payments, we refer readers to section VIII.C. of the proposed rule and this final rule with comment period. To ensure that the estimated CY 2019 aggregate outlier payments would equal 1.0 percent of estimated aggregate total payments under the OPPS, we proposed that the hospital outlier threshold be set so that outlier payments would be triggered when a hospital’s cost of furnishing a service exceeds 1.75 times the APC payment amount and exceeds the APC payment amount plus $4,600. We calculated the proposed fixeddollar threshold of $4,600 using the standard methodology most recently used for CY 2018 (82 FR 59267 through 59268). For purposes of estimating outlier payments for the proposed rule, we used the hospital-specific overall ancillary CCRs available in the April PO 00000 Frm 00058 Fmt 4701 Sfmt 4700 2018 update to the Outpatient ProviderSpecific File (OPSF). The OPSF contains provider-specific data, such as the most current CCRs, which are maintained by the MACs and used by the OPPS Pricer to pay claims. The claims that we use to model each OPPS update lag by 2 years. In order to estimate the CY 2019 hospital outlier payments for the proposed rule, we inflated the charges on the CY 2017 claims using the same inflation factor of 1.085868 that we used to estimate the IPPS fixed-dollar outlier threshold for the FY 2019 IPPS/LTCH PPS proposed rule (83 FR 20581). We used an inflation factor of 1.04205 to estimate CY 2018 charges from the CY 2017 charges reported on CY 2017 claims. The methodology for determining this charge inflation factor is discussed in the FY 2018 IPPS/LTCH PPS final rule (82 FR 20581). As we stated in the CY 2005 OPPS final rule with comment period (69 FR 65845), we believe that the use of these charge inflation factors is appropriate for the OPPS because, with the exception of the inpatient routine service cost centers, hospitals use the same ancillary and outpatient cost centers to capture costs and charges for inpatient and outpatient services. As noted in the CY 2007 OPPS/ASC final rule with comment period (71 FR 68011), we are concerned that we could systematically overestimate the OPPS hospital outlier threshold if we did not apply a CCR inflation adjustment factor. Therefore, we proposed to apply the same CCR inflation adjustment factor that we proposed to apply for the FY 2019 IPPS outlier calculation to the CCRs used to simulate the proposed CY 2019 OPPS outlier payments to determine the fixed-dollar threshold. Specifically, for CY 2019, we proposed to apply an adjustment factor of 0.987842 to the CCRs that were in the April 2018 OPSF to trend them forward from CY 2018 to CY 2019. The methodology for calculating the proposed adjustment is discussed in the FY 2019 IPPS/LTCH PPS proposed rule (83 FR 20582). To model hospital outlier payments for the proposed rule, we applied the overall CCRs from the April 2018 OPSF after adjustment (using the proposed CCR inflation adjustment factor of 0.987842 to approximate CY 2019 CCRs) to charges on CY 2017 claims that were adjusted (using the proposed charge inflation factor of 1.085868 to approximate CY 2019 charges). We simulated aggregated CY 2019 hospital outlier payments using these costs for several different fixed-dollar thresholds, holding the 1.75 multiplier threshold E:\FR\FM\21NOR2.SGM 21NOR2 khammond on DSK30JT082PROD with RULES2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations constant and assuming that outlier payments would continue to be made at 50 percent of the amount by which the cost of furnishing the service would exceed 1.75 times the APC payment amount, until the total outlier payments equaled 1.0 percent of aggregated estimated total CY 2019 OPPS payments. We estimated that a proposed fixed-dollar threshold of $4,600, combined with the proposed multiplier threshold of 1.75 times the APC payment rate, would allocate 1.0 percent of aggregated total OPPS payments to outlier payments. For CMHCs, we proposed that, if a CMHC’s cost for partial hospitalization services, paid under APC 5853, exceeds 3.40 times the payment rate for APC 5853, the outlier payment would be calculated as 50 percent of the amount by which the cost exceeds 3.40 times the APC 5853 payment rate. Section 1833(t)(17)(A) of the Act, which applies to hospitals, as defined under section 1886(d)(1)(B) of the Act, requires that hospitals that fail to report data required for the quality measures selected by the Secretary, in the form and manner required by the Secretary under section 1833(t)(17)(B) of the Act, incur a 2.0 percentage point reduction to their OPD fee schedule increase factor; that is, the annual payment update factor. The application of a reduced OPD fee schedule increase factor results in reduced national unadjusted payment rates that will apply to certain outpatient items and services furnished by hospitals that are required to report outpatient quality data and that fail to meet the Hospital OQR Program requirements. For hospitals that fail to meet the Hospital OQR Program requirements, as we proposed, we are continuing the policy that we implemented in CY 2010 that the hospitals’ costs will be compared to the reduced payments for purposes of outlier eligibility and payment calculation. For more information on the Hospital OQR Program, we referred readers to section XIII. of this final rule with comment period. Comment: One commenter expressed concern that, due to the increase in the proposed fixed-dollar threshold to $4,600 relative to the previous CY 2018 fixed-dollar outlier threshold of $4,150, the drastic reduction in outlier payments would have an adverse effect on access to services for Medicare beneficiaries. Therefore, the commenter requested that the threshold be transitioned over a 3-year period. Response: As indicated earlier, we introduced a fixed-dollar threshold in order to better target outlier payments to those high-cost and complex procedures VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 where a very costly service could present a hospital with significant financial loss. We maintain the target outlier percentage of 1.0 percent of estimated aggregate total payment under the OPPS and have a fixed-dollar threshold so that OPPS outlier payments are made only when the hospital would experience a significant loss for furnishing a particular service. The methodology we use to calculate the fixed-dollar threshold for the prospective payment year factors is based on several data inputs that may change from prior payment years. For instance, updated hospital CCR data and changes to the OPPS payment methodology influence projected outlier payments in the prospective year. We do not believe that it is appropriate to transition towards implementation of the CY 2019 OPPS fixed-dollar outlier threshold in the manner described by the commenter. The fixed-dollar outlier threshold is specifically developed in order to best estimate aggregate outlier payments of 1 percent of the OPPS. In addition, transitioning in this suggested manner would remove the consideration of updated data, which is critical in best estimating the fixed-dollar threshold that would result in total OPPS outliers being 1 percent of aggregate OPPS payments. Finally, we note that the increase in the fixed-dollar outlier threshold does not necessarily result in a decrease in aggregate OPPS outlier payments. Rather, it ensures that the aggregate pool remains at 1 percent and that outlier payments are directed towards the high cost and complex procedures associated with potential financial risk. After consideration of the public comment we received, we are finalizing our proposal, without modification, to continue our policy of estimating outlier payments to be 1.0 percent of the estimated aggregate total payments under the OPPS and to use our established methodology to set the OPPS outlier fixed-dollar loss threshold for CY 2019. 3. Final Outlier Calculation Consistent with historical practice, we used updated data for this final rule with comment period for outlier calculations. For CY 2019, we are applying the overall CCRs from the October 2018 OPSF file after adjustment (using the CCR inflation adjustment factor of 0.9813 to approximate CY 2019 CCRs) to charges on CY 2017 claims that were adjusted using a charge inflation factor of 1.0434 to approximate CY 2019 charges. These are the same CCR adjustment and charge inflation factors PO 00000 Frm 00059 Fmt 4701 Sfmt 4700 58875 that were used to set the IPPS fixeddollar thresholds for the FY 2019 IPPS/ LTCH PPS final rule (83 FR 41722). We simulated aggregated CY 2019 hospital outlier payments using these costs for several different fixed-dollar thresholds, holding the 1.75 multiple-threshold constant and assuming that outlier payments will continue to be made at 50 percent of the amount by which the cost of furnishing the service would exceed 1.75 times the APC payment amount, until the total outlier payment equaled 1.0 percent of aggregated estimated total CY 2019 OPPS payments. We estimate that a fixed-dollar threshold of $4,825 combined with the multiple threshold of 1.75 times the APC payment rate, will allocated the 1.0 percent of aggregated total OPPS payments to outlier payments. For CMHCs, if a CMHC’s cost for partial hospitalization services, paid under PAC 5853, exceeds 3.40 times the payment rate the outlier payment will be calculated as 50 percent of the amount by which the cost exceeds 3.40 times APC 5853. H. Calculation of an Adjusted Medicare Payment From the National Unadjusted Medicare Payment The basic methodology for determining prospective payment rates for HOPD services under the OPPS is set forth in existing regulations at 42 CFR part 419, subparts C and D. For this CY 2019 OPPS/ASC final rule with comment period, the payment rate for most services and procedures for which payment is made under the OPPS is the product of the conversion factor calculated in accordance with section II.B. of this final rule with comment period and the relative payment weight determined under section II.A. of this final rule with comment period. Therefore, the national unadjusted payment rate for most APCs contained in Addendum A to this final rule with comment period (which is available via the internet on the CMS website) and for most HCPCS codes to which separate payment under the OPPS has been assigned in Addendum B to this final rule with comment period (which is available via the internet on the CMS website) was calculated by multiplying the CY 2019 scaled weight for the APC by the CY 2019 conversion factor. We note that section 1833(t)(17) of the Act, which applies to hospitals as defined under section 1886(d)(1)(B) of the Act, requires that hospitals that fail to submit data required to be submitted on quality measures selected by the Secretary, in the form and manner and at a time specified by the Secretary, incur a reduction of 2.0 percentage E:\FR\FM\21NOR2.SGM 21NOR2 khammond on DSK30JT082PROD with RULES2 58876 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations points to their OPD fee schedule increase factor, that is, the annual payment update factor. The application of a reduced OPD fee schedule increase factor results in reduced national unadjusted payment rates that apply to certain outpatient items and services provided by hospitals that are required to report outpatient quality data and that fail to meet the Hospital OQR Program (formerly referred to as the Hospital Outpatient Quality Data Reporting Program (HOP QDRP)) requirements. For further discussion of the payment reduction for hospitals that fail to meet the requirements of the Hospital OQR Program, we refer readers to section XIII. of this final rule with comment period. In the CY 2019 OPPS/ASC proposed rule (83 FR 37082), we demonstrated the steps to determine the APC payments that will be made in a calendar year under the OPPS to a hospital that fulfills the Hospital OQR Program requirements and to a hospital that fails to meet the Hospital OQR Program requirements for a service that has any of the following status indicator assignments: ‘‘J1’’, ‘‘J2’’, ‘‘P’’, ‘‘Q1’’, ‘‘Q2’’, ‘‘Q3’’, ‘‘Q4’’, ‘‘R’’, ‘‘S’’, ‘‘T’’, ‘‘U’’, or ‘‘V’’ (as defined in Addendum D1 to the proposed rule, which is available via the internet on the CMS website), in a circumstance in which the multiple procedure discount does not apply, the procedure is not bilateral, and conditionally packaged services (status indicator of ‘‘Q1’’ and ‘‘Q2’’) qualify for separate payment. We noted that, although blood and blood products with status indicator ‘‘R’’ and brachytherapy sources with status indicator ‘‘U’’ are not subject to wage adjustment, they are subject to reduced payments when a hospital fails to meet the Hospital OQR Program requirements. We did not receive any public comments specific to the steps under the methodology that we included in the proposed rule to determine the APC payments for CY 2019. Therefore, we are finalizing use of the steps in the methodology specified below, as we proposed, to demonstrate the calculation of the final CY 2019 OPPS payments using the same parameters. Individual providers interested in calculating the payment amount that they will receive for a specific service from the national unadjusted payment rates presented in Addenda A and B to this final rule with comment period (which are available via the internet on the CMS website) should follow the formulas presented in the following steps. For purposes of the payment calculations below, we refer to the national unadjusted payment rate for VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 hospitals that meet the requirements of the Hospital OQR Program as the ‘‘full’’ national unadjusted payment rate. We refer to the national unadjusted payment rate for hospitals that fail to meet the requirements of the Hospital OQR Program as the ‘‘reduced’’ national unadjusted payment rate. The reduced national unadjusted payment rate is calculated by multiplying the reporting ratio of 0.980 times the ‘‘full’’ national unadjusted payment rate. The national unadjusted payment rate used in the calculations below is either the full national unadjusted payment rate or the reduced national unadjusted payment rate, depending on whether the hospital met its Hospital OQR Program requirements in order to receive the full CY 2019 OPPS fee schedule increase factor. Step 1. Calculate 60 percent (the labor-related portion) of the national unadjusted payment rate. Since the initial implementation of the OPPS, we have used 60 percent to represent our estimate of that portion of costs attributable, on average, to labor. We refer readers to the April 7, 2000 OPPS final rule with comment period (65 FR 18496 through 18497) for a detailed discussion of how we derived this percentage. During our regression analysis for the payment adjustment for rural hospitals in the CY 2006 OPPS final rule with comment period (70 FR 68553), we confirmed that this laborrelated share for hospital outpatient services is appropriate. The formula below is a mathematical representation of Step 1 and identifies the labor-related portion of a specific payment rate for a specific service. X is the labor-related portion of the national unadjusted payment rate. X = .60 * (national unadjusted payment rate). Step 2. Determine the wage index area in which the hospital is located and identify the wage index level that applies to the specific hospital. We note that, under the CY 2019 OPPS policy for continuing to use the OMB labor market area delineations based on the 2010 Decennial Census data for the wage indexes used under the IPPS, a hold harmless policy for the wage index may apply, as discussed in section II.C. of this final rule with comment period. The wage index values assigned to each area reflect the geographic statistical areas (which are based upon OMB standards) to which hospitals are assigned for FY 2019 under the IPPS, reclassifications through the Metropolitan Geographic Classification Review Board (MGCRB), section 1886(d)(8)(B) ‘‘Lugar’’ hospitals, PO 00000 Frm 00060 Fmt 4701 Sfmt 4700 reclassifications under section 1886(d)(8)(E) of the Act, as defined in § 412.103 of the regulations, and hospitals designated as urban under section 601(g) of Public Law 98–21. For further discussion of the changes to the FY 2019 IPPS wage indexes, as applied to the CY 2019 OPPS, we refer readers to section II.C. of this final rule with comment period. We are continuing to apply a wage index floor of 1.00 to frontier States, in accordance with section 10324 of the Affordable Care Act of 2010. Step 3. Adjust the wage index of hospitals located in certain qualifying counties that have a relatively high percentage of hospital employees who reside in the county, but who work in a different county with a higher wage index, in accordance with section 505 of Public Law 108–173. Addendum L to this final rule with comment period (which is available via the internet on the CMS website) contains the qualifying counties and the associated wage index increase developed for the FY 2019 IPPS, which are listed in Table 2 associated with the FY 2019 IPPS/ LTCH PPS final rule available via the internet on the CMS website at: https:// www.cms.gov/Medicare/Medicare-Feefor-Service-Payment/ AcuteInpatientPPS/. (Click on the link on the left side of the screen titled ‘‘FY 2019 IPPS Final Rule Home Page’’ and select ‘‘FY 2019 Final Rule Tables.’’) This step is to be followed only if the hospital is not reclassified or redesignated under section 1886(d)(8) or section 1886(d)(10) of the Act. Step 4. Multiply the applicable wage index determined under Steps 2 and 3 by the amount determined under Step 1 that represents the labor-related portion of the national unadjusted payment rate. The formula below is a mathematical representation of Step 4 and adjusts the labor-related portion of the national unadjusted payment rate for the specific service by the wage index. Xa is the labor-related portion of the national unadjusted payment rate (wage adjusted). Xa = .60 * (national unadjusted payment rate) * applicable wage index. Step 5. Calculate 40 percent (the nonlabor-related portion) of the national unadjusted payment rate and add that amount to the resulting product of Step 4. The result is the wage index adjusted payment rate for the relevant wage index area. The formula below is a mathematical representation of Step 5 and calculates the remaining portion of the national payment rate, the amount not E:\FR\FM\21NOR2.SGM 21NOR2 khammond on DSK30JT082PROD with RULES2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations attributable to labor, and the adjusted payment for the specific service. Y is the nonlabor-related portion of the national unadjusted payment rate. Y = .40 * (national unadjusted payment rate). Adjusted Medicare Payment = Y + Xa. Step 6. If a provider is an SCH, as set forth in the regulations at § 412.92, or an EACH, which is considered to be an SCH under section 1886(d)(5)(D)(iii)(III) of the Act, and located in a rural area, as defined in § 412.64(b), or is treated as being located in a rural area under § 412.103, multiply the wage index adjusted payment rate by 1.071 to calculate the total payment. The formula below is a mathematical representation of Step 6 and applies the rural adjustment for rural SCHs. Adjusted Medicare Payment (SCH or EACH) = Adjusted Medicare Payment * 1.071. We are providing examples below of the calculation of both the full and reduced national unadjusted payment rates that will apply to certain outpatient items and services performed by hospitals that meet and that fail to meet the Hospital OQR Program requirements, using the steps outlined above. For purposes of this example, we used a provider that is located in Brooklyn, New York that is assigned to CBSA 35614. This provider bills one service that is assigned to APC 5071 (Level 1 Excision/Biopsy/Incision and Drainage). The CY 2019 full national unadjusted payment rate for APC 5071 is approximately $579.34. The reduced national unadjusted payment rate for APC 5071 for a hospital that fails to meet the Hospital OQR Program requirements is approximately $567.75. This reduced rate is calculated by multiplying the reporting ratio of 0.980 by the full unadjusted payment rate for APC 5071. The FY 2019 wage index for a provider located in CBSA 35614 in New York is 1.2853. The labor-related portion of the full national unadjusted payment is approximately $446.77 (.60 * $579.34 * 1.2853). The labor-related portion of the reduced national unadjusted payment is approximately $437.84 (.60 * 567.75 * 1.2853). The nonlabor-related portion of the full national unadjusted payment is approximately $231.74 (.40 * $579.34). The nonlabor-related portion of the reduced national unadjusted payment is approximately $227.10 (.40 * $567.75). The sum of the labor-related and nonlabor-related portions of the full national adjusted payment is approximately $678.51 ($446.77 + $231.74). The sum of the portions of the VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 reduced national adjusted payment is approximately $664.94 ($437.84 + $227.10). I. Beneficiary Copayments 1. Background Section 1833(t)(3)(B) of the Act requires the Secretary to set rules for determining the unadjusted copayment amounts to be paid by beneficiaries for covered OPD services. Section 1833(t)(8)(C)(ii) of the Act specifies that the Secretary must reduce the national unadjusted copayment amount for a covered OPD service (or group of such services) furnished in a year in a manner so that the effective copayment rate (determined on a national unadjusted basis) for that service in the year does not exceed a specified percentage. As specified in section 1833(t)(8)(C)(ii)(V) of the Act, the effective copayment rate for a covered OPD service paid under the OPPS in CY 2006, and in calendar years thereafter, shall not exceed 40 percent of the APC payment rate. Section 1833(t)(3)(B)(ii) of the Act provides that, for a covered OPD service (or group of such services) furnished in a year, the national unadjusted copayment amount cannot be less than 20 percent of the OPD fee schedule amount. However, section 1833(t)(8)(C)(i) of the Act limits the amount of beneficiary copayment that may be collected for a procedure (including items such as drugs and biologicals) performed in a year to the amount of the inpatient hospital deductible for that year. Section 4104 of the Affordable Care Act eliminated the Medicare Part B coinsurance for preventive services furnished on and after January 1, 2011, that meet certain requirements, including flexible sigmoidoscopies and screening colonoscopies, and waived the Part B deductible for screening colonoscopies that become diagnostic during the procedure. Our discussion of the changes made by the Affordable Care Act with regard to copayments for preventive services furnished on and after January 1, 2011, may be found in section XII.B. of the CY 2011 OPPS/ASC final rule with comment period (75 FR 72013). 2. OPPS Copayment Policy In the CY 2019 OPPS/ASC proposed rule (83 FR 37083), for CY 2019, we proposed to determine copayment amounts for new and revised APCs using the same methodology that we implemented beginning in CY 2004. (We refer readers to the November 7, 2003 OPPS final rule with comment PO 00000 Frm 00061 Fmt 4701 Sfmt 4700 58877 period (68 FR 63458).) In addition, we proposed to use the same standard rounding principles that we have historically used in instances where the application of our standard copayment methodology would result in a copayment amount that is less than 20 percent and cannot be rounded, under standard rounding principles, to 20 percent. (We refer readers to the CY 2008 OPPS/ASC final rule with comment period (72 FR 66687) in which we discuss our rationale for applying these rounding principles.) The proposed national unadjusted copayment amounts for services payable under the OPPS that would be effective January 1, 2019 were included in Addenda A and B to the proposed rule (which are available via the internet on the CMS website). As discussed in section XIII.E. of the proposed rule and this final rule with comment period, for CY 2019, the Medicare beneficiary’s minimum unadjusted copayment and national unadjusted copayment for a service to which a reduced national unadjusted payment rate applies will equal the product of the reporting ratio and the national unadjusted copayment, or the product of the reporting ratio and the minimum unadjusted copayment, respectively, for the service. We note that OPPS copayments may increase or decrease each year based on changes in the calculated APC payment rates due to updated cost report and claims data, and any changes to the OPPS cost modeling process. However, as described in the CY 2004 OPPS final rule with comment period, the development of the copayment methodology generally moves beneficiary copayments closer to 20 percent of OPPS APC payments (68 FR 63458 through 63459). In the CY 2004 OPPS final rule with comment period (68 FR 63459), we adopted a new methodology to calculate unadjusted copayment amounts in situations including reorganizing APCs, and we finalized the following rules to determine copayment amounts in CY 2004 and subsequent years. • When an APC group consists solely of HCPCS codes that were not paid under the OPPS the prior year because they were packaged or excluded or are new codes, the unadjusted copayment amount would be 20 percent of the APC payment rate. • If a new APC that did not exist during the prior year is created and consists of HCPCS codes previously assigned to other APCs, the copayment amount is calculated as the product of the APC payment rate and the lowest E:\FR\FM\21NOR2.SGM 21NOR2 khammond on DSK30JT082PROD with RULES2 58878 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations coinsurance percentage of the codes comprising the new APC. • If no codes are added to or removed from an APC and, after recalibration of its relative payment weight, the new payment rate is equal to or greater than the prior year’s rate, the copayment amount remains constant (unless the resulting coinsurance percentage is less than 20 percent). • If no codes are added to or removed from an APC and, after recalibration of its relative payment weight, the new payment rate is less than the prior year’s rate, the copayment amount is calculated as the product of the new payment rate and the prior year’s coinsurance percentage. • If HCPCS codes are added to or deleted from an APC and, after recalibrating its relative payment weight, holding its unadjusted copayment amount constant results in a decrease in the coinsurance percentage for the reconfigured APC, the copayment amount would not change (unless retaining the copayment amount would result in a coinsurance rate less than 20 percent). • If HCPCS codes are added to an APC and, after recalibrating its relative payment weight, holding its unadjusted copayment amount constant results in an increase in the coinsurance percentage for the reconfigured APC, the copayment amount would be calculated as the product of the payment rate of the reconfigured APC and the lowest coinsurance percentage of the codes being added to the reconfigured APC. We noted in the CY 2004 OPPS final rule with comment period that we would seek to lower the copayment percentage for a service in an APC from the prior year if the copayment percentage was greater than 20 percent. We noted that this principle was consistent with section 1833(t)(8)(C)(ii) of the Act, which accelerates the reduction in the national unadjusted coinsurance rate so that beneficiary liability will eventually equal 20 percent of the OPPS payment rate for all OPPS services to which a copayment applies, and with section 1833(t)(3)(B) of the Act, which achieves a 20-percent copayment percentage when fully phased in and gives the Secretary the authority to set rules for determining copayment amounts for new services. We further noted that the use of this methodology would, in general, reduce the beneficiary coinsurance rate and copayment amount for APCs for which the payment rate changes as the result of the reconfiguration of APCs and/or recalibration of relative payment weights (68 FR 63459). VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 Comment: One commenter supported the beneficiary copayment limit that may be collected for certain drugs to the amount of the inpatient hospital deductible for that year. Response: We appreciate the commenter’s support. We note that section 1833(t)(8)(C)(i) of the Act requires us to limit the amount of beneficiary copayment that may be collected for a procedure (including items such as drugs and biologicals) performed in a year to the amount of the inpatient hospital deductible for that year. 3. Calculation of an Adjusted Copayment Amount for an APC Group Individuals interested in calculating the national copayment liability for a Medicare beneficiary for a given service provided by a hospital that met or failed to meet its Hospital OQR Program requirements should follow the formulas presented in the following steps. Step 1. Calculate the beneficiary payment percentage for the APC by dividing the APC’s national unadjusted copayment by its payment rate. For example, using APC 5071, $115.87 is approximately 20 percent of the full national unadjusted payment rate of $579.34. For APCs with only a minimum unadjusted copayment in Addenda A and B to this final rule with comment period (which are available via the internet on the CMS website), the beneficiary payment percentage is 20 percent. The formula below is a mathematical representation of Step 1 and calculates the national copayment as a percentage of national payment for a given service. B is the beneficiary payment percentage. B = National unadjusted copayment for APC/national unadjusted payment rate for APC. Step 2. Calculate the appropriate wage-adjusted payment rate for the APC for the provider in question, as indicated in Steps 2 through 4 under section II.H. of this final rule with comment period. Calculate the rural adjustment for eligible providers as indicated in Step 6 under section II.H. of this final rule with comment period. Step 3. Multiply the percentage calculated in Step 1 by the payment rate calculated in Step 2. The result is the wage-adjusted copayment amount for the APC. The formula below is a mathematical representation of Step 3 and applies the beneficiary payment percentage to the adjusted payment rate for a service calculated under section II.H. of this final rule with comment period, with PO 00000 Frm 00062 Fmt 4701 Sfmt 4700 and without the rural adjustment, to calculate the adjusted beneficiary copayment for a given service. Wage-adjusted copayment amount for the APC = Adjusted Medicare Payment * B. Wage-adjusted copayment amount for the APC (SCH or EACH) = (Adjusted Medicare Payment * 1.071) * B. Step 4. For a hospital that failed to meet its Hospital OQR Program requirements, multiply the copayment calculated in Step 3 by the reporting ratio of 0.980. The unadjusted copayments for services payable under the OPPS that will be effective January 1, 2019, are shown in Addenda A and B to this final rule with comment period (which are available via the internet on the CMS website). We note that the national unadjusted payment rates and copayment rates shown in Addenda A and B to this final rule with comment period reflect the CY 2019 OPD fee schedule increase factor discussed in section II.B. of this final rule with comment period. In addition, as noted earlier, section 1833(t)(8)(C)(i) of the Act limits the amount of beneficiary copayment that may be collected for a procedure performed in a year to the amount of the inpatient hospital deductible for that year. III. OPPS Ambulatory Payment Classification (APC) Group Policies A. OPPS Treatment of New CPT and Level II HCPCS Codes CPT and Level II HCPCS codes are used to report procedures, services, items, and supplies under the hospital OPPS. Specifically, CMS recognizes the following codes on OPPS claims: • Category I CPT codes, which describe surgical procedures and medical services; • Category III CPT codes, which describe new and emerging technologies, services, and procedures; and • Level II HCPCS codes, which are used primarily to identify products, supplies, temporary procedures, and services not described by CPT codes. CPT codes are established by the American Medical Association (AMA) and the Level II HCPCS codes are established by CMS. These codes are updated and changed throughout the year. CPT and HCPCS code changes that affect the OPPS are published both through the annual rulemaking cycle and through the OPPS quarterly update Change Requests (CRs). CMS releases new Level II HCPCS codes to the public E:\FR\FM\21NOR2.SGM 21NOR2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 payment or more accurate payment for these items or services in a timelier manner than if we waited for the annual rulemaking process. We solicit public comments on these new codes and finalize our proposals related to these codes through our annual rulemaking process. We note that, under the OPPS, the APC assignment determines the payment rate for an item, procedure, or service. Those items, procedures, or services not paid separately under the hospital OPPS are assigned to PO 00000 Frm 00063 Fmt 4701 Sfmt 4725 appropriate status indicators. Certain payment status indicators provide separate payment, while other payment status indicators do not. Section XI. of this final rule with comment period discusses the various status indicators used under the OPPS. In Table 11 below, we summarize our current process for updating codes through our OPPS quarterly update CRs, seeking public comments, and finalizing the treatment of these new codes under the OPPS. BILLING CODE 4120–01–P E:\FR\FM\21NOR2.SGM 21NOR2 ER21NO18.021</GPH> khammond on DSK30JT082PROD with RULES2 or recognizes the release of new CPT codes by the AMA and makes these codes effective (that is, the codes can be reported on Medicare claims) outside of the formal rulemaking process via OPPS quarterly update CRs. Based on our review, we assign the new CPT and Level II HCPCS codes to interim status indicators (SIs) and APCs. These interim assignments are finalized in the OPPS/ ASC final rules. This quarterly process offers hospitals access to codes that may more accurately describe items or services furnished and provides 58879 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations Through the April 2018 OPPS quarterly update CR (Transmittal 4005, Change Request 10515, dated March 20, 2018), we made effective nine new Level II HCPCS codes for separate payment under the OPPS. In the CY 2019 OPPS/ASC proposed rule (83 FR 37085), we solicited public comments on the proposed APC and status indicator assignments for these Level II HCPCS codes, which were listed in Table 8 of the proposed rule. We received some public comments related to HCPCS code C9749 (Repair of nasal vestibular lateral wall stenosis with implant(s)), which we address in section III.D.16. of this final rule with comment period. With the exception of HCPCS code C9749, we did not receive any public comments on the proposed OPPS APC and status indicator assignments for the new Level II HCPCS codes implemented in April 2018. Therefore, we are finalizing the proposed APC and status indicator assignments for these codes, as indicated in Table 12 below. We note that several of the HCPCS C-codes have been replaced with HCPCS J-codes, effective January 1, 2019. Their replacement codes are listed in Table 12. The final payment rates for these codes can be found in Addendum B to this final rule with comment period (which is available via the internet on the CMS website). In addition, the status indicator meanings can be found in Addendum D1 to this final rule with comment period (which is available via the internet on the CMS website). In addition, there were several new laboratory CPT Multianalyte Assays with Algorithmic Analyses (MAAA) codes (M-codes) and Proprietary Laboratory Analyses (PLA) codes (Ucodes) that were effective April 1, 2018, but were too late to include in the April 2018 OPPS Update. Because these codes were released on the American Medical Association’s (AMA) CPT website in February 2018, they were too late for us to include in the April 2018 OPPS Update CR and in the April 2018 Integrated Outpatient Code Editor (IOCE) and, consequently, were included in the July 2018 OPPS Update with an effective date of April 1, 2018. These CPT codes were listed in Table 9 of the CY 2019 OPPS/ASC proposed rule (83 FR 37086). In the proposed rule, we solicited public comments on the proposed APC and status indicator assignments for these CPT codes. The proposed payment rates for these codes, where applicable, were included in Addendum B to the proposed rule (which is available via the internet on the CMS website). Comment: One commenter stated that the test described by CPT code 0037U (Targeted genomic sequence analysis, solid organ neoplasm, DNA analysis of 324 genes, interrogation for sequence variants, gene copy number amplifications, gene rearrangements, microsatellite instability and tumor mutational burden) specifically, FoundationOne CDxTM, is a human DNA tumor mutation profiling test that is covered by Medicare and has been designated as an Advanced Diagnostic Laboratory Test (ADLT) under the Clinical Laboratory Fee Schedule (CLFS). The commenter supported the proposed OPPS status indicator assignment of ‘‘A’’ (Not paid under OPPS. Paid by MACs under a fee schedule or payment system other than OPPS) for CPT code 0037U. Response: We thank the commenter for the feedback. CPT code 0037U, khammond on DSK30JT082PROD with RULES2 1. Treatment of New HCPCS Codes That Were Effective April 1, 2018 for Which We Solicited Public Comments in the CY 2019 OPPS/ASC Proposed Rule VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 PO 00000 Frm 00064 Fmt 4701 Sfmt 4700 E:\FR\FM\21NOR2.SGM 21NOR2 ER21NO18.022</GPH> 58880 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations khammond on DSK30JT082PROD with RULES2 which is covered by Medicare, met the criteria for classification as a new ADLT and received its ADLT status in May 2018. Under the OPPS, codes that receive ADLT status under section 1834A(d)(5)(A) of the Act are assigned to status indicator ‘‘A’’. Therefore, we VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 are finalizing the OPPS status indicator ‘‘A’’ for CPT code 0037U as proposed. After consideration of the public comment we received, we are finalizing the proposed status indicator assignments for the new MAAA and PLA CPT codes effective April 1, 2018. The final status indicator assignments PO 00000 Frm 00065 Fmt 4701 Sfmt 4700 58881 for the CPT codes are listed in Table 13 below. The status indicator meanings can be found in Addendum D1 (OPPS Payment Status Indicators for CY 2019) to this final rule with comment period (which is available via the internet on the CMS website). E:\FR\FM\21NOR2.SGM 21NOR2 58882 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations CY2018 HCPCS Code 0012M 0013M 0035U 0036U 0037U 0038U 0039U khammond on DSK30JT082PROD with RULES2 0040U 0041U VerDate Sep<11>2014 CY 2018 Long Descriptor Oncology (urothelial), mRNA, gene expression profiling by real-time quantitative PCR of five genes (MDK, HOXA13, CDC2 [CDKI], IGFBP5, and XCR2), utilizing urine, algorithm reported as a risk score for having urothelial carcinoma Oncology (urothelial), mRNA, gene expression profiling by real-time quantitative PCR of five genes (MDK, HOXA13, CDC2 [CDKI ], IGFBP5, and CXCR2), utilizing urine, algorithm reported as a risk score for having recurrent urothelial carcinoma Neurology (prion disease), cerebrospinal fluid, detection ofprion protein by quaking-induced conformational conversion, qualitative Exome (ie, somatic mutations), paired formalin-fixed paraffin-embedded tumor tissue and normal specimen, sequence analyses Targeted genomic sequence analysis, solid organ neoplasm, DNA analysis of 324 genes, interrogation for sequence variants, gene copy number amplifications, gene rearrangements, microsatellite instability and tumor mutational burden Vitamin D, 25 hydroxy D2 and D3, by LCMS/MS, serum microsample, quantitative Deoxyribonucleic acid (DNA) antibody, double stranded, high avidity BCR/ABLI (t(9;22)) (eg, chronic myelogenous leukemia) translocation analysis, major breakpoint, quantitative Borrelia burgdorferi, antibody detection of 5 recombinant protein groups, by immunoblot, IgM 20:42 Nov 20, 2018 Jkt 247001 PO 00000 Frm 00066 Fmt 4701 Sfmt 4725 Final CY2019 SI Final CY2019 APC A N/A A N/A Q4 N/A A N/A A N/A Q4 N/A Q4 N/A A N/A Q4 N/A E:\FR\FM\21NOR2.SGM 21NOR2 ER21NO18.023</GPH> TABLE 13.-NEW CPT MAAA AND PROPRIETARY LABORATORY ANALYSES (PLA) CODES EFFECTIVE APRIL 1, 2018 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations khammond on DSK30JT082PROD with RULES2 Through the July 2018 OPPS quarterly update CR (Transmittal 4075, Change Request 1078, dated June 15, 2018), we made 4 new Category III CPT codes and 10 Level II HCPCS codes effective July 1, 2018 (14 codes total), and assigned them to appropriate interim OPPS status indicators and APCs. As listed in Table 10 of the CY 2019 OPPS/ASC proposed rule (83 FR 37086 through 37087), 13 of the 14 HCPCS codes are separately payable under the OPPS while 1 HCPCS code is not. Specifically, HCPCS code Q9994 is assigned to status indicator ‘‘E1’’ to indicate that the item is not payable by Medicare. In addition, we note that HCPCS code C9469 was deleted June 30, 2018, and replaced with HCPCS code Q9993 effective July VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 1, 2018. Because HCPCS code Q9993 describes the same drug as HCPCS code C9469, we proposed to continue the drug’s pass-through payment status and to assign HCPCS code Q9993 to the same APC and status indicators as its predecessor HCPCS code C9469, as shown in Table 10 of the proposed rule. In the CY 2019 OPPS/ASC proposed rule, we solicited public comments on the proposed APC and status indicator assignments for CY 2019 for the CPT and Level II HCPCS codes implemented on July 1, 2018, all of which were listed in Table 10 of the proposed rule. The proposed payment rates and status indicators for these codes, where applicable, were included in Addendum B to the proposed rule (which is available via the internet on the CMS website). We did not receive any public comments on the proposed APC and PO 00000 Frm 00067 Fmt 4701 Sfmt 4700 status indicator assignments for the new Category III CPT codes and Level II HCPCS codes implemented in July 2018. Therefore, we are finalizing the proposed APC and status indicator assignments for these codes, as indicated in Table 14 below. We note that several of the HCPCS C and Qcodes have been replaced with HCPCS J-codes effective January 1, 2019. Their replacement codes are listed in Table 14 below. The final payment rates for these codes can be found in Addendum B to this final rule with comment period (which is available via the internet on the CMS website). In addition, the status indicator meanings can be found in Addendum D1 (OPPS Payment Status Indicators for CY 2019) to this final rule with comment period (which is available via the internet on the CMS website). E:\FR\FM\21NOR2.SGM 21NOR2 ER21NO18.024</GPH> 2. Treatment of New HCPCS Codes That Were Effective July 1, 2018 for Which We Solicited Public Comments in the CY 2019 OPPS/ASC Proposed Rule 58883 58884 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations CY2018 HCPCS Code C9030 C9031 khammond on DSK30JT082PROD with RULES2 A9513 J3398 Q5105 Q5105 Q5106 Q5106 Q9991 Q9991 Q9992 Q9992 Q9993* J3304* Q9994 Q9994 0505T VerDate Sep<11>2014 J9057 C9032 Q9995 Final CY2019 SI Final CY 2019 APC G 9030 G 9067 G 9070 G 9096 G 9097 G 9073 G 9239 G 9469 E1 N/A Injection, emicizumab-kxwh, 0.5 mg G 9257 Endovenous femoral-popliteal arterial revascularization, with transcatheter placement of intravascular stent graft( s) and closure by any method, including percutaneous or open vascular access, ultrasound guidance for vascular access when performed, all catheterization(s) and intraprocedural roadmapping and imaging guidance necessary to complete the intervention, all associated radiological supervision and interpretation, when performed, with crossing of the occlusive lesion in an extraluminal fashion J1 5193 CY2019 HCPCS Code 17170 0505T 20:42 Nov 20, 2018 Jkt 247001 CY 2019 Long Descriptor Injection, copanlisib, 1 mg Lutetium Lu 177, dotatate, therapeutic, 1 millicurie Injection, voretigene neparvovec-rzy1, 1 billion vector genome Injection, epoetin alfa, biosimilar, (Retacrit) (for esrd on dialysis), 100 units Injection, epoetin alfa, biosimilar, (Retacrit) (for non-esrd use), 1000 units Injection, buprenorphine extended-release (Sublocade), less than or equal to 100 mg Injection, buprenorphine extended-release (Sublocade ), greater than 100 mg Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg In-line cartridge containing digestive enzyme( s) for enteral feeding, each PO 00000 Frm 00068 Fmt 4701 Sfmt 4725 E:\FR\FM\21NOR2.SGM 21NOR2 ER21NO18.025</GPH> TABLE 14.-NEW HCPCS CODES EFFECTIVE JULY 1, 2018 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 proposed rule (83 FR 37087), we solicited public comments on the proposed APC and status indicator assignments for the CPT codes. The proposed payment rates for these codes, where applicable, were included in Addendum B to the proposed rule (which is available via the internet on the CMS website). We did not receive any public comments on the proposed status indicator assignments for the PLA codes PO 00000 Frm 00069 Fmt 4701 Sfmt 4700 effective July 1, 2018. Therefore, we are finalizing the proposed status indicator assignments for these codes, as indicated in Table 15 below. We note that the status indicator meanings can be found in Addendum D1 (OPPS Payment Status Indicators for CY 2019) to this final rule with comment period (which is available via the internet on the CMS website). E:\FR\FM\21NOR2.SGM 21NOR2 ER21NO18.026</GPH> khammond on DSK30JT082PROD with RULES2 In addition, there are several new PLA codes (U-codes) that were effective July 1, 2018, but were too late to include in the July 2018 OPPS Update. Consequently, the codes were included in the October 2018 OPPS Update with an effective date of July 1, 2018. The CPT codes were listed in Table 11 of the CY 2019 OPPS/ASC proposed rule along with the proposed APC and status indicator assignments for these CPT codes. In the CY 2019 OPPS/ASC 58885 58886 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations CY2018 HCPCS Code 0045U 0046U 0047U 0048U 0049U 0050U khammond on DSK30JT082PROD with RULES2 0051U VerDate Sep<11>2014 20:42 Nov 20, 2018 CY 2018 Long Descriptor Oncology (breast ductal carcinoma in situ), mRNA, gene expression profiling by real-time R T-PCR of 12 genes (7 content and 5 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as recurrence score FLT3 (fms-related tyrosine kinase 3) (eg, acute myeloid leukemia) internal tandem duplication (lTD} variants, quantitative Oncology (prostate), mRNA, gene expression profiling by real-time RT-PCR of 17 genes (12 content and 5 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a risk score Oncology (solid organ neoplasia), DNA, targeted sequencing of protein-coding exons of 468 cancer-associated genes, including interrogation for somatic mutations and microsatellite instability, matched with normal specimens, utilizing formalin-fixed paraffinembedded tumor tissue, report of clinically significant mutation( s) NPMl (nucleophosmin) (eg, acute myeloid leukemia) gene analysis, quantitative Targeted genomic sequence analysis panel, acute myelogenous leukemia, DNA analysis, 194 genes, interrogation for sequence variants, copy number variants or rearrangements Prescription drug monitoring, evaluation of drugs present by LC-MS/MS, urine, 31 drug panel, reported as quantitative results, detected or not detected, per date of service Jkt 247001 PO 00000 Frm 00070 Fmt 4701 Sfmt 4725 Final CY 2019 SI Final CY 2019 APC A N/A A N/A A N/A A N/A A N/A A N/A Q4 N/A E:\FR\FM\21NOR2.SGM 21NOR2 ER21NO18.027</GPH> TABLE 15.-NEW CPT PROPRIETARY LABORATORY ANALYSES (PLA) CODES EFFECTIVE JULY 1, 2018 CY2018 HCPCS Code 0052U 0053U 0054U 0055U 0056U 0057U khammond on DSK30JT082PROD with RULES2 0058U 0059U VerDate Sep<11>2014 20:42 Nov 20, 2018 CY 2018 Long Descriptor Lipoprotein, blood, high resolution fractionation and quantitation of lipoproteins, including all five major lipoprotein classes and subclasses ofHDL, LDL, and VLDL by vertical auto profile ultracentrifugation Oncology (prostate cancer), FISH analysis of 4 genes (ASAPl, HDAC9, CHDl and PTEN), needle biopsy specimen, algorithm reported as probability of higher tumor grade Prescription drug monitoring, 14 or more classes of drugs and substances, definitive tandem mass spectrometry with chromatography, capillary blood, quantitative report with therapeutic and toxic ranges, including steady-state range for the prescribed dose when detected, per date of service Cardiology (heart transplant), cell-free DNA, PCR assay of96 DNA target sequences (94 single nucleotide polymorphism targets and two control targets), plasma Hematology (acute myelogenous leukemia), DNA, whole genome next-generation sequencing to detect gene rearrangement(s), blood or bone marrow, report of specific gene rearrangement( s) Oncology (solid organ neoplasia), mRNA, gene expression profiling by massively parallel sequencing for analysis of 51 genes, utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a normalized percentile rank Oncology (Merkel cell carcinoma), detection of antibodies to the Merkel cell polyoma virus oncoprotein (small T antigen), serum, quantitative Oncology (Merkel cell carcinoma), detection of antibodies to the Merkel cell polyoma virus capsid protein (VPl), serum, reported as positive or negative Jkt 247001 PO 00000 Frm 00071 Fmt 4701 Sfmt 4725 Final CY 2019 SI Final CY 2019 APC Q4 N/A A N/A Q4 N/A A N/A A N/A A N/A Q4 N/A Q4 N/A E:\FR\FM\21NOR2.SGM 21NOR2 58887 ER21NO18.028</GPH> Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations BILLING CODE 4120–01–C khammond on DSK30JT082PROD with RULES2 3. Process for New Level II HCPCS Codes That Are Effective October 1, 2018 or Will Be Effective on January 1, 2019 for Which We Are Soliciting Public Comments in This CY 2019 OPPS/ASC Final Rule With Comment Period As has been our practice in the past, we incorporate those new Level II HCPCS codes that are effective October 1 and January 1 in the final rule with comment period, thereby updating the OPPS for the following calendar year, as displayed in Table 11 of this final rule with comment period. These codes are released to the public through the October and January OPPS quarterly update CRs and via the CMS HCPCS website (for Level II HCPCS codes). For CY 2019, these codes are flagged with comment indicator ‘‘NI’’ in Addendum B to this OPPS/ASC final rule with comment period to indicate that we are assigning them an interim payment status which is subject to public comment. Specifically, the interim status indicator and APC assignments for codes flagged with comment indicator ‘‘NI’’ are open to public comment in this final rule with comment period, and we will respond to these public comments in the OPPS/ ASC final rule with comment period for the next year’s OPPS/ASC update. In the CY 2019 OPPS/ASC proposed rule (83 FR 37088), we proposed to continue this process for CY 2019. Specifically, for CY 2019, we proposed to include in Addendum B to the CY 2019 OPPS/ASC final rule with comment period the following new HCPCS codes: • New Level II HCPCS codes effective October 1, 2018, that would be VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 incorporated in the October 2018 OPPS quarterly update CR; and • New Level II HCPCS codes effective January 1, 2019, that would be incorporated in the January 2019 OPPS quarterly update CR. As stated above, the October 1, 2018 and January 1, 2019 codes are flagged with comment indicator ‘‘NI’’ in Addendum B to this CY 2019 OPPS/ ASC final rule with comment period to indicate that we have assigned these codes an interim OPPS payment status for CY 2019. We are inviting public comments on the interim status indicator and APC assignments for these codes, if applicable, that will be finalized in the CY 2020 OPPS/ASC final rule with comment period. 4. Treatment of New and Revised CY 2019 Category I and III CPT Codes That Will Be Effective January 1, 2019 for Which We Solicited Public Comments in the CY 2019 OPPS/ASC Proposed Rule In the CY 2015 OPPS/ASC final rule with comment period (79 FR 66841 through 66844), we finalized a revised process of assigning APC and status indicators for new and revised Category I and III CPT codes that would be effective January 1. Specifically, for the new/revised CPT codes that we receive in a timely manner from the AMA’s CPT Editorial Panel, we finalized our proposal to include the codes that would be effective January 1 in the OPPS/ASC proposed rules, along with proposed APC and status indicator assignments for them, and to finalize the APC and status indicator assignments in the OPPS/ASC final rules beginning with the CY 2016 OPPS update. For those new/revised CPT codes that were received too late for inclusion in the OPPS/ASC proposed rule, we finalized PO 00000 Frm 00072 Fmt 4701 Sfmt 4700 our proposal to establish and use HCPCS G-codes that mirror the predecessor CPT codes and retain the current APC and status indicator assignments for a year until we can propose APC and status indicator assignments in the following year’s rulemaking cycle. We note that even if we find that we need to create HCPCS G-codes in place of certain CPT codes for the PFS proposed rule, we do not anticipate that these HCPCS G-codes will always be necessary for OPPS purposes. We will make every effort to include proposed APC and status indicator assignments for all new and revised CPT codes that the AMA makes publicly available in time for us to include them in the annual proposed rule, and to avoid the resort to HCPCS G-codes and the resulting delay in utilization of the most current CPT codes. Also, we finalized our proposal to make interim APC and status indicator assignments for CPT codes that are not available in time for the proposed rule and that describe wholly new services (such as new technologies or new surgical procedures), solicit public comments, and finalize the specific APC and status indicator assignments for those codes in the following year’s final rule. For the CY 2019 OPPS update, we received the CY 2019 CPT codes from AMA in time for inclusion in the CY 2019 OPPS/ASC proposed rule. The new, revised, and deleted CY 2019 Category I and III CPT codes were included in Addendum B to the proposed rule (which is available via the internet on the CMS website). We noted in the proposed rule that the new and revised codes are assigned to new comment indicator ‘‘NP’’ to indicate that the code is new for the next calendar year or the code is an existing E:\FR\FM\21NOR2.SGM 21NOR2 ER21NO18.029</GPH> 58888 khammond on DSK30JT082PROD with RULES2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations code with substantial revision to its code descriptor in the next calendar year as compared to current calendar year with a proposed APC assignment, and that comments will be accepted on the proposed APC and status indicator assignments. Further, we reminded readers that the CPT code descriptors that appear in Addendum B are short descriptors and do not accurately describe the complete procedure, service, or item described by the CPT code. Therefore, we included the 5-digit placeholder codes and their long descriptors for the new and revised CY 2019 CPT codes in Addendum O to the proposed rule (which is available via the internet on the CMS website) so that the public could adequately comment on the proposed APCs and status indicator assignments. The 5-digit placeholder codes were included in Addendum O, specifically under the column labeled ‘‘CY 2019 OPPS/ASC Proposed Rule 5-Digit AMA Placeholder Code,’’ to the proposed rule. We noted that the final CPT code numbers will be included in this CY 2019 OPPS/ASC final rule with comment period. We also noted that not every code listed in Addendum O is subject to public comment. For the new and revised Category I and III CPT codes, we requested public comments on only those codes that are assigned to comment indicator ‘‘NP’’. In summary, in the CY 2019 OPPS/ ASC proposed rule, we solicited public comments on the proposed CY 2019 status indicator and APC assignments for the new and revised Category I and III CPT codes that will be effective January 1, 2019. The CPT codes were listed in Addendum B to the proposed rule with short descriptors only. We listed them again in Addendum O to the proposed rule with long descriptors. We also proposed to finalize the status indicator and APC assignments for these codes (with their final CPT code numbers) in the CY 2019 OPPS/ASC final rule with comment period. The proposed status indicator and APC assignments for these codes were included in Addendum B to the proposed rule (which is available via the internet on the CMS website). Commenters addressed several of the new CPT codes that were assigned to comment indicator ‘‘NP’’ in Addendum B to the CY 2019 OPPS/ASC proposed rule. We have responded to those public comments in sections II.A.2.b. (Comprehensive APCs), III.D. (OPPS APC-Specific Policies), IV.B. (DeviceIntensive Procedures) and XII. (Updates to the ASC Payment System) of this CY 2019 OPPS/ASC final rule with comment period. VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 The final status indicators, APC assignments, and payment rates for the new CPT codes that are effective January 1, 2019 can be found in Addendum B to this final rule with comment period (which is available via the internet on the CMS website). In addition, the status indicator meanings can be found in Addendum D1 (OPPS Payment Status Indicators for CY 2019) to this final rule with comment period (which is available via the internet on the CMS website). B. OPPS Changes—Variations Within APCs 1. Background Section 1833(t)(2)(A) of the Act requires the Secretary to develop a classification system for covered hospital outpatient department services. Section 1833(t)(2)(B) of the Act provides that the Secretary may establish groups of covered OPD services within this classification system, so that services classified within each group are comparable clinically and with respect to the use of resources. In accordance with these provisions, we developed a grouping classification system, referred to as Ambulatory Payment Classifications (APCs), as set forth in regulations at 42 CFR 419.31. We use Level I and Level II HCPCS codes to identify and group the services within each APC. The APCs are organized such that each group is homogeneous both clinically and in terms of resource use. Using this classification system, we have established distinct groups of similar services. We also have developed separate APC groups for certain medical devices, drugs, biologicals, therapeutic radiopharmaceuticals, and brachytherapy devices that are not packaged into the payment for the procedure. We have packaged into the payment for each procedure or service within an APC group the costs associated with those items and services that are typically ancillary and supportive to a primary diagnostic or therapeutic modality and, in those cases, are an integral part of the primary service they support. Therefore, we do not make separate payment for these packaged items or services. In general, packaged items and services include, but are not limited to, the items and services listed in regulations at 42 CFR 419.2(b). A further discussion of packaged services is included in section II.A.3. of this final rule with comment period. Under the OPPS, we generally pay for covered hospital outpatient services on a rate-per-service basis, where the PO 00000 Frm 00073 Fmt 4701 Sfmt 4700 58889 service may be reported with one or more HCPCS codes. Payment varies according to the APC group to which the independent service or combination of services is assigned. In the CY 2019 OPPS/ASC proposed rule (83 FR 37089), for CY 2019, we proposed that each APC relative payment weight represents the hospital cost of the services included in that APC, relative to the hospital cost of the services included in APC 5012 (Clinic Visits and Related Services). The APC relative payment weights are scaled to APC 5012 because it is the hospital clinic visit APC and clinic visits are among the most frequently furnished services in the hospital outpatient setting. 2. Application of the 2 Times Rule Section 1833(t)(9)(A) of the Act requires the Secretary to review, not less often than annually, and revise the APC groups, the relative payment weights, and the wage and other adjustments described in paragraph (2) to take into account changes in medical practice, changes in technology, the addition of new services, new cost data, and other relevant information and factors. Section 1833(t)(9)(A) of the Act also requires the Secretary to consult with an expert outside advisory panel composed of an appropriate selection of representatives of providers to review (and advise the Secretary concerning) the clinical integrity of the APC groups and the relative payment weights. We note that the HOP Panel recommendations for specific services for the CY 2019 OPPS update are discussed in the relevant specific sections throughout this CY 2019 OPPS/ ASC final rule with comment period. In addition, section 1833(t)(2) of the Act provides that, subject to certain exceptions, the items and services within an APC group cannot be considered comparable with respect to the use of resources if the highest cost for an item or service in the group is more than 2 times greater than the lowest cost for an item or service within the same group (referred to as the ‘‘2 times rule’’). The statute authorizes the Secretary to make exceptions to the 2 times rule in unusual cases, such as low-volume items and services (but the Secretary may not make such an exception in the case of a drug or biological that has been designated as an orphan drug under section 526 of the Federal Food, Drug, and Cosmetic Act). In determining the APCs with a 2 times rule violation, we consider only those HCPCS codes that are significant based on the number of claims. We note that, for purposes of identifying significant procedure codes for examination under E:\FR\FM\21NOR2.SGM 21NOR2 khammond on DSK30JT082PROD with RULES2 58890 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations the 2 times rule, we consider procedure codes that have more than 1,000 single major claims or procedure codes that both have more than 99 single major claims and contribute at least 2 percent of the single major claims used to establish the APC cost to be significant (75 FR 71832). This longstanding definition of when a procedure code is significant for purposes of the 2 times rule was selected because we believe that a subset of 1,000 or fewer claims is negligible within the set of approximately 100 million single procedure or single session claims we use for establishing costs. Similarly, a procedure code for which there are fewer than 99 single claims and that comprises less than 2 percent of the single major claims within an APC will have a negligible impact on the APC cost (75 FR 71832). In the CY 2019 OPPS/ASC proposed rule (83 FR 37089), for CY 2019, we proposed to make exceptions to this limit on the variation of costs within each APC group in unusual cases, such as for certain lowvolume items and services. For the CY 2019 OPPS update, in the CY 2019 OPPS/ASC proposed rule, we identified the APCs with violations of the 2 times rule. Therefore, we proposed changes to the procedure codes assigned to these APCs in Addendum B to the proposed rule. We noted that Addendum B does not appear in the printed version of the Federal Register as part of the CY 2019 OPPS/ASC proposed rule. Rather, it is published and made available via the internet on the CMS website at: https:// www.cms.gov/Medicare/Medicare-Feefor-Service-Payment/ HospitalOutpatientPPS/. To eliminate a violation of the 2 times rule and improve clinical and resource homogeneity, we proposed to reassign these procedure codes to new APCs that contain services that are similar with regard to both their clinical and resource characteristics. In many cases, the proposed procedure code reassignments and associated APC reconfigurations for CY 2019 included in the proposed rule were related to changes in costs of services that were observed in the CY 2017 claims data newly available for CY 2019 ratesetting. Addendum B to the CY 2019 OPPS/ASC proposed rule identified with a comment indicator ‘‘CH’’ those procedure codes for which we proposed a change to the APC assignment or status indicator, or both, that were initially assigned in the July 1, 2018 OPPS Addendum B Update (available via the internet on the CMS website at: https://www.cms.gov/Medicare/ VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 Medicare-Fee-for-Service-Payment/ HospitalOutpatientPPS/Addendum-Aand-Addendum-B-Updates.html). 3. APC Exceptions to the 2 Times Rule Taking into account the APC changes that we proposed to make for CY 2019 in the CY 2019 OPPS/ASC proposed rule, we reviewed all of the APCs to determine which APCs would not meet the requirements of the 2 times rule. We used the following criteria to evaluate whether to propose exceptions to the 2 times rule for affected APCs: • Resource homogeneity; • Clinical homogeneity; • Hospital outpatient setting utilization; • Frequency of service (volume); and • Opportunity for upcoding and code fragments. Based on the CY 2017 claims data available for the CY 2019 proposed rule, we found 16 APCs with violations of the 2 times rule. We applied the criteria as described above to identify the APCs for which we proposed to make exceptions under the 2 times rule for CY 2019, and found that all of the 16 APCs we identified met the criteria for an exception to the 2 times rule based on the CY 2017 claims data available for the proposed rule. We did not include in that determination those APCs where a 2 times rule violation was not a relevant concept, such as APC 5401 (Dialysis), which only has two HCPCS codes assigned to it that have a similar geometric mean costs and do not create a 2 time rule violation. Therefore, we only identified those APCs, including those with criteria-based costs, such as device-dependent CPT/HCPCS codes, with violations of the 2 times rule. We note that, for cases in which a recommendation by the HOP Panel appears to result in or allow a violation of the 2 times rule, we may accept the HOP Panel’s recommendation because those recommendations are based on explicit consideration (that is, a review of the latest OPPS claims data and group discussion of the issue) of resource use, clinical homogeneity, site of service, and the quality of the claims data used to determine the APC payment rates. Table 12 of the proposed rule listed the 16 APCs that we proposed to make an exception for under the 2 times rule for CY 2019 based on the criteria cited above and claims data submitted between January 1, 2017, and December 31, 2017, and processed on or before December 31, 2017. In the proposed rule, we stated that, for the final rule with comment period, we intend to use claims data for dates of service between January 1, 2017, and December 31, 2017, that were processed on or before June PO 00000 Frm 00074 Fmt 4701 Sfmt 4700 30, 2018, and updated CCRs, if available. Based on the updated final rule CY 2017 claims data used for this CY 2019 final rule with comment period, we were able to remedy 1 APC violation out of the 16 APCs that appeared in Table 12 of the CY 2019 OPPS/ASC proposed rule. Specifically, APC 5735 (Level 5 Minor Procedures) no longer met the criteria for exception to the 2 times rule in this final rule with comment period. In addition, based on our analysis of the final rule claims data, we found a total of 17 APCs with violations of the 2 times rule. Of these 17 total APCs, 15 were identified in the proposed rule and 2 are newly identified APCs. Specifically, we found the following 15 APCs that were identified for the proposed rule that continued to have violations of the 2 times rule for this final rule with comment period: • APC 5071 (Level 1 Excision/Biopsy/ Incision and Drainage); • APC 5113 (Level 3 Musculoskeletal Procedures); • APC 5521 (Level 1 Imaging without Contrast); • APC 5522 (Level 2 Imaging without Contrast); •APC 5523 (Level 3 Imaging without Contrast); • APC 5571 (Level 1 Imaging with Contrast); • APC 5612 (Level 2 Therapeutic Radiation Treatment Preparation); • APC 5691 (Level 1 Drug Administration); • APC 5692 (Level 2 Drug Administration); • APC 5721 (Level 1 Diagnostic Tests and Related Services); • APC 5724 (Level 4 Diagnostic Tests and Related Services); • APC 5731 (Level 1 Minor Procedures); • APC 5732 (Level 2 Minor Procedures); • APC 5822 (Level 2 Health and Behavior Services); and • APC 5823 (Level 3 Health and Behavior Services). In addition, we found that the following two additional APCs violated the 2 times rule using the final rule with comment period claims data: • APC 5193 (Level 3 Endovascular Procedures); and • APC 5524 (Level 4 Imaging without Contrast). After considering the public comments we received on proposed APC assignments and our analysis of the CY 2017 costs from hospital claims and cost report data available for this CY 2019 final rule with comment period, we are finalizing our proposals, with some modifications. Specifically, we are E:\FR\FM\21NOR2.SGM 21NOR2 finalizing our proposal to except 15 of the 16 proposed APCs from the 2 times rule for CY 2019 and also excepting 2 additional APCs (APCs 5193 and 5524). As noted above, we were able to remedy one of the proposed rule 2 time rule violations in this final rule with comment period (APC 5735). Table 16 below lists the 17 APCs that we are excepting from the 2 times rule for CY 2019 based on the criteria described earlier and a review of updated claims data for dates of service between January 1, 2017 and December 31, 2017, that were processed on or before June 30, 2018, and updated CCRs, if available. We note that, for cases in which a recommendation by the HOP Panel appears to result in or allow a violation of the 2 times rule, we generally accept the HOP Panel’s recommendation because those recommendations are based on explicit consideration of resource use, clinical homogeneity, site of service, and the quality of the claims data used to determine the APC payment rates. The geometric mean costs for hospital outpatient services for these and all other APCs that were used in the development of this final rule with comment period can be found on the CMS website at: https://www.cms.gov. C. New Technology APCs to make the cost intervals more consistent across payment levels and refined the cost bands for these APCs to retain two parallel sets of New Technology APCs, one set with a status indicator of ‘‘S’’ (Significant Procedures, Not Discounted when Multiple. Paid under OPPS; separate APC payment) and the other set with a status indicator of ‘‘T’’ (Significant Procedure, Multiple Reduction Applies. Paid under OPPS; separate APC payment). These current New Technology APC configurations allow us to price new technology services more appropriately and consistently. For CY 2018, there were 52 New Technology APC levels, ranging from the lowest cost band assigned to APC 1491 (New Technology—Level 1A ($0– $10)) through the highest cost band assigned to APC 1908 (New Technology—Level 52 ($145,001– $160,000)). We note that the cost bands for the New Technology APCs, specifically, APCs 1491 through 1599 and 1901 through 1908, vary with increments ranging from $10 to $14,999. These cost bands identify the APCs to which new technology procedures and services with estimated service costs that fall within those cost bands are assigned under the OPPS. Payment for each APC is made at the mid-point of the APC’s assigned cost band. For example, payment for New Technology APC 1507 (New Technology—Level 7 ($501–$600)) is made at $550.50. Under the OPPS, one of our goals is to make payments that are appropriate for the services that are necessary for the treatment of Medicare beneficiaries. The OPPS, like other Medicare payment systems, is budget neutral and increases are limited to the annual hospital inpatient market basket increase. We 1. Background khammond on DSK30JT082PROD with RULES2 58891 In the November 30, 2001 final rule (66 FR 59903), we finalized changes to the time period in which a service can be eligible for payment under a New Technology APC. Beginning in CY 2002, we retain services within New Technology APC groups until we gather sufficient claims data to enable us to assign the service to an appropriate clinical APC. This policy allows us to move a service from a New Technology APC in less than 2 years if sufficient data are available. It also allows us to retain a service in a New Technology APC for more than 2 years if sufficient data upon which to base a decision for reassignment have not been collected. In the CY 2004 OPPS final rule with comment period (68 FR 63416), we restructured the New Technology APCs VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 PO 00000 Frm 00075 Fmt 4701 Sfmt 4700 E:\FR\FM\21NOR2.SGM 21NOR2 ER21NO18.030</GPH> Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations khammond on DSK30JT082PROD with RULES2 58892 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations believe that our payment rates generally reflect the costs that are associated with providing care to Medicare beneficiaries. Furthermore, we believe that our payment rates are adequate to ensure access to services (80 FR 70374). For many emerging technologies, there is a transitional period during which utilization may be low, often because providers are first learning about the techniques and their clinical utility. Quite often, parties request that Medicare make higher payment amounts under the New Technology APCs for new procedures in that transitional phase. These requests, and their accompanying estimates for expected total patient utilization, often reflect very low rates of patient use of expensive equipment, resulting in high per use costs for which requesters believe Medicare should make full payment. Medicare does not, and we believe should not, assume responsibility for more than its share of the costs of procedures based on projected utilization for Medicare beneficiaries and does not set its payment rates based on initial projections of low utilization for services that require expensive capital equipment. For the OPPS, we rely on hospitals to make informed business decisions regarding the acquisition of high-cost capital equipment, taking into consideration their knowledge about their entire patient base (Medicare beneficiaries included) and an understanding of Medicare’s and other payers’ payment policies. (We refer readers to the CY 2013 OPPS/ASC final rule with comment period (77 FR 68314) for further discussion regarding this payment policy.) We note that, in a budget neutral system, payments may not fully cover hospitals’ costs in a particular circumstance, including those for the purchase and maintenance of capital equipment. We rely on hospitals to make their decisions regarding the acquisition of high-cost equipment with the understanding that the Medicare program must be careful to establish its initial payment rates, including those made through New Technology APCs, for new services that lack hospital claims data based on realistic utilization projections for all such services delivered in cost-efficient hospital outpatient settings. As the OPPS acquires claims data regarding hospital costs associated with new procedures, we regularly examine the claims data and any available new information regarding the clinical aspects of new procedures to confirm that our OPPS payments remain appropriate for procedures as they transition into VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 mainstream medical practice (77 FR 68314). For CY 2019, we included the proposed payment rates for New Technology APCs 1491 to 1599 and 1901 through 1908 in Addendum A to the CY 2019 OPPS/ASC proposed rule (which is available via the internet on the CMS website). The final payment rates for these New Technology APCs are included in Addendum A to the CY 2019 OPPS/ASC final rule with comment period (which is available via the internet on the CMS website). 2. Establishing Payment Rates for LowVolume New Technology Procedures Procedures that are assigned to New Technology APCs are typically new procedures that do not have sufficient claims history to establish an accurate payment for the procedures. One of the objectives of establishing New Technology APCs is to generate sufficient claims data for a new procedure so that it can be assigned to an appropriate clinical APC. Some procedures that are assigned to New Technology APCs have very low annual volume, which we consider to be fewer than 100 claims. We consider procedures with fewer than 100 claims annually as low-volume procedures because there is a higher probability that the payment data for a procedure may not have a normal statistical distribution, which could affect the quality of our standard cost methodology that is used to assign services to an APC. In addition, services with fewer than 100 claims per year are not generally considered to be a significant contributor to the APC ratesetting calculations and, therefore, are not included in the assessment of the 2 times rule. For these low-volume procedures, we are concerned that the methodology we use to estimate the cost of a procedure under the OPPS by calculating the geometric mean for all separately paid claims for a HCPCS procedure code from the most recent available year of claims data may not generate an accurate estimate of the actual cost of the procedure. In accordance with section 1833(t)(2)(B) of the Act, services classified within each APC must be comparable clinically and with respect to the use of resources. As described earlier, assigning a procedure to a new technology APC allows us to gather claims data to price the procedure and assign it to the APC with services that use similar resources and are clinically comparable. However, where utilization of services assigned to a New Technology APC is low, it can lead to wide variation in payment rates from year to year, resulting in even lower PO 00000 Frm 00076 Fmt 4701 Sfmt 4700 utilization and potential barriers to access to new technologies, which ultimately limits our ability to assign the service to the appropriate clinical APC. To mitigate these issues, we believe that it is appropriate to utilize our equitable adjustment authority at section 1833(t)(2)(E) of the Act to adjust how we determine the costs for lowvolume services assigned to New Technology APCs. We have utilized our equitable adjustment authority at section 1833(t)(2)(E) of the Act, which states that the Secretary shall establish, in a budget neutral manner, other adjustments as determined to be necessary to ensure equitable payments, to estimate an appropriate payment amount for low-volume new technology procedures in the past (82 FR 59281). Although we have used this adjustment authority on a case-by-case basis in the past, we believe that it is appropriate to adopt an adjustment for low-volume services assigned to New Technology APCs in order mitigate the wide payment fluctuations that can occur for new technology services with fewer than 100 claims and to provide more predictable payment for these services. For purposes of this adjustment, we believe that it is appropriate to use up to 4 years of claims data in calculating the applicable payment rate for the prospective year, rather than using solely the most recent available year of claims data, when a service assigned to a New Technology APC has a low annual volume of claims, which, for purposes of this adjustment, we define as fewer than 100 claims annually. We consider procedures with fewer than 100 claims annually as low-volume procedures because there is a higher probability that the payment data for a procedure may not have a normal statistical distribution, which could affect the quality of our standard cost methodology that is used to assign services to an APC. For these lowvolume procedures, we are concerned that the methodology we use to estimate the cost of a procedure under the OPPS by calculating the geometric mean for all separately paid claims for a HCPCS procedure code from the most recent available year of claims data may not generate an accurate estimate of the actual cost of the procedure. Using multiple years of claims data will potentially allow for more than 100 claims to be used to set the payment rate, which would, in turn, create a more statistically reliable payment rate. In addition, to better approximate the cost of a low-volume service within a New Technology APC, we believe that using the median or arithmetic mean rather than the geometric mean (which E:\FR\FM\21NOR2.SGM 21NOR2 khammond on DSK30JT082PROD with RULES2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations ‘‘trims’’ the costs of certain claims out) may be more appropriate in some circumstances, given the extremely low volume of claims. Low claim volumes increase the impact of ‘‘outlier’’ claims; that is, claims with either a very low or very high payment rate as compared to the average claim, which would have a substantial impact on any statistical methodology used to estimate the most appropriate payment rate for a service. We believe that having the flexibility to utilize an alternative statistical methodology to calculate the payment rate in the case of low-volume new technology services would help to create a more stable payment rate. Therefore, in the CY 2019 OPPS/ASC proposed rule (83 FR 37091 through 37092), we proposed that, in each of our annual rulemakings, we would seek public comments on which statistical methodology should be used for each low-volume New Technology APC. In the preamble of each annual rulemaking, we stated that we will present the result of each statistical methodology and solicit public comment on which methodology should be used to establish the payment rate for a low-volume new technology service. In addition, we will use our assessment of the resources used to perform a service and guidance from the developer or manufacturer of the service, as well as other stakeholders, to determine the most appropriate payment rate. Once we identify the most appropriate payment rate for a service, we would assign the service to the New Technology APC with the cost band that includes its payment rate. Accordingly, in the CY 2019 OPPS/ ASC proposed rule (83 FR 37091 through 37092), for CY 2019, we proposed to establish a different payment methodology for services assigned to New Technology APCs with fewer than 100 claims using our equitable adjustment authority under section 1833(t)(2)(E) of the Act. Under this proposal, we proposed to use up to 4 years of claims data to establish a payment rate for each applicable service both for purposes of assigning a service to a New Technology APC and for assigning a service to a regular APC at the conclusion of payment for the service through a New Technology APC. The goal of such a policy is to promote transparency and stability in the payment rates for these low-volume new technology procedures and to mitigate wide variation from year to year for such services. We also proposed to use the geometric mean, the median, or the arithmetic mean to calculate the cost of furnishing the applicable service, VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 present the result of each statistical methodology in our annual rulemaking, and solicit public comment on which methodology should be used to establish the payment rate. We stated that the geometric mean may not be representative of the actual cost of a service when fewer than 100 claims are present because the payment amounts for the claims may not be distributed normally. We stated that, under this proposal, we would have the option to use the median payment amount or the arithmetic mean to assign a more representative payment for the service. Once we identify the payment rate for a service, we would assign the service to the New Technology APC with the cost band that includes its payment rate. Comment: One commenter requested that CMS expand the proposal to cover all low-volume procedures with fewer than 100 claims annually in the OPPS rather than only those procedures assigned to New Technology APCs. The commenter noted the issues cited for establishing the low-volume policy, including data not having a normal statistical distribution, excessive influence of outliers, and the quality of claims data affect all low-volume procedures, and not just those procedure assigned to a New Technology APC. Response: We disagree with the commenter’s request. The fact that a procedure has been assigned to a clinical APC means we have some idea of the resources used for a low-volume procedure and what the cost of the procedure should be. Concerns over the appropriate APC assignment for an individual procedure may be addressed on a case-by-case basis through our annual rulemaking. We remind commenters that they can submit public comments on the appropriate APC assignment for a particular code during that process. We believe reviewing each procedure assigned to a clinical APC annually to determine if the arithmetic mean, geometric mean, or median of the claims data should be used to determine the procedure cost is both unnecessary and operationally infeasible. The lowvolume policy instead is intended only for those procedures assigned to New Technology APCs with such limited claims data that we are not able to assign them to clinical APCs and need as much available data to determine the payment rate for a procedure. Comment: One commenter asked that CMS use the equitable adjustment authority under section 1833(t)(2)(E) of the Act in other instances not covered by the proposed low-volume policy where a procedure that has recently been introduced to the outpatient PO 00000 Frm 00077 Fmt 4701 Sfmt 4700 58893 setting has inconsistent payment data due to small number of claims. Response: We retain the ability to use our equitable adjustment authority under section 1833(t)(2)(E) of the Act when we determine that it is needed. Comment: Several commenters supported the proposal to use up to 4 years of claims data and to have flexibility to use the geometric mean, arithmetic mean, or median of claims data to establish a payment rate for lowvolume procedures assigned to a New Technology APC. Response: We appreciate the commenters’ support. After consideration of the public comments we received, we are finalizing our proposed policy to establish payment rates for low-volume procedures with fewer than 100 claims per year that are assigned to New Technology APCs, without modification. We may use up to 4 years of claims data to establish a payment rate for each applicable service both for purposes of assigning a service to a New Technology APC and for assigning a service to a regular APC at the conclusion of payment for the service through a New Technology APC. We will use the geometric mean, the median, or the arithmetic mean to calculate the cost of furnishing the applicable service, present the result of each statistical methodology in our annual rulemaking, and solicit public comment on which methodology should be used to establish the payment rate. Once we identify the payment rate for a service, we would assign the service to the New Technology APC with the cost band that includes its payment rate. 3. Procedures Assigned to New Technology APC Groups for CY 2019 As we explained in the CY 2002 OPPS final rule with comment period (66 FR 59902), we generally retain a procedure in the New Technology APC to which it is initially assigned until we have obtained sufficient claims data to justify reassignment of the procedure to a clinically appropriate APC. In addition, in cases where we find that our initial New Technology APC assignment was based on inaccurate or inadequate information (although it was the best information available at the time), where we obtain new information that was not available at the time of our initial New Technology APC assignment, or where the New Technology APCs are restructured, we may, based on more recent resource utilization information (including claims data) or the availability of refined New Technology APC cost bands, reassign the procedure or service to a E:\FR\FM\21NOR2.SGM 21NOR2 58894 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations khammond on DSK30JT082PROD with RULES2 different New Technology APC that more appropriately reflects its cost (66 FR 59903). Consistent with our current policy, for CY 2019, in the CY 2019 OPPS/ASC proposed rule (83 FR 37092), we proposed to retain services within New Technology APC groups until we obtain sufficient claims data to justify reassignment of the service to a clinically appropriate APC. The flexibility associated with this policy allows us to reassign a service from a New Technology APC in less than 2 years if sufficient claims data are available. It also allows us to retain a service in a New Technology APC for more than 2 years if sufficient claims data upon which to base a decision for reassignment have not been obtained (66 FR 59902). a. Magnetic Resonance-Guided Focused Ultrasound Surgery (MRgFUS) (APCs 1537, 5114, and 5414) Currently, there are four CPT/HCPCS codes that describe magnetic resonance image-guided, high-intensity focused ultrasound (MRgFUS) procedures, three of which we proposed to continue to assign to standard APCs, and one that we proposed to reassign to a different New Technology APC for CY 2019. These codes include CPT codes 0071T, 0072T, and 0398T, and HCPCS code C9734. CPT codes 0071T and 0072T describe procedures for the treatment of uterine fibroids, CPT code 0398T describes procedures for the treatment of essential tremor, and HCPCS code C9734 describes procedures for pain palliation for metastatic bone cancer. As shown in Table 13 of the CY 2019 OPPS/ASC proposed rule, and as listed in Addendum B to the CY 2019 OPPS/ ASC proposed rule, we proposed to continue to assign the procedures described by CPT codes 0071T and 0072T to APC 5414 (Level 4 Gynecologic Procedures), with a proposed payment rate of approximately $2,410 for CY 2019. We also proposed to continue to assign the APC to status indicator ‘‘J1’’ (Hospital Part B services paid through a comprehensive APC) to indicate that payment for all covered Part B services reported on the claim are packaged with the payment for the primary ‘‘J1’’ service for the claim, except for services assigned to OPPS status indicator ‘‘F’’, ‘‘G’’, ‘‘H’’, ‘‘L’’, and ‘‘U’’; ambulance services; diagnostic and screening mammography; all preventive services; and certain Part B inpatient services. In addition, we proposed to continue to assign the services described by HCPCS code C9734 (Focused ultrasound ablation/ therapeutic intervention, other than VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 uterine leiomyomata, with magnetic resonance (mr) guidance) to APC 5115 (Level 5 Musculoskeletal Procedures), with a proposed payment rate of approximately $10,936 for CY 2019. We also proposed to continue to assign HCPCS code C9734 to status indicator ‘‘J1’’. For procedures described by CPT code 0398T, we have only identified one paid claim for a procedure in CY 2016 and two paid claims in CY 2017, for a total of three paid claims. We note that the procedures described by CPT code 0398T were first assigned to a New Technology APC in CY 2016. Accordingly, there are only 2 years of claims data available for the OPPS ratesetting purposes. The payment amounts for the claims varied widely, with a cost of $29,254 for the sole CY 2016 claim and a geometric mean cost of $4,647 for the two CY 2017 claims. In the proposed rule, we expressed concerned that the reported geometric mean cost for CY 2017, which we would normally use to determine the proposed payment rate for the procedures described by CPT code 0398T, was significantly lower than the reported cost of the claim received in CY 2016, as well as the payment rate for the procedures for CY 2017 ($9,750.50) and for CY 2018 ($17,500.50). In accordance with section 1833(t)(2)(B) of the Act, we must establish that services classified within each APC are comparable clinically and with respect to the use of resources. Therefore, as mentioned in section III.C.2. of the proposed rule, we proposed to use our equitable adjustment authority under section 1833(t)(2)(E) of the Act, which states that the Secretary shall establish, in a budget neutral manner, other adjustments as determined to be necessary to ensure equitable payments, to establish a payment rate that is more likely to be representative of the cost of the procedures described by CPT code 0398T, despite the low geometric mean costs for procedures described by CPT code 0398T available in the claims data used for the proposed rule. We stated that we continue to believe that this situation for the procedures described by CPT code 0398T is unique, given the very limited number of claims for the procedures and the high variability for the cost of the claims which makes it challenging to determine a reliable payment rate for the procedures. Our analysis found that the arithmetic mean of the three claims is $12,849.11, the geometric mean of the three claims is $8,579.91 (compared to $4,646.56 for CY 2017), and the median of the claims is $4,676.77. Consistent with what we PO 00000 Frm 00078 Fmt 4701 Sfmt 4700 stated in section III.C.2. of the proposed rule, we presented the result of each statistical methodology in this preamble, and we sought public comments on which method should be used to establish payment for the procedures described by CPT code 0398T. We believe that the arithmetic mean is the most appropriate representative cost of the procedures described by CPT code 0398T, which gives consideration to the payment rates established for the procedures in CY 2017 and CY 2018, without any trimming. The arithmetic mean also gives consideration to the full range in cost for the three paid claims, which represent 2 years of claims data for the procedures. We proposed to estimate the proposed payment rate for the procedures described by CPT code 0398T by calculating the arithmetic mean of the three paid claims for the procedures in CY 2016 and CY 2017, and assigning the procedures described by CPT code 0398T to the New Technology APC that includes the estimated cost. Accordingly, we proposed to reassign the procedures described by CPT code 0398T from APC 1576 (New Technology—Level 39 ($15,001–$20,000)) to APC 1575 (New Technology—Level 38 ($10,001– $15,000)), with a proposed payment rate of $12,500.50 for CY 2019. We refer readers to Addendum B to the proposed rule for the proposed payment rates for all codes reportable under the OPPS. Addendum B is available via the internet on the CMS website. Comment: Several commenters opposed the proposed reassignment of CPT code 0398T to APC 1575 (New Technology—Level 38 ($10,001– $15,000)), which has a payment rate of $12,500.50. These commenters asked CMS to maintain the CY 2018 assignment of CPT code 0398T to APC 1576 (New Technology—Level 39 ($15,001–$20,000)). The commenters believed the cost of the services described by CPT code 0398T is more than the proposed payment rate of $12,500.50, and reducing payment would discourage use of this new technology. One commenter, the developer of the procedure, stated that the reduced payment rate would be particularly problematic as it would take effect just as MACs are issuing local coverage determinations to allow the procedure to be covered more widely by Medicare. This commenter also believed the two claims from CY 2017 with a geometric mean cost of $4,647 had too low of a payment rate and submitted additional payment data to CMS to support that position. E:\FR\FM\21NOR2.SGM 21NOR2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations khammond on DSK30JT082PROD with RULES2 Response: Since the proposed rule was issued, there have been several more claims for services described by CPT code 0398T that were paid in CY 2017. Currently, there are 11 paid claims for services described by CPT code 0398T for CY 2017, and these 11 claims have an estimated cost of between $4,186.51 and $5,153.28. We performed our low-volume new technology process for CPT code 0398T for all available claims from CY 2017 and included the one claim of $29,254 from CY 2016. The results of our analysis found that for claims billed with CPT code 0398T, the geometric mean cost was $5,360.99, the arithmetic mean cost was $6,654.68, and the median cost was $4,581.45. We have concerns about using the claims data available for this final rule with comment period to set the payment rate for CPT code 0398T for CY 2019. The payment rate for CPT code 0398T for CY 2018 was $17,500.50, and in the CY 2019 proposed rule (83 FR 37093), we proposed a payment rate of $12,500.50. However for this final rule with comment period, the highest payment rate using the most recent available claims data and the newly adopted smoothing methodology for low-volume New Technology APCs is $6,750.50, which is the mid-point of New Technology APC 1531. New Technology APC 1531 is the cost band for the arithmetic mean cost of CPT code 0398T. A payment rate of $6,750.50 would be the result of a $10,750 reduction in the payment rate in a period of just 1 year, or a payment rate reduction of over 60 percent. In addition, this payment reduction would be based on a total of 14 claims that have been billed for CPT code 0398T since we first received claims for this procedure in CY 2016. We believe that it is important to mitigate significant VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 payment differences, especially payment differences that result in shifts of over $10,000 in a single year, while also basing payment rates on available costs information and claims data. We are concerned that these large changes in payment could potentially create an access to care issue for services described by CPT code 0398T; especially, when the procedure is starting to receive local coverage determinations from MACs allowing more Medicare beneficiaries to use the procedure. While the proposed payment rate of $12,500.50 is also a decrease from the current payment rate, we believe that it would be appropriate to finalize the proposed rate to mitigate a much sharper decline in payment from one year to the next. In accordance with section 1833(t)(2)(B) of the Act, we must establish that services classified within each APC are comparable clinically and with respect to the use of resources. Accordingly, we are using our equitable adjustment authority under section 1833(t)(2)(E) of the Act, which states that the Secretary shall establish, in a budget neutral manner, other adjustments as determined to be necessary to ensure equitable payments, to maintain the proposed rate for this procedure, despite the lower geometric mean, arithmetic mean, and median costs calculated from the claims data used for this final rule with comment period. As stated earlier, we believe that this situation is unique, given the large reduction in payment this would represent for CPT code 0398T and the very limited number of claims reported for the procedure. Therefore, for CY 2019, we are reassigning CPT code 0398T from APC 1576 to APC 1575 (New Technology—Level 38 ($10,001– $15,000)). This APC assignment will establish a payment rate for CPT code PO 00000 Frm 00079 Fmt 4701 Sfmt 4700 58895 0398T of $12,500.50, which was the proposed payment rate for the procedure in the CY 2019 OPPS/ASC proposed rule. As we do each year, we acquire claims data regarding hospital costs associated with new procedures. We regularly examine the claims data and any available new information regarding the clinical aspects of new procedures to confirm that our OPPS payments remain appropriate for procedures like CPT code 0398T as they transition into mainstream medical practice (77 FR 68314). Comment: One commenter supported the proposed increase in Medicare payment for MRI-guided high intensity focused ultrasound procedures described by CPT codes 0071T and 0072T. Response: We appreciate the commenter’s support. In summary, after consideration of the public comments we received, we are finalizing our proposal for the APC assignment of CPT code 0398T. Specifically, we are reassigning this code to New Technology APC 1575 (New Technology—Level 38 ($10,001– $15,000)), with a payment rate of $12,500.50, for CY 2019 through use of our equitable adjustment authority. In addition, we are finalizing our proposal, without modification, to assign HCPCS code C9734 to APC 5114. We also are finalizing our proposal to continue to assign CPT codes 0071T and 0072T to APC 5414, without modification. Table 17 below lists the final CY 2018 status indicator and APC assignments for MRgFUS procedures. We refer readers to Addendum B of this final rule with comment period for the final payment rates for all codes reportable under the OPPS. Addendum B is available via the internet on the CMS website. BILLING CODE 4120–01–P E:\FR\FM\21NOR2.SGM 21NOR2 58896 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations TABLE 17.-CY 2019 STATUS INDICATOR (SI), APC ASSIGNMENT, AND PAYMENT RATE FOR THE MAGNETIC RESONANCE IMAGE GUIDED HIGH INTENSITY FOCUSED ULTRASOUND (MRgFUS) PROCEDURES CPT/ HCPCS !Long Descriptor Code CY 2018 OPPS SI CY 2018 OPPS APC CY2018 OPPS Payment Rate CY2019 OPPS SI CY2019 OPPS APC CY2019 OPPS Payment Rate IF ocused ultrasound khammond on DSK30JT082PROD with RULES2 !Magnetic esonance Image guided high intensity focused !Ultrasound (mrgfus), stereotactic 0398T ablation lesion, intracranial for !movement disorder including stereotactic !navigation and frame placement ~hen performed. VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 Refer to J1 5414 $2,272.77 J1 5414 OPPS Addendum B. Refer to J1 5414 $2,272.77 J1 5414 OPPS Addendum B. Refer to s PO 00000 1576 Frm 00080 Fmt 4701 $17,500.50 Sfmt 4725 s E:\FR\FM\21NOR2.SGM 1575 21NOR2 OPPS Addendum B. ER21NO18.031</GPH> ablation of uterine leiomyomata, 0071T including mr guidance; total leiomyomata tvolume less than ~00 cc of tissue. Focused ultrasound ablation of uterine leiomyomata, 0072T including mr guidance; total leiomyomata volume greater or equal to 200 cc of tissue. khammond on DSK30JT082PROD with RULES2 BILLING CODE 4120–01–C b. Retinal Prosthesis Implant Procedure CPT code 0100T (Placement of a subconjunctival retinal prosthesis receiver and pulse generator, and implantation of intra-ocular retinal electrode array, with vitrectomy) describes the implantation of a retinal prosthesis, specifically, a procedure involving the use of the Argus® II Retinal Prosthesis System. This first retinal prosthesis was approved by the Food and Drug Administration (FDA) in 2013 for adult patients diagnosed with severe to profound retinitis pigmentosa. Pass-through payment status was granted for the Argus® II device under HCPCS code C1841 (Retinal prosthesis, includes all internal and external components) beginning October 1, 2013, and this status expired on December 31, 2015. We note that after pass-through payment status expires for a medical device, the payment for the device is packaged into the payment for the associated surgical procedure. Consequently, for CY 2016, the device described by HCPCS code C1841 was assigned to OPPS status indicator ‘‘N’’ to indicate that payment for the device is packaged and included in the payment rate for the surgical procedure described by CPT code 0100T. For CY 2016, the procedure described by CPT code 0100T was assigned to New Technology APC 1599, with a payment rate of $95,000, which was the highest paying New Technology APC for that year. This payment includes both the surgical procedure (CPT code 0100T) and the use of the Argus® II device (HCPCS code C1841). However, stakeholders (including the device manufacturer and hospitals) believed that the CY 2016 payment rate for the procedure involving the Argus® II System was insufficient to cover the hospital cost of performing the procedure, which includes the cost of VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 the retinal prosthesis at the retail price of approximately $145,000. For CY 2017, analysis of the CY 2015 OPPS claims data used for the CY 2017 final rule with comment period showed 9 single claims (out of 13 total claims) for the procedure described by CPT code 0100T, with a geometric mean cost of approximately $142,003 based on claims submitted between January 1, 2015, through December 31, 2015, and processed through June 30, 2016. Based on the CY 2015 OPPS claims data available for the final rule with comment period and our understanding of the Argus® II procedure, we reassigned the procedure described by CPT code 0100T from New Technology APC 1599 to New Technology APC 1906, with a final payment rate of $150,000.50 for CY 2017. We noted that this payment rate included the cost of both the surgical procedure (CPT code 0100T) and the retinal prosthesis device (HCPCS code C1841). For CY 2018, the reported cost of the Argus® II procedure based on CY 2016 hospital outpatient claims data used for the CY 2018 OPPS/ASC final rule with comment period was approximately $94,455, which was more than $55,000 less than the payment rate for the procedure in CY 2017. We noted that the costs of the Argus® II procedure are extraordinarily high compared to many other procedures paid under the OPPS. In addition, the number of claims submitted has been very low and has not exceeded 10 claims within a single year. We believed that it is important to mitigate significant payment differences, especially shifts of several tens of thousands of dollars, while also basing payment rates on available cost information and claims data. In CY 2016, the payment rate for the Argus® II procedure was $95,000.50. The payment rate increased to $150,000.50 in CY 2017. For CY 2018, if we had established the payment rate based on PO 00000 Frm 00081 Fmt 4701 Sfmt 4700 58897 updated final rule claims data, the payment rate would have decreased to $95,000.50 for CY 2018, a decrease of $55,000 relative to CY 2017. We were concerned that these large changes in payment could potentially create an access to care issue for the Argus® II procedure, and we wanted to establish a payment rate to mitigate the potential sharp decline in payment from CY 2017 to CY 2018. In accordance with section 1833(t)(2)(B) of the Act, we must establish that services classified within each APC are comparable clinically and with respect to the use of resources. Therefore, we used our equitable adjustment authority under section 1833(t)(2)(E) of the Act, which states that the Secretary shall establish, in a budget neutral manner, other adjustments as determined to be necessary to ensure equitable payments, to maintain the payment rate for this procedure, despite the lower geometric mean costs available in the claims data used for the final rule with comment period. For CY 2018, we reassigned the Argus® II procedure to APC 1904 (New Technology—Level 50 ($115,001– $130,000)), which established a payment rate for the Argus® II procedure of $122,500.50, which was the arithmetic mean of the payment rates for the procedure for CY 2016 and CY 2017. As discussed in the CY 2019 OPPS/ ASC proposed rule (83 FR 37093 through 37094), for CY 2019, the reported cost of the Argus® II procedure based on CY 2017 hospital outpatient claims data used for the CY 2019 OPPS/ ASC proposed rule was approximately $152,021, which was $29,520 more than the payment rate for the procedure for CY 2018. In the proposed rule, we continued to note that the costs of the Argus® II procedure are extraordinarily high compared to many other procedures paid under the OPPS. In E:\FR\FM\21NOR2.SGM 21NOR2 ER21NO18.032</GPH> Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations khammond on DSK30JT082PROD with RULES2 58898 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations addition, the number of claims submitted has been very low and did not exceed 10 claims for CY 2017. We stated that we continue to believe that it is important to mitigate significant payment differences, especially shifts of several tens of thousands of dollars, while also basing payment rates on available cost information and claims data because we are concerned that large decreases in the payment rate could potentially create an access to care issue for the Argus® II procedure. In addition, we indicated that we wanted to establish a payment rate to mitigate the potential sharp increase in payment from CY 2018 to CY 2019, and potentially ensure a more stable payment rate in future years. In accordance with section 1833(t)(2)(B) of the Act, we must establish that services classified within each APC are comparable clinically and with respect to the use of resources. Therefore, as discussed in section III.C.2. of the proposed rule, we proposed to use our equitable adjustment authority under section 1833(t)(2)(E) of the Act, which states that the Secretary shall establish, in a budget neutral manner, other adjustments as determined to be necessary to ensure equitable payments, to establish a payment rate that is more representative of the likely cost of the service. We stated that we believe the likely cost of the Argus® II procedure is lower than the geometric mean cost calculated from the CY 2017 claims data used for the proposed rule and closer to the CY 2018 payment rate. We analyzed claims data for the Argus® II procedure using the last 3 years of available data from CY 2015 through CY 2017. These data included claims from the last year (CY 2015) that the Argus® II received transitional device pass-through payments and the first 2 years since device pass-through payment status for the Argus® II expired. We found the geometric mean for the procedure to be $129,891 (compared to $152,021 in CY 2017 alone), the arithmetic mean to be $134,619, and the median to be $133,679. As indicated in our proposal in section III.C.2. of the proposed rule (83 FR 37091 through 37092), we presented the result of each statistical methodology in the preamble of the proposed rule, and requested public comment on which methodology should be used to establish a payment rate. We proposed to use the arithmetic mean, which generates the highest payment rate of the three statistical methodologies, to estimate the cost of the Argus® II procedure as a means to balance the fluctuations in the costs of VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 the procedure that have occurred from CY 2015 through CY 2017, while acknowledging the higher payment rates for the procedure in CY 2015 and CY 2017. Therefore, for CY 2019, we proposed to reassign the Argus® II procedure from APC 1904 (New Technology—Level 50 ($115,001– $130,000)) to APC 1906 (New Technology—Level 51 ($130,001– $145,000)), which resulted in a proposed payment rate for the Argus® II procedure of $137,500.50. As we do each year, we acquired claims data regarding hospital costs associated with new procedures. We regularly examine the claims data and any available new information regarding the clinical aspects of new procedures to confirm that our OPPS payments remain appropriate for procedures like the Argus® II procedure as they transition into mainstream medical practice (77 FR 68314). We noted that the proposed payment rate included both the surgical procedure (CPT code 0100T) and the use of the Argus® II device (HCPCS code C1841). Comment: Several commenters requested that CMS reassign CPT code 0100T to APC 1908 (New Technology— Level 52 ($145,001–$160,000)) with a payment rate of $152,500.50. The commenters were concerned that the proposed assignment of APC 1906 (New Technology—Level 51 ($130,001– $145,000)) with a payment rate of $137,500.50 will not cover all of the costs of the procedure. Response: We have updated our payment rate for CPT code 0100T. We analyzed claims data for the Argus® II procedure using the last 3 years of available data from CY 2015 through CY 2017, which was updated with additional claims from CY 2017. These data included claims from the last year (CY 2015) that the Argus® II received transitional device pass-through payments and the first 2 years since device pass-through payment status for the Argus® II expired. We found the updated geometric mean cost for the procedure to be $145,808 (compared to $129,891 in the proposed rule), the arithmetic mean cost to be $151,367, and the median cost to be $151,266. All three of these methods of calculating the cost of the Argus® II procedure map to the cost band associated with APC 1908 (New Technology—Level 52 ($145,001– $160,000)), which has a payment rate of $152,500.50. After reviewing the comments we received and updating our data analysis, we are reassigning the Argus® II procedure (CPT code 0100T) to APC 1908 (New Technology—Level 52 PO 00000 Frm 00082 Fmt 4701 Sfmt 4700 ($145,001–$160,000)) with a payment rate of $152,500.50 for CY 2019. We discussed in the CY 2019 OPPS/ ASC proposed rule that the most recent claims data available have shown another payment issue with regard to the Argus® II procedure. We have found that payment for the Argus® II procedure is sometimes bundled into the payment for another procedure. We identified two possible instances in the CY 2017 claims data in which this may have occurred. The bundling of payment for the Argus® II procedure occurs when the procedure is reported with other eye procedures assigned to a comprehensive APC (C–APC). A C–APC bundles payment for all services related to the primary service into one payment rate. We stated in the proposed rule that we were concerned that when payment for new technology services is bundled into the payment for comprehensive procedures, there is not complete claims information to estimate accurately the cost of these services to allow their assignment to clinical APCs. Therefore, we proposed to exclude payment for all procedures assigned to New Technology APCs from being bundled into the payment for procedures assigned to a C– APC. This action would allow for separate payment for the Argus® II procedure even when it is performed with another comprehensive service, which would provide more cost information regarding the procedure. This proposal was also discussed in section II.A.2.c. of the proposed rule. Comment: A number of commenters supported the proposal. Response: We appreciate the commenters’ support. After consideration of the public comments we received, we are finalizing our proposal to exclude payment for all procedures assigned to New Technology APCs from being bundled into the payment for procedures assigned to a C–APC for CY 2019. c. Bronchoscopy With Transbronchial Ablation of Lesion(s) by Microwave Energy CMS has established HCPCS code C9751 (Bronchoscopy, rigid or flexible, transbronchial ablation of lesion(s) by microwave energy, including fluoroscopic guidance, when performed, with computed tomography acquisition(s) and 3-D rendering, computer-assisted, image-guided navigation, and endobronchial ultrasound (EBUS) guided transtracheal and/or transbronchial sampling (e.g., aspiration[s]/biopsy[ies]) and all mediastinal and/or hilar lymph node stations or structures and therapeutic E:\FR\FM\21NOR2.SGM 21NOR2 intervention(s)), effective January 1, 2019. This microwave ablation procedure utilizes a flexible catheter to access the lung tumor via a working channel and may be used as an alternative procedure to a percutaneous microwave approach. Based on our review of the New Technology APC application for this service and the service’s clinical similarity to existing services paid under the OPPS, we estimated the likely cost of the procedure to be between $8,001 and $8,500. Therefore, we are assigning the procedure described by HCPCS code C9751 to New Technology APC 1571 (New Technology—Level 34 ($8,001– $8,500)), with a payment rate of $8,250.50 for CY 2019. Details regarding HCPCS code C9751 are shown in Table 18. D. OPPS APC-Specific Policies was listed as code 538X3 (the 5-digit CMS placeholder code) in Addendum B, with the short descriptor, and in Addendum O, with the long descriptor, to the CY 2019 OPPS/ASC proposed rule. We also assigned CPT code 53854 to comment indicator ‘‘NP’’ in Addendum B to indicate that the code is new for CY 2019 with a proposed APC assignment. Comment: Several commenters addressed the proposed APC assignment for the Rezum Therapy procedure (CPT code 53854), as well as the APC assignments for the following other benign prostatic hyperplasia treatment procedures: • Transurethral microwave therapy (TUMT) procedure, which is described by CPT code 53850, and which we proposed to continue to assign to APC 5374 (Level 4 Urology and Related Services), with a proposed payment rate of approximately $2,756; • Transurethral needle ablation procedure (TUNA), which is described by CPT 53852, and which we proposed to continue to assign to APC 5375 (Level 5 Urology and Related Services) with a proposed payment rate of approximately $3,776. We note that Table 19 lists the long descriptors for the Rezum Therapy, TUMT, and TUNA procedures. One commenter disagreed with the proposed assignment for the Rezum Therapy procedure described by CPT code 53854 to APC 5373, and indicated that APC 5373 does not contain other procedures that are similar clinically or in resource costs. The commenter stated that the Rezum Therapy procedure is comparable to the TUMT procedure, which is proposed to be assigned to APC 5374, and the TUNA procedure, which is proposed to be assigned to APC 5375. Therefore, the commenter requested that CPT code 53854, which describes the Rezum Therapy procedure, be assigned to APC 5375 instead of APC 5373. In addition, the commenter requested that the TUMT procedure described by CPT code 53850 be reassigned from APC 5374 to APC 5375. The commenter further stated that all three benign prostatic hyperplasia treatment procedures are comparable and suggested that they be assigned to APC 5375 based on clinical homogeneity and resource costs. Another commenter also believed that the Rezum Therapy procedure described by CPT code 53854 should be assigned to APC 5375. Response: Review of our claims data used for this final rule with comment period, which is based on claims submitted between January 1, 2017 and December 31, 2017, and processed through June 30, 2018, reveals that the resource costs for these three benign prostatic hyperplasia treatment procedures are significantly different. Our analysis shows that the geometric mean cost for CPT code 53850 (the TUMT procedure) is approximately 1. Benign Prostatic Hyperplasia Treatments (APCs 5373 and 5374) khammond on DSK30JT082PROD with RULES2 58899 For the CY 2019 OPPS update, the CPT Editorial Panel established new CPT code 53854 to describe the Rezum Therapy procedure, which is also known as steam therapy or water vapor therapy, for the treatment of benign prostatic hyperplasia. Prior to January 1, 2019, the Rezum Therapy procedure was described by HCPCS code C9748, which was assigned to APC 5373 (Level 3 Urology and Related Services) when the code was established effective January 1, 2018. HCPCS code C9748 will be deleted on December 31, 2018 because it will be replaced with new CPT code 53854, effective January 1, 2019. We note that Table 19 below lists the long descriptors for both HCPCS code C9748 and CPT code 53854. As displayed in Table 19 below, and in Addendum B to the CY 2019 OPPS/ ASC proposed rule, we proposed to delete HCPCS code C9748 and assign the code to status indicator ‘‘D’’ to indicate that the code would be deleted for the January 2019 OPPS update. We also proposed to assign the new replacement code, CPT code 53854, to APC 5373, with a proposed payment rate of approximately $1,731. We note that the predecessor HCPCS code for CPT code 53854 (HCPCS code C9748) was also assigned to APC 5373. In addition, we note that CPT code 53854 VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 PO 00000 Frm 00083 Fmt 4701 Sfmt 4700 E:\FR\FM\21NOR2.SGM 21NOR2 ER21NO18.033</GPH> Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations 58900 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations khammond on DSK30JT082PROD with RULES2 $3,272 (based on 107 single claims out of 107 total claims) compared to CPT code 53852 (the TUNA procedure) whose geometric mean cost is approximately $2,989 (based on 408 single claims out of 410 total claims). In addition, in September 2017, CMS received a New Technology APC application requesting a new HCPCS code for the Rezum Therapy procedure because, according to the applicant, the only available CPT code to report the procedure was CPT code 53899 (Unlisted procedure, urinary system). Based on our review of the application, assessment of the procedure, and input from our clinical advisors, we established HCPCS code C9748, effective January 1, 2018, and assigned the code to APC 5373, with a payment rate of approximately $1,696. We announced this new HCPCS C-code and APC assignment in the CY 2018 OPPS/ ASC final rule with comment period (82 FR 59320) and stated that we believed the Rezum Therapy procedure shares similar resource costs and clinical homogeneity to the other procedures assigned to APC 5373. Further, because of the public comments received on the Rezum Therapy procedure, we conducted a preliminary claims review for HCPCS code C9748, and found that, based on 73 claims that were processed on or before July 27, 2018, the geometric mean cost for the procedure is approximately $1,711, which is significantly lower than the geometric mean cost for either CPT code 53850 (TUMT procedure) at approximately $3,272 or CPT code 53852 (TUNA procedure) at approximately $2,989. In addition, a presenter at the August 20, 2018 HOP Panel meeting requested that the HOP Panel recommend that CMS reassign placeholder CPT code 538X3 (CPT code 53854) to APC 5374 or 5375 based on clinical similarity to the procedures described by CPT codes 53850 and 53852. Based on the information presented at the meeting, the HOP Panel made no recommendation to revise the APC assignment for the Rezum Therapy procedure. However, based on the public comments received for the VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 reassignment for all three benign prostatic hyperplasia treatment procedures, we reviewed the procedures assigned to the family of Urology APCs for this final rule with comment period and made some modifications to more appropriately reflect the resource costs and clinical characteristics of the services within each APC grouping. Specifically, we revised the APC assignment of the procedures assigned to the family of Urology APCs to more appropriately reflect a prospective payment system that is based on payment groupings and not codespecific payment rates, while maintaining clinical and resource homogeneity. Based on our review and modification, we revised the APC assignment for CPT code 53852 (the TUNA procedure) from APC 5375 (Level 5 Urology and Related Services) to APC 5374 (Level 4 Urology and Related Services) based on its clinical and resource homogeneity to the other procedures in the APC 5374. Specifically, our claims data show that the geometric mean cost for CPT code 53852 is approximately $2,989, which is comparable to the geometric mean cost of approximately $2,952 for APC 5374, rather than the geometric mean cost of approximately $4,055 for APC 5375. We believe that this modification to the proposed assignment of CPT code 53852 to APC 5374 is appropriate. In addition, based on our latest claims data used for the final rule with comment period, we believe that CPT codes 53850 (the TUMT procedure) and 53852 (the TUNA procedure) are appropriately assigned to APC 5374. We also believe that, based on our assessment of the Rezum Therapy procedure and its cost, as reported in the CMS New Technology application, and based on our preliminary claims review for HCPCS code C9748 (which is the predecessor code for CPT code 53854), the Rezum Therapy procedure continues to be appropriately assigned to APC 5373 based on its clinical and resource homogeneity to the other procedures in the APC. Comment: One commenter agreed with the proposed continued APC assignment for CPT code 53852 (the PO 00000 Frm 00084 Fmt 4701 Sfmt 4700 TUNA procedure) to APC 5375. The commenter also contended that, while the presenter at the August 20, 2018 HOP Panel meeting recommended an assignment of APC 5374 or APC 5375 for the procedure, the Rezum Therapy procedure is less costly to perform than the TUNA procedure, and also noted that the HOP Panel made no recommendation to CMS to change the APC assignment for either procedure. Response: Based on our comprehensive review of the procedures assigned to the Urology APCs, and analysis of the latest claims data, we do not agree that that we should continue to assign the procedure described by CPT code 58352 (the TUNA procedure) to APC 5375 because the geometric mean cost of the procedure of approximately $2,989 is significantly less than the geometric mean cost of approximately $4,055 for APC 5375. We believe that the geometric mean cost of approximately $2,989 for the procedure described by CPT code 53852 is more comparable to the geometric mean cost of approximately $2,952 for APC 5374. Therefore, for this final rule with comment period, we are revising the proposed APC assignment for the procedure described by CPT code 58352 and assigning the procedure to APC 5374 for CY 2019. After consideration of the public comments we received, and based on the information presented above, as well as our evaluation of the latest claims data for the TUMT, TUNA, and Rezum Therapy procedures, we are finalizing the proposed APC assignment for the procedures described by CPT code 53850 and CPT code 53854, and revising the APC assignment for the procedure described by CPT code 53852 to APC 5374 (instead of APC 5375). The final APC and status indicator assignments are listed in Table 19 below. We refer readers to Addendum B to this final rule with comment period for the final payment rates for all codes reportable under the OPPS. Addendum B is available via the internet on the CMS website. E:\FR\FM\21NOR2.SGM 21NOR2 2. Cardiac Contractility Modulation (CCM) Therapy (APC 5231) For CY 2019, we proposed to continue to assign the procedure described by CPT code 0408T (Insertion or replacement of permanent cardiac contractility modulation system, including contractility evaluation when performed, and programming of sensing and therapeutic parameters; pulse generator with transvenous electrodes) to APC 5231 (Level 1 ICD and Similar Procedures) with a proposed payment rate of approximately $22,242. Comment: One commenter disagreed with the proposed APC assignment of the procedure described by CPT code 0408T to APC 5231 and requested that CMS assign the procedure to APC 5232 (Level 2 ICD and Similar Procedures), which had a proposed payment rate of approximately $30,862. The commenter stated that the proposed payment rate for APC 5231 does not accurately reflect the cost or clinical characteristics of the procedure and technology. The commenter added that while the procedure code has had an extremely low volume of OPPS claims, the number of claims reporting this procedure code is expected to increase in the future after the completion of a large, prospective multicenter study to VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 evaluate CCM and its impact on the quality of life and long-term mortality in patients with moderate to severe heart failure. The commenter stated that the cost of the complete CCM system is approximately $25,000, which is comparable to the cost of an ICD system ($20,000) and CRT–D system ($30,000) whose procedure codes are assigned to APC 5232. Moreover, the commenter noted that, under the IPPS, the procedures describing the insertion of the complete system are assigned to one MS–DRG, and suggested that CMS adopt this same methodology under the OPPS. Specifically, the commenter recommended that CMS assign the procedure describing the insertion of the complete systems for the CCM, ICD, and CRT–D systems to APC 5232. Response: The commenter suggested that we assign the procedures describing the insertion of the complete CCM, ICD, and CRT–D to one APC but did not provide the specific CPT codes associated with the ICD and CRT–D systems. Based on the information provided, we believe that the commenter is requesting that we assign to APC 5232 the following codes: • Cardiac contractility modulation (CCM): CPT code 0408T (which we PO 00000 Frm 00085 Fmt 4701 Sfmt 4700 58901 proposed in APC 5231 (Level 1 ICD and Similar Procedures)); • Implantable cardioverterdefibrillator (ICD): CPT code 33249 (which we proposed in APC 5232 (Level 2 ICD and Similar Procedures)); and • Cardiac Resynchronization Therapy Defibrillator (CRT–D): CPT codes 33249 (which we proposed to assign to APC 5232 (Level 2 ICD and Similar Procedures) and 33225 (which we proposed to package payment because this is an add-on code), or CPT code 33270 (which we proposed to assign to APC 5232 (Level 2 ICD and Similar Procedures)). Based on the latest hospital outpatient claims data used for this final rule with comment period, our analysis does not support the assignment of the procedures describing the insertion of the complete CCM systems (described by CPT code 0408T) to APC 5232. We examined the latest hospital outpatient claims data for CPT code 0408T for dates of service between January 1, 2017, and December 31, 2017, that were processed on or before June 30, 2018. Our analysis of the claims data show a geometric mean cost of approximately $15,131 for CPT code 0408T, based on 2 single claims (out of 2 total claims). We do not believe that it is appropriate E:\FR\FM\21NOR2.SGM 21NOR2 ER21NO18.034</GPH> khammond on DSK30JT082PROD with RULES2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations to assign the procedure described by CPT code 0408T to APC 5232 because its geometric mean cost is approximately $30,921, which is significantly higher than the geometric mean cost of approximately $15,131 for CPT code 0408T. Therefore, assigning the procedure described by CPT code 0408T to APC 5232 would result in an overpayment for the procedure. We believe that APC 5231 is the most appropriate APC assignment for the procedure described by CPT code 0408T based on its clinical and resource homogeneity to the other procedures assigned to this APC. We also analyzed the latest hospital outpatient claims data for the procedure for the insertion of the complete systems for ICD and CRT–D. The insertion of a complete ICD system is described by CPT code 33249, and our analysis reveals that the geometric mean cost of approximately $33,384 for CPT code 33249 based on 29,451 single claims (out of 29,867 total claims) is significantly higher than that of CPT code 0408T whose geometric mean cost is approximately $15,131. The insertion of a complete CRT–D system is described by either CPT code 33249 or 33270. Similar to the procedure described by CPT code 33249, our findings reveal that the geometric mean cost for the procedure described by CPT code 33270 is approximately $35,361 based on 1,011 single claims (out of 1,023 total claims), which is significantly greater than that of CPT code 0408T. Based on our claims data, we do not believe that we should reassign the procedure described by CPT code 0408T (the insertion of the complete CCM systems) to APC 5232, which is the APC assignment for the insertion of the complete ICD and CRT– D systems. We believe that the geometric mean cost of approximately $15,131 for CPT code 0408T is comparable to the geometric mean cost of about $22,187 for APC 5231. We also believe that the geometric mean cost of approximately $33,384 for CPT code 33249, and the geometric mean cost of approximately $35,361 for CPT code 33270 are comparable to the geometric mean cost of approximately $30,921 for APC 5232. Therefore, after consideration of the public comment we received, we are finalizing our proposal, without modification, to assign CPT code 0408T to APC 5231, and to continue to assign CPT code 33249 and 33270 to APC 5232 for CY 2019. The final CY 2019 payment rate for the code can be found in Addendum B to this final rule with comment period (which is available via the internet on the CMS website). As we do every year, we will reevaluate the APC assignment for CPT codes 0408T, 33249, and 33270 for the next rulemaking cycle. We remind hospitals that we review, on an annual basis, the APC assignments for all items and services paid under the OPPS. Comment: One commenter disagreed with CMS’ proposed APC assignments for certain cardiac resynchronization Category III CPT codes that are new for CY 2019 and therefore do not have associated claims data available. Specifically, the commenter requested that five of the eight new CPT codes be reassigned to the following APCs: • CPT code 0515T (Insertion of wireless cardiac stimulator for left ventricular pacing, including device interrogation and programming, and imaging supervision and interpretation VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 PO 00000 Frm 00086 Fmt 4701 Sfmt 4700 3. Cardiac Resynchronization Therapy (APCs 5221, 5222, 5231, 5731, and 5741) In Addendum B to the CY 2019 OPPS/ASC proposed rule, we proposed to assign eight new CY 2019 cardiac resynchronization therapy CPT codes to various APCs, which are listed in Table 20 below. The codes were listed as 06X5T, 06X6T, 06X7T, 06X8T, 06X9T, 07X2T, 06X0T, and 07X0T (the 5-digit CMS placeholder codes) in Addendum B with short descriptors and in Addendum O with long descriptors to the CY 2019 OPPS/ASC proposed rule. We also assigned these codes to comment indicator ‘‘NP’’ in Addendum B to the proposed rule to indicate that the codes are new for CY 2019 with proposed APC assignments and that public comments would be accepted on their proposed APC assignments. We note that these codes will be effective January 1, 2019. E:\FR\FM\21NOR2.SGM 21NOR2 ER21NO18.035</GPH> khammond on DSK30JT082PROD with RULES2 58902 khammond on DSK30JT082PROD with RULES2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations when performed; complete system (includes electrode and generator [transmitter and battery]))—from the proposed assignment to APC 5222 (Level 2 Pacemaker and Similar Procedures) to APC 5231 (Level 1 ICD and Similar Procedures); • CPT code 0516T (Insertion of wireless cardiac stimulator for left ventricular pacing, including device interrogation and programming, and imaging supervision and interpretation when performed; electrode only)—from the proposed assignment to APC 5221 (Level 1 Pacemaker and Similar Procedures) to APC 5194 (Level 4 Endovascular Procedures); • CPT code 0517T (Insertion of wireless cardiac stimulator for left ventricular pacing, including device interrogation and programming, and imaging supervision and interpretation when performed; pulse generator component(s) only (battery and/or transmitter))—from the proposed assignment to APC 5221 to APC 5222 (Level 2 Pacemaker and Similar Procedures); • CPT code 0520T (Removal and replacement of wireless cardiac stimulator for left ventricular pacing; pulse generator component(s) (battery and/or transmitter) including placement of a new electrode)—from the proposed assignment to APC 5221 to APC 5231; and • CPT code 0521T (Interrogation device evaluation (in person) with analysis, review and report, includes connection, recording, and disconnection per patient encounter, wireless cardiac stimulator for left ventricular pacing)—from the proposed assignment to APC 5731 (Level 1 Minor Procedures) to APC 5741 (Level 1 Electronic Analysis of Devices) First, the commenter stated that CPT codes 0515T and 0520T describe the implantation or removal/replacement of the complete system and, consequently, these procedures should be assigned to APC 5231. Second, the commenter stated that the resources associated with the procedure described by CPT 0516T are similar to those procedures described by CPT code 33274 (Transcatheter insertion or replacement of permanent leadless pacemaker, right ventricular, including imaging guidance (e.g., fluoroscopy, venous ultrasound, ventriculography, femoral venography) VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 and device evaluation (e.g., interrogation or programming), when performed), which is assigned to APC 5194, and, therefore, this new code should also be assigned to the same APC. In addition, the commenter indicated that the procedure described by CPT code 0517T shares the same clinical and resource homogeneity as the procedure described by CPT code 33212 (Insertion of pacemaker pulse generator only; with existing single lead), which is assigned to APC 5222, and the procedure described by CPT code 33213 (Insertion of pacemaker pulse generator only; with existing dual leads), which is assigned to APC 5223 ((Level 3 Pacemaker and Similar Procedures). Further, the commenter stated that the resources associated with the procedure described by CPT code 0521T are similar to those for the procedures described by existing CPT codes 93261 (Interrogation device evaluation (in person) with analysis, review and report by a physician or other qualified health care professional, includes connection, recording and disconnection per patient encounter; implantable subcutaneous lead defibrillator system), CPT codes 93288 (Interrogation device evaluation (in person) with analysis, review and report by a physician or other qualified health care professional, includes connection, recording and disconnection per patient encounter; single, dual, or multiple lead pacemaker system), 93289 (Interrogation device evaluation (in person) with analysis, review and report by a physician or other qualified health care professional, includes connection, recording and disconnection per patient encounter; single, dual, or multiple lead transvenous implantable defibrillator system, including analysis of heart rhythm derived data elements), 93290 (Interrogation device evaluation (in person) with analysis, review and report by a physician or other qualified health care professional, includes connection, recording and disconnection per patient encounter; implantable cardiovascular monitor system, including analysis of 1 or more recorded physiologic cardiovascular data elements from all internal and external sensors), and 93292 (Interrogation device evaluation (in person) with analysis, review and report by a physician or other qualified health care professional, includes PO 00000 Frm 00087 Fmt 4701 Sfmt 4700 58903 connection, recording and disconnection per patient encounter; wearable defibrillator system), which are all assigned to APC 5741, and, consequently, the procedure described by CPT code 0521T also should be assigned to this same APC. Response: Based on our clinical review, we agree with the commenter that there is greater homogeneity, both clinically and in terms of resource use, by assigning CPT codes 0515T and 0520T to APC 5231. We also agree with the commenter that CPT code 0517T is more homogenous clinically and in terms of resource use with the procedures assigned to APC 5222. However, we disagree with the commenter’s recommendation to assign the procedure described by CPT 0516T to APC 5194. Based on our review of the procedure, we believe that CPT code 0516T is appropriately assigned to APC 5222 because of its clinical and resource homogeneity to the other procedures assigned to this APC. We also disagree with the commenter’s suggestion to assign the procedure described by CPT code 0521T to APC 5741 because the resources required in performing this procedure are not as intensive as those required for the procedure described by CPT code 0522T, which we proposed to assign to APC 5741. We believe that the procedure described by CPT code 0521T is appropriately assigned to APC 5731 because of its clinical and resource homogeneity to the other procedures assigned to this APC. Table 21 below summarizes the commenter’s requested APC assignment for each of the codes along with our decision and the final APC and status indicator assignments. In summary, after consideration of the public comment we received, we are finalizing our proposal to assign the procedures described by CPT codes 0518T, 0519T, 0521T, and 0522T to the final APCs listed in Table 21 below. We are modifying our proposed APC assignment of the procedures described by CPT codes 0515T, 0516T, 0517T, and 0520T, and these modifications are reflected in the final APCs listed in Table 21 below. The final CY 2019 payment rate for CPT codes 0515T through 0521T can be found in Addendum B to this final rule with comment period (which is available via the internet on the CMS website). BILLING CODE 4120–01–P E:\FR\FM\21NOR2.SGM 21NOR2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations BILLING CODE 4120–01–C khammond on DSK30JT082PROD with RULES2 4. Chimeric Antigen Receptor T-Cell (CAR T) Therapy (APCs 5694, 9035, and 9094) Chimeric Antigen Receptor (CAR) Tcell therapy is a cell-based gene therapy in which T-cells are collected and genetically engineered to express a chimeric antigen receptor that will bind to a certain protein on a patient’s cancerous cells. The CAR T-cells are then administered to the patient to attack certain cancerous cells and the individual is observed for potential serious side effects that would require medical intervention. Two CAR T-cell therapies received FDA approval in 2017. KYMRIAH® (manufactured by Novartis Pharmaceuticals Corporation) was approved for use in the treatment of patients up to 25 years of age with Bcell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse. In May 2018, KYMRIAH® received FDA approval for a second indication, treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL), high grade B-cell lymphoma, and DLBCL VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 arising from follicular lymphoma. YESCARTA® (manufactured by Kite Pharma, Inc.) was approved for use in the treatment of adult patients with relapsed or refractory large B-cell lymphoma and who have not responded to or who have relapsed after at least two other kinds of treatment. As indicated in the CY 2019 OPPS/ ASC proposed rule (83 FR 37114), the HCPCS code to describe the use of KYMRIAH® (HCPCS code Q2040) has been active since January 1, 2018 for OPPS, and the HCPCS code to describe the use of YESCARTA® (HCPCS code Q2041) has been active since April, 1, 2018 for OPPS. The HCPCS coding for the currently approved CAR T-cell therapies include leukapheresis and dose preparation procedures because these services are included in the manufacturing of these biologicals. Both of these CAR T-cell therapies were approved for transitional pass-through payment status, effective April 1, 2018. The HCPCS codes that describe the use of these CAR T-cell therapies were assigned status indicator ‘‘G’’ in Addenda A and B to the CY 2019 OPPS/ ASC proposed rule. As discussed in section V.A.4. (Drugs, Biologicals, and Radiopharmaceuticals with New or Continuing Pass-Through PO 00000 Frm 00088 Fmt 4701 Sfmt 4700 Payment Status in CY 2019) of this final rule with comment period, we are finalizing our proposal to continue passthrough payment status for HCPCS code Q2040 (which is being deleted and replaced with HCPCS code Q2042, effective January 1, 2019) and HCPCS code Q2041 for CY 2019. In section V.A.4. of this final rule with comment period, we also are finalizing our proposal to determine the pass-through payment rate following the standard ASP methodology, updating passthrough payment rates on a quarterly basis if applicable information indicates that adjustments to the payment rates are necessary. The AMA created four Category III CPT codes that are related to CAR T-cell therapy, effective January 1, 2019. As listed in Addendum B of the CY 2019 OPPS/ASC proposed rule, we proposed to assign procedures described by these CPT codes, 0537T, 0538T, 0539T, and 0540T, to status indicator ‘‘B’’ (Codes that are not recognized by OPPS when submitted on an outpatient hospital Part B bill type (12x and 13x)) to indicate that the services are not paid under the OPPS. We note that, these codes were listed as placeholder CPT codes 05X1T, 05X2T, 05X3T, and 05X4T in both Addendum B and O to the CY 2019 E:\FR\FM\21NOR2.SGM 21NOR2 ER21NO18.036</GPH> 58904 khammond on DSK30JT082PROD with RULES2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations OPPS/ASC proposed rule. Addendum B listed the short descriptor, with the proposed status indicator of ‘‘B’’, while Addendum O listed the complete long descriptors under placeholder CPT codes 05X1T, 05X2T, 05X3T, and 05X4T. The final CPT codes and long descriptors, with their respective proposed OPPS status indicators, are listed in Table 23 at the end of this section. At the summer 2018 meeting of the HOP Panel, the HOP Panel recommended that CMS reassign the status indicator for procedures described by these specific CPT codes from ‘‘B’’ to ‘‘S’’. The Panel further recommended that CMS assign the procedures described by CPT code 0537T and CPT code 0540T to APC 5242 (Level 2 Blood Product Exchange and Related Services), and the procedures described by CPT code 0538T and CPT code 0539T to APC 5241 (Level 1 Blood Product Exchange and Related Services). Comment: Some commenters disagreed with the proposed status indicator assignment of ‘‘B’’ for the procedures described by CPT codes 0537T, 0538T, 0539T, and 0540T, and requested that CMS recognize these procedures and the services described by the CPT codes under the OPPS and pay separately for them. Some of these commenters urged CMS to accept and finalize the HOP Panel’s recommendations for assignment of these CPT codes. Commenters stated that providers may currently use the unlisted code (38999) to bill for the services described by the new CPT codes because the currently available CPT codes fail to accurately describe the procedure being rendered. The commenters indicated that these services are similar to stem cell transplant services, and suggested that the similarities between various codes, including similarities between the procedures described by CPT code 05X1T (0537T) and CPT code 38206 (Blood-derived hematopoietic progenitor cell harvesting for transplantation, per collection; autologous), which is assigned to APC 5242 (Level 2 Blood Product Exchange and Related Services); CPT code 05X2T (0538T) and CPT code 38207 (Transplant preparation of hematopoietic progenitor cells; cryopreservation and storage), which is assigned to APC 5241 (Level 1 Blood Product Exchange and Related Services); CPT code 05X3T (0539T) and CPT code 38208 (Transplant preparation of hematopoietic progenitor cells; cryopreservation and storage; thawing of previously frozen harvest, without VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 washing, per donor), which is assigned to APC 5241 (Level 1 Blood Product Exchange and Related Services), and finally CPT code 05X4T (0540T) and CPT code 38241(Hematopoietic progenitor cell (hpc); autologous transplantation), which is assigned to APC 5242 (Level 2 Blood Product Exchange and Related Services), be validly recognized and considered when determining applicable policy and assignments. A few commenters believed that there are possible similarities between the CAR T-cell procedure CPT code 0540T and chemotherapy codes, in general. However, other commenters asserted that CAR T-cell services were distinct from the services associated with chemotherapy and stem cell transplant codes, but noted that the codes suggested were the best available approximations for payment at present and could provide useful benchmarks of resource utilization. Some commenters also supported the creation of a new Autologous HCT C–APC to adequately compensate providers for providing CAR T-cell related services. Some commenters requested that the existing Q-codes for CAR T-cell therapies be revised to reference only the CAR T-cell products, and that leukapheresis and other services related to the preparation, collection and treatment be separately coded and paid. A few commenters referenced the National Coverage Decision (NCD) for apheresis (effective 1992), which provides coverage only under limited conditions for therapeutic apheresis, and asked CMS to clarify whether it applies to harvesting blood-derived Tlymphocytes for development of genetically modified autologous CAR Tcells. Some commenters referenced the ongoing National Coverage Analysis (NCA) for CAR T-cells, and asked CMS to provide guidance in the interim on how to bill for CAR T-cells and its therapies’ administration. The commenters also suggested additional modifications to HCPCS codes Q2040 and Q2041, such as adopting HCPCS J-codes instead of HCPCS Q-codes. Some commenters requested guidance on how to bill for specific services, incomplete services, or partial services related to CAR T-cell therapy, including but not limited to, billing for pre-infusion steps, billing for services provided a number of days before the infusion, billing if the CAR Tcell product is not infused, and billing if services are provided at different facilities, such as both inpatient and outpatient facilities. Finally, another commenter supported the proposal not to pay PO 00000 Frm 00089 Fmt 4701 Sfmt 4700 58905 separately for procedures described by CPT codes 0537T, 0538T and 0539T because the commenters maintained that payment for these CPT codes and the performance of the services describe various steps of the manufacturing process and, therefore, are appropriately included and conveyed in the descriptors of and the existence of Qcodes for CAR T-cell therapies. The commenter supported the appropriateness of including these steps in the payment for the drug as a means to ensure the manufacturer can preserve the integrity of the process and to maximize the quality of therapy. Finally, one commenter believed that separate payments for leukapheresis would increase beneficiary cost-sharing. Response: We do not believe that separate payment under the OPPS is necessary for procedures described by CPT codes 0537T, 0538T, and 0539T. The existing CAR T-cell therapies on the market were approved as biologics and, therefore, provisions of the Medicare statute providing for payment for biologicals apply. The procedures described by CPT codes 0537T, 0538T, and 0539T describe various steps required to collect and prepare the genetically modified T-cells, and Medicare does not generally pay separately for each step used to manufacture a drug or biological. We note that the HCPCS coding for the currently approved CAR T-cell therapy drugs, HCPCS codes Q2040 and Q2041, includes leukapheresis and dose preparation procedures because these services are included in the manufacturing of these biologicals. We also note that, for OPPS billing purposes, the Q-codes are treated in the same manner as J-codes, and a procedure assignment conversion to a Jcode for payment classification purposes would not affect payment by Medicare. Q-codes can be updated quarterly, which allows for greater frequency of modifications and, therefore, we believe are appropriate for these new therapies. HOPDs can bill Medicare for reasonable and necessary services that are otherwise payable under the OPPS, and we believe that the comments in reference to payment for services provided in settings not payable under OPPS are outside the scope of the proposed rule. With respect to NCD 110.14 for apheresis (Therapeutic Pheresis) (https://www.cms.gov/medicarecoverage-database/details/ncddetails.aspx?NCDId=;82&ncdver=1&bc= AAAAgAAAAAAA&), we note that it refers only to therapeutic treatments where blood is taken from the patient, processed, and returned to the patient as E:\FR\FM\21NOR2.SGM 21NOR2 58906 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations khammond on DSK30JT082PROD with RULES2 part of a continuous procedure and is distinguished from situations where a patient is transfused at a later date. With respect to comments referencing the ongoing NCA for CAR T-cells, we remind readers that coverage analysis and determination do not determine what code or payment is assigned a particular item or service, but information on this NCA and process may be found at: https://www.cms.gov/ medicare-coverage-database/details/ nca-tracking-sheet.aspx?NCAId=291. Accordingly, we are not revising the existing Q-codes for CAR T-cell therapies to remove leukapheresis and dose preparation procedures, and we are not accepting the HOP Panel’s recommendations for procedures described by CPT codes 0537T, 0538T and 0539T. In regard to comments concerning CPT code 0540T, we were persuaded by commenters that the administration of CAR T-cell services would be more specifically described by CPT code 0540T. Because CPT code 0540T is a new code for CY 2019, we do not have any claims data on which to base our proposed payment rate. In the absence of claims data, we reviewed the clinical characteristics of the procedures to determine whether they are similar to existing procedures. After reviewing information from public commenters and input from our medical advisors, we believe that new CPT code 0540T is clinically similar to the services assigned to APC 5694 (Level IV Drug Administration), with a proposed payment rate of approximately $291, such as the procedure described by CPT code 96413 (Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug). We acknowledge commenters’ supporting data and indications that CAR T-cell service is complex, distinct from chemotherapy, and has the potential for highly adverse reactions. However, we note that CPT’s prefatory language for the ‘‘Chemotherapy and Other Highly Complex Drug or Highly Complex Biologic Agent Administration’’ section in which the procedure described by CPT code 96413, and some other services assigned to APC 5694 are listed, describes these procedures as VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 administration of highly complex drugs or biologic agents with greater incidence of severe adverse patient reaction. We also note that the unique toxicities associated with CAR T-cell therapies tend not to occur at time of infusion, and services to monitor or treat adverse reactions on a subsequent day would not be included in the procedure described by CPT code 0540T. Therefore, we are accepting the HOP Panel’s recommendation and the commenters’ request to reassign the status indicator assignment of the procedure described by CPT code 0540T from ‘‘B’’ to ‘‘S.’’ However, we are not accepting the HOP Panel’s recommendation and the commenters’ request to assign the procedure described by CPT code 0540T to APC 5242 (Level 2 Blood Product Exchange and Related Services), but instead are assigning the procedure described by CPT code 0540T to APC 5694 (Level IV Drug Administration) for CY 2019. We remind hospitals that every year, we review the APC assignments for all services and items paid under the OPPS, and we will reevaluate the APC assignment for the procedures described by CPT code 0540T once sufficient claims data for this code become available. Comment: Some commenters suggested that separately paying for the services described by new CPT codes for CAR T-cell therapy under the OPPS would allow Medicare and others to track utilization and cost data of these specific services. Some commenters also noted that the National Uniform Billing Committee (NUBC) established two new revenue codes and a value code related to CAR T-cell therapy, and expressed support for CMS’ creation of a new CAR T-cell-related cost center (or centers) to assist with tracking CAR T-cell-related costs. Response: The existing HCPCS codes for CAR T-cell therapies include both leukapheresis and dose-preparation procedures, and for the reasons stated previously, there is no separate payment by Medicare for these steps in the manufacturing process. However, it will be possible for Medicare to track utilization and cost data from hospitals reporting these services, even for codes reported for services in which no PO 00000 Frm 00090 Fmt 4701 Sfmt 4700 separate payment is made. The CAR Tcell related revenue codes and value code established by the NUBC will be reportable on HOPD claims, and will be available for tracking utilization and cost data, effective for claims received on or after April 1, 2019. At this time, we do not believe that the additional creation by CMS of a new cost center is necessary as the currently established methods for tracking CAR T-cell related costs are sufficient. However, we will monitor for this issue to determine if a distinct cost center should be established in the future. Comment: Some commenters noted that HCPCS code Q2040 describes doses of ‘‘up to 250 million’’ cells, and requested guidance on how to bill for an adult indication that may require doses of ‘‘up to 600 million cells.’’ Response: HCPCS code Q2040 (which is being replaced by HCPCS code Q2042, effective January 1, 2019) is billed only once per infusion. For CY 2019, we revised the descriptor for HCPCS code Q2042 to describe doses ‘‘up to 600 million cells . . . per therapeutic dose.’’ For CY 2019, we also revised the descriptor for HCPCS code Q2041, in order to maintain consistency in the HCPCS coding for CAR T-cells. In summary, after consideration of the public comments we received, we are adopting as final, without modification, the proposal to assign status indicator ‘‘B’’ to CPT codes 0537T, 0538T, and 0539T for CY 2019. We are revising our proposal and finalizing the policy to assign status indicator ‘‘S’’ to CPT code 0540T and to assign CPT code 0540T to APC 5694 for CY 2019. Additionally, for CY 2019, we are assigning status indicator ‘‘D’’ to CPT code Q2040, status indicator ‘‘G’’ to HCPCS code Q2041, and status indicator ‘‘G’’ to HCPCS code Q2042, as summarized in Table 22 below. We refer readers to Addendum B to this final rule with comment period for the payment rates for all codes reportable under the OPPS. Addendum B is available via the internet on the CMS website. In addition, we refer readers to Addendum D1 to this final rule with comment period for the complete list of the OPPS payment status indicators and their definitions for CY 2019. BILLING CODE 4120–01–P E:\FR\FM\21NOR2.SGM 21NOR2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations HCPCS Code Q2040 TABLE 22.-FINAL CY 2019 APC AND SI FOR HCPCS CODES Q2040, Q2041, AND Q2042 Final Final CY CY October CY CY Final CY 2019 Long 2018 2018 2018 OPPS 2019 2019 OPPS Descriptors OPPS OPPS Payment OPP OPPS Payment Rate SI APC Rate S SI APC Tisagenlecleucel, up to 250 million car-positive viable t cells, including leukapheresis and dose preparation procedures, per infusion* Axicabtagene ciloleucel, up to 200 million autologous anticd 19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose** G 9081 $500,901.94 D NIA NIA G 9035 $395,380.00 G 9035 Refer to OPPS AddendumB Tisagenlecleucel, up to 600 million car-positive viable t cells, including Refer to OPPS 9194 Q2042 G leukapheresis AddendumB and dose preparation procedures, per therapeutic dose * HCPCS code Q2040: As d1scussed above m th1s sectwn, CMS deleted HCPCS Code Q2040, replaced 1t with HCPCS Code Q2042, and revised the long descriptor to "Tisagenlecleucel, up to 600 million carpositive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose" effective January 1, 2019." ** HCPCS code Q2041: As discussed above in this section, CMS revised the long descriptor to "Axicabtagene ciloleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose" effective January 1, 2019. VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 PO 00000 Frm 00091 Fmt 4701 Sfmt 4725 E:\FR\FM\21NOR2.SGM 21NOR2 ER21NO18.037</GPH> khammond on DSK30JT082PROD with RULES2 Q2041 58907 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations BILLING CODE 4120–01–C khammond on DSK30JT082PROD with RULES2 5. Drug-Eluting Implant (APC 5733) For CY 2019, we proposed to continue to assign CPT code 0356T (Insertion of drug-eluting implant (including punctal dilation and implant removal when performed) into lacrimal canaliculus, each) to APC 5733 (Level 3 Minor Procedures) with a proposed payment rate of approximately $57. We also proposed to continue to assign the CPT code to status indicator ‘‘Q1’’ to indicate one of the following with regards to payment: • Packaged APC payment if billed on the same claim as a HCPCS code assigned status indicator ‘‘S’’, ‘‘T’’, or ‘‘V’’; or • Composite APC payment if billed with specific combinations of services based on OPPS composite-specific payment criteria. Payment is packaged VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 into a single payment for specific combinations of services; or • In other circumstances, payment is made through a separate APC payment. Comment: Several commenters disagreed with the proposed continuation of the status indicator assignment of ‘‘Q1’’ for CPT code 0356T and recommended an assignment to a significant procedure status indicator instead of a conditionally packaged status indicator. One commenter indicated that the procedure described by CPT code 0356T represents a nonsurgical, independent procedure that is not based on any other primary procedure, and believed that a status indicator reassignment would ensure proper claims processing for providers. Response: As indicated above and in OPPS Addendum D1 of the CY 2019 OPPS/ASC proposed rule, status PO 00000 Frm 00092 Fmt 4701 Sfmt 4700 indicator ‘‘Q1’’ represents one of three potential payment assignments. Depending on the claim submitted, and whether the procedure described by CPT code 0356T is performed with any other surgeries or services on the same day, the procedure described by CPT code 0356T may be paid separately through an APC (in this case APC 5733) or paid as part of a payment when included in the more significant procedure that is reported on the claim. Based on the nature of this procedure, which may be performed by itself or with other procedures on the same day, we believe that the continued assignment of status indicator ‘‘Q1’’ is appropriate for the procedure described by CPT code 0356T. After consideration of the public comments we received, we are finalizing our proposal, without E:\FR\FM\21NOR2.SGM 21NOR2 ER21NO18.038</GPH> 58908 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations modification, to assign CPT code 0356T to status indicator ‘‘Q1’’ for CY 2019. The final CY 2019 payment rate for the CPT code can be found in Addendum B to this final rule with comment period (which is available via the internet on the CMS website). khammond on DSK30JT082PROD with RULES2 6. Endovascular Procedures (APCs 5191 Through 5194) At the annual meeting for the HOP Panel held on August 21, 2017, the HOP Panel recommended that, for CY 2018, CMS examine the number of APCs for endovascular procedures. The HOP Panel also recommended that the appropriate Panel subcommittee review the APCs for endovascular procedures to determine whether more granularity (that is, more APCs) is warranted. In the CY 2018 OPPS/ASC final rule with comment period (82 FR 59293 through 59294), we stated that we believed that the current C–APC levels for the Endovascular Procedures C–APC family provide an appropriate distinction between the resource costs at each level and clinical homogeneity. We also stated that we would continue to review the C–APC structure for endovascular procedures to determine if any additional granularity is necessary for this C–APC family. Using the most recent data available for the CY 2019 OPPS/ASC proposed rule, we analyzed the four existing levels of the Endovascular Procedures C–APCs. We did not observe any violations of the 2 times rule within the current Endovascular Procedures C– APC structure. Some stakeholders have suggested that for certain procedures, such as angioplasty procedures involving the use of a drug-coated balloon in addition to a nondrug-coated balloon, resource costs are significantly higher than the geometric mean cost (and associated C–APC payment) for all of the angioplasty procedures combined. We stated in the proposed rule that we recognize that the costs of a given procedure, involving additional devices, will be higher than the costs of the procedure when it does not involve such additional devices. However, the OPPS is a prospective payment system based on a system of averages in which the costs of some cases within an APC will be more costly than the APC payment rate, while the costs of other VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 cases will be less costly. While we believe that there is sufficient granularity within the existing Endovascular Procedures C–APC structure and at least one stakeholder agrees, we stated that we have also received input from other stakeholders who have suggested alternative structures for this C–APC family that include a five-level structure and a sixlevel structure. An illustration of these proposed C–APC structure levels was displayed in Table 15 and Table 16, respectively, of the proposed rule. Because interested stakeholders have suggested a variety of options for the endovascular procedures C–APC structure, including keeping the existing C–APC structure, in the CY 2019 OPPS/ ASC proposed rule, we proposed to maintain the existing four-level structure for this C–APC family listed in Table 14 of the proposed rule. However, we invited public comments on our proposal, as well as the stakeholderrequested five-level and six-level structures displayed in the Tables 15 and 16 of the proposed rule. We noted that the approximate geometric mean costs associated with the suggested fivelevel and six-level C–APC structures shown in Tables 15 and 16 of the proposed rule were only estimates and, if either of the suggested structure levels were adopted, they would be subject to change, depending on the final rule with comment period data and the particular services that are assigned to each C–APC. Comment: Several commenters supported CMS’ proposal to continue with a four-level APC structure, along with the proposed CPT code assignments to each of the endovascular APCs as described in the CY 2019 OPPS/ASC proposed rule. These commenters stated that adding additional APCs to the endovascular series could result in some APCs containing very few procedures, and further believed that this policy change would also be contrary to the concept of broader APC groupings under the OPPS. Another commenter requested that CMS provide greater detail about future proposals in order for stakeholders to be able to provide fully informed comments and recommendations. Other commenters also agreed with CMS’ assessment that the four-level PO 00000 Frm 00093 Fmt 4701 Sfmt 4700 58909 APC structure and the assignment of the procedures to these APCs does not result in any 2 times rule violations, and believed that the current granularity within the existing Endovascular Procedures C–APCs’ structure sufficiently represents resource cost and clinical homogeneity. Response: We appreciate the commenters’ input and support. At this time, we believe that the current APC structure levels for the Endovascular Procedures C–APC family provide an appropriate distinction between resource costs at each level and clinical homogeneity. Comment: Several commenters believed that the current structure of the Endovascular Procedures APCs violates the 2 times rule when certain code combinations, such as the procedures described by CPT 37224 (Revascularization, endovascular, open or percutaneous, femoral, popliteal artery(s), unilateral; with transluminal angioplasty) and HCPCS code C2623 (Catheter, transluminal angioplasty, drug-coated, non-laser), are reported in combination. As a result, the commenters requested that CMS make a complexity adjustment for CY 2019 by assigning cases for the procedures described by CPT code 37224 and HCPCS code C2623 when reported in combination with one another to APC 5193. Some of these commenters believed that the current structure of the Endovascular Procedures APCs is insufficiently granular, and noted that the current APC structure has significant differentials in payments of over $5,000 between the current procedures assigned to Level 2 (APC 5192) and between the procedures assigned to Level 3 and Level 4 (APC 5194). These commenters further contended that the large numbers of procedures assigned to each level of APC, coupled with the high total volume of procedures assigned to each level within each APC, prevent technology costs from being adequately and accurately reflected in the OPPS payment rates. As a result, these commenters requested that CMS create a six-level structure Endovascular Procedure APC reflecting the following cost bands: E:\FR\FM\21NOR2.SGM 21NOR2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations Some of these commenters also specifically suggested that the procedures described by CPT code 37224 (Revascularization, endovascular, open or percutaneous, femoral, popliteal artery(s), unilateral; with transluminal angioplasty) and HCPCS code C2623 (Catheter, transluminal angioplasty, drug-coated, non-laser); and CPT code 37726 (Revascularization, endovascular, open or percutaneous, femoral, popliteal artery(s), unilateral; with transluminal stent placement(s), includes angioplasty within the same vessel, when performed) and HCPCS code C1874 (Stent, coated/covered, with delivery system) be assigned to the newly leveled structure within APC 5193 and APC 5195, respectively, in order to take into consideration the performance of and utilization of procedures involving drug-coated balloons and drug eluting stents that are required for these procedures. Several of these same commenters requested that CMS create new HCPCS code modifiers to take into account the performance of the procedures described by CPT code 37724 when reported in combination with HCPCS code C2623, and CPT code 37226 when reported in combination with HCPCS code C1874. The commenters provided that CMS could model the costs for these cases using CY 2017 and CY 2018 claims data when these codes are reported in combination with one another. The commenters further believed that the creation of new HCPCS code modifiers are necessary in order to differentiate drug-coated device procedures from non-drug-coated device procedures, and will provide the granularity in HCPCS and APC coding that will allow CMS to collect data for the CPT/HCPCS codes to appropriately calculate payment rates within the APCs. Another commenter further stated that these procedures should be assigned to the newly created APC 5193 and APC 5195, respectively. Response: We appreciate the commenters’ suggestion. As noted in the proposed rule, we understand that some stakeholders have suggested that when certain procedures, such as those VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 described by CPT code 37224 and HCPCS code C2623 are reported in combination, a 2 times rule violation occurs. However, we recognize that the costs of a given procedure, involving additional devices, will be higher than the costs of the procedure when it does not involve such additional devices, and we do not believe that these types of 2 times rule violations are avoidable, given the nature of a prospective payment system (83 FR 37095). Using the most recent data available for this final rule with comment period, we analyzed the various alternative suggestions for the recommended HCPCS code placements, including maintaining the CY 2018 APC groupings, creating a six-level APC, and reconfiguring significant HCPCS code placements within the current structure. We note that, when we modeled the creation of a six-level structure APC and modeled a reconfiguration of significant HCPCS code placements, we noticed significant downward payment fluctuations for several services, some as high as a $2,500 decrease relative to the payment rate in CY 2018. Furthermore, based on these findings, we are still not convinced that we should pay for a complexity adjustment for the procedure described by CPT code 37224 when reported in combination with HCPCS code C2623 or for the procedure described by CPT code 37226 when reported in combination with HCPCS code C1874. As noted above and as provided in the proposed rule, the OPPS is a prospective payment system based on a system of averages in which the costs of some cases within an APC will be more costly than the APC payment rate, while the costs of other cases will be less costly and in these particular procedures we believe that if a complexity adjustment would be applied it would adversely affect the APC payment (83 FR 37095). Additionally, at this time, we do not support the creation of any new HCPCS codes for inclusion in the Endovascular Procedures APCs. Specifically, we do not believe that we have the needed evidence and data to support combining payment for either the procedure PO 00000 Frm 00094 Fmt 4701 Sfmt 4700 described by CPT code 37724 when reported in combination with HCPCS code C2623 or the procedure described by CPT code 37226 when reported in combination with HCPCS code C1874 because we believe that payment for these services are currently adequate. However, we do share similar concerns with the commenters regarding the significant differential payments between the procedures assigned within the current four-level structure of the Endovascular Procedures APCs and intend to revisit this particular issue in future rulemaking. Therefore, after consideration of the public comments and suggestions we received, we are maintaining the CY 2018 APC structure of four levels for the Endovascular Procedures APCs. We understand the importance of payment stability for providers and believe that continuation of the four levels within the Endovascular Procedures APCs will minimize fluctuation in payment rates from CY 2018 to CY 2019. As displayed in the ‘‘Two Times Listing’’ file to this final rule with comment period, which is available via the internet on the CMS website, the APC geometric mean costs for APCs 5521 through 5524 are consistent with the CY 2018 APC geometric mean costs for the same APCs, indicating the relative weights that are used to calculate payment are stable. We will continue to review this APC structure to determine if additional granularity is necessary for this C–APC family, including if additional HCPCS codes should be created in future rulemaking. We refer readers to Addendum B to this final rule with comment period for the payment rates for all codes reported under the OPPS. Additionally, we refer readers to Addendum A to this final rule with comment period for the complete list of APCs and their payment rates under the OPPS. Both Addendum A and Addendum B are available via the internet on the CMS website. E:\FR\FM\21NOR2.SGM 21NOR2 ER21NO18.039</GPH> khammond on DSK30JT082PROD with RULES2 58910 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations commenter’s suggestion of recommending a Urology APC assignment (C–APC 5373) for the procedure described by CPT code 10011 when this procedure describes a fine needle aspiration biopsy, which is not a urology-specific procedure. Therefore, we are not accepting the commenter’s recommendation. In addition, we remind hospitals that, every year, we review the APC assignments for all services and items paid under the OPPS. We will reevaluate the APC assignment for the procedures described by CPT codes 10009 and 10011 once we have claims data for the codes. After consideration of the public comment received, we are finalizing our proposal, without modification, to assign the procedures described by CPT codes 10009 and 10011 to APC 5071 for CY 2019. The final APC and status indicator assignments are listed in Table 25 below. We refer readers to Addendum B of this final rule with comment period for the final payment rates for all codes reportable under the OPPS. Addendum B is available via the internet on the CMS website. ER21NO18.041</GPH> appropriate because the resource cost of the CT guidance used in the procedure is higher than the resource cost of ultrasound or fluoroscopy. The commenter disagreed with the proposed assignment of the procedure described by CPT code 10011 to APC 5071 and recommended that APC C–5373 (Level 3 Urology and Related Services), with a proposed payment rate of approximately $1,731, is more appropriate because the cost of the MRI guidance used in the procedure is clinically similar to the other services in this APC. Response: Because CPT codes 10009 and 10011 are new codes for CY 2019, we do not have claims data on which to base the payment rates. However, in the absence of claims data, we reviewed the clinical characteristics of the procedures described by CPT codes 10009 and 10011 to determine whether they are similar to existing procedures. After reviewing information from the public commenter and input from our medical advisors, we believe that the procedures described by new CPT codes 10009 and 10011 are clinically similar to those procedures assigned to APC 5071. We are unclear of the rationale for the VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 PO 00000 Frm 00095 Fmt 4701 Sfmt 4725 E:\FR\FM\21NOR2.SGM 21NOR2 ER21NO18.040</GPH> khammond on DSK30JT082PROD with RULES2 7. Fine Needle Aspiration Biopsy (APC 5071) As displayed in Table 25 below and in Addendum B to the CY 2019 OPPS/ ASC proposed rule, we proposed to assign CPT codes 10009 and 10011 to APC 5071 (Level 1 Excision/Biopsy/ Incision and Drainage), with a proposed payment rate of approximately $582. The codes were listed as 10X16 and 10X18 (the 5-digit CMS placeholder codes), respectively, in Addendum B with the short descriptors and in Addendum O with the long descriptors to the CY 2019 OPPS/ASC proposed rule. We also assigned these codes to comment indicator ‘‘NP’’ in Addendum B to indicate that the codes are new for CY 2019, with proposed APC assignments, and that public comments would be accepted on their proposed APC assignments. We note that these codes will be effective January 1, 2019. Comment: One commenter disagreed with the proposed assignment of the procedure described by CPT code 10009 to APC 5071 and suggested that APC 5072 (Level 2 Excision/Biopsy/Incision and Drainage), with a proposed payment rate of approximately $1,370, is more 58911 58912 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations 8. Fluorescence In Situ Hybridization (FISH) Assays (APCs 5672 and 5673) khammond on DSK30JT082PROD with RULES2 As displayed in Table 26 below and in Addendum B to the CY 2019 OPPS/ ASC proposed rule, we proposed to assign the procedures described by CPT codes 88364 through 88377 to status indicator ‘‘N’’ to indicate a packaged payment status, or status indicators ‘‘Q1’’ and ‘‘Q2’’ to indicate a conditionally packaged payment status, with APC assignments to either APC 5672 (Level 2 Pathology), with a proposed payment rate of approximately $145, or APC 5673 (Level 3 Pathology), with a proposed payment rate of approximately $273. Comment: One commenter urged CMS to exclude certain FISH assays from the OPPS packaging policy. Specifically, the commenter stated that the technical component of services that are associated with the services described by CPT codes 88364, 88365, 88366, 88367, 88368, 88369, 88373, 88374, and 88377 have unique clinical utilization that is distinct from conventional laboratory tests, and suggested that the services described by these codes be excluded from the OPPS payment packaging policy. The commenter further stated that these tests are utilized in both the hospital outpatient and hospital inpatient setting similar to molecular pathology tests and advanced diagnostic laboratory tests (ADLTs). Response: As stated in the CY 2017 OPPS/ASC final rule with comment period (81 FR 79593), payment for most laboratory tests is packaged under OPPS. Under our current policy, payment for certain clinical diagnostic laboratory tests that are listed on the Clinical Laboratory Fee Schedule (CLFS) is packaged in the OPPS as integral, ancillary, supportive, dependent, or adjunctive to the primary service or services provided in the VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 hospital outpatient setting (81 FR 79593 and 42 CFR 419.2(b)(17)). However, we have established exceptions to the OPPS laboratory test packaging policy for molecular pathology tests, certain ADLTs, and preventive laboratory tests. Specifically, we exclude from packaging the following laboratory tests: • Molecular pathology tests, because these relatively new tests may have a different pattern of clinical use than more conventional laboratory tests, which may make them generally less tied to a primary service in the hospital outpatient setting than the more common and routine laboratory tests that are packaged (80 FR 70348 through 70350); • ADLTs, as designated under the CLFS, that meet the criteria of section 1834A(d)(5)(A) of the Act (81 FR 79593 through 79594), and • Preventive laboratory tests that are listed in Section 1.2, Chapter 18 of the Medicare Claims Processing Manual (Pub. 100–04) (80 FR 70349). We note that laboratory tests also are paid separately when they are the only services provided to a beneficiary on a claim (81 FR 79593). When payment for laboratory tests is not packaged under the OPPS, and the tests are listed on the CLFS, the payment is made at the CLFS payment rates, outside the OPPS, under Medicare Part B. With regard to the services described by CPT codes 88364, 88369, and 88373, we proposed to continue to assign these add-on services to status indicator ‘‘N’’ because, under the OPPS, payment for services described by add-on codes are packaged in accordance with the regulations at § 419.2(b)(18). In addition, with regard to the services described by CPT codes 88365, 88366, 88374, and 88377, we proposed to continue to assign these codes to status indicator ‘‘Q1’’ to indicate that these services are separately payable when not billed on the same claim as a PO 00000 Frm 00096 Fmt 4701 Sfmt 4700 HCPCS code assigned status indicator ‘‘S’’, ‘‘T’’, or ‘‘V’’. Further, with regard to the services described by CPT codes 88367 and 88368, we proposed to continue to assign these codes to status indicator ‘‘Q2’’ to indicate that payment for these services will be packaged in the APC payment if billed on the same date of service as a HCPCS code assigned to status indicator ‘‘T’’, but in all other circumstances, separate APC payment for the services would be made. Based on the nature of these services, we believe the payment for the services described by CPT codes 88365, 88366, 88367, 88368, 88374, and 88377 should continue to be conditionally packaged under the OPPS because these laboratory tests may be performed with other procedures on the same day. In summary, because the services described by CPT codes 88364, 88365, 88366, 88367, 88368, 88369, 88373, 88374, and 88377 are not molecular pathology laboratory tests, ADLTs, or preventive laboratory tests as stated in the above response, we believe that we should continue to package the payment for these services under the OPPS. Therefore, after consideration of the public comment received, we are finalizing our proposal, without modification, to assign the services described by CPT codes 88364, 88365, 88366, 88367, 88368, 88369, 88373, 88374, and 88377 to the final APCs and status indicator assignments listed in Table 26 below. We refer readers to Addendum B of this final rule with comment period for the payment rates for all codes reportable under the OPPS. Addendum B is available via the internet on the CMS website. In addition, we refer readers to Addendum D1 of this final rule with comment period for the complete list of the OPPS payment status indicators and their definitions for CY 2019. BILLING CODE 4120–01–P E:\FR\FM\21NOR2.SGM 21NOR2 BILLING CODE 4120–01–C khammond on DSK30JT082PROD with RULES2 9. Immediate Breast Implant Following Mastopexy/Mastectomy (C–APC 5092) For CY 2019, we proposed to continue to assign the procedures described by CPT code 19340 (Immediate insertion of breast prosthesis following mastopexy, mastectomy or in reconstruction) to C– APC 5092 (Level 2 Breast/Lymphatic Surgery and Related Procedures), with a VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 proposed payment rate of approximately $4,960. Comment: Some commenters disagreed with the proposed continued APC assignment for the procedure described by CPT code 19340 to C–APC 5092 and suggested instead a reassignment to C–APC 5093 (Level 3 Breast/Lymphatic Surgery and Related Procedures), with a proposed payment rate of approximately $7,432. One commenter believed that the procedure PO 00000 Frm 00097 Fmt 4701 Sfmt 4700 58913 described by CPT code 19340 shares similar clinical and resource characteristics as the procedures described by CPT codes 19325 (Mammaplasty, augmentation; with prosthetic implant) and 19342 (Delayed insertion of breast prosthesis following mastopexy, mastectomy or in reconstruction), which are assigned to C–APC 5093. Another commenter requested a review and reconfiguration of C–APCs 5092 and 5093, and believed E:\FR\FM\21NOR2.SGM 21NOR2 ER21NO18.042</GPH> Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations that the cost of performing the procedure described by CPT code 19340 is similar to the surgical procedures assigned to C–APC 5093. Response: Analysis of the hospital outpatient claims data used for this final rule with comment period, which is based on claims submitted between January 1, 2017 and December 31, 2017, and processed through June 30, 2018, do not support a reassignment of the procedure described by CPT code 19340 to C–APC 5093. Specifically, our claims data show a geometric mean cost of approximately $5,341 for the procedure described by CPT code 19340 based on 1,187 single claims (out of 1,203 total claims), which is comparable to the geometric mean cost of approximately $4,958 for C–APC 5092. In contrast, our claims data show a higher geometric mean cost for the procedures described by CPT codes 19325 (approximately $6,326 based on 209 single claims out of 210 total claims) and 19342 (approximately $6,232 based on 1,190 single claims out of 1,202 total claims) that is comparable to the geometric mean cost of approximately $7,513 for C–APC 5093. Based on our analysis, we believe that the procedure described by CPT code 19340 is appropriately assigned to C–APC 5092 based on resource and clinical homogeneity to the other procedures in the APC. We note that all of the procedures described by CPT codes assigned to this Breast/ Lymphatic Surgery and Related Procedures C–APC are clinically similar and that the resource similarity is based on the geometric mean costs derived from claims submitted by hospitals performing these procedures. After consideration of the public comments we received and based on our analysis of the latest hospital outpatient claims data for the procedures described by CPT codes 19340, 19325, and 19342, we are finalizing our proposal, without modification, to continue to assign CPT code 19340 to C–APC 5092. We refer readers to Addendum B of this final rule with comment period for the payment rates for all codes reportable under the OPPS. Addendum B is available via the internet on the CMS website. 10. Intracardiac Ischemia Monitoring (APCs 5221, 5222, 5223, and 5741) Comment: One commenter disagreed with CMS’ proposed APC assignment for the new intracardiac ischemia monitoring Category III CPT code 0525T (Insertion or replacement of intracardiac ischemia monitoring system, including testing of the lead and monitor, initial system programming, and imaging supervision and interpretation; complete system (electrode and implantable monitor)) and requested assignment to APC 5224 (Level 4 Pacemaker and Similar Procedures) instead of APC 5223. The commenter suggested that the procedure described by CPT code 0525T be assigned to APC 5224, which is the same APC that was assigned to its predecessor CPT code 0302T (Insertion or removal and replacement of intracardiac ischemia monitoring system including imaging supervision and interpretation when performed and intra-operative interrogation and programming when performed; complete system (includes device and electrode)) when the code was active during CY 2017. The commenter also stated that the procedure described by CPT code 0525T is more complex and requires significantly more resources than the other procedures assigned to APC 5223. The commenter further indicated that the cost of the Guardian System alone, which is related to the CPT codes of concern, is between $8,000 to $8,700, while the overall cost for the insertion of the complete system is between $15,700 and $16,400. VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 PO 00000 Frm 00098 Fmt 4701 Sfmt 4700 In Addendum B to the CY 2019 OPPS/ASC proposed rule, we proposed to assign eight new intracardiac ischemia monitoring CPT codes to various APCs, which are listed in Table 27 below. The codes were listed as 00X0T through 00X7T (the 5-digit CMS placeholder codes) in Addendum B with short descriptors and in Addendum O with long descriptors to the CY 2019 OPPS/ASC proposed rule. We also assigned these codes to comment indicator ‘‘NP’’ in Addendum B to the proposed rule to indicate that the codes are new for CY 2019, with proposed APC assignments, and that public comments would be accepted on their proposed APC assignments. We note these codes will be effective January 1, 2019. Although the codes are new for CY 2019, the services associated with intracardiac ischemia monitoring were previously described by CPT codes 0302T through 0307T, which were deleted on December 31, 2017. E:\FR\FM\21NOR2.SGM 21NOR2 ER21NO18.043</GPH> khammond on DSK30JT082PROD with RULES2 58914 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations khammond on DSK30JT082PROD with RULES2 Response: For CY 2018, CMS received a New Technology APC application requesting a new HCPCS code for the insertion of an intracardiac ischemia monitoring system because no current CPT code existed to describe the procedure, and because its predecessor CPT code 0302T was deleted on December 31, 2017. Based on our review of the application, evaluation of the procedure, and input from our clinical advisors, we agreed that no existing code appropriately describes the insertion of an intracardiac ischemia monitoring system and, therefore, established HCPCS code C9750 (Insertion or removal and replacement of intracardiac ischemia monitoring system including imaging supervision and interpretation and peri-operative interrogation and programming; complete system (includes device and electrode)), effective October 1, 2018. For the October 2018 OPPS update, we assigned HCPCS code C9750 to APC 5223 (Level 3 Pacemaker and Similar Procedures) with a payment rate of approximately $9,748. We announced this new HCPCS code and APC assignment in the October 2018 OPPS quarterly update CR (Transmittal 4123, Change Request 10923, dated August 24, 2018). Because the procedure described by CPT code 0525T is the same procedure described by HCPCS code C9750, we proposed to assign CPT code 0525T to APC 5223. In addition, we reviewed our claims data for the predecessor CPT code 0302T that were submitted during CY 2012 through CY 2017. We note that predecessor CPT code 0302T became effective July 1, 2012 and was deleted on December 31, 2017. Our analysis of the claims data for CPT code 0302T revealed no single claim submitted for CY 2017, CY 2016, CY 2014, CY 2013, or CY 2012. We did find one claim that was submitted during CY 2015 with a geometric mean cost of approximately $4,619. However, based on cost information submitted to CMS in the New Technology APC application, we believe that APC 5223, whose geometric VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 mean cost is approximately $9,964, is the appropriate APC assignment for the procedure described by CPT code 0525T. We believe that the procedure described by CPT code 0525T shares similar resource and clinical homogeneity to the other procedures currently assigned to APC 5223. Consequently, we did not assign the code to a New Technology APC because the services assigned to APC 5223 are clinically similar to the service described by CPT code 0525T. Therefore, we believe that APC 5223 is the more appropriate APC assignment for the procedure described by CPT code 0525T. Comment: One commenter also disagreed with the proposed assignment of the service described by CPT code 0528T to APC 5741, and requested that the service be assigned to APC 5743 (Level 3 Electronic Analysis of Devices) instead. The commenter stated that the service generally takes about 60 minutes to perform, which is similar to the following services assigned to APC 5743: • CPT code 0462T (Programming device evaluation (in person) with iterative adjustment of the implantable mechano-electrical skin interface and/or external driver to test the function of the device and select optimal permanent programmed values with analysis, including review and report, implantable aortic counterpulsation ventricular assist system, per day); • CPT code 0463T (Interrogation device evaluation (in person) with analysis, review and report, includes connection, recording and disconnection per patient encounter, implantable aortic counterpulsation ventricular assist system, per day); and • CPT code 0472T (Device evaluation, interrogation, and initial programming of intraocular retinal electrode array (e.g., retinal prosthesis), in person, with iterative adjustment of the implantable device to test functionality, select optimal permanent programmed values with analysis, including visual training, PO 00000 Frm 00099 Fmt 4701 Sfmt 4700 58915 with review and report by a qualified health care professional). Response: Based on our review of the predecessor CPT codes for the intracardiac ischemia monitoring systems that were in existence from July 1, 2012 through December 31, 2017, we found that the service described by CPT code 0528T (Programming device evaluation (in person) of intracardiac ischemia monitoring system with iterative adjustment of programmed values, with analysis, review, and report) was previously described by predecessor CPT code 0305T (Programming device evaluation (in person) of intracardiac ischemia monitoring system with iterative adjustment of programmed values, with analysis, review, and report). Similar to predecessor CPT code 0302T, predecessor CPT code 0305T became effective July 1, 2012 and was deleted on December 31, 2017. Our analysis of the claims data for the service described by CPT code 0305T revealed no single claim submitted during CY 2012 through CY 2017. Based on input from our medical advisors and our APC assignment for predecessor CPT code 0305T to APC 5741, we believe that APC 5741 is the appropriate APC assignment for the service described by CPT code 0528T, based on similar programming device evaluation codes assigned to this APC. In summary, after consideration of the public comment we received, we are finalizing our proposal, without modification, to assign the services described by CPT codes 0525T through 0532T to the final APCs listed in Table 28 below. We note that HCPCS code C9750 will be deleted December 31, 2018, because it will be replaced with CPT code 0525T, effective January 1, 2019. The final CY 2019 payment rate for CPT codes 0525T through 0532T can be found in Addendum B to this final rule with comment period (which is available via the internet on the CMS website). BILLING CODE 4120–01–P E:\FR\FM\21NOR2.SGM 21NOR2 58916 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations TABLE 28.-FINAL CY 2019 OPPS APCs AND STATUS INDICATORS (SI) FOR THE INTRACARDIAC ISCHEMIA MONITORING CPT CODES 0525T Insertion or replacement of intracardiac ischemia monitoring system, including testing of the lead and monitor, initial system programming, and imaging supervision and interpretation; complete system (electrode and implantable monitor) J1 5223 0526T Insertion or replacement of intracardiac ischemia monitoring system, including testing of the lead and monitor, initial system programming, and imaging supervision and interpretation; electrode only J1 5222 0527T Insertion or replacement of intracardiac ischemia monitoring system, including testing of the lead and monitor, initial system programming, and imaging supervision and interpretation; implantable monitor only J1 5222 0528T Programming device evaluation (in person) of intracardiac ischemia monitoring system with iterative adjustment of programmed values, with analysis, review, and report Q1 5741 0529T Interrogation device evaluation (in person) of intracardiac ischemia monitoring system with analysis, review, and report Q1 5741 0530T Removal of intracardiac ischemia monitoring system, including all imaging supervision and interpretation; complete system (electrode and implantable monitor) Q2 5221 0531T Removal of intracardiac ischemia monitoring system, including all imaging supervision and interpretation; electrode only Q2 5221 0532T Removal of intracardiac ischemia monitoring system, including all imaging supervision and interpretation; implantable monitor only Q2 5221 11. Intraocular Retinal Electrode Programming and Reprogramming (APCs 5742 and 5743) As noted in Table 29 below, for CY 2019, we proposed to continue to assign the procedure described by CPT code VerDate Sep<11>2014 Final CY Final CY 2019 SI 2019 APC Long Descriptor 20:42 Nov 20, 2018 Jkt 247001 0472T to APC 5743 (Level 3 Electronic Analysis of Devices), with a proposed payment rate of approximately $280. We also proposed to continue to assign the procedure described by CPT code 0473T to APC 5742 (Level 2 Electronic PO 00000 Frm 00100 Fmt 4701 Sfmt 4700 Analysis of Devices), with a proposed payment rate of approximately $115. Comment: One commenter supported CMS’ proposal to continue to assign the programming services for Argus II, which are described by CPT codes E:\FR\FM\21NOR2.SGM 21NOR2 ER21NO18.044</GPH> khammond on DSK30JT082PROD with RULES2 CY 2019 CPT Code 58917 0472T and 0473T, to APCs 5743 and 5742. Response: We appreciate the commenter’s support. Based on input from our medical advisors, we believe that CPT codes 0472T and 0473T are appropriately assigned to APCs 5743 and 5742, respectively, based on clinical and resource homogeneity to the other services assigned to these APCs. Therefore, after consideration of the public comment received, we are finalizing our proposal, without modification, to continue to assign the procedures described by CPT codes 0472T and 0473T to APCs 5743 and APC 5742, respectively, for CY 2019. The final APC and status indicator assignments are listed in Table 29 below. The final payment rates for these codes, where applicable, can be found in Addendum B to this final rule with comment period (which is available via the internet on the CMS website). BILLING CODE 4120–01–C public comments would be accepted on the proposed APC assignment. We note that this code will be effective January 1, 2019. Comment: One commenter disagreed with the proposed assignment of CPT code 50436 to C–APC 5373 and instead recommended assignment to C–APC 5374 (Level 3 Urology and Related Services), with a proposed payment rate of approximately $2,755, because of the higher resource costs associated with the procedure. Response: Because CPT code 50436 is a new code for CY 2019, we do not have claims data on which to base a payment rate. However, in the absence of claims data, we reviewed the clinical characteristics of the procedure to determine whether the surgical procedure is similar to existing procedures. After review of the procedure and input from our clinical advisors, we believe that the procedure described by new CPT code 50436 is clinically similar to those procedures assigned to C–APC 5373. We will reevaluate the APC assignment for the procedure described by CPT code 50436 once claims data for this procedure become available. We note that as we do every year, we review the APC assignments for all services and items paid under the OPPS. After consideration of the public comment we received, we are finalizing our proposal to assign the procedure described by CPT code 50436 to C–APC 5373. We refer readers to Addendum B of this final rule with comment period for the payment rates for all codes reportable under the OPPS. Addendum B is available via the internet on the CMS website. 12. Kidney Dilation of Tract (C–APC 5373) In Addendum B to the CY 2019 OPPS/ASC proposed rule, we proposed to assign the procedure described by CPT code 50436 (Dilation of existing tract, percutaneous, for an endourologic procedure including imaging guidance (e.g., ultrasound and/or fluoroscopy) and all associated radiological supervision and interpretation, with postprocedure tube placement, when performed) to C–APC 5373 (Level 3 Urology and Related Services), with a proposed payment rate of approximately $1,731. This code was listed as 50X39 (the 5-digit CMS placeholder code) in Addendum B, with the short descriptor, and in Addendum O, with the long descriptor, to the CY 2019 OPPS/ASC proposed rule. We also proposed to assign this code to comment indicator ‘‘NP’’ in Addendum B to indicate that the code is new for CY 2019 with a proposed APC assignment and that VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 PO 00000 Frm 00101 Fmt 4701 Sfmt 4700 13. Intraocular Procedures (APC 5494) In prior years, the procedure described by CPT code 0308T (Insertion of ocular telescope prosthesis including removal of crystalline lens or intraocular lens prosthesis) has been assigned to the APC 5495 (Level 5 E:\FR\FM\21NOR2.SGM 21NOR2 ER21NO18.045</GPH> khammond on DSK30JT082PROD with RULES2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations khammond on DSK30JT082PROD with RULES2 58918 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations Intraocular Procedures) based on its estimated costs. In addition, its relative payment weight has been based on its median under our payment policy for low-volume device-intensive procedures established in the CY 2016 OPPS because the APC contained a low volume of claims. The low-volume device-intensive procedures policy is discussed in more detail in section III.C.2. of the proposed rule and this final rule with comment period. In reviewing the claims data available for the proposed rule for CY 2019 OPPS ratesetting, we found that there were only two claims containing procedures described by CPT code 0308T, with a geometric mean of $5,438.99 and a median of $8,237.56. Based on those two claims, APC 5495 would have had a proposed geometric mean of $5,438.99 and a proposed median of $8,237.56. However, based on its estimated costs in the most recently available claims data, we stated in the proposed rule that we believe that the procedure described by CPT code 0308T is more appropriately placed in the APC 5493, which has a geometric mean cost of $9,821.47, which is more comparable to that of the procedure described by CPT code 0308T. Therefore, for CY 2019, we proposed to reassign the procedure described by CPT code 0308T from APC 5495 to APC 5493 (Level 3 Intraocular Procedures) and to delete APC 5495. We stated that we would continue to monitor the volume of claims reporting a procedure described by CPT code 0308T available to us for future ratesetting. Comment: One commenter requested that the procedure described by CPT code 0308T be assigned to a New Technology APC based on the proposed low-volume New Technology policy, without requesting a specific New Technology APC or cost band. The commenter believed that the reasons for developing the low volume New Technology policy are consistent with issues related to the procedure described by CPT code 0308T, including the quality and volume of claims data, and resulting cost fluctuation. The commenter noted that because those issues facing low-volume procedures would be the same, regardless of whether the procedures are assigned to a New Technology or clinical APC, it would be appropriate to assign the procedure described by CPT code 0308T to a New Technology APC. However, the commenter requested that, if that change were not to be made, CMS instead assign the procedure described by the CPT code to APC 5495, which was previously for ‘‘Level 5 Intraocular Procedures’’ and that the same VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 smoothing methodology for low volume New Technology procedures, which includes use of multiple years of claims data, apply to the procedure described by CPT code 0308T, given its low volume. Response: In previous years, the procedure described by CPT code 0308T was assigned to APC 5495 (Level 5 Intraocular Procedures) using a medianbased weight under the low-volume device intensive policy. Based on the CY 2017 claims data available for ratesetting, in the CY 2019 OPPS/ASC proposed rule, we proposed to assign the procedure described by CPT code 0308T to APC 5493, noting that we would continue to monitor the data. In the CY 2019 OPPS final rule claims data, the estimated cost of the single claim with CPT code 0308T as the primary service is approximately $12,939.75. While we appreciate the stakeholder’s comments regarding changes in estimated costs based on the claims data available for ratesetting, we have concerns with establishing a New Technology APC methodology for a clinical APC especially in the absence of a New Technology application, which is used to evaluate new technology APC requests. We also note that the procedure described by CPT code 0308T has historically been assigned to a clinical APC beginning with the CY 2013 OPPS. Recognizing the estimated cost based on the final rule claims data and the commenter’s concerns, we believe that the procedure described by CPT code 0308T is appropriate for assignment to clinical APC 5494 (Level 4 Intraocular Procedures). CPT code 0308T has device-intensive status based on its device offset percentage and the fact that the APC to which the procedure is assigned has fewer than 100 total claims. Therefore, the low-volume device intensive policy of using the median cost for OPPS ratesetting would apply. After consideration of the public comment we received, we are modifying our proposal to assign the procedure described by CPT code 0308T to APC 5493 and instead are assigning the procedure described by CPT code 0308T to APC 5494 (Level 4 Intraocular Procedures) for CY 2019. 14. Magnetocardiography As displayed in Table 30 below and in Addendum B to the CY 2019 OPPS/ ASC proposed rule, we proposed to assign the services described by CPT codes 0541T and 0542T to status indicator ‘‘E1’’ to indicate that these codes are not payable by Medicare when PO 00000 Frm 00102 Fmt 4701 Sfmt 4700 submitted on outpatient claims (any outpatient bill type) because the services associated with these codes are either not covered by any Medicare outpatient benefit category, statutorily excluded by Medicare, or not reasonable and necessary. The codes were listed as 0X01T and 0X02T (the 5-digit CMS placeholder codes), respectively, in Addendum B, with the short descriptors, and in Addendum O, with the long descriptors, to the CY 2019 OPPS/ASC proposed rule. We also assigned these codes to comment indicator ‘‘NP’’ in Addendum B to indicate that the codes are new for CY 2019 and that public comments would be accepted on their proposed status indicator assignments. We note that these codes will be effective January 1, 2019. Comment: One commenter disagreed with the proposed status indicator assignment of ‘‘E1’’ for CPT codes 0541T and 0542T, and stated that the technology was approved by the FDA. The commenter explained that these codes describe magnetocardiography (MCG), which is a ‘‘high-fidelity biomagnetic imaging technique that utilizes highly sensitive magnetometers and a compact shield in order to measure, image and analyze the repolarization patterns of the heart.’’ The commenter also indicated that MCG may be used to replace or avoid the need for additional cardiac stress and related testing, myocardial perfusion imaging, and/or PET procedures, and rapidly triage patients who present to the ED with chest pain or other symptoms of cardiac ischemia. Because the technology has been approved by the FDA, the commenter requested that CMS assign the procedures described by both CPT codes to APC 5593 (Level 3 Nuclear Medicine) or APC 5724 (Level 4 Diagnostic Tests and Related Services). Although the commenter requested an assignment to either APC 5593 or 5724, the commenter also noted that the services described by CPT codes 0541T and 0542T are clinically comparable to the services that are assigned to the following three APCs: • APC 5593 (Level 3 Nuclear Medicine), with a proposed payment rate of approximately $1,228, which includes— Æ CPT code 78451 (Myocardial perfusion imaging); and Æ CPT code 78452 (Myocardial perfusion imaging) • APC 5594 (Level 4 Nuclear Medicine), with a proposed payment rate of approximately $1,386, which includes— E:\FR\FM\21NOR2.SGM 21NOR2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations khammond on DSK30JT082PROD with RULES2 Æ CPT code 78491 (Positron Emission Tomography (PET) myocardial functional imaging); and Æ CPT code 78492 (Positron Emission Tomography (PET) myocardial functional imaging) • APC 5724 (Level 4 Diagnostic Tests and Related Services), with a proposed payment rate of approximately $918, which includes— Æ CPT code 95965 (Magnetoencephalography (MEG)); and Æ CPT code 95966 (Magnetoencephalography (MEG)) In addition to the requested APC assignment, the commenter requested that CMS assign the codes status indicator ‘‘S’’ (Procedure or Service, Not Discounted When Multiple. Paid under OPPS; separate APC payment), instead of status indicator ‘‘E1’’, similar to the status indicator assignment for the comparable codes in APCs 5593, 5594, and 5724. Response: Based on our understanding of the procedure, we VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 found that the service associated with these codes are currently in clinical trial (Study Title: ‘‘Magnetocardiography Using a Novel Analysis System (Cardioflux) in the Evaluation of Emergency Department Observation Unit Chest Pain Patients’’; ClinicalTrials.gov Identifier: NCT03255772). Further review of the clinical trial revealed that the clinical study has not yet met CMS’ standards for coverage, nor does it appear on the CMS Approved IDE List, which can be found at this CMS website: https:// www.cms.gov/Medicare/Coverage/IDE/ Approved-IDE-Studies.html. Moreover, based on our review associated with the technology, we have not found evidence of FDA approval or clearance of the Cardioflux System as it appears that an application is pending with FDA, even though predicate devices have already been approved and are on the market. Because this specific MCG technology has not been approved for Medicare coverage or cleared by the FDA, we PO 00000 Frm 00103 Fmt 4701 Sfmt 4700 58919 believe that we should continue to assign the procedures described by CPT codes 0541T and 0542T to status indicator ‘‘E1’’ for CY 2019. If this technology later meets CMS’ standards for coverage, we will reassess the APC assignment for the codes in a future quarterly update and/or rulemaking cycle. Therefore, after consideration of the public comment received, we are finalizing our proposal, without modification, for the assignment of status indicator ‘‘E1’’ to the procedures described by CPT codes 0541T and 0542T. The final status indicator assignment for both codes is listed in Table 30 below. We refer readers to Addendum D1 of this final rule with comment period for the complete list of the OPPS payment status indicators and their definitions for CY 2019. Addendum D1 is available via the internet on the CMS website. BILLING CODE 4120–01–P E:\FR\FM\21NOR2.SGM 21NOR2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations BILLING CODE 4120–01–C khammond on DSK30JT082PROD with RULES2 15. Musculoskeletal Procedures (APCs 5111 Through 5116) Prior to the CY 2016 OPPS, payment for musculoskeletal procedures was primarily divided according to anatomy and the type of musculoskeletal procedure. As part of the CY 2016 reorganization to better structure the OPPS payments towards prospective payment packages, we consolidated those individual APCs so that they became a general Musculoskeletal VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 Procedures APC series (80 FR 70397 through 70398). In the CY 2018 OPPS/ASC final rule with comment period (82 FR 59300), we continued to apply a six-level structure for the Musculoskeletal APCs because doing so provided an appropriate distinction for resource costs at each level and to provide clinical homogeneity. However, we also indicated that we would continue to review the structure of these APCs to determine whether additional granularity would be necessary. PO 00000 Frm 00104 Fmt 4701 Sfmt 4700 While we did not propose any changes to the 2019 OPPS structure of the Musculoskeletal Procedures APC series in the CY 2019 OPPS/ASC proposed rule, we stated that we recognize that commenters have previously expressed concerns regarding the granularity of the current APC levels and requested establishment of additional APC levels. Therefore, we solicited public comments on the creation of a new APC level between the current Level 5 and Level 6 within the Musculoskeletal Procedures APC series. E:\FR\FM\21NOR2.SGM 21NOR2 ER21NO18.046</GPH> 58920 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 reported certain device costs, rather than using all claims to calculate the geometric mean costs of the service. Response: We appreciate the commenters’ support for maintaining the current APC structure. While we have previously stated that we believe that the six level APC structure for the Musculoskeletal Procedures APC series remains appropriate in providing distinction between resource costs at each level and clinical homogeneity (82 FR 59300), in the CY 2019 proposed rule, we solicited comment on whether additional levels might be appropriate based on stakeholder concerns (83 FR 37096). Based on that stakeholder input, we will maintain the existing six level Musculoskeletal Procedures APC structure for the CY 2019 OPPS. While we are not creating additional APC levels in this final rule with comment period, we reviewed the APC assignment of individual HCPCS codes that commenters requested be reassigned if additional APC levels were created to confirm whether their current assignment was appropriate. We believe that the APC assignment of CPT code 27279 (Arthrodesis sacroiliac joint) to APC 5116, and CPT codes 28740 (Fusion of foot bones) and 28297 (Correction hallux valgus) to APC 5114 remain appropriate based on their geometric mean costs. With regards to the placement of the total knee arthroplasty procedure in APC 5115 (Level 5 Musculoskeletal Procedures), we continue to believe that C–APC 5115 is an appropriate APC assignment for the procedures described by CPT code 27447, which has an estimated geometric mean cost of $9,997.45. Further, we note that the 50th percentile IPPS payment for total knee arthroplasty procedures without major complications or comorbidities PO 00000 Frm 00105 Fmt 4701 Sfmt 4725 (MS–DRG 470) is approximately $11,550 for FY 2019. We note that the final CY 2019 payment for New Technology APC 1575 is $12,500.50. As previously stated in the CY 2018 OPPS/ ASC final rule with comment period (82 FR 58394 through 59385), we would expect that beneficiaries selected for outpatient total knee arthroplasty procedures would generally be expected to be less complex than those treated as hospital inpatients. Therefore, we do not believe that it would be appropriate for the OPPS payment rate to exceed the IPPS payment rate for total knee arthroplasty procedures without major complications/comorbidities because IPPS cases would generally be expected to be more complicated and complex than those performed in the hospital outpatient setting. We note that we rely on hospitals to bill all HCPCS codes accurately in accordance with their code descriptors and CPT and CMS instructions, as applicable, and to report charges on claims and charges and costs on their Medicare hospital cost reports appropriately (77 FR 68324). As we do every year, we will review and evaluate the APC groupings based on the latest available data in the next rulemaking cycle. After consideration of the public comments we received, we are finalizing the six level Musculoskeletal Procedures APC structure. We also are finalizing the proposed assignments of the procedures described by CPT codes 27279 (Arthrodesis sacroiliac joint) to APC 5116, the procedures described by CPT codes 28740 (Fusion of foot bones) and 28297 (Correction hallux valgus) to APC 5114, and the procedures described by CPT code 27447 (Total knee arthroplasty) to APC 5115. E:\FR\FM\21NOR2.SGM 21NOR2 ER21NO18.047</GPH> khammond on DSK30JT082PROD with RULES2 Table 18 of the proposed rule listed the Musculoskeletal Procedures APCs, the HCPCS codes assigned to the APCs, and the proposed APC geometric mean cost. Comment: Many commenters requested that CMS maintain the current six-level APC structure. Some of these commenters stated that the current structure provides sufficient granularity in the APCs, while other commenters suggested that, because Medicare previously made changes to create additional APCs in the Musculoskeletal Procedures APC series in the CY 2016 and CY 2017 OPPS, CMS delay any additional changes. Some commenters requested that CMS create additional levels and assign specific codes to either the new levels or existing levels within the relative structure. One commenter requested CMS maintain the procedure described by CPT code 27279 (Arthrodesis sacroiliac joint) at the highest level APC based on its geometric mean cost, if any additional high cost APC level above the current Level 6 were created. Another commenter requested that CMS create additional intermediate levels between the existing APC Levels 4 and 5 and between Levels 5 and 6, and assign the procedures described by CPT code 28740 (Fusion of foot bones) and CPT code 28297 (Correction hallux valgus) to the new APC level between Levels 4 and 5. One commenter requested that, if a level were to be created between the current Levels 5 and 6, the procedure described by CPT code 27447 (Total knee arthroplasty) be assigned to that APC level. Other commenters requested that total knee arthroplasty be assigned to APC 1575 (New Technology—Level 38 ($10,001–$15,000)) for CY 2019, which has a payment rate at $12,500 based on their analysis of the costs of the procedure for only those claims that 58921 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations 16. Nasal Airway Obstruction Treatment (APC 5164) khammond on DSK30JT082PROD with RULES2 For CY 2019, we proposed to continue to assign the procedures described by HCPCS code C9749 (Repair of nasal vestibular lateral wall stenosis with implant(s)) to APC 5164 (Level 4 ENT Procedures) with a proposed payment rate of approximately $2,241. We note that HCPCS code C9749 describes the Latera absorbable implant procedure for nasal airway obstruction. Comment: One commenter disagreed with the proposed APC assignment of the procedure described by HCPCS code C9749 to APC 5164 and requested that CMS assign the procedure to New Technology APC 1523 (New Technology—Level 23 ($2,501–$3,000)), which had a proposed payment rate of approximately $2,751. The commenter stated that the cost for a pair of the Latera implants is $1,325, and that the proposed payment rate for APC 5164 does not cover the cost of performing the procedure. The commenter further stated that information from clinical experts and medical directors suggests that the complexity and resources to perform the Latera implant procedure Comment: One commenter requested that CMS create a new modifier to identify the performance of continuous nerve block procedures that are performed as a secondary procedure, and to allow payment for the performance of such procedures, for example, the procedure described by CPT code 64416 (Injection, anesthetic agent; brachial plexus, continuous infusion by catheter (including catheter placement)), not to be packaged if reported in combination with the procedure described by CPT code 29827 (Arthroscopy, shoulder, surgical; with rotator cuff repair). Instead, the commenter suggested a modifier to VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 are similar to those associated with procedures assigned to APC 5165 (Level 5 ENT Procedures). Response: In December 2017, CMS received a New Technology APC application requesting a new HCPCS code for the Latera implant because, according to the applicant, the only available CPT code to report the procedure is CPT code 30999 (Unlisted procedure, nose). Based on our review of the application, assessment of the procedure, and input from our clinical advisors, we established HCPCS code C9749 effective April 1, 2018. For the April 2018 OPPS Update, we assigned HCPCS code C9749 to APC 5164 with a payment rate of approximately $2,199. We announced this new HCPCS code and APC assignment in the April 2018 OPPS quarterly update change request (Transmittal 4005, Change Request 10515, dated March 20, 2018). Based on cost information submitted to CMS in the New Technology APC application, we assigned the procedure to APC 5164 rather than New Technology APC 1523. However, based on further assessment on the nature of the procedure, and input from public commenters and our clinical advisors, we believe that HCPCS code C9749 should be reassigned to APC 5165 (Level 5 ENT Procedures) to more appropriately reflect the resource costs and clinical characteristics associated with the Latera implant procedure. allow for payment at a full OPPS rate. The commenter noted that continuous nerve block procedure codes are assigned to status indicator ‘‘T,’’ which further provides that payment for the procedures are currently packaged when reported in combination with procedures that are assigned to C–APCs and, therefore, are not separately paid. The commenter stated that packaging payment for the certain procedures discourages hospitals from using nonopioid postsurgical pain alternative approaches, such as a continuous nerve block procedure. The commenter further believed that CMS should create a new HCPCS code modifier in order to track, research, and identify the use of non-opioid pain management alternatives that are resulting in positive beneficiary health care impacts and outcomes, which are reducing opioid use and combatting the opioid crisis. Additionally, the commenter included a list of applicable continuous nerve block procedure codes (shown in the table below) to which the commenter suggested that a HCPCS modifier could be appended to indicate that the procedure would receive separate payment. PO 00000 Frm 00106 Fmt 4701 Sfmt 4700 Therefore, after consideration of the public comment we received, we are finalizing our proposal, without modification, to assign the procedure described by HCPCS code C9749 from APC 5164 to APC 5165. The final payment rate for HCPCS code C9749 can be found in Addendum B to this final rule with comment period (which is available via the internet on the CMS website). 17. Nerve Procedures and Services (APCs 5431 Through 5432) For CY 2019, we proposed to continue the existing two-level structure of the Nerve Procedures APCs (APC 5431 through 5432), as displayed in Table 32 below and in Addendum A to the CY 2019 OPPS/ASC proposed rule (which is available via the internet on the CMS website). E:\FR\FM\21NOR2.SGM 21NOR2 ER21NO18.048</GPH> 58922 Response: We appreciate the commenter’s suggestion to create a new HCPCS modifier to identify the continuous nerve block procedures when performed as a secondary procedure, as well as recommending the list of CPT codes that should be considered for such inclusion for separate payment. However, payment for these continuous nerve block procedures is currently packaged under the OPPS because they are adjunctive to the primary service rendered and, therefore, represent components of a complete service. Therefore, at this time we will continue to package payment for these services, and consider the creation of a new HCPCS modifier and separate payment for such non-opioid alternatives approaches in future rulemaking. Comment: One commenter suggested that CMS restructure the two-level Nerve Procedure APCs (APCs 5431 and 5432) to provide more payment granularity for the types of procedures included in the APCs by creating a third level. The commenter believed that there is a substantial payment differential between the procedures assigned to Level 1 Nerve Procedures APC 5431 and Level 2 Nerve Procedures APC 5432, and that the current payment for some of these procedures does not adequately cover the cost of providing the services. The commenter further stated that, as an example, the procedures described by CPT codes 64633 (Destruction by neurolytic agent, paravertebral facet joint nerve(s), with imaging guidance (fluoroscopy or CT); cervical or thoracic, single facet joint) and 64635 (destruction by neurolytic agent paravertebral facet joint nerve(s), with imaging guidance (fluoroscopy or CT); lumbar or sacral, single facet joint), which are assigned to APC 5431 with a proposed payment rate of approximately $1,644, while the geometric means for each of the procedures described by CPT codes 64633 and 64635 are $1,482 and $1,729, respectively. The commenter recommended a potential geometric mean cost for a potential three-level APC structure within the Nerve Procedures APCs and submitted a three-level APC structure, along with estimated payment rates, which is shown in the table below. The commenter also recommended that CMS develop two new HCPCS G-codes to describe the performance of radiofrequency nerve ablation procedures. The commenter suggested that one of the G-codes could be created to describe procedures involving the genicular nerve, and the other G-code could be created to describe procedures VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 PO 00000 Frm 00107 Fmt 4701 Sfmt 4700 E:\FR\FM\21NOR2.SGM 21NOR2 ER21NO18.050</GPH> 58923 ER21NO18.049</GPH> khammond on DSK30JT082PROD with RULES2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations khammond on DSK30JT082PROD with RULES2 58924 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations involving the sacroiliac joint. The commenter further recommended that both of these G-codes be created to describe procedures describing nonopioid treatment alternatives for chronic pain management, and to assign both of these newly created G-codes to Level 2 Nerve Procedures APC 5232 based on its recommended three-level APC structure, with an estimated payment rate of $2,431. The commenter was aware that Category I CPT codes are in development, but will not be ready for release until CY 2020 at the earliest. Therefore, the commenter requested that CMS create such G-codes in order to allow for physicians and hospitals to report the performance of the procedures and use of the approach, and to be paid for utilization of these procedures in the interim. The commenter supplied a suggested descriptor for the G-code for the genicular nerve as: Radiofrequency nerve ablation; genicular nerves, including imaging guidance, when performed. The commenter also supplied a suggested descriptor for the G-code for the sacroiliac joint as: Radiofrequency never ablation; sacroiliac joint, including imaging guidance, when performed. Response: We appreciate the commenter’s suggestions. However, at this time, we believe that the current two-level structure Nerve Procedures APCs provide an appropriate distinction between the resource costs at each level and clinical homogeneity. We will continue to review the APCs’ structure to determine if additional granularity is necessary for this APC family in future rulemaking. In addition, we believe that more analysis of such groupings is necessary before adopting such change. With regard to the request to establish new HCPCS G-codes, although new CPT codes are in development for release for the CY 2020 update, we note that it does not appear that a request for new temporary Category III codes was made for CY 2019. Nonetheless, we intend to take the commenter’s request for new HCPCS G-codes under advisement. Therefore, after consideration of the public comment received, we are finalizing our CY 2019 Nerve Procedures APCs two-level structure, as proposed. We refer readers to Addendum A to this final rule with comment period for the complete list of APCs and their payment rates. In addition, we refer readers to Addendum B to this final rule with comment period for the payment rates for all codes reported under the OPPS. Both Addendum A and Addendum B are available via the internet on the CMS website. VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 18. Radiology and Procedures and Services a. Imaging Procedures and Services (APCs 5521 Through 5524 and 5571 Through 5573) Section 1833(t)(2)(G) of the Act requires the Secretary to create additional groups of covered OPD services that classify separately those procedures that utilize contrast agents from those procedures that do not utilize contrast agents. In CY 2016, as a part of our comprehensive review of the structure of the APCs and procedure code assignments, we restructured the APCs that contain imaging services (80 FR 70392). The purpose of this restructuring was to more appropriately reflect the resource costs and clinical characteristics of the services classified within the Imaging APCs. The restructuring of the Imaging APCs resulted in broader groupings that removed the excessive granularity of grouping imaging services according to organ or physiologic system, which did not necessarily reflect either significant differences in resources or how these services are delivered in the hospital outpatient setting. In CY 2017, in response to public comments on the CY 2017 OPPS/ASC proposed rule, we further consolidated the Imaging APCs from 17 APCs in CY 2016 to 7 APCs in CY 2017 (81 FR 79633). These included four Imaging without Contrast APCs and three Imaging with Contrast APCs. For CY 2018, we proposed to establish a new Level 5 Imaging without Contrast APC to more appropriately group certain imaging services with higher resource costs and stated that our latest claims data supported splitting the CY 2017 Level 4 Imaging without Contrast APC into two APCs such that the Level 4 Imaging without Contrast APC would include high frequency, low-cost services and the proposed Level 5 Imaging without Contrast APC would include low frequency, high-cost services. Therefore, for CY 2018, we proposed to add a fifth level within the Imaging without Contrast APCs (82 FR 33608). However, based on public comments, we did not finalize this proposal. In general, commenters disagreed with CMS’ proposal to add a fifth level within the Imaging without Contrast APC series because they believed that the addition of a fifth level would reduce payment for several imaging services, including vascular ultrasound procedures (82 FR 59309 through 59311). Commenters also noted that the lower payment rates under the OPPS would also apply under the PFS. For the CY 2019 OPPS/ASC proposed rule (83 FR 37096 through 37097), we PO 00000 Frm 00108 Fmt 4701 Sfmt 4700 reviewed the services assigned to the seven imaging APCs listed in Table 17 of the proposed rule. Specifically, we evaluated the resource costs and clinical coherence of the procedures associated with the four levels of Imaging without Contrast APCs and the three levels of Imaging with Contrast APCs, as well as identified for correction any 2 times rule violations, to the extent feasible. Based on the geometric mean cost for each APC, which was listed in Table 17 of the proposed rule, for CY 2019, we proposed to maintain the seven Imaging APCs, which consist of four levels of Imaging without Contrast APCs and three levels of Imaging with Contrast APCs, and to make minor reassignments to the HCPCS codes within this series to resolve or mitigate any violations of the 2 times rule, or both. We invited public comments on our proposal. Moreover, we specifically expressed an interest in receiving public comments and recommendations on the proposed HCPCS code reassignments associated with each of the seven Imaging APCs. We referred readers to Addendum B to the proposed rule (which is available via the internet on the CMS website) for the proposed list of specific codes that would be reassigned to each Imaging APC. Comment: Commenters generally agreed with CMS’ proposal to maintain the Imaging APCs: Four levels of Imaging without Contrast APCs and three levels of Imaging with Contrast APCs. The commenters stated that maintaining the current Imaging APC structure would provide more stability for these services and would allow for cost trends to be assessed over time. Several of these commenters believed that the cost data for the procedures within these APCs have been consistent for many years and cautioned CMS against changing payment for services assigned to these APCs. Commenters recommended that if CMS believes any revision to the current APCs is necessary, the revisions be considered for future rulemaking and be subject to review and comment from stakeholders, in order to continue to maintain stability and sufficient payment and in order for hospitals to be able to continue to provide these services. Response: We appreciate the commenters’ support for maintaining the seven Imaging APCs consisting of four levels of Imaging without Contrast APCs and three levels of Imaging with Contrast APCs. Comment: One commenter supported CMS’ proposal to maintain the Level 3 Imaging with Contrast APC (APC 5573) as proposed for CY 2019. The commenter further stated that the E:\FR\FM\21NOR2.SGM 21NOR2 khammond on DSK30JT082PROD with RULES2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations proposed payment rate for services in this APC appropriately reflects use of contrast agents and that a lower payment rate may lead to lower utilization of medically necessary contrast agents and may lead to use of more costly advanced imaging modalities such as cardiac MRI and nuclear perfusion studies, which will increase overall cost. Response: As noted in the CY 2019 OPPS/ASC proposed rule (83 FR 37096 through 37097), we reviewed the resource costs and clinical coherence of the procedures associated with the four levels of Imaging without Contrast APCs and the three levels of Imaging with Contrast APCs, as well as reviewed any 2 times rule violations. Based on this review, we decided to maintain the seven Imaging APCs structure based on the clinical similarities and resource costs and in light of commenters’ support of this proposal. Comment: One commenter noted the lack of payment stability for the procedure described by CPT code 93307 (Echocardiography, transthoracic, realtime with image documentation (2d), includes M-mode recording, when performed, complete, without spectral or color Doppler echocardiography). The commenter noted that CMS proposed to reassign the procedure described by CPT code 93307 to APC 5523, and that, in CY 2018, this code was assigned to APC 5524. The commenter stated that the reassignment of CPT code 93307 to APC 5523 is inappropriate because it is not similar to the other procedures in that APC in regard to either clinical or resource use, and would result in a 52-percent decrease in payment for CY 2019 compared to the CY 2018 payment rate. Response: We acknowledge the commenter’s concern. However, we believe that the assignment of the procedure described by CPT code 93307 to APC 5523 is more appropriate based on clinical similarities and resource use. Specifically, we note that, based on the data available for this final rule with comment period, the lowest significant procedure geometric mean cost within APC 5523 is HCPCS code 76000 (Fluoroscopy (separate procedure), up to 1 hour physician or other qualified health care professional time), with a geometric mean of $174.34, and the highest significant procedure cost within APC 5523 is HCPCS code 74455 (Urethrocystography, voiding, radiological supervision and interpretation), with a geometric mean cost of $358.11. The geometric mean cost of CPT 93307 is $352.15, which is similar to that of other procedures assigned to APC 5523. VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 Furthermore, the highest significant cost for a procedure within APC 5524 is for the procedure described by HCPCS 93312 (Echocardiography, transesophageal, real-time with image documentation (2d) (with or without mmode recording); including probe placement, image acquisition, interpretation and report), which has a geometric mean cost of $854.45. This proposed reassignment would have a greater impact on the 2 times violation by being over the violation limit by approximately $138, compared to the assignment of the CPT code to APC 5523, which also has a 2 times violation, but to a lesser extent (that is, approximately $31). Therefore, based on this information, we are finalizing the proposed structure of APC 5523, with assignment of the CPT codes as proposed in the CY 2019 OPPS/ASC proposed rule. We will continue to monitor clinical homogeneity and resource costs within these APCs to identify any payment changes that may be warranted in future rulemaking. Comment: One commenter disagreed with the proposal to maintain the procedure described by HCPCS code G0297 (Low dose CT for lung cancer screening) in APC 5521 and believed the calculation of the geometric mean using the CT cost center does not sufficiently estimate costs, although CMS has 61,505 single claims to calculate the geometric mean cost for the procedure described by HCPCS code G0297. Based on its analysis, the commenter believed that using the diagnostic radiology cost center, which would result in estimated costs of $96.55 for the service, is more appropriate than the geometric mean cost of using the CT cost center, which is $37.96. The commenter believed that use of the CT cost centers is depressing payment for imaging services and believed all imaging studies should use the diagnostic radiology cost centers instead. Response: We believe that the procedure described by HCPCS code G0297 is appropriately assigned to APC 5521, based on its estimated cost relative to that of the other procedures in the APC. We believe that the manner in which we establish the geometric mean for estimating service costs for the Imaging APCs is appropriate. As part of changes to establish more accurate cost reporting, we developed the CT, MRI, and Cardiac Catherization cost centers in the CMS 2552–10 form. Since the CY 2014 OPPS, in which we first included those cost centers for ratesetting, we have included a methodology that removes cost data from providers reporting the standard CT and MRI cost centers using ‘‘square feet’’ as the cost PO 00000 Frm 00109 Fmt 4701 Sfmt 4700 58925 allocation statistic. We continue to believe this is appropriate as discussed in section II.A.1.b. of this final rule with comment period. However, we will continue to monitor payment for these imaging services and will consider the most appropriate methodology for ratesetting for such services in future rulemaking. Additionally, we refer readers to the Medicare CY 2019 OPPS Final Rule Claims Accounting narrative for additional details regarding the calculation of the geometric mean costs. Comment: One commenter expressed concern regarding payment stability for cardiac magnetic imaging with contrast services, specifically cardiac magnetic resonance imaging (MRI) for morphology with dye (the procedure described by CPT code 75561 within APC 5572). The commenter was concerned that the proposed payment for this service is set to decline by 15 percent from the CY 2018 payment rate and believed that this would threaten hospitals’ ability to maintain equipment, supplies, and agents used for these services. The commenter requested that CMS continue to monitor payment for cardiac MR services, specifically the procedure described by CPT code 75561. The commenter suggested that CMS study how best to assign low volume procedures to an APC. Response: Our analysis of the final rule updated claims data revealed a geometric mean cost of approximately $416.84 for CPT code 75561 based on 8,248 single claims out of 15,022 total claims. The geometric mean cost for APC 5572 is approximately $390. After reviewing the procedures assigned to APC 5572, we believe that the geometric mean cost for the procedure described by CPT code 75561 indicates that it is appropriately assigned to APC 5572 based on its clinical homogeneity and resource costs. As we do each year, we will continue to review the APC assignments for all services and items paid under the OPPS. Comment: One commenter expressed concern regarding the payment amount for the procedure described by CPT code 75574 (Computed tomographic angiography, heart, coronary arteries and bypass grafts (when present), with contrast material, including 3d image postprocessing (including evaluation of cardiac structure and morphology, assessment of cardiac function, and evaluation of venous structures, if performed)) within APC 5571. Specifically, the commenter noted a 20percent reduction from CY 2018 to CY 2019 within this APC. The commenter stated that the procedure described by E:\FR\FM\21NOR2.SGM 21NOR2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations CPT code 75574 should be considered a low-volume service compared to other services within the APC and that highvolume codes within this APC are diluting the effect of the procedure described by CPT code 75574 on the APC payment rate. As a result, the commenter requested that CMS study how the APC structure could be modified to define low volume services and foster payment adequacy for lowvolume codes such as CPT code 75574. Response: We acknowledge the commenter’s concerns regarding payment for CPT code 75574. At this point, we do not believe we have the necessary data to finalize a change based on the lack of information that the payment is insufficient. However, we will take under advisement and consider studying the impact of the APC structures on services that make up lower volume HCPCS and CPT codes in comparison to other services in higher volume HCPCS and CPT codes within an APC in future rulemaking. We remind hospitals that every year, we review the APC assignments for all services and items paid under the OPPS. We will reevaluate the APC assignment for the service described by CPT code 75574 for next year’s rulemaking. After consideration of the public comments we received, we are finalizing our proposal to maintain the existing levels of the Imaging APCs, which consist of four levels of Imaging without Contrast APCs and three levels of Imaging with Contrast APCs. Table 33 below compares the CY 2018 and CY 2019 geometric mean costs for the imaging APCs. We refer readers to Addendum B to this final rule with comment period for the payment rates for all codes reported under the OPPS. In addition, we refer readers to Addendum D1 to this final rule with comment period for the status indicator meanings for all codes reported under the OPPS. Both Addendum B and Addendum D1 are available via the internet on the CMS website. b. Non-Ophthalmic Fluorescent Vascular Angiography (APC 5572) commenter believed that hospitals are underreporting the costs for the procedure described by HCPCS code C9733 based on its review of the CMS cost file which showed a geometric mean cost of $252.43, which is below the cost of the supplies associated with this procedure. The commenter suggested that hospitals may not be reporting this code when performed with an outpatient visit because payment for the service described by HCPCS code C9733 is conditionally packaged. Because of the perceived underreporting, the commenter requested that CMS provide instructions to hospitals in an upcoming MLN Matters article on appropriate billing for the procedure described by HCPCS code C9733. Response: Based on our review of the CY 2019 final rule claims data, the procedure described by HCPCS code C9733 has a geometric mean cost of approximately $250 based on 173 single claims (out of 982 total claims). Because this procedure involves the use of a contrast agent, we believe that a reassignment to one of the existing Imaging with Contrast APCs would be more appropriate for HCPCS code C9733. Specifically, we believe that a reassignment to APC 5572 (Level 2 Imaging with Contrast), with a geometric mean cost of approximately $389 is appropriate. We believe this reassignment will improve clinical homogeneity and align the resource costs of the service described by HCPCS code C9733 with those of imaging with contrast procedures assigned to APC 5572. In addition, with regard to the comment that hospitals underreport the procedure described by HCPCS code C9733, based on our analysis of the CY 2019 hospital outpatient claims data used for this final rule with comment period, we are unable to determine whether hospitals are underreporting the procedure. It is generally not our policy to judge the accuracy of hospital coding and charging for purposes of ratesetting. We rely on hospitals to accurately report the use of HCPCS codes in accordance with their code descriptors and CPT and CMS instructions, and to report services on As listed in Addendum B of the CY 2019 OPPS/ASC proposed rule, we proposed to continue to assign the procedure described by HCPCS code C9733 to APC 5523 (Level 3 Imaging without Contrast) with a proposed payment rate of approximately $232. We also proposed to maintain the status indicator assignment of ‘‘Q2’’ (Tpackaged) to indicate that payment for the service is conditionally packaged when performed in conjunction with other procedures on the same day but paid separately when performed as a stand-alone service. Comment: One commenter stated that HCPCS code C9733 describes a procedure that includes disposable components and a contrast agent (indocyanine green) that cost hospitals approximately $455. Consequently, the commenter disagreed with the proposed APC assignment of this service to APC 5523 because the APC payment rate only covers 50 percent of the hospital costs for the procedure. In addition, the VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 PO 00000 Frm 00110 Fmt 4701 Sfmt 4700 E:\FR\FM\21NOR2.SGM 21NOR2 ER21NO18.051</GPH> khammond on DSK30JT082PROD with RULES2 58926 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 Addendum B is available via the internet on the CMS website. 19. Remote Physiologic Monitoring (APCs 5012 and 5741) As displayed in Table 34 below and in Addendum B to the CY 2019 OPPS/ ASC proposed rule, we proposed to assign the procedure described by CPT code 99453 to APC 5012 (Clinic Visits and Related Services) with a proposed payment rate of approximately $116. We also proposed to assign the procedure described by CPT code 99454 to APC 5741 (Level 1 Electronic Analysis of Devices) with a proposed payment rate of approximately $37. The long descriptors for CPT codes 99453 and 99454 can be found in Table 34 below. The codes were listed as 990X0 and 990X1 (the 5-digit CMS placeholder codes), respectively, in Addendum B, with short descriptors, and in Addendum O, with long descriptors, to the CY 2019 OPPS/ASC proposed rule. We also assigned these codes to comment indicator ‘‘NP’’ in Addendum B to the proposed rule to indicate that the codes are new for CY 2019 with proposed APC assignments, and that public comments would be accepted on PO 00000 Frm 00111 Fmt 4701 Sfmt 4725 their proposed APC assignments. We note that these codes will be effective January 1, 2019. Comment: One commenter supported the APC assignments for both CPT codes 99453 and 99454 and requested that CMS finalize the APC assignments for CY 2019. Response: We appreciate the commenter’s support. Based on input from our medical advisors, we believe that procedures described by CPT codes 99453 and 99454 are appropriately assigned in APCs 5012 and 5741, respectively, based on clinical and resource homogeneity to the other services assigned to these APCs. Therefore, after consideration of the public comment received, we are finalizing our proposal without modification for the procedures described by CPT codes 99453 and 99454. The final APC and status indicator assignments are listed in Table 34 below. The final payment rates for these codes, where applicable, can be found in Addendum B to this final rule with comment period (which is available via the internet on the CMS website). E:\FR\FM\21NOR2.SGM 21NOR2 ER21NO18.052</GPH> khammond on DSK30JT082PROD with RULES2 claims and charges and costs for the services on their Medicare hospital cost report appropriately. However, we do not specify the methodologies that hospitals use to set charges for this or any other service. In addition, we state in Chapter 4 of the Medicare Claims Processing Manual that ‘‘it is extremely important that hospitals report all HCPCS codes consistent with their descriptors; CPT and/or CMS instructions and correct coding principles, and all charges for all services they furnish, whether payment for the services is made separately paid or is packaged’’ to enable CMS to establish future ratesetting for OPPS services.’’ After consideration of the public comment received, we are finalizing our proposal with modification. Specifically, we are reassigning the procedure described by HCPCS code C9733 to APC 5572 instead of APC 5523, based on its clinical and resource homogeneity to the other procedures assigned to APC 5572. We refer readers to Addendum B to this final rule with comment period for the payment rates for all codes reportable under the OPPS. 58927 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations 20. Sclerotherapy (APC 5054) khammond on DSK30JT082PROD with RULES2 As displayed in Table 35 below and in Addendum B of the CY 2019 OPPS/ ASC proposed rule, we proposed to continue to assign CPT codes 36465 and 36466 to APC 5054 (Level 4 Skin Procedures), with a proposed payment rate of approximately $1,565. Comment: One commenter disagreed with the proposed assignment of the procedures described by CPT codes 36465 and 36466 to APC 5054 and requested a reassignment to APC 5183 (Level 3 Vascular Procedures), which had a proposed payment rate of approximately $2,648. The commenter stated that the per-procedure cost for the Varithena foam sclerosant used in the procedure is $1,064. The commenter stated that APC 5183 is more clinically appropriate and reflects the resources required to perform the procedure. Specifically, the commenter indicated that the procedures described by CPT codes 36465 and 36466 share similar clinical and resource characteristics to the following surgical procedures that are assigned to APC 5183: VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 • CPT code 36473 (Endovenous ablation therapy of incompetent vein, extremity, inclusive of all imaging guidance and monitoring, percutaneous, mechanochemical; first vein treated); • CPT code 36475 (Endovenous ablation therapy of incompetent vein, extremity, inclusive of all imaging guidance and monitoring, percutaneous, radiofrequency; first vein treated); and • CPT code 36478 (Endovenous ablation therapy of incompetent vein, extremity, inclusive of all imaging guidance and monitoring, percutaneous, laser; first vein treated). Response: Based on input from our clinical advisors, we believe that the procedures described by CPT codes 36465 and 36466 are clinically similar to the procedures assigned to APC 5054. We do not believe that the resources used for the procedures described by CPT codes 36465 and 36466 are comparable to the procedures described by CPT codes 36473, 36475, and 36478, which are assigned to C–APC 5183. Consequently, we believe that APC 5054 appropriately reflects the resources and PO 00000 Frm 00112 Fmt 4701 Sfmt 4725 clinical characteristics associated with the procedures described by CPT codes 36465 and 36466. We note that the geometric mean cost for APC 5054 is approximately $1,562, which exceeds the cost of the Varithena foam sclerosant (as reported by the commenter) used in the procedure. Therefore, after consideration of the public comment received, we are finalizing our proposal without modification for assignment of the procedures described by CPT codes 36465 and 36466 to APC 5054. The final APC and status indicator assignments are listed in Table 35 below. As we do every year, we review the APC assignments for all services and items paid under the OPPS. We will reassess the APC assignment for the procedures described by CPT codes 36465 and 36466 for the CY 2020 rulemaking. We refer readers to Addendum B to this final rule with comment period for the payment rates for all codes reportable under the OPPS. Addendum B is available via the internet on the CMS website. E:\FR\FM\21NOR2.SGM 21NOR2 ER21NO18.053</GPH> 58928 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations IV. OPPS Payment for Devices A. Pass-Through Payments for Devices 1. Beginning Eligibility Date for Device Pass-Through Status and Quarterly Expiration of Device Pass-Through Payments khammond on DSK30JT082PROD with RULES2 a. Background Under section 1833(t)(6)(B)(iii) of the Act, the period for which a device category eligible for transitional passthrough payments under the OPPS can be in effect is at least 2 years but not more than 3 years. Prior to CY 2017, our regulation at 42 CFR 419.66(g) provided that this pass-through payment eligibility period began on the date CMS established a particular transitional pass-through category of devices, and we based the pass-through status expiration date for a device category on the date on which pass-through payment was effective for the category. In the CY 2017 OPPS/ASC final rule with comment period (81 FR 79654), in accordance with section 1833(t)(6)(B)(iii)(II) of the Act, we amended § 419.66(g) to provide that the pass-through eligibility period for a device category begins on the first date on which pass-through payment is made under the OPPS for any medical device described by such category. In addition, prior to CY 2017, our policy was to propose and finalize the dates for expiration of pass-through status for device categories as part of the OPPS annual update. This means that device pass-through status would expire at the end of a calendar year when at least 2 years of pass-through payments have been made, regardless of the quarter in which the device was approved. In the CY 2017 OPPS/ASC final rule with comment period (81 FR 79655), we changed our policy to allow for quarterly expiration of pass-through payment status for devices, beginning with pass-through devices approved in CY 2017 and subsequent calendar years, to afford a pass-through payment period that is as close to a full 3 years as possible for all pass-through payment devices. We refer readers to the CY 2017 OPPS/ASC final rule with comment period (81 FR 79648 through 79661) for a full discussion of the changes to the device pass-through payment policy. We also have an established policy to package the costs of the devices that are no longer eligible for pass-through payments into the costs of the procedures with which the devices are reported in the claims data used to set the payment rates (67 FR 66763). VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 b. Expiration of Transitional PassThrough Payments for Certain Devices As stated earlier, section 1833(t)(6)(B)(iii) of the Act requires that, under the OPPS, a category of devices be eligible for transitional pass-through payments for at least 2 years, but not more than 3 years. There currently are no device categories eligible for passthrough payment. 2. New Device Pass-Through Applications a. Background Section 1833(t)(6) of the Act provides for pass-through payments for devices, and section 1833(t)(6)(B) of the Act requires CMS to use categories in determining the eligibility of devices for pass-through payments. As part of implementing the statute through regulations, we have continued to believe that it is important for hospitals to receive pass-through payments for devices that offer substantial clinical improvement in the treatment of Medicare beneficiaries to facilitate access by beneficiaries to the advantages of the new technology. Conversely, we have noted that the need for additional payments for devices that offer little or no clinical improvement over previously existing devices is less apparent. In such cases, these devices can still be used by hospitals, and hospitals will be paid for them through appropriate APC payment. Moreover, a goal is to target pass-through payments for those devices where cost considerations might be most likely to interfere with patient access (66 FR 55852; 67 FR 66782; and 70 FR 68629). As specified in regulations at 42 CFR 419.66(b)(1) through (3), to be eligible for transitional pass-through payment under the OPPS, a device must meet the following criteria: (1) If required by FDA, the device must have received FDA approval or clearance (except for a device that has received an FDA investigational device exemption (IDE) and has been classified as a Category B device by the FDA), or meet another appropriate FDA exemption; and the pass-through payment application must be submitted within 3 years from the date of the initial FDA approval or clearance, if required, unless there is a documented, verifiable delay in U.S. market availability after FDA approval or clearance is granted, in which case CMS will consider the pass-through payment application if it is submitted within 3 years from the date of market availability; (2) the device is determined to be reasonable and necessary for the diagnosis or treatment of an illness or injury or to improve the functioning of PO 00000 Frm 00113 Fmt 4701 Sfmt 4700 58929 a malformed body part, as required by section 1862(a)(1)(A) of the Act; and (3) the device is an integral part of the service furnished, is used for one patient only, comes in contact with human tissue, and is surgically implanted or inserted (either permanently or temporarily), or applied in or on a wound or other skin lesion. In addition, according to § 419.66(b)(4), a device is not eligible to be considered for device pass-through payment if it is any of the following: (1) Equipment, an instrument, apparatus, implement, or item of this type for which depreciation and financing expenses are recovered as depreciation assets as defined in Chapter 1 of the Medicare Provider Reimbursement Manual (CMS Pub. 15– 1); or (2) a material or supply furnished incident to a service (for example, a suture, customized surgical kit, or clip, other than a radiological site marker). Separately, we use the following criteria, as set forth under § 419.66(c), to determine whether a new category of pass-through payment devices should be established. The device to be included in the new category must— • Not be appropriately described by an existing category or by any category previously in effect established for transitional pass-through payments, and was not being paid for as an outpatient service as of December 31, 1996; • Have an average cost that is not ‘‘insignificant’’ relative to the payment amount for the procedure or service with which the device is associated as determined under § 419.66(d) by demonstrating: (1) The estimated average reasonable costs of devices in the category exceeds 25 percent of the applicable APC payment amount for the service related to the category of devices; (2) the estimated average reasonable cost of the devices in the category exceeds the cost of the devicerelated portion of the APC payment amount for the related service by at least 25 percent; and (3) the difference between the estimated average reasonable cost of the devices in the category and the portion of the APC payment amount for the device exceeds 10 percent of the APC payment amount for the related service (with the exception of brachytherapy and temperature-monitored cryoblation, which are exempt from the cost requirements as specified at § 419.66(c)(3) and (e)); and • Demonstrate a substantial clinical improvement, that is, substantially improve the diagnosis or treatment of an illness or injury or improve the functioning of a malformed body part compared to the benefits of a device or E:\FR\FM\21NOR2.SGM 21NOR2 58930 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations khammond on DSK30JT082PROD with RULES2 devices in a previously established category or other available treatment. Beginning in CY 2016, we changed our device pass-through evaluation and determination process. Device passthrough applications are still submitted to CMS through the quarterly subregulatory process, but the applications will be subject to noticeand-comment rulemaking in the next applicable OPPS annual rulemaking cycle. Under this process, all applications that are preliminarily approved upon quarterly review will automatically be included in the next applicable OPPS annual rulemaking cycle, while submitters of applications that are not approved upon quarterly review will have the option of being included in the next applicable OPPS annual rulemaking cycle or withdrawing their application from consideration. Under this notice-andcomment process, applicants may submit new evidence, such as clinical trial results published in a peerreviewed journal or other materials for consideration during the public comment process for the proposed rule. This process allows those applications that we are able to determine meet all the criteria for device pass-through payment under the quarterly review process to receive timely pass-through payment status, while still allowing for a transparent, public review process for all applications (80 FR 70417 through 70418). More details on the requirements for device pass-through payment applications are included on the CMS website in the application form itself at: https://www.cms.gov/Medicare/ Medicare-Fee-for-Service-Payment/ HospitalOutpatientPPS/passthrough_ payment.html, in the ‘‘Downloads’’ section. In addition, CMS is amenable to meeting with applicants or potential applicants to discuss research trial design in advance of any device passthrough application or to discuss application criteria, including the substantial clinical improvement criterion. b. Applications Received for Device Pass-Through Payment for CY 2019 We received seven applications by the March 1, 2018 quarterly deadline, which was the last quarterly deadline for applications to be received in time to be included in the CY 2019 OPPS/ ASC proposed rule. We received four of the applications in the second quarter of 2017, one of the applications in the third quarter of 2017, and two of the applications in the first quarter of 2018. None of the seven applications were approved for device pass-through VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 payment during the quarterly review process. Applications received for the later deadlines for the remaining 2018 quarters (June 1, September 1, and December 1), if any, will be presented in the CY 2020 OPPS/ASC proposed rule. We note that the quarterly application process and requirements have not changed in light of the addition of rulemaking review. Detailed instructions on submission of a quarterly device pass-through payment application are included on the CMS website at: https://www.cms.gov/ Medicare/Medicare-Fee-for-ServicePayment/HospitalOutpatientPPS/ Downloads/catapp.pdf. A discussion of the seven applications received by the March 1, 2018 deadline is presented below, as detailed in the CY 2019 OPPS/ ASC proposed rule (83 FR 37098 through 37107). (1) AquaBeam System PROCEPT BioRobotics Corporation submitted an application for a new device category for transitional passthrough payment status for the AquaBeam System. The AquaBeam System is intended for the resection and removal of prostate tissue in males suffering from lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH). The applicant stated that this is a very common condition typically occurring in elderly men. The clinical symptoms of this condition can include diminished urinary stream and partial urethral obstruction.16 According to the applicant, the AquaBeam system resects the prostate to relieve symptoms of urethral compression. The resection is performed robotically using a high velocity, nonheated sterile saline water jet (in a procedure called Aquablation). The applicant stated that the AquaBeam System utilizes real-time intra-operative ultrasound guidance to allow the surgeon to precisely plan the surgical resection area of the prostate and then the system delivers Aquablation therapy to accurately resect the obstructive prostate tissue without the use of heat. The materials submitted by the applicant state that the AquaBeam System consists of a disposable, singleuse handpiece as well as other components that are considered capital equipment. With respect to the eligibility criterion at § 419.66(b)(3), according to the applicant, the AquaBeam System is integral to the service provided, is used 16 Chungtai B. Forde JC. Thomas DDM et al. Benign Prostatic Hyperplasia. Nature Reviews Disease Primers 2 (2016) article 16031. PO 00000 Frm 00114 Fmt 4701 Sfmt 4700 for one patient only, comes in contact with human skin, and is surgically implanted or inserted (either permanently or temporarily). The applicant also claimed the AquaBeam System meets the device eligibility requirements of § 419.66(b)(4) because it is not an instrument, apparatus, implement, or items for which depreciation and financing expenses are recovered, and it is not a supply or material furnished incident to a service. However, in the CY 2000 interim final rule with comment period (65 FR 67804 through 67805), we explained how we interpreted § 419.43(e)(4)(iv). We stated that we consider a device to be surgically implanted or inserted if it is surgically inserted or implanted via a natural or surgically created orifice, or inserted or implanted via a surgically created incision. We also stated that we do not consider an item used to cut or otherwise create a surgical opening to be a device that is surgically implanted or inserted. We consider items used to create incisions, such as scalpels, electrocautery units, biopsy apparatuses, or other commonly used operating room instruments, to be supplies or capital equipment, not eligible for transitional pass-through payments. We stated that we believe the function of these items is different and distinct from that of devices that are used for surgical implantation or insertion. Finally, we stated that, generally, we would expect that surgical implantation or insertion of a device occurs after the surgeon uses certain primary tools, supplies, or instruments to create the surgical path or site for implanting the device. In the CY 2006 final rule with comment period (70 FR 68629 and 68630), we adopted as final our interpretation that surgical insertion or implantation criteria include devices that are surgically inserted or implanted via a natural or surgically created orifice, as well as those devices that are inserted or implanted via a surgically created incision. We reiterated that we maintain all of the other criteria in § 419.66 of the regulations, namely, that we do not consider an item used to cut or otherwise create a surgical opening to be a device that is surgically implanted or inserted. We invited public comments on whether the AquaBeam System meets the eligibility criteria at § 419.66(b). Comment: Commenters, including the manufacturer of AquaBeam and stakeholders, believed that the AquaBeam System met the eligibility criteria at § 419.66(b). Response: We appreciate the commenters’ input. However, we do not believe that the AquaBeam device meets E:\FR\FM\21NOR2.SGM 21NOR2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations khammond on DSK30JT082PROD with RULES2 the eligibility criteria described at § 419.66(b). Specifically, we do not believe that the device is surgically implanted or inserted. As stated earlier, we have described in previous rulemaking (65 FR 67804 through 67805 and 70 FR 68329 through 68630) how we interpret the surgical insertion or implantation criteria, and we do not believe that the use of the Aquabeam device is consistent with that interpretation; namely, that we do not consider an item used to cut or otherwise create a surgical opening to be a device that is surgically implanted or inserted (70 FR 68630). Because we have determined that the AquaBeam device does not meet the basic eligibility criterion for transitional passthrough payment status, we have not evaluated this product to determine whether it meets the other criteria required for transitional pass-through payment for devices; that is the newness criterion, the substantial clinical improvement criterion, and the cost criterion. After consideration of the public comments we received, we are not approving device pass-through payment status for the AquaBeam System for CY 2019. (2) BioBag® (Larval Debridement Therapy in a Contained Dressing) BioMonde US, LLC resubmitted an application for a new device passthrough category for the BioBag® (larval debridement therapy in a contained dressing), hereinafter referred to as the BioBag®. The application submitted contained similar information to the previous application received in March 2016 that was evaluated in the CY 2017 OPPS/ASC final rule with comment period (81 FR 79650). The only new information provided by the applicant were additional studies completed since the original application addressing the substantial clinical improvement criterion. According to the applicant, the BioBag® is a biosurgical wound treatment (‘‘maggot therapy’’) consisting of disinfected, living larvae (Lucilia sericata) in a polyester net bag; the larvae remove dead tissue from wounds. The BioBag® is indicated for debridement of nonhealing necrotic skin and soft tissue wounds, including pressure ulcers, venous stasis ulcers, neuropathic foot ulcers, and nonhealing traumatic or postsurgical wounds. Debridement, which is the action of removing devitalized tissue and bacteria from a wound, is required to treat or prevent infection and to allow the wound to progress through the healing process. This system contains VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 disinfected, living larvae that remove the dead tissue from wounds and leave healthy tissue undisturbed. The larvae are provided in a sterile polyester net bag, available in different sizes. The only other similar product is free-range (that is, uncontained) larvae. Free-range larvae are not widely used in the United States because application is time consuming, there is a fear of larvae escaping from the wound, and there are concerns about proper and safe handling of the larvae. The total number of treatment cycles depends on the characteristics of the wound, the response of the wound, and the aim of the therapy. Most ulcers are completely debrided within 1 to 6 treatment cycles. With respect to the newness criterion at § 419.66(b)(1), the applicant received FDA clearance for the BioBag® through the premarket notification section 510(k) process on August 28, 2013, and the first U.S. sale of the BioBag® occurred in April 2015. The June 1, 2017 application is more than 3 years after FDA clearance but less than 3 years after its first U.S. sale. We invited public comments on whether the BioBag® meets the newness criterion. Comment: The manufacturer stated that, although the BioBag® received its 510(k) clearance in 2013, BioBag® was not commercially available in the United States until its American-based production facility was established in 2015 to make the product available on the market. Response: We appreciate the additional clarification from the manufacturer regarding the availability of the BioBag®. Based on this clarification, we have determined that BioBag® meets the newness criterion. With respect to the eligibility criterion at § 419.66(b)(3), the applicant claimed that the BioBag® is an integral part of the wound debridement, is used for one patient only, comes in contact with human skin, and is applied in or on a wound. In addition, the applicant stated that the BioBag® meets the device eligibility requirements of § 419.66(b)(4) because it is not an instrument, apparatus, or item for which depreciation and financing expenses are recovered. We also had determined in the CY 2017 OPPS/ASC final rule with comment period (81 FR 79650) that the BioBag® is not a material or supply furnished incident to a service. We invited public comments on whether the BioBag® meets the eligibility criterion. Comment: The manufacturer presented several reasons why the BioBag® is not a medical supply, but instead is a treatment for wound debridement, including the specialized PO 00000 Frm 00115 Fmt 4701 Sfmt 4700 58931 nature of the product, that the product is not purchased in bulk, and that it provides a treatment outcome for nonhealing wounds. Response: We appreciate the additional information provided by the manufacturer to demonstrate that the BioBag® is not a material or medical supply. Based on this information, we have determined that the BioBag® meets the eligibility criterion. The criteria for establishing new device categories are specified at § 419.66(c). The first criterion, at § 419.66(c)(1), provides that CMS determines that a device to be included in the category is not appropriately described by any existing categories or by any category previously in effect, and was not being paid for as an outpatient service as of December 31, 1996. With respect to the existence of a previous pass-through device category that describes the BioBag®, the applicant suggested a category descriptor of ‘‘Contained medicinal larvae for the debridement of necrotic non-healing skin and soft tissue wounds.’’ We have not identified an existing pass-through payment category that describes the BioBag®. The second criterion for establishing a device category, at § 419.66(c)(2), provides that CMS determines that a device to be included in the category has demonstrated that it will substantially improve the diagnosis or treatment of an illness or injury or improve the functioning of a malformed body part compared to the benefits of a device or devices in a previously established category or other available treatment. With respect to the substantial clinical improvement criterion, the applicant provided substantial evidence that larval therapy may improve outcomes compared to other methods of wound debridement. However, given the existence of the Medical Maggots®, another form of larval therapy that has been on the market since 2004, the relevant comparison is between the BioBag® and the Medical Maggots®. There are many reasons to suspect that the BioBag® could improve outcomes and be preferable to the Medical Maggots®. In essence, with the latter, the maggots are directly placed on the wound, which may result in escape, leading to infection control issues as well as dosing variability. In addition, there are the issues with patient comfort. With the Biobag®, the maggots are in a sealed container so escape is not an issue. The applicant cited a study showing large decreases in maggot escape with the BioBag® as opposed to the Medical Maggots®. However, the applicant did E:\FR\FM\21NOR2.SGM 21NOR2 khammond on DSK30JT082PROD with RULES2 58932 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations not provide any data that clinical outcomes are improved using the BioBag® as opposed to the Medical Maggots®. Based on the studies presented, we believe there are insufficient data to determine whether the BioBag® offers a substantial clinical improvement over other treatments for wound care. We invited public comments on whether the BioBag® meets the substantial clinical improvement criterion. Comment: The manufacturer identified four items to indicate that the BioBag® may provide substantial clinical improvement over other available treatments. These items include debridement of wounds infected with MRSA, removing more tissue than loose maggots, the ease of use of the BioBag® over loose maggots, and less pain during debridement. The commenter stated that these items were supported by journal citations. Several other commenters discussed the benefits of the BioBag®, and a few commenters discussed the benefits of larval debridement of wounds more generally. The commenters cited benefits that included that the BioBag® debrides only dead tissue, that BioBag® makes it easier to apply and remove maggots from wounds, and that BioBag® is a lower-cost and less-invasive treatment than surgical debridement. The commenters did not provide any support of these benefits by medical studies. Response: We have reviewed these public comments and the additional journal citations and believe that most of the information provided by commenters reenforced our discussion in the proposed rule that stated that there are many reasons why the BioBag® may be preferable to treatment from loose maggots. However, we have not been provided with sufficient support from clinical studies to determine that the BioBag® meets the substantial clinical improvement criterion. Each of the three clinical studies cited by the manufacturer did identify possible benefits from the use of the BioBag® over treatment from loose maggots, hydrogel, or other surgical debridement methods. However, the findings had only marginal clinical significance, and did not reflect sufficient clinical support to reach the threshold of demonstrating significant clinical improvement. For example, the study of debridement through containment,17 was done in vitro (that is, in a laboratory 17 Blake, F. et al. The biosurgical wound debridement: Experimental investigation of efficiency and practicability. Wound Rep Reg, 2007: 15; 756–761. 3. VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 setting) and not in vivo (that is, through testing on human subjects). Therefore, we are uncertain how the study findings would extrapolate to a patient receiving treatment. Second, we did not find that the clinical evidence fully supported the commenters’ claimed benefits. For instance, a commenter, the manufacturer provided data comparing the amount of material debrided by the BioBag® at 4 days to free larvae at 3 days from the same study of debridement through containment.18 To help demonstrate substantial clinical improvement, we believe that the commenter should have compared the amount of material debrided by both treatment methods over a similar time period. When similar time periods are compared between both treatment methods, the study found the amount of material debrided by the BioBag® and the free larvae is similar. In another study cited by the commenter discussing the prevalence of pain during maggot debridement therapy,19 the share of study patients experiencing pain was similar for people receiving treatment using a BioBag® device when compared to people receiving maggot debridement therapy from free larvae kept in a cage-like dressing. After consideration of the public comments we received, we have determined that the BioBag® does not meet the significant clinical improvement criterion. The third criterion for establishing a device category, at § 419.66(c)(3), requires us to determine that the cost of a device is not insignificant, as described in § 419.66(d). Section 419.66(d) includes three cost significance criteria that must each be met. With respect to the cost criterion, the applicant stated that the BioBag® would be reported with CPT code 97602 (Removal of devitalized tissue from wound(s), non-selective debridement, without anesthesia (e.g., wet-to-moist dressings, enzymatic, abrasion, larval therapy), including topical application(s), wound assessment, and instruction(s) for ongoing care, per session). CPT code 97602 is assigned to APC 5051 (Level 1 Skin Procedures), with a payment rate of $153.12, and a device offset of $0.02. The price of the BioBag® varies with the size of the bag ($375 to $435 per bag), and bag size selection is based on the size of the wound. Section 419.66(d)(1), the first cost significance requirement, provides that 18 Ibid. Blake, F. et al. K. et al. Pain related to maggot debridement therapy. J Wound Care. 2012;21(8): 400–405. 19 Mumcuoglu, PO 00000 Frm 00116 Fmt 4701 Sfmt 4700 the estimated average reasonable cost of devices in the category must exceed 25 percent of the applicable APC payment amount for the service related to the category of devices. The estimated reasonable cost of $435 for the BioBag® exceeds the applicable APC amount for the service related to the category of devices of $153.12 by 284.09 percent ($435/$153.12 × 100 = 284.09 percent). Thus, we determined that the BioBag® appears to meet the first cost significance test. The second cost significance test, at § 419.66(d)(2), provides that the estimated average reasonable cost of devices in the category must exceed the cost of the device-related portion of the APC payment amount by at least 25 percent, which means the device cost needs to be at least 125 percent of the device offset amount (the device-related portion of the APC found on the offset list). The estimated average reasonable cost of $435 for the BioBag® exceeds the proposed device-related portion of the APC amount for the related service of $0.02 by 2,175,000 percent ($435/$0.02 × 100 = 2,175,000 percent). Thus, we determined that the BioBag® appears to meet the second cost significance test. Section 419.66(d)(3), the third cost significance test, requires that the difference between the estimated average reasonable cost of the devices in the category and the portion of the APC payment amount determined to be associated with the device exceeds 10 percent of the APC payment amount for the related service. The difference between the estimated average reasonable cost of $435 for the BioBag® and the portion of the proposed APC payment for the device of $0.02 exceeds 10 percent at 284.08 percent (($435¥$0.02)/$153.12 × 100 = 284.08 percent). Thus, we determined that the BioBag® appears to meet the third cost significance test and satisfies the cost significance criterion. We invited public comments on whether the BioBag® meets the device pass-through payment criteria discussed in this section, including all three cost criteria. We did not receive any public comments on the cost criteria for the BioBag®. Therefore, we have determined that the BioBag® does meet all three cost criteria. After consideration of the public comments we received and our review of the criteria necessary to receive device pass-through payment, we are not approving the application for the BioBag® to receive device pass-through payment status in CY 2019 because the BioBag® does not meet the substantial clinical improvement criterion. E:\FR\FM\21NOR2.SGM 21NOR2 khammond on DSK30JT082PROD with RULES2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations (3) BlastXTM Antimicrobial Wound Gel Next ScienceTM has submitted an application for a new device category for transitional pass-through payment status for BlastXTM. According to the manufacturer, BlastXTM is a PEG-based aqueous hydrogel which contains citric acid, sodium citrate, and benzalkonium chloride, buffered to a pH of 4.0 at 2.33 osmolarity. BlastXTM received a 510(k) clearance from the FDA on March 6, 2017. BlastXTM is indicated for the management of wounds such as Stage I– IV pressure ulcers, partial and full thickness wounds, diabetic foot and leg ulcers, postsurgical wounds, first and second degree burns, and grafted and donor sites. The manufacturer stated in its application for transitional pass-through payment status that BlastXTM works by disrupting the biofilm matrix in a wound and eliminating the bacteria absorbed within the gel. The manufacturer asserted that disrupting and eliminating the biofilm removes a major barrier to wound healing. The manufacturer also asserted that BlastXTM is not harmful to host tissue and stated that BlastXTM is applied to the wound every other day as a thin layer throughout the entire wound healing process. When used as an adjunct to debridement, BlastXTM is applied immediately after debridement to eliminate any remaining biofilm and prevent the growth of new biofilm. Based on the evidence provided in the manufacturer’s application, BlastXTM is not a skin substitute and cannot be considered for transitional pass-through payment status as a device. To be considered a device for purposes of the medical device pass-through payment process under the OPPS, a skin substitute needs to be applied in or on a wound or other skin lesion based on 42 CFR 419.66(b)(3). It should be a product that is primarily used in conjunction with the skin graft procedures described by CPT codes 15271 through 15278 or HCPCS codes C5271 through C5278 (78 FR 74937). The skin substitute should only be applied a few times during a typical treatment episode. BlastXTM, according to the manufacturer, may be used in many other procedures other than skin graft procedures, including several debridement and active wound care management procedures. The manufacturer also stated that BlastXTM would be used in association with any currently available skin substitute product and that the product should be applied every other day, which is not how skin substitute products for skin graft procedures are used to heal VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 wounds. BlastXTM is not a required component of the skin graft service, and is used as a supply that may assist with the wound healing process that occurs primarily because of the use of a sheet skin substitute product in a skin graft procedure. Therefore, with respect to the eligibility criterion at § 419.66(b)(3), in the proposed rule, we determined that BlastXTM is not integral to the service provided (which is a skin graft procedure using a sheet skin substitute), is a material or supply furnished incidentally to a service, and is not surgically inserted into a patient. BlastXTM does not meet the eligibility criterion to be considered a device for transitional pass-through payment. Therefore, we did not evaluate the product on the other criteria required for transitional pass-through payment for devices, including the newness criterion, the substantial clinical improvement criterion, and the cost criterion. We invited public comments on the eligibility of BlastXTM for transitional pass-through payment for devices. We did not receive any public comments regarding the eligibility of BlastXTM for transitional pass-through payment for devices. Therefore, we are not approving BlastXTM for transitional pass-through payment status for CY 2019 because the product does not meet the eligibility criterion to be considered a device. (4) EpiCord® MiMedx® submitted an application for a new OPPS device category for transitional pass-through payment status for EpiCord®, a skin substitute product. According to the applicant, EpiCord® is a minimally manipulated, dehydrated, devitalized cellular umbilical cord allograft for homologous use that provides a protective environment for the healing process. According to the applicant, EpiCord® is comprised of the protective elements of the umbilical cord with a thin amnion layer and a thicker Wharton’s Jelly mucopolysaccharides component. The Wharton’s Jelly contains collagen, hyaluronic acid, and chondroitin sulfate, which are the components principally responsible for its mechanical properties. The applicant stated that EpiCord® is packaged as an individual unit in two sizes, 2 cm x 3 cm and 3 cm x 5 cm. The applicant asserted that EpiCord® is clinically superior to other skin substitutes because it is much thicker than dehydrated amnion/chorion allografts, which allows for application over exposed bone, tendon, nerves, PO 00000 Frm 00117 Fmt 4701 Sfmt 4700 58933 muscle, joint capsule and hardware. According to the applicant, due to its unique thicker, stiffer structure, clinicians are able to apply or suture EpiCord® for deep, tunneling wounds where other products cannot fill the entire wound bed or dead spaces. With respect to the newness criterion at § 419.66(b)(1), EpiCord® was added to the MiMedx® registration for human cells, tissues, and cellular and tissuebased products (HCT/Ps) on December 31, 2015. In adding EpiCord, MiMedx® asserted that EpiCord® conformed to the requirements for HCT/Ps regulated solely under section 361 of the Public Health Service Act and the regulations at 21 CFR part 1271. For these products, FDA requires that the manufacturer register and list its HCT/Ps with the FDA’s Center for Biologics Evaluation and Research (CBER) within 5 days after beginning operations and update its registration annually, and MiMedx® provided documentation verifying that EpiCord® had been registered. However, no documentation regarding an FDA determination that EpiCord® is appropriate for regulation solely under section 361 of the Public Health Service Act had been submitted. According to the applicant, December 31, 2015 was the first date of sale within the United States for EpiCord®. Therefore, it appears that market availability of EpiCord® is within 3 years of this application. We note that a product that is regulated solely under section 361 of the Public Health Service Act and the regulations in 21 CFR part 1271, as asserted by the manufacturer of Epicord®, is not regulated as a device under the Federal Food, Drug, and Cosmetic Act. The regulations at 21 CFR 1271.20 state that ‘‘If you are an establishment that manufactures an HCT/P that does not meet the criteria set out in § 1271.10(a) [for regulation solely under section 361 of the Public Health Service Act and the regulations in part 1271], and you do not qualify for any of the exceptions in § 1271.15, your HCT/P will be regulated as a drug, device, and/or biological product. . . .’’ The Federal Food, Drug, and Cosmetic Act requires that manufacturers of devices that are not exempt obtain marketing approval or clearance for their products from FDA before they may offer them for sale in the United States. We did not receive documentation from the applicant that EpiCord® is regulated as a device by FDA in accordance with Medicare regulations at 42 CFR 419.66(b)(1). We invited public comments on whether EpiCord® meets the newness criterion. E:\FR\FM\21NOR2.SGM 21NOR2 khammond on DSK30JT082PROD with RULES2 58934 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations Comment: The manufacturer believed that EpiCord® meets the newness criterion. The manufacturer stated that HCT/P products are regulated by the FDA through a registration process and have been paid by CMS for many years under the current regulatory structure. The manufacturer believed the newness criterion requirement for FDA approval for a product should only apply when FDA approval is required for that product. The manufacturer stated that FDA approval does not apply to EpiCord® because of its HCT/P status. The manufacturer stated that the passthrough payment application for EpiCord® was submitted within 3 years of EpiCord® being introduced onto the U.S. market. Finally, the manufacturer noted that the Medicare statute requires that biologicals be included in the category of products that can be considered for pass-through payment status and stated that, if HCT/Ps cannot be considered for transitional passthrough payment through the device pathway, the HCT/P products should be returned to the drug and biological transitional pass-through pathway. Response: To be able to determine whether a product meets the newness criterion, we need to determine a date when a product could first be used in the United States. Generally, we use the FDA clearance or approval date. We also have a provision in the newness criterion to use the date of first United States sale of the product rather than the FDA approval date, to accommodate the rare cases where a device receives FDA approval but the manufacturer experiences a significant delay establishing a manufacturing and distribution capacity for the new device. We agree that FDA approval cannot be required to be used for the newness criterion when there is no requirement for a new product to receive FDA approval. However, we still need some means to determine whether a product has been able for use in the United States for 3 years or less. The best alternative that we can identify to establish the date a product is considered new is to rely on registration to the FDA HCT/P registry, which indicates the existence of a new product. Comment: One commenter did not believe that EpiCord® meets the newness criterion. The commenter asserted that EpiCord® is considered to be the same product as EpiFix® that was introduced onto the U.S. market in 2011, and that the application for passthrough payment status for EpiCord® was submitted after the 3-year timeframe for a new product to apply for pass-through payment status. The VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 commenter cited a HCPCS Workgroup decision in 2016 that assigned the use of EpiCord® to HCPCS code Q4131, which, until December 31, 2018, was the identifying HCPCS code for the use of EpiFix®. The commenter also asserted that EpiFix® may also receive pass-through payments, which the commenter believed should not occur, because it will be difficult to determine whether HCPCS code Q4131 is being billed for the use of EpiFix® or EpiCord®. Response: We disagree with the commenter’s assertion that EpiFix® and EpiCord® are the same product. On December 31, 2015, MiMedx, the manufacturer of EpiCord®, submitted a filing to the FDA HCT/P registry representing EpiCord® as a new product that is a separate product from EpiFix®. In addition, the HCPCS Workgroup has made a decision, effective on January 1, 2019, to designate separate HCPCS codes for EpiFix® (Q4186) and EpiCord® (Q4187) that also demonstrates EpiCord® is a separate product from EpiFix®. We believe that EpiCord® is a separate product from EpiFix®. After consideration of the public comments we received, we have determined that EpiCord® meets the newness criterion. With respect to the eligibility criterion at § 419.66(b)(3), according to the applicant, EpiCord® is a skin substitute product that is integral to the service provided, is used for one patient only, comes in contact with human tissue, and is surgically inserted into the patient. The applicant also claimed EpiCord® meets the device eligibility requirements of § 419.66(b)(4) because EpiCord® is not an instrument, apparatus, implement, or item for which depreciation and financing expenses are recovered, and it is not a supply or material. We invited public comments on whether EpiCord® meets these eligibility criteria. We did not receive any public comments regarding whether EpiCord® meets the eligibility criterion. Based on the information we have received, we have determined that EpiCord® meets the eligibility criterion. The criteria for establishing new device categories are specified at § 419.66(c). The first criterion, at § 419.66(c)(1), provides that CMS determines that a device to be included in the category is not appropriately described by any of the existing categories or by any category previously in effect, and was not being paid for as an outpatient service as of December 31, 1996. We have not identified an existing pass-through category that describes PO 00000 Frm 00118 Fmt 4701 Sfmt 4700 EpiCord®. There are no present or previously established device categories for pass-through status that describe minimally manipulated, lyophilized, nonviable cellular umbilical membrane allografts regulated solely under section 361 of the Public Health Service Act and the regulations at 21 CFR part 1271. MiMedx® suggested a new device category descriptor of ‘‘Dehydrated Human Umbilical Cord Allografts’’ for EpiCord®. The second criterion for establishing a device category, at § 419.66(c)(2), provides that CMS determines that a device to be included in the category has demonstrated that it will substantially improve the diagnosis or treatment of an illness or injury or improve the functioning of a malformed body part compared to the benefits of a device or devices in a previously established category or other available treatment. With regard to the substantial clinical improvement criterion, the applicant asserted that EpiCord® reduces the mortality rate with use of the device; reduces the rate of devicerelated complications; decreases the rate of subsequent diagnostic or therapeutic interventions; decreases the number of future hospitalizations or physician visits; provides more rapid beneficial resolution of the disease process treated because of the use of the device; decreases pain, bleeding, or other quantifiable symptom; and reduces recovery time. To determine if the product meets the substantial improvement criterion, we compared EpiCord® to other skin substitute products. Compared to NEOX CORD 1K Wound Allograft, EpiCord® has half the levels of Vascular Endothelial Growth Factor (VEGF) and insulin-like growth factor binding protein-4 (IGFBP–4) and lower levels of Glial Cell Line Derived Neurotrophic Factor (GDNF) and Epidermal Growth Factor (EGF). Despite EpiCord® having higher levels of other growth factors, the cumulative effect of these differences has not been sufficiently demonstrated in the application. Moreover, most professional opinions do not compare EpiCord® to specific alternative skin substitutes; the few that do are, for the most part, of limited specificity (in terms of foci of superiority to other skin substitutes). Studies demonstrated 41 percent higher relative rates (4.1 percent higher absolute rates) of severe complications for EpiCord® compared to standard of care. Additionally, the control group was moist dressings and offloading (instead of another umbilical or biologic product). Furthermore, 38 percent of EpiCord® patients in the study were smokers versus 58 percent of E:\FR\FM\21NOR2.SGM 21NOR2 khammond on DSK30JT082PROD with RULES2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations control patients (smoking impairs wound healing; thus, this important dissimilarity between intervention and study populations casts doubt on attributing observed benefit to the intervention). Based on the evidence submitted with the application, we had insufficient evidence that EpiCord® provides a substantial clinical improvement over other treatments for wound care. We invited public comments on whether EpiCord® meets the substantial clinical improvement criterion. Comment: The manufacturer responded to several statements regarding EpiCord® and substantial clinical improvement in the CY 2019 OPPS/ASC proposed rule. The analysis in the proposal rule noted that the passthrough application for EpiCord® stated that EpiCord® had higher levels of some growth factors and lower levels of other growth factors than NEOX CORD 1K Allograft. However the original application did not clarify what the overall effect the differences in growth factors had on the effectiveness of EpiCord® for wound care and the proposed rule text expressed concern regarding comparisons to individual skin substitute products. The manufacturer asserted that the findings in the application, which were updated by the manufacturer, show that the combination of growth factors and proteins working together does improve wound healing in a complex environment. Also, the manufacturer stated that EpiCord® is the only umbilical cord wound product with a published multi-center, prospective, randomized-controlled, comparative parallel study. The manufacturer responded to a statement in the proposed rule that noted 41 percent higher relative rates of severe complications for EpiCord® compared to the standard of care, and concerns the control group in the studies were moist dressings and offloading instead of a biologic product. The manufacturer indicated that the studies include adverse events from all causes and a new study in progress will show no adverse events directly related to EpiCord® or alginate dressings. The manufacturer also stated that many wound experts do not attempt to compare new products to each other because of the high variability of the composition of products, how they are applied, and the dynamics of how different products work. The manufacturer replied to a statement in the CY 2019 OPPS/ASC proposed rule questioning the substantial higher amount of smokers in the control group for the primary study VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 compared to the group of EpiCord® patients. The manufacturer noted that the concern is that smoking impairs wound healing, and the presence of a higher number of smokers in the control group casts doubt on the conclusion that the difference in outcomes between the control group and the EpiCord® group was because of the use of EpiCord®. The manufacturer performed statistical analyses and the manufacturer reported that it found the effect of the higher proportion of smokers in the control group was not statistically significant. Finally, the manufacturer asserted that EpiCord® meets the substantial clinical improvement criterion as a result of the published multi-center randomized controlled study showing an 81-percent healing rate within 12 weeks, which increases to a 96-percent healing rate when adequate debridement is performed. Response: We appreciate the detailed response to the questions we had regarding the study the manufacturer submitted as evidence that EpiCord® would have substantial clinical improvement over comparable wound care treatments. However, this study on its own is not sufficient to establish substantial clinical improvement. First, independent replication of the findings of the study has not been performed. The study indicates beneficial effects from the use of EpiCord®; however, it is not clear if the findings can be reproduced. Multiple studies with similar conditions, and a more equitable distribution of smokers in the control and intervention groups, would be a first step to determine if the findings are valid. Second, more comparisons need to be done with different classes of biological skin substitute products. Given the number of skin substitute products on the U.S. market, it is not possible to compare EpiCord® to each product. However, we believe that studies comparing the product against products made with epithelial tissue, other human-sourced products, and animal-sourced products could provide more evidence demonstrating the clinical superiority of EpiCord®. Comment: Multiple commenters supported granting EpiCord® transitional pass-through payment status. Many of the commenters discussed the strength of the structure of EpiCord®, the high levels of human growth factors found in the product, and its ability to heal complex wounds, but did not provide support by studies or other clinical research. Response: We appreciate the additional information that the commenters provided on the performance and the benefits of PO 00000 Frm 00119 Fmt 4701 Sfmt 4700 58935 EpiCord®. However, many skin substitute products can be used to heal complex wounds. In addition, none of the commenters provided clinical evidence of how the high levels of human growth factors led to EpiCord® having a superior performance to other skin substitute products. After consideration of the public comments we received, we have determined that EpiCord® does not meet the substantial clinical improvement criterion. The third criterion for establishing a device category, at § 419.66(c)(3), requires us to determine that the cost of the device is not insignificant, as described in § 419.66(d). Section 419.66(d) includes three cost significance criteria that must each be met. The applicant provided the following information in support of the cost significance requirements. EpiCord® would be reported with CPT code 15271 or 15275. CPT code 15271 describes the application of skin substitute graft to trunk, arms, legs, total wound surface area up to 100 sq cm; first 25 sq cm or less wound surface area. CPT code 15275 describes the application of skin substitute graft to face, scalp, eyelids, mouth, neck, ears, orbits, genitalia, hands, feet, and/or multiple digits, total wound surface area up to 100 sq cm; first 25 sq cm or less wound surface area. Both codes are assigned to APC 5054 (Level 4 Skin Procedures). CPT codes 15271 through 15278 are assigned to either APC 5054 (Level 4 Skin Procedures), with a payment rate of $1,427.77 and a device offset of $4.70, or APC 5055 (Level 5 Skin Procedures), with a payment rate of $2,504.69 and a device offset of $35.01. The price of EpiCord® is $1,595 for the 2 cm x 3 cm and $3,695 for the 3 cm x 5 cm product size. To meet the cost criterion for device pass-through payment, a device must pass all three tests of the cost criterion for at least one APC. Section 419.66(d)(1), the first cost significance requirement, provides that the estimated average reasonable cost of devices in the category must exceed 25 percent of the applicable APC payment amount for the service related to the category of devices. The estimated average reasonable cost of $3,695 for the 3 cm x 5 cm product exceeds the applicable APC amount for the service related to the category of devices of $1,427.77 by 258.80 percent ($3,695/$1427.77 × 100 percent = 258.80 percent). Therefore, it appears that EpiCord® meets the first cost significance test. The second cost significance test, at § 419.66(d)(2), provides that the estimated average reasonable cost of the E:\FR\FM\21NOR2.SGM 21NOR2 58936 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations khammond on DSK30JT082PROD with RULES2 devices in the category must exceed the cost of the device-related portion of the APC payment amount for the related service by at least 25 percent, which means that the device cost needs to be at least 125 percent of the offset amount (the device-related portion of the APC found on the offset list). The estimated average reasonable cost of $3,695 for the 3 cm x 5 cm product exceeds the devicerelated portion of the APC payment amount for the related service of $4.70 by 78,617.02 percent ($3,695/$4.70 × 100 percent = 78,617.02 percent). Therefore, it appears that EpiCord® meets the second cost significance test. Section 419.66(d)(3), the third cost significance test, requires that the difference between the estimated average reasonable cost of the devices in the category and the portion of the APC payment amount for the device must exceed 10 percent of the APC payment amount for the related service. The difference between the estimated average reasonable cost of $3,695 for the 3 cm x 5 cm product and the portion of the APC payment amount for the device of $4.70 exceeds 10 percent at 258.47 percent (($3,695¥$4.70)/$1,427.77) × 100 percent = 258.47 percent). Therefore, it appears that EpiCord® meets the third cost significance test. Based on the costs submitted by the applicant and the calculations noted earlier, it appears that EpiCord® meets the cost criterion at § 419.66(c)(3) for new device categories. We invited public comments on whether EpiCord® meets the cost criterion for device passthrough payment. We did not receive any public comments regarding the cost criteria for EpiCord®. Based on the information that we received, we have determined that EpiCord® meets the cost criteria. After consideration of the public comments and additional information we have received, we are not approving EpiCord® for transition pass-through payment status in CY 2019 because the product does not meet the substantial clinical improvement criterion. (5) remede¯® System Transvenous Neurostimulator Respicardia, Inc. submitted an application for a new device category for transitional pass-through payment status for the remede¯® System Transvenous Neurostimulator. According to the applicant, the remede¯® System is an implantable phrenic nerve stimulator indicated for the treatment of moderate to severe central sleep apnea (CSA) in adult patients. The applicant stated that the remede¯® System is the first and only implantable neurostimulator to use transvenous VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 sensing and stimulation technology. The applicant also stated that the remede¯® System consists of an implantable pulse generator, a transvenous lead to stimulate the phrenic nerve and a transvenous sensing lead to sense respiration via transthoracic impedance. Lastly, the applicant stated that the device stimulates a nerve located in the chest (phrenic nerve) that is responsible for sending signals to the diaphragm to stimulate breathing to restore normal sleep and respiration in patients with moderate to severe central sleep apnea (CSA). With respect to the newness criterion at § 419.66(b)(1), the applicant received a Category B Investigational Device Exemption (IDE) from FDA on April 18, 2013. Subsequently, the applicant received approval of its premarket approval (PMA) application from FDA on October 6, 2017. The application for a new device category for transitional pass-through payment status for the remede¯® System was received on May 31, 2017, which is within 3 years of the date of the initial FDA approval or clearance. We invited public comments on whether the remede¯® System meets the newness criterion. Comment: The manufacturer believed that that the remede¯® System meets the newness criterion. Response: We appreciate the commenter’s input. After consideration of the public comments we received, we believe that the remede¯® System meets the newness criterion. With respect to the eligibility criterion at § 419.66(b)(3), according to the applicant, the remede¯® System is integral to the service provided, is used for one patient only, comes in contact with human skin, and is applied in or on a wound or other skin lesion. The applicant also claimed the remede¯® System meets the device eligibility requirements of § 419.66(b)(4) because it is not an instrument, apparatus, implement, or item for which depreciation and financing expenses are recovered, and it is not a supply or material furnished incident to a service. The criteria for establishing new device categories are specified at § 419.66(c). The first criterion, at § 419.66(c)(1), provides that CMS determines that a device to be included in the category is not appropriately described by any of the existing categories or by any category previously in effect, and was not being paid for as an outpatient service as of December 31, 1996. We have not identified an existing pass-through payment category that describes the remede¯® System. The applicant proposed a category PO 00000 Frm 00120 Fmt 4701 Sfmt 4700 descriptor for the remede¯® System of ‘‘generator, neurostimulator (implantable), non-rechargeable, with transvenous sensing and stimulation.’’ We invited public comments on this issue. Comment: The manufacturer of the device indicated that there is no an existing pass-through payment category that describes the remede¯® System. Response: We appreciate the manufacturer’s input. After consideration of the public comments we received, we believe that the remede¯® System meets the eligibility criterion. The second criterion for establishing a device category, at § 419.66(c)(2), provides that CMS determines that a device to be included in the category has demonstrated that it will substantially improve the diagnosis or treatment of an illness or injury or improve the functioning of a malformed body part compared to the benefits of a device or devices in a previously established category or other available treatment. With respect to this criterion, the applicant submitted several journal articles that discussed the health effects of central sleep apnea (CSA) which include fatigue, decreased mental acuity, myocardial ischemia, and dysrhythmias. The applicant stated that patients with CSA may suffer from poor clinical outcomes, including myocardial infarction and congestive heart failure.20 The applicant claims that the remede¯® System has been found to significantly improve apnea-hypopnea index (AHI), which is an index used to indicate the severity of sleep apnea. AHI is represented by the number of apnea and hypopnea events per hour of sleep and was used as the primary effectiveness endpoint in the remede¯® System pivotal trial. The applicant noted that the remede¯® System was shown to improve AHI in small, selfcontrolled studies as well as in larger trials. The applicant reported that in the pivotal study, a large, multicenter, randomized controlled trial of CSA patients, intention-to-treat analysis found that 51 percent (35/68) of CSA patients using the remede¯® System had greater than 50 percent reduction of apnea-hypopnea index (AHI) from baseline at 6 months compared to 11 percent (8/73) of the control group (p<0.0001). Per-protocol analysis found that 60 percent (35/58) of remede¯® System patients had a greater than 50 20 Costanzo, M.R., et al., Mechanisms and Clinical Consequences of Untreated Central Sleep Apnea in Heart Failure. Journal of the American College of Cardiology, 2015. 65(1): p. 72–84. E:\FR\FM\21NOR2.SGM 21NOR2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations khammond on DSK30JT082PROD with RULES2 percent reduction of AHI and in 74 percent (26/35) of these patients AHI dropped to <20.21 According to the applicant, an exploratory post-hoc analysis of patients with CSA and congestive heart failure (CHF) in the Pivotal trial found that, at 6 months, the remede¯® System group had a greater percentage of patients with >=50 percent reduction in AHI compared to control group (63 percent versus 4 percent, p< 0.001).22 The applicant noted that patient symptoms and quality of life were improved with the remede¯® System therapy. The mean Epworth Sleepiness Scale (ESS) score significantly decreased in remede¯® System patients, indicating less daytime sleepiness.23 Adverse events associated with remede¯® System insertion and therapy included lead dislodgement/dislocation, hematoma, migraine, atypical chest pain, pocket perforation, pocket infection, extra-respiratory stimulation, concomitant device interaction, and elevated transaminases.24 There were no patient deaths that were related to the device implantation or therapy. One concern regarding the remede¯® System is the potential for complications in patients with coexisting cardiac devices, such as pacemakers or ICDs, given that the remede¯® System device requires lead placement and generation of electric impulses. Another concern with the evidence of substantial clinical improvement is that there is limited long-term data on patients with remede¯® System implants. The pivotal trial included only 6 months of followup. Also, while the applicant reported a reduction in AHI in the treatment group, the applicant did not establish that that level of change was biologically meaningful in the population(s) being studied. The applicant did not conduct a power analysis to determine the necessary size of the study population and the necessary duration of the study to detect both early and late events. In addition, patients in the pivotal study were not characterized by the use 21 Costanzo, M.R., et al. (2016). Transvenous neurostimulation for central sleep apnoea: a randomised controlled trial. The Lancet, 388(10048): p. 974–982. 22 Goldberg, L.R., et al. (2017). In Heart Failure Patients with CSA, Stimulation of the Phrenic Nerve Improves Sleep and Quality of Life. Journal of Cardiac Failure, 23(8): p. S15. 23 Costanzo, M.R., et al. (2016). Transvenous neurostimulation for central sleep apnoea: a randomised controlled trial. The Lancet, 388(10048): p. 974–982. 24 Costanzo, M.R., et al. (2016). Transvenous neurostimulation for central sleep apnoea: a randomised controlled trial. The Lancet, 388(10048): p. 974–982. VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 of cardiac devices. Cardiac resynchronization therapy (CRT), in particular, is known to improve chronic sleep apnea in addition to its primary effects on heart failure, and central apnea is a marker of the severity of the congestive heart failure. The applicant did not conduct subset analyses to assess the impact of cardiac resynchronization therapy. Lastly, while evaluation of AHI and quality of life metrics show improvement with the remede¯® System, the translation of those effects to mortality benefit is yet to be determined. Further studies of the remede¯® System are likely needed to determine long-term effects of the device, and as well as its efficacy compared to existing treatments of CPAP or medications. Based on the evidence submitted with the application, we had insufficient evidence that the remede¯® System provides a substantial clinical improvement over other similar products and invited public comments on whether the remede¯® System meets the substantial clinical improvement criterion. Comment: The manufacturer of the remede¯® System believed that this device meets the substantial clinical improvement criterion and provided additional data to support this assertion. The manufacturer noted that the primary endpoint of the pivotal study was a reduction of at least 50 percent in the apnea-hyponea index that is used to classify apnea severity and has been used as a common endpoint in predicate studies testing apnea therapy in sleep literature. The manufacturer further indicated that the remede¯® System significantly improves secondary endpoints. Patients had improved oxygenation, reduced hypoxia, and 79 percent of treatment group subjects reported improved quality of life as assessed through the Patient Global Assessment. The manufacturer asserted that the study cited was the first randomized study in central sleep apnea to demonstrate improvements in REM sleep and arousals. Further, the manufacturer noted that the treatment group experienced a 3.7 percentage point improvement in the Epworth sleepiness scale, meaning these patients were less sleepy than the control group. The manufacturer indicated, in response to CMS’ questions, that its clinical trials were not designed to establish a clinical improvement in mortality from this device. However, the manufacturer asserted that post-trial analysis indicated some improvement in left ventricular ejection fraction, which is associated with reduced mortality, and PO 00000 Frm 00121 Fmt 4701 Sfmt 4700 58937 increased time to first hospitalization for New York Heart Association heart failure patients with reduced ejection fraction. The manufacturer also indicated that reductions in the Apnea Hypopnea Index for trial participants that received the remede¯® System was now greater at 12 months than it was at 6 months. In response to CMS’ question regarding why an untreated control group was used in the pivotal trial, as opposed to a direct comparison with CPAP or other treatments, the manufacturer presented several reasons, such as considerable controversy about CPAP in CSA patients with heart failure due to CPAP patients with an ejection fraction less than 40 percent having higher mortality, and a dearth of prospective, randomized clinical data on the safety and efficacy of using CPAP, ASV, or medications to treat patients with non-heart failure CSA. Regarding CMS’ question of why no power analysis was performed to determine the necessary size of the study population and the necessary duration of the study to detect both early and late events, the manufacturer noted that it worked directly with clinical experts and consulted with the FDA in designing the clinical trial, which the manufacturer maintains was effective and well-rounded. The manufacturer noted that the rationale was that the remede¯® System would be evaluated on a continuum of efficacy versus safety, but noted that had they determined to power the study for a primary safety endpoint based on the threshold of other implantable cardiac devices, the pivotal trial would have been adequately powered based on the study design (132 patients needed versus 151 enrolled). In response to CMS’ question regarding potential complications in patients with coexisting cardiac devices, the manufacturer noted that it was understood that many CSA patients would likely have other cardiac devices already implanted and that this led to the design of both implant and testing procedures that accommodated concomitant devices. The manufacturer noted that the remede¯® System is typically placed on the right side of the chest to leave room for patients to have a cardiac device, which are typically placed on the left side, and that, in the pivotal trial, implantation of the remede¯® System in patients with a concomitant device did not demonstrate any increased risk. Further, the manufacturer noted that key metrics of implant duration, use of contrast dye, and fluoroscopy time were similar between patients with and without a E:\FR\FM\21NOR2.SGM 21NOR2 khammond on DSK30JT082PROD with RULES2 58938 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations concomitant cardiac device. Regarding specific study results, the manufacturer noted that 42 percent (64 of 151) of patients in the pivotal trial had a concomitant device and 98 percent (63 of 64) of patients with a concomitant cardiac device were successfully implanted, as compared to 96 percent (81 of 84) of patients with no concomitant device. The manufacturer believed that there is no increased risk at the time of implant for patients with a coexisting cardiac device. With regard to safety post-procedure, the commenter noted there was no difference in related SAEs between the groups with and without a concomitant cardiac device. Regarding CMS’ question about whether the impact of cardiac resynchronization therapy (CRT) drove improvement for heart failure patient with a concomitant CRT device, the manufacturer noted limited literature available on this topic, but stated that the literature that does exist suggests that CRT may improve the apnea hypopnea index in some patients, which may be due to an improvement in ejection fraction. However, the manufacturer noted that all CRT patients in the remede¯® System pivotal trial had their CRT devices for a minimum of nine months and that despite having CRT for a significant duration, still had severe CSA at baseline. Accordingly, the manufacturer believed that it is unlikely that significant CSA improvements were based on CRT rather than the remede¯® System. The manufacturer noted that statistically significant subgroup analysis on CRT was difficult, but believed that the CRT subgroup did not lead to the overall results on the primary endpoint because the CRT subgroup ‘‘underperformed’’ relative to the non-CRT subgroup. Finally, with respect to CMS’ question regarding whether the clinical results and patient response were durable and sustainable over time, the manufacturer asserted that it continues to collect effectiveness data beyond the 6-month endpoints of the pivotal IDE trial and that 12-month follow-up results on the pivotal IDE trial were recently published, demonstrating a trend towards increasing benefit for the treatment group at 12 months. Specifically, the commenter stated that, at 12 months, 91 percent of patients saw a reduction of AHI and with 67 percent achieving a 50 percent or greater reduction in AHI (compared to 60 percent at 6 months). Several commenters, individual physicians who have treated CSA patients with the remede¯® System, stated that, for these patients, traditional VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 types of positive pressure ventilation did not work and the remede¯® System is the only treatment available. Response: We appreciate the commenters’ input. After reviewing the additional information provided during the public comment period, we agree that the remede¯® System has been shown to improve patients symptoms of central sleep apnea, improve quality of life, requires minimal patient compliance compared to other treatments, and has a low adverse event profile. However, with regard to our questions about impacts on mortality, the applicant did note that its studies were not powered to demonstrate a mortality benefit. Commenters have adequately addressed the clinical concerns that we outlined in the proposed rule with additional evidence, longer follow-up from the pivotal IDE trial, the interplay of the remede¯® System and a concomitant cardiac device, and information about power calculations and other data summarized above. Further, we believe that the remede¯® System offers a treatment option for a patient population unresponsive to, or ineligible for, treatment involving currently available options. That is, those patients who have been diagnosed with moderate to severe CSA have no other available treatment options than the remede¯® System. Accordingly, we have determined that the remede¯® System has demonstrated substantial clinical improvement relative to existing treatment options for patients diagnosed with moderate to severe CSA. The third criterion for establishing a device category, at § 419.66(c)(3), requires us to determine that the cost of the device is not insignificant, as described in § 419.66(d). Section 419.66(d) includes three cost significance criteria that must each be met. The applicant provided the following information in support of the cost significance requirements. The applicant stated that the remede¯® System would be reported with CPT code 0424T. CPT code 0424T is assigned to APC 5464 (Level 4 Neurostimulator and Related Procedures). To meet the cost criterion for device pass-through payment, a device must pass all three tests of the cost criterion for at least one APC. For our calculations, we used APC 5464, which had a CY 2017 payment rate of $27,047.11 at the time the application was received. Beginning in CY 2017, we calculate the device offset amount at the HCPCS/CPT code level instead of the APC level (81 FR 79657). CPT code 0424T had a device offset amount of $11,089 at the time the application was PO 00000 Frm 00122 Fmt 4701 Sfmt 4700 received. According to the applicant, the cost of the remede¯® System was $34,500. Section 419.66(d)(1), the first cost significance requirement, provides that the estimated average reasonable cost of devices in the category must exceed 25 percent of the applicable APC payment amount for the service related to the category of devices. The estimated average reasonable cost of $34,500 for the remede¯® System exceeds 127 percent of the applicable APC payment amount for the service related to the category of devices of $27,047.11 ($34,500/$27,047.11 × 100 = 127.5 percent). Therefore, we believe the remede¯® System meets the first cost significance test. The second cost significance test, at § 419.66(d)(2), provides that the estimated average reasonable cost of the devices in the category must exceed the cost of the device-related portion of the APC payment amount for the related service by at least 25 percent, which means that the device cost needs to be at least 125 percent of the offset amount (the device-related portion of the APC found on the offset list). The estimated average reasonable cost of $34,500 for the remede¯® System exceeds the cost of the device-related portion of the proposed APC payment amount for the related service of $11,089 by 311 percent ($34,500¥$11,089) × 100 = 311 percent). Therefore, we believe that the remede¯® System meets the second cost significance test. The third cost significance test, at § 419.66(d)(3), requires that the difference between the estimated average reasonable cost of the devices in the category and the portion of the APC payment amount for the device must exceed 10 percent of the APC payment amount for the related service. The difference between the estimated average reasonable cost of $34,500 for the remede¯® System and the portion of the proposed APC payment amount for the device of $11,089 exceeds the APC payment amount for the related service of $27,047.11 by 87 percent (($34,500/ 11,089)/$27,047.11 × 100 = 86.6 percent). Therefore, we believe that the remede¯® System meets the third cost significance test. We invited public comments on whether the remede¯® System meets the device pass-through payment criteria discussed in this section, including the cost criteria for device pass-through payment. Comment: The manufacturer of the remede¯® System believed that the remede¯® System meets the cost criterion for device pass-through payment status. E:\FR\FM\21NOR2.SGM 21NOR2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations khammond on DSK30JT082PROD with RULES2 Response: We appreciate the manufacturer’s input. After consideration of the public comments we received, we are approving the remede¯® System for device pass-through payment status for CY 2019. (6) Restrata® Wound Matrix Acera Surgical, Inc. submitted an application for a new device category for transitional pass-through payment status for Restrata® Wound Matrix. Restrata® Wound Matrix is a sterile, single-use product intended for use in local management of wounds. According to the applicant, Restrata® Wound Matrix is a soft, white, conformable, nonfriable, absorbable matrix that works as a wound care management product by acting as a protective covering for wound defects, providing a moist environment for the body’s natural healing process to occur. Restrata® Wound Matrix is made from synthetic biocompatible materials and was designed with a nanoscale nonwoven fibrous structure with high porosity, similar to native extracellular matrix. Restrata® Wound Matrix allows for cellular infiltration, new tissue formation, neovascularization, and wound healing before completely degrading via hydrolysis. The product permits the ingress of cells and soft tissue formation in the defect space/ wound bed. Restrata® Wound Matrix can be used to manage wounds, including: Partial and full-thickness wounds, pressure sores/ulcers, venous ulcers, diabetic ulcers, chronic vascular ulcers, tunneled/undermined wounds, surgical wounds (for example, donor site/grafts, post-laser surgery, post-Mohs surgery, podiatric wounds, wound dehiscence), trauma wounds (for example, abrasions, lacerations, partial thickness burns, skin tears), and draining wounds. With respect to the eligibility criterion at § 419.66(b)(3), according to the applicant, Restrata® Wound Matrix is a product that is integral to the service provided, is used for one patient only, comes in contact with human skin, and is surgically inserted into the patient. The description of Restrata® Wound Matrix shows the product meets the device eligibility requirements of § 419.66(b)(4) because Restrata® Wound Matrix is not an instrument, apparatus, implement, or item for which depreciation and financing expenses are recovered, and it is not a supply or material. We invited public comment on whether Restrata® Wound Matrix meets the eligibility criteria. We did not receive any public comments on whether Restrata® Wound VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 Matrix meets the eligibility criteria. However, after the CY 2019 OPPS/ASC proposed rule was released, CMS determined that Restrata® Wound Matrix is an alginate dressing described with the HCPCS code series A6196 through A6198 (Alginate or other fiber gelling dressing, wound cover, sterile). Alginate dressings are not skin substitute products and are considered to be a supply. According to the eligibility criterion, a supply or material is not eligible to receive device passthrough payment. Based on this determination, we were required to reassess our initial view on whether or not Restrata® Wound Matrix meets the eligibility criterion for device passthrough payment status. After consideration of all of the information we have received, we have determined that Restrata® Wound Matrix is an alginate dressing and is a supply, and the product does not meet the eligibility criterion for device passthrough payment status. Because we have determined that Restrata® Wound Matrix does not meet the basic eligibility criterion for transitional passthrough payment status, we have not evaluated this product to determine whether it meets the other criteria required for transitional pass-through payment for devices; that is, the newness criterion, the substantial clinical improvement criterion, and the cost criterion. After consideration of the public comments we received, we are not approving device pass-through payment status for Restrata® Wound Matrix for CY 2019. (7) SpaceOAR® System Augmenix, Inc. submitted an application for a new device category for transitional pass-through payment status for the SpaceOAR® System. According to the applicant, the SpaceOAR® System is a polyethylene glycol hydrogel spacer that temporarily positions the anterior rectal wall away from the prostate to reduce the radiation delivered to the anterior rectum during prostate cancer radiotherapy treatment. The applicant stated that the SpaceOAR® System reduces some of the side effects associated with radiotherapy, which are collectively known as ‘‘rectal toxicity’’ (diarrhea, rectal bleeding, painful defecation, and erectile dysfunction, among other conditions). The applicant stated that the SpaceOAR® is implanted several weeks before radiotherapy; the hydrogel maintains space between the prostate and rectum for the entire course of radiotherapy and is completely PO 00000 Frm 00123 Fmt 4701 Sfmt 4700 58939 absorbed by the patient’s body within 6 months. With respect to the newness criterion at § 419.66(b)(1), FDA granted a De Novo request classifying the SpaceOAR® System as a class II device under section 513(f)(2) of the Federal Food, Drug, and Cosmetic Act on April 1, 2015. We received the application for a new device category for transitional pass-through payment status for the SpaceOAR® System on June 1, 2017, which is within 3 years of the date of the initial FDA approval or clearance. We invited public comments on whether the SpaceOAR® System meets the newness criterion. Comment: The manufacturer of SpaceOAR® System believed this device meets the eligibility criteria for device pass-through payment, but did not specifically comment on the newness criterion. Response: We appreciate the manufacturer’s input. After consideration of the public comments we received, we believe that the SpaceOAR® System meets the newness criterion for device passthrough payment status. With respect to the eligibility criterion at § 419.66(b)(3), according to the applicant, the SpaceOAR® System is integral to the service provided, is used for one patient only, comes in contact with human skin, and is applied in or on a wound or other skin lesion. The applicant also claimed the SpaceOAR® System meets the device eligibility requirements of § 419.66(b)(4) because it is not an instrument, apparatus, implement, or item for which depreciation and financing expenses are recovered, and it is not a supply or material furnished incident to a service. The criteria for establishing new device categories are specified at § 419.66(c). The first criterion, at § 419.66(c)(1), provides that CMS determines that a device to be included in the category is not appropriately described by any of the existing categories or by any category previously in effect, and was not being paid for as an outpatient service as of December 31, 1996. We have not identified an existing pass-through payment category that describes the SpaceOAR® System. The applicant suggested a category descriptor for the SpaceOAR® System of ‘‘Absorbable perirectal spacer’’. We invited public comments on this issue. Comment: The manufacturer of the SpaceOAR® System believed that this device meets the eligibility criteria for device pass-through payment status, but did not specifically comment on whether a current pass-through payment E:\FR\FM\21NOR2.SGM 21NOR2 58940 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations khammond on DSK30JT082PROD with RULES2 category appropriately describes this device. Response: We appreciate the manufacturer’s input. After consideration of the public comments we received, we believe that there is no existing pass-through payment category that appropriately describes the SpaceOAR® System and that the SpaceOAR® System meets the eligibility criterion. The second criterion for establishing a device category, at § 419.66(c)(2), provides that CMS determines that a device to be included in the category has demonstrated that it will substantially improve the diagnosis or treatment of an illness or injury or improve the functioning of a malformed body part compared to the benefits of a device or devices in a previously established category or other available treatment. With respect to this criterion, the applicant submitted studies which discussed the techniques for using hydrogel spacers to limit radiation exposure to the rectum in prostate radiotherapy. In support of its assertion that SpaceOAR is a substantial clinical improvement, the applicant submitted several studies that examined the effect that the SpaceOAR® System had on outcomes such as rectal dose, radiation toxicity, and quality of life declines after image guided intensity modulated radiation therapy for prostate cancer. Articles by Mariados et al.25 and Hamstra et al.26 discussed the results of a single-blind phase III trial of image guided intensity modulated radiation therapy with 15 months and 3 years of follow-up, respectively. In the studies, a total of 222 men were randomized 2:1 to the spacer or control group and received 79.2 Gy in 1.8-Gy fractions to the prostate with or without the seminal vesicles. The results of this study 27 showed that after 3 years, compared with the control group, the participants who received the SpaceOAR® System injection had a statistically significant smaller volume of the rectum receiving a threshold radiation exposure, which was the primary effectiveness endpoint. The results also showed that in an 25 Mariados N, et al. (2015). Hydrogel Spacer Prospective Multicenter Randomized Controlled Pivotal Trial: Dosimetric and Clinical Effects of Perirectal Spacer Application in Men Undergoing Prostate Image Guided Intensity Modulated Radiation Therapy. Int J Radiat Oncol Biol Phys.92(5):971–977. Epub 2015 Apr 23. PMID: 26054865. 26 Hamstra DA, et al. (2017). Continued Benefit to Rectal Separation for Prostate Radiation Therapy: Final Results of a Phase III Trial. Int J Radiat Oncol Biol Phys. Apr 1;97(5):976–985. Epub 2016 Dec 23. PMID:28209443. 27 Ibid. VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 extended follow up period, the control group experienced larger declines in bowel and urinary quality of life compared to participants who received the SpaceOAR® System treatment. Lastly, in an extended follow-up period, the probability of grade ≥1 rectal toxicity was decreased in the SpaceOAR® System arm (9 percent control group, 2 percent SpaceOAR® System group, p <.03) and no ≥ grade 2 rectal toxicity was observed in the SpaceOAR® System arm. However, the control arm had low rates of rectal toxicity in general. The results of this 3year follow-up of these participants showed that the differences identified in the 15-month follow-up study were maintained or increased.28 The applicant also included a secondary analysis of the phase III trial data which showed that participants who received lower radiation doses to the penile bulb, associated with the SpaceOAR® System injection, reported similar erectile function compared with the control group based on patientreported sexual quality of life.29 A 2017 retrospective cohort study by Pinkawa et al.30 evaluated quality of life changes up to 5 years after RT for prostate cancer with the SpaceOAR® System and showed that 5 years after radiation therapy, no patients who received the SpaceOAR® System reported moderate/ big problems with bowel urgency, losing control of stools, or with bowel habits overall. However, there were no statistically significant differences in mean score changes for urinary, bowel, or sexual bother between the percentage of participants in the SpaceOAR® System and control groups at either 11⁄2 years or 5 years postradiation therapy. CMS had concerns regarding the phase III trial include inclusion of only low to moderate risk prostate cancer in the study population and failing to use a clinical outcome as a primary endpoint, although the purpose of the spacer is to reduce the side effects of undesired radiation to the rectum including bleeding, diarrhea, fistula, pain, and/or stricture. Notwithstanding acknowledgement that rectal complications may be reduced using biodegradable biomaterials placed to increase the distance between the rectum and the prostate, it is not clear 28 Ibid. 29 Hamstra, DA et al. (2018) Sexual quality of life following prostate intensity modulated radiation therapy (IMRT) with a rectal/prostate spacer: Secondary analysis of a phase 3 trial. Practical Radiation Oncology, 8, e7–e15. 30 Pinkawa, M. et al. (2017). Quality of Life after Radiation Therapy for Prostate Cancer With a Hydrogel Spacer: Five Year Results. Int J Radiat Oncol Biol Phys., Vol. 99, No. 2, pp. 374e377. PO 00000 Frm 00124 Fmt 4701 Sfmt 4700 that the SpaceOAR® System is superior to existing alternative biodegradable biomaterials currently utilized for spacing in the context of prostate radiotherapy. Based on the evidence submitted with the application, we have insufficient evidence that the SpaceOAR® System provides a substantial clinical improvement over other similar products. We invited public comments on whether the SpaceOAR® System meets the substantial clinical improvement criterion. Comment: The manufacturer of the SpaceOAR® System identified several points which supported this device meeting the substantial clinical improvement criterion. In response to the statement in the proposed rule that the control arm of the phase III trial had low rates of rectal toxicity in general, the manufacturer noted that the low rates of rectal toxicity in the control arm of the study were due to: (1) The radiation plans in both the treatment and control groups were evaluated and approved by an independent core laboratory for compliance to protocol guidelines, which led to low toxicity in the control group relative to standard practice; and (2) all study dose plans used CT and MRI image fusion to improve plan accuracy, while typical plans only use CT imaging. The manufacturer noted that patients in the SpaceOAR® System group still had statistically significant reductions in rectal toxicity and improvements in quality of life in comparison to the control group. The manufacturer disagreed with a statement in the proposed rule where CMS indicated that the SpaceOAR® System patients ‘‘reported similar erectile function compared with the control group based on patient-reported sexual quality of life.’’ The commenter noted that the patient reported quality of life analysis of baseline potent men at three years found that men treated with the SpaceOAR® System had improved scores on ‘‘erections sufficient for intercourse’’ as well as better scores on seven of the 13 items regarding sexual function.31 In response to the statement in the proposed rule that the submitted studies included only low to moderate risk prostate cancer in the study population and failed to use a clinical outcome as a primary endpoint, the manufacturer noted that the phase III trial design specifically selected a low and 31 Hamstra, DA et al. (2018) Sexual quality of life following prostate intensity modulated radiation therapy (IMRT) with a rectal/prostate spacer: Secondary analysis of a phase 3 trial. Practical Radiation Oncology, 8, e7–e15. E:\FR\FM\21NOR2.SGM 21NOR2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations khammond on DSK30JT082PROD with RULES2 intermediate risk prostate cancer population to better allow for a safety determination. The manufacturer also noted that the significant reductions in late rectal toxicity and improvements in quality of life at 3 years demonstrate that the clinical benefits of this device are better than anticipated when the study was originally developed. In response to the statement in the proposed rule that it was unclear that the SpaceOAR® System was superior to existing alternative spacers used for prostate radiotherapy, the manufacturer noted that the SpaceOAR® System is the only prostate-rectum spacer authorized for marketing by the FDA for use in prostate radiotherapy. The manufacturer indicated that the closest comparable product is the endorectal balloon, and that a study comparing the rectalspacing capabilities of these two products during prostate cancer stereotactic body radiation therapy found significantly less rectal radiation dose in the patients who received the SpaceOAR System®.32 The manufacturer noted a study of these two products during proton radiotherapy found that, with the SpaceOAR® System, a larger area around the prostate could be radiated while still significantly reducing the rectum radiation dose.33 The manufacturer indicated that several studies found that prostate stability was comparable using these two products.34 35 36 The manufacturer also noted that reductions in placement error and patient comfort favors the SpaceOAR® System compared to endorectal balloons.37 The manufacturer asserted that the combined impacts of these results make the SpaceOAR® System a substantial 32 Jones, RT et al. Oosimetric comparison of rectal-sparingcapabilities of rectal balloon vs inje ctab:e spacer gelin stereotactic body radiation therapy forprostate cancer: lessons learned from prospective trials. Medical Dosimetry, Volume 42, Issue 4, winter 2017, Pages 341–347. 33 Fagundes MA et al, Evolving Rectal Sparing In Flducfal • BasedImage Guided Proton Therapy for Localized Prostate Cancer. International Journal of Radiation Oncology • Biology • Physics, Vol. 96, Issue 2, E279, 2016. 34 Hedrick SG et al. A comparison between hydrogel spacer and endorectal balloon: An analysis of lntrafraction prostate motion during proton therapy. J. Appl. Clln. Med. Phys., Vol. 18, pp. 106–112, 2017. 35 Su Z et al. Hvdrogel Spacer Or Gas Release Rectal Balloon, a Comparative Study of Prostate lntrafraction Motion in Proton Therapy. Med Phys. 201S;45(6):el 4l. 36 Rendall R. Comparison of hydrogel spacer and rectal immobilization on Intra-fraction motion efficiency using Image guidance prostate proton therapy. PTCOG 55,PS02, May 27, 2016. 37 EI-Bassiounl et al. Target motion variability and on-line positioning accuracy during external beam radiation therapy of prostate cancer with an endorectal balloon device. Strahlenther Onkol. 2006 Sep;1S2(9):53l·6. VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 clinical improvement over endorectal balloons. Several commenters, representing various oncological and urologic specialty societies, believed that the SpaceOAR® System meets the substantial clinical improvement criterion. These commenters noted that there were no other alternative biodegradable biomaterials with FDA marketing authorization currently utilized for spacing in the context of prostate radiotherapy and that this device provided physicians with an option to help ensure patients are provided with the best clinical outcomes with the fewest adverse effects. Response: We appreciate the manufacturer’s and the commenters’ input. We reviewed these comments and the associated literature on this topic and found that the application did not support that the SpaceOAR® System demonstrated a substantial clinical improvement as a prostate-rectum spacer for men receiving prostate radiotherapy treatment. While the studies provided by the applicant do indicate that the device provides a dose reduction at the rectum during IMRT for prostate cancer, we found the clinical results of these studies were equivocal and did not provide definitive evidence of substantial clinical improvement of radiation toxicity and quality of life scores after radiation therapy. In response to our concern that the control arm of the study had very low rates of rectal toxicity (the manufacturers quoted rates of late rectal toxicity of between 14 and 25 percent for studies without the use of the SpaceOAR® System), the commenter responded that the low rates of rectal toxicity in the control arm of the study were due to (1) the radiation plans in both the treatment group and the control group were evaluated and approved by an independent core laboratory for compliance with protocol guidelines, which led to low toxicity in the control group relative to standard practice, and (2) all study dose plans used CT and MRI image fusion to improve plan accuracy, while typical plans only use CT imaging. The commenter further noted that, despite low rates of rectal toxicity in the control arm of the phase III trial, patients in the SpaceOAR® System group still had statistically significant reductions in rectal toxicity and improvements in quality of life in comparison to the control group. We are still concerned that the low rates of rectal toxicity demonstrated in the control group may not support claims of substantial clinical improvement of the SpaceOAR® System. For example, the PO 00000 Frm 00125 Fmt 4701 Sfmt 4700 58941 rates of late grade one or higher rectal toxicity in the control population in the clinical trials submitted by the applicant were 7 percent 38 and 9.2 percent,39 respectively. The rates of late grade one or higher rectal toxicity in the SpaceOAR® System groups in the clinical trials submitted by the applicant were 2 percent in both studies.40 41 We note that image guided radiation therapy has drastically improved radiation dose effects, and conventional radiotherapy is well tolerated by the vast majority of patients.42 It remains unclear if further reduction in radiation dose effects with the SpaceOAR® System translates to a substantial clinical improvement that is maintained over time when compared to patients who did not receive the SpaceOAR® System. The applicant’s explanation that all study dose plans used CT and MRI image fusion to improve plan accuracy, while typical plans only use CT imaging is not supported in the literature, which states that IMRT is considered the standard of care in RT treatment centers; in both the United States and Europe, it has largely replaced older forms of 3D–CRT.43 44 The response that the radiation plans in both the treatment group and the control group were evaluated and approved by an independent core laboratory for compliance to protocol guidelines, which led to low toxicity in the control group relative to standard practice, further calls into question the direct role of the SpaceOAR® System in reducing toxicity versus more precise planning 38 Mariados N, et al. (2015). Hydrogel Spacer Prospective Multicenter Randomized Controlled Pivotal Trial: Dosimetric and Clinical Effects of Perirectal Spacer Application in Men Undergoing Prostate Image Guided Intensity Modulated Radiation Therapy. Int J Radiat Oncol Biol Phys. 92(5):971–977. Epub 2015 Apr 23. PMID: 26054865. 39 Hamstra DA, et al. (2017). Continued Benefit to Rectal Separation for Prostate Radiation Therapy: Final Results of a Phase III Trial. Int J Radiat Oncol Biol Phys. Apr 1;97(5):976–985. Epub 2016 Dec 23. PMID:28209443. 40 Ibid. 41 Ibid. 42 Uhl et al. (2014). Absorbable hydrogel spacer use in men undergoing prostate cancer radiotherapy: 12 month toxicity and proctoscopy results of a prospective multicenter phase II trial. Radiation Oncology, 9:96. 43 Sheets NC, Goldin GH, Meyer AM, Wu Y, Chang Y, Stu¨rmer T, Holmes JA, Reeve BB, Godley PA, Carpenter WR, Chen RC. (2012). Intensitymodulated radiation therapy, proton therapy, or conformal radiation therapy and morbidity and disease control in localized prostate cancer. JAMA.; 307(15):1611. 44 Bauman G, Rumble RB, Chen J, Loblaw A, Warde P, Members of the IMRT Indications Expert Panel.(2012). Intensity-modulated radiotherapy in the treatment of prostate cancer. Clin Oncol (R Coll Radiol), Sep;24(7):461–73. Epub 2012 Jun 4. E:\FR\FM\21NOR2.SGM 21NOR2 58942 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations khammond on DSK30JT082PROD with RULES2 protocols and the importance of adhering to guidance protocols. As discussed further below, we continue to have concerns regarding the applicant’s claims that the statistically significant reduction in late rectal toxicity as well as the improvements in QOL scores lend to substantial clinical improvement, despite the relatively low rates of rectal toxicity in the control group. We note that the data showing reduction in rectal toxicity and improvements in quality are from studies that were not designed with primary clinical outcomes to show superiority, but rather were designed primarily to evaluate the threshold of radiation exposure to the rectum and adverse events related to the procedure. Consequently, the studied clinical outcomes have many differences that did not meet statistical significance or were not sustained over time. In the pivotal trial,45 no differences in acute rectal or urinary toxicity from the time of the procedure through the 3month visit were observed between the SpaceOAR® System group and the control group. In this study,46 there was a statistically significant difference noted between the SpaceOAR® System group and the control group in late rectal toxicity (3 to 15 months after the procedure). In the SpaceOAR® System group, 2 percent of the patients (n=3) experienced late rectal toxicity, while 7 percent of patients in the control group (n=5) experienced late rectal toxicity. There was one incidence of the more clinically serious (grade 3) late rectal toxicity reported in the control group and no incidence of grade 4 rectal toxicity in either group. Even at 3 years after the procedure, the control arm had very low rates of rectal toxicity. The 3-year incidence of grade ≥1 rectal toxicity was 9.2 percent (approximately 4 patients) in the control group versus 2.0 percent (approximately 2 patients) in the SpaceOAR® System group. The cumulative rate of grade ≥2 rectal bowel toxicity was 6 percent at 3 years in the control arm, with no cases of grade ≥2 rectal toxicity in the SpaceOAR® System group.47 With regard to corresponding improvements in quality of life, the 45 Mariados N, et al. (2015). Hydrogel Spacer Prospective Multicenter Randomized Controlled Pivotal Trial: Dosimetric and Clinical Effects of Perirectal Spacer Application in Men Undergoing Prostate Image Guided Intensity Modulated Radiation Therapy. Int J Radiat Oncol Biol Phys. 92(5):971–977. Epub 2015 Apr 23. PMID: 26054865. 46 Ibid. 47 Hamstra DA, et al. (2017). Continued Benefit to Rectal Separation for Prostate Radiation Therapy: Final Results of a Phase III Trial. Int J Radiat Oncol Biol Phys. Apr 1;97(5):976–985. Epub 2016 Dec 23. PMID:28209443. VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 pivotal trial,48 at 3 months, showed there was no statistically significant difference between the SpaceOAR® System group and the control group in mean changes in bowel and urinary quality of life domains. Although, at 6, 12, and 15 months, a lower percentage of patients in the SpaceOAR® System group reported declines in bowel quality of life compared to those in the control group, at 15 months, 11.6 percent and 21.4 percent of the SpaceOAR® System patients and the control group patients, respectively, experienced 10-point declines in bowel quality of life. However, this difference was not statistically significant. In terms of urinary quality of life at 6 months, a higher percentage of patients in the control group (22.2 percent) had 10point urinary declines in comparison to the the SpaceOAR® System group (8.8 percent). However, again the durability of these improvements disappeared over time because there was no difference between the SpaceOAR® System group and the control group in urinary quality of life decline at 12 and 15 months follow-ups.49 The commenter claimed that when followed up at 3 years, patients in the phase III trial receiving the SpaceOAR® System prior to their prostate cancer radiotherapy demonstrated significant rectal (bowel), urinary, and sexual benefit. However, we found the data to be inconsistent and unreliable to support this claim. Specifically, in the study including 3 years of follow-up data,50 quality of life was examined using the Expanded Prostate Cancer Index Composite (EPIC) questionnaire, a comprehensive instrument designed to evaluate patient function and bother after prostate cancer treatment. For the average bowel summary score, both the SpaceOAR® System group and the control group had similar acute declines in bowel quality of life between enrollment and 3 months after treatment. Also, at 3 months after treatment, there were no patients in the control group that reported acute bowel pain while 6.8 percent of the SpaceOAR® System patients reported acute bowel pain. In this study, the proportion of patients with measurable changes in bowel quality of life meeting the minimally important difference (MID) threshold (5 points) or twice that threshold (10 points) was evaluated. 48 Ibid. 49 Ibid. 50 Hamstra DA, et al. (2017). Continued Benefit to Rectal Separation for Prostate Radiation Therapy: Final Results of a Phase III Trial. Int J Radiat Oncol Biol Phys. Apr 1;97(5):976–985. Epub 2016 Dec 23. PMID:28209443. PO 00000 Frm 00126 Fmt 4701 Sfmt 4700 According to the authors, these thresholds give an idea of when patientreported symptoms are likely to be clinically meaningful to prostate cancer patients, with a 10-point decline indicating a more serious clinical effect. From 6 months through 3 years, more men in the control group had a MID in bowel quality of life meeting the threshold of 5 points, but no difference was found for a 10-point decline. At 3 years, the SpaceOAR® System group patients were less likely than the control group patients to have a detectable decline in bowel quality of life for both MID thresholds (5-point: 41 percent (control) versus 14 percent (the SpaceOAR® System; 10-point: 21 percent (control) versus 5 percent (the SpaceOAR® System).51 However, more than 30 percent of the patients in both the SpaceOAR® System group (n=55) and the control group (n=27) were lost by the 3-year follow-up and the followup data were taken from volunteer centers that decided to continue in the study. It is unclear if the differences observed at 3 years are due to the large number of respondents who did not participate at year 3, resulting in a smaller sample size and more unreliable data. For example, regarding urinary quality of life, when averaged over the entire follow-up duration, no significant difference was found in the mean urinary quality of life between the two groups. However, at the 3-year point, a statistically significant difference was found in urinary quality of life favoring the SpaceOAR® System group compared with the control group. The researchers in this study also assessed the percent of patients with moderate or big problems in quality of life. The researchers found that, at 3 years, only one item showed a statistically significant difference between the treatment groups (moderate to big bother for urinary frequency: The control group of 18 percent versus the SpaceOAR® System group of 5 percent; P <.05). At 3 years after treatment, 2.2 percent of the men in the SpaceOAR® System group evaluated their overall bowel function as a big or moderate bother. This compares to 4.4 percent in the control group, which was not a statistically significant difference. None of the components of rectal bother were statistically significantly better in the men who received the SpaceOAR® System. In contrast, regarding the question of bowel pain, none of the control group patients reported a moderate or big bother after 3 years, while 1.1 percent of the SpaceOAR® System group patients reported that 51 Ibid. E:\FR\FM\21NOR2.SGM 21NOR2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations bowel pain was a moderate or big bother.52 The study by Pinkawa et al.53 looking at 11⁄2 and 5 year results comparing quality of life of patients pretreated with hydrogel and controls further demonstrates inconsistency in looking at substantial improvements with the SpaceOAR® System. In this study percentages of big problems with bowel urgency, control of stools and bowel habitus overall favored SpaceOAR at 11⁄2 years. However, only differences in percentage of problems of bowel urgency remained after the 5-year follow-up. Also, no statistically significant difference was shown between the SpaceOAR® System group and the control group in comparing mean bowl bother scores at 11⁄2 years and 5 years after radiation therapy. The manufacturer stated that CMS incorrectly stated in the proposed rule that the SpaceOAR® System patients reported similar erectile function compared with the control group based on patient-reported sexual quality of life. The manufacturer is correct; in a study by Hamstra et al.,54 the patientreported quality of life analysis of baseline potent men found that men in this group treated with the SpaceOAR® System had improved ‘‘erections sufficient for intercourse’’ as well as statistically significant higher scores on 7 of 13 items in the sexual domain in comparison to the control group at 3 years. However, at baseline, sexual functioning in the study was low; only 41 percent of patients had no sexual dysfunction at baseline (EPIC sexual quality of life scores >60, n=88). When comparing men with poor baseline sexual quality of life (EPIC score ≤60, n=125), there was no difference between the SpaceOAR® System group and the control group in function, bother, or sexual summary score at the 3-year follow up.55 We also note that the Pinkawa 56 study shows that more men with the SpaceOAR® System reported erections firm enough for intercourse to be statistically significant. However, again the same study reported the changes in sexual quality of life bother score were not statistically different khammond on DSK30JT082PROD with RULES2 52 Ibid. 53 Pinkawa, M. et al. (2017). Quality of Life after Radiation Therapy for Prostate Cancer With a Hydrogel Spacer: Five Year Results. Int J Radiat Oncol Biol Phys., Vol. 99, No. 2, pp. 374e377. 54 Hamstra, DA et al. (2018) Sexual quality of life following prostate intensity modulated radiation therapy (IMRT) with a rectal/prostate spacer: secondary analysis of a phase 3 trial. Practical Radiation Oncology, Vol. 8, e7–e15. 55 Ibid. 56 Pinkawa, M. et al. (2017). Quality of Life after Radiation Therapy for Prostate Cancer With a Hydrogel Spacer: Five Year Results. Int J Radiat Oncol Biol Phys., Vol. 99, No. 2, pp. 374e377. VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 between the two groups at 5 years. Again, along with the instability of the 3-year data stated above, the fact that the data are inconsistent and not supported by the long-term quality of life data, we are unable to substantiate substantial clinical improvement. We appreciate the comments received from the urological and the oncological community as well members of the public in support of this technology. The SpaceOAR® System device effectively displaces the anterior wall reducing the dose of radiation the rectum receives during radiation treatment for prostate cancer. However, after consideration of the public comments and the application materials we received, at this time we do not believe that the SpaceOAR® System meets the substantial clinical improvement criterion to receive device pass-through payment. The submitted studies were not designed to show primary clinical outcomes, and consequently the data on toxicity and quality of life improvement are inconsistent and fail to show enduring improvements. It is difficult to attribute the reductions in late rectal toxicity solely to the device, given improvements in radiation therapy and planning as well as the large number of nonresponders at 3 years postradiation and the 3-year follow-up data were being taken from volunteer centers that decided to continue in the study. We note that many favorable clinical outcomes were not statistically significant but trended in favor of the SpaceOAR® System group. We agree with many authors that seem to suggest that the greatest utility of the SpaceOAR® System will be its use in populations at greatest risk for radiation toxicity such as hypofractionated treatment or other dose intensifications. The third criterion for establishing a device category, at § 419.66(c)(3), requires us to determine that the cost of the device is not insignificant, as described in § 419.66(d). Section 419.66(d) includes three cost significance criteria that must each be met. The applicant provided the following information in support of the cost significance requirements. The applicant stated that the SpaceOAR® System would be reported with CPT code 0438T (which was deleted and replaced with CPT code 55874, effective January 1, 2018). CPT code 0438T was assigned to APC 5374 (Level 4 Urology and Related Services). To meet the cost criterion for device pass-through payment, a device must pass all three tests of the cost criterion for at least one APC. For our calculations, we used APC 5374, which had a CY 2017 payment PO 00000 Frm 00127 Fmt 4701 Sfmt 4700 58943 rate of $2,542.56 at the time the application was received. Beginning in CY 2017, we calculate the device offset amount at the HCPCS/CPT code level instead of the APC level (81 FR 79657). CPT code 0438T had a device offset amount of $587.07 at the time the application was received. According to the applicant, the cost of the SpaceOAR® System was $2,850. Section 419.66(d)(1), the first cost significance requirement, provides that the estimated average reasonable cost of devices in the category must exceed 25 percent of the applicable APC payment amount for the service related to the category of devices. The estimated average reasonable cost of $2,850 for the SpaceOAR® System exceeds 112 percent of the applicable APC payment amount for the service related to the category of devices of $2,542.56 ($2850/ $2,542.56 × 100 = 112 percent). Therefore, we believe the SpaceOAR® system meets the first cost significance test. The second cost significance test, at § 419.66(d)(2), provides that the estimated average reasonable cost of the devices in the category must exceed the cost of the device-related portion of the APC payment amount for the related service by at least 25 percent, which means that the device cost needs to be at least 125 percent of the offset amount (the device-related portion of the APC found on the offset list). The estimated average reasonable cost of $2,850 for the SpaceOAR® System exceeds the cost of the device-related portion of the APC payment amount for the related service of $587.07 by 485 percent ($2,850/ $587.07) × 100 = 485 percent). Therefore, we believe that the SpaceOAR® System meets the second cost significance test. The third cost significance test, at § 419.66(d)(3), requires that the difference between the estimated average reasonable cost of the devices in the category and the portion of the APC payment amount for the device must exceed 10 percent of the APC payment amount for the related service. The difference between the estimated average reasonable cost of $2,850 for the SpaceOAR® System and the portion of the APC payment amount for the device of $587.07 exceeds the APC payment amount for the related service of $2,542.56 by 89 percent (($2,850¥$587.07)/$2,542.56 × 100 = 89 percent). Therefore, we believe that the SpaceOAR® System meets the third cost significance test. We invited public comments on whether the SpaceOAR® System meets the device pass-through payment E:\FR\FM\21NOR2.SGM 21NOR2 58944 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations criteria discussed in this section, including the cost criteria. Comment: The manufacturer of the SpaceOAR® System believed this device meets the eligibility criteria for device pass-through payment status, but did not specifically comment on whether this device meets the cost criterion. Response: We appreciate the manufacturer’s input. After consideration of the public comments we received, we believe that SpaceOAR® System meets the cost criterion for device pass-through payment status. After consideration of the public comments we received, we believe that SpaceOAR® System does not qualify for device pass-through payment status because it does not meet the substantial clinical improvement criterion, although it may have clinical benefit for certain patients. As such, we are not approving the application for device pass-through payment status for the SpaceOAR® System for CY 2019. B. Device-Intensive Procedures khammond on DSK30JT082PROD with RULES2 1. Background Under the OPPS, prior to CY 2017, device-intensive status for procedures was determined at the APC level for APCs with a device offset percentage greater than 40 percent (79 FR 66795). Beginning in CY 2017, CMS began determining device-intensive status at the HCPCS code level. In assigning device-intensive status to an APC prior to CY 2017, the device costs of all the procedures within the APC were calculated and the geometric mean device offset of all of the procedures had to exceed 40 percent. Almost all of the procedures assigned to device-intensive APCs utilized devices, and the device costs for the associated HCPCS codes exceeded the 40-percent threshold. The no cost/full credit and partial credit device policy (79 FR 66872 through 66873) applies to device-intensive APCs and is discussed in detail in section IV.B.4. of this final rule with comment period. A related device policy was the requirement that certain procedures assigned to device-intensive APCs require the reporting of a device code on the claim (80 FR 70422). For further background information on the deviceintensive APC policy, we refer readers to the CY 2016 OPPS/ASC final rule with comment period (80 FR 70421 through 70426). a. HCPCS Code-Level Device-Intensive Determination As stated earlier, prior to CY 2017, the device-intensive methodology assigned device-intensive status to all procedures VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 requiring the implantation of a device that were assigned to an APC with a device offset greater than 40 percent and, beginning in CY 2015, that met the three criteria listed below. Historically, the device-intensive designation was at the APC level and applied to the applicable procedures within that APC. In the CY 2017 OPPS/ASC final rule with comment period (81 FR 79658), we changed our methodology to assign device-intensive status at the individual HCPCS code level rather than at the APC level. Under this policy, a procedure could be assigned deviceintensive status regardless of its APC assignment, and device-intensive APCs were no longer applied under the OPPS or the ASC payment system. We believe that a HCPCS code-level device offset is, in most cases, a better representation of a procedure’s device cost than an APC-wide average device offset based on the average device offset of all of the procedures assigned to an APC. Unlike a device offset calculated at the APC level, which is a weighted average offset for all devices used in all of the procedures assigned to an APC, a HCPCS code-level device offset is calculated using only claims for a single HCPCS code. We believe that this methodological change results in a more accurate representation of the cost attributable to implantation of a highcost device, which ensures consistent device-intensive designation of procedures with a significant device cost. Further, we believe a HCPCS codelevel device offset removes inappropriate device-intensive status for procedures without a significant device cost that are granted such status because of APC assignment. Under our existing policy, procedures that meet the criteria listed below in section IV.B.1.b. of this final rule with comment period are identified as device-intensive procedures and are subject to all the policies applicable to procedures assigned device-intensive status under our established methodology, including our policies on device edits and no cost/full credit and partial credit devices discussed in sections IV.B.3. and IV.B.4. of this final rule with comment period, respectively. b. Use of the Three Criteria To Designate Device-Intensive Procedures We clarified our established policy in the CY 2018 OPPS/ASC final rule with comment period (82 FR 52474), where we explained that device-intensive procedures require the implantation of a device and additionally are subject to the following criteria: • All procedures must involve implantable devices that would be PO 00000 Frm 00128 Fmt 4701 Sfmt 4700 reported if device insertion procedures were performed; • The required devices must be surgically inserted or implanted devices that remain in the patient’s body after the conclusion of the procedure (at least temporarily); and • The device offset amount must be significant, which is defined as exceeding 40 percent of the procedure’s mean cost. We changed our policy to apply these three criteria to determine whether procedures qualify as device-intensive in the CY 2015 OPPS/ASC final rule with comment period (79 FR 66926), where we stated that we would apply the no cost/full credit and partial credit device policy—which includes the three criteria listed above—to all deviceintensive procedures beginning in CY 2015. We reiterated this position in the CY 2016 OPPS/ASC final rule with comment period (80 FR 70424), where we explained that we were finalizing our proposal to continue using the three criteria established in the CY 2007 OPPS/ASC final rule with comment period for determining the APCs to which the CY 2016 device intensive policy will apply. Under the policies we adopted in CYs 2015, 2016, and 2017, all procedures that require the implantation of a device and meet the above criteria are assigned deviceintensive status, regardless of their APC placement. 2. Changes to the Device-Intensive Procedure Policy for CY 2019 and Subsequent Years As part of CMS’ effort to better capture costs for procedures with significant device costs, in the CY 2019 OPPS/ASC proposed rule (83 FR 37108), for CY 2019, we proposed to modify our criteria for device-intensive procedures. We have heard from stakeholders that the current criteria exclude some procedures that stakeholders believe should qualify as device-intensive procedures. Specifically, we were persuaded by stakeholder arguments that procedures requiring expensive surgically inserted or implanted devices that are not capital equipment should qualify as device-intensive procedures, regardless of whether the device remains in the patient’s body after the conclusion of the procedure. We agreed that a broader definition of deviceintensive procedures was warranted, and proposed two modifications to the criteria for CY 2019. First, we proposed to allow procedures that involve surgically inserted or implanted, singleuse devices that meet the device offset percentage threshold to qualify as device-intensive procedures, regardless E:\FR\FM\21NOR2.SGM 21NOR2 khammond on DSK30JT082PROD with RULES2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations of whether the device remains in the patient’s body after the conclusion of the procedure. We proposed this policy because we no longer believed that whether a device remains in the patient’s body should affect its designation as a device-intensive procedure, as such devices could, nonetheless, comprise a large portion of the cost of the applicable procedure. Second, we proposed to modify our criteria to lower the device offset percentage threshold from 40 percent to 30 percent, to allow a greater number of procedures to qualify as deviceintensive. We stated in the proposed rule that we believe allowing these additional procedures to qualify for device-intensive status will help ensure these procedures receive more appropriate payment in the ASC setting, which will help encourage the provision of these services in the ASC setting. In addition, we stated in the proposed rule that this proposed change would help to ensure that more procedures containing relatively high-cost devices are subject to the device edits, which leads to more correctly coded claims and greater accuracy in our claims data. Specifically, for CY 2019 and subsequent years, we proposed that device-intensive procedures would be subject to the following criteria: • All procedures must involve implantable devices assigned a CPT or HCPCS code; • The required devices (including single-use devices) must be surgically inserted or implanted; and • The device offset amount must be significant, which is defined as exceeding 30 percent of the procedure’s mean cost. In addition, to further align the device-intensive policy with the criteria used for device pass-through payment status, we proposed to specify, for CY 2019 and subsequent years, that for purposes of satisfying the deviceintensive criteria, a device-intensive procedure must involve a device that: • Has received FDA marketing authorization, has received an FDA investigational device exemption (IDE), and has been classified as a Category B device by the FDA in accordance with 42 CFR 405.203 through 405.207 and 405.211 through 405.215, or meets another appropriate FDA exemption from premarket review; • Is an integral part of the service furnished; • Is used for one patient only; • Comes in contact with human tissue; • Is surgically implanted or inserted (either permanently or temporarily); and • Is not any of the following: VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 (a) Equipment, an instrument, apparatus, implement, or item of this type for which depreciation and financing expenses are recovered as depreciable assets as defined in Chapter 1 of the Medicare Provider Reimbursement Manual (CMS Pub. 15–1); or (b) A material or supply furnished incident to a service (for example, a suture, customized surgical kit, scalpel, or clip, other than a radiological site marker). As part of this proposal, we solicited public comment on these proposed revised criteria, including whether there are any devices that are not capital equipment that commenters believe should be deemed part of deviceintensive procedures that would not meet the proposed definition of singleuse devices. In addition, we solicited public comments on the full list of proposed CY 2019 OPPS deviceintensive procedures provided in Addendum P to the proposed rule, which is available at: https:// www.cms.gov/Medicare/Medicare-Feefor-Service-Payment/ HospitalOutpatientPPS/HospitalOutpatient-Regulations-andNotices.html. Specifically, we invited public comment on whether any procedures proposed to receive deviceintensive status for CY 2019 should not receive device-intensive status according to the proposed criteria, or if we did not assign device-intensive status for CY 2019 to any procedures commenters believed should receive device-intensive status based on the proposed criteria. Comment: The majority of commenters supported CMS’ proposal to modify the device-intensive criteria to allow procedures that involve singleuse devices, regardless of whether they remain in the body after the conclusion of the procedure, to qualify as deviceintensive procedures. The commenters believed that this proposed policy change will better support accurate payment for procedures where an implantable device is a significant proportion of the total cost of the procedure. Some commenters indicated that this proposed change would help to spur innovation in the device industry. Response: We appreciate the commenters’ support. Comment: The majority of commenters supported the proposal to lower the device offset percentage threshold for procedures to qualify as device-intensive from greater than 40 percent to greater than 30 percent. The commenters believed that this proposed policy change will encourage migration of services from the hospital outpatient PO 00000 Frm 00129 Fmt 4701 Sfmt 4700 58945 department into the ASC setting, resulting in cost savings to the Medicare program and Medicare beneficiaries. Some of these commenters encouraged CMS to further modify its proposal and instead lower the device offset percentage threshold for procedures to qualify as device-intensive to 25 percent instead of 30 percent, to allow even more procedures to be designated as device-intensive. Response: We appreciate commenters’ support. At this time, we continue to believe that applying a device offset percentage threshold of greater than 30 percent for procedures to qualify as device-intensive is most appropriate for the reasons described in our original proposal. Because the ASC payment system is budget neutral, when the device-intensive threshold is set lower, it results in transfer of payment from services with high device offsets or that do not qualify as device-intensive to the services being newly designated as device-intensive. As a result, it is important that the device-intensive threshold not be set too low or it will result in the transfer of payments from procedures with high device offsets to procedures with low device offsets, which is the opposite of the intended purpose of this policy. We will take the commenters’ suggestion of applying a device offset percentage threshold of greater than 25 percent for procedures to qualify as device-intensive into consideration for future rulemaking. In addition, for new HCPCS codes describing procedures requiring the implantation of medical devices that do not yet have associated claims data, in the CY 2017 OPPS/ASC final rule with comment period (81 FR 79658), we finalized a policy for CY 2017 to apply device-intensive status with a default device offset set at 41 percent for new HCPCS codes describing procedures requiring the implantation or insertion of a medical device that do not yet have associated claims data until claims data are available to establish the HCPCS code-level device offset for the procedures. This default device offset amount of 41 percent is not calculated from claims data; instead, it is applied as a default until claims data are available upon which to calculate an actual device offset for the new code. The purpose of applying the 41-percent default device offset to new codes that describe procedures that implant or insert medical devices is to ensure ASC access for new procedures until claims data become available. As discussed in the CY 2019 OPPS/ ASC proposed rule (83 FR 37108 through 37109), in accordance with our proposal stated above to lower the E:\FR\FM\21NOR2.SGM 21NOR2 khammond on DSK30JT082PROD with RULES2 58946 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations device offset percentage threshold for procedures to qualify as deviceintensive from greater than 40 percent to greater than 30 percent, for CY 2019 and subsequent years, we proposed to modify this policy and apply a 31percent default device offset to new HCPCS codes describing procedures requiring the implantation of a medical device that do not yet have associated claims data until claims data are available to establish the HCPCS codelevel device offset for the procedures. In conjunction with the proposal to lower the default device offset from 41 percent to 31 percent, we proposed to continue our current policy of, in certain rare instances (for example, in the case of a very expensive implantable device), temporarily assigning a higher offset percentage if warranted by additional information such as pricing data from a device manufacturer (81 FR 79658). Once claims data are available for a new procedure requiring the implantation of a medical device, device-intensive status will be applied to the code if the HCPCS code-level device offset is greater than 30 percent, according to our policy of determining device-intensive status by calculating the HCPCS codelevel device offset. In addition, in the proposed rule, we clarified that since the adoption of our policy in effect as of CY 2018, the associated claims data used for purposes of determining whether or not to apply the default device offset are the associated claims data for either the new HCPCS code or any predecessor code, as described by CPT coding guidance, for the new HCPCS code. Additionally, for CY 2019 and subsequent years, in limited instances where a new HCPCS code does not have a predecessor code as defined by CPT, but describes a procedure that was previously described by an existing code, we proposed to use clinical discretion to identify HCPCS codes that are clinically related or similar to the new HCPCS code but are not officially recognized as a predecessor code by CPT, and to use the claims data of the clinically related or similar code(s) for purposes of determining whether or not to apply the default device offset to the new HCPCS code. Clinically related and similar procedures for purposes of this policy are procedures that have little or no clinical differences and use the same devices as the new HCPCS code. In addition, clinically related and similar codes for purposes of this policy are codes that either currently or previously describe the procedure described by the new HCPCS code. Under this proposal, claims data from clinically related and VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 similar codes would be included as associated claims data for a new code, and where an existing HCPCS code is found to be clinically related or similar to a new HCPCS code, we proposed to apply the device offset percentage derived from the existing clinically related or similar HCPCS code’s claims data to the new HCPCS code for determining the device offset percentage. We stated in the proposed rule that we believe that claims data for HCPCS codes describing procedures that have very minor differences from the procedures described by new HCPCS codes would provide an accurate depiction of the cost relationship between the procedure and the device(s) that are used, and would be appropriate to use to set a new code’s device offset percentage, in the same way that predecessor codes are used. For instance, for CY 2019, we proposed to use the claims data from existing CPT code 36568 (Insertion of peripherally inserted central venous catheter (PICC), without subcutaneous port or pump; younger than 5 years of age), for which the description as of January 1, 2019 is changing to ‘‘(Insertion of peripherally inserted central venous catheter (PICC), without subcutaneous port or pump, without imaging guidance; younger than 5 years of age)’’, to determine the appropriate device offset percentage for new CPT code 36X72 (Insertion of peripherally inserted central venous catheter (PICC), without subcutaneous port or pump, including all imaging guidance, image documentation, and all associated radiological supervision and interpretation required to perform the insertion; younger than 5 years of age). We believe that although CPT code 36568 is not identified as a predecessor code by CPT, the procedure described by new CPT code 36X72 was previously described by CPT code 36568 and, therefore, CPT code 36X72 is clinically related and similar to CPT code 36568, and the device offset percentage for CPT code 36568 can be accurately applied to both codes. If a new HCPCS code has multiple predecessor codes, the claims data for the predecessor code that has the highest individual HCPCS-level device offset percentage would be used to determine whether the new HCPCS code qualifies for device-intensive status. Similarly, in the event that a new HCPCS code does not have a predecessor code but has multiple clinically related or similar codes, the claims data for the clinically related or similar code that has the highest individual HCPCS level device offset percentage would be used to determine PO 00000 Frm 00130 Fmt 4701 Sfmt 4700 whether the new HCPCS code qualifies for device-intensive status. In the CY 2019 OPPS/ASC proposed rule, we indicated that additional information for our consideration of an offset percentage higher than the proposed default of 31 percent for new HCPCS codes describing procedures requiring the implantation (or, in some cases, the insertion) of a medical device that do not yet have associated claims data, such as pricing data or invoices from a device manufacturer, should be directed to the Division of Outpatient Care, Mail Stop C4–01–26, Centers for Medicare and Medicaid Services, 7500 Security Boulevard, Baltimore, MD 21244–1850, or electronically at outpatientpps@cms.hhs.gov. Additional information can be submitted prior to issuance of an OPPS/ASC proposed rule or as a public comment in response to an issued OPPS/ASC proposed rule. Device offset percentages will be set in each year’s final rule. The full listing of proposed CY 2019 OPPS device-intensive procedures was included in Addendum P to the proposed rule (which is available via the internet on the CMS website). Comment: Commenters supported the proposal to apply a default device offset of 31 percent to procedures requiring devices that do not yet have claims data, as well as the proposal to use claims data from clinically similar and related codes to establish device offsets for procedures with new codes that do not have direct predecessor codes according to CPT. Response: We appreciate the commenters’ support. Comment: A few commenters suggested that CMS only adjust the nondevice portion of the payment by the wage index, consistent with the Agency’s policy for separately payable drugs and biologicals. Response: While we did not make such a proposal in this year’s proposed rule, we will take this comment into consideration for future rulemaking. We note that such a policy would increase payments to providers with a wage index value of less than 1 and be offset by a budget neutral decrease in payments to other providers. Comment: A group of commenters urged CMS to calculate the device offset percentage for potential deviceintensive procedures using the standard (noncomprehensive APC) ASC ratesetting methodology and to assign device-intensive status in the ASC system based on that device offset percentage, as they believed it is more consistent with the overall ASC payment system. One commenter requested some clarification in the final E:\FR\FM\21NOR2.SGM 21NOR2 khammond on DSK30JT082PROD with RULES2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations rule about the current methodology for calculating the device offset percentage for device-intensive procedures and specifically asked that CMS: • Confirm that the ASC deviceintensive status as assigned by CMS is based on the offset calculated according to the ASC ratesetting methodology; • Disclose what offset data (meaning the calculation methodology used) appear in the second spreadsheet of Addendum P titled ‘‘2019 NPRM HCPCS Offsets’’; • Display the device offsets in Addendum P, in future rulemaking, based on the ASC methodology and not the OPPS methodology if the offset data displayed in the second spreadsheet of Addendum P is based on the OPPS methodology and device intensive status is based on the ASC methodology; and • Modify the second worksheet of Addendum P titled ‘‘2019 NPRM HCPCS Offsets’’ to only include the codes for procedures that employ implantable and insertable devices and exclude all of the codes that do not employ implantable or insertable devices. Response: As stated in the CY 2019 OPPS/ASC proposed rule (83 FR 37158), according to our established ASC payment methodology, we apply the device offset percentage based on the standard OPPS APC ratesetting methodology to the OPPS national unadjusted payment to determine the device cost included in the OPPS payment rate for a device-intensive ASC covered surgical procedure, which we then set as equal to the device portion of the national unadjusted ASC payment rate for the procedure. We calculate the service portion of the ASC payment for device-intensive procedures by applying the uniform ASC conversion factor to the service (nondevice) portion of the OPPS relative payment weight for the device-intensive procedure. Finally, we sum the ASC device portion and ASC service portion to establish the full payment for the device-intensive procedure under the ASC payment system. In response to the commenter’s questions and suggestions relating to Addendum P, we note that the device offset percentages reflected in both worksheets of Addendum P are based upon the OPPS methodology (including the C–APC methodology). We believe this is appropriate as Addendum P is created to display the device offsets, device offset percentages, and deviceintensive codes under the OPPS. Specific to the commenter’s suggestion that we modify the second worksheet of Addendum P titled ‘‘2019 NPRM VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 HCPCS Offsets’’ to only include the codes for procedures that employ implantable and insertable devices and exclude all of the codes that do not employ implantable or insertable devices, we note that the second worksheet of Addendum P is intended to display the device offsets and device offset percentages for all codes for which we have such data under the OPPS. In addition, the list of services that qualify as device-intensive under the ASC payment system and the services’ device offset percentages for the ASC payment system are included on the CMS website at https:// www.cms.gov/Medicare/Medicare-Feefor-Service-Payment/ASCPayment/ASCPolicy-Files.html as ‘‘CY 2019 Final ASC Device-Intensive Procedures and Procedures to which the No Cost/Full Credit and Partial Credit Device Adjustment Policy Applies.’’ Comment: Commenters supported the proposed device-intensive status for the following CPT codes: • CPT code 28297 (Correction, hallux valgus (bunionectomy), with sesamoidectomy, when performed; with first metatarsal and medial cuneiform joint arthrodesis, any method); • CPT code 28730 (Arthrodesis, midtarsal or tarsometatarsal, multiple or transverse); • CPT code 28740 (Arthrodesis, midtarsal or tarsometatarsal, single joint); • CPT code 36903 (Introduction of needle(s) and/or catheter(s), dialysis circuit, with diagnostic angiography of the dialysis circuit, including all direct puncture(s) and catheter placement(s), injection(s) of contrast, all necessary imaging from the arterial anastomosis and adjacent artery through entire venous outflow including the inferior or superior vena cava, fluoroscopic guidance, radiological supervision and interpretation and image documentation and report; with transcatheter placement of intravascular stent(s), peripheral dialysis segment, including all imaging and radiological supervision and interpretation necessary to perform the stenting, and all angioplasty within the peripheral dialysis segment); • CPT code 36904 (Percutaneous transluminal mechanical thrombectomy and/or infusion for thrombolysis, dialysis circuit, any method, including all imaging and radiological supervision and interpretation, diagnostic angiography, fluoroscopic guidance, catheter placement(s), and intraprocedural pharmacological thrombolytic injection(s)); and • CPT code 36906 (Percutaneous transluminal mechanical thrombectomy and/or infusion for thrombolysis, PO 00000 Frm 00131 Fmt 4701 Sfmt 4700 58947 dialysis circuit, any method, including all imaging and radiological supervision and interpretation, diagnostic angiography, fluoroscopic guidance, catheter placement(s), and intraprocedural pharmacological thrombolytic injection(s); with transcatheter placement of intravascular stent(s), peripheral dialysis segment, including all imaging and radiological supervision and interpretation necessary to perform the stenting, and all angioplasty within the peripheral dialysis circuit). Other commenters requested that CMS assign device-intensive status to: • HCPCS code C9747 (Ablation of prostate, transrectal, high intensity focused ultrasound (hifu), including imaging guidance); • CPT code 43210 (Esophagogastroduodenoscopy, flexible, transoral; with esophagogastric fundoplasty, partial or complete, includes duodenoscopy when performed); • CPT code 0275T (Percutaneous laminotomy/laminectomy (interlaminar approach) for decompression of neural elements, (with or without ligamentous resection, discectomy, facetectomy and/ or foraminotomy), any method, under indirect image guidance (e.g., fluoroscopic, ct), single or multiple levels, unilateral or bilateral; lumbar); • CPT code 55874 (Transperineal placement of biodegradable material, peri-prostatic, single or multiple injection(s), including image guidance, when performed); • CPT code 0409T (Insertion or replacement of permanent cardiac contractility modulation system, including contractility evaluation when performed, and programming of sensing and therapeutic parameters; pulse generator only); • CPT code 0410T (Insertion or replacement of permanent cardiac contractility modulation system, including contractility evaluation when performed, and programming of sensing and therapeutic parameters; atrial electrode only); • CPT code 0411T (Insertion or replacement of permanent cardiac contractility modulation system, including contractility evaluation when performed, and programming of sensing and therapeutic parameters; ventricular electrode only); and • CPT code 0414T (Removal and replacement of permanent cardiac contractility modulation system pulse generator only). Response: We appreciate the commenters’ support. With respect to the commenters’ request that we assign the device-intensive designation to E:\FR\FM\21NOR2.SGM 21NOR2 58948 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations khammond on DSK30JT082PROD with RULES2 HCPCS code C9747 and CPT codes 43210, 0275T, and 55874, we note that the device offset percentage for all four of these procedures (as identified by the above mentioned HCPCS codes or predecessor codes) is not above the 30percent threshold, and therefore these procedures are not eligible to be assigned device-intensive status. CPT codes 0409T, 0410T, 0411T, and 0414T were inadvertently omitted from the listing of proposed device-intensive procedures in the CY 2019 OPPS/ASC proposed rule. However, we have included them as device-intensive procedures in this final rule with comment period. CPT code 36904 was proposed as a device-intensive procedure. However, using the most currently available data for this CY 2019 OPPS/ASC final rule with comment period, we have determined that its device offset percentage is not above the 30-percent threshold, and therefore this procedure is not eligible to be assigned device-intensive status. Comment: One commenter stated that CPT code 86891 (Autologous blood or component, collection processing and storage; intra- or postoperative salvage) was incorrectly proposed to have device-intensive status for CY 2019. Response: We agree with the commenter. CPT code 86891 was inadvertently included in the listing of device-intensive procedures in Addendum P to the CY 2019 OPPS/ASC proposed rule. After consideration of the public comments we received, we are finalizing our proposals to allow procedures that involve surgically VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 inserted or implanted, single-use devices that meet the device offset percentage threshold to qualify as device-intensive procedures, regardless of whether the device remains in the patient’s body after the conclusion of the procedure and to modify our criteria to lower the device offset percentage threshold from 40 percent to 30 percent. The full listing of the final CY 2019 device-intensive procedures is included in Addendum P to this final rule with comment period (which is available via the internet on the CMS website). 3. Device Edit Policy In the CY 2015 OPPS/ASC final rule with comment period (79 FR 66795), we finalized a policy and implemented claims processing edits that require any of the device codes used in the previous device-to-procedure edits to be present on the claim whenever a procedure code assigned to any of the APCs listed in Table 5 of the CY 2015 OPPS/ASC final rule with comment period (the CY 2015 device-dependent APCs) is reported on the claim. In addition, in the CY 2016 OPPS/ASC final rule with comment period (80 FR 70422), we modified our previously existing policy and applied the device coding requirements exclusively to procedures that require the implantation of a device that are assigned to a device-intensive APC. In the CY 2016 OPPS/ASC final rule with comment period, we also finalized our policy that the claims processing edits are such that any device code, when reported on a claim with a procedure assigned to a device-intensive APC (listed in Table 42 of the CY 2016 OPPS/ PO 00000 Frm 00132 Fmt 4701 Sfmt 4700 ASC final rule with comment period (80 FR 70422)) will satisfy the edit. In the CY 2017 OPPS/ASC final rule with comment period (81 FR 79658 through 79659), we changed our policy for CY 2017 and subsequent years to apply the CY 2016 device coding requirements to the newly defined device-intensive procedures. For CY 2017 and subsequent years, we also specified that any device code, when reported on a claim with a deviceintensive procedure, will satisfy the edit. In addition, we created HCPCS code C1889 to recognize devices furnished during a device-intensive procedure that are not described by a specific Level II HCPCS Category Ccode. Reporting HCPCS code C1889 with a device-intensive procedure will satisfy the edit requiring a device code to be reported on a claim with a deviceintensive procedure. We did not propose any changes to this policy for CY 2019. Comment: Some commenters expressed concern about a potential claims processing issue that would arise from a number of codes (listed below in Table 36) that were proposed to have device-intensive status, which, in their clinical opinion, do not always require the involvement of implantable or insertable single-use devices and, therefore, could be subject to the claims edit requiring device-intensive procedures to be billed with a device., when the procedure may not require the involvement of a device. BILLING CODE 4120–01–P E:\FR\FM\21NOR2.SGM 21NOR2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations 58949 TABLE 36.-LIST OF CODES PROPOSED TO HAVE DEVICE-INTENSIVE STATUS IDENTIFIED BY COMMENTERS THAT DO NOT ALWAYS REQUIRE THE INVOLVEMENT OF A DEVICE AND THAT INCORRECTLY MAY BE SUBJECT TO CLAIMS DEVICE EDIT 23585 24685 27784 28485 27792 28555 24575 27814 28300 25525 27822 25515 28465 24579 khammond on DSK30JT082PROD with RULES2 28615 28445 23515 23680 VerDate Sep<11>2014 Long Descriptor Open treatment of scapular fracture (body, glenoid or acromion) includes internal fixation, when performed Open treatment of ulnar fracture, proximal end (eg, olecranon or coronoid process[es]), includes internal fixation, when performed Open treatment of proximal fibula or shaft fracture, includes internal fixation, when performed Open treatment of metatarsal fracture, includes internal fixation, when performed, each Open treatment of distal fibular fracture (lateral malleolus), includes internal fixation, when performed Open treatment of tarsal bone dislocation, includes internal fixation, when performed Open treatment of humeral epicondylar fracture, medial or lateral, includes internal fixation, when performed Open treatment of bimalleolar ankle fracture (eg, lateral and medial malleoli, or lateral and posterior malleoli, or medial and posterior malleoli), includes internal fixation, when performed Osteotomy; calcaneus (eg, Dwyer or Chambers type procedure), with or without internal fixation Open treatment of radial shaft fracture, includes internal fixation, when performed, and closed treatment of distal radioulnar joint dislocation (Galeazzi fracture/ dislocation), includes percutaneous skeletal fixation, when performed Open treatment of trimalleolar ankle fracture, includes internal fixation, when performed, medial and/or lateral malleolus; without fixation of posterior lip Open treatment of radial shaft fracture, includes internal fixation, when performed Open treatment of tarsal bone fracture (except talus and calcaneus), includes internal fixation, when performed, each Open treatment of humeral condylar fracture, medial or lateral, includes internal fixation, when performed Open treatment of tarsometatarsal joint dislocation, includes internal fixation, when performed Open treatment of talus fracture, includes internal fixation, when performed Open treatment of clavicular fracture, includes internal fixation, when performed Open treatment of shoulder dislocation, with surgical or anatomical neck fracture, includes internal fixation, when performed 20:42 Nov 20, 2018 Jkt 247001 PO 00000 Frm 00133 Fmt 4701 Sfmt 4725 E:\FR\FM\21NOR2.SGM 21NOR2 ER21NO18.054</GPH> HCPCS Code Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations khammond on DSK30JT082PROD with RULES2 BILLING CODE 4120–01–C Response: We have noted the commenters’ concern. We have performed a clinical examination of the potential device-intensive procedures and believe the codes listed in Addendum P to this CY 2019 OPPS/ ASC final rule with comment period (which is available via the internet on the CMS website) as OPPS deviceintensive meet the newly finalized criteria of being a device-intensive procedure. To address any potential claims processing issues pertaining to the device edit policy, we will use subregulatory authority to ensure that the device edit does not improperly prevent correctly coded claims from being paid. Comment: One commenter requested that CMS either revise the descriptor for HCPCS code C1889 (Implantable/ insertable device for device-intensive procedure, not otherwise classified) to remove the specific applicability to device-intensive procedures or establish a new ‘‘Not Otherwise Classified’’ (NOC) HCPCS code for devices that do not have a specific device HCPCS code or are used in a procedure not designated as device-intensive. Response: We agree with the commenter and have revised the NOC HCPCS code to remove the specific applicability to device-intensive procedures. HCPCS code C1889 now reads ‘‘(Implantable/insertable device, not otherwise classified)’’. Comment: One commenter requested that CMS restore the device-toprocedure and procedure-to-device edits. Response: As we stated in the CY 2015 OPPS/ASC final rule with comment period (79 FR 66794), we continue to believe that the elimination of device-to-procedure edits and procedure-to-device edits is appropriate due to the experience hospitals now have in coding and reporting these claims fully. More specifically, for the more costly devices, we believe the C–APCs will reliably reflect the cost of the device if charges for the device are included anywhere on the claim. We note that, under our current policy, VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 hospitals are still expected to adhere to the guidelines of correct coding and append the correct device code to the claim when applicable. We also note that, as with all other items and services recognized under the OPPS, we expect hospitals to code and report their costs appropriately, regardless of whether there are claims processing edits in place. 4. Adjustment to OPPS Payment for No Cost/Full Credit and Partial Credit Devices a. Background To ensure equitable OPPS payment when a hospital receives a device without cost or with full credit, in CY 2007, we implemented a policy to reduce the payment for specified device-dependent APCs by the estimated portion of the APC payment attributable to device costs (that is, the device offset) when the hospital receives a specified device at no cost or with full credit (71 FR 68071 through 68077). Hospitals were instructed to report no cost/full credit device cases on the claim using the ‘‘FB’’ modifier on the line with the procedure code in which the no cost/full credit device is used. In cases in which the device is furnished without cost or with full credit, hospitals were instructed to report a token device charge of less than $1.01. In cases in which the device being inserted is an upgrade (either of the same type of device or to a different type of device) with a full credit for the device being replaced, hospitals were instructed to report as the device charge the difference between the hospital’s usual charge for the device being implanted and the hospital’s usual charge for the device for which it received full credit. In CY 2008, we expanded this payment adjustment policy to include cases in which hospitals receive partial credit of 50 percent or more of the cost of a specified device. Hospitals were instructed to append the ‘‘FC’’ modifier to the procedure code that reports the service provided to furnish the device when they receive a partial credit of 50 percent or more of the cost of the new PO 00000 Frm 00134 Fmt 4701 Sfmt 4700 device. We refer readers to the CY 2008 OPPS/ASC final rule with comment period for more background information on the ‘‘FB’’ and ‘‘FC’’ modifiers payment adjustment policies (72 FR 66743 through 66749). In the CY 2014 OPPS/ASC final rule with comment period (78 FR 75005 through 75007), beginning in CY 2014, we modified our policy of reducing OPPS payment for specified APCs when a hospital furnishes a specified device without cost or with a full or partial credit. For CY 2013 and prior years, our policy had been to reduce OPPS payment by 100 percent of the device offset amount when a hospital furnishes a specified device without cost or with a full credit and by 50 percent of the device offset amount when the hospital receives partial credit in the amount of 50 percent or more of the cost for the specified device. For CY 2014, we reduced OPPS payment, for the applicable APCs, by the full or partial credit a hospital receives for a replaced device. Specifically, under this modified policy, hospitals are required to report on the claim the amount of the credit in the amount portion for value code ‘‘FD’’ (Credit Received from the Manufacturer for a Replaced Medical Device) when the hospital receives a credit for a replaced device that is 50 percent or greater than the cost of the device. For CY 2014, we also limited the OPPS payment deduction for the applicable APCs to the total amount of the device offset when the ‘‘FD’’ value code appears on a claim. For CY 2015, we continued our policy of reducing OPPS payment for specified APCs when a hospital furnishes a specified device without cost or with a full or partial credit and to use the three criteria established in the CY 2007 OPPS/ASC final rule with comment period (71 FR 68072 through 68077) for determining the APCs to which our CY 2015 policy will apply (79 FR 66872 through 66873). In the CY 2016 OPPS/ASC final rule with comment period (80 FR 70424), we finalized our policy to no longer specify a list of devices to which the OPPS payment adjustment for no cost/full credit and partial credit devices would E:\FR\FM\21NOR2.SGM 21NOR2 ER21NO18.055</GPH> 58950 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations apply and instead apply this APC payment adjustment to all replaced devices furnished in conjunction with a procedure assigned to a device-intensive APC when the hospital receives a credit for a replaced specified device that is 50 percent or greater than the cost of the device. khammond on DSK30JT082PROD with RULES2 b. Policy for No Cost/Full Credit and Partial Credit Devices In the CY 2017 OPPS/ASC final rule with comment period (81 FR 79659 through 79660), for CY 2017 and subsequent years, we finalized our policy to reduce OPPS payment for device-intensive procedures, by the full or partial credit a provider receives for a replaced device, when a hospital furnishes a specified device without cost or with a full or partial credit. Under our current policy, hospitals continue to be required to report on the claim the amount of the credit in the amount portion for value code ‘‘FD’’ when the hospital receives a credit for a replaced device that is 50 percent or greater than the cost of the device. In the CY 2019 OPPS/ASC proposed rule (83 FR 37110), for CY 2019 and subsequent years, we proposed to apply our no cost/full credit and partial credit device policies to all procedures that qualify as device-intensive under our proposed modified criteria discussed in section IV.B.2. of the proposed rule and this final rule with comment period. We did not receive any public comments on this proposal. Therefore, we are finalizing our proposal to apply our no cost/full credit and partial credit device policies to all procedures that qualify as device-intensive under our finalized modified criteria discussed in section IV.B.2. of this final rule with comment period, for CY 2019 and subsequent years. 5. Payment Policy for Low-Volume Device-Intensive Procedures In CY 2016, we used our equitable adjustment authority under section 1833(t)(2)(E) of the Act and used the median cost (instead of the geometric mean cost per our standard methodology) to calculate the payment rate for the implantable miniature telescope procedure described by CPT code 0308T (Insertion of ocular telescope prosthesis including removal of crystalline lens or intraocular lens prosthesis), which is the only code assigned to APC 5494 (Level 4 Intraocular Procedures) (80 FR 70388). We note that, as stated in the CY 2017 OPPS/ASC proposed rule (81 FR 45656), we proposed to reassign the procedure described by CPT code 0308T to APC 5495 (Level 5 Intraocular Procedures) VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 for CY 2017, but it would be the only procedure code assigned to APC 5495. The payment rates for a procedure described by CPT code 0308T (including the predecessor HCPCS code C9732) were $15,551 in CY 2014, $23,084 in CY 2015, and $17,551 in CY 2016. The procedure described by CPT code 0308T is a high-cost deviceintensive surgical procedure that has a very low volume of claims (in part because most of the procedures described by CPT code 0308T are performed in ASCs), and we believe that the median cost is a more appropriate measure of the central tendency for purposes of calculating the cost and the payment rate for this procedure because the median cost is impacted to a lesser degree than the geometric mean cost by more extreme observations. We stated that, in future rulemaking, we would consider proposing a general policy for the payment rate calculation for very low-volume device-intensive APCs (80 FR 70389). For CY 2017, we proposed and finalized a payment policy for lowvolume device-intensive procedures that is similar to the policy applied to the procedure described by CPT code 0308T in CY 2016. In the CY 2017 OPPS/ASC final rule with comment period (81 FR 79660 through 79661), we established our current policy that the payment rate for any device-intensive procedure that is assigned to a clinical APC with fewer than 100 total claims for all procedures in the APC be calculated using the median cost instead of the geometric mean cost, for the reasons described above for the policy applied to the procedure described by CPT code 0308T in CY 2016. The CY 2018 final rule geometric mean cost for the procedure described by CPT code 0308T (based on 19 claims containing the device HCPCS C-code, in accordance with the device-intensive edit policy) was approximately $21,302, and the median cost was approximately $19,521. The final CY 2018 payment rate (calculated using the median cost) was approximately $17,560. In the CY 2019 OPPS/ASC proposed rule (83 FR 37111), for CY 2019, we proposed to continue with our current policy of establishing the payment rate for any device-intensive procedure that is assigned to a clinical APC with fewer than 100 total claims for all procedures in the APC based on calculations using the median cost instead of the geometric mean cost. We stated in the proposed rule that, due to the proposed change in APC assignment for CPT code 0308T to APC 5493 (Level 3 Intraocular Procedures) from APC 5495 (Level 5 Intraocular Procedures), our payment PO 00000 Frm 00135 Fmt 4701 Sfmt 4700 58951 policy for low-volume device-intensive procedures would not apply to CPT code 0308T for CY 2019 because there are now more than 100 total claims for the APC to which CPT code 0308T would be assigned. For more information on the proposed and final APC assignment change for CPT code 0308T, we refer readers to section III.D.13. of this final rule with comment period. Based on the CY 2017 claims data available for ratesetting, in the CY 2019 OPPS/ASC proposed rule, we proposed to assign CPT code 0308T to APC 5493, noting that we would continue to monitor the data. In the CY 2019 OPPS final rule claims data, we found that the estimated cost of the single claim with CPT code 0308T as the primary service is $12,939.75. To recognize the estimated cost based on the final rule claims data, we have assigned CPT code 0308T to APC 5494 (Level 4 Intraocular Procedures) for CY 2019 instead of APC 5493. Due to the assignment of CPT code 0308T to APC 5494 for CY 2019, our payment policy for low-volume device-intensive procedures will apply to CPT code 0308T for CY 2019 because there are less than 100 total claims for the APC to which CPT code 0308T is assigned. For more information on the proposed and final APC assignment change for CPT code 0308T, including a summary of public comments and our responses, we refer readers to section III.D.13. of this final rule with comment period. V. OPPS Payment Changes for Drugs, Biologicals, and Radiopharmaceuticals A. OPPS Transitional Pass-Through Payment for Additional Costs of Drugs, Biologicals, and Radiopharmaceuticals 1. Background Section 1833(t)(6) of the Act provides for temporary additional payments or ‘‘transitional pass-through payments’’ for certain drugs and biologicals. Throughout this final rule with comment period, the term ‘‘biological’’ is used because this is the term that appears in section 1861(t) of the Act. A ‘‘biological’’ as used in this final rule with comment period includes (but is not necessarily limited to) a ‘‘biological product’’ or a ‘‘biologic’’ as defined in the Public Health Service Act. As enacted by the Medicare, Medicaid, and SCHIP Balanced Budget Refinement Act of 1999 (BBRA) (Pub. L. 106–113), this pass-through payment provision requires the Secretary to make additional payments to hospitals for: Current orphan drugs, as designated under section 526 of the Federal Food, Drug, and Cosmetic Act; current drugs E:\FR\FM\21NOR2.SGM 21NOR2 khammond on DSK30JT082PROD with RULES2 58952 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations and biologicals and brachytherapy sources used in cancer therapy; and current radiopharmaceutical drugs and biologicals. ‘‘Current’’ refers to those types of drugs or biologicals mentioned above that are hospital outpatient services under Medicare Part B for which transitional pass-through payment was made on the first date the hospital OPPS was implemented. Transitional pass-through payments also are provided for certain ‘‘new’’ drugs and biologicals that were not being paid for as an HOPD service as of December 31, 1996 and whose cost is ‘‘not insignificant’’ in relation to the OPPS payments for the procedures or services associated with the new drug or biological. For pass-through payment purposes, radiopharmaceuticals are included as ‘‘drugs.’’ As required by statute, transitional pass-through payments for a drug or biological described in section 1833(t)(6)(C)(i)(II) of the Act can be made for a period of at least 2 years, but not more than 3 years, after the payment was first made for the product as a hospital outpatient service under Medicare Part B. CY 2019 pass-through drugs and biologicals and their designated APCs are assigned status indicator ‘‘G’’ in Addenda A and B to this final rule with comment period (which are available via the internet on the CMS website). Section 1833(t)(6)(D)(i) of the Act specifies that the pass-through payment amount, in the case of a drug or biological, is the amount by which the amount determined under section 1842(o) of the Act for the drug or biological exceeds the portion of the otherwise applicable Medicare OPD fee schedule that the Secretary determines is associated with the drug or biological. The methodology for determining the pass-through payment amount is set forth in regulations at 42 CFR 419.64. These regulations specify that the passthrough payment equals the amount determined under section 1842(o) of the Act minus the portion of the APC payment that CMS determines is associated with the drug or biological. Section 1847A of the Act establishes the average sales price (ASP) methodology, which is used for payment for drugs and biologicals described in section 1842(o)(1)(C) of the Act furnished on or after January 1, 2005. The ASP methodology, as applied under the OPPS, uses several sources of data as a basis for payment, including the ASP, the wholesale acquisition cost (WAC), and the average wholesale price (AWP). In this final rule with comment period, the term ‘‘ASP methodology’’ and ‘‘ASP-based’’ are inclusive of all data sources and methodologies VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 described therein. Additional information on the ASP methodology can be found on the CMS website at: https://www.cms.gov/Medicare/ Medicare-Fee-for-Service-Part-B-Drugs/ McrPartBDrugAvgSalesPrice/ index.html. The pass-through application and review process for drugs and biologicals is described on the CMS website at: https://www.cms.gov/Medicare/ Medicare-Fee-for-Service-Payment/ HospitalOutpatientPPS/passthrough_ payment.html. 2. Three-Year Transitional Pass-Through Payment Period for All Pass-Through Drugs, Biologicals, and Radiopharmaceuticals and Quarterly Expiration of Pass-Through Status As required by statute, transitional pass-through payments for a drug or biological described in section 1833(t)(6)(C)(i)(II) of the Act can be made for a period of at least 2 years, but not more than 3 years, after the payment was first made for the product as a hospital outpatient service under Medicare Part B. Our current policy is to accept pass-through applications on a quarterly basis and to begin passthrough payments for newly approved pass-through drugs and biologicals on a quarterly basis through the next available OPPS quarterly update after the approval of a product’s pass-through status. However, prior to CY 2017, we expired pass-through status for drugs and biologicals on an annual basis through notice-and-comment rulemaking (74 FR 60480). In the CY 2017 OPPS/ASC final rule with comment period (81 FR 79662), we finalized a policy change, beginning with pass-through drugs and biologicals newly approved in CY 2017 and subsequent calendar years, to allow for a quarterly expiration of pass-through payment status for drugs, biologicals, and radiopharmaceuticals to afford a pass-through payment period that is as close to a full 3 years as possible for all pass-through drugs, biologicals, and radiopharmaceuticals. This change eliminated the variability of the pass-through payment eligibility period, which previously varied based on when a particular application was initially received. We adopted this change for pass-through approvals beginning on or after CY 2017, to allow, on a prospective basis, for the maximum pass-through payment period for each pass-through drug without exceeding the statutory limit of 3 years. PO 00000 Frm 00136 Fmt 4701 Sfmt 4700 3. Drugs and Biologicals With Expiring Pass-Through Payment Status in CY 2018 In the CY 2019 OPPS/ASC proposed rule (83 FR 37112), we proposed that the pass-through payment status of 23 drugs and biologicals would expire on December 31, 2018, as listed in Table 19 of the proposed rule (83 FR 37112). All of these drugs and biologicals will have received OPPS pass-through payment for at least 2 years and no more than 3 years by December 31, 2018. These drugs and biologicals were approved for pass-through payment status on or before January 1, 2017. In accordance with the policy finalized in CY 2017 and described earlier, pass-through payment status for drugs and biologicals newly approved in CY 2017 and subsequent years will expire on a quarterly basis, with a pass-through payment period as close to 3 years as possible. With the exception of those groups of drugs and biologicals that are always packaged when they do not have pass-through payment status (specifically, anesthesia drugs; drugs, biologicals, and radiopharmaceuticals that function as supplies when used in a diagnostic test or procedure (including diagnostic radiopharmaceuticals, contrast agents, and stress agents); and drugs and biologicals that function as supplies when used in a surgical procedure), our standard methodology for providing payment for drugs and biologicals with expiring pass-through payment status in an upcoming calendar year is to determine the product’s estimated per day cost and compare it with the OPPS drug packaging threshold for that calendar year (which is $125 for CY 2019), as discussed further in section V.B.2. of this final rule with comment period. In the CY 2019 OPPS/ ASC proposed rule (83 FR 37112), we proposed that if the estimated per day cost for the drug or biological is less than or equal to the applicable OPPS drug packaging threshold, we would package payment for the drug or biological into the payment for the associated procedure in the upcoming calendar year. If the estimated per day cost of the drug or biological is greater than the OPPS drug packaging threshold, we proposed to provide separate payment at the applicable relative ASP-based payment amount (which was proposed at ASP+6 percent for CY 2019, and is finalized at ASP+6 percent for CY 2019, as discussed further in section V.B.3. of this final rule with comment period). Comment: A number of commenters requested that pass-through payment status for HCPCS code A9515 (Choline E:\FR\FM\21NOR2.SGM 21NOR2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations khammond on DSK30JT082PROD with RULES2 c-11, diagnostic, per study dose up to 20 millicuries) be extended until March 2019 to give 3 full years of pass-through payment status for the drug. The drug described by HCPCS code A9515 received pass-through status in April 2016, and in the CY 2019 OPPS/ASC proposed rule, the pass-through payment period for the drug was scheduled to end on December 31, 2018, consistent with the policy in effect in CY 2016 that drugs and biologicals receive at least 2 years but no more than 3 years of pass-through payment status where pass-through payment status for drugs and biologicals was expired on an annual basis through notice-andcomment rulemaking. One commenter requested an extension of pass-through payment status to allow for the collection of more cost data for HCPCS code A9515. Another commenter believed pass-through payment status for HCPCS code A9515 should be extended because of concern that the cost of HCPCS code A9515 exceeds the payment rate for the nuclear medicine services with which HCPCS code A9515 will be packaged. The commenter cited data showing the pass-through payment rate for HCPCS code A9515 was $5,700, while the highest APC payment rate for a nuclear medicine service was $1,377.22 with a drug offset of $248.31. Two commenters also requested that HCPCS codes Q9982 (Flutemetamol f18, diagnostic, per study dose, up to 5 millicuries) and Q9983 (Florbetaben f18, diagnostic, per study dose, up to 8.1 millicuries) not be taken off of passthrough payment status due to similar concerns. Response: As noted in the proposed rule, all three radiopharmaceuticals are covered under the pass-through payment expiration policy in effect in CY 2016 which stated that drugs and biologicals receive at least 2 years and no more than 3 years of pass-through payment status, with the pass-through payment period expiring at the end of a calendar year. Beginning with passthrough drugs and biologicals newly approved in CY 2017 and subsequent calendar years, a new policy is in effect to allow for a quarterly expiration of VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 pass-through payment status for drugs and biologicals to afford a pass-through payment period that is as close to a full 3 years as possible for all pass-through drugs, biologicals, and radiopharmaceuticals (82 FR 59337). HCPCS codes A9515, Q9982, and Q9983 are covered by the policy in effect for CY 2016, and pass-through payment status for these HCPCS codes will end on December 31, 2018. We note that when a radiopharmaceutical or other drug or biological is newly packaged into a related medical procedure, the amount of the payment rate for the related medical procedure does not stay the same. Instead, the payment rate for the medical procedure will be adjusted to reflect the additional cost of the newly packaged radiopharmaceutical in the overall cost of the medical procedure. Comment: Some commenters recommended that CMS allow products covered by Medicare in the context of a coverage with evidence development (CED) clinical trial to retain their passthrough payment status for the duration of the CED trial. Two of the commenters focused on the packaging of diagnostic radiopharmaceuticals that do not have pass-through payment status. One of the commenters requested that pass-through payment status for NeuraceqTM (florbetaben F18, HCPCS code Q9982) and VizamylTM (flutemetamol F18, HCPCS code Q9983), which is scheduled to end on December 31, 2018, be extended because of a current CED trial for amyloid positron emission tomography (PET) that will be active through at least CY 2019. (Information on this CED trial can be found on the CMS website at https://www.cms.gov/ Medicare/Coverage/Coverage-withEvidence-Development/AmyloidPET.html). This commenter also suggested that if pass-through payment status is not extended, these drugs could be paid separately under their own assigned APCs to avoid having the cost of these drugs packaged into the primary procedures for which they are used. Another commenter was more broadly concerned about not receiving payment for a drug or biological when PO 00000 Frm 00137 Fmt 4701 Sfmt 4700 58953 a CED trial is ongoing and a drug or biological used in the trial loses passthrough payment status and becomes packaged. The commenters were concerned that ending pass-through payment for drugs that will no longer be paid separately could negatively impact CED trials as hospitals would be less likely to participate because of the risk of receiving lower payment for the services covered by the CED trial. Response: We disagree with the commenters’ concern that expiration of pass-through payment status for NeuraceqTM (HCPCS code Q9982) and VizamylTM (HCPCS code Q9983), and subsequent packaging of them as ‘‘policy-packaged’’ drugs, will affect trial results. We note that hospitals are not precluded from billing for NeuraceqTM and VizamylTM in the context of a CED trial once their passthrough payment status expires. We also note that the payment for both NeuraceqTM and VizamylTM will be reflected in the payment rate for the associated procedure. With respect to the request that we create a new APC for NeuraceqTM and VizamylTM, we do not believe it is appropriate, prudent, or practicable to create unique APCs for specific drugs or biologicals or other individual items that are furnished with a particular procedure or procedures. Finally, with respect to the commenters’ request that we allow drug or biological pass-through payment status for products covered by a CED trial for the duration of the CED trial, we reiterate that the statute limits the period of passthrough payment eligibility to no more than 3 years after the product’s first payment as a hospital outpatient service under Medicare Part B. As such, we are unable to extend pass-through payment status beyond 3 years. After consideration of the public comments we received, we are finalizing our proposal, without modification, to expire the pass-through payment status of the 23 drugs and biologicals listed in Table 37 below on December 31, 2018. BILLING CODE 4120–01–P E:\FR\FM\21NOR2.SGM 21NOR2 58954 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations CY2019 HCPCS Code A9515 C9460 C9482 J1942 12182 12786 12840 17202 17207 17209 17322 17342 17503 19022 19145 19176 19205 19295 19325 19352 Q5101 Q9982 khammond on DSK30JT082PROD with RULES2 Q9983 CY 2019 Long Descriptor Final CY 2019 APC N K K K K K K N/A 9460 9482 9470 9473 9481 9478 PassThrough Payment Effective Date 04/01/2016 01/01/2016 10/0112016 04/01/2016 04/01/2016 10/01/2016 07/01/2016 K 9171 10/01/2016 K 1844 04/01/2016 K 1846 04/01/2016 K 9471 04/01/2016 K 9479 07/01/2016 K 1845 04/01/2016 K K K K K 9483 9476 9477 9474 9475 10/01/2016 07/01/2016 07/0112016 04/01/2016 04/0112016 K 9472 04/01/2016 K 9480 07/01/2016 K 1822 07/01/2015 N N/A 01/01/2016 N N/A 01/01/2016 Choline C 11, diagnostic, per study dose Injection, cangrelor, 1 mg Injection, sotalol hydrochloride, 1 mg Injection, aripiprazole lauroxil, 1 mg Injection, mepolizumab, 1 mg Injection, reslizumab, 1 mg Injection, sebelipase alfa, 1 mg Injection, Factor IX, albumin fusion protein (recombinant), Idelvion, 1 i.u. Injection, Factor VIII (antihemophilic factor, recombinant) PEGylated, 1 I.U. Injection, Factor VIII (antihemophilic factor, recombinant) (Nuwiq), per i.u. Hyaluronan or derivative, Hymovis, for intra-articular injection, 1 mg Instillation, ciprofloxacin otic suspension, 6 mg Tacrolimus, extended release, (envarsus xr), oral, 0.25 mg Injection, atezolizumab, 10 mg Injection, daratumumab, 10 mg Injection, elotuzumab, 1 mg Injection, irinotecan liposome, 1 mg Injection, necitumumab, 1 mg Injection, talimogene laherparepvec, 1 million plaque forming units (PFU) Injection, trabectedin, 0.1 mg Injection, filgrastim-sndz, biosimilar, (zarxio ), 1 microgram Flutemetamol F18, diagnostic, per study dose, up to 5 millicuries Florbetaben F18, diagnostic, per study dose, up to 8.1 millicuries The final packaged or separately payable status of each of these drugs or biologicals is listed in Addendum B to this final rule with comment period (which is available via the internet on the CMS website). VerDate Sep<11>2014 Final CY 2019 Status Indicator 20:42 Nov 20, 2018 Jkt 247001 4. Drugs, Biologicals, and Radiopharmaceuticals With New or Continuing Pass-Through Payment Status in CY 2019 In the CY 2019 OPPS/ASC proposed rule (83 FR 37112), we proposed to continue pass-through payment status in CY 2019 for 45 drugs and biologicals. PO 00000 Frm 00138 Fmt 4701 Sfmt 4700 These drugs and biologicals, which were approved for pass-through payment status between January 1, 2017, and July 1, 2018, were listed in Table 20 of the proposed rule (83 FR 37113 through 37114). The APCs and HCPCS codes for these drugs and biologicals approved for pass-through E:\FR\FM\21NOR2.SGM 21NOR2 ER21NO18.056</GPH> TABLE 37.-DRUGS AND BIOLOGICALS FOR WHICH PASS-THROUGH PAYMENT STATUS EXPIRES DECEMBER31, 2018 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations khammond on DSK30JT082PROD with RULES2 payment status through December 31, 2018 were assigned status indicator ‘‘G’’ in Addenda A and B to the proposed rule (which are available via the internet on the CMS website). In addition, as indicated in the proposed rule, there are four drugs and biologicals that have already had 3 years of pass-through payment status but for which passthrough payment status is required to be extended for an additional 2 years under section 1833(t)(6)(G) of the Act, as added by section 1301(a)(1)(C) of the Consolidated Appropriations Act of 2018 (Pub. L. 115–141). Because of this requirement, these drugs and biologicals were also included in Table 20 of the proposed rule, which brought the total number of drugs and biologicals with proposed pass-through payment status in CY 2019 to 49. The requirements of section 1301 of Public Law 115–141 are described in further detail in section V.A.5. of this final rule with comment period, and we address public comments that we received related to this topic in that section. Section 1833(t)(6)(D)(i) of the Act sets the amount of pass-through payment for pass-through drugs and biologicals (the pass-through payment amount) as the difference between the amount authorized under section 1842(o) of the Act and the portion of the otherwise applicable OPD fee schedule that the Secretary determines is associated with the drug or biological. For CY 2019, we proposed to continue to pay for passthrough drugs and biologicals at ASP+6 percent, equivalent to the payment rate these drugs and biologicals would receive in the physician’s office setting in CY 2019. We proposed that a $0 passthrough payment amount would be paid for pass-through drugs and biologicals under the CY 2019 OPPS because the difference between the amount authorized under section 1842(o) of the VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 Act, which was proposed at ASP+6 percent, and the portion of the otherwise applicable OPD fee schedule that the Secretary determines is appropriate, which was proposed at ASP+6 percent, is $0. In the case of policy-packaged drugs (which include the following: Anesthesia drugs; drugs, biologicals, and radiopharmaceuticals that function as supplies when used in a diagnostic test or procedure (including contrast agents, diagnostic radiopharmaceuticals, and stress agents); and drugs and biologicals that function as supplies when used in a surgical procedure), we proposed that their pass-through payment amount would be equal to ASP+6 percent for CY 2019 minus a payment offset for any predecessor drug products contributing to the passthrough payment as described in section V.A.6. of the proposed rule. We made this proposal because, if not for the pass-through payment status of these policy-packaged products, payment for these products would be packaged into the associated procedure. We proposed to continue to update pass-through payment rates on a quarterly basis on the CMS website during CY 2019 if later quarter ASP submissions (or more recent WAC or AWP information, as applicable) indicate that adjustments to the payment rates for these pass-through payment drugs or biologicals are necessary. For a full description of this policy, we refer readers to the CY 2006 OPPS/ASC final rule with comment period (70 FR 68632 through 68635). For CY 2019, consistent with our CY 2018 policy for diagnostic and therapeutic radiopharmaceuticals, we proposed to provide payment for both diagnostic and therapeutic radiopharmaceuticals that are granted pass-through payment status based on PO 00000 Frm 00139 Fmt 4701 Sfmt 4700 58955 the ASP methodology. As stated earlier, for purposes of pass-through payment, we consider radiopharmaceuticals to be drugs under the OPPS. Therefore, if a diagnostic or therapeutic radiopharmaceutical receives passthrough payment status during CY 2019, we proposed to follow the standard ASP methodology to determine the passthrough payment rate that drugs receive under section 1842(o) of the Act, which was proposed at ASP+6 percent. If ASP data are not available for a radiopharmaceutical, we proposed to provide pass-through payment at WAC+3 percent (consistent with our proposed policy in section V.B.2.b. of the proposed rule), the equivalent payment provided to pass-through payment drugs and biologicals without ASP information. Additional detail and comments on the WAC+3 percent payment policy can be found in section V.B.2.b. of this final rule. If WAC information also is not available, we proposed to provide payment for the pass-through radiopharmaceutical at 95 percent of its most recent AWP. We did not receive any public comments regarding our proposals. Therefore, we are implementing these proposals for CY 2019 without modification. We note that public comments pertaining to our proposal to pay WAC+3 percent for drugs and biologicals without ASP information as well as public comments on section 1301 pass-through payment status extensions are addressed elsewhere in this final rule with comment period. The drugs and biologicals that continue to have pass-through payment status for CY 2019 or have been granted pass-through payment status as of January 2019 are shown in Table 38 below. E:\FR\FM\21NOR2.SGM 21NOR2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations TABLE 38.-DRUGS AND BIOLOGICALS WITH PASS-THROUGH PAYMENT STATUS IN CY 2019 PassCY CY2019 CY2019 Through CY2019 Long CY2019 2018 HCPCS Payment Status Descriptor HCPCS APC Code Indicator Effective Code Date Florbetapir fl8, diagnostic, per study A9586 A9586 9084 10/01/2018 G dose, up to 10 millicuries Gallium ga-68, dotatate, A9587 A9587 diagnostic, 0.1 01/01/2017 G 9056 millicurie Fluciclovine f-18, A9588 A9588 9052 01/01/2017 G diagnostic, 1 millicurie Injection, cerliponase G 9014 01/01/2018 10567 C9014 alfa, 1 mg Injection, c-1 esterase 10599 inhibitor (human), G 9015 01/01/2018 C9015 (haegarda), 10 units Injection, triptorelin, C9016 13316 extended-release, 3.75 9016 01/01/2018 G mg Injection, liposomal, 1 mg daunorubicin and C9024 19153 G 9302 01/01/2018 2.27 mg cytarabine Injection, inotuzumab G 9028 01/01/2018 19229 C9028 ozogamicin, 0.1 mg Injection, guselkumab, C9029 11628 9029 01/01/2018 G 1 mg Injection, copanlisib, 1 19057 G 9030 07/01/2018 C9030 mg Lutetium Lu 177, C9031 A9513 dotatate, therapeutic, 1 07/01/2018 G 9067 millicurie Injection, voretigene 07/01/2018 C9032 neparvovec-rzyl, 1 G 9070 13398 billion vector genomes Injection, fosnetupitant C9033 11454 235 mg and G 9099 10/01/2018 palonosetron 0.25 mg Injection, C9034 C9034 dexamethasone 9%, 9172 10/01/2018 G intraocular, 1 meg VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 PO 00000 Frm 00140 Fmt 4701 Sfmt 4725 E:\FR\FM\21NOR2.SGM 21NOR2 ER21NO18.057</GPH> khammond on DSK30JT082PROD with RULES2 58956 khammond on DSK30JT082PROD with RULES2 CY 2018 HCPCS Code CY2019 HCPCS Code C9447 C9447 C9462 C9462 C9463 10185 C9464 12797 C9465 17318 C9466 10517 C9467 19311 C9468 17203 C9488 C9488 C9492 19173 C9493 11301 10565 10565 10570 10570 11428 11428 11627 11627 12326 12326 VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 CY2019 Long Descriptor Injection, phenylephrine and ketorolac, 4 ml vial Injection, delafloxacin, 1 mg Injection, aprepitant, 1 mg Injection, rolapitant, 0.5 mg Hyaluronan or derivative, durolane, for intra-articular injection, 1 mg Injection, benralizumab, 1 mg Injection, rituximab 10 mg and hyaluronidase Injection factor ix, (antihemophilic factor, recombinant), glycopegylated, (rebinyn), 1 iu Injection, conivaptan hydrochloride, 1 mg Injection, durvalumab, 10mg Injection, edaravone, 1 mg Injection, bezlotoxumab, 10 mg Buprenorphine implant, 74.2 mg Injection, eteplirsen, 10 mg Injection, granisetron extended release, 0.1 mg Injection, nusinersen, 0.1 mg PO 00000 Frm 00141 Fmt 4701 Sfmt 4725 CY2019 Status Indicator CY2019 APC PassThrough Payment Effective Date G 9083 10/01/2018 G 9462 04/01/2018 G 9463 04/01/2018 G 9464 04/01/2018 G 9174 04/01/2018 G 9466 04/01/2018 G 9467 04/01/2018 G 9468 04/01/2018 G 9488 04/01/2017 G 9492 10/01/2017 G 9493 10/01/2017 G 9490 07/01/2017 G 9058 01/01/2017 G 9484 04/01/2017 G 9486 04/01/2017 G 9489 07/01/2017 E:\FR\FM\21NOR2.SGM 21NOR2 58957 ER21NO18.058</GPH> Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations CY 2018 HCPCS Code CY2019 HCPCS Code 12350 12350 J3358 J3358 17179 17179 17210 17210 17328 17328 17345 17345 19023 19023 19034 19034 19203 19203 19285 19285 khammond on DSK30JT082PROD with RULES2 Q2041 VerDate Sep<11>2014 Q2041 20:42 Nov 20, 2018 Jkt 247001 CY2019 Long Descriptor Injection, ocrelizumab, 1 mg U stekinumab, for Intravenous Injection, 1 mg Injection, von willebrand factor (recombinant), (Vonvendi), 1 i.u. vwf:rco Injection, factor viii, (antihemophilic factor, recombinant), (afstyla), 1 i.u. Hyaluronan or derivative, gelsyn-3, for intra-articular injection, 0.1 mg Aminolevulinic acid hcl for topical administration, 10% gel, 10 mg Injection, avelumab, 10 mg Injection, bendamustine hcl (Bendeka), 1 mg Injection, gemtuzumab ozogamicin, 0.1 mg Injection, olaratumab, 10mg Axicabtagene ciloleucel, up to 200 million autologous anticd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose PO 00000 Frm 00142 Fmt 4701 Sfmt 4725 CY2019 Status Indicator CY2019 APC PassThrough Payment Effective Date G 9494 10/01/2017 G 9487 04/01/2017 G 9059 01/01/2017 G 9043 01/01/2017 G 1862 01/01/2016 G 9301 01/01/2018 G 9491 10/01/2017 G 1861 01/01/2017 G 9495 01/01/2018 G 9485 04/01/2017 G 9035 04/01/2018 E:\FR\FM\21NOR2.SGM 21NOR2 ER21NO18.059</GPH> 58958 khammond on DSK30JT082PROD with RULES2 CY 2018 HCPCS Code CY2019 HCPCS Code N/A Q2042* Q4172 Q4195 Q4172 Q4196 Q5103 Q5103 Q5104 Q5104 Q5105 Q5105 Q5106 Q5106 Q9950 Q9950 Q9991 Q9991 Q9992 Q9992 VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 CY2019 Long Descriptor Tisagenlecleucel, up to 600 million car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose Puraply, per square centimeter Puraply am, per square centimeter Injection, infliximabdyyb, biosimilar, (inflectra), 10 mg Injection, infliximababda, biosimilar, (renflexis), 10 mg Injection, epoetin alfa, biosimilar, (Retacrit) (for esrd on dialysis), 100 units Injection, epoetin alfa, biosimilar, (Retacrit) (for non-esrd use), 1000 units Injection, sulfur hexafluoride lipid microsphere, per ml Injection, buprenorphine extended-release (Sublocade ), less than or equal to 100 mg Injection, buprenorphine extended-release (Sublocade ), greater than 100 mg PO 00000 Frm 00143 Fmt 4701 Sfmt 4725 58959 CY2019 Status Indicator CY2019 APC PassThrough Payment Effective Date G 9194 04/01/2018 G 9175 10/01/2018 G 9176 10/01/2018 G 1847 04/01/2018 G 9036 04/01/2018 G 9096 10/01/2018 G 9097 10/01/2018 G 9085 10/01/2018 G 9073 07/01/2018 G 9239 07/01/2018 E:\FR\FM\21NOR2.SGM 21NOR2 ER21NO18.060</GPH> Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations BILLING CODE 4120–01–C khammond on DSK30JT082PROD with RULES2 5. Drugs, Biologicals, and Radiopharmaceuticals With PassThrough Status as a Result of Section 1301 of the Consolidated Appropriations Act of 2018 (Pub. L. 115–141) As mentioned earlier, section 1301(a)(1) of the Consolidated Appropriations Act of 2018 (Pub. L. 115–141) amended section 1833(t)(6) of the Act and added a new section 1833(t)(6)(G), which provides that for drugs or biologicals whose period of pass-through payment status ended on December 31, 2017 and for which payment was packaged into a covered hospital outpatient service furnished beginning January 1, 2018, such passthrough payment status shall be extended for a 2-year period beginning on October 1, 2018 through September VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 30, 2020. There are four products whose period of drug and biological passthrough payment status ended on December 31, 2017. These products were listed in Table 21 of the CY 2019 OPPS/ASC proposed rule (83 FR 37115). For CY 2019, we proposed to continue pass-through payment status for the drugs and biologicals listed in Table 21 of the proposed rule (we note that these drugs and biologicals were also listed in Table 20 of the proposed rule). The APCs and HCPCS codes for these drugs and biologicals approved for passthrough payment status were assigned status indicator ‘‘G’’ in Addenda A and B to the proposed rule (which are available via the internet on the CMS website). In addition, new section 1833(t)(6)(H) of the Act specifies that the payment amount for such drug or biological under this subsection that is furnished PO 00000 Frm 00144 Fmt 4701 Sfmt 4700 during the period beginning on October 1, 2018, and ending on March 31, 2019, shall be the greater of: (i) The payment amount that would otherwise apply under section 1833(t)(6)(D)(i) of the Act for such drug or biological during such period; or (ii) the payment amount that applied under section 1833(t)(6)(D)(i) of the Act for such drug or biological on December 31, 2017. We stated in the proposed rule that we intended to address pass-through payment for these drugs and biologicals for the last quarter of CY 2018 through program instruction. The program instruction covering passthrough payment for these drugs and biologicals for the last quarter of CY 2018 is Transmittal 4123 titled ‘‘October 2018 Update of the Hospital Outpatient Prospective Payment System (OPPS)’’, and can be found on the CMS website at: https://www.cms.gov/Regulationsand-Guidance/Guidance/Transmittals/ E:\FR\FM\21NOR2.SGM 21NOR2 ER21NO18.061</GPH> 58960 khammond on DSK30JT082PROD with RULES2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations 2018Downloads/R4123CP.pdf. For January 1, 2019 through March 31, 2019, we proposed that pass-through payment for these four drugs and biologicals would be the greater of: (1) ASP+6 percent based on current ASP data; or (2) the payment rate for the drug or biological on December 31, 2017. We also proposed for the period of April 1, 2019 through December 31, 2019 that the pass-through payment amount for these drugs and biologicals would be the amount that applies under section 1833(t)(6)(D)(i) of the Act. We proposed to continue to update pass-through payment rates for these four drugs and biologicals on a quarterly basis on the CMS website during CY 2019 if later quarter ASP submissions (or more recent WAC or AWP information, as applicable) indicate that adjustments to the payment rates for these pass-through drugs or biologicals are necessary. For a full description of this policy, we refer readers to the CY 2006 OPPS/ASC final rule with comment period (70 FR 68632 through 68635). The four drugs and biologicals that we proposed would have pass-through payment status for CY 2019 under section 1833(t)(6)(G) of the Act, as added by section 1301(a)(1)(C) of the Consolidated Appropriations Act of 2018, were shown in Table 21 of the CY 2019 OPPS/ASC proposed rule (83 FR 37115). Included as one of the four drugs and biologicals with pass-through payment status for CY 2019 is HCPCS code Q4172 (Puraply, and Puraply AM per square centimeter). PuraPly is a skin substitute product that was approved for pass-through payment status on January 1, 2015 through the drug and biological pass-through payment process. Beginning on April 1, 2015, skin substitute products are evaluated for pass-through payment status through the device pass-through payment process. However, we stated in the CY 2015 OPPS/ASC final rule with comment period (79 FR 66887) that skin substitutes that are approved for passthrough payment status as biologicals effective on or before January 1, 2015 would continue to be paid as passthrough biologicals for the duration of their pass-through payment period. Because PuraPly was approved for passthrough payment status through the drug and biological pass-through payment pathway, we proposed to consider PuraPly to be a drug or biological as described by section 1833(t)(6)(G) of the Act, as added by section 1301(a)(1)(C) of the Consolidated Appropriations Act of 2018, and to be eligible for extended VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 pass-through payment under our proposal for CY 2019. Comment: Several commenters were opposed to PuraPly and PuraPly AM receiving pass-through payment status for CY 2019. These commenters stated that because PuraPly and PuraPly AM received a 510(k) clearance from the FDA, PuraPly and PuraPly AM should be considered devices rather than drugs or biologicals or that there is at least some ambiguity about whether PuraPly and PuraPly AM are devices. The commenters encouraged CMS to use its discretion and consider PuraPly and PuraPly AM to be devices along the same lines of reasoning as CMS has considered biologicals used as skin substitutes to be considered devices for the purposes of receiving pass-through payment since April 2015. In addition, the commenters noted that PuraPly and PuraPly AM should not have passthrough payment status extended because they are no longer new products. Further, the commenters noted that these products would receive a significant market advantage by being the only graft skin substitute product to receive separate payment. Other commenters noted that extending the pass-through payment status of PuraPly and PuraPly AM would work against the goals CMS has stated in other parts of the proposed rule regarding skin substitute payment. Finally, these commenters maintained that extending pass-through payment status would encourage the use of more high-cost skin substitute products and lead to increased pricing instability by increasing the cost thresholds for the high-cost skin substitute group. Another commenter opposed extending passthrough payment status for PuraPly and PuraPly AM based on the belief that the manufacturer of these products may be unfairly increasing the prices for these products when they return to passthrough payment status. Response: In the CY 2015 OPPS/ASC final rule with comment period (79 FR 66887), we stated that skin substitutes that are approved for pass-through payment status as biologicals effective on or before January 1, 2015 would continue to be paid as pass-through biologicals for the duration of their passthrough payment period. PuraPly and PuraPly AM were originally approved for pass-through payment status on January 1, 2015 under the drug and biological pass-through payment pathway as biologicals. We interpret section 1833(t)(6)(G) of the Act, as added by section 1301(a)(1)(C) of the Consolidated Appropriations Act of 2018, as extending the original passthrough payment period that was PO 00000 Frm 00145 Fmt 4701 Sfmt 4700 58961 established for PuraPly and PuraPly AM on January 1, 2015, and therefore, PuraPly and PuraPly AM will continue to be paid as pass-through drugs and biologicals. While we acknowledge the comments pointing out that we currently treat skin substitute products as devices for purposes of pass-through payment status, this does not change the fact that PuraPly and PuraPly AM were originally approved for pass-through payments as biologicals. We believe that PuraPly and PuraPly AM’s original approval for pass-through status as biologicals means that they should continue to receive pass-through payments under section 1833(t)(6)(G) of the Act. We also recognize that the commenters raised important concerns about the impact that extending passthrough payment status for PuraPly and PuraPly AM could have on the payment of wound care services using graft skin substitute products. However, we nonetheless believe that section 1833(t)(6)(G) of the Act requires us to extend the pass-through payment period for PuraPly and PuraPly AM. Comment: One commenter, the manufacturer of PuraPly and PuraPly AM, urged CMS to implement the proposal to give PuraPly and PuraPly AM pass-through payment status based on the requirements of section 1833(t)(6)(G) of the Act, as added by section 1301(a)(1)(C) of the Consolidated Appropriations Act of 2018. The commenter stated that PuraPly and PuraPly AM are biologicals and cited language in OPPS regulations supporting that designation. The commenter also made the point that the pass-through payment status granted to PuraPly and PuraPly AM starting on October 1, 2018 was described in the statute as an extension of the original pass-through payment status and not a new pass-through payment period. The commenter stated that this means the requirements in effect when passthrough payment status for PuraPly and PuraPly AM was established on January 1, 2015 apply to the extended passthrough payment period. The commenter noted that CMS changed how skin substitute products are evaluated for pass-through payment status by evaluating skin substitutes through the medical device passthrough pathway in April of 2015, but emphasized that the change was not retroactive. Therefore, the commenter agreed that PuraPly and PuraPly AM should continue to receive pass-through payment status. Several members of Congress supported extending pass-through payment status for PuraPly and PuraPly E:\FR\FM\21NOR2.SGM 21NOR2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations AM and requested that CMS consider the products to be biologicals that are covered by section 1833(t)(6)(G) of the Act, as added by section 1301(a)(1)(C) of the Consolidated Appropriations Act of 2018. Response: We appreciate the commenters’ support. We are finalizing our proposal to extend pass-through payment status for PuraPly and PuraPly AM based on section 1833(t)(6)(G) of the Act, as added by section 1301(a)(1)(C) of the Consolidated Appropriations Act of 2018. Comment: One commenter, the manufacturer of Omidria (HCPCS code C9447), supported the extended passthrough payment status for Omidria. Likewise, a second commenter, the manufacturer of Lumason® (HCPCS code Q9950), supported the extended pass-through payment status for Lumason®. Response: We appreciate the commenters’ support. After consideration of the public comments we received, we are finalizing our proposals, with modification, to accommodate a coding change related to the PuraPly products. Specifically, after the proposed rule was published, we became aware that HCPCS code Q4172 (Puraply, and Puraply AM per square centimeter) will be deleted effective January 1, 2019, and will be replaced by three new HCPCS codes: Q4195 (Puraply, per square centimeter); Q4196 (Puraply am, per square centimeter); and Q4197 (Puraply xt, per square centimeter), effective January 1, 2019. Two of these products, PuraPly (HCPCS code Q4195) and PuraPly AM (HCPCS code Q4196), were products that received original passthrough payment status on January 1, 2015, and will continue to receive passthrough payment status in CY 2019 when our finalized policies are implemented. For January 1, 2019 through March 31, 2019, we are finalizing our proposal that pass-through payment for the covered drugs and biologicals will be the greater of: (1) ASP+6 percent based on current ASP data; or (2) the payment rate for the drug or biological on December 31, 2017. We also are finalizing our proposal that the passthrough payment amount for these drugs and biologicals will be the amount that applies under section 1833(t)(6)(D)(i) of the Act for the period of April 1, 2019 through December 31, 2019. We are finalizing our proposal to continue to update pass-through payment rates for these covered drugs and biologicals on a quarterly basis on the CMS website during CY 2019 if later quarter ASP submissions (or more recent WAC or AWP information, as applicable) indicate that adjustments to the payment rates for these pass-through drugs or biologicals are necessary. We refer readers to Table 39 below for the drugs and biologicals covered by the requirements of this section. 6. Provisions for Reducing Transitional Pass-Through Payments for PolicyPackaged Drugs, Biologicals, and Radiopharmaceuticals To Offset Costs Packaged Into APC Groups drugs. Also under 42 CFR 419.2(b), nonpass-through drugs and biologicals that function as supplies in a surgical procedure are packaged in the OPPS. This category includes skin substitutes and other surgical-supply drugs and biologicals. As described earlier, section 1833(t)(6)(D)(i) of the Act specifies that the transitional pass-through payment amount for pass-through drugs and biologicals is the difference between the amount paid under section 1842(o) of the Act and the otherwise applicable OPD fee schedule amount. Because a payment offset is necessary in order to provide an appropriate transitional pass-through payment, we deduct from the pass-through payment for policypackaged drugs, biologicals, and radiopharmaceuticals an amount reflecting the portion of the APC payment associated with predecessor products in order to ensure no duplicate payment is made. This amount reflecting the portion of the APC payment associated with predecessor products is called the payment offset. The payment offset policy applies to all policy packaged drugs, biologicals, and radiopharmaceuticals. For a full Under the regulations at 42 CFR 419.2(b), nonpass-through drugs, biologicals, and radiopharmaceuticals that function as supplies when used in a diagnostic test or procedure are packaged in the OPPS. This category includes diagnostic radiopharmaceuticals, contrast agents, stress agents, and other diagnostic VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 PO 00000 Frm 00146 Fmt 4701 Sfmt 4700 E:\FR\FM\21NOR2.SGM 21NOR2 ER21NO18.062</GPH> khammond on DSK30JT082PROD with RULES2 58962 58963 description of the payment offset policy as applied to diagnostic radiopharmaceuticals, contrast agents, stress agents, and skin substitutes, we refer readers to the discussion in the CY 2016 OPPS/ASC final rule with comment period (80 FR 70430 through 70432). In the CY 2019 OPPS/ASC proposed rule (83 FR 37115), for CY 2019, as we did in CY 2018, we proposed to continue to apply the same policy packaged offset policy to payment for pass-through diagnostic radiopharmaceuticals, pass-through contrast agents, pass-through stress agents, and pass-through skin substitutes. The proposed APCs to which a payment offset may be applicable for pass-through diagnostic radiopharmaceuticals, pass-through contrast agents, pass-through stress agents, and pass-through skin substitutes were identified in Table 22 of the proposed rule (83 FR 37115). We did not receive any comments on this proposal. Therefore, we are finalizing this proposal without modification. In the CY 2019 OPPS/ASC proposed rule, we proposed to continue to post annually on the CMS website at: https:// www.cms.gov/Medicare/Medicare-Feefor-Service-Payment/ HospitalOutpatientPPS/Annual-PolicyFiles.html a file that contains the APC offset amounts that will be used for that year for purposes of both evaluating cost significance for candidate pass-through payment device categories and drugs and biologicals and establishing any appropriate APC offset amounts. Specifically, the file will continue to provide the amounts and percentages of APC payment associated with packaged implantable devices, policy-packaged drugs, and threshold packaged drugs and biologicals for every OPPS clinical APC. We did not receive any public comments on our proposal, and therefore are finalizing it without modification. B. OPPS Payment for Drugs, Biologicals, and Radiopharmaceuticals Without Pass-Through Payment Status (which is discussed in more detail in the CY 2007 OPPS/ASC final rule with comment period (71 FR 68085 through 68086)), we set the packaging threshold for establishing separate APCs for drugs and biologicals at $120 for CY 2018 (82 FR 59343). Following the CY 2007 methodology, for this CY 2019 OPPS/ASC final rule with comment period, we used the most recently available four quarter moving average PPI levels to trend the $50 threshold forward from the third quarter of CY 2005 to the third quarter of CY 2019 and rounded the resulting dollar amount ($127.01) to the nearest $5 increment, which yielded a figure of $125. In performing this calculation, we used the most recent forecast of the quarterly index levels for the PPI for Pharmaceuticals for Human Use (Prescription) (Bureau of Labor Statistics series code WPUSI07003) from CMS’ Office of the Actuary. For this CY 2019 OPPS/ASC final rule with comment period, based on these calculations using the CY 2007 OPPS methodology, VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 1. Criteria for Packaging Payment for Drugs, Biologicals, and Radiopharmaceuticals a. Packaging Threshold In accordance with section 1833(t)(16)(B) of the Act, the threshold for establishing separate APCs for payment of drugs and biologicals was set to $50 per administration during CYs 2005 and 2006. In CY 2007, we used the four quarter moving average Producer Price Index (PPI) levels for Pharmaceutical Preparations (Prescription) to trend the $50 threshold forward from the third quarter of CY 2005 (when the Pub. L. 108–173 mandated threshold became effective) to the third quarter of CY 2007. We then rounded the resulting dollar amount to the nearest $5 increment in order to determine the CY 2007 threshold amount of $55. Using the same methodology as that used in CY 2007 PO 00000 Frm 00147 Fmt 4701 Sfmt 4700 E:\FR\FM\21NOR2.SGM 21NOR2 ER21NO18.063</GPH> khammond on DSK30JT082PROD with RULES2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations 58964 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations khammond on DSK30JT082PROD with RULES2 we are finalizing a packaging threshold for CY 2019 of $125. b. Packaging of Payment for HCPCS Codes That Describe Certain Drugs, Certain Biologicals, and Therapeutic Radiopharmaceuticals Under the Cost Threshold (‘‘Threshold-Packaged Drugs’’) In the CY 2019 OPPS/ASC proposed rule (83 FR 37116), to determine the proposed CY 2019 packaging status for all nonpass-through drugs and biologicals that are not policy packaged, we calculated, on a HCPCS codespecific basis, the per day cost of all drugs, biologicals, and therapeutic radiopharmaceuticals (collectively called ‘‘threshold-packaged’’ drugs) that had a HCPCS code in CY 2017 and were paid (via packaged or separate payment) under the OPPS. We used data from CY 2017 claims processed before January 1, 2018 for this calculation. However, we did not perform this calculation for those drugs and biologicals with multiple HCPCS codes that include different dosages, as described in section V.B.1.d. of the proposed rule, or for the following policy-packaged items that we proposed to continue to package in CY 2019: Anesthesia drugs; drugs, biologicals, and radiopharmaceuticals that function as supplies when used in a diagnostic test or procedure; and drugs and biologicals that function as supplies when used in a surgical procedure. In order to calculate the per day costs for drugs, biologicals, and therapeutic radiopharmaceuticals to determine their proposed packaging status in CY 2019, we used the methodology that was described in detail in the CY 2006 OPPS proposed rule (70 FR 42723 through 42724) and finalized in the CY 2006 OPPS final rule with comment period (70 FR 68636 through 68638). For each drug and biological HCPCS code, we used an estimated payment rate of ASP+6 percent (which is the payment rate we proposed for separately payable drugs and biologicals for CY 2019, as discussed in more detail in section V.B.2.b. of the proposed rule) to calculate the CY 2019 proposed rule per day costs. We used the manufacturersubmitted ASP data from the fourth quarter of CY 2017 (data that were used for payment purposes in the physician’s office setting, effective April 1, 2018) to determine the proposed rule per day cost. As is our standard methodology, for CY 2019, we proposed to use payment rates based on the ASP data from the first quarter of CY 2018 for budget neutrality estimates, packaging determinations, impact analyses, and completion of Addenda A and B to the VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 proposed rule (which are available via the internet on the CMS website) because these were the most recent data available for use at the time of development of the proposed rule. These data also were the basis for drug payments in the physician’s office setting, effective April 1, 2018. For items that did not have an ASP-based payment rate, such as some therapeutic radiopharmaceuticals, we used their mean unit cost derived from the CY 2017 hospital claims data to determine their per day cost. We proposed to package items with a per day cost less than or equal to $125, and identify items with a per day cost greater than $125 as separately payable unless they are policy-packaged. Consistent with our past practice, we cross-walked historical OPPS claims data from the CY 2017 HCPCS codes that were reported to the CY 2018 HCPCS codes that we displayed in Addendum B to the proposed rule (which is available via the internet on the CMS website) for proposed payment in CY 2019. Comment: A few commenters requested that CMS not finalize the proposed increase to the packaging threshold to $125 and suggested that CMS instead lower the packaging threshold. These commenters expressed concern with the annual increases in the drug packaging threshold, citing that yearly increases have outpaced conversion factor updates and place a financial burden on providers. Response: We have received and addressed similar comments in prior rules, including most recently in the CY 2017 OPPS/ASC final rule with comment period (81 FR 79666). As we stated in the CY 2007 OPPS/ASC final rule with comment period (71 FR 68086), we believe that packaging certain items is a fundamental component of a prospective payment system, that updating the packaging threshold of $50 for the CY 2005 OPPS is consistent with industry and government practices, and that the PPI for Prescription Drugs is an appropriate mechanism to gauge Part B drug inflation. Therefore, because packaging is a fundamental component of a prospective payment system that continues to provide important flexibility and efficiency in the delivery of high quality hospital outpatient services, we are not adopting the commenters’ recommendation to delay updating the packaging threshold or freeze the packaging threshold at $120. After consideration of the public comments we received, and consistent with our methodology for establishing the packaging threshold using the most PO 00000 Frm 00148 Fmt 4701 Sfmt 4700 recent PPI forecast data, we are adopting a CY 2019 packaging threshold of $125. Our policy during previous cycles of the OPPS has been to use updated ASP and claims data to make final determinations of the packaging status of HCPCS codes for drugs, biologicals, and therapeutic radiopharmaceuticals for the OPPS/ASC final rule with comment period. We note that it is also our policy to make an annual packaging determination for a HCPCS code only when we develop the OPPS/ASC final rule with comment period for the update year. Only HCPCS codes that are identified as separately payable in the final rule with comment period are subject to quarterly updates. For our calculation of per day costs of HCPCS codes for drugs and biologicals in this CY 2019 OPPS/ASC final rule with comment period, we used ASP data from the third quarter of CY 2018, which is the basis for calculating payment rates for drugs and biologicals in the physician’s office setting using the ASP methodology, effective July 1, 2018, along with updated hospital claims data from CY 2017. We note that we also used these data for budget neutrality estimates and impact analyses for this CY 2019 OPPS/ASC final rule with comment period. Payment rates for HCPCS codes for separately payable drugs and biologicals included in Addenda A and B for this final rule with comment period are based on ASP data from the third quarter of CY 2018. These data are the basis for calculating payment rates for drugs and biologicals in the physician’s office setting using the ASP methodology, effective October 1, 2018. These payment rates will then be updated in the January 2019 OPPS update, based on the most recent ASP data to be used for physician’s office and OPPS payment as of January 1, 2019. For items that do not currently have an ASP-based payment rate, we proposed to recalculate their mean unit cost from all of the CY 2017 claims data and updated cost report information available for this CY 2019 final rule with comment period to determine their final per day cost. Consequently, as stated in the CY 2019 OPPS/ASC proposed rule (83 FR 37117), the packaging status of some HCPCS codes for drugs, biologicals, and therapeutic radiopharmaceuticals in the proposed rule may be different from the same drug HCPCS code’s packaging status determined based on the data used for this final rule with comment period. Under such circumstances, in the CY 2019 OPPS/ASC proposed rule (83 FR 37117), we proposed to continue to follow the established policies E:\FR\FM\21NOR2.SGM 21NOR2 khammond on DSK30JT082PROD with RULES2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations initially adopted for the CY 2005 OPPS (69 FR 65780) in order to more equitably pay for those drugs whose costs fluctuate relative to the proposed CY 2019 OPPS drug packaging threshold and the drug’s payment status (packaged or separately payable) in CY 2018. These established policies have not changed for many years and are the same as described in the CY 2016 OPPS/ ASC final rule with comment period (80 FR 70434). Specifically, for CY 2019, consistent with our historical practice, we proposed to apply the following policies to these HCPCS codes for drugs, biologicals, and therapeutic radiopharmaceuticals whose relationship to the drug packaging threshold changes based on the updated drug packaging threshold and on the final updated data: • HCPCS codes for drugs and biologicals that were paid separately in CY 2018 and that were proposed for separate payment in CY 2019, and that then have per day costs equal to or less than the CY 2019 final rule drug packaging threshold, based on the updated ASPs and hospital claims data used for this CY 2019 final rule, would continue to receive separate payment in CY 2019. • HCPCS codes for drugs and biologicals that were packaged in CY 2018 and that were proposed for separate payment in CY 2019, and that then have per day costs equal to or less than the CY 2019 final rule drug packaging threshold, based on the updated ASPs and hospital claims data used for this CY 2019 final rule, would remain packaged in CY 2019. • HCPCS codes for drugs and biologicals for which we proposed packaged payment in CY 2019 but that then have per-day costs greater than the CY 2019 final rule drug packaging threshold, based on the updated ASPs and hospital claims data used for this CY 2019 final rule, would receive separate payment in CY 2019. We did not receive any public comments on our proposal to recalculate the mean unit cost for items that do not currently have an ASP-based payment rate from all of the CY 2017 claims data and updated cost report information available for this CY 2019 final rule with comment period to determine their final per day cost. We also did not receive any public comments on our proposal to continue to follow the established policies, initially adopted for the CY 2005 OPPS (69 FR 65780), when the packaging status of some HCPCS codes for drugs, biologicals, and therapeutic radiopharmaceuticals in the proposed rule may be different from the same VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 drug HCPCS code’s packaging status determined based on the data used for the final rule with comment period. Therefore, for CY 2019, we are finalizing these two proposals without modification. c. Policy Packaged Drugs, Biologicals, and Radiopharmaceuticals As mentioned earlier in this section, in the OPPS, we package several categories of drugs, biologicals, and radiopharmaceuticals, regardless of the cost of the products. Because the products are packaged according to the policies in 42 CFR 419.2(b), we refer to these packaged drugs, biologicals, and radiopharmaceuticals as ‘‘policypackaged’’ drugs, biologicals, and radiopharmaceuticals. These policies are either longstanding or based on longstanding principles and inherent to the OPPS and are as follows: • Anesthesia, certain drugs, biologicals, and other pharmaceuticals; medical and surgical supplies and equipment; surgical dressings; and devices used for external reduction of fractures and dislocations (§ 419.2(b)(4)); • Intraoperative items and services (§ 419.2(b)(14)); • Drugs, biologicals, and radiopharmaceuticals that function as supplies when used in a diagnostic test or procedure (including, but not limited to, diagnostic radiopharmaceuticals, contrast agents, and pharmacologic stress agents) (§ 419.2(b)(15)); and • Drugs and biologicals that function as supplies when used in a surgical procedure (including, but not limited to, skin substitutes and similar products that aid wound healing and implantable biologicals) (§ 419.2(b)(16)). The policy at § 419.2(b)(16) is broader than that at § 419.2(b)(14). As we stated in the CY 2015 OPPS/ASC final rule with comment period: ‘‘We consider all items related to the surgical outcome and provided during the hospital stay in which the surgery is performed, including postsurgical pain management drugs, to be part of the surgery for purposes of our drug and biological surgical supply packaging policy’’ (79 FR 66875). The category described by § 419.2(b)(15) is large and includes diagnostic radiopharmaceuticals, contrast agents, stress agents, and some other products. The category described by § 419.2(b)(16) includes skin substitutes and some other products. We believe it is important to reiterate that cost consideration is not a factor when determining whether an item is a surgical supply (79 FR 66875). PO 00000 Frm 00149 Fmt 4701 Sfmt 4700 58965 We did not make any proposals to revise our policy-packaged drug policy. We solicited public comment on the general OPPS packaging policies as discussed in section II.3.a. of this final rule with comment period. Comment: One commenter recommended that CMS continue to apply the nuclear medicine procedure to radiolabeled product edits to ensure that all packaged costs are included on nuclear medicine claims in order to establish appropriate payment rates in the future. The commenter was concerned that many providers performing nuclear medicine procedures are not including the cost of diagnostic radiopharmaceuticals used for the procedures in their claims submissions. The commenter believed this lack of drug cost reporting is causing the cost of nuclear medicine procedures to be underreported, and that the radiolabeled product edits will ensure providers are reporting the cost of diagnostic radiopharmaceuticals in their claims data. Response: We do not agree with the commenter that we should reinstate the nuclear medicine procedure to radiolabeled product edits, which required a diagnostic radiopharmaceutical to be present on the same claim as a nuclear medicine procedure for payment under the OPPS to be made. The edits were in place between CY 2008 and CY 2014 (78 FR 75033). We believe the period of time in which the edits were in place was sufficient for hospitals to gain experience reporting procedures involving radiolabeled products and to become accustomed to ensuring that they code and report charges so that their claims fully and appropriately reflect the costs of those radiolabeled products. As with all other items and services recognized under the OPPS, we expect hospitals to code and report their costs appropriately, regardless of whether there are claims processing edits in place. Comment: Several commenters requested that diagnostic radiopharmaceuticals be paid separately in all cases, not just when the drugs have pass-through payment status. The commenters provided limited data that showed that procedures where diagnostic radiopharmaceuticals are considered to be a surgical supply often are paid at a lower rate than what the payment rate is for the diagnostic radiopharmaceutical itself when the drug is paid separately on pass-through payment status. The commenters stated that diagnostic radiopharmaceuticals are highly complex drugs that undergo a rigorous approval process by the FDA. E:\FR\FM\21NOR2.SGM 21NOR2 58966 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations The commenters believed that the type of procedure in which a drug or biological is used should not dictate whether that drug or biological is a supply and is packaged. Response: We continue to believe that diagnostic radiopharmaceuticals are an integral component of many nuclear medicine and imaging procedures and charges associated with radiopharmaceuticals should be reported on hospital claims to the extent they are used. Therefore, payment for the radiopharmaceuticals is reflected within the payment for the primary procedure. While at least one commenter provided limited data showing the proposed cost of the packaged procedure in CY 2019 is substantially lower than the cost of the separately paid radiopharmaceutical on pass-through payment plus the cost of the procedure associated with the radiopharmaceutical, we note the rates are established in a manner that takes the average (more specifically, the geometric mean) of reported costs to furnish the procedure based on data submitted to us from all hospitals paid under the OPPS. Accordingly, the costs that are calculated by Medicare reflect the average costs of items and services that are packaged into a primary procedure and will not necessarily equal the sum of the cost of the primary procedure and the average sales price of items and services because the billing patterns of hospitals may not reflect that a particular item or service is always billed with the primary procedure. Further, the costs will be based on the reported costs submitted to Medicare by hospitals, not the list price established by the manufacturer. Claims data that include the radiopharmaceutical packaged with the associate procedure reflect the combined cost of the procedure and the radiopharmaceutical used in the procedure. khammond on DSK30JT082PROD with RULES2 d. High Cost/Low Cost Threshold for Packaged Skin Substitutes In the CY 2014 OPPS/ASC final rule with comment period (78 FR 74938), we unconditionally packaged skin substitute products into their associated surgical procedures as part of a broader policy to package all drugs and biologicals that function as supplies when used in a surgical procedure. As part of the policy to finalize the packaging of skin substitutes, we also finalized a methodology that divides the skin substitutes into a high cost group and a low cost group, in order to ensure adequate resource homogeneity among APC assignments for the skin substitute application procedures (78 FR 74933). VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 Skin substitutes assigned to the high cost group are described by HCPCS codes 15271 through 15278. Skin substitutes assigned to the low cost group are described by HCPCS codes C5271 through C5278. Geometric mean costs for the various procedures are calculated using only claims for the skin substitutes that are assigned to each group. Specifically, claims billed with HCPCS code 15271, 15273, 15275, or 15277 are used to calculate the geometric mean costs for procedures assigned to the high cost group, and claims billed with HCPCS code C5271, C5273, C5275, or C5277 are used to calculate the geometric mean costs for procedures assigned to the low cost group (78 FR 74935). Each of the HCPCS codes described above are assigned to one of the following three skin procedure APCs according to the geometric mean cost for the code: APC 5053 (Level 3 Skin Procedures) (HCPCS codes C5271, C5275, and C5277); APC 5054 (Level 4 Skin Procedures) (HCPCS codes C5273, 15271, 15275, and 15277); or APC 5055 (Level 5 Skin Procedures) (HCPCS code 15273). In CY 2018, the payment rate for APC 5053 (Level 3 Skin Procedures) was $488.20, the payment rate for APC 5054 (Level 4 Skin Procedures) was $1,568.43, and the payment rate for APC 5055 (Level 5 Skin Procedures) was $2,710.48. This information also is available in Addenda A and B of the CY 2018 OPPS/ASC final rule with comment period (which is available via the internet on the CMS website). We have continued the high cost/low cost categories policy since CY 2014, and in the CY 2019 OPPS/ASC proposed rule (83 FR 37117), we proposed to continue it for CY 2019. Under this current policy, skin substitutes in the high cost category are reported with the skin substitute application CPT codes, and skin substitutes in the low cost category are reported with the analogous skin substitute HCPCS C-codes. For a discussion of the CY 2014 and CY 2015 methodologies for assigning skin substitutes to either the high cost group or the low cost group, we refer readers to the CY 2014 OPPS/ASC final rule with comment period (78 FR 74932 through 74935) and the CY 2015 OPPS/ ASC final rule with comment period (79 FR 66882 through 66885). For a discussion of the high cost/low cost methodology that was adopted in CY 2016 and has been in effect since then, we refer readers to the CY 2016 OPPS/ASC final rule with comment period (80 FR 70434 through 70435). For CY 2019, as with our policy since CY 2016, we proposed to continue to PO 00000 Frm 00150 Fmt 4701 Sfmt 4700 determine the high cost/low cost status for each skin substitute product based on either a product’s geometric mean unit cost (MUC) exceeding the geometric MUC threshold or the product’s per day cost (PDC) (the total units of a skin substitute multiplied by the mean unit cost and divided by the total number of days) exceeding the PDC threshold. For CY 2019, as for CY 2018, we proposed to assign each skin substitute that exceeds either the MUC threshold or the PDC threshold to the high cost group. In addition, as described in more detail later in this section, for CY 2019, as for CY 2018, we proposed to assign any skin substitute with a MUC or a PDC that does not exceed either the MUC threshold or the PDC threshold to the low cost group. For CY 2019, we proposed that any skin substitute product that was assigned to the high cost group in CY 2018 would be assigned to the high cost group for CY 2019, regardless of whether it exceeds or falls below the CY 2019 MUC or PDC threshold. For this CY 2019 OPPS/ASC final rule with comment period, consistent with the methodology as established in the CY 2014 through CY 2017 final rules with comment period, we analyzed updated CY 2017 claims data to calculate the MUC threshold (a weighted average of all skin substitutes’ MUCs) and the PDC threshold (a weighted average of all skin substitutes’ PDCs). The final CY 2019 MUC threshold is $49 per cm2 (rounded to the nearest $1) (proposed at $49 per cm2) and the final CY 2019 PDC threshold is $872 (rounded to the nearest $1) (proposed at $895). For CY 2019, we proposed to continue to assign skin substitutes with passthrough payment status to the high cost category. We proposed to assign skin substitutes with pricing information but without claims data to calculate a geometric MUC or PDC to either the high cost or low cost category based on the product’s ASP+6 percent payment rate as compared to the MUC threshold. If ASP is not available, we proposed to use WAC+3 percent to assign a product to either the high cost or low cost category. Finally, if neither ASP nor WAC is available, we stated in the proposed rule that we would use 95 percent of AWP to assign a skin substitute to either the high cost or low cost category. We proposed to use WAC+3 percent instead of WAC+6 percent to conform to our proposed policy described in section V.B.2.b. of the proposed rule to establish a payment rate of WAC+3 percent for separately payable drugs and biologicals that do not have ASP data available. We also E:\FR\FM\21NOR2.SGM 21NOR2 khammond on DSK30JT082PROD with RULES2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations stated in the proposed rule that new skin substitutes without pricing information would be assigned to the low cost category until pricing information is available to compare to the CY 2019 MUC threshold. For a discussion of our existing policy under which we assign skin substitutes without pricing information to the low cost category until pricing information is available, we refer readers to the CY 2016 OPPS/ASC final rule with comment period (80 FR 70436). Some skin substitute manufacturers have raised concerns about significant fluctuation in both the MUC threshold and the PDC threshold from year to year. The fluctuation in the thresholds may result in the reassignment of several skin substitutes from the high cost group to the low cost group which, under current payment rates, can be a difference of approximately $1,000 in the payment amount for the same procedure. In addition, these stakeholders were concerned that the inclusion of cost data from skin substitutes with pass-through payment status in the MUC and PDC calculations would artificially inflate the thresholds. Skin substitute stakeholders requested that CMS consider alternatives to the current methodology used to calculate the MUC and PDC thresholds and also requested that CMS consider whether it might be appropriate to establish a new cost group in between the low cost group and the high cost group to allow for assignment of moderately priced skin substitutes to a newly created middle group. We share the goal of promoting payment stability for skin substitute products and their related procedures as price stability allows hospitals using such products to more easily anticipate future payments associated with these products. We have attempted to limit year-to-year shifts for skin substitute products between the high cost and low cost groups through multiple initiatives implemented since CY 2014, including: Establishing separate skin substitute application procedure codes for lowcost skin substitutes (78 FR 74935); using a skin substitute’s MUC calculated from outpatient hospital claims data instead of an average of ASP+6 percent as the primary methodology to assign products to the high cost or low cost group (79 FR 66883); and establishing the PDC threshold as an alternate methodology to assign a skin substitute to the high cost group (80 FR 70434 through 70435). To allow additional time to evaluate concerns and suggestions from stakeholders about the volatility of the MUC and PDC thresholds, in the CY VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 2018 OPPS/ASC proposed rule (82 FR 33627), for CY 2018, we proposed that a skin substitute that was assigned to the high cost group for CY 2017 would be assigned to the high cost group for CY 2018, even if it does not exceed the CY 2018 MUC or PDC thresholds. We finalized this policy in the CY 2018 OPPS/ASC final rule with comment period (82 FR 59347). We stated in the CY 2018 OPPS/ASC proposed rule that the goal of our proposal to retain the same skin substitute cost group assignments in CY 2018 as in CY 2017 was to maintain similar levels of payment for skin substitute products for CY 2018 while we study our skin substitute payment methodology to determine whether refinement to the existing policies is consistent with our policy goal of providing payment stability for skin substitutes. We stated in the CY 2018 OPPS/ASC final rule with comment period (82 FR 59347) that we would continue to study issues related to the payment of skin substitutes and take these comments into consideration for future rulemaking. We received many responses to our requests for comments in the CY 2018 OPPS/ASC proposed rule about possible refinements to the existing payment methodology for skin substitutes that would be consistent with our policy goal of providing payment stability for these products. In addition, several stakeholders have made us aware of additional concerns and recommendations since the release of the CY 2018 OPPS/ASC final rule with comment period. As discussed in the CY 2019 OPPS/ASC proposed rule (83 FR 37118 through 37119), we have identified four potential methodologies that have been raised to us that we encouraged the public to review and provide comments on. We stated in the proposed rule that we are especially interested in any specific feedback on policy concerns with any of the options presented as they relate to skin substitutes with differing per day or per episode costs and sizes and other factors that may differ among the dozens of skin substitutes currently on the market. We also specified in the proposed rule that we are interested in any new ideas that are not represented below along with an analysis of how different skin substitute products would fare under such ideas. We stated that we intend to explore the full array of public comments on these ideas for the CY 2020 rulemaking, and we indicated that we will consider the feedback received in response to our requests for comments in the CY 2019 proposed rule in developing proposals for CY 2020. PO 00000 Frm 00151 Fmt 4701 Sfmt 4700 58967 • Establish a lump-sum ‘‘episodebased’’ payment for a wound care episode. Under this option, a hospital would receive a lump sum payment for all wound care services involving procedures using skin substitutes. The payment would be made for a wound care ‘‘episode’’ (such as 12 weeks) for one wound. The lump sum payment could be the same for all skin substitutes or could vary based on the estimated number of applications for a given skin substitute during the wound care episode. Under this option, payment to the provider could be made at the start of treatment, or at a different time, and could be made once or split into multiple payments. Quality metrics, such as using the recommended number of treatments for a given skin substitute during a treatment episode, and establishing a plan of care for patients who do not experience 30 percent wound healing after 4 weeks, could be established to ensure the beneficiary receives appropriate care while limiting excessive additional applications of skin substitute products. • Eliminate the high cost/low cost categories for skin substitutes and only have one payment category and set of procedure codes for all skin substitute products. This option would reduce the financial incentives to use expensive skin substitutes and would provide incentives to use less costly skin substitute products that have been shown to have similar efficacy treating wounds as more expensive skin substitute products. A single payment category would likely have a payment rate that is between the current rates paid for high cost and low cost skin substitute procedures. Initially, a single payment category may lead to substantially higher payment for skin graft procedures performed with cheaper skin substitutes as compared to their costs. However, over time, payment for skin graft procedures using skin substitutes might reflect the lower cost of the procedures. • Allow for the payment of current add-on codes or create additional procedure codes to pay for skin graft services between 26 cm2 and 99 cm2 and substantially over 100 cm2. Under this option, payment for skin substitutes would be made more granularly based on the size of the skin substitute product being applied. This option also would reduce the risk that hospitals may not use enough of a skin substitute to save money when performing a procedure. However, such granularity in the use of skin substitutes could conflict with the goals of a prospective payment system, which is based on a system of averages. Specifically, it is expected that E:\FR\FM\21NOR2.SGM 21NOR2 khammond on DSK30JT082PROD with RULES2 58968 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations some skin graft procedures will be less than 25 cm2 or around 100 cm2 and will receive higher payments compared to the cost of the services. Conversely, services between 26 cm2 and 99 cm2 or those that are substantially larger than 100 cm2 will receive lower payments compared to the cost of the services, but the payments will average over many skin graft procedures to an appropriate payment rate for the provider. • Keep the high cost/low cost skin substitute categories, but change the threshold used to assign skin substitutes in the high cost or low cost group. Consider using other benchmarks that would establish more stable thresholds for the high cost and low cost groups. Ideas include, but are not limited to, fixing the MUC or PDC threshold at an amount from a prior year, or setting global payment targets for high cost and low cost skin substitutes and establishing a threshold that meets the payment targets. Establishing different thresholds for the high cost and low cost groups could allow for the use of a mix of lower cost and higher cost skin substitute products that acknowledges that a large share of skin substitutes products used by Medicare providers are higher cost products but still providing substantial cost savings for skin graft procedures. Different thresholds may also reduce the number of skin substitute products that switch between the high cost and low cost groups in a given year to give more payment stability for skin substitute products. Comment: Several commenters supported the four options presented in the CY 2019 OPPS proposed rule (83 FR 37118 through 37119). Other commenters opposed the four options. Response: We appreciate the feedback we received from the commenters. We will continue to study issues related to changing the methodology for paying for skin substitute products, and we will take these comments into consideration for CY 2020 rulemaking. To allow stakeholders time to analyze and comment on the potential ideas raised above, in the CY 2019 OPPS/ASC proposed rule (83 FR 37119), for CY 2019, we proposed to continue our policy established in CY 2018 to assign skin substitutes to the low cost or high cost group. However, for CY 2020, we stated in the proposed rule that we may revise our policy to reflect one of the potential new methodologies discussed above or a new methodology included in public comments in response to the CY 2019 proposed rule. Specifically, for CY 2019, we proposed to assign a skin substitute with a MUC or a PDC that does not exceed either the MUC VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 threshold or the PDC threshold to the low cost group, unless the product was assigned to the high cost group in CY 2018, in which case we would assign the product to the high cost group for CY 2019, regardless of whether it exceeds the CY 2019 MUC or PDC threshold. We also proposed to assign to the high cost group any skin substitute product that exceeds the CY 2019 MUC or PDC thresholds and assign to the low cost group any skin substitute product that does not exceed the CY 2019 MUC or PDC thresholds and were not assigned to the high cost group in CY 2018. We proposed to continue to use payment methodologies including ASP+6 percent and 95 percent of AWP for skin substitute products that have pricing information but do not have claims data to determine if their costs exceed the CY 2019 MUC. In addition, we proposed to use WAC+3 percent instead of WAC+6 percent for skin substitute products that do not have ASP pricing information or have claims data to determine if those products’ costs exceed the CY 2019 MUC. We also proposed to retain our established policy to assign new skin substitute products with pricing information to the low cost group. Table 23 in the CY 2019 OPPS/ASC proposed rule (83 FR 37119 through 37120) displayed the proposed CY 2019 high cost or low cost category assignment for each skin substitute product. Comment: Two commenters requested that CMS implement a single skin substitute payment category in CY 2019 rather than keeping the current high cost and low cost categories. The commenters believed that the existence of separate categories for high cost and low cost skin substitutes encourages the over-utilization of high cost skin substitutes which increases program cost for CMS and copayments for beneficiaries. Response: At this time, we do not believe that establishing one cost category for all skin substitute products is prudent. While several commenters supported a single payment category for skin substitutes as a potential future refinement to the payment policy for these products, several other commenters expressed significant concern about this payment method. Accordingly, we do not believe it would be appropriate to establish such a major payment change in this final rule with comment period without having proposed it. Comment: A number of commenters supported the proposal to assign a skin substitute with a MUC or a PDC that does not exceed either the MUC PO 00000 Frm 00152 Fmt 4701 Sfmt 4700 threshold or the PDC threshold to the low cost group, unless the product was assigned to the high cost group in CY 2018, in which case CMS would assign the product to the high cost group for CY 2019, regardless of whether it exceeds the CY 2019 MUC or PDC threshold. These commenters also supported the proposal to assign to the high cost group any skin substitute product that exceeds the CY 2019 MUC or PDC thresholds and assign to the low cost group any skin substitute product that does not exceed the CY 2019 MUC or PDC thresholds and was not assigned to the high cost group in CY 2018. One of the commenters supported the proposal for CY 2019, but requested that CMS establish new skin substitute payment policy for CY 2020. Another commenter requested that CMS maintain the current payment methodologies for up to 5 years until a new skin substitute payment system is implemented. Response: We appreciate the support from the commenters for our proposals and their support for developing a new methodology for paying for skin substitute procedures in future rulemaking. Comment: One commenter expressed appreciation to CMS for assigning HCPCS codes Q4122 (Dermacell, per square centimeter) and Q4150 (Allowrap ds or dry, per square centimeter) to the high cost group. Response: We appreciate the commenter’s support. After consideration of the public comments we received, we are finalizing our proposal to assign a skin substitute with a MUC or a PDC that does not exceed either the MUC threshold or the PDC threshold to the low cost group, unless the product was assigned to the high cost group in CY 2018, in which case we would assign the product to the high cost group for CY 2019, regardless of whether it exceeds the CY 2019 MUC or PDC threshold. We also are finalizing our proposal to assign to the high cost group any skin substitute product that exceeds the CY 2019 MUC or PDC thresholds and assign to the low cost group any skin substitute product that does not exceed the CY 2019 MUC or PDC thresholds and was not assigned to the high cost group in CY 2018. We are finalizing our proposal to continue to use payment methodologies including ASP+6 percent and 95 percent of AWP for skin substitute products that have pricing information but do not have claims data to determine if their costs exceed the CY 2019 MUC. In addition, we are finalizing our proposal to use WAC+3 percent instead of WAC+6 E:\FR\FM\21NOR2.SGM 21NOR2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations khammond on DSK30JT082PROD with RULES2 percent for skin substitute products that do not have ASP pricing information or claims data to determine if those products’ costs exceed the CY 2019 MUC. We also are finalizing our VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 proposal to retain our established policy to assign new skin substitute products with pricing information to the low cost group. PO 00000 Frm 00153 Fmt 4701 Sfmt 4700 58969 Table 41 below displays the final CY 2019 cost category assignment for each skin substitute product. BILLING CODE 4120–01–P E:\FR\FM\21NOR2.SGM 21NOR2 58970 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations CY2019 HCPCS Code CY 2019 Short Descriptor C9363 Q4100 Q4101 Q4102 Q4103 Q4104 Q4105 Q4106 Q4107 Q4108 Q4110 Q4111 Q4115 Q4116 Q4117 Q4121 Q4122 Q4123 Q4124 Q4126 Q4127 Q4128 Q4132 Q4133 Q4134 Q4135 Q4136 Q4137 Q4138 Q4140 Q4141 Q4143 Q4146 Q4147 Q4148 Q4150 Integra Meshed Bil Wound Mat Skin Substitute, NOS Apligraf Oasis Wound Matrix Oasis Burn Matrix Integra BMWD Integra DRT Dermagraft GraftJacket Integra Matrix Primatrix Gammagraft Alloskin Alloderm Hyalomatrix Theraskin Dermacell Alloskin Oasis Tri-layer Wound Matrix Memoderm/derma/tranz/integup Talymed Flexhd/Allopatchhd/Matrixhd Grafix core, grafixpl core Grafix stravix prime pl sqcm hMatrix Mediskin Ezderm Amnioexcel biodexcel, 1 sq em Biodfence DryFlex, 1cm Biodfence 1em Alloskin ac, 1em Repriza, 1em Tensix, 1CM Architect ecm, 1em N eox neox rt or clarix cord Allowrap DS or Dry 1 sq em VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 PO 00000 Frm 00154 Fmt 4701 Sfmt 4725 CY2018 High/Low Assignment High Low High Low High High High High High High High Low Low High Low High High High Low High High High High High Low Low Low High High High High High High High High High E:\FR\FM\21NOR2.SGM CY2019 High/Low Assignment High Low High Low High* High High* High High High High* Low Low High Low High* High High Low High* High High High High Low Low Low High High High High* High High High* High High 21NOR2 ER21NO18.064</GPH> khammond on DSK30JT082PROD with RULES2 TABLE 41.-SKIN SUBSTITUTE ASSIGNMENTS TO HIGH COST AND LOW COST GROUPS FOR CY 2019 CY2019 HCPCS Code khammond on DSK30JT082PROD with RULES2 Q4151 Q4152 Q4153 Q4154 Q4156 Q4157 Q4158 Q4159 Q4160 Q4161 Q4163 Q4164 Q4165 Q4166 Q4167 Q4169 Q4170 Q4173 Q4175 Q4176 Q4178 Q4179 Q4180 Q4181 Q4182 Q4183 Q4184 Q4186 Q4187 Q4188 Q4190 Q4191 Q4193 Q4194 Q4195+ Q4196+ Q4197 Q4198 Q4200 Q4201 VerDate Sep<11>2014 20:42 Nov 20, 2018 CY 2019 Short Descriptor AmnioBand, Guardian 1 sq em Dermapure 1 square em Dermavest 1 square em Biovance 1 square em Neox 100 or clarix 100 Revitalon 1 square em Kerecis omega3, per sq em Affinity 1 square em NuShield 1 square em Bio-Connekt per square em Woundex, bioskin, per sq em Helicoll, per square em Keramatrix, per square em Cytal, per square em Truskin, per square em Artacent wound, per sq em Cygnus, per square em Palingen or palingen xplus Miroderm, per square em Neopatch, per square centimeter Floweramniopatch, per sq em Flowerderm, per sq em Revita, per sq em Amnio wound, per square em Transcyte, per sq centimeter Surgigraft, 1 sq em Cellesta, 1 sq em Epifix 1 sq em Epicord 1 sq em Amnioarmor 1 sq em Artacent ac 1 sq em Restorigin 1 sq em Coll-e-derm 1 sq em Novachor 1 sq em Puraply 1 sq em Puraply am 1 sq em Puraply xt 1 sq em Genesis amnio membrane 1sqcm Skin te 1 sq em Matrion 1 sq em Jkt 247001 PO 00000 Frm 00155 Fmt 4701 Sfmt 4725 CY2018 High/Low CY2019 High/Low Assi~nment Assi~nment High High High High High High High High High High High High Low Low Low High Low High High Low High Low High High Low Low Low High High Low Low Low Low Low High High High Low High High High High High High* High* High High High High High* Low Low Low High* Low High High Low High Low High High* Low Low Low High High Low Low Low Low Low High High High Low Low Low Low Low E:\FR\FM\21NOR2.SGM 21NOR2 58971 ER21NO18.065</GPH> Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations e. Packaging Determination for HCPCS Codes That Describe the Same Drug or Biological but Different Dosages khammond on DSK30JT082PROD with RULES2 In the CY 2010 OPPS/ASC final rule with comment period (74 FR 60490 through 60491), we finalized a policy to make a single packaging determination for a drug, rather than an individual HCPCS code, when a drug has multiple HCPCS codes describing different dosages because we believed that adopting the standard HCPCS codespecific packaging determinations for these codes could lead to inappropriate payment incentives for hospitals to report certain HCPCS codes instead of others. We continue to believe that making packaging determinations on a drug-specific basis eliminates payment incentives for hospitals to report certain HCPCS codes for drugs and allows hospitals flexibility in choosing to report all HCPCS codes for different dosages of the same drug or only the lowest dosage HCPCS code. Therefore, in the CY 2019 OPPS/ASC proposed rule (83 FR 37121), we proposed to continue our policy to make packaging determinations on a drug-specific basis, rather than a HCPCS code-specific basis, for those HCPCS codes that describe the same drug or biological but different dosages in CY 2019. VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 For CY 2019, in order to propose a packaging determination that is consistent across all HCPCS codes that describe different dosages of the same drug or biological, we aggregated both our CY 2017 claims data and our pricing information at ASP+6 percent across all of the HCPCS codes that describe each distinct drug or biological in order to determine the mean units per day of the drug or biological in terms of the HCPCS code with the lowest dosage descriptor. The following drugs did not have pricing information available for the ASP methodology for the CY 2019 OPPS/ASC proposed rule, and as is our current policy for determining the packaging status of other drugs, we used the mean unit cost available from the CY 2017 claims data to make the proposed packaging determinations for these drugs: HCPCS code J1840 (Injection, kanamycin sulfate, up to 500 mg); HCPCS code J1850 (Injection, kanamycin sulfate, up to 75 mg); HCPCS code J3472 (Injection, hyaluronidase, ovine, preservative free, per 1,000 usp units); HCPCS code J7100 (Infusion, dextran 40, 500 ml); and HCPCS code J7110 (Infusion, dextran 75, 500 ml). For all other drugs and biologicals that have HCPCS codes describing different doses, we then multiplied the proposed weighted average ASP+6 percent per unit payment amount across PO 00000 Frm 00156 Fmt 4701 Sfmt 4700 all dosage levels of a specific drug or biological by the estimated units per day for all HCPCS codes that describe each drug or biological from our claims data to determine the estimated per day cost of each drug or biological at less than or equal to the proposed CY 2019 drug packaging threshold of $125 (so that all HCPCS codes for the same drug or biological would be packaged) or greater than the proposed CY 2019 drug packaging threshold of $125 (so that all HCPCS codes for the same drug or biological would be separately payable). The proposed packaging status of each drug and biological HCPCS code to which this methodology would apply in CY 2019 was displayed in Table 24 of the CY 2019 OPPS/ASC proposed rule (83 FR 37121). We did not receive any public comments on this proposal. Therefore, for CY 2019, we are finalizing our CY 2019 proposal, without modification, to continue our policy to make packaging determinations on a drug-specific basis, rather than a HCPCS code-specific basis, for those HCPCS codes that describe the same drug or biological but different dosages. Table 42 below displays the final packaging status of each drug and biological HCPCS code to which the finalized methodology applies for CY 2019. E:\FR\FM\21NOR2.SGM 21NOR2 ER21NO18.066</GPH> 58972 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations 58973 TABLE 42.-HCPCS CODES TO WHICH THE CY 2019 DRUG-SPECIFIC PACKAGING DETERMINATION METHODOLOGY APPLIES C9257 J9035 J1020 J1030 J1040 J1460 J1560 J1642 J1644 J1840 J1850 J2788 J2790 J2920 J2930 J3471 khammond on DSK30JT082PROD with RULES2 J3472 J7030 J7040 J7050 J7100 J7110 J7515 J7502 J8520 J8521 J9250 J9260 VerDate Sep<11>2014 CY2019 Status Indicator (SI) CY 2019 Long Descriptor Injection, bevacizumab, 0.25 mg I11:iection, bevacizumab, 10 mg Injection, methylprednisolone acetate, 20 mg Injection, methylprednisolone acetate, 40 mg Injection, methylprednisolone acetate, 80 mg Injection, gamma globulin, intramuscular, 1 cc Injection, gamma globulin, intramuscular over 10 cc Injection, heparin sodium, (heparin lock flush), per 10 units Injection, heparin sodium, per 1000 units l11:jection, kanamycin sulfate, up to 500 mg I11:iection, kanamycin sulfate, up to 75 mg Injection, rho d immune globulin, human, minidose, 50 micrograms (250 i.u.) Injection, rho d immune globulin, human, full dose, 300 micrograms (1500 i.u.) Injection, methylprednisolone sodium succinate, up to 40 mg l11:jection, methylprednisolone sodium succinate, up to 125 mg Injection, hyaluronidase, ovine, preservative free, per 1 usp unit (up to 999 usp units) Injection, hyaluronidase, ovine, preservative free, per 1000 usp units Infusion, normal saline solution, 1000 cc Infusion, normal saline solution, sterile (500 ml=1 unit) Infusion, normal saline solution, 250 cc Infusion, dextran 40, 500 ml Infusion, dextran 75, 500 ml Cyclosporine, oral, 25 mg Cyclosporine, oral, 100 mg Capecitabine, oral, 150 mg Capecitabine, oral, 500 mg Methotrexate sodium, 5 mg Methotrexate sodium, 50 mg 20:42 Nov 20, 2018 Jkt 247001 PO 00000 Frm 00157 Fmt 4701 Sfmt 4725 E:\FR\FM\21NOR2.SGM 21NOR2 K K N N N K K N N N N N N N N N N N N N N N N N N N N N ER21NO18.067</GPH> CY2019 HCPCS Code 58974 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations BILLING CODE 4120–01–C khammond on DSK30JT082PROD with RULES2 2. Payment for Drugs and Biologicals Without Pass-Through Status That Are Not Packaged a. Payment for Specified Covered Outpatient Drugs (SCODs) and Other Separately Payable and Packaged Drugs and Biologicals Section 1833(t)(14) of the Act defines certain separately payable radiopharmaceuticals, drugs, and biologicals and mandates specific payments for these items. Under section 1833(t)(14)(B)(i) of the Act, a ‘‘specified covered outpatient drug’’ (known as a SCOD) is defined as a covered outpatient drug, as defined in section 1927(k)(2) of the Act, for which a separate APC has been established and that either is a radiopharmaceutical agent or is a drug or biological for which payment was made on a pass-through basis on or before December 31, 2002. Under section 1833(t)(14)(B)(ii) of the Act, certain drugs and biologicals are designated as exceptions and are not included in the definition of SCODs. These exceptions are— • A drug or biological for which payment is first made on or after January 1, 2003, under the transitional pass-through payment provision in section 1833(t)(6) of the Act. • A drug or biological for which a temporary HCPCS code has not been assigned. • During CYs 2004 and 2005, an orphan drug (as designated by the Secretary). Section 1833(t)(14)(A)(iii) of the Act requires that payment for SCODs in CY 2006 and subsequent years be equal to the average acquisition cost for the drug for that year as determined by the Secretary, subject to any adjustment for overhead costs and taking into account the hospital acquisition cost survey data collected by the Government Accountability Office (GAO) in CYs 2004 and 2005, and later periodic surveys conducted by the Secretary as set forth in the statute. If hospital acquisition cost data are not available, the law requires that payment be equal to payment rates established under the methodology described in section 1842(o), section 1847A, or section 1847B of the Act, as calculated and adjusted by the Secretary as necessary for purposes of paragraph (14). We refer to this alternative methodology as the ‘‘statutory default.’’ Most physician Part B drugs are paid at ASP+6 percent in accordance with section 1842(o) and section 1847A of the Act. Section 1833(t)(14)(E)(ii) of the Act provides for an adjustment in OPPS payment rates for SCODs to take into VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 account overhead and related expenses, such as pharmacy services and handling costs. Section 1833(t)(14)(E)(i) of the Act required MedPAC to study pharmacy overhead and related expenses and to make recommendations to the Secretary regarding whether, and if so how, a payment adjustment should be made to compensate hospitals for overhead and related expenses. Section 1833(t)(14)(E)(ii) of the Act authorizes the Secretary to adjust the weights for ambulatory procedure classifications for SCODs to take into account the findings of the MedPAC study.57 It has been our policy since CY 2006 to apply the same treatment to all separately payable drugs and biologicals, which include SCODs, and drugs and biologicals that are not SCODs. Therefore, we apply the payment methodology in section 1833(t)(14)(A)(iii) of the Act to SCODs, as required by statute, but we also apply it to separately payable drugs and biologicals that are not SCODs, which is a policy determination rather than a statutory requirement. In the CY 2019 OPPS/ASC proposed rule (83 FR 37122), we proposed to apply section 1833(t)(14)(A)(iii)(II) of the Act to all separately payable drugs and biologicals, including SCODs. Although we do not distinguish SCODs in this discussion, we note that we are required to apply section 1833(t)(14)(A)(iii)(II) of the Act to SCODs, but we also are applying this provision to other separately payable drugs and biologicals, consistent with our history of using the same payment methodology for all separately payable drugs and biologicals. For a detailed discussion of our OPPS drug payment policies from CY 2006 to CY 2012, we refer readers to the CY 2013 OPPS/ASC final rule with comment period (77 FR 68383 through 68385). In the CY 2013 OPPS/ASC final rule with comment period (77 FR 68386 through 68389), we first adopted the statutory default policy to pay for separately payable drugs and biologicals at ASP+6 percent based on section 1833(t)(14)(A)(iii)(II) of the Act. We continued this policy of paying for separately payable drugs and biologicals at the statutory default for CYs 2014 through 2018. Comment: One commenter requested that HCPCS code J0476 (Injection, baclofen, 50 mcg for intrathecal trial) be separately payable in CY 2019 and be 57 Medicare Payment Advisory Committee. June 2005 Report to the Congress. Chapter 6: Payment for pharmacy handling costs in hospital outpatient departments. Available at: https://www.medpac.gov/ docs/default-source/reports/June05_ ch6.pdf?sfvrsn=0. PO 00000 Frm 00158 Fmt 4701 Sfmt 4700 assigned status indicator ‘‘K’’ (Paid under OPPS; separate APC payment). Response: The per day cost of the drug described by HCPCS code J0476 is less than the drug packaging threshold amount of $125. Therefore, the drug described by HCPCS code J0476 will be packaged into the cost of the related services for CY 2019. Comment: One commenter supported the assignment of GenVisc 850, described by HCPCS code J7320, to a separately payable status with status indicator ‘‘K’’ (Paid under OPPS; separate APC payment) for CY 2019. The commenter also requested that TriVisc, described by HCPCS code J7329, also be assigned to a separately payable status for CY 2019. Response: We appreciate the commenter’s support. For HCPCS code J7329, we are not able to assign the code to a payable status because no pricing information is available for the code. If pricing information becomes available prior to the next rulemaking cycle, we would expect to assign a payable status in a quarterly update to the OPPS. b. CY 2019 Payment Policy In the CY 2019 OPPS/ASC proposed rule (83 FR 37122), for CY 2019, we proposed to continue our payment policy that has been in effect since CY 2013 to pay for separately payable drugs and biologicals at ASP+6 percent in accordance with section 1833(t)(14)(A)(iii)(II) of the Act (the statutory default). We proposed to continue to pay for separately payable nonpass-through drugs acquired with a 340B discount at a rate of ASP minus 22.5 percent. We refer readers to section V.A.7. of the proposed rule and this final rule with comment period for more information about how the payment rate for drugs acquired with a 340B discount was established. In the case of a drug or biological during an initial sales period in which data on the prices for sales for the drug or biological are not sufficiently available from the manufacturer, section 1847A(c)(4) of the Act permits the Secretary to make payments that are based on WAC. Under section 1833(t)(14)(A)(iii)(II), the amount of payment for a separately payable drug equals the average price for the drug for the year established under, among other authorities, section 1847A of the Act. As explained in greater detail in the CY 2019 PFS proposed rule, under section 1847A(c)(4), although payments may be based on WAC, unlike section 1847A(b) of the Act (which specifies that certain payments must be made with a 6 percent add-on), section 1847A(c)(4) of the Act does not require that a particular E:\FR\FM\21NOR2.SGM 21NOR2 khammond on DSK30JT082PROD with RULES2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations add-on amount be applied to partial quarter WAC-based pricing. Consistent with section 1847A(c)(4) of the Act, in the CY 2019 PFS proposed rule, we proposed that, effective January 1, 2019, WAC-based payments for Part B drugs made under section 1847A(c)(4) of the Act would utilize a 3 percent add-on in place of the 6 percent add-on that is currently being used per our policy in effect as of CY 2018. For the OPPS, in the CY 2019 OPPS/ASC proposed rule (83 FR 37122), we also proposed to utilize a 3 percent add-on instead of a 6 percent add-on for WAC-based drugs pursuant to our authority under section 1833(t)(14)(A)(iii)(II) of the Act, which provides, in part, that the amount of payment for a SCOD is the average price of the drug in the year established under section 1847A of the Act. We also apply this provision to non-SCOD separately payable drugs. Because we proposed to establish the average price for a WACbased drug under section 1847A of the Act as WAC+3 percent instead of WAC+6 percent, we believe it is appropriate to price separately payable WAC-based drugs at the same amount under the OPPS. We proposed that, if finalized, our proposal to pay for drugs or biologicals at WAC+3 percent, rather than WAC+6 percent, would apply whenever WAC-based pricing is used for a drug or biological. We stated in the proposed rule that for drugs and biologicals that would otherwise be subject to a payment reduction because they were acquired under the 340B Program, the 340B Program rate (in this case, WAC minus 22.5 percent) would continue to apply. We referred readers to the CY 2019 PFS proposed rule for additional background on this anticipated proposal. In the CY 2019 OPPS/ASC proposed rule (83 FR 37123), we proposed that payments for separately payable drugs and biologicals are included in the budget neutrality adjustments, under the requirements in section 1833(t)(9)(B) of the Act. We also proposed that the budget neutral weight scalar not be applied in determining payments for these separately paid drugs and biologicals. We note that separately payable drug and biological payment rates listed in Addenda A and B to this final rule with comment period (available via the internet on the CMS website), which illustrate the final CY 2019 payment of ASP+6 percent for separately payable nonpass-through drugs and biologicals and ASP+6 percent for pass-through drugs and biologicals, reflect either ASP information that is the basis for calculating payment rates for drugs and biologicals in the physician’s office VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 setting effective October 1, 2018, or WAC, AWP, or mean unit cost from CY 2017 claims data and updated cost report information available for this final rule with comment period. In general, these published payment rates are not the same as the actual January 2019 payment rates. This is because payment rates for drugs and biologicals with ASP information for January 2019 will be determined through the standard quarterly process where ASP data submitted by manufacturers for the third quarter of CY 2018 (July 1, 2018 through September 30, 2018) will be used to set the payment rates that are released for the quarter beginning in January 2019 near the end of December 2018. In addition, payment rates for drugs and biologicals in Addenda A and B to this final rule with comment period for which there was no ASP information available for October 2018 are based on mean unit cost in the available CY 2017 claims data. If ASP information becomes available for payment for the quarter beginning in January 2019, we will price payment for these drugs and biologicals based on their newly available ASP information. Finally, there may be drugs and biologicals that have ASP information available for this final rule with comment period (reflecting October 2018 ASP data) that do not have ASP information available for the quarter beginning in January 2019. As stated in the CY 2019 OPPS/ASC proposed rule (83 FR 37123), these drugs and biologicals will then be paid based on mean unit cost data derived from CY 2017 hospital claims. Therefore, the payment rates listed in Addenda A and B to this final rule with comment period are not for January 2019 payment purposes and are only illustrative of the CY 2019 OPPS payment methodology using the most recently available information at the time of issuance of this final rule with comment period. Comment: A number of commenters supported CMS’ proposal to continue to pay for separately payable drugs and biologicals based on the statutory default rate of ASP+6 percent. Response: We appreciate the commenters’ support. Comment: Several commenters supported the proposal to utilize a 3 percent add-on instead of a 6 percent add-on for drugs that are paid based on WAC under section 1847A(c)(4) of the Act, pursuant to CMS’ authority under section 1833(t)(14)(A)(iii)(II) of the Act. These commenters recommended this as a first step to lowering drug costs for beneficiaries and the Medicare Program as well as removing the financial incentive associated with a specific PO 00000 Frm 00159 Fmt 4701 Sfmt 4700 58975 prescribing choice. The commenters suggested modifying the add-on to be a flat fee. Response: We appreciate the commenters’ support. We proposed a fixed percentage, instead of a flat fee, in order to be consistent with other provisions in section 1847A of the Act that specify fixed add-on percentages of 6 percent (section 1847A(b) of the Act) or 3 percent (section 1847A(d)(3)(C) of the Act). A fixed percentage is also administratively simple to implement and administer, is predictable, and is easy for manufacturers, providers and the public to understand. Comment: Many commenters opposed the proposal to utilize a 3 percent addon instead of a 6 percent add-on for drugs that are paid based on WAC under section 1847A(c)(4) of the Act. Several commenters were concerned that paying less for new drugs may discourage the use of innovative drugs due to concerns about decreased payment, especially with the sequestration cuts decreasing the payment further. The commenters also were concerned that the proposal would only affect payment to the provider, and would not address pricing on the pharmaceutical manufacturer side. The commenters requested additional studies to analyze the appropriateness and accuracy of the 3 percent reduction, and encouraged additional modifications to ASP reporting, such as requiring all Part B drug manufacturers to report pricing information and for all Part B drugs to be included in the ASP quarterly update file. Response: We appreciate these comments. The implementation of these proposals will improve Medicare payment rates by better aligning payments with drug acquisition costs, which is of great importance to CMS because spending on Part B drugs has grown significantly. A WAC+3 percent add-on is more comparable to an ASP+6 percent add-on, as the WAC pricing does not reflect many of the discounts associated with ASP, such as rebates. The utilization of a 3 percent add-on instead of a 6 percent add-on for drugs that are paid based on WAC under section 1847A(c)(4) of the Act is consistent with MedPAC’s analysis and recommendations cited in its June 2017 Report to the Congress, and as discussed in the CY 2019 PFS proposed rule (83 FR 35854 through 35855). Overall, this policy still represents a net payment greater than the WAC. In addition, this policy decreases beneficiary costsharing for these drugs, which would help Medicare beneficiaries afford to pay for new drugs by reducing out-ofpocket expenses. E:\FR\FM\21NOR2.SGM 21NOR2 khammond on DSK30JT082PROD with RULES2 58976 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations Comment: Some commenters did not support the inclusion of radiopharmaceuticals in the proposal to utilize a 3 percent add-on instead of a 6 percent add-on for drugs that are paid based on WAC. The commenters cited pharmacy overhead and handling costs for radiopharmaceuticals, pointed out that these costs are higher than for any other class of drugs, and suggested an increased payment rate. In addition, the commenters were concerned that this reduction would disproportionately affect the pass-through payments for diagnostic radiopharmaceuticals. Response: We appreciate these comments. We recognize that radiopharmaceuticals tend to utilize the WAC-based payment methodology more compared to other products. However, no significant evidence has been presented to substantiate that a 3 percent add-on instead of a 6 percent add-on for drugs that are paid based on WAC would negatively affect access, including during the pass-through payment status period, if applicable. We received limited current data from commenters to justify the exclusion of radiopharmaceuticals from this proposal. Comment: Several commenters made recommendations to exclude certain drugs and biologicals from this proposal, including skin substitutes and biosimilar biological products. The commenters were concerned about skin substitutes being assigned to the highor low-cost category when ASP data are not available based on a WAC+3 percent methodology compared to a WAC+6 percent methodology. The commenters recommended maintaining payment for biosimilars at WAC+6 percent to encourage the increase in utilization of biosimilars. Response: We appreciate these comments. However, use of a 3 percent add-on instead of a 6 percent add-on for drugs that are paid based on WAC under section 1847A(c)(4) of the Act is consistent with MedPAC’s analysis and recommendations cited in its June 2017 Report to the Congress, and as discussed in the CY 2019 PFS proposed rule (83 FR 35854 through 35855). This policy is not meant to give preferential treatment to any drugs or biologicals. Comment: Commenters were concerned about coverage for drugs that are not included in the ASP Quarterly Update File being paid at WAC+3 percent instead of the current rate of ASP+6 percent. For example, the commenters were concerned that OTIPRIO (HCPCS code J7342), a drug that is not included in the ASP Quarterly Update File, will not be paid at ASP+6 percent, and would be paid at VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 WAC+3 percent. In addition, the commenters requested clarification regarding MAC payment for drugs that fall under sections 1847A(c)(4) and 1847A(b)(1) of the Act. Response: Drugs that are not included in the ASP Quarterly Update File will continue to be paid at their current rate of ASP+6 percent as long as the manufacturer continues to submit ASP information to CMS on a timely basis and assuming the drug is not packaged. After consideration of the public comments we received, we are finalizing our proposal, without modification, to utilize a 3 percent addon instead of a 6 percent add-on for drugs that are paid based on WAC under section 1847A(c)(4) of the Act pursuant to our authority under section 1833(t)(14)(A)(iii)(II) of the Act. c. Biosimilar Biological Products For CY 2016 and CY 2017, we finalized a policy to pay for biosimilar biological products based on the payment allowance of the product as determined under section 1847A of the Act and to subject nonpass-through biosimilar biological products to our annual threshold-packaged policy (for CY 2016, 80 FR 70445 through 70446; and for CY 2017, 81 FR 79674). In the CY 2018 OPPS/ASC proposed rule (82 FR 33630), for CY 2018, we proposed to continue this same payment policy for biosimilar biological products. In the CY 2018 OPPS/ASC final rule with comment period (82 FR 59351), we noted that, with respect to comments we received regarding OPPS payment for biosimilar biological products, in the CY 2018 PFS final rule, CMS finalized a policy to implement separate HCPCS codes for biosimilar biological products. Therefore, consistent with our established OPPS drug, biological, and radiopharmaceutical payment policy, HCPCS coding for biosimilar biological products will be based on policy established under the CY 2018 PFS final rule. In the CY 2018 OPPS/ASC final rule with comment period (82 FR 59351), after consideration of the public comments we received, we finalized our proposed payment policy for biosimilar biological products, with the following technical correction: All biosimilar biological products will be eligible for pass-through payment and not just the first biosimilar biological product for a reference product. In the CY 2019 OPPS/ASC proposed rule (83 FR 37123), for CY 2019, we proposed to continue the policy in place from CY 2018 to make all biosimilar biological products eligible for pass-through payment and PO 00000 Frm 00160 Fmt 4701 Sfmt 4700 not just the first biosimilar biological product for a reference product. In addition, in CY 2018, we adopted a policy that biosimilars without passthrough payment status that were acquired under the 340B Program would be paid the ASP of the biosimilar minus 22.5 percent of the reference product (82 FR 59367). We adopted this policy in the CY 2018 OPPS/ASC final rule with comment period because we believe that biosimilars without pass-through payment status acquired under the 340B Program should be treated in the same manner as other drugs and biologicals acquired through the 340B Program. As noted earlier, biosimilars with passthrough payment status are paid their own ASP+6 percent of the reference product’s ASP. Separately payable biosimilars that do not have passthrough payment status and are not acquired under the 340B Program are also paid their own ASP+6 percent of the reference product’s ASP. As noted in the CY 2019 OPPS/ASC proposed rule (83 FR 37123), several stakeholders raised concerns to us that the current payment policy for biosimilars acquired under the 340B Program could unfairly lower the OPPS payment for biosimilars not on passthrough payment status because the payment reduction would be based on the reference product’s ASP, which would generally be expected to be priced higher than the biosimilar, thus resulting in a more significant reduction in payment than if the 22.5 percent was calculated based on the biosimilar’s ASP. We agreed with stakeholders that the current payment policy could unfairly lower the price of biosimilars without pass-through payment status that are acquired under the 340B Program. In addition, we believed that these changes would better reflect the resources and production costs that biosimilar manufacturers incur. We also believed this approach is more consistent with the payment methodology for 340B-acquired drugs and biologicals, for which the 22.5 percent reduction is calculated based on the drug or biological’s ASP, rather than the ASP of another product. In addition, we believed that paying for biosimilars acquired under the 340B Program at ASP minus 22.5 percent of the biosimilar’s ASP, rather than 22.5 percent of the reference product’s ASP, will more closely approximate hospitals’ acquisition costs for these products. Accordingly, in the CY 2019 OPPS/ ASC proposed rule (83 FR 37123), for CY 2019, we proposed changes to our Medicare Part B drug payment methodology for biosimilars acquired E:\FR\FM\21NOR2.SGM 21NOR2 khammond on DSK30JT082PROD with RULES2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations under the 340B Program. Specifically, for CY 2019 and subsequent years, in accordance with section 1833(t)(14)(A)(iii)(II) of the Act, we proposed to pay nonpass-through biosimilars acquired under the 340B Program at ASP minus 22.5 percent of the biosimilar’s ASP instead of the biosimilar’s ASP minus 22.5 percent of the reference product’s ASP. Comment: Many commenters supported CMS’ proposal to pay nonpass-through biosimilars acquired under the 340B Program at ASP minus 22.5 percent of the biosimilar’s ASP, in accordance with section 1833(t)(14)(A)(iii)(II) of the Act. The commenters stated that this proposal would ensure fair access to biosimilar treatments. Response: We appreciate the commenters’ support. We believe this proposal appropriately reflects the resources and production costs that manufacturers incur, as well as more closely aligns with the hospitals’ acquisition costs for these products. Comment: Several commenters supported CMS’ proposal to continue the policy in place from CY 2018 to make all biosimilar biological products eligible for pass-through payment and not just the first biosimilar biological product for a reference product. The commenters stated that this proposal would continue to lower costs and improve access to treatments. Response: We appreciate the commenters’ support. Comment: Some commenters recommended eliminating the proposal to continue the policy in place from CY 2018 to make all biosimilar biological products eligible for pass-through payment and not just the first biosimilar biological product for a reference product. The commenters believed this policy could potentially encourage inappropriate treatment changes from a reference product without pass-through payment to a biosimilar product with pass-through payment. Response: We are not convinced that making all biosimilar biological products eligible for pass-through payment will lead to inappropriate treatment changes from a reference product without pass-through payment to a biosimilar product with passthrough payment. Eligibility for passthrough payment status reflects the unique, complex nature of biosimilars and is important as biosimilars become established in the market, just as it is for all other new drugs and biologicals. After consideration of the public comments we received, we are finalizing our proposed payment policy for biosimilar products, without VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 modification, to continue the policy in place from CY 2018 to make all biosimilar biological products eligible for pass-through payment and not just the first biosimilar biological product for a reference product. We also are finalizing our proposal to pay nonpassthrough biosimilars acquired under the 340B Program at the biosimilar’s ASP minus 22.5 percent of the biosimilar’s ASP instead of the biosimilar’s ASP minus 22.5 percent of the reference product’s ASP, in accordance with section 1833(t)(14)(A)(iii)(II) of the Act. 3. Payment Policy for Therapeutic Radiopharmaceuticals In the CY 2019 OPPS/ASC proposed rule (83 FR 37123), for CY 2019, we proposed to continue the payment policy for therapeutic radiopharmaceuticals that began in CY 2010. We pay for separately payable therapeutic radiopharmaceuticals under the ASP methodology adopted for separately payable drugs and biologicals. If ASP information is unavailable for a therapeutic radiopharmaceutical, we base therapeutic radiopharmaceutical payment on mean unit cost data derived from hospital claims. We believe that the rationale outlined in the CY 2010 OPPS/ASC final rule with comment period (74 FR 60524 through 60525) for applying the principles of separately payable drug pricing to therapeutic radiopharmaceuticals continues to be appropriate for nonpass-through, separately payable therapeutic radiopharmaceuticals in CY 2019. Therefore, we proposed for CY 2019 to pay all nonpass-through, separately payable therapeutic radiopharmaceuticals at ASP+6 percent, based on the statutory default described in section 1833(t)(14)(A)(iii)(II) of the Act. For a full discussion of ASP-based payment for therapeutic radiopharmaceuticals, we refer readers to the CY 2010 OPPS/ASC final rule with comment period (74 FR 60520 through 60521). We also proposed to rely on CY 2017 mean unit cost data derived from hospital claims data for payment rates for therapeutic radiopharmaceuticals for which ASP data are unavailable and to update the payment rates for separately payable therapeutic radiopharmaceuticals according to our usual process for updating the payment rates for separately payable drugs and biologicals on a quarterly basis if updated ASP information is unavailable. For a complete history of the OPPS payment policy for therapeutic radiopharmaceuticals, we refer readers to the CY 2005 OPPS final rule with PO 00000 Frm 00161 Fmt 4701 Sfmt 4700 58977 comment period (69 FR 65811), the CY 2006 OPPS final rule with comment period (70 FR 68655), and the CY 2010 OPPS/ASC final rule with comment period (74 FR 60524). The proposed CY 2019 payment rates for nonpassthrough, separately payable therapeutic radiopharmaceuticals were included in Addenda A and B to the proposed rule (which are available via the internet on the CMS website). Comment: Commenters supported continuation of the policy to pay ASP+6 percent for therapeutic radiopharmaceuticals, if available, and to base payment on the mean unit cost derived from hospital claims data when not available. The commenters also requested that CMS examine ways to compensate hospitals for their documented higher overhead and handling costs associated with radiopharmaceuticals. Response: We appreciate the commenters’ support. However, as we stated earlier in section V.B.1.c. of this final rule with comment period in response to a similar request for additional radiopharmaceutical payment and as previously stated in the CY 2018 OPPS final rule with comment period (82 FR 59352), we continue to believe that a single payment is appropriate for radiopharmaceuticals with pass-through payment status in CY 2019 and that the payment rate of ASP+6 percent is appropriate to provide payment for both the radiopharmaceutical’s acquisition cost and any associated nuclear medicine handling and compounding costs incurred by the hospital pharmacy. Payment for the radiopharmaceutical and radiopharmaceutical processing services is made through the single ASP-based payment. We refer readers to the CMS guidance document available via the internet at https://www.cms.gov/ Medicare/Medicare-Fee-for-ServicePayment/HospitalOutpatientPPS/ Archives.html for details on submission of ASP data for therapeutic radiopharmaceuticals. Comment: One commenter asked CMS to clarify the payment rate reported for APC 1675, P32 Na phosphate (HCPCS code A9563), which is based on geometric mean unit cost. The commenter stated that, in the proposed rule, the payment rate for HCPCS code A9563 was reported as $256.00, but the mean unit cost for the radiopharmaceutical as reported in data files accompanying the proposed rule was $519.21. Response: We thank the commenter for bringing this reporting error to our attention. We are providing a corrected payment rate for APC 1675, P32 Na E:\FR\FM\21NOR2.SGM 21NOR2 58978 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations khammond on DSK30JT082PROD with RULES2 phosphate (HCPCS code A9563) in Addenda A and B of this final rule with comment period (which is available via the internet on the CMS website). After consideration of the public comments we received, we are finalizing our proposal, without modification, to continue to pay all nonpass-through, separately payable therapeutic radiopharmaceuticals at ASP+6 percent. We also are finalizing our proposal to continue to rely on CY 2017 mean unit cost data derived from hospital claims data for payment rates for therapeutic radiopharmaceuticals for which ASP data are unavailable. The CY 2019 final payment rates for nonpassthrough separately payable therapeutic radiopharmaceuticals are included in Addenda A and B to this final rule with comment period (which are available via the internet on the CMS website). 4. Payment Adjustment Policy for Radioisotopes Derived From NonHighly Enriched Uranium Sources Radioisotopes are widely used in modern medical imaging, particularly for cardiac imaging and predominantly for the Medicare population. Some of the Technetium-99 (Tc-99m), the radioisotope used in the majority of such diagnostic imaging services, is produced in legacy reactors outside of the United States using highly enriched uranium (HEU). The United States would like to eliminate domestic reliance on these reactors, and is promoting the conversion of all medical radioisotope production to non-HEU sources. Alternative methods for producing Tc99m without HEU are technologically and economically viable, and conversion to such production has begun. We expect that this change in the supply source for the radioisotope used for modern medical imaging will introduce new costs into the payment system that are not accounted for in the historical claims data. Therefore, beginning in CY 2013, we finalized a policy to provide an additional payment of $10 for the marginal cost for radioisotopes produced by non-HEU sources (77 FR 68323). Under this policy, hospitals report HCPCS code Q9969 (Tc-99m from non-highly enriched uranium source, full cost recovery add-on per study dose) once per dose along with any diagnostic scan or scans furnished using Tc-99m as long as the Tc-99m doses used can be certified by the hospital to be at least 95 percent derived from nonHEU sources (77 FR 68321). We stated in the CY 2013 OPPS/ASC final rule with comment period (77 FR 68321) that our expectation is that this VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 additional payment will be needed for the duration of the industry’s conversion to alternative methods to producing Tc-99m without HEU. We also stated that we would reassess, and propose if necessary, on an annual basis whether such an adjustment continued to be necessary and whether any changes to the adjustment were warranted (77 FR 68316). A 2016 report from the National Academies of Sciences, Engineering, and Medicine anticipates the conversion of Tc-99m production from non-HEU sources will not be complete until the end of 2019.58 In addition, one of the manufacturers of Tc-99m generators sent a letter to CMS to support continuing the payment adjustment at the current level because only 30 percent of Tc-99m is produced from non-HEU sources. We also met with a trade group of nuclear pharmacies and cyclotron operators who support an increase in the payment adjustment by the rate of inflation to cover more of the cost of Tc-99m from non-HEU sources. We appreciate the feedback from stakeholders. However, as stated in the CY 2019 OPPS/ASC proposed rule, we continue to believe that the current adjustment is sufficient for the reasons we have outlined in this and prior rulemakings. The information from stakeholders and the National Academies of Sciences, Engineering, and Medicine indicates that the conversion of the production of Tc-99m from non-HEU sources may take more than 1 year after CY 2018. Therefore, in the CY 2019 OPPS/ASC proposed rule (83 FR 37124), for CY 2019 and subsequent years, we proposed to continue to provide an additional $10 payment for radioisotopes produced by non-HEU sources. We noted in the proposed rule our intention to reassess this payment policy once conversion to non-HEU sources is closer to completion or has been completed. Comment: Several commenters requested that the additional payment for radioisotopes produced by non-HEU sources be increased to either $30 or $10 plus the percentage increase in hospital charge data for APC 1442 for the period of 2014 through 2019, which appears to be a request from the commenter to increase the payment by the rate of hospital inflation. One of the commenters supported this request by supplying provider cost data showing the cost difference between HEU Mo-99 58 National Academies of Sciences, Engineering, and Medicine. 2016. Molybdenum-99 for Medical Imaging. Washington, DC: The National Academies Press. Available at: https://doi.org/10.17226/23563. PO 00000 Frm 00162 Fmt 4701 Sfmt 4700 and non-HEU Mo-99 in 2017 per curie was around $30. One commenter requested that CMS provide an explanation for not applying an annual inflation update to the $10 payment for radioisotopes produced by non-HEU sources, provide details on plans to offset nuclear medicine procedures by the amount of cost paid through the non-HEU policy, and make available to the public data regarding the claims submitted to date under this policy. The commenter also stated that CMS should assess whether the beneficiary copayment policy is adversely impacting patient access. Response: We appreciate the information we received from stakeholders supporting an increase to the payment rate of $10 for HCPCS code Q9969. As we stated in the CY 2013 OPPS/ASC final rule with comment period (77 FR 68317), ‘‘The purpose for the additional payment is limited to mitigating any adverse impact of existing payment policy and is based on the authority set forth at section 1833(t)(2)(E) of the Act.’’ However, we are open to further study of this issue and are interested in exploring whether a higher add-on payment, such as $30, may be warranted for a future year. We invite stakeholders to continue to submit data and evidence for further consideration as we continue to evaluate this policy. As discussed in the CY 2013 OPPS/ASC final rule with comment period, we did not finalize a policy to use the usual OPPS methodologies to update the non-HEU add-on payment (77 FR 68317). The purpose of the additional payment is limited to mitigating any adverse impact of transitioning to non-HEU sources and is based on the authority set forth at section 1833(t)(2)(E) of the Act. Therefore, we will maintain the current payment rate of $10. With respect to the comment that we should assess whether the beneficiary copayment amount is adversely affecting patient access, we will consider the commenter’s concern. However, we note that increasing the add-on payment from the current level as the commenter suggested would necessarily increase the beneficiary copayment liability. Finally, the offset for nuclear medicine procedures does not include the cost of the non-HEU add-on payment. Comment: One commenter requested that CMS provide detailed data on hospital costs associated with radiopharmaceuticals reported with HCPCS code Q9969. Response: It is unclear what specific data this commenter is seeking that are not already available through public use E:\FR\FM\21NOR2.SGM 21NOR2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations khammond on DSK30JT082PROD with RULES2 files. We note that, in 2017, HCPCS code Q9969 was billed 34,439 times and is commonly reported with Level II HCPCS codes A9500 (Technetium tc99m sestamibi, diagnostic, per study dose) and A9503 (Technetium tc-99m medronate, diagnostic, per study dose, up to 30 millicuries). The geometric mean costs of this and all Level II HCPCS drug codes, including radiopharmaceutical drug codes, can be found in the cost statistics file that is released with this final rule with comment period. After consideration of the public comments we received, we are finalizing our proposal, without modification, to continue the policy of providing an additional $10 payment for radioisotopes produced by non-HEU sources for CY 2019 and subsequent years. We will reassess this payment policy once conversion to non-HEU sources is closer to completion or has been completed. 5. Payment for Blood Clotting Factors For CY 2018, we provided payment for blood clotting factors under the same methodology as other nonpass-through separately payable drugs and biologicals under the OPPS and continued paying an updated furnishing fee (82 FR 59353). That is, for CY 2018, we provided payment for blood clotting factors under the OPPS at ASP+6 percent, plus an additional payment for the furnishing fee. We note that when blood clotting factors are provided in physicians’ offices under Medicare Part B and in other Medicare settings, a furnishing fee is also applied to the payment. The CY 2018 updated furnishing fee was $0.215 per unit. In the CY 2019 OPPS/ASC proposed rule (83 FR 37124), for CY 2019, we proposed to pay for blood clotting factors at ASP+6 percent, consistent with our proposed payment policy for other nonpass-through, separately payable drugs and biologicals, and to continue our policy for payment of the furnishing fee using an updated amount. Our policy to pay for a furnishing fee for blood clotting factors under the OPPS is consistent with the methodology applied in the physician’s office and in the inpatient hospital setting. These methodologies were first articulated in the CY 2006 OPPS final rule with comment period (70 FR 68661) and later discussed in the CY 2008 OPPS/ASC final rule with comment period (72 FR 66765). The proposed furnishing fee update was based on the percentage increase in the Consumer Price Index (CPI) for medical care for the 12-month period ending with June of the previous year. Because the Bureau of Labor VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 Statistics releases the applicable CPI data after the PFS and OPPS/ASC proposed rules are published, we were not able to include the actual updated furnishing fee in the proposed rules. Therefore, in accordance with our policy, as finalized in the CY 2008 OPPS/ASC final rule with comment period (72 FR 66765), we proposed to announce the actual figure for the percent change in the applicable CPI and the updated furnishing fee calculated based on that figure through applicable program instructions and posting on the CMS website at: https:// www.cms.gov/Medicare/Medicare-Feefor-Service-Part-B-Drugs/ McrPartBDrugAvgSalesPrice/ index.html. Comment: Commenters supported CMS’ proposal to continue to pay for blood clotting factors at ASP+6 percent plus a blood clotting factor furnishing fee in the hospital outpatient department. Response: We appreciate the commenters’ support. After consideration of the public comments we received, we are finalizing our proposal, without modification, to provide payment for blood clotting factors under the same methodology as other separately payable drugs and biologicals under the OPPS and to continue payment of an updated furnishing fee. We will announce the actual figure of the percent change in the applicable CPI and the updated furnishing fee calculation based on that figure through the applicable program instructions and posting on the CMS website. 6. Payment for Nonpass-Through Drugs, Biologicals, and Radiopharmaceuticals With HCPCS Codes but Without OPPS Hospital Claims Data In the CY 2019 OPPS/ASC proposed rule (83 FR 37125), for CY 2019, we proposed to continue to use the same payment policy as in CY 2018 for nonpass-through drugs, biologicals, and radiopharmaceuticals with HCPCS codes but without OPPS hospital claims data, which describes how we determine the payment rate for drugs, biologicals, or radiopharmaceuticals without an ASP. For a detailed discussion of the payment policy and methodology, we refer readers to the CY 2016 OPPS/ASC final rule with comment period (80 FR 70442 through 70443). The proposed CY 2019 payment status of each of the nonpass-through drugs, biologicals, and radiopharmaceuticals with HCPCS codes but without OPPS hospital claims data was listed in Addendum B to the PO 00000 Frm 00163 Fmt 4701 Sfmt 4700 58979 proposed rule, which is available via the internet on the CMS website. We did not receive any comments on our proposal. Therefore, we are finalizing our CY 2019 proposal without modification, including our proposal to assign drug or biological products status indicator ‘‘K’’ and pay for them separately for the remainder of CY 2019 if pricing information becomes available. The CY 2019 payment status of each of the nonpass-through drugs, biologicals, and radiopharmaceuticals with HCPCS codes but without OPPS hospital claims data is listed in Addendum B to this final rule with comment period, which is available via the internet on the CMS website. 7. CY 2019 OPPS Payment Methodology for 340B Purchased Drugs In the CY 2018 OPPS/ASC proposed rule (82 FR 33558 through 33724), we proposed changes to the Medicare Part B drug payment methodology for 340B hospitals. We proposed these changes to better, and more accurately, reflect the resources and acquisition costs that these hospitals incur. We believed that such changes would allow Medicare beneficiaries (and the Medicare program) to pay a more appropriate amount when hospitals participating in the 340B Program furnish drugs to Medicare beneficiaries that are purchased under the 340B Program. Subsequently, in the CY 2018 OPPS/ ASC final rule with comment period (82 FR 59369 through 59370), we finalized our proposal and adjusted the payment rate for separately payable drugs and biologicals (other than drugs on passthrough payment status and vaccines) acquired under the 340B Program from average sales price (ASP)+6 percent to ASP minus 22.5 percent. Our goal is to make Medicare payment for separately payable drugs more aligned with the resources expended by hospitals to acquire such drugs, while recognizing the intent of the 340B Program to allow covered entities, including eligible hospitals, to stretch scarce resources in ways that enable hospitals to continue providing access to care for Medicare beneficiaries and other patients. Critical access hospitals are not included in this 340B policy change because they are paid under section 1834(g) of the Act. We also excepted rural sole community hospitals, children’s hospitals, and PPSexempt cancer hospitals from the 340B payment adjustment in CY 2018. In addition, as stated in the CY 2018 OPPS/ASC final rule with comment period, this policy change does not apply to drugs on pass-through payment status, which are required to be paid based on the ASP methodology, or E:\FR\FM\21NOR2.SGM 21NOR2 khammond on DSK30JT082PROD with RULES2 58980 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations vaccines, which are excluded from the 340B Program. As discussed in the CY 2019 OPPS/ ASC proposed rule (83 FR 37125), another topic that has been brought to our attention since we finalized the payment adjustment for 340B-acquired drugs in the CY 2018 OPPS/ASC final rule with comment period is whether drugs that do not have ASP pricing but instead receive WAC or AWP pricing are subject to the 340B payment adjustment. We did not receive public comments on this topic in response to the CY 2018 OPPS/ASC proposed rule. However, we have since heard from stakeholders that there has been some confusion about this issue. We clarified in the CY 2019 proposed rule that the 340B payment adjustment applies to drugs that are priced using either WAC or AWP, and it has been our policy to subject 340B-acquired drugs that use these pricing methodologies to the 340B payment adjustment since the policy was first adopted. The 340B payment adjustment for WAC-priced drugs is WAC minus 22.5 percent and AWPpriced drugs have a payment rate of 69.46 percent of AWP when the 340B payment adjustment is applied. The 69.46 percent of AWP is calculated by first reducing the original 95 percent of AWP price by 6 percent to generate a value that is similar to ASP or WAC with no percentage markup. Then we apply the 22.5 percent reduction to ASP/WAC-similar AWP value to obtain the 69.46 percent of AWP, which is similar to either ASP minus 22.5 percent or WAC minus 22.5 percent. The number of separately payable drugs receiving WAC or AWP pricing that are affected by the 340B payment adjustment is small—consisting of less than 10 percent of all separately payable Medicare Part B drugs in April 2018. Furthermore, data limitations previously inhibited our ability to identify which drugs were acquired under the 340B Program in the Medicare OPPS claims data. This lack of information within the claims data has limited researchers’ and our ability to precisely analyze differences in acquisition cost of 340B and non-340B acquired drugs with Medicare claims data. Accordingly, in the CY 2018 OPPS/ASC proposed rule (82 FR 33633), we stated our intent to establish a modifier, to be effective January 1, 2018, for hospitals to report with separately payable drugs that were not acquired under the 340B Program. Because a significant portion of hospitals paid under the OPPS participate in the 340B Program, we stated our belief that it is appropriate to presume that a separately payable drug reported on an OPPS claim VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 was purchased under the 340B Program, unless the hospital identifies that the drug was not purchased under the 340B Program. We stated in the CY 2018 proposed rule that we intended to provide further details about this modifier in the CY 2018 OPPS/ASC final rule with comment period and/or through subregulatory guidance, including guidance related to billing for dually eligible beneficiaries (that is, beneficiaries covered under Medicare and Medicaid) for whom covered entities do not receive a discount under the 340B Program. As discussed in the CY 2018 OPPS/ASC final rule with comment period (82 FR 59369 through 59370), to effectuate the payment adjustment for 340B-acquired drugs, CMS implemented modifier ‘‘JG’’, effective January 1, 2018. Hospitals paid under the OPPS, other than a type of hospital excluded from the OPPS (such as critical access hospitals or those hospitals paid under the Maryland waiver), or excepted from the 340B drug payment policy for CY 2018, are required to report modifier ‘‘JG’’ on the same claim line as the drug HCPCS code to identify a 340B-acquired drug. For CY 2018, rural sole community hospitals, children’s hospitals and PPS-exempt cancer hospitals are excepted from the 340B payment adjustment. These hospitals are required to report informational modifier ‘‘TB’’ for 340Bacquired drugs, and continue to be paid ASP+6 percent. We refer readers to the CY 2018 OPPS/ASC final rule with comment period (82 FR 59353 through 59370) for a full discussion and rationale for the CY 2018 policies and use of modifier ‘‘JG’’. In the CY 2019 OPPS/ASC proposed rule (83 FR 37125), for CY 2019, we proposed to continue the 340B Program policies that were implemented in CY 2018 with the exception of the way we calculate payment for 340B-acquired biosimilars (that is, we proposed to pay for nonpass-through 340B-acquired biosimilars at ASP minus 22.5 percent of the biosimilar’s ASP, rather than of the reference product’s ASP). More information on our revised policy for the payment of biosimilars acquired through the 340B Program is available in section V.B.2.c. of this final rule. We proposed, in accordance with section 1833(t)(14)(A)(iii)(II) of the Act, to pay for separately payable Medicare Part B drugs (assigned status indicator ‘‘K’’), other than vaccines and drugs on passthrough payment status, that meet the definition of ‘‘covered outpatient drug’’ as defined in section 1927(k) of the Act, that are acquired through the 340B Program at ASP minus 22.5 percent PO 00000 Frm 00164 Fmt 4701 Sfmt 4700 when billed by a hospital paid under the OPPS that is not excepted from the payment adjustment. Medicare Part B drugs or biologicals excluded from the 340B payment adjustment include vaccines (assigned status indicator ‘‘L’’ or ‘‘M’’) and drugs with OPPS transitional pass-through payment status (assigned status indicator ‘‘G’’). As discussed in section V.B.2.c. of the proposed rule, we proposed to pay nonpass-through biosimilars acquired under the 340B Program at the biosimilar’s ASP minus 22.5 percent of the biosimilar’s ASP. We also proposed that Medicare would continue to pay for drugs or biologicals that were not purchased with a 340B discount at ASP+6 percent. As stated earlier, to effectuate the payment adjustment for 340B-acquired drugs, CMS implemented modifier ‘‘JG’’, effective January 1, 2018. For CY 2019, we proposed that hospitals paid under the OPPS, other than a type of hospital excluded from the OPPS, or excepted from the 340B drug payment policy for CY 2018, continue to be required to report modifier ‘‘JG’’ on the same claim line as the drug HCPCS code to identify a 340B-acquired drug. We also proposed for CY 2019 that rural sole community hospitals, children’s hospitals, and PPSexempt cancer hospitals continue to be excepted from the 340B payment adjustment. We proposed that these hospitals be required to report informational modifier ‘‘TB’’ for 340Bacquired drugs, and continue to be paid ASP+6 percent. Comment: One commenter supported the proposal to continue to pay for separately payable drugs and biologicals obtained through the 340B program at ASP minus 22.5 percent. The commenter believed the payment rate of ASP minus 22.5 percent will help CMS address the large amount of growth in the 340B Program by increasing oversight and promoting the integrity of the program. Another commenter, MedPAC, also supported the proposal. MedPAC believed a lower payment rate allows beneficiaries to share in the savings from the 340B Program, better targets resources to hospitals providing the most uncompensated care, and still allows 340B hospitals to make a profit off the drugs obtained through the program. MedPAC preferred that the payment rate be ASP+6 percent minus a 10 percent discount with the savings assigned to a Medicare-funded uncompensated care pool, but noted that this policy requires Congressional action. Response: We appreciate the commenters’ support. E:\FR\FM\21NOR2.SGM 21NOR2 khammond on DSK30JT082PROD with RULES2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations Comment: Several commenters opposed the CY 2019 proposal to continue to pay for separately payable drugs and biologicals obtained through the 340B Program at ASP minus 22.5 percent. Many commenters stated that the new payment rate has hurt hospitals financially and has hurt efforts by hospitals to provide safety-net care to their patients. The commenters were also concerned about the same service costing more at non-340B hospitals than at hospitals enrolled in the 340B Program because drugs furnished at a non-340B hospital would be paid at ASP+6 percent while drugs furnished at a 340B hospital would be paid at ASP minus 22.5 percent. One commenter whose hospital provides cancer treatment stated the reductions in 340B payment mean the hospital cannot provide the broader cancer care options available at non-340B hospitals. Commenters also stated that reducing payment for drugs acquired through the 340B Program does not help reduce high drug costs. Many commenters asserted, as they have previously done, that CMS does not have the legal authority to implement payment reductions for drugs and biologicals obtained through the 340B Program. The commenters requested that CMS end its policy of paying for drugs obtained through the 340B program at ASP minus 22.5 percent. Instead, the commenters suggested that CMS go back to the payment policy that was in place before CY 2018 where drugs acquired through the 340B Program were paid at ASP+6 percent. Response: The commenters stated that the payment rate of ASP minus 22.5 percent for drugs and biologicals has caused financial harm to hospitals and has caused problems for hospitals to provide safety-net care to their patients. We noted in the CY 2018 final rule with comment period (82 FR 59358 through 59359) that the OPPS payment rate of ASP+6 percent at that time significantly exceeded the discounts received for covered outpatient drugs by hospitals enrolled in the 340B Program, which can be as much as 50 percent below ASP (or higher through the PVP). As stated throughout that section, ASP minus 22.5 percent represents the average minimum discount that 340B enrolled hospitals paid under the OPPS receive. Regarding the concerns of the commenters that drugs and biologicals and services where drugs and biologicals are packaged into the cost of the service would cost more at hospitals that do not participate in the 340B Program as compared to hospitals participating in the 340B Program, any VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 differential in these costs is a feature of the 340B Program rather than Medicare payment policy. In fact, one of the objectives of our payment policy for drugs and biologicals acquired through the 340B Program is to lower costs for Medicare beneficiaries, and we believe it is appropriate that hospitals participating in the 340B Program pass the cost savings they receive to their beneficiaries. Finally, regarding the commenters’ assertion that CMS lacks the legal authority to continue requiring payment reductions for drugs and biologicals obtained through the 340B Program, we refer these commenters to our detailed response regarding our statutory authority to require payment reductions for drugs and biologicals obtained through the 340B Program in the CY 2018 OPPS/ASC final rule with comment period (82 FR 59359 through 59364). After consideration of the public comments we received, we are finalizing our proposals without modification. For CY 2019, we are continuing the 340B Program policies that were implemented in CY 2018 with the exception of the way we are calculating payment for 340B-acquired biosimilars, which is discussed in section V.B.2.c. of this final rule with comment period. We refer readers to the CY 2018 final rule with comment period (82 FR 59369 through 59370) for more detail on the policies implemented in CY 2018 for drugs acquired through the 340B Program. VI. Estimate of OPPS Transitional PassThrough Spending for Drugs, Biologicals, Radiopharmaceuticals, and Devices A. Background Section 1833(t)(6)(E) of the Act limits the total projected amount of transitional pass-through payments for drugs, biologicals, radiopharmaceuticals, and categories of devices for a given year to an ‘‘applicable percentage,’’ currently not to exceed 2.0 percent of total program payments estimated to be made for all covered services under the OPPS furnished for that year. If we estimate before the beginning of the calendar year that the total amount of passthrough payments in that year would exceed the applicable percentage, section 1833(t)(6)(E)(iii) of the Act requires a uniform prospective reduction in the amount of each of the transitional pass-through payments made in that year to ensure that the limit is not exceeded. We estimate the pass-through spending to determine PO 00000 Frm 00165 Fmt 4701 Sfmt 4700 58981 whether payments exceed the applicable percentage and the appropriate pro-rata reduction to the conversion factor for the projected level of pass-through spending in the following year to ensure that total estimated pass-through spending for the prospective payment year is budget neutral, as required by section 1833(t)(6)(E) of the Act. For devices, developing an estimate of pass-through spending in CY 2019 entails estimating spending for two groups of items. The first group of items consists of device categories that are currently eligible for pass-through payment and that will continue to be eligible for pass-through payment in CY 2019. The CY 2008 OPPS/ASC final rule with comment period (72 FR 66778) describes the methodology we have used in previous years to develop the pass-through spending estimate for known device categories continuing into the applicable update year. The second group of items consists of items that we know are newly eligible, or project may be newly eligible, for device passthrough payment in the remaining quarters of CY 2018 or beginning in CY 2019. The sum of the CY 2019 passthrough spending estimates for these two groups of device categories equals the total CY 2019 pass-through spending estimate for device categories with passthrough payment status. We base the device pass-through estimated payments for each device category on the amount of payment as established in section 1833(t)(6)(D)(ii) of the Act, and as outlined in previous rules, including the CY 2014 OPPS/ASC final rule with comment period (78 FR 75034 through 75036). We note that, beginning in CY 2010, the pass-through evaluation process and pass-through payment for implantable biologicals newly approved for pass-through payment beginning on or after January 1, 2010, that are surgically inserted or implanted (through a surgical incision or a natural orifice) use the device pass-through process and payment methodology (74 FR 60476). As has been our past practice (76 FR 74335), in the CY 2019 OPPS/ ASC proposed rule (83 FR 37126), we proposed to include an estimate of any implantable biologicals eligible for passthrough payment in our estimate of pass-through spending for devices. Similarly, we finalized a policy in CY 2015 that applications for pass-through payment for skin substitutes and similar products be evaluated using the medical device pass-through process and payment methodology (76 FR 66885 through 66888). Therefore, as we did beginning in CY 2015, for CY 2019, we E:\FR\FM\21NOR2.SGM 21NOR2 khammond on DSK30JT082PROD with RULES2 58982 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations also proposed to include an estimate of any skin substitutes and similar products in our estimate of pass-through spending for devices. For drugs and biologicals eligible for pass-through payment, section 1833(t)(6)(D)(i) of the Act establishes the pass-through payment amount as the amount by which the amount authorized under section 1842(o) of the Act (or, if the drug or biological is covered under a competitive acquisition contract under section 1847B of the Act, an amount determined by the Secretary equal to the average price for the drug or biological for all competitive acquisition areas and year established under such section as calculated and adjusted by the Secretary) exceeds the portion of the otherwise applicable fee schedule amount that the Secretary determines is associated with the drug or biological. Our estimate of drug and biological pass-through payment for CY 2019 for this group of items is $0, as discussed below, because we proposed to pay for most nonpass-through separately payable drugs and biologicals under the CY 2019 OPPS at ASP+6 percent (with the exception of 340Bacquired separately payable drugs, for which we do not yet have sufficient data to estimate a share of total drug payments), and because we proposed to pay for CY 2019 pass-through payment drugs and biologicals at ASP+6 percent, as we discuss in section V.A. of the proposed rule and this final rule with comment period. Furthermore, payment for certain drugs, specifically diagnostic radiopharmaceuticals and contrast agents without pass-through payment status is packaged into payment for the associated procedures, and these products will not be separately paid. In addition, we policy-package all nonpass-through drugs, biologicals, and radiopharmaceuticals that function as supplies when used in a diagnostic test or procedure and drugs and biologicals that function as supplies when used in a surgical procedure, as discussed in section II.A.3. of the proposed rule and this final rule with comment period. In the CY 2019 OPPS/ASC proposed rule (83 FR 37126), we proposed that all of these policy-packaged drugs and biologicals with pass-through payment status would be paid at ASP+6 percent, like other pass-through drugs and biologicals, for CY 2019. Therefore, our estimate of pass-through payment for policy-packaged drugs and biologicals with pass-through payment status approved prior to CY 2019 was not $0, as discussed below. In section V.A.5. of the proposed rule, we discussed our policy to determine if the costs of VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 certain policy-packaged drugs or biologicals are already packaged into the existing APC structure. If we determine that a policy-packaged drug or biological approved for pass-through payment resembles predecessor drugs or biologicals already included in the costs of the APCs that are associated with the drug receiving pass-through payment, we proposed to offset the amount of pass-through payment for the policypackaged drug or biological. For these drugs or biologicals, the APC offset amount is the portion of the APC payment for the specific procedure performed with the pass-through drug or biological, which we refer to as the policy-packaged drug APC offset amount. If we determine that an offset is appropriate for a specific policypackaged drug or biological receiving pass-through payment, we proposed to reduce our estimate of pass-through payments for these drugs or biologicals by this amount. Similar to pass-through spending estimates for devices, the first group of drugs and biologicals requiring a passthrough payment estimate consists of those products that were recently made eligible for pass-through payment and that will continue to be eligible for passthrough payment in CY 2019. The second group contains drugs and biologicals that we know are newly eligible, or project will be newly eligible in the remaining quarters of CY 2018 or beginning in CY 2019. The sum of the CY 2019 pass-through spending estimates for these two groups of drugs and biologicals equals the total CY 2019 pass-through spending estimate for drugs and biologicals with pass-through payment status. B. Estimate of Pass-Through Spending In the CY 2019 OPPS/ASC proposed rule (83 FR 37127), we proposed to set the applicable pass-through payment percentage limit at 2.0 percent of the total projected OPPS payments for CY 2019, consistent with section 1833(t)(6)(E)(ii)(II) of the Act and our OPPS policy from CY 2004 through CY 2018 (82 FR 59371 through 59373). For the first group, consisting of device categories that are currently eligible for pass-through payment and will continue to be eligible for passthrough payment in CY 2019, there are no active categories for CY 2019. Because there are no active device categories for CY 2019, we proposed an estimate for the first group of devices of $0. We did not receive any public comments on the proposal. Therefore, we are finalizing the proposed estimate for the first group of devices of $0 for CY 2019. PO 00000 Frm 00166 Fmt 4701 Sfmt 4700 In estimating our proposed CY 2019 pass-through spending for device categories in the second group, we included: Device categories that we knew at the time of the development of the proposed rule will be newly eligible for pass-through payment in CY 2019; additional device categories that we estimated could be approved for passthrough status subsequent to the development of the proposed rule and before January 1, 2019; and contingent projections for new device categories established in the second through fourth quarters of CY 2019. In the CY 2019 OPPS/ASC proposed rule (83 FR 37127), we proposed to use the general methodology described in the CY 2008 OPPS/ASC final rule with comment period (72 FR 66778), while also taking into account recent OPPS experience in approving new pass-through device categories. For the proposed rule, the estimate of CY 2019 pass-through spending for this second group of device categories was $10 million. We did not receive any public comments on this proposal. As stated earlier in this final rule with comment period, we have decided to approve one device to receive pass-through status, the remede¯® System Transvenous Neurostimulator. The manufacturer of the remede¯® System provided utilization data that indicate the spending for the device would be approximately $2.5 million. However, it is possible that additional new devices may receive pass-through payment status during CY 2019, which would lead to the higher pass-through spending for new devices closer to our proposed estimate of $10 million. Therefore, we are finalizing the proposed estimate for this second group of devices of $10 million for CY 2019. To estimate proposed CY 2019 passthrough spending for drugs and biologicals in the first group, specifically those drugs and biologicals recently made eligible for pass-through payment and continuing on passthrough payment status for CY 2019, we proposed to use the most recent Medicare hospital outpatient claims data regarding their utilization, information provided in the respective pass-through applications, historical hospital claims data, pharmaceutical industry information, and clinical information regarding those drugs or biologicals to project the CY 2019 OPPS utilization of the products. For the known drugs and biologicals (excluding policy-packaged diagnostic radiopharmaceuticals, contrast agents, drugs, biologicals, and radiopharmaceuticals that function as supplies when used in a diagnostic test E:\FR\FM\21NOR2.SGM 21NOR2 khammond on DSK30JT082PROD with RULES2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations or procedure, and drugs and biologicals that function as supplies when used in a surgical procedure) that will be continuing on pass-through payment status in CY 2019, we estimated the pass-through payment amount as the difference between ASP+6 percent and the payment rate for nonpass-through drugs and biologicals that will be separately paid at ASP+6 percent, which is zero for this group of drugs. Because payment for policy-packaged drugs and biologicals is packaged if the product was not paid separately due to its pass-through payment status, we proposed to include in the CY 2019 pass-through estimate the difference between payment for the policypackaged drug or biological at ASP+6 percent (or WAC+6 percent, or 95 percent of AWP, if ASP or WAC information is not available) and the policy-packaged drug APC offset amount, if we determine that the policypackaged drug or biological approved for pass-through payment resembles a predecessor drug or biological already included in the costs of the APCs that are associated with the drug receiving pass-through payment. For the proposed rule, using the proposed methodology described above, we calculated a CY 2019 proposed spending estimate for this first group of drugs and biologicals of approximately $61.5 million. We did not receive any public comments on our proposal. Using our methodology for this final rule with comment period, we calculated a CY 2019 spending estimate for this first group of drugs and biologicals of approximately $50.9 million. To estimate proposed CY 2019 passthrough spending for drugs and biologicals in the second group (that is, drugs and biologicals that we knew at the time of development of the proposed rule were newly eligible for passthrough payment in CY 2019, additional drugs and biologicals that we estimated could be approved for pass-through status subsequent to the development of the proposed rule and before January 1, 2018, and projections for new drugs and biologicals that could be initially eligible for pass-through payment in the second through fourth quarters of CY 2019), we proposed to use utilization estimates from pass-through applicants, pharmaceutical industry data, clinical information, recent trends in the per unit ASPs of hospital outpatient drugs, and projected annual changes in service volume and intensity as our basis for making the CY 2019 pass-through payment estimate. We also proposed to consider the most recent OPPS experience in approving new passthrough drugs and biologicals. Using VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 our proposed methodology for estimating CY 2019 pass-through payments for this second group of drugs, we calculated a proposed spending estimate for this second group of drugs and biologicals of approximately $55.2 million. We did not receive any public comments on our proposal. Therefore, for CY 2019, we are continuing to use the general methodology described above. For this final rule with comment period, we calculated a CY 2019 spending estimate for this second group of drugs and biologicals of approximately $39.9 million. In summary, in accordance with the methodology described earlier in this section, for this final rule with comment period, we estimate that total passthrough spending for the device categories and the drugs and biologicals that are continuing to receive passthrough payment in CY 2019 and those device categories, drugs, and biologicals that first become eligible for passthrough payment during CY 2019 is approximately $100.8 million (approximately $10 million for device categories and approximately $90.8 million for drugs and biologicals) which represents 0.14 percent of total projected OPPS payments for CY 2019 (approximately $74 billion). Therefore, we estimate that pass-through spending in CY 2019 will not amount to 2.0 percent of total projected OPPS CY 2019 program spending. VII. OPPS Payment for Hospital Outpatient Visits and Critical Care Services In the CY 2019 OPPS/ASC proposed rule (83 FR 37128), for CY 2019, we proposed to continue with our current clinic and emergency department (ED) hospital outpatient visits payment policies. For a description of the current clinic and ED hospital outpatient visits policies, we refer readers to the CY 2016 OPPS/ASC final rule with comment period (80 FR 70448). We also proposed to continue and did not propose any change to our payment policy for critical care services for CY 2019. For a description of the current payment policy for critical care services, we refer readers to the CY 2016 OPPS/ASC final rule with comment period (80 FR 70449), and for the history of the payment policy for critical care services, we refer readers to the CY 2014 OPPS/ ASC final rule with comment period (78 FR 75043). In the CY 2019 OPPS/ASC proposed rule, we sought public comments on any changes to these codes that we should consider for future rulemaking cycles. We continue to encourage commenters to provide the PO 00000 Frm 00167 Fmt 4701 Sfmt 4700 58983 data and analysis necessary to justify any suggested changes. We did not receive any public comments on our proposals to continue our current clinic and ED hospital outpatient visits payment policies and our current critical care services payment policies. Therefore, we are adopting these proposals as final without modification. In section X.V. of the CY 2019 OPPS/ ASC proposed rule (83 FR 37138 through 37143), for 2019, we proposed a method to control unnecessary increases in the volume of covered outpatient department services under section 1833(t)(2)(F) of the Act by utilizing a Medicare Physician Fee Schedule (PFS)-equivalent payment rate for the hospital outpatient clinic visit (HCPCS code G0463) when it is furnished by excepted off-campus provider-based departments (PBDs). For a full discussion of the proposal as well as the comment solicitation on potential methods to control for unnecessary increases in the volume of covered outpatient department services, we refer readers to section X.B. of this final rule with comment period. VIII. Payment for Partial Hospitalization Services A. Background A partial hospitalization program (PHP) is an intensive outpatient program of psychiatric services provided as an alternative to inpatient psychiatric care for individuals who have an acute mental illness, which includes, but is not limited to, conditions such as depression, schizophrenia, and substance use disorders. Section 1861(ff)(1) of the Act defines partial hospitalization services as the items and services described in paragraph (2) prescribed by a physician and provided under a program described in paragraph (3) under the supervision of a physician pursuant to an individualized, written plan of treatment established and periodically reviewed by a physician (in consultation with appropriate staff participating in such program), which sets forth the physician’s diagnosis, the type, amount, frequency, and duration of the items and services provided under the plan, and the goals for treatment under the plan. Section 1861(ff)(2) of the Act describes the items and services included in partial hospitalization services. Section 1861(ff)(3)(A) of the Act specifies that a PHP is a program furnished by a hospital to its outpatients or by a community mental health center (CMHC), as a distinct and organized E:\FR\FM\21NOR2.SGM 21NOR2 khammond on DSK30JT082PROD with RULES2 58984 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations intensive ambulatory treatment service, offering less than 24-hour-daily care, in a location other than an individual’s home or inpatient or residential setting. Section 1861(ff)(3)(B) of the Act defines a CMHC for purposes of this benefit. Section 1833(t)(1)(B)(i) of the Act provides the Secretary with the authority to designate the outpatient department (OPD) services to be covered under the OPPS. The Medicare regulations that implement this provision specify, at 42 CFR 419.21, that payments under the OPPS will be made for partial hospitalization services furnished by CMHCs as well as Medicare Part B services furnished to hospital outpatients designated by the Secretary, which include partial hospitalization services (65 FR 18444 through 18445). Section 1833(t)(2)(C) of the Act requires the Secretary, in part, to establish relative payment weights for covered OPD services (and any groups of such services described in section 1833(t)(2)(B) of the Act) based on median (or, at the election of the Secretary, mean) hospital costs using data on claims from 1996 and data from the most recent available cost reports. In pertinent part, section 1833(t)(2)(B) of the Act provides that the Secretary may establish groups of covered OPD services, within a classification system developed by the Secretary for covered OPD services, so that services classified within each group are comparable clinically and with respect to the use of resources. In accordance with these provisions, we have developed the PHP APCs. Because a day of care is the unit that defines the structure and scheduling of partial hospitalization services, we established a per diem payment methodology for the PHP APCs, effective for services furnished on or after July 1, 2000 (65 FR 18452 through 18455). Under this methodology, the median per diem costs were used to calculate the relative payment weights for the PHP APCs. Section 1833(t)(9)(A) of the Act requires the Secretary to review, not less often than annually, and revise the groups, the relative payment weights, and the wage and other adjustments described in section 1833(t)(2) of the Act to take into account changes in medical practice, changes in technology, the addition of new services, new cost data, and other relevant information and factors. We began efforts to strengthen the PHP benefit through extensive data analysis, along with policy and payment changes finalized in the CY 2008 OPPS/ ASC final rule with comment period (72 FR 66670 through 66676). In that final VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 rule with comment period, we made two refinements to the methodology for computing the PHP median: The first remapped 10 revenue codes that are common among hospital-based PHP claims to the most appropriate cost centers; and the second refined our methodology for computing the PHP median per diem cost by computing a separate per diem cost for each day rather than for each bill. In CY 2009, we implemented several regulatory, policy, and payment changes, including a two-tier payment approach for partial hospitalization services under which we paid one amount for days with 3 services under PHP APC 0172 (Level 1 Partial Hospitalization) and a higher amount for days with 4 or more services under PHP APC 0173 (Level 2 Partial Hospitalization) (73 FR 68688 through 68693). We also finalized our policy to deny payment for any PHP claims submitted for days when fewer than 3 units of therapeutic services are provided (73 FR 68694). Furthermore, for CY 2009, we revised the regulations at 42 CFR 410.43 to codify existing basic PHP patient eligibility criteria and to add a reference to current physician certification requirements under 42 CFR 424.24 to conform our regulations to our longstanding policy (73 FR 68694 through 68695). We also revised the partial hospitalization benefit to include several coding updates (73 FR 68695 through 68697). For CY 2010, we retained the two-tier payment approach for partial hospitalization services and used only hospital-based PHP data in computing the PHP APC per diem costs, upon which PHP APC per diem payment rates are based. We used only hospital-based PHP data because we were concerned about further reducing both PHP APC per diem payment rates without knowing the impact of the policy and payment changes we made in CY 2009. Because of the 2-year lag between data collection and rulemaking, the changes we made in CY 2009 were reflected for the first time in the claims data that we used to determine payment rates for the CY 2011 rulemaking (74 FR 60556 through 60559). In the CY 2011 OPPS/ASC final rule with comment period (75 FR 71994), we established four separate PHP APC per diem payment rates: Two for CMHCs (APC 0172 (for Level 1 services) and APC 0173 (for Level 2 services)) and two for hospital-based PHPs (APC 0175 (for Level 1 services) and 0176 (for Level 2 services)), based on each provider type’s own unique data. For CY 2011, we also instituted a 2-year transition period for CMHCs to the CMHC APC per diem PO 00000 Frm 00168 Fmt 4701 Sfmt 4700 payment rates based solely on CMHC data. Under the transition methodology, CMHC APCs Level 1 and Level 2 per diem costs were calculated by taking 50 percent of the difference between the CY 2010 final hospital-based PHP median costs and the CY 2011 final CMHC median costs and then adding that number to the CY 2011 final CMHC median costs. A 2-year transition under this methodology moved us in the direction of our goal, which is to pay appropriately for partial hospitalization services based on each provider type’s data, while at the same time allowing providers time to adjust their business operations and protect access to care for Medicare beneficiaries. We also stated that we would review and analyze the data during the CY 2012 rulemaking cycle and, based on these analyses, we might further refine the payment mechanism. We refer readers to section X.B. of the CY 2011 OPPS/ASC final rule with comment period (75 FR 71991 through 71994) for a full discussion. In addition, in accordance with section 1301(b) of the Health Care and Education Reconciliation Act of 2010 (HCERA 2010), we amended the description of a PHP in our regulations to specify that a PHP must be a distinct and organized intensive ambulatory treatment program offering less than 24hour daily care other than in an individual’s home or in an inpatient or residential setting. In accordance with section 1301(a) of HCERA 2010, we revised the definition of a CMHC in the regulations to conform to the revised definition now set forth under section 1861(ff)(3)(B) of the Act (75 FR 71990). For CY 2012, as discussed in the CY 2012 OPPS/ASC final rule with comment period (76 FR 74348 through 74352), we determined the relative payment weights for partial hospitalization services provided by CMHCs based on data derived solely from CMHCs and the relative payment weights for partial hospitalization services provided by hospital-based PHPs based exclusively on hospital data. In the CY 2013 OPPS/ASC final rule with comment period, we finalized our proposal to base the relative payment weights that underpin the OPPS APCs, including the four PHP APCs (APCs 0172, 0173, 0175, and 0176), on geometric mean costs rather than on the median costs. We established these four PHP APC per diem payment rates based on geometric mean cost levels calculated using the most recent claims and cost data for each provider type. For a detailed discussion on this policy, we refer readers to the CY 2013 OPPS/ASC E:\FR\FM\21NOR2.SGM 21NOR2 khammond on DSK30JT082PROD with RULES2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations final rule with comment period (77 FR 68406 through 68412). In the CY 2014 OPPS/ASC proposed rule (78 FR 43621 through 43622), we solicited comments on possible future initiatives that may help to ensure the long-term stability of PHPs and further improve the accuracy of payment for PHP services, but proposed no changes. In the CY 2014 OPPS/ASC final rule with comment period (78 FR 75050 through 75053), we summarized the comments received on those possible future initiatives. We also continued to apply our established policies to calculate the four PHP APC per diem payment rates based on geometric mean per diem costs using the most recent claims data for each provider type. For a detailed discussion on this policy, we refer readers to the CY 2014 OPPS/ASC final rule with comment period (78 FR 75047 through 75050). In the CY 2015 OPPS/ASC final rule with comment period (79 FR 66902 through 66908), we continued to apply our established policies to calculate the four PHP APC per diem payment rates based on PHP APC geometric mean per diem costs, using the most recent claims and cost data for each provider type. In the CY 2016 OPPS/ASC final rule with comment period (80 FR 70455 through 70465), we described our extensive analysis of the claims and cost data and ratesetting methodology. We found aberrant data from some hospitalbased PHP providers that were not captured using the existing OPPS ±3 standard deviation trims for extreme cost-to-charge ratios (CCRs) and excessive CMHC charges resulting in CMHC geometric mean costs per day that were approximately the same as or more than the daily payment for inpatient psychiatric facility services. Consequently, we implemented a trim to remove hospital-based PHP service days that use a CCR that was greater than 5 to calculate costs for at least one of their component services, and a trim on CMHCs with a geometric mean cost per day that is above or below 2 (±2) standard deviations from the mean. We stated in the CY 2016 OPPS/ASC final rule with comment period (80 FR 70456) that, without using a trimming process, the data from these providers would inappropriately skew the geometric mean per diem cost for Level 2 CMHC services. In addition, in the CY 2016 OPPS/ ASC final rule with comment period (80 FR 70459 through 70460), we corrected a cost inversion that occurred in the final rule data with respect to hospitalbased PHP providers. We corrected the cost inversion with an equitable adjustment to the actual geometric mean VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 per diem costs by increasing the Level 2 hospital-based PHP APC geometric mean per diem costs and decreasing the Level 1 hospital-based PHP APC geometric mean per diem costs by the same factor, to result in a percentage difference equal to the average percent difference between the hospital-based Level 1 PHP APC and the Level 2 PHP APC for partial hospitalization services from CY 2013 through CY 2015. Finally, we renumbered the PHP APCs, which were previously 0172, 0173, 0175, and 0176, to 5851, 5852, 5861, and 5862, respectively. For a detailed discussion of the PHP ratesetting process, we refer readers to the CY 2016 OPPS/ASC final rule with comment period (80 FR 70462 through 70467). In the CY 2017 OPPS/ASC final rule with comment period (81 FR 79687 through 79691), we continued to apply our established policies to calculate the PHP APC per diem payment rates based on geometric mean per diem costs using the most recent claims and cost data for each provider type. However, we finalized a policy to combine the Level 1 and Level 2 PHP APCs for CMHCs and to combine the Level 1 and Level 2 APCs for hospital-based PHPs because we believed this would best reflect actual geometric mean per diem costs going forward, provide more predictable per diem costs, particularly given the small number of CMHCs, and generate more appropriate payments for these services, for example by avoiding the cost inversions for hospital-based PHPs addressed in the CY 2016 and CY 2017 OPPS/ASC final rules with comment period (80 FR 70459 and 81 FR 79682). We implemented an 8-percent outlier cap for CMHCs to mitigate potential outlier billing vulnerabilities by limiting the impact of inflated CMHC charges on outlier payments. We will continue to monitor the trends in outlier payments and consider policy adjustments as necessary. In the CY 2018 OPPS/ASC final rule with comment period (82 FR 59373 through 59381), we continued to apply our established policies to calculate the PHP APC per diem payment rates based on geometric mean per diem costs using the most recent claims and cost data for each provider type. We continued to designate a portion of the estimated 1.0 percent hospital outpatient outlier threshold specifically for CMHCs, consistent with the percentage of projected payments to CMHCs under the OPPS, excluding outlier payments. For a comprehensive description of PHP payment policy, including a detailed methodology for determining PHP per diem amounts, we refer readers PO 00000 Frm 00169 Fmt 4701 Sfmt 4700 58985 to the CY 2016 and CY 2017 OPPS/ASC final rules with comment period (80 FR 70453 through 70455 and 81 FR 79678 through 79680). B. PHP APC Update for CY 2019 1. PHP APC Geometric Mean per Diem Costs For CY 2019, in the CY 2019 OPPS/ ASC proposed rule (83 FR 37130), we proposed to continue to apply our established policies to calculate the PHP APC per diem payment rates based on geometric mean per diem costs using the most recent claims and cost data for each provider type. Specifically, we proposed to continue to use CMHC APC 5853 (Partial Hospitalization (3 or More Services Per Day)) and hospital-based PHP APC 5863 (Partial Hospitalization (3 or More Services Per Day)). We proposed to continue to calculate the geometric mean per diem costs for CY 2019 for APC 5853 for CMHCs using only CY 2017 CMHC claims data and the most recent CMHC cost data, and the CY 2019 geometric mean per diem costs for APC 5863 for hospital-based PHPs using only CY 2017 hospital-based PHP claims data and the most recent hospital cost data. We summarize the public comments we received related to these PHP proposals and methodology and include our responses in the sections below focused on CMHC ratesetting and on hospital-based PHP ratesetting in this CY 2019 OPPS/ASC final rule with comment period. 2. Development of the PHP APC Geometric Mean per Diem Costs In the CY 2019 OPPS/ASC proposed rule (83 FR 37130), for CY 2019 and subsequent years, we proposed to follow the PHP ratesetting methodology described in section VIII.B.2. of the CY 2016 OPPS/ASC final rule with comment period (80 FR 70462 through 70466) to determine the PHP APCs’ geometric mean per diem costs and to calculate the payment rates for APCs 5853 and 5863, incorporating the modifications made in the CY 2017 OPPS/ASC final rule with comment period. As discussed in section VIII.B.1. of the CY 2017 OPPS/ASC final rule with comment period (81 FR 79680 through 79687), the geometric mean per diem cost for hospital-based PHP APC 5863 is based upon actual hospitalbased PHP claims and costs for PHP service days providing 3 or more services. Similarly, the geometric mean per diem cost for CMHC APC 5853 is based upon actual CMHC claims and costs for CMHC service days providing 3 or more services. E:\FR\FM\21NOR2.SGM 21NOR2 58986 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations khammond on DSK30JT082PROD with RULES2 The CMHC or hospital-based PHP APC per diem costs are the providertype specific costs derived from the most recent claims and cost data. The CMHC or hospital-based PHP APC per diem payment rates are the national unadjusted payment rates calculated from the CMHC or hospital-based PHP APC per diem costs, after applying the OPPS budget neutrality adjustments described in section II.A.4. of this final rule with comment period. As previously stated, in the CY 2019 OPPS/ASC proposed rule, we proposed to apply our established methodologies in developing the CY 2019 geometric mean per diem costs and payment rates, including the application of a ±2 standard deviation trim on costs per day for CMHCs and a CCR greater than 5 hospital service day trim for hospitalbased PHP providers. These two trims were finalized in the CY 2016 OPPS/ ASC final rule with comment period (80 FR 70455 through 70462) for CY 2016 and subsequent years. a. CMHC Data Preparation: Data Trims, Exclusions, and CCR Adjustments For this CY 2019 final rule with comment period, prior to calculating the final geometric mean per diem cost for CMHC APC 5853, we prepared the data by first applying trims and data exclusions, and assessing CCRs as described in the CY 2016 OPPS/ASC final rule with comment period (80 FR 70463 through 70465), so that ratesetting is not skewed by providers with extreme data. For this CY 2019 OPPS/ASC final rule with comment period, we used the same data preparation steps. Before any trims or exclusions were applied, there were 45 CMHCs in the final PHP claims data file (compared to 44 in the CY 2019 OPPS/ ASC proposed rule). Under the ±2 standard deviation trim policy, we excluded any data from a CMHC for ratesetting purposes when the CMHC’s geometric mean cost per day was more than ±2 standard deviations from the geometric mean cost per day for all CMHCs. By applying this trim for CY 2019 ratesetting, in this final rule with comment period, we excluded 4 CMHCs with geometric mean costs per day below the trim’s lower limit of $49.86 and 2 CMHCs with geometric mean costs per day above the trim’s upper limit of $293.60. This standard deviation trim removed 6 providers from the ratesetting whose overall effect on the data would have skewed downward the calculation of the final geometric mean per diem costs for CMHCs. In accordance with our PHP ratesetting methodology, as stated in the VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 proposed rule, we also remove service days with no wage index values, because we use the wage index data to remove the effects of geographic variation in costs prior to APC geometric mean per diem cost calculation (80 FR 70465). For this CY 2019 final rule with comment period ratesetting, 1 CMHC was missing wage index data for all of its service days and was excluded. In addition to our trims and data exclusions, before determining the PHP APC geometric mean per diem costs, we also assess CCRs (80 FR 70463). Our longstanding PHP OPPS ratesetting methodology defaults any CMHC CCR greater than 1 to the statewide hospital CCR (80 FR 70457). For this CY 2019 final rule with comment period ratesetting, we identified 3 CMHCs that had CCRs greater than 1. These CMHCs’ CCRs were 1.053, 1.009, and 1.025, and each was defaulted to its appropriate statewide hospital CCR for CY 2019 ratesetting purposes. In summary, these data preparation steps adjusted the CCR for 3 CMHCs by defaulting to the appropriate statewide hospital CCR and excluded 7 CMHCs, resulting in the inclusion of a total of 38 CMHCs (45 total—7 excluded) in our CY 2019 final rule with comment period ratesetting modeling (compared to a total of 36 CMHCs in our modeling in the CY 2019 OPPS/ASC proposed rule). The ±2 standard deviation trim and the exclusion for missing wage index data removed 425 CMHC claims out of a total of 14,431 CMHC claims, resulting in 14,006 CMHC claims used for ratesetting purposes. We believe that excluding providers with extremely low or high geometric mean costs per day or extremely low or high CCRs protects CMHCs from having that data inappropriately skew the calculation of the CMHC APC geometric mean per diem cost. After applying all of the above trims, exclusions, and adjustments, we followed the methodology described in the CY 2016 OPPS/ASC final rule with comment period (80 FR 70464 through 70465) and modified in the CY 2017 OPPS/ASC final rule with comment period (81 FR 79687 through 79688, and 79691) to calculate the final PHP APC geometric mean per diem cost.59 The 59 Each revenue code on the CMHC claim must have a HCPCS code and charge associated with it. We multiply each claim service line’s charges by the CMHC’s overall CCR (or statewide CCR, where the overall CCR was greater than 1) to estimate CMHC costs. Only the claims service lines containing PHP allowable HCPCS codes and PHP allowable revenue codes from the CMHC claims remaining after trimming are retained for CMHC cost determination. The costs, payments, and service units for all service lines occurring on the PO 00000 Frm 00170 Fmt 4701 Sfmt 4700 final CY 2019 geometric mean per diem cost for all CMHCs for providing 3 or more services per day (CMHC PHP APC 5853) is $121.62 (compared to the proposed geometric mean per diem cost of $119.51). Below we summarize the public comments we received on our proposals related to continuing to follow our existing CMHC ratesetting methodology and the calculation of the CMHC geometric mean per diem costs. Comment: Two commenters objected to the continuation of separate APCs by provider type for CY 2019, stating that CMHCs and hospital-based PHPs provide the same services and follow the same regulations, but CMHCs provide them for less costs. One commenter acknowledged that hospitals have higher cost structures, which the commenter asserted was due to hospitals’ higher overhead allocation, but believed that CMHCs are being punished for providing more costeffective and more intensive services. Response: We disagree that CMHCs are being punished for providing more cost-effective and more intensive services. The difference in payment between CMHCs and hospital-based PHPs reflects differences in resource use. When Congress required the Secretary to implement a hospital outpatient prospective payment system, it required the payment system to group covered services with respect to clinical similarity and resource use (section 1833(t)(2) of the Act). Because CMHCs’ and hospital-based PHPs’ resource uses are different, these two provider types are paid under different APCs, based on their actual resource use. Because the cost of providing partial hospitalization services differs significantly by site of service, we established different PHP payment rates for hospital-based PHPs and CMHCs in the CY 2011 OPPS/ASC final rule with comment period (75 FR 71991 through 71994). With respect to the continued use of PHP APC geometric mean per diem costs for determining payment rates by provider, we refer readers to the CY 2013 OPPS/ASC final rule with comment period (77 FR 68406 through same service date, by the same provider, and for the same beneficiary are summed. CMHC service days must have 3 or more services provided to be assigned to CMHC APC 5853. The geometric mean per diem cost for CMHC APC 5853 is calculated by taking the nth root of the product of n numbers, for days where 3 or more services were provided. CMHC service days with costs ±3 standard deviations from the geometric mean costs within APC 5853 are deleted and removed from modeling. The remaining PHP service days are used to calculate the geometric mean per diem cost for each PHP APC by taking the nth root of the product of n numbers for days where 3 or more services were provided. E:\FR\FM\21NOR2.SGM 21NOR2 khammond on DSK30JT082PROD with RULES2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations 68412) for a discussion of the implementation of this policy. The resulting payment rates reflect the geometric mean cost of what providers expend to maintain such programs, based on data provided by CMHCs and hospital-based PHPs, which we believe is an improvement over the two-tiered methodology calculated based on median costs using only hospital-based data. Comment: Two commenters opposed the continued use of the single-tiered payment system implemented in CY 2017 OPPS/ASC rulemaking. One of these commenters asserted that the single-tiered system was implemented due to the cost inversion in hospitalbased PHP data and, therefore, was unfairly applied to CMHCs. Another commenter did not object to the single payment tier, but suggested that CMS monitor the data to ensure that the single-tiered APCs do not result in a decrease in the number of operational PHPs. Response: We thank the commenters for their input. In the CY 2017 OPPS/ ASC final rule with comment period, we cited several reasons for implementing the single-tiered payment system (81 FR 79682 through 79686), including the cost inversion in the hospital-based PHP data which the commenter cited. A cost inversion exists when, under a 2-tiered payment system, the Level 1 geometric mean per diem cost for providing exactly 3 services per day exceeds the Level 2 PHP APC geometric mean per diem cost for providing 4 or more services per day. The commenter is correct that CMHCs were not affected by a cost inversion as hospital-based PHPs were. However, in that same CY 2017 OPPS/ASC final rule with comment period, we noted that another primary reason for combining the 2-tiered system into a single tier, by provider type, was the decrease in the number of CMHCs (81 FR 79683). With a small number of providers, data from large providers with a high percentage of all PHP service days and unusually high or low geometric mean costs per day would have a more pronounced effect on the PHP APCs geometric mean per diem costs, skewing costs up or down. The effect would be magnified by continuing to split the geometric mean per diem costs further by distinguishing between Level 1 and Level 2 PHP services. A single PHP APC for each provider type for providing 3 or more PHP services per day reduces these cost fluctuations and provides more stability in the PHP APC geometric mean per diem costs. We do not believe that the single-tier payment system will lead to a reduction VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 in the number of PHPs because total payments to an individual CMHC using the single-tier payment system are approximately equal to total payments to that same CMHC if the previous 2tiered payment system were used instead. The calculated rates for APCs 5853 and 5863 continue to be based upon the actual costs for CMHCs and hospital-based PHPs, respectively. Therefore, the payment rates for the single-tier PHP APCs are an appropriate approximation of provider costs, and should not result in reduced access. As we noted in the CY 2017 OPPS/ASC final rule with comment period (81 FR 79685), the single-tier PHP APCs are calculated by following the existing methodology for ratesetting, except that the geometric mean per diem costs for each provider type were calculated for days providing 3 or more partial hospitalization services, as opposed to being calculated separately for days with exactly 3 services and for days with 4 or more services, as was previously done. The combined PHP APCs’ geometric mean costs are similar to a weighted average of actual provider costs. As such, combining the PHP APCs geometric mean per diem costs does not reduce total costs or total payments by provider type. We refer readers to the CY 2017 OPPS/ASC final rule with comment period for a detailed review of the methodology used in determining per diem costs using the single-tier PHP APCs (81 FR 79686 through 79688). The 2017 claims data used for this CY 2019 ratesetting are the first year of data using the single-tier payment system. We will monitor the data for any unintended consequences on the number of operational PHPs associated with using the single-tier payment system. We note that the number of PHP providers is generally affected by multiple factors, such as business and market conditions, competition, estimated profit margins, private insurance coverage changes, Federal and State fraud and abuse efforts, and community support for mental health treatment. Comment: Several commenters questioned CMS’ use of the ±2 standard deviation trim on CMHC costs/per day, and asked why it was different from the OPPS ±3 standard deviation trim which is applied to hospital-based PHPs. The commenters noted that the trims were implemented to help prevent inappropriate fluctuations in the data, but were concerned that this trim removed CMHCs from the data, and that this trim resulted in the decline in the costs per day. PO 00000 Frm 00171 Fmt 4701 Sfmt 4700 58987 Response: The ±2 standard deviation trim on CMHC costs/per day was implemented in the CY 2016 OPPS final rule with comment period (80 FR 70455 through 70462) in order to protect CMHCs from having extreme costs per day inappropriately skew the CMHC PHP APC geometric mean per diem costs. As part of the effort to increase the accuracy of the PHP per diem costs, for the CY 2016 ratesetting, we completed an extensive analysis of the claims and cost data. That analysis identified aberrant data from several providers that impacted the calculation of the proposed PHP geometric mean per diem costs. For example, we found claims with excessive CMHC charges resulting in CMHC geometric mean costs per day that were approximately the same as or more than the daily payment for inpatient psychiatric facility services. For an outpatient program like PHP, because it does not incur room and board costs such as an inpatient stay would, these costs per day were excessive. In addition, we found some CMHCs had very low costs per day (less than $25 per day) (80 FR 70456). The ±2 standard deviation trim on CMHC costs per day excludes providers with extremely low or extremely high costs per day, and protects CMHCs from having those extreme costs inappropriately skew the CMHC PHP APC geometric mean per diem costs. In addition, in that CY 2016 OPPS final rule with comment, we noted that the ±2 standard deviation trim aligned the geometric mean and median per diem costs for the CMHC Level 2 PHP APC payment tier, which indicated that the trim removed the skewing in the data caused by the inclusion of aberrant data (80 FR 70456). We continue to believe that the ±2 standard deviation trim excludes CMHCs with aberrant data from the ratesetting process while allowing for the use of as much data as possible. In addition, we stated that implementing a ±2 standard deviation trim on CMHCs would target these aberrancies without limiting overall per diem cost increases. For normally distributed data, ±2 standard deviations from the mean capture approximately 95 percent of the data. Our analyses for the CY 2016 ratesetting also showed that a higher trim level, such as a ±2.5 standard deviation trim or the ±3 standard deviation trim used by the rest of OPPS, did not remove the CMHCs with aberrant data from the ratesetting process (80 FR 70456 and 70457). In this CY 2019 OPPS/ASC final rule, the ±2 standard deviation trim on CMHC costs/day removed 6 CMHCs from ratesetting, which affected the final E:\FR\FM\21NOR2.SGM 21NOR2 khammond on DSK30JT082PROD with RULES2 58988 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations per diem costs. It removed both low-cost and high-cost providers that fail the trim; its net effect on the CY 2019 ratesetting data was to increase CMHC geometric mean per diem costs. For CY 2019, if we did not apply the ±2 standard deviation trim on CMHC costs/ day, the final CMHC geometric mean per diem cost would have been $120.77. This is less than the geometric mean per diem cost of $121.62 which we are finalizing, and which is after applying the ±2 standard deviation trim. With regard to the questions about why the same trims are not used for both CMHCs and hospital-based PHPs, we refer readers to the discussion in the CY 2016 OPPS/ASC final rule with comment period (80 FR 70458). As we noted in that CY 2016 OPPS/ASC final rule with comment period, there are differences in the ratesetting process between hospital-based PHPs and CMHCs, which are largely due to differences between the hospital cost reports and the CMHC cost reports, and we believe that having different trims more appropriately targets aberrant data for each provider type. As noted previously, the OPPS ±3 standard deviation trim on per diem costs did not remove the aberrant CMHC data. We considered applying the ±2 standard deviation trim on per diem costs to hospital-based PHP providers, but an alternative trim on hospital-based CCRs greater than 5 allowed for use of more data from hospital-based providers and still removed aberrant data. We continue to believe this trim based on hospital-based PHP CCRs is more effective in removing aberrant hospitalbased PHP data and allows for the use and retention of more data than a ±2 standard deviation trim on hospitalbased PHP costs per day. Comment: Several commenters objected to the decline in the CMHC per diem costs that were proposed, and were concerned about the ability to maintain access to services. One commenter noted that CMHCs cannot provide all of the services they provide on a daily basis at the proposed payment rate. Some commenters also stated that CMHCs incur extra costs to meet the CMHC conditions of participation (CoPs), have more costly staff, or have experienced an increase in bad debt expense. A few commenters noted that the number of CMHCs nationally had declined greatly as a result of declines in payment and payment fluctuations. One commenter stated that setting CMHCs’ payment rates based on a small number of CMHCs does not reflect the actual cost of providing these services and expressed concern that basing payments VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 at the mean or median level would result in half of CMHCs receiving payments less than their cost, which would guarantee that more CMHCs would close, further limiting access. Commenters requested that CMS reconsider the payment rate reduction, which one commenter believed resulted in PHP services moving toward extinction in the current mode. Another commenter questioned if CMS had a veiled motivation to eliminate CMHCs altogether, and wondered if CMHCs were still considered the ‘‘fraud benefit.’’ Commenters also were concerned that if CMHC access declined, beneficiaries would be pushed toward higher-cost outpatient departments, resulting in higher out-ofpocket costs for beneficiaries. One commenter noted that CMHCs are in keeping with the health care trend to service patients in their communities, rather than forcing patients to travel to a medical center. Response: The OPPS pays for outpatient services, including partial hospitalization services, based on the geometric mean per diem costs of providing services using provider data from claims and cost reports, in accordance with statute. For this CY 2019 OPPS/ASC final rule with comment period, the final geometric mean per diem cost for CMHC APC 5853 is $121.62, which is a slight increase from the proposed geometric mean per diem cost, but a 15-percent reduction from the CY 2018 final geometric mean per diem cost. In response to commenters concerned that CMHCs cannot provide all of the services offered on a daily basis at the proposed payment rate, we remind commenters that we calculate the PHP APC geometric mean per diem costs based on the data provided for each type of provider to determine payment for these services. The final PHP APC geometric mean per diem costs for CY 2019 reflect actual provider costs of covered services. We believe that this system provides appropriate payment for covered partial hospitalization services based on actual provider costs. We further note that section 1861(ff)(2)(I) of the Act explicitly prohibits Medicare from paying for the costs of meals or transportation, which some CMHCs incur. Therefore, these costs, although incurred by CMHCs, are not covered under the OPPS. In response to the commenters who stated that CMHCs incur extra costs to meet the CMHC CoPs, most (if not all) of the costs associated with adhering to CoPs should be captured in the cost report data used in ratesetting and, therefore, are accounted for when PO 00000 Frm 00172 Fmt 4701 Sfmt 4700 computing the geometric mean per diem costs. Similar to the requirement for CMHCs to comply with CMHC CoPs, hospital-based PHPs must also comply with hospital CoPs. All Medicareparticipating facilities have CoPs or other requirements that must be met, and CMHCs are not specifically being singled out for compliance, nor are there ‘‘extra’’ costs associated with the CMHC CoPs. Allowable labor costs for providing direct patient care would also be captured in the cost report data used for ratesetting. We refer the commenters to the instructions for the CMHC cost reports for more information on capturing the costs associated with meeting CoPs and with labor costs for direct patient care, which are available online in links to Chapters 18 and 45 found at: https://www.cms.gov/ Regulations-and-Guidance/Guidance/ Manuals/Paper-Based-Manuals-Items/ CMS021935.html?DLPage=1& DLEntries=10&DLSort=0&DLSortDir= scending. The covered costs of providing PHP care to beneficiaries at CMHCs are captured as part of CMHC ratesetting, and include allowable labor costs and the costs of complying with CoPs. The reduction to bad debt reimbursement was a result of provisions of section 3201 of the Middle Class Tax Extension and Job Creation Act of 2012 (Pub. L. 112–96). The reduction to bad debt reimbursement impacted all providers eligible to receive bad debt reimbursement, as discussed in the CY 2013 End-Stage Renal Disease final rule (77 FR 67518). Medicare currently reimburses bad debt for eligible providers at 65 percent. Therefore, CMHCs are not specifically being singled out for a payment reduction as a result of bad debt expenses. Because this percentage was enacted by Congress, CMS does not have the authority to change the percentage. We appreciate the commenter’s input regarding the effect any reduction in PHP payment rates would have on access to care, but we disagree with the commenter’s assertion that CMS considers CMHCs to be a ‘‘fraud benefit’’ or that CMS has any motivation (veiled or otherwise) to eliminate CMHCs. Both are simply not true; we appreciate the work CMHCs do to care for a particularly vulnerable population with serious mental illnesses. We are very concerned about the decline in the number of CMHCs, but, as noted in a previous comment response in this section, we believe that a number of factors affect PHP provider closures. We will continue working to strengthen E:\FR\FM\21NOR2.SGM 21NOR2 khammond on DSK30JT082PROD with RULES2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations access to both CMHCs and hospitalbased PHPs for eligible Medicare beneficiaries. As part of that process, we regularly review our methodology to ensure that it is appropriately capturing the cost of care reported by providers. For example, for the CY 2016 ratesetting, we extensively reviewed the methodology used for PHP ratesetting. In the CY 2016 OPPS/ASC final rule with comment period (80 FR 70462 through 70466), we also included a detailed description of the ratesetting process to help all PHP providers record costs correctly so that we can more fully capture PHP costs in ratesetting. We want to ensure that CMHCs remain a viable option as providers of mental health care in the beneficiary’s own community. We agree that beneficiaries receiving care at a CMHC instead of a hospital-based PHP would have a lower out-of-pocket cost, which increases the attractiveness of CMHCs to those needing their services. We will continue to explore policy options for strengthening the PHP benefit and increasing access to the valuable services provided by CMHCs as well as by hospital-based PHPs. Comment: One commenter suggested that CMS consider paying CMHCs using a quality-based payment system, and that CMS use value-based purchasing. The commenter recommended that, instead of basing payment rates on estimated actual median costs of claims, CMS look at the value provided by the quality of provided services using different methods such as records reviews, denials due to lack of medical necessity or inadequate documentation, site visits, interviews with patients, and, most importantly, patient outcomes. The commenter believed that rewarding providers for higher-quality care, as measured by selected standards instead of rewarding providers by increasing costs, is a better way to improve the quality of any service. Response: Currently, there is no statutory language explicitly authorizing a value-based purchasing program for PHPs. We responded to a similar public comment in the CY 2016 OPPS/ASC final rule with comment period (80 FR 70462) and refer readers to a summary of that comment and our response. To reiterate, sections 1833(t)(2) and 1833(t)(9) of the Act set forth the requirements for establishing and adjusting OPPS payment rates, which include PHP payment rates. Section 1833(t)(17) of the Act authorizes the Hospital OQR Program, which applies a payment reduction to subsection (d) hospitals that fail to meet program requirements. In the CY 2015 OPPS/ ASC proposed rule (79 FR 41040), we VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 considered future inclusion of, and requested comments on, the following quality measures addressing PHP issues that would apply in the hospital outpatient setting: (1) 30-day Readmission; (2) Group Therapy; and (3) No Individual Therapy. We also refer readers to the CY 2015 OPPS/ASC final rule with comment period (79 FR 66957 through 66958) for a more detailed discussion of PHP measures considered for inclusion in the Hospital OQR Program in future years. The Hospital OQR Program does not apply to CMHCs, and there are no quality measures applied to CMHCs. Comment: One commenter noted that, in the past, CMS stated that CMHCs provide fewer services and have less costly staff than hospitals. Response: We believe that the commenter may be referring to the CY 2011 OPPS/ASC final rule with comment period (75 FR 71991), wherein CMS stated we believe that CMHCs have a lower cost structure than their hospital-based PHP counterparts because the data showed that CMHCs provide fewer PHP services in a day and use less costly staff than hospital-based PHPs. Those statements were based on CY 2009 claims and cost data, which differ from more recent claims and cost data. Each year, we calculate geometric mean per diem costs based on updated claims and cost reports. For example, our CY 2019 geometric mean per diem costs and the APC payment rates are based upon CY 2017 claims and cost data. We refer the commenter to the utilization data in section VIII.B.4. of this CY 2019 final rule with comment period for details on current CMHC utilization. In addition, we continually seek to increase the accuracy of our payment rates. As noted previously, as part of the effort to increase the accuracy of the PHP APCs’ per diem costs, for the CY 2016 ratesetting, we completed an extensive analysis of the claims and cost data. That analysis identified aberrant data from several providers that impacted the calculation of the proposed PHP APCs’ geometric mean per diem costs. b. Hospital-Based PHP Data Preparation: Data Trims and Exclusions For the CY 2019 proposed rule and for this CY 2019 final rule with comment period, we followed a data preparation process for hospital-based PHP providers that is similar to that used for CMHCs by applying trims and data exclusions as described in the CY 2016 OPPS/ASC final rule with comment period (80 FR 70463 through 70465) so that our ratesetting is not skewed by providers with extreme data. Before any PO 00000 Frm 00173 Fmt 4701 Sfmt 4700 58989 trimming or exclusions were applied, there were 426 hospital-based PHP providers in the final CY 2017 PHP claims data used in this CY 2019 OPPS/ ASC final rule with comment period (compared to 394 hospital-based PHPs in the CY 2019 OPPS/ASC proposed rule). For hospital-based PHP providers, we applied a trim on hospital service days when the CCR was greater than 5 at the cost center level. This trim removed hospital-based PHP service days that use a CCR greater than 5 to calculate costs for at least one of their component services. Unlike the ±2 standard deviation trim, which excluded CMHC providers that failed the trim, the CCR greater than 5 trim excluded any hospital-based PHP service day where any of the services provided on that day were associated with a CCR greater than 5 (in other words, the CCR greater than 5 trim is a (service) day-level trim in contrast to the CMHC ±2 standard deviation trim, which is a provider-level trim). Applying this CCR greater than 5 trim removed from our final rule ratesetting affected service days from 3 hospital-based PHP providers with CCRs greater than 5. However, 100 percent of the service days for 1 of these affected hospital-based PHP providers had at least 1 service associated with a CCR of 9.5744, so the trim removed that 1 provider entirely from our final rule ratesetting. The two other providers remained in the ratesetting data, but with affected service days trimmed out. In addition, 48 hospital-based PHPs were removed for having no PHP costs and, therefore, no days with PHP payment. No hospital-based PHPs were removed for missing wage index data or by the OPPS ±3 standard deviation trim on costs per day. Therefore, we trimmed out 49 hospital-based PHP providers [(1 with all service days having a CCR greater than 5) + (48 with zero daily costs and no PHP payment)], resulting in 377 (426 total¥49 excluded) hospital-based PHP providers in the data used for final rule with comment period ratesetting (compared to 374 hospital-based PHPs in the CY 2019 OPPS/ASC proposed rule). No hospital-based PHP providers were defaulted to using their overall hospital ancillary CCRs due to outlier cost center CCR values. After completing these data preparation steps, we calculated the final CY 2019 geometric mean per diem cost for hospital-based PHP APC 5863 for hospital-based PHP services by following the methodology described in the CY 2016 OPPS/ASC final rule with comment period (80 FR 70464 through 70465) and modified in the CY 2017 E:\FR\FM\21NOR2.SGM 21NOR2 58990 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations khammond on DSK30JT082PROD with RULES2 OPPS/ASC final rule with comment period (81 FR 79687 and 79691) to calculate the geometric mean per diem cost.60 The final CY 2019 geometric mean per diem cost for hospital-based PHP providers that provide 3 or more services per service day (hospital-based PHP APC 5863) is $222.76 (compared to $220.52 in the CY 2019 OPPS/ASC proposed rule). Comment: One commenter appreciated the CY 2019 per diem increase for hospital-based PHPs. The commenter stated that the minimum rate should be set at the geometric mean rate, rather than at the 2-percent reduction rate of $216.55, as providers are hit with a second 2-percent reduction again at actual claim payout. The commenter stated this reduced the hospital-based PHP rate by 4 percent total, and places more than half of the providers in a payment setting below their daily costs of providing the services. Response: The final hospital-based PHP APC geometric mean per diem cost is $222.76, which is a slight increase from the proposed $220.52 geometric mean per diem cost in the CY 2019 OPPS/ASC proposed rule (83 FR 37131), and a 7-percent increase from the $208.09 CY 2018 final geometric mean per diem cost (82 FR 59378). In the OPPS ratesetting, the geometric mean per diem costs are the basis for the final per diem rates. However, those costs undergo additional ratesetting steps before they are developed into payment rates, a process which is described in Part 2 of the Claims Accounting narrative under supporting documentation for this CY 2019 OPPS/ ASC final rule with comment period available on the CMS website at: https:// 60 Each revenue code on the hospital-based PHP claim must have a HCPCS code and charge associated with it. We multiply each claim service line’s charges by the hospital’s department-level CCR; that CCR is determined by using the OPPS Revenue-code-to-cost-center crosswalk. Only the claims service lines containing PHP-allowable HCPCS codes and PHP-allowable revenue codes from the hospital-based PHP claims remaining after trimming are retained for hospital-based PHP cost determination. The costs, payments, and service units for all service lines occurring on the same service date, by the same provider, and for the same beneficiary are summed. Hospital-based PHP service days must have 3 or more services provided to be assigned to hospital-based PHP APC 5863. The geometric mean per diem cost for hospital-based PHP APC 5863 is calculated by taking the nth root of the product of n numbers, for days where 3 or more services were provided. Hospital-based PHP service days with costs ±3 standard deviations from the geometric mean costs within APC 5863 are deleted and removed from modeling. The remaining hospital-based PHP service days are used to calculate the geometric mean per diem cost for hospital-based PHP APC 5863. VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 www.cms.gov/Medicare/Medicare-Feefor-Service-Payment/ HospitalOutpatientPPS/. We believe that the commenter may have misunderstood that these steps are not simply a ‘‘standard’’ 2-percent reduction applied to those costs when we determine PHP APC per diem payment rates. Rather, those costs follow a ratesetting process, which can result in the final per diem payment rates being more or less than the final per diem costs due to budget neutrality and other adjustments. It is also possible that the commenter has not misunderstood the ratesetting process, but is referring to the 2 percentage point reduction in the provider’s annual ratesetting update factor due to failure to comply with Hospital Outpatient Quality Reporting Program requirements, which is described in more detail in section XIII.E. of this final rule with comment period. For the second 2-percent reduction that the commenter referenced, which the commenter noted occurs at actual claim payout, we believe that the commenter is referencing the required sequestration 2-percent reduction to the Medicare portion of claim payments. That reduction is a Congressionallymandated decrease, established by the Budget Control Act of 2011 (Pub. L. 112–25) and amended by the American Taxpayer Relief Act of 2012 (Pub. L. 112–240). Sequestration is discussed in a Medicare Fee-for-Service Provider eNews article available at: https:// www.cms.gov/Outreach-and-Education/ Outreach/FFSProvPartProg/Downloads/ 2013-03-08-standalone.pdf. The reduction in payments due to sequestration is outside the scope of the CY 2019 OPPS/ASC proposed rule and this final rule with comment period. Regarding the usage of the geometric mean per diem cost for determining payment rates, as we noted in a previous comment response in this section, we refer readers to the CY 2013 OPPS/ASC final rule with comment period (77 FR 68406 through 68412) for a discussion of the implementation of this policy. We believe that this system provides appropriate payment for partial hospitalization services based on actual provider costs. The final PHP APC geometric mean per diem costs for CY 2019 reflect these actual provider costs, using our existing methodology. After consideration of the public comments we received, we are finalizing our proposals, without modification, to continue to follow our existing ratesetting methodologies for both CMHCs and for hospital-based PO 00000 Frm 00174 Fmt 4701 Sfmt 4700 PHPs in determining geometric mean per diem costs. Specifically, we are applying our established methodologies in developing the CY 2019 geometric mean per diem costs and payment rates, including the application of a ±2 standard deviation trim on costs per day for CMHCs and a CCR greater than 5 hospital service day trim for hospitalbased PHP providers. We also are finalizing our proposals, without modification, to continue to use CMHC APC 5853 (Partial Hospitalization (3 or More Services Per Day)) and hospitalbased PHP APC 5863 (Partial Hospitalization (3 or More Services Per Day)) and base the CMHC geometric mean per diem costs on the most recent available CMHC claims and CMHC cost data, and the hospital-based PHP geometric mean per diem costs on the most recent available hospital claims and cost data. The final CY 2019 PHP APC geometric mean per diem costs for CMHC PHP APC 5853 are $121.62 and for hospital-based PHP APC 5863 are $222.76, as stated above and shown in Table 43. The final PHP APCs payment rates, which are derived from these PHP APCs geometric mean per diem costs, are included in Addendum A to this final rule with comment period (which is available on the CMS website at: https://www.cms.gov/Medicare/ Medicare-Fee-for-Service-Payment/ HospitalOutpatientPPS/HospitalOutpatient-Regulations-andNotices.html).61 61 As discussed in section II.A. of this CY 2019 OPPS/ASC final rule with comment period, OPPS APC geometric mean per diem costs (including PHP APC geometric mean per diem costs) are divided by the geometric mean per diem costs for APC 5012 (Clinic Visits and Related Services) to calculate each PHP APC’s unscaled relative payment weight. An unscaled relative payment weight is one that is not yet adjusted for budget neutrality. Budget neutrality is required under section 1833(t)(9)(B) of the Act, and ensures that the estimated aggregate weight under the OPPS for a calendar year is neither greater than nor less than the estimated aggregate weight that would have been made without the changes. To adjust for budget neutrality (that is, to scale the weights), we compare the estimated aggregated weight using the scaled relative payment weights from the previous calendar year at issue. We refer readers to the ratesetting procedures described in Part 2 of the OPPS Claims Accounting narrative and in section II. of this final rule with comment period for more information on scaling the weights, and for details on the final steps of the process that lead to PHP APC per diem payment rates. The OPPS Claims Accounting narrative is available on the CMS website at: https://www.cms.gov/Medicare/ Medicare-Fee-for-Service-Payment/ HospitalOutpatientPPS/Hospital-OutpatientRegulations-and-Notices.html. E:\FR\FM\21NOR2.SGM 21NOR2 3. Changes to the Revenue-Code-to-Cost Center Crosswalk In the CY 2017 OPPS/ASC final rule with comment period (81 FR 79691), we received public comments identifying an issue that may have contributed to a decreased PHP median cost for hospitalbased PHPs. The commenters stated that the lack of a required standardized PHP cost center on the Medicare cost report may be creating some cost-finding nuances in the cost report itself—for example, inaccurate step-down of overhead cost allocations to the PHP program, diluted CCRs by the comingling of PHP and ‘‘Intensive Outpatient Program (IOP)’’ on the cost report, among others. We agreed with the commenters that, if PHP costs are combined with other less intensive outpatient mental health treatment costs in the same cost center, the CCR values could be diluted, leading to lower geometric mean per diem costs being calculated. We stated in response that we would consider adding a cost center to the hospital cost report for PHP costs only. On November 17, 2017, in Transmittal No. 12, we added a new cost center, ‘‘Partial Hospitalization Program,’’ on Line 93.99 of Worksheet A (Line 93.99 is also displayed on Worksheets B, Parts I and II, B–1; and C, Parts I and II) for hospital-based PHPs, for cost reporting periods ending on or after August 31, 2017 (https://www.cms.gov/Regulationsand-Guidance/Guidance/Transmittals/ 2017Downloads/R12P240.pdf). On January 30, 2018, in Transmittal No. 13, we changed the implementation date from cost reporting periods ending on or after August 31, 2017, to cost reporting periods ending on or after September 30, 2017 (https://www.cms.gov/ Regulations-and-Guidance/Guidance/ Transmittals/2017Downloads/ R12P240.pdf). The instructions for this new PHP cost center (Line 93.99) indicate that effective for cost reporting periods ending on or after September VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 30, 2017, the provider is to enter the costs of providing hospital-based partial hospitalization program (PHP) services as defined in section 1861(ff) of the Act. Therefore, this cost center is to include all costs associated with providing PHP services, as defined in the statute (for example, occupational therapy, individual and group therapy, among others). It should not include costs for non-PHP outpatient mental health services, such as costs from what providers refer to as ‘‘Intensive Outpatient Programs.’’ During current hospital-based PHP ratesetting, costs are estimated by multiplying revenue code charges on the claim by the appropriate cost centerlevel CCR from the hospital cost report (80 FR 70465). Each PHP revenue code is associated with particular cost centers on the cost report (80 FR 70464). The appropriate cost center-level CCR is identified by using the OPPS RevenueCode-to-Cost-Center crosswalk; the current crosswalk is discussed in the CY 2018 OPPS/ASC final rule with comment period (82 FR 59228) and is available on the CMS website at: https:// www.cms.gov/apps/ama/ license.asp?file=/Medicare/MedicareFee-for-Service-Payment/ HospitalOutpatientPPS/Downloads/ CMS-1678-FC-2018-OPPS-FR-RevenueCode-to-Cost-Center-Crosswalk.zip. The Revenue-Code-to-Cost-Center crosswalk identifies the primary, secondary (if any), and tertiary (if any) cost centers that are associated with each PHP revenue code, and which are the source for the CCRs used in PHP ratesetting. As discussed in the CY 2002 OPPS interim final rule (66 FR 59885), hospital-based PHP CCRs are assessed by applying the existing OPPS ±3 standard deviation trim to hospital-based PHP CCRs within each cost center and to the overall hospital ancillary CCR. In the CY 2016 OPPS/ASC final rule with comment period (80 FR 70464), we stated that, if the primary cost center has no CCR or PO 00000 Frm 00175 Fmt 4701 Sfmt 4700 58991 if it fails the ±3 standard deviation trim, the ratesetting system will look for a CCR in the secondary cost center. If the secondary cost center has no CCR or if it fails the ±3 standard deviation trim, the system will move to the tertiary cost center to look for a CCR. If the tertiary cost center has no CCR or if it fails the ±3 standard deviation trim, the ratesetting system will default to using the hospital’s overall ancillary CCR. If the hospital’s overall ancillary CCR fails the ±3 standard deviation trim, we exclude the hospital from ratesetting. While the hierarchy requires a primary cost center to be associated with a given revenue code, it is optional for there to be secondary or tertiary cost centers. With the new PHP cost center, the crosswalk must be updated for hospitalbased PHP cost estimation to correctly match hospital-based PHP revenue code charges with the PHP cost center CCR for future ratesetting. However, because the PHP-allowable revenue codes are also used for reporting non-PHP mental health services, we could not designate the PHP cost center as the primary cost center in the existing OPPS RevenueCode-to-Cost-Center crosswalk. Therefore, in the CY 2019 OPPS/ASC proposed rule (83 FR 37132 through 37133), we proposed to create a separate PHP-only Revenue-Code-to-Cost-Center crosswalk for use in CY 2019 and subsequent years, which would provide a more accurate and operationally simpler method of matching hospitalbased PHP charges to the correct hospital-based PHP cost center CCR without affecting non-PHP ratesetting. We note that, because CMHCs have their own cost reports, we use each CMHC’s overall CCR in estimating costs for PHP ratesetting (80 FR 70463 through 70464). As such, CMHCs do not have a crosswalk and, therefore, the proposal to create a PHP-only crosswalk does not apply to CMHCs. Therefore, we proposed that, for CY 2019 and subsequent years, hospital- E:\FR\FM\21NOR2.SGM 21NOR2 ER21NO18.068</GPH> khammond on DSK30JT082PROD with RULES2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations 58992 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations khammond on DSK30JT082PROD with RULES2 based PHPs would follow a new Revenue-Code-to-Cost-Center crosswalk that only applies to hospital-based PHPs. We proposed that this new PHPonly Revenue-Code-to-Cost-Center crosswalk would be comprised of the existing PHP-allowable revenue codes and would map each of those PHPallowable revenue codes to the new PHP cost center Line 93.99 as the primary cost center source for the CCR. We also proposed to designate as the new secondary cost center the cost center that is currently listed as the existing primary cost center, and to designate as the new tertiary cost center the cost center that is listed as the existing secondary cost center. In addition, we proposed one exception to this policy for the mapping VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 for revenue code 0904, which is the only PHP-allowable revenue code in the existing crosswalk with a tertiary cost center source for the CCR. We proposed that for revenue code 0904, the secondary cost center for CY 2019 and subsequent years would be the existing secondary cost center 3550 (‘‘Psychiatric/Psychological Services’’). Similarly, we proposed that for revenue code 0904, the tertiary cost center for CY 2019 and subsequent years would be existing tertiary cost center 9000 (‘‘Clinic’’). We considered expanding the Revenue-Code-to-Cost-Center crosswalk hierarchy to add a 4th or quaternary level to the hierarchy, before the system would default to the overall hospital ancillary CCR. However, we evaluated the usage of the current PO 00000 Frm 00176 Fmt 4701 Sfmt 4700 hierarchy for revenue code 0904 for the CY 2017, CY 2018, and CY 2019 PHP ratesetting modelling, and found that expanding the hierarchy would not be necessary. Our analysis showed that the existing primary cost center 3580 (‘‘Recreational Therapy’’) for revenue code 0904 had not been used during any of the past 3 years. We did not receive any public comments on our proposals related to the PHP-only Revenue-Code-to-CostCenter crosswalk and, therefore, are finalizing our proposals, as proposed, for CY 2019 and subsequent years. Our previous and newly finalized PHP-only Revenue-Code-to-Cost-Center Crosswalks are shown in Table 44 below. BILLING CODE 4120–01–P E:\FR\FM\21NOR2.SGM 21NOR2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations 58993 TABLE 44.-PREVIOUS AND NEWLY FINALIZED PHP-ONLY REVENUE-CODE-TO-COST -CENTER CROSSWALKS PHP Primary Cost Allowable Center Revenue Source for Code CCR 6700 0430 Occupational Therapy 6700 0431 Occupational Therapy 6700 0432 Occupational Therapy 6700 0433 Occupational Therapy 6700 0434 Occupational Therapy 0435 RESERVED 0436 RESERVED 0437 RESERVED 0438 RESERVED 6700 0439 Occupational Therapy 3550 (Psychiatric/ 0900 Psychological Services khammond on DSK30JT082PROD with RULES2 0904 VerDate Sep<11>2014 3580 (Recreational Therapy) 20:42 Nov 20, 2018 Jkt 247001 Secondary Cost Center Source for CCR Tertiary Cost Center Source forCCR Finalized New PHP-only Hierarchy (applicable in CY 2019 and beyond) Tertiary Primary Cost Cost Secondary Center Center Cost Center Source Source Source for forCCR forCCR CCR 6700 9399 Occupational (PHP) Therapy 6700 9399 Occupational (PHP) Therapy 6700 9399 Occupational (PHP) Therapy 6700 9399 Occupational (PHP) Therapy 6700 9399 Occupational (PHP) Therapy 9399 (PHP) 9399 (PHP) 9000 (Clinic) 3550 (Psychiatric/ Psychological Services PO 00000 Frm 00177 9000 (Clinic) Fmt 4701 Sfmt 4725 9399 (PHP) 6700 Occupational Therapy 3550 (Psychiatric/ Psychological Services) 3550 (Psychiatric/ Psychological Services) E:\FR\FM\21NOR2.SGM 21NOR2 9000 (Clinic) 9000 (Clinic) ER21NO18.069</GPH> Previous Hierarchy (applicable in CY 2018) 58994 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations 4. PHP Service Utilization Updates ER21NO18.071</GPH> claims data used for this CY 2019 final rule with comment period revealed some changes in the provision of individual therapy compared to CY 2016 and CY 2015 claims data as shown in the Table 45 below. VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 PO 00000 Frm 00178 Fmt 4701 Sfmt 4725 E:\FR\FM\21NOR2.SGM 21NOR2 ER21NO18.070</GPH> khammond on DSK30JT082PROD with RULES2 We stated in the CY 2019 OPPS/ASC proposed rule (83 FR 37133 through 37134) that, while we were not proposing any changes to the policy on PHP service utilization, we would continue to monitor the provision of days with only 3 services. In the CY 2016 OPPS/ASC final rule with comment period (81 FR 79684 through 79685), we expressed concern over the low frequency of individual therapy provided to beneficiaries. The CY 2017 58995 As shown in Table 45, both CMHCs and hospital-based PHPs have decreased the provision of individual therapy, based on the CY 2017 claims used for this final rule with comment period. In the CY 2018 OPPS/ASC proposed rule and final rule with comment period (82 FR 33640 and 82 FR 59378), we stated that we are aware that our singletier payment policy may influence a change in service provision because providers are able to obtain payment that is heavily weighted to the cost of providing 4 or more services when they provide only 3 services. We indicated that we are interested in ensuring that providers furnish an appropriate number of services to beneficiaries enrolled in PHPs. Therefore, with the CY 2017 implementation of APC 5853 and APC 5863 for providing 3 or more PHP services per day, we are continuing to monitor utilization of days with only 3 PHP services. For this CY 2019 OPPS/ASC final rule with comment period, we used the final update of the CY 2017 claims data. Table 46 below shows the utilization findings based on the most recent claims data. BILLING CODE 4120–01–C and the declining level of utilization of days with 3 services only by hospitalbased PHPs indicates that these providers did not reduce care for this patient population. It is too early to determine if the increase in days providing 3 services only by CMHCs is a trend. We will continue to monitor the data for both hospital-based PHPs and CMHCs. It is important to reiterate our expectation that days with only 3 services are meant to be an exception and not the typical PHP day. In the CY 2009 OPPS/ASC final rule with comment period (73 FR 68694), we clearly stated that we consider the acceptable minimum units of PHP services required in a PHP day to be 3 and explained that it was never our intention that 3 units of service represent the number of services to be provided in a typical PHP day. PHP is furnished in lieu of inpatient psychiatric hospitalization and is intended to be more intensive than a half-day program. We further indicated that a typical PHP day should generally consist of 5 to 6 units of service (73 FR 68689). We explained that days with only 3 units of services may be appropriate to bill in certain limited circumstances, such as when a patient might need to leave early for a medical appointment and, therefore, would be unable to complete a full day of PHP treatment. At that time, we noted that if a PHP were to only provide days with 3 services, it would be difficult for patients to meet the eligibility requirement in 42 CFR 410.43(c)(1), that patients must require a minimum of 20 hours per week of therapeutic services as evidenced in their plan of care (73 FR 68689). We made no proposals in this section of the CY 2019 OPPS/ASC proposed rule, but received several public comments related to utilization. Comment: Some commenters were concerned that the single-tiered payment system implemented in CY 2017 could have unintended consequences, including reducing the number of services provided per day, and urged CMS to monitor the data. As shown in Table 46, the CY 2017 claims data used for this final rule with comment period showed that PHPs maintained an appropriately low utilization of 3 service days compared to CY 2016 and CY 2015. Compared to CY 2016, hospital-based PHPs have provided fewer days with 3 services only, fewer days with 4 services only, and more days with 5 or more services. Compared to CY 2016, CMHCs have slightly increased their provision of 3 service days, increased their provision of days with 4 services, but have decreased their provision of days with 5 or more services. As we noted in the CY 2017 OPPS/ ASC final rule with comment period (81 FR 79685), we will continue to monitor the provision of days with only 3 services, particularly now that the single-tier PHP APCs 5853 and 5863 are in place for providing 3 or more services per day to CMHCs and hospital-based PHPs, respectively. The CY 2017 data are the first year of claims data to reflect the change to the single-tier PHP APCs, VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 PO 00000 Frm 00179 Fmt 4701 Sfmt 4700 E:\FR\FM\21NOR2.SGM 21NOR2 ER21NO18.072</GPH> khammond on DSK30JT082PROD with RULES2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations 58996 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations Another commenter thanked CMS for not instituting a code edit for 20 hours per week, and welcomed a further discussion of clinical intensity and situations affecting weekly attendance. This commenter offered to convene a meeting of experts from the field to discuss, develop, and recommend ideas on how best to ensure the appropriate clinical intensity in PHPs. Another commenter wrote that the utilization data in Table 28 of the CY 2019 OPPS/ ASC proposed rule demonstrated the commitment of both CMHCs and hospital-based PHPs to fully comply with and exceed the expectations of the 20-hour rule. Response: We appreciate these comments and will take them into consideration. C. Outlier Policy for CMHCs In the CY 2019 OPPS/ASC proposed rule (83 FR 37134 through 37136), for CY 2019, we proposed to continue to calculate the CMHC outlier percentage, cutoff point and percentage payment amount, outlier reconciliation, outlier payment cap, and fixed-dollar threshold according to previously established policies. These topics are discussed in more detail below. We refer readers to section II.G. of this final rule with comment period for our general policies for hospital outpatient outlier payments. khammond on DSK30JT082PROD with RULES2 1. Background As discussed in the CY 2004 OPPS final rule with comment period (68 FR 63469 through 63470), we noted a significant difference in the amount of outlier payments made to hospitals and CMHCs for PHP services. Given the difference in PHP charges between hospitals and CMHCs, we did not believe it was appropriate to make outlier payments to CMHCs using the outlier percentage target amount and threshold established for hospitals. Therefore, beginning in CY 2004, we created a separate outlier policy specific to the estimated costs and OPPS payments provided to CMHCs. We designated a portion of the estimated OPPS outlier threshold specifically for CMHCs, consistent with the percentage of projected payments to CMHCs under the OPPS each year, excluding outlier payments, and established a separate outlier threshold for CMHCs. This separate outlier threshold for CMHCs resulted in $1.8 million in outlier payments to CMHCs in CY 2004 and $0.5 million in outlier payments to CMHCs in CY 2005 (82 FR 59381). In contrast, in CY 2003, more than $30 million was paid to CMHCs in outlier payments (82 FR 59381). VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 2. CMHC Outlier Percentage In the CY 2018 OPPS/ASC final rule with comment period (82 FR 59267 through 59268), we described the current outlier policy for hospital outpatient payments and CMHCs. We note that we also discussed our outlier policy for CMHCs in more detail in section VIII. C. of that same final rule (82 FR 59381). We set our projected target for all OPPS aggregate outlier payments at 1.0 percent of the estimated aggregate total payments under the OPPS (82 FR 59267). We estimate CMHC per diem payments and outlier payments by using the most recent available utilization and charges from CMHC claims, updated CCRs, and the updated payment rate for APC 5853. For increased transparency, we are providing a more detailed explanation of the existing calculation process for determining the CMHC outlier percentages below. As previously stated, we proposed to continue to calculate the CMHC outlier percentage according to previously established policies, and we did not propose any changes to our current methodology for calculating the CMHC outlier percentage for CY 2019. To calculate the CMHC outlier percentage, we followed three steps: • Step 1: We multiplied the OPPS outlier threshold, which is 1.0 percent, by the total estimated OPPS Medicare payments (before outliers) for the prospective year to calculate the estimated total OPPS outlier payments: (0.01 × Estimated Total OPPS Payments) = Estimated Total OPPS Outlier Payments. • Step 2: We estimated CMHC outlier payments by taking each provider’s estimated costs (based on their allowable charges multiplied by the provider’s CCR) minus each provider’s estimated CMHC outlier multiplier threshold (we refer readers to section VIII.C.3. of this final rule with comment period). That threshold was determined by multiplying the provider’s estimated paid days by 3.4 times the CMHC PHP APC payment rate. If the provider’s costs exceeded the threshold, we multiplied that excess by 50 percent, as described in section VIII.C.3. of this final rule with comment period, to determine the estimated outlier payments for that provider. CMHC outlier payments are capped at 8 percent of the provider’s estimated total per diem payments (including the beneficiary’s copayment), as described in section VIII.C.5. of this final rule with comment period, so any provider’s costs that exceed the CMHC outlier cap will have its payments adjusted downward. After accounting for the CMHC outlier PO 00000 Frm 00180 Fmt 4701 Sfmt 4700 cap, we summed all of the estimated outlier payments to determine the estimated total CMHC outlier payments. (Each Provider’s Estimated Costs— Each Provider’s Estimated Multiplier Threshold) = A. If A is greater than 0, then (A × 0.50) = Estimated CMHC Outlier Payment (before cap) = B. If B is greater than (0.08 × Provider’s Total Estimated Per Diem Payments), then cap-adjusted B = (0.08 × Provider’s Total Estimated Per Diem Payments); otherwise, B = B. Sum (B or capadjusted B) for Each Provider = Total CMHC Outlier Payments. • Step 3: We determined the percentage of all OPPS outlier payments that CMHCs represent by dividing the estimated CMHC outlier payments from Step 2 by the total OPPS outlier payments from Step 1: (Estimated CMHC Outlier Payments/ Total OPPS Outlier Payments). In CY 2018, we designated approximately 0.03 percent of that estimated 1.0 percent hospital outpatient outlier threshold for CMHCs (82 FR 59381), based on this methodology. In the proposed rule, we proposed to continue to use the same methodology for CY 2019. Therefore, based on our CY 2019 payment estimates, CMHCs are projected to receive 0.02 percent of total hospital outpatient payments in CY 2019, excluding outlier payments. We proposed to designate approximately less than 0.01 percent of the estimated 1.0 percent hospital outpatient outlier threshold for CMHCs. This percentage is based upon the formula given in Step 3 above. We did not receive any public comments on our proposal and, therefore, are finalizing our proposal, without modification, to continue with this existing policy on outliers, and are implementing this policy as proposed for CY 2019. 3. Cutoff Point and Percentage Payment Amount As described in the CY 2018 OPPS/ ASC final rule with comment period (82 FR 59381), our policy has been to pay CMHCs for outliers if the estimated cost of the day exceeds a cutoff point. In CY 2006, we set the cutoff point for outlier payments at 3.4 times the highest CMHC PHP APC payment rate implemented for that calendar year (70 FR 68551). This cutoff point is sometimes called a multiplier threshold (70 FR 68550). For CY 2018, the highest CMHC PHP APC payment rate is the payment rate for CMHC PHP APC 5853. In addition, in 2002, the final OPPS outlier payment percentage for costs above the multiplier threshold was set at 50 percent (66 FR E:\FR\FM\21NOR2.SGM 21NOR2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations khammond on DSK30JT082PROD with RULES2 59889). In CY 2018, we continued to apply the same 50 percent outlier payment percentage that applies to hospitals to CMHCs and continued to use the existing cutoff point (82 FR 59381). Therefore, for CY 2018, we continued to pay for partial hospitalization services that exceeded 3.4 times the CMHC PHP APC payment rate at 50 percent of the amount of CMHC PHP APC geometric mean per diem costs over the cutoff point. For example, for CY 2018, if a CMHC’s cost for partial hospitalization services paid under CMHC PHP APC 5853 exceeds 3.4 times the CY 2018 payment rate for CMHC PHP APC 5853, the outlier payment would be calculated as 50 percent of the amount by which the cost exceeds 3.4 times the CY 2018 payment rate for CMHC PHP APC 5853 [0.50 × (CMHC Cost¥(3.4 × APC 5853 rate))]. In the CY 2019 OPPS/ASC proposed rule (83 FR 37135), for CY 2019, in accordance with our existing policy, we proposed to continue to pay for partial hospitalization services that exceed 3.4 times the proposed CMHC PHP APC payment rate at 50 percent of the CMHC PHP APC geometric mean per diem costs over the cutoff point. That is, for CY 2019, if a CMHC’s cost for partial hospitalization services paid under CMHC PHP APC 5853 exceeds 3.4 times the payment rate for CMHC APC 5853, the outlier payment will be calculated as [0.50 × (CMHC Cost¥(3.4 × APC 5853 rate))]. We did not receive any public comments on our proposals. We are finalizing our proposals, without modification, to continue to calculate the CMHC outlier percentage according to previously established policies, and are implementing this policy as proposed for CY 2019. 4. Outlier Reconciliation In the CY 2009 OPPS/ASC final rule with comment period (73 FR 68594 through 68599), we established an outlier reconciliation policy to address charging aberrations related to OPPS outlier payments. We addressed vulnerabilities in the OPPS outlier payment system that lead to differences between billed charges and charges included in the overall CCR, which are used to estimate cost and would apply to all hospitals and CMHCs paid under the OPPS. The main vulnerability in the OPPS outlier payment system is the time lag between the update of the CCRs that are based on the latest settled cost report and the current charges that creates the potential for hospitals and CMHCs to set their own charges to exploit the delay in calculating new CCRs. CMS initiated steps to ensure that VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 outlier payments appropriately account for the financial risk when providing an extraordinarily costly and complex service, but are only being made for services that legitimately qualify for the additional payment. The current outlier reconciliation policy requires that providers whose outlier payments meet a specified threshold (currently $500,000 for hospitals and any outlier payments for CMHCs) and whose overall ancillary CCRs change by plus or minus 10 percentage points or more, are subject to outlier reconciliation, pending approval of the CMS Central Office and Regional Office (73 FR 68596 through 68599). The policy also includes provisions related to CCRs and to calculating the time value of money for reconciled outlier payments due to or due from Medicare, as detailed in the CY 2009 OPPS/ASC final rule with comment period and in the Medicare Claims Processing Manual (73 FR 68595 through 68599 and Medicare Claims Processing internet Only Manual, Chapter 4, Section 10.7.2 and its subsections, available online at: https:// www.cms.gov/Regulations-andGuidance/Guidance/Manuals/ Downloads/clm104c04.pdf). In the CY 2019 OPPS/ASC proposed rule (83 FR 37135), we proposed to continue these policies for CY 2019. We did not receive any public comments on our proposals and, therefore, are finalizing our proposals, without modification, to continue our existing policy for CY 2019. 5. Outlier Payment Cap In the CY 2017 OPPS/ASC final rule with comment period, we implemented a CMHC outlier payment cap to be applied at the provider level, such that in any given year, an individual CMHC will receive no more than a set percentage of its CMHC total per diem payments in outlier payments (81 FR 79692 through 79695). We finalized the CMHC outlier payment cap to be set at 8 percent of the CMHC’s total per diem payments (81 FR 79694 through 79695). This outlier payment cap only affects CMHCs, does not affect other provider types (that is, hospital-based PHPs), and is in addition to and separate from the current outlier policy and reconciliation policy in effect. For CY 2018, we continued this policy in the CY 2018 OPPS/ASC final rule with comment period (82 FR 59381). In the CY 2019 OPPS/ASC proposed rule (83 FR 37135 through 37136), we proposed to continue this policy for CY 2019, such that the CMHC outlier payment cap would be 8 percent of the CMHC’s total per diem payments. PO 00000 Frm 00181 Fmt 4701 Sfmt 4700 58997 We did not receive any public comments on our proposal and, therefore, are finalizing our proposal, without modification, to continue our existing policy for CY 2019, such that the CMHC outlier payment cap will be 8 percent of the CMHC’s total per diem payments. 6. Fixed-Dollar Threshold In the CY 2018 OPPS/ASC final rule with comment period (82 FR 59267 through 59268), for the hospital outpatient outlier payment policy, we set a fixed-dollar threshold in addition to an APC multiplier threshold. Fixeddollar thresholds are typically used to drive outlier payments for very costly items or services, such as cardiac pacemaker insertions. CMHC PHP APC 5853 is the only APC for which CMHCs may receive payment under the OPPS, and is for providing a defined set of services that are relatively low cost when compared to other OPPS services. Because of the relatively low cost of CMHC services that are used to comprise the structure of CMHC PHP APC 5853, it is not necessary to also impose a fixed-dollar threshold on CMHCs. Therefore, in the CY 2018 OPPS/ASC final rule with comment period, we did not set a fixed-dollar threshold for CMHC outlier payments (82 FR 59381). In the CY 2019 OPPS/ASC proposed rule (83 FR 37134 through 37136), we proposed to continue this policy for CY 2019. We did not receive any public comments on our proposal and, therefore, are finalizing our proposal, without modification, to continue with this existing policy, and are implementing this policy as proposed for CY 2019. D. Proposed Update to PHP Allowable HCPCS Codes CMS received the CY 2019 CPT codes from the AMA in time for inclusion in the CY 2019 OPPS/ASC proposed rule (83 FR 37088). The new, revised, and deleted CY 2019 Category I and III CPT codes were included in Addendum B to the proposed rule (which is available via the internet on the CMS website). We are aware that the AMA will be deleting the following psychological and neuropsychological testing CPT codes, which affect PHPs, as of January 1, 2019: • CPT code 96101 (Psychological testing by psychologist/physician); • CPT code 96102 (Psychological testing by technician); • CPT code 96103 (Psychological testing administered by computer); E:\FR\FM\21NOR2.SGM 21NOR2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations khammond on DSK30JT082PROD with RULES2 • CPT code 96118 (Neuropsychological testing by psychologist/physician) • CPT code 96119 (Neuropsychological testing by technician); and • CPT code 96120 (Neuropsychological test administered w/computer). In the CY 2019 OPPS/ASC proposed rule (83 FR 37088), we proposed to delete these 6 CPT codes for the 2019 OPPS update under section III.A.4. (‘‘Proposed Treatment of New and Revised CY 2019 Category I and III CPT Codes That Will Be Effective January 1, 2019 For Which We Are Soliciting Public Comments In This CY 2019 OPPS/ASC Proposed Rule’’). In addition, the AMA will be adding the following psychological and neuropsychological testing CPT codes to replace the deleted codes, as of January 1, 2019: • CPT code 96130 (Psychological testing evaluation by physician/ qualified health care professional; first hour); • CPT code 93131 (Psychological testing evaluation by physician/ qualified health care professional; each additional hour); • CPT code 96132 (Neuropsychological testing evaluation VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 by physician/qualified health care professional; first hour); • CPT code 96133 (Neuropsychological testing evaluation by physician/qualified health care professional; each additional hour); • CPT code 96136 (Psychological/ neuropsychological testing by physician/qualified health care professional; first 30 minutes); • CPT code 96137 (Psychological/ neuropsychological testing by physician/qualified health care professional; each additional 30 minutes); • CPT code 96138 (Psychological/ neuropsychological testing by technician; first 30 minutes); • CPT code 96139 (Psychological/ neuropsychological testing by technician; each additional 30 minutes); and • CPT code 96146 (Psychological/ neuropsychological testing; automated result only). In the CY 2019 OPPS/ASC proposed rule (83 FR 37088), we also proposed to recognize and assign these 9 CPT codes under the CY 2019 OPPS in section III.A.4. (‘‘Proposed Treatment of New and Revised CY 2019 Category I and III CPT Codes That Will Be Effective January 1, 2019 For Which We Are PO 00000 Frm 00182 Fmt 4701 Sfmt 4725 Soliciting Public Comments In This CY 2019 OPPS/ASC Proposed Rule’’). While these proposed changes to the above-referenced codes were included in the CY 2019 OPPS/ASC proposed rule (and are being finalized in section III.A.3. in this final rule with comment period for the CY 2019 OPPS), PHP is a part of the OPPS and PHP providers may not have been aware of those proposed changes because we did not also include the proposals in the PHP discussion presented in the proposed rule. To ensure that PHP providers are aware of the codes and have the opportunity to comment on the proposed changes, we are utilizing a practice similar to the one we use under the OPPS for new Level II HCPCS codes that become effective after the proposed rule is published. Therefore, in this final rule with comment period, we are proposing to delete the same 6 CPT codes listed above from the PHPallowable code set for CMHC APC 5853 and hospital-based PHP APC 5863, and replace them with 9 new CPT codes as shown in Table 47 below, effective January 1, 2019. We are soliciting public comments on these proposals. We will consider the public comments we receive and seek to finalize our proposed actions in the CY 2020 OPPS/ ASC final rule with comment period. E:\FR\FM\21NOR2.SGM 21NOR2 ER21NO18.073</GPH> 58998 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations IX. Procedures That Will Be Paid Only as Inpatient Procedures A. Background We refer readers to the CY 2012 OPPS/ASC final rule with comment period (76 FR 74352 through 74353) for a full historical discussion of our longstanding policies on how we identify procedures that are typically provided only in an inpatient setting (referred to as the inpatient only (IPO) list) and, therefore, will not be paid by Medicare under the OPPS, and on the criteria that we use to review the IPO list each year to determine whether or not any procedures should be removed from the list. The complete list of codes that describe procedures that will be paid by Medicare in CY 2019 as inpatient only procedures is included as Addendum E to this CY 2019 OPPS/ ASC final rule with comment period, which is available via the internet on the CMS website. khammond on DSK30JT082PROD with RULES2 B. Changes to the Inpatient Only (IPO) List 1. Methodology for Identifying Appropriate Changes to IPO List In the CY 2019 OPPS/ASC proposed rule (83 FR 37136 through 37143), for CY 2019, we proposed to use the same methodology (described in the November 15, 2004 final rule with comment period (69 FR 65834)) of reviewing the current list of procedures on the IPO list to identify any procedures that may be removed from the list. We have established five criteria that are part of this methodology. As noted in the CY 2012 OPPS/ASC final rule with comment period (76 FR 74353), we utilize these criteria when reviewing procedures to determine whether or not they should be removed from the IPO list and assigned to an APC group for payment under the OPPS when provided in the hospital outpatient setting. We note that a procedure is not required to meet all of the established criteria to be removed from the IPO list. The criteria include the following: 1. Most outpatient departments are equipped to provide the services to the Medicare population. 2. The simplest procedure described by the code may be performed in most outpatient departments. 3. The procedure is related to codes that we have already removed from the IPO list. 4. A determination is made that the procedure is being performed in numerous hospitals on an outpatient basis. 5. A determination is made that the procedure can be appropriately and VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 safely performed in an ASC and is on the list of approved ASC procedures or has been proposed by us for addition to the ASC list. Using the above-listed criteria, for the CY 2019 OPPS, we identified two procedures described by the following codes that we proposed to remove from the IPO list for CY 2019: CPT code 31241 (Nasal/sinus endoscopy, surgical; with ligation of sphenopalatine artery) and CPT code 01402 (Anesthesia for open or surgical arthroscopic procedures on knee joint; total knee arthroplasty). We also proposed to add to the IPO list for CY 2019 the procedure described by HCPCS code C9606 (Percutaneous transluminal revascularization of acute total/subtotal occlusion during acute myocardial infarction, coronary artery or coronary artery bypass graft, any combination of drug-eluting intracoronary stent, artherectomy and angioplasty, including aspiration thrombectomy when performed, single vessel). Table 29 of the proposed rule (83 FR 37137) displayed the proposed changes to the IPO list for CY 2019 and subsequent years, including the HCPCS codes, long descriptors, and the proposed CY 2019 payment indicators. As noted earlier, we proposed to remove the procedure described by CPT code 31241 from the IPO list for CY 2019. Specifically, we stated that after reviewing the clinical characteristics of the procedure described by CPT code 31241 and consulting with stakeholders and our clinical advisors regarding this procedure, we believed that this procedure met criterion 3; that is, the procedure is related to codes that we have already removed from the IPO list. We proposed that the procedure described by CPT code 31241 be assigned to C–APC 5153 (Level 3 Airway Endoscopy) with a status indicator of ‘‘J1.’’ We sought public comments on whether the public believes that the procedure described by CPT code 31241 meets criterion 3 and whether the procedure meets any of the other five criteria for removal from the IPO list. Comment: A majority of the commenters supported the proposed removal of CPT code 31241 from the IPO list and the proposed APC assignment to APC 5153 with a status indicator of ‘‘J1’’. The commenters agreed that the procedure described by CPT code 31241 meets criterion 3 (that is, the procedure described by CPT code 31241 is related to codes that we have already removed from the IPO list). Response: We appreciate the commenters’ support. PO 00000 Frm 00183 Fmt 4701 Sfmt 4700 58999 Comment: One commenter opposed the removal of CPT code 31241. However, the commenter did not provide a rationale for its opposition. Response: We have noted the commenter’s general opposition. However, for the reasons cited in the proposed rule, we continue to believe that removal of the procedure described by CPT code 31241from the IPO list is appropriate. In addition, we received support for the removal of CPT code 31241 from the IPO list from many other stakeholders. After consideration of the public comments we received, we are finalizing our proposal, without modification, to remove CPT code 31241 from the IPO list and to assign the procedure to C–APC 5153 (Level 3 Airway Endoscopy) with a status indicator of ‘‘J1’’. In the CY 2019 OPPS/ASC proposed rule (83 FR 37136), we also proposed to remove the procedure described by CPT code 01402 from the IPO list. We reviewed the clinical characteristics of the procedure described by CPT code 01402, and proposed that this procedure be removed from the IPO list because it meets above-listed criteria 3 and 4. This procedure is typically billed with the procedure described by CPT code 27447 (Arthroplasty, knee, condyle and plateau; medial and lateral compartments with or without patella resurfacing (total knee arthroplasty)), which was removed from the IPO list for CY 2018 (82 FR 52526). This procedure is also often performed safely in the outpatient department setting. We sought public comments on whether the procedure described by CPT code 01402 meets criteria 3 and 4 and whether the procedure meets any of the other five criteria for removal from the IPO list. Comment: Commenters supported the removal of the procedure described by CPT code 01402 from the IPO list and agreed that the procedure described by CPT code 01402 was both related to codes that were previously removed from the IPO list and is performed safely in numerous hospitals on an outpatient basis. Response: We thank the commenters for their support. Comment: One commenter opposed the removal of the procedure described by CPT code 01402 from the IPO list because the commenter believed that there would be potential detrimental lateral impacts on hospitals participating in the Comprehensive Care for Joint Replacement (CJR) Model, the Bundled Payments for Care Improvement (BPCI) Initiative, the Hospital Value-Based Purchasing (VBP) E:\FR\FM\21NOR2.SGM 21NOR2 khammond on DSK30JT082PROD with RULES2 59000 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations Program, and the Hospital Readmissions Reduction Program (HRRP). Response: Removal of the procedure described by CPT code 01402 does not in any way affect a provider’s ability to participate in any of the initiatives the commenter mentioned. We remind readers that the removal of any procedure from the IPO list does not mandate that all cases be performed on an outpatient basis. Rather, such removal allows for Medicare payment to be made to the hospital when the procedure is performed in the hospital outpatient department setting. The decision to admit a patient is a complex medical judgment that is made by the treating physician. We refer readers to the CY 2017 OPPS/ASC final rule with comment period (81 FR 79698 through 79699) in which we originally proposed to remove total knee arthroplasty (TKA) procedure codes from the IPO list and sought comments on how to modify the CJR Model and the BPCI Initiative to reflect the shift of some Medicare beneficiaries from an inpatient TKA procedure to an outpatient TKA procedure in the BPCI Initiative and the CJR Model pricing methodologies, including target price calculations and reconciliation processes. However, we invite interested parties to direct any questions about these initiatives to the CMS Center for Medicare and Medicaid Innovation. Comment: One commenter representing a coalition of industry stakeholders recommended that CMS collect and publish data on morbidity and mortality rates for TKA performed in the outpatient setting versus in the inpatient setting. The commenter believed that collecting these data would allow CMS to evaluate the quality of services in both settings since the removal of TKA procedures from the IPO list. Response: We note that since we removed the CPT codes related to TKA from the IPO list, TKA procedures have only been payable under the OPPS for less than one year. Accordingly, we do not believe that we have sufficient data at this time for a meaningful comparison of quality outcomes associated with TKA procedures performed in the hospital outpatient setting versus the hospital inpatient setting. However, we will consider reviewing mortality rates in the future when appropriate data are available. We would not expect there to be statistically significant differences in morbidity and mortality among Medicare beneficiaries based solely on whether the patient was admitted to the hospital or remained a hospital outpatient (especially because it is likely the same surgeon, the same VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 clinical protocol, and the same staff at a given hospital for both inpatient and outpatient orthopaedic procedures) and would expect that other factors, such as underlying disease-state and condition of the patient, surgical complications, and ability to avoid blood clots and other potential adverse event within 90 days postsurgery. We remind readers that there are several short stay inpatient cases with a length of stay of 1 or 2 days, which is generally similar to the length of stay for outpatient cases. To be clear, there is a plethora of surgical procedures that may be performed on either an inpatient basis or an outpatient basis. However, we are not aware of differences in clinical outcomes for patients based solely on this factor. While there are some studies relating to the non-Medicare population regarding differences in outcomes, depending on whether the care setting is inpatient versus outpatient (which could include ASCs), we are not aware of any such studies since the TKA has become a payable procedure under the OPPS in 2018. In addition, we note that interested stakeholders are welcome to research these or other statistics by analyzing data that Medicare makes available. The Hospital Inpatient Quality Reporting (IQR) Program and the Hospital Outpatient Quality Reporting (OQR) Program collect and share information regarding the quality of care in both the hospital inpatient setting and the hospital outpatient setting. Specifically, the Hospital IQR Program maintains measures that include complications and deaths during inpatient hip/knee replacement procedures. However, an analogous measure for outpatient procedures does not currently exist. Comment: One commenter requested that CMS provide guidance and education regarding the removal of TKA procedures from the IPO list beginning in CY 2018. The commenter noted that there was confusion around the policy for hospital systems and health insurance plans, and that many hospital systems and Medicare Advantage plans were denying inpatient admissions by default and requiring Medicare patients to undergo a TKA procedure as a hospital outpatient. Response: As previously stated in the discussion of the CY 2018 OPPS/ASC final rule with comment period (82 FR 59383), we continue to believe that the decision regarding the most appropriate care setting for a given surgical procedure is a complex medical judgment made by the physician based on the beneficiary’s individual clinical needs and preferences and on the general requirement that any procedure PO 00000 Frm 00184 Fmt 4701 Sfmt 4700 be reasonable and necessary. We also reiterate our previous statement that the removal of any procedure from the IPO list does not require the procedure to be performed only on an outpatient basis. Rather, we believe that as technology and clinical practice continue to evolve, beneficiaries should continue to receive care in the most appropriate setting. While we continue to expect providers who perform an outpatient TKA procedure on Medicare beneficiaries to use comprehensive patient selection criteria to identify appropriate candidates for the procedure, we believe that the surgeons, clinical staff, and medical specialty societies representing physicians who perform outpatient TKA procedures and possess specialized clinical knowledge and experience are most suited to create such guidelines. After consideration of the public comments we received, we are adopting, as final without modification, our proposal to remove the procedure described by CPT code 01402 from the IPO list. In accordance with the regulations at 42 CFR 419.2(b)(4), under the OPPS, this anesthesia service is packaged with the associated procedure and assigned status indicator ‘‘N’’ (Items and Services Packaged into APC Rates) for CY 2019. In addition, in the CY 2019 OPPS/ ASC proposed rule (83 FR 37136 through 37137), we proposed to add the procedure described by HCPCS code C9606 (Percutaneous transluminal revascularization of acute total/subtotal occlusion during acute myocardial infarction, coronary artery or coronary artery bypass graft, any combination of drug-eluting intracoronary stent, atherectomy and angioplasty, including aspiration thrombectomy when performed, single vessel) to the IPO list for CY 2019. The IPO list specifies those procedures and services for which the hospital will be paid only when the procedures are provided in the inpatient setting because of the nature of the procedure, the underlying physical condition of the patient, or the need for at least 24 hours of postoperative recovery time or monitoring before the patient can be safely discharged (76 FR 74353). After evaluating the procedure described by HCPCS code C9606 using the criteria described above, we believe that the procedure should be added to the IPO list because this procedure is performed during acute myocardial infarction and it is similar to a procedure already on the IPO list (that is, the procedure described by CPT code 92941 (Percutaneous transluminal revascularization of acute total/subtotal occlusion during acute myocardial E:\FR\FM\21NOR2.SGM 21NOR2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations infarction, coronary artery or coronary artery bypass graft, any combination of intracoronary stent, artherectomy and angioplasty, including aspiration thrombectomy when performed, single vessel)), which was added to the IPO list for CY 2018 (82 FR 52526). We sought public comments on whether the procedure described by HCPCS code C9606 should be added to the IPO list for CY 2019 and subsequent years. Comment: Several commenters, largely from specialty medical societies, supported adding the procedure described by HCPCS code C9606 to the IPO list for CY 2019. Response: We appreciate the commenters’ support. After consideration of the public comments we received, we are adopting as final without modification, our proposal to add the procedure described by HCPCS code C9606 (Percutaneous transluminal revascularization of acute total/subtotal occlusion during acute myocardial infarction, coronary artery or coronary artery bypass graft, any combination of drug eluting intracoronary stent, atherectomy and angioplasty, including aspiration thrombectomy when performed, single vessel) to the IPO list for CY 2019. 2. Summary of Public Comments Received in Response to CMS’ Solicitation on the Potential Removal of Procedure Described by CPT Code 0266T From the IPO List and Our Responses khammond on DSK30JT082PROD with RULES2 CPT code 0266T describes the implantation or replacement of carotid sinus baroreflex activation device; total system (includes generator placement, unilateral or bilateral lead placement, intra-operative interrogation, programming, and repositioning, when performed). The procedure described by CPT code 0266T has been included on the IPO list since the procedure code became effective in CY 2011. There are several codes that describe procedures that are similar to the procedure described by CPT code 0266T VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 that are not on the IPO list, including: CPT code 0267T (Implantation or replacement of carotid sinus baroreflex activation device; lead only, unilateral (includes intra-operative interrogation, programming, and repositioning, when performed)) and CPT code 0268T (Implantation or replacement of carotid sinus baroreflex activation device; pulse generator only (includes intra-operative interrogation, programming, and repositioning, when performed)). The device that is billed with these two procedures has been granted a Category B Investigational Device Exemption (IDE) from FDA.62 Currently, there is limited information available to determine the typical site of service and the ability for the procedure to be safely performed in the outpatient setting. At the time of development of the CY 2019 OPPS/ASC proposed rule, we did not believe that we had adequate information to determine whether the procedure described by CPT code 0266T should be removed from the IPO list. Therefore, we sought public comments on the removal of the procedure described by CPT code 0266T from the IPO list. Specifically, we sought public comments on whether the procedure described by CPT code 0266T meets any of the criteria to be removed from the IPO list as well as the appropriate APC assignment and status indicator for this code. Comment: Numerous commenters responded to CMS’ solicitation for discussion of the removal of the Barostim procedure from the IPO list. Commenters included the manufacturer and practitioners, specifically cardiologists and cardiovascular surgeons, who have performed the Barostim procedure multiple times. Commenters referenced their personal experience with the procedure described by CPT code 0266T, the advancements and safety of the procedure, and patients’ experience after undergoing the procedure. These 62 Available at: https://www.cms.gov/Medicare/ Coverage/IDE/Approved-IDE-Studies.html. PO 00000 Frm 00185 Fmt 4701 Sfmt 4700 59001 commenters argued that procedures related to CPT code 0266T are commonly being performed safely in the hospital outpatient department. The manufacturer specifically cited the CY 2019 NPRM CPT Cost Statistics Files associated with the proposed rule to show the number of related procedures that have been performed in the hospital outpatient department this year. Further, another commenter supported the assertion provided in the proposed rule that the simplest procedures described by CPT code 0266T, the procedure to implant or replace the lead or IPG, currently have separate and distinct CPT codes (0267T and 0268T) that are not included on the IPO list. Response: We reviewed clinical characteristics of the Barostim procedure and related evidence, including input from multiple physician and cardiology specialty societies, and determined that the procedure described by CPT code 0266T is an appropriate candidate for removal from the IPO list. CPT code 0266T is similar to CPT code 0268T, which is performed in numerous hospitals on an outpatient basis (criterion 3). Furthermore, we believe that most outpatient departments are equipped to provide the described services to the Medicare population (criterion 1). Therefore, we are removing the procedure described by CPT code 0266T from the IPO list for CY 2019. Comment: Several commenters recommended the removal of several procedures not originally proposed by CMS for removal from the IPO list for CY 2019. These recommended procedures related to other procedures that were recently removed from the IPO. In addition, several commenters recommended the removal of all orthopaedic, arthroplasty, and joint replacement procedures from the IPO list. Table 48 below contains the procedures that were explicitly requested by the commenters to be removed from the IPO list for CY 2019. E:\FR\FM\21NOR2.SGM 21NOR2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations khammond on DSK30JT082PROD with RULES2 Response: We appreciate the diligence that commenters continue to show in proposing changes to the IPO list. For the CY 2019 OPPS, we believe that it is appropriate to remove the procedure described by CPT code 00670 from the IPO list, as recommended by the commenters. We refer readers to the CY 2017 OPPS/ASC final rule with comment period (81 FR 79695 through 79696) in which CMS removed six related codes (four spine procedure codes and two laryngoplasty codes) from the IPO list for CY 2017. We believe that the procedure described by CPT code 00670 is appropriate for removal from the IPO list because it relates to the following codes that CMS removed from the IPO list in CY 2017: CPT code 22840 (Posterior nonsegmental instrumentation (e.g., Harrington rod technique, pedicle fixation across 1 interspace, atlantoaxial transarticular screw fixation, sublaminar wiring at C1, facet screw fixation) (List separately in addition to code for primary procedure)); CPT code 22842 (Posterior segmental instrumentation (e.g., pedicle fixation, dual rods with multiple hooks and sublaminar wires); 3 to 6 vertebral segments (List separately in addition to code for primary procedure)); CPT code 22845 (Anterior instrumentation; 2 to 3 vertebral VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 segments (List separately in addition to code for primary procedure)); and CPT code 22858 (Total disc arthroplasty (artificial disc), anterior approach, including discectomy with end plate preparation (includes osteophytectomy for nerve root or spinal cord decompression and microdissection); second level, cervical (List separately in addition to code for primary procedure)). We also believe that this procedure is being performed in numerous hospitals on an outpatient basis. Accordingly, we are removing the procedure described by CPT code 00670 from the IPO list for CY 2019. Because this spine procedure code is an add-on code, in accordance with the regulations at 42 CFR 419.2(b)(18), under the OPPS, this procedure is packaged with the associated procedure and assigned status indicator ‘‘N’’ (Items and Services Packaged into APC Rates) for CY 2019. With respect to the commenters’ recommendation that we remove CPT code 63265 (Laminectomy for excision or evacuation of intraspinal lesion other than neoplasm, extradural; cervical), CPT code 63266 (Laminectomy for excision or evacuation of intraspinal lesion other than neoplasm, extradural; thoracic), CPT code 63267 (Laminectomy for excision or evacuation of intraspinal lesion other PO 00000 Frm 00186 Fmt 4701 Sfmt 4700 than neoplasm, extradural; lumbar), and CPT code 63268 (Laminectomy for excision or evacuation of intraspinal lesion other than neoplasm, extradural; sacral) from the IPO list, we intend to continue to review these procedures and the appropriateness of the potential removal from the IPO list for subsequent rulemaking. In regard to the commenters’ recommendation to remove all orthropaedic, arthroplasty, and joint replacement procedures from the IPO list, we do not believe that we have sufficient data to support removal of all orthopaedic, arthroplasty, and joint replacement procedures from the IPO list. However, we encourage stakeholders to submit specific procedures, along with evidence, to support their requests for removal from the IPO list. In conclusion, the complete list of procedure codes that are placed on the IPO list for CY 2019 is included as Addendum E to this CY 2019 OPPS/ ASC final rule with comment period (which is available via the internet on the CMS website). Table 49 below contains the final changes that we are making to the IPO list for CY 2019. BILLING CODE 4120–01–P E:\FR\FM\21NOR2.SGM 21NOR2 ER21NO18.074</GPH> 59002 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations khammond on DSK30JT082PROD with RULES2 X. Nonrecurring Policy Changes A. Collecting Data on Services Furnished in Off-Campus ProviderBased Emergency Departments The June 2017 Report to Congress 63 by the Medicare Payment Advisory Commission (MedPAC) states that, in recent years, there has been significant growth in the number of health care facilities located apart from hospitals that are devoted primarily to emergency department services. This includes both off-campus provider-based emergency departments that are eligible for payment under the OPPS and independent freestanding emergency 63 Available at: https://www.medpac.gov/docs/ default-source/reports/jun17_reporttocongress_ sec.pdf. VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 departments not affiliated with a hospital that are not eligible for payment under the OPPS. Since 2010, we have observed a noticeable increase in the number of hospital outpatient emergency department visits furnished under the OPPS. MedPAC and other entities have expressed concern that services may be shifting to the higher acuity and higher cost emergency department setting due to: (1) Higher payment rates for services performed in off-campus provider-based emergency departments compared to similar services provided in other settings (that is, physician offices or urgent care clinics); and (2) the exemption for services provided in an emergency department included under section 603 of the Bipartisan Budget Act of 2015 (Pub. L. 114–25), whereby all items and PO 00000 Frm 00187 Fmt 4701 Sfmt 4700 services (emergency and nonemergency) furnished in an emergency department are excepted from the payment implications of section 603, as long as the department maintains its status as an emergency department under the regulation at 42 CFR 489.24(b). MedPAC and other entities are concerned that these payment incentives may be a key factor contributing to the growth in the number of emergency departments located off-campus from a hospital. MedPAC recommended in its March 2017 64 and June 2017 Reports to Congress that CMS require hospitals to append a modifier to claims for all services furnished in off-campus 64 Available at: https://medpac.gov/docs/defaultsouce/reports/mar17_entirereport.pdf. E:\FR\FM\21NOR2.SGM 21NOR2 ER21NO18.075</GPH> BILLING CODE 4120–01–C 59003 khammond on DSK30JT082PROD with RULES2 59004 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations provider-based emergency departments, so that CMS can track the growth of OPPS services provided in this setting. In order to participate in Medicare as a hospital, the facility must meet the statutory definition of a hospital at section 1861(e) of the Act, which requires a facility to be primarily engaged in providing care and services to inpatients. In addition, 42 CFR 482.55 requires hospital emergency department services (to include off-campus provider-based emergency departments) to be fully integrated with departments and services of the hospital. The integration must be such that the hospital can immediately make available the full extent of its patient care resources to assess and furnish appropriate care for an emergency patient. Such services would include, but are not limited to, surgical services, laboratory services, and radiology services, among others. The emergency department must also be integrated with inpatient services, which means the hospital must have a sufficient number of inpatient beds and nursing units to support the volume of emergency department patients that could require inpatient services. The provision of services, equipment, personnel and resources of other hospital departments and services to emergency department patients must be within timeframes that protect the health and safety of patients and is within acceptable standards of practice. We agree with MedPAC’s recommendation and believe we need to develop data to assess the extent to which OPPS services are shifting to offcampus provider-based emergency departments. Therefore, we announced in the CY 2019 OPPS/ASC proposed rule (83 FR 37138) that we are implementing through the subregulatory HCPCS modifier process a new modifier for this purpose, effective beginning January 1, 2019. We stated in the proposed rule that we will create a HCPCS modifier (‘‘ER’’—Items and services furnished by a provider-based off-campus emergency department) that is to be reported with every claim line for outpatient hospital services furnished in an off-campus provider-based emergency department. We specified in the proposed rule that the modifier would be reported on the UB–04 form (CMS Form 1450) for hospital outpatient services. We stated that critical access hospitals (CAHs) would not be required to report this modifier. In response to our announcement of the creation of HCPCS modifier ‘‘ER’’ (Items and services furnished by a provider-based off-campus emergency VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 department), we received the following feedback from commenters in response to the CY 2019 OPPS/ASC proposed rule: Some commenters, including MedPAC, supported the creation of HCPCS modifier ‘‘ER’’, citing the opportunity to facilitate the collection of data on services furnished in off-campus emergency departments. Other commenters were opposed to the creation of the HCPCS modifier ‘‘ER’’ because they believed it would be an undue and unnecessary administrative burden on hospitals. Another commenter expressed a desire to have a better understanding of the reasoning for the creation of the modifier. While we note that the creation of the HCPCS modifier ‘‘ER’’ was included in the CY 2019 OPPS/ASC proposed rule as an announcement, as opposed to a proposal, and therefore was not subject to public comment, we nonetheless appreciate the feedback provided by interested stakeholders, and will consider such feedback in potential future policy development. B. Method To Control for Unnecessary Increases in the Volume of Outpatient Services As discussed in the CY 2019 OPPS/ ASC proposed rule (83 FR 37138 through 37143), when the Medicare program was first implemented, payment for hospital services (inpatient and outpatient) was based on hospitalspecific reasonable costs attributable to furnishing services to Medicare beneficiaries. Although payment for most Medicare hospital inpatient services became subject to a prospective payment system (PPS) under section 1886(d) of the Act in 1983, Medicare hospital outpatient services continued to be paid based on hospital-specific costs. This methodology for payment provided little incentive for hospitals to furnish such outpatient services efficiently and in a cost effective manner. At the same time, advances in medical technology and changes in practice patterns were bringing about a shift in the site of medical care from the hospital inpatient setting to the hospital outpatient setting. In the Omnibus Budget Reconciliation Act of 1986 (OBRA 1986) (Pub. L. 99– 509), the Congress paved the way for development of a PPS for hospital outpatient services. Section 9343(g) of OBRA 1986 mandated that fiscal intermediaries require hospitals to report claims for services under the Healthcare Common Procedure Coding System (HCPCS). Section 9343(c) of OBRA 1986 extended the prohibition against unbundling of hospital services under section 1862(a)(14) of the Act to PO 00000 Frm 00188 Fmt 4701 Sfmt 4700 include outpatient services as well as inpatient services. The codes under the HCPCS enabled us to determine which specific procedures and services were billed, while the extension of the prohibition against unbundling ensured that all nonphysician services provided to hospital outpatients were reported on hospital bills and captured in the hospital outpatient data that were used to develop an outpatient PPS. The brisk increase in hospital outpatient services further led to an interest in creating payment incentives to promote more efficient delivery of hospital outpatient services through a Medicare outpatient PPS. Section 9343(f) of OBRA 1986 and section 4151(b)(2) of the Omnibus Budget Reconciliation Act of 1990 (OBRA 1990) (Pub. L. 101–508) required that we develop a proposal to replace the existing hospital outpatient payment system with a PPS and submit a report to the Congress on a new proposed system. The statutory framework for the Outpatient Prospective Payment System (OPPS) was established by section 4523 of the Balanced Budget Act (BBA) of 1997 (Pub. L. 105–33), which amended section 1833 of the Act by adding subsection (t), which establishes a PPS for hospital outpatient department services, and by section 201 of the Balanced Budget Reconciliation Act (BBRA) of 1999 (Pub. L. 106–113), which amended section 1833(t) of the Act to require outlier and transitional pass-through payments. At the outset of the OPPS, there was significant concern over observed increases in the volume of outpatient services and corresponding rapidly growing beneficiary coinsurance. Accordingly, most of the focus was on finding ways to address those issues. When section 4523 of the BBA of 1997 established the OPPS, it included specific authority under section 1833(t)(2)(F) of the Act that requires the Secretary to develop a method for controlling unnecessary increases in the volume of covered outpatient department (OPD) services.65 In the initial rule that proposed to implement the OPPS (63 FR 47585 through 47587), we discussed several possible approaches for controlling the volume of covered outpatient department services furnished in subsequent years, solicited comments on those options, and stated that the agency would propose an appropriate ‘‘volume control’’ mechanism for services furnished in CY 2001 and beyond after completing further analysis. For the CY 65 Available at: https://www.ssa.gov/OP_Home/ ssact/title18/1833.htm. E:\FR\FM\21NOR2.SGM 21NOR2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations khammond on DSK30JT082PROD with RULES2 2000 OPPS, we proposed to implement a method that was similar to the one used under the Medicare Physician Fee Schedule (PFS) (known as the sustainable growth rate or ‘‘SGR’’), which would be triggered when expenditure targets, based on such factors as volume, intensity, and beneficiary enrollment, were exceeded (63 FR 47586 through 47587). However, as we discussed in the CY 2001 OPPS final rule (65 FR 18503) and the CY 2002 OPPS final rule (66 FR 59908), we delayed the implementation of the proposed volume control method as suggested by the ‘‘President’s Plan to Modernize and Strengthen Medicare for the 21st Century’’ to give hospitals time to adjust to the OPPS and CMS time to continue to examine methods to control unnecessary increases in the volume of covered OPD services. In the CY 2008 OPPS/ASC final rule with comment period (72 FR 66611 through 66612), we noted that we had significant concerns about the growth in program expenditures for hospital outpatient services, and that while the OPPS was developed in order to address some of those concerns, its implementation had not generally slowed that growth in expenditures. To address some of those concerns, we established a set of packaging policies beginning in CY 2008 that would explicitly encourage efficiency in the provision of services in the hospital outpatient setting and potentially control future growth in the volume of OPPS services (72 FR 66612). Specifically, in the CY 2008 OPPS/ASC final rule with comment period (72 FR 66580), we adopted a policy to package seven categories of items and services into the payment for the primary diagnostic or therapeutic modality to which we believe these items are typically ancillary or supportive. Similarly, in the CY 2014 OPPS/ASC final rule with comment period (78 FR 74925 through 74948), we expanded our packaging policies to include more VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 categories of packaged items and services as part of a broader initiative to make the OPPS more like a prospective payment system and less like a per service fee schedule. Packaging can encourage hospitals to furnish services efficiently while also enabling hospitals to manage their resources with the maximum flexibility, thereby encouraging long-term cost containment, which is an essential component of a prospective payment system. While most of the packaging policies established in the CY 2014 OPPS focused on ancillary services that were part of a primary procedure, we also introduced the concept of comprehensive APCs (C–APCs) (78 FR 74861 through 74910), which were implemented beginning in the CY 2015 OPPS (79 FR 66798 through 66810). Comprehensive APCs package payment for adjunctive and secondary items, services, and procedures into the most costly primary procedure under the OPPS at the claim level. While we have developed many payment policies with these goals in mind, growth in program expenditures for hospital outpatient services paid under the OPPS continues. As illustrated in Table 30 in the CY 2019 OPPS/ASC proposed rule (83 FR 37139), total spending has been growing at a rate of roughly 8 percent per year under the OPPS, and total spending under the OPPS is projected to further increase by more than $5 billion from approximately $70 billion in CY 2018 through CY 2019 to nearly $75 billion. This is approximately twice the total estimated spending in CY 2008, a decade ago. We continue to be concerned with this rate of increase in program expenditures under the OPPS for several reasons. The OPPS was originally designed to manage Medicare spending growth. What was once a costbased system was mandated by law to become a prospective payment system, which arguably should have slowed the increases in program spending. To the PO 00000 Frm 00189 Fmt 4701 Sfmt 4700 59005 contrary, the OPPS has been the fastest growing sector of Medicare payments out of all payment systems under Medicare Parts A and B. Furthermore, we are concerned that the rate of growth suggests that payment incentives, rather than patient acuity or medical necessity, are affecting site-of-service decisionmaking. This site-of-service selection has an impact on not only the Medicare program, but also on Medicare beneficiary out-of-pocket spending. Therefore, to the extent that there are lower-cost sites-of-service available, we believe that beneficiaries and the physicians treating them should have that choice and not be encouraged to receive or provide care in higher paid settings solely for financial reasons. For example, to provide for easier comparisons between hospital outpatient departments and ASCs, as previously discussed in the CY 2018 OPPS/ASC final rule with comment period (82 FR 59389), we stated in the CY 2019 OPPS/ASC proposed rule that we also will make available a website that provides comparison information between the OPPS and ASC payment and copayment rates, as required under section 4011 of the 21st Century Cures Act (Pub. L. 114–255). Making this information available can help beneficiaries and their physicians determine the cost and appropriateness of receiving care at different sites-ofservice. Although resources such as this website will help beneficiaries and physicians select a site-of-service, we do not believe this information alone is enough to control unnecessary volume increases. The growth in OPPS expenditures and the increase in the volume and intensity of hospital outpatient services were illustrated in Tables 30 and 31, respectively, of the CY 2019 OPPS/ASC proposed rule (83 FR 37139 through 37140). These tables, which include updated information, are presented below. BILLING CODE 4120–01–P E:\FR\FM\21NOR2.SGM 21NOR2 khammond on DSK30JT082PROD with RULES2 BILLING CODE 4120–01–C As noted in its March 2018 Report to Congress, the Medicare Payment Advisory Commission (MedPAC) found that, from 2011 through 2016, combined program spending and beneficiary costsharing on services covered under the OPPS increased by 51 percent, from $39.8 billion to $60.0 billion, an average of 8.6 percent per year.66 In its 2018 report, MedPAC also noted that ‘‘A large source of growth in spending on services furnished in hospital outpatient departments (HOPDs) appears to be the result of the shift of services from (lower cost) physician offices to (higher cost) HOPDs’’. 67 We consider these shifts in 66 Available at: https://www.medpac.gov/docs/ default-source/reports/mar18_medpac_ entirereport_sec.pdf?sfvrsn=0. 67 Ibid. VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 the sites of service unnecessary if the beneficiary can safely receive the same services in a lower cost setting but instead receives care in a higher cost setting. As noted in MedPAC’s March 2017 Report to Congress, ‘‘from 2014 to 2015, the use of outpatient services increased by 2.2 percent per Medicare FFS beneficiary. Over the decade ending in 2015, volume per beneficiary grew by 47 percent. One-third of the growth in outpatient volume from 2014 to 2015 was due to an increase in the number of evaluation and management (E&M) visits billed as outpatient services. This growth in part reflects hospitals purchasing freestanding physician practices and converting the billing from the Physician Fee Schedule to higher paying hospital outpatient PO 00000 Frm 00190 Fmt 4701 Sfmt 4700 department (HOPD) visits. These conversions shift market share from freestanding physician offices to HOPDs. From 2012 to 2015, hospitalbased E&M visits per beneficiary grew by 22 percent, compared with a 1-percent decline in physician officebased visits.’’ 68 MedPAC has documented how the billing for these services has shifted from physician offices to higher-cost outpatient sites of care for several years. At the same time, MedPAC has repeated its recommendation that the difference in payment rates between hospital outpatient departments and physician offices should be reduced or eliminated. It specifically recommended in its 2012 68 Available at: https://www.medpac.gov/docs/ default-source/reports/mar17_medpac_ ch3.pdf?sfvrsn=0. E:\FR\FM\21NOR2.SGM 21NOR2 ER21NO18.077</GPH> Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations ER21NO18.076</GPH> 59006 khammond on DSK30JT082PROD with RULES2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations Report to Congress that the payment rates for E&M visits provided in hospital outpatient departments be reduced so that total payment rates for these visits are the same, whether the service is provided in a hospital outpatient department or a physician office. In its 2014 Report to Congress, MedPAC recommended that Congress direct the Secretary to reduce or eliminate differences in payment rates between hospital outpatient departments and physician offices for selected APCs. Both of these recommendations were reiterated in MedPAC’s March 2017 Report to Congress. As previously noted, in addition to the concern that the difference in payment is leading to unnecessary increases in the volume of covered outpatient department services, we also are concerned that this shift in care setting increases beneficiary costsharing liability because Medicare payment rates for the same or similar services are generally higher in hospital outpatient departments than in freestanding physician offices. For example, MedPAC estimates that ‘‘the Medicare program spent $1.0 billion more in 2009, $1.3 billion more in 2014, and $1.6 billion more in 2015 than it would have if payment rates for E&M office visits in HOPDs were the same as freestanding office rates. Relatedly, beneficiaries’ cost-sharing was $260 million higher in 2009, $325 million higher in 2014, and $400 million higher in 2015 than it would have been because of the higher rates paid in HOPD settings.’’ 69 We believe that this volume growth and the resulting increase in beneficiary cost-sharing is unnecessary because it appears to have been incentivized by the difference in payment for each setting rather than patient acuity. If there was not a difference in payment rates, we believe that we would not have seen the increase in beneficiaries’ cost-sharing and the shift in site-of-service. In the CY 2015 OPPS/ASC proposed rule (79 FR 41013), we stated that we continued to seek a better understanding of how the growing trend toward hospital acquisition of physicians’ offices and subsequent treatment of those locations as offcampus provider-based departments (PBDs) of hospitals affects payments under the PFS and the OPPS, as well as beneficiary cost-sharing obligations. We noted that MedPAC continued to question the appropriateness of increased Medicare payment and beneficiary cost-sharing when physicians’ offices become hospital 69 Ibid. VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 outpatient departments and that MedPAC recommended that Medicare pay selected hospital outpatient services at PFS rates (MedPAC March 2012 and June 2013 Reports to Congress). To understand how this trend was affecting Medicare, we explained that we needed information on the extent to which this shift was occurring. To that end, during the CY 2014 OPPS/ASC rulemaking cycle, we sought public comment regarding the best method for collecting information and data that would allow us to analyze the frequency, type, and payment for physicians’ services and hospital outpatient services furnished in offcampus PBDs of hospitals (78 FR 75061 through 75062 and 78 FR 74427 through 74428). Based on our analysis of the public comments we received, we believed that the most efficient and equitable means of gathering this important information across two different payment systems would be to create a HCPCS modifier to be reported with every code for physicians’ services and hospital outpatient services furnished in an off-campus PBD of a hospital on both the CMS–1500 claim form for physicians’ services and the UB–04 form (CMS Form 1450 and OMB Control Number 0938–0997) for hospital outpatient services. We noted that a main provider may treat an off-campus facility as provider-based if certain requirements at 42 CFR 413.65 are satisfied, and we define a ‘‘campus’’ at 42 CFR 413.65(a)(2) to be the physical area immediately adjacent to the provider’s main buildings, other areas and structures that are not strictly contiguous to the main buildings but are located within 250 yards of the main buildings, and any other areas determined on an individual case basis, by the CMS regional office, to be part of the provider’s campus. In 2015, the Congress took steps to address the higher Medicare payments for services furnished by certain offcampus PBDs that may be associated with hospital acquisition of physicians’ offices through section 603 of the Bipartisan Budget Act of 2015 (Pub. L. 114–74), enacted on November 2, 2015. In the CY 2017 OPPS/ASC proposed rule, we discussed section 603 of the Bipartisan Budget Act of 2015, which amended section 1833(t) of the Act. For the full discussion of our initial implementation of this provision, we refer readers to the CY 2017 OPPS/ASC final rule with comment period (81 FR 79699 through 79719) and the interim final rule with comment period (79720 through 79729). Section 603 of the Bipartisan Budget Act of 2015 (Section 603) amended PO 00000 Frm 00191 Fmt 4701 Sfmt 4700 59007 section 1833(t) of the Act by amending paragraph (1)(B) and adding a new paragraph (21). As a general matter, under sections 1833(t)(1)(B)(v) and (t)(21) of the Act, applicable items and services furnished by certain off-campus outpatient departments of a provider on or after January 1, 2017 are not considered covered OPD services as defined under section 1833(t)(1)(B) of the Act for purposes of payment under the OPPS and are instead paid ‘‘under the applicable payment system’’ under Medicare Part B if the requirements for such payment are otherwise met. We note that, in order to be considered part of a hospital, an off-campus department of a hospital must meet the providerbased criteria established under 42 CFR 413.65. Section 603 amended section 1833(t)(1)(B) of the Act by adding a new clause (v), which excludes from the definition of ‘‘covered OPD services’’ applicable items and services (defined in paragraph (21)(A) of the section) that are furnished on or after January 1, 2017, by an off-campus PBD, as defined in paragraph (21)(B) of the section. Section 603 also added a new paragraph (21) to section 1833(t) of the Act, which defines the terms ‘‘applicable items and services’’ and ‘‘off-campus outpatient department of a provider,’’ requires the Secretary to make payments for such applicable items and services furnished by an off-campus PBD under an applicable payment system (other than the OPPS), provides that hospitals shall report on information as needed for implementation of the provision, and establishes a limitation on administrative and judicial review of the Secretary’s determinations of applicable items and services, applicable payment system, whether a department meets the definition of an off-campus outpatient department of a provider, and information hospitals are required to report. In defining the term ‘‘off-campus outpatient department of a provider,’’ section 1833(t)(21)(B)(i) of the Act specifies that the term means a department of a provider (as defined at 42 CFR 413.65(a)(2) as that regulation was in effect on November 2, 2015, the date of enactment of Pub. L. 114–74) that is not located on the campus of such provider, or within the distance from a remote location of a hospital facility. Section 1833(t)(21)(B)(ii) of the Act excepts from the definition of ‘‘offcampus outpatient department of a provider,’’ for purposes of paragraphs (1)(B)(v) and (21)(B) of the section, an off-campus PBD that was billing under section 1833(t) of the Act with respect to covered OPD services furnished prior E:\FR\FM\21NOR2.SGM 21NOR2 khammond on DSK30JT082PROD with RULES2 59008 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations to the date of enactment of the Bipartisan Budget Act of 2015, that is, November 2, 2015. We note that the definition of ‘‘applicable items and services’’ specifically excludes items and services furnished by a dedicated emergency department as defined at 42 CFR 489.24(b) and the definition of ‘‘offcampus outpatient department of a provider’’ does not include PBDs located on the campus of a hospital or within the distance (described in the definition of campus at § 413.65(a)(2)) from a remote location of a hospital facility; the items and services furnished by these excepted off-campus PBDs on or after January 1, 2017 continued to be paid under the OPPS. In the CY 2017 OPPS/ASC final rule with comment period (81 FR 79699 through 79720), we established a number of policies to implement section 603 of the Bipartisan Budget Act of 2015. Broadly, we: (1) Defined applicable items and services in accordance with section 1833(t)(21)(A) of the Act for purposes of determining whether such items and services are covered OPD services under section 1833(t)(1)(B)(v) of the Act or whether payment for such items and services will instead be made under the applicable payment system designated under section 1833(t)(21)(C) of the Act; (2) defined off-campus PBD for purposes of sections 1833(t)(1)(B)(v) and (t)(21) of the Act; and (3) established policies for payment for applicable items and services furnished by an off-campus PBD (nonexcepted items and services) under section 1833(t)(21)(C) of the Act. To do so, we finalized policies that define whether certain items and services furnished by a given offcampus PBD may be considered excepted and, thus, continue to be paid under the OPPS; established the requirements for the off-campus PBDs to maintain excepted status (both for the excepted off-campus PBDs and for the items and services furnished by such excepted off-campus PBDs); and described the applicable payment system for nonexcepted items and services (generally, the PFS). As part of developing policies to implement the section 603 amendments to section 1833(t) of the Act, we solicited public comments on information collection requirements for implementing this provision in accordance with section 1833(t)(21)(D) of the Act (81 FR 45686; 81 FR 79709 through 79710). In the CY 2017 OPPS/ ASC final rule with comment period (81 FR 79719 and 79725), we created modifier ‘‘PN’’ to collect data for purposes of implementing section 603 but also to trigger payment under the VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 newly adopted PFS rates for nonexcepted items and services. While the changes required by the section 603 amendments to section 1833(t) of the Act address some of the concerns related to shifts in settings of care and overutilization in the hospital outpatient setting, the majority of hospital off-campus departments continue to receive full OPPS payment (including off-campus emergency departments and excepted off-campus departments of a hospital), which is often higher than the payment that would have been made if a similar service had been furnished in the physician office setting. Therefore, the current site-based payment creates an incentive for an unnecessary increase in the volume of this type of OPD service, which results in higher costs for the Medicare program, its beneficiaries, and taxpayers more generally. These differences in payment rates have unnecessarily shifted services away from the lower paying physician’s office to the higher paying hospital outpatient department. We believe that the higher payment that is made under the OPPS, as compared to payment under the PFS, contributes to incentivizing providers to furnish care in the hospital outpatient setting rather than the physician office setting. In 2012, Medicare was paying approximately 80 percent more for a 15minute office visit in a hospital outpatient department than in a freestanding physician office.70 For example, under Medicare payment policy in effect for CY 2018, the Medicare program would pay more for a clinic visit (HCPCS code G0463) furnished under the OPPS than it would for the visit codes under the PFS. In the CY 2017 OPPS/ASC interim final rule, we noted that the most frequently billed service with the ‘‘PO’’ modifier was described by HCPCS code G0463 (Hospital outpatient clinic visit for assessment and management of a patient), which is paid under APC 5012 (Clinic Visits and Related Services); the total number of CY 2017 claim lines for this service was approximately 10.8 million lines with the ‘‘PO’’ modifier as of October 2018, out of a total 30.5 million lines in CY 2017. When services are furnished in the hospital outpatient setting, an additional payment for the professional services is generally made under the PFS using the ‘‘facility’’ rate. For example, in CY 2017, the OPPS payment rate for APC 5012, which is the APC to which the outpatient clinic visit code was assigned, was $106.56. The CY 70 Available at: https://www.medpac.gov/docs/ default-source/reports/march-2012-report-to-thecongress-medicare-payment-policy.pdf. PO 00000 Frm 00192 Fmt 4701 Sfmt 4700 2017 PFS ‘‘facility’’ payment rate for a Level 3 visit, a service that commonly corresponds to the OPPS clinic visit, was $77.88 for a new patient and $51.68 for an established patient. However, when services are furnished in the physician office setting, only one payment is made—typically, the ‘‘nonfacility’’ rate under the PFS. The CY 2017 PFS nonfacility payment rates for a Level 3 visit, a commonly billed service under the PFS, was $109.46 for a new patient and $73.93 for an established patient. Therefore, the total Medicare Part B payment rate (for the hospital and professional service) for a new patient when the service was furnished in the hospital outpatient setting was $184.44 ($106.56 + $77.88) compared to $109.46 in the physician office setting (approximately $75 or 68 percent more per visit), or for an established patient, $158.24 ($106.56 + $51.68) in the hospital outpatient setting compared to $73.93 in the physician office setting (approximately $84 or 114 percent more per visit). Under these examples, the payment rate was approximately $75 to $84 more for the same service when furnished in the hospital outpatient setting instead of the physician office setting, 20 percent of which was the responsibility of the beneficiary. Taking into account that this payment discrepancy occurs across tens of millions of claims each year, this is a significant source of unnecessary spending by Medicare beneficiaries directly (in the form of unnecessarily high copayments) and on behalf of Medicare beneficiaries (in the form of unnecessarily high Medicare payments for services that could be performed in a different setting). We understand that many off-campus departments converted from physicians’ offices to hospital outpatient departments without a change in either the physical location or a change in the acuity of the patients seen. To the extent that similar services can be safely provided in more than one setting, we do not believe it is prudent for the Medicare program to pay more for these services in one setting than another. We believe the difference in payment for these services is a significant factor in the shift in services from the physician’s office to the hospital outpatient department, thus unnecessarily increasing hospital outpatient department volume and Medicare program and beneficiary expenditures. We consider the shift of services from the physician office to the hospital outpatient department unnecessary if the beneficiary can safely receive the same services in a lower cost setting but is instead receiving services in the E:\FR\FM\21NOR2.SGM 21NOR2 khammond on DSK30JT082PROD with RULES2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations higher paid setting due to payment incentives. We believe the increase in the volume of clinic visits is due to the payment incentive that exists to provide this service in the higher cost setting. Because these services could likely be safely provided in a lower cost setting, we believe that the growth in clinic visits paid under the OPPS is unnecessary. Further, we believe that capping the OPPS payment at the PFSequivalent rate would be an effective method to control the volume of these unnecessary services because the payment differential that is driving the site-of-service decision will be removed. In particular, we believe this method of capping payment will control unnecessary volume increases both in terms of numbers of covered outpatient department services furnished and costs of those services. Therefore, given the unnecessary increases in the volume of clinic visits in hospital outpatient departments, in the CY 2019 OPPS/ASC proposed rule (83 FR 37142), for the CY 2019 OPPS, we proposed to use our authority under section 1833(t)(2)(F) of the Act to apply an amount equal to the site-specific PFS payment rate for nonexcepted items and services furnished by a nonexcepted offcampus PBD (the PFS payment rate) for the clinic visit service, as described by HCPCS code G0463, when provided at an off-campus PBD excepted from section 1833(t)(21) of the Act (departments that bill the modifier ‘‘PO’’ on claim lines). Off-campus PBDs that are not excepted from section 603 (departments that bill the modifier ‘‘PN’’) already receive a PFS-equivalent payment rate for the clinic visit. In CY 2019, for an individual Medicare beneficiary, the standard unadjusted Medicare OPPS proposed payment for the clinic visit was approximately $116, with approximately $23 being the average copayment. The proposed PFS equivalent rate for Medicare payment for a clinic visit was approximately $46, and the copayment would be approximately $9. Under this proposal, an excepted off-campus PBD would continue to bill HCPCS code G0463 with the ‘‘PO’’ modifier in CY 2019, but the payment rate for services described by HCPCS code G0463 when billed with modifier ‘‘PO’’ would now be equivalent to the payment rate for services described by HCPCS code G0463 when billed with modifier ‘‘PN’’. This would save beneficiaries an average of $14 per visit. For a discussion of the amount paid under the PFS for clinic visits furnished by nonexcepted off-campus PBDs, we referred readers to the CY 2018 PFS final rule (82 FR 53023 VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 through 53024), as well as the CY 2019 PFS proposed rule and final rule. In addition, in the CY 2019 OPPS/ ASC proposed rule (83 FR 37142), we proposed to implement this proposed method in a nonbudget neutral manner. Specifically, while section 1833(t)(9)(B) of the Act requires that certain changes made under the OPPS be made in a budget neutral manner, we note that this section does not apply to the volume control method under section 1833(t)(2)(F) of the Act. In particular, section 1833(t)(9)(A) of the Act, titled ‘‘Periodic review,’’ provides, in part, that the Secretary must annually review and revise the groups, the relative payment weights, and the wage and other adjustments described in paragraph (2) to take into account changes in medical practice, changes in technology, the addition of new services, new cost data, and other relevant information and factors’’ (emphasis added). Section 1833(t)(9)(B) of the Act, titled ‘‘Budget neutrality adjustment’’ provides that if ‘‘the Secretary makes adjustments under subparagraph (A), then the adjustments for a year may not cause the estimated amount of expenditures under this part for the year to increase or decrease from the estimated amount of expenditures under this part that would have been made if the adjustments had not been made’’ (emphasis added). However, section 1833(t)(2)(F) of the Act is not an ‘‘adjustment’’ under paragraph (2). Unlike the wage adjustment under section 1833(t)(2)(D) of the Act and the outlier, transitional pass-through, and equitable adjustments under section 1833(t)(2)(E) of the Act, section 1833(t)(2)(F) of the Act refers to a ‘‘method’’ for controlling unnecessary increases in the volume of covered OPD services, not an adjustment. Likewise, sections 1833(t)(2)(D) and (E) of the Act also explicitly require the adjustments authorized by those paragraphs to be budget neutral, while the volume control method authority at section 1833(t)(2)(F) of the Act does not. Therefore, the volume control method proposed under section 1833(t)(2)(F) of the Act is not one of the adjustments under section 1833(t)(2) of the Act that is referenced under section 1833(t)(9)(A) of the Act that must be included in the budget neutrality adjustment under section 1833(t)(9)(B) of the Act. Moreover, section 1833(t)(9)(C) of the Act specifies that if the Secretary determines under methodologies described in paragraph (2)(F) that the volume of services paid for under this subsection increased beyond amounts established through those PO 00000 Frm 00193 Fmt 4701 Sfmt 4700 59009 methodologies, the Secretary may appropriately adjust the update to the conversion factor otherwise applicable in a subsequent year. We interpret this provision to mean that the Secretary will have implemented a volume control method under section 1833(t)(2)(F) of the Act in a nonbudget neutral manner in the year in which the method is implemented, and that the Secretary may then make further adjustments to the conversion factor in a subsequent year to account for volume increases that are beyond the amounts estimated by the Secretary under the volume control method. We stated in the CY 2019 OPPS/ASC proposed rule (83 FR 37143) that we believe implementing a volume control method in a budget neutral manner would not appropriately reduce the overall unnecessary volume of covered OPD services, and instead would simply shift the movement of the volume within the OPPS system in the aggregate, a concern similar to the one we discussed in the CY 2008 OPPS final rule with comment period (72 FR 66613). This estimated payment impact was displayed in Column 5 of Table 42.— Estimated Impact of the Proposed Changes for the Hospital Outpatient Prospective Payment System in the CY 2019 OPPS/ASC proposed rule (83 FR 37228 through 37229). An estimate that includes the effects of estimated changes in enrollment, utilization, and case-mix based on the FY 2019 President’s Budget approximates the estimated savings at $760 million, with $610 million of the savings accruing to Medicare, and $150 million saved by Medicare beneficiaries in the form of reduced copayments. In order to effectively establish a method for controlling the unnecessary growth in the volume of clinic visits furnished by excepted off-campus PBDs that does not simply reallocate expenditures that are unnecessary within the OPPS, we believe that this method must be adopted in a nonbudget neutral manner. The impact associated with this proposal is further described in section XXI. of the CY 2019 OPPS/ASC proposed rule. Comment: Numerous commenters, including organizations representing private health insurance plans, physician associations, specialty medical associations, and individual Medicare beneficiaries, supported the proposal. Some of these commenters commended CMS for its proposal, which they believed will help to control costs for both beneficiaries and the Medicare program, as well as foster greater competition in the physician services market. Commenters were E:\FR\FM\21NOR2.SGM 21NOR2 khammond on DSK30JT082PROD with RULES2 59010 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations supportive of the immediate impact this policy would have in lowering Medicare beneficiaries’ out-of-pocket costs. One commenter noted that there ‘‘is no principled basis for treating excepted and nonexcepted PBDs differently with respect to payment for E&M services or for perpetuating the payment differential between off-campus PBDs and physician offices.’’ Several commenters supported implementing this policy in a nonbudget neutral manner because they believed to do otherwise would be simply to redistribute expenditures for unnecessary services within the OPPS rather than eliminating those expenditures from the OPPS altogether. A number of commenters urged CMS to continue on a path to bring full parity in payment for outpatient services, regardless of the site-of-service, to lower beneficiary cost-sharing, reduce Medicare expenditures, and stem the tide of provider consolidation. Two commenters believed that several factors demonstrate to them that HOPDs drive up volume for several other common outpatient services, including: • Patients receive more chemotherapy administration sessions, on average, when treated in the HOPD. Chemotherapy days per beneficiary were an estimated 9 to 12 percent higher in the hospital outpatient department than the physician office setting.71 • Differences in utilization of chemotherapy drugs and services between hospital outpatient departments and physicians’ offices resulted in an estimated increase in Medicare payments and Medicare beneficiary copayments of $167 million. Over 93 percent of the additional payments were related to chemotherapy and other chemotherapy-related drugs.72 • Cardiac imaging procedures resulted in higher payments for a 3-day episode (217 percent) and 22-day episodes (80 percent) when performed in a HOPD compared to a physician’s office.73 • For certain cardiology, orthopedic, and gastroenterology services, employed physicians were seven times more likely to perform services in a HOPD setting than independent physicians, resulting in additional costs of $2.7 billion to 71 The Moran Company: Cost Differences in Cancer Care Across Settings; August 2013. 72 BRG: Impact of Medicare Payments of Shift in Site of Care for Chemotherapy Administration; June 2014. 73 Avalere: Medicare Payment Differentials Across Outpatient Settings of Care; February 2016. VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 Medicare and $411 million in patient copayments over a 3-year period.74 One commenter believed that payment differentials between independent physician practices and hospital outpatient departments stem in part from inadequate Medicare physician payment rates and that any savings from site neutrality proposals derived from OPPS should be reinvested in increasing payment rates elsewhere in Part B, including payments to physicians. Some commenters urged HHS to work with Congress to expand site-neutral policies in the OPPS. Response: We appreciate the commenters’ support. As mentioned in the proposed rule (83 FR 37138 through 37143), we share the commenters’ concern that the current payment incentives, rather than patient acuity or medical necessity, are affecting site-ofservice decision-making. As we noted in the proposed rule (83 FR 37138 through 37143), ‘‘[a] large source of growth in spending on services furnished in hospital outpatient departments (HOPDs) appears to be the result of the shift of services from (lower cost) physician offices to (higher cost) HOPDs’’.75 We continue to believe that these shifts in the sites of service are unnecessary if the beneficiary can safely receive the same services in a lower cost setting but instead receives care in a higher cost setting due to payment incentives. In addition to the concern that the difference in payment is leading to unnecessary increases in the volume of covered outpatient department services, we remain concerned that this shift in care setting increases beneficiary cost-sharing liability because Medicare payment rates for the same or similar services are generally higher in hospital outpatient departments than in physician offices. We appreciate the comments supporting the implementation of this policy in a nonbudget neutral manner. As we stated in the proposed rule (83 FR 37138 through 37143), we believe implementing a volume control method in a budget neutral manner would not appropriately reduce the overall unnecessary volume of covered OPD services, and instead would simply shift the volume of services within the OPPS system in the aggregate. As detailed later in this section, we are finalizing our proposal, with modifications, in response to public comments. We will continue to take information submitted 74 Avalere, PAI: Physician Practice Acquisition Study: National and Regional Employment Changes, October 2016. 75 Available at: https://www.medpac.gov/docs/ default-source/reports/mar18_medpac_ entirereport_sec.pdf?sfvrsn=0. PO 00000 Frm 00194 Fmt 4701 Sfmt 4700 by the commenters into consideration for future study. With respect to the comment that it is inappropriate to establish a PFSequivalent rate because PFS rates are inadequate and that any savings should be redistributed across Medicare Part B, we disagree that PFS rates as a whole are inadequate and note that the methodology to develop such rates was established by law and regulations and is updated each year through noticeand-comment rulemaking. We note that the overall amount of Medicare payments to physicians and other entities made under the PFS is determined by the PFS statute, and the rates for individual services are determined based on the resources involved in furnishing these services relative to other services paid under the PFS. To the extent the commenter believes that the PFS rate for a particular service is misvalued relative to other PFS services, we encourage the commenter to nominate the service for review as a potentially misvalued service under the PFS. Comment: MedPAC supported the proposal to reduce the OPPS payment rate for clinic visits provided in an excepted off-campus PBD to a PFSequivalent payment rate. MedPAC noted that the policy would be consistent with its past recommendations for siteneutral payments between HOPDs and freestanding physician offices. In its comments, MedPAC highlighted two key points from its March 2012 recommendation on site-neutral payments. While MedPAC recommended that OPPS payment rates for clinic visits be reduced so that Medicare payments for these services are the same whether they are provided in HOPDs or physician offices, it also recommended that this policy be phased in over 3 years to allow providers time to adjust to lower payment rates. During the phase-in, MedPAC recommended that payment reductions to hospitals with a disproportionate share (DSH) patient percentage at or above the median be limited to 2 percent of overall Medicare payments because these hospitals are often the primary source of care for low-income beneficiaries and limiting the reduction in revenue would help maintain access to care for these beneficiaries. Response: We thank MedPAC for its comments and support of this policy. In its comments, MedPAC recommended this policy be phased in over 3 years to allow providers time to adjust to lower payment rates. As detailed later in this section, we will be implementing this policy with a 2-year phase-in. We believe that a 2-year phase-in allows us E:\FR\FM\21NOR2.SGM 21NOR2 khammond on DSK30JT082PROD with RULES2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations to balance the immediate need to address the unnecessary increases in the volume of clinic visits with concerns like those articulated by MedPAC regarding providers’ need for time to adjust to these payment changes. While we acknowledge and share MedPAC’s concern about beneficiary access to care, we do not believe that a limit on the payment reduction to hospitals with a DSH patient percentage at or above the median is necessary because we believe the increase in the volume of clinic visits in excepted off-campus providerbased departments of hospitals with high DSH percentages is equally unnecessary as it is at other hospitals. Many commenters challenged the statutory authority for various aspects of the proposal. These comments are summarized below. Comment: Several commenters disagreed with CMS’ interpretation of section 1833(t)(2)(F) of the Act. The commenters contended that section 1833(t)(2)(F) of the Act does not confer direct authority on CMS to modify OPPS payment rates for specific services. Rather, the commenters asserted that section 1833(t)(2)(F) of the Act only permits the agency to develop a ‘‘method,’’ which the commenters interpreted to mean a ‘‘way of doing things’’ or a ‘‘plan.’’ The commenters stated that utilizing the authority at section 1833(t)(2)(F) of the Act to reduce payments to excepted off-campus PBDs to rates that equal the lower payment amounts received by nonexcepted offcampus PBDs was improper. The commenters maintained that the Secretary can only control unnecessary increases in volume using authority conferred by other provisions of section 1833(t) of the Act, such as through the equitable adjustment authority at section 1833(t)(2)(E) of the Act. The commenters believed that the clinic visit proposal was arbitrary and capricious for this and other reasons. In particular, the commenters expressed concern that there was no data-driven basis to conclude that OPD services have increased unnecessarily. The commenters also claimed that the proposal is based on unsupported assertions and assumptions regarding increases in volume. The commenters were concerned that other factors, such as the shift from inpatient services to outpatient services or the 2-midnight policy, might be driving the increases in the volume of outpatient services. Other commenters asserted that CMS should consider the impact of severity of illness and patient demographics on outpatient volume prior to moving forward with any payment changes. One commenter stated that, relative to patients seen in VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 physician offices, patients seen in HOPDs: • Have more severe chronic conditions; • Have higher prior utilization of hospitals and EDs; • Are more likely to live in lowincome areas; • Are 1.8 times more likely to be dually eligible for Medicare and Medicaid; • Are 1.4 times more likely to be nonwhite; • Are 1.6 times more likely to be under age 65 and disabled; and • Are 1.1 times more likely to be over 85 years old. The commenters also noted that Medicare beneficiaries with cancer seen in HOPDs relative to those beneficiaries seen in physician offices have more severe chronic conditions, higher prior utilization of services in hospitals and emergency departments, and higher likelihood of residing in low-income areas. In addition, the commenters noted that these cancer patients were more likely to be dually eligible for Medicare and Medicaid and be nonwhite, under age 65, and disabled. Response: After consideration of these comments, we continue to believe that section 1833(t)(2)(F) of the Act gives the Secretary broad authority to develop a method for controlling unnecessary increases in the volume of covered outpatient department (OPD) services, including a method that controls unnecessary volume increases by removing a payment differential that is driving a site-of-service decision, and as a result, is unnecessarily increasing service volume.76 We continue to believe shifts in the sites of service described in the preceding paragraphs are inherently unnecessary if the beneficiary can safely receive the same services in a lower cost setting but instead receives care in a higher cost setting due to the payment incentives created by the difference in payment amounts. While we did receive some data illustrating that HOPDs serve unique patient populations and provide services to medically complex beneficiaries, these data did not demonstrate the need for higher payment for all clinic visits provided in HOPDs. The fact that the commenters did not supply data supporting these assertions is suggestive that the payment differential may be the main driver for unnecessary volume increases in outpatient department services, particularly clinic visits. 76 Available at: https://www.ssa.gov/OP_Home/ ssact/title18/1833.htm. PO 00000 Frm 00195 Fmt 4701 Sfmt 4700 59011 In fact, the Government Accountability Office (GAO) found that ‘‘the percentage of E/M visits—as well as the number of E/M office visits per beneficiary—performed in HOPDs, rather than physician offices, was generally higher in counties with higher levels of vertical consolidation in 2007– 2013.’’ 77 Vertical consolidation is the practice of hospitals acquiring physician practices. We believe that higher payment rates for services furnished in HOPDs, which include clinic visits, have led hospitals to increasingly purchase physician practices. We believe there is a correlation among the increasing volume of HOPD clinic visits, vertical integration, and the higher OPPS payment rates for clinic visits. The GAO discovered that ‘‘the median percentage of E/M office visits performed in HOPDs in counties with the lowest levels of vertical consolidation was 4.1 percent in 2013. In contrast, this rate was 14.1 percent for counties with the highest levels of consolidation.’’ The GAO also found that, in 2013, the number of E/M office visits performed in HOPDs per 100 beneficiaries was 26 for the counties with low levels of vertical consolidation, whereas the number was substantially higher—82 services per 100 beneficiaries—in counties with the highest levels of vertical consolidation.78 The GAO determined that the association between higher levels of vertical consolidation and high utilization of E/M office visits in HOPDs remained even after controlling for differences in county-level characteristics and other market factors that could affect the setting in which E/ M office visits are performed. The GAO describes the model it ran as a ‘‘regression model that controlled for county characteristics that do not change over relatively short periods of time, such as whether a county is urban or rural, and county characteristics that could change over time, such as the level of competition among hospitals and physicians within counties.’’ The GAO explained that its ‘‘regression model’s results were similar to [its] initial results: the level of vertical consolidation in a county was significantly and positively associated with a higher number and percentage of E/M office visits performed in HOPDs— that is, as vertical consolidation increased in a given county, the number and percentage of E/M office visits 77 Available at: https://www.gao.gov/assets/680/ 674347.pdf. 78 Ibid. E:\FR\FM\21NOR2.SGM 21NOR2 khammond on DSK30JT082PROD with RULES2 59012 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations performed in HOPDs in that county also tended to be higher.’’ 79 The GAO findings align with our assertions in the proposed rule (83 FR 37138 through 37143). Paying substantially more for the same service when performed in an HOPD rather than a physician office provides an incentive to shift services that were once performed in physician offices to HOPDs after consolidation has occurred. The GAO findings suggest that providers responded to this financial incentive: E/M office visits were more frequently performed in HOPDs in counties with higher levels of vertical consolidation. The GAO found this association in both of its analyses of E/ M office visit utilization in counties with varying levels of vertical consolidation and in its regression analyses. We heard from many commenters that the higher payment rate was justified by the fact that HOPDs were treating sicker patient populations. The GAO’s study did not support this conclusion. It examined counties that experienced large growth in the billing of clinic visits in HOPDs and was able to determine that: ‘‘Beneficiaries from counties with higher levels of vertical consolidation were not sicker, on average, than beneficiaries from counties with lower levels of consolidation. Specifically, beneficiaries from counties with higher levels of vertical consolidation tended to have either similar or slightly lower median risk scores, death rates, rates of endstage renal disease, and rates of disability compared to those from counties with lower levels of consolidation. Further, counties with higher levels of consolidation had a lower percentage of beneficiaries dually eligible for Medicaid, who tend to be sicker and have higher Medicare spending than Medicare beneficiaries who are not dually eligible for Medicaid.’’ This suggests that areas with higher E/ M office visit utilization in HOPDs are not composed of sicker-than-average beneficiaries. As we stated in the proposed rule (83 FR 37138 through 37143), paying more for the same service when performed in an HOPD rather than a physician’s office provides an incentive to shift services that were once performed in physician offices to HOPDs. The GAO’s findings suggest that providers responded to this financial incentive. As we noted in the proposed rule (83 FR 37138 through 37143), we have developed many payment policies, 79 Available at: https://www.gao.gov/assets/680/ 674347.pdf. VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 such as packaging policies and comprehensive APCs, to address the rapid growth of services in the OPPS. However, these policies have not been able to control for unnecessary increases in volume that are due to site-of-service payment differentials, which create an incentive to furnish a service in the OPD that could be furnished in a lower cost setting based solely on the higher payment amount available under the OPPS. Here, the clinic visit service furnished in excepted off-campus PBDs is the same as the clinic visit service furnished in nonexcepted off-campus PBDs. We believe that applying an amount equal to the site-specific PFS payment rate for nonexcepted items and services furnished by a nonexcepted offcampus PBD (the PFS payment rate) for the clinic visit service, as described by HCPCS code G0463, when provided at an off-campus PBD excepted from section 1833(t)(21) of the Act is an appropriate method to control the unnecessary increase in the volume of outpatient services. Comment: Several commenters expressed concern that CMS lacks the statutory authority to reduce OPPS payments for certain clinic visit services furnished at off-campus PBDs that are excepted from payment ‘‘under the applicable payment system’’ under section 1833(t)(21) of the Act. The commenters stated that Congress expressly chose in section 603 of the Bipartisan Budget Act of 2015 not to confer on CMS authority to pay excepted off-campus PBDs at the reduced rates paid to nonexcepted offcampus PBDs. The commenters asserted that CMS is ignoring the express and statutorily mandated grandfathering exception created by section 603. Response: We believe the changes required by section 603 of the Bipartisan Budget Act of 2015 made in section 1833(t) of the Act address some of the concerns related to shifts in settings of care and overutilization of services in the hospital outpatient setting for new off-campus PBDs after November 1, 2015. However, the majority of hospital off-campus departments continue to receive full OPPS payment (including off-campus emergency departments and excepted off-campus departments of a hospital), which is often higher than the payment that would have been made if a similar service had been furnished in the physician office setting. Therefore, the current site-based payment creates an incentive for an unnecessary increase in the volume of this type of OPD service, which results in higher costs for the Medicare program, beneficiaries, and taxpayers more generally. We interpret our authority under section PO 00000 Frm 00196 Fmt 4701 Sfmt 4700 1833(t)(2)(F) of the Act to allow us to implement our proposed method of applying an amount equal to the sitespecific PFS payment rate for nonexcepted items and services furnished by a nonexcepted off-campus PBD (the PFS payment rate) for the clinic visit service, as described by HCPCS code G0463, when provided at off-campus PBDs, even those that are excepted from section 1833(t)(21) of the Act. We believe that this is an appropriate method because the clinic visit service is the same service furnished in excepted and nonexcepted off-campus PBDs. When Congress passed the Bipartisan Budget Act of 2015, Medicare OPPS expenditures were $56 billion and growing at an annual rate of about 7.3 percent. In addition, the percentage increase in volume and intensity of outpatient services was increasing at 3.4 percent. For the upcoming 2019 calendar year, we estimate that, without this policy, OPPS expenditures would be $74.5 billion, growing at a rate of 9.1 percent, with the volume and intensity of outpatient services increasing at 5.4 percent, based on the Midsession Review for 2019. While it is clear that the action Congress took in 2015 to address certain off-campus PBDs helped stem the tide of these increases in the volume of OPD services, it is likewise clear that the more specific payment adjustment has not adequately addressed the overall increase in the volume of these types of OPD services because most off-campus PBDs continue to be paid the higher OPPS amount for these services. We would not be able to adequately address the unnecessary increases in the volume of clinic visits in HOPDs if we did not apply this policy to all off-campus HOPDs. We do not believe that the section 603 amendments to section 1833(t) of the Act, which exclude applicable items and services furnished by nonexcepted off-campus PBDs from payments under the OPPS, preclude us from exercising our authority in section 1833(t)(2)(F) of the Act to develop a method for controlling unnecessary increases in the volume of covered outpatient department services under the OPPS. Comment: Several commenters believed that CMS does not have statutory authority to implement this policy in a nonbudget neutral manner. The commenters explained that, because CMS lacks the authority to reduce clinic visit payment rates as a method to control unnecessary increases in the volume of covered outpatient department services under section 1833(t)(2)(F) of the Act, that provision cannot provide authority for the E:\FR\FM\21NOR2.SGM 21NOR2 khammond on DSK30JT082PROD with RULES2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations payment reduction to be made in a nonbudget neutral way. The commenters also claimed that the only nonbudget neutral option available to the agency is to adjust the conversion factor in a subsequent year, as provided under section 1833(t)(9)(C) of the Act. The commenters argued that if Congress had intended to give CMS the authority to make a volume control method nonbudget neutral, it would have done so in clearer and more express terms. Other commenters stated that if this policy is finalized, it should be done so only in a budget neutral manner. Response: We maintain that while section 1833(t)(9)(B) of the Act does require that certain changes made under the OPPS be made in a budget neutral manner, this provision does not apply to the volume control method under section 1833(t)(2)(F) of the Act as outlined through our proposal. As we noted in the proposed rule (83 FR 37138 through 37143), unlike the wage adjustment under section 1833(t)(2)(D) of the Act and the outlier, transitional pass-through, and equitable adjustments under section 1833(t)(2)(E) of the Act, section 1833(t)(2)(F) of the Act refers to a ‘‘method’’ for controlling unnecessary increases in the volume of covered OPD services, not an adjustment. Likewise, sections 1833(t)(2)(D) and (E) of the Act also explicitly require the adjustments authorized by those paragraphs to be budget neutral, while the volume control method authority at section 1833(t)(2)(F) of the Act does not include such a requirement. Therefore, we maintain that the volume control method proposed under section 1833(t)(2)(F) of the Act is not one of the adjustments under section 1833(t)(2) of the Act that is referenced under section 1833(t)(9)(A) of the Act that must be included in the budget neutrality adjustment under section 1833(t)(9)(B) of the Act. Moreover, section 1833(t)(9)(C) of the Act specifies that if the Secretary determines under methodologies described in paragraph (2)(F) of section 1833(t) of the Act that the volume of services paid for under this subsection increased beyond amounts established through those methodologies, the Secretary may appropriately adjust the update to the conversion factor otherwise applicable in a subsequent year. We continue to interpret this provision to mean that the Secretary will have implemented a volume control method under section 1833(t)(2)(F) of the Act in a nonbudget neutral manner in the year in which the method is implemented. Further, as we stated in the proposed rule (83 FR 37138 through 37143), we believe that VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 implementing a volume control method in a budget neutral manner would not appropriately reduce the overall unnecessary volume of covered OPD services, and instead would simply shift the volume within the OPPS system in the aggregate. Comment: Several commenters supported the recommendation from the HOP Panel not to implement this proposal and to instead study the matter to better understand the reasons for increased utilization. Response: Section 1833(t)(9)(A) of the Act provides that the Secretary shall consult with the Panel on policies affecting the clinical integrity of the ambulatory payment classifications and their associated weights under the OPPS. The Panel met on August 20, 2018 and made recommendations on this proposed policy, and we consulted with the Panel on those recommendations. The HOP Panel’s recommendations, along with public comments on provisions of the proposed rule, have been taken into consideration in the development of this final rule with comment period. While we are not accepting the HOP Panel’s recommendation to not implement this proposal, we will continue to monitor and study the utilization of outpatient services as recommended by the Panel. Comment: Several commenters expressed concern that this policy proposal would disproportionately affect safety net hospitals and rural providers. Numerous commenters representing providers and beneficiaries in the State of Washington expressed concerned about the impact this proposal would have on their area. Several commenters also requested that sole community hospitals (urban and rural), rural referral centers, and Medicare-dependent hospitals be exempted from this policy. A number of commenters, including many State hospital associations, expressed concern that the magnitude of the proposed payment reduction would have a drastic effect on their margins and endanger the investments many hospitals have made in their provider-based facilities. In addition, commenters suggested that the reduction in payment would ultimately lead to a reduction of services that would adversely affect vulnerable patient populations. One commenter conducted a trend analysis and found that 200 hospitals would shoulder 73 percent of the proposed payment reduction. According to this commenter’s analysis, for the 200 hospitals most affected by this proposal, the average reduction would be 5.5 percent. For the remaining hospitals, the average reduction would be 0.5 percent. PO 00000 Frm 00197 Fmt 4701 Sfmt 4700 59013 Response: We share the commenters’ concerns about access to care, especially in rural areas where access issues may be more pronounced than in other areas of the country. Medicare has long recognized the unique needs of rural communities and the financial challenges for rural providers. Across the various Medicare payment systems, CMS has implemented a number of special payment provisions for rural providers to maintain access and deliver high quality care to beneficiaries in rural areas. With respect to the OPPS, section 1833(t)(13) of the Act provided the Secretary the authority to make an adjustment to OPPS payments for rural hospitals, effective January 1, 2006, if justified by a study of the difference in costs by APC between hospitals in rural areas and hospitals in urban areas. Our analysis showed a difference in costs for rural sole community hospitals. Therefore, for the CY 2006 OPPS, we finalized a payment adjustment for rural sole community hospitals of 7.1 percent for all services and procedures paid under the OPPS, excluding separately payable drugs and biologicals, brachytherapy sources, and devices paid under the pass-through payment policy, in accordance with section 1833(t)(13)(B) of the Act. We have continued this 7.1 percent payment adjustment since 2006. In the CY 2019 OPPS/ASC proposed rule (83 FR 37143), we sought public comment on how we might account in the future for providers that serve Medicare beneficiaries in provider shortage areas, which may include certain rural areas. In addition, we sought public comment on whether there should be exceptions from this policy for rural providers, such as those providers that are at risk of hospital closure or those providers that are sole community hospitals. Taking into consideration the comments regarding rural hospitals, we believe that implementing this policy with a 2year phase-in will help to mitigate the immediate impact on rural hospitals. We may revisit this policy to consider potential exemptions in the CY 2020 OPPS rulemaking. After consideration of the public comments we received, we are finalizing our proposal to use our authority under section 1833(t)(2)(F) of the Act to apply an amount equal to the site-specific PFS payment rate for nonexcepted items and services furnished by a nonexcepted off-campus PBD (the PFS payment rate) for the clinic visit service, as described by HCPCS code G0463, when provided at an off-campus PBD excepted from section 1833(t)(21) of the Act E:\FR\FM\21NOR2.SGM 21NOR2 khammond on DSK30JT082PROD with RULES2 59014 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations (departments that bill the modifier ‘‘PO’’ on claim lines). In addition, we are finalizing our proposal to implement this policy in a nonbudget neutral manner. We will continue to monitor the impacts of this policy as it is phased in to ensure that beneficiaries continue to have access to quality care. In response to public comments we received, we will be phasing in the application of the reduction in payment for HCPCS code G0463 in this setting over 2 years. In CY 2019, the payment reduction will be transitioned by applying 50 percent of the total reduction in payment that would apply if these departments were paid the sitespecific PFS rate for the clinic visit service. The final payment rates are available in Addendum B to this final rule with comment period (which is available via the internet on the CMS website). The PFS-equivalent amount paid to nonexcepted off-campus PBDs is 40 percent of OPPS payment (that is, 60 percent less than the OPPS rate) for CY 2019. Based on a 2-year phase-in of this policy, half of the total 60-percent payment reduction, a 30-percent reduction, will apply in CY 2019. In other words, these departments will be paid approximately 70 percent of the OPPS rate (100 percent of the OPPS rate minus the 30-percent payment reduction that applies in CY 2019) for the clinic visit service in CY 2019. In CY 2020, these departments will be paid the site-specific PFS rate for the clinic visit service. We note that by phasing in this policy over 2 years, the estimated savings associated with this policy will change. Considering the effects of estimated changes in enrollment, utilization, and case-mix, this policy results in an estimated CY 2019 savings of approximately $380 million, with approximately $300 million of the savings accruing to Medicare, and approximately $80 million saved by Medicare beneficiaries in the form of reduced copayments. We will continue to monitor the effect of this change in Medicare payment policy, including the volume of these types of OPD services. While we are exploring developing a method to systematically control for unnecessary increases in the volume of other hospital outpatient department services that we may propose in future rulemaking, we continue to recognize the importance of not impeding development or beneficiary access to new innovations. In the CY 2019 OPPS/ ASC proposed rule (83 FR 37143), we solicited public comments on how to maintain access to new innovations while controlling for unnecessary increases in the volume of covered hospital OPD services. VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 In addition, we solicited public comments on how to expand the application of the Secretary’s statutory authority under section 1833(t)(2)(F) of the Act to additional items and services paid under the OPPS that may represent unnecessary increases in the utilization of OPD services. Therefore, we sought public comment on the following: • How might Medicare define the terms ‘‘unnecessary’’ and ‘‘increase’’ for services (other than the clinic visit) that can be performed in multiple settings of care? Should the method to control for unnecessary increases in the volume of covered OPD services include consideration of factors such as enrollment, severity of illness, and patient demographics? • While we proposed to pay the sitespecific PFS payment rate for clinic visits beginning in CY 2019, we also were interested in other methods to control for unnecessary increases in the volume of outpatient services. Prior authorization is a requirement that a health care provider obtain approval from the insurer prior to providing a given service in order for the insurer to cover the service. Private health insurance plans often require prior authorization for certain services. Should prior authorization be considered as a method for controlling overutilization of services? • For what reasons might it ever be appropriate to pay a higher OPPS rate for services that can be performed in lower cost settings? • Several private health plans use utilization management as a costcontainment strategy. How might Medicare use the authority at section 1833(t)(2)(F) of the Act to implement an evidence-based, clinical support process to assist physicians in evaluating the use of medical services based on medical necessity, appropriateness, and efficiency? Could utilization management help reduce the overuse of inappropriate or unnecessary services? • How should we account for providers that serve Medicare beneficiaries in provider shortage areas, which may include certain rural areas? With respect to rural providers, should there be exceptions from this policy, such as for providers who are at risk of hospital closure or that are sole community hospitals? • What impact on beneficiaries and the health care market would such a method to control for unnecessary increases in the volume of covered OPD services have? • What exceptions, if any, should be made if additional proposals to control for unnecessary increases in the volume of outpatient services are made? PO 00000 Frm 00198 Fmt 4701 Sfmt 4700 We received feedback on a variety of issues in response to the comment solicitation on additional future considerations. These comments are summarized below. Comment: In response to the solicitation on how CMS might expand the application of the Secretary’s statutory authority under section 1833(t)(2)(F) of the Act to additional items and services paid under the OPPS that may represent unnecessary increases in OPD volume, MedPAC suggested that CMS consider using the five criteria that MedPAC has developed for identifying services for which it is reasonable to have site-neutral payments between freestanding physician offices and HOPDs.80 In response to the solicitation on whether prior authorization should be considered as a method for controlling overutilization of services, most commenters believed that, while prior authorization may be a good method for controlling overutilization of services, it can also lead to increased administrative burden and inhibit patient access. One commenter suggested that CMS consider applying prior authorization for providers with service volumes that are statistical outliers or for those whose ordering rates are not in compliance with clinical guidelines. In response to the comment solicitation on when it might be appropriate to pay a higher OPPS payment rate for a service that can be performed safely in a lower cost setting, several commenters believed that it would be appropriate to pay a higher OPPS rate for services that can be performed in a lower cost setting if providing this higher payment can improve patient experience, efficiency, and quality of care. Several commenters also mentioned that the comprehensive care management and coordination that accompanies receiving services at an off-campus PBD of a hospital might justify the higher OPPS payment rate. Commenters also asserted that the additional certifications required for services furnished in PBDs compared to services furnished in physician offices justify a higher payment rate. In response to the comment solicitation on utilization management, several commenters were opposed to this concept and stated that utilization management would increase provider burden and delay patient access to care. One commenter supported the concept 80 Medicare Payment Advisory Commission. 2013. Report to the Congress: Medicare and the health care delivery system. Washington, DC: MedPAC. E:\FR\FM\21NOR2.SGM 21NOR2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations of utilization management, but believed that it must be based on clinical validity, support the continuity of patient care, be transparent and fair, provide timely access to care and administrative efficiency, and provide alternatives and exemptions to those clinicians with appropriate utilization rates. Other commenters supported appropriate use criteria and evidencebased clinical guidelines and pathways as effective clinical-decision support tools to assist clinicians and hospitals in the reduction of potentially harmful or rarely appropriate services. Response: We thank commenters for their responses to our comment solicitation. We will consider these comments for future rulemaking. C. Application of the 340B Drug Payment Policy to Nonexcepted OffCampus Departments of a Hospital khammond on DSK30JT082PROD with RULES2 1. Historical Perspective a. Section 603 of the Bipartisan Budget Act of 2015 In the CY 2017 OPPS/ASC final rule with comment period (81 FR 79699), we discussed implementation of section 603 of the Bipartisan Budget Act of 2015 (Pub. L. 114–74), enacted on November 2, 2015, which amended section 1833(t) of the Act. Specifically, this provision amended section 1833(t) of the Act by amending paragraph (1)(B) and adding a new paragraph (21). As a general matter, under sections 1833(t)(1)(B)(v) and (t)(21) of the Act, applicable items and services furnished by certain off-campus outpatient departments of a provider on or after January 1, 2017 are not considered covered OPD services as defined under section 1833(t)(1)(B) of the Act for purposes of payment under the OPPS and are instead paid ‘‘under the applicable payment system’’ under Medicare Part B if the requirements for such payment are otherwise met. We indicated that, in order to be considered part of a hospital, an off-campus department of a hospital must meet the provider-based criteria established under 42 CFR 413.65. Accordingly, we refer to an ‘‘off-campus outpatient department of a provider,’’ which is the term used in section 603 of the Bipartisan Budget Act of 2015, as an ‘‘off-campus outpatient provider-based department’’ or an ‘‘off-campus PBD.’’ For a detailed discussion of the legislative history and statutory authority related to payments under section 603 of the Bipartisan Budget Act of 2015, we refer readers to the CY 2017 OPPS/ASC final rule with comment period (81 FR 79699 through 79719) and interim final rule with comment period (81 FR 79720 through 79729). VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 b. Applicable Payment System As we stated in the CY 2019 OPPS/ ASC proposed rule (83 FR 37143 through 37144), to implement the amendments made by section 603 of Public Law 114–74, we issued an interim final rule with comment period (81 FR 79720) which accompanied the CY 2017 OPPS/ASC final rule with comment period to establish the Medicare PFS as the ‘‘applicable payment system’’ that applies in most cases, and we established payment rates under the PFS for those nonexcepted items and services furnished by nonexcepted off-campus PBDs. As we discussed in the CY 2017 OPPS/ASC interim final rule with comment period (81 FR 79718) and reiterated in the CY 2018 PFS final rule with comment period (82 FR 53028), payment for Medicare Part B drugs that would be separately payable under the OPPS (assigned a status indicator of ‘‘K’’), but are not payable under the OPPS because they are furnished by nonexcepted offcampus PBDs, is made in accordance with section 1847A of the Act (generally, at a rate of ASP+6 percent), consistent with Part B drug payment policy for items or services furnished in the physician office (nonfacility) setting. We did not propose or make an adjustment to payment for 340Bacquired drugs in nonexcepted offcampus PBDs in CY 2018, but indicated we may consider doing so through future notice-and-comment rulemaking. In the interim final rule with comment period that accompanied the CY 2017 OPPS/ASC final rule with comment period, we established payment policies under the Medicare PFS for nonexcepted items and services furnished by a nonexcepted off-campus PBD on or after January 1, 2017. In accordance with sections 1848(b) and (c) of the Act, Medicare PFS payment is based on the relative value of the resources involved in furnishing particular services (81 FR 79790). Resource-based relative values are established for each item and service (described by a HCPCS code(s)) based on the work (time and intensity), practice expense (such as clinical staff, supplies and equipment, office rent, and overhead), and malpractice expense required to furnish the typical case of the service. Because Medicare makes separate payment under institutional payment systems (such as the OPPS) for the facility costs associated with many of the same services that are valued under the PFS, we establish two different PFS payment rates for many of these services—one that applies when the service is furnished in a location PO 00000 Frm 00199 Fmt 4701 Sfmt 4700 59015 where a facility bills and is paid for the service under a Medicare payment system other than the PFS (the facility rate), and another that applies when the billing practitioner or supplier furnishes and bills for the entire service (the nonfacility rate). Consistent with the long-established policy under the PFS to make payment to the billing practitioner at the facility rate when Medicare makes a corresponding payment to the facility (under the OPPS, for instance) for the same service, physicians and nonphysician practitioners furnishing services in nonexcepted PBDs continue to report their services on a professional claim form and are paid for their services at the PFS facility rate. Similarly, there are many (mostly diagnostic) services paid under the PFS that have two distinct portions of the service: A technical component (TC) and a professional component (PC). These components can be furnished independently in time or by different suppliers, or they may be furnished and billed together as a ‘‘global’’ service (82 FR 52981). Payment for these services can also be made under a combination of payment systems; for example, under the PFS for the professional component and the OPPS for the facility portion. For instance, for a diagnostic CT scan, the technical component relates to the portion of the service during which the image is captured and might be furnished in an office or HOPD setting, and the professional component relates to the interpretation and report by a radiologist. In the CY 2017 interim final rule with comment period, we stated that we continue to believe that it is operationally infeasible for nonexcepted off-campus PBDs to bill directly under the PFS for the subset of PFS services for which there is a separately valued technical component (81 FR 79721). In addition, we explained that we believe hospitals that furnish nonexcepted items and services are likely to furnish a broader range of services than other provider or supplier types for which there is a separately valued technical component under the PFS. We stated that we therefore believe it is necessary to establish a new set of payment rates under the PFS that reflect the relative resource costs of furnishing the technical component of a broad range of services to be paid under the PFS that is specific to one site of service (the offcampus PBD of a hospital) with the packaging (bundling) rules that are significantly different from current PFS rules (81 FR 79721). In continuing to implement the requirements of sections 1833(t)(1)(B) and (t)(21) of the Act, we recognize that E:\FR\FM\21NOR2.SGM 21NOR2 khammond on DSK30JT082PROD with RULES2 59016 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations there is no established mechanism for allowing hospitals to report and bill under the PFS for the portion of resources incurred in furnishing the full range of nonexcepted items and services. This is because hospitals with nonexcepted off-campus PBDs that furnish nonexcepted items and services generally furnish a broader range of services than other provider or supplier types for which there is a separately valued technical component under the PFS. As such, we established a new set of payment rates under the PFS that reflected the relative resource costs of furnishing the technical component of a broad range of services to be paid under the PFS specific to the nonexcepted offcampus PBDs of a hospital. Specifically, we established a PFS relativity adjuster that is applied to the OPPS rate for the billed nonexcepted items and services furnished in a nonexcepted off-campus PBD in order to calculate payment rates under the PFS. The PFS relativity adjuster reflects the estimated overall difference between the payment that would otherwise be made to a hospital under the OPPS for the nonexcepted items and services furnished in nonexcepted off-campus PBDs and the resource-based payment under the PFS for the technical aspect of those services with reference to the difference between the facility and nonfacility (office) rates and policies under the PFS. The current PFS relativity adjuster is set at 40 percent of the amount that would have been paid under the OPPS (82 FR 53028). These PFS rates incorporate the same packaging rules that are unique to the hospital outpatient setting under the OPPS, including the packaging of drugs that are unconditionally packaged under the OPPS. This includes packaging certain drugs and biologicals that would ordinarily be separately payable under the PFS when furnished in the physician office setting. Nonexcepted off-campus PBDs continue to bill for nonexcepted items and services on the institutional claim utilizing a new claim line (modifier ‘‘PN’’) to indicate that an item or service is a nonexcepted item or service. For a detailed discussion of the current PFS relativity adjuster related to payments under section 603 of Public Law 114– 74, we refer readers to the CY 2018 OPPS/ASC final rule with comment period (82 FR 52356 through 52637), the CY 2018 PFS final rule with comment period (82 FR 53019 through 53025), and the CY 2019 PFS proposed rule. c. Section 340B of the Public Health Service Act As discussed in the CY 2019 OPPS/ ASC proposed rule (83 FR 37144 VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 through 37145), the 340B Program, which was established by section 340B of the Public Health Service Act by the Veterans Health Care Act of 1992, is administered by the Health Resources and Services Administration (HRSA) within HHS. The 340B Program allows participating hospitals and other health care providers to purchase certain ‘‘covered outpatient drugs’’ (as defined under section 1927(k) of the Act and interpreted by HRSA through various guidance documents) at discounted prices from drug manufacturers. In the CY 2018 OPPS/ASC proposed rule (82 FR 33632 through 33635), we proposed changes to the payment methodology under the OPPS for separately payable drugs and biologicals acquired under the 340B Program. We stated that these changes would better, and more appropriately, reflect the resources and acquisition costs that these hospitals incur. Such changes would allow Medicare beneficiaries (and the Medicare program) to pay less when hospitals participating in the 340B Program furnish drugs that are purchased under the 340B Program to Medicare beneficiaries. Subsequently, in the CY 2018 OPPS/ASC final rule with comment period, we finalized our proposal that separately payable, covered outpatient drugs and biologicals (other than drugs on pass-through payment status and vaccines) acquired under the 340B Program will be paid ASP minus 22.5 percent, rather than ASP+6 percent, when billed by a hospital paid under the OPPS that is not excepted from the payment adjustment. CAHs are not subject to this 340B policy change because they are paid under section 1834(g) of the Act. Rural sole community hospitals, children’s hospitals, and PPS-exempt cancer hospitals are excepted from the alternative payment methodology for 340B-acquired drugs and biologicals. In addition, as stated in the CY 2018 OPPS/ASC final rule with comment period, this policy change does not apply to drugs with pass-through payment status, which are required to be paid based on the ASP methodology, or to vaccines, which are excluded from the 340B Program. 2. Proposal and Final Policy To Pay an Adjusted Amount for 340B-Acquired Drugs and Biologicals Furnished in Nonexcepted Off-Campus PBDs in CY 2019 and Subsequent Years As noted in the CY 2017 OPPS/ASC final rule with comment period (81 FR 79716), prior to the implementation of the payment adjustment under the OPPS for drugs and biologicals acquired under the 340B program, separately PO 00000 Frm 00200 Fmt 4701 Sfmt 4700 payable drugs and biologicals were paid the same rate at both excepted and nonexcepted off-campus departments of a hospital. The policy we finalized in the CY 2018 OPPS/ASC final rule with comment period, in which we adjusted the payment rate for separately payable drugs and biologicals (other than drugs on pass-through payment status and vaccines) acquired under the 340B Program from ASP+6 percent to ASP minus 22.5 percent, applies to separately payable drugs and biologicals paid under the OPPS (81 FR 59353 through 59369). Under sections 1833(t)(1)(B)(v) and (t)(21) of the Act, however, in accordance with our policy in effect as of CY 2018, nonexcepted items and services furnished by nonexcepted off-campus PBDs are no longer covered outpatient department services and, therefore, are not payable under the OPPS. This means that nonexcepted off-campus PBDs are not subject to the payment changes finalized in the CY 2018 OPPS/ASC final rule with comment period that apply to hospitals and PBDs paid under the OPPS. Because the separately payable drugs and biologicals acquired under the 340B Program and furnished in nonexcepted off-campus PBDs are no longer covered outpatient department services, as of CY 2018, these drugs and biologicals are currently paid in the same way Medicare Part B drugs are paid in the physician office and other nonhospital settings—typically at ASP+6 percent—regardless of whether they are acquired under the 340B Program. The current PFS payment policies for nonexcepted items and services incorporate a significant number of payment policies and adjustments made under the OPPS (81 FR 79726; 82 FR 53024 through 53025). In establishing these policies in prior rulemaking, we pointed out that the adoption of these policies was necessary in order to maintain the integrity of the PFS relativity adjuster because it adjusts payment rates developed under the OPPS (81 FR 79726). For example, it is necessary to incorporate OPPS packaging rules into the site-specific PFS rate because the PFS relativity adjuster is applied to OPPS rates that were developed based on those packaging rules. In addition, many of the OPPS policies and adjustments are replicated under the nonexcepted offcampus PBD site-specific PFS rates because they are specifically applicable to hospitals as a setting of care. For example, we adopted the geographic adjustments used for hospitals instead of the adjustments developed for the E:\FR\FM\21NOR2.SGM 21NOR2 khammond on DSK30JT082PROD with RULES2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations PFS localities, which reflect cost differences calculated for professionals and suppliers rather than hospitals (81 FR 79726). We note that, ordinarily, Medicare pays for drugs and biologicals furnished in the physician’s office setting at ASP+6 percent. This is because section 1842(o)(1)(A) of the Act provides that if a physician’s, supplier’s, or any other person’s bill or request for payment for services includes a charge for a drug or biological for which payment may be made under Medicare Part B and the drug or biological is not paid on a cost or prospective payment basis as otherwise provided in this part, the amount for the drug or biological is equal to the following: The amount provided under section 1847, section 1847A, section 1847B, or section 1881(b)(13) of the Act, as the case may be for the drug or biological. Generally, in the hospital outpatient department setting, low-cost drugs and biologicals are packaged into the payment for other services billed under the OPPS. Separately payable drugs (1) have pass-through payment status, (2) have a per-day cost exceeding a threshold, or (3) are not policy-packaged or packaged in a C–APC. As described in section V.A.1. of the CY 2019 OPPS/ ASC proposed rule, section 1847A of the Act establishes the ASP methodology, which is used for payment for drugs and biologicals described in section 1842(o)(1)(C) of the Act furnished on or after January 1, 2005. The ASP methodology, as applied under the OPPS, uses several sources of data as a basis for payment, including the ASP, the WAC, and the AWP (82 FR 59337). As noted in section V.B.2.b. of the CY 2019 OPPS/ASC proposed rule, since CY 2013, our policy has been to pay for separately payable drugs and biologicals at ASP plus 6 percent in accordance with section 1833(t)(14)(A)(iii)(II) of the Act (the statutory default) (82 FR 59350). Consequently, in the case of services furnished in a hospital outpatient department, Medicare pays ASP+6 percent for separately payable Part B drugs and biologicals unless those drugs or biologicals are acquired under the 340B Program, in which case they are paid at ASP minus 22.5 percent. For a detailed discussion of our current OPPS drug payment policies, we refer readers to the CY 2018 OPPS/ASC final rule with comment period (82 FR 59343 through 59371). As discussed in the CY 2019 OPPS/ ASC proposed rule (83 FR 37146), as a general matter, in the nonexcepted offcampus PBD setting, we pay hospitals under the PFS for all drugs and VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 biologicals that are packaged under the OPPS based on a percentage of the OPPS payment rate, which is determined using the PFS relativity adjuster. Because OPPS packaging rules apply to the PFS payments to nonexcepted off-campus PBDs, the PFS payment for some nonexcepted items and services that are packaged includes payment for some drugs and biologicals that would be separately payable under the PFS if a similar service had been furnished in the office-based setting. As we noted in the CY 2017 final rule with comment period, in analyzing the term ‘‘applicable payment system,’’ we considered whether and how the requirements for payment could be met under alternative payment systems in order to pay for nonexcepted items and services, and considered several payment systems under which payment is made for similar items and services (81 FR 79712). Because the PFS relativity adjuster that is applied to calculate payment to hospitals for nonexcepted items and services furnished in nonexcepted off-campus PBDs is based on a percentage (40 percent) of the amount determined under the OPPS for a particular item or service, and the OPPS is a prospective payment system, we believe that items and services furnished by nonexcepted off-campus PBDs paid under the PFS are payable on a prospective payment basis. Therefore, we believe we have flexibility to pay for separately payable drugs and biologicals furnished in nonexcepted off-campus PBDs at an amount other than the amount dictated by sections 1842(o)(1)(C) and 1847A of the Act. As we discussed in the CY 2018 OPPS/ASC final rule with comment period (82 FR 59354), several recent studies and reports on Medicare Part B payments for 340B-acquired drugs highlight a difference in Medicare Part B drug spending between 340B hospitals and non-340B hospitals as well as varying differences in the amount by which the Part B payment exceeds the drug acquisition cost. When we initially developed the policy for nonexcepted off-campus PBDs, most separately payable drugs and biologicals were paid, both in the OPPS and in other Part B settings, such as physician offices, through similar methodologies under section 1847A/1842(o) of the Act. For drugs and biologicals that are packaged in the OPPS, we adopted similar packaging payment policies for purposes of making the site-specific payment under the PFS for nonexcepted off-campus PBDs. Because hospitals can, in some cases, acquire drugs and PO 00000 Frm 00201 Fmt 4701 Sfmt 4700 59017 biologicals under the 340B Program for use in nonexcepted off-campus PBDs, we believe that not adjusting payment exclusively for these departments would present a significant incongruity between the payment amounts for these drugs depending upon where (for example, excepted PBD or nonexcepted PBD) they are furnished. This incongruity would distort the relative accuracy of the resource-based payment amounts under the site-specific PFS rates and could result in significant perverse incentives for hospitals to acquire drugs and biologicals under the 340B Program and avoid Medicare payment adjustments that account for the discount by providing these drugs to patients predominantly in nonexcepted off-campus PBDs. In light of the significant drug payment differences between excepted and nonexcepted offcampus PBDs, in combination with the potential eligibility for discounts, which result in reduced costs under the 340B Program for both kinds of departments, our current payment policy could undermine the validity of the use of the OPPS payment structure in nonexcepted off-campus PBDs. In order to avoid such perverse incentives and the potential resulting distortions in drug payment, in the CY 2019 OPPS/ASC proposed rule (83 FR 37146), we proposed, pursuant to our authority at section 1833(t)(21)(C) of the Act, to identify the PFS as the ‘‘applicable payment system’’ for 340Bacquired drugs and biologicals and, accordingly, to pay under the PFS instead of under section 1847A/1842(o) of the Act an amount equal to ASP minus 22.5 percent for drugs and biologicals acquired under the 340B Program that are furnished by nonexcepted off-campus PBDs. We stated in the proposed rule that we believe this proposed change in policy would eliminate the significant incongruity between the payment amounts for these drugs, depending upon whether they are furnished by excepted off-campus PBDs or nonexcepted off-campus PBDs, which we believe is an unnecessary difference in payment where the 340B Program does not differentiate between PBDs paid under the OPPS and PBDs paid under the PFS using the PFS relativity adjuster. In the CY 2018 OPPS/ASC final rule with comment period (82 FR 59367 through 59368), we discussed public comments that we received that noted that the alternative payment methodology for 340B-acquired drugs and biologicals did not apply to nonexcepted off-campus PBDs of a hospital and could result in behavioral E:\FR\FM\21NOR2.SGM 21NOR2 khammond on DSK30JT082PROD with RULES2 59018 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations changes that may undermine CMS’ policy goals of reducing beneficiary cost-sharing liability and undercut the goals of section 603 of Public Law 114– 74. Commenters recommended that, if CMS adopted a final policy to establish an alternative payment methodology for 340B drugs in CY 2018, CMS also apply the same adjustment to payment rates for drugs furnished in nonexcepted offcampus PBDs of a hospital if such drugs were acquired under the 340B Program (82 FR 59367). While we did not propose to adjust payment for 340Bacquired drugs in nonexcepted offcampus PBDs in CY 2018, we indicated that we would consider adopting such a policy in future rulemaking. We agree with commenters that the difference in the payment amounts for 340B-acquired drugs furnished by hospital outpatient departments, excepted off-campus PBDs versus nonexcepted off-campus PBDs, creates an incentive for hospitals to move drug administration services for 340Bacquired drugs to nonexcepted offcampus PBDs to receive a higher payment amount for these drugs, thereby undermining our goals of reducing beneficiary cost-sharing for these drugs and biologicals and moving towards site neutrality through the section 603 amendments to section 1833(t) of the Act. Therefore, in the CY 2019 OPPS/ASC proposed rule (83 FR 37145), we proposed changes to the Medicare Part B drug payment methodology for drugs and biologicals furnished and billed by nonexcepted off-campus departments of a hospital that were acquired under the 340B Program. Specifically, for CY 2019 and subsequent years, we proposed to pay under the PFS the adjusted payment amount of ASP minus 22.5 percent for separately payable drugs and biologicals (other than drugs on pass-through payment status and vaccines) acquired under the 340B Program when they are furnished by nonexcepted off-campus PBDs of a hospital. Furthermore, we proposed to except rural sole community hospitals, children’s hospitals, and PPS-exempt cancer hospitals from this payment adjustment (83 FR 37145). We stated that we believe that our proposed payment policy would better reflect the resources and acquisition costs that nonexcepted offcampus PBDs incur for these drugs and biologicals. Comment: Some commenters, including organizations representing physician oncology practices, orthopaedic surgeons, pharmaceutical research and manufacturing companies, a large network of community-based oncology practices, physician VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 organizations, and health insurers, supported the proposal. Some of these commenters commended CMS for its proposal, which they believed would help address the growth of the 340B Program, stem physician practice consolidation with hospitals, preserve patient access to community-based care, and address the significant incongruity between the payment amounts for 340Bacquired drugs, depending upon the setting in which they are furnished. One of these commenters, a pharmaceutical company, stated that the 340B Program has grown beyond its original intent and needs to be refocused to better meet the needs of vulnerable patients. The commenter noted that there is an incentive to inappropriately shift administration of drugs from excepted to nonexcepted off-campus PBDs for the purpose of securing higher payment. In addition, the commenter urged HHS to adopt policies ‘‘that prevent the unjustified expansion of the 340B program to unintended populations through contract pharmacies, child sites, and individuals who Congress did not intend to be considered 340B patients.’’ A few commenters, including organizations representing community oncology practices, stated that the opportunity for 340B-participating hospitals to get substantial revenue from cancer drugs has created financial incentives for hospitals to expand oncology services, notably through the acquisition of independent community oncology practices. Furthermore, one of these commenters asserted that, when these facilities purchased by 340Bparticipating entities become offcampus PBDs, they also become eligible for 340B Program discounts, thus ‘‘further fueling the program’s staggering growth.’’ These commenters cited a report that states that, over the last decade, 658 community oncology practices have been acquired by hospitals, and 3 out of 4 of these acquisitions were by hospitals already eligible for the 340B Program. Accordingly, these commenters believe that the growth of Part B drug spending in recent years has been disproportionately driven by higher payments in the hospital outpatient setting. Another commenter asserted that the current situation creates two undesirable incentives. First, it creates an incentive for physicians to join a hospital to furnish the same types of services that could have been furnished in the physician office setting, thereby increasing costs to the Medicare program, Medicare beneficiaries, and taxpayers without any associated PO 00000 Frm 00202 Fmt 4701 Sfmt 4700 increase in access to care for Medicare beneficiaries, particularly low-income beneficiaries. Second, it encourages hospitals to move services off the hospital campus for financial incentives. Some commenters urged CMS and HRSA to work with Congress to reform the 340B Program. One commenter recommended that CMS gather additional data to better understand 340B Program acquisition costs and the impact of payment reductions on 340B Program providers. In addition, a few commenters recommended that CMS revise the definition of ‘‘patient’’ to reflect the program’s original intent. Response: We thank commenters for their support and recommendations. We agree with the commenters that the difference in the payment amounts for 340B-acquired drugs furnished by different types of hospital outpatient departments, excepted off-campus PBDs versus nonexcepted off-campus PBDs, creates an incentive for hospitals to move drug administration services for 340B-acquired drugs to nonexcepted offcampus PBDs to receive a higher payment amount for these drugs, thereby undermining our goals of reducing beneficiary cost-sharing for these drugs and biologicals and moving towards site neutrality through the section 603 amendments to section 1833(t) of the Act. Therefore, we continue to believe that our proposed policy will better align Medicare payment for separately payable drugs acquired under the 340B Program with the actual resources expended to acquire such drugs in nonexcepted offcampus PBDs of a hospital. As we previously stated, CMS does not administer the 340B Program. Accordingly, comments related to eligibility for the 340B Program as well as 340B Program policies are outside the scope of the proposed rule and are not addressed in this final rule with comment period. Comment: One commenter, who cited studies conducted by the GAO, OIG, and MedPAC, suggested that CMS make additional downward adjustments to drug payments under the 340B Program in future years because the 22.5 percent payment reduction ‘‘was conservative’’ and the actual average discount experienced by 340B hospitals is likely much higher than 22.5 percent. The commenter asserted that 22.5 percent reflects the average minimum discount that 340B hospitals receive for drugs acquired under the program, and that discounts across all 340B providers average 33.6 percent of ASP. Response: We thank the commenter for this feedback. We will continue to E:\FR\FM\21NOR2.SGM 21NOR2 khammond on DSK30JT082PROD with RULES2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations analyze the data on these drugs for future rulemaking. As we mentioned in the CY 2019 OPPS/ASC proposed rule, we share the commenter’s concern that current Medicare payments for drugs acquired by nonexcepted off-campus PBDs are well in excess of the overhead and acquisition costs for drugs purchased under the 340B Program. We also continue to believe that Medicare beneficiaries should be able to benefit from the significant discounts hospitals receive on 340B-acquired drugs through reduced copayments. Comment: One commenter, an organization representing children’s hospitals, supported the proposal to except children’s hospitals from the proposed payment policy for drugs purchased under the 340B Program. However, the commenter asserted that children’s hospitals are undercompensated by government programs, and that a recent report found that the overall Medicare margin for all hospitals is negative. Furthermore, the commenter stated that, while selfgoverning children’s hospitals are excepted from the payment policy, children’s hospitals within academic medical centers or health care systems remain subject to this policy, which will curtail the ability of such children’s hospitals to care for needy children. The commenter urged CMS not to apply this policy to children’s hospitals within academic medical centers or health care systems. Response: We thank the commenter for its support and feedback. As we stated in the CY 2018 OPPS/ASC final rule with comment period (82 FR 59366), because of how children’s hospitals are paid under the OPPS, we acknowledged that the 340B drug payment policy may not result in reduced payments for these hospitals in the aggregate. While the payment policy we are establishing in this final rule with comment period applies to nonexcepted departments of a hospital that are paid under the PFS rather than the OPPS, we believe that adopting an analogous policy, regardless of status, is prudent so that a generally excepted hospital receives payment for drugs in the same manner, regardless of the status (excepted or nonexcepted) of each PBD of the hospital. In addition, it is unclear from the comment whether the referenced children’s hospitals ‘‘within academic medical centers or health care systems’’ are enrolled in the Medicare program as children’s hospitals or whether they are simply a department of an enrolled hospital provider. However, any separately enrolled children’s hospital that is paid as such is exempt from the VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 340B-acquired drug payment reduction, while children’s units that are not separately enrolled would not be exempt from the 340-acquired drug payment policy. Comment: A few commenters, including organizations representing sole community hospitals, supported the proposal to extend the exception for rural sole community hospitals from the proposed 340B Program payment adjustment. However, these commenters remained concerned that other vulnerable hospitals continue to be subject to the 340B Program payment reduction. Accordingly, these commenters recommended that CMS exempt urban sole community hospitals, Medicare-dependent hospitals, and hospitals with rural referral center status from the payment adjustment. In addition, rural hospitals recommended that rural providers be permanently excepted from this policy. Response: We share commenters’ concerns about access to care, especially in rural areas where access issues may be more pronounced than in other areas of the country. Medicare has long recognized the unique needs of rural communities and the financial challenges rural hospital providers face. Across the various Medicare payment systems, CMS has established a number of special payment provisions for rural providers to maintain access to care and to deliver high quality care to beneficiaries in rural areas. Consequently, for CY 2019, we are excluding rural sole community hospitals (as described under the regulations at 42 CFR 412.92 and designated as rural for Medicare purposes) from this policy. However, we do not believe that a payment exemption for nonexcepted off-campus departments of urban SCHs is necessary because these hospitals are not exempted from the 340B payment policy for hospital departments paid under the OPPS. Nonetheless, we will continue to analyze the data for these hospitals to determine whether urban SCHs should be exempt from this payment policy, as well as whether permanent exemption for rural SCHs is warranted in future rulemaking. With respect to rural referral centers, in the CY 2018 OPPS/ASC final rule with comment period, we noted that there is no special payment designation for rural referral centers under the OPPS. By definition, rural referral centers must have at least 275 beds and therefore are larger relative to rural sole community hospitals. In addition, rural referral centers are not subject to a distance requirement from other hospitals. Accordingly, rural referral PO 00000 Frm 00203 Fmt 4701 Sfmt 4700 59019 centers are neither as small (in terms of bed size) or as isolated (in terms of proximity to other hospitals) as rural SCHs, nor are they generally eligible for special payment status under the OPPS, and we do not believe that a payment exemption from this policy for these centers is warranted. Furthermore, as stated earlier in this section, we believe that we should adopt an analogous payment policy across hospital settings, regardless of the status of each PBD. Because we did not exempt grandfathered off-campus PBDs with MDH classification from the 340B payment adjustment in CY 2018, we do not believe that nonexcepted off-campus PBDs with Medicare-dependent hospital status should be exempted at this time. Therefore, for CY 2019, Medicaredependent hospitals will not be exempt from this payment policy. For CY 2019, rural sole community hospitals, children’s hospitals, and PPSexempt cancer hospitals will be excepted from the alternative payment methodology for 340B-acquired drugs and biologicals furnished in nonexcepted off-campus PBDs, and therefore will be required to bill under the PFS using the institutional claim form and report the informational modifier ‘‘TB’’ for 340B-acquired drugs and biologicals. These providers will continue to be paid ASP+6 percent for 340B-acquired drugs and biologicals under the PFS. In addition, as we stated in the CY 2018 OPPS/ASC final rule with comment period, this policy change does not apply to drugs with pass-through payment status, which are required to be paid based on the ASP methodology, or to vaccines, which are excluded from the 340B Program. We note that this policy does not alter covered entities’ access to the 340B Program. The expansion of the alternative 340B drug payment methodology solely changes Medicare payment for drugs furnished in nonexcepted off-campus PBDs of a hospital if such drugs were acquired under the 340B Program. We may revisit our policy regarding exceptions to the 340B drug payment reduction in the CY 2020 OPPS/ASC rulemaking. Comment: In its comment, MedPAC reiterated recommendations included in its March 2016 Report to Congress. In this report, MedPAC recommended that payment rates for all separately payable drugs provided in a 340B hospital be reduced by 10 percent of the current payment rate of ASP+6 percent (resulting in ASP minus 5.3 percent after taking application of the sequester into account). MedPAC noted that its March 2016 report also included a recommendation to Congress that E:\FR\FM\21NOR2.SGM 21NOR2 khammond on DSK30JT082PROD with RULES2 59020 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations savings from the reduced payment rates be directed to the Medicare-funded uncompensated care pool, which would target hospitals providing the most care to the uninsured and in that way benefit indigent patients, and that payments be distributed in proportion to the amount of uncompensated care that hospitals provide. MedPAC believed that legislation would be needed to direct drug payment savings to the uncompensated care pool and noted that current law requires the savings to be retained with the OPPS to make the payment system budget neutral. MedPAC encouraged the Secretary to work with Congress to enact legislation necessary to allow MedPAC’s recommendation to be implemented, if such a recommendation could not be implemented administratively. MedPAC further noted that legislation would also allow Medicare to apply the policy to all OPPS separately payable drugs, including those on pass-through payment status. Accordingly, MedPAC recognized that CMS does not have the legal authority to implement its March 2016 recommendation and shares CMS’ concern that the lack of site-neutral payments may cause a shift in administration of nonpass-through separately payable drugs to nonexcepted off-campus PBDs. Additionally, MedPAC stated that CMS should ensure that payment for 340B-acquired drugs is equal across settings. Response: We thank MedPAC for its support and feedback. As we stated in the CY 2018 OPPS/ASC final rule with comment period (82 FR 59364 through 59365), we do not believe that reducing the Medicare payment rate by only 10 percentage points below the current payment rate of ASP+6 percent (that is, ASP minus 4 percent) would better reflect the acquisition costs incurred by 340B-participating hospitals. We note that we responded to a similar public comment in the CY 2018 OPPS/ASC final rule with comment period (82 FR 59364 through 59365) and refer readers to a summary of that comment and our response. Comment: Many commenters stated that the Secretary lacks statutory authority to impose such a large reduction in the payment rate for 340B drugs acquired in off-campus PBDs, and contended that the expansion of the 340B payment policy at nonexcepted off-campus PBDs would ‘‘effectively eviscerate’’ the 340B Program. These commenters further noted that extending the Medicare payment cuts to nonexcepted off-campus PBDs would greatly undermine 340B hospitals’ ability to continue programs designed to improve access to services. VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 One commenter, an organization representing over 1,300 public and nonprofit providers enrolled in the 340B Program, argued that since the 340B payment policy took effect in January 2018, many hospitals have experienced financial and operational challenges, including staff reductions, fewer free or discounted drugs for patients, clinic and pharmacy closures, and reductions in services provided. The commenter opposed the 340B payment proposal for a number of reasons, primarily because the commenter believed that the current OPPS 340B payment rate harms hospitals’ ability to treat low-income patients and the proposals to continue and expand the cuts would worsen the impact. Furthermore, the commenter argued that CMS’ proposed payment reduction does not reduce patient costs or Medicare spending or address ‘‘skyrocketing drug prices’’; CMS’ payment reduction violates the 340B statute; CMS’ payment reduction violates the Medicare statute; and CMS’ payment reduction relies on a ‘‘faulty premise that fails to recognize that 340B hospitals serve patients with more expensive medical needs.’’ The commenter further asserted that Congress, as well as ‘‘one-hundred percent of hospitals,’’ have expressed concern about the payment reduction’s impact on 340B providers’ ability to serve their patients. Many additional commenters, including some hospital associations, contended that CMS does not have the legal authority to apply the OPPS Medicare payment rate to nonexcepted off-campus PBDs in 340B-participating hospitals because section 1833(t)(21)(C) of the Act does not authorize CMS to pay at a rate that is less than the rate paid under the selected ‘‘applicable payment system.’’ Specifically, a few commenters asserted that payment for these drugs and biologicals is determined pursuant to the rules of section 1842(o)(1)(C) of the Act, which mandates that payment is to be made for these drugs and biologicals when furnished by nonexcepted off-campus PBDs pursuant to the rules of section 1847A of the Act. Response: We do not believe that the proposed payment policy violates section 340B of the Public Health Service Act or the Social Security Act. There is no requirement in the Public Health Service Act that drugs or biologicals acquired under the 340B Program generate a profit margin for hospitals through Medicare payments, and there is no requirement in any part of section 1833(t) of the Social Security Act to pay a particular minimum rate for a hospital enrolled in the 340B Program. PO 00000 Frm 00204 Fmt 4701 Sfmt 4700 Further, we disagree with the commenter’s assertion that CMS’ payment reduction does not reduce patient costs or Medicare spending. Based on our proposed adjustment for CY 2019, we estimated that the Medicare Program and beneficiaries would save approximately $49 million under the PFS. We also disagree with commenters who believe that the OPPS payment rate for 340B-acquired drugs will ‘‘effectively eviscerate’’ the 340B Program as well as the implication that extending the same rate that applies to 340B-acquired drugs and biologicals furnished by hospital departments under the OPPS to nonexcepted offcampus PBDs will perpetuate that concern. The findings from several 340B studies conducted by the GAO, OIG, and MedPAC show a wide range of discounts that are afforded to 340B hospitals, with some reports finding discounts of up to 50 percent. Indeed, in some cases, beneficiary coinsurance alone exceeds the amount the hospital paid to acquire the drug under the 340B Program (OIG November 2015, Report OEI–12–14–00030, page 9). As stated in the CY 2018 final rule with comment period, we believe that ASP minus 22.5 percent is a conservative estimate of the discount for 340B-acquired drugs, and that even with the reduced payments, hospitals will continue to receive savings that can be directed at programs and services to carry out the intent of the 340B Program. We also have noted that 340B Program participation does not appear to be well aligned with the provision of uncompensated care, as some commenters suggested (82 FR 59359). Payment under the ‘‘applicable payment system’’ pursuant to section 1833(t)(21)(C) of the Act is made under the PFS for most services, including for the many drugs that are packaged under the OPPS, using a PFS relativity adjuster that is applied to the OPPS payment rate. As such, the PFS payment for nonexcepted items and services in nonexcepted off-campus PBDs is made on a prospective payment basis, and we are therefore not required to make payment under section 1847A/1842(o) of the Act for those packaged drugs, many of which would be separately payable under the PFS. Further, as we stated in the CY 2019 OPPS/ASC proposed rule (83 FR 37145), the current PFS payment policies for nonexcepted items and services incorporate a significant number of payment policies and adjustments made under the OPPS (81 FR 79726; 82 FR 53024 through 53025). In establishing these policies in prior rulemaking, we pointed out that E:\FR\FM\21NOR2.SGM 21NOR2 khammond on DSK30JT082PROD with RULES2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations the adoption of these policies was necessary in order to maintain the integrity of the PFS relativity adjuster because it adjusts payment rates developed under the OPPS (81 FR 79726). For example, it is necessary to incorporate OPPS packaging rules into the site-specific PFS rate because the PFS relativity adjuster is applied to OPPS rates that were developed based on those packaging rules. In addition, many of the OPPS policies and adjustments are replicated under the nonexcepted off-campus PBD sitespecific PFS rates because they are specifically applicable to hospitals as a setting of care. For example, we adopted the geographic adjustments used for hospitals instead of the adjustments developed for the PFS localities, which reflect cost differences calculated for professionals and suppliers rather than hospitals (81 FR 79726). Since we have adopted the payment adjustment under the OPPS for 340Bacquired separately payable drugs, we have become concerned that there would be a perverse incentive for hospitals to circumvent the OPPS payment adjustment by furnishing 340B-acquired drugs in nonexcepted off-campus PBDs where Medicare currently makes payment for those drugs at ASP+6 percent. To avoid this payment incongruity and perverse incentive, we proposed to designate the PFS as the ‘‘applicable payment system’’ for 340B-acquired separately payable drugs furnished in nonexcepted offcampus PBDs, and to make payment at the OPPS-comparable rate. Comment: A few commenters asserted that, while CMS estimated that the payment change would result in a payment cut of $48.5 million in CY 2019, CMS provided no data to support this estimate and failed to provide sufficient access to data, its methodology, or its analysis to allow the public to assess and replicate the proposed CY 2019 340B payment policy. One commenter recommended that CMS delay extension of the 340B payment policy until more information is available related to the impact on Medicare beneficiaries. Many commenters opposed reducing payments to hospitals for 340B drugs in a nonbudget-neutral manner and instead suggested that such policy be implemented in a budget neutral manner as was implemented in the CY 2018 OPPS/ASC final rule with comment period. In addition, some commenters recommended that CMS annually calculate a budget neutral adjustment for the 340B policy, as the approach is consistent with other VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 budget neutral policies included in the OPPS. Response: We thank the commenters for their input. We disagree that this policy should be implemented in a budget neutral manner because the payments made to nonexcepted offcampus departments of a hospital are not paid under the OPPS. As we stated in the CY 2019 OPPS/ASC proposed rule, to develop an estimated impact of this proposal, we analyzed the CY 2017 outpatient claims data used in ratesetting for the CY 2019 proposed rule. Based on the most recent claims data from CY 2017 reporting, we found 117 unique nonexcepted off-campus PBDs associated with 340B hospitals that billed for status indicator ‘‘K’’ drugs. Their ‘‘K’’ billing represents approximately $182.5 million in Medicare payments based on a payment rate of ASP+6 percent. Based on our proposed adjustment, for CY 2019, we estimated that the Medicare Program and beneficiaries would save approximately $49 million under the PFS. Regarding budget neutrality requirements, we note that when we initially developed the payment policy for nonexcepted items and services furnished by nonexcepted off-campus PBDs, most separately payable drugs and biologicals were paid at the same rates specified under section 1847A/ 1842(o) of the Act (generally, ASP+6) when furnished in the HOPD and in other outpatient settings, such as physician offices. When we initially established the ASP methodology under section 1847A/1842(o) of the Act as the ‘‘applicable payment system’’ for separately payable drugs under section 1833(t)(21)(C) of the Act, there was no applicable budget neutrality requirement. For the proposed change in CY 2019 to establish the PFS as the applicable payment system for separately payable 340–B-acquired drugs furnished by nonexcepted offcampus PBDs, we believe the sitespecific PFS payment for these drugs and biologicals represents new utilization under the PFS and would, consequently, not be subject to the PFS budget neutrality requirements under 1848(c) of the Act for CY 2019. We will consider any applicable budget neutrality requirements regarding the site-specific payment under the PFS for future rulemaking. Comment: Numerous commenters argued that reducing payments for 340B-acquired drugs could encourage hospitals to selectively purchase certain drugs at higher prices outside of the 340B Program to maximize revenue. One of these commenters recommended the implementation of alternate PO 00000 Frm 00205 Fmt 4701 Sfmt 4700 59021 reimbursement methodologies for 340Bpurchased drugs, such as a 6 percent add-on payment to the product-specific estimated 340B cost, in order to discourage hospitals from selectively purchasing some drugs outside of the 340B Program (resulting in ASP minus 16.5 percent after taking application of the add-on payment into account). Response: While participation in the 340B Program has always been voluntary and hospitals have always had the ability to choose to purchase drugs outside the 340B Program, we do not see the relevance of these points to our proposed policy. That is, the policy we proposed with respect to payment for 340B-acquired drugs in nonexcepted departments for CY 2019 simply aligns with the policy already established for 340B-acquired drugs under the OPPS for CY 2018. In addition, as we explained in CY 2018 OPPS rulemaking, the payment rate of ASP minus 22.5 percent is better aligned with the average resources to acquire a 340B drug, and therefore, we do not believe that a higher payment rate for 340B-acquired drugs in nonexcepted departments is warranted. We thank the commenters for their feedback. After consideration of the public comments we received, we are finalizing our proposal, without modification, to make payment for separately payable 340B-acquired drugs furnished by nonexcepted off-campus departments of a hospital under the PFS, and to establish the payment rate for those drugs at ASP minus 22.5 percent. This policy is expected to lower the cost of drugs and biologicals for Medicare beneficiaries and ensure that they benefit from the discounts provided through the program, and to do so more equitably across HOPD settings. In summary, for CY 2019, in accordance with section 1833(t)(21)(C) of the Act and our established 340B payment methodology as described in the CY 2018 OPPS/ASC final rule with comment period, separately payable Part B drugs and biologicals (assigned status indicator ‘‘K’’), other than vaccines and drugs with pass-through payment status, that are acquired through the 340B Program or through the 340B PVP at or below the 340B ceiling price will be paid at a rate of ASP minus 22.5 percent when billed by a hospital that is not excepted from the payment adjustment. Part B drugs or biologicals excluded from the 340B payment adjustment include vaccines (assigned status indicator ‘‘L’’ or ‘‘M’’) and drugs and biologicals with transitional pass-through payment status (assigned status indicator ‘‘G’’). E:\FR\FM\21NOR2.SGM 21NOR2 59022 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations Medicare will continue to pay for drugs and biologicals that are not purchased with a 340B Program discount at ASP+6 percent. To effectuate the payment adjustment for 340B-acquired drugs and biologicals, CMS implemented modifier ‘‘JG’’, effective January 1, 2018. Hospitals paid under the OPPS (other than a type of hospital excluded from the OPPS or excepted from the 340B drug payment policy for CY 2019) and, beginning January 1, 2019, nonexcepted offcampus PBDs of a hospital paid under the PFS, are required to report modifier ‘‘JG’’ on the same claim line as the drug or biological HCPCS code to identify a 340B-acquired drug or biological. For CY 2019, rural sole community hospitals, children’s hospitals, and PPSexempt cancer hospitals are excepted from the 340B payment adjustment. These hospitals will be required to report informational modifier ‘‘TB’’ for 340B-acquired drugs and biologicals, and will continue to be paid ASP+6 percent. D. Expansion of Clinical Families of Services at Excepted Off-Campus Departments of a Provider khammond on DSK30JT082PROD with RULES2 1. Background a. Section 603 of the Bipartisan Budget Act of 2015 We refer readers to section X.C.1.a. of the CY 2019 OPPS/ASC proposed rule (83 FR 37143) for a discussion of the provisions of section 603 of the Bipartisan Budget Act of 2015 (Pub. L. 114–74), as implemented in the CY 2017 OPPS/ASC final rule with comment period (81 FR 79699 through 79719). As discussed in the CY 2017 OPPS/ASC final rule with comment period, we adopted the PFS as the applicable payment system for nonexcepted items and services furnished and billed by nonexcepted off-campus PBDs. In addition, we indicated that, in order to be considered part of a hospital, an offcampus department of a hospital must meet the provider-based criteria established under 42 CFR 413.65. For a detailed discussion of the history and statutory authority related to payments under section 603 of Public Law 114– 74, we refer readers to the CY 2017 OPPS/ASC final rule with comment period (81 FR 79699 through 79719) and the interim final rule with comment period (81 FR 79720 through 79729). b. Expansion of Services at an OffCampus PBD Excepted Under Section 1833(t)(21)(B)(ii) of the Act In the CY 2017 OPPS/ASC proposed rule (81 FR 45685), we noted that we had received questions from some VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 hospitals regarding whether an excepted off-campus PBD could expand the number or type of services the department furnishes and maintain excepted status for purposes of paragraphs (1)(B)(v) and (21) of section 1833(t) of the Act. We indicated that we were concerned that if excepted offcampus PBDs could expand the types of services provided at the excepted offcampus PBDs and also be paid OPPS rates for these new types of services, hospitals may be able to purchase additional physician practices and expand services furnished by existing excepted off-campus PBDs as a result (81 FR 45685). This could result in newly purchased physician practices furnishing services that are paid at OPPS rates, which we believed these amendments to section 1833(t) of the Act were intended to address (81 FR 45685). We believed section 1833(t)(21)(B)(ii) of the Act excepted offcampus PBDs and the items and services that are furnished by such excepted off-campus PBDs for purposes of paragraphs (1)(B)(v) and (21) of section 1833(t) of the Act as they were being furnished on the date of enactment of section 603 of the Bipartisan Budget Act of 2015, as guided by our regulatory definition at § 413.65(a)(2) of a department of a provider (81 FR 45685). Thus, in the CY 2017 OPPS/ASC proposed rule, we proposed that if an excepted off-campus PBD furnished items and services from a clinical family of services (clinical families of services were identified in Table 21 of the CY 2017 proposed rule (81 FR 45685 through 45686) that it did not furnish prior to November 2, 2015, and thus did not also bill for, services from these new expanded clinical families of services would not be covered OPD services, and instead would be subject to paragraphs (1)(B)(v) and (21) of section 1833(t) of the Act, as described in section X.A.1.c. of the CY 2017 proposed rule. In addition, in that rule, we proposed not to limit the volume of excepted items and services within a clinical family of services that an excepted off-campus PBD could furnish (81 FR 45685). The majority of commenters, including several hospital associations, regional health systems, and medical equipment manufacturers opposed the proposal primarily because they believed: (1) CMS exceeded its statutory authority, as the statutory language included in section 603 does not address changes in service mix by excepted off-campus PBDs; (2) CMS’ proposal did not account for evolving technologies and would hinder PO 00000 Frm 00206 Fmt 4701 Sfmt 4700 beneficiary access to those innovative technologies; (3) the term ‘‘clinical families of service’’ appeared to be a new term created by CMS for the purpose of implementing section 603 and it would be difficult for CMS and hospitals to manage changes in the composition of APCs and HCPCS code changes contained in those APCs; and (4) the proposal created significant operational challenges and administrative burden for both CMS and hospitals because commenters believed it was unnecessarily complex (81 FR 79706 through 79707). In addition, MedPAC explained in its comment letter that the proposal was unnecessarily complex and instead suggested that CMS adopt a different approach by determining how much the Medicare program had paid an excepted off-campus PBD for services billed under the OPPS during a 12-month baseline period that preceded November 2, 2015 and to cap the OPPS payment made to the off-campus PBD at the amount paid during the baseline period.81 Some commenters, including physician group stakeholders, supported CMS’ intent to monitor service line expansion and changes in billing patterns by excepted off-campus PBDs. These commenters urged CMS to work to operationalize a method that would preclude an excepted off-campus PBD from expanding the excepted services for which it is paid under the OPPS into wholly new clinical areas, as they believed an excepted, off-campus PBD should only be able to bill under the OPPS for those items and services for which it submitted claims prior to November 2, 2015 (82 FR 33647). In response to public comments, we did not finalize our proposal to limit the expansion of excepted services at excepted off-campus PBDs. However, we stated our intent to monitor this issue and expressed interest in additional feedback to help us consider whether excepted off-campus PBDs that expand the types of services offered after November 2, 2015 should be paid for furnishing those items and services under the applicable payment system (that is, the PFS) instead of the OPPS. Specifically, we requested comments on how either a limitation on volume or a limitation on lines of service would work in practice (81 FR 79707). In addition, in the CY 2017 OPPS/ ASC final rule with comment period (81 FR 79707), we sought public comments on how either a limitation on volume of services, or a limitation on lines of 81 Available at: https://medpac.gov/docs/defaultsource/comment-letters/08172016_opps_asc_ comment_2017_medpac_sec.pdf?sfvrsn=0. E:\FR\FM\21NOR2.SGM 21NOR2 khammond on DSK30JT082PROD with RULES2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations service, as we laid out in the CY 2017 OPPS/ASC proposed rule, could be implemented. Specifically, we stated that we were interested in what data were available or could be collected that would have allowed us to implement a limitation on the expansion of excepted services. We provided a summary of and responses to comments received in response to the CY 2017 OPPS/ASC final rule with comment period in the CY 2018 OPPS/ASC proposed rule. As stated in that rule, several of the public comments received in response to the comment solicitation included in the CY 2017 OPPS/ASC final rule with comment period were repeated from the same stakeholders in response to the CY 2017 OPPS/ASC proposed rule. These commenters again expressed concern regarding CMS’ authority to address changes in service-mix; that a limitation on service expansion or volume would stifle innovative care delivery and use of new technologies; and that limiting service line expansion using clinical families of service was not workable. Because these commenters did not provide new information, we referred readers to the CY 2017 OPPS/ASC final rule with comment period for our responses to comments on statutory authority and concerns about hindering access to innovative technologies (81 FR 79707 and 82 FR 59388). A summary of and our responses to the other comments received in response to the comment solicitation included in the CY 2017 OPPS/ASC final rule with comment period were included in the CY 2018 OPPS/ASC proposed rule (82 FR 33645 through 33648). In the CY 2018 OPPS/ASC proposed rule, we did not propose any policies related to clinical service line expansion or volume increases at excepted offcampus PBDs. However, we stated that we would continue to monitor claims data for changes in billing patterns and utilization, and we again invited public comments on the issue of service line expansion. In response to the CY 2018 comment solicitation, MedPAC largely reiterated the comments it submitted in response to the CY 2017 OPPS/ASC rulemaking and acknowledged the challenges of implementing its recommended approach as such approach would necessitate CMS requiring hospitals to report the amount of OPPS payments received by each excepted off-campus PBD during the baseline period (such as November 2014 through November 2015) because CMS was not collecting data on payments made to each individual PBD during that period. In its comments, MedPAC recommended that, to help ensure the VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 accuracy of these data, CMS could selectively audit hospitals.82 Another commenter expressed support for CMS’ efforts to continue to implement and expand site-neutral payment policies for services where payment differentials are not warranted, such as between HOPDs and ASCs or physician offices. 2. CY 2019 Proposal and Final Policy As we previously expressed in CYs 2017 and 2018 OPPS/ASC rulemaking, we continue to be concerned that if excepted off-campus PBDs may furnish new types of services that were not provided at the excepted off-campus PBDs prior to the date of enactment of the Bipartisan Budget Act of 2015 and can be paid OPPS rates for these new types of services, hospitals may be able to purchase additional physician practices and add those physicians to existing excepted off-campus PBDs. This could result in newly purchased physician practices furnishing services that are paid at OPPS rates, which we believe the section 603 amendments to section 1833(t) of the Act are intended to prevent. Of note, these statutory amendments ‘‘came after years of nonpartisan economists, health policy experts, and providers expressing concern over the Medicare program’s [OPPS] paying more for the same services provided at HOPDs than in other settings—such as an ambulatory surgery center, physician office, or community outpatient facility.’’ 83 Experts raised concerns that this payment inequity drove the acquisition of ‘‘standalone or independent practices and facilities by hospitals, resulted in higher costs for the Medicare system and taxpayers, and also resulted in beneficiaries needlessly facing higher cost-sharing in some settings than in others.’’ 84 In addition, some experts argued that, ‘‘to the extent this payment differential accelerated consolidation of providers, this would result in reduced competition among both hospitals and nonaffiliated outpatient service providers. This, in turn, could reduce large hospital systems’ incentives to reduce costs, increase efficiency, or focus on patient outcomes.’’ 85 The Government Accountability Office (GAO) stated in its December 2015 Report to the Congress that ‘‘from 2007 through 2013, the number of 82 Available at: https://medpac.gov/docs/defaultsource/comment-letters/09082017_opps_ asc_2018_medpac_comment_sec.pdf?sfvrsn=0. 83 Available at: https://archivesenergycommerce.house.gov/sites/ republicans.energycommerce.house.gov/files/114/ Letters/20160205SiteNeutralLetter%5b1%5d.pdf. 84 Ibid. 85 Ibid. PO 00000 Frm 00207 Fmt 4701 Sfmt 4700 59023 vertically consolidated physicians nearly doubled, with faster growth in more recent years.’’ GAO concluded that, ‘‘regardless of what has driven hospitals and physicians to vertically consolidate, paying substantially more for the same service when performed in an HOPD rather than a physician office provides an incentive to shift services that were once performed in physician offices to HOPDs after consolidations have occurred.’’ 86 While there is no Congressional Record available for section 603 of the Bipartisan Budget Act of 2015, we do not believe that Congress intended to allow for new service lines to be paid OPPS rates because providing for such payment would allow for excepted offcampus PBDs to be paid higher rates for types of services they were not furnishing prior to the date of enactment of the Bipartisan Budget Act of 2015 and that would be paid at lower rates if performed in a nonexcepted off-campus PBD. Similarly, we are concerned that a potential shift of services from nonexcepted off-campus PBDs to excepted off-campus PBDs may be occurring, given the higher payment rate in this setting. We believe that the growth of service lines in currently excepted off-campus PBDs may be an unintended consequence of our current policy, which allows continued full OPPS payment for any services furnished by excepted off-campus PBDs, including services in new service lines. In prior rulemaking, and as discussed in section X.A. of the CY 2019 OPPS/ ASC proposed rule, we noted our concerns and discussed our efforts to begin collecting data and monitoring billing patterns for off-campus PBDs. Specifically, as described in the CY 2015 OPPS/ASC final rule with comment period (79 FR 66910 through 66914), we created HCPCS modifier ‘‘PO’’ (Services, procedures, and/or surgeries furnished at off-campus provider-based outpatient departments) for hospital claims to be reported with every code for outpatient hospital items and services furnished in an off-campus PBD of a hospital. Reporting of this new modifier was voluntary for CY 2015, with reporting required beginning on January 1, 2016. In addition, we established modifier ‘‘PN’’ (Nonexcepted service provided at an offcampus, outpatient, provider-based department of a hospital) to identify and pay nonexcepted items and services billed on an institutional claim. 86 GA0–16–189, ‘‘Increasing Hospital-Physician Consolidation Highlights Need for Payment Reform.’’ Available at: https://www.gao.gov/assets/ 680/674347.pdf. E:\FR\FM\21NOR2.SGM 21NOR2 khammond on DSK30JT082PROD with RULES2 59024 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations Effective January 1, 2017, nonexcepted off-campus PBDs of a hospital were required to report this modifier on each claim line for nonexcepted items and services to trigger payment under the PFS instead of the OPPS. As a conforming revision, effective January 1, 2017, the modifier ‘‘PO’’ descriptor was revised to ‘‘excepted service provided at an off-campus, outpatient, providerbased department of a hospital’’ and this modifier continued to be used to identify items and services furnished by an excepted off-campus PBD of a hospital. As discussed in the CY 2018 OPPS/ ASC proposed rule (82 FR 33647), a few commenters supported CMS’ intent to monitor service line expansion and changes in billing patterns by excepted off-campus PBDs. These commenters urged CMS to work to operationalize a method that would preclude an excepted off-campus PBD from increasing its payment advantage under the OPPS by expanding into wholly new clinical areas (82 FR 33647). Moreover, a few commenters urged CMS to pursue a limitation on service line expansion to ensure designation as an excepted offcampus PBD is not ‘‘abused’’ (82 FR 33647). One commenter suggested that CMS evaluate outpatient claims with the ‘‘PO’’ modifier to develop a list of ‘‘grandfathered’’ items and services for which the excepted off-campus PBD may continue to be paid under the OPPS (82 FR 33647). In response to these comments, we stated that we were concerned with the practicality of developing a list of excepted items and services for each excepted off-campus PBD, given the magnitude of such a list (82 FR 33647). We noted in the CY 2018 OPPS/ASC final rule with comment period, however, that we continued to monitor claims data for changes in billing patterns and utilization, and invited comments on this issue (82 FR 59388). In light of our prior stated concerns about the expansion of services in excepted off-campus PBDs, in the CY 2019 OPPS/ASC proposed rule (83 FR 37148 through 37149), for CY 2019 and subsequent years, we proposed that if an excepted off-campus PBD furnishes services from any clinical family of services (as clinical families of services are defined in Table 32 of that proposed rule) from which it did not furnish an item or service during a baseline period from November 1, 2014 through November 1, 2015 (and subsequently bill under the OPPS for that item or service), items and services from these new clinical families of services would not be excepted items and services and, thus, would not be covered OPD VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 services. Instead, they would be subject to paragraphs (1)(B)(v) and (21) of section 1833(t) of the Act and paid under the PFS. Furthermore, in the CY 2019 OPPS/ASC proposed rule, we proposed to revise 42 CFR 419.48 to limit the definition of ‘‘excepted items and services’’ in accordance with this proposal. Generally, excepted items and services are items or services that are furnished on or after January 1, 2017 by an excepted off-campus PBD (as defined in § 419.48) that has not impermissibly relocated or changed ownership. Under this proposal, beginning on January 1, 2019, excepted items and services would be items or services that are furnished and billed by an excepted offcampus PBD (defined in § 419.48) only from the clinical families of services (described later in this section) for which the excepted off-campus PBD furnished (and subsequently billed under the OPPS) for at least one item or service from November 1, 2014 through November 1, 2015. Further, for purposes of this section, ‘‘new clinical families of services’’ would be items or services: (1) That are furnished and billed by an excepted off-campus PBD; (2) that are otherwise paid under the OPPS through one of the APCs included in Table 32 of the CY 2019 OPPS/ASC proposed rule; and (3) that belong to a clinical family listed in Table 32 of the proposed rule from which the excepted offcampus PBD did not furnish an item or service during the baseline period from November 1, 2014 through November 1, 2015 (and subsequently bill for that service under the OPPS). In addition, for CY 2019, we proposed that if an excepted off-campus PBD furnishes a new item or service from a clinical family of services listed in Table 32 of the proposed rule from which the offcampus PBD furnished a service from November 1, 2014 through November 1, 2015, such service would continue to be paid under the OPPS because items and services from within a clinical family of services for which the excepted offcampus PBD furnished an item or service during the baseline period would not be considered a ‘‘service expansion.’’ As discussed in the CY 2019 OPPS/ ASC proposed rule (83 FR 37149), in order to determine the types of services provided at an excepted off-campus PBD, for purposes of OPPS payment eligibility, excepted off-campus PBDs would be required to ascertain the clinical families from which they furnished services from November 1, 2014 through November 1, 2015 (that were subsequently billed under the OPPS). In addition, items and services PO 00000 Frm 00208 Fmt 4701 Sfmt 4700 furnished by an excepted off-campus PBD that were not identified in Table 32 of the proposed rule would be reported with modifier ‘‘PN’’. We selected the year prior to the date of enactment of the Bipartisan Budget Act of 2015 as the baseline period because it is the most recent year preceding the date of enactment of section 603 and we believed that a full year of claims data would adequately reflect the types of service lines furnished and billed by an excepted off-campus PBD. We considered expanding the baseline period to include a timeframe prior to November 2014, but did not propose this alternative due to the possibility that hospital claims data for an earlier time period might not be readily available and reviewing claims from a longer timeframe may impose undue burden. If an excepted off-campus PBD did not furnish services under the OPPS until after November 1, 2014, we proposed that the 1-year baseline period begins on the first date the off-campus PBD furnished covered OPD services prior to November 2, 2015. For providers that met the mid-build requirement (as defined at section 1833(t)(21)(B)(v) of the Act), we proposed to establish a 1-year baseline period that begins on the first date the off-campus PBDs furnished a service billed under the OPPS. We proposed changes to our regulation at 42 CFR 419.48 to include these alternative baseline periods. For guidance on the implementation of sections 16001 and 16002 of the 21st Century Cures Act, we refer readers to the CMS website at: https://www.cms.gov/Medicare/ Medicare-Fee-for-Service-Payment/ HospitalOutpatientPPS/Downloads/ Sections-16001-16002.pdf. We stated in the proposed rule that we were concerned that a 1-year baseline may be unnecessarily long to the extent that such baseline would be, at least in part, a prospective period during which such departments would have time and an incentive to bill services from as many service lines as possible, thereby limiting the effect of this policy. We welcomed public comment on whether a different baseline period, such as 3 or 6 months, should be used for offcampus PBDs that began furnishing services and billing after November 1, 2014, or that met the mid-build requirement. As discussed in the CY 2019 OPPS/ ASC proposed rule (83 FR 37149), we were aware of past stakeholder concern regarding limiting service line expansion for excepted off-campus PBDs using the 19 clinical families identified in Table 32 of the proposed E:\FR\FM\21NOR2.SGM 21NOR2 khammond on DSK30JT082PROD with RULES2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations rule. However, we believed that the proposed clinical families recognized all clinically distinct service lines for which a PBD might bill under the OPPS, while at the same time allowing for new services within a clinical family of services to be considered for designation as ‘‘excepted items and services’’, as defined in the regulations at 42 CFR 419.48 where the types of services within a clinical family expand due to new technology or innovation. We stated in the proposed rule that we believed that requiring excepted offcampus PBDs to limit their services to the exact same services they furnished during the proposed baseline period would be too restrictive and administratively burdensome. We requested public comments on the proposed clinical families. We also solicited public comments on whether any specific groups of hospitals should be excluded from our proposal to limit the expansion of excepted services, such as certain rural hospitals (for example, rural sole community hospitals), in light of recent reports of hospital closures in rural areas. In addition, we solicited public comments on alternate methodologies to limit the expansion of excepted services in excepted off-campus PBDs for CY 2019. Specifically, we invited public comments on the adoption and implementation of other methodologies, such as the approach recommended by MedPAC (discussed earlier in this section) in response to the CY 2017 and CY 2018 proposals whereby CMS would establish a baseline service volume for each applicable off-campus PBD, cap excepted services (regardless of clinical family) at that limit, and when the hospital reaches the annual cap for that location, additional services furnished by that off-campus PBD would no longer be considered covered OPD services and would instead be paid under the PFS (the annual cap could be updated based on the annual updates to the OPPS payment rates). Under such alternate approach, hospitals would need to report service volume for each offcampus PBD for the applicable period (such as November 1, 2014–November 1, 2015) and such applicable periods would be subject to audit. Comment: Some commenters, including an organization representing orthopaedic surgeons, commended CMS for its efforts to expand the application of site neutral payments to additional items and services in excepted offcampus PBDs. These commenters asserted that the expansion of services in excepted off-campus PBDs has an adverse effect on the control of unnecessary utilization of services in VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 PBDs. One commenter who supported the proposal stated that ‘‘all sites of service should provide the same service at the same cost’’ and that Medicare ‘‘should not be in the business of supporting or favoring more expensive sites of service, when the service can be furnished safely at a less expensive’’ and more efficient setting. Another commenter argued that the consolidation of these facilities effectively inhibits a physician’s ability to refer freely to the best specialists or most affordable health centers, and obstructs patients’ access to potentially better, more affordable care without their knowledge. One commenter, a pharmaceutical research and manufacturing organization, stated that this proposal ‘‘strikes a reasonable balance’’ in that the proposal would not limit PBDs to exactly the same services that they provided in the past, but would allow them to adjust their service-mix within relevant clinical families that reflect their specialties. The commenter contended that this provision would permit appropriate changes to the services excepted off-campus PBDs offer as clinical practices evolve. Additionally, the commenter stated that this policy proposal would prevent attempts to circumvent ‘‘the obvious intent of the law to reign in conversion of non-hospital entities into PBDs primarily in order to secure better payment, but without commensurate clinical benefit.’’ A few commenters stated that most off-campus PBDs are able to take advantage of higher payment rates for a wide variety of services. Specifically, the commenters asserted that, given the significant payment disparities for certain services (for example, based on OPPS rates versus PFS rates— chemotherapy: $281 versus $136; cardiac imaging: $2,078 versus $655; and colonoscopy: $1,383 versus $625), hospital systems have been purchasing physician practices and, by integrating them with excepted off-campus PBDs, secured OPPS payment rates for these services. Another commenter asserted that CMS is taking important steps to close loopholes that have enabled hospitals to continue driving volume of services through excepted off-campus PBDs. Moreover, the commenter noted that the current policy has caused ‘‘hundreds of hospitals that have already absorbed physician practices and converted them into PBDs . . . to enjoy an unfair reimbursement advantage’’ over other providers. The commenter further asserted that the proposal does not sufficiently limit the items and services PO 00000 Frm 00209 Fmt 4701 Sfmt 4700 59025 for which an excepted off-campus PBD can seek payment under the OPPS, and that the proposal would still allow a PBD to expand its services ‘‘no matter how limited the PBD’s range or volume of services were within that clinical family’’ during the baseline period. The commenter also expressed concern that CMS did not propose to limit the volume of excepted items and services within a clinical family of services that an excepted off-campus PBD can furnish, and indicated that, without such limitation, an excepted off-campus PBD has every incentive to grow the scope of its practice in order to maximize its ability to seek payment under the OPPS. Moreover, this commenter contended that CMS could require that ‘‘excepted’’ status be tied to those physicians and particular services that were in place at the off-campus PBD prior to November 2, 2015. In other words, an excepted off-campus PBD would not be able to seek payment under the OPPS with respect to: (1) Items or services furnished by a physician (as identified by National Provider Identifier) who did not furnish items or services at the off-campus PBD prior to November 2, 2015; or (2) any items or services that were not among the items or services for which the offcampus PBD billed Medicare at any point in the 12 months preceding November 2, 2015. Accordingly, the commenter urged CMS to modify the portion of the proposed rule that would enable excepted PBDs to bill under the OPPS for any and all items and services within the clinical families through which the excepted PBDs had furnished care during the 12 months prior to November 2, 2015, and to adopt, instead, a policy that would limit excepted off-campus PBDs to billing under the OPPS for those items and services furnished in a hospital’s outpatient department in the year prior to November 2, 2015, and within the specific, excepted PBD in 2016. Response: We thank the commenters for their support and for the many detailed comments on this topic. As mentioned in the proposed rule, we are concerned that if excepted off-campus PBDs can expand the types of services provided at the excepted off-campus PBDs and also be paid OPPS rates for these new types of services, hospitals may be able to purchase additional physician practices and add those physicians to existing excepted offcampus PBDs. This could result in newly purchased physician practices furnishing services that are paid at OPPS rates, which we believe the E:\FR\FM\21NOR2.SGM 21NOR2 khammond on DSK30JT082PROD with RULES2 59026 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations amendments to section 1833(t) of the Act are intended to prevent. However, while we continue to believe that section 1833(t)(21)(B)(ii) of the Act excepted off-campus PBDs as they existed at the time that Pub. L. 114–74 was enacted, and provides the authority to define excepted off-campus PBDs, including those items and services furnished and billed by such a PBD that may be paid under the OPPS, we are concerned that the implementation of this payment policy may pose operational challenges and administrative burden for both CMS and hospitals. After consideration of the public comments we received, we are not finalizing this policy as detailed below. Comment: A few commenters suggested that CMS revise the proposed clinical families to modify the proposed 19 clinical APC groups and services. We will continue to study issues related to the expansion of services at excepted off-campus PBDs and take these comments into consideration for future rulemaking. Response: We appreciate the feedback we received from the commenters. Comment: One commenter asserted that the proposed 12-month baseline period was not ‘‘necessary,’’ and suggested that a 6-month baseline period would adequately capture any service line initially intended for provision at a PBD. However, another commenter suggested that CMS extend the baseline period to 3 years prior to the enactment of the BBA of 2015, to ensure that all items and services provided by an excepted off-campus PBD prior to November 2, 2015 would be excepted from the proposed payment policy. Response: We thank the commenters for their feedback. We are not finalizing our proposed policy at this time. We intend to monitor the expansion of services in excepted off-campus PBDs. We may propose to adopt a limitation on the expansion of services in future rulemaking and will take this comment into consideration. Comment: The majority of commenters, including individual stakeholders and hospital systems and associations, opposed the proposal to limit the expansion of services in excepted off-campus PBDs. The commonly cited concerns among the commenters who opposed the proposed policy were as follows: Many commenters stated that the proposal is arbitrary and capricious, that CMS lacks statutory authority to pay new clinical families of service in excepted off-campus PBDs at the rate paid to nonexcepted PBDs, and that the VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 proposal would pose operational challenges and create administrative burden on hospitals. In addition, some commenters asserted that the requirements for provider-based status are designed to ‘‘ensure integration with the main hospital’’ and, accordingly, these facilities should be able to ‘‘furnish health care services of the same type as the main provider.’’ MedPAC expressed concern that CMS’ proposed approach to address the issue of undesirable incentives for excepted PBDs was unnecessarily complex. MedPAC believed that a better approach would be for CMS to determine how much the Medicare program had paid an off-campus PBD for items and services billed under the OPPS during a 12-month baseline period, specifically, CY 2017. Then, beginning January 1, 2019, annual program spending for items and services billed by the PBD under the OPPS would be capped at the amount paid to the PBD during the baseline period. However, MedPAC acknowledged that, for hospitals that have more than one excepted off-campus PBD, CMS would have to determine which claims to attribute to each excepted off-campus PBD. MedPAC believed that this approach would be easier to administer and would curb the ability of hospitals to benefit financially from purchasing freestanding physician practices and converting them to off-campus PBDs. Several commenters argued that offcampus PBDs must be able to expand the items and services that they offer in order to meet changes in clinical practice and the changing needs of their communities without losing their ability to be paid under the OPPS. Generally, these commenters asserted that finalizing this proposal would significantly discourage hospitals from offering new and enhanced outpatient services and, as a result, the payment policy would hinder beneficiary access to innovative technologies. Many commenters asserted that it is unclear how CMS or hospitals will determine what service families were being provided during the baseline period, given the lack of departmentspecific data and that provider-based attestations are voluntary. In addition, these commenters contended that, even if CMS and the providers could identify the clinical families of services furnished during the baseline period, it would be exceedingly complicated and burdensome to providers and CMS to ensure services belonging to a new clinical family for the PBD are accurately reported. Response: We appreciate the detailed comments that were submitted, and we PO 00000 Frm 00210 Fmt 4701 Sfmt 4700 recognize that services provided in offcampus PBDs may evolve to reflect changes in clinical practice and community health care needs. As discussed in the CY 2017 OPPS/ASC proposed rule and final rule with comment period (81 FR 45685 through 45686 and 81 FR 79706 through 79707), we believe section 1833(t)(21)(B)(ii) of the Act, as added by section 603 of Public Law 114–74, excepts off-campus provider-based departments and the items and services that are furnished by such excepted off-campus PBDs for purposes of paragraphs (1)(B)(v) and (21) of section 1833(t) of the Act as they were being furnished on the date of enactment of section 603 of Public Law 114–74, as guided by our regulatory definition of a department of a provider at § 413.65(a)(2). We also believe that we have the authority to define excepted items and services furnished and billed by excepted off-campus PBDs that may be paid under the OPPS. While we disagree with the commenters’ assertion that section 603 does not provide us the authority to adopt a policy that would limit OPPS payment to the type of services that had been furnished and billed at an off-campus PBD prior to enactment of Public Law 114–74, we are concerned that the implementation of this payment policy may be operationally complex and could create an administrative burden for hospitals. We believe the statute gives us the authority to limit the volume of services furnished to the level that was furnished prior to the date of enactment; however, we did not propose to do so. As we mentioned in the proposed rule and reiterated earlier in this section, we are concerned that if excepted off-campus PBDs could expand the types of services provided at the excepted off-campus PBDs and also be paid OPPS rates for these new types of services, hospitals may be able to purchase additional physician practices and add those physicians to existing excepted offcampus PBDs. Several commenters, including MedPAC, asserted that our proposed policy could be operationally complex and could create an administrative burden for hospitals, CMS, and CMS contractors to identify, track, and monitor billing for clinical services. We agree with these commenters regarding these concerns. Therefore, we are not finalizing our proposed policy. Comment: Some commenters, specifically hospital associations that opposed the proposal, asserted that CMS did not provide any claims-based or other supporting evidence that demonstrates that excepted off-campus PBDs are taking advantage of the current E:\FR\FM\21NOR2.SGM 21NOR2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations policy. Further, these commenters noted that many of the services listed in the detailed families of services are not payable in a physician office setting and can only be provided in a hospital setting. In addition, some of these commenters urged CMS to exempt rural sole community hospitals and other vulnerable facilities from the policy proposal. Response: We appreciate the commenters’ detailed responses to our proposal. We are collecting data on the claims billed by off-campus PBDs with modifier ‘‘PO’’ (for excepted services) and modifier ‘‘PN’’ (for nonexcepted services). We believe that data collected using these modifiers will be a useful tool in furthering our efforts to monitor the expansion of services at excepted off-campus PBDs and to address any issues as they may arise. We will continue to monitor claims data for changes in billing patterns and utilization and investigate methods to ensure all hospitals are treated as fairly as possible within the program. After consideration of the public comments we received, we are not finalizing this proposal at this time. However, we intend to monitor expansion of services in off-campus PBDs and, if appropriate, may propose to adopt a limitation on the expansion of excepted services in future rulemaking. In that event, we will consider the concerns expressed by commenters on the proposed policy in development of any future rulemaking on service line expansion. Therefore, an excepted off-campus PBD will continue to receive payments under the OPPS in CY 2019 for all billed items and services that are paid under the OPPS, regardless of whether it furnished such items and services prior to the date of enactment of Public Law 114–74, as long as the excepted off-campus PBD remains excepted, including meeting the relocation and change of ownership requirements adopted in the CY 2017 OPPS/ASC final rule with comment period if applicable (81 FR 79705 through 79706 and 79708 through 79709). As mentioned earlier in this section, we intend to monitor this issue and continue to consider how potential policies could address this issue. khammond on DSK30JT082PROD with RULES2 XI. CY 2019 OPPS Payment Status and Comment Indicators A. CY 2019 OPPS Payment Status Indicator Definitions Payment status indicators (SIs) that we assign to HCPCS codes and APCs serve an important role in determining payment for services under the OPPS. They indicate whether a service VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 represented by a HCPCS code is payable under the OPPS or another payment system, and also, whether particular OPPS policies apply to the code. In the CY 2019 OPPS/ASC proposed rule (83 FR 37150), for CY 2019, we did not propose to make any changes to the definitions of status indicators that were listed in Addendum D1 to the CY 2018 OPPS/ASC final rule with comment period available on the CMS website at: https://www.cms.gov/Medicare/ Medicare-Fee-for-Service-Payment/ HospitalOutpatientPPS/HospitalOutpatient-Regulations-and-NoticesItems/CMS-1656-FC.html? DLPage=1&DLEntries= 10&DLSort=2&DLSortDir=descending. Comment: One commenter recommended that CMS split status indicator ‘‘C’’ into ‘‘C1’’ and ‘‘C2’’ in the interest of improved clarity and transparency. The commenter noted this methodology is very similar to the way Medicare split status indicator ‘‘E’’ into indicators ‘‘E1’’ and ‘‘E2.’’ The commenter requested that CMS identify inpatient only (IPO) procedures that are on the separate procedure list (as determined by the American Medical Association) with a unique status indicator such as ‘‘C1’’ and others as ‘‘C2’’. The commenter believed that the presence of a unique status indicator would ultimately assist providers in ensuring that their claims processing system edits are set up to bill these scenarios on an OPPS claim to CMS, and that CMS would benefit by having more accurate claims data submitted. The commenter believed that this will also increase the number of claims available for capturing cost data and utilizing for future ratesetting. The commenter also requested that CMS reiterate that the I/OCE logic regarding IPO procedures that are classified as a separate procedure (for example, status indicator of ‘‘C1’’) is a line item rejection and does not cause the entire claim to be rejected. Response: We appreciate the commenter’s concerns. However, at this time, we do not believe it is necessary to establish a unique status indicator to identify IPO procedures that are on the separate procedures list. As stated in the latest October 2018 Integrated (IOCE) CMS Specifications V19.3 document, these procedures are bypassed when performed incidental to a surgical procedure with status indicator ‘‘T’’, or effective January 1, 2015, if reported on a claim with a comprehensive APC procedure (status indicator = ‘‘J1’’). The line(s) with the inpatient-separate procedure is/are rejected by the I/OCE with Edit 45 ‘‘Inpatient separate procedures not paid’’ and the claim is PO 00000 Frm 00211 Fmt 4701 Sfmt 4700 59027 processed per usual OPPS rules. Therefore, there is no need to split the definition of status indicator ‘‘C’’ and to establish a new status indicator ‘‘C1’’ as suggested by the commenter. As discussed previously, our status indicators exist for purposes of assisting in determining payment, and a single status indicator ‘‘C’’ is sufficient for services that CMS designates to be ‘‘inpatient only’’ services, regardless of whether or not they are on the separate procedure list. There are currently 26 different status indicators in Addendum D1 that are used to indicate whether a service described by a HCPCS code is payable under the OPPS or another payment system and whether particular OPPS payment policies apply to the code. We believe that it is important to maintain only status indicators in the OPPS that convey the necessary payment-related information, and that additional indicators should only be created when necessary for payment policy purposes. In regard to the comment related to the I/OCE, the latest October 2018 I/OCE CMS Specifications V19.3 document on the CMS website located at: https:// www.cms.gov/Medicare/Coding/ OutpatientCodeEdit/OCEQtrRelease Specs.html already contains the correct logic regarding IPO procedures that are classified as a separate procedures. After considering the comments received, we continue to believe that the existing definitions of the OPPS status indicators will be appropriate for CY 2019. Therefore, we are finalizing our proposed policy without modifications. The complete list of the payment status indicators and their definitions that will apply for CY 2019 is displayed in Addendum D1 to this final rule with comment period, which is available on the CMS website at: https:// www.cms.gov/Medicare/Medicare-Feefor-Service-Payment/ HospitalOutpatientPPS/. The CY 2019 payment status indicator assignments for APCs and HCPCS codes are shown in Addendum A and Addendum B, respectively, to this final rule with comment period, which are available on the CMS website at: https:// www.cms.gov/Medicare/Medicare-Feefor-Service-Payment/ HospitalOutpatientPPS/. B. CY 2019 Comment Indicator Definitions In the CY 2019 OPPS/ASC proposed rule (83 FR 37150), we proposed to use four comment indicators for the CY 2019 OPPS. These comment indicators, ‘‘CH’’, ‘‘NC’’, ‘‘NI’’, and ‘‘NP’’, are in effect for CY 2018 and we proposed to continue their use in CY 2019. The E:\FR\FM\21NOR2.SGM 21NOR2 59028 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations proposed CY 2019 OPPS comment indicators are as follows: • ‘‘CH’’—Active HCPCS code in current and next calendar year, status indicator and/or APC assignment has changed; or active HCPCS code that will be discontinued at the end of the current calendar year. • ‘‘NC’’—New code for the next calendar year or existing code with substantial revision to its code descriptor in the next calendar year, as compared to current calendar year for which we requested comments in the proposed rule, final APC assignment; comments will not be accepted on the final APC assignment for the new code. • ‘‘NI’’—New code for the next calendar year or existing code with substantial revision to its code descriptor in the next calendar year, as compared to current calendar year, interim APC assignment; comments will be accepted on the interim APC assignment for the new code. • ‘‘NP’’—New code for the next calendar year or existing code with substantial revision to its code descriptor in the next calendar year, as compared to current calendar year, proposed APC assignment; comments will be accepted on the proposed APC assignment for the new code. We did not receive any public comments regarding the proposed CY 2019 OPPS comment indicators. Therefore, we are adopting, as final, our proposal to continue to use for CY 2019 comment indicators ‘‘CH’’, ‘‘NI’’, ‘‘NP’’, and ‘‘NP’’. The definitions of the final OPPS comment indicators for CY 2019 are listed in Addendum D2 to this final rule with comment period, which is available on the CMS website at: https:// www.cms.gov/Medicare/Medicare-Feefor-Service-Payment/ HospitalOutpatientPPS/. XII. Updates to the Ambulatory Surgical Center (ASC) Payment System khammond on DSK30JT082PROD with RULES2 A. Background 1. Legislative History, Statutory Authority, and Prior Rulemaking for the ASC Payment System For a detailed discussion of the legislative history and statutory authority related to payments to ASCs under Medicare, we refer readers to the CY 2012 OPPS/ASC final rule with comment period (76 FR 74377 through 74378) and the June 12, 1998 proposed rule (63 FR 32291 through 32292). For a discussion of prior rulemaking on the ASC payment system, we refer readers to the CYs 2012, 2013, 2014, 2015, 2016, 2017 and 2018 OPPS/ASC final rules with comment period (76 FR 74378 through 74379; 77 FR 68434 through VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 68467; 78 FR 75064 through 75090; 79 FR 66915 through 66940; 80 FR 70474 through 70502; 81 FR 79732 through 79753; and 82 FR 59401 through 59424, respectively). 2. Policies Governing Changes to the Lists of Codes and Payment Rates for ASC Covered Surgical Procedures and Covered Ancillary Services Under 42 CFR 416.2 and 416.166 of the Medicare regulations, subject to certain exclusions, covered surgical procedures in an ASC are surgical procedures that are separately paid under the OPPS, that would not be expected to pose a significant risk to beneficiary safety when performed in an ASC, and for which standard medical practice dictates that the beneficiary would not typically be expected to require active medical monitoring and care at midnight following the procedure (‘‘overnight stay’’). We adopted this standard for defining which surgical procedures are covered under the ASC payment system as an indicator of the complexity of the procedure and its appropriateness for Medicare payment in ASCs. We use this standard only for purposes of evaluating procedures to determine whether or not they are appropriate to be furnished to Medicare beneficiaries in ASCs. We define surgical procedures as those described by Category I CPT codes in the surgical range from 10000 through 69999 as well as those Category III CPT codes and Level II HCPCS codes that directly crosswalk or are clinically similar to procedures in the CPT surgical range that we have determined do not pose a significant safety risk, that we would not expect to require an overnight stay when performed in ASCs, and that are separately paid under the OPPS (72 FR 42478). In the August 2, 2007 final rule (72 FR 42495), we also established our policy to make separate ASC payments for the following ancillary items and services when they are provided integral to ASC covered surgical procedures: (1) Brachytherapy sources; (2) certain implantable items that have passthrough payment status under the OPPS; (3) certain items and services that we designate as contractor-priced, including, but not limited to, procurement of corneal tissue; (4) certain drugs and biologicals for which separate payment is allowed under the OPPS; and (5) certain radiology services for which separate payment is allowed under the OPPS. In the CY 2015 OPPS/ ASC final rule with comment period (79 FR 66932 through 66934), we expanded the scope of ASC covered ancillary services to include certain diagnostic PO 00000 Frm 00212 Fmt 4701 Sfmt 4700 tests within the medicine range of CPT codes for which separate payment is allowed under the OPPS when they are provided integral to an ASC covered surgical procedure. Covered ancillary services are specified in § 416.164(b) and, as stated previously, are eligible for separate ASC payment. Payment for ancillary items and services that are not paid separately under the ASC payment system is packaged into the ASC payment for the covered surgical procedure. We update the lists of, and payment rates for, covered surgical procedures and covered ancillary services in ASCs in conjunction with the annual proposed and final rulemaking process to update the OPPS and the ASC payment system (§ 416.173; 72 FR 42535). We base ASC payment and policies for most covered surgical procedures, drugs, biologicals, and certain other covered ancillary services on the OPPS payment policies, and we use quarterly change requests (CRs) to update services covered under the OPPS. We also provide quarterly update CRs for ASC covered surgical procedures and covered ancillary services throughout the year (January, April, July, and October). We release new and revised Level II HCPCS codes and recognize the release of new and revised CPT codes by the AMA and make these codes effective (that is, the codes are recognized on Medicare claims) via these ASC quarterly update CRs. We recognize the release of new and revised Category III CPT codes in the July and January CRs. These updates implement newly created and revised Level II HCPCS and Category III CPT codes for ASC payments and update the payment rates for separately paid drugs and biologicals based on the most recently submitted ASP data. New and revised Category I CPT codes, except vaccine codes, are released only once a year, and are implemented only through the January quarterly CR update. New and revised Category I CPT vaccine codes are released twice a year and are implemented through the January and July quarterly CR updates. We refer readers to Table 41 in the CY 2012 OPPS/ASC proposed rule for an example of how this process, which we finalized in the CY 2012 OPPS/ASC final rule with comment period, is used to update HCPCS and CPT codes (76 FR 42291; 76 FR 74380 through 74381). In our annual updates to the ASC list of, and payment rates for, covered surgical procedures and covered ancillary services, we undertake a review of excluded surgical procedures (including all procedures newly proposed for removal from the OPPS E:\FR\FM\21NOR2.SGM 21NOR2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations khammond on DSK30JT082PROD with RULES2 inpatient list), new codes, and codes with revised descriptors, to identify any that we believe meet the criteria for designation as ASC covered surgical procedures or covered ancillary services. Updating the lists of ASC covered surgical procedures and covered ancillary services, as well as their payment rates, in association with the annual OPPS rulemaking cycle is particularly important because the OPPS relative payment weights and, in some cases, payment rates, are used as the basis for the payment of many covered surgical procedures and covered ancillary services under the revised ASC payment system. This joint update process ensures that the ASC updates occur in a regular, predictable, and timely manner. 3. Definition of ASC Covered Surgical Procedures Since the implementation of the ASC prospective payment system, we have defined a ‘‘surgical’’ procedure under the payment system as any procedure described within the range of Category I CPT codes that the CPT Editorial Panel of the American Medical Association (AMA) defines as ‘‘surgery’’ (CPT codes 10000 through 69999) (72 FR 42478). We also have included as ‘‘surgical,’’ procedures that are described by Level II HCPCS codes or by Category III CPT codes that directly crosswalk or are clinically similar to procedures in the CPT surgical range that we have determined do not pose a significant safety risk, would not expect to require an overnight stay when performed in an ASC, and are separately paid under the OPPS (72 FR 42478). As we noted in the CY 2008 final rule that implemented the revised ASC payment system, using this definition of surgery would exclude from ASC payment certain invasive, ‘‘surgery-like’’ procedures, such as cardiac catheterization or certain radiation treatment services that are assigned codes outside the CPT surgical range (72 FR 42477). We stated in that final rule that we believed continuing to rely on the CPT definition of surgery is administratively straightforward, is logically related to the categorization of services by physician experts who both establish the codes and perform the procedures, and is consistent with a policy to allow ASC payment for all outpatient surgical procedures (72 FR 42477). In the CY 2018 OPPS/ASC final rule with comment period (82 FR 59402 through 59403), we noted that some stakeholders have suggested that certain procedures that are outside the CPT surgical range but that are similar to VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 surgical procedures currently covered in an ASC setting should be ASC covered surgical procedures. For example, some stakeholders have recommended adding certain cardiovascular procedures to the ASC Covered Procedures List (CPL) due to their similarity to currently covered peripheral endovascular procedures in the surgical code range for surgery and the cardiovascular system. Further, stakeholders also noted that the AMA’s CPT code manual states that the listing of a procedure in a specific section of the book may reflect historical or other considerations and should not be interpreted as strictly classifying the procedure as ‘‘surgery’’ or ‘‘not surgery’’ for insurance purposes. As the CPT codebook states: ‘‘It is equally important to recognize that as techniques in medicine and surgery have evolved, new types of services, including minimally invasive surgery, as well as endovascular, percutaneous, and endoscopic interventions have challenged the traditional distinction of Surgery vs Medicine. Thus, the listing of a service or procedure in a specific section of this book should not be interpreted as strictly classifying the service or procedure as ‘surgery’ or ‘not surgery’ for insurance or other purposes. The placement of a given service in a specific section of the book may reflect historical or other considerations (e.g., placement of the percutaneous peripheral vascular endovascular interventions in the Surgery/ Cardiovascular System section, while the percutaneous coronary interventions appear in the Medicine/Cardiovascular section)’’ (emphasis added) (CPT® 2018 Professional Edition, ‘‘Instructions for Use of the CPT Code Book,’’ page xii.). While we continue to believe that using the CPT code range to define surgery represents a logical, appropriate, and straightforward approach to defining a surgical procedure, we also believe it may be appropriate for us to use the CPT surgical range as a guide rather than a strict determinant as to whether a procedure is surgical, which would give us more flexibility to include ‘‘surgery-like’’ procedures on the ASC CPL. We also are cognizant of the dynamic nature of ambulatory surgery and the continued shift of services from the inpatient setting to the outpatient setting over the past decade. In the CY 2018 OPPS/ASC final rule with comment period (82 FR 59402 through 59403), we responded to public comments that we had solicited regarding services that are described by Category I CPT codes outside of the surgical range, or Level II HCPCS codes PO 00000 Frm 00213 Fmt 4701 Sfmt 4700 59029 or Category III CPT codes that do not directly crosswalk and are not clinically similar to procedures in the CPT surgical range, but that nonetheless may be appropriate to include as covered surgical procedures that are payable when furnished in the ASC setting. Commenters offered mixed views of changing the current definition of surgery; however, most commenters were supportive of changing the definition. Some commenters recommended broadening the definition of surgery to include procedures not described by the CPT surgical range. Another commenter recommended making all surgical codes payable in a hospital outpatient department payable in an ASC and further suggested that CMS at least redefine surgical procedures to include invasive procedures such as percutaneous transluminal angioplasty and cardiac catheterization. One commenter recommended using a definition of surgery developed by the AMA Specialty Society Relative Value Scale Update Society for use in the agency’s Physician Fee Schedule (PFS) professional liability insurance relative values. In calculating the professional liability insurance relative values, certain cardiology codes outside the CPT surgical range are considered surgical codes for both the calculation and assignment of the surgery-specific malpractice risk factors. However, we note that the distinction between ‘‘surgical’’ and ‘‘nonsurgical’’ codes developed by the AMA Specialty Society Relative Value Scale Update Society is used by CMS to calculate professional liability risk factors and not necessarily to define surgery. The codes considered surgeries by the AMA Society Relative Value Scale Update Society were most recently displayed on the CMS website for the CY 2018 Medicare Physician Fee Schedule final rule under the file ‘‘Invasive Cardiology Services Outside of Surgical HCPCS Code Range Considered Surgery.’’ We refer readers to that file, which is available on the CMS website at: https:// www.cms.gov/Medicare/Medicare-Feefor-Service-Payment/ PhysicianFeeSched/Downloads/ CY2018-PFS-FR-InvasiveCardiology.zip. In the CY 2019 OPPS/ASC proposed rule (83 FR 37152), after further consideration of comments we received in response to the CY 2018 OPPS/ASC final rule with comment period, we proposed to revise our definition of ‘‘surgery’’ for CY 2019 to account for ‘‘surgery-like’’ procedures that are assigned codes outside the CPT surgical range (10000 through 69999). We E:\FR\FM\21NOR2.SGM 21NOR2 khammond on DSK30JT082PROD with RULES2 59030 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations believe it is appropriate to expand our definition of covered surgical procedures to include Category I CPT codes that are not in the Category I CPT surgical range but that directly crosswalk or are clinically similar to procedures in the Category I CPT code surgical range because, as commenters have noted, the CPT Codebook’s classification of certain procedures as ‘‘surgical’’ should not be considered dispositive of whether a procedure is or is not surgery. We also believe that considering these codes for potential inclusion on the covered surgical procedures list is consistent with our policy for Level II HCPCS codes and Category III CPT codes. For CY 2019, we proposed that these newly eligible ‘‘surgery-like’’ procedures are procedures that are described by Category I CPT codes that are not in the surgical range but, like procedures described by Level II HCPCS codes or by Category III CPT codes under our current policy, directly crosswalk or are clinically similar to procedures in the Category I CPT surgical range. These Category I CPT codes would be limited to those that we have determined do not pose a significant safety risk, would not be expected to require an overnight stay when performed in an ASC, and are separately paid under the OPPS. We invited comments on our proposal to revise the definition of surgery for the ASC prospective payment system. We also solicited comments on whether we should expand our definition of ‘‘surgery’’ to include procedures that fall outside the CPT surgical range, but fall within the definition of ‘‘surgery’’ developed by the AMA Specialty Society Relative Value Scale Update Society for use in the agency’s Physician Fee Schedule (PFS) professional liability insurance relative values, that we determine do not pose a significant safety risk, would not be expected to require an overnight stay when performed in an ASC, and are separately paid under the OPPS. Comment: A majority of commenters supported the proposal, stating that the expansion of the definition of surgery would allow Medicare beneficiaries access to these procedures at a safe, lower-priced and more convenient site of service. One commenter expressed general concern about the proposal to revise the definition of surgery, citing ‘‘surgery-like’’ procedures that might expose Medicare beneficiaries to a significant safety risk when performed in an ASC. Response: We appreciate commenters’ support. As we stated in the CY 2019 OPPS/ASC proposed rule (83 FR 37152), VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 we are cognizant of the dynamic nature of ambulatory surgery and the continued shift of services from the inpatient setting to the outpatient setting over the past decade. We also noted that the AMA’s CPT code manual states that the listing of a procedure in a specific section of the book may reflect historical or other considerations and should not be interpreted as strictly classifying the procedure as ‘‘surgery’’ or ‘‘not surgery’’ for insurance or other purposes. With respect to the commenter’s concern that this proposal may expose beneficiaries to significant safety risk, we note that any procedure added to the ASC CPL is evaluated against the existing regulatory criteria and would not be expected pose a significant safety risk, would not be expected to require an overnight stay when performed in an ASC, and is separately paid under the OPPS. In addition, we expect that physicians treating beneficiaries are well-equipped to decide whether the ASC setting would be appropriate based on the clinical needs of the patient, among other factors. Therefore, we do not share the commenter’s concern. Comment: One commenter asked CMS to clarify if it bases its determination of whether a procedure is an ASC covered surgical procedure on the fact that the procedure does not require an ‘‘overnight’’ stay or the fact that the procedure requires less than 24 hours of active medical care following the procedure. Response: As codified in our regulations at 42 CFR 416.166(b), covered surgical procedures are surgical procedures for which, among other things, standard medical practice dictates that the beneficiary would not typically be expected to require active medical monitoring and care at midnight following the procedure. In the CY 2019 OPPS/ASC proposed rule (83 FR 37151), we explained this requirement by stating that we would not expect a covered surgical procedure to require an overnight stay when performed in the ASC. Also in the CY 2019 OPPS/ASC proposed rule, we explained that we adopted this standard for defining which surgical procedures are covered surgical procedures under the ASC payment system as an indicator of the complexity of the procedure and its appropriateness for Medicare payment in ASCs (83 FR 37151). We use this standard only for purposes of evaluating procedures to determine whether or not they are appropriate for Medicare beneficiaries in ASCs. After consideration of the public comments we received, we are finalizing our proposal to define a PO 00000 Frm 00214 Fmt 4701 Sfmt 4700 surgical procedure under the ASC payment system as any procedure described within the range of Category I CPT codes that the CPT Editorial Panel of the American Medical Association (AMA) defines as ‘‘surgery’’ (CPT codes 10000 through 69999) (72 FR 42478), as well as procedures that are described by Level II HCPCS codes or by Category I CPT codes or by Category III CPT codes that directly crosswalk or are clinically similar to procedures in the CPT surgical range that we have determined are not expected to pose a significant risk to beneficiary safety when performed in an ASC, for which standard medical practice dictates that the beneficiary would not typically be expected to require an overnight stay following the procedure, and are separately paid under the OPPS. B. Treatment of New and Revised Codes 1. Background on Current Process for Recognizing New and Revised Category I and Category III CPT Codes and Level II HCPCS Codes Category I CPT, Category III CPT, and Level II HCPCS codes are used to report procedures, services, items, and supplies under the ASC payment system. Specifically, we recognize the following codes on ASC claims: • Category I CPT codes, which describe surgical procedures and vaccine codes; • Category III CPT codes, which describe new and emerging technologies, services, and procedures; and • Level II HCPCS codes, which are used primarily to identify items, supplies, temporary procedures, and services not described by CPT codes. We finalized a policy in the August 2, 2007 final rule (72 FR 42533 through 42535) to evaluate each year all new and revised Category I and Category III CPT codes and Level II HCPCS codes that describe surgical procedures, and to make preliminary determinations during the annual OPPS/ASC rulemaking process regarding whether or not they meet the criteria for payment in the ASC setting as covered surgical procedures and, if so, whether or not they are office-based procedures. In addition, we identify new and revised codes as ASC covered ancillary services based upon the final payment policies of the revised ASC payment system. In prior rulemakings, we refer to this process as recognizing new codes. However, this process has always involved the recognition of new and revised codes. We consider revised codes to be new when they have substantial revision to their code E:\FR\FM\21NOR2.SGM 21NOR2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations khammond on DSK30JT082PROD with RULES2 In the CY 2019 OPPS/ASC proposed rule (83 FR 37152 through 37155), we separated our discussion based on when the codes were released and whether we were soliciting public comments in the proposed rule (and responding to those comments in this CY 2019 OPPS/ASC final rule with comment period) or whether we would be soliciting public comments in this CY 2019 OPPS/ASC final rule with comment period (and responding to those comments in the CY VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 2020 OPPS/ASC final rule with comment period). We note that we sought public comments in the CY 2018 OPPS/ASC final rule with comment period (82 FR 59405 through 59406) on the new and revised Level II HCPCS codes effective October 1, 2017 or January 1, 2018. These new and revised codes, with an effective date of October 1, 2017 or January 1, 2018, were flagged with comment indicator ‘‘NI’’ in Addenda AA and BB to the CY 2018 OPPS/ASC final rule with comment period to indicate that we were assigning them an interim payment status and payment rate, if applicable, which were subject to public comment following publication PO 00000 Frm 00215 Fmt 4701 Sfmt 4725 of the CY 2018 OPPS/ASC final rule with comment period. In the CY 2019 OPPS/ASC proposed rule, we stated that we will respond to public comments and finalize the treatment of these codes under the ASC payment system in this CY 2019 OPPS/ASC final rule with comment period. As we did in Table 33 of the CY 2019 OPPS/ASC proposed rule (83 FR 37153), in Table 52 below, we summarize our process for updating codes through our ASC quarterly update CRs, seeking public comments, and finalizing the treatment of these new codes under the OPPS. BILLING CODE 4120–01–P E:\FR\FM\21NOR2.SGM 21NOR2 ER21NO18.078</GPH> descriptors that necessitate a change in the current ASC payment indicator. To clarify, we referred to these codes as new and revised in the CY 2018 OPPS/ ASC proposed rule. 59031 59032 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations 2. Treatment of New and Revised Level II HCPCS Codes Implemented in April 2018 for Which We Solicited Public Comments in the CY 2019 OPPS/ASC Proposed Rule khammond on DSK30JT082PROD with RULES2 As discussed in the CY 2019 OPPS/ ASC proposed rule (83 FR 37153), in the April 2018 ASC quarterly update (Transmittal 3996, Change Request 10530, dated March 09, 2018), we added nine new Level II HCPCS codes to the ASC CPL and list of covered ancillary services. Table 34 of the proposed rule (83 FR 37153) listed the new Level II HCPCS codes that were implemented April 1, 2018, along with their proposed payment indicators for CY 2019. We invited public comments on these proposed payment indicators and the proposed payment rates for the new Level II HCPCS codes that were recognized as ASC covered surgical procedures or ancillary services in April 2018 through the quarterly update CRs, as listed in Table 34 of the proposed rule. We proposed to finalize their payment indicators and their payment rates in this CY 2019 OPPS/ASC final rule with comment period. Comment: Several commenters supported the addition of HCPCS code C9749 (Repair of nasal vestibular lateral wall stenosis with implant(s)), which describes the Latera implant surgical procedure, to the ASC covered surgical procedures list and its designation as a device-intensive procedure. However, VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 they expressed concern that the proposed ASC payment rate for the procedure does not sufficiently cover the full cost of providing the surgery. One commenter stated that the proposed ASC payment rate of approximately $1,271 does not cover the cost of the device implant, let alone the full cost of the procedure including the device. These commenters believed that the low payment rate would hinder physicians from offering the procedure in ASCs. The commenters requested that CMS review the payment rate and adjust it appropriately so that physicians can continue to perform this procedure safely and effectively in the ASC setting. Response: The OPPS and the ASC payment system utilize different conversion factors to establish payment rates for covered services to account for changes in expenditures. In the CY 2019 OPPS/ASC proposed rule, we stated that the proposed OPPS conversion factor was $79.546, while the proposed ASC conversion factor was $46.500. Consequently, the proposed ASC payment rate of approximately $1,271 for HCPCS code C9749 would be less than the proposed OPPS payment rate of approximately $2,241. We have used different conversion factor updates for the OPPS and the ASC payment system since the revised ASC payment system was implemented on January 1, 2008. For more information regarding the payment methodology for ASC services, PO 00000 Frm 00216 Fmt 4701 Sfmt 4700 we refer readers to section XII.G. (Calculation of the ASC Payment Rates and the ASC Conversion Factor) of this CY 2019 OPPS/ASC final rule with comment period. Further, we also note that HCPCS code C9749 has been assigned a payment indicator of ‘‘J8’’ and is therefore designated as a deviceintensive procedure. As discussed in section XII.C.1.b. of this final rule with comment period, under the ASC payment system, device-intensive procedures are paid a higher payment than if the procedure was not designated as device-intensive. After consideration of the public comments we received, we are adopting as final the CY 2019 proposed payment indicators for new level II HCPCS codes for covered surgical procedures and ancillary services effective on April 1, 2018, as indicated in Table 53. We note that several of the HCPCS C-codes have been replaced with HCPCS J-codes, effective January 1, 2019. The replacement codes are listed in Table 53. The final payment rates for these codes can be found in Addendum BB to this final rule with comment period (which is available via the internet on the CMS website). In addition, the payment indicator definitions can be found in Addendum DD1 to this final rule with comment period (which is available via the internet on the CMS website). E:\FR\FM\21NOR2.SGM 21NOR2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations khammond on DSK30JT082PROD with RULES2 As discussed in the CY 2019 OPPS/ ASC proposed rule (83 FR 37154), in the July 2018 ASC quarterly update (Transmittal 4076, Change Request 10788, dated June 26, 2018), we added eight new Level II HCPCS codes to the list of covered ancillary services. In Table 35 of the proposed rule (83 FR 37154), we listed the new HCPCS codes that are effective July 1, 2018. In addition, through the July 2018 quarterly update CR, we also implemented one new Category III CPT code as an ASC covered ancillary service effective July 1, 2018. This code VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 was listed in Table 36 of the proposed rule, along with its proposed payment indicator. The proposed payment rate for this new Category III CPT code was included in Addendum AA to the proposed rule (which is available via the internet on the CMS website). We invited public comments on these proposed payment indicators and the proposed payment rates for the new Category III CPT code and Level II HCPCS codes that were expected to be newly recognized as ASC covered surgical procedures or covered ancillary services in July 2018 through the quarterly update CRs, as listed in Tables 35 and 36 of the proposed rule. We proposed to finalize their payment indicators and their payment rates in the CY 2019 OPPS/ASC final rule with comment period. PO 00000 Frm 00217 Fmt 4701 Sfmt 4700 We did not receive any public comments regarding these proposed ASC payment indicators and payment rates. Therefore, we are adopting as final the CY 2019 proposed payment indicators for these codes, as indicated in Tables 54 and 55. We note that several of the HCPCS C-codes have been replaced with HCPCS J-codes, effective January 1, 2019. Their replacement codes are listed in Table 55. The final payment rates for these codes for CY 2019 can be found in Addendum BB to this final rule with comment period (which is available via the internet on the CMS website). In addition, the payment indicator definitions can be found in Addendum DD1 to this final rule with comment period (which is available via the internet on the CMS website). E:\FR\FM\21NOR2.SGM 21NOR2 ER21NO18.079</GPH> 3. Treatment of New and Revised Category III CPT and Level II HCPCS Codes Implemented in July 2018 for Which We Solicited Public Comments in the CY 2019 OPPS/ASC Proposed Rule 59033 khammond on DSK30JT082PROD with RULES2 BILLING CODE 4120–01–C 4. Process for New and Revised Level II HCPCS Codes That Will Be Effective October 1, 2018 and January 1, 2019 for Which We Are Soliciting Public Comments in This CY 2019 OPPS/ASC Final Rule With Comment Period As has been our practice in the past, we incorporate those new and revised Level II HCPCS codes that are effective January 1 in the final rule with comment period, thereby updating the OPPS and the ASC payment system for VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 the following calendar year. These codes are released to the public via the CMS HCPCS website, and also through the January OPPS quarterly update CRs. In the past, we also released new and revised Level II HCPCS codes that are effective October 1 through the October OPPS quarterly update CRs and incorporated these new codes in the final rule with comment period. In the CY 2019 OPPS/ASC proposed rule (83 FR 37154), for CY 2019, consistent with our established policy, we proposed that the Level II HCPCS PO 00000 Frm 00218 Fmt 4701 Sfmt 4700 codes that will be effective October 1, 2018 and January 1, 2019 would be flagged with comment indicator ‘‘NI’’ in Addendum B to the CY 2019 OPPS/ASC final rule with comment period to indicate that we have assigned the codes an interim OPPS payment status for CY 2019. We did not receive any public comments on our proposal. As we stated that we would do in the proposed rule, we are inviting public comments in this CY 2019 OPPS/ASC final rule with comment period on the interim status indicator and APC assignments, and E:\FR\FM\21NOR2.SGM 21NOR2 ER21NO18.081</GPH> Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations ER21NO18.080</GPH> 59034 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations khammond on DSK30JT082PROD with RULES2 payment rates for these codes that will be finalized in the CY 2020 OPPS/ASC final rule with comment period. 5. Process for Recognizing New and Revised Category I and Category III CPT Codes That Will Be Effective January 1, 2019 for Which We Are Soliciting Public Comments in This CY 2019 OPPS/ASC Final Rule With Comment Period We generally include the new and revised CPT codes that are effective January 1 of a calendar year in the proposed rule to request public comments on the ASC payment indicator assignments. In addition, these codes are assigned to comment indicator ‘‘NP’’ to indicate that the code is new for the next calendar year or the code is an existing code with substantial revision to its code descriptor in the next calendar year as compared to current calendar year and that comments will be accepted on the proposed payment indicator. There are no existing codes with substantial revision to the code descriptor effective January 1, 2019. However, we inadvertently omitted most of the new Category I and III CPT codes effective January 1, 2019 from ASC Addendum AA, BB, and EE to the CY 2019 OPPS/ ASC proposed rule. We did not omit eight new CPT codes that we proposed to designate as temporarily office based effective January 1, 2019. We refer readers to Table 39 of the proposed rule. Therefore, in addition to the Level II HCPCS codes that will be effective October 1, 2018, and January 1, 2019, we are flagging the new Category I and III CPT codes that will be effective January 1, 2019, that were omitted from the CY 2019 OPPS/ASC proposed rule, with comment indicator ‘‘NI’’ in ASC Addendum AA, BB, and EE to this CY 2019 OPPS/ASC final rule with comment period to indicate that we have assigned the codes an interim ASC payment indicator for CY 2019. We are inviting public comments on the interim ASC payment indicator assignments and payment rates for these codes that we intend to finalize in the CY 2020 OPPS/ ASC final rule with comment period. We note that we are finalizing the ASC payment indicators for the eight codes that we proposed to designate as temporarily office based effective January 1, 2019 because we previously sought comments on their ASC payment indicator assignment. Table 58 of this final rule with comment period contains the list of these eight codes and their final ASC payment indicators. Further, we remind readers that the CPT code descriptors that appear in ASC Addendum AA, BB, and EE are VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 short descriptors and do not fully describe the complete procedure, service, or item described by the CPT code. Therefore, we have included the 5-digit CPT codes and their long descriptors for the new CPT codes in Addendum O (which is available via the internet on the CMS website) so that the public can adequately comment on our interim ASC payment indicator assignments. In summary, we are soliciting public comments on the interim ASC payment indicators for the new Category I and III CPT codes that will be effective January 1, 2019, which we have assigned to ASC comment indicator ‘‘NI’’ in this CY 2019 OPPS/ASC final rule with comment period. We intend to finalize the interim ASC payment indicators in the CY 2020 OPPS/ASC final rule with comment period. The CPT codes are listed in ASC Addendum AA, BB, and EE with short descriptors only but we list them again in Addendum O with long descriptors. C. Update to the List of ASC Covered Surgical Procedures and Covered Ancillary Services 1. Covered Surgical Procedures a. Covered Surgical Procedures Designated as Office-Based (1) Background In the August 2, 2007 ASC final rule, we finalized our policy to designate as ‘‘office-based’’ those procedures that are added to the ASC CPL in CY 2008 or later years that we determine are performed predominantly (more than 50 percent of the time) in physicians’ offices based on consideration of the most recent available volume and utilization data for each individual procedure code and/or, if appropriate, the clinical characteristics, utilization, and volume of related codes. In that rule, we also finalized our policy to exempt all procedures on the CY 2007 ASC list from application of the officebased classification (72 FR 42512). The procedures that were added to the ASC CPL beginning in CY 2008 that we determined were office-based were identified in Addendum AA to that rule by payment indicator ‘‘P2’’ (Officebased surgical procedure added to ASC list in CY 2008 or later with MPFS nonfacility PE RVUs; payment based on OPPS relative payment weight); ‘‘P3’’ (Office-based surgical procedures added to ASC list in CY 2008 or later with MPFS nonfacility PE RVUs; payment based on MPFS nonfacility PE RVUs); or ‘‘R2’’ (Office-based surgical procedure added to ASC list in CY 2008 or later without MPFS nonfacility PE RVUs; payment based on OPPS relative PO 00000 Frm 00219 Fmt 4701 Sfmt 4700 59035 payment weight), depending on whether we estimated the procedure would be paid according to the standard ASC payment methodology based on its OPPS relative payment weight or at the MPFS nonfacility PE RVU-based amount. Consistent with our final policy to annually review and update the ASC CPL eligible for payment in ASCs, each year we identify covered surgical procedures as either temporarily officebased (these are new procedure codes with little or no utilization data that we have determined are clinically similar to other procedures that are permanently office-based), permanently office-based, or nonoffice-based, after taking into account updated volume and utilization data. (2) Changes for CY 2019 to Covered Surgical Procedures Designated as Office-Based In developing the CY 2019 OPPS/ASC proposed rule and this final rule with comment period, we followed our policy to annually review and update the covered surgical procedures for which ASC payment is made and to identify new procedures that may be appropriate for ASC payment, including their potential designation as officebased. We reviewed CY 2017 volume and utilization data and the clinical characteristics for all covered surgical procedures that are assigned payment indicator ‘‘G2’’ (Nonoffice-based surgical procedure added in CY 2008 or later; payment based on OPPS relative payment weight) in CY 2017, as well as for those procedures assigned one of the temporary office-based payment indicators, specifically ‘‘P2’’, ‘‘P3’’, or ‘‘R2’’ in the CY 2018 OPPS/ASC final rule with comment period (82 FR 59406 through 59408). As discussed in the CY 2019 OPPS/ ASC proposed rule (83 FR 37155 through 37157), our review of the CY 2017 volume and utilization data resulted in our identification of 4 covered surgical procedures that we believe meet the criteria for designation as office-based. The data indicate that these procedures are performed more than 50 percent of the time in physicians’ offices, and we believe that the services are of a level of complexity consistent with other procedures performed routinely in physicians’ offices. The CPT codes that we proposed to permanently designate as office-based for CY 2019 were listed in Table 37 of the proposed rule (83 FR 37156). Comment: Several commenters disagreed with the proposal to designate CPT codes 36902 (Intro cath dialysis circuit) and 36905 (Thrmbc/nfs dialysis E:\FR\FM\21NOR2.SGM 21NOR2 khammond on DSK30JT082PROD with RULES2 59036 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations circuit) as permanently office-based. Commenters suggested that a permanent office-based designation, and therefore a permanent payment rate of the lesser of the PFS nonfacility PE RVU-based or the OPPS relative weight amount, would pay too little to make it a viable option for ASCs to perform these vascular access services, which the commenters suggested is the optimal setting for receiving vascular access services. Commenters also suggested that a permanent office-based designation may inadvertently incentivize the migration of vascular access procedures to the more costly hospital setting. Further, commenters noted that vascular access procedure codes (CPT codes 36901 through 36909) became effective January 1, 2017, and were added to the ASC CPL for CY 2017. Because several of these procedures were not included on the ASC CPL prior to that time, commenters expressed concern that CMS is not likely to have data that accurately reflect the ASC utilization of the full suite of vascular access procedures until CY 2020 or later. Some commenters recommended that CMS delay the proposal to designate CPT codes 36902 and 36905 as officebased procedures. Other commenters recommended that CMS permanently exempt such CPT codes from officebased designations, similar to the existing exemptions from the policy governing payment for covered ancillary radiology services for certain nuclear medicine procedures (CPT codes 78000 through 78999) and those covered ancillary radiology services that use a contrast agent as codified under 42 CFR 416.171(d). Commenters believed that such an exemption is warranted because certain vascular access add-on procedures (that is, CPT codes 36907, 36908, and 36909) are often billed with CPT codes 36902 and 36905, which are separately payable under the PFS but are packaged under the OPPS and the ASC payment system. Therefore, the commenters stated, the ASC payment rate for an office-based vascular access procedure with a vascular access add-on procedure may be lower than would otherwise be paid under the PFS. Response: We appreciate the commenters’ feedback on our proposal. As noted in the proposed rule, we assign office-based designations when our data indicate that these procedures are performed more than 50 percent of the time in physicians’ offices, and we believe that the services are of a level of complexity consistent with other procedures performed routinely in physicians’ offices. We believe this is VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 the most appropriate approach to prevent creating a payment incentive to migrate lower complexity services on the ASC CPL from physicians’ offices to ASCs. In response to the comment recommending that we establish a permanent office-based designation exemption for vascular access procedures, we do not believe such an exemption is necessary at this time. However, we would like to study this issue further in future policy development. As stated in the CY 2011 OPPS/ASC final rule with comment period (75 FR 72050), we established an exemption to the policy governing payment for covered ancillary radiology services for certain nuclear medicine procedures (CPT codes 78000 through 78999) because the PFS nonfacility PE RVU amounts did not reflect the diagnostic radiopharmaceutical costs, which are paid separately under the MPFS. In addition, as stated in the CY 2012 OPPS/ASC final rule with comment period (76 FR 74429 through 74430), because the same issue exists for radiology procedures that use contrast agents (the contrast agent is packaged under the ASC payment system but is separately paid under the PFS), we exempted radiology services that use contrast agents from our policy governing payment for covered ancillary radiology services so that payment for these procedures will be based on the OPPS relative payment weight and will, therefore, include the cost for the contrast agent. We did not propose an equivalent exception for vascular access codes for CY 2019, and do not believe permanent exemption would be appropriate at this time. However, we intend to examine whether CPT codes 36902 and 36905 may be subject to circumstances similar to those that led to the exemptions for certain nuclear medicine procedures and radiology procedures that use contrast agents in future rulemaking. The most recent full year for which we have claims, volume, and utilization data is CY 2017. We believe these data are generally an appropriate source to inform our decisions regarding the predominant site of service for procedures. As stated in the CY 2010 OPPS/ASC final rule with comment period (74 FR 60605 through 60606), when we believe that the available data in our review process are inadequate to make a determination that a procedure should be office-based, we either make no change to the procedure’s payment status or make the change temporary and reevaluate our decision using data PO 00000 Frm 00220 Fmt 4701 Sfmt 4700 that become available for our next evaluation. We believe that it is appropriate to continue using our judgment regarding whether the volume of cases and the proportion of cases that are provided in the physicians’ office setting indicate that the procedures is an office-based procedure in addition to our medical advisors’ clinical judgments, utilization data for procedures that are closely related to the procedures being evaluated, and any other information that is available to us. While the currently available data for CPT codes 36902 and 36905 support our office-based designation proposal, we agree with the commenters that CY 2017 claims data may not be sufficiently adequate to capture the current volume and utilization for the ASC and physician office sites of service for CPT codes 36902 and 36905. Because we share commenters’ concerns that the available data may not be adequate to make a determination that these procedures should be office-based, we believe it is premature to assign officebased payment for these procedures at this time. Therefore, we are not designating CPT codes 36902 and 36905 as office-based procedures for CY 2019. We will reevaluate these procedures in our CY 2020 rulemaking period. For CY 2019, these procedures will retain their current payment indicator, ‘‘G2.’’ We did not receive any public comments related to our proposal to designate CPT codes 31573 (Laryngoscopy, flexible; with therapeutic injection(s) (e.g., chemodenervation agent or corticosteroid, injected percutaneous, transoral, or via endoscope channel), unilateral) and 36513 (Therapeutic apheresis; for platelets) as office-based procedures. Therefore, we are finalizing our proposal, without modification, to designate CPT codes 31573 and 36513 as permanently office-based procedures. However, in response to public comments we received, we are not finalizing our proposal to designate CPT codes 36902 and 36905 as office-based. CPT codes 36902 and 36905 will retain the same payment indicator, ‘‘G2’’, that the procedures were assigned in CY 2018. We intend to reevaluate these using the most recent available volume and utilization data procedures in our CY 2020 rulemaking period. The procedures we are designating as permanently office-based beginning in CY 2019 are listed in Table 56 below. BILLING CODE 4120–01–P E:\FR\FM\21NOR2.SGM 21NOR2 khammond on DSK30JT082PROD with RULES2 BILLING CODE 4120–01–C We also reviewed CY 2017 volume and utilization data and other information for 10 procedures designated as temporarily office-based in Tables 84 and 85 in the CY 2018 OPPS/ASC final rule with comment period (82 FR 59408). Of these 10 procedures, there were very few claims in our data and no claims data for 4 procedures described by CPT codes 38222, 65785, 67229, and 0402T. Consequently, we proposed to maintain the temporary office-based designations for these 4 CPT codes for CY 2019. We included codes for which we proposed to maintain the temporary office-based VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 designations for CY 2019 in Table 38 of the proposed rule which listed the covered surgical procedures we designated as temporary office-based in the CY 2018 OPPS/ASC final rule with comment period. The procedures for which the proposed office-based designations for CY 2019 are temporary also were indicated by asterisks in Addendum AA to the proposed rule (which is available via the internet on the CMS website). The volume and utilization data for 3 procedures that have a temporary officebased designation for CY 2018, described by CPT codes 36473 and 36901 and HCPCS code G0429, are PO 00000 Frm 00221 Fmt 4701 Sfmt 4700 59037 sufficient to indicate that these procedures are performed predominantly in physicians’ offices and, therefore, should be assigned an office-based payment indicator in CY 2019. Consequently, we proposed to designate these procedures as permanently office based and assign payment indicator ‘‘P2’’, ‘‘P3’’, ‘‘R2’’ to these covered surgical procedure codes in CY 2019. These procedures are displayed above in Table 56. The volume and utilization data for the remaining three procedures that have a temporary office-based designation for CY 2018, described by CPT codes 10030, 64461, and 64463, are sufficient E:\FR\FM\21NOR2.SGM 21NOR2 ER21NO18.082</GPH> Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations 59038 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations khammond on DSK30JT082PROD with RULES2 to indicate that these covered surgical procedures were not performed predominantly in physicians’ offices and, therefore, should be assigned nonoffice-based payment indicator ‘‘G2’’ in CY 2019. Comment: One commenter requested that CMS exempt CPT code 36901 from the office-based designation, similar to the existing office-based exemptions for certain nuclear medicine procedures (CPT codes 78000 through 78999) as well as ancillary radiology services that use a contrast agent as codified under 42 CFR 416.171(d). The commenter suggested that the payment volatility over the past several years would limit patient access to vascular access services in the ASC setting and encourage the migration of these services to the more expensive hospital setting. Response: We do not believe establishing an office-based exemption for CPT code 36901 is warranted. We note that the exceptions for certain nuclear medicine procedures and for ancillary radiology services that use a contrast agent are exceptions to our policy governing payment for covered ancillary radiology services, not exceptions to our office-based policy. In addition, as stated in the CY 2011 OPPS/ASC final rule with comment period (75 FR 72050), we established the exemption to our policy governing payment for covered ancillary radiology VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 services for certain nuclear medicine procedures (CPT codes 78000 through 78999) because the PFS nonfacility PE RVU amounts did not reflect the diagnostic radiopharmaceutical costs which are paid separately under the MPFS. In addition, as stated in the CY 2012 OPPS/ASC final rule with comment period (76 FR 74429 through 74430), because the same issue exists for radiology procedures that use contrast agents (the contrast agent is packaged under the ASC payment system but is separately paid under the MPFS), we also exempted radiology services that use contrast agents from this policy, so that payment for these procedures will be based on the OPPS relative payment weight which includes the cost for the contrast agent. Because its predecessor code was office-based, we have designated CPT code 36901 as office-based since it was established in CY 2017. As stated in the CY 2018 OPPS/ASC final rule with comment period (82 FR 59407), we reviewed the clinical characteristics, utilization, and volume of related codes and determined that the procedure described by CPT code 36901 would be predominantly performed in physician offices. However, because we did not have utilization data for this procedure, we made the office-based designation temporary rather than permanent for CY 2018. Our review of the CY 2017 volume and utilization data indicates PO 00000 Frm 00222 Fmt 4701 Sfmt 4700 that CPT code 36901 is performed 54 percent of the time in physicians’ offices. Our policy is to designate as office-based those procedures that are performed more than 50 percent of the time in physicians’ offices. We do not believe that there is a justification for exempting this procedure from officebased status for CY 2019. Therefore, we are designating CPT code 36901 as permanently office-based for CY 2019 as proposed. While we assigned CPT codes 10030, 64461, and 64463 payment indicators of ‘‘G2’’ (Non-office-based surgical procedure added in CY 2008 or later; payment based on OPPS relative payment weight) in Table 38 of the CY 2019 OPPS/ASC proposed rule, we inadvertently indicated in the preamble of the proposed rule that those were office-based procedures (83 FR 37156). We are not designating CPT codes 10030, 64461, and 64463 as office-based procedures for CY 2019 and are finalizing our payment indicator of ‘‘G2’’ for such procedures. We note that we did not receive any public comments on these codes. After consideration of the public comment we received, we are finalizing our proposal, with modification, to designate the procedures shown in Table 57 below as temporarily officebased for CY 2019. BILLING CODE 4120–01–P E:\FR\FM\21NOR2.SGM 21NOR2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 described by these new CPT codes, we proposed to make the office-based designation temporary rather than permanent, and stated that we will reevaluate the procedures when data become available. The procedures for which the proposed office-based designation for CY 2019 is temporary were indicated by asterisks in Addendum AA to the proposed rule (which is available via the internet on the CMS website). PO 00000 Frm 00223 Fmt 4701 Sfmt 4700 We did not receive any public comments on our proposal. Therefore, we are finalizing our proposal, without modification, to designate the procedures shown in Table 58 below as temporarily office-based. The procedures for which the office-based designation for CY 2019 is temporary are indicated by an asterisk in Addendum AA to this final rule with comment period (which is available via the internet on the CMS website). E:\FR\FM\21NOR2.SGM 21NOR2 ER21NO18.083</GPH> khammond on DSK30JT082PROD with RULES2 For CY 2019, we proposed to designate 8 new CY 2019 CPT codes for ASC covered surgical procedures as temporarily office-based, as displayed in Table 39 of the proposed rule. After reviewing the clinical characteristics, utilization, and volume of related procedure codes, we determined that the procedures described by the new CPT codes would be predominantly performed in physicians’ offices. However, because we had no utilization data for the procedures specifically 59039 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations BILLING CODE 4120–01–C b. ASC Covered Surgical Procedures To Be Designated as Device-Intensive khammond on DSK30JT082PROD with RULES2 (1) Background As discussed in the CY 2017 OPPS/ ASC final rule with comment period (81 FR 79739 through 79740), we implemented a payment methodology for calculating the ASC payment rates for covered surgical procedures that are designated as device-intensive. According to this ASC payment methodology, we apply the device offset percentage based on the standard OPPS APC ratesetting methodology (which does not include the C–APC methodology) to the OPPS national unadjusted payment to determine the device cost included in the OPPS VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 payment rate for a device-intensive ASC covered surgical procedure, which we then set as equal to the device portion of the national unadjusted ASC payment rate for the procedure. We calculate the service portion of the ASC payment for device-intensive procedures by applying the uniform ASC conversion factor to the service (non-device) portion of the OPPS relative payment weight for the device-intensive procedure. Finally, we sum the ASC device portion and ASC service portion to establish the full payment for the device-intensive procedure under the ASC payment system. We also finalized in the CY 2017 OPPS/ASC final rule that deviceintensive procedures will be subject to all of the payment policies applicable to PO 00000 Frm 00224 Fmt 4701 Sfmt 4700 procedures designated as an ASC device-intensive procedure under our established methodology, including our policies on no cost/full credit and partial credit devices and discontinued procedures. In addition, in the CY 2017 OPPS/ ASC final rule with comment period (81 FR 79739 through 79740), we adopted a policy for new HCPCS codes describing procedures involving the implantation of medical devices that do not yet have associated claims data, to designate these procedures as device-intensive with a default device offset set at 41 percent until claims data are available to establish the HCPCS code-level device offset for the procedures. This default device offset amount of 41 percent is not calculated from claims data; instead, it E:\FR\FM\21NOR2.SGM 21NOR2 ER21NO18.084</GPH> 59040 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations khammond on DSK30JT082PROD with RULES2 is applied as a default until claims data are available upon which to calculate an actual device offset for the new code. The purpose of applying the 41-percent default device offset to new codes that describe procedures that involve the implantation of medical devices would be to ensure ASC access for new procedures until claims data become available. However, in certain rare instances, for example, in the case of a very expensive implantable device, we indicated we might temporarily assign a higher offset percentage if warranted by additional information, such as pricing data from a device manufacturer. Once claims data are available for a new procedure involving the implantation of a medical device, the device-intensive designation is applied to the code if the HCPCS code device offset is greater than 40 percent, according to our policy of determining device-intensive status, by calculating the HCPCS code-level device offset. (2) Changes to List of ASC Covered Surgical Procedures Designated as Device-Intensive for CY 2019 In the CY 2019 OPPS/ASC proposed rule (83 FR 37158), we noted that, as discussed in section IV.B.2. of the proposed rule, for CY 2019 we proposed to modify our criteria for deviceintensive procedures to better capture costs for procedures with significant device costs. We proposed to allow procedures that involve surgically inserted or implanted, high-cost, singleuse devices to qualify as deviceintensive procedures. In addition, we proposed to modify our criteria to lower the device offset percentage threshold from 40 percent to 30 percent. Specifically, for CY 2019 and subsequent years, we proposed that device-intensive procedures would be subject to the following criteria: • All procedures must involve implantable devices assigned a CPT or HCPCS code; • The required devices (including single-use devices) must be surgically inserted or implanted; and • The device offset amount must be significant, which is defined as exceeding 30 percent of the procedure’s mean cost. Corresponding to this change in the cost criterion we proposed that the default device offset for new codes that describe procedures that involve the implantation of medical devices would be 31 percent beginning in CY 2019. For new codes describing procedures that are payable when furnished in an ASC involving the implantation of a medical device, we proposed that the default device offset would be applied in the same manner VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 as proposed in section IV.B.2. of the proposed rule. We proposed to amend § 416.171(b)(2) of the regulations to reflect these new device criteria. In addition, as also proposed in section IV.B.2. of the proposed rule, to further align the device-intensive policy with the criteria used for device passthrough status, we proposed to specify, for CY 2019 and subsequent years, that for purposes of satisfying the deviceintensive criteria, a device-intensive procedure must involve a device that: • Has received FDA marketing authorization, has received an FDA investigational device exemption (IDE) and has been classified as a Category B device by the FDA in accordance with 42 CFR 405.203 through 405.207 and 405.211 through 405.215, or meets another appropriate FDA exemption from premarket review; • Is an integral part of the service furnished; • Is used for one patient only; • Comes in contact with human tissue; • Is surgically implanted or inserted (either permanently or temporarily); and • Is not any of the following: (a) Equipment, an instrument, apparatus, implement, or item of this type for which depreciation and financing expenses are recovered as depreciable assets as defined in Chapter 1 of the Medicare Provider Reimbursement Manual (CMS Pub. 15– 1); or (b) A material or supply furnished incident to a service (for example, a suture, customized surgical kit, scalpel, or clip, other than a radiological site marker). Based on our proposed modifications to our device-intensive criteria, for CY 2019, we proposed to update the ASC CPL that are eligible for payment according to our proposed deviceintensive procedure payment methodology, reflecting the proposed individual HCPCS code device-offset percentages based on CY 2017 OPPS claims and cost report data available for the proposed rule. The ASC covered surgical procedures that we proposed to designate as deviceintensive, and therefore subject to the device-intensive procedure payment methodology for CY 2019, were assigned payment indicator ‘‘J8’’ and were included in ASC Addendum AA to the proposed rule (which is available on the CMS website). The CPT code, the CPT code short descriptor, and the proposed CY 2019 ASC payment indicator, and an indication of whether the full credit/partial credit (FB/FC) device adjustment policy would apply because the procedure is designated as PO 00000 Frm 00225 Fmt 4701 Sfmt 4700 59041 device intensive also are included in Addendum AA to the proposed rule. In addition, for CY 2019, we proposed to only apply our proposed deviceintensive procedure payment methodology to device-intensive procedures under the ASC payment system when the device-intensive procedure is furnished with a surgically inserted or implanted device (including single use medical devices). Under this proposal, the payment rate under the ASC payment system for deviceintensive procedures furnished without an implantable or inserted medical device would be calculated by applying the uniform ASC conversion factor to both the device portion and service (nondevice) portion of the OPPS relative payment weight for the device-intensive procedure and summing both portions (device and service) to establish the ASC payment rate. Comment: The majority of commenters supported the proposal to lower the device offset percentage threshold for procedures to qualify as device-intensive from greater than 40 percent to greater than 30 percent. The commenters believed that the proposed policy change will encourage migration of services into the high-quality, lessexpensive ASC setting, resulting in cost savings to the Medicare program and Medicare beneficiaries. Some of these commenters encouraged CMS to further modify its proposal and instead lower the device offset percentage threshold for procedures to qualify as deviceintensive to 25 percent instead of 30 percent. Response: We appreciate commenters’ support. At this time, we continue to believe that applying a device offset percentage threshold of greater than 30 percent for procedures to qualify as device-intensive is most appropriate for the reasons described in our original proposal. We will take commenters’ suggestion of applying a device offset percentage threshold of greater than 25 percent for procedures to qualify as device-intensive into consideration for future rulemaking. Comment: The majority of commenters supported CMS proposal to modify the device-intensive criteria to allow procedures that involve single-use devices, regardless of whether they remain in the body after the conclusion of the procedure, to qualify as deviceintensive procedures. The commenters believed that this proposed policy change will better support accurate payment for procedures where an implantable device is a significant proportion of total costs and, ultimately, will spur innovation. E:\FR\FM\21NOR2.SGM 21NOR2 khammond on DSK30JT082PROD with RULES2 59042 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations Response: We appreciate the commenters’ support. Comment: One commenter requested that CMS assign device-intensive status, payment indicator ‘‘J8’’, to CPT codes 0410T (Insertion or replacement of permanent cardiac contractility modulation system, including contractility evaluation when performed, and programming of sensing and therapeutic parameters; pulse generator only), 0411T (Insertion or replacement of permanent cardiac contractility modulation system, including contractility evaluation when performed, and programming of sensing and therapeutic parameters; ventricular electrode only), and 0414T (Removal and replacement of permanent cardiac contractility modulation system pulse generator only). Response: We agree with the commenter’s request and have assigned CPT codes 0410T, 0411T, and 0414T to payment indicator ‘‘J8’’ for CY 2019. These CPT codes represent procedures requiring the implantation of medical devices that do not yet have associated claims data and therefore have been granted device-intensive status with our current default device offset percentage of 31 percent, in accordance with our current policy outlined in the CY 2017 OPPS/ASC final rule with comment period (81 FR 79658). Comment: A few commenters suggested that CMS only adjust the nondevice portion of the payment by the wage index, consistent with the Agency’s policy for separately payable drugs and biologicals. Response: In response to the commenters’ suggestion that CMS only adjust the non-device portion of the payment by the wage index, we note that such a policy would increase payment for providers with a relatively low wage index (that is, a wage index value of less than 1) and decrease it for providers with a relatively high wage index (that is, a wage index value of greater than 1), and that we did not make such a proposal. However, we will take this comment into consideration for future rulemaking. Comment: A few commenters urged CMS to calculate the device offset percentage for potential deviceintensive procedures using the standard (non-comprehensive APC) ASC ratesetting methodology and to assign device-intensive status in the ASC system based on that device offset percentage because they believed it is more consistent with the overall ASC payment system. One commenter requested some clarification in the final rule with comment period about CMS’ current methodology for calculating the VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 device offset percentage for deviceintensive procedures and specifically asked that CMS: • Confirm that the ASC deviceintensive status as assigned by CMS is based on the offset calculated according to the ASC rate setting methodology; • Disclose what offset data (meaning the calculation methodology used) appears in the second spreadsheet of Addendum P titled ‘‘2019 NPRM HCPCS Offsets’’; • Display the device offsets, in future rulemaking, based on the ASC methodology and not the OPPS methodology if the offset data displayed in the second spreadsheet of Addendum P is based on the OPPS methodology and device-intensive status is based on the ASC methodology; and • Modify the second worksheet of Addendum P titled ‘‘2019 NPRM HCPCS Offsets’’ to only include the codes for procedures that employ implantable and insertable devices and exclude all of the irrelevant codes that do not employ implantable or insertable devices. Response: As stated in the CY 2019 OPPS/ASC proposed rule (83 FR 37158), according to our established ASC payment methodology, we apply the device offset percentage based on the standard OPPS APC ratesetting methodology (which does not include the C–APC methodology) to the OPPS national unadjusted payment to determine the device cost included in the OPPS payment rate for a deviceintensive ASC covered surgical procedure, which we then set as equal to the device portion of the national unadjusted ASC payment rate for the procedure. We calculate the service portion of the ASC payment for deviceintensive procedures by applying the uniform ASC conversion factor to the service (nondevice) portion of the OPPS relative payment weight for the deviceintensive procedure. Finally, we sum the ASC device portion and ASC service portion to establish the full payment for the device-intensive procedure under the ASC payment system. In response to commenter’s questions and suggestions relating to Addendum P, we note that the device offset percentages reflected in both worksheets of Addendum P are based upon the OPPS C–APC methodology. We believe this is appropriate as Addendum P is created to display the device offsets, device offset percentages, and deviceintensive codes under the OPPS. Specific to the commenter’s suggestion that we modify the second worksheet of Addendum P titled ‘‘2019 NPRM HCPCS Offsets’’ to only include the codes for procedures that employ PO 00000 Frm 00226 Fmt 4701 Sfmt 4700 implantable and insertable devices and exclude all of the codes that do not employ implantable or insertable devices, we note that the second worksheet of Addendum P is intended to display the device offsets and device offset percentages for all codes for which we have such data for under the OPPS. The applicable device offset percentages for the ASC payment system are included on the CMS website at: https://www.cms.gov/Medicare/ Medicare-Fee-for-Service-Payment/ ASCPayment/ASC-Policy-Files.html under the revised title of ‘‘CY 2019 Final ASC Device Offset Percentages and Procedures to which the No Cost/ Full Credit and Partial Credit Device Adjustment Policy Applies.’’ Comment: Commenters supported the existing policy of granting deviceintensive status and applying a default device offset to procedures requiring devices that do not yet have claims data, as well as the proposal to use claims data from clinically similar and related codes to establish device offsets for procedures with new codes that do not have direct predecessor codes according to CPT. Response: We appreciate the commenters’ support. Comment: Commenters supported CMS’ proposed device-intensive status for CPT codes: • 28297 (Correction, hallux valgus (bunionectomy), with sesamoidectomy, when performed; with first metatarsal and medial cuneiform joint arthrodesis, any method); • 28730 (Arthrodesis, midtarsal or tarsometatarsal, multiple or transverse;); • 28740 (Arthrodesis, midtarsal or tarsometatarsal, single joint); • 36903 (Introduction of needle(s) and/or catheter(s), dialysis circuit, with diagnostic angiography of the dialysis circuit, including all direct puncture(s) and catheter placement(s), injection(s) of contrast, all necessary imaging from the arterial anastomosis and adjacent artery through entire venous outflow including the inferior or superior vena cava, fluoroscopic guidance, radiological supervision and interpretation and image documentation and report; with transcatheter placement of intravascular stent(s), peripheral dialysis segment, including all imaging and radiological supervision and interpretation necessary to perform the stenting, and all angioplasty within the peripheral dialysis segment); • 36904 (Percutaneous transluminal mechanical thrombectomy and/or infusion for thrombolysis, dialysis circuit, any method, including all imaging and radiological supervision and interpretation, diagnostic E:\FR\FM\21NOR2.SGM 21NOR2 khammond on DSK30JT082PROD with RULES2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations angiography, fluoroscopic guidance, catheter placement(s), and intraprocedural pharmacological thrombolytic injection(s);); and • 36906 (Percutaneous transluminal mechanical thrombectomy and/or infusion for thrombolysis, dialysis circuit, any method, including all imaging and radiological supervision and interpretation, diagnostic angiography, fluoroscopic guidance, catheter placement(s), and intraprocedural pharmacological thrombolytic injection(s); with transcatheter placement of intravascular stent(s), peripheral dialysis segment, including all imaging and radiological supervision and interpretation necessary to perform the stenting, and all angioplasty within the peripheral dialysis circuit). Other commenters requested that CMS assign device-intensive status to— • HCPCS code C9747 (Ablation of prostate, transrectal, high intensity focused ultrasound (hifu), including imaging guidance); • CPT code 43210 (Esophagogastroduodenoscopy, flexible, transoral; with esophagogastric fundoplasty, partial or complete, includes duodenoscopy when performed), 0275T (Percutaneous laminotomy/laminectomy (interlaminar approach) for decompression of neural elements, (with or without ligamentous resection, discectomy, facetectomy and/ or foraminotomy), any method, under indirect image guidance (e.g., fluoroscopic, ct), single or multiple levels, unilateral or bilateral; lumbar); • CPT code 55874 (Transperineal placement of biodegradable material, peri-prostatic, single or multiple injection(s), including image guidance, when performed); • CPT code 0409T (Insertion or replacement of permanent cardiac contractility modulation system, including contractility evaluation when performed, and programming of sensing and therapeutic parameters; pulse generator only); • CPT code 0410T (Insertion or replacement of permanent cardiac contractility modulation system, including contractility evaluation when performed, and programming of sensing and therapeutic parameters; atrial electrode only); • CPT code 0411T (Insertion or replacement of permanent cardiac contractility modulation system, including contractility evaluation when performed, and programming of sensing and therapeutic parameters; ventricular electrode only); and • CPT code 0414T (Removal and replacement of permanent cardiac VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 contractility modulation system pulse generator only). Response: We appreciate the commenters’ support. With respect to the commenters’ request that we assign the device-intensive designation to HCPCS code C9747 and CPT codes 43210, 0275T, and 55874, we note that the device offset percentage for all four of these procedures (as identified by the above mentioned HCPCS codes or predecessor codes) is not above the 30percent threshold, and therefore these procedures are not eligible to be assigned device-intensive status. CPT codes 0409T, 0410T, 0411T, and 0414T were inadvertently omitted from the listing of proposed device-intensive procedures in the CY 2019 OPPS/ASC proposed rule. We are including them as device-intensive procedures in this final rule with comment period. CPT code 36904 was proposed as a deviceintensive procedure. However, using the most currently available data for this CY 2019 OPPS/ASC final rule with comment period, we determined that its device offset percentage is not above the 30-percent threshold, and therefore this procedure is not eligible to be assigned device-intensive status. For new codes describing procedures that are payable when furnished in an ASC involving the implantation of a medical device, we proposed that the default device offset would be applied in the same manner as proposed in section IV.B.2. of the proposed rule. In addition, as also discussed in section IV.B.2. of this final rule with comment period, to further align the device-intensive policy with the criteria used for device pass-through payment status, we are finalizing our proposal to specify, for CY 2019 and subsequent years, that for purposes of satisfying the device-intensive criteria, a deviceintensive procedure must involve a device that: • Has received FDA marketing authorization, has received an FDA investigational device exemption (IDE) and has been classified as a Category B device by the FDA in accordance with 42 CFR 405.203 through 405.207 and 405.211 through 405.215, or meets another appropriate FDA exemption from premarket review; • Is an integral part of the service furnished; • Is used for one patient only; • Comes in contact with human tissue; • Is surgically implanted or inserted (either permanently or temporarily); and • Is not any of the following: (a) Equipment, an instrument, apparatus, implement, or item of this type for which depreciation and PO 00000 Frm 00227 Fmt 4701 Sfmt 4700 59043 financing expenses are recovered as depreciable assets as defined in Chapter 1 of the Medicare Provider Reimbursement Manual (CMS Pub. 15– 1); or (b) A material or supply furnished incident to a service (for example, a suture, customized surgical kit, scalpel, or clip, other than a radiological site marker). In conjunction with our modifications to the device-intensive criteria, we are finalizing our proposal, without modification, to amend § 416.171(b)(2) of the regulations to reflect three new device criteria. After consideration of the public comments we received, we are finalizing our proposal to modify our criteria for device-intensive procedures to better capture costs for procedures with significant device costs. We are finalizing our proposal to allow procedures that involve surgically inserted or implanted, high-cost, singleuse devices to qualify as deviceintensive procedures. In addition, we are finalizing our proposal to modify our criteria to lower the device offset percentage threshold from 40 percent to 30 percent. Specifically, for CY 2019 and subsequent years, we are finalizing our proposal that device-intensive procedures would be subject to the following criteria: • All procedures must involve implantable devices assigned a CPT or HCPCS code; • The required devices (including single-use devices) must be surgically inserted or implanted; and • The device offset amount must be significant, which is defined as exceeding 30 percent of the procedure’s mean cost. Corresponding to this change in the cost criterion we proposed that the default device offset for new codes that describe procedures that involve the implantation of medical devices would be 31 percent beginning in CY 2019. Further, after consideration of the public comments we received, we are designating the ASC covered surgical procedures displayed in Addendum AA as device-intensive and subject to the device-intensive procedure payment methodology for CY 2019. c. Adjustment to ASC Payments for No Cost/Full Credit and Partial Credit Devices Our ASC payment policy for costly devices implanted in ASCs at no cost/ full credit or partial credit, as set forth in § 416.179 of our regulations, is consistent with the OPPS policy that was in effect until CY 2014. Specifically, the OPPS policy that was E:\FR\FM\21NOR2.SGM 21NOR2 khammond on DSK30JT082PROD with RULES2 59044 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations in effect through CY 2013 provided a reduction in OPPS payment by 100 percent of the device offset amount when a hospital furnishes a specified device without cost or with a full credit and by 50 percent of the device offset amount when the hospital receives partial credit in the amount of 50 percent or more of the cost for the specified device (77 FR 68356 through 68358). The established ASC policy reduces payment to ASCs when a specified device is furnished without cost or with full credit or partial credit for the cost of the device for those ASC covered surgical procedures that are assigned to APCs under the OPPS to which this policy applies. We refer readers to the CY 2009 OPPS/ASC final rule with comment period (73 FR 68742 through 68744) for a full discussion of the ASC payment adjustment policy for no cost/full credit and partial credit devices. In the CY 2019 OPPS/ASC proposed rule (83 FR 37159), we noted that, as discussed in section IV.B. of the CY 2014 OPPS/ASC final rule with comment period (78 FR 75005 through 75006), we finalized our proposal to modify our former policy of reducing OPPS payment for specified APCs when a hospital furnishes a specified device without cost or with a full or partial credit. Formerly, under the OPPS, our policy was to reduce OPPS payment by 100 percent of the device offset amount when a hospital furnished a specified device without cost or with a full credit and by 50 percent of the device offset amount when the hospital received partial credit in the amount of 50 percent or more (but less than 100 percent) of the cost for the specified device. For CY 2014, we finalized our proposal to reduce OPPS payment for applicable APCs by the full or partial credit a provider receives for a replaced device, capped at the device offset amount. Although we finalized our proposal to modify the policy of reducing payments when a hospital furnishes a specified device without cost or with full or partial credit under the OPPS, in that final rule with comment period (78 FR 75076 through 75080), we finalized our proposal to maintain our ASC policy for reducing payments to ASCs for specified device-intensive procedures when the ASC furnishes a device without cost or with full or partial credit. Unlike the OPPS, there is currently no mechanism within the ASC claims processing system for ASCs to submit to CMS the actual credit received when furnishing a specified device at full or partial credit. Therefore, under the ASC payment VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 system, we finalized our proposal for CY 2014 to continue to reduce ASC payments by 100 percent or 50 percent of the device offset amount when an ASC furnishes a device without cost or with full or partial credit, respectively. All ASC covered device-intensive procedures are subject to the no cost/ full credit and partial credit device adjustment policy. Specifically, when a device-intensive procedure is performed to implant a device that is furnished at no cost or with full credit from the manufacturer, the ASC would append the HCPCS ‘‘FB’’ modifier on the line in the claim with the procedure to implant the device. The contractor would reduce payment to the ASC by the device offset amount that we estimate represents the cost of the device when the necessary device is furnished without cost or with full credit to the ASC. We continue to believe that the reduction of ASC payment in these circumstances is necessary to pay appropriately for the covered surgical procedure furnished by the ASC. In the CY 2019 OPPS/ASC proposed rule (83 FR 37159 through 37160), for partial credit, we proposed to reduce the payment for a device-intensive procedure for which the ASC receives partial credit by one-half of the device offset amount that would be applied if a device was provided at no cost or with full credit, if the credit to the ASC is 50 percent or more (but less than 100 percent) of the cost of the new device. The ASC would append the HCPCS ‘‘FC’’ modifier to the HCPCS code for the device-intensive surgical procedure when the facility receives a partial credit of 50 percent or more (but less than 100 percent) of the cost of a device. To report that the ASC received a partial credit of 50 percent or more (but less than 100 percent) of the cost of a new device, ASCs would have the option of either: (1) Submitting the claim for the device replacement procedure to their Medicare contractor after the procedure’s performance, but prior to manufacturer acknowledgment of credit for the device, and subsequently contacting the contractor regarding a claim adjustment, once the credit determination is made; or (2) holding the claim for the device implantation procedure until a determination is made by the manufacturer on the partial credit and submitting the claim with the ‘‘FC’’ modifier appended to the implantation procedure HCPCS code if the partial credit is 50 percent or more (but less than 100 percent) of the cost of the replacement device. Beneficiary coinsurance would be based on the reduced payment amount. As finalized in the CY 2015 OPPS/ASC final rule PO 00000 Frm 00228 Fmt 4701 Sfmt 4700 with comment period (79 FR 66926), to ensure our policy covers any situation involving a device-intensive procedure where an ASC may receive a device at no cost or receive full credit or partial credit for the device, we apply our ‘‘FB’’/‘‘FC’’ modifier policy to all device-intensive procedures. We did not receive any public comment on these proposals. Therefore, we are finalizing these proposals without modification. Specifically, we will apply the HCPCS ‘‘FB’’/‘‘FC’’ modifier policy to all device-intensive procedures in CY 2019. For CY 2019, we will reduce the payment for the procedures in the ASC device adjustment file by the full device offset amount if a device is furnished without cost or with full credit. ASCs must append the HCPCS modifier ‘‘FB’’ to the HCPCS code for a surgical procedure listed in the ASC device adjustment file previously mentioned when the device is furnished without cost or with full credit. In addition, for CY 2019, we will reduce the payment for the procedures listed in the ASC device adjustment file by one-half of the device offset amount if a device is provided with partial credit, if the credit to the ASC is 50 percent or more (but less than 100 percent) of the device cost. The ASC must append the HCPCS ‘‘FC’’ modifier to the HCPCS code for a surgical procedure listed in the ASC device adjustment file when facility receives a partial credit of 50 percent or more (but less than 100 percent) of the cost of a device. The CPT code, the CPT code short descriptor, the final CY 2019 ASC payment indicator, and an indication of whether the full credit/partial credit (FB/FC) device adjustment policy will apply are included in the ASC policy file labeled ‘‘CY 2019 Final ASC Device Offset Percentages and Procedures to which the No Cost/Full Credit and Partial Credit Device Adjustment Policy Applies’’, which is available via the internet on the CMS website at: https:// www.cms.gov/Medicare?medicare-Feefor-Service-Payment/ASCPayment/ASCPolicy-Files.html. d. Additions to the List of ASC Covered Surgical Procedures As discussed in section XII.A.3. of the proposed rule (83 FR 37159), we proposed to revise our definition of surgery for CY 2019 to include certain ‘‘surgery-like’’ procedures that are assigned codes outside the CPT surgical range. For CY 2019, we proposed to include procedures that are described by Category I CPT codes that are not in the surgical range but directly crosswalk or are clinically similar to procedures in E:\FR\FM\21NOR2.SGM 21NOR2 khammond on DSK30JT082PROD with RULES2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations the Category I CPT code surgical range that we have determined do not pose a significant safety risk, would not be expected to require an overnight stay when performed in an ASC, and are separately paid under the OPPS. We also are continuing to include in our definition of surgical procedures those procedures described by Category I CPT codes in the surgical range from 10000 through 69999 as well as those Category III CPT codes and Level II HCPCS codes that directly crosswalk or are clinically similar to procedures in the CPT surgical range that we have determined do not pose a significant safety risk, that we would not expect to require an overnight stay when performed in ASCs, and that are separately paid under the OPPS. As discussed in section XII.A.3. of this final rule with comment period, we are finalizing our proposal to revise our definition of ‘‘surgery’’ for CY 2019 and subsequent years to include procedures that are described by Category I CPT codes that are not in the CPT surgical range but directly crosswalk or are clinically similar to procedures in the Category I CPT code surgical range that we have determined do not pose a significant safety risk, would not be expected to require an overnight stay when performed in an ASC, and are separately paid under the OPPS. We conducted a review of HCPCS codes that currently are paid under the OPPS, but not included on the ASC CPL, and that meet our proposed definition of surgery to determine if changes in technology and/or medical practice affected the clinical appropriateness of these procedures for the ASC setting. Based on this review, we proposed to update the list of ASC covered surgical procedures by adding 12 cardiac catheterization procedures to the list for CY 2019, as shown in Table 40 of the proposed rule (83 FR 37160). After reviewing the clinical characteristics of these procedures and consulting with stakeholders and our clinical advisors, we determined that these 12 procedures are separately paid under the OPPS, would not be expected to pose a significant risk to beneficiary safety when performed in an ASC, and would not be expected to require active medical monitoring and care of the beneficiary at midnight following the procedure. Our regulation at 42 CFR 416.166(c) lists general exclusions from the list of ASC covered surgical procedures based primarily on factors relating to safety, including procedures that generally result in extensive blood loss, require major or prolonged invasion of body cavities, or directly VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 involve major blood vessels. We have assessed each of the proposed added procedures against the regulatory safety criteria and believe that these procedures meet each of the criteria. Although the proposed cardiac catheterization procedures may involve blood vessels that could be considered major, based on our review of the clinical characteristics of the procedures and their similarity to other procedures that are currently included on the ASC CPL, we believe these procedures may be appropriately performed in an ASC. Therefore, we proposed to include these 12 procedures on the list of ASC covered surgical procedures for CY 2019. As stated in the August 2, 2007 ASC final rule (72 FR 42481), we believe the involvement of major blood vessels is best considered in the context of the clinical characteristics of individual procedures, and we do not believe that it is logically or clinically consistent to exclude certain cardiac procedures from the list of ASC covered surgical procedures on the basis of the involvement of major blood vessels, yet continue to provide ASC payment for similar procedures involving major blood vessels that have a history of safe performance in ASCs, such as CPT code 36473 (Mechanicochemical destruction of insufficient vein of arm or leg, accessed through the skin using imaging guidance) and CPT code 37223 (Insertion of stents into groin artery, endovascular, accessed through the skin or open procedure). However, in the CY 2019 proposed rule, we stated that we were interested in hearing any specific safety concerns from stakeholders regarding these 12 cardiac catheterization procedures and requested comments on whether these procedures may be safely performed in an ASC in light of the regulatory criteria governing which procedures may be added to the ASC covered procedures list. Comment: The majority of commenters supported the proposal to add 12 cardiac catheterization procedures to the list of ASC covered surgical procedures. Commenters noted that these procedures may be performed in a physician office setting, would not inherently pose a significant risk to beneficiary safety or require active medical monitoring at midnight following the procedure, and are regularly performed on commercial patients in the ASC setting. The commenters also noted that many of these services are currently provided in a hospital outpatient setting and, therefore, the Medicare program and beneficiaries would achieve savings to PO 00000 Frm 00229 Fmt 4701 Sfmt 4700 59045 the extent such services migrate to the ASC setting. Some commenters were concerned that the proposal would expose beneficiaries to significant risks. The commenters noted that certain cardiac catheterization procedures may reveal blockages in the coronary arteries that require an immediate intervention involving hospital-level care. One commenter requested that CMS ensure that the same facility standards that apply to hospital-based cardiac catheterization laboratories also apply to ASCs performing these services. The commenter further stated that CMS should not add any cardiac catheterization procedures to the list of ASC covered services until it has ensured that the conditions of coverage and accreditation requirements that would be applied to ASCs furnishing such services are at least as stringent as the standards applied to hospital cardiac catheterization labs, with additional attention to the issues created by engaging in procedures involving the major vessels and the heart without the immediate accessibility of the facilities of an acute care hospital. In addition, the commenters suggested that the proposal may lead to ‘‘cherry-picking’’ with a sicker, more complex, and higher cost patient population being treated in the hospital outpatient setting. Response: We appreciate the commenters’ support. We disagree with the commenters that our proposal to add 12 cardiac catheterization procedures would expose beneficiaries to significant risks. As noted by many of the commenters, many of these procedures are already performed safely in the physician’s office setting. The procedures have been reviewed by CMS medical officers and we have assessed each against the regulatory safety criteria and believe that they meet all of those criteria. Further, we believe these procedures are clinically similar to peripheral endovascular procedures which are already currently included on the ASC CPL. As stated in the proposed rule, although the proposed cardiac catheterization procedures may involve blood vessels that could be considered major, based on our review of the clinical characteristics of the procedures and their similarity to other procedures that are currently included on the ASC CPL, we believe these procedures may be appropriately performed in an ASC. While we acknowledge that it may be more appropriate for certain beneficiaries to receive these procedures in a hospital-level setting, which typically have a greater range of items and services available when compared E:\FR\FM\21NOR2.SGM 21NOR2 59046 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations khammond on DSK30JT082PROD with RULES2 to an ASC setting, including onsite cardiac surgery backup, we believe that many beneficiaries could be ideal candidates to receive these services in an ASC setting and that beneficiaries and their physicians should be able to choose an appropriate site of service for surgeries based on the clinical characteristics of the patient and other factors. We also note that our conditions of coverage for ASCs, including 42 CFR 416.42, require surgical procedures to be performed in a safe manner by qualified VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 physicians who have been granted clinical privileges by the governing body of the ASC in accordance with approved policies and procedures of the ASC. While we agree with commenters that a relatively healthier and less complex Medicare patient population would, in general, be a more ideal patient population to receive cardiac catheterization procedures in an ASC setting, we disagree that we should prohibit such procedures on that basis. PO 00000 Frm 00230 Fmt 4701 Sfmt 4700 We believe that relatively healthy and less complex patients would benefit from the shorter length of stay and reduced cost-sharing that would be expected in an ASC setting. Comment: Commenters recommended that CMS add additional cardiovascular procedures that are related to the proposed additions to the ASC CPL. The commenters’ recommended codes are shown in Table 59 below. BILLING CODE 4120–01–P E:\FR\FM\21NOR2.SGM 21NOR2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations 59047 TABLE 59.-CARDIOVASCULAR PROCEDURES REQUESTED BY COMMENTERS FOR ADDITION TO THE CY 2019 LIST OF ASC COVERED SURGICAL PROCEDURES CY2019 CPT Code 92921 92924 92928 92929 92937 92938 92960 92973 92978 khammond on DSK30JT082PROD with RULES2 92979 VerDate Sep<11>2014 20:42 Nov 20, 2018 Percutaneous transluminal coronary angioplasty; single major coronary artery or branch Percutaneous transluminal coronary angioplasty; each additional branch of a major coronary artery (list separately in addition to code for primary procedure) Percutaneous transluminal coronary atherectomy, with coronary angioplasty when performed; single major coronary artery or branch Percutaneous transcatheter placement of intracoronary stent( s), with coronary angioplasty when performed; single major coronary artery or branch Percutaneous transcatheter placement ofintracoronary stent(s), with coronary angioplasty when performed; each additional branch of a major coronary artery (list separately in addition to code for primary procedure) Percutaneous transluminal revascularization of or through coronary artery bypass graft (internal mammary, free arterial, venous), any combination of intracoronary stent, atherectomy and angioplasty, including distal protection when performed; single vessel Percutaneous transluminal revascularization of or through coronary artery bypass graft (internal mammary, free arterial, venous), any combination of intracoronary stent, atherectomy and angioplasty, including distal protection when performed; each additional branch subtended by the bypass graft (list separately in addition to code for primary procedure) Cardioversion, elective, electrical conversion of arrhythmia; external Percutaneous transluminal coronary thrombectomy mechanical (list separately in addition to code for primary procedure) Endoluminal imaging of coronary vessel or graft using intravascular ultrasound (ivus) or optical coherence tomography (oct) during diagnostic evaluation and/or therapeutic intervention including imaging supervision, interpretation and report; initial vessel (list separately in addition to code for primary procedure) Endoluminal imaging of coronary vessel or graft using intravascular ultrasound (ivus) or optical coherence tomography (oct) during diagnostic evaluation and/or therapeutic intervention including imaging supervision, interpretation and report; each additional vessel (list separately in addition to code for primary procedure) Jkt 247001 PO 00000 Frm 00231 Fmt 4701 Sfmt 4725 E:\FR\FM\21NOR2.SGM 21NOR2 ER21NO18.085</GPH> 92920 CY 2019 Long Descriptor Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations CY2019 CPT Code 93282 93284 93312 93313 93315 93316 93463 93464 93505 93530 93531 khammond on DSK30JT082PROD with RULES2 93532 VerDate Sep<11>2014 20:42 Nov 20, 2018 CY 2019 Long Descriptor Programming device evaluation (in person) with iterative adjustment of the implantable device to test the function of the device and select optimal permanent programmed values with analysis, review and report by a physician or other qualified health care professional; single lead transvenous implantable defibrillator system Programming device evaluation (in person) with iterative adjustment of the implantable device to test the function of the device and select optimal permanent programmed values with analysis, review and report by a physician or other qualified health care professional; multiple lead transvenous implantable defibrillator system Echocardiography, transesophageal, real-time with image documentation (2d) (with or without m-mode recording); including probe placement, image acquisition, interpretation and report Echocardiography, transesophageal, real-time with image documentation (2d) (with or without m-mode recording); placement oftransesophageal probe only Transesophageal echocardiography for congenital cardiac anomalies; including probe placement, image acquisition, interpretation and report Transesophageal echocardiography for congenital cardiac anomalies; placement oftransesophageal probe only Pharmacologic agent administration (eg, inhaled nitric oxide, intravenous infusion of nitroprusside, dobutamine, milrinone, or other agent) including assessing hemodynamic measurements before, during, after and repeat pharmacologic agent administration, when performed (list separately in addition to code for primary procedure) Physiologic exercise study (eg, bicycle or arm ergometry) including assessing hemodynamic measurements before and after (list separately in addition to code for primary procedure) Endomyocardial biopsy Right heart catheterization, for congenital cardiac anomalies Combined right heart catheterization and retrograde left heart catheterization, for congenital cardiac anomalies Combined right heart catheterization and transseptalleft heart catheterization through intact septum with or without retrograde left heart catheterization, for congenital cardiac anomalies Jkt 247001 PO 00000 Frm 00232 Fmt 4701 Sfmt 4725 E:\FR\FM\21NOR2.SGM 21NOR2 ER21NO18.086</GPH> 59048 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations CY2019 CPT Code 93561 93562 93563 93564 93565 93566 93567 93568 khammond on DSK30JT082PROD with RULES2 93571 VerDate Sep<11>2014 20:42 Nov 20, 2018 CY 2019 Long Descriptor Combined right heart catheterization and transseptalleft heart catheterization through existing septal opening, with or without retrograde left heart catheterization, for congenital cardiac anomalies Indicator dilution studies such as dye or thermodilution, including arterial and/or venous catheterization; with cardiac output measurement(separateprocedure) Indicator dilution studies such as dye or thermodilution, including arterial and/or venous catheterization; subsequent measurement of cardiac output Injection procedure during cardiac catheterization including imaging supervision, interpretation, and report; for selective coronary angiography during congenital heart catheterization (list separately in addition to code for primary procedure) Injection procedure during cardiac catheterization including imaging supervision, interpretation, and report; for selective opacification of aortocoronary venous or arterial bypass graft(s) (eg, aortocoronary saphenous vein, free radial artery, or free mammary artery graft) to one or more coronary arteries and in situ arterial conduits (eg, internal mammary), whether native or used for bypass to one or more coronary arteries during congenital heart catheterization, when performed (list separately in addition to code for primary procedure) Injection procedure during cardiac catheterization including imaging supervision, interpretation, and report; for selective left ventricular or left atrial angiography (list separately in addition to code for primary procedure) Injection procedure during cardiac catheterization including imaging supervision, interpretation, and report; for selective right ventricular or right atrial angiography (list separately in addition to code for primary procedure) Injection procedure during cardiac catheterization including imaging supervision, interpretation, and report; for supravalvular aortography (list separately in addition to code for primary procedure) Injection procedure during cardiac catheterization including imaging supervision, interpretation, and report; for pulmonary angiography (list separately in addition to code for primary procedure) Intravascular doppler velocity and/or pressure derived coronary flow reserve measurement (coronary vessel or graft) during coronary angiography including pharmacologically induced stress; initial vessel (list separately in addition to code for primary procedure) Jkt 247001 PO 00000 Frm 00233 Fmt 4701 Sfmt 4725 E:\FR\FM\21NOR2.SGM 21NOR2 ER21NO18.087</GPH> 93533 59049 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations khammond on DSK30JT082PROD with RULES2 BILLING CODE 4120–01–C Response: We appreciate the commenters’ recommendations for procedures that may be suitable candidates for addition to the list of ASC covered surgical procedures. We have reviewed the recommended procedures and believe some procedures would not be expected to pose a significant risk to beneficiary safety when performed in an ASC, would not be expected to require active medical monitoring and care of the beneficiary at midnight following the procedure, and are separately paid under the OPPS. Therefore, we are accepting the commenters’ recommendation, in part, to include the following procedures to our list of ASC covered surgical procedures: • CPT code 93566 (Injection procedure during cardiac VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 catheterization including imaging supervision, interpretation, and report; for selective right ventricular or right atrial angiography (list separately in addition to code for primary procedure)); • CPT code 93567 Injection procedure during cardiac catheterization including imaging supervision, interpretation, and report; for supravalvular aortography (list separately in addition to code for primary procedure); • CPT code 93568 (Injection procedure during cardiac catheterization including imaging supervision, interpretation, and report; for pulmonary angiography (list separately in addition to code for primary procedure)); • CPT code 93571 Intravascular doppler velocity and/or pressure PO 00000 Frm 00234 Fmt 4701 Sfmt 4700 derived coronary flow reserve measurement (coronary vessel or graft) during coronary angiography including pharmacologically induced stress; initial vessel (list separately in addition to code for primary procedure); • CPT code 93572 Intravascular doppler velocity and/or pressure derived coronary flow reserve measurement (coronary vessel or graft) during coronary angiography including pharmacologically induced stress; each additional vessel (list separately in addition to code for primary procedure). However, we do not believe that the remaining procedures displayed in Table 59 above meet the criteria to be added to the ASC CPL. If new evidence, clinical studies, or data become available that may support adding such procedures to the ASC CPL, we will E:\FR\FM\21NOR2.SGM 21NOR2 ER21NO18.088</GPH> 59050 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations khammond on DSK30JT082PROD with RULES2 consider the commenters’ recommendations in future rulemaking. Comment: Commenters recommended that CMS add several additional procedures to the covered surgical procedures list that were not proposed to be added to the ASC CPL. These included discography, wound therapy, joint replacement, urological, gastroenterological, and peripheral arterial disease diagnostic procedures. Some commenters suggested that any procedure that is payable under the OPPS should automatically be added to the ASC CPL. Response: We appreciate the commenters’ recommendations. Based on our review, we did not determine that any of these procedures should be added to the ASC CPL for CY 2019, however, we recognize that ongoing VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 review is necessary to determine if changes in technology and/or medical practice affect the clinical appropriateness of these procedures for the ASC setting. Accordingly, while we are not adding the recommended procedures to the ASC CPL for CY 2019, we will take these public comments into consideration in future rulemaking. With respect to automatically adding procedures that are payable under the OPPS, we note that we must evaluate each procedure against the regulatory criteria for inclusion on the ASC CPL; therefore, we are not accepting this recommendation. After consideration of the public comments we received, we are finalizing our proposal to add 12 cardiac catheterization procedures to the list of ASC covered surgical procedures. In PO 00000 Frm 00235 Fmt 4701 Sfmt 4700 59051 addition, based on public comments, we are adding five procedures performed during cardiac catheterization procedures to the list of ASC covered surgical procedures (CPT codes 93566, 93567, 93568, 93571, and 93572). We believe these procedures would not be expected to pose a significant risk to beneficiary safety when performed in an ASC, would not be expected to require active medical monitoring and care of the beneficiary at midnight following the procedure and are separately paid under the OPPS. The 17 procedures that we are adding to the ASC CPL, including the long code descriptors and the final CY 2019 payment indicators, are displayed in Table 60 below. BILLING CODE 4120–01–P E:\FR\FM\21NOR2.SGM 21NOR2 59052 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations TABLE 60.-ADDITIONS TO THE LIST OF ASC COVERED SURGICAL PROCEDURES FOR CY 2019 93451 93452 93453 93454 93455 93456 93457 khammond on DSK30JT082PROD with RULES2 93458 VerDate Sep<11>2014 20:42 Nov 20, 2018 CY2019 ASC Payment Indicator CY 2019 Long Descriptor Right heart catheterization including measurement(s) of oxygen saturation and cardiac output, when performed Left heart catheterization including intraprocedural injection(s) for left ventriculography, imaging supervision and interpretation, when performed Combined right and left heart catheterization including intraprocedural injection(s) for left ventriculography, imaging supervision and interpretation, when performed Catheter placement in coronary artery( s) for coronary angiography, including intraprocedural injection(s) for coronary angiography, imaging supervision and interpretation; Catheter placement in coronary artery( s) for coronary angiography, including intraprocedural injection(s) for coronary angiography, imaging supervision and interpretation; with catheter placement( s) in bypass graft(s) (internal mammary, free arterial, venous grafts) including intraprocedural injection(s) for bypass graft angiography Catheter placement in coronary artery( s) for coronary angiography, including intraprocedural injection(s) for coronary angiography, imaging supervision and interpretation; with right heart catheterization Catheter placement in coronary artery( s) for coronary angiography, including intraprocedural injection(s) for coronary angiography, imaging supervision and interpretation; with catheter placement(s) in bypass graft(s) (internal mammary, free arterial, venous grafts) including intraprocedural injection(s) for bypass graft angiography and right heart catheterization Catheter placement in coronary artery( s) for coronary angiography, including intraprocedural injection(s) for coronary angiography, imaging supervision and interpretation; with left heart catheterization including intraprocedural injection(s) for left ventriculography, when performed Jkt 247001 PO 00000 Frm 00236 Fmt 4701 Sfmt 4725 E:\FR\FM\21NOR2.SGM 21NOR2 G2 G2 G2 G2 G2 G2 G2 G2 ER21NO18.089</GPH> CY2019 CPT Code Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations 93459 93460 93461 93462 93566 93567 khammond on DSK30JT082PROD with RULES2 93568 VerDate Sep<11>2014 20:42 Nov 20, 2018 CY 2019 ASC Payment Indicator CY 2019 Long Descriptor Catheter placement in coronary artery( s) for coronary angiography, including intraprocedural injection(s) for coronary angiography, imaging supervision and interpretation; with left heart catheterization including intraprocedural injection(s) for left ventriculography, when performed, catheter placement(s) in bypass graft(s) (internal mammary, free arterial, venous grafts) with bypass graft angiography Catheter placement in coronary artery( s) for coronary angiography, including intraprocedural injection(s) for coronary angiography, imaging supervision and interpretation; with right and left heart catheterization including intraprocedural injection(s) for left ventriculography, when performed Catheter placement in coronary artery(s) for coronary angiography, including intraprocedural injection(s) for coronary angiography, imaging supervision and interpretation; with right and left heart catheterization including intraprocedural injection(s) for left ventriculography, when performed, catheter placement(s) in bypass graft(s) (internal mammary, free arterial, venous grafts) with bypass graft angiography Left heart catheterization by transseptal puncture through intact septum or by transapical puncture (list separately in addition to code for primary procedure) Injection procedure during cardiac catheterization including imaging supervision, interpretation, and report; for selective right ventricular or right atrial angiography (list separately in addition to code for primary procedure) Injection procedure during cardiac catheterization including imaging supervision, interpretation, and report; for supravalvular aortography (list separately in addition to code for primary procedure) Injection procedure during cardiac catheterization including imaging supervision, interpretation, and report; for pulmonary angiography (list separately in addition to code for primary procedure) Jkt 247001 PO 00000 Frm 00237 Fmt 4701 Sfmt 4725 E:\FR\FM\21NOR2.SGM 21NOR2 G2 G2 G2 Nl Nl Nl Nl ER21NO18.090</GPH> CY 2019 CPT Code 59053 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations BILLING CODE 4120–01–C khammond on DSK30JT082PROD with RULES2 e. Review of Recently Added Procedures to the ASC Covered Procedures List Section 1833(i)(1) of the Act requires us to specify, in consultation with appropriate medical organizations, surgical procedures that are appropriately performed on an inpatient basis in a hospital but that can be safely performed in an ASC, a CAH, or an HOPD and to review and update the list of ASC procedures at least every 2 years. As noted in section XII.C.1. of the CY 2019 OPPS/ASC proposed rule, we evaluate the ASC covered procedures list (ASC CPL) each year to determine whether procedures should be added or removed from the list, and changes to the list are often made in response to specific concerns raised by stakeholders. Often, when a procedure is added to the ASC CPL, the provider community has limited experience in performing the procedure on the Medicare population, even if providers have greater experience with other patient populations. Because ASCs generally provide a subset of items and services that are offered by hospitals and because Medicare beneficiaries tend to be frailer and exhibit a higher number of comorbidities than other populations, we believe it may be appropriate to reevaluate recently added procedures. Specifically, in the CY 2019 OPPS/ ASC proposed rule (83 FR 37161 through 37162), we proposed to review all procedures that were added to the ASC CPL within the 3 calendar years prior to the year in which we are engaging in rulemaking to assess the safety, effectiveness, and beneficiary experience of these newly added procedures when performed in the ASC setting. Our review began with procedures added to the ASC CPL in VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 CYs 2015, 2016, and 2017, to assess whether newly added procedures continue to meet our criteria, including whether they continue not to be expected to pose a significant safety risk to a Medicare beneficiary when performed in an ASC and continue not to be expected to require active medical monitoring and care of the beneficiary at midnight following the procedure. This review included taking into account recent clinical developments and available safety findings related to the recently added procedures. We proposed to review all 38 procedures that were added to the ASC CPL for CYs 2015, 2016, and 2017. The 38 procedures that were added to the ASC CPL during this time were displayed in Table 41 of the proposed rule (82 FR 37161 through 37162), along with their HCPCS code long descriptors, the CY 2018 payment indicators, and the calendar year that each procedure was added to the ASC CPL. We also sought public comment about these recently added procedures from members of the public, including Medicare beneficiaries, ASCs, and physicians performing these procedures in the ASC setting. In addition, we sought public comment on whether these procedures continue to meet the criteria to remain on the ASC CPL. We stated our intent to evaluate each of these 38 procedures using all available data, including clinical characteristics, utilization reflected in ASC claims and pricing data, prevailing medical practice, and any public comments we received to determine whether they continue to meet the criteria to be a covered surgical procedure. In addition, we solicited public comment regarding how our systematic review should be structured in the future, including the length of time PO 00000 Frm 00238 Fmt 4701 Sfmt 4700 procedures should be considered recently added, how frequently reviews should be performed in light of the time required to accumulate meaningful data and whether any future reviews should examine procedures added during a period of time greater or less than the previous 3 completed calendar years. Comment: Many commenters supported the proposal to review procedures that were recently added to the ASC CPL. A number of commenters (patients and providers) noted that the procedures shown in Table 41 of the proposed rule can be safely and effectively performed in an ASC setting and recommended retaining the procedures on the ASC CPL. One commenter also noted that CPT codes 0171T (Insertion of posterior spinous process distraction device (including necessary removal of bone or ligament for insertion and imaging guidance), lumbar; single level) and 0172T (Insertion of posterior spinous process distraction device (including necessary removal of bone or ligament for insertion and imaging guidance), lumbar; each additional level) were deleted as of January 1, 2017. A number of commenters believed there may not be enough data on the 38 procedures to adequately assess if the procedures continue to meet the criteria to remain on the ASC CPL. The commenters recommended reviewing procedures on the CPL after the procedure has been added to the CPL for a minimum of 3 to 5 years. Further, commenters requested additional information regarding the methodology and supporting materials that CMS would use to determine that a procedure should no longer remain on the ASC CPL. The commenters requested that stakeholders receive appropriate notice that CMS is E:\FR\FM\21NOR2.SGM 21NOR2 ER21NO18.091</GPH> 59054 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations proposing to remove a procedure so that stakeholders have an opportunity to comment. Response: We appreciate the commenters’ feedback regarding the safety and efficacy of these procedures in the ASC setting. We note that we did not receive any public comments in support of removing these recently added procedures from the ASC CPL. khammond on DSK30JT082PROD with RULES2 We note that CPT codes 0171T and 0172T were inadvertently included in Table 41 of the proposed rule. These codes were deleted effective January 1, 2017, and no longer remain on the ASC CPL. In our evaluation of the remaining 36 procedures, we did not find any clinical evidence, data, or other materials to justify removing these procedures from the ASC CPL. Therefore, for CY 2019, we are not removing any of the remaining 36 VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 procedures displayed in Table 41 of the proposed rule from the ASC CPL. In response to commenters’ recommendation to wait a minimum of 3 to 5 years to assess whether a procedure meets our criteria to remain on the ASC CPL, we agree that a longer timeframe may provide better data to adequately determine whether or not the procedure meets our criteria. We will consider the commenters’ recommendations in future rulemaking. In response to the commenters’ request for additional information regarding the methodology and supporting materials that we would use to determine that a procedure no longer meets the criteria to remain on the ASC CPL, we note that in the CY 2019 OPPS/ ASC proposed rule (83 FR 37161), we stated our intent to evaluate each of the procedures using all available data, including clinical characteristics, PO 00000 Frm 00239 Fmt 4701 Sfmt 4700 59055 utilization reflected in ASC claims and pricing data, prevailing medical practice, and any public comments we receive. After consideration of the public comments we received, we are retaining the procedures displayed in Table 61 on the ASC CPL for CY 2019, with the exception of CPT codes 0171T and 0172T, which were deleted from the ASC CPL effective January 1, 2017 and, therefore, will not be included on the ASC CPL for CY 2019. However, based on the public comments we received about the re-review process generally, we do not believe it is necessary to finalize any proposal regarding ongoing reviews of recently added procedures at this time. Rather, we will take all commenters’ suggestions into account as we consider future refinements to our review of the ASC CPL. BILLING CODE 4120–01–P E:\FR\FM\21NOR2.SGM 21NOR2 59056 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations TABLE 61.-ADDITIONS TO THE LIST OF ASC COVERED SURGICAL PROCEDURES FOR CY 2015, 2016, AND 2017 0171T 0172T 20936 20937 khammond on DSK30JT082PROD with RULES2 20938 VerDate Sep<11>2014 CY 2019 Long Descriptor CY2018 ASC Payment Indicator Calendar Year Added to ASCCPL 18 2016 CPT code deleted N1 2016 CPT code deleted N1 2017 Will remain onASC CPL N1 2017 Will remain onASC CPL 2017 Will remain onASC CPL Insertion of posterior spinous process distraction device (including necessary removal of bone or ligament for insertion and imaging guidance), lumbar; single level Insertion of posterior spinous process distraction device (including necessary removal of bone or ligament for insertion and imaging guidance), lumbar; each additional level Autograft for spine surgery only (includes harvesting the graft); local (eg, ribs, spinous process, or laminar fragments) obtained from same incision (list separately in addition to code for primary procedure) Autograft for spine surgery only (includes harvesting the graft); morselized (through separate skin or fascial incision) (list separately in addition to code for primary procedure) Autograft for spine surgery only (includes harvesting the graft); structural, bicortical or tricortical (through separate skin or fascial incision) (list separately in addition to code for primary procedure) 20:42 Nov 20, 2018 Jkt 247001 PO 00000 Frm 00240 Fmt 4701 N1 Sfmt 4725 E:\FR\FM\21NOR2.SGM 21NOR2 ASC CPL Review Results ER21NO18.092</GPH> CY2019 CPT Code Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations 22551 22552 22554 22612 22614 khammond on DSK30JT082PROD with RULES2 22840 VerDate Sep<11>2014 CY 2019 Long Descriptor CY2018 ASC Payment Indicator Arthrodesis, anterior interbody, including disc space preparation, discectomy, osteophytectomy and decompression of spinal cord and/or nerve roots; cervical below c2 Arthrodesis, anterior interbody, including disc space preparation, discectomy, osteophytectomy and decompression of spinal cord and/or nerve roots; cervical below c2, each additional interspace (list separately in addition to code for separate procedure) Arthrodesis, anterior interbody technique, including minimal discectomy to prepare interspace (other than for decompression); cervical below c2 Arthrodesis, posterior or posterolateral technique, single level; lumbar (with lateral transverse technique, when performed) Arthrodesis, posterior or posterolateral technique, single level; each additional vertebral segment (list separately in addition to code for primary procedure) Posterior non-segmental instrumentation (eg, harrington rod technique, pedicle fixation across 1 interspace, atlantoaxial transarticular screw fixation, sub laminar wiring at c 1, facet screw fixation) (list separately in addition to code for primary procedure) 20:42 Nov 20, 2018 Jkt 247001 PO 00000 Frm 00241 Fmt 4701 ASC CPL Review Results 2015 Will remain onASC CPL N1 2017 Will remain onASC CPL 18 2015 Will remain onASC CPL 18 2015 Will remain onASC CPL N1 2015 Will remain onASC CPL 2017 Will remain onASC CPL 18 N1 Sfmt 4725 Calendar Year Added to ASCCPL E:\FR\FM\21NOR2.SGM 21NOR2 ER21NO18.093</GPH> CY2019 CPT Code 59057 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations CY2019 CPT Code 22842 22845 22853 khammond on DSK30JT082PROD with RULES2 22854 VerDate Sep<11>2014 CY 2019 Long Descriptor CY2018 ASC Payment Indicator Calendar Year Added to ASCCPL Nl 2017 Will remain onASC CPL 2017 Will remain onASC CPL Nl 2017 Will remain onASC CPL Nl 2017 Will remain onASC CPL Posterior segmental instrumentation (eg, pedicle fixation, dual rods with multiple hooks and sublaminar wires); 3 to 6 vertebral segments (list separately in addition to code for primary procedure) Anterior instrumentation; 2 to 3 vertebral segments (list separately in addition to code for primary procedure) Insertion of interbody biomechanical device( s) (eg, synthetic cage, mesh) with integral anterior instrumentation for device anchoring (eg, screws, flanges), when performed, to intervertebral disc space in conjunction with interbody arthrodesis, each interspace (list separately in addition to code for primary procedure) Insertion of intervertebral biomechanical device( s) (eg, synthetic cage, mesh) with integral anterior instrumentation for device anchoring (eg, screws, flanges), when performed, to vertebral corpectomy(ies) (vertebral body resection, partial or complete) defect, in conjunction with interbody arthrodesis, each contiguous defect (list separately in addition to code for primary procedure) 20:42 Nov 20, 2018 Jkt 247001 PO 00000 Frm 00242 Fmt 4701 Nl Sfmt 4725 E:\FR\FM\21NOR2.SGM 21NOR2 ASC CPL Review Results ER21NO18.094</GPH> 59058 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations 22859 37241 khammond on DSK30JT082PROD with RULES2 37242 VerDate Sep<11>2014 CY 2019 Long Descriptor CY2018 ASC Payment Indicator Insertion of intervertebral biomechanical device( s) (eg, synthetic cage, mesh, methylmethacrylate) to intervertebral disc space or vertebral body defect without interbody arthrodesis, each contiguous defect (list separately in addition to code for primary procedure) Vascular embolization or occlusion, inclusive of all radiological supervision and interpretation, intraprocedural roadmapping, and imaging guidance necessary to complete the intervention; venous, other than hemorrhage (eg, congenital or acquired venous malformations, venous and capillary hemangiomas, varices, varicoceles) Vascular embolization or occlusion, inclusive of all radiological supervision and interpretation, intraprocedural roadmapping, and imaging guidance necessary to complete the intervention; arterial, other than hemorrhage or tumor (eg, congenital or acquired arterial malformations, arteriovenous malformations, arteriovenous fistulas, aneurysms, pseudoaneurysms) 20:42 Nov 20, 2018 Jkt 247001 PO 00000 Frm 00243 Fmt 4701 N1 J8 J8 Sfmt 4725 Calendar Year Added to ASCCPL ASC CPL Review Results 2017 Will remain onASC CPL 2016 Will remain onASC CPL 2016 Will remain onASC CPL E:\FR\FM\21NOR2.SGM 21NOR2 ER21NO18.095</GPH> CY2019 CPT Code 59059 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations CY2019 CPT Code 37243 49406 J8 2016 Will remain onASC CPL 2016 Will remain onASC CPL Vascular embolization or occlusion, inclusive of all radiological supervision and interpretation, intraprocedural roadmapping, and imaging guidance necessary to complete the intervention; for tumors, organ ischemia, or infarction Image-guided fluid collection drainage by catheter (eg, abscess, hematoma, seroma, lymphocele, cyst); peritoneal or retroperitoneal, percutaneous G2 ASC CPL Review Results Will remain onASC CPL Will remain onASC CPL Will remain onASC CPL Will remain onASC CPL Will remain onASC CPL Colpocleisis (le fort type) G2 2016 57310 Closure of urethrovaginal fistula; G2 2016 58260 Vaginal hysterectomy, for uterus 250 g or less; G2 2016 G2 2016 G2 2016 G2 2016 Will remain onASC CPL G2 2016 Will remain onASC CPL 2016 Will remain onASC CPL 58543 58544 58553 58554 khammond on DSK30JT082PROD with RULES2 Calendar Year Added to ASCCPL 57120 58262 VerDate Sep<11>2014 CY 2019 Long Descriptor CY2018 ASC Payment Indicator Vaginal hysterectomy, for uterus 250 g or less; with removal of tube(s), and/or ovary(s) Laparoscopy, surgical, supracervical hysterectomy, for uterus greater than 250 g; Laparoscopy, surgical, supracervical hysterectomy, for uterus greater than 250 g; with removal oftube(s) and/or ovary(s) Laparoscopy, surgical, with vaginal hysterectomy, for uterus greater than 250 g; Laparoscopy, surgical, with vaginal hysterectomy, for uterus greater than 250 g; with removal oftube(s) and/or ovary(s) 20:42 Nov 20, 2018 Jkt 247001 PO 00000 Frm 00244 Fmt 4701 G2 Sfmt 4725 E:\FR\FM\21NOR2.SGM 21NOR2 ER21NO18.096</GPH> 59060 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations 58573 63020 63030 63042 khammond on DSK30JT082PROD with RULES2 63044 VerDate Sep<11>2014 CY 2019 Long Descriptor CY2018 ASC Payment Indicator Calendar Year Added to ASCCPL G2 2016 Will remain onASC CPL G2 2015 Will remain onASC CPL 2015 Will remain onASC CPL G2 2015 Will remain onASC CPL N1 2015 Will remain onASC CPL Laparoscopy, surgical, with total hysterectomy, for uterus greater than 250 g; with removal of tube(s) and/or ovary(s) Laminotomy (hemilaminectomy), with decompression of nerve root(s), including partial facetectomy, foraminotomy and/or excision of herniated intervertebral disc; 1 interspace, cervical Laminotomy (hemilaminectomy), with decompression of nerve root(s), including partial facetectomy, foraminotomy and/or excision of herniated intervertebral disc; 1 interspace, lumbar Laminotomy (hemilaminectomy), with decompression of nerve root(s), including partial facetectomy, foraminotomy and/or excision of herniated intervertebral disc, reexploration, single interspace; lumbar Laminotomy (hemilaminectomy), with decompression of nerve root(s), including partial facetectomy, foraminotomy and/or excision of herniated intervertebral disc, reexploration, single interspace; each additional lumbar interspace (list separately in addition to code for primary procedure) 20:42 Nov 20, 2018 Jkt 247001 PO 00000 Frm 00245 Fmt 4701 G2 Sfmt 4725 E:\FR\FM\21NOR2.SGM 21NOR2 ASC CPL Review Results ER21NO18.097</GPH> CY2019 CPT Code 59061 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations BILLING CODE 4120–01–C khammond on DSK30JT082PROD with RULES2 2. Covered Ancillary Services In the CY 2019 OPPS/ASC proposed rule (83 FE 37163), consistent with the established ASC payment system policy (72 FR 42497), we proposed to update the ASC list of covered ancillary services to reflect the payment status for the services under the CY 2019 OPPS. Maintaining consistency with the OPPS may result in proposed changes to ASC VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 payment indicators for some covered ancillary services because of changes that we proposed under the OPPS for CY 2019. For example, if a covered ancillary service was separately paid under the ASC payment system in CY 2018, but is proposed for packaged status under the CY 2019 OPPS, to maintain consistency with the OPPS, we also proposed to package the ancillary service under the ASC payment system for CY 2019. We proposed to continue PO 00000 Frm 00246 Fmt 4701 Sfmt 4700 this reconciliation of packaged status for subsequent calendar years. Comment indicator ‘‘CH’’, which is discussed in section XII.F. of the proposed rule, was used in Addendum BB to the proposed rule (which is available via the internet on the CMS website) to indicate covered ancillary services for which we proposed a change in the ASC payment indicator to reflect a proposed change in the OPPS treatment of the service for CY 2019. E:\FR\FM\21NOR2.SGM 21NOR2 ER21NO18.098</GPH> 59062 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations All ASC covered ancillary services and their proposed payment indicators for CY 2019 were included in Addendum BB to the proposed rule (which is available via the internet on the CMS website). We did not receive any public comments on these proposals. Therefore, we are finalizing, without modification, our proposal to update the ASC list of covered ancillary services to reflect the payment status for the services under the OPPS. All CY 2019 ASC covered ancillary services and their final payment indicators are included in Addendum BB to this final rule with comment period (which is available via the internet on the CMS website). D. ASC Payment for Covered Surgical Procedures and Covered Ancillary Services khammond on DSK30JT082PROD with RULES2 1. ASC Payment for Covered Surgical Procedures a. Background Our ASC payment policies for covered surgical procedures under the revised ASC payment system are fully described in the CY 2008 OPPS/ASC final rule with comment period (72 FR 66828 through 66831). Under our established policy, we use the ASC standard ratesetting methodology of multiplying the ASC relative payment weight for the procedure by the ASC conversion factor for that same year to calculate the national unadjusted payment rates for procedures with payment indicators ‘‘G2’’ and ‘‘A2’’. Payment indicator ‘‘A2’’ was developed to identify procedures that were included on the list of ASC covered surgical procedures in CY 2007 and, therefore, were subject to transitional payment prior to CY 2011. Although the 4-year transitional period has ended and payment indicator ‘‘A2’’ is no longer required to identify surgical procedures subject to transitional payment, we retained payment indicator ‘‘A2’’ because it is used to identify procedures that are exempted from the application of the office-based designation. The rate calculation established for device-intensive procedures (payment indicator ‘‘J8’’) is structured so that the packaged device payment amount is the same as under the OPPS, and only the service portion of the rate is subject to the ASC standard ratesetting methodology. In the CY 2017 OPPS/ ASC final rule with comment period (81 FR 79732 through 79753), we updated the CY 2016 ASC payment rates for ASC covered surgical procedures with payment indicators of ‘‘A2’’, ‘‘G2’’, and ‘‘J8’’ using CY 2015 data, consistent with the CY 2017 OPPS update. We also VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 updated payment rates for deviceintensive procedures to incorporate the CY 2017 OPPS device offset percentages calculated under the standard APC ratesetting methodology, as discussed earlier in this section. Payment rates for office-based procedures (payment indicators ‘‘P2’’, ‘‘P3’’, and ‘‘R2’’) are the lower of the PFS nonfacility PE RVU-based amount (we refer readers to the CY 2018 PFS proposed and final rules) or the amount calculated using the ASC standard rate setting methodology for the procedure. In the CY 2018 OPPS/ASC final rule with comment period, we updated the payment amounts for office-based procedures (payment indicators ‘‘P2’’, ‘‘P3’’, and ‘‘R2’’) using the most recent available MPFS and OPPS data. We compared the estimated CY 2018 rate for each of the office-based procedures, calculated according to the ASC standard rate setting methodology, to the PFS nonfacility PE RVU-based amount to determine which was lower and, therefore, would be the CY 2018 payment rate for the procedure under our final policy for the revised ASC payment system (§ 416.171(d)). In the CY 2014 OPPS/ASC final rule with comment period (78 FR 75081), we finalized our proposal to calculate the CY 2014 payment rates for ASC covered surgical procedures according to our established methodologies, with the exception of device removal procedures. For CY 2014, we finalized a policy to conditionally package payment for device removal codes under the OPPS. Under the OPPS, a conditionally packaged code (status indicators ‘‘Q1’’ and ‘‘Q2’’) describes a HCPCS code where the payment is packaged when it is provided with a significant procedure but is separately paid when the service appears on the claim without a significant procedure. Because ASC services always include a covered surgical procedure, HCPCS codes that are conditionally packaged under the OPPS are always packaged (payment indicator ‘‘N1’’) under the ASC payment system. Under the OPPS, device removal procedures are conditionally packaged and, therefore, would be packaged under the ASC payment system. There would be no Medicare payment made when a device removal procedure is performed in an ASC without another surgical procedure included on the claim; therefore, no Medicare payment would be made if a device was removed but not replaced. To address this concern, for the device removal procedures that are conditionally packaged in the OPPS (status indicator ‘‘Q2’’), we assigned the current ASC payment indicators PO 00000 Frm 00247 Fmt 4701 Sfmt 4700 59063 associated with these procedures and continued to provide separate payment since CY 2014. b. Update to ASC Covered Surgical Procedure Payment Rates for CY 2019 In the CY 2019 OPPS/ASC proposed rule (83 FR 37163 through 37164), we proposed to update ASC payment rates for CY 2019 and subsequent years using the established rate calculation methodologies under § 416.171 and using our definition of device-intensive procedures, as discussed in section XII.C.1.b. of the proposed rule. Because the proposed OPPS relative payment weights are based on geometric mean costs, the ASC system would use geometric means to determine proposed relative payment weights under the ASC standard methodology. We proposed to continue to use the amount calculated under the ASC standard ratesetting methodology for procedures assigned payment indicators ‘‘A2’’ and ‘‘G2’’. We proposed to calculate payment rates for office-based procedures (payment indicators ‘‘P2’’, ‘‘P3’’, and ‘‘R2’’) and device-intensive procedures (payment indicator ‘‘J8’’) according to our established policies and, for deviceintensive procedures, using our modified definition of device-intensive procedures, as discussed in section XII.C.1.b. of the proposed rule. Therefore, we proposed to update the payment amount for the service portion of the device-intensive procedures using the ASC standard rate setting methodology and the payment amount for the device portion based on the proposed CY 2019 OPPS device offset percentages that have been calculated using the standard OPPS APC ratesetting methodology. Payment for office-based procedures would be at the lesser of the proposed CY 2019 MPFS nonfacility PE RVU-based amount or the proposed CY 2018 ASC payment amount calculated according to the ASC standard ratesetting methodology. As we did for CYs 2014 through 2018, for CY 2019, we proposed to continue our policy for device removal procedures, such that device removal procedures that are conditionally packaged in the OPPS (status indicators ‘‘Q1’’ and ‘‘Q2’’) would be assigned the current ASC payment indicators associated with these procedures and would continue to be paid separately under the ASC payment system. Comment: One commenter recommended that CMS change CPT code 0356T (Insertion of drug delivery implant into tear ducts) from payment indicator ‘‘N1’’ to ‘‘R2.’’ Response: We note that, in the CY 2019 OPPS/ASC proposed rule, we E:\FR\FM\21NOR2.SGM 21NOR2 khammond on DSK30JT082PROD with RULES2 59064 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations proposed to assign CPT code 0356T a status indicator of ‘‘Q1’’ under the OPPS. As stated in the CY 2019 OPPS/ ASC proposed rule (83 FR 37163 through 37164), HCPCS codes that are conditionally packaged under the OPPS (status indicators ‘‘Q1’’ and ‘‘Q2’’) and are not a device removal procedure are always packaged (payment indicator ‘‘N1’’) under the ASC payment system. Therefore, we are finalizing our proposal to assign payment indicator ‘‘N1’’ to CPT code 0356T under the ASC payment system for CY 2019. Comment: Several commenters disagreed with the proposed CY 2019 ASC payment rates for the surgical procedures described by the following CPT/HCPCS codes: • CPT code 22513 (Injection of bone cement into body of middle spine bone accessed through the skin using imaging guidance); • CPT code 22514 (Injection of bone cement into body of lower spine bone accessed through the skin using imaging guidance); • CPT code 43210 (Diagnostic examination of esophagus, stomach, and/or upper small bowel with repair of muscle at esophagus and stomach using an endoscope); • CPT code 62264 (Injection or mechanical removal of spinal canal scar tissue, percutaneous procedure, accessed through the skin, multiple sessions in 1 day); • CPT code 62321 (Injection of substance into spinal canal of upper or middle back using imaging guidance); • CPT code 62323 (Injection of substance into spinal canal of lower back or sacrum using imaging guidance); • CPT code 62380 (Decompression of spinal cord and/or nerve root in lower back using endoscope); • CPT code 63650 (Implantation of spinal neurostimulator electrodes, accessed through the skin); • CPT code 63685 (Insertion of spinal neurostimulator pulse generator or receiver); and • HCPCS code C9749 (Repair of nasal vestibular lateral wall stenosis with implant(s)). Some commenters noted that payment rates for some of these procedures are lower than their payment levels from several years ago. Other commenters suggested that the cost of the procedure significantly exceeds Medicare’s payment and questioned the validity of some of the hospital cost data on which the ASC payment rates were based. Response: We are required by law to review and update the data on which we establish payment rates on an annual basis. The ASC payment is dependent VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 upon the APC assignment for the procedure. Based on our analysis of the latest hospital outpatient and ASC claims data used for this final rule with comment period, we are updating ASC payment rates for CY 2019 using the established rate calculation methodologies under § 416.171 of the regulations and using our finalized modified definition of device-intensive procedures, as discussed in section XII.C.1.b. of this final rule with comment period. We do not generally make additional payment adjustments to specific procedures. As such, we are finalizing the APC assignment and payment indicators for CPT codes 22513, 22514, 43210, 62264, 62321, 62323, 62380, 63650, 63685, and C9749. Comment: One commenter recommended that the ASC payment system allow procedures conditionally packaged under the OPPS (status indicator ‘‘Q1’’ and ‘‘Q2’’) to be paid separately under the ASC payment system when they are performed with another procedure. The commenters also suggest that certain conditionally packaged codes are performed without another major procedure more than half of the time. Response: Under the OPPS, a conditionally packaged code describes a HCPCS code where the payment is packaged when it is provided with a significant procedure but is separately paid when the service appears on the claim without a significant procedure. Because ASC services always include a surgical procedure, HCPCS codes that are conditionally packaged under the OPPS, and which are not device removal procedures, are always packaged (payment indicator ‘‘N1’’) under the ASC payment system, no matter how frequently they are billed without a significant procedure under the OPPS. Therefore, we are not accepting this recommendation. Comment: One commenter recommended that CMS eliminate the prohibition against billing for services using an unlisted CPT surgical procedure code. Response: Under 42 CFR 416.166(c)(7), covered surgical procedures do not include procedures that can only be reported using a CPT unlisted surgical procedure code. Therefore, such procedures are not payable under the ASC payment system. As discussed in the August 2, 2008 final rule (72 FR 42484 through 42486), it is not possible to know what specific procedure would be represented by an unlisted code. CMS is required to evaluate each surgical procedure for potential safety risk and the expected need for overnight monitoring and to PO 00000 Frm 00248 Fmt 4701 Sfmt 4700 exclude such procedures from ASC payment. It is not possible to evaluate procedures that would be reported by unlisted CPT codes according to these criteria. Therefore, we are not accepting this recommendation. After consideration of the public comments we received, we are finalizing our proposed policies, without modification, to calculate the CY 2019 payment rates for ASC covered surgical procedures according to our established methodologies using the modified definition of device-intensive procedures. For those covered officebased surgical procedures where the payment rate is the lower of the final rates under the ASC standard ratesetting methodology and the PFS nonfacility PE RVU-based amount, the final payment indicators and rates set forth in this final rule with comment period are based on a comparison using the PFS PE RVUs and the conversion factor effective January 1, 2019. For a discussion of the PFS rates, we refer readers to the CY 2019 PFS final rule with comment period. 2. Payment for Covered Ancillary Services a. Background Our payment policies under the ASC payment system for covered ancillary services vary according to the particular type of service and its payment policy under the OPPS. Our overall policy provides separate ASC payment for certain ancillary items and services integrally related to the provision of ASC covered surgical procedures that are paid separately under the OPPS and provides packaged ASC payment for other ancillary items and services that are packaged or conditionally packaged (status indicators ‘‘N’’, ‘‘Q1’’, and ‘‘Q2’’) under the OPPS. In the CY 2013 OPPS/ ASC rulemaking (77 FR 45169 and 77 FR 68457 through 68458), we further clarified our policy regarding the payment indicator assignment of codes that are conditionally packaged in the OPPS (status indicators ‘‘Q1’’ and ‘‘Q2’’). Under the OPPS, a conditionally packaged code describes a HCPCS code where the payment is packaged when it is provided with a significant procedure but is separately paid when the service appears on the claim without a significant procedure. Because ASC services always include a surgical procedure, HCPCS codes that are conditionally packaged under the OPPS are generally packaged (payment indictor ‘‘N1’’) under the ASC payment system (except for device removal codes, as discussed in section IV. of the proposed rule). Thus, our policy E:\FR\FM\21NOR2.SGM 21NOR2 khammond on DSK30JT082PROD with RULES2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations generally aligns ASC payment bundles with those under the OPPS (72 FR 42495). In all cases, in order for those ancillary services also to be paid, ancillary items and services must be provided integral to the performance of ASC covered surgical procedures for which the ASC bills Medicare. Our ASC payment policies generally provide separate payment for drugs and biologicals that are separately paid under the OPPS at the OPPS rates. We generally pay for separately payable radiology services at the lower of the PFS nonfacility PE RVU-based (or technical component) amount or the rate calculated according to the ASC standard ratesetting methodology (72 FR 42497). However, as finalized in the CY 2011 OPPS/ASC final rule with comment period (75 FR 72050), payment indicators for all nuclear medicine procedures (defined as CPT codes in the range of 78000 through 78999) that are designated as radiology services that are paid separately when provided integral to a surgical procedure on the ASC list are set to ‘‘Z2’’ so that payment is made based on the ASC standard ratesetting methodology rather than the MPFS nonfacility PE RVU amount (‘‘Z3’’), regardless of which is lower. 42 CFR 416.171(d)(1). Similarly, we also finalized our policy to set the payment indicator to ‘‘Z2’’ for radiology services that use contrast agents so that payment for these procedures will be based on the OPPS relative payment weight using the ASC standard ratesetting methodology and, therefore, will include the cost for the contrast agent. 42 CFR 416.171(d)(2). ASC payment policy for brachytherapy sources mirrors the payment policy under the OPPS. ASCs are paid for brachytherapy sources provided integral to ASC covered surgical procedures at prospective rates adopted under the OPPS or, if OPPS rates are unavailable, at contractorpriced rates (72 FR 42499). Since December 31, 2009, ASCs have been paid for brachytherapy sources provided integral to ASC covered surgical procedures at prospective rates adopted under the OPPS. Our ASC policies also provide separate payment for: (1) Certain items and services that CMS designates as contractor-priced, including, but not limited to, the procurement of corneal tissue; and (2) certain implantable items that have pass-through payment status under the OPPS. These categories do not have prospectively established ASC payment rates according to ASC payment system policies (72 FR 42502 and 42508 through 42509; 42 CFR VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 416.164(b)). Under the ASC payment system, we have designated corneal tissue acquisition and hepatitis B vaccines as contractor-priced. Corneal tissue acquisition is contractor-priced based on the invoiced costs for acquiring the corneal tissue for transplantation. Hepatitis B vaccines are contractor-priced based on invoiced costs for the vaccine. Devices that are eligible for passthrough payment under the OPPS are separately paid under the ASC payment system and are contractor-priced. Under the revised ASC payment system (72 FR 42502), payment for the surgical procedure associated with the passthrough device is made according to our standard methodology for the ASC payment system, based on only the service (non-device) portion of the procedure’s OPPS relative payment weight if the APC weight for the procedure includes other packaged device costs. We also refer to this methodology as applying a ‘‘device offset’’ to the ASC payment for the associated surgical procedure. This ensures that duplicate payment is not provided for any portion of an implanted device with OPPS passthrough payment status. In the CY 2015 OPPS/ASC final rule with comment period (79 FR 66933 through 66934), we finalized that, beginning in CY 2015, certain diagnostic tests within the medicine range of CPT codes for which separate payment is allowed under the OPPS are covered ancillary services when they are integral to an ASC covered surgical procedure. We finalized that diagnostic tests within the medicine range of CPT codes include all Category I CPT codes in the medicine range established by CPT, from 90000 to 99999, and Category III CPT codes and Level II HCPCS codes that describe diagnostic tests that crosswalk or are clinically similar to procedures in the medicine range established by CPT. In the CY 2015 OPPS/ASC final rule with comment period, we also finalized our policy to pay for these tests at the lower of the PFS nonfacility PE RVU-based (or technical component) amount or the rate calculated according to the ASC standard ratesetting methodology (79 FR 66933 through 66934). We finalized that the diagnostic tests for which the payment is based on the ASC standard ratesetting methodology be assigned to payment indicator ‘‘Z2’’ and revised the definition of payment indicator ‘‘Z2’’ to include a reference to diagnostic services and those for which the payment is based on the PFS nonfacility PE RVU-based amount be assigned payment indicator ‘‘Z3,’’ and revised the PO 00000 Frm 00249 Fmt 4701 Sfmt 4700 59065 definition of payment indicator ‘‘Z3’’ to include a reference to diagnostic services. b. Payment for Covered Ancillary Services for CY 2019 In the CY 2019 OPPS/ASC proposed rule (83 FR 37164 through 37165), for CY 2019 and subsequent years, we proposed to update the ASC payment rates and to make changes to ASC payment indicators, as necessary, to maintain consistency between the OPPS and ASC payment system regarding the packaged or separately payable status of services and the proposed CY 2019 OPPS and ASC payment rates and subsequent year payment rates. We also proposed to continue to set the CY 2019 ASC payment rates and subsequent year payment rates for brachytherapy sources and separately payable drugs and biologicals equal to the OPPS payment rates for CY 2019 and subsequent year payment rates. Covered ancillary services and their proposed payment indicators for CY 2019 were listed in Addendum BB to the proposed rule (which is available via the internet on the CMS website). For those covered ancillary services where the payment rate is the lower of the proposed rates under the ASC standard rate setting methodology and the PFS proposed rates, the proposed payment indicators and rates set forth in the proposed rule are based on a comparison using the proposed PFS rates effective January 1, 2019. For a discussion of the PFS rates, we refer readers to the CY 2019 PFS proposed rule that is available on the CMS website at: https://www.cms.gov/ Medicare/Medicare-Fee-for-ServicePayment/PhysicianFeeSched/PFSFederal-Regulation-Notices.html. Comment: Commenters recommended that CMS pay separately for Cysview®, HCPCS code C9275 (hexaminolevulinate HCl), similar to the proposal to pay separately for Exparel. Commenters also recommended that CMS use its equitable payment adjustment authority under section 1833(t)(2)(E) of the Act to provide a drug ‘‘add-on’’ payment for certain procedures. Response: As discussed in the CY 2017 OPPS/ASC final rule with comment period (81 FR 79668), we continue to believe that Cysview® is a drug that functions as a supply in a diagnostic test or procedure and therefore is packaged with payment for the surgical procedure. In the CY 2019 OPPS/ASC proposed rule, we did not propose to make any changes to the ‘‘drugs that function as a supply in a diagnostic test or procedure’’ packaging E:\FR\FM\21NOR2.SGM 21NOR2 59066 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations khammond on DSK30JT082PROD with RULES2 policy or propose any drug ‘‘add-on’’ policies. Therefore, we are not accepting the commenters’ recommendation. Comment: One commenter recommended that CMS develop a policy that pays separately for drugs that are administered at the time of cataract surgery, but are not integral or necessary to the cataract procedure, and have an FDA-approved indication to treat/prevent postoperative issues. Response: We appreciate the commenter’s recommendation. We refer readers to section II.A.3. of this final rule with comment period for details related to the packaging policy for drugs that function as a supply in a surgical procedure or diagnostic test. While we did not propose such a change in the CY 2019 OPPS/ASC proposed rule, we will consider this recommendation in future rulemaking. 3. CY 2019 ASC Packaging Policy for Non-Opioid Pain Management Treatments In the CY 2018 OPPS/ASC proposed rule (82 FR 33588), within the framework of existing packaging categories, such as drugs that function as supplies in a surgical procedure or diagnostic test or procedure, we requested stakeholder feedback on common clinical scenarios involving currently packaged items and services described by HCPCS codes that stakeholders believe should not be packaged under the OPPS. We also expressed interest in stakeholder feedback on common clinical scenarios involving separately payable HCPCS codes for which payment would be most appropriately packaged under the OPPS. Commenters expressed a variety of views on packaging under the OPPS. In the CY 2018 OPPS/ASC final rule with comment period, we summarized the comments received in response to our request (82 FR 59255). The comments ranged from requests to unpackage most items and services that are either conditionally or unconditionally packaged under the OPPS, including drugs and devices, to specific requests for separate payment for a specific drug or device. We stated in the CY 2018 OPPS/ASC final rule with comment period that CMS would continue to explore and evaluate packaging policies under the OPPS and consider these policies in future rulemaking. In addition to stakeholder feedback regarding OPPS packaging policies, the President’s Commission on Combating Drug Addiction and the Opioid Crisis (the Commission) recently recommended that CMS examine payment policies for certain drugs that function as a supply, specifically non- VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 opioid pain management treatments. The Commission was established in 2017 to study ways to combat and treat drug abuse, addiction, and the opioid crisis. The Commission’s report 87 included a recommendation for CMS to ‘‘review and modify ratesetting policies that discourage the use of non-opioid treatments for pain, such as certain bundled payments that make alternative treatment options cost prohibitive for hospitals and doctors, particularly those options for treating immediate postsurgical pain. . . .’’ 88 With respect to the packaging policy, the Commission’s report states that ‘‘the current CMS payment policy for ‘supplies’ related to surgical procedures creates unintended incentives to prescribe opioid medications to patients for postsurgical pain instead of administering non-opioid pain medications. Under current policies, CMS provides one all-inclusive bundled payment to hospitals for all ‘surgical supplies,’ which includes hospitaladministered drug products intended to manage patients’ postsurgical pain. This policy results in the hospitals receiving the same fixed fee from Medicare whether the surgeon administers a nonopioid medication or not.’’ 89 HHS also presented an Opioid Strategy in April 2017 90 that aims in part to support cutting-edge research and advance the practice of pain management. On October 26, 2017, the opioid crisis was declared a national public health emergency under Federal law 91 and this determination was renewed on April 20, 2018.92 As discussed in the CY 2019 OPPS/ ASC proposed rule (83 FR 37067 through 37071), in response to stakeholder comments on the CY 2018 OPPS/ASC proposed rule and in light of the recommendations regarding payment policies for certain drugs, we recently evaluated the impact of our packaging policy for drugs that function as a supply when used in a surgical procedure on the utilization of these drugs in both the hospital outpatient 87 President’s Commission on Combating Drug Addiction and the Opioid Crisis, Report (2017). Available at: https://www.whitehouse.gov/sites/ whitehouse.gov/files/images/Final_Report_Draft_ 11-1-2017.pdf. 88 Ibid, at page 57, Recommendation 19. 89 Ibid. 90 Available at: https://www.hhs.gov/about/ leadership/secretary/speeches/2017-speeches/ secretary-price-announces-hhs-strategy-for-fightingopioid-crisis/. 91 Available at: https://www.hhs.gov/about/news/ 2017/10/26/hhs-acting-secretary-declares-publichealth-emergency-address-national-opioidcrisis.html. 92 Available at: https://www.phe.gov/emergency/ news/healthactions/phe/Pages/default.aspx. PO 00000 Frm 00250 Fmt 4701 Sfmt 4700 department and the ASC setting. Currently, as noted above, drugs that function as a supply are packaged under the OPPS and the ASC payment system, regardless of the costs of the drugs. The costs associated with packaged drugs that function as a supply are included in the ratesetting methodology for the surgical procedures with which they are billed and the payment rate for the associated procedure reflects the costs of the packaged drugs and other packaged items and services to the extent they are billed with the procedure. In our evaluation, we used currently available data to analyze the utilization patterns associated with specific drugs that function as a supply over a 5-year time period (CYs 2013 through 2017) to determine whether this packaging policy has reduced the use of these drugs. If the packaging policy discouraged the use of drugs that function as a supply or impeded access to these products, we would expect to see a significant decline in utilization of these drugs over time, although we note that a decline in utilization could also reflect other factors, such as the availability of alternative products. We did not observe significant declines in the total number of units used in the hospital outpatient department for a majority of the drugs included in our analysis. In fact, under the OPPS, we observed the opposite effect for several drugs that function as a supply, including Exparel (HCPCS code C9290). Exparel is a liposome injection of bupivacaine, an amide local anesthetic, indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. In 2011, Exparel was approved by the FDA for administration into the postsurgical site to provide postsurgical analgesia.93 Exparel had pass-through payment status from CYs 2012 through 2014 and was separately paid under both the OPPS and the ASC payment system during this 3-year period. Beginning in CY 2015, Exparel was packaged as a surgical supply under both the OPPS and the ASC payment system. Exparel is currently the only non-opioid pain management drug that is packaged as a drug that functions as a supply when used in a surgical procedure under the OPPS and the ASC payment system. From CYs 2013 through 2017, there was an overall increase in the OPPS Medicare utilization of Exparel of approximately 229 percent (from 2.3 million units to 7.7 million units) during this 5-year time period. The total number of claims reporting Exparel 93 Available at: https://www.accessdata.fda.gov/ drugsatfda_docs/label/2011/022496s000lbl.pdf. E:\FR\FM\21NOR2.SGM 21NOR2 khammond on DSK30JT082PROD with RULES2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations increased by 222 percent (from 10,609 claims to 34,183 claims) over this time period. This increase in utilization continued, even after the 3-year drug pass-through payment period ended for this product in 2014, with 18 percent overall growth in the total number of units used from CYs 2015 through 2017 (from 6.5 million units to 7.7 million units). The number of claims reporting Exparel increased by 21 percent during this time period (from 28,166 claims to 34,183 claims). Thus, we have not found evidence to support the notion that the OPPS packaging policy has had an unintended consequence of discouraging the use of non-opioid treatment for postsurgical pain management in the hospital outpatient department. Therefore, based on this data analysis, we stated in the CY 2019 OPPS/ASC proposed rule that we did not believe that changes were necessary under the OPPS for the packaged drug policy for drugs that function as a surgical supply when used in a surgical procedure in this setting at this time. In terms of Exparel in particular, we have received several requests to pay separately for the drug rather than packaging payment for it as a surgical supply. In the CY 2015 OPPS/ASC final rule with comment period (79 FR 66874 and 66875), in response to comments from stakeholders requesting separate payment for Exparel, we stated that we considered Exparel to be a drug that functions as a surgical supply because it is indicated for the alleviation of postoperative pain. We also stated that we consider all items related to the surgical outcome and provided during the hospital stay in which the surgery is performed, including postsurgical pain management drugs, to be part of the surgery for purposes of our drug and biological surgical supply packaging policy. In the CY 2018 OPPS/ASC final rule with comment period (82 FR 59345), we reiterated our position with regard to payment for Exparel, stating that we believed that payment for this drug is appropriately packaged with the primary surgical procedure. In addition, we have reviewed recently available literature with respect to Exparel, including a briefing document 94 submitted for the FDA Advisory Committee Meeting held February 14– 15, 2018, by the manufacturer of Exparel that notes that ‘‘Bupivacaine, the active 94 Food and Drug Administration, Meeting of the Anesthetic and Analgesic Drug Products Advisory Committee Briefing Document (2018). Available at: https://www.fda.gov/downloads/ AdvisoryCommittees/CommitteesMeetingMaterials/ Drugs/AnestheticAndAnalgesicDrug ProductsAdvisoryCommittee/UCM596314.pdf. VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 pharmaceutical ingredient in Exparel, is a local anesthetic that has been used for infiltration/field block and peripheral nerve block for decades’’ and that ‘‘since its approval, Exparel has been used extensively, with an estimated 3.5 million patient exposures in the US.’’ 95 On April 6, 2018, the FDA approved Exparel’s new indication for use as an interscalene brachial plexus nerve block to produce postsurgical regional analgesia.96 Therefore, we also stated in the CY 2019 OPPS/ASC proposed rule that, based on our review of currently available OPPS Medicare claims data and public information from the manufacturer of the drug, we did not believe that the OPPS packaging policy had discouraged the use of Exparel for either of the drug’s indications. Accordingly, we continue to believe it is appropriate to package payment for Exparel as we do with other postsurgical pain management drugs when it is furnished in a hospital outpatient department. However, we invited public comments on whether separate payment would nonetheless further incentivize appropriate use of Exparel in the hospital outpatient setting and peerreviewed evidence that such increased utilization would lead to a decrease in opioid use and addiction among Medicare beneficiaries. Comment: Several commenters requested that CMS pay separately for Exparel in the hospital outpatient setting. Some of these commenters noted that Exparel is used more frequently in this setting and the use of non-opioid pain management treatments should also be encouraged in the hospital outpatient department (HOPD). One commenter stated that since drug became packaged in 2015, utilization of the drug in the HOPD has remained flat while the opioid crisis has continued to worsen. The commenter suggested that to address the opioid crisis among Medicare beneficiaries, CMS should promote ‘‘increased penetration of nonopioid therapies in the HOPD setting— or in other words, higher rates of usage of non-opioid treatments for the same number of surgical procedures.’’ Response: This comment and other comments specific to packaging under the OPPS payment system are addressed in section II.A.3.b. of this final rule with comment period. We also stated in the proposed rule that, although we found increases in utilization for Exparel when it is paid under the OPPS, we did notice different effects on Exparel utilization when 95 Ibid, page 9. at: https://www.accessdata.fda.gov/ drugsatfda_docs/label/2018/022496s009lbledt.pdf. 96 Available PO 00000 Frm 00251 Fmt 4701 Sfmt 4700 59067 examining the effects of our packaging policy under the ASC payment system. In particular, during the same 5-year period of CYs 2013 through 2017, the total number of units of Exparel used in the ASC setting decreased by 25 percent (from 98,160 total units to 73,595 total units) and the total number of claims reporting Exparel decreased by 16 percent (from 527 claims to 441 claims). In the ASC setting, after the passthrough payment period ended for Exparel at the end of CY 2014, the total number of units of Exparel used decreased by 70 percent (from 244,757 units to 73,595 units) between CYs 2015 and 2017. The total number of claims reporting Exparel also decreased during this time period by 62 percent (from 1,190 claims to 441 claims). However, there was an increase of 238 percent (from 98,160 total units to 331,348 total units) in the total number of units of Exparel used in the ASC setting during the time period of CYs 2013 and 2014 when the drug received pass-through payments, indicating that the payment rate of ASP+6 percent for Exparel may have an impact on its usage in the ASC setting. The total number of claims reporting Exparel also increased during this time period from 527 total claims to 1,540 total claims, an increase of 192 percent. While several variables may contribute to this difference between utilization and claims reporting in the hospital outpatient department and the ASC setting, one potential explanation is that, in comparison to hospital outpatient departments, ASCs tend to provide specialized care and a more limited range of services. Also, ASCs are paid, in aggregate, approximately 55 percent of the OPPS rate. Therefore, fluctuations in payment rates for specific services may impact these providers more acutely than hospital outpatient departments, and therefore, ASCs may be less likely to choose to furnish non-opioid postsurgical pain management treatments, which are typically more expensive than opioids, as a result. Another possible contributing factor is that ASCs do not typically report packaged items and services and, accordingly, our analysis may be undercounting the number of Exparel units utilized in the ASC setting. In light of the results of our evaluation of packaging policies under the OPPS and the ASC payment system, which showed decreased utilization for certain drugs that function as a supply in the ASC setting in comparison to the hospital outpatient department setting, as well as the Commission’s recommendation to examine payment E:\FR\FM\21NOR2.SGM 21NOR2 khammond on DSK30JT082PROD with RULES2 59068 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations policies for non-opioid pain management drugs that function as a supply, we stated in the proposed rule that we believe a change in how we pay for non-opioid pain management drugs that function as surgical supplies may be warranted. In particular, we believe it may be appropriate to pay separately for evidence-based non-opioid pain management drugs that function as a supply in a surgical procedure in the ASC setting to address the decreased utilization of these drugs and to encourage use of these types of drugs rather than prescription opioids. Therefore, we proposed in section XII.D.3. of the CY 2019 OPPS/ASC proposed rule (83 FR 37068 through 37071) to unpackage and pay separately at ASP+6 percent for the cost of nonopioid pain management drugs that function as surgical supplies when they are furnished in the ASC setting for CY 2019. We have stated previously (82 FR 59250) that our packaging policies are designed to support our strategic goal of using larger payment bundles in the OPPS to maximize hospitals’ incentives to provide care in the most efficient manner. The packaging policies established under the OPPS also typically apply when services are provided in the ASC setting, and the policies have the same strategic goals in both settings. While the CY 2019 proposal is a departure from our current ASC packaging policy for drugs (specifically, non-opioid pain management drugs) that function as a supply when used in a surgical procedure, we stated in the proposed rule we believe that the proposed change will incentivize the use of nonopioid pain management drugs and is responsive to the Commission’s recommendation to examine payment policies for non-opioid pain management drugs that function as a supply, with the overall goal of combating the current opioid addiction crisis. As previously noted, a discussion of the CY 2019 proposal for payment of non-opioid pain management drugs in the ASC setting was presented in further detail in the proposed rule, and we include a further discussion of the final policy for CY 2019 below. However, we also stated in the CY 2019 OPPS/ASC proposed rule that we were interested in peer-reviewed evidence that demonstrates that non-opioid alternatives, such as Exparel, in the outpatient setting actually do lead to a decrease in prescription opioid use and addiction and invited public comments containing evidence that demonstrate whether and how such non-opioid VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 alternatives affect prescription opioid use during or after an outpatient visit or procedure. As noted above, for CY 2019, we proposed to pay separately at average sales price (ASP)+6 percent for nonopioid pain management drugs that function as a supply when used in a surgical procedure when the procedure is performed in the ASC setting. As described in section V.A.1. of the proposed rule, section 1847A of the Act establishes the ASP methodology, which is used for payment for drugs and biologicals described in section 1842(o)(1)(C) of the Act furnished on or after January 1, 2005. The ASP methodology, as applied under the OPPS, uses several sources of data as a basis for payment, including the ASP, the wholesale acquisition cost (WAC), and the average wholesale price (AWP) (82 FR 59337). As noted in section V.B.2.b. of the proposed rule, since CY 2013, our policy has been to pay for separately payable drugs and biologicals at ASP+6 percent in accordance with section 1833(t)(14)(A)(iii)(II) of the Act (the statutory default) (82 FR 59350). In the proposed rule (83 FR 37167), we did not propose a change to the packaging policy under the OPPS for CY 2019. However, we proposed to pay separately at ASP+6 percent for nonopioid pain management drugs that function as a supply when used in a surgical procedure when the procedure is performed in the ASC setting for CY 2019. Because the ASC payment rate also includes packaged payment for non-opioid pain management drugs, we intend to remove the packaged costs attributable to non-opioid pain management drugs—at this time, only Exparel qualifies—from the applicable OPPS rates prior to establishing the ASC rates in order to prevent potential overpayment of these procedures when separate payment is provided in the ASC setting. Of the drugs that are currently packaged in the ASC setting, this policy would apply to Exparel. Exparel is the only non-opioid pain management drug that functions as a supply when used in a surgical procedure that is covered under Medicare Part B. While there are other non-opioid pain management drugs available that are also administered post-surgically, such as non-steroidal anti-inflammatory drugs (‘‘NSAIDs’’), Exparel is the currently the only drug used in the ASC setting that is both covered under Medicare Part B and policy packaged as a drug that functions as a supply in a surgical procedure. To the extent that other nonopioid drugs that function as surgical supplies come onto the U.S. market, we PO 00000 Frm 00252 Fmt 4701 Sfmt 4700 proposed that this policy would apply to them as well in CY 2019. This proposal was also presented in section II.A.3.b. of the proposed rule for the OPPS. We proposed several conforming changes to the ASC regulation to implement this proposal. Specifically, at 42 CFR 416.164(a)(4), we proposed a change to exclude nonopioid pain management drugs that function as a supply when used in a surgical procedure from our policy to package drugs and biologicals for which separate payment is not allowed under the OPPS into the ASC payment for a covered surgical procedure. Similarly, we proposed to add 42 CFR 416.164(b)(6) to include non-opioid pain management drugs that function as a supply when used in a surgical procedure as a covered ancillary service. Finally, we proposed a conforming change to 42 CFR 416.171(b)(1) to exclude non-opioid pain management drugs that function as a supply when used in a surgical procedure from our policy to pay for ASC covered ancillary services an amount derived from the payment rate for the equivalent item or service set under the OPPS. Comment: Several commenters supported the proposal to unpackage and pay separately at ASP+6 percent for the cost of non-opioid pain management drugs that function as a supply in the ASC setting, such as Exparel, for CY 2019. These commenters believed that packaged payment for non-opioid alternatives presents a barrier to care and that separate payment for nonopioid pain management drugs would be an appropriate response to the opioid drug abuse epidemic. Other commenters, including MedPAC, did not support this proposal and stated that the policy was counter to the OPPS packaging policies created to encourage efficiencies and could set a precedent for unpackaging services. One commenter stated that Exparel is more costly, but not more effective than bupivacaine, a less costly non-opioid alternative. Other commenters expressed concerns that the proposal may have the unintended consequence of limiting access to opioid prescriptions for beneficiaries for whom an opioid prescription would be appropriate. The commenters noted that some non-opioid pain management treatments may pose other risks for patients and patient safety. Response: We appreciate the commenters’ input. We continue to believe that, under current circumstances, it is appropriate to pay separately for non-opioid pain management drugs that function as a supply in a surgical procedure in the E:\FR\FM\21NOR2.SGM 21NOR2 khammond on DSK30JT082PROD with RULES2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations ASC setting where there is evidence that their use leads to decreased opioid use and/or addiction among Medicare beneficiaries following an outpatient visit or procedure. We believe this policy will encourage use of these types of drugs rather than prescription opioids. With regard to the comments that paying separately for these drugs could set a precedent for unpackaging other services, while we acknowledge that this policy is a departure from the current ASC packaging policy for drugs that function as a supply, we also believe that the limited scope of this policy, in terms of both the services included (evidence-based non-opioid pain management drugs) and the setting (ASCs) is sufficiently narrow and will not set an unwarranted precedent for the unpackaging of other OPPS or ASC services. We also do not believe that this policy will limit access to opioid prescriptions for beneficiaries for whom an opioid prescription would be appropriate. Exparel and other nonopioid pain management drugs packaged under the drugs that function as a supply policy are used to treat acute post-surgical pain and paying separately for these drugs under the ASC payment system will not prevent physicians from prescribing opioids for treating pain when appropriate. Also, we have a longstanding recognition that the decision on how to best treat a patient is a complex medical judgment made by the physician based on each individual beneficiary’s unique clinical circumstances. With regard to concerns that some non-opioid pain management treatments pose other risks for patients and patient safety, the commenter did not identify any specific non-opioid pain management treatments in its comment. Exparel, the only drug to which the proposed policy applies, is currently being safely used in both the OPPS and ASC settings. This comment is also presented in section II.A.3.b of this final rule with comment period. In addition, as noted in section XII.D.3. of the proposed rule, we sought comments on whether the proposed policy would decrease the dose, duration, and/or number of opioid prescriptions beneficiaries receive during and following an outpatient visit or procedure (especially for beneficiaries at high-risk for opioid addiction) as well as whether there are other non-opioid pain management alternatives that would have similar effects and may warrant separate payment. For example, we stated we were interested in identifying whether single post-surgical analgesic injections, such as Exparel, or other non-opioid VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 drugs or devices that are used during an outpatient visit or procedure are associated with decreased opioid prescriptions and/or reduced cases of associated opioid addiction following such an outpatient visit or procedure. We also requested comments that provide evidence (such as published peer-reviewed literature) we could use to determine whether these products help to deter or avoid prescription opioid use and addiction as well as evidence that the current packaged payment for such non-opioid alternatives presents a barrier to access to care and, therefore, warrants separate payment under either or both the OPPS and the ASC payment system. We stated that any evidence demonstrating the reduction or avoidance of prescription opioids would be the criteria we use to determine whether separate payment is warranted for CY 2019. We also stated that, should evidence change over time, we would consider whether a reexamination of any policy adopted in the final rule would be necessary. Comment: With regard to whether the proposed policy would decrease the dose, duration, and/or number of opioid prescriptions beneficiaries receive during and following an outpatient visit or procedure and supportive evidence of these reductions, a commenter submitted studies that claimed that the use of Exparel by Medicare patients undergoing total knee replacement procedures reduced prescription opioid consumption by 90 percent compared to the control group measured at 48 hours post-surgery.97 The commenter submitted additional studies claiming statistically significant reductions in opioid use with the use of Exparel for various surgeries including laparotomy, shoulder replacement, and breast reconstruction. Several commenters identified other non-opioid pain management drugs that they believe decrease the dose, duration, and/or number of opioid prescriptions beneficiaries receive during and following an outpatient visit or procedure (especially for beneficiaries at high-risk for opioid addiction) and may warrant separate payment for CY 2019. Several commenters submitted supporting studies which claimed that a non-opioid intrathecal infusion drug indicated for the management of severe chronic pain reduced opioid use in patients with chronic pain. Other commenters representing hospitals, hospital associations, and 97 Michael A. Mont et al., Local Infiltration Analgesia With Liposomal Bupivacaine Improves Pain Scores and Reduces Opioid Use After Total Knee Arthroplasty: Results of a Randomized Controlled Trial. J. of Arthroplasty (2018). PO 00000 Frm 00253 Fmt 4701 Sfmt 4700 59069 clinical specialty organizations requested separate payment for IV acetaminophen, IV ibuprofen, and epidural steroid injections. In addition, one commenter, the manufacturers of a non-opioid analgesic containing bupivacaine hcl, but not currently approved by FDA, requested clarification regarding whether the proposal would also apply to this drug once it receives FDA approval. Several commenters requested separate payment for a drug which treats post-operative pain after cataract surgery, currently has drug pass-through status, and therefore is not packaged under the OPPS or ASC. The commenters requested that CMS explicitly state this drug will also be paid for separately in the ASC setting after pass-through status ends for the drug in 2020. Lastly, one commenter requested that a diagnostic drug that is not a non-opioid receive separate payment. Response: We appreciate these comments. After reviewing the studies provided by the commenters, we continue to believe the separate payment is appropriate for Exparel in the ASC setting. At this time, we have not found compelling evidence for other non-opioid pain management drugs described above to warrant separate payment at this time. Also, with regard to the requests for CMS to confirm that the proposed policy would also apply in the future to certain non-opioid pain management drugs, we reiterate that the proposed policy is for CY 2019 and is applicable to non-opioid pain management drugs that that are currently packaged under the policy for drugs that function as a surgical supply when used in the ASC setting, which currently is only Exparel. To the extent that other non-opioid pain management drugs that function as a surgical supply become available in the U.S. market in CY 2019, this policy would also apply to those drugs. As noted above, we stated in the proposed rule that we were interested in comments regarding other non-opioid treatments besides Exparel that might be affected by OPPS and ASC packaging policies, including alternative, nonopioid pain treatments, such as devices or therapy services that are not currently separable payable. We stated that we were specifically interested in comments regarding whether CMS should consider separate payment for items and services for which payment is currently packaged under the OPPS and the ASC payment system that are effective non-opioid alternatives as well as evidence that demonstrates such items and services lead to a decrease in prescription opioid use and/or E:\FR\FM\21NOR2.SGM 21NOR2 khammond on DSK30JT082PROD with RULES2 59070 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations addiction during or after an outpatient visit or procedure in order to determine whether separate payment may be warranted. As previously stated, we intended to examine the evidence submitted to determine whether to adopt a final policy in this final rule with comment period that incentivizes use of non-opioid alternative items and services that have evidence to demonstrate an associated decrease in prescription opioid use and/or addiction following an outpatient visit or procedure. Some examples of evidence that may be relevant could include an indication on the product’s FDA label or studies published in peerreviewed literature that such product aids in the management of acute or chronic pain and is an evidence-based non-opioid alternative for acute and/or chronic pain management. We indicated in the proposed rule that we also were interested in evidence relating to products that have shown clinical improvement over other alternatives, such as a device that has been shown to provide a substantial clinical benefit over the standard of care for pain management. We stated this could include, for example, spinal cord stimulators used to treat chronic pain such as the devices described by HCPCS codes C1822 (Generator, neurostimulator (implantable), high frequency, with rechargeable battery and charging system), C1820 (Generator, neurostimulator (implantable), with rechargeable battery and charging system), and C1767 (Generator, neurostimulator (implantable), nonrechargeable) which are primarily assigned to APCs 5463 and 5464 (Levels 3 and 4 Neurostimulator and Related Procedures) with proposed CY 2019 payment rates of $18,718 and $27,662, respectively, that have received passthrough payment status as well as other similar devices. Currently, all devices are packaged under the OPPS and the ASC payment system unless they have pass-through payment status. However, we stated in the proposed rule that, in light of the Commission’s recommendation to review and modify ratesetting policies that discourage the use of non-opioid treatments for pain, we were interested in comments from stakeholders regarding whether, similar to the goals of the proposed payment policy for nonopioid pain management drugs that function as a supply when used in a surgical procedure, a policy of providing separate payment (rather than packaged payment) for these products, indefinitely or for a specified period of time, would also incentivize the use of VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 alternative non-opioid pain management treatments and improve access to non-opioid alternatives, particularly for innovative and lowvolume items and services. We also stated that we were interested in comments regarding whether we should provide separate payment for non-opioid pain management treatments or products using a mechanism such as an equitable payment adjustment under our authority at section 1833(t)(2)(E) of the Act, which states that the Secretary shall establish, in a budget neutral manner, other adjustments as determined to be necessary to ensure equitable payments. For example, we stated in the proposed rule that we were considering whether an equitable payment adjustment in the form of an add-on payment for APCs that use a non-opioid pain management drug, device, or service would be appropriate. We indicated that, to the extent that commenters provided evidence to support this approach, we would consider adopting a final policy in this final rule with comment period, which could include regulatory changes that would allow for an exception to the packaging of certain nonpass-through devices that represent non-opioid alternatives for acute or chronic pain that have evidence to demonstrate that their use leads to a decrease in opioid prescriptions and/or addictions during or after an outpatient visit or procedure to effectuate such change. Comment: Several commenters stated that separate payment for spinal cord stimulators (SCS) was also warranted because these devices provide an alternative treatment option to opioids for patients with chronic, leg or back pain. One commenter provided supporting studies which claimed that patients treated with their device reported a statistically significant average decrease in opioid use compared to the control group.98 This commenter also submitted data that showed a decline in the mean daily dosage of opioid medication taken and that fewer patients were relying on opioids at all to manage their pain when they used the manufacturer’s device.99 98 Kapural L, Yu C, Doust MW, Gliner BE, Vallejo R, Sitzman BT, Amirdelfan K, Morgan DM, Brown LL, Yearwood TL, Bundschu R, Burton AW, Yang T, Benyamin R, Burgher AH. Novel 10-kHz highfrequency therapy (HF10 therapy) is superior to traditional low-frequency spinal cord stimulation for the treatment of chronic back and leg pain: The SENZA–RCT randomized controlled trial, ANESTHESIOLOGY. 2015 Oct;123(4):851–60. 99 Al-Kaisy A, Van Buyten JP, Smet I, Palmisani S, Pang D, Smith T. Sustained effectiveness of 10 kHz high-frequency spinal cord stimulation for patients with chronic, low back pain: 24-month results of a prospective multicenter study. PAIN MED. 2014 Mar; 15(3):347–54. PO 00000 Frm 00254 Fmt 4701 Sfmt 4700 Another commenter stated that there are few peer-reviewed studies that evaluate opioid elimination and/or reduction following SCS and that there is a need for more population based research with opioid reduction or elimination as a study endpoint. However, this commenter believed that current studies suggest that opioid use may be reduced following SCS therapy. Other commenters requested separate payments for various non-opioid pain management treatments such as: Continuous nerve blocks (including a disposable elastomeric pump that delivers non-opioid local anesthetic to a surgical site or nerve); cooled thermal radiofrequency ablation for nonsurgical, chronic nerve pain; and physical therapy services. These commenters also stated that while ‘‘certainly not a solution to the opioid epidemic, unpackaging appropriate nonopioid therapies, like Exparel, is a lowcost tactic that could change longstanding practice patterns without major negative consequences.’’ One commenter suggested that Medicare consider separate payment for Polar ice devices for post-operative pain relief after knee procedures. The commenter also noted that therapeutic massage, topically applied THC oil, acupuncture, and dry needling procedures are very effective therapies for relief of both postoperative pain and long-term and chronic pain. Commenters suggested various mechanisms through which separate payment or a higher paying APC assignment for the primary service could be made. Commenters offered reports, studies and anecdotal evidence to support why the items or services about which the commenters believed offered alternatives to or reduction of the need for opioid prescriptions. Response: We appreciate the thoughtful response to our solicitation for comments on this topic. We plan to take these suggestions into consideration for future rulemaking. We agree that providing incentives to avoid and/or reduce opioid prescriptions may be one of several strategies for addressing the opioid epidemic. To the extent that the items and services mentioned by the commenters are effective alternatives to opioid prescriptions, we encourage providers to use them when medically necessary. We note that some of the items and services mentioned by commenters are not covered by Medicare and we do not intend to establish payment for noncovered items and services. We look forward to working with stakeholders as we further consider suggested refinements to the OPPS and the ASC E:\FR\FM\21NOR2.SGM 21NOR2 khammond on DSK30JT082PROD with RULES2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations payment system that will encourage use of medically necessary items and services that have demonstrated efficacy in decreasing opioid prescriptions and/or addictions during or after an outpatient visit or procedure. Comment: One commenter suggested that CMS provide separate payment for HCPCS code A4306 (Disposable drug delivery system, flow rate of less than 50 ml per hour) in the hospital outpatient department and the ASC settings following a post-surgery procedure. This commenter explained that if a patient needs additional pain relief three to five days post-surgery, a facility cannot receive payment for providing a replacement disposable drug delivery system HCPCS code A4306 unless the entire continuous nerve block procedure is performed. This commenter believed that CMS should allow for HCPCS code A4306 to be dispensed to the patient as long as the patient is in pain, the pump is empty, and the delivery catheters are still in place. The commenter believed that the ASC payment system should incentivize the continued use of nonopioid alternatives when needed. Several commenters stated that CMS should use an equitable payment adjustment under its authority at section 1833(t)(2)(E) of the Act to establish addon payments for packaged devices used as non-opioid alternatives. Response: We appreciate the commenters’ suggestions. We acknowledge that use of these items may help in the reduction of opioid use post operatively. However, we note that packaged payment of such item does not prevent the use of these items. We remind readers that payment for packaged items is included in the payment for the primary service. We share the commenter’s concern about the need to reduce opioid use and will take the commenter’s suggestion into consideration for future rulemaking. After reviewing the non-opioid pain management alternatives suggested by the commenters as well as the studies and other data provided to support the request for separate payment, we have not determined that separate payment is warranted at this time for any of the non-opioid pain management alternatives discussed above. We also invited comments on whether a reorganization of the APC structure for procedures involving non-opioid products or establishing more granular APC groupings for specific procedure and device combinations to ensure that the payment rate for such services is aligned with the resources associated with procedures involving specific devices would better achieve our goal of VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 incentivizing increased use of nonopioid alternatives, with the aim of reducing opioid use and subsequent addiction. For example, we stated we would consider finalizing a policy to establish new APCs for procedures involving non-opioid pain management packaged items or services if such APCs would better recognize the resources involved in furnishing such items and services and decrease or eliminate the need for prescription opioids. In addition, given the general desire to encourage provider efficiency through creating larger bundles of care and packaging items and services that are integral, ancillary, supportive, dependent, or adjunctive to a primary service, we also invited comments on how such alternative payment structures would continue to balance the goals of incentivizing provider efficiencies with encouraging the use of non-opioid alternatives to pain management. Furthermore, because patients may receive opioid prescriptions following receipt of a non-opioid drug or implantation of a device, we stated that we were interested in identifying any cost implications for the patient and the Medicare program caused by this potential change in policy. We also stated that the implications of incentivizing use of non-opioid pain management drugs available for postsurgical acute pain relief during or after an outpatient visit or procedure are of interest. The goal is to encourage appropriate use of such non-opioid alternatives. As previously stated, this comment solicitation is also discussed in section XII.D.3. of this final rule with comment period. Comment: One commenter suggested that CMS restructure the two-level Nerve Procedure APCs (5431 and 5432) to provide more payment granularity for the procedures included in the APCs by creating a third level. Response: We refer readers to section III.D.6. of this final rule with comment period for a discussion of this comment. We believe that the current two-level APCs for the Nerve Procedures provide an appropriate distinction between the resource costs at each level and provide clinical homogeneity. We will continue to review this APC structure, to determine if additional granularity is necessary for this APC family in future rulemaking. In addition, we believe that more analysis of such groupings is necessary before adopting such change. In addition, we invited the public to submit ideas on regulatory, subregulatory, policy, practice, and procedural changes to help prevent opioid use disorders and improve access PO 00000 Frm 00255 Fmt 4701 Sfmt 4700 59071 to treatment under the Medicare program. We stated that we were interested in identifying barriers that may inhibit access to non-opioid alternatives for pain treatment and management or access to opioid use disorder treatment, including those barriers related to payment methodologies or coverage. In addition, consistent with our ‘‘Patients Over Paperwork’’ Initiative, we stated that we were interested in suggestions to improve existing requirements in order to more effectively address the opioid epidemic. Comment: Several commenters offered views regarding payment barriers that may inhibit access to nonopioid pain management treatments which have been previously discussed throughout this section. With regard to barriers related to payment methodologies or coverage, some commenters suggested that CMS support multi-modal pain management and enhanced recovery after surgery (ERAS) and encourage patient access to certified registered nurse anesthetist (CRNA) pain management. One commenter also suggested that CMS reduce cost sharing and eliminate the need for prior authorization for nonopioid pain management strategies. Response: We appreciate the various, insightful comments received from stakeholders regarding barriers that may inhibit access to non-opioid alternatives for pain treatment and management in order to more effectively address the opioid epidemic. Many of these comments have been previously addressed throughout this section. After consideration of the public comments that we received, we are finalizing the policy to unpackage and pay separately at ASP+6 percent for the cost of non-opioid pain management drugs that function as surgical supplies when they are furnished in the ASC setting for CY 2019 as proposed. We also are finalizing our conforming changes to the ASC regulation as proposed. Specifically, we are finalizing our proposed conforming changes to 42 CFR 416.164(a)(4) to exclude non-opioid pain management drugs that function as a supply when used in a surgical procedure from our policy to package payment for drugs and biologicals for which separate payment is not allowed under the OPPS into the ASC payment for the covered surgical procedure. We also are adding a new paragraph (6) to 42 CFR 416.164(b) to include nonopioid pain management drugs that function as a supply when used in a surgical procedure as covered ancillary services that are integral to a covered surgical procedure. Finally, we are E:\FR\FM\21NOR2.SGM 21NOR2 59072 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations finalizing our proposed change to 42 CFR 416.171(b)(1) to exclude nonopioid pain management drugs that function as a supply when used in a surgical procedure from our policy to pay for ASC covered ancillary services an amount derived from the payment rate for the equivalent item or service set under the OPPS. We will continue to analyze this issue on access to non-opioid alternatives in the OPPS and ASC settings as we implement section 6082 of the Substance Use—Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act (Pub. L. 115–271) enacted on October 24, 2018. This policy is also discussed in section II.A.3.b. of this final rule with comment period. khammond on DSK30JT082PROD with RULES2 E. New Technology Intraocular Lenses (NTIOLs) New Technology Intraocular Lenses (NTIOLs) are intraocular lenses that replace a patient’s natural lens that has been removed in cataract surgery and that also meet the requirements listed in 42 CFR 416.195. 1. NTIOL Application CycleOur process for reviewing applications to establish new classes of NTIOLs is as follows: • Applicants submit their NTIOL requests for review to CMS by the annual deadline. For a request to be considered complete, we require submission of the information that is found in the guidance document entitled ‘‘Application Process and Information Requirements for Requests for a New Class of New Technology Intraocular Lenses (NTIOLs) or Inclusion of an IOL in an Existing NTIOL Class’’ posted on the CMS website at: https://www.cms.gov/ Medicare/Medicare-Fee-for-ServicePayment/ASCPayment/NTIOLs.html. • We announce annually, in the proposed rule updating the ASC and OPPS payment rates for the following calendar year, a list of all requests to establish new NTIOL classes accepted for review during the calendar year in which the proposal is published. In accordance with section 141(b)(3) of Public Law 103–432 and our regulations at 42 CFR 416.185(b), the deadline for receipt of public comments is 30 days following publication of the list of requests in the proposed rule. • In the final rule updating the ASC and OPPS payment rates for the following calendar year, we— ++ Provide a list of determinations made as a result of our review of all new NTIOL class requests and public comments; VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 ++ When a new NTIOL class is created, identify the predominant characteristic of NTIOLs in that class that sets them apart from other IOLs (including those previously approved as members of other expired or active NTIOL classes) and that is associated with an improved clinical outcome. ++ Set the date of implementation of a payment adjustment in the case of approval of an IOL as a member of a new NTIOL class prospectively as of 30 days after publication of the ASC payment update final rule, consistent with the statutory requirement. ++ Announce the deadline for submitting requests for review of an application for a new NTIOL class for the following calendar year. 2. Requests To Establish New NTIOL Classes for CY 2019 We did not receive any requests for review to establish a new NTIOL class for CY 2019 by March 1, 2018, the due date published in the CY 2018 OPPS/ ASC final rule with comment period (82 FR 59416). 3. Payment Adjustment The current payment adjustment for a 5-year period from the implementation date of a new NTIOL class is $50 per lens. Since implementation of the process for adjustment of payment amounts for NTIOLs in 1999, we have not revised the payment adjustment amount, and we are not proposing to revise the payment adjustment amount for CY 2019. 4. Announcement of CY 2020 Deadline for Submitting Requests for CMS Review of Applications for a New Class of NTIOLs In accordance with § 416.185(a) of our regulations, CMS announces that in order to be considered for payment effective beginning in CY 2020, requests for review of applications for a new class of new technology IOLs must be received at CMS by 5:00 p.m. EST, on March 1, 2019. Send requests to ASC/ NTIOL, Division of Outpatient Care, Mailstop C4–05–17, Centers for Medicare and Medicaid Services, 7500 Security Boulevard, Baltimore, MD 21244–1850. To be considered, requests for NTIOL reviews must include the information requested on the CMS website at: https://www.cms.gov/ Medicare/Medicare-Fee-for-ServicePayment/ASCPayment/NTIOLs.html. F. ASC Payment and Comment Indicators 1. Background In addition to the payment indicators that we introduced in the August 2, PO 00000 Frm 00256 Fmt 4701 Sfmt 4700 2007 final rule, we created final comment indicators for the ASC payment system in the CY 2008 OPPS/ ASC final rule with comment period (72 FR 66855). We created Addendum DD1 to define ASC payment indicators that we use in Addenda AA and BB to provide payment information regarding covered surgical procedures and covered ancillary services, respectively, under the revised ASC payment system. The ASC payment indicators in Addendum DD1 are intended to capture policy-relevant characteristics of HCPCS codes that may receive packaged or separate payment in ASCs, such as whether they were on the ASC CPL prior to CY 2008; payment designation, such as device-intensive or office-based, and the corresponding ASC payment methodology; and their classification as separately payable ancillary services, including radiology services, brachytherapy sources, OPPS passthrough devices, corneal tissue acquisition services, drugs or biologicals, or NTIOLs. We also created Addendum DD2 that lists the ASC comment indicators. The ASC comment indicators used in Addenda AA and BB to the proposed rules and final rules with comment period serve to identify, for the revised ASC payment system, the status of a specific HCPCS code and its payment indicator with respect to the timeframe when comments will be accepted. The comment indicator ‘‘NP’’ is used in the OPPS/ASC proposed rule to indicate new codes for the next calendar year for which the interim payment indicator assigned is subject to comment. The comment indicator ‘‘NP’’ also is assigned to existing codes with substantial revisions to their descriptors, such that we consider them to be describing new services, as discussed in the CY 2010 OPPS/ASC final rule with comment period (74 FR 60622). In the CY 2017 OPPS/ASC final rule with comment period, we responded to public comments and finalized the ASC treatment of all codes that were labeled with comment indicator ‘‘NP’’ in Addenda AA and BB to the CY 2016 OPPS/ASC final rule with comment period (80 FR 70497). The ‘‘CH’’ comment indicator is used in Addenda AA and BB to the proposed rule (which are available via the internet on the CMS website) to indicate that the payment indicator assignment has changed for an active HCPCS code in the current year and the next calendar year, for example if an active HCPCS code is newly recognized as payable in ASCs; or an active HCPCS code is discontinued at the end of the current calendar year. The ‘‘CH’’ comment E:\FR\FM\21NOR2.SGM 21NOR2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations indicators that are published in the final rule with comment period are provided to alert readers that a change has been made from one calendar year to the next, but do not indicate that the change is subject to comment. In the CY 2017 OPPS/ASC final rule with comment period (81 FR 79748 through 79749), for CY 2017 and subsequent years, we finalized our policy to continue using the current comment indicators of ‘‘NP’’ and ‘‘CH’’. khammond on DSK30JT082PROD with RULES2 2. ASC Payment and Comment Indicators In the CY 2019 OPPS/ASC proposed rule, for CY 2019, there were proposed new and revised Category I and III CPT codes as well as new and revised Level II HCPCS codes. Therefore, proposed Category I and III CPT codes that are new and revised for CY 2018 and any new and existing Level II HCPCS codes with substantial revisions to the code descriptors for CY 2019 compared to the CY 2018 descriptors that were included in ASC Addenda AA and BB to the proposed rule are labeled with proposed comment indicator ‘‘NP’’ to indicate that these CPT and Level II HCPCS codes are open for comment as part of the proposed rule. Proposed comment indicator ‘‘NP’’ means a new code for the next calendar year or an existing code with substantial revision to its code descriptor in the next calendar year, as compared to current calendar year; and denotes that comments will be accepted on the proposed ASC payment indicator for the new code. In the proposed rule, we stated that we would respond to public comments on ASC payment and comment indicators and finalize their ASC assignment in this CY 2019 OPPS/ASC final rule with comment period. We refer readers to Addenda DD1 and DD2 to the proposed rule (which are available via the internet on the CMS website) for the complete list of ASC payment and comment indicators proposed for the CY 2019 update. We did not receive any public comments on the ASC payment and comment indicators. Therefore, we are finalizing their use as proposed without modification. Addenda DD1 and DD2 to this final rule with comment period (which are available via the internet on the CMS website) contain the complete list of ASC payment and comment indicators for the CY 2019 update. G. Calculation of the ASC Payment Rates and the ASC Conversion Factor 1. Background In the August 2, 2007 final rule (72 FR 42493), we established our policy to VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 base ASC relative payment weights and payment rates under the revised ASC payment system on APC groups and the OPPS relative payment weights. Consistent with that policy and the requirement at section 1833(i)(2)(D)(ii) of the Act that the revised payment system be implemented so that it would be budget neutral, the initial ASC conversion factor (CY 2008) was calculated so that estimated total Medicare payments under the revised ASC payment system in the first year would be budget neutral to estimated total Medicare payments under the prior (CY 2007) ASC payment system (the ASC conversion factor is multiplied by the relative payment weights calculated for many ASC services in order to establish payment rates). That is, application of the ASC conversion factor was designed to result in aggregate Medicare expenditures under the revised ASC payment system in CY 2008 being equal to aggregate Medicare expenditures that would have occurred in CY 2008 in the absence of the revised system, taking into consideration the cap on ASC payments in CY 2007, as required under section 1833(i)(2)(E) of the Act (72 FR 42522). We adopted a policy to make the system budget neutral in subsequent calendar years (72 FR 42532 through 42533; 42 CFR 416.171(e)). We note that we consider the term ‘‘expenditures’’ in the context of the budget neutrality requirement under section 1833(i)(2)(D)(ii) of the Act to mean expenditures from the Medicare Part B Trust Fund. We do not consider expenditures to include beneficiary coinsurance and copayments. This distinction was important for the CY 2008 ASC budget neutrality model that considered payments across the OPPS, ASC, and MPFS payment systems. However, because coinsurance is almost always 20 percent for ASC services, this interpretation of expenditures has minimal impact for subsequent budget neutrality adjustments calculated within the revised ASC payment system. In the CY 2008 OPPS/ASC final rule with comment period (72 FR 66857 through 66858), we set out a step-bystep illustration of the final budget neutrality adjustment calculation based on the methodology finalized in the August 2, 2007 final rule (72 FR 42521 through 42531) and as applied to updated data available for the CY 2008 OPPS/ASC final rule with comment period. The application of that methodology to the data available for the CY 2008 OPPS/ASC final rule with comment period resulted in a budget neutrality adjustment of 0.65. PO 00000 Frm 00257 Fmt 4701 Sfmt 4700 59073 For CY 2008, we adopted the OPPS relative payment weights as the ASC relative payment weights for most services and, consistent with the final policy, we calculated the CY 2008 ASC payment rates by multiplying the ASC relative payment weights by the final CY 2008 ASC conversion factor of $41.401. For covered office-based surgical procedures, covered ancillary radiology services (excluding covered ancillary radiology services involving certain nuclear medicine procedures or involving the use of contrast agents, as discussed in section XII.D.2. of this final rule with comment period), and certain diagnostic tests within the medicine range that are covered ancillary services, the established policy is to set the payment rate at the lower of the MPFS unadjusted nonfacility PE RVU-based amount or the amount calculated using the ASC standard ratesetting methodology. Further, as discussed in the CY 2008 OPPS/ASC final rule with comment period (72 FR 66841 through 66843), we also adopted alternative ratesetting methodologies for specific types of services (for example, deviceintensive procedures). As discussed in the August 2, 2007 final rule (72 FR 42517 through 42518) and as codified at § 416.172(c) of the regulations, the revised ASC payment system accounts for geographic wage variation when calculating individual ASC payments by applying the pre-floor and pre-reclassified IPPS hospital wage indexes to the labor-related share, which is 50 percent of the ASC payment amount based on a GAO report of ASC costs using 2004 survey data. Beginning in CY 2008, CMS accounted for geographic wage variation in labor costs when calculating individual ASC payments by applying the pre-floor and pre-reclassified hospital wage index values that CMS calculates for payment under the IPPS, using updated Core Based Statistical Areas (CBSAs) issued by OMB in June 2003. The reclassification provision in section 1886(d)(10) of the Act is specific to hospitals. We believe that using the most recently available pre-floor and pre-reclassified IPPS hospital wage indexes results in the most appropriate adjustment to the labor portion of ASC costs. We continue to believe that the unadjusted hospital wage indexes, which are updated yearly and are used by many other Medicare payment systems, appropriately account for geographic variation in labor costs for ASCs. Therefore, the wage index for an ASC is the pre-floor and pre-reclassified hospital wage index under the IPPS of the CBSA that maps to the CBSA where the ASC is located. E:\FR\FM\21NOR2.SGM 21NOR2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations On February 28, 2013, OMB issued OMB Bulletin No. 13–01, which provides the delineations of all Metropolitan Statistical Areas, Metropolitan Divisions, Micropolitan Statistical Areas, Combined Statistical Areas, and New England City and Town Areas in the United States and Puerto Rico based on the standards published on June 28, 2010 in the Federal Register (75 FR 37246 through 37252) and 2010 Census Bureau data. (A copy of this bulletin may be obtained at: https:// www.whitehouse.gov/sites/ whitehouse.gov/files/omb/bulletins/ 2013/b13-01.pdf.) In the FY 2015 IPPS/ LTCH PPS final rule (79 FR 49951 through 49963), we implemented the use of the CBSA delineations issued by OMB in OMB Bulletin 13–01 for the IPPS hospital wage index beginning in FY 2015. In the CY 2015 OPPS/ASC final rule with comment period (79 FR 66937), we finalized a 1-year transition policy that we applied in CY 2015 for all ASCs that experienced any decrease in their actual wage index exclusively due to the implementation of the new OMB delineations. This transition does not apply in CY 2019. Generally, OMB issues major revisions to statistical areas every 10 years, based on the results of the decennial census. However, OMB occasionally issues minor updates and revisions to statistical areas in the years between the decennial censuses. On July 15, 2015, OMB issued OMB Bulletin No. 15–01, which provides updates to and supersedes OMB Bulletin No. 13–01 that was issued on February 28, 2013. The attachment to OMB Bulletin No. 15–01 provides detailed information on the update to statistical areas since February 28, 2013. The updates provided in OMB Bulletin No. 15–01 are based on the application of the 2010 Standards for Delineating Metropolitan and Micropolitan Statistical Areas to Census Bureau population estimates for July 1, 2012 and July 1, 2013. The complete list of statistical areas incorporating these changes is provided in the attachment to OMB Bulletin No. 15–01. According to OMB, ‘‘[t]his bulletin establishes revised delineations for the Nation’s Metropolitan Statistical Areas, Micropolitan Statistical Areas, and Combined Statistical Areas. The bulletin also provides delineations of Metropolitan Divisions as well as delineations of New England City and Town Areas.’’ (A copy of this bulletin may be obtained at: https:// www.whitehouse.gov/sites/ whitehouse.gov/files/omb/bulletins/ 2015/15-01.pdf.) OMB Bulletin No. 15–01 made changes that are relevant to the IPPS and ASC wage index. We refer readers to the CY 2017 OPPS/ASC final rule with comment period (81 FR 79750) for a discussion of these changes and our implementation of these revisions. In OMB Bulletin No. 17–01, OMB announced that one Micropolitan Statistical Area now qualifies as a Metropolitan Statistical Area. The new urban CBSA is as follows: • Twin Falls, Idaho (CBSA 46300). This CBSA is comprised of the principal city of Twin Falls, Idaho in Jerome County, Idaho and Twin Falls County, Idaho. The OMB bulletin is available at: https://www.whitehouse.gov/sites/ whitehouse.gov/files/omb/bulletins/ 2017/b-17-01.pdf. We note that we did not have sufficient time to include this change in the computation of the proposed FY 2019 IPPS wage index. We stated that this new CBSA may affect the budget neutrality factors and wage indexes, depending on the impact of the overall payments of ASCs located in this new CBSA. In the CY 2019 OPPS/ASC proposed rule (83 FR 37075), we provided an estimate (shown below) of this new area’s wage index based on the average hourly wages for new CBSA 46300 and the national average hourly wages from the wage data for the proposed FY 2019 wage index (described in section III.B. of the preamble of the FY 2019 IPPS/LTCH PPS proposed rule). Currently, provider 130002 is the only hospital located in Twin Falls County, Idaho, and there are no hospitals located in Jerome County, Idaho. Thus, the proposed wage index for CBSA 46300 was calculated using the average hourly wage data for one provider (provider 130002). Other than the previously described wage index, for CY 2019, the final CY 2019 ASC wage indexes fully reflect the OMB labor market area delineations (including the revisions to the OMB labor market delineations discussed above, as set forth in OMB Bulletin Nos. 15–01 and 17–01). We note that, in certain instances, there might be urban or rural areas for which there is no IPPS hospital that has wage index data that could be used to set the wage index for that area. For these areas, our policy has been to use the average of the wage indexes for CBSAs (or metropolitan divisions as applicable) that are contiguous to the area that has no wage index (where ‘‘contiguous’’ is defined as sharing a border). For example, for CY 2014, we applied a proxy wage index based on this methodology to ASCs located in CBSA 25980 (Hinesville-Fort Stewart, GA) and CBSA 08 (Rural Delaware). When all of the areas contiguous to the urban CBSA of interest are rural and there is no IPPS hospital that has wage index data that could be used to set the wage index for that area, we determine the ASC wage index by calculating the average of all wage indexes for urban areas in the State (75 FR 72058 through 72059). (In other situations, where there are no IPPS hospitals located in a relevant labor market area, we continue our current policy of calculating an urban or rural area’s wage index by calculating the average of the wage indexes for CBSAs (or metropolitan VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 PO 00000 Frm 00258 Fmt 4701 Sfmt 4700 E:\FR\FM\21NOR2.SGM 21NOR2 ER21NO18.099</GPH> khammond on DSK30JT082PROD with RULES2 59074 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations divisions where applicable) that are contiguous to the area with no wage index.) khammond on DSK30JT082PROD with RULES2 2. Calculation of the ASC Payment Rates a. Updating the ASC Relative Payment Weights for CY 2019 and Future Years We update the ASC relative payment weights each year using the national OPPS relative payment weights (and PFS nonfacility PE RVU-based amounts, as applicable) for that same calendar year and uniformly scale the ASC relative payment weights for each update year to make them budget neutral (72 FR 42533). In the CY 2019 OPPS/ASC proposed rule (83 FR 37171), consistent with our established policy, we proposed to scale the CY 2019 relative payment weights for ASCs according to the following method. Holding ASC utilization, the ASC conversion factor, and the mix of services constant from CY 2017, we proposed to compare the total payment using the CY 2018 ASC relative payment weights with the total payment using the CY 2019 ASC relative payment weights to take into account the changes in the OPPS relative payment weights between CY 2018 and CY 2019. We proposed to use the ratio of CY 2018 to CY 2019 total payments (the weight scalar) to scale the ASC relative payment weights for CY 2019. The proposed CY 2019 ASC weight scalar was 0.8854 and scaling would apply to the ASC relative payment weights of the covered surgical procedures, covered ancillary radiology services, and certain diagnostic tests within the medicine range of CPT codes, which are covered ancillary services for which the ASC payment rates are based on OPPS relative payment weights. Scaling would not apply in the case of ASC payment for separately payable covered ancillary services that have a predetermined national payment amount (that is, their national ASC payment amounts are not based on OPPS relative payment weights), such as drugs and biologicals that are separately paid or services that are contractor-priced or paid at reasonable cost in ASCs. Any service with a predetermined national payment amount would be included in the ASC budget neutrality comparison, but scaling of the ASC relative payment weights would not apply to those services. The ASC payment weights for those services without predetermined national payment amounts (that is, those services with national payment amounts that would be based on OPPS relative payment weights) would be scaled to eliminate any difference in the VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 total payment between the current year and the update year. For any given year’s ratesetting, we typically use the most recent full calendar year of claims data to model budget neutrality adjustments. At the time of the proposed rule, we had available 98 percent of CY 2017 ASC claims data. To create an analytic file to support calculation of the weight scalar and budget neutrality adjustment for the wage index (discussed below), we summarized available CY 2017 ASC claims by ASC and by HCPCS code. We used the National Provider Identifier for the purpose of identifying unique ASCs within the CY 2017 claims data. We used the supplier zip code reported on the claim to associate State, county, and CBSA with each ASC. This file, available to the public as a supporting data file for the proposed rule, is posted on the CMS website at: https:// www.cms.gov/Research-Statistics-Dataand-Systems/Files-for-Order/ LimitedDataSets/ ASCPaymentSystem.html. b. Updating the ASC Conversion Factor Under the OPPS, we typically apply a budget neutrality adjustment for provider level changes, most notably a change in the wage index values for the upcoming year, to the conversion factor. Consistent with our final ASC payment policy, for the CY 2017 ASC payment system and subsequent years, in the CY 2017 OPPS/ASC final rule with comment period (81 FR 79751 through 79753), we finalized our policy to calculate and apply a budget neutrality adjustment to the ASC conversion factor for supplier level changes in wage index values for the upcoming year, just as the OPPS wage index budget neutrality adjustment is calculated and applied to the OPPS conversion factor. For CY 2019, we calculated the proposed adjustment for the ASC payment system by using the most recent CY 2017 claims data available and estimating the difference in total payment that would be created by introducing the proposed CY 2019 ASC wage indexes. Specifically, holding CY 2017 ASC utilization, service-mix, and the proposed CY 2019 national payment rates after application of the weight scalar constant, we calculated the total adjusted payment using the CY 2018 ASC wage indexes (which would fully reflect the new OMB delineations) and the total adjusted payment using the proposed CY 2019 ASC wage indexes. We used the 50-percent labor-related share for both total adjusted payment calculations. We then compared the total adjusted payment calculated with PO 00000 Frm 00259 Fmt 4701 Sfmt 4700 59075 the CY 2018 ASC wage indexes to the total adjusted payment calculated with the proposed CY 2019 ASC wage indexes and applied the resulting ratio of 1.0003 (the proposed CY 2019 ASC wage index budget neutrality adjustment) to the CY 2018 ASC conversion factor to calculate the proposed CY 2019 ASC conversion factor. Section 1833(i)(2)(C)(i) of the Act requires that, if the Secretary has not updated amounts established under the revised ASC payment system in a calendar year, the payment amounts shall be increased by the percentage increase in the Consumer Price Index for all urban consumers (CPI–U), U.S. city average, as estimated by the Secretary for the 12-month period ending with the midpoint of the year involved. The statute does not mandate the adoption of any particular update mechanism, but it requires the payment amounts to be increased by the CPI–U in the absence of any update. Because the Secretary updates the ASC payment amounts annually, we adopted a policy, which we codified at 42 CFR 416.171(a)(2)(ii)), to update the ASC conversion factor using the CPI–U for CY 2010 and subsequent calendar years. In the CY 2018 OPPS/ASC rulemaking (82 FR 33668 through 33670; 59422 through 59424), we solicited and discussed comments regarding our current policy, codified at 42 CFR 416.171(a)(2)(ii), to update the ASC conversion factor using the CPI–U for CY 2010 and subsequent calendar years. In the CY 2018 OPPS/ASC final rule with comment period, we noted that in 2008 facilities paid under the ASC payment system received approximately 65 percent of the payment that hospitals paid under the OPPS received for an average service. The differential between ASC facility payment and OPPS provider payment has continued to increase since 2008, and by 2017, facilities paid under the ASC payment system received approximately 56 percent of the payment that hospitals paid under the OPPS received for an average service. At the same time, indicators of ASC payment adequacy, such as capacity and supply of providers and providers’ access to capital, suggest that Medicare beneficiaries have adequate access to ASC services.100 The Administration recognizes the value that ASCs may bring to the Medicare Program that results in the delivery of efficient, high-quality care to beneficiaries at a lower cost. The Administration is promoting greater 100 MedPAC. E:\FR\FM\21NOR2.SGM Report to the Congress: March 2018. 21NOR2 khammond on DSK30JT082PROD with RULES2 59076 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations price transparency across all of Medicare’s payment systems. Both beneficiaries and the Medicare Program benefit from reduced expenditures when a beneficiary’s clinical needs allow for a procedure to be performed in lower cost settings, such as ASCs relative to hospital outpatient departments.101 As articulated in the FY 2019 President’s Budget, the Administration supports payment reforms that base payment on patient characteristics rather than the site of care. To that end, we are exploring ways to align payments with the costs of care and to incentivize use of the most efficient and clinically appropriate sites of care including hospital outpatient departments, ASCs, and physician offices, to the extent feasible, in future rulemaking. In the near term, however, there is concern by some stakeholders that the differential between payment updates for HOPDs and ASCs is resulting in inefficient and unnecessary shifts of care to the hospital outpatient setting and away from ASCs. We are concerned about the potential unintended consequences of using the CPI–U to update payments for ASCs, such as consolidation of ASCs or fewer physician-owned ASCs, which may contribute to higher prices; stagnation in number of ASC facilities and number of multispecialty ASC facilities; and payments being misaligned with the cost of treatment for complex patients. We recognize prior public commenters’ belief that ASCs may incur some of the same costs that hospitals incur, which may be better reflected in the hospital market basket update than the CPI–U. Nevertheless, we recognize also that ASCs are among the only health care facilities in Medicare that do not submit cost information and therefore their rates are not updated based on a related market basket. We do not believe that the ASC cost structure is identical to the hospital cost structure for a few reasons (these differences are illustrative and not exhaustive). First, the majority of ASCs are single specialty (61 percent based on 2016 data), whereas hospitals provide a wider variety of services, and also provide inpatient care and room and board. Second, the vast majority of ASCs are for-profit and located in urban areas, whereas hospital ownership is varied and hospitals are located in more 101 Medicare Beneficiaries Could Save Billions if CMS Reduces Hospital Outpatient Department Payment Rates for Ambulatory Surgical CenterApproved Procedures to Ambulatory Surgical Center Payment Rates, Department of Health and Human Services, Office of Inspector General, April 2014. VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 geographically diverse locations. Third, compliance with certain laws, such as the Emergency Medical Treatment and Labor Act (EMTALA), apply to hospitals and do not apply to ASCs. These differences illustrate why there is reason to believe there is a measure of misalignment between the HOPD and ASC cost structure, and should be considered when assessing the suitability of using the hospital market basket as a better proxy for ASC costs than the CPI–U. According to commenters on the CY 2018 OPPS/ASC proposed rule, only 8.5 percent of the CPI–U inputs are related to health care, and even those inputs are based on a consumer’s experience purchasing health care items, rather than a provider’s experience purchasing the items necessary to furnish a health care service, and do not measure whether a facility’s costs increase, such as the cost of purchasing supplies and equipment or personnel labor costs. We also acknowledge prior public commenters’ concern that the disparity in payments between the OPPS and the ASC payment system may reduce the migration of services from the HOPD setting to the less costly ASC setting. For example, one study looked at the impact of the difference in facility fees paid to ASCs versus hospital outpatient departments on ASC growth using a fixed effects model.102 The study found results indicating that, as ASC payments increase, patients are more likely to undergo outpatient procedures in an ASC than they are in a hospital. Another study found that the opening of an ASC in a hospital service area resulted in a decline in hospital-based outpatient surgery without increasing mortality or admission.103 In markets where facilities opened, procedure growth at ASCs was greater than the decline in outpatient surgery use at their respective hospitals. If a migration of services from the hospital setting to ASCs occurred, it may potentially yield savings to the Medicare program and beneficiaries if the savings from the migration of services net of any increases in total volume of services does not exceed the cost of a higher rate update factor. ASC payment rates would still generally be significantly less than under the OPPS. To the extent that it is clinically appropriate for a beneficiary to receive 102 Munnich EL, Parente ST. Returns to Specialization: Evidence from the Outpatient Surgery Market. Journal of Health Economics,Volume 57, January 2018. 103 Hollenbeck BK, Dunn RL, et. al. Ambulatory Surgery Centers and Their Intended Effects on Outpatient Surgery. HSR: Health Services Research. 50:5. October 2015. PO 00000 Frm 00260 Fmt 4701 Sfmt 4700 services in a lower cost setting, we believe it would be appropriate to continue to develop payment incentives and remove payment disincentives to facilitate this choice. While there are several factors that contribute to the divergence in payment between the two systems (which were identified in the comment solicitation on ASC payment reform in the CY 2018 OPPS/ASC rulemaking), such as different distribution of costs between hospitals and ASCs and different ratesetting methodologies between the OPPS and the ASC payment system, we believe that an alternative update factor could stabilize the differential between the OPPS payment and the ASC payment, to the extent that the CPI–U has been lower than the hospital market basket, and encourage the migration of services to lower cost settings as clinically appropriate (82 FR 59422 through 59424). In addition, we note that there are many services that can safely be performed in either the hospital setting or the ASC setting and a common rate update factor recognizes that the two provider types often compete for the same patients though patient acuity is likely higher in hospitals. Therefore, we believe providing ASCs with the same rate update mechanism as hospitals could encourage the migration of services from the hospital setting to the ASC setting and increase the presence of ASCs in health care markets or geographic areas where previously there were none or few, thus promoting better beneficiary access to care. However, because physicians have a financial interest in ASCs, higher payments could also lead to greater utilization of services.104 At the same time, we are cognizant of concerns that Medicare does not currently collect cost data from ASCs, which makes it difficult to assess payment adequacy in the same way that it is assessed for hospitals, to validate alignment between ASC and hospital cost structure, or to establish an ASC-specific market basket. Accordingly, until we have information on the ASC cost structure, we would like to balance our desire to promote migration of services away from the HOPD to ASCs where clinically appropriate with our desire to minimize increases in beneficiary out-of-pocket costs. In the CY 2019 OPPS/ASC proposed rule (83 FR 37173 through 37175), therefore, as described in more specific detail below, we proposed to apply a hospital market basket update to 104 Munnich EL, Parente ST. Returns to Specialization: Evidence from the Outpatient Surgery Market. Journal of Health Economics, Volume 57, January 2018. E:\FR\FM\21NOR2.SGM 21NOR2 khammond on DSK30JT082PROD with RULES2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations ASCs for an interim period of 5 years but sought comments on ASC costs to assess whether the hospital market basket is an appropriate proxy for ASC costs. We noted that the hospital market basket is collected under OMB Control No. 0938–0050 and the information collected through hospital cost reports is used, in part, to inform the calculation of the hospital market basket. We proposed that the hospital market basket update applied to ASC payment rates would be derived using the same hospital inpatient market basket percentage increase that we proposed to use to derive the OPD fee increase factor as described in section II.B. of the CY 2019 OPPS/ASC proposed rule and would be adjusted for multifactor productivity. We proposed this payment update methodology for a 5-year period, during which we proposed to assess whether there is a migration of procedures from the hospital setting to the ASC setting as a result of the use of a hospital market basket update, as well as whether there are any unintended consequences (for example, an unnecessary increase in the overall volume of services or beneficiaries’ outof-pocket costs). We believed that 5 years would be an appropriate number of years to assess changes in the migration of services, as it should provide us enough time to confirm that trends in the data are consistent over time. In the proposed rule, we welcomed comment on whether implementing the hospital market basket update for a different number of years might be more appropriate. In the proposed rule, we stated that we were interested in commenter feedback on additional ways we can evaluate the impacts of this payment change over the 5-year period. For example, we welcomed input on how we should delineate between changes in the volume of a particular service due to the higher update, versus changes in the volume of a service due to changes in enrollment, patient acuity, or utilization, and what would be an appropriate interval to measure such migration of services. During this 5-year period, we intend to assess the feasibility of collaborating with stakeholders to collect ASC cost data in a minimally burdensome manner and could propose a plan to collect such information. As previously mentioned, in response to the comment solicitation in the CY 2018 OPPS/ASC proposed rule, stakeholders indicated a willingness to work with CMS to collect cost information in the least burdensome manner (82 FR 59422 through 59424). VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 Therefore, for CY 2019 through 2023, in response to stakeholder concerns described in the CY 2018 OPPS/ASC final rule with comment period (82 FR 59420 through 59421) that ASCs may incur some of the same costs that hospitals incur and that are better reflected in the hospital market basket update than the CPI–U, and including the concern that the payment differentials between the different settings of care due to the use of the CPI–U may stagnate the migration of services from hospitals to the ASC setting, even though those services can be safely performed in ASCs, we proposed to update ASC payment rates using the hospital market basket and to revise our regulations under 42 CFR 416.171(a)(2), which address the annual update to the ASC conversion factor, to reflect this proposal. In addition, we requested comments and evidence to assess whether the hospital market basket is an appropriate proxy for ASC costs. Under this proposal, for CY 2019, we proposed to use the FY 2019 hospital market basket update as published in the FY 2019 IPPS/LTCH PPS proposed rule (83 FR 20381). This proposed update to ASC payment rates was derived using the same hospital inpatient market basket percentage increase that we proposed to use to derive the OPD fee increase factor as described in section II.B. of the CY 2019 OPPS/ASC proposed rule. We also sought comments on an alternative proposal to maintain using the CPI–U for the annual ASC payment update while collecting evidence to justify a different payment update, or adopting the new proposed payment update based on the hospital market basket permanently. We requested comments on what type of evidence should be used to justify a different payment update and how CMS should go about collecting that information in the least burdensome way possible. Section 1833(t)(3)(G)(v) of the Act applies an additional adjustment of 0.75 for CY 2019 to hospitals. We noted that such adjustment was authorized by the Affordable Care Act and that, while the Affordable Care Act authorized a productivity adjustment for ASCs (as it did for hospitals), it expressly did not authorize the ‘‘additional adjustment’’ that was mandated for hospitals. The additional adjustment is separate and distinct from the productivity adjustment that already applies to both hospitals and ASCs and there does not appear to be a correlation between the productivity adjustment and the additional adjustment. Further, application of the additional adjustment PO 00000 Frm 00261 Fmt 4701 Sfmt 4700 59077 may be contrary to the goals we have articulated that led us to propose to apply the hospital market basket to the ASC payment system in the first place; that is, we believe that proposing to apply the hospital market basket to ASC rates may encourage the migration of services from the hospital setting to the ASC setting. However, if we had proposed to apply the additional adjustment, the ASC rate update would have been 1.25 percent, instead of the proposed 2.0 percent. The 1.25 percent was lower than applying the CPI–U rate update factor, which at the time of the CY 2019 OPPS/ASC proposed rule would have been 1.3 percent for CY 2019. This lower update would appear contrary to the goals set forth earlier in this section. However, we sought comment on whether applying this additional adjustment may nonetheless be appropriate. While we expect this policy will increase spending, by both the government and beneficiaries, relative to the current update factor over the 5year period, as previously stated, we also believe that the proposal could encourage the migration of services that are currently performed in the hospital outpatient setting to the ASC setting, which could result in savings to beneficiaries and the Medicare program. We believe that it is important to maximize patient choice to obtain services at a lower cost to the extent feasible. We believe also that without cost data from ASCs to examine their cost structure and adequacy of payment, we lack key data that may help inform the development of payment policies that are based on patients’ clinical needs rather than the site of care. In the proposed rule, we stated that, if, after review of all comments and all available evidence, we chose to finalize this proposal, we would continue to monitor site-of-service shifts for the duration of this policy to determine if services move safely to lower cost settings and to explore collecting additional data that may help inform further development of the ASC payment system. We proposed to continue to use the adjusted hospital market basket update through CY 2023 (for 5 years total). We proposed that we intend to reassess whether application of the hospital market basket update to ASC rates has provided more patient choice to obtain services at a lower cost beginning with the CY 2024 rulemaking period, or sooner if appropriate. Section 3401(k) of the Affordable Care Act amended section 1833(i)(2)(D) of the Act by adding a new clause (v), which requires that any annual update under the ASC payment system for the year, E:\FR\FM\21NOR2.SGM 21NOR2 khammond on DSK30JT082PROD with RULES2 59078 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations after application of clause (iv), shall be reduced by the productivity adjustment described in section 1886(b)(3)(B)(xi)(II) of the Act, effective with the calendar year beginning January 1, 2011. The statute defines the productivity adjustment to be equal to the 10-year moving average of changes in annual economy-wide private nonfarm business multifactor productivity (MFP) (as projected by the Secretary for the 10year period ending with the applicable fiscal year, year, cost reporting period, or other annual period) (the ‘‘MFP adjustment’’). Clause (iv) of section 1833(i)(2)(D) of the Act authorizes the Secretary to provide for a reduction in any annual update for failure to report on quality measures. Clause (v) of section 1833(i)(2)(D) of the Act states that application of the MFP adjustment to the ASC payment system may result in the update to the ASC payment system being less than zero for a year and may result in payment rates under the ASC payment system for a year being less than such payment rates for the preceding year. In the CY 2012 OPPS/ASC final rule with comment period (76 FR 74516), we finalized a policy that ASCs begin submitting data on quality measures for services beginning on October 1, 2012 for the CY 2014 payment determination under the ASC Quality Reporting (ASCQR) Program. In the CY 2013 OPPS/ASC final rule with comment period (77 FR 68499 through 68500), we finalized a methodology to calculate reduced national unadjusted payment rates using the ASCQR Program reduced update conversion factor that would apply to ASCs that fail to meet their quality reporting requirements for the CY 2014 payment determination and subsequent years. The application of the 2.0 percentage point reduction to the annual update factor, which we proposed to be the hospital market basket update, may result in the update to the ASC payment system being less than zero for a year for ASCs that fail to meet the ASCQR Program requirements. We amended §§ 416.160(a)(1) and 416.171 to reflect these policies. In prior years, in accordance with section 1833(i)(2)(C)(i) of the Act, before applying the MFP adjustment, the Secretary first determined the ‘‘percentage increase’’ in the CPI–U, which we interpreted cannot be a negative percentage. Thus, in the instance where the percentage change in the CPI–U for a year was negative, we would hold the CPI–U update factor for the ASC payment system to zero (75 FR 72062). Consistent with past practice, in the instance where the percentage VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 change in the hospital market basket for a year is negative, we proposed to hold the hospital market basket update factor for the ASC payment system to zero. For the CY 2014 payment determination and subsequent years, under section 1833(i)(2)(D)(iv) of the Act, we would reduce the annual update by 2.0 percentage points for an ASC that fails to submit quality information under the policies established by the Secretary in accordance with section 1833(i)(7) of the Act. Section 1833(i)(2)(D)(v) of the Act, as added by section 3401(k) of the Affordable Care Act, requires that the Secretary reduce the annual update factor, after application of any quality reporting reduction, by the MFP adjustment, and states that application of the MFP adjustment to the annual update factor after application of any quality reporting reduction may result in the update being less than zero for a year. If the application of the MFP adjustment to the annual update factor after application of any quality reporting reduction would result in an MFPadjusted update factor that is less than zero, the resulting update to the ASC payment rates would be negative and payments would decrease relative to the prior year. We refer readers to the CY 2011 OPPS/ASC final rule with comment period (75 FR 72062 through 72064) for examples of how the MFP adjustment is applied to the ASC payment system. For the CY 2019 OPPS/ASC proposed rule, the hospital market basket update for CY 2019 was projected to be 2.8 percent, as published in the FY 2019 IPPS/LTCH PPS proposed rule (83 FR 20381), based on IHS Global Inc.’s (IGI’s) 2017 fourth quarter forecast with historical data through the third quarter of 2017. For this final rule with comment period, as published in the FY 2019 IPPS/LTCH PPS final rule (83 FR 41395), based on IGI’s 2018 second quarter forecast with historical data through the first quarter of 2018, the hospital market basket update for CY 2019 is 2.9 percent. We finalized the methodology for calculating the MFP adjustment in the CY 2011 PFS final rule with comment period (75 FR 73394 through 73396) and revised it in the CY 2012 PFS final rule with comment period (76 FR 73300 through 73301) and the CY 2016 OPPS/ ASC final rule with comment period (80 FR 70500 through 70501). For the CY 2019 OPPS/ASC proposed rule, the proposed MFP adjustment for CY 2019 was projected to be 0.8 percentage point, as published in the FY 2019 IPPS/LTCH PPS proposed rule (83 FR 20382) based on IGI’s 2017 fourth quarter forecast. For this final rule with PO 00000 Frm 00262 Fmt 4701 Sfmt 4700 comment period, as published in the FY 2019 IPPS/LTCH PPS final rule (83 FR 41395) based on IGI’s 2018 second quarter forecast, the final MFP adjustment for CY 2019 is 0.8 percentage point. We note that the update factor for CY 2019 under the current policy, which is to increase the payment amounts by the percentage increase in the CPI–U, U.S. city average, as estimated by the Secretary for the 12-month period ending with the midpoint of the year involved, is currently projected to be 2.6 percent (based on IGI’s third quarter 2018 forecast). The MFP adjustment that aligns with this payment update under current policy (ending with the midpoint of the year involved) is 0.8 percentage point, resulting in an update amount under the current policy of 1.8 percent (CPI–U of 2.6 percent less MFP adjustment of 0.8 percentage point). For CY 2019, we proposed to utilize the hospital market basket update of 2.8 percent minus the MFP adjustment of 0.8 percentage point, resulting in an MFP-adjusted hospital market basket update factor of 2.0 percent for ASCs meeting the quality reporting requirements. Therefore, we proposed to apply a 2.0 percent MFP-adjusted hospital market basket update factor to the CY 2018 ASC conversion factor for ASCs meeting the quality reporting requirements to determine the CY 2019 ASC payment amounts. The ASCQR Program affected payment rates beginning in CY 2014 and, under this program, there is a 2.0 percentage point reduction to the update factor for ASCs that fail to meet the ASCQR Program requirements. We proposed to utilize the hospital market basket update of 2.8 percent reduced by 2.0 percentage points for ASCs that do not meet the quality reporting requirements and then subtract the 0.8 percentage point MFP adjustment. Therefore, we proposed to apply a 0.0 percent MFP-adjusted hospital market basket update factor to the CY 2018 ASC conversion factor for ASCs not meeting the quality reporting requirements. We also proposed that if more recent data were subsequently available (for example, a more recent estimate of the hospital market basket update and MFP), we would use such data, if appropriate, to determine the CY 2019 ASC update for the final rule with comment period. For CY 2019, we proposed to adjust the CY 2018 ASC conversion factor ($45.575) by the proposed wage index budget neutrality factor of 1.0003 in addition to the MFP-adjusted hospital market basket update factor of 2.0 percent discussed above, which resulted in a proposed CY 2019 ASC conversion E:\FR\FM\21NOR2.SGM 21NOR2 khammond on DSK30JT082PROD with RULES2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations factor of $46.500 for ASCs meeting the quality reporting requirements. For ASCs not meeting the quality reporting requirements, we proposed to adjust the CY 2018 ASC conversion factor ($45.575) by the proposed wage index budget neutrality factor of 1.0003 in addition to the quality reporting/MFPadjusted hospital market basket update factor of 0.0 percent discussed above, which resulted in a proposed CY 2019 ASC conversion factor of $45.589. Comment: The majority of commenters supported the proposal to update ASC payment rates using the hospital market basket update. A number of commenters suggested that the CPI–U is not a suitable inflation index to update ASC payments because it does not accurately represent the costs of ASCs or health care facilities, broadly. One commenter noted that only 8 percent of the CPI–U index is comprised of health care-related items and no other Medicare payment system utilizes the CPI–U as a provider inflation-metric as many payment systems for other providers utilize a provider-specific market basket index. The commenter also noted that, while the hospital market basket update is the most appropriate update factor to apply to ASC payment system rates, alternative update factors (for example, the Medicare Economic Index) would have been preferable to the CPI–U. Other commenters in support of the proposal suggested that ASCs may incur some of the same costs that hospitals incur. In addition, commenters suggested that utilizing the hospital market basket update as the update mechanism would promote site neutrality and help restore relativity of average ASC payment rates to average HOPD payment rates. Some commenters recommended that CMS establish the hospital market basket update permanently as the ASC rate update mechanism rather than on an interim basis over 5 years. Commenters also supported the proposal to not apply the additional adjustment of 0.75 percentage points that applies to hospitals under section 1833(t)(3)(G)(v) of the Act. However, some commenters, including MedPAC, disagreed with the proposal and recommended collecting cost data from ASCs to inform an ASCspecific market basket index for updating payment rates under the ASC payment system. MedPAC noted that ASCs are fully capable of submitting cost report data, similar to other providers, such as ESRD facilities, hospices, and home health agencies. In addition, MedPAC suggested that, to minimize burden on ASCs and CMS, VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 CMS could require all ASCs to submit streamlined cost reports or require a random sample of ASCs to submit cost data. Response: We appreciate the commenters’ support. We recognize the commenters’ belief that ASCs may incur some of the same costs that hospitals incur, which may be better reflected in the hospital market basket update than the CPI–U. We also are aware that only a relatively small percentage of the CPI– U inputs are related to health care, and even those inputs are based on a consumer’s experience purchasing health care items, rather than a provider’s experience purchasing the items necessary to furnish a health care service, and do not directly relate to a facility’s costs, such as the cost of purchasing supplies and equipment or labor costs. We also acknowledge commenters’ concern that the disparity in payments between the OPPS and the ASC payment system may reduce the migration of services from the HOPD setting to the less costly ASC setting. We believe providing ASCs with the same rate update mechanism as hospitals could encourage the migration of services from the hospital setting to the ASC setting and increase the presence of ASCs in health care markets or geographic areas where previously there were none or few, thus promoting better beneficiary access to care. We believe that it is important to encourage such migration of services and that this policy would give physicians and patients greater choice in selecting the best care setting. In addition, we acknowledge commenters recommendations regarding the collection of ASC cost data to inform an ASC-specific market basket index for updating payment rates under the ASC payment system. We appreciate these comments and will take these comments into consideration in future policy development. Comment: Many commenters recommended that CMS discontinue ‘‘rescaling’’ the ASC relative weights and, instead, apply the OPPS relative weights as developed under the standard ratesetting methodology. The commenters argued that the weight scalar distorts ASC payments and further increases the payment differential between HOPDs and ASCs. Response: We note that applying the weight scalar in calculation of ASC payment rates, which for this final rule with comment period is 0.8792, ensures that the ASC payment system remains budget neutral. For a detailed discussion on why we apply a budget neutrality adjustment to the ASC ratesetting methodology, we refer PO 00000 Frm 00263 Fmt 4701 Sfmt 4700 59079 readers to the August 2, 2008 final rule (72 FR 42531 through 42533). After consideration of the public comments we received, we are finalizing our proposal to apply the hospital market basket update to ASC payment system rates for an interim period of 5 years (CY 2019 through CY 2023), during which we will assess whether there is a migration of the performance of procedures from the hospital setting to the ASC setting as a result of the use of a hospital market basket update, as well as whether there are any unintended consequences, such as less than expected migration of the performance of procedures from the hospital setting to the ASC setting. In addition, we are finalizing our proposal to revise our regulations under 42 CFR 416.171(a)(2), which address the annual update to the ASC conversion factor. Therefore, as proposed, to determine the CY 2019 ASC update for this final rule with comment period, we are incorporating a more recent estimate of the hospital market basket update and the MFP adjustment. For this CY 2019 OPPS/ASC final rule with comment period, as published in the FY 2019 IPPS/LTCH PPS final rule (83 FR 41395), based on IGI’s 2018 second quarter forecast with historical data through the first quarter of 2018, the MFP-adjusted hospital market basket update for CY 2019 is 2.1 percent (that is, the hospital market basket increase of 2.9 percent minus the MFP adjustment of 0.8 percentage point). Therefore, we are finalizing the application of a 2.1 percent MFP-adjusted hospital market basket update factor to the CY 2018 ASC conversion factor for ASCs meeting the quality reporting requirements to determine the CY 2019 ASC payment amounts. The ASCQR Program affected payment rates beginning in CY 2014 and, under this program, there is a 2.0 percentage point reduction to the update factor for ASCs that fail to meet the ASCQR Program requirements. We are finalizing to utilize the hospital market basket update of 2.9 percent reduced by 2.0 percentage points for ASCs that do not meet the quality reporting requirements and then subtract the 0.8 percentage point MFP adjustment. Therefore, we are applying a 0.1 percent MFP-adjusted hospital market basket update factor to the CY 2018 ASC conversion factor for ASCs not meeting the quality reporting requirements. For CY 2019, we are adjusting the CY 2018 ASC conversion factor ($45.575) by the proposed wage index budget neutrality factor of 1.0004 in addition to the MFP-adjusted hospital market basket update factor of 2.1 percent E:\FR\FM\21NOR2.SGM 21NOR2 59080 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations khammond on DSK30JT082PROD with RULES2 discussed above, which results in a CY 2019 ASC conversion factor of $46.551 for ASCs meeting the quality reporting requirements. For ASCs not meeting the quality reporting requirements, we are adjusting the CY 2018 ASC conversion factor ($45.575) by the proposed wage index budget neutrality factor of 1.0004 in addition to the quality reporting/ MFP-adjusted hospital market basket update factor of 0.1 percent discussed above, which results in a CY 2019 ASC conversion factor of $45.639. 3. Display of CY 2019 ASC Payment Rates Addenda AA and BB to this final rule with comment period (which are available on the CMS website) display the final updated ASC payment rates for CY 2019 for covered surgical procedures and covered ancillary services, respectively. For those covered surgical procedures and covered ancillary services where the payment rate is the lower of the final rates under the ASC standard ratesetting methodology and the MPFS final rates, the final payment indicators and rates set forth in this final rule with comment period are based on a comparison using the final PFS rates that will be effective January 1, 2019. For a discussion of the PFS rates, we refer readers to the CY 2019 PFS final rule with comment period. The final payment rates included in these addenda reflect the full ASC payment update and not the reduced payment update used to calculate payment rates for ASCs not meeting the quality reporting requirements under the ASCQR Program. These addenda contain several types of information related to the final CY 2019 payment rates. Specifically, in Addendum AA, a ‘‘Y’’ in the column titled ‘‘To be Subject to Multiple Procedure Discounting’’ indicates that the surgical procedure would be subject to the multiple procedure payment reduction policy. As discussed in the CY 2008 OPPS/ASC final rule with comment period (72 FR 66829 through 66830), most covered surgical procedures are subject to a 50percent reduction in the ASC payment for the lower-paying procedure when more than one procedure is performed in a single operative session. Display of the comment indicator ‘‘CH’’ in the column titled ‘‘Comment Indicator’’ indicates a change in payment policy for the item or service, including identifying discontinued HCPCS codes, designating items or services newly payable under the ASC payment system, and identifying items or services with changes in the ASC payment indicator for CY 2018. Display of the comment indicator ‘‘NI’’ in the VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 column titled ‘‘Comment Indicator’’ indicates that the code is new (or substantially revised) and that comments will be accepted on the interim payment indicator for the new code. Display of the comment indicator ‘‘NP’’ in the column titled ‘‘Comment Indicator’’ indicates that the code is new (or substantially revised) and that comments will be accepted on the ASC payment indicator for the new code. The values displayed in the column titled ‘‘Final CY 2019 Payment Weight’’ are the final relative payment weights for each of the listed services for CY 2019. The final relative payment weights for all covered surgical procedures and covered ancillary services where the ASC payment rates are based on OPPS relative payment weights were scaled for budget neutrality. Therefore, scaling was not applied to the device portion of the device-intensive procedures, services that are paid at the MPFS nonfacility PE RVU-based amount, separately payable covered ancillary services that have a predetermined national payment amount, such as drugs and biologicals and brachytherapy sources that are separately paid under the OPPS, or services that are contractor-priced or paid at reasonable cost in ASCs. To derive the final CY 2019 payment rate displayed in the ‘‘Final CY 2019 Payment Rate’’ column, each ASC payment weight in the ‘‘Final CY 2019 Payment Weight’’ column was multiplied by the final CY 2019 conversion factor of $46.551. The final conversion factor includes a budget neutrality adjustment for changes in the wage index values and the annual update factor as reduced by the productivity adjustment (as discussed in section XII.G.2.b. of this final rule with comment period). In Addendum BB, there are no relative payment weights displayed in the ‘‘Final CY 2019 Payment Weight’’ column for items and services with predetermined national payment amounts, such as separately payable drugs and biologicals. The ‘‘Final CY 2019 Payment’’ column displays the final CY 2019 national unadjusted ASC payment rates for all items and services. The final CY 2019 ASC payment rates listed in Addendum BB for separately payable drugs and biologicals are based on ASP data used for payment in physicians’ offices in October 2018. Addendum EE provides the HCPCS codes and short descriptors for surgical procedures that are to be excluded from payment in ASCs for CY 2019. PO 00000 Frm 00264 Fmt 4701 Sfmt 4700 XIII. Requirements for the Hospital Outpatient Quality Reporting (OQR) Program A. Background 1. Overview CMS seeks to promote higher quality and more efficient healthcare for Medicare beneficiaries. Consistent with these goals, CMS has implemented quality reporting programs for multiple care settings including the quality reporting program for hospital outpatient care, known as the Hospital Outpatient Quality Reporting (OQR) Program, formerly known as the Hospital Outpatient Quality Data Reporting Program (HOP QDRP). The Hospital OQR Program is generally aligned with the quality reporting program for hospital inpatient services known as the Hospital Inpatient Quality Reporting (IQR) Program (formerly known as the Reporting Hospital Quality Data for Annual Payment Update (RHQDAPU) Program). In addition to the Hospital IQR and Hospital OQR Programs, CMS has implemented quality reporting programs as well as value-based purchasing programs for other care settings. We refer readers to section I.A.2. of this final rule with comment period where we discuss our new Meaningful Measures Initiative and our approach in evaluating quality program measures. 2. Statutory History of the Hospital OQR Program We refer readers to the CY 2011 OPPS/ASC final rule with comment period (75 FR 72064 through 72065) for a detailed discussion of the statutory history of the Hospital OQR Program. 3. Regulatory History of the Hospital OQR Program We refer readers to the CY 2008 through 2018 OPPS/ASC final rules with comment period (72 FR 66860 through 66875; 73 FR 68758 through 68779; 74 FR 60629 through 60656; 75 FR 72064 through 72110; 76 FR 74451 through 74492; 77 FR 68467 through 68492; 78 FR 75090 through 75120; 79 FR 66940 through 66966; 80 FR 70502 through 70526; and 81 FR 79753 through 79797; 82 FR 59424 through 59445). We have also codified certain requirements under the Hospital OQR Program at 42 CFR 419.46. 4. Meaningful Measures Initiative In the CY 2019 OPPS/ASC proposed rule, we proposed a number of new policies for the Hospital OQR Program (83 FR 37179). We developed these proposals after conducting an overall review of the program under our new E:\FR\FM\21NOR2.SGM 21NOR2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations Meaningful Measures Initiative, which is discussed in more detail in section I.A.2. of this final rule with comment period. The proposals reflect our efforts to ensure that the Hospital OQR Program measure set continues to promote improved health outcomes for our beneficiaries while minimizing costs, which can consist of several different types of costs including, but not limited to: (1) Facility information collection burden and related cost and burden associated with the submitting/ reporting of quality measures to CMS; (2) the facility cost associated with complying with other quality programmatic requirements; (3) the facility cost associated with participating in multiple quality programs, and tracking multiple similar or duplicative measures within or across those programs; (4) the CMS cost associated with the program oversight of the measure, including measure maintenance and public display; and (5) the facility cost associated with compliance with other federal and/or State regulations (if applicable). These proposals also reflect our efforts to improve the usefulness of the data that we publicly report in the Hospital OQR Program. Our goal is to improve the usefulness and usability of CMS quality program data by streamlining how facilities are reporting and accessing data, while maintaining or improving consumer understanding of the data publicly reported on a Compare website. We believe this framework will allow hospitals and patients to continue to obtain meaningful information about HOPD performance and incentivize quality improvement while also streamlining the measure sets to reduce duplicative measures and program complexity so that the costs to hospitals associated with participating in this program do not outweigh the benefits of improving beneficiary care. B. Hospital OQR Program Quality Measures khammond on DSK30JT082PROD with RULES2 1. Considerations in the Selection of Hospital OQR Program Quality Measures We refer readers to the CY 2012 OPPS/ASC final rule with comment period (76 FR 74458 through 74460) for a detailed discussion of the priorities we consider for the Hospital OQR Program quality measure selection. In the CY 2019 OPPS/ASC proposed rule (83 FR 37176) we did not propose any changes to these policies. VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 2. Accounting for Social Risk Factors in the Hospital OQR Program In the CY 2018 OPPS/ASC final rule with comment period (82 FR 59425 through 59427), we discussed the importance of improving beneficiary outcomes including reducing health disparities. We also discussed our commitment to ensuring that medically complex patients, as well as those with social risk factors, receive excellent care. We discussed how studies show that social risk factors, such as being near or below the poverty level as determined by HHS, belonging to a racial or ethnic minority group, or living with a disability, can be associated with poor health outcomes and how some of this disparity is related to the quality of health care.105 Among our core objectives, we aim to improve health outcomes, attain health equity for all beneficiaries, and ensure that complex patients as well as those with social risk factors receive excellent care. Within this context, reports by the Office of the Assistant Secretary for Planning and Evaluation (ASPE) and the National Academy of Medicine have examined the influence of social risk factors in CMS value-based purchasing programs.106 As we noted in the CY 2018 OPPS/ASC final rule with comment period (82 FR 59425), ASPE’s report to Congress found that, in the context of value-based purchasing programs, dual eligibility was the most powerful predictor of poor health care outcomes among those social risk factors that they examined and tested. In addition, as we noted in the CY 2018 OPPS/ASC final rule with comment period (82 FR 59425), the National Quality Forum (NQF) undertook a 2year trial period in which certain new measures and measures undergoing maintenance review have been assessed to determine if risk adjustment for social risk factors is appropriate for these measures.107 The trial period ended in 105 See, for example United States Department of Health and Human Services. ‘‘Healthy People 2020: Disparities. 2014.’’ Available at: https:// www.healthypeople.gov/2020/about/foundationhealth-measures/Disparities; or National Academies of Sciences, Engineering, and Medicine. Accounting for Social Risk Factors in Medicare Payment: Identifying Social Risk Factors. Washington, DC: National Academies of Sciences, Engineering, and Medicine 2016. 106 Department of Health and Human Services Office of the Assistant Secretary for Planning and Evaluation (ASPE), ‘‘Report to Congress: Social Risk Factors and Performance Under Medicare’s ValueBased Purchasing Programs.’’ December 2016. Available at: https://aspe.hhs.gov/pdf-report/reportcongress-social-risk-factors-and-performanceunder-medicares-value-based-purchasingprograms. 107 National Quality Forum. Final ReportDisparities Project. September 2017. Available at: PO 00000 Frm 00265 Fmt 4701 Sfmt 4700 59081 April 2017 and a final report is available at: https://www.qualityforum.org/SES_ Trial_Period.aspx. The trial concluded that ‘‘measures with a conceptual basis for adjustment generally did not demonstrate an empirical relationship’’ between social risk factors and the outcomes measured. This discrepancy may be explained in part by the methods used for adjustment and the limited availability of robust data on social risk factors. NQF has extended the socioeconomic status (SES) trial,108 allowing further examination of social risk factors in outcome measures. In the FY 2018 and CY 2018 proposed rules for our quality reporting and value-based purchasing programs, we solicited feedback on which social risk factors provide the most valuable information to stakeholders and the methodology for illuminating differences in outcomes rates among patient groups within a hospital or facility that would also allow for a comparison of those differences, or disparities, across facilities. Feedback we received through our quality reporting programs included encouraging CMS to explore whether factors that could be used to stratify or risk adjust the measures (beyond dual eligibility); considering the full range of differences in patients’ backgrounds that might affect outcomes; exploring risk adjustment approaches; and offering careful consideration of what type of information display would be most useful to the public. We also sought public comment on confidential reporting and future public reporting of some of our measures stratified by patient dual eligibility. In general, commenters noted that stratified measures could serve as tools for hospitals to identify gaps in outcomes for different groups of patients, improve the quality of health care for all patients, and empower beneficiaries and other consumers to make informed decisions about health care. Commenters encouraged us to stratify measures by other social risk factors such as age, income, and educational attainment. With regard to value-based purchasing programs, commenters also cautioned to balance fair and equitable payment while avoiding payment penalties that mask health disparities or discourage the provision of care to more medically complex patients. Commenters also noted that value-based purchasing program measure selection, domain https://www.qualityforum.org/SES_Trial_ Period.aspx. 108 National Quality Forum. Health Equity Program: Social Risk Initiative 2.0. 2017. Available at: https://www.qualityforum.org/WorkArea/ linkit.aspx?LinkIdentifier=id&ItemID=86357. E:\FR\FM\21NOR2.SGM 21NOR2 59082 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations weighting, performance scoring, and payment methodology must account for social risk. As a next step, CMS is considering options to reduce health disparities among patient groups within and across health care settings by increasing the transparency of disparities as shown by quality measures. We also are considering how this work applies to other CMS quality programs in the future. We refer readers to the FY 2018 IPPS/LTCH PPS final rule (82 FR 38403 through 38409) for more details, where we discuss the potential stratification of certain Hospital IQR Program outcome measures. Furthermore, we continue to consider options to address equity and disparities in our value-based purchasing programs. We plan to continue working with ASPE, the public, and other key stakeholders on this important issue to identify policy solutions that achieve the goals of attaining health equity for all beneficiaries and minimizing unintended consequences. While we did not specifically request comment on social risk factors in the CY 2019 proposed rule, we received several comments with respect to social risk factors. We thank commenters for sharing their views and their willingness to support the efforts of CMS and NQF on this important issue. We take this feedback seriously and will continue to review social risk factors on an on-going and continuous basis. In addition, we both welcome and appreciate stakeholder feedback as we continue our work on these issues. khammond on DSK30JT082PROD with RULES2 3. Retention of Hospital OQR Program Measures Adopted in Previous Payment Determinations We previously adopted a policy to retain measures from a previous year’s Hospital OQR Program measure set for subsequent years’ measure sets in the CY 2013 OPPS/ASC final rule with comment period (77 FR 68471). Thus, quality measures adopted in a previous year’s rulemaking are retained in the Hospital OQR Program for use in subsequent years unless otherwise specified. We refer readers to that final rule with comment period for more information. In the CY 2019 OPPS/ASC proposed rule (83 FR 37177), we did not propose any changes to our retention policy; however, we proposed to codify this policy at 42 CFR 419.46(h)(1). We did not receive any public comments and are finalizing our proposal to codify at 42 CFR 419.46(h)(1) our policy to retain measures from a previous year’s Hospital OQR Program measure set for VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 subsequent years’ measure sets as proposed. 4. Removal of Quality Measures From the Hospital OQR Program Measure Set In the CY 2010 OPPS/ASC final rule with comment period (74 FR 60315), we finalized a process to use the regular rulemaking process to remove a measure for circumstances for which we do not believe that continued use of a measure raises specific patient safety concerns.109 In the CY 2019 OPPS/ASC proposed rule (83 FR 37177), we did not propose any changes to this policy; however, we proposed to codify this policy at 42 CFR 419.46(h)(3). We refer readers to section XIII.B.4.a. of this final rule with comment period for more details. We did not receive any public comments and are finalizing our proposal to codify at 42 CFR 419.46(h)(3) our policy to use the regular rulemaking process to remove a measure for circumstances for which we do not believe that continued use of a measure raises specific patient safety concerns as proposed. a. Considerations in Removing Quality Measures From the Hospital OQR Program (1) Immediate Removal In the CY 2010 OPPS/ASC final rule with comment period (74 FR 60634 through 60635), we finalized a process for immediate retirement, which we later termed ‘‘removal,’’ of Hospital OQR Program measures, based on evidence that the continued use of the measure as specified raise patient safety concerns.110 In the CY 2019 OPPS/ASC proposed rule (83 FR 37177), we did not propose any changes to our policy to immediately remove measures as a result of patient safety concerns; however, we proposed to codify that policy at 42 CFR 419.46(h)(2). We did not receive any public comments and are finalizing our proposal to codify at 42 CFR 419.46(h)(2) our policy to immediately remove measures as a result of patient safety concerns as proposed. (2) Consideration Factors for Removing Measures In the CY 2013 OPPS/ASC final rule with comment period, we finalized a set 109 We initially referred to this process as ‘‘retirement’’ of a measure in the 2010 OPPS/ASC proposed rule, but later changed it to ‘‘removal’’ during final rulemaking. 110 We refer readers to the CY 2013 OPPS/ASC final rule with comment period (77 FR 68472 through 68473) for a discussion of our reasons for changing the term ‘‘retirement’’ to ‘‘removal’’ in the Hospital OQR Program. PO 00000 Frm 00266 Fmt 4701 Sfmt 4700 of factors 111 for determining whether to remove measures from the Hospital OQR Program (77 FR 68472 through 68473). These factors are: • Factor 1. Measure performance among hospitals is so high and unvarying that meaningful distinctions and improvements in performance can no longer be made (‘‘topped out’’ measures). • Factor 2. Performance or improvement on a measure does not result in better patient outcomes. • Factor 3. A measure does not align with current clinical guidelines or practice. • Factor 4. The availability of a more broadly applicable (across settings, populations, or conditions) measure for the topic. • Factor 5. The availability of a measure that is more proximal in time to desired patient outcomes for the particular topic. • Factor 6. The availability of a measure that is more strongly associated with desired patient outcomes for the particular topic. • Factor 7. Collection or public reporting of a measure leads to negative unintended consequences such as patient harm. In addition, we refer readers to the CY 2015 OPPS/ASC final rule with comment period where we finalized the criteria for determining when a measure is ‘‘topped-out’’ (79 FR 66769). In that final rule with comment period, we finalized two criteria for determining when a measure is ‘‘topped out’’ under the Hospital OQR Program: (1) When there is statistically indistinguishable performance at the 75th and 90th percentiles of national facility performance; and (2) when the measure’s truncated coefficient of variation (TCOV) is less than or equal to 0.10 (79 FR 66942). The benefits of removing a measure from the Hospital OQR Program are assessed on a case-by-case basis (79 FR 66941 through 66942). In the proposed rule, we noted that, under this case-bycase approach, a measure will not be removed solely on the basis of meeting any specific factor. We also noted that in the CY 2015 OPPS/ASC final rule with comment period (79 FR 66967), a similar measure removal policy was finalized for the ASCQR Program. In the CY 2019 OPPS/ASC proposed rule (83 FR 37177 through 37178), we 111 We note that we previously referred to these factors as ‘‘criteria’’ (for example, 77 FR 68472 through 68473); we now use the term ‘‘factors’’ in order to align the Hospital OQR Program terminology with the terminology we use in other CMS quality reporting and pay-for-performance (value-based purchasing) programs. E:\FR\FM\21NOR2.SGM 21NOR2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations proposed to: (1) Update measure removal Factor 7; (2) add a new removal Factor 8; and (3) codify our measure removal policies and factors at 42 CFR 419.46(h) effective upon finalization of the CY 2019 OPPS/ASC final rule and for subsequent years. We also provided clarification of our ‘‘topped-out’’ criteria. khammond on DSK30JT082PROD with RULES2 (3) Update To Measure Removal Factor 7 As shown above, Factor 7 under the Hospital OQR Program states, ‘‘collection or public reporting of a measure leads to negative unintended consequences such as patient harm.’’ In contrast, under the ASCQR Program, Factor 7 reads as follows, ‘‘collection or public reporting of a measure leads to negative unintended consequences other than patient harm’’ (79 FR 66967). We believe the wording in the ASCQR Program is more appropriate because measures causing patient harm would be removed from the program immediately, outside of rulemaking, in accordance with our previously finalized policy to immediately remove measures as a result of patient safety concerns (74 FR 60634 and discussed above). Therefore, in the proposed rule, we proposed to change measure removal Factor 7 in the Hospital OQR Program to ‘‘collection or public reporting of a measure leads to negative unintended consequences other than patient harm’’ such that it aligns with measure removal Factor 7 in the ASCQR Program. Comment: Several commenters supported CMS’ proposal to update measure removal Factor 7 to read, ‘‘collection or public reporting of a measure leads to negative unintended consequences other than patient harm’’ to align with the ASCQR Program. Response: We thank the commenters for their support. After consideration of the public comments we received, we are finalizing our proposal as proposed to revise measure removal Factor 7 to read, ‘‘collection or public reporting of a measure leads to negative unintended consequences other than patient harm.’’ (4) New Measure Removal Factor 8 In the CY 2019 OPPS/ASC proposed rule (83 FR 37178 through 37179), we proposed to adopt an additional factor to consider when evaluating measures for removal from the Hospital OQR Program measure set: • Factor 8. The costs associated with a measure outweigh the benefit of its continued use in the program. As we discuss in section I.A.2. of the proposed rule and this final rule with comment period with respect to our VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 new Meaningful Measures Initiative, we are engaging in efforts to ensure that the Hospital OQR Program measure set continues to promote improved health outcomes for beneficiaries while minimizing the overall costs associated with the program. We believe these costs are multifaceted and include not only the burden associated with reporting, but also the costs associated with implementing and maintaining the program. We have identified several different types of costs, including, but not limited to: (1) Facility information collection burden and related costs and burden associated with the submission/ reporting of quality measures to CMS; (2) the facility cost associated with complying with other programmatic requirements; (3) the facility cost associated with participating in multiple quality programs and tracking multiple similar or duplicative measures within or across those programs; (4) the CMS cost associated with the program oversight of the measure including measure maintenance and public display; and (5) the facility cost associated with compliance with other Federal and State regulations (if applicable). For example, it may be needlessly costly and/or of limited benefit to retain or maintain a measure which our analyses show no longer meaningfully supports program objectives (for example, informing beneficiary choice or payment scoring). It may also be costly for health care providers to track confidential feedback, preview reports, and publicly reported information on a measure where we use the measure in more than one program. CMS may also have to expend unnecessary resources to maintain the specifications for the measure, as well as the tools needed to collect, validate, analyze, and publicly report the measure data. Furthermore, beneficiaries may find it confusing to see public reporting on the same measure in different programs. In weighing the costs against the benefits, we evaluate the benefits of the measure, but, we assess the benefits through the framework of our Meaningful Measures Initiative, as we discussed in section I.A.2. of the proposed rule and this final rule with comment period. One key aspect of patient benefits is assessing the improved beneficiary health outcomes if a measure is retained in our measure set. We believe that these benefits are multifaceted and are illustrated through the Meaningful Measures framework’s 6 domains and 19 areas. For example, we assessed the Healthcare Worker Influenza Vaccination and patient PO 00000 Frm 00267 Fmt 4701 Sfmt 4700 59083 Influenza Vaccination measures categorized in the Quality Priority ‘‘Promote Effective Prevention and Treatment of Chronic Disease’’ in the meaningful measure area of ‘‘Preventive Care’’ across multiple CMS programs, and considered: Patient outcomes, such as mortality and hospitalizations associated with influenza; CMS measure performance in a program; and other available and reported influenza process measures, such as population influenza vaccination coverage. When these costs outweigh the evidence supporting the benefits to patients with the continued use of a measure in the Hospital OQR Program, we believe it may be appropriate to remove the measure from the program. Although we recognize that one of the main goals of the Hospital OQR Program is to improve beneficiary outcomes by incentivizing health care facilities to focus on specific care issues and making public data related to those issues, we also recognize that those goals can have limited utility where, for example, the publicly reported data (including percentage payment adjustment data) is of limited use because it cannot be easily interpreted by beneficiaries, and used to inform their choice of facility. In these cases, removing the measure from the Hospital OQR Program may better accommodate the costs of program administration and compliance without sacrificing improved health outcomes and beneficiary choice. We proposed that we would remove measures based on this factor assessing costs versus benefits on a case-by-case basis. We might, for example, decide to retain a measure that is burdensome for health care facilities to report if we conclude that the benefit to beneficiaries justifies the reporting burden. Our goal is to move the program forward in the least burdensome manner possible, while maintaining a parsimonious set of meaningful quality measures and continuing to incentivize improvement in the quality of care provided to patients. We refer readers to section XIII.B.4.b. of the proposed rule (83 FR 37179 through 37186), where we proposed to remove two measures based on this proposed measure removal factor. In the proposed rule, we noted that we also proposed this same removal factor for the ASCQR Program in section XIV.B.3.b. of the proposed rule (83 FR 37195 through 37196), as well as for other quality reporting and value-based purchasing programs for FY 2019 including: The Hospital Value-Based Purchasing (VBP) Program (83 FR 20409), the Hospital IQR Program (83 FR 20472); the PPS-exempt Cancer E:\FR\FM\21NOR2.SGM 21NOR2 khammond on DSK30JT082PROD with RULES2 59084 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations Hospital Quality Reporting (PCHQR) Program (83 FR 20501 through 20502); the Long-Term Care Hospital Quality Reporting Program (LTCH QRP) (83 FR 20512); the Hospice Quality Reporting Program (HQRP) (83 FR 20956); the Inpatient Rehabilitation Facility Quality Reporting Program (IRF QRP) (83 FR 21000); the Skilled Nursing Facility Quality Reporting Program (SNF QRP) (83 FR 21082); and the Inpatient Psychiatric Facilities Quality Reporting (IPFQR) Program (83 FR 21118). We invited public comment on our proposal to adopt an additional measure removal Factor 8, the costs associated with a measure outweigh the benefit of its continued use in the program, beginning with the effective date of the CY 2019 OPPS/ASC final rule with comment period and for subsequent years. Comment: Several commenters supported CMS’ proposal to adopt an additional measure removal Factor 8, the costs associated with a measure outweigh the benefit of its continued use in the program. A few commenters noted that this removal factor will help CMS to remove unnecessary cost and burden from the Hospital OQR Program and allow providers of care to focus on improving quality through innovation. Commenters also praised CMS for aligning this and other removal factors across quality reporting programs. Response: We thank the commenters for their support. Comment: A few commenters opposed CMS’ proposal to add a new measure removal Factor 8. A few commenters requested clarification on the types of costs that CMS will consider and requested transparency in the process of evaluation in the costs and benefits of measures. One commenter expressed concern that the costs described under measure removal Factor 8 are not defined. One commenter noted that there are costs associated with changing measures to facilities, providers, and measure developers. Another commenter expressed concern that CMS may deem a measure too costly to implement, while providers and patients may continue to find it meaningful. Commenters also recommended direct and indirect costs that CMS may consider in evaluating measures under measure removal Factor 8. These costs included those associated with: (1) Measures that require data collection from multiple data sources, rather than just one; (2) contracting with vendors; (3) tracking performance and investing in resources for quality improvement. One commenter stated it opposed the new factor unless costs and benefits are VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 defined as only costs and benefits to beneficiaries and the public. Response: As noted in the proposed rule (83 FR 37176), we have defined costs, for the purpose of evaluating measures under proposed measure removal Factor 8, as including but not limited to: (1) Facility information collection burden and related costs and burden associated with the submission/ reporting of quality measures to CMS; (2) the facility cost associated with complying with other programmatic requirements; (3) the facility cost associated with participating in multiple quality programs, and tracking multiple similar or duplicative measures within or across those programs; (4) the CMS cost associated with the program oversight of the measure including measure maintenance and public display; and (5) the facility cost associated with compliance with other federal and/or State regulations (if applicable). This was not intended to be a complete list of the potential factors to consider in evaluating measures. In addition, as we apply this measure removal factor in future rulemaking, we will describe our rationale for the removal of a measure and will include the costs and benefits we considered. We thank commenters for their suggestions regarding additional costs to consider. We will use this feedback as well as input from all stakeholders as we apply measure removal Factor 8 in future rulemaking. We believe that various stakeholders may have different perspectives on how to define costs as well as benefits. Because of these challenges, we intend to evaluate each measure on a case-bycase basis, while considering input from a variety of stakeholders, including, but not limited to: Patients, caregivers, patient and family advocates, providers, provider associations, healthcare researchers, healthcare purchasers, data vendors, and other stakeholders with insight into the direct and indirect benefits and costs (financial and otherwise) of maintaining any specific measure in the Hospital OQR Program. However, we also believe that while a measure’s use in the Hospital OQR Program may benefit many entities, the primary benefit is to patients and their caregivers through incentivizing highquality care and providing publicly reported data regarding the quality of care available. We note that we intend to assess the costs and benefits to program stakeholders, including but not limited to, those listed above. Therefore, we intend to consider the benefits, especially those to patients and their families, when evaluating measures PO 00000 Frm 00268 Fmt 4701 Sfmt 4700 under this measure removal factor. As noted above, we have offered a definition of costs. However, this was not intended to be a complete list of the potential factors to consider in evaluating measures and we intend to consider the additional examples of cost described in public comment, including the costs and benefits to beneficiaries and the public, as recommended by some commenters. Comment: A few commenters recommended that CMS seek input from hospitals, physicians, and other stakeholders when evaluating the costs and benefits of quality reporting. Response: We thank the commenters for their feedback and note that we will consider stakeholder input when evaluating both the costs of quality reporting as well as the benefits of collecting and reporting quality data. As stated above, we intend to evaluate costs and benefits for each measure on a caseby-case basis, while considering input from a variety of stakeholders, including, but not limited to: Patients, caregivers, patient and family advocates, providers, provider associations, healthcare researchers, healthcare purchasers, data vendors, and other stakeholders with insight into the direct and indirect benefits and costs (financial and otherwise) of maintaining any specific measure in the Hospital OQR Program. Comment: A few commenters recommended that CMS consider measure sets as a whole as well as the consistency of quality reporting program measure sets. One commenter recommended that when a measure is removed under Factor 8 that it should be replaced by a measure that is easier to implement and aimed at improving care within the same measure domain to avoid gaps in the measure set. A commenter further recommended that measure sets should include actionable process measures that contribute to the outcomes being measured. Response: We intend to continue to develop a robust measure set for the Hospital OQR Program and appreciate the commenters’ feedback. We intend to consider the measure set as a whole, the types of measures in the measure set, and the consistency throughout quality reporting programs when assessing whether the costs outweigh the benefits of a measure’s continued use in the Hospital OQR Program. We continually seek ways to improve the Hospital OQR Program measure set, including through identification of more efficient means of capturing data. Retaining a strong measure set that addresses critical quality issues is one benefit that we would consider in evaluating whether a E:\FR\FM\21NOR2.SGM 21NOR2 khammond on DSK30JT082PROD with RULES2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations measure should be potentially removed from the Hospital OQR Program measure set. In addition, we note that in this final rule with comment period, we are not finalizing our proposals to remove two measures under Factor 8: OP–29: Endoscopy/Polyp Surveillance: Appropriate Follow-up Interval for Normal Colonoscopy in Average Risk Patients, and OP–31: Cataracts— Improvement in Patient’s Visual Function within 90 Days Following Cataract Surgery. This is discussed in more detail further below. After consideration of the public comments we received, we are finalizing our proposal to adopt measure removal Factor 8, the costs associated with a measure outweigh the benefit of its continued use in the program, for the Hospital OQR Program beginning with the effective date of this CY 2019 OPPS/ ASC final rule with comment period, as proposed. As a result of the finalization of our proposals to update measure removal Factor 7 and add new removal Factor 8 as proposed, the new measure removal factors list for the Hospital OQR Program consists of the following: • Factor 1. Measure performance among hospitals is so high and unvarying that meaningful distinctions and improvements in performance can no longer be made (‘‘topped out’’ measures). • Factor 2. Performance or improvement on a measure does not result in better patient outcomes. • Factor 3. A measure does not align with current clinical guidelines or practice. • Factor 4. The availability of a more broadly applicable (across settings, populations, or conditions) measure for the topic. • Factor 5. The availability of a measure that is more proximal in time to desired patient outcomes for the particular topic. • Factor 6. The availability of a measure that is more strongly associated with desired patient outcomes for the particular topic. • Factor 7. Collection or public reporting of a measure leads to negative unintended consequences other than patient harm. • Factor 8. The costs associated with a measure outweigh the benefit of its continued use in the program. (5) Codification at 42 CFR 419.46(h)(2) and (3) In the CY 2019 OPPS/ASC proposed rule (83 FR 37179), we proposed to codify our measure removal policies, including proposals made in the VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 proposed rule, if finalized, at 42 CFR 419.46(h)(2) and (3). We did not receive any public comments and are finalizing our proposal to codify our measure removal policies, at 42 CFR 419.46(h)(2) and (3) as proposed. (6) Clarification of Removal Factor 1: ‘‘Topped-Out’’ Measures As noted above, we refer readers to the CY 2015 OPPS/ASC final rule with comment period (79 FR 66769), where we finalized the criteria for determining when a measure is ‘‘topped-out.’’ In that final rule with comment period, we finalized two criteria for determining when a measure is ‘‘topped out’’ under the Hospital OQR Program: (1) When there is statistically indistinguishable performance at the 75th and 90th percentiles of national facility performance; and (2) when the measure’s truncated coefficient of variation (TCOV) is less than or equal to 0.10 (79 FR 66942). In the CY 2019 OPPS/ASC proposed rule (83 FR 37179), we clarified our process for calculating the truncated coefficient of variation (TCOV), particularly for two of the measures (OP–11 and OP–14) proposed for removal from the Hospital OQR Program. In accordance with our finalized methodology (79 FR 66942), we determine the truncated coefficient of variation (TCOV) by calculating the truncated standard deviation (SD) divided by the truncated mean. As discussed above, our finalized removal criteria state that to be considered ‘‘topped-out,’’ a measure must have a truncated TCOV of less than 0.10. We utilize the TCOV because it is generally a good measure of variability and provides a relative methodology for comparing different types of measures. Unlike the majority of the measures, for which a higher rate (indicating a higher proportion of a desired event) is the preferred outcome, some measures— in particular, OP–11 and OP–14—assess the rate of rare, undesired events for which a lower rate is preferred. For example, OP–11 assesses the use of both a contrast and non-contrast CT Thorax study at the same time, which is not recommended, as no clinical guidelines or peer-reviewed literature supports such CT Thorax ‘‘combined studies.’’ However, when determining the TCOV for a measure assessing rare, undesired events, the mean—or average rate of event occurrence—is very low, and the result is a TCOV that increases rapidly and approaches infinity as the PO 00000 Frm 00269 Fmt 4701 Sfmt 4700 59085 proportion of rare events declines.112 In the proposed rule, we noted that the SD, the variability statistic, is the same in magnitude for measures assessing rare and non-rare events. In the proposed rule, we proposed to remove two measures that assess the rate of rare, undesired events for which a lower rate is preferred—OP–11 and OP–14—and refer readers to section XIII.B.4.b.(2)(c) of the proposed rule and this final rule with comment period, where these proposals are discussed in detail. Because by design these measures have maintained very low rates of rare, undesired events (indicating the preferred outcomes), we utilized the mean of non-adverse events in our calculation of the TCOV. For example, for OP–11, to calculate the TCOV, we divide the SD by the average rate of patients not receiving both contrast and non-contrast abdominal CT (1.0 minus the rate of patients receiving both), rather than the rate of those receiving both types of CT. Utilizing this methodology results in a TCOV that is comparable to that calculated for other measures and allows us to assess rareevent measures by still generally using our previously finalized topped-out criteria. b. Removal of Quality Measures From the Hospital OQR Program Measure Set In the CY 2019 OPPS/ASC proposed rule (83 FR 37179 through 37186), we proposed to remove a total of 10 measures from the Hospital OQR Program measure set across the CY 2020 and CY 2021 payment determinations. Specifically, beginning with the CY 2020 payment determination, we proposed to remove (1) OP–27: Influenza Vaccination Coverage Among Healthcare Personnel (NQF #0431); and beginning with the CY 2021 payment determination, we proposed to remove—(2) OP–5: Median Time to ECG (NQF #0289); (3) OP 31: Cataracts— Improvement in Patient’s Visual Function within 90 Days Following Cataract Surgery (NQF #1536); (4) OP– 29: Endoscopy/Polyp Surveillance: Appropriate Follow-up Interval for Normal Colonoscopy in Average Risk Patients (NQF #0658); (5) OP–30: Endoscopy/Polyp Surveillance: Colonoscopy Interval for Patients with a History of Adenomatous Polyps— Avoidance of Inappropriate Use (NQF #0659); (6) OP–9: Mammography Follow-up Rates (no NQF number); (7) OP–11: Thorax Computed Tomography 112 Rose-Hulman Institute of Technology. Denominator approaching zero. Available at: https://www.rose-hulman.edu/media/89584/ lclimitsguide.pdf. E:\FR\FM\21NOR2.SGM 21NOR2 khammond on DSK30JT082PROD with RULES2 59086 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations (CT)—Use of Contrast Material (NQF #0513); (8) OP–12: The Ability for Providers with HIT (Health Information Technology) to Receive Laboratory Data Electronically Directly into Their Qualified/Certified EHR System as Discrete Searchable Data (NQF endorsement removed); (9) OP–14: Simultaneous Use of Brain Computed Tomography (CT) and Sinus CT (no NQF number); and (10) OP–17: Tracking Clinical Results between Visits (NQF endorsement removed). We proposed to remove these measures under the following removal factors: Proposed measure removal Factor 8, the costs associated with a measure outweigh the benefit of its continued use in the program; measure removal Factor 3, a measure does not align with current clinical guidelines or practice; measure removal Factor 1, measure performance among hospitals is so high and unvarying that meaningful distinctions and improvements in performance can no longer be made (‘‘topped-out’’ measures); and measure removal Factor 2, performance or improvement on a measure does not result in better patient outcomes. These proposed measure-specific removals are discussed in detail further below. We also received several general comments regarding these proposals as a whole and are discussing those first. Comment: Many commenters supported CMS’ proposals to remove 10 measures from the Hospital OQR Program measure set. Some noted that the proposals will reduce burden, simplify hospital reporting, and reduce duplication. Several commenters suggested that CMS remove all 10 measures beginning with CY 2020, rather than delaying removal of nine measures until CY 2021. Commenters agreed with CMS’ rationale for removals and noted that topped-out or not beneficial measures should be removed as soon as possible. Response: We thank the commenters for their support. Data collection and reporting for the CY 2020 payment determination has already begun for all nine of the measures proposed for removal. Specifically, as finalized in the CY 2016 OPPS/ASC final rule with comment period (80 FR 70519 through 70520), data collection began with Q2, (April 1) of 2018. Thus, by the effective date of this final rule with comment period, hospitals will have already reported almost three quarters of data for these measures. In consideration of hospitals’ efforts already exerted, we are finalizing removal of these measures starting with the next proximate payment determination. VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 Comment: One commenter opposed all of CMS’ proposals to remove measures from the Hospital OQR Program, citing its belief that consumers should be offered more quality information, rather than less, that can be used in selecting facilities. Another commenter recommended that CMS maintain the existing measure set and, instead of removing measures, work to reduce provider burden through alignment across programs. Response: We thank the commenters for their feedback and note our agreement that consumers should be provided with as much valuable quality information as possible. As described in the proposed rule, we proposed to remove these measures because the costs associated with a measure outweigh the benefit of its continued use in the program; the measure does not align with current clinical guidelines or practice, measure performance among hospitals is so high and unvarying that meaningful distinctions and improvements in performance can no longer be made (‘‘topped-out’’ measures); or because performance or improvement on a measure does not result in better patient outcomes. We have identified these and other measure removal factors specifically to ensure that the data provided to consumers is meaningful and valuable. We do not believe it is beneficial to maintain program measures indefinitely. However, we agree that burden should be reduced through program alignment and will continue to seek opportunities to do this. In the CY 2019 OPPS/ASC proposed rule, we proposed several policies to align with the ASCQR Program, including updating our measure removal factors and removing OP–27 and ASC–8, OP–29 and ASC–9, OP–30 and ASC–10, and OP–31 and ASC–11, and we are finalizing several of these aligned proposals in this final rule with comment period. Comment: One commenter recommended that CMS consider the impact of the proposed removal of OP– 5, OP–14, OP–27, OP–29, and OP–30 on the Hospital Compare overall hospital ratings. Response: Although these measure removals will reduce the number of outpatient measures in the Hospital Overall Star Ratings, a representative measure set remains and includes OP– 32: 7-day visit rate after colonoscopy, OP–4: Aspirin on arrival, OP–22: Patient Left Without Being Seen, OP–23: Head CT or MRI Scan Results for Acute Ischemic Stroke or Hemorrhagic Stroke Patients who Received Head CT or MRI Scan Interpretation Within 45 minutes PO 00000 Frm 00270 Fmt 4701 Sfmt 4700 of ED Arrival, OP–33: External Beam Radiotherapy for Bone Metastases, OP– 3: Median Time to Transfer to Another Facility for Acute Coronary Intervention, and OP–18: Median Time from Emergency Department (ED) Arrival to ED Departure for Discharged ED Patients. Additional measures, including surgery and chemotherapy measures, may be considered for adoption in future years. (We refer readers to our web page at: https:// www.medicare.gov/hospitalcompare/ About/Hospital-overall-ratings.html for a discussion of Hospital Compare overall hospital ratings.) (1) Measure Removal for the CY 2020 Payment Determination and Subsequent Years—Removal of OP–27: Influenza Vaccination Coverage Among Healthcare Personnel (NQF #0431) For the CY 2020 payment determination and subsequent years, we proposed to remove one NHSN measure under proposed measure removal Factor 8, the costs associated with this measure outweigh the benefit of its continued use in the program. We refer readers to the CY 2014 OPPS/ASC final rule with comment period (78 FR 75099), where we adopted OP–27: Influenza Vaccination Coverage Among Healthcare Personnel (NQF #0431), beginning with the CY 2016 payment determination and for subsequent years. This process-of-care measure, also a National Healthcare Safety Network (NHSN) measure, assesses the percentage of healthcare personnel who have been immunized for influenza during the flu season. We initially adopted this measure based on our recognition that influenza immunization is an important public health issue and vital component to preventing healthcare associated infections. We believe that the measure addresses this public health concern by assessing influenza vaccination in the HOPD among health care personnel (HCP), who can serve as vectors for influenza transmission. In the proposed rule, we proposed to remove OP–27, beginning with the CY 2020 payment determination under our proposed measure removal Factor 8 because we have concluded that the costs associated with this measure outweigh the benefit of its continued use in the program. The information collection burden for the Influenza Vaccination Coverage Among Healthcare Personnel measure is less than for measures that require chart-abstraction of patient data because influenza vaccination among healthcare personnel can be calculated through review of records maintained in E:\FR\FM\21NOR2.SGM 21NOR2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations khammond on DSK30JT082PROD with RULES2 administrative systems and because facilities have fewer healthcare personnel than patients. As such, OP–27 does not require review of as many records. However, this measure does still pose information collection burden on facilities due to the requirement to identify personnel who have been vaccinated against influenza and for those not vaccinated, the reason why. Furthermore, as we stated in section XIII.B.4.a. of the proposed rule and this final rule with comment period, costs are multi-faceted and include not only the burden associated with reporting, but also the costs associated with implementing and maintaining the program. For example, it may be costly for health care providers to maintain general administrative knowledge to report these measures. In addition, CMS must expend resources in maintaining information collection systems, analyzing reported data, and providing public reporting of the collected information. In our analysis of the Hospital OQR Program measure set, we recognized that some facilities face challenges with respect to the administrative requirements of the NHSN in their reporting of the Influenza Vaccination Coverage Among Healthcare Personnel measure. These administrative requirements (which are unique to NHSN) include annually completing NHSN system user authentication. Enrolling in NHSN is a five-step process that the Centers for Disease Control and Prevention (CDC) estimates takes an average of 263 minutes per facility.113 Furthermore, submission via NHSN requires the system security administrator of participating facilities to re-consent electronically, ensure that contact information is kept current, ensure that the hospital has an active facility administrator account, keep Secure Access Management Service (SAMS) credentials active by logging in approximately every two months and changing their password, create a monthly reporting plan, and ensure the facility’s CCN information is up-to-date. Unlike acute care hospital which participate in other quality programs, such as the Hospital IQR and HAC Reduction Programs, HOPDs are only required to participate in NHSN to submit data for this one measure. 113 CDC, National Healthcare Safety Network (NHSN). Five-Step Enrollment for Acute Care Hospitals/Facilities. Available at: https:// www.cdc.gov/nhsn/acute-care-hospital/enroll.html (the estimates for time to complete are 2 hours 45 minutes for step 1, 10 minutes for step 2, 16 minutes for step 3a, 35 minutes for step 3b, 32 minutes for step 4, and 5 minutes for step 5; totaling 263 minutes). VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 In our assessment, we also considered that the vast majority (99.7 percent) of Hospital OQR Program eligible hospitals already report this measure in the Hospital IQR Program for workers providing any services to inpatient care. The Hospital IQR Program measure includes the vast majority of all hospital personnel since many workers in outpatient departments provide services to both inpatient and outpatient departments (adopted at 76 FR 51631 through 51633). These workers include most emergency department clinicians, specialists such as pharmacists and imaging professionals, and custodians and other support staff working across the hospital. We continue to believe that the OP– 27: Influenza Vaccination Coverage Among Healthcare Personnel (NQF #0431) measure provides the benefit of protecting patients against influenza. However, we believe that these benefits are offset by other efforts to reduce influenza infection among patients, such as numerous healthcare employer requirements for health care personnel to be vaccinated against influenza.114 115 We also expect that a portion of MIPSeligible clinicians nationwide will report on the Preventive Care and Screening: Influenza Immunization measure through the Quality Payment Program (QPP).116 Although MIPSeligible clinicians may voluntarily select measures from a list of options, HOPD providers that are MIPS-eligible will have the opportunity to continue collecting information for the measure. We remain responsive to the public health concern of influenza infection within the Medicare FFS population by collecting data on rates of influenza immunization among patients.117 Thus, the public health concern of influenza immunization is addressed via these other efforts to track influenza vaccination. The availability of this measure in another CMS program demonstrates CMS’ continued commitment to this measure area. In addition, as we discussed in section XIII.B.4.a of the proposed rule, where we proposed to adopt measure removal Factor 8, beneficiaries may find it 114 CDC, Influenza Vaccination Information for Health Care Workers. Available at: https:// www.cdc.gov/flu/healthcareworkers.htm. 115 CDC Influenza Vaccination Coverage Among Health Care Personnel—United States, 2013–14 Influenza Season. Available at: https:// www.cdc.gov/mmwr/preview/mmwrhtml/ mm6337a1.htm. 116 QPP 2017 Measures Selection: Influenza. Retrieved from: https://qpp.cms.gov/mips/qualitymeasures. 117 Ibid. PO 00000 Frm 00271 Fmt 4701 Sfmt 4700 59087 confusing to see public reporting on the same measure in different programs. We wish to minimize the level of cost of our programs for participating facilities, as discussed under the Meaningful Measures Initiative, described in section I.A.2. of the proposed rule and this final rule with comment period. In our assessment of the Hospital OQR Program measure set, we prioritized measures that align with this Initiative’s framework as the most important to the Hospital OQR Program’s population. Our assessment concluded that while the OP–27 measure continues to provide benefits, these benefits are diminished by other factors and are outweighed by the costs and burdens of reporting this chartabstracted measure. For these reasons, we proposed to remove OP–27: NHSN Influenza Vaccination Coverage among Healthcare Personnel (NQF #0431) from the Hospital OQR Program beginning with the CY 2020 payment determination and for subsequent years. In the proposed rule, we noted that if proposed measure removal Factor 8 is not finalized, removal of this measure would also not be finalized. We also noted that a similar measure was also proposed for removal from the ASCQR Program in section XIV.B.3.c. of the proposed rule and the IPFQR Program in the FY 2019 IPF PPS proposed rule (83 FR 21104). Comment: Several commenters supported CMS’ proposal to remove OP–27 from the Hospital OQR Program measure set, and noted that the proposal will reduce burden and costs to hospitals and that levels of vaccination of health care employees is already very high. Response: We thank the commenters for their support regarding the burden associated with the OP–27 measure. Comment: Several commenters opposed CMS’ proposal to remove OP– 27 from the Hospital OQR Program. A few commenters expressed concern that influenza is a critical public health issue and that influenza vaccination coverage of healthcare workers helps create a safe environment for patients, visitors, and employees. A few commenters expressed concern that removal of OP– 27 would result in lower vaccination rates among healthcare workers. A few commenters noted that the Medicare population may be more susceptible to vaccine preventable illnesses such as influenza. Response: We thank these commenters for their input. We agree that influenza vaccination for both patients and healthcare personnel is important in the outpatient hospital setting, as well as other healthcare E:\FR\FM\21NOR2.SGM 21NOR2 khammond on DSK30JT082PROD with RULES2 59088 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations settings, and we believe that these two activities are both intended to address the public health concern of reducing influenza infection. However, while we agree that Medicare beneficiaries may have additional risk of contracting influenza, as noted in our proposal, we believe the effects of removing this measure from the Hospital OQR Program are mitigated as the issue is addressed by other initiatives such as State laws and employer programs that require influenza vaccination of healthcare workers. Because of this, we do not believe that retaining this measure would result in lower rates of vaccination coverage among healthcare personnel. Further, we have retained the measure in the Hospital IQR Program (83 FR 41579), thus requiring reporting in the short-term, acute care hospital setting. In addition, we believe that the burden of this measure on hospitals outweighs the limited benefit of addressing this topic again under the Hospital OQR Program in addition to the many other vaccination initiatives. Comment: A few commenters stated that OP–27 plays a critical role in the CMS Quality Strategy and the National Quality Strategy in terms of immunization efforts. A few commenters suggested that removal of the measure would create greater inconsistency across quality reporting programs. Response: We agree that influenza is a critical public health issue that is part of the CMS Quality Strategy and the National Quality Strategy. Through our Meaningful Measures Initiative, it is our goal to ensure that we are addressing high-impact measure areas that safeguard public health while minimizing the level of burden for providers and suppliers. We continue to believe in the importance of influenza vaccination coverage for health care workers, particularly in acute care settings, and have retained this measure in the Hospital IQR Program (83 FR 41579) in order to address this concern. As we noted above, the burden of reporting this measure is greater for outpatient hospitals compared to the relative burden for hospitals participating in the Hospital IQR and HAC Reduction Programs. The entire burden of registering for and maintaining access to the CDC’s NHSN system is due to this one measure; whereas hospitals paid under IPPS, participating in the Hospital IQR Program, the HAC Reduction Program and the Hospital VBP Program, for example, must register and maintain NHSN access for several healthcare safety measures, not just one. However, VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 we note that, beyond the Hospital OQR Program, HOPDs may independently choose to voluntarily report data to NHSN on vaccination rates using the NHSN Healthcare Personnel Safety Component. Comment: One commenter stated that the cost associated with mitigating an influenza outbreak outweighs the cost of retaining OP–27 in the Hospital OQR Program. Response: As we noted above, we have retained the measure in the Hospital IQR Program (83 FR 41579) in order to address concerns about influenza as a public health issue. In addition, as noted above, we believe the effects of removing this measure from the Hospital OQR Program are mitigated as the topic is addressed by other initiatives such as State laws and employer programs that require influenza vaccination of healthcare workers.118 119 As a result, we do not believe removing this measure from the Hospital OQR Program will result in lower rates of vaccination coverage among healthcare personnel in the HOPD setting or increase the risk of an outbreak. After consideration of the public comments we received, we are finalizing our proposal, as proposed, to remove OP–27: NHSN Influenza Vaccination Coverage among Healthcare Personnel (NQF #0431) from the Hospital OQR Program beginning with the CY 2020 payment determination and for subsequent years. (2) Measure Removals for the CY 2021 Payment Determination and Subsequent Years In the CY 2019 OPPS/ASC proposed rule (83 FR 37181 through 37186), for the CY 2021 payment determination and subsequent years, we proposed to remove: Four measures under proposed measure removal Factor 8; one measure under measure removal Factor 3; two measures under removal Factor 1; and two measures under measure removal Factor 2. (a) Measure Removals Under Finalized Removal Factor 8: OP–5, OP–29, OP–30, and OP–31 In the proposed rule, we proposed to remove four measures under measure removal Factor 8, which is being finalized in this final rule with 118 CDC. Influenza Vaccination Information for Health Care Workers. Available at: https:// www.cdc.gov/flu/healthcareworkers.htm. 119 CDC Influenza Vaccination Coverage Among Health Care Personnel—United States, 2013–14 Influenza Season. Available at: https:// www.cdc.gov/mmwr/preview/mmwrhtml/ mm6337a1.htm. PO 00000 Frm 00272 Fmt 4701 Sfmt 4700 comment period, for the CY 2021 payment determination and subsequent years: OP–5, OP–29, OP–30, and OP–31. In the proposed rule, we noted that if proposed measure removal Factor 8 was not finalized, removal of these measures would also not be finalized. The proposals are discussed in more detail below. In the proposed rule, we noted that in crafting our proposals, we considered removing these measures beginning with the CY 2020 payment determination, but we decided on proposing to delay removal until the CY 2021 payment determination to be sensitive to facilities’ planning and operational procedures given that data collection for this measure begins during CY 2018 for the CY 2020 payment determination. • Removal of OP–5: Median Time to ECG (NQF #0289) We refer readers to the CY 2008 OPPS/ASC final rule with comment period (72 FR 66865) where we adopted OP–5: Median Time to ECG (NQF #0289) beginning with the CY 2009 payment determination.120 This chartabstracted measure assesses the median number of minutes before outpatients with heart attack (or chest pain that suggests a possible heart attack) received an electrocardiograph (ECG) test to help diagnose heart attack. We proposed to remove the OP–5 measure beginning with the CY 2021 payment determination under our proposed measure removal Factor 8, the costs associated with the measure outweigh the benefit of its continued use in the program. As noted above, OP–5 is a chart-abstracted measure, which can be potentially more challenging for facilities to report than claims-based or structural measures. Chart-abstraction requires facilities to select a sample population, access historical records from several clinical data quarters past, and interpret that patient data. This process is typically more time and resource-consuming than for other measure types. As described in section I.A.2. of the proposed rule and this final rule with comment period, our Meaningful Measures Initiative is intended to reduce costs and minimize burden, and we believe that removing this chart-abstracted measure from the Hospital OQR Program would reduce program complexity. However, we do not believe the use of chart-abstracted measure data alone is sufficient justification for removal of a measure under proposed measure 120 This measure was formerly called ‘‘ED–AMI– 4—Median Time to Electrocardiogram (ECG)’’ in the cited Federal Register. E:\FR\FM\21NOR2.SGM 21NOR2 59089 removal Factor 8. The costs of collection and submission of chart-abstracted measure data is burdensome for facilities, especially when taking into consideration that, although this measure is not topped-out, we have come to the conclusion that the benefit of this measure is limited. Based on our analysis of data submitted by 1,995 hospitals from Quarter 3 in 2016 through Quarter 2 in 2017 the variation in average measure performance between hospitals is minimal, with a difference in median time to ECG of less than two minutes between the 75th and 90th percentile hospitals. Furthermore, the difference between the 25th and 75th percentile, distinguishing between high and low performers, is only 5.5 minutes. Given clinical guidelines recommend that ECG be obtained within 10 minutes of arrival to the emergency department (ED), we do not believe this difference is clinically significant and further indicates that variations are not sufficiently large to inform beneficiary decision-making to justify the costs of collecting the data.121 These data are demonstrated in the table below. We believe that the minimal variation in hospital performance does not help beneficiaries to make informed care decisions, since distinguishing meaningful differences in hospital performance on this measure is difficult. As such, the measure benefit is limited, and no longer meaningfully supports program objectives of informing beneficiary choice. Thus, we believe that costs and burdens to both facilities and CMS such as program oversight, measure maintenance, and public display, associated with keeping this measure in the program outweigh the limited benefit associated with the measure’s continued use. Therefore, we proposed to remove OP–5: Median Time to ECG from the Hospital OQR Program beginning with the CY 2021 payment determination and for subsequent years. Comment: Many commenters supported CMS’ proposal to remove OP–5. One commenter stated that the burden of collecting data for this chartabstraction measure exceeds the value. Many other commenters praised CMS’ measure removals in general due to the resulting burden reduction. Response: We thank the commenters for their support. Comment: A few commenters recommended retaining OP–5. One commenter noted that ECG findings are important in managing acute coronary symptoms and affect patient morbidity. This commenter also noted that it is not overly burdensome to report the measure. Another commenter recommended that the measure be retained and revised so that patients admitted for observation or inpatient care are included. Response: We thank commenters for this feedback. We agree that ECG findings are important, but our assessment indicates that there is minimal variation in hospital performance on this measure, and therefore, the opportunity to improve the management and patient morbidity associated with acute coronary symptoms is severely limited. In addition, we disagree that the measure is not burdensome to report overall, as it requires chart-abstraction. Many commenters supported removal and cited burden reduction as a benefit of this proposal. As a result, we believe it is appropriate to remove this measure and we do not intend to retain or revise it. After consideration of the public comments we received, we are finalizing our proposal, as proposed, to remove OP–5: Median Time to ECG from the Hospital OQR Program beginning with the CY 2021 payment determination and for subsequent years. chart-abstracted process measure assesses the ‘‘[p]ercentage of patients aged 50 years and older receiving a screening colonoscopy without biopsy or polypectomy who had a recommended follow-up interval of at least 10 years for repeat colonoscopy documented in their colonoscopy report.’’ (78 FR 75099). This measure aims to assess whether average risk patients with normal colonoscopies receive a recommendation to receive a repeat colonoscopy in an interval that is less than the recommended amount of 10 years. In the proposed rule, we proposed to remove OP–29: Endoscopy/Polyp Surveillance Follow-up Interval for Normal Colonoscopy in Average Risk Patients beginning with the CY 2021 payment determination and for subsequent years under our proposed measure removal Factor 8, the costs associated with a measure outweigh the benefit of its continued use in the program. We adopted OP–29: Endoscopy/Polyp Surveillance Followup Interval for Normal Colonoscopy in Average Risk Patients in the CY 2014 OPPS/ASC final rule with comment period (78 FR 75099 through 75100) noting that performing colonoscopy too frequently increases patients’ exposure to procedural harm. However, we noted concern in the proposed rule that the costs of this measure outweigh the benefit of its continued use in the program. Chart-abstraction requires facilities to select a sample population, access historical records from several current and historic clinical data quarters, and • Proposal To Remove OP–29: Endoscopy/Polyp Surveillance: Appropriate Follow-Up Interval for Normal Colonoscopy in Average Risk Patients We refer readers to the CY 2014 OPPS/ASC final rule with comment period (78 FR 75099 through 75100) where we adopted OP–29: Endoscopy/ Polyp Surveillance: Appropriate Follow-up Interval for Normal Colonoscopy in Average Risk Patients (NQF #0659) beginning with the CY 2016 payment determination. This 121 Diercks et al. 2006. Door-to-ECG time in patients with chest pain presenting to the ED. AJEM. VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 PO 00000 Frm 00273 Fmt 4701 Sfmt 4700 E:\FR\FM\21NOR2.SGM 21NOR2 ER21NO18.100</GPH> khammond on DSK30JT082PROD with RULES2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations khammond on DSK30JT082PROD with RULES2 59090 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations interpret that patient data. This process is typically more time and resourceconsuming than for other measure types. In addition to submission of manually chart-abstracted data, we take all burden and costs into account when evaluating a measure. We noted in the proposed rule that removing OP–29 would reduce the burden and cost to facilities associated with collection of information and reporting on their performance associated with the measure. However, we also acknowledged that we do not believe the use of chartabstracted measure data alone is sufficient justification for removal of a measure under proposed measure removal Factor 8. The costs of collection and submission of chart-abstracted measure data is burdensome for facilities especially when taking into consideration the availability of other CMS quality measures that are relevant in the clinical condition and highly correlated in performance across measures. In the proposed rule, we noted another colonoscopy-related measure required in the Hospital OQR Program, OP–32: Facility 7-Day RiskStandardized Hospital Visit Rate after Outpatient Colonoscopy (NQF #2539), which measures all-cause, unplanned hospital visits (admissions, observation stays, and emergency department visits) within 7 days of an outpatient colonoscopy procedure (79 FR 66949). This claims-based outcomes measure does not require chart-abstraction, and similarly contributes data on quality of care related to colonoscopy procedures, although the measure does not specifically track processes such as follow-up intervals. When we adopted OP–32, we believed this measure would reduce adverse patient outcomes associated with preparation for colonoscopy, the procedure itself, and follow-up care by capturing and making more visible to facilities and patients all unplanned hospital visits following the procedure (79 FR 66949). Furthermore, in the proposed rule, we noted our belief that the potential benefits of keeping OP–29 in the program are mitigated by the existence of the same measure (Appropriate Follow-up Interval for Normal Colonoscopy in Average Risk Patients) 122 for gastroenterologists in the Merit-Based Incentive Payment System (MIPS) for the 2019 performance period in the QPP (82 FR 30292). Thus, we noted that the issue of preventing harm to patients 122 QPP Measure Selection: Appropriate Followup Interval for Normal Colonoscopy in Average Risk Patients. Available at: https://qpp.cms.gov/ mips/quality-measures. VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 from colonoscopy procedures that are performed too frequently is adequately addressed through MIPS in the QPP, because we expect a portion of MIPSeligible clinicians reporting on the measure nationwide to provide meaningful data to CMS. In the proposed rule, we noted that although MIPS-eligible clinicians may voluntarily select measures from a list of options, HOPD providers that are MIPS-eligible will have the opportunity to continue collecting information for the measure without being penalized if they determine there is value for various quality improvement efforts.123 The availability of this measure in another CMS program demonstrates CMS’ continued commitment to this measure area. Furthermore, we seek to align our quality reporting work with the Patients Over Paperwork and the Meaningful Measures Initiatives described in section I.A.2. of the proposed rule and this final rule with comment period. The purpose of this effort is to hold providers accountable for only the measures that are most important to patients and clinicians and those that are focused on patient outcomes in particular, because outcome measures evaluate the actual results of care. As described in section I.A.2. of the proposed rule and this final rule with comment period, our Meaningful Measures Initiative is intended to reduce costs and minimize burden, and we believe that removing this chartabstracted measure from the Hospital OQR Program would reduce program complexity. In addition, as we discussed in section XIV.B.3.b. of the proposed rule, where we proposed to adopt measure removal Factor 8, we noted that beneficiaries may find it confusing to see public reporting on the same measure in different programs. Therefore, due to the combination of factors of the costs of collecting data for this chart-abstracted measure, the preference for an outcomes measure in the Hospital OQR Program that provides valuable data for the same procedure, and the existence of the same measure in another CMS program, we noted in the proposed rule that the burdens and costs associated with this measure outweigh the limited benefit to beneficiaries. As a result, we proposed 123 CMS finalized that services furnished by an eligible clinician that are payable under the ASC, HHA, Hospice, or HOPD methodology will not be subject to the MIPS payments adjustments, but eligible clinicians payable under those methodologies may have the option to still voluntarily report on applicable measures and the data reported will not be used to determine future eligibility (82 FR 53586). PO 00000 Frm 00274 Fmt 4701 Sfmt 4700 to remove OP–29: Endoscopy/Polyp Surveillance Follow-up Interval for Normal Colonoscopy in Average Risk Patients beginning with the CY 2021 payment determination and for subsequent years. In the proposed rule, we noted that we also proposed to remove a similar measure in the ASCQR Program in section XIV.B.3.c. of the proposed rule. Comment: Several commenters opposed CMS’ proposal to remove OP– 29 from the Hospital OQR Program. A few commenters expressed concern that physicians may not follow the recommended guidelines for colonoscopy screenings and noted that there is a potential for patient harm from unnecessary colonoscopy screenings that pose significant costs. One commenter believed that solely retaining the measure in MIPS is insufficient because the measure is voluntary in that program. A few commenters stated that OP–29 and OP– 32 assess distinct and different aspects of colonoscopies, because OP–32 focuses on coordination and does not evaluate the interval between colonoscopies or the appropriate use of care. One commenter noted that OP–29 and OP–32 fall into different Meaningful Measures categories, Preventable Healthcare Harm and Admissions and Readmissions, respectively. Some commenters recommended retaining OP–29 to achieve a holistic approach to measuring the quality of care in this clinical area. One commenter asserted that OP–29 is not overly burdensome to collect and report. Some commenters disagreed with CMS’ assessment that the costs of the measure outweigh the benefits. Response: Although MIPS-eligible clinicians may voluntarily select measures from a list of options, in crafting our proposal, we believed that MIPS reporting would mitigate the impact of removing this measure and provide some meaningful data in this clinical area. After considering the commenters’ views, however, we acknowledge that although a similar measure is available in the QPP, OP–29 provides valuable information to beneficiaries specifically about the outpatient hospital setting, where high volumes of colonoscopies are performed. We agree that adherence to clinical guidelines for colonoscopy screening intervals is an important issue due to many studies that document inappropriate use.124 125 126 One study 124 Sheffield et al. 2013. Potentially Inappropriate Screening Colonoscopy in Medicare Patients: E:\FR\FM\21NOR2.SGM 21NOR2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations khammond on DSK30JT082PROD with RULES2 showed high rates of inappropriate colonoscopies performed in older adult populations: 10 percent in adults aged 70–75, 39 percent in adults aged 76–85, and 25 percent in adults aged ≥86.127 Thus, we believe that OP–29 is a critical measure for the Hospital OQR Program because there is demonstrated substantial overuse of surveillance colonoscopies among low-risk patients,128 with research showing that colonoscopies are often recommended at shorter intervals than are advised by guidelines among patients with normal colonoscopy results.129 We believe it is especially important to assess this topic due to the high-volume of these procedures that occur in the outpatient setting. Furthermore, while OP–29 and OP–32 assess the topic of colonoscopies generally, we acknowledge that they assess distinct clinical areas. OP–32 tracks adverse patient outcomes that result in unplanned hospital visits, whereas, OP–29 provides information about colonoscopies occurring at inappropriate intervals that may increase costs to beneficiaries and to CMS, a priority of our Meaningful Measures Initiative. While OP–32 provides vital data about patient outcomes after colonoscopies, OP–29 focuses on adherence to guideline recommendations for screening colonoscopy follow-up intervals, as noted by NQF’s evaluation report.130 Despite the costs and burdens of chart-abstraction or the presence of other measures assessing a similar clinical topic, after considering incoming comments and reevaluating our data, we now believe OP–29 is a Variation by Provider and Geographic Region. JAMA Intern Med. 125 Schoen R. E., Pinsky P. F., Weissfeld J. L., et al. Utilization of surveillance colonoscopy in community practice. Gastroenterology. 2010;138(1):73–81. doi: 10.1053/ j.gastro.2009.09.062. 126 Krist, AH, Jones, RM, Woolf, SH et al. Timing of Repeat Colonoscopy: Disparity Between Guidelines and Endoscopists’ Recommendation. American Journal of Preventive Medicine. 2007. 127 Sheffield et al. 2013. Potentially Inappropriate Screening Colonoscopy in Medicare Patients: Variation by Provider and Geographic Region. JAMA Intern Med. 128 Schoen R. E., Pinsky P. F., Weissfeld J. L., et al. Utilization of surveillance colonoscopy in community practice. Gastroenterology. 2010;138(1):73–81. doi: 10.1053/ j.gastro.2009.09.062. 129 Krist, AH, Jones, RM, Woolf, SH et al. Timing of Repeat Colonoscopy: Disparity Between Guidelines and Endoscopists’ Recommendation. American Journal of Preventive Medicine. 2007. 130 NQF #0658 Endoscopy/Polyp Surveillance: Appropriate follow-up interval for normal colonoscopy in average risk patients, Date Submitted: Jul 09, 2012 National Quality Form, Stage 1 Concept Submission and Evaluation Worksheet 1.0. VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 more critical measure for the Hospital OQR Program than initially perceived in the proposed rule. Specifically, as discussed above, upon reviewing the measure set as a whole, we now believe that OP–29 assesses a distinct clinical area not addressed by OP–32. Further, although we noted that OP–29 requires the burden of chart-abstraction to report, we believe this measure is significantly less burdensome than OP–30 due to the significant burden of obtaining patient histories required for that measure. We also appreciate commenters’ feedback that OP–29 is not overly burdensome to report. Because this measure tracks the number of patients who had a recommended follow-up interval of at least 10 years for repeat colonoscopy documented in their colonoscopy report, we believe it provides important information to beneficiaries on the avoidance of inappropriate endoscopies/colonoscopies. OP–29 evaluates overutilization that can lead to the overuse of resources and unnecessary risks to beneficiaries from possible procedural complications and harms. Accordingly, after considering the public comments we received and upon further review of the benefits of the measure, we no longer believe that the costs associated with this measure outweigh the benefit of its continued use in the Hospital OQR Program. In section I.A.2. of the proposed and this final rule with comment period, we describe our Meaningful Measures Initiative that is intended to reduce costs and minimize burden. We believe that while removing this chartabstracted measure from the Hospital OQR Program would reduce program complexity, retaining it provides pertinent information about colonoscopies occurring at inappropriate intervals that may contribute to increased costs to beneficiaries and to CMS, a priority of our Meaningful Measures Initiative. Therefore, we are not finalizing our proposal to remove this measure. We believe retaining this measure is responsive to those comments as it is a valuable process measure and assesses a distinct clinical area. Comment: A few commenters stated that OP–29 should be retained to promote program alignment across outpatient settings and allow for comparisons between facility types. Response: We have considered program alignment by adding and removing measures in tandem for the ASCQR and Hospital OQR Programs, such as ASC–9/OP–29: Endoscopy/ Polyp Surveillance: Appropriate Follow-up Interval for Normal PO 00000 Frm 00275 Fmt 4701 Sfmt 4700 59091 Colonoscopy in Average Risk Patients. As noted above, we adopted OP–29 into the Hospital OQR Program because we believe it is important for HOPDs to be active partners in avoiding inappropriate use and ensuring that beneficiaries at their facilities are referred for follow-up care at appropriate intervals in alignment with current guidelines. As stated above, we are not finalizing our proposal to remove OP–29. We are similarly retaining the corresponding measure (ASC–9) in the ASCQR Program in section XIV.B.3.c. of this final rule with comment period. Comment: One commenter did not support CMS’ proposal to remove OP– 29 because it is included in the Core Quality Measures Collaborative (CQMC) Gastroenterology Core Set and is widely used in the private sector. Response: The CMS CQMC identifies core sets of quality measures that payers have committed to using for reporting as soon as feasible.131 The guiding principles used by the Collaborative in developing the core measure sets are that they be meaningful to patients, consumers, and physicians, while reducing variability in measure selection, collection burden, and cost. Its goal is to establish broadly agreed upon core measure sets that could be harmonized across both commercial and government payers.132 We agree that the inclusion of OP–29 in the CQMC Gastroenterology Core Set speaks to its clinical value. However, although we are retaining OP–29 for the reasons described in this section, we note that the inclusion of measures in the CQMC Core Sets does not necessitate retention in the Hospital OQR Program. Comment: One commenter recommended that CMS retain the measure and explore how to automate tracking of the information to reduce the resource-intensive use of chartabstracted data. Response: We thank the commenter for the suggestion regarding automated data submission and will take this into consideration for the future. As discussed in section I.A.2 of this final rule with comment period, our Meaningful Measures Initiative prioritizes the least burdensome measure sets for our quality reporting programs, and we will continue to evaluate the Hospital OQR Program measure set through this framework. We continually seek opportunities to reduce 131 Core Measures. Retrieved from: https:// www.cms.gov/Medicare/Quality-Initiatives-PatientAssessment-Instruments/QualityMeasures/CoreMeasures.html. 132 Ibid. E:\FR\FM\21NOR2.SGM 21NOR2 59092 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations khammond on DSK30JT082PROD with RULES2 the reporting burden of our programs but note that collecting data for OP–29 still currently requires chart-abstraction. Comment: Many commenters supported CMS’ proposal to remove OP–29, noting that the proposal reduces burden and duplication between programs. A few commenters noted that the measure was developed to assess provider, rather than facility-level, performance. Response: We thank the commenters for their support. As noted in our proposal above, this same measure is available through MIPS in the QPP and, although MIPS-eligible clinicians may voluntarily select measures from a list of options, we expect a portion of MIPSeligible clinicians reporting on the measure nationwide to provide meaningful data to CMS about avoiding inappropriate use. While this measure was initially developed at the physician level, it has been field-tested in the HOPD facility setting by the measure stewards (78 FR 75099). Further, we believe it is important for HOPDs to be active partners in avoiding inappropriate use and ensuring that patients at their facilities are referred for follow-up care at appropriate intervals in alignment with current guidelines. In addition, after considering the public comments we received and upon further review of the benefits of the measure, we no longer believe that the costs associated with this measure outweigh the benefit of its continued use in the program as this measure assesses a unique and clinically important topic area not covered otherwise addressed by the Hospital OQR Program measure set. After consideration of the public comments we received, we are not finalizing our proposal to remove OP– 29: Endoscopy/Polyp Surveillance: Appropriate Follow-up Interval for Normal Colonoscopy in Average Risk Patients from the Hospital OQR Program beginning with the CY 2021 payment determination and for subsequent years. This measure will remain in the program under our measure retention policies, unless we take future action under our measure removal policies. We note that we also are not finalizing our proposal to remove ASC–9 under the ASCQR Program, and we refer readers to section XIV.B.3.c. of this final rule with comment period for more information. • Removal of OP–30: Endoscopy/Polyp Surveillance: Colonoscopy Interval for Patients With a History of Adenomatous Polyps—Avoidance of Inappropriate Use We refer readers to CY 2014 OPPS/ ASC final rule with comment period (78 FR 75102) where we adopted OP–30: VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 Endoscopy/Polyp Surveillance: Colonoscopy Interval for Patients with a History of Adenomatous PolypsAvoidance of Inappropriate Use (NQF #0659) beginning with the CY 2016 payment determination. This chartabstracted process measure assesses the percentage of patients aged 18 years and older receiving a surveillance colonoscopy, with a history of a prior colonic polyp in previous colonoscopy findings, who had a follow-up interval of three or more years since their last colonoscopy documented in the colonoscopy report. In the proposed rule, we proposed to remove OP–30: Endoscopy/Polyp Surveillance: Colonoscopy Interval for Patients with a History of Adenomatous Polyps-Avoidance of Inappropriate Use beginning with the CY 2021 payment determination and for subsequent years under our proposed measure removal Factor 8, the costs associated with a measure outweigh the benefit of its continued use in the program. We adopted OP–30: Endoscopy/Polyp Surveillance: Colonoscopy Interval for Patients with a History of Adenomatous Polyps-Avoidance of Inappropriate Use in the CY 2014 OPPS/ASC final rule with comment period (78 FR 75102) noting that colonoscopy screening for high risk patients is recommended based on risk factors and one such factor is a history of adenomatous polyps. The frequency of colonoscopy screening varies depending on the size and amount of polyps found, with the general recommendation of a 3-year follow-up. We stated that this measure is appropriate for the measurement of quality of care furnished by hospital outpatient departments because colonoscopy screening is commonly performed in these settings (78 FR 75102). However, we now believe that the costs of this measure outweigh the benefit of its continued use in the program. Chart-abstraction requires facilities to select a sample population, access historical records from several clinical data quarters past, and interpret that patient data. This process is typically more time and resource-consuming than for other measure types. In addition to submission of manually chart-abstracted data, we take all burden and costs into account when evaluating a measure. Removing OP–30 would reduce the burden and cost to facilities associated with collection of information and reviewing their data and performance associated with the measure. However, we do not believe the use of chart-abstracted measure data alone is sufficient justification for removal of a measure under proposed measure PO 00000 Frm 00276 Fmt 4701 Sfmt 4700 removal Factor 8. The costs of collection and submission of chart-abstracted measure data is burdensome for facilities especially when taking into consideration the availability of other CMS quality measures. Another colonoscopy-related measure required in the Hospital OQR Program, OP–32: Facility 7-Day Risk-Standardized Hospital Visit Rate after Outpatient Colonoscopy (NQF #2539) measures allcause, unplanned hospital visits (admissions, observation stays, and emergency department visits) within 7 days of an outpatient colonoscopy procedure (79 FR 66949). This claimsbased outcome measure does not require chart-abstraction, and similarly contributes data on quality of care related to colonoscopy procedures, although the measure does not specifically track processes such as follow-up intervals. When we adopted OP–32, we believed this measure would reduce adverse patient outcomes associated with preparation for colonoscopy, the procedure itself, and follow-up care by capturing and making more visible to facilities and patients all unplanned hospital visits following the procedure (79 FR 66949). Furthermore, the potential benefits of keeping OP–30 in the program are mitigated by the existence of the same measure for gastroenterologists in the Merit-Based Incentive Payment System (MIPS) for the 2019 performance period in the QPP (82 FR 30292). Thus, we believe the issue of preventing harm to patients from colonoscopy procedures that are performed too frequently is adequately addressed through MIPS in the QPP because we expect a portion of MIPSeligible clinicians reporting on the measure nationwide to provide meaningful data to CMS. Although MIPS-eligible clinicians may voluntarily select measures from a list of options, HOPD providers that are MIPS-eligible will have the opportunity to continue collecting information for the measure without being penalized if they determine there is value for various quality improvement efforts.133 The availability of this measure in another CMS program demonstrates CMS’ continued commitment to this measure area. Furthermore, we seek to align our quality reporting work with the Patients 133 CMS finalized that services furnished by an eligible clinician that are payable under the ASC, HHA, Hospice, or HOPD methodology will not be subject to the MIPS payments adjustments, but eligible clinicians payable under those methodologies may have the option to still voluntarily report on applicable measures and the data reported will not be used to determine future eligibility (82 FR 53586). E:\FR\FM\21NOR2.SGM 21NOR2 khammond on DSK30JT082PROD with RULES2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations Over Paperwork and the Meaningful Measures Initiatives described in section I.A.2. of the proposed rule and this final rule with comment period. The purpose of this effort is to hold providers accountable for only the measures that are most important to patients and clinicians and those that are focused on patient outcomes in particular, because outcome measures evaluate the actual results of care. As described in section I.A.2. of the proposed rule and this final rule with comment period, our Meaningful Measures Initiative is intended to reduce costs and minimize burden, and we believe that removing this chartabstracted measure from the Hospital OQR Program would reduce program complexity. In addition, as we discussed in section XIII.B.4.a. of the proposed rule, where we proposed to adopt measure removal Factor 8, beneficiaries may find it confusing to see public reporting on the same measure in different programs. Therefore, due to the combination of factors of the costs of collecting data for this chart-abstracted measure, the preference for an outcomes measure in OQR that provides valuable data for the same procedure, and the existence of the same measure in the MIPS program, we believe that the burdens and costs associated with manual chart abstraction outweigh the limited benefit to beneficiaries of receiving this information. As a result, we proposed to remove OP–30: Endoscopy/Polyp Surveillance: Colonoscopy Interval for Patients with a History of Adenomatous Polyps-Avoidance of Inappropriate Use beginning with the CY 2021 payment determination and for subsequent years. In the proposed rule, we noted that we also proposed to remove a similar measure in the ASCQR Program in section XIV.B.3.c. of the proposed rule. Comment: Many commenters supported CMS’ proposal to remove OP–30. A few commenters noted that the measure is burdensome and costly to report, in part due to the volume of cases that must be reviewed to identify patients that meet the inclusion and exclusion criteria. Some commenters agreed that the cost of the measure outweighs the benefits due to data collection challenges that are specific to OP–30, due to the extensive patient histories required and because data may need to be obtained from different settings. Response: We thank the commenters for their support. In addition to the burden of chart-abstraction, we agree with the commenter that pointed out the unique burden of OP–30, which requires that facilities conduct extensive VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 patient histories and contact other facilities in order to obtain documentation of a history of adenomatous polyps.134 Thus, the costs and burdens are higher for this measure than for the other colonoscopy measure considered for removal, OP–29, which requires less information from patients and does not require historical documentation. We thank the commenter for its feedback on the burden associated with identifying patients meeting the inclusion and exclusion criteria for this measure. We are finalizing our proposal to remove OP–30. Comment: One commenter noted that the measure specifications for OP–30 will be updated soon and recommended that CMS retain the measure until new guidelines are available. A few commenters disagreed with CMS’ assessment that the cost of the measure outweighs the benefit, and one commenter recommended that CMS try to automate tracking of data needed for the measure to reduce its burden. Response: We understand that the measure steward is planning to update OP–30; however, because these updates will not eliminate the need to collect patient histories, we do not believe such updates will lessen burden. Due to the burden of data collection for this measure, which includes taking extensive patient histories, we believe the costs outweigh the benefits and, therefore, we do not believe it is appropriate to retain the measure. We thank the commenter for the suggestion regarding automated data submission and will take this into consideration for the future. As discussed in section I.A.2 of this final rule with comment period, our Meaningful Measures Initiative prioritizes burden reduction in our quality reporting programs, and we will continue to evaluate the Hospital OQR Program measure set through this framework. We continually seek opportunities to reduce the reporting burden of our programs, but note that currently, collecting data for OP–30 still requires chart-abstraction. Comment: Several commenters noted that OP–30 was developed and tested as a provider-level measure and they did not believe it is appropriate for the hospital setting. One commenter stated that this measure is already being reported through the MIPS (formerly PQRS) and that MIPS is the appropriate program because OP–30 is a providerlevel measure. Another commenter 134 OP–30 Measure Information Form. Available at: https://www.qualitynet.org/dcs/ContentServer?c= Page&pagename=QnetPublic%2FPage%2FSpecs ManualTemplate&cid=1228776612884. PO 00000 Frm 00277 Fmt 4701 Sfmt 4700 59093 stated that duplicate reporting in CMS’ quality reporting programs has caused unnecessary provider burden without adding new information to the pool of quality data available to the public. Another commenter noted that relying on MIPS reporting of this measure is inadequate, as MIPS is a voluntary measure in that program. Response: We adopted OP–30 into the Hospital OQR Program because we believe it is important for HOPDs to be active partners in avoiding inappropriate use and ensuring that beneficiaries at their facilities are referred for follow-up care at appropriate intervals in alignment with current guidelines. And, while this measure was initially developed at the physician level, it has been field-tested in the HOPD facility setting by the measure stewards (78 FR 75099). As noted in our proposal, this same measure is available through MIPS in the QPP and, although MIPS-eligible clinicians may voluntarily select measures from a list of options, we expect a portion of MIPS-eligible clinicians reporting on the measure nationwide to provide meaningful data to CMS about avoiding inappropriate use. A primary goal of our Meaningful Measures Initiative is to reduce provider burden through the deduplication of measures across quality reporting programs. As discussed above, after considering comments and revaluating our measure sets as a whole, we are not finalizing our proposal to remove OP–29 in order to retain a measure assessing inappropriate use of endoscopies/ colonoscopies in the Hospital OQR Program. We believe there may be a measurement gap if both OP–29 and OP–30 are removed and because of the unique burden associated with OP–30, we are finalizing its removal while retaining OP–29. Removing OP–30 while retaining OP–29 best enables us to assess this important clinical area while ensuring that the costs of measure do not outweigh the benefits. Thus, due in part to the duplication of this measure through MIPS in the QPP and the additional burden to hospitals of obtaining patient records, we are finalizing our proposal to remove OP–30 from the Hospital OQR Program measure set beginning with the CY 2021 payment determination, as proposed. Comment: A few commenters opposed CMS’ proposal to remove OP– 30 from the Hospital OQR Program. One commenter noted that OP–30 is a cost measure and helps avoid inappropriate use or missed opportunities to screen patients that could result in significant harm to beneficiaries. One commenter E:\FR\FM\21NOR2.SGM 21NOR2 khammond on DSK30JT082PROD with RULES2 59094 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations expressed concern that physicians may not follow the recommended guidelines for colonoscopy screenings and noted that there is a potential for patient harm from unnecessary colonoscopy screenings that poses significant costs. Response: We agree that adherence to clinical guidelines for colonoscopy screening intervals is an important issue. Measuring the inappropriate use of colonoscopy screenings is critical to preventing the waste of resources and potential patient harm. In part for this reason, we are retaining OP–29 in the Hospital OQR Program measure set and will continue to require reporting on appropriate follow-up intervals for normal risk patients. We believe that retaining OP–29 in the Hospital OQR Program enables us to address concerns regarding patient harm from unnecessary colonoscopy screenings. Further, due to the unique documentation burden specifically for OP–30, we believe it adds undue burden especially in comparison to OP–29. After considering stakeholder comments, reevaluating our measure sets as a whole, and balancing the clinical value of measures with the costs, we believe it is appropriate to retain OP–29 while finalizing our proposal to remove OP–30. Comment: One commenter did not support CMS’ proposal to remove OP– 30 because it is included in the CQMC Gastroenterology Core Set and is widely used in the private sector. Response: The CMS CQMC Gastroenterology Core Set is a set of measures identified as being meaningful to patients, consumers, and physicians, while reducing variability in measure selection, collection burden, and cost and is intended for use by payers who are part of the CQMC.135 Because of this, we believe beneficiaries will continue to receive this data to help them make health care decisions. We agree that this measure is valuable to many stakeholders and support its continued reporting through other quality reporting programs and in the private sector. However, due to the measure’s requirement to obtain historical patient records, we believe that this measure adds undue burden to HOPDs. In addition, we note that the inclusion of measures in the CQMC Core Sets does not necessitate retention in the Hospital OQR Program. Comment: A few commenters stated that OP–30 and OP–32 assess distinct different aspects of colonoscopies, 135 Core Measures. Retrieved from: https:// www.cms.gov/Medicare/Quality-Initiatives-PatientAssessment-Instruments/QualityMeasures/CoreMeasures.html. VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 because OP–32 focuses on care coordination and does not evaluate the interval between colonoscopies or the appropriate use of care. One commenter noted that OP–30 and OP–32 fall into different Meaningful Measures categories, Preventable Healthcare Harm and Admissions and Readmissions, respectively. Response: We thank the commenters for their feedback. We agree that OP–30 and OP–32 assess distinct clinical areas but do assess the topic of colonoscopies generally. While OP–32 tracks adverse patient outcomes that result in unplanned hospital visits, OP–30 provides information about colonoscopies occurring at inappropriate intervals for beneficiaries that may contribute to increased costs to beneficiaries and to CMS, a priority of our Meaningful Measures Initiative. However, we believe OP–30 should be removed because it is uniquely burdensome, as described in a previous response. After considering stakeholder comments, reevaluating our measure sets as a whole, and balancing the clinical value of measures with the costs, we believe it is appropriate to remove OP–30. We note that our retention of OP–29 allows us to continue to address inappropriate use of colonoscopy screening. After consideration of the public comments we received, we are finalizing our proposal to remove OP– 30: Endoscopy/Polyp Surveillance: Colonoscopy Interval for Patients with a History of Adenomatous PolypsAvoidance of Inappropriate Use beginning with the CY 2021 payment determination and for subsequent years. We refer readers to section XIV.B.3.c. of this final rule with comment period where we are removing a similar measure from the ASCQR Program. • Proposal To Remove OP–31: Cataracts—Improvement in Patient’s Visual Function Within 90 Days Following Cataract Surgery We refer readers to the CY 2014 OPPS/ASC final rule with comment period (78 FR 75103) where we adopted OP–31: Cataracts: Improvement in Patient’s Visual Function within 90 Days Following Cataract Surgery (NQF #1536) beginning with the CY 2016 payment determination and subsequent years. This measure assesses the rate of patients 18 years and older (with a diagnosis of uncomplicated cataract) in a sample who had improvement in visual function achieved within 90 days following cataract surgery based on completing both a pre-operative and post-operative visual function survey. PO 00000 Frm 00278 Fmt 4701 Sfmt 4700 Since the adoption of this measure, we came to believe that it can be operationally difficult for facilities to collect and report the measure (79 FR 66947). Specifically, we were concerned that the results of the survey used to assess the pre-operative and postoperative visual function of the patient may not be shared across clinicians and facilities, making it difficult for facilities to have knowledge of the visual function of the patient before and after surgery (79 FR 66947). We were also concerned about the surveys used to assess visual function; the measure allows for the use of any validated survey and results may be inconsistent should clinicians use different surveys (79 FR 66947). Therefore, on December 31, 2013, we issued guidance stating that we would delay data collection for OP–31 for 3 months (data collection would commence with April 1, 2014 encounters) for the CY 2016 payment determination (https:// www.qualitynet.org/dcs/ ContentServer?c=Page&pagename= QnetPublic%2FPage%2F QnetTier3&cid=1228772854917). We issued additional guidance on April 2, 2014, stating that we would further delay the implementation of OP–31 for an additional nine months, until January 1, 2015 for the CY 2016 payment determination, due to continued concerns (https:// www.qualitynet.org/dcs/ ContentServer?c=Page&pagename= QnetPublic%2FPage%2 FQnetTier3&cid=1228773786593). As a result of these concerns, in the CY 2015 OPPS/ASC final rule with comment period (79 FR 66948), we finalized our proposal to allow voluntary data collection and reporting of this measure beginning with the CY 2017 payment determination and for subsequent years. In the proposed rule, we proposed to remove OP–31: Cataracts: Improvement in Patient’s Visual Function within 90 Days Following Cataract Surgery beginning with the CY 2021 and for subsequent years under our proposed measure removal Factor 8, the costs associated with the measure outweigh the benefit of its continued use in the program. We originally adopted OP–31 because we believe facilities should be a partner in care with physicians and other clinicians using their facility and that this measure would provide an opportunity to do so (79 FR 66947). However, in light of the history of complications and upon reviewing this measure within our Meaningful Measures framework, we have concluded that it is overly burdensome for facilities to report this measure due E:\FR\FM\21NOR2.SGM 21NOR2 khammond on DSK30JT082PROD with RULES2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations to the difficulty of tracking care that occurs outside of the HOPD setting. In order to report on this measure to CMS, a facility would need to obtain the visual function assessment results from the appropriate ophthalmologist and ensure that the assessment utilized is validated for the population for which it is being used. If the assessment is not able to be used or is not available, the facility would then need to administer the survey directly and ensure that the same visual function assessment tool is utilized preoperatively and postoperatively. There is no simple, preexisting means for information sharing between ophthalmologists and facilities, so a facility would need to obtain assessment results from each individual patient’s ophthalmologist both preoperatively and postoperatively. The high administrative costs of the technical tracking of this information presents an undue cost, and also burden associated with submission and reporting of OP–31 to CMS, especially for small facilities with limited staffing capacity. Furthermore, this measure currently provides limited benefits. Since making the measure voluntary, only 59 136 facilities have reported this measure to CMS, compared to approximately 4,798 total facilities for all other measures, resulting in only 1.2 percent of facilities reporting. Consequently, we have been unable to uniformly offer pertinent information to beneficiaries on how the measure assesses facility performance. This reinforces comments made in the CY 2015 OPPS/ASC final rule with comment period in which commenters expressed concern that the incomplete display of data associated with voluntary reporting is confusing and not meaningful to beneficiaries and other consumers (79 FR 66947). Furthermore, commenters feared that the display of data from some hospitals, but not others, would lead some patients to conclude that some hospitals are more committed to improving cataract surgery. As described in section I.A.2. of the proposed rule and this final rule with comment period, we strive to ensure that beneficiaries are empowered to make decisions about their health care using information from data-driven insights. Because of the lack of sufficient data, this measure may be difficult for beneficiaries to interpret or use to aid in their choice of where to obtain care; thus, the benefits of this measure are limited. 136 OQR Hospital Compare. Available at: https:// data.medicare.gov/Hospital-Compare/Timely-andEffective-Care-Hospital/yv7e-xc69. VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 Thus, we stated that we believed the high technical and administrative costs of this measure, coupled with the high technical and administrative burden, outweigh the limited benefit associated with the measure’s continued use in the Hospital OQR Program. As discussed in section I.A.2. of the proposed rule and this final rule with comment period, above, our Meaningful Measures Initiative is intended to reduce costs and minimize burden. We believed that removing this measure from the Hospital OQR Program will reduce program burden, costs, and complexity. Therefore, we proposed to remove OP– 31: Cataracts: Improvement in Patient’s Visual Function within 90 Days Following Cataract Surgery beginning with the CY 2021 payment determination and for subsequent years. In the proposed rule, we noted that we also proposed to remove a similar measure under the ASCQR Program in section XIV.B.3.c. of the proposed rule. Comment: A few commenters opposed all of CMS’ proposals to remove measures, including OP–31. Response: In response to these comments requesting that measures, including OP–31, be retained, we reevaluated our measures and data. We found that a core group of facilities (between 52 and 66 for the CY 2017 through CY 2019 payment determinations) reported on this voluntary measure. Although only a subset of hospitals voluntarily report data for this measure, we believe this measure is considered very meaningful by those that do report; a subset of reporting hospitals report consistently (11 hospitals submitted consistently for the CY 2017 through CY 2019 payment determinations). Because this subset of hospitals has consistently reported this measure we are able to make the data publicly available year after year—in this case, for the CYs 2017, 2018, and 2019 payment determinations.137 We believe providing data on this voluntary measure is still helpful for the public because it shows how a HOPD performs over time and in comparison to other HOPDs even if compared to a small group of HOPDs. Furthermore, this is the only measure in the Hospital OQR Program measure set that deals with cataract surgery, which is commonly performed in the HOPD setting. If it is removed, the program will have a gap in coverage for this clinical area. As a result, we now believe that this measure maintains coverage in an important clinical area in the Hospital OQR Program and 137 Hospital Compare: https://www.medicare.gov/ hospitalcompare/Data/Data-Updated.html. PO 00000 Frm 00279 Fmt 4701 Sfmt 4700 59095 meaningful information can be provided to consumers regarding those facilities. In addition, when this measure was made voluntary in the CY 2015 OPPS/ ASC final rule with comment period (79 FR 66947 through 66948), commenters expressed support, indicating that some stakeholders value the measure. Furthermore, we have reassessed our evaluation that the costs of this measure outweigh the benefits. Due to the voluntary nature of the measure, we believe that it is inherently not more burdensome than valuable. Because hospitals are not required to submit data, those that do not have the capacity to report, do not have to, thus creating no extra burden. Those that do report, do so voluntarily and have continued to report over the years—specifically since the CY 2015 reporting period—despite any burdens. Because of this, we believe the measure is meaningful to the core group of facilities that do consistently report. After consideration of public comments and reassessing our analysis, we are not finalizing our proposal to remove OP–31: Cataracts: Improvement in Patient’s Visual Function within 90 Days Following Cataract Surgery from the Hospital OQR Program beginning with the CY 2021 payment determination and for subsequent years. This measure will remain in the program under our measure retention policies, unless we take future action under our measure removal policies. Comment: Many commenters supported CMS’ proposal to remove OP–31. A few commenters noted that data collection for this measure is difficult as it requires following up with clinical settings outside of the hospital. Another commenter supported removal and noted that the measure is meant for physician level-use, rather than facilitylevel reporting. One commenter questioned the validity of the measure and noted that it allows providers to use different surveys to collect measure information. Response: We thank the commenters for their support. As noted in the proposed rule, we agree that data collection for this measure may be difficult, and as a result in the CY 2015 OPPS/ASC final rule with comment period (79 FR 66948), we finalized our proposal to allow voluntary data collection and reporting of this measure beginning with the CY 2017 payment determination and for subsequent years. While this measure was initially developed at the physician level, it has been field-tested in the HOPD facility setting by the measure stewards (78 FR 75099). E:\FR\FM\21NOR2.SGM 21NOR2 59096 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations khammond on DSK30JT082PROD with RULES2 In addition, we believe it is important for HOPDs to be active partners in care with physicians and other clinicians using their facility and this measure is an opportunity for hospitals to demonstrate this capability if they choose to report data. Further, as noted above, we no longer believe that the costs of this measure outweigh the benefits, as the measure is meaningful to the core group of outpatient hospitals that do consistently report and can provide valuable data to consumers on those specific facilities. While data collection for this measure can be difficult, those facilities that choose to report do so because they have systems in place to data from ophthalmologists’ medical records. We agree that as a voluntary measure, only a subset of hospitals report on the measure, but note it is a meaningful measure to beneficiaries given that our analyses show that a consistent group of facilities report data on this measure. So, while data is not available for all facilities, the data that is available is meaningful. In addition, this measure has been appropriately validated for the population for which it being used, even acknowledging that various survey methods can be used.138 This same measure is available through MIPS in the QPP and, although MIPS-eligible clinicians may voluntarily select measures from a list of options, we expect a portion of MIPS-eligible clinicians reporting on the measure nationwide to provide meaningful data to CMS about this important outcome for beneficiaries. After consideration of the public comments we received and reassessing our analysis, we are not finalizing our proposal to remove OP–31: Cataracts: Improvement in Patient’s Visual Function within 90 Days Following Cataract Surgery beginning with the CY 2021 payment determination and for subsequent years. We are also retaining a similar measure in the ASCQR Program (ASC–11: Cataracts: Improvement in Patient’s Visual Function within 90 Days Following Cataract Surgery) in section XIV.B.3.b. of this final rule with comment period. (b) Measure Removal Under Removal Factor 3: OP–9: Mammography FollowUp Rates We refer readers to the CY 2009 OPPS/ASC final rule with comment period (73 FR 68766) where we adopted OP–9: Mammography Follow-up Rates beginning with the CY 2010 payment 138 NQF Measure Evaluation available at: https:// www.qualityforum.org/WorkArea/linkit.aspx? LinkIdentifier=id&ItemID=68317. VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 determination. This claims-based measure assesses the percentage of patients with mammography screening studies that are followed by a diagnostic mammography, ultrasound, or MRI of the breast in an outpatient or office setting within 45 days. In the proposed rule (83 FR 37184 through 37185), we proposed to remove this measure under measure removal Factor 3, a measure does not align with current clinical guidelines or practice. An examination of the measure specifications 139 shows that recent changes in clinical practice are not incorporated into the measure calculation. Since development of this measure in 2008, advancements in imaging technology and clinical practice for mammography warrant updating the measure’s specifications to align with current clinical practice guidelines and peer-reviewed literature. Specifically, findings from the annual Literature Reviews and Environmental Scans conducted by the measure developer suggest that there is additional clinical benefit in performing adjuvant digital breast tomosynthesis (DBT) concomitant with full-field digital mammography (FFDM) or conventional mammography (currently included in the measure denominator), especially in women with dense breast tissue.140 141 142 In addition, in 2016, the American College of Radiology (ACR) updated its Breast Cancer Screening Appropriateness Criteria® to include DBT.143 The ACR notes that DBT can better detect potential false-positive findings without the need for recall. Furthermore, the cancer detection rate is increased with 139 Hospital Outpatient Quality Reporting Specifications Manual. Version 11.0a. Available at: https://www.qualitynet.org/dcs/ContentServer?c= Page&pagename=QnetPublic% 2FPage%2FSpecsManual Template&cid=1228776146046. 140 Bernardi, D., Macaskill, P., Pellegrini, M., Valentini, M., Fanto, C., Ostillio, L., Houssami, N. (2016). Breast cancer screening with tomosynthesis (3D mammography) with acquired or synthetic 2D mammography compared with 2D mammography alone (STORM–2): a population-based prospective study. Lancet Oncol, 17(8), 1105–1113. doi: 10.1016/s1470–2045(16)30101–2. 141 Bian, T., Lin, Q., Cui, C., Li, L., Qi, C., Fei, J., & Su, X. (2016). Digital Breast Tomosynthesis: A New Diagnostic Method for Mass-Like Lesions in Dense Breasts. Breast J, 22(5), 535–540. doi: 10.1111/tbj.12622. 142 Pozz, A., Corte, A. D., Lakis, M. A., & Jeong, H. (2016). Digital Breast Tomosynthesis in Addition to Conventional 2DMammography Reduces Recall Rates and is Cost Effective. Asian Pac J Cancer Prev, 17(7), 3521–3526. 143 Mainiero MB, Bailey L, D’Orsi C, Green ED, Holbrook AI, Lee SJ, Lourenco AP, Moy L, Sepulveda KA, Slanetz PJ, Trikha S, Yepes MM, Newell MS, Expert Panel on Breast Imaging. ACR Appropriateness Criteria® breast cancer screening. Reston (VA): American College of Radiology (ACR); 2016. 7 p. PO 00000 Frm 00280 Fmt 4701 Sfmt 4700 use of DBT compared with traditional mammography alone.144 A 2014 study published in the Journal of the American College of Radiology assessed the utilization of DBT among physician members of the Society of Breast Imaging and found that 30 percent of respondents reported using DBT concurrent with traditional mammography.145 With the update of the ACR clinical practice guidelines (that is, the Breast Cancer Screening Appropriateness Criteria®) to include DBT, use of this technology is expected to increase. As currently specified, the measure does not adequately capture this shift in clinical practice. Thus, we believe this measure as specified does not align with current clinical guidelines or practice, and we proposed to remove OP–9: Mammography Follow-up Rates from the program for the CY 2021 payment determination and subsequent years. We intend to investigate respecification of this measure and consider it for adoption to the program through future rulemaking. Specifically, we will consider ways to capture a broader, more comprehensive spectrum of mammography services including adding diagnostic digital breast tomosynthesis. In the proposed rule, we noted that, in crafting our proposal, we considered removing this measure beginning with the CY 2020 payment determination, but decided on proposing to delay removal until the CY 2021 payment determination and subsequent years to be sensitive to facilities’ planning and operational procedures given that data collection for this measure begins during CY 2018 for the CY 2020 payment determination. Comment: Many commenters supported CMS’ proposal to remove OP–9 from the Hospital OQR Program measure set and noted that the measure does not align with clinical guidelines. One commenter noted that the measure is meant for physician-level use, rather than facility-level reporting. Response: We thank the commenters for their support. We note that while the measure was developed for physicianlevel use, as we stated when adopting the measure, it has been tested and was determined to be appropriate for the Hospital OQR Program by the consensus-based development process that meets the statutory requirement for adoption of a measure (73 FR 68765). 144 Ibid. 145 Hardesty LA, Kreidler SM, Glueck DH. Digital breast tomosynthesis utilization in the United States: a survey of physician members of the Society of Breast Imaging. Journal of the American College of Radiology. 2014. 11(6): 594–599. E:\FR\FM\21NOR2.SGM 21NOR2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations (c) Measure Removals Under Removal Factor 1: OP–11 and OP–14 In the proposed rule (83 FR 37185 through 37186), for the CY 2021 payment determination and subsequent years, we proposed to remove OP–11 and OP–14 under removal Factor 1, measure performance among providers is so high and unvarying that meaningful distinctions and improvements in performance can no longer be made. The Hospital OQR Program previously finalized two criteria for determining when a measure is ‘‘topped-out’’: (1) When there is statistically indistinguishable performance at the 75th and 90th percentiles of national facility performance; and (2) when the measure’s truncated coefficient of khammond on DSK30JT082PROD with RULES2 As displayed in the table above, there is a statistically indistinguishable difference in hospital performance between the 75th and 90th percentiles, and the truncated coefficient of variation has been below 0.10 since 2012. VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 variation is less than or equal to 0.10 (79 FR 66968 through 66969). We refer readers to section XIII.B.4.a.(6) of the proposed rule, where we clarified and discussed how we calculate the TCOV for measures that assess the rate of rare, undesired events for which a lower rate is preferred such as OP–11 and OP–14. For each of these measures, we believe that removal from the Hospital OQR Program measure set is appropriate as there is little room for improvement. In addition, as discussed in section I.A.2. of the proposed rule and this final rule with comment period, our Meaningful Measures Initiative is intended to reduce costs and minimize burden. We believe that removing these measures from the Hospital OQR Program will reduce program burden, costs, and complexity. As such, we believe the burden associated with reporting these measures outweighs the benefits of keeping them in the Hospital OQR Program. Each measure is discussed in more detail below. In the proposed rule, we also noted that in crafting our proposals, we considered removing these measures beginning with the CY 2020 payment determination but decided on proposing to delay removal until the CY 2021 payment determination and subsequent years to be sensitive to providers’ planning and operational procedures given that data collection for the measures begins during CY 2018 for the CY 2020 payment determination. • Removal of OP–14: Simultaneous Use of Brain Computed Tomography (CT) and Sinus CT measure assesses the extent to which patients with a headache who have a brain CT also have a sinus CT performed on the same date at the same facility. We refer readers to the CY 2010 OPPS/ASC final rule with comment period (75 FR 72082) where we adopted OP–14: Simultaneous Use of Brain Computed Tomography (CT) and Sinus CT beginning with the CY 2012 payment determination and for subsequent years. This claims-based PO 00000 Frm 00281 Fmt 4701 Sfmt 4700 • Removal of OP–11: Thorax CT Use of Contrast Material We refer readers to the CY 2009 OPPS/ASC final rule with comment period (73 FR 68766) where we adopted OP–11: Thorax CT Use of Contrast Material (NQF #0513) beginning with the CY 2010 payment determination. This claims-based measure assesses the percentage of thorax studies that are performed with and without contrast out of all thorax studies performed. Based on our analysis of Hospital OQR Program measure data, we have determined that this measure meets our measure removal Factor 1. These analyses are captured in the table below. Based on our analysis of Hospital OQR Program measure data, we have determined that this measure meets our measure removal Factor 1. These analyses are captured in the table below. E:\FR\FM\21NOR2.SGM 21NOR2 ER21NO18.101</GPH> After consideration of the public comments we received, we are finalizing our proposal, as proposed, to remove OP–9: Mammography Followup Rates from the program for the CY 2021 payment determination and subsequent years. 59097 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations As displayed in the table above, there is a statistically indistinguishable difference in hospital performance between the 75th and 90th percentiles, and the truncated coefficient of variation has been below 0.10 since 2012. Therefore, we invited public comment on our proposals to remove: (1) OP–11: Thorax CT Use of Contrast Material, and (2) OP–14: Simultaneous Use of Brain Computed Tomography (CT) and Sinus CT measure for the CY 2021 payment determination and subsequent years as discussed above. Comment: Many commenters supported CMS’ proposals to remove OP–11 and OP–14, noting agreement that the proposals will reduce burden and that the measures have limited use for quality improvement. Response: We thank the commenters for their support. We agree that these topped-out measures have limited value. Comment: A few commenters opposed CMS’ proposals to remove OP– 11 and OP–14. One commenter expressed concern that measures should not be removed from the program based solely on topped-out status. This commenter recommended that CMS ensure the measure is topped-out for a number of years, evaluate whether there are unintended consequences of removal, and continue monitoring performance on topped-out safety measures. Another commenter expressed concern that variation in measure performance exists between high and low performing States. Response: We thank the commenters for their feedback and note that we would consider re-proposing these measures for the Hospital OQR Program in the future if data and research indicate that performance in this area has declined, thus mitigating any potential unintended consequences of measure removal. In the meantime, however, we believe it is appropriate to remove these topped-out measures from the Hospital OQR Program, as we believe these measures have limited VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 ability to encourage quality improvement or provide beneficiaries with information on differences in quality across hospitals. We have previously finalized our policy to consider measures for removal if they meet topped-out status (79 FR 66769) and accordingly, we disagree with commenters that topped-out status is not sufficient grounds for measure removal. In addition, ‘‘topped-out’’ status is only one of many factors we consider in removing measures. We consider the removal of each topped-out measure on a case-by-case basis, as appropriate, and determine whether a clinical or other quality improvement need for the measure justifies the retention of a topped-out measure that otherwise meets our criteria. We also note that the measures have been topped-out for four years. However, if it becomes evident that performance on this measure topic declines over time, we will consider re-introducing this or similar measures and will do so through the rulemaking process. While slight variation may exist in measure performance, our analyses demonstrate that this variation is statistically indistinguishable. The Hospital OQR Program has finalized the ‘‘topped-out’’ methodology to evaluate variation in performance among HOPDs (79 FR 66769), in line with other quality reporting and valuebased purchasing programs including the ASCQR (79 FR 66968), Hospital IQR (80 FR 49641 through 49643), Hospital VBP (79 FR 50055), IPFQR (82 FR 38463 through 38465), and PCHQR (81 FR 57182 through 57183) Programs. Our topped-out methodology does not evaluate variation at the State level, but rather at the level of individual ASCs. Our analyses demonstrate that the variation in performance among HOPDs for these measures is statistically indistinguishable. As shown in the tables above, hospitals performing at the 90th vs. 75th percentile have a rate of 98.5 percent as compared to a rate of PO 00000 Frm 00282 Fmt 4701 Sfmt 4700 97.4 percent for OP–11 and a rate of 98.8 percent vs. 98.5 percent for OP–14. After consideration of the public comments we received, we are finalizing our proposals, as proposed, to remove: (1) OP–11: Thorax CT Use of Contrast Material, and (2) OP–14: Simultaneous Use of Brain Computed Tomography (CT) and Sinus CT measure for the CY 2021 payment determination and subsequent years. (d) Measure Removals Under Measure Removal Factor 2: OP–12 and OP–17 In the proposed rule (83 FR 37186), for the CY 2021 payment determination and subsequent years, we proposed to remove two measures under our measure removal Factor 2, performance or improvement on a measure does not result in better patient outcomes: OP–12 and OP–17. The proposals are discussed in more detail below. As discussed in section I.A.2. of the proposed rule and this final rule with comment period, our Meaningful Measures Initiative is intended to reduce costs and minimize burden. We believe that removing these measures from the Hospital OQR Program will reduce program burden, costs, and complexity. In addition, we noted that in crafting our proposals, we considered removing these measures beginning with the CY 2020 payment determination but decided on proposing to delay removal until the CY 2021 payment determination to be sensitive to facilities’ planning and operational procedures given that data collection for this measure begins during CY 2018 for the CY 2020 payment determination. • Removal of OP–12: The Ability for Providers With HIT To Receive Laboratory Data Electronically Directly Into Their Qualified/Certified EHR System as Discrete Searchable Data We refer readers to CY 2011 OPPS/ ASC final rule with comment period (75 FR 72076) where we adopted OP–12: The Ability for Providers with HIT to Receive Laboratory Data Electronically Directly into Their Qualified/Certified EHR System as Discrete Searchable Data E:\FR\FM\21NOR2.SGM 21NOR2 ER21NO18.102</GPH> khammond on DSK30JT082PROD with RULES2 59098 khammond on DSK30JT082PROD with RULES2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations beginning with the CY 2012 payment determination. This web-based measure assesses the extent to which a provider uses an Office of the National Coordinator for Health Information Technology (ONC) certified electronic health record (EHR) system that incorporates an electronic data interchange with one or more laboratories allowing for direct electronic transmission of laboratory data in the EHR as discrete searchable data elements. In the proposed rule, we proposed to remove OP–12 beginning with the CY 2021 payment determination and for subsequent years under our measure removal Factor 2, performance or improvement on a measure does not result in better patient outcomes. OP–12 is a process measure that tracks the transmittal of data but does not directly assess quality or patient outcomes. In the CY 2011 OPPS/ASC final rule with comment period (75 FR 72075), commenters expressed concern that the measure only assesses HIT functionality and does not assess the quality of care provided. As discussed in section I.A.2. of the proposed rule and this final rule with comment period, one of the goals of our Meaningful Measures Initiative is to reduce burden associated with payment policy, quality measures, documentation requirements, conditions of participation, and health information technology. As also discussed in section I.A.2. of the proposed rule and this final rule with comment period, one of the goals of our Meaningful Measures Initiative is to utilize measures that are ‘‘outcomebased where possible.’’ We do not believe OP–12 adds to these goals. In fact, we believe that provider performance in the measure is not an indicator for patient outcomes and continued collection provides little benefit. Therefore, we proposed to remove OP–12 from the Hospital OQR Program beginning with the CY 2021 payment determination and for subsequent years. Comment: Many commenters supported CMS’ proposal to remove OP–12. One commenter noted that the measure does not directly assess quality of care or patient outcomes. Response: We thank the commenters for their support. Comment: A few commenters opposed CMS’ proposal to remove OP– 12. One commenter requested that CMS revise the measure so that it assesses quality of care in addition to HIT functionality. Another commenter recognized the value of removing OP–12 from the program but recommended that VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 CMS continue to promote interoperability in the outpatient hospital setting. Response: We thank the commenters for their feedback. We note that as a structural measure, OP–12 is limited to evaluating whether or not a provider uses an ONC-certified EHR system, and does not provide data on patient outcomes. We agree that a measure assessing the impact of EHR use on quality would be valuable and we intend to identify and consider other measures that assess interoperability and care quality for future inclusion in the program as appropriate measures become available. Due to this measure’s limitations as a structural measure, we do not believe it is possible to revise the measure in order to assess patient outcomes or quality of care directly. Due to the limitations of OP–12, we believe it is appropriate to remove this measure from the Hospital OQR Program. After consideration of the public comments we received, we are finalizing our proposal, as proposed, to remove OP–12 beginning with the CY 2021 payment determination and for subsequent years. • Removal of OP–17: Tracking Clinical Results Between Visits We refer readers to CY 2011 OPPS/ ASC final rule with comment period (75 FR 72085) where we adopted OP–17: Tracking Clinical Results between Visits beginning with the CY 2013 payment determination. This web-based measure assesses the extent to which a provider uses a certified/qualified EHR system to track pending laboratory tests, diagnostic studies (including common preventive screenings), or patient referrals. In the proposed rule, we proposed to remove OP–17 beginning with the CY 2021 payment determination and for subsequent years under our measure removal Factor 2, performance or improvement on a measure does not result in better patient outcomes. OP–17 is a process measure that tabulates only the ability for transmittal of data but does not directly assess quality or patient outcomes. In the CY 2011 OPPS/ASC final rule with comment period (75 FR 72075), commenters expressed concern that the measure only assesses HIT functionality and does not assess the quality of care provided. As discussed in section I.A.2. of the proposed rule and this final rule with comment period, one of the goals of our Meaningful Measures Initiative is to reduce burden associated with payment policy, quality measures, documentation requirements, conditions of participation, and health PO 00000 Frm 00283 Fmt 4701 Sfmt 4700 59099 information technology. As also discussed in section I.A.2. of the proposed rule and this final rule with comment period, one of the goals of our Meaningful Measures Initiative is to utilize measures that ‘‘outcome-based where possible.’’ We do not believe OP– 17 supports this goal. In fact, we believe that provider performance in the measure does not improve patient outcomes and continued collection provides little benefit. Therefore, we proposed to remove OP–17 from the Hospital OQR Program beginning with the CY 2021 payment determination and for subsequent years. Comment: Many commenters supported CMS’ proposal to remove OP–17. A few commenters noted that the measure does not directly assess quality of care or patient outcomes. Response: We thank the commenters for their support. Comment: A few commenters opposed CMS’ proposal to remove OP– 17. One commenter noted that the ability to transfer electronic records can hasten diagnosis and treatment and reduce service duplication. Another commenter recognized the value of removing OP–17 from the ASCQR Program, but recommended that CMS continue to promote interoperability in the outpatient hospital setting. Response: We thank the commenters for their feedback. We note that as a structural measure, OP–17 is limited to evaluating whether or not a provider uses an ONC certified EHR system to track laboratory tests, diagnostic studies, or patient referrals but does not provide information of the impact on outcomes such as diagnosis and treatment. We intend to identify and consider other measures that assess interoperability and care quality for future inclusion in the program as appropriate measures become available. Due to the limitation of OP–17 as a structural measure, we do not believe it is possible to revise it to assess patient outcomes or quality of care directly. Due to the limitations of OP–17, we believe it is appropriate to remove this measure from the Hospital OQR Program. After consideration of the public comments we received, we are finalizing our proposal, as proposed, to remove OP–17 beginning with the CY 2021 payment determination and for subsequent years. 5. Summary of Hospital OQR Program Measure Sets for the CY 2020 and CY 2021 Payment Determinations In the proposed rule, we did not propose any new measures for the Hospital OQR Program. We refer readers to the CY 2018 OPPS/ASC final rule E:\FR\FM\21NOR2.SGM 21NOR2 59100 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations with comment period (82 FR 59434 through 59435) for the previously finalized measure set for the CY 2020 payment determination and subsequent years. The tables below summarize the Hospital OQR Program measure sets as finalized in this final rule with comment period for the CY 2020 and 2021 payment determinations and subsequent years (including previously adopted measures and excluding measures removed in this final rule with comment period). BILLING CODE 4120–01–P 0514 None None 0513 None 0669 None 0491 0496 0499 0661 0658 0659 1536 2539 1822 khammond on DSK30JT082PROD with RULES2 None 2687 None None None None VerDate Sep<11>2014 OP-8: MRI Lumbar Spine for Low Back Pain OP-9: Mammography Follow-up Rates OP-10: Abdomen CT- Use of Contrast Material OP-11: Thorax CT- Use of Contrast Material OP-12: The Ability for Providers with HIT to Receive Laboratory Data Electronically Directly into their ONC-Certified EHR System as Discrete Searchable Data OP-13: Cardiac Imaging for Preoperative Risk Assessment for Non-Cardiac, Low-Risk Surgery OP-14: Simultaneous Use ofBrain Computed Tomography (CT) and Sinus Computed Tomography (CT) OP-17: Tracking Clinical Results between Visitst OP-18: Median Time from ED Arrival to ED Departure for Discharged ED Patients OP-22: Left Without Being Seent OP-23: Head CT or MRI Scan Results for Acute Ischemic Stroke or Hemorrhagic Stroke who Received Head CT or MRI Scan Interpretation Within 45 minutes of ED Arrival OP-29: Appropriate Follow-Up Interval for Normal Colonoscopy in Average Risk Patients* OP-30: Colonoscopy Interval for Patients with a History of Adenomatous Polyps - A voidance of Inappropriate Use* OP-31: Cataracts: Improvement in Patient's Visual Function within 90 Days Following Cataract Surgery** OP-32: Facility 7-Day Risk-Standardized Hospital Visit Rate after Outpatient Colonoscopy OP-33: External Beam Radiotherapy for Bone Metastases OP-35: Admissions and Emergency Department (ED) Visits for Patients Receiving Outpatient Chemotherapy OP-36: Hospital Visits after Hospital Outpatient Surgery OP-37a: OAS CAHPS- About Facilities and Staff*** OP-37b: OAS CAHPS- Communication About Procedure*** OP-37c: OAS CAHPS- Preparation for Discharge and Recovery*** OP-37d: OAS CAHPS- Overall Rating of Facility*** 20:42 Nov 20, 2018 Jkt 247001 PO 00000 Frm 00284 Fmt 4701 Sfmt 4725 E:\FR\FM\21NOR2.SGM 21NOR2 ER21NO18.103</GPH> Hospital OQR Pro~ram Measure Set for the CY 2020 Payment Determination NQF# Measure Name 0288 OP-2: Fibrinolytic Therapy Received Within 30 Minutes ofED Arrival OP-3: Median Time to Transfer to Another Facility for Acute Coronary 0290 Intervention OP-5: Median Time to ECG·i· 0289 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations 59101 Hospital OQR Program Measure Set for the CY 2020 Payment Determination NQF # Measure Name None OP-37e: OAS CARPS- Recommendation of Facility*** t VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 PO 00000 Frm 00285 Fmt 4701 Sfmt 4725 E:\FR\FM\21NOR2.SGM 21NOR2 ER21NO18.104</GPH> khammond on DSK30JT082PROD with RULES2 We note that NQF endorsement for th1s measure was removed. * OP-26: Procedure categories and corresponding HCPCS codes are located at: https://www.gualitvnet.org/dcs/ContentServer?c=Page&pagename=QnetPublic%2FPage%2FQnetTier3&ci d=ll96289981244. ** We note that measure name was revised to reflect NQF title. ***Measure voluntarily collected as set forth in section XIII.D.3.b. of the CY 2015 OPPS/ASC fmal rule with comment period (79 FR 66946 through 6694 7). **** Measure reporting delayed beginning with CY 2018 reporting and for subsequent years as discussed in section XIII.B.5. of the CY 2018 OPPS/ASC fmal rule with comment period (82 FR 59432 through 59433). 59102 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations Hospital OQR Program Measure Set for the CY 2021 Payment Determination and Subsequent Years NQF# Measure Name 0288 OP-2: Fibrinolytic Therapy Received Within 30 Minutes of ED Arrival OP-3: Median Time to Transfer to Another Facility for Acute Coronary 0290 Intervention OP-8: MRl Lumbar Spine for Low Back Pain 0514 OP-10: Abdomen CT- Use of Contrast Material None OP-13: Cardiac Imaging for Preoperative Risk Assessment for Non-Cardiac, 0669 Low-Risk Surgery OP-18: Median Time from ED Arrival to ED Departure for Discharged ED 0496 Patients OP-22: Left Without Being Seent 0499 0661 OP-23: Head CT or MRl Scan Results for Acute Ischemic Stroke or Hemorrhagic Stroke who Received Head CT or MRl Scan Interpretation Within 45 minutes of ED Arrival OP-29: Appropriate Follow-Up Interval for Normal Colonoscopy in Average 0658 Risk Patients* OP-31: Cataracts: Improvement in Patient's Visual Function within 90 Days 1536 Following Cataract Surgery** OP-32: Facility 7-Day Risk-Standardized Hospital Visit Rate after 2539 Outpatient Colonoscopy 1822 OP-33: External Beam Radiotherapy for Bone Metastases OP-35: Admissions and Emergency Department (ED) Visits for Patients None Receiving Outpatient Chemotherapy 2687 OP-36: Hospital Visits after Hospital Outpatient Surgery None OP-37a: OAS CARPS- About Facilities and Staff** None OP-37b: OAS CARPS- Communication About Procedure** None OP-37c: OAS CARPS- Preparation for Discharge and Recovery** None OP-37d: OAS CARPS- Overall Rating of Facility** None OP-37e: OAS CARPS- Recommendation of Facility** t We note that NQF endorsement for th1s measure was removed. OP-26: Procedure categories and corresponding HCPCS codes are located at: https://www.gualitvnet.org/dcs/ContentServer?c=Page&pagename=QnetPublic%2FPage%2FQnetTier3&ci d=1196289981244. *We note that measure name was revised to reflect NQF title. **Measure reporting delayed beginning with CY 2018 reporting and for subsequent years as discussed in section XIII.B.5. of the CY 2018 OPPS/ASC fmal rule with comment period (82 FR 59432 through 59433). khammond on DSK30JT082PROD with RULES2 BILLING CODE 4120–01–C 6. Hospital OQR Program Measures and Topics for Future Consideration In the CY 2019 OPPS/ASC proposed rule (83 FR 37188), we requested public comment on future measure topics for the Hospital OQR Program. We seek to develop a comprehensive set of quality measures to be available for widespread VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 use for informed decision-making and quality improvement in the hospital outpatient setting. The current measure set for the Hospital OQR Program includes measures that assess process of care, imaging efficiency patterns, care transitions, ED throughput efficiency, Health Information Technology (health IT) use, care coordination, and patient PO 00000 Frm 00286 Fmt 4701 Sfmt 4700 safety. Measures are of various types, including those of process, structure, outcome, and efficiency. Through future rulemaking, we intend to propose new measures that help us further our goal of achieving better health care and improved health for Medicare beneficiaries who receive health care in hospital outpatient settings, while E:\FR\FM\21NOR2.SGM 21NOR2 ER21NO18.105</GPH> o khammond on DSK30JT082PROD with RULES2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations aligning quality measures across the Medicare program to the extent possible. We are moving towards greater use of outcome measures and away from use of clinical process measures across our Medicare quality reporting and valuebased purchasing programs. We invited public comments on possible measure topics for future consideration in the Hospital OQR Program. We specifically requested comment on any outcome measures that would be useful to add to as well as any process measures that should be eliminated from the Hospital OQR Program. Comment: Several commenters recommended measure topics for future consideration in the Hospital OQR Program. Commenters’ recommendations included: (1) Antibiotic-use related measures to assess inappropriate prescribing; (2) a focus on clinical and population based outcome measures; (3) cancer care measures including two measures related to referral to radiation therapy for both post-breast conserving surgery (NQF 0219) and post-mastectomy (MASTRT); (4) psychiatric care and behavioral health measures; (5) measures identified as meaningful to providers as well patients and their families; (6) rural health measures; (7) measures assessing access to care; (8) measures assessing substance abuse; (9) management of chronic conditions; (10) measures that promote advance care planning and shared-decision making; (11) surgical site infections (SSIs) and medication safety measures such as the Ambulatory Breast Procedure Surgical Site Infection (SSI) Outcome Measure (NQF #3025) measure; (12) measures using the same unit of analysis that allow comparison between hospitals and ASCs; and, (13) adult immunization measures. Several commenters also supported outcome measures but noted the value of process measures for addressing topics where there is insufficient evidence or standardized data to assess an outcome. One commenter also recommended that CMS consider the recommendations of the 2018 National Quality Forum (NQF) Report titled, ‘‘A Core Set of RuralRelevant Measures and Measuring and Improving Access to Care: 2018 Recommendations from the MAP Rural Health Workgroup.’’ Another commenter encouraged CMS to recognize composite measures, especially for surgical care, that span across phases of care. Response: We thank the commenters for their recommendations and suggestions and agree that there are additional high priority topic VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 measurement areas that may be appropriate for the Hospital OQR Program. We will consider the suggested topic areas for future rulemaking and intend to work with stakeholders as we continue to develop the Hospital OQR Program measure set. We thank the commenters for their views and will consider them as we develop future Hospital OQR Program measures and topics. 7. Maintenance of Technical Specifications for Quality Measures CMS maintains technical specifications for previously adopted Hospital OQR Program measures. These specifications are updated as we modify the Hospital OQR Program measure set. The manuals that contain specifications for the previously adopted measures can be found on the QualityNet website at: https://www.qualitynet.org/dcs/ ContentServer?c =Page&pagename=QnetPublic %2FPage%2FQnetTier2&cid=1196289 981244. In the proposed rule, we proposed to change the frequency of the Hospital OQR Program Specifications Manual release beginning with CY 2019 and for subsequent years and we refer readers to section XIII.D.2. of the proposed rule and this final rule with comment period for more details. 8. Public Display of Quality Measures We refer readers to the CY 2014 and CY 2017 OPPS/ASC final rules with comment period (78 FR 75092 and 81 FR 79791 respectively) for our previously finalized policies regarding public display of quality measures. In the CY 2019 OPPS/ASC proposed rule (83 FR 37188), we did not propose any changes to our previously finalized public display policies. C. Administrative Requirements 1. QualityNet Account and Security Administrator The previously finalized QualityNet security administrator requirements, including setting up a QualityNet account and the associated timelines, are described in the CY 2014 OPPS/ASC final rule with comment period (78 FR 75108 through 75109). In that final rule with comment period, we codified these procedural requirements at 42 CFR 419.46(a). In the CY 2019 OPPS/ASC proposed rule (83 FR 37188), we did not propose any changes to our requirements for the QualityNet account and security administrator. 2. Requirements Regarding Participation Status In the CY 2019 OPPS/ASC proposed rule (83 FR 37188), we proposed to PO 00000 Frm 00287 Fmt 4701 Sfmt 4700 59103 update our requirements related to the Notice of Participation (NOP) form. a. Background We refer readers to the CY 2014 OPPS/ASC final rule with comment period (78 FR 75108 through 75109) and the CY 2016 OPPS/ASC final rule with comment period (80 FR 70519) for requirements for participation and withdrawal from the Hospital OQR Program. We also codified these procedural requirements at 42 CFR 419.46(a) and (b). b. Removal of the Notice of Participation (NOP) Form Requirement We finalized in the CY 2014 OPPS/ ASC final rule with comment period (78 FR 75108 through 75109) that participation in the Hospital OQR Program requires that hospitals must: (1) Register on the QualityNet website before beginning to report data; (2) identify and register a QualityNet security administrator; and (3) complete and submit an online participation form, the Notice of Participation (NOP) form, available at the QualityNet website if this form has not been previously completed, if a hospital has previously withdrawn, or if the hospital acquires a new CMS Certification Number (CCN). In addition, in the CY 2014 OPPS/ASC final rule with comment period (78 FR 75108 through 75109), we finalized the requirement that that hospitals must submit the NOP according to the below deadlines. These requirements are also codified at 42 CFR 419.46(a). • If a hospital has a Medicare acceptance date before January 1 of the year prior to the affected annual payment update, the hospital must complete and submit to CMS a completed Hospital OQR Notice of Participation Form by July 31 of the calendar year prior to the affected annual payment update. • If a hospital has a Medicare acceptance date on or after January 1 of the year prior to the affected annual payment update, the hospital must submit a completed participation form no later than 180 days from the date identified as its Medicare acceptance date. In the proposed rule (83 FR 37188), beginning with the CY 2018 reporting period/CY 2020 payment determination, we proposed to remove submission of the NOP form as a requirement for the Hospital OQR Program. After reevaluating program requirements, we have concluded that this form does not provide CMS with any unique information, and as such, we believe it is unnecessarily burdensome for E:\FR\FM\21NOR2.SGM 21NOR2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations hospitals to complete and submit. In place of the NOP form, we proposed that submission of any Hospital OQR Program data would indicate a hospital’s status as a participant in the program. This includes submitting just one data element. That is, hospitals would no longer be required to submit the NOP form as was previously required. Instead, hospitals would need to do the following to be a participant in the Hospital OQR Program: (1) Register on the QualityNet website before beginning to report data; (2) identify and register a QualityNet security administrator; and (3) submit data. We also proposed to update 42 CFR 419.46(a) to reflect these changes. Comment: A few commenters supported CMS’ proposal to remove the NOP as a requirement for the Hospital OQR Program. Response: We thank the commenters for their support. After consideration of the public comments we received, we are finalizing our proposals, as proposed, to no longer require hospitals to submit the NOP form, and update 42 CFR 419.46(a) to reflect these changes. In the CY 2018 OPPS/ASC final rule with comment period, we finalized a policy to align the initial data submission timeline for all hospitals that did not participate in the previous year’s Hospital OQR Program and made conforming revisions at 42 CFR 419.46(c)(3). In the CY 2019 OPPS/ASC proposed rule (83 FR 37188 through 37189), we did not propose any changes to these policies. process provided it is a nonsubstantive change. We expect to continue to make the determination of what constitutes a substantive versus a nonsubstantive change on a case-by-case basis. Examples of nonsubstantive changes to measures might include updated diagnosis or procedure codes, medication updates for categories of medications, broadening of age ranges, and exclusions for a measure (such as the addition of a hospice exclusion to the 30-day mortality measures). We believe that nonsubstantive changes may include updates to measures based upon changes to guidelines upon which the measures are based. For a history of our policies regarding maintenance of technical specifications for quality measures, we refer readers to the CY 2010 OPPS/ASC final rule with comment period (74 FR 60631), the CY 2011 OPPS/ASC final rule with comment period (75 FR 72069), and the CY 2013 OPPS/ASC final rule with comment period (77 FR 68469 through 68470). In the proposed rule, we noted that we will continue to use rulemaking to adopt substantive updates to measures we have adopted for the Hospital OQR Program. We believe that this policy adequately balances our need to incorporate nonsubstantive khammond on DSK30JT082PROD with RULES2 2. Change to the Frequency of Hospital Outpatient Quality Reporting Specifications Manual Release Beginning With CY 2019 and for Subsequent Years In the CY 2019 OPPS/ASC proposed rule (83 FR 37189), we proposed to change the frequency of the Hospital Outpatient Quality Reporting Specifications Manual release beginning with CY 2019 and for subsequent years. In the CY 2009 OPPS/ASC final rule with comment period (73 FR 68766 through 68767), we established a subregulatory process for making updates to the measures we have adopted for the Hospital OQR Program. As stated in CY 2014 OPPS/ASC final rule with comment period (78 FR 75091), we believe that a measure can be updated through this subregulatory VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 D. Form, Manner, and Timing of Data Submitted for the Hospital OQR Program 1. Hospital OQR Program Annual Payment Determinations ASC final rule with comment period (80 FR 70519 through 70520), we specified our data submission deadlines. We also codified our submission requirements at 42 CFR 419.46(c). We refer readers to the CY 2016 OPPS/ASC final rule with comment period (80 FR 70519 through 70520), where we finalized our proposal to shift the quarters upon which the Hospital OQR Program payment determinations are based, beginning with the CY 2018 payment determination. The finalized deadlines for the CY 2020 payment determination and subsequent years are illustrated in the table below. In the CY 2014 OPPS/ASC final rule with comment period (78 FR 75110 through 75111) and the CY 2016 OPPS/ PO 00000 Frm 00288 Fmt 4701 Sfmt 4700 updates to Hospital OQR Program measures in the most expeditious manner possible, while preserving the public’s ability to comment on updates that so fundamentally change an endorsed measure that it is no longer the same measure that we originally adopted. We also noted that the NQF process incorporates an opportunity for public comment and engagement in the measure maintenance process. As stated in CY 2014 OPPS/ASC final rule with comment period (78 FR 75091), under current policy, technical specifications for the Hospital OQR Program measures are listed in the Hospital Outpatient Quality Reporting Specifications Manual, which is posted on the CMS QualityNet website at: https://www.qualitynet.org/dcs/ ContentServer?c=Page&pagename=Qne tPublic%2FPage%2FSpecsManual Template&cid=1228772438492. We maintain the technical specifications for the measures by updating this Hospital Outpatient Quality Reporting Specifications Manual and including detailed instructions and calculation algorithms. In some cases where the specifications are available elsewhere, we may include links to websites hosting technical specifications. These resources are for hospitals to use when E:\FR\FM\21NOR2.SGM 21NOR2 ER21NO18.106</GPH> 59104 khammond on DSK30JT082PROD with RULES2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations collecting and submitting data on required measures. We revise the Hospital Outpatient Quality Reporting Specifications Manual so that it clearly identifies the updates and provide links to where additional information on the updates can be found. We provide sufficient lead time for facilities to implement the changes where changes to the data collection systems would be necessary. We generally release the Hospital Outpatient Quality Reporting Specifications Manual every six months and release addenda as necessary. This release schedule provides at least three months of advance notice for nonsubstantive changes such as changes to ICD–10, CPT, NUBC, and HCPCS codes, and at least six months of advance notice for changes to data elements that would require significant systems changes (78 FR 75091). However, we believe that unnecessarily releasing two manuals a year has the potential to cause confusion for Hospital OQR Program participants. Therefore, in the proposed rule, we proposed to update the frequency with which we release Hospital Outpatient Quality Reporting Specifications Manuals, such that instead of every 6 months, we would release Specifications Manuals every six to 12 months beginning with CY 2019 and for subsequent years. Under this proposal, we would release a Hospital Outpatient Quality Reporting Specifications Manual (Specifications Manual) one to two times per calendar year, depending on the need for an updated release and consideration of our policy to provide at least six months’ notice for substantive changes. Comment: Several commenters supported CMS’ proposal to release the Specifications Manual less frequently than every six months. However, a few commenters noted that ad hoc timing for release of the Specifications Manual may be confusing and recommended that CMS release the Specifications Manual once annually. One commenter requested that CMS notify hospitals and vendors about whether or not there will be an update on a 6-month schedule, even if the Specifications Manual is only released every 12 months. Response: We thank the commenters for their support. We clarify that under our proposal, we would release a full manual once or twice a year, depending on need, as well as any addenda as necessary. Addenda would include discrete updates and do not constitute full manual releases. We acknowledge that ad hoc specifications manual releases could be confusing. After considering public comments and in an VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 effort to provide greater consistency, we are modifying our proposal that we would release a Hospital Outpatient Quality Reporting Specifications Manual one to two times per calendar year; instead, we are finalizing that we will release a full manual once every 12 months and release any addenda as necessary. This reduces manual releases from one to two times per year as proposed, to consistently only once a year. Specifications manuals and addenda will be provided via QualityNet. After consideration of the public comments we received, we are finalizing a modification of our proposal, beginning with CY 2019 and for subsequent years, to release Specifications Manuals every six to 12 months, such that we will instead release a manual once every 12 months and release addenda as necessary. 3. Requirements for Chart-Abstracted Measures Where Patient-Level Data Are Submitted Directly to CMS for the CY 2020 Payment Determination and Subsequent Years We refer readers to the CY 2013 OPPS/ASC final rule with comment period (77 FR 68481 through 68484) for a discussion of the form, manner, and timing for data submission requirements of chart-abstracted measures for the CY 2014 payment determination and subsequent years. In the CY 2019 OPPS/ ASC proposed rule (83 FR 37189), we did not propose any changes to our policies regarding the submission of chart-abstracted measure data where patient-level data are submitted directly to CMS. We note that, in section XIII.B.4.b.(2)(a) of this final rule with comment period, we are finalizing our proposal to remove OP–5: Median Time to ECG for the CY 2021 payment determination and subsequent years. Therefore, the following previously finalized Hospital OQR Program chartabstracted measures will require patient-level data to be submitted for the CY 2021 payment determination and subsequent years: • OP–2: Fibrinolytic Therapy Received Within 30 Minutes of ED Arrival (NQF #0288); • OP–3: Median Time to Transfer to Another Facility for Acute Coronary Intervention (NQF #0290); • OP–18: Median Time from ED Arrival to ED Departure for Discharged ED Patients (NQF #0496); and • OP–23: Head CT Scan Results for Acute Ischemic Stroke or Hemorrhagic Stroke Patients who Received Head CT PO 00000 Frm 00289 Fmt 4701 Sfmt 4700 59105 Scan Interpretation Within 45 Minutes of ED Arrival (NQF #0661). 4. Claims-Based Measure Data Requirements for the CY 2020 Payment Determination and Subsequent Years In the CY 2019 OPPS/ASC proposed rule (83 FR 37189 through 37191), we proposed to extend the reporting period 146 for OP–32: Facility 7-Day Risk-Standardized Hospital Visit Rate after Outpatient Colonoscopy. a. General We refer readers to the CY 2014 OPPS/ASC final rule with comment period (78 FR 75111 through 75112) for a discussion of the general claims-based measure data submission requirements for the CY 2015 payment determination and subsequent years. In the proposed rule, we did not propose changes to our general requirements for claims-based measure data but refer readers to the section below for discussion regarding our proposal specific to OP–32. We note that, in section XIII.B.4.b. of the proposed rule, we proposed to remove OP–9: Mammography Followup Rates, OP–11: Thorax CT Use of Contrast Material, and OP–14: Simultaneous Use of Brain Computed Tomography (CT) and Sinus CT for the CY 2021 payment determination and subsequent years. As discussed in section XIII.B.4.b. of this final rule with comment period, we are finalizing the removals of all of these measures as proposed. Accordingly, the following previously finalized Hospital OQR Program claims-based measures will be required for the CY 2021 payment determination and subsequent years: • OP–8: MRI Lumbar Spine for Low Back Pain (NQF #0514); • OP–10: Abdomen CT—Use of Contrast Material; • OP–13: Cardiac Imaging for Preoperative Risk Assessment for NonCardiac, Low Risk Surgery (NQF #0669); • OP–32: Facility 7-Day RiskStandardized Hospital Visit Rate after Outpatient Colonoscopy (NQF #2539); • OP–35: Admissions and Emergency Department Visits for Patients Receiving Outpatient Chemotherapy; and • OP–36: Hospital Visits after Hospital Outpatient Surgery (NQF #2687). 146 We note that we previously referred to these reporting periods as ‘‘collection periods’’ (for example, 82 FR 59440); we now use the term ‘‘reporting period’’ in order to align the Hospital OQR Program terminology with the terminology we use in other CMS quality reporting and pay for performance (value-based purchasing) programs. E:\FR\FM\21NOR2.SGM 21NOR2 59106 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations b. Extension of the Reporting Period for OP–32: Facility 7-Day RiskStandardized Hospital Visit Rate After Outpatient Colonoscopy khammond on DSK30JT082PROD with RULES2 In the CY 2015 OPPS/ASC final rule with comment period (79 FR 66949), we finalized the adoption of OP–32: Facility 7-Day Risk-Standardized Hospital Visit Rate after Outpatient Colonoscopy into the Hospital OQR Program for the CY 2018 payment determination and subsequent years, with public display to begin on or after December 1, 2017. This measure is calculated with data obtained from paid Medicare FFS claims (79 FR 66950). For this reason, facilities are not required to submit any additional information. In that final rule with comment period, we also finalized the reporting period for measure calculation as claims data from two calendar years prior to the payment determination year. Specifically, for the CY 2018 payment determination, we stated we would use paid Medicare FFS claims from January 1, 2016 to December 31, 2016 to calculate measure results (79 FR 66955). We finalized a 1year reporting period, as it adequately balanced competing interests of measure reliability and timeliness for payment determination purposes and explained that we would continue to assess this during the dry run (79 FR 66955). We noted we would complete a dry run of the measure in 2015 using three or four years of data, and, from the results of this dry run, we would review the appropriate volume cutoff for facilities to ensure statistical reliability in reporting the measure score (79 FR 66953). Our analyses of the 2015 dry run using data from July 2011 through June 2014 showed that a reporting period of one year had moderate to high reliability for measure calculation. Specifically, using data from July 2013 through June 2014, we calculated facility-level reliability estimates as the ratio of true variance to observed variance.147 Consistent with the original measure specifications as described in the 2014 technical report,148 this 147 Snijders TA, Bosker RJ. Multilevel Analysis: An introduction to basic and advanced multilevel modeling. SAGE Publications. 2000. London. 148 Additional methodology details and information obtained from public comments for measure development are available at: https:// www.cms.gov/Medicare/Quality-Initiatives-Patient- VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 calculation was performed combining the measure results for HOPDs and ASCs. We found that for a facility with median case size, the reliability estimate was high (over 0.90), but the minimum reliability estimate for facilities with 30 cases (the minimum case size chosen for public reporting) was only moderate (that is, between 0.40 and 0.60).149 However, after the 2015 dry run, CMS calculated the HOPD and ASC scores separately to compare similar types of providers to each other. During subsequent analysis of the 1-year period July 2013 through June 2014, we confirmed that a 1-year reporting period with separate calculations for HOPDs and ASCs was sufficient but did result in lower reliability and decreased precision compared to these measures calculated from longer reporting periods (two or three years). Based on analyses conducted using data from July 2013 through June 2014 (1-year reporting period) and 2017 measure specifications,150 we found that the median facility-level reliability was 0.74 for ASCs and 0.51 for HOPDs. Using a 2-year reporting period (data from July 2012–June 2014), we found that median facility-level reliability was 0.81 for ASCs and 0.67 for HOPDs. When the reporting period was extended to three years (using data from July 2011 through June 2014), we found that median facility-level reliability was higher for both ASCs and HOPDs: 0.87 for ASCs and 0.75 for HOPDs. These results indicate that a larger portion of the included facilities have scores measured with higher reliability when three years of data are used rather than one year of data. Using three years of data, compared to just one year, is estimated to increase the number of HOPDs with eligible cases for OP–32 by 5 percent, adding approximately 235 additional facilities to the measure calculation. Facilities reporting the measure would increase Assessment-Instruments/HospitalQualityInits/ Measure-Methodology.html under ‘‘Hospital Outpatient Colonoscopy.’’ 149 Landis JR, Koch GG. The Measurement of Observer Agreement for Categorical Data. Biometrics. 1977;33(1):159–174. 150 Current and past measure specifications are available at: https://www.qualitynet.org/dcs/ ContentServer?c=Page&pagename= QnetPublic%2FPage%2FQnetTier3&cid=1228775 214597. PO 00000 Frm 00290 Fmt 4701 Sfmt 4700 their sample sizes and, in turn, increase the precision and reliability of their measure scores. Thus, we believe extending the reporting period to three years from one year for purposes of increasing reliability would be beneficial for providing better information to beneficiaries regarding the quality of care associated with lowrisk outpatient colonoscopy procedures. In crafting our proposal, we considered extending the reporting period to two years beginning with the CY 2020 payment determinations and subsequent years, but decided on proposing three years instead, because a higher level of reliability is achieved with a 3-year reporting period compared to two years. Therefore, we proposed to change the reporting period for OP–32: Facility 7Day Risk-Standardized Hospital Visit Rate after Outpatient Colonoscopy from one year to three years beginning with the CY 2020 payment determination (which would use claims data from January 1, 2016 through December 31, 2018) and for subsequent years. Under this proposal, the annual reporting requirements for facilities would not change, because this is a claims-based measure. However, with a 3-year reporting period, the most current year of data would be supplemented by the addition of two prior years. For example, for the CY 2020 payment determination, we would use a reporting period of CY 2018 data plus 2 prior years of data (CYs 2016 and 2017). In the proposed rule, we noted that since implementation of this measure began with the CY 2018 payment determination, we have already used paid Medicare fee-for-service claims from January 1, 2016 to December 31, 2016 to calculate measure scores, which have been previously previewed by facilities and publicly displayed. In crafting our proposal, we also considered timeliness related to payment determinations and public display. Because we would utilize data already collected to supplement current data, our proposal to use three years of data would not disrupt payment determinations or public display. We refer readers to the table below for example reporting periods and public display dates corresponding to the CY 2020, CY 2021, and CY 2022 payment determinations: E:\FR\FM\21NOR2.SGM 21NOR2 We refer readers to section XIV.D.4.b. of the proposed rule, where we discussed a similar proposal under the ASCQR Program. Comment: Several commenters supported CMS’ proposal to extend the reporting period for OP–32. A few commenters supported a 3-year reporting period, noting that the extension will mirror the Alternative Payment Model (APM) being presented by ACEP to the Payment Model Technical Advisory Committee (PTAC) and urged CMS to seek stakeholder feedback on developing a methodology and releasing a methodology report for public review and comment. Response: We thank the commenters for their support for extending the reporting period for OP–32. Regarding the request to release a methodology report, we note that a methodology already exists. We publish annual updates and measures specifications reports, which is a description of the measure updates and measure results from reevaluation and includes detailed measure specifications.151 This report describes the measure methodology for a given reporting period. We encourage stakeholders to submit comments on the measure’s methodology via the Outpatient and ASC Question and Answer tool, https://cmsocsq.custhelp.com/. Comment: One commenter supported a 2-year reporting period, specifically stating that the priority should be giving beneficiaries critical information they can use today; two years of data typically yields the best mix of reliability and predicting performance today; the larger increase in reliability occurs between one and two years; and the face validity for the measure is poor when using three years of data. Response: A 3-year reporting period substantially improves the reliability of the measure, as described above. Using a 1-year reporting period, we found that the median facility-level reliability was 0.74 for ASCs and 0.51 for HOPDs, and for a 2-year reporting period 0.81 for ASCs and 0.67 for HOPDS. However, 151 Measure Methodology. Colonoscopy measure. Available at: https://www.qualitynet.org/dcs/ ContentServer?c=Page&pagename=Qnet Public%2FPage%2FQne tTier3&cid=1228775197506. VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 the median facility-level reliability was highest for both ASCs and HOPDs using a 3-year reporting period: 0.87 for ASCs and 0.75 for HOPDs. In addition, we note that using a 3-year reporting period does not affect the timeliness of our ability to report on this measure, as the data being used have already been collected. Specifically, we note that the most current year of data would be supplemented by the addition of two prior years. For example, for the CY 2020 payment determination, we would use a reporting period of CY 2018 data plus two prior years of data (CYs 2016 and 2017). Comment: A few commenters did not support CMS’ proposal to extend the reporting period for OP–32, and stated that the five percent increase in the number of HOPDs with eligible cases given the extension in the reporting period is not substantial enough, given that a 3-year reporting period makes the data impractical and meaningless to inform quality improvement efforts and may not reflect system improvements put in place at later dates to comply with new measures. Response: While extending the measure to include three years of data does increase the number of facilities that can be reported on, the main intent of increasing the reporting period to three years is to increase measure reliability, as described above. Comment: One commenter provided general feedback on the measure not specifically related to the proposed extension of the reporting period for OP–32. This commenter suggested the measure methodology be updated to exclude diagnosis codes and/or procedures that are obviously indicative of an unforeseen and/or unrelated event. Response: We measure all-cause hospital visits to encourage OPDs and ASCs to minimize all types of risks that may lead to the need for a hospital visit after a colonoscopy. Measuring only hospital visits that are potentially related to a colonoscopy, such as gastrointestinal bleeding, would limit the measure’s impact on quality improvement efforts. Measuring allcause patient outcomes encourages facilities to minimize the risk of a broad range of outcomes, including the risk of dehydration, pain, dizziness, and PO 00000 Frm 00291 Fmt 4701 Sfmt 4700 59107 urinary retention. These are common problems that may be related or unrelated to a recent colonoscopy. We have structured the measure so that OPDs and ASCs that most effectively minimize patient risk of these outcomes will perform better. After consideration of the public comments we received, we are finalizing our proposal, as proposed, to change the reporting period for OP–32: Facility 7-Day Risk-Standardized Hospital Visit Rate after Outpatient Colonoscopy from one year to three years beginning with the CY 2020 payment determination and for subsequent years. We refer readers to section XIV.D.4.b. of this final rule with comment period, where we are finalizing a similar policy under the ASCQR Program. 5. Data Submission Requirements for the OP–37a–e: Outpatient and Ambulatory Surgery Consumer Assessment of Healthcare Providers and Systems (OAS CAHPS) Survey-Based Measures for the CY 2020 Payment Determination and Subsequent Years We refer readers to the CY 2017 OPPS/ASC final rule with comment period (81 FR 79792 through 79794) for a discussion of the previously finalized requirements related to survey administration and vendors for the OAS CAHPS Survey-based measures. In addition, we refer readers to the CY 2018 OPPS/ASC final rule with comment period (82 FR 59432 through 59433), where we finalized a policy to delay implementation of the OP–37a–e OAS CAHPS Survey-based measures beginning with the CY 2020 payment determination (2018 reporting period) until further action in future rulemaking. In the CY 2019 OPPS/ASC proposed rule (83 FR 37191), we did not propose any changes to the previously finalized requirements related to survey administration and vendors for the OAS CAHPS Survey-based measures. 6. Data Submission Requirements for Previously Finalized Measures for Data Submitted via a Web-Based Tool for the CY 2020 Payment Determination and Subsequent Years We refer readers to the CY 2014 OPPS/ASC final rule with comment E:\FR\FM\21NOR2.SGM 21NOR2 ER21NO18.107</GPH> khammond on DSK30JT082PROD with RULES2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations khammond on DSK30JT082PROD with RULES2 59108 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations period (78 FR 75112 through 75115) and the CY 2016 OPPS/ASC final rule with comment period (80 FR 70521) and the CMS QualityNet website (https:// www.qualitynet.org/dcs/ ContentServer?c=Page&pagename=Qne tPublic%2FPage%2FQnetTier2&cid =1205442125082) for a discussion of the requirements for measure data submitted via the CMS QualityNet website for the CY 2017 payment determination and subsequent years. In addition, we refer readers to the CY 2014 OPPS/ASC final rule with comment period (78 FR 75097 through 75100) for a discussion of the requirements for measure data submitted via the CDC NHSN website. In the CY 2019 OPPS/ASC proposed rule (83 FR 37191), we did not propose any changes to our policies regarding the submission of measure data submitted via a web-based tool. We note that, in section XIII.B.4.b.(1) of the proposed rule, we proposed to remove of OP–27: Influenza Vaccination Coverage Among Healthcare Personnel beginning with the CY 2020 payment determination and for subsequent years. Because we are finalizing this removal as proposed, for the CY 2020 payment determination, the following web-based quality measures will be required: • OP–12: The Ability for Providers with HIT to Receive Laboratory Data Electronically Directly into their ONCCertified EHR System as Discrete Searchable Data (via CMS’ QualityNet website); • OP–17: Tracking Clinical Results between Visits (NQF #0491) (via CMS’ QualityNet website); • OP–22: Left Without Being Seen (NQF #0499) (via CMS’ QualityNet website); • OP–29: Appropriate Follow-up Interval for Normal Colonoscopy in Average Risk Patients (NQF #0658) (via CMS’ QualityNet website); • OP–30: Colonoscopy Interval for Patients with a History of Adenomatous Polyps—Avoidance of Inappropriate Use (NQF #0659) (via CMS’ QualityNet website); • OP–31: Cataracts: Improvement in Patient’s Visual Function within 90 Days Following Cataract Surgery (NQF #1536) (via CMS’ QualityNet website); and • OP–33: External Beam Radiotherapy (EBRT) for Bone Metastases (NQF #1822) (via CMS’ QualityNet website). Furthermore, we note that in section XIII.B.4.b.(2) of the proposed rule, for the CY 2021 payment determination and subsequent years, we proposed to remove: OP–12: The Ability for Providers with HIT to Receive VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 Laboratory Data Electronically Directly into Their Qualified/Certified EHR System as Discrete Searchable Data; OP– 17: Tracking Clinical Results between Visits; OP–29: Endoscopy/Polyp Surveillance: Appropriate Follow-up Interval for Normal Colonoscopy in Average Risk Patients; OP–30: Endoscopy/Polyp Surveillance: Colonoscopy Interval for Patients with a History of Adenomatous PolypsAvoidance of Inappropriate Use; and OP–31: Cataracts: Improvement in Patient’s Visual Function within 90 Days Following Cataract Surgery beginning with the CY 2021 payment determination and for subsequent years. In section XIII.B.4.b.(2) of this final rule with comment period, we are finalizing the removal of OP–30 as proposed. However, as discussed in section XIII.B.4.b.(2)(a) of this final rule with comment period, we are not finalizing the removal of OP–29 or OP–31. Accordingly, the following web-based quality measures will require data to be submitted via a web-based tool for the CY 2021 payment determination and subsequent years: • OP–22: Left Without Being Seen (NQF #0499) (via CMS’ QualityNet website); • OP–29: Endoscopy/Polyp Surveillance: Appropriate Follow-up Interval for Normal Colonoscopy in Average Risk Patients (NQF #0658) (via CMS’ QualityNet website); • OP–31: Cataracts: Improvement in Patient’s Visual Function within 90 Days Following Cataract Surgery (NQF #1536) (via CMS’ QualityNet website); and • OP–33: External Beam Radiotherapy (EBRT) for Bone Metastases (NQF #1822) (via CMS’ QualityNet website). 7. Population and Sampling Data Requirements for the CY 2020 Payment Determination and Subsequent Years We refer readers to the CY 2011 OPPS/ASC final rule with comment period (75 FR 72100 through 72103) and the CY 2012 OPPS/ASC final rule with comment period (76 FR 74482 through 74483) for discussions of our population and sampling requirements. In the CY 2019 OPPS/ASC proposed rule (83 FR 37191), we did not propose any changes to our population and sampling requirements for chart-abstracted measures. 8. Hospital OQR Program Validation Requirements We refer readers to the CY 2013 OPPS/ASC final rule with comment period (77 FR 68484 through 68487), the CY 2015 OPPS/ASC final rule with PO 00000 Frm 00292 Fmt 4701 Sfmt 4700 comment period (79 FR 66964 through 66965), the CY 2016 OPPS/ASC final rule with comment period (80 FR 70524), and the CY 2018 OPPS/ASC final rule with comment period (82 FR 59441 through 59443), and 42 CFR 419.46(e) for our policies regarding validation. In the CY 2019 OPPS/ASC proposed rule (83 FR 37191 through 37192), we did not propose any changes to these policies. 9. Extraordinary Circumstances Exception (ECE) Process for the CY 2020 Payment Determination and Subsequent Years We refer readers to the CY 2013 OPPS/ASC final rule with comment period (77 FR 68489), the CY 2014 OPPS/ASC final rule with comment period (78 FR 75119 through 75120), the CY 2015 OPPS/ASC final rule with comment period (79 FR 66966), the CY 2016 OPPS/ASC final rule with comment period (80 FR 70524), the CY 2017 OPPS/ASC final rule with comment period (81 FR 79795), the CY 2018 OPPS/ASC final rule with comment period (82 FR 59444), and 42 CFR 419.46(d) for a complete discussion of our extraordinary circumstances exception (ECE) process under the Hospital OQR Program. In the CY 2019 OPPS/ASC proposed rule (83 FR 37192), we did not propose any changes to our ECE policy. 10. Hospital OQR Program Reconsideration and Appeals Procedures for the CY 2020 Payment Determination and Subsequent Years We refer readers to the CY 2013 OPPS/ASC final rule with comment period (77 FR 68487 through 68489), the CY 2014 OPPS/ASC final rule with comment period (78 FR 75118 through 75119), the CY 2016 OPPS/ASC final rule with comment period (80 FR 70524), the CY 2017 OPPS/ASC final rule with comment period (81 FR 79795), and 42 CFR 419.46(f) for our reconsideration and appeals procedures. In the CY 2019 OPPS/ASC proposed rule (83 FR 37192), we did not propose any changes to our reconsideration and appeals procedures. E. Payment Reduction for Hospitals That Fail To Meet the Hospital OQR Program Requirements for the CY 2019 Payment Determination 1. Background Section 1833(t)(17) of the Act, which applies to subsection (d) hospitals (as defined under section 1886(d)(1)(B) of the Act), states that hospitals that fail to report data required to be submitted on measures selected by the Secretary, in E:\FR\FM\21NOR2.SGM 21NOR2 khammond on DSK30JT082PROD with RULES2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations the form and manner, and at a time, specified by the Secretary will incur a 2.0 percentage point reduction to their Outpatient Department (OPD) fee schedule increase factor; that is, the annual payment update factor. Section 1833(t)(17)(A)(ii) of the Act specifies that any reduction applies only to the payment year involved and will not be taken into account in computing the applicable OPD fee schedule increase factor for a subsequent year. The application of a reduced OPD fee schedule increase factor results in reduced national unadjusted payment rates that apply to certain outpatient items and services provided by hospitals that are required to report outpatient quality data in order to receive the full payment update factor and that fail to meet the Hospital OQR Program requirements. Hospitals that meet the reporting requirements receive the full OPPS payment update without the reduction. For a more detailed discussion of how this payment reduction was initially implemented, we refer readers to the CY 2009 OPPS/ ASC final rule with comment period (73 FR 68769 through 68772). The national unadjusted payment rates for many services paid under the OPPS equal the product of the OPPS conversion factor and the scaled relative payment weight for the APC to which the service is assigned. The OPPS conversion factor, which is updated annually by the OPD fee schedule increase factor, is used to calculate the OPPS payment rate for services with the following status indicators (listed in Addendum B to this final rule with comment period, which is available via the internet on the CMS website): ‘‘J1’’, ‘‘J2’’, ‘‘P’’, ‘‘Q1’’, ‘‘Q2’’, ‘‘Q3’’, ‘‘R’’, ‘‘S’’, ‘‘T’’, ‘‘V’’, or ‘‘U’’. In the CY 2017 OPPS/ ASC final rule with comment period (81 FR 79796), we clarified that the reporting ratio does not apply to codes with status indicator ‘‘Q4’’ because services and procedures coded with status indicator ‘‘Q4’’ are either packaged or paid through the Clinical Laboratory Fee Schedule and are never paid separately through the OPPS. Payment for all services assigned to these status indicators will be subject to the reduction of the national unadjusted payment rates for hospitals that fail to meet Hospital OQR Program requirements, with the exception of services assigned to New Technology APCs with assigned status indicator ‘‘S’’ or ‘‘‘T’’. We refer readers to the CY 2009 OPPS/ASC final rule with comment period (73 FR 68770 through 68771) for a discussion of this policy. The OPD fee schedule increase factor is an input into the OPPS conversion VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 factor, which is used to calculate OPPS payment rates. To reduce the OPD fee schedule increase factor for hospitals that fail to meet reporting requirements, we calculate two conversion factors—a full market basket conversion factor (that is, the full conversion factor), and a reduced market basket conversion factor (that is, the reduced conversion factor). We then calculate a reduction ratio by dividing the reduced conversion factor by the full conversion factor. We refer to this reduction ratio as the ‘‘reporting ratio’’ to indicate that it applies to payment for hospitals that fail to meet their reporting requirements. Applying this reporting ratio to the OPPS payment amounts results in reduced national unadjusted payment rates that are mathematically equivalent to the reduced national unadjusted payment rates that would result if we multiplied the scaled OPPS relative payment weights by the reduced conversion factor. For example, to determine the reduced national unadjusted payment rates that applied to hospitals that failed to meet their quality reporting requirements for the CY 2010 OPPS, we multiplied the final full national unadjusted payment rate found in Addendum B of the CY 2010 OPPS/ASC final rule with comment period by the CY 2010 OPPS final reporting ratio of 0.980 (74 FR 60642). In the CY 2009 OPPS/ASC final rule with comment period (73 FR 68771 through 68772), we established a policy that the Medicare beneficiary’s minimum unadjusted copayment and national unadjusted copayment for a service to which a reduced national unadjusted payment rate applies would each equal the product of the reporting ratio and the national unadjusted copayment or the minimum unadjusted copayment, as applicable, for the service. Under this policy, we apply the reporting ratio to both the minimum unadjusted copayment and national unadjusted copayment for services provided by hospitals that receive the payment reduction for failure to meet the Hospital OQR Program reporting requirements. This application of the reporting ratio to the national unadjusted and minimum unadjusted copayments is calculated according to § 419.41 of our regulations, prior to any adjustment for a hospital’s failure to meet the quality reporting standards according to § 419.43(h). Beneficiaries and secondary payers thereby share in the reduction of payments to these hospitals. In the CY 2009 OPPS/ASC final rule with comment period (73 FR 68772), we established the policy that all other applicable adjustments to the OPPS PO 00000 Frm 00293 Fmt 4701 Sfmt 4700 59109 national unadjusted payment rates apply when the OPD fee schedule increase factor is reduced for hospitals that fail to meet the requirements of the Hospital OQR Program. For example, the following standard adjustments apply to the reduced national unadjusted payment rates: The wage index adjustment; the multiple procedure adjustment; the interrupted procedure adjustment; the rural sole community hospital adjustment; and the adjustment for devices furnished with full or partial credit or without cost. Similarly, OPPS outlier payments made for high cost and complex procedures will continue to be made when outlier criteria are met. For hospitals that fail to meet the quality data reporting requirements, the hospitals’ costs are compared to the reduced payments for purposes of outlier eligibility and payment calculation. We established this policy in the OPPS beginning in the CY 2010 OPPS/ASC final rule with comment period (74 FR 60642). For a complete discussion of the OPPS outlier calculation and eligibility criteria, we refer readers to section II.G. of this final rule with comment period. 2. Reporting Ratio Application and Associated Adjustment Policy for CY 2019 In the CY 2019 OPPS/ASC proposed rule (83 FR 37193), we proposed to continue our established policy of applying the reduction of the OPD fee schedule increase factor through the use of a reporting ratio for those hospitals that fail to meet the Hospital OQR Program requirements for the full CY 2019 annual payment update factor. For the CY 2019 OPPS, the proposed reporting ratio was 0.980, calculated by dividing the proposed reduced conversion factor of 77.955 by the proposed full conversion factor of 79.546. We proposed to continue to apply the reporting ratio to all services calculated using the OPPS conversion factor. For the CY 2019 OPPS, we proposed to apply the reporting ratio, when applicable, to all HCPCS codes to which we have proposed status indicator assignments of ‘‘J1’’, ‘‘J2’’, ‘‘P’’, ‘‘Q1’’, ‘‘Q2’’, ‘‘Q3’’, ‘‘R’’, ‘‘S’’, ‘‘T’’, ‘‘V’’, and ‘‘U’’ (other than new technology APCs to which we have proposed status indicator assignment of ‘‘S’’ and ‘‘T’’). We proposed to continue to exclude services paid under New Technology APCs. We proposed to continue to apply the reporting ratio to the national unadjusted payment rates and the minimum unadjusted and national unadjusted copayment rates of all applicable services for those hospitals that fail to meet the Hospital OQR E:\FR\FM\21NOR2.SGM 21NOR2 59110 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations Program reporting requirements. We also proposed to continue to apply all other applicable standard adjustments to the OPPS national unadjusted payment rates for hospitals that fail to meet the requirements of the Hospital OQR Program. Similarly, we proposed to continue to calculate OPPS outlier eligibility and outlier payment based on the reduced payment rates for those hospitals that fail to meet the reporting requirements. We did not receive any public comments on these proposals. For the CY 2019 OPPS, the final reporting ratio is 0.980, calculated by dividing the final reduced conversion factor of 77.900 by the final full conversion factor of 79.490. We also are finalizing the remainder of our proposals regarding the payment reduction for hospitals that fail to meet the Hospital OQR Program requirements for CY 2019 payment determination without modification. XIV. Requirements for the Ambulatory Surgical Center Quality Reporting (ASCQR) Program A. Background 1. Overview We refer readers to section XIII.A.1. of the proposed rule for a general overview of our quality reporting programs and to section I.A.2. of the proposed rule and this final rule with comment period for a discussion of our new Meaningful Measures Initiative. khammond on DSK30JT082PROD with RULES2 2. Statutory History of the ASCQR Program We refer readers to section XIV.K.1. of the CY 2012 OPPS/ASC final rule with comment period (76 FR 74492 through 74494) for a detailed discussion of the statutory history of the ASCQR Program. 3. Regulatory History of the ASCQR Program We seek to promote higher quality and more efficient health care for beneficiaries. This effort is supported by the adoption of widely-agreed-upon quality measures. We have worked with relevant stakeholders to define measures of quality in almost every healthcare setting and currently measure some aspect of care for almost all Medicare beneficiaries. These measures assess structural aspects of care, clinical processes, patient experiences with care, and outcomes. We have implemented quality measure reporting programs for multiple settings of care. To measure the quality of ASC services and to make such information publicly available, we implemented the ASCQR Program. We refer readers to section XV.A.3. of the CY 2014 OPPS/ASC final VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 rule with comment period (78 FR 75122), section XIV. of the CY 2015 OPPS/ASC final rule with comment period (79 FR 66966 through 66987), section XIV. of the CY 2016 OPPS/ASC final rule with comment period (80 FR 70526 through 70538), section XIV. of the CY 2017 OPPS/ASC final rule with comment period (81 FR 79797 through 79826) and section XIV. of the CY 2018 OPPS/ASC final rule with comment period (82 FR 59445 through 59476) for an overview of the regulatory history of the ASCQR Program. 4. Meaningful Measures Initiative In the proposed rule, we proposed a number of new policies for the ASCQR Program. We developed these proposals after conducting an overall review of the Program under our new Meaningful Measures Initiative, which is discussed in more detail in section I.A.2. of the proposed rule and this final rule with comment period. The proposals reflected our efforts to ensure that the ASCQR Program measure set continues to promote improved health outcomes for our beneficiaries while minimizing costs, which can consist of several different types of costs, including, but not limited to: (1) Facility information collection burden and related cost and burden associated with the submitting/ reporting of quality measures to CMS; (2) the facility cost associated with complying with other quality programmatic requirements; (3) the facility cost associated with participating in multiple quality programs, and tracking multiple similar or duplicative measures within or across those programs; (4) the CMS cost associated with the program oversight of the measure, including measure maintenance and public display; and (5) the facility cost associated with compliance with other federal and/or State regulations (if applicable). These proposals also reflected our efforts to improve the usefulness of the data that we publicly report in the ASCQR Program. Our goal is to improve the usefulness and usability of CMS quality program data by streamlining how facilities are reporting and accessing data, while maintaining or improving consumer understanding of the data publicly reported on a Compare website. We believe this framework will allow ASCs and patients to continue to obtain meaningful information about ASC performance and incentivize quality improvement while also streamlining the measure sets to reduce duplicative measures and program complexity so that the costs to ASCs associated with participating in this PO 00000 Frm 00294 Fmt 4701 Sfmt 4700 program do not outweigh the benefits of improving beneficiary care. B. ASCQR Program Quality Measures 1. Considerations in the Selection of ASCQR Program Quality Measures We refer readers to the CY 2013 OPPS/ASC final rule with comment period (77 FR 68493 through 68494) for a detailed discussion of the priorities we consider for ASCQR Program quality measure selection. In the CY 2019 OPPS/ASC proposed rule (83 FR 37193), we did not propose any changes to these policies. 2. Accounting for Social Risk Factors in the ASCQR Program In the CY 2018 OPPS/ASC final rule with comment period (82 FR 59445 through 59447), we discussed the importance of improving beneficiary outcomes including reducing health disparities. We also discussed our commitment to ensuring that medically complex patients, as well as those with social risk factors, receive excellent care. We discussed how studies show that social risk factors, such as being near or below the poverty level as determined by HHS, belonging to a racial or ethnic minority group, or living with a disability, can be associated with poor health outcomes and how some of this disparity is related to the quality of health care.152 Among our core objectives, we aim to improve health outcomes, attain health equity for all beneficiaries, and ensure that complex patients as well as those with social risk factors receive excellent care. Within this context, reports by the Office of the Assistant Secretary for Planning and Evaluation (ASPE) and the National Academy of Medicine have examined the influence of social risk factors in CMS value-based purchasing programs.153 As we noted in the CY 2018 OPPS/ASC final rule with comment period (82 FR 59445 through 59447), ASPE’s report to Congress found that, in the context of value-based 152 See, for example, United States Department of Health and Human Services. ‘‘Healthy People 2020: Disparities. 2014.’’ Available at: https:// www.healthypeople.gov/2020/about/foundationhealth-measures/Disparities; or National Academies of Sciences, Engineering, and Medicine. Accounting for Social Risk Factors in Medicare Payment: Identifying Social Risk Factors. Washington, DC: National Academies of Sciences, Engineering, and Medicine 2016. 153 Department of Health and Human Services Office of the Assistant Secretary for Planning and Evaluation (ASPE), ‘‘Report to Congress: Social Risk Factors and Performance Under Medicare’s ValueBased Purchasing Programs.’’ December 2016. Available at: https://aspe.hhs.gov/pdf-report/reportcongress-social-risk-factors-and-performanceunder-medicares-value-based-purchasingprograms. E:\FR\FM\21NOR2.SGM 21NOR2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations khammond on DSK30JT082PROD with RULES2 purchasing programs, dual eligibility was the most powerful predictor of poor health care outcomes among those social risk factors that they examined and tested. In addition, as we noted in the CY 2018 OPPS/ASC final rule with comment period (82 FR 59446), the National Quality Forum (NQF) undertook a 2-year trial period in which certain new measures and measures undergoing maintenance review have been assessed to determine if risk adjustment for social risk factors is appropriate for these measures.154 The trial period ended in April 2017 and a final report is available at: https:// www.qualityforum.org/SES_Trial_ Period.aspx. The trial concluded that ‘‘measures with a conceptual basis for adjustment generally did not demonstrate an empirical relationship’’ between social risk factors and the outcomes measured. This discrepancy may be explained in part by the methods used for adjustment and the limited availability of robust data on social risk factors. NQF is now undertaking an extension of the socioeconomic status (SES) trial,155 allowing further examination of social risk factors in outcome measures. In the FY 2018 and CY 2018 proposed rules for our quality reporting and value-based purchasing programs, we solicited feedback on which social risk factors provide the most valuable information to stakeholders and the methodology for illuminating differences in outcomes rates among patient groups within a hospital or facility that would also allow for a comparison of those differences, or disparities, across facilities. Feedback we received through our quality reporting programs included encouraging CMS to explore whether factors that could be used to stratify or risk adjust the measures (beyond dual eligibility); considering the full range of differences in patients’ backgrounds that might affect outcomes; exploring risk adjustment approaches; and offering careful consideration of what type of information display would be most useful to the public. We also sought public comment on confidential reporting and future public reporting of some of our measures stratified by patient dual eligibility. In general, commenters noted that stratified measures could serve as tools for 154 National Quality Forum. Final ReportDisparities Project. September 2017. Available at: https://www.qualityforum.org/ SES_Trial_Period.aspx. 155 National Quality Forum. Health Equity Program: Social Risk Initiative 2.0. 2017. Available at: https://www.qualityforum.org/WorkArea/ linkit.aspx?LinkIdentifier=id&ItemID=86357. VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 facilities to identify gaps in outcomes for different groups of patients, improve the quality of health care for all patients, and empower beneficiaries and other consumers to make informed decisions about health care. Commenters encouraged us to stratify measures by other social risk factors such as age, income, and educational attainment. With regard to value-based purchasing programs, commenters also cautioned to balance fair and equitable payment while avoiding payment penalties that mask health disparities or discourage the provision of care to more medically complex patients. Commenters also noted that value-based payment program measure selection, domain weighting, performance scoring, and payment methodology must account for social risk. As a next step, CMS is considering options to reduce health disparities among patient groups within and across healthcare settings by increasing the transparency of disparities as shown by quality measures. We also are considering how this work applies to other CMS quality programs in the future. We refer readers to the FY 2018 IPPS/LTCH PPS final rule (82 FR 38403 through 38409) for more details, where we discuss the potential stratification of certain Hospital Inpatient Quality Reporting Program outcome measures. Furthermore, we continue to consider options to address equity and disparities in our value-based purchasing programs. We plan to continue working with ASPE, the public, and other key stakeholders on this important issue to identify policy solutions that achieve the goals of attaining health equity for all beneficiaries and minimizing unintended consequences. 3. Policies for Retention and Removal of Quality Measures From the ASCQR Program a. Retention of Previously Adopted ASCQR Program Measures We previously adopted a policy that quality measures adopted for an ASCQR Program measure set for a previous payment determination year be retained in the ASCQR Program for measure sets for subsequent payment determination years, except when they are removed, suspended, or replaced as indicated (76 FR 74494 and 74504; 77 FR 68494 through 68495; 78 FR 75122; and 79 FR 66967 through 66969). In the CY 2019 OPPS/ASC proposed rule (83 FR 37194), we did not propose any changes to this policy. PO 00000 Frm 00295 Fmt 4701 Sfmt 4700 59111 b. Removal Factors for ASCQR Program Measures (1) Previously Finalized Policy We refer readers to the CY 2015 OPPS/ASC final rule with comment period (79 FR 66967 through 66969) and 42 CFR 416.320 for a detailed discussion of the process for removing adopted measures from the ASCQR Program. In the CY 2015 OPPS/ASC final rule with comment period (79 FR 66967 through 66969), we finalized the ASCQR Program measure removal factors 156 for determining whether to remove ASCQR Program measures as follows: • Factor 1. Measure performance among ASCs is so high and unvarying that meaningful distinctions and improvements in performance can no longer be made (‘‘topped-out’’ measures). • Factor 2. Availability of alternative measures with a stronger relationship to patient outcomes. • Factor 3. A measure does not align with current clinical guidelines or practice. • Factor 4. The availability of a more broadly applicable (across settings, populations, or conditions) measure for the topic. • Factor 5. The availability of a measure that is more proximal in time to desired patient outcomes for the particular topic. • Factor 6. The availability of a measure that is more strongly associated with desired patient outcomes for the particular topic. • Factor 7. Collection or public reporting of a measure leads to negative unintended consequences other than patient harm. In that final rule with comment period, we stated that the benefits of removing a measure from the ASCQR Program will be assessed on a case-bycase basis (79 FR 66969). Under this case-by-case approach, a measure will not be removed solely on the basis of meeting any specific factor. We noted that in the CY 2013 OPPS/ASC final rule with comment period (77 FR 68472 through 68473), similar measure removal factors were finalized for the Hospital OQR Program. In the CY 2019 OPPS/ASC proposed rule (83 FR 37194 through 37197), we proposed to: (1) Remove one factor; (2) add two new measure removal factors, 156 We note that we previously referred to these factors as ‘‘criteria’’ (for example, 82 FR 59474 through 59475); we now use the term ‘‘factors’’ in order to align the ASCQR Program terminology with the terminology we use in other CMS quality reporting and pay for performance (value-based purchasing) programs. E:\FR\FM\21NOR2.SGM 21NOR2 59112 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations and (3) update 42 CFR 416.320(c) to better reflect our measure removal policies. We also made one clarification to measure removal Factor 1. These items are discussed in detail below. khammond on DSK30JT082PROD with RULES2 (2) Removal of Factor 2 In the CY 2019 OPPS/ASC proposed rule (83 FR 37195), we proposed to remove the ASCQR Program’s measure removal Factor 2, availability of alternative measures with a stronger relationship to patient outcomes. We received comments in the CY 2015 OPPS/ASC final rule with comment period (79 FR 66967) remarking on the duplicative nature of the ASCQR Program’s measure removal Factor 2, availability of alternative measures with a stronger relationship to patient outcomes, with measure removal Factor 6, the availability of a measure that is more strongly associated with desired patient outcomes for the particular topic. In that final rule with comment period, we stated that ‘‘criterion (2) applies when there is more than one alternative measure with a stronger relationship to patient outcomes that is available, and criterion (6) applies where there is only one measure that is strongly and specifically associated with desired patient outcomes for the particular topic that is available’’ (79 FR 66967). Since reevaluating those comments, we have now come to agree that ASCQR measure removal Factor 2 is repetitive with Factor 6. Therefore, we proposed to remove Factor 2, ‘‘availability of alternative measures with a stronger relationship to patient outcomes,’’ beginning with the effective date of the CY 2019 OPPS/ASC final rule with comment period. We invited public comment on our proposal as discussed above. Comment: One commenter supported CMS’ proposal to remove measure removal Factor 2, noting its repetitive nature with removal Factor 6. Response: We thank the commenter for its support. After consideration of the public comments we received, we are finalizing our proposal to remove measure removal Factor 2, ‘‘availability of alternative measures with a stronger relationship to patient outcomes,’’ from the ASCQR Program beginning with the effective date of this CY 2019 OPPS/ ASC final rule with comment period, as proposed. (3) Addition of Two New Measure Removal Factors (a) Measure Removal Factor 2 We want the ASCQR Program measure removal factors to be fully VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 aligned with the Hospital OQR Program to provide consistency across these two outpatient setting quality reporting programs. We believe it is important to evaluate the appropriateness of measures across programs using similar standards. In evaluating the two programs’ removal factors, we became aware that the Hospital OQR Program includes one factor not currently in the ASCQR Program. The Hospital OQR Program’s second measure removal factor specifies ‘‘performance or improvement on a measure does not result in better patient outcomes’’ (75 FR 50185). Therefore, in the CY 2019 OPPS/ASC proposed rule (83 FR 37195), we proposed to add ‘‘performance or improvement on a measure does not result in better patient outcomes’’ as the new removal Factor 2 for the ASCQR Program (replacing the previously adopted factor removed above). We believe that this factor is applicable in evaluating the ASCQR Program quality measures for removal because we have found it useful for evaluating measures in the Hospital OQR Program, which also evaluates the outpatient setting. In the proposed rule, we also noted that this proposed factor is already included in the Hospital IQR (80 FR 49641 through 49642), the PCHQR (82 FR 38411), the LTCH QRP (77 FR 53614 through 53615), and the IPFQR (82 FR 38463) Programs. We proposed to add a new removal factor to the ASCQR Program: ‘‘performance or improvement on a measure does not result in better patient outcomes’’ beginning with the effective date of the CY 2019 OPPS/ASC final rule with comment period. We invited public comments on our proposal, as discussed above. Comment: A few commenters supported CMS’ proposal to add a new measure removal Factor 2, noting it would align the ASCQR and Hospital OQR Programs and provide consistency for evaluating measures across quality reporting programs. Response: We thank the commenters for their support. After consideration of the public comments we received, we are finalizing our proposal to add a new removal factor to the ASCQR Program, ‘‘performance or improvement on a measure does not result in better patient outcomes’’ beginning with the effective date of the CY 2019 OPPS/ASC final rule with comment period, as proposed. (b) New Measure Removal Factor 8 In the CY 2019 OPPS/ASC proposed rule (83 FR 37195), we proposed to adopt an additional factor to consider PO 00000 Frm 00296 Fmt 4701 Sfmt 4700 when evaluating measures for removal from the ASCQR Program measure set: • Factor 8. The costs associated with a measure outweigh the benefit of its continued use in the program. As we discuss in section I.A.2. of the proposed rule and this final rule with comment period with respect to our new Meaningful Measures Initiative, we are engaging in efforts to ensure that the ASCQR Program measure set continues to promote improved health outcomes for beneficiaries while minimizing the overall costs associated with the program. We believe these costs are multifaceted and include not only the burden associated with reporting, but also the costs associated with implementing and maintaining the program. We have identified several different types of costs, including, but not limited to: (1) Facility information collection burden and related costs and burden associated with the submission/ reporting of quality measures to CMS; (2) the facility cost associated with complying with other programmatic requirements; (3) the facility cost associated with participating in multiple quality programs, and tracking multiple similar or duplicative measures within or across those programs; (4) the CMS cost associated with the program oversight of the measure including measure maintenance and public display; and (5) the facility cost associated with compliance with other federal and/or State regulations (if applicable). For example, it may be needlessly costly and/or of limited benefit to retain or maintain a measure which our analyses show no longer meaningfully supports program objectives (for example, informing beneficiary choice or payment scoring). It may also be costly for ASCs to track confidential feedback, preview reports, and publicly reported information on a measure where we use the measure in more than one program. CMS may also have to expend unnecessary resources to maintain the specifications for the measure, as well as the tools needed to collect, validate, analyze, and publicly report the measure data. Furthermore, beneficiaries may find it confusing to see public reporting on the same measure in different programs. In weighing the costs against the benefits, we evaluate the benefits of the measure as a whole, but in particular, we assess the benefits through the framework of our Meaningful Measures Initiative, as we discussed in section I.A.2. of the proposed rule and this final rule with comment period. One key aspect of patient benefits is assessing the improved beneficiary health E:\FR\FM\21NOR2.SGM 21NOR2 khammond on DSK30JT082PROD with RULES2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations outcomes if a measure is retained in our measure set. We believe that these benefits are multifaceted and are illustrated through the Meaningful Measures framework’s 6 domains and 19 areas. For example, we assessed the Healthcare Worker Influenza Vaccination and patient Influenza Vaccination measures categorized in the Quality Priority ‘‘Promote Effective Prevention and Treatment of Chronic Disease’’ in the meaningful measure area of ‘‘Preventive Care’’ across multiple CMS programs, and considered: Patient outcomes, such as mortality and hospitalizations associated with influenza; CMS measure performance in a program; and other available and reported influenza process measures, such as population influenza vaccination coverage. When these costs outweigh the evidence supporting the benefits to patients with the continued use of a measure in the ASCQR Program, we believe it may be appropriate to remove the measure from the Program. Although we recognize that one of the main goals of the ASCQR Program is to improve beneficiary outcomes by incentivizing health care facilities to focus on specific care issues and making public data related to those issues, we also recognize that those goals can have limited utility where, for example, the publicly reported data (including percentage payment adjustment data) is of limited use because it cannot be easily interpreted by beneficiaries and used to inform their choice of facility. In these cases, removing the measure from the ASCQR Program may better accommodate the costs of program administration and compliance without sacrificing improved health outcomes and beneficiary choice. We proposed that we would remove measures based on this factor assessing costs versus benefits on a case-by-case basis. We might, for example, decide to retain a measure that is burdensome for ASCs to report if we conclude that the benefit to beneficiaries justifies the reporting burden. Our goal is to move the program forward in the least burdensome manner possible, while maintaining a parsimonious set of meaningful quality measures and continuing to incentivize improvement in the quality of care provided to patients. We invited public comment on our proposal to adopt an additional measure removal Factor 8, the costs associated with a measure outweigh the benefit of its continued use in the program, beginning with the effective date of the CY 2019 OPPS/ASC final rule with VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 comment period and for subsequent years. We referred readers to section XIV.B.3.c. of the proposed rule, where we proposed to remove four measures based on this proposed measure removal factor. We noted that we had also proposed this same measure removal factor for the Hospital OQR Program in section XIII.B.4.a.(4) of the proposed rule, as well as for other quality reporting and value-based purchasing programs for FY 2019 including: the Hospital VBP Program (83 FR 41442), the Hospital IQR Program (83 FR 41544); the PCHQR Program (83 FR 41609 through 41610); the LTCH QRP (83 FR 41625 through 41627); the HQRP (83 FR 41625 through 41627); the IRF QRP (83 FR 38556 through 38557); the SNF QRP (83 FR 39267 through 39269); and the IPFQR Program (83 FR 38591 through 38593). Comment: Several commenters supported CMS’ proposal to add measure removal Factor 8, and noted that it will allow CMS to reduce cost and burden, promote alignment of measure removal criteria across quality reporting programs and the Meaningful Measures Initiative, and allow providers to focus on improving care. Response: We thank the commenters for their support. Comment: A few commenters opposed CMS’ proposal to add measure removal Factor 8. A few commenters requested clarification on the types of costs that CMS will consider and requested transparency in the process of evaluation in the costs and benefits of measures. One commenter expressed concern that the costs described under measure removal Factor 8 are not defined. One commenter noted the costs with changing measures to facilities, providers, and measure developers. Another commenter expressed concern that CMS may deem a measure too costly to implement, while providers and patients may continue to find it meaningful. Commenters also recommended direct and indirect costs that CMS may consider in evaluating measures under measure removal Factor 8. These costs included those associated with: (1) Measures that require data collection from multiple data sources, rather than just one; (2) contracting with vendors; (3) tracking performance and investing in resources for quality improvement. One commenter stated it would oppose the new factor unless costs and benefits are defined as only costs and benefits to beneficiaries and the public. Response: As noted in the proposed rule (83 FR 37193), we have defined costs, for the purpose of evaluating PO 00000 Frm 00297 Fmt 4701 Sfmt 4700 59113 measures under measure removal Factor 8, as including, but not limited to: (1) Facility information collection burden and related costs and burden associated with the submission/reporting of quality measures to CMS; (2) the facility cost associated with complying with other programmatic requirements; (3) the facility cost associated with participating in multiple quality programs, and tracking multiple similar or duplicative measures within or across those programs; (4) the CMS cost associated with the program oversight of the measure including measure maintenance and public display; and (5) the facility cost associated with compliance with other federal and/or State regulations (if applicable). This was not intended to be a complete list of the potential factors to consider in evaluating measures. In addition, as we apply this measure removal factor in future rulemaking, we will describe our rationale for the removal of a measure and will include the costs and benefits we considered. We thank commenters for their suggestions regarding additional costs to consider. We will use this feedback, as well as input from all stakeholders, as we apply measure removal Factor 8 in future rulemaking. With respect to the commenter that suggested that costs and benefits should be defined as only costs and benefits to beneficiaries and the public, we believe that various stakeholders may have different perspectives on how to define costs as well as benefits. Because of these challenges, we intend to evaluate costs and benefits for each measure on a case-by-case basis, while considering input from a variety of stakeholders, including, but not limited to: Patients, caregivers, patient and family advocates, providers, provider associations, healthcare researchers, healthcare purchasers, data vendors, and other stakeholders with insight into the direct and indirect benefits and costs (financial and otherwise) of maintaining any specific measure in the ASCQR Program. However, we believe that while a measure’s use in the ASCQR Program may benefit many entities, the primary benefit is to patients and their caregivers through incentivizing highquality care and providing publicly reported data regarding the quality of care available. We note that we intend to assess the costs and benefits to program stakeholders, including but not limited to, those listed in the proposed rule. Therefore, we intend to consider the benefits, especially those to patients and their families, when evaluating measures under this measure removal factor. As noted above, we have offered E:\FR\FM\21NOR2.SGM 21NOR2 khammond on DSK30JT082PROD with RULES2 59114 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations a definition of costs. However, this was not intended to be a complete list of the potential factors to consider in evaluating measures and we intend to consider additional examples of cost described in public comment, including the costs and benefits to beneficiaries and the public, as recommended above. Comment: A few commenters recommended that CMS seek input from hospitals, physicians, and other stakeholders when evaluating the costs and benefits of quality reporting. Response: We thank the commenters for their feedback and note that we will consider stakeholder input when evaluating both the costs of quality reporting as well as the benefits of collecting and reporting quality data. As stated above, we intend to evaluate costs and benefits for each measure on a caseby-case basis, while considering input from a variety of stakeholders, including, but not limited to: patients, caregivers, patient and family advocates, providers, provider associations, healthcare researchers, healthcare purchasers, data vendors, and other stakeholders with insight into the direct and indirect benefits and costs (financial and otherwise) of maintaining any specific measure in the ASCQR Program. Comment: A few commenters recommended that CMS consider measure sets as a whole and the consistency of quality reporting program measure sets. Another commenter recommended that when a measure is removed under Factor 8 that it should be replaced by a measure that is easier to implement and aimed at improving care within the same measure domain to avoid gaps in the measure set. One commenter further recommended that measure sets should include actionable process measures that contribute to the outcomes being measured. Response: We intend to continue to develop a robust measure set for the ASCQR Program and appreciate the commenters’ feedback. We consider the measure set as a whole, the types of measures in the measure set, and the consistency throughout quality reporting programs, among other things, when assessing measures in the ASCQR Program. We continually seek ways to improve the ASCQR Program measure set, including through identification of more efficient means of capturing data. Retaining a strong measure set that addresses critical quality issues is one benefit that we would consider in evaluating whether a measure should be potentially removed from the ASCQR Program measure set. In addition, we note that in this final rule with comment period, as discussed in more VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 detail further below, we are not finalizing our proposals below to remove two measures (ASC–9 and ASC– 11) under Factor 8 in part to maintain a more balanced and cohesive ASCQR Program measure set. After consideration of the public comments we received, we are finalizing our proposal to adopt measure removal Factor 8, the costs associated with a measure outweigh the benefit of its continued use in the program, for the ASCQR Program beginning with the effective date of this CY 2019 OPPS/ ASC final rule with comment period, as proposed. As a result of the finalization of our proposals to remove one and add two new removal factors as proposed, the new measure removal factors list for the ASCQR Program consists of the following: • Factor 1. Measure performance among ASCs is so high and unvarying that meaningful distinctions and improvements in performance can no longer be made (‘‘topped-out’’ measures). • Factor 2. Performance or improvement on a measure does not result in better patient outcomes. • Factor 3. A measure does not align with current clinical guidelines or practice. • Factor 4. The availability of a more broadly applicable (across settings, populations, or conditions) measure for the topic. • Factor 5. The availability of a measure that is more proximal in time to desired patient outcomes for the particular topic. • Factor 6. The availability of a measure that is more strongly associated with desired patient outcomes for the particular topic. • Factor 7. Collection or public reporting of a measure leads to negative unintended consequences other than patient harm. • Factor 8. The costs associated with a measure outweigh the benefit of its continued use in the program. (4) Revisions to 42 CFR 416.320(c) In the CY 2019 OPPS/ASC proposed rule (83 FR 37196), we proposed to revise 42 CFR 416.320(c) to better reflect our considerations for removing measures policy in light of the above proposals. We did not receive any comments on our proposal. Therefore, we are finalizing our proposal to revise 42 CFR 416.320(c), as proposed. (5) Clarification for Removal Factor 1: ‘‘Topped-Out’’ Measures We refer readers to the CY 2015 OPPS/ASC final rule with comment PO 00000 Frm 00298 Fmt 4701 Sfmt 4700 period where we finalized the criteria for determining when a measure is ‘‘topped-out’’ (79 FR 66968). In that final rule with comment period, we finalized two criteria for determining when a measure is ‘‘topped-out’’ under the ASCQR Program: (1) When there is statistically indistinguishable performance at the 75th and 90th percentiles of national facility performance; and (2) when the measure’s truncated coefficient of variation (TCOV) is less than or equal to 0.10 (79 FR 66968 through 66969). In the CY 2019 OPPS/ASC proposed rule (83 FR 37196), we did not propose any changes to this policy; however, we clarified our process for calculating the truncated coefficient of variation (TCOV) for four of the measures (ASC– 1, ASC–2, ASC–3, and ASC–4) proposed for removal from the ASCQR Program. Utilizing our finalized methodology (79 FR 66968), we determine the truncated coefficient of variation (TCOV) by calculating the truncated standard deviation (SD) divided by the truncated mean. As discussed above, our finalized removal criteria state that to be considered ‘‘topped-out,’’ a measure must have a TCOV of less than 0.10. We utilize the TCOV because it is generally a good measure of variability and provides a relative methodology for comparing different types of measures. Unlike the majority of our measures, for which a higher rate (indicating a higher proportion of a desired event) is the preferred outcome, some measures— in particular, ASC–1, ASC–2, ASC–3, and ASC–4—assess the rate of rare, undesired events for which a lower rate is preferred. For example, ASC–1 assesses the occurrence of patient burns, a patient safety issue. However, when determining the TCOV for a measure assessing rare, undesired events, the mean, or average rate of event occurrence, is very low and the result is a TCOV that increases rapidly and approaches infinity as the proportion of rare events declines.157 We note that the SD, the variability statistic, is the same in magnitude for measures assessing rare and non-rare events. In the proposed rule, we proposed to remove a number of measures that assess the rate of rare, undesired events for which a lower rate is preferred— ASC–1, ASC–2, ASC–3, and ASC–4— and referred readers to section XIV.B.3.c. of the proposed rule where these proposed measure removals are discussed in detail. Because by design 157 Rose-Hulman Institute of Technology. Denominator approaching zero. Retrieved from: https://www.rose-hulman.edu/media/89584/ lclimitsguide.pdf. E:\FR\FM\21NOR2.SGM 21NOR2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations khammond on DSK30JT082PROD with RULES2 these measures have maintained very low rates (indicating the preferred outcome), we utilized the mean of nonadverse events in our calculation of the TCOV. For example, for ASC–1, to calculate the TCOV we divide the SD by the average rate of patients not receiving burns (1 minus the rate of patients receiving burns) rather than the rate of patients receiving burns. Utilizing this methodology results in a TCOV that is comparable to that calculated for other measures and allows us to assess rareevent measures by still generally using our previously finalized topped-out criteria. c. Removal of Quality Measures From the ASCQR Program Measure Set In the CY 2019 OPPS/ASC proposed rule (83 FR 37197 through 37202), we proposed to remove a total of eight measures from the ASCQR Program measure set across the CY 2020 and CY 2021 payment determinations. Specifically, beginning with the CY 2020 payment determination, we proposed to remove: (1) ASC–8: Influenza Vaccination Coverage Among Healthcare Personnel (NQF #0431); and beginning with the CY 2021 payment determination, we proposed to remove: (2) ASC–1: Patient Burn (NQF #0263); (3) ASC–2: Patient Fall (NQF #0266); (4) ASC–3: Wrong Site, Wrong Side, Wrong Patient, Wrong Procedure, Wrong Implant (NQF #0267); (5) ASC–4: AllCause Hospital Transfer/Admission (NQF #0265); (6) ASC–9: Endoscopy/ Polyp Surveillance Follow-up Interval for Normal Colonoscopy in Average Risk Patients (NQF #0658); (7) ASC–10: Endoscopy/Polyp Surveillance: Colonoscopy Interval for Patients with a History of Adenomatous Polyps— Avoidance of Inappropriate Use (NQF #0659); and (8) ASC–11: Cataracts— Improvement in Patient’s Visual Function within 90 Days Following Cataract Surgery (NQF #1536). We proposed to remove these measures under the following measure removal factors: Factor 1—measure performance among ASCs is so high and unvarying that meaningful distinctions and improvements in performance can no longer be made (‘‘topped-out’’ measures); and Factor 8—the costs associated with a measure outweigh the benefit of its continued use in the program. We are finalizing the removal of two measures out of the eight measure removals we proposed. The proposed measure-specific removals are discussed in detail further below. However, because we received several general comments regarding all eight proposals as a whole, we are discussing those first. VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 Comment: Many commenters supported all of CMS’ proposals to remove measures from the ASCQR Program measure set. Some of these commenters noted that the proposals will reduce burden, simplify facility reporting, and reduce duplication. One commenter suggested that CMS remove all eight measures beginning with CY 2020, rather than delaying removal of seven measures until CY 2021. Some commenters agreed with CMS’ rationale for removals and noted that topped-out or not beneficial measures should be removed as soon as possible. Response: We thank the commenters for their support for our proposed measure removals. However, data collection and reporting for the CY 2020 payment determination already began in January 2018 for all eight of the measures proposed for removal. Thus, by the effective date of this final rule with comment period, facilities will have already collected 11 months of data for the CY 2020 payment determination. In consideration of facilities’ efforts already exerted, we are finalizing removal of these measures starting with the next proximate payment determination. Comment: One commenter opposed CMS’ proposal to remove measures from the ASCQR Program, citing its belief that consumers should be offered more quality information, rather than less, that can be used in selecting facilities. Another commenter recommended that CMS maintain the existing measure set and work to reduce provider burden through alignment across programs instead. Response: We thank the commenters for their feedback and note our agreement that consumers should be provided with as much valuable quality information as possible. As described in the proposed rule, we proposed to remove some measures because the costs associated with a measure outweigh the benefit of its continued use in the program and measure performance among facilities is so high and unvarying that meaningful distinctions and improvements in performance can no longer be made (‘‘topped-out’’ measures). We have identified these and other measure removal factors specifically to ensure that the data provided to consumers is meaningful and valuable. We do not believe it is beneficial to maintain program measures indefinitely. However, we agree that burden should be reduced through program alignment and will continue to seek opportunities to do this. In the proposed rule, we proposed several policies to align with the Hospital OQR Program including PO 00000 Frm 00299 Fmt 4701 Sfmt 4700 59115 updating our measure removal factors and removing OP–27 and ASC–8, OP– 29 and ASC–9, OP–30 and ASC–10, and OP–31 and ASC–11, and we are finalizing several of these aligned proposals in this final rule with comment period. (1) Measure Removal for the CY 2020 Payment Determination and Subsequent Years—ASC–8: Influenza Vaccination Coverage Among Healthcare Personnel For the CY 2020 payment determination and subsequent years, we proposed to remove one NHSN measure under proposed measure removal Factor 8, the costs associated with this measure outweigh the benefit of its continued use in the program. We refer readers to the CY 2012 OPPS/ASC final rule with comment period (76 FR 74510), where we adopted ASC–8: Influenza Vaccination Coverage Among Healthcare Personnel (NQF #0431), beginning with the CY 2016 payment determination and for subsequent years. This process of care measure, also a National Healthcare Safety Network (NHSN) measure, assesses the percentage of healthcare personnel who have been immunized for influenza during the flu season. We initially adopted this measure based on our recognition that influenza immunization is an important public health issue and vital component to preventing healthcare associated infections. We believe that the measure addresses this public health concern by assessing influenza vaccination in the ASC among healthcare personnel (HCP), who can serve as vectors for influenza transmission. In the proposed rule, we proposed to remove ASC–8: Influenza Vaccination Coverage Among Healthcare Personnel beginning with the CY 2020 payment determination under proposed measure removal Factor 8, because we have concluded that the costs associated with this measure outweigh the benefit of its continued use in the program. The information collection burden for the Influenza Vaccination Coverage Among Healthcare Personnel measure is less than for measures that require chart abstraction of patient data because influenza vaccination among health care personnel can be calculated through review of records maintained in administrative systems and because facilities have fewer health care personnel than patients. As such, ASC– 8 does not require review of as many records. However, this measure does still pose information collection burden on facilities due to the requirement to identify personnel who have been E:\FR\FM\21NOR2.SGM 21NOR2 khammond on DSK30JT082PROD with RULES2 59116 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations vaccinated against influenza and for those not vaccinated, the reason why. Furthermore, as we stated in section XIV.B.3.b. of the proposed rule, costs are multifaceted and include not only the burden associated with reporting, but also the costs associated with implementing and maintaining the program. For example, it may be costly for health care providers to maintain general administrative knowledge to report these measures. In addition, CMS must expend resources in maintaining information collection systems, analyzing reported data, and providing public reporting of the collected information. In our analysis of the ASCQR Program measure set, we recognized that some ASCs face challenges with respect to the administrative requirements of the NHSN in their reporting of the Influenza Vaccination Coverage Among Healthcare Personnel measure. These administrative requirements (which are unique to NHSN) include annually completing NHSN system user authentication. Enrolling in NHSN is a five-step process that the CDC estimates takes an average of 263 minutes per ASC.158 Furthermore, submission via NHSN requires the system security administrator of participating facilities to re-consent electronically, ensure that contact information is kept current, ensure that the ASC has an active facility administrator account, keep Secure Access Management Service (SAMS) credentials active by logging in approximately every two (2) months and changing their password, create a monthly reporting plan, and ensure the ASC’s CCN information is up-to-date. Unlike short-term acute care hospitals which participate in other quality programs, such as the Hospital IQR and HAC Reduction Programs, ASCs are only required to participate in NHSN to submit data for this one measure. This may unduly disadvantage smaller ASCs, specifically those that are not part of larger hospital systems, because these ASCs do not have NHSN access for other quality reporting or value-based payment programs. It is our goal to ensure that the ASCQR Program is equitable to all ASCs and this measure may disproportionately affect small, independent ASCs. Especially for these small, independent ASCs, the incremental costs of this measure, as compared to other measures in the ASCQR Program measure set, are 158 Available at: https://www.cdc.gov/nhsn/ ambulatory-surgery/enroll.html (the estimates for time to complete are 2 hours 45 minutes for step 1, 10 minutes for step 2, 16 minutes for step 3a, 35 minutes for step 3b, 32 minutes for step 4, and 5 minutes for step 5; totaling 263 minutes). VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 significant because of the requirements imposed by NHSN participation. We continue to believe that the Influenza Vaccination Coverage Among Healthcare Personnel measure provides the benefit of protecting ASC patients against influenza. However, we believe that these benefits are offset by other efforts to reduce influenza infection among ASC patients, such as numerous healthcare employer requirements for healthcare personnel to be vaccinated against influenza.159 160 We also expect that a portion of MIPS-eligible clinicians nationwide will report on the Preventive Care and Screening: Influenza Immunization measure (NQF #0041) through the Quality Payment Program (QPP).161 Although MIPSeligible clinicians may voluntarily select measures from a list of options, ASC providers that are MIPS-eligible will have the opportunity to continue collecting information for the measure. CMS remains responsive to the public health concern of influenza infection within the Medicare FFS population by collecting data on rates of influenza immunization among patients.162 Thus, the public health concern is addressed via these other efforts to track influenza vaccination. The availability of this measure in another CMS program demonstrates CMS’ continued commitment to this measure area. In addition, as we discussed in section XIV.B.3.b. of the proposed rule, where we proposed to adopt measure removal Factor 8, beneficiaries may find it confusing to see public reporting on the same measure in different programs. We wish to minimize the level of cost of our programs for participating facilities, as discussed under the Meaningful Measures Initiative described in section I.A.2. of the proposed rule and this final rule with comment period. In our assessment of the ASCQR Program measure set, we prioritized measures that align with this Framework as the most important to the ASC population. Our assessment concluded that while the Influenza Vaccination Coverage Among Healthcare Personnel measure continues to provide benefits, these benefits are diminished by other factors and are 159 CDC, Influenza Vaccination Information for Health Care Workers. Available at: https:// www.cdc.gov/flu/healthcareworkers.htm. 160 CDC Influenza Vaccination Coverage Among Health Care Personnel—United States, 2013–14 Influenza Season. Available at: https:// www.cdc.gov/mmwr/preview/mmwrhtml/ mm6337a1.htm. 161 QPP 2017 Measures Selection: Influenza. Retrieved from: https://qpp.cms.gov/mips/qualitymeasures. 162 Ibid. PO 00000 Frm 00300 Fmt 4701 Sfmt 4700 outweighed by the costs and burdens of reporting this measure. For these reasons, we proposed to remove ASC–8: Influenza Vaccination Coverage among Healthcare Personnel (NQF #0431) from the ASCQR Program beginning with the CY 2020 payment determination and for subsequent years because the costs associated with the measure outweigh the benefit of its continued use in the program. We noted that if proposed measure removal Factor 8 is not finalized, removal of this measure would also not be finalized. We also noted that a similar measure was also proposed for removal from the Hospital OQR Program in section XIII.B.4.b.(1) of the proposed rule and the IPFQR Program in the FY 2019 IPF PPS proposed rule (83 FR 21104). We invited public comments on our proposal to remove ASC–8: Influenza Vaccination Coverage Among Healthcare Personnel from the ASCQR Program beginning with the CY 2020 payment determination under measure removal Factor 8, because we have concluded that the costs associated with this measure outweigh the benefit of its continued use in the program, as discussed above. Comment: Many commenters supported all of CMS’ proposals to remove measures from the ASCQR Program. Many commenters specifically supported CMS’ proposal to remove ASC–8 because the costs of the measure outweigh its continued use in the ASCQR Program. One commenter remarked that while immunization is a critical component of preventing influenza transmission, that many employer-based programs and requirements already promote vaccination. Another commenter noted that many ASCs may fail to receive the APU due to failing to submit data related to ASC–8. Response: We thank the commenters for their support. Comment: A few commenters noted that the NHSN website is very burdensome and it is difficult for ASCs to keep their accounts active when it utilized only once per year. One commenter noted that keeping such accounts active may be particularly difficult for ASCs that are not part of a hospital system. A few commenters recommended that the measure could be redeveloped and submitted via QualityNet in the future. Response: We thank the commenters for their support and agree that ASCs face an undue burden from registering and maintaining access to the CDC’s NHSN system for this one measure as compared to other quality reporting programs that require access for several E:\FR\FM\21NOR2.SGM 21NOR2 khammond on DSK30JT082PROD with RULES2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations healthcare safety measures. We will continue to assess the ASCQR Program measure set and will consider future measures, including the potential for a re-developed measure submitted via QualityNet that addresses influenza vaccinations for health care workers, as part of our goal to maintain a robust measure set. Comment: One commenter stated that although the process to register on NHSN is tedious, that it is not impossible and that reporting on the site is easy. Another commenter noted that the burden to submit the measure via NHSN is minimal once the data is collected and that having ASCs participate in NHSN reporting will provide benefit as new measures are developed in partnership with the CDC. Response: We thank the commenters for their input. We remain concerned that the burden of reporting this measure is greater for ASCs compared to the relative burden for hospitals participating in the Hospital IQR and HAC Reduction Programs. The entire burden of registering for and maintaining access to the CDC’s NHSN system for ASCs, especially independent or freestanding ASCs, is due to this one measure; whereas hospitals paid under the IPPS, participating in the Hospital IQR Program, the HAC Reduction Program and the Hospital VBP Program, for example, must register and maintain NHSN access for several healthcare safety measures, not just one. However, we note that, beyond the ASCQR Program, facilities may independently choose to voluntarily report data to NHSN on vaccination rates using the NHSN Healthcare Personnel Safety Component. Comment: Several commenters opposed CMS’ proposal to remove ASC– 8 from the ASCQR Program. A few commenters expressed concern that influenza is a critical public health issue and that influenza vaccination coverage of healthcare workers helps create a safe environment for patients, visitors, and employees. A few commenters expressed concern that removal of ASC– 8 would result in lower vaccination rates among healthcare workers. A few commenters noted that the Medicare population may be more susceptible to vaccine preventable illnesses such as influenza. Response: We agree that influenza vaccination for both patients and healthcare personnel is important in the ASC setting, as well as other healthcare settings, and we believe that these two activities are both intended to address the public health concern of reducing influenza infection. VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 However, while we agree that Medicare beneficiaries may have additional risk of contracting influenza, as noted in our proposal, we believe the effects of removing this measure from the ASCQR Program are mitigated as the issue is addressed in other initiatives such as State laws and employer programs that require influenza vaccination of healthcare workers.163 164 Because of this, we do not believe that retaining this measure would result in lower rates of vaccination coverage among healthcare personnel. Further, we have retained the measure in the Hospital IQR Program (83 FR 41579), thus, requiring reporting in the shortterm, acute care hospital setting. In addition, we believe that the burden of this measure on ASCs, especially independent or freestanding ASCs, outweighs the limited benefit of addressing this topic again under the ASCQR Program in addition to the many other vaccination initiatives. Comment: A few commenters stated that ASC–8 plays a critical role in the CMS Quality Strategy and the National Quality Strategy in terms of immunization efforts. A few commenters stated that removal of the measure would create greater inconsistency across quality reporting programs. Response: We agree that influenza is a critical public health issue that is part of the CMS Quality Strategy and the National Quality Strategy. Through our Meaningful Measures Initiative, it is our goal to ensure that we are addressing high-impact measure areas that safeguard public health while minimizing the level of burden for providers and suppliers. We continue to believe in the importance of influenza vaccination coverage for health care workers, particularly in acute care settings, and have retained this measure in the Hospital IQR Program (83 FR 41579) in order to address this concern. As we noted above, the burden of reporting this measure is greater for ASCs compared to the relative burden for hospitals participating in the Hospital IQR and HAC Reduction Programs. The entire burden of registering for and maintaining access to the CDC’s NHSN system for ASCs, especially independent or freestanding ASCs, is due to this one measure; whereas, hospitals paid under the IPPS, 163 CDC. Influenza Vaccination Information for Health Care Workers. Available at: https:// www.cdc.gov/flu/healthcareworkers.htm. 164 CDC Influenza Vaccination Coverage Among Health Care Personnel—United States, 2013–14 Influenza Season. Available at: https:// www.cdc.gov/mmwr/preview/mmwrhtml/ mm6337a1.htm. PO 00000 Frm 00301 Fmt 4701 Sfmt 4700 59117 participating in the Hospital IQR Program, the HAC Reduction Program, and the Hospital VBP Program, for example, must register and maintain NHSN access for several healthcare safety measures, not just one. Comment: One commenter stated that the cost associated with mitigating an influenza outbreak outweighs the cost of retaining ASC–8 in the ASCQR Program. Response: As noted above, because this issue is addressed in other initiatives at the State-level and through employers, we do not believe it would result in lower rates of vaccination coverage among healthcare personnel in ASCs or increase the risk of an outbreak. After consideration of the public comments we received, we are finalizing our proposal to remove ASC– 8: Influenza Vaccination Coverage Among Healthcare Personnel from the ASCQR Program beginning with the CY 2020 payment determination, as proposed. (2) Measure Removals for the CY 2021 Payment Determination and Subsequent Years For the CY 2021 payment determination and subsequent years, we proposed to remove: (1) Four claimsbased measures under measure removal Factor 1, ‘‘topped-out’’ status; as well as (2) two chart-abstracted measures and (3) one web-based tool measure under proposed measure removal Factor 8. (a) Proposals To Remove Measures Under Removal Factor 1: ASC–1, ASC– 2, ASC–3, and ASC–4 In the proposed rule, beginning with the CY 2021 payment determination and subsequent years, we proposed to remove ASC–1, ASC–2, ASC–3, and ASC–4 under measure removal Factor 1, measure performance among ASCs is so high and unvarying that meaningful distinctions and improvements in performance can no longer be made. The ASCQR Program previously finalized two criteria for determining when a measure is ‘‘topped-out’’: (1) When there is statistically indistinguishable performance at the 75th and 90th percentiles of national facility performance; and (2) when the measure’s truncated coefficient of variation is less than or equal to 0.10 (79 FR 66968 through 66969). In the proposed rule, we referred readers to section XIV.B.3.b. of the proposed rule, where we clarified and discussed how we calculate the TCOV for measures that assess the rate of rare, undesired events for which a lower rate is preferred, such as ASC–1, ASC–2, ASC– 3, and ASC–4. E:\FR\FM\21NOR2.SGM 21NOR2 khammond on DSK30JT082PROD with RULES2 59118 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations For each of these measures, we stated that we believed that removal from the ASCQR Program measure set is appropriate as there is little room for improvement. In addition, removal would alleviate the maintenance costs and administrative burden to ASCs associated with retaining the measures. As such, we stated that we believed the burden associated with reporting these measures outweighs the benefits of keeping them in the program. We also note that in crafting our proposals, we considered removing these measures beginning with the CY 2020 payment determination, but opted to delay removal until the CY 2021 payment determination to be sensitive to facilities’ planning and operational procedures given that data collection for the measures begins during CY 2018 for the CY 2020 payment determination. Each measure is discussed in more detail further below. However, because we received several general comments regarding these proposals as a whole, we are discussing those first. Comment: Many commenters supported all of CMS’ proposals to remove measures from the ASCQR Program. Several commenters specifically supported the removal of ASC–1, ASC–2, ASC–3, and ASC–4. Response: We thank the commenters for their support. Comment: Several commenters opposed CMS’ proposals to remove ASC–1, ASC–2, ASC–3, and ASC–4, noting that although the measures are topped-out, that these measures provide important data for facilities and patients. A few commenters noted that they measure rare events for which the occurrence should be zero and that the measures should not be eliminated in order to continue to prevent and detect these types of occurrences. One commenter stated that measures should not be removed from the program based solely on topped-out status. This commenter recommended that CMS ensure the measure is topped-out for a number of years, evaluate whether there are unintended consequences of removal, and continue monitoring performance on topped-out safety measures. Another commenter expressed concern that variation in measure performance exists between high and low performing States. Another commenter was concerned that if the measures are removed that there may be no other national-level data sources about the quality of care that is being provided in ASCs, and another added that private insurers have started using them as well. Another commenter believed that these measures are crucial because they are applicable to all ASCs VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 and was concerned that there are no other measures in the ASCQR Program that are reported by all ASCs. Response: We thank the commenters for their feedback. The ASCQR Program finalized the ‘‘topped-out’’ methodology to evaluate variation in performance among ASCs (79 FR 66968) consistent with other quality reporting and valuebased programs, including the Hospital OQR (79 FR 66769), Hospital IQR (80 FR 49641 through 49643), Hospital VBP (79 FR 50055), IPFQR (82 FR 38463 through 38465), and PCHQR (81 FR 57182 through 57183) Programs. Our toppedout methodology does not evaluate variation at the State level, but rather at the level of individual ASCs. Our analyses demonstrate that the variation in performance among ASCs for these measures is statistically indistinguishable. As shown in the tables provided for each proposal, facilities have a rate of 100 percent performance at both the 90th and 75th percentiles for the past five years of reporting. Due to public comments, we have reevaluated our data. In the proposed rule, we believed that the measures’ performance among ASCs is so high and unvarying that meaningful distinctions and improvements in performance can no longer be made and that the measures met the criteria for being topped-out. However, we have reviewed many studies, in addition to the public comments we received, that show the importance of measuring and reporting the data for these measures, as discussed in each proposal below. Therefore, we have now come to believe that these measures may be more valuable to stakeholders than we initially perceived in the proposed rule. We agree that it is important to continue to monitor these types of events considering the potential negative impacts to patients’ morbidity and mortality, in order to continue to prevent their occurrence and ensure that they remain rare. We acknowledge that these measures provide critical data to beneficiaries and further transparency for care provided in the ASC setting that would be useful in choosing an ASC for care, and that these measures are valuable to the ASC community. Despite little room for improvement, these measures provide beneficiaries and ASCs with vital information about patient burns, patient falls, wrong site, wrong side, wrong patient, wrong procedure, wrong implant events, and hospital transfers/admissions that take place in the ASC setting and we believe it would be prudent to keep them in the program at this time in order to continue to detect and prevent these PO 00000 Frm 00302 Fmt 4701 Sfmt 4700 events. Further, we acknowledge that having measures that apply to all ASCs provides beneficiaries with the most comprehensive patient safety data to use when making decisions about a site of care. ASC–1, ASC–2, ASC–3, and ASC– 4 are measures for which all ASCs, regardless of specialty area, can submit data in contrast to other measures, such as ASC–14: Unplanned Anterior Vitrectomy, which would only apply to ASCs where specialty-specific procedures are performed, such as ophthalmology procedures in the case of ASC–14. Therefore, we are not finalizing our proposals to remove ASC– 1, ASC–2, ASC–3, and ASC–4. These measures will remain in the program under our measure retention policies, unless we take future action under our measure removal policies. Comment: A few commenters who opposed the removal of these measures were also concerned about the data submitted for them. One commenter expressed concern that only 50 percent of claims are required to have QDCs and questioned how some ASCs are able to report that no errors occurred in their facilities. Another commenter was concerned about the proportion of ASCs that had missing data for these measures, noting that the missing data would affect their eligibility to receive the APU, but does not impact their status as a Medicare provider. Another commenter was concerned about underreporting and recommended that CMS conduct data validation studies and empirical analyses of these measures, particularly for ASC–1, ASC–2, and ASC–3. This commenter also recommended that the denominator for ASC–1, ASC–2, and ASC–3 should only include cases that present risk for the adverse event as utilizing an amplified denominator would provide a false reading of lower rates. A few commenters who supported the removal of these measures suggested that the measures could be redeveloped and submitted via QualityNet in the future. One commenter suggested that revising the data submission method in this way could capture data from all payers. One commenter noted that ASC–1, ASC–2, and ASC–3 specifically should include all patients in the denominator. A few commenters who opposed CMS’ proposals to remove the measures stated that the measures could be redeveloped for all payers and could be reported via QualityNet in order to further reduce burden and ensure data is posted publicly for accountability and for quality improvement. A few commenters recommended that the measures could be included as part of E:\FR\FM\21NOR2.SGM 21NOR2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations khammond on DSK30JT082PROD with RULES2 a composite measure that encompasses the various phases of care. Response: The ASCQR Program is a quality reporting program for which ASCs must meet program requirements including the submission of quality measure data, else they are subject to a two percent reduction in their annual payment update. As a quality reporting program, the data collected is publicly reported in order to aide beneficiaries in choosing sites of care. Our regulations at 42 CFR part 416 detail the requirements that determine a facility’s eligibility to participate as a Medicare supplier of ambulatory surgical services. We will continue to assess our measure set in light of stakeholder concerns and within the framework of our Meaningful Measures Initiative. Currently, ASCs are only able to report adverse events for Medicare feefor-service beneficiaries and that adverse events that have occurred to patients with other payers are not reflected in the currently reported data. As such, it is possible for an ASC to report zero adverse events via the ASCQR Program because no adverse events occurred to Medicare FFS beneficiaries within the reporting period. In addition, we thank the commenters for their suggestions regarding redeveloping the measure to capture all payers and to submit via QualityNet to reduce burden. We note that because the data for these measures are currently collected via Medicare FFS claims, as specified in the Specifications Manual,165 we are unable to include data from other payers for which Medicare does not receive FFS claims. We thank the commenters for the feedback and note that we are also concerned about some of the data submitted for these measures. In the FY 2013 IPPS/LTCH PPS final rule (77 FR 53641), we finalized our policy that the minimum threshold for successful reporting be that at least 50 percent of claims meeting measure specifications contain QDCs. At that time, we believed that 50 percent was a reasonable minimum threshold for the initial implementation years of the ASCQR Program, because ASCs were not yet familiar with how to report quality data 165 Ambulatory Surgical Center Quality Reporting Specifications Manual, v7.0a. Available at: https:// www.qualitynet.org/dcs/ ContentServer?c=Page&pagename= QnetPublic%2FPage%2FQnetTier2&cid=1228772 475754. VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 under the ASCQR Program and because many ASCs are relatively small and may have needed more time to set up reporting systems. We stated in that final rule that we intended to propose to increase this percentage for subsequent years’ payment determinations as ASCs become more familiar with reporting requirements for the ASCQR Program. We have assessed this reporting threshold annually and have found that over 78 percent of reporting ASCs report data for at least 90 percent of eligible claims. However, we believe that the current data submission method for these measures may impact the completeness and accuracy of the data due to the inability of ASCs to correct the QDC codes that are used to calculate these measures from Medicare FFS claims. Currently, a facility that identifies an erroneous or missing QDC code is unable to correct or add a QDC code if the claim has already been submitted to Medicare. We believe that revising the data submission method for the measures, such as via QualityNet, would address this issue and allow facilities to correct any data submissions errors, resulting in more complete and accurate data. Further, we will conduct additional empirical analyses to identify any other potential issues with the data submitted for these measures. We refer readers to section XIV.B.6. of this final rule with comment period, where we discuss public comments received about the potential future validation of ASCQR Program measures. We are committed to work with stakeholders to ensure the ASCQR Program measure set does not place an inappropriate amount of burden on facilities while addressing and providing information about these types of patient safety, adverse, rare events to patients and other consumers. As such, while we will retain ASC–1, ASC–2, ASC–3, and ASC–4 in the program as discussed above, after considering public comments and reevaluating our concerns about data submission, we will also suspend their data collection beginning with the CY 2019 reporting period/CY 2021 payment determination until further action in rulemaking with the goal of updating the data submission method for the measures. In other words, starting with the CY 2021 payment determination, facilities would not be required to submit data for these PO 00000 Frm 00303 Fmt 4701 Sfmt 4700 59119 four measures as part of ASCQR Program requirements although the measures would remain in the ASCQR Program measure set. As we develop future revisions for the data collected for these measures, we will take into consideration other data submission methods that may allow for the reporting of adverse events across payers and will consider commenters’ feedback toward the future updates to the measures. Comment: A few commenters noted that it would be beneficial to also have these measures included in the Hospital OQR Program in order to provide patients with more meaningful data to compare sites of service. Response: We thank the commenters for their feedback. We will take this into consideration for the future. Comment: One commenter stated that the NQF endorsement of these measures was removed because they were allowed to lapse by the measure steward, not because they failed the endorsement maintenance process, and noted that the ASCQR Program did not provide this as a rationale for removing the measures. The commenter noted that all of these measures have ongoing support from the ASC community. Response: NQF endorsement, or lack thereof, does not automatically qualify or disqualify a measure for removal from the ASCQR Program. We thank the commenter for its comment as ASC stakeholder feedback is important, and we will weigh the benefits of support of the ASC community in our consideration of our proposals to ensuring that the ASCQR Program has a robust and responsive measure set. • Proposal To Remove ASC–1: Patient Burn We refer readers to the CY 2012 OPPS/ASC final rule with comment period (76 FR 74497 through 74498) where we adopted ASC–1: Patient Burn beginning with the CY 2014 payment determination (NQF #0263). This claims-based outcome measure assesses the percentage of ASC admissions experiencing a burn prior to discharge. Based on our analysis of ASCQR Program measure data for CYs 2013 to 2017 encounters, the ASC–1 measure meets our measure removal Factor 1. These analyses are captured in the table below. E:\FR\FM\21NOR2.SGM 21NOR2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations As displayed in the analysis above, there is no distinguishable difference in ASC performance between the 75th and 90th percentiles, and the truncated coefficient of variation has been below 0.10 since 2013. In the proposed rule, we also noted that NQF endorsement of this measure (NQF #0263) was removed on May 24, 2016.166 Comment: One commenter specifically opposed the removal of ASC–1, noting that it measures rare, isolated events and that it is valuable to monitor for consumers as a burn measure. Response: We thank the commenter for its feedback. While the measure is topped-out, we acknowledge that it is still valuable. In the CY 2012 OPPS/ASC final rule with comment period (76 FR 74497), we adopted this measure for ASCs because they serve surgical patients who may face the risk of burns during ambulatory surgical procedures and because we agree monitoring patient burns is valuable to patients and other stakeholders. Further, we have reviewed numerous studies demonstrating the high impact of monitoring patient burns due to the large number of surgeries performed in the outpatient setting,167 because patient burns are serious reportable events in healthcare,168 and because of patient burns are preventable.169 170 We note that we are not finalizing our proposal to remove ASC–1 as discussed in the section above. • Proposal To Remove ASC–2: Patient Fall As displayed in the analysis above, there is no distinguishable difference in ASC performance between the 75th and 90th percentiles and the truncated coefficient of variation has been below 0.10 since 2013. Comment: One commenter specifically opposed the removal of ASC–2, noting that ASC–2 measures rare, isolated events and that it is valuable to monitor for consumers as a patient fall measure. Response: We thank the commenter for its feedback. While the measure is topped-out, we acknowledge that it is still valuable. In the CY 2012 OPPS/ASC final rule with comment period (76 FR 74498), we adopted this measure for ASCs because falls, particularly in the elderly, can cause injury and loss of functional status, because the use of anxiolytics, sedatives, and anesthetic agents may put patients undergoing outpatient surgery at increased risk for falls, and because falls in healthcare settings can be prevented through the assessment of risk, care planning, and patient monitoring. Further, we have reviewed numerous studies demonstrating the high impact of monitoring patient burns due to the large number of surgeries performed in the outpatient setting,171 because patient falls are serious reportable events in healthcare,172 and because of patient falls are preventable.173 Because 166 National Quality Forum. Available at: https:// www.qualityforum.org/QPS/0263. 167 U.S. Department of Health and Human Services. Centers for Medicare & Medicaid Services. https://www.cms.gov/. 168 National Quality Forum. Serious Reportable Events in Healthcare 2006 Update. Washington, DC: NQF, 2007. 169 ECRI Institute. New clinical guide to surgical fire prevention. Health Devices 2009 Oct;38(10):314–32. 170 National Fire Protection Association (NFPA). NFPA 99: Standard for health care facilities. Quincy (MA): NFPA; 2005. 171 U.S. Department of Health and Human Services. Centers for Medicare & Medicaid Services. https://www.cms.gov/. 172 National Quality Forum. Serious Reportable Events in Healthcare—2006 Update: A Consensus Report. March 2007. 173 Boushon B, Nielsen G, Quigley P, Rutherford P, Taylor J, Shannon D. Transforming Care at the Bedside How-to Guide: Reducing Patient Injuries from Falls. Cambridge, MA: Institute for Healthcare Improvement; 2008. VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 PO 00000 Frm 00304 Fmt 4701 Sfmt 4700 E:\FR\FM\21NOR2.SGM 21NOR2 ER21NO18.109</GPH> We refer readers to the CY 2012 OPPS/ASC final rule with comment period (76 FR 74498) where we adopted ASC–2: Patient Fall beginning with the CY 2014 payment determination. This NQF-endorsed (NQF #0266), claimsbased measure assesses the percentage of ASC admissions experiencing a fall in the ASC. Based on our analysis of ASCQR Program measure data for CYs 2013 to 2017 encounters, the ASC–2 measure meets our measure removal Factor 1. These analyses are captured in the table below. ER21NO18.108</GPH> khammond on DSK30JT082PROD with RULES2 59120 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations • Proposal To Remove ASC–3: Wrong Site, Wrong Side, Wrong Patient, Wrong Procedure, Wrong Implant As displayed in the analysis above, there is no distinguishable difference in ASC performance between the 75th and 90th percentiles and the truncated coefficient of variation has been below 0.10 since 2013. In the proposed rule, we also noted that NQF endorsement of this measure (NQF #0267) was removed on May 24, 2016.174 Comment: One commenter specifically opposed the removal of ASC–3, noting that although wrong site surgery is infrequent, it is an egregious error. The commenter was concerned that removing the measure would imply that it is no longer important to providers and also noted their belief that because ASCs tend to have more rapid patient turnover that may make them prone to ‘‘never events’’ such as wrong site surgeries. Response: We thank the commenter for its feedback. While the measure is topped-out, we acknowledge that it is still valuable. In the CY 2012 OPPS/ASC final rule with comment period (76 FR 74498 through 74499), we adopted this measure for ASCs because surgeries and procedures performed on the wrong site/side, and wrong patient can result in significant impact on patients, including complications, serious disability or death. We also stated that while the prevalence of such serious errors may be rare, such events are considered serious reportable events. Further, we have reviewed numerous studies demonstrating the high impact of monitoring wrong site, wrong side, wrong patient, wrong procedure, wrong implant procedures and surgeries due to the large number of surgeries performed in the outpatient setting,175 because these types of errors are serious reportable events in healthcare,176 and because of these errors are preventable.177 178 Because of this, we Quality Forum. Available at: https:// www.qualityforum.org/QPS/0267. khammond on DSK30JT082PROD with RULES2 174 National VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 We refer readers to the CY 2012 OPPS/ASC final rule with comment period (76 FR 74498 through 74499) where we adopted ASC–3: Wrong Site, Wrong Side, Wrong Patient, Wrong Procedure, Wrong Implant beginning with the CY 2014 payment determination (NQF #0267). This 175 U.S. Department of Health and Human Services. Centers for Medicare & Medicaid Services. https://www.cms.gov/. 176 National Quality Forum. Serious Reportable Events in Healthcare—2006 Update: A Consensus Report. March 2007. 177 American College of Obstetricians and Gynecologists. ACOG committee opinion #464: patient safety in the surgical environment. Obstet Gynecol. 2010;116(3):786–790. PO 00000 Frm 00305 Fmt 4701 Sfmt 4700 claims-based outcome measure assesses the percentage of ASC admissions experiencing a wrong site, wrong side, wrong patient, wrong procedure, or wrong implant. Based on our analysis of ASCQR Program measure data for CYs 2013 to 2017 encounters, the ASC–3 measure meets our measure removal Factor 1. These analyses are captured in the table below. agree that it is important to monitor this measure in ASCs, which perform a large volume of outpatient surgeries every year. We note that we are not finalizing our proposal to remove ASC–3 as discussed in the previous section. • Proposal To Remove ASC–4: AllCause Hospital Transfer/Admission We refer readers to the CY 2012 OPPS/ASC final rule with comment period (76 FR 74499) where we adopted ASC–4: All-Cause Hospital Transfer/ Admission beginning with the CY 2014 payment determination (NQF #0265). This claims-based outcome measure assesses the rate of ASC admissions requiring a hospital transfer or hospital admission upon discharge from the ASC. Based on our analysis of ASCQR Program measure data for CYs 2013 to 2017 encounters, the ASC–4 measure meets our measure removal Factor 1. These analyses are captured in the table below. 178 Joint Commission. Ambulatory Health Care: 2019 National Patient Safety Goals available at https://www.jointcommission.org/ahc_2017_npsgs/. E:\FR\FM\21NOR2.SGM 21NOR2 ER21NO18.110</GPH> of these concerns, we agree that monitoring patient falls is valuable to patients and other stakeholders. We note that we are not finalizing our proposal to remove ASC–2 as discussed in the previous section. 59121 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations khammond on DSK30JT082PROD with RULES2 As displayed in the analysis above, there is no distinguishable difference in ASC performance between the 75th and 90th percentiles and the truncated coefficient of variation has been below 0.10 since 2013. In the proposed rule, we also noted that NQF endorsement of this measure (NQF #0265) was removed on February 4, 2016.179 Comment: One commenter specifically supported the inclusion of ASC–4 in the ASCQR Program, noting that it believed that the issues surrounding transfers to hospitals, although infrequent, are significant. The commenter noted that it believed that ASCs can only function safely if there is a hospital available to care for patients with unanticipated problems, noting that there can be an unclear and competitive relationship between the ASC and the hospital. Response: While the measure is topped-out, we acknowledge that it is still valuable. In the CY 2012 OPPS/ASC final rule with comment period (76 FR 74499), we adopted this measure for ASCs because the transfer or admission of a surgical patient from an outpatient setting to an acute care setting can be an indication of a complication, serious medical error, or other unplanned negative patient outcome. We also stated that while acute intervention may be necessary in these circumstances, a high rate of such incidents may indicate suboptimal practices or patient selection criteria. Further, we have reviewed numerous studies demonstrating the high impact of monitoring patient transfers and admissions due to the large number of surgeries performed in the outpatient setting,180 and because facilities can take steps to prevent and reduce these types of events.181 182 183 On 179 National Quality Forum. Available at: https:// www.qualityforum.org/QPS/0265. 180 U.S. Department of Health and Human Services. Centers for Medicare & Medicaid Services. https://www.cms.gov/. 181 Coley KC, Williams BA, DaPos SV, Chen C, Smith RB. Retrospective evaluation of unanticipated admissions and readmissions after same day surgery and associated costs. J Clin Anesth. 2002 Aug; 14(5):349–53. VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 this basis, we agree that the issue of patient transfers to hospitals within the ASC setting are significant adverse events to beneficiaries and ASC stakeholders, even if infrequent. Currently, 42 CFR 416.41(b)(3)(i) and (ii) requires ASCs to have a written transfer agreement with a hospital that meets certain Medicare requirements or ensure all physicians performing surgery in the ASC have admitting privileges in a hospital that meets certain Medicare requirements. A written transfer agreement and physician admitting privileges are intended to ensure there is a relationship between the ASC and local hospital that would serve the patient in the event of a medical emergency. We note that changes to these requirements were proposed in the Medicare and Medicaid Programs; Regulatory Provisions To Promote Program Efficiency, Transparency, and Burden Reduction proposed rule (83 FR 47686) due to the difficulty of obtaining these agreements. Over the past 5 years, we have heard from the largest ASC trade association and multiple ASCs that we need to address the widespread issue of the growing number of hospitals that are declining to work with ASCs (either by declining to sign a transfer agreement or by declining to allow admitting privileges to the hospital by physicians who work in ASCs) due to competition between hospital outpatient surgery departments and ASCs. We have continually worked with the ASCs and hospitals directly to resolve this requirement issue. However, we are aware that several facilities have not been able to reach a positive outcome. On September 20, 2018, we issued a proposed rule in the Federal Register titled ‘‘Medicare and Medicaid 182 Fortier J, Chung F, Su J. Unanticipated admission after ambulatory surgery—a prospective study. Can J Anaesth. 1998 Jul;45(7):612–9. 183 Junger A, Klasen J, Benson M, Sciuk G, Hartmann B, Sticher J, Hempelmann G. Factors determining length of stay of surgical day-case patients. Eur J Anaesthesiol. 2001 May;18(5):314– 21. PO 00000 Frm 00306 Fmt 4701 Sfmt 4700 Programs: Regulatory Provisions To Promote Program Efficiency, Transparency, and Burden Reduction’’ (83 FR 47686 through 47762). In that proposed rule (83 FR 47693 through 47694), we discussed proposals regarding ASC transfer agreements and admitting privileges. We noted that we have seen no evidence of negative patient outcomes due to a lack of such transfer agreements and admitting privileges, and research reports published by the ASC Quality Collaborative indicate the national hospital transfer rate from an ASC to a hospital for care is about 1.25 per 1,000 ASC admissions (https://www.cms.gov/ Medicare/Quality-Initiatives-PatientAssessment-Instruments/ASC-QualityReporting/). As we also noted in that proposed rule, ASCs are already required to have personnel trained and available for emergency response when there is a patient in the ASC, and the ASC is expected to provide initial stabilizing treatment until the patient is transferred. Finally, we noted that the current requirement dates back to 1982, when ASCs were a newly emerging medical care option and there was reasonable concern as to needed emergency care being available. As we noted above, we are not finalizing our proposal to remove ASC–4 as discussed in the section above. Comment: One commenter was concerned that ASC–4 only includes data for Medicare patients and the potential for this to skew the data and misrepresent the facility’s transfer rate, and recommended that CMS collect data for all cases regardless of payer type. The commenter was also concerned that by only reporting Medicare data for the measure, that it may create a disincentive for facilities to transfer a Medicare patient because it would raise their transfer rate. Another commenter recommended that CMS expand ASC–4 to include patients who visit a hospital for an inpatient admission or emergency department visit in the days following their ASC procedure. E:\FR\FM\21NOR2.SGM 21NOR2 ER21NO18.111</GPH> 59122 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations khammond on DSK30JT082PROD with RULES2 Response: We do not believe that the ASC–4 measure, as specified in the ASCQR Program Specifications Manual,184 would create a disincentive for facilities to transfer a Medicare patient to a hospital because both the denominator, and the numerator as noted by the commenter, is comprised of all Medicare FFS beneficiaries that have been admitted to the ASC. We also note, that because ASC–4 is a claimsbased measure, it is only able to assess transfer rates for Medicare FFS beneficiaries for which claims are received by CMS. We agree that measuring hospital visits after ASC procedures may be a valuable metric to Medicare beneficiaries and the public due to concerns about patient harm or complications. As such, we have already incorporated multiple measures assessing this area by adopting ASC–12: Facility 7-Day Risk-Standardized Hospital Visit Rate after Outpatient Colonoscopy (79 FR 66970), ASC–17: Hospital Visits After Orthopedic Ambulatory Surgical Center Procedures (82 FR 59454), and ASC–18: Hospital Visits After Urology Ambulatory Surgical Center Procedures (82 FR 59463) into the ASCQR Program measure set. We will continue to evaluate the ASCQR Program measure set to ensure it is robust and responsive to beneficiary needs and thank the commenter for the feedback. We note that we are not finalizing our proposal to remove ASC–4 as discussed in the previous section. (b) Measure Removals Under Removal Factor 8: ASC–9, ASC–10, and ASC–11 In the proposed rule, we proposed to remove three measures (ASC–9, ASC– 10, and ASC–11) under proposed measure removal Factor 8, the costs associated with a measure outweigh the benefit of its continued use in the program, for the CY 2021 payment determination and subsequent years. In the proposed rule, we noted that if proposed measure removal Factor 8 is not finalized, removal of these measures would also not be finalized. The proposals are discussed in more detail below. We note that in crafting our proposals, we considered removing these measures beginning with the CY 2020 payment determination but opted to delay removal until the CY 2021 payment determination to be sensitive to facilities’ planning and operational procedures given that data collection for 184 Version 7.0a of the ASCQR Program Specifications Manual is available at: https:// www.qualitynet.org/dcs/ ContentServer?c=Page&pagename= QnetPublic%2FPage%2FSpecsManualTemplate& cid=1228776140694. VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 these measures begins during CY 2018 for the CY 2020 payment determination. • Proposal To Remove ASC–9: Endoscopy/Polyp Surveillance: Appropriate Follow-Up Interval for Normal Colonoscopy in Average Risk Patients We refer readers to the CY 2014 OPPS/ASC final rule with comment period (78 FR 75127 through 75128) where we adopted ASC–9: Endoscopy/ Polyp Surveillance: Appropriate Follow-up Interval for Normal Colonoscopy in Average Risk Patients (NQF #0659) beginning with the CY 2016 payment determination. This chart-abstracted process measure assesses the ‘‘[p]ercentage of patients aged 50 years and older receiving a screening colonoscopy without biopsy or polypectomy who had a recommended follow-up interval of at least ten (10) years for repeat colonoscopy documented in their colonoscopy report.’’ (78 FR 75127). This measure aims to assess whether average risk patients with normal colonoscopies receive a recommendation to receive a repeat colonoscopy in an interval that is less than the recommended amount of ten (10) years. In the proposed rule, we proposed to remove ASC–9: Endoscopy/Polyp Surveillance Follow-up Interval for Normal Colonoscopy in Average Risk Patients beginning with the CY 2021 payment determination and for subsequent years under our measure removal Factor 8, the costs associated with a measure outweigh the benefit of its continued use in the program. We adopted ASC–9: Endoscopy/Polyp Surveillance Follow-up Interval for Normal Colonoscopy in Average Risk Patients in the CY 2014 OPPS/ASC final rule with comment period (78 FR 75127 through 75128) noting that performing colonoscopy too frequently increases patients’ exposure to procedural harm. However, we noted concern in the proposed rule that the costs of this measure outweigh the benefit of its continued use in the program. Chart-abstraction requires facilities to select a sample population, access historical records from several current and historic clinical data quarters and interpret that patient data. This process is typically more time and resourceconsuming than for other measure types. In addition to submission of manually chart-abstracted data, we take all burden and costs into account when evaluating a measure. We noted in the proposed rule that removing ASC–9 would reduce the burden and cost to facilities associated with collection of PO 00000 Frm 00307 Fmt 4701 Sfmt 4700 59123 information and reviewing their data and performance associated with the measure. However, we also acknowledged that we do not believe the use of chartabstracted measure data alone is sufficient justification for removal of a measure under proposed measure removal Factor 8. The costs of collection and submission of chart-abstracted measure data is burdensome for facilities, especially when taking into consideration the availability of other CMS quality measures that are relevant in the clinical condition and highly correlated in performance across measures. In the proposed rule we noted another colonoscopy-related measure required in the ASCQR Program, ASC– 12: Facility 7-Day Risk-Standardized Hospital Visit Rate after Outpatient Colonoscopy (NQF #2539) which measures all-cause, unplanned hospital visits (admissions, observation stays, and emergency department visits) within seven (7) days of an outpatient colonoscopy procedure (79 FR 66970). This claims-based outcome measure does not require chart-abstraction, and similarly contributes data on quality of care related to colonoscopy procedures, although the measure does not specifically track processes such as follow-up intervals. When we adopted ASC–12, we believed this measure would reduce adverse patient outcomes associated with preparation for colonoscopy, the procedure itself, and follow-up care by capturing and making more visible to facilities and patients all unplanned hospital visits following the procedure (79 FR 66970). Furthermore, in the proposed rule we noted our belief that the potential benefits of keeping ASC–9 in the program are mitigated by the existence of the same measure (Appropriate Follow-up Interval for Normal Colonoscopy in Average Risk Patients) 185 for gastroenterologists in the Merit-Based Incentive Payment System (MIPS) for the 2019 performance period in the QPP (82 FR 30292). Thus, we noted that the issue of preventing harm to patients from colonoscopy procedures that are performed too frequently is adequately addressed through MIPS in the QPP, because we expect a portion of MIPS-eligible clinicians reporting on the measure nationwide to provide meaningful data to CMS. Although MIPS-eligible clinicians may voluntarily select measures from a list of options, ASC providers that are MIPS-eligible will 185 QPP Measure Selection: Appropriate Followup Interval for Normal Colonoscopy in Average Risk Patients. Retrieved from: https://qpp.cms.gov/ mips/quality-measures. E:\FR\FM\21NOR2.SGM 21NOR2 59124 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations khammond on DSK30JT082PROD with RULES2 have the opportunity to continue collecting information for the measure without being penalized if they determine there is value for various quality improvement efforts.186 The availability of this measure in another CMS program demonstrates CMS’ continued commitment to this measure area. Furthermore, we seek to align our quality reporting work with the Patients Over Paperwork and the Meaningful Measures Initiatives described in section I.A.2. of the proposed rule and this final rule with comment period. The purpose of this effort is to hold providers accountable for only the measures that are most important to patients and clinicians and those that are focused on patient outcomes in particular, because outcome measures evaluate the actual results of care. As described in section I.A.2. of the proposed rule and this final rule with comment period, our Meaningful Measures Initiative is intended to reduce costs and minimize burden, and we believe that removing this chartabstracted measure from the ASCQR Program would reduce program complexity. In addition, as we discussed in section XIV.B.3.b. of the proposed rule, where we proposed to adopt measure removal Factor 8, we noted that beneficiaries may find it confusing to see public reporting on the same measure in different programs. Therefore, due to the combination of factors of the costs of collecting data for this chart-abstracted measure, the preference for an outcomes measure in the ASCQR Program that provides valuable data for the same procedure, and the existence of the same measure in another CMS program, we noted in the proposed rule that the burdens and costs associated with this measure outweigh the limited benefit to beneficiaries. As a result, we proposed to remove ASC–9: Endoscopy/Polyp Surveillance: Appropriate Follow-up Interval for Normal Colonoscopy in Average Risk Patients beginning with the CY 2021 payment determination and for subsequent years. We note that the Hospital OQR Program proposed to remove a similar measure, OP–29: Endoscopy/Polyp Surveillance Followup Interval for Normal Colonoscopy in 186 CMS finalized that services furnished by an eligible clinician that are payable under the ASC, HHA, Hospice, or HOPD methodology will not be subject to the MIPS payments adjustments, but eligible clinicians payable under those methodologies may have the option to still voluntarily report on applicable measures and the data reported will not be used to determine future eligibility (82 FR 53586). VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 Average Risk Patients in section XIII.B.4.b. of the proposed rule. Comment: Several commenters opposed CMS’ proposal to remove ASC– 9 from the ASCQR Program. A few commenters expressed concern that physicians may not follow the recommended guidelines for colonoscopy screenings and noted that there is a potential for patient harm from unnecessary colonoscopy screenings that pose significant costs. One commenter suggested that solely retaining the measure in MIPS is insufficient because the measure is voluntary in that program. A few commenters stated that ASC–9 and ASC–12 assess distinct and different aspects of colonoscopies, because ASC– 12 focuses on coordination and does not evaluate the interval between colonoscopies or the appropriate use of care. One commenter noted that ASC– 9 and ASC–12 fall into different Meaningful Measures categories, Preventable Healthcare Harm and Admissions and Readmissions, respectively. These commenters recommended retaining ASC–9 to achieve a holistic approach to measuring the quality of care in this clinical area. One commenter noted that ASC–9 is not overly burdensome to collect and report. Some commenters disagreed with CMS’ assessment that the costs of the measure outweigh the benefit. Response: Although MIPS-eligible clinicians may voluntarily select measures from a list of options, we believe that MIPS reporting would provide some meaningful data in this clinical area. While we proposed to remove this measure because we believed the costs associated with a measure outweigh the benefit of its continued use in the program, after reviewing public comments, we reevaluated our data and analysis. We acknowledge that adherence to clinical guidelines for colonoscopy screening intervals is an important issue due to studies that document inappropriate use.187 188 189 One study showed high rates of inappropriate colonoscopies performed in older adult populations: 10 percent in adults aged 70–75; 39 187 Sheffield et al. 2013. Potentially Inappropriate Screening Colonoscopy in Medicare Patients: Variation by Provider and Geographic Region. JAMA Intern Med. 188 Schoen R. E., Pinsky P. F., Weissfeld J. L., et al. Utilization of surveillance colonoscopy in community practice. Gastroenterology. 2010;138(1):73–81. doi: 10.1053/ j.gastro.2009.09.062. 189 Krist, AH, Jones, RM, Woolf, SH et al. Timing of Repeat Colonoscopy: Disparity Between Guidelines and Endoscopists’ Recommendation. American Journal of Preventive Medicine. 2007. PO 00000 Frm 00308 Fmt 4701 Sfmt 4700 percent in adults aged 76–85; and 25 percent in adults aged ≥86.190 We believe that ASC–9 is a critical measure for the ASCQR Program because there is demonstrated substantial overuse of surveillance colonoscopies among lowrisk patients,191 with research showing that colonoscopies are often recommended at shorter intervals than are advised by guidelines among patients with normal colonoscopy results.192 We believe it is especially important to assess this topic due to the high-volume of these procedures that occur in the outpatient setting. Furthermore, while ASC–9 and ASC– 12 assess the topic of colonoscopies generally, we acknowledge that they assess distinct clinical areas. ASC–12 tracks adverse patient outcomes that result in unplanned hospital visits; ASC–9 provides information about colonoscopies occurring at inappropriate intervals that may contribute to increased costs to beneficiaries and to CMS, a priority of our Meaningful Measures Initiative. While ASC–12 provides vital data about patient outcomes after colonoscopies, ASC–9 focuses on adherence to guideline recommendations for screening colonoscopy follow-up intervals, as noted by NQF’s evaluation report.193 Upon reviewing the measure set as a whole, we now believe that ASC–9 assesses a distinct clinical area not addressed by ASC–12 and as a result, there may be a measurement gap if both ASC–9 and ASC–10 are removed. Further, although we noted that ASC–9 requires the burden of chart-abstraction to report, we believe it is significantly less burdensome than ASC–10 due to the significant burden of obtaining patient histories required for that measure. We also appreciate commenters’ feedback that ASC–9 is not overly burdensome to report. Because this measure tracks the number of beneficiaries who had a recommended follow-up interval of at least 10 years for repeat colonoscopy documented in their 190 Sheffield et al. 2013. Potentially Inappropriate Screening Colonoscopy in Medicare Patients: Variation by Provider and Geographic Region. JAMA Intern Med. 191 Schoen R. E., Pinsky P. F., Weissfeld J. L., et al. Utilization of surveillance colonoscopy in community practice. Gastroenterology. 2010;138(1):73–81. doi: 10.1053/ j.gastro.2009.09.062. 192 Krist, AH, Jones, RM, Woolf, SH et al. Timing of Repeat Colonoscopy: Disparity Between Guidelines and Endoscopists’ Recommendation. American Journal of Preventive Medicine. 2007. 193 NQF #0658 Endoscopy/Polyp Surveillance: Appropriate follow-up interval for normal colonoscopy in average risk patients, Date Submitted: Jul 09, 2012 National Quality Form, Stage 1 Concept Submission and Evaluation Worksheet 1.0. E:\FR\FM\21NOR2.SGM 21NOR2 khammond on DSK30JT082PROD with RULES2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations colonoscopy report, we believe it provides important information to beneficiaries on the avoidance of inappropriate endoscopies/ colonoscopies. ASC–9 evaluates overutilization that can lead to the overuse of resources and unnecessary risks to beneficiaries from possible procedural complications and harms. In section I.A.2. of the proposed rule and this final rule with comment period, we describe our Meaningful Measures Initiative that is intended to reduce costs and minimize burden. We believe that although removing this chart-abstracted measure from the ASCQR Program would reduce program complexity, retaining it provides pertinent information about colonoscopies occurring at inappropriate intervals that may contribute to increased costs to beneficiaries and to CMS, a priority of our Meaningful Measures Initiative. Despite the costs and burdens of chart-abstraction or the presence of other measures assessing a similar clinical topic, after considering incoming comments and reevaluating our data, we now believe ASC–9 is a more critical measure for the ASCQR Program than we initially perceived in the proposed rule. Accordingly, upon further review of the benefits of the measure, we no longer believe that the costs associated with this measure outweigh the benefit of its continued use in the program. Therefore, we are not finalizing our proposal to remove this measure. This measure will remain in the program under our measure retention policies, unless we take future action under our measure removal policies. Comment: A few commenters stated that CMS should retain ASC–9 in order to promote program alignment across outpatient settings and allow for comparisons between facility types. Response: We have considered program alignment by adding and removing measures in tandem for the ASCQR and Hospital OQR Programs so that measures may be compared across facility types, such as ASC–9/OP–29: Endoscopy/Polyp Surveillance: Appropriate Follow-up Interval for Normal Colonoscopy in Average Risk Patients. As noted above, we adopted ASC–9 into the ASCQR Program because we believe it is important for ASCs to be active partners in avoiding inappropriate use and ensuring that beneficiaries at their facilities are referred for follow-up care at appropriate intervals in alignment with current guidelines. As stated above, we are not finalizing our proposal to remove ASC–9. We are similarly VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 retaining the corresponding measure (OP–29) in the Hospital OQR Program in section XIII.B.4.b. of this final rule with comment period. Comment: One commenter did not support CMS’ proposal to remove ASC– 9 because it is included in the CMS Core Quality Measures Collaborative (CQMC) Gastroenterology Core Set and is widely used in the private sector. Response: The CMS CQMC identifies core sets of quality measures that payers have committed to using for reporting as soon as feasible.194 The guiding principles used by the Collaborative in developing the core measure sets are that they be meaningful to patients, consumers, and physicians, while reducing variability in measure selection, collection burden, and cost. The goal is to establish broadly agreed upon core measure sets that could be harmonized across both commercial and government payers.195 We agree that the inclusion of ASC–9 in the CMS CQMC Gastroenterology Core Set speaks to its clinical value. However, although we are retaining ASC–9 for the reasons discussed in this section, we note that the inclusion of measures in the CQMC Core Sets does not necessitate retention in the ASCQR Program. Comment: One commenter recommended that CMS retain ASC–9 and explore how to automate tracking of the information to reduce the resourceintensive use of chart-abstracted data. Another commenter recommended that CMS retain the measure because it could be useful for validation, as it is a chart-abstracted measure. Response: We thank the commenter for the suggestion regarding automated data submission and will take this into consideration for the future. As discussed in section I.A.2 of this final rule with comment period, our Meaningful Measures Initiative prioritizes burden reduction in our quality reporting programs, and we will continue to evaluate the ASCQR Program measure set through this framework. We continually seek opportunities to reduce the reporting burden of our programs, but note that collecting data for ASC–9 still currently requires chart-abstraction. In section XIV.B.6. of this final rule with comment period, we discuss public comments we received on the possible future validation of ASCQR Program measures and will include this comment in our consideration of that 194 Core Measures. Retrieved from: https:// www.cms.gov/Medicare/Quality-Initiatives-PatientAssessment-Instruments/QualityMeasures/CoreMeasures.html. 195 Ibid. PO 00000 Frm 00309 Fmt 4701 Sfmt 4700 59125 request for information. As discussed in detail above, after consideration of the public comments we received, we are not finalizing our proposal to remove ASC–9. Comment: Many commenters supported all of CMS’ proposals to remove measures from the ASCQR Program. Several commenters specifically supported CMS’ proposal to remove ASC–9 from the ASCQR Program, noting that it was developed and tested as a provider-level measure and they did not believe it is appropriate for the ASC setting. A few commenters further stated that this measure is already being reported through the MIPS (formerly PQRS) and that MIPS is the appropriate program because ASC–9 is a provider-level measure. Response: We thank the commenters for their support. As noted in our proposal, this same measure is available through MIPS in the QPP and, although MIPS-eligible clinicians may voluntarily select measures from a list of options, we expect a portion of MIPS-eligible clinicians reporting on the measure nationwide to provide meaningful data to CMS about avoiding inappropriate use. In addition, as noted when we adopted this measure (78 FR 75125), it was specified for the ASC setting and field tested at the ASC facility setting level by the measure steward. Further, we believe it is important for ASCs to be active partners in avoiding inappropriate use and ensuring that patients at their facilities are referred for follow-up care at appropriate intervals in alignment with current guidelines. In addition, after considering the public comments we received and upon further review of the benefits of the measure, we no longer believe that the costs associated with this measure outweigh the benefit of its continued use in the program as this measure assesses a unique and clinically important topic area not covered otherwise addressed by the ASCQR Program measure set. After consideration of the comments we received, we are not finalizing our proposal to remove ASC–9: Endoscopy/ Polyp Surveillance: Appropriate Follow-up Interval for Normal Colonoscopy in Average Risk Patients from the ASCQR Program beginning with the CY 2021 payment determination and for subsequent years. This measure will remain in the program under our measure retention policies, unless we take future action under our measure removal policies. We note that we are also not finalizing our proposal to remove OP–29 under the Hospital OQR Program, and we refer readers to section XIII.B.4.b. of this final E:\FR\FM\21NOR2.SGM 21NOR2 59126 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations khammond on DSK30JT082PROD with RULES2 rule with comment period for more information. • Removal of ASC–10: Endoscopy/ Polyp Surveillance: Colonoscopy Interval for Patients With a History of Adenomatous Polyps—Avoidance of Inappropriate Use We refer readers to CY 2014 OPPS/ ASC final rule with comment period (78 FR 75128) where we adopted ASC–10: Endoscopy/Polyp Surveillance: Colonoscopy Interval for Patients with a History of Adenomatous Polyps— Avoidance of Inappropriate Use (NQF #0659) beginning with the CY 2016 payment determination. This chartabstracted process measure assesses the percentage of patients aged 18 years and older receiving a surveillance colonoscopy, with a history of a prior colonic polyp in previous colonoscopy findings, who had a follow-up interval of 3 or more years since their last colonoscopy documented in the colonoscopy report. In the proposed rule, we proposed to remove ASC–10: Endoscopy/Polyp Surveillance: Colonoscopy Interval for Patients with a History of Adenomatous Polyps—Avoidance of Inappropriate Use beginning with the CY 2021 payment determination and for subsequent years under our proposed measure removal Factor 8, the costs associated with a measure outweigh the benefit of its continued use in the program. We adopted ASC–10: Endoscopy/ Polyp Surveillance: Colonoscopy Interval for Patients with a History of Adenomatous Polyps—Avoidance of Inappropriate Use in the CY 2014 OPPS/ ASC final rule with comment period (78 FR 75128) noting that colonoscopy screening for high risk patients is recommended based on risk factors, and one such factor is a history of adenomatous polyps. The frequency of colonoscopy screening varies depending on the size and amount of polyps found, with the general recommendation of a 3year follow-up. We stated that this measure is appropriate for the measurement of quality of care furnished by ASCs, because colonoscopy screening is commonly performed in these settings (78 FR 75128). However, we now believe that the costs of this measure outweigh the benefit of its continued use in the program. Chart-abstraction requires facilities to select a sample population, access historical records from several clinical data quarters past, and interpret that patient data. This process is typically more time and resource-consuming than for other measure types. In addition to VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 submission of manually chart-abstracted data, we take all burden and costs into account when evaluating a measure. Removing ASC–10 would reduce the burden and cost to facilities associated with collection of information and reporting on their performance associated with the measure. However, we do not believe the use of chart-abstracted measure data alone is sufficient justification for removal of a measure under proposed measure removal Factor 8. The costs of collection and submission of chart-abstracted measure data is burdensome for facilities especially when taking into consideration the availability of other CMS quality measures. Another colonoscopy-related measure required in the ASCQR Program, ASC–12: Facility 7-Day Risk-Standardized Hospital Visit Rate after Outpatient Colonoscopy (NQF #2539) measures allcause, unplanned hospital visits (admissions, observation stays, and emergency department visits) within seven (7) days of an outpatient colonoscopy procedure (79 FR 66970). This claims-based outcome measure does not require chart-abstraction, and similarly contributes data on quality of care related to colonoscopy procedures, although the measure does not specifically track processes such as follow-up intervals. When we adopted ASC–12, we believed this measure would reduce adverse patient outcomes associated with preparation for colonoscopy, the procedure itself, and follow-up care by capturing and making more visible to facilities and patients all unplanned hospital visits following the procedure (79 FR 66970). Furthermore, the potential benefits of keeping ASC– 10 in the ASCQR Program are mitigated by the existence of the same measure (Colonoscopy Interval for Patients with a History of Adenomatous PolypsAvoidance of Inappropriate Use) 196 for gastroenterologists in the Merit-Based Incentive Payment System (MIPS) for the 2019 performance period in the QPP (82 FR 30292). Thus, we believe the issue of preventing harm to patients from colonoscopy procedures that are performed too frequently is adequately addressed through MIPS in the QPP, because we expect a portion of MIPSeligible clinicians reporting on the measure nationwide to provide meaningful data to CMS. Although MIPS-eligible clinicians may voluntarily select measures from a list of options, ASC providers that are MIPS-eligible 196 QPP Measure Selection: Colonoscopy Interval for Patients with a History of Adenomatous Polyps—Avoidance of Inappropriate Use. Retrieved from: https://qpp.cms.gov/mips/quality-measures. PO 00000 Frm 00310 Fmt 4701 Sfmt 4700 will have the opportunity to continue collecting information for the measure without being penalized if they determine there is value for various quality improvement efforts.197 The availability of this measure in another CMS program demonstrates CMS’ continued commitment to this measure area. Furthermore, we seek to align our quality reporting work with the Patients Over Paperwork and the Meaningful Measures Initiatives described in section I.A.2. of the proposed rule and this final rule with comment period. The purpose of this effort is to hold providers accountable for only the measures that are most important to patients and clinicians and that are focused on patient outcomes in particular, because outcome measures evaluate the actual results of care. As described in section I.A.2. of the proposed rule and this final rule with comment period, our Meaningful Measures Initiative is intended to reduce costs and minimize burden, and we believe that removing this chartabstracted measure from the ASCQR Program would reduce program complexity. In addition, as we discussed in section XIV.B.3.b. of the proposed rule, where we proposed to adopt measure removal Factor 8, beneficiaries may find it confusing to see public reporting on the same measure in different programs. Therefore, due to the combination of factors of the costs of collecting data for this chart-abstracted measure, the preference for an outcomes measure in the ASCQR Program that provides valuable data for the same procedure, and the existence of the same measure in the MIPS program, we believe that the burdens and costs associated with manual chart abstraction outweigh the limited benefit to beneficiaries of receiving this information. As a result, we proposed to remove ASC–10: Endoscopy/Polyp Surveillance: Colonoscopy Interval for Patients with a History of Adenomatous Polyps— Avoidance of Inappropriate Use from the ASCQR Program beginning with the CY 2021 payment determination and for subsequent years. We note that we proposed to remove a similar measure from the Hospital OQR Program in section XIII.B.4.b. of the proposed rule. 197 CMS finalized that services furnished by an eligible clinician that are payable under the ASC, HHA, Hospice, or HOPD methodology will not be subject to the MIPS payments adjustments, but eligible clinicians payable under those methodologies may have the option to still voluntarily report on applicable measures and the data reported will not be used to determine future eligibility (82 FR 53586). E:\FR\FM\21NOR2.SGM 21NOR2 khammond on DSK30JT082PROD with RULES2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations Comment: Many commenters supported all of CMS’ proposals to remove measures from the ASCQR Program. Several commenters specifically supported CMS’ proposal to remove ASC–10 from the ASCQR Program because the costs outweigh the benefits of retaining it in the ASCQR Program. One commenter noted that unless the reporting facility was the site of the patient’s previous procedure, the reporting facility would not have the data necessary from their medical records and would need to obtain it from other providers, including the date of the procedure, and the number types, and locations of any polyps found. One commenter recommended that CMS remove ASC–10 beginning with the CY 2020 payment determination, so that facilities may shift resources dedicated to operationalizing the measure sooner. Response: We thank the commenters for their support. In addition to the burden of chart-abstraction, we acknowledge the unique burden of ASC–10, which requires that facilities conduct extensive patient histories and contact other facilities in order to obtain documentation of a history of adenomatous polyps.198 Thus, the costs and burdens are higher for this measure than for the other coloscopy measure considered for removal, ASC–9, which requires less information from patients and does not require historical documentation. Comment: Several commenters noted that ASC–10 was developed and tested as a provider-level measure and they do not believe it is appropriate for the ASC setting. One commenter stated that this measure is already being reported through the MIPS (formerly PQRS) and that MIPS is the appropriate program because ASC–10 is a provider-level measure. Another commenter stated that duplicate reporting in CMS’ quality reporting programs has caused unnecessary provider burden without adding new information to the pool of quality data available to the public. Response: We adopted ASC–10 into the ASCQR Program because we believe it is important for ASCs to be active partners in avoiding inappropriate use and ensuring that beneficiaries at their ASCs are referred for follow-up care at appropriate intervals in alignment with current guidelines. In addition, as noted when we adopted this measure (78 FR 75125), it was specified for the ASC setting and field tested at the ASC setting level by the measure steward. As 198 ASC–10 Measure Information Form. Available at: https://www.qualitynet.org/dcs/ContentServer ?c=Page&pagename=QnetPublic%2FPage%2 FSpecsManualTemplate&cid=1228776607946. VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 noted in our proposal, this same measure is available through MIPS in the QPP and, although MIPS-eligible clinicians may voluntarily select measures from a list of options, we expect a portion of MIPS-eligible clinicians reporting on the measure nationwide to provide meaningful data to CMS about avoiding inappropriate use. As discussed above, we are retaining ASC–9 in order to retain a measure assessing inappropriate use of endoscopies/colonoscopies in the ASCQR Program. After reconsideration, we believe there may be a measurement gap if both ASC–9 and ASC–10 are removed and because of the unique burden associated with ASC–10, we are finalizing our removal of this measure but retaining ASC–9. A primary goal of our Meaningful Measures Initiative is to reduce provider burden through the deduplication of measures across quality reporting programs. Thus, due in part to the duplication of this measure through MIPS in the QPP and the additional burden to ASCs of obtaining patient records, we believe ASC–10 is the more appropriate measure to be removed from the ASCQR Program measure set. Removing ASC–10 while retaining ASC–9 best enables us to assess this important clinical area while ensuring that the costs of measure do not outweigh the benefits. Comment: A few commenters opposed CMS’ proposal to remove ASC– 10 from the ASCQR Program. One commenter noted that ASC–10 is a cost measure and helps avoid inappropriate use or missed opportunities to screen patients that could result in significant harm to beneficiaries. One commenter expressed concern that physicians may not follow the recommended guidelines for colonoscopy screenings and noted that there is a potential for patient harm from unnecessary colonoscopy screenings that poses significant costs. Response: We agree that adherence to clinical guidelines for colonoscopy screening intervals is an important issue. Measuring the inappropriate use of colonoscopy screenings is critical to preventing the waste of resources and potential patient harm. In part for this reason, we are retaining ASC–9 in the ASCQR Program measure set and will continue to require reporting on appropriate follow-up intervals for normal risk patients. We believe that retaining ASC–9 in the ASCQR Program enables us to address concerns regarding patient harm from unnecessary colonoscopy screenings. Further, due to the unique documentation burden specifically for ASC–10, we believe it adds undue PO 00000 Frm 00311 Fmt 4701 Sfmt 4700 59127 burden to ASCs, particularly small ASCs and those that do not have EHRs and is more burdensome than ASC–9. After review of public comments we received, we reevaluated our data and our measure set as a whole. To balance the clinical value of measures with the costs, we believe it is appropriate to retain ASC–9 while finalizing our proposal to remove ASC–10. Comment: One commenter did not support CMS’ proposal to remove ASC– 10 because it is included in the CMS CQMC Gastroenterology Core Set and is widely used in the private sector. Response: The CMS CQMC Gastroenterology Core Set is a set of measures identified as being meaningful to patients, consumers, and physicians, while reducing variability in measure selection, collection burden, and cost and is intended for use by payers who are part of the CQMC.199 Because of this, we believe beneficiaries will continue to receive this data to help them make health care decisions. We agree that this measure is valuable to many stakeholders and support its continued reporting through other quality reporting programs and in the private sector. However, due to the measure’s requirement to obtain historical patient records, we believe that this measure adds undue burden to ASCs, particularly small ASCs and those that do not have EHRs. In addition, we note that the inclusion of measures in the CQMC Core Sets does not necessitate retention in the ASCQR Program. Comment: A few commenters stated that ASC–10 and ASC–12 assess distinct different aspects of colonoscopies, because ASC–12 focuses on care coordination and does not evaluate the interval between colonoscopies or the appropriate use of care. One commenter notes that ASC–10 and ASC–12 fall into different Meaningful Measures categories, Preventable Healthcare Harm and Admissions and Readmissions, respectively. Response: We thank the commenters for their feedback. We agree that ASC– 10 and ASC–12 assess distinct clinical areas, but do assess the topic of colonoscopies generally. While ASC–12 tracks adverse patient outcomes that result in unplanned hospital visits, ASC–10 provides information about colonoscopies occurring at inappropriate intervals for beneficiaries that may contribute to increased costs to beneficiaries and to CMS, a priority of 199 Core Measures. Retrieved from: https:// www.cms.gov/Medicare/Quality-Initiatives-PatientAssessment-Instruments/QualityMeasures/CoreMeasures.html. E:\FR\FM\21NOR2.SGM 21NOR2 59128 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations khammond on DSK30JT082PROD with RULES2 our Meaningful Measures Initiative. However, we believe ASC–10 should be removed because it is uniquely burdensome, as described above, and because our retention of ASC–9 allows us to continue to address inappropriate use of colonoscopy screening. After consideration of the public comments we received, we are finalizing our proposal to remove ASC– 10: Endoscopy/Polyp Surveillance: Colonoscopy Interval for Patients with a History of Adenomatous Polyps— Avoidance of Inappropriate Use from the ASCQR Program beginning with the CY 2021 payment determination and for subsequent years, as proposed. We refer readers to section XIII.B.4.b. of this final rule with comment period where we are removing a similar measure from the Hospital OQR Program. • Proposal To Remove ASC–11: Cataracts: Improvement in Patient’s Visual Function Within 90 Days Following Cataract Surgery We refer readers to the CY 2014 OPPS/ASC final rule with comment period (78 FR 75129) where we adopted ASC–11: Cataracts: Improvement in Patient’s Visual Function within 90 Days Following Cataract Surgery (NQF #1536) beginning with the CY 2016 payment determination. This measure assesses the rate of patients 18 years and older (with a diagnosis of uncomplicated cataract) in a sample who had improvement in visual function achieved within 90 days following cataract surgery based on completing both a preoperative and postoperative visual function survey. Since the adoption of this measure, we came to believe that it can be operationally difficult for ASCs to collect and report the measure (79 FR 66984). Specifically, we were concerned that the results of the survey used to assess the preoperative and postoperative visual function of the patient may not be shared across clinicians and facilities, making it difficult for ASCs to have knowledge of the visual function of the patient before and after surgery (79 FR 66984). We were also concerned about the surveys used to assess visual function; the measure allows for the use of any validated survey and results may be inconsistent should clinicians use different surveys (79 FR 66984). Therefore, on December 31, 2013, we issued guidance stating that we would delay data collection for ASC–11 for three (3) months (data collection would commence with April 1, 2014 encounters) for the CY 2016 payment determination (https:// www.qualitynet.org/dcs/ ContentServer?c=Page&pagename= VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 QnetPublic%2FPage%2FQnetTier3& cid=1228772879036). We issued additional guidance on April 2, 2014, stating that we would further delay the implementation of ASC–11 for an additional 9 months, until January 1, 2015 for the CY 2016 payment determination, due to continued concerns (https://www.qualitynet.org/ dcs/ContentServer?c=Page&pagename= QnetPublic%2FPage%2FQnetTier3& cid=1228773811586). As a result of these concerns, in the CY 2015 OPPS/ ASC final rule with comment period (79 FR 66984 through 66985), we finalized our proposal to allow voluntary data collection and reporting of this measure beginning with the CY 2017 payment determination and for subsequent years. In the proposed rule, we proposed to remove ASC–11: Cataracts: Improvement in Patient’s Visual Function within 90 Days Following Cataract Surgery from the ASCQR Program beginning with the CY 2021 payment determination under proposed measure removal Factor 8, the costs associated with the measure outweigh the benefit of its continued use in the program. We originally adopted ASC–11 because we believe ASCs should be a partner in care with physicians and other clinicians using their facility and that this measure would provide an opportunity to do so (79 FR 66984). However, in light of the history of complications and upon reviewing this measure within our Meaningful Measures framework, we have concluded that it is overly burdensome for ASCs to report this measure due to the difficulty of tracking care that occurs outside of the ASC setting. In order to report on this measure to CMS, a facility would need to obtain the visual function assessment results from the appropriate ophthalmologist and ensure that the assessment utilized is validated for the population for which it is being used. If the assessment is not able to be used or is not available, the ASC would then need to administer the survey directly and ensure that the same visual function assessment tool is utilized preoperatively and postoperatively. There is no simple, preexisting means for information sharing between ophthalmologists and ASCs, so an ASC would need to obtain assessment results from each individual patient’s ophthalmologist both preoperatively and postoperatively. The high administrative costs of the technical tracking of this information presents an undue cost, and also burden associated with submission and reporting of ASC–11 to CMS, especially for small ASCs with limited staffing capacity. PO 00000 Frm 00312 Fmt 4701 Sfmt 4700 Furthermore, this measure currently provides limited benefits. Since making the measure voluntary, only 118 ASCs have reported this measure to CMS, compared to approximately 5,121 total ASCs for all other measures, resulting in only 2.3 percent of ASC reporting.200 Consequently, we have been unable to uniformly offer pertinent information to beneficiaries on how the measure assesses ASC performance. This reinforces comments made in the CY 2015 OPPS/ASC final rule with comment period, in which commenters expressed concern that the voluntary reporting of this measure would result in incomplete data that may be confusing to beneficiaries and other consumers (79 FR 66984). As we state in section I.A.2. of the proposed rule and this final rule with comment period, we strive to ensure that beneficiaries are empowered to make decisions about their healthcare using information from data-driven insights. Because of the lack of sufficient data, this measure may be difficult for beneficiaries to interpret or use to aid in their choice of where to obtain care; thus, the benefits of this measure are limited. Therefore, we stated that we believed the high technical and administrative costs of this measure outweigh the limited benefit associated with its continued use in the ASCQR Program. As discussed in section I.A.2. of the proposed rule and this final rule with comment period, our Meaningful Measures Initiative is intended to reduce costs and minimize burden. We believed that removing this measure from the ASCQR Program will reduce program burden, costs, and complexity. As a result, we proposed to remove ASC–11 beginning with the CY 2021 payment determination and for subsequent years. We also proposed to remove a similar measure under the Hospital OQR Program in section XIII.B.4.b. of the proposed rule. Comment: A few commenters opposed all of CMS’ proposals to remove measures, including ASC–11. Response: In response to the commenters who requested that measures, including ASC–11, be retained, we reevaluated our measures and data. We found that a core group of ASCs (between 107 and 137 for each year between the CY 2017 through CY 2019 payment determinations) report on this voluntary measure. Although only a subset of ASCs voluntarily report this measure, we believe it is considered 200 ASCQR Compare Data. Available at: https:// data.medicare.gov/Hospital-Compare/AmbulatorySurgical-Quality-Measures-Facility/4jcv-atw7/data. E:\FR\FM\21NOR2.SGM 21NOR2 khammond on DSK30JT082PROD with RULES2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations very meaningful by those ASCs that do report because these facilities do so consistently (38 ASCs submitted consistently for the CY 2017 through CY 2019 payment determinations). Because this subset of ASCs has consistently reported this measure we are able to make the data publicly available year after year—in this case, for the CYs 2017, 2018, and 2019 payment determinations.201 We think providing data on this voluntary measure is still helpful for the public because it shows how an ASC performs over time and in comparison to other ASCs even if compared to a small group of ASCs. Furthermore, this is the only measure in the ASCQR Program measure set that deals with cataract surgery, which is commonly performed in the ASC setting. If it is removed, the program will have a gap in coverage for this clinical area. As a result, we now believe that meaningful information can be provided to consumers regarding those facilities. In addition, when this measure was made voluntary in the CY 2015 OPPS/ASC final rule with comment period (79 FR 66984) commenters stated that the measure would promote and improve care coordination among providers. Furthermore, we have reassessed our evaluation that the costs of this measure outweigh the benefits. Due to the voluntary nature of the measure, we believe that it is inherently not more burdensome than valuable. Because ASCs are not required to submit data, those that do not have the capacity to report, do not have to, thus creating no extra burden. Those that do report, do so voluntarily and have continued to report over the years—specifically since the CY 2015 reporting period—despite any burdens. Because of this, we believe the measure is meaningful to the core group of facilities that do consistently report. Therefore, we are not finalizing our proposal to remove ASC–11: Cataracts: Improvement in Patient’s Visual Function within 90 Days Following Cataract Surgery from the ASCQR Program beginning with the CY 2021 payment determination and for subsequent years. This measure will remain in the program under our measure retention policies, unless we take future action under our measure removal policies. Comment: Many commenters supported all of CMS’ proposals to remove measures from the ASCQR 201 Hospital Compare ASCQR: https:// www.medicare.gov/hospitalcompare/ascascqr.html. VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 Program. Several commenters specifically supported CMS’ proposal to remove ASC–11 and agreed with CMS’ assessment that the costs of this measure outweigh the benefit of retaining it in the ASCQR Program. One commenter remarked that the lack of consistent data and the difficulty of abstracting the data from ophthalmologists’ medical records posed a significant and unacceptable data collection burden for the measure. One commenter recommended that CMS remove ASC–11 beginning with the CY 2020 payment determination, so that ASCs may shift resources dedicated to operationalizing the measure sooner. Response: We thank the commenters for their support. As noted in the proposed rule, we agree that data collection for this measure may be difficult, and as a result in the CY 2015 OPPS/ASC final rule with comment period (79 FR 66984 through 66985), we finalized our proposal to allow voluntary data collection and reporting of this measure beginning with the CY 2017 payment determination and for subsequent years. However, we believe ASCs should be a partner in care with physicians and other clinicians using their facility and this measure is an opportunity for hospitals to demonstrate this capability if they choose to report it. In addition, as noted above, we no longer believe that the costs of this measure outweigh the benefits, as the measure is meaningful. Further, while data collection for this measure can be difficult, those facilities that choose to report do so year after year despite any burdens. Comment: Several commenters noted that the measure was endorsed by the NQF as a physician-level, rather than facility-level, measure and that therefore it was never intended for the ASC setting. A few commenters noted that the measure is included in the MIPS (former PQRS Program) as a clinicianlevel measure and is therefore redundant in the ASC setting. One commenter noted that as a voluntary measure, ASC–11 did not have widespread participation and therefore had minimal impact on the care of patients. Response: As we noted when we adopted this measure (78 FR 75125), it was specified for the ASC setting and field tested at the ASC facility setting level by the measure steward. We believe it is important for ASCs to be active partners in ensuring improvement in patients’ visual function following cataract surgeries. As commenters correctly noted, this same PO 00000 Frm 00313 Fmt 4701 Sfmt 4700 59129 measure is available through MIPS in the QPP and, although MIPS-eligible clinicians may voluntarily select measures from a list of options, and we expect a portion of MIPS-eligible clinicians reporting on the measure nationwide to provide meaningful data to CMS about this important outcome for beneficiaries. We agree that as a voluntary measure that only a subset of ASCs participating in the ASCQR Program reported on the measure, but note it is a meaningful measure to beneficiaries given that our analyses show that a consistent group of facilities report data on this measure. So, while data is not available for all facilities, the data that is available is meaningful. After consideration of the public comments we received, we are not finalizing our proposal to remove ASC– 11: Cataracts: Improvement in Patient’s Visual Function within 90 Days Following Cataract Surgery from the ASCQR Program beginning with the CY 2021 payment determination and for subsequent years. We also note that we are retaining a similar measure under the Hospital OQR Program, OP–31: Cataracts: Improvement in Patient’s Visual Function within 90 Days Following Cataract Surgery in section XIII.B.4.b.(2)(a) of this final rule with comment period. 4. ASCQR Program Quality Measures Adopted in Previous Rulemaking We refer readers to the CY 2018 OPPS/ASC final rule with comment period (82 FR 59470) for the previously finalized ASCQR Program measure set for the CY 2020 payment determination and subsequent years. 5. Summary of ASCQR Program Quality Measure Sets Finalized for the CY 2020, CY 2021, and CY 2022 Payment Determinations In the CY 2019 OPPS/ASC proposed rule, we did not propose any new measures for the ASCQR Program. The tables below summarize the ASCQR Program measure sets as finalized in this final rule with comment period for the CY 2020, 2021, and 2022 payment determinations (including previously adopted measures and measures finalized for removal in this final rule with comment period). We note that the tables reflect that we are finalizing our proposal to change the reporting period for one previously adopted measure, ASC–12, and we refer readers to section E:\FR\FM\21NOR2.SGM 21NOR2 59130 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations XIV.D.4.b. of this final rule with comment period for details. BILLING CODE 4120–01–P Finalized ASCQR Program Measure Set for the CY 2020 Payment Determination and Subsequent Years ASC# NQF# Measure Name ASC-1 Patient Burn 0263t ASC-2 0266 Patient Fall ASC-3 Wrong Site, Wrong Side, Wrong Patient, Wrong Procedure, 0267t Wrong Implant 0265T ASC-4 All-Cause Hospital Transfer/Admission ASC-9 Endoscopy/Polyp Surveillance: Appropriate Follow-Up Interval 0658 for Normal Colonoscopy in Average Risk Patients ASC-10 0659 Endoscopy/Polyp Surveillance: Colonoscopy Interval for Patients with a History of Adenomatous Polyps-Avoidance of Inappropriate Use ASC-11 1536 Cataracts: Improvement in Patient's Visual Function within 90 Days Following Cataract Surgery* ASC-12 2539 Facility 7-Day Risk-Standardized Hospital Visit Rate after Outpatient Colonoscopy ASC-13 None Normothermia Outcome ASC-14 None Unplanned Anterior Vitrectomy ASC-15a None OAS CARPS- About Facilities and Staff** ASC-15b None OAS CARPS- Communication About Procedure** ASC-15c None OAS CARPS - Preparation for Discharge and Recovery** OAS CARPS- Overall Rating of Facility** ASC-15d None ASC-15e None OAS CARPS- Recommendation of Facility** t NQF endorsement was removed. VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 PO 00000 Frm 00314 Fmt 4701 Sfmt 4700 E:\FR\FM\21NOR2.SGM 21NOR2 ER21NO18.112</GPH> khammond on DSK30JT082PROD with RULES2 * Measure voluntarily collected effective beginning with the CY 2017 payment determination as set forth in section XIV.E.3.c. of the CY 2015 OPPS/ASC final rule with comment period (79 FR 66984 through 66985). **Measure fmalized for delay in reporting beginning with the CY 2020 payment determination (CY 2018 data collection) until further action in future rulemaking as discussed in section XIV.B.4. of the CY 2018 OPPS/ASC fmal rule with comment period (82 FR 59450 through 59451). Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations 59131 Finalized ASCQR Program Measure Set for the CY 2021 Payment Determination and Subsequent Years ASC# NQF# Measure Name ASC-1 Patient Burn* 0263t ASC-2 0266 Patient Fall* ASC-3 Wrong Site, Wrong Side, Wrong Patient, Wrong Procedure, 0267t Wrong Implant* 0265T ASC-4 All-Cause Hospital Transfer/Admission* ASC-9 Endoscopy/Polyp Surveillance: Appropriate Follow-Up Interval 0658 for Normal Colonoscopy in Average Risk Patients ASC-11 Cataracts: Improvement in Patient's Visual Function within 1536 90 Days Following Cataract Surgery** ASC-12 Facility 7-Day Risk-Standardized Hospital Visit Rate after 2539 Outpatient Colonoscopy ASC-13 None Normothermia Outcome ASC-14 None Unplanned Anterior Vitrectomy OAS CARPS- About Facilities and Staff*** ASC-15a None ASC-15b None OAS CARPS- Communication About Procedure*** OAS CARPS- Preparation for Discharge and Recovery*** ASC-15c None ASC-15d None OAS CARPS- Overall Rating of Facility*** OAS CARPS- Recommendation of Facility*** ASC-15e None t NQF endorsement was removed. VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 PO 00000 Frm 00315 Fmt 4701 Sfmt 4700 E:\FR\FM\21NOR2.SGM 21NOR2 ER21NO18.113</GPH> khammond on DSK30JT082PROD with RULES2 * Measure fmalized for suspension in reporting beginning with the CY 2021 payment determination (CY 2019 data collection) until further action in future rulemaking as discussed in section XIV.B.3.c.(2)(a) of this fmal rule with comment period. ** Measure voluntarily collected effective beginning with the CY 2017 payment determination as set forth in section XIV.E.3.c. of the CY 2015 OPPS/ASC final rule with comment period (79 FR 66984 through 66985). ***Measure fmalized for delay in reporting beginning with the CY 2020 payment determination (CY 2018 data collection) until further action in future rulemaking as discussed in section XIV.B.4. of the CY 2018 OPPS/ASC fmal rule with comment period (82 FR 59450 through 59451). Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations BILLING CODE 4120–01–C khammond on DSK30JT082PROD with RULES2 6. ASCQR Program Measures and Topics for Future Consideration: Possible Future Validation of ASCQR Program Measures In the CY 2019 OPPS/ASC proposed rule (83 FR 37204), we requested public comment on the possible future validation of ASCQR Program measures. There is currently no validation of ASCQR measure data, and we believe ASCs may benefit from the opportunity to better understand their data and examine potential discrepancies. We believe the ASCQR Program may similarly benefit from the opportunity to produce a more reliable estimate of whether an ASC’s submitted data have VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 been abstracted correctly and provide more statistically reliable estimates of the quality of care delivered in each selected ASC as well as at the national level. We believe the Hospital OQR Program validation policy could be a good model for the ASCQR Program and are requesting comment on the validation methodology and identifying one measure with which to start. The Hospital OQR Program requires validation of its chart-abstracted measures. We refer readers to the CY 2013 OPPS/ASC final rule with comment period (77 FR 68484 through 68487) and the CY 2015 OPPS/ASC final rule with comment period (79 FR 66964 through 66965) for a discussion of finalized policies regarding Hospital PO 00000 Frm 00316 Fmt 4701 Sfmt 4700 OQR Program validation requirements, which are also codified at 42 CFR 419.46(e). Under the Hospital OQR Program, CMS selects a random sample of 450 hospitals and an additional 50 hospitals based on the following criteria: (1) The hospital failing of the validation requirement that applies to the previous year’s payment determination; or (2) the hospital having an outlier value for a measure based on data that it submits. An ‘‘outlier value’’ is defined as a measure value that is greater than 5 standard deviations from the mean of the measure values for other hospitals, and indicates a poor score. Then, CMS or its contractor provides written requests to the randomly selected hospitals by requesting E:\FR\FM\21NOR2.SGM 21NOR2 ER21NO18.114</GPH> 59132 khammond on DSK30JT082PROD with RULES2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations supporting medical record documentation used for purposes of data submission under the program. The hospital must submit the supporting medical record documentation within 45 days of the date written in the request. A hospital meets the validation requirement with respect to a calendar year if it achieves at least a 75 percent reliability score, as determined by CMS. Specifically, for the ASCQR Program, we are interested in the validation of chart-abstracted measures. We believe it would be beneficial to start with validation of just one measure, such as ASC–13: Normothermia Outcome, prior to expanding to more measures. ASC– 13: Normothermia Outcome was finalized in the 2017 OPPS/ASC final rule with comment period (81 FR 79798 through 79801) and assesses the percentage of patients having surgical procedures under general or neuraxial anesthesia of 60 minutes or more in duration who are normothermic within 15 minutes of arrival in the postanesthesia care unit. We also considered starting with ASC–14: Unplanned Anterior Vitrectomy instead, which was finalized in the 2017 OPPS/ASC final rule with comment period (81 FR 79801 through 79803) and assesses the percentage of cataract surgery patients who have an unplanned anterior vitrectomy. However, we believe ASC– 13 would be the most feasible measure for validation because it assesses surgical cases and would have a larger population of cases from which to sample. ASC–14, which assesses rare, unplanned events that are less common, would have a smaller population of cases from which to sample. Therefore, we invited public comment on the possible future validation of ASCQR Program measures. We specifically request comment on whether Hospital OQR Program’s validation policies could be an appropriate model for the ASCQR Program, the possible ASC sample size, sampling methodology, number of cases to sample, validation score methodology, and reduced annual payment updates for facilities that do not pass validation requirements. We also requested comment on possibly starting with only one measure, specifically ASC–13, before expanding to more measures. Comment: A few commenters supported the possible validation of ASCQR Program data through a program similar to Hospital OQR Program validation. These commenters noted that this would further align the programs and provide accountability for the accuracy of reporting. VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 Response: We thank the commenters for their support. Comment: One commenter opposed validation of ASCQR Program measures, citing the cost and burden to providers and CMS. This commenter recommended that CMS instead invest in ways to receive timelier and meaningful data related to patient quality and safety. One commenter was concerned about the burden to ASCs of the validation process due to the low level of EHR adoption among ASCs as compared to hospital outpatient departments, noting that the majority of ASCs may need to submit paper records. Response: We thank the commenters for their feedback regarding additional program impact of validation for the ASCQR Program. As noted above, we will take facility burden into consideration regarding the selection of measures for the potential future validation of ASCQR Program measures. Comment: One commenter was concerned that setting the sample size of ASCs at or around 500, comparable to Hospital OQR Program, would represent a significantly larger percentage of ASCs reporting chart-abstracted measures under the ASCQR Program than under the Hospital OQR Program. The commenter recommended that a smaller number of ASCs be selected for validation, perhaps based on the percentage of HOPDs selected for validation under the Hospital OQR Program. Another commenter stated that a similar random sample to the Hospital OQR Program (450 ASCs) could be utilized, as well as an additional number of ASC’s with outlier values. One commenter was concerned about ASCs that fail to record adverse events and recommended that CMS develop additional sampling criteria based on selecting ASCs that have a ‘‘good score’’ outlier rate. Response: We thank the commenters for their suggestions regarding sampling for any validation scheme considered for the ASCQR Program and will take these into consideration as we move forward. Comment: A few commenters supported beginning validation with only one measure, with one noting it would allow participants time to understand the program and its implications for payment. Some commenters supported using ASC–13 as an initial measure for validation within the ASCQR Program, with a few commenters noting it is an important and prescient measure for outpatient settings. Response: We thank the commenters for their feedback supporting validation for the ASCQR Program and the possible PO 00000 Frm 00317 Fmt 4701 Sfmt 4700 59133 use of ASC–13 for this purpose. We agree that it is most feasible to begin potential future validation of measures in the ASCQR Program with a single measure. Comment: A few commenters expressed concern about using ASC–13 as an initial measure for validation within the ASCQR Program. One commenter noted their belief that ASC– 13 is not indicative of care at an ASC. Another commenter expressed concern that ASC–13 is reported as a sample with an aggregated-web based metric and that patient-level information is not submitted by ASCs. One commenter was concerned about incongruent definitions of normothermia among quality reporting programs and recommended that if discrepancies are found during the validation process that anesthesia professionals be held harmless. Another commenter stated that ASC–14 would be a better initial measure for validation, noting that cases requiring general or neuraxial anesthesia are less common than cataract surgery and would likely have a smaller population of cases from which to sample. Response: We thank the commenters for their feedback and will further examine ASC–13 and ASC–14 case volumes, appropriate methods of validation of aggregated web-based metrics, and normothermia definitions among quality reporting programs. Comment: A commenter noted that not all ASCs report data for ASC–13 and ASC–14 due to not performing cases involving general/neuraxial anesthesia of 60 minutes or more in duration (ASC–13) and/or cataract surgery (ASC– 14), and noted their concern that ASCs that do report these measure would bear more burden and be required to meet a higher threshold for retaining their APU. The commenter recommended only selecting measures for validation that are applicable to all ASCs. Another commenter recommended that all measures should be validated, with the prioritization for ASC–1, ASC–2, and ASC–3 in order to study closely the occurrence of adverse events. A commenter recommended that the ASCQR Program implement validation only when more manually abstracted measures are added to the program, noting that implementing a validation process for a small number of measures is burdensome and may yield only limited value to CMS. Response: We thank the commenters for their feedback regarding alternate measures to consider for validation under the ASCQR Program. We agree that the percentage of ASCs actually reporting on a measure is an important E:\FR\FM\21NOR2.SGM 21NOR2 59134 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations khammond on DSK30JT082PROD with RULES2 consideration in choosing measures for validation. We will investigate the feasibility of validating ASC–1, ASC–2, and ASC–3. We will further assess the potential burden impact of the potential future validation of any ASCQR Program measures. We note that one of the goals of our Meaningful Measures Initiative is to move the ASCQR Program forward in the least burdensome manner possible, while maintaining a parsimonious set of meaningful quality measures. Comment: One commenter was concerned that ASCs submit aggregated web-based data on an annual basis and that sampling is allowed for the submission of ASC–13 data without patient identifying information. The commenter recommended that CMS consider selection bias if ASC–13 data is validated. Response: We thank the commenter for its feedback and agree that there is a potential for selection bias if the aggregated web-based data for ASC–13 is validated. We will take this potential for selection bias into consideration as we craft future policy. We thank the commenters for their views and will take them into consideration as we determine future policy regarding validation in the ASCQR Program. 7. Maintenance of Technical Specifications for Quality Measures We refer readers to the CY 2012 OPPS/ASC final rule with comment period (76 FR 74513 through 74514), where we finalized our proposal to follow the same process for updating the ASCQR Program measures that we adopted for the Hospital OQR Program measures, including the subregulatory process for updating adopted measures. In the CY 2013 OPPS/ASC final rule with comment period (77 FR 68496 through 68497), the CY 2014 OPPS/ASC final rule (78 FR 75131), and the CY 2015 OPPS/ASC final rule with comment period (79 FR 66981), we provided additional clarification regarding the ASCQR Program policy in the context of the previously finalized Hospital OQR Program policy, including the processes for addressing nonsubstantive and substantive changes to adopted measures. In the CY 2016 OPPS/ASC final rule with comment period (80 FR 70531), we provided clarification regarding our decision to not display the technical specifications for the ASCQR Program on the CMS website, but stated that we will continue to display the technical specifications for the ASCQR Program on the QualityNet website. In addition, our policies regarding the maintenance of VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 technical specifications for the ASCQR Program are codified at 42 CFR 416.325. In the CY 2019 OPPS/ASC proposed rule (83 FR 37204), we did not propose any changes to our policies regarding the maintenance of technical specifications for the ASCQR Program. 8. Public Reporting of ASCQR Program Data In the CY 2012 OPPS/ASC final rule with comment period (76 FR 74514 through 74515), we finalized a policy to make data that an ASC submitted for the ASCQR Program publicly available on a CMS website after providing an ASC an opportunity to review the data to be made public. In the CY 2016 OPPS/ASC final rule with comment period (80 FR 70531 through 70533), we finalized our policy to publicly display data by the National Provider Identifier (NPI) when the data are submitted by the NPI and to publicly display data by the CCN when the data are submitted by the CCN. In addition, we codified our policies regarding the public reporting of ASCQR Program data at 42 CFR 416.315 (80 FR 70533). In the CY 2017 OPPS/ASC final rule with comment period (81 FR 79819 through 79820), we formalized our current public display practices regarding timing of public display and the preview period by finalizing our proposals to: Publicly display data on the Hospital Compare website, or other CMS website as soon as practicable after measure data have been submitted to CMS; to generally provide ASCs with approximately 30 days to review their data before publicly reporting the data; and to announce the timeframes for each preview period starting with the CY 2018 payment determination on a CMS website and/or on our applicable listservs. In the CY 2018 OPPS/ASC final rule with comment period (82 FR 59455 through 59470), we discussed specific public reporting policies associated with two measures beginning with the CY 2022 payment determination: ASC–17: Hospital Visits after Orthopedic Ambulatory Surgical Center Procedures, and ASC–18: Hospital Visits after Urology Ambulatory Surgical Center Procedures. In the CY 2019 OPPS/ASC proposed rule (83 FR 37204 through 37205), we did not propose any changes to our public reporting policies. C. Administrative Requirements 1. Requirements Regarding QualityNet Account and Security Administrator We refer readers to the CY 2014 OPPS/ASC final rule with comment period (78 FR 75132 through 75133) for PO 00000 Frm 00318 Fmt 4701 Sfmt 4700 a detailed discussion of the QualityNet security administrator requirements, including setting up a QualityNet account, and the associated timelines, for the CY 2014 payment determination and subsequent years. In the CY 2016 OPPS/ASC final rule with comment period (80 FR 70533), we codified the administrative requirements regarding maintenance of a QualityNet account and security administrator for the ASCQR Program at 42 CFR 416.310(c)(1)(i). In the CY 2018 OPPS/ ASC final rule (82 FR 59473), we finalized expanded submission via the CMS online tool to also allow for batch data submission and made corresponding changes to the 42 CFR 416.310(c)(1)(i). In the CY 2019 OPPS/ ASC proposed rule (83 FR 37205), we did not propose any changes to these policies. 2. Requirements Regarding Participation Status We refer readers to the CY 2014 OPPS/ASC final rule with comment period (78 FR 75133 through 75135) for a complete discussion of the participation status requirements for the CY 2014 payment determination and subsequent years. In the CY 2016 OPPS/ ASC final rule with comment period (80 FR 70533 and 70534), we codified these requirements regarding participation status for the ASCQR Program at 42 CFR 416.305. In the CY 2019 OPPS/ASC proposed rule (83 FR 37205), we did not propose any changes to these policies. D. Form, Manner, and Timing of Data Submitted for the ASCQR Program 1. Requirements Regarding Data Processing and Collection Periods for Claims-Based Measures Using Quality Data Codes (QDCs) We refer readers to the CY 2014 OPPS/ASC final rule with comment period (78 FR 75135) for a complete summary of the data processing and collection periods for the claims-based measures using QDCs for the CY 2014 payment determination and subsequent years. In the CY 2016 OPPS/ASC final rule with comment period (80 FR 70534), we codified the requirements regarding data processing and collection periods for claims-based measures using QDCs for the ASCQR Program at 42 CFR 416.310(a)(1) and (2). In the CY 2019 OPPS/ASC proposed rule (83 FR 37205), we did not propose any changes to these requirements. However, in the proposed rule we noted that in section XIV.B.3.c. of the proposed rule, beginning with the CY 2021 payment determination and for subsequent years, we proposed to E:\FR\FM\21NOR2.SGM 21NOR2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations remove all four claims-based measures currently using QDCs: • ASC–1: Patient Burn; • ASC–2: Patient Fall; • ASC–3: Wrong Site, Wrong Side, Wrong Patient, Wrong Procedure, Wrong Implant; and • ASC–4: Hospital Transfer/ Admission. We are not finalizing our proposals to remove ASC–1, ASC–2, ASC–3, and ASC–4, as described further in section XIV.B.3.c.(2)(a) of this final rule with comment period, and are instead retaining the measures in the ASCQR Program and suspending their data collection beginning with the CY 2019 reporting period/CY 2021 payment determination until further action in rulemaking with the goal of updating the measures. However, we did not propose any changes to our requirements regarding data processing and collection periods for these types of measures. These requirements will apply to any future claims-based measures using QDCs adopted in the program. 2. Minimum Threshold, Minimum Case Volume, and Data Completeness for Claims-Based Measures Using QDCs We refer readers to the CY 2018 OPPS/ASC final rule with comment period (82 FR 59472) (and the previous rulemakings cited therein), as well as 42 CFR 416.310(a)(3) and 42 CFR 416.305(c) for our policies about minimum threshold, minimum case volume, and data completeness for claims-based measures using QDCs. In the CY 2019 OPPS/ASC proposed rule (83 FR 37205), we did not propose any changes to these policies. khammond on DSK30JT082PROD with RULES2 3. Requirements for Data Submitted via an Online Data Submission Tool We refer readers to the CY 2018 OPPS/ASC final rule with comment period (82 FR 59472) (and the previous rulemakings cited therein) and 42 CFR 416.310(c) for our previously finalized policies for data submitted via an online data submission tool. For more information on data submission using QualityNet, we refer readers to: https:// www.qualitynet.org/dcs/ContentServer ?c=Page&pagename=QnetPublic %2✖QnetTier2&cid=1228773314768. a. Requirements for Data Submitted via a Non-CMS Online Data Submission Tool We refer readers to the CY 2014 OPPS/ASC final rule with comment period (78 FR 75139 through 75140) and the CY 2015 OPPS/ASC final rule with comment period (79 FR 66985 through 66986) for our requirements regarding VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 data submitted via a non-CMS online data submission tool (that is, the CDC NHSN website). We codified our existing policies regarding the data collection time periods for measures involving online data submission and the deadline for data submission via a non-CMS online data submission tool at 42 CFR 416.310(c)(2). Currently, we only have one measure (ASC–8: Influenza Vaccination Coverage among Healthcare Personnel) that is submitted via a non-CMS online data submission tool. In the proposed rule, we noted that we proposed this measure for removal for the CY 2020 payment determination and subsequent years in section XIV.B.3.c. of the proposed rule. Because we are finalizing the removal of ASC–8 as proposed, no measures submitted via a non-CMS online data submission tool will remain in the ASCQR Program beginning with the CY 2020 payment determination. However, we did not propose any changes to our non-CMS online data submission tool reporting requirements; these requirements would apply to any future non-CMS online data submission tool measures adopted in the program. b. Requirements for Data Submitted via a CMS Online Data Submission Tool We refer readers to the CY 2018 OPPS/ASC final rule with comment period (82 FR 59473) (and the previous rulemakings cited therein) and 42 CFR 416.310(c)(1) for our requirements regarding data submitted via a CMS online data submission tool. We are currently using the QualityNet website as our CMS online data submission tool: https://www.qualitynet.org/dcs/ ContentServer?c=Page&pagename=Qnet Public%2FPage%2FQnet Homepage&cid=1120143435383. We note that in the CY 2018 OPPS/ASC final rule with comment period (82 FR 59473), we finalized expanded submission via the CMS online tool to also allow for batch data submission and made corresponding changes to the 42 CFR 416.310(c)(1)(i). In the CY 2019 OPPS/ASC proposed rule (83 FR 37205 through 37206), we did not propose any changes to this policy. However, in the proposed rule we noted that in sections XIV.B.3.c. of the proposed rule, we proposed to remove three measures collected via a CMS online data submission tool— ASC–9: Endoscopy/Polyp Surveillance: Appropriate Follow-Up Interval for Normal Colonoscopy in Average Risk Patients, ASC–10: Endoscopy/Polyp Surveillance: Colonoscopy Interval for Patients with a History of Adenomatous Polyps—Avoidance of Inappropriate Use, and ASC–11: Cataracts: PO 00000 Frm 00319 Fmt 4701 Sfmt 4700 59135 Improvement in Patients’ Visual Function within 90 Days Following Cataract Surgery 202 beginning with the CY 2021 payment determination. Because we are finalizing ASC–10 for removal as proposed and are not finalizing our proposals to remove ASC– 9 and ASC–11 in the ASCQR Program measure set (these measures will remain in the program), the following measures will require data to be submitted via a CMS online data submission tool for the CY 2021 payment determination and subsequent years: • ASC–9: Endoscopy/Polyp Surveillance: Appropriate Follow-Up Interval for Normal Colonoscopy in Average Risk Patients • ASC–11: Cataracts: Improvement in Patients’ Visual Function within 90 Days Following Cataract Surgery • ASC–13: Normothermia Outcome • ASC–14: Unplanned Anterior Vitrectomy 4. Requirements for Non-QDC Based, Claims-Based Measure Data In the CY 2019 OPPS/ASC proposed rule (83 FR 37206 through 37207), we did not propose any changes to our requirements for non-QDC based, claims-based measures. However, in the proposed rule we proposed to change the reporting period for the previously adopted measure, ASC–12: Facility 7Day Risk-Standardized Hospital Visit Rate after Outpatient Colonoscopy. This proposal is discussed in more detail further below. a. General We refer readers to the CY 2015 OPPS/ASC final rule with comment period (79 FR 66985) and the CY 2016 OPPS/ASC final rule with comment period (80 FR 70536) for our previously adopted policies regarding data processing and reporting periods for claims-based measures for the CY 2018 payment determination and subsequent years. In addition, in the CY 2016 OPPS/ASC final rule with comment period (80 FR 70536), we codified these policies at 42 CFR 416.310(b). In the proposed rule, we did not propose any changes to these policies. We note that the non-QDC, claims-based measures in the program are as follows: • CY 2020 payment determination and subsequent years: ASC 12: Facility 7Day Risk Standardized Hospital Visit Rate after Outpatient Colonoscopy (79 FR 66970 through 66978) 202 We note that the ASC–11 measure is voluntarily collected effective beginning with the CY 2017 payment determination, as set forth in section XIV.E.3.c. of the CY 2015 OPPS/ASC final rule with comment period (79 FR 66984 through 66985). E:\FR\FM\21NOR2.SGM 21NOR2 59136 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations • CY 2022 payment determination and subsequent years: •• ASC–17: Hospital Visits after Orthopedic Ambulatory Surgical Center Procedures (82 FR 59455 through 59470) •• ASC–18: Hospital Visits after Urology Ambulatory Surgical Center Procedures (82 FR 59455 through 59470) khammond on DSK30JT082PROD with RULES2 b. Extension of the Reporting Period for ASC–12: Facility Seven-Day RiskStandardized Hospital Visit Rate After Outpatient Colonoscopy In the CY 2015 OPPS/ASC final rule with comment period (79 FR 66970 through 66978), we finalized the adoption of ASC–12: Facility 7-Day Risk-Standardized Hospital Visit Rate after Outpatient Colonoscopy into the ASCQR Program for the CY 2018 payment determination and subsequent years, with public display to begin on or after December 1, 2017. This measure is calculated with data obtained from paid Medicare FFS claims (79 FR 66978). For this reason, facilities are not required to submit any additional information. In that final rule with comment period, we also finalized the reporting period for measure calculation as claims data from two calendar years prior to the payment determination year. Specifically, for the CY 2018 payment determination, we stated we would use paid Medicare FFS claims from January 1, 2016 to December 31, 2016 to calculate measure results (79 FR 66985). We finalized a 1year reporting period as it adequately balanced competing interests of measure reliability and timeliness for payment determination purposes, and explained that we would continue to assess this during the dry run (79 FR 66973). We noted we would complete a dry run of the measure in 2015 using three or four years of data, and, from the results of this dry run, we would review the appropriate volume cutoff for facilities to ensure statistical reliability in reporting the measure score (79 FR 66974). Our analyses of the 2015 dry run using data from July 2011 through June 2014 showed that a reporting period of one year had moderate to high reliability for measure calculation. Specifically, using data from July 2013 through June 2014, we calculated facility-level reliability estimates as the ratio of true variance to observed variance.203 Consistent with the original 203 Snijders TA, Bosker RJ. Multilevel Analysis: An introduction to basic and advanced multilevel modeling. SAGE Publications. 2000. London. VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 measure specifications as described in the 2014 technical report,204 this calculation was performed combining the measure results for HOPDs and ASCs. We found that for a facility with median case size, the reliability estimate was high (over 0.90), but the minimum reliability estimate for facilities with 30 cases (the minimum case size chosen for public reporting) was only moderate (that is, between 0.40 and 0.60).205 However, after the 2015 dry run, CMS calculated the HOPD and ASC scores separately to compare similar types of facilities to each other. During subsequent analysis of the 1-year reporting period of July 2013 through June 2014, we confirmed that a 1-year reporting period with separate calculations for HOPDs and ASCs was sufficient, but did result in lower reliability and decreased precision, compared to results calculated with longer reporting periods (two or three years). Based on analyses conducted using data from July 2013 through June 2014 (1-year reporting period) and 2017 measure specifications,206 we found that the median facility-level reliability was 0.74 for ASCs and 0.51 for HOPDs. Using a 2-year reporting period (data from July 2012–June 2014), we found that median facility-level reliability was 0.81 for ASCs and 0.67 for HOPDs. When the reporting period was extended to three years (using data from July 2011 through June 2014), we found that median facility-level reliability was higher for both ASCs and HOPDs: 0.87 for ASCs and 0.75 for HOPDs. These results indicate that a larger portion of the included facilities have scores measured with higher reliability when three years of data are used rather than one year of data. Using three years of data, compared to just one year, is estimated to increase the number of ASCs with eligible cases for ASC–12 by 10 percent, adding approximately 235 additional ASCs to the measure calculation. ASCs reporting the measure would increase their 204 Additional methodology details and information obtained from public comments for measure development are available at: https:// www.cms.gov/Medicare/Quality-Initiatives-PatientAssessment-Instruments/HospitalQualityInits/ Measure-Methodology.html under ‘‘Hospital Outpatient Colonoscopy.’’ 205 Landis JR, Koch GG. The Measurement of Observer Agreement for Categorical Data. Biometrics. 1977;33(1):159–174. 206 Current and past measure specifications are available at: https://www.qualitynet.org/dcs/ ContentServer?c=Page&pagename=Qnet Public%2FPage%2FQnetTier3& cid=1228775214597. PO 00000 Frm 00320 Fmt 4701 Sfmt 4700 sample sizes and, in turn, increase the precision and reliability of their measure scores. Thus, we believe extending the reporting period to three years from one year for purposes of increasing reliability would be beneficial for providing better information to beneficiaries regarding the quality of care associated with lowrisk outpatient colonoscopy procedures. In crafting our proposal, we considered extending the reporting period to two years beginning with the CY 2020 payment determinations and subsequent years, but decided on proposing three years instead, because a higher level of reliability is achieved with a 3-year reporting period compared to two years. Therefore, in the CY 2019 OPPS/ASC proposed rule (83 FR 37206 through 37207), we proposed to change the reporting period for ASC–12: Facility 7Day Risk-Standardized Hospital Visit Rate after Outpatient Colonoscopy from one year to three years beginning with the CY 2020 payment determination (which would use claims data from January 1, 2016 through December 31, 2018) and for subsequent years. Under this proposal, the annual reporting requirements for ASCs would not change because this is a claims-based measure. However, with a 3-year reporting period, the most current year of data would be supplemented by the addition of two prior years. For example, for the CY 2020 payment determination, we would use a reporting period of CY 2018 data plus two prior years of data (CYs 2016 and 2017). In the proposed rule, we noted that since implementation of this measure began with the CY 2018 payment determination, we have already used paid Medicare FFS claims from January 1, 2016 to December 31, 2016 to calculate the measure scores, which have been previously previewed by ASCs and publicly displayed. In crafting our proposal, we also considered timeliness related to payment determinations and public display. Because we would utilize data already collected to supplement current data, our proposal to use three years of data would not disrupt payment determinations or public display. We refer readers to the table below for example reporting periods and public display dates corresponding to the CY 2020, CY 2021, and CY 2022 payment determinations: E:\FR\FM\21NOR2.SGM 21NOR2 We refer readers to section XIII.D.4.b. of the proposed rule, where we discussed a similar proposal under the Hospital OQR Program. Comment: Several commenters supported the proposed extension of the reporting period for ASC–12: Facility 7Day Risk-Standardized Hospital Visit Rate after Outpatient Colonoscopy. A few commenters supported a 3-year reporting period, noting that the reliability of measure data intended for public reporting and accountability is important and urged CMS to seek stakeholder feedback on developing a methodology and release a methodology report for public review and comment. Response: We thank the commenters for their support for extending the reporting period for ASC–12. Regarding the request to release a methodology report, we publish an annual update and measures specifications report, which is a description of the measure updates and measure results from reevaluation and includes detailed measure specifications.207 This report describes the measure methodology for a given reporting period. CMS encourages stakeholders to submit comments on the measure’s methodology via the Outpatient and ASC Question and Answer tool, https:// cms-ocsq.custhelp.com/. Comment: One commenter stated that in order to make the measure data as reliable as possible, CMS should increase the minimum case volume threshold from less than thirty cases to less than one hundred cases. Response: While it is true that a higher minimum case count would result in a higher minimum reliability, we must balance the goal of adequate reliability with the goal of providing measure performance information on as many facilities as possible. The minimum case count of 30 was set during the dry run of the measure and resulted in a minimum reliability estimate that was ‘‘moderate’’ for those facilities meeting the requirement. While the measure now calculates score for ASCs and OPDs separately, increasing the number years used for the 207 Measure Methodology. Colonoscopy measure. Available at: https://www.qualitynet.org/dcs/ ContentServer?c=Page&pagename=Qnet Public%2FPage%2FQnetTier3&cid= 1228775197506. VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 measure should increase reliability for facilities meeting this minimum case count. We must balance the goal of adequate reliability with the goal of providing timely measure information that can inform quality improvement efforts. A 3-year reporting period improves the reliability of the measure and increases the number of facilities that meet the minimum case count. Comment: A few commenters supported a 2-year reporting period, stating that priority interest should be giving beneficiaries critical information they can use today and two years of data typically yields the best mix of reliability and predicting performance today. Response: We chose to propose a 3year reporting period for the colonoscopy measure because using three years of data would increase the number of facilities meeting minimum case count requirements and increase the overall reliability of each facility measure score by increasing sample sizes. We balance the goal of adequate reliability with the goal of providing timely measure information that can inform quality improvement efforts. A 3-year reporting period substantially improves the reliability of the measure, as described above. Using a 1-year reporting period, we found that the median facility-level reliability was 0.74 for ASCs and 0.51 for HOPDs, and for a 2-year reporting period 0.81 for ASCs and 0.67 for HOPDS. However, the median facility-level reliability was highest for both ASCs and HOPDs using a 3-year reporting period: 0.87 for ASCs and 0.75 for HOPDs. In addition, we note that using a 3-year reporting period does not affect the timeliness of our ability to report on this measure, as the data being used has already been collected. Specifically, we note that the most current year of data would be supplemented by the addition of two prior years. For example, for the CY 2020 payment determination, we would use a reporting period of CY 2018 data plus two prior years of data (CYs 2016 and 2017). Comment: Several commenters provided general feedback on the measure. A few noted that the data reported for the two measures (ASC–12 and OP–32) reflects fundamental claim and billing policy differences—such as PO 00000 Frm 00321 Fmt 4701 Sfmt 4700 59137 the CMS three-day payment window— between the two settings (ASCs and HOPDs) that preclude valid comparisons, and the two measures should be clearly distinguished. A few commenters noted that the all-cause ED visit outcome is too broad and is not giving any specific information about the quality of care given at an endoscopy center, and that the measure does not help the consumer make distinctions among ASCs. Response: We thank commenters for their feedback on the measure. The commenter is correct that there are differences between the ASC and HOPD colonoscopy measures (ASC–12 and OP–32) that specifically relate to billing differences between the two settings. For example, for outpatient (HOPD) colonoscopies that occur in the three calendar days preceding the date of a beneficiary’s inpatient admission, the facility claim is bundled with the inpatient claim, and therefore would not be identified using only outpatient facility claims. Therefore, for OP–32, cases subject to the 3-day payment window are identified with a matching algorithm that uses inpatient and physician (Medicare Part B) claims to attribute the colonoscopy procedure to the appropriate outpatient facility (HOPD).208 209 We also calculate the measure scores separately for ASCs and HOPDs; HOPDs are only compared to other HOPDs, and ASCs to other ASCs, therefore the difference in methodology does not affect the overall evaluation of ASCs or HOPDs within each measure’s calculation. Furthermore, we note that ASC–12 and OP–32 performance data are presented separately on Hospital Compare. In the future, we intend to update publicly available resource materials to clarify that ASC–12 and OP–32 are calculated separately using 208 Ranasinghe I, Parzynski C, Searfoss S, et al. Facility 7-Day Risk-Standardized Hospital Visit Rate after Outpatient Colonoscopy: A Quality Measure for Profiling Facility Performance Using Claims Data. 2014; https://www.qualitynet.org/dcs/ ContentServer?c=Page&pagename=QnetPublic %2FPage%2FQnetTier3&cid=1228775197506. Accessed October 22, 2018. 209 Version 7.0a of the ASCQR Program Specifications Manual is available at: https:// www.qualitynet.org/dcs/ ContentServer?c=Page&pagename= QnetPublic%2Page%2FSpecs ManualTemplate&cid=1228776140694. E:\FR\FM\21NOR2.SGM 21NOR2 ER21NO18.115</GPH> khammond on DSK30JT082PROD with RULES2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations khammond on DSK30JT082PROD with RULES2 59138 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations different benchmarks and should not be compared. In addition, we measure all-cause hospital visits (including Emergency department visits) to encourage OPDs and ASCs to minimize all types of risks that may lead to hospital visits after a colonoscopy. Measuring only hospital visits that are narrow procedural complications of colonoscopy, such as gastrointestinal bleeding, would limit the measure’s impact on quality improvement efforts and miss events such as dehydration, pain, dizziness, and urinary retention that are often related to the colonoscopy or the preparation for the colonoscopy and present to the ED. From the patient’s perspective, these events reflect the quality of care for the full episode of care. Measuring all-cause patient outcomes encourages facilities and their clinicians minimizes the risk of a broad range of outcomes. We have structured the measure so that OPDs and ASCs that most effectively minimize patient risk of these outcomes will perform better. While we employ a conservative approach to categorizing facility performance relative to the national rate, the distribution of measure scores for both ASC–12 and OP–32 demonstrate meaningful variation. This variation provides valuable information to facilities about their performance and the possibility for reducing complications following low risk colonoscopies. Using claims from January 1, 2016 through December 31, 2016, we characterize the degree of variability by calculating the median odds ratio (MOR). The median odds ratio represents the median increase in odds of a hospital visit if a procedure on a single patient was performed at a higher risk facility compared to a lower risk facility. Both median odds ratios indicate the impact of quality on the outcome rate is substantial at both ASCs and HOPDs. • For HOPDs, a value of 1.23 indicates that a patient has a 23 percent increase in the odds of a hospital visit if the same procedure was performed at higher risk HOPD compared to a lower risk HOPD. • For ASCs, a value of 1.19 indicates that a patient has a 19 percent increase in the odds of a hospital visit if the same procedure was performed at higher risk ASC compared to a lower risk ASC. After consideration of the public comments we received, we are finalizing our proposal to change the reporting period for ASC–12: Facility 7Day Risk-Standardized Hospital Visit Rate after Outpatient Colonoscopy from one year to three years beginning with the CY 2020 payment determination and VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 for subsequent years, as proposed. We refer readers to section XIII.D.4.b. of this final rule with comment period, where we are finalizing a similar policy under the Hospital OQR Program. 416.330 for the ASCQR Program’s reconsideration policy. In the CY 2019 OPPS/ASC proposed rule (83 FR 37207), we did not propose any changes to this policy. 5. Requirements for Data Submission for ASC–15a–e: Outpatient and Ambulatory Surgery Consumer Assessment of Healthcare Providers and Systems (OAS CAHPS) Survey-Based Measures We refer readers to the CY 2017 OPPS/ASC final rule with comment period (81 FR 79822 through 79824) for our previously finalized policies regarding survey administration and vendor requirements for the CY 2020 payment determination and subsequent years. In addition, we codified these policies at 42 CFR 416.310(e). However, in the CY 2018 OPPS/ASC final rule with comment period (82 FR 59450 through 59451), we delayed implementation of the ASC–15a–e: OAS CAHPS Survey-based measures beginning with the CY 2020 payment determination (CY 2018 data submission) until further action in future rulemaking, and we refer readers to that discussion for more details. In the CY 2019 OPPS/ASC proposed rule (83 FR 37207), we did not propose any changes to this policy. E. Payment Reduction for ASCs That Fail To Meet the ASCQR Program Requirements 6. Extraordinary Circumstances Exception (ECE) Process for the CY 2020 Payment Determination and Subsequent Years We refer readers to the CY 2018 OPPS/ASC final rule with comment period (82 FR 59474 through 59475) (and the previous rulemakings cited therein) and 42 CFR 416.310(d) for the ASCQR Program’s policies for extraordinary circumstance exceptions (ECE) requests. In the CY 2018 OPPS/ASC final rule with comment period (82 FR 59474 through 59475), we: (1) Changed the name of this policy from ‘‘extraordinary circumstances extensions or exemption’’ to ‘‘extraordinary circumstances exceptions’’ for the ASCQR Program, beginning January 1, 2018; and (2) revised 42 CFR 416.310(d) of our regulations to reflect this change. We also clarified that we will strive to complete our review of each request within 90 days of receipt. In the CY 2019 OPPS/ASC proposed rule (83 FR 37207), we did not propose any changes to these policies. 7. ASCQR Program Reconsideration Procedures We refer readers to the CY 2016 OPPS/ASC final rule with comment period (82 FR 59475) (and the previous rulemakings cited therein) and 42 CFR PO 00000 Frm 00322 Fmt 4701 Sfmt 4700 1. Statutory Background We refer readers to section XVI.D.1. of the CY 2013 OPPS/ASC final rule with comment period (77 FR 68499) for a detailed discussion of the statutory background regarding payment reductions for ASCs that fail to meet the ASCQR Program requirements. 2. Policy Regarding Reduction to the ASC Payment Rates for ASCs That Fail To Meet the ASCQR Program Requirements for a Payment Determination Year The national unadjusted payment rates for many services paid under the ASC payment system equal the product of the ASC conversion factor and the scaled relative payment weight for the APC to which the service is assigned. For CY 2019, the ASC conversion factor we are finalizing is equal to the conversion factor calculated for the previous year updated by the multifactor productivity (MFP)-adjusted hospital market basket update factor. The MFP adjustment is set forth in section 1833(i)(2)(D)(v) of the Act. The MFP-adjusted hospital market basket update is the annual update for the ASC payment system for an interim 5-year period (CY 2019 through CY 2023). As discussed in the CY 2011 OPPS/ASC final rule with comment period (75 FR 72062), if the CPI–U update factor is a negative number, the CPI–U update factor would be held to zero. In the CY 2019 OPPS/ASC proposed rule (83 FR 37207), consistent with past practice, in the event the percentage change in the hospital market basket for a year is negative, we proposed to hold the hospital market basket update factor for the ASC payment system to zero. Under the ASCQR Program in accordance with section 1833(i)(7)(A) of the Act and as discussed in the CY 2013 OPPS/ASC final rule with comment period (77 FR 68499), any annual increase shall be reduced by 2.0 percentage points for ASCs that fail to meet the reporting requirements of the ASCQR Program. This reduction applied beginning with the CY 2014 payment rates (77 FR 68500). For a complete discussion of the calculation of the ASC conversion factor and our proposal to update the ASC payment rates using the inpatient hospital market basket update for CYs E:\FR\FM\21NOR2.SGM 21NOR2 khammond on DSK30JT082PROD with RULES2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations 2019 through 2023, we refer readers to section XII.G. of this final rule with comment period. In the CY 2013 OPPS/ASC final rule with comment period (77 FR 68499 through 68500), in order to implement the requirement to reduce the annual update for ASCs that fail to meet the ASCQR Program requirements, we finalized our proposal that we would calculate two conversion factors: A full update conversion factor and an ASCQR Program reduced update conversion factor. We finalized our proposal to calculate the reduced national unadjusted payment rates using the ASCQR Program reduced update conversion factor that would apply to ASCs that fail to meet their quality reporting requirements for that calendar year payment determination. We finalized our proposal that application of the 2.0 percentage point reduction to the annual update may result in the update to the ASC payment system being less than zero prior to the application of the MFP adjustment. The ASC conversion factor is used to calculate the ASC payment rate for services with the following payment indicators (listed in Addenda AA and BB to the proposed rule, which are available via the internet on the CMS website): ‘‘A2’’, ‘‘G2’’, ‘‘P2’’, ‘‘R2’’ and ‘‘Z2’’, as well as the service portion of device-intensive procedures identified by ‘‘J8’’ (77 FR 68500). We finalized our proposal that payment for all services assigned the payment indicators listed above would be subject to the reduction of the national unadjusted payment rates for applicable ASCs using the ASCQR Program reduced update conversion factor (77 FR 68500). The conversion factor is not used to calculate the ASC payment rates for separately payable services that are assigned status indicators other than payment indicators ‘‘A2’’, ‘‘G2’’, ‘‘J8’’, ‘‘P2’’, ‘‘R2’’ and ‘‘Z2.’’ These services include separately payable drugs and biologicals, pass-through devices that are contractor-priced, brachytherapy sources that are paid based on the OPPS payment rates, and certain office-based procedures, radiology services and diagnostic tests where payment is based on the PFS nonfacility PE RVU-based amount, and a few other specific services that receive cost-based payment (77 FR 68500). As a result, we also finalized our proposal that the ASC payment rates for these services would not be reduced for failure to meet the ASCQR Program requirements because the payment rates for these services are not calculated using the ASC conversion factor and, therefore, not affected by VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 reductions to the annual update (77 FR 68500). Office-based surgical procedures (generally those performed more than 50 percent of the time in physicians’ offices) and separately paid radiology services (excluding covered ancillary radiology services involving certain nuclear medicine procedures or involving the use of contrast agents) are paid at the lesser of the PFS nonfacility PE RVU-based amounts or the amount calculated under the standard ASC ratesetting methodology. Similarly, in section XII.D.2.b. of the CY 2015 OPPS/ ASC final rule with comment period (79 FR 66933 through 66934), we finalized our proposal that payment for certain diagnostic test codes within the medical range of CPT codes for which separate payment is allowed under the OPPS and when they are integral to covered ASC surgical procedures will be at the lower of the PFS nonfacility PE RVU-based (or technical component) amount or the rate calculated according to the standard ASC ratesetting methodology. In the CY 2013 OPPS/ASC final rule with comment period (77 FR 68500), we finalized our proposal that the standard ASC ratesetting methodology for this type of comparison would use the ASC conversion factor that has been calculated using the full ASC update adjusted for productivity. This is necessary so that the resulting ASC payment indicator, based on the comparison, assigned to these procedures or services is consistent for each HCPCS code, regardless of whether payment is based on the full update conversion factor or the reduced update conversion factor. For ASCs that receive the reduced ASC payment for failure to meet the ASCQR Program requirements, we believe that it is both equitable and appropriate that a reduction in the payment for a service should result in proportionately reduced coinsurance liability for beneficiaries (77 FR 68500). Therefore, in the CY 2013 OPPS/ASC final rule with comment period (77 FR 68500), we finalized our proposal that the Medicare beneficiary’s national unadjusted coinsurance for a service to which a reduced national unadjusted payment rate applies will be based on the reduced national unadjusted payment rate. In that final rule with comment period, we finalized our proposal that all other applicable adjustments to the ASC national unadjusted payment rates would apply in those cases when the annual update is reduced for ASCs that fail to meet the requirements of the ASCQR Program (77 FR 68500). For example, the following standard PO 00000 Frm 00323 Fmt 4701 Sfmt 4700 59139 adjustments would apply to the reduced national unadjusted payment rates: The wage index adjustment; the multiple procedure adjustment; the interrupted procedure adjustment; and the adjustment for devices furnished with full or partial credit or without cost (77 FR 68500). We believe that these adjustments continue to be equally applicable to payment for ASCs that do not meet the ASCQR Program requirements (77 FR 68500). In the CY 2015, CY 2016, CY 2017, and CY 2018 OPPS/ASC final rules with comment period (79 FR 66981 through 66982; 80 FR 70537 through 70538; 81 FR 79825 through 79826; and 82 FR 59475 through 59476, respectively), we did not make any other changes to these policies. We did not propose any changes to these existing policies for CY 2019 in the CY 2019 OPPS/ASC proposed rule (83 FR 37207 through 37208). We did not receive any public comments on our proposal that, in the event the percentage change in the hospital market basket for a year is negative, we would hold the hospital market basket update factor for the ASC payment system to zero. We also did not receive any public comments on our existing policies for all other applicable adjustments to the ASC national unadjusted payment rates discussed earlier. Therefore, we are finalizing our proposal without modification and continuing the existing policies for CY 2019. XV. Comments Received in Response To Requests for Information (RFIs) Included in the CY 2019 OPPS/ASC Proposed Rule In the CY 2019 OPPS/ASC proposed rule (83 FR 37208 through 37217), we included three requests for information (RFIs). We stated in the proposed rule that the RFIs were issued solely for information and planning purposes; none of the RFIs constituted a Request for Proposal (RFP), application, proposal abstract, or quotation. In addition, we stated that the RFIs did not commit the U.S. Government to contract for any supplies or services or make a grant award. Further, we stated that CMS was not seeking proposals through these RFIs and would not accept unsolicited proposals. Responders were advised that the U.S. Government will not pay for any information or administrative costs incurred in response to these RFIs; all costs associated with responding to these RFIs would be solely at the interested party’s expense. In addition, we stated in the proposed rule that failing to respond to either RFI would not E:\FR\FM\21NOR2.SGM 21NOR2 59140 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations preclude participation in any future procurement, if conducted. We also stated that it is the responsibility of the potential responders to monitor each RFI announcement for additional information pertaining to the request. We also noted that CMS would not respond to questions about the policy issues raised in these RFIs. In addition, we stated that CMS may or may not choose to contact individual responders, and that such communications would only serve to further clarify written responses. In the proposed rule, we stated that contractor support personnel may be used to review RFI responses. We also stated that responses to these RFIs were not offers and cannot be accepted by the U.S. Government to form a binding contract or issue a grant. We stated that information obtained as a result of these RFIs may be used by the U.S. Government for program planning on a non-attribution basis and that respondents should not include any information that might be considered proprietary or confidential. We stated that these RFIs should not be construed as a commitment or authorization to incur cost for which reimbursement would be required or sought. We also stated that all submissions become U.S. Government property and will not be returned. We posted the public comments that CMS received on the three RFIs as part of the posting of the public comments received on the CY 2019 OPPS/ASC proposed rule on the website at: www.regulations.gov. khammond on DSK30JT082PROD with RULES2 A. Comments Received in Response To Request for Information on Promoting Interoperability and Electronic Healthcare Information Exchange Through Possible Revisions to the CMS Patient Health and Safety Requirements for Hospitals and Other Medicare- and Medicaid-Participating Providers and Suppliers In the CY 2019 OPPS/ASC proposed rule (83 FR 37209 through 37211), we included a Request for Information (RFI) related to promoting interoperability and electronic health care information exchange. We received over 60 timely pieces of correspondence on this RFI. We appreciate the input provided by commenters. B. Comments Received in Response To Request for Information on Price Transparency: Improving Beneficiary Access to Provider and Supplier Charge Information In the CY 2019 OPPS/ASC proposed rule (83 FR 37211 and 37212), we included a Request for Information (RFI) related to improving beneficiary access to provider and supplier charge VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 information as part of our price transparency initiatives. We received over 90 timely pieces of correspondence on this RFI. We appreciate the input provided by commenters. C. Comments Received in Response To Request for Information on Leveraging the Authority for the Competitive Acquisition Program (CAP) for Part B Drugs and Biologicals for a Potential CMS Innovation Center Model In the CY 2019 OPPS/ASC proposed rule (83 FR 37212 through 37217), we included a Request for Information (RFI) related to leveraging the authority for the Competitive Acquisition Program (CAP) for Part B drugs and biologicals for a potential CMS Innovation Center Model. We received approximately 80 timely pieces of correspondence on this RFI. We appreciate the input provided by commenters. XVI. Additional Hospital Inpatient Quality Reporting (IQR) Program Policies A. Background We refer readers to the FY 2010 IPPS/ LTCH PPS final rule (74 FR 43860 through 43861) and the FY 2011 IPPS/ LTCH PPS final rule (75 FR 50180 through 50181) for detailed discussions of the history of the Hospital IQR Program, including the statutory history, and to the FY 2015 IPPS/LTCH PPS final rule (79 FR 50217 through 50249), the FY 2016 IPPS/LTCH PPS final rule (80 FR 49660 through 49692), the FY 2017 IPPS/LTCH PPS final rule (81 FR 57148 through 57150), and the FY 2018 IPPS/LTCH PPS final rule (82 FR 38323 through 38411) for the measures and program policies we have adopted for the Hospital IQR Program through the FY 2020 payment determination and subsequent years. In addition to the proposed and finalized policies discussed in this section, we also refer readers to the FY 2019 IPPS/LTCH PPS final rule (83 FR 41537 through 41609) for a full discussion of the Hospital IQR Program and its policies. B. Update to the HCAHPS Survey Measure (NQF #0166) for the FY 2021 Payment Determination and Subsequent Years 1. Background of the HCAHPS Survey in the Hospital IQR Program As discussed in the CY 2019 OPPS/ ASC proposed rule (83 FR 37218), CMS partnered with the Agency for Healthcare Research and Quality (AHRQ) to develop the Hospital Consumer Assessment of Healthcare Providers and Systems (HCAHPS) patient experience of care survey (NQF PO 00000 Frm 00324 Fmt 4701 Sfmt 4700 #0166) 210 (hereinafter referred to as the HCAHPS Survey). We adopted the HCAHPS Survey in the Hospital IQR Program (at the time called the Reporting Hospital Quality Data Annual Payment Update Program, or RHQDAPU) in the CY 2007 OPPS final rule with comment period (71 FR 68202 through 68204) beginning with the FY 2008 payment determination and for subsequent years. We refer readers to the FY 2010 IPPS/LTCH PPS final rule (74 FY 43882), the FY 2011 IPPS/LTCH PPS final rule (75 FR 50220 through 50222), the FY 2012 IPPS/LTCH PPS final rule (76 FR 51641 through 51643), the FY 2013 IPPS/LTCH PPS final rule (77 FR 53537 through 53538), the FY 2014 IPPS/LTCH PPS final rule (78 FR 50819 through 50820), and the FY 2018 IPPS/LTCH PPS final rule (82 FR 38328 to 38342) for details on previouslyadopted HCAHPS Survey requirements. The HCAHPS Survey (OMB control number 0938–0981) is the first national, standardized, publicly reported survey of patients’ experience of hospital care and asks discharged patients 32 questions about their recent hospital stay. The HCAHPS Survey is administered to a random sample of adult patients who receive medical, surgical, or maternity care between 48 hours and 6 weeks (42 calendar days) after discharge and is not restricted to Medicare beneficiaries.211 Hospitals must survey patients throughout each month of the year.212 The HCAHPS Survey is available in official English, Spanish, Chinese, Russian, Vietnamese, and Portuguese versions. The HCAHPS Survey and its protocols for sampling, data collection and coding, and file submission can be found in the current HCAHPS Quality Assurance Guidelines, which is available on the official HCAHPS website at: https:// www.hcahpsonline.org/en/qualityassurance/. AHRQ carried out a rigorous scientific process to develop and test the HCAHPS Survey instrument. This process entailed multiple steps, including: a public call for measures; literature reviews; cognitive interviews; consumer focus groups; multiple opportunities for additional stakeholder 210 The HCAHPS measure also includes the NQFendorsed Care Transition Measure (CTM–3) (NQF #0228), which we added in the FY 2013 IPPS/LTCH PPS final rule (77 FR 53513 through 53516). We added the Communication About Pain composite measure in the FY 2018 IPPS/LTCH PPS final rule (38328 through 38342), and stated that we would seek NQF endorsement for this measure. 211 We refer readers to the FY 2018 IPPS/LTCH PPS final rule (82 FR 38328 to 38342, 38398) and to the official HCAHPS website at: https:// www.hcahpsonline.org for details on HCAHPS requirements. 212 Ibid. E:\FR\FM\21NOR2.SGM 21NOR2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations khammond on DSK30JT082PROD with RULES2 input; a 3-State pilot test; small-scale field tests; and notice-and-comment rulemaking. In May 2005, the HCAHPS Survey was first endorsed by the NQF.213 In the FY 2018 IPPS/LTCH PPS final rule (82 FR 38328 through 38342), out of an abundance of caution, in the face of a nationwide epidemic of opioid overprescription, we finalized a refinement to the HCAHPS Survey measure as used in the Hospital IQR Program by removing the previously adopted pain management questions and incorporating new Communication About Pain questions beginning with patients discharged in January 2018, for the FY 2020 payment determination and subsequent years.214 These three survey questions within the HCAHPS Survey, collectively known as the Communication About Pain questions,215 address how providers communicate with patients about pain. These questions are as follows: 216 • HP1: ‘‘During this hospital stay, did you have any pain?’’ b Yes b No → If No, Go to Question ll • HP2: ‘‘During this hospital stay, how often did hospital staff talk with you about how much pain you had?’’ b Never b Sometimes b Usually b Always • HP3: ‘‘During this hospital stay, how often did hospital staff talk with you about how to treat your pain?’’ b Never b Sometimes b Usually b Always In addition, we finalized public reporting on the Communication About Pain questions, such that hospital performance data on those questions would be publicly reported on the Hospital Compare website beginning 213 Available at: https://www.qualityforum.org/ Publications/2008/08/National_Voluntary_ Consensus_Standards_for_Hospital_Care_ 2007__Performance_Measures.aspx. 214 In the CY 2017 OPPS/ASC final rule with comment period (81 FR 79855 through 79862), the Hospital VBP Program removed the Pain Management dimension of the HCAHPS Survey in the Patient and Caregiver-Centered Experience of Care/Care Coordination domain of the Hospital VBP Program beginning with the FY 2018 program year. Under the Hospital VBP Program, payment adjustments are tied to hospitals’ performance on the measures that are used to calculate each hospital’s Total Performance Score. 215 Available at: https://hcahpsonline.org/en/ survey-instruments/. 216 We note that in the CY 2019 OPPS/ASC proposed rule, we inadvertently omitted the ‘‘If No, Go to Question ll’’ phrase that accompanies the ‘‘No’’ response option for the first question. We have added the language above to reflect the full question. VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 October 2020, using CY 2019 data. We also stated that we would provide performance results based on CY 2018 data on the Communication About Pain questions to hospitals in confidential preview reports, upon the availability of four quarters of data, as early as July 2019. We believed implementing the Communication About Pain questions as soon as feasible was necessary to address any perceived conflict between appropriate management of opioid use and patient satisfaction by relieving any potential pressure physicians may feel to overprescribe opioids (82 FR 38333). 2. Updates to the HCAHPS Survey: Removal of Communication About Pain Questions As discussed in the CY 2019 OPPS/ ASC proposed rule (83 FR 37218), since we finalized the Communication About Pain questions, we have received feedback that some stakeholders are concerned that, although the revised questions focus on communications with patients about their pain and treatment of that pain, rather than how well their pain was controlled, the questions still could potentially impose pressure on hospital staff to prescribe more opioids in order to achieve higher scores on the HCAHPS Survey. In addition, in its final report, the President’s Commission on Combating Drug Addiction and the Opioid Crisis recommended removal of the HCAHPS Pain Management questions in order to ensure providers are not incentivized to offer opioids to raise their HCAHPS Survey score.217 Other potential factors outside the control of CMS quality program requirements may contribute to the perception of a link between the Communication About Pain questions and opioid prescribing practices, including: misuse of the HCAHPS Survey (such as using it for outpatient emergency room care instead of inpatient care, or using it for determining individual physician performance); failure to recognize that the HCAHPS Survey excludes certain populations from the sampling frame (such as those with a primary substance use disorder diagnosis); and the addition of supplemental pain-related survey questions by the hospital that are not formally part of the HCAHPS Survey or otherwise required by CMS. Because some hospitals have identified patient experience of care as a potential source of competitive advantage, we have heard from 217 Available at: https://www.whitehouse.gov/ sites/whitehouse.gov/files/images/Final_Report_ Draft_11-15-2017.pdf. PO 00000 Frm 00325 Fmt 4701 Sfmt 4700 59141 stakeholders that some hospitals may be disaggregating their raw HCAHPS Survey data to compare, assess, and incentivize individual physicians, nurses, and other hospital staff. Some hospitals also may be using the HCAHPS Survey to assess their emergency and outpatient departments. To be clear, the HCAHPS Survey was never designed or intended to be used in these ways.218 In our HCAHPS Quality Assurance Guidelines,219 which sets forth current survey administration protocols, we strongly discourage the unofficial use of HCAHPS scores for comparisons within hospitals, such as for comparisons of particular wards, floors, and individual staff hospital members. The standardization of HCAHPS Survey administration and data collection methodologies is also emphasized during the required introductory and annual update trainings for hospitals/survey vendors. As we stated in the CY 2019 OPPS/ ASC proposed rule, we continue to believe that pain management is a critical part of routine patient care on which hospitals should focus and an important concern for patients, their families, and their caregivers. It is important to reiterate that the HCAHPS Survey does not specify any particular type of pain control method. The revised questions focus entirely on communication about pain with patients and do not refer to, recommend, or imply that any particular type of treatment is appropriate (82 FR 38333). In addition, appropriate pain management includes communication with patients about pain-related issues, setting expectations about pain, shared decision-making, proper prescription practices, and alternative treatments for pain management. Although we are not aware of any scientific studies that support an association between scores on the prior or current iterations of the Communication About Pain questions and opioid prescribing practices, out of an abundance of caution and to avoid any potential unintended consequences, in the CY 2019 OPPS/ASC proposed rule (83 FR 37218), we proposed to update the HCAHPS Survey by removing the Communication About Pain questions effective with January 218 Tefera L, Lehrman WG, and Conway P. ‘‘Measurement of the Patient Experience: Clarifying Facts, Myths, and Approaches.’’ Journal of the American Medical Association. Available at: https:// jama.jamanetwork.com/ article.aspx?articleid=2503222. 219 HCAHPS Quality Assurance Guidelines (v. 13.0), available at: https://www.hcahpsonline.org/en/ quality-assurance/. E:\FR\FM\21NOR2.SGM 21NOR2 khammond on DSK30JT082PROD with RULES2 59142 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations 2022 discharges, for the FY 2024 payment determination and subsequent years. This proposal would reduce the overall length of the HCAHPS Survey from 32 to 29 questions, and the final four quarters of reported Communication About Pain data (comprising data from the first, second, third, and fourth quarters 2021) would be publicly reported on Hospital Compare in October 2022 and then subsequently discontinued. As stated above, in its final report, the President’s Commission on Combating Drug Addiction and the Opioid Crisis recommended removal of the HCAHPS Pain Management Survey questions in order to ensure providers are not incentivized to offer opioids to raise their HCAHPS Survey score.220 In proposing removal of the Communication About Pain questions, we did not propose to change how performance scores are calculated for the remaining questions on the HCAHPS Survey. The Hospital IQR Program is a quality data reporting program; payments to hospitals will not be affected so long as hospitals timely submit data on required measures and meet all other program requirements. We stated in the proposed rule that we would continue to use the remaining 29 questions of the HCAHPS Survey to assess patients’ experience of care, and would continue to publicly report hospital scores on those questions in order to ensure patients and consumers have access to these data while making decisions about their care. Patients and providers can continue to review data from responses to the remaining 29 questions of the HCAHPS Survey on the Hospital Compare website. In crafting our proposal, we considered whether the Communication About Pain questions should be retained in both the HCAHPS Survey and the Hospital IQR Program but with a further delay in public reporting. For example, instead of public reporting starting in October 2020 as previously finalized, we could have proposed to delay public reporting of the Communication About Pain questions until October 2021. We stated we were interested in feedback on whether the Communication About Pain questions should be retained in both the HCAHPS Survey and the Hospital IQR Program but with a further delay in public reporting. Delay in public reporting would allow further time to engage a broad range of stakeholders and assess their feedback regarding use 220 Final Report, The President’s Commission on Combating Drug Addiction and the Opioid Crisis, available at: https://www.whitehouse.gov/sites/ whitehouse.gov/files/images/Final_Report_ Draft_11-15-2017.pdf. VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 of the Communication About Pain questions in the HCAHPS Survey and the Hospital IQR Program and to assess the impact of the new Communication About Pain questions. However, we chose to propose to remove the Communication About Pain questions as discussed above instead, so providers would not perceive that there are incentives for prescribing opioids to increase HCAHPS Survey scores. In crafting our proposal, we also considered proposing earlier removal of the Communication About Pain questions from the HCAHPS Survey effective as early as January 2020 discharges, for the FY 2022 payment determination and subsequent years. However, we stated that removing the questions effective with January 2020 discharges would not allow sufficient time to make necessary updates to the data collection tools, including the CMS data submission warehouse and associated reporting tools, as well as to update the HCAHPS Survey administration protocols and the survey tool itself. In addition, our proposal to make these updates effective later, with January 2022 discharges, would allow time to assess the potential impact of using the Communication About Pain questions while monitoring unintended consequences. It would also allow time for empirical testing for any potential effect the removal of the Communication About Pain questions might have on responses to the remaining non-pain related survey items. We invited public comment on our proposal as discussed above and whether the questions should be removed from the HCAHPS Survey and Hospital IQR Program. We stated that we were particularly interested in receiving feedback on any potential implications on patient care related to removing these questions. We also expressed interest in receiving feedback from stakeholders on: (1) The importance of receiving feedback from patients related to communication about pain management and the importance of publicly reporting this information for use both by patients in healthcare decision-making and by hospitals in focusing their quality improvement efforts; (2) additional analyses demonstrating a relationship between the use of pain questions in patient surveys and prescribing behavior, including unpublished data, if available; (3) input from clinicians and other providers concerning whether it would be valuable for CMS to issue guidance suggesting that hospitals do not administer any surveys with painrelated questions, including adding PO 00000 Frm 00326 Fmt 4701 Sfmt 4700 hospital-specific supplemental items to the HCAHPS Survey, as well as the potential implementation of a third party quality assurance program to assure that hospitals are not misusing survey data by creating pressure on individual clinicians to provide inappropriate clinical care; (4) information from clinicians and other providers concerning instances of hospital administrators using results from the HCAHPS Survey to compare individual clinician performance directly to other clinicians at the same facility or institution and examples where, as a result, clinicians have felt pressured to prescribe opioids inappropriately (in terms of either quantity or appropriateness for particular patients); (5) suggestions for other measures that would capture facets of pain management and related patient education, for instance, collecting data about a hospital’s pain management plan, and provide that information back to consumers; and (6) how other measures could take into account provider-supplied information on appropriate pain management and whether patients are informed about the risks of opioid use and about non-opioid pain management alternatives. Comment: A number of commenters responded to CMS’ request for feedback regarding potential misuse of the HCAHPS Survey and its impact on provider decision-making. Commenters indicated the Communication About Pain questions in the HCAHPS Survey unduly influence providers’ decisionmaking by encouraging providers to focus on improving patient satisfaction scores regarding pain management. One commenter indicated this influence is significant enough to compel providers to prescribe opioids to patients showing signs of drug-seeking behavior. Other commenters expressed concern that some hospitals use disaggregated survey results to assess individual clinician performance, with some hospitals tying these disaggregated survey results to individual compensation. Response: We thank the commenters for their feedback. We also reiterate that the HCAHPS Survey was never intended to be used to assess the performance of individual clinicians or provider groups within a hospital. The HCAHPS Survey is designed to evaluate the performance of a hospital as a whole, not individuals or groups within the larger hospital setting; 221 therefore, 221 Tefera L, Lehrman WG, and Conway P. ‘‘Measurement of the Patient Experience: Clarifying Facts, Myths, and Approaches.’’ Journal of the American Medical Association. Available at: https:// jama.jamanetwork.com/ article.aspx?articleid=2503222. E:\FR\FM\21NOR2.SGM 21NOR2 khammond on DSK30JT082PROD with RULES2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations its use for evaluating or incentivizing individual providers or groups within the hospital is contrary to the survey’s design and policy aim. During annual survey vendor training for HCAHPS and in the HCAHPS Quality Assurance Guidelines, we clearly state the purpose and the proper use of HCAHPS data: Official HCAHPS Survey scores are published on the Hospital Compare website. CMS emphasizes that HCAHPS scores are designed and intended for use at the hospital level for the comparison of hospitals (designated by their CMS Certification Number) to each other. CMS does not review or endorse the use of HCAHPS scores for comparisons within hospitals, such as comparison of HCAHPS scores associated with a particular ward, floor, individual staff member, etc. to others. Such comparisons are unreliable unless adequate sample sizes are collected at the ward, floor, or individual staff member level. In addition, since HCAHPS questions inquire about broad categories of hospital staff (such as doctors in general and nurses in general rather than specific individuals), HCAHPS is not appropriate for comparing or assessing individual hospital staff members. Using HCAHPS scores to compare or assess individual staff members is inappropriate and is strongly discouraged by CMS.222 Comment: The majority of commenters supported CMS’ proposal to remove the Communication About Pain questions from the HCAHPS Survey. A number of commenters who supported removal of the Communication About Pain questions also recommended CMS remove the questions earlier than proposed. Several commenters specifically recommended that CMS remove these questions immediately, asserting that the severity and urgency of the opioid crisis justifies immediate termination of the questions. One commenter recommended immediate removal of the Communication About Pain questions due to concerns that the subjective nature of the HCAHPS Survey, and the Communication About Pain questions, may not accurately represent hospital performance. Other commenters recommended that CMS remove the Communication About Pain questions as soon as feasible, with one commenter specifically recommending removal effective with January 2020 discharges, due to the 222 HCAHPS Quality Assurance Guidelines, V13.0. pp. 23–24, available at: https:// www.hcahpsonline.org/globalassets/hcahps/ quality-assurance/2018_qag_v13.0.pdf. VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 potential unintended consequences associated with continued use of the questions. These commenters further recommended that CMS first remove the Communication About Pain questions, then evaluate alternate methods of determining the impacts of removal and the value of collecting pain management data, rather than delaying removal in order to collect more data. Response: We thank the commenters for their feedback and their support of our proposal to remove the Communication About Pain questions from the HCAHPS Survey. We believe that removing the Communication About Pain questions from the HCAHPS Survey will address potential confusion about the appropriate use of the HCAHPS Survey, is responsive to concerns regarding the public health issues arising from the opioid epidemic, and addresses the recommendation of the President’s Commission on Combating Drug Addiction and the Opioid Crisis. In addition, section 6104 of the Substance Use—Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act (SUPPORT for Patients and Communities Act) (Pub. L. 115–271) enacted on October 24, 2018, prohibits HCAHPS Surveys conducted on or after January 1, 2020 from including questions about communication by hospital staff with an individual about such individual’s pain, unless such questions take into account, as applicable, whether an individual experiencing pain was informed about risks associated with the use of opioids and about non-opioid alternatives for the treatment of pain. Section 6104 of the SUPPORT for Patients and Communities Act also states that the Secretary shall not include any measures based on the pain communication questions on the HCAHPS Survey in 2018 or 2019 on the Hospital Compare website and in the Hospital Value-Based Purchasing (VBP) Program. We proposed to remove the Communication About Pain questions beginning with January 2022 discharges for the FY 2024 payment determination in an effort to avoid imposing undue burden on providers or their survey vendors to make necessary updates to surveys and data collection tools while also providing us additional time to assess the potential impact of using these questions in the HCAHPS Survey and the impact removal may have on responses to subsequent survey items (83 FR 37218 through 38220). Based on the stakeholder comments supporting removal of these questions, particularly PO 00000 Frm 00327 Fmt 4701 Sfmt 4700 59143 those who requested we remove them immediately or as soon as possible, we assessed the feasibility of removing the questions as soon as operationally possible. Upon further review of the operational timelines for making necessary updates to the HCAHPS Survey administration protocols, including conducting associated training of survey vendors and hospitals, and making updates to the CMS data submission warehouse and associated reporting tools, we found that it would be operationally feasible to remove the Communication About Pain questions earlier than we proposed. Furthermore, because the SUPPORT for Patients and Communities Act prohibits use of the Communication About Pain questions in HCAHPS Surveys conducted on or after January 1, 2020, it is appropriate to remove these questions from the HCAHPS Survey sooner than proposed—effective with October 2019 discharges, for the FY 2021 payment determination and subsequent years. We also note that removing these questions effective with October 2019 discharges, for the FY 2021 payment determination and subsequent years is responsive to commenters who recommended that we remove the Communication About Pain questions immediately or as soon as possible. Although we are removing the Communication About Pain questions, we will continue to consider the value of collecting data that relates to pain management. We will examine the effect of the absence of the Communication About Pain items on subsequent survey items once these items have been removed. Therefore, in response to stakeholder feedback, to comply with the requirements of the SUPPORT for Patients and Communities Act, and upon further review of the operational considerations involved in removing the Communication About Pain questions, we are finalizing a modification to our proposal and will remove the questions effective with October 2019 discharges, for the FY 2021 payment determination and subsequent years. Comment: A few commenters also recommended that CMS remove the Communication About Pain questions from public reporting. One commenter further recommended that CMS not publicly report performance data on the Communication About Pain questions until further research on the impact and utility of the questions is performed. Another commenter recommended that while the Communication About Pain questions remain in the HCAHPS Survey, CMS should remove them from E:\FR\FM\21NOR2.SGM 21NOR2 khammond on DSK30JT082PROD with RULES2 59144 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations the scoring calculation to minimize potential adverse consequences. Response: We appreciate the commenters’ feedback regarding public reporting of the Communication About Pain questions. Due in part to stakeholder input urging us to remove the Communication About Pain questions immediately or as soon as possible, as discussed above, we have assessed the operational considerations and are finalizing a modification to our proposal to remove the questions effective with October 2019 discharges, which is the earliest we can feasibility implement removal of the Communication About Pain questions. We are finalizing a modification of our public display proposal that we publicly reporting the Communication about Pain questions on Hospital Compare until October 2022 (comprising data from the first, second, third, and fourth quarters 2021) and then subsequently discontinue public reporting. Instead, we are finalizing that we will not publicly report data from the Communication about Pain questions at all because: We will no longer collect four quarters of CY 2019 Communication About Pain questions data; stakeholders’ recommendations that we not publicly report the Communication About Pain data at all in order to avoid exacerbating any possible link between these questions and inappropriate prescribing practices; and the requirements of the SUPPORT for Patients and Communities Act, which prohibit publicly reporting on Hospital Compare any measures based on the Communication About Pain questions appearing in the HCAHPS Survey in 2018 or 2019. Not publicly reporting the data collected from the Communication About Pain questions also aligns with our efforts to mitigate any potential tie between the Communication About Pain questions and inappropriate opioid prescribing practices. We note that in the FY 2018 IPPS/ LTCH PPS final rule (82 FR 38342), we finalized a delay in public reporting, such that hospital performance data on the refined Communication About Pain composite measure questions would not be publicly reported on the Hospital Compare website until October of CY 2020, using CY 2019 data. We stated that we would provide performance results, based on CY 2018 data on the refined Communication About Pain composite measure questions to hospitals in confidential preview reports, upon the availability of four quarters of data. We stated that we anticipated that these confidential preview reports would be available as VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 early as July 2019. The effect of the modified policy we are finalizing in this final rule with comment period is that Communication About Pain data from the final CY 2019 reporting period (which would consist of three quarters of data, 1st quarter through 3rd quarter 2019) will also not be publicly reported. However, we still plan to provide performance results based on these data to hospitals in confidential preview reports upon the availability of four quarters of CY 2018 data, as early as July 2019. Updated confidential reports will be provided on a quarterly basis with the availability of each new calendar quarter of data. The last confidential preview report containing the Communication About Pain questions data will reflect data from the fourth quarter of 2018 (October 1, 2018) through the third quarter of 2019 (September 30, 2019). We also note that the data collected from these questions will not be scored for purposes of CMS payments to hospitals, because the Hospital IQR Program is a pay-forreporting, not pay-for-performance quality program and these questions are not part of the Hospital VBP Program. Comment: Many commenters supported CMS’ proposal to remove the current Communication About Pain questions from the HCAHPS Survey beginning with January 2022 discharges for the FY 2024 payment determination and subsequent years. Many commenters supported removing the Communication About Pain questions based on concerns about unintended consequences of their continued use, specifically that the questions may incentivize or pressure clinicians into inappropriately prescribing opioids. Some commenters asserted that removing these questions from the HCAHPS Survey would allow providers to address patients’ pain in a safer manner, avoid inadvertently fostering an environment that could potentially promote the inappropriate use of opioids, and change perceptions about pain management. One commenter noted the Communication About Pain questions may also disincentivize the use of alternative methods of pain management in an effort to address patients’ pain in the most efficient manner (that is, prescription of opioids). Another commenter specifically cited agreement with the recommendation of the President’s Commission on Combating Drug Addiction and the Opioid Crisis in supporting removal of the Communication About Pain questions. Several commenters supported removal of the Communication About Pain questions because the commenters’ PO 00000 Frm 00328 Fmt 4701 Sfmt 4700 believe pain is subjective and is therefore, difficult to measure using a standardized set of survey questions. A number of other commenters supported removal of these questions due to their concern the questions correlate pain treatment with patient satisfaction, thereby creating unrealistic patient expectations regarding pain management. These commenters also expressed concern the questions contribute to an environment in which patients expect to be pain free, whereas the goal of pain therapy should be to appropriately manage, not eliminate, pain. One commenter specifically supported removal of these questions because the commenter believed the questions elevate pain too highly as a factor in patient satisfaction and, thereby, in hospital reimbursement. Another commenter supported removing the Communication About Pain questions because the commenter believed the approach to pain management is too complicated and unclear to be assessed using survey questions. Response: We thank the commenters for their support. We are not aware of any scientific studies that support an association between scores on the Communication About Pain questions and opioid prescribing practices. In addition, we continue to believe that many factors outside the control of our quality program requirements may contribute to the perception of a link between the Communication About Pain questions and opioid prescribing practices, that pain management is an appropriate part of routine care that hospitals should manage and that pain management is an important concern for patients, their families, and their caregivers. Furthermore, we continue to believe the HCAHPS Survey is a valid and reliable measure of hospital quality that encourages hospitals to assess and improve patient experience. However, we believe that removing the Communication About Pain questions from the HCAHPS Survey will address potential confusion about the appropriate use of the HCAHPS Survey, is responsive to concerns regarding the public health issues arising from the opioid epidemic, and addresses both the recommendation of the President’s Commission on Combating Drug Addiction and the Opioid Crisis and the prohibitions in the SUPPORT for Patients and Communities Act. Comment: A few commenters encouraged CMS to remove the Communication About Pain questions from both payment programs (for example, the Hospital VBP Program) and public reporting programs (for E:\FR\FM\21NOR2.SGM 21NOR2 khammond on DSK30JT082PROD with RULES2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations example, the Hospital IQR Program) given the concern about unintended consequences. One commenter stated that the Communication About Pain questions and related bonus payments led to an overuse of opioids and that removing the questions is important to addressing the current opioid crisis. Response: To be clear, the Communication About Pain questions in the HCAHPS Survey are only used in the Hospital IQR Program. While the Hospital VBP Program uses HCAHPS Survey data to score the Patient and Community Engagement domain, it does not include the Pain Management dimension of the HCAHPS Survey—the predecessor of the current Communication About Pain questions. This dimension was removed from the Hospital VBP Program in the CY 2017 OPPS/ASC final rule with comment period (81 FR 79855 through 79862) beginning with the FY 2018 program year. The Hospital VBP Program also does not use the current Communication About Pain questions. In addition, the Hospital IQR Program is a pay-for-reporting quality program, as opposed to a pay-for-performance quality program, and does not award incentive payments of any kind, including based on performance. Comment: Several commenters acknowledged the lack of scientific evidence demonstrating an impact of the Communication About Pain questions on providers’ prescribing practices, but supported removal of the questions out of an abundance of caution. One commenter noted that CMS programs can significantly influence trends in the opioid epidemic and agreed it was prudent, despite the lack of scientific evidence, to remove the Communication About Pain questions until a better understanding of the link between the questions and prescribing practices is reached. Another commenter acknowledged the value of patient satisfaction surveys but expressed concern about tying these surveys to publicly reported hospital ratings and accountability, and therefore, supported removal of the Communication About Pain questions from the HCAHPS Survey. Other commenters stated that the questions are only tenuously linked to improved quality of care, and that the questions are of limited value in their current state. Response: We thank the commenters for their support. As noted above, we are not aware of any scientific studies that support an association between scores on the Communication About Pain questions and opioid prescribing practices. However, we believe that VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 removing these questions from the HCAHPS Survey will address potential confusion about the appropriate use of the HCAHPS Survey, and is responsive to concerns regarding the public health concerns about the opioid epidemic as well as the provisions of the SUPPORT for Patients and Communities Act. Comment: A few commenters supported removal of the Communication About Pain questions due to concerns regarding the wording and focus of the questions. One commenter expressed its belief the questions focus on the frequency of communication about pain management rather than the quality or impact of this communication on the patient’s expectations and understanding about pain, while another commenter expressed concern that the questions fail to address population-specific challenges and variations in pain treatment regimens due to physician preference, patient behavior, or health care facility practices. A third commenter stated its belief the questions do not allow for a nuanced discussion of pain management and patient expectations. Another commenter asserted that the Communication About Pain questions create patient expectations that hospital personnel should always discuss pain and its treatment with patients, which the commenter believes can encourage inappropriate prescribing and unrealistic expectations. This commenter further asserted that the wording of the questions encourages providers to overemphasize pain when it may not be an issue for a particular patient. One commenter supported removal of the Communication About Pain questions to preserve the Survey’s integrity. Another commenter supported removal of the Communication About Pain questions due to concerns that the subjective nature of the HCAHPS Survey, and the Communication About Pain questions, may not accurately represent hospital performance. A third commenter expressed concern that including any questions about pain might cause patients who were unhappy about their pain treatment to provide negative responses to other, unrelated questions. Response: We thank the commenters for their support of our proposal to remove the Communication About Pain questions from the HCAHPS Survey. We continue to believe the HCAHPS Survey as a whole, and the Communication About Pain questions, are valid and reliable measures of hospital quality that encourage hospitals to assess and improve patient experience. Further, we PO 00000 Frm 00329 Fmt 4701 Sfmt 4700 59145 recognize that our programs may have an influence over trends in the opioid epidemic, which underscores our decision to remove the Communication About Pain questions from the HCAHPS Survey earlier than originally proposed. We believe that removing the Communication About Pain questions from the HCAHPS Survey out of an abundance of caution and to comply with the provisions of the SUPPORT for Patients and Communities Act will address potential confusion about the appropriate use of the HCAHPS Survey, and is responsive to concerns regarding the public health issues arising from the opioid epidemic. Comment: A few commenters also noted the lack of National Quality Forum (NQF) endorsement as a reason to remove the Communication About Pain questions from the HCAHPS Survey and recommended that regardless of whether the questions are removed, CMS should submit the Communication About Pain questions for NQF endorsement. Response: We note that, while the Hospital IQR Program is not statutorily limited to only using NQF-endorsed measures,223 we consider NQF endorsement status when evaluating measures for adoption into the measure set. While the Communication About Pain questions are not currently NQF endorsed, because we are removing the Communication About Pain questions from the HCAHPS Survey in the Hospital IQR Program, we do not believe it prudent to submit the questions for NQF endorsement at this time. However, we will take commenters’ feedback and recommendations into account as we continue to assess whether and how the Hospital IQR Program should assess communications about pain management. We note, however, that the HCAHPS Survey, in its entirety, is in fact NQF-endorsed (NQF #0166).224 Comment: A few commenters supported removal of the Communication About Pain questions because the commenters believe that it is inappropriate to tie pain management to hospital reimbursement. One commenter supported removal of the Communication About Pain questions because the commenter believed that incentivizing providers to base care on patient satisfaction increases healthcare costs. Another commenter expressed its belief that decreasing the incentive to prescribe opioids for pain management 223 Section 1886(b)(3)(B)(viii)(IX)(bb) of the Act. measure description and history, including NQF endorsement status, available at: https://www.qualityforum.org/QPS/0166/. 224 HCAHPS E:\FR\FM\21NOR2.SGM 21NOR2 khammond on DSK30JT082PROD with RULES2 59146 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations could reduce healthcare costs because opioid use can lead to a cascade of negative health effects that can increase lengths of stay and healthcare costs. Other commenters supported removal of the Communication About Pain questions because they believe it will help to reduce administrative burden and costs associated with data collection and reporting. Response: As noted above, we continue to believe the HCAHPS Survey and Communication About Pain questions are reliable measures of hospital quality that encourage hospitals to assess and improve patient experience, and that pain management is a critical part of routine patient care on which hospitals should focus and an important concern for patients, their families, and their caregivers. We believe the HCAHPS Survey is appropriate for use in CMS quality programs for public display of quality measurement data and tying hospital performance to Medicare reimbursement. However, out of an abundance of caution, and in the face of a nationwide epidemic of opioid overprescription, we believe that removal of the Communication About Pain questions from the HCAHPS Survey is warranted in order to resolve any perceived conflict between appropriate management of opioid use and patient satisfaction. Moreover, the SUPPORT for Patients and Communities Act prohibits inclusion of the Communication About Pain questions in HCAHPS Surveys conducted on or after January 1, 2020. Comment: Many commenters did not support removal of the Communication About Pain questions based on concerns that removal of the questions may minimize the importance of appropriate communication about pain management in the hospital setting. Specifically, a number of commenters stated that pain management is a critical part of routine patient care on which hospitals should focus and an important concern for patients, their families, and their caregivers, and expressed concern that removing the Communication About Pain questions may result in potential negative consequences for both patients and providers. A few commenters expressed particular concern that removal of these questions could have a negative impact on the appropriate treatment of pain associated with complex chronic and end-of-life illnesses. Some of these commenters expressed concern that removing the Communication About Pain questions might lead hospitals and providers to place less importance on communicating with patients about VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 their pain and pain management. One commenter also noted that The Joint Commission has included engaging patients in treatment decisions about their pain management as part of the pain assessment and management standards for 2018 accreditation standards.225 Some commenters who did not support removal of the pain questions urged CMS not to overlook the need to measure and evaluate how patient care is delivered and the role of appropriate communication about pain management during a hospital stay, including legitimate pain management using opioids in addition to other pain management methods. Other commenters asserted that removal of the pain questions would be tantamount to CMS refusing to acknowledge, or avoiding, the legitimate pain management needs of patients. Response: We acknowledge commenters’ concern that removal of the Communication About Pain questions may result in potential negative consequences for both patients and providers. We remain concerned, however, about the potential negative consequences resulting from retaining the Communication About Pain questions in the HCAHPS Survey, including confusion regarding the appropriate use of the questions. We believe these concerns, coupled with the severity and urgency of the nationwide opioid epidemic, warrant removing the Communication About Pain questions to relieve any potential pressure clinicians may feel to prescribe opioids in order to achieve higher scores on the HCAHPS Survey. By removing the Communication About Pain questions from the HCAHPS Survey, the Survey neither encourages nor discourages clinicians from communicating with their patients about their pain and how best to manage their pain as appropriate for the particular patient. In addition, we disagree with commenters’ assertions that removal of the Communication About Pain questions might lead hospitals and providers to place less importance on communication with their patients about their pain and pain management, or might lead to a negative impact on appropriate pain treatment, including treatment for pain associated with complex chronic and end-of-life 225 More information about The Joint Commission’s new and revised pain assessment and management standards effective January 1, 2018 is available at: https://www.jointcommission.org/ joint_commission_enhances_pain_assessment_ and_management_requirements_ for_accredited_hospitals_/. PO 00000 Frm 00330 Fmt 4701 Sfmt 4700 illnesses. As a number of commenters noted, pain management is an appropriate part of routine patient care upon which hospitals should focus and an important concern for patients, their families, and their caregivers, and we do not believe removal of the Communication About Pain questions will necessarily result in hospitals no longer focusing on maintaining a high level of performance. Rather, we remain confident that hospitals will continue to focus on appropriate pain management, including communicating with their patients about pain, as part of their commitment to the patient experience and ongoing quality improvement efforts. In addition, as one commenter noted, engaging patients in treatment decisions about their pain management is required under the enhanced pain assessment and management requirements, applicable to all Joint Commission-accredited hospitals, effective January 1, 2018.226 With respect to commenters’ requests that we not overlook the need to measure and evaluate how patient care is delivered and the role of appropriate communication about pain management during a hospital stay, including legitimate pain management using opioids in addition to other pain management methods, we reiterate that we remain dedicated to improving the quality of care provided to patients, including patients’ experience in receiving care, and continue to consider the appropriate management of pain and communication between patients and their providers regarding pain as important aspects of care quality. As previously stated, we believe that removing the Communication About Pain questions will relieve any potential undue pressure on clinicians to prescribe opioids in order to achieve high patient satisfaction scores. We also believe that removing any such potential pressure on clinicians to prescribe opioids will ensure that providers can use their best judgment regarding pain management methods most appropriate for their patients, which may include non-opioid 226 Ibid. The enhanced standards require that the hospital involves patients in the pain management treatment planning process through the following: Developing realistic expectations and measurable goals that are understood by the patient for the degree, duration, and reduction of pain; discussing the objectives used to evaluate treatment progress (for example, relief of pain and improved physical and psychosocial function); and providing education on pain management, treatment options, and safe use of opioid and non-opioid medications when prescribed. The enhanced standards also require, among other things, the hospital to analyze data collected on pain assessment and pain management to identify areas that need change to increase safety and quality for patients. E:\FR\FM\21NOR2.SGM 21NOR2 khammond on DSK30JT082PROD with RULES2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations management methods. Moreover, the SUPPORT for Patients and Communities Act prohibits inclusion of the Communication About Pain questions in HCAHPS Surveys conducted on or after January 1, 2020. Finally, we disagree with commenters’ assertion that removing the Communication About Pain questions is tantamount to CMS’ refusal to acknowledge, or avoiding, the legitimate pain management needs of patients. In the CY 2019 OPPS/ASC proposed rule (83 FR 37220), we solicited feedback regarding suggestions for other measures that would capture facets of pain management and related patient education, for instance, for collecting data about a hospital’s pain management plan and providing that information back to consumers, and how other measures could take into account provider-supplied information on appropriate pain management and whether patients are informed about the risks of opioid use and about non-opioid pain management alternatives. Numerous commenters responded to our requests for feedback, and we summarize these responses later in this discussion. We will take commenters’ suggestions into consideration as we continue to consider how best to capture and assess facets of pain management through quality measurement. Comment: A number of commenters did not support removal of the Communication About Pain questions due to the lack of empirical evidence that the questions are influencing providers to prescribe opiates or demonstrating a link between patient experience scores and opiate prescribing. One commenter further asserted that the Communication About Pain survey questions do not put more pressure on providers to prescribe opioids, but rather encourage providers to communicate about and address pain using multiple treatment methods. Response: As previously stated, we are unaware of any empirical evidence demonstrating that failing to prescribe opioids lowers a hospital’s HCAHPS Survey scores. While we intended for the Communication About Pain questions to encourage providers to communicate with patients about pain management-related issues, including non-opioid pain management therapies (82 FR 38330), out of an abundance of caution, and in the face of a nationwide epidemic of opioid overprescription, we believe that removal of the Communication About Pain questions is warranted in order to resolve any perceived conflict between appropriate management of opioid use and patient VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 satisfaction. Moreover, because the SUPPORT for Patients and Communities Act prohibits the inclusion of such questions in HCAHPS Surveys conducted on or after January 1, 2020, removal of the Communication About Pain questions is required. We believe that removing these questions will resolve any potential confusion by ensuring providers can use their best judgment in appropriately managing patients’ pain without any potential undue pressure stemming from fear of negative feedback on the HCAHPS Survey. We note that hospitals will continue to be required to administer the HCAHPS Survey comprised of the remaining 29 questions to eligible patients, and that hospital performance on HCAHPS Survey measures based on the remaining questions will continue to be publicly reported on Hospital Compare. Comment: Some commenters opposed removal of the Communication About Pain questions because hospitals rely on the data for quality and performance improvement purposes. A few commenters asserted historical HCAHPS Survey data is one of the most effective tools hospitals have to improve patient experience of care. Some commenters noted that hospitals rely on HCAHPS Survey data to inform their quality and performance improvement efforts, including data from the Communication About Pain questions to assess how well they are discussing pain and communicating issues about pain management to patients. A few commenters noted that removal of the questions would force hospitals to rely on their vendors for any pain communication composite calculations or benchmarks for internal assessment purposes, as opposed to the national and State averages provided by CMS under the HCAHPS Survey. These commenters recommended that CMS furnish providers with important care experience metrics by making current pain communication scores, along with national and State benchmarks, available through hospital preview reports, from October 2019 onward. Commenters further requested CMS include these scores in CMS data files for providers’ benchmarking and analysis. Response: We appreciate commenters’ feedback about their concerns, experiences using HCAHPS Survey data, and recommendations. We acknowledge that removal of the Communication About Pain questions will eliminate our ability to calculate State and national averages, but we believe the importance of removing any perceived pressure of opioid PO 00000 Frm 00331 Fmt 4701 Sfmt 4700 59147 overprescribing justifies removal of the questions during the national opioid epidemic. Moreover, the SUPPORT for Patients and Communities Act prohibits inclusion of the Communication About Pain questions in HCAHPS Surveys conducted on or after January 1, 2020. As described above, we will provide each hospital with feedback on its own performance in confidential preview reports starting with four quarters of CY 2018 Communication About Pain question data, and then on a rolling four-quarter basis through the final quarter of CY 2019 Communication About Pain question data (that is, the 3rd quarter of 2019). These confidential reports will include State and national averages for the reporting periods when this measure is collected. Comment: A number of commenters recommended that CMS retain the Communication About Pain questions in order to further investigate the relationship between these questions and opiate prescribing patterns, asserting that continued data collection would enable CMS to make a datadriven decision to retain or remove the questions based on available evidence. A few commenters questioned removal of the Communication About Pain questions based on concerns that the Communication About Pain questions were only recently implemented in January 2018. These commenters recommended that CMS retain the Communication About Pain questions in order to engage a broad range of stakeholders and assess their feedback regarding the use and impact of the Communication About Pain questions on opioid prescribing practices, hospital quality improvement efforts, and patient care. Other commenters recommended convening Technical Expert Panels and a pilot study to better assess the implications of removing the pain questions on patient care before removing the Communication About Pain questions. Response: We thank commenters for their recommendations to postpone removal of the Communication About Pain questions until additional analyses can be performed. While we agree delaying removal of these questions would increase the amount of data available to potentially assess the questions’ effect on physician prescription practices and the link between patient experience scores and opiate prescribing, we believe concerns regarding the potential negative consequences of retaining the questions and public health concerns about the opioid epidemic outweigh the benefits of additional data collection. We believe the importance of removing any E:\FR\FM\21NOR2.SGM 21NOR2 khammond on DSK30JT082PROD with RULES2 59148 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations perceived pressure of opioid overprescribing justifies removal of the questions during the national opioid epidemic. Moreover, the SUPPORT for Patients and Communities Act prohibits inclusion of the Communication About Pain questions in HCAHPS Surveys conducted on or after January 1, 2020. For these reasons, as discussed above, we are finalizing a modification of our proposal and are removing the Communication About Pain questions beginning with October 2019 discharges for the FY 2021 payment determination and subsequent years. Comment: Many commenters who did not support removal of the Communication About Pain questions due to the importance of capturing pain management experience data also recommended that CMS delay public reporting on the questions beyond October 2020 to allow further time for additional assessment of the questions. A number of these commenters recommended that CMS continue to test the questions and delay public reporting until the questions are valid, reliable, and do not pose a risk of unintended consequences. A few commenters also supported delaying public reporting based on their concerns about the absence of any evidence demonstrating a relationship between the use of the Communication About Pain questions and opioid prescribing behavior. Response: We thank commenters for their recommendations. We continue to believe the HCAHPS Survey as a whole, and the Communication About Pain questions, are valid and reliable measures of hospital quality that encourage hospitals to assess and improve patient experience. However, we believe that removing the Communication About Pain questions from the HCAHPS Survey during the national opioid epidemic will remove any perceived pressure of opioid overprescribing, and will address potential confusion about the appropriate use of the HCAHPS Survey. Therefore, as stated above, upon consideration of the comments received and public health concerns about the opioid epidemic, as well as to comply with the SUPPORT for Patients and Communities Act, we will not publicly report data collected from the Communication About Pain questions. Comment: A number of commenters responded to CMS’ request for feedback in the proposed rule (83 FR 37220) regarding whether it would be valuable for CMS to issue guidance suggesting that hospitals do not administer any surveys with pain-related questions, including adding hospital-specific supplemental items to HCAHPS, as well VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 as the potential implementation of a third party quality assurance program to assure that hospitals are not misusing survey data by creating pressure on individual clinicians to provide inappropriate clinical care. A few commenters recommended that CMS consider issuing guidance to providers and hospitals regarding appropriate use of the HCAHPS Survey, specifically against the disaggregation of HCAHPS Survey data. These commenters stated their belief that clearer survey use guidance would mitigate inappropriate use of survey results, such as using disaggregated data to assess providers’ performance, to compare performance across providers or wards, and/or to influence provider performance by tying disaggregated survey results to individual clinician compensation. One commenter asserted that CMS guideline adherence works best when an HCAHPS Survey vendor provides hospitals and healthcare systems with clear communication and interpretation of those guidelines, and therefore recommended against implementation of an HCAHPS Survey-specific quality assurance program. This commenter recommended that CMS consider future implementation of a third-party quality assurance program for all CMSmandated CAHPS surveys. Other commenters recommended against CMS disallowing administration of supplemental pain management related questions alongside the HCAHPS Survey. These commenters noted pain remains one of the most important aspects of a patient’s experience of care, that hospitals rely on this survey-based information for research and evaluation regarding their quality and efficacy of care, and that disallowing these supplemental questions would effectively omit a critical care experience factor from hospitals’ quality improvement efforts. Response: We thank the commenters for their feedback and will take these recommendations into consideration as we move forward with the HCAHPS Survey. Comment: A number of commenters responded to CMS’ request for feedback regarding suggestions for other measures that would capture facets of pain management and related patient education, and that would provide that information back to consumers, as well as CMS’ request for feedback regarding how other measures could take into account provider-supplied information on appropriate pain management and whether patients are informed about the risks of opioid use and about non-opioid pain management alternatives. Many commenters encouraged CMS to engage PO 00000 Frm 00332 Fmt 4701 Sfmt 4700 with stakeholders, including hospitals, clinicians, experts in pain management and palliative care, measure developers, researchers, the NQF, and the Measure Applications Partnership (MAP) to explore a range of approaches to assessing how healthcare systems and hospitals are addressing pain management, including further revisions to the pain questions in HCAHPS Survey and the use of other measurement methods, including pain assessments that are more sensitive to beneficiaries’ needs. Several commenters recommended that CMS engage in further research on the current version of the Communication About Pain questions, including assessing the potential tie between the questions and opioid prescribing practices. A few commenters provided specific recommendations for improving pain management assessment within the HCAHPS Survey. Some commenters recommended that CMS revise the current pain management questions to focus more on alternative pain management methods, such as ice packs and over-the-counter pain medication, and to better assess whether the patient was given sufficient guidance on how to manage pain post-discharge. Another commenter recommended that CMS develop new pain management questions focused on pain management processes and evidence-based standards of care rather than patient-reported outcomes. A third commenter recommended that CMS develop alternate questions assessing the role and behaviors of different clinicians in a patient’s pain management because the commenter believed these alternatives are more objective than the current Communication About Pain questions and would provide a better picture of the assessment and treatment undertaken by the clinician for the patient’s pain. Another commenter encouraged CMS to conduct additional research on pain-related survey questions and prescribing practices in emergency departments. One commenter recommended that CMS continue to collect the current Communication About Pain questions while evaluating potential new measures due to the importance of continuing to collect data on hospitals’ communication about pain management as a critical component of patient experience and because more time is needed to collect feedback on potential alternatives. One commenter suggested CMS evaluate assessing communication about pain management within the context of specific care episodes because these E:\FR\FM\21NOR2.SGM 21NOR2 khammond on DSK30JT082PROD with RULES2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations assessments could focus on the use of targeted pain management modalities, unlike the global HCAHPS Survey. This commenter further recommended that CMS focus on developing high-priority pain measures that can improve functional assessment scores with reduced opioid use. Another commenter recommended that CMS evaluate the use of patient-reported outcome measures to assess pain management and communication about pain because the commenter believed these types of measures would provide hospitals with valuable experience of care data relative to the investment required to update infrastructure and workflow investment. A third commenter expressed support for development of meaningful measures of pain management but urged caution about the potential for measures to create undue barriers to access to appropriate pain medication for patients suffering from chronic pain and therefore recommended that CMS strive to make measures more sensitive to patients’ disease state. Another commenter encouraged additional research and measure development specific to emergency department care and emergency nursing. Response: We appreciate the feedback from commenters and will take these comments into consideration as we continue to consider how best to capture and assess facets of pain management through quality measurement, including the role of appropriate communication about pain during a hospital stay, informing patients about the risks associated with the use of opioids, and educating patients on non-opioid alternative pain management methods. As stated above, we believe that removing the Communication About Pain questions from the HCAHPS Survey out of an abundance of caution during the national opioid epidemic will help to address any potential confusion about the appropriate use of the HCAHPS Survey by relieving any potential pressure or undue influence on clinicians’ opioid prescribing practices. Comment: Some commenters recommended that CMS focus on mitigating any unintended consequences of pain management assessment before developing new measures, and further recommended against the adoption of measures that increase administrative burden and/or are not linked to improved outcomes. These commenters also recommended that CMS enable hospitals and physicians to monitor the administration of opioids and promote their evidence-based use through programs that are tailored to the needs VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 of the hospital and its patient population. One commenter specifically recommended against development of pain management-specific measures because the commenter believes a set of measures designed to be applied universally would downplay critical factors that are necessary to create individualized pain management plans. One commenter requested a model of the impact of the removal of the Communication About Pain questions on overall HCAHPS scores and urged CMS to carefully balance the need to remove the questions with the need to retain an important component of patient experience. Response: We appreciate the feedback from commenters and will take these comments into consideration as we continue to consider how best to capture and assess facets of pain management through quality measurement, including the role of appropriate communication about pain during a hospital stay, informing patients about the risks associated with the use of opioids, and educating patients on non-opioid alternative pain management methods. We will continue to consider unintended consequences of pain management assessment and we encourage hospitals to monitor the administration of opioids through programs that are tailored to the needs of the specific hospitals and patient populations. We do not anticipate that removing the Communication About Pain questions would impact the overall HCAHPS scores. We note that the data collected from the Communication About Pain questions will not be scored for purposes of CMS payments to hospitals, because the Hospital IQR Program is a pay-for-reporting not payfor-performance quality program. Further, we note that the data from the Communication About Pain question will not be publicly reported. Our decision to remove the Communication About Pain questions from the HCAHPS Survey was based upon careful consideration of the importance of addressing patients’ experience, stakeholder feedback, and the nationwide opioid epidemic. Comment: A few commenters recommended that instead of removing the Communication About Pain questions, CMS consider incentivizing alternative pain management methods. Specifically, one commenter recommended that CMS consider alternate ways to ensure adequate patient awareness of non-opioid alternative treatments because the commenter believed that in the future there will be more ways to treat chronic and acute pain. Another commenter PO 00000 Frm 00333 Fmt 4701 Sfmt 4700 59149 expressed the belief that there is a need for additional funding or other incentives to increase research supporting evidence-based practices around effective pain assessment and intervention and to develop operational guidelines and clinical practice standards for use in hospitals. A few commenters who supported both the importance of assessing patient experience, as well as of avoiding incentivizing inappropriate opioid prescribing, urged CMS to ensure that CMS does not adopt policies that could impede access to medication for patients who legitimately need opioids. Response: We appreciate the feedback from commenters and will take these comments into consideration as we continue to consider how best to capture and assess facets of pain management through quality measurement, including the role of appropriate communication about pain during a hospital stay, informing patients about the risks associated with the use of opioids, and educating patients on non-opioid alternative pain management methods. After consideration of the public comments we received, and as required by the SUPPORT for Patients and Communities Act, we are finalizing a modified version of our proposals regarding removal of the Communication About Pain questions from the HCAHPS Survey in the Hospital IQR Program. Instead of removing the questions effective with January 2022 discharges, for the FY 2024 payment determination and subsequent years as proposed, we are finalizing removing them effective with October 2019 discharges, for the FY 2021 payment determination and subsequent years. In addition, instead of publicly reporting the data from October 2020 until October 2022 and then subsequently discontinuing public reporting as proposed, we are finalizing that we will not publicly report the data collected from the Communication About Pain questions at all. XVII. Additional PPS-Exempt Cancer Hospital Quality Reporting (PCHQR) Program Policies A. Background Section 1866(k)(1) of the Act requires that, for FY 2014 and each subsequent fiscal year, hospitals described in section 1886(d)(1)(B)(v) of the Act (referred to as ‘‘PPS-Exempt Cancer Hospitals’’ or ‘‘PCHs’’) submit data to the Secretary in accordance with section 1866(k)(2) of the Act with respect to such fiscal year. E:\FR\FM\21NOR2.SGM 21NOR2 59150 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations The PPS-Exempt Cancer Hospital Quality Reporting (PCHQR) Program strives to put patients first by ensuring they, along with their clinicians, are empowered to make decisions about their own health care using data-driven insights that are increasingly aligned with meaningful quality measures. To this end, we support technology that reduces burden and allows clinicians to focus on providing high quality health care to their patients. We also support innovative approaches to improve the quality, accessibility, and affordability of care, while paying particular attention to improving clinicians’ and beneficiaries’ experiences when participating in CMS programs. In combination with other efforts across the Department of Health and Human Services (HHS), we believe the PCHQR Program incentivizes PCHs to improve their health care quality and value, while giving patients the tools and information needed to make the best decisions. For additional background information, including previously finalized measures and other policies for the PCHQR Program, we refer readers to the following final rules: The FY 2013 IPPS/LTCH PPS final rule (77 FR 53556 through 53561); the FY 2014 IPPS/LTCH PPS final rule (78 FR 50838 through 50846); the FY 2015 IPPS/LTCH PPS final rule (79 FR 50277 through 50288); the FY 2016 IPPS/LTCH PPS final rule (80 FR 49713 through 49723); the FY 2017 IPPS/LTCH PPS final rule (81 FR 57182 through 57193); the FY 2018 IPPS/LTCH PPS final rule (82 FR 38411 through 38425); and the FY 2019 IPPS/LTCH PPS final rule (83 FR 41609 through 41624). khammond on DSK30JT082PROD with RULES2 B. Retention of Two Safety Measures in the PCHQR Program In the FY 2019 IPPS/LTCH PPS final rule (83 FR 41611 through 41616), we finalized the removal of four previously finalized measures and finalized one new quality measure for the FY 2021 program year and subsequent years. We also discussed our proposal in the FY 2019 IPPS/LTCH PPS proposed rule (83 FR 20503) to remove two National Healthcare Safety Network (NHSN) chart-abstracted measures from the PCHQR Program beginning with the FY 2021 program year under proposed removal Factor 8, ‘‘the costs associated with the measure outweigh the benefit of its continued use in the program.’’ The measures we had proposed to remove under this removal factor are: • NHSN Catheter-Associated Urinary Tract Infection (CAUTI) Outcome Measure (PCH–5/NQF #0138); and VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 • NHSN Central Line-Associated Bloodstream Infection (CLABSI) Outcome Measure (PCH–4/NQF #0139). We noted that we had first adopted the CAUTI and CLABSI measures for the FY 2014 program year in the FY 2013 IPPS/LTCH PPS final rule (77 FR 53557 through 53559), and we referred readers to that final rule for a detailed discussion of the measures. We also stated that we had proposed to remove these measures from the PCHQR Program based on our belief that removing these measures would reduce program costs and complexities associated with the use of these data by patients in decision-making. We also believed the costs, coupled with the high technical and administrative burden on PCHs associated with collecting and reporting this measure data, outweighed the benefits of the continued use of the CAUTI and CLABSI measures in the program. Further, we noted that it has become difficult to publicly report these measures due to the low volume of data produced and reported by the small number of facilities participating in the PCHQR Program and the corresponding lack of an appropriate methodology to publicly report these data. We stated in the FY 2019 IPPS/LTCH PPS final rule (83 FR 41613) that we had invited public comment on our proposals to remove the CAUTI and CLABSI measures from the PCHQR Program beginning with the FY 2021 program year. We also stated that we would defer making a final decision on the removal or retention of the CAUTI and CLABSI measures from the PCHQR Program in order to conduct additional data analyses to assess measure performance based on new information provided by the CDC which was not available at the time we had proposed the removal of these measures. Lastly, we stated that we wished to evaluate those data for trends that link positive improvements (that is, a decrease in the reporting burden and/or cost, and/or demonstrated feasibility for public reporting) to these measures. We also noted that we would reconcile the public comments we received in future rulemaking. Comment: Many commenters supported the proposed removal of the CAUTI and CLABSI measures from the PCHQR Program. Commenters indicated that an appropriate statistical method to publicly report the data has not been identified and believed that these definitional and statistical issues may hamper the cancer hospitals’ ability to identify opportunities for internal performance improvement activities related to these measures. Commenters PO 00000 Frm 00334 Fmt 4701 Sfmt 4700 also noted that the low number of PCHs, the heterogeneous makeup of the hospitals, and the nationwide dispersion of the sites make it difficult to provide meaningful comparisons for consumers. Commenters supported CMS’ efforts in streamlining the PCHQR Program measure set, consistent with CMS’ commitment to using a smaller set of more meaningful measures and reducing paperwork and reporting burden on providers. Nevertheless, given the potential negative impact of health-care acquired infections (HAIs) on patients, particularly for the cancer patient population, commenters encouraged the CDC and CMS to continue to work collaboratively with professional societies to standardize definitions, reporting, and sharing of data to foster performance improvement in these areas. Response: We thank the commenters for their support. We will continue to work collaboratively to standardize definitions, and to develop a sufficient reporting mechanism for quality metrics that assess the impact of HAIs on patients, particularly for the cancer patient population. However, for the reasons discussed in more detail below, we are not finalizing our proposals to remove the CAUTI and CLABSI measures from the PCHQR Program. Comment: Some commenters did not support the proposed removal of the CAUTI and CLABSI measures from the PCHQR Program, asserting that the application of proposed removal Factor 8 was inadequate for measure removal because consumers’ needs have not been appropriately factored into the value assessment of the measures. Commenters specifically expressed concern that removing these measures might inappropriately deemphasize the importance of patient safety in quality care delivery. The commenters further questioned whether cost is the direct driving factor for the low volume of reporting on the CAUTI and CLABSI measures. Commenters also noted that because cancer hospitals will still be required to complete NHSN reporting for other measures, removal of the CAUTI and CLABSI measures would not necessarily lead to significant burden reduction. Lastly, commenters encouraged CMS to continue to work with the measures’ developer to consider alternative methodologies for publicly reporting the measure data. Response: We thank the commenters for their feedback. We believe the primary benefit of a measure’s use in the PCHQR Program is to empower consumers through incentivizing the provision of high quality care and providing publicly reported data E:\FR\FM\21NOR2.SGM 21NOR2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations regarding the quality of care available for use in making decisions about their care. Therefore, we intend to consider the benefits, especially to patients and their families, when evaluating measures under measure removal Factor 8, which we finalized in the FY 2019 IPPS/LTCH PPS final rule (83 FR 41609 through 41611). We emphasize that consumers’ needs and interests are factored into the value assessment of measures prior to any proposal to remove a measure from the PCHQR Program, and further note that we regularly solicit consumer feedback on the PCHQR Program via public comment periods and education and outreach activities, and that this feedback informs our policy development efforts. khammond on DSK30JT082PROD with RULES2 At the time that we proposed to remove the CAUTI and CLABSI measures from the PCHQR Program, the available performance data did not enable us to assess PCH performance relative to oncology unit performance in other care settings. In addition, CDC’s previous analytic work used to develop the rebaselined predictive models had demonstrated that PCH status was not a significant predictor for either CAUTIs or CLABSIs. Since that time, we have conducted our own updated analyses regarding the continued use of the CAUTI and CLABSI measures in the PCHQR Program using updated CDC data. Although CDC had previously believed that oncology unit locations, including those in PCHs, had a higher incidence of infections than other types of units in acute care hospitals, CDC now believes, after controlling for location type, that oncology unit locations in PCHs do not have a higher incidence of infection than oncology units within other acute care hospitals. CDC’s updated analysis also produced a consistent finding that cancer hospital status was not a significant risk factor in any of the device-associated HAI risk models, including those used for VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 CLABSI and CAUTI.227 We believe that these results indicate that reporting PCH CAUTI and CLABSI performance measure data is just as important as reporting acute care hospital CAUTI and CLABSI performance measure data. We are aware that the CLABSI and CAUTI measures specifications were recently updated to use new standard infection ratio (SIR) calculations that can be applied to cancer hospitals, including PCHs. This SIR calculation method is different than the current CLABSI and CAUTI measure methodology, which provides raw location-stratified rates. We are also aware that there may be concern that the CAUTI and CLABSI data calculated under the current methodology may inaccurately appear to show lower performance among PCHs than the performance reported by acute care hospitals that are reporting CLABSI and CAUTI data under the newly updated methodology. We believe this recent update 228 of the CAUTI and CLABSI measures addresses these concerns. Specifically, the updates include rates that are stratified by patient care locations within PCHs, and no predictive models or comparisons are used in these rate calculations. We intend to propose to adopt these updated versions of the CLABSI and CAUTI measures in future rulemaking but believe that, until that time, the importance of emphasizing patient safety in quality care delivery justifies retaining the current versions of the CLABSI and CAUTI measures in the PCHQR Program. Despite the fact that infection rates are not higher in the PCHs, we believe it is important to measure CLABSI and CAUTI in this setting. However, we will work closely with the CDC to assess the updated riskadjusted versions of CAUTI and CLABSI, and evaluate the data provided 227 SIR Guide: August 2018 Update. Available at: https://www.cdc.gov/nhsn/pdfs/ps-analysisresources/nhsn-sir-guide.pdf. 228 NHSN Patient Safety Component Manual: January 2018 Update. Available at: https:// www.cdc.gov/nhsn/pdfs/pscmanual/pcsmanual_ current.pdf. PO 00000 Frm 00335 Fmt 4701 Sfmt 4700 59151 in the form of SIRs for each PCH, for the purposes of future program implementation and public reporting. After consideration of the public comments we received, and consideration of the most recent information provided by the CDC, we are not finalizing our proposals to remove the Catheter-Associated Urinary Tract Infection (CAUTI) Outcome Measure (PCH–5/NQF #0138) and Central Line-Associated Bloodstream Infection (CLABSI) Outcome Measure (PCH–4/NQF #0139) from the PCHQR measures beginning with the FY 2021 program year. We agree with the conclusions drawn from the CDC’s data analyses, which demonstrate that reporting PCH CAUTI and CLABSI performance measure data is just as important as reporting acute care hospital CAUTI and CLABSI performance measure data. Further, we believe that these measures have the potential to provide beneficiaries with valuable information on PCH performance in avoiding hospitalacquired infections and improving patient safety. However, for the reasons discussed in section XVII.C.2. of this final rule with comment period, we are continuing to defer public reporting of these measure data. We believe this approach most effectively balances the needs of the PCHQR Program and the importance of collecting patient safety data while taking into consideration the impact on the 11 PCHs of reporting raw data to CMS. We hope to introduce the refined CAUTI and CLABSI measures with adequate risk adjustment into the PCHQR Program in the near future. We note any such change will be made via rulemaking, and that we will solicit input from the Measures Application Partnership (MAP) to garner multistakeholder input on the updated versions prior to proposing to adopt these refined measures. The table below summarizes the PCHQR Program measure set for the FY 2021 program year: BILLING CODE 4120–01–P E:\FR\FM\21NOR2.SGM 21NOR2 59152 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations FY 2021 PCHQR Program Measure Set Short Name NQF Measure Name Number Safety and Healthcare-Associated Infection (HAl) CAUTI 0138 CLABSI 0139 Colon and Abdominal Hysterectomy SSI 0753 CDI 1717 MRSA 1716 HCP 0431 National Healthcare Safety Network (NHSN) Catheter Associated Urinary Tract Infection (CAUTI) Outcome Measure National Healthcare Safety Network (NHSN) Central Line Associated Bloodstream Infection (CLABSI) Outcome Measure American College of Surgeons - Centers for Disease Control and Prevention (ACS-CDC) Harmonized Procedure Specific Surgical Site Infection (SSI) Outcome Measure [currently includes SSis following Colon Surgery and Abdominal Hysterectomy Surgery] National Healthcare Safety Network (NHSN) Facility-wide Inpatient Hospital-onset Clostridium Di{ficile Infection (CDI) Outcome Measure National Healthcare Safety Network (NHSN) Facility-wide Inpatient Hospital-onset Methicillin-resistant Staphylococcus Aureus Bacteremia Outcome Measure National Healthcare Safety Network (NHSN) Influenza Vaccination Coverage Among Healthcare Personnel Clinical Process/Oncology Care Measures N/A 0383 EOL-Chemo 0210 EOL-Hospice 0215 Oncology: Plan of Care for Pain- Medical Oncology and Radiation Oncology Proportion of Patients Who Died from Cancer Receiving Chemotherapy in the Last 14 Days of Life Proportion of Patients Who Died from Cancer Not Admitted to Hospice Intermediate Clinical Outcome Measures EOL-ICU 0213 EOL-3DH 0216 Proportion of Patients Who Died from Cancer Admitted to the ICU in the Last 30 Days of Life Proportion of Patients Who Died from Cancer Admitted to Hospice for Less Than Three Days Patient Engagement/Experience of Care HCAHPS 0166 HCAHPS EBRT VerDate Sep<11>2014 20:42 Nov 20, 2018 1822 Jkt 247001 PO 00000 External Beam Radiotherapy for Bone Metastases Frm 00336 Fmt 4701 Sfmt 4725 E:\FR\FM\21NOR2.SGM 21NOR2 ER21NO18.116</GPH> khammond on DSK30JT082PROD with RULES2 Clinical Effectiveness Measure Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations C. Continued Deferment of Public Display of the NHSN Measures 1. Background Under section 1866(k)(4) of the Act, we are required to establish procedures for making the data submitted under the PCHQR Program available to the public. Such procedures must ensure that a PCH has the opportunity to review the data that are to be made public with respect to the PCH prior to such data being made public. Section 1866(k)(4) of the Act also provides that the Secretary must report quality measures of process, structure, outcome, patients’ perspective on care, efficiency, and costs of care that relate to services furnished in such hospitals on the CMS website. 2. Deferment of Public Display of National Healthcare Safety Network (NHSN) Measures In the FY 2019 IPPS/LTCH PPS final rule (83 FR 41622), we indicated that all PCHs are reporting Colon and Abdominal Hysterectomy SSI, MRSA, CDI, and HCP data to the NHSN under the PCHQR Program. In 2016, the CDC announced that HAI data reported to NHSN for 2015 will be used as the new baseline, serving as a new ‘‘reference point’’ for comparing progress.229 The results of the rebaselining allow for year-to-year comparisons beginning with 2015 data; beginning with FY 2019, we will have more than 2 years of comparable data available for evaluation. We are currently still evaluating the data resulting from the 3. Update on Public Display of the Admissions and Emergency Department (ED) Visits for Patients Receiving Outpatient Chemotherapy Measure In the FY 2017 IPPS/LTCH PPS final rule (81 FR 57187 through 57188), we 229 Centers khammond on DSK30JT082PROD with RULES2 for Disease Control and Prevention. ‘‘Paving Path Forward: 2015 Rebase line.’’ Available at: https://www.cdc.gov/nhsn/2015rebaseline/ index.html. rebaselining to properly assess trends.230 Therefore, in that final rule (83 FR 41622), we finalized a modification of our proposal to delay public reporting of data for the SSI, MRSA, CDI, and HCP measures until CY 2019. Based on stakeholder feedback, we finalized a policy to provide stakeholders with performance data as soon as practicable (that is, if useable data is available sooner than CY 2019, we will publicly report it on the Hospital Compare website via the next available Hospital Compare release). As discussed above, we are not finalizing our proposal to remove the CAUTI and CLABSI measures. However, we will continue to defer public reporting for the CAUTI and CLABSI measures as indicated in the FY 2018 IPPS/LTCH PPS final rule (82 FR 38423). Based on our intent to propose to adopt the revised versions of the measures in the PCQHR Program in future rulemaking, we are continuing to evaluate the performance data for the updated versions of the CAUTI and CLABSI measures to draw conclusions about their statistical significance, in accordance with current risk adjustment methods defined by CDC. For these reasons, we are finalizing that we will provide stakeholders with performance data for the CAUTI and CLABSI measures as soon as practicable. VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 230 Rebase line Timeline FAQ Document. Available at: https://www.cdc.gov/nhsn/pdfs/ rebaseline/faq-timeline-rebaseline.pdf. PO 00000 Frm 00337 Fmt 4701 Sfmt 4700 stated that we would publicly report the risk-standardized admission rate (RSAR) and risk-standardized ED visit rate (RSEDR) for the Admissions and Emergency Department (ED) Visits for the Patients Receiving Outpatient Chemotherapy measure for all participating PCHs with 25 or more eligible patients per measurement period to maintain a reliability of at least 0.4 (as measured by the interclass correlation coefficient, (ICC)). We also noted that if a PCH did not meet the 25eligible patient threshold, we would include a footnote on the Hospital Compare website indicating that the number of cases is too small to reliably measure that PCH’s rate, but that these patients and PCHs would still be included when calculating the national rates for both the RSAR and RSEDR. Lastly, we indicated that to prepare PCHs for public reporting, we would conduct a confidential national reporting (dry run) of measure results prior to public reporting. We recently completed the confidential national reporting (dry run) for this measure and are currently assessing the results to ensure data accuracy and completeness. We intend to propose a timeframe for public reporting of this measure in the FY 2020 IPPS/LTCH PPS proposed rule. 4. Summary of Public Display Requirements for the FY 2021 Program Year Our public display policies for the FY 2021 program year are shown in the following table: E:\FR\FM\21NOR2.SGM 21NOR2 ER21NO18.117</GPH> BILLING CODE 4120–01–C 59153 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations khammond on DSK30JT082PROD with RULES2 XVIII. Files Available to the Public via the Internet The Addenda to the OPPS/ASC proposed rules and the final rules with comment period are published and available via the internet on the CMS website. In the CY 2019 OPPS/ASC proposed rule (83 FR 37220), for CY 2019, we proposed to change the format of the OPPS Addenda A, B, and C, by adding a column entitled ‘‘Copayment Capped at the Inpatient Deductible of $1,364.00’’ where we would flag, through use of an asterisk, those items and services with a copayment that is equal to or greater than the inpatient hospital deductible amount for any given year (the copayment amount for a procedure performed in a year cannot exceed the amount of the inpatient hospital deductible established under section 1813(b) of the Act for that year). We requested public comments on this proposed change to the OPPS Addenda A, B, and C for CY 2019. We did not receive any public comments regarding the proposed CY 2019 format changes for the OPPS Addenda A, B, and C. Therefore, for CY 2019, we are finalizing our proposal to add an additional column entitled VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 ‘‘Copayment Capped at the Inpatient Deductible of $1,364.00’’ where we flag, through use of an asterisk, those items and services with a copayment that is equal to or greater than the inpatient hospital deductible amount for any given year for which the copayment will be capped at the inpatient deductible amount. To view the Addenda to this final rule with comment period pertaining to CY 2019 payments under the OPPS, we refer readers to the CMS website at: https://www.cms.gov/Medicare/ Medicare-Fee-for-Service-Payment/ HospitalOutpatientPPS/HospitalOutpatient-Regulations-andNotices.html; select ‘‘1695–FC’’ from the list of regulations. All OPPS Addenda to this final rule with comment period are contained in the zipped folder entitled ‘‘2019 OPPS 1695–FC Addenda’’ at the bottom of the page. To view the Addenda to this final rule with comment period pertaining to CY 2019 payments under the ASC payment system, we refer readers to the CMS website at: https://www.cms.gov/ Medicare/Medicare-Fee-for-ServicePayment/ASCPayment/ASCRegulations-and-Notices.html; select PO 00000 Frm 00338 Fmt 4701 Sfmt 4700 ‘‘1695–FC’’ from the list of regulations. All ASC Addenda to this final rule with comment period are contained in the zipped folders entitled ‘‘Addendum AA, BB, DD1, DD2, and EE.’’ XIX. Collection of Information Requirements A. Statutory Requirement for Solicitation of Comments Under the Paperwork Reduction Act of 1995, we are required to provide 60day notice in the Federal Register and solicit public comment before a collection of information requirement is submitted to the Office of Management and Budget (OMB) for review and approval. In order to fairly evaluate whether an information collection should be approved by OMB, section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995 requires that we solicit comment on the following issues: • The need for the information collection and its usefulness in carrying out the proper functions of our agency. • The accuracy of our estimate of the information collection burden. • The quality, utility, and clarity of the information to be collected. E:\FR\FM\21NOR2.SGM 21NOR2 ER21NO18.118</GPH> 59154 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations • Recommendations to minimize the information collection burden on the affected public, including automated collection techniques. In the CY 2019 OPPS/ASC proposed rule (83 FR 37720), we solicited public comment on each of these issues for the following sections of this document that contain information collection requirements (ICRs). khammond on DSK30JT082PROD with RULES2 B. ICRs for the Hospital OQR Program 1. Background The Hospital OQR Program is generally aligned with the CMS quality reporting program for hospital inpatient services known as the Hospital IQR Program. We refer readers to the CY 2011 through CY 2018 OPPS/ASC final rules with comment periods (75 FR 72111 through 72114; 76 FR 74549 through 74554; 77 FR 68527 through 68532; 78 FR 75170 through 75172; 79 FR 67012 through 67015; 80 FR 70580 through 70582; 81 FR 79862 through 79863; and 82 FR 59476 through 59479, respectively) for detailed discussions of Hospital OQR Program information collection requirements we have previously finalized. The information collection requirements associated with the Hospital OQR Program are currently approved under OMB control number 0938–1109. Below we discuss only the changes in burden that will result from the newly finalized policies in this final rule with comment period. In section XIII.B.4.b. of the proposed rule, we proposed to remove a total of 10 measures. Specifically, beginning with the CY 2020 payment determination, we proposed to remove: (1) OP–27: Influenza Vaccination Coverage Among Healthcare Personnel; and beginning with the CY 2021 payment determination, we proposed to remove: (2) OP–5: Median Time to ECG; (3) OP–9: Mammography Follow-up Rates; (4) OP–11: Thorax CT Use of Contrast Material; (5) OP–12: The Ability for Providers with HIT to Receive Laboratory Data Electronically Directly into Their Qualified/Certified EHR System as Discrete Searchable Data; (6) OP–14: Simultaneous Use of Brain Computed Tomography (CT) and Sinus CT; (7) OP–17: Tracking Clinical Results between Visits; (8) OP–29: Endoscopy/Polyp Surveillance: Appropriate Follow-up Interval for Normal Colonoscopy in Average Risk Patients; (9) OP–30: Endoscopy/Polyp Surveillance: Colonoscopy Interval for Patients with a History of Adenomatous Polyps—Avoidance of Inappropriate Use; and (10) OP–31: Cataracts— Improvement in Patient’s Visual Function within 90 Days Following VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 Cataract Surgery. However, after consideration of public comments we received, in this final rule with comment period we are not finalizing our proposals to remove two measures: OP–29: Endoscopy/Polyp Surveillance: Appropriate Follow-up Interval for Normal Colonoscopy in Average Risk Patients; and OP–31: Cataracts— Improvement in Patient’s Visual Function within 90 Days Following Cataract Surgery beginning with the CY 2021 payment determination. The reduction in burden associated with our finalized policies is discussed below in sections XIX.B.3. and 4. of this final rule with comment period. In section XIII.D.2. of this final rule with comment period, we are finalizing our proposal to update the frequency with which we will release HOPD Specifications Manuals, with modification, such that instead of releasing the full manual once or twice a year, as proposed, we would release specifications manuals every 12 months beginning with CY 2019 and for subsequent years and release addenda (specific updates rather than full manual releases) as necessary. In section XIII.C.2. of this final rule with comment period, beginning with the CY 2020 payment determination, we are finalizing our proposal to remove the Notice of Participation (NOP) form as a requirement for the Hospital OQR Program and to update 42 CFR 419.46(a) to reflect these policies. As discussed below, we do not expect these finalized policies to affect our collection of information burden estimates. 2. Update to the Frequency of Releasing Hospital Outpatient Quality Reporting Specifications Manuals Beginning With CY 2019 and for Subsequent Years In section XIII.D.2. of this final rule with comment period, we are finalizing our proposal, with modification, to update the frequency with which we will release Hospital Outpatient Quality Reporting Specifications Manuals, with modification such that instead of releasing the full manual once or twice each year, as proposed, we will release the Specifications Manuals once every 12 months and release addenda as necessary, beginning with CY 2019 and for subsequent years. We anticipate that this change will reduce hospital confusion, as releasing fewer manuals per year reduces the need to review updates as frequently as was previously necessary. However, because this change does not affect Hospital OQR Program participation requirements or data reporting requirements, we do not expect a change in the information PO 00000 Frm 00339 Fmt 4701 Sfmt 4700 59155 collection burden experienced by hospitals. 3. Estimated Burden of Hospital OQR Program Newly Finalized Policies for the CY 2020 Payment Determination and Subsequent Years a. Removal of the Notice of Participation (NOP) Form Requirement In section XIII.C.2.b. of this final rule with comment period, beginning with the CY 2020 payment determination, we are finalizing our proposal to remove the NOP form as a requirement. As a result, to be a participant in the Hospital OQR Program, hospitals will need to: (1) Register on the QualityNet website; (2) identify and register a QualityNet security administrator, and (3) submit data. In addition, we are finalizing our proposal to update 42 CFR 419.46(a) to reflect these policies. We have previously estimated in the CY 2014 OPPS/ASC final rule with comment period (78 FR 75171) that the burden associated with administrative requirements including completing program requirements, system requirements, and managing facility operations is 42 hours per hospital or 138,600 hours across 3,300 hospitals. We believe that removal of the NOP requirement will reduce administrative burden experienced by hospitals by only a nominal amount, as it is not required every year, but only at the start of a hospital’s participation. As a result, this finalized policy does not influence our information collection burden estimates. b. Removal of OP–27 for the CY 2020 Payment Determination and Subsequent Years In section XIII.B.4.b. of this final rule with comment period, we are finalizing our proposal to remove the OP–27: Influenza Vaccination Coverage Among Healthcare Personnel (NQF #0431) measure beginning with the CY 2020 payment determination and for subsequent years. The burden associated with OP–27, a National Healthcare Safety Network (NHSN) measure, is accounted for under a separate information collection request, OMB control number 0920–0666. Because burden associated with submitting data for this measure is captured under a separate OMB control number, we are not providing an estimate of the information collection burden associated with this measure for the Hospital OQR Program. E:\FR\FM\21NOR2.SGM 21NOR2 59156 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations 4. Estimated Burden of Hospital OQR Program Newly Finalized Policies for the CY 2021 Payment Determination and Subsequent Years a. Removal of Chart-Abstracted Measures for the CY 2021 Payment Determination and Subsequent Years In section XIII.B.4.b. of this final rule with comment period, we are finalizing our proposal to remove one chartabstracted measure for the CY 2021 payment determination and subsequent years: OP–5: Median Time to ECG. With regard to chart-abstracted measures for which patient-level data is submitted directly to CMS, we have previously estimated it would take 2.9 minutes, or 0.049 hours, per measure to collect and submit the data for each submitted case (80 FR 70582). In addition, based on the most recent data, we estimate that 947 cases are reported per hospital for chartabstracted measures. Therefore, we estimate that it will take approximately 46 hours (0.049 hours × 947 cases) to collect and report data for each chartabstracted measure. Accordingly, we believe that the removal of this chartabstracted measure for the CY 2021 payment determination will reduce burden by 151,800 hours (46 hours × 3,300 hospitals) and $5.6 million (151,800 hours × $36.58 231). khammond on DSK30JT082PROD with RULES2 b. Removal of Measures Submitted Via a Web-Based Tool for the CY 2021 Payment Determination and Subsequent Years While we proposed to remove five measures submitted via a web-based tool beginning with the CY 2021 payment determination and for subsequent years, in section XIII.B.4.b. of this final rule with comment period, we are only finalizing our proposals to remove three measures: (1) OP–12: The Ability for Providers with HIT to Receive Laboratory Data Electronically Directly into Their Qualified/Certified EHR System as Discrete Searchable Data; (2) OP–17: Tracking Clinical Results between Visits; and (3) OP–30: Endoscopy/Polyp Surveillance: Colonoscopy Interval for Patients with a History of Adenomatous Polyps— Avoidance of Inappropriate Use. In section XIII.B.4.b. of this final rule with comment period, we are not finalizing 231 In the CY 2018 OPPS/ASC final rule with comment period (82 FR 59477), we finalized an hourly labor cost to hospitals of $36.58 and specified that this cost included both wage ($18.29) and 100 percent overhead and fringe benefit costs (an additional $18.29). The estimate for this duty is available in the Bureau of Labor Statistics report on Occupation Employment and Wages for May 2016, 29–2071 Medical Records and Health Information Technicians at: https://www.bls.gov/ oes/2016/may/oes292071.htm. VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 our proposals to remove the following web-based measures for the CY 2021 payment determination and subsequent years: OP–29: Endoscopy/Polyp Surveillance: Appropriate Follow-up Interval for Normal Colonoscopy in Average Risk Patients; and OP–31: Cataracts—Improvement in Patient’s Visual Function within 90 Days Following Cataract Surgery. Therefore, we are revising the initially estimated burden reduction from the CY 2019 OPPS/ASC proposed rule. As we stated in the CY 2016 OPPS/ ASC final rule with comment period (80 FR 70582), we estimate that hospitals spend approximately 10 minutes, or 0.167 hours, per measure to report webbased measures. Accordingly, we believe that the removal of OP–12, OP– 17, and OP–30 for the CY 2021 payment determination will reduce burden by 0.501 hours per hospital (3 measures × 0.167 hours per measure) and 1,653 hours (0.501 hours × 3,300 hospitals) across 3,300 hospitals. In addition, we estimate that OP–30 requires 25 additional minutes (0.417 hours) per case per measure to chart-abstract and that hospitals would each abstract 384 cases per year for this measure. This number is based on previous analysis (78 FR 75171) where we estimated that each of the approximately 3,300 responding hospitals will have a case volume adequate to support quarterly sample sizes of 96 cases, for a total of 384 cases (96 cases per quarter × 4 quarters) to be abstracted by each hospital annually. Therefore, we estimate an additional burden reduction of 528,422 hours (3,300 hospitals × 0.417 hours × 384 cases per measure) for all participating hospitals for OP–30. In total, we estimate a burden reduction of 530,075 hours (1,653 hours for web submission + 528,422 hours for chartabstraction of OP–30) and $19.4 million (530,075 hours × $36.58) due to the removal of three web-based measures from the Hospital OQR Program for the CY 2021 payment determination and for subsequent years. c. Removal of Claims-Based Measures for the CY 2021 Payment Determination and Subsequent Years In section XIII.B.4.b. of this final rule with comment period, we are finalizing our proposals to remove three claimsbased measures beginning with the CY 2021 payment determination: OP–9: Mammography Follow-up Rates; OP–11: Thorax CT Use of Contrast Material; and OP–14: Simultaneous Use of Brain Computed Tomography (CT) and Sinus CT. Claims-based measures are derived through analysis of administrative claims data and do not require PO 00000 Frm 00340 Fmt 4701 Sfmt 4700 additional effort or burden on hospitals. As a result, we do not expect these removals to affect collection of information burden for the CY 2021 payment determination. In total for the CY 2021 payment determination, we expect the information collection burden will be reduced by 151,800 hours due to the removal of one chart-abstracted measure, and 530,075 hours due to the removal of three measures submitted via a web-based tool. In total, we estimate an information collection burden reduction of 681,875 hours (151,800 hours for the removal of one chartabstracted measure + 530,075 hours for the removal of three web-based measures) and $24.9 million (681,875 hours × $36.58) for the CY 2021 payment determination. C. ICRs for the ASCQR Program 1. Background We refer readers to the CY 2012 OPPS/ASC final rule with comment period (76 FR 74554), the FY 2013 IPPS/ LTCH PPS final rule (77 FR 53672), and the CY 2013, CY 2014, CY 2015, CY 2016, CY 2017, and CY 2018 OPPS/ASC final rules with comment period (77 FR 68532 through 68533; 78 FR 75172 through 75174; 79 FR 67015 through 67016; 80 FR 70582 through 70584; 81 FR 79863 through 79865; and 82 FR 59479 through 59481, respectively) for detailed discussions of the ASCQR Program information collection requirements we have previously finalized. The information collection requirements associated with the ASCQR Program are currently approved under OMB control number 0938–1270. Below we discuss only the changes in burden that would result from the newly finalized provisions in this final rule with comment period. While we proposed to remove eight measures, in section XIV.B.3.c. of this final rule with comment period, we are only finalizing the removal of two measures: One measure beginning with the CY 2020 payment determination, ASC–8: Influenza Vaccination Coverage Among Healthcare Personnel, and one measure beginning with the CY 2021 payment determination: ASC–10: Endoscopy/Polyp Surveillance: Colonoscopy Interval for Patients with a History of Adenomatous Polyps— Avoidance of Inappropriate Use. We expect these finalized policies will reduce the overall burden of reporting data for the ASCQR Program, as discussed below. In section XIV.B.3.c. of this final rule with comment period, we are not finalizing our proposal to remove ASC–9: Endoscopy/Polyp E:\FR\FM\21NOR2.SGM 21NOR2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations Surveillance Follow-up Interval for Normal Colonoscopy in Average Risk Patients beginning with the CY 2021 payment determination and ASC–11: Cataracts: Improvement in Patient’s Visual Function within 90 Days Following Cataract Surgery. In addition, we are not finalizing our proposals to remove ASC–1: Patient Burn; ASC–2: Patient Fall; ASC–3: Wrong Site, Wrong Side, Wrong Patient, Wrong Procedure, Wrong Implant; and ASC–4: All-Cause Hospital Transfer/Admission, but are instead retaining the measures in the ASCQR Program and suspending their data collection beginning with the CY 2019 reporting period/CY 2021 payment determination until further action in rulemaking with the goal of updating the measures. khammond on DSK30JT082PROD with RULES2 2. Estimated Burden of ASCQR Program Newly Finalized Policy Beginning With CY 2020 Payment Determination and Subsequent Years: Removal of ASC–8 In section XIV.B.3.c. of this final rule with comment period, we are finalizing the removal of one measure beginning with the CY 2020 payment determination, ASC–8: Influenza Vaccination Coverage Among Healthcare Personnel. Data for ASC–8 are submitted via a non-CMS online data submission tool, to the NHSN. However, we note that the information collection burden associated with ASC– 8, a NHSN measure, is accounted for under a separate information collection request, OMB control number 0920– 0666. As such, we are not providing an estimate of the information collection burden associated with this measure under the ASCQR Program OMB control number. 3. Estimated Burden of ASCQR Program Newly Finalized Measure Removals for the CY 2021 Payment Determination While we proposed to remove seven measures beginning with the CY 2021 payment determination, in section XIV.B.3.c. of this final rule with comment period, we are only finalizing our proposal to remove one measure: ASC–10: Endoscopy/Polyp Surveillance: Colonoscopy Interval for Patients with a History of Adenomatous Polyps—Avoidance of Inappropriate Use. In section XIV.B.3.c. of this final rule with comment period we are not finalizing our proposals to remove ASC– 9: Endoscopy/Polyp Surveillance Follow-up Interval for Normal Colonoscopy in Average Risk Patients and ASC–11: Cataracts—Improvement in Patient’s Visual Function within 90 Days Following Cataract Surgery. In addition, we are not finalizing our proposals to remove ASC–1: Patient VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 Burn; ASC–2: Patient Fall; ASC–3: Wrong Site, Wrong Side, Wrong Patient, Wrong Procedure, Wrong Implant; and ASC–4: All-Cause Hospital Transfer/ Admission, but are instead retaining the measures in the ASCQR Program and suspending their data collection beginning with the CY 2019 reporting period/CY 2021 payment determination until further action in rulemaking with the goal of updating the measures. Therefore, we are revising the estimated information collection burden changes from the estimates included in the CY 2019 OPPS/ASC proposed rule (83 FR 37222). a. Removal of One Chart-Abstracted Measure for the CY 2021 Payment Determination and Subsequent Years In section XIV.B.3.c. of this final rule with comment period, we are finalizing the removal of one chart-abstracted measure from the ASCQR Program measure set beginning with the CY 2021 payment determination: ASC–10: Endoscopy/Polyp Surveillance: Colonoscopy Interval for Patients with a History of Adenomatous Polyps— Avoidance of Inappropriate Use. We believe 3,937 ASCs will experience a reduction in information collection burden associated with our finalized policy to remove ASC–10 from the ASCQR Program measure set. In the CY 2017 OPPS/ASC final rule with comment period (81 FR 79864), we finalized our estimates that each participating ASC would spend 0.25 hours (15 minutes) per case per measure per year to collect and submit the required data for ASC–10. We estimate that the average number of patients per ASC is 63 based on the historic average. In addition, we estimate the total annual information collection burden per ASC to be 15 hours and 45 minutes (15.75 hours) per measure (0.25 hours × 63 cases). Therefore, for ASC–10, we estimate the total annualized information collection burden to be 62,008 hours (3,937 ASCs × 15.75 hours per ASC) and $2,268,244 (3,937 ASCs × 15.75 hours per ASC × $36.58 per hour 232). Therefore, we estimate a total reduction in information collection burden of 62,008 hours and $2,268,244 as a result of our removal of ASC–10 from the ASCQR Program measure set for the CY 2021 payment determination. 232 In the CY 2018 OPPS/ASC final rule with comment period (82 FR 59479 through 59480), we finalized an hourly labor cost to hospitals of $36.58 and specified that this cost included both wage and overhead and fringe benefit costs. The estimate for this duty is available in the Bureau of Labor Statistics report on Occupation Employment and Wages for May 2016, 29–2071 Medical Records and Health Information Technicians at: https:// www.bls.gov/oes/2016/may/oes292071.htm. PO 00000 Frm 00341 Fmt 4701 Sfmt 4700 59157 The reduction in information collection burden associated with these requirements is available for review and comment under OMB control number 0938–1270. D. ICRs for the Update to the HCAHPS Survey Measure in the Hospital IQR Program As described in section XVI. of this final rule with comment period, we are finalizing a modified version of our proposals regarding the Communication About Pain questions from the HCAHPS Survey in the Hospital IQR Program. Instead of removing the questions effective with January 2022 discharges, for the FY 2024 payment determination and subsequent years as proposed, we are finalizing to remove them effective with October 2019 discharges, for the FY 2021 payment determination and subsequent years. In addition, instead of publicly reporting the data in October 2022 and then subsequently discontinuing as proposed, we are finalizing that we will not publicly report the data collected from the Communication About Pain questions at all. While we anticipate that the removal of these questions will reduce the burden associated with reporting this measure, as further discussed below, the burden estimate for the Hospital IQR Program excludes the burden associated with the HCAHPS Survey measure, which is submitted under a separate information collection request and approved under OMB control number 0938–0981. For discussion of the burden estimate for the Hospital IQR Program under OMB control number 0938–1022, we refer readers to the FY 2019 IPPS/LTCH PPS final rule (83 FR 41689 through 41694). For details on the burden estimate specifically for the HCAHPS Survey, including use of the Communication About Pain questions, we refer readers to the notice published in the Federal Register on Information Collection for the National Implementation of the Hospital CAHPS Survey (83 FR 21296 through 21297). We note that a revised information collection request under OMB control number 0938–0981 will be submitted to OMB based on the update to the HCAHPS Survey in accordance with this final rule with comment period. As noted above, the removal of the Communication About Pain questions does not change the estimated burden for the Hospital IQR Program under the program’s OMB control number 0938– 1022. However, we believe that overall cost and burden will change slightly for hospitals and HCAHPS Survey respondents. Under HCAHPS Survey E:\FR\FM\21NOR2.SGM 21NOR2 59158 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations khammond on DSK30JT082PROD with RULES2 OMB control number 0938–0981, it is estimated that the average cost and hour burdens for hospitals are $4,000 and 1 hour per hospital for HCAHPS data collection activities. Because these estimates include administrative activities and overhead costs, we believe our removal of the Communication About Pain questions from the HCAHPS Survey will not reduce these estimates of hospital burden or will only nominally and temporarily increase the average cost and hour burdens associated with the removal of these questions from the survey, given the need to adjust the survey instrument and instructional materials and, therefore, marginally reduce the burden due to the shortening of the survey instrument. Under HCAHPS Survey OMB control number 0938–0981, the average time for a respondent to answer the 32 question survey is estimated at 8 minutes, which we estimate to be 0.25 minutes per question (8 minutes/32 questions = 0.25 minutes per question). In addition, under this OMB control number, the number of respondents is estimated at 3,104,200 respondents. In this final rule with comment period, we are finalizing a modified version of our proposal to remove 3 questions, which we estimate would reduce the time burden by 0.75 minutes (0.25 minutes per question × 3 questions), or 0.0125 hours (0.75 minutes/60 minutes) per respondent. We anticipate a total hourly burden reduction for respondents of 38,803 hours (0.0125 hours × 3,104,200 respondents). Further, under OMB control number 0938–0981, the cost of respondent time is based on the average hourly earnings of $26.71 per hour, as reported by the U.S. Bureau of Labor VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 Statistics final January 2018 estimates available on the website at: https:// www.bls.gov/eag/eag.us.htm.233 We anticipate a total cost reduction for respondents associated with the proposal to remove the three Communication About Pain questions of $1,036,428 (38,803 total hours × respondent earnings estimate of $26.71 per hour) for the FY 2021 payment determination. E. ICRs for PPS-Exempt Cancer Hospital Quality Reporting (PCHQR) Program for the FY 2021 Program Year In the FY 2019 IPPS/LTCH PPS proposed rule (83 FR 20503), we proposed to remove two NHSN measures, Catheter-Associated Urinary Tract Infection (CAUTI) Outcome Measure (PCH–5/NQF #0138) and Central Line-Associated Bloodstream Infection (CLABSI) Outcome Measure (PCH–4/NQF #0139), from the PCHQR Program beginning with the FY 2021 program year. In section VIII.B.3.b.(2) of the preamble of the FY 2019 IPPS/LTCH PPS final rule (83 FR 41613), we indicated that we would take final action regarding our proposals to remove the CAUTI and CLABSI measures in a future 2018 final rule. In section XVII. of this final rule with comment period, after consideration of the public comments received, and consideration of the most recent information provided by the CDC, we are not finalizing our proposals to remove the CAUTI and CLABSI measures. We note that this CDC information was not available at the 233 Average hourly earnings of $26.71 per hour based on the average hourly earnings of all employees on private non-farm payrolls, seasonally adjusted, per the U.S. Bureau of Labor Statistics. PO 00000 Frm 00342 Fmt 4701 Sfmt 4700 time when we proposed the removal of these measures from the PCHQR Program. In the FY 2019 IPPS/LTCH PPS final rule (83 FR 41695) we reconciled the burden estimates associated with the NHSN measures (CLABSI, CAUTI, CDI, HCP, MRSA and Colon and Abdominal Hysterectomy SSI) included in the PCHQR Program, which were formerly accounted for under both the PCHQR Program’s estimates OMB control number 0938–1175 and the CDC’s estimates under OMB control number 0920–0666. Because the CDC maintains the NHSN system used to collect this data and captures the burden associated with this data collection under its estimates in OMB control number 0920– 0666, we removed the duplicative burden estimate from the PCHQR Program’s OMB Control Number, 0938– 1175. As a result, there is no change in burden under the PCHQR Program associated with not finalizing removal of the CLABSI and CAUTI measures. In summary, our decisions not to remove the CAUTI and CLABSI measures in the PCHQR Program for FY 2021 program year and subsequent years does not change the information collection estimates for the PCHQR Program. We refer readers to section XIV.B.4 of the FY 2019 IPPS/LTCH PPS final rule (83 FR 41694 through 41695) for more detail on the information collection calculations for the finalized policies in the PCHQR Program. F. Total Reduction in Burden Hours and in Costs Below is a chart reflecting the total burden and associated costs for the provisions included in this final rule with comment period. E:\FR\FM\21NOR2.SGM 21NOR2 XX. Response to Comments Because of the large number of public comments we normally receive on Federal Register documents, we are not able to acknowledge or respond to them individually. We will consider all comments we receive by the date and time specified in the DATES section of this final rule with comment period, and, when we proceed with a subsequent document(s), we will respond to those comments in the preamble to that document. XXI. Economic Analyses khammond on DSK30JT082PROD with RULES2 A. Statement of Need This final rule with comment period is necessary to make updates to the Medicare hospital OPPS rates. It is necessary to make changes to the payment policies and rates for outpatient services furnished by hospitals and CMHCs in CY 2019. We are required under section 1833(t)(3)(C)(ii) of the Act to update annually the OPPS conversion factor used to determine the payment rates for APCs. We also are required under section 1833(t)(9)(A) of the Act to review, not less often than annually, and revise the groups, the relative payment weights, and the wage and other adjustments described in section 1833(t)(2) of the Act. We must review the clinical integrity of payment groups and relative payment weights at least annually. We are revising the APC VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 relative payment weights using claims data for services furnished on and after January 1, 2017, through and including December 31, 2017, and processed through June 30, 2018, and updated cost report information. We note that we are finalizing our proposal to control unnecessary increases in the volume of covered outpatient department services by paying for clinic visits furnished at offcampus PBDs at an amount equal to the site-specific PFS payment rate for nonexcepted items and services furnished by a nonexcepted off-campus PBD (the PFS payment rate). The sitespecific PFS payment rate for clinic visits furnished in excepted off-campus PBDs is the OPPS rate reduced to the amount paid for clinic visits furnished by nonexcepted off-campus PBDs under the PFS, which is 40 percent of the OPPS rate. We expect that, by removing the payment differential, we will control unnecessary volume increases both in terms of the number of covered outpatient services furnished and the costs of those services. We are implementing this policy with a 2-year phase-in. In CY 2019, the payment reduction will be transitioned by applying 50 percent of the total reduction in payment that would apply if these off-campus PBDs were paid the site-specific PFS payment rate for the clinic visit service. In other words, these excepted off-campus PBDs will be paid 70 percent of the OPPS rate for the PO 00000 Frm 00343 Fmt 4701 Sfmt 4700 59159 clinic visit service in CY 2019. In CY 2020, we will complete the transition to paying the PFS-equivalent amount for clinic visits furnished in excepted offcampus PBDs. In other words, these excepted off-campus PBDs will be paid 40 percent of the OPPS rate for the clinic visit service in CY 2020. This final rule with comment period also is necessary to make updates to the ASC payment rates for CY 2019, enabling CMS to make changes to payment policies and payment rates for covered surgical procedures and covered ancillary services that are performed in an ASC in CY 2019. Because ASC payment rates are based on the OPPS relative payment weights for most of the procedures performed in ASCs, the ASC payment rates are updated annually to reflect annual changes to the OPPS relative payment weights. In addition, we are required under section 1833(i)(1) of the Act to review and update the list of surgical procedures that can be performed in an ASC, not less frequently than every 2 years. For CYs 2019 through 2023, we are finalizing our proposal to update the ASC payment system rates using the hospital market basket update instead of the CPI–U. We believe that this finalized proposal could stabilize the differential between OPPS payments and ASC payments, given that the CPI–U has been generally lower than the hospital market basket, and encourage the E:\FR\FM\21NOR2.SGM 21NOR2 ER21NO18.119</GPH> Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations 59160 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations khammond on DSK30JT082PROD with RULES2 migration of services to lower cost settings as clinically appropriate. B. Overall Impact for Provisions of This Final Rule With Comment Period We have examined the impacts of this final rule with comment period, as required by Executive Order 12866 on Regulatory Planning and Review (September 30, 1993), Executive Order 13563 on Improving Regulation and Regulatory Review (January 18, 2011), the Regulatory Flexibility Act (RFA) (September 19, 1980, Pub. L. 96–354), section 1102(b) of the Social Security Act, section 202 of the Unfunded Mandates Reform Act of 1995 (UMRA) (March 22, 1995, Pub. L. 104–4), Executive Order 13132 on Federalism (August 4, 1999), the Congressional Review Act (5 U.S.C. 804(2)), and Executive Order 13771 on Reducing Regulation and Controlling Regulatory Costs (January 30, 2017). This section of this final rule with comment period contains the impact and other economic analyses for the provisions we are finalizing for CY 2019. Executive Orders 12866 and 13563 direct agencies to assess all costs and benefits of available regulatory alternatives and, if regulation is necessary, to select regulatory approaches that maximize net benefits (including potential economic, environmental, public health and safety effects, distributive impacts, and equity). Executive Order 13563 emphasizes the importance of quantifying both costs and benefits, of reducing costs, of harmonizing rules, and of promoting flexibility. This final rule with comment period has been designated as an economically significant rule under section 3(f)(1) of Executive Order 12866 and a major rule under the Congressional Review Act. Accordingly, this final rule with comment period has been reviewed by the Office of Management and Budget. We have prepared a regulatory impact analysis that, to the best of our ability, presents the costs and benefits of the provisions of this final rule with comment period. In the CY 2019 OPPS/ ASC proposed rule (83 FR 37224), we solicited public comments on the regulatory impact analysis in the proposed rule, and we address any public comments we received in this final rule with comment period, as appropriate. We estimate that the total increase in Federal government expenditures under the OPPS for CY 2019, compared to CY 2018, due only to the changes to the OPPS in this final rule with comment period, will be approximately $440 million. Taking into account our VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 estimated changes in enrollment, utilization, and case-mix for CY 2019, we estimate that the OPPS expenditures, including beneficiary cost-sharing, for CY 2019 will be approximately $74.1 billion; approximately $5.8 billion higher than estimated OPPS expenditures in CY 2018. We note that these spending estimates include the final CY 2019 final policy to control for unnecessary increases in the volume of covered outpatient department services by paying for clinic visits furnished at excepted off-campus PBDs at a rate that will be 70 percent of the OPPS rate for a clinic visit service. Because the provisions of the OPPS are part of a final rule that is economically significant, as measured by the threshold of an additional $100 million in expenditures in 1 year, we have prepared this regulatory impact analysis that, to the best of our ability, presents its costs and benefits. Table 62 of this final rule with comment period displays the distributional impact of the CY 2019 changes in OPPS payment to various groups of hospitals and for CMHCs. As noted in sections V.B.7. and X.C.2. of this final rule with comment period, we are finalizing our proposal for CY 2019 to pay for separately payable drugs and biological products that do not have pass-through payment status and are not acquired under the 340B program at WAC+3 percent instead of WAC+6 percent, if ASP data are unavailable for payment purposes. If WAC data are not available for a drug or biological product, we will continue our policy to pay separately payable drugs and biological products at 95 percent of the AWP. Drugs and biologicals that are acquired under the 340B Program will continue to be paid at ASP minus 22.5 percent, WAC minus 22.5 percent, or 69.46 percent of AWP, as applicable. We estimate that the update to the conversion factor and other adjustments (not including the effects of outlier payments, the pass-through payment estimates, the application of the frontier State wage adjustment for CY 2019, and the finalized proposal to control for unnecessary increases in the volume of covered outpatient department services described in section X.B. of this final rule with comment period) will increase total OPPS payments by 1.3 percent in CY 2019. The changes to the APC relative payment weights, the changes to the wage indexes, the continuation of a payment adjustment for rural SCHs, including EACHs, and the payment adjustment for cancer hospitals will not increase OPPS payments because these changes to the OPPS are budget neutral. However, these updates will change the distribution of payments within the PO 00000 Frm 00344 Fmt 4701 Sfmt 4700 budget neutral system. We estimate that the total change in payments between CY 2018 and CY 2019, considering all budget neutral payment adjustments, changes in estimated total outlier payments, pass-through payments, the application of the frontier State wage adjustment, and the finalized proposal to control unnecessary increases in the volume of outpatient services as described in section X.B. of this final rule with comment period, in addition to the application of the OPD fee schedule increase factor after all adjustments required by sections 1833(t)(3)(F), 1833(t)(3)(G), and 1833(t)(17) of the Act, will increase total estimated OPPS payments by 0.6 percent. We estimate the total increase (from changes to the ASC provisions in this final rule with comment period as well as from enrollment, utilization, and case-mix changes) in Medicare expenditures (not including beneficiary cost-sharing) under the ASC payment system for CY 2019 compared to CY 2018, to be approximately $200 million. Because the provisions for the ASC payment system are part of a final rule that is economically significant, as measured by the $100 million threshold, we have prepared a regulatory impact analysis of the changes to the ASC payment system that, to the best of our ability, presents the costs and benefits of this portion of this final rule with comment period. Tables 63 and 64 of this final rule with comment period display the redistributive impact of the CY 2019 changes regarding ASC payments, grouped by specialty area and then grouped by procedures with the greatest ASC expenditures, respectively. C. Detailed Economic Analyses 1. Estimated Effects of OPPS Changes in This Final Rule With Comment Period a. Limitations of Our Analysis The distributional impacts presented here are the projected effects of the CY 2019 policy changes on various hospital groups. We post on the CMS website our hospital-specific estimated payments for CY 2019 with the other supporting documentation for this final rule with comment period. To view the hospitalspecific estimates, we refer readers to the CMS website at: https:// www.cms.gov/Medicare/Medicare-Feefor-Service-Payment/ HospitalOutpatientPPS/. At the website, select ‘‘regulations and notices’’ from the left side of the page and then select ‘‘CMS–1695–FC’’ from the list of regulations and notices. The hospital-specific file layout and the E:\FR\FM\21NOR2.SGM 21NOR2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations khammond on DSK30JT082PROD with RULES2 hospital-specific file are listed with the other supporting documentation for this final rule with comment period. We show hospital-specific data only for hospitals whose claims were used for modeling the impacts shown in Table 62 below. We do not show hospitalspecific impacts for hospitals whose claims we were unable to use. We refer readers to section II.A. of this final rule with comment period for a discussion of the hospitals whose claims we do not use for ratesetting and impact purposes. We estimate the effects of the individual policy changes by estimating payments per service, while holding all other payment policies constant. We use the best data available, but do not attempt to predict behavioral responses to our policy changes in order to isolate the effects associated with specific policies or updates, but any policy that changes payment could have a behavioral response. In addition, we have not made adjustments for future changes in variables, such as service volume, service-mix, or number of encounters. b. Estimated Effects of the Finalized Proposal To Control for Unnecessary Increases in the Volume of Outpatient Services In section X.B. of this final rule with comment period, we discuss our CY 2019 finalized proposal to control for unnecessary increases in the volume of outpatient department services by paying for clinic visits furnished at an off-campus PBD at an amount equal to the site-specific PFS payment rate for nonexcepted items and services furnished by a nonexcepted off-campus PBD (the PFS payment rate). Specifically, we are finalizing our proposal to pay for HCPCS code G0463 (Hospital outpatient clinic visit for assessment and management of a patient) when billed with modifier ‘‘PO’’ at an amount equal to the sitespecific PFS payment rate for nonexcepted items and services furnished by a nonexcepted off-campus PBD (the PFS payment rate), with a 2year transition period. For a discussion of the PFS payment amount for outpatient clinic visits furnished at nonexcepted off-campus PBDs, we refer readers to the CY 2018 PFS final rule with comment period discussion (82 FR 53023 through 53024), as well as the CY 2019 PFS final rule. To develop an estimated impact of this policy, we began with CY 2017 outpatient claims data used in ratesetting for the CY 2019 OPPS. We then flagged all claim lines for HCPCS code G0463 that contained modifier ‘‘PO’’ because the presence of this VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 modifier indicates that such claims were billed for services furnished by an offcampus department of a hospital paid under the OPPS. Next, we excluded those that were billed as a component of C–APC 8011 (Comprehensive Observation Services) or packaged into another C–APC because in those instances OPPS payment is made for a broader package of services. We then simulated payment for the remaining claim lines as if they were paid at the PFS-equivalent rate. An estimate of the policy that includes the effects of estimated changes in enrollment, utilization, and case-mix based on the FY 2019 President’s budget approximates the estimated decrease in total payment under the OPPS at $380 million, with Medicare OPPS payments decreasing by $300 million and beneficiary copayments decreasing by $80 million in CY 2019. This estimate is utilized for the accounting statement displayed in Table 65 of this final rule with comment period because the impact of this CY 2019 policy, which is not budget neutral, is combined with the impact of the OPD update, which is also not budget neutral, to estimate changes in Medicare spending under the OPPS as a result of the changes in this final rule with comment period. The estimated decrease in payment due to this policy is not as great as in the proposed rule because we are proposing to transition the application of this policy over 2 years. We note that our estimates may differ from the actual effect of the policy due to offsetting factors, such as changes in provider behavior. We note that, by removing this payment differential that may influence site-of-service decisionmaking, we anticipate an associated decrease in the volume of clinic visits provided in the excepted off-campus PBD setting. In the proposed rule, we reminded readers that this estimate could change in this final rule with comment period based on a number of factors such as the availability of updated data, changes in the final payment policy, and/or the method of assessing the payment impact in the final rule with comment period. This estimate changed due to the final policy of establishing a 2-year phase-in. As discussed in more detail in section X.B. of the proposed rule, we sought public comment on both our proposed payment policy for clinic visits furnished at off-campus PBDs as well as how to apply methods for controlling overutilization of services more broadly. We refer readers to section X.B. of this final rule with comment period for our PO 00000 Frm 00345 Fmt 4701 Sfmt 4700 59161 discussion of the public comments we received. c. Estimated Effects of Finalized Proposal To Apply the 340B Drug Payment Policy to Nonexcepted OffCampus Departments of Hospitals In section X.C. of this final rule with comment period, we discuss the proposal we are finalizing to pay average sales price (ASP) minus 22.5 percent under the PFS for separately payable 340B-acquired drugs furnished by nonexcepted, off-campus PBDs beginning in CY 2019. This is consistent with the payment methodology adopted in CY 2018 for 340B-acquired drugs furnished in hospital departments paid under the OPPS. To develop an estimated impact of this finalized proposal, we began with CY 2017 outpatient claims data used in ratesetting for the CY 2019 OPPS. We then flagged all claim lines that contained modifier ‘‘PN’’ because the presence of this modifier indicates that such claims were billed for services furnished by a nonexcepted off-campus department of a hospital paid under the PFS. We further subset this population by identifying 340B hospitals that billed for status indicator ‘‘K’’ drugs or biologicals (that is, nonpass-through, separately payable drugs) because such drugs may have been subject to the 340B discount. We found 117 unique nonexcepted off-campus PBDs associated with 340B hospitals billed for status indicator ‘‘K’’ drugs. Their ‘‘K’’ billing represents approximately $183 million in Medicare payments (including beneficiary copayments) based on a payment rate of ASP+6 percent. Based on our adjustment, for CY 2019, we estimate that the Medicare Program and beneficiaries will save approximately $49.1 million, under the PFS. This estimate represents an upper bound of potential savings under the PFS for this policy change and does not include adjustments for beneficiary enrollment, case-mix, or potential offsetting behaviors. We noted in the proposed rule that the estimated effect of the proposed policy could change in this final rule with comment period based on a number of factors such as the availability of updated data, changes in the final payment policy, and/or the method of assessing the payment impact in the final rule. d. Estimated Effects of OPPS Changes on Hospitals Table 62 below shows the estimated impact of this final rule with comment period on hospitals. Historically, the first line of the impact table, which estimates the change in payments to all E:\FR\FM\21NOR2.SGM 21NOR2 khammond on DSK30JT082PROD with RULES2 59162 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations facilities, has always included cancer and children’s hospitals, which are held harmless to their pre-BBA amount. We also include CMHCs in the first line that includes all providers. We include a second line for all hospitals, excluding permanently held harmless hospitals and CMHCs. We present separate impacts for CMHCs in Table 62, and we discuss them separately below, because CMHCs are paid only for partial hospitalization services under the OPPS and are a different provider type from hospitals. In CY 2019, we are paying CMHCs for partial hospitalization services under APC 5853 (Partial Hospitalization for CMHCs), and we are paying hospitals for partial hospitalization services under APC 5863 (Partial Hospitalization for Hospital-Based PHPs). The estimated increase in the total payments made under the OPPS is determined largely by the increase to the conversion factor under the statutory methodology. The distributional impacts presented do not include assumptions about changes in volume and service-mix. The conversion factor is updated annually by the OPD fee schedule increase factor, as discussed in detail in section II.B. of this final rule with comment period. Section 1833(t)(3)(C)(iv) of the Act provides that the OPD fee schedule increase factor is equal to the market basket percentage increase applicable under section 1886(b)(3)(B)(iii) of the Act, which we refer to as the IPPS market basket percentage increase. The IPPS market basket percentage increase for FY 2019 is 2.9 percent (83 FR 41395). Section 1833(t)(3)(F)(i) of the Act reduces that 2.9 percent by the multifactor productivity adjustment described in section 1886(b)(3)(B)(xi)(II) of the Act, which is 0.8 percentage point for FY 2019 (which is also the MFP adjustment for FY 2019 in the FY 2019 IPPS/LTCH PPS final rule (83 FR 41395)), and sections 1833(t)(3)(F)(ii) and 1833(t)(3)(G)(v) of the Act further reduce the market basket percentage increase by 0.75 percentage point, resulting in the OPD fee schedule increase factor of 1.35 percent. We are using the OPD fee schedule increase factor of 1.35 percent in the calculation of the CY 2019 OPPS conversion factor. Section 10324 of the Affordable Care Act, as amended by HCERA, further authorized additional expenditures outside budget neutrality for hospitals in certain frontier States that have a wage index less than 1.0000. The amounts attributable to this frontier State wage index adjustment are incorporated in the CY 2019 estimates VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 in Table 62 of this final rule with comment period. To illustrate the impact of the CY 2019 changes, our analysis begins with a baseline simulation model that uses the CY 2018 relative payment weights, the FY 2018 final IPPS wage indexes that include reclassifications, and the final CY 2018 conversion factor. Table 62 shows the estimated redistribution of the increase or decrease in payments for CY 2019 over CY 2018 payments to hospitals and CMHCs as a result of the following factors: The impact of the APC reconfiguration and recalibration changes between CY 2018 and CY 2019 (Column 2); the wage indexes and the provider adjustments (Column 3); the combined impact of all of the changes described in the preceding columns plus the 1.35 percent OPD fee schedule increase factor update to the conversion factor (Column 4); the finalized offcampus PBD clinic visits payment policy (Column 5), and the estimated impact taking into account all payments for CY 2019 relative to all payments for CY 2018, including the impact of changes in estimated outlier payments, the frontier State wage adjustment, and changes to the pass-through payment estimate (Column 6). We did not model an explicit budget neutrality adjustment for the rural adjustment for SCHs because we are maintaining the current adjustment percentage for CY 2019. Because the updates to the conversion factor (including the update of the OPD fee schedule increase factor), the estimated cost of the rural adjustment, and the estimated cost of projected pass-through payment for CY 2019 are applied uniformly across services, observed redistributions of payments in the impact table for hospitals largely depend on the mix of services furnished by a hospital (for example, how the APCs for the hospital’s most frequently furnished services will change), and the impact of the wage index changes on the hospital. However, total payments made under this system and the extent to which this final rule with comment period will redistribute money during implementation also will depend on changes in volume, practice patterns, and the mix of services billed between CY 2018 and CY 2019 by various groups of hospitals, which CMS cannot forecast. Overall, we estimate that the rates for CY 2019 will increase Medicare OPPS payments by an estimated 0.6 percent. Removing payments to cancer and children’s hospitals because their payments are held harmless to the preOPPS ratio between payment and cost and removing payments to CMHCs PO 00000 Frm 00346 Fmt 4701 Sfmt 4700 results in an estimated 0.6 percent increase in Medicare payments to all other hospitals. These estimated payments will not significantly impact other providers. Column 1: Total Number of Hospitals The first line in Column 1 in Table 62 shows the total number of facilities (3,840), including designated cancer and children’s hospitals and CMHCs, for which we were able to use CY 2017 hospital outpatient and CMHC claims data to model CY 2018 and CY 2019 payments, by classes of hospitals, for CMHCs and for dedicated cancer hospitals. We excluded all hospitals and CMHCs for which we could not plausibly estimate CY 2018 or CY 2019 payment and entities that are not paid under the OPPS. The latter entities include CAHs, all-inclusive hospitals, and hospitals located in Guam, the U.S. Virgin Islands, Northern Mariana Islands, American Samoa, and the State of Maryland. This process is discussed in greater detail in section II.A. of this final rule with comment period. At this time, we are unable to calculate a DSH variable for hospitals that are not also paid under the IPPS because DSH payments are only made to hospitals paid under the IPPS. Hospitals for which we do not have a DSH variable are grouped separately and generally include freestanding psychiatric hospitals, rehabilitation hospitals, and long-term care hospitals. We show the total number of OPPS hospitals (3,727), excluding the hold-harmless cancer and children’s hospitals and CMHCs, on the second line of the table. We excluded cancer and children’s hospitals because section 1833(t)(7)(D) of the Act permanently holds harmless cancer hospitals and children’s hospitals to their ‘‘pre-BBA amount’’ as specified under the terms of the statute, and therefore, we removed them from our impact analyses. We show the isolated impact on the 46 CMHCs at the bottom of the impact table and discuss that impact separately below. Column 2: APC Recalibration—All Changes Column 2 shows the estimated effect of APC recalibration. Column 2 also reflects any changes in multiple procedure discount patterns or conditional packaging that occur as a result of the changes in the relative magnitude of payment weights. As a result of APC recalibration, we estimate that urban hospitals will experience no change, with the impact ranging from an increase of 0.4 percent to a decrease of 0.1 percent, depending on the number of beds. Rural hospitals will experience E:\FR\FM\21NOR2.SGM 21NOR2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations khammond on DSK30JT082PROD with RULES2 an increase of 0.1 percent, with the impact ranging from a decrease of 0.3 percent to an increase of 0.4 percent, depending on the number of beds. Major teaching hospitals will experience no change. Column 3: Wage Indexes and the Effect of the Provider Adjustments Column 3 demonstrates the combined budget neutral impact of the APC recalibration; the updates for the wage indexes with the FY 2019 IPPS postreclassification wage indexes; the rural adjustment; and the cancer hospital payment adjustment. We modeled the independent effect of the budget neutrality adjustments and the OPD fee schedule increase factor by using the relative payment weights and wage indexes for each year, and using a CY 2018 conversion factor that included the OPD fee schedule increase and a budget neutrality adjustment for differences in wage indexes. Column 3 reflects the independent effects of the updated wage indexes, including the application of budget neutrality for the rural floor policy on a nationwide basis. This column excludes the effects of the frontier State wage index adjustment, which is not budget neutral and is included in Column 6. We did not model a budget neutrality adjustment for the rural adjustment for SCHs because we are continuing the rural payment adjustment of 7.1 percent to rural SCHs for CY 2019, as described in section II.E. of this final rule with comment period. We also did not model a budget neutrality adjustment for the cancer hospital payment adjustment because we are using a payment-to-cost ratio target for the cancer hospital payment adjustment in CY 2019 of 0.89, which is the same ratio that was reported for the CY 2018 OPPS/ASC final rule with comment period (82 FR 59266). We note that, in accordance with section 16002 of the 21st Century Cures Act, we are applying a budget neutrality factor calculated as if the cancer hospital adjustment target payment-to-cost ratio was 0.89, not the 0.88 target payment-to-cost ratio we are applying in section II.F. of this final rule with comment period. We modeled the independent effect of updating the wage indexes by varying only the wage indexes, holding APC relative payment weights, service-mix, and the rural adjustment constant and using the CY 2019 scaled weights and a CY 2018 conversion factor that included a budget neutrality adjustment for the effect of the changes to the wage indexes between CY 2018 and CY 2019. The FY 2019 wage policy results in modest redistributions. VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 Column 4: All Budget Neutrality Changes Combined With the Market Basket Update Column 4 demonstrates the combined impact of all of the changes previously described and the update to the conversion factor of 1.35 percent. Overall, these changes will increase payments to urban hospitals by 1.4 percent and to rural hospitals by 1.3 percent. Urban hospitals will receive an increase in line with the 1.4 percent overall increase for all facilities after the update is applied to the budget neutrality adjustments. The increase for classes of rural hospitals will be more variable with sole community hospitals receiving a 1.1 percent increase and other rural hospitals receiving an increase of 1.6 percent. Column 5: Off-Campus PBD Visits Payment Policy Column 5 displays the estimated effect of our finalized CY 2019 volume control method to pay for clinic visit HCPCS code G0463 ((Hospital outpatient clinic visit for assessment and management of a patient) when billed with modifier ‘‘PO’’ by an excepted off-campus PBD at a rate that will be 70 percent of the OPPS rate for a clinic visit service for CY 2019. We note that the numbers provided in this column isolate the estimated effect of this policy adjustment relative to the numerator of Column 4. Therefore, the numbers reported in Column 5 show how much of the difference between the estimates in Column 4 and the estimates in Column 6 are a result of the finalized off-campus PBD visits policy. Column 6: All Changes for CY 2019 Column 6 depicts the full impact of the CY 2019 policies on each hospital group by including the effect of all changes for CY 2019 and comparing them to all estimated payments in CY 2018. Column 6 shows the combined budget neutral effects of Columns 2 through 3; the OPD fee schedule increase; the effect of the finalized offcampus PBD visits policy, the impact of the frontier State wage index adjustment; the impact of estimated OPPS outlier payments, as discussed in section II.G. of this final rule with comment period; the change in the Hospital OQR Program payment reduction for the small number of hospitals in our impact model that failed to meet the reporting requirements (discussed in section XIII. of this final rule with comment period); and the difference in total OPPS payments dedicated to transitional passthrough payments. PO 00000 Frm 00347 Fmt 4701 Sfmt 4700 59163 Of those hospitals that failed to meet the Hospital OQR Program reporting requirements for the full CY 2018 update (and assumed, for modeling purposes, to be the same number for CY 2019), we included 72 hospitals in our model because they had both CY 2017 claims data and recent cost report data. We estimate that the cumulative effect of all changes for CY 2019 will increase payments to all facilities by 0.6 percent for CY 2019. We modeled the independent effect of all changes in Column 6 using the final relative payment weights for CY 2018 and the relative payment weights for CY 2019. We used the final conversion factor for CY 2018 of $78.636 and the final CY 2019 conversion factor of $79.490 discussed in section II.B. of this final rule with comment period. Column 6 contains simulated outlier payments for each year. We used the 1year charge inflation factor used in the FY 2019 IPPS/LTCH PPS final rule (83 FR 41722) of 4.3 percent (1.04338) to increase individual costs on the CY 2017 claims, and we used the most recent overall CCR in the October 2018 Outpatient Provider-Specific File (OPSF) to estimate outlier payments for CY 2018. Using the CY 2017 claims and a 4.3 percent charge inflation factor, we currently estimate that outlier payments for CY 2018, using a multiple threshold of 1.75 and a fixed-dollar threshold of $4,150, will be approximately 1.01 percent of total payments. The estimated current outlier payments of 1.01 percent are incorporated in the comparison in Column 6. We used the same set of claims and a charge inflation factor of 8.9 percent (1.08864) and the CCRs in the October 2018 OPSF, with an adjustment of 0.981397, to reflect relative changes in cost and charge inflation between CY 2017 and CY 2019, to model the CY 2019 outliers at 1.0 percent of estimated total payments using a multiple threshold of 1.75 and a fixed-dollar threshold of $4,825. The charge inflation and CCR inflation factors are discussed in detail in the FY 2019 IPPS/LTCH PPS final rule (83 FR 41722). Overall, we estimate that facilities will experience an increase of 0.6 percent under this final rule with comment period in CY 2019 relative to total spending in CY 2018. This projected increase (shown in Column 6) of Table 62 reflects the 1.35 percent OPD fee schedule increase factor, minus 0.6 percent for the off-campus PBD visits policy, minus 0.10 percent for the change in the pass-through payment estimate between CY 2018 and CY 2019, plus a decrease of 0.01 percent for the difference in estimated outlier payments E:\FR\FM\21NOR2.SGM 21NOR2 59164 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations between CY 2018 (1.01 percent) and CY 2019 (1.00 percent). We estimate that the combined effect of all changes for CY 2019 will increase payments to urban hospitals by 0.7 percent. Overall, we estimate that rural hospitals will experience a 0.5 percent increase as a result of the combined effects of all the changes for CY 2019. Among hospitals, by teaching status, we estimate that the impacts resulting from the combined effects of all changes will include an increase of 0.4 percent for major teaching hospitals and an increase of 0.9 percent for nonteaching hospitals. Minor teaching hospitals will experience an estimated increase of 0.5 percent. In our analysis, we also have categorized hospitals by type of ownership. Based on this analysis, we estimate that voluntary hospitals will experience an increase of 0.6 percent, proprietary hospitals will experience an increase of 1.0 percent, and governmental hospitals will experience an increase of 0.5 percent. khammond on DSK30JT082PROD with RULES2 BILLING CODE 4120–01–P VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 PO 00000 Frm 00348 Fmt 4701 Sfmt 4700 E:\FR\FM\21NOR2.SGM 21NOR2 59165 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations (2) (3) APC Recalibration (all changes) New Wage Index and Provider Adjustments (4) All Budget Neutral Changes (combined cols 2 and 3) with Market Basket Update 0.0 0.0 1.3 1.4 -0.6 -0.6 0.6 0.6 (1) Number of Hospitals 3,840 0.0 ALL FACILITIES* 3,727 0.0 ALL HOSPITALS (excludes hospitals permanently held harmless and CMHCs) (6) Off-Campus ProviderBased Department Visits Policy All Changes URBAN HOSPITALS LARGE URBAN (GT 1 MILL.) OTHER URBAN (LE 1 MILL.) 2,938 1,542 0.0 0.1 0.0 -0.1 1.4 1.3 -0.6 -0.5 0.7 0.7 1,396 0.0 0.1 1.5 -0.7 0.6 RURAL HOSPITALS SOLE COMMUNITY OTHER RURAL 789 370 0.1 -0.1 -0.2 -0.2 1.3 1.1 -0.6 -0.7 0.5 0.2 419 0.4 -0.1 1.6 -0.6 0.9 BEDS (URBAN) 0-99 BEDS 100-199 BEDS 200-299 BEDS 300-499 BEDS 500 +BEDS 1,018 846 468 390 216 0.4 0.1 0.0 -0.1 0.0 -0.1 -0.1 0.1 0.0 0.1 1.6 1.4 1.5 1.3 1.4 -0.4 -0.5 -0.5 -0.6 -0.8 1.1 0.7 0.9 0.5 0.5 BEDS (RURAL) 0-49 BEDS 50- 100 BEDS 101- 149 BEDS 150- 199 BEDS 200 +BEDS 328 288 89 47 37 0.4 0.2 0.2 0.1 -0.3 0.0 -0.1 -0.2 -0.4 -0.3 1.7 1.4 1.3 1.1 0.7 -0.2 -0.8 -0.5 -1.1 -0.5 1.3 0.5 0.7 -0.1 0.1 143 336 0.2 0.0 1.7 -0.2 3.3 1.1 -1.0 -0.4 2.1 0.6 469 0.0 -0.4 1.0 -0.5 0.4 REGION (URBAN) NEW ENGLAND MIDDLE ATLANTIC SOUTH ATLANTIC khammond on DSK30JT082PROD with RULES2 (5) VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 PO 00000 Frm 00349 Fmt 4701 Sfmt 4725 E:\FR\FM\21NOR2.SGM 21NOR2 ER21NO18.120</GPH> TABLE 62.-ESTIMATED IMPACT OF THE CY 2019 CHANGES FOR THE HOSPITAL OUTPATIENT PROSPECTIVE PAYMENT SYSTEM Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations (2) (1) (4) (5) (6) All Budget Neutral Changes (combined cols 2 and 3) with Market Basket Update Off-Campus ProviderBased Department Visits Policy All Changes Number of Hospitals APC Recalibration (all changes) New Wage Index and Provider Ad_justments 469 0.0 -0.3 1.0 -0.8 0.1 178 0.0 -0.2 1.2 -0.2 0.9 182 -0.2 -0.2 1.0 -0.6 0.1 517 0.1 0.0 1.4 -0.5 0.8 214 384 46 0.0 0.1 -0.6 0.2 0.5 -1.2 1.5 1.9 -0.4 -0.6 -0.6 0.0 0.8 1.1 -0.4 21 54 -0.1 0.2 -0.7 0.1 0.5 1.6 -2.0 -1.0 -1.6 0.5 122 120 0.1 0.3 -0.2 -0.2 1.3 1.5 -0.2 -0.8 1.0 0.5 152 0.1 0.1 1.5 -0.3 1.1 95 -0.2 -0.2 1.0 -0.8 -0.2 151 0.5 0.2 2.0 -0.3 1.6 51 23 -0.2 0.1 -0.6 -0.4 0.5 1.1 -0.2 -1.0 0.9 -0.1 TEACHING STATUS NON-TEACHING MINOR MAJOR 2,599 776 352 0.1 0.0 0.0 -0.1 0.0 0.1 1.4 1.3 1.5 -0.4 -0.6 -0.9 0.9 0.5 0.4 DSH PATIENT PERCENT 0 GT0-0.10 0.10-0.16 0.16-0.23 0.23-0.35 GE 0.35 11 265 241 575 1,113 953 -0.8 0.1 0.0 -0.1 0.1 0.1 -0.5 -0.2 -0.1 -0.2 0.0 0.1 0.1 1.3 1.2 1.0 1.4 1.6 0.0 -0.4 -0.4 -0.6 -0.7 -0.6 0.2 0.8 0.7 0.3 0.6 0.8 EAST NORTH CENT. EAST SOUTH CENT. WEST NORTH CENT. WEST SOUTH CENT. MOUNTAIN PACIFIC PUERTO RICO REGION (RURAL) NEW ENGLAND MIDDLE ATLANTIC SOUTH ATLANTIC EAST NORTH CENT. EAST SOUTH CENT. WEST NORTH CENT. WEST SOUTH CENT. MOUNTAIN PACIFIC khammond on DSK30JT082PROD with RULES2 (3) VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 PO 00000 Frm 00350 Fmt 4701 Sfmt 4725 E:\FR\FM\21NOR2.SGM 21NOR2 ER21NO18.121</GPH> 59166 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations 59167 (2) (3) Number of Hospitals APC Recalibration (all changes) New Wage Index and Provider Ad_justments (4) All Budget Neutral Changes (combined cols 2 and 3) with Market Basket Update 569 2.5 0.0 3.9 -0.3 3.4 1,013 1,369 0.0 0.1 0.1 0.0 1.4 1.4 -0.7 -0.4 0.5 0.9 10 1.2 -1.0 1.5 0.0 1.3 545 2.5 0.0 3.9 -0.3 3.4 1,977 1,281 469 0.0 0.1 0.0 0.0 0.0 0.1 1.4 1.4 1.4 -0.7 -0.2 -0.7 0.6 1.0 0.5 46 -16.8 0.7 -15.0 0.0 -15.1 (1) DSHNOT AVAILABLE ** URBAN TEACHING/DSH TEACHING & DSH NO TEACHING/DSH NO TEACHING/NO DSH DSHNOT AVAILABLE** TYPE OF OWNERSHIP VOLUNTARY PROPRIETARY GOVERNMENT CMHCs (5) (6) Off-Campus ProviderBased Department Visits Policy All Changes Column (1) shows total hospitals and/or CMHCs. Column (2) includes all CY 2019 OPPS policies and compares those to the CY 2018 OPPS. Column (3) shows the budget neutral impact of updating the wage index by applying the FY 2019 hospital inpatient wage index. The rural SCH adjustment continues our current policy of 7.1 percent so the budget neutrality factor is 1. The budget neutrality adjustment for the cancer hospital adjustment is 1 because in CY 2019 the target payment-to-cost ratio is the same as it was in CY 2018 (0.88). khammond on DSK30JT082PROD with RULES2 BILLING CODE 4120–01–C e. Estimated Effects of OPPS Changes on CMHCs The last line of Table 62 demonstrates the isolated impact on CMHCs, which furnish only partial hospitalization services under the OPPS. In CY 2018, CMHCs are paid under APC 5853 (Partial Hospitalization (3 or more VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 services) for CMHCs). We modeled the impact of this APC policy assuming CMHCs will continue to provide the same number of days of PHP care as seen in the CY 2017 claims used for ratesetting in this final rule with comment period. We excluded days with 1 or 2 services because our policy only pays a per diem rate for partial PO 00000 Frm 00351 Fmt 4701 Sfmt 4700 hospitalization when 3 or more qualifying services are provided to the beneficiary. We estimate that CMHCs will experience an overall 15.1 percent decrease in payments from CY 2018 (shown in Column 6). We note that this includes the trimming methodology described in section VIII.B. of this final rule with comment period. E:\FR\FM\21NOR2.SGM 21NOR2 ER21NO18.122</GPH> Column (4) shows the impact of all budget neutrality adjustments and the addition of the 1.35 percent OPD fee schedule update factor (2.9 percent reduced by 0.8 percentage point for the productivity adjustment and further reduced by 0.75 percentage point as required by law). Column (5) shows the additional impact of the policy to pay clinic visits for nonexcepted providers under the otherwise applicable payment system. We note that we are applying a 2-year phase-in so the amount of the reduction will be 50 percent of the difference in CY 2019 (or payment at 70 percent of the OPPS rate). Column (6) shows the additional adjustments to the conversion factor resulting from the frontier adjustment, a change in the pass-through estimate, and adding estimated outlier payments. *These 3,840 providers include children and cancer hospitals, which are held harmless to pre-BBA amounts, and CMHCs. **Complete DSH numbers are not available for providers that are not paid under IPPS, including rehabilitation, psychiatric, and long-term care hospitals. 59168 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations Column 3 shows that the estimated impact of adopting the FY 2019 wage index values will result in an increase of 0.7 percent to CMHCs. Column 4 shows that combining this OPD fee schedule increase factor, along with changes in APC policy for CY 2019 and the FY 2019 wage index updates, will result in an estimated decrease of 15.0 percent. Column 5 shows that the offcampus PBD clinic visits payment policy has no effect on CMHCs. Column 6 shows that adding the changes in outlier and pass-through payments will result in a total 15.1 percent decrease in payment for CMHCs. This reflects all changes to CMHCs for CY 2019. khammond on DSK30JT082PROD with RULES2 f. Estimated Effect of OPPS Changes on Beneficiaries For services for which the beneficiary pays a copayment of 20 percent of the payment rate, the beneficiary’s payment will increase for services for which the OPPS payments will rise and will decrease for services for which the OPPS payments will fall. For further discussion on the calculation of the national unadjusted copayments and minimum unadjusted copayments, we refer readers to section II.I. of this final rule with comment period. In all cases, section 1833(t)(8)(C)(i) of the Act limits beneficiary liability for copayment for a procedure performed in a year to the hospital inpatient deductible for the applicable year. We estimate that the aggregate beneficiary coinsurance percentage will be 18.5 percent for all services paid under the OPPS in CY 2019. The estimated aggregate beneficiary coinsurance reflects general system adjustments, including the CY 2019 comprehensive APC payment policy discussed in section II.A.2.b. of this final rule with comment period. The aggregate coinsurance percentage reflects changes that we have made for the CY 2019 OPPS. Total estimated copayments over total estimated payments results in 18.6 percent. Under the C–APC payment methodology, the copayment is based on the claim level for the C–APC rather than the service line level. Because outpatient copayment is capped at the inpatient deductible, this can lead to an aggregate cost-sharing below 20 percent. g. Estimated Effects of OPPS Changes on Other Providers The relative payment weights and payment amounts established under the OPPS affect the payments made to ASCs, as discussed in section XII. of this final rule with comment period. We do not anticipate that any types of providers or suppliers other than VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 hospitals, CMHCs, and ASCs will be affected by the changes in this final rule with comment period. However, we are interested in exploring how these Medicare changes may affect others in the health care marketplace. h. Estimated Effects of OPPS Changes on the Medicare and Medicaid Programs The effect on the Medicare program is expected to be an increase of $440 million in program payments for OPPS services furnished in CY 2019. The effect on the Medicaid program is expected to be limited to copayments that Medicaid may make on behalf of Medicaid recipients who are also Medicare beneficiaries. We estimate that the changes in this final rule with comment period will increase these Medicaid beneficiary payments by approximately $35 million in CY 2019. Currently, there are approximately 10 million dual-eligible beneficiaries, which represents approximately one third of Part B FFS beneficiaries. The impact on Medicaid was determined by taking one-third of the beneficiary costsharing impact. The national average split of Medicaid payments is 57 percent Federal payments and 43 percent State payments. Therefore, for the estimated $35 million Medicaid increase, approximately $20 million would be from the Federal Government and $15 million would be from State government. i. Alternative OPPS Policies Considered Alternatives to the OPPS changes we are making and the reasons for our selected alternatives are discussed throughout this final rule with comment period. • Alternatives Considered for the Method to Control for Unnecessary Increases in the Volume of Outpatient Services We refer readers to section X.B. of this final rule with comment period for a discussion of our policy to use our authority under section 1833(t)(2)(F) of the Act to apply an amount equal to the site-specific PFS payment rate for nonexcepted items and services furnished by a nonexcepted off-campus PBD for the clinic visit service, as described by HCPCS code G0463, when provided at an off-campus PBD excepted from section 1833(t)(21) of the Act. For 2019, we proposed to apply a PFS-equivalent payment rate for this service. However, after consideration of public comments received, we are phasing in the application of the reduction in payment for HCPCS code G0463 in this setting over 2 years. In CY 2019, the payment reduction will be PO 00000 Frm 00352 Fmt 4701 Sfmt 4700 transitioned by applying 50 percent of the total reduction in payment that would apply if these departments were paid the site-specific PFS rate for the clinic visit service. We also considered, but did not finalize, fully applying this payment reduction in CY 2019. Had we done so, total Medicare and beneficiary copayments in CY 2019 would have decreased by $750 million, compared to the decrease of $380 million as a result of the phase-in. • Alternatives Considered for the Methodology for Assigning Skin Substitutes to High or Low Cost Groups We refer readers to section V.B.1.d. of this final rule with comment period for a discussion of our policy to assign any skin substitute product that was assigned to the high cost group in CY 2018 to the high cost group in CY 2019, regardless of whether the product’s mean unit cost (MUC) or the product’s per day cost (PDC) exceeds or falls below the overall CY 2019 MUC or PDC threshold. We will continue to assign products that exceed either the overall CY 2019 MUC or PDC threshold to the high cost group. We also considered, but did not propose, reinstating our methodology from CY 2017 and assigning skin substitutes to the high cost group based on whether an individual product’s MUC or PDC exceeded the overall CY 2019 MUC or PDC threshold based on calculations done for either the proposed rule or the final rule with comment period. • Alternatives Considered for the Methodology for Payment for NonOpioid Pain Management Treatments We refer readers to sections II.A.3.b. and XII.D.3. of the proposed rule and this final rule with comment period for a discussion of our change in the packaging policy for certain drugs when administered in the ASC setting and policy provide separate payment for non-opioid pain management drugs that function as a supply when used in a surgical procedure when the procedure is performed in an ASC. In those sections of the proposed rule, we also solicited comments on whether we should pay separately for other nonopioid treatments for pain under the OPPS and the ASC payment system. We discuss the comments we received in those sections of this final rule with comment period. In the proposed rule, we also considered and solicited comments on an alternative policy that would use our equitable adjustment authority under section 1833(t)(2)(E) of the Act to establish an incentive payment for non-opioid alternatives that would apply to drugs and devices under E:\FR\FM\21NOR2.SGM 21NOR2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations the OPPS that are not currently separately paid, are supported by evidence that demonstrates such drugs and devices are effective at treating acute or chronic pain, and would result in decreased use of prescription opioid drugs and any associated opioid addiction, when furnished in the outpatient setting. We discuss the comments we received in those sections of this final rule with comment period. khammond on DSK30JT082PROD with RULES2 2. Estimated Effects of CY 2019 ASC Payment System Changes in This Final Rule With Comment Period Most ASC payment rates are calculated by multiplying the ASC conversion factor by the ASC relative payment weight. As discussed fully in section XII. of this final rule with comment period, we are setting the CY 2019 ASC relative payment weights by scaling the CY 2019 OPPS relative payment weights by the ASC scalar of 0.8792. The estimated effects of the updated relative payment weights on payment rates are varied and are reflected in the estimated payments displayed in Tables 63 and 64 below. Beginning in CY 2011, section 3401 of the Affordable Care Act requires that the annual update to the ASC payment system (which will be the hospital market basket for CY 2019) after application of any quality reporting reduction be reduced by a productivity adjustment. The Affordable Care Act defines the productivity adjustment to be equal to the 10-year moving average of changes in annual economy-wide private nonfarm business multifactor productivity (MFP) (as projected by the Secretary for the 10-year period, ending with the applicable fiscal year, year, cost reporting period, or other annual period). For ASCs that fail to meet their quality reporting requirements, the CY 2019 payment determinations will be based on the application of a 2.0 percentage point reduction to the annual update factor, which will be the hospital market basket for CY 2019. We calculated the CY 2019 ASC conversion factor by adjusting the CY 2018 ASC conversion factor by 1.0004 to account for changes in the pre-floor and prereclassified hospital wage indexes between CY 2018 and CY 2019 and by applying the CY 2019 MFP-adjusted hospital market basket update factor of 2.1 percent (hospital market basket update of 2.9 percent minus a projected productivity adjustment of 0.8 percentage point). The CY 2019 ASC conversion factor is $46.555 for ASCs that successfully meet the quality reporting requirements. VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 a. Limitations of Our Analysis Presented here are the projected effects of the changes for CY 2019 on Medicare payment to ASCs. A key limitation of our analysis is our inability to predict changes in ASC service-mix between CY 2017 and CY 2019 with precision. We believe the net effect on Medicare expenditures resulting from the CY 2019 changes will be small in the aggregate for all ASCs. However, such changes may have differential effects across surgical specialty groups, as ASCs continue to adjust to the payment rates based on the policies of the revised ASC payment system. We are unable to accurately project such changes at a disaggregated level. Clearly, individual ASCs will experience changes in payment that differ from the aggregated estimated impacts presented below. b. Estimated Effects of ASC Payment System Policies on ASCs Some ASCs are multispecialty facilities that perform a wide range of surgical procedures from excision of lesions to hernia repair to cataract extraction; others focus on a single specialty and perform only a limited range of surgical procedures, such as eye, digestive system, or orthopedic procedures. The combined effect on an individual ASC of the update to the CY 2019 payments will depend on a number of factors, including, but not limited to, the mix of services the ASC provides, the volume of specific services provided by the ASC, the percentage of its patients who are Medicare beneficiaries, and the extent to which an ASC provides different services in the coming year. The following discussion presents tables that display estimates of the impact of the CY 2019 updates to the ASC payment system on Medicare payments to ASCs, assuming the same mix of services, as reflected in our CY 2017 claims data. Table 63 depicts the estimated aggregate percent change in payment by surgical specialty or ancillary items and services group by comparing estimated CY 2018 payments to estimated CY 2019 payments, and Table 64 shows a comparison of estimated CY 2018 payments to estimated CY 2019 payments for procedures that we estimate will receive the most Medicare payment in CY 2018. In Table 63, we have aggregated the surgical HCPCS codes by specialty group, grouped all HCPCS codes for covered ancillary items and services into a single group, and then estimated the effect on aggregated payment for surgical specialty and ancillary items and services groups. The groups are PO 00000 Frm 00353 Fmt 4701 Sfmt 4700 59169 sorted for display in descending order by estimated Medicare program payment to ASCs. The following is an explanation of the information presented in Table 63. • Column 1—Surgical Specialty or Ancillary Items and Services Group indicates the surgical specialty into which ASC procedures are grouped and the ancillary items and services group which includes all HCPCS codes for covered ancillary items and services. To group surgical procedures by surgical specialty, we used the CPT code range definitions and Level II HCPCS codes and Category III CPT codes, as appropriate, to account for all surgical procedures to which the Medicare program payments are attributed. • Column 2—Estimated CY 2018 ASC Payments were calculated using CY 2017 ASC utilization data (the most recent full year of ASC utilization) and CY 2018 ASC payment rates. The surgical specialty and ancillary items and services groups are displayed in descending order based on estimated CY 2018 ASC payments. • Column 3—Estimated CY 2019 Percent Change is the aggregate percentage increase or decrease in Medicare program payment to ASCs for each surgical specialty or ancillary items and services group that are attributable to updates to ASC payment rates for CY 2019 compared to CY 2018. As shown in Table 63, for the six specialty groups that account for the most ASC utilization and spending, we estimate that the update to ASC payment rates for CY 2019 will result in a 1-percent decrease in aggregate payment amounts for eye and ocular adnexa procedures, a 3-percent increase in aggregate payment amounts for nervous system procedures, 3-percent increase in aggregate payment amounts for digestive system procedures, a 3percent increase in aggregate payment amounts for musculoskeletal system procedures, a 1-percent increase in aggregate payment amounts for genitourinary system procedures, and a 1-percent decrease in aggregate payment amounts for integumentary system procedures. We note that these changes can be a result of different factors, including updated data, payment weight changes, and changes in policy. In general, spending in each of these categories of services is increasing due to the 2.1 percent payment rate update. After the payment rate update is accounted for, aggregate payment increases or decreases for a category of services can be higher or lower than a 2.1 percent increase, depending on if payment weights in the OPPS APCs that correspond to the applicable services E:\FR\FM\21NOR2.SGM 21NOR2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations increased or decreased or if the most recent data show an increase or a decrease in the volume of services performed in an ASC for a category. For example, we estimate a 1-percent decrease in aggregate eye and ocular adnexa procedure payments due to a reduction in hospital reported costs for the primary payment grouping for this category under the OPPS. This lowers the payment weights for eye and ocular adnexa procedure payments and, overall, offsets the 2.1 percent ASC rate update for these procedures. For estimated changes for selected procedures, we refer readers to Table 64 provided later in this section. Also displayed in Table 63 is a separate estimate of Medicare ASC payments for the group of separately payable covered ancillary items and services. The payment estimates for the covered surgical procedures include the costs of packaged ancillary items and services. We estimate that aggregate payments for these items and services will increase by 79 percent for CY 2019. This is largely attributed to the introduction of utilization data for HCPCS code C9447 (Inj, phenylephrine ketorolac), Omidria®, and HCPCS code Q4172 (Puraply or puraply am), a highcost skin substitute. Table 64 below shows the estimated impact of the updates to the revised ASC payment system on aggregate ASC payments for selected surgical procedures during CY 2019. The table displays 30 of the procedures receiving the greatest estimated CY 2018 aggregate Medicare payments to ASCs. The HCPCS codes are sorted in descending order by estimated CY 2018 program payment. • Column 1—CPT/HCPCS code. • Column 2—Short Descriptor of the HCPCS code. • Column 3—Estimated CY 2018 ASC Payments were calculated using CY 2017 ASC utilization (the most recent full year of ASC utilization) and the CY 2018 ASC payment rates. The estimated CY 2018 payments are expressed in millions of dollars. VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 PO 00000 Frm 00354 Fmt 4701 Sfmt 4700 • Column 4—Estimated CY 2019 Percent Change reflects the percent differences between the estimated ASC payment for CY 2018 and the estimated payment for CY 2019 based on the update. BILLING CODE 4120–01–P E:\FR\FM\21NOR2.SGM 21NOR2 ER21NO18.123</GPH> khammond on DSK30JT082PROD with RULES2 59170 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations 59171 TABLE 64.-ESTIMATED IMPACT OF THE CY 2019 UPDATE TO THE ASC PAYMENT SYSTEM ON AGGREGATE PAYMENTS FOR SELECTED PROCEDURES Short Descriptor (2) Cataract surg w/iol 1 stage Colonoscopy and biopsy Insrt/redo spine n generator Egd biopsy single/multiple Implant neuroelectrodes Colonoscopy w/lesion removal Inj foramen epidural lis Insert ant segment drain int Cataract surgery complex Destroy lumb/sac facet jnt After cataract laser surgery Arthroscop rotator cuff repr Inj paravert f jnt 1/s 1 lev Njx interlaminar lmbr/sac Insrt/redo pn/gastr stimul Colorectal scm; hi risk ind Colon ca scm not hi rsk ind Diagnostic colonoscopy Carpal tunnel surgery Revision of upper eyelid Knee arthroscopy/surgery Cysto impl 4 or more Implant neuroelectrodes Vit for macular hole Knee arthroscopy/surgery Incise finger tendon sheath Repair of hammertoe Implant neuroelectrodes Cystoscopy Inj for sacroiliac jt anesth BILLING CODE 4120–01–C c. Estimated Effects of ASC Payment System Policies on Beneficiaries We estimate that the CY 2019 update to the ASC payment system will be VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 generally positive (that is, result in lower cost-sharing) for beneficiaries with respect to the new procedures we are adding to the ASC list of covered surgical procedures, the existing covered surgical procedures we PO 00000 Frm 00355 Fmt 4701 Sfmt 4700 Estimated CY2019 Percent Change (4) -2 4 -1 1 -3 4 13 4 -2 -1 1 1 13 9 3 4 4 4 -1 -2 -2 2 -2 0 -2 -4 -2 5 -2 9 reviewed as safe to perform in an ASC, and for those surgical procedures we are designating as office-based for CY 2019. For example, using 2017 utilization data and CY 2019 OPPS and ASC payment rates, we estimate that if 5 percent of E:\FR\FM\21NOR2.SGM 21NOR2 ER21NO18.124</GPH> khammond on DSK30JT082PROD with RULES2 CPT/HCPCS Code (1) 66984 45380 63685 43239 63650 45385 64483 0191T 66982 64635 66821 29827 64493 62323 64590 G0105 G0121 45378 64721 15823 29881 C9740 64561 67042 29880 26055 28285 63655 52000 G0260 Estimated CY2018 ASC Payment (in millions) (3) $1,206 $228 $221 $180 $166 $156 $101 $96 $89 $75 $69 $65 $63 $53 $51 $47 $42 $41 $34 $33 $29 $28 $26 $26 $25 $25 $24 $24 $23 $22 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations khammond on DSK30JT082PROD with RULES2 cardiac catheterization procedures migrate from the hospital outpatient setting to the ASC setting as a result of this policy, Medicare payments will be reduced by approximately $36 million in CY 2019 and total beneficiary copayments will decline by approximately $14 million in CY 2019. First, other than certain preventive services where coinsurance and the Part B deductible is waived to comply with sections 1833(a)(1) and (b) of the Act, the ASC coinsurance rate for all procedures is 20 percent. This contrasts with procedures performed in HOPDs under the OPPS, where the beneficiary is responsible for copayments that range from 20 percent to 40 percent of the procedure payment (other than for certain preventive services), although the majority of HOPD procedures have a 20-percent copayment. Second, in almost all cases, the ASC payment rates under the ASC payment system are lower than payment rates for the same procedures under the OPPS. Therefore, the beneficiary coinsurance amount under the ASC payment system will almost always be less than the OPPS copayment amount for the same services. (The only exceptions will be if the ASC coinsurance amount exceeds the inpatient deductible. The statute requires that copayment amounts under the OPPS not exceed the inpatient deductible.) Beneficiary coinsurance for services migrating from physicians’ offices to ASCs may decrease or increase under the revised ASC payment system, depending on the particular service and the relative payment amounts under the MPFS compared to the ASC. While the ASC payment system bases most of its payment rates on hospital cost data used to set OPPS relative payment weights, services that are performed a majority of the time in a physician office are generally paid the lesser of the ASC amount according to the standard ASC rate setting methodology or at the VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 nonfacility practice expense based amount payable under the PFS. Because of this fact, we do not believe that the increase in ASC payment rates that will result from this policy will cause any significant migration of services from the physician office setting to the ASC setting. For those additional procedures that we are designating as office-based in CY 2019, the beneficiary coinsurance amount under the ASC payment system generally will be no greater than the beneficiary coinsurance under the PFS because the coinsurance under both payment systems generally is 20 percent (except for certain preventive services where the coinsurance is waived under both payment systems). d. Alternative ASC Payment Policies Considered Alternatives to the ASC changes we are making and the reasons for our selected alternatives are discussed throughout this final rule with comment period. • Alternatives Considered for the CY 2019 ASC Rate Update As discussed in section XII. of this final rule with comment period, for CY 2019 through CY 2023 (5 years total), in response to stakeholder concerns regarding the application of CPI–U to update ASC payment rates, we are updating ASC payment rates using the hospital market basket and revising our regulations under 42 CFR 416.171(a), which address the annual update to the ASC conversion factor, to reflect this policy. As an alternative proposal, we considered whether to continue applying the CPI–U as the update factor. If we were to update ASC payment rates for CY 2019 with an update factor based on CPI–U, the update would have been 1.8 percent (the 2.6 percentage point CPI–U less the 0.8 percentage point MFP adjustment). This update factor would have resulted in increased PO 00000 Frm 00356 Fmt 4701 Sfmt 4725 payments to ASCs in CY 2019 of approximately $60 million, compared to the increased payments to ASCs in CY 2019 of approximately $80 million as a result of the 2.1 percent update based on the hospital market basket. 3. Accounting Statements and Tables As required by OMB Circular A–4 (available on the Office of Management and Budget website at: https:// www.whitehouse.gov/omb/circulars_ a004_a-4#a),we have prepared accounting statements to illustrate the impacts of the OPPS and ASC changes in this final rule with comment period. The first accounting statement, Table 65 below, illustrates the classification of expenditures for the CY 2019 estimated hospital OPPS incurred benefit impacts associated with the CY 2019 OPD fee schedule increase. This $440 million in additional Medicare spending estimate includes the $740 million in additional Medicare spending associated with updating the CY 2018 OPPS payment rates by the hospital market basket update for CY 2019, offset by the $300 million in Medicare savings associated with the finalized policy to pay for clinic visits furnished at off-campus PBDs at a PFS-equivalent rate. In addition, we estimate that OPPS changes in this final rule with comment period will increase copayments that Medicaid may make on behalf of Medicaid recipients who are also Medicare beneficiaries by approximately $35 million in CY 2019. The second accounting statement, Table 66 below illustrates the classification of expenditures associated with the 2.1 percent CY 2019 update to the ASC payment system, based on the provisions of this final rule with comment period and the baseline spending estimates for ASCs. Both tables classify most estimated impacts as transfers. BILLING CODE 4120–01–P E:\FR\FM\21NOR2.SGM 21NOR2 ER21NO18.125</GPH> 59172 khammond on DSK30JT082PROD with RULES2 4. Effects of Changes in Requirements for the Hospital OQR Program a. Background We refer readers to the CY 2018 OPPS/ASC final rule with comment period (82 FR 59492 through 59494), for the previously estimated effects of changes to the Hospital OQR Program for the CY 2018, CY 2019, and CY 2020 payment determinations. Of the approximately 3,300 hospitals that met eligibility requirements for the CY 2018 payment determination, we determined that 36 hospitals did not meet the requirements to receive the full OPD fee schedule increase factor. Many of these hospitals (18 of the 36), chose not to participate in the Hospital OQR Program for the CY 2018 payment determination. In the proposed rule, we did not propose to add any quality measures to the Hospital OQR Program measure set for the CY 2020 or CY 2021 payment determinations, and, in this final rule with comment period we are finalizing our proposals to remove eight measures from the program measure set; we are not finalizing our proposals to remove two measures, as discussed in section XIII.B.4.b. of this final rule with comment period. We do not believe that the finalized policies will increase the number of hospitals that do not receive a full annual payment update for the CY 2020 or CY 2021 payment determinations. In section XIII.B.4.b. of this final rule with comment period, we are finalizing our proposals to remove a total of eight measures. Specifically, beginning with the CY 2020 payment determination, we VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 are finalizing the removal of: (1) OP–27: Influenza Vaccination Coverage Among Healthcare Personnel; and beginning with the CY 2021 payment determination, we are removing: (2) OP– 5: Median Time to ECG; (3) OP–9: Mammography Follow-up Rates; (4) OP–11: Thorax CT Use of Contrast Material; (5) OP–12: The Ability for Providers with HIT to Receive Laboratory Data Electronically Directly into Their Qualified/Certified EHR System as Discrete Searchable Data; (6) OP–14: Simultaneous Use of Brain Computed Tomography (CT) and Sinus CT; (7) OP–17: Tracking Clinical Results between Visits; and (8) OP–30: Endoscopy/Polyp Surveillance: Colonoscopy Interval for Patients with a History of Adenomatous Polyps— Avoidance of Inappropriate Use. However, we are not finalizing our proposals to remove two measures: OP– 29: Endoscopy/Polyp Surveillance: Appropriate Follow-up Interval for Normal Colonoscopy in Average Risk Patients; and OP–31: Cataracts— Improvement in Patient’s Visual Function within 90 Days Following Cataract Surgery for the CY 2021 payment determination and subsequent years. Therefore, we are revising the estimated burden changes found in the CY 2019 OPPS/ASC proposed rule (83 FR 37234 through 32736). The reduction in burden associated with our finalized policies is discussed below. In section XIII.B.4.a. of this final rule with comment period, beginning with the effective date of this CY 2019 OPPS/ ASC final rule with comment period, we are updating one removal factor and PO 00000 Frm 00357 Fmt 4701 Sfmt 4700 adding one removal factor. We are also codifying our measure removal policies and factors at 42 CFR 419.46(h) effective upon finalization of this CY 2019 OPPS/ ASC final rule with comment period and for subsequent years. In addition, in section XIII.D.2. of this final rule with comment period, we are updating the frequency with which we will release Hospital Outpatient Quality Reporting Specifications Manuals, such that instead of releasing the full manual once or twice each year, as proposed, we will release the Specifications Manuals once every 12 months and release addenda as necessary, beginning with CY 2019 and for subsequent years. In section XIII.C.2. of this final rule with comment period, beginning with the CY 2020 payment determination, we are removing the Notice of Participation (NOP) form as a requirement for the Hospital OQR Program and updating 42 CFR 419.46(a)(3) to reflect this policy. Finally, in section XIII.D.4.b. of this final rule with comment period, we are changing the data reporting period for OP–32: Facility Seven-Day RiskStandardized Hospital Visit Rate after Outpatient Colonoscopy from one year to three years beginning with the CY 2020 payment determination. As discussed below, we do not expect these policies to affect our burden estimates. However, as further explained in section XIX.B. of this final rule with comment period, we believe that there will be an overall decrease in the estimated information collection burden for hospitals due to the other finalized policies. We refer readers to section XIX.B. of this final rule with comment E:\FR\FM\21NOR2.SGM 21NOR2 ER21NO18.127</GPH> BILLING CODE 4120–01–C 59173 ER21NO18.126</GPH> Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations 59174 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations period for a summary of our information collection burden estimate calculations. The effects of these proposals are discussed in more detail further below. b. Estimated Effects of Hospital OQR Program Beginning With the Effective Date of This CY 2019 OPPS/ASC Final Rule With Comment Period In section XIII.B.4.a. of this final rule with comment period, we are: (1) Updating measure removal Factor 7; (2) adding one new removal factor; and (3) codifying our removal factors policy at 42 CFR 419.46(h). We do not expect a change in the information collection burden or other costs experienced by hospitals because these changes do not affect Hospital OQR Program participation requirements or data reporting requirements. c. Update to the Frequency of Releasing the Hospital Outpatient Quality Reporting Specifications Manual Beginning With CY 2019 and for Subsequent Years In section XIII.D.2. of this final rule with comment period, we are finalizing with modification our proposal to update the frequency with which we will release a Hospital Outpatient Quality Reporting Specifications Manual such that instead of releasing a full manual once or twice each year, as proposed, we will release the Specifications Manuals once every 12 months and release addenda as necessary, beginning with CY 2019 and for subsequent years. We anticipate that this change will reduce hospital confusion, as potentially releasing fewer manuals per year reduces the need to review updates as frequently as was previously necessary. However, because this change does not affect Hospital OQR Program participation requirements or data reporting requirements, we do not estimate a change in our calculation of the information collection burden experienced by hospitals. khammond on DSK30JT082PROD with RULES2 d. Estimated Effects of Hospital OQR Program Finalized Proposals for the CY 2020 Payment Determination and Subsequent Years (1) Removal of the Notice of Participation (NOP) Form Requirement In section XIII.C.2. of this final rule with comment period, beginning with the CY 2020 payment determination, we are removing the NOP form as a requirement. As a result, to be a participant in the Hospital OQR Program, hospitals will need to: (1) Register on the QualityNet website, (2) identify and register a QualityNet security administrator, and (3) submit VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 data. In addition, we are updating 42 CFR 419.46(a) to reflect these policies. We believe that the finalized policy to remove the NOP will reduce administrative burden experienced by hospitals by only a nominal amount. As a result, this finalized policy does not influence our information collection burden estimates. We refer readers to section XIX.B. of this final rule with comment period, where our burden calculations for the Hospital OQR Program are discussed in detail. In addition, we anticipate that this finalized proposal will reduce the possibility of hospitals failing to meet Hospital OQR Program requirements due to a failure to submit the NOP. (2) Extension of the Reporting Period for OP–32: Facility 7-Day RiskStandardized Hospital Visit Rate After Outpatient Colonoscopy In section XIII.D.4.b. of this final rule with comment period, we are increasing the data reporting period for OP–32: Facility Seven-Day Risk-Standardized Hospital Visit Rate after Outpatient Colonoscopy from one year to three years beginning with the CY 2020 payment determination. We expect this policy to increase the reliability of OP– 32 data allowing better information to be publicly reported. However, the policy does not change our data reporting requirements, such that hospitals will be required to continue reporting claims data that are used to calculate this measure. Therefore, we do not expect a change in the information collection burden experienced by hospitals. (3) Removal of OP–27 for the CY 2020 Payment Determination and Subsequent Years In section XIII.B.4.b. of this final rule with comment period, we are removing OP–27: Influenza Vaccination Coverage Among Healthcare Personnel (NQF #0431) beginning with the CY 2020 payment determination and for subsequent years. The burden associated with OP–27, a NHSN measure, is accounted for under a separate Paperwork Reduction Act Package, OMB control number 0920– 0666. Because burden associated with submitting data for this measure is captured under a separate OMB control number, we are not providing an estimate of the information collection burden associated with this measure for the Hospital OQR Program. Aside from burden associated with information collection however, we also anticipate that hospitals will experience a general burden and cost reduction associated with this proposal stemming from no PO 00000 Frm 00358 Fmt 4701 Sfmt 4700 longer having to review and track program requirements associated with this measure. e. Estimated Effects of Hospital OQR Program Proposals for the CY 2021 Payment Determination and Subsequent Years (1) Removal of Chart-Abstracted Measures for the CY 2021 Payment Determination and Subsequent Years In section XIII.B.4.b. of this final rule with comment period, we are removing OP–5: Median Time to ECG, a chartabstracted measure, for the CY 2021 payment determination and subsequent years. We believe that the removal of this chart-abstracted measure for the CY 2021 payment determination will reduce collection of information burden by 151,800 hours and $5.6 million (151,800 hours × $36.58), as discussed in section XIX.B. of this final rule with comment period. Aside from burden associated with information collection however, we also anticipate that hospitals will experience a general burden and cost reduction associated with this proposal stemming from no longer having to review and track program requirements associated with this measure. (2) Removal of Measures Submitted via a Web-Based Tool for the CY 2021 Payment Determination and Subsequent Years In section XIII.B.4.b. of this final rule with comment period, while we proposed to remove five measures, we are only finalizing the removal of three measures submitted via a web-based tool beginning with the CY 2021 payment determination and for subsequent years: OP–12: The Ability for Providers with HIT to Receive Laboratory Data Electronically Directly into Their Qualified/Certified EHR System as Discrete Searchable Data; OP– 17: Tracking Clinical Results between Visits; and OP–30: Endoscopy/Polyp Surveillance: Colonoscopy Interval for Patients with a History of Adenomatous Polyps—Avoidance of Inappropriate Use. We are not finalizing the removal of OP–29: Endoscopy/Polyp Surveillance: Appropriate Follow-up Interval for Normal Colonoscopy in Average Risk Patients; and OP–31: Cataracts—Improvement in Patient’s Visual Function within 90 Days Following Cataract Surgery. Therefore, we are revising the estimated burden changes found in the CY 2019 OPPS/ ASC proposed rule (83 FR 37234 through 32736). As discussed in section XIX.B. of this final rule with comment period, we anticipate a burden E:\FR\FM\21NOR2.SGM 21NOR2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations reduction of 530,075 hours and $19.4 million associated with the removal of OP–12, OP–17, and OP–30 for the CY 2021 payment determination. Aside from burden associated with information collection however, we also anticipate that hospitals will experience a general burden and cost reduction associated with these measure removals stemming from no longer having to implement, review, track, and maintain program requirements associated with these measures. (3) Removal of Claims-Based Measures for the CY 2021 Payment Determination and Subsequent Years In section XIII.B.4.b. of this final rule with comment period, we are removing three claims-based measures beginning with the CY 2021 payment determination: OP–9: Mammography Follow-up Rates; OP–11: Thorax CT Use of Contrast Material; and OP–14: Simultaneous Use of Brain Computed Tomography (CT) and Sinus CT. These claims-based measures are calculated using only data already reported to the Medicare program for payment purposes, therefore, we do not believe removing these measures will affect the information collection burden on hospitals. Nonetheless, we anticipate that hospitals will experience a general burden reduction associated with these proposals stemming from no longer having to review and track various associated program requirements. In total for the CY 2021 payment determination, we expect information collection burden will be reduced by 151,800 hours due to our removal of one chart-abstracted measure, and 530,075 hours due to our removal of three measures submitted via a web-based tool. In total, we estimate an information collection burden reduction of 681,875 hours (151,800 hours for the removal of one chart-abstracted measure + 530,075 hours for the removal of three web-based measures) and $24.9 million (681,875 hours × $36.58) for the CY 2021 payment determination. 5. Effects of Requirements for the ASCQR Program khammond on DSK30JT082PROD with RULES2 a. Background In section XIV. of this final rule with comment period, we discuss our adopted policies affecting the ASCQR Program. For the CY 2018 payment determination, of the 6,683 ASCs that met eligibility requirements for the ASCQR Program, 233 ASCs did not meet the requirements to receive the full annual payment update. We note that, in the CY 2017 OPPS/ASC final rule with comment period (81 FR 79874), we VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 used the CY 2016 payment determination numbers as a baseline, and estimated that approximately 200 ASCs will not receive the full annual payment update in CY 2019 due to failure to meet the ASCQR Program requirements (CY 2017 and CY 2018 payment determination information were not yet available). In the proposed rule, we did not propose to add any new quality measures to the ASCQR Program measure set for the CY 2020 payment determination and subsequent determinations, and we do not believe that the other measures we previously adopted will cause any additional ASCs to fail to meet the ASCQR Program requirements. Therefore, we do not believe that our finalized proposals will increase the number of ASCs that do not receive a full annual payment update for the CY 2020 payment determination. Below we discuss only the effects that will result from the newly finalized provisions in this final rule with comment period. In section XIV.B.3.c. of this final rule with comment period, we are removing one measure beginning with the CY 2020 payment determination (ASC–8: Influenza Vaccination Coverage Among Healthcare Personnel) and removing one measure beginning with the CY 2021 payment determination (ASC–10: Endoscopy/Polyp Surveillance: Colonoscopy Interval for Patients with a History of Adenomatous Polyps— Avoidance of Inappropriate Use). We expect these measure removals will reduce the overall burden of reporting data for the ASCQR Program, as discussed further below. In section XIV.B.3.c. of this final rule with comment period, we are not finalizing our proposals to remove ASC–9: Endoscopy/Polyp Surveillance Followup Interval for Normal Colonoscopy in Average Risk Patients and ASC–11: Cataracts—Improvement in Patient’s Visual Function within 90 Days Following Cataract Surgery. In addition, we are not finalizing our proposals to remove ASC–1: Patient Burn; ASC–2: Patient Fall; ASC–3: Wrong Site, Wrong Side, Wrong Patient, Wrong Procedure, Wrong Implant; and ASC–4: All-Cause Hospital Transfer/Admission, but are instead retaining the measures in the ASCQR Program and suspending their data collection beginning with the CY 2019 reporting period/CY 2021 payment determination until further action in rulemaking with the goal of updating the measures. Therefore, we are revising the estimated burden changes found in the CY 2019 OPPS/ASC proposed rule (83 FR 37236 through 32737). In sections XIV.B.3.b. and XIV.D.4.b. of this final rule with comment period, PO 00000 Frm 00359 Fmt 4701 Sfmt 4700 59175 beginning with the effective date of this CY 2019 OPPS/ASC final rule with comment period, we are finalizing our proposals to: (1) Remove one measure removal factor; (2) adding two new measure removal factors, and (3) update 42 CFR 416.320(c) to better reflect our measure removal policies; we are also: (4) Extend the reporting period for ASC– 12: Facility Seven-Day Risk Standardized Hospital Visit Rate after Outpatient Colonoscopy from 1 to 3 years beginning with the CY 2020 payment determination. As discussed below, we do not expect these policies will affect our burden estimates. However, as further explained in section XIX.C. of this final rule with comment period, we believe that there will be an overall decrease in the estimated information collection burden for ASCs due to the other finalized policies. We refer readers to section XIX.C. of this final rule with comment period for a summary of our information collection burden estimate calculations. The effects of these policies are discussed in more detail below. b. Estimated Effects of ASCQR Program Newly Finalized Policies Beginning With the Effective Date of This CY 2019 OPPS/ASC Final Rule With Comment Period In section XIV.B.3.a. of this final rule with comment period, we are, beginning with the effective date of this CY 2019 OPPS/ASC final rule with comment period, removing one measure removal factor, adding two new measure removal factors, and updating 42 CFR 416.320(c) to better reflect our measure removal policies for the ASCQR Program. Because these changes do not affect ASCQR Program participation requirements or data reporting requirements, we do not expect these newly finalized policies to change the information collection burden or other costs experienced by ASCs. c. Estimated Effects of ASCQR Program Newly Finalized Policies for the CY 2020 Payment Determination and Subsequent Years (1) Extension of the Reporting Period for ASC–12: Facility 7-Day RiskStandardized Hospital Visit Rate After Outpatient Colonoscopy In section XIV.D.4.b. of this final rule with comment period, we are extending the data reporting period for ASC–12: Facility Seven-Day Risk-Standardized Hospital Visit Rate after Outpatient Colonoscopy from one year to three years beginning with the CY 2020 payment determination. We expect this newly finalized policy to increase the E:\FR\FM\21NOR2.SGM 21NOR2 59176 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations reliability of ASC–12 data allowing better information to be publicly reported. However, the policy does not change our data reporting requirements, because ASC–12 is a claims-based measure that is calculated based on claims data that facilities already submit to CMS. Therefore, we do not expect a change in the information collection burden or other costs experienced by ASCs. khammond on DSK30JT082PROD with RULES2 (2) Removal of ASC–8 for the CY 2020 Payment Determination and Subsequent Years In section XIV.B.3.c. of this final rule with comment period, we are removing one measure from the ASCQR Program measure set beginning with the CY 2020 payment determination, ASC–8: Influenza Vaccination Coverage Among Healthcare Personnel. As discussed in section XIX.C.3.b. of this final rule with comment period, the information collection burden associated with ASC– 8, a NHSN measure, is accounted for under a separate information collection request, OMB control number 0920– 0666. As such, we are not providing an estimate of the information collection burden associated with this measure under the ASCQR Program control number. Aside from burden associated with information collection however, we anticipate that facilities will experience a general burden and cost reduction associated with this proposal stemming from no longer having to review and track program requirements associated with this measure. d. Estimated Effects of ASCQR Program Newly Finalized Policies for the CY 2021 Payment Determination and Subsequent Years: Removal of One Chart-Abstracted Measure for the CY 2021 Payment Determination and Subsequent Years In section XIV.B.3.c. of this final rule with comment period, we proposed to remove seven measures; we are finalizing the removal of only one measure from the ASCQR Program measure set beginning with the CY 2021 payment determination: ASC–10: Endoscopy/Polyp Surveillance: Colonoscopy Interval for Patients with a History of Adenomatous Polyps— Avoidance of Inappropriate Use. In section XIV.B.3.c. of this final rule with comment period we are not finalizing our proposal to remove ASC–9: Endoscopy/Polyp Surveillance Followup Interval for Normal Colonoscopy in Average Risk Patients and ASC–11: Cataracts—Improvement in Patient’s Visual Function within 90 Days Following Cataract Surgery. In addition, we are not finalizing our proposals to VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 remove ASC–1: Patient Burn; ASC–2: Patient Fall; ASC–3: Wrong Site, Wrong Side, Wrong Patient, Wrong Procedure, Wrong Implant; and ASC–4: All Cause Hospital Transfer/Admission, but are instead retaining the measures in the ASCQR Program and suspending their data collection beginning with the CY 2019 reporting period/CY 2021 payment determination until further action in rulemaking with the goal of updating the measures. Therefore, we are revising the estimated burden changes found in the CY 2019 OPPS/ASC proposed rule (83 FR 37222). While we proposed to remove three chart-abstracted measures, in section XIV.B.3.c. of this final rule with comment period, we are finalizing the removal of only one chart-abstracted measure from the ASCQR Program measure set beginning with the CY 2021 payment determination: ASC–10: Endoscopy/Polyp Surveillance: Colonoscopy Interval for Patients with a History of Adenomatous Polyps— Avoidance of Inappropriate Use. We are not finalizing the removal of ASC–9: Endoscopy/Polyp Surveillance Followup Interval for Normal Colonoscopy in Average Risk Patients and ASC–11: Cataracts—Improvement in Patient’s Visual Function within 90 Days Following Cataract Surgery. As discussed in section XIX.C.4.b. of this final rule with comment period, we believe the removal of ASC–10 will result in a burden reduction for ASCs. For ASC–10, we estimate the total annualized burden reduction to be 62,008 hours and $2,268,244 (3,937 ASCs × 15.75 hours × $36.58 per hour). Aside from burden associated with information collection however, we anticipate that facilities will experience a general burden and cost reduction associated with these removals stemming from no longer having to review and track program requirements associated with this measure. Therefore, as noted in section XIX.C.4. of this final rule with comment period, we believe the removal of a total of one measure (ASC–10) from the ASCQR measure set for the CY 2021 payment determination will result in a total annual reduction in information collection burden of 62,008 hours and $2,268,244. D. Effects of the Update to the HCAHPS Survey Measure in the Hospital IQR Program As discussed in section XVI. of this final rule with comment period, we are finalizing a modified version of our proposals regarding the Communication About Pain questions from the HCAHPS Survey in the Hospital IQR Program. PO 00000 Frm 00360 Fmt 4701 Sfmt 4700 Instead of removing the questions effective with January 2022 discharges, for the FY 2024 payment determination and subsequent years as proposed, we are finalizing to remove them effective with October 2019 discharges, for the FY 2021 payment determination and subsequent years. In addition, instead of publicly reporting the data in October 2022 and then subsequently discontinuing as proposed, we are finalizing that we will not publicly report the data collected from the Communication About Pain questions at all. We anticipate that the removal of these questions will result in only a nominal and temporary increase on the information collection burden on providers associated with adjusting the survey instrument and instructional materials, and a burden decrease for survey respondents. We note that the burden estimate for the Hospital IQR Program under the program’s OMB control number 0938–1022 excludes the burden associated with the HCAHPS Survey measure, which is submitted under a separate information collection request and approved under OMB control number 0938–0981. We address the anticipated information collection burden reduction in section XVIII.D. of this final rule with comment period. E. Effects of Requirements for the PPSExempt Cancer Hospital Quality Reporting (PCHQR) Program As described in section XVII.B. of this final rule with comment period, we are not finalizing our proposals made in the FY 2019 IPPS/LTCH PPS proposed rule (83 FR 20503) to remove two chartabstracted, NHSN measures, the Catheter-Associated Urinary Tract Infection (CAUTI) Outcome Measure (PCH–5/NQF #0138) and the Central Line-Associated Bloodstream Infection (CLABSI) Outcome Measure (PCH–4/ NQF #0139) from the PCHQR Program beginning with the FY 2021 program year. We estimate that not finalizing our proposals to remove the CAUTI and CLABSI measures will result in no changes to our previously finalized burden estimates under the PCHQR Program. We refer readers to section XIX.E. of this final rule with comment period for a discussion of the information collection estimates for the CAUTI and CLABSI measures. We refer readers to section XIV.B.4. of the preamble of the FY 2019 IPPS/LTCH PPS final rule (83 FR 41694 through 41695) and Appendix A, section I.L. of that final rule (83 FR 41772) for more detail regarding our previously finalized information collection and burden estimates under the PCHQR Program. E:\FR\FM\21NOR2.SGM 21NOR2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations khammond on DSK30JT082PROD with RULES2 F. Regulatory Review Costs If regulations impose administrative costs on private entities, such as the time needed to read and interpret a rule, we should estimate the cost associated with regulatory review. Due to the uncertainty involved with accurately quantifying the number of entities that will review a rule, we assumed that the number of commenters on the CY 2019 OPPS/ASC proposed rule (2,994) will be the number of reviewers of this final rule with comment period. We acknowledge that this assumption may understate or overstate the costs of reviewing this final rule with comment period. It is possible that not all commenters will review this final rule with comment period in detail, and it is also possible that some reviewers will choose not to comment on this final rule with comment period. Nonetheless, we believe that the number of commenters on the CY 2019 OPPS/ASC proposed rule will be a fair estimate of the number of reviewers of this final rule with comment period. In the CY 2019 OPPS/ASC proposed rule (83 FR 37237), we welcomed any comments on the approach in estimating the number of entities that will review the proposed rule. We also recognize that different types of entities are, in many cases, affected by mutually exclusive sections of the proposed rule and this final rule with comment period, and, therefore, for the purposes of our estimate, we assumed that each reviewer reads approximately 50 percent of the rule. In the proposed rule, we sought public comments. We did not receive any public comments specific to our solicitation. Using the wage information from the BLS for medical and health service managers (Code 11–9111), we estimated that the cost of reviewing this rule is $107.38 per hour, including overhead and fringe benefits (https://www.bls.gov/ oes/current/oes_nat.htm). Assuming an average reading speed, we estimate that it will take approximately 8 hours for the staff to review half of this final rule with comment period. For each facility that reviewed this final rule with comment period, the estimated cost is $859.04 (8 hours × $107.38). Therefore, we estimated that the total cost of reviewing this final rule with comment period is $2,571,966 ($859.04 × 2,994 reviewers). G. Regulatory Flexibility Act (RFA) Analysis The RFA requires agencies to analyze options for regulatory relief of small entities, if a rule has a significant impact on a substantial number of small VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 entities. For purposes of the RFA, we estimate that most hospitals, ASCs and CMHCs are small entities as that term is used in the RFA. For purposes of the RFA, most hospitals are considered small businesses according to the Small Business Administration’s size standards with total revenues of $38.5 million or less in any single year or by the hospital’s not-for-profit status. Most ASCs and most CMHCs are considered small businesses with total revenues of $15 million or less in any single year. For details, we refer readers to the Small Business Administration’s ‘‘Table of Size Standards’’ at: https://www.sba.gov/ content/table-small-business-sizestandards. In addition, section 1102(b) of the Act requires us to prepare a regulatory impact analysis if a rule may have a significant impact on the operations of a substantial number of small rural hospitals. This analysis must conform to the provisions of section 603 of the RFA. For purposes of section 1102(b) of the Act, we define a small rural hospital as a hospital that is located outside of a metropolitan statistical area and has 100 or fewer beds. We estimate that this final rule with comment period will increase payments to small rural hospitals by less than 3 percent; therefore, it should not have a significant impact on approximately 616 small rural hospitals. The analysis above, together with the remainder of this preamble, provides a regulatory flexibility analysis and a regulatory impact analysis. H. Unfunded Mandates Reform Act Analysis Section 202 of the Unfunded Mandates Reform Act of 1995 (UMRA) also requires that agencies assess anticipated costs and benefits before issuing any rule whose mandates require spending in any 1 year of $100 million in 1995 dollars, updated annually for inflation. That threshold level is currently approximately $150 million. This final rule with comment period does not mandate any requirements for State, local, or tribal governments, or for the private sector. I. Reducing Regulation and Controlling Regulatory Costs Executive Order 13771, titled Reducing Regulation and Controlling Regulatory Costs, was issued on January 30, 2017. It has been determined that this final rule with comment period, will be a deregulatory action for the purposes of Executive Order 13771. We estimate that this final rule with comment period will generate $22.52 million in annualized cost savings at a PO 00000 Frm 00361 Fmt 4701 Sfmt 4700 59177 7-percent discount rate, discounted relative to 2016, over a perpetual time horizon. J. Conclusion The changes we are making in this final rule with comment period will affect all classes of hospitals paid under the OPPS and will affect both CMHCs and ASCs. We estimate that most classes of hospitals paid under the OPPS will experience a modest increase or a minimal decrease in payment for services furnished under the OPPS in CY 2019. Table 62 demonstrates the estimated distributional impact of the OPPS budget neutrality requirements that will result in a 0.6 percent increase in payments for all services paid under the OPPS in CY 2019, after considering all of the changes to APC reconfiguration and recalibration, as well as the OPD fee schedule increase factor, wage index changes, including the frontier State wage index adjustment, estimated payment for outliers, the finalized off-campus provider-based department clinic visits payment policy, and changes to the pass-through payment estimate. However, some classes of providers that are paid under the OPPS will experience more significant gains or losses in OPPS payments in CY 2019. The updates to the ASC payment system for CY 2019 will affect each of the approximately 5,500 ASCs currently approved for participation in the Medicare program. The effect on an individual ASC will depend on its mix of patients, the proportion of the ASC’s patients who are Medicare beneficiaries, the degree to which the payments for the procedures offered by the ASC are changed under the ASC payment system, and the extent to which the ASC provides a different set of procedures in the coming year. Table 63 demonstrates the estimated distributional impact among ASC surgical specialties of the MFP-adjusted hospital market basket update factor of 2.1 percent for CY 2019. XXII. Federalism Analysis Executive Order 13132 establishes certain requirements that an agency must meet when it promulgates a proposed rule (and subsequent final rule) that imposes substantial direct costs on State and local governments, preempts State law, or otherwise has Federalism implications. We have examined the OPPS and ASC provisions included in this final rule with comment period in accordance with Executive Order 13132, Federalism, and have determined that they will not have a substantial direct effect on State, local or tribal governments, preempt State E:\FR\FM\21NOR2.SGM 21NOR2 59178 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations law, or otherwise have a Federalism implication. As reflected in Table 62 of this final rule with comment period, we estimate that OPPS payments to governmental hospitals (including State and local governmental hospitals) will increase by 0.5 percent under this final rule with comment period. While we do not know the number of ASCs or CMHCs with government ownership, we anticipate that it is small. The analyses we have provided in this section of this final rule with comment period, in conjunction with the remainder of this document, demonstrate that this final rule with comment period is consistent with the regulatory philosophy and principles identified in Executive Order 12866, the RFA, and section 1102(b) of the Act. This final rule with comment period will affect payments to a substantial number of small rural hospitals and a small number of rural ASCs, as well as other classes of hospitals, CMHCs, and ASCs, and some effects may be significant. List of Subjects 42 CFR Part 416 Health facilities, Health professions, Medicare, Reporting and recordkeeping requirements. 42 CFR Part 419 Hospitals, Medicare, Reporting and recordkeeping requirements. For reasons stated in the preamble of this document, the Centers for Medicare & Medicaid Services is amending 42 CFR chapter IV as set forth below: PART 416—AMBULATORY SURGICAL SERVICES 1. The authority citation for part 416 is revised to read as follows: ■ Authority: 42 U.S.C. 273, 1302, 1320b–8, and 1395hh. 2. Section 416.164 is amended— a. By revising paragraph (a)(4); b. In paragraph (b)(5), by removing the period and adding in its place ‘‘; and’’; and ■ c. By adding paragraph (b)(6). The revision and addition read as follows: ■ ■ ■ khammond on DSK30JT082PROD with RULES2 § 416.164 Scope of ASC services. (a) * * * (4) Drugs and biologicals for which separate payment is not allowed under the hospital outpatient prospective payment system (OPPS), with the exception of non-opioid pain management drugs that function as a supply when used in a surgical procedure; * * * * * VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 (b) * * * (6) Non-opioid pain management drugs that function as a supply when used in a surgical procedure. * * * * * ■ 3. Section 416.171 is amended by revising paragraphs (a)(2) and (b)(1) and (2) to read as follows: § 416.171 Determination of payment rates for ASC services. (a) * * * (2) Conversion factor for CY 2009 and subsequent calendar years. The conversion factor for a calendar year is equal to the conversion factor calculated for the previous year, updated as follows: (i) For CY 2009, the update is equal to zero percent. (ii) For CY 2010 through CY 2018, the update is the Consumer Price Index for All Urban Consumers (U.S. city average) as estimated by the Secretary for the 12month period ending with the midpoint of the year involved. (iii) For CY 2019 through CY 2023, the update is the hospital inpatient market basket percentage increase applicable under section 1886(b)(3)(B)(iii) of the Act. (iv) For CY 2024 and subsequent years, the update is the Consumer Price Index for All Urban Consumers (U.S. city average) as estimated by the Secretary for the 12-month period ending with the midpoint of the year involved. (v) For CY 2014 through CY 2018, the Consumer Price Index for All Urban Consumers update determined under paragraph (a)(2)(ii) of this section is reduced by 2.0 percentage points for an ASC that fails to meet the standards for reporting of ASC quality measures as established by the Secretary for the corresponding calendar year. (vi) For CY 2019 through CY 2023, the hospital inpatient market basket update determined under paragraph (a)(2)(iii) of this section is reduced by 2.0 percentage points for an ASC that fails to meet the standards for reporting of ASC quality measures as established by the Secretary for the corresponding calendar year. (vii) For CY 2024 and subsequent years, the Consumer Price Index for All Urban Consumers update determined under paragraph (a)(2)(iv) of this section is reduced by 2.0 percentage points for an ASC that fails to meet the standards for reporting of ASC quality measures as established by the Secretary for the corresponding calendar year. (viii)(A) For CY 2011 through CY 2018, the Consumer Price Index for All Urban Consumers determined under paragraph (a)(2)(ii) of this section, after application of any reduction under PO 00000 Frm 00362 Fmt 4701 Sfmt 4700 paragraph (a)(2)(iv) of this section, is reduced by the productivity adjustment described in section 1886(b)(3)(B)(xi)(II) of the Act. (B) For CY 2019 through CY 2023, the hospital inpatient market basket update determined under paragraph (a)(2)(iii) of this section, after application of any reduction under paragraph (a)(2)(vi) of this section, is reduced by the productivity adjustment described in section 1886(b)(3)(B)(xi)(II) of the Act. (C) For CY 2024 and subsequent years, the Consumer Price Index for All Urban Consumers determined under paragraph (a)(2)(iv) of this section, after application of any reduction under paragraph (a)(2)(vii) of this section, is reduced by the productivity adjustment described in section 1886(b)(3)(B)(xi)(II) of the Act. (D) The application of the provisions of paragraph (a)(2)(viii)(A), (B), or (C) of this section may result in the update being less than zero percent for a year, and may result in payment rates for a year being less than the payment rates for the preceding year. (b) * * * (1) Covered ancillary services specified in § 416.164(b), with the exception of radiology services and certain diagnostic tests as provided in § 416.164(b)(5) and non-opioid pain management drugs that function as a supply when used in a surgical procedure as provided in § 416.164(b)(6). (2) The device portion of deviceintensive procedures, which are procedures that— (i) Involve implantable devices assigned a CPT or HCPCS code; (ii) Utilize devices (including singleuse devices) that must be surgically inserted or implanted; and (iii) Have a HCPCS code-level device offset of greater than 30 percent when calculated according to the standard OPPS ASC ratesetting methodology. * * * * * ■ 4. Section 416.320 is amended by revising paragraph (c) to read as follows: § 416.320 Retention and removal of quality measures under the ASCQR Program. * * * * * (c) Removal of quality measures—(1) General rule for the removal of quality measures. Unless a measure raises specific safety concerns as set forth in paragraph (b) of this section, CMS will use the regular rulemaking process to remove, suspend, or replace quality measures in the ASCQR Program to allow for public comment. (2) Factors for consideration of removal of quality measures. CMS will E:\FR\FM\21NOR2.SGM 21NOR2 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations weigh whether to remove measures based on the following factors: (i) Factor 1. Measure performance among ASCs is so high and unvarying that meaningful distinctions and improvements in performance can no longer be made (topped-out measures); (ii) Factor 2. Performance or improvement on a measure does not result in better patient outcomes; (iii) Factor 3. A measure does not align with current clinical guidelines or practice; (iv) Factor 4. The availability of a more broadly applicable (across settings, populations, or conditions) measure for the topic; (v) Factor 5. The availability of a measure that is more proximal in time to desired patient outcomes for the particular topic; (vi) Factor 6. The availability of a measure that is more strongly associated with desired patient outcomes for the particular topic; (vii) Factor 7. Collection or public reporting of a measure leads to negative unintended consequences other than patient harm; and (viii) Factor 8. The costs associated with a measure outweigh the benefit of its continued use in the program. (3) Criteria to determine topped-out measures. For the purposes of the ASCQR Program, a measure is considered to be topped-out under paragraph (c)(2)(i) of this section when it meets both of the following criteria: (i) Statistically indistinguishable performance at the 75th and 90th percentiles (defined as when the difference between the 75th and 90th percentiles for an ASC’s measure is within two times the standard error of the full data set); and (ii) A truncated coefficient of variation less than or equal to 0.10. (4) Application of measure removal factors. The benefits of removing a measure from the ASCQR Program will be assessed on a case-by-case basis. A measure will not be removed solely on the basis of meeting any specific factor or criterion. khammond on DSK30JT082PROD with RULES2 PART 419—PROSPECTIVE PAYMENT SYSTEM FOR HOSPITAL OUTPATIENT DEPARTMENT SERVICES 5. The authority citation for part 419 is revised to read as follows: ■ Authority: 42 U.S.C. 1302, 1395l(t), and 1395hh. 6. Section 419.32 is amended by adding paragraph (b)(1)(iv)(B)(10) to read as follows: ■ VerDate Sep<11>2014 20:42 Nov 20, 2018 Jkt 247001 § 419.32 Calculation of prospective payment rates for hospital outpatient services. * * * * * (b) * * * (1) * * * (iv) * * * (B) * * * (10) For calendar year 2019, a multifactor productivity adjustment (as determined by CMS) and 0.75 percentage point. * * * * * ■ 7. Section 419.46 is amended by revising paragraphs (a)(1) through (3) and adding paragraph (h) to read as follows: § 419.46 Participation, data submission, and validation requirements under the Hospital Outpatient Quality Reporting (OQR) Program. (a) * * * (1) Register on the QualityNet website before beginning to report data; (2) Identify and register a QualityNet security administrator as part of the registration process under paragraph (a)(1) of this section; and (3) Submit at least one data element. * * * * * (h) Retention and removal of quality measures under the Hospital OQR Program—(1) General rule for the retention of quality measures. Quality measures adopted for the Hospital OQR Program measure set for a previous payment determination year are retained for use in subsequent payment determination years, except when they are removed, suspended, or replaced as set forth in paragraphs (h)(2) and (3) of this section. (2) Immediate measure removal. For cases in which CMS believes that the continued use of a measure as specified raises patient safety concerns, CMS will immediately remove a quality measure from the Hospital OQR Program and will promptly notify hospitals and the public of the removal of the measure and the reasons for its removal through the Hospital OQR Program ListServ and the QualityNet website. (3) Measure removal, suspension, or replacement through the rulemaking process. Unless a measure raises specific safety concerns as set forth in paragraph (h)(2) of this section, CMS will use the regular rulemaking process to remove, suspend, or replace quality measures in the Hospital OQR Program to allow for public comment. (i) Factors for consideration of removal of quality measures. CMS will weigh whether to remove measures based on the following factors: (A) Factor 1. Measure performance among hospitals is so high and PO 00000 Frm 00363 Fmt 4701 Sfmt 9990 59179 unvarying that meaningful distinctions and improvements in performance can no longer be made (‘‘topped out’’ measures); (B) Factor 2. Performance or improvement on a measure does not result in better patient outcomes; (C) Factor 3. A measure does not align with current clinical guidelines or practice; (D) Factor 4. The availability of a more broadly applicable (across settings, populations, or conditions) measure for the topic; (E) Factor 5. The availability of a measure that is more proximal in time to desired patient outcomes for the particular topic; (F) Factor 6. The availability of a measure that is more strongly associated with desired patient outcomes for the particular topic; (G) Factor 7. Collection or public reporting of a measure leads to negative unintended consequences other than patient harm; and (H) Factor 8. The costs associated with a measure outweigh the benefit of its continued use in the program. (ii) Criteria to determine topped-out measures. For the purposes of the Hospital OQR Program, a measure is considered to be topped-out under paragraph (h)(3)(i)(A) of this section when it meets both of the following criteria: (A) Statistically indistinguishable performance at the 75th and 90th percentiles (defined as when the difference between the 75th and 90th percentiles for a hospital’s measure is within two times the standard error of the full data set); and (B) A truncated coefficient of variation less than or equal to 0.10. (iii) Application of measure removal factors. The benefits of removing a measure from the Hospital OQR Program will be assessed on a case-bycase basis. Under this case-by-case approach, a measure will not be removed solely on the basis of meeting any specific factor. Dated: October 26, 2018. Seema Verma, Administrator, Centers for Medicare and Medicaid Services. Dated: October 29, 2018. Alex M. Azar II, Secretary, Department of Health and Human Services. [FR Doc. 2018–24243 Filed 11–2–18; 8:45 am] BILLING CODE 4120–01–P E:\FR\FM\21NOR2.SGM 21NOR2

Agencies

[Federal Register Volume 83, Number 225 (Wednesday, November 21, 2018)]
[Rules and Regulations]
[Pages 58818-59179]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-24243]



[[Page 58817]]

Vol. 83

Wednesday,

No. 225

November 21, 2018

Part II





Department of Health and Human Services





-----------------------------------------------------------------------





Centers for Medicare & Medicaid Services





-----------------------------------------------------------------------





42 CFR Parts 416 and 419





Medicare Program: Changes to Hospital Outpatient Prospective Payment 
and Ambulatory Surgical Center Payment Systems and Quality Reporting 
Programs; Rules

Federal Register / Vol. 83 , No. 225 / Wednesday, November 21, 2018 / 
Rules and Regulations

[[Page 58818]]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Medicare & Medicaid Services

42 CFR Parts 416 and 419

[CMS-1695-FC]
RIN 0938-AT30


Medicare Program: Changes to Hospital Outpatient Prospective 
Payment and Ambulatory Surgical Center Payment Systems and Quality 
Reporting Programs

AGENCY: Centers for Medicare & Medicaid Services (CMS), HHS.

ACTION: Final rule with comment period.

-----------------------------------------------------------------------

SUMMARY: This final rule with comment period revises the Medicare 
hospital outpatient prospective payment system (OPPS) and the Medicare 
ambulatory surgical center (ASC) payment system for CY 2019 to 
implement changes arising from our continuing experience with these 
systems. In this final rule with comment period, we describe the 
changes to the amounts and factors used to determine the payment rates 
for Medicare services paid under the OPPS and those paid under the ASC 
payment system. In addition, this final rule with comment period 
updates and refines the requirements for the Hospital Outpatient 
Quality Reporting (OQR) Program and the ASC Quality Reporting (ASCQR) 
Program. In addition, we are updating the Hospital Consumer Assessment 
of Healthcare Providers and Systems (HCAHPS) Survey measure under the 
Hospital Inpatient Quality Reporting (IQR) Program by removing the 
Communication about Pain questions; and retaining two measures that 
were proposed for removal, the Catheter-Associated Urinary Tract 
Infection (CAUTI) Outcome Measure and Central Line-Associated 
Bloodstream Infection (CLABSI) Outcome Measure, in the PPS-Exempt 
Cancer Hospital Quality Reporting (PCHQR) Program beginning with the FY 
2021 program year.

DATES: 
    Effective date: This final rule with comment period is effective on 
January 1, 2019.
    Comment period: To be assured consideration, comments on the 
payment classifications assigned to the interim APC assignments and/or 
status indicators of new or replacement Level II HCPCS codes in this 
final rule with comment period must be received at one of the addresses 
provided in the ADDRESSES section no later than 5 p.m. EST on December 
3, 2018.

ADDRESSES: In commenting, please refer to file code CMS-1695-FC when 
commenting on the issues in this final rule with comment period. 
Because of staff and resource limitations, we cannot accept comments by 
facsimile (FAX) transmission.
    Comments, including mass comment submissions, must be submitted in 
one of the following three ways (please choose only one of the ways 
listed):
    1. Electronically. You may (and we encourage you to) submit 
electronic comments on this regulation to https://www.regulations.gov. 
Follow the instructions under the ``submit a comment'' tab.
    2. By regular mail. You may mail written comments to the following 
address ONLY:

Centers for Medicare & Medicaid Services, Department of Health and 
Human Services, Attention: CMS-1695-FC, P.O. Box 8013, Baltimore, MD 
21244-1850.

    Please allow sufficient time for mailed comments to be received 
before the close of the comment period.
    3. By express or overnight mail. You may send written comments via 
express or overnight mail to the following address ONLY:

Centers for Medicare & Medicaid Services, Department of Health and 
Human Services, Attention: CMS-1695-FC, Mail Stop C4-26-05, 7500 
Security Boulevard, Baltimore, MD 21244-1850.

    b. For delivery in Baltimore, MD--

Centers for Medicare & Medicaid Services, Department of Health and 
Human Services, 7500 Security Boulevard, Baltimore, MD 21244-1850.

    For information on viewing public comments, we refer readers to the 
beginning of the SUPPLEMENTARY INFORMATION section.

FOR FURTHER INFORMATION CONTACT: 
    340B Drug Payment Policy to Nonexcepted Off-Campus Departments of a 
Hospital, contact Juan Cortes via email [email protected] or at 
410-786-4325.
    Advisory Panel on Hospital Outpatient Payment (HOP Panel), contact 
the HOP Panel mailbox at [email protected].
    Ambulatory Surgical Center (ASC) Payment System, contact Scott 
Talaga via email [email protected] or at 410-786-4142.
    Ambulatory Surgical Center Quality Reporting (ASCQR) Program 
Administration, Validation, and Reconsideration Issues, contact Anita 
Bhatia via email [email protected] or at 410-786-7236.
    Ambulatory Surgical Center Quality Reporting (ASCQR) Program 
Measures, contact Vinitha Meyyur via email [email protected] 
or at 410-786-8819.
    Blood and Blood Products, contact Josh McFeeters via email 
[email protected] or at 410-786-9732.
    Cancer Hospital Payments, contact Scott Talaga via email 
[email protected] or at 410-786-4142.
    CMS Web Posting of the OPPS and ASC Payment Files, contact Chuck 
Braver via email [email protected] or at 410-786-6719.
    CPT Codes, contact Marjorie Baldo via email 
[email protected] or at 410-786-4617.
    Collecting Data on Services Furnished in Off-Campus Provider-Based 
Emergency Departments, contact Twi Jackson via email 
[email protected] or at 410-786-1159.
    Control for Unnecessary Increases in Volume of Outpatient Services, 
contact Elise Barringer via email [email protected] or at 
410-786-9222.
    Composite APCs (Low Dose Brachytherapy and Multiple Imaging), 
contact Elise Barringer via email [email protected] or at 
410-786-9222.
    Comprehensive APCs (C-APCs), contact Lela Strong-Holloway via email 
[email protected] or at 410-786-3213.
    Expansion of Clinical Families of Services at Excepted Off-Campus 
Departments of a Provider, contact Juan Cortes via email 
[email protected] or at 410-786-4325.
    Hospital Outpatient Quality Reporting (OQR) Program Administration, 
Validation, and Reconsideration Issues, contact Anita Bhatia via email 
[email protected] or at 410-786-7236.
    Hospital Outpatient Quality Reporting (OQR) Program Measures, 
contact Vinitha Meyyur via email [email protected] or at 410-
786-8819.
    Hospital Outpatient Visits (Emergency Department Visits and 
Critical Care Visits), contact Twi Jackson via email 
[email protected] or at 410-786-1159.
    Inpatient Only (IPO) Procedures List, contact Lela Strong-Holloway 
via email [email protected] or at 410-786-3213.
    New Technology Intraocular Lenses (NTIOLs), contact Scott Talaga 
via email

[[Page 58819]]

[email protected] or at 410-786-4142.
    No Cost/Full Credit and Partial Credit Devices, contact Twi Jackson 
via email [email protected] or at 410-786-1159.
    OPPS Brachytherapy, contact Scott Talaga via email 
[email protected] or at 410-786-4142.
    OPPS Data (APC Weights, Conversion Factor, Copayments, Cost-to-
Charge Ratios (CCRs), Data Claims, Geometric Mean Calculation, Outlier 
Payments, and Wage Index), contact Erick Chuang via email 
[email protected] or at 410-786-1816, Steven Johnson via email 
[email protected] or at 410-786-3332, or Scott Talaga via 
email [email protected] or at 410-786-4142.
    OPPS Drugs, Radiopharmaceuticals, Biologicals, and Biosimilar 
Products, contact Josh McFeeters via email [email protected] 
or at 410-786-9732.
    OPPS New Technology Procedures/Services, contact the New Technology 
APC email at [email protected].
    OPPS Exceptions to the 2 Times Rule, contact Marjorie Baldo via 
email [email protected] or at 410-786-4617.
    OPPS Packaged Items/Services, contact Lela Strong-Holloway via 
email [email protected] or at 410-786-3213.
    OPPS Pass-Through Devices, contact the Device Pass-Through email at 
[email protected].
    OPPS Status Indicators (SI) and Comment Indicators (CI), contact 
Marina Kushnirova via email [email protected] or at 410-
786-2682.
    Partial Hospitalization Program (PHP) and Community Mental Health 
Center (CMHC) Issues, contact the PHP Payment Policy Mailbox at 
[email protected].
    PPS-Exempt Cancer Hospital Quality Reporting (PCHQR) Program 
measures, contact Nekeshia McInnis via email 
[email protected].
    Rural Hospital Payments, contact Josh McFeeters via email 
[email protected] or at 410-786-9732.
    Skin Substitutes, contact Josh McFeeters via email 
[email protected] or at 410-786-9732.
    All Other Issues Related to Hospital Outpatient and Ambulatory 
Surgical Center Payments Not Previously Identified, contact Marjorie 
Baldo via email [email protected] or at 410-786-4617.

SUPPLEMENTARY INFORMATION: Inspection of Public Comments: All comments 
received before the close of the comment period are available for 
viewing by the public, including any personally identifiable or 
confidential business information that is included in a comment. We 
post all comments received before the close of the comment period on 
the following website as soon as possible after they have been 
received: https://www.regulations.gov/. Follow the search instructions 
on that website to view public comments.

Electronic Access

    This Federal Register document is also available from the Federal 
Register online database through Federal Digital System (FDsys), a 
service of the U.S. Government Publishing Office. This database can be 
accessed via the internet at https://www.gpo.gov/fdsys/.

Addenda Available Only Through the Internet on the CMS Website

    In the past, a majority of the Addenda referred to in our OPPS/ASC 
proposed and final rules were published in the Federal Register as part 
of the annual rulemakings. However, beginning with the CY 2012 OPPS/ASC 
proposed rule, all of the Addenda no longer appear in the Federal 
Register as part of the annual OPPS/ASC proposed and final rules to 
decrease administrative burden and reduce costs associated with 
publishing lengthy tables. Instead, these Addenda are published and 
available only on the CMS website. The Addenda relating to the OPPS are 
available at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/HospitalOutpatientPPS/. The Addenda relating to the 
ASC payment system are available at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/HospitalOutpatientPPS/.

Current Procedural Terminology (CPT) Copyright Notice

    Throughout this final rule with comment period, we use CPT codes 
and descriptions to refer to a variety of services. We note that CPT 
codes and descriptions are copyright 2018 American Medical Association. 
All Rights Reserved. CPT is a registered trademark of the American 
Medical Association (AMA). Applicable Federal Acquisition Regulations 
(FAR) and Defense Federal Acquisition Regulations (DFAR) apply.

Table of Contents

I. Summary and Background
    A. Executive Summary of This Document
    B. Legislative and Regulatory Authority for the Hospital OPPS
    C. Excluded OPPS Services and Hospitals
    D. Prior Rulemaking
    E. Advisory Panel on Hospital Outpatient Payment (the HOP Panel 
or the Panel)
    F. Public Comments Received in Response to the CY 2019 OPPS/ASC 
Proposed Rule
    G. Public Comments Received in Response to the CY 2018 OPPS/ASC 
Final Rule With Comment Period
II. Updates Affecting OPPS Payments
    A. Recalibration of APC Relative Payment Weights
    B. Conversion Factor Update
    C. Wage Index Changes
    D. Statewide Average Default Cost-to-Charge Ratios (CCRs)
    E. Adjustment for Rural Sole Community Hospitals (SCHs) and 
Essential Access Community Hospitals (EACHs) Under Section 
1833(t)(13)(B) of the Act
    F. Payment Adjustment for Certain Cancer Hospitals for CY 2019
    G. Hospital Outpatient Outlier Payments
    H. Calculation of an Adjusted Medicare Payment From the National 
Unadjusted Medicare Payment
    I. Beneficiary Copayments
III. OPPS Ambulatory Payment Classification (APC) Group Policies
    A. OPPS Treatment of New CPT and Level II HCPCS Codes
    B. OPPS Changes--Variations Within APCs
    C. New Technology APCs
    D. OPPS APC-Specific Policies
IV. OPPS Payment for Devices
    A. Pass-Through Payments for Devices
    B. Device-Intensive Procedures
V. OPPS Payment Changes for Drugs, Biologicals, and 
Radiopharmaceuticals
    A. OPPS Transitional Pass-Through Payment for Additional Costs 
of Drugs, Biologicals, and Radiopharmaceuticals
    B. OPPS Payment for Drugs, Biologicals, and Radiopharmaceuticals 
Without Pass-Through Payment Status
VI. Estimate of OPPS Transitional Pass-Through Spending for Drugs, 
Biologicals, Radiopharmaceuticals, and Devices
    A. Background
    B. Estimate of Pass-Through Spending
VII. OPPS Payment for Hospital Outpatient Visits and Critical Care 
Services
VIII. Payment for Partial Hospitalization Services
    A. Background
    B. PHP APC Update for CY 2019
    C. Outlier Policy for CMHCs
    D. Proposed Update to PHP Allowable HCPCS Codes
IX. Procedures That Will Be Paid Only as Inpatient Procedures
    A. Background
    B. Changes to the Inpatient Only (IPO) List
X. Nonrecurring Policy Changes
    A. Collecting Data on Services Furnished in Off-Campus Provider-
Based Emergency Departments
    B. Method To Control Unnecessary Increases in the Volume of 
Outpatient Services
    C. Application of the 340B Drug Payment Policy to Nonexcepted 
Off-Campus Departments of a Hospital
    D. Expansion of Clinical Families of Services at Excepted Off-
Campus Departments of a Provider

[[Page 58820]]

XI. CY 2019 OPPS Payment Status and Comment Indicators
    A. CY 2019 OPPS Payment Status Indicator Definitions
    B. CY 2019 Comment Indicator Definitions
XII. Updates to the Ambulatory Surgical Center (ASC) Payment System
    A. Background
    B. Treatment of New and Revised Codes
    C. Update to the List of ASC Covered Surgical Procedures and 
Covered Ancillary Services
    D. ASC Payment for Covered Surgical Procedures and Covered 
Ancillary Services
    E. New Technology Intraocular Lenses (NTIOLs)
    F. ASC Payment and Comment Indicators
    G. Calculation of the ASC Payment Rates and the ASC Conversion 
Factor
XIII. Requirements for the Hospital Outpatient Quality Reporting 
(OQR) Program
    A. Background
    B. Hospital OQR Program Quality Measures
    C. Administrative Requirements
    D. Form, Manner, and Timing of Data Submitted for the Hospital 
OQR Program
    E. Payment Reduction for Hospitals That Fail To Meet the 
Hospital OQR Program Requirements for the CY 2019 Payment 
Determination
XIV. Requirements for the Ambulatory Surgical Center Quality 
Reporting (ASCQR) Program
    A. Background
    B. ASCQR Program Quality Measures
    C. Administrative Requirements
    D. Form, Manner, and Timing of Data Submitted for the ASCQR 
Program
    E. Payment Reduction for ASCs That Fail To Meet the ASCQR 
Program Requirements
XV. Comments Received in Response to Requests for Information (RFIs)
    A. Comments Received in Response to Request for Information on 
Promoting Interoperability and Electronic Health Care Information 
Exchange Through Possible Revisions to the CMS Patient Health and 
Safety Requirements for Hospitals and Other Medicare-Participating 
and Medicaid-Participating Providers and Suppliers
    B. Comments Received in Response to Request for Information on 
Price Transparency: Improving Beneficiary Access to Provider and 
Supplier Charge Information
    C. Comments Received in Response to Request for Information on 
Leveraging the Authority for the Competitive Acquisition Program 
(CAP) for Part B Drugs and Biologicals for a Potential CMS 
Innovation Center Model
XVI. Additional Hospital Inpatient Quality Reporting (IQR) Program 
Policies
XVII. Additional PPS-Exempt Cancer Hospital Quality Reporting 
(PCHQR) Program Policies
    A. Background
    B. Retention and Removal of Previously Finalized Quality 
Measures for PCHs Beginning With the FY 2021 Program Year
    C. Public Display Requirements
XVIII. Files Available to the Public via the Internet
XIX. Collection of Information Requirements
    A. Statutory Requirement for Solicitation of Comments
    B. ICRs for the Hospital OQR Program
    C. ICRs for the ASCQR Program
    D. ICRs for the Update to the HCAHPS Survey Measure in the 
Hospital IQR Program
    E. Total Reduction in Burden Hours and in Costs
XX. Response to Comments
XXI. Economic Analyses
    A. Statement of Need
    B. Overall Impact for the Provisions of This Final Rule With 
Comment Period
    C. Detailed Economic Analyses
    D. Effects of the Update to the HCAHPS Survey Measure in the 
Hospital IQR Program
    E. Effects of Requirements for the PPS-Exempt Cancer Hospital 
Quality Reporting (PCHQR) Program
    F. Regulatory Review Costs
    G. Regulatory Flexibility Act (RFA) Analysis
    H. Unfunded Mandates Reform Act Analysis
    I. Reducing Regulation and Controlling Regulatory Costs
    J. Conclusion
XXII. Federalism Analysis
Regulation Text

I. Summary and Background

A. Executive Summary of This Document

1. Purpose
    In this final rule with comment period, we are updating the payment 
policies and payment rates for services furnished to Medicare 
beneficiaries in hospital outpatient departments (HOPDs) and ambulatory 
surgical centers (ASCs), beginning January 1, 2019. Section 1833(t) of 
the Social Security Act (the Act) requires us to annually review and 
update the payment rates for services payable under the Hospital 
Outpatient Prospective Payment System (OPPS). Specifically, section 
1833(t)(9)(A) of the Act requires the Secretary to review certain 
components of the OPPS not less often than annually, and to revise the 
groups, relative payment weights, and the wage and other adjustments 
that take into account changes in medical practices, changes in 
technologies, and the addition of new services, new cost data, and 
other relevant information and factors. In addition, under section 
1833(i) of the Act, we annually review and update the ASC payment 
rates. This final rule with comment period also includes additional 
policy changes made in accordance with our experience with the OPPS and 
the ASC payment system. We describe these and various other statutory 
authorities in the relevant sections of this final rule with comment 
period. In addition, this final rule with comment period updates and 
refines the requirements for the Hospital Outpatient Quality Reporting 
(OQR) Program and the ASC Quality Reporting (ASCQR) Program.
    In this final rule with comment period, two quality reporting 
policies that impact inpatient hospitals are updated due to their time 
sensitivity. In the Hospital IQR Program, we are updating the HCAHPS 
Survey measure by removing the Communication about Pain questions from 
the HCAHPS Survey, which are used to assess patients' experiences of 
care, effective with October 2019 discharges for the FY 2021 payment 
determination and subsequent years. This policy addresses public health 
concerns about opioid overprescribing through patient pain management 
questions that were recommended for removal in the President's 
Commission on Combating Drug Addiction and the Opioid Crisis report. In 
addition, we are finalizing that we will not publicly report any data 
collected from the Communication Abut Pain questions--a modification 
from what we proposed. We also are retaining two measures that we 
proposed for removal in the PCHQR Program beginning with the FY 2021 
program year, the Catheter-Associated Urinary Tract Infection (CAUTI) 
Outcome Measure and Central Line-Associated Bloodstream Infection 
(CLABSI) Outcome Measure. This policy impacts infection measurement and 
public reporting for PPS-exempt cancer hospitals and was deferred to 
this rule from the CY 2019 IPPS/LTCH PPS final rule published in August 
2018.
2. Improving Patient Outcomes and Reducing Burden Through Meaningful 
Measures
    Regulatory reform and reducing regulatory burden are high 
priorities for CMS. To reduce the regulatory burden on the healthcare 
industry, lower health care costs, and enhance patient care, in October 
2017, we launched the Meaningful Measures Initiative.\1\ This 
initiative is one component of our agency-wide Patients Over Paperwork 
Initiative,\2\ which is aimed at evaluating and streamlining 
regulations with a goal

[[Page 58821]]

to reduce unnecessary cost and burden, increase efficiencies, and 
improve beneficiary experience. The Meaningful Measures Initiative is 
aimed at identifying the highest priority areas for quality measurement 
and quality improvement in order to assess the core quality of care 
issues that are most vital to advancing our work to improve patient 
outcomes. The Meaningful Measures Initiative represents a new approach 
to quality measures that fosters operational efficiencies, and will 
reduce costs including, collection and reporting burden, while 
producing quality measurement that is more focused on meaningful 
outcomes.
---------------------------------------------------------------------------

    \1\ Meaningful Measures web page: https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/QualityInitiativesGenInfo/MMF/General-info-Sub-Page.html.
    \2\ Remarks by Administrator Seema Verma at the Health Care 
Payment Learning and Action Network (LAN) Fall Summit, as prepared 
for delivery on October 30, 2017. Available at: https://www.cms.gov/Newsroom/MediaReleaseDatabase/Fact-sheets/2017-Fact-Sheet-items/2017-10-30.html.
---------------------------------------------------------------------------

    The Meaningful Measures framework has the following objectives:
     Address high-impact measure areas that safeguard public 
health;
     Patient-centered and meaningful to patients;
     Outcome-based where possible;
     Fulfill each program's statutory requirements;
     Minimize the level of burden for health care providers;
     Significant opportunity for improvement;
     Address measure needs for population based payment through 
alternative payment models; and
     Align across programs and/or with other payers.
    In order to achieve these objectives, we have identified 19 
Meaningful Measures areas and mapped them to six overarching quality 
priorities, as shown in the table below.
BILLING CODE 4120-01-P
[GRAPHIC] [TIFF OMITTED] TR21NO18.000

BILLING CODE 4120-01-C
    By including Meaningful Measures in our programs, we believe that 
we can also address the following cross-cutting measure criteria:
     Eliminating disparities;
     Tracking measurable outcomes and impact;
     Safeguarding public health;
     Achieving cost savings;
     Improving access for rural communities; and
     Reducing burden.
    We believe that the Meaningful Measures Initiative will improve 
outcomes for patients, their families, and health care providers while 
reducing burden and costs for clinicians and providers as well as 
promoting operational efficiencies.
    We received numerous comments from stakeholders regarding the 
Meaningful Measures Initiative and the impact of its implementation in 
CMS' quality programs. Many of these comments pertained to specific 
program proposals, and are discussed in the appropriate program-
specific sections of this final rule with comment period. However, 
commenters also provided insights and recommendations for the ongoing 
development of the Meaningful Measures Initiative generally, including: 
ensuring transparency in public reporting and usability of publicly 
reported data; evaluating the benefit of individual measures to 
patients via use in quality programs weighed against the burden to 
providers of collecting and

[[Page 58822]]

reporting that measure data; and identifying additional opportunities 
for alignment across CMS quality programs. We look forward to 
continuing to work with stakeholders to refine and further implement 
the Meaningful Measures Initiative, and will take commenters' insights 
and recommendations into account moving forward.
3. Summary of the Major Provisions
     OPPS Update: For CY 2019, we are increasing the payment 
rates under the OPPS by an outpatient department (OPD) fee schedule 
increase factor of 1.35 percent. This increase factor is based on the 
final hospital inpatient market basket percentage increase of 2.9 
percent for inpatient services paid under the hospital inpatient 
prospective payment system (IPPS), minus the multifactor productivity 
(MFP) adjustment of 0.8 percentage point, and minus a 0.75 percentage 
point adjustment required by the Affordable Care Act. Based on this 
update, we estimate that total payments to OPPS providers (including 
beneficiary cost-sharing and estimated changes in enrollment, 
utilization, and case-mix) for CY 2019 will be approximately $74.1 
billion, an increase of approximately $5.8 billion compared to 
estimated CY 2018 OPPS payments.
    We are continuing to implement the statutory 2.0 percentage point 
reduction in payments for hospitals failing to meet the hospital 
outpatient quality reporting requirements, by applying a reporting 
factor of 0.980 to the OPPS payments and copayments for all applicable 
services.
     Comprehensive APCs: For CY 2019, we are creating three new 
comprehensive APCs (C-APCs). These new C-APCs include ears, nose, and 
throat (ENT) and vascular procedures. This increases the total number 
of C-APCs to 65.
     Changes to the Inpatient Only List: For CY 2019, we are 
removing four procedures from the inpatient only list and adding one 
procedure to the list.
     Method to Control Unnecessary Increases in Volume of 
Outpatient Services: To the extent that similar services are safely 
provided in more than one setting, it is not prudent for the OPPS to 
pay more for such services because that leads to an unnecessary 
increase in the number of those services provided in the OPPS setting. 
We believe that capping the OPPS payment at the Physician Fee Schedule 
(PFS)-equivalent rate is an effective method to control the volume of 
the unnecessary increases in certain services because the payment 
differential that is driving the site-of-service decision will be 
removed. In particular, we believe this method of capping payment will 
control unnecessary volume increases both in terms of numbers of 
covered outpatient department services furnished and costs of those 
services. Therefore, as we proposed, we are using our authority under 
section 1833(t)(2)(F) of the Act to apply an amount equal to the site-
specific PFS payment rate for nonexcepted items and services furnished 
by a nonexcepted off-campus provider-based department (PBD) of a 
hospital (the PFS payment rate) for the clinic visit service, as 
described by HCPCS code G0463, when provided at an off-campus PBD 
excepted from section 1833(t)(21) of the Act. We will be phasing in the 
application of the reduction in payment for code G0463 in this setting 
over 2 years. In CY 2019, the payment reduction will be transitioned by 
applying 50 percent of the total reduction in payment that would apply 
if these departments were paid the site-specific PFS rate for the 
clinic visit service. In other words, these departments will be paid 70 
percent of the OPPS rate for the clinic visit service in CY 2019. In CY 
2020 and subsequent years, these departments will be paid the site-
specific PFS rate for the clinic visit service. That is, these 
departments will be paid 40 percent of the OPPS rate for the clinic 
visit in CY 2020 and subsequent years. In addition to this proposal, we 
solicited public comments on how to expand the application of the 
Secretary's statutory authority under section 1833(t)(2)(F) of the Act 
to additional items and services paid under the OPPS that may represent 
unnecessary increases in OPD utilization. The public comment we 
received will be considered for future rulemaking.
     Expansion of Clinical Families of Services at 
Excepted Off-Campus Provider-Based Departments (PBDs) of a Hospital: 
For CY 2019, we proposed that if an excepted off-campus PBD furnished 
items and services from a clinical family of services from which it did 
not furnish items and services (and subsequently bill for those items 
and services) during a baseline period, services from the new clinical 
family of services would not be covered OPD services. Instead, services 
in the new clinical family of services would be paid under the PFS. 
While we are not finalizing this proposal at this time, we intend to 
monitor the expansion of services in excepted off-campus PBDs.
     Application of 340B Drug Payment Policy to 
Nonexcepted Off-Campus Provider-Based Departments of a Hospital: For CY 
2019, as we proposed, we are paying the average sales price (ASP) minus 
22.5 percent under the PFS for separately payable 340B-acquired drugs 
furnished by nonexcepted, off-campus provider-based departments (PBDs) 
of a hospital. This is consistent with the payment methodology adopted 
in CY 2018 for 340B-acquired drugs furnished in hospital departments 
paid under the OPPS.
     Payment Policy for Biosimilar Biological 
Products without Pass-Through Status That Are Acquired under the 340B 
Program: For CY 2019, we are making payment for nonpass-through 
biosimilars acquired under the 340B program at ASP minus 22.5 percent 
of the biosimilar's own ASP rather than ASP minus 22.5 percent of the 
reference product's ASP.
     Payment of Drugs, Biologicals, and 
Radiopharmaceuticals If Average Sales Price (ASP) Data Are Not 
Available: For CY 2019, we are making payment for separately payable 
drugs and biologicals that do not have pass-through payment status and 
are not acquired under the 340B Program at wholesale acquisition cost 
(WAC)+3 percent instead of WAC+6 percent if ASP data are not available. 
If WAC data are not available for a drug or biological product, we are 
continuing our policy to pay for separately payable drugs and 
biologicals at 95 percent of the average wholesale price (AWP). Drugs 
and biologicals that are acquired under the 340B Program will continue 
to be paid at ASP minus 22.5 percent, WAC minus 22.5 percent, or 69.46 
percent of AWP, as applicable.
     Device-Intensive Procedure Criteria: For CY 2019, we are 
modifying the device-intensive criteria to allow procedures that 
involve single-use devices, regardless of whether or not they remain in 
the body after the conclusion of the procedure, to qualify as device-
intensive procedures. We also are allowing procedures with a device 
offset percentage of greater than 30 percent to qualify as device-
intensive procedures.
     Device Pass-Through Payment Applications: For CY 2019, we 
evaluated seven applications for device pass-through payments and based 
on public comments received, we are approving one of these applications 
for device pass-through payment status.
     New Technology APC Payment for Extremely Low-Volume 
Procedures: For CY 2019 and future years, we are establishing a 
different payment methodology for services assigned to New Technology 
APCs with fewer than 100 claims using our equitable adjustment 
authority under section 1833(t)(2)(E) of the Act. We will use a 
``smoothing methodology'' based on multiple years of claims data to

[[Page 58823]]

establish a more stable rate for services assigned to New Technology 
APCs with fewer than 100 claims per year under the OPPS. Under this 
policy, we will calculate the geometric mean costs, the median costs, 
and the arithmetic mean costs for these procedures and adopt through 
our annual rulemaking the most appropriate payment rate for the service 
using one of these methodologies. We will use this approach to 
establish a payment rate for each low-volume service both for purposes 
of assigning the service to a New Technology APC and to a clinical APC 
at the conclusion of payment for the service through a New Technology 
APC. In addition, we are excluding services assigned to New Technology 
APCs from bundling into C-APC procedures.
     Cancer Hospital Payment Adjustment: For CY 2019, we are 
continuing to provide additional payments to cancer hospitals so that 
the cancer hospital's payment-to-cost ratio (PCR) after the additional 
payments is equal to the weighted average PCR for the other OPPS 
hospitals using the most recently submitted or settled cost report 
data. However, section 16002(b) of the 21st Century Cures Act requires 
that this weighted average PCR be reduced by 1.0 percentage point. 
Based on the data and the required 1.0 percentage point reduction, we 
are providing that a target PCR of 0.88 will be used to determine the 
CY 2019 cancer hospital payment adjustment to be paid at cost report 
settlement. That is, the payment adjustments will be the additional 
payments needed to result in a PCR equal to 0.88 for each cancer 
hospital.
     Rural Adjustment: For 2019 and subsequent years, we are 
continuing the 7.1 percent adjustment to OPPS payments for certain 
rural SCHs, including essential access community hospitals (EACHs). We 
intend to continue the 7.1 percent adjustment for future years in the 
absence of data to suggest a different percentage adjustment should 
apply.
     Ambulatory Surgical Center (ASC) Payment Update: For CYs 
2019 through 2023, we are updating the ASC payment system using the 
hospital market basket update instead of the CPI-U. However, during 
this 5-year period, we intend to examine whether such adjustment leads 
to a migration of services from other settings to the ASC setting. 
Using the hospital market basket methodology, for CY 2019, we are 
increasing payment rates under the ASC payment system by 2.1 percent 
for ASCs that meet the quality reporting requirements under the ASCQR 
Program. This increase is based on a hospital market basket percentage 
increase of 2.9 percent minus a MFP adjustment required by the 
Affordable Care Act of 0.8 percentage point.
    Based on this update, we estimate that total payments to ASCs 
(including beneficiary cost-sharing and estimated changes in 
enrollment, utilization, and case-mix) for CY 2019 will be 
approximately $4.85 billion, an increase of approximately $200 million 
compared to estimated CY 2018 Medicare payments to ASCs. We note that 
the CY 2019 ASC payment update, under our prior policy, would have been 
1.8 percent, based on a projected CPI-U update of 2.6 percent minus a 
MFP adjustment required by the Affordable Care Act of 0.8 percentage 
point. In addition, we will continue to assess the feasibility of 
collaborating with stakeholders to collect ASC cost data in a minimally 
burdensome manner for future policy development.
     Changes to the List of ASC Covered Surgical Procedures: 
For CY 2019, we are revising our definition of ``surgery'' in the ASC 
payment system to account for certain ``surgery-like'' procedures that 
are assigned codes outside the Current Procedural Terminology (CPT) 
surgical range. In addition, as we proposed, we are adding 12 cardiac 
catheterization procedures, and, in response to public comments, an 
additional 5 related procedures to the ASC covered procedures list. At 
this time, we are not finalizing our proposal to establish an 
additional review of recently added procedures to the ASC covered 
procedures list.
     Payment for Non-Opioid Pain Management Therapy: For CY 
2019, in response to the recommendation from the President's Commission 
on Combating Drug Addiction and the Opioid Crisis, we are changing the 
packaging policy for certain drugs when administered in the ASC setting 
and providing separate payment for non-opioid pain management drugs 
that function as a supply when used in a surgical procedure when the 
procedure is performed in an ASC.
     Hospital Outpatient Quality Reporting (OQR) Program: For 
the Hospital OQR Program, we are making changes effective with this 
final rule with comment period and for the CY 2019, CY 2020, and CY 
2021 payment determinations and subsequent years. Effective on the 
effective date of this final rule with comment period, we are codifying 
several previously established policies: to retain measures from a 
previous year's Hospital OQR Program measure set for subsequent years' 
measure sets at 42 CFR 419.46(h)(1); to use the rulemaking process to 
remove a measure for circumstances for which we do not believe that 
continued use of a measure raises specific patient safety concerns at 
42 CFR 419.46(h)(3); and to immediately remove measures as a result of 
patient safety concerns at 42 CFR 419.46(h)(2). Effective on the 
effective date of this final rule with comment period, we also are 
updating measure removal Factor 7; adding a new removal Factor 8; and 
codifying our measure removal policies and factors. We also are 
providing clarification of our criteria for ``topped-out'' measures. 
These changes align the Hospital OQR Program measure removal factors 
with those used in the ASCQR Program.
    Beginning with CY 2019, we are updating the frequency with which we 
will release a Hospital OQR Program Specifications Manual, such that it 
will occur every 12 months--a modification from what we proposed.
    For the CY 2020 payment determination and subsequent years, we are 
updating the participation status requirements by removing the Notice 
of Participation (NOP) form; extending the reporting period for the OP-
32: Facility Seven-Day Risk-Standardized Hospital Visit Rate after 
Outpatient Colonoscopy measure to 3 years; and removing the OP-27: 
Influenza Vaccination Coverage Among Healthcare Personnel measure.
    Beginning with the CY 2021 payment determination and subsequent 
years, we are removing the following seven measures: OP-5: Median Time 
to ECG; OP-9: Mammography Follow-up Rates; OP-11: Thorax CT Use of 
Contrast Material; OP-12: The Ability for Providers with HIT to Receive 
Laboratory Data Electronically Directly into Their Qualified/Certified 
EHR System as Discrete Searchable Data; OP-14: Simultaneous Use of 
Brain Computed Tomography (CT) and Sinus CT; OP-17: Tracking Clinical 
Results between Visits; and OP-30: Endoscopy/Polyp Surveillance: 
Colonoscopy Interval for Patients with a History of Adenomatous 
Polyps--Avoidance of Inappropriate Use. We are not finalizing our 
proposals to remove the OP-29 or OP-31 measures.
     Ambulatory Surgical Center Quality Reporting (ASCQR) 
Program: For the ASCQR Program, we are making changes in policies 
effective with this final rule with comment period and for the CY 2019, 
CY 2020, and CY 2021 payment determinations and subsequent years. 
Effective on the effective date of this final rule with comment period, 
we are removing one measure removal factor; adding two new measure 
removal factors; and updating the regulations to better reflect our 
measure removal policies. We also are making one clarification to 
measure removal Factor

[[Page 58824]]

1. These changes align the ASCQR Program measure removal factors with 
those used in the Hospital OQR Program.
    Beginning with the CY 2020 payment determination and subsequent 
years, we are extending the reporting period for the ASC-12: Facility 
Seven-Day Risk-Standardized Hospital Visit Rate after Outpatient 
Colonoscopy measure to 3 years; and removing the ASC-8: Influenza 
Vaccination Coverage Among Healthcare Personnel measure.
    Beginning with the CY 2021 payment determination and subsequent 
years, we are removing the ASC-10: Endoscopy/Polyp Surveillance: 
Colonoscopy Interval for Patients with a History of Adenomatous 
Polyps--Avoidance of Inappropriate Use measure. We are not finalizing 
our proposals to remove the following measures: ASC-9: Endoscopy/Polyp 
Surveillance Follow-up Interval for Normal Colonoscopy in Average Risk 
Patients and ASC-11: Cataracts--Improvement in Patient's Visual 
Function within 90 Days Following Cataract Surgery. We also are not 
finalizing our proposals to remove the following measures: ASC-1: 
Patient Burn; ASC-2: Patient Fall; ASC-3: Wrong Site, Wrong Side, Wrong 
Patient, Wrong Procedure, Wrong Implant; and ASC-4: All-Cause Hospital 
Transfer/Admission, but are retaining these measures in the ASCQR 
Program and suspending data collection for them until further action in 
rulemaking with the goal of revising the measures.
     Hospital Inpatient Quality Reporting (IQR) Program Update: 
In this final rule with comment period, we are finalizing a 
modification of our proposals to update the HCAHPS Survey measure by 
finalizing the removal of the Communication About Pain questions from 
the HCAHPS Survey for the Hospital IQR Program, effective with October 
2019 discharges for the FY 2021 payment determination and subsequent 
years. In addition, instead of publicly reporting the data from October 
2020 until October 2022 and then subsequently discontinuing reporting 
as proposed, we are finalizing that we will not publicly report any 
data collected from the Communication About Pain questions.
4. Summary of Costs and Benefits
    In sections XXI. and XXII. of this CY 2019 OPPS/ASC final rule with 
comment period, we set forth a detailed analysis of the regulatory and 
Federalism impacts that the changes will have on affected entities and 
beneficiaries. Key estimated impacts are described below.
a. Impacts of All OPPS Changes
    Table 62 in section XXI. of this final rule with comment period 
displays the distributional impact of all the OPPS changes on various 
groups of hospitals and CMHCs for CY 2019 compared to all estimated 
OPPS payments in CY 2018. We estimate that the policies in this final 
rule with comment period will result in a 0.6 percent overall increase 
in OPPS payments to providers. We estimate that total OPPS payments for 
CY 2019, including beneficiary cost-sharing, to the approximately 3,840 
facilities paid under the OPPS (including general acute care hospitals, 
children's hospitals, cancer hospitals, and CMHCs) will increase by 
approximately $360 million compared to CY 2018 payments, excluding our 
estimated changes in enrollment, utilization, and case-mix.
    We estimated the isolated impact of our OPPS policies on CMHCs 
because CMHCs are only paid for partial hospitalization services under 
the OPPS. Continuing the provider-specific structure we adopted 
beginning in CY 2011, and basing payment fully on the type of provider 
furnishing the service, we estimate a 15.1 percent decrease in CY 2019 
payments to CMHCs relative to their CY 2018 payments.
b. Impacts of the Updated Wage Indexes
    We estimate that our update of the wage indexes based on the FY 
2019 IPPS final rule wage indexes will result in no estimated payment 
change for urban hospitals under the OPPS and an estimated decrease of 
0.2 percent for rural hospitals. These wage indexes include the 
continued implementation of the OMB labor market area delineations 
based on 2010 Decennial Census data, with updates, as discussed in 
section II.C. of this final rule with comment period.
c. Impacts of the Rural Adjustment and the Cancer Hospital Payment 
Adjustment
    There are no significant impacts of our CY 2019 payment policies 
for hospitals that are eligible for the rural adjustment or for the 
cancer hospital payment adjustment. We are not making any change in 
policies for determining the rural hospital payment adjustments. While 
we are implementing the required reduction to the cancer hospital 
payment adjustment required by section 16002 of the 21st Century Cures 
Act for CY 2019, the target payment-to-cost ratio (PCR) for CY 2019 
remains the same as in CY 2018 and therefore does not impact the budget 
neutrality adjustments.
d. Impacts of the OPD Fee Schedule Increase Factor
    For the CY 2019 OPPS/ASC, we are establishing an OPD fee schedule 
increase factor of 1.35 percent and applying that increase factor to 
the conversion factor for CY 2019. As a result of the OPD fee schedule 
increase factor and other budget neutrality adjustments, we estimate 
that rural and urban hospitals will experience an increase of 
approximately 1.4 percent for urban hospitals and 1.3 percent for rural 
hospitals. Classifying hospitals by teaching status, we estimate 
nonteaching hospitals will experience an increase of 1.4 percent, minor 
teaching hospitals will experience an increase of 1.3 percent, and 
major teaching hospitals will experience an increase of 1.5 percent. We 
also classified hospitals by the type of ownership. We estimate that 
hospitals with voluntary ownership, hospitals with proprietary 
ownership, and hospitals with government ownership will all experience 
an increase of 1.4 percent in payments.
e. Impacts of the Policy To Control for Unnecessary Increases in the 
Volume of Outpatient Services
    In section X.B. of this CY 2019 OPPS/ASC final rule with comment 
period, we discuss our CY 2019 proposal and finalized policies to 
control for unnecessary increases in the volume of outpatient service 
by paying for clinic visits furnished at an off-campus PBD of a 
hospital at a PFS-equivalent rate under the OPPS rather than at the 
standard OPPS rate. As a result of this finalized policy, we estimated 
decreases of 0.6 percent to urban hospitals, and estimated decreases of 
0.6 percent to rural hospitals, with the estimated effect for 
individual groups of hospitals depending on the volume of clinic visits 
provided at the hospitals' off-campus PBDs.
f. Impacts of the ASC Payment Update
    For impact purposes, the surgical procedures on the ASC list of 
covered procedures are aggregated into surgical specialty groups using 
CPT and HCPCS code range definitions. The percentage change in 
estimated total payments by specialty groups under the CY 2019 payment 
rates, compared to estimated CY 2018 payment rates, generally ranges 
between an increase of 1 and 3 percent, depending on the service, with 
some exceptions. We estimate the impact of applying the hospital market 
basket update to ASC payment rates will increase payments by $80 
million under the ASC payment system in CY 2019,

[[Page 58825]]

compared to an increase of $60 million if we had applied an update 
based on CPI-U.
c. Impact of the Changes to the Hospital OQR Program
    Across 3,300 hospitals participating in the Hospital OQR Program, 
we estimate that our requirements will result in the following changes 
to costs and burdens related to information collection for the Hospital 
OQR Program compared to previously adopted requirements: (1) No change 
in the total collection of information burden or costs for the CY 2020 
payment determination; (2) a total collection of information burden 
reduction of 681,735 hours and a total collection of information cost 
reduction of approximately $24.9 million for the CY 2021 payment 
determination due to the removal of four measures: OP-5, OP-12, OP-17, 
and OP-30.
    Further, we anticipate that the removal of a total of eight 
measures will result in a reduction in costs unrelated to information 
collection. For example, it may be costly for health care providers to 
track the confidential feedback, preview reports, and publicly reported 
information on a measure where we use the measure in more than one 
program. Also, when measures are in multiple programs, maintaining the 
specifications for those measures, as well as the tools we need to 
collect, validate, analyze, and publicly report the measure data may 
result in costs to CMS. In addition, beneficiaries may find it 
confusing to see public reporting on the same measure in different 
programs.
d. Impact of the Changes to the ASCQR Program
    Across 3,937 ASCs participating in the ASCQR Program, we estimate 
that our requirements will result in the following changes to costs and 
burdens related to information collection for the ASCQR Program, 
compared to previously adopted requirements: (1) No change in the total 
collection of information burden or costs for the CY 2020 payment 
determination; (2) a total collection of information burden reduction 
of 62,008 hours and a total collection of information cost reduction of 
approximately $2,268,244 for the CY 2021 payment determination due to 
the removal of ASC-10.
    Further, we anticipate that the removal of ASC-10 will result in a 
reduction in costs unrelated to information collection. For example, it 
may be costly for health care providers to track the confidential 
feedback, preview reports, and publicly reported information on a 
measure where we use the measure in more than one program. Also, when 
measures are in multiple programs, maintaining the specifications for 
those measures as well as the tools we need to collect, analyze, and 
publicly report the measure data may result in costs to CMS. In 
addition, beneficiaries may find it confusing to see public reporting 
on the same measure in different programs.

B. Legislative and Regulatory Authority for the Hospital OPPS

    When Title XVIII of the Social Security Act was enacted, Medicare 
payment for hospital outpatient services was based on hospital-specific 
costs. In an effort to ensure that Medicare and its beneficiaries pay 
appropriately for services and to encourage more efficient delivery of 
care, the Congress mandated replacement of the reasonable cost-based 
payment methodology with a prospective payment system (PPS). The 
Balanced Budget Act of 1997 (BBA) (Pub. L. 105-33) added section 
1833(t) to the Act, authorizing implementation of a PPS for hospital 
outpatient services. The OPPS was first implemented for services 
furnished on or after August 1, 2000. Implementing regulations for the 
OPPS are located at 42 CFR parts 410 and 419.
    The Medicare, Medicaid, and SCHIP Balanced Budget Refinement Act of 
1999 (BBRA) (Pub. L. 106-113) made major changes in the hospital OPPS. 
The following Acts made additional changes to the OPPS: the Medicare, 
Medicaid, and SCHIP Benefits Improvement and Protection Act of 2000 
(BIPA) (Pub. L. 106-554); the Medicare Prescription Drug, Improvement, 
and Modernization Act of 2003 (MMA) (Pub. L. 108-173); the Deficit 
Reduction Act of 2005 (DRA) (Pub. L. 109-171), enacted on February 8, 
2006; the Medicare Improvements and Extension Act under Division B of 
Title I of the Tax Relief and Health Care Act of 2006 (MIEA-TRHCA) 
(Pub. L. 109-432), enacted on December 20, 2006; the Medicare, 
Medicaid, and SCHIP Extension Act of 2007 (MMSEA) (Pub. L. 110-173), 
enacted on December 29, 2007; the Medicare Improvements for Patients 
and Providers Act of 2008 (MIPPA) (Pub. L. 110-275), enacted on July 
15, 2008; the Patient Protection and Affordable Care Act (Pub. L. 111-
148), enacted on March 23, 2010, as amended by the Health Care and 
Education Reconciliation Act of 2010 (Pub. L. 111-152), enacted on 
March 30, 2010 (these two public laws are collectively known as the 
Affordable Care Act); the Medicare and Medicaid Extenders Act of 2010 
(MMEA, Pub. L. 111-309); the Temporary Payroll Tax Cut Continuation Act 
of 2011 (TPTCCA, Pub. L. 112-78), enacted on December 23, 2011; the 
Middle Class Tax Relief and Job Creation Act of 2012 (MCTRJCA, Pub. L. 
112-96), enacted on February 22, 2012; the American Taxpayer Relief Act 
of 2012 (Pub. L. 112-240), enacted January 2, 2013; the Pathway for SGR 
Reform Act of 2013 (Pub. L. 113-67) enacted on December 26, 2013; the 
Protecting Access to Medicare Act of 2014 (PAMA, Pub. L. 113-93), 
enacted on March 27, 2014; the Medicare Access and CHIP Reauthorization 
Act (MACRA) of 2015 (Pub. L. 114-10), enacted April 16, 2015; the 
Bipartisan Budget Act of 2015 (Pub. L. 114-74), enacted November 2, 
2015; the Consolidated Appropriations Act, 2016 (Pub. L. 114-113), 
enacted on December 18, 2015, the 21st Century Cures Act (Pub. L. 114-
255), enacted on December 13, 2016, the Consolidated Appropriations 
Act, 2018 (Pub. L. 115-141), enacted on March 23, 2018, and the 
Substance Use-Disorder Prevention that Promotes Opioid Recovery and 
Treatment for Patients and Communities Act (Pub. L. 115-271), enacted 
on October 24, 2018.
    Under the OPPS, we generally pay for hospital Part B services on a 
rate-per-service basis that varies according to the APC group to which 
the service is assigned. We use the Healthcare Common Procedure Coding 
System (HCPCS) (which includes certain Current Procedural Terminology 
(CPT) codes) to identify and group the services within each APC. The 
OPPS includes payment for most hospital outpatient services, except 
those identified in section I.C. of this final rule with comment 
period. Section 1833(t)(1)(B) of the Act provides for payment under the 
OPPS for hospital outpatient services designated by the Secretary 
(which includes partial hospitalization services furnished by CMHCs), 
and certain inpatient hospital services that are paid under Medicare 
Part B.
    The OPPS rate is an unadjusted national payment amount that 
includes the Medicare payment and the beneficiary copayment. This rate 
is divided into a labor-related amount and a nonlabor-related amount. 
The labor-related amount is adjusted for area wage differences using 
the hospital inpatient wage index value for the locality in which the 
hospital or CMHC is located.
    All services and items within an APC group are comparable 
clinically and with respect to resource use (section 1833(t)(2)(B) of 
the Act). In accordance with section 1833(t)(2)(B) of the Act, subject 
to certain exceptions, items and services within an APC group cannot be 
considered comparable with respect to

[[Page 58826]]

the use of resources if the highest median cost (or mean cost, if 
elected by the Secretary) for an item or service in the APC group is 
more than 2 times greater than the lowest median cost (or mean cost, if 
elected by the Secretary) for an item or service within the same APC 
group (referred to as the ``2 times rule''). In implementing this 
provision, we generally use the cost of the item or service assigned to 
an APC group.
    For new technology items and services, special payments under the 
OPPS may be made in one of two ways. Section 1833(t)(6) of the Act 
provides for temporary additional payments, which we refer to as 
``transitional pass-through payments,'' for at least 2 but not more 
than 3 years for certain drugs, biological agents, brachytherapy 
devices used for the treatment of cancer, and categories of other 
medical devices. For new technology services that are not eligible for 
transitional pass-through payments, and for which we lack sufficient 
clinical information and cost data to appropriately assign them to a 
clinical APC group, we have established special APC groups based on 
costs, which we refer to as New Technology APCs. These New Technology 
APCs are designated by cost bands which allow us to provide appropriate 
and consistent payment for designated new procedures that are not yet 
reflected in our claims data. Similar to pass-through payments, an 
assignment to a New Technology APC is temporary; that is, we retain a 
service within a New Technology APC until we acquire sufficient data to 
assign it to a clinically appropriate APC group.

C. Excluded OPPS Services and Hospitals

    Section 1833(t)(1)(B)(i) of the Act authorizes the Secretary to 
designate the hospital outpatient services that are paid under the 
OPPS. While most hospital outpatient services are payable under the 
OPPS, section 1833(t)(1)(B)(iv) of the Act excludes payment for 
ambulance, physical and occupational therapy, and speech-language 
pathology services, for which payment is made under a fee schedule. It 
also excludes screening mammography, diagnostic mammography, and 
effective January 1, 2011, an annual wellness visit providing 
personalized prevention plan services. The Secretary exercises the 
authority granted under the statute to also exclude from the OPPS 
certain services that are paid under fee schedules or other payment 
systems. Such excluded services include, for example, the professional 
services of physicians and nonphysician practitioners paid under the 
Medicare Physician Fee Schedule (MPFS); certain laboratory services 
paid under the Clinical Laboratory Fee Schedule (CLFS); services for 
beneficiaries with end-stage renal disease (ESRD) that are paid under 
the ESRD prospective payment system; and services and procedures that 
require an inpatient stay that are paid under the hospital IPPS. In 
addition, section 1833(t)(1)(B)(v) of the Act does not include 
applicable items and services (as defined in subparagraph (A) of 
paragraph (21)) that are furnished on or after January 1, 2017 by an 
off-campus outpatient department of a provider (as defined in 
subparagraph (B) of paragraph (21). We set forth the services that are 
excluded from payment under the OPPS in regulations at 42 CFR 419.22.
    Under Sec.  419.20(b) of the regulations, we specify the types of 
hospitals that are excluded from payment under the OPPS. These excluded 
hospitals include:
     Critical access hospitals (CAHs);
     Hospitals located in Maryland and paid under the Maryland 
All-Payer Model;
     Hospitals located outside of the 50 States, the District 
of Columbia, and Puerto Rico; and
     Indian Health Service (IHS) hospitals.

D. Prior Rulemaking

    On April 7, 2000, we published in the Federal Register a final rule 
with comment period (65 FR 18434) to implement a prospective payment 
system for hospital outpatient services. The hospital OPPS was first 
implemented for services furnished on or after August 1, 2000. Section 
1833(t)(9)(A) of the Act requires the Secretary to review certain 
components of the OPPS, not less often than annually, and to revise the 
groups, relative payment weights, and the wage and other adjustments 
that take into account changes in medical practices, changes in 
technologies, and the addition of new services, new cost data, and 
other relevant information and factors.
    Since initially implementing the OPPS, we have published final 
rules in the Federal Register annually to implement statutory 
requirements and changes arising from our continuing experience with 
this system. These rules can be viewed on the CMS website at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/HospitalOutpatientPPS/Hospital-Outpatient-Regulations-and-Notices.html.

E. Advisory Panel on Hospital Outpatient Payment (the HOP Panel or the 
Panel)

1. Authority of the Panel
    Section 1833(t)(9)(A) of the Act, as amended by section 201(h) of 
Pub. L. 106-113, and redesignated by section 202(a)(2) of Pub. L. 106-
113, requires that we consult with an external advisory panel of 
experts to annually review the clinical integrity of the payment groups 
and their weights under the OPPS. In CY 2000, based on section 
1833(t)(9)(A) of the Act, the Secretary established the Advisory Panel 
on Ambulatory Payment Classification Groups (APC Panel) to fulfill this 
requirement. In CY 2011, based on section 222 of the Public Health 
Service Act, which gives discretionary authority to the Secretary to 
convene advisory councils and committees, the Secretary expanded the 
panel's scope to include the supervision of hospital outpatient 
therapeutic services in addition to the APC groups and weights. To 
reflect this new role of the panel, the Secretary changed the panel's 
name to the Advisory Panel on Hospital Outpatient Payment (the HOP 
Panel or the Panel). The HOP Panel is not restricted to using data 
compiled by CMS, and in conducting its review, it may use data 
collected or developed by organizations outside the Department.
2. Establishment of the Panel
    On November 21, 2000, the Secretary signed the initial charter 
establishing the Panel, and, at that time, named the APC Panel. This 
expert panel is composed of appropriate representatives of providers 
(currently employed full-time, not as consultants, in their respective 
areas of expertise) who review clinical data and advise CMS about the 
clinical integrity of the APC groups and their payment weights. Since 
CY 2012, the Panel also is charged with advising the Secretary on the 
appropriate level of supervision for individual hospital outpatient 
therapeutic services. The Panel is technical in nature, and it is 
governed by the provisions of the Federal Advisory Committee Act 
(FACA). The current charter specifies, among other requirements, that 
the Panel--
     May advise on the clinical integrity of Ambulatory Payment 
Classification (APC) groups and their associated weights;
     May advise on the appropriate supervision level for 
hospital outpatient services;
     Continues to be technical in nature;
     Is governed by the provisions of the FACA;

[[Page 58827]]

     Has a Designated Federal Official (DFO); and
     Is chaired by a Federal Official designated by the 
Secretary.
    The Panel's charter was amended on November 15, 2011, renaming the 
Panel and expanding the Panel's authority to include supervision of 
hospital outpatient therapeutic services and to add critical access 
hospital (CAH) representation to its membership. The Panel's charter 
was also amended on November 6, 2014 (80 FR 23009), and the number of 
members was revised from up to 19 to up to 15 members. The Panel's 
current charter was approved on November 21, 2016, for a 2-year period 
(81 FR 94378).
    The current Panel membership and other information pertaining to 
the Panel, including its charter, Federal Register notices, membership, 
meeting dates, agenda topics, and meeting reports, can be viewed on the 
CMS website at: https://www.cms.gov/Regulations-and-Guidance/Guidance/FACA/AdvisoryPanelonAmbulatoryPaymentClassificationGroups.html.
3. Panel Meetings and Organizational Structure
    The Panel has held many meetings, with the last meeting taking 
place on August 20, 2018. Prior to each meeting, we publish a notice in 
the Federal Register to announce the meeting and, when necessary, to 
solicit nominations for Panel membership, to announce new members and 
to announce any other changes of which the public should be aware. 
Beginning in CY 2017, we have transitioned to one meeting per year (81 
FR 31941). Further information on the 2018 summer meeting can be found 
in the meeting notice titled ``Medicare Program: Announcement of the 
Advisory Panel on Hospital Outpatient Payment (the Panel) Meeting on 
August 20-21, 2018'' (83 FR 19785).
    In addition, the Panel has established an operational structure 
that, in part, currently includes the use of three subcommittees to 
facilitate its required review process. The three current subcommittees 
include the following:
     APC Groups and Status Indicator Assignments Subcommittee, 
which advises the Panel on the appropriate status indicators to be 
assigned to HCPCS codes, including but not limited to whether a HCPCS 
code or a category of codes should be packaged or separately paid, as 
well as the appropriate APC assignment of HCPCS codes regarding 
services for which separate payment is made;
     Data Subcommittee, which is responsible for studying the 
data issues confronting the Panel and for recommending options for 
resolving them; and
     Visits and Observation Subcommittee, which reviews and 
makes recommendations to the Panel on all technical issues pertaining 
to observation services and hospital outpatient visits paid under the 
OPPS.
    Each of these subcommittees was established by a majority vote from 
the full Panel during a scheduled Panel meeting, and the Panel 
recommended at the August 20, 2018 meeting that the subcommittees 
continue. We accepted this recommendation.
    Discussions of the other recommendations made by the Panel at the 
August 20, 2018 Panel meeting, namely CPT codes and a comprehensive APC 
for autologous hematopoietic stem cell transplantation, OPPS payment 
for outpatient clinic visits and restrictions to service line 
expansions, and packaging policies, were discussed in the CY 2019 OPPS/
ASC proposed rule (83 FR 37138 through 37143) or are included in the 
sections of this final rule with comment period that are specific to 
each recommendation. For discussions of earlier Panel meetings and 
recommendations, we refer readers to previously published OPPS/ASC 
proposed and final rules, the CMS website mentioned earlier in this 
section, and the FACA database at https://facadatabase.gov.

F. Public Comments Received in Response to the CY 2019 OPPS/ASC 
Proposed Rule

    We received over 2,990 timely pieces of correspondence on the CY 
2019 OPPS/ASC proposed rule that appeared in the Federal Register on 
July 31, 2018 (83 FR 37046). We note that we received some public 
comments that were outside the scope of the CY 2019 OPPS/ASC proposed 
rule. Out-of-scope public comments are not addressed in this CY 2019 
OPPS/ASC final rule with comment period. Summaries of those public 
comments that are within the scope of the proposed rule and our 
responses are set forth in the various sections of this final rule with 
comment period under the appropriate headings.

G. Public Comments Received on the CY 2018 OPPS/ASC Final Rule With 
Comment Period

    We received over 125 timely pieces of correspondence on the CY 2018 
OPPS/ASC final rule with comment period that appeared in the Federal 
Register on December 14, 2017 (82 FR 59216), some of which contained 
comments on the interim APC assignments and/or status indicators of new 
or replacement Level II HCPCS codes (identified with comment indicator 
``NI'' in OPPS Addendum B, ASC Addendum AA, and ASC Addendum BB to that 
final rule). Summaries of the public comments are set forth in the CY 
2019 proposed rule and this final rule with comment period under the 
appropriate subject matter headings.

II. Updates Affecting OPPS Payments

A. Recalibration of APC Relative Payment Weights

1. Database Construction
a. Database Source and Methodology
    Section 1833(t)(9)(A) of the Act requires that the Secretary review 
not less often than annually and revise the relative payment weights 
for APCs. In the April 7, 2000 OPPS final rule with comment period (65 
FR 18482), we explained in detail how we calculated the relative 
payment weights that were implemented on August 1, 2000 for each APC 
group.
    In the CY 2019 OPPS/ASC proposed rule (83 FR 37055), for CY 2019, 
we proposed to recalibrate the APC relative payment weights for 
services furnished on or after January 1, 2019, and before January 1, 
2020 (CY 2019), using the same basic methodology that we described in 
the CY 2018 OPPS/ASC final rule with comment period (82 FR 52367 
through 52370), using updated CY 2017 claims data. That is, as we 
proposed, we recalibrate the relative payment weights for each APC 
based on claims and cost report data for hospital outpatient department 
(HOPD) services, using the most recent available data to construct a 
database for calculating APC group weights.
    For the purpose of recalibrating the APC relative payment weights 
for CY 2019, we began with approximately 163 million final action 
claims (claims for which all disputes and adjustments have been 
resolved and payment has been made) for HOPD services furnished on or 
after January 1, 2017, and before January 1, 2018, before applying our 
exclusionary criteria and other methodological adjustments. After the 
application of those data processing changes, we used approximately 86 
million final action claims to develop the proposed CY 2019 OPPS 
payment weights. For exact numbers of claims used and additional 
details on the claims accounting process, we refer readers to the 
claims accounting narrative under supporting documentation for the CY 
2019 OPPS/ASC proposed rule on the CMS website at: https://www.cms.gov/
Medicare/

[[Page 58828]]

Medicare-Fee-for-Service-Payment/Hospital>OutpatientPPS/.
    Addendum N to the proposed rule (which is available via the 
internet on the CMS website) included the proposed list of bypass codes 
for CY 2019. The proposed list of bypass codes contained codes that 
were reported on claims for services in CY 2017 and, therefore, 
included codes that were in effect in CY 2017 and used for billing, but 
were deleted for CY 2018. We retained these deleted bypass codes on the 
proposed CY 2019 bypass list because these codes existed in CY 2017 and 
were covered OPD services in that period, and CY 2017 claims data were 
used to calculate CY 2019 payment rates. Keeping these deleted bypass 
codes on the bypass list potentially allows us to create more 
``pseudo'' single procedure claims for ratesetting purposes. ``Overlap 
bypass codes'' that are members of the proposed multiple imaging 
composite APCs were identified by asterisks (*) in the third column of 
Addendum N to the proposed rule. HCPCS codes that we proposed to add 
for CY 2019 were identified by asterisks (*) in the fourth column of 
Addendum N.
    In the CY 2019 OPPS/ASC proposed rule, we did not propose to remove 
any codes from the CY 2019 bypass list.
    We did not receive any public comments on our general proposal to 
recalibrate the relative payment weights for each APC based on claims 
and cost report data for HOPD services or on our proposed bypass code 
process. Therefore, we are adopting as final the proposed ``pseudo'' 
single claims process and the final CY 2019 bypass list of 169 HCPCS 
codes, as displayed in Addendum N to this final rule with comment 
period (which is available via the internet on the CMS website). For 
this final rule with comment period, for purposes of recalibrating the 
final APC relative payment weights for CY 2019, we used approximately 
91 million final action claims (claims for which all disputes and 
adjustments have been resolved and payment has been made) for HOPD 
services furnished on or after January 1, 2017 and before January 1, 
2018. For exact numbers of claims used and additional details on the 
claims accounting process, we refer readers to the claims accounting 
narrative under supporting documentation for this CY 2019 OPPS/ASC 
final rule with comment period on the CMS website at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/HospitalOutpatientPPS/.
b. Calculation and Use of Cost-to-Charge Ratios (CCRs)
    For CY 2019, in the CY 2019 OPPS/ASC proposed rule (83 FR 37055), 
we proposed to continue to use the hospital-specific overall ancillary 
and departmental cost-to-charge ratios (CCRs) to convert charges to 
estimated costs through application of a revenue code-to-cost center 
crosswalk. To calculate the APC costs on which the CY 2019 APC payment 
rates are based, we calculated hospital-specific overall ancillary CCRs 
and hospital-specific departmental CCRs for each hospital for which we 
had CY 2017 claims data by comparing these claims data to the most 
recently available hospital cost reports, which, in most cases, are 
from CY 2016. For the proposed CY 2019 OPPS payment rates, we used the 
set of claims processed during CY 2017. We applied the hospital-
specific CCR to the hospital's charges at the most detailed level 
possible, based on a revenue code-to-cost center crosswalk that 
contains a hierarchy of CCRs used to estimate costs from charges for 
each revenue code. That crosswalk is available for review and 
continuous comment on the CMS website at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/HospitalOutpatientPPS/.
    To ensure the completeness of the revenue code-to-cost center 
crosswalk, we reviewed changes to the list of revenue codes for CY 2017 
(the year of claims data we used to calculate the proposed CY 2019 OPPS 
payment rates) and found that the National Uniform Billing Committee 
(NUBC) did not add any new revenue codes to the NUBC 2017 Data 
Specifications Manual.
    In accordance with our longstanding policy, we calculate CCRs for 
the standard and nonstandard cost centers accepted by the electronic 
cost report database. In general, the most detailed level at which we 
calculate CCRs is the hospital-specific departmental level. For a 
discussion of the hospital-specific overall ancillary CCR calculation, 
we refer readers to the CY 2007 OPPS/ASC final rule with comment period 
(71 FR 67983 through 67985). The calculation of blood costs is a 
longstanding exception (since the CY 2005 OPPS) to this general 
methodology for calculation of CCRs used for converting charges to 
costs on each claim. This exception is discussed in detail in the CY 
2007 OPPS/ASC final rule with comment period and discussed further in 
section II.A.2.a.(1) of the proposed rule and this final rule with 
comment period.
    In the CY 2014 OPPS/ASC final rule with comment period (78 FR 74840 
through 74847), we finalized our policy of creating new cost centers 
and distinct CCRs for implantable devices, magnetic resonance imaging 
(MRIs), computed tomography (CT) scans, and cardiac catheterization. 
However, in response to the CY 2014 OPPS/ASC proposed rule, commenters 
reported that some hospitals currently use an imprecise ``square feet'' 
allocation methodology for the costs of large moveable equipment like 
CT scan and MRI machines. They indicated that while CMS recommended 
using two alternative allocation methods, ``direct assignment'' or 
``dollar value,'' as a more accurate methodology for directly assigning 
equipment costs, industry analysis suggested that approximately only 
half of the reported cost centers for CT scans and MRIs rely on these 
preferred methodologies. In response to concerns from commenters, we 
finalized a policy for the CY 2014 OPPS to remove claims from providers 
that use a cost allocation method of ``square feet'' to calculate CCRs 
used to estimate costs associated with the APCs for CT and MRI (78 FR 
74847). Further, we finalized a transitional policy to estimate the 
imaging APC relative payment weights using only CT and MRI cost data 
from providers that do not use ``square feet'' as the cost allocation 
statistic. We provided that this finalized policy would sunset in 4 
years to provide a sufficient time for hospitals to transition to a 
more accurate cost allocation method and for the related data to be 
available for ratesetting purposes (78 FR 74847). Therefore, beginning 
CY 2018, with the sunset of the transition policy, we would estimate 
the imaging APC relative payment weights using cost data from all 
providers, regardless of the cost allocation statistic employed. 
However, in the CY 2018 OPPS/ASC final rule with comment period (82 FR 
59228 and 59229), we finalized a policy to extend the transition policy 
for 1 additional year and continued to remove claims from providers 
that use a cost allocation method of ``square feet'' to calculate CT 
and MRI CCRs for the CY 2018 OPPS.
    As we discussed in the CY 2018 OPPS/ASC final rule with comment 
period (82 FR 59228), some stakeholders have raised concerns regarding 
using claims from all providers to calculate CT and MRI CCRs, 
regardless of the cost allocations statistic employed (78 FR 74840 
through 74847). Stakeholders noted that providers continue to use the 
``square feet'' cost allocation method and that including claims from 
such providers would cause significant

[[Page 58829]]

reductions in the imaging APC payment rates.
    Table 1 below demonstrates the relative effect on imaging APC 
payments after removing cost data for providers that report CT and MRI 
standard cost centers using ``square feet'' as the cost allocation 
method by extracting HCRIS data on Worksheet B-1. Table 2 below 
provides statistical values based on the CT and MRI standard cost 
center CCRs using the different cost allocation methods.

BILLING CODE 4120-01-P
[GRAPHIC] [TIFF OMITTED] TR21NO18.001


    [GRAPHIC] [TIFF OMITTED] TR21NO18.002
    
    Our analysis shows that since the CY 2014 OPPS in which we 
established the transition policy, the number of valid MRI CCRs has 
increased by 17.5 percent to 2,177 providers and the number of valid CT 
CCRs has increased by 15.1 percent to 2,251 providers. However, as 
shown in Table 1 above, nearly all imaging APCs would see an increase 
in payment rates for CY 2019 if claims from providers that report using 
the ``square feet'' cost allocation method were removed. This can be 
attributed to the generally lower CCR values from providers that use a 
cost allocation method of ``square feet'' as shown in Table 2 above.
    In response to provider concerns and to provide added flexibility 
for hospitals to improve their cost allocation methods, for the CY 2019 
OPPS, in the CY 2019 OPPS/ASC proposed rule (83 FR 37056), we proposed 
to extend our transition policy and remove claims from providers that 
use a cost allocation method of ``square feet'' to calculate CCRs used 
to estimate costs with the APCs for CT and MRI identified in Table 2 
above. We stated in the proposed rule that this proposed extension 
would mean that CMS would now be providing 6 years for providers to 
transition from a ``square feet'' cost allocation method to another 
cost allocation method. We stated in the proposed rule that we do not 
believe

[[Page 58830]]

another extension in CY 2020 will be warranted and expect to determine 
the imaging APC relative payment weights for CY 2020 using cost data 
from all providers, regardless of the cost allocation method employed.
    Comment: Some commenters supported CMS' proposal to extend its 
transition policy an additional year and determine imaging APC relative 
payment weights for CY 2020 using cost data from all providers.
    Response: We thank the commenters for their support.
    Comment: Some commenters recommended that CMS discontinue the use 
of CT and MRI cost centers for developing CT and MRI CCRs and use a 
single diagnostic radiology CCR instead. One commenter suggested that 
CCRs for CT and MRI are inaccurate, too low, and equalize the payment 
rates for advanced and nonadvanced imaging. This commenter also noted 
that if CMS were to use CCRs from all cost allocation methods, 
including ``square feet,'' such a change would impact technical 
payments under the Medicare Physician Fee Schedule because OPPS 
payments for imaging services would fall below the technical payments 
for such services under the Medicare Physician Fee Schedule and would 
require a reduction as required by section 1848(b)(4) of the Act.
    Further, the commenter noted that a significant number of CT and 
MRI CCRs are close to zero. The commenter suggested that this probably 
reflects that the costs of the equipment and dedicated space for these 
services are likely spread across to other departments of hospitals. 
The commenter also suggested that hospitals have standard accounting 
practices for high-cost moveable equipment and that it would be 
burdensome and inconsistent to apply a different standard for costs 
associated with CT and MRI.
    Response: We appreciate the comments regarding the use of standard 
CT and MRI cost center CCRs. As we stated in prior rulemaking, we 
recognize the concerns with regard to the application of the CT and MRI 
standard cost center CCRs and their use in OPPS ratesetting in lieu of 
the previously used single diagnostic radiology CCR. As compared to the 
IPPS, there is greater sensitivity to the cost allocation method being 
used on the cost report forms for these relatively new standard imaging 
cost centers under the OPPS due to the limited size of the OPPS payment 
bundles and because the OPPS applies the CCRs at the departmental level 
for cost estimation purposes. However, we note that since the time we 
initially established the transition policy in the OPPS, we have made 
changes toward making the OPPS more of a prospective payment system, 
including greater packaging and the development of the comprehensive 
APCs. As we have made changes to package a greater number of items and 
services with imaging payments under the OPPS, and CT and MRI 
procedures are not solely based on the CCR applied to each procedure, 
we believe there is less sensitivity to imaging payments that is 
attributable to the cost allocation method being used on the cost 
report forms.
    Table 3 and Table 4 below display the largest and smallest CT and 
MRI CCRs based on the cost allocation method, respectively. 
Specifically, Tables 3 and 4 display the minimum, 5th percentile, 10th 
percentile, 90th percentile, 95th percentile, and maximum CCRs based on 
the cost allocation method. While we note that there are differences in 
CT and MRI CCR values by the cost allocation method, we also note that 
the CT CCR distributions and MRI CCR distributions are largely similar 
across the cost allocation method. As stated in past rulemaking, we 
also note that our current trimming methodology excludes CCRs that are 
+/-3 standard deviations from the geometric mean. While we acknowledge 
the commenter's concern that a number of CCRs, particular those CT CCRs 
from hospitals that use a cost allocation method of ``square feet,'' 
are below 0.0100, we do not believe it would be appropriate to modify 
our standard trimming methodology because it is not our general policy 
to judge the accuracy of hospital charging and hospital cost reporting 
practices for purposes of ratesetting.
[GRAPHIC] [TIFF OMITTED] TR21NO18.003


[[Page 58831]]


[GRAPHIC] [TIFF OMITTED] TR21NO18.004

BILLING CODE 4120-01-C
    In addition, as we stated in the CY 2014 OPPS/ASC final rule with 
comment period (78 FR 74845), we have noted the potential impact the CT 
and MRI CCRs may have on other payment systems. We understand that 
payment reductions for imaging services under the OPPS could have 
significant payment impacts under the Physician Fee Schedule where the 
technical component payment for many imaging services is capped at the 
OPPS payment amount. We will continue to monitor OPPS imaging payments 
in the future and consider the potential impacts of payment changes to 
other payment systems.
    Over the past several years, we have encouraged hospitals to use 
more precise cost reporting methods through cost reporting instructions 
and communication with Medicare contractors regarding the approval of 
hospitals' request to switch from the square feet statistical 
allocation method. While we have not seen a substantial decline in the 
number of hospitals that use the square feet cost allocation method, 
and we acknowledge that there are costs and challenges with 
transitioning to a different accounting method for CT and MRI costs, we 
continue to believe that adopting CT and MRI cost center CCRs fosters 
more specific cost reporting and improves the data contained in the 
electronic cost report data files and, therefore, the accuracy of our 
cost estimation process for the OPPS relative weights. Therefore, for 
CY 2019, after consideration of the public comments we received, for CY 
2019, we are finalizing our proposal to extend our transition policy 
for 1 additional year and continue to remove claims from providers that 
use a ``square feet'' cost allocation method to calculate CT and MRI 
CCRs for the CY 2019 OPPS.
2. Data Development Process and Calculation of Costs Used for 
Ratesetting
    In this section of this final rule with comment period, we discuss 
the use of claims to calculate the OPPS payment rates for CY 2019. The 
Hospital OPPS page on the CMS website on which this final rule is 
posted (https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/HospitalOutpatientPPS/) provides an accounting of claims used 
in the development of the final payment rates. That accounting provides 
additional detail regarding the number of claims derived at each stage 
of the process. In addition, below in this section we discuss the file 
of claims that comprises the data set that is available upon payment of 
an administrative fee under a CMS data use agreement. The CMS website, 
https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/HospitalOutpatientPPS/, includes information about obtaining 
the ``OPPS Limited Data Set,'' which now includes the additional 
variables previously available only in the OPPS Identifiable Data Set, 
including ICD-10-CM diagnosis codes and revenue code payment amounts. 
This file is derived from the CY 2017 claims that were used to 
calculate the final payment rates for this CY 2019 OPPS/ASC final rule 
with comment period.
    Previously, the OPPS established the scaled relative weights, on 
which payments are based using APC median costs, a process described in 
the CY 2012 OPPS/ASC final rule with comment period (76 FR 74188). 
However, as discussed in more detail in section II.A.2.f. of the CY 
2013 OPPS/ASC final rule with comment period (77 FR 68259 through 
68271), we finalized the use of geometric mean costs to calculate the 
relative weights on which the CY 2013 OPPS payment rates were based. 
While this policy changed the cost metric on which the relative 
payments are based, the data process in general remained the same, 
under the methodologies that we used to obtain appropriate claims data 
and accurate cost information in determining estimated service cost. In 
the CY 2019 OPPS/ASC proposed rule (83 FR 37057), we proposed to 
continue to use geometric mean costs to calculate the relative weights 
on which the CY 2019 OPPS payment rates are based.
    Comment: One commenter believed that revenue code 0815 (Allogeneic 
Stem Cell Acquisition Services) was inadvertently excluded from the 
packaged revenue code list for use in the OPPS ratesetting. The 
commenter stated that this would primarily have an impact on APC 5244 
(Level 4 Blood Product Exchange and Related Services) which would 
potentially include those packaged costs. The commenter requested that 
CMS include revenue code 0815 on the packaged revenue code list in 
order to be consistent with the C-APC ratesetting approach from prior 
years.
    Response: We thank the commenter for bringing this omission to our 
attention. As discussed in the CY 2018 OPPS/ASC final rule with comment 
period (81 FR 79586), beginning in CY 2017, we would include the 
revenue code for purposes of identifying costs associated with stem 
cell transplants. We agree that the revenue code was inadvertently not 
included on the packaged revenue code list and therefore have included 
it in this final rule with comment period for the CY 2019 OPPS 
ratesetting.
    After consideration of the public comment on the proposed process 
we received, we are adding revenue code 0815 to the packaged revenue 
code list and are finalizing our proposed methodology for calculating 
geometric mean costs for purposes of creating relative payment weights 
and subsequent APC payment rates for the CY 2019 OPPS. For more 
information

[[Page 58832]]

regarding the stem cell transplants, we refer readers to section 
II.A.2.b. of this final rule with comment period. We used the 
methodology described in sections II.A.2.a. through II.A.2.c. of this 
final rule with comment period to calculate the costs we used to 
establish the relative payment weights used in calculating the OPPS 
payment rates for CY 2019 shown in Addenda A and B to this final rule 
with comment period (which are available via the internet on the CMS 
website). We refer readers to section II.A.4. of this final rule with 
comment period for a discussion of the conversion of APC costs to 
scaled payment weights.
    We note that this is the first year in which claims data containing 
lines with the modifier ``PN'' are available, which indicate 
nonexcepted items and services furnished and billed by off-campus 
provider-based departments (PBDs) of hospitals. Because nonexcepted 
services are not paid under the OPPS, in the CY 2019 OPPS/ASC proposed 
rule (83 FR 37057), we proposed to remove those claim lines reported 
with modifier ``PN'' from the claims data used in ratesetting for the 
CY 2019 OPPS and subsequent years.
    Comment: One commenter requested that CMS not finalize the removal 
of claims with modifier ``PN'' from the CY 2019 OPPS and future 
ratesetting. The commenter believed that this could result in unfair 
adjustments against hospital outpatient departments with large off-
campus PBD presence and that CMS should perform ratesetting with and 
without the modifier in CY 2020 and continue to gather stakeholder 
input until the impact of removing those lines is fully understood.
    Response: While we generally attempt to obtain more information 
from the claims and cost data available to us, we do so to obtain 
accurate cost information for OPPS services. As discussed in the 
proposed rule, we do not believe that lines with modifier ``PN'' should 
be included as part of the OPPS ratesetting process because they are 
paid under the otherwise applicable payment system, rather than the 
OPPS (83 FR 37056 and 37057). We note that the impact of removing these 
modifier ``PN'' lines has only a nominal effect on the APC geometric 
mean costs due to the relatively low number of claims reported with 
modifier ``PN''.
    After consideration of the public comment we received, we are 
finalizing the policy of removing lines with the ``PN'' modifier as 
proposed.
    For details of the claims process used in this final rule with 
comment period, we refer readers to the claims accounting narrative 
under supporting documentation for this CY 2019 OPPS/ASC final rule 
with comment period on the CMS website at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/HospitalOutpatientPPS/.
a. Calculation of Single Procedure APC Criteria-Based Costs
(1) Blood and Blood Products
(a) Methodology
    Since the implementation of the OPPS in August 2000, we have made 
separate payments for blood and blood products through APCs rather than 
packaging payment for them into payments for the procedures with which 
they are administered. Hospital payments for the costs of blood and 
blood products, as well as for the costs of collecting, processing, and 
storing blood and blood products, are made through the OPPS payments 
for specific blood product APCs.
    In the CY 2019 OPPS/ASC proposed rule (83 FR 37057 through 37058), 
we proposed to continue to establish payment rates for blood and blood 
products using our blood-specific CCR methodology, which utilizes 
actual or simulated CCRs from the most recently available hospital cost 
reports to convert hospital charges for blood and blood products to 
costs. This methodology has been our standard ratesetting methodology 
for blood and blood products since CY 2005. It was developed in 
response to data analysis indicating that there was a significant 
difference in CCRs for those hospitals with and without blood-specific 
cost centers, and past public comments indicating that the former OPPS 
policy of defaulting to the overall hospital CCR for hospitals not 
reporting a blood-specific cost center often resulted in an 
underestimation of the true hospital costs for blood and blood 
products. Specifically, in order to address the differences in CCRs and 
to better reflect hospitals' costs, we proposed to continue to simulate 
blood CCRs for each hospital that does not report a blood cost center 
by calculating the ratio of the blood-specific CCRs to hospitals' 
overall CCRs for those hospitals that do report costs and charges for 
blood cost centers. We also proposed to apply this mean ratio to the 
overall CCRs of hospitals not reporting costs and charges for blood 
cost centers on their cost reports in order to simulate blood-specific 
CCRs for those hospitals. We proposed to calculate the costs upon which 
the proposed CY 2019 payment rates for blood and blood products are 
based using the actual blood-specific CCR for hospitals that reported 
costs and charges for a blood cost center and a hospital-specific, 
simulated blood-specific CCR for hospitals that did not report costs 
and charges for a blood cost center.
    We continue to believe that the hospital-specific, simulated blood-
specific, CCR methodology better responds to the absence of a blood-
specific CCR for a hospital than alternative methodologies, such as 
defaulting to the overall hospital CCR or applying an average blood-
specific CCR across hospitals. Because this methodology takes into 
account the unique charging and cost accounting structure of each 
hospital, we believe that it yields more accurate estimated costs for 
these products. We stated in the proposed rule that we continue to 
believe that this methodology in CY 2019 would result in costs for 
blood and blood products that appropriately reflect the relative 
estimated costs of these products for hospitals without blood cost 
centers and, therefore, for these blood products in general.
    We note that, as discussed in section II.A.2.b. of the CY 2018 
OPPS/ASC final rule with comment period (82 FR 59234 through 59239), we 
defined a comprehensive APC (C-APC) as a classification for the 
provision of a primary service and all adjunctive services provided to 
support the delivery of the primary service. Under this policy, we 
include the costs of blood and blood products when calculating the 
overall costs of these C-APCs. In the CY 2019 OPPS/ASC proposed rule 
(83 FR 37057 through 37058), we proposed to continue to apply the 
blood-specific CCR methodology described in this section when 
calculating the costs of the blood and blood products that appear on 
claims with services assigned to the C-APCs. Because the costs of blood 
and blood products would be reflected in the overall costs of the C-
APCs (and, as a result, in the payment rates of the C-APCs), we 
proposed to not make separate payments for blood and blood products 
when they appear on the same claims as services assigned to the C-APCs 
(we refer readers to the CY 2015 OPPS/ASC final rule with comment 
period (79 FR 66796)).
    We also referred readers to Addendum B to the CY 2019 OPPS/ASC 
proposed rule (which is available via the internet on the CMS website) 
for the proposed CY 2019 payment rates for blood and blood products 
(which are identified with status indicator ``R''). For a more detailed 
discussion of the blood-specific CCR methodology, we refer readers to 
the CY 2005 OPPS proposed rule (69 FR 50524 through

[[Page 58833]]

50525). For a full history of OPPS payment for blood and blood 
products, we refer readers to the CY 2008 OPPS/ASC final rule with 
comment period (72 FR 66807 through 66810).
    We did not receive any public comments for these proposals. 
Therefore, we are finalizing our proposals, without modification, to 
continue to apply the blood-specific CCR methodology described in this 
section when calculating the costs of the blood and blood products that 
appear on claims with services assigned to the C-APCs and to not make 
separate payments for blood and blood products when they appear on the 
same claims as services assigned to the C-APCs for CY 2019.
(b) Pathogen-Reduced Platelets Payment Rate
    In the CY 2016 OPPS/ASC final rule with comment period (80 FR 70322 
through 70323), we reiterated that we calculate payment rates for blood 
and blood products using our blood-specific CCR methodology, which 
utilizes actual or simulated CCRs from the most recently available 
hospital cost reports to convert hospital charges for blood and blood 
products to costs. Because HCPCS code P9072 (Platelets, pheresis, 
pathogen reduced or rapid bacterial tested, each unit), the predecessor 
code to HCPCS code P9073 (Platelets, pheresis, pathogen-reduced, each 
unit), was new for CY 2016, there were no claims data available on the 
charges and costs for this blood product upon which to apply our blood-
specific CCR methodology. Therefore, we established an interim payment 
rate for HCPCS code P9072 based on a crosswalk to existing blood 
product HCPCS code P9037 (Platelets, pheresis, leukocytes reduced, 
irradiated, each unit), which we believed provided the best proxy for 
the costs of the new blood product. In addition, we stated that once we 
had claims data for HCPCS code P9072, we would calculate its payment 
rate using the claims data that should be available for the code 
beginning in CY 2018, which is our practice for other blood product 
HCPCS codes for which claims data have been available for 2 years.
    We stated in the CY 2018 OPPS/ASC final rule with comment period 
(82 FR 59232) that, although our standard practice for new codes 
involves using claims data to set payment rates once claims data become 
available, we were concerned that there may have been confusion among 
the provider community about the services that HCPCS code P9072 
described. That is, as early as 2016, there were discussions about 
changing the descriptor for HCPCS code P9072 to include the phrase ``or 
rapid bacterial tested'', which is a less costly technology than 
pathogen reduction. In addition, effective January 2017, the code 
descriptor for HCPCS code P9072 was changed to describe rapid bacterial 
testing of platelets and, effective July 1, 2017, the descriptor for 
the temporary successor code for HCPCS code P9072 (HCPCS code Q9988) 
was changed again back to the original descriptor for HCPCS code P9072 
that was in place for 2016.
    Based on the ongoing discussions involving changes to the original 
HCPCS code P9072 established in CY 2016, we believed that claims from 
CY 2016 for pathogen reduced platelets may have potentially reflected 
certain claims for rapid bacterial testing of platelets. Therefore, we 
decided to continue to crosswalk the payment amount for services 
described by HCPCS code P9073 to the payment amount for services 
described by HCPCS P9037 for CY 2018 (82 FR 59232), as had been done 
previously, to determine the payment rate for services described by 
HCPCS code P9072. In the CY 2019 OPPS/ASC proposed rule (83 FR 37058), 
for CY 2019, we discussed that we had reviewed the CY 2017 claims data 
for the two predecessor codes to HCPCS code P9073 (HCPCS codes P9072 
and Q9988), along with the claims data for the CY 2017 temporary code 
for pathogen test for platelets (HCPCS code Q9987), which describes 
rapid bacterial testing of platelets.
    We found that there were over 2,200 claims billed with either HCPCS 
code P9072 or Q9988. Accordingly, we believe that there are a 
sufficient number of claims to use to calculate a payment rate for 
HCPCS code P9073 for CY 2019. We also performed checks to estimate the 
share of claims that may have been billed for rapid bacterial testing 
of platelets as compared to the share of claims that may have been 
billed for pathogen-reduced, pheresis platelets (based on when HCPCS 
code P9072 was an active procedure code from January 1, 2017 to June 
30, 2017). First, we found that the geometric mean cost for pathogen-
reduced, pheresis platelets, as reported by HCPCS code Q9988 when 
billed separately from rapid bacterial testing of platelets, was 
$453.87, and that over 1,200 claims were billed for services described 
by HCPCS code Q9988. Next, we found that the geometric mean cost for 
rapid bacterial testing of platelets, as reported by HCPCS code Q9987 
on claims, was $33.44, and there were 59 claims reported for services 
described by HCPCS code Q9987, of which 3 were separately paid.
    These findings imply that almost all of the claims billed for 
services reported with HCPCS code P9072 were for pathogen-reduced, 
pheresis platelets. In addition, the geometric mean cost for services 
described by HCPCS code P9072, which may contain rapid bacterial 
testing of platelets claims, was $468.11, which is higher than the 
geometric mean cost for services described by HCPCS code Q9988 of 
$453.87, which should not have contained claims for rapid bacterial 
testing of platelets. Because the geometric mean for services described 
by HCPCS code Q9987 is only $33.44, it would be expected that if a 
significant share of claims billed for services described by HCPCS code 
P9072 were for the rapid bacterial testing of platelets, the geometric 
mean cost for services described by HCPCS code P9072 would be lower 
than the geometric mean cost for services described by HCPCS code 
Q9988. Instead, we found that the geometric mean cost for services 
described by HCPCS code Q9988 is higher than the geometric mean cost 
for services described by HCPCS code P9072.
    Based on our analysis of claims data, we stated in the CY 2019 
OPPS/ASC proposed rule that we believed there were sufficient claims 
available to establish a payment rate for pathogen-reduced pheresis 
platelets without using a crosswalk. Therefore, we proposed to 
calculate the payment rate for services described by HCPCS code P9073 
in CY 2019 and in subsequent years using claims payment history, which 
is the standard methodology used by the OPPS for HCPCS and CPT codes 
with at least 2 years of claims history. We referred readers to 
Addendum B of the proposed rule for the proposed payment rate for 
services described by HCPCS code P9073 reportable under the OPPS. 
Addendum B is available via the internet on the CMS website.
    Comment: Several commenters opposed the proposal to use claims 
history to calculate the payment rate for services described by HCPCS 
code P9073. Instead, the commenters requested that CMS calculate the 
payment rate for services described by HCPCS code P9072 based on a 
crosswalk to existing blood product HCPCS code P9037 through either CY 
2019 or CY 2020. The commenters stated that the acquisition cost for 
pathogen-reduced platelets is over $600, which is substantially higher 
than the proposed payment rate for services described by HCPCS code 
P9073 found in Addendum B to the proposed rule

[[Page 58834]]

and closer to the payment rate for services described by HCPCS code 
P9073. Some commenters indicated that the cost for pathogen-reduced 
platelets is higher than the cost of leukocytes reduced and irradiated 
platelets, the product covered by HCPCS code P9073, the crosswalked 
code. Several of the commenters believed the claim costs for pathogen-
reduced platelets were lower than actual costs because of coding errors 
by providers, providers who did not use pathogen-reduced platelets 
billing the service, and confusion over whether to use the hospital CCR 
or the blood center CCR to report charges for pathogen-reduced 
platelets. One commenter also stated that a provider that billed 
several claims for pathogen-reduced platelets believed that CMS 
assigned an unusually low CCR to its claims, leading the provider to 
report lower than actual costs for the service.
    Response: We appreciate the concerns of the commenters. Pathogen-
reduced platelets (HCPCS code P9073) are a relatively new service. As 
we noted in the CY 2019 OPPS/ASC proposed rule (83 FR 37058), there 
were many changes to the procedure code billed for pathogen-reduced 
platelets, as well as with the services covered by the procedure codes 
for pathogen-reduced platelets and the code descriptors. We had 
concerns that all of these coding changes could lead to billing 
confusion. The comments we received from providers, stakeholder groups, 
and the developer of the pathogen-reduced technology support that there 
indeed may have been confusion about billing that has led to 
aberrancies in the data we have available for ratesetting.
    After consideration of the public comments we received, we are not 
finalizing our proposal to calculate the payment rate for services 
described by HCPCS code P9073 in CY 2019 using claims payment history. 
Instead, for CY 2019 (that is, for one more year), we are establishing 
the payment rate for services described by HCPCS code P9073 by 
performing a crosswalk from the payment amount for services described 
by HCPCS code P9073 to the payment amount for services described by 
HCPCS P9037. We refer readers to Addendum B to this final rule with 
comment period for the final payment rate for services described by 
HCPCS code P9073 reportable under the OPPS. Addendum B is available via 
the internet on the CMS website.
(2) Brachytherapy Sources
    Section 1833(t)(2)(H) of the Act mandates the creation of 
additional groups of covered OPD services that classify devices of 
brachytherapy consisting of a seed or seeds (or radioactive source) 
(``brachytherapy sources'') separately from other services or groups of 
services. The statute provides certain criteria for the additional 
groups. For the history of OPPS payment for brachytherapy sources, we 
refer readers to prior OPPS final rules, such as the CY 2012 OPPS/ASC 
final rule with comment period (77 FR 68240 through 68241). As we have 
stated in prior OPPS updates, we believe that adopting the general OPPS 
prospective payment methodology for brachytherapy sources is 
appropriate for a number of reasons (77 FR 68240). The general OPPS 
methodology uses costs based on claims data to set the relative payment 
weights for hospital outpatient services. This payment methodology 
results in more consistent, predictable, and equitable payment amounts 
per source across hospitals by averaging the extremely high and low 
values, in contrast to payment based on hospitals' charges adjusted to 
costs. We believe that the OPPS methodology, as opposed to payment 
based on hospitals' charges adjusted to cost, also would provide 
hospitals with incentives for efficiency in the provision of 
brachytherapy services to Medicare beneficiaries. Moreover, this 
approach is consistent with our payment methodology for the vast 
majority of items and services paid under the OPPS. We refer readers to 
the CY 2016 OPPS/ASC final rule with comment period (80 FR 70323 
through 70325) for further discussion of the history of OPPS payment 
for brachytherapy sources.
    In the CY 2019 OPPS/ASC proposed rule (83 FR 37059), for CY 2019, 
we proposed to use the costs derived from CY 2017 claims data to set 
the proposed CY 2019 payment rates for brachytherapy sources because CY 
2017 is the same year of data we proposed to use to set the proposed 
payment rates for most other items and services that would be paid 
under the CY 2019 OPPS. We proposed to base the payment rates for 
brachytherapy sources on the geometric mean unit costs for each source, 
consistent with the methodology that we proposed for other items and 
services paid under the OPPS, as discussed in section II.A.2. of the 
proposed rule. We also proposed to continue the other payment policies 
for brachytherapy sources that we finalized and first implemented in 
the CY 2010 OPPS/ASC final rule with comment period (74 FR 60537). We 
proposed to pay for the stranded and nonstranded not otherwise 
specified (NOS) codes, HCPCS codes C2698 (Brachytherapy source, 
stranded, not otherwise specified, per source) and C2699 (Brachytherapy 
source, non-stranded, not otherwise specified, per source), at a rate 
equal to the lowest stranded or nonstranded prospective payment rate 
for such sources, respectively, on a per source basis (as opposed to, 
for example, a per mCi), which is based on the policy we established in 
the CY 2008 OPPS/ASC final rule with comment period (72 FR 66785). We 
also proposed to continue the policy we first implemented in the CY 
2010 OPPS/ASC final rule with comment period (74 FR 60537) regarding 
payment for new brachytherapy sources for which we have no claims data, 
based on the same reasons we discussed in the CY 2008 OPPS/ASC final 
rule with comment period (72 FR 66786; which was delayed until January 
1, 2010 by section 142 of Pub. L. 110-275). Specifically, this policy 
is intended to enable us to assign new HCPCS codes for new 
brachytherapy sources to their own APCs, with prospective payment rates 
set based on our consideration of external data and other relevant 
information regarding the expected costs of the sources to hospitals. 
The proposed CY 2019 payment rates for brachytherapy sources were 
included in Addendum B to the proposed rule (which is available via the 
internet on the CMS website) and were identified with status indicator 
``U''. For CY 2019, we proposed to continue to assign status indicator 
``U'' (Brachytherapy Sources, Paid under OPPS; separate APC payment) to 
HCPCS code C2645 (Brachytherapy planar source, palladium-103, per 
square millimeter) and to use external data (invoice prices) and other 
relevant information to establish the proposed APC payment rate for 
HCPCS code C2645. Specifically, we proposed to set the payment rate at 
$4.69 per mm\2\, the same rate that was in effect for CYs 2017 and 
2018.
    We note that, for CY 2019, we proposed to assign status indicator 
``E2'' (Items and Services for Which Pricing Information and Claims 
Data Are Not Available) to HCPCS code C2644 (Brachytherapy cesium-131 
chloride) because this code was not reported on CY 2017 claims. 
Therefore, we were unable to calculate a proposed payment rate based on 
the general OPPS ratesetting methodology described earlier. Although 
HCPCS code C2644 became effective July 1, 2014, there are no CY 2017 
claims reporting this code. Therefore, we proposed to assign new 
proposed status indicator ``E2'' to HCPCS code C2644 in the CY 2019 
OPPS.

[[Page 58835]]

    Comment: One commenter expressed concern regarding CMS' policy to 
establish prospective payment rates for brachytherapy sources using the 
general OPPS methodology, which uses costs based on claims data to set 
the relative payment weights for hospital outpatient services. The 
commenter stated that, as a result of use of these cost data from 
claims, payments for low-volume brachytherapy sources have fluctuated 
significantly under the OPPS.
    Response: As we stated in the CY 2012 OPPS/ASC final rule with 
comment period (76 FR 74161) when we established a prospective payment 
for brachytherapy sources, the OPPS relies on the concept of averaging, 
where the payment may be more or less than the estimated cost of 
providing a service for a particular patient; however, with the 
exception of outlier cases, we believe that such a prospective payment 
is adequate to ensure access to appropriate care. We acknowledge that 
payment for brachytherapy sources based on geometric mean costs from a 
small set of claims may be more variable on a year-to-year basis when 
compared to geometric mean costs for brachytherapy sources from a 
larger claims set. However, as illustrated in Table 5 below, we believe 
that payment for currently payable brachytherapy sources has been 
relatively consistent over the years and that a prospective payment for 
brachytherapy sources based on geometric mean costs is appropriate and 
provides hospitals with the greatest incentives for efficiency in 
furnishing brachytherapy treatment. For CY 2019 OPPS payment rates for 
the brachytherapy sources listed in Table 5, we refer readers to 
Addendum B of this final rule with comment period (which is available 
via the internet on the CMS website).
BILLING CODE 4120-01-P

[[Page 58836]]

[GRAPHIC] [TIFF OMITTED] TR21NO18.005

BILLING CODE 4120-01-C

    After consideration of the public comments we received, we are 
finalizing our proposal to continue to set the payment rates for 
brachytherapy sources using our established prospective payment 
methodology. We also are finalizing our proposal to assign status 
indicator ``U'' (Brachytherapy Sources, Paid under OPPS; separate APC 
payment) to HCPCS code C2645 (Brachytherapy planar source, palladium-
103, per square millimeter) and to use external data (invoice prices) 
and other relevant information to establish the APC payment rate for 
HCPCS code C2645 for CY 2019.
    Lastly, because we were unable to calculate a payment rate for 
HCPCS code C2644 (Brachytherapy cesium-131 chloride) based on the 
general OPPS ratesetting methodology, we are finalizing our proposal to 
assign HCPCS code C2644 status indicator ``E2'' (Items and Services for 
Which Pricing Information and Claims Data Are Not Available) for CY 
2019.
    The final CY 2019 payment rates for brachytherapy sources are 
included in Addendum B to this final rule with comment period (which is 
available via the internet on the CMS website) and are identified with 
status indicator ``U''.
    We continue to invite hospitals and other parties to submit 
recommendations to us for new codes to describe new brachytherapy 
sources. Such recommendations should be

[[Page 58837]]

directed to the Division of Outpatient Care, Mail Stop C4-01-26, 
Centers for Medicare and Medicaid Services, 7500 Security Boulevard, 
Baltimore, MD 21244. We will continue to add new brachytherapy source 
codes and descriptors to our systems for payment on a quarterly basis.
b. Comprehensive APCs (C-APCs) for CY 2019
(1) Background
    In the CY 2014 OPPS/ASC final rule with comment period (78 FR 74861 
through 74910), we finalized a comprehensive payment policy that 
packages payment for adjunctive and secondary items, services, and 
procedures into the most costly primary procedure under the OPPS at the 
claim level. The policy was finalized in CY 2014, but the effective 
date was delayed until January 1, 2015, to allow additional time for 
further analysis, opportunity for public comment, and systems 
preparation. The comprehensive APC (C-APC) policy was implemented 
effective January 1, 2015, with modifications and clarifications in 
response to public comments received regarding specific provisions of 
the C-APC policy (79 FR 66798 through 66810).
    A C-APC is defined as a classification for the provision of a 
primary service and all adjunctive services provided to support the 
delivery of the primary service. We established C-APCs as a category 
broadly for OPPS payment and implemented 25 C-APCs beginning in CY 2015 
(79 FR 66809 through 66810). In the CY 2016 OPPS/ASC final rule with 
comment period (80 FR 70332), we finalized 10 additional C-APCs to be 
paid under the existing C-APC payment policy and added one additional 
level to both the Orthopedic Surgery and Vascular Procedures clinical 
families, which increased the total number of C-APCs to 37 for CY 2016. 
In the CY 2017 OPPS/ASC final rule with comment period (81 FR 79584 
through 79585), we finalized another 25 C-APCs for a total of 62 C-
APCs. In the CY 2018 OPPS/ASC final rule with comment period, we did 
not change the total number of C-APCs from 62.
    Under this policy, we designate a service described by a HCPCS code 
assigned to a C-APC as the primary service when the service is 
identified by OPPS status indicator ``J1''. When such a primary service 
is reported on a hospital outpatient claim, taking into consideration 
the few exceptions that are discussed below, we make payment for all 
other items and services reported on the hospital outpatient claim as 
being integral, ancillary, supportive, dependent, and adjunctive to the 
primary service (hereinafter collectively referred to as ``adjunctive 
services'') and representing components of a complete comprehensive 
service (78 FR 74865 and 79 FR 66799). Payments for adjunctive services 
are packaged into the payments for the primary services. This results 
in a single prospective payment for each of the primary, comprehensive 
services based on the costs of all reported services at the claim 
level.
    Services excluded from the C-APC policy under the OPPS include 
services that are not covered OPD services, services that cannot by 
statute be paid for under the OPPS, and services that are required by 
statute to be separately paid. This includes certain mammography and 
ambulance services that are not covered OPD services in accordance with 
section 1833(t)(1)(B)(iv) of the Act; brachytherapy seeds, which also 
are required by statute to receive separate payment under section 
1833(t)(2)(H) of the Act; pass-through payment drugs and devices, which 
also require separate payment under section 1833(t)(6) of the Act; 
self-administered drugs (SADs) that are not otherwise packaged as 
supplies because they are not covered under Medicare Part B under 
section 1861(s)(2)(B) of the Act; and certain preventive services (78 
FR 74865 and 79 FR 66800 through 66801). A list of services excluded 
from the C-APC policy is included in Addendum J to this final rule with 
comment period (which is available via the internet on the CMS 
website).
    The C-APC policy payment methodology set forth in the CY 2014 OPPS/
ASC final rule with comment period for the C-APCs and modified and 
implemented beginning in CY 2015 is summarized as follows (78 FR 74887 
and 79 FR 66800):
    Basic Methodology. As stated in the CY 2015 OPPS/ASC final rule 
with comment period, we define the C-APC payment policy as including 
all covered OPD services on a hospital outpatient claim reporting a 
primary service that is assigned to status indicator ``J1'', excluding 
services that are not covered OPD services or that cannot by statute be 
paid for under the OPPS. Services and procedures described by HCPCS 
codes assigned to status indicator ``J1'' are assigned to C-APCs based 
on our usual APC assignment methodology by evaluating the geometric 
mean costs of the primary service claims to establish resource 
similarity and the clinical characteristics of each procedure to 
establish clinical similarity within each APC.
    In the CY 2016 OPPS/ASC final rule with comment period, we expanded 
the C-APC payment methodology to qualifying extended assessment and 
management encounters through the ``Comprehensive Observation 
Services'' C-APC (C-APC 8011). Services within this APC are assigned 
status indicator ``J2''. Specifically, we make a payment through C-APC 
8011 for a claim that:
     Does not contain a procedure described by a HCPCS code to 
which we have assigned status indicator ``T'' that is reported with a 
date of service on the same day or 1 day earlier than the date of 
service associated with services described by HCPCS code G0378;
     Contains 8 or more units of services described by HCPCS 
code G0378 (Hospital observation services, per hour);
     Contains services provided on the same date of service or 
1 day before the date of service for HCPCS code G0378 that are 
described by one of the following codes: HCPCS code G0379 (Direct 
admission of patient for hospital observation care) on the same date of 
service as HCPCS code G0378; CPT code 99281 (Emergency department visit 
for the evaluation and management of a patient (Level 1)); CPT code 
99282 (Emergency department visit for the evaluation and management of 
a patient (Level 2)); CPT code 99283 (Emergency department visit for 
the evaluation and management of a patient (Level 3)); CPT code 99284 
(Emergency department visit for the evaluation and management of a 
patient (Level 4)); CPT code 99285 (Emergency department visit for the 
evaluation and management of a patient (Level 5)) or HCPCS code G0380 
(Type B emergency department visit (Level 1)); HCPCS code G0381 (Type B 
emergency department visit (Level 2)); HCPCS code G0382 (Type B 
emergency department visit (Level 3)); HCPCS code G0383 (Type B 
emergency department visit (Level 4)); HCPCS code G0384 (Type B 
emergency department visit (Level 5)); CPT code 99291 (Critical care, 
evaluation and management of the critically ill or critically injured 
patient; first 30-74 minutes); or HCPCS code G0463 (Hospital outpatient 
clinic visit for assessment and management of a patient); and
     Does not contain services described by a HCPCS code to 
which we have assigned status indicator ``J1''.
    The assignment of status indicator ``J2'' to a specific combination 
of services performed in combination with each other allows for all 
other OPPS payable services and items reported on the claim (excluding 
services that are

[[Page 58838]]

not covered OPD services or that cannot by statute be paid for under 
the OPPS) to be deemed adjunctive services representing components of a 
comprehensive service and resulting in a single prospective payment for 
the comprehensive service based on the costs of all reported services 
on the claim (80 FR 70333 through 70336).
    Services included under the C-APC payment packaging policy, that 
is, services that are typically adjunctive to the primary service and 
provided during the delivery of the comprehensive service, include 
diagnostic procedures, laboratory tests, and other diagnostic tests and 
treatments that assist in the delivery of the primary procedure; visits 
and evaluations performed in association with the procedure; uncoded 
services and supplies used during the service; durable medical 
equipment as well as prosthetic and orthotic items and supplies when 
provided as part of the outpatient service; and any other components 
reported by HCPCS codes that represent services that are provided 
during the complete comprehensive service (78 FR 74865 and 79 FR 
66800).
    In addition, payment for hospital outpatient department services 
that are similar to therapy services and delivered either by therapists 
or nontherapists is included as part of the payment for the packaged 
complete comprehensive service. These services that are provided during 
the perioperative period are adjunctive services and are deemed not to 
be therapy services as described in section 1834(k) of the Act, 
regardless of whether the services are delivered by therapists or other 
nontherapist health care workers. We have previously noted that therapy 
services are those provided by therapists under a plan of care in 
accordance with section 1835(a)(2)(C) and section 1835(a)(2)(D) of the 
Act and are paid for under section 1834(k) of the Act, subject to 
annual therapy caps as applicable (78 FR 74867 and 79 FR 66800). 
However, certain other services similar to therapy services are 
considered and paid for as hospital outpatient department services. 
Payment for these nontherapy outpatient department services that are 
reported with therapy codes and provided with a comprehensive service 
is included in the payment for the packaged complete comprehensive 
service. We note that these services, even though they are reported 
with therapy codes, are hospital outpatient department services and not 
therapy services. Therefore, the requirement for functional reporting 
under the regulations at 42 CFR 410.59(a)(4) and 42 CFR 410.60(a)(4) 
does not apply. We refer readers to the July 2016 OPPS Change Request 
9658 (Transmittal 3523) for further instructions on reporting these 
services in the context of a C-APC service.
    Items included in the packaged payment provided in conjunction with 
the primary service also include all drugs, biologicals, and 
radiopharmaceuticals, regardless of cost, except those drugs with pass-
through payment status and SADs, unless they function as packaged 
supplies (78 FR 74868 through 74869 and 74909 and 79 FR 66800). We 
refer readers to Section 50.2M, Chapter 15, of the Medicare Benefit 
Policy Manual for a description of our policy on SADs treated as 
hospital outpatient supplies, including lists of SADs that function as 
supplies and those that do not function as supplies.
    We define each hospital outpatient claim reporting a single unit of 
a single primary service assigned to status indicator ``J1'' as a 
single ``J1'' unit procedure claim (78 FR 74871 and 79 FR 66801). Line 
item charges for services included on the C-APC claim are converted to 
line item costs, which are then summed to develop the estimated APC 
costs. These claims are then assigned one unit of the service with 
status indicator ``J1'' and later used to develop the geometric mean 
costs for the C-APC relative payment weights. (We note that we use the 
term ``comprehensive'' to describe the geometric mean cost of a claim 
reporting ``J1'' service(s) or the geometric mean cost of a C-APC, 
inclusive of all of the items and services included in the C-APC 
service payment bundle.) Charges for services that would otherwise be 
separately payable are added to the charges for the primary service. 
This process differs from our traditional cost accounting methodology 
only in that all such services on the claim are packaged (except 
certain services as described above). We apply our standard data trims, 
which exclude claims with extremely high primary units or extreme 
costs.
    The comprehensive geometric mean costs are used to establish 
resource similarity and, along with clinical similarity, dictate the 
assignment of the primary services to the C-APCs. We establish a 
ranking of each primary service (single unit only) to be assigned to 
status indicator ``J1'' according to its comprehensive geometric mean 
costs. For the minority of claims reporting more than one primary 
service assigned to status indicator ``J1'' or units thereof, we 
identify one ``J1'' service as the primary service for the claim based 
on our cost-based ranking of primary services. We then assign these 
multiple ``J1'' procedure claims to the C-APC to which the service 
designated as the primary service is assigned. If the reported ``J1'' 
services on a claim map to different C-APCs, we designate the ``J1'' 
service assigned to the C-APC with the highest comprehensive geometric 
mean cost as the primary service for that claim. If the reported 
multiple ``J1'' services on a claim map to the same C-APC, we designate 
the most costly service (at the HCPCS code level) as the primary 
service for that claim. This process results in initial assignments of 
claims for the primary services assigned to status indicator ``J1'' to 
the most appropriate C-APCs based on both single and multiple procedure 
claims reporting these services and clinical and resource homogeneity.
    Complexity Adjustments. We use complexity adjustments to provide 
increased payment for certain comprehensive services. We apply a 
complexity adjustment by promoting qualifying paired ``J1'' service 
code combinations or paired code combinations of ``J1'' services and 
certain add-on codes (as described further below) from the originating 
C-APC (the C-APC to which the designated primary service is first 
assigned) to the next higher paying C-APC in the same clinical family 
of C-APCs. We apply this type of complexity adjustment when the paired 
code combination represents a complex, costly form or version of the 
primary service according to the following criteria:
     Frequency of 25 or more claims reporting the code 
combination (frequency threshold); and
     Violation of the 2 times rule in the originating C-APC 
(cost threshold).
    These criteria identify paired code combinations that occur 
commonly and exhibit materially greater resource requirements than the 
primary service. The CY 2017 OPPS/ASC final rule with comment period 
(81 FR 79582) included a revision to the complexity adjustment 
eligibility criteria. Specifically, we finalized a policy to 
discontinue the requirement that a code combination (that qualifies for 
a complexity adjustment by satisfying the frequency and cost criteria 
thresholds described above) also not create a 2 times rule violation in 
the higher level or receiving APC.
    After designating a single primary service for a claim, we evaluate 
that service in combination with each of the other procedure codes 
reported on the claim assigned to status indicator ``J1'' (or certain 
add-on codes) to determine if

[[Page 58839]]

there are paired code combinations that meet the complexity adjustment 
criteria. For a new HCPCS code, we determine initial C-APC assignment 
and qualification for a complexity adjustment using the best available 
information, crosswalking the new HCPCS code to a predecessor code(s) 
when appropriate.
    Once we have determined that a particular code combination of 
``J1'' services (or combinations of ``J1'' services reported in 
conjunction with certain add-on codes) represents a complex version of 
the primary service because it is sufficiently costly, frequent, and a 
subset of the primary comprehensive service overall according to the 
criteria described above, we promote the claim including the complex 
version of the primary service as described by the code combination to 
the next higher cost C-APC within the clinical family, unless the 
primary service is already assigned to the highest cost APC within the 
C-APC clinical family or assigned to the only C-APC in a clinical 
family. We do not create new APCs with a comprehensive geometric mean 
cost that is higher than the highest geometric mean cost (or only) C-
APC in a clinical family just to accommodate potential complexity 
adjustments. Therefore, the highest payment for any claim including a 
code combination for services assigned to a C-APC would be the highest 
paying C-APC in the clinical family (79 FR 66802).
    We package payment for all add-on codes into the payment for the C-
APC. However, certain primary service add-on combinations may qualify 
for a complexity adjustment. As noted in the CY 2016 OPPS/ASC final 
rule with comment period (80 FR 70331), all add-on codes that can be 
appropriately reported in combination with a base code that describes a 
primary ``J1'' service are evaluated for a complexity adjustment.
    To determine which combinations of primary service codes reported 
in conjunction with an add-on code may qualify for a complexity 
adjustment for CY 2019, in the CY 2019 OPPS/ASC proposed rule (83 FR 
37061), we proposed to apply the frequency and cost criteria thresholds 
discussed above, testing claims reporting one unit of a single primary 
service assigned to status indicator ``J1'' and any number of units of 
a single add-on code for the primary ``J1'' service. If the frequency 
and cost criteria thresholds for a complexity adjustment are met and 
reassignment to the next higher cost APC in the clinical family is 
appropriate (based on meeting the criteria outlined above), we make a 
complexity adjustment for the code combination; that is, we reassign 
the primary service code reported in conjunction with the add-on code 
to the next higher cost C-APC within the same clinical family of C-
APCs. As previously stated, we package payment for add-on codes into 
the C-APC payment rate. If any add-on code reported in conjunction with 
the ``J1'' primary service code does not qualify for a complexity 
adjustment, payment for the add-on service continues to be packaged 
into the payment for the primary service and is not reassigned to the 
next higher cost C-APC. We listed the complexity adjustments proposed 
for ``J1'' and add-on code combinations for CY 2019, along with all of 
the other proposed complexity adjustments, in Addendum J to the CY 2019 
OPPS/ASC proposed rule (which is available via the internet on the CMS 
website).
    Addendum J to the proposed rule included the cost statistics for 
each code combination that would qualify for a complexity adjustment 
(including primary code and add-on code combinations). Addendum J to 
the proposed rule also contained summary cost statistics for each of 
the paired code combinations that describe a complex code combination 
that would qualify for a complexity adjustment and were proposed to be 
reassigned to the next higher cost C-APC within the clinical family. 
The combined statistics for all proposed reassigned complex code 
combinations were represented by an alphanumeric code with the first 4 
digits of the designated primary service followed by a letter. For 
example, the proposed geometric mean cost listed in Addendum J for the 
code combination described by complexity adjustment assignment 3320R, 
which is assigned to C-APC 5224 (Level 4 Pacemaker and Similar 
Procedures), includes all paired code combinations that were proposed 
to be reassigned to C-APC 5224 when CPT code 33208 is the primary code. 
Providing the information contained in Addendum J to the proposed rule 
allowed stakeholders the opportunity to better assess the impact 
associated with the proposed reassignment of claims with each of the 
paired code combinations eligible for a complexity adjustment.
    Comment: Several commenters requested that CMS alter the C-APC 
complexity adjustment eligibility criteria to allow additional code 
combinations to qualify for complexity adjustments. The commenters 
requested that CMS consider clusters of ``J1'' and add-on codes, rather 
than only code pairs, and also consider code combinations of ``J1'' 
codes and devices such as drug-coated balloons and drug-eluting stents. 
The commenters also requested that CMS eliminate the 25-claim frequency 
threshold. Another commenter requested that CMS consider patient 
complexity and procedures assigned to status indicator ``S'' or ``T'' 
when evaluating procedures for a complexity adjustment. One commenter 
suggested that procedures initially eligible for a complexity 
adjustment by meeting the applicable requirements in a year maintain 
that complexity adjustment for a total period of 3 years, regardless of 
whether they continue to meet the criteria after the first year.
    In terms of payment for complexity adjustments, one commenter 
requested that CMS promote the qualifying code combination to two APC 
levels higher than the originating APC rather than to the next higher 
paying C-APC. Another commenter suggested that CMS pay the geometric 
mean cost of the highest ranking procedure in the qualifying code 
combination at 100 percent, and then each secondary procedure at 50 
percent of the geometric mean cost of the secondary procedure.
    Other commenters also requested an explanation of how the geometric 
mean costs of the code combinations evaluated for complexity 
adjustments are calculated, stating that the geometric mean cost of 
certain code combinations represented in Addendum J were lower than the 
geometric mean costs of the primary service when the service is billed 
without an additional ``J1'' or ``J1'' add-on procedure. Commenters 
also requested that CMS establish complexity adjustments for the 
specific code combinations listed in Table 6 below.
BILLING CODE 4120-01-P

[[Page 58840]]

[GRAPHIC] [TIFF OMITTED] TR21NO18.006


[[Page 58841]]


[GRAPHIC] [TIFF OMITTED] TR21NO18.007


[[Page 58842]]


[GRAPHIC] [TIFF OMITTED] TR21NO18.008

BILLING CODE 4120-01-C

    Response: We appreciate these comments. However, at this time, we 
do not believe changes to the C-APC complexity adjustment criteria are 
necessary or that we should make exceptions to the criteria to allow 
claims with the code combinations suggested by the commenters to 
receive complexity adjustments. As stated previously (81 FR 79582), we 
continue to believe that the complexity adjustment criteria, which 
require a frequency of 25 or more claims reporting a code combination 
and a violation of the 2 times rule in the originating C-APC in order 
to receive payment in the next higher cost C-APC within the clinical 
family, are adequate to determine if a combination of procedures 
represents a complex, costly subset of the primary service. If a code 
combination meets these criteria, the combination receives payment at 
the next higher cost C-APC. Code combinations that do not meet these 
criteria receive the C-APC payment rate associated with the primary 
``J1'' service. A minimum of 25 claims is already very low for a 
national payment system. Lowering the minimum of 25 claims further 
could lead to unnecessary complexity adjustments for service 
combinations that are rarely performed. The complexity adjustment cost 
threshold compares the code combinations to the lowest cost-significant 
procedure assigned to the APC. If the cost of the code combination does 
not exceed twice the cost of the lowest cost-significant procedure 
within the APC, no complexity adjustment is made. Lowering or 
eliminating this threshold could remove so many claims from the 
accounting for the primary ``J1'' service that the geometric mean costs 
attributed to the primary procedure could be skewed.
    With regard to the specific complexity adjustments requested by 
commenters listed in Table 6 above, we note that we did not propose 
that claims with these code combinations would receive complexity 
adjustments because they did not meet the cost and frequency criteria 
for the adjustment. Therefore, we do not believe it is appropriate to 
change the complexity adjustment criteria at this time, and because the 
suggested code combinations do not meet the existing criteria, we do 
not believe it is appropriate to establish complexity adjustments for 
these code combinations at this time.
    Regarding the request for a code combination that qualified for a 
complexity adjustment in a year to continue to qualify for the 
adjustment for the next 2 years for a total period of 3 years, we note 
that we evaluate code combinations each year against our complexity 
adjustment criteria using the latest available data. At this time, we 
do not believe it is necessary to expand the ability for code 
combinations to meet the complexity adjustment criteria in this manner 
because we believe that the existing criteria that were already 
established sufficiently reflect those combinations of procedures that 
are commonly billed together and are costly enough to merit a 
complexity adjustment. Further, we believe that code combinations 
should be evaluated each year to determine if they meet the criteria 
based on the latest hospital billing and utilization data. We also do 
not believe that it is necessary to provide payment for claims 
including qualifying code combinations at two APC levels higher than 
the originating APC or for CMS to pay based on the geometric mean cost 
of the highest ranking procedure in the qualifying code combination at 
100 percent, and then each secondary procedure based on 50 percent of 
the geometric mean cost of the secondary procedure. We believe that 
payment at the next higher paying C-APC is adequate for code 
combinations that exhibit materially greater resource requirements than 
the primary service and that, in many cases, paying the rate assigned 
to two levels higher may lead to a significant overpayment. As 
mentioned previously, we do not create new APCs with a comprehensive 
geometric mean cost that is higher than the highest geometric mean cost 
(or only) C-APC in a clinical family just to accommodate potential 
complexity adjustments. The highest payment for any claim including a 
code combination for services assigned to a C-APC would be the highest 
paying C-APC in the clinical family (79 FR 66802). Therefore, a policy 
to pay for claims with qualifying code combinations at two C-APC levels 
higher than the originating APC is not always feasible. Likewise, while 
paying 100 percent of the highest ranking procedure and paying 50 
percent of the

[[Page 58843]]

secondary procedure is the established payment policy under the 
multiple procedure payment reduction policy that applies to services 
assigned to status indicator ``T,'' we continue to believe that the 
established C-APC complexity adjustment policy is appropriate for 
services assigned to status indicator ``J1'' or ``J2'', and we do not 
believe that it should be replaced with a multiple procedure payment 
reduction payment methodology.
    In response to the request for an explanation of the cost 
statistics for the paired ``J1'' code combinations or paired code 
combinations of ``J1'' services and certain add-on codes evaluated for 
complexity adjustments, the geometric mean costs of these code 
combinations shown in Addendum J are calculated using only claims that 
include these code pairings. As stated previously, the cost of the code 
combination must exceed twice the cost of the lowest cost-significant 
procedure within the APC in order for the combination to qualify for a 
complexity adjustment.
    Lastly, as stated in the CY 2018 OPPS/ASC final rule with comment 
period (82 FR 59238), we do not believe that it is necessary to adjust 
the complexity adjustment criteria to allow claims that include a drug 
or device code, more than two ``J1'' procedures, or procedures 
performed at certain hospitals to qualify for a complexity adjustment. 
As mentioned earlier, we believe the current criteria are adequate to 
determine if a combination of procedures represents a complex, costly 
subset of the primary service.
    After consideration of the public comments we received on the 
proposed complexity adjustment policy, we are finalizing the C-APC 
complexity adjustment policy for CY 2019, as proposed, without 
modification.
(2) Additional C-APCs for CY 2019
    For CY 2019 and subsequent years, in the CY 2019 OPPS/ASC proposed 
rule (83 FR 37062), we proposed to continue to apply the C-APC payment 
policy methodology made effective in CY 2015 and updated with the 
implementation of status indicator ``J2'' in CY 2016. We refer readers 
to the CY 2017 OPPS/ASC final rule with comment period (81 FR 79583) 
for a discussion of the C-APC payment policy methodology and revisions.
    Each year, in accordance with section 1833(t)(9)(A) of the Act, we 
review and revise the services within each APC group and the APC 
assignments under the OPPS. As a result of our annual review of the 
services and the APC assignments under the OPPS, in the proposed rule 
(83 FR 37062), we proposed to add three C-APCs under the existing C-APC 
payment policy beginning in CY 2019: Proposed C-APC 5163 (Level 3 ENT 
Procedures); proposed C-APC 5183 (Level 3 Vascular Procedures); and 
proposed C-APC 5184 (Level 4 Vascular Procedures). These APCs were 
selected to be included in this proposal because, similar to other C-
APCs, these APCs include primary, comprehensive services, such as major 
surgical procedures, that are typically reported with other ancillary 
and adjunctive services. Also, similar to other APCs that have been 
converted to C-APCs, there are higher APC levels within the clinical 
family or related clinical family of these APCs that have previously 
been assigned to a C-APC. Table 3 of the proposed rule listed the 
proposed C-APCs for CY 2019. All C-APCs were displayed in Addendum J to 
the proposed rule (which is available via the internet on the CMS 
website). Addendum J to the proposed rule also contained all of the 
data related to the C-APC payment policy methodology, including the 
list of proposed complexity adjustments and other information.
    Comment: Several commenters supported the proposals. Other 
commenters, including device manufacturer associations, expressed 
ongoing concerns that the C-APC payment rates may not adequately 
reflect the costs associated with the services and requested that CMS 
not establish any additional C-APCs. These commenters also requested 
that CMS provide an analysis of the impact of the C-APC policy on 
affected procedures.
    Response: We appreciate the commenters' responses. We continue to 
believe that the proposed C-APCs for CY 2019 are appropriate to be 
added to the existing C-APC payment policy. We also note that, in the 
CY 2018 OPPS/ASC final rule with comment period (82 FR 59246), we 
conducted an analysis of the effects of the C-APC policy. The analysis 
looked at data from CY 2016 OPPS/ASC final rule with comment period, 
the CY 2017 OPPS/ASC final rule with comment period, and the CY 2018 
OPPS/ASC proposed rule, which involved claims data from CY 2014 (before 
C-APCs became effective) to CY 2016. We looked at separately payable 
codes that were then assigned to C-APCs and, overall, we observed an 
increase in claim line frequency, units billed, and Medicare payment 
for those procedures, which suggest that the C-APC payment policy did 
not adversely affect access to care or reduce payments to hospitals.
    Comment: Several commenters requested that CMS discontinue the C-
APC payment policy for several brachytherapy insertion procedures and 
single session stereotactic radiosurgery procedures, stating concerns 
that the C-APC methodology does not account for the complexity of 
delivering radiation therapy and fails to capture appropriately coded 
claims. The commenters also requested that CMS continue to make 
separate payments for the 10 planning and preparation codes related to 
stereotactic radiosurgery (SRS) and include the HCPCS code for IMRT 
planning (77301) on the list of planning and preparation codes, stating 
that the service has become more common in single fraction radiosurgery 
treatment planning.
    Response: At this time, we do not believe that it is necessary to 
discontinue the C-APCs that include brachytherapy insertion procedures 
and single session SRS procedures. We continue to believe that the C-
APC policy is appropriately applied to these surgical procedures for 
the reasons cited when this policy was first adopted and note that the 
commenters did not provide any empirical evidence to support their 
claims that the existing C-APC policy does not adequately pay for these 
procedures. Also, we will continue in CY 2019 to pay separately for the 
10 planning and preparation services (HCPCS codes 70551, 70552, 70553, 
77011, 77014, 77280, 77285, 77290, 77295, and 77336) adjunctive to the 
delivery of the SRS treatment using either the Cobalt-60-based or LINAC 
based technology when furnished to a beneficiary within 1 month of the 
SRS treatment for CY 2019 (82 FR 59242 and 59243).
    Comment: Several commenters representing stem cell transplant 
organizations requested that CMS also establish a new C-APC for 
autologous stem cell transplants for CY 2019. These commenters stated 
that the C-APC methodology will allow CMS to better capture the costs 
of additional services, such as laboratory tests, provided with the 
autologous transplant. The Advisory Panel on Hospital Outpatient 
Payment (HOP Panel) also recommended that CMS study the appropriateness 
of creating a comprehensive APC for autologous hematopoietic stem cell 
transplantation.
    Response: We appreciate these comments and may consider the 
creation of a C-APC for autologous stem cell transplants for future 
rulemaking as recommended by the HOP Panel.
    Comment: Two manufacturers of drugs used in ocular procedures 
requested that CMS discontinue the C-APC payment policy for existing C-
APCs that include procedures involving

[[Page 58844]]

their drugs and instead provide separate payment for the drugs. The 
manufacturer commenters, as well as several physicians, believed that 
the C-APC packaging policy, which packages payment for certain drugs 
that are adjunctive to the primary service, results in underpayment for 
the drugs.
    Response: We continue to believe that the procedures assigned to 
the proposed C-APCs, including the procedures involving the drugs used 
in ocular procedures mentioned by the commenters, are appropriately 
paid through a comprehensive APC and the costs of drugs (as well as 
other items or services furnished with the procedures) are reflected in 
hospital billing, and therefore the rates that are established for the 
ocular procedures. As stated in the CY 2017 OPPS/ASC final rule with 
comment period (81 FR 79584), procedures assigned to C-APCs are primary 
services (mostly major surgical procedures) that are typically the 
focus of the hospital outpatient stay. In addition, with regard to the 
packaging of the drugs based on the C-APC policy, as stated in previous 
rules (78 FR 74868 through 74869 and 74909 and 79 FR 66800), items 
included in the packaged payment provided with the primary ``J1'' 
service include all drugs, biologicals, and radiopharmaceuticals 
payable under the OPPS, regardless of cost, except those drugs with 
pass-through payment status.
    After consideration of the public comments we received, we are 
finalizing the proposed C-APCs for CY 2019. Table 7 below lists the 
final C-APCs for CY 2019. All C-APCs are displayed in Addendum J to 
this final rule with comment period (which is available via the 
internet on the CMS website). Addendum J to this final rule with 
comment period also contains all of the data related to the C-APC 
payment policy methodology, including the list of complexity 
adjustments and other information for CY 2019.

BILLING CODE 4120-01-P

[[Page 58845]]

[GRAPHIC] [TIFF OMITTED] TR21NO18.009


[[Page 58846]]


[GRAPHIC] [TIFF OMITTED] TR21NO18.010


[[Page 58847]]


[GRAPHIC] [TIFF OMITTED] TR21NO18.011

BILLING CODE 4120-01-C
(3) Exclusion of Procedures Assigned to New Technology APCs From the C-
APC Policy
    Services that are assigned to New Technology APCs are typically new 
procedures that do not have sufficient claims history to establish an 
accurate payment for the procedures. Beginning in CY 2002, we retain 
services within New Technology APC groups until we gather sufficient 
claims data to enable us to assign the service to an appropriate 
clinical APC. This policy allows us to move a service from a New 
Technology APC in less than 2 years if sufficient data are available. 
It also allows us to retain a service in a New Technology APC for more 
than 2 years if sufficient data upon which to base a decision for 
reassignment have not been collected (82 FR 59277).
    The C-APC payment policy packages payment for adjunctive and 
secondary items, services, and procedures into the most costly primary 
procedure under the OPPS at the claim level. When a procedure assigned 
to a New Technology APC is included on the claim with a primary 
procedure, identified by OPPS status indicator ``J1'', payment for the 
new technology service is typically packaged into the payment for the 
primary procedure. Because the new technology service is not separately 
paid in this scenario, the overall number of single claims available to 
determine an appropriate clinical APC for the new service is reduced. 
This is contrary to the objective of the New Technology APC payment 
policy, which is to gather sufficient claims data to enable us to 
assign the service to an appropriate clinical APC.
    For example, for CY 2017, there were seven claims generated for 
HCPCS code 0100T (Placement of a subconjunctival retinal prosthesis 
receiver and pulse generator, and implantation of intraocular retinal 
electrode array, with vitrectomy), which involves the use of the 
Argus[supreg] II Retinal Prosthesis System. However, several of these 
claims were not available for ratesetting because HCPCS code 0100T was 
reported with a ``J1'' procedure and, therefore, payment was packaged 
into the associated C-APC payment. If these services had been 
separately paid under the OPPS, there would be at least two additional 
single claims available for ratesetting. As mentioned previously, the 
purpose of the new technology APC policy is to ensure that there are 
sufficient claims data for new services, which is particularly 
important for services with a low volume such as procedures described 
by HCPCS code 0100T. Another concern is the costs reported for the 
claims when payment is not packaged for a new technology procedure may 
not be representative of all of the services included on a claim that 
is generated, which may also affect our ability to assign the new 
service to the most appropriate clinical APC.
    To address this issue and help ensure that there is sufficient 
claims data for services assigned to New Technology APCs, in the CY 
2019 OPPS/ASC proposed rule (83 FR 37063), we proposed to exclude 
payment for any procedure that is assigned to a New Technology APC 
(APCs 1491 through 1599 and APCs 1901 through 1908) from being packaged 
when included on a claim with a ``J1'' service assigned to a C-APC. 
This issue is also addressed in section III.C.3.b. of the proposed rule 
and this final rule with comment period.
    Comment: Numerous commenters supported the proposal.
    Response: We appreciate the commenters' support.
    After consideration of the public comments we received, we are 
finalizing the proposal, without modification, to exclude payment for 
any procedure that is assigned to a New Technology APC (APCs 1491 
through 1599 and APCs 1901 through 1908) from being packaged when 
included on a claim with a ``J1'' service assigned to a C-APC.
c. Calculation of Composite APC Criteria-Based Costs
    As discussed in the CY 2008 OPPS/ASC final rule with comment period 
(72 FR 66613), we believe it is important that the OPPS enhance 
incentives for hospitals to provide necessary, high quality care as 
efficiently as possible. For CY 2008, we developed composite APCs to 
provide a single payment for groups of services that are typically 
performed together during a single clinical encounter and that result 
in the provision of a complete service. Combining payment for multiple, 
independent services into a single OPPS payment in this way enables 
hospitals to manage their resources with maximum flexibility by 
monitoring and adjusting the volume and efficiency of services 
themselves. An additional advantage to the composite APC model is that 
we can use data from correctly coded multiple procedure claims to

[[Page 58848]]

calculate payment rates for the specified combinations of services, 
rather than relying upon single procedure claims which may be low in 
volume and/or incorrectly coded. Under the OPPS, we currently have 
composite policies for mental health services and multiple imaging 
services. (We note that, in the CY 2018 OPPS/ASC final rule with 
comment period, we finalized a policy to delete the composite APC 8001 
(LDR Prostate Brachytherapy Composite) for CY 2018 and subsequent 
years.) We refer readers to the CY 2008 OPPS/ASC final rule with 
comment period (72 FR 66611 through 66614 and 66650 through 66652) for 
a full discussion of the development of the composite APC methodology, 
and the CY 2012 OPPS/ASC final rule with comment period (76 FR 74163) 
and the CY 2018 OPPS/ASC final rule with comment period (82 FR 59241 
through 59242 and 59246 through 52950) for more recent background.
    In the CY 2019 OPPS/ASC proposed rule (83 FR 37064), for CY 2019 
and subsequent years, we proposed to continue our composite APC payment 
policies for mental health services and multiple imaging services, as 
discussed below. In addition, as discussed in section II.A.2.b.(3) and 
II.A.2.c. of the CY 2018 OPPS/ASC proposed rule and final rule with 
comment period (82 FR 33577 through 33578 and 59241 through 59242 and 
59246, respectively), in the CY 2019 proposed rule, we proposed to 
continue to assign CPT code 55875 (Transperineal placement of needles 
or catheters into prostate for interstitial radioelement application, 
with or without cystoscopy) to status indicator ``J1'' and to continue 
to assign the services described by CPT code 55875 to C-APC 5375 (Level 
5 Urology and Related Services) for CY 2019. We did not receive any 
public comments on these proposed assignments. Therefore, for CY 2019, 
we are continuing to assign CPT code 55875 to status indicator ``J1'' 
and to assign services described by CPT code 55875 to C-APC 5375.
(1) Mental Health Services Composite APC
    In the CY 2019 OPPS/ASC proposed rule (83 FR 37064), we proposed to 
continue our longstanding policy of limiting the aggregate payment for 
specified less resource-intensive mental health services furnished on 
the same date to the payment for a day of partial hospitalization 
services provided by a hospital, which we consider to be the most 
resource intensive of all outpatient mental health services. We refer 
readers to the April 7, 2000 OPPS final rule with comment period (65 FR 
18452 through 18455) for the initial discussion of this longstanding 
policy and the CY 2012 OPPS/ASC final rule with comment period (76 FR 
74168) for more recent background.
    In the CY 2017 OPPS/ASC final rule with comment period (81 FR 79588 
through 79589), we finalized a policy to combine the existing Level 1 
and Level 2 hospital-based PHP APCs into a single hospital-based PHP 
APC, and thereby discontinue APCs 5861 (Level 1 Partial Hospitalization 
(3 services) for Hospital-Based PHPs) and 5862 (Level 2 Partial 
Hospitalization (4 or more services) for Hospital-Based PHPs) and 
replace them with APC 5863 (Partial Hospitalization (3 or more services 
per day)).
    In the CY 2018 OPPS/ASC proposed rule and final rule with comment 
period (82 FR 33580 through 33581 and 59246 through 59247, 
respectively), we proposed and finalized the policy for CY 2018 and 
subsequent years that, when the aggregate payment for specified mental 
health services provided by one hospital to a single beneficiary on a 
single date of service, based on the payment rates associated with the 
APCs for the individual services, exceeds the maximum per diem payment 
rate for partial hospitalization services provided by a hospital, those 
specified mental health services will be paid through composite APC 
8010 (Mental Health Services Composite). In addition, we set the 
payment rate for composite APC 8010 for CY 2018 at the same payment 
rate that will be paid for APC 5863, which is the maximum partial 
hospitalization per diem payment rate for a hospital, and finalized a 
policy that the hospital will continue to be paid the payment rate for 
composite APC 8010. Under this policy, the I/OCE will continue to 
determine whether to pay for these specified mental health services 
individually, or to make a single payment at the same payment rate 
established for APC 5863 for all of the specified mental health 
services furnished by the hospital on that single date of service. We 
continue to believe that the costs associated with administering a 
partial hospitalization program at a hospital represent the most 
resource intensive of all outpatient mental health services. Therefore, 
we do not believe that we should pay more for mental health services 
under the OPPS than the highest partial hospitalization per diem 
payment rate for hospitals.
    In the CY 2019 OPPS/ASC proposed rule (83 FR 37064), for CY 2019, 
we proposed that when the aggregate payment for specified mental health 
services provided by one hospital to a single beneficiary on a single 
date of service, based on the payment rates associated with the APCs 
for the individual services, exceeds the maximum per diem payment rate 
for partial hospitalization services provided by a hospital, those 
specified mental health services would be paid through composite APC 
8010 for CY 2019. In addition, we proposed to set the proposed payment 
rate for composite APC 8010 at the same payment rate that we proposed 
for APC 5863, which is the maximum partial hospitalization per diem 
payment rate for a hospital, and that the hospital continue to be paid 
the proposed payment rate for composite APC 8010.
    Comment: One commenter supported equalizing payments between the 
outpatient APC rate and the PHP per diem rate. The commenter also 
supported the increase in the proposed CY 2019 payment rates from the 
CY 2018 payment rates.
    Response: We appreciate the commenter's support.
    After consideration of the public comment we received, we are 
finalizing our CY 2019 proposal, without modification, that when the 
aggregate payment for specified mental health services provided by one 
hospital to a single beneficiary on a single date of service, based on 
the payment rates associated with the APCs for the individual services, 
exceeds the maximum per diem payment rate for partial hospitalization 
services provided by a hospital, those specified mental health services 
will be paid through composite APC 8010 for CY 2019. In addition, we 
are finalizing our CY 2019 proposal, without modification, to set the 
payment rate for composite APC 8010 at the same payment rate as APC 
5863, which is the maximum partial hospitalization per diem payment 
rate for a hospital, and that the hospital continue to be paid the 
payment rate for composite APC 8010.
(2) Multiple Imaging Composite APCs (APCs 8004, 8005, 8006, 8007, and 
8008)
    Effective January 1, 2009, we provide a single payment each time a 
hospital submits a claim for more than one imaging procedure within an 
imaging family on the same date of service, in order to reflect and 
promote the efficiencies hospitals can achieve when performing multiple 
imaging procedures during a single session (73 FR 41448 through 41450). 
We utilize three imaging families based on imaging modality for 
purposes of this methodology: (1) Ultrasound; (2) computed tomography 
(CT) and computed tomographic angiography (CTA); and (3) magnetic 
resonance

[[Page 58849]]

imaging (MRI) and magnetic resonance angiography (MRA). The HCPCS codes 
subject to the multiple imaging composite policy and their respective 
families are listed in Table 12 of the CY 2014 OPPS/ASC final rule with 
comment period (78 FR 74920 through 74924).
    While there are three imaging families, there are five multiple 
imaging composite APCs due to the statutory requirement under section 
1833(t)(2)(G) of the Act that we differentiate payment for OPPS imaging 
services provided with and without contrast. While the ultrasound 
procedures included under the policy do not involve contrast, both CT/
CTA and MRI/MRA scans can be provided either with or without contrast. 
The five multiple imaging composite APCs established in CY 2009 are:
     APC 8004 (Ultrasound Composite);
     APC 8005 (CT and CTA without Contrast Composite);
     APC 8006 (CT and CTA with Contrast Composite);
     APC 8007 (MRI and MRA without Contrast Composite); and
     APC 8008 (MRI and MRA with Contrast Composite).
    We define the single imaging session for the ``with contrast'' 
composite APCs as having at least one or more imaging procedures from 
the same family performed with contrast on the same date of service. 
For example, if the hospital performs an MRI without contrast during 
the same session as at least one other MRI with contrast, the hospital 
will receive payment based on the payment rate for APC 8008, the ``with 
contrast'' composite APC.
    We make a single payment for those imaging procedures that qualify 
for payment based on the composite APC payment rate, which includes any 
packaged services furnished on the same date of service. The standard 
(noncomposite) APC assignments continue to apply for single imaging 
procedures and multiple imaging procedures performed across families. 
For a full discussion of the development of the multiple imaging 
composite APC methodology, we refer readers to the CY 2009 OPPS/ASC 
final rule with comment period (73 FR 68559 through 68569).
    In the CY 2019 OPPS/ASC proposed rule (83 FR 37065), we proposed, 
for CY 2019 and subsequent years, to continue to pay for all multiple 
imaging procedures within an imaging family performed on the same date 
of service using the multiple imaging composite APC payment 
methodology. We stated that we continue to believe that this policy 
would reflect and promote the efficiencies hospitals can achieve when 
performing multiple imaging procedures during a single session.
    The proposed CY 2019 payment rates for the five multiple imaging 
composite APCs (APCs 8004, 8005, 8006, 8007, and 8008) were based on 
proposed geometric mean costs calculated from a partial year of CY 2017 
claims available for the CY 2019 OPPS/ASC proposed rule that qualified 
for composite payment under the current policy (that is, those claims 
reporting more than one procedure within the same family on a single 
date of service). To calculate the proposed geometric mean costs, we 
used the same methodology that we have used to calculate the geometric 
mean costs for these composite APCs since CY 2014, as described in the 
CY 2014 OPPS/ASC final rule with comment period (78 FR 74918). The 
imaging HCPCS codes referred to as ``overlap bypass codes'' that we 
removed from the bypass list for purposes of calculating the proposed 
multiple imaging composite APC geometric mean costs, in accordance with 
our established methodology as stated in the CY 2014 OPPS/ASC final 
rule with comment period (78 FR 74918), were identified by asterisks in 
Addendum N to the CY 2019 OPPS/ASC proposed rule (which is available 
via the internet on the CMS website) and were discussed in more detail 
in section II.A.1.b. of the CY 2019 OPPS/ASC proposed rule.
    For the CY 2019 OPPS/ASC proposed rule, we were able to identify 
approximately 638,902 ``single session'' claims out of an estimated 1.7 
million potential claims for payment through composite APCs from our 
ratesetting claims data, which represents approximately 37 percent of 
all eligible claims, to calculate the proposed CY 2019 geometric mean 
costs for the multiple imaging composite APCs. Table 4 of the CY 2019 
OPPS/ASC proposed rule listed the proposed HCPCS codes that would be 
subject to the multiple imaging composite APC policy and their 
respective families and approximate composite APC proposed geometric 
mean costs for CY 2019.
    We did not receive any public comments on these proposals. However, 
in the CY 2019 OPPS/ASC proposed rule (83 FR 37065), we inadvertently 
omitted the new CPT codes that will be effective January 1, 2019 from 
Table 4. We did include these codes in Addendum M to the proposed rule 
(which was available via the internet on the CMS website). Therefore, 
new Category I CPT codes that will be effective January 1, 2019 are 
flagged with comment indicator ``NI'' in Addendum M to this CY 2019 
OPPS/ASC final rule with comment period to indicate that we have 
assigned the codes an interim APC assignment for CY 2019. We are 
inviting public comments in this CY 2019 OPPS/ASC final rule with 
comment period on the interim APC assignments and payment rates for the 
new codes in Addendum M that will be finalized in the CY 2020 OPPS/ASC 
final rule with comment period.
    Table 8 below lists the HCPCS codes that will be subject to the 
multiple imaging composite APC policy and their respective families and 
approximate composite APC final geometric mean costs for CY 2019.
BILLING CODE 4120-01-P

[[Page 58850]]

[GRAPHIC] [TIFF OMITTED] TR21NO18.012


[[Page 58851]]


[GRAPHIC] [TIFF OMITTED] TR21NO18.013


[[Page 58852]]


[GRAPHIC] [TIFF OMITTED] TR21NO18.014


[[Page 58853]]


[GRAPHIC] [TIFF OMITTED] TR21NO18.015

BILLING CODE 4120-01-C
3. Changes to Packaged Items and Services
a. Background and Rationale for Packaging in the OPPS
    Like other prospective payment systems, the OPPS relies on the 
concept of averaging to establish a payment rate for services. The 
payment may be more or less than the estimated cost of providing a 
specific service or a bundle of specific services for a particular 
patient. The OPPS packages payments

[[Page 58854]]

for multiple interrelated items and services into a single payment to 
create incentives for hospitals to furnish services most efficiently 
and to manage their resources with maximum flexibility. Our packaging 
policies support our strategic goal of using larger payment bundles in 
the OPPS to maximize hospitals' incentives to provide care in the most 
efficient manner. For example, where there are a variety of devices, 
drugs, items, and supplies that could be used to furnish a service, 
some of which are more costly than others, packaging encourages 
hospitals to use the most cost-efficient item that meets the patient's 
needs, rather than to routinely use a more expensive item, which often 
occurs if separate payment is provided for the item.
    Packaging also encourages hospitals to effectively negotiate with 
manufacturers and suppliers to reduce the purchase price of items and 
services or to explore alternative group purchasing arrangements, 
thereby encouraging the most economical health care delivery. 
Similarly, packaging encourages hospitals to establish protocols that 
ensure that necessary services are furnished, while scrutinizing the 
services ordered by practitioners to maximize the efficient use of 
hospital resources. Packaging payments into larger payment bundles 
promotes the predictability and accuracy of payment for services over 
time. Finally, packaging may reduce the importance of refining service-
specific payment because packaged payments include costs associated 
with higher cost cases requiring many ancillary items and services and 
lower cost cases requiring fewer ancillary items and services. Because 
packaging encourages efficiency and is an essential component of a 
prospective payment system, packaging payments for items and services 
that are typically integral, ancillary, supportive, dependent, or 
adjunctive to a primary service has been a fundamental part of the OPPS 
since its implementation in August 2000. For an extensive discussion of 
the history and background of the OPPS packaging policy, we refer 
readers to the CY 2000 OPPS final rule (65 FR 18434), the CY 2008 OPPS/
ASC final rule with comment period (72 FR 66580), the CY 2014 OPPS/ASC 
final rule with comment period (78 FR 74925), the CY 2015 OPPS/ASC 
final rule with comment period (79 FR 66817), the CY 2016 OPPS/ASC 
final rule with comment period (80 FR 70343), the CY 2017 OPPS/ASC 
final rule with comment period (81 FR 79592), and the CY 2018 OPPS/ASC 
final rule with comment period (82 FR 59250). As we continue to develop 
larger payment groups that more broadly reflect services provided in an 
encounter or episode of care, we have expanded the OPPS packaging 
policies. Most, but not necessarily all, categories of items and 
services currently packaged in the OPPS are listed in 42 CFR 419.2(b). 
Our overarching goal is to make payments for all services under the 
OPPS more consistent with those of a prospective payment system and 
less like those of a per-service fee schedule, which pays separately 
for each coded item. As a part of this effort, we have continued to 
examine the payment for items and services provided under the OPPS to 
determine which OPPS services can be packaged to further achieve the 
objective of advancing the OPPS toward a more prospective payment 
system.
    For CY 2019, we examined the items and services currently provided 
under the OPPS, reviewing categories of integral, ancillary, 
supportive, dependent, or adjunctive items and services for which we 
believe payment would be appropriately packaged into payment of the 
primary service that they support. Specifically, we examined the HCPCS 
code definitions (including CPT code descriptors) and outpatient 
hospital billing patterns to determine whether there were categories of 
codes for which packaging would be appropriate according to existing 
OPPS packaging policies or a logical expansion of those existing OPPS 
packaging policies. In the CY 2019 OPPS/ASC proposed rule (83 37067 
through 37071), for CY 2019, we proposed to conditionally package the 
costs of selected newly identified ancillary services into payment with 
a primary service where we believe that the packaged item or service is 
integral, ancillary, supportive, dependent, or adjunctive to the 
provision of care that was reported by the primary service HCPCS code. 
Below we discuss the proposed and finalized changes to the packaging 
policies beginning in CY 2019.
b. CY 2019 Packaging Policy for Non-Opioid Pain Management Treatments
    In the CY 2018 OPPS/ASC proposed rule (82 FR 33588), within the 
framework of existing packaging categories, such as drugs that function 
as supplies in a surgical procedure or diagnostic test or procedure, we 
requested stakeholder feedback on common clinical scenarios involving 
currently packaged items and services described by HCPCS codes that 
stakeholders believe should not be packaged under the OPPS. We also 
expressed interest in stakeholder feedback on common clinical scenarios 
involving separately payable HCPCS codes for which payment would be 
most appropriately packaged under the OPPS. Commenters expressed a 
variety of views on packaging under the OPPS. In the CY 2018 OPPS/ASC 
final rule with comment period, we summarized the comments received in 
response to our request (82 FR 59255). The comments ranged from 
requests to unpackage most items and services that are either 
conditionally or unconditionally packaged under the OPPS, including 
drugs and devices, to specific requests for separate payment for a 
specific drug or device. We stated in the CY 2018 OPPS/ASC final rule 
with comment period that CMS would continue to explore and evaluate 
packaging policies under the OPPS and consider these policies in future 
rulemaking.
    In addition to stakeholder feedback regarding OPPS packaging 
policies, the President's Commission on Combating Drug Addiction and 
the Opioid Crisis (the Commission) recently recommended that CMS 
examine payment policies for certain drugs that function as a supply, 
specifically non-opioid pain management treatments. The Commission was 
established in 2017 to study ways to combat and treat drug abuse, 
addiction, and the opioid crisis. The Commission's report \3\ included 
a recommendation for CMS to ``. . . review and modify ratesetting 
policies that discourage the use of non-opioid treatments for pain, 
such as certain bundled payments that make alternative treatment 
options cost prohibitive for hospitals and doctors, particularly those 
options for treating immediate postsurgical pain. . . .'' \4\ With 
respect to the packaging policy, the Commission's report states that 
``. . . the current CMS payment policy for `supplies' related to 
surgical procedures creates unintended incentives to prescribe opioid 
medications to patients for postsurgical pain instead of administering 
non-opioid pain medications. Under current policies, CMS provides one 
all-inclusive bundled payment to hospitals for all `surgical supplies,' 
which includes hospital-administered drug products intended to manage 
patients' postsurgical pain. This policy results in the hospitals 
receiving the same fixed fee from Medicare whether the surgeon

[[Page 58855]]

administers a non-opioid medication or not.'' \5\ HHS also presented an 
Opioid Strategy in April 2017 \6\ that aims in part to support cutting-
edge research and advance the practice of pain management. On October 
26, 2017, the opioid crisis was declared a national public health 
emergency under Federal law \7\ and this determination was renewed on 
April 20, 2018.\8\
---------------------------------------------------------------------------

    \3\ President's Commission on Combating Drug Addiction and the 
Opioid Crisis, Report (2017). Available at: https://www.whitehouse.gov/sites/whitehouse.gov/files/images/Final_Report_Draft_11-1-2017.pdf.
    \4\ Ibid, at page 57, Recommendation 19.
    \5\ Ibid.
    \6\ Available at: https://www.hhs.gov/about/leadership/secretary/speeches/2017-speeches/secretary-price-announces-hhs-strategy-for-fighting-opioid-crisis/.
    \7\ Available at: https://www.hhs.gov/about/news/2017/10/26/hhs-acting-secretary-declares-public-health-emergency-address-national-opioid-crisis.html.
    \8\ Available at: https://www.phe.gov/emergency/news/healthactions/phe/Pages/default.aspx.
---------------------------------------------------------------------------

    As discussed in the CY 2019 OPPS/ASC proposed rule (83 FR 37068 
through 37071), in response to stakeholder comments on the CY 2018 
OPPS/ASC proposed rule and in light of the recommendations regarding 
payment policies for certain drugs, we recently evaluated the impact of 
our packaging policy for drugs that function as a supply when used in a 
surgical procedure on the utilization of these drugs in both the 
hospital outpatient department and the ASC setting. Currently, as noted 
above, drugs that function as a supply are packaged under the OPPS and 
the ASC payment system, regardless of the costs of the drugs. The costs 
associated with packaged drugs that function as a supply are included 
in the ratesetting methodology for the surgical procedures with which 
they are billed and the payment rate for the associated procedure 
reflects the costs of the packaged drugs and other packaged items and 
services to the extent they are billed with the procedure. In our 
evaluation, we used currently available data to analyze the utilization 
patterns associated with specific drugs that function as a supply over 
a 5-year time period (CYs 2013 through 2017) to determine whether this 
packaging policy has reduced the use of these drugs. If the packaging 
policy discouraged the use of drugs that function as a supply or 
impeded access to these products, we would expect to see a significant 
decline in utilization of these drugs over time, although we note that 
a decline in utilization could also reflect other factors, such as the 
availability of alternative products. We did not observe significant 
declines in the total number of units used in the hospital outpatient 
department for a majority of the drugs included in our analysis.
    In fact, under the OPPS, we observed the opposite effect for 
several drugs that function as a supply, including Exparel (HCPCS code 
C9290). Exparel is a liposome injection of bupivacaine, an amide local 
anesthetic, indicated for single-dose infiltration into the surgical 
site to produce postsurgical analgesia. In 2011, Exparel was approved 
by the FDA for administration into the postsurgical site to provide 
postsurgical analgesia.\9\ Exparel had pass-through payment status from 
CYs 2012 through 2014 and was separately paid under both the OPPS and 
the ASC payment system during this 3-year period. Beginning in CY 2015, 
Exparel was packaged as a surgical supply under both the OPPS and the 
ASC payment system. Exparel is currently the only non-opioid pain 
management drug that is packaged as a drug that functions as a supply 
when used in a surgical procedure under the OPPS and the ASC payment 
system.
---------------------------------------------------------------------------

    \9\ Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022496s000lbl.pdf.
---------------------------------------------------------------------------

    From CYs 2013 through 2017, there was an overall increase in the 
OPPS Medicare utilization of Exparel of approximately 229 percent (from 
2.3 million units to 7.7 million units) during this 5-year time period. 
The total number of claims reporting Exparel increased by 222 percent 
(from 10,609 claims to 34,183 claims) over this time period. This 
increase in utilization continued, even after the 3-year drug pass-
through payment period ended for this product in 2014, with 18 percent 
overall growth in the total number of units used from CYs 2015 through 
2017 (from 6.5 million units to 7.7 million units). The number of 
claims reporting Exparel increased by 21 percent during this time 
period (from 28,166 claims to 34,183 claims).
    Thus, we have not found evidence to support the notion that the 
OPPS packaging policy has had an unintended consequence of discouraging 
the use of non-opioid treatment for postsurgical pain management in the 
hospital outpatient department. Therefore, based on this data analysis, 
we stated in the CY 2019 OPPS/ASC proposed rule that we did not believe 
that changes were necessary under the OPPS for the packaged drug policy 
for drugs that function as a surgical supply when used in a surgical 
procedure in this setting at this time.
    In terms of Exparel in particular, we have received several 
requests to pay separately for the drug rather than packaging payment 
for it as a surgical supply. In the CY 2015 OPPS/ASC final rule with 
comment period (79 FR 66874 and 66875), in response to comments from 
stakeholders requesting separate payment for Exparel, we stated that we 
considered Exparel to be a drug that functions as a surgical supply 
because it is indicated for the alleviation of postoperative pain. We 
also stated that we consider all items related to the surgical outcome 
and provided during the hospital stay in which the surgery is 
performed, including postsurgical pain management drugs, to be part of 
the surgery for purposes of our drug and biological surgical supply 
packaging policy. In the CY 2018 OPPS/ASC final rule with comment 
period (82 FR 59345), we reiterated our position with regard to payment 
for Exparel, stating that we believed that payment for this drug is 
appropriately packaged with the primary surgical procedure. In 
addition, we have reviewed recently available literature with respect 
to Exparel, including a briefing document \10\ submitted for the FDA 
Advisory Committee Meeting held February 14-15, 2018, by the 
manufacturer of Exparel that notes that ``. . . Bupivacaine, the active 
pharmaceutical ingredient in Exparel, is a local anesthetic that has 
been used for infiltration/field block and peripheral nerve block for 
decades'' and that ``since its approval, Exparel has been used 
extensively, with an estimated 3.5 million patient exposures in the 
US.'' \11\ On April 6, 2018, the FDA approved Exparel's new indication 
for use as an interscalene brachial plexus nerve block to produce 
postsurgical regional analgesia.\12\ Therefore, we also stated in the 
CY 2019 OPPS/ASC proposed rule that, based on our review of currently 
available OPPS Medicare claims data and public information from the 
manufacturer of the drug, we did not believe that the OPPS packaging 
policy had discouraged the use of Exparel for either of the drug's 
indications. Accordingly, we continue to believe it is appropriate to 
package payment for Exparel as we do with other postsurgical pain 
management drugs when it is furnished in a hospital outpatient 
department. However, we invited public comments on whether separate 
payment would nonetheless further incentivize appropriate use of 
Exparel in the hospital outpatient setting and peer-reviewed evidence 
that such increased utilization would lead to a decrease in

[[Page 58856]]

opioid use and addiction among Medicare beneficiaries.
---------------------------------------------------------------------------

    \10\ Food and Drug Administration, Meeting of the Anesthetic and 
Analgesic Drug Products Advisory Committee Briefing Document (2018). 
Available at: https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AnestheticAndAnalgesicDrugProductsAdvisoryCommittee/UCM596314.pdf.
    \11\ Ibid, page 9.
    \12\ Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022496s009lbledt.pdf.
---------------------------------------------------------------------------

    Comment: Several commenters, including hospital associations, 
medical specialty societies, and drug manufacturers, requested that CMS 
pay separately for Exparel in the hospital outpatient setting. Some of 
these commenters noted that Exparel is used more frequently in this 
setting and the use of non-opioid pain management treatments should 
also be encouraged in the hospital outpatient department. The 
manufacturer of Exparel, Pacira Pharmaceuticals, stated that since the 
drug became packaged in 2015, utilization of the drug in the hospital 
outpatient department has remained flat while the opioid crisis has 
continued to worsen. The manufacturer suggested that, to address the 
opioid crisis among Medicare beneficiaries, CMS should promote 
``increased penetration of non-opioid therapies in the HOPD setting--or 
in other words, higher rates of usage of non-opioid treatments for the 
same number of surgical procedures.''
    Response: While these commenters advocated paying separately for 
Exparel in the hospital outpatient setting, we do not believe that 
there is sufficient evidence that non-opioid pain management drugs 
should be paid separately in the hospital outpatient setting at this 
time. The commenters submitted some peer-reviewed studies, discussed in 
further detail below, that showed that the use of Exparel could lead to 
a decrease in opioid use in the treatment of acute post-surgical pain 
among Medicare beneficiaries. However, the commenters did not provide 
evidence that the OPPS packaging policy for Exparel (or other non-
opioid drugs) creates a barrier to use of Exparel in the hospital 
setting. Further, while we received some public comments suggesting 
that, as a result of using Exparel in the OPPS setting, providers may 
prescribe fewer opioids for Medicare beneficiaries, we do not believe 
that the OPPS payment policy presents a barrier to use of Exparel or 
affects the likelihood that providers may prescribe fewer opioids in 
the HOPD setting. Several drugs are packaged under the OPPS and payment 
for such drugs is included in the payment for the associated primary 
procedure. We were not persuaded by the anecdotal information supplied 
by commenters suggesting that some providers avoid use of non-opioid 
alternatives (including Exparel) solely because of the OPPS packaged 
payment policy. Finally, while the rate of growth for Exparel use in 
the HOPD setting has declined over recent years, such trend might be 
expected because absolute utilization tends to be smaller in the 
initial period when a drug first comes available on the U.S. market. 
Additionally, we observed that the total number of providers billing 
for Exparel under the OPPS has increased each year from 2012 to 2017. 
Therefore, we do not believe that the current OPPS payment methodology 
for Exparel and other non-opioid pain management drugs presents a 
barrier to their use.
    In addition, higher use in the hospital outpatient setting not only 
supports the notion that the packaged payment for Exparel is not 
causing an access to care issue, but also that the payment rate for 
primary procedures in the HOPD using Exparel adequately reflects the 
cost of the drug. That is, because Exparel is commonly used and billed 
under the OPPS, the APC rates for the primary procedures reflect such 
utilization. Therefore, the higher utilization in the OPPS setting 
should mitigate the need for separate payment. We remind readers that 
the OPPS is a prospective payment system, not a cost-based system and, 
by design, is based on a system of averages whereby payment for certain 
cases may exceed the costs incurred, while for others, it may not. As 
stated earlier in this section, the OPPS packages payments for multiple 
interrelated items and services into a single payment to create 
incentives for hospitals to furnish services most efficiently and to 
manage their resources with maximum flexibility. Our packaging policies 
support our strategic goal of using larger payment bundles in the OPPS 
to maximize hospitals' incentives to provide care in the most efficient 
manner. We will continue to analyze the evidence and monitor 
utilization of non-opioid alternatives in the OPD and ASC settings for 
potential future rulemaking.
    We also stated in the proposed rule that, although we found 
increases in utilization for Exparel when it is paid under the OPPS, we 
did notice different effects on Exparel utilization when examining the 
effects of our packaging policy under the ASC payment system. In 
particular, during the same 5-year period of CYs 2013 through 2017, the 
total number of units of Exparel used in the ASC setting decreased by 
25 percent (from 98,160 total units to 73,595 total units) and the 
total number of claims reporting Exparel decreased by 16 percent (from 
527 claims to 441 claims). In the ASC setting, after the pass-through 
payment period ended for Exparel at the end of CY 2014, the total 
number of units of Exparel used decreased by 70 percent (from 244,757 
units to 73,595 units) between CYs 2015 and 2017. The total number of 
claims reporting Exparel also decreased during this time period by 62 
percent (from 1,190 claims to 441 claims). However, there was an 
increase of 238 percent (from 98,160 total units to 331,348 total 
units) in the total number of units of Exparel used in the ASC setting 
during the time period of CYs 2013 and 2014 when the drug received 
pass-through payments, indicating that the payment rate of ASP+6 
percent for Exparel may have had an impact on its usage in the ASC 
setting. The total number of claims reporting Exparel also increased 
during this time period from 527 total claims to 1,540 total claims, an 
increase of 192 percent.
    While several variables may contribute to this difference in 
utilization and claims reporting between the hospital outpatient 
department and the ASC setting, one potential explanation is that, in 
comparison to hospital outpatient departments, ASCs tend to provide 
specialized care and a more limited range of services. Also, ASCs are 
paid, in aggregate, approximately 55 percent of the OPPS rate. 
Therefore, fluctuations in payment rates for specific services may 
impact these providers more acutely than hospital outpatient 
departments, and therefore, ASCs may be less likely to choose to 
furnish non-opioid postsurgical pain management treatments, which are 
typically more expensive than opioids, as a result. Another possible 
contributing factor is that ASCs do not typically report packaged items 
and services and, accordingly, our analysis may be undercounting the 
number of Exparel units utilized in the ASC setting.
    In light of the results of our evaluation of packaging policies 
under the OPPS and the ASC payment system, which showed decreased 
utilization for certain drugs that function as a supply in the ASC 
setting in comparison to the hospital outpatient department setting, as 
well as the Commission's recommendation to examine payment policies for 
non-opioid pain management drugs that function as a supply, we stated 
in the proposed rule that we believe a change in how we pay for non-
opioid pain management drugs that function as surgical supplies may be 
warranted. In particular, we stated that we believe it may be 
appropriate to pay separately for evidence-based non-opioid pain 
management drugs that function as a supply in a surgical procedure in 
the ASC setting to address the decreased utilization of these drugs and 
to encourage use of these types of drugs rather than prescription 
opioids. Therefore, we proposed in section XII.D.3. of the CY 2019 
OPPS/ASC

[[Page 58857]]

proposed rule to unpackage and pay separately for the cost of non-
opioid pain management drugs that function as surgical supplies when 
they are furnished in the ASC setting for CY 2019 (83 FR 37065).
    We have stated previously (82 FR 59250) that our packaging policies 
are designed to support our strategic goal of using larger payment 
bundles in the OPPS to maximize hospitals' incentives to provide care 
in the most efficient manner. The packaging policies established under 
the OPPS also typically apply when services are provided in the ASC 
setting, and the policies have the same strategic goals in both 
settings. While the CY 2019 proposal is a departure from our current 
ASC packaging policy for drugs (specifically, non-opioid pain 
management drugs) that function as a supply when used in a surgical 
procedure, we stated in the proposed rule that we believe that the 
proposed change will incentivize the use of non-opioid pain management 
drugs and is responsive to the Commission's recommendation to examine 
payment policies for non-opioid pain management drugs that function as 
a supply, with the overall goal of combating the current opioid 
addiction crisis. As previously noted, a discussion of the CY 2019 
proposal for payment of non-opioid pain management drugs in the ASC 
setting was presented in further detail in section XII.D.3. of the 
proposed rule, and we refer readers to section XII.D.3. of this CY 2019 
OPPS/ASC final rule with comment period for further discussion of the 
final policy for CY 2019. We also stated in the CY 2019 OPPS/ASC 
proposed rule that we were interested in peer-reviewed evidence that 
demonstrates that use of non-opioid alternatives, such as Exparel, 
furnished in the outpatient setting actually does lead to a decrease in 
prescription opioid use and addiction and invited public comments 
containing evidence that demonstrate whether and how such non-opioid 
alternatives affect prescription opioid use during or after an 
outpatient visit or procedure.
    Comment: Several commenters, including individual stakeholders, 
hospital and physician groups, national medical associations, drug 
rehabilitation specialists, device manufacturers, and groups 
representing the pharmaceutical industry, supported the proposal to 
unpackage and pay separately for the cost of non-opioid pain management 
drugs that function as surgical supplies, such as Exparel, in the ASC 
setting for CY 2019. These commenters believed that packaged payment 
for non-opioid alternatives presents a barrier to care and that 
separate payment for non-opioid pain management drugs would be an 
appropriate response to the opioid drug abuse epidemic.
    Other commenters, including MedPAC, did not support this proposal 
and stated that the policy was counter to the OPPS packaging policies 
created to encourage efficiencies and could set a precedent for 
unpackaging services. One commenter stated that Exparel is more costly, 
but not more effective than bupivacaine, a less costly non-opioid 
alternative. Other commenters expressed concerns that the proposal may 
have the unintended consequence of limiting access to opioid 
prescriptions for beneficiaries for whom an opioid prescription would 
be appropriate. The commenters noted that some non-opioid pain 
management treatments may pose other risks for patients and patient 
safety.
    Response: This comment and other comments specific to packaging 
under the ASC payment system are addressed in section XII.D.3. of this 
final rule with comment period.
    In addition, as noted in section XII.D.3. of the proposed rule (83 
FR 37065 through 37068), we sought comments on whether the proposed 
policy would decrease the dose, duration, and/or number of opioid 
prescriptions beneficiaries receive during and following an outpatient 
visit or procedure (especially for beneficiaries at high-risk for 
opioid addiction) as well as whether there are other non-opioid pain 
management alternatives that would have similar effects and may warrant 
separate payment. For example, we stated we were interested in 
identifying whether single post-surgical analgesic injections, such as 
Exparel, or other non-opioid drugs or devices that are used during an 
outpatient visit or procedure are associated with decreased opioid 
prescriptions and/or reduced cases of associated opioid addiction 
following such an outpatient visit or procedure. We also requested 
comments that provide evidence (such as published peer-reviewed 
literature) we could use to determine whether these products help to 
deter or avoid prescription opioid use and addiction as well as 
evidence that the current packaged payment for such non-opioid 
alternatives presents a barrier to access to care and, therefore, 
warrants separate payment under either or both the OPPS and the ASC 
payment system. We stated that any evidence demonstrating the reduction 
or avoidance of prescription opioids would be the criterion we use to 
determine whether separate payment is warranted for CY 2019. We also 
stated that if evidence changes over time, we would consider whether a 
reexamination of any policy adopted in the final rule would be 
necessary.
    Comment: With regard to whether the proposed policy would decrease 
the dose, duration, and/or number of opioid prescriptions beneficiaries 
receive during and following an outpatient visit or procedure and 
supportive evidence of these reductions, one commenter, the 
manufacturer of Exparel, submitted studies that claimed that the use of 
Exparel by Medicare patients undergoing total knee replacement 
procedures reduced prescription opioid consumption by 90 percent 
compared to the control group measured at 48 hours post-surgery.\13\ 
The manufacturer submitted additional studies claiming statistically 
significant reductions in opioid use with the use of Exparel for 
various surgeries, including laparotomy, shoulder replacement, and 
breast reconstruction.
---------------------------------------------------------------------------

    \13\ Michael A. Mont et al., Local Infiltration Analgesia With 
Liposomal Bupivacaine Improves Pain Scores and Reduces Opioid Use 
After Total Knee Arthroplasty: Results of a Randomized Controlled 
Trial. J. of Arthroplasty (2018).
---------------------------------------------------------------------------

    Several commenters identified other non-opioid pain management 
drugs that they believe decrease the dose, duration, and/or number of 
opioid prescriptions beneficiaries receive during and following an 
outpatient visit or procedure (especially for beneficiaries at high-
risk for opioid addiction) and may warrant separate payment for CY 
2019. Commenters from the makers of other packaged non-opioid pain 
management drugs, including a non-opioid intrathecal infusion drug 
indicated for the management of severe chronic pain, submitted 
supporting studies which claimed that the drug reduced opioid use in 
patients with chronic pain.
    Several commenters, from hospitals, hospital associations, and 
clinical specialty organizations, requested separate payment for IV 
acetaminophen, IV ibuprofen, and epidural steroid injections. In 
addition, one commenter, the manufacturer of a non-opioid analgesic 
containing bupivacaine hcl not currently approved by FDA, requested 
clarification regarding whether the proposal would also apply to this 
drug once it receives FDA approval. Several commenters requested 
separate payment for a drug that treats postoperative pain after 
cataract surgery, currently has drug pass-through payment status, and 
therefore is not packaged under the OPPS or the ASC payment system. The 
commenters requested that CMS explicitly state that this drug will also 
be paid for separately in the ASC setting after pass-through

[[Page 58858]]

payment status ends for the drug in 2020. Lastly, one commenter, the 
makers of a diagnostic drug that is not a non-opioid, requested 
separate payment.
    Response: We appreciate these comments. After reviewing the studies 
provided by the commenters, we continue to believe the separate payment 
is appropriate for Exparel in the ASC setting. At this time, we have 
not found compelling evidence for other non-opioid pain management 
drugs described above to warrant separate payment under the ASC payment 
system for CY 2019. Also, with regard to the requests for CMS to 
confirm that the proposed policy would also apply in the future to 
certain non-opioid pain management drugs, we reiterate that the 
proposed policy is for CY 2019 and is applicable to non-opioid pain 
management drugs that are currently packaged under the policy for drugs 
that function as a surgical supply when used in the ASC setting, which 
currently is only Exparel. To the extent that other non-opioid pain 
management drugs become available on the U.S. market in 2019, this 
policy would also apply to those drugs.
    As noted above, we stated in the proposed rule that we were 
interested in comments regarding other non-opioid treatments besides 
Exparel that might be affected by our OPPS and ASC packaging policies, 
including alternative, non-opioid pain management treatments, such as 
devices or therapy services that are not currently separable payable. 
We stated that we were specifically interested in comments regarding 
whether CMS should consider separate payment for items and services for 
which payment is currently packaged under the OPPS and the ASC payment 
system that are effective non-opioid alternatives as well as evidence 
that demonstrates such items and services lead to a decrease in 
prescription opioid use and/or addiction during or after an outpatient 
visit or procedure in order to determine whether separate payment may 
be warranted. As previously stated, we intended to examine the evidence 
submitted to determine whether to adopt a final policy in this final 
rule with comment period that incentivizes use of non-opioid 
alternative items and services that have evidence to demonstrate an 
associated decrease in prescription opioid use and/or addiction 
following an outpatient visit or procedure. We stated that some 
examples of evidence that may be relevant could include an indication 
on the product's FDA label or studies published in peer-reviewed 
literature that such product aids in the management of acute or chronic 
pain and is an evidence-based non-opioid alternative for acute and/or 
chronic pain management. We indicated in the proposed rule that we also 
were interested in evidence relating to products that have shown 
clinical improvement over other alternatives, such as a device that has 
been shown to provide a substantial clinical benefit over the standard 
of care for pain management. We stated that this could include, for 
example, spinal cord stimulators used to treat chronic pain, such as 
the devices described by HCPCS codes C1822 (Generator, neurostimulator 
(implantable), high frequency, with rechargeable battery and charging 
system), C1820 (Generator, neurostimulator (implantable), with 
rechargeable battery and charging system), and C1767 (Generator, 
neurostimulator (implantable), nonrechargeable) which are primarily 
assigned to APCs 5463 and 5464 (Levels 3 and 4 Neurostimulator and 
Related Procedures) with proposed CY 2019 payment rates of $18,718 and 
$27,662, respectively, that have received pass-through payment status 
as well as other similar devices.
    Currently, all devices are packaged under the OPPS and the ASC 
payment system unless they have pass-through payment status. However, 
we stated in the proposed rule that, in light of the Commission's 
recommendation to review and modify ratesetting policies that 
discourage the use of non-opioid treatments for pain, we were 
interested in comments from stakeholders regarding whether, similar to 
the goals of the proposed payment policy for non-opioid pain management 
drugs that function as a supply when used in a surgical procedure, a 
policy of providing separate payment (rather than packaged payment) for 
these products, indefinitely or for a specified period of time, would 
also incentivize the use of alternative non-opioid pain management 
treatments and improve access to non-opioid alternatives, particularly 
for innovative and low-volume items and services.
    We also stated that we were interested in comments regarding 
whether we should provide separate payment for non-opioid pain 
management treatments or products using a mechanism such as an 
equitable payment adjustment under our authority at section 
1833(t)(2)(E) of the Act, which states that the Secretary shall 
establish, in a budget neutral manner, other adjustments as determined 
to be necessary to ensure equitable payments. For example, we stated in 
the proposed rule that we were considering whether an equitable payment 
adjustment in the form of an add-on payment for APCs that use a non-
opioid pain management drug, device, or service would be appropriate. 
We indicated that, to the extent that commenters provided evidence to 
support this approach, we would consider adopting a final policy in 
this final rule with comment period, which could include regulatory 
changes that would allow for an exception to the packaging of certain 
nonpass-through devices that represent non-opioid alternatives for 
acute or chronic pain that have evidence to demonstrate that their use 
leads to a decrease in opioid prescriptions and/or opioid abuse or 
misuse during or after an outpatient visit or procedure to effectuate 
such change.
    Comment: Several commenters, manufacturers of spinal cord 
stimulators (SCS), stated that separate payment was also warranted for 
these devices because they provide an alternative treatment option to 
opioids for patients with chronic, leg, or back pain. One of the 
manufacturers of a high-frequency SCS device provided supporting 
studies which claimed that patients treated with their device reported 
a statistically significant average decrease in opioid use compared to 
the control group.\14\ This commenter also submitted data that showed a 
decline in the mean daily dosage of opioid medication taken and that 
fewer patients were relying on opioids at all to manage their pain when 
they used the manufacturer's device.\15\ Another commenter, a SCS 
manufacturer, stated that there are few peer-reviewed studies that 
evaluate opioid elimination and/or reduction following SCS and that 
there is a need for more population-based research with opioid 
reduction or elimination as a study endpoint. However, this commenter 
believed that current studies suggest that opioid use may be reduced 
following SCS therapy.
---------------------------------------------------------------------------

    \14\ Kapural L, Yu C, Doust MW, Gliner BE, Vallejo R, Sitzman 
BT, Amirdelfan K, Morgan DM, Brown LL, Yearwood TL, Bundschu R, 
Burton AW, Yang T, Benyamin R, Burgher AH. Novel 10-kHz high-
frequency therapy (HF10 therapy) is superior to traditional low-
frequency spinal cord stimulation for the treatment of chronic back 
and leg pain: The SENZA-RCT randomized controlled trial, 
Anesthesiology. 2015 Oct;123(4):851-60.
    \15\ Al-Kaisy A, Van Buyten JP, Smet I, Palmisani S, Pang D, 
Smith T. Sustained effectiveness of 10 kHz high-frequency spinal 
cord stimulation for patients with chronic, low back pain: 24-month 
results of a prospective multicenter study. Pain Med. 2014 Mar; 
15(3):347-54.
---------------------------------------------------------------------------

    Commenters representing various stakeholders requested separate 
payments for various non-opioid pain management treatments, such as

[[Page 58859]]

continuous nerve blocks (including a disposable elastomeric pump that 
delivers non-opioid local anesthetic to a surgical site or nerve), 
cooled thermal radiofrequency ablation for nonsurgical, chronic nerve 
pain, and physical therapy services. These commenters, including 
national hospital associations, recommended that while ``certainly not 
a solution to the opioid epidemic, unpackaging appropriate non-opioid 
therapies, like Exparel, is a low-cost tactic that could change long-
standing practice patterns without major negative consequences.'' This 
same commenter suggested that Medicare consider separate payment for 
Polar ice devices for postoperative pain relief after knee procedures. 
The commenter also noted that therapeutic massage, topically applied 
THC oil, acupuncture, and dry needling procedures are very effective 
therapies for relief of both postoperative pain and long-term and 
chronic pain.
    Commenters suggested various mechanisms through which separate 
payment or a higher-paying APC assignment for the primary service could 
be made. Commenters offered reports, studies, and anecdotal evidence of 
varying degrees to support why the items or services about which they 
were writing offered an alternative to or reduction of the need for 
opioid prescriptions.
    Response: We appreciate the detailed responses to our solicitation 
for comments on this topic. We plan to take these comments and 
suggestions into consideration for future rulemaking. We agree that 
providing incentives to avoid and/or reduce opioid prescriptions may be 
one of several strategies for addressing the opioid epidemic. To the 
extent that the items and services mentioned by the commenters are 
effective alternatives to opioid prescriptions, we encourage providers 
to use them when medically necessary. We note that some of the items 
and services mentioned by commenters are not covered by Medicare, and 
we do not intend to establish payment for noncovered items and 
services. We look forward to working with stakeholders as we further 
consider suggested refinements to the OPPS and the ASC payment system 
that will encourage use of medically necessary items and services that 
have demonstrated efficacy in decreasing opioid prescriptions and/or 
opioid abuse or misuse during or after an outpatient visit or 
procedure.
    Comment: One commenter suggested that CMS provide separate payment 
for HCPCS code A4306 (Disposable drug delivery system, flow rate of 
less than 50 ml per hour) in the hospital outpatient department setting 
and the ASC setting following a post-surgery procedure. This commenter 
explained that if a patient needs additional pain relief 3 to 5 days 
post-surgery, a facility cannot receive payment for providing a 
replacement disposable drug delivery system (HCPCS code A4306) unless 
the entire continuous nerve block procedure is performed. This 
commenter believed that CMS should allow for HCPCS code A4306 to be 
dispensed to the patient as long as the patient is in pain, the pump is 
empty, and the delivery catheters are still in place. The commenter 
believed that the drug delivery system should incentivize the continued 
use of non-opioid alternatives when needed. In addition, several 
commenters stated that CMS should use an equitable payment adjustment 
under our authority at section 1833(t)(2)(E) of the Act to establish 
add-on payments for packaged devices used as non-opioid alternatives.
    Response: We appreciate the commenter's suggestion. We acknowledge 
that use of these items may help in the reduction of opioid use 
postoperatively. However, we note that packaged payment of such an item 
does not prevent the use of these items. We remind readers that payment 
for packaged items is included in the payment for the primary service. 
We share the commenter's concern about the need to reduce opioid use 
and will take the commenter's suggestion into consideration for future 
rulemaking.
    After reviewing the non-opioid pain management alternatives 
suggested by the commenters as well as the studies and other data 
provided to support the request for separate payment, we have not 
determined that separate payment is warranted at this time for any of 
the non-opioid pain management alternatives discussed above.
    We also invited public comments on whether a reorganization of the 
APC structure for procedures involving non-opioid products or 
establishing more granular APC groupings for specific procedure and 
device combinations to ensure that the payment rate for such services 
is aligned with the resources associated with procedures involving 
specific devices would better achieve our goal of incentivizing 
increased use of non-opioid alternatives, with the aim of reducing 
opioid use and subsequent addiction. For example, we stated we would 
consider finalizing a policy to establish new APCs for procedures 
involving non-opioid pain management packaged items or services if such 
APCs would better recognize the resources involved in furnishing such 
items and services and decrease or eliminate the need for prescription 
opioids. In addition, given the general desire to encourage provider 
efficiency through creating larger bundles of care and packaging items 
and services that are integral, ancillary, supportive, dependent, or 
adjunctive to a primary service, we also invited comments on how such 
alternative payment structures would continue to balance the goals of 
incentivizing provider efficiencies with encouraging the use of non-
opioid alternatives to pain management.
    Furthermore, because patients may receive opioid prescriptions 
following receipt of a non-opioid drug or implantation of a device, we 
stated that we were interested in identifying any cost implications for 
the patient and the Medicare program caused by this potential change in 
policy. We also stated that the implications of incentivizing use of 
non-opioid pain management drugs available for postsurgical acute pain 
relief during or after an outpatient visit or procedure are of 
interest. The goal is to encourage appropriate use of such non-opioid 
alternatives. As previously stated, this comment solicitation is also 
discussed in section XII.D.3. of this final rule with comment period 
relating to the ASC payment system.
    Comment: Regarding APC reorganization, one commenter suggested that 
CMS restructure the two-level Nerve Procedure APCs (5431 and 5432) to 
provide more payment granularity for the procedures included in the 
APCs by creating a third level.
    Response: This comment is addressed in section III.D.17. of this 
final rule with comment period. As stated in that section, we believe 
that the current two-level APCs for the Nerve Procedures provide an 
appropriate distinction between the resource costs at each level and 
provide clinical homogeneity. We will continue to review this APC 
structure to determine if additional granularity is necessary for this 
APC family in future rulemaking. In addition, we believe that more 
analysis of such groupings is necessary before adopting such change.
    In addition, in the proposed rule, we invited the public to submit 
ideas on regulatory, subregulatory, policy, practice, and procedural 
changes to help prevent opioid use disorders and improve access to 
treatment under the Medicare program. We stated that we were interested 
in identifying barriers that may inhibit access to non-opioid 
alternatives for pain treatment and management or access to opioid use 
disorder treatment, including those barriers related to payment 
methodologies or coverage. In addition, consistent with our ``Patients 
Over

[[Page 58860]]

Paperwork'' Initiative, we stated that we were interested in 
suggestions to improve existing requirements in order to more 
effectively address the opioid epidemic.
    Comment: Several commenters addressed payment barriers that may 
inhibit access to non-opioid pain management treatments previously 
discussed throughout this section. With regard to barriers related to 
payment methodologies or coverage, one commenter, a clinical specialty 
society, suggested that CMS support multi-modal pain management and 
enhanced recovery after surgery (ERAS) and encourage patient access to 
certified registered nurse anesthetist (CRNA) pain management. One 
commenter also suggested that CMS reduce cost-sharing and eliminate the 
need for prior authorization for non-opioid pain management strategies.
    Response: We appreciate the various, insightful comments we 
received from stakeholders regarding barriers that may inhibit access 
to non-opioid alternatives for pain treatment and management in order 
to more effectively address the opioid epidemic. Many of these comments 
have been previously addressed throughout this section.
    After consideration of the public comments that we received, we are 
finalizing the proposed policy, without modification, to unpackage and 
pay separately at ASP+6 percent for the cost of non-opioid pain 
management drugs that function as surgical supplies when they are 
furnished in the ASC setting for CY 2019. We will continue to analyze 
the issue of access to non-opioid alternatives in the OPD and the ASC 
settings as we implement section 6082 of the Substance Use-Disorder 
Prevention that Promotes Opioid Recovery and Treatment for Patients and 
Communities Act (Pub. L. 115-271 enacted on October 24, 2018. This 
policy is also discussed in section XII.D.3 of this final rule with 
comment period.
4. Calculation of OPPS Scaled Payment Weights
    We established a policy in the CY 2013 OPPS/ASC final rule with 
comment period (77 FR 68283) of using geometric mean-based APC costs to 
calculate relative payment weights under the OPPS. In the CY 2018 OPPS/
ASC final rule with comment period (82 FR 59255 through 59256), we 
applied this policy and calculated the relative payment weights for 
each APC for CY 2018 that were shown in Addenda A and B to that final 
rule with comment period (which were made available via the internet on 
the CMS website) using the APC costs discussed in sections II.A.1. and 
II.A.2. of that final rule with comment period. For CY 2019, as we did 
for CY 2018, in the CY 2019 OPPS/ASC proposed rule (83 FR 37071), we 
proposed to continue to apply the policy established in CY 2013 and 
calculate relative payment weights for each APC for CY 2019 using 
geometric mean-based APC costs.
    For CY 2012 and CY 2013, outpatient clinic visits were assigned to 
one of five levels of clinic visit APCs, with APC 0606 representing a 
mid-level clinic visit. In the CY 2014 OPPS/ASC final rule with comment 
period (78 FR 75036 through 75043), we finalized a policy that created 
alphanumeric HCPCS code G0463 (Hospital outpatient clinic visit for 
assessment and management of a patient), representing any and all 
clinic visits under the OPPS. HCPCS code G0463 was assigned to APC 0634 
(Hospital Clinic Visits). We also finalized a policy to use CY 2012 
claims data to develop the CY 2014 OPPS payment rates for HCPCS code 
G0463 based on the total geometric mean cost of the levels one through 
five CPT E/M codes for clinic visits previously recognized under the 
OPPS (CPT codes 99201 through 99205 and 99211 through 99215). In 
addition, we finalized a policy to no longer recognize a distinction 
between new and established patient clinic visits.
    For CY 2016, we deleted APC 0634 and reassigned the outpatient 
clinic visit HCPCS code G0463 to APC 5012 (Level 2 Examinations and 
Related Services) (80 FR 70372). For CY 2019, as we did for CY 2018, we 
proposed to continue to standardize all of the relative payment weights 
to APC 5012. We believe that standardizing relative payment weights to 
the geometric mean of the APC to which HCPCS code G0463 is assigned 
maintains consistency in calculating unscaled weights that represent 
the cost of some of the most frequently provided OPPS services. For CY 
2019, as we did for CY 2018, we proposed to assign APC 5012 a relative 
payment weight of 1.00 and to divide the geometric mean cost of each 
APC by the geometric mean cost for APC 5012 to derive the unscaled 
relative payment weight for each APC. The choice of the APC on which to 
standardize the relative payment weights does not affect payments made 
under the OPPS because we scale the weights for budget neutrality.
    We did not receive any public comments on our proposal to continue 
to use the geometric mean cost of APC 5012 to standardize relative 
payment weights for CY 2019. Therefore, we are finalizing our proposal 
and assigning APC 5012 the relative payment weight of 1.00, and using 
the relative payment weight for APC 5012 to derive the unscaled 
relative payment weight for each APC for CY 2019.
    We note that, in section X.B. of the OPPS/ASC proposed rule (83 FR 
37137 through 37138) and of this final rule with comment period, we 
discuss our CY 2019 proposal and established final policy to control 
for unnecessary increases in the volume of covered outpatient 
department services by paying for clinic visits furnished at excepted 
off-campus provider-based department (PBD) at an amount of 70 percent 
of the OPPS rate for a clinic visit service in CY 2019, rather than at 
the standard OPPS rate. While the volume associated with these visits 
is included in the impact model, and thus used in calculating the 
weight scalar, the proposal and final policy have only a negligible 
effect on the scalar. Specifically, under the proposed and final 
policy, there is no change to the relativity of the OPPS payment 
weights because the adjustment is made at the payment level rather than 
in the cost modeling. Further, under our proposed and final policy, the 
savings that will result from the change in payments for these clinic 
visits will not be budget neutral. Therefore, the impact of the 
proposed and final policy will generally not be reflected in the budget 
neutrality adjustments, whether the adjustment is to the OPPS relative 
weights or to the OPPS conversion factor. We refer readers to section 
X.B. of this CY 2019 OPPS/ASC final rule with comment period for 
further discussion of this final policy.
    Section 1833(t)(9)(B) of the Act requires that APC reclassification 
and recalibration changes, wage index changes, and other adjustments be 
made in a budget neutral manner. Budget neutrality ensures that the 
estimated aggregate weight under the OPPS for CY 2019 is neither 
greater than nor less than the estimated aggregate weight that would 
have been made without the changes. To comply with this requirement 
concerning the APC changes, in the CY 2019 OPPS/ASC proposed rule (83 
FR 37071 through 37072), we proposed to compare the estimated aggregate 
weight using the CY 2018 scaled relative payment weights to the 
estimated aggregate weight using the proposed CY 2019 unscaled relative 
payment weights.
    For CY 2018, we multiplied the CY 2018 scaled APC relative payment 
weight applicable to a service paid under the OPPS by the volume of 
that service from CY 2017 claims to calculate the total relative 
payment weight for

[[Page 58861]]

each service. We then added together the total relative payment weight 
for each of these services in order to calculate an estimated aggregate 
weight for the year. For CY 2019, we proposed to apply the same process 
using the estimated CY 2019 unscaled relative payment weights rather 
than scaled relative payment weights. We proposed to calculate the 
weight scalar by dividing the CY 2018 estimated aggregate weight by the 
unscaled CY 2019 estimated aggregate weight.
    For a detailed discussion of the weight scalar calculation, we 
refer readers to the OPPS claims accounting document available on the 
CMS website at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/HospitalOutpatientPPS/. Click on the CY 2019 OPPS 
final rule link and open the claims accounting document link at the 
bottom of the page.
    We proposed to compare the estimated unscaled relative payment 
weights in CY 2019 to the estimated total relative payment weights in 
CY 2018 using CY 2017 claims data, holding all other components of the 
payment system constant to isolate changes in total weight. Based on 
this comparison, we proposed to adjust the calculated CY 2019 unscaled 
relative payment weights for purposes of budget neutrality. We proposed 
to adjust the estimated CY 2019 unscaled relative payment weights by 
multiplying them by a proposed weight scalar of 1.4553 to ensure that 
the proposed CY 2019 relative payment weights are scaled to be budget 
neutral. The proposed CY 2019 relative payment weights listed in 
Addenda A and B to the proposed rule (which are available via the 
internet on the CMS website) were scaled and incorporated the 
recalibration adjustments discussed in sections II.A.1. and II.A.2. of 
the proposed rule.
    Section 1833(t)(14) of the Act provides the payment rates for 
certain SCODs. Section 1833(t)(14)(H) of the Act provides that 
additional expenditures resulting from this paragraph shall not be 
taken into account in establishing the conversion factor, weighting, 
and other adjustment factors for 2004 and 2005 under paragraph (9), but 
shall be taken into account for subsequent years. Therefore, the cost 
of those SCODs (as discussed in section V.B.2. of this final rule with 
comment period) is included in the budget neutrality calculations for 
the CY 2019 OPPS.
    We did not receive any public comments on the proposed weight 
scalar calculation. Therefore, we are finalizing our proposal to use 
the calculation process described in the proposed rule, without 
modification, for CY 2019. Using updated final rule claims data, we are 
updating the estimated CY 2019 unscaled relative payment weights by 
multiplying them by a weight scalar of 1.4574 to ensure that the final 
CY 2019 relative payment weights are scaled to be budget neutral.
    The final CY 2019 relative payments weights listed in Addenda A and 
B to this final rule with comment period (which are available via the 
internet on the CMS website) were scaled and incorporate the 
recalibration adjustments discussed in sections II.A.1. and II.A.2. of 
this final rule with comment period.

B. Conversion Factor Update

    Section 1833(t)(3)(C)(ii) of the Act requires the Secretary to 
update the conversion factor used to determine the payment rates under 
the OPPS on an annual basis by applying the OPD fee schedule increase 
factor. For purposes of section 1833(t)(3)(C)(iv) of the Act, subject 
to sections 1833(t)(17) and 1833(t)(3)(F) of the Act, the OPD fee 
schedule increase factor is equal to the hospital inpatient market 
basket percentage increase applicable to hospital discharges under 
section 1886(b)(3)(B)(iii) of the Act. As stated in the CY 2019 OPPS/
ASC proposed rule, in the FY 2019 IPPS/LTCH PPS proposed rule (83 FR 
20381), consistent with current law, based on IHS Global, Inc.'s fourth 
quarter 2017 forecast of the FY 2019 market basket increase, the 
proposed FY 2019 IPPS market basket update was 2.8 percent. However, 
sections 1833(t)(3)(F) and 1833(t)(3)(G)(v) of the Act, as added by 
section 3401(i) of the Patient Protection and Affordable Care Act of 
2010 (Pub. L. 111-148) and as amended by section 10319(g) of that law 
and further amended by section 1105(e) of the Health Care and Education 
Reconciliation Act of 2010 (Pub. L. 111-152), provide adjustments to 
the OPD fee schedule increase factor for CY 2019.
    Specifically, section 1833(t)(3)(F)(i) of the Act requires that, 
for 2012 and subsequent years, the OPD fee schedule increase factor 
under subparagraph (C)(iv) be reduced by the productivity adjustment 
described in section 1886(b)(3)(B)(xi)(II) of the Act. Section 
1886(b)(3)(B)(xi)(II) of the Act defines the productivity adjustment as 
equal to the 10-year moving average of changes in annual economy-wide, 
private nonfarm business multifactor productivity (MFP) (as projected 
by the Secretary for the 10-year period ending with the applicable 
fiscal year, year, cost reporting period, or other annual period) (the 
``MFP adjustment''). In the FY 2012 IPPS/LTCH PPS final rule (76 FR 
51689 through 51692), we finalized our methodology for calculating and 
applying the MFP adjustment, and then revised this methodology as 
discussed in the FY 2016 IPPS/LTCH PPS final rule (80 FR 49509). In the 
CY 2019 OPPS/ASC proposed rule (83 FR 37072), the proposed MFP 
adjustment for FY 2019 was 0.8 percentage point.
    In the CY 2019 OPPS/ASC proposed rule (83 FR 37072), we proposed 
that if more recent data became subsequently available after the 
publication of the proposed rule (for example, a more recent estimate 
of the market basket increase and the MFP adjustment), we would use 
such updated data, if appropriate, to determine the CY 2019 market 
basket update and the MFP adjustment, which are components in 
calculating the OPD fee schedule increase factor under sections 
1833(t)(3)(C)(iv) and 1833(t)(3)(F) of the Act, in this CY 2019 OPPS/
ASC final rule with comment period.
    In addition, section 1833(t)(3)(F)(ii) of the Act requires that, 
for each of years 2010 through 2019, the OPD fee schedule increase 
factor under section 1833(t)(3)(C)(iv) of the Act be reduced by the 
adjustment described in section 1833(t)(3)(G) of the Act. For CY 2019, 
section 1833(t)(3)(G)(v) of the Act provides a 0.75 percentage point 
reduction to the OPD fee schedule increase factor under section 
1833(t)(3)(C)(iv) of the Act. Therefore, in accordance with sections 
1833(t)(3)(F)(ii) and 1833(t)(3)(G)(v) of the Act, in the CY 2019 OPPS/
ASC proposed rule, we proposed to apply a 0.75 percentage point 
reduction to the OPD fee schedule increase factor for CY 2019.
    We note that section 1833(t)(3)(F) of the Act provides that 
application of this subparagraph may result in the OPD fee schedule 
increase factor under section 1833(t)(3)(C)(iv) of the Act being less 
than 0.0 percent for a year, and may result in OPPS payment rates being 
less than rates for the preceding year. As described in further detail 
below, we are applying an OPD fee schedule increase factor of 1.35 
percent for the CY 2019 OPPS (which is 2.9 percent, the final estimate 
of the hospital inpatient market basket percentage increase, less the 
final 0.8 percentage point MFP adjustment, and less the 0.75 percentage 
point additional adjustment).
    Hospitals that fail to meet the Hospital OQR Program reporting 
requirements are subject to an additional reduction of 2.0 percentage 
points from the OPD fee schedule increase factor adjustment to the 
conversion factor that would be used to

[[Page 58862]]

calculate the OPPS payment rates for their services, as required by 
section 1833(t)(17) of the Act. For further discussion of the Hospital 
OQR Program, we refer readers to section XIII. of this final rule with 
comment period.
    In the CY 2019 OPPS/ASC proposed rule, we proposed to amend 42 CFR 
419.32(b)(1)(iv)(B) by adding a new paragraph (10) to reflect the 
requirement in section 1833(t)(3)(F)(i) of the Act that, for CY 2019, 
we reduce the OPD fee schedule increase factor by the MFP adjustment as 
determined by CMS, and to reflect the requirement in section 
1833(t)(3)(G)(v) of the Act, as required by section 1833(t)(3)(F)(ii) 
of the Act, that we reduce the OPD fee schedule increase factor by an 
additional 0.75 percentage point for CY 2019.
    To set the OPPS conversion factor for the CY 2019 OPPS/ASC proposed 
rule, we proposed to increase the CY 2018 conversion factor of $78.636 
by 1.25 percent (83 FR 37073). In accordance with section 1833(t)(9)(B) 
of the Act, we proposed further to adjust the conversion factor for CY 
2019 to ensure that any revisions made to the wage index and rural 
adjustment were made on a budget neutral basis. We proposed to 
calculate an overall budget neutrality factor of 1.0004 for wage index 
changes by comparing proposed total estimated payments from our 
simulation model using the proposed FY 2019 IPPS wage indexes to those 
payments using the FY 2018 IPPS wage indexes, as adopted on a calendar 
year basis for the OPPS.
    For the CY 2019 OPPS/ASC proposed rule, we proposed to maintain the 
current rural adjustment policy, as discussed in section II.E. of the 
proposed rule and this final rule with comment period. Therefore, the 
proposed budget neutrality factor for the rural adjustment was 1.0000.
    For the CY 2019 OPPS/ASC proposed rule, we proposed to continue 
previously established policies for implementing the cancer hospital 
payment adjustment described in section 1833(t)(18) of the Act, as 
discussed in section II.F. of the proposed rule and this final rule 
with comment period. We proposed to calculate a CY 2019 budget 
neutrality adjustment factor for the cancer hospital payment adjustment 
by comparing estimated total CY 2019 payments under section 1833(t) of 
the Act, including the proposed CY 2019 cancer hospital payment 
adjustment, to estimated CY 2019 total payments using the CY 2018 final 
cancer hospital payment adjustment as required under section 
1833(t)(18)(B) of the Act. The CY 2019 proposed estimated payments 
applying the proposed CY 2019 cancer hospital payment adjustment were 
the same as estimated payments applying the CY 2018 final cancer 
hospital payment adjustment. Therefore, we proposed to apply a budget 
neutrality adjustment factor of 1.0000 to the conversion factor for the 
cancer hospital payment adjustment. In accordance with section 16002(b) 
of the 21st Century Cures Act, we stated in the proposed rule that we 
are applying a budget neutrality factor calculated as if the proposed 
cancer hospital adjustment target payment-to-cost ratio was 0.89, not 
the 0.88 target payment-to-cost ratio we are applying as stated in 
section II.F. of the proposed rule.
    For the CY 2019 OPPS/ASC proposed rule, we estimated that proposed 
pass-through spending for drugs, biologicals, and devices for CY 2019 
would equal approximately $126.7 million, which represented 0.17 
percent of total projected CY 2019 OPPS spending. Therefore, the 
proposed conversion factor would be adjusted by the difference between 
the 0.04 percent estimate of pass-through spending for CY 2018 and the 
0.17 percent estimate of proposed pass-through spending for CY 2019, 
resulting in a proposed decrease for CY 2019 of 0.13 percent. Proposed 
estimated payments for outliers would remain at 1.0 percent of total 
OPPS payments for CY 2019. We estimated for the proposed rule that 
outlier payments would be 1.02 percent of total OPPS payments in CY 
2018; the 1.00 percent for proposed outlier payments in CY 2019 would 
constitute a 0.02 percent increase in payment in CY 2019 relative to CY 
2018.
    For the CY 2019 OPPS/ASC proposed rule, we also proposed that 
hospitals that fail to meet the reporting requirements of the Hospital 
OQR Program would continue to be subject to a further reduction of 2.0 
percentage points to the OPD fee schedule increase factor. For 
hospitals that fail to meet the requirements of the Hospital OQR 
Program, we proposed to make all other adjustments discussed above, but 
use a reduced OPD fee schedule update factor of -0.75 percent (that is, 
the proposed OPD fee schedule increase factor of 1.25 percent further 
reduced by 2.0 percentage points). This would result in a proposed 
reduced conversion factor for CY 2019 of $77.955 for hospitals that 
fail to meet the Hospital OQR Program requirements (a difference of -
1.591 in the conversion factor relative to hospitals that met the 
requirements).
    In summary, for CY 2019, we proposed to amend Sec.  
419.32(b)(1)(iv)(B) by adding a new paragraph (10) to reflect the 
reductions to the OPD fee schedule increase factor that are required 
for CY 2019 to satisfy the statutory requirements of sections 
1833(t)(3)(F) and (t)(3)(G)(v) of the Act. We proposed to use a reduced 
conversion factor of $77.955 in the calculation of payments for 
hospitals that fail to meet the Hospital OQR Program requirements (a 
difference of -1.591 in the conversion factor relative to hospitals 
that met the requirements).
    For CY 2019, we proposed to use a conversion factor of $79.546 in 
the calculation of the national unadjusted payment rates for those 
items and services for which payment rates are calculated using 
geometric mean costs; that is, the proposed OPD fee schedule increase 
factor of 1.25 percent for CY 2019, the required proposed wage index 
budget neutrality adjustment of approximately 1.0004, the proposed 
cancer hospital payment adjustment of 1.0000, and the proposed 
adjustment of -0.13 percentage point of projected OPPS spending for the 
difference in pass-through spending that resulted in a proposed 
conversion factor for CY 2019 of $79.546.
    We invited public comments on these proposals. However, we did not 
receive any public comments. Therefore, we are finalizing these 
proposals without modification. For CY 2019, we proposed to continue 
previously established policies for implementing the cancer hospital 
payment adjustment described in section 1833(t)(18) of the Act 
(discussed in section II.F. of this final rule with comment period). 
Based on the final rule updated data used in calculating the cancer 
hospital payment adjustment in section II.F. of this final rule with 
comment period, the target payment-to-cost ratio for the cancer 
hospital payment adjustment, which was 0.88 for CY 2018, is 0.88 for CY 
2019. As a result, we are applying a budget neutrality adjustment 
factor of 1.0000 to the conversion factor for the cancer hospital 
payment adjustment.
    As a result of these finalized policies, the OPD fee schedule 
increase factor for the CY 2019 OPPS is 1.35 percent (which reflects 
the 2.9 percent final estimate of the hospital inpatient market basket 
percentage increase, less the final 0.8 percentage point MFP 
adjustment, and less the 0.75 percentage point additional adjustment). 
For CY 2019, we are using a conversion factor of $79.490 in the 
calculation of the national unadjusted payment rates for those items 
and services for which payment rates are calculated using geometric 
mean costs; that is, the OPD fee schedule increase factor of 1.35 
percent for CY 2019, the required wage index budget neutrality 
adjustment of

[[Page 58863]]

approximately 0.9984, and the adjustment of -0.10 percentage point of 
projected OPPS spending for the difference in pass-through spending 
that results in a conversion factor for CY 2019 of $79.490.

C. Wage Index Changes

    Section 1833(t)(2)(D) of the Act requires the Secretary to 
determine a wage adjustment factor to adjust the portion of payment and 
coinsurance attributable to labor-related costs for relative 
differences in labor and labor-related costs across geographic regions 
in a budget neutral manner (codified at 42 CFR 419.43(a)). This portion 
of the OPPS payment rate is called the OPPS labor-related share. Budget 
neutrality is discussed in section II.B. of this final rule with 
comment period.
    The OPPS labor-related share is 60 percent of the national OPPS 
payment. This labor-related share is based on a regression analysis 
that determined that, for all hospitals, approximately 60 percent of 
the costs of services paid under the OPPS were attributable to wage 
costs. We confirmed that this labor-related share for outpatient 
services is appropriate during our regression analysis for the payment 
adjustment for rural hospitals in the CY 2006 OPPS final rule with 
comment period (70 FR 68553). In the CY 2019 OPPS/ASC proposed rule (83 
FR 37073), we proposed to continue this policy for the CY 2019 OPPS. We 
refer readers to section II.H. of this final rule with comment period 
for a description and an example of how the wage index for a particular 
hospital is used to determine payment for the hospital.
    We did not receive any public comments on this proposal. Therefore, 
for the reasons discussed above and in the CY 2019 OPPS/ASC proposed 
rule (83 FR 37073), we are finalizing our proposal, without 
modification, to continue this policy as discussed above for the CY 
2019 OPPS.
    As discussed in the claims accounting narrative included with the 
supporting documentation for this final rule with comment period (which 
is available via the internet on the CMS website), for estimating APC 
costs, we standardize 60 percent of estimated claims costs for 
geographic area wage variation using the same FY 2019 pre-reclassified 
wage index that the IPPS uses to standardize costs. This 
standardization process removes the effects of differences in area wage 
levels from the determination of a national unadjusted OPPS payment 
rate and copayment amount.
    Under 42 CFR 419.41(c)(1) and 419.43(c) (published in the OPPS 
April 7, 2000 final rule with comment period (65 FR 18495 and 18545)), 
the OPPS adopted the final fiscal year IPPS post-reclassified wage 
index as the calendar year wage index for adjusting the OPPS standard 
payment amounts for labor market differences. Therefore, the wage index 
that applies to a particular acute care, short-stay hospital under the 
IPPS also applies to that hospital under the OPPS. As initially 
explained in the September 8, 1998 OPPS proposed rule (63 FR 47576), we 
believe that using the IPPS wage index as the source of an adjustment 
factor for the OPPS is reasonable and logical, given the inseparable, 
subordinate status of the HOPD within the hospital overall. In 
accordance with section 1886(d)(3)(E) of the Act, the IPPS wage index 
is updated annually.
    The Affordable Care Act contained several provisions affecting the 
wage index. These provisions were discussed in the CY 2012 OPPS/ASC 
final rule with comment period (76 FR 74191). Section 10324 of the 
Affordable Care Act added section 1886(d)(3)(E)(iii)(II) to the Act, 
which defines a frontier State and amended section 1833(t) of the Act 
to add paragraph (19), which requires a frontier State wage index floor 
of 1.00 in certain cases, and states that the frontier State floor 
shall not be applied in a budget neutral manner. We codified these 
requirements at Sec.  419.43(c)(2) and (c)(3) of our regulations. For 
the CY 2019 OPPS, we proposed to implement this provision in the same 
manner as we have since CY 2011. Under this policy, the frontier State 
hospitals would receive a wage index of 1.00 if the otherwise 
applicable wage index (including reclassification, the rural floor, and 
rural floor budget neutrality) is less than 1.00 (as discussed below 
and in the CY 2019 OPPS/ASC proposed rule (83 FR 37074 through 37076), 
we proposed not to extend the imputed floor under the OPPS for CY 2019 
and subsequent years, consistent with our proposal in the FY 2019 IPPS/
LTCH PPS proposed rule (83 FR 20362 and 20363) not to extend the 
imputed floor under the IPPS for FY 2019 and subsequent fiscal years). 
Because the HOPD receives a wage index based on the geographic location 
of the specific inpatient hospital with which it is associated, we 
stated that the frontier State wage index adjustment applicable for the 
inpatient hospital also would apply for any associated HOPD. In the CY 
2019 OPPS/ASC proposed rule (83 FR 37074), we referred readers to the 
FY 2011 through FY 2018 IPPS/LTCH PPS final rules for discussions 
regarding this provision, including our methodology for identifying 
which areas meet the definition of ``frontier States'' as provided for 
in section 1886(d)(3)(E)(iii)(II) of the Act: For FY 2011, 75 FR 50160 
through 50161; for FY 2012, 76 FR 51793, 51795, and 51825; for FY 2013, 
77 FR 53369 through 53370; for FY 2014, 78 FR 50590 through 50591; for 
FY 2015, 79 FR 49971; for FY 2016, 80 FR 49498; for FY 2017, 81 FR 
56922; and for FY 2018, 82 FR 38142.
    We did not receive any public comments on this proposal. Therefore, 
for the reasons discussed above and in the CY 2019 OPPS/ASC proposed 
rule (83 FR 37074), we are finalizing our proposal to implement the 
frontier State floor under the OPPS in the same manner as we have since 
CY 2011.
    In addition to the changes required by the Affordable Care Act, we 
note that the FY 2019 IPPS wage indexes continue to reflect a number of 
adjustments implemented over the past few years, including, but not 
limited to, reclassification of hospitals to different geographic 
areas, the rural floor provisions, an adjustment for occupational mix, 
and an adjustment to the wage index based on commuting patterns of 
employees (the out-migration adjustment). We refer readers to the FY 
2019 IPPS/LTCH PPS proposed rule (83 FR 20353 through 20377) and final 
rule (83 FR 41362 through 41390) for a detailed discussion of all 
proposed and final changes to the FY 2019 IPPS wage indexes. We note 
that, in the FY 2019 IPPS/LTCH PPS proposed rule (83 FR 20362 through 
20363), we proposed not to apply the imputed floor to the IPPS wage 
index computations for FY 2019 and subsequent fiscal years. Consistent 
with this, we proposed in the CY 2019 OPPS/ASC proposed rule (83 FR 
37074) not to extend the imputed floor policy under the OPPS beyond 
December 31, 2018 (the date the imputed floor policy is set to expire 
under the OPPS). In the FY 2019 IPPS/LTCH PPS final rule (83 FR 41376 
through 41380), we finalized our proposal to not extend the imputed 
floor policy under the IPPS. We refer readers to the FY 2019 IPPS/LTCH 
PPS final rule (83 FR 41376 through 41380) for a detailed discussion of 
our rationale for discontinuing the imputed floor under the IPPS.
    Summarized below are the comments we received regarding our 
proposal to discontinue the imputed floor under the OPPS, along with 
our response.
    Comment: Several commenters agreed with the proposal not to extend 
the imputed floor policy under the OPPS beyond December 31, 2018.
    Response: We appreciate the commenters' support.

[[Page 58864]]

    After consideration of the public comments we received, for the 
reasons discussed above and in the CY 2019 OPPS/ASC proposed rule (83 
FR 37074), consistent with the FY 2019 IPPS/LTCH PPS final rule, we are 
finalizing our proposal not to extend the imputed floor policy under 
the OPPS beyond December 31, 2018.
    As discussed in the FY 2015 IPPS/LTCH PPS final rule (79 FR 49951 
through 49963) and in each subsequent IPPS/LTCH PPS final rule, 
including the FY 2019 IPPS/LTCH PPS final rule (83 FR 41362 through 
41363), the Office of Management and Budget (OMB) issued revisions to 
the labor market area delineations on February 28, 2013 (based on 2010 
Decennial Census data), that included a number of significant changes 
such as new Core Based Statistical Areas (CBSAs), urban counties that 
became rural, rural counties that became urban, and existing CBSAs that 
were split apart (OMB Bulletin 13-01). This bulletin can be found at: 
https://obamawhitehouse.archives.gov/sites/default/files/omb/bulletins/2013/b13-01.pdf. In the FY 2015 IPPS/LTCH PPS final rule (79 FR 49950 
through 49985), for purposes of the IPPS, we adopted the use of the OMB 
statistical area delineations contained in OMB Bulletin No. 13-01, 
effective October 1, 2014. For purposes of the OPPS, in the CY 2015 
OPPS/ASC final rule with comment period (79 FR 66826 through 66828), we 
adopted the use of the OMB statistical area delineations contained in 
OMB Bulletin No. 13-01, effective January 1, 2015, beginning with the 
CY 2015 OPPS wage indexes. In the FY 2017 IPPS/LTCH PPS final rule (81 
FR 56913), we adopted revisions to statistical areas contained in OMB 
Bulletin No. 15-01, issued on July 15, 2015, which provided updates to 
and superseded OMB Bulletin No. 13-01 that was issued on February 28, 
2013. For purposes of the OPPS, in the CY 2017 OPPS/ASC final rule with 
comment period (81 FR 79598), we adopted the revisions to the OMB 
statistical area delineations contained in OMB Bulletin No. 15-01, 
effective January 1, 2017, beginning with the CY 2017 OPPS wage 
indexes. We believe that it is important for the OPPS to use the latest 
labor market area delineations available as soon as is reasonably 
possible in order to maintain a more accurate and up-to-date payment 
system that reflects the reality of population shifts and labor market 
conditions.
    On August 15, 2017, OMB issued OMB Bulletin No. 17-01, which 
provided updates to and superseded OMB Bulletin No. 15-01 that was 
issued on July 15, 2015. The attachments to OMB Bulletin No. 17-01 
provide detailed information on the update to the statistical areas 
since July 15, 2015, and are based on the application of the 2010 
Standards for Delineating Metropolitan and Micropolitan Statistical 
Areas to Census Bureau population estimates for July 1, 2014 and July 
1, 2015. In OMB Bulletin No. 17-01, OMB announced that one Micropolitan 
Statistical Area now qualifies as a Metropolitan Statistical Area. The 
new urban CBSA is as follows:
     Twin Falls, Idaho (CBSA 46300). This CBSA is comprised of 
the principal city of Twin Falls, Idaho in Jerome County, Idaho and 
Twin Falls County, Idaho.
    The OMB Bulletin No. 17-01 is available on the OMB website at 
https://www.whitehouse.gov/sites/whitehouse.gov/files/omb/bulletins/2017/b-17-01.pdf. In the FY 2019 IPPS/LTCH PPS proposed rule (83 FR 
20354), we noted that we did not have sufficient time to include this 
change in the computation of the proposed FY 2019 IPPS wage index, 
ratesetting, and Tables 2 and 3 associated with the FY 2019 IPPS/LTCH 
PPS proposed rule. We stated that this new CBSA may affect the IPPS 
budget neutrality factors and wage indexes, depending on whether the 
area is eligible for the rural floor and the impact of the overall 
payments of the hospital located in this new CBSA. As we did in the FY 
2019 IPPS/LTCH PPS proposed rule (83 FR 20354), in the CY 2019 OPPS/ASC 
proposed rule (83 FR 37075), we provided an estimate of this new area's 
wage index based on the average hourly wages for new CBSA 46300 and the 
national average hourly wages from the wage data for the proposed FY 
2019 IPPS wage index (described in section III.B. of the preamble of 
the FY 2019 IPPS/LTCH PPS proposed rule). Currently, provider 130002 is 
the only hospital located in Twin Falls County, Idaho, and there are no 
hospitals located in Jerome County, Idaho. Thus, the proposed wage 
index for CBSA 46300 was calculated using the average hourly wage data 
for one provider (provider 130002).
    In the CY 2019 OPPS/ASC proposed rule (83 FR 37075), we provided 
the proposed FY 2019 IPPS unadjusted and occupational mix adjusted 
national average hourly wages and the estimated CBSA average hourly 
wages. Taking the estimated average hourly wage of new CBSA 46300 and 
dividing by the proposed national average hourly wage resulted in the 
estimated wage indexes shown in the table in the proposed rule (83 FR 
37075), which is also provided below.
[GRAPHIC] [TIFF OMITTED] TR21NO18.016

    As we stated in the FY 2019 IPPS/LTCH PPS final rule (83 FR 41363), 
for the FY 2019 IPPS wage indexes, we used the OMB delineations that 
were adopted beginning with FY 2015 to calculate the area wage indexes, 
with updates as reflected in OMB Bulletin Nos. 13-01, 15-01, and 17-01, 
and incorporated the revision from OMB Bulletin No. 17-01 in the final 
FY 2019 IPPS wage index, ratesetting, and tables. Similarly, in the CY 
2019 OPPS/ASC proposed rule (82 FR 37075), for the proposed CY 2019 
OPPS wage indexes, we proposed to use the OMB

[[Page 58865]]

delineations that were adopted beginning with CY 2015 to calculate the 
area wage indexes, with updates as reflected in OMB Bulletin Nos. 13-
01, 15-01, and 17-01, and stated that we would incorporate the revision 
from OMB Bulletin No. 17-01 in the final CY 2019 OPPS wage index, 
ratesetting, and tables.
    We did not receive any public comments on our proposals. 
Accordingly, for the reasons discussed above and in the CY 2019 OPPS/
ASC proposed rule (83 FR 37074 through 37075), we are finalizing the 
proposal, without modification, to use the OMB delineations that were 
adopted beginning with CY 2015 to calculate the area wage indexes, with 
updates as reflected in OMB Bulletin Nos. 13-01, 15-01, and 17-01, and 
have incorporated the revision from OMB Bulletin No. 17-01 in the final 
CY 2019 OPPS wage index, ratesetting, and tables.
    CBSAs are made up of one or more constituent counties. Each CBSA 
and constituent county has its own unique identifying codes. The FY 
2018 IPPS/LTCH PPS final rule (82 FR 38130) discussed the two different 
lists of codes to identify counties: Social Security Administration 
(SSA) codes and Federal Information Processing Standard (FIPS) codes. 
Historically, CMS listed and used SSA and FIPS county codes to identify 
and crosswalk counties to CBSA codes for purposes of the IPPS and OPPS 
wage indexes. However, the SSA county codes are no longer being 
maintained and updated, although the FIPS codes continue to be 
maintained by the U.S. Census Bureau. The Census Bureau's most current 
statistical area information is derived from ongoing census data 
received since 2010; the most recent data are from 2015. In the FY 2018 
IPPS/LTCH PPS final rule (82 FR 38130), for purposes of crosswalking 
counties to CBSAs for the IPPS wage index, we finalized our proposal to 
discontinue the use of the SSA county codes and begin using only the 
FIPS county codes. Similarly, for the purposes of crosswalking counties 
to CBSAs for the OPPS wage index, in the CY 2018 OPPS/ASC final rule 
with comment period (82 FR 59260), we finalized our proposal to 
discontinue the use of SSA county codes and begin using only the FIPS 
county codes for the purposes of crosswalking counties to CBSAs for the 
OPPS wage index.
    The Census Bureau maintains a complete list of changes to counties 
or county equivalent entities on the website at: https://www.census.gov/geo/reference/county-changes.html. In our transition to 
using only FIPS codes for counties for the IPPS wage index, in the FY 
2018 IPPS/LTCH PPS final rule (82 FR 38130), we updated the FIPS codes 
used for crosswalking counties to CBSAs for the IPPS wage index 
effective October 1, 2017, to incorporate changes to the counties or 
county equivalent entities included in the Census Bureau's most recent 
list. We included these updates to calculate the area IPPS wage indexes 
in a manner that is generally consistent with the CBSA-based 
methodologies finalized in the FY 2005 IPPS final rule and the FY 2015 
IPPS/LTCH PPS final rule. In the CY 2018 OPPS/ASC final rule with 
comment period (82 FR 59261), we finalized our proposal to implement 
these FIPS code updates for the OPPS wage index effective January 1, 
2018, beginning with the CY 2018 OPPS wage indexes.
    In the CY 2019 OPPS/ASC proposed rule (83 FR 37075), we proposed to 
use the FY 2019 hospital IPPS post-reclassified wage index for urban 
and rural areas as the wage index for the OPPS to determine the wage 
adjustments for both the OPPS payment rate and the copayment 
standardized amount for CY 2019. Therefore, we stated in the proposed 
rule that any adjustments for the FY 2019 IPPS post-reclassified wage 
index would be reflected in the final CY 2019 OPPS wage index. (We 
refer readers to the FY 2019 IPPS/LTCH PPS proposed rule (83 FR 20353 
through 20377) and final rule (83 FR 41362 through 41390), and the 
proposed and final FY 2019 hospital wage index files posted on the CMS 
website.) We stated in the CY 2019 OPPS/ASC proposed rule (83 FR 37075) 
that we believe that using the IPPS wage index as the source of an 
adjustment factor for the OPPS is reasonable and logical, given the 
inseparable, subordinate status of the HOPD within the hospital 
overall.
    Summarized below are the comments we received regarding this 
proposal, along with our response.
    Comment: Several commenters opposed applying a budget neutrality 
adjustment for the rural floor under the OPPS on a national basis. The 
commenters believed applying budget neutrality on a national basis 
disadvantages hospitals in most States while benefiting hospitals in a 
few States that have taken advantage of the system where a rural 
hospital has a wage index higher than most or all urban hospitals in a 
State. The commenters stated that rural floor budget neutrality 
currently requires all wage indexes for hospitals throughout the Nation 
to be reduced. However, the commenters added, hospitals in those States 
that have higher wage indexes because of the rural floor are not 
substantially affected by the wage index reductions. One of the 
commenters supported calculating rural floor budget neutrality under 
the OPPS for each individual State.
    Response: We appreciate these comments. As we stated in the CY 2018 
OPPS/ASC final rule with comment period (82 FR 59259), we acknowledge 
that the application of the wage index and applicable wage index 
adjustments to OPPS payment rates may create distributional payment 
variations, especially within a budget neutral system. However, we 
continue to believe it is reasonable and appropriate to continue the 
current policy of applying budget neutrality for the rural floor under 
the OPPS on a national basis, consistent with the IPPS. We believe that 
hospital inpatient and outpatient departments are subject to the same 
labor cost environment, and therefore, the wage index and any 
applicable wage index adjustments (including the rural floor and rural 
floor budget neutrality) should be applied in the same manner under the 
IPPS and OPPS. Furthermore, we believe that applying the rural floor 
and rural floor budget neutrality in the same manner under the IPPS and 
OPPS is reasonable and logical, given the inseparable, subordinate 
status of the HOPD within the hospital overall. In addition, we believe 
the application of different wage indexes and wage index adjustments 
under the IPPS and OPPS would add a level of administrative complexity 
that is overly burdensome and unnecessary. Therefore, we are continuing 
the current policy of applying budget neutrality for the rural floor 
under the OPPS on a national basis, consistent with the IPPS.
    After consideration of the public comments we received, for the 
reasons discussed above and in the CY 2019 OPPS/ASC proposed rule (83 
FR 37075), we are finalizing our proposal, without modification, to use 
the FY 2019 hospital IPPS post-reclassified wage index for urban and 
rural areas as the wage index for the OPPS to determine the wage 
adjustments for both the OPPS payment rate and the copayment 
standardized amount for CY 2019. Therefore, any adjustments for the FY 
2019 IPPS post-reclassified wage index are reflected in the final CY 
2019 OPPS wage index. As stated earlier, we continue to believe that 
using the final fiscal year IPPS post-reclassified wage index, 
inclusive of any adjustments, as the wage index for the OPPS to 
determine the wage adjustments for both the OPPS payment rate and the 
copayment standardized amount is reasonable and logical, given the

[[Page 58866]]

inseparable, subordinate status of the HOPD within the hospital 
overall.
    Hospitals that are paid under the OPPS, but not under the IPPS, do 
not have an assigned hospital wage index under the IPPS. Therefore, for 
non-IPPS hospitals paid under the OPPS, it is our longstanding policy 
to assign the wage index that would be applicable if the hospital were 
paid under the IPPS, based on its geographic location and any 
applicable wage index adjustments. In the CY 2019 OPPS/ASC proposed 
rule (83 FR 37075), we proposed to continue this policy for CY 2019, 
and included a brief summary of the major proposed FY 2019 IPPS wage 
index policies and adjustments that we proposed to apply to these 
hospitals under the OPPS for CY 2019, which we have summarized below. 
We invited public comments on these proposals. We refer readers to the 
FY 2019 IPPS/LTCH PPS final rule (83 FR 41362 through 41390) for a 
detailed discussion of the changes to the FY 2019 IPPS wage indexes.
    It has been our longstanding policy to allow non-IPPS hospitals 
paid under the OPPS to qualify for the out-migration adjustment if they 
are located in a section 505 out-migration county (section 505 of the 
Medicare Prescription Drug, Improvement, and Modernization Act of 2003 
(MMA)). Applying this adjustment is consistent with our policy of 
adopting IPPS wage index policies for hospitals paid under the OPPS. We 
note that, because non-IPPS hospitals cannot reclassify, they are 
eligible for the out-migration wage adjustment if they are located in a 
section 505 out-migration county. This is the same out-migration 
adjustment policy that applies if the hospital were paid under the 
IPPS. For CY 2019, we proposed to continue our policy of allowing non-
IPPS hospitals paid under the OPPS to qualify for the out-migration 
adjustment if they are located in a section 505 out-migration county 
(section 505 of the MMA).
    We did not receive any public comments on these proposals. 
Therefore, for the reasons discussed above and in the CY 2019 OPPS/ASC 
proposed rule (83 FR 37075 through 37076), we are finalizing these 
proposals without modification.
    As stated earlier, in the FY 2015 IPPS/LTCH PPS final rule, we 
adopted the OMB labor market area delineations issued by OMB in OMB 
Bulletin No. 13-01 on February 28, 2013, based on standards published 
on June 28, 2010 (75 FR 37246 through 37252) and the 2010 Census data 
to delineate labor market areas for purposes of the IPPS wage index. 
For IPPS wage index purposes, for hospitals that were located in urban 
CBSAs in FY 2014 but were designated as rural under these revised OMB 
labor market area delineations, we generally assigned them the urban 
wage index value of the CBSA in which they were physically located for 
FY 2014 for a period of 3 fiscal years (79 FR 49957 through 49960). To 
be consistent, we applied the same policy to hospitals paid under the 
OPPS but not under the IPPS so that such hospitals maintained the wage 
index of the CBSA in which they were physically located for FY 2014 for 
3 calendar years (until December 31, 2017). Because this 3-year 
transition ended at the end of CY 2017, it was not applied beginning in 
CY 2018.
    In addition, in the FY 2019 IPPS/LTCH PPS proposed rule (83 FR 
20362 through 20363), we proposed not to extend the imputed floor 
policy under the IPPS for FY 2019 and subsequent fiscal years, and in 
the FY 2019 IPPS/LTCH PPS final rule (83 FR 41376 through 41380), we 
finalized this proposal. Similarly, in the CY 2019 OPPS/ASC proposed 
rule, we proposed not to extend the imputed floor policy under the OPPS 
beyond December 31, 2018 (the date the policy is set to expire). The 
comments we received on this proposal, along with our response, are 
summarized above. As discussed earlier, consistent with the FY 2019 
IPPS/LTCH PPS final rule, in this CY 2019 OPPS/ASC final rule with 
comment period, we are finalizing our proposal not to extend the 
imputed floor policy under the OPPS beyond December 31, 2018.
    For CMHCs, for CY 2019, we proposed to continue to calculate the 
wage index by using the post-reclassification IPPS wage index based on 
the CBSA where the CMHC is located. As with OPPS hospitals and for the 
same reasons, for CMHCs previously located in urban CBSAs that were 
designated as rural under the revised OMB labor market area 
delineations in OMB Bulletin No. 13-01, we finalized a policy to 
maintain the urban wage index value of the CBSA in which they were 
physically located for CY 2014 for 3 calendar years (until December 31, 
2017). Because this 3-year transition ended at the end of CY 2017, it 
was not applied beginning in CY 2018. We proposed that the wage index 
that would apply to CMHCs for CY 2019 would include the rural floor 
adjustment, but would not include the imputed floor adjustment because, 
as discussed above, we proposed to not extend the imputed floor policy 
beyond December 31, 2018. Also, we proposed that the wage index that 
would apply to CMHCs would not include the out-migration adjustment 
because that adjustment only applies to hospitals.
    We did not receive any public comments on these proposals. 
Therefore, for the reasons discussed above and in the CY 2019 OPPS/ASC 
proposed rule (83 FR 37076), we are finalizing these proposals without 
modification.
    Table 2 associated with the FY 2019 IPPS/LTCH PPS final rule 
(available via the internet on the CMS website at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/) 
identifies counties eligible for the out-migration adjustment and IPPS 
hospitals that will receive the adjustment for FY 2019. We are 
including the out-migration adjustment information from Table 2 
associated with the FY 2019 IPPS/LTCH PPS final rule as Addendum L to 
this final rule with comment period with the addition of non-IPPS 
hospitals that will receive the section 505 out-migration adjustment 
under the CY 2019 OPPS. Addendum L is available via the internet on the 
CMS website. We refer readers to the CMS website for the OPPS at: 
https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/HospitalOutpatientPPS/. At this link, readers will find a 
link to the final FY 2019 IPPS wage index tables and Addendum L.

D. Statewide Average Default Cost-to-Charge Ratios (CCRs)

    In addition to using CCRs to estimate costs from charges on claims 
for ratesetting, CMS uses overall hospital-specific CCRs calculated 
from the hospital's most recent cost report to determine outlier 
payments, payments for pass-through devices, and monthly interim 
transitional corridor payments under the OPPS during the PPS year. MACs 
cannot calculate a CCR for some hospitals because there is no cost 
report available. For these hospitals, CMS uses the statewide average 
default CCRs to determine the payments mentioned earlier until a 
hospital's MAC is able to calculate the hospital's actual CCR from its 
most recently submitted Medicare cost report. These hospitals include, 
but are not limited to, hospitals that are new, hospitals that have not 
accepted assignment of an existing hospital's provider agreement, and 
hospitals that have not yet submitted a cost report. CMS also uses the 
statewide average default CCRs to determine payments for hospitals that 
appear to have a biased CCR (that is, the CCR falls outside the 
predetermined ceiling threshold for a valid CCR) or for hospitals in 
which the most recent cost report reflects an all-

[[Page 58867]]

inclusive rate status (Medicare Claims Processing Manual (Pub. 100-04), 
Chapter 4, Section 10.11).
    In the CY 2019 OPPS/ASC proposed rule (83 FR 37076), we proposed to 
update the default ratios for CY 2019 using the most recent cost report 
data. We discussed our policy for using default CCRs, including setting 
the ceiling threshold for a valid CCR, in the CY 2009 OPPS/ASC final 
rule with comment period (73 FR 68594 through 68599) in the context of 
our adoption of an outlier reconciliation policy for cost reports 
beginning on or after January 1, 2009. For detail on our process for 
calculating the statewide average CCRs, we referred readers to the CY 
2019 OPPS proposed rule Claims Accounting Narrative that is posted on 
the CMS website. Table 5 published in the proposed rule (83 FR 37076 
through 37078) listed the proposed statewide average default CCRs for 
OPPS services furnished on or after January 1, 2019, based on proposed 
rule data.
    We did not receive any public comments on our proposal to use 
statewide average default CCRs if a MAC cannot calculate a CCR for a 
hospital and to use these CCRs to adjust charges to costs on claims 
data for setting the final CY 2019 OPPS relative payment weights. 
Therefore, we are finalizing our proposal without modification.
    Table 9 below lists the statewide average default CCRs for OPPS 
services furnished on or after January 1, 2019, based on final rule 
data.

BILLING CODE 4120-01-P

[[Page 58868]]

[GRAPHIC] [TIFF OMITTED] TR21NO18.017


[[Page 58869]]


[GRAPHIC] [TIFF OMITTED] TR21NO18.018


[[Page 58870]]


[GRAPHIC] [TIFF OMITTED] TR21NO18.019

BILLING CODE 4120-01-C

E. Adjustment for Rural Sole Community Hospitals (SCHs) and Essential 
Access Community Hospitals (EACHs) Under Section 1833(t)(13)(B) of the 
Act for CY 2019

    In the CY 2006 OPPS final rule with comment period (70 FR 68556), 
we finalized a payment increase for rural sole community hospitals 
(SCHs) of 7.1 percent for all services and procedures paid under the 
OPPS, excluding drugs, biologicals, brachytherapy sources, and devices 
paid under the pass-through payment policy, in accordance with section 
1833(t)(13)(B) of the Act, as added by section 411 of the Medicare 
Prescription Drug, Improvement, and Modernization Act of 2003 (MMA) 
(Pub. L. 108-173). Section 1833(t)(13) of the Act provided the 
Secretary the authority to make an adjustment to OPPS payments for 
rural hospitals, effective January 1, 2006, if justified by a study of 
the difference in costs by APC between hospitals in rural areas and 
hospitals in urban areas. Our analysis

[[Page 58871]]

showed a difference in costs for rural SCHs. Therefore, for the CY 2006 
OPPS, we finalized a payment adjustment for rural SCHs of 7.1 percent 
for all services and procedures paid under the OPPS, excluding 
separately payable drugs and biologicals, brachytherapy sources, and 
devices paid under the pass-through payment policy, in accordance with 
section 1833(t)(13)(B) of the Act.
    In the CY 2007 OPPS/ASC final rule with comment period (71 FR 68010 
and 68227), for purposes of receiving this rural adjustment, we revised 
Sec.  419.43(g) of the regulations to clarify that essential access 
community hospitals (EACHs) also are eligible to receive the rural SCH 
adjustment, assuming these entities otherwise meet the rural adjustment 
criteria. Currently, two hospitals are classified as EACHs, and as of 
CY 1998, under section 4201(c) of Pub. L. 105-33, a hospital can no 
longer become newly classified as an EACH.
    This adjustment for rural SCHs is budget neutral and applied before 
calculating outlier payments and copayments. We stated in the CY 2006 
OPPS final rule with comment period (70 FR 68560) that we would not 
reestablish the adjustment amount on an annual basis, but we may review 
the adjustment in the future and, if appropriate, would revise the 
adjustment. We provided the same 7.1 percent adjustment to rural SCHs, 
including EACHs, again in CYs 2008 through 2018. Further, in the CY 
2009 OPPS/ASC final rule with comment period (73 FR 68590), we updated 
the regulations at Sec.  419.43(g)(4) to specify, in general terms, 
that items paid at charges adjusted to costs by application of a 
hospital-specific CCR are excluded from the 7.1 percent payment 
adjustment.
    In the CY 2019 OPPS/ASC proposed rule (83 FR 37078), for the CY 
2019 OPPS, we proposed to continue the current policy of a 7.1 percent 
payment adjustment that is done in a budget neutral manner for rural 
SCHs, including EACHs, for all services and procedures paid under the 
OPPS, excluding separately payable drugs and biologicals, devices paid 
under the pass-through payment policy, and items paid at charges 
reduced to costs. We invited public comment on our proposal.
    In addition, we proposed to maintain this 7.1 percent payment 
adjustment for the years after CY 2019 until we identify data in the 
future that would support a change to this payment adjustment. We 
invited public comments on our proposal.
    Comment: Several commenters supported the proposal to continue the 
7.1 percent payment adjustment for rural SCHs, including EACHs, for all 
services and procedures paid under the OPPS, excluding separately 
payable drugs and biologicals, devices paid under the pass-through 
payment policy, and items paid at charges reduced to costs. A few 
commenters explicitly supported the part of the proposal that would 
allow the adjustment to continue after CY 2019 until CMS identifies 
data that would cause CMS to reassess the adjustment. These commenters 
approved of having more certainty about whether the rural SCH 
adjustment would be in effect on an ongoing basis, because it would 
help hospitals covered by the adjustment improve their budget 
forecasting based on expected revenues.
    Response: We appreciate the commenters' support.
    Comment: One commenter suggested that CMS further examine whether 
the payment adjustment for rural SCHs, including EACHs, should continue 
to be 7.1 percent. The commenter noted the rate of the payment 
adjustment was based on data analyses that are more than 10 years old.
    Response: While the data for the initial analyses are more than 10 
years old, we periodically review the calculations used to generate the 
rural SCHs and EACHs adjustment. For any given year, the level of 
increased costs experienced by rural SCH and EACH may be higher or 
lower than the current 7.1 percent adjustment. Since being established 
in CY 2008, we believe the payment increase of 7.1 percent has 
continued to reasonably reflect the increased costs that rural SCHs and 
EACHs face when providing outpatient hospital services based on 
regression analyses performed on the claims data.
    Comment: Some commenters requested that CMS expand the payment 
adjustment for rural SCHs and EACHs to additional types of hospitals. 
One commenter requested that the payment adjustment apply to include 
urban SCHs because, according to the commenter, urban SCHs care for 
patient populations similar to rural SCHs and EACHs, face similar 
financial challenges to rural SCHs and EACHs, and act as safety net 
providers for rural areas despite their designation as urban providers. 
Another commenter requested that the payment adjustment also apply to 
Medicare-dependent hospitals (MDHs) because, according to the 
commenter, these hospitals face similar financial challenges to rural 
SCHs and EACHs, and MDHs play a similar safety net role to rural SCHs 
and EACHs, especially for Medicare. One commenter requested that 
payment rates for OPPS services for all rural hospitals be increased to 
reduce financial vulnerability for rural hospitals related to the high 
share of Medicare and Medicaid beneficiaries they serve.
    Response: We thank the commenters for their comments. However, the 
analysis we did to compare costs of urban providers to those of rural 
providers did not support an add-on adjustment for providers other than 
rural SCHs and EACHs, and our follow-up analyses performed in recent 
years have not shown differences in costs for all services for any of 
the additional types of providers mentioned by the commenters. 
Accordingly, we do not believe we currently have a basis to expand the 
payment adjustment to any other providers other than rural SCHs and 
EACHs.
    After consideration of the public comments we received, we are 
implementing our proposals, without modification, to continue the 
current policy of a 7.1 percent payment adjustment that is done in a 
budget neutral manner for rural SCHs, including EACHs, for all services 
and procedures paid under the OPPS, excluding separately payable drugs 
and biologicals, devices paid under the pass-through payment policy, 
and items paid at charges reduced to costs. In addition, we will 
maintain this 7.1 percent payment adjustment for the years after CY 
2019 until our data support a change to this payment adjustment.

F. Payment Adjustment for Certain Cancer Hospitals for CY 2019

1. Background
    Since the inception of the OPPS, which was authorized by the 
Balanced Budget Act of 1997 (BBA) (Pub. L. 105-33), Medicare has paid 
the 11 hospitals that meet the criteria for cancer hospitals identified 
in section 1886(d)(1)(B)(v) of the Act under the OPPS for covered 
outpatient hospital services. These cancer hospitals are exempted from 
payment under the IPPS. With the Medicare, Medicaid and SCHIP Balanced 
Budget Refinement Act of 1999 (Pub. L. 106-113), Congress established 
section 1833(t)(7) of the Act, ``Transitional Adjustment to Limit 
Decline in Payment,'' to determine OPPS payments to cancer and 
children's hospitals based on their pre-BBA payment amount (often 
referred to as ``held harmless'').
    As required under section 1833(t)(7)(D)(ii) of the Act, a cancer 
hospital receives the full amount of the difference between payments 
for covered outpatient services under the OPPS and a ``pre-BBA 
amount.'' That is, cancer hospitals are permanently held harmless to 
their ``pre-BBA amount,''

[[Page 58872]]

and they receive transitional outpatient payments (TOPs) or hold 
harmless payments to ensure that they do not receive a payment that is 
lower in amount under the OPPS than the payment amount they would have 
received before implementation of the OPPS, as set forth in section 
1833(t)(7)(F) of the Act. The ``pre-BBA amount'' is the product of the 
hospital's reasonable costs for covered outpatient services occurring 
in the current year and the base payment-to-cost ratio (PCR) for the 
hospital defined in section 1833(t)(7)(F)(ii) of the Act. The ``pre-BBA 
amount'' and the determination of the base PCR are defined at 42 CFR 
419.70(f). TOPs are calculated on Worksheet E, Part B, of the Hospital 
Cost Report or the Hospital Health Care Complex Cost Report (Form CMS-
2552-96 or Form CMS-2552-10, respectively), as applicable each year. 
Section 1833(t)(7)(I) of the Act exempts TOPs from budget neutrality 
calculations.
    Section 3138 of the Affordable Care Act amended section 1833(t) of 
the Act by adding a new paragraph (18), which instructs the Secretary 
to conduct a study to determine if, under the OPPS, outpatient costs 
incurred by cancer hospitals described in section 1886(d)(1)(B)(v) of 
the Act with respect to APC groups exceed outpatient costs incurred by 
other hospitals furnishing services under section 1833(t) of the Act, 
as determined appropriate by the Secretary. Section 1833(t)(18)(A) of 
the Act requires the Secretary to take into consideration the cost of 
drugs and biologicals incurred by cancer hospitals and other hospitals. 
Section 1833(t)(18)(B) of the Act provides that, if the Secretary 
determines that cancer hospitals' costs are higher than those of other 
hospitals, the Secretary shall provide an appropriate adjustment under 
section 1833(t)(2)(E) of the Act to reflect these higher costs. In 
2011, after conducting the study required by section 1833(t)(18)(A) of 
the Act, we determined that outpatient costs incurred by the 11 
specified cancer hospitals were greater than the costs incurred by 
other OPPS hospitals. For a complete discussion regarding the cancer 
hospital cost study, we refer readers to the CY 2012 OPPS/ASC final 
rule with comment period (76 FR 74200 through 74201).
    Based on these findings, we finalized a policy to provide a payment 
adjustment to the 11 specified cancer hospitals that reflects their 
higher outpatient costs, as discussed in the CY 2012 OPPS/ASC final 
rule with comment period (76 FR 74202 through 74206). Specifically, we 
adopted a policy to provide additional payments to the cancer hospitals 
so that each cancer hospital's final PCR for services provided in a 
given calendar year is equal to the weighted average PCR (which we 
refer to as the ``target PCR'') for other hospitals paid under the 
OPPS. The target PCR is set in advance of the calendar year and is 
calculated using the most recently submitted or settled cost report 
data that are available at the time of final rulemaking for the 
calendar year. The amount of the payment adjustment is made on an 
aggregate basis at cost report settlement. We note that the changes 
made by section 1833(t)(18) of the Act do not affect the existing 
statutory provisions that provide for TOPs for cancer hospitals. The 
TOPs are assessed, as usual, after all payments, including the cancer 
hospital payment adjustment, have been made for a cost reporting 
period. For CYs 2012 and 2013, the target PCR for purposes of the 
cancer hospital payment adjustment was 0.91. For CY 2014, the target 
PCR for purposes of the cancer hospital payment adjustment was 0.89. 
For CY 2015, the target PCR was 0.90. For CY 2016, the target PCR was 
0.92, as discussed in the CY 2016 OPPS/ASC final rule with comment 
period (80 FR 70362 through 70363). For CY 2017, the target PCR was 
0.91, as discussed in the CY 2017 OPPS/ASC final rule with comment 
period (81 FR 79603 through 79604). For CY 2018, the target PCR was 
0.88, as discussed in the CY 2018 OPPS/ASC final rule with comment 
period (82 FR 59265 through 59266).
2. Policy for CY 2019
    Section 16002(b) of the 21st Century Cures Act (Pub. L. 114-255) 
amended section 1833(t)(18) of the Act by adding subparagraph (C), 
which requires that in applying 42 CFR 419.43(i) (that is, the payment 
adjustment for certain cancer hospitals) for services furnished on or 
after January 1, 2018, the target PCR adjustment be reduced by 1.0 
percentage point less than what would otherwise apply. Section 16002(b) 
also provides that, in addition to the percentage reduction, the 
Secretary may consider making an additional percentage point reduction 
to the target PCR that takes into account payment rates for applicable 
items and services described under section 1833(t)(21)(C) of the Act 
for hospitals that are not cancer hospitals described under section 
1886(d)(1)(B)(v) of the Act. Further, in making any budget neutrality 
adjustment under section 1833(t) of the Act, the Secretary shall not 
take into account the reduced expenditures that result from application 
of section 1833(t)(18)(C) of the Act.
    In the CY 2019 OPPS/ASC proposed rule (83 FR 37079), for CY 2019, 
we proposed to provide additional payments to the 11 specified cancer 
hospitals so that each cancer hospital's final PCR is equal to the 
weighted average PCR (or ``target PCR'') for the other OPPS hospitals 
using the most recent submitted or settled cost report data that were 
available at the time of the development of the proposed rule, reduced 
by 1.0 percentage point, to comply with section 16002(b) of the 21st 
Century Cures Act. We invited public comment on our proposal.
    We did not propose an additional reduction beyond the 1.0 
percentage point reduction required by section 16002(b) for CY 2019. To 
calculate the proposed CY 2019 target PCR, we used the same extract of 
cost report data from HCRIS, as discussed in section II.A. of the 
proposed rule and this final rule with comment period, used to estimate 
costs for the CY 2019 OPPS. Using these cost report data, we included 
data from Worksheet E, Part B, for each hospital, using data from each 
hospital's most recent cost report, whether as submitted or settled.
    We then limited the dataset to the hospitals with CY 2017 claims 
data that we used to model the impact of the proposed CY 2019 APC 
relative payment weights (3,676 hospitals) because it is appropriate to 
use the same set of hospitals that are being used to calibrate the 
modeled CY 2019 OPPS. The cost report data for the hospitals in this 
dataset were from cost report periods with fiscal year ends ranging 
from 2014 to 2017. We then removed the cost report data of the 43 
hospitals located in Puerto Rico from our dataset because we did not 
believe their cost structure reflected the costs of most hospitals paid 
under the OPPS, and, therefore, their inclusion may bias the 
calculation of hospital-weighted statistics. We also removed the cost 
report data of 18 hospitals because these hospitals had cost report 
data that were not complete (missing aggregate OPPS payments, missing 
aggregate cost data, or missing both), so that all cost reports in the 
study would have both the payment and cost data necessary to calculate 
a PCR for each hospital, leading to a proposed analytic file of 3,615 
hospitals with cost report data.
    Using this smaller dataset of cost report data, we estimated that, 
on average, the OPPS payments to other hospitals furnishing services 
under the OPPS were approximately 89 percent of reasonable cost 
(weighted average PCR of 0.89). Therefore, after applying the

[[Page 58873]]

1.0 percentage point reduction, as required by section 16002(b) of the 
21st Century Cures Act, we proposed that the payment amount associated 
with the cancer hospital payment adjustment to be determined at cost 
report settlement would be the additional payment needed to result in a 
proposed target PCR equal to 0.88 for each cancer hospital.
    We did not receive any public comments on our proposals. Therefore, 
we are finalizing our proposed cancer hospital payment adjustment 
methodology without modification. For this final rule with comment 
period, we are using the most recent cost report data through June 30, 
2018 to update the adjustment. This update yields a target PCR of 0.89. 
We limited the dataset to the hospitals with CY 2017 claims data that 
we used to model the impact of the CY 2019 APC relative payment weights 
(3,696 hospitals) because it is appropriate to use the same set of 
hospitals that we are using to calibrate the modeled CY 2019 OPPS. The 
cost report data for the hospitals in the dataset were from cost report 
periods with fiscal year ends ranging from 2010 to 2018. We then 
removed the cost report data of the 46 hospitals located in Puerto Rico 
from our dataset because we do not believe that their cost structure 
reflects the costs of most hospitals paid under the OPPS and, 
therefore, their inclusion may bias the calculation of hospital-
weighted statistics. We also removed the cost report data of 22 
hospitals because these hospitals had cost report data that were not 
complete (missing aggregate OPPS payments, missing aggregate cost data, 
or missing both), so that all cost reports in the study would have both 
the payment and cost data necessary to calculate a PCR for each 
hospital, leading to an analytic file of 3,628 hospitals with cost 
report data.
    Using this smaller dataset of cost report data, we estimated a 
target PCR of 0.89. Therefore, after applying the 1.0 percentage point 
reduction as required by section 16002(b) of the 21st Century Cures 
Act, we are finalizing that the payment amount associated with the 
cancer hospital payment adjustment to be determined at cost report 
settlement will be the additional payment needed to result in a PCR 
equal to 0.88 for each cancer hospital. Table 10 below shows the 
estimated percentage increase in OPPS payments to each cancer hospital 
for CY 2019, due to the cancer hospital payment adjustment policy. The 
actual amount of the CY 2019 cancer hospital payment adjustment for 
each cancer hospital will be determined at cost report settlement and 
will depend on each hospital's CY 2019 payments and costs. We note that 
the requirements contained in section 1833(t)(18) of the Act do not 
affect the existing statutory provisions that provide for TOPs for 
cancer hospitals. The TOPs will be assessed, as usual, after all 
payments, including the cancer hospital payment adjustment, have been 
made for a cost reporting period.
BILLING CODE 4120-01-P
[GRAPHIC] [TIFF OMITTED] TR21NO18.020


[[Page 58874]]


BILLING CODE 4120-01-C

G. Hospital Outpatient Outlier Payments

1. Background
    The OPPS provides outlier payments to hospitals to help mitigate 
the financial risk associated with high-cost and complex procedures, 
where a very costly service could present a hospital with significant 
financial loss. As explained in the CY 2015 OPPS/ASC final rule with 
comment period (79 FR 66832 through 66834), we set our projected target 
for aggregate outlier payments at 1.0 percent of the estimated 
aggregate total payments under the OPPS for the prospective year. 
Outlier payments are provided on a service-by-service basis when the 
cost of a service exceeds the APC payment amount multiplier threshold 
(the APC payment amount multiplied by a certain amount) as well as the 
APC payment amount plus a fixed-dollar amount threshold (the APC 
payment plus a certain amount of dollars). In CY 2018, the outlier 
threshold was met when the hospital's cost of furnishing a service 
exceeded 1.75 times (the multiplier threshold) the APC payment amount 
and exceeded the APC payment amount plus $4,150 (the fixed-dollar 
amount threshold) (82 FR 59267 through 59268). If the cost of a service 
exceeds both the multiplier threshold and the fixed-dollar threshold, 
the outlier payment is calculated as 50 percent of the amount by which 
the cost of furnishing the service exceeds 1.75 times the APC payment 
amount. Beginning with CY 2009 payments, outlier payments are subject 
to a reconciliation process similar to the IPPS outlier reconciliation 
process for cost reports, as discussed in the CY 2009 OPPS/ASC final 
rule with comment period (73 FR 68594 through 68599).
    It has been our policy to report the actual amount of outlier 
payments as a percent of total spending in the claims being used to 
model the OPPS. Our estimate of total outlier payments as a percent of 
total CY 2017 OPPS payments, using CY 2017 claims available for the CY 
2019 OPPS/ASC proposed rule (83 FR 37080 through 37081), was 
approximately 1.0 percent of the total aggregated OPPS payments. 
Therefore, for CY 2017, we estimated that we paid the outlier target of 
1.0 percent of total aggregated OPPS payments. Using an updated claims 
dataset for this CY 2019 OPPS final rule with comment period, we 
estimate that we paid approximately 1.12 percent of the total 
aggregated OPPS payments in outliers for CY 2017.
    For the CY 2019 OPPS/ASC proposed rule, using CY 2017 claims data 
and CY 2018 payment rates, we estimate that the aggregate outlier 
payments for CY 2018 would be approximately 1.02 percent of the total 
CY 2018 OPPS payments. We provided estimated CY 2019 outlier payments 
for hospitals and CMHCs with claims included in the claims data that we 
used to model impacts in the Hospital-Specific Impacts--Provider-
Specific Data file on the CMS website at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/HospitalOutpatientPPS/.
2. Outlier Calculation for CY 2019
    In the CY 2019 OPPS/ASC proposed rule (83 FR 37080 through 37081), 
for CY 2019, we proposed to continue our policy of estimating outlier 
payments to be 1.0 percent of the estimated aggregate total payments 
under the OPPS. We proposed that a portion of that 1.0 percent, an 
amount equal to less than 0.01 percent of outlier payments (or 0.0001 
percent of total OPPS payments), would be allocated to CMHCs for PHP 
outlier payments. This is the amount of estimated outlier payments that 
would result from the proposed CMHC outlier threshold as a proportion 
of total estimated OPPS outlier payments. As discussed in section 
VIII.C. of the CY 2019 OPPS/ASC proposed rule (83 FR 37134 through 
37136), we proposed to continue our longstanding policy that if a 
CMHC's cost for partial hospitalization services, paid under APC 5853 
(Partial Hospitalization for CMHCs), exceeds 3.40 times the payment 
rate for proposed APC 5853, the outlier payment would be calculated as 
50 percent of the amount by which the cost exceeds 3.40 times the 
proposed APC 5853 payment rate.
    For further discussion of CMHC outlier payments, we refer readers 
to section VIII.C. of the proposed rule and this final rule with 
comment period.
    To ensure that the estimated CY 2019 aggregate outlier payments 
would equal 1.0 percent of estimated aggregate total payments under the 
OPPS, we proposed that the hospital outlier threshold be set so that 
outlier payments would be triggered when a hospital's cost of 
furnishing a service exceeds 1.75 times the APC payment amount and 
exceeds the APC payment amount plus $4,600.
    We calculated the proposed fixed-dollar threshold of $4,600 using 
the standard methodology most recently used for CY 2018 (82 FR 59267 
through 59268). For purposes of estimating outlier payments for the 
proposed rule, we used the hospital-specific overall ancillary CCRs 
available in the April 2018 update to the Outpatient Provider-Specific 
File (OPSF). The OPSF contains provider-specific data, such as the most 
current CCRs, which are maintained by the MACs and used by the OPPS 
Pricer to pay claims. The claims that we use to model each OPPS update 
lag by 2 years.
    In order to estimate the CY 2019 hospital outlier payments for the 
proposed rule, we inflated the charges on the CY 2017 claims using the 
same inflation factor of 1.085868 that we used to estimate the IPPS 
fixed-dollar outlier threshold for the FY 2019 IPPS/LTCH PPS proposed 
rule (83 FR 20581). We used an inflation factor of 1.04205 to estimate 
CY 2018 charges from the CY 2017 charges reported on CY 2017 claims. 
The methodology for determining this charge inflation factor is 
discussed in the FY 2018 IPPS/LTCH PPS final rule (82 FR 20581). As we 
stated in the CY 2005 OPPS final rule with comment period (69 FR 
65845), we believe that the use of these charge inflation factors is 
appropriate for the OPPS because, with the exception of the inpatient 
routine service cost centers, hospitals use the same ancillary and 
outpatient cost centers to capture costs and charges for inpatient and 
outpatient services.
    As noted in the CY 2007 OPPS/ASC final rule with comment period (71 
FR 68011), we are concerned that we could systematically overestimate 
the OPPS hospital outlier threshold if we did not apply a CCR inflation 
adjustment factor. Therefore, we proposed to apply the same CCR 
inflation adjustment factor that we proposed to apply for the FY 2019 
IPPS outlier calculation to the CCRs used to simulate the proposed CY 
2019 OPPS outlier payments to determine the fixed-dollar threshold. 
Specifically, for CY 2019, we proposed to apply an adjustment factor of 
0.987842 to the CCRs that were in the April 2018 OPSF to trend them 
forward from CY 2018 to CY 2019. The methodology for calculating the 
proposed adjustment is discussed in the FY 2019 IPPS/LTCH PPS proposed 
rule (83 FR 20582).
    To model hospital outlier payments for the proposed rule, we 
applied the overall CCRs from the April 2018 OPSF after adjustment 
(using the proposed CCR inflation adjustment factor of 0.987842 to 
approximate CY 2019 CCRs) to charges on CY 2017 claims that were 
adjusted (using the proposed charge inflation factor of 1.085868 to 
approximate CY 2019 charges). We simulated aggregated CY 2019 hospital 
outlier payments using these costs for several different fixed-dollar 
thresholds, holding the 1.75 multiplier threshold

[[Page 58875]]

constant and assuming that outlier payments would continue to be made 
at 50 percent of the amount by which the cost of furnishing the service 
would exceed 1.75 times the APC payment amount, until the total outlier 
payments equaled 1.0 percent of aggregated estimated total CY 2019 OPPS 
payments. We estimated that a proposed fixed-dollar threshold of 
$4,600, combined with the proposed multiplier threshold of 1.75 times 
the APC payment rate, would allocate 1.0 percent of aggregated total 
OPPS payments to outlier payments. For CMHCs, we proposed that, if a 
CMHC's cost for partial hospitalization services, paid under APC 5853, 
exceeds 3.40 times the payment rate for APC 5853, the outlier payment 
would be calculated as 50 percent of the amount by which the cost 
exceeds 3.40 times the APC 5853 payment rate.
    Section 1833(t)(17)(A) of the Act, which applies to hospitals, as 
defined under section 1886(d)(1)(B) of the Act, requires that hospitals 
that fail to report data required for the quality measures selected by 
the Secretary, in the form and manner required by the Secretary under 
section 1833(t)(17)(B) of the Act, incur a 2.0 percentage point 
reduction to their OPD fee schedule increase factor; that is, the 
annual payment update factor. The application of a reduced OPD fee 
schedule increase factor results in reduced national unadjusted payment 
rates that will apply to certain outpatient items and services 
furnished by hospitals that are required to report outpatient quality 
data and that fail to meet the Hospital OQR Program requirements. For 
hospitals that fail to meet the Hospital OQR Program requirements, as 
we proposed, we are continuing the policy that we implemented in CY 
2010 that the hospitals' costs will be compared to the reduced payments 
for purposes of outlier eligibility and payment calculation. For more 
information on the Hospital OQR Program, we referred readers to section 
XIII. of this final rule with comment period.
    Comment: One commenter expressed concern that, due to the increase 
in the proposed fixed-dollar threshold to $4,600 relative to the 
previous CY 2018 fixed-dollar outlier threshold of $4,150, the drastic 
reduction in outlier payments would have an adverse effect on access to 
services for Medicare beneficiaries. Therefore, the commenter requested 
that the threshold be transitioned over a 3-year period.
    Response: As indicated earlier, we introduced a fixed-dollar 
threshold in order to better target outlier payments to those high-cost 
and complex procedures where a very costly service could present a 
hospital with significant financial loss. We maintain the target 
outlier percentage of 1.0 percent of estimated aggregate total payment 
under the OPPS and have a fixed-dollar threshold so that OPPS outlier 
payments are made only when the hospital would experience a significant 
loss for furnishing a particular service. The methodology we use to 
calculate the fixed-dollar threshold for the prospective payment year 
factors is based on several data inputs that may change from prior 
payment years. For instance, updated hospital CCR data and changes to 
the OPPS payment methodology influence projected outlier payments in 
the prospective year.
    We do not believe that it is appropriate to transition towards 
implementation of the CY 2019 OPPS fixed-dollar outlier threshold in 
the manner described by the commenter. The fixed-dollar outlier 
threshold is specifically developed in order to best estimate aggregate 
outlier payments of 1 percent of the OPPS. In addition, transitioning 
in this suggested manner would remove the consideration of updated 
data, which is critical in best estimating the fixed-dollar threshold 
that would result in total OPPS outliers being 1 percent of aggregate 
OPPS payments. Finally, we note that the increase in the fixed-dollar 
outlier threshold does not necessarily result in a decrease in 
aggregate OPPS outlier payments. Rather, it ensures that the aggregate 
pool remains at 1 percent and that outlier payments are directed 
towards the high cost and complex procedures associated with potential 
financial risk.
    After consideration of the public comment we received, we are 
finalizing our proposal, without modification, to continue our policy 
of estimating outlier payments to be 1.0 percent of the estimated 
aggregate total payments under the OPPS and to use our established 
methodology to set the OPPS outlier fixed-dollar loss threshold for CY 
2019.
3. Final Outlier Calculation
    Consistent with historical practice, we used updated data for this 
final rule with comment period for outlier calculations. For CY 2019, 
we are applying the overall CCRs from the October 2018 OPSF file after 
adjustment (using the CCR inflation adjustment factor of 0.9813 to 
approximate CY 2019 CCRs) to charges on CY 2017 claims that were 
adjusted using a charge inflation factor of 1.0434 to approximate CY 
2019 charges. These are the same CCR adjustment and charge inflation 
factors that were used to set the IPPS fixed-dollar thresholds for the 
FY 2019 IPPS/LTCH PPS final rule (83 FR 41722). We simulated aggregated 
CY 2019 hospital outlier payments using these costs for several 
different fixed-dollar thresholds, holding the 1.75 multiple-threshold 
constant and assuming that outlier payments will continue to be made at 
50 percent of the amount by which the cost of furnishing the service 
would exceed 1.75 times the APC payment amount, until the total outlier 
payment equaled 1.0 percent of aggregated estimated total CY 2019 OPPS 
payments. We estimate that a fixed-dollar threshold of $4,825 combined 
with the multiple threshold of 1.75 times the APC payment rate, will 
allocated the 1.0 percent of aggregated total OPPS payments to outlier 
payments.
    For CMHCs, if a CMHC's cost for partial hospitalization services, 
paid under PAC 5853, exceeds 3.40 times the payment rate the outlier 
payment will be calculated as 50 percent of the amount by which the 
cost exceeds 3.40 times APC 5853.

H. Calculation of an Adjusted Medicare Payment From the National 
Unadjusted Medicare Payment

    The basic methodology for determining prospective payment rates for 
HOPD services under the OPPS is set forth in existing regulations at 42 
CFR part 419, subparts C and D. For this CY 2019 OPPS/ASC final rule 
with comment period, the payment rate for most services and procedures 
for which payment is made under the OPPS is the product of the 
conversion factor calculated in accordance with section II.B. of this 
final rule with comment period and the relative payment weight 
determined under section II.A. of this final rule with comment period. 
Therefore, the national unadjusted payment rate for most APCs contained 
in Addendum A to this final rule with comment period (which is 
available via the internet on the CMS website) and for most HCPCS codes 
to which separate payment under the OPPS has been assigned in Addendum 
B to this final rule with comment period (which is available via the 
internet on the CMS website) was calculated by multiplying the CY 2019 
scaled weight for the APC by the CY 2019 conversion factor.
    We note that section 1833(t)(17) of the Act, which applies to 
hospitals as defined under section 1886(d)(1)(B) of the Act, requires 
that hospitals that fail to submit data required to be submitted on 
quality measures selected by the Secretary, in the form and manner and 
at a time specified by the Secretary, incur a reduction of 2.0 
percentage

[[Page 58876]]

points to their OPD fee schedule increase factor, that is, the annual 
payment update factor. The application of a reduced OPD fee schedule 
increase factor results in reduced national unadjusted payment rates 
that apply to certain outpatient items and services provided by 
hospitals that are required to report outpatient quality data and that 
fail to meet the Hospital OQR Program (formerly referred to as the 
Hospital Outpatient Quality Data Reporting Program (HOP QDRP)) 
requirements. For further discussion of the payment reduction for 
hospitals that fail to meet the requirements of the Hospital OQR 
Program, we refer readers to section XIII. of this final rule with 
comment period.
    In the CY 2019 OPPS/ASC proposed rule (83 FR 37082), we 
demonstrated the steps to determine the APC payments that will be made 
in a calendar year under the OPPS to a hospital that fulfills the 
Hospital OQR Program requirements and to a hospital that fails to meet 
the Hospital OQR Program requirements for a service that has any of the 
following status indicator assignments: ``J1'', ``J2'', ``P'', ``Q1'', 
``Q2'', ``Q3'', ``Q4'', ``R'', ``S'', ``T'', ``U'', or ``V'' (as 
defined in Addendum D1 to the proposed rule, which is available via the 
internet on the CMS website), in a circumstance in which the multiple 
procedure discount does not apply, the procedure is not bilateral, and 
conditionally packaged services (status indicator of ``Q1'' and ``Q2'') 
qualify for separate payment. We noted that, although blood and blood 
products with status indicator ``R'' and brachytherapy sources with 
status indicator ``U'' are not subject to wage adjustment, they are 
subject to reduced payments when a hospital fails to meet the Hospital 
OQR Program requirements.
    We did not receive any public comments specific to the steps under 
the methodology that we included in the proposed rule to determine the 
APC payments for CY 2019. Therefore, we are finalizing use of the steps 
in the methodology specified below, as we proposed, to demonstrate the 
calculation of the final CY 2019 OPPS payments using the same 
parameters.
    Individual providers interested in calculating the payment amount 
that they will receive for a specific service from the national 
unadjusted payment rates presented in Addenda A and B to this final 
rule with comment period (which are available via the internet on the 
CMS website) should follow the formulas presented in the following 
steps. For purposes of the payment calculations below, we refer to the 
national unadjusted payment rate for hospitals that meet the 
requirements of the Hospital OQR Program as the ``full'' national 
unadjusted payment rate. We refer to the national unadjusted payment 
rate for hospitals that fail to meet the requirements of the Hospital 
OQR Program as the ``reduced'' national unadjusted payment rate. The 
reduced national unadjusted payment rate is calculated by multiplying 
the reporting ratio of 0.980 times the ``full'' national unadjusted 
payment rate. The national unadjusted payment rate used in the 
calculations below is either the full national unadjusted payment rate 
or the reduced national unadjusted payment rate, depending on whether 
the hospital met its Hospital OQR Program requirements in order to 
receive the full CY 2019 OPPS fee schedule increase factor.
    Step 1. Calculate 60 percent (the labor-related portion) of the 
national unadjusted payment rate. Since the initial implementation of 
the OPPS, we have used 60 percent to represent our estimate of that 
portion of costs attributable, on average, to labor. We refer readers 
to the April 7, 2000 OPPS final rule with comment period (65 FR 18496 
through 18497) for a detailed discussion of how we derived this 
percentage. During our regression analysis for the payment adjustment 
for rural hospitals in the CY 2006 OPPS final rule with comment period 
(70 FR 68553), we confirmed that this labor-related share for hospital 
outpatient services is appropriate.
    The formula below is a mathematical representation of Step 1 and 
identifies the labor-related portion of a specific payment rate for a 
specific service.

X is the labor-related portion of the national unadjusted payment rate.
X = .60 * (national unadjusted payment rate).

    Step 2. Determine the wage index area in which the hospital is 
located and identify the wage index level that applies to the specific 
hospital. We note that, under the CY 2019 OPPS policy for continuing to 
use the OMB labor market area delineations based on the 2010 Decennial 
Census data for the wage indexes used under the IPPS, a hold harmless 
policy for the wage index may apply, as discussed in section II.C. of 
this final rule with comment period. The wage index values assigned to 
each area reflect the geographic statistical areas (which are based 
upon OMB standards) to which hospitals are assigned for FY 2019 under 
the IPPS, reclassifications through the Metropolitan Geographic 
Classification Review Board (MGCRB), section 1886(d)(8)(B) ``Lugar'' 
hospitals, reclassifications under section 1886(d)(8)(E) of the Act, as 
defined in Sec.  412.103 of the regulations, and hospitals designated 
as urban under section 601(g) of Public Law 98-21. For further 
discussion of the changes to the FY 2019 IPPS wage indexes, as applied 
to the CY 2019 OPPS, we refer readers to section II.C. of this final 
rule with comment period. We are continuing to apply a wage index floor 
of 1.00 to frontier States, in accordance with section 10324 of the 
Affordable Care Act of 2010.
    Step 3. Adjust the wage index of hospitals located in certain 
qualifying counties that have a relatively high percentage of hospital 
employees who reside in the county, but who work in a different county 
with a higher wage index, in accordance with section 505 of Public Law 
108-173. Addendum L to this final rule with comment period (which is 
available via the internet on the CMS website) contains the qualifying 
counties and the associated wage index increase developed for the FY 
2019 IPPS, which are listed in Table 2 associated with the FY 2019 
IPPS/LTCH PPS final rule available via the internet on the CMS website 
at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/. (Click on the link on the left side of 
the screen titled ``FY 2019 IPPS Final Rule Home Page'' and select ``FY 
2019 Final Rule Tables.'') This step is to be followed only if the 
hospital is not reclassified or redesignated under section 1886(d)(8) 
or section 1886(d)(10) of the Act.
    Step 4. Multiply the applicable wage index determined under Steps 2 
and 3 by the amount determined under Step 1 that represents the labor-
related portion of the national unadjusted payment rate.
    The formula below is a mathematical representation of Step 4 and 
adjusts the labor-related portion of the national unadjusted payment 
rate for the specific service by the wage index.

Xa is the labor-related portion of the national unadjusted 
payment rate (wage adjusted).
Xa = .60 * (national unadjusted payment rate) * applicable 
wage index.

    Step 5. Calculate 40 percent (the nonlabor-related portion) of the 
national unadjusted payment rate and add that amount to the resulting 
product of Step 4. The result is the wage index adjusted payment rate 
for the relevant wage index area.
    The formula below is a mathematical representation of Step 5 and 
calculates the remaining portion of the national payment rate, the 
amount not

[[Page 58877]]

attributable to labor, and the adjusted payment for the specific 
service.

Y is the nonlabor-related portion of the national unadjusted payment 
rate.
Y = .40 * (national unadjusted payment rate).
Adjusted Medicare Payment = Y + Xa.

    Step 6. If a provider is an SCH, as set forth in the regulations at 
Sec.  412.92, or an EACH, which is considered to be an SCH under 
section 1886(d)(5)(D)(iii)(III) of the Act, and located in a rural 
area, as defined in Sec.  412.64(b), or is treated as being located in 
a rural area under Sec.  412.103, multiply the wage index adjusted 
payment rate by 1.071 to calculate the total payment.
    The formula below is a mathematical representation of Step 6 and 
applies the rural adjustment for rural SCHs.

Adjusted Medicare Payment (SCH or EACH) = Adjusted Medicare Payment * 
1.071.

    We are providing examples below of the calculation of both the full 
and reduced national unadjusted payment rates that will apply to 
certain outpatient items and services performed by hospitals that meet 
and that fail to meet the Hospital OQR Program requirements, using the 
steps outlined above. For purposes of this example, we used a provider 
that is located in Brooklyn, New York that is assigned to CBSA 35614. 
This provider bills one service that is assigned to APC 5071 (Level 1 
Excision/Biopsy/Incision and Drainage). The CY 2019 full national 
unadjusted payment rate for APC 5071 is approximately $579.34. The 
reduced national unadjusted payment rate for APC 5071 for a hospital 
that fails to meet the Hospital OQR Program requirements is 
approximately $567.75. This reduced rate is calculated by multiplying 
the reporting ratio of 0.980 by the full unadjusted payment rate for 
APC 5071.
    The FY 2019 wage index for a provider located in CBSA 35614 in New 
York is 1.2853. The labor-related portion of the full national 
unadjusted payment is approximately $446.77 (.60 * $579.34 * 1.2853). 
The labor-related portion of the reduced national unadjusted payment is 
approximately $437.84 (.60 * 567.75 * 1.2853). The nonlabor-related 
portion of the full national unadjusted payment is approximately 
$231.74 (.40 * $579.34). The nonlabor-related portion of the reduced 
national unadjusted payment is approximately $227.10 (.40 * $567.75). 
The sum of the labor-related and nonlabor-related portions of the full 
national adjusted payment is approximately $678.51 ($446.77 + $231.74). 
The sum of the portions of the reduced national adjusted payment is 
approximately $664.94 ($437.84 + $227.10).

I. Beneficiary Copayments

1. Background
    Section 1833(t)(3)(B) of the Act requires the Secretary to set 
rules for determining the unadjusted copayment amounts to be paid by 
beneficiaries for covered OPD services. Section 1833(t)(8)(C)(ii) of 
the Act specifies that the Secretary must reduce the national 
unadjusted copayment amount for a covered OPD service (or group of such 
services) furnished in a year in a manner so that the effective 
copayment rate (determined on a national unadjusted basis) for that 
service in the year does not exceed a specified percentage. As 
specified in section 1833(t)(8)(C)(ii)(V) of the Act, the effective 
copayment rate for a covered OPD service paid under the OPPS in CY 
2006, and in calendar years thereafter, shall not exceed 40 percent of 
the APC payment rate.
    Section 1833(t)(3)(B)(ii) of the Act provides that, for a covered 
OPD service (or group of such services) furnished in a year, the 
national unadjusted copayment amount cannot be less than 20 percent of 
the OPD fee schedule amount. However, section 1833(t)(8)(C)(i) of the 
Act limits the amount of beneficiary copayment that may be collected 
for a procedure (including items such as drugs and biologicals) 
performed in a year to the amount of the inpatient hospital deductible 
for that year.
    Section 4104 of the Affordable Care Act eliminated the Medicare 
Part B coinsurance for preventive services furnished on and after 
January 1, 2011, that meet certain requirements, including flexible 
sigmoidoscopies and screening colonoscopies, and waived the Part B 
deductible for screening colonoscopies that become diagnostic during 
the procedure. Our discussion of the changes made by the Affordable 
Care Act with regard to copayments for preventive services furnished on 
and after January 1, 2011, may be found in section XII.B. of the CY 
2011 OPPS/ASC final rule with comment period (75 FR 72013).
2. OPPS Copayment Policy
    In the CY 2019 OPPS/ASC proposed rule (83 FR 37083), for CY 2019, 
we proposed to determine copayment amounts for new and revised APCs 
using the same methodology that we implemented beginning in CY 2004. 
(We refer readers to the November 7, 2003 OPPS final rule with comment 
period (68 FR 63458).) In addition, we proposed to use the same 
standard rounding principles that we have historically used in 
instances where the application of our standard copayment methodology 
would result in a copayment amount that is less than 20 percent and 
cannot be rounded, under standard rounding principles, to 20 percent. 
(We refer readers to the CY 2008 OPPS/ASC final rule with comment 
period (72 FR 66687) in which we discuss our rationale for applying 
these rounding principles.) The proposed national unadjusted copayment 
amounts for services payable under the OPPS that would be effective 
January 1, 2019 were included in Addenda A and B to the proposed rule 
(which are available via the internet on the CMS website).
    As discussed in section XIII.E. of the proposed rule and this final 
rule with comment period, for CY 2019, the Medicare beneficiary's 
minimum unadjusted copayment and national unadjusted copayment for a 
service to which a reduced national unadjusted payment rate applies 
will equal the product of the reporting ratio and the national 
unadjusted copayment, or the product of the reporting ratio and the 
minimum unadjusted copayment, respectively, for the service.
    We note that OPPS copayments may increase or decrease each year 
based on changes in the calculated APC payment rates due to updated 
cost report and claims data, and any changes to the OPPS cost modeling 
process. However, as described in the CY 2004 OPPS final rule with 
comment period, the development of the copayment methodology generally 
moves beneficiary copayments closer to 20 percent of OPPS APC payments 
(68 FR 63458 through 63459).
    In the CY 2004 OPPS final rule with comment period (68 FR 63459), 
we adopted a new methodology to calculate unadjusted copayment amounts 
in situations including reorganizing APCs, and we finalized the 
following rules to determine copayment amounts in CY 2004 and 
subsequent years.
     When an APC group consists solely of HCPCS codes that were 
not paid under the OPPS the prior year because they were packaged or 
excluded or are new codes, the unadjusted copayment amount would be 20 
percent of the APC payment rate.
     If a new APC that did not exist during the prior year is 
created and consists of HCPCS codes previously assigned to other APCs, 
the copayment amount is calculated as the product of the APC payment 
rate and the lowest

[[Page 58878]]

coinsurance percentage of the codes comprising the new APC.
     If no codes are added to or removed from an APC and, after 
recalibration of its relative payment weight, the new payment rate is 
equal to or greater than the prior year's rate, the copayment amount 
remains constant (unless the resulting coinsurance percentage is less 
than 20 percent).
     If no codes are added to or removed from an APC and, after 
recalibration of its relative payment weight, the new payment rate is 
less than the prior year's rate, the copayment amount is calculated as 
the product of the new payment rate and the prior year's coinsurance 
percentage.
     If HCPCS codes are added to or deleted from an APC and, 
after recalibrating its relative payment weight, holding its unadjusted 
copayment amount constant results in a decrease in the coinsurance 
percentage for the reconfigured APC, the copayment amount would not 
change (unless retaining the copayment amount would result in a 
coinsurance rate less than 20 percent).
     If HCPCS codes are added to an APC and, after 
recalibrating its relative payment weight, holding its unadjusted 
copayment amount constant results in an increase in the coinsurance 
percentage for the reconfigured APC, the copayment amount would be 
calculated as the product of the payment rate of the reconfigured APC 
and the lowest coinsurance percentage of the codes being added to the 
reconfigured APC.
    We noted in the CY 2004 OPPS final rule with comment period that we 
would seek to lower the copayment percentage for a service in an APC 
from the prior year if the copayment percentage was greater than 20 
percent. We noted that this principle was consistent with section 
1833(t)(8)(C)(ii) of the Act, which accelerates the reduction in the 
national unadjusted coinsurance rate so that beneficiary liability will 
eventually equal 20 percent of the OPPS payment rate for all OPPS 
services to which a copayment applies, and with section 1833(t)(3)(B) 
of the Act, which achieves a 20-percent copayment percentage when fully 
phased in and gives the Secretary the authority to set rules for 
determining copayment amounts for new services. We further noted that 
the use of this methodology would, in general, reduce the beneficiary 
coinsurance rate and copayment amount for APCs for which the payment 
rate changes as the result of the reconfiguration of APCs and/or 
recalibration of relative payment weights (68 FR 63459).
    Comment: One commenter supported the beneficiary copayment limit 
that may be collected for certain drugs to the amount of the inpatient 
hospital deductible for that year.
    Response: We appreciate the commenter's support. We note that 
section 1833(t)(8)(C)(i) of the Act requires us to limit the amount of 
beneficiary copayment that may be collected for a procedure (including 
items such as drugs and biologicals) performed in a year to the amount 
of the inpatient hospital deductible for that year.
3. Calculation of an Adjusted Copayment Amount for an APC Group
    Individuals interested in calculating the national copayment 
liability for a Medicare beneficiary for a given service provided by a 
hospital that met or failed to meet its Hospital OQR Program 
requirements should follow the formulas presented in the following 
steps.
    Step 1. Calculate the beneficiary payment percentage for the APC by 
dividing the APC's national unadjusted copayment by its payment rate. 
For example, using APC 5071, $115.87 is approximately 20 percent of the 
full national unadjusted payment rate of $579.34. For APCs with only a 
minimum unadjusted copayment in Addenda A and B to this final rule with 
comment period (which are available via the internet on the CMS 
website), the beneficiary payment percentage is 20 percent.
    The formula below is a mathematical representation of Step 1 and 
calculates the national copayment as a percentage of national payment 
for a given service.

B is the beneficiary payment percentage.
B = National unadjusted copayment for APC/national unadjusted payment 
rate for APC.

    Step 2. Calculate the appropriate wage-adjusted payment rate for 
the APC for the provider in question, as indicated in Steps 2 through 4 
under section II.H. of this final rule with comment period. Calculate 
the rural adjustment for eligible providers as indicated in Step 6 
under section II.H. of this final rule with comment period.
    Step 3. Multiply the percentage calculated in Step 1 by the payment 
rate calculated in Step 2. The result is the wage-adjusted copayment 
amount for the APC.
    The formula below is a mathematical representation of Step 3 and 
applies the beneficiary payment percentage to the adjusted payment rate 
for a service calculated under section II.H. of this final rule with 
comment period, with and without the rural adjustment, to calculate the 
adjusted beneficiary copayment for a given service.

Wage-adjusted copayment amount for the APC = Adjusted Medicare Payment 
* B.
Wage-adjusted copayment amount for the APC (SCH or EACH) = (Adjusted 
Medicare Payment * 1.071) * B.

    Step 4. For a hospital that failed to meet its Hospital OQR Program 
requirements, multiply the copayment calculated in Step 3 by the 
reporting ratio of 0.980.
    The unadjusted copayments for services payable under the OPPS that 
will be effective January 1, 2019, are shown in Addenda A and B to this 
final rule with comment period (which are available via the internet on 
the CMS website). We note that the national unadjusted payment rates 
and copayment rates shown in Addenda A and B to this final rule with 
comment period reflect the CY 2019 OPD fee schedule increase factor 
discussed in section II.B. of this final rule with comment period.
    In addition, as noted earlier, section 1833(t)(8)(C)(i) of the Act 
limits the amount of beneficiary copayment that may be collected for a 
procedure performed in a year to the amount of the inpatient hospital 
deductible for that year.

III. OPPS Ambulatory Payment Classification (APC) Group Policies

A. OPPS Treatment of New CPT and Level II HCPCS Codes

    CPT and Level II HCPCS codes are used to report procedures, 
services, items, and supplies under the hospital OPPS. Specifically, 
CMS recognizes the following codes on OPPS claims:
     Category I CPT codes, which describe surgical procedures 
and medical services;
     Category III CPT codes, which describe new and emerging 
technologies, services, and procedures; and
     Level II HCPCS codes, which are used primarily to identify 
products, supplies, temporary procedures, and services not described by 
CPT codes.
    CPT codes are established by the American Medical Association (AMA) 
and the Level II HCPCS codes are established by CMS. These codes are 
updated and changed throughout the year. CPT and HCPCS code changes 
that affect the OPPS are published both through the annual rulemaking 
cycle and through the OPPS quarterly update Change Requests (CRs). CMS 
releases new Level II HCPCS codes to the public

[[Page 58879]]

or recognizes the release of new CPT codes by the AMA and makes these 
codes effective (that is, the codes can be reported on Medicare claims) 
outside of the formal rulemaking process via OPPS quarterly update CRs. 
Based on our review, we assign the new CPT and Level II HCPCS codes to 
interim status indicators (SIs) and APCs. These interim assignments are 
finalized in the OPPS/ASC final rules. This quarterly process offers 
hospitals access to codes that may more accurately describe items or 
services furnished and provides payment or more accurate payment for 
these items or services in a timelier manner than if we waited for the 
annual rulemaking process. We solicit public comments on these new 
codes and finalize our proposals related to these codes through our 
annual rulemaking process.
    We note that, under the OPPS, the APC assignment determines the 
payment rate for an item, procedure, or service. Those items, 
procedures, or services not paid separately under the hospital OPPS are 
assigned to appropriate status indicators. Certain payment status 
indicators provide separate payment, while other payment status 
indicators do not. Section XI. of this final rule with comment period 
discusses the various status indicators used under the OPPS.
    In Table 11 below, we summarize our current process for updating 
codes through our OPPS quarterly update CRs, seeking public comments, 
and finalizing the treatment of these new codes under the OPPS.
BILLING CODE 4120-01-P
[GRAPHIC] [TIFF OMITTED] TR21NO18.021


[[Page 58880]]


1. Treatment of New HCPCS Codes That Were Effective April 1, 2018 for 
Which We Solicited Public Comments in the CY 2019 OPPS/ASC Proposed 
Rule
    Through the April 2018 OPPS quarterly update CR (Transmittal 4005, 
Change Request 10515, dated March 20, 2018), we made effective nine new 
Level II HCPCS codes for separate payment under the OPPS. In the CY 
2019 OPPS/ASC proposed rule (83 FR 37085), we solicited public comments 
on the proposed APC and status indicator assignments for these Level II 
HCPCS codes, which were listed in Table 8 of the proposed rule.
    We received some public comments related to HCPCS code C9749 
(Repair of nasal vestibular lateral wall stenosis with implant(s)), 
which we address in section III.D.16. of this final rule with comment 
period. With the exception of HCPCS code C9749, we did not receive any 
public comments on the proposed OPPS APC and status indicator 
assignments for the new Level II HCPCS codes implemented in April 2018. 
Therefore, we are finalizing the proposed APC and status indicator 
assignments for these codes, as indicated in Table 12 below. We note 
that several of the HCPCS C-codes have been replaced with HCPCS J-
codes, effective January 1, 2019. Their replacement codes are listed in 
Table 12. The final payment rates for these codes can be found in 
Addendum B to this final rule with comment period (which is available 
via the internet on the CMS website). In addition, the status indicator 
meanings can be found in Addendum D1 to this final rule with comment 
period (which is available via the internet on the CMS website).
[GRAPHIC] [TIFF OMITTED] TR21NO18.022

    In addition, there were several new laboratory CPT Multianalyte 
Assays with Algorithmic Analyses (MAAA) codes (M-codes) and Proprietary 
Laboratory Analyses (PLA) codes (U-codes) that were effective April 1, 
2018, but were too late to include in the April 2018 OPPS Update. 
Because these codes were released on the American Medical Association's 
(AMA) CPT website in February 2018, they were too late for us to 
include in the April 2018 OPPS Update CR and in the April 2018 
Integrated Outpatient Code Editor (IOCE) and, consequently, were 
included in the July 2018 OPPS Update with an effective date of April 
1, 2018. These CPT codes were listed in Table 9 of the CY 2019 OPPS/ASC 
proposed rule (83 FR 37086). In the proposed rule, we solicited public 
comments on the proposed APC and status indicator assignments for these 
CPT codes. The proposed payment rates for these codes, where 
applicable, were included in Addendum B to the proposed rule (which is 
available via the internet on the CMS website).
    Comment: One commenter stated that the test described by CPT code 
0037U (Targeted genomic sequence analysis, solid organ neoplasm, DNA 
analysis of 324 genes, interrogation for sequence variants, gene copy 
number amplifications, gene rearrangements, microsatellite instability 
and tumor mutational burden) specifically, FoundationOne 
CDx^TM, is a human DNA tumor mutation profiling test that is 
covered by Medicare and has been designated as an Advanced Diagnostic 
Laboratory Test (ADLT) under the Clinical Laboratory Fee Schedule 
(CLFS). The commenter supported the proposed OPPS status indicator 
assignment of ``A'' (Not paid under OPPS. Paid by MACs under a fee 
schedule or payment system other than OPPS) for CPT code 0037U.
    Response: We thank the commenter for the feedback. CPT code 0037U,

[[Page 58881]]

which is covered by Medicare, met the criteria for classification as a 
new ADLT and received its ADLT status in May 2018. Under the OPPS, 
codes that receive ADLT status under section 1834A(d)(5)(A) of the Act 
are assigned to status indicator ``A''. Therefore, we are finalizing 
the OPPS status indicator ``A'' for CPT code 0037U as proposed.
    After consideration of the public comment we received, we are 
finalizing the proposed status indicator assignments for the new MAAA 
and PLA CPT codes effective April 1, 2018. The final status indicator 
assignments for the CPT codes are listed in Table 13 below. The status 
indicator meanings can be found in Addendum D1 (OPPS Payment Status 
Indicators for CY 2019) to this final rule with comment period (which 
is available via the internet on the CMS website).

[[Page 58882]]

[GRAPHIC] [TIFF OMITTED] TR21NO18.023


[[Page 58883]]


[GRAPHIC] [TIFF OMITTED] TR21NO18.024

2. Treatment of New HCPCS Codes That Were Effective July 1, 2018 for 
Which We Solicited Public Comments in the CY 2019 OPPS/ASC Proposed 
Rule
    Through the July 2018 OPPS quarterly update CR (Transmittal 4075, 
Change Request 1078, dated June 15, 2018), we made 4 new Category III 
CPT codes and 10 Level II HCPCS codes effective July 1, 2018 (14 codes 
total), and assigned them to appropriate interim OPPS status indicators 
and APCs. As listed in Table 10 of the CY 2019 OPPS/ASC proposed rule 
(83 FR 37086 through 37087), 13 of the 14 HCPCS codes are separately 
payable under the OPPS while 1 HCPCS code is not. Specifically, HCPCS 
code Q9994 is assigned to status indicator ``E1'' to indicate that the 
item is not payable by Medicare. In addition, we note that HCPCS code 
C9469 was deleted June 30, 2018, and replaced with HCPCS code Q9993 
effective July 1, 2018. Because HCPCS code Q9993 describes the same 
drug as HCPCS code C9469, we proposed to continue the drug's pass-
through payment status and to assign HCPCS code Q9993 to the same APC 
and status indicators as its predecessor HCPCS code C9469, as shown in 
Table 10 of the proposed rule.
    In the CY 2019 OPPS/ASC proposed rule, we solicited public comments 
on the proposed APC and status indicator assignments for CY 2019 for 
the CPT and Level II HCPCS codes implemented on July 1, 2018, all of 
which were listed in Table 10 of the proposed rule. The proposed 
payment rates and status indicators for these codes, where applicable, 
were included in Addendum B to the proposed rule (which is available 
via the internet on the CMS website).
    We did not receive any public comments on the proposed APC and 
status indicator assignments for the new Category III CPT codes and 
Level II HCPCS codes implemented in July 2018. Therefore, we are 
finalizing the proposed APC and status indicator assignments for these 
codes, as indicated in Table 14 below. We note that several of the 
HCPCS C and Q-codes have been replaced with HCPCS J-codes effective 
January 1, 2019. Their replacement codes are listed in Table 14 below. 
The final payment rates for these codes can be found in Addendum B to 
this final rule with comment period (which is available via the 
internet on the CMS website). In addition, the status indicator 
meanings can be found in Addendum D1 (OPPS Payment Status Indicators 
for CY 2019) to this final rule with comment period (which is available 
via the internet on the CMS website).

[[Page 58884]]

[GRAPHIC] [TIFF OMITTED] TR21NO18.025


[[Page 58885]]


[GRAPHIC] [TIFF OMITTED] TR21NO18.026

    In addition, there are several new PLA codes (U-codes) that were 
effective July 1, 2018, but were too late to include in the July 2018 
OPPS Update. Consequently, the codes were included in the October 2018 
OPPS Update with an effective date of July 1, 2018. The CPT codes were 
listed in Table 11 of the CY 2019 OPPS/ASC proposed rule along with the 
proposed APC and status indicator assignments for these CPT codes. In 
the CY 2019 OPPS/ASC proposed rule (83 FR 37087), we solicited public 
comments on the proposed APC and status indicator assignments for the 
CPT codes. The proposed payment rates for these codes, where 
applicable, were included in Addendum B to the proposed rule (which is 
available via the internet on the CMS website).
    We did not receive any public comments on the proposed status 
indicator assignments for the PLA codes effective July 1, 2018. 
Therefore, we are finalizing the proposed status indicator assignments 
for these codes, as indicated in Table 15 below. We note that the 
status indicator meanings can be found in Addendum D1 (OPPS Payment 
Status Indicators for CY 2019) to this final rule with comment period 
(which is available via the internet on the CMS website).

[[Page 58886]]

[GRAPHIC] [TIFF OMITTED] TR21NO18.027


[[Page 58887]]


[GRAPHIC] [TIFF OMITTED] TR21NO18.028


[[Page 58888]]


[GRAPHIC] [TIFF OMITTED] TR21NO18.029

BILLING CODE 4120-01-C
3. Process for New Level II HCPCS Codes That Are Effective October 1, 
2018 or Will Be Effective on January 1, 2019 for Which We Are 
Soliciting Public Comments in This CY 2019 OPPS/ASC Final Rule With 
Comment Period
    As has been our practice in the past, we incorporate those new 
Level II HCPCS codes that are effective October 1 and January 1 in the 
final rule with comment period, thereby updating the OPPS for the 
following calendar year, as displayed in Table 11 of this final rule 
with comment period. These codes are released to the public through the 
October and January OPPS quarterly update CRs and via the CMS HCPCS 
website (for Level II HCPCS codes). For CY 2019, these codes are 
flagged with comment indicator ``NI'' in Addendum B to this OPPS/ASC 
final rule with comment period to indicate that we are assigning them 
an interim payment status which is subject to public comment. 
Specifically, the interim status indicator and APC assignments for 
codes flagged with comment indicator ``NI'' are open to public comment 
in this final rule with comment period, and we will respond to these 
public comments in the OPPS/ASC final rule with comment period for the 
next year's OPPS/ASC update.
    In the CY 2019 OPPS/ASC proposed rule (83 FR 37088), we proposed to 
continue this process for CY 2019. Specifically, for CY 2019, we 
proposed to include in Addendum B to the CY 2019 OPPS/ASC final rule 
with comment period the following new HCPCS codes:
     New Level II HCPCS codes effective October 1, 2018, that 
would be incorporated in the October 2018 OPPS quarterly update CR; and
     New Level II HCPCS codes effective January 1, 2019, that 
would be incorporated in the January 2019 OPPS quarterly update CR.
    As stated above, the October 1, 2018 and January 1, 2019 codes are 
flagged with comment indicator ``NI'' in Addendum B to this CY 2019 
OPPS/ASC final rule with comment period to indicate that we have 
assigned these codes an interim OPPS payment status for CY 2019. We are 
inviting public comments on the interim status indicator and APC 
assignments for these codes, if applicable, that will be finalized in 
the CY 2020 OPPS/ASC final rule with comment period.
4. Treatment of New and Revised CY 2019 Category I and III CPT Codes 
That Will Be Effective January 1, 2019 for Which We Solicited Public 
Comments in the CY 2019 OPPS/ASC Proposed Rule
    In the CY 2015 OPPS/ASC final rule with comment period (79 FR 66841 
through 66844), we finalized a revised process of assigning APC and 
status indicators for new and revised Category I and III CPT codes that 
would be effective January 1. Specifically, for the new/revised CPT 
codes that we receive in a timely manner from the AMA's CPT Editorial 
Panel, we finalized our proposal to include the codes that would be 
effective January 1 in the OPPS/ASC proposed rules, along with proposed 
APC and status indicator assignments for them, and to finalize the APC 
and status indicator assignments in the OPPS/ASC final rules beginning 
with the CY 2016 OPPS update. For those new/revised CPT codes that were 
received too late for inclusion in the OPPS/ASC proposed rule, we 
finalized our proposal to establish and use HCPCS G-codes that mirror 
the predecessor CPT codes and retain the current APC and status 
indicator assignments for a year until we can propose APC and status 
indicator assignments in the following year's rulemaking cycle. We note 
that even if we find that we need to create HCPCS G-codes in place of 
certain CPT codes for the PFS proposed rule, we do not anticipate that 
these HCPCS G-codes will always be necessary for OPPS purposes. We will 
make every effort to include proposed APC and status indicator 
assignments for all new and revised CPT codes that the AMA makes 
publicly available in time for us to include them in the annual 
proposed rule, and to avoid the resort to HCPCS G-codes and the 
resulting delay in utilization of the most current CPT codes. Also, we 
finalized our proposal to make interim APC and status indicator 
assignments for CPT codes that are not available in time for the 
proposed rule and that describe wholly new services (such as new 
technologies or new surgical procedures), solicit public comments, and 
finalize the specific APC and status indicator assignments for those 
codes in the following year's final rule.
    For the CY 2019 OPPS update, we received the CY 2019 CPT codes from 
AMA in time for inclusion in the CY 2019 OPPS/ASC proposed rule. The 
new, revised, and deleted CY 2019 Category I and III CPT codes were 
included in Addendum B to the proposed rule (which is available via the 
internet on the CMS website). We noted in the proposed rule that the 
new and revised codes are assigned to new comment indicator ``NP'' to 
indicate that the code is new for the next calendar year or the code is 
an existing

[[Page 58889]]

code with substantial revision to its code descriptor in the next 
calendar year as compared to current calendar year with a proposed APC 
assignment, and that comments will be accepted on the proposed APC and 
status indicator assignments.
    Further, we reminded readers that the CPT code descriptors that 
appear in Addendum B are short descriptors and do not accurately 
describe the complete procedure, service, or item described by the CPT 
code. Therefore, we included the 5-digit placeholder codes and their 
long descriptors for the new and revised CY 2019 CPT codes in Addendum 
O to the proposed rule (which is available via the internet on the CMS 
website) so that the public could adequately comment on the proposed 
APCs and status indicator assignments. The 5-digit placeholder codes 
were included in Addendum O, specifically under the column labeled ``CY 
2019 OPPS/ASC Proposed Rule 5-Digit AMA Placeholder Code,'' to the 
proposed rule. We noted that the final CPT code numbers will be 
included in this CY 2019 OPPS/ASC final rule with comment period. We 
also noted that not every code listed in Addendum O is subject to 
public comment. For the new and revised Category I and III CPT codes, 
we requested public comments on only those codes that are assigned to 
comment indicator ``NP''.
    In summary, in the CY 2019 OPPS/ASC proposed rule, we solicited 
public comments on the proposed CY 2019 status indicator and APC 
assignments for the new and revised Category I and III CPT codes that 
will be effective January 1, 2019. The CPT codes were listed in 
Addendum B to the proposed rule with short descriptors only. We listed 
them again in Addendum O to the proposed rule with long descriptors. We 
also proposed to finalize the status indicator and APC assignments for 
these codes (with their final CPT code numbers) in the CY 2019 OPPS/ASC 
final rule with comment period. The proposed status indicator and APC 
assignments for these codes were included in Addendum B to the proposed 
rule (which is available via the internet on the CMS website).
    Commenters addressed several of the new CPT codes that were 
assigned to comment indicator ``NP'' in Addendum B to the CY 2019 OPPS/
ASC proposed rule. We have responded to those public comments in 
sections II.A.2.b. (Comprehensive APCs), III.D. (OPPS APC-Specific 
Policies), IV.B. (Device-Intensive Procedures) and XII. (Updates to the 
ASC Payment System) of this CY 2019 OPPS/ASC final rule with comment 
period.
    The final status indicators, APC assignments, and payment rates for 
the new CPT codes that are effective January 1, 2019 can be found in 
Addendum B to this final rule with comment period (which is available 
via the internet on the CMS website). In addition, the status indicator 
meanings can be found in Addendum D1 (OPPS Payment Status Indicators 
for CY 2019) to this final rule with comment period (which is available 
via the internet on the CMS website).

B. OPPS Changes--Variations Within APCs

1. Background
    Section 1833(t)(2)(A) of the Act requires the Secretary to develop 
a classification system for covered hospital outpatient department 
services. Section 1833(t)(2)(B) of the Act provides that the Secretary 
may establish groups of covered OPD services within this classification 
system, so that services classified within each group are comparable 
clinically and with respect to the use of resources. In accordance with 
these provisions, we developed a grouping classification system, 
referred to as Ambulatory Payment Classifications (APCs), as set forth 
in regulations at 42 CFR[thinsp]419.31. We use Level I and Level II 
HCPCS codes to identify and group the services within each APC. The 
APCs are organized such that each group is homogeneous both clinically 
and in terms of resource use. Using this classification system, we have 
established distinct groups of similar services. We also have developed 
separate APC groups for certain medical devices, drugs, biologicals, 
therapeutic radiopharmaceuticals, and brachytherapy devices that are 
not packaged into the payment for the procedure.
    We have packaged into the payment for each procedure or service 
within an APC group the costs associated with those items and services 
that are typically ancillary and supportive to a primary diagnostic or 
therapeutic modality and, in those cases, are an integral part of the 
primary service they support. Therefore, we do not make separate 
payment for these packaged items or services. In general, packaged 
items and services include, but are not limited to, the items and 
services listed in regulations at 42 CFR 419.2(b). A further discussion 
of packaged services is included in section II.A.3. of this final rule 
with comment period.
    Under the OPPS, we generally pay for covered hospital outpatient 
services on a rate-per-service basis, where the service may be reported 
with one or more HCPCS codes. Payment varies according to the APC group 
to which the independent service or combination of services is 
assigned. In the CY 2019 OPPS/ASC proposed rule (83 FR 37089), for CY 
2019, we proposed that each APC relative payment weight represents the 
hospital cost of the services included in that APC, relative to the 
hospital cost of the services included in APC 5012 (Clinic Visits and 
Related Services). The APC relative payment weights are scaled to APC 
5012 because it is the hospital clinic visit APC and clinic visits are 
among the most frequently furnished services in the hospital outpatient 
setting.
2. Application of the 2 Times Rule
    Section 1833(t)(9)(A) of the Act requires the Secretary to review, 
not less often than annually, and revise the APC groups, the relative 
payment weights, and the wage and other adjustments described in 
paragraph (2) to take into account changes in medical practice, changes 
in technology, the addition of new services, new cost data, and other 
relevant information and factors. Section 1833(t)(9)(A) of the Act also 
requires the Secretary to consult with an expert outside advisory panel 
composed of an appropriate selection of representatives of providers to 
review (and advise the Secretary concerning) the clinical integrity of 
the APC groups and the relative payment weights. We note that the HOP 
Panel recommendations for specific services for the CY 2019 OPPS update 
are discussed in the relevant specific sections throughout this CY 2019 
OPPS/ASC final rule with comment period.
    In addition, section 1833(t)(2) of the Act provides that, subject 
to certain exceptions, the items and services within an APC group 
cannot be considered comparable with respect to the use of resources if 
the highest cost for an item or service in the group is more than 2 
times greater than the lowest cost for an item or service within the 
same group (referred to as the ``2 times rule''). The statute 
authorizes the Secretary to make exceptions to the 2 times rule in 
unusual cases, such as low-volume items and services (but the Secretary 
may not make such an exception in the case of a drug or biological that 
has been designated as an orphan drug under section 526 of the Federal 
Food, Drug, and Cosmetic Act). In determining the APCs with a 2 times 
rule violation, we consider only those HCPCS codes that are significant 
based on the number of claims. We note that, for purposes of 
identifying significant procedure codes for examination under

[[Page 58890]]

the 2 times rule, we consider procedure codes that have more than 1,000 
single major claims or procedure codes that both have more than 99 
single major claims and contribute at least 2 percent of the single 
major claims used to establish the APC cost to be significant (75 FR 
71832). This longstanding definition of when a procedure code is 
significant for purposes of the 2 times rule was selected because we 
believe that a subset of 1,000 or fewer claims is negligible within the 
set of approximately 100 million single procedure or single session 
claims we use for establishing costs. Similarly, a procedure code for 
which there are fewer than 99 single claims and that comprises less 
than 2 percent of the single major claims within an APC will have a 
negligible impact on the APC cost (75 FR 71832). In the CY 2019 OPPS/
ASC proposed rule (83 FR 37089), for CY 2019, we proposed to make 
exceptions to this limit on the variation of costs within each APC 
group in unusual cases, such as for certain low-volume items and 
services.
    For the CY 2019 OPPS update, in the CY 2019 OPPS/ASC proposed rule, 
we identified the APCs with violations of the 2 times rule. Therefore, 
we proposed changes to the procedure codes assigned to these APCs in 
Addendum B to the proposed rule. We noted that Addendum B does not 
appear in the printed version of the Federal Register as part of the CY 
2019 OPPS/ASC proposed rule. Rather, it is published and made available 
via the internet on the CMS website at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/HospitalOutpatientPPS/. To 
eliminate a violation of the 2 times rule and improve clinical and 
resource homogeneity, we proposed to reassign these procedure codes to 
new APCs that contain services that are similar with regard to both 
their clinical and resource characteristics. In many cases, the 
proposed procedure code reassignments and associated APC 
reconfigurations for CY 2019 included in the proposed rule were related 
to changes in costs of services that were observed in the CY 2017 
claims data newly available for CY 2019 ratesetting. Addendum B to the 
CY 2019 OPPS/ASC proposed rule identified with a comment indicator 
``CH'' those procedure codes for which we proposed a change to the APC 
assignment or status indicator, or both, that were initially assigned 
in the July 1, 2018 OPPS Addendum B Update (available via the internet 
on the CMS website at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/HospitalOutpatientPPS/Addendum-A-and-Addendum-B-Updates.html).
3. APC Exceptions to the 2 Times Rule
    Taking into account the APC changes that we proposed to make for CY 
2019 in the CY 2019 OPPS/ASC proposed rule, we reviewed all of the APCs 
to determine which APCs would not meet the requirements of the 2 times 
rule. We used the following criteria to evaluate whether to propose 
exceptions to the 2 times rule for affected APCs:
     Resource homogeneity;
     Clinical homogeneity;
     Hospital outpatient setting utilization;
     Frequency of service (volume); and
     Opportunity for upcoding and code fragments.
    Based on the CY 2017 claims data available for the CY 2019 proposed 
rule, we found 16 APCs with violations of the 2 times rule. We applied 
the criteria as described above to identify the APCs for which we 
proposed to make exceptions under the 2 times rule for CY 2019, and 
found that all of the 16 APCs we identified met the criteria for an 
exception to the 2 times rule based on the CY 2017 claims data 
available for the proposed rule. We did not include in that 
determination those APCs where a 2 times rule violation was not a 
relevant concept, such as APC 5401 (Dialysis), which only has two HCPCS 
codes assigned to it that have a similar geometric mean costs and do 
not create a 2 time rule violation. Therefore, we only identified those 
APCs, including those with criteria-based costs, such as device-
dependent CPT/HCPCS codes, with violations of the 2 times rule.
    We note that, for cases in which a recommendation by the HOP Panel 
appears to result in or allow a violation of the 2 times rule, we may 
accept the HOP Panel's recommendation because those recommendations are 
based on explicit consideration (that is, a review of the latest OPPS 
claims data and group discussion of the issue) of resource use, 
clinical homogeneity, site of service, and the quality of the claims 
data used to determine the APC payment rates.
    Table 12 of the proposed rule listed the 16 APCs that we proposed 
to make an exception for under the 2 times rule for CY 2019 based on 
the criteria cited above and claims data submitted between January 1, 
2017, and December 31, 2017, and processed on or before December 31, 
2017. In the proposed rule, we stated that, for the final rule with 
comment period, we intend to use claims data for dates of service 
between January 1, 2017, and December 31, 2017, that were processed on 
or before June 30, 2018, and updated CCRs, if available.
    Based on the updated final rule CY 2017 claims data used for this 
CY 2019 final rule with comment period, we were able to remedy 1 APC 
violation out of the 16 APCs that appeared in Table 12 of the CY 2019 
OPPS/ASC proposed rule. Specifically, APC 5735 (Level 5 Minor 
Procedures) no longer met the criteria for exception to the 2 times 
rule in this final rule with comment period. In addition, based on our 
analysis of the final rule claims data, we found a total of 17 APCs 
with violations of the 2 times rule. Of these 17 total APCs, 15 were 
identified in the proposed rule and 2 are newly identified APCs. 
Specifically, we found the following 15 APCs that were identified for 
the proposed rule that continued to have violations of the 2 times rule 
for this final rule with comment period:
     APC 5071 (Level 1 Excision/Biopsy/Incision and Drainage);
     APC 5113 (Level 3 Musculoskeletal Procedures);
     APC 5521 (Level 1 Imaging without Contrast);
     APC 5522 (Level 2 Imaging without Contrast);
    APC 5523 (Level 3 Imaging without Contrast);
     APC 5571 (Level 1 Imaging with Contrast);
     APC 5612 (Level 2 Therapeutic Radiation Treatment 
Preparation);
     APC 5691 (Level 1 Drug Administration);
     APC 5692 (Level 2 Drug Administration);
     APC 5721 (Level 1 Diagnostic Tests and Related Services);
     APC 5724 (Level 4 Diagnostic Tests and Related Services);
     APC 5731 (Level 1 Minor Procedures);
     APC 5732 (Level 2 Minor Procedures);
     APC 5822 (Level 2 Health and Behavior Services); and
     APC 5823 (Level 3 Health and Behavior Services).
    In addition, we found that the following two additional APCs 
violated the 2 times rule using the final rule with comment period 
claims data:
     APC 5193 (Level 3 Endovascular Procedures); and
     APC 5524 (Level 4 Imaging without Contrast).
    After considering the public comments we received on proposed APC 
assignments and our analysis of the CY 2017 costs from hospital claims 
and cost report data available for this CY 2019 final rule with comment 
period, we are finalizing our proposals, with some modifications. 
Specifically, we are

[[Page 58891]]

finalizing our proposal to except 15 of the 16 proposed APCs from the 2 
times rule for CY 2019 and also excepting 2 additional APCs (APCs 5193 
and 5524). As noted above, we were able to remedy one of the proposed 
rule 2 time rule violations in this final rule with comment period (APC 
5735).
    Table 16 below lists the 17 APCs that we are excepting from the 2 
times rule for CY 2019 based on the criteria described earlier and a 
review of updated claims data for dates of service between January 1, 
2017 and December 31, 2017, that were processed on or before June 30, 
2018, and updated CCRs, if available. We note that, for cases in which 
a recommendation by the HOP Panel appears to result in or allow a 
violation of the 2 times rule, we generally accept the HOP Panel's 
recommendation because those recommendations are based on explicit 
consideration of resource use, clinical homogeneity, site of service, 
and the quality of the claims data used to determine the APC payment 
rates. The geometric mean costs for hospital outpatient services for 
these and all other APCs that were used in the development of this 
final rule with comment period can be found on the CMS website at: 
https://www.cms.gov.
[GRAPHIC] [TIFF OMITTED] TR21NO18.030

C. New Technology APCs

1. Background
    In the November 30, 2001 final rule (66 FR 59903), we finalized 
changes to the time period in which a service can be eligible for 
payment under a New Technology APC. Beginning in CY 2002, we retain 
services within New Technology APC groups until we gather sufficient 
claims data to enable us to assign the service to an appropriate 
clinical APC. This policy allows us to move a service from a New 
Technology APC in less than 2 years if sufficient data are available. 
It also allows us to retain a service in a New Technology APC for more 
than 2 years if sufficient data upon which to base a decision for 
reassignment have not been collected.
    In the CY 2004 OPPS final rule with comment period (68 FR 63416), 
we restructured the New Technology APCs to make the cost intervals more 
consistent across payment levels and refined the cost bands for these 
APCs to retain two parallel sets of New Technology APCs, one set with a 
status indicator of ``S'' (Significant Procedures, Not Discounted when 
Multiple. Paid under OPPS; separate APC payment) and the other set with 
a status indicator of ``T'' (Significant Procedure, Multiple Reduction 
Applies. Paid under OPPS; separate APC payment). These current New 
Technology APC configurations allow us to price new technology services 
more appropriately and consistently.
    For CY 2018, there were 52 New Technology APC levels, ranging from 
the lowest cost band assigned to APC 1491 (New Technology--Level 1A 
($0-$10)) through the highest cost band assigned to APC 1908 (New 
Technology--Level 52 ($145,001-$160,000)). We note that the cost bands 
for the New Technology APCs, specifically, APCs 1491 through 1599 and 
1901 through 1908, vary with increments ranging from $10 to $14,999. 
These cost bands identify the APCs to which new technology procedures 
and services with estimated service costs that fall within those cost 
bands are assigned under the OPPS. Payment for each APC is made at the 
mid-point of the APC's assigned cost band. For example, payment for New 
Technology APC 1507 (New Technology--Level 7 ($501-$600)) is made at 
$550.50.
    Under the OPPS, one of our goals is to make payments that are 
appropriate for the services that are necessary for the treatment of 
Medicare beneficiaries. The OPPS, like other Medicare payment systems, 
is budget neutral and increases are limited to the annual hospital 
inpatient market basket increase. We

[[Page 58892]]

believe that our payment rates generally reflect the costs that are 
associated with providing care to Medicare beneficiaries. Furthermore, 
we believe that our payment rates are adequate to ensure access to 
services (80 FR 70374).
    For many emerging technologies, there is a transitional period 
during which utilization may be low, often because providers are first 
learning about the techniques and their clinical utility. Quite often, 
parties request that Medicare make higher payment amounts under the New 
Technology APCs for new procedures in that transitional phase. These 
requests, and their accompanying estimates for expected total patient 
utilization, often reflect very low rates of patient use of expensive 
equipment, resulting in high per use costs for which requesters believe 
Medicare should make full payment. Medicare does not, and we believe 
should not, assume responsibility for more than its share of the costs 
of procedures based on projected utilization for Medicare beneficiaries 
and does not set its payment rates based on initial projections of low 
utilization for services that require expensive capital equipment. For 
the OPPS, we rely on hospitals to make informed business decisions 
regarding the acquisition of high-cost capital equipment, taking into 
consideration their knowledge about their entire patient base (Medicare 
beneficiaries included) and an understanding of Medicare's and other 
payers' payment policies. (We refer readers to the CY 2013 OPPS/ASC 
final rule with comment period (77 FR 68314) for further discussion 
regarding this payment policy.)
    We note that, in a budget neutral system, payments may not fully 
cover hospitals' costs in a particular circumstance, including those 
for the purchase and maintenance of capital equipment. We rely on 
hospitals to make their decisions regarding the acquisition of high-
cost equipment with the understanding that the Medicare program must be 
careful to establish its initial payment rates, including those made 
through New Technology APCs, for new services that lack hospital claims 
data based on realistic utilization projections for all such services 
delivered in cost-efficient hospital outpatient settings. As the OPPS 
acquires claims data regarding hospital costs associated with new 
procedures, we regularly examine the claims data and any available new 
information regarding the clinical aspects of new procedures to confirm 
that our OPPS payments remain appropriate for procedures as they 
transition into mainstream medical practice (77 FR 68314). For CY 2019, 
we included the proposed payment rates for New Technology APCs 1491 to 
1599 and 1901 through 1908 in Addendum A to the CY 2019 OPPS/ASC 
proposed rule (which is available via the internet on the CMS website). 
The final payment rates for these New Technology APCs are included in 
Addendum A to the CY 2019 OPPS/ASC final rule with comment period 
(which is available via the internet on the CMS website).
2. Establishing Payment Rates for Low-Volume New Technology Procedures
    Procedures that are assigned to New Technology APCs are typically 
new procedures that do not have sufficient claims history to establish 
an accurate payment for the procedures. One of the objectives of 
establishing New Technology APCs is to generate sufficient claims data 
for a new procedure so that it can be assigned to an appropriate 
clinical APC. Some procedures that are assigned to New Technology APCs 
have very low annual volume, which we consider to be fewer than 100 
claims. We consider procedures with fewer than 100 claims annually as 
low-volume procedures because there is a higher probability that the 
payment data for a procedure may not have a normal statistical 
distribution, which could affect the quality of our standard cost 
methodology that is used to assign services to an APC. In addition, 
services with fewer than 100 claims per year are not generally 
considered to be a significant contributor to the APC ratesetting 
calculations and, therefore, are not included in the assessment of the 
2 times rule. For these low-volume procedures, we are concerned that 
the methodology we use to estimate the cost of a procedure under the 
OPPS by calculating the geometric mean for all separately paid claims 
for a HCPCS procedure code from the most recent available year of 
claims data may not generate an accurate estimate of the actual cost of 
the procedure.
    In accordance with section 1833(t)(2)(B) of the Act, services 
classified within each APC must be comparable clinically and with 
respect to the use of resources. As described earlier, assigning a 
procedure to a new technology APC allows us to gather claims data to 
price the procedure and assign it to the APC with services that use 
similar resources and are clinically comparable. However, where 
utilization of services assigned to a New Technology APC is low, it can 
lead to wide variation in payment rates from year to year, resulting in 
even lower utilization and potential barriers to access to new 
technologies, which ultimately limits our ability to assign the service 
to the appropriate clinical APC. To mitigate these issues, we believe 
that it is appropriate to utilize our equitable adjustment authority at 
section 1833(t)(2)(E) of the Act to adjust how we determine the costs 
for low-volume services assigned to New Technology APCs. We have 
utilized our equitable adjustment authority at section 1833(t)(2)(E) of 
the Act, which states that the Secretary shall establish, in a budget 
neutral manner, other adjustments as determined to be necessary to 
ensure equitable payments, to estimate an appropriate payment amount 
for low-volume new technology procedures in the past (82 FR 59281). 
Although we have used this adjustment authority on a case-by-case basis 
in the past, we believe that it is appropriate to adopt an adjustment 
for low-volume services assigned to New Technology APCs in order 
mitigate the wide payment fluctuations that can occur for new 
technology services with fewer than 100 claims and to provide more 
predictable payment for these services.
    For purposes of this adjustment, we believe that it is appropriate 
to use up to 4 years of claims data in calculating the applicable 
payment rate for the prospective year, rather than using solely the 
most recent available year of claims data, when a service assigned to a 
New Technology APC has a low annual volume of claims, which, for 
purposes of this adjustment, we define as fewer than 100 claims 
annually. We consider procedures with fewer than 100 claims annually as 
low-volume procedures because there is a higher probability that the 
payment data for a procedure may not have a normal statistical 
distribution, which could affect the quality of our standard cost 
methodology that is used to assign services to an APC. For these low-
volume procedures, we are concerned that the methodology we use to 
estimate the cost of a procedure under the OPPS by calculating the 
geometric mean for all separately paid claims for a HCPCS procedure 
code from the most recent available year of claims data may not 
generate an accurate estimate of the actual cost of the procedure. 
Using multiple years of claims data will potentially allow for more 
than 100 claims to be used to set the payment rate, which would, in 
turn, create a more statistically reliable payment rate.
    In addition, to better approximate the cost of a low-volume service 
within a New Technology APC, we believe that using the median or 
arithmetic mean rather than the geometric mean (which

[[Page 58893]]

``trims'' the costs of certain claims out) may be more appropriate in 
some circumstances, given the extremely low volume of claims. Low claim 
volumes increase the impact of ``outlier'' claims; that is, claims with 
either a very low or very high payment rate as compared to the average 
claim, which would have a substantial impact on any statistical 
methodology used to estimate the most appropriate payment rate for a 
service. We believe that having the flexibility to utilize an 
alternative statistical methodology to calculate the payment rate in 
the case of low-volume new technology services would help to create a 
more stable payment rate. Therefore, in the CY 2019 OPPS/ASC proposed 
rule (83 FR 37091 through 37092), we proposed that, in each of our 
annual rulemakings, we would seek public comments on which statistical 
methodology should be used for each low-volume New Technology APC. In 
the preamble of each annual rulemaking, we stated that we will present 
the result of each statistical methodology and solicit public comment 
on which methodology should be used to establish the payment rate for a 
low-volume new technology service. In addition, we will use our 
assessment of the resources used to perform a service and guidance from 
the developer or manufacturer of the service, as well as other 
stakeholders, to determine the most appropriate payment rate. Once we 
identify the most appropriate payment rate for a service, we would 
assign the service to the New Technology APC with the cost band that 
includes its payment rate.
    Accordingly, in the CY 2019 OPPS/ASC proposed rule (83 FR 37091 
through 37092), for CY 2019, we proposed to establish a different 
payment methodology for services assigned to New Technology APCs with 
fewer than 100 claims using our equitable adjustment authority under 
section 1833(t)(2)(E) of the Act. Under this proposal, we proposed to 
use up to 4 years of claims data to establish a payment rate for each 
applicable service both for purposes of assigning a service to a New 
Technology APC and for assigning a service to a regular APC at the 
conclusion of payment for the service through a New Technology APC. The 
goal of such a policy is to promote transparency and stability in the 
payment rates for these low-volume new technology procedures and to 
mitigate wide variation from year to year for such services. We also 
proposed to use the geometric mean, the median, or the arithmetic mean 
to calculate the cost of furnishing the applicable service, present the 
result of each statistical methodology in our annual rulemaking, and 
solicit public comment on which methodology should be used to establish 
the payment rate. We stated that the geometric mean may not be 
representative of the actual cost of a service when fewer than 100 
claims are present because the payment amounts for the claims may not 
be distributed normally. We stated that, under this proposal, we would 
have the option to use the median payment amount or the arithmetic mean 
to assign a more representative payment for the service. Once we 
identify the payment rate for a service, we would assign the service to 
the New Technology APC with the cost band that includes its payment 
rate.
    Comment: One commenter requested that CMS expand the proposal to 
cover all low-volume procedures with fewer than 100 claims annually in 
the OPPS rather than only those procedures assigned to New Technology 
APCs. The commenter noted the issues cited for establishing the low-
volume policy, including data not having a normal statistical 
distribution, excessive influence of outliers, and the quality of 
claims data affect all low-volume procedures, and not just those 
procedure assigned to a New Technology APC.
    Response: We disagree with the commenter's request. The fact that a 
procedure has been assigned to a clinical APC means we have some idea 
of the resources used for a low-volume procedure and what the cost of 
the procedure should be. Concerns over the appropriate APC assignment 
for an individual procedure may be addressed on a case-by-case basis 
through our annual rulemaking. We remind commenters that they can 
submit public comments on the appropriate APC assignment for a 
particular code during that process. We believe reviewing each 
procedure assigned to a clinical APC annually to determine if the 
arithmetic mean, geometric mean, or median of the claims data should be 
used to determine the procedure cost is both unnecessary and 
operationally infeasible. The low-volume policy instead is intended 
only for those procedures assigned to New Technology APCs with such 
limited claims data that we are not able to assign them to clinical 
APCs and need as much available data to determine the payment rate for 
a procedure.
    Comment: One commenter asked that CMS use the equitable adjustment 
authority under section 1833(t)(2)(E) of the Act in other instances not 
covered by the proposed low-volume policy where a procedure that has 
recently been introduced to the outpatient setting has inconsistent 
payment data due to small number of claims.
    Response: We retain the ability to use our equitable adjustment 
authority under section 1833(t)(2)(E) of the Act when we determine that 
it is needed.
    Comment: Several commenters supported the proposal to use up to 4 
years of claims data and to have flexibility to use the geometric mean, 
arithmetic mean, or median of claims data to establish a payment rate 
for low-volume procedures assigned to a New Technology APC.
    Response: We appreciate the commenters' support.
    After consideration of the public comments we received, we are 
finalizing our proposed policy to establish payment rates for low-
volume procedures with fewer than 100 claims per year that are assigned 
to New Technology APCs, without modification. We may use up to 4 years 
of claims data to establish a payment rate for each applicable service 
both for purposes of assigning a service to a New Technology APC and 
for assigning a service to a regular APC at the conclusion of payment 
for the service through a New Technology APC. We will use the geometric 
mean, the median, or the arithmetic mean to calculate the cost of 
furnishing the applicable service, present the result of each 
statistical methodology in our annual rulemaking, and solicit public 
comment on which methodology should be used to establish the payment 
rate. Once we identify the payment rate for a service, we would assign 
the service to the New Technology APC with the cost band that includes 
its payment rate.
3. Procedures Assigned to New Technology APC Groups for CY 2019
    As we explained in the CY 2002 OPPS final rule with comment period 
(66 FR 59902), we generally retain a procedure in the New Technology 
APC to which it is initially assigned until we have obtained sufficient 
claims data to justify reassignment of the procedure to a clinically 
appropriate APC.
    In addition, in cases where we find that our initial New Technology 
APC assignment was based on inaccurate or inadequate information 
(although it was the best information available at the time), where we 
obtain new information that was not available at the time of our 
initial New Technology APC assignment, or where the New Technology APCs 
are restructured, we may, based on more recent resource utilization 
information (including claims data) or the availability of refined New 
Technology APC cost bands, reassign the procedure or service to a

[[Page 58894]]

different New Technology APC that more appropriately reflects its cost 
(66 FR 59903).
    Consistent with our current policy, for CY 2019, in the CY 2019 
OPPS/ASC proposed rule (83 FR 37092), we proposed to retain services 
within New Technology APC groups until we obtain sufficient claims data 
to justify reassignment of the service to a clinically appropriate APC. 
The flexibility associated with this policy allows us to reassign a 
service from a New Technology APC in less than 2 years if sufficient 
claims data are available. It also allows us to retain a service in a 
New Technology APC for more than 2 years if sufficient claims data upon 
which to base a decision for reassignment have not been obtained (66 FR 
59902).
a. Magnetic Resonance-Guided Focused Ultrasound Surgery (MRgFUS) (APCs 
1537, 5114, and 5414)
    Currently, there are four CPT/HCPCS codes that describe magnetic 
resonance image-guided, high-intensity focused ultrasound (MRgFUS) 
procedures, three of which we proposed to continue to assign to 
standard APCs, and one that we proposed to reassign to a different New 
Technology APC for CY 2019. These codes include CPT codes 0071T, 0072T, 
and 0398T, and HCPCS code C9734. CPT codes 0071T and 0072T describe 
procedures for the treatment of uterine fibroids, CPT code 0398T 
describes procedures for the treatment of essential tremor, and HCPCS 
code C9734 describes procedures for pain palliation for metastatic bone 
cancer.
    As shown in Table 13 of the CY 2019 OPPS/ASC proposed rule, and as 
listed in Addendum B to the CY 2019 OPPS/ASC proposed rule, we proposed 
to continue to assign the procedures described by CPT codes 0071T and 
0072T to APC 5414 (Level 4 Gynecologic Procedures), with a proposed 
payment rate of approximately $2,410 for CY 2019. We also proposed to 
continue to assign the APC to status indicator ``J1'' (Hospital Part B 
services paid through a comprehensive APC) to indicate that payment for 
all covered Part B services reported on the claim are packaged with the 
payment for the primary ``J1'' service for the claim, except for 
services assigned to OPPS status indicator ``F'', ``G'', ``H'', ``L'', 
and ``U''; ambulance services; diagnostic and screening mammography; 
all preventive services; and certain Part B inpatient services. In 
addition, we proposed to continue to assign the services described by 
HCPCS code C9734 (Focused ultrasound ablation/therapeutic intervention, 
other than uterine leiomyomata, with magnetic resonance (mr) guidance) 
to APC 5115 (Level 5 Musculoskeletal Procedures), with a proposed 
payment rate of approximately $10,936 for CY 2019. We also proposed to 
continue to assign HCPCS code C9734 to status indicator ``J1''.
    For procedures described by CPT code 0398T, we have only identified 
one paid claim for a procedure in CY 2016 and two paid claims in CY 
2017, for a total of three paid claims. We note that the procedures 
described by CPT code 0398T were first assigned to a New Technology APC 
in CY 2016. Accordingly, there are only 2 years of claims data 
available for the OPPS ratesetting purposes. The payment amounts for 
the claims varied widely, with a cost of $29,254 for the sole CY 2016 
claim and a geometric mean cost of $4,647 for the two CY 2017 claims. 
In the proposed rule, we expressed concerned that the reported 
geometric mean cost for CY 2017, which we would normally use to 
determine the proposed payment rate for the procedures described by CPT 
code 0398T, was significantly lower than the reported cost of the claim 
received in CY 2016, as well as the payment rate for the procedures for 
CY 2017 ($9,750.50) and for CY 2018 ($17,500.50). In accordance with 
section 1833(t)(2)(B) of the Act, we must establish that services 
classified within each APC are comparable clinically and with respect 
to the use of resources.
    Therefore, as mentioned in section III.C.2. of the proposed rule, 
we proposed to use our equitable adjustment authority under section 
1833(t)(2)(E) of the Act, which states that the Secretary shall 
establish, in a budget neutral manner, other adjustments as determined 
to be necessary to ensure equitable payments, to establish a payment 
rate that is more likely to be representative of the cost of the 
procedures described by CPT code 0398T, despite the low geometric mean 
costs for procedures described by CPT code 0398T available in the 
claims data used for the proposed rule. We stated that we continue to 
believe that this situation for the procedures described by CPT code 
0398T is unique, given the very limited number of claims for the 
procedures and the high variability for the cost of the claims which 
makes it challenging to determine a reliable payment rate for the 
procedures.
    Our analysis found that the arithmetic mean of the three claims is 
$12,849.11, the geometric mean of the three claims is $8,579.91 
(compared to $4,646.56 for CY 2017), and the median of the claims is 
$4,676.77. Consistent with what we stated in section III.C.2. of the 
proposed rule, we presented the result of each statistical methodology 
in this preamble, and we sought public comments on which method should 
be used to establish payment for the procedures described by CPT code 
0398T. We believe that the arithmetic mean is the most appropriate 
representative cost of the procedures described by CPT code 0398T, 
which gives consideration to the payment rates established for the 
procedures in CY 2017 and CY 2018, without any trimming. The arithmetic 
mean also gives consideration to the full range in cost for the three 
paid claims, which represent 2 years of claims data for the procedures. 
We proposed to estimate the proposed payment rate for the procedures 
described by CPT code 0398T by calculating the arithmetic mean of the 
three paid claims for the procedures in CY 2016 and CY 2017, and 
assigning the procedures described by CPT code 0398T to the New 
Technology APC that includes the estimated cost. Accordingly, we 
proposed to reassign the procedures described by CPT code 0398T from 
APC 1576 (New Technology--Level 39 ($15,001-$20,000)) to APC 1575 (New 
Technology--Level 38 ($10,001-$15,000)), with a proposed payment rate 
of $12,500.50 for CY 2019. We refer readers to Addendum B to the 
proposed rule for the proposed payment rates for all codes reportable 
under the OPPS. Addendum B is available via the internet on the CMS 
website.
    Comment: Several commenters opposed the proposed reassignment of 
CPT code 0398T to APC 1575 (New Technology--Level 38 ($10,001-
$15,000)), which has a payment rate of $12,500.50. These commenters 
asked CMS to maintain the CY 2018 assignment of CPT code 0398T to APC 
1576 (New Technology--Level 39 ($15,001-$20,000)). The commenters 
believed the cost of the services described by CPT code 0398T is more 
than the proposed payment rate of $12,500.50, and reducing payment 
would discourage use of this new technology. One commenter, the 
developer of the procedure, stated that the reduced payment rate would 
be particularly problematic as it would take effect just as MACs are 
issuing local coverage determinations to allow the procedure to be 
covered more widely by Medicare. This commenter also believed the two 
claims from CY 2017 with a geometric mean cost of $4,647 had too low of 
a payment rate and submitted additional payment data to CMS to support 
that position.

[[Page 58895]]

    Response: Since the proposed rule was issued, there have been 
several more claims for services described by CPT code 0398T that were 
paid in CY 2017. Currently, there are 11 paid claims for services 
described by CPT code 0398T for CY 2017, and these 11 claims have an 
estimated cost of between $4,186.51 and $5,153.28. We performed our 
low-volume new technology process for CPT code 0398T for all available 
claims from CY 2017 and included the one claim of $29,254 from CY 2016. 
The results of our analysis found that for claims billed with CPT code 
0398T, the geometric mean cost was $5,360.99, the arithmetic mean cost 
was $6,654.68, and the median cost was $4,581.45.
    We have concerns about using the claims data available for this 
final rule with comment period to set the payment rate for CPT code 
0398T for CY 2019. The payment rate for CPT code 0398T for CY 2018 was 
$17,500.50, and in the CY 2019 proposed rule (83 FR 37093), we proposed 
a payment rate of $12,500.50. However for this final rule with comment 
period, the highest payment rate using the most recent available claims 
data and the newly adopted smoothing methodology for low-volume New 
Technology APCs is $6,750.50, which is the mid-point of New Technology 
APC 1531. New Technology APC 1531 is the cost band for the arithmetic 
mean cost of CPT code 0398T. A payment rate of $6,750.50 would be the 
result of a $10,750 reduction in the payment rate in a period of just 1 
year, or a payment rate reduction of over 60 percent. In addition, this 
payment reduction would be based on a total of 14 claims that have been 
billed for CPT code 0398T since we first received claims for this 
procedure in CY 2016. We believe that it is important to mitigate 
significant payment differences, especially payment differences that 
result in shifts of over $10,000 in a single year, while also basing 
payment rates on available costs information and claims data. We are 
concerned that these large changes in payment could potentially create 
an access to care issue for services described by CPT code 0398T; 
especially, when the procedure is starting to receive local coverage 
determinations from MACs allowing more Medicare beneficiaries to use 
the procedure. While the proposed payment rate of $12,500.50 is also a 
decrease from the current payment rate, we believe that it would be 
appropriate to finalize the proposed rate to mitigate a much sharper 
decline in payment from one year to the next.
    In accordance with section 1833(t)(2)(B) of the Act, we must 
establish that services classified within each APC are comparable 
clinically and with respect to the use of resources. Accordingly, we 
are using our equitable adjustment authority under section 
1833(t)(2)(E) of the Act, which states that the Secretary shall 
establish, in a budget neutral manner, other adjustments as determined 
to be necessary to ensure equitable payments, to maintain the proposed 
rate for this procedure, despite the lower geometric mean, arithmetic 
mean, and median costs calculated from the claims data used for this 
final rule with comment period. As stated earlier, we believe that this 
situation is unique, given the large reduction in payment this would 
represent for CPT code 0398T and the very limited number of claims 
reported for the procedure. Therefore, for CY 2019, we are reassigning 
CPT code 0398T from APC 1576 to APC 1575 (New Technology--Level 38 
($10,001-$15,000)). This APC assignment will establish a payment rate 
for CPT code 0398T of $12,500.50, which was the proposed payment rate 
for the procedure in the CY 2019 OPPS/ASC proposed rule. As we do each 
year, we acquire claims data regarding hospital costs associated with 
new procedures. We regularly examine the claims data and any available 
new information regarding the clinical aspects of new procedures to 
confirm that our OPPS payments remain appropriate for procedures like 
CPT code 0398T as they transition into mainstream medical practice (77 
FR 68314).
    Comment: One commenter supported the proposed increase in Medicare 
payment for MRI-guided high intensity focused ultrasound procedures 
described by CPT codes 0071T and 0072T.
    Response: We appreciate the commenter's support.
    In summary, after consideration of the public comments we received, 
we are finalizing our proposal for the APC assignment of CPT code 
0398T. Specifically, we are reassigning this code to New Technology APC 
1575 (New Technology--Level 38 ($10,001-$15,000)), with a payment rate 
of $12,500.50, for CY 2019 through use of our equitable adjustment 
authority. In addition, we are finalizing our proposal, without 
modification, to assign HCPCS code C9734 to APC 5114. We also are 
finalizing our proposal to continue to assign CPT codes 0071T and 0072T 
to APC 5414, without modification. Table 17 below lists the final CY 
2018 status indicator and APC assignments for MRgFUS procedures. We 
refer readers to Addendum B of this final rule with comment period for 
the final payment rates for all codes reportable under the OPPS. 
Addendum B is available via the internet on the CMS website.

BILLING CODE 4120-01-P

[[Page 58896]]

[GRAPHIC] [TIFF OMITTED] TR21NO18.031


[[Page 58897]]


[GRAPHIC] [TIFF OMITTED] TR21NO18.032

BILLING CODE 4120-01-C
b. Retinal Prosthesis Implant Procedure
    CPT code 0100T (Placement of a subconjunctival retinal prosthesis 
receiver and pulse generator, and implantation of intra-ocular retinal 
electrode array, with vitrectomy) describes the implantation of a 
retinal prosthesis, specifically, a procedure involving the use of the 
Argus[supreg] II Retinal Prosthesis System. This first retinal 
prosthesis was approved by the Food and Drug Administration (FDA) in 
2013 for adult patients diagnosed with severe to profound retinitis 
pigmentosa. Pass-through payment status was granted for the 
Argus[supreg] II device under HCPCS code C1841 (Retinal prosthesis, 
includes all internal and external components) beginning October 1, 
2013, and this status expired on December 31, 2015. We note that after 
pass-through payment status expires for a medical device, the payment 
for the device is packaged into the payment for the associated surgical 
procedure. Consequently, for CY 2016, the device described by HCPCS 
code C1841 was assigned to OPPS status indicator ``N'' to indicate that 
payment for the device is packaged and included in the payment rate for 
the surgical procedure described by CPT code 0100T. For CY 2016, the 
procedure described by CPT code 0100T was assigned to New Technology 
APC 1599, with a payment rate of $95,000, which was the highest paying 
New Technology APC for that year. This payment includes both the 
surgical procedure (CPT code 0100T) and the use of the Argus[supreg] II 
device (HCPCS code C1841). However, stakeholders (including the device 
manufacturer and hospitals) believed that the CY 2016 payment rate for 
the procedure involving the Argus[supreg] II System was insufficient to 
cover the hospital cost of performing the procedure, which includes the 
cost of the retinal prosthesis at the retail price of approximately 
$145,000.
    For CY 2017, analysis of the CY 2015 OPPS claims data used for the 
CY 2017 final rule with comment period showed 9 single claims (out of 
13 total claims) for the procedure described by CPT code 0100T, with a 
geometric mean cost of approximately $142,003 based on claims submitted 
between January 1, 2015, through December 31, 2015, and processed 
through June 30, 2016. Based on the CY 2015 OPPS claims data available 
for the final rule with comment period and our understanding of the 
Argus[supreg] II procedure, we reassigned the procedure described by 
CPT code 0100T from New Technology APC 1599 to New Technology APC 1906, 
with a final payment rate of $150,000.50 for CY 2017. We noted that 
this payment rate included the cost of both the surgical procedure (CPT 
code 0100T) and the retinal prosthesis device (HCPCS code C1841).
    For CY 2018, the reported cost of the Argus[supreg] II procedure 
based on CY 2016 hospital outpatient claims data used for the CY 2018 
OPPS/ASC final rule with comment period was approximately $94,455, 
which was more than $55,000 less than the payment rate for the 
procedure in CY 2017. We noted that the costs of the Argus[supreg] II 
procedure are extraordinarily high compared to many other procedures 
paid under the OPPS. In addition, the number of claims submitted has 
been very low and has not exceeded 10 claims within a single year. We 
believed that it is important to mitigate significant payment 
differences, especially shifts of several tens of thousands of dollars, 
while also basing payment rates on available cost information and 
claims data. In CY 2016, the payment rate for the Argus[supreg] II 
procedure was $95,000.50. The payment rate increased to $150,000.50 in 
CY 2017. For CY 2018, if we had established the payment rate based on 
updated final rule claims data, the payment rate would have decreased 
to $95,000.50 for CY 2018, a decrease of $55,000 relative to CY 2017. 
We were concerned that these large changes in payment could potentially 
create an access to care issue for the Argus[supreg] II procedure, and 
we wanted to establish a payment rate to mitigate the potential sharp 
decline in payment from CY 2017 to CY 2018.
    In accordance with section 1833(t)(2)(B) of the Act, we must 
establish that services classified within each APC are comparable 
clinically and with respect to the use of resources. Therefore, we used 
our equitable adjustment authority under section 1833(t)(2)(E) of the 
Act, which states that the Secretary shall establish, in a budget 
neutral manner, other adjustments as determined to be necessary to 
ensure equitable payments, to maintain the payment rate for this 
procedure, despite the lower geometric mean costs available in the 
claims data used for the final rule with comment period. For CY 2018, 
we reassigned the Argus[supreg] II procedure to APC 1904 (New 
Technology--Level 50 ($115,001-$130,000)), which established a payment 
rate for the Argus[supreg] II procedure of $122,500.50, which was the 
arithmetic mean of the payment rates for the procedure for CY 2016 and 
CY 2017.
    As discussed in the CY 2019 OPPS/ASC proposed rule (83 FR 37093 
through 37094), for CY 2019, the reported cost of the Argus[supreg] II 
procedure based on CY 2017 hospital outpatient claims data used for the 
CY 2019 OPPS/ASC proposed rule was approximately $152,021, which was 
$29,520 more than the payment rate for the procedure for CY 2018. In 
the proposed rule, we continued to note that the costs of the 
Argus[supreg] II procedure are extraordinarily high compared to many 
other procedures paid under the OPPS. In

[[Page 58898]]

addition, the number of claims submitted has been very low and did not 
exceed 10 claims for CY 2017. We stated that we continue to believe 
that it is important to mitigate significant payment differences, 
especially shifts of several tens of thousands of dollars, while also 
basing payment rates on available cost information and claims data 
because we are concerned that large decreases in the payment rate could 
potentially create an access to care issue for the Argus[supreg] II 
procedure. In addition, we indicated that we wanted to establish a 
payment rate to mitigate the potential sharp increase in payment from 
CY 2018 to CY 2019, and potentially ensure a more stable payment rate 
in future years.
    In accordance with section 1833(t)(2)(B) of the Act, we must 
establish that services classified within each APC are comparable 
clinically and with respect to the use of resources. Therefore, as 
discussed in section III.C.2. of the proposed rule, we proposed to use 
our equitable adjustment authority under section 1833(t)(2)(E) of the 
Act, which states that the Secretary shall establish, in a budget 
neutral manner, other adjustments as determined to be necessary to 
ensure equitable payments, to establish a payment rate that is more 
representative of the likely cost of the service. We stated that we 
believe the likely cost of the Argus[supreg] II procedure is lower than 
the geometric mean cost calculated from the CY 2017 claims data used 
for the proposed rule and closer to the CY 2018 payment rate.
    We analyzed claims data for the Argus[supreg] II procedure using 
the last 3 years of available data from CY 2015 through CY 2017. These 
data included claims from the last year (CY 2015) that the 
Argus[supreg] II received transitional device pass-through payments and 
the first 2 years since device pass-through payment status for the 
Argus[supreg] II expired. We found the geometric mean for the procedure 
to be $129,891 (compared to $152,021 in CY 2017 alone), the arithmetic 
mean to be $134,619, and the median to be $133,679. As indicated in our 
proposal in section III.C.2. of the proposed rule (83 FR 37091 through 
37092), we presented the result of each statistical methodology in the 
preamble of the proposed rule, and requested public comment on which 
methodology should be used to establish a payment rate. We proposed to 
use the arithmetic mean, which generates the highest payment rate of 
the three statistical methodologies, to estimate the cost of the 
Argus[supreg] II procedure as a means to balance the fluctuations in 
the costs of the procedure that have occurred from CY 2015 through CY 
2017, while acknowledging the higher payment rates for the procedure in 
CY 2015 and CY 2017. Therefore, for CY 2019, we proposed to reassign 
the Argus[supreg] II procedure from APC 1904 (New Technology--Level 50 
($115,001-$130,000)) to APC 1906 (New Technology--Level 51 ($130,001-
$145,000)), which resulted in a proposed payment rate for the 
Argus[supreg] II procedure of $137,500.50.
    As we do each year, we acquired claims data regarding hospital 
costs associated with new procedures. We regularly examine the claims 
data and any available new information regarding the clinical aspects 
of new procedures to confirm that our OPPS payments remain appropriate 
for procedures like the Argus[supreg] II procedure as they transition 
into mainstream medical practice (77 FR 68314). We noted that the 
proposed payment rate included both the surgical procedure (CPT code 
0100T) and the use of the Argus[supreg] II device (HCPCS code C1841).
    Comment: Several commenters requested that CMS reassign CPT code 
0100T to APC 1908 (New Technology--Level 52 ($145,001-$160,000)) with a 
payment rate of $152,500.50. The commenters were concerned that the 
proposed assignment of APC 1906 (New Technology--Level 51 ($130,001-
$145,000)) with a payment rate of $137,500.50 will not cover all of the 
costs of the procedure.
    Response: We have updated our payment rate for CPT code 0100T. We 
analyzed claims data for the Argus[supreg] II procedure using the last 
3 years of available data from CY 2015 through CY 2017, which was 
updated with additional claims from CY 2017. These data included claims 
from the last year (CY 2015) that the Argus[supreg] II received 
transitional device pass-through payments and the first 2 years since 
device pass-through payment status for the Argus[supreg] II expired. We 
found the updated geometric mean cost for the procedure to be $145,808 
(compared to $129,891 in the proposed rule), the arithmetic mean cost 
to be $151,367, and the median cost to be $151,266. All three of these 
methods of calculating the cost of the Argus[supreg] II procedure map 
to the cost band associated with APC 1908 (New Technology--Level 52 
($145,001-$160,000)), which has a payment rate of $152,500.50.
    After reviewing the comments we received and updating our data 
analysis, we are reassigning the Argus[supreg] II procedure (CPT code 
0100T) to APC 1908 (New Technology--Level 52 ($145,001-$160,000)) with 
a payment rate of $152,500.50 for CY 2019.
    We discussed in the CY 2019 OPPS/ASC proposed rule that the most 
recent claims data available have shown another payment issue with 
regard to the Argus[supreg] II procedure. We have found that payment 
for the Argus[supreg] II procedure is sometimes bundled into the 
payment for another procedure. We identified two possible instances in 
the CY 2017 claims data in which this may have occurred. The bundling 
of payment for the Argus[supreg] II procedure occurs when the procedure 
is reported with other eye procedures assigned to a comprehensive APC 
(C-APC). A C-APC bundles payment for all services related to the 
primary service into one payment rate. We stated in the proposed rule 
that we were concerned that when payment for new technology services is 
bundled into the payment for comprehensive procedures, there is not 
complete claims information to estimate accurately the cost of these 
services to allow their assignment to clinical APCs. Therefore, we 
proposed to exclude payment for all procedures assigned to New 
Technology APCs from being bundled into the payment for procedures 
assigned to a C-APC. This action would allow for separate payment for 
the Argus[supreg] II procedure even when it is performed with another 
comprehensive service, which would provide more cost information 
regarding the procedure. This proposal was also discussed in section 
II.A.2.c. of the proposed rule.
    Comment: A number of commenters supported the proposal.
    Response: We appreciate the commenters' support.
    After consideration of the public comments we received, we are 
finalizing our proposal to exclude payment for all procedures assigned 
to New Technology APCs from being bundled into the payment for 
procedures assigned to a C-APC for CY 2019.
c. Bronchoscopy With Transbronchial Ablation of Lesion(s) by Microwave 
Energy
    CMS has established HCPCS code C9751 (Bronchoscopy, rigid or 
flexible, transbronchial ablation of lesion(s) by microwave energy, 
including fluoroscopic guidance, when performed, with computed 
tomography acquisition(s) and 3-D rendering, computer-assisted, image-
guided navigation, and endobronchial ultrasound (EBUS) guided 
transtracheal and/or transbronchial sampling (e.g., aspiration[s]/
biopsy[ies]) and all mediastinal and/or hilar lymph node stations or 
structures and therapeutic

[[Page 58899]]

intervention(s)), effective January 1, 2019. This microwave ablation 
procedure utilizes a flexible catheter to access the lung tumor via a 
working channel and may be used as an alternative procedure to a 
percutaneous microwave approach. Based on our review of the New 
Technology APC application for this service and the service's clinical 
similarity to existing services paid under the OPPS, we estimated the 
likely cost of the procedure to be between $8,001 and $8,500. 
Therefore, we are assigning the procedure described by HCPCS code C9751 
to New Technology APC 1571 (New Technology--Level 34 ($8,001-$8,500)), 
with a payment rate of $8,250.50 for CY 2019. Details regarding HCPCS 
code C9751 are shown in Table 18.
[GRAPHIC] [TIFF OMITTED] TR21NO18.033

D. OPPS APC-Specific Policies

1. Benign Prostatic Hyperplasia Treatments (APCs 5373 and 5374)
    For the CY 2019 OPPS update, the CPT Editorial Panel established 
new CPT code 53854 to describe the Rezum Therapy procedure, which is 
also known as steam therapy or water vapor therapy, for the treatment 
of benign prostatic hyperplasia. Prior to January 1, 2019, the Rezum 
Therapy procedure was described by HCPCS code C9748, which was assigned 
to APC 5373 (Level 3 Urology and Related Services) when the code was 
established effective January 1, 2018. HCPCS code C9748 will be deleted 
on December 31, 2018 because it will be replaced with new CPT code 
53854, effective January 1, 2019. We note that Table 19 below lists the 
long descriptors for both HCPCS code C9748 and CPT code 53854.
    As displayed in Table 19 below, and in Addendum B to the CY 2019 
OPPS/ASC proposed rule, we proposed to delete HCPCS code C9748 and 
assign the code to status indicator ``D'' to indicate that the code 
would be deleted for the January 2019 OPPS update. We also proposed to 
assign the new replacement code, CPT code 53854, to APC 5373, with a 
proposed payment rate of approximately $1,731. We note that the 
predecessor HCPCS code for CPT code 53854 (HCPCS code C9748) was also 
assigned to APC 5373. In addition, we note that CPT code 53854 was 
listed as code 538X3 (the 5-digit CMS placeholder code) in Addendum B, 
with the short descriptor, and in Addendum O, with the long descriptor, 
to the CY 2019 OPPS/ASC proposed rule. We also assigned CPT code 53854 
to comment indicator ``NP'' in Addendum B to indicate that the code is 
new for CY 2019 with a proposed APC assignment.
    Comment: Several commenters addressed the proposed APC assignment 
for the Rezum Therapy procedure (CPT code 53854), as well as the APC 
assignments for the following other benign prostatic hyperplasia 
treatment procedures:
     Transurethral microwave therapy (TUMT) procedure, which is 
described by CPT code 53850, and which we proposed to continue to 
assign to APC 5374 (Level 4 Urology and Related Services), with a 
proposed payment rate of approximately $2,756;
     Transurethral needle ablation procedure (TUNA), which is 
described by CPT 53852, and which we proposed to continue to assign to 
APC 5375 (Level 5 Urology and Related Services) with a proposed payment 
rate of approximately $3,776.
    We note that Table 19 lists the long descriptors for the Rezum 
Therapy, TUMT, and TUNA procedures.
    One commenter disagreed with the proposed assignment for the Rezum 
Therapy procedure described by CPT code 53854 to APC 5373, and 
indicated that APC 5373 does not contain other procedures that are 
similar clinically or in resource costs. The commenter stated that the 
Rezum Therapy procedure is comparable to the TUMT procedure, which is 
proposed to be assigned to APC 5374, and the TUNA procedure, which is 
proposed to be assigned to APC 5375. Therefore, the commenter requested 
that CPT code 53854, which describes the Rezum Therapy procedure, be 
assigned to APC 5375 instead of APC 5373. In addition, the commenter 
requested that the TUMT procedure described by CPT code 53850 be 
reassigned from APC 5374 to APC 5375. The commenter further stated that 
all three benign prostatic hyperplasia treatment procedures are 
comparable and suggested that they be assigned to APC 5375 based on 
clinical homogeneity and resource costs. Another commenter also 
believed that the Rezum Therapy procedure described by CPT code 53854 
should be assigned to APC 5375.
    Response: Review of our claims data used for this final rule with 
comment period, which is based on claims submitted between January 1, 
2017 and December 31, 2017, and processed through June 30, 2018, 
reveals that the resource costs for these three benign prostatic 
hyperplasia treatment procedures are significantly different.
    Our analysis shows that the geometric mean cost for CPT code 53850 
(the TUMT procedure) is approximately

[[Page 58900]]

$3,272 (based on 107 single claims out of 107 total claims) compared to 
CPT code 53852 (the TUNA procedure) whose geometric mean cost is 
approximately $2,989 (based on 408 single claims out of 410 total 
claims). In addition, in September 2017, CMS received a New Technology 
APC application requesting a new HCPCS code for the Rezum Therapy 
procedure because, according to the applicant, the only available CPT 
code to report the procedure was CPT code 53899 (Unlisted procedure, 
urinary system). Based on our review of the application, assessment of 
the procedure, and input from our clinical advisors, we established 
HCPCS code C9748, effective January 1, 2018, and assigned the code to 
APC 5373, with a payment rate of approximately $1,696. We announced 
this new HCPCS C-code and APC assignment in the CY 2018 OPPS/ASC final 
rule with comment period (82 FR 59320) and stated that we believed the 
Rezum Therapy procedure shares similar resource costs and clinical 
homogeneity to the other procedures assigned to APC 5373.
    Further, because of the public comments received on the Rezum 
Therapy procedure, we conducted a preliminary claims review for HCPCS 
code C9748, and found that, based on 73 claims that were processed on 
or before July 27, 2018, the geometric mean cost for the procedure is 
approximately $1,711, which is significantly lower than the geometric 
mean cost for either CPT code 53850 (TUMT procedure) at approximately 
$3,272 or CPT code 53852 (TUNA procedure) at approximately $2,989.
    In addition, a presenter at the August 20, 2018 HOP Panel meeting 
requested that the HOP Panel recommend that CMS reassign placeholder 
CPT code 538X3 (CPT code 53854) to APC 5374 or 5375 based on clinical 
similarity to the procedures described by CPT codes 53850 and 53852. 
Based on the information presented at the meeting, the HOP Panel made 
no recommendation to revise the APC assignment for the Rezum Therapy 
procedure. However, based on the public comments received for the 
reassignment for all three benign prostatic hyperplasia treatment 
procedures, we reviewed the procedures assigned to the family of 
Urology APCs for this final rule with comment period and made some 
modifications to more appropriately reflect the resource costs and 
clinical characteristics of the services within each APC grouping. 
Specifically, we revised the APC assignment of the procedures assigned 
to the family of Urology APCs to more appropriately reflect a 
prospective payment system that is based on payment groupings and not 
code-specific payment rates, while maintaining clinical and resource 
homogeneity. Based on our review and modification, we revised the APC 
assignment for CPT code 53852 (the TUNA procedure) from APC 5375 (Level 
5 Urology and Related Services) to APC 5374 (Level 4 Urology and 
Related Services) based on its clinical and resource homogeneity to the 
other procedures in the APC 5374. Specifically, our claims data show 
that the geometric mean cost for CPT code 53852 is approximately 
$2,989, which is comparable to the geometric mean cost of approximately 
$2,952 for APC 5374, rather than the geometric mean cost of 
approximately $4,055 for APC 5375. We believe that this modification to 
the proposed assignment of CPT code 53852 to APC 5374 is appropriate.
    In addition, based on our latest claims data used for the final 
rule with comment period, we believe that CPT codes 53850 (the TUMT 
procedure) and 53852 (the TUNA procedure) are appropriately assigned to 
APC 5374. We also believe that, based on our assessment of the Rezum 
Therapy procedure and its cost, as reported in the CMS New Technology 
application, and based on our preliminary claims review for HCPCS code 
C9748 (which is the predecessor code for CPT code 53854), the Rezum 
Therapy procedure continues to be appropriately assigned to APC 5373 
based on its clinical and resource homogeneity to the other procedures 
in the APC.
    Comment: One commenter agreed with the proposed continued APC 
assignment for CPT code 53852 (the TUNA procedure) to APC 5375. The 
commenter also contended that, while the presenter at the August 20, 
2018 HOP Panel meeting recommended an assignment of APC 5374 or APC 
5375 for the procedure, the Rezum Therapy procedure is less costly to 
perform than the TUNA procedure, and also noted that the HOP Panel made 
no recommendation to CMS to change the APC assignment for either 
procedure.
    Response: Based on our comprehensive review of the procedures 
assigned to the Urology APCs, and analysis of the latest claims data, 
we do not agree that that we should continue to assign the procedure 
described by CPT code 58352 (the TUNA procedure) to APC 5375 because 
the geometric mean cost of the procedure of approximately $2,989 is 
significantly less than the geometric mean cost of approximately $4,055 
for APC 5375. We believe that the geometric mean cost of approximately 
$2,989 for the procedure described by CPT code 53852 is more comparable 
to the geometric mean cost of approximately $2,952 for APC 5374. 
Therefore, for this final rule with comment period, we are revising the 
proposed APC assignment for the procedure described by CPT code 58352 
and assigning the procedure to APC 5374 for CY 2019.
    After consideration of the public comments we received, and based 
on the information presented above, as well as our evaluation of the 
latest claims data for the TUMT, TUNA, and Rezum Therapy procedures, we 
are finalizing the proposed APC assignment for the procedures described 
by CPT code 53850 and CPT code 53854, and revising the APC assignment 
for the procedure described by CPT code 53852 to APC 5374 (instead of 
APC 5375). The final APC and status indicator assignments are listed in 
Table 19 below. We refer readers to Addendum B to this final rule with 
comment period for the final payment rates for all codes reportable 
under the OPPS. Addendum B is available via the internet on the CMS 
website.

[[Page 58901]]

[GRAPHIC] [TIFF OMITTED] TR21NO18.034

2. Cardiac Contractility Modulation (CCM) Therapy (APC 5231)
    For CY 2019, we proposed to continue to assign the procedure 
described by CPT code 0408T (Insertion or replacement of permanent 
cardiac contractility modulation system, including contractility 
evaluation when performed, and programming of sensing and therapeutic 
parameters; pulse generator with transvenous electrodes) to APC 5231 
(Level 1 ICD and Similar Procedures) with a proposed payment rate of 
approximately $22,242.
    Comment: One commenter disagreed with the proposed APC assignment 
of the procedure described by CPT code 0408T to APC 5231 and requested 
that CMS assign the procedure to APC 5232 (Level 2 ICD and Similar 
Procedures), which had a proposed payment rate of approximately 
$30,862. The commenter stated that the proposed payment rate for APC 
5231 does not accurately reflect the cost or clinical characteristics 
of the procedure and technology. The commenter added that while the 
procedure code has had an extremely low volume of OPPS claims, the 
number of claims reporting this procedure code is expected to increase 
in the future after the completion of a large, prospective multicenter 
study to evaluate CCM and its impact on the quality of life and long-
term mortality in patients with moderate to severe heart failure. The 
commenter stated that the cost of the complete CCM system is 
approximately $25,000, which is comparable to the cost of an ICD system 
($20,000) and CRT-D system ($30,000) whose procedure codes are assigned 
to APC 5232. Moreover, the commenter noted that, under the IPPS, the 
procedures describing the insertion of the complete system are assigned 
to one MS-DRG, and suggested that CMS adopt this same methodology under 
the OPPS. Specifically, the commenter recommended that CMS assign the 
procedure describing the insertion of the complete systems for the CCM, 
ICD, and CRT-D systems to APC 5232.
    Response: The commenter suggested that we assign the procedures 
describing the insertion of the complete CCM, ICD, and CRT-D to one APC 
but did not provide the specific CPT codes associated with the ICD and 
CRT-D systems. Based on the information provided, we believe that the 
commenter is requesting that we assign to APC 5232 the following codes:
     Cardiac contractility modulation (CCM): CPT code 0408T 
(which we proposed in APC 5231 (Level 1 ICD and Similar Procedures));
     Implantable cardioverter-defibrillator (ICD): CPT code 
33249 (which we proposed in APC 5232 (Level 2 ICD and Similar 
Procedures)); and
     Cardiac Resynchronization Therapy Defibrillator (CRT-D): 
CPT codes 33249 (which we proposed to assign to APC 5232 (Level 2 ICD 
and Similar Procedures) and 33225 (which we proposed to package payment 
because this is an add-on code), or CPT code 33270 (which we proposed 
to assign to APC 5232 (Level 2 ICD and Similar Procedures)).
    Based on the latest hospital outpatient claims data used for this 
final rule with comment period, our analysis does not support the 
assignment of the procedures describing the insertion of the complete 
CCM systems (described by CPT code 0408T) to APC 5232. We examined the 
latest hospital outpatient claims data for CPT code 0408T for dates of 
service between January 1, 2017, and December 31, 2017, that were 
processed on or before June 30, 2018. Our analysis of the claims data 
show a geometric mean cost of approximately $15,131 for CPT code 0408T, 
based on 2 single claims (out of 2 total claims). We do not believe 
that it is appropriate

[[Page 58902]]

to assign the procedure described by CPT code 0408T to APC 5232 because 
its geometric mean cost is approximately $30,921, which is 
significantly higher than the geometric mean cost of approximately 
$15,131 for CPT code 0408T. Therefore, assigning the procedure 
described by CPT code 0408T to APC 5232 would result in an overpayment 
for the procedure. We believe that APC 5231 is the most appropriate APC 
assignment for the procedure described by CPT code 0408T based on its 
clinical and resource homogeneity to the other procedures assigned to 
this APC.
    We also analyzed the latest hospital outpatient claims data for the 
procedure for the insertion of the complete systems for ICD and CRT-D. 
The insertion of a complete ICD system is described by CPT code 33249, 
and our analysis reveals that the geometric mean cost of approximately 
$33,384 for CPT code 33249 based on 29,451 single claims (out of 29,867 
total claims) is significantly higher than that of CPT code 0408T whose 
geometric mean cost is approximately $15,131. The insertion of a 
complete CRT-D system is described by either CPT code 33249 or 33270. 
Similar to the procedure described by CPT code 33249, our findings 
reveal that the geometric mean cost for the procedure described by CPT 
code 33270 is approximately $35,361 based on 1,011 single claims (out 
of 1,023 total claims), which is significantly greater than that of CPT 
code 0408T. Based on our claims data, we do not believe that we should 
reassign the procedure described by CPT code 0408T (the insertion of 
the complete CCM systems) to APC 5232, which is the APC assignment for 
the insertion of the complete ICD and CRT-D systems. We believe that 
the geometric mean cost of approximately $15,131 for CPT code 0408T is 
comparable to the geometric mean cost of about $22,187 for APC 5231. We 
also believe that the geometric mean cost of approximately $33,384 for 
CPT code 33249, and the geometric mean cost of approximately $35,361 
for CPT code 33270 are comparable to the geometric mean cost of 
approximately $30,921 for APC 5232.
    Therefore, after consideration of the public comment we received, 
we are finalizing our proposal, without modification, to assign CPT 
code 0408T to APC 5231, and to continue to assign CPT code 33249 and 
33270 to APC 5232 for CY 2019. The final CY 2019 payment rate for the 
code can be found in Addendum B to this final rule with comment period 
(which is available via the internet on the CMS website).
    As we do every year, we will reevaluate the APC assignment for CPT 
codes 0408T, 33249, and 33270 for the next rulemaking cycle. We remind 
hospitals that we review, on an annual basis, the APC assignments for 
all items and services paid under the OPPS.
3. Cardiac Resynchronization Therapy (APCs 5221, 5222, 5231, 5731, and 
5741)
    In Addendum B to the CY 2019 OPPS/ASC proposed rule, we proposed to 
assign eight new CY 2019 cardiac resynchronization therapy CPT codes to 
various APCs, which are listed in Table 20 below. The codes were listed 
as 06X5T, 06X6T, 06X7T, 06X8T, 06X9T, 07X2T, 06X0T, and 07X0T (the 5-
digit CMS placeholder codes) in Addendum B with short descriptors and 
in Addendum O with long descriptors to the CY 2019 OPPS/ASC proposed 
rule. We also assigned these codes to comment indicator ``NP'' in 
Addendum B to the proposed rule to indicate that the codes are new for 
CY 2019 with proposed APC assignments and that public comments would be 
accepted on their proposed APC assignments. We note that these codes 
will be effective January 1, 2019.
[GRAPHIC] [TIFF OMITTED] TR21NO18.035

    Comment: One commenter disagreed with CMS' proposed APC assignments 
for certain cardiac resynchronization Category III CPT codes that are 
new for CY 2019 and therefore do not have associated claims data 
available. Specifically, the commenter requested that five of the eight 
new CPT codes be reassigned to the following APCs:
     CPT code 0515T (Insertion of wireless cardiac stimulator 
for left ventricular pacing, including device interrogation and 
programming, and imaging supervision and interpretation

[[Page 58903]]

when performed; complete system (includes electrode and generator 
[transmitter and battery]))--from the proposed assignment to APC 5222 
(Level 2 Pacemaker and Similar Procedures) to APC 5231 (Level 1 ICD and 
Similar Procedures);
     CPT code 0516T (Insertion of wireless cardiac stimulator 
for left ventricular pacing, including device interrogation and 
programming, and imaging supervision and interpretation when performed; 
electrode only)--from the proposed assignment to APC 5221 (Level 1 
Pacemaker and Similar Procedures) to APC 5194 (Level 4 Endovascular 
Procedures);
     CPT code 0517T (Insertion of wireless cardiac stimulator 
for left ventricular pacing, including device interrogation and 
programming, and imaging supervision and interpretation when performed; 
pulse generator component(s) only (battery and/or transmitter))--from 
the proposed assignment to APC 5221 to APC 5222 (Level 2 Pacemaker and 
Similar Procedures);
     CPT code 0520T (Removal and replacement of wireless 
cardiac stimulator for left ventricular pacing; pulse generator 
component(s) (battery and/or transmitter) including placement of a new 
electrode)--from the proposed assignment to APC 5221 to APC 5231; and
     CPT code 0521T (Interrogation device evaluation (in 
person) with analysis, review and report, includes connection, 
recording, and disconnection per patient encounter, wireless cardiac 
stimulator for left ventricular pacing)--from the proposed assignment 
to APC 5731 (Level 1 Minor Procedures) to APC 5741 (Level 1 Electronic 
Analysis of Devices)
    First, the commenter stated that CPT codes 0515T and 0520T describe 
the implantation or removal/replacement of the complete system and, 
consequently, these procedures should be assigned to APC 5231. Second, 
the commenter stated that the resources associated with the procedure 
described by CPT 0516T are similar to those procedures described by CPT 
code 33274 (Transcatheter insertion or replacement of permanent 
leadless pacemaker, right ventricular, including imaging guidance 
(e.g., fluoroscopy, venous ultrasound, ventriculography, femoral 
venography) and device evaluation (e.g., interrogation or programming), 
when performed), which is assigned to APC 5194, and, therefore, this 
new code should also be assigned to the same APC. In addition, the 
commenter indicated that the procedure described by CPT code 0517T 
shares the same clinical and resource homogeneity as the procedure 
described by CPT code 33212 (Insertion of pacemaker pulse generator 
only; with existing single lead), which is assigned to APC 5222, and 
the procedure described by CPT code 33213 (Insertion of pacemaker pulse 
generator only; with existing dual leads), which is assigned to APC 
5223 ((Level 3 Pacemaker and Similar Procedures). Further, the 
commenter stated that the resources associated with the procedure 
described by CPT code 0521T are similar to those for the procedures 
described by existing CPT codes 93261 (Interrogation device evaluation 
(in person) with analysis, review and report by a physician or other 
qualified health care professional, includes connection, recording and 
disconnection per patient encounter; implantable subcutaneous lead 
defibrillator system), CPT codes 93288 (Interrogation device evaluation 
(in person) with analysis, review and report by a physician or other 
qualified health care professional, includes connection, recording and 
disconnection per patient encounter; single, dual, or multiple lead 
pacemaker system), 93289 (Interrogation device evaluation (in person) 
with analysis, review and report by a physician or other qualified 
health care professional, includes connection, recording and 
disconnection per patient encounter; single, dual, or multiple lead 
transvenous implantable defibrillator system, including analysis of 
heart rhythm derived data elements), 93290 (Interrogation device 
evaluation (in person) with analysis, review and report by a physician 
or other qualified health care professional, includes connection, 
recording and disconnection per patient encounter; implantable 
cardiovascular monitor system, including analysis of 1 or more recorded 
physiologic cardiovascular data elements from all internal and external 
sensors), and 93292 (Interrogation device evaluation (in person) with 
analysis, review and report by a physician or other qualified health 
care professional, includes connection, recording and disconnection per 
patient encounter; wearable defibrillator system), which are all 
assigned to APC 5741, and, consequently, the procedure described by CPT 
code 0521T also should be assigned to this same APC.
    Response: Based on our clinical review, we agree with the commenter 
that there is greater homogeneity, both clinically and in terms of 
resource use, by assigning CPT codes 0515T and 0520T to APC 5231. We 
also agree with the commenter that CPT code 0517T is more homogenous 
clinically and in terms of resource use with the procedures assigned to 
APC 5222. However, we disagree with the commenter's recommendation to 
assign the procedure described by CPT 0516T to APC 5194. Based on our 
review of the procedure, we believe that CPT code 0516T is 
appropriately assigned to APC 5222 because of its clinical and resource 
homogeneity to the other procedures assigned to this APC. We also 
disagree with the commenter's suggestion to assign the procedure 
described by CPT code 0521T to APC 5741 because the resources required 
in performing this procedure are not as intensive as those required for 
the procedure described by CPT code 0522T, which we proposed to assign 
to APC 5741. We believe that the procedure described by CPT code 0521T 
is appropriately assigned to APC 5731 because of its clinical and 
resource homogeneity to the other procedures assigned to this APC. 
Table 21 below summarizes the commenter's requested APC assignment for 
each of the codes along with our decision and the final APC and status 
indicator assignments.
    In summary, after consideration of the public comment we received, 
we are finalizing our proposal to assign the procedures described by 
CPT codes 0518T, 0519T, 0521T, and 0522T to the final APCs listed in 
Table 21 below. We are modifying our proposed APC assignment of the 
procedures described by CPT codes 0515T, 0516T, 0517T, and 0520T, and 
these modifications are reflected in the final APCs listed in Table 21 
below. The final CY 2019 payment rate for CPT codes 0515T through 0521T 
can be found in Addendum B to this final rule with comment period 
(which is available via the internet on the CMS website).
BILLING CODE 4120-01-P

[[Page 58904]]

[GRAPHIC] [TIFF OMITTED] TR21NO18.036

BILLING CODE 4120-01-C
4. Chimeric Antigen Receptor T-Cell (CAR T) Therapy (APCs 5694, 9035, 
and 9094)
    Chimeric Antigen Receptor (CAR) T-cell therapy is a cell-based gene 
therapy in which T-cells are collected and genetically engineered to 
express a chimeric antigen receptor that will bind to a certain protein 
on a patient's cancerous cells. The CAR T-cells are then administered 
to the patient to attack certain cancerous cells and the individual is 
observed for potential serious side effects that would require medical 
intervention.
    Two CAR T-cell therapies received FDA approval in 2017. 
KYMRIAH[supreg] (manufactured by Novartis Pharmaceuticals Corporation) 
was approved for use in the treatment of patients up to 25 years of age 
with B-cell precursor acute lymphoblastic leukemia (ALL) that is 
refractory or in second or later relapse. In May 2018, KYMRIAH[supreg] 
received FDA approval for a second indication, treatment of adult 
patients with relapsed or refractory large B-cell lymphoma after two or 
more lines of systemic therapy, including diffuse large B-cell lymphoma 
(DLBCL), high grade B-cell lymphoma, and DLBCL arising from follicular 
lymphoma. YESCARTA[supreg] (manufactured by Kite Pharma, Inc.) was 
approved for use in the treatment of adult patients with relapsed or 
refractory large B-cell lymphoma and who have not responded to or who 
have relapsed after at least two other kinds of treatment.
    As indicated in the CY 2019 OPPS/ASC proposed rule (83 FR 37114), 
the HCPCS code to describe the use of KYMRIAH[supreg] (HCPCS code 
Q2040) has been active since January 1, 2018 for OPPS, and the HCPCS 
code to describe the use of YESCARTA[supreg] (HCPCS code Q2041) has 
been active since April, 1, 2018 for OPPS. The HCPCS coding for the 
currently approved CAR T-cell therapies include leukapheresis and dose 
preparation procedures because these services are included in the 
manufacturing of these biologicals. Both of these CAR T-cell therapies 
were approved for transitional pass-through payment status, effective 
April 1, 2018. The HCPCS codes that describe the use of these CAR T-
cell therapies were assigned status indicator ``G'' in Addenda A and B 
to the CY 2019 OPPS/ASC proposed rule.
    As discussed in section V.A.4. (Drugs, Biologicals, and 
Radiopharmaceuticals with New or Continuing Pass-Through Payment Status 
in CY 2019) of this final rule with comment period, we are finalizing 
our proposal to continue pass-through payment status for HCPCS code 
Q2040 (which is being deleted and replaced with HCPCS code Q2042, 
effective January 1, 2019) and HCPCS code Q2041 for CY 2019. In section 
V.A.4. of this final rule with comment period, we also are finalizing 
our proposal to determine the pass-through payment rate following the 
standard ASP methodology, updating pass-through payment rates on a 
quarterly basis if applicable information indicates that adjustments to 
the payment rates are necessary.
    The AMA created four Category III CPT codes that are related to CAR 
T-cell therapy, effective January 1, 2019. As listed in Addendum B of 
the CY 2019 OPPS/ASC proposed rule, we proposed to assign procedures 
described by these CPT codes, 0537T, 0538T, 0539T, and 0540T, to status 
indicator ``B'' (Codes that are not recognized by OPPS when submitted 
on an outpatient hospital Part B bill type (12x and 13x)) to indicate 
that the services are not paid under the OPPS. We note that, these 
codes were listed as placeholder CPT codes 05X1T, 05X2T, 05X3T, and 
05X4T in both Addendum B and O to the CY 2019

[[Page 58905]]

OPPS/ASC proposed rule. Addendum B listed the short descriptor, with 
the proposed status indicator of ``B'', while Addendum O listed the 
complete long descriptors under placeholder CPT codes 05X1T, 05X2T, 
05X3T, and 05X4T. The final CPT codes and long descriptors, with their 
respective proposed OPPS status indicators, are listed in Table 23 at 
the end of this section.
    At the summer 2018 meeting of the HOP Panel, the HOP Panel 
recommended that CMS reassign the status indicator for procedures 
described by these specific CPT codes from ``B'' to ``S''. The Panel 
further recommended that CMS assign the procedures described by CPT 
code 0537T and CPT code 0540T to APC 5242 (Level 2 Blood Product 
Exchange and Related Services), and the procedures described by CPT 
code 0538T and CPT code 0539T to APC 5241 (Level 1 Blood Product 
Exchange and Related Services).
    Comment: Some commenters disagreed with the proposed status 
indicator assignment of ``B'' for the procedures described by CPT codes 
0537T, 0538T, 0539T, and 0540T, and requested that CMS recognize these 
procedures and the services described by the CPT codes under the OPPS 
and pay separately for them. Some of these commenters urged CMS to 
accept and finalize the HOP Panel's recommendations for assignment of 
these CPT codes. Commenters stated that providers may currently use the 
unlisted code (38999) to bill for the services described by the new CPT 
codes because the currently available CPT codes fail to accurately 
describe the procedure being rendered. The commenters indicated that 
these services are similar to stem cell transplant services, and 
suggested that the similarities between various codes, including 
similarities between the procedures described by CPT code 05X1T (0537T) 
and CPT code 38206 (Blood-derived hematopoietic progenitor cell 
harvesting for transplantation, per collection; autologous), which is 
assigned to APC 5242 (Level 2 Blood Product Exchange and Related 
Services); CPT code 05X2T (0538T) and CPT code 38207 (Transplant 
preparation of hematopoietic progenitor cells; cryopreservation and 
storage), which is assigned to APC 5241 (Level 1 Blood Product Exchange 
and Related Services); CPT code 05X3T (0539T) and CPT code 38208 
(Transplant preparation of hematopoietic progenitor cells; 
cryopreservation and storage; thawing of previously frozen harvest, 
without washing, per donor), which is assigned to APC 5241 (Level 1 
Blood Product Exchange and Related Services), and finally CPT code 
05X4T (0540T) and CPT code 38241(Hematopoietic progenitor cell (hpc); 
autologous transplantation), which is assigned to APC 5242 (Level 2 
Blood Product Exchange and Related Services), be validly recognized and 
considered when determining applicable policy and assignments.
    A few commenters believed that there are possible similarities 
between the CAR T-cell procedure CPT code 0540T and chemotherapy codes, 
in general. However, other commenters asserted that CAR T-cell services 
were distinct from the services associated with chemotherapy and stem 
cell transplant codes, but noted that the codes suggested were the best 
available approximations for payment at present and could provide 
useful benchmarks of resource utilization. Some commenters also 
supported the creation of a new Autologous HCT C-APC to adequately 
compensate providers for providing CAR T-cell related services. Some 
commenters requested that the existing Q-codes for CAR T-cell therapies 
be revised to reference only the CAR T-cell products, and that 
leukapheresis and other services related to the preparation, collection 
and treatment be separately coded and paid.
    A few commenters referenced the National Coverage Decision (NCD) 
for apheresis (effective 1992), which provides coverage only under 
limited conditions for therapeutic apheresis, and asked CMS to clarify 
whether it applies to harvesting blood-derived T-lymphocytes for 
development of genetically modified autologous CAR T-cells. Some 
commenters referenced the ongoing National Coverage Analysis (NCA) for 
CAR T-cells, and asked CMS to provide guidance in the interim on how to 
bill for CAR T-cells and its therapies' administration.
    The commenters also suggested additional modifications to HCPCS 
codes Q2040 and Q2041, such as adopting HCPCS J-codes instead of HCPCS 
Q-codes. Some commenters requested guidance on how to bill for specific 
services, incomplete services, or partial services related to CAR T-
cell therapy, including but not limited to, billing for pre-infusion 
steps, billing for services provided a number of days before the 
infusion, billing if the CAR T-cell product is not infused, and billing 
if services are provided at different facilities, such as both 
inpatient and outpatient facilities.
    Finally, another commenter supported the proposal not to pay 
separately for procedures described by CPT codes 0537T, 0538T and 0539T 
because the commenters maintained that payment for these CPT codes and 
the performance of the services describe various steps of the 
manufacturing process and, therefore, are appropriately included and 
conveyed in the descriptors of and the existence of Q-codes for CAR T-
cell therapies. The commenter supported the appropriateness of 
including these steps in the payment for the drug as a means to ensure 
the manufacturer can preserve the integrity of the process and to 
maximize the quality of therapy. Finally, one commenter believed that 
separate payments for leukapheresis would increase beneficiary cost-
sharing.
    Response: We do not believe that separate payment under the OPPS is 
necessary for procedures described by CPT codes 0537T, 0538T, and 
0539T. The existing CAR T-cell therapies on the market were approved as 
biologics and, therefore, provisions of the Medicare statute providing 
for payment for biologicals apply. The procedures described by CPT 
codes 0537T, 0538T, and 0539T describe various steps required to 
collect and prepare the genetically modified T-cells, and Medicare does 
not generally pay separately for each step used to manufacture a drug 
or biological. We note that the HCPCS coding for the currently approved 
CAR T-cell therapy drugs, HCPCS codes Q2040 and Q2041, includes 
leukapheresis and dose preparation procedures because these services 
are included in the manufacturing of these biologicals. We also note 
that, for OPPS billing purposes, the Q-codes are treated in the same 
manner as J-codes, and a procedure assignment conversion to a J-code 
for payment classification purposes would not affect payment by 
Medicare. Q-codes can be updated quarterly, which allows for greater 
frequency of modifications and, therefore, we believe are appropriate 
for these new therapies. HOPDs can bill Medicare for reasonable and 
necessary services that are otherwise payable under the OPPS, and we 
believe that the comments in reference to payment for services provided 
in settings not payable under OPPS are outside the scope of the 
proposed rule.
    With respect to NCD 110.14 for apheresis (Therapeutic Pheresis) 
(https://www.cms.gov/medicare-coverage-database/details/ncd-details.aspx?NCDId=;82&ncdver=1&bc=AAAAgAAAAAAA&), we note that it 
refers only to therapeutic treatments where blood is taken from the 
patient, processed, and returned to the patient as

[[Page 58906]]

part of a continuous procedure and is distinguished from situations 
where a patient is transfused at a later date. With respect to comments 
referencing the ongoing NCA for CAR T-cells, we remind readers that 
coverage analysis and determination do not determine what code or 
payment is assigned a particular item or service, but information on 
this NCA and process may be found at: https://www.cms.gov/medicare-coverage-database/details/nca-tracking-sheet.aspx?NCAId=291. 
Accordingly, we are not revising the existing Q-codes for CAR T-cell 
therapies to remove leukapheresis and dose preparation procedures, and 
we are not accepting the HOP Panel's recommendations for procedures 
described by CPT codes 0537T, 0538T and 0539T.
    In regard to comments concerning CPT code 0540T, we were persuaded 
by commenters that the administration of CAR T-cell services would be 
more specifically described by CPT code 0540T. Because CPT code 0540T 
is a new code for CY 2019, we do not have any claims data on which to 
base our proposed payment rate. In the absence of claims data, we 
reviewed the clinical characteristics of the procedures to determine 
whether they are similar to existing procedures. After reviewing 
information from public commenters and input from our medical advisors, 
we believe that new CPT code 0540T is clinically similar to the 
services assigned to APC 5694 (Level IV Drug Administration), with a 
proposed payment rate of approximately $291, such as the procedure 
described by CPT code 96413 (Chemotherapy administration, intravenous 
infusion technique; up to 1 hour, single or initial substance/drug). We 
acknowledge commenters' supporting data and indications that CAR T-cell 
service is complex, distinct from chemotherapy, and has the potential 
for highly adverse reactions. However, we note that CPT's prefatory 
language for the ``Chemotherapy and Other Highly Complex Drug or Highly 
Complex Biologic Agent Administration'' section in which the procedure 
described by CPT code 96413, and some other services assigned to APC 
5694 are listed, describes these procedures as administration of highly 
complex drugs or biologic agents with greater incidence of severe 
adverse patient reaction. We also note that the unique toxicities 
associated with CAR T-cell therapies tend not to occur at time of 
infusion, and services to monitor or treat adverse reactions on a 
subsequent day would not be included in the procedure described by CPT 
code 0540T. Therefore, we are accepting the HOP Panel's recommendation 
and the commenters' request to reassign the status indicator assignment 
of the procedure described by CPT code 0540T from ``B'' to ``S.'' 
However, we are not accepting the HOP Panel's recommendation and the 
commenters' request to assign the procedure described by CPT code 0540T 
to APC 5242 (Level 2 Blood Product Exchange and Related Services), but 
instead are assigning the procedure described by CPT code 0540T to APC 
5694 (Level IV Drug Administration) for CY 2019. We remind hospitals 
that every year, we review the APC assignments for all services and 
items paid under the OPPS, and we will reevaluate the APC assignment 
for the procedures described by CPT code 0540T once sufficient claims 
data for this code become available.
    Comment: Some commenters suggested that separately paying for the 
services described by new CPT codes for CAR T-cell therapy under the 
OPPS would allow Medicare and others to track utilization and cost data 
of these specific services. Some commenters also noted that the 
National Uniform Billing Committee (NUBC) established two new revenue 
codes and a value code related to CAR T-cell therapy, and expressed 
support for CMS' creation of a new CAR T-cell-related cost center (or 
centers) to assist with tracking CAR T-cell-related costs.
    Response: The existing HCPCS codes for CAR T-cell therapies include 
both leukapheresis and dose-preparation procedures, and for the reasons 
stated previously, there is no separate payment by Medicare for these 
steps in the manufacturing process. However, it will be possible for 
Medicare to track utilization and cost data from hospitals reporting 
these services, even for codes reported for services in which no 
separate payment is made. The CAR T-cell related revenue codes and 
value code established by the NUBC will be reportable on HOPD claims, 
and will be available for tracking utilization and cost data, effective 
for claims received on or after April 1, 2019. At this time, we do not 
believe that the additional creation by CMS of a new cost center is 
necessary as the currently established methods for tracking CAR T-cell 
related costs are sufficient. However, we will monitor for this issue 
to determine if a distinct cost center should be established in the 
future.
    Comment: Some commenters noted that HCPCS code Q2040 describes 
doses of ``up to 250 million'' cells, and requested guidance on how to 
bill for an adult indication that may require doses of ``up to 600 
million cells.''
    Response: HCPCS code Q2040 (which is being replaced by HCPCS code 
Q2042, effective January 1, 2019) is billed only once per infusion. For 
CY 2019, we revised the descriptor for HCPCS code Q2042 to describe 
doses ``up to 600 million cells . . . per therapeutic dose.'' For CY 
2019, we also revised the descriptor for HCPCS code Q2041, in order to 
maintain consistency in the HCPCS coding for CAR T-cells.
    In summary, after consideration of the public comments we received, 
we are adopting as final, without modification, the proposal to assign 
status indicator ``B'' to CPT codes 0537T, 0538T, and 0539T for CY 
2019. We are revising our proposal and finalizing the policy to assign 
status indicator ``S'' to CPT code 0540T and to assign CPT code 0540T 
to APC 5694 for CY 2019. Additionally, for CY 2019, we are assigning 
status indicator ``D'' to CPT code Q2040, status indicator ``G'' to 
HCPCS code Q2041, and status indicator ``G'' to HCPCS code Q2042, as 
summarized in Table 22 below. We refer readers to Addendum B to this 
final rule with comment period for the payment rates for all codes 
reportable under the OPPS. Addendum B is available via the internet on 
the CMS website. In addition, we refer readers to Addendum D1 to this 
final rule with comment period for the complete list of the OPPS 
payment status indicators and their definitions for CY 2019.
BILLING CODE 4120-01-P

[[Page 58907]]

[GRAPHIC] [TIFF OMITTED] TR21NO18.037


[[Page 58908]]


[GRAPHIC] [TIFF OMITTED] TR21NO18.038

BILLING CODE 4120-01-C
5. Drug-Eluting Implant (APC 5733)
    For CY 2019, we proposed to continue to assign CPT code 0356T 
(Insertion of drug-eluting implant (including punctal dilation and 
implant removal when performed) into lacrimal canaliculus, each) to APC 
5733 (Level 3 Minor Procedures) with a proposed payment rate of 
approximately $57. We also proposed to continue to assign the CPT code 
to status indicator ``Q1'' to indicate one of the following with 
regards to payment:
     Packaged APC payment if billed on the same claim as a 
HCPCS code assigned status indicator ``S'', ``T'', or ``V''; or
     Composite APC payment if billed with specific combinations 
of services based on OPPS composite-specific payment criteria. Payment 
is packaged into a single payment for specific combinations of 
services; or
     In other circumstances, payment is made through a separate 
APC payment.
    Comment: Several commenters disagreed with the proposed 
continuation of the status indicator assignment of ``Q1'' for CPT code 
0356T and recommended an assignment to a significant procedure status 
indicator instead of a conditionally packaged status indicator. One 
commenter indicated that the procedure described by CPT code 0356T 
represents a nonsurgical, independent procedure that is not based on 
any other primary procedure, and believed that a status indicator 
reassignment would ensure proper claims processing for providers.
    Response: As indicated above and in OPPS Addendum D1 of the CY 2019 
OPPS/ASC proposed rule, status indicator ``Q1'' represents one of three 
potential payment assignments. Depending on the claim submitted, and 
whether the procedure described by CPT code 0356T is performed with any 
other surgeries or services on the same day, the procedure described by 
CPT code 0356T may be paid separately through an APC (in this case APC 
5733) or paid as part of a payment when included in the more 
significant procedure that is reported on the claim. Based on the 
nature of this procedure, which may be performed by itself or with 
other procedures on the same day, we believe that the continued 
assignment of status indicator ``Q1'' is appropriate for the procedure 
described by CPT code 0356T.
    After consideration of the public comments we received, we are 
finalizing our proposal, without

[[Page 58909]]

modification, to assign CPT code 0356T to status indicator ``Q1'' for 
CY 2019. The final CY 2019 payment rate for the CPT code can be found 
in Addendum B to this final rule with comment period (which is 
available via the internet on the CMS website).
6. Endovascular Procedures (APCs 5191 Through 5194)
    At the annual meeting for the HOP Panel held on August 21, 2017, 
the HOP Panel recommended that, for CY 2018, CMS examine the number of 
APCs for endovascular procedures. The HOP Panel also recommended that 
the appropriate Panel subcommittee review the APCs for endovascular 
procedures to determine whether more granularity (that is, more APCs) 
is warranted.
    In the CY 2018 OPPS/ASC final rule with comment period (82 FR 59293 
through 59294), we stated that we believed that the current C-APC 
levels for the Endovascular Procedures C-APC family provide an 
appropriate distinction between the resource costs at each level and 
clinical homogeneity. We also stated that we would continue to review 
the C-APC structure for endovascular procedures to determine if any 
additional granularity is necessary for this C-APC family.
    Using the most recent data available for the CY 2019 OPPS/ASC 
proposed rule, we analyzed the four existing levels of the Endovascular 
Procedures C-APCs. We did not observe any violations of the 2 times 
rule within the current Endovascular Procedures C-APC structure. Some 
stakeholders have suggested that for certain procedures, such as 
angioplasty procedures involving the use of a drug-coated balloon in 
addition to a nondrug-coated balloon, resource costs are significantly 
higher than the geometric mean cost (and associated C-APC payment) for 
all of the angioplasty procedures combined. We stated in the proposed 
rule that we recognize that the costs of a given procedure, involving 
additional devices, will be higher than the costs of the procedure when 
it does not involve such additional devices. However, the OPPS is a 
prospective payment system based on a system of averages in which the 
costs of some cases within an APC will be more costly than the APC 
payment rate, while the costs of other cases will be less costly. While 
we believe that there is sufficient granularity within the existing 
Endovascular Procedures C-APC structure and at least one stakeholder 
agrees, we stated that we have also received input from other 
stakeholders who have suggested alternative structures for this C-APC 
family that include a five-level structure and a six-level structure. 
An illustration of these proposed C-APC structure levels was displayed 
in Table 15 and Table 16, respectively, of the proposed rule. Because 
interested stakeholders have suggested a variety of options for the 
endovascular procedures C-APC structure, including keeping the existing 
C-APC structure, in the CY 2019 OPPS/ASC proposed rule, we proposed to 
maintain the existing four-level structure for this C-APC family listed 
in Table 14 of the proposed rule. However, we invited public comments 
on our proposal, as well as the stakeholder-requested five-level and 
six-level structures displayed in the Tables 15 and 16 of the proposed 
rule. We noted that the approximate geometric mean costs associated 
with the suggested five-level and six-level C-APC structures shown in 
Tables 15 and 16 of the proposed rule were only estimates and, if 
either of the suggested structure levels were adopted, they would be 
subject to change, depending on the final rule with comment period data 
and the particular services that are assigned to each C-APC.
    Comment: Several commenters supported CMS' proposal to continue 
with a four-level APC structure, along with the proposed CPT code 
assignments to each of the endovascular APCs as described in the CY 
2019 OPPS/ASC proposed rule. These commenters stated that adding 
additional APCs to the endovascular series could result in some APCs 
containing very few procedures, and further believed that this policy 
change would also be contrary to the concept of broader APC groupings 
under the OPPS. Another commenter requested that CMS provide greater 
detail about future proposals in order for stakeholders to be able to 
provide fully informed comments and recommendations.
    Other commenters also agreed with CMS' assessment that the four-
level APC structure and the assignment of the procedures to these APCs 
does not result in any 2 times rule violations, and believed that the 
current granularity within the existing Endovascular Procedures C-APCs' 
structure sufficiently represents resource cost and clinical 
homogeneity.
    Response: We appreciate the commenters' input and support. At this 
time, we believe that the current APC structure levels for the 
Endovascular Procedures C-APC family provide an appropriate distinction 
between resource costs at each level and clinical homogeneity.
    Comment: Several commenters believed that the current structure of 
the Endovascular Procedures APCs violates the 2 times rule when certain 
code combinations, such as the procedures described by CPT 37224 
(Revascularization, endovascular, open or percutaneous, femoral, 
popliteal artery(s), unilateral; with transluminal angioplasty) and 
HCPCS code C2623 (Catheter, transluminal angioplasty, drug-coated, non-
laser), are reported in combination. As a result, the commenters 
requested that CMS make a complexity adjustment for CY 2019 by 
assigning cases for the procedures described by CPT code 37224 and 
HCPCS code C2623 when reported in combination with one another to APC 
5193.
    Some of these commenters believed that the current structure of the 
Endovascular Procedures APCs is insufficiently granular, and noted that 
the current APC structure has significant differentials in payments of 
over $5,000 between the current procedures assigned to Level 2 (APC 
5192) and between the procedures assigned to Level 3 and Level 4 (APC 
5194). These commenters further contended that the large numbers of 
procedures assigned to each level of APC, coupled with the high total 
volume of procedures assigned to each level within each APC, prevent 
technology costs from being adequately and accurately reflected in the 
OPPS payment rates. As a result, these commenters requested that CMS 
create a six-level structure Endovascular Procedure APC reflecting the 
following cost bands:

[[Page 58910]]

[GRAPHIC] [TIFF OMITTED] TR21NO18.039

    Some of these commenters also specifically suggested that the 
procedures described by CPT code 37224 (Revascularization, 
endovascular, open or percutaneous, femoral, popliteal artery(s), 
unilateral; with transluminal angioplasty) and HCPCS code C2623 
(Catheter, transluminal angioplasty, drug-coated, non-laser); and CPT 
code 37726 (Revascularization, endovascular, open or percutaneous, 
femoral, popliteal artery(s), unilateral; with transluminal stent 
placement(s), includes angioplasty within the same vessel, when 
performed) and HCPCS code C1874 (Stent, coated/covered, with delivery 
system) be assigned to the newly leveled structure within APC 5193 and 
APC 5195, respectively, in order to take into consideration the 
performance of and utilization of procedures involving drug-coated 
balloons and drug eluting stents that are required for these 
procedures.
    Several of these same commenters requested that CMS create new 
HCPCS code modifiers to take into account the performance of the 
procedures described by CPT code 37724 when reported in combination 
with HCPCS code C2623, and CPT code 37226 when reported in combination 
with HCPCS code C1874. The commenters provided that CMS could model the 
costs for these cases using CY 2017 and CY 2018 claims data when these 
codes are reported in combination with one another. The commenters 
further believed that the creation of new HCPCS code modifiers are 
necessary in order to differentiate drug-coated device procedures from 
non-drug-coated device procedures, and will provide the granularity in 
HCPCS and APC coding that will allow CMS to collect data for the CPT/
HCPCS codes to appropriately calculate payment rates within the APCs. 
Another commenter further stated that these procedures should be 
assigned to the newly created APC 5193 and APC 5195, respectively.
    Response: We appreciate the commenters' suggestion. As noted in the 
proposed rule, we understand that some stakeholders have suggested that 
when certain procedures, such as those described by CPT code 37224 and 
HCPCS code C2623 are reported in combination, a 2 times rule violation 
occurs. However, we recognize that the costs of a given procedure, 
involving additional devices, will be higher than the costs of the 
procedure when it does not involve such additional devices, and we do 
not believe that these types of 2 times rule violations are avoidable, 
given the nature of a prospective payment system (83 FR 37095).
    Using the most recent data available for this final rule with 
comment period, we analyzed the various alternative suggestions for the 
recommended HCPCS code placements, including maintaining the CY 2018 
APC groupings, creating a six-level APC, and reconfiguring significant 
HCPCS code placements within the current structure. We note that, when 
we modeled the creation of a six-level structure APC and modeled a 
reconfiguration of significant HCPCS code placements, we noticed 
significant downward payment fluctuations for several services, some as 
high as a $2,500 decrease relative to the payment rate in CY 2018. 
Furthermore, based on these findings, we are still not convinced that 
we should pay for a complexity adjustment for the procedure described 
by CPT code 37224 when reported in combination with HCPCS code C2623 or 
for the procedure described by CPT code 37226 when reported in 
combination with HCPCS code C1874. As noted above and as provided in 
the proposed rule, the OPPS is a prospective payment system based on a 
system of averages in which the costs of some cases within an APC will 
be more costly than the APC payment rate, while the costs of other 
cases will be less costly and in these particular procedures we believe 
that if a complexity adjustment would be applied it would adversely 
affect the APC payment (83 FR 37095). Additionally, at this time, we do 
not support the creation of any new HCPCS codes for inclusion in the 
Endovascular Procedures APCs. Specifically, we do not believe that we 
have the needed evidence and data to support combining payment for 
either the procedure described by CPT code 37724 when reported in 
combination with HCPCS code C2623 or the procedure described by CPT 
code 37226 when reported in combination with HCPCS code C1874 because 
we believe that payment for these services are currently adequate.
    However, we do share similar concerns with the commenters regarding 
the significant differential payments between the procedures assigned 
within the current four-level structure of the Endovascular Procedures 
APCs and intend to revisit this particular issue in future rulemaking. 
Therefore, after consideration of the public comments and suggestions 
we received, we are maintaining the CY 2018 APC structure of four 
levels for the Endovascular Procedures APCs. We understand the 
importance of payment stability for providers and believe that 
continuation of the four levels within the Endovascular Procedures APCs 
will minimize fluctuation in payment rates from CY 2018 to CY 2019. As 
displayed in the ``Two Times Listing'' file to this final rule with 
comment period, which is available via the internet on the CMS website, 
the APC geometric mean costs for APCs 5521 through 5524 are consistent 
with the CY 2018 APC geometric mean costs for the same APCs, indicating 
the relative weights that are used to calculate payment are stable.
    We will continue to review this APC structure to determine if 
additional granularity is necessary for this C-APC family, including if 
additional HCPCS codes should be created in future rulemaking. We refer 
readers to Addendum B to this final rule with comment period for the 
payment rates for all codes reported under the OPPS. Additionally, we 
refer readers to Addendum A to this final rule with comment period for 
the complete list of APCs and their payment rates under the OPPS. Both 
Addendum A and Addendum B are available via the internet on the CMS 
website.

[[Page 58911]]

[GRAPHIC] [TIFF OMITTED] TR21NO18.040

7. Fine Needle Aspiration Biopsy (APC 5071)
    As displayed in Table 25 below and in Addendum B to the CY 2019 
OPPS/ASC proposed rule, we proposed to assign CPT codes 10009 and 10011 
to APC 5071 (Level 1 Excision/Biopsy/Incision and Drainage), with a 
proposed payment rate of approximately $582. The codes were listed as 
10X16 and 10X18 (the 5-digit CMS placeholder codes), respectively, in 
Addendum B with the short descriptors and in Addendum O with the long 
descriptors to the CY 2019 OPPS/ASC proposed rule. We also assigned 
these codes to comment indicator ``NP'' in Addendum B to indicate that 
the codes are new for CY 2019, with proposed APC assignments, and that 
public comments would be accepted on their proposed APC assignments. We 
note that these codes will be effective January 1, 2019.
    Comment: One commenter disagreed with the proposed assignment of 
the procedure described by CPT code 10009 to APC 5071 and suggested 
that APC 5072 (Level 2 Excision/Biopsy/Incision and Drainage), with a 
proposed payment rate of approximately $1,370, is more appropriate 
because the resource cost of the CT guidance used in the procedure is 
higher than the resource cost of ultrasound or fluoroscopy. The 
commenter disagreed with the proposed assignment of the procedure 
described by CPT code 10011 to APC 5071 and recommended that APC C-5373 
(Level 3 Urology and Related Services), with a proposed payment rate of 
approximately $1,731, is more appropriate because the cost of the MRI 
guidance used in the procedure is clinically similar to the other 
services in this APC.
    Response: Because CPT codes 10009 and 10011 are new codes for CY 
2019, we do not have claims data on which to base the payment rates. 
However, in the absence of claims data, we reviewed the clinical 
characteristics of the procedures described by CPT codes 10009 and 
10011 to determine whether they are similar to existing procedures. 
After reviewing information from the public commenter and input from 
our medical advisors, we believe that the procedures described by new 
CPT codes 10009 and 10011 are clinically similar to those procedures 
assigned to APC 5071. We are unclear of the rationale for the 
commenter's suggestion of recommending a Urology APC assignment (C-APC 
5373) for the procedure described by CPT code 10011 when this procedure 
describes a fine needle aspiration biopsy, which is not a urology-
specific procedure. Therefore, we are not accepting the commenter's 
recommendation. In addition, we remind hospitals that, every year, we 
review the APC assignments for all services and items paid under the 
OPPS. We will reevaluate the APC assignment for the procedures 
described by CPT codes 10009 and 10011 once we have claims data for the 
codes.
    After consideration of the public comment received, we are 
finalizing our proposal, without modification, to assign the procedures 
described by CPT codes 10009 and 10011 to APC 5071 for CY 2019. The 
final APC and status indicator assignments are listed in Table 25 
below. We refer readers to Addendum B of this final rule with comment 
period for the final payment rates for all codes reportable under the 
OPPS. Addendum B is available via the internet on the CMS website.
[GRAPHIC] [TIFF OMITTED] TR21NO18.041


[[Page 58912]]


8. Fluorescence In Situ Hybridization (FISH) Assays (APCs 5672 and 
5673)
    As displayed in Table 26 below and in Addendum B to the CY 2019 
OPPS/ASC proposed rule, we proposed to assign the procedures described 
by CPT codes 88364 through 88377 to status indicator ``N'' to indicate 
a packaged payment status, or status indicators ``Q1'' and ``Q2'' to 
indicate a conditionally packaged payment status, with APC assignments 
to either APC 5672 (Level 2 Pathology), with a proposed payment rate of 
approximately $145, or APC 5673 (Level 3 Pathology), with a proposed 
payment rate of approximately $273.
    Comment: One commenter urged CMS to exclude certain FISH assays 
from the OPPS packaging policy. Specifically, the commenter stated that 
the technical component of services that are associated with the 
services described by CPT codes 88364, 88365, 88366, 88367, 88368, 
88369, 88373, 88374, and 88377 have unique clinical utilization that is 
distinct from conventional laboratory tests, and suggested that the 
services described by these codes be excluded from the OPPS payment 
packaging policy. The commenter further stated that these tests are 
utilized in both the hospital outpatient and hospital inpatient setting 
similar to molecular pathology tests and advanced diagnostic laboratory 
tests (ADLTs).
    Response: As stated in the CY 2017 OPPS/ASC final rule with comment 
period (81 FR 79593), payment for most laboratory tests is packaged 
under OPPS. Under our current policy, payment for certain clinical 
diagnostic laboratory tests that are listed on the Clinical Laboratory 
Fee Schedule (CLFS) is packaged in the OPPS as integral, ancillary, 
supportive, dependent, or adjunctive to the primary service or services 
provided in the hospital outpatient setting (81 FR 79593 and 42 CFR 
419.2(b)(17)). However, we have established exceptions to the OPPS 
laboratory test packaging policy for molecular pathology tests, certain 
ADLTs, and preventive laboratory tests. Specifically, we exclude from 
packaging the following laboratory tests:
     Molecular pathology tests, because these relatively new 
tests may have a different pattern of clinical use than more 
conventional laboratory tests, which may make them generally less tied 
to a primary service in the hospital outpatient setting than the more 
common and routine laboratory tests that are packaged (80 FR 70348 
through 70350);
     ADLTs, as designated under the CLFS, that meet the 
criteria of section 1834A(d)(5)(A) of the Act (81 FR 79593 through 
79594), and
     Preventive laboratory tests that are listed in Section 
1.2, Chapter 18 of the Medicare Claims Processing Manual (Pub. 100-04) 
(80 FR 70349).
    We note that laboratory tests also are paid separately when they 
are the only services provided to a beneficiary on a claim (81 FR 
79593). When payment for laboratory tests is not packaged under the 
OPPS, and the tests are listed on the CLFS, the payment is made at the 
CLFS payment rates, outside the OPPS, under Medicare Part B.
    With regard to the services described by CPT codes 88364, 88369, 
and 88373, we proposed to continue to assign these add-on services to 
status indicator ``N'' because, under the OPPS, payment for services 
described by add-on codes are packaged in accordance with the 
regulations at Sec.  419.2(b)(18).
    In addition, with regard to the services described by CPT codes 
88365, 88366, 88374, and 88377, we proposed to continue to assign these 
codes to status indicator ``Q1'' to indicate that these services are 
separately payable when not billed on the same claim as a HCPCS code 
assigned status indicator ``S'', ``T'', or ``V''. Further, with regard 
to the services described by CPT codes 88367 and 88368, we proposed to 
continue to assign these codes to status indicator ``Q2'' to indicate 
that payment for these services will be packaged in the APC payment if 
billed on the same date of service as a HCPCS code assigned to status 
indicator ``T'', but in all other circumstances, separate APC payment 
for the services would be made. Based on the nature of these services, 
we believe the payment for the services described by CPT codes 88365, 
88366, 88367, 88368, 88374, and 88377 should continue to be 
conditionally packaged under the OPPS because these laboratory tests 
may be performed with other procedures on the same day.
    In summary, because the services described by CPT codes 88364, 
88365, 88366, 88367, 88368, 88369, 88373, 88374, and 88377 are not 
molecular pathology laboratory tests, ADLTs, or preventive laboratory 
tests as stated in the above response, we believe that we should 
continue to package the payment for these services under the OPPS. 
Therefore, after consideration of the public comment received, we are 
finalizing our proposal, without modification, to assign the services 
described by CPT codes 88364, 88365, 88366, 88367, 88368, 88369, 88373, 
88374, and 88377 to the final APCs and status indicator assignments 
listed in Table 26 below. We refer readers to Addendum B of this final 
rule with comment period for the payment rates for all codes reportable 
under the OPPS. Addendum B is available via the internet on the CMS 
website. In addition, we refer readers to Addendum D1 of this final 
rule with comment period for the complete list of the OPPS payment 
status indicators and their definitions for CY 2019.
BILLING CODE 4120-01-P

[[Page 58913]]

[GRAPHIC] [TIFF OMITTED] TR21NO18.042

BILLING CODE 4120-01-C
9. Immediate Breast Implant Following Mastopexy/Mastectomy (C-APC 5092)
    For CY 2019, we proposed to continue to assign the procedures 
described by CPT code 19340 (Immediate insertion of breast prosthesis 
following mastopexy, mastectomy or in reconstruction) to C-APC 5092 
(Level 2 Breast/Lymphatic Surgery and Related Procedures), with a 
proposed payment rate of approximately $4,960.
    Comment: Some commenters disagreed with the proposed continued APC 
assignment for the procedure described by CPT code 19340 to C-APC 5092 
and suggested instead a reassignment to C-APC 5093 (Level 3 Breast/
Lymphatic Surgery and Related Procedures), with a proposed payment rate 
of approximately $7,432. One commenter believed that the procedure 
described by CPT code 19340 shares similar clinical and resource 
characteristics as the procedures described by CPT codes 19325 
(Mammaplasty, augmentation; with prosthetic implant) and 19342 (Delayed 
insertion of breast prosthesis following mastopexy, mastectomy or in 
reconstruction), which are assigned to C-APC 5093. Another commenter 
requested a review and reconfiguration of C-APCs 5092 and 5093, and 
believed

[[Page 58914]]

that the cost of performing the procedure described by CPT code 19340 
is similar to the surgical procedures assigned to C-APC 5093.
    Response: Analysis of the hospital outpatient claims data used for 
this final rule with comment period, which is based on claims submitted 
between January 1, 2017 and December 31, 2017, and processed through 
June 30, 2018, do not support a reassignment of the procedure described 
by CPT code 19340 to C-APC 5093. Specifically, our claims data show a 
geometric mean cost of approximately $5,341 for the procedure described 
by CPT code 19340 based on 1,187 single claims (out of 1,203 total 
claims), which is comparable to the geometric mean cost of 
approximately $4,958 for C-APC 5092. In contrast, our claims data show 
a higher geometric mean cost for the procedures described by CPT codes 
19325 (approximately $6,326 based on 209 single claims out of 210 total 
claims) and 19342 (approximately $6,232 based on 1,190 single claims 
out of 1,202 total claims) that is comparable to the geometric mean 
cost of approximately $7,513 for C-APC 5093. Based on our analysis, we 
believe that the procedure described by CPT code 19340 is appropriately 
assigned to C-APC 5092 based on resource and clinical homogeneity to 
the other procedures in the APC. We note that all of the procedures 
described by CPT codes assigned to this Breast/Lymphatic Surgery and 
Related Procedures C-APC are clinically similar and that the resource 
similarity is based on the geometric mean costs derived from claims 
submitted by hospitals performing these procedures.
    After consideration of the public comments we received and based on 
our analysis of the latest hospital outpatient claims data for the 
procedures described by CPT codes 19340, 19325, and 19342, we are 
finalizing our proposal, without modification, to continue to assign 
CPT code 19340 to C-APC 5092. We refer readers to Addendum B of this 
final rule with comment period for the payment rates for all codes 
reportable under the OPPS. Addendum B is available via the internet on 
the CMS website.
10. Intracardiac Ischemia Monitoring (APCs 5221, 5222, 5223, and 5741)
    In Addendum B to the CY 2019 OPPS/ASC proposed rule, we proposed to 
assign eight new intracardiac ischemia monitoring CPT codes to various 
APCs, which are listed in Table 27 below. The codes were listed as 
00X0T through 00X7T (the 5-digit CMS placeholder codes) in Addendum B 
with short descriptors and in Addendum O with long descriptors to the 
CY 2019 OPPS/ASC proposed rule. We also assigned these codes to comment 
indicator ``NP'' in Addendum B to the proposed rule to indicate that 
the codes are new for CY 2019, with proposed APC assignments, and that 
public comments would be accepted on their proposed APC assignments. We 
note these codes will be effective January 1, 2019. Although the codes 
are new for CY 2019, the services associated with intracardiac ischemia 
monitoring were previously described by CPT codes 0302T through 0307T, 
which were deleted on December 31, 2017.
[GRAPHIC] [TIFF OMITTED] TR21NO18.043

    Comment: One commenter disagreed with CMS' proposed APC assignment 
for the new intracardiac ischemia monitoring Category III CPT code 
0525T (Insertion or replacement of intracardiac ischemia monitoring 
system, including testing of the lead and monitor, initial system 
programming, and imaging supervision and interpretation; complete 
system (electrode and implantable monitor)) and requested assignment to 
APC 5224 (Level 4 Pacemaker and Similar Procedures) instead of APC 
5223. The commenter suggested that the procedure described by CPT code 
0525T be assigned to APC 5224, which is the same APC that was assigned 
to its predecessor CPT code 0302T (Insertion or removal and replacement 
of intracardiac ischemia monitoring system including imaging 
supervision and interpretation when performed and intra-operative 
interrogation and programming when performed; complete system (includes 
device and electrode)) when the code was active during CY 2017. The 
commenter also stated that the procedure described by CPT code 0525T is 
more complex and requires significantly more resources than the other 
procedures assigned to APC 5223. The commenter further indicated that 
the cost of the Guardian System alone, which is related to the CPT 
codes of concern, is between $8,000 to $8,700, while the overall cost 
for the insertion of the complete system is between $15,700 and 
$16,400.

[[Page 58915]]

    Response: For CY 2018, CMS received a New Technology APC 
application requesting a new HCPCS code for the insertion of an 
intracardiac ischemia monitoring system because no current CPT code 
existed to describe the procedure, and because its predecessor CPT code 
0302T was deleted on December 31, 2017. Based on our review of the 
application, evaluation of the procedure, and input from our clinical 
advisors, we agreed that no existing code appropriately describes the 
insertion of an intracardiac ischemia monitoring system and, therefore, 
established HCPCS code C9750 (Insertion or removal and replacement of 
intracardiac ischemia monitoring system including imaging supervision 
and interpretation and peri-operative interrogation and programming; 
complete system (includes device and electrode)), effective October 1, 
2018. For the October 2018 OPPS update, we assigned HCPCS code C9750 to 
APC 5223 (Level 3 Pacemaker and Similar Procedures) with a payment rate 
of approximately $9,748. We announced this new HCPCS code and APC 
assignment in the October 2018 OPPS quarterly update CR (Transmittal 
4123, Change Request 10923, dated August 24, 2018). Because the 
procedure described by CPT code 0525T is the same procedure described 
by HCPCS code C9750, we proposed to assign CPT code 0525T to APC 5223.
    In addition, we reviewed our claims data for the predecessor CPT 
code 0302T that were submitted during CY 2012 through CY 2017. We note 
that predecessor CPT code 0302T became effective July 1, 2012 and was 
deleted on December 31, 2017. Our analysis of the claims data for CPT 
code 0302T revealed no single claim submitted for CY 2017, CY 2016, CY 
2014, CY 2013, or CY 2012. We did find one claim that was submitted 
during CY 2015 with a geometric mean cost of approximately $4,619. 
However, based on cost information submitted to CMS in the New 
Technology APC application, we believe that APC 5223, whose geometric 
mean cost is approximately $9,964, is the appropriate APC assignment 
for the procedure described by CPT code 0525T. We believe that the 
procedure described by CPT code 0525T shares similar resource and 
clinical homogeneity to the other procedures currently assigned to APC 
5223. Consequently, we did not assign the code to a New Technology APC 
because the services assigned to APC 5223 are clinically similar to the 
service described by CPT code 0525T. Therefore, we believe that APC 
5223 is the more appropriate APC assignment for the procedure described 
by CPT code 0525T.
    Comment: One commenter also disagreed with the proposed assignment 
of the service described by CPT code 0528T to APC 5741, and requested 
that the service be assigned to APC 5743 (Level 3 Electronic Analysis 
of Devices) instead. The commenter stated that the service generally 
takes about 60 minutes to perform, which is similar to the following 
services assigned to APC 5743:
     CPT code 0462T (Programming device evaluation (in person) 
with iterative adjustment of the implantable mechano-electrical skin 
interface and/or external driver to test the function of the device and 
select optimal permanent programmed values with analysis, including 
review and report, implantable aortic counterpulsation ventricular 
assist system, per day);
     CPT code 0463T (Interrogation device evaluation (in 
person) with analysis, review and report, includes connection, 
recording and disconnection per patient encounter, implantable aortic 
counterpulsation ventricular assist system, per day); and
     CPT code 0472T (Device evaluation, interrogation, and 
initial programming of intraocular retinal electrode array (e.g., 
retinal prosthesis), in person, with iterative adjustment of the 
implantable device to test functionality, select optimal permanent 
programmed values with analysis, including visual training, with review 
and report by a qualified health care professional).
    Response: Based on our review of the predecessor CPT codes for the 
intracardiac ischemia monitoring systems that were in existence from 
July 1, 2012 through December 31, 2017, we found that the service 
described by CPT code 0528T (Programming device evaluation (in person) 
of intracardiac ischemia monitoring system with iterative adjustment of 
programmed values, with analysis, review, and report) was previously 
described by predecessor CPT code 0305T (Programming device evaluation 
(in person) of intracardiac ischemia monitoring system with iterative 
adjustment of programmed values, with analysis, review, and report). 
Similar to predecessor CPT code 0302T, predecessor CPT code 0305T 
became effective July 1, 2012 and was deleted on December 31, 2017. Our 
analysis of the claims data for the service described by CPT code 0305T 
revealed no single claim submitted during CY 2012 through CY 2017. 
Based on input from our medical advisors and our APC assignment for 
predecessor CPT code 0305T to APC 5741, we believe that APC 5741 is the 
appropriate APC assignment for the service described by CPT code 0528T, 
based on similar programming device evaluation codes assigned to this 
APC.
    In summary, after consideration of the public comment we received, 
we are finalizing our proposal, without modification, to assign the 
services described by CPT codes 0525T through 0532T to the final APCs 
listed in Table 28 below. We note that HCPCS code C9750 will be deleted 
December 31, 2018, because it will be replaced with CPT code 0525T, 
effective January 1, 2019. The final CY 2019 payment rate for CPT codes 
0525T through 0532T can be found in Addendum B to this final rule with 
comment period (which is available via the internet on the CMS 
website).
BILLING CODE 4120-01-P

[[Page 58916]]

[GRAPHIC] [TIFF OMITTED] TR21NO18.044

11. Intraocular Retinal Electrode Programming and Reprogramming (APCs 
5742 and 5743)
    As noted in Table 29 below, for CY 2019, we proposed to continue to 
assign the procedure described by CPT code 0472T to APC 5743 (Level 3 
Electronic Analysis of Devices), with a proposed payment rate of 
approximately $280. We also proposed to continue to assign the 
procedure described by CPT code 0473T to APC 5742 (Level 2 Electronic 
Analysis of Devices), with a proposed payment rate of approximately 
$115.
    Comment: One commenter supported CMS' proposal to continue to 
assign the programming services for Argus II, which are described by 
CPT codes

[[Page 58917]]

0472T and 0473T, to APCs 5743 and 5742.
    Response: We appreciate the commenter's support. Based on input 
from our medical advisors, we believe that CPT codes 0472T and 0473T 
are appropriately assigned to APCs 5743 and 5742, respectively, based 
on clinical and resource homogeneity to the other services assigned to 
these APCs.
    Therefore, after consideration of the public comment received, we 
are finalizing our proposal, without modification, to continue to 
assign the procedures described by CPT codes 0472T and 0473T to APCs 
5743 and APC 5742, respectively, for CY 2019. The final APC and status 
indicator assignments are listed in Table 29 below. The final payment 
rates for these codes, where applicable, can be found in Addendum B to 
this final rule with comment period (which is available via the 
internet on the CMS website).
[GRAPHIC] [TIFF OMITTED] TR21NO18.045

BILLING CODE 4120-01-C
12. Kidney Dilation of Tract (C-APC 5373)
    In Addendum B to the CY 2019 OPPS/ASC proposed rule, we proposed to 
assign the procedure described by CPT code 50436 (Dilation of existing 
tract, percutaneous, for an endourologic procedure including imaging 
guidance (e.g., ultrasound and/or fluoroscopy) and all associated 
radiological supervision and interpretation, with postprocedure tube 
placement, when performed) to C-APC 5373 (Level 3 Urology and Related 
Services), with a proposed payment rate of approximately $1,731. This 
code was listed as 50X39 (the 5-digit CMS placeholder code) in Addendum 
B, with the short descriptor, and in Addendum O, with the long 
descriptor, to the CY 2019 OPPS/ASC proposed rule. We also proposed to 
assign this code to comment indicator ``NP'' in Addendum B to indicate 
that the code is new for CY 2019 with a proposed APC assignment and 
that public comments would be accepted on the proposed APC assignment. 
We note that this code will be effective January 1, 2019.
    Comment: One commenter disagreed with the proposed assignment of 
CPT code 50436 to C-APC 5373 and instead recommended assignment to C-
APC 5374 (Level 3 Urology and Related Services), with a proposed 
payment rate of approximately $2,755, because of the higher resource 
costs associated with the procedure.
    Response: Because CPT code 50436 is a new code for CY 2019, we do 
not have claims data on which to base a payment rate. However, in the 
absence of claims data, we reviewed the clinical characteristics of the 
procedure to determine whether the surgical procedure is similar to 
existing procedures. After review of the procedure and input from our 
clinical advisors, we believe that the procedure described by new CPT 
code 50436 is clinically similar to those procedures assigned to C-APC 
5373. We will reevaluate the APC assignment for the procedure described 
by CPT code 50436 once claims data for this procedure become available. 
We note that as we do every year, we review the APC assignments for all 
services and items paid under the OPPS.
    After consideration of the public comment we received, we are 
finalizing our proposal to assign the procedure described by CPT code 
50436 to C-APC 5373. We refer readers to Addendum B of this final rule 
with comment period for the payment rates for all codes reportable 
under the OPPS. Addendum B is available via the internet on the CMS 
website.
13. Intraocular Procedures (APC 5494)
    In prior years, the procedure described by CPT code 0308T 
(Insertion of ocular telescope prosthesis including removal of 
crystalline lens or intraocular lens prosthesis) has been assigned to 
the APC 5495 (Level 5

[[Page 58918]]

Intraocular Procedures) based on its estimated costs. In addition, its 
relative payment weight has been based on its median under our payment 
policy for low-volume device-intensive procedures established in the CY 
2016 OPPS because the APC contained a low volume of claims. The low-
volume device-intensive procedures policy is discussed in more detail 
in section III.C.2. of the proposed rule and this final rule with 
comment period.
    In reviewing the claims data available for the proposed rule for CY 
2019 OPPS ratesetting, we found that there were only two claims 
containing procedures described by CPT code 0308T, with a geometric 
mean of $5,438.99 and a median of $8,237.56. Based on those two claims, 
APC 5495 would have had a proposed geometric mean of $5,438.99 and a 
proposed median of $8,237.56. However, based on its estimated costs in 
the most recently available claims data, we stated in the proposed rule 
that we believe that the procedure described by CPT code 0308T is more 
appropriately placed in the APC 5493, which has a geometric mean cost 
of $9,821.47, which is more comparable to that of the procedure 
described by CPT code 0308T. Therefore, for CY 2019, we proposed to 
reassign the procedure described by CPT code 0308T from APC 5495 to APC 
5493 (Level 3 Intraocular Procedures) and to delete APC 5495. We stated 
that we would continue to monitor the volume of claims reporting a 
procedure described by CPT code 0308T available to us for future 
ratesetting.
    Comment: One commenter requested that the procedure described by 
CPT code 0308T be assigned to a New Technology APC based on the 
proposed low-volume New Technology policy, without requesting a 
specific New Technology APC or cost band. The commenter believed that 
the reasons for developing the low volume New Technology policy are 
consistent with issues related to the procedure described by CPT code 
0308T, including the quality and volume of claims data, and resulting 
cost fluctuation. The commenter noted that because those issues facing 
low-volume procedures would be the same, regardless of whether the 
procedures are assigned to a New Technology or clinical APC, it would 
be appropriate to assign the procedure described by CPT code 0308T to a 
New Technology APC. However, the commenter requested that, if that 
change were not to be made, CMS instead assign the procedure described 
by the CPT code to APC 5495, which was previously for ``Level 5 
Intraocular Procedures'' and that the same smoothing methodology for 
low volume New Technology procedures, which includes use of multiple 
years of claims data, apply to the procedure described by CPT code 
0308T, given its low volume.
    Response: In previous years, the procedure described by CPT code 
0308T was assigned to APC 5495 (Level 5 Intraocular Procedures) using a 
median-based weight under the low-volume device intensive policy. Based 
on the CY 2017 claims data available for ratesetting, in the CY 2019 
OPPS/ASC proposed rule, we proposed to assign the procedure described 
by CPT code 0308T to APC 5493, noting that we would continue to monitor 
the data. In the CY 2019 OPPS final rule claims data, the estimated 
cost of the single claim with CPT code 0308T as the primary service is 
approximately $12,939.75.
    While we appreciate the stakeholder's comments regarding changes in 
estimated costs based on the claims data available for ratesetting, we 
have concerns with establishing a New Technology APC methodology for a 
clinical APC especially in the absence of a New Technology application, 
which is used to evaluate new technology APC requests. We also note 
that the procedure described by CPT code 0308T has historically been 
assigned to a clinical APC beginning with the CY 2013 OPPS.
    Recognizing the estimated cost based on the final rule claims data 
and the commenter's concerns, we believe that the procedure described 
by CPT code 0308T is appropriate for assignment to clinical APC 5494 
(Level 4 Intraocular Procedures). CPT code 0308T has device-intensive 
status based on its device offset percentage and the fact that the APC 
to which the procedure is assigned has fewer than 100 total claims. 
Therefore, the low-volume device intensive policy of using the median 
cost for OPPS ratesetting would apply.
    After consideration of the public comment we received, we are 
modifying our proposal to assign the procedure described by CPT code 
0308T to APC 5493 and instead are assigning the procedure described by 
CPT code 0308T to APC 5494 (Level 4 Intraocular Procedures) for CY 
2019.
14. Magnetocardiography
    As displayed in Table 30 below and in Addendum B to the CY 2019 
OPPS/ASC proposed rule, we proposed to assign the services described by 
CPT codes 0541T and 0542T to status indicator ``E1'' to indicate that 
these codes are not payable by Medicare when submitted on outpatient 
claims (any outpatient bill type) because the services associated with 
these codes are either not covered by any Medicare outpatient benefit 
category, statutorily excluded by Medicare, or not reasonable and 
necessary. The codes were listed as 0X01T and 0X02T (the 5-digit CMS 
placeholder codes), respectively, in Addendum B, with the short 
descriptors, and in Addendum O, with the long descriptors, to the CY 
2019 OPPS/ASC proposed rule. We also assigned these codes to comment 
indicator ``NP'' in Addendum B to indicate that the codes are new for 
CY 2019 and that public comments would be accepted on their proposed 
status indicator assignments. We note that these codes will be 
effective January 1, 2019.
    Comment: One commenter disagreed with the proposed status indicator 
assignment of ``E1'' for CPT codes 0541T and 0542T, and stated that the 
technology was approved by the FDA. The commenter explained that these 
codes describe magnetocardiography (MCG), which is a ``high-fidelity 
biomagnetic imaging technique that utilizes highly sensitive 
magnetometers and a compact shield in order to measure, image and 
analyze the repolarization patterns of the heart.'' The commenter also 
indicated that MCG may be used to replace or avoid the need for 
additional cardiac stress and related testing, myocardial perfusion 
imaging, and/or PET procedures, and rapidly triage patients who present 
to the ED with chest pain or other symptoms of cardiac ischemia.
    Because the technology has been approved by the FDA, the commenter 
requested that CMS assign the procedures described by both CPT codes to 
APC 5593 (Level 3 Nuclear Medicine) or APC 5724 (Level 4 Diagnostic 
Tests and Related Services). Although the commenter requested an 
assignment to either APC 5593 or 5724, the commenter also noted that 
the services described by CPT codes 0541T and 0542T are clinically 
comparable to the services that are assigned to the following three 
APCs:
     APC 5593 (Level 3 Nuclear Medicine), with a proposed 
payment rate of approximately $1,228, which includes--
    [cir] CPT code 78451 (Myocardial perfusion imaging); and
    [cir] CPT code 78452 (Myocardial perfusion imaging)
     APC 5594 (Level 4 Nuclear Medicine), with a proposed 
payment rate of approximately $1,386, which includes--

[[Page 58919]]

    [cir] CPT code 78491 (Positron Emission Tomography (PET) myocardial 
functional imaging); and
    [cir] CPT code 78492 (Positron Emission Tomography (PET) myocardial 
functional imaging)
     APC 5724 (Level 4 Diagnostic Tests and Related Services), 
with a proposed payment rate of approximately $918, which includes--
    [cir] CPT code 95965 (Magnetoencephalography (MEG)); and
    [cir] CPT code 95966 (Magnetoencephalography (MEG))
    In addition to the requested APC assignment, the commenter 
requested that CMS assign the codes status indicator ``S'' (Procedure 
or Service, Not Discounted When Multiple. Paid under OPPS; separate APC 
payment), instead of status indicator ``E1'', similar to the status 
indicator assignment for the comparable codes in APCs 5593, 5594, and 
5724.
    Response: Based on our understanding of the procedure, we found 
that the service associated with these codes are currently in clinical 
trial (Study Title: ``Magnetocardiography Using a Novel Analysis System 
(Cardioflux) in the Evaluation of Emergency Department Observation Unit 
Chest Pain Patients''; ClinicalTrials.gov Identifier: NCT03255772). 
Further review of the clinical trial revealed that the clinical study 
has not yet met CMS' standards for coverage, nor does it appear on the 
CMS Approved IDE List, which can be found at this CMS website: https://www.cms.gov/Medicare/Coverage/IDE/Approved-IDE-Studies.html. Moreover, 
based on our review associated with the technology, we have not found 
evidence of FDA approval or clearance of the Cardioflux System as it 
appears that an application is pending with FDA, even though predicate 
devices have already been approved and are on the market. Because this 
specific MCG technology has not been approved for Medicare coverage or 
cleared by the FDA, we believe that we should continue to assign the 
procedures described by CPT codes 0541T and 0542T to status indicator 
``E1'' for CY 2019. If this technology later meets CMS' standards for 
coverage, we will reassess the APC assignment for the codes in a future 
quarterly update and/or rulemaking cycle.
    Therefore, after consideration of the public comment received, we 
are finalizing our proposal, without modification, for the assignment 
of status indicator ``E1'' to the procedures described by CPT codes 
0541T and 0542T. The final status indicator assignment for both codes 
is listed in Table 30 below. We refer readers to Addendum D1 of this 
final rule with comment period for the complete list of the OPPS 
payment status indicators and their definitions for CY 2019. Addendum 
D1 is available via the internet on the CMS website.
BILLING CODE 4120-01-P

[[Page 58920]]

[GRAPHIC] [TIFF OMITTED] TR21NO18.046

BILLING CODE 4120-01-C
15. Musculoskeletal Procedures (APCs 5111 Through 5116)
    Prior to the CY 2016 OPPS, payment for musculoskeletal procedures 
was primarily divided according to anatomy and the type of 
musculoskeletal procedure. As part of the CY 2016 reorganization to 
better structure the OPPS payments towards prospective payment 
packages, we consolidated those individual APCs so that they became a 
general Musculoskeletal Procedures APC series (80 FR 70397 through 
70398).
    In the CY 2018 OPPS/ASC final rule with comment period (82 FR 
59300), we continued to apply a six-level structure for the 
Musculoskeletal APCs because doing so provided an appropriate 
distinction for resource costs at each level and to provide clinical 
homogeneity. However, we also indicated that we would continue to 
review the structure of these APCs to determine whether additional 
granularity would be necessary.
    While we did not propose any changes to the 2019 OPPS structure of 
the Musculoskeletal Procedures APC series in the CY 2019 OPPS/ASC 
proposed rule, we stated that we recognize that commenters have 
previously expressed concerns regarding the granularity of the current 
APC levels and requested establishment of additional APC levels. 
Therefore, we solicited public comments on the creation of a new APC 
level between the current Level 5 and Level 6 within the 
Musculoskeletal Procedures APC series.

[[Page 58921]]

Table 18 of the proposed rule listed the Musculoskeletal Procedures 
APCs, the HCPCS codes assigned to the APCs, and the proposed APC 
geometric mean cost.
    Comment: Many commenters requested that CMS maintain the current 
six-level APC structure. Some of these commenters stated that the 
current structure provides sufficient granularity in the APCs, while 
other commenters suggested that, because Medicare previously made 
changes to create additional APCs in the Musculoskeletal Procedures APC 
series in the CY 2016 and CY 2017 OPPS, CMS delay any additional 
changes. Some commenters requested that CMS create additional levels 
and assign specific codes to either the new levels or existing levels 
within the relative structure. One commenter requested CMS maintain the 
procedure described by CPT code 27279 (Arthrodesis sacroiliac joint) at 
the highest level APC based on its geometric mean cost, if any 
additional high cost APC level above the current Level 6 were created. 
Another commenter requested that CMS create additional intermediate 
levels between the existing APC Levels 4 and 5 and between Levels 5 and 
6, and assign the procedures described by CPT code 28740 (Fusion of 
foot bones) and CPT code 28297 (Correction hallux valgus) to the new 
APC level between Levels 4 and 5. One commenter requested that, if a 
level were to be created between the current Levels 5 and 6, the 
procedure described by CPT code 27447 (Total knee arthroplasty) be 
assigned to that APC level. Other commenters requested that total knee 
arthroplasty be assigned to APC 1575 (New Technology--Level 38 
($10,001-$15,000)) for CY 2019, which has a payment rate at $12,500 
based on their analysis of the costs of the procedure for only those 
claims that reported certain device costs, rather than using all claims 
to calculate the geometric mean costs of the service.
    Response: We appreciate the commenters' support for maintaining the 
current APC structure. While we have previously stated that we believe 
that the six level APC structure for the Musculoskeletal Procedures APC 
series remains appropriate in providing distinction between resource 
costs at each level and clinical homogeneity (82 FR 59300), in the CY 
2019 proposed rule, we solicited comment on whether additional levels 
might be appropriate based on stakeholder concerns (83 FR 37096). Based 
on that stakeholder input, we will maintain the existing six level 
Musculoskeletal Procedures APC structure for the CY 2019 OPPS. While we 
are not creating additional APC levels in this final rule with comment 
period, we reviewed the APC assignment of individual HCPCS codes that 
commenters requested be reassigned if additional APC levels were 
created to confirm whether their current assignment was appropriate. We 
believe that the APC assignment of CPT code 27279 (Arthrodesis 
sacroiliac joint) to APC 5116, and CPT codes 28740 (Fusion of foot 
bones) and 28297 (Correction hallux valgus) to APC 5114 remain 
appropriate based on their geometric mean costs.
    With regards to the placement of the total knee arthroplasty 
procedure in APC 5115 (Level 5 Musculoskeletal Procedures), we continue 
to believe that C-APC 5115 is an appropriate APC assignment for the 
procedures described by CPT code 27447, which has an estimated 
geometric mean cost of $9,997.45. Further, we note that the 50th 
percentile IPPS payment for total knee arthroplasty procedures without 
major complications or comorbidities (MS-DRG 470) is approximately 
$11,550 for FY 2019. We note that the final CY 2019 payment for New 
Technology APC 1575 is $12,500.50. As previously stated in the CY 2018 
OPPS/ASC final rule with comment period (82 FR 58394 through 59385), we 
would expect that beneficiaries selected for outpatient total knee 
arthroplasty procedures would generally be expected to be less complex 
than those treated as hospital inpatients. Therefore, we do not believe 
that it would be appropriate for the OPPS payment rate to exceed the 
IPPS payment rate for total knee arthroplasty procedures without major 
complications/comorbidities because IPPS cases would generally be 
expected to be more complicated and complex than those performed in the 
hospital outpatient setting.
    We note that we rely on hospitals to bill all HCPCS codes 
accurately in accordance with their code descriptors and CPT and CMS 
instructions, as applicable, and to report charges on claims and 
charges and costs on their Medicare hospital cost reports appropriately 
(77 FR 68324). As we do every year, we will review and evaluate the APC 
groupings based on the latest available data in the next rulemaking 
cycle.
    After consideration of the public comments we received, we are 
finalizing the six level Musculoskeletal Procedures APC structure. We 
also are finalizing the proposed assignments of the procedures 
described by CPT codes 27279 (Arthrodesis sacroiliac joint) to APC 
5116, the procedures described by CPT codes 28740 (Fusion of foot 
bones) and 28297 (Correction hallux valgus) to APC 5114, and the 
procedures described by CPT code 27447 (Total knee arthroplasty) to APC 
5115.
[GRAPHIC] [TIFF OMITTED] TR21NO18.047


[[Page 58922]]


16. Nasal Airway Obstruction Treatment (APC 5164)
    For CY 2019, we proposed to continue to assign the procedures 
described by HCPCS code C9749 (Repair of nasal vestibular lateral wall 
stenosis with implant(s)) to APC 5164 (Level 4 ENT Procedures) with a 
proposed payment rate of approximately $2,241. We note that HCPCS code 
C9749 describes the Latera absorbable implant procedure for nasal 
airway obstruction.
    Comment: One commenter disagreed with the proposed APC assignment 
of the procedure described by HCPCS code C9749 to APC 5164 and 
requested that CMS assign the procedure to New Technology APC 1523 (New 
Technology--Level 23 ($2,501-$3,000)), which had a proposed payment 
rate of approximately $2,751. The commenter stated that the cost for a 
pair of the Latera implants is $1,325, and that the proposed payment 
rate for APC 5164 does not cover the cost of performing the procedure. 
The commenter further stated that information from clinical experts and 
medical directors suggests that the complexity and resources to perform 
the Latera implant procedure are similar to those associated with 
procedures assigned to APC 5165 (Level 5 ENT Procedures).
    Response: In December 2017, CMS received a New Technology APC 
application requesting a new HCPCS code for the Latera implant because, 
according to the applicant, the only available CPT code to report the 
procedure is CPT code 30999 (Unlisted procedure, nose). Based on our 
review of the application, assessment of the procedure, and input from 
our clinical advisors, we established HCPCS code C9749 effective April 
1, 2018. For the April 2018 OPPS Update, we assigned HCPCS code C9749 
to APC 5164 with a payment rate of approximately $2,199. We announced 
this new HCPCS code and APC assignment in the April 2018 OPPS quarterly 
update change request (Transmittal 4005, Change Request 10515, dated 
March 20, 2018). Based on cost information submitted to CMS in the New 
Technology APC application, we assigned the procedure to APC 5164 
rather than New Technology APC 1523. However, based on further 
assessment on the nature of the procedure, and input from public 
commenters and our clinical advisors, we believe that HCPCS code C9749 
should be reassigned to APC 5165 (Level 5 ENT Procedures) to more 
appropriately reflect the resource costs and clinical characteristics 
associated with the Latera implant procedure.
    Therefore, after consideration of the public comment we received, 
we are finalizing our proposal, without modification, to assign the 
procedure described by HCPCS code C9749 from APC 5164 to APC 5165. The 
final payment rate for HCPCS code C9749 can be found in Addendum B to 
this final rule with comment period (which is available via the 
internet on the CMS website).
17. Nerve Procedures and Services (APCs 5431 Through 5432)
    For CY 2019, we proposed to continue the existing two-level 
structure of the Nerve Procedures APCs (APC 5431 through 5432), as 
displayed in Table 32 below and in Addendum A to the CY 2019 OPPS/ASC 
proposed rule (which is available via the internet on the CMS website).
[GRAPHIC] [TIFF OMITTED] TR21NO18.048

    Comment: One commenter requested that CMS create a new modifier to 
identify the performance of continuous nerve block procedures that are 
performed as a secondary procedure, and to allow payment for the 
performance of such procedures, for example, the procedure described by 
CPT code 64416 (Injection, anesthetic agent; brachial plexus, 
continuous infusion by catheter (including catheter placement)), not to 
be packaged if reported in combination with the procedure described by 
CPT code 29827 (Arthroscopy, shoulder, surgical; with rotator cuff 
repair). Instead, the commenter suggested a modifier to allow for 
payment at a full OPPS rate. The commenter noted that continuous nerve 
block procedure codes are assigned to status indicator ``T,'' which 
further provides that payment for the procedures are currently packaged 
when reported in combination with procedures that are assigned to C-
APCs and, therefore, are not separately paid. The commenter stated that 
packaging payment for the certain procedures discourages hospitals from 
using non-opioid postsurgical pain alternative approaches, such as a 
continuous nerve block procedure.
    The commenter further believed that CMS should create a new HCPCS 
code modifier in order to track, research, and identify the use of non-
opioid pain management alternatives that are resulting in positive 
beneficiary health care impacts and outcomes, which are reducing opioid 
use and combatting the opioid crisis. Additionally, the commenter 
included a list of applicable continuous nerve block procedure codes 
(shown in the table below) to which the commenter suggested that a 
HCPCS modifier could be appended to indicate that the procedure would 
receive separate payment.

[[Page 58923]]

[GRAPHIC] [TIFF OMITTED] TR21NO18.049

    Response: We appreciate the commenter's suggestion to create a new 
HCPCS modifier to identify the continuous nerve block procedures when 
performed as a secondary procedure, as well as recommending the list of 
CPT codes that should be considered for such inclusion for separate 
payment. However, payment for these continuous nerve block procedures 
is currently packaged under the OPPS because they are adjunctive to the 
primary service rendered and, therefore, represent components of a 
complete service. Therefore, at this time we will continue to package 
payment for these services, and consider the creation of a new HCPCS 
modifier and separate payment for such non-opioid alternatives 
approaches in future rulemaking.
    Comment: One commenter suggested that CMS restructure the two-level 
Nerve Procedure APCs (APCs 5431 and 5432) to provide more payment 
granularity for the types of procedures included in the APCs by 
creating a third level. The commenter believed that there is a 
substantial payment differential between the procedures assigned to 
Level 1 Nerve Procedures APC 5431 and Level 2 Nerve Procedures APC 
5432, and that the current payment for some of these procedures does 
not adequately cover the cost of providing the services. The commenter 
further stated that, as an example, the procedures described by CPT 
codes 64633 (Destruction by neurolytic agent, paravertebral facet joint 
nerve(s), with imaging guidance (fluoroscopy or CT); cervical or 
thoracic, single facet joint) and 64635 (destruction by neurolytic 
agent paravertebral facet joint nerve(s), with imaging guidance 
(fluoroscopy or CT); lumbar or sacral, single facet joint), which are 
assigned to APC 5431 with a proposed payment rate of approximately 
$1,644, while the geometric means for each of the procedures described 
by CPT codes 64633 and 64635 are $1,482 and $1,729, respectively. The 
commenter recommended a potential geometric mean cost for a potential 
three-level APC structure within the Nerve Procedures APCs and 
submitted a three-level APC structure, along with estimated payment 
rates, which is shown in the table below.
[GRAPHIC] [TIFF OMITTED] TR21NO18.050

    The commenter also recommended that CMS develop two new HCPCS G-
codes to describe the performance of radiofrequency nerve ablation 
procedures. The commenter suggested that one of the G-codes could be 
created to describe procedures involving the genicular nerve, and the 
other G-code could be created to describe procedures

[[Page 58924]]

involving the sacroiliac joint. The commenter further recommended that 
both of these G-codes be created to describe procedures describing non-
opioid treatment alternatives for chronic pain management, and to 
assign both of these newly created G-codes to Level 2 Nerve Procedures 
APC 5232 based on its recommended three-level APC structure, with an 
estimated payment rate of $2,431. The commenter was aware that Category 
I CPT codes are in development, but will not be ready for release until 
CY 2020 at the earliest. Therefore, the commenter requested that CMS 
create such G-codes in order to allow for physicians and hospitals to 
report the performance of the procedures and use of the approach, and 
to be paid for utilization of these procedures in the interim. The 
commenter supplied a suggested descriptor for the G-code for the 
genicular nerve as: Radiofrequency nerve ablation; genicular nerves, 
including imaging guidance, when performed. The commenter also supplied 
a suggested descriptor for the G-code for the sacroiliac joint as: 
Radiofrequency never ablation; sacroiliac joint, including imaging 
guidance, when performed.
    Response: We appreciate the commenter's suggestions. However, at 
this time, we believe that the current two-level structure Nerve 
Procedures APCs provide an appropriate distinction between the resource 
costs at each level and clinical homogeneity. We will continue to 
review the APCs' structure to determine if additional granularity is 
necessary for this APC family in future rulemaking. In addition, we 
believe that more analysis of such groupings is necessary before 
adopting such change.
    With regard to the request to establish new HCPCS G-codes, although 
new CPT codes are in development for release for the CY 2020 update, we 
note that it does not appear that a request for new temporary Category 
III codes was made for CY 2019. Nonetheless, we intend to take the 
commenter's request for new HCPCS G-codes under advisement.
    Therefore, after consideration of the public comment received, we 
are finalizing our CY 2019 Nerve Procedures APCs two-level structure, 
as proposed. We refer readers to Addendum A to this final rule with 
comment period for the complete list of APCs and their payment rates. 
In addition, we refer readers to Addendum B to this final rule with 
comment period for the payment rates for all codes reported under the 
OPPS. Both Addendum A and Addendum B are available via the internet on 
the CMS website.
18. Radiology and Procedures and Services
a. Imaging Procedures and Services (APCs 5521 Through 5524 and 5571 
Through 5573)
    Section 1833(t)(2)(G) of the Act requires the Secretary to create 
additional groups of covered OPD services that classify separately 
those procedures that utilize contrast agents from those procedures 
that do not utilize contrast agents. In CY 2016, as a part of our 
comprehensive review of the structure of the APCs and procedure code 
assignments, we restructured the APCs that contain imaging services (80 
FR 70392). The purpose of this restructuring was to more appropriately 
reflect the resource costs and clinical characteristics of the services 
classified within the Imaging APCs. The restructuring of the Imaging 
APCs resulted in broader groupings that removed the excessive 
granularity of grouping imaging services according to organ or 
physiologic system, which did not necessarily reflect either 
significant differences in resources or how these services are 
delivered in the hospital outpatient setting. In CY 2017, in response 
to public comments on the CY 2017 OPPS/ASC proposed rule, we further 
consolidated the Imaging APCs from 17 APCs in CY 2016 to 7 APCs in CY 
2017 (81 FR 79633). These included four Imaging without Contrast APCs 
and three Imaging with Contrast APCs.
    For CY 2018, we proposed to establish a new Level 5 Imaging without 
Contrast APC to more appropriately group certain imaging services with 
higher resource costs and stated that our latest claims data supported 
splitting the CY 2017 Level 4 Imaging without Contrast APC into two 
APCs such that the Level 4 Imaging without Contrast APC would include 
high frequency, low-cost services and the proposed Level 5 Imaging 
without Contrast APC would include low frequency, high-cost services. 
Therefore, for CY 2018, we proposed to add a fifth level within the 
Imaging without Contrast APCs (82 FR 33608). However, based on public 
comments, we did not finalize this proposal. In general, commenters 
disagreed with CMS' proposal to add a fifth level within the Imaging 
without Contrast APC series because they believed that the addition of 
a fifth level would reduce payment for several imaging services, 
including vascular ultrasound procedures (82 FR 59309 through 59311). 
Commenters also noted that the lower payment rates under the OPPS would 
also apply under the PFS.
    For the CY 2019 OPPS/ASC proposed rule (83 FR 37096 through 37097), 
we reviewed the services assigned to the seven imaging APCs listed in 
Table 17 of the proposed rule. Specifically, we evaluated the resource 
costs and clinical coherence of the procedures associated with the four 
levels of Imaging without Contrast APCs and the three levels of Imaging 
with Contrast APCs, as well as identified for correction any 2 times 
rule violations, to the extent feasible. Based on the geometric mean 
cost for each APC, which was listed in Table 17 of the proposed rule, 
for CY 2019, we proposed to maintain the seven Imaging APCs, which 
consist of four levels of Imaging without Contrast APCs and three 
levels of Imaging with Contrast APCs, and to make minor reassignments 
to the HCPCS codes within this series to resolve or mitigate any 
violations of the 2 times rule, or both.
    We invited public comments on our proposal. Moreover, we 
specifically expressed an interest in receiving public comments and 
recommendations on the proposed HCPCS code reassignments associated 
with each of the seven Imaging APCs. We referred readers to Addendum B 
to the proposed rule (which is available via the internet on the CMS 
website) for the proposed list of specific codes that would be 
reassigned to each Imaging APC.
    Comment: Commenters generally agreed with CMS' proposal to maintain 
the Imaging APCs: Four levels of Imaging without Contrast APCs and 
three levels of Imaging with Contrast APCs. The commenters stated that 
maintaining the current Imaging APC structure would provide more 
stability for these services and would allow for cost trends to be 
assessed over time. Several of these commenters believed that the cost 
data for the procedures within these APCs have been consistent for many 
years and cautioned CMS against changing payment for services assigned 
to these APCs. Commenters recommended that if CMS believes any revision 
to the current APCs is necessary, the revisions be considered for 
future rulemaking and be subject to review and comment from 
stakeholders, in order to continue to maintain stability and sufficient 
payment and in order for hospitals to be able to continue to provide 
these services.
    Response: We appreciate the commenters' support for maintaining the 
seven Imaging APCs consisting of four levels of Imaging without 
Contrast APCs and three levels of Imaging with Contrast APCs.
    Comment: One commenter supported CMS' proposal to maintain the 
Level 3 Imaging with Contrast APC (APC 5573) as proposed for CY 2019. 
The commenter further stated that the

[[Page 58925]]

proposed payment rate for services in this APC appropriately reflects 
use of contrast agents and that a lower payment rate may lead to lower 
utilization of medically necessary contrast agents and may lead to use 
of more costly advanced imaging modalities such as cardiac MRI and 
nuclear perfusion studies, which will increase overall cost.
    Response: As noted in the CY 2019 OPPS/ASC proposed rule (83 FR 
37096 through 37097), we reviewed the resource costs and clinical 
coherence of the procedures associated with the four levels of Imaging 
without Contrast APCs and the three levels of Imaging with Contrast 
APCs, as well as reviewed any 2 times rule violations. Based on this 
review, we decided to maintain the seven Imaging APCs structure based 
on the clinical similarities and resource costs and in light of 
commenters' support of this proposal.
    Comment: One commenter noted the lack of payment stability for the 
procedure described by CPT code 93307 (Echocardiography, transthoracic, 
real-time with image documentation (2d), includes M-mode recording, 
when performed, complete, without spectral or color Doppler 
echocardiography). The commenter noted that CMS proposed to reassign 
the procedure described by CPT code 93307 to APC 5523, and that, in CY 
2018, this code was assigned to APC 5524. The commenter stated that the 
reassignment of CPT code 93307 to APC 5523 is inappropriate because it 
is not similar to the other procedures in that APC in regard to either 
clinical or resource use, and would result in a 52-percent decrease in 
payment for CY 2019 compared to the CY 2018 payment rate.
    Response: We acknowledge the commenter's concern. However, we 
believe that the assignment of the procedure described by CPT code 
93307 to APC 5523 is more appropriate based on clinical similarities 
and resource use. Specifically, we note that, based on the data 
available for this final rule with comment period, the lowest 
significant procedure geometric mean cost within APC 5523 is HCPCS code 
76000 (Fluoroscopy (separate procedure), up to 1 hour physician or 
other qualified health care professional time), with a geometric mean 
of $174.34, and the highest significant procedure cost within APC 5523 
is HCPCS code 74455 (Urethrocystography, voiding, radiological 
supervision and interpretation), with a geometric mean cost of $358.11. 
The geometric mean cost of CPT 93307 is $352.15, which is similar to 
that of other procedures assigned to APC 5523.
    Furthermore, the highest significant cost for a procedure within 
APC 5524 is for the procedure described by HCPCS 93312 
(Echocardiography, transesophageal, real-time with image documentation 
(2d) (with or without m-mode recording); including probe placement, 
image acquisition, interpretation and report), which has a geometric 
mean cost of $854.45. This proposed reassignment would have a greater 
impact on the 2 times violation by being over the violation limit by 
approximately $138, compared to the assignment of the CPT code to APC 
5523, which also has a 2 times violation, but to a lesser extent (that 
is, approximately $31). Therefore, based on this information, we are 
finalizing the proposed structure of APC 5523, with assignment of the 
CPT codes as proposed in the CY 2019 OPPS/ASC proposed rule. We will 
continue to monitor clinical homogeneity and resource costs within 
these APCs to identify any payment changes that may be warranted in 
future rulemaking.
    Comment: One commenter disagreed with the proposal to maintain the 
procedure described by HCPCS code G0297 (Low dose CT for lung cancer 
screening) in APC 5521 and believed the calculation of the geometric 
mean using the CT cost center does not sufficiently estimate costs, 
although CMS has 61,505 single claims to calculate the geometric mean 
cost for the procedure described by HCPCS code G0297. Based on its 
analysis, the commenter believed that using the diagnostic radiology 
cost center, which would result in estimated costs of $96.55 for the 
service, is more appropriate than the geometric mean cost of using the 
CT cost center, which is $37.96. The commenter believed that use of the 
CT cost centers is depressing payment for imaging services and believed 
all imaging studies should use the diagnostic radiology cost centers 
instead.
    Response: We believe that the procedure described by HCPCS code 
G0297 is appropriately assigned to APC 5521, based on its estimated 
cost relative to that of the other procedures in the APC. We believe 
that the manner in which we establish the geometric mean for estimating 
service costs for the Imaging APCs is appropriate. As part of changes 
to establish more accurate cost reporting, we developed the CT, MRI, 
and Cardiac Catherization cost centers in the CMS 2552-10 form. Since 
the CY 2014 OPPS, in which we first included those cost centers for 
ratesetting, we have included a methodology that removes cost data from 
providers reporting the standard CT and MRI cost centers using ``square 
feet'' as the cost allocation statistic. We continue to believe this is 
appropriate as discussed in section II.A.1.b. of this final rule with 
comment period. However, we will continue to monitor payment for these 
imaging services and will consider the most appropriate methodology for 
ratesetting for such services in future rulemaking.
    Additionally, we refer readers to the Medicare CY 2019 OPPS Final 
Rule Claims Accounting narrative for additional details regarding the 
calculation of the geometric mean costs.
    Comment: One commenter expressed concern regarding payment 
stability for cardiac magnetic imaging with contrast services, 
specifically cardiac magnetic resonance imaging (MRI) for morphology 
with dye (the procedure described by CPT code 75561 within APC 5572). 
The commenter was concerned that the proposed payment for this service 
is set to decline by 15 percent from the CY 2018 payment rate and 
believed that this would threaten hospitals' ability to maintain 
equipment, supplies, and agents used for these services. The commenter 
requested that CMS continue to monitor payment for cardiac MR services, 
specifically the procedure described by CPT code 75561. The commenter 
suggested that CMS study how best to assign low volume procedures to an 
APC.
    Response: Our analysis of the final rule updated claims data 
revealed a geometric mean cost of approximately $416.84 for CPT code 
75561 based on 8,248 single claims out of 15,022 total claims. The 
geometric mean cost for APC 5572 is approximately $390. After reviewing 
the procedures assigned to APC 5572, we believe that the geometric mean 
cost for the procedure described by CPT code 75561 indicates that it is 
appropriately assigned to APC 5572 based on its clinical homogeneity 
and resource costs. As we do each year, we will continue to review the 
APC assignments for all services and items paid under the OPPS.
    Comment: One commenter expressed concern regarding the payment 
amount for the procedure described by CPT code 75574 (Computed 
tomographic angiography, heart, coronary arteries and bypass grafts 
(when present), with contrast material, including 3d image 
postprocessing (including evaluation of cardiac structure and 
morphology, assessment of cardiac function, and evaluation of venous 
structures, if performed)) within APC 5571. Specifically, the commenter 
noted a 20-percent reduction from CY 2018 to CY 2019 within this APC. 
The commenter stated that the procedure described by

[[Page 58926]]

CPT code 75574 should be considered a low-volume service compared to 
other services within the APC and that high-volume codes within this 
APC are diluting the effect of the procedure described by CPT code 
75574 on the APC payment rate. As a result, the commenter requested 
that CMS study how the APC structure could be modified to define low 
volume services and foster payment adequacy for low-volume codes such 
as CPT code 75574.
    Response: We acknowledge the commenter's concerns regarding payment 
for CPT code 75574. At this point, we do not believe we have the 
necessary data to finalize a change based on the lack of information 
that the payment is insufficient. However, we will take under 
advisement and consider studying the impact of the APC structures on 
services that make up lower volume HCPCS and CPT codes in comparison to 
other services in higher volume HCPCS and CPT codes within an APC in 
future rulemaking. We remind hospitals that every year, we review the 
APC assignments for all services and items paid under the OPPS. We will 
reevaluate the APC assignment for the service described by CPT code 
75574 for next year's rulemaking.
    After consideration of the public comments we received, we are 
finalizing our proposal to maintain the existing levels of the Imaging 
APCs, which consist of four levels of Imaging without Contrast APCs and 
three levels of Imaging with Contrast APCs. Table 33 below compares the 
CY 2018 and CY 2019 geometric mean costs for the imaging APCs. We refer 
readers to Addendum B to this final rule with comment period for the 
payment rates for all codes reported under the OPPS. In addition, we 
refer readers to Addendum D1 to this final rule with comment period for 
the status indicator meanings for all codes reported under the OPPS. 
Both Addendum B and Addendum D1 are available via the internet on the 
CMS website.
[GRAPHIC] [TIFF OMITTED] TR21NO18.051

b. Non-Ophthalmic Fluorescent Vascular Angiography (APC 5572)
    As listed in Addendum B of the CY 2019 OPPS/ASC proposed rule, we 
proposed to continue to assign the procedure described by HCPCS code 
C9733 to APC 5523 (Level 3 Imaging without Contrast) with a proposed 
payment rate of approximately $232. We also proposed to maintain the 
status indicator assignment of ``Q2'' (T-packaged) to indicate that 
payment for the service is conditionally packaged when performed in 
conjunction with other procedures on the same day but paid separately 
when performed as a stand-alone service.
    Comment: One commenter stated that HCPCS code C9733 describes a 
procedure that includes disposable components and a contrast agent 
(indocyanine green) that cost hospitals approximately $455. 
Consequently, the commenter disagreed with the proposed APC assignment 
of this service to APC 5523 because the APC payment rate only covers 50 
percent of the hospital costs for the procedure. In addition, the 
commenter believed that hospitals are underreporting the costs for the 
procedure described by HCPCS code C9733 based on its review of the CMS 
cost file which showed a geometric mean cost of $252.43, which is below 
the cost of the supplies associated with this procedure. The commenter 
suggested that hospitals may not be reporting this code when performed 
with an outpatient visit because payment for the service described by 
HCPCS code C9733 is conditionally packaged. Because of the perceived 
underreporting, the commenter requested that CMS provide instructions 
to hospitals in an upcoming MLN Matters article on appropriate billing 
for the procedure described by HCPCS code C9733.
    Response: Based on our review of the CY 2019 final rule claims 
data, the procedure described by HCPCS code C9733 has a geometric mean 
cost of approximately $250 based on 173 single claims (out of 982 total 
claims). Because this procedure involves the use of a contrast agent, 
we believe that a reassignment to one of the existing Imaging with 
Contrast APCs would be more appropriate for HCPCS code C9733. 
Specifically, we believe that a reassignment to APC 5572 (Level 2 
Imaging with Contrast), with a geometric mean cost of approximately 
$389 is appropriate. We believe this reassignment will improve clinical 
homogeneity and align the resource costs of the service described by 
HCPCS code C9733 with those of imaging with contrast procedures 
assigned to APC 5572.
    In addition, with regard to the comment that hospitals underreport 
the procedure described by HCPCS code C9733, based on our analysis of 
the CY 2019 hospital outpatient claims data used for this final rule 
with comment period, we are unable to determine whether hospitals are 
underreporting the procedure. It is generally not our policy to judge 
the accuracy of hospital coding and charging for purposes of 
ratesetting. We rely on hospitals to accurately report the use of HCPCS 
codes in accordance with their code descriptors and CPT and CMS 
instructions, and to report services on

[[Page 58927]]

claims and charges and costs for the services on their Medicare 
hospital cost report appropriately. However, we do not specify the 
methodologies that hospitals use to set charges for this or any other 
service. In addition, we state in Chapter 4 of the Medicare Claims 
Processing Manual that ``it is extremely important that hospitals 
report all HCPCS codes consistent with their descriptors; CPT and/or 
CMS instructions and correct coding principles, and all charges for all 
services they furnish, whether payment for the services is made 
separately paid or is packaged'' to enable CMS to establish future 
ratesetting for OPPS services.''
    After consideration of the public comment received, we are 
finalizing our proposal with modification. Specifically, we are 
reassigning the procedure described by HCPCS code C9733 to APC 5572 
instead of APC 5523, based on its clinical and resource homogeneity to 
the other procedures assigned to APC 5572. We refer readers to Addendum 
B to this final rule with comment period for the payment rates for all 
codes reportable under the OPPS. Addendum B is available via the 
internet on the CMS website.
19. Remote Physiologic Monitoring (APCs 5012 and 5741)
    As displayed in Table 34 below and in Addendum B to the CY 2019 
OPPS/ASC proposed rule, we proposed to assign the procedure described 
by CPT code 99453 to APC 5012 (Clinic Visits and Related Services) with 
a proposed payment rate of approximately $116. We also proposed to 
assign the procedure described by CPT code 99454 to APC 5741 (Level 1 
Electronic Analysis of Devices) with a proposed payment rate of 
approximately $37. The long descriptors for CPT codes 99453 and 99454 
can be found in Table 34 below. The codes were listed as 990X0 and 
990X1 (the 5-digit CMS placeholder codes), respectively, in Addendum B, 
with short descriptors, and in Addendum O, with long descriptors, to 
the CY 2019 OPPS/ASC proposed rule. We also assigned these codes to 
comment indicator ``NP'' in Addendum B to the proposed rule to indicate 
that the codes are new for CY 2019 with proposed APC assignments, and 
that public comments would be accepted on their proposed APC 
assignments. We note that these codes will be effective January 1, 
2019.
    Comment: One commenter supported the APC assignments for both CPT 
codes 99453 and 99454 and requested that CMS finalize the APC 
assignments for CY 2019.
    Response: We appreciate the commenter's support. Based on input 
from our medical advisors, we believe that procedures described by CPT 
codes 99453 and 99454 are appropriately assigned in APCs 5012 and 5741, 
respectively, based on clinical and resource homogeneity to the other 
services assigned to these APCs.
    Therefore, after consideration of the public comment received, we 
are finalizing our proposal without modification for the procedures 
described by CPT codes 99453 and 99454. The final APC and status 
indicator assignments are listed in Table 34 below. The final payment 
rates for these codes, where applicable, can be found in Addendum B to 
this final rule with comment period (which is available via the 
internet on the CMS website).
[GRAPHIC] [TIFF OMITTED] TR21NO18.052


[[Page 58928]]


20. Sclerotherapy (APC 5054)
    As displayed in Table 35 below and in Addendum B of the CY 2019 
OPPS/ASC proposed rule, we proposed to continue to assign CPT codes 
36465 and 36466 to APC 5054 (Level 4 Skin Procedures), with a proposed 
payment rate of approximately $1,565.
    Comment: One commenter disagreed with the proposed assignment of 
the procedures described by CPT codes 36465 and 36466 to APC 5054 and 
requested a reassignment to APC 5183 (Level 3 Vascular Procedures), 
which had a proposed payment rate of approximately $2,648. The 
commenter stated that the per-procedure cost for the Varithena foam 
sclerosant used in the procedure is $1,064. The commenter stated that 
APC 5183 is more clinically appropriate and reflects the resources 
required to perform the procedure. Specifically, the commenter 
indicated that the procedures described by CPT codes 36465 and 36466 
share similar clinical and resource characteristics to the following 
surgical procedures that are assigned to APC 5183:
     CPT code 36473 (Endovenous ablation therapy of incompetent 
vein, extremity, inclusive of all imaging guidance and monitoring, 
percutaneous, mechanochemical; first vein treated);
     CPT code 36475 (Endovenous ablation therapy of incompetent 
vein, extremity, inclusive of all imaging guidance and monitoring, 
percutaneous, radiofrequency; first vein treated); and
     CPT code 36478 (Endovenous ablation therapy of incompetent 
vein, extremity, inclusive of all imaging guidance and monitoring, 
percutaneous, laser; first vein treated).
    Response: Based on input from our clinical advisors, we believe 
that the procedures described by CPT codes 36465 and 36466 are 
clinically similar to the procedures assigned to APC 5054. We do not 
believe that the resources used for the procedures described by CPT 
codes 36465 and 36466 are comparable to the procedures described by CPT 
codes 36473, 36475, and 36478, which are assigned to C-APC 5183. 
Consequently, we believe that APC 5054 appropriately reflects the 
resources and clinical characteristics associated with the procedures 
described by CPT codes 36465 and 36466. We note that the geometric mean 
cost for APC 5054 is approximately $1,562, which exceeds the cost of 
the Varithena foam sclerosant (as reported by the commenter) used in 
the procedure.
    Therefore, after consideration of the public comment received, we 
are finalizing our proposal without modification for assignment of the 
procedures described by CPT codes 36465 and 36466 to APC 5054. The 
final APC and status indicator assignments are listed in Table 35 
below. As we do every year, we review the APC assignments for all 
services and items paid under the OPPS. We will reassess the APC 
assignment for the procedures described by CPT codes 36465 and 36466 
for the CY 2020 rulemaking. We refer readers to Addendum B to this 
final rule with comment period for the payment rates for all codes 
reportable under the OPPS. Addendum B is available via the internet on 
the CMS website.
[GRAPHIC] [TIFF OMITTED] TR21NO18.053


[[Page 58929]]



IV. OPPS Payment for Devices

A. Pass-Through Payments for Devices

1. Beginning Eligibility Date for Device Pass-Through Status and 
Quarterly Expiration of Device Pass-Through Payments
a. Background
    Under section 1833(t)(6)(B)(iii) of the Act, the period for which a 
device category eligible for transitional pass-through payments under 
the OPPS can be in effect is at least 2 years but not more than 3 
years. Prior to CY 2017, our regulation at 42 CFR 419.66(g) provided 
that this pass-through payment eligibility period began on the date CMS 
established a particular transitional pass-through category of devices, 
and we based the pass-through status expiration date for a device 
category on the date on which pass-through payment was effective for 
the category. In the CY 2017 OPPS/ASC final rule with comment period 
(81 FR 79654), in accordance with section 1833(t)(6)(B)(iii)(II) of the 
Act, we amended Sec.  419.66(g) to provide that the pass-through 
eligibility period for a device category begins on the first date on 
which pass-through payment is made under the OPPS for any medical 
device described by such category.
    In addition, prior to CY 2017, our policy was to propose and 
finalize the dates for expiration of pass-through status for device 
categories as part of the OPPS annual update. This means that device 
pass-through status would expire at the end of a calendar year when at 
least 2 years of pass-through payments have been made, regardless of 
the quarter in which the device was approved. In the CY 2017 OPPS/ASC 
final rule with comment period (81 FR 79655), we changed our policy to 
allow for quarterly expiration of pass-through payment status for 
devices, beginning with pass-through devices approved in CY 2017 and 
subsequent calendar years, to afford a pass-through payment period that 
is as close to a full 3 years as possible for all pass-through payment 
devices. We refer readers to the CY 2017 OPPS/ASC final rule with 
comment period (81 FR 79648 through 79661) for a full discussion of the 
changes to the device pass-through payment policy. We also have an 
established policy to package the costs of the devices that are no 
longer eligible for pass-through payments into the costs of the 
procedures with which the devices are reported in the claims data used 
to set the payment rates (67 FR 66763).
b. Expiration of Transitional Pass-Through Payments for Certain Devices
    As stated earlier, section 1833(t)(6)(B)(iii) of the Act requires 
that, under the OPPS, a category of devices be eligible for 
transitional pass-through payments for at least 2 years, but not more 
than 3 years. There currently are no device categories eligible for 
pass-through payment.
2. New Device Pass-Through Applications
a. Background
    Section 1833(t)(6) of the Act provides for pass-through payments 
for devices, and section 1833(t)(6)(B) of the Act requires CMS to use 
categories in determining the eligibility of devices for pass-through 
payments. As part of implementing the statute through regulations, we 
have continued to believe that it is important for hospitals to receive 
pass-through payments for devices that offer substantial clinical 
improvement in the treatment of Medicare beneficiaries to facilitate 
access by beneficiaries to the advantages of the new technology. 
Conversely, we have noted that the need for additional payments for 
devices that offer little or no clinical improvement over previously 
existing devices is less apparent. In such cases, these devices can 
still be used by hospitals, and hospitals will be paid for them through 
appropriate APC payment. Moreover, a goal is to target pass-through 
payments for those devices where cost considerations might be most 
likely to interfere with patient access (66 FR 55852; 67 FR 66782; and 
70 FR 68629).
    As specified in regulations at 42 CFR 419.66(b)(1) through (3), to 
be eligible for transitional pass-through payment under the OPPS, a 
device must meet the following criteria: (1) If required by FDA, the 
device must have received FDA approval or clearance (except for a 
device that has received an FDA investigational device exemption (IDE) 
and has been classified as a Category B device by the FDA), or meet 
another appropriate FDA exemption; and the pass-through payment 
application must be submitted within 3 years from the date of the 
initial FDA approval or clearance, if required, unless there is a 
documented, verifiable delay in U.S. market availability after FDA 
approval or clearance is granted, in which case CMS will consider the 
pass-through payment application if it is submitted within 3 years from 
the date of market availability; (2) the device is determined to be 
reasonable and necessary for the diagnosis or treatment of an illness 
or injury or to improve the functioning of a malformed body part, as 
required by section 1862(a)(1)(A) of the Act; and (3) the device is an 
integral part of the service furnished, is used for one patient only, 
comes in contact with human tissue, and is surgically implanted or 
inserted (either permanently or temporarily), or applied in or on a 
wound or other skin lesion. In addition, according to Sec.  
419.66(b)(4), a device is not eligible to be considered for device 
pass-through payment if it is any of the following: (1) Equipment, an 
instrument, apparatus, implement, or item of this type for which 
depreciation and financing expenses are recovered as depreciation 
assets as defined in Chapter 1 of the Medicare Provider Reimbursement 
Manual (CMS Pub. 15-1); or (2) a material or supply furnished incident 
to a service (for example, a suture, customized surgical kit, or clip, 
other than a radiological site marker).
    Separately, we use the following criteria, as set forth under Sec.  
419.66(c), to determine whether a new category of pass-through payment 
devices should be established. The device to be included in the new 
category must--
     Not be appropriately described by an existing category or 
by any category previously in effect established for transitional pass-
through payments, and was not being paid for as an outpatient service 
as of December 31, 1996;
     Have an average cost that is not ``insignificant'' 
relative to the payment amount for the procedure or service with which 
the device is associated as determined under Sec.  419.66(d) by 
demonstrating: (1) The estimated average reasonable costs of devices in 
the category exceeds 25 percent of the applicable APC payment amount 
for the service related to the category of devices; (2) the estimated 
average reasonable cost of the devices in the category exceeds the cost 
of the device-related portion of the APC payment amount for the related 
service by at least 25 percent; and (3) the difference between the 
estimated average reasonable cost of the devices in the category and 
the portion of the APC payment amount for the device exceeds 10 percent 
of the APC payment amount for the related service (with the exception 
of brachytherapy and temperature-monitored cryoblation, which are 
exempt from the cost requirements as specified at Sec.  419.66(c)(3) 
and (e)); and
     Demonstrate a substantial clinical improvement, that is, 
substantially improve the diagnosis or treatment of an illness or 
injury or improve the functioning of a malformed body part compared to 
the benefits of a device or

[[Page 58930]]

devices in a previously established category or other available 
treatment.
    Beginning in CY 2016, we changed our device pass-through evaluation 
and determination process. Device pass-through applications are still 
submitted to CMS through the quarterly subregulatory process, but the 
applications will be subject to notice-and-comment rulemaking in the 
next applicable OPPS annual rulemaking cycle. Under this process, all 
applications that are preliminarily approved upon quarterly review will 
automatically be included in the next applicable OPPS annual rulemaking 
cycle, while submitters of applications that are not approved upon 
quarterly review will have the option of being included in the next 
applicable OPPS annual rulemaking cycle or withdrawing their 
application from consideration. Under this notice-and-comment process, 
applicants may submit new evidence, such as clinical trial results 
published in a peer-reviewed journal or other materials for 
consideration during the public comment process for the proposed rule. 
This process allows those applications that we are able to determine 
meet all the criteria for device pass-through payment under the 
quarterly review process to receive timely pass-through payment status, 
while still allowing for a transparent, public review process for all 
applications (80 FR 70417 through 70418).
    More details on the requirements for device pass-through payment 
applications are included on the CMS website in the application form 
itself at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/HospitalOutpatientPPS/passthrough_payment.html, in the 
``Downloads'' section. In addition, CMS is amenable to meeting with 
applicants or potential applicants to discuss research trial design in 
advance of any device pass-through application or to discuss 
application criteria, including the substantial clinical improvement 
criterion.
b. Applications Received for Device Pass-Through Payment for CY 2019
    We received seven applications by the March 1, 2018 quarterly 
deadline, which was the last quarterly deadline for applications to be 
received in time to be included in the CY 2019 OPPS/ASC proposed rule. 
We received four of the applications in the second quarter of 2017, one 
of the applications in the third quarter of 2017, and two of the 
applications in the first quarter of 2018. None of the seven 
applications were approved for device pass-through payment during the 
quarterly review process.
    Applications received for the later deadlines for the remaining 
2018 quarters (June 1, September 1, and December 1), if any, will be 
presented in the CY 2020 OPPS/ASC proposed rule. We note that the 
quarterly application process and requirements have not changed in 
light of the addition of rulemaking review. Detailed instructions on 
submission of a quarterly device pass-through payment application are 
included on the CMS website at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/HospitalOutpatientPPS/Downloads/catapp.pdf. A 
discussion of the seven applications received by the March 1, 2018 
deadline is presented below, as detailed in the CY 2019 OPPS/ASC 
proposed rule (83 FR 37098 through 37107).
(1) AquaBeam System
    PROCEPT BioRobotics Corporation submitted an application for a new 
device category for transitional pass-through payment status for the 
AquaBeam System. The AquaBeam System is intended for the resection and 
removal of prostate tissue in males suffering from lower urinary tract 
symptoms (LUTS) due to benign prostatic hyperplasia (BPH). The 
applicant stated that this is a very common condition typically 
occurring in elderly men. The clinical symptoms of this condition can 
include diminished urinary stream and partial urethral obstruction.\16\ 
According to the applicant, the AquaBeam system resects the prostate to 
relieve symptoms of urethral compression. The resection is performed 
robotically using a high velocity, nonheated sterile saline water jet 
(in a procedure called Aquablation). The applicant stated that the 
AquaBeam System utilizes real-time intra-operative ultrasound guidance 
to allow the surgeon to precisely plan the surgical resection area of 
the prostate and then the system delivers Aquablation therapy to 
accurately resect the obstructive prostate tissue without the use of 
heat. The materials submitted by the applicant state that the AquaBeam 
System consists of a disposable, single-use handpiece as well as other 
components that are considered capital equipment.
---------------------------------------------------------------------------

    \16\ Chungtai B. Forde JC. Thomas DDM et al. Benign Prostatic 
Hyperplasia. Nature Reviews Disease Primers 2 (2016) article 16031.
---------------------------------------------------------------------------

    With respect to the eligibility criterion at Sec.  419.66(b)(3), 
according to the applicant, the AquaBeam System is integral to the 
service provided, is used for one patient only, comes in contact with 
human skin, and is surgically implanted or inserted (either permanently 
or temporarily). The applicant also claimed the AquaBeam System meets 
the device eligibility requirements of Sec.  419.66(b)(4) because it is 
not an instrument, apparatus, implement, or items for which 
depreciation and financing expenses are recovered, and it is not a 
supply or material furnished incident to a service. However, in the CY 
2000 interim final rule with comment period (65 FR 67804 through 
67805), we explained how we interpreted Sec.  419.43(e)(4)(iv). We 
stated that we consider a device to be surgically implanted or inserted 
if it is surgically inserted or implanted via a natural or surgically 
created orifice, or inserted or implanted via a surgically created 
incision. We also stated that we do not consider an item used to cut or 
otherwise create a surgical opening to be a device that is surgically 
implanted or inserted. We consider items used to create incisions, such 
as scalpels, electrocautery units, biopsy apparatuses, or other 
commonly used operating room instruments, to be supplies or capital 
equipment, not eligible for transitional pass-through payments. We 
stated that we believe the function of these items is different and 
distinct from that of devices that are used for surgical implantation 
or insertion. Finally, we stated that, generally, we would expect that 
surgical implantation or insertion of a device occurs after the surgeon 
uses certain primary tools, supplies, or instruments to create the 
surgical path or site for implanting the device. In the CY 2006 final 
rule with comment period (70 FR 68629 and 68630), we adopted as final 
our interpretation that surgical insertion or implantation criteria 
include devices that are surgically inserted or implanted via a natural 
or surgically created orifice, as well as those devices that are 
inserted or implanted via a surgically created incision. We reiterated 
that we maintain all of the other criteria in Sec.  419.66 of the 
regulations, namely, that we do not consider an item used to cut or 
otherwise create a surgical opening to be a device that is surgically 
implanted or inserted. We invited public comments on whether the 
AquaBeam System meets the eligibility criteria at Sec.  419.66(b).
    Comment: Commenters, including the manufacturer of AquaBeam and 
stakeholders, believed that the AquaBeam System met the eligibility 
criteria at Sec.  419.66(b).
    Response: We appreciate the commenters' input. However, we do not 
believe that the AquaBeam device meets

[[Page 58931]]

the eligibility criteria described at Sec.  419.66(b). Specifically, we 
do not believe that the device is surgically implanted or inserted. As 
stated earlier, we have described in previous rulemaking (65 FR 67804 
through 67805 and 70 FR 68329 through 68630) how we interpret the 
surgical insertion or implantation criteria, and we do not believe that 
the use of the Aquabeam device is consistent with that interpretation; 
namely, that we do not consider an item used to cut or otherwise create 
a surgical opening to be a device that is surgically implanted or 
inserted (70 FR 68630). Because we have determined that the AquaBeam 
device does not meet the basic eligibility criterion for transitional 
pass-through payment status, we have not evaluated this product to 
determine whether it meets the other criteria required for transitional 
pass-through payment for devices; that is the newness criterion, the 
substantial clinical improvement criterion, and the cost criterion.
    After consideration of the public comments we received, we are not 
approving device pass-through payment status for the AquaBeam System 
for CY 2019.
(2) BioBag[supreg] (Larval Debridement Therapy in a Contained Dressing)
    BioMonde US, LLC resubmitted an application for a new device pass-
through category for the BioBag[supreg] (larval debridement therapy in 
a contained dressing), hereinafter referred to as the BioBag[supreg]. 
The application submitted contained similar information to the previous 
application received in March 2016 that was evaluated in the CY 2017 
OPPS/ASC final rule with comment period (81 FR 79650). The only new 
information provided by the applicant were additional studies completed 
since the original application addressing the substantial clinical 
improvement criterion.
    According to the applicant, the BioBag[supreg] is a biosurgical 
wound treatment (``maggot therapy'') consisting of disinfected, living 
larvae (Lucilia sericata) in a polyester net bag; the larvae remove 
dead tissue from wounds. The BioBag[supreg] is indicated for 
debridement of nonhealing necrotic skin and soft tissue wounds, 
including pressure ulcers, venous stasis ulcers, neuropathic foot 
ulcers, and nonhealing traumatic or postsurgical wounds. Debridement, 
which is the action of removing devitalized tissue and bacteria from a 
wound, is required to treat or prevent infection and to allow the wound 
to progress through the healing process. This system contains 
disinfected, living larvae that remove the dead tissue from wounds and 
leave healthy tissue undisturbed. The larvae are provided in a sterile 
polyester net bag, available in different sizes. The only other similar 
product is free-range (that is, uncontained) larvae. Free-range larvae 
are not widely used in the United States because application is time 
consuming, there is a fear of larvae escaping from the wound, and there 
are concerns about proper and safe handling of the larvae. The total 
number of treatment cycles depends on the characteristics of the wound, 
the response of the wound, and the aim of the therapy. Most ulcers are 
completely debrided within 1 to 6 treatment cycles.
    With respect to the newness criterion at Sec.  419.66(b)(1), the 
applicant received FDA clearance for the BioBag[supreg] through the 
premarket notification section 510(k) process on August 28, 2013, and 
the first U.S. sale of the BioBag[supreg] occurred in April 2015. The 
June 1, 2017 application is more than 3 years after FDA clearance but 
less than 3 years after its first U.S. sale. We invited public comments 
on whether the BioBag[supreg] meets the newness criterion.
    Comment: The manufacturer stated that, although the BioBag[supreg] 
received its 510(k) clearance in 2013, BioBag[supreg] was not 
commercially available in the United States until its American-based 
production facility was established in 2015 to make the product 
available on the market.
    Response: We appreciate the additional clarification from the 
manufacturer regarding the availability of the BioBag[supreg]. Based on 
this clarification, we have determined that BioBag[supreg] meets the 
newness criterion.
    With respect to the eligibility criterion at Sec.  419.66(b)(3), 
the applicant claimed that the BioBag[supreg] is an integral part of 
the wound debridement, is used for one patient only, comes in contact 
with human skin, and is applied in or on a wound. In addition, the 
applicant stated that the BioBag[supreg] meets the device eligibility 
requirements of Sec.  419.66(b)(4) because it is not an instrument, 
apparatus, or item for which depreciation and financing expenses are 
recovered. We also had determined in the CY 2017 OPPS/ASC final rule 
with comment period (81 FR 79650) that the BioBag[supreg] is not a 
material or supply furnished incident to a service. We invited public 
comments on whether the BioBag[supreg] meets the eligibility criterion.
    Comment: The manufacturer presented several reasons why the 
BioBag[supreg] is not a medical supply, but instead is a treatment for 
wound debridement, including the specialized nature of the product, 
that the product is not purchased in bulk, and that it provides a 
treatment outcome for non-healing wounds.
    Response: We appreciate the additional information provided by the 
manufacturer to demonstrate that the BioBag[supreg] is not a material 
or medical supply. Based on this information, we have determined that 
the BioBag[supreg] meets the eligibility criterion.
    The criteria for establishing new device categories are specified 
at Sec.  419.66(c). The first criterion, at Sec.  419.66(c)(1), 
provides that CMS determines that a device to be included in the 
category is not appropriately described by any existing categories or 
by any category previously in effect, and was not being paid for as an 
outpatient service as of December 31, 1996. With respect to the 
existence of a previous pass-through device category that describes the 
BioBag[supreg], the applicant suggested a category descriptor of 
``Contained medicinal larvae for the debridement of necrotic non-
healing skin and soft tissue wounds.'' We have not identified an 
existing pass-through payment category that describes the 
BioBag[supreg].
    The second criterion for establishing a device category, at Sec.  
419.66(c)(2), provides that CMS determines that a device to be included 
in the category has demonstrated that it will substantially improve the 
diagnosis or treatment of an illness or injury or improve the 
functioning of a malformed body part compared to the benefits of a 
device or devices in a previously established category or other 
available treatment. With respect to the substantial clinical 
improvement criterion, the applicant provided substantial evidence that 
larval therapy may improve outcomes compared to other methods of wound 
debridement. However, given the existence of the Medical 
Maggots[supreg], another form of larval therapy that has been on the 
market since 2004, the relevant comparison is between the 
BioBag[supreg] and the Medical Maggots[supreg]. There are many reasons 
to suspect that the BioBag[supreg] could improve outcomes and be 
preferable to the Medical Maggots[supreg]. In essence, with the latter, 
the maggots are directly placed on the wound, which may result in 
escape, leading to infection control issues as well as dosing 
variability. In addition, there are the issues with patient comfort. 
With the Biobag[supreg], the maggots are in a sealed container so 
escape is not an issue. The applicant cited a study showing large 
decreases in maggot escape with the BioBag[supreg] as opposed to the 
Medical Maggots[supreg]. However, the applicant did

[[Page 58932]]

not provide any data that clinical outcomes are improved using the 
BioBag[supreg] as opposed to the Medical Maggots[supreg]. Based on the 
studies presented, we believe there are insufficient data to determine 
whether the BioBag[supreg] offers a substantial clinical improvement 
over other treatments for wound care. We invited public comments on 
whether the BioBag[supreg] meets the substantial clinical improvement 
criterion.
    Comment: The manufacturer identified four items to indicate that 
the BioBag[supreg] may provide substantial clinical improvement over 
other available treatments. These items include debridement of wounds 
infected with MRSA, removing more tissue than loose maggots, the ease 
of use of the BioBag[supreg] over loose maggots, and less pain during 
debridement. The commenter stated that these items were supported by 
journal citations.
    Several other commenters discussed the benefits of the 
BioBag[supreg], and a few commenters discussed the benefits of larval 
debridement of wounds more generally. The commenters cited benefits 
that included that the BioBag[supreg] debrides only dead tissue, that 
BioBag[supreg] makes it easier to apply and remove maggots from wounds, 
and that BioBag[supreg] is a lower-cost and less-invasive treatment 
than surgical debridement. The commenters did not provide any support 
of these benefits by medical studies.
    Response: We have reviewed these public comments and the additional 
journal citations and believe that most of the information provided by 
commenters reenforced our discussion in the proposed rule that stated 
that there are many reasons why the BioBag[supreg] may be preferable to 
treatment from loose maggots. However, we have not been provided with 
sufficient support from clinical studies to determine that the 
BioBag[supreg] meets the substantial clinical improvement criterion. 
Each of the three clinical studies cited by the manufacturer did 
identify possible benefits from the use of the BioBag[supreg] over 
treatment from loose maggots, hydrogel, or other surgical debridement 
methods. However, the findings had only marginal clinical significance, 
and did not reflect sufficient clinical support to reach the threshold 
of demonstrating significant clinical improvement.
    For example, the study of debridement through containment,\17\ was 
done in vitro (that is, in a laboratory setting) and not in vivo (that 
is, through testing on human subjects). Therefore, we are uncertain how 
the study findings would extrapolate to a patient receiving treatment. 
Second, we did not find that the clinical evidence fully supported the 
commenters' claimed benefits. For instance, a commenter, the 
manufacturer provided data comparing the amount of material debrided by 
the BioBag[supreg] at 4 days to free larvae at 3 days from the same 
study of debridement through containment.\18\ To help demonstrate 
substantial clinical improvement, we believe that the commenter should 
have compared the amount of material debrided by both treatment methods 
over a similar time period. When similar time periods are compared 
between both treatment methods, the study found the amount of material 
debrided by the BioBag[supreg] and the free larvae is similar. In 
another study cited by the commenter discussing the prevalence of pain 
during maggot debridement therapy,\19\ the share of study patients 
experiencing pain was similar for people receiving treatment using a 
BioBag[supreg] device when compared to people receiving maggot 
debridement therapy from free larvae kept in a cage-like dressing.
---------------------------------------------------------------------------

    \17\ Blake, F. et al. The biosurgical wound debridement: 
Experimental investigation of efficiency and practicability. Wound 
Rep Reg, 2007: 15; 756-761. 3.
    \18\ Ibid. Blake, F. et al.
    \19\ Mumcuoglu, K. et al. Pain related to maggot debridement 
therapy. J Wound Care. 2012;21(8): 400-405.
---------------------------------------------------------------------------

    After consideration of the public comments we received, we have 
determined that the BioBag[supreg] does not meet the significant 
clinical improvement criterion.
    The third criterion for establishing a device category, at Sec.  
419.66(c)(3), requires us to determine that the cost of a device is not 
insignificant, as described in Sec.  419.66(d). Section 419.66(d) 
includes three cost significance criteria that must each be met. With 
respect to the cost criterion, the applicant stated that the 
BioBag[supreg] would be reported with CPT code 97602 (Removal of 
devitalized tissue from wound(s), non-selective debridement, without 
anesthesia (e.g., wet-to-moist dressings, enzymatic, abrasion, larval 
therapy), including topical application(s), wound assessment, and 
instruction(s) for ongoing care, per session). CPT code 97602 is 
assigned to APC 5051 (Level 1 Skin Procedures), with a payment rate of 
$153.12, and a device offset of $0.02. The price of the BioBag[supreg] 
varies with the size of the bag ($375 to $435 per bag), and bag size 
selection is based on the size of the wound.
    Section 419.66(d)(1), the first cost significance requirement, 
provides that the estimated average reasonable cost of devices in the 
category must exceed 25 percent of the applicable APC payment amount 
for the service related to the category of devices. The estimated 
reasonable cost of $435 for the BioBag[supreg] exceeds the applicable 
APC amount for the service related to the category of devices of 
$153.12 by 284.09 percent ($435/$153.12 x 100 = 284.09 percent). Thus, 
we determined that the BioBag[supreg] appears to meet the first cost 
significance test.
    The second cost significance test, at Sec.  419.66(d)(2), provides 
that the estimated average reasonable cost of devices in the category 
must exceed the cost of the device-related portion of the APC payment 
amount by at least 25 percent, which means the device cost needs to be 
at least 125 percent of the device offset amount (the device-related 
portion of the APC found on the offset list). The estimated average 
reasonable cost of $435 for the BioBag[supreg] exceeds the proposed 
device-related portion of the APC amount for the related service of 
$0.02 by 2,175,000 percent ($435/$0.02 x 100 = 2,175,000 percent). 
Thus, we determined that the BioBag[supreg] appears to meet the second 
cost significance test.
    Section 419.66(d)(3), the third cost significance test, requires 
that the difference between the estimated average reasonable cost of 
the devices in the category and the portion of the APC payment amount 
determined to be associated with the device exceeds 10 percent of the 
APC payment amount for the related service. The difference between the 
estimated average reasonable cost of $435 for the BioBag[supreg] and 
the portion of the proposed APC payment for the device of $0.02 exceeds 
10 percent at 284.08 percent (($435-$0.02)/$153.12 x 100 = 284.08 
percent). Thus, we determined that the BioBag[supreg] appears to meet 
the third cost significance test and satisfies the cost significance 
criterion. We invited public comments on whether the BioBag[supreg] 
meets the device pass-through payment criteria discussed in this 
section, including all three cost criteria.
    We did not receive any public comments on the cost criteria for the 
BioBag[supreg]. Therefore, we have determined that the BioBag[supreg] 
does meet all three cost criteria.
    After consideration of the public comments we received and our 
review of the criteria necessary to receive device pass-through 
payment, we are not approving the application for the BioBag[supreg] to 
receive device pass-through payment status in CY 2019 because the 
BioBag[supreg] does not meet the substantial clinical improvement 
criterion.

[[Page 58933]]

(3) BlastX\TM\ Antimicrobial Wound Gel
    Next Science\TM\ has submitted an application for a new device 
category for transitional pass-through payment status for BlastX\TM\. 
According to the manufacturer, BlastX\TM\ is a PEG-based aqueous 
hydrogel which contains citric acid, sodium citrate, and benzalkonium 
chloride, buffered to a pH of 4.0 at 2.33 osmolarity. BlastX\TM\ 
received a 510(k) clearance from the FDA on March 6, 2017. BlastX\TM\ 
is indicated for the management of wounds such as Stage I-IV pressure 
ulcers, partial and full thickness wounds, diabetic foot and leg 
ulcers, postsurgical wounds, first and second degree burns, and grafted 
and donor sites.
    The manufacturer stated in its application for transitional pass-
through payment status that BlastX\TM\ works by disrupting the biofilm 
matrix in a wound and eliminating the bacteria absorbed within the gel. 
The manufacturer asserted that disrupting and eliminating the biofilm 
removes a major barrier to wound healing. The manufacturer also 
asserted that BlastX\TM\ is not harmful to host tissue and stated that 
BlastX\TM\ is applied to the wound every other day as a thin layer 
throughout the entire wound healing process. When used as an adjunct to 
debridement, BlastX\TM\ is applied immediately after debridement to 
eliminate any remaining biofilm and prevent the growth of new biofilm.
    Based on the evidence provided in the manufacturer's application, 
BlastX\TM\ is not a skin substitute and cannot be considered for 
transitional pass-through payment status as a device. To be considered 
a device for purposes of the medical device pass-through payment 
process under the OPPS, a skin substitute needs to be applied in or on 
a wound or other skin lesion based on 42 CFR 419.66(b)(3). It should be 
a product that is primarily used in conjunction with the skin graft 
procedures described by CPT codes 15271 through 15278 or HCPCS codes 
C5271 through C5278 (78 FR 74937). The skin substitute should only be 
applied a few times during a typical treatment episode. BlastX\TM\, 
according to the manufacturer, may be used in many other procedures 
other than skin graft procedures, including several debridement and 
active wound care management procedures. The manufacturer also stated 
that BlastX\TM\ would be used in association with any currently 
available skin substitute product and that the product should be 
applied every other day, which is not how skin substitute products for 
skin graft procedures are used to heal wounds. BlastX\TM\ is not a 
required component of the skin graft service, and is used as a supply 
that may assist with the wound healing process that occurs primarily 
because of the use of a sheet skin substitute product in a skin graft 
procedure.
    Therefore, with respect to the eligibility criterion at Sec.  
419.66(b)(3), in the proposed rule, we determined that BlastX\TM\ is 
not integral to the service provided (which is a skin graft procedure 
using a sheet skin substitute), is a material or supply furnished 
incidentally to a service, and is not surgically inserted into a 
patient. BlastX\TM\ does not meet the eligibility criterion to be 
considered a device for transitional pass-through payment. Therefore, 
we did not evaluate the product on the other criteria required for 
transitional pass-through payment for devices, including the newness 
criterion, the substantial clinical improvement criterion, and the cost 
criterion. We invited public comments on the eligibility of BlastX\TM\ 
for transitional pass-through payment for devices.
    We did not receive any public comments regarding the eligibility of 
BlastX\TM\ for transitional pass-through payment for devices. 
Therefore, we are not approving BlastX\TM\ for transitional pass-
through payment status for CY 2019 because the product does not meet 
the eligibility criterion to be considered a device.
(4) EpiCord[supreg]
    MiMedx[supreg] submitted an application for a new OPPS device 
category for transitional pass-through payment status for 
EpiCord[supreg], a skin substitute product. According to the applicant, 
EpiCord[supreg] is a minimally manipulated, dehydrated, devitalized 
cellular umbilical cord allograft for homologous use that provides a 
protective environment for the healing process. According to the 
applicant, EpiCord[supreg] is comprised of the protective elements of 
the umbilical cord with a thin amnion layer and a thicker Wharton's 
Jelly mucopolysaccharides component. The Wharton's Jelly contains 
collagen, hyaluronic acid, and chondroitin sulfate, which are the 
components principally responsible for its mechanical properties.
    The applicant stated that EpiCord[supreg] is packaged as an 
individual unit in two sizes, 2 cm x 3 cm and 3 cm x 5 cm. The 
applicant asserted that EpiCord[supreg] is clinically superior to other 
skin substitutes because it is much thicker than dehydrated amnion/
chorion allografts, which allows for application over exposed bone, 
tendon, nerves, muscle, joint capsule and hardware. According to the 
applicant, due to its unique thicker, stiffer structure, clinicians are 
able to apply or suture EpiCord[supreg] for deep, tunneling wounds 
where other products cannot fill the entire wound bed or dead spaces.
    With respect to the newness criterion at Sec.  419.66(b)(1), 
EpiCord[supreg] was added to the MiMedx[supreg] registration for human 
cells, tissues, and cellular and tissue-based products (HCT/Ps) on 
December 31, 2015. In adding EpiCord, MiMedx[supreg] asserted that 
EpiCord[supreg] conformed to the requirements for HCT/Ps regulated 
solely under section 361 of the Public Health Service Act and the 
regulations at 21 CFR part 1271. For these products, FDA requires that 
the manufacturer register and list its HCT/Ps with the FDA's Center for 
Biologics Evaluation and Research (CBER) within 5 days after beginning 
operations and update its registration annually, and MiMedx[supreg] 
provided documentation verifying that EpiCord[supreg] had been 
registered. However, no documentation regarding an FDA determination 
that EpiCord[supreg] is appropriate for regulation solely under section 
361 of the Public Health Service Act had been submitted. According to 
the applicant, December 31, 2015 was the first date of sale within the 
United States for EpiCord[supreg]. Therefore, it appears that market 
availability of EpiCord[supreg] is within 3 years of this application.
    We note that a product that is regulated solely under section 361 
of the Public Health Service Act and the regulations in 21 CFR part 
1271, as asserted by the manufacturer of Epicord[supreg], is not 
regulated as a device under the Federal Food, Drug, and Cosmetic Act. 
The regulations at 21 CFR 1271.20 state that ``If you are an 
establishment that manufactures an HCT/P that does not meet the 
criteria set out in Sec.  1271.10(a) [for regulation solely under 
section 361 of the Public Health Service Act and the regulations in 
part 1271], and you do not qualify for any of the exceptions in Sec.  
1271.15, your HCT/P will be regulated as a drug, device, and/or 
biological product. . . .'' The Federal Food, Drug, and Cosmetic Act 
requires that manufacturers of devices that are not exempt obtain 
marketing approval or clearance for their products from FDA before they 
may offer them for sale in the United States. We did not receive 
documentation from the applicant that EpiCord[supreg] is regulated as a 
device by FDA in accordance with Medicare regulations at 42 CFR 
419.66(b)(1). We invited public comments on whether EpiCord[supreg] 
meets the newness criterion.

[[Page 58934]]

    Comment: The manufacturer believed that EpiCord[supreg] meets the 
newness criterion. The manufacturer stated that HCT/P products are 
regulated by the FDA through a registration process and have been paid 
by CMS for many years under the current regulatory structure. The 
manufacturer believed the newness criterion requirement for FDA 
approval for a product should only apply when FDA approval is required 
for that product. The manufacturer stated that FDA approval does not 
apply to EpiCord[supreg] because of its HCT/P status. The manufacturer 
stated that the pass-through payment application for EpiCord[supreg] 
was submitted within 3 years of EpiCord[supreg] being introduced onto 
the U.S. market. Finally, the manufacturer noted that the Medicare 
statute requires that biologicals be included in the category of 
products that can be considered for pass-through payment status and 
stated that, if HCT/Ps cannot be considered for transitional pass-
through payment through the device pathway, the HCT/P products should 
be returned to the drug and biological transitional pass-through 
pathway.
    Response: To be able to determine whether a product meets the 
newness criterion, we need to determine a date when a product could 
first be used in the United States. Generally, we use the FDA clearance 
or approval date. We also have a provision in the newness criterion to 
use the date of first United States sale of the product rather than the 
FDA approval date, to accommodate the rare cases where a device 
receives FDA approval but the manufacturer experiences a significant 
delay establishing a manufacturing and distribution capacity for the 
new device. We agree that FDA approval cannot be required to be used 
for the newness criterion when there is no requirement for a new 
product to receive FDA approval. However, we still need some means to 
determine whether a product has been able for use in the United States 
for 3 years or less. The best alternative that we can identify to 
establish the date a product is considered new is to rely on 
registration to the FDA HCT/P registry, which indicates the existence 
of a new product.
    Comment: One commenter did not believe that EpiCord[supreg] meets 
the newness criterion. The commenter asserted that EpiCord[supreg] is 
considered to be the same product as EpiFix[supreg] that was introduced 
onto the U.S. market in 2011, and that the application for pass-through 
payment status for EpiCord[supreg] was submitted after the 3-year 
timeframe for a new product to apply for pass-through payment status. 
The commenter cited a HCPCS Workgroup decision in 2016 that assigned 
the use of EpiCord[supreg] to HCPCS code Q4131, which, until December 
31, 2018, was the identifying HCPCS code for the use of EpiFix[supreg]. 
The commenter also asserted that EpiFix[supreg] may also receive pass-
through payments, which the commenter believed should not occur, 
because it will be difficult to determine whether HCPCS code Q4131 is 
being billed for the use of EpiFix[supreg] or EpiCord[supreg].
    Response: We disagree with the commenter's assertion that 
EpiFix[supreg] and EpiCord[supreg] are the same product. On December 
31, 2015, MiMedx, the manufacturer of EpiCord[supreg], submitted a 
filing to the FDA HCT/P registry representing EpiCord[supreg] as a new 
product that is a separate product from EpiFix[supreg]. In addition, 
the HCPCS Workgroup has made a decision, effective on January 1, 2019, 
to designate separate HCPCS codes for EpiFix[supreg] (Q4186) and 
EpiCord[supreg] (Q4187) that also demonstrates EpiCord[supreg] is a 
separate product from EpiFix[supreg]. We believe that EpiCord[supreg] 
is a separate product from EpiFix[supreg].
    After consideration of the public comments we received, we have 
determined that EpiCord[supreg] meets the newness criterion.
    With respect to the eligibility criterion at Sec.  419.66(b)(3), 
according to the applicant, EpiCord[supreg] is a skin substitute 
product that is integral to the service provided, is used for one 
patient only, comes in contact with human tissue, and is surgically 
inserted into the patient. The applicant also claimed EpiCord[supreg] 
meets the device eligibility requirements of Sec.  419.66(b)(4) because 
EpiCord[supreg] is not an instrument, apparatus, implement, or item for 
which depreciation and financing expenses are recovered, and it is not 
a supply or material. We invited public comments on whether 
EpiCord[supreg] meets these eligibility criteria.
    We did not receive any public comments regarding whether 
EpiCord[supreg] meets the eligibility criterion. Based on the 
information we have received, we have determined that EpiCord[supreg] 
meets the eligibility criterion.
    The criteria for establishing new device categories are specified 
at Sec.  419.66(c). The first criterion, at Sec.  419.66(c)(1), 
provides that CMS determines that a device to be included in the 
category is not appropriately described by any of the existing 
categories or by any category previously in effect, and was not being 
paid for as an outpatient service as of December 31, 1996. We have not 
identified an existing pass-through category that describes 
EpiCord[supreg]. There are no present or previously established device 
categories for pass-through status that describe minimally manipulated, 
lyophilized, nonviable cellular umbilical membrane allografts regulated 
solely under section 361 of the Public Health Service Act and the 
regulations at 21 CFR part 1271. MiMedx[supreg] suggested a new device 
category descriptor of ``Dehydrated Human Umbilical Cord Allografts'' 
for EpiCord[supreg].
    The second criterion for establishing a device category, at Sec.  
419.66(c)(2), provides that CMS determines that a device to be included 
in the category has demonstrated that it will substantially improve the 
diagnosis or treatment of an illness or injury or improve the 
functioning of a malformed body part compared to the benefits of a 
device or devices in a previously established category or other 
available treatment. With regard to the substantial clinical 
improvement criterion, the applicant asserted that EpiCord[supreg] 
reduces the mortality rate with use of the device; reduces the rate of 
device-related complications; decreases the rate of subsequent 
diagnostic or therapeutic interventions; decreases the number of future 
hospitalizations or physician visits; provides more rapid beneficial 
resolution of the disease process treated because of the use of the 
device; decreases pain, bleeding, or other quantifiable symptom; and 
reduces recovery time.
    To determine if the product meets the substantial improvement 
criterion, we compared EpiCord[supreg] to other skin substitute 
products. Compared to NEOX CORD 1K Wound Allograft, EpiCord[supreg] has 
half the levels of Vascular Endothelial Growth Factor (VEGF) and 
insulin-like growth factor binding protein-4 (IGFBP-4) and lower levels 
of Glial Cell Line Derived Neurotrophic Factor (GDNF) and Epidermal 
Growth Factor (EGF). Despite EpiCord[supreg] having higher levels of 
other growth factors, the cumulative effect of these differences has 
not been sufficiently demonstrated in the application. Moreover, most 
professional opinions do not compare EpiCord[supreg] to specific 
alternative skin substitutes; the few that do are, for the most part, 
of limited specificity (in terms of foci of superiority to other skin 
substitutes). Studies demonstrated 41 percent higher relative rates 
(4.1 percent higher absolute rates) of severe complications for 
EpiCord[supreg] compared to standard of care. Additionally, the control 
group was moist dressings and offloading (instead of another umbilical 
or biologic product). Furthermore, 38 percent of EpiCord[supreg] 
patients in the study were smokers versus 58 percent of

[[Page 58935]]

control patients (smoking impairs wound healing; thus, this important 
dissimilarity between intervention and study populations casts doubt on 
attributing observed benefit to the intervention).
    Based on the evidence submitted with the application, we had 
insufficient evidence that EpiCord[supreg] provides a substantial 
clinical improvement over other treatments for wound care. We invited 
public comments on whether EpiCord[supreg] meets the substantial 
clinical improvement criterion.
    Comment: The manufacturer responded to several statements regarding 
EpiCord[supreg] and substantial clinical improvement in the CY 2019 
OPPS/ASC proposed rule. The analysis in the proposal rule noted that 
the pass-through application for EpiCord[supreg] stated that 
EpiCord[supreg] had higher levels of some growth factors and lower 
levels of other growth factors than NEOX CORD 1K Allograft. However the 
original application did not clarify what the overall effect the 
differences in growth factors had on the effectiveness of 
EpiCord[supreg] for wound care and the proposed rule text expressed 
concern regarding comparisons to individual skin substitute products. 
The manufacturer asserted that the findings in the application, which 
were updated by the manufacturer, show that the combination of growth 
factors and proteins working together does improve wound healing in a 
complex environment. Also, the manufacturer stated that EpiCord[supreg] 
is the only umbilical cord wound product with a published multi-center, 
prospective, randomized-controlled, comparative parallel study.
    The manufacturer responded to a statement in the proposed rule that 
noted 41 percent higher relative rates of severe complications for 
EpiCord[supreg] compared to the standard of care, and concerns the 
control group in the studies were moist dressings and offloading 
instead of a biologic product. The manufacturer indicated that the 
studies include adverse events from all causes and a new study in 
progress will show no adverse events directly related to 
EpiCord[supreg] or alginate dressings. The manufacturer also stated 
that many wound experts do not attempt to compare new products to each 
other because of the high variability of the composition of products, 
how they are applied, and the dynamics of how different products work.
    The manufacturer replied to a statement in the CY 2019 OPPS/ASC 
proposed rule questioning the substantial higher amount of smokers in 
the control group for the primary study compared to the group of 
EpiCord[supreg] patients. The manufacturer noted that the concern is 
that smoking impairs wound healing, and the presence of a higher number 
of smokers in the control group casts doubt on the conclusion that the 
difference in outcomes between the control group and the 
EpiCord[supreg] group was because of the use of EpiCord[supreg]. The 
manufacturer performed statistical analyses and the manufacturer 
reported that it found the effect of the higher proportion of smokers 
in the control group was not statistically significant.
    Finally, the manufacturer asserted that EpiCord[supreg] meets the 
substantial clinical improvement criterion as a result of the published 
multi-center randomized controlled study showing an 81-percent healing 
rate within 12 weeks, which increases to a 96-percent healing rate when 
adequate debridement is performed.
    Response: We appreciate the detailed response to the questions we 
had regarding the study the manufacturer submitted as evidence that 
EpiCord[supreg] would have substantial clinical improvement over 
comparable wound care treatments. However, this study on its own is not 
sufficient to establish substantial clinical improvement. First, 
independent replication of the findings of the study has not been 
performed. The study indicates beneficial effects from the use of 
EpiCord[supreg]; however, it is not clear if the findings can be 
reproduced. Multiple studies with similar conditions, and a more 
equitable distribution of smokers in the control and intervention 
groups, would be a first step to determine if the findings are valid. 
Second, more comparisons need to be done with different classes of 
biological skin substitute products. Given the number of skin 
substitute products on the U.S. market, it is not possible to compare 
EpiCord[supreg] to each product. However, we believe that studies 
comparing the product against products made with epithelial tissue, 
other human-sourced products, and animal-sourced products could provide 
more evidence demonstrating the clinical superiority of 
EpiCord[supreg].
    Comment: Multiple commenters supported granting EpiCord[supreg] 
transitional pass-through payment status. Many of the commenters 
discussed the strength of the structure of EpiCord[supreg], the high 
levels of human growth factors found in the product, and its ability to 
heal complex wounds, but did not provide support by studies or other 
clinical research.
    Response: We appreciate the additional information that the 
commenters provided on the performance and the benefits of 
EpiCord[supreg]. However, many skin substitute products can be used to 
heal complex wounds. In addition, none of the commenters provided 
clinical evidence of how the high levels of human growth factors led to 
EpiCord[supreg] having a superior performance to other skin substitute 
products.
    After consideration of the public comments we received, we have 
determined that EpiCord[supreg] does not meet the substantial clinical 
improvement criterion.
    The third criterion for establishing a device category, at Sec.  
419.66(c)(3), requires us to determine that the cost of the device is 
not insignificant, as described in Sec.  419.66(d). Section 419.66(d) 
includes three cost significance criteria that must each be met. The 
applicant provided the following information in support of the cost 
significance requirements. EpiCord[supreg] would be reported with CPT 
code 15271 or 15275. CPT code 15271 describes the application of skin 
substitute graft to trunk, arms, legs, total wound surface area up to 
100 sq cm; first 25 sq cm or less wound surface area. CPT code 15275 
describes the application of skin substitute graft to face, scalp, 
eyelids, mouth, neck, ears, orbits, genitalia, hands, feet, and/or 
multiple digits, total wound surface area up to 100 sq cm; first 25 sq 
cm or less wound surface area. Both codes are assigned to APC 5054 
(Level 4 Skin Procedures). CPT codes 15271 through 15278 are assigned 
to either APC 5054 (Level 4 Skin Procedures), with a payment rate of 
$1,427.77 and a device offset of $4.70, or APC 5055 (Level 5 Skin 
Procedures), with a payment rate of $2,504.69 and a device offset of 
$35.01. The price of EpiCord[supreg] is $1,595 for the 2 cm x 3 cm and 
$3,695 for the 3 cm x 5 cm product size.
    To meet the cost criterion for device pass-through payment, a 
device must pass all three tests of the cost criterion for at least one 
APC. Section 419.66(d)(1), the first cost significance requirement, 
provides that the estimated average reasonable cost of devices in the 
category must exceed 25 percent of the applicable APC payment amount 
for the service related to the category of devices. The estimated 
average reasonable cost of $3,695 for the 3 cm x 5 cm product exceeds 
the applicable APC amount for the service related to the category of 
devices of $1,427.77 by 258.80 percent ($3,695/$1427.77 x 100 percent = 
258.80 percent). Therefore, it appears that EpiCord[supreg] meets the 
first cost significance test.
    The second cost significance test, at Sec.  419.66(d)(2), provides 
that the estimated average reasonable cost of the

[[Page 58936]]

devices in the category must exceed the cost of the device-related 
portion of the APC payment amount for the related service by at least 
25 percent, which means that the device cost needs to be at least 125 
percent of the offset amount (the device-related portion of the APC 
found on the offset list). The estimated average reasonable cost of 
$3,695 for the 3 cm x 5 cm product exceeds the device-related portion 
of the APC payment amount for the related service of $4.70 by 78,617.02 
percent ($3,695/$4.70 x 100 percent = 78,617.02 percent). Therefore, it 
appears that EpiCord[supreg] meets the second cost significance test.
    Section 419.66(d)(3), the third cost significance test, requires 
that the difference between the estimated average reasonable cost of 
the devices in the category and the portion of the APC payment amount 
for the device must exceed 10 percent of the APC payment amount for the 
related service. The difference between the estimated average 
reasonable cost of $3,695 for the 3 cm x 5 cm product and the portion 
of the APC payment amount for the device of $4.70 exceeds 10 percent at 
258.47 percent (($3,695-$4.70)/$1,427.77) x 100 percent = 258.47 
percent). Therefore, it appears that EpiCord[supreg] meets the third 
cost significance test. Based on the costs submitted by the applicant 
and the calculations noted earlier, it appears that EpiCord[supreg] 
meets the cost criterion at Sec.  419.66(c)(3) for new device 
categories. We invited public comments on whether EpiCord[supreg] meets 
the cost criterion for device pass-through payment.
    We did not receive any public comments regarding the cost criteria 
for EpiCord[supreg]. Based on the information that we received, we have 
determined that EpiCord[supreg] meets the cost criteria.
    After consideration of the public comments and additional 
information we have received, we are not approving EpiCord[supreg] for 
transition pass-through payment status in CY 2019 because the product 
does not meet the substantial clinical improvement criterion.
(5) remed[emacr][supreg] System Transvenous Neurostimulator
    Respicardia, Inc. submitted an application for a new device 
category for transitional pass-through payment status for the 
remed[emacr][supreg] System Transvenous Neurostimulator. According to 
the applicant, the remed[emacr][supreg] System is an implantable 
phrenic nerve stimulator indicated for the treatment of moderate to 
severe central sleep apnea (CSA) in adult patients. The applicant 
stated that the remed[emacr][supreg] System is the first and only 
implantable neurostimulator to use transvenous sensing and stimulation 
technology. The applicant also stated that the remed[emacr][supreg] 
System consists of an implantable pulse generator, a transvenous lead 
to stimulate the phrenic nerve and a transvenous sensing lead to sense 
respiration via transthoracic impedance. Lastly, the applicant stated 
that the device stimulates a nerve located in the chest (phrenic nerve) 
that is responsible for sending signals to the diaphragm to stimulate 
breathing to restore normal sleep and respiration in patients with 
moderate to severe central sleep apnea (CSA).
    With respect to the newness criterion at Sec.  419.66(b)(1), the 
applicant received a Category B Investigational Device Exemption (IDE) 
from FDA on April 18, 2013. Subsequently, the applicant received 
approval of its premarket approval (PMA) application from FDA on 
October 6, 2017. The application for a new device category for 
transitional pass-through payment status for the remed[emacr][supreg] 
System was received on May 31, 2017, which is within 3 years of the 
date of the initial FDA approval or clearance. We invited public 
comments on whether the remed[emacr][supreg] System meets the newness 
criterion.
    Comment: The manufacturer believed that that the 
remed[emacr][supreg] System meets the newness criterion.
    Response: We appreciate the commenter's input.
    After consideration of the public comments we received, we believe 
that the remed[emacr][supreg] System meets the newness criterion.
    With respect to the eligibility criterion at Sec.  419.66(b)(3), 
according to the applicant, the remed[emacr][supreg] System is integral 
to the service provided, is used for one patient only, comes in contact 
with human skin, and is applied in or on a wound or other skin lesion. 
The applicant also claimed the remed[emacr][supreg] System meets the 
device eligibility requirements of Sec.  419.66(b)(4) because it is not 
an instrument, apparatus, implement, or item for which depreciation and 
financing expenses are recovered, and it is not a supply or material 
furnished incident to a service.
    The criteria for establishing new device categories are specified 
at Sec.  419.66(c). The first criterion, at Sec.  419.66(c)(1), 
provides that CMS determines that a device to be included in the 
category is not appropriately described by any of the existing 
categories or by any category previously in effect, and was not being 
paid for as an outpatient service as of December 31, 1996. We have not 
identified an existing pass-through payment category that describes the 
remed[emacr][supreg] System. The applicant proposed a category 
descriptor for the remed[emacr][supreg] System of ``generator, 
neurostimulator (implantable), non-rechargeable, with transvenous 
sensing and stimulation.'' We invited public comments on this issue.
    Comment: The manufacturer of the device indicated that there is no 
an existing pass-through payment category that describes the 
remed[emacr][supreg] System.
    Response: We appreciate the manufacturer's input.
    After consideration of the public comments we received, we believe 
that the remed[emacr][supreg] System meets the eligibility criterion.
    The second criterion for establishing a device category, at Sec.  
419.66(c)(2), provides that CMS determines that a device to be included 
in the category has demonstrated that it will substantially improve the 
diagnosis or treatment of an illness or injury or improve the 
functioning of a malformed body part compared to the benefits of a 
device or devices in a previously established category or other 
available treatment. With respect to this criterion, the applicant 
submitted several journal articles that discussed the health effects of 
central sleep apnea (CSA) which include fatigue, decreased mental 
acuity, myocardial ischemia, and dysrhythmias. The applicant stated 
that patients with CSA may suffer from poor clinical outcomes, 
including myocardial infarction and congestive heart failure.\20\
---------------------------------------------------------------------------

    \20\ Costanzo, M.R., et al., Mechanisms and Clinical 
Consequences of Untreated Central Sleep Apnea in Heart Failure. 
Journal of the American College of Cardiology, 2015. 65(1): p. 72-
84.
---------------------------------------------------------------------------

    The applicant claims that the remed[emacr][supreg] System has been 
found to significantly improve apnea-hypopnea index (AHI), which is an 
index used to indicate the severity of sleep apnea. AHI is represented 
by the number of apnea and hypopnea events per hour of sleep and was 
used as the primary effectiveness endpoint in the remed[emacr][supreg] 
System pivotal trial. The applicant noted that the remed[emacr][supreg] 
System was shown to improve AHI in small, self-controlled studies as 
well as in larger trials.
    The applicant reported that in the pivotal study, a large, 
multicenter, randomized controlled trial of CSA patients, intention-to-
treat analysis found that 51 percent (35/68) of CSA patients using the 
remed[emacr][supreg] System had greater than 50 percent reduction of 
apnea-hypopnea index (AHI) from baseline at 6 months compared to 11 
percent (8/73) of the control group (p<0.0001). Per-protocol analysis 
found that 60 percent (35/58) of remed[emacr][supreg] System patients 
had a greater than 50

[[Page 58937]]

percent reduction of AHI and in 74 percent (26/35) of these patients 
AHI dropped to <20.\21\
---------------------------------------------------------------------------

    \21\ Costanzo, M.R., et al. (2016). Transvenous neurostimulation 
for central sleep apnoea: a randomised controlled trial. The Lancet, 
388(10048): p. 974-982.
---------------------------------------------------------------------------

    According to the applicant, an exploratory post-hoc analysis of 
patients with CSA and congestive heart failure (CHF) in the Pivotal 
trial found that, at 6 months, the remed[emacr][supreg] System group 
had a greater percentage of patients with >=50 percent reduction in AHI 
compared to control group (63 percent versus 4 percent, p< 0.001).\22\
---------------------------------------------------------------------------

    \22\ Goldberg, L.R., et al. (2017). In Heart Failure Patients 
with CSA, Stimulation of the Phrenic Nerve Improves Sleep and 
Quality of Life. Journal of Cardiac Failure, 23(8): p. S15.
---------------------------------------------------------------------------

    The applicant noted that patient symptoms and quality of life were 
improved with the remed[emacr][supreg] System therapy. The mean Epworth 
Sleepiness Scale (ESS) score significantly decreased in 
remed[emacr][supreg] System patients, indicating less daytime 
sleepiness.\23\
---------------------------------------------------------------------------

    \23\ Costanzo, M.R., et al. (2016). Transvenous neurostimulation 
for central sleep apnoea: a randomised controlled trial. The Lancet, 
388(10048): p. 974-982.
---------------------------------------------------------------------------

    Adverse events associated with remed[emacr][supreg] System 
insertion and therapy included lead dislodgement/dislocation, hematoma, 
migraine, atypical chest pain, pocket perforation, pocket infection, 
extra-respiratory stimulation, concomitant device interaction, and 
elevated transaminases.\24\ There were no patient deaths that were 
related to the device implantation or therapy.
---------------------------------------------------------------------------

    \24\ Costanzo, M.R., et al. (2016). Transvenous neurostimulation 
for central sleep apnoea: a randomised controlled trial. The Lancet, 
388(10048): p. 974-982.
---------------------------------------------------------------------------

    One concern regarding the remed[emacr][supreg] System is the 
potential for complications in patients with coexisting cardiac 
devices, such as pacemakers or ICDs, given that the 
remed[emacr][supreg] System device requires lead placement and 
generation of electric impulses. Another concern with the evidence of 
substantial clinical improvement is that there is limited long-term 
data on patients with remed[emacr][supreg] System implants. The pivotal 
trial included only 6 months of follow-up. Also, while the applicant 
reported a reduction in AHI in the treatment group, the applicant did 
not establish that that level of change was biologically meaningful in 
the population(s) being studied. The applicant did not conduct a power 
analysis to determine the necessary size of the study population and 
the necessary duration of the study to detect both early and late 
events.
    In addition, patients in the pivotal study were not characterized 
by the use of cardiac devices. Cardiac resynchronization therapy (CRT), 
in particular, is known to improve chronic sleep apnea in addition to 
its primary effects on heart failure, and central apnea is a marker of 
the severity of the congestive heart failure. The applicant did not 
conduct subset analyses to assess the impact of cardiac 
resynchronization therapy.
    Lastly, while evaluation of AHI and quality of life metrics show 
improvement with the remed[emacr][supreg] System, the translation of 
those effects to mortality benefit is yet to be determined. Further 
studies of the remed[emacr][supreg] System are likely needed to 
determine long-term effects of the device, and as well as its efficacy 
compared to existing treatments of CPAP or medications.
    Based on the evidence submitted with the application, we had 
insufficient evidence that the remed[emacr][supreg] System provides a 
substantial clinical improvement over other similar products and 
invited public comments on whether the remed[emacr][supreg] System 
meets the substantial clinical improvement criterion.
    Comment: The manufacturer of the remed[emacr][supreg] System 
believed that this device meets the substantial clinical improvement 
criterion and provided additional data to support this assertion. The 
manufacturer noted that the primary endpoint of the pivotal study was a 
reduction of at least 50 percent in the apnea-hyponea index that is 
used to classify apnea severity and has been used as a common endpoint 
in predicate studies testing apnea therapy in sleep literature. The 
manufacturer further indicated that the remed[emacr][supreg] System 
significantly improves secondary endpoints. Patients had improved 
oxygenation, reduced hypoxia, and 79 percent of treatment group 
subjects reported improved quality of life as assessed through the 
Patient Global Assessment. The manufacturer asserted that the study 
cited was the first randomized study in central sleep apnea to 
demonstrate improvements in REM sleep and arousals. Further, the 
manufacturer noted that the treatment group experienced a 3.7 
percentage point improvement in the Epworth sleepiness scale, meaning 
these patients were less sleepy than the control group. The 
manufacturer indicated, in response to CMS' questions, that its 
clinical trials were not designed to establish a clinical improvement 
in mortality from this device. However, the manufacturer asserted that 
post-trial analysis indicated some improvement in left ventricular 
ejection fraction, which is associated with reduced mortality, and 
increased time to first hospitalization for New York Heart Association 
heart failure patients with reduced ejection fraction. The manufacturer 
also indicated that reductions in the Apnea Hypopnea Index for trial 
participants that received the remed[emacr][supreg] System was now 
greater at 12 months than it was at 6 months.
    In response to CMS' question regarding why an untreated control 
group was used in the pivotal trial, as opposed to a direct comparison 
with CPAP or other treatments, the manufacturer presented several 
reasons, such as considerable controversy about CPAP in CSA patients 
with heart failure due to CPAP patients with an ejection fraction less 
than 40 percent having higher mortality, and a dearth of prospective, 
randomized clinical data on the safety and efficacy of using CPAP, ASV, 
or medications to treat patients with non-heart failure CSA.
    Regarding CMS' question of why no power analysis was performed to 
determine the necessary size of the study population and the necessary 
duration of the study to detect both early and late events, the 
manufacturer noted that it worked directly with clinical experts and 
consulted with the FDA in designing the clinical trial, which the 
manufacturer maintains was effective and well-rounded. The manufacturer 
noted that the rationale was that the remed[emacr][supreg] System would 
be evaluated on a continuum of efficacy versus safety, but noted that 
had they determined to power the study for a primary safety endpoint 
based on the threshold of other implantable cardiac devices, the 
pivotal trial would have been adequately powered based on the study 
design (132 patients needed versus 151 enrolled).
    In response to CMS' question regarding potential complications in 
patients with coexisting cardiac devices, the manufacturer noted that 
it was understood that many CSA patients would likely have other 
cardiac devices already implanted and that this led to the design of 
both implant and testing procedures that accommodated concomitant 
devices. The manufacturer noted that the remed[emacr][supreg] System is 
typically placed on the right side of the chest to leave room for 
patients to have a cardiac device, which are typically placed on the 
left side, and that, in the pivotal trial, implantation of the 
remed[emacr][supreg] System in patients with a concomitant device did 
not demonstrate any increased risk. Further, the manufacturer noted 
that key metrics of implant duration, use of contrast dye, and 
fluoroscopy time were similar between patients with and without a

[[Page 58938]]

concomitant cardiac device. Regarding specific study results, the 
manufacturer noted that 42 percent (64 of 151) of patients in the 
pivotal trial had a concomitant device and 98 percent (63 of 64) of 
patients with a concomitant cardiac device were successfully implanted, 
as compared to 96 percent (81 of 84) of patients with no concomitant 
device. The manufacturer believed that there is no increased risk at 
the time of implant for patients with a coexisting cardiac device. With 
regard to safety post[hyphen]procedure, the commenter noted there was 
no difference in related SAEs between the groups with and without a 
concomitant cardiac device.
    Regarding CMS' question about whether the impact of cardiac 
resynchronization therapy (CRT) drove improvement for heart failure 
patient with a concomitant CRT device, the manufacturer noted limited 
literature available on this topic, but stated that the literature that 
does exist suggests that CRT may improve the apnea hypopnea index in 
some patients, which may be due to an improvement in ejection fraction. 
However, the manufacturer noted that all CRT patients in the 
remed[emacr][supreg] System pivotal trial had their CRT devices for a 
minimum of nine months and that despite having CRT for a significant 
duration, still had severe CSA at baseline. Accordingly, the 
manufacturer believed that it is unlikely that significant CSA 
improvements were based on CRT rather than the remed[emacr][supreg] 
System. The manufacturer noted that statistically significant subgroup 
analysis on CRT was difficult, but believed that the CRT subgroup did 
not lead to the overall results on the primary endpoint because the CRT 
subgroup ``underperformed'' relative to the non-CRT subgroup.
    Finally, with respect to CMS' question regarding whether the 
clinical results and patient response were durable and sustainable over 
time, the manufacturer asserted that it continues to collect 
effectiveness data beyond the 6-month endpoints of the pivotal IDE 
trial and that 12-month follow-up results on the pivotal IDE trial were 
recently published, demonstrating a trend towards increasing benefit 
for the treatment group at 12 months. Specifically, the commenter 
stated that, at 12 months, 91 percent of patients saw a reduction of 
AHI and with 67 percent achieving a 50 percent or greater reduction in 
AHI (compared to 60 percent at 6 months).
    Several commenters, individual physicians who have treated CSA 
patients with the remed[emacr][supreg] System, stated that, for these 
patients, traditional types of positive pressure ventilation did not 
work and the remed[emacr][supreg] System is the only treatment 
available.
    Response: We appreciate the commenters' input. After reviewing the 
additional information provided during the public comment period, we 
agree that the remed[emacr][supreg] System has been shown to improve 
patients symptoms of central sleep apnea, improve quality of life, 
requires minimal patient compliance compared to other treatments, and 
has a low adverse event profile. However, with regard to our questions 
about impacts on mortality, the applicant did note that its studies 
were not powered to demonstrate a mortality benefit.
    Commenters have adequately addressed the clinical concerns that we 
outlined in the proposed rule with additional evidence, longer follow-
up from the pivotal IDE trial, the interplay of the 
remed[emacr][supreg] System and a concomitant cardiac device, and 
information about power calculations and other data summarized above. 
Further, we believe that the remed[emacr][supreg] System offers a 
treatment option for a patient population unresponsive to, or 
ineligible for, treatment involving currently available options. That 
is, those patients who have been diagnosed with moderate to severe CSA 
have no other available treatment options than the remed[emacr][supreg] 
System. Accordingly, we have determined that the remed[emacr][supreg] 
System has demonstrated substantial clinical improvement relative to 
existing treatment options for patients diagnosed with moderate to 
severe CSA.
    The third criterion for establishing a device category, at Sec.  
419.66(c)(3), requires us to determine that the cost of the device is 
not insignificant, as described in Sec.  419.66(d). Section 419.66(d) 
includes three cost significance criteria that must each be met. The 
applicant provided the following information in support of the cost 
significance requirements. The applicant stated that the 
remed[emacr][supreg] System would be reported with CPT code 0424T. CPT 
code 0424T is assigned to APC 5464 (Level 4 Neurostimulator and Related 
Procedures). To meet the cost criterion for device pass-through 
payment, a device must pass all three tests of the cost criterion for 
at least one APC. For our calculations, we used APC 5464, which had a 
CY 2017 payment rate of $27,047.11 at the time the application was 
received. Beginning in CY 2017, we calculate the device offset amount 
at the HCPCS/CPT code level instead of the APC level (81 FR 79657). CPT 
code 0424T had a device offset amount of $11,089 at the time the 
application was received. According to the applicant, the cost of the 
remed[emacr][supreg] System was $34,500.
    Section 419.66(d)(1), the first cost significance requirement, 
provides that the estimated average reasonable cost of devices in the 
category must exceed 25 percent of the applicable APC payment amount 
for the service related to the category of devices. The estimated 
average reasonable cost of $34,500 for the remed[emacr][supreg] System 
exceeds 127 percent of the applicable APC payment amount for the 
service related to the category of devices of $27,047.11 ($34,500/
$27,047.11 x 100 = 127.5 percent). Therefore, we believe the 
remed[emacr][supreg] System meets the first cost significance test.
    The second cost significance test, at Sec.  419.66(d)(2), provides 
that the estimated average reasonable cost of the devices in the 
category must exceed the cost of the device-related portion of the APC 
payment amount for the related service by at least 25 percent, which 
means that the device cost needs to be at least 125 percent of the 
offset amount (the device-related portion of the APC found on the 
offset list). The estimated average reasonable cost of $34,500 for the 
remed[emacr][supreg] System exceeds the cost of the device-related 
portion of the proposed APC payment amount for the related service of 
$11,089 by 311 percent ($34,500-$11,089) x 100 = 311 percent). 
Therefore, we believe that the remed[emacr][supreg] System meets the 
second cost significance test.
    The third cost significance test, at Sec.  419.66(d)(3), requires 
that the difference between the estimated average reasonable cost of 
the devices in the category and the portion of the APC payment amount 
for the device must exceed 10 percent of the APC payment amount for the 
related service. The difference between the estimated average 
reasonable cost of $34,500 for the remed[emacr][supreg] System and the 
portion of the proposed APC payment amount for the device of $11,089 
exceeds the APC payment amount for the related service of $27,047.11 by 
87 percent (($34,500/11,089)/$27,047.11 x 100 = 86.6 percent). 
Therefore, we believe that the remed[emacr][supreg] System meets the 
third cost significance test.
    We invited public comments on whether the remed[emacr][supreg] 
System meets the device pass-through payment criteria discussed in this 
section, including the cost criteria for device pass-through payment.
    Comment: The manufacturer of the remed[emacr][supreg] System 
believed that the remed[emacr][supreg] System meets the cost criterion 
for device pass-through payment status.

[[Page 58939]]

    Response: We appreciate the manufacturer's input.
    After consideration of the public comments we received, we are 
approving the remed[emacr][supreg] System for device pass-through 
payment status for CY 2019.
(6) Restrata[supreg] Wound Matrix
    Acera Surgical, Inc. submitted an application for a new device 
category for transitional pass-through payment status for 
Restrata[supreg] Wound Matrix. Restrata[supreg] Wound Matrix is a 
sterile, single-use product intended for use in local management of 
wounds. According to the applicant, Restrata[supreg] Wound Matrix is a 
soft, white, conformable, nonfriable, absorbable matrix that works as a 
wound care management product by acting as a protective covering for 
wound defects, providing a moist environment for the body's natural 
healing process to occur. Restrata[supreg] Wound Matrix is made from 
synthetic biocompatible materials and was designed with a nanoscale 
nonwoven fibrous structure with high porosity, similar to native 
extracellular matrix. Restrata[supreg] Wound Matrix allows for cellular 
infiltration, new tissue formation, neovascularization, and wound 
healing before completely degrading via hydrolysis. The product permits 
the ingress of cells and soft tissue formation in the defect space/
wound bed. Restrata[supreg] Wound Matrix can be used to manage wounds, 
including: Partial and full-thickness wounds, pressure sores/ulcers, 
venous ulcers, diabetic ulcers, chronic vascular ulcers, tunneled/
undermined wounds, surgical wounds (for example, donor site/grafts, 
post-laser surgery, post-Mohs surgery, podiatric wounds, wound 
dehiscence), trauma wounds (for example, abrasions, lacerations, 
partial thickness burns, skin tears), and draining wounds.
    With respect to the eligibility criterion at Sec.  419.66(b)(3), 
according to the applicant, Restrata[supreg] Wound Matrix is a product 
that is integral to the service provided, is used for one patient only, 
comes in contact with human skin, and is surgically inserted into the 
patient. The description of Restrata[supreg] Wound Matrix shows the 
product meets the device eligibility requirements of Sec.  419.66(b)(4) 
because Restrata[supreg] Wound Matrix is not an instrument, apparatus, 
implement, or item for which depreciation and financing expenses are 
recovered, and it is not a supply or material. We invited public 
comment on whether Restrata[supreg] Wound Matrix meets the eligibility 
criteria.
    We did not receive any public comments on whether Restrata[supreg] 
Wound Matrix meets the eligibility criteria. However, after the CY 2019 
OPPS/ASC proposed rule was released, CMS determined that 
Restrata[supreg] Wound Matrix is an alginate dressing described with 
the HCPCS code series A6196 through A6198 (Alginate or other fiber 
gelling dressing, wound cover, sterile). Alginate dressings are not 
skin substitute products and are considered to be a supply. According 
to the eligibility criterion, a supply or material is not eligible to 
receive device pass-through payment. Based on this determination, we 
were required to reassess our initial view on whether or not 
Restrata[supreg] Wound Matrix meets the eligibility criterion for 
device pass-through payment status.
    After consideration of all of the information we have received, we 
have determined that Restrata[supreg] Wound Matrix is an alginate 
dressing and is a supply, and the product does not meet the eligibility 
criterion for device pass-through payment status. Because we have 
determined that Restrata[supreg] Wound Matrix does not meet the basic 
eligibility criterion for transitional pass-through payment status, we 
have not evaluated this product to determine whether it meets the other 
criteria required for transitional pass-through payment for devices; 
that is, the newness criterion, the substantial clinical improvement 
criterion, and the cost criterion.
    After consideration of the public comments we received, we are not 
approving device pass-through payment status for Restrata[supreg] Wound 
Matrix for CY 2019.
(7) SpaceOAR[supreg] System
    Augmenix, Inc. submitted an application for a new device category 
for transitional pass-through payment status for the SpaceOAR[supreg] 
System. According to the applicant, the SpaceOAR[supreg] System is a 
polyethylene glycol hydrogel spacer that temporarily positions the 
anterior rectal wall away from the prostate to reduce the radiation 
delivered to the anterior rectum during prostate cancer radiotherapy 
treatment. The applicant stated that the SpaceOAR[supreg] System 
reduces some of the side effects associated with radiotherapy, which 
are collectively known as ``rectal toxicity'' (diarrhea, rectal 
bleeding, painful defecation, and erectile dysfunction, among other 
conditions). The applicant stated that the SpaceOAR[supreg] is 
implanted several weeks before radiotherapy; the hydrogel maintains 
space between the prostate and rectum for the entire course of 
radiotherapy and is completely absorbed by the patient's body within 6 
months.
    With respect to the newness criterion at Sec.  419.66(b)(1), FDA 
granted a De Novo request classifying the SpaceOAR[supreg] System as a 
class II device under section 513(f)(2) of the Federal Food, Drug, and 
Cosmetic Act on April 1, 2015. We received the application for a new 
device category for transitional pass-through payment status for the 
SpaceOAR[supreg] System on June 1, 2017, which is within 3 years of the 
date of the initial FDA approval or clearance. We invited public 
comments on whether the SpaceOAR[supreg] System meets the newness 
criterion.
    Comment: The manufacturer of SpaceOAR[supreg] System believed this 
device meets the eligibility criteria for device pass-through payment, 
but did not specifically comment on the newness criterion.
    Response: We appreciate the manufacturer's input.
    After consideration of the public comments we received, we believe 
that the SpaceOAR[supreg] System meets the newness criterion for device 
pass-through payment status.
    With respect to the eligibility criterion at Sec.  419.66(b)(3), 
according to the applicant, the SpaceOAR[supreg] System is integral to 
the service provided, is used for one patient only, comes in contact 
with human skin, and is applied in or on a wound or other skin lesion. 
The applicant also claimed the SpaceOAR[supreg] System meets the device 
eligibility requirements of Sec.  419.66(b)(4) because it is not an 
instrument, apparatus, implement, or item for which depreciation and 
financing expenses are recovered, and it is not a supply or material 
furnished incident to a service.
    The criteria for establishing new device categories are specified 
at Sec.  419.66(c). The first criterion, at Sec.  419.66(c)(1), 
provides that CMS determines that a device to be included in the 
category is not appropriately described by any of the existing 
categories or by any category previously in effect, and was not being 
paid for as an outpatient service as of December 31, 1996. We have not 
identified an existing pass-through payment category that describes the 
SpaceOAR[supreg] System. The applicant suggested a category descriptor 
for the SpaceOAR[supreg] System of ``Absorbable perirectal spacer''. We 
invited public comments on this issue.
    Comment: The manufacturer of the SpaceOAR[supreg] System believed 
that this device meets the eligibility criteria for device pass-through 
payment status, but did not specifically comment on whether a current 
pass-through payment

[[Page 58940]]

category appropriately describes this device.
    Response: We appreciate the manufacturer's input.
    After consideration of the public comments we received, we believe 
that there is no existing pass-through payment category that 
appropriately describes the SpaceOAR[supreg] System and that the 
SpaceOAR[supreg] System meets the eligibility criterion.
    The second criterion for establishing a device category, at Sec.  
419.66(c)(2), provides that CMS determines that a device to be included 
in the category has demonstrated that it will substantially improve the 
diagnosis or treatment of an illness or injury or improve the 
functioning of a malformed body part compared to the benefits of a 
device or devices in a previously established category or other 
available treatment. With respect to this criterion, the applicant 
submitted studies which discussed the techniques for using hydrogel 
spacers to limit radiation exposure to the rectum in prostate 
radiotherapy. In support of its assertion that SpaceOAR is a 
substantial clinical improvement, the applicant submitted several 
studies that examined the effect that the SpaceOAR[supreg] System had 
on outcomes such as rectal dose, radiation toxicity, and quality of 
life declines after image guided intensity modulated radiation therapy 
for prostate cancer. Articles by Mariados et al.\25\ and Hamstra et 
al.\26\ discussed the results of a single-blind phase III trial of 
image guided intensity modulated radiation therapy with 15 months and 3 
years of follow-up, respectively. In the studies, a total of 222 men 
were randomized 2:1 to the spacer or control group and received 79.2 Gy 
in 1.8-Gy fractions to the prostate with or without the seminal 
vesicles.
---------------------------------------------------------------------------

    \25\ Mariados N, et al. (2015). Hydrogel Spacer Prospective 
Multicenter Randomized Controlled Pivotal Trial: Dosimetric and 
Clinical Effects of Perirectal Spacer Application in Men Undergoing 
Prostate Image Guided Intensity Modulated Radiation Therapy. Int J 
Radiat Oncol Biol Phys.92(5):971-977. Epub 2015 Apr 23. PMID: 
26054865.
    \26\ Hamstra DA, et al. (2017). Continued Benefit to Rectal 
Separation for Prostate Radiation Therapy: Final Results of a Phase 
III Trial. Int J Radiat Oncol Biol Phys. Apr 1;97(5):976-985. Epub 
2016 Dec 23. PMID:28209443.
---------------------------------------------------------------------------

    The results of this study \27\ showed that after 3 years, compared 
with the control group, the participants who received the 
SpaceOAR[supreg] System injection had a statistically significant 
smaller volume of the rectum receiving a threshold radiation exposure, 
which was the primary effectiveness endpoint. The results also showed 
that in an extended follow up period, the control group experienced 
larger declines in bowel and urinary quality of life compared to 
participants who received the SpaceOAR[supreg] System treatment. 
Lastly, in an extended follow-up period, the probability of grade >=1 
rectal toxicity was decreased in the SpaceOAR[supreg] System arm (9 
percent control group, 2 percent SpaceOAR[supreg] System group, p <.03) 
and no >= grade 2 rectal toxicity was observed in the SpaceOAR[supreg] 
System arm. However, the control arm had low rates of rectal toxicity 
in general. The results of this 3-year follow-up of these participants 
showed that the differences identified in the 15-month follow-up study 
were maintained or increased.\28\
---------------------------------------------------------------------------

    \27\ Ibid.
    \28\ Ibid.
---------------------------------------------------------------------------

    The applicant also included a secondary analysis of the phase III 
trial data which showed that participants who received lower radiation 
doses to the penile bulb, associated with the SpaceOAR[supreg] System 
injection, reported similar erectile function compared with the control 
group based on patient-reported sexual quality of life.\29\ A 2017 
retrospective cohort study by Pinkawa et al.\30\ evaluated quality of 
life changes up to 5 years after RT for prostate cancer with the 
SpaceOAR[supreg] System and showed that 5 years after radiation 
therapy, no patients who received the SpaceOAR[supreg] System reported 
moderate/big problems with bowel urgency, losing control of stools, or 
with bowel habits overall. However, there were no statistically 
significant differences in mean score changes for urinary, bowel, or 
sexual bother between the percentage of participants in the 
SpaceOAR[supreg] System and control groups at either 1\1/2\ years or 5 
years postradiation therapy. CMS had concerns regarding the phase III 
trial include inclusion of only low to moderate risk prostate cancer in 
the study population and failing to use a clinical outcome as a primary 
endpoint, although the purpose of the spacer is to reduce the side 
effects of undesired radiation to the rectum including bleeding, 
diarrhea, fistula, pain, and/or stricture. Notwithstanding 
acknowledgement that rectal complications may be reduced using 
biodegradable biomaterials placed to increase the distance between the 
rectum and the prostate, it is not clear that the SpaceOAR[supreg] 
System is superior to existing alternative biodegradable biomaterials 
currently utilized for spacing in the context of prostate radiotherapy.
---------------------------------------------------------------------------

    \29\ Hamstra, DA et al. (2018) Sexual quality of life following 
prostate intensity modulated radiation therapy (IMRT) with a rectal/
prostate spacer: Secondary analysis of a phase 3 trial. Practical 
Radiation Oncology, 8, e7-e15.
    \30\ Pinkawa, M. et al. (2017). Quality of Life after Radiation 
Therapy for Prostate Cancer With a Hydrogel Spacer: Five Year 
Results. Int J Radiat Oncol Biol Phys., Vol. 99, No. 2, pp. 374e377.
---------------------------------------------------------------------------

    Based on the evidence submitted with the application, we have 
insufficient evidence that the SpaceOAR[supreg] System provides a 
substantial clinical improvement over other similar products. We 
invited public comments on whether the SpaceOAR[supreg] System meets 
the substantial clinical improvement criterion.
    Comment: The manufacturer of the SpaceOAR[supreg] System identified 
several points which supported this device meeting the substantial 
clinical improvement criterion. In response to the statement in the 
proposed rule that the control arm of the phase III trial had low rates 
of rectal toxicity in general, the manufacturer noted that the low 
rates of rectal toxicity in the control arm of the study were due to: 
(1) The radiation plans in both the treatment and control groups were 
evaluated and approved by an independent core laboratory for compliance 
to protocol guidelines, which led to low toxicity in the control group 
relative to standard practice; and (2) all study dose plans used CT and 
MRI image fusion to improve plan accuracy, while typical plans only use 
CT imaging. The manufacturer noted that patients in the 
SpaceOAR[supreg] System group still had statistically significant 
reductions in rectal toxicity and improvements in quality of life in 
comparison to the control group.
    The manufacturer disagreed with a statement in the proposed rule 
where CMS indicated that the SpaceOAR[supreg] System patients 
``reported similar erectile function compared with the control group 
based on patient-reported sexual quality of life.'' The commenter noted 
that the patient reported quality of life analysis of baseline potent 
men at three years found that men treated with the SpaceOAR[supreg] 
System had improved scores on ``erections sufficient for intercourse'' 
as well as better scores on seven of the 13 items regarding sexual 
function.\31\
---------------------------------------------------------------------------

    \31\ Hamstra, DA et al. (2018) Sexual quality of life following 
prostate intensity modulated radiation therapy (IMRT) with a rectal/
prostate spacer: Secondary analysis of a phase 3 trial. Practical 
Radiation Oncology, 8, e7-e15.
---------------------------------------------------------------------------

    In response to the statement in the proposed rule that the 
submitted studies included only low to moderate risk prostate cancer in 
the study population and failed to use a clinical outcome as a primary 
endpoint, the manufacturer noted that the phase III trial design 
specifically selected a low and

[[Page 58941]]

intermediate risk prostate cancer population to better allow for a 
safety determination. The manufacturer also noted that the significant 
reductions in late rectal toxicity and improvements in quality of life 
at 3 years demonstrate that the clinical benefits of this device are 
better than anticipated when the study was originally developed.
    In response to the statement in the proposed rule that it was 
unclear that the SpaceOAR[supreg] System was superior to existing 
alternative spacers used for prostate radiotherapy, the manufacturer 
noted that the SpaceOAR[supreg] System is the only prostate-rectum 
spacer authorized for marketing by the FDA for use in prostate 
radiotherapy. The manufacturer indicated that the closest comparable 
product is the endorectal balloon, and that a study comparing the 
rectal-spacing capabilities of these two products during prostate 
cancer stereotactic body radiation therapy found significantly less 
rectal radiation dose in the patients who received the SpaceOAR 
System[supreg].\32\ The manufacturer noted a study of these two 
products during proton radiotherapy found that, with the 
SpaceOAR[supreg] System, a larger area around the prostate could be 
radiated while still significantly reducing the rectum radiation 
dose.\33\ The manufacturer indicated that several studies found that 
prostate stability was comparable using these two 
products.^{34 35 36} The manufacturer also noted that 
reductions in placement error and patient comfort favors the 
SpaceOAR[supreg] System compared to endorectal balloons.\37\ The 
manufacturer asserted that the combined impacts of these results make 
the SpaceOAR[supreg] System a substantial clinical improvement over 
endorectal balloons.
---------------------------------------------------------------------------

    \32\ Jones, RT et al. Oosimetric comparison of rectal-
sparingcapabilities of rectal balloon vs inje ctab:e spacer gelin 
stereotactic body radiation therapy forprostate cancer: lessons 
learned from prospective trials. Medical Dosimetry, Volume 42, Issue 
4, winter 2017, Pages 341-347.
    \33\ Fagundes MA et al, Evolving Rectal Sparing In Flducfal 
 BasedImage Guided Proton Therapy for Localized Prostate 
Cancer. International Journal of Radiation Oncology 
 Biology  Physics, Vol. 96, 
Issue 2, E279, 2016.
    \34\ Hedrick SG et al. A comparison between hydrogel spacer and 
endorectal balloon: An analysis of lntrafraction prostate motion 
during proton therapy. J. Appl. Clln. Med. Phys., Vol. 18, pp. 106-
112, 2017.
    \35\ Su Z et al. Hvdrogel Spacer Or Gas Release Rectal Balloon, 
a Comparative Study of Prostate lntrafraction Motion in Proton 
Therapy. Med Phys. 201S;45(6):el 4l.
    \36\ Rendall R. Comparison of hydrogel spacer and rectal 
immobilization on Intra-fraction motion efficiency using Image 
guidance prostate proton therapy. PTCOG 55,PS02, May 27, 2016.
    \37\ EI-Bassiounl et al. Target motion variability and on-line 
positioning accuracy during external beam radiation therapy of 
prostate cancer with an endorectal balloon device. Strahlenther 
Onkol. 2006 Sep;1S2(9):53l[middot]6.
---------------------------------------------------------------------------

    Several commenters, representing various oncological and urologic 
specialty societies, believed that the SpaceOAR[supreg] System meets 
the substantial clinical improvement criterion. These commenters noted 
that there were no other alternative biodegradable biomaterials with 
FDA marketing authorization currently utilized for spacing in the 
context of prostate radiotherapy and that this device provided 
physicians with an option to help ensure patients are provided with the 
best clinical outcomes with the fewest adverse effects.
    Response: We appreciate the manufacturer's and the commenters' 
input. We reviewed these comments and the associated literature on this 
topic and found that the application did not support that the 
SpaceOAR[supreg] System demonstrated a substantial clinical improvement 
as a prostate-rectum spacer for men receiving prostate radiotherapy 
treatment. While the studies provided by the applicant do indicate that 
the device provides a dose reduction at the rectum during IMRT for 
prostate cancer, we found the clinical results of these studies were 
equivocal and did not provide definitive evidence of substantial 
clinical improvement of radiation toxicity and quality of life scores 
after radiation therapy.
    In response to our concern that the control arm of the study had 
very low rates of rectal toxicity (the manufacturers quoted rates of 
late rectal toxicity of between 14 and 25 percent for studies without 
the use of the SpaceOAR[supreg] System), the commenter responded that 
the low rates of rectal toxicity in the control arm of the study were 
due to (1) the radiation plans in both the treatment group and the 
control group were evaluated and approved by an independent core 
laboratory for compliance with protocol guidelines, which led to low 
toxicity in the control group relative to standard practice, and (2) 
all study dose plans used CT and MRI image fusion to improve plan 
accuracy, while typical plans only use CT imaging. The commenter 
further noted that, despite low rates of rectal toxicity in the control 
arm of the phase III trial, patients in the SpaceOAR[supreg] System 
group still had statistically significant reductions in rectal toxicity 
and improvements in quality of life in comparison to the control group. 
We are still concerned that the low rates of rectal toxicity 
demonstrated in the control group may not support claims of substantial 
clinical improvement of the SpaceOAR[supreg] System. For example, the 
rates of late grade one or higher rectal toxicity in the control 
population in the clinical trials submitted by the applicant were 7 
percent \38\ and 9.2 percent,\39\ respectively. The rates of late grade 
one or higher rectal toxicity in the SpaceOAR[supreg] System groups in 
the clinical trials submitted by the applicant were 2 percent in both 
studies.^{40 41} We note that image guided radiation therapy 
has drastically improved radiation dose effects, and conventional 
radiotherapy is well tolerated by the vast majority of patients.\42\ It 
remains unclear if further reduction in radiation dose effects with the 
SpaceOAR[supreg] System translates to a substantial clinical 
improvement that is maintained over time when compared to patients who 
did not receive the SpaceOAR[supreg] System. The applicant's 
explanation that all study dose plans used CT and MRI image fusion to 
improve plan accuracy, while typical plans only use CT imaging is not 
supported in the literature, which states that IMRT is considered the 
standard of care in RT treatment centers; in both the United States and 
Europe, it has largely replaced older forms of 3D-CRT.^{43 44} 
The response that the radiation plans in both the treatment group and 
the control group were evaluated and approved by an independent core 
laboratory for compliance to protocol guidelines, which led to low 
toxicity in the control group relative to standard practice, further 
calls into question the direct role of the SpaceOAR[supreg] System in 
reducing toxicity versus more precise planning

[[Page 58942]]

protocols and the importance of adhering to guidance protocols.
---------------------------------------------------------------------------

    \38\ Mariados N, et al. (2015). Hydrogel Spacer Prospective 
Multicenter Randomized Controlled Pivotal Trial: Dosimetric and 
Clinical Effects of Perirectal Spacer Application in Men Undergoing 
Prostate Image Guided Intensity Modulated Radiation Therapy. Int J 
Radiat Oncol Biol Phys. 92(5):971-977. Epub 2015 Apr 23. PMID: 
26054865.
    \39\ Hamstra DA, et al. (2017). Continued Benefit to Rectal 
Separation for Prostate Radiation Therapy: Final Results of a Phase 
III Trial. Int J Radiat Oncol Biol Phys. Apr 1;97(5):976-985. Epub 
2016 Dec 23. PMID:28209443.
    \40\ Ibid.
    \41\ Ibid.
    \42\ Uhl et al. (2014). Absorbable hydrogel spacer use in men 
undergoing prostate cancer radiotherapy: 12 month toxicity and 
proctoscopy results of a prospective multicenter phase II trial. 
Radiation Oncology, 9:96.
    \43\ Sheets NC, Goldin GH, Meyer AM, Wu Y, Chang Y, St[uuml]rmer 
T, Holmes JA, Reeve BB, Godley PA, Carpenter WR, Chen RC. (2012). 
Intensity-modulated radiation therapy, proton therapy, or conformal 
radiation therapy and morbidity and disease control in localized 
prostate cancer. JAMA.; 307(15):1611.
    \44\ Bauman G, Rumble RB, Chen J, Loblaw A, Warde P, Members of 
the IMRT Indications Expert Panel.(2012). Intensity-modulated 
radiotherapy in the treatment of prostate cancer. Clin Oncol (R Coll 
Radiol), Sep;24(7):461-73. Epub 2012 Jun 4.
---------------------------------------------------------------------------

    As discussed further below, we continue to have concerns regarding 
the applicant's claims that the statistically significant reduction in 
late rectal toxicity as well as the improvements in QOL scores lend to 
substantial clinical improvement, despite the relatively low rates of 
rectal toxicity in the control group. We note that the data showing 
reduction in rectal toxicity and improvements in quality are from 
studies that were not designed with primary clinical outcomes to show 
superiority, but rather were designed primarily to evaluate the 
threshold of radiation exposure to the rectum and adverse events 
related to the procedure. Consequently, the studied clinical outcomes 
have many differences that did not meet statistical significance or 
were not sustained over time.
    In the pivotal trial,\45\ no differences in acute rectal or urinary 
toxicity from the time of the procedure through the 3-month visit were 
observed between the SpaceOAR[supreg] System group and the control 
group. In this study,\46\ there was a statistically significant 
difference noted between the SpaceOAR[supreg] System group and the 
control group in late rectal toxicity (3 to 15 months after the 
procedure). In the SpaceOAR[supreg] System group, 2 percent of the 
patients (n=3) experienced late rectal toxicity, while 7 percent of 
patients in the control group (n=5) experienced late rectal toxicity. 
There was one incidence of the more clinically serious (grade 3) late 
rectal toxicity reported in the control group and no incidence of grade 
4 rectal toxicity in either group.
---------------------------------------------------------------------------

    \45\ Mariados N, et al. (2015). Hydrogel Spacer Prospective 
Multicenter Randomized Controlled Pivotal Trial: Dosimetric and 
Clinical Effects of Perirectal Spacer Application in Men Undergoing 
Prostate Image Guided Intensity Modulated Radiation Therapy. Int J 
Radiat Oncol Biol Phys. 92(5):971-977. Epub 2015 Apr 23. PMID: 
26054865.
    \46\ Ibid.
---------------------------------------------------------------------------

    Even at 3 years after the procedure, the control arm had very low 
rates of rectal toxicity. The 3-year incidence of grade >=1 rectal 
toxicity was 9.2 percent (approximately 4 patients) in the control 
group versus 2.0 percent (approximately 2 patients) in the 
SpaceOAR[supreg] System group. The cumulative rate of grade >=2 rectal 
bowel toxicity was 6 percent at 3 years in the control arm, with no 
cases of grade >=2 rectal toxicity in the SpaceOAR[supreg] System 
group.\47\
---------------------------------------------------------------------------

    \47\ Hamstra DA, et al. (2017). Continued Benefit to Rectal 
Separation for Prostate Radiation Therapy: Final Results of a Phase 
III Trial. Int J Radiat Oncol Biol Phys. Apr 1;97(5):976-985. Epub 
2016 Dec 23. PMID:28209443.
---------------------------------------------------------------------------

    With regard to corresponding improvements in quality of life, the 
pivotal trial,\48\ at 3 months, showed there was no statistically 
significant difference between the SpaceOAR[supreg] System group and 
the control group in mean changes in bowel and urinary quality of life 
domains. Although, at 6, 12, and 15 months, a lower percentage of 
patients in the SpaceOAR[supreg] System group reported declines in 
bowel quality of life compared to those in the control group, at 15 
months, 11.6 percent and 21.4 percent of the SpaceOAR[supreg] System 
patients and the control group patients, respectively, experienced 10-
point declines in bowel quality of life. However, this difference was 
not statistically significant. In terms of urinary quality of life at 6 
months, a higher percentage of patients in the control group (22.2 
percent) had 10-point urinary declines in comparison to the the 
SpaceOAR[supreg] System group (8.8 percent). However, again the 
durability of these improvements disappeared over time because there 
was no difference between the SpaceOAR[supreg] System group and the 
control group in urinary quality of life decline at 12 and 15 months 
follow-ups.\49\
---------------------------------------------------------------------------

    \48\ Ibid.
    \49\ Ibid.
---------------------------------------------------------------------------

    The commenter claimed that when followed up at 3 years, patients in 
the phase III trial receiving the SpaceOAR[supreg] System prior to 
their prostate cancer radiotherapy demonstrated significant rectal 
(bowel), urinary, and sexual benefit. However, we found the data to be 
inconsistent and unreliable to support this claim. Specifically, in the 
study including 3 years of follow-up data,\50\ quality of life was 
examined using the Expanded Prostate Cancer Index Composite (EPIC) 
questionnaire, a comprehensive instrument designed to evaluate patient 
function and bother after prostate cancer treatment. For the average 
bowel summary score, both the SpaceOAR[supreg] System group and the 
control group had similar acute declines in bowel quality of life 
between enrollment and 3 months after treatment. Also, at 3 months 
after treatment, there were no patients in the control group that 
reported acute bowel pain while 6.8 percent of the SpaceOAR[supreg] 
System patients reported acute bowel pain.
---------------------------------------------------------------------------

    \50\ Hamstra DA, et al. (2017). Continued Benefit to Rectal 
Separation for Prostate Radiation Therapy: Final Results of a Phase 
III Trial. Int J Radiat Oncol Biol Phys. Apr 1;97(5):976-985. Epub 
2016 Dec 23. PMID:28209443.
---------------------------------------------------------------------------

    In this study, the proportion of patients with measurable changes 
in bowel quality of life meeting the minimally important difference 
(MID) threshold (5 points) or twice that threshold (10 points) was 
evaluated. According to the authors, these thresholds give an idea of 
when patient-reported symptoms are likely to be clinically meaningful 
to prostate cancer patients, with a 10-point decline indicating a more 
serious clinical effect. From 6 months through 3 years, more men in the 
control group had a MID in bowel quality of life meeting the threshold 
of 5 points, but no difference was found for a 10-point decline. At 3 
years, the SpaceOAR[supreg] System group patients were less likely than 
the control group patients to have a detectable decline in bowel 
quality of life for both MID thresholds (5-point: 41 percent (control) 
versus 14 percent (the SpaceOAR[supreg] System; 10-point: 21 percent 
(control) versus 5 percent (the SpaceOAR[supreg] System).\51\ However, 
more than 30 percent of the patients in both the SpaceOAR[supreg] 
System group (n=55) and the control group (n=27) were lost by the 3-
year follow-up and the follow-up data were taken from volunteer centers 
that decided to continue in the study. It is unclear if the differences 
observed at 3 years are due to the large number of respondents who did 
not participate at year 3, resulting in a smaller sample size and more 
unreliable data. For example, regarding urinary quality of life, when 
averaged over the entire follow-up duration, no significant difference 
was found in the mean urinary quality of life between the two groups. 
However, at the 3-year point, a statistically significant difference 
was found in urinary quality of life favoring the SpaceOAR[supreg] 
System group compared with the control group.
---------------------------------------------------------------------------

    \51\ Ibid.
---------------------------------------------------------------------------

    The researchers in this study also assessed the percent of patients 
with moderate or big problems in quality of life. The researchers found 
that, at 3 years, only one item showed a statistically significant 
difference between the treatment groups (moderate to big bother for 
urinary frequency: The control group of 18 percent versus the 
SpaceOAR[supreg] System group of 5 percent; P <.05). At 3 years after 
treatment, 2.2 percent of the men in the SpaceOAR[supreg] System group 
evaluated their overall bowel function as a big or moderate bother. 
This compares to 4.4 percent in the control group, which was not a 
statistically significant difference. None of the components of rectal 
bother were statistically significantly better in the men who received 
the SpaceOAR[supreg] System. In contrast, regarding the question of 
bowel pain, none of the control group patients reported a moderate or 
big bother after 3 years, while 1.1 percent of the SpaceOAR[supreg] 
System group patients reported that

[[Page 58943]]

bowel pain was a moderate or big bother.\52\ The study by Pinkawa et 
al.\53\ looking at 1\1/2\ and 5 year results comparing quality of life 
of patients pretreated with hydrogel and controls further demonstrates 
inconsistency in looking at substantial improvements with the 
SpaceOAR[supreg] System. In this study percentages of big problems with 
bowel urgency, control of stools and bowel habitus overall favored 
SpaceOAR at 1\1/2\ years. However, only differences in percentage of 
problems of bowel urgency remained after the 5-year follow-up. Also, no 
statistically significant difference was shown between the 
SpaceOAR[supreg] System group and the control group in comparing mean 
bowl bother scores at 1\1/2\ years and 5 years after radiation therapy.
---------------------------------------------------------------------------

    \52\ Ibid.
    \53\ Pinkawa, M. et al. (2017). Quality of Life after Radiation 
Therapy for Prostate Cancer With a Hydrogel Spacer: Five Year 
Results. Int J Radiat Oncol Biol Phys., Vol. 99, No. 2, pp. 374e377.
---------------------------------------------------------------------------

    The manufacturer stated that CMS incorrectly stated in the proposed 
rule that the SpaceOAR[supreg] System patients reported similar 
erectile function compared with the control group based on patient-
reported sexual quality of life. The manufacturer is correct; in a 
study by Hamstra et al.,\54\ the patient-reported quality of life 
analysis of baseline potent men found that men in this group treated 
with the SpaceOAR[supreg] System had improved ``erections sufficient 
for intercourse'' as well as statistically significant higher scores on 
7 of 13 items in the sexual domain in comparison to the control group 
at 3 years. However, at baseline, sexual functioning in the study was 
low; only 41 percent of patients had no sexual dysfunction at baseline 
(EPIC sexual quality of life scores >60, n=88). When comparing men with 
poor baseline sexual quality of life (EPIC score <=60, n=125), there 
was no difference between the SpaceOAR[supreg] System group and the 
control group in function, bother, or sexual summary score at the 3-
year follow up.\55\ We also note that the Pinkawa \56\ study shows that 
more men with the SpaceOAR[supreg] System reported erections firm 
enough for intercourse to be statistically significant. However, again 
the same study reported the changes in sexual quality of life bother 
score were not statistically different between the two groups at 5 
years. Again, along with the instability of the 3-year data stated 
above, the fact that the data are inconsistent and not supported by the 
long-term quality of life data, we are unable to substantiate 
substantial clinical improvement.
---------------------------------------------------------------------------

    \54\ Hamstra, DA et al. (2018) Sexual quality of life following 
prostate intensity modulated radiation therapy (IMRT) with a rectal/
prostate spacer: secondary analysis of a phase 3 trial. Practical 
Radiation Oncology, Vol. 8, e7-e15.
    \55\ Ibid.
    \56\ Pinkawa, M. et al. (2017). Quality of Life after Radiation 
Therapy for Prostate Cancer With a Hydrogel Spacer: Five Year 
Results. Int J Radiat Oncol Biol Phys., Vol. 99, No. 2, pp. 374e377.
---------------------------------------------------------------------------

    We appreciate the comments received from the urological and the 
oncological community as well members of the public in support of this 
technology. The SpaceOAR[supreg] System device effectively displaces 
the anterior wall reducing the dose of radiation the rectum receives 
during radiation treatment for prostate cancer. However, after 
consideration of the public comments and the application materials we 
received, at this time we do not believe that the SpaceOAR[supreg] 
System meets the substantial clinical improvement criterion to receive 
device pass-through payment. The submitted studies were not designed to 
show primary clinical outcomes, and consequently the data on toxicity 
and quality of life improvement are inconsistent and fail to show 
enduring improvements. It is difficult to attribute the reductions in 
late rectal toxicity solely to the device, given improvements in 
radiation therapy and planning as well as the large number of 
nonresponders at 3 years postradiation and the 3-year follow-up data 
were being taken from volunteer centers that decided to continue in the 
study. We note that many favorable clinical outcomes were not 
statistically significant but trended in favor of the SpaceOAR[supreg] 
System group. We agree with many authors that seem to suggest that the 
greatest utility of the SpaceOAR[supreg] System will be its use in 
populations at greatest risk for radiation toxicity such as 
hypofractionated treatment or other dose intensifications.
    The third criterion for establishing a device category, at Sec.  
419.66(c)(3), requires us to determine that the cost of the device is 
not insignificant, as described in Sec.  419.66(d). Section 419.66(d) 
includes three cost significance criteria that must each be met. The 
applicant provided the following information in support of the cost 
significance requirements. The applicant stated that the 
SpaceOAR[supreg] System would be reported with CPT code 0438T (which 
was deleted and replaced with CPT code 55874, effective January 1, 
2018). CPT code 0438T was assigned to APC 5374 (Level 4 Urology and 
Related Services). To meet the cost criterion for device pass-through 
payment, a device must pass all three tests of the cost criterion for 
at least one APC. For our calculations, we used APC 5374, which had a 
CY 2017 payment rate of $2,542.56 at the time the application was 
received. Beginning in CY 2017, we calculate the device offset amount 
at the HCPCS/CPT code level instead of the APC level (81 FR 79657). CPT 
code 0438T had a device offset amount of $587.07 at the time the 
application was received. According to the applicant, the cost of the 
SpaceOAR[supreg] System was $2,850.
    Section 419.66(d)(1), the first cost significance requirement, 
provides that the estimated average reasonable cost of devices in the 
category must exceed 25 percent of the applicable APC payment amount 
for the service related to the category of devices. The estimated 
average reasonable cost of $2,850 for the SpaceOAR[supreg] System 
exceeds 112 percent of the applicable APC payment amount for the 
service related to the category of devices of $2,542.56 ($2850/
$2,542.56 x 100 = 112 percent). Therefore, we believe the 
SpaceOAR[supreg] system meets the first cost significance test.
    The second cost significance test, at Sec.  419.66(d)(2), provides 
that the estimated average reasonable cost of the devices in the 
category must exceed the cost of the device-related portion of the APC 
payment amount for the related service by at least 25 percent, which 
means that the device cost needs to be at least 125 percent of the 
offset amount (the device-related portion of the APC found on the 
offset list). The estimated average reasonable cost of $2,850 for the 
SpaceOAR[supreg] System exceeds the cost of the device-related portion 
of the APC payment amount for the related service of $587.07 by 485 
percent ($2,850/$587.07) x 100 = 485 percent). Therefore, we believe 
that the SpaceOAR[supreg] System meets the second cost significance 
test.
    The third cost significance test, at Sec.  419.66(d)(3), requires 
that the difference between the estimated average reasonable cost of 
the devices in the category and the portion of the APC payment amount 
for the device must exceed 10 percent of the APC payment amount for the 
related service. The difference between the estimated average 
reasonable cost of $2,850 for the SpaceOAR[supreg] System and the 
portion of the APC payment amount for the device of $587.07 exceeds the 
APC payment amount for the related service of $2,542.56 by 89 percent 
(($2,850-$587.07)/$2,542.56 x 100 = 89 percent). Therefore, we believe 
that the SpaceOAR[supreg] System meets the third cost significance 
test.
    We invited public comments on whether the SpaceOAR[supreg] System 
meets the device pass-through payment

[[Page 58944]]

criteria discussed in this section, including the cost criteria.
    Comment: The manufacturer of the SpaceOAR[supreg] System believed 
this device meets the eligibility criteria for device pass-through 
payment status, but did not specifically comment on whether this device 
meets the cost criterion.
    Response: We appreciate the manufacturer's input.
    After consideration of the public comments we received, we believe 
that SpaceOAR[supreg] System meets the cost criterion for device pass-
through payment status.
    After consideration of the public comments we received, we believe 
that SpaceOAR[supreg] System does not qualify for device pass-through 
payment status because it does not meet the substantial clinical 
improvement criterion, although it may have clinical benefit for 
certain patients. As such, we are not approving the application for 
device pass-through payment status for the SpaceOAR[supreg] System for 
CY 2019.

B. Device-Intensive Procedures

1. Background
    Under the OPPS, prior to CY 2017, device-intensive status for 
procedures was determined at the APC level for APCs with a device 
offset percentage greater than 40 percent (79 FR 66795). Beginning in 
CY 2017, CMS began determining device-intensive status at the HCPCS 
code level. In assigning device-intensive status to an APC prior to CY 
2017, the device costs of all the procedures within the APC were 
calculated and the geometric mean device offset of all of the 
procedures had to exceed 40 percent. Almost all of the procedures 
assigned to device-intensive APCs utilized devices, and the device 
costs for the associated HCPCS codes exceeded the 40-percent threshold. 
The no cost/full credit and partial credit device policy (79 FR 66872 
through 66873) applies to device-intensive APCs and is discussed in 
detail in section IV.B.4. of this final rule with comment period. A 
related device policy was the requirement that certain procedures 
assigned to device-intensive APCs require the reporting of a device 
code on the claim (80 FR 70422). For further background information on 
the device-intensive APC policy, we refer readers to the CY 2016 OPPS/
ASC final rule with comment period (80 FR 70421 through 70426).
a. HCPCS Code-Level Device-Intensive Determination
    As stated earlier, prior to CY 2017, the device-intensive 
methodology assigned device-intensive status to all procedures 
requiring the implantation of a device that were assigned to an APC 
with a device offset greater than 40 percent and, beginning in CY 2015, 
that met the three criteria listed below. Historically, the device-
intensive designation was at the APC level and applied to the 
applicable procedures within that APC. In the CY 2017 OPPS/ASC final 
rule with comment period (81 FR 79658), we changed our methodology to 
assign device-intensive status at the individual HCPCS code level 
rather than at the APC level. Under this policy, a procedure could be 
assigned device-intensive status regardless of its APC assignment, and 
device-intensive APCs were no longer applied under the OPPS or the ASC 
payment system.
    We believe that a HCPCS code-level device offset is, in most cases, 
a better representation of a procedure's device cost than an APC-wide 
average device offset based on the average device offset of all of the 
procedures assigned to an APC. Unlike a device offset calculated at the 
APC level, which is a weighted average offset for all devices used in 
all of the procedures assigned to an APC, a HCPCS code-level device 
offset is calculated using only claims for a single HCPCS code. We 
believe that this methodological change results in a more accurate 
representation of the cost attributable to implantation of a high-cost 
device, which ensures consistent device-intensive designation of 
procedures with a significant device cost. Further, we believe a HCPCS 
code-level device offset removes inappropriate device-intensive status 
for procedures without a significant device cost that are granted such 
status because of APC assignment.
    Under our existing policy, procedures that meet the criteria listed 
below in section IV.B.1.b. of this final rule with comment period are 
identified as device-intensive procedures and are subject to all the 
policies applicable to procedures assigned device-intensive status 
under our established methodology, including our policies on device 
edits and no cost/full credit and partial credit devices discussed in 
sections IV.B.3. and IV.B.4. of this final rule with comment period, 
respectively.
b. Use of the Three Criteria To Designate Device-Intensive Procedures
    We clarified our established policy in the CY 2018 OPPS/ASC final 
rule with comment period (82 FR 52474), where we explained that device-
intensive procedures require the implantation of a device and 
additionally are subject to the following criteria:
     All procedures must involve implantable devices that would 
be reported if device insertion procedures were performed;
     The required devices must be surgically inserted or 
implanted devices that remain in the patient's body after the 
conclusion of the procedure (at least temporarily); and
     The device offset amount must be significant, which is 
defined as exceeding 40 percent of the procedure's mean cost.
    We changed our policy to apply these three criteria to determine 
whether procedures qualify as device-intensive in the CY 2015 OPPS/ASC 
final rule with comment period (79 FR 66926), where we stated that we 
would apply the no cost/full credit and partial credit device policy--
which includes the three criteria listed above--to all device-intensive 
procedures beginning in CY 2015. We reiterated this position in the CY 
2016 OPPS/ASC final rule with comment period (80 FR 70424), where we 
explained that we were finalizing our proposal to continue using the 
three criteria established in the CY 2007 OPPS/ASC final rule with 
comment period for determining the APCs to which the CY 2016 device 
intensive policy will apply. Under the policies we adopted in CYs 2015, 
2016, and 2017, all procedures that require the implantation of a 
device and meet the above criteria are assigned device-intensive 
status, regardless of their APC placement.
2. Changes to the Device-Intensive Procedure Policy for CY 2019 and 
Subsequent Years
    As part of CMS' effort to better capture costs for procedures with 
significant device costs, in the CY 2019 OPPS/ASC proposed rule (83 FR 
37108), for CY 2019, we proposed to modify our criteria for device-
intensive procedures. We have heard from stakeholders that the current 
criteria exclude some procedures that stakeholders believe should 
qualify as device-intensive procedures. Specifically, we were persuaded 
by stakeholder arguments that procedures requiring expensive surgically 
inserted or implanted devices that are not capital equipment should 
qualify as device-intensive procedures, regardless of whether the 
device remains in the patient's body after the conclusion of the 
procedure. We agreed that a broader definition of device-intensive 
procedures was warranted, and proposed two modifications to the 
criteria for CY 2019. First, we proposed to allow procedures that 
involve surgically inserted or implanted, single-use devices that meet 
the device offset percentage threshold to qualify as device-intensive 
procedures, regardless

[[Page 58945]]

of whether the device remains in the patient's body after the 
conclusion of the procedure. We proposed this policy because we no 
longer believed that whether a device remains in the patient's body 
should affect its designation as a device-intensive procedure, as such 
devices could, nonetheless, comprise a large portion of the cost of the 
applicable procedure. Second, we proposed to modify our criteria to 
lower the device offset percentage threshold from 40 percent to 30 
percent, to allow a greater number of procedures to qualify as device-
intensive. We stated in the proposed rule that we believe allowing 
these additional procedures to qualify for device-intensive status will 
help ensure these procedures receive more appropriate payment in the 
ASC setting, which will help encourage the provision of these services 
in the ASC setting. In addition, we stated in the proposed rule that 
this proposed change would help to ensure that more procedures 
containing relatively high-cost devices are subject to the device 
edits, which leads to more correctly coded claims and greater accuracy 
in our claims data. Specifically, for CY 2019 and subsequent years, we 
proposed that device-intensive procedures would be subject to the 
following criteria:
     All procedures must involve implantable devices assigned a 
CPT or HCPCS code;
     The required devices (including single-use devices) must 
be surgically inserted or implanted; and
     The device offset amount must be significant, which is 
defined as exceeding 30 percent of the procedure's mean cost.
    In addition, to further align the device-intensive policy with the 
criteria used for device pass-through payment status, we proposed to 
specify, for CY 2019 and subsequent years, that for purposes of 
satisfying the device-intensive criteria, a device-intensive procedure 
must involve a device that:
     Has received FDA marketing authorization, has received an 
FDA investigational device exemption (IDE), and has been classified as 
a Category B device by the FDA in accordance with 42 CFR 405.203 
through 405.207 and 405.211 through 405.215, or meets another 
appropriate FDA exemption from premarket review;
     Is an integral part of the service furnished;
     Is used for one patient only;
     Comes in contact with human tissue;
     Is surgically implanted or inserted (either permanently or 
temporarily); and
     Is not any of the following:
    (a) Equipment, an instrument, apparatus, implement, or item of this 
type for which depreciation and financing expenses are recovered as 
depreciable assets as defined in Chapter 1 of the Medicare Provider 
Reimbursement Manual (CMS Pub. 15-1); or
    (b) A material or supply furnished incident to a service (for 
example, a suture, customized surgical kit, scalpel, or clip, other 
than a radiological site marker).
    As part of this proposal, we solicited public comment on these 
proposed revised criteria, including whether there are any devices that 
are not capital equipment that commenters believe should be deemed part 
of device-intensive procedures that would not meet the proposed 
definition of single-use devices. In addition, we solicited public 
comments on the full list of proposed CY 2019 OPPS device-intensive 
procedures provided in Addendum P to the proposed rule, which is 
available at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/HospitalOutpatientPPS/Hospital-Outpatient-Regulations-and-Notices.html. Specifically, we invited public comment on whether any 
procedures proposed to receive device-intensive status for CY 2019 
should not receive device-intensive status according to the proposed 
criteria, or if we did not assign device-intensive status for CY 2019 
to any procedures commenters believed should receive device-intensive 
status based on the proposed criteria.
    Comment: The majority of commenters supported CMS' proposal to 
modify the device-intensive criteria to allow procedures that involve 
single-use devices, regardless of whether they remain in the body after 
the conclusion of the procedure, to qualify as device-intensive 
procedures. The commenters believed that this proposed policy change 
will better support accurate payment for procedures where an 
implantable device is a significant proportion of the total cost of the 
procedure. Some commenters indicated that this proposed change would 
help to spur innovation in the device industry.
    Response: We appreciate the commenters' support.
    Comment: The majority of commenters supported the proposal to lower 
the device offset percentage threshold for procedures to qualify as 
device-intensive from greater than 40 percent to greater than 30 
percent. The commenters believed that this proposed policy change will 
encourage migration of services from the hospital outpatient department 
into the ASC setting, resulting in cost savings to the Medicare program 
and Medicare beneficiaries. Some of these commenters encouraged CMS to 
further modify its proposal and instead lower the device offset 
percentage threshold for procedures to qualify as device-intensive to 
25 percent instead of 30 percent, to allow even more procedures to be 
designated as device-intensive.
    Response: We appreciate commenters' support. At this time, we 
continue to believe that applying a device offset percentage threshold 
of greater than 30 percent for procedures to qualify as device-
intensive is most appropriate for the reasons described in our original 
proposal. Because the ASC payment system is budget neutral, when the 
device-intensive threshold is set lower, it results in transfer of 
payment from services with high device offsets or that do not qualify 
as device-intensive to the services being newly designated as device-
intensive. As a result, it is important that the device-intensive 
threshold not be set too low or it will result in the transfer of 
payments from procedures with high device offsets to procedures with 
low device offsets, which is the opposite of the intended purpose of 
this policy. We will take the commenters' suggestion of applying a 
device offset percentage threshold of greater than 25 percent for 
procedures to qualify as device-intensive into consideration for future 
rulemaking.
    In addition, for new HCPCS codes describing procedures requiring 
the implantation of medical devices that do not yet have associated 
claims data, in the CY 2017 OPPS/ASC final rule with comment period (81 
FR 79658), we finalized a policy for CY 2017 to apply device-intensive 
status with a default device offset set at 41 percent for new HCPCS 
codes describing procedures requiring the implantation or insertion of 
a medical device that do not yet have associated claims data until 
claims data are available to establish the HCPCS code-level device 
offset for the procedures. This default device offset amount of 41 
percent is not calculated from claims data; instead, it is applied as a 
default until claims data are available upon which to calculate an 
actual device offset for the new code. The purpose of applying the 41-
percent default device offset to new codes that describe procedures 
that implant or insert medical devices is to ensure ASC access for new 
procedures until claims data become available.
    As discussed in the CY 2019 OPPS/ASC proposed rule (83 FR 37108 
through 37109), in accordance with our proposal stated above to lower 
the

[[Page 58946]]

device offset percentage threshold for procedures to qualify as device-
intensive from greater than 40 percent to greater than 30 percent, for 
CY 2019 and subsequent years, we proposed to modify this policy and 
apply a 31-percent default device offset to new HCPCS codes describing 
procedures requiring the implantation of a medical device that do not 
yet have associated claims data until claims data are available to 
establish the HCPCS code-level device offset for the procedures. In 
conjunction with the proposal to lower the default device offset from 
41 percent to 31 percent, we proposed to continue our current policy 
of, in certain rare instances (for example, in the case of a very 
expensive implantable device), temporarily assigning a higher offset 
percentage if warranted by additional information such as pricing data 
from a device manufacturer (81 FR 79658). Once claims data are 
available for a new procedure requiring the implantation of a medical 
device, device-intensive status will be applied to the code if the 
HCPCS code-level device offset is greater than 30 percent, according to 
our policy of determining device-intensive status by calculating the 
HCPCS code-level device offset.
    In addition, in the proposed rule, we clarified that since the 
adoption of our policy in effect as of CY 2018, the associated claims 
data used for purposes of determining whether or not to apply the 
default device offset are the associated claims data for either the new 
HCPCS code or any predecessor code, as described by CPT coding 
guidance, for the new HCPCS code. Additionally, for CY 2019 and 
subsequent years, in limited instances where a new HCPCS code does not 
have a predecessor code as defined by CPT, but describes a procedure 
that was previously described by an existing code, we proposed to use 
clinical discretion to identify HCPCS codes that are clinically related 
or similar to the new HCPCS code but are not officially recognized as a 
predecessor code by CPT, and to use the claims data of the clinically 
related or similar code(s) for purposes of determining whether or not 
to apply the default device offset to the new HCPCS code. Clinically 
related and similar procedures for purposes of this policy are 
procedures that have little or no clinical differences and use the same 
devices as the new HCPCS code. In addition, clinically related and 
similar codes for purposes of this policy are codes that either 
currently or previously describe the procedure described by the new 
HCPCS code. Under this proposal, claims data from clinically related 
and similar codes would be included as associated claims data for a new 
code, and where an existing HCPCS code is found to be clinically 
related or similar to a new HCPCS code, we proposed to apply the device 
offset percentage derived from the existing clinically related or 
similar HCPCS code's claims data to the new HCPCS code for determining 
the device offset percentage. We stated in the proposed rule that we 
believe that claims data for HCPCS codes describing procedures that 
have very minor differences from the procedures described by new HCPCS 
codes would provide an accurate depiction of the cost relationship 
between the procedure and the device(s) that are used, and would be 
appropriate to use to set a new code's device offset percentage, in the 
same way that predecessor codes are used. For instance, for CY 2019, we 
proposed to use the claims data from existing CPT code 36568 (Insertion 
of peripherally inserted central venous catheter (PICC), without 
subcutaneous port or pump; younger than 5 years of age), for which the 
description as of January 1, 2019 is changing to ``(Insertion of 
peripherally inserted central venous catheter (PICC), without 
subcutaneous port or pump, without imaging guidance; younger than 5 
years of age)'', to determine the appropriate device offset percentage 
for new CPT code 36X72 (Insertion of peripherally inserted central 
venous catheter (PICC), without subcutaneous port or pump, including 
all imaging guidance, image documentation, and all associated 
radiological supervision and interpretation required to perform the 
insertion; younger than 5 years of age). We believe that although CPT 
code 36568 is not identified as a predecessor code by CPT, the 
procedure described by new CPT code 36X72 was previously described by 
CPT code 36568 and, therefore, CPT code 36X72 is clinically related and 
similar to CPT code 36568, and the device offset percentage for CPT 
code 36568 can be accurately applied to both codes. If a new HCPCS code 
has multiple predecessor codes, the claims data for the predecessor 
code that has the highest individual HCPCS-level device offset 
percentage would be used to determine whether the new HCPCS code 
qualifies for device-intensive status. Similarly, in the event that a 
new HCPCS code does not have a predecessor code but has multiple 
clinically related or similar codes, the claims data for the clinically 
related or similar code that has the highest individual HCPCS level 
device offset percentage would be used to determine whether the new 
HCPCS code qualifies for device-intensive status.
    In the CY 2019 OPPS/ASC proposed rule, we indicated that additional 
information for our consideration of an offset percentage higher than 
the proposed default of 31 percent for new HCPCS codes describing 
procedures requiring the implantation (or, in some cases, the 
insertion) of a medical device that do not yet have associated claims 
data, such as pricing data or invoices from a device manufacturer, 
should be directed to the Division of Outpatient Care, Mail Stop C4-01-
26, Centers for Medicare and Medicaid Services, 7500 Security 
Boulevard, Baltimore, MD 21244-1850, or electronically at 
[email protected]. Additional information can be submitted 
prior to issuance of an OPPS/ASC proposed rule or as a public comment 
in response to an issued OPPS/ASC proposed rule. Device offset 
percentages will be set in each year's final rule.
    The full listing of proposed CY 2019 OPPS device-intensive 
procedures was included in Addendum P to the proposed rule (which is 
available via the internet on the CMS website).
    Comment: Commenters supported the proposal to apply a default 
device offset of 31 percent to procedures requiring devices that do not 
yet have claims data, as well as the proposal to use claims data from 
clinically similar and related codes to establish device offsets for 
procedures with new codes that do not have direct predecessor codes 
according to CPT.
    Response: We appreciate the commenters' support.
    Comment: A few commenters suggested that CMS only adjust the non-
device portion of the payment by the wage index, consistent with the 
Agency's policy for separately payable drugs and biologicals.
    Response: While we did not make such a proposal in this year's 
proposed rule, we will take this comment into consideration for future 
rulemaking. We note that such a policy would increase payments to 
providers with a wage index value of less than 1 and be offset by a 
budget neutral decrease in payments to other providers.
    Comment: A group of commenters urged CMS to calculate the device 
offset percentage for potential device-intensive procedures using the 
standard (noncomprehensive APC) ASC ratesetting methodology and to 
assign device-intensive status in the ASC system based on that device 
offset percentage, as they believed it is more consistent with the 
overall ASC payment system. One commenter requested some clarification 
in the final

[[Page 58947]]

rule about the current methodology for calculating the device offset 
percentage for device-intensive procedures and specifically asked that 
CMS:
     Confirm that the ASC device-intensive status as assigned 
by CMS is based on the offset calculated according to the ASC 
ratesetting methodology;
     Disclose what offset data (meaning the calculation 
methodology used) appear in the second spreadsheet of Addendum P titled 
``2019 NPRM HCPCS Offsets'';
     Display the device offsets in Addendum P, in future 
rulemaking, based on the ASC methodology and not the OPPS methodology 
if the offset data displayed in the second spreadsheet of Addendum P is 
based on the OPPS methodology and device intensive status is based on 
the ASC methodology; and
     Modify the second worksheet of Addendum P titled ``2019 
NPRM HCPCS Offsets'' to only include the codes for procedures that 
employ implantable and insertable devices and exclude all of the codes 
that do not employ implantable or insertable devices.
    Response: As stated in the CY 2019 OPPS/ASC proposed rule (83 FR 
37158), according to our established ASC payment methodology, we apply 
the device offset percentage based on the standard OPPS APC ratesetting 
methodology to the OPPS national unadjusted payment to determine the 
device cost included in the OPPS payment rate for a device-intensive 
ASC covered surgical procedure, which we then set as equal to the 
device portion of the national unadjusted ASC payment rate for the 
procedure. We calculate the service portion of the ASC payment for 
device-intensive procedures by applying the uniform ASC conversion 
factor to the service (nondevice) portion of the OPPS relative payment 
weight for the device-intensive procedure. Finally, we sum the ASC 
device portion and ASC service portion to establish the full payment 
for the device-intensive procedure under the ASC payment system.
    In response to the commenter's questions and suggestions relating 
to Addendum P, we note that the device offset percentages reflected in 
both worksheets of Addendum P are based upon the OPPS methodology 
(including the C-APC methodology). We believe this is appropriate as 
Addendum P is created to display the device offsets, device offset 
percentages, and device-intensive codes under the OPPS. Specific to the 
commenter's suggestion that we modify the second worksheet of Addendum 
P titled ``2019 NPRM HCPCS Offsets'' to only include the codes for 
procedures that employ implantable and insertable devices and exclude 
all of the codes that do not employ implantable or insertable devices, 
we note that the second worksheet of Addendum P is intended to display 
the device offsets and device offset percentages for all codes for 
which we have such data under the OPPS. In addition, the list of 
services that qualify as device-intensive under the ASC payment system 
and the services' device offset percentages for the ASC payment system 
are included on the CMS website at https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/ASCPayment/ASC-Policy-Files.html as 
``CY 2019 Final ASC Device-Intensive Procedures and Procedures to which 
the No Cost/Full Credit and Partial Credit Device Adjustment Policy 
Applies.''
    Comment: Commenters supported the proposed device-intensive status 
for the following CPT codes:
     CPT code 28297 (Correction, hallux valgus (bunionectomy), 
with sesamoidectomy, when performed; with first metatarsal and medial 
cuneiform joint arthrodesis, any method);
     CPT code 28730 (Arthrodesis, midtarsal or tarsometatarsal, 
multiple or transverse);
     CPT code 28740 (Arthrodesis, midtarsal or tarsometatarsal, 
single joint);
     CPT code 36903 (Introduction of needle(s) and/or 
catheter(s), dialysis circuit, with diagnostic angiography of the 
dialysis circuit, including all direct puncture(s) and catheter 
placement(s), injection(s) of contrast, all necessary imaging from the 
arterial anastomosis and adjacent artery through entire venous outflow 
including the inferior or superior vena cava, fluoroscopic guidance, 
radiological supervision and interpretation and image documentation and 
report; with transcatheter placement of intravascular stent(s), 
peripheral dialysis segment, including all imaging and radiological 
supervision and interpretation necessary to perform the stenting, and 
all angioplasty within the peripheral dialysis segment);
     CPT code 36904 (Percutaneous transluminal mechanical 
thrombectomy and/or infusion for thrombolysis, dialysis circuit, any 
method, including all imaging and radiological supervision and 
interpretation, diagnostic angiography, fluoroscopic guidance, catheter 
placement(s), and intraprocedural pharmacological thrombolytic 
injection(s)); and
     CPT code 36906 (Percutaneous transluminal mechanical 
thrombectomy and/or infusion for thrombolysis, dialysis circuit, any 
method, including all imaging and radiological supervision and 
interpretation, diagnostic angiography, fluoroscopic guidance, catheter 
placement(s), and intraprocedural pharmacological thrombolytic 
injection(s); with transcatheter placement of intravascular stent(s), 
peripheral dialysis segment, including all imaging and radiological 
supervision and interpretation necessary to perform the stenting, and 
all angioplasty within the peripheral dialysis circuit).
    Other commenters requested that CMS assign device-intensive status 
to:
     HCPCS code C9747 (Ablation of prostate, transrectal, high 
intensity focused ultrasound (hifu), including imaging guidance);
     CPT code 43210 (Esophagogastroduodenoscopy, flexible, 
transoral; with esophagogastric fundoplasty, partial or complete, 
includes duodenoscopy when performed);
     CPT code 0275T (Percutaneous laminotomy/laminectomy 
(interlaminar approach) for decompression of neural elements, (with or 
without ligamentous resection, discectomy, facetectomy and/or 
foraminotomy), any method, under indirect image guidance (e.g., 
fluoroscopic, ct), single or multiple levels, unilateral or bilateral; 
lumbar);
     CPT code 55874 (Transperineal placement of biodegradable 
material, peri-prostatic, single or multiple injection(s), including 
image guidance, when performed);
     CPT code 0409T (Insertion or replacement of permanent 
cardiac contractility modulation system, including contractility 
evaluation when performed, and programming of sensing and therapeutic 
parameters; pulse generator only);
     CPT code 0410T (Insertion or replacement of permanent 
cardiac contractility modulation system, including contractility 
evaluation when performed, and programming of sensing and therapeutic 
parameters; atrial electrode only);
     CPT code 0411T (Insertion or replacement of permanent 
cardiac contractility modulation system, including contractility 
evaluation when performed, and programming of sensing and therapeutic 
parameters; ventricular electrode only); and
     CPT code 0414T (Removal and replacement of permanent 
cardiac contractility modulation system pulse generator only).
    Response: We appreciate the commenters' support. With respect to 
the commenters' request that we assign the device-intensive designation 
to

[[Page 58948]]

HCPCS code C9747 and CPT codes 43210, 0275T, and 55874, we note that 
the device offset percentage for all four of these procedures (as 
identified by the above mentioned HCPCS codes or predecessor codes) is 
not above the 30-percent threshold, and therefore these procedures are 
not eligible to be assigned device-intensive status. CPT codes 0409T, 
0410T, 0411T, and 0414T were inadvertently omitted from the listing of 
proposed device-intensive procedures in the CY 2019 OPPS/ASC proposed 
rule. However, we have included them as device-intensive procedures in 
this final rule with comment period. CPT code 36904 was proposed as a 
device-intensive procedure. However, using the most currently available 
data for this CY 2019 OPPS/ASC final rule with comment period, we have 
determined that its device offset percentage is not above the 30-
percent threshold, and therefore this procedure is not eligible to be 
assigned device-intensive status.
    Comment: One commenter stated that CPT code 86891 (Autologous blood 
or component, collection processing and storage; intra- or 
postoperative salvage) was incorrectly proposed to have device-
intensive status for CY 2019.
    Response: We agree with the commenter. CPT code 86891 was 
inadvertently included in the listing of device-intensive procedures in 
Addendum P to the CY 2019 OPPS/ASC proposed rule.
    After consideration of the public comments we received, we are 
finalizing our proposals to allow procedures that involve surgically 
inserted or implanted, single-use devices that meet the device offset 
percentage threshold to qualify as device-intensive procedures, 
regardless of whether the device remains in the patient's body after 
the conclusion of the procedure and to modify our criteria to lower the 
device offset percentage threshold from 40 percent to 30 percent. The 
full listing of the final CY 2019 device-intensive procedures is 
included in Addendum P to this final rule with comment period (which is 
available via the internet on the CMS website).
3. Device Edit Policy
    In the CY 2015 OPPS/ASC final rule with comment period (79 FR 
66795), we finalized a policy and implemented claims processing edits 
that require any of the device codes used in the previous device-to-
procedure edits to be present on the claim whenever a procedure code 
assigned to any of the APCs listed in Table 5 of the CY 2015 OPPS/ASC 
final rule with comment period (the CY 2015 device-dependent APCs) is 
reported on the claim. In addition, in the CY 2016 OPPS/ASC final rule 
with comment period (80 FR 70422), we modified our previously existing 
policy and applied the device coding requirements exclusively to 
procedures that require the implantation of a device that are assigned 
to a device-intensive APC. In the CY 2016 OPPS/ASC final rule with 
comment period, we also finalized our policy that the claims processing 
edits are such that any device code, when reported on a claim with a 
procedure assigned to a device-intensive APC (listed in Table 42 of the 
CY 2016 OPPS/ASC final rule with comment period (80 FR 70422)) will 
satisfy the edit.
    In the CY 2017 OPPS/ASC final rule with comment period (81 FR 79658 
through 79659), we changed our policy for CY 2017 and subsequent years 
to apply the CY 2016 device coding requirements to the newly defined 
device-intensive procedures. For CY 2017 and subsequent years, we also 
specified that any device code, when reported on a claim with a device-
intensive procedure, will satisfy the edit. In addition, we created 
HCPCS code C1889 to recognize devices furnished during a device-
intensive procedure that are not described by a specific Level II HCPCS 
Category C-code. Reporting HCPCS code C1889 with a device-intensive 
procedure will satisfy the edit requiring a device code to be reported 
on a claim with a device-intensive procedure.
    We did not propose any changes to this policy for CY 2019.
    Comment: Some commenters expressed concern about a potential claims 
processing issue that would arise from a number of codes (listed below 
in Table 36) that were proposed to have device-intensive status, which, 
in their clinical opinion, do not always require the involvement of 
implantable or insertable single-use devices and, therefore, could be 
subject to the claims edit requiring device-intensive procedures to be 
billed with a device., when the procedure may not require the 
involvement of a device.

BILLING CODE 4120-01-P

[[Page 58949]]

[GRAPHIC] [TIFF OMITTED] TR21NO18.054


[[Page 58950]]


[GRAPHIC] [TIFF OMITTED] TR21NO18.055

BILLING CODE 4120-01-C

    Response: We have noted the commenters' concern. We have performed 
a clinical examination of the potential device-intensive procedures and 
believe the codes listed in Addendum P to this CY 2019 OPPS/ASC final 
rule with comment period (which is available via the internet on the 
CMS website) as OPPS device-intensive meet the newly finalized criteria 
of being a device-intensive procedure. To address any potential claims 
processing issues pertaining to the device edit policy, we will use 
subregulatory authority to ensure that the device edit does not 
improperly prevent correctly coded claims from being paid.
    Comment: One commenter requested that CMS either revise the 
descriptor for HCPCS code C1889 (Implantable/insertable device for 
device-intensive procedure, not otherwise classified) to remove the 
specific applicability to device-intensive procedures or establish a 
new ``Not Otherwise Classified'' (NOC) HCPCS code for devices that do 
not have a specific device HCPCS code or are used in a procedure not 
designated as device-intensive.
    Response: We agree with the commenter and have revised the NOC 
HCPCS code to remove the specific applicability to device-intensive 
procedures. HCPCS code C1889 now reads ``(Implantable/insertable 
device, not otherwise classified)''.
    Comment: One commenter requested that CMS restore the device-to-
procedure and procedure-to-device edits.
    Response: As we stated in the CY 2015 OPPS/ASC final rule with 
comment period (79 FR 66794), we continue to believe that the 
elimination of device-to-procedure edits and procedure-to-device edits 
is appropriate due to the experience hospitals now have in coding and 
reporting these claims fully. More specifically, for the more costly 
devices, we believe the C-APCs will reliably reflect the cost of the 
device if charges for the device are included anywhere on the claim. We 
note that, under our current policy, hospitals are still expected to 
adhere to the guidelines of correct coding and append the correct 
device code to the claim when applicable. We also note that, as with 
all other items and services recognized under the OPPS, we expect 
hospitals to code and report their costs appropriately, regardless of 
whether there are claims processing edits in place.
4. Adjustment to OPPS Payment for No Cost/Full Credit and Partial 
Credit Devices
a. Background
    To ensure equitable OPPS payment when a hospital receives a device 
without cost or with full credit, in CY 2007, we implemented a policy 
to reduce the payment for specified device-dependent APCs by the 
estimated portion of the APC payment attributable to device costs (that 
is, the device offset) when the hospital receives a specified device at 
no cost or with full credit (71 FR 68071 through 68077). Hospitals were 
instructed to report no cost/full credit device cases on the claim 
using the ``FB'' modifier on the line with the procedure code in which 
the no cost/full credit device is used. In cases in which the device is 
furnished without cost or with full credit, hospitals were instructed 
to report a token device charge of less than $1.01. In cases in which 
the device being inserted is an upgrade (either of the same type of 
device or to a different type of device) with a full credit for the 
device being replaced, hospitals were instructed to report as the 
device charge the difference between the hospital's usual charge for 
the device being implanted and the hospital's usual charge for the 
device for which it received full credit. In CY 2008, we expanded this 
payment adjustment policy to include cases in which hospitals receive 
partial credit of 50 percent or more of the cost of a specified device. 
Hospitals were instructed to append the ``FC'' modifier to the 
procedure code that reports the service provided to furnish the device 
when they receive a partial credit of 50 percent or more of the cost of 
the new device. We refer readers to the CY 2008 OPPS/ASC final rule 
with comment period for more background information on the ``FB'' and 
``FC'' modifiers payment adjustment policies (72 FR 66743 through 
66749).
    In the CY 2014 OPPS/ASC final rule with comment period (78 FR 75005 
through 75007), beginning in CY 2014, we modified our policy of 
reducing OPPS payment for specified APCs when a hospital furnishes a 
specified device without cost or with a full or partial credit. For CY 
2013 and prior years, our policy had been to reduce OPPS payment by 100 
percent of the device offset amount when a hospital furnishes a 
specified device without cost or with a full credit and by 50 percent 
of the device offset amount when the hospital receives partial credit 
in the amount of 50 percent or more of the cost for the specified 
device. For CY 2014, we reduced OPPS payment, for the applicable APCs, 
by the full or partial credit a hospital receives for a replaced 
device. Specifically, under this modified policy, hospitals are 
required to report on the claim the amount of the credit in the amount 
portion for value code ``FD'' (Credit Received from the Manufacturer 
for a Replaced Medical Device) when the hospital receives a credit for 
a replaced device that is 50 percent or greater than the cost of the 
device. For CY 2014, we also limited the OPPS payment deduction for the 
applicable APCs to the total amount of the device offset when the 
``FD'' value code appears on a claim. For CY 2015, we continued our 
policy of reducing OPPS payment for specified APCs when a hospital 
furnishes a specified device without cost or with a full or partial 
credit and to use the three criteria established in the CY 2007 OPPS/
ASC final rule with comment period (71 FR 68072 through 68077) for 
determining the APCs to which our CY 2015 policy will apply (79 FR 
66872 through 66873). In the CY 2016 OPPS/ASC final rule with comment 
period (80 FR 70424), we finalized our policy to no longer specify a 
list of devices to which the OPPS payment adjustment for no cost/full 
credit and partial credit devices would

[[Page 58951]]

apply and instead apply this APC payment adjustment to all replaced 
devices furnished in conjunction with a procedure assigned to a device-
intensive APC when the hospital receives a credit for a replaced 
specified device that is 50 percent or greater than the cost of the 
device.
b. Policy for No Cost/Full Credit and Partial Credit Devices
    In the CY 2017 OPPS/ASC final rule with comment period (81 FR 79659 
through 79660), for CY 2017 and subsequent years, we finalized our 
policy to reduce OPPS payment for device-intensive procedures, by the 
full or partial credit a provider receives for a replaced device, when 
a hospital furnishes a specified device without cost or with a full or 
partial credit. Under our current policy, hospitals continue to be 
required to report on the claim the amount of the credit in the amount 
portion for value code ``FD'' when the hospital receives a credit for a 
replaced device that is 50 percent or greater than the cost of the 
device.
    In the CY 2019 OPPS/ASC proposed rule (83 FR 37110), for CY 2019 
and subsequent years, we proposed to apply our no cost/full credit and 
partial credit device policies to all procedures that qualify as 
device-intensive under our proposed modified criteria discussed in 
section IV.B.2. of the proposed rule and this final rule with comment 
period.
    We did not receive any public comments on this proposal. Therefore, 
we are finalizing our proposal to apply our no cost/full credit and 
partial credit device policies to all procedures that qualify as 
device-intensive under our finalized modified criteria discussed in 
section IV.B.2. of this final rule with comment period, for CY 2019 and 
subsequent years.
5. Payment Policy for Low-Volume Device-Intensive Procedures
    In CY 2016, we used our equitable adjustment authority under 
section 1833(t)(2)(E) of the Act and used the median cost (instead of 
the geometric mean cost per our standard methodology) to calculate the 
payment rate for the implantable miniature telescope procedure 
described by CPT code 0308T (Insertion of ocular telescope prosthesis 
including removal of crystalline lens or intraocular lens prosthesis), 
which is the only code assigned to APC 5494 (Level 4 Intraocular 
Procedures) (80 FR 70388). We note that, as stated in the CY 2017 OPPS/
ASC proposed rule (81 FR 45656), we proposed to reassign the procedure 
described by CPT code 0308T to APC 5495 (Level 5 Intraocular 
Procedures) for CY 2017, but it would be the only procedure code 
assigned to APC 5495. The payment rates for a procedure described by 
CPT code 0308T (including the predecessor HCPCS code C9732) were 
$15,551 in CY 2014, $23,084 in CY 2015, and $17,551 in CY 2016. The 
procedure described by CPT code 0308T is a high-cost device-intensive 
surgical procedure that has a very low volume of claims (in part 
because most of the procedures described by CPT code 0308T are 
performed in ASCs), and we believe that the median cost is a more 
appropriate measure of the central tendency for purposes of calculating 
the cost and the payment rate for this procedure because the median 
cost is impacted to a lesser degree than the geometric mean cost by 
more extreme observations. We stated that, in future rulemaking, we 
would consider proposing a general policy for the payment rate 
calculation for very low-volume device-intensive APCs (80 FR 70389).
    For CY 2017, we proposed and finalized a payment policy for low-
volume device-intensive procedures that is similar to the policy 
applied to the procedure described by CPT code 0308T in CY 2016. In the 
CY 2017 OPPS/ASC final rule with comment period (81 FR 79660 through 
79661), we established our current policy that the payment rate for any 
device-intensive procedure that is assigned to a clinical APC with 
fewer than 100 total claims for all procedures in the APC be calculated 
using the median cost instead of the geometric mean cost, for the 
reasons described above for the policy applied to the procedure 
described by CPT code 0308T in CY 2016. The CY 2018 final rule 
geometric mean cost for the procedure described by CPT code 0308T 
(based on 19 claims containing the device HCPCS C-code, in accordance 
with the device-intensive edit policy) was approximately $21,302, and 
the median cost was approximately $19,521. The final CY 2018 payment 
rate (calculated using the median cost) was approximately $17,560.
    In the CY 2019 OPPS/ASC proposed rule (83 FR 37111), for CY 2019, 
we proposed to continue with our current policy of establishing the 
payment rate for any device-intensive procedure that is assigned to a 
clinical APC with fewer than 100 total claims for all procedures in the 
APC based on calculations using the median cost instead of the 
geometric mean cost. We stated in the proposed rule that, due to the 
proposed change in APC assignment for CPT code 0308T to APC 5493 (Level 
3 Intraocular Procedures) from APC 5495 (Level 5 Intraocular 
Procedures), our payment policy for low-volume device-intensive 
procedures would not apply to CPT code 0308T for CY 2019 because there 
are now more than 100 total claims for the APC to which CPT code 0308T 
would be assigned. For more information on the proposed and final APC 
assignment change for CPT code 0308T, we refer readers to section 
III.D.13. of this final rule with comment period.
    Based on the CY 2017 claims data available for ratesetting, in the 
CY 2019 OPPS/ASC proposed rule, we proposed to assign CPT code 0308T to 
APC 5493, noting that we would continue to monitor the data. In the CY 
2019 OPPS final rule claims data, we found that the estimated cost of 
the single claim with CPT code 0308T as the primary service is 
$12,939.75. To recognize the estimated cost based on the final rule 
claims data, we have assigned CPT code 0308T to APC 5494 (Level 4 
Intraocular Procedures) for CY 2019 instead of APC 5493. Due to the 
assignment of CPT code 0308T to APC 5494 for CY 2019, our payment 
policy for low-volume device-intensive procedures will apply to CPT 
code 0308T for CY 2019 because there are less than 100 total claims for 
the APC to which CPT code 0308T is assigned. For more information on 
the proposed and final APC assignment change for CPT code 0308T, 
including a summary of public comments and our responses, we refer 
readers to section III.D.13. of this final rule with comment period.

V. OPPS Payment Changes for Drugs, Biologicals, and 
Radiopharmaceuticals

A. OPPS Transitional Pass-Through Payment for Additional Costs of 
Drugs, Biologicals, and Radiopharmaceuticals

1. Background
    Section 1833(t)(6) of the Act provides for temporary additional 
payments or ``transitional pass-through payments'' for certain drugs 
and biologicals. Throughout this final rule with comment period, the 
term ``biological'' is used because this is the term that appears in 
section 1861(t) of the Act. A ``biological'' as used in this final rule 
with comment period includes (but is not necessarily limited to) a 
``biological product'' or a ``biologic'' as defined in the Public 
Health Service Act. As enacted by the Medicare, Medicaid, and SCHIP 
Balanced Budget Refinement Act of 1999 (BBRA) (Pub. L. 106-113), this 
pass-through payment provision requires the Secretary to make 
additional payments to hospitals for: Current orphan drugs, as 
designated under section 526 of the Federal Food, Drug, and Cosmetic 
Act; current drugs

[[Page 58952]]

and biologicals and brachytherapy sources used in cancer therapy; and 
current radiopharmaceutical drugs and biologicals. ``Current'' refers 
to those types of drugs or biologicals mentioned above that are 
hospital outpatient services under Medicare Part B for which 
transitional pass-through payment was made on the first date the 
hospital OPPS was implemented.
    Transitional pass-through payments also are provided for certain 
``new'' drugs and biologicals that were not being paid for as an HOPD 
service as of December 31, 1996 and whose cost is ``not insignificant'' 
in relation to the OPPS payments for the procedures or services 
associated with the new drug or biological. For pass-through payment 
purposes, radiopharmaceuticals are included as ``drugs.'' As required 
by statute, transitional pass-through payments for a drug or biological 
described in section 1833(t)(6)(C)(i)(II) of the Act can be made for a 
period of at least 2 years, but not more than 3 years, after the 
payment was first made for the product as a hospital outpatient service 
under Medicare Part B. CY 2019 pass-through drugs and biologicals and 
their designated APCs are assigned status indicator ``G'' in Addenda A 
and B to this final rule with comment period (which are available via 
the internet on the CMS website).
    Section 1833(t)(6)(D)(i) of the Act specifies that the pass-through 
payment amount, in the case of a drug or biological, is the amount by 
which the amount determined under section 1842(o) of the Act for the 
drug or biological exceeds the portion of the otherwise applicable 
Medicare OPD fee schedule that the Secretary determines is associated 
with the drug or biological. The methodology for determining the pass-
through payment amount is set forth in regulations at 42 CFR 419.64. 
These regulations specify that the pass-through payment equals the 
amount determined under section 1842(o) of the Act minus the portion of 
the APC payment that CMS determines is associated with the drug or 
biological.
    Section 1847A of the Act establishes the average sales price (ASP) 
methodology, which is used for payment for drugs and biologicals 
described in section 1842(o)(1)(C) of the Act furnished on or after 
January 1, 2005. The ASP methodology, as applied under the OPPS, uses 
several sources of data as a basis for payment, including the ASP, the 
wholesale acquisition cost (WAC), and the average wholesale price 
(AWP). In this final rule with comment period, the term ``ASP 
methodology'' and ``ASP-based'' are inclusive of all data sources and 
methodologies described therein. Additional information on the ASP 
methodology can be found on the CMS website at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Part-B-Drugs/McrPartBDrugAvgSalesPrice/.
    The pass-through application and review process for drugs and 
biologicals is described on the CMS website at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/HospitalOutpatientPPS/passthrough_payment.html.
2. Three-Year Transitional Pass-Through Payment Period for All Pass-
Through Drugs, Biologicals, and Radiopharmaceuticals and Quarterly 
Expiration of Pass-Through Status
    As required by statute, transitional pass-through payments for a 
drug or biological described in section 1833(t)(6)(C)(i)(II) of the Act 
can be made for a period of at least 2 years, but not more than 3 
years, after the payment was first made for the product as a hospital 
outpatient service under Medicare Part B. Our current policy is to 
accept pass-through applications on a quarterly basis and to begin 
pass-through payments for newly approved pass-through drugs and 
biologicals on a quarterly basis through the next available OPPS 
quarterly update after the approval of a product's pass-through status. 
However, prior to CY 2017, we expired pass-through status for drugs and 
biologicals on an annual basis through notice-and-comment rulemaking 
(74 FR 60480). In the CY 2017 OPPS/ASC final rule with comment period 
(81 FR 79662), we finalized a policy change, beginning with pass-
through drugs and biologicals newly approved in CY 2017 and subsequent 
calendar years, to allow for a quarterly expiration of pass-through 
payment status for drugs, biologicals, and radiopharmaceuticals to 
afford a pass-through payment period that is as close to a full 3 years 
as possible for all pass-through drugs, biologicals, and 
radiopharmaceuticals.
    This change eliminated the variability of the pass-through payment 
eligibility period, which previously varied based on when a particular 
application was initially received. We adopted this change for pass-
through approvals beginning on or after CY 2017, to allow, on a 
prospective basis, for the maximum pass-through payment period for each 
pass-through drug without exceeding the statutory limit of 3 years.
3. Drugs and Biologicals With Expiring Pass-Through Payment Status in 
CY 2018
    In the CY 2019 OPPS/ASC proposed rule (83 FR 37112), we proposed 
that the pass-through payment status of 23 drugs and biologicals would 
expire on December 31, 2018, as listed in Table 19 of the proposed rule 
(83 FR 37112). All of these drugs and biologicals will have received 
OPPS pass-through payment for at least 2 years and no more than 3 years 
by December 31, 2018. These drugs and biologicals were approved for 
pass-through payment status on or before January 1, 2017. In accordance 
with the policy finalized in CY 2017 and described earlier, pass-
through payment status for drugs and biologicals newly approved in CY 
2017 and subsequent years will expire on a quarterly basis, with a 
pass-through payment period as close to 3 years as possible. With the 
exception of those groups of drugs and biologicals that are always 
packaged when they do not have pass-through payment status 
(specifically, anesthesia drugs; drugs, biologicals, and 
radiopharmaceuticals that function as supplies when used in a 
diagnostic test or procedure (including diagnostic 
radiopharmaceuticals, contrast agents, and stress agents); and drugs 
and biologicals that function as supplies when used in a surgical 
procedure), our standard methodology for providing payment for drugs 
and biologicals with expiring pass-through payment status in an 
upcoming calendar year is to determine the product's estimated per day 
cost and compare it with the OPPS drug packaging threshold for that 
calendar year (which is $125 for CY 2019), as discussed further in 
section V.B.2. of this final rule with comment period. In the CY 2019 
OPPS/ASC proposed rule (83 FR 37112), we proposed that if the estimated 
per day cost for the drug or biological is less than or equal to the 
applicable OPPS drug packaging threshold, we would package payment for 
the drug or biological into the payment for the associated procedure in 
the upcoming calendar year. If the estimated per day cost of the drug 
or biological is greater than the OPPS drug packaging threshold, we 
proposed to provide separate payment at the applicable relative ASP-
based payment amount (which was proposed at ASP+6 percent for CY 2019, 
and is finalized at ASP+6 percent for CY 2019, as discussed further in 
section V.B.3. of this final rule with comment period).
    Comment: A number of commenters requested that pass-through payment 
status for HCPCS code A9515 (Choline

[[Page 58953]]

c-11, diagnostic, per study dose up to 20 millicuries) be extended 
until March 2019 to give 3 full years of pass-through payment status 
for the drug. The drug described by HCPCS code A9515 received pass-
through status in April 2016, and in the CY 2019 OPPS/ASC proposed 
rule, the pass-through payment period for the drug was scheduled to end 
on December 31, 2018, consistent with the policy in effect in CY 2016 
that drugs and biologicals receive at least 2 years but no more than 3 
years of pass-through payment status where pass-through payment status 
for drugs and biologicals was expired on an annual basis through 
notice-and-comment rulemaking. One commenter requested an extension of 
pass-through payment status to allow for the collection of more cost 
data for HCPCS code A9515. Another commenter believed pass-through 
payment status for HCPCS code A9515 should be extended because of 
concern that the cost of HCPCS code A9515 exceeds the payment rate for 
the nuclear medicine services with which HCPCS code A9515 will be 
packaged. The commenter cited data showing the pass-through payment 
rate for HCPCS code A9515 was $5,700, while the highest APC payment 
rate for a nuclear medicine service was $1,377.22 with a drug offset of 
$248.31. Two commenters also requested that HCPCS codes Q9982 
(Flutemetamol f18, diagnostic, per study dose, up to 5 millicuries) and 
Q9983 (Florbetaben f18, diagnostic, per study dose, up to 8.1 
millicuries) not be taken off of pass-through payment status due to 
similar concerns.
    Response: As noted in the proposed rule, all three 
radiopharmaceuticals are covered under the pass-through payment 
expiration policy in effect in CY 2016 which stated that drugs and 
biologicals receive at least 2 years and no more than 3 years of pass-
through payment status, with the pass-through payment period expiring 
at the end of a calendar year. Beginning with pass-through drugs and 
biologicals newly approved in CY 2017 and subsequent calendar years, a 
new policy is in effect to allow for a quarterly expiration of pass-
through payment status for drugs and biologicals to afford a pass-
through payment period that is as close to a full 3 years as possible 
for all pass-through drugs, biologicals, and radiopharmaceuticals (82 
FR 59337). HCPCS codes A9515, Q9982, and Q9983 are covered by the 
policy in effect for CY 2016, and pass-through payment status for these 
HCPCS codes will end on December 31, 2018. We note that when a 
radiopharmaceutical or other drug or biological is newly packaged into 
a related medical procedure, the amount of the payment rate for the 
related medical procedure does not stay the same. Instead, the payment 
rate for the medical procedure will be adjusted to reflect the 
additional cost of the newly packaged radiopharmaceutical in the 
overall cost of the medical procedure.
    Comment: Some commenters recommended that CMS allow products 
covered by Medicare in the context of a coverage with evidence 
development (CED) clinical trial to retain their pass-through payment 
status for the duration of the CED trial. Two of the commenters focused 
on the packaging of diagnostic radiopharmaceuticals that do not have 
pass-through payment status. One of the commenters requested that pass-
through payment status for Neuraceq^TM (florbetaben F18, 
HCPCS code Q9982) and Vizamyl^TM (flutemetamol F18, HCPCS 
code Q9983), which is scheduled to end on December 31, 2018, be 
extended because of a current CED trial for amyloid positron emission 
tomography (PET) that will be active through at least CY 2019. 
(Information on this CED trial can be found on the CMS website at 
https://www.cms.gov/Medicare/Coverage/Coverage-with-Evidence-Development/Amyloid-PET.html). This commenter also suggested that if 
pass-through payment status is not extended, these drugs could be paid 
separately under their own assigned APCs to avoid having the cost of 
these drugs packaged into the primary procedures for which they are 
used. Another commenter was more broadly concerned about not receiving 
payment for a drug or biological when a CED trial is ongoing and a drug 
or biological used in the trial loses pass-through payment status and 
becomes packaged. The commenters were concerned that ending pass-
through payment for drugs that will no longer be paid separately could 
negatively impact CED trials as hospitals would be less likely to 
participate because of the risk of receiving lower payment for the 
services covered by the CED trial.
    Response: We disagree with the commenters' concern that expiration 
of pass-through payment status for Neuraceq^TM (HCPCS code 
Q9982) and Vizamyl^TM (HCPCS code Q9983), and subsequent 
packaging of them as ``policy-packaged'' drugs, will affect trial 
results. We note that hospitals are not precluded from billing for 
Neuraceq^TM and Vizamyl^TM in the context of a CED 
trial once their pass-through payment status expires. We also note that 
the payment for both Neuraceq^TM and Vizamyl^TM 
will be reflected in the payment rate for the associated procedure. 
With respect to the request that we create a new APC for 
Neuraceq^TM and Vizamyl^TM, we do not believe it is 
appropriate, prudent, or practicable to create unique APCs for specific 
drugs or biologicals or other individual items that are furnished with 
a particular procedure or procedures. Finally, with respect to the 
commenters' request that we allow drug or biological pass-through 
payment status for products covered by a CED trial for the duration of 
the CED trial, we reiterate that the statute limits the period of pass-
through payment eligibility to no more than 3 years after the product's 
first payment as a hospital outpatient service under Medicare Part B. 
As such, we are unable to extend pass-through payment status beyond 3 
years.
    After consideration of the public comments we received, we are 
finalizing our proposal, without modification, to expire the pass-
through payment status of the 23 drugs and biologicals listed in Table 
37 below on December 31, 2018.
BILLING CODE 4120-01-P

[[Page 58954]]

[GRAPHIC] [TIFF OMITTED] TR21NO18.056

    The final packaged or separately payable status of each of these 
drugs or biologicals is listed in Addendum B to this final rule with 
comment period (which is available via the internet on the CMS 
website).
4. Drugs, Biologicals, and Radiopharmaceuticals With New or Continuing 
Pass-Through Payment Status in CY 2019
    In the CY 2019 OPPS/ASC proposed rule (83 FR 37112), we proposed to 
continue pass-through payment status in CY 2019 for 45 drugs and 
biologicals. These drugs and biologicals, which were approved for pass-
through payment status between January 1, 2017, and July 1, 2018, were 
listed in Table 20 of the proposed rule (83 FR 37113 through 37114). 
The APCs and HCPCS codes for these drugs and biologicals approved for 
pass-through

[[Page 58955]]

payment status through December 31, 2018 were assigned status indicator 
``G'' in Addenda A and B to the proposed rule (which are available via 
the internet on the CMS website). In addition, as indicated in the 
proposed rule, there are four drugs and biologicals that have already 
had 3 years of pass-through payment status but for which pass-through 
payment status is required to be extended for an additional 2 years 
under section 1833(t)(6)(G) of the Act, as added by section 
1301(a)(1)(C) of the Consolidated Appropriations Act of 2018 (Pub. L. 
115-141). Because of this requirement, these drugs and biologicals were 
also included in Table 20 of the proposed rule, which brought the total 
number of drugs and biologicals with proposed pass-through payment 
status in CY 2019 to 49. The requirements of section 1301 of Public Law 
115-141 are described in further detail in section V.A.5. of this final 
rule with comment period, and we address public comments that we 
received related to this topic in that section.
    Section 1833(t)(6)(D)(i) of the Act sets the amount of pass-through 
payment for pass-through drugs and biologicals (the pass-through 
payment amount) as the difference between the amount authorized under 
section 1842(o) of the Act and the portion of the otherwise applicable 
OPD fee schedule that the Secretary determines is associated with the 
drug or biological. For CY 2019, we proposed to continue to pay for 
pass-through drugs and biologicals at ASP+6 percent, equivalent to the 
payment rate these drugs and biologicals would receive in the 
physician's office setting in CY 2019. We proposed that a $0 pass-
through payment amount would be paid for pass-through drugs and 
biologicals under the CY 2019 OPPS because the difference between the 
amount authorized under section 1842(o) of the Act, which was proposed 
at ASP+6 percent, and the portion of the otherwise applicable OPD fee 
schedule that the Secretary determines is appropriate, which was 
proposed at ASP+6 percent, is $0.
    In the case of policy-packaged drugs (which include the following: 
Anesthesia drugs; drugs, biologicals, and radiopharmaceuticals that 
function as supplies when used in a diagnostic test or procedure 
(including contrast agents, diagnostic radiopharmaceuticals, and stress 
agents); and drugs and biologicals that function as supplies when used 
in a surgical procedure), we proposed that their pass-through payment 
amount would be equal to ASP+6 percent for CY 2019 minus a payment 
offset for any predecessor drug products contributing to the pass-
through payment as described in section V.A.6. of the proposed rule. We 
made this proposal because, if not for the pass-through payment status 
of these policy-packaged products, payment for these products would be 
packaged into the associated procedure.
    We proposed to continue to update pass-through payment rates on a 
quarterly basis on the CMS website during CY 2019 if later quarter ASP 
submissions (or more recent WAC or AWP information, as applicable) 
indicate that adjustments to the payment rates for these pass-through 
payment drugs or biologicals are necessary. For a full description of 
this policy, we refer readers to the CY 2006 OPPS/ASC final rule with 
comment period (70 FR 68632 through 68635).
    For CY 2019, consistent with our CY 2018 policy for diagnostic and 
therapeutic radiopharmaceuticals, we proposed to provide payment for 
both diagnostic and therapeutic radiopharmaceuticals that are granted 
pass-through payment status based on the ASP methodology. As stated 
earlier, for purposes of pass-through payment, we consider 
radiopharmaceuticals to be drugs under the OPPS. Therefore, if a 
diagnostic or therapeutic radiopharmaceutical receives pass-through 
payment status during CY 2019, we proposed to follow the standard ASP 
methodology to determine the pass-through payment rate that drugs 
receive under section 1842(o) of the Act, which was proposed at ASP+6 
percent. If ASP data are not available for a radiopharmaceutical, we 
proposed to provide pass-through payment at WAC+3 percent (consistent 
with our proposed policy in section V.B.2.b. of the proposed rule), the 
equivalent payment provided to pass-through payment drugs and 
biologicals without ASP information. Additional detail and comments on 
the WAC+3 percent payment policy can be found in section V.B.2.b. of 
this final rule. If WAC information also is not available, we proposed 
to provide payment for the pass-through radiopharmaceutical at 95 
percent of its most recent AWP.
    We did not receive any public comments regarding our proposals. 
Therefore, we are implementing these proposals for CY 2019 without 
modification. We note that public comments pertaining to our proposal 
to pay WAC+3 percent for drugs and biologicals without ASP information 
as well as public comments on section 1301 pass-through payment status 
extensions are addressed elsewhere in this final rule with comment 
period.
    The drugs and biologicals that continue to have pass-through 
payment status for CY 2019 or have been granted pass-through payment 
status as of January 2019 are shown in Table 38 below.

[[Page 58956]]

[GRAPHIC] [TIFF OMITTED] TR21NO18.057


[[Page 58957]]


[GRAPHIC] [TIFF OMITTED] TR21NO18.058


[[Page 58958]]


[GRAPHIC] [TIFF OMITTED] TR21NO18.059


[[Page 58959]]


[GRAPHIC] [TIFF OMITTED] TR21NO18.060


[[Page 58960]]


[GRAPHIC] [TIFF OMITTED] TR21NO18.061

BILLING CODE 4120-01-C
5. Drugs, Biologicals, and Radiopharmaceuticals With Pass-Through 
Status as a Result of Section 1301 of the Consolidated Appropriations 
Act of 2018 (Pub. L. 115-141)
    As mentioned earlier, section 1301(a)(1) of the Consolidated 
Appropriations Act of 2018 (Pub. L. 115-141) amended section 1833(t)(6) 
of the Act and added a new section 1833(t)(6)(G), which provides that 
for drugs or biologicals whose period of pass-through payment status 
ended on December 31, 2017 and for which payment was packaged into a 
covered hospital outpatient service furnished beginning January 1, 
2018, such pass-through payment status shall be extended for a 2-year 
period beginning on October 1, 2018 through September 30, 2020. There 
are four products whose period of drug and biological pass-through 
payment status ended on December 31, 2017. These products were listed 
in Table 21 of the CY 2019 OPPS/ASC proposed rule (83 FR 37115). For CY 
2019, we proposed to continue pass-through payment status for the drugs 
and biologicals listed in Table 21 of the proposed rule (we note that 
these drugs and biologicals were also listed in Table 20 of the 
proposed rule). The APCs and HCPCS codes for these drugs and 
biologicals approved for pass-through payment status were assigned 
status indicator ``G'' in Addenda A and B to the proposed rule (which 
are available via the internet on the CMS website).
    In addition, new section 1833(t)(6)(H) of the Act specifies that 
the payment amount for such drug or biological under this subsection 
that is furnished during the period beginning on October 1, 2018, and 
ending on March 31, 2019, shall be the greater of: (i) The payment 
amount that would otherwise apply under section 1833(t)(6)(D)(i) of the 
Act for such drug or biological during such period; or (ii) the payment 
amount that applied under section 1833(t)(6)(D)(i) of the Act for such 
drug or biological on December 31, 2017. We stated in the proposed rule 
that we intended to address pass-through payment for these drugs and 
biologicals for the last quarter of CY 2018 through program 
instruction. The program instruction covering pass-through payment for 
these drugs and biologicals for the last quarter of CY 2018 is 
Transmittal 4123 titled ``October 2018 Update of the Hospital 
Outpatient Prospective Payment System (OPPS)'', and can be found on the 
CMS website at: https://www.cms.gov/Regulations-and-Guidance/Guidance/
Transmittals/

[[Page 58961]]

2018Downloads/R4123CP.pdf. For January 1, 2019 through March 31, 2019, 
we proposed that pass-through payment for these four drugs and 
biologicals would be the greater of: (1) ASP+6 percent based on current 
ASP data; or (2) the payment rate for the drug or biological on 
December 31, 2017. We also proposed for the period of April 1, 2019 
through December 31, 2019 that the pass-through payment amount for 
these drugs and biologicals would be the amount that applies under 
section 1833(t)(6)(D)(i) of the Act.
    We proposed to continue to update pass-through payment rates for 
these four drugs and biologicals on a quarterly basis on the CMS 
website during CY 2019 if later quarter ASP submissions (or more recent 
WAC or AWP information, as applicable) indicate that adjustments to the 
payment rates for these pass-through drugs or biologicals are 
necessary. For a full description of this policy, we refer readers to 
the CY 2006 OPPS/ASC final rule with comment period (70 FR 68632 
through 68635).
    The four drugs and biologicals that we proposed would have pass-
through payment status for CY 2019 under section 1833(t)(6)(G) of the 
Act, as added by section 1301(a)(1)(C) of the Consolidated 
Appropriations Act of 2018, were shown in Table 21 of the CY 2019 OPPS/
ASC proposed rule (83 FR 37115). Included as one of the four drugs and 
biologicals with pass-through payment status for CY 2019 is HCPCS code 
Q4172 (Puraply, and Puraply AM per square centimeter). PuraPly is a 
skin substitute product that was approved for pass-through payment 
status on January 1, 2015 through the drug and biological pass-through 
payment process. Beginning on April 1, 2015, skin substitute products 
are evaluated for pass-through payment status through the device pass-
through payment process. However, we stated in the CY 2015 OPPS/ASC 
final rule with comment period (79 FR 66887) that skin substitutes that 
are approved for pass-through payment status as biologicals effective 
on or before January 1, 2015 would continue to be paid as pass-through 
biologicals for the duration of their pass-through payment period. 
Because PuraPly was approved for pass-through payment status through 
the drug and biological pass-through payment pathway, we proposed to 
consider PuraPly to be a drug or biological as described by section 
1833(t)(6)(G) of the Act, as added by section 1301(a)(1)(C) of the 
Consolidated Appropriations Act of 2018, and to be eligible for 
extended pass-through payment under our proposal for CY 2019.
    Comment: Several commenters were opposed to PuraPly and PuraPly AM 
receiving pass-through payment status for CY 2019. These commenters 
stated that because PuraPly and PuraPly AM received a 510(k) clearance 
from the FDA, PuraPly and PuraPly AM should be considered devices 
rather than drugs or biologicals or that there is at least some 
ambiguity about whether PuraPly and PuraPly AM are devices. The 
commenters encouraged CMS to use its discretion and consider PuraPly 
and PuraPly AM to be devices along the same lines of reasoning as CMS 
has considered biologicals used as skin substitutes to be considered 
devices for the purposes of receiving pass-through payment since April 
2015. In addition, the commenters noted that PuraPly and PuraPly AM 
should not have pass-through payment status extended because they are 
no longer new products. Further, the commenters noted that these 
products would receive a significant market advantage by being the only 
graft skin substitute product to receive separate payment. Other 
commenters noted that extending the pass-through payment status of 
PuraPly and PuraPly AM would work against the goals CMS has stated in 
other parts of the proposed rule regarding skin substitute payment. 
Finally, these commenters maintained that extending pass-through 
payment status would encourage the use of more high-cost skin 
substitute products and lead to increased pricing instability by 
increasing the cost thresholds for the high-cost skin substitute group. 
Another commenter opposed extending pass-through payment status for 
PuraPly and PuraPly AM based on the belief that the manufacturer of 
these products may be unfairly increasing the prices for these products 
when they return to pass-through payment status.
    Response: In the CY 2015 OPPS/ASC final rule with comment period 
(79 FR 66887), we stated that skin substitutes that are approved for 
pass-through payment status as biologicals effective on or before 
January 1, 2015 would continue to be paid as pass-through biologicals 
for the duration of their pass-through payment period. PuraPly and 
PuraPly AM were originally approved for pass-through payment status on 
January 1, 2015 under the drug and biological pass-through payment 
pathway as biologicals. We interpret section 1833(t)(6)(G) of the Act, 
as added by section 1301(a)(1)(C) of the Consolidated Appropriations 
Act of 2018, as extending the original pass-through payment period that 
was established for PuraPly and PuraPly AM on January 1, 2015, and 
therefore, PuraPly and PuraPly AM will continue to be paid as pass-
through drugs and biologicals. While we acknowledge the comments 
pointing out that we currently treat skin substitute products as 
devices for purposes of pass-through payment status, this does not 
change the fact that PuraPly and PuraPly AM were originally approved 
for pass-through payments as biologicals. We believe that PuraPly and 
PuraPly AM's original approval for pass-through status as biologicals 
means that they should continue to receive pass-through payments under 
section 1833(t)(6)(G) of the Act.
    We also recognize that the commenters raised important concerns 
about the impact that extending pass-through payment status for PuraPly 
and PuraPly AM could have on the payment of wound care services using 
graft skin substitute products. However, we nonetheless believe that 
section 1833(t)(6)(G) of the Act requires us to extend the pass-through 
payment period for PuraPly and PuraPly AM.
    Comment: One commenter, the manufacturer of PuraPly and PuraPly AM, 
urged CMS to implement the proposal to give PuraPly and PuraPly AM 
pass-through payment status based on the requirements of section 
1833(t)(6)(G) of the Act, as added by section 1301(a)(1)(C) of the 
Consolidated Appropriations Act of 2018. The commenter stated that 
PuraPly and PuraPly AM are biologicals and cited language in OPPS 
regulations supporting that designation. The commenter also made the 
point that the pass-through payment status granted to PuraPly and 
PuraPly AM starting on October 1, 2018 was described in the statute as 
an extension of the original pass-through payment status and not a new 
pass-through payment period. The commenter stated that this means the 
requirements in effect when pass-through payment status for PuraPly and 
PuraPly AM was established on January 1, 2015 apply to the extended 
pass-through payment period. The commenter noted that CMS changed how 
skin substitute products are evaluated for pass-through payment status 
by evaluating skin substitutes through the medical device pass-through 
pathway in April of 2015, but emphasized that the change was not 
retroactive. Therefore, the commenter agreed that PuraPly and PuraPly 
AM should continue to receive pass-through payment status.
    Several members of Congress supported extending pass-through 
payment status for PuraPly and PuraPly

[[Page 58962]]

AM and requested that CMS consider the products to be biologicals that 
are covered by section 1833(t)(6)(G) of the Act, as added by section 
1301(a)(1)(C) of the Consolidated Appropriations Act of 2018.
    Response: We appreciate the commenters' support. We are finalizing 
our proposal to extend pass-through payment status for PuraPly and 
PuraPly AM based on section 1833(t)(6)(G) of the Act, as added by 
section 1301(a)(1)(C) of the Consolidated Appropriations Act of 2018.
    Comment: One commenter, the manufacturer of Omidria (HCPCS code 
C9447), supported the extended pass-through payment status for Omidria. 
Likewise, a second commenter, the manufacturer of Lumason[supreg] 
(HCPCS code Q9950), supported the extended pass-through payment status 
for Lumason[supreg].
    Response: We appreciate the commenters' support.
    After consideration of the public comments we received, we are 
finalizing our proposals, with modification, to accommodate a coding 
change related to the PuraPly products. Specifically, after the 
proposed rule was published, we became aware that HCPCS code Q4172 
(Puraply, and Puraply AM per square centimeter) will be deleted 
effective January 1, 2019, and will be replaced by three new HCPCS 
codes: Q4195 (Puraply, per square centimeter); Q4196 (Puraply am, per 
square centimeter); and Q4197 (Puraply xt, per square centimeter), 
effective January 1, 2019. Two of these products, PuraPly (HCPCS code 
Q4195) and PuraPly AM (HCPCS code Q4196), were products that received 
original pass-through payment status on January 1, 2015, and will 
continue to receive pass-through payment status in CY 2019 when our 
finalized policies are implemented.
    For January 1, 2019 through March 31, 2019, we are finalizing our 
proposal that pass-through payment for the covered drugs and 
biologicals will be the greater of: (1) ASP+6 percent based on current 
ASP data; or (2) the payment rate for the drug or biological on 
December 31, 2017. We also are finalizing our proposal that the pass-
through payment amount for these drugs and biologicals will be the 
amount that applies under section 1833(t)(6)(D)(i) of the Act for the 
period of April 1, 2019 through December 31, 2019.
    We are finalizing our proposal to continue to update pass-through 
payment rates for these covered drugs and biologicals on a quarterly 
basis on the CMS website during CY 2019 if later quarter ASP 
submissions (or more recent WAC or AWP information, as applicable) 
indicate that adjustments to the payment rates for these pass-through 
drugs or biologicals are necessary. We refer readers to Table 39 below 
for the drugs and biologicals covered by the requirements of this 
section.
[GRAPHIC] [TIFF OMITTED] TR21NO18.062

6. Provisions for Reducing Transitional Pass-Through Payments for 
Policy-Packaged Drugs, Biologicals, and Radiopharmaceuticals To Offset 
Costs Packaged Into APC Groups
    Under the regulations at 42 CFR 419.2(b), nonpass-through drugs, 
biologicals, and radiopharmaceuticals that function as supplies when 
used in a diagnostic test or procedure are packaged in the OPPS. This 
category includes diagnostic radiopharmaceuticals, contrast agents, 
stress agents, and other diagnostic drugs. Also under 42 CFR 419.2(b), 
nonpass-through drugs and biologicals that function as supplies in a 
surgical procedure are packaged in the OPPS. This category includes 
skin substitutes and other surgical-supply drugs and biologicals. As 
described earlier, section 1833(t)(6)(D)(i) of the Act specifies that 
the transitional pass-through payment amount for pass-through drugs and 
biologicals is the difference between the amount paid under section 
1842(o) of the Act and the otherwise applicable OPD fee schedule 
amount. Because a payment offset is necessary in order to provide an 
appropriate transitional pass-through payment, we deduct from the pass-
through payment for policy-packaged drugs, biologicals, and 
radiopharmaceuticals an amount reflecting the portion of the APC 
payment associated with predecessor products in order to ensure no 
duplicate payment is made. This amount reflecting the portion of the 
APC payment associated with predecessor products is called the payment 
offset.
    The payment offset policy applies to all policy packaged drugs, 
biologicals, and radiopharmaceuticals. For a full

[[Page 58963]]

description of the payment offset policy as applied to diagnostic 
radiopharmaceuticals, contrast agents, stress agents, and skin 
substitutes, we refer readers to the discussion in the CY 2016 OPPS/ASC 
final rule with comment period (80 FR 70430 through 70432). In the CY 
2019 OPPS/ASC proposed rule (83 FR 37115), for CY 2019, as we did in CY 
2018, we proposed to continue to apply the same policy packaged offset 
policy to payment for pass-through diagnostic radiopharmaceuticals, 
pass-through contrast agents, pass-through stress agents, and pass-
through skin substitutes. The proposed APCs to which a payment offset 
may be applicable for pass-through diagnostic radiopharmaceuticals, 
pass-through contrast agents, pass-through stress agents, and pass-
through skin substitutes were identified in Table 22 of the proposed 
rule (83 FR 37115).
    We did not receive any comments on this proposal. Therefore, we are 
finalizing this proposal without modification.
[GRAPHIC] [TIFF OMITTED] TR21NO18.063

    In the CY 2019 OPPS/ASC proposed rule, we proposed to continue to 
post annually on the CMS website at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/HospitalOutpatientPPS/Annual-Policy-Files.html a file that contains the APC offset amounts that will be 
used for that year for purposes of both evaluating cost significance 
for candidate pass-through payment device categories and drugs and 
biologicals and establishing any appropriate APC offset amounts. 
Specifically, the file will continue to provide the amounts and 
percentages of APC payment associated with packaged implantable 
devices, policy-packaged drugs, and threshold packaged drugs and 
biologicals for every OPPS clinical APC. We did not receive any public 
comments on our proposal, and therefore are finalizing it without 
modification.

B. OPPS Payment for Drugs, Biologicals, and Radiopharmaceuticals 
Without Pass-Through Payment Status

1. Criteria for Packaging Payment for Drugs, Biologicals, and 
Radiopharmaceuticals
a. Packaging Threshold
    In accordance with section 1833(t)(16)(B) of the Act, the threshold 
for establishing separate APCs for payment of drugs and biologicals was 
set to $50 per administration during CYs 2005 and 2006. In CY 2007, we 
used the four quarter moving average Producer Price Index (PPI) levels 
for Pharmaceutical Preparations (Prescription) to trend the $50 
threshold forward from the third quarter of CY 2005 (when the Pub. L. 
108-173 mandated threshold became effective) to the third quarter of CY 
2007. We then rounded the resulting dollar amount to the nearest $5 
increment in order to determine the CY 2007 threshold amount of $55. 
Using the same methodology as that used in CY 2007 (which is discussed 
in more detail in the CY 2007 OPPS/ASC final rule with comment period 
(71 FR 68085 through 68086)), we set the packaging threshold for 
establishing separate APCs for drugs and biologicals at $120 for CY 
2018 (82 FR 59343).
    Following the CY 2007 methodology, for this CY 2019 OPPS/ASC final 
rule with comment period, we used the most recently available four 
quarter moving average PPI levels to trend the $50 threshold forward 
from the third quarter of CY 2005 to the third quarter of CY 2019 and 
rounded the resulting dollar amount ($127.01) to the nearest $5 
increment, which yielded a figure of $125. In performing this 
calculation, we used the most recent forecast of the quarterly index 
levels for the PPI for Pharmaceuticals for Human Use (Prescription) 
(Bureau of Labor Statistics series code WPUSI07003) from CMS' Office of 
the Actuary. For this CY 2019 OPPS/ASC final rule with comment period, 
based on these calculations using the CY 2007 OPPS methodology,

[[Page 58964]]

we are finalizing a packaging threshold for CY 2019 of $125.
b. Packaging of Payment for HCPCS Codes That Describe Certain Drugs, 
Certain Biologicals, and Therapeutic Radiopharmaceuticals Under the 
Cost Threshold (``Threshold-Packaged Drugs'')
    In the CY 2019 OPPS/ASC proposed rule (83 FR 37116), to determine 
the proposed CY 2019 packaging status for all nonpass-through drugs and 
biologicals that are not policy packaged, we calculated, on a HCPCS 
code-specific basis, the per day cost of all drugs, biologicals, and 
therapeutic radiopharmaceuticals (collectively called ``threshold-
packaged'' drugs) that had a HCPCS code in CY 2017 and were paid (via 
packaged or separate payment) under the OPPS. We used data from CY 2017 
claims processed before January 1, 2018 for this calculation. However, 
we did not perform this calculation for those drugs and biologicals 
with multiple HCPCS codes that include different dosages, as described 
in section V.B.1.d. of the proposed rule, or for the following policy-
packaged items that we proposed to continue to package in CY 2019: 
Anesthesia drugs; drugs, biologicals, and radiopharmaceuticals that 
function as supplies when used in a diagnostic test or procedure; and 
drugs and biologicals that function as supplies when used in a surgical 
procedure.
    In order to calculate the per day costs for drugs, biologicals, and 
therapeutic radiopharmaceuticals to determine their proposed packaging 
status in CY 2019, we used the methodology that was described in detail 
in the CY 2006 OPPS proposed rule (70 FR 42723 through 42724) and 
finalized in the CY 2006 OPPS final rule with comment period (70 FR 
68636 through 68638). For each drug and biological HCPCS code, we used 
an estimated payment rate of ASP+6 percent (which is the payment rate 
we proposed for separately payable drugs and biologicals for CY 2019, 
as discussed in more detail in section V.B.2.b. of the proposed rule) 
to calculate the CY 2019 proposed rule per day costs. We used the 
manufacturer-submitted ASP data from the fourth quarter of CY 2017 
(data that were used for payment purposes in the physician's office 
setting, effective April 1, 2018) to determine the proposed rule per 
day cost.
    As is our standard methodology, for CY 2019, we proposed to use 
payment rates based on the ASP data from the first quarter of CY 2018 
for budget neutrality estimates, packaging determinations, impact 
analyses, and completion of Addenda A and B to the proposed rule (which 
are available via the internet on the CMS website) because these were 
the most recent data available for use at the time of development of 
the proposed rule. These data also were the basis for drug payments in 
the physician's office setting, effective April 1, 2018. For items that 
did not have an ASP-based payment rate, such as some therapeutic 
radiopharmaceuticals, we used their mean unit cost derived from the CY 
2017 hospital claims data to determine their per day cost.
    We proposed to package items with a per day cost less than or equal 
to $125, and identify items with a per day cost greater than $125 as 
separately payable unless they are policy-packaged. Consistent with our 
past practice, we cross-walked historical OPPS claims data from the CY 
2017 HCPCS codes that were reported to the CY 2018 HCPCS codes that we 
displayed in Addendum B to the proposed rule (which is available via 
the internet on the CMS website) for proposed payment in CY 2019.
    Comment: A few commenters requested that CMS not finalize the 
proposed increase to the packaging threshold to $125 and suggested that 
CMS instead lower the packaging threshold. These commenters expressed 
concern with the annual increases in the drug packaging threshold, 
citing that yearly increases have outpaced conversion factor updates 
and place a financial burden on providers.
    Response: We have received and addressed similar comments in prior 
rules, including most recently in the CY 2017 OPPS/ASC final rule with 
comment period (81 FR 79666). As we stated in the CY 2007 OPPS/ASC 
final rule with comment period (71 FR 68086), we believe that packaging 
certain items is a fundamental component of a prospective payment 
system, that updating the packaging threshold of $50 for the CY 2005 
OPPS is consistent with industry and government practices, and that the 
PPI for Prescription Drugs is an appropriate mechanism to gauge Part B 
drug inflation. Therefore, because packaging is a fundamental component 
of a prospective payment system that continues to provide important 
flexibility and efficiency in the delivery of high quality hospital 
outpatient services, we are not adopting the commenters' recommendation 
to delay updating the packaging threshold or freeze the packaging 
threshold at $120.
    After consideration of the public comments we received, and 
consistent with our methodology for establishing the packaging 
threshold using the most recent PPI forecast data, we are adopting a CY 
2019 packaging threshold of $125.
    Our policy during previous cycles of the OPPS has been to use 
updated ASP and claims data to make final determinations of the 
packaging status of HCPCS codes for drugs, biologicals, and therapeutic 
radiopharmaceuticals for the OPPS/ASC final rule with comment period. 
We note that it is also our policy to make an annual packaging 
determination for a HCPCS code only when we develop the OPPS/ASC final 
rule with comment period for the update year. Only HCPCS codes that are 
identified as separately payable in the final rule with comment period 
are subject to quarterly updates. For our calculation of per day costs 
of HCPCS codes for drugs and biologicals in this CY 2019 OPPS/ASC final 
rule with comment period, we used ASP data from the third quarter of CY 
2018, which is the basis for calculating payment rates for drugs and 
biologicals in the physician's office setting using the ASP 
methodology, effective July 1, 2018, along with updated hospital claims 
data from CY 2017. We note that we also used these data for budget 
neutrality estimates and impact analyses for this CY 2019 OPPS/ASC 
final rule with comment period.
    Payment rates for HCPCS codes for separately payable drugs and 
biologicals included in Addenda A and B for this final rule with 
comment period are based on ASP data from the third quarter of CY 2018. 
These data are the basis for calculating payment rates for drugs and 
biologicals in the physician's office setting using the ASP 
methodology, effective October 1, 2018. These payment rates will then 
be updated in the January 2019 OPPS update, based on the most recent 
ASP data to be used for physician's office and OPPS payment as of 
January 1, 2019. For items that do not currently have an ASP-based 
payment rate, we proposed to recalculate their mean unit cost from all 
of the CY 2017 claims data and updated cost report information 
available for this CY 2019 final rule with comment period to determine 
their final per day cost.
    Consequently, as stated in the CY 2019 OPPS/ASC proposed rule (83 
FR 37117), the packaging status of some HCPCS codes for drugs, 
biologicals, and therapeutic radiopharmaceuticals in the proposed rule 
may be different from the same drug HCPCS code's packaging status 
determined based on the data used for this final rule with comment 
period. Under such circumstances, in the CY 2019 OPPS/ASC proposed rule 
(83 FR 37117), we proposed to continue to follow the established 
policies

[[Page 58965]]

initially adopted for the CY 2005 OPPS (69 FR 65780) in order to more 
equitably pay for those drugs whose costs fluctuate relative to the 
proposed CY 2019 OPPS drug packaging threshold and the drug's payment 
status (packaged or separately payable) in CY 2018. These established 
policies have not changed for many years and are the same as described 
in the CY 2016 OPPS/ASC final rule with comment period (80 FR 70434). 
Specifically, for CY 2019, consistent with our historical practice, we 
proposed to apply the following policies to these HCPCS codes for 
drugs, biologicals, and therapeutic radiopharmaceuticals whose 
relationship to the drug packaging threshold changes based on the 
updated drug packaging threshold and on the final updated data:
     HCPCS codes for drugs and biologicals that were paid 
separately in CY 2018 and that were proposed for separate payment in CY 
2019, and that then have per day costs equal to or less than the CY 
2019 final rule drug packaging threshold, based on the updated ASPs and 
hospital claims data used for this CY 2019 final rule, would continue 
to receive separate payment in CY 2019.
     HCPCS codes for drugs and biologicals that were packaged 
in CY 2018 and that were proposed for separate payment in CY 2019, and 
that then have per day costs equal to or less than the CY 2019 final 
rule drug packaging threshold, based on the updated ASPs and hospital 
claims data used for this CY 2019 final rule, would remain packaged in 
CY 2019.
     HCPCS codes for drugs and biologicals for which we 
proposed packaged payment in CY 2019 but that then have per-day costs 
greater than the CY 2019 final rule drug packaging threshold, based on 
the updated ASPs and hospital claims data used for this CY 2019 final 
rule, would receive separate payment in CY 2019.
    We did not receive any public comments on our proposal to 
recalculate the mean unit cost for items that do not currently have an 
ASP-based payment rate from all of the CY 2017 claims data and updated 
cost report information available for this CY 2019 final rule with 
comment period to determine their final per day cost. We also did not 
receive any public comments on our proposal to continue to follow the 
established policies, initially adopted for the CY 2005 OPPS (69 FR 
65780), when the packaging status of some HCPCS codes for drugs, 
biologicals, and therapeutic radiopharmaceuticals in the proposed rule 
may be different from the same drug HCPCS code's packaging status 
determined based on the data used for the final rule with comment 
period. Therefore, for CY 2019, we are finalizing these two proposals 
without modification.
c. Policy Packaged Drugs, Biologicals, and Radiopharmaceuticals
    As mentioned earlier in this section, in the OPPS, we package 
several categories of drugs, biologicals, and radiopharmaceuticals, 
regardless of the cost of the products. Because the products are 
packaged according to the policies in 42 CFR 419.2(b), we refer to 
these packaged drugs, biologicals, and radiopharmaceuticals as 
``policy-packaged'' drugs, biologicals, and radiopharmaceuticals. These 
policies are either longstanding or based on longstanding principles 
and inherent to the OPPS and are as follows:
     Anesthesia, certain drugs, biologicals, and other 
pharmaceuticals; medical and surgical supplies and equipment; surgical 
dressings; and devices used for external reduction of fractures and 
dislocations (Sec.  419.2(b)(4));
     Intraoperative items and services (Sec.  419.2(b)(14));
     Drugs, biologicals, and radiopharmaceuticals that function 
as supplies when used in a diagnostic test or procedure (including, but 
not limited to, diagnostic radiopharmaceuticals, contrast agents, and 
pharmacologic stress agents) (Sec.  419.2(b)(15)); and
     Drugs and biologicals that function as supplies when used 
in a surgical procedure (including, but not limited to, skin 
substitutes and similar products that aid wound healing and implantable 
biologicals) (Sec.  419.2(b)(16)).
    The policy at Sec.  419.2(b)(16) is broader than that at Sec.  
419.2(b)(14). As we stated in the CY 2015 OPPS/ASC final rule with 
comment period: ``We consider all items related to the surgical outcome 
and provided during the hospital stay in which the surgery is 
performed, including postsurgical pain management drugs, to be part of 
the surgery for purposes of our drug and biological surgical supply 
packaging policy'' (79 FR 66875). The category described by Sec.  
419.2(b)(15) is large and includes diagnostic radiopharmaceuticals, 
contrast agents, stress agents, and some other products. The category 
described by Sec.  419.2(b)(16) includes skin substitutes and some 
other products. We believe it is important to reiterate that cost 
consideration is not a factor when determining whether an item is a 
surgical supply (79 FR 66875).
    We did not make any proposals to revise our policy-packaged drug 
policy. We solicited public comment on the general OPPS packaging 
policies as discussed in section II.3.a. of this final rule with 
comment period.
    Comment: One commenter recommended that CMS continue to apply the 
nuclear medicine procedure to radiolabeled product edits to ensure that 
all packaged costs are included on nuclear medicine claims in order to 
establish appropriate payment rates in the future. The commenter was 
concerned that many providers performing nuclear medicine procedures 
are not including the cost of diagnostic radiopharmaceuticals used for 
the procedures in their claims submissions. The commenter believed this 
lack of drug cost reporting is causing the cost of nuclear medicine 
procedures to be underreported, and that the radiolabeled product edits 
will ensure providers are reporting the cost of diagnostic 
radiopharmaceuticals in their claims data.
    Response: We do not agree with the commenter that we should 
reinstate the nuclear medicine procedure to radiolabeled product edits, 
which required a diagnostic radiopharmaceutical to be present on the 
same claim as a nuclear medicine procedure for payment under the OPPS 
to be made. The edits were in place between CY 2008 and CY 2014 (78 FR 
75033). We believe the period of time in which the edits were in place 
was sufficient for hospitals to gain experience reporting procedures 
involving radiolabeled products and to become accustomed to ensuring 
that they code and report charges so that their claims fully and 
appropriately reflect the costs of those radiolabeled products. As with 
all other items and services recognized under the OPPS, we expect 
hospitals to code and report their costs appropriately, regardless of 
whether there are claims processing edits in place.
    Comment: Several commenters requested that diagnostic 
radiopharmaceuticals be paid separately in all cases, not just when the 
drugs have pass-through payment status. The commenters provided limited 
data that showed that procedures where diagnostic radiopharmaceuticals 
are considered to be a surgical supply often are paid at a lower rate 
than what the payment rate is for the diagnostic radiopharmaceutical 
itself when the drug is paid separately on pass-through payment status. 
The commenters stated that diagnostic radiopharmaceuticals are highly 
complex drugs that undergo a rigorous approval process by the FDA.

[[Page 58966]]

The commenters believed that the type of procedure in which a drug or 
biological is used should not dictate whether that drug or biological 
is a supply and is packaged.
    Response: We continue to believe that diagnostic 
radiopharmaceuticals are an integral component of many nuclear medicine 
and imaging procedures and charges associated with radiopharmaceuticals 
should be reported on hospital claims to the extent they are used. 
Therefore, payment for the radiopharmaceuticals is reflected within the 
payment for the primary procedure. While at least one commenter 
provided limited data showing the proposed cost of the packaged 
procedure in CY 2019 is substantially lower than the cost of the 
separately paid radiopharmaceutical on pass-through payment plus the 
cost of the procedure associated with the radiopharmaceutical, we note 
the rates are established in a manner that takes the average (more 
specifically, the geometric mean) of reported costs to furnish the 
procedure based on data submitted to us from all hospitals paid under 
the OPPS. Accordingly, the costs that are calculated by Medicare 
reflect the average costs of items and services that are packaged into 
a primary procedure and will not necessarily equal the sum of the cost 
of the primary procedure and the average sales price of items and 
services because the billing patterns of hospitals may not reflect that 
a particular item or service is always billed with the primary 
procedure. Further, the costs will be based on the reported costs 
submitted to Medicare by hospitals, not the list price established by 
the manufacturer. Claims data that include the radiopharmaceutical 
packaged with the associate procedure reflect the combined cost of the 
procedure and the radiopharmaceutical used in the procedure.
d. High Cost/Low Cost Threshold for Packaged Skin Substitutes
    In the CY 2014 OPPS/ASC final rule with comment period (78 FR 
74938), we unconditionally packaged skin substitute products into their 
associated surgical procedures as part of a broader policy to package 
all drugs and biologicals that function as supplies when used in a 
surgical procedure. As part of the policy to finalize the packaging of 
skin substitutes, we also finalized a methodology that divides the skin 
substitutes into a high cost group and a low cost group, in order to 
ensure adequate resource homogeneity among APC assignments for the skin 
substitute application procedures (78 FR 74933).
    Skin substitutes assigned to the high cost group are described by 
HCPCS codes 15271 through 15278. Skin substitutes assigned to the low 
cost group are described by HCPCS codes C5271 through C5278. Geometric 
mean costs for the various procedures are calculated using only claims 
for the skin substitutes that are assigned to each group. Specifically, 
claims billed with HCPCS code 15271, 15273, 15275, or 15277 are used to 
calculate the geometric mean costs for procedures assigned to the high 
cost group, and claims billed with HCPCS code C5271, C5273, C5275, or 
C5277 are used to calculate the geometric mean costs for procedures 
assigned to the low cost group (78 FR 74935).
    Each of the HCPCS codes described above are assigned to one of the 
following three skin procedure APCs according to the geometric mean 
cost for the code: APC 5053 (Level 3 Skin Procedures) (HCPCS codes 
C5271, C5275, and C5277); APC 5054 (Level 4 Skin Procedures) (HCPCS 
codes C5273, 15271, 15275, and 15277); or APC 5055 (Level 5 Skin 
Procedures) (HCPCS code 15273). In CY 2018, the payment rate for APC 
5053 (Level 3 Skin Procedures) was $488.20, the payment rate for APC 
5054 (Level 4 Skin Procedures) was $1,568.43, and the payment rate for 
APC 5055 (Level 5 Skin Procedures) was $2,710.48. This information also 
is available in Addenda A and B of the CY 2018 OPPS/ASC final rule with 
comment period (which is available via the internet on the CMS 
website).
    We have continued the high cost/low cost categories policy since CY 
2014, and in the CY 2019 OPPS/ASC proposed rule (83 FR 37117), we 
proposed to continue it for CY 2019. Under this current policy, skin 
substitutes in the high cost category are reported with the skin 
substitute application CPT codes, and skin substitutes in the low cost 
category are reported with the analogous skin substitute HCPCS C-codes. 
For a discussion of the CY 2014 and CY 2015 methodologies for assigning 
skin substitutes to either the high cost group or the low cost group, 
we refer readers to the CY 2014 OPPS/ASC final rule with comment period 
(78 FR 74932 through 74935) and the CY 2015 OPPS/ASC final rule with 
comment period (79 FR 66882 through 66885).
    For a discussion of the high cost/low cost methodology that was 
adopted in CY 2016 and has been in effect since then, we refer readers 
to the CY 2016 OPPS/ASC final rule with comment period (80 FR 70434 
through 70435). For CY 2019, as with our policy since CY 2016, we 
proposed to continue to determine the high cost/low cost status for 
each skin substitute product based on either a product's geometric mean 
unit cost (MUC) exceeding the geometric MUC threshold or the product's 
per day cost (PDC) (the total units of a skin substitute multiplied by 
the mean unit cost and divided by the total number of days) exceeding 
the PDC threshold. For CY 2019, as for CY 2018, we proposed to assign 
each skin substitute that exceeds either the MUC threshold or the PDC 
threshold to the high cost group. In addition, as described in more 
detail later in this section, for CY 2019, as for CY 2018, we proposed 
to assign any skin substitute with a MUC or a PDC that does not exceed 
either the MUC threshold or the PDC threshold to the low cost group. 
For CY 2019, we proposed that any skin substitute product that was 
assigned to the high cost group in CY 2018 would be assigned to the 
high cost group for CY 2019, regardless of whether it exceeds or falls 
below the CY 2019 MUC or PDC threshold.
    For this CY 2019 OPPS/ASC final rule with comment period, 
consistent with the methodology as established in the CY 2014 through 
CY 2017 final rules with comment period, we analyzed updated CY 2017 
claims data to calculate the MUC threshold (a weighted average of all 
skin substitutes' MUCs) and the PDC threshold (a weighted average of 
all skin substitutes' PDCs). The final CY 2019 MUC threshold is $49 per 
cm\2\ (rounded to the nearest $1) (proposed at $49 per cm\2\) and the 
final CY 2019 PDC threshold is $872 (rounded to the nearest $1) 
(proposed at $895).
    For CY 2019, we proposed to continue to assign skin substitutes 
with pass-through payment status to the high cost category. We proposed 
to assign skin substitutes with pricing information but without claims 
data to calculate a geometric MUC or PDC to either the high cost or low 
cost category based on the product's ASP+6 percent payment rate as 
compared to the MUC threshold. If ASP is not available, we proposed to 
use WAC+3 percent to assign a product to either the high cost or low 
cost category. Finally, if neither ASP nor WAC is available, we stated 
in the proposed rule that we would use 95 percent of AWP to assign a 
skin substitute to either the high cost or low cost category. We 
proposed to use WAC+3 percent instead of WAC+6 percent to conform to 
our proposed policy described in section V.B.2.b. of the proposed rule 
to establish a payment rate of WAC+3 percent for separately payable 
drugs and biologicals that do not have ASP data available. We also

[[Page 58967]]

stated in the proposed rule that new skin substitutes without pricing 
information would be assigned to the low cost category until pricing 
information is available to compare to the CY 2019 MUC threshold. For a 
discussion of our existing policy under which we assign skin 
substitutes without pricing information to the low cost category until 
pricing information is available, we refer readers to the CY 2016 OPPS/
ASC final rule with comment period (80 FR 70436).
    Some skin substitute manufacturers have raised concerns about 
significant fluctuation in both the MUC threshold and the PDC threshold 
from year to year. The fluctuation in the thresholds may result in the 
reassignment of several skin substitutes from the high cost group to 
the low cost group which, under current payment rates, can be a 
difference of approximately $1,000 in the payment amount for the same 
procedure. In addition, these stakeholders were concerned that the 
inclusion of cost data from skin substitutes with pass-through payment 
status in the MUC and PDC calculations would artificially inflate the 
thresholds. Skin substitute stakeholders requested that CMS consider 
alternatives to the current methodology used to calculate the MUC and 
PDC thresholds and also requested that CMS consider whether it might be 
appropriate to establish a new cost group in between the low cost group 
and the high cost group to allow for assignment of moderately priced 
skin substitutes to a newly created middle group.
    We share the goal of promoting payment stability for skin 
substitute products and their related procedures as price stability 
allows hospitals using such products to more easily anticipate future 
payments associated with these products. We have attempted to limit 
year-to-year shifts for skin substitute products between the high cost 
and low cost groups through multiple initiatives implemented since CY 
2014, including: Establishing separate skin substitute application 
procedure codes for low-cost skin substitutes (78 FR 74935); using a 
skin substitute's MUC calculated from outpatient hospital claims data 
instead of an average of ASP+6 percent as the primary methodology to 
assign products to the high cost or low cost group (79 FR 66883); and 
establishing the PDC threshold as an alternate methodology to assign a 
skin substitute to the high cost group (80 FR 70434 through 70435).
    To allow additional time to evaluate concerns and suggestions from 
stakeholders about the volatility of the MUC and PDC thresholds, in the 
CY 2018 OPPS/ASC proposed rule (82 FR 33627), for CY 2018, we proposed 
that a skin substitute that was assigned to the high cost group for CY 
2017 would be assigned to the high cost group for CY 2018, even if it 
does not exceed the CY 2018 MUC or PDC thresholds. We finalized this 
policy in the CY 2018 OPPS/ASC final rule with comment period (82 FR 
59347). We stated in the CY 2018 OPPS/ASC proposed rule that the goal 
of our proposal to retain the same skin substitute cost group 
assignments in CY 2018 as in CY 2017 was to maintain similar levels of 
payment for skin substitute products for CY 2018 while we study our 
skin substitute payment methodology to determine whether refinement to 
the existing policies is consistent with our policy goal of providing 
payment stability for skin substitutes.
    We stated in the CY 2018 OPPS/ASC final rule with comment period 
(82 FR 59347) that we would continue to study issues related to the 
payment of skin substitutes and take these comments into consideration 
for future rulemaking. We received many responses to our requests for 
comments in the CY 2018 OPPS/ASC proposed rule about possible 
refinements to the existing payment methodology for skin substitutes 
that would be consistent with our policy goal of providing payment 
stability for these products. In addition, several stakeholders have 
made us aware of additional concerns and recommendations since the 
release of the CY 2018 OPPS/ASC final rule with comment period. As 
discussed in the CY 2019 OPPS/ASC proposed rule (83 FR 37118 through 
37119), we have identified four potential methodologies that have been 
raised to us that we encouraged the public to review and provide 
comments on. We stated in the proposed rule that we are especially 
interested in any specific feedback on policy concerns with any of the 
options presented as they relate to skin substitutes with differing per 
day or per episode costs and sizes and other factors that may differ 
among the dozens of skin substitutes currently on the market. We also 
specified in the proposed rule that we are interested in any new ideas 
that are not represented below along with an analysis of how different 
skin substitute products would fare under such ideas. We stated that we 
intend to explore the full array of public comments on these ideas for 
the CY 2020 rulemaking, and we indicated that we will consider the 
feedback received in response to our requests for comments in the CY 
2019 proposed rule in developing proposals for CY 2020.
     Establish a lump-sum ``episode-based'' payment for a wound 
care episode. Under this option, a hospital would receive a lump sum 
payment for all wound care services involving procedures using skin 
substitutes. The payment would be made for a wound care ``episode'' 
(such as 12 weeks) for one wound. The lump sum payment could be the 
same for all skin substitutes or could vary based on the estimated 
number of applications for a given skin substitute during the wound 
care episode. Under this option, payment to the provider could be made 
at the start of treatment, or at a different time, and could be made 
once or split into multiple payments. Quality metrics, such as using 
the recommended number of treatments for a given skin substitute during 
a treatment episode, and establishing a plan of care for patients who 
do not experience 30 percent wound healing after 4 weeks, could be 
established to ensure the beneficiary receives appropriate care while 
limiting excessive additional applications of skin substitute products.
     Eliminate the high cost/low cost categories for skin 
substitutes and only have one payment category and set of procedure 
codes for all skin substitute products. This option would reduce the 
financial incentives to use expensive skin substitutes and would 
provide incentives to use less costly skin substitute products that 
have been shown to have similar efficacy treating wounds as more 
expensive skin substitute products. A single payment category would 
likely have a payment rate that is between the current rates paid for 
high cost and low cost skin substitute procedures. Initially, a single 
payment category may lead to substantially higher payment for skin 
graft procedures performed with cheaper skin substitutes as compared to 
their costs. However, over time, payment for skin graft procedures 
using skin substitutes might reflect the lower cost of the procedures.
     Allow for the payment of current add-on codes or create 
additional procedure codes to pay for skin graft services between 26 
cm\2\ and 99 cm\2\ and substantially over 100 cm\2\. Under this option, 
payment for skin substitutes would be made more granularly based on the 
size of the skin substitute product being applied. This option also 
would reduce the risk that hospitals may not use enough of a skin 
substitute to save money when performing a procedure. However, such 
granularity in the use of skin substitutes could conflict with the 
goals of a prospective payment system, which is based on a system of 
averages. Specifically, it is expected that

[[Page 58968]]

some skin graft procedures will be less than 25 cm\2\ or around 100 
cm\2\ and will receive higher payments compared to the cost of the 
services. Conversely, services between 26 cm\2\ and 99 cm\2\ or those 
that are substantially larger than 100 cm\2\ will receive lower 
payments compared to the cost of the services, but the payments will 
average over many skin graft procedures to an appropriate payment rate 
for the provider.
     Keep the high cost/low cost skin substitute categories, 
but change the threshold used to assign skin substitutes in the high 
cost or low cost group. Consider using other benchmarks that would 
establish more stable thresholds for the high cost and low cost groups. 
Ideas include, but are not limited to, fixing the MUC or PDC threshold 
at an amount from a prior year, or setting global payment targets for 
high cost and low cost skin substitutes and establishing a threshold 
that meets the payment targets. Establishing different thresholds for 
the high cost and low cost groups could allow for the use of a mix of 
lower cost and higher cost skin substitute products that acknowledges 
that a large share of skin substitutes products used by Medicare 
providers are higher cost products but still providing substantial cost 
savings for skin graft procedures. Different thresholds may also reduce 
the number of skin substitute products that switch between the high 
cost and low cost groups in a given year to give more payment stability 
for skin substitute products.
    Comment: Several commenters supported the four options presented in 
the CY 2019 OPPS proposed rule (83 FR 37118 through 37119). Other 
commenters opposed the four options.
    Response: We appreciate the feedback we received from the 
commenters. We will continue to study issues related to changing the 
methodology for paying for skin substitute products, and we will take 
these comments into consideration for CY 2020 rulemaking.
    To allow stakeholders time to analyze and comment on the potential 
ideas raised above, in the CY 2019 OPPS/ASC proposed rule (83 FR 
37119), for CY 2019, we proposed to continue our policy established in 
CY 2018 to assign skin substitutes to the low cost or high cost group. 
However, for CY 2020, we stated in the proposed rule that we may revise 
our policy to reflect one of the potential new methodologies discussed 
above or a new methodology included in public comments in response to 
the CY 2019 proposed rule. Specifically, for CY 2019, we proposed to 
assign a skin substitute with a MUC or a PDC that does not exceed 
either the MUC threshold or the PDC threshold to the low cost group, 
unless the product was assigned to the high cost group in CY 2018, in 
which case we would assign the product to the high cost group for CY 
2019, regardless of whether it exceeds the CY 2019 MUC or PDC 
threshold. We also proposed to assign to the high cost group any skin 
substitute product that exceeds the CY 2019 MUC or PDC thresholds and 
assign to the low cost group any skin substitute product that does not 
exceed the CY 2019 MUC or PDC thresholds and were not assigned to the 
high cost group in CY 2018. We proposed to continue to use payment 
methodologies including ASP+6 percent and 95 percent of AWP for skin 
substitute products that have pricing information but do not have 
claims data to determine if their costs exceed the CY 2019 MUC. In 
addition, we proposed to use WAC+3 percent instead of WAC+6 percent for 
skin substitute products that do not have ASP pricing information or 
have claims data to determine if those products' costs exceed the CY 
2019 MUC. We also proposed to retain our established policy to assign 
new skin substitute products with pricing information to the low cost 
group.
    Table 23 in the CY 2019 OPPS/ASC proposed rule (83 FR 37119 through 
37120) displayed the proposed CY 2019 high cost or low cost category 
assignment for each skin substitute product.
    Comment: Two commenters requested that CMS implement a single skin 
substitute payment category in CY 2019 rather than keeping the current 
high cost and low cost categories. The commenters believed that the 
existence of separate categories for high cost and low cost skin 
substitutes encourages the over-utilization of high cost skin 
substitutes which increases program cost for CMS and copayments for 
beneficiaries.
    Response: At this time, we do not believe that establishing one 
cost category for all skin substitute products is prudent. While 
several commenters supported a single payment category for skin 
substitutes as a potential future refinement to the payment policy for 
these products, several other commenters expressed significant concern 
about this payment method. Accordingly, we do not believe it would be 
appropriate to establish such a major payment change in this final rule 
with comment period without having proposed it.
    Comment: A number of commenters supported the proposal to assign a 
skin substitute with a MUC or a PDC that does not exceed either the MUC 
threshold or the PDC threshold to the low cost group, unless the 
product was assigned to the high cost group in CY 2018, in which case 
CMS would assign the product to the high cost group for CY 2019, 
regardless of whether it exceeds the CY 2019 MUC or PDC threshold. 
These commenters also supported the proposal to assign to the high cost 
group any skin substitute product that exceeds the CY 2019 MUC or PDC 
thresholds and assign to the low cost group any skin substitute product 
that does not exceed the CY 2019 MUC or PDC thresholds and was not 
assigned to the high cost group in CY 2018. One of the commenters 
supported the proposal for CY 2019, but requested that CMS establish 
new skin substitute payment policy for CY 2020. Another commenter 
requested that CMS maintain the current payment methodologies for up to 
5 years until a new skin substitute payment system is implemented.
    Response: We appreciate the support from the commenters for our 
proposals and their support for developing a new methodology for paying 
for skin substitute procedures in future rulemaking.
    Comment: One commenter expressed appreciation to CMS for assigning 
HCPCS codes Q4122 (Dermacell, per square centimeter) and Q4150 
(Allowrap ds or dry, per square centimeter) to the high cost group.
    Response: We appreciate the commenter's support.
    After consideration of the public comments we received, we are 
finalizing our proposal to assign a skin substitute with a MUC or a PDC 
that does not exceed either the MUC threshold or the PDC threshold to 
the low cost group, unless the product was assigned to the high cost 
group in CY 2018, in which case we would assign the product to the high 
cost group for CY 2019, regardless of whether it exceeds the CY 2019 
MUC or PDC threshold. We also are finalizing our proposal to assign to 
the high cost group any skin substitute product that exceeds the CY 
2019 MUC or PDC thresholds and assign to the low cost group any skin 
substitute product that does not exceed the CY 2019 MUC or PDC 
thresholds and was not assigned to the high cost group in CY 2018. We 
are finalizing our proposal to continue to use payment methodologies 
including ASP+6 percent and 95 percent of AWP for skin substitute 
products that have pricing information but do not have claims data to 
determine if their costs exceed the CY 2019 MUC. In addition, we are 
finalizing our proposal to use WAC+3 percent instead of WAC+6

[[Page 58969]]

percent for skin substitute products that do not have ASP pricing 
information or claims data to determine if those products' costs exceed 
the CY 2019 MUC. We also are finalizing our proposal to retain our 
established policy to assign new skin substitute products with pricing 
information to the low cost group.
    Table 41 below displays the final CY 2019 cost category assignment 
for each skin substitute product.
BILLING CODE 4120-01-P

[[Page 58970]]

[GRAPHIC] [TIFF OMITTED] TR21NO18.064


[[Page 58971]]


[GRAPHIC] [TIFF OMITTED] TR21NO18.065


[[Page 58972]]


[GRAPHIC] [TIFF OMITTED] TR21NO18.066

e. Packaging Determination for HCPCS Codes That Describe the Same Drug 
or Biological but Different Dosages
    In the CY 2010 OPPS/ASC final rule with comment period (74 FR 60490 
through 60491), we finalized a policy to make a single packaging 
determination for a drug, rather than an individual HCPCS code, when a 
drug has multiple HCPCS codes describing different dosages because we 
believed that adopting the standard HCPCS code-specific packaging 
determinations for these codes could lead to inappropriate payment 
incentives for hospitals to report certain HCPCS codes instead of 
others. We continue to believe that making packaging determinations on 
a drug-specific basis eliminates payment incentives for hospitals to 
report certain HCPCS codes for drugs and allows hospitals flexibility 
in choosing to report all HCPCS codes for different dosages of the same 
drug or only the lowest dosage HCPCS code. Therefore, in the CY 2019 
OPPS/ASC proposed rule (83 FR 37121), we proposed to continue our 
policy to make packaging determinations on a drug-specific basis, 
rather than a HCPCS code-specific basis, for those HCPCS codes that 
describe the same drug or biological but different dosages in CY 2019.
    For CY 2019, in order to propose a packaging determination that is 
consistent across all HCPCS codes that describe different dosages of 
the same drug or biological, we aggregated both our CY 2017 claims data 
and our pricing information at ASP+6 percent across all of the HCPCS 
codes that describe each distinct drug or biological in order to 
determine the mean units per day of the drug or biological in terms of 
the HCPCS code with the lowest dosage descriptor. The following drugs 
did not have pricing information available for the ASP methodology for 
the CY 2019 OPPS/ASC proposed rule, and as is our current policy for 
determining the packaging status of other drugs, we used the mean unit 
cost available from the CY 2017 claims data to make the proposed 
packaging determinations for these drugs: HCPCS code J1840 (Injection, 
kanamycin sulfate, up to 500 mg); HCPCS code J1850 (Injection, 
kanamycin sulfate, up to 75 mg); HCPCS code J3472 (Injection, 
hyaluronidase, ovine, preservative free, per 1,000 usp units); HCPCS 
code J7100 (Infusion, dextran 40, 500 ml); and HCPCS code J7110 
(Infusion, dextran 75, 500 ml).
    For all other drugs and biologicals that have HCPCS codes 
describing different doses, we then multiplied the proposed weighted 
average ASP+6 percent per unit payment amount across all dosage levels 
of a specific drug or biological by the estimated units per day for all 
HCPCS codes that describe each drug or biological from our claims data 
to determine the estimated per day cost of each drug or biological at 
less than or equal to the proposed CY 2019 drug packaging threshold of 
$125 (so that all HCPCS codes for the same drug or biological would be 
packaged) or greater than the proposed CY 2019 drug packaging threshold 
of $125 (so that all HCPCS codes for the same drug or biological would 
be separately payable). The proposed packaging status of each drug and 
biological HCPCS code to which this methodology would apply in CY 2019 
was displayed in Table 24 of the CY 2019 OPPS/ASC proposed rule (83 FR 
37121).
    We did not receive any public comments on this proposal. Therefore, 
for CY 2019, we are finalizing our CY 2019 proposal, without 
modification, to continue our policy to make packaging determinations 
on a drug-specific basis, rather than a HCPCS code-specific basis, for 
those HCPCS codes that describe the same drug or biological but 
different dosages. Table 42 below displays the final packaging status 
of each drug and biological HCPCS code to which the finalized 
methodology applies for CY 2019.

[[Page 58973]]

[GRAPHIC] [TIFF OMITTED] TR21NO18.067


[[Page 58974]]


BILLING CODE 4120-01-C
2. Payment for Drugs and Biologicals Without Pass-Through Status That 
Are Not Packaged
a. Payment for Specified Covered Outpatient Drugs (SCODs) and Other 
Separately Payable and Packaged Drugs and Biologicals
    Section 1833(t)(14) of the Act defines certain separately payable 
radiopharmaceuticals, drugs, and biologicals and mandates specific 
payments for these items. Under section 1833(t)(14)(B)(i) of the Act, a 
``specified covered outpatient drug'' (known as a SCOD) is defined as a 
covered outpatient drug, as defined in section 1927(k)(2) of the Act, 
for which a separate APC has been established and that either is a 
radiopharmaceutical agent or is a drug or biological for which payment 
was made on a pass-through basis on or before December 31, 2002.
    Under section 1833(t)(14)(B)(ii) of the Act, certain drugs and 
biologicals are designated as exceptions and are not included in the 
definition of SCODs. These exceptions are--
     A drug or biological for which payment is first made on or 
after January 1, 2003, under the transitional pass-through payment 
provision in section 1833(t)(6) of the Act.
     A drug or biological for which a temporary HCPCS code has 
not been assigned.
     During CYs 2004 and 2005, an orphan drug (as designated by 
the Secretary).
    Section 1833(t)(14)(A)(iii) of the Act requires that payment for 
SCODs in CY 2006 and subsequent years be equal to the average 
acquisition cost for the drug for that year as determined by the 
Secretary, subject to any adjustment for overhead costs and taking into 
account the hospital acquisition cost survey data collected by the 
Government Accountability Office (GAO) in CYs 2004 and 2005, and later 
periodic surveys conducted by the Secretary as set forth in the 
statute. If hospital acquisition cost data are not available, the law 
requires that payment be equal to payment rates established under the 
methodology described in section 1842(o), section 1847A, or section 
1847B of the Act, as calculated and adjusted by the Secretary as 
necessary for purposes of paragraph (14). We refer to this alternative 
methodology as the ``statutory default.'' Most physician Part B drugs 
are paid at ASP+6 percent in accordance with section 1842(o) and 
section 1847A of the Act.
    Section 1833(t)(14)(E)(ii) of the Act provides for an adjustment in 
OPPS payment rates for SCODs to take into account overhead and related 
expenses, such as pharmacy services and handling costs. Section 
1833(t)(14)(E)(i) of the Act required MedPAC to study pharmacy overhead 
and related expenses and to make recommendations to the Secretary 
regarding whether, and if so how, a payment adjustment should be made 
to compensate hospitals for overhead and related expenses. Section 
1833(t)(14)(E)(ii) of the Act authorizes the Secretary to adjust the 
weights for ambulatory procedure classifications for SCODs to take into 
account the findings of the MedPAC study.\57\
---------------------------------------------------------------------------

    \57\ Medicare Payment Advisory Committee. June 2005 Report to 
the Congress. Chapter 6: Payment for pharmacy handling costs in 
hospital outpatient departments. Available at: https://www.medpac.gov/docs/default-source/reports/June05_ch6.pdf?sfvrsn=0.
---------------------------------------------------------------------------

    It has been our policy since CY 2006 to apply the same treatment to 
all separately payable drugs and biologicals, which include SCODs, and 
drugs and biologicals that are not SCODs. Therefore, we apply the 
payment methodology in section 1833(t)(14)(A)(iii) of the Act to SCODs, 
as required by statute, but we also apply it to separately payable 
drugs and biologicals that are not SCODs, which is a policy 
determination rather than a statutory requirement. In the CY 2019 OPPS/
ASC proposed rule (83 FR 37122), we proposed to apply section 
1833(t)(14)(A)(iii)(II) of the Act to all separately payable drugs and 
biologicals, including SCODs. Although we do not distinguish SCODs in 
this discussion, we note that we are required to apply section 
1833(t)(14)(A)(iii)(II) of the Act to SCODs, but we also are applying 
this provision to other separately payable drugs and biologicals, 
consistent with our history of using the same payment methodology for 
all separately payable drugs and biologicals.
    For a detailed discussion of our OPPS drug payment policies from CY 
2006 to CY 2012, we refer readers to the CY 2013 OPPS/ASC final rule 
with comment period (77 FR 68383 through 68385). In the CY 2013 OPPS/
ASC final rule with comment period (77 FR 68386 through 68389), we 
first adopted the statutory default policy to pay for separately 
payable drugs and biologicals at ASP+6 percent based on section 
1833(t)(14)(A)(iii)(II) of the Act. We continued this policy of paying 
for separately payable drugs and biologicals at the statutory default 
for CYs 2014 through 2018.
    Comment: One commenter requested that HCPCS code J0476 (Injection, 
baclofen, 50 mcg for intrathecal trial) be separately payable in CY 
2019 and be assigned status indicator ``K'' (Paid under OPPS; separate 
APC payment).
    Response: The per day cost of the drug described by HCPCS code 
J0476 is less than the drug packaging threshold amount of $125. 
Therefore, the drug described by HCPCS code J0476 will be packaged into 
the cost of the related services for CY 2019.
    Comment: One commenter supported the assignment of GenVisc 850, 
described by HCPCS code J7320, to a separately payable status with 
status indicator ``K'' (Paid under OPPS; separate APC payment) for CY 
2019. The commenter also requested that TriVisc, described by HCPCS 
code J7329, also be assigned to a separately payable status for CY 
2019.
    Response: We appreciate the commenter's support. For HCPCS code 
J7329, we are not able to assign the code to a payable status because 
no pricing information is available for the code. If pricing 
information becomes available prior to the next rulemaking cycle, we 
would expect to assign a payable status in a quarterly update to the 
OPPS.
b. CY 2019 Payment Policy
    In the CY 2019 OPPS/ASC proposed rule (83 FR 37122), for CY 2019, 
we proposed to continue our payment policy that has been in effect 
since CY 2013 to pay for separately payable drugs and biologicals at 
ASP+6 percent in accordance with section 1833(t)(14)(A)(iii)(II) of the 
Act (the statutory default). We proposed to continue to pay for 
separately payable nonpass-through drugs acquired with a 340B discount 
at a rate of ASP minus 22.5 percent. We refer readers to section V.A.7. 
of the proposed rule and this final rule with comment period for more 
information about how the payment rate for drugs acquired with a 340B 
discount was established.
    In the case of a drug or biological during an initial sales period 
in which data on the prices for sales for the drug or biological are 
not sufficiently available from the manufacturer, section 1847A(c)(4) 
of the Act permits the Secretary to make payments that are based on 
WAC. Under section 1833(t)(14)(A)(iii)(II), the amount of payment for a 
separately payable drug equals the average price for the drug for the 
year established under, among other authorities, section 1847A of the 
Act. As explained in greater detail in the CY 2019 PFS proposed rule, 
under section 1847A(c)(4), although payments may be based on WAC, 
unlike section 1847A(b) of the Act (which specifies that certain 
payments must be made with a 6 percent add-on), section 1847A(c)(4) of 
the Act does not require that a particular

[[Page 58975]]

add-on amount be applied to partial quarter WAC-based pricing. 
Consistent with section 1847A(c)(4) of the Act, in the CY 2019 PFS 
proposed rule, we proposed that, effective January 1, 2019, WAC-based 
payments for Part B drugs made under section 1847A(c)(4) of the Act 
would utilize a 3 percent add-on in place of the 6 percent add-on that 
is currently being used per our policy in effect as of CY 2018. For the 
OPPS, in the CY 2019 OPPS/ASC proposed rule (83 FR 37122), we also 
proposed to utilize a 3 percent add-on instead of a 6 percent add-on 
for WAC-based drugs pursuant to our authority under section 
1833(t)(14)(A)(iii)(II) of the Act, which provides, in part, that the 
amount of payment for a SCOD is the average price of the drug in the 
year established under section 1847A of the Act. We also apply this 
provision to non-SCOD separately payable drugs. Because we proposed to 
establish the average price for a WAC-based drug under section 1847A of 
the Act as WAC+3 percent instead of WAC+6 percent, we believe it is 
appropriate to price separately payable WAC-based drugs at the same 
amount under the OPPS. We proposed that, if finalized, our proposal to 
pay for drugs or biologicals at WAC+3 percent, rather than WAC+6 
percent, would apply whenever WAC-based pricing is used for a drug or 
biological. We stated in the proposed rule that for drugs and 
biologicals that would otherwise be subject to a payment reduction 
because they were acquired under the 340B Program, the 340B Program 
rate (in this case, WAC minus 22.5 percent) would continue to apply. We 
referred readers to the CY 2019 PFS proposed rule for additional 
background on this anticipated proposal.
    In the CY 2019 OPPS/ASC proposed rule (83 FR 37123), we proposed 
that payments for separately payable drugs and biologicals are included 
in the budget neutrality adjustments, under the requirements in section 
1833(t)(9)(B) of the Act. We also proposed that the budget neutral 
weight scalar not be applied in determining payments for these 
separately paid drugs and biologicals.
    We note that separately payable drug and biological payment rates 
listed in Addenda A and B to this final rule with comment period 
(available via the internet on the CMS website), which illustrate the 
final CY 2019 payment of ASP+6 percent for separately payable nonpass-
through drugs and biologicals and ASP+6 percent for pass-through drugs 
and biologicals, reflect either ASP information that is the basis for 
calculating payment rates for drugs and biologicals in the physician's 
office setting effective October 1, 2018, or WAC, AWP, or mean unit 
cost from CY 2017 claims data and updated cost report information 
available for this final rule with comment period. In general, these 
published payment rates are not the same as the actual January 2019 
payment rates. This is because payment rates for drugs and biologicals 
with ASP information for January 2019 will be determined through the 
standard quarterly process where ASP data submitted by manufacturers 
for the third quarter of CY 2018 (July 1, 2018 through September 30, 
2018) will be used to set the payment rates that are released for the 
quarter beginning in January 2019 near the end of December 2018. In 
addition, payment rates for drugs and biologicals in Addenda A and B to 
this final rule with comment period for which there was no ASP 
information available for October 2018 are based on mean unit cost in 
the available CY 2017 claims data. If ASP information becomes available 
for payment for the quarter beginning in January 2019, we will price 
payment for these drugs and biologicals based on their newly available 
ASP information. Finally, there may be drugs and biologicals that have 
ASP information available for this final rule with comment period 
(reflecting October 2018 ASP data) that do not have ASP information 
available for the quarter beginning in January 2019. As stated in the 
CY 2019 OPPS/ASC proposed rule (83 FR 37123), these drugs and 
biologicals will then be paid based on mean unit cost data derived from 
CY 2017 hospital claims. Therefore, the payment rates listed in Addenda 
A and B to this final rule with comment period are not for January 2019 
payment purposes and are only illustrative of the CY 2019 OPPS payment 
methodology using the most recently available information at the time 
of issuance of this final rule with comment period.
    Comment: A number of commenters supported CMS' proposal to continue 
to pay for separately payable drugs and biologicals based on the 
statutory default rate of ASP+6 percent.
    Response: We appreciate the commenters' support.
    Comment: Several commenters supported the proposal to utilize a 3 
percent add-on instead of a 6 percent add-on for drugs that are paid 
based on WAC under section 1847A(c)(4) of the Act, pursuant to CMS' 
authority under section 1833(t)(14)(A)(iii)(II) of the Act. These 
commenters recommended this as a first step to lowering drug costs for 
beneficiaries and the Medicare Program as well as removing the 
financial incentive associated with a specific prescribing choice. The 
commenters suggested modifying the add-on to be a flat fee.
    Response: We appreciate the commenters' support. We proposed a 
fixed percentage, instead of a flat fee, in order to be consistent with 
other provisions in section 1847A of the Act that specify fixed add-on 
percentages of 6 percent (section 1847A(b) of the Act) or 3 percent 
(section 1847A(d)(3)(C) of the Act). A fixed percentage is also 
administratively simple to implement and administer, is predictable, 
and is easy for manufacturers, providers and the public to understand.
    Comment: Many commenters opposed the proposal to utilize a 3 
percent add-on instead of a 6 percent add-on for drugs that are paid 
based on WAC under section 1847A(c)(4) of the Act. Several commenters 
were concerned that paying less for new drugs may discourage the use of 
innovative drugs due to concerns about decreased payment, especially 
with the sequestration cuts decreasing the payment further. The 
commenters also were concerned that the proposal would only affect 
payment to the provider, and would not address pricing on the 
pharmaceutical manufacturer side. The commenters requested additional 
studies to analyze the appropriateness and accuracy of the 3 percent 
reduction, and encouraged additional modifications to ASP reporting, 
such as requiring all Part B drug manufacturers to report pricing 
information and for all Part B drugs to be included in the ASP 
quarterly update file.
    Response: We appreciate these comments. The implementation of these 
proposals will improve Medicare payment rates by better aligning 
payments with drug acquisition costs, which is of great importance to 
CMS because spending on Part B drugs has grown significantly. A WAC+3 
percent add-on is more comparable to an ASP+6 percent add-on, as the 
WAC pricing does not reflect many of the discounts associated with ASP, 
such as rebates. The utilization of a 3 percent add-on instead of a 6 
percent add-on for drugs that are paid based on WAC under section 
1847A(c)(4) of the Act is consistent with MedPAC's analysis and 
recommendations cited in its June 2017 Report to the Congress, and as 
discussed in the CY 2019 PFS proposed rule (83 FR 35854 through 35855). 
Overall, this policy still represents a net payment greater than the 
WAC. In addition, this policy decreases beneficiary cost-sharing for 
these drugs, which would help Medicare beneficiaries afford to pay for 
new drugs by reducing out-of-pocket expenses.

[[Page 58976]]

    Comment: Some commenters did not support the inclusion of 
radiopharmaceuticals in the proposal to utilize a 3 percent add-on 
instead of a 6 percent add-on for drugs that are paid based on WAC. The 
commenters cited pharmacy overhead and handling costs for 
radiopharmaceuticals, pointed out that these costs are higher than for 
any other class of drugs, and suggested an increased payment rate. In 
addition, the commenters were concerned that this reduction would 
disproportionately affect the pass-through payments for diagnostic 
radiopharmaceuticals.
    Response: We appreciate these comments. We recognize that 
radiopharmaceuticals tend to utilize the WAC-based payment methodology 
more compared to other products. However, no significant evidence has 
been presented to substantiate that a 3 percent add-on instead of a 6 
percent add-on for drugs that are paid based on WAC would negatively 
affect access, including during the pass-through payment status period, 
if applicable. We received limited current data from commenters to 
justify the exclusion of radiopharmaceuticals from this proposal.
    Comment: Several commenters made recommendations to exclude certain 
drugs and biologicals from this proposal, including skin substitutes 
and biosimilar biological products. The commenters were concerned about 
skin substitutes being assigned to the high- or low-cost category when 
ASP data are not available based on a WAC+3 percent methodology 
compared to a WAC+6 percent methodology. The commenters recommended 
maintaining payment for biosimilars at WAC+6 percent to encourage the 
increase in utilization of biosimilars.
    Response: We appreciate these comments. However, use of a 3 percent 
add-on instead of a 6 percent add-on for drugs that are paid based on 
WAC under section 1847A(c)(4) of the Act is consistent with MedPAC's 
analysis and recommendations cited in its June 2017 Report to the 
Congress, and as discussed in the CY 2019 PFS proposed rule (83 FR 
35854 through 35855). This policy is not meant to give preferential 
treatment to any drugs or biologicals.
    Comment: Commenters were concerned about coverage for drugs that 
are not included in the ASP Quarterly Update File being paid at WAC+3 
percent instead of the current rate of ASP+6 percent. For example, the 
commenters were concerned that OTIPRIO (HCPCS code J7342), a drug that 
is not included in the ASP Quarterly Update File, will not be paid at 
ASP+6 percent, and would be paid at WAC+3 percent. In addition, the 
commenters requested clarification regarding MAC payment for drugs that 
fall under sections 1847A(c)(4) and 1847A(b)(1) of the Act.
    Response: Drugs that are not included in the ASP Quarterly Update 
File will continue to be paid at their current rate of ASP+6 percent as 
long as the manufacturer continues to submit ASP information to CMS on 
a timely basis and assuming the drug is not packaged.
    After consideration of the public comments we received, we are 
finalizing our proposal, without modification, to utilize a 3 percent 
add-on instead of a 6 percent add-on for drugs that are paid based on 
WAC under section 1847A(c)(4) of the Act pursuant to our authority 
under section 1833(t)(14)(A)(iii)(II) of the Act.
c. Biosimilar Biological Products
    For CY 2016 and CY 2017, we finalized a policy to pay for 
biosimilar biological products based on the payment allowance of the 
product as determined under section 1847A of the Act and to subject 
nonpass-through biosimilar biological products to our annual threshold-
packaged policy (for CY 2016, 80 FR 70445 through 70446; and for CY 
2017, 81 FR 79674). In the CY 2018 OPPS/ASC proposed rule (82 FR 
33630), for CY 2018, we proposed to continue this same payment policy 
for biosimilar biological products.
    In the CY 2018 OPPS/ASC final rule with comment period (82 FR 
59351), we noted that, with respect to comments we received regarding 
OPPS payment for biosimilar biological products, in the CY 2018 PFS 
final rule, CMS finalized a policy to implement separate HCPCS codes 
for biosimilar biological products. Therefore, consistent with our 
established OPPS drug, biological, and radiopharmaceutical payment 
policy, HCPCS coding for biosimilar biological products will be based 
on policy established under the CY 2018 PFS final rule.
    In the CY 2018 OPPS/ASC final rule with comment period (82 FR 
59351), after consideration of the public comments we received, we 
finalized our proposed payment policy for biosimilar biological 
products, with the following technical correction: All biosimilar 
biological products will be eligible for pass-through payment and not 
just the first biosimilar biological product for a reference product. 
In the CY 2019 OPPS/ASC proposed rule (83 FR 37123), for CY 2019, we 
proposed to continue the policy in place from CY 2018 to make all 
biosimilar biological products eligible for pass-through payment and 
not just the first biosimilar biological product for a reference 
product.
    In addition, in CY 2018, we adopted a policy that biosimilars 
without pass-through payment status that were acquired under the 340B 
Program would be paid the ASP of the biosimilar minus 22.5 percent of 
the reference product (82 FR 59367). We adopted this policy in the CY 
2018 OPPS/ASC final rule with comment period because we believe that 
biosimilars without pass-through payment status acquired under the 340B 
Program should be treated in the same manner as other drugs and 
biologicals acquired through the 340B Program. As noted earlier, 
biosimilars with pass-through payment status are paid their own ASP+6 
percent of the reference product's ASP. Separately payable biosimilars 
that do not have pass-through payment status and are not acquired under 
the 340B Program are also paid their own ASP+6 percent of the reference 
product's ASP.
    As noted in the CY 2019 OPPS/ASC proposed rule (83 FR 37123), 
several stakeholders raised concerns to us that the current payment 
policy for biosimilars acquired under the 340B Program could unfairly 
lower the OPPS payment for biosimilars not on pass-through payment 
status because the payment reduction would be based on the reference 
product's ASP, which would generally be expected to be priced higher 
than the biosimilar, thus resulting in a more significant reduction in 
payment than if the 22.5 percent was calculated based on the 
biosimilar's ASP. We agreed with stakeholders that the current payment 
policy could unfairly lower the price of biosimilars without pass-
through payment status that are acquired under the 340B Program. In 
addition, we believed that these changes would better reflect the 
resources and production costs that biosimilar manufacturers incur. We 
also believed this approach is more consistent with the payment 
methodology for 340B-acquired drugs and biologicals, for which the 22.5 
percent reduction is calculated based on the drug or biological's ASP, 
rather than the ASP of another product. In addition, we believed that 
paying for biosimilars acquired under the 340B Program at ASP minus 
22.5 percent of the biosimilar's ASP, rather than 22.5 percent of the 
reference product's ASP, will more closely approximate hospitals' 
acquisition costs for these products.
    Accordingly, in the CY 2019 OPPS/ASC proposed rule (83 FR 37123), 
for CY 2019, we proposed changes to our Medicare Part B drug payment 
methodology for biosimilars acquired

[[Page 58977]]

under the 340B Program. Specifically, for CY 2019 and subsequent years, 
in accordance with section 1833(t)(14)(A)(iii)(II) of the Act, we 
proposed to pay nonpass-through biosimilars acquired under the 340B 
Program at ASP minus 22.5 percent of the biosimilar's ASP instead of 
the biosimilar's ASP minus 22.5 percent of the reference product's ASP.
    Comment: Many commenters supported CMS' proposal to pay nonpass-
through biosimilars acquired under the 340B Program at ASP minus 22.5 
percent of the biosimilar's ASP, in accordance with section 
1833(t)(14)(A)(iii)(II) of the Act. The commenters stated that this 
proposal would ensure fair access to biosimilar treatments.
    Response: We appreciate the commenters' support. We believe this 
proposal appropriately reflects the resources and production costs that 
manufacturers incur, as well as more closely aligns with the hospitals' 
acquisition costs for these products.
    Comment: Several commenters supported CMS' proposal to continue the 
policy in place from CY 2018 to make all biosimilar biological products 
eligible for pass-through payment and not just the first biosimilar 
biological product for a reference product. The commenters stated that 
this proposal would continue to lower costs and improve access to 
treatments.
    Response: We appreciate the commenters' support.
    Comment: Some commenters recommended eliminating the proposal to 
continue the policy in place from CY 2018 to make all biosimilar 
biological products eligible for pass-through payment and not just the 
first biosimilar biological product for a reference product. The 
commenters believed this policy could potentially encourage 
inappropriate treatment changes from a reference product without pass-
through payment to a biosimilar product with pass-through payment.
    Response: We are not convinced that making all biosimilar 
biological products eligible for pass-through payment will lead to 
inappropriate treatment changes from a reference product without pass-
through payment to a biosimilar product with pass-through payment. 
Eligibility for pass-through payment status reflects the unique, 
complex nature of biosimilars and is important as biosimilars become 
established in the market, just as it is for all other new drugs and 
biologicals.
    After consideration of the public comments we received, we are 
finalizing our proposed payment policy for biosimilar products, without 
modification, to continue the policy in place from CY 2018 to make all 
biosimilar biological products eligible for pass-through payment and 
not just the first biosimilar biological product for a reference 
product. We also are finalizing our proposal to pay nonpass-through 
biosimilars acquired under the 340B Program at the biosimilar's ASP 
minus 22.5 percent of the biosimilar's ASP instead of the biosimilar's 
ASP minus 22.5 percent of the reference product's ASP, in accordance 
with section 1833(t)(14)(A)(iii)(II) of the Act.
3. Payment Policy for Therapeutic Radiopharmaceuticals
    In the CY 2019 OPPS/ASC proposed rule (83 FR 37123), for CY 2019, 
we proposed to continue the payment policy for therapeutic 
radiopharmaceuticals that began in CY 2010. We pay for separately 
payable therapeutic radiopharmaceuticals under the ASP methodology 
adopted for separately payable drugs and biologicals. If ASP 
information is unavailable for a therapeutic radiopharmaceutical, we 
base therapeutic radiopharmaceutical payment on mean unit cost data 
derived from hospital claims. We believe that the rationale outlined in 
the CY 2010 OPPS/ASC final rule with comment period (74 FR 60524 
through 60525) for applying the principles of separately payable drug 
pricing to therapeutic radiopharmaceuticals continues to be appropriate 
for nonpass-through, separately payable therapeutic 
radiopharmaceuticals in CY 2019. Therefore, we proposed for CY 2019 to 
pay all nonpass-through, separately payable therapeutic 
radiopharmaceuticals at ASP+6 percent, based on the statutory default 
described in section 1833(t)(14)(A)(iii)(II) of the Act. For a full 
discussion of ASP-based payment for therapeutic radiopharmaceuticals, 
we refer readers to the CY 2010 OPPS/ASC final rule with comment period 
(74 FR 60520 through 60521). We also proposed to rely on CY 2017 mean 
unit cost data derived from hospital claims data for payment rates for 
therapeutic radiopharmaceuticals for which ASP data are unavailable and 
to update the payment rates for separately payable therapeutic 
radiopharmaceuticals according to our usual process for updating the 
payment rates for separately payable drugs and biologicals on a 
quarterly basis if updated ASP information is unavailable. For a 
complete history of the OPPS payment policy for therapeutic 
radiopharmaceuticals, we refer readers to the CY 2005 OPPS final rule 
with comment period (69 FR 65811), the CY 2006 OPPS final rule with 
comment period (70 FR 68655), and the CY 2010 OPPS/ASC final rule with 
comment period (74 FR 60524). The proposed CY 2019 payment rates for 
nonpass-through, separately payable therapeutic radiopharmaceuticals 
were included in Addenda A and B to the proposed rule (which are 
available via the internet on the CMS website).
    Comment: Commenters supported continuation of the policy to pay 
ASP+6 percent for therapeutic radiopharmaceuticals, if available, and 
to base payment on the mean unit cost derived from hospital claims data 
when not available. The commenters also requested that CMS examine ways 
to compensate hospitals for their documented higher overhead and 
handling costs associated with radiopharmaceuticals.
    Response: We appreciate the commenters' support. However, as we 
stated earlier in section V.B.1.c. of this final rule with comment 
period in response to a similar request for additional 
radiopharmaceutical payment and as previously stated in the CY 2018 
OPPS final rule with comment period (82 FR 59352), we continue to 
believe that a single payment is appropriate for radiopharmaceuticals 
with pass-through payment status in CY 2019 and that the payment rate 
of ASP+6 percent is appropriate to provide payment for both the 
radiopharmaceutical's acquisition cost and any associated nuclear 
medicine handling and compounding costs incurred by the hospital 
pharmacy. Payment for the radiopharmaceutical and radiopharmaceutical 
processing services is made through the single ASP-based payment. We 
refer readers to the CMS guidance document available via the internet 
at https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/HospitalOutpatientPPS/Archives.html for details on submission of ASP 
data for therapeutic radiopharmaceuticals.
    Comment: One commenter asked CMS to clarify the payment rate 
reported for APC 1675, P32 Na phosphate (HCPCS code A9563), which is 
based on geometric mean unit cost. The commenter stated that, in the 
proposed rule, the payment rate for HCPCS code A9563 was reported as 
$256.00, but the mean unit cost for the radiopharmaceutical as reported 
in data files accompanying the proposed rule was $519.21.
    Response: We thank the commenter for bringing this reporting error 
to our attention. We are providing a corrected payment rate for APC 
1675, P32 Na

[[Page 58978]]

phosphate (HCPCS code A9563) in Addenda A and B of this final rule with 
comment period (which is available via the internet on the CMS 
website).
    After consideration of the public comments we received, we are 
finalizing our proposal, without modification, to continue to pay all 
nonpass-through, separately payable therapeutic radiopharmaceuticals at 
ASP+6 percent. We also are finalizing our proposal to continue to rely 
on CY 2017 mean unit cost data derived from hospital claims data for 
payment rates for therapeutic radiopharmaceuticals for which ASP data 
are unavailable. The CY 2019 final payment rates for nonpass-through 
separately payable therapeutic radiopharmaceuticals are included in 
Addenda A and B to this final rule with comment period (which are 
available via the internet on the CMS website).
4. Payment Adjustment Policy for Radioisotopes Derived From Non-Highly 
Enriched Uranium Sources
    Radioisotopes are widely used in modern medical imaging, 
particularly for cardiac imaging and predominantly for the Medicare 
population. Some of the Technetium-99 (Tc-99m), the radioisotope used 
in the majority of such diagnostic imaging services, is produced in 
legacy reactors outside of the United States using highly enriched 
uranium (HEU).
    The United States would like to eliminate domestic reliance on 
these reactors, and is promoting the conversion of all medical 
radioisotope production to non-HEU sources. Alternative methods for 
producing Tc-99m without HEU are technologically and economically 
viable, and conversion to such production has begun. We expect that 
this change in the supply source for the radioisotope used for modern 
medical imaging will introduce new costs into the payment system that 
are not accounted for in the historical claims data.
    Therefore, beginning in CY 2013, we finalized a policy to provide 
an additional payment of $10 for the marginal cost for radioisotopes 
produced by non-HEU sources (77 FR 68323). Under this policy, hospitals 
report HCPCS code Q9969 (Tc-99m from non-highly enriched uranium 
source, full cost recovery add-on per study dose) once per dose along 
with any diagnostic scan or scans furnished using Tc-99m as long as the 
Tc-99m doses used can be certified by the hospital to be at least 95 
percent derived from non-HEU sources (77 FR 68321).
    We stated in the CY 2013 OPPS/ASC final rule with comment period 
(77 FR 68321) that our expectation is that this additional payment will 
be needed for the duration of the industry's conversion to alternative 
methods to producing Tc-99m without HEU. We also stated that we would 
reassess, and propose if necessary, on an annual basis whether such an 
adjustment continued to be necessary and whether any changes to the 
adjustment were warranted (77 FR 68316). A 2016 report from the 
National Academies of Sciences, Engineering, and Medicine anticipates 
the conversion of Tc-99m production from non-HEU sources will not be 
complete until the end of 2019.\58\ In addition, one of the 
manufacturers of Tc-99m generators sent a letter to CMS to support 
continuing the payment adjustment at the current level because only 30 
percent of Tc-99m is produced from non-HEU sources. We also met with a 
trade group of nuclear pharmacies and cyclotron operators who support 
an increase in the payment adjustment by the rate of inflation to cover 
more of the cost of Tc-99m from non-HEU sources.
---------------------------------------------------------------------------

    \58\ National Academies of Sciences, Engineering, and Medicine. 
2016. Molybdenum-99 for Medical Imaging. Washington, DC: The 
National Academies Press. Available at: https://doi.org/10.17226/23563.
---------------------------------------------------------------------------

    We appreciate the feedback from stakeholders. However, as stated in 
the CY 2019 OPPS/ASC proposed rule, we continue to believe that the 
current adjustment is sufficient for the reasons we have outlined in 
this and prior rulemakings. The information from stakeholders and the 
National Academies of Sciences, Engineering, and Medicine indicates 
that the conversion of the production of Tc-99m from non-HEU sources 
may take more than 1 year after CY 2018. Therefore, in the CY 2019 
OPPS/ASC proposed rule (83 FR 37124), for CY 2019 and subsequent years, 
we proposed to continue to provide an additional $10 payment for 
radioisotopes produced by non-HEU sources. We noted in the proposed 
rule our intention to reassess this payment policy once conversion to 
non-HEU sources is closer to completion or has been completed.
    Comment: Several commenters requested that the additional payment 
for radioisotopes produced by non-HEU sources be increased to either 
$30 or $10 plus the percentage increase in hospital charge data for APC 
1442 for the period of 2014 through 2019, which appears to be a request 
from the commenter to increase the payment by the rate of hospital 
inflation. One of the commenters supported this request by supplying 
provider cost data showing the cost difference between HEU Mo-99 and 
non-HEU Mo-99 in 2017 per curie was around $30.
    One commenter requested that CMS provide an explanation for not 
applying an annual inflation update to the $10 payment for 
radioisotopes produced by non-HEU sources, provide details on plans to 
offset nuclear medicine procedures by the amount of cost paid through 
the non-HEU policy, and make available to the public data regarding the 
claims submitted to date under this policy. The commenter also stated 
that CMS should assess whether the beneficiary copayment policy is 
adversely impacting patient access.
    Response: We appreciate the information we received from 
stakeholders supporting an increase to the payment rate of $10 for 
HCPCS code Q9969. As we stated in the CY 2013 OPPS/ASC final rule with 
comment period (77 FR 68317), ``The purpose for the additional payment 
is limited to mitigating any adverse impact of existing payment policy 
and is based on the authority set forth at section 1833(t)(2)(E) of the 
Act.'' However, we are open to further study of this issue and are 
interested in exploring whether a higher add-on payment, such as $30, 
may be warranted for a future year. We invite stakeholders to continue 
to submit data and evidence for further consideration as we continue to 
evaluate this policy. As discussed in the CY 2013 OPPS/ASC final rule 
with comment period, we did not finalize a policy to use the usual OPPS 
methodologies to update the non-HEU add-on payment (77 FR 68317). The 
purpose of the additional payment is limited to mitigating any adverse 
impact of transitioning to non-HEU sources and is based on the 
authority set forth at section 1833(t)(2)(E) of the Act. Therefore, we 
will maintain the current payment rate of $10.
    With respect to the comment that we should assess whether the 
beneficiary copayment amount is adversely affecting patient access, we 
will consider the commenter's concern. However, we note that increasing 
the add-on payment from the current level as the commenter suggested 
would necessarily increase the beneficiary copayment liability. 
Finally, the offset for nuclear medicine procedures does not include 
the cost of the non-HEU add-on payment.
    Comment: One commenter requested that CMS provide detailed data on 
hospital costs associated with radiopharmaceuticals reported with HCPCS 
code Q9969.
    Response: It is unclear what specific data this commenter is 
seeking that are not already available through public use

[[Page 58979]]

files. We note that, in 2017, HCPCS code Q9969 was billed 34,439 times 
and is commonly reported with Level II HCPCS codes A9500 (Technetium 
tc-99m sestamibi, diagnostic, per study dose) and A9503 (Technetium tc-
99m medronate, diagnostic, per study dose, up to 30 millicuries). The 
geometric mean costs of this and all Level II HCPCS drug codes, 
including radiopharmaceutical drug codes, can be found in the cost 
statistics file that is released with this final rule with comment 
period.
    After consideration of the public comments we received, we are 
finalizing our proposal, without modification, to continue the policy 
of providing an additional $10 payment for radioisotopes produced by 
non-HEU sources for CY 2019 and subsequent years. We will reassess this 
payment policy once conversion to non-HEU sources is closer to 
completion or has been completed.
5. Payment for Blood Clotting Factors
    For CY 2018, we provided payment for blood clotting factors under 
the same methodology as other nonpass-through separately payable drugs 
and biologicals under the OPPS and continued paying an updated 
furnishing fee (82 FR 59353). That is, for CY 2018, we provided payment 
for blood clotting factors under the OPPS at ASP+6 percent, plus an 
additional payment for the furnishing fee. We note that when blood 
clotting factors are provided in physicians' offices under Medicare 
Part B and in other Medicare settings, a furnishing fee is also applied 
to the payment. The CY 2018 updated furnishing fee was $0.215 per unit.
    In the CY 2019 OPPS/ASC proposed rule (83 FR 37124), for CY 2019, 
we proposed to pay for blood clotting factors at ASP+6 percent, 
consistent with our proposed payment policy for other nonpass-through, 
separately payable drugs and biologicals, and to continue our policy 
for payment of the furnishing fee using an updated amount. Our policy 
to pay for a furnishing fee for blood clotting factors under the OPPS 
is consistent with the methodology applied in the physician's office 
and in the inpatient hospital setting. These methodologies were first 
articulated in the CY 2006 OPPS final rule with comment period (70 FR 
68661) and later discussed in the CY 2008 OPPS/ASC final rule with 
comment period (72 FR 66765). The proposed furnishing fee update was 
based on the percentage increase in the Consumer Price Index (CPI) for 
medical care for the 12-month period ending with June of the previous 
year. Because the Bureau of Labor Statistics releases the applicable 
CPI data after the PFS and OPPS/ASC proposed rules are published, we 
were not able to include the actual updated furnishing fee in the 
proposed rules. Therefore, in accordance with our policy, as finalized 
in the CY 2008 OPPS/ASC final rule with comment period (72 FR 66765), 
we proposed to announce the actual figure for the percent change in the 
applicable CPI and the updated furnishing fee calculated based on that 
figure through applicable program instructions and posting on the CMS 
website at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Part-B-Drugs/McrPartBDrugAvgSalesPrice/.
    Comment: Commenters supported CMS' proposal to continue to pay for 
blood clotting factors at ASP+6 percent plus a blood clotting factor 
furnishing fee in the hospital outpatient department.
    Response: We appreciate the commenters' support.
    After consideration of the public comments we received, we are 
finalizing our proposal, without modification, to provide payment for 
blood clotting factors under the same methodology as other separately 
payable drugs and biologicals under the OPPS and to continue payment of 
an updated furnishing fee. We will announce the actual figure of the 
percent change in the applicable CPI and the updated furnishing fee 
calculation based on that figure through the applicable program 
instructions and posting on the CMS website.
6. Payment for Nonpass-Through Drugs, Biologicals, and 
Radiopharmaceuticals With HCPCS Codes but Without OPPS Hospital Claims 
Data
    In the CY 2019 OPPS/ASC proposed rule (83 FR 37125), for CY 2019, 
we proposed to continue to use the same payment policy as in CY 2018 
for nonpass-through drugs, biologicals, and radiopharmaceuticals with 
HCPCS codes but without OPPS hospital claims data, which describes how 
we determine the payment rate for drugs, biologicals, or 
radiopharmaceuticals without an ASP. For a detailed discussion of the 
payment policy and methodology, we refer readers to the CY 2016 OPPS/
ASC final rule with comment period (80 FR 70442 through 70443). The 
proposed CY 2019 payment status of each of the nonpass-through drugs, 
biologicals, and radiopharmaceuticals with HCPCS codes but without OPPS 
hospital claims data was listed in Addendum B to the proposed rule, 
which is available via the internet on the CMS website.
    We did not receive any comments on our proposal. Therefore, we are 
finalizing our CY 2019 proposal without modification, including our 
proposal to assign drug or biological products status indicator ``K'' 
and pay for them separately for the remainder of CY 2019 if pricing 
information becomes available. The CY 2019 payment status of each of 
the nonpass-through drugs, biologicals, and radiopharmaceuticals with 
HCPCS codes but without OPPS hospital claims data is listed in Addendum 
B to this final rule with comment period, which is available via the 
internet on the CMS website.
7. CY 2019 OPPS Payment Methodology for 340B Purchased Drugs
    In the CY 2018 OPPS/ASC proposed rule (82 FR 33558 through 33724), 
we proposed changes to the Medicare Part B drug payment methodology for 
340B hospitals. We proposed these changes to better, and more 
accurately, reflect the resources and acquisition costs that these 
hospitals incur. We believed that such changes would allow Medicare 
beneficiaries (and the Medicare program) to pay a more appropriate 
amount when hospitals participating in the 340B Program furnish drugs 
to Medicare beneficiaries that are purchased under the 340B Program. 
Subsequently, in the CY 2018 OPPS/ASC final rule with comment period 
(82 FR 59369 through 59370), we finalized our proposal and adjusted the 
payment rate for separately payable drugs and biologicals (other than 
drugs on pass-through payment status and vaccines) acquired under the 
340B Program from average sales price (ASP)+6 percent to ASP minus 22.5 
percent. Our goal is to make Medicare payment for separately payable 
drugs more aligned with the resources expended by hospitals to acquire 
such drugs, while recognizing the intent of the 340B Program to allow 
covered entities, including eligible hospitals, to stretch scarce 
resources in ways that enable hospitals to continue providing access to 
care for Medicare beneficiaries and other patients. Critical access 
hospitals are not included in this 340B policy change because they are 
paid under section 1834(g) of the Act. We also excepted rural sole 
community hospitals, children's hospitals, and PPS-exempt cancer 
hospitals from the 340B payment adjustment in CY 2018. In addition, as 
stated in the CY 2018 OPPS/ASC final rule with comment period, this 
policy change does not apply to drugs on pass-through payment status, 
which are required to be paid based on the ASP methodology, or

[[Page 58980]]

vaccines, which are excluded from the 340B Program.
    As discussed in the CY 2019 OPPS/ASC proposed rule (83 FR 37125), 
another topic that has been brought to our attention since we finalized 
the payment adjustment for 340B-acquired drugs in the CY 2018 OPPS/ASC 
final rule with comment period is whether drugs that do not have ASP 
pricing but instead receive WAC or AWP pricing are subject to the 340B 
payment adjustment. We did not receive public comments on this topic in 
response to the CY 2018 OPPS/ASC proposed rule. However, we have since 
heard from stakeholders that there has been some confusion about this 
issue. We clarified in the CY 2019 proposed rule that the 340B payment 
adjustment applies to drugs that are priced using either WAC or AWP, 
and it has been our policy to subject 340B-acquired drugs that use 
these pricing methodologies to the 340B payment adjustment since the 
policy was first adopted. The 340B payment adjustment for WAC-priced 
drugs is WAC minus 22.5 percent and AWP-priced drugs have a payment 
rate of 69.46 percent of AWP when the 340B payment adjustment is 
applied. The 69.46 percent of AWP is calculated by first reducing the 
original 95 percent of AWP price by 6 percent to generate a value that 
is similar to ASP or WAC with no percentage markup. Then we apply the 
22.5 percent reduction to ASP/WAC-similar AWP value to obtain the 69.46 
percent of AWP, which is similar to either ASP minus 22.5 percent or 
WAC minus 22.5 percent. The number of separately payable drugs 
receiving WAC or AWP pricing that are affected by the 340B payment 
adjustment is small--consisting of less than 10 percent of all 
separately payable Medicare Part B drugs in April 2018.
    Furthermore, data limitations previously inhibited our ability to 
identify which drugs were acquired under the 340B Program in the 
Medicare OPPS claims data. This lack of information within the claims 
data has limited researchers' and our ability to precisely analyze 
differences in acquisition cost of 340B and non-340B acquired drugs 
with Medicare claims data. Accordingly, in the CY 2018 OPPS/ASC 
proposed rule (82 FR 33633), we stated our intent to establish a 
modifier, to be effective January 1, 2018, for hospitals to report with 
separately payable drugs that were not acquired under the 340B Program. 
Because a significant portion of hospitals paid under the OPPS 
participate in the 340B Program, we stated our belief that it is 
appropriate to presume that a separately payable drug reported on an 
OPPS claim was purchased under the 340B Program, unless the hospital 
identifies that the drug was not purchased under the 340B Program. We 
stated in the CY 2018 proposed rule that we intended to provide further 
details about this modifier in the CY 2018 OPPS/ASC final rule with 
comment period and/or through subregulatory guidance, including 
guidance related to billing for dually eligible beneficiaries (that is, 
beneficiaries covered under Medicare and Medicaid) for whom covered 
entities do not receive a discount under the 340B Program. As discussed 
in the CY 2018 OPPS/ASC final rule with comment period (82 FR 59369 
through 59370), to effectuate the payment adjustment for 340B-acquired 
drugs, CMS implemented modifier ``JG'', effective January 1, 2018. 
Hospitals paid under the OPPS, other than a type of hospital excluded 
from the OPPS (such as critical access hospitals or those hospitals 
paid under the Maryland waiver), or excepted from the 340B drug payment 
policy for CY 2018, are required to report modifier ``JG'' on the same 
claim line as the drug HCPCS code to identify a 340B-acquired drug. For 
CY 2018, rural sole community hospitals, children's hospitals and PPS-
exempt cancer hospitals are excepted from the 340B payment adjustment. 
These hospitals are required to report informational modifier ``TB'' 
for 340B-acquired drugs, and continue to be paid ASP+6 percent.
    We refer readers to the CY 2018 OPPS/ASC final rule with comment 
period (82 FR 59353 through 59370) for a full discussion and rationale 
for the CY 2018 policies and use of modifier ``JG''.
    In the CY 2019 OPPS/ASC proposed rule (83 FR 37125), for CY 2019, 
we proposed to continue the 340B Program policies that were implemented 
in CY 2018 with the exception of the way we calculate payment for 340B-
acquired biosimilars (that is, we proposed to pay for nonpass-through 
340B-acquired biosimilars at ASP minus 22.5 percent of the biosimilar's 
ASP, rather than of the reference product's ASP). More information on 
our revised policy for the payment of biosimilars acquired through the 
340B Program is available in section V.B.2.c. of this final rule. We 
proposed, in accordance with section 1833(t)(14)(A)(iii)(II) of the 
Act, to pay for separately payable Medicare Part B drugs (assigned 
status indicator ``K''), other than vaccines and drugs on pass-through 
payment status, that meet the definition of ``covered outpatient drug'' 
as defined in section 1927(k) of the Act, that are acquired through the 
340B Program at ASP minus 22.5 percent when billed by a hospital paid 
under the OPPS that is not excepted from the payment adjustment. 
Medicare Part B drugs or biologicals excluded from the 340B payment 
adjustment include vaccines (assigned status indicator ``L'' or ``M'') 
and drugs with OPPS transitional pass-through payment status (assigned 
status indicator ``G''). As discussed in section V.B.2.c. of the 
proposed rule, we proposed to pay nonpass-through biosimilars acquired 
under the 340B Program at the biosimilar's ASP minus 22.5 percent of 
the biosimilar's ASP. We also proposed that Medicare would continue to 
pay for drugs or biologicals that were not purchased with a 340B 
discount at ASP+6 percent.
    As stated earlier, to effectuate the payment adjustment for 340B-
acquired drugs, CMS implemented modifier ``JG'', effective January 1, 
2018. For CY 2019, we proposed that hospitals paid under the OPPS, 
other than a type of hospital excluded from the OPPS, or excepted from 
the 340B drug payment policy for CY 2018, continue to be required to 
report modifier ``JG'' on the same claim line as the drug HCPCS code to 
identify a 340B-acquired drug. We also proposed for CY 2019 that rural 
sole community hospitals, children's hospitals, and PPS-exempt cancer 
hospitals continue to be excepted from the 340B payment adjustment. We 
proposed that these hospitals be required to report informational 
modifier ``TB'' for 340B-acquired drugs, and continue to be paid ASP+6 
percent.
    Comment: One commenter supported the proposal to continue to pay 
for separately payable drugs and biologicals obtained through the 340B 
program at ASP minus 22.5 percent. The commenter believed the payment 
rate of ASP minus 22.5 percent will help CMS address the large amount 
of growth in the 340B Program by increasing oversight and promoting the 
integrity of the program.
    Another commenter, MedPAC, also supported the proposal. MedPAC 
believed a lower payment rate allows beneficiaries to share in the 
savings from the 340B Program, better targets resources to hospitals 
providing the most uncompensated care, and still allows 340B hospitals 
to make a profit off the drugs obtained through the program. MedPAC 
preferred that the payment rate be ASP+6 percent minus a 10 percent 
discount with the savings assigned to a Medicare-funded uncompensated 
care pool, but noted that this policy requires Congressional action.
    Response: We appreciate the commenters' support.

[[Page 58981]]

    Comment: Several commenters opposed the CY 2019 proposal to 
continue to pay for separately payable drugs and biologicals obtained 
through the 340B Program at ASP minus 22.5 percent. Many commenters 
stated that the new payment rate has hurt hospitals financially and has 
hurt efforts by hospitals to provide safety-net care to their patients. 
The commenters were also concerned about the same service costing more 
at non-340B hospitals than at hospitals enrolled in the 340B Program 
because drugs furnished at a non-340B hospital would be paid at ASP+6 
percent while drugs furnished at a 340B hospital would be paid at ASP 
minus 22.5 percent. One commenter whose hospital provides cancer 
treatment stated the reductions in 340B payment mean the hospital 
cannot provide the broader cancer care options available at non-340B 
hospitals. Commenters also stated that reducing payment for drugs 
acquired through the 340B Program does not help reduce high drug costs. 
Many commenters asserted, as they have previously done, that CMS does 
not have the legal authority to implement payment reductions for drugs 
and biologicals obtained through the 340B Program. The commenters 
requested that CMS end its policy of paying for drugs obtained through 
the 340B program at ASP minus 22.5 percent. Instead, the commenters 
suggested that CMS go back to the payment policy that was in place 
before CY 2018 where drugs acquired through the 340B Program were paid 
at ASP+6 percent.
    Response: The commenters stated that the payment rate of ASP minus 
22.5 percent for drugs and biologicals has caused financial harm to 
hospitals and has caused problems for hospitals to provide safety-net 
care to their patients. We noted in the CY 2018 final rule with comment 
period (82 FR 59358 through 59359) that the OPPS payment rate of ASP+6 
percent at that time significantly exceeded the discounts received for 
covered outpatient drugs by hospitals enrolled in the 340B Program, 
which can be as much as 50 percent below ASP (or higher through the 
PVP). As stated throughout that section, ASP minus 22.5 percent 
represents the average minimum discount that 340B enrolled hospitals 
paid under the OPPS receive.
    Regarding the concerns of the commenters that drugs and biologicals 
and services where drugs and biologicals are packaged into the cost of 
the service would cost more at hospitals that do not participate in the 
340B Program as compared to hospitals participating in the 340B 
Program, any differential in these costs is a feature of the 340B 
Program rather than Medicare payment policy. In fact, one of the 
objectives of our payment policy for drugs and biologicals acquired 
through the 340B Program is to lower costs for Medicare beneficiaries, 
and we believe it is appropriate that hospitals participating in the 
340B Program pass the cost savings they receive to their beneficiaries.
    Finally, regarding the commenters' assertion that CMS lacks the 
legal authority to continue requiring payment reductions for drugs and 
biologicals obtained through the 340B Program, we refer these 
commenters to our detailed response regarding our statutory authority 
to require payment reductions for drugs and biologicals obtained 
through the 340B Program in the CY 2018 OPPS/ASC final rule with 
comment period (82 FR 59359 through 59364).
    After consideration of the public comments we received, we are 
finalizing our proposals without modification. For CY 2019, we are 
continuing the 340B Program policies that were implemented in CY 2018 
with the exception of the way we are calculating payment for 340B-
acquired biosimilars, which is discussed in section V.B.2.c. of this 
final rule with comment period. We refer readers to the CY 2018 final 
rule with comment period (82 FR 59369 through 59370) for more detail on 
the policies implemented in CY 2018 for drugs acquired through the 340B 
Program.

VI. Estimate of OPPS Transitional Pass-Through Spending for Drugs, 
Biologicals, Radiopharmaceuticals, and Devices

A. Background

    Section 1833(t)(6)(E) of the Act limits the total projected amount 
of transitional pass-through payments for drugs, biologicals, 
radiopharmaceuticals, and categories of devices for a given year to an 
``applicable percentage,'' currently not to exceed 2.0 percent of total 
program payments estimated to be made for all covered services under 
the OPPS furnished for that year. If we estimate before the beginning 
of the calendar year that the total amount of pass-through payments in 
that year would exceed the applicable percentage, section 
1833(t)(6)(E)(iii) of the Act requires a uniform prospective reduction 
in the amount of each of the transitional pass-through payments made in 
that year to ensure that the limit is not exceeded. We estimate the 
pass-through spending to determine whether payments exceed the 
applicable percentage and the appropriate pro-rata reduction to the 
conversion factor for the projected level of pass-through spending in 
the following year to ensure that total estimated pass-through spending 
for the prospective payment year is budget neutral, as required by 
section 1833(t)(6)(E) of the Act.
    For devices, developing an estimate of pass-through spending in CY 
2019 entails estimating spending for two groups of items. The first 
group of items consists of device categories that are currently 
eligible for pass-through payment and that will continue to be eligible 
for pass-through payment in CY 2019. The CY 2008 OPPS/ASC final rule 
with comment period (72 FR 66778) describes the methodology we have 
used in previous years to develop the pass-through spending estimate 
for known device categories continuing into the applicable update year. 
The second group of items consists of items that we know are newly 
eligible, or project may be newly eligible, for device pass-through 
payment in the remaining quarters of CY 2018 or beginning in CY 2019. 
The sum of the CY 2019 pass-through spending estimates for these two 
groups of device categories equals the total CY 2019 pass-through 
spending estimate for device categories with pass-through payment 
status. We base the device pass-through estimated payments for each 
device category on the amount of payment as established in section 
1833(t)(6)(D)(ii) of the Act, and as outlined in previous rules, 
including the CY 2014 OPPS/ASC final rule with comment period (78 FR 
75034 through 75036). We note that, beginning in CY 2010, the pass-
through evaluation process and pass-through payment for implantable 
biologicals newly approved for pass-through payment beginning on or 
after January 1, 2010, that are surgically inserted or implanted 
(through a surgical incision or a natural orifice) use the device pass-
through process and payment methodology (74 FR 60476). As has been our 
past practice (76 FR 74335), in the CY 2019 OPPS/ASC proposed rule (83 
FR 37126), we proposed to include an estimate of any implantable 
biologicals eligible for pass-through payment in our estimate of pass-
through spending for devices. Similarly, we finalized a policy in CY 
2015 that applications for pass-through payment for skin substitutes 
and similar products be evaluated using the medical device pass-through 
process and payment methodology (76 FR 66885 through 66888). Therefore, 
as we did beginning in CY 2015, for CY 2019, we

[[Page 58982]]

also proposed to include an estimate of any skin substitutes and 
similar products in our estimate of pass-through spending for devices.
    For drugs and biologicals eligible for pass-through payment, 
section 1833(t)(6)(D)(i) of the Act establishes the pass-through 
payment amount as the amount by which the amount authorized under 
section 1842(o) of the Act (or, if the drug or biological is covered 
under a competitive acquisition contract under section 1847B of the 
Act, an amount determined by the Secretary equal to the average price 
for the drug or biological for all competitive acquisition areas and 
year established under such section as calculated and adjusted by the 
Secretary) exceeds the portion of the otherwise applicable fee schedule 
amount that the Secretary determines is associated with the drug or 
biological. Our estimate of drug and biological pass-through payment 
for CY 2019 for this group of items is $0, as discussed below, because 
we proposed to pay for most nonpass-through separately payable drugs 
and biologicals under the CY 2019 OPPS at ASP+6 percent (with the 
exception of 340B-acquired separately payable drugs, for which we do 
not yet have sufficient data to estimate a share of total drug 
payments), and because we proposed to pay for CY 2019 pass-through 
payment drugs and biologicals at ASP+6 percent, as we discuss in 
section V.A. of the proposed rule and this final rule with comment 
period.
    Furthermore, payment for certain drugs, specifically diagnostic 
radiopharmaceuticals and contrast agents without pass-through payment 
status is packaged into payment for the associated procedures, and 
these products will not be separately paid. In addition, we policy-
package all nonpass-through drugs, biologicals, and 
radiopharmaceuticals that function as supplies when used in a 
diagnostic test or procedure and drugs and biologicals that function as 
supplies when used in a surgical procedure, as discussed in section 
II.A.3. of the proposed rule and this final rule with comment period. 
In the CY 2019 OPPS/ASC proposed rule (83 FR 37126), we proposed that 
all of these policy-packaged drugs and biologicals with pass-through 
payment status would be paid at ASP+6 percent, like other pass-through 
drugs and biologicals, for CY 2019. Therefore, our estimate of pass-
through payment for policy-packaged drugs and biologicals with pass-
through payment status approved prior to CY 2019 was not $0, as 
discussed below. In section V.A.5. of the proposed rule, we discussed 
our policy to determine if the costs of certain policy-packaged drugs 
or biologicals are already packaged into the existing APC structure. If 
we determine that a policy-packaged drug or biological approved for 
pass-through payment resembles predecessor drugs or biologicals already 
included in the costs of the APCs that are associated with the drug 
receiving pass-through payment, we proposed to offset the amount of 
pass-through payment for the policy-packaged drug or biological. For 
these drugs or biologicals, the APC offset amount is the portion of the 
APC payment for the specific procedure performed with the pass-through 
drug or biological, which we refer to as the policy-packaged drug APC 
offset amount. If we determine that an offset is appropriate for a 
specific policy-packaged drug or biological receiving pass-through 
payment, we proposed to reduce our estimate of pass-through payments 
for these drugs or biologicals by this amount.
    Similar to pass-through spending estimates for devices, the first 
group of drugs and biologicals requiring a pass-through payment 
estimate consists of those products that were recently made eligible 
for pass-through payment and that will continue to be eligible for 
pass-through payment in CY 2019. The second group contains drugs and 
biologicals that we know are newly eligible, or project will be newly 
eligible in the remaining quarters of CY 2018 or beginning in CY 2019. 
The sum of the CY 2019 pass-through spending estimates for these two 
groups of drugs and biologicals equals the total CY 2019 pass-through 
spending estimate for drugs and biologicals with pass-through payment 
status.

B. Estimate of Pass-Through Spending

    In the CY 2019 OPPS/ASC proposed rule (83 FR 37127), we proposed to 
set the applicable pass-through payment percentage limit at 2.0 percent 
of the total projected OPPS payments for CY 2019, consistent with 
section 1833(t)(6)(E)(ii)(II) of the Act and our OPPS policy from CY 
2004 through CY 2018 (82 FR 59371 through 59373).
    For the first group, consisting of device categories that are 
currently eligible for pass-through payment and will continue to be 
eligible for pass-through payment in CY 2019, there are no active 
categories for CY 2019. Because there are no active device categories 
for CY 2019, we proposed an estimate for the first group of devices of 
$0. We did not receive any public comments on the proposal. Therefore, 
we are finalizing the proposed estimate for the first group of devices 
of $0 for CY 2019.
    In estimating our proposed CY 2019 pass-through spending for device 
categories in the second group, we included: Device categories that we 
knew at the time of the development of the proposed rule will be newly 
eligible for pass-through payment in CY 2019; additional device 
categories that we estimated could be approved for pass-through status 
subsequent to the development of the proposed rule and before January 
1, 2019; and contingent projections for new device categories 
established in the second through fourth quarters of CY 2019. In the CY 
2019 OPPS/ASC proposed rule (83 FR 37127), we proposed to use the 
general methodology described in the CY 2008 OPPS/ASC final rule with 
comment period (72 FR 66778), while also taking into account recent 
OPPS experience in approving new pass-through device categories. For 
the proposed rule, the estimate of CY 2019 pass-through spending for 
this second group of device categories was $10 million.
    We did not receive any public comments on this proposal. As stated 
earlier in this final rule with comment period, we have decided to 
approve one device to receive pass-through status, the 
remed[emacr][supreg] System Transvenous Neurostimulator. The 
manufacturer of the remed[emacr][supreg] System provided utilization 
data that indicate the spending for the device would be approximately 
$2.5 million. However, it is possible that additional new devices may 
receive pass-through payment status during CY 2019, which would lead to 
the higher pass-through spending for new devices closer to our proposed 
estimate of $10 million. Therefore, we are finalizing the proposed 
estimate for this second group of devices of $10 million for CY 2019.
    To estimate proposed CY 2019 pass-through spending for drugs and 
biologicals in the first group, specifically those drugs and 
biologicals recently made eligible for pass-through payment and 
continuing on pass-through payment status for CY 2019, we proposed to 
use the most recent Medicare hospital outpatient claims data regarding 
their utilization, information provided in the respective pass-through 
applications, historical hospital claims data, pharmaceutical industry 
information, and clinical information regarding those drugs or 
biologicals to project the CY 2019 OPPS utilization of the products.
    For the known drugs and biologicals (excluding policy-packaged 
diagnostic radiopharmaceuticals, contrast agents, drugs, biologicals, 
and radiopharmaceuticals that function as supplies when used in a 
diagnostic test

[[Page 58983]]

or procedure, and drugs and biologicals that function as supplies when 
used in a surgical procedure) that will be continuing on pass-through 
payment status in CY 2019, we estimated the pass-through payment amount 
as the difference between ASP+6 percent and the payment rate for 
nonpass-through drugs and biologicals that will be separately paid at 
ASP+6 percent, which is zero for this group of drugs. Because payment 
for policy-packaged drugs and biologicals is packaged if the product 
was not paid separately due to its pass-through payment status, we 
proposed to include in the CY 2019 pass-through estimate the difference 
between payment for the policy-packaged drug or biological at ASP+6 
percent (or WAC+6 percent, or 95 percent of AWP, if ASP or WAC 
information is not available) and the policy-packaged drug APC offset 
amount, if we determine that the policy-packaged drug or biological 
approved for pass-through payment resembles a predecessor drug or 
biological already included in the costs of the APCs that are 
associated with the drug receiving pass-through payment. For the 
proposed rule, using the proposed methodology described above, we 
calculated a CY 2019 proposed spending estimate for this first group of 
drugs and biologicals of approximately $61.5 million.
    We did not receive any public comments on our proposal. Using our 
methodology for this final rule with comment period, we calculated a CY 
2019 spending estimate for this first group of drugs and biologicals of 
approximately $50.9 million.
    To estimate proposed CY 2019 pass-through spending for drugs and 
biologicals in the second group (that is, drugs and biologicals that we 
knew at the time of development of the proposed rule were newly 
eligible for pass-through payment in CY 2019, additional drugs and 
biologicals that we estimated could be approved for pass-through status 
subsequent to the development of the proposed rule and before January 
1, 2018, and projections for new drugs and biologicals that could be 
initially eligible for pass-through payment in the second through 
fourth quarters of CY 2019), we proposed to use utilization estimates 
from pass-through applicants, pharmaceutical industry data, clinical 
information, recent trends in the per unit ASPs of hospital outpatient 
drugs, and projected annual changes in service volume and intensity as 
our basis for making the CY 2019 pass-through payment estimate. We also 
proposed to consider the most recent OPPS experience in approving new 
pass-through drugs and biologicals. Using our proposed methodology for 
estimating CY 2019 pass-through payments for this second group of 
drugs, we calculated a proposed spending estimate for this second group 
of drugs and biologicals of approximately $55.2 million.
    We did not receive any public comments on our proposal. Therefore, 
for CY 2019, we are continuing to use the general methodology described 
above. For this final rule with comment period, we calculated a CY 2019 
spending estimate for this second group of drugs and biologicals of 
approximately $39.9 million.
    In summary, in accordance with the methodology described earlier in 
this section, for this final rule with comment period, we estimate that 
total pass-through spending for the device categories and the drugs and 
biologicals that are continuing to receive pass-through payment in CY 
2019 and those device categories, drugs, and biologicals that first 
become eligible for pass-through payment during CY 2019 is 
approximately $100.8 million (approximately $10 million for device 
categories and approximately $90.8 million for drugs and biologicals) 
which represents 0.14 percent of total projected OPPS payments for CY 
2019 (approximately $74 billion). Therefore, we estimate that pass-
through spending in CY 2019 will not amount to 2.0 percent of total 
projected OPPS CY 2019 program spending.

VII. OPPS Payment for Hospital Outpatient Visits and Critical Care 
Services

    In the CY 2019 OPPS/ASC proposed rule (83 FR 37128), for CY 2019, 
we proposed to continue with our current clinic and emergency 
department (ED) hospital outpatient visits payment policies. For a 
description of the current clinic and ED hospital outpatient visits 
policies, we refer readers to the CY 2016 OPPS/ASC final rule with 
comment period (80 FR 70448). We also proposed to continue and did not 
propose any change to our payment policy for critical care services for 
CY 2019. For a description of the current payment policy for critical 
care services, we refer readers to the CY 2016 OPPS/ASC final rule with 
comment period (80 FR 70449), and for the history of the payment policy 
for critical care services, we refer readers to the CY 2014 OPPS/ASC 
final rule with comment period (78 FR 75043). In the CY 2019 OPPS/ASC 
proposed rule, we sought public comments on any changes to these codes 
that we should consider for future rulemaking cycles. We continue to 
encourage commenters to provide the data and analysis necessary to 
justify any suggested changes.
    We did not receive any public comments on our proposals to continue 
our current clinic and ED hospital outpatient visits payment policies 
and our current critical care services payment policies. Therefore, we 
are adopting these proposals as final without modification.
    In section X.V. of the CY 2019 OPPS/ASC proposed rule (83 FR 37138 
through 37143), for 2019, we proposed a method to control unnecessary 
increases in the volume of covered outpatient department services under 
section 1833(t)(2)(F) of the Act by utilizing a Medicare Physician Fee 
Schedule (PFS)-equivalent payment rate for the hospital outpatient 
clinic visit (HCPCS code G0463) when it is furnished by excepted off-
campus provider-based departments (PBDs). For a full discussion of the 
proposal as well as the comment solicitation on potential methods to 
control for unnecessary increases in the volume of covered outpatient 
department services, we refer readers to section X.B. of this final 
rule with comment period.

VIII. Payment for Partial Hospitalization Services

A. Background

    A partial hospitalization program (PHP) is an intensive outpatient 
program of psychiatric services provided as an alternative to inpatient 
psychiatric care for individuals who have an acute mental illness, 
which includes, but is not limited to, conditions such as depression, 
schizophrenia, and substance use disorders. Section 1861(ff)(1) of the 
Act defines partial hospitalization services as the items and services 
described in paragraph (2) prescribed by a physician and provided under 
a program described in paragraph (3) under the supervision of a 
physician pursuant to an individualized, written plan of treatment 
established and periodically reviewed by a physician (in consultation 
with appropriate staff participating in such program), which sets forth 
the physician's diagnosis, the type, amount, frequency, and duration of 
the items and services provided under the plan, and the goals for 
treatment under the plan. Section 1861(ff)(2) of the Act describes the 
items and services included in partial hospitalization services. 
Section 1861(ff)(3)(A) of the Act specifies that a PHP is a program 
furnished by a hospital to its outpatients or by a community mental 
health center (CMHC), as a distinct and organized

[[Page 58984]]

intensive ambulatory treatment service, offering less than 24-hour-
daily care, in a location other than an individual's home or inpatient 
or residential setting. Section 1861(ff)(3)(B) of the Act defines a 
CMHC for purposes of this benefit.
    Section 1833(t)(1)(B)(i) of the Act provides the Secretary with the 
authority to designate the outpatient department (OPD) services to be 
covered under the OPPS. The Medicare regulations that implement this 
provision specify, at 42 CFR 419.21, that payments under the OPPS will 
be made for partial hospitalization services furnished by CMHCs as well 
as Medicare Part B services furnished to hospital outpatients 
designated by the Secretary, which include partial hospitalization 
services (65 FR 18444 through 18445).
    Section 1833(t)(2)(C) of the Act requires the Secretary, in part, 
to establish relative payment weights for covered OPD services (and any 
groups of such services described in section 1833(t)(2)(B) of the Act) 
based on median (or, at the election of the Secretary, mean) hospital 
costs using data on claims from 1996 and data from the most recent 
available cost reports. In pertinent part, section 1833(t)(2)(B) of the 
Act provides that the Secretary may establish groups of covered OPD 
services, within a classification system developed by the Secretary for 
covered OPD services, so that services classified within each group are 
comparable clinically and with respect to the use of resources. In 
accordance with these provisions, we have developed the PHP APCs. 
Because a day of care is the unit that defines the structure and 
scheduling of partial hospitalization services, we established a per 
diem payment methodology for the PHP APCs, effective for services 
furnished on or after July 1, 2000 (65 FR 18452 through 18455). Under 
this methodology, the median per diem costs were used to calculate the 
relative payment weights for the PHP APCs. Section 1833(t)(9)(A) of the 
Act requires the Secretary to review, not less often than annually, and 
revise the groups, the relative payment weights, and the wage and other 
adjustments described in section 1833(t)(2) of the Act to take into 
account changes in medical practice, changes in technology, the 
addition of new services, new cost data, and other relevant information 
and factors.
    We began efforts to strengthen the PHP benefit through extensive 
data analysis, along with policy and payment changes finalized in the 
CY 2008 OPPS/ASC final rule with comment period (72 FR 66670 through 
66676). In that final rule with comment period, we made two refinements 
to the methodology for computing the PHP median: The first remapped 10 
revenue codes that are common among hospital-based PHP claims to the 
most appropriate cost centers; and the second refined our methodology 
for computing the PHP median per diem cost by computing a separate per 
diem cost for each day rather than for each bill.
    In CY 2009, we implemented several regulatory, policy, and payment 
changes, including a two-tier payment approach for partial 
hospitalization services under which we paid one amount for days with 3 
services under PHP APC 0172 (Level 1 Partial Hospitalization) and a 
higher amount for days with 4 or more services under PHP APC 0173 
(Level 2 Partial Hospitalization) (73 FR 68688 through 68693). We also 
finalized our policy to deny payment for any PHP claims submitted for 
days when fewer than 3 units of therapeutic services are provided (73 
FR 68694). Furthermore, for CY 2009, we revised the regulations at 42 
CFR 410.43 to codify existing basic PHP patient eligibility criteria 
and to add a reference to current physician certification requirements 
under 42 CFR 424.24 to conform our regulations to our longstanding 
policy (73 FR 68694 through 68695). We also revised the partial 
hospitalization benefit to include several coding updates (73 FR 68695 
through 68697).
    For CY 2010, we retained the two-tier payment approach for partial 
hospitalization services and used only hospital-based PHP data in 
computing the PHP APC per diem costs, upon which PHP APC per diem 
payment rates are based. We used only hospital-based PHP data because 
we were concerned about further reducing both PHP APC per diem payment 
rates without knowing the impact of the policy and payment changes we 
made in CY 2009. Because of the 2-year lag between data collection and 
rulemaking, the changes we made in CY 2009 were reflected for the first 
time in the claims data that we used to determine payment rates for the 
CY 2011 rulemaking (74 FR 60556 through 60559).
    In the CY 2011 OPPS/ASC final rule with comment period (75 FR 
71994), we established four separate PHP APC per diem payment rates: 
Two for CMHCs (APC 0172 (for Level 1 services) and APC 0173 (for Level 
2 services)) and two for hospital-based PHPs (APC 0175 (for Level 1 
services) and 0176 (for Level 2 services)), based on each provider 
type's own unique data. For CY 2011, we also instituted a 2-year 
transition period for CMHCs to the CMHC APC per diem payment rates 
based solely on CMHC data. Under the transition methodology, CMHC APCs 
Level 1 and Level 2 per diem costs were calculated by taking 50 percent 
of the difference between the CY 2010 final hospital-based PHP median 
costs and the CY 2011 final CMHC median costs and then adding that 
number to the CY 2011 final CMHC median costs. A 2-year transition 
under this methodology moved us in the direction of our goal, which is 
to pay appropriately for partial hospitalization services based on each 
provider type's data, while at the same time allowing providers time to 
adjust their business operations and protect access to care for 
Medicare beneficiaries. We also stated that we would review and analyze 
the data during the CY 2012 rulemaking cycle and, based on these 
analyses, we might further refine the payment mechanism. We refer 
readers to section X.B. of the CY 2011 OPPS/ASC final rule with comment 
period (75 FR 71991 through 71994) for a full discussion.
    In addition, in accordance with section 1301(b) of the Health Care 
and Education Reconciliation Act of 2010 (HCERA 2010), we amended the 
description of a PHP in our regulations to specify that a PHP must be a 
distinct and organized intensive ambulatory treatment program offering 
less than 24-hour daily care other than in an individual's home or in 
an inpatient or residential setting. In accordance with section 1301(a) 
of HCERA 2010, we revised the definition of a CMHC in the regulations 
to conform to the revised definition now set forth under section 
1861(ff)(3)(B) of the Act (75 FR 71990).
    For CY 2012, as discussed in the CY 2012 OPPS/ASC final rule with 
comment period (76 FR 74348 through 74352), we determined the relative 
payment weights for partial hospitalization services provided by CMHCs 
based on data derived solely from CMHCs and the relative payment 
weights for partial hospitalization services provided by hospital-based 
PHPs based exclusively on hospital data.
    In the CY 2013 OPPS/ASC final rule with comment period, we 
finalized our proposal to base the relative payment weights that 
underpin the OPPS APCs, including the four PHP APCs (APCs 0172, 0173, 
0175, and 0176), on geometric mean costs rather than on the median 
costs. We established these four PHP APC per diem payment rates based 
on geometric mean cost levels calculated using the most recent claims 
and cost data for each provider type. For a detailed discussion on this 
policy, we refer readers to the CY 2013 OPPS/ASC

[[Page 58985]]

final rule with comment period (77 FR 68406 through 68412).
    In the CY 2014 OPPS/ASC proposed rule (78 FR 43621 through 43622), 
we solicited comments on possible future initiatives that may help to 
ensure the long-term stability of PHPs and further improve the accuracy 
of payment for PHP services, but proposed no changes. In the CY 2014 
OPPS/ASC final rule with comment period (78 FR 75050 through 75053), we 
summarized the comments received on those possible future initiatives. 
We also continued to apply our established policies to calculate the 
four PHP APC per diem payment rates based on geometric mean per diem 
costs using the most recent claims data for each provider type. For a 
detailed discussion on this policy, we refer readers to the CY 2014 
OPPS/ASC final rule with comment period (78 FR 75047 through 75050).
    In the CY 2015 OPPS/ASC final rule with comment period (79 FR 66902 
through 66908), we continued to apply our established policies to 
calculate the four PHP APC per diem payment rates based on PHP APC 
geometric mean per diem costs, using the most recent claims and cost 
data for each provider type.
    In the CY 2016 OPPS/ASC final rule with comment period (80 FR 70455 
through 70465), we described our extensive analysis of the claims and 
cost data and ratesetting methodology. We found aberrant data from some 
hospital-based PHP providers that were not captured using the existing 
OPPS 3 standard deviation trims for extreme cost-to-charge 
ratios (CCRs) and excessive CMHC charges resulting in CMHC geometric 
mean costs per day that were approximately the same as or more than the 
daily payment for inpatient psychiatric facility services. 
Consequently, we implemented a trim to remove hospital-based PHP 
service days that use a CCR that was greater than 5 to calculate costs 
for at least one of their component services, and a trim on CMHCs with 
a geometric mean cost per day that is above or below 2 (2) 
standard deviations from the mean. We stated in the CY 2016 OPPS/ASC 
final rule with comment period (80 FR 70456) that, without using a 
trimming process, the data from these providers would inappropriately 
skew the geometric mean per diem cost for Level 2 CMHC services.
    In addition, in the CY 2016 OPPS/ASC final rule with comment period 
(80 FR 70459 through 70460), we corrected a cost inversion that 
occurred in the final rule data with respect to hospital-based PHP 
providers. We corrected the cost inversion with an equitable adjustment 
to the actual geometric mean per diem costs by increasing the Level 2 
hospital-based PHP APC geometric mean per diem costs and decreasing the 
Level 1 hospital-based PHP APC geometric mean per diem costs by the 
same factor, to result in a percentage difference equal to the average 
percent difference between the hospital-based Level 1 PHP APC and the 
Level 2 PHP APC for partial hospitalization services from CY 2013 
through CY 2015.
    Finally, we renumbered the PHP APCs, which were previously 0172, 
0173, 0175, and 0176, to 5851, 5852, 5861, and 5862, respectively. For 
a detailed discussion of the PHP ratesetting process, we refer readers 
to the CY 2016 OPPS/ASC final rule with comment period (80 FR 70462 
through 70467).
    In the CY 2017 OPPS/ASC final rule with comment period (81 FR 79687 
through 79691), we continued to apply our established policies to 
calculate the PHP APC per diem payment rates based on geometric mean 
per diem costs using the most recent claims and cost data for each 
provider type. However, we finalized a policy to combine the Level 1 
and Level 2 PHP APCs for CMHCs and to combine the Level 1 and Level 2 
APCs for hospital-based PHPs because we believed this would best 
reflect actual geometric mean per diem costs going forward, provide 
more predictable per diem costs, particularly given the small number of 
CMHCs, and generate more appropriate payments for these services, for 
example by avoiding the cost inversions for hospital-based PHPs 
addressed in the CY 2016 and CY 2017 OPPS/ASC final rules with comment 
period (80 FR 70459 and 81 FR 79682). We implemented an 8-percent 
outlier cap for CMHCs to mitigate potential outlier billing 
vulnerabilities by limiting the impact of inflated CMHC charges on 
outlier payments. We will continue to monitor the trends in outlier 
payments and consider policy adjustments as necessary.
    In the CY 2018 OPPS/ASC final rule with comment period (82 FR 59373 
through 59381), we continued to apply our established policies to 
calculate the PHP APC per diem payment rates based on geometric mean 
per diem costs using the most recent claims and cost data for each 
provider type. We continued to designate a portion of the estimated 1.0 
percent hospital outpatient outlier threshold specifically for CMHCs, 
consistent with the percentage of projected payments to CMHCs under the 
OPPS, excluding outlier payments.
    For a comprehensive description of PHP payment policy, including a 
detailed methodology for determining PHP per diem amounts, we refer 
readers to the CY 2016 and CY 2017 OPPS/ASC final rules with comment 
period (80 FR 70453 through 70455 and 81 FR 79678 through 79680).

B. PHP APC Update for CY 2019

1. PHP APC Geometric Mean per Diem Costs
    For CY 2019, in the CY 2019 OPPS/ASC proposed rule (83 FR 37130), 
we proposed to continue to apply our established policies to calculate 
the PHP APC per diem payment rates based on geometric mean per diem 
costs using the most recent claims and cost data for each provider 
type. Specifically, we proposed to continue to use CMHC APC 5853 
(Partial Hospitalization (3 or More Services Per Day)) and hospital-
based PHP APC 5863 (Partial Hospitalization (3 or More Services Per 
Day)). We proposed to continue to calculate the geometric mean per diem 
costs for CY 2019 for APC 5853 for CMHCs using only CY 2017 CMHC claims 
data and the most recent CMHC cost data, and the CY 2019 geometric mean 
per diem costs for APC 5863 for hospital-based PHPs using only CY 2017 
hospital-based PHP claims data and the most recent hospital cost data.
    We summarize the public comments we received related to these PHP 
proposals and methodology and include our responses in the sections 
below focused on CMHC ratesetting and on hospital-based PHP ratesetting 
in this CY 2019 OPPS/ASC final rule with comment period.
2. Development of the PHP APC Geometric Mean per Diem Costs
    In the CY 2019 OPPS/ASC proposed rule (83 FR 37130), for CY 2019 
and subsequent years, we proposed to follow the PHP ratesetting 
methodology described in section VIII.B.2. of the CY 2016 OPPS/ASC 
final rule with comment period (80 FR 70462 through 70466) to determine 
the PHP APCs' geometric mean per diem costs and to calculate the 
payment rates for APCs 5853 and 5863, incorporating the modifications 
made in the CY 2017 OPPS/ASC final rule with comment period. As 
discussed in section VIII.B.1. of the CY 2017 OPPS/ASC final rule with 
comment period (81 FR 79680 through 79687), the geometric mean per diem 
cost for hospital-based PHP APC 5863 is based upon actual hospital-
based PHP claims and costs for PHP service days providing 3 or more 
services. Similarly, the geometric mean per diem cost for CMHC APC 5853 
is based upon actual CMHC claims and costs for CMHC service days 
providing 3 or more services.

[[Page 58986]]

    The CMHC or hospital-based PHP APC per diem costs are the provider-
type specific costs derived from the most recent claims and cost data. 
The CMHC or hospital-based PHP APC per diem payment rates are the 
national unadjusted payment rates calculated from the CMHC or hospital-
based PHP APC per diem costs, after applying the OPPS budget neutrality 
adjustments described in section II.A.4. of this final rule with 
comment period.
    As previously stated, in the CY 2019 OPPS/ASC proposed rule, we 
proposed to apply our established methodologies in developing the CY 
2019 geometric mean per diem costs and payment rates, including the 
application of a 2 standard deviation trim on costs per day 
for CMHCs and a CCR greater than 5 hospital service day trim for 
hospital-based PHP providers. These two trims were finalized in the CY 
2016 OPPS/ASC final rule with comment period (80 FR 70455 through 
70462) for CY 2016 and subsequent years.
a. CMHC Data Preparation: Data Trims, Exclusions, and CCR Adjustments
    For this CY 2019 final rule with comment period, prior to 
calculating the final geometric mean per diem cost for CMHC APC 5853, 
we prepared the data by first applying trims and data exclusions, and 
assessing CCRs as described in the CY 2016 OPPS/ASC final rule with 
comment period (80 FR 70463 through 70465), so that ratesetting is not 
skewed by providers with extreme data. For this CY 2019 OPPS/ASC final 
rule with comment period, we used the same data preparation steps. 
Before any trims or exclusions were applied, there were 45 CMHCs in the 
final PHP claims data file (compared to 44 in the CY 2019 OPPS/ASC 
proposed rule). Under the 2 standard deviation trim policy, 
we excluded any data from a CMHC for ratesetting purposes when the 
CMHC's geometric mean cost per day was more than 2 standard 
deviations from the geometric mean cost per day for all CMHCs. By 
applying this trim for CY 2019 ratesetting, in this final rule with 
comment period, we excluded 4 CMHCs with geometric mean costs per day 
below the trim's lower limit of $49.86 and 2 CMHCs with geometric mean 
costs per day above the trim's upper limit of $293.60. This standard 
deviation trim removed 6 providers from the ratesetting whose overall 
effect on the data would have skewed downward the calculation of the 
final geometric mean per diem costs for CMHCs.
    In accordance with our PHP ratesetting methodology, as stated in 
the proposed rule, we also remove service days with no wage index 
values, because we use the wage index data to remove the effects of 
geographic variation in costs prior to APC geometric mean per diem cost 
calculation (80 FR 70465). For this CY 2019 final rule with comment 
period ratesetting, 1 CMHC was missing wage index data for all of its 
service days and was excluded.
    In addition to our trims and data exclusions, before determining 
the PHP APC geometric mean per diem costs, we also assess CCRs (80 FR 
70463). Our longstanding PHP OPPS ratesetting methodology defaults any 
CMHC CCR greater than 1 to the statewide hospital CCR (80 FR 70457). 
For this CY 2019 final rule with comment period ratesetting, we 
identified 3 CMHCs that had CCRs greater than 1. These CMHCs' CCRs were 
1.053, 1.009, and 1.025, and each was defaulted to its appropriate 
statewide hospital CCR for CY 2019 ratesetting purposes.
    In summary, these data preparation steps adjusted the CCR for 3 
CMHCs by defaulting to the appropriate statewide hospital CCR and 
excluded 7 CMHCs, resulting in the inclusion of a total of 38 CMHCs (45 
total--7 excluded) in our CY 2019 final rule with comment period 
ratesetting modeling (compared to a total of 36 CMHCs in our modeling 
in the CY 2019 OPPS/ASC proposed rule). The 2 standard 
deviation trim and the exclusion for missing wage index data removed 
425 CMHC claims out of a total of 14,431 CMHC claims, resulting in 
14,006 CMHC claims used for ratesetting purposes. We believe that 
excluding providers with extremely low or high geometric mean costs per 
day or extremely low or high CCRs protects CMHCs from having that data 
inappropriately skew the calculation of the CMHC APC geometric mean per 
diem cost.
    After applying all of the above trims, exclusions, and adjustments, 
we followed the methodology described in the CY 2016 OPPS/ASC final 
rule with comment period (80 FR 70464 through 70465) and modified in 
the CY 2017 OPPS/ASC final rule with comment period (81 FR 79687 
through 79688, and 79691) to calculate the final PHP APC geometric mean 
per diem cost.\59\ The final CY 2019 geometric mean per diem cost for 
all CMHCs for providing 3 or more services per day (CMHC PHP APC 5853) 
is $121.62 (compared to the proposed geometric mean per diem cost of 
$119.51).
---------------------------------------------------------------------------

    \59\ Each revenue code on the CMHC claim must have a HCPCS code 
and charge associated with it. We multiply each claim service line's 
charges by the CMHC's overall CCR (or statewide CCR, where the 
overall CCR was greater than 1) to estimate CMHC costs. Only the 
claims service lines containing PHP allowable HCPCS codes and PHP 
allowable revenue codes from the CMHC claims remaining after 
trimming are retained for CMHC cost determination. The costs, 
payments, and service units for all service lines occurring on the 
same service date, by the same provider, and for the same 
beneficiary are summed. CMHC service days must have 3 or more 
services provided to be assigned to CMHC APC 5853. The geometric 
mean per diem cost for CMHC APC 5853 is calculated by taking the nth 
root of the product of n numbers, for days where 3 or more services 
were provided. CMHC service days with costs 3 standard 
deviations from the geometric mean costs within APC 5853 are deleted 
and removed from modeling. The remaining PHP service days are used 
to calculate the geometric mean per diem cost for each PHP APC by 
taking the nth root of the product of n numbers for days where 3 or 
more services were provided.
---------------------------------------------------------------------------

    Below we summarize the public comments we received on our proposals 
related to continuing to follow our existing CMHC ratesetting 
methodology and the calculation of the CMHC geometric mean per diem 
costs.
    Comment: Two commenters objected to the continuation of separate 
APCs by provider type for CY 2019, stating that CMHCs and hospital-
based PHPs provide the same services and follow the same regulations, 
but CMHCs provide them for less costs. One commenter acknowledged that 
hospitals have higher cost structures, which the commenter asserted was 
due to hospitals' higher overhead allocation, but believed that CMHCs 
are being punished for providing more cost-effective and more intensive 
services.
    Response: We disagree that CMHCs are being punished for providing 
more cost-effective and more intensive services. The difference in 
payment between CMHCs and hospital-based PHPs reflects differences in 
resource use. When Congress required the Secretary to implement a 
hospital outpatient prospective payment system, it required the payment 
system to group covered services with respect to clinical similarity 
and resource use (section 1833(t)(2) of the Act). Because CMHCs' and 
hospital-based PHPs' resource uses are different, these two provider 
types are paid under different APCs, based on their actual resource 
use.
    Because the cost of providing partial hospitalization services 
differs significantly by site of service, we established different PHP 
payment rates for hospital-based PHPs and CMHCs in the CY 2011 OPPS/ASC 
final rule with comment period (75 FR 71991 through 71994). With 
respect to the continued use of PHP APC geometric mean per diem costs 
for determining payment rates by provider, we refer readers to the CY 
2013 OPPS/ASC final rule with comment period (77 FR 68406 through

[[Page 58987]]

68412) for a discussion of the implementation of this policy. The 
resulting payment rates reflect the geometric mean cost of what 
providers expend to maintain such programs, based on data provided by 
CMHCs and hospital-based PHPs, which we believe is an improvement over 
the two-tiered methodology calculated based on median costs using only 
hospital-based data.
    Comment: Two commenters opposed the continued use of the single-
tiered payment system implemented in CY 2017 OPPS/ASC rulemaking. One 
of these commenters asserted that the single-tiered system was 
implemented due to the cost inversion in hospital-based PHP data and, 
therefore, was unfairly applied to CMHCs. Another commenter did not 
object to the single payment tier, but suggested that CMS monitor the 
data to ensure that the single-tiered APCs do not result in a decrease 
in the number of operational PHPs.
    Response: We thank the commenters for their input. In the CY 2017 
OPPS/ASC final rule with comment period, we cited several reasons for 
implementing the single-tiered payment system (81 FR 79682 through 
79686), including the cost inversion in the hospital-based PHP data 
which the commenter cited. A cost inversion exists when, under a 2-
tiered payment system, the Level 1 geometric mean per diem cost for 
providing exactly 3 services per day exceeds the Level 2 PHP APC 
geometric mean per diem cost for providing 4 or more services per day. 
The commenter is correct that CMHCs were not affected by a cost 
inversion as hospital-based PHPs were. However, in that same CY 2017 
OPPS/ASC final rule with comment period, we noted that another primary 
reason for combining the 2-tiered system into a single tier, by 
provider type, was the decrease in the number of CMHCs (81 FR 79683). 
With a small number of providers, data from large providers with a high 
percentage of all PHP service days and unusually high or low geometric 
mean costs per day would have a more pronounced effect on the PHP APCs 
geometric mean per diem costs, skewing costs up or down. The effect 
would be magnified by continuing to split the geometric mean per diem 
costs further by distinguishing between Level 1 and Level 2 PHP 
services. A single PHP APC for each provider type for providing 3 or 
more PHP services per day reduces these cost fluctuations and provides 
more stability in the PHP APC geometric mean per diem costs.
    We do not believe that the single-tier payment system will lead to 
a reduction in the number of PHPs because total payments to an 
individual CMHC using the single-tier payment system are approximately 
equal to total payments to that same CMHC if the previous 2-tiered 
payment system were used instead. The calculated rates for APCs 5853 
and 5863 continue to be based upon the actual costs for CMHCs and 
hospital-based PHPs, respectively. Therefore, the payment rates for the 
single-tier PHP APCs are an appropriate approximation of provider 
costs, and should not result in reduced access. As we noted in the CY 
2017 OPPS/ASC final rule with comment period (81 FR 79685), the single-
tier PHP APCs are calculated by following the existing methodology for 
ratesetting, except that the geometric mean per diem costs for each 
provider type were calculated for days providing 3 or more partial 
hospitalization services, as opposed to being calculated separately for 
days with exactly 3 services and for days with 4 or more services, as 
was previously done. The combined PHP APCs' geometric mean costs are 
similar to a weighted average of actual provider costs. As such, 
combining the PHP APCs geometric mean per diem costs does not reduce 
total costs or total payments by provider type. We refer readers to the 
CY 2017 OPPS/ASC final rule with comment period for a detailed review 
of the methodology used in determining per diem costs using the single-
tier PHP APCs (81 FR 79686 through 79688).
    The 2017 claims data used for this CY 2019 ratesetting are the 
first year of data using the single-tier payment system. We will 
monitor the data for any unintended consequences on the number of 
operational PHPs associated with using the single-tier payment system. 
We note that the number of PHP providers is generally affected by 
multiple factors, such as business and market conditions, competition, 
estimated profit margins, private insurance coverage changes, Federal 
and State fraud and abuse efforts, and community support for mental 
health treatment.
    Comment: Several commenters questioned CMS' use of the 2 standard deviation trim on CMHC costs/per day, and asked why it 
was different from the OPPS 3 standard deviation trim which 
is applied to hospital-based PHPs. The commenters noted that the trims 
were implemented to help prevent inappropriate fluctuations in the 
data, but were concerned that this trim removed CMHCs from the data, 
and that this trim resulted in the decline in the costs per day.
    Response: The 2 standard deviation trim on CMHC costs/
per day was implemented in the CY 2016 OPPS final rule with comment 
period (80 FR 70455 through 70462) in order to protect CMHCs from 
having extreme costs per day inappropriately skew the CMHC PHP APC 
geometric mean per diem costs.
    As part of the effort to increase the accuracy of the PHP per diem 
costs, for the CY 2016 ratesetting, we completed an extensive analysis 
of the claims and cost data. That analysis identified aberrant data 
from several providers that impacted the calculation of the proposed 
PHP geometric mean per diem costs. For example, we found claims with 
excessive CMHC charges resulting in CMHC geometric mean costs per day 
that were approximately the same as or more than the daily payment for 
inpatient psychiatric facility services. For an outpatient program like 
PHP, because it does not incur room and board costs such as an 
inpatient stay would, these costs per day were excessive. In addition, 
we found some CMHCs had very low costs per day (less than $25 per day) 
(80 FR 70456). The 2 standard deviation trim on CMHC costs 
per day excludes providers with extremely low or extremely high costs 
per day, and protects CMHCs from having those extreme costs 
inappropriately skew the CMHC PHP APC geometric mean per diem costs.
    In addition, in that CY 2016 OPPS final rule with comment, we noted 
that the 2 standard deviation trim aligned the geometric 
mean and median per diem costs for the CMHC Level 2 PHP APC payment 
tier, which indicated that the trim removed the skewing in the data 
caused by the inclusion of aberrant data (80 FR 70456). We continue to 
believe that the 2 standard deviation trim excludes CMHCs 
with aberrant data from the ratesetting process while allowing for the 
use of as much data as possible. In addition, we stated that 
implementing a 2 standard deviation trim on CMHCs would 
target these aberrancies without limiting overall per diem cost 
increases. For normally distributed data, 2 standard 
deviations from the mean capture approximately 95 percent of the data. 
Our analyses for the CY 2016 ratesetting also showed that a higher trim 
level, such as a 2.5 standard deviation trim or the 3 standard deviation trim used by the rest of OPPS, did not 
remove the CMHCs with aberrant data from the ratesetting process (80 FR 
70456 and 70457).
    In this CY 2019 OPPS/ASC final rule, the 2 standard 
deviation trim on CMHC costs/day removed 6 CMHCs from ratesetting, 
which affected the final

[[Page 58988]]

per diem costs. It removed both low-cost and high-cost providers that 
fail the trim; its net effect on the CY 2019 ratesetting data was to 
increase CMHC geometric mean per diem costs. For CY 2019, if we did not 
apply the 2 standard deviation trim on CMHC costs/day, the 
final CMHC geometric mean per diem cost would have been $120.77. This 
is less than the geometric mean per diem cost of $121.62 which we are 
finalizing, and which is after applying the 2 standard 
deviation trim.
    With regard to the questions about why the same trims are not used 
for both CMHCs and hospital-based PHPs, we refer readers to the 
discussion in the CY 2016 OPPS/ASC final rule with comment period (80 
FR 70458). As we noted in that CY 2016 OPPS/ASC final rule with comment 
period, there are differences in the ratesetting process between 
hospital-based PHPs and CMHCs, which are largely due to differences 
between the hospital cost reports and the CMHC cost reports, and we 
believe that having different trims more appropriately targets aberrant 
data for each provider type. As noted previously, the OPPS 3 standard deviation trim on per diem costs did not remove the 
aberrant CMHC data. We considered applying the 2 standard 
deviation trim on per diem costs to hospital-based PHP providers, but 
an alternative trim on hospital-based CCRs greater than 5 allowed for 
use of more data from hospital-based providers and still removed 
aberrant data. We continue to believe this trim based on hospital-based 
PHP CCRs is more effective in removing aberrant hospital-based PHP data 
and allows for the use and retention of more data than a 2 
standard deviation trim on hospital-based PHP costs per day.
    Comment: Several commenters objected to the decline in the CMHC per 
diem costs that were proposed, and were concerned about the ability to 
maintain access to services. One commenter noted that CMHCs cannot 
provide all of the services they provide on a daily basis at the 
proposed payment rate. Some commenters also stated that CMHCs incur 
extra costs to meet the CMHC conditions of participation (CoPs), have 
more costly staff, or have experienced an increase in bad debt expense. 
A few commenters noted that the number of CMHCs nationally had declined 
greatly as a result of declines in payment and payment fluctuations. 
One commenter stated that setting CMHCs' payment rates based on a small 
number of CMHCs does not reflect the actual cost of providing these 
services and expressed concern that basing payments at the mean or 
median level would result in half of CMHCs receiving payments less than 
their cost, which would guarantee that more CMHCs would close, further 
limiting access. Commenters requested that CMS reconsider the payment 
rate reduction, which one commenter believed resulted in PHP services 
moving toward extinction in the current mode. Another commenter 
questioned if CMS had a veiled motivation to eliminate CMHCs 
altogether, and wondered if CMHCs were still considered the ``fraud 
benefit.'' Commenters also were concerned that if CMHC access declined, 
beneficiaries would be pushed toward higher-cost outpatient 
departments, resulting in higher out-of-pocket costs for beneficiaries. 
One commenter noted that CMHCs are in keeping with the health care 
trend to service patients in their communities, rather than forcing 
patients to travel to a medical center.
    Response: The OPPS pays for outpatient services, including partial 
hospitalization services, based on the geometric mean per diem costs of 
providing services using provider data from claims and cost reports, in 
accordance with statute. For this CY 2019 OPPS/ASC final rule with 
comment period, the final geometric mean per diem cost for CMHC APC 
5853 is $121.62, which is a slight increase from the proposed geometric 
mean per diem cost, but a 15-percent reduction from the CY 2018 final 
geometric mean per diem cost.
    In response to commenters concerned that CMHCs cannot provide all 
of the services offered on a daily basis at the proposed payment rate, 
we remind commenters that we calculate the PHP APC geometric mean per 
diem costs based on the data provided for each type of provider to 
determine payment for these services. The final PHP APC geometric mean 
per diem costs for CY 2019 reflect actual provider costs of covered 
services. We believe that this system provides appropriate payment for 
covered partial hospitalization services based on actual provider 
costs. We further note that section 1861(ff)(2)(I) of the Act 
explicitly prohibits Medicare from paying for the costs of meals or 
transportation, which some CMHCs incur. Therefore, these costs, 
although incurred by CMHCs, are not covered under the OPPS.
    In response to the commenters who stated that CMHCs incur extra 
costs to meet the CMHC CoPs, most (if not all) of the costs associated 
with adhering to CoPs should be captured in the cost report data used 
in ratesetting and, therefore, are accounted for when computing the 
geometric mean per diem costs. Similar to the requirement for CMHCs to 
comply with CMHC CoPs, hospital-based PHPs must also comply with 
hospital CoPs. All Medicare-participating facilities have CoPs or other 
requirements that must be met, and CMHCs are not specifically being 
singled out for compliance, nor are there ``extra'' costs associated 
with the CMHC CoPs.
    Allowable labor costs for providing direct patient care would also 
be captured in the cost report data used for ratesetting. We refer the 
commenters to the instructions for the CMHC cost reports for more 
information on capturing the costs associated with meeting CoPs and 
with labor costs for direct patient care, which are available online in 
links to Chapters 18 and 45 found at: https://www.cms.gov/Regulations-and-Guidance/Guidance/Manuals/Paper-Based-Manuals-Items/CMS021935.html?DLPage=1&DLEntries=10&DLSort=0&DLSortDir=scending. The 
covered costs of providing PHP care to beneficiaries at CMHCs are 
captured as part of CMHC ratesetting, and include allowable labor costs 
and the costs of complying with CoPs.
    The reduction to bad debt reimbursement was a result of provisions 
of section 3201 of the Middle Class Tax Extension and Job Creation Act 
of 2012 (Pub. L. 112-96). The reduction to bad debt reimbursement 
impacted all providers eligible to receive bad debt reimbursement, as 
discussed in the CY 2013 End-Stage Renal Disease final rule (77 FR 
67518). Medicare currently reimburses bad debt for eligible providers 
at 65 percent. Therefore, CMHCs are not specifically being singled out 
for a payment reduction as a result of bad debt expenses. Because this 
percentage was enacted by Congress, CMS does not have the authority to 
change the percentage.
    We appreciate the commenter's input regarding the effect any 
reduction in PHP payment rates would have on access to care, but we 
disagree with the commenter's assertion that CMS considers CMHCs to be 
a ``fraud benefit'' or that CMS has any motivation (veiled or 
otherwise) to eliminate CMHCs. Both are simply not true; we appreciate 
the work CMHCs do to care for a particularly vulnerable population with 
serious mental illnesses. We are very concerned about the decline in 
the number of CMHCs, but, as noted in a previous comment response in 
this section, we believe that a number of factors affect PHP provider 
closures. We will continue working to strengthen

[[Page 58989]]

access to both CMHCs and hospital-based PHPs for eligible Medicare 
beneficiaries. As part of that process, we regularly review our 
methodology to ensure that it is appropriately capturing the cost of 
care reported by providers. For example, for the CY 2016 ratesetting, 
we extensively reviewed the methodology used for PHP ratesetting. In 
the CY 2016 OPPS/ASC final rule with comment period (80 FR 70462 
through 70466), we also included a detailed description of the 
ratesetting process to help all PHP providers record costs correctly so 
that we can more fully capture PHP costs in ratesetting.
    We want to ensure that CMHCs remain a viable option as providers of 
mental health care in the beneficiary's own community. We agree that 
beneficiaries receiving care at a CMHC instead of a hospital-based PHP 
would have a lower out-of-pocket cost, which increases the 
attractiveness of CMHCs to those needing their services. We will 
continue to explore policy options for strengthening the PHP benefit 
and increasing access to the valuable services provided by CMHCs as 
well as by hospital-based PHPs.
    Comment: One commenter suggested that CMS consider paying CMHCs 
using a quality-based payment system, and that CMS use value-based 
purchasing. The commenter recommended that, instead of basing payment 
rates on estimated actual median costs of claims, CMS look at the value 
provided by the quality of provided services using different methods 
such as records reviews, denials due to lack of medical necessity or 
inadequate documentation, site visits, interviews with patients, and, 
most importantly, patient outcomes. The commenter believed that 
rewarding providers for higher-quality care, as measured by selected 
standards instead of rewarding providers by increasing costs, is a 
better way to improve the quality of any service.
    Response: Currently, there is no statutory language explicitly 
authorizing a value-based purchasing program for PHPs. We responded to 
a similar public comment in the CY 2016 OPPS/ASC final rule with 
comment period (80 FR 70462) and refer readers to a summary of that 
comment and our response. To reiterate, sections 1833(t)(2) and 
1833(t)(9) of the Act set forth the requirements for establishing and 
adjusting OPPS payment rates, which include PHP payment rates. Section 
1833(t)(17) of the Act authorizes the Hospital OQR Program, which 
applies a payment reduction to subsection (d) hospitals that fail to 
meet program requirements. In the CY 2015 OPPS/ASC proposed rule (79 FR 
41040), we considered future inclusion of, and requested comments on, 
the following quality measures addressing PHP issues that would apply 
in the hospital outpatient setting: (1) 30-day Readmission; (2) Group 
Therapy; and (3) No Individual Therapy. We also refer readers to the CY 
2015 OPPS/ASC final rule with comment period (79 FR 66957 through 
66958) for a more detailed discussion of PHP measures considered for 
inclusion in the Hospital OQR Program in future years. The Hospital OQR 
Program does not apply to CMHCs, and there are no quality measures 
applied to CMHCs.
    Comment: One commenter noted that, in the past, CMS stated that 
CMHCs provide fewer services and have less costly staff than hospitals.
    Response: We believe that the commenter may be referring to the CY 
2011 OPPS/ASC final rule with comment period (75 FR 71991), wherein CMS 
stated we believe that CMHCs have a lower cost structure than their 
hospital-based PHP counterparts because the data showed that CMHCs 
provide fewer PHP services in a day and use less costly staff than 
hospital-based PHPs. Those statements were based on CY 2009 claims and 
cost data, which differ from more recent claims and cost data. Each 
year, we calculate geometric mean per diem costs based on updated 
claims and cost reports. For example, our CY 2019 geometric mean per 
diem costs and the APC payment rates are based upon CY 2017 claims and 
cost data. We refer the commenter to the utilization data in section 
VIII.B.4. of this CY 2019 final rule with comment period for details on 
current CMHC utilization. In addition, we continually seek to increase 
the accuracy of our payment rates. As noted previously, as part of the 
effort to increase the accuracy of the PHP APCs' per diem costs, for 
the CY 2016 ratesetting, we completed an extensive analysis of the 
claims and cost data. That analysis identified aberrant data from 
several providers that impacted the calculation of the proposed PHP 
APCs' geometric mean per diem costs.
b. Hospital-Based PHP Data Preparation: Data Trims and Exclusions
    For the CY 2019 proposed rule and for this CY 2019 final rule with 
comment period, we followed a data preparation process for hospital-
based PHP providers that is similar to that used for CMHCs by applying 
trims and data exclusions as described in the CY 2016 OPPS/ASC final 
rule with comment period (80 FR 70463 through 70465) so that our 
ratesetting is not skewed by providers with extreme data. Before any 
trimming or exclusions were applied, there were 426 hospital-based PHP 
providers in the final CY 2017 PHP claims data used in this CY 2019 
OPPS/ASC final rule with comment period (compared to 394 hospital-based 
PHPs in the CY 2019 OPPS/ASC proposed rule).
    For hospital-based PHP providers, we applied a trim on hospital 
service days when the CCR was greater than 5 at the cost center level. 
This trim removed hospital-based PHP service days that use a CCR 
greater than 5 to calculate costs for at least one of their component 
services. Unlike the 2 standard deviation trim, which 
excluded CMHC providers that failed the trim, the CCR greater than 5 
trim excluded any hospital-based PHP service day where any of the 
services provided on that day were associated with a CCR greater than 5 
(in other words, the CCR greater than 5 trim is a (service) day-level 
trim in contrast to the CMHC 2 standard deviation trim, 
which is a provider-level trim). Applying this CCR greater than 5 trim 
removed from our final rule ratesetting affected service days from 3 
hospital-based PHP providers with CCRs greater than 5. However, 100 
percent of the service days for 1 of these affected hospital-based PHP 
providers had at least 1 service associated with a CCR of 9.5744, so 
the trim removed that 1 provider entirely from our final rule 
ratesetting. The two other providers remained in the ratesetting data, 
but with affected service days trimmed out. In addition, 48 hospital-
based PHPs were removed for having no PHP costs and, therefore, no days 
with PHP payment. No hospital-based PHPs were removed for missing wage 
index data or by the OPPS 3 standard deviation trim on 
costs per day.
    Therefore, we trimmed out 49 hospital-based PHP providers [(1 with 
all service days having a CCR greater than 5) + (48 with zero daily 
costs and no PHP payment)], resulting in 377 (426 total-49 excluded) 
hospital-based PHP providers in the data used for final rule with 
comment period ratesetting (compared to 374 hospital-based PHPs in the 
CY 2019 OPPS/ASC proposed rule). No hospital-based PHP providers were 
defaulted to using their overall hospital ancillary CCRs due to outlier 
cost center CCR values. After completing these data preparation steps, 
we calculated the final CY 2019 geometric mean per diem cost for 
hospital-based PHP APC 5863 for hospital-based PHP services by 
following the methodology described in the CY 2016 OPPS/ASC final rule 
with comment period (80 FR 70464 through 70465) and modified in the CY 
2017

[[Page 58990]]

OPPS/ASC final rule with comment period (81 FR 79687 and 79691) to 
calculate the geometric mean per diem cost.\60\ The final CY 2019 
geometric mean per diem cost for hospital-based PHP providers that 
provide 3 or more services per service day (hospital-based PHP APC 
5863) is $222.76 (compared to $220.52 in the CY 2019 OPPS/ASC proposed 
rule).
---------------------------------------------------------------------------

    \60\ Each revenue code on the hospital-based PHP claim must have 
a HCPCS code and charge associated with it. We multiply each claim 
service line's charges by the hospital's department-level CCR; that 
CCR is determined by using the OPPS Revenue-code-to-cost-center 
crosswalk. Only the claims service lines containing PHP-allowable 
HCPCS codes and PHP-allowable revenue codes from the hospital-based 
PHP claims remaining after trimming are retained for hospital-based 
PHP cost determination. The costs, payments, and service units for 
all service lines occurring on the same service date, by the same 
provider, and for the same beneficiary are summed. Hospital-based 
PHP service days must have 3 or more services provided to be 
assigned to hospital-based PHP APC 5863. The geometric mean per diem 
cost for hospital-based PHP APC 5863 is calculated by taking the nth 
root of the product of n numbers, for days where 3 or more services 
were provided. Hospital-based PHP service days with costs 3 standard deviations from the geometric mean costs within APC 
5863 are deleted and removed from modeling. The remaining hospital-
based PHP service days are used to calculate the geometric mean per 
diem cost for hospital-based PHP APC 5863.
---------------------------------------------------------------------------

    Comment: One commenter appreciated the CY 2019 per diem increase 
for hospital-based PHPs. The commenter stated that the minimum rate 
should be set at the geometric mean rate, rather than at the 2-percent 
reduction rate of $216.55, as providers are hit with a second 2-percent 
reduction again at actual claim payout. The commenter stated this 
reduced the hospital-based PHP rate by 4 percent total, and places more 
than half of the providers in a payment setting below their daily costs 
of providing the services.
    Response: The final hospital-based PHP APC geometric mean per diem 
cost is $222.76, which is a slight increase from the proposed $220.52 
geometric mean per diem cost in the CY 2019 OPPS/ASC proposed rule (83 
FR 37131), and a 7-percent increase from the $208.09 CY 2018 final 
geometric mean per diem cost (82 FR 59378). In the OPPS ratesetting, 
the geometric mean per diem costs are the basis for the final per diem 
rates. However, those costs undergo additional ratesetting steps before 
they are developed into payment rates, a process which is described in 
Part 2 of the Claims Accounting narrative under supporting 
documentation for this CY 2019 OPPS/ASC final rule with comment period 
available on the CMS website at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/HospitalOutpatientPPS/. We believe 
that the commenter may have misunderstood that these steps are not 
simply a ``standard'' 2-percent reduction applied to those costs when 
we determine PHP APC per diem payment rates. Rather, those costs follow 
a ratesetting process, which can result in the final per diem payment 
rates being more or less than the final per diem costs due to budget 
neutrality and other adjustments. It is also possible that the 
commenter has not misunderstood the ratesetting process, but is 
referring to the 2 percentage point reduction in the provider's annual 
ratesetting update factor due to failure to comply with Hospital 
Outpatient Quality Reporting Program requirements, which is described 
in more detail in section XIII.E. of this final rule with comment 
period.
    For the second 2-percent reduction that the commenter referenced, 
which the commenter noted occurs at actual claim payout, we believe 
that the commenter is referencing the required sequestration 2-percent 
reduction to the Medicare portion of claim payments. That reduction is 
a Congressionally-mandated decrease, established by the Budget Control 
Act of 2011 (Pub. L. 112-25) and amended by the American Taxpayer 
Relief Act of 2012 (Pub. L. 112-240). Sequestration is discussed in a 
Medicare Fee-for-Service Provider eNews article available at: https://www.cms.gov/Outreach-and-Education/Outreach/FFSProvPartProg/Downloads/2013-03-08-standalone.pdf. The reduction in payments due to 
sequestration is outside the scope of the CY 2019 OPPS/ASC proposed 
rule and this final rule with comment period.
    Regarding the usage of the geometric mean per diem cost for 
determining payment rates, as we noted in a previous comment response 
in this section, we refer readers to the CY 2013 OPPS/ASC final rule 
with comment period (77 FR 68406 through 68412) for a discussion of the 
implementation of this policy. We believe that this system provides 
appropriate payment for partial hospitalization services based on 
actual provider costs. The final PHP APC geometric mean per diem costs 
for CY 2019 reflect these actual provider costs, using our existing 
methodology.
    After consideration of the public comments we received, we are 
finalizing our proposals, without modification, to continue to follow 
our existing ratesetting methodologies for both CMHCs and for hospital-
based PHPs in determining geometric mean per diem costs. Specifically, 
we are applying our established methodologies in developing the CY 2019 
geometric mean per diem costs and payment rates, including the 
application of a 2 standard deviation trim on costs per day 
for CMHCs and a CCR greater than 5 hospital service day trim for 
hospital-based PHP providers. We also are finalizing our proposals, 
without modification, to continue to use CMHC APC 5853 (Partial 
Hospitalization (3 or More Services Per Day)) and hospital-based PHP 
APC 5863 (Partial Hospitalization (3 or More Services Per Day)) and 
base the CMHC geometric mean per diem costs on the most recent 
available CMHC claims and CMHC cost data, and the hospital-based PHP 
geometric mean per diem costs on the most recent available hospital 
claims and cost data.
    The final CY 2019 PHP APC geometric mean per diem costs for CMHC 
PHP APC 5853 are $121.62 and for hospital-based PHP APC 5863 are 
$222.76, as stated above and shown in Table 43. The final PHP APCs 
payment rates, which are derived from these PHP APCs geometric mean per 
diem costs, are included in Addendum A to this final rule with comment 
period (which is available on the CMS website at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/HospitalOutpatientPPS/Hospital-Outpatient-Regulations-and-Notices.html).\61\
---------------------------------------------------------------------------

    \61\ As discussed in section II.A. of this CY 2019 OPPS/ASC 
final rule with comment period, OPPS APC geometric mean per diem 
costs (including PHP APC geometric mean per diem costs) are divided 
by the geometric mean per diem costs for APC 5012 (Clinic Visits and 
Related Services) to calculate each PHP APC's unscaled relative 
payment weight. An unscaled relative payment weight is one that is 
not yet adjusted for budget neutrality. Budget neutrality is 
required under section 1833(t)(9)(B) of the Act, and ensures that 
the estimated aggregate weight under the OPPS for a calendar year is 
neither greater than nor less than the estimated aggregate weight 
that would have been made without the changes. To adjust for budget 
neutrality (that is, to scale the weights), we compare the estimated 
aggregated weight using the scaled relative payment weights from the 
previous calendar year at issue. We refer readers to the ratesetting 
procedures described in Part 2 of the OPPS Claims Accounting 
narrative and in section II. of this final rule with comment period 
for more information on scaling the weights, and for details on the 
final steps of the process that lead to PHP APC per diem payment 
rates. The OPPS Claims Accounting narrative is available on the CMS 
website at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/HospitalOutpatientPPS/Hospital-Outpatient-Regulations-and-Notices.html.

---------------------------------------------------------------------------

[[Page 58991]]

[GRAPHIC] [TIFF OMITTED] TR21NO18.068

3. Changes to the Revenue-Code-to-Cost Center Crosswalk
    In the CY 2017 OPPS/ASC final rule with comment period (81 FR 
79691), we received public comments identifying an issue that may have 
contributed to a decreased PHP median cost for hospital-based PHPs. The 
commenters stated that the lack of a required standardized PHP cost 
center on the Medicare cost report may be creating some cost-finding 
nuances in the cost report itself--for example, inaccurate step-down of 
overhead cost allocations to the PHP program, diluted CCRs by the 
comingling of PHP and ``Intensive Outpatient Program (IOP)'' on the 
cost report, among others. We agreed with the commenters that, if PHP 
costs are combined with other less intensive outpatient mental health 
treatment costs in the same cost center, the CCR values could be 
diluted, leading to lower geometric mean per diem costs being 
calculated. We stated in response that we would consider adding a cost 
center to the hospital cost report for PHP costs only.
    On November 17, 2017, in Transmittal No. 12, we added a new cost 
center, ``Partial Hospitalization Program,'' on Line 93.99 of Worksheet 
A (Line 93.99 is also displayed on Worksheets B, Parts I and II, B-1; 
and C, Parts I and II) for hospital-based PHPs, for cost reporting 
periods ending on or after August 31, 2017 (https://www.cms.gov/Regulations-and-Guidance/Guidance/Transmittals/2017Downloads/R12P240.pdf). On January 30, 2018, in Transmittal No. 13, we changed 
the implementation date from cost reporting periods ending on or after 
August 31, 2017, to cost reporting periods ending on or after September 
30, 2017 (https://www.cms.gov/Regulations-and-Guidance/Guidance/Transmittals/2017Downloads/R12P240.pdf). The instructions for this new 
PHP cost center (Line 93.99) indicate that effective for cost reporting 
periods ending on or after September 30, 2017, the provider is to enter 
the costs of providing hospital-based partial hospitalization program 
(PHP) services as defined in section 1861(ff) of the Act. Therefore, 
this cost center is to include all costs associated with providing PHP 
services, as defined in the statute (for example, occupational therapy, 
individual and group therapy, among others). It should not include 
costs for non-PHP outpatient mental health services, such as costs from 
what providers refer to as ``Intensive Outpatient Programs.''
    During current hospital-based PHP ratesetting, costs are estimated 
by multiplying revenue code charges on the claim by the appropriate 
cost center-level CCR from the hospital cost report (80 FR 70465). Each 
PHP revenue code is associated with particular cost centers on the cost 
report (80 FR 70464). The appropriate cost center-level CCR is 
identified by using the OPPS Revenue-Code-to-Cost-Center crosswalk; the 
current crosswalk is discussed in the CY 2018 OPPS/ASC final rule with 
comment period (82 FR 59228) and is available on the CMS website at: 
https://www.cms.gov/apps/ama/license.asp?file=/Medicare/Medicare-Fee-for-Service-Payment/HospitalOutpatientPPS/Downloads/CMS-1678-FC-2018-OPPS-FR-Revenue-Code-to-Cost-Center-Crosswalk.zip. The Revenue-Code-to-
Cost-Center crosswalk identifies the primary, secondary (if any), and 
tertiary (if any) cost centers that are associated with each PHP 
revenue code, and which are the source for the CCRs used in PHP 
ratesetting. As discussed in the CY 2002 OPPS interim final rule (66 FR 
59885), hospital-based PHP CCRs are assessed by applying the existing 
OPPS 3 standard deviation trim to hospital-based PHP CCRs 
within each cost center and to the overall hospital ancillary CCR. In 
the CY 2016 OPPS/ASC final rule with comment period (80 FR 70464), we 
stated that, if the primary cost center has no CCR or if it fails the 
3 standard deviation trim, the ratesetting system will look 
for a CCR in the secondary cost center. If the secondary cost center 
has no CCR or if it fails the 3 standard deviation trim, 
the system will move to the tertiary cost center to look for a CCR. If 
the tertiary cost center has no CCR or if it fails the 3 
standard deviation trim, the ratesetting system will default to using 
the hospital's overall ancillary CCR. If the hospital's overall 
ancillary CCR fails the 3 standard deviation trim, we 
exclude the hospital from ratesetting. While the hierarchy requires a 
primary cost center to be associated with a given revenue code, it is 
optional for there to be secondary or tertiary cost centers.
    With the new PHP cost center, the crosswalk must be updated for 
hospital-based PHP cost estimation to correctly match hospital-based 
PHP revenue code charges with the PHP cost center CCR for future 
ratesetting. However, because the PHP-allowable revenue codes are also 
used for reporting non-PHP mental health services, we could not 
designate the PHP cost center as the primary cost center in the 
existing OPPS Revenue-Code-to-Cost-Center crosswalk. Therefore, in the 
CY 2019 OPPS/ASC proposed rule (83 FR 37132 through 37133), we proposed 
to create a separate PHP-only Revenue-Code-to-Cost-Center crosswalk for 
use in CY 2019 and subsequent years, which would provide a more 
accurate and operationally simpler method of matching hospital-based 
PHP charges to the correct hospital-based PHP cost center CCR without 
affecting non-PHP ratesetting. We note that, because CMHCs have their 
own cost reports, we use each CMHC's overall CCR in estimating costs 
for PHP ratesetting (80 FR 70463 through 70464). As such, CMHCs do not 
have a crosswalk and, therefore, the proposal to create a PHP-only 
crosswalk does not apply to CMHCs.
    Therefore, we proposed that, for CY 2019 and subsequent years, 
hospital-

[[Page 58992]]

based PHPs would follow a new Revenue-Code-to-Cost-Center crosswalk 
that only applies to hospital-based PHPs. We proposed that this new 
PHP-only Revenue-Code-to-Cost-Center crosswalk would be comprised of 
the existing PHP-allowable revenue codes and would map each of those 
PHP-allowable revenue codes to the new PHP cost center Line 93.99 as 
the primary cost center source for the CCR. We also proposed to 
designate as the new secondary cost center the cost center that is 
currently listed as the existing primary cost center, and to designate 
as the new tertiary cost center the cost center that is listed as the 
existing secondary cost center.
    In addition, we proposed one exception to this policy for the 
mapping for revenue code 0904, which is the only PHP-allowable revenue 
code in the existing crosswalk with a tertiary cost center source for 
the CCR. We proposed that for revenue code 0904, the secondary cost 
center for CY 2019 and subsequent years would be the existing secondary 
cost center 3550 (``Psychiatric/Psychological Services''). Similarly, 
we proposed that for revenue code 0904, the tertiary cost center for CY 
2019 and subsequent years would be existing tertiary cost center 9000 
(``Clinic''). We considered expanding the Revenue-Code-to-Cost-Center 
crosswalk hierarchy to add a 4th or quaternary level to the hierarchy, 
before the system would default to the overall hospital ancillary CCR. 
However, we evaluated the usage of the current hierarchy for revenue 
code 0904 for the CY 2017, CY 2018, and CY 2019 PHP ratesetting 
modelling, and found that expanding the hierarchy would not be 
necessary. Our analysis showed that the existing primary cost center 
3580 (``Recreational Therapy'') for revenue code 0904 had not been used 
during any of the past 3 years.
    We did not receive any public comments on our proposals related to 
the PHP-only Revenue-Code-to-Cost-Center crosswalk and, therefore, are 
finalizing our proposals, as proposed, for CY 2019 and subsequent 
years.
    Our previous and newly finalized PHP-only Revenue-Code-to-Cost-
Center Crosswalks are shown in Table 44 below.
BILLING CODE 4120-01-P

[[Page 58993]]

[GRAPHIC] [TIFF OMITTED] TR21NO18.069


[[Page 58994]]


[GRAPHIC] [TIFF OMITTED] TR21NO18.070

4. PHP Service Utilization Updates
    We stated in the CY 2019 OPPS/ASC proposed rule (83 FR 37133 
through 37134) that, while we were not proposing any changes to the 
policy on PHP service utilization, we would continue to monitor the 
provision of days with only 3 services. In the CY 2016 OPPS/ASC final 
rule with comment period (81 FR 79684 through 79685), we expressed 
concern over the low frequency of individual therapy provided to 
beneficiaries. The CY 2017 claims data used for this CY 2019 final rule 
with comment period revealed some changes in the provision of 
individual therapy compared to CY 2016 and CY 2015 claims data as shown 
in the Table 45 below.
[GRAPHIC] [TIFF OMITTED] TR21NO18.071


[[Page 58995]]


    As shown in Table 45, both CMHCs and hospital-based PHPs have 
decreased the provision of individual therapy, based on the CY 2017 
claims used for this final rule with comment period.
    In the CY 2018 OPPS/ASC proposed rule and final rule with comment 
period (82 FR 33640 and 82 FR 59378), we stated that we are aware that 
our single-tier payment policy may influence a change in service 
provision because providers are able to obtain payment that is heavily 
weighted to the cost of providing 4 or more services when they provide 
only 3 services. We indicated that we are interested in ensuring that 
providers furnish an appropriate number of services to beneficiaries 
enrolled in PHPs. Therefore, with the CY 2017 implementation of APC 
5853 and APC 5863 for providing 3 or more PHP services per day, we are 
continuing to monitor utilization of days with only 3 PHP services.
    For this CY 2019 OPPS/ASC final rule with comment period, we used 
the final update of the CY 2017 claims data. Table 46 below shows the 
utilization findings based on the most recent claims data.
[GRAPHIC] [TIFF OMITTED] TR21NO18.072

BILLING CODE 4120-01-C

    As shown in Table 46, the CY 2017 claims data used for this final 
rule with comment period showed that PHPs maintained an appropriately 
low utilization of 3 service days compared to CY 2016 and CY 2015. 
Compared to CY 2016, hospital-based PHPs have provided fewer days with 
3 services only, fewer days with 4 services only, and more days with 5 
or more services. Compared to CY 2016, CMHCs have slightly increased 
their provision of 3 service days, increased their provision of days 
with 4 services, but have decreased their provision of days with 5 or 
more services.
    As we noted in the CY 2017 OPPS/ASC final rule with comment period 
(81 FR 79685), we will continue to monitor the provision of days with 
only 3 services, particularly now that the single-tier PHP APCs 5853 
and 5863 are in place for providing 3 or more services per day to CMHCs 
and hospital-based PHPs, respectively. The CY 2017 data are the first 
year of claims data to reflect the change to the single-tier PHP APCs, 
and the declining level of utilization of days with 3 services only by 
hospital-based PHPs indicates that these providers did not reduce care 
for this patient population. It is too early to determine if the 
increase in days providing 3 services only by CMHCs is a trend. We will 
continue to monitor the data for both hospital-based PHPs and CMHCs.
    It is important to reiterate our expectation that days with only 3 
services are meant to be an exception and not the typical PHP day. In 
the CY 2009 OPPS/ASC final rule with comment period (73 FR 68694), we 
clearly stated that we consider the acceptable minimum units of PHP 
services required in a PHP day to be 3 and explained that it was never 
our intention that 3 units of service represent the number of services 
to be provided in a typical PHP day. PHP is furnished in lieu of 
inpatient psychiatric hospitalization and is intended to be more 
intensive than a half-day program. We further indicated that a typical 
PHP day should generally consist of 5 to 6 units of service (73 FR 
68689). We explained that days with only 3 units of services may be 
appropriate to bill in certain limited circumstances, such as when a 
patient might need to leave early for a medical appointment and, 
therefore, would be unable to complete a full day of PHP treatment. At 
that time, we noted that if a PHP were to only provide days with 3 
services, it would be difficult for patients to meet the eligibility 
requirement in 42 CFR 410.43(c)(1), that patients must require a 
minimum of 20 hours per week of therapeutic services as evidenced in 
their plan of care (73 FR 68689).
    We made no proposals in this section of the CY 2019 OPPS/ASC 
proposed rule, but received several public comments related to 
utilization.
    Comment: Some commenters were concerned that the single-tiered 
payment system implemented in CY 2017 could have unintended 
consequences, including reducing the number of services provided per 
day, and urged CMS to monitor the data.

[[Page 58996]]

Another commenter thanked CMS for not instituting a code edit for 20 
hours per week, and welcomed a further discussion of clinical intensity 
and situations affecting weekly attendance. This commenter offered to 
convene a meeting of experts from the field to discuss, develop, and 
recommend ideas on how best to ensure the appropriate clinical 
intensity in PHPs. Another commenter wrote that the utilization data in 
Table 28 of the CY 2019 OPPS/ASC proposed rule demonstrated the 
commitment of both CMHCs and hospital-based PHPs to fully comply with 
and exceed the expectations of the 20-hour rule.
    Response: We appreciate these comments and will take them into 
consideration.

C. Outlier Policy for CMHCs

    In the CY 2019 OPPS/ASC proposed rule (83 FR 37134 through 37136), 
for CY 2019, we proposed to continue to calculate the CMHC outlier 
percentage, cutoff point and percentage payment amount, outlier 
reconciliation, outlier payment cap, and fixed-dollar threshold 
according to previously established policies. These topics are 
discussed in more detail below. We refer readers to section II.G. of 
this final rule with comment period for our general policies for 
hospital outpatient outlier payments.
1. Background
    As discussed in the CY 2004 OPPS final rule with comment period (68 
FR 63469 through 63470), we noted a significant difference in the 
amount of outlier payments made to hospitals and CMHCs for PHP 
services. Given the difference in PHP charges between hospitals and 
CMHCs, we did not believe it was appropriate to make outlier payments 
to CMHCs using the outlier percentage target amount and threshold 
established for hospitals. Therefore, beginning in CY 2004, we created 
a separate outlier policy specific to the estimated costs and OPPS 
payments provided to CMHCs. We designated a portion of the estimated 
OPPS outlier threshold specifically for CMHCs, consistent with the 
percentage of projected payments to CMHCs under the OPPS each year, 
excluding outlier payments, and established a separate outlier 
threshold for CMHCs. This separate outlier threshold for CMHCs resulted 
in $1.8 million in outlier payments to CMHCs in CY 2004 and $0.5 
million in outlier payments to CMHCs in CY 2005 (82 FR 59381). In 
contrast, in CY 2003, more than $30 million was paid to CMHCs in 
outlier payments (82 FR 59381).
2. CMHC Outlier Percentage
    In the CY 2018 OPPS/ASC final rule with comment period (82 FR 59267 
through 59268), we described the current outlier policy for hospital 
outpatient payments and CMHCs. We note that we also discussed our 
outlier policy for CMHCs in more detail in section VIII. C. of that 
same final rule (82 FR 59381). We set our projected target for all OPPS 
aggregate outlier payments at 1.0 percent of the estimated aggregate 
total payments under the OPPS (82 FR 59267). We estimate CMHC per diem 
payments and outlier payments by using the most recent available 
utilization and charges from CMHC claims, updated CCRs, and the updated 
payment rate for APC 5853. For increased transparency, we are providing 
a more detailed explanation of the existing calculation process for 
determining the CMHC outlier percentages below. As previously stated, 
we proposed to continue to calculate the CMHC outlier percentage 
according to previously established policies, and we did not propose 
any changes to our current methodology for calculating the CMHC outlier 
percentage for CY 2019. To calculate the CMHC outlier percentage, we 
followed three steps:
     Step 1: We multiplied the OPPS outlier threshold, which is 
1.0 percent, by the total estimated OPPS Medicare payments (before 
outliers) for the prospective year to calculate the estimated total 
OPPS outlier payments:
    (0.01 x Estimated Total OPPS Payments) = Estimated Total OPPS 
Outlier Payments.
     Step 2: We estimated CMHC outlier payments by taking each 
provider's estimated costs (based on their allowable charges multiplied 
by the provider's CCR) minus each provider's estimated CMHC outlier 
multiplier threshold (we refer readers to section VIII.C.3. of this 
final rule with comment period). That threshold was determined by 
multiplying the provider's estimated paid days by 3.4 times the CMHC 
PHP APC payment rate. If the provider's costs exceeded the threshold, 
we multiplied that excess by 50 percent, as described in section 
VIII.C.3. of this final rule with comment period, to determine the 
estimated outlier payments for that provider. CMHC outlier payments are 
capped at 8 percent of the provider's estimated total per diem payments 
(including the beneficiary's copayment), as described in section 
VIII.C.5. of this final rule with comment period, so any provider's 
costs that exceed the CMHC outlier cap will have its payments adjusted 
downward. After accounting for the CMHC outlier cap, we summed all of 
the estimated outlier payments to determine the estimated total CMHC 
outlier payments.
    (Each Provider's Estimated Costs--Each Provider's Estimated 
Multiplier Threshold) = A. If A is greater than 0, then (A x 0.50) = 
Estimated CMHC Outlier Payment (before cap) = B. If B is greater than 
(0.08 x Provider's Total Estimated Per Diem Payments), then cap-
adjusted B = (0.08 x Provider's Total Estimated Per Diem Payments); 
otherwise, B = B. Sum (B or cap-adjusted B) for Each Provider = Total 
CMHC Outlier Payments.
     Step 3: We determined the percentage of all OPPS outlier 
payments that CMHCs represent by dividing the estimated CMHC outlier 
payments from Step 2 by the total OPPS outlier payments from Step 1:
    (Estimated CMHC Outlier Payments/Total OPPS Outlier Payments).
    In CY 2018, we designated approximately 0.03 percent of that 
estimated 1.0 percent hospital outpatient outlier threshold for CMHCs 
(82 FR 59381), based on this methodology. In the proposed rule, we 
proposed to continue to use the same methodology for CY 2019. 
Therefore, based on our CY 2019 payment estimates, CMHCs are projected 
to receive 0.02 percent of total hospital outpatient payments in CY 
2019, excluding outlier payments. We proposed to designate 
approximately less than 0.01 percent of the estimated 1.0 percent 
hospital outpatient outlier threshold for CMHCs. This percentage is 
based upon the formula given in Step 3 above.
    We did not receive any public comments on our proposal and, 
therefore, are finalizing our proposal, without modification, to 
continue with this existing policy on outliers, and are implementing 
this policy as proposed for CY 2019.
3. Cutoff Point and Percentage Payment Amount
    As described in the CY 2018 OPPS/ASC final rule with comment period 
(82 FR 59381), our policy has been to pay CMHCs for outliers if the 
estimated cost of the day exceeds a cutoff point. In CY 2006, we set 
the cutoff point for outlier payments at 3.4 times the highest CMHC PHP 
APC payment rate implemented for that calendar year (70 FR 68551). This 
cutoff point is sometimes called a multiplier threshold (70 FR 68550). 
For CY 2018, the highest CMHC PHP APC payment rate is the payment rate 
for CMHC PHP APC 5853. In addition, in 2002, the final OPPS outlier 
payment percentage for costs above the multiplier threshold was set at 
50 percent (66 FR

[[Page 58997]]

59889). In CY 2018, we continued to apply the same 50 percent outlier 
payment percentage that applies to hospitals to CMHCs and continued to 
use the existing cutoff point (82 FR 59381). Therefore, for CY 2018, we 
continued to pay for partial hospitalization services that exceeded 3.4 
times the CMHC PHP APC payment rate at 50 percent of the amount of CMHC 
PHP APC geometric mean per diem costs over the cutoff point. For 
example, for CY 2018, if a CMHC's cost for partial hospitalization 
services paid under CMHC PHP APC 5853 exceeds 3.4 times the CY 2018 
payment rate for CMHC PHP APC 5853, the outlier payment would be 
calculated as 50 percent of the amount by which the cost exceeds 3.4 
times the CY 2018 payment rate for CMHC PHP APC 5853 [0.50 x (CMHC 
Cost-(3.4 x APC 5853 rate))].
    In the CY 2019 OPPS/ASC proposed rule (83 FR 37135), for CY 2019, 
in accordance with our existing policy, we proposed to continue to pay 
for partial hospitalization services that exceed 3.4 times the proposed 
CMHC PHP APC payment rate at 50 percent of the CMHC PHP APC geometric 
mean per diem costs over the cutoff point. That is, for CY 2019, if a 
CMHC's cost for partial hospitalization services paid under CMHC PHP 
APC 5853 exceeds 3.4 times the payment rate for CMHC APC 5853, the 
outlier payment will be calculated as [0.50 x (CMHC Cost-(3.4 x APC 
5853 rate))].
    We did not receive any public comments on our proposals. We are 
finalizing our proposals, without modification, to continue to 
calculate the CMHC outlier percentage according to previously 
established policies, and are implementing this policy as proposed for 
CY 2019.
4. Outlier Reconciliation
    In the CY 2009 OPPS/ASC final rule with comment period (73 FR 68594 
through 68599), we established an outlier reconciliation policy to 
address charging aberrations related to OPPS outlier payments. We 
addressed vulnerabilities in the OPPS outlier payment system that lead 
to differences between billed charges and charges included in the 
overall CCR, which are used to estimate cost and would apply to all 
hospitals and CMHCs paid under the OPPS. The main vulnerability in the 
OPPS outlier payment system is the time lag between the update of the 
CCRs that are based on the latest settled cost report and the current 
charges that creates the potential for hospitals and CMHCs to set their 
own charges to exploit the delay in calculating new CCRs. CMS initiated 
steps to ensure that outlier payments appropriately account for the 
financial risk when providing an extraordinarily costly and complex 
service, but are only being made for services that legitimately qualify 
for the additional payment.
    The current outlier reconciliation policy requires that providers 
whose outlier payments meet a specified threshold (currently $500,000 
for hospitals and any outlier payments for CMHCs) and whose overall 
ancillary CCRs change by plus or minus 10 percentage points or more, 
are subject to outlier reconciliation, pending approval of the CMS 
Central Office and Regional Office (73 FR 68596 through 68599). The 
policy also includes provisions related to CCRs and to calculating the 
time value of money for reconciled outlier payments due to or due from 
Medicare, as detailed in the CY 2009 OPPS/ASC final rule with comment 
period and in the Medicare Claims Processing Manual (73 FR 68595 
through 68599 and Medicare Claims Processing internet Only Manual, 
Chapter 4, Section 10.7.2 and its subsections, available online at: 
https://www.cms.gov/Regulations-and-Guidance/Guidance/Manuals/Downloads/clm104c04.pdf).
    In the CY 2019 OPPS/ASC proposed rule (83 FR 37135), we proposed to 
continue these policies for CY 2019.
    We did not receive any public comments on our proposals and, 
therefore, are finalizing our proposals, without modification, to 
continue our existing policy for CY 2019.
5. Outlier Payment Cap
    In the CY 2017 OPPS/ASC final rule with comment period, we 
implemented a CMHC outlier payment cap to be applied at the provider 
level, such that in any given year, an individual CMHC will receive no 
more than a set percentage of its CMHC total per diem payments in 
outlier payments (81 FR 79692 through 79695). We finalized the CMHC 
outlier payment cap to be set at 8 percent of the CMHC's total per diem 
payments (81 FR 79694 through 79695). This outlier payment cap only 
affects CMHCs, does not affect other provider types (that is, hospital-
based PHPs), and is in addition to and separate from the current 
outlier policy and reconciliation policy in effect. For CY 2018, we 
continued this policy in the CY 2018 OPPS/ASC final rule with comment 
period (82 FR 59381).
    In the CY 2019 OPPS/ASC proposed rule (83 FR 37135 through 37136), 
we proposed to continue this policy for CY 2019, such that the CMHC 
outlier payment cap would be 8 percent of the CMHC's total per diem 
payments.
    We did not receive any public comments on our proposal and, 
therefore, are finalizing our proposal, without modification, to 
continue our existing policy for CY 2019, such that the CMHC outlier 
payment cap will be 8 percent of the CMHC's total per diem payments.
6. Fixed-Dollar Threshold
    In the CY 2018 OPPS/ASC final rule with comment period (82 FR 59267 
through 59268), for the hospital outpatient outlier payment policy, we 
set a fixed-dollar threshold in addition to an APC multiplier 
threshold. Fixed-dollar thresholds are typically used to drive outlier 
payments for very costly items or services, such as cardiac pacemaker 
insertions. CMHC PHP APC 5853 is the only APC for which CMHCs may 
receive payment under the OPPS, and is for providing a defined set of 
services that are relatively low cost when compared to other OPPS 
services. Because of the relatively low cost of CMHC services that are 
used to comprise the structure of CMHC PHP APC 5853, it is not 
necessary to also impose a fixed-dollar threshold on CMHCs. Therefore, 
in the CY 2018 OPPS/ASC final rule with comment period, we did not set 
a fixed-dollar threshold for CMHC outlier payments (82 FR 59381).
    In the CY 2019 OPPS/ASC proposed rule (83 FR 37134 through 37136), 
we proposed to continue this policy for CY 2019.
    We did not receive any public comments on our proposal and, 
therefore, are finalizing our proposal, without modification, to 
continue with this existing policy, and are implementing this policy as 
proposed for CY 2019.

D. Proposed Update to PHP Allowable HCPCS Codes

    CMS received the CY 2019 CPT codes from the AMA in time for 
inclusion in the CY 2019 OPPS/ASC proposed rule (83 FR 37088). The new, 
revised, and deleted CY 2019 Category I and III CPT codes were included 
in Addendum B to the proposed rule (which is available via the internet 
on the CMS website). We are aware that the AMA will be deleting the 
following psychological and neuropsychological testing CPT codes, which 
affect PHPs, as of January 1, 2019:
     CPT code 96101 (Psychological testing by psychologist/
physician);
     CPT code 96102 (Psychological testing by technician);
     CPT code 96103 (Psychological testing administered by 
computer);

[[Page 58998]]

     CPT code 96118 (Neuropsychological testing by 
psychologist/physician)
     CPT code 96119 (Neuropsychological testing by technician); 
and
     CPT code 96120 (Neuropsychological test administered w/
computer).
    In the CY 2019 OPPS/ASC proposed rule (83 FR 37088), we proposed to 
delete these 6 CPT codes for the 2019 OPPS update under section 
III.A.4. (``Proposed Treatment of New and Revised CY 2019 Category I 
and III CPT Codes That Will Be Effective January 1, 2019 For Which We 
Are Soliciting Public Comments In This CY 2019 OPPS/ASC Proposed 
Rule'').
    In addition, the AMA will be adding the following psychological and 
neuropsychological testing CPT codes to replace the deleted codes, as 
of January 1, 2019:
     CPT code 96130 (Psychological testing evaluation by 
physician/qualified health care professional; first hour);
     CPT code 93131 (Psychological testing evaluation by 
physician/qualified health care professional; each additional hour);
     CPT code 96132 (Neuropsychological testing evaluation by 
physician/qualified health care professional; first hour);
     CPT code 96133 (Neuropsychological testing evaluation by 
physician/qualified health care professional; each additional hour);
     CPT code 96136 (Psychological/neuropsychological testing 
by physician/qualified health care professional; first 30 minutes);
     CPT code 96137 (Psychological/neuropsychological testing 
by physician/qualified health care professional; each additional 30 
minutes);
     CPT code 96138 (Psychological/neuropsychological testing 
by technician; first 30 minutes);
     CPT code 96139 (Psychological/neuropsychological testing 
by technician; each additional 30 minutes); and
     CPT code 96146 (Psychological/neuropsychological testing; 
automated result only).
    In the CY 2019 OPPS/ASC proposed rule (83 FR 37088), we also 
proposed to recognize and assign these 9 CPT codes under the CY 2019 
OPPS in section III.A.4. (``Proposed Treatment of New and Revised CY 
2019 Category I and III CPT Codes That Will Be Effective January 1, 
2019 For Which We Are Soliciting Public Comments In This CY 2019 OPPS/
ASC Proposed Rule'').
    While these proposed changes to the above-referenced codes were 
included in the CY 2019 OPPS/ASC proposed rule (and are being finalized 
in section III.A.3. in this final rule with comment period for the CY 
2019 OPPS), PHP is a part of the OPPS and PHP providers may not have 
been aware of those proposed changes because we did not also include 
the proposals in the PHP discussion presented in the proposed rule. To 
ensure that PHP providers are aware of the codes and have the 
opportunity to comment on the proposed changes, we are utilizing a 
practice similar to the one we use under the OPPS for new Level II 
HCPCS codes that become effective after the proposed rule is published. 
Therefore, in this final rule with comment period, we are proposing to 
delete the same 6 CPT codes listed above from the PHP-allowable code 
set for CMHC APC 5853 and hospital-based PHP APC 5863, and replace them 
with 9 new CPT codes as shown in Table 47 below, effective January 1, 
2019. We are soliciting public comments on these proposals. We will 
consider the public comments we receive and seek to finalize our 
proposed actions in the CY 2020 OPPS/ASC final rule with comment 
period.
[GRAPHIC] [TIFF OMITTED] TR21NO18.073


[[Page 58999]]



IX. Procedures That Will Be Paid Only as Inpatient Procedures

A. Background

    We refer readers to the CY 2012 OPPS/ASC final rule with comment 
period (76 FR 74352 through 74353) for a full historical discussion of 
our longstanding policies on how we identify procedures that are 
typically provided only in an inpatient setting (referred to as the 
inpatient only (IPO) list) and, therefore, will not be paid by Medicare 
under the OPPS, and on the criteria that we use to review the IPO list 
each year to determine whether or not any procedures should be removed 
from the list. The complete list of codes that describe procedures that 
will be paid by Medicare in CY 2019 as inpatient only procedures is 
included as Addendum E to this CY 2019 OPPS/ASC final rule with comment 
period, which is available via the internet on the CMS website.

B. Changes to the Inpatient Only (IPO) List

1. Methodology for Identifying Appropriate Changes to IPO List
    In the CY 2019 OPPS/ASC proposed rule (83 FR 37136 through 37143), 
for CY 2019, we proposed to use the same methodology (described in the 
November 15, 2004 final rule with comment period (69 FR 65834)) of 
reviewing the current list of procedures on the IPO list to identify 
any procedures that may be removed from the list. We have established 
five criteria that are part of this methodology. As noted in the CY 
2012 OPPS/ASC final rule with comment period (76 FR 74353), we utilize 
these criteria when reviewing procedures to determine whether or not 
they should be removed from the IPO list and assigned to an APC group 
for payment under the OPPS when provided in the hospital outpatient 
setting. We note that a procedure is not required to meet all of the 
established criteria to be removed from the IPO list. The criteria 
include the following:
    1. Most outpatient departments are equipped to provide the services 
to the Medicare population.
    2. The simplest procedure described by the code may be performed in 
most outpatient departments.
    3. The procedure is related to codes that we have already removed 
from the IPO list.
    4. A determination is made that the procedure is being performed in 
numerous hospitals on an outpatient basis.
    5. A determination is made that the procedure can be appropriately 
and safely performed in an ASC and is on the list of approved ASC 
procedures or has been proposed by us for addition to the ASC list.
    Using the above-listed criteria, for the CY 2019 OPPS, we 
identified two procedures described by the following codes that we 
proposed to remove from the IPO list for CY 2019: CPT code 31241 
(Nasal/sinus endoscopy, surgical; with ligation of sphenopalatine 
artery) and CPT code 01402 (Anesthesia for open or surgical 
arthroscopic procedures on knee joint; total knee arthroplasty). We 
also proposed to add to the IPO list for CY 2019 the procedure 
described by HCPCS code C9606 (Percutaneous transluminal 
revascularization of acute total/subtotal occlusion during acute 
myocardial infarction, coronary artery or coronary artery bypass graft, 
any combination of drug-eluting intracoronary stent, artherectomy and 
angioplasty, including aspiration thrombectomy when performed, single 
vessel). Table 29 of the proposed rule (83 FR 37137) displayed the 
proposed changes to the IPO list for CY 2019 and subsequent years, 
including the HCPCS codes, long descriptors, and the proposed CY 2019 
payment indicators.
    As noted earlier, we proposed to remove the procedure described by 
CPT code 31241 from the IPO list for CY 2019. Specifically, we stated 
that after reviewing the clinical characteristics of the procedure 
described by CPT code 31241 and consulting with stakeholders and our 
clinical advisors regarding this procedure, we believed that this 
procedure met criterion 3; that is, the procedure is related to codes 
that we have already removed from the IPO list. We proposed that the 
procedure described by CPT code 31241 be assigned to C-APC 5153 (Level 
3 Airway Endoscopy) with a status indicator of ``J1.'' We sought public 
comments on whether the public believes that the procedure described by 
CPT code 31241 meets criterion 3 and whether the procedure meets any of 
the other five criteria for removal from the IPO list.
    Comment: A majority of the commenters supported the proposed 
removal of CPT code 31241 from the IPO list and the proposed APC 
assignment to APC 5153 with a status indicator of ``J1''. The 
commenters agreed that the procedure described by CPT code 31241 meets 
criterion 3 (that is, the procedure described by CPT code 31241 is 
related to codes that we have already removed from the IPO list).
    Response: We appreciate the commenters' support.
    Comment: One commenter opposed the removal of CPT code 31241. 
However, the commenter did not provide a rationale for its opposition.
    Response: We have noted the commenter's general opposition. 
However, for the reasons cited in the proposed rule, we continue to 
believe that removal of the procedure described by CPT code 31241from 
the IPO list is appropriate. In addition, we received support for the 
removal of CPT code 31241 from the IPO list from many other 
stakeholders.
    After consideration of the public comments we received, we are 
finalizing our proposal, without modification, to remove CPT code 31241 
from the IPO list and to assign the procedure to C-APC 5153 (Level 3 
Airway Endoscopy) with a status indicator of ``J1''.
    In the CY 2019 OPPS/ASC proposed rule (83 FR 37136), we also 
proposed to remove the procedure described by CPT code 01402 from the 
IPO list. We reviewed the clinical characteristics of the procedure 
described by CPT code 01402, and proposed that this procedure be 
removed from the IPO list because it meets above-listed criteria 3 and 
4. This procedure is typically billed with the procedure described by 
CPT code 27447 (Arthroplasty, knee, condyle and plateau; medial and 
lateral compartments with or without patella resurfacing (total knee 
arthroplasty)), which was removed from the IPO list for CY 2018 (82 FR 
52526). This procedure is also often performed safely in the outpatient 
department setting. We sought public comments on whether the procedure 
described by CPT code 01402 meets criteria 3 and 4 and whether the 
procedure meets any of the other five criteria for removal from the IPO 
list.
    Comment: Commenters supported the removal of the procedure 
described by CPT code 01402 from the IPO list and agreed that the 
procedure described by CPT code 01402 was both related to codes that 
were previously removed from the IPO list and is performed safely in 
numerous hospitals on an outpatient basis.
    Response: We thank the commenters for their support.
    Comment: One commenter opposed the removal of the procedure 
described by CPT code 01402 from the IPO list because the commenter 
believed that there would be potential detrimental lateral impacts on 
hospitals participating in the Comprehensive Care for Joint Replacement 
(CJR) Model, the Bundled Payments for Care Improvement (BPCI) 
Initiative, the Hospital Value-Based Purchasing (VBP)

[[Page 59000]]

Program, and the Hospital Readmissions Reduction Program (HRRP).
    Response: Removal of the procedure described by CPT code 01402 does 
not in any way affect a provider's ability to participate in any of the 
initiatives the commenter mentioned. We remind readers that the removal 
of any procedure from the IPO list does not mandate that all cases be 
performed on an outpatient basis. Rather, such removal allows for 
Medicare payment to be made to the hospital when the procedure is 
performed in the hospital outpatient department setting. The decision 
to admit a patient is a complex medical judgment that is made by the 
treating physician. We refer readers to the CY 2017 OPPS/ASC final rule 
with comment period (81 FR 79698 through 79699) in which we originally 
proposed to remove total knee arthroplasty (TKA) procedure codes from 
the IPO list and sought comments on how to modify the CJR Model and the 
BPCI Initiative to reflect the shift of some Medicare beneficiaries 
from an inpatient TKA procedure to an outpatient TKA procedure in the 
BPCI Initiative and the CJR Model pricing methodologies, including 
target price calculations and reconciliation processes. However, we 
invite interested parties to direct any questions about these 
initiatives to the CMS Center for Medicare and Medicaid Innovation.
    Comment: One commenter representing a coalition of industry 
stakeholders recommended that CMS collect and publish data on morbidity 
and mortality rates for TKA performed in the outpatient setting versus 
in the inpatient setting. The commenter believed that collecting these 
data would allow CMS to evaluate the quality of services in both 
settings since the removal of TKA procedures from the IPO list.
    Response: We note that since we removed the CPT codes related to 
TKA from the IPO list, TKA procedures have only been payable under the 
OPPS for less than one year. Accordingly, we do not believe that we 
have sufficient data at this time for a meaningful comparison of 
quality outcomes associated with TKA procedures performed in the 
hospital outpatient setting versus the hospital inpatient setting. 
However, we will consider reviewing mortality rates in the future when 
appropriate data are available. We would not expect there to be 
statistically significant differences in morbidity and mortality among 
Medicare beneficiaries based solely on whether the patient was admitted 
to the hospital or remained a hospital outpatient (especially because 
it is likely the same surgeon, the same clinical protocol, and the same 
staff at a given hospital for both inpatient and outpatient orthopaedic 
procedures) and would expect that other factors, such as underlying 
disease-state and condition of the patient, surgical complications, and 
ability to avoid blood clots and other potential adverse event within 
90 days postsurgery. We remind readers that there are several short 
stay inpatient cases with a length of stay of 1 or 2 days, which is 
generally similar to the length of stay for outpatient cases. To be 
clear, there is a plethora of surgical procedures that may be performed 
on either an inpatient basis or an outpatient basis. However, we are 
not aware of differences in clinical outcomes for patients based solely 
on this factor. While there are some studies relating to the non-
Medicare population regarding differences in outcomes, depending on 
whether the care setting is inpatient versus outpatient (which could 
include ASCs), we are not aware of any such studies since the TKA has 
become a payable procedure under the OPPS in 2018. In addition, we note 
that interested stakeholders are welcome to research these or other 
statistics by analyzing data that Medicare makes available. The 
Hospital Inpatient Quality Reporting (IQR) Program and the Hospital 
Outpatient Quality Reporting (OQR) Program collect and share 
information regarding the quality of care in both the hospital 
inpatient setting and the hospital outpatient setting. Specifically, 
the Hospital IQR Program maintains measures that include complications 
and deaths during inpatient hip/knee replacement procedures. However, 
an analogous measure for outpatient procedures does not currently 
exist.
    Comment: One commenter requested that CMS provide guidance and 
education regarding the removal of TKA procedures from the IPO list 
beginning in CY 2018. The commenter noted that there was confusion 
around the policy for hospital systems and health insurance plans, and 
that many hospital systems and Medicare Advantage plans were denying 
inpatient admissions by default and requiring Medicare patients to 
undergo a TKA procedure as a hospital outpatient.
    Response: As previously stated in the discussion of the CY 2018 
OPPS/ASC final rule with comment period (82 FR 59383), we continue to 
believe that the decision regarding the most appropriate care setting 
for a given surgical procedure is a complex medical judgment made by 
the physician based on the beneficiary's individual clinical needs and 
preferences and on the general requirement that any procedure be 
reasonable and necessary. We also reiterate our previous statement that 
the removal of any procedure from the IPO list does not require the 
procedure to be performed only on an outpatient basis. Rather, we 
believe that as technology and clinical practice continue to evolve, 
beneficiaries should continue to receive care in the most appropriate 
setting.
    While we continue to expect providers who perform an outpatient TKA 
procedure on Medicare beneficiaries to use comprehensive patient 
selection criteria to identify appropriate candidates for the 
procedure, we believe that the surgeons, clinical staff, and medical 
specialty societies representing physicians who perform outpatient TKA 
procedures and possess specialized clinical knowledge and experience 
are most suited to create such guidelines.
    After consideration of the public comments we received, we are 
adopting, as final without modification, our proposal to remove the 
procedure described by CPT code 01402 from the IPO list. In accordance 
with the regulations at 42 CFR 419.2(b)(4), under the OPPS, this 
anesthesia service is packaged with the associated procedure and 
assigned status indicator ``N'' (Items and Services Packaged into APC 
Rates) for CY 2019.
    In addition, in the CY 2019 OPPS/ASC proposed rule (83 FR 37136 
through 37137), we proposed to add the procedure described by HCPCS 
code C9606 (Percutaneous transluminal revascularization of acute total/
subtotal occlusion during acute myocardial infarction, coronary artery 
or coronary artery bypass graft, any combination of drug-eluting 
intracoronary stent, atherectomy and angioplasty, including aspiration 
thrombectomy when performed, single vessel) to the IPO list for CY 
2019. The IPO list specifies those procedures and services for which 
the hospital will be paid only when the procedures are provided in the 
inpatient setting because of the nature of the procedure, the 
underlying physical condition of the patient, or the need for at least 
24 hours of postoperative recovery time or monitoring before the 
patient can be safely discharged (76 FR 74353). After evaluating the 
procedure described by HCPCS code C9606 using the criteria described 
above, we believe that the procedure should be added to the IPO list 
because this procedure is performed during acute myocardial infarction 
and it is similar to a procedure already on the IPO list (that is, the 
procedure described by CPT code 92941 (Percutaneous transluminal 
revascularization of acute total/subtotal occlusion during acute 
myocardial

[[Page 59001]]

infarction, coronary artery or coronary artery bypass graft, any 
combination of intracoronary stent, artherectomy and angioplasty, 
including aspiration thrombectomy when performed, single vessel)), 
which was added to the IPO list for CY 2018 (82 FR 52526). We sought 
public comments on whether the procedure described by HCPCS code C9606 
should be added to the IPO list for CY 2019 and subsequent years.
    Comment: Several commenters, largely from specialty medical 
societies, supported adding the procedure described by HCPCS code C9606 
to the IPO list for CY 2019.
    Response: We appreciate the commenters' support.
    After consideration of the public comments we received, we are 
adopting as final without modification, our proposal to add the 
procedure described by HCPCS code C9606 (Percutaneous transluminal 
revascularization of acute total/subtotal occlusion during acute 
myocardial infarction, coronary artery or coronary artery bypass graft, 
any combination of drug eluting intracoronary stent, atherectomy and 
angioplasty, including aspiration thrombectomy when performed, single 
vessel) to the IPO list for CY 2019.
2. Summary of Public Comments Received in Response to CMS' Solicitation 
on the Potential Removal of Procedure Described by CPT Code 0266T From 
the IPO List and Our Responses
    CPT code 0266T describes the implantation or replacement of carotid 
sinus baroreflex activation device; total system (includes generator 
placement, unilateral or bilateral lead placement, intra-operative 
interrogation, programming, and repositioning, when performed). The 
procedure described by CPT code 0266T has been included on the IPO list 
since the procedure code became effective in CY 2011.
    There are several codes that describe procedures that are similar 
to the procedure described by CPT code 0266T that are not on the IPO 
list, including: CPT code 0267T (Implantation or replacement of carotid 
sinus baroreflex activation device; lead only, unilateral (includes 
intra-operative interrogation, programming, and repositioning, when 
performed)) and CPT code 0268T (Implantation or replacement of carotid 
sinus baroreflex activation device; pulse generator only (includes 
intra-operative interrogation, programming, and repositioning, when 
performed)). The device that is billed with these two procedures has 
been granted a Category B Investigational Device Exemption (IDE) from 
FDA.\62\ Currently, there is limited information available to determine 
the typical site of service and the ability for the procedure to be 
safely performed in the outpatient setting. At the time of development 
of the CY 2019 OPPS/ASC proposed rule, we did not believe that we had 
adequate information to determine whether the procedure described by 
CPT code 0266T should be removed from the IPO list. Therefore, we 
sought public comments on the removal of the procedure described by CPT 
code 0266T from the IPO list. Specifically, we sought public comments 
on whether the procedure described by CPT code 0266T meets any of the 
criteria to be removed from the IPO list as well as the appropriate APC 
assignment and status indicator for this code.
---------------------------------------------------------------------------

    \62\ Available at: https://www.cms.gov/Medicare/Coverage/IDE/Approved-IDE-Studies.html.
---------------------------------------------------------------------------

    Comment: Numerous commenters responded to CMS' solicitation for 
discussion of the removal of the Barostim procedure from the IPO list. 
Commenters included the manufacturer and practitioners, specifically 
cardiologists and cardiovascular surgeons, who have performed the 
Barostim procedure multiple times. Commenters referenced their personal 
experience with the procedure described by CPT code 0266T, the 
advancements and safety of the procedure, and patients' experience 
after undergoing the procedure. These commenters argued that procedures 
related to CPT code 0266T are commonly being performed safely in the 
hospital outpatient department. The manufacturer specifically cited the 
CY 2019 NPRM CPT Cost Statistics Files associated with the proposed 
rule to show the number of related procedures that have been performed 
in the hospital outpatient department this year. Further, another 
commenter supported the assertion provided in the proposed rule that 
the simplest procedures described by CPT code 0266T, the procedure to 
implant or replace the lead or IPG, currently have separate and 
distinct CPT codes (0267T and 0268T) that are not included on the IPO 
list.
    Response: We reviewed clinical characteristics of the Barostim 
procedure and related evidence, including input from multiple physician 
and cardiology specialty societies, and determined that the procedure 
described by CPT code 0266T is an appropriate candidate for removal 
from the IPO list. CPT code 0266T is similar to CPT code 0268T, which 
is performed in numerous hospitals on an outpatient basis (criterion 
3). Furthermore, we believe that most outpatient departments are 
equipped to provide the described services to the Medicare population 
(criterion 1). Therefore, we are removing the procedure described by 
CPT code 0266T from the IPO list for CY 2019.
    Comment: Several commenters recommended the removal of several 
procedures not originally proposed by CMS for removal from the IPO list 
for CY 2019. These recommended procedures related to other procedures 
that were recently removed from the IPO. In addition, several 
commenters recommended the removal of all orthopaedic, arthroplasty, 
and joint replacement procedures from the IPO list. Table 48 below 
contains the procedures that were explicitly requested by the 
commenters to be removed from the IPO list for CY 2019.

[[Page 59002]]

[GRAPHIC] [TIFF OMITTED] TR21NO18.074

    Response: We appreciate the diligence that commenters continue to 
show in proposing changes to the IPO list. For the CY 2019 OPPS, we 
believe that it is appropriate to remove the procedure described by CPT 
code 00670 from the IPO list, as recommended by the commenters. We 
refer readers to the CY 2017 OPPS/ASC final rule with comment period 
(81 FR 79695 through 79696) in which CMS removed six related codes 
(four spine procedure codes and two laryngoplasty codes) from the IPO 
list for CY 2017. We believe that the procedure described by CPT code 
00670 is appropriate for removal from the IPO list because it relates 
to the following codes that CMS removed from the IPO list in CY 2017: 
CPT code 22840 (Posterior non-segmental instrumentation (e.g., 
Harrington rod technique, pedicle fixation across 1 interspace, 
atlantoaxial transarticular screw fixation, sublaminar wiring at C1, 
facet screw fixation) (List separately in addition to code for primary 
procedure)); CPT code 22842 (Posterior segmental instrumentation (e.g., 
pedicle fixation, dual rods with multiple hooks and sublaminar wires); 
3 to 6 vertebral segments (List separately in addition to code for 
primary procedure)); CPT code 22845 (Anterior instrumentation; 2 to 3 
vertebral segments (List separately in addition to code for primary 
procedure)); and CPT code 22858 (Total disc arthroplasty (artificial 
disc), anterior approach, including discectomy with end plate 
preparation (includes osteophytectomy for nerve root or spinal cord 
decompression and microdissection); second level, cervical (List 
separately in addition to code for primary procedure)). We also believe 
that this procedure is being performed in numerous hospitals on an 
outpatient basis. Accordingly, we are removing the procedure described 
by CPT code 00670 from the IPO list for CY 2019. Because this spine 
procedure code is an add-on code, in accordance with the regulations at 
42 CFR 419.2(b)(18), under the OPPS, this procedure is packaged with 
the associated procedure and assigned status indicator ``N'' (Items and 
Services Packaged into APC Rates) for CY 2019.
    With respect to the commenters' recommendation that we remove CPT 
code 63265 (Laminectomy for excision or evacuation of intraspinal 
lesion other than neoplasm, extradural; cervical), CPT code 63266 
(Laminectomy for excision or evacuation of intraspinal lesion other 
than neoplasm, extradural; thoracic), CPT code 63267 (Laminectomy for 
excision or evacuation of intraspinal lesion other than neoplasm, 
extradural; lumbar), and CPT code 63268 (Laminectomy for excision or 
evacuation of intraspinal lesion other than neoplasm, extradural; 
sacral) from the IPO list, we intend to continue to review these 
procedures and the appropriateness of the potential removal from the 
IPO list for subsequent rulemaking.
    In regard to the commenters' recommendation to remove all 
orthropaedic, arthroplasty, and joint replacement procedures from the 
IPO list, we do not believe that we have sufficient data to support 
removal of all orthopaedic, arthroplasty, and joint replacement 
procedures from the IPO list. However, we encourage stakeholders to 
submit specific procedures, along with evidence, to support their 
requests for removal from the IPO list.
    In conclusion, the complete list of procedure codes that are placed 
on the IPO list for CY 2019 is included as Addendum E to this CY 2019 
OPPS/ASC final rule with comment period (which is available via the 
internet on the CMS website).
    Table 49 below contains the final changes that we are making to the 
IPO list for CY 2019.
BILLING CODE 4120-01-P

[[Page 59003]]

[GRAPHIC] [TIFF OMITTED] TR21NO18.075

BILLING CODE 4120-01-C

X. Nonrecurring Policy Changes

A. Collecting Data on Services Furnished in Off-Campus Provider-Based 
Emergency Departments

    The June 2017 Report to Congress \63\ by the Medicare Payment 
Advisory Commission (MedPAC) states that, in recent years, there has 
been significant growth in the number of health care facilities located 
apart from hospitals that are devoted primarily to emergency department 
services. This includes both off-campus provider-based emergency 
departments that are eligible for payment under the OPPS and 
independent freestanding emergency departments not affiliated with a 
hospital that are not eligible for payment under the OPPS. Since 2010, 
we have observed a noticeable increase in the number of hospital 
outpatient emergency department visits furnished under the OPPS. MedPAC 
and other entities have expressed concern that services may be shifting 
to the higher acuity and higher cost emergency department setting due 
to: (1) Higher payment rates for services performed in off-campus 
provider-based emergency departments compared to similar services 
provided in other settings (that is, physician offices or urgent care 
clinics); and (2) the exemption for services provided in an emergency 
department included under section 603 of the Bipartisan Budget Act of 
2015 (Pub. L. 114-25), whereby all items and services (emergency and 
nonemergency) furnished in an emergency department are excepted from 
the payment implications of section 603, as long as the department 
maintains its status as an emergency department under the regulation at 
42 CFR 489.24(b).
---------------------------------------------------------------------------

    \63\ Available at: https://www.medpac.gov/docs/default-source/reports/jun17_reporttocongress_sec.pdf.
---------------------------------------------------------------------------

    MedPAC and other entities are concerned that these payment 
incentives may be a key factor contributing to the growth in the number 
of emergency departments located off-campus from a hospital. MedPAC 
recommended in its March 2017 \64\ and June 2017 Reports to Congress 
that CMS require hospitals to append a modifier to claims for all 
services furnished in off-campus

[[Page 59004]]

provider-based emergency departments, so that CMS can track the growth 
of OPPS services provided in this setting.
---------------------------------------------------------------------------

    \64\ Available at: https://medpac.gov/docs/default-souce/reports/mar17_entirereport.pdf.
---------------------------------------------------------------------------

    In order to participate in Medicare as a hospital, the facility 
must meet the statutory definition of a hospital at section 1861(e) of 
the Act, which requires a facility to be primarily engaged in providing 
care and services to inpatients. In addition, 42 CFR 482.55 requires 
hospital emergency department services (to include off-campus provider-
based emergency departments) to be fully integrated with departments 
and services of the hospital. The integration must be such that the 
hospital can immediately make available the full extent of its patient 
care resources to assess and furnish appropriate care for an emergency 
patient. Such services would include, but are not limited to, surgical 
services, laboratory services, and radiology services, among others. 
The emergency department must also be integrated with inpatient 
services, which means the hospital must have a sufficient number of 
inpatient beds and nursing units to support the volume of emergency 
department patients that could require inpatient services. The 
provision of services, equipment, personnel and resources of other 
hospital departments and services to emergency department patients must 
be within timeframes that protect the health and safety of patients and 
is within acceptable standards of practice.
    We agree with MedPAC's recommendation and believe we need to 
develop data to assess the extent to which OPPS services are shifting 
to off-campus provider-based emergency departments. Therefore, we 
announced in the CY 2019 OPPS/ASC proposed rule (83 FR 37138) that we 
are implementing through the subregulatory HCPCS modifier process a new 
modifier for this purpose, effective beginning January 1, 2019.
    We stated in the proposed rule that we will create a HCPCS modifier 
(``ER''--Items and services furnished by a provider-based off-campus 
emergency department) that is to be reported with every claim line for 
outpatient hospital services furnished in an off-campus provider-based 
emergency department. We specified in the proposed rule that the 
modifier would be reported on the UB-04 form (CMS Form 1450) for 
hospital outpatient services. We stated that critical access hospitals 
(CAHs) would not be required to report this modifier.
    In response to our announcement of the creation of HCPCS modifier 
``ER'' (Items and services furnished by a provider-based off-campus 
emergency department), we received the following feedback from 
commenters in response to the CY 2019 OPPS/ASC proposed rule: Some 
commenters, including MedPAC, supported the creation of HCPCS modifier 
``ER'', citing the opportunity to facilitate the collection of data on 
services furnished in off-campus emergency departments. Other 
commenters were opposed to the creation of the HCPCS modifier ``ER'' 
because they believed it would be an undue and unnecessary 
administrative burden on hospitals. Another commenter expressed a 
desire to have a better understanding of the reasoning for the creation 
of the modifier.
    While we note that the creation of the HCPCS modifier ``ER'' was 
included in the CY 2019 OPPS/ASC proposed rule as an announcement, as 
opposed to a proposal, and therefore was not subject to public comment, 
we nonetheless appreciate the feedback provided by interested 
stakeholders, and will consider such feedback in potential future 
policy development.

B. Method To Control for Unnecessary Increases in the Volume of 
Outpatient Services

    As discussed in the CY 2019 OPPS/ASC proposed rule (83 FR 37138 
through 37143), when the Medicare program was first implemented, 
payment for hospital services (inpatient and outpatient) was based on 
hospital-specific reasonable costs attributable to furnishing services 
to Medicare beneficiaries. Although payment for most Medicare hospital 
inpatient services became subject to a prospective payment system (PPS) 
under section 1886(d) of the Act in 1983, Medicare hospital outpatient 
services continued to be paid based on hospital-specific costs. This 
methodology for payment provided little incentive for hospitals to 
furnish such outpatient services efficiently and in a cost effective 
manner. At the same time, advances in medical technology and changes in 
practice patterns were bringing about a shift in the site of medical 
care from the hospital inpatient setting to the hospital outpatient 
setting.
    In the Omnibus Budget Reconciliation Act of 1986 (OBRA 1986) (Pub. 
L. 99-509), the Congress paved the way for development of a PPS for 
hospital outpatient services. Section 9343(g) of OBRA 1986 mandated 
that fiscal intermediaries require hospitals to report claims for 
services under the Healthcare Common Procedure Coding System (HCPCS). 
Section 9343(c) of OBRA 1986 extended the prohibition against 
unbundling of hospital services under section 1862(a)(14) of the Act to 
include outpatient services as well as inpatient services. The codes 
under the HCPCS enabled us to determine which specific procedures and 
services were billed, while the extension of the prohibition against 
unbundling ensured that all nonphysician services provided to hospital 
outpatients were reported on hospital bills and captured in the 
hospital outpatient data that were used to develop an outpatient PPS.
    The brisk increase in hospital outpatient services further led to 
an interest in creating payment incentives to promote more efficient 
delivery of hospital outpatient services through a Medicare outpatient 
PPS. Section 9343(f) of OBRA 1986 and section 4151(b)(2) of the Omnibus 
Budget Reconciliation Act of 1990 (OBRA 1990) (Pub. L. 101-508) 
required that we develop a proposal to replace the existing hospital 
outpatient payment system with a PPS and submit a report to the 
Congress on a new proposed system. The statutory framework for the 
Outpatient Prospective Payment System (OPPS) was established by section 
4523 of the Balanced Budget Act (BBA) of 1997 (Pub. L. 105-33), which 
amended section 1833 of the Act by adding subsection (t), which 
establishes a PPS for hospital outpatient department services, and by 
section 201 of the Balanced Budget Reconciliation Act (BBRA) of 1999 
(Pub. L. 106-113), which amended section 1833(t) of the Act to require 
outlier and transitional pass-through payments. At the outset of the 
OPPS, there was significant concern over observed increases in the 
volume of outpatient services and corresponding rapidly growing 
beneficiary coinsurance. Accordingly, most of the focus was on finding 
ways to address those issues.
    When section 4523 of the BBA of 1997 established the OPPS, it 
included specific authority under section 1833(t)(2)(F) of the Act that 
requires the Secretary to develop a method for controlling unnecessary 
increases in the volume of covered outpatient department (OPD) 
services.\65\ In the initial rule that proposed to implement the OPPS 
(63 FR 47585 through 47587), we discussed several possible approaches 
for controlling the volume of covered outpatient department services 
furnished in subsequent years, solicited comments on those options, and 
stated that the agency would propose an appropriate ``volume control'' 
mechanism for services furnished in CY 2001 and beyond after completing 
further analysis. For the CY

[[Page 59005]]

2000 OPPS, we proposed to implement a method that was similar to the 
one used under the Medicare Physician Fee Schedule (PFS) (known as the 
sustainable growth rate or ``SGR''), which would be triggered when 
expenditure targets, based on such factors as volume, intensity, and 
beneficiary enrollment, were exceeded (63 FR 47586 through 47587). 
However, as we discussed in the CY 2001 OPPS final rule (65 FR 18503) 
and the CY 2002 OPPS final rule (66 FR 59908), we delayed the 
implementation of the proposed volume control method as suggested by 
the ``President's Plan to Modernize and Strengthen Medicare for the 
21st Century'' to give hospitals time to adjust to the OPPS and CMS 
time to continue to examine methods to control unnecessary increases in 
the volume of covered OPD services.
---------------------------------------------------------------------------

    \65\ Available at: https://www.ssa.gov/OP_Home/ssact/title18/1833.htm.
---------------------------------------------------------------------------

    In the CY 2008 OPPS/ASC final rule with comment period (72 FR 66611 
through 66612), we noted that we had significant concerns about the 
growth in program expenditures for hospital outpatient services, and 
that while the OPPS was developed in order to address some of those 
concerns, its implementation had not generally slowed that growth in 
expenditures. To address some of those concerns, we established a set 
of packaging policies beginning in CY 2008 that would explicitly 
encourage efficiency in the provision of services in the hospital 
outpatient setting and potentially control future growth in the volume 
of OPPS services (72 FR 66612). Specifically, in the CY 2008 OPPS/ASC 
final rule with comment period (72 FR 66580), we adopted a policy to 
package seven categories of items and services into the payment for the 
primary diagnostic or therapeutic modality to which we believe these 
items are typically ancillary or supportive.
    Similarly, in the CY 2014 OPPS/ASC final rule with comment period 
(78 FR 74925 through 74948), we expanded our packaging policies to 
include more categories of packaged items and services as part of a 
broader initiative to make the OPPS more like a prospective payment 
system and less like a per service fee schedule. Packaging can 
encourage hospitals to furnish services efficiently while also enabling 
hospitals to manage their resources with the maximum flexibility, 
thereby encouraging long-term cost containment, which is an essential 
component of a prospective payment system. While most of the packaging 
policies established in the CY 2014 OPPS focused on ancillary services 
that were part of a primary procedure, we also introduced the concept 
of comprehensive APCs (C-APCs) (78 FR 74861 through 74910), which were 
implemented beginning in the CY 2015 OPPS (79 FR 66798 through 66810). 
Comprehensive APCs package payment for adjunctive and secondary items, 
services, and procedures into the most costly primary procedure under 
the OPPS at the claim level.
    While we have developed many payment policies with these goals in 
mind, growth in program expenditures for hospital outpatient services 
paid under the OPPS continues. As illustrated in Table 30 in the CY 
2019 OPPS/ASC proposed rule (83 FR 37139), total spending has been 
growing at a rate of roughly 8 percent per year under the OPPS, and 
total spending under the OPPS is projected to further increase by more 
than $5 billion from approximately $70 billion in CY 2018 through CY 
2019 to nearly $75 billion. This is approximately twice the total 
estimated spending in CY 2008, a decade ago. We continue to be 
concerned with this rate of increase in program expenditures under the 
OPPS for several reasons. The OPPS was originally designed to manage 
Medicare spending growth. What was once a cost-based system was 
mandated by law to become a prospective payment system, which arguably 
should have slowed the increases in program spending. To the contrary, 
the OPPS has been the fastest growing sector of Medicare payments out 
of all payment systems under Medicare Parts A and B. Furthermore, we 
are concerned that the rate of growth suggests that payment incentives, 
rather than patient acuity or medical necessity, are affecting site-of-
service decision-making. This site-of-service selection has an impact 
on not only the Medicare program, but also on Medicare beneficiary out-
of-pocket spending. Therefore, to the extent that there are lower-cost 
sites-of-service available, we believe that beneficiaries and the 
physicians treating them should have that choice and not be encouraged 
to receive or provide care in higher paid settings solely for financial 
reasons. For example, to provide for easier comparisons between 
hospital outpatient departments and ASCs, as previously discussed in 
the CY 2018 OPPS/ASC final rule with comment period (82 FR 59389), we 
stated in the CY 2019 OPPS/ASC proposed rule that we also will make 
available a website that provides comparison information between the 
OPPS and ASC payment and copayment rates, as required under section 
4011 of the 21st Century Cures Act (Pub. L. 114-255). Making this 
information available can help beneficiaries and their physicians 
determine the cost and appropriateness of receiving care at different 
sites-of-service. Although resources such as this website will help 
beneficiaries and physicians select a site-of-service, we do not 
believe this information alone is enough to control unnecessary volume 
increases. The growth in OPPS expenditures and the increase in the 
volume and intensity of hospital outpatient services were illustrated 
in Tables 30 and 31, respectively, of the CY 2019 OPPS/ASC proposed 
rule (83 FR 37139 through 37140). These tables, which include updated 
information, are presented below.
BILLING CODE 4120-01-P

[[Page 59006]]

[GRAPHIC] [TIFF OMITTED] TR21NO18.076

[GRAPHIC] [TIFF OMITTED] TR21NO18.077

BILLING CODE 4120-01-C
    As noted in its March 2018 Report to Congress, the Medicare Payment 
Advisory Commission (MedPAC) found that, from 2011 through 2016, 
combined program spending and beneficiary cost-sharing on services 
covered under the OPPS increased by 51 percent, from $39.8 billion to 
$60.0 billion, an average of 8.6 percent per year.\66\ In its 2018 
report, MedPAC also noted that ``A large source of growth in spending 
on services furnished in hospital outpatient departments (HOPDs) 
appears to be the result of the shift of services from (lower cost) 
physician offices to (higher cost) HOPDs''. \67\ We consider these 
shifts in the sites of service unnecessary if the beneficiary can 
safely receive the same services in a lower cost setting but instead 
receives care in a higher cost setting.
---------------------------------------------------------------------------

    \66\ Available at: https://www.medpac.gov/docs/default-source/reports/mar18_medpac_entirereport_sec.pdf?sfvrsn=0.
    \67\ Ibid.
---------------------------------------------------------------------------

    As noted in MedPAC's March 2017 Report to Congress, ``from 2014 to 
2015, the use of outpatient services increased by 2.2 percent per 
Medicare FFS beneficiary. Over the decade ending in 2015, volume per 
beneficiary grew by 47 percent. One-third of the growth in outpatient 
volume from 2014 to 2015 was due to an increase in the number of 
evaluation and management (E&M) visits billed as outpatient services. 
This growth in part reflects hospitals purchasing freestanding 
physician practices and converting the billing from the Physician Fee 
Schedule to higher paying hospital outpatient department (HOPD) visits. 
These conversions shift market share from freestanding physician 
offices to HOPDs. From 2012 to 2015, hospital-based E&M visits per 
beneficiary grew by 22 percent, compared with a 1-percent decline in 
physician office-based visits.'' \68\
---------------------------------------------------------------------------

    \68\ Available at: https://www.medpac.gov/docs/default-source/reports/mar17_medpac_ch3.pdf?sfvrsn=0.
---------------------------------------------------------------------------

    MedPAC has documented how the billing for these services has 
shifted from physician offices to higher-cost outpatient sites of care 
for several years. At the same time, MedPAC has repeated its 
recommendation that the difference in payment rates between hospital 
outpatient departments and physician offices should be reduced or 
eliminated. It specifically recommended in its 2012

[[Page 59007]]

Report to Congress that the payment rates for E&M visits provided in 
hospital outpatient departments be reduced so that total payment rates 
for these visits are the same, whether the service is provided in a 
hospital outpatient department or a physician office. In its 2014 
Report to Congress, MedPAC recommended that Congress direct the 
Secretary to reduce or eliminate differences in payment rates between 
hospital outpatient departments and physician offices for selected 
APCs. Both of these recommendations were reiterated in MedPAC's March 
2017 Report to Congress.
    As previously noted, in addition to the concern that the difference 
in payment is leading to unnecessary increases in the volume of covered 
outpatient department services, we also are concerned that this shift 
in care setting increases beneficiary cost-sharing liability because 
Medicare payment rates for the same or similar services are generally 
higher in hospital outpatient departments than in freestanding 
physician offices. For example, MedPAC estimates that ``the Medicare 
program spent $1.0 billion more in 2009, $1.3 billion more in 2014, and 
$1.6 billion more in 2015 than it would have if payment rates for E&M 
office visits in HOPDs were the same as freestanding office rates. 
Relatedly, beneficiaries' cost-sharing was $260 million higher in 2009, 
$325 million higher in 2014, and $400 million higher in 2015 than it 
would have been because of the higher rates paid in HOPD settings.'' 
\69\ We believe that this volume growth and the resulting increase in 
beneficiary cost-sharing is unnecessary because it appears to have been 
incentivized by the difference in payment for each setting rather than 
patient acuity. If there was not a difference in payment rates, we 
believe that we would not have seen the increase in beneficiaries' 
cost-sharing and the shift in site-of-service.
---------------------------------------------------------------------------

    \69\ Ibid.
---------------------------------------------------------------------------

    In the CY 2015 OPPS/ASC proposed rule (79 FR 41013), we stated that 
we continued to seek a better understanding of how the growing trend 
toward hospital acquisition of physicians' offices and subsequent 
treatment of those locations as off-campus provider-based departments 
(PBDs) of hospitals affects payments under the PFS and the OPPS, as 
well as beneficiary cost-sharing obligations. We noted that MedPAC 
continued to question the appropriateness of increased Medicare payment 
and beneficiary cost-sharing when physicians' offices become hospital 
outpatient departments and that MedPAC recommended that Medicare pay 
selected hospital outpatient services at PFS rates (MedPAC March 2012 
and June 2013 Reports to Congress).
    To understand how this trend was affecting Medicare, we explained 
that we needed information on the extent to which this shift was 
occurring. To that end, during the CY 2014 OPPS/ASC rulemaking cycle, 
we sought public comment regarding the best method for collecting 
information and data that would allow us to analyze the frequency, 
type, and payment for physicians' services and hospital outpatient 
services furnished in off-campus PBDs of hospitals (78 FR 75061 through 
75062 and 78 FR 74427 through 74428). Based on our analysis of the 
public comments we received, we believed that the most efficient and 
equitable means of gathering this important information across two 
different payment systems would be to create a HCPCS modifier to be 
reported with every code for physicians' services and hospital 
outpatient services furnished in an off-campus PBD of a hospital on 
both the CMS-1500 claim form for physicians' services and the UB-04 
form (CMS Form 1450 and OMB Control Number 0938-0997) for hospital 
outpatient services. We noted that a main provider may treat an off-
campus facility as provider-based if certain requirements at 42 CFR 
413.65 are satisfied, and we define a ``campus'' at 42 CFR 413.65(a)(2) 
to be the physical area immediately adjacent to the provider's main 
buildings, other areas and structures that are not strictly contiguous 
to the main buildings but are located within 250 yards of the main 
buildings, and any other areas determined on an individual case basis, 
by the CMS regional office, to be part of the provider's campus.
    In 2015, the Congress took steps to address the higher Medicare 
payments for services furnished by certain off-campus PBDs that may be 
associated with hospital acquisition of physicians' offices through 
section 603 of the Bipartisan Budget Act of 2015 (Pub. L. 114-74), 
enacted on November 2, 2015. In the CY 2017 OPPS/ASC proposed rule, we 
discussed section 603 of the Bipartisan Budget Act of 2015, which 
amended section 1833(t) of the Act. For the full discussion of our 
initial implementation of this provision, we refer readers to the CY 
2017 OPPS/ASC final rule with comment period (81 FR 79699 through 
79719) and the interim final rule with comment period (79720 through 
79729).
    Section 603 of the Bipartisan Budget Act of 2015 (Section 603) 
amended section 1833(t) of the Act by amending paragraph (1)(B) and 
adding a new paragraph (21). As a general matter, under sections 
1833(t)(1)(B)(v) and (t)(21) of the Act, applicable items and services 
furnished by certain off-campus outpatient departments of a provider on 
or after January 1, 2017 are not considered covered OPD services as 
defined under section 1833(t)(1)(B) of the Act for purposes of payment 
under the OPPS and are instead paid ``under the applicable payment 
system'' under Medicare Part B if the requirements for such payment are 
otherwise met. We note that, in order to be considered part of a 
hospital, an off-campus department of a hospital must meet the 
provider-based criteria established under 42 CFR 413.65.
    Section 603 amended section 1833(t)(1)(B) of the Act by adding a 
new clause (v), which excludes from the definition of ``covered OPD 
services'' applicable items and services (defined in paragraph (21)(A) 
of the section) that are furnished on or after January 1, 2017, by an 
off-campus PBD, as defined in paragraph (21)(B) of the section. Section 
603 also added a new paragraph (21) to section 1833(t) of the Act, 
which defines the terms ``applicable items and services'' and ``off-
campus outpatient department of a provider,'' requires the Secretary to 
make payments for such applicable items and services furnished by an 
off-campus PBD under an applicable payment system (other than the 
OPPS), provides that hospitals shall report on information as needed 
for implementation of the provision, and establishes a limitation on 
administrative and judicial review of the Secretary's determinations of 
applicable items and services, applicable payment system, whether a 
department meets the definition of an off-campus outpatient department 
of a provider, and information hospitals are required to report. In 
defining the term ``off-campus outpatient department of a provider,'' 
section 1833(t)(21)(B)(i) of the Act specifies that the term means a 
department of a provider (as defined at 42 CFR 413.65(a)(2) as that 
regulation was in effect on November 2, 2015, the date of enactment of 
Pub. L. 114-74) that is not located on the campus of such provider, or 
within the distance from a remote location of a hospital facility. 
Section 1833(t)(21)(B)(ii) of the Act excepts from the definition of 
``off-campus outpatient department of a provider,'' for purposes of 
paragraphs (1)(B)(v) and (21)(B) of the section, an off-campus PBD that 
was billing under section 1833(t) of the Act with respect to covered 
OPD services furnished prior

[[Page 59008]]

to the date of enactment of the Bipartisan Budget Act of 2015, that is, 
November 2, 2015. We note that the definition of ``applicable items and 
services'' specifically excludes items and services furnished by a 
dedicated emergency department as defined at 42 CFR 489.24(b) and the 
definition of ``off-campus outpatient department of a provider'' does 
not include PBDs located on the campus of a hospital or within the 
distance (described in the definition of campus at Sec.  413.65(a)(2)) 
from a remote location of a hospital facility; the items and services 
furnished by these excepted off-campus PBDs on or after January 1, 2017 
continued to be paid under the OPPS.
    In the CY 2017 OPPS/ASC final rule with comment period (81 FR 79699 
through 79720), we established a number of policies to implement 
section 603 of the Bipartisan Budget Act of 2015. Broadly, we: (1) 
Defined applicable items and services in accordance with section 
1833(t)(21)(A) of the Act for purposes of determining whether such 
items and services are covered OPD services under section 
1833(t)(1)(B)(v) of the Act or whether payment for such items and 
services will instead be made under the applicable payment system 
designated under section 1833(t)(21)(C) of the Act; (2) defined off-
campus PBD for purposes of sections 1833(t)(1)(B)(v) and (t)(21) of the 
Act; and (3) established policies for payment for applicable items and 
services furnished by an off-campus PBD (nonexcepted items and 
services) under section 1833(t)(21)(C) of the Act. To do so, we 
finalized policies that define whether certain items and services 
furnished by a given off-campus PBD may be considered excepted and, 
thus, continue to be paid under the OPPS; established the requirements 
for the off-campus PBDs to maintain excepted status (both for the 
excepted off-campus PBDs and for the items and services furnished by 
such excepted off-campus PBDs); and described the applicable payment 
system for nonexcepted items and services (generally, the PFS).
    As part of developing policies to implement the section 603 
amendments to section 1833(t) of the Act, we solicited public comments 
on information collection requirements for implementing this provision 
in accordance with section 1833(t)(21)(D) of the Act (81 FR 45686; 81 
FR 79709 through 79710). In the CY 2017 OPPS/ASC final rule with 
comment period (81 FR 79719 and 79725), we created modifier ``PN'' to 
collect data for purposes of implementing section 603 but also to 
trigger payment under the newly adopted PFS rates for nonexcepted items 
and services.
    While the changes required by the section 603 amendments to section 
1833(t) of the Act address some of the concerns related to shifts in 
settings of care and overutilization in the hospital outpatient 
setting, the majority of hospital off-campus departments continue to 
receive full OPPS payment (including off-campus emergency departments 
and excepted off-campus departments of a hospital), which is often 
higher than the payment that would have been made if a similar service 
had been furnished in the physician office setting. Therefore, the 
current site-based payment creates an incentive for an unnecessary 
increase in the volume of this type of OPD service, which results in 
higher costs for the Medicare program, its beneficiaries, and taxpayers 
more generally. These differences in payment rates have unnecessarily 
shifted services away from the lower paying physician's office to the 
higher paying hospital outpatient department. We believe that the 
higher payment that is made under the OPPS, as compared to payment 
under the PFS, contributes to incentivizing providers to furnish care 
in the hospital outpatient setting rather than the physician office 
setting. In 2012, Medicare was paying approximately 80 percent more for 
a 15-minute office visit in a hospital outpatient department than in a 
freestanding physician office.\70\
---------------------------------------------------------------------------

    \70\ Available at: https://www.medpac.gov/docs/default-source/reports/march-2012-report-to-the-congress-medicare-payment-policy.pdf.
---------------------------------------------------------------------------

    For example, under Medicare payment policy in effect for CY 2018, 
the Medicare program would pay more for a clinic visit (HCPCS code 
G0463) furnished under the OPPS than it would for the visit codes under 
the PFS. In the CY 2017 OPPS/ASC interim final rule, we noted that the 
most frequently billed service with the ``PO'' modifier was described 
by HCPCS code G0463 (Hospital outpatient clinic visit for assessment 
and management of a patient), which is paid under APC 5012 (Clinic 
Visits and Related Services); the total number of CY 2017 claim lines 
for this service was approximately 10.8 million lines with the ``PO'' 
modifier as of October 2018, out of a total 30.5 million lines in CY 
2017. When services are furnished in the hospital outpatient setting, 
an additional payment for the professional services is generally made 
under the PFS using the ``facility'' rate. For example, in CY 2017, the 
OPPS payment rate for APC 5012, which is the APC to which the 
outpatient clinic visit code was assigned, was $106.56. The CY 2017 PFS 
``facility'' payment rate for a Level 3 visit, a service that commonly 
corresponds to the OPPS clinic visit, was $77.88 for a new patient and 
$51.68 for an established patient.
    However, when services are furnished in the physician office 
setting, only one payment is made--typically, the ``nonfacility'' rate 
under the PFS. The CY 2017 PFS nonfacility payment rates for a Level 3 
visit, a commonly billed service under the PFS, was $109.46 for a new 
patient and $73.93 for an established patient. Therefore, the total 
Medicare Part B payment rate (for the hospital and professional 
service) for a new patient when the service was furnished in the 
hospital outpatient setting was $184.44 ($106.56 + $77.88) compared to 
$109.46 in the physician office setting (approximately $75 or 68 
percent more per visit), or for an established patient, $158.24 
($106.56 + $51.68) in the hospital outpatient setting compared to 
$73.93 in the physician office setting (approximately $84 or 114 
percent more per visit). Under these examples, the payment rate was 
approximately $75 to $84 more for the same service when furnished in 
the hospital outpatient setting instead of the physician office 
setting, 20 percent of which was the responsibility of the beneficiary. 
Taking into account that this payment discrepancy occurs across tens of 
millions of claims each year, this is a significant source of 
unnecessary spending by Medicare beneficiaries directly (in the form of 
unnecessarily high copayments) and on behalf of Medicare beneficiaries 
(in the form of unnecessarily high Medicare payments for services that 
could be performed in a different setting).
    We understand that many off-campus departments converted from 
physicians' offices to hospital outpatient departments without a change 
in either the physical location or a change in the acuity of the 
patients seen. To the extent that similar services can be safely 
provided in more than one setting, we do not believe it is prudent for 
the Medicare program to pay more for these services in one setting than 
another. We believe the difference in payment for these services is a 
significant factor in the shift in services from the physician's office 
to the hospital outpatient department, thus unnecessarily increasing 
hospital outpatient department volume and Medicare program and 
beneficiary expenditures.
    We consider the shift of services from the physician office to the 
hospital outpatient department unnecessary if the beneficiary can 
safely receive the same services in a lower cost setting but is instead 
receiving services in the

[[Page 59009]]

higher paid setting due to payment incentives. We believe the increase 
in the volume of clinic visits is due to the payment incentive that 
exists to provide this service in the higher cost setting. Because 
these services could likely be safely provided in a lower cost setting, 
we believe that the growth in clinic visits paid under the OPPS is 
unnecessary. Further, we believe that capping the OPPS payment at the 
PFS-equivalent rate would be an effective method to control the volume 
of these unnecessary services because the payment differential that is 
driving the site-of-service decision will be removed. In particular, we 
believe this method of capping payment will control unnecessary volume 
increases both in terms of numbers of covered outpatient department 
services furnished and costs of those services.
    Therefore, given the unnecessary increases in the volume of clinic 
visits in hospital outpatient departments, in the CY 2019 OPPS/ASC 
proposed rule (83 FR 37142), for the CY 2019 OPPS, we proposed to use 
our authority under section 1833(t)(2)(F) of the Act to apply an amount 
equal to the site-specific PFS payment rate for nonexcepted items and 
services furnished by a nonexcepted off-campus PBD (the PFS payment 
rate) for the clinic visit service, as described by HCPCS code G0463, 
when provided at an off-campus PBD excepted from section 1833(t)(21) of 
the Act (departments that bill the modifier ``PO'' on claim lines). 
Off-campus PBDs that are not excepted from section 603 (departments 
that bill the modifier ``PN'') already receive a PFS-equivalent payment 
rate for the clinic visit.
    In CY 2019, for an individual Medicare beneficiary, the standard 
unadjusted Medicare OPPS proposed payment for the clinic visit was 
approximately $116, with approximately $23 being the average copayment. 
The proposed PFS equivalent rate for Medicare payment for a clinic 
visit was approximately $46, and the copayment would be approximately 
$9. Under this proposal, an excepted off-campus PBD would continue to 
bill HCPCS code G0463 with the ``PO'' modifier in CY 2019, but the 
payment rate for services described by HCPCS code G0463 when billed 
with modifier ``PO'' would now be equivalent to the payment rate for 
services described by HCPCS code G0463 when billed with modifier 
``PN''. This would save beneficiaries an average of $14 per visit. For 
a discussion of the amount paid under the PFS for clinic visits 
furnished by nonexcepted off-campus PBDs, we referred readers to the CY 
2018 PFS final rule (82 FR 53023 through 53024), as well as the CY 2019 
PFS proposed rule and final rule.
    In addition, in the CY 2019 OPPS/ASC proposed rule (83 FR 37142), 
we proposed to implement this proposed method in a nonbudget neutral 
manner. Specifically, while section 1833(t)(9)(B) of the Act requires 
that certain changes made under the OPPS be made in a budget neutral 
manner, we note that this section does not apply to the volume control 
method under section 1833(t)(2)(F) of the Act. In particular, section 
1833(t)(9)(A) of the Act, titled ``Periodic review,'' provides, in 
part, that the Secretary must annually review and revise the groups, 
the relative payment weights, and the wage and other adjustments 
described in paragraph (2) to take into account changes in medical 
practice, changes in technology, the addition of new services, new cost 
data, and other relevant information and factors'' (emphasis added). 
Section 1833(t)(9)(B) of the Act, titled ``Budget neutrality 
adjustment'' provides that if ``the Secretary makes adjustments under 
subparagraph (A), then the adjustments for a year may not cause the 
estimated amount of expenditures under this part for the year to 
increase or decrease from the estimated amount of expenditures under 
this part that would have been made if the adjustments had not been 
made'' (emphasis added). However, section 1833(t)(2)(F) of the Act is 
not an ``adjustment'' under paragraph (2). Unlike the wage adjustment 
under section 1833(t)(2)(D) of the Act and the outlier, transitional 
pass-through, and equitable adjustments under section 1833(t)(2)(E) of 
the Act, section 1833(t)(2)(F) of the Act refers to a ``method'' for 
controlling unnecessary increases in the volume of covered OPD 
services, not an adjustment. Likewise, sections 1833(t)(2)(D) and (E) 
of the Act also explicitly require the adjustments authorized by those 
paragraphs to be budget neutral, while the volume control method 
authority at section 1833(t)(2)(F) of the Act does not. Therefore, the 
volume control method proposed under section 1833(t)(2)(F) of the Act 
is not one of the adjustments under section 1833(t)(2) of the Act that 
is referenced under section 1833(t)(9)(A) of the Act that must be 
included in the budget neutrality adjustment under section 
1833(t)(9)(B) of the Act. Moreover, section 1833(t)(9)(C) of the Act 
specifies that if the Secretary determines under methodologies 
described in paragraph (2)(F) that the volume of services paid for 
under this subsection increased beyond amounts established through 
those methodologies, the Secretary may appropriately adjust the update 
to the conversion factor otherwise applicable in a subsequent year. We 
interpret this provision to mean that the Secretary will have 
implemented a volume control method under section 1833(t)(2)(F) of the 
Act in a nonbudget neutral manner in the year in which the method is 
implemented, and that the Secretary may then make further adjustments 
to the conversion factor in a subsequent year to account for volume 
increases that are beyond the amounts estimated by the Secretary under 
the volume control method.
    We stated in the CY 2019 OPPS/ASC proposed rule (83 FR 37143) that 
we believe implementing a volume control method in a budget neutral 
manner would not appropriately reduce the overall unnecessary volume of 
covered OPD services, and instead would simply shift the movement of 
the volume within the OPPS system in the aggregate, a concern similar 
to the one we discussed in the CY 2008 OPPS final rule with comment 
period (72 FR 66613). This estimated payment impact was displayed in 
Column 5 of Table 42.-- Estimated Impact of the Proposed Changes for 
the Hospital Outpatient Prospective Payment System in the CY 2019 OPPS/
ASC proposed rule (83 FR 37228 through 37229). An estimate that 
includes the effects of estimated changes in enrollment, utilization, 
and case-mix based on the FY 2019 President's Budget approximates the 
estimated savings at $760 million, with $610 million of the savings 
accruing to Medicare, and $150 million saved by Medicare beneficiaries 
in the form of reduced copayments. In order to effectively establish a 
method for controlling the unnecessary growth in the volume of clinic 
visits furnished by excepted off-campus PBDs that does not simply 
reallocate expenditures that are unnecessary within the OPPS, we 
believe that this method must be adopted in a nonbudget neutral manner. 
The impact associated with this proposal is further described in 
section XXI. of the CY 2019 OPPS/ASC proposed rule.
    Comment: Numerous commenters, including organizations representing 
private health insurance plans, physician associations, specialty 
medical associations, and individual Medicare beneficiaries, supported 
the proposal. Some of these commenters commended CMS for its proposal, 
which they believed will help to control costs for both beneficiaries 
and the Medicare program, as well as foster greater competition in the 
physician services market. Commenters were

[[Page 59010]]

supportive of the immediate impact this policy would have in lowering 
Medicare beneficiaries' out-of-pocket costs. One commenter noted that 
there ``is no principled basis for treating excepted and nonexcepted 
PBDs differently with respect to payment for E&M services or for 
perpetuating the payment differential between off-campus PBDs and 
physician offices.'' Several commenters supported implementing this 
policy in a nonbudget neutral manner because they believed to do 
otherwise would be simply to redistribute expenditures for unnecessary 
services within the OPPS rather than eliminating those expenditures 
from the OPPS altogether. A number of commenters urged CMS to continue 
on a path to bring full parity in payment for outpatient services, 
regardless of the site-of-service, to lower beneficiary cost-sharing, 
reduce Medicare expenditures, and stem the tide of provider 
consolidation. Two commenters believed that several factors demonstrate 
to them that HOPDs drive up volume for several other common outpatient 
services, including:
     Patients receive more chemotherapy administration 
sessions, on average, when treated in the HOPD. Chemotherapy days per 
beneficiary were an estimated 9 to 12 percent higher in the hospital 
outpatient department than the physician office setting.\71\
---------------------------------------------------------------------------

    \71\ The Moran Company: Cost Differences in Cancer Care Across 
Settings; August 2013.
---------------------------------------------------------------------------

     Differences in utilization of chemotherapy drugs and 
services between hospital outpatient departments and physicians' 
offices resulted in an estimated increase in Medicare payments and 
Medicare beneficiary copayments of $167 million. Over 93 percent of the 
additional payments were related to chemotherapy and other 
chemotherapy-related drugs.\72\
---------------------------------------------------------------------------

    \72\ BRG: Impact of Medicare Payments of Shift in Site of Care 
for Chemotherapy Administration; June 2014.
---------------------------------------------------------------------------

     Cardiac imaging procedures resulted in higher payments for 
a 3-day episode (217 percent) and 22-day episodes (80 percent) when 
performed in a HOPD compared to a physician's office.\73\
---------------------------------------------------------------------------

    \73\ Avalere: Medicare Payment Differentials Across Outpatient 
Settings of Care; February 2016.
---------------------------------------------------------------------------

     For certain cardiology, orthopedic, and gastroenterology 
services, employed physicians were seven times more likely to perform 
services in a HOPD setting than independent physicians, resulting in 
additional costs of $2.7 billion to Medicare and $411 million in 
patient copayments over a 3-year period.\74\
---------------------------------------------------------------------------

    \74\ Avalere, PAI: Physician Practice Acquisition Study: 
National and Regional Employment Changes, October 2016.
---------------------------------------------------------------------------

    One commenter believed that payment differentials between 
independent physician practices and hospital outpatient departments 
stem in part from inadequate Medicare physician payment rates and that 
any savings from site neutrality proposals derived from OPPS should be 
reinvested in increasing payment rates elsewhere in Part B, including 
payments to physicians. Some commenters urged HHS to work with Congress 
to expand site-neutral policies in the OPPS.
    Response: We appreciate the commenters' support. As mentioned in 
the proposed rule (83 FR 37138 through 37143), we share the commenters' 
concern that the current payment incentives, rather than patient acuity 
or medical necessity, are affecting site-of-service decision-making. As 
we noted in the proposed rule (83 FR 37138 through 37143), ``[a] large 
source of growth in spending on services furnished in hospital 
outpatient departments (HOPDs) appears to be the result of the shift of 
services from (lower cost) physician offices to (higher cost) 
HOPDs''.\75\ We continue to believe that these shifts in the sites of 
service are unnecessary if the beneficiary can safely receive the same 
services in a lower cost setting but instead receives care in a higher 
cost setting due to payment incentives. In addition to the concern that 
the difference in payment is leading to unnecessary increases in the 
volume of covered outpatient department services, we remain concerned 
that this shift in care setting increases beneficiary cost-sharing 
liability because Medicare payment rates for the same or similar 
services are generally higher in hospital outpatient departments than 
in physician offices.
---------------------------------------------------------------------------

    \75\ Available at: https://www.medpac.gov/docs/default-source/reports/mar18_medpac_entirereport_sec.pdf?sfvrsn=0.
---------------------------------------------------------------------------

    We appreciate the comments supporting the implementation of this 
policy in a nonbudget neutral manner. As we stated in the proposed rule 
(83 FR 37138 through 37143), we believe implementing a volume control 
method in a budget neutral manner would not appropriately reduce the 
overall unnecessary volume of covered OPD services, and instead would 
simply shift the volume of services within the OPPS system in the 
aggregate. As detailed later in this section, we are finalizing our 
proposal, with modifications, in response to public comments. We will 
continue to take information submitted by the commenters into 
consideration for future study.
    With respect to the comment that it is inappropriate to establish a 
PFS-equivalent rate because PFS rates are inadequate and that any 
savings should be redistributed across Medicare Part B, we disagree 
that PFS rates as a whole are inadequate and note that the methodology 
to develop such rates was established by law and regulations and is 
updated each year through notice-and-comment rulemaking. We note that 
the overall amount of Medicare payments to physicians and other 
entities made under the PFS is determined by the PFS statute, and the 
rates for individual services are determined based on the resources 
involved in furnishing these services relative to other services paid 
under the PFS. To the extent the commenter believes that the PFS rate 
for a particular service is misvalued relative to other PFS services, 
we encourage the commenter to nominate the service for review as a 
potentially misvalued service under the PFS.
    Comment: MedPAC supported the proposal to reduce the OPPS payment 
rate for clinic visits provided in an excepted off-campus PBD to a PFS-
equivalent payment rate. MedPAC noted that the policy would be 
consistent with its past recommendations for site-neutral payments 
between HOPDs and freestanding physician offices. In its comments, 
MedPAC highlighted two key points from its March 2012 recommendation on 
site-neutral payments. While MedPAC recommended that OPPS payment rates 
for clinic visits be reduced so that Medicare payments for these 
services are the same whether they are provided in HOPDs or physician 
offices, it also recommended that this policy be phased in over 3 years 
to allow providers time to adjust to lower payment rates. During the 
phase-in, MedPAC recommended that payment reductions to hospitals with 
a disproportionate share (DSH) patient percentage at or above the 
median be limited to 2 percent of overall Medicare payments because 
these hospitals are often the primary source of care for low-income 
beneficiaries and limiting the reduction in revenue would help maintain 
access to care for these beneficiaries.
    Response: We thank MedPAC for its comments and support of this 
policy. In its comments, MedPAC recommended this policy be phased in 
over 3 years to allow providers time to adjust to lower payment rates. 
As detailed later in this section, we will be implementing this policy 
with a 2-year phase-in. We believe that a 2-year phase-in allows us

[[Page 59011]]

to balance the immediate need to address the unnecessary increases in 
the volume of clinic visits with concerns like those articulated by 
MedPAC regarding providers' need for time to adjust to these payment 
changes. While we acknowledge and share MedPAC's concern about 
beneficiary access to care, we do not believe that a limit on the 
payment reduction to hospitals with a DSH patient percentage at or 
above the median is necessary because we believe the increase in the 
volume of clinic visits in excepted off-campus provider-based 
departments of hospitals with high DSH percentages is equally 
unnecessary as it is at other hospitals.
    Many commenters challenged the statutory authority for various 
aspects of the proposal. These comments are summarized below.
    Comment: Several commenters disagreed with CMS' interpretation of 
section 1833(t)(2)(F) of the Act. The commenters contended that section 
1833(t)(2)(F) of the Act does not confer direct authority on CMS to 
modify OPPS payment rates for specific services. Rather, the commenters 
asserted that section 1833(t)(2)(F) of the Act only permits the agency 
to develop a ``method,'' which the commenters interpreted to mean a 
``way of doing things'' or a ``plan.'' The commenters stated that 
utilizing the authority at section 1833(t)(2)(F) of the Act to reduce 
payments to excepted off-campus PBDs to rates that equal the lower 
payment amounts received by nonexcepted off-campus PBDs was improper. 
The commenters maintained that the Secretary can only control 
unnecessary increases in volume using authority conferred by other 
provisions of section 1833(t) of the Act, such as through the equitable 
adjustment authority at section 1833(t)(2)(E) of the Act. The 
commenters believed that the clinic visit proposal was arbitrary and 
capricious for this and other reasons. In particular, the commenters 
expressed concern that there was no data-driven basis to conclude that 
OPD services have increased unnecessarily. The commenters also claimed 
that the proposal is based on unsupported assertions and assumptions 
regarding increases in volume. The commenters were concerned that other 
factors, such as the shift from inpatient services to outpatient 
services or the 2-midnight policy, might be driving the increases in 
the volume of outpatient services. Other commenters asserted that CMS 
should consider the impact of severity of illness and patient 
demographics on outpatient volume prior to moving forward with any 
payment changes. One commenter stated that, relative to patients seen 
in physician offices, patients seen in HOPDs:
     Have more severe chronic conditions;
     Have higher prior utilization of hospitals and EDs;
     Are more likely to live in low-income areas;
     Are 1.8 times more likely to be dually eligible for 
Medicare and Medicaid;
     Are 1.4 times more likely to be nonwhite;
     Are 1.6 times more likely to be under age 65 and disabled; 
and
     Are 1.1 times more likely to be over 85 years old.
    The commenters also noted that Medicare beneficiaries with cancer 
seen in HOPDs relative to those beneficiaries seen in physician offices 
have more severe chronic conditions, higher prior utilization of 
services in hospitals and emergency departments, and higher likelihood 
of residing in low-income areas. In addition, the commenters noted that 
these cancer patients were more likely to be dually eligible for 
Medicare and Medicaid and be nonwhite, under age 65, and disabled.
    Response: After consideration of these comments, we continue to 
believe that section 1833(t)(2)(F) of the Act gives the Secretary broad 
authority to develop a method for controlling unnecessary increases in 
the volume of covered outpatient department (OPD) services, including a 
method that controls unnecessary volume increases by removing a payment 
differential that is driving a site-of-service decision, and as a 
result, is unnecessarily increasing service volume.\76\ We continue to 
believe shifts in the sites of service described in the preceding 
paragraphs are inherently unnecessary if the beneficiary can safely 
receive the same services in a lower cost setting but instead receives 
care in a higher cost setting due to the payment incentives created by 
the difference in payment amounts. While we did receive some data 
illustrating that HOPDs serve unique patient populations and provide 
services to medically complex beneficiaries, these data did not 
demonstrate the need for higher payment for all clinic visits provided 
in HOPDs. The fact that the commenters did not supply data supporting 
these assertions is suggestive that the payment differential may be the 
main driver for unnecessary volume increases in outpatient department 
services, particularly clinic visits.
---------------------------------------------------------------------------

    \76\ Available at: https://www.ssa.gov/OP_Home/ssact/title18/1833.htm.
---------------------------------------------------------------------------

    In fact, the Government Accountability Office (GAO) found that 
``the percentage of E/M visits--as well as the number of E/M office 
visits per beneficiary--performed in HOPDs, rather than physician 
offices, was generally higher in counties with higher levels of 
vertical consolidation in 2007-2013.'' \77\ Vertical consolidation is 
the practice of hospitals acquiring physician practices. We believe 
that higher payment rates for services furnished in HOPDs, which 
include clinic visits, have led hospitals to increasingly purchase 
physician practices. We believe there is a correlation among the 
increasing volume of HOPD clinic visits, vertical integration, and the 
higher OPPS payment rates for clinic visits. The GAO discovered that 
``the median percentage of E/M office visits performed in HOPDs in 
counties with the lowest levels of vertical consolidation was 4.1 
percent in 2013. In contrast, this rate was 14.1 percent for counties 
with the highest levels of consolidation.'' The GAO also found that, in 
2013, the number of E/M office visits performed in HOPDs per 100 
beneficiaries was 26 for the counties with low levels of vertical 
consolidation, whereas the number was substantially higher--82 services 
per 100 beneficiaries--in counties with the highest levels of vertical 
consolidation.\78\ The GAO determined that the association between 
higher levels of vertical consolidation and high utilization of E/M 
office visits in HOPDs remained even after controlling for differences 
in county-level characteristics and other market factors that could 
affect the setting in which E/M office visits are performed. The GAO 
describes the model it ran as a ``regression model that controlled for 
county characteristics that do not change over relatively short periods 
of time, such as whether a county is urban or rural, and county 
characteristics that could change over time, such as the level of 
competition among hospitals and physicians within counties.'' The GAO 
explained that its ``regression model's results were similar to [its] 
initial results: the level of vertical consolidation in a county was 
significantly and positively associated with a higher number and 
percentage of E/M office visits performed in HOPDs--that is, as 
vertical consolidation increased in a given county, the number and 
percentage of E/M office visits

[[Page 59012]]

performed in HOPDs in that county also tended to be higher.'' \79\
---------------------------------------------------------------------------

    \77\ Available at: https://www.gao.gov/assets/680/674347.pdf.
    \78\ Ibid.
    \79\ Available at: https://www.gao.gov/assets/680/674347.pdf.
---------------------------------------------------------------------------

    The GAO findings align with our assertions in the proposed rule (83 
FR 37138 through 37143). Paying substantially more for the same service 
when performed in an HOPD rather than a physician office provides an 
incentive to shift services that were once performed in physician 
offices to HOPDs after consolidation has occurred. The GAO findings 
suggest that providers responded to this financial incentive: E/M 
office visits were more frequently performed in HOPDs in counties with 
higher levels of vertical consolidation. The GAO found this association 
in both of its analyses of E/M office visit utilization in counties 
with varying levels of vertical consolidation and in its regression 
analyses.
    We heard from many commenters that the higher payment rate was 
justified by the fact that HOPDs were treating sicker patient 
populations. The GAO's study did not support this conclusion. It 
examined counties that experienced large growth in the billing of 
clinic visits in HOPDs and was able to determine that: ``Beneficiaries 
from counties with higher levels of vertical consolidation were not 
sicker, on average, than beneficiaries from counties with lower levels 
of consolidation. Specifically, beneficiaries from counties with higher 
levels of vertical consolidation tended to have either similar or 
slightly lower median risk scores, death rates, rates of end-stage 
renal disease, and rates of disability compared to those from counties 
with lower levels of consolidation. Further, counties with higher 
levels of consolidation had a lower percentage of beneficiaries dually 
eligible for Medicaid, who tend to be sicker and have higher Medicare 
spending than Medicare beneficiaries who are not dually eligible for 
Medicaid.''
    This suggests that areas with higher E/M office visit utilization 
in HOPDs are not composed of sicker-than-average beneficiaries. As we 
stated in the proposed rule (83 FR 37138 through 37143), paying more 
for the same service when performed in an HOPD rather than a 
physician's office provides an incentive to shift services that were 
once performed in physician offices to HOPDs. The GAO's findings 
suggest that providers responded to this financial incentive. As we 
noted in the proposed rule (83 FR 37138 through 37143), we have 
developed many payment policies, such as packaging policies and 
comprehensive APCs, to address the rapid growth of services in the 
OPPS. However, these policies have not been able to control for 
unnecessary increases in volume that are due to site-of-service payment 
differentials, which create an incentive to furnish a service in the 
OPD that could be furnished in a lower cost setting based solely on the 
higher payment amount available under the OPPS. Here, the clinic visit 
service furnished in excepted off-campus PBDs is the same as the clinic 
visit service furnished in nonexcepted off-campus PBDs. We believe that 
applying an amount equal to the site-specific PFS payment rate for 
nonexcepted items and services furnished by a nonexcepted off-campus 
PBD (the PFS payment rate) for the clinic visit service, as described 
by HCPCS code G0463, when provided at an off-campus PBD excepted from 
section 1833(t)(21) of the Act is an appropriate method to control the 
unnecessary increase in the volume of outpatient services.
    Comment: Several commenters expressed concern that CMS lacks the 
statutory authority to reduce OPPS payments for certain clinic visit 
services furnished at off-campus PBDs that are excepted from payment 
``under the applicable payment system'' under section 1833(t)(21) of 
the Act. The commenters stated that Congress expressly chose in section 
603 of the Bipartisan Budget Act of 2015 not to confer on CMS authority 
to pay excepted off-campus PBDs at the reduced rates paid to 
nonexcepted off-campus PBDs. The commenters asserted that CMS is 
ignoring the express and statutorily mandated grandfathering exception 
created by section 603.
    Response: We believe the changes required by section 603 of the 
Bipartisan Budget Act of 2015 made in section 1833(t) of the Act 
address some of the concerns related to shifts in settings of care and 
overutilization of services in the hospital outpatient setting for new 
off-campus PBDs after November 1, 2015. However, the majority of 
hospital off-campus departments continue to receive full OPPS payment 
(including off-campus emergency departments and excepted off-campus 
departments of a hospital), which is often higher than the payment that 
would have been made if a similar service had been furnished in the 
physician office setting. Therefore, the current site-based payment 
creates an incentive for an unnecessary increase in the volume of this 
type of OPD service, which results in higher costs for the Medicare 
program, beneficiaries, and taxpayers more generally. We interpret our 
authority under section 1833(t)(2)(F) of the Act to allow us to 
implement our proposed method of applying an amount equal to the site-
specific PFS payment rate for nonexcepted items and services furnished 
by a nonexcepted off-campus PBD (the PFS payment rate) for the clinic 
visit service, as described by HCPCS code G0463, when provided at off-
campus PBDs, even those that are excepted from section 1833(t)(21) of 
the Act. We believe that this is an appropriate method because the 
clinic visit service is the same service furnished in excepted and 
nonexcepted off-campus PBDs.
    When Congress passed the Bipartisan Budget Act of 2015, Medicare 
OPPS expenditures were $56 billion and growing at an annual rate of 
about 7.3 percent. In addition, the percentage increase in volume and 
intensity of outpatient services was increasing at 3.4 percent. For the 
upcoming 2019 calendar year, we estimate that, without this policy, 
OPPS expenditures would be $74.5 billion, growing at a rate of 9.1 
percent, with the volume and intensity of outpatient services 
increasing at 5.4 percent, based on the Midsession Review for 2019. 
While it is clear that the action Congress took in 2015 to address 
certain off-campus PBDs helped stem the tide of these increases in the 
volume of OPD services, it is likewise clear that the more specific 
payment adjustment has not adequately addressed the overall increase in 
the volume of these types of OPD services because most off-campus PBDs 
continue to be paid the higher OPPS amount for these services. We would 
not be able to adequately address the unnecessary increases in the 
volume of clinic visits in HOPDs if we did not apply this policy to all 
off-campus HOPDs. We do not believe that the section 603 amendments to 
section 1833(t) of the Act, which exclude applicable items and services 
furnished by nonexcepted off-campus PBDs from payments under the OPPS, 
preclude us from exercising our authority in section 1833(t)(2)(F) of 
the Act to develop a method for controlling unnecessary increases in 
the volume of covered outpatient department services under the OPPS.
    Comment: Several commenters believed that CMS does not have 
statutory authority to implement this policy in a nonbudget neutral 
manner. The commenters explained that, because CMS lacks the authority 
to reduce clinic visit payment rates as a method to control unnecessary 
increases in the volume of covered outpatient department services under 
section 1833(t)(2)(F) of the Act, that provision cannot provide 
authority for the

[[Page 59013]]

payment reduction to be made in a nonbudget neutral way. The commenters 
also claimed that the only nonbudget neutral option available to the 
agency is to adjust the conversion factor in a subsequent year, as 
provided under section 1833(t)(9)(C) of the Act. The commenters argued 
that if Congress had intended to give CMS the authority to make a 
volume control method nonbudget neutral, it would have done so in 
clearer and more express terms. Other commenters stated that if this 
policy is finalized, it should be done so only in a budget neutral 
manner.
    Response: We maintain that while section 1833(t)(9)(B) of the Act 
does require that certain changes made under the OPPS be made in a 
budget neutral manner, this provision does not apply to the volume 
control method under section 1833(t)(2)(F) of the Act as outlined 
through our proposal. As we noted in the proposed rule (83 FR 37138 
through 37143), unlike the wage adjustment under section 1833(t)(2)(D) 
of the Act and the outlier, transitional pass-through, and equitable 
adjustments under section 1833(t)(2)(E) of the Act, section 
1833(t)(2)(F) of the Act refers to a ``method'' for controlling 
unnecessary increases in the volume of covered OPD services, not an 
adjustment. Likewise, sections 1833(t)(2)(D) and (E) of the Act also 
explicitly require the adjustments authorized by those paragraphs to be 
budget neutral, while the volume control method authority at section 
1833(t)(2)(F) of the Act does not include such a requirement. 
Therefore, we maintain that the volume control method proposed under 
section 1833(t)(2)(F) of the Act is not one of the adjustments under 
section 1833(t)(2) of the Act that is referenced under section 
1833(t)(9)(A) of the Act that must be included in the budget neutrality 
adjustment under section 1833(t)(9)(B) of the Act. Moreover, section 
1833(t)(9)(C) of the Act specifies that if the Secretary determines 
under methodologies described in paragraph (2)(F) of section 1833(t) of 
the Act that the volume of services paid for under this subsection 
increased beyond amounts established through those methodologies, the 
Secretary may appropriately adjust the update to the conversion factor 
otherwise applicable in a subsequent year. We continue to interpret 
this provision to mean that the Secretary will have implemented a 
volume control method under section 1833(t)(2)(F) of the Act in a 
nonbudget neutral manner in the year in which the method is 
implemented. Further, as we stated in the proposed rule (83 FR 37138 
through 37143), we believe that implementing a volume control method in 
a budget neutral manner would not appropriately reduce the overall 
unnecessary volume of covered OPD services, and instead would simply 
shift the volume within the OPPS system in the aggregate.
    Comment: Several commenters supported the recommendation from the 
HOP Panel not to implement this proposal and to instead study the 
matter to better understand the reasons for increased utilization.
    Response: Section 1833(t)(9)(A) of the Act provides that the 
Secretary shall consult with the Panel on policies affecting the 
clinical integrity of the ambulatory payment classifications and their 
associated weights under the OPPS. The Panel met on August 20, 2018 and 
made recommendations on this proposed policy, and we consulted with the 
Panel on those recommendations. The HOP Panel's recommendations, along 
with public comments on provisions of the proposed rule, have been 
taken into consideration in the development of this final rule with 
comment period. While we are not accepting the HOP Panel's 
recommendation to not implement this proposal, we will continue to 
monitor and study the utilization of outpatient services as recommended 
by the Panel.
    Comment: Several commenters expressed concern that this policy 
proposal would disproportionately affect safety net hospitals and rural 
providers. Numerous commenters representing providers and beneficiaries 
in the State of Washington expressed concerned about the impact this 
proposal would have on their area. Several commenters also requested 
that sole community hospitals (urban and rural), rural referral 
centers, and Medicare-dependent hospitals be exempted from this policy. 
A number of commenters, including many State hospital associations, 
expressed concern that the magnitude of the proposed payment reduction 
would have a drastic effect on their margins and endanger the 
investments many hospitals have made in their provider-based 
facilities. In addition, commenters suggested that the reduction in 
payment would ultimately lead to a reduction of services that would 
adversely affect vulnerable patient populations. One commenter 
conducted a trend analysis and found that 200 hospitals would shoulder 
73 percent of the proposed payment reduction. According to this 
commenter's analysis, for the 200 hospitals most affected by this 
proposal, the average reduction would be 5.5 percent. For the remaining 
hospitals, the average reduction would be 0.5 percent.
    Response: We share the commenters' concerns about access to care, 
especially in rural areas where access issues may be more pronounced 
than in other areas of the country. Medicare has long recognized the 
unique needs of rural communities and the financial challenges for 
rural providers. Across the various Medicare payment systems, CMS has 
implemented a number of special payment provisions for rural providers 
to maintain access and deliver high quality care to beneficiaries in 
rural areas. With respect to the OPPS, section 1833(t)(13) of the Act 
provided the Secretary the authority to make an adjustment to OPPS 
payments for rural hospitals, effective January 1, 2006, if justified 
by a study of the difference in costs by APC between hospitals in rural 
areas and hospitals in urban areas. Our analysis showed a difference in 
costs for rural sole community hospitals. Therefore, for the CY 2006 
OPPS, we finalized a payment adjustment for rural sole community 
hospitals of 7.1 percent for all services and procedures paid under the 
OPPS, excluding separately payable drugs and biologicals, brachytherapy 
sources, and devices paid under the pass-through payment policy, in 
accordance with section 1833(t)(13)(B) of the Act. We have continued 
this 7.1 percent payment adjustment since 2006. In the CY 2019 OPPS/ASC 
proposed rule (83 FR 37143), we sought public comment on how we might 
account in the future for providers that serve Medicare beneficiaries 
in provider shortage areas, which may include certain rural areas. In 
addition, we sought public comment on whether there should be 
exceptions from this policy for rural providers, such as those 
providers that are at risk of hospital closure or those providers that 
are sole community hospitals. Taking into consideration the comments 
regarding rural hospitals, we believe that implementing this policy 
with a 2-year phase-in will help to mitigate the immediate impact on 
rural hospitals. We may revisit this policy to consider potential 
exemptions in the CY 2020 OPPS rulemaking.
    After consideration of the public comments we received, we are 
finalizing our proposal to use our authority under section 
1833(t)(2)(F) of the Act to apply an amount equal to the site-specific 
PFS payment rate for nonexcepted items and services furnished by a 
nonexcepted off-campus PBD (the PFS payment rate) for the clinic visit 
service, as described by HCPCS code G0463, when provided at an off-
campus PBD excepted from section 1833(t)(21) of the Act

[[Page 59014]]

(departments that bill the modifier ``PO'' on claim lines). In 
addition, we are finalizing our proposal to implement this policy in a 
nonbudget neutral manner. We will continue to monitor the impacts of 
this policy as it is phased in to ensure that beneficiaries continue to 
have access to quality care.
    In response to public comments we received, we will be phasing in 
the application of the reduction in payment for HCPCS code G0463 in 
this setting over 2 years. In CY 2019, the payment reduction will be 
transitioned by applying 50 percent of the total reduction in payment 
that would apply if these departments were paid the site-specific PFS 
rate for the clinic visit service. The final payment rates are 
available in Addendum B to this final rule with comment period (which 
is available via the internet on the CMS website). The PFS-equivalent 
amount paid to nonexcepted off-campus PBDs is 40 percent of OPPS 
payment (that is, 60 percent less than the OPPS rate) for CY 2019. 
Based on a 2-year phase-in of this policy, half of the total 60-percent 
payment reduction, a 30-percent reduction, will apply in CY 2019. In 
other words, these departments will be paid approximately 70 percent of 
the OPPS rate (100 percent of the OPPS rate minus the 30-percent 
payment reduction that applies in CY 2019) for the clinic visit service 
in CY 2019. In CY 2020, these departments will be paid the site-
specific PFS rate for the clinic visit service. We note that by phasing 
in this policy over 2 years, the estimated savings associated with this 
policy will change. Considering the effects of estimated changes in 
enrollment, utilization, and case-mix, this policy results in an 
estimated CY 2019 savings of approximately $380 million, with 
approximately $300 million of the savings accruing to Medicare, and 
approximately $80 million saved by Medicare beneficiaries in the form 
of reduced copayments. We will continue to monitor the effect of this 
change in Medicare payment policy, including the volume of these types 
of OPD services.
    While we are exploring developing a method to systematically 
control for unnecessary increases in the volume of other hospital 
outpatient department services that we may propose in future 
rulemaking, we continue to recognize the importance of not impeding 
development or beneficiary access to new innovations. In the CY 2019 
OPPS/ASC proposed rule (83 FR 37143), we solicited public comments on 
how to maintain access to new innovations while controlling for 
unnecessary increases in the volume of covered hospital OPD services.
    In addition, we solicited public comments on how to expand the 
application of the Secretary's statutory authority under section 
1833(t)(2)(F) of the Act to additional items and services paid under 
the OPPS that may represent unnecessary increases in the utilization of 
OPD services. Therefore, we sought public comment on the following:
     How might Medicare define the terms ``unnecessary'' and 
``increase'' for services (other than the clinic visit) that can be 
performed in multiple settings of care? Should the method to control 
for unnecessary increases in the volume of covered OPD services include 
consideration of factors such as enrollment, severity of illness, and 
patient demographics?
     While we proposed to pay the site-specific PFS payment 
rate for clinic visits beginning in CY 2019, we also were interested in 
other methods to control for unnecessary increases in the volume of 
outpatient services. Prior authorization is a requirement that a health 
care provider obtain approval from the insurer prior to providing a 
given service in order for the insurer to cover the service. Private 
health insurance plans often require prior authorization for certain 
services. Should prior authorization be considered as a method for 
controlling overutilization of services?
     For what reasons might it ever be appropriate to pay a 
higher OPPS rate for services that can be performed in lower cost 
settings?
     Several private health plans use utilization management as 
a cost-containment strategy. How might Medicare use the authority at 
section 1833(t)(2)(F) of the Act to implement an evidence-based, 
clinical support process to assist physicians in evaluating the use of 
medical services based on medical necessity, appropriateness, and 
efficiency? Could utilization management help reduce the overuse of 
inappropriate or unnecessary services?
     How should we account for providers that serve Medicare 
beneficiaries in provider shortage areas, which may include certain 
rural areas? With respect to rural providers, should there be 
exceptions from this policy, such as for providers who are at risk of 
hospital closure or that are sole community hospitals?
     What impact on beneficiaries and the health care market 
would such a method to control for unnecessary increases in the volume 
of covered OPD services have?
     What exceptions, if any, should be made if additional 
proposals to control for unnecessary increases in the volume of 
outpatient services are made?
    We received feedback on a variety of issues in response to the 
comment solicitation on additional future considerations. These 
comments are summarized below.
    Comment: In response to the solicitation on how CMS might expand 
the application of the Secretary's statutory authority under section 
1833(t)(2)(F) of the Act to additional items and services paid under 
the OPPS that may represent unnecessary increases in OPD volume, MedPAC 
suggested that CMS consider using the five criteria that MedPAC has 
developed for identifying services for which it is reasonable to have 
site-neutral payments between freestanding physician offices and 
HOPDs.\80\
---------------------------------------------------------------------------

    \80\ Medicare Payment Advisory Commission. 2013. Report to the 
Congress: Medicare and the health care delivery system. Washington, 
DC: MedPAC.
---------------------------------------------------------------------------

    In response to the solicitation on whether prior authorization 
should be considered as a method for controlling overutilization of 
services, most commenters believed that, while prior authorization may 
be a good method for controlling overutilization of services, it can 
also lead to increased administrative burden and inhibit patient 
access. One commenter suggested that CMS consider applying prior 
authorization for providers with service volumes that are statistical 
outliers or for those whose ordering rates are not in compliance with 
clinical guidelines.
    In response to the comment solicitation on when it might be 
appropriate to pay a higher OPPS payment rate for a service that can be 
performed safely in a lower cost setting, several commenters believed 
that it would be appropriate to pay a higher OPPS rate for services 
that can be performed in a lower cost setting if providing this higher 
payment can improve patient experience, efficiency, and quality of 
care. Several commenters also mentioned that the comprehensive care 
management and coordination that accompanies receiving services at an 
off-campus PBD of a hospital might justify the higher OPPS payment 
rate. Commenters also asserted that the additional certifications 
required for services furnished in PBDs compared to services furnished 
in physician offices justify a higher payment rate.
    In response to the comment solicitation on utilization management, 
several commenters were opposed to this concept and stated that 
utilization management would increase provider burden and delay patient 
access to care. One commenter supported the concept

[[Page 59015]]

of utilization management, but believed that it must be based on 
clinical validity, support the continuity of patient care, be 
transparent and fair, provide timely access to care and administrative 
efficiency, and provide alternatives and exemptions to those clinicians 
with appropriate utilization rates. Other commenters supported 
appropriate use criteria and evidence-based clinical guidelines and 
pathways as effective clinical-decision support tools to assist 
clinicians and hospitals in the reduction of potentially harmful or 
rarely appropriate services.
    Response: We thank commenters for their responses to our comment 
solicitation. We will consider these comments for future rulemaking.

C. Application of the 340B Drug Payment Policy to Nonexcepted Off-
Campus Departments of a Hospital

1. Historical Perspective
a. Section 603 of the Bipartisan Budget Act of 2015
    In the CY 2017 OPPS/ASC final rule with comment period (81 FR 
79699), we discussed implementation of section 603 of the Bipartisan 
Budget Act of 2015 (Pub. L. 114-74), enacted on November 2, 2015, which 
amended section 1833(t) of the Act. Specifically, this provision 
amended section 1833(t) of the Act by amending paragraph (1)(B) and 
adding a new paragraph (21). As a general matter, under sections 
1833(t)(1)(B)(v) and (t)(21) of the Act, applicable items and services 
furnished by certain off-campus outpatient departments of a provider on 
or after January 1, 2017 are not considered covered OPD services as 
defined under section 1833(t)(1)(B) of the Act for purposes of payment 
under the OPPS and are instead paid ``under the applicable payment 
system'' under Medicare Part B if the requirements for such payment are 
otherwise met. We indicated that, in order to be considered part of a 
hospital, an off-campus department of a hospital must meet the 
provider-based criteria established under 42 CFR 413.65. Accordingly, 
we refer to an ``off-campus outpatient department of a provider,'' 
which is the term used in section 603 of the Bipartisan Budget Act of 
2015, as an ``off-campus outpatient provider-based department'' or an 
``off-campus PBD.'' For a detailed discussion of the legislative 
history and statutory authority related to payments under section 603 
of the Bipartisan Budget Act of 2015, we refer readers to the CY 2017 
OPPS/ASC final rule with comment period (81 FR 79699 through 79719) and 
interim final rule with comment period (81 FR 79720 through 79729).
b. Applicable Payment System
    As we stated in the CY 2019 OPPS/ASC proposed rule (83 FR 37143 
through 37144), to implement the amendments made by section 603 of 
Public Law 114-74, we issued an interim final rule with comment period 
(81 FR 79720) which accompanied the CY 2017 OPPS/ASC final rule with 
comment period to establish the Medicare PFS as the ``applicable 
payment system'' that applies in most cases, and we established payment 
rates under the PFS for those nonexcepted items and services furnished 
by nonexcepted off-campus PBDs. As we discussed in the CY 2017 OPPS/ASC 
interim final rule with comment period (81 FR 79718) and reiterated in 
the CY 2018 PFS final rule with comment period (82 FR 53028), payment 
for Medicare Part B drugs that would be separately payable under the 
OPPS (assigned a status indicator of ``K''), but are not payable under 
the OPPS because they are furnished by nonexcepted off-campus PBDs, is 
made in accordance with section 1847A of the Act (generally, at a rate 
of ASP+6 percent), consistent with Part B drug payment policy for items 
or services furnished in the physician office (nonfacility) setting. We 
did not propose or make an adjustment to payment for 340B-acquired 
drugs in nonexcepted off-campus PBDs in CY 2018, but indicated we may 
consider doing so through future notice-and-comment rulemaking.
    In the interim final rule with comment period that accompanied the 
CY 2017 OPPS/ASC final rule with comment period, we established payment 
policies under the Medicare PFS for nonexcepted items and services 
furnished by a nonexcepted off-campus PBD on or after January 1, 2017. 
In accordance with sections 1848(b) and (c) of the Act, Medicare PFS 
payment is based on the relative value of the resources involved in 
furnishing particular services (81 FR 79790). Resource-based relative 
values are established for each item and service (described by a HCPCS 
code(s)) based on the work (time and intensity), practice expense (such 
as clinical staff, supplies and equipment, office rent, and overhead), 
and malpractice expense required to furnish the typical case of the 
service. Because Medicare makes separate payment under institutional 
payment systems (such as the OPPS) for the facility costs associated 
with many of the same services that are valued under the PFS, we 
establish two different PFS payment rates for many of these services--
one that applies when the service is furnished in a location where a 
facility bills and is paid for the service under a Medicare payment 
system other than the PFS (the facility rate), and another that applies 
when the billing practitioner or supplier furnishes and bills for the 
entire service (the nonfacility rate). Consistent with the long-
established policy under the PFS to make payment to the billing 
practitioner at the facility rate when Medicare makes a corresponding 
payment to the facility (under the OPPS, for instance) for the same 
service, physicians and nonphysician practitioners furnishing services 
in nonexcepted PBDs continue to report their services on a professional 
claim form and are paid for their services at the PFS facility rate.
    Similarly, there are many (mostly diagnostic) services paid under 
the PFS that have two distinct portions of the service: A technical 
component (TC) and a professional component (PC). These components can 
be furnished independently in time or by different suppliers, or they 
may be furnished and billed together as a ``global'' service (82 FR 
52981). Payment for these services can also be made under a combination 
of payment systems; for example, under the PFS for the professional 
component and the OPPS for the facility portion. For instance, for a 
diagnostic CT scan, the technical component relates to the portion of 
the service during which the image is captured and might be furnished 
in an office or HOPD setting, and the professional component relates to 
the interpretation and report by a radiologist.
    In the CY 2017 interim final rule with comment period, we stated 
that we continue to believe that it is operationally infeasible for 
nonexcepted off-campus PBDs to bill directly under the PFS for the 
subset of PFS services for which there is a separately valued technical 
component (81 FR 79721). In addition, we explained that we believe 
hospitals that furnish nonexcepted items and services are likely to 
furnish a broader range of services than other provider or supplier 
types for which there is a separately valued technical component under 
the PFS. We stated that we therefore believe it is necessary to 
establish a new set of payment rates under the PFS that reflect the 
relative resource costs of furnishing the technical component of a 
broad range of services to be paid under the PFS that is specific to 
one site of service (the off-campus PBD of a hospital) with the 
packaging (bundling) rules that are significantly different from 
current PFS rules (81 FR 79721).
    In continuing to implement the requirements of sections 
1833(t)(1)(B) and (t)(21) of the Act, we recognize that

[[Page 59016]]

there is no established mechanism for allowing hospitals to report and 
bill under the PFS for the portion of resources incurred in furnishing 
the full range of nonexcepted items and services. This is because 
hospitals with nonexcepted off-campus PBDs that furnish nonexcepted 
items and services generally furnish a broader range of services than 
other provider or supplier types for which there is a separately valued 
technical component under the PFS. As such, we established a new set of 
payment rates under the PFS that reflected the relative resource costs 
of furnishing the technical component of a broad range of services to 
be paid under the PFS specific to the nonexcepted off-campus PBDs of a 
hospital. Specifically, we established a PFS relativity adjuster that 
is applied to the OPPS rate for the billed nonexcepted items and 
services furnished in a nonexcepted off-campus PBD in order to 
calculate payment rates under the PFS. The PFS relativity adjuster 
reflects the estimated overall difference between the payment that 
would otherwise be made to a hospital under the OPPS for the 
nonexcepted items and services furnished in nonexcepted off-campus PBDs 
and the resource-based payment under the PFS for the technical aspect 
of those services with reference to the difference between the facility 
and nonfacility (office) rates and policies under the PFS. The current 
PFS relativity adjuster is set at 40 percent of the amount that would 
have been paid under the OPPS (82 FR 53028). These PFS rates 
incorporate the same packaging rules that are unique to the hospital 
outpatient setting under the OPPS, including the packaging of drugs 
that are unconditionally packaged under the OPPS. This includes 
packaging certain drugs and biologicals that would ordinarily be 
separately payable under the PFS when furnished in the physician office 
setting.
    Nonexcepted off-campus PBDs continue to bill for nonexcepted items 
and services on the institutional claim utilizing a new claim line 
(modifier ``PN'') to indicate that an item or service is a nonexcepted 
item or service. For a detailed discussion of the current PFS 
relativity adjuster related to payments under section 603 of Public Law 
114-74, we refer readers to the CY 2018 OPPS/ASC final rule with 
comment period (82 FR 52356 through 52637), the CY 2018 PFS final rule 
with comment period (82 FR 53019 through 53025), and the CY 2019 PFS 
proposed rule.
c. Section 340B of the Public Health Service Act
    As discussed in the CY 2019 OPPS/ASC proposed rule (83 FR 37144 
through 37145), the 340B Program, which was established by section 340B 
of the Public Health Service Act by the Veterans Health Care Act of 
1992, is administered by the Health Resources and Services 
Administration (HRSA) within HHS. The 340B Program allows participating 
hospitals and other health care providers to purchase certain ``covered 
outpatient drugs'' (as defined under section 1927(k) of the Act and 
interpreted by HRSA through various guidance documents) at discounted 
prices from drug manufacturers.
    In the CY 2018 OPPS/ASC proposed rule (82 FR 33632 through 33635), 
we proposed changes to the payment methodology under the OPPS for 
separately payable drugs and biologicals acquired under the 340B 
Program. We stated that these changes would better, and more 
appropriately, reflect the resources and acquisition costs that these 
hospitals incur. Such changes would allow Medicare beneficiaries (and 
the Medicare program) to pay less when hospitals participating in the 
340B Program furnish drugs that are purchased under the 340B Program to 
Medicare beneficiaries. Subsequently, in the CY 2018 OPPS/ASC final 
rule with comment period, we finalized our proposal that separately 
payable, covered outpatient drugs and biologicals (other than drugs on 
pass-through payment status and vaccines) acquired under the 340B 
Program will be paid ASP minus 22.5 percent, rather than ASP+6 percent, 
when billed by a hospital paid under the OPPS that is not excepted from 
the payment adjustment. CAHs are not subject to this 340B policy change 
because they are paid under section 1834(g) of the Act. Rural sole 
community hospitals, children's hospitals, and PPS-exempt cancer 
hospitals are excepted from the alternative payment methodology for 
340B-acquired drugs and biologicals. In addition, as stated in the CY 
2018 OPPS/ASC final rule with comment period, this policy change does 
not apply to drugs with pass-through payment status, which are required 
to be paid based on the ASP methodology, or to vaccines, which are 
excluded from the 340B Program.
2. Proposal and Final Policy To Pay an Adjusted Amount for 340B-
Acquired Drugs and Biologicals Furnished in Nonexcepted Off-Campus PBDs 
in CY 2019 and Subsequent Years
    As noted in the CY 2017 OPPS/ASC final rule with comment period (81 
FR 79716), prior to the implementation of the payment adjustment under 
the OPPS for drugs and biologicals acquired under the 340B program, 
separately payable drugs and biologicals were paid the same rate at 
both excepted and nonexcepted off-campus departments of a hospital. The 
policy we finalized in the CY 2018 OPPS/ASC final rule with comment 
period, in which we adjusted the payment rate for separately payable 
drugs and biologicals (other than drugs on pass-through payment status 
and vaccines) acquired under the 340B Program from ASP+6 percent to ASP 
minus 22.5 percent, applies to separately payable drugs and biologicals 
paid under the OPPS (81 FR 59353 through 59369). Under sections 
1833(t)(1)(B)(v) and (t)(21) of the Act, however, in accordance with 
our policy in effect as of CY 2018, nonexcepted items and services 
furnished by nonexcepted off-campus PBDs are no longer covered 
outpatient department services and, therefore, are not payable under 
the OPPS. This means that nonexcepted off-campus PBDs are not subject 
to the payment changes finalized in the CY 2018 OPPS/ASC final rule 
with comment period that apply to hospitals and PBDs paid under the 
OPPS. Because the separately payable drugs and biologicals acquired 
under the 340B Program and furnished in nonexcepted off-campus PBDs are 
no longer covered outpatient department services, as of CY 2018, these 
drugs and biologicals are currently paid in the same way Medicare Part 
B drugs are paid in the physician office and other nonhospital 
settings--typically at ASP+6 percent--regardless of whether they are 
acquired under the 340B Program.
    The current PFS payment policies for nonexcepted items and services 
incorporate a significant number of payment policies and adjustments 
made under the OPPS (81 FR 79726; 82 FR 53024 through 53025). In 
establishing these policies in prior rulemaking, we pointed out that 
the adoption of these policies was necessary in order to maintain the 
integrity of the PFS relativity adjuster because it adjusts payment 
rates developed under the OPPS (81 FR 79726). For example, it is 
necessary to incorporate OPPS packaging rules into the site-specific 
PFS rate because the PFS relativity adjuster is applied to OPPS rates 
that were developed based on those packaging rules. In addition, many 
of the OPPS policies and adjustments are replicated under the 
nonexcepted off-campus PBD site-specific PFS rates because they are 
specifically applicable to hospitals as a setting of care. For example, 
we adopted the geographic adjustments used for hospitals instead of the 
adjustments developed for the

[[Page 59017]]

PFS localities, which reflect cost differences calculated for 
professionals and suppliers rather than hospitals (81 FR 79726).
    We note that, ordinarily, Medicare pays for drugs and biologicals 
furnished in the physician's office setting at ASP+6 percent. This is 
because section 1842(o)(1)(A) of the Act provides that if a 
physician's, supplier's, or any other person's bill or request for 
payment for services includes a charge for a drug or biological for 
which payment may be made under Medicare Part B and the drug or 
biological is not paid on a cost or prospective payment basis as 
otherwise provided in this part, the amount for the drug or biological 
is equal to the following: The amount provided under section 1847, 
section 1847A, section 1847B, or section 1881(b)(13) of the Act, as the 
case may be for the drug or biological.
    Generally, in the hospital outpatient department setting, low-cost 
drugs and biologicals are packaged into the payment for other services 
billed under the OPPS. Separately payable drugs (1) have pass-through 
payment status, (2) have a per-day cost exceeding a threshold, or (3) 
are not policy-packaged or packaged in a C-APC. As described in section 
V.A.1. of the CY 2019 OPPS/ASC proposed rule, section 1847A of the Act 
establishes the ASP methodology, which is used for payment for drugs 
and biologicals described in section 1842(o)(1)(C) of the Act furnished 
on or after January 1, 2005. The ASP methodology, as applied under the 
OPPS, uses several sources of data as a basis for payment, including 
the ASP, the WAC, and the AWP (82 FR 59337). As noted in section 
V.B.2.b. of the CY 2019 OPPS/ASC proposed rule, since CY 2013, our 
policy has been to pay for separately payable drugs and biologicals at 
ASP plus 6 percent in accordance with section 1833(t)(14)(A)(iii)(II) 
of the Act (the statutory default) (82 FR 59350). Consequently, in the 
case of services furnished in a hospital outpatient department, 
Medicare pays ASP+6 percent for separately payable Part B drugs and 
biologicals unless those drugs or biologicals are acquired under the 
340B Program, in which case they are paid at ASP minus 22.5 percent. 
For a detailed discussion of our current OPPS drug payment policies, we 
refer readers to the CY 2018 OPPS/ASC final rule with comment period 
(82 FR 59343 through 59371).
    As discussed in the CY 2019 OPPS/ASC proposed rule (83 FR 37146), 
as a general matter, in the nonexcepted off-campus PBD setting, we pay 
hospitals under the PFS for all drugs and biologicals that are packaged 
under the OPPS based on a percentage of the OPPS payment rate, which is 
determined using the PFS relativity adjuster. Because OPPS packaging 
rules apply to the PFS payments to nonexcepted off-campus PBDs, the PFS 
payment for some nonexcepted items and services that are packaged 
includes payment for some drugs and biologicals that would be 
separately payable under the PFS if a similar service had been 
furnished in the office-based setting. As we noted in the CY 2017 final 
rule with comment period, in analyzing the term ``applicable payment 
system,'' we considered whether and how the requirements for payment 
could be met under alternative payment systems in order to pay for 
nonexcepted items and services, and considered several payment systems 
under which payment is made for similar items and services (81 FR 
79712). Because the PFS relativity adjuster that is applied to 
calculate payment to hospitals for nonexcepted items and services 
furnished in nonexcepted off-campus PBDs is based on a percentage (40 
percent) of the amount determined under the OPPS for a particular item 
or service, and the OPPS is a prospective payment system, we believe 
that items and services furnished by nonexcepted off-campus PBDs paid 
under the PFS are payable on a prospective payment basis. Therefore, we 
believe we have flexibility to pay for separately payable drugs and 
biologicals furnished in nonexcepted off-campus PBDs at an amount other 
than the amount dictated by sections 1842(o)(1)(C) and 1847A of the 
Act.
    As we discussed in the CY 2018 OPPS/ASC final rule with comment 
period (82 FR 59354), several recent studies and reports on Medicare 
Part B payments for 340B-acquired drugs highlight a difference in 
Medicare Part B drug spending between 340B hospitals and non-340B 
hospitals as well as varying differences in the amount by which the 
Part B payment exceeds the drug acquisition cost. When we initially 
developed the policy for nonexcepted off-campus PBDs, most separately 
payable drugs and biologicals were paid, both in the OPPS and in other 
Part B settings, such as physician offices, through similar 
methodologies under section 1847A/1842(o) of the Act. For drugs and 
biologicals that are packaged in the OPPS, we adopted similar packaging 
payment policies for purposes of making the site-specific payment under 
the PFS for nonexcepted off-campus PBDs. Because hospitals can, in some 
cases, acquire drugs and biologicals under the 340B Program for use in 
nonexcepted off-campus PBDs, we believe that not adjusting payment 
exclusively for these departments would present a significant 
incongruity between the payment amounts for these drugs depending upon 
where (for example, excepted PBD or nonexcepted PBD) they are 
furnished. This incongruity would distort the relative accuracy of the 
resource-based payment amounts under the site-specific PFS rates and 
could result in significant perverse incentives for hospitals to 
acquire drugs and biologicals under the 340B Program and avoid Medicare 
payment adjustments that account for the discount by providing these 
drugs to patients predominantly in nonexcepted off-campus PBDs. In 
light of the significant drug payment differences between excepted and 
nonexcepted off-campus PBDs, in combination with the potential 
eligibility for discounts, which result in reduced costs under the 340B 
Program for both kinds of departments, our current payment policy could 
undermine the validity of the use of the OPPS payment structure in 
nonexcepted off-campus PBDs. In order to avoid such perverse incentives 
and the potential resulting distortions in drug payment, in the CY 2019 
OPPS/ASC proposed rule (83 FR 37146), we proposed, pursuant to our 
authority at section 1833(t)(21)(C) of the Act, to identify the PFS as 
the ``applicable payment system'' for 340B-acquired drugs and 
biologicals and, accordingly, to pay under the PFS instead of under 
section 1847A/1842(o) of the Act an amount equal to ASP minus 22.5 
percent for drugs and biologicals acquired under the 340B Program that 
are furnished by nonexcepted off-campus PBDs. We stated in the proposed 
rule that we believe this proposed change in policy would eliminate the 
significant incongruity between the payment amounts for these drugs, 
depending upon whether they are furnished by excepted off-campus PBDs 
or nonexcepted off-campus PBDs, which we believe is an unnecessary 
difference in payment where the 340B Program does not differentiate 
between PBDs paid under the OPPS and PBDs paid under the PFS using the 
PFS relativity adjuster.
    In the CY 2018 OPPS/ASC final rule with comment period (82 FR 59367 
through 59368), we discussed public comments that we received that 
noted that the alternative payment methodology for 340B-acquired drugs 
and biologicals did not apply to nonexcepted off-campus PBDs of a 
hospital and could result in behavioral

[[Page 59018]]

changes that may undermine CMS' policy goals of reducing beneficiary 
cost-sharing liability and undercut the goals of section 603 of Public 
Law 114-74. Commenters recommended that, if CMS adopted a final policy 
to establish an alternative payment methodology for 340B drugs in CY 
2018, CMS also apply the same adjustment to payment rates for drugs 
furnished in nonexcepted off-campus PBDs of a hospital if such drugs 
were acquired under the 340B Program (82 FR 59367). While we did not 
propose to adjust payment for 340B-acquired drugs in nonexcepted off-
campus PBDs in CY 2018, we indicated that we would consider adopting 
such a policy in future rulemaking.
    We agree with commenters that the difference in the payment amounts 
for 340B-acquired drugs furnished by hospital outpatient departments, 
excepted off-campus PBDs versus nonexcepted off-campus PBDs, creates an 
incentive for hospitals to move drug administration services for 340B-
acquired drugs to nonexcepted off-campus PBDs to receive a higher 
payment amount for these drugs, thereby undermining our goals of 
reducing beneficiary cost-sharing for these drugs and biologicals and 
moving towards site neutrality through the section 603 amendments to 
section 1833(t) of the Act. Therefore, in the CY 2019 OPPS/ASC proposed 
rule (83 FR 37145), we proposed changes to the Medicare Part B drug 
payment methodology for drugs and biologicals furnished and billed by 
nonexcepted off-campus departments of a hospital that were acquired 
under the 340B Program. Specifically, for CY 2019 and subsequent years, 
we proposed to pay under the PFS the adjusted payment amount of ASP 
minus 22.5 percent for separately payable drugs and biologicals (other 
than drugs on pass-through payment status and vaccines) acquired under 
the 340B Program when they are furnished by nonexcepted off-campus PBDs 
of a hospital. Furthermore, we proposed to except rural sole community 
hospitals, children's hospitals, and PPS-exempt cancer hospitals from 
this payment adjustment (83 FR 37145). We stated that we believe that 
our proposed payment policy would better reflect the resources and 
acquisition costs that nonexcepted off-campus PBDs incur for these 
drugs and biologicals.
    Comment: Some commenters, including organizations representing 
physician oncology practices, orthopaedic surgeons, pharmaceutical 
research and manufacturing companies, a large network of community-
based oncology practices, physician organizations, and health insurers, 
supported the proposal. Some of these commenters commended CMS for its 
proposal, which they believed would help address the growth of the 340B 
Program, stem physician practice consolidation with hospitals, preserve 
patient access to community-based care, and address the significant 
incongruity between the payment amounts for 340B-acquired drugs, 
depending upon the setting in which they are furnished. One of these 
commenters, a pharmaceutical company, stated that the 340B Program has 
grown beyond its original intent and needs to be refocused to better 
meet the needs of vulnerable patients. The commenter noted that there 
is an incentive to inappropriately shift administration of drugs from 
excepted to nonexcepted off-campus PBDs for the purpose of securing 
higher payment. In addition, the commenter urged HHS to adopt policies 
``that prevent the unjustified expansion of the 340B program to 
unintended populations through contract pharmacies, child sites, and 
individuals who Congress did not intend to be considered 340B 
patients.''
    A few commenters, including organizations representing community 
oncology practices, stated that the opportunity for 340B-participating 
hospitals to get substantial revenue from cancer drugs has created 
financial incentives for hospitals to expand oncology services, notably 
through the acquisition of independent community oncology practices. 
Furthermore, one of these commenters asserted that, when these 
facilities purchased by 340B-participating entities become off-campus 
PBDs, they also become eligible for 340B Program discounts, thus 
``further fueling the program's staggering growth.'' These commenters 
cited a report that states that, over the last decade, 658 community 
oncology practices have been acquired by hospitals, and 3 out of 4 of 
these acquisitions were by hospitals already eligible for the 340B 
Program. Accordingly, these commenters believe that the growth of Part 
B drug spending in recent years has been disproportionately driven by 
higher payments in the hospital outpatient setting. Another commenter 
asserted that the current situation creates two undesirable incentives. 
First, it creates an incentive for physicians to join a hospital to 
furnish the same types of services that could have been furnished in 
the physician office setting, thereby increasing costs to the Medicare 
program, Medicare beneficiaries, and taxpayers without any associated 
increase in access to care for Medicare beneficiaries, particularly 
low-income beneficiaries. Second, it encourages hospitals to move 
services off the hospital campus for financial incentives.
    Some commenters urged CMS and HRSA to work with Congress to reform 
the 340B Program. One commenter recommended that CMS gather additional 
data to better understand 340B Program acquisition costs and the impact 
of payment reductions on 340B Program providers. In addition, a few 
commenters recommended that CMS revise the definition of ``patient'' to 
reflect the program's original intent.
    Response: We thank commenters for their support and 
recommendations. We agree with the commenters that the difference in 
the payment amounts for 340B-acquired drugs furnished by different 
types of hospital outpatient departments, excepted off-campus PBDs 
versus nonexcepted off-campus PBDs, creates an incentive for hospitals 
to move drug administration services for 340B-acquired drugs to 
nonexcepted off-campus PBDs to receive a higher payment amount for 
these drugs, thereby undermining our goals of reducing beneficiary 
cost-sharing for these drugs and biologicals and moving towards site 
neutrality through the section 603 amendments to section 1833(t) of the 
Act. Therefore, we continue to believe that our proposed policy will 
better align Medicare payment for separately payable drugs acquired 
under the 340B Program with the actual resources expended to acquire 
such drugs in nonexcepted off-campus PBDs of a hospital.
    As we previously stated, CMS does not administer the 340B Program. 
Accordingly, comments related to eligibility for the 340B Program as 
well as 340B Program policies are outside the scope of the proposed 
rule and are not addressed in this final rule with comment period.
    Comment: One commenter, who cited studies conducted by the GAO, 
OIG, and MedPAC, suggested that CMS make additional downward 
adjustments to drug payments under the 340B Program in future years 
because the 22.5 percent payment reduction ``was conservative'' and the 
actual average discount experienced by 340B hospitals is likely much 
higher than 22.5 percent. The commenter asserted that 22.5 percent 
reflects the average minimum discount that 340B hospitals receive for 
drugs acquired under the program, and that discounts across all 340B 
providers average 33.6 percent of ASP.
    Response: We thank the commenter for this feedback. We will 
continue to

[[Page 59019]]

analyze the data on these drugs for future rulemaking. As we mentioned 
in the CY 2019 OPPS/ASC proposed rule, we share the commenter's concern 
that current Medicare payments for drugs acquired by nonexcepted off-
campus PBDs are well in excess of the overhead and acquisition costs 
for drugs purchased under the 340B Program. We also continue to believe 
that Medicare beneficiaries should be able to benefit from the 
significant discounts hospitals receive on 340B-acquired drugs through 
reduced copayments.
    Comment: One commenter, an organization representing children's 
hospitals, supported the proposal to except children's hospitals from 
the proposed payment policy for drugs purchased under the 340B Program. 
However, the commenter asserted that children's hospitals are 
undercompensated by government programs, and that a recent report found 
that the overall Medicare margin for all hospitals is negative. 
Furthermore, the commenter stated that, while self-governing children's 
hospitals are excepted from the payment policy, children's hospitals 
within academic medical centers or health care systems remain subject 
to this policy, which will curtail the ability of such children's 
hospitals to care for needy children. The commenter urged CMS not to 
apply this policy to children's hospitals within academic medical 
centers or health care systems.
    Response: We thank the commenter for its support and feedback. As 
we stated in the CY 2018 OPPS/ASC final rule with comment period (82 FR 
59366), because of how children's hospitals are paid under the OPPS, we 
acknowledged that the 340B drug payment policy may not result in 
reduced payments for these hospitals in the aggregate. While the 
payment policy we are establishing in this final rule with comment 
period applies to nonexcepted departments of a hospital that are paid 
under the PFS rather than the OPPS, we believe that adopting an 
analogous policy, regardless of status, is prudent so that a generally 
excepted hospital receives payment for drugs in the same manner, 
regardless of the status (excepted or nonexcepted) of each PBD of the 
hospital.
    In addition, it is unclear from the comment whether the referenced 
children's hospitals ``within academic medical centers or health care 
systems'' are enrolled in the Medicare program as children's hospitals 
or whether they are simply a department of an enrolled hospital 
provider. However, any separately enrolled children's hospital that is 
paid as such is exempt from the 340B-acquired drug payment reduction, 
while children's units that are not separately enrolled would not be 
exempt from the 340-acquired drug payment policy.
    Comment: A few commenters, including organizations representing 
sole community hospitals, supported the proposal to extend the 
exception for rural sole community hospitals from the proposed 340B 
Program payment adjustment. However, these commenters remained 
concerned that other vulnerable hospitals continue to be subject to the 
340B Program payment reduction. Accordingly, these commenters 
recommended that CMS exempt urban sole community hospitals, Medicare-
dependent hospitals, and hospitals with rural referral center status 
from the payment adjustment. In addition, rural hospitals recommended 
that rural providers be permanently excepted from this policy.
    Response: We share commenters' concerns about access to care, 
especially in rural areas where access issues may be more pronounced 
than in other areas of the country. Medicare has long recognized the 
unique needs of rural communities and the financial challenges rural 
hospital providers face. Across the various Medicare payment systems, 
CMS has established a number of special payment provisions for rural 
providers to maintain access to care and to deliver high quality care 
to beneficiaries in rural areas. Consequently, for CY 2019, we are 
excluding rural sole community hospitals (as described under the 
regulations at 42 CFR 412.92 and designated as rural for Medicare 
purposes) from this policy. However, we do not believe that a payment 
exemption for nonexcepted off-campus departments of urban SCHs is 
necessary because these hospitals are not exempted from the 340B 
payment policy for hospital departments paid under the OPPS. 
Nonetheless, we will continue to analyze the data for these hospitals 
to determine whether urban SCHs should be exempt from this payment 
policy, as well as whether permanent exemption for rural SCHs is 
warranted in future rulemaking.
    With respect to rural referral centers, in the CY 2018 OPPS/ASC 
final rule with comment period, we noted that there is no special 
payment designation for rural referral centers under the OPPS. By 
definition, rural referral centers must have at least 275 beds and 
therefore are larger relative to rural sole community hospitals. In 
addition, rural referral centers are not subject to a distance 
requirement from other hospitals. Accordingly, rural referral centers 
are neither as small (in terms of bed size) or as isolated (in terms of 
proximity to other hospitals) as rural SCHs, nor are they generally 
eligible for special payment status under the OPPS, and we do not 
believe that a payment exemption from this policy for these centers is 
warranted.
    Furthermore, as stated earlier in this section, we believe that we 
should adopt an analogous payment policy across hospital settings, 
regardless of the status of each PBD. Because we did not exempt 
grandfathered off-campus PBDs with MDH classification from the 340B 
payment adjustment in CY 2018, we do not believe that nonexcepted off-
campus PBDs with Medicare-dependent hospital status should be exempted 
at this time. Therefore, for CY 2019, Medicare-dependent hospitals will 
not be exempt from this payment policy.
    For CY 2019, rural sole community hospitals, children's hospitals, 
and PPS-exempt cancer hospitals will be excepted from the alternative 
payment methodology for 340B-acquired drugs and biologicals furnished 
in nonexcepted off-campus PBDs, and therefore will be required to bill 
under the PFS using the institutional claim form and report the 
informational modifier ``TB'' for 340B-acquired drugs and biologicals. 
These providers will continue to be paid ASP+6 percent for 340B-
acquired drugs and biologicals under the PFS. In addition, as we stated 
in the CY 2018 OPPS/ASC final rule with comment period, this policy 
change does not apply to drugs with pass-through payment status, which 
are required to be paid based on the ASP methodology, or to vaccines, 
which are excluded from the 340B Program.
    We note that this policy does not alter covered entities' access to 
the 340B Program. The expansion of the alternative 340B drug payment 
methodology solely changes Medicare payment for drugs furnished in 
nonexcepted off-campus PBDs of a hospital if such drugs were acquired 
under the 340B Program. We may revisit our policy regarding exceptions 
to the 340B drug payment reduction in the CY 2020 OPPS/ASC rulemaking.
    Comment: In its comment, MedPAC reiterated recommendations included 
in its March 2016 Report to Congress. In this report, MedPAC 
recommended that payment rates for all separately payable drugs 
provided in a 340B hospital be reduced by 10 percent of the current 
payment rate of ASP+6 percent (resulting in ASP minus 5.3 percent after 
taking application of the sequester into account). MedPAC noted that 
its March 2016 report also included a recommendation to Congress that

[[Page 59020]]

savings from the reduced payment rates be directed to the Medicare-
funded uncompensated care pool, which would target hospitals providing 
the most care to the uninsured and in that way benefit indigent 
patients, and that payments be distributed in proportion to the amount 
of uncompensated care that hospitals provide. MedPAC believed that 
legislation would be needed to direct drug payment savings to the 
uncompensated care pool and noted that current law requires the savings 
to be retained with the OPPS to make the payment system budget neutral. 
MedPAC encouraged the Secretary to work with Congress to enact 
legislation necessary to allow MedPAC's recommendation to be 
implemented, if such a recommendation could not be implemented 
administratively. MedPAC further noted that legislation would also 
allow Medicare to apply the policy to all OPPS separately payable 
drugs, including those on pass-through payment status. Accordingly, 
MedPAC recognized that CMS does not have the legal authority to 
implement its March 2016 recommendation and shares CMS' concern that 
the lack of site-neutral payments may cause a shift in administration 
of nonpass-through separately payable drugs to nonexcepted off-campus 
PBDs. Additionally, MedPAC stated that CMS should ensure that payment 
for 340B-acquired drugs is equal across settings.
    Response: We thank MedPAC for its support and feedback. As we 
stated in the CY 2018 OPPS/ASC final rule with comment period (82 FR 
59364 through 59365), we do not believe that reducing the Medicare 
payment rate by only 10 percentage points below the current payment 
rate of ASP+6 percent (that is, ASP minus 4 percent) would better 
reflect the acquisition costs incurred by 340B-participating hospitals.
    We note that we responded to a similar public comment in the CY 
2018 OPPS/ASC final rule with comment period (82 FR 59364 through 
59365) and refer readers to a summary of that comment and our response.
    Comment: Many commenters stated that the Secretary lacks statutory 
authority to impose such a large reduction in the payment rate for 340B 
drugs acquired in off-campus PBDs, and contended that the expansion of 
the 340B payment policy at nonexcepted off-campus PBDs would 
``effectively eviscerate'' the 340B Program. These commenters further 
noted that extending the Medicare payment cuts to nonexcepted off-
campus PBDs would greatly undermine 340B hospitals' ability to continue 
programs designed to improve access to services.
    One commenter, an organization representing over 1,300 public and 
nonprofit providers enrolled in the 340B Program, argued that since the 
340B payment policy took effect in January 2018, many hospitals have 
experienced financial and operational challenges, including staff 
reductions, fewer free or discounted drugs for patients, clinic and 
pharmacy closures, and reductions in services provided. The commenter 
opposed the 340B payment proposal for a number of reasons, primarily 
because the commenter believed that the current OPPS 340B payment rate 
harms hospitals' ability to treat low-income patients and the proposals 
to continue and expand the cuts would worsen the impact. Furthermore, 
the commenter argued that CMS' proposed payment reduction does not 
reduce patient costs or Medicare spending or address ``skyrocketing 
drug prices''; CMS' payment reduction violates the 340B statute; CMS' 
payment reduction violates the Medicare statute; and CMS' payment 
reduction relies on a ``faulty premise that fails to recognize that 
340B hospitals serve patients with more expensive medical needs.'' The 
commenter further asserted that Congress, as well as ``one-hundred 
percent of hospitals,'' have expressed concern about the payment 
reduction's impact on 340B providers' ability to serve their patients.
    Many additional commenters, including some hospital associations, 
contended that CMS does not have the legal authority to apply the OPPS 
Medicare payment rate to nonexcepted off-campus PBDs in 340B-
participating hospitals because section 1833(t)(21)(C) of the Act does 
not authorize CMS to pay at a rate that is less than the rate paid 
under the selected ``applicable payment system.'' Specifically, a few 
commenters asserted that payment for these drugs and biologicals is 
determined pursuant to the rules of section 1842(o)(1)(C) of the Act, 
which mandates that payment is to be made for these drugs and 
biologicals when furnished by nonexcepted off-campus PBDs pursuant to 
the rules of section 1847A of the Act.
    Response: We do not believe that the proposed payment policy 
violates section 340B of the Public Health Service Act or the Social 
Security Act. There is no requirement in the Public Health Service Act 
that drugs or biologicals acquired under the 340B Program generate a 
profit margin for hospitals through Medicare payments, and there is no 
requirement in any part of section 1833(t) of the Social Security Act 
to pay a particular minimum rate for a hospital enrolled in the 340B 
Program. Further, we disagree with the commenter's assertion that CMS' 
payment reduction does not reduce patient costs or Medicare spending. 
Based on our proposed adjustment for CY 2019, we estimated that the 
Medicare Program and beneficiaries would save approximately $49 million 
under the PFS.
    We also disagree with commenters who believe that the OPPS payment 
rate for 340B-acquired drugs will ``effectively eviscerate'' the 340B 
Program as well as the implication that extending the same rate that 
applies to 340B-acquired drugs and biologicals furnished by hospital 
departments under the OPPS to nonexcepted off-campus PBDs will 
perpetuate that concern. The findings from several 340B studies 
conducted by the GAO, OIG, and MedPAC show a wide range of discounts 
that are afforded to 340B hospitals, with some reports finding 
discounts of up to 50 percent. Indeed, in some cases, beneficiary 
coinsurance alone exceeds the amount the hospital paid to acquire the 
drug under the 340B Program (OIG November 2015, Report OEI-12-14-00030, 
page 9). As stated in the CY 2018 final rule with comment period, we 
believe that ASP minus 22.5 percent is a conservative estimate of the 
discount for 340B-acquired drugs, and that even with the reduced 
payments, hospitals will continue to receive savings that can be 
directed at programs and services to carry out the intent of the 340B 
Program. We also have noted that 340B Program participation does not 
appear to be well aligned with the provision of uncompensated care, as 
some commenters suggested (82 FR 59359).
    Payment under the ``applicable payment system'' pursuant to section 
1833(t)(21)(C) of the Act is made under the PFS for most services, 
including for the many drugs that are packaged under the OPPS, using a 
PFS relativity adjuster that is applied to the OPPS payment rate. As 
such, the PFS payment for nonexcepted items and services in nonexcepted 
off-campus PBDs is made on a prospective payment basis, and we are 
therefore not required to make payment under section 1847A/1842(o) of 
the Act for those packaged drugs, many of which would be separately 
payable under the PFS. Further, as we stated in the CY 2019 OPPS/ASC 
proposed rule (83 FR 37145), the current PFS payment policies for 
nonexcepted items and services incorporate a significant number of 
payment policies and adjustments made under the OPPS (81 FR 79726; 82 
FR 53024 through 53025). In establishing these policies in prior 
rulemaking, we pointed out that

[[Page 59021]]

the adoption of these policies was necessary in order to maintain the 
integrity of the PFS relativity adjuster because it adjusts payment 
rates developed under the OPPS (81 FR 79726). For example, it is 
necessary to incorporate OPPS packaging rules into the site-specific 
PFS rate because the PFS relativity adjuster is applied to OPPS rates 
that were developed based on those packaging rules. In addition, many 
of the OPPS policies and adjustments are replicated under the 
nonexcepted off-campus PBD site-specific PFS rates because they are 
specifically applicable to hospitals as a setting of care. For example, 
we adopted the geographic adjustments used for hospitals instead of the 
adjustments developed for the PFS localities, which reflect cost 
differences calculated for professionals and suppliers rather than 
hospitals (81 FR 79726).
    Since we have adopted the payment adjustment under the OPPS for 
340B-acquired separately payable drugs, we have become concerned that 
there would be a perverse incentive for hospitals to circumvent the 
OPPS payment adjustment by furnishing 340B-acquired drugs in 
nonexcepted off-campus PBDs where Medicare currently makes payment for 
those drugs at ASP+6 percent. To avoid this payment incongruity and 
perverse incentive, we proposed to designate the PFS as the 
``applicable payment system'' for 340B-acquired separately payable 
drugs furnished in nonexcepted off-campus PBDs, and to make payment at 
the OPPS-comparable rate.
    Comment: A few commenters asserted that, while CMS estimated that 
the payment change would result in a payment cut of $48.5 million in CY 
2019, CMS provided no data to support this estimate and failed to 
provide sufficient access to data, its methodology, or its analysis to 
allow the public to assess and replicate the proposed CY 2019 340B 
payment policy. One commenter recommended that CMS delay extension of 
the 340B payment policy until more information is available related to 
the impact on Medicare beneficiaries.
    Many commenters opposed reducing payments to hospitals for 340B 
drugs in a nonbudget-neutral manner and instead suggested that such 
policy be implemented in a budget neutral manner as was implemented in 
the CY 2018 OPPS/ASC final rule with comment period. In addition, some 
commenters recommended that CMS annually calculate a budget neutral 
adjustment for the 340B policy, as the approach is consistent with 
other budget neutral policies included in the OPPS.
    Response: We thank the commenters for their input. We disagree that 
this policy should be implemented in a budget neutral manner because 
the payments made to nonexcepted off-campus departments of a hospital 
are not paid under the OPPS. As we stated in the CY 2019 OPPS/ASC 
proposed rule, to develop an estimated impact of this proposal, we 
analyzed the CY 2017 outpatient claims data used in ratesetting for the 
CY 2019 proposed rule. Based on the most recent claims data from CY 
2017 reporting, we found 117 unique nonexcepted off-campus PBDs 
associated with 340B hospitals that billed for status indicator ``K'' 
drugs. Their ``K'' billing represents approximately $182.5 million in 
Medicare payments based on a payment rate of ASP+6 percent. Based on 
our proposed adjustment, for CY 2019, we estimated that the Medicare 
Program and beneficiaries would save approximately $49 million under 
the PFS. Regarding budget neutrality requirements, we note that when we 
initially developed the payment policy for nonexcepted items and 
services furnished by nonexcepted off-campus PBDs, most separately 
payable drugs and biologicals were paid at the same rates specified 
under section 1847A/1842(o) of the Act (generally, ASP+6) when 
furnished in the HOPD and in other outpatient settings, such as 
physician offices. When we initially established the ASP methodology 
under section 1847A/1842(o) of the Act as the ``applicable payment 
system'' for separately payable drugs under section 1833(t)(21)(C) of 
the Act, there was no applicable budget neutrality requirement. For the 
proposed change in CY 2019 to establish the PFS as the applicable 
payment system for separately payable 340-B-acquired drugs furnished by 
nonexcepted off-campus PBDs, we believe the site-specific PFS payment 
for these drugs and biologicals represents new utilization under the 
PFS and would, consequently, not be subject to the PFS budget 
neutrality requirements under 1848(c) of the Act for CY 2019. We will 
consider any applicable budget neutrality requirements regarding the 
site-specific payment under the PFS for future rulemaking.
    Comment: Numerous commenters argued that reducing payments for 
340B-acquired drugs could encourage hospitals to selectively purchase 
certain drugs at higher prices outside of the 340B Program to maximize 
revenue. One of these commenters recommended the implementation of 
alternate reimbursement methodologies for 340B-purchased drugs, such as 
a 6 percent add-on payment to the product-specific estimated 340B cost, 
in order to discourage hospitals from selectively purchasing some drugs 
outside of the 340B Program (resulting in ASP minus 16.5 percent after 
taking application of the add-on payment into account).
    Response: While participation in the 340B Program has always been 
voluntary and hospitals have always had the ability to choose to 
purchase drugs outside the 340B Program, we do not see the relevance of 
these points to our proposed policy. That is, the policy we proposed 
with respect to payment for 340B-acquired drugs in nonexcepted 
departments for CY 2019 simply aligns with the policy already 
established for 340B-acquired drugs under the OPPS for CY 2018. In 
addition, as we explained in CY 2018 OPPS rulemaking, the payment rate 
of ASP minus 22.5 percent is better aligned with the average resources 
to acquire a 340B drug, and therefore, we do not believe that a higher 
payment rate for 340B-acquired drugs in nonexcepted departments is 
warranted.
    We thank the commenters for their feedback. After consideration of 
the public comments we received, we are finalizing our proposal, 
without modification, to make payment for separately payable 340B-
acquired drugs furnished by nonexcepted off-campus departments of a 
hospital under the PFS, and to establish the payment rate for those 
drugs at ASP minus 22.5 percent. This policy is expected to lower the 
cost of drugs and biologicals for Medicare beneficiaries and ensure 
that they benefit from the discounts provided through the program, and 
to do so more equitably across HOPD settings.
    In summary, for CY 2019, in accordance with section 1833(t)(21)(C) 
of the Act and our established 340B payment methodology as described in 
the CY 2018 OPPS/ASC final rule with comment period, separately payable 
Part B drugs and biologicals (assigned status indicator ``K''), other 
than vaccines and drugs with pass-through payment status, that are 
acquired through the 340B Program or through the 340B PVP at or below 
the 340B ceiling price will be paid at a rate of ASP minus 22.5 percent 
when billed by a hospital that is not excepted from the payment 
adjustment. Part B drugs or biologicals excluded from the 340B payment 
adjustment include vaccines (assigned status indicator ``L'' or ``M'') 
and drugs and biologicals with transitional pass-through payment status 
(assigned status indicator ``G'').

[[Page 59022]]

Medicare will continue to pay for drugs and biologicals that are not 
purchased with a 340B Program discount at ASP+6 percent.
    To effectuate the payment adjustment for 340B-acquired drugs and 
biologicals, CMS implemented modifier ``JG'', effective January 1, 
2018. Hospitals paid under the OPPS (other than a type of hospital 
excluded from the OPPS or excepted from the 340B drug payment policy 
for CY 2019) and, beginning January 1, 2019, nonexcepted off-campus 
PBDs of a hospital paid under the PFS, are required to report modifier 
``JG'' on the same claim line as the drug or biological HCPCS code to 
identify a 340B-acquired drug or biological. For CY 2019, rural sole 
community hospitals, children's hospitals, and PPS-exempt cancer 
hospitals are excepted from the 340B payment adjustment. These 
hospitals will be required to report informational modifier ``TB'' for 
340B-acquired drugs and biologicals, and will continue to be paid ASP+6 
percent.

D. Expansion of Clinical Families of Services at Excepted Off-Campus 
Departments of a Provider

1. Background
a. Section 603 of the Bipartisan Budget Act of 2015
    We refer readers to section X.C.1.a. of the CY 2019 OPPS/ASC 
proposed rule (83 FR 37143) for a discussion of the provisions of 
section 603 of the Bipartisan Budget Act of 2015 (Pub. L. 114-74), as 
implemented in the CY 2017 OPPS/ASC final rule with comment period (81 
FR 79699 through 79719). As discussed in the CY 2017 OPPS/ASC final 
rule with comment period, we adopted the PFS as the applicable payment 
system for nonexcepted items and services furnished and billed by 
nonexcepted off-campus PBDs. In addition, we indicated that, in order 
to be considered part of a hospital, an off-campus department of a 
hospital must meet the provider-based criteria established under 42 CFR 
413.65. For a detailed discussion of the history and statutory 
authority related to payments under section 603 of Public Law 114-74, 
we refer readers to the CY 2017 OPPS/ASC final rule with comment period 
(81 FR 79699 through 79719) and the interim final rule with comment 
period (81 FR 79720 through 79729).
b. Expansion of Services at an Off-Campus PBD Excepted Under Section 
1833(t)(21)(B)(ii) of the Act
    In the CY 2017 OPPS/ASC proposed rule (81 FR 45685), we noted that 
we had received questions from some hospitals regarding whether an 
excepted off-campus PBD could expand the number or type of services the 
department furnishes and maintain excepted status for purposes of 
paragraphs (1)(B)(v) and (21) of section 1833(t) of the Act. We 
indicated that we were concerned that if excepted off-campus PBDs could 
expand the types of services provided at the excepted off-campus PBDs 
and also be paid OPPS rates for these new types of services, hospitals 
may be able to purchase additional physician practices and expand 
services furnished by existing excepted off-campus PBDs as a result (81 
FR 45685). This could result in newly purchased physician practices 
furnishing services that are paid at OPPS rates, which we believed 
these amendments to section 1833(t) of the Act were intended to address 
(81 FR 45685). We believed section 1833(t)(21)(B)(ii) of the Act 
excepted off-campus PBDs and the items and services that are furnished 
by such excepted off-campus PBDs for purposes of paragraphs (1)(B)(v) 
and (21) of section 1833(t) of the Act as they were being furnished on 
the date of enactment of section 603 of the Bipartisan Budget Act of 
2015, as guided by our regulatory definition at Sec.  413.65(a)(2) of a 
department of a provider (81 FR 45685). Thus, in the CY 2017 OPPS/ASC 
proposed rule, we proposed that if an excepted off-campus PBD furnished 
items and services from a clinical family of services (clinical 
families of services were identified in Table 21 of the CY 2017 
proposed rule (81 FR 45685 through 45686) that it did not furnish prior 
to November 2, 2015, and thus did not also bill for, services from 
these new expanded clinical families of services would not be covered 
OPD services, and instead would be subject to paragraphs (1)(B)(v) and 
(21) of section 1833(t) of the Act, as described in section X.A.1.c. of 
the CY 2017 proposed rule. In addition, in that rule, we proposed not 
to limit the volume of excepted items and services within a clinical 
family of services that an excepted off-campus PBD could furnish (81 FR 
45685).
    The majority of commenters, including several hospital 
associations, regional health systems, and medical equipment 
manufacturers opposed the proposal primarily because they believed: (1) 
CMS exceeded its statutory authority, as the statutory language 
included in section 603 does not address changes in service mix by 
excepted off-campus PBDs; (2) CMS' proposal did not account for 
evolving technologies and would hinder beneficiary access to those 
innovative technologies; (3) the term ``clinical families of service'' 
appeared to be a new term created by CMS for the purpose of 
implementing section 603 and it would be difficult for CMS and 
hospitals to manage changes in the composition of APCs and HCPCS code 
changes contained in those APCs; and (4) the proposal created 
significant operational challenges and administrative burden for both 
CMS and hospitals because commenters believed it was unnecessarily 
complex (81 FR 79706 through 79707).
    In addition, MedPAC explained in its comment letter that the 
proposal was unnecessarily complex and instead suggested that CMS adopt 
a different approach by determining how much the Medicare program had 
paid an excepted off-campus PBD for services billed under the OPPS 
during a 12-month baseline period that preceded November 2, 2015 and to 
cap the OPPS payment made to the off-campus PBD at the amount paid 
during the baseline period.\81\ Some commenters, including physician 
group stakeholders, supported CMS' intent to monitor service line 
expansion and changes in billing patterns by excepted off-campus PBDs. 
These commenters urged CMS to work to operationalize a method that 
would preclude an excepted off-campus PBD from expanding the excepted 
services for which it is paid under the OPPS into wholly new clinical 
areas, as they believed an excepted, off-campus PBD should only be able 
to bill under the OPPS for those items and services for which it 
submitted claims prior to November 2, 2015 (82 FR 33647).
---------------------------------------------------------------------------

    \81\ Available at: https://medpac.gov/docs/default-source/comment-letters/08172016_opps_asc_comment_2017_medpac_sec.pdf?sfvrsn=0.
---------------------------------------------------------------------------

    In response to public comments, we did not finalize our proposal to 
limit the expansion of excepted services at excepted off-campus PBDs. 
However, we stated our intent to monitor this issue and expressed 
interest in additional feedback to help us consider whether excepted 
off-campus PBDs that expand the types of services offered after 
November 2, 2015 should be paid for furnishing those items and services 
under the applicable payment system (that is, the PFS) instead of the 
OPPS. Specifically, we requested comments on how either a limitation on 
volume or a limitation on lines of service would work in practice (81 
FR 79707).
    In addition, in the CY 2017 OPPS/ASC final rule with comment period 
(81 FR 79707), we sought public comments on how either a limitation on 
volume of services, or a limitation on lines of

[[Page 59023]]

service, as we laid out in the CY 2017 OPPS/ASC proposed rule, could be 
implemented. Specifically, we stated that we were interested in what 
data were available or could be collected that would have allowed us to 
implement a limitation on the expansion of excepted services.
    We provided a summary of and responses to comments received in 
response to the CY 2017 OPPS/ASC final rule with comment period in the 
CY 2018 OPPS/ASC proposed rule. As stated in that rule, several of the 
public comments received in response to the comment solicitation 
included in the CY 2017 OPPS/ASC final rule with comment period were 
repeated from the same stakeholders in response to the CY 2017 OPPS/ASC 
proposed rule. These commenters again expressed concern regarding CMS' 
authority to address changes in service-mix; that a limitation on 
service expansion or volume would stifle innovative care delivery and 
use of new technologies; and that limiting service line expansion using 
clinical families of service was not workable. Because these commenters 
did not provide new information, we referred readers to the CY 2017 
OPPS/ASC final rule with comment period for our responses to comments 
on statutory authority and concerns about hindering access to 
innovative technologies (81 FR 79707 and 82 FR 59388). A summary of and 
our responses to the other comments received in response to the comment 
solicitation included in the CY 2017 OPPS/ASC final rule with comment 
period were included in the CY 2018 OPPS/ASC proposed rule (82 FR 33645 
through 33648).
    In the CY 2018 OPPS/ASC proposed rule, we did not propose any 
policies related to clinical service line expansion or volume increases 
at excepted off-campus PBDs. However, we stated that we would continue 
to monitor claims data for changes in billing patterns and utilization, 
and we again invited public comments on the issue of service line 
expansion. In response to the CY 2018 comment solicitation, MedPAC 
largely reiterated the comments it submitted in response to the CY 2017 
OPPS/ASC rulemaking and acknowledged the challenges of implementing its 
recommended approach as such approach would necessitate CMS requiring 
hospitals to report the amount of OPPS payments received by each 
excepted off-campus PBD during the baseline period (such as November 
2014 through November 2015) because CMS was not collecting data on 
payments made to each individual PBD during that period. In its 
comments, MedPAC recommended that, to help ensure the accuracy of these 
data, CMS could selectively audit hospitals.\82\ Another commenter 
expressed support for CMS' efforts to continue to implement and expand 
site-neutral payment policies for services where payment differentials 
are not warranted, such as between HOPDs and ASCs or physician offices.
---------------------------------------------------------------------------

    \82\ Available at: https://medpac.gov/docs/default-source/comment-letters/09082017_opps_asc_2018_medpac_comment_sec.pdf?sfvrsn=0.
---------------------------------------------------------------------------

2. CY 2019 Proposal and Final Policy
    As we previously expressed in CYs 2017 and 2018 OPPS/ASC 
rulemaking, we continue to be concerned that if excepted off-campus 
PBDs may furnish new types of services that were not provided at the 
excepted off-campus PBDs prior to the date of enactment of the 
Bipartisan Budget Act of 2015 and can be paid OPPS rates for these new 
types of services, hospitals may be able to purchase additional 
physician practices and add those physicians to existing excepted off-
campus PBDs. This could result in newly purchased physician practices 
furnishing services that are paid at OPPS rates, which we believe the 
section 603 amendments to section 1833(t) of the Act are intended to 
prevent. Of note, these statutory amendments ``came after years of 
nonpartisan economists, health policy experts, and providers expressing 
concern over the Medicare program's [OPPS] paying more for the same 
services provided at HOPDs than in other settings--such as an 
ambulatory surgery center, physician office, or community outpatient 
facility.'' \83\ Experts raised concerns that this payment inequity 
drove the acquisition of ``standalone or independent practices and 
facilities by hospitals, resulted in higher costs for the Medicare 
system and taxpayers, and also resulted in beneficiaries needlessly 
facing higher cost-sharing in some settings than in others.'' \84\ In 
addition, some experts argued that, ``to the extent this payment 
differential accelerated consolidation of providers, this would result 
in reduced competition among both hospitals and nonaffiliated 
outpatient service providers. This, in turn, could reduce large 
hospital systems' incentives to reduce costs, increase efficiency, or 
focus on patient outcomes.'' \85\
---------------------------------------------------------------------------

    \83\ Available at: https://archives-energycommerce.house.gov/sites/republicans.energycommerce.house.gov/files/114/Letters/20160205SiteNeutralLetter%5b1%5d.pdf.
    \84\ Ibid.
    \85\ Ibid.
---------------------------------------------------------------------------

    The Government Accountability Office (GAO) stated in its December 
2015 Report to the Congress that ``from 2007 through 2013, the number 
of vertically consolidated physicians nearly doubled, with faster 
growth in more recent years.'' GAO concluded that, ``regardless of what 
has driven hospitals and physicians to vertically consolidate, paying 
substantially more for the same service when performed in an HOPD 
rather than a physician office provides an incentive to shift services 
that were once performed in physician offices to HOPDs after 
consolidations have occurred.'' \86\
---------------------------------------------------------------------------

    \86\ GA0-16-189, ``Increasing Hospital-Physician Consolidation 
Highlights Need for Payment Reform.'' Available at: https://www.gao.gov/assets/680/674347.pdf.
---------------------------------------------------------------------------

    While there is no Congressional Record available for section 603 of 
the Bipartisan Budget Act of 2015, we do not believe that Congress 
intended to allow for new service lines to be paid OPPS rates because 
providing for such payment would allow for excepted off-campus PBDs to 
be paid higher rates for types of services they were not furnishing 
prior to the date of enactment of the Bipartisan Budget Act of 2015 and 
that would be paid at lower rates if performed in a nonexcepted off-
campus PBD. Similarly, we are concerned that a potential shift of 
services from nonexcepted off-campus PBDs to excepted off-campus PBDs 
may be occurring, given the higher payment rate in this setting. We 
believe that the growth of service lines in currently excepted off-
campus PBDs may be an unintended consequence of our current policy, 
which allows continued full OPPS payment for any services furnished by 
excepted off-campus PBDs, including services in new service lines.
    In prior rulemaking, and as discussed in section X.A. of the CY 
2019 OPPS/ASC proposed rule, we noted our concerns and discussed our 
efforts to begin collecting data and monitoring billing patterns for 
off-campus PBDs. Specifically, as described in the CY 2015 OPPS/ASC 
final rule with comment period (79 FR 66910 through 66914), we created 
HCPCS modifier ``PO'' (Services, procedures, and/or surgeries furnished 
at off-campus provider-based outpatient departments) for hospital 
claims to be reported with every code for outpatient hospital items and 
services furnished in an off-campus PBD of a hospital. Reporting of 
this new modifier was voluntary for CY 2015, with reporting required 
beginning on January 1, 2016. In addition, we established modifier 
``PN'' (Nonexcepted service provided at an off-campus, outpatient, 
provider-based department of a hospital) to identify and pay 
nonexcepted items and services billed on an institutional claim.

[[Page 59024]]

Effective January 1, 2017, nonexcepted off-campus PBDs of a hospital 
were required to report this modifier on each claim line for 
nonexcepted items and services to trigger payment under the PFS instead 
of the OPPS. As a conforming revision, effective January 1, 2017, the 
modifier ``PO'' descriptor was revised to ``excepted service provided 
at an off-campus, outpatient, provider-based department of a hospital'' 
and this modifier continued to be used to identify items and services 
furnished by an excepted off-campus PBD of a hospital.
    As discussed in the CY 2018 OPPS/ASC proposed rule (82 FR 33647), a 
few commenters supported CMS' intent to monitor service line expansion 
and changes in billing patterns by excepted off-campus PBDs. These 
commenters urged CMS to work to operationalize a method that would 
preclude an excepted off-campus PBD from increasing its payment 
advantage under the OPPS by expanding into wholly new clinical areas 
(82 FR 33647). Moreover, a few commenters urged CMS to pursue a 
limitation on service line expansion to ensure designation as an 
excepted off-campus PBD is not ``abused'' (82 FR 33647). One commenter 
suggested that CMS evaluate outpatient claims with the ``PO'' modifier 
to develop a list of ``grandfathered'' items and services for which the 
excepted off-campus PBD may continue to be paid under the OPPS (82 FR 
33647). In response to these comments, we stated that we were concerned 
with the practicality of developing a list of excepted items and 
services for each excepted off-campus PBD, given the magnitude of such 
a list (82 FR 33647). We noted in the CY 2018 OPPS/ASC final rule with 
comment period, however, that we continued to monitor claims data for 
changes in billing patterns and utilization, and invited comments on 
this issue (82 FR 59388).
    In light of our prior stated concerns about the expansion of 
services in excepted off-campus PBDs, in the CY 2019 OPPS/ASC proposed 
rule (83 FR 37148 through 37149), for CY 2019 and subsequent years, we 
proposed that if an excepted off-campus PBD furnishes services from any 
clinical family of services (as clinical families of services are 
defined in Table 32 of that proposed rule) from which it did not 
furnish an item or service during a baseline period from November 1, 
2014 through November 1, 2015 (and subsequently bill under the OPPS for 
that item or service), items and services from these new clinical 
families of services would not be excepted items and services and, 
thus, would not be covered OPD services. Instead, they would be subject 
to paragraphs (1)(B)(v) and (21) of section 1833(t) of the Act and paid 
under the PFS. Furthermore, in the CY 2019 OPPS/ASC proposed rule, we 
proposed to revise 42 CFR 419.48 to limit the definition of ``excepted 
items and services'' in accordance with this proposal. Generally, 
excepted items and services are items or services that are furnished on 
or after January 1, 2017 by an excepted off-campus PBD (as defined in 
Sec.  419.48) that has not impermissibly relocated or changed 
ownership. Under this proposal, beginning on January 1, 2019, excepted 
items and services would be items or services that are furnished and 
billed by an excepted off-campus PBD (defined in Sec.  419.48) only 
from the clinical families of services (described later in this 
section) for which the excepted off-campus PBD furnished (and 
subsequently billed under the OPPS) for at least one item or service 
from November 1, 2014 through November 1, 2015. Further, for purposes 
of this section, ``new clinical families of services'' would be items 
or services: (1) That are furnished and billed by an excepted off-
campus PBD; (2) that are otherwise paid under the OPPS through one of 
the APCs included in Table 32 of the CY 2019 OPPS/ASC proposed rule; 
and (3) that belong to a clinical family listed in Table 32 of the 
proposed rule from which the excepted off-campus PBD did not furnish an 
item or service during the baseline period from November 1, 2014 
through November 1, 2015 (and subsequently bill for that service under 
the OPPS). In addition, for CY 2019, we proposed that if an excepted 
off-campus PBD furnishes a new item or service from a clinical family 
of services listed in Table 32 of the proposed rule from which the off-
campus PBD furnished a service from November 1, 2014 through November 
1, 2015, such service would continue to be paid under the OPPS because 
items and services from within a clinical family of services for which 
the excepted off-campus PBD furnished an item or service during the 
baseline period would not be considered a ``service expansion.''
    As discussed in the CY 2019 OPPS/ASC proposed rule (83 FR 37149), 
in order to determine the types of services provided at an excepted 
off-campus PBD, for purposes of OPPS payment eligibility, excepted off-
campus PBDs would be required to ascertain the clinical families from 
which they furnished services from November 1, 2014 through November 1, 
2015 (that were subsequently billed under the OPPS). In addition, items 
and services furnished by an excepted off-campus PBD that were not 
identified in Table 32 of the proposed rule would be reported with 
modifier ``PN''. We selected the year prior to the date of enactment of 
the Bipartisan Budget Act of 2015 as the baseline period because it is 
the most recent year preceding the date of enactment of section 603 and 
we believed that a full year of claims data would adequately reflect 
the types of service lines furnished and billed by an excepted off-
campus PBD. We considered expanding the baseline period to include a 
timeframe prior to November 2014, but did not propose this alternative 
due to the possibility that hospital claims data for an earlier time 
period might not be readily available and reviewing claims from a 
longer timeframe may impose undue burden. If an excepted off-campus PBD 
did not furnish services under the OPPS until after November 1, 2014, 
we proposed that the 1-year baseline period begins on the first date 
the off-campus PBD furnished covered OPD services prior to November 2, 
2015. For providers that met the mid-build requirement (as defined at 
section 1833(t)(21)(B)(v) of the Act), we proposed to establish a 1-
year baseline period that begins on the first date the off-campus PBDs 
furnished a service billed under the OPPS. We proposed changes to our 
regulation at 42 CFR 419.48 to include these alternative baseline 
periods. For guidance on the implementation of sections 16001 and 16002 
of the 21st Century Cures Act, we refer readers to the CMS website at: 
https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/HospitalOutpatientPPS/Downloads/Sections-16001-16002.pdf. We stated in 
the proposed rule that we were concerned that a 1-year baseline may be 
unnecessarily long to the extent that such baseline would be, at least 
in part, a prospective period during which such departments would have 
time and an incentive to bill services from as many service lines as 
possible, thereby limiting the effect of this policy. We welcomed 
public comment on whether a different baseline period, such as 3 or 6 
months, should be used for off-campus PBDs that began furnishing 
services and billing after November 1, 2014, or that met the mid-build 
requirement.
    As discussed in the CY 2019 OPPS/ASC proposed rule (83 FR 37149), 
we were aware of past stakeholder concern regarding limiting service 
line expansion for excepted off-campus PBDs using the 19 clinical 
families identified in Table 32 of the proposed

[[Page 59025]]

rule. However, we believed that the proposed clinical families 
recognized all clinically distinct service lines for which a PBD might 
bill under the OPPS, while at the same time allowing for new services 
within a clinical family of services to be considered for designation 
as ``excepted items and services'', as defined in the regulations at 42 
CFR 419.48 where the types of services within a clinical family expand 
due to new technology or innovation. We stated in the proposed rule 
that we believed that requiring excepted off-campus PBDs to limit their 
services to the exact same services they furnished during the proposed 
baseline period would be too restrictive and administratively 
burdensome. We requested public comments on the proposed clinical 
families. We also solicited public comments on whether any specific 
groups of hospitals should be excluded from our proposal to limit the 
expansion of excepted services, such as certain rural hospitals (for 
example, rural sole community hospitals), in light of recent reports of 
hospital closures in rural areas.
    In addition, we solicited public comments on alternate 
methodologies to limit the expansion of excepted services in excepted 
off-campus PBDs for CY 2019. Specifically, we invited public comments 
on the adoption and implementation of other methodologies, such as the 
approach recommended by MedPAC (discussed earlier in this section) in 
response to the CY 2017 and CY 2018 proposals whereby CMS would 
establish a baseline service volume for each applicable off-campus PBD, 
cap excepted services (regardless of clinical family) at that limit, 
and when the hospital reaches the annual cap for that location, 
additional services furnished by that off-campus PBD would no longer be 
considered covered OPD services and would instead be paid under the PFS 
(the annual cap could be updated based on the annual updates to the 
OPPS payment rates). Under such alternate approach, hospitals would 
need to report service volume for each off-campus PBD for the 
applicable period (such as November 1, 2014-November 1, 2015) and such 
applicable periods would be subject to audit.
    Comment: Some commenters, including an organization representing 
orthopaedic surgeons, commended CMS for its efforts to expand the 
application of site neutral payments to additional items and services 
in excepted off-campus PBDs. These commenters asserted that the 
expansion of services in excepted off-campus PBDs has an adverse effect 
on the control of unnecessary utilization of services in PBDs. One 
commenter who supported the proposal stated that ``all sites of service 
should provide the same service at the same cost'' and that Medicare 
``should not be in the business of supporting or favoring more 
expensive sites of service, when the service can be furnished safely at 
a less expensive'' and more efficient setting. Another commenter argued 
that the consolidation of these facilities effectively inhibits a 
physician's ability to refer freely to the best specialists or most 
affordable health centers, and obstructs patients' access to 
potentially better, more affordable care without their knowledge.
    One commenter, a pharmaceutical research and manufacturing 
organization, stated that this proposal ``strikes a reasonable 
balance'' in that the proposal would not limit PBDs to exactly the same 
services that they provided in the past, but would allow them to adjust 
their service-mix within relevant clinical families that reflect their 
specialties. The commenter contended that this provision would permit 
appropriate changes to the services excepted off-campus PBDs offer as 
clinical practices evolve. Additionally, the commenter stated that this 
policy proposal would prevent attempts to circumvent ``the obvious 
intent of the law to reign in conversion of non-hospital entities into 
PBDs primarily in order to secure better payment, but without 
commensurate clinical benefit.''
    A few commenters stated that most off-campus PBDs are able to take 
advantage of higher payment rates for a wide variety of services. 
Specifically, the commenters asserted that, given the significant 
payment disparities for certain services (for example, based on OPPS 
rates versus PFS rates--chemotherapy: $281 versus $136; cardiac 
imaging: $2,078 versus $655; and colonoscopy: $1,383 versus $625), 
hospital systems have been purchasing physician practices and, by 
integrating them with excepted off-campus PBDs, secured OPPS payment 
rates for these services.
    Another commenter asserted that CMS is taking important steps to 
close loopholes that have enabled hospitals to continue driving volume 
of services through excepted off-campus PBDs. Moreover, the commenter 
noted that the current policy has caused ``hundreds of hospitals that 
have already absorbed physician practices and converted them into PBDs 
. . . to enjoy an unfair reimbursement advantage'' over other 
providers. The commenter further asserted that the proposal does not 
sufficiently limit the items and services for which an excepted off-
campus PBD can seek payment under the OPPS, and that the proposal would 
still allow a PBD to expand its services ``no matter how limited the 
PBD's range or volume of services were within that clinical family'' 
during the baseline period. The commenter also expressed concern that 
CMS did not propose to limit the volume of excepted items and services 
within a clinical family of services that an excepted off-campus PBD 
can furnish, and indicated that, without such limitation, an excepted 
off-campus PBD has every incentive to grow the scope of its practice in 
order to maximize its ability to seek payment under the OPPS. Moreover, 
this commenter contended that CMS could require that ``excepted'' 
status be tied to those physicians and particular services that were in 
place at the off-campus PBD prior to November 2, 2015. In other words, 
an excepted off-campus PBD would not be able to seek payment under the 
OPPS with respect to: (1) Items or services furnished by a physician 
(as identified by National Provider Identifier) who did not furnish 
items or services at the off-campus PBD prior to November 2, 2015; or 
(2) any items or services that were not among the items or services for 
which the off-campus PBD billed Medicare at any point in the 12 months 
preceding November 2, 2015.
    Accordingly, the commenter urged CMS to modify the portion of the 
proposed rule that would enable excepted PBDs to bill under the OPPS 
for any and all items and services within the clinical families through 
which the excepted PBDs had furnished care during the 12 months prior 
to November 2, 2015, and to adopt, instead, a policy that would limit 
excepted off-campus PBDs to billing under the OPPS for those items and 
services furnished in a hospital's outpatient department in the year 
prior to November 2, 2015, and within the specific, excepted PBD in 
2016.
    Response: We thank the commenters for their support and for the 
many detailed comments on this topic. As mentioned in the proposed 
rule, we are concerned that if excepted off-campus PBDs can expand the 
types of services provided at the excepted off-campus PBDs and also be 
paid OPPS rates for these new types of services, hospitals may be able 
to purchase additional physician practices and add those physicians to 
existing excepted off-campus PBDs. This could result in newly purchased 
physician practices furnishing services that are paid at OPPS rates, 
which we believe the

[[Page 59026]]

amendments to section 1833(t) of the Act are intended to prevent.
    However, while we continue to believe that section 
1833(t)(21)(B)(ii) of the Act excepted off-campus PBDs as they existed 
at the time that Pub. L. 114-74 was enacted, and provides the authority 
to define excepted off-campus PBDs, including those items and services 
furnished and billed by such a PBD that may be paid under the OPPS, we 
are concerned that the implementation of this payment policy may pose 
operational challenges and administrative burden for both CMS and 
hospitals. After consideration of the public comments we received, we 
are not finalizing this policy as detailed below.
    Comment: A few commenters suggested that CMS revise the proposed 
clinical families to modify the proposed 19 clinical APC groups and 
services. We will continue to study issues related to the expansion of 
services at excepted off-campus PBDs and take these comments into 
consideration for future rulemaking.
    Response: We appreciate the feedback we received from the 
commenters.
    Comment: One commenter asserted that the proposed 12-month baseline 
period was not ``necessary,'' and suggested that a 6-month baseline 
period would adequately capture any service line initially intended for 
provision at a PBD. However, another commenter suggested that CMS 
extend the baseline period to 3 years prior to the enactment of the BBA 
of 2015, to ensure that all items and services provided by an excepted 
off-campus PBD prior to November 2, 2015 would be excepted from the 
proposed payment policy.
    Response: We thank the commenters for their feedback. We are not 
finalizing our proposed policy at this time. We intend to monitor the 
expansion of services in excepted off-campus PBDs. We may propose to 
adopt a limitation on the expansion of services in future rulemaking 
and will take this comment into consideration.
    Comment: The majority of commenters, including individual 
stakeholders and hospital systems and associations, opposed the 
proposal to limit the expansion of services in excepted off-campus 
PBDs. The commonly cited concerns among the commenters who opposed the 
proposed policy were as follows:
    Many commenters stated that the proposal is arbitrary and 
capricious, that CMS lacks statutory authority to pay new clinical 
families of service in excepted off-campus PBDs at the rate paid to 
nonexcepted PBDs, and that the proposal would pose operational 
challenges and create administrative burden on hospitals. In addition, 
some commenters asserted that the requirements for provider-based 
status are designed to ``ensure integration with the main hospital'' 
and, accordingly, these facilities should be able to ``furnish health 
care services of the same type as the main provider.''
    MedPAC expressed concern that CMS' proposed approach to address the 
issue of undesirable incentives for excepted PBDs was unnecessarily 
complex. MedPAC believed that a better approach would be for CMS to 
determine how much the Medicare program had paid an off-campus PBD for 
items and services billed under the OPPS during a 12-month baseline 
period, specifically, CY 2017. Then, beginning January 1, 2019, annual 
program spending for items and services billed by the PBD under the 
OPPS would be capped at the amount paid to the PBD during the baseline 
period. However, MedPAC acknowledged that, for hospitals that have more 
than one excepted off-campus PBD, CMS would have to determine which 
claims to attribute to each excepted off-campus PBD. MedPAC believed 
that this approach would be easier to administer and would curb the 
ability of hospitals to benefit financially from purchasing 
freestanding physician practices and converting them to off-campus 
PBDs.
    Several commenters argued that off-campus PBDs must be able to 
expand the items and services that they offer in order to meet changes 
in clinical practice and the changing needs of their communities 
without losing their ability to be paid under the OPPS. Generally, 
these commenters asserted that finalizing this proposal would 
significantly discourage hospitals from offering new and enhanced 
outpatient services and, as a result, the payment policy would hinder 
beneficiary access to innovative technologies.
    Many commenters asserted that it is unclear how CMS or hospitals 
will determine what service families were being provided during the 
baseline period, given the lack of department-specific data and that 
provider-based attestations are voluntary. In addition, these 
commenters contended that, even if CMS and the providers could identify 
the clinical families of services furnished during the baseline period, 
it would be exceedingly complicated and burdensome to providers and CMS 
to ensure services belonging to a new clinical family for the PBD are 
accurately reported.
    Response: We appreciate the detailed comments that were submitted, 
and we recognize that services provided in off-campus PBDs may evolve 
to reflect changes in clinical practice and community health care 
needs. As discussed in the CY 2017 OPPS/ASC proposed rule and final 
rule with comment period (81 FR 45685 through 45686 and 81 FR 79706 
through 79707), we believe section 1833(t)(21)(B)(ii) of the Act, as 
added by section 603 of Public Law 114-74, excepts off-campus provider-
based departments and the items and services that are furnished by such 
excepted off-campus PBDs for purposes of paragraphs (1)(B)(v) and (21) 
of section 1833(t) of the Act as they were being furnished on the date 
of enactment of section 603 of Public Law 114-74, as guided by our 
regulatory definition of a department of a provider at Sec.  
413.65(a)(2). We also believe that we have the authority to define 
excepted items and services furnished and billed by excepted off-campus 
PBDs that may be paid under the OPPS. While we disagree with the 
commenters' assertion that section 603 does not provide us the 
authority to adopt a policy that would limit OPPS payment to the type 
of services that had been furnished and billed at an off-campus PBD 
prior to enactment of Public Law 114-74, we are concerned that the 
implementation of this payment policy may be operationally complex and 
could create an administrative burden for hospitals.
    We believe the statute gives us the authority to limit the volume 
of services furnished to the level that was furnished prior to the date 
of enactment; however, we did not propose to do so. As we mentioned in 
the proposed rule and reiterated earlier in this section, we are 
concerned that if excepted off-campus PBDs could expand the types of 
services provided at the excepted off-campus PBDs and also be paid OPPS 
rates for these new types of services, hospitals may be able to 
purchase additional physician practices and add those physicians to 
existing excepted off-campus PBDs.
    Several commenters, including MedPAC, asserted that our proposed 
policy could be operationally complex and could create an 
administrative burden for hospitals, CMS, and CMS contractors to 
identify, track, and monitor billing for clinical services. We agree 
with these commenters regarding these concerns. Therefore, we are not 
finalizing our proposed policy.
    Comment: Some commenters, specifically hospital associations that 
opposed the proposal, asserted that CMS did not provide any claims-
based or other supporting evidence that demonstrates that excepted off-
campus PBDs are taking advantage of the current

[[Page 59027]]

policy. Further, these commenters noted that many of the services 
listed in the detailed families of services are not payable in a 
physician office setting and can only be provided in a hospital 
setting. In addition, some of these commenters urged CMS to exempt 
rural sole community hospitals and other vulnerable facilities from the 
policy proposal.
    Response: We appreciate the commenters' detailed responses to our 
proposal. We are collecting data on the claims billed by off-campus 
PBDs with modifier ``PO'' (for excepted services) and modifier ``PN'' 
(for nonexcepted services). We believe that data collected using these 
modifiers will be a useful tool in furthering our efforts to monitor 
the expansion of services at excepted off-campus PBDs and to address 
any issues as they may arise. We will continue to monitor claims data 
for changes in billing patterns and utilization and investigate methods 
to ensure all hospitals are treated as fairly as possible within the 
program.
    After consideration of the public comments we received, we are not 
finalizing this proposal at this time. However, we intend to monitor 
expansion of services in off-campus PBDs and, if appropriate, may 
propose to adopt a limitation on the expansion of excepted services in 
future rulemaking. In that event, we will consider the concerns 
expressed by commenters on the proposed policy in development of any 
future rulemaking on service line expansion. Therefore, an excepted 
off-campus PBD will continue to receive payments under the OPPS in CY 
2019 for all billed items and services that are paid under the OPPS, 
regardless of whether it furnished such items and services prior to the 
date of enactment of Public Law 114-74, as long as the excepted off-
campus PBD remains excepted, including meeting the relocation and 
change of ownership requirements adopted in the CY 2017 OPPS/ASC final 
rule with comment period if applicable (81 FR 79705 through 79706 and 
79708 through 79709). As mentioned earlier in this section, we intend 
to monitor this issue and continue to consider how potential policies 
could address this issue.

XI. CY 2019 OPPS Payment Status and Comment Indicators

A. CY 2019 OPPS Payment Status Indicator Definitions

    Payment status indicators (SIs) that we assign to HCPCS codes and 
APCs serve an important role in determining payment for services under 
the OPPS. They indicate whether a service represented by a HCPCS code 
is payable under the OPPS or another payment system, and also, whether 
particular OPPS policies apply to the code.
    In the CY 2019 OPPS/ASC proposed rule (83 FR 37150), for CY 2019, 
we did not propose to make any changes to the definitions of status 
indicators that were listed in Addendum D1 to the CY 2018 OPPS/ASC 
final rule with comment period available on the CMS website at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/HospitalOutpatientPPS/Hospital-Outpatient-Regulations-and-Notices-Items/CMS-1656-FC.html?DLPage=1&DLEntries=10&DLSort=2&DLSortDir=descending.
    Comment: One commenter recommended that CMS split status indicator 
``C'' into ``C1'' and ``C2'' in the interest of improved clarity and 
transparency. The commenter noted this methodology is very similar to 
the way Medicare split status indicator ``E'' into indicators ``E1'' 
and ``E2.'' The commenter requested that CMS identify inpatient only 
(IPO) procedures that are on the separate procedure list (as determined 
by the American Medical Association) with a unique status indicator 
such as ``C1'' and others as ``C2''. The commenter believed that the 
presence of a unique status indicator would ultimately assist providers 
in ensuring that their claims processing system edits are set up to 
bill these scenarios on an OPPS claim to CMS, and that CMS would 
benefit by having more accurate claims data submitted. The commenter 
believed that this will also increase the number of claims available 
for capturing cost data and utilizing for future ratesetting.
    The commenter also requested that CMS reiterate that the I/OCE 
logic regarding IPO procedures that are classified as a separate 
procedure (for example, status indicator of ``C1'') is a line item 
rejection and does not cause the entire claim to be rejected.
    Response: We appreciate the commenter's concerns. However, at this 
time, we do not believe it is necessary to establish a unique status 
indicator to identify IPO procedures that are on the separate 
procedures list. As stated in the latest October 2018 Integrated (IOCE) 
CMS Specifications V19.3 document, these procedures are bypassed when 
performed incidental to a surgical procedure with status indicator 
``T'', or effective January 1, 2015, if reported on a claim with a 
comprehensive APC procedure (status indicator = ``J1''). The line(s) 
with the inpatient-separate procedure is/are rejected by the I/OCE with 
Edit 45 ``Inpatient separate procedures not paid'' and the claim is 
processed per usual OPPS rules. Therefore, there is no need to split 
the definition of status indicator ``C'' and to establish a new status 
indicator ``C1'' as suggested by the commenter. As discussed 
previously, our status indicators exist for purposes of assisting in 
determining payment, and a single status indicator ``C'' is sufficient 
for services that CMS designates to be ``inpatient only'' services, 
regardless of whether or not they are on the separate procedure list.
    There are currently 26 different status indicators in Addendum D1 
that are used to indicate whether a service described by a HCPCS code 
is payable under the OPPS or another payment system and whether 
particular OPPS payment policies apply to the code. We believe that it 
is important to maintain only status indicators in the OPPS that convey 
the necessary payment-related information, and that additional 
indicators should only be created when necessary for payment policy 
purposes.
    In regard to the comment related to the I/OCE, the latest October 
2018 I/OCE CMS Specifications V19.3 document on the CMS website located 
at: https://www.cms.gov/Medicare/Coding/OutpatientCodeEdit/OCEQtrReleaseSpecs.html already contains the correct logic regarding 
IPO procedures that are classified as a separate procedures.
    After considering the comments received, we continue to believe 
that the existing definitions of the OPPS status indicators will be 
appropriate for CY 2019. Therefore, we are finalizing our proposed 
policy without modifications.
    The complete list of the payment status indicators and their 
definitions that will apply for CY 2019 is displayed in Addendum D1 to 
this final rule with comment period, which is available on the CMS 
website at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/HospitalOutpatientPPS/.
    The CY 2019 payment status indicator assignments for APCs and HCPCS 
codes are shown in Addendum A and Addendum B, respectively, to this 
final rule with comment period, which are available on the CMS website 
at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/HospitalOutpatientPPS/.

B. CY 2019 Comment Indicator Definitions

    In the CY 2019 OPPS/ASC proposed rule (83 FR 37150), we proposed to 
use four comment indicators for the CY 2019 OPPS. These comment 
indicators, ``CH'', ``NC'', ``NI'', and ``NP'', are in effect for CY 
2018 and we proposed to continue their use in CY 2019. The

[[Page 59028]]

proposed CY 2019 OPPS comment indicators are as follows:
     ``CH''--Active HCPCS code in current and next calendar 
year, status indicator and/or APC assignment has changed; or active 
HCPCS code that will be discontinued at the end of the current calendar 
year.
     ``NC''--New code for the next calendar year or existing 
code with substantial revision to its code descriptor in the next 
calendar year, as compared to current calendar year for which we 
requested comments in the proposed rule, final APC assignment; comments 
will not be accepted on the final APC assignment for the new code.
     ``NI''--New code for the next calendar year or existing 
code with substantial revision to its code descriptor in the next 
calendar year, as compared to current calendar year, interim APC 
assignment; comments will be accepted on the interim APC assignment for 
the new code.
     ``NP''--New code for the next calendar year or existing 
code with substantial revision to its code descriptor in the next 
calendar year, as compared to current calendar year, proposed APC 
assignment; comments will be accepted on the proposed APC assignment 
for the new code.
    We did not receive any public comments regarding the proposed CY 
2019 OPPS comment indicators. Therefore, we are adopting, as final, our 
proposal to continue to use for CY 2019 comment indicators ``CH'', 
``NI'', ``NP'', and ``NP''. The definitions of the final OPPS comment 
indicators for CY 2019 are listed in Addendum D2 to this final rule 
with comment period, which is available on the CMS website at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/HospitalOutpatientPPS/.

XII. Updates to the Ambulatory Surgical Center (ASC) Payment System

A. Background

1. Legislative History, Statutory Authority, and Prior Rulemaking for 
the ASC Payment System
    For a detailed discussion of the legislative history and statutory 
authority related to payments to ASCs under Medicare, we refer readers 
to the CY 2012 OPPS/ASC final rule with comment period (76 FR 74377 
through 74378) and the June 12, 1998 proposed rule (63 FR 32291 through 
32292). For a discussion of prior rulemaking on the ASC payment system, 
we refer readers to the CYs 2012, 2013, 2014, 2015, 2016, 2017 and 2018 
OPPS/ASC final rules with comment period (76 FR 74378 through 74379; 77 
FR 68434 through 68467; 78 FR 75064 through 75090; 79 FR 66915 through 
66940; 80 FR 70474 through 70502; 81 FR 79732 through 79753; and 82 FR 
59401 through 59424, respectively).
2. Policies Governing Changes to the Lists of Codes and Payment Rates 
for ASC Covered Surgical Procedures and Covered Ancillary Services
    Under 42 CFR 416.2 and 416.166 of the Medicare regulations, subject 
to certain exclusions, covered surgical procedures in an ASC are 
surgical procedures that are separately paid under the OPPS, that would 
not be expected to pose a significant risk to beneficiary safety when 
performed in an ASC, and for which standard medical practice dictates 
that the beneficiary would not typically be expected to require active 
medical monitoring and care at midnight following the procedure 
(``overnight stay''). We adopted this standard for defining which 
surgical procedures are covered under the ASC payment system as an 
indicator of the complexity of the procedure and its appropriateness 
for Medicare payment in ASCs. We use this standard only for purposes of 
evaluating procedures to determine whether or not they are appropriate 
to be furnished to Medicare beneficiaries in ASCs. We define surgical 
procedures as those described by Category I CPT codes in the surgical 
range from 10000 through 69999 as well as those Category III CPT codes 
and Level II HCPCS codes that directly crosswalk or are clinically 
similar to procedures in the CPT surgical range that we have determined 
do not pose a significant safety risk, that we would not expect to 
require an overnight stay when performed in ASCs, and that are 
separately paid under the OPPS (72 FR 42478).
    In the August 2, 2007 final rule (72 FR 42495), we also established 
our policy to make separate ASC payments for the following ancillary 
items and services when they are provided integral to ASC covered 
surgical procedures: (1) Brachytherapy sources; (2) certain implantable 
items that have pass-through payment status under the OPPS; (3) certain 
items and services that we designate as contractor-priced, including, 
but not limited to, procurement of corneal tissue; (4) certain drugs 
and biologicals for which separate payment is allowed under the OPPS; 
and (5) certain radiology services for which separate payment is 
allowed under the OPPS. In the CY 2015 OPPS/ASC final rule with comment 
period (79 FR 66932 through 66934), we expanded the scope of ASC 
covered ancillary services to include certain diagnostic tests within 
the medicine range of CPT codes for which separate payment is allowed 
under the OPPS when they are provided integral to an ASC covered 
surgical procedure. Covered ancillary services are specified in Sec.  
416.164(b) and, as stated previously, are eligible for separate ASC 
payment. Payment for ancillary items and services that are not paid 
separately under the ASC payment system is packaged into the ASC 
payment for the covered surgical procedure.
    We update the lists of, and payment rates for, covered surgical 
procedures and covered ancillary services in ASCs in conjunction with 
the annual proposed and final rulemaking process to update the OPPS and 
the ASC payment system (Sec.  416.173; 72 FR 42535). We base ASC 
payment and policies for most covered surgical procedures, drugs, 
biologicals, and certain other covered ancillary services on the OPPS 
payment policies, and we use quarterly change requests (CRs) to update 
services covered under the OPPS. We also provide quarterly update CRs 
for ASC covered surgical procedures and covered ancillary services 
throughout the year (January, April, July, and October). We release new 
and revised Level II HCPCS codes and recognize the release of new and 
revised CPT codes by the AMA and make these codes effective (that is, 
the codes are recognized on Medicare claims) via these ASC quarterly 
update CRs. We recognize the release of new and revised Category III 
CPT codes in the July and January CRs. These updates implement newly 
created and revised Level II HCPCS and Category III CPT codes for ASC 
payments and update the payment rates for separately paid drugs and 
biologicals based on the most recently submitted ASP data. New and 
revised Category I CPT codes, except vaccine codes, are released only 
once a year, and are implemented only through the January quarterly CR 
update. New and revised Category I CPT vaccine codes are released twice 
a year and are implemented through the January and July quarterly CR 
updates. We refer readers to Table 41 in the CY 2012 OPPS/ASC proposed 
rule for an example of how this process, which we finalized in the CY 
2012 OPPS/ASC final rule with comment period, is used to update HCPCS 
and CPT codes (76 FR 42291; 76 FR 74380 through 74381).
    In our annual updates to the ASC list of, and payment rates for, 
covered surgical procedures and covered ancillary services, we 
undertake a review of excluded surgical procedures (including all 
procedures newly proposed for removal from the OPPS

[[Page 59029]]

inpatient list), new codes, and codes with revised descriptors, to 
identify any that we believe meet the criteria for designation as ASC 
covered surgical procedures or covered ancillary services. Updating the 
lists of ASC covered surgical procedures and covered ancillary 
services, as well as their payment rates, in association with the 
annual OPPS rulemaking cycle is particularly important because the OPPS 
relative payment weights and, in some cases, payment rates, are used as 
the basis for the payment of many covered surgical procedures and 
covered ancillary services under the revised ASC payment system. This 
joint update process ensures that the ASC updates occur in a regular, 
predictable, and timely manner.
3. Definition of ASC Covered Surgical Procedures
    Since the implementation of the ASC prospective payment system, we 
have defined a ``surgical'' procedure under the payment system as any 
procedure described within the range of Category I CPT codes that the 
CPT Editorial Panel of the American Medical Association (AMA) defines 
as ``surgery'' (CPT codes 10000 through 69999) (72 FR 42478). We also 
have included as ``surgical,'' procedures that are described by Level 
II HCPCS codes or by Category III CPT codes that directly crosswalk or 
are clinically similar to procedures in the CPT surgical range that we 
have determined do not pose a significant safety risk, would not expect 
to require an overnight stay when performed in an ASC, and are 
separately paid under the OPPS (72 FR 42478).
    As we noted in the CY 2008 final rule that implemented the revised 
ASC payment system, using this definition of surgery would exclude from 
ASC payment certain invasive, ``surgery-like'' procedures, such as 
cardiac catheterization or certain radiation treatment services that 
are assigned codes outside the CPT surgical range (72 FR 42477). We 
stated in that final rule that we believed continuing to rely on the 
CPT definition of surgery is administratively straightforward, is 
logically related to the categorization of services by physician 
experts who both establish the codes and perform the procedures, and is 
consistent with a policy to allow ASC payment for all outpatient 
surgical procedures (72 FR 42477).
    In the CY 2018 OPPS/ASC final rule with comment period (82 FR 59402 
through 59403), we noted that some stakeholders have suggested that 
certain procedures that are outside the CPT surgical range but that are 
similar to surgical procedures currently covered in an ASC setting 
should be ASC covered surgical procedures. For example, some 
stakeholders have recommended adding certain cardiovascular procedures 
to the ASC Covered Procedures List (CPL) due to their similarity to 
currently covered peripheral endovascular procedures in the surgical 
code range for surgery and the cardiovascular system. Further, 
stakeholders also noted that the AMA's CPT code manual states that the 
listing of a procedure in a specific section of the book may reflect 
historical or other considerations and should not be interpreted as 
strictly classifying the procedure as ``surgery'' or ``not surgery'' 
for insurance purposes. As the CPT codebook states: ``It is equally 
important to recognize that as techniques in medicine and surgery have 
evolved, new types of services, including minimally invasive surgery, 
as well as endovascular, percutaneous, and endoscopic interventions 
have challenged the traditional distinction of Surgery vs Medicine. 
Thus, the listing of a service or procedure in a specific section of 
this book should not be interpreted as strictly classifying the service 
or procedure as `surgery' or `not surgery' for insurance or other 
purposes. The placement of a given service in a specific section of the 
book may reflect historical or other considerations (e.g., placement of 
the percutaneous peripheral vascular endovascular interventions in the 
Surgery/Cardiovascular System section, while the percutaneous coronary 
interventions appear in the Medicine/Cardiovascular section)'' 
(emphasis added) (CPT[supreg] 2018 Professional Edition, ``Instructions 
for Use of the CPT Code Book,'' page xii.). While we continue to 
believe that using the CPT code range to define surgery represents a 
logical, appropriate, and straightforward approach to defining a 
surgical procedure, we also believe it may be appropriate for us to use 
the CPT surgical range as a guide rather than a strict determinant as 
to whether a procedure is surgical, which would give us more 
flexibility to include ``surgery-like'' procedures on the ASC CPL.
    We also are cognizant of the dynamic nature of ambulatory surgery 
and the continued shift of services from the inpatient setting to the 
outpatient setting over the past decade. In the CY 2018 OPPS/ASC final 
rule with comment period (82 FR 59402 through 59403), we responded to 
public comments that we had solicited regarding services that are 
described by Category I CPT codes outside of the surgical range, or 
Level II HCPCS codes or Category III CPT codes that do not directly 
crosswalk and are not clinically similar to procedures in the CPT 
surgical range, but that nonetheless may be appropriate to include as 
covered surgical procedures that are payable when furnished in the ASC 
setting. Commenters offered mixed views of changing the current 
definition of surgery; however, most commenters were supportive of 
changing the definition. Some commenters recommended broadening the 
definition of surgery to include procedures not described by the CPT 
surgical range. Another commenter recommended making all surgical codes 
payable in a hospital outpatient department payable in an ASC and 
further suggested that CMS at least redefine surgical procedures to 
include invasive procedures such as percutaneous transluminal 
angioplasty and cardiac catheterization.
    One commenter recommended using a definition of surgery developed 
by the AMA Specialty Society Relative Value Scale Update Society for 
use in the agency's Physician Fee Schedule (PFS) professional liability 
insurance relative values. In calculating the professional liability 
insurance relative values, certain cardiology codes outside the CPT 
surgical range are considered surgical codes for both the calculation 
and assignment of the surgery-specific malpractice risk factors. 
However, we note that the distinction between ``surgical'' and 
``nonsurgical'' codes developed by the AMA Specialty Society Relative 
Value Scale Update Society is used by CMS to calculate professional 
liability risk factors and not necessarily to define surgery. The codes 
considered surgeries by the AMA Society Relative Value Scale Update 
Society were most recently displayed on the CMS website for the CY 2018 
Medicare Physician Fee Schedule final rule under the file ``Invasive 
Cardiology Services Outside of Surgical HCPCS Code Range Considered 
Surgery.'' We refer readers to that file, which is available on the CMS 
website at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/PhysicianFeeSched/Downloads/CY2018-PFS-FR-Invasive-Cardiology.zip.
    In the CY 2019 OPPS/ASC proposed rule (83 FR 37152), after further 
consideration of comments we received in response to the CY 2018 OPPS/
ASC final rule with comment period, we proposed to revise our 
definition of ``surgery'' for CY 2019 to account for ``surgery-like'' 
procedures that are assigned codes outside the CPT surgical range 
(10000 through 69999). We

[[Page 59030]]

believe it is appropriate to expand our definition of covered surgical 
procedures to include Category I CPT codes that are not in the Category 
I CPT surgical range but that directly crosswalk or are clinically 
similar to procedures in the Category I CPT code surgical range 
because, as commenters have noted, the CPT Codebook's classification of 
certain procedures as ``surgical'' should not be considered dispositive 
of whether a procedure is or is not surgery. We also believe that 
considering these codes for potential inclusion on the covered surgical 
procedures list is consistent with our policy for Level II HCPCS codes 
and Category III CPT codes.
    For CY 2019, we proposed that these newly eligible ``surgery-like'' 
procedures are procedures that are described by Category I CPT codes 
that are not in the surgical range but, like procedures described by 
Level II HCPCS codes or by Category III CPT codes under our current 
policy, directly crosswalk or are clinically similar to procedures in 
the Category I CPT surgical range. These Category I CPT codes would be 
limited to those that we have determined do not pose a significant 
safety risk, would not be expected to require an overnight stay when 
performed in an ASC, and are separately paid under the OPPS.
    We invited comments on our proposal to revise the definition of 
surgery for the ASC prospective payment system. We also solicited 
comments on whether we should expand our definition of ``surgery'' to 
include procedures that fall outside the CPT surgical range, but fall 
within the definition of ``surgery'' developed by the AMA Specialty 
Society Relative Value Scale Update Society for use in the agency's 
Physician Fee Schedule (PFS) professional liability insurance relative 
values, that we determine do not pose a significant safety risk, would 
not be expected to require an overnight stay when performed in an ASC, 
and are separately paid under the OPPS.
    Comment: A majority of commenters supported the proposal, stating 
that the expansion of the definition of surgery would allow Medicare 
beneficiaries access to these procedures at a safe, lower-priced and 
more convenient site of service. One commenter expressed general 
concern about the proposal to revise the definition of surgery, citing 
``surgery-like'' procedures that might expose Medicare beneficiaries to 
a significant safety risk when performed in an ASC.
    Response: We appreciate commenters' support. As we stated in the CY 
2019 OPPS/ASC proposed rule (83 FR 37152), we are cognizant of the 
dynamic nature of ambulatory surgery and the continued shift of 
services from the inpatient setting to the outpatient setting over the 
past decade. We also noted that the AMA's CPT code manual states that 
the listing of a procedure in a specific section of the book may 
reflect historical or other considerations and should not be 
interpreted as strictly classifying the procedure as ``surgery'' or 
``not surgery'' for insurance or other purposes.
    With respect to the commenter's concern that this proposal may 
expose beneficiaries to significant safety risk, we note that any 
procedure added to the ASC CPL is evaluated against the existing 
regulatory criteria and would not be expected pose a significant safety 
risk, would not be expected to require an overnight stay when performed 
in an ASC, and is separately paid under the OPPS. In addition, we 
expect that physicians treating beneficiaries are well-equipped to 
decide whether the ASC setting would be appropriate based on the 
clinical needs of the patient, among other factors. Therefore, we do 
not share the commenter's concern.
    Comment: One commenter asked CMS to clarify if it bases its 
determination of whether a procedure is an ASC covered surgical 
procedure on the fact that the procedure does not require an 
``overnight'' stay or the fact that the procedure requires less than 24 
hours of active medical care following the procedure.
    Response: As codified in our regulations at 42 CFR 416.166(b), 
covered surgical procedures are surgical procedures for which, among 
other things, standard medical practice dictates that the beneficiary 
would not typically be expected to require active medical monitoring 
and care at midnight following the procedure. In the CY 2019 OPPS/ASC 
proposed rule (83 FR 37151), we explained this requirement by stating 
that we would not expect a covered surgical procedure to require an 
overnight stay when performed in the ASC. Also in the CY 2019 OPPS/ASC 
proposed rule, we explained that we adopted this standard for defining 
which surgical procedures are covered surgical procedures under the ASC 
payment system as an indicator of the complexity of the procedure and 
its appropriateness for Medicare payment in ASCs (83 FR 37151). We use 
this standard only for purposes of evaluating procedures to determine 
whether or not they are appropriate for Medicare beneficiaries in ASCs.
    After consideration of the public comments we received, we are 
finalizing our proposal to define a surgical procedure under the ASC 
payment system as any procedure described within the range of Category 
I CPT codes that the CPT Editorial Panel of the American Medical 
Association (AMA) defines as ``surgery'' (CPT codes 10000 through 
69999) (72 FR 42478), as well as procedures that are described by Level 
II HCPCS codes or by Category I CPT codes or by Category III CPT codes 
that directly crosswalk or are clinically similar to procedures in the 
CPT surgical range that we have determined are not expected to pose a 
significant risk to beneficiary safety when performed in an ASC, for 
which standard medical practice dictates that the beneficiary would not 
typically be expected to require an overnight stay following the 
procedure, and are separately paid under the OPPS.

B. Treatment of New and Revised Codes

1. Background on Current Process for Recognizing New and Revised 
Category I and Category III CPT Codes and Level II HCPCS Codes
    Category I CPT, Category III CPT, and Level II HCPCS codes are used 
to report procedures, services, items, and supplies under the ASC 
payment system. Specifically, we recognize the following codes on ASC 
claims:
     Category I CPT codes, which describe surgical procedures 
and vaccine codes;
     Category III CPT codes, which describe new and emerging 
technologies, services, and procedures; and
     Level II HCPCS codes, which are used primarily to identify 
items, supplies, temporary procedures, and services not described by 
CPT codes.
    We finalized a policy in the August 2, 2007 final rule (72 FR 42533 
through 42535) to evaluate each year all new and revised Category I and 
Category III CPT codes and Level II HCPCS codes that describe surgical 
procedures, and to make preliminary determinations during the annual 
OPPS/ASC rulemaking process regarding whether or not they meet the 
criteria for payment in the ASC setting as covered surgical procedures 
and, if so, whether or not they are office-based procedures. In 
addition, we identify new and revised codes as ASC covered ancillary 
services based upon the final payment policies of the revised ASC 
payment system. In prior rulemakings, we refer to this process as 
recognizing new codes. However, this process has always involved the 
recognition of new and revised codes. We consider revised codes to be 
new when they have substantial revision to their code

[[Page 59031]]

descriptors that necessitate a change in the current ASC payment 
indicator. To clarify, we referred to these codes as new and revised in 
the CY 2018 OPPS/ASC proposed rule.
    In the CY 2019 OPPS/ASC proposed rule (83 FR 37152 through 37155), 
we separated our discussion based on when the codes were released and 
whether we were soliciting public comments in the proposed rule (and 
responding to those comments in this CY 2019 OPPS/ASC final rule with 
comment period) or whether we would be soliciting public comments in 
this CY 2019 OPPS/ASC final rule with comment period (and responding to 
those comments in the CY 2020 OPPS/ASC final rule with comment period).
    We note that we sought public comments in the CY 2018 OPPS/ASC 
final rule with comment period (82 FR 59405 through 59406) on the new 
and revised Level II HCPCS codes effective October 1, 2017 or January 
1, 2018. These new and revised codes, with an effective date of October 
1, 2017 or January 1, 2018, were flagged with comment indicator ``NI'' 
in Addenda AA and BB to the CY 2018 OPPS/ASC final rule with comment 
period to indicate that we were assigning them an interim payment 
status and payment rate, if applicable, which were subject to public 
comment following publication of the CY 2018 OPPS/ASC final rule with 
comment period. In the CY 2019 OPPS/ASC proposed rule, we stated that 
we will respond to public comments and finalize the treatment of these 
codes under the ASC payment system in this CY 2019 OPPS/ASC final rule 
with comment period.
    As we did in Table 33 of the CY 2019 OPPS/ASC proposed rule (83 FR 
37153), in Table 52 below, we summarize our process for updating codes 
through our ASC quarterly update CRs, seeking public comments, and 
finalizing the treatment of these new codes under the OPPS.
BILLING CODE 4120-01-P
[GRAPHIC] [TIFF OMITTED] TR21NO18.078


[[Page 59032]]


2. Treatment of New and Revised Level II HCPCS Codes Implemented in 
April 2018 for Which We Solicited Public Comments in the CY 2019 OPPS/
ASC Proposed Rule
    As discussed in the CY 2019 OPPS/ASC proposed rule (83 FR 37153), 
in the April 2018 ASC quarterly update (Transmittal 3996, Change 
Request 10530, dated March 09, 2018), we added nine new Level II HCPCS 
codes to the ASC CPL and list of covered ancillary services. Table 34 
of the proposed rule (83 FR 37153) listed the new Level II HCPCS codes 
that were implemented April 1, 2018, along with their proposed payment 
indicators for CY 2019. We invited public comments on these proposed 
payment indicators and the proposed payment rates for the new Level II 
HCPCS codes that were recognized as ASC covered surgical procedures or 
ancillary services in April 2018 through the quarterly update CRs, as 
listed in Table 34 of the proposed rule. We proposed to finalize their 
payment indicators and their payment rates in this CY 2019 OPPS/ASC 
final rule with comment period.
    Comment: Several commenters supported the addition of HCPCS code 
C9749 (Repair of nasal vestibular lateral wall stenosis with 
implant(s)), which describes the Latera implant surgical procedure, to 
the ASC covered surgical procedures list and its designation as a 
device-intensive procedure. However, they expressed concern that the 
proposed ASC payment rate for the procedure does not sufficiently cover 
the full cost of providing the surgery. One commenter stated that the 
proposed ASC payment rate of approximately $1,271 does not cover the 
cost of the device implant, let alone the full cost of the procedure 
including the device. These commenters believed that the low payment 
rate would hinder physicians from offering the procedure in ASCs. The 
commenters requested that CMS review the payment rate and adjust it 
appropriately so that physicians can continue to perform this procedure 
safely and effectively in the ASC setting.
    Response: The OPPS and the ASC payment system utilize different 
conversion factors to establish payment rates for covered services to 
account for changes in expenditures. In the CY 2019 OPPS/ASC proposed 
rule, we stated that the proposed OPPS conversion factor was $79.546, 
while the proposed ASC conversion factor was $46.500. Consequently, the 
proposed ASC payment rate of approximately $1,271 for HCPCS code C9749 
would be less than the proposed OPPS payment rate of approximately 
$2,241. We have used different conversion factor updates for the OPPS 
and the ASC payment system since the revised ASC payment system was 
implemented on January 1, 2008. For more information regarding the 
payment methodology for ASC services, we refer readers to section 
XII.G. (Calculation of the ASC Payment Rates and the ASC Conversion 
Factor) of this CY 2019 OPPS/ASC final rule with comment period.
    Further, we also note that HCPCS code C9749 has been assigned a 
payment indicator of ``J8'' and is therefore designated as a device-
intensive procedure. As discussed in section XII.C.1.b. of this final 
rule with comment period, under the ASC payment system, device-
intensive procedures are paid a higher payment than if the procedure 
was not designated as device-intensive.
    After consideration of the public comments we received, we are 
adopting as final the CY 2019 proposed payment indicators for new level 
II HCPCS codes for covered surgical procedures and ancillary services 
effective on April 1, 2018, as indicated in Table 53. We note that 
several of the HCPCS C-codes have been replaced with HCPCS J-codes, 
effective January 1, 2019. The replacement codes are listed in Table 
53. The final payment rates for these codes can be found in Addendum BB 
to this final rule with comment period (which is available via the 
internet on the CMS website). In addition, the payment indicator 
definitions can be found in Addendum DD1 to this final rule with 
comment period (which is available via the internet on the CMS 
website).

[[Page 59033]]

[GRAPHIC] [TIFF OMITTED] TR21NO18.079

3. Treatment of New and Revised Category III CPT and Level II HCPCS 
Codes Implemented in July 2018 for Which We Solicited Public Comments 
in the CY 2019 OPPS/ASC Proposed Rule
    As discussed in the CY 2019 OPPS/ASC proposed rule (83 FR 37154), 
in the July 2018 ASC quarterly update (Transmittal 4076, Change Request 
10788, dated June 26, 2018), we added eight new Level II HCPCS codes to 
the list of covered ancillary services. In Table 35 of the proposed 
rule (83 FR 37154), we listed the new HCPCS codes that are effective 
July 1, 2018.
    In addition, through the July 2018 quarterly update CR, we also 
implemented one new Category III CPT code as an ASC covered ancillary 
service effective July 1, 2018. This code was listed in Table 36 of the 
proposed rule, along with its proposed payment indicator. The proposed 
payment rate for this new Category III CPT code was included in 
Addendum AA to the proposed rule (which is available via the internet 
on the CMS website).
    We invited public comments on these proposed payment indicators and 
the proposed payment rates for the new Category III CPT code and Level 
II HCPCS codes that were expected to be newly recognized as ASC covered 
surgical procedures or covered ancillary services in July 2018 through 
the quarterly update CRs, as listed in Tables 35 and 36 of the proposed 
rule. We proposed to finalize their payment indicators and their 
payment rates in the CY 2019 OPPS/ASC final rule with comment period.
    We did not receive any public comments regarding these proposed ASC 
payment indicators and payment rates. Therefore, we are adopting as 
final the CY 2019 proposed payment indicators for these codes, as 
indicated in Tables 54 and 55. We note that several of the HCPCS C-
codes have been replaced with HCPCS J-codes, effective January 1, 2019. 
Their replacement codes are listed in Table 55. The final payment rates 
for these codes for CY 2019 can be found in Addendum BB to this final 
rule with comment period (which is available via the internet on the 
CMS website). In addition, the payment indicator definitions can be 
found in Addendum DD1 to this final rule with comment period (which is 
available via the internet on the CMS website).

[[Page 59034]]

[GRAPHIC] [TIFF OMITTED] TR21NO18.080

[GRAPHIC] [TIFF OMITTED] TR21NO18.081

BILLING CODE 4120-01-C
4. Process for New and Revised Level II HCPCS Codes That Will Be 
Effective October 1, 2018 and January 1, 2019 for Which We Are 
Soliciting Public Comments in This CY 2019 OPPS/ASC Final Rule With 
Comment Period
    As has been our practice in the past, we incorporate those new and 
revised Level II HCPCS codes that are effective January 1 in the final 
rule with comment period, thereby updating the OPPS and the ASC payment 
system for the following calendar year. These codes are released to the 
public via the CMS HCPCS website, and also through the January OPPS 
quarterly update CRs. In the past, we also released new and revised 
Level II HCPCS codes that are effective October 1 through the October 
OPPS quarterly update CRs and incorporated these new codes in the final 
rule with comment period.
    In the CY 2019 OPPS/ASC proposed rule (83 FR 37154), for CY 2019, 
consistent with our established policy, we proposed that the Level II 
HCPCS codes that will be effective October 1, 2018 and January 1, 2019 
would be flagged with comment indicator ``NI'' in Addendum B to the CY 
2019 OPPS/ASC final rule with comment period to indicate that we have 
assigned the codes an interim OPPS payment status for CY 2019. We did 
not receive any public comments on our proposal. As we stated that we 
would do in the proposed rule, we are inviting public comments in this 
CY 2019 OPPS/ASC final rule with comment period on the interim status 
indicator and APC assignments, and

[[Page 59035]]

payment rates for these codes that will be finalized in the CY 2020 
OPPS/ASC final rule with comment period.
5. Process for Recognizing New and Revised Category I and Category III 
CPT Codes That Will Be Effective January 1, 2019 for Which We Are 
Soliciting Public Comments in This CY 2019 OPPS/ASC Final Rule With 
Comment Period
    We generally include the new and revised CPT codes that are 
effective January 1 of a calendar year in the proposed rule to request 
public comments on the ASC payment indicator assignments. In addition, 
these codes are assigned to comment indicator ``NP'' to indicate that 
the code is new for the next calendar year or the code is an existing 
code with substantial revision to its code descriptor in the next 
calendar year as compared to current calendar year and that comments 
will be accepted on the proposed payment indicator. There are no 
existing codes with substantial revision to the code descriptor 
effective January 1, 2019. However, we inadvertently omitted most of 
the new Category I and III CPT codes effective January 1, 2019 from ASC 
Addendum AA, BB, and EE to the CY 2019 OPPS/ASC proposed rule. We did 
not omit eight new CPT codes that we proposed to designate as 
temporarily office based effective January 1, 2019. We refer readers to 
Table 39 of the proposed rule.
    Therefore, in addition to the Level II HCPCS codes that will be 
effective October 1, 2018, and January 1, 2019, we are flagging the new 
Category I and III CPT codes that will be effective January 1, 2019, 
that were omitted from the CY 2019 OPPS/ASC proposed rule, with comment 
indicator ``NI'' in ASC Addendum AA, BB, and EE to this CY 2019 OPPS/
ASC final rule with comment period to indicate that we have assigned 
the codes an interim ASC payment indicator for CY 2019. We are inviting 
public comments on the interim ASC payment indicator assignments and 
payment rates for these codes that we intend to finalize in the CY 2020 
OPPS/ASC final rule with comment period. We note that we are finalizing 
the ASC payment indicators for the eight codes that we proposed to 
designate as temporarily office based effective January 1, 2019 because 
we previously sought comments on their ASC payment indicator 
assignment. Table 58 of this final rule with comment period contains 
the list of these eight codes and their final ASC payment indicators.
    Further, we remind readers that the CPT code descriptors that 
appear in ASC Addendum AA, BB, and EE are short descriptors and do not 
fully describe the complete procedure, service, or item described by 
the CPT code. Therefore, we have included the 5-digit CPT codes and 
their long descriptors for the new CPT codes in Addendum O (which is 
available via the internet on the CMS website) so that the public can 
adequately comment on our interim ASC payment indicator assignments.
    In summary, we are soliciting public comments on the interim ASC 
payment indicators for the new Category I and III CPT codes that will 
be effective January 1, 2019, which we have assigned to ASC comment 
indicator ``NI'' in this CY 2019 OPPS/ASC final rule with comment 
period. We intend to finalize the interim ASC payment indicators in the 
CY 2020 OPPS/ASC final rule with comment period. The CPT codes are 
listed in ASC Addendum AA, BB, and EE with short descriptors only but 
we list them again in Addendum O with long descriptors.

C. Update to the List of ASC Covered Surgical Procedures and Covered 
Ancillary Services

1. Covered Surgical Procedures
a. Covered Surgical Procedures Designated as Office-Based
(1) Background
    In the August 2, 2007 ASC final rule, we finalized our policy to 
designate as ``office-based'' those procedures that are added to the 
ASC CPL in CY 2008 or later years that we determine are performed 
predominantly (more than 50 percent of the time) in physicians' offices 
based on consideration of the most recent available volume and 
utilization data for each individual procedure code and/or, if 
appropriate, the clinical characteristics, utilization, and volume of 
related codes. In that rule, we also finalized our policy to exempt all 
procedures on the CY 2007 ASC list from application of the office-based 
classification (72 FR 42512). The procedures that were added to the ASC 
CPL beginning in CY 2008 that we determined were office-based were 
identified in Addendum AA to that rule by payment indicator ``P2'' 
(Office-based surgical procedure added to ASC list in CY 2008 or later 
with MPFS nonfacility PE RVUs; payment based on OPPS relative payment 
weight); ``P3'' (Office-based surgical procedures added to ASC list in 
CY 2008 or later with MPFS nonfacility PE RVUs; payment based on MPFS 
nonfacility PE RVUs); or ``R2'' (Office-based surgical procedure added 
to ASC list in CY 2008 or later without MPFS nonfacility PE RVUs; 
payment based on OPPS relative payment weight), depending on whether we 
estimated the procedure would be paid according to the standard ASC 
payment methodology based on its OPPS relative payment weight or at the 
MPFS nonfacility PE RVU-based amount.
    Consistent with our final policy to annually review and update the 
ASC CPL eligible for payment in ASCs, each year we identify covered 
surgical procedures as either temporarily office-based (these are new 
procedure codes with little or no utilization data that we have 
determined are clinically similar to other procedures that are 
permanently office-based), permanently office-based, or nonoffice-
based, after taking into account updated volume and utilization data.
(2) Changes for CY 2019 to Covered Surgical Procedures Designated as 
Office-Based
    In developing the CY 2019 OPPS/ASC proposed rule and this final 
rule with comment period, we followed our policy to annually review and 
update the covered surgical procedures for which ASC payment is made 
and to identify new procedures that may be appropriate for ASC payment, 
including their potential designation as office-based. We reviewed CY 
2017 volume and utilization data and the clinical characteristics for 
all covered surgical procedures that are assigned payment indicator 
``G2'' (Nonoffice-based surgical procedure added in CY 2008 or later; 
payment based on OPPS relative payment weight) in CY 2017, as well as 
for those procedures assigned one of the temporary office-based payment 
indicators, specifically ``P2'', ``P3'', or ``R2'' in the CY 2018 OPPS/
ASC final rule with comment period (82 FR 59406 through 59408).
    As discussed in the CY 2019 OPPS/ASC proposed rule (83 FR 37155 
through 37157), our review of the CY 2017 volume and utilization data 
resulted in our identification of 4 covered surgical procedures that we 
believe meet the criteria for designation as office-based. The data 
indicate that these procedures are performed more than 50 percent of 
the time in physicians' offices, and we believe that the services are 
of a level of complexity consistent with other procedures performed 
routinely in physicians' offices. The CPT codes that we proposed to 
permanently designate as office-based for CY 2019 were listed in Table 
37 of the proposed rule (83 FR 37156).
    Comment: Several commenters disagreed with the proposal to 
designate CPT codes 36902 (Intro cath dialysis circuit) and 36905 
(Thrmbc/nfs dialysis

[[Page 59036]]

circuit) as permanently office-based. Commenters suggested that a 
permanent office-based designation, and therefore a permanent payment 
rate of the lesser of the PFS nonfacility PE RVU-based or the OPPS 
relative weight amount, would pay too little to make it a viable option 
for ASCs to perform these vascular access services, which the 
commenters suggested is the optimal setting for receiving vascular 
access services. Commenters also suggested that a permanent office-
based designation may inadvertently incentivize the migration of 
vascular access procedures to the more costly hospital setting. 
Further, commenters noted that vascular access procedure codes (CPT 
codes 36901 through 36909) became effective January 1, 2017, and were 
added to the ASC CPL for CY 2017. Because several of these procedures 
were not included on the ASC CPL prior to that time, commenters 
expressed concern that CMS is not likely to have data that accurately 
reflect the ASC utilization of the full suite of vascular access 
procedures until CY 2020 or later.
    Some commenters recommended that CMS delay the proposal to 
designate CPT codes 36902 and 36905 as office-based procedures. Other 
commenters recommended that CMS permanently exempt such CPT codes from 
office-based designations, similar to the existing exemptions from the 
policy governing payment for covered ancillary radiology services for 
certain nuclear medicine procedures (CPT codes 78000 through 78999) and 
those covered ancillary radiology services that use a contrast agent as 
codified under 42 CFR 416.171(d). Commenters believed that such an 
exemption is warranted because certain vascular access add-on 
procedures (that is, CPT codes 36907, 36908, and 36909) are often 
billed with CPT codes 36902 and 36905, which are separately payable 
under the PFS but are packaged under the OPPS and the ASC payment 
system. Therefore, the commenters stated, the ASC payment rate for an 
office-based vascular access procedure with a vascular access add-on 
procedure may be lower than would otherwise be paid under the PFS.
    Response: We appreciate the commenters' feedback on our proposal. 
As noted in the proposed rule, we assign office-based designations when 
our data indicate that these procedures are performed more than 50 
percent of the time in physicians' offices, and we believe that the 
services are of a level of complexity consistent with other procedures 
performed routinely in physicians' offices. We believe this is the most 
appropriate approach to prevent creating a payment incentive to migrate 
lower complexity services on the ASC CPL from physicians' offices to 
ASCs.
    In response to the comment recommending that we establish a 
permanent office-based designation exemption for vascular access 
procedures, we do not believe such an exemption is necessary at this 
time. However, we would like to study this issue further in future 
policy development. As stated in the CY 2011 OPPS/ASC final rule with 
comment period (75 FR 72050), we established an exemption to the policy 
governing payment for covered ancillary radiology services for certain 
nuclear medicine procedures (CPT codes 78000 through 78999) because the 
PFS nonfacility PE RVU amounts did not reflect the diagnostic 
radiopharmaceutical costs, which are paid separately under the MPFS. In 
addition, as stated in the CY 2012 OPPS/ASC final rule with comment 
period (76 FR 74429 through 74430), because the same issue exists for 
radiology procedures that use contrast agents (the contrast agent is 
packaged under the ASC payment system but is separately paid under the 
PFS), we exempted radiology services that use contrast agents from our 
policy governing payment for covered ancillary radiology services so 
that payment for these procedures will be based on the OPPS relative 
payment weight and will, therefore, include the cost for the contrast 
agent. We did not propose an equivalent exception for vascular access 
codes for CY 2019, and do not believe permanent exemption would be 
appropriate at this time. However, we intend to examine whether CPT 
codes 36902 and 36905 may be subject to circumstances similar to those 
that led to the exemptions for certain nuclear medicine procedures and 
radiology procedures that use contrast agents in future rulemaking.
    The most recent full year for which we have claims, volume, and 
utilization data is CY 2017. We believe these data are generally an 
appropriate source to inform our decisions regarding the predominant 
site of service for procedures. As stated in the CY 2010 OPPS/ASC final 
rule with comment period (74 FR 60605 through 60606), when we believe 
that the available data in our review process are inadequate to make a 
determination that a procedure should be office-based, we either make 
no change to the procedure's payment status or make the change 
temporary and reevaluate our decision using data that become available 
for our next evaluation. We believe that it is appropriate to continue 
using our judgment regarding whether the volume of cases and the 
proportion of cases that are provided in the physicians' office setting 
indicate that the procedures is an office-based procedure in addition 
to our medical advisors' clinical judgments, utilization data for 
procedures that are closely related to the procedures being evaluated, 
and any other information that is available to us.
    While the currently available data for CPT codes 36902 and 36905 
support our office-based designation proposal, we agree with the 
commenters that CY 2017 claims data may not be sufficiently adequate to 
capture the current volume and utilization for the ASC and physician 
office sites of service for CPT codes 36902 and 36905. Because we share 
commenters' concerns that the available data may not be adequate to 
make a determination that these procedures should be office-based, we 
believe it is premature to assign office-based payment for these 
procedures at this time. Therefore, we are not designating CPT codes 
36902 and 36905 as office-based procedures for CY 2019. We will 
reevaluate these procedures in our CY 2020 rulemaking period. For CY 
2019, these procedures will retain their current payment indicator, 
``G2.''
    We did not receive any public comments related to our proposal to 
designate CPT codes 31573 (Laryngoscopy, flexible; with therapeutic 
injection(s) (e.g., chemodenervation agent or corticosteroid, injected 
percutaneous, transoral, or via endoscope channel), unilateral) and 
36513 (Therapeutic apheresis; for platelets) as office-based 
procedures. Therefore, we are finalizing our proposal, without 
modification, to designate CPT codes 31573 and 36513 as permanently 
office-based procedures. However, in response to public comments we 
received, we are not finalizing our proposal to designate CPT codes 
36902 and 36905 as office-based. CPT codes 36902 and 36905 will retain 
the same payment indicator, ``G2'', that the procedures were assigned 
in CY 2018. We intend to reevaluate these using the most recent 
available volume and utilization data procedures in our CY 2020 
rulemaking period. The procedures we are designating as permanently 
office-based beginning in CY 2019 are listed in Table 56 below.
BILLING CODE 4120-01-P

[[Page 59037]]

[GRAPHIC] [TIFF OMITTED] TR21NO18.082

BILLING CODE 4120-01-C

    We also reviewed CY 2017 volume and utilization data and other 
information for 10 procedures designated as temporarily office-based in 
Tables 84 and 85 in the CY 2018 OPPS/ASC final rule with comment period 
(82 FR 59408). Of these 10 procedures, there were very few claims in 
our data and no claims data for 4 procedures described by CPT codes 
38222, 65785, 67229, and 0402T. Consequently, we proposed to maintain 
the temporary office-based designations for these 4 CPT codes for CY 
2019. We included codes for which we proposed to maintain the temporary 
office-based designations for CY 2019 in Table 38 of the proposed rule 
which listed the covered surgical procedures we designated as temporary 
office-based in the CY 2018 OPPS/ASC final rule with comment period. 
The procedures for which the proposed office-based designations for CY 
2019 are temporary also were indicated by asterisks in Addendum AA to 
the proposed rule (which is available via the internet on the CMS 
website).
    The volume and utilization data for 3 procedures that have a 
temporary office-based designation for CY 2018, described by CPT codes 
36473 and 36901 and HCPCS code G0429, are sufficient to indicate that 
these procedures are performed predominantly in physicians' offices 
and, therefore, should be assigned an office-based payment indicator in 
CY 2019. Consequently, we proposed to designate these procedures as 
permanently office based and assign payment indicator ``P2'', ``P3'', 
``R2'' to these covered surgical procedure codes in CY 2019. These 
procedures are displayed above in Table 56. The volume and utilization 
data for the remaining three procedures that have a temporary office-
based designation for CY 2018, described by CPT codes 10030, 64461, and 
64463, are sufficient

[[Page 59038]]

to indicate that these covered surgical procedures were not performed 
predominantly in physicians' offices and, therefore, should be assigned 
non-office-based payment indicator ``G2'' in CY 2019.
    Comment: One commenter requested that CMS exempt CPT code 36901 
from the office-based designation, similar to the existing office-based 
exemptions for certain nuclear medicine procedures (CPT codes 78000 
through 78999) as well as ancillary radiology services that use a 
contrast agent as codified under 42 CFR 416.171(d). The commenter 
suggested that the payment volatility over the past several years would 
limit patient access to vascular access services in the ASC setting and 
encourage the migration of these services to the more expensive 
hospital setting.
    Response: We do not believe establishing an office-based exemption 
for CPT code 36901 is warranted. We note that the exceptions for 
certain nuclear medicine procedures and for ancillary radiology 
services that use a contrast agent are exceptions to our policy 
governing payment for covered ancillary radiology services, not 
exceptions to our office-based policy. In addition, as stated in the CY 
2011 OPPS/ASC final rule with comment period (75 FR 72050), we 
established the exemption to our policy governing payment for covered 
ancillary radiology services for certain nuclear medicine procedures 
(CPT codes 78000 through 78999) because the PFS nonfacility PE RVU 
amounts did not reflect the diagnostic radiopharmaceutical costs which 
are paid separately under the MPFS. In addition, as stated in the CY 
2012 OPPS/ASC final rule with comment period (76 FR 74429 through 
74430), because the same issue exists for radiology procedures that use 
contrast agents (the contrast agent is packaged under the ASC payment 
system but is separately paid under the MPFS), we also exempted 
radiology services that use contrast agents from this policy, so that 
payment for these procedures will be based on the OPPS relative payment 
weight which includes the cost for the contrast agent.
    Because its predecessor code was office-based, we have designated 
CPT code 36901 as office-based since it was established in CY 2017. As 
stated in the CY 2018 OPPS/ASC final rule with comment period (82 FR 
59407), we reviewed the clinical characteristics, utilization, and 
volume of related codes and determined that the procedure described by 
CPT code 36901 would be predominantly performed in physician offices. 
However, because we did not have utilization data for this procedure, 
we made the office-based designation temporary rather than permanent 
for CY 2018. Our review of the CY 2017 volume and utilization data 
indicates that CPT code 36901 is performed 54 percent of the time in 
physicians' offices. Our policy is to designate as office-based those 
procedures that are performed more than 50 percent of the time in 
physicians' offices. We do not believe that there is a justification 
for exempting this procedure from office-based status for CY 2019. 
Therefore, we are designating CPT code 36901 as permanently office-
based for CY 2019 as proposed.
    While we assigned CPT codes 10030, 64461, and 64463 payment 
indicators of ``G2'' (Non-office-based surgical procedure added in CY 
2008 or later; payment based on OPPS relative payment weight) in Table 
38 of the CY 2019 OPPS/ASC proposed rule, we inadvertently indicated in 
the preamble of the proposed rule that those were office-based 
procedures (83 FR 37156). We are not designating CPT codes 10030, 
64461, and 64463 as office-based procedures for CY 2019 and are 
finalizing our payment indicator of ``G2'' for such procedures. We note 
that we did not receive any public comments on these codes.
    After consideration of the public comment we received, we are 
finalizing our proposal, with modification, to designate the procedures 
shown in Table 57 below as temporarily office-based for CY 2019.
BILLING CODE 4120-01-P

[[Page 59039]]

[GRAPHIC] [TIFF OMITTED] TR21NO18.083

    For CY 2019, we proposed to designate 8 new CY 2019 CPT codes for 
ASC covered surgical procedures as temporarily office-based, as 
displayed in Table 39 of the proposed rule. After reviewing the 
clinical characteristics, utilization, and volume of related procedure 
codes, we determined that the procedures described by the new CPT codes 
would be predominantly performed in physicians' offices. However, 
because we had no utilization data for the procedures specifically 
described by these new CPT codes, we proposed to make the office-based 
designation temporary rather than permanent, and stated that we will 
reevaluate the procedures when data become available. The procedures 
for which the proposed office-based designation for CY 2019 is 
temporary were indicated by asterisks in Addendum AA to the proposed 
rule (which is available via the internet on the CMS website).
    We did not receive any public comments on our proposal. Therefore, 
we are finalizing our proposal, without modification, to designate the 
procedures shown in Table 58 below as temporarily office-based. The 
procedures for which the office-based designation for CY 2019 is 
temporary are indicated by an asterisk in Addendum AA to this final 
rule with comment period (which is available via the internet on the 
CMS website).

[[Page 59040]]

[GRAPHIC] [TIFF OMITTED] TR21NO18.084

BILLING CODE 4120-01-C
b. ASC Covered Surgical Procedures To Be Designated as Device-Intensive
(1) Background
    As discussed in the CY 2017 OPPS/ASC final rule with comment period 
(81 FR 79739 through 79740), we implemented a payment methodology for 
calculating the ASC payment rates for covered surgical procedures that 
are designated as device-intensive.
    According to this ASC payment methodology, we apply the device 
offset percentage based on the standard OPPS APC ratesetting 
methodology (which does not include the C-APC methodology) to the OPPS 
national unadjusted payment to determine the device cost included in 
the OPPS payment rate for a device-intensive ASC covered surgical 
procedure, which we then set as equal to the device portion of the 
national unadjusted ASC payment rate for the procedure. We calculate 
the service portion of the ASC payment for device-intensive procedures 
by applying the uniform ASC conversion factor to the service (non-
device) portion of the OPPS relative payment weight for the device-
intensive procedure. Finally, we sum the ASC device portion and ASC 
service portion to establish the full payment for the device-intensive 
procedure under the ASC payment system.
    We also finalized in the CY 2017 OPPS/ASC final rule that device-
intensive procedures will be subject to all of the payment policies 
applicable to procedures designated as an ASC device-intensive 
procedure under our established methodology, including our policies on 
no cost/full credit and partial credit devices and discontinued 
procedures.
    In addition, in the CY 2017 OPPS/ASC final rule with comment period 
(81 FR 79739 through 79740), we adopted a policy for new HCPCS codes 
describing procedures involving the implantation of medical devices 
that do not yet have associated claims data, to designate these 
procedures as device-intensive with a default device offset set at 41 
percent until claims data are available to establish the HCPCS code-
level device offset for the procedures. This default device offset 
amount of 41 percent is not calculated from claims data; instead, it

[[Page 59041]]

is applied as a default until claims data are available upon which to 
calculate an actual device offset for the new code. The purpose of 
applying the 41-percent default device offset to new codes that 
describe procedures that involve the implantation of medical devices 
would be to ensure ASC access for new procedures until claims data 
become available. However, in certain rare instances, for example, in 
the case of a very expensive implantable device, we indicated we might 
temporarily assign a higher offset percentage if warranted by 
additional information, such as pricing data from a device 
manufacturer. Once claims data are available for a new procedure 
involving the implantation of a medical device, the device-intensive 
designation is applied to the code if the HCPCS code device offset is 
greater than 40 percent, according to our policy of determining device-
intensive status, by calculating the HCPCS code-level device offset.
(2) Changes to List of ASC Covered Surgical Procedures Designated as 
Device-Intensive for CY 2019
    In the CY 2019 OPPS/ASC proposed rule (83 FR 37158), we noted that, 
as discussed in section IV.B.2. of the proposed rule, for CY 2019 we 
proposed to modify our criteria for device-intensive procedures to 
better capture costs for procedures with significant device costs. We 
proposed to allow procedures that involve surgically inserted or 
implanted, high-cost, single-use devices to qualify as device-intensive 
procedures. In addition, we proposed to modify our criteria to lower 
the device offset percentage threshold from 40 percent to 30 percent. 
Specifically, for CY 2019 and subsequent years, we proposed that 
device-intensive procedures would be subject to the following criteria:
     All procedures must involve implantable devices assigned a 
CPT or HCPCS code;
     The required devices (including single-use devices) must 
be surgically inserted or implanted; and
     The device offset amount must be significant, which is 
defined as exceeding 30 percent of the procedure's mean cost. 
Corresponding to this change in the cost criterion we proposed that the 
default device offset for new codes that describe procedures that 
involve the implantation of medical devices would be 31 percent 
beginning in CY 2019. For new codes describing procedures that are 
payable when furnished in an ASC involving the implantation of a 
medical device, we proposed that the default device offset would be 
applied in the same manner as proposed in section IV.B.2. of the 
proposed rule. We proposed to amend Sec.  416.171(b)(2) of the 
regulations to reflect these new device criteria.
    In addition, as also proposed in section IV.B.2. of the proposed 
rule, to further align the device-intensive policy with the criteria 
used for device pass-through status, we proposed to specify, for CY 
2019 and subsequent years, that for purposes of satisfying the device-
intensive criteria, a device-intensive procedure must involve a device 
that:
     Has received FDA marketing authorization, has received an 
FDA investigational device exemption (IDE) and has been classified as a 
Category B device by the FDA in accordance with 42 CFR 405.203 through 
405.207 and 405.211 through 405.215, or meets another appropriate FDA 
exemption from premarket review;
     Is an integral part of the service furnished;
     Is used for one patient only;
     Comes in contact with human tissue;
     Is surgically implanted or inserted (either permanently or 
temporarily); and
     Is not any of the following:
    (a) Equipment, an instrument, apparatus, implement, or item of this 
type for which depreciation and financing expenses are recovered as 
depreciable assets as defined in Chapter 1 of the Medicare Provider 
Reimbursement Manual (CMS Pub. 15-1); or
    (b) A material or supply furnished incident to a service (for 
example, a suture, customized surgical kit, scalpel, or clip, other 
than a radiological site marker).
    Based on our proposed modifications to our device-intensive 
criteria, for CY 2019, we proposed to update the ASC CPL that are 
eligible for payment according to our proposed device-intensive 
procedure payment methodology, reflecting the proposed individual HCPCS 
code device-offset percentages based on CY 2017 OPPS claims and cost 
report data available for the proposed rule.
    The ASC covered surgical procedures that we proposed to designate 
as device-intensive, and therefore subject to the device-intensive 
procedure payment methodology for CY 2019, were assigned payment 
indicator ``J8'' and were included in ASC Addendum AA to the proposed 
rule (which is available on the CMS website). The CPT code, the CPT 
code short descriptor, and the proposed CY 2019 ASC payment indicator, 
and an indication of whether the full credit/partial credit (FB/FC) 
device adjustment policy would apply because the procedure is 
designated as device intensive also are included in Addendum AA to the 
proposed rule. In addition, for CY 2019, we proposed to only apply our 
proposed device-intensive procedure payment methodology to device-
intensive procedures under the ASC payment system when the device-
intensive procedure is furnished with a surgically inserted or 
implanted device (including single use medical devices). Under this 
proposal, the payment rate under the ASC payment system for device-
intensive procedures furnished without an implantable or inserted 
medical device would be calculated by applying the uniform ASC 
conversion factor to both the device portion and service (nondevice) 
portion of the OPPS relative payment weight for the device-intensive 
procedure and summing both portions (device and service) to establish 
the ASC payment rate.
    Comment: The majority of commenters supported the proposal to lower 
the device offset percentage threshold for procedures to qualify as 
device-intensive from greater than 40 percent to greater than 30 
percent. The commenters believed that the proposed policy change will 
encourage migration of services into the high-quality, less-expensive 
ASC setting, resulting in cost savings to the Medicare program and 
Medicare beneficiaries. Some of these commenters encouraged CMS to 
further modify its proposal and instead lower the device offset 
percentage threshold for procedures to qualify as device-intensive to 
25 percent instead of 30 percent.
    Response: We appreciate commenters' support. At this time, we 
continue to believe that applying a device offset percentage threshold 
of greater than 30 percent for procedures to qualify as device-
intensive is most appropriate for the reasons described in our original 
proposal. We will take commenters' suggestion of applying a device 
offset percentage threshold of greater than 25 percent for procedures 
to qualify as device-intensive into consideration for future 
rulemaking.
    Comment: The majority of commenters supported CMS proposal to 
modify the device-intensive criteria to allow procedures that involve 
single-use devices, regardless of whether they remain in the body after 
the conclusion of the procedure, to qualify as device-intensive 
procedures. The commenters believed that this proposed policy change 
will better support accurate payment for procedures where an 
implantable device is a significant proportion of total costs and, 
ultimately, will spur innovation.

[[Page 59042]]

    Response: We appreciate the commenters' support.
    Comment: One commenter requested that CMS assign device-intensive 
status, payment indicator ``J8'', to CPT codes 0410T (Insertion or 
replacement of permanent cardiac contractility modulation system, 
including contractility evaluation when performed, and programming of 
sensing and therapeutic parameters; pulse generator only), 0411T 
(Insertion or replacement of permanent cardiac contractility modulation 
system, including contractility evaluation when performed, and 
programming of sensing and therapeutic parameters; ventricular 
electrode only), and 0414T (Removal and replacement of permanent 
cardiac contractility modulation system pulse generator only).
    Response: We agree with the commenter's request and have assigned 
CPT codes 0410T, 0411T, and 0414T to payment indicator ``J8'' for CY 
2019. These CPT codes represent procedures requiring the implantation 
of medical devices that do not yet have associated claims data and 
therefore have been granted device-intensive status with our current 
default device offset percentage of 31 percent, in accordance with our 
current policy outlined in the CY 2017 OPPS/ASC final rule with comment 
period (81 FR 79658).
    Comment: A few commenters suggested that CMS only adjust the non-
device portion of the payment by the wage index, consistent with the 
Agency's policy for separately payable drugs and biologicals.
    Response: In response to the commenters' suggestion that CMS only 
adjust the non-device portion of the payment by the wage index, we note 
that such a policy would increase payment for providers with a 
relatively low wage index (that is, a wage index value of less than 1) 
and decrease it for providers with a relatively high wage index (that 
is, a wage index value of greater than 1), and that we did not make 
such a proposal. However, we will take this comment into consideration 
for future rulemaking.
    Comment: A few commenters urged CMS to calculate the device offset 
percentage for potential device-intensive procedures using the standard 
(non-comprehensive APC) ASC ratesetting methodology and to assign 
device-intensive status in the ASC system based on that device offset 
percentage because they believed it is more consistent with the overall 
ASC payment system. One commenter requested some clarification in the 
final rule with comment period about CMS' current methodology for 
calculating the device offset percentage for device-intensive 
procedures and specifically asked that CMS:
     Confirm that the ASC device-intensive status as assigned 
by CMS is based on the offset calculated according to the ASC rate 
setting methodology;
     Disclose what offset data (meaning the calculation 
methodology used) appears in the second spreadsheet of Addendum P 
titled ``2019 NPRM HCPCS Offsets'';
     Display the device offsets, in future rulemaking, based on 
the ASC methodology and not the OPPS methodology if the offset data 
displayed in the second spreadsheet of Addendum P is based on the OPPS 
methodology and device-intensive status is based on the ASC 
methodology; and
     Modify the second worksheet of Addendum P titled ``2019 
NPRM HCPCS Offsets'' to only include the codes for procedures that 
employ implantable and insertable devices and exclude all of the 
irrelevant codes that do not employ implantable or insertable devices.
    Response: As stated in the CY 2019 OPPS/ASC proposed rule (83 FR 
37158), according to our established ASC payment methodology, we apply 
the device offset percentage based on the standard OPPS APC ratesetting 
methodology (which does not include the C-APC methodology) to the OPPS 
national unadjusted payment to determine the device cost included in 
the OPPS payment rate for a device-intensive ASC covered surgical 
procedure, which we then set as equal to the device portion of the 
national unadjusted ASC payment rate for the procedure. We calculate 
the service portion of the ASC payment for device-intensive procedures 
by applying the uniform ASC conversion factor to the service 
(nondevice) portion of the OPPS relative payment weight for the device-
intensive procedure. Finally, we sum the ASC device portion and ASC 
service portion to establish the full payment for the device-intensive 
procedure under the ASC payment system.
    In response to commenter's questions and suggestions relating to 
Addendum P, we note that the device offset percentages reflected in 
both worksheets of Addendum P are based upon the OPPS C-APC 
methodology. We believe this is appropriate as Addendum P is created to 
display the device offsets, device offset percentages, and device-
intensive codes under the OPPS. Specific to the commenter's suggestion 
that we modify the second worksheet of Addendum P titled ``2019 NPRM 
HCPCS Offsets'' to only include the codes for procedures that employ 
implantable and insertable devices and exclude all of the codes that do 
not employ implantable or insertable devices, we note that the second 
worksheet of Addendum P is intended to display the device offsets and 
device offset percentages for all codes for which we have such data for 
under the OPPS. The applicable device offset percentages for the ASC 
payment system are included on the CMS website at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/ASCPayment/ASC-Policy-Files.html under the revised title of ``CY 2019 Final ASC Device Offset 
Percentages and Procedures to which the No Cost/Full Credit and Partial 
Credit Device Adjustment Policy Applies.''
    Comment: Commenters supported the existing policy of granting 
device-intensive status and applying a default device offset to 
procedures requiring devices that do not yet have claims data, as well 
as the proposal to use claims data from clinically similar and related 
codes to establish device offsets for procedures with new codes that do 
not have direct predecessor codes according to CPT.
    Response: We appreciate the commenters' support.
    Comment: Commenters supported CMS' proposed device-intensive status 
for CPT codes:
     28297 (Correction, hallux valgus (bunionectomy), with 
sesamoidectomy, when performed; with first metatarsal and medial 
cuneiform joint arthrodesis, any method);
     28730 (Arthrodesis, midtarsal or tarsometatarsal, multiple 
or transverse;);
     28740 (Arthrodesis, midtarsal or tarsometatarsal, single 
joint);
     36903 (Introduction of needle(s) and/or catheter(s), 
dialysis circuit, with diagnostic angiography of the dialysis circuit, 
including all direct puncture(s) and catheter placement(s), 
injection(s) of contrast, all necessary imaging from the arterial 
anastomosis and adjacent artery through entire venous outflow including 
the inferior or superior vena cava, fluoroscopic guidance, radiological 
supervision and interpretation and image documentation and report; with 
transcatheter placement of intravascular stent(s), peripheral dialysis 
segment, including all imaging and radiological supervision and 
interpretation necessary to perform the stenting, and all angioplasty 
within the peripheral dialysis segment);
     36904 (Percutaneous transluminal mechanical thrombectomy 
and/or infusion for thrombolysis, dialysis circuit, any method, 
including all imaging and radiological supervision and interpretation, 
diagnostic

[[Page 59043]]

angiography, fluoroscopic guidance, catheter placement(s), and 
intraprocedural pharmacological thrombolytic injection(s);); and
     36906 (Percutaneous transluminal mechanical thrombectomy 
and/or infusion for thrombolysis, dialysis circuit, any method, 
including all imaging and radiological supervision and interpretation, 
diagnostic angiography, fluoroscopic guidance, catheter placement(s), 
and intraprocedural pharmacological thrombolytic injection(s); with 
transcatheter placement of intravascular stent(s), peripheral dialysis 
segment, including all imaging and radiological supervision and 
interpretation necessary to perform the stenting, and all angioplasty 
within the peripheral dialysis circuit).
    Other commenters requested that CMS assign device-intensive status 
to--
     HCPCS code C9747 (Ablation of prostate, transrectal, high 
intensity focused ultrasound (hifu), including imaging guidance);
     CPT code 43210 (Esophagogastroduodenoscopy, flexible, 
transoral; with esophagogastric fundoplasty, partial or complete, 
includes duodenoscopy when performed), 0275T (Percutaneous laminotomy/
laminectomy (interlaminar approach) for decompression of neural 
elements, (with or without ligamentous resection, discectomy, 
facetectomy and/or foraminotomy), any method, under indirect image 
guidance (e.g., fluoroscopic, ct), single or multiple levels, 
unilateral or bilateral; lumbar);
     CPT code 55874 (Transperineal placement of biodegradable 
material, peri-prostatic, single or multiple injection(s), including 
image guidance, when performed);
     CPT code 0409T (Insertion or replacement of permanent 
cardiac contractility modulation system, including contractility 
evaluation when performed, and programming of sensing and therapeutic 
parameters; pulse generator only);
     CPT code 0410T (Insertion or replacement of permanent 
cardiac contractility modulation system, including contractility 
evaluation when performed, and programming of sensing and therapeutic 
parameters; atrial electrode only);
     CPT code 0411T (Insertion or replacement of permanent 
cardiac contractility modulation system, including contractility 
evaluation when performed, and programming of sensing and therapeutic 
parameters; ventricular electrode only); and
     CPT code 0414T (Removal and replacement of permanent 
cardiac contractility modulation system pulse generator only).
    Response: We appreciate the commenters' support. With respect to 
the commenters' request that we assign the device-intensive designation 
to HCPCS code C9747 and CPT codes 43210, 0275T, and 55874, we note that 
the device offset percentage for all four of these procedures (as 
identified by the above mentioned HCPCS codes or predecessor codes) is 
not above the 30-percent threshold, and therefore these procedures are 
not eligible to be assigned device-intensive status.
    CPT codes 0409T, 0410T, 0411T, and 0414T were inadvertently omitted 
from the listing of proposed device-intensive procedures in the CY 2019 
OPPS/ASC proposed rule. We are including them as device-intensive 
procedures in this final rule with comment period. CPT code 36904 was 
proposed as a device-intensive procedure. However, using the most 
currently available data for this CY 2019 OPPS/ASC final rule with 
comment period, we determined that its device offset percentage is not 
above the 30-percent threshold, and therefore this procedure is not 
eligible to be assigned device-intensive status.
    For new codes describing procedures that are payable when furnished 
in an ASC involving the implantation of a medical device, we proposed 
that the default device offset would be applied in the same manner as 
proposed in section IV.B.2. of the proposed rule.
    In addition, as also discussed in section IV.B.2. of this final 
rule with comment period, to further align the device-intensive policy 
with the criteria used for device pass-through payment status, we are 
finalizing our proposal to specify, for CY 2019 and subsequent years, 
that for purposes of satisfying the device-intensive criteria, a 
device-intensive procedure must involve a device that:
     Has received FDA marketing authorization, has received an 
FDA investigational device exemption (IDE) and has been classified as a 
Category B device by the FDA in accordance with 42 CFR 405.203 through 
405.207 and 405.211 through 405.215, or meets another appropriate FDA 
exemption from premarket review;
     Is an integral part of the service furnished;
     Is used for one patient only;
     Comes in contact with human tissue;
     Is surgically implanted or inserted (either permanently or 
temporarily); and
     Is not any of the following:
    (a) Equipment, an instrument, apparatus, implement, or item of this 
type for which depreciation and financing expenses are recovered as 
depreciable assets as defined in Chapter 1 of the Medicare Provider 
Reimbursement Manual (CMS Pub. 15-1); or
    (b) A material or supply furnished incident to a service (for 
example, a suture, customized surgical kit, scalpel, or clip, other 
than a radiological site marker).
    In conjunction with our modifications to the device-intensive 
criteria, we are finalizing our proposal, without modification, to 
amend Sec.  416.171(b)(2) of the regulations to reflect three new 
device criteria.
    After consideration of the public comments we received, we are 
finalizing our proposal to modify our criteria for device-intensive 
procedures to better capture costs for procedures with significant 
device costs. We are finalizing our proposal to allow procedures that 
involve surgically inserted or implanted, high-cost, single-use devices 
to qualify as device-intensive procedures. In addition, we are 
finalizing our proposal to modify our criteria to lower the device 
offset percentage threshold from 40 percent to 30 percent. 
Specifically, for CY 2019 and subsequent years, we are finalizing our 
proposal that device-intensive procedures would be subject to the 
following criteria:
     All procedures must involve implantable devices assigned a 
CPT or HCPCS code;
     The required devices (including single-use devices) must 
be surgically inserted or implanted; and
     The device offset amount must be significant, which is 
defined as exceeding 30 percent of the procedure's mean cost. 
Corresponding to this change in the cost criterion we proposed that the 
default device offset for new codes that describe procedures that 
involve the implantation of medical devices would be 31 percent 
beginning in CY 2019.
    Further, after consideration of the public comments we received, we 
are designating the ASC covered surgical procedures displayed in 
Addendum AA as device-intensive and subject to the device-intensive 
procedure payment methodology for CY 2019.
c. Adjustment to ASC Payments for No Cost/Full Credit and Partial 
Credit Devices
    Our ASC payment policy for costly devices implanted in ASCs at no 
cost/full credit or partial credit, as set forth in Sec.  416.179 of 
our regulations, is consistent with the OPPS policy that was in effect 
until CY 2014. Specifically, the OPPS policy that was

[[Page 59044]]

in effect through CY 2013 provided a reduction in OPPS payment by 100 
percent of the device offset amount when a hospital furnishes a 
specified device without cost or with a full credit and by 50 percent 
of the device offset amount when the hospital receives partial credit 
in the amount of 50 percent or more of the cost for the specified 
device (77 FR 68356 through 68358). The established ASC policy reduces 
payment to ASCs when a specified device is furnished without cost or 
with full credit or partial credit for the cost of the device for those 
ASC covered surgical procedures that are assigned to APCs under the 
OPPS to which this policy applies. We refer readers to the CY 2009 
OPPS/ASC final rule with comment period (73 FR 68742 through 68744) for 
a full discussion of the ASC payment adjustment policy for no cost/full 
credit and partial credit devices.
    In the CY 2019 OPPS/ASC proposed rule (83 FR 37159), we noted that, 
as discussed in section IV.B. of the CY 2014 OPPS/ASC final rule with 
comment period (78 FR 75005 through 75006), we finalized our proposal 
to modify our former policy of reducing OPPS payment for specified APCs 
when a hospital furnishes a specified device without cost or with a 
full or partial credit. Formerly, under the OPPS, our policy was to 
reduce OPPS payment by 100 percent of the device offset amount when a 
hospital furnished a specified device without cost or with a full 
credit and by 50 percent of the device offset amount when the hospital 
received partial credit in the amount of 50 percent or more (but less 
than 100 percent) of the cost for the specified device. For CY 2014, we 
finalized our proposal to reduce OPPS payment for applicable APCs by 
the full or partial credit a provider receives for a replaced device, 
capped at the device offset amount.
    Although we finalized our proposal to modify the policy of reducing 
payments when a hospital furnishes a specified device without cost or 
with full or partial credit under the OPPS, in that final rule with 
comment period (78 FR 75076 through 75080), we finalized our proposal 
to maintain our ASC policy for reducing payments to ASCs for specified 
device-intensive procedures when the ASC furnishes a device without 
cost or with full or partial credit. Unlike the OPPS, there is 
currently no mechanism within the ASC claims processing system for ASCs 
to submit to CMS the actual credit received when furnishing a specified 
device at full or partial credit. Therefore, under the ASC payment 
system, we finalized our proposal for CY 2014 to continue to reduce ASC 
payments by 100 percent or 50 percent of the device offset amount when 
an ASC furnishes a device without cost or with full or partial credit, 
respectively.
    All ASC covered device-intensive procedures are subject to the no 
cost/full credit and partial credit device adjustment policy. 
Specifically, when a device-intensive procedure is performed to implant 
a device that is furnished at no cost or with full credit from the 
manufacturer, the ASC would append the HCPCS ``FB'' modifier on the 
line in the claim with the procedure to implant the device. The 
contractor would reduce payment to the ASC by the device offset amount 
that we estimate represents the cost of the device when the necessary 
device is furnished without cost or with full credit to the ASC. We 
continue to believe that the reduction of ASC payment in these 
circumstances is necessary to pay appropriately for the covered 
surgical procedure furnished by the ASC.
    In the CY 2019 OPPS/ASC proposed rule (83 FR 37159 through 37160), 
for partial credit, we proposed to reduce the payment for a device-
intensive procedure for which the ASC receives partial credit by one-
half of the device offset amount that would be applied if a device was 
provided at no cost or with full credit, if the credit to the ASC is 50 
percent or more (but less than 100 percent) of the cost of the new 
device. The ASC would append the HCPCS ``FC'' modifier to the HCPCS 
code for the device-intensive surgical procedure when the facility 
receives a partial credit of 50 percent or more (but less than 100 
percent) of the cost of a device. To report that the ASC received a 
partial credit of 50 percent or more (but less than 100 percent) of the 
cost of a new device, ASCs would have the option of either: (1) 
Submitting the claim for the device replacement procedure to their 
Medicare contractor after the procedure's performance, but prior to 
manufacturer acknowledgment of credit for the device, and subsequently 
contacting the contractor regarding a claim adjustment, once the credit 
determination is made; or (2) holding the claim for the device 
implantation procedure until a determination is made by the 
manufacturer on the partial credit and submitting the claim with the 
``FC'' modifier appended to the implantation procedure HCPCS code if 
the partial credit is 50 percent or more (but less than 100 percent) of 
the cost of the replacement device. Beneficiary coinsurance would be 
based on the reduced payment amount. As finalized in the CY 2015 OPPS/
ASC final rule with comment period (79 FR 66926), to ensure our policy 
covers any situation involving a device-intensive procedure where an 
ASC may receive a device at no cost or receive full credit or partial 
credit for the device, we apply our ``FB''/``FC'' modifier policy to 
all device-intensive procedures.
    We did not receive any public comment on these proposals. 
Therefore, we are finalizing these proposals without modification. 
Specifically, we will apply the HCPCS ``FB''/``FC'' modifier policy to 
all device-intensive procedures in CY 2019. For CY 2019, we will reduce 
the payment for the procedures in the ASC device adjustment file by the 
full device offset amount if a device is furnished without cost or with 
full credit. ASCs must append the HCPCS modifier ``FB'' to the HCPCS 
code for a surgical procedure listed in the ASC device adjustment file 
previously mentioned when the device is furnished without cost or with 
full credit. In addition, for CY 2019, we will reduce the payment for 
the procedures listed in the ASC device adjustment file by one-half of 
the device offset amount if a device is provided with partial credit, 
if the credit to the ASC is 50 percent or more (but less than 100 
percent) of the device cost. The ASC must append the HCPCS ``FC'' 
modifier to the HCPCS code for a surgical procedure listed in the ASC 
device adjustment file when facility receives a partial credit of 50 
percent or more (but less than 100 percent) of the cost of a device.
    The CPT code, the CPT code short descriptor, the final CY 2019 ASC 
payment indicator, and an indication of whether the full credit/partial 
credit (FB/FC) device adjustment policy will apply are included in the 
ASC policy file labeled ``CY 2019 Final ASC Device Offset Percentages 
and Procedures to which the No Cost/Full Credit and Partial Credit 
Device Adjustment Policy Applies'', which is available via the internet 
on the CMS website at: https://www.cms.gov/Medicare?medicare-Fee-for-Service-Payment/ASCPayment/ASC-Policy-Files.html.
d. Additions to the List of ASC Covered Surgical Procedures
    As discussed in section XII.A.3. of the proposed rule (83 FR 
37159), we proposed to revise our definition of surgery for CY 2019 to 
include certain ``surgery-like'' procedures that are assigned codes 
outside the CPT surgical range. For CY 2019, we proposed to include 
procedures that are described by Category I CPT codes that are not in 
the surgical range but directly crosswalk or are clinically similar to 
procedures in

[[Page 59045]]

the Category I CPT code surgical range that we have determined do not 
pose a significant safety risk, would not be expected to require an 
overnight stay when performed in an ASC, and are separately paid under 
the OPPS. We also are continuing to include in our definition of 
surgical procedures those procedures described by Category I CPT codes 
in the surgical range from 10000 through 69999 as well as those 
Category III CPT codes and Level II HCPCS codes that directly crosswalk 
or are clinically similar to procedures in the CPT surgical range that 
we have determined do not pose a significant safety risk, that we would 
not expect to require an overnight stay when performed in ASCs, and 
that are separately paid under the OPPS. As discussed in section 
XII.A.3. of this final rule with comment period, we are finalizing our 
proposal to revise our definition of ``surgery'' for CY 2019 and 
subsequent years to include procedures that are described by Category I 
CPT codes that are not in the CPT surgical range but directly crosswalk 
or are clinically similar to procedures in the Category I CPT code 
surgical range that we have determined do not pose a significant safety 
risk, would not be expected to require an overnight stay when performed 
in an ASC, and are separately paid under the OPPS.
    We conducted a review of HCPCS codes that currently are paid under 
the OPPS, but not included on the ASC CPL, and that meet our proposed 
definition of surgery to determine if changes in technology and/or 
medical practice affected the clinical appropriateness of these 
procedures for the ASC setting. Based on this review, we proposed to 
update the list of ASC covered surgical procedures by adding 12 cardiac 
catheterization procedures to the list for CY 2019, as shown in Table 
40 of the proposed rule (83 FR 37160). After reviewing the clinical 
characteristics of these procedures and consulting with stakeholders 
and our clinical advisors, we determined that these 12 procedures are 
separately paid under the OPPS, would not be expected to pose a 
significant risk to beneficiary safety when performed in an ASC, and 
would not be expected to require active medical monitoring and care of 
the beneficiary at midnight following the procedure. Our regulation at 
42 CFR 416.166(c) lists general exclusions from the list of ASC covered 
surgical procedures based primarily on factors relating to safety, 
including procedures that generally result in extensive blood loss, 
require major or prolonged invasion of body cavities, or directly 
involve major blood vessels. We have assessed each of the proposed 
added procedures against the regulatory safety criteria and believe 
that these procedures meet each of the criteria. Although the proposed 
cardiac catheterization procedures may involve blood vessels that could 
be considered major, based on our review of the clinical 
characteristics of the procedures and their similarity to other 
procedures that are currently included on the ASC CPL, we believe these 
procedures may be appropriately performed in an ASC. Therefore, we 
proposed to include these 12 procedures on the list of ASC covered 
surgical procedures for CY 2019.
    As stated in the August 2, 2007 ASC final rule (72 FR 42481), we 
believe the involvement of major blood vessels is best considered in 
the context of the clinical characteristics of individual procedures, 
and we do not believe that it is logically or clinically consistent to 
exclude certain cardiac procedures from the list of ASC covered 
surgical procedures on the basis of the involvement of major blood 
vessels, yet continue to provide ASC payment for similar procedures 
involving major blood vessels that have a history of safe performance 
in ASCs, such as CPT code 36473 (Mechanicochemical destruction of 
insufficient vein of arm or leg, accessed through the skin using 
imaging guidance) and CPT code 37223 (Insertion of stents into groin 
artery, endovascular, accessed through the skin or open procedure). 
However, in the CY 2019 proposed rule, we stated that we were 
interested in hearing any specific safety concerns from stakeholders 
regarding these 12 cardiac catheterization procedures and requested 
comments on whether these procedures may be safely performed in an ASC 
in light of the regulatory criteria governing which procedures may be 
added to the ASC covered procedures list.
    Comment: The majority of commenters supported the proposal to add 
12 cardiac catheterization procedures to the list of ASC covered 
surgical procedures. Commenters noted that these procedures may be 
performed in a physician office setting, would not inherently pose a 
significant risk to beneficiary safety or require active medical 
monitoring at midnight following the procedure, and are regularly 
performed on commercial patients in the ASC setting. The commenters 
also noted that many of these services are currently provided in a 
hospital outpatient setting and, therefore, the Medicare program and 
beneficiaries would achieve savings to the extent such services migrate 
to the ASC setting.
    Some commenters were concerned that the proposal would expose 
beneficiaries to significant risks. The commenters noted that certain 
cardiac catheterization procedures may reveal blockages in the coronary 
arteries that require an immediate intervention involving hospital-
level care. One commenter requested that CMS ensure that the same 
facility standards that apply to hospital-based cardiac catheterization 
laboratories also apply to ASCs performing these services. The 
commenter further stated that CMS should not add any cardiac 
catheterization procedures to the list of ASC covered services until it 
has ensured that the conditions of coverage and accreditation 
requirements that would be applied to ASCs furnishing such services are 
at least as stringent as the standards applied to hospital cardiac 
catheterization labs, with additional attention to the issues created 
by engaging in procedures involving the major vessels and the heart 
without the immediate accessibility of the facilities of an acute care 
hospital. In addition, the commenters suggested that the proposal may 
lead to ``cherry-picking'' with a sicker, more complex, and higher cost 
patient population being treated in the hospital outpatient setting.
    Response: We appreciate the commenters' support. We disagree with 
the commenters that our proposal to add 12 cardiac catheterization 
procedures would expose beneficiaries to significant risks. As noted by 
many of the commenters, many of these procedures are already performed 
safely in the physician's office setting. The procedures have been 
reviewed by CMS medical officers and we have assessed each against the 
regulatory safety criteria and believe that they meet all of those 
criteria. Further, we believe these procedures are clinically similar 
to peripheral endovascular procedures which are already currently 
included on the ASC CPL.
    As stated in the proposed rule, although the proposed cardiac 
catheterization procedures may involve blood vessels that could be 
considered major, based on our review of the clinical characteristics 
of the procedures and their similarity to other procedures that are 
currently included on the ASC CPL, we believe these procedures may be 
appropriately performed in an ASC. While we acknowledge that it may be 
more appropriate for certain beneficiaries to receive these procedures 
in a hospital-level setting, which typically have a greater range of 
items and services available when compared

[[Page 59046]]

to an ASC setting, including onsite cardiac surgery backup, we believe 
that many beneficiaries could be ideal candidates to receive these 
services in an ASC setting and that beneficiaries and their physicians 
should be able to choose an appropriate site of service for surgeries 
based on the clinical characteristics of the patient and other factors. 
We also note that our conditions of coverage for ASCs, including 42 CFR 
416.42, require surgical procedures to be performed in a safe manner by 
qualified physicians who have been granted clinical privileges by the 
governing body of the ASC in accordance with approved policies and 
procedures of the ASC.
    While we agree with commenters that a relatively healthier and less 
complex Medicare patient population would, in general, be a more ideal 
patient population to receive cardiac catheterization procedures in an 
ASC setting, we disagree that we should prohibit such procedures on 
that basis. We believe that relatively healthy and less complex 
patients would benefit from the shorter length of stay and reduced 
cost-sharing that would be expected in an ASC setting.
    Comment: Commenters recommended that CMS add additional 
cardiovascular procedures that are related to the proposed additions to 
the ASC CPL. The commenters' recommended codes are shown in Table 59 
below.

BILLING CODE 4120-01-P

[[Page 59047]]

[GRAPHIC] [TIFF OMITTED] TR21NO18.085


[[Page 59048]]


[GRAPHIC] [TIFF OMITTED] TR21NO18.086


[[Page 59049]]


[GRAPHIC] [TIFF OMITTED] TR21NO18.087


[[Page 59050]]


[GRAPHIC] [TIFF OMITTED] TR21NO18.088

BILLING CODE 4120-01-C

    Response: We appreciate the commenters' recommendations for 
procedures that may be suitable candidates for addition to the list of 
ASC covered surgical procedures. We have reviewed the recommended 
procedures and believe some procedures would not be expected to pose a 
significant risk to beneficiary safety when performed in an ASC, would 
not be expected to require active medical monitoring and care of the 
beneficiary at midnight following the procedure, and are separately 
paid under the OPPS. Therefore, we are accepting the commenters' 
recommendation, in part, to include the following procedures to our 
list of ASC covered surgical procedures:
     CPT code 93566 (Injection procedure during cardiac 
catheterization including imaging supervision, interpretation, and 
report; for selective right ventricular or right atrial angiography 
(list separately in addition to code for primary procedure));
     CPT code 93567 Injection procedure during cardiac 
catheterization including imaging supervision, interpretation, and 
report; for supravalvular aortography (list separately in addition to 
code for primary procedure);
     CPT code 93568 (Injection procedure during cardiac 
catheterization including imaging supervision, interpretation, and 
report; for pulmonary angiography (list separately in addition to code 
for primary procedure));
     CPT code 93571 Intravascular doppler velocity and/or 
pressure derived coronary flow reserve measurement (coronary vessel or 
graft) during coronary angiography including pharmacologically induced 
stress; initial vessel (list separately in addition to code for primary 
procedure);
     CPT code 93572 Intravascular doppler velocity and/or 
pressure derived coronary flow reserve measurement (coronary vessel or 
graft) during coronary angiography including pharmacologically induced 
stress; each additional vessel (list separately in addition to code for 
primary procedure).
    However, we do not believe that the remaining procedures displayed 
in Table 59 above meet the criteria to be added to the ASC CPL. If new 
evidence, clinical studies, or data become available that may support 
adding such procedures to the ASC CPL, we will

[[Page 59051]]

consider the commenters' recommendations in future rulemaking.
    Comment: Commenters recommended that CMS add several additional 
procedures to the covered surgical procedures list that were not 
proposed to be added to the ASC CPL. These included discography, wound 
therapy, joint replacement, urological, gastroenterological, and 
peripheral arterial disease diagnostic procedures. Some commenters 
suggested that any procedure that is payable under the OPPS should 
automatically be added to the ASC CPL.
    Response: We appreciate the commenters' recommendations. Based on 
our review, we did not determine that any of these procedures should be 
added to the ASC CPL for CY 2019, however, we recognize that ongoing 
review is necessary to determine if changes in technology and/or 
medical practice affect the clinical appropriateness of these 
procedures for the ASC setting. Accordingly, while we are not adding 
the recommended procedures to the ASC CPL for CY 2019, we will take 
these public comments into consideration in future rulemaking. With 
respect to automatically adding procedures that are payable under the 
OPPS, we note that we must evaluate each procedure against the 
regulatory criteria for inclusion on the ASC CPL; therefore, we are not 
accepting this recommendation.
    After consideration of the public comments we received, we are 
finalizing our proposal to add 12 cardiac catheterization procedures to 
the list of ASC covered surgical procedures. In addition, based on 
public comments, we are adding five procedures performed during cardiac 
catheterization procedures to the list of ASC covered surgical 
procedures (CPT codes 93566, 93567, 93568, 93571, and 93572). We 
believe these procedures would not be expected to pose a significant 
risk to beneficiary safety when performed in an ASC, would not be 
expected to require active medical monitoring and care of the 
beneficiary at midnight following the procedure and are separately paid 
under the OPPS. The 17 procedures that we are adding to the ASC CPL, 
including the long code descriptors and the final CY 2019 payment 
indicators, are displayed in Table 60 below.

BILLING CODE 4120-01-P

[[Page 59052]]

[GRAPHIC] [TIFF OMITTED] TR21NO18.089


[[Page 59053]]


[GRAPHIC] [TIFF OMITTED] TR21NO18.090


[[Page 59054]]


[GRAPHIC] [TIFF OMITTED] TR21NO18.091

BILLING CODE 4120-01-C
e. Review of Recently Added Procedures to the ASC Covered Procedures 
List
    Section 1833(i)(1) of the Act requires us to specify, in 
consultation with appropriate medical organizations, surgical 
procedures that are appropriately performed on an inpatient basis in a 
hospital but that can be safely performed in an ASC, a CAH, or an HOPD 
and to review and update the list of ASC procedures at least every 2 
years. As noted in section XII.C.1. of the CY 2019 OPPS/ASC proposed 
rule, we evaluate the ASC covered procedures list (ASC CPL) each year 
to determine whether procedures should be added or removed from the 
list, and changes to the list are often made in response to specific 
concerns raised by stakeholders. Often, when a procedure is added to 
the ASC CPL, the provider community has limited experience in 
performing the procedure on the Medicare population, even if providers 
have greater experience with other patient populations. Because ASCs 
generally provide a subset of items and services that are offered by 
hospitals and because Medicare beneficiaries tend to be frailer and 
exhibit a higher number of comorbidities than other populations, we 
believe it may be appropriate to reevaluate recently added procedures.
    Specifically, in the CY 2019 OPPS/ASC proposed rule (83 FR 37161 
through 37162), we proposed to review all procedures that were added to 
the ASC CPL within the 3 calendar years prior to the year in which we 
are engaging in rulemaking to assess the safety, effectiveness, and 
beneficiary experience of these newly added procedures when performed 
in the ASC setting. Our review began with procedures added to the ASC 
CPL in CYs 2015, 2016, and 2017, to assess whether newly added 
procedures continue to meet our criteria, including whether they 
continue not to be expected to pose a significant safety risk to a 
Medicare beneficiary when performed in an ASC and continue not to be 
expected to require active medical monitoring and care of the 
beneficiary at midnight following the procedure. This review included 
taking into account recent clinical developments and available safety 
findings related to the recently added procedures.
    We proposed to review all 38 procedures that were added to the ASC 
CPL for CYs 2015, 2016, and 2017. The 38 procedures that were added to 
the ASC CPL during this time were displayed in Table 41 of the proposed 
rule (82 FR 37161 through 37162), along with their HCPCS code long 
descriptors, the CY 2018 payment indicators, and the calendar year that 
each procedure was added to the ASC CPL. We also sought public comment 
about these recently added procedures from members of the public, 
including Medicare beneficiaries, ASCs, and physicians performing these 
procedures in the ASC setting. In addition, we sought public comment on 
whether these procedures continue to meet the criteria to remain on the 
ASC CPL. We stated our intent to evaluate each of these 38 procedures 
using all available data, including clinical characteristics, 
utilization reflected in ASC claims and pricing data, prevailing 
medical practice, and any public comments we received to determine 
whether they continue to meet the criteria to be a covered surgical 
procedure.
    In addition, we solicited public comment regarding how our 
systematic review should be structured in the future, including the 
length of time procedures should be considered recently added, how 
frequently reviews should be performed in light of the time required to 
accumulate meaningful data and whether any future reviews should 
examine procedures added during a period of time greater or less than 
the previous 3 completed calendar years.
    Comment: Many commenters supported the proposal to review 
procedures that were recently added to the ASC CPL. A number of 
commenters (patients and providers) noted that the procedures shown in 
Table 41 of the proposed rule can be safely and effectively performed 
in an ASC setting and recommended retaining the procedures on the ASC 
CPL. One commenter also noted that CPT codes 0171T (Insertion of 
posterior spinous process distraction device (including necessary 
removal of bone or ligament for insertion and imaging guidance), 
lumbar; single level) and 0172T (Insertion of posterior spinous process 
distraction device (including necessary removal of bone or ligament for 
insertion and imaging guidance), lumbar; each additional level) were 
deleted as of January 1, 2017.
    A number of commenters believed there may not be enough data on the 
38 procedures to adequately assess if the procedures continue to meet 
the criteria to remain on the ASC CPL. The commenters recommended 
reviewing procedures on the CPL after the procedure has been added to 
the CPL for a minimum of 3 to 5 years.
    Further, commenters requested additional information regarding the 
methodology and supporting materials that CMS would use to determine 
that a procedure should no longer remain on the ASC CPL. The commenters 
requested that stakeholders receive appropriate notice that CMS is

[[Page 59055]]

proposing to remove a procedure so that stakeholders have an 
opportunity to comment.
    Response: We appreciate the commenters' feedback regarding the 
safety and efficacy of these procedures in the ASC setting. We note 
that we did not receive any public comments in support of removing 
these recently added procedures from the ASC CPL.
    We note that CPT codes 0171T and 0172T were inadvertently included 
in Table 41 of the proposed rule. These codes were deleted effective 
January 1, 2017, and no longer remain on the ASC CPL. In our evaluation 
of the remaining 36 procedures, we did not find any clinical evidence, 
data, or other materials to justify removing these procedures from the 
ASC CPL. Therefore, for CY 2019, we are not removing any of the 
remaining 36 procedures displayed in Table 41 of the proposed rule from 
the ASC CPL.
    In response to commenters' recommendation to wait a minimum of 3 to 
5 years to assess whether a procedure meets our criteria to remain on 
the ASC CPL, we agree that a longer timeframe may provide better data 
to adequately determine whether or not the procedure meets our 
criteria. We will consider the commenters' recommendations in future 
rulemaking.
    In response to the commenters' request for additional information 
regarding the methodology and supporting materials that we would use to 
determine that a procedure no longer meets the criteria to remain on 
the ASC CPL, we note that in the CY 2019 OPPS/ASC proposed rule (83 FR 
37161), we stated our intent to evaluate each of the procedures using 
all available data, including clinical characteristics, utilization 
reflected in ASC claims and pricing data, prevailing medical practice, 
and any public comments we receive.
    After consideration of the public comments we received, we are 
retaining the procedures displayed in Table 61 on the ASC CPL for CY 
2019, with the exception of CPT codes 0171T and 0172T, which were 
deleted from the ASC CPL effective January 1, 2017 and, therefore, will 
not be included on the ASC CPL for CY 2019. However, based on the 
public comments we received about the re-review process generally, we 
do not believe it is necessary to finalize any proposal regarding 
ongoing reviews of recently added procedures at this time. Rather, we 
will take all commenters' suggestions into account as we consider 
future refinements to our review of the ASC CPL.
BILLING CODE 4120-01-P

[[Page 59056]]

[GRAPHIC] [TIFF OMITTED] TR21NO18.092


[[Page 59057]]


[GRAPHIC] [TIFF OMITTED] TR21NO18.093


[[Page 59058]]


[GRAPHIC] [TIFF OMITTED] TR21NO18.094


[[Page 59059]]


[GRAPHIC] [TIFF OMITTED] TR21NO18.095


[[Page 59060]]


[GRAPHIC] [TIFF OMITTED] TR21NO18.096


[[Page 59061]]


[GRAPHIC] [TIFF OMITTED] TR21NO18.097


[[Page 59062]]


[GRAPHIC] [TIFF OMITTED] TR21NO18.098

BILLING CODE 4120-01-C
2. Covered Ancillary Services
    In the CY 2019 OPPS/ASC proposed rule (83 FE 37163), consistent 
with the established ASC payment system policy (72 FR 42497), we 
proposed to update the ASC list of covered ancillary services to 
reflect the payment status for the services under the CY 2019 OPPS. 
Maintaining consistency with the OPPS may result in proposed changes to 
ASC payment indicators for some covered ancillary services because of 
changes that we proposed under the OPPS for CY 2019. For example, if a 
covered ancillary service was separately paid under the ASC payment 
system in CY 2018, but is proposed for packaged status under the CY 
2019 OPPS, to maintain consistency with the OPPS, we also proposed to 
package the ancillary service under the ASC payment system for CY 2019. 
We proposed to continue this reconciliation of packaged status for 
subsequent calendar years. Comment indicator ``CH'', which is discussed 
in section XII.F. of the proposed rule, was used in Addendum BB to the 
proposed rule (which is available via the internet on the CMS website) 
to indicate covered ancillary services for which we proposed a change 
in the ASC payment indicator to reflect a proposed change in the OPPS 
treatment of the service for CY 2019.

[[Page 59063]]

    All ASC covered ancillary services and their proposed payment 
indicators for CY 2019 were included in Addendum BB to the proposed 
rule (which is available via the internet on the CMS website).
    We did not receive any public comments on these proposals. 
Therefore, we are finalizing, without modification, our proposal to 
update the ASC list of covered ancillary services to reflect the 
payment status for the services under the OPPS. All CY 2019 ASC covered 
ancillary services and their final payment indicators are included in 
Addendum BB to this final rule with comment period (which is available 
via the internet on the CMS website).

D. ASC Payment for Covered Surgical Procedures and Covered Ancillary 
Services

1. ASC Payment for Covered Surgical Procedures
a. Background
    Our ASC payment policies for covered surgical procedures under the 
revised ASC payment system are fully described in the CY 2008 OPPS/ASC 
final rule with comment period (72 FR 66828 through 66831). Under our 
established policy, we use the ASC standard ratesetting methodology of 
multiplying the ASC relative payment weight for the procedure by the 
ASC conversion factor for that same year to calculate the national 
unadjusted payment rates for procedures with payment indicators ``G2'' 
and ``A2''. Payment indicator ``A2'' was developed to identify 
procedures that were included on the list of ASC covered surgical 
procedures in CY 2007 and, therefore, were subject to transitional 
payment prior to CY 2011. Although the 4-year transitional period has 
ended and payment indicator ``A2'' is no longer required to identify 
surgical procedures subject to transitional payment, we retained 
payment indicator ``A2'' because it is used to identify procedures that 
are exempted from the application of the office-based designation.
    The rate calculation established for device-intensive procedures 
(payment indicator ``J8'') is structured so that the packaged device 
payment amount is the same as under the OPPS, and only the service 
portion of the rate is subject to the ASC standard ratesetting 
methodology. In the CY 2017 OPPS/ASC final rule with comment period (81 
FR 79732 through 79753), we updated the CY 2016 ASC payment rates for 
ASC covered surgical procedures with payment indicators of ``A2'', 
``G2'', and ``J8'' using CY 2015 data, consistent with the CY 2017 OPPS 
update. We also updated payment rates for device-intensive procedures 
to incorporate the CY 2017 OPPS device offset percentages calculated 
under the standard APC ratesetting methodology, as discussed earlier in 
this section.
    Payment rates for office-based procedures (payment indicators 
``P2'', ``P3'', and ``R2'') are the lower of the PFS nonfacility PE 
RVU-based amount (we refer readers to the CY 2018 PFS proposed and 
final rules) or the amount calculated using the ASC standard rate 
setting methodology for the procedure. In the CY 2018 OPPS/ASC final 
rule with comment period, we updated the payment amounts for office-
based procedures (payment indicators ``P2'', ``P3'', and ``R2'') using 
the most recent available MPFS and OPPS data. We compared the estimated 
CY 2018 rate for each of the office-based procedures, calculated 
according to the ASC standard rate setting methodology, to the PFS 
nonfacility PE RVU-based amount to determine which was lower and, 
therefore, would be the CY 2018 payment rate for the procedure under 
our final policy for the revised ASC payment system (Sec.  416.171(d)).
    In the CY 2014 OPPS/ASC final rule with comment period (78 FR 
75081), we finalized our proposal to calculate the CY 2014 payment 
rates for ASC covered surgical procedures according to our established 
methodologies, with the exception of device removal procedures. For CY 
2014, we finalized a policy to conditionally package payment for device 
removal codes under the OPPS. Under the OPPS, a conditionally packaged 
code (status indicators ``Q1'' and ``Q2'') describes a HCPCS code where 
the payment is packaged when it is provided with a significant 
procedure but is separately paid when the service appears on the claim 
without a significant procedure. Because ASC services always include a 
covered surgical procedure, HCPCS codes that are conditionally packaged 
under the OPPS are always packaged (payment indicator ``N1'') under the 
ASC payment system. Under the OPPS, device removal procedures are 
conditionally packaged and, therefore, would be packaged under the ASC 
payment system. There would be no Medicare payment made when a device 
removal procedure is performed in an ASC without another surgical 
procedure included on the claim; therefore, no Medicare payment would 
be made if a device was removed but not replaced. To address this 
concern, for the device removal procedures that are conditionally 
packaged in the OPPS (status indicator ``Q2''), we assigned the current 
ASC payment indicators associated with these procedures and continued 
to provide separate payment since CY 2014.
b. Update to ASC Covered Surgical Procedure Payment Rates for CY 2019
    In the CY 2019 OPPS/ASC proposed rule (83 FR 37163 through 37164), 
we proposed to update ASC payment rates for CY 2019 and subsequent 
years using the established rate calculation methodologies under Sec.  
416.171 and using our definition of device-intensive procedures, as 
discussed in section XII.C.1.b. of the proposed rule. Because the 
proposed OPPS relative payment weights are based on geometric mean 
costs, the ASC system would use geometric means to determine proposed 
relative payment weights under the ASC standard methodology. We 
proposed to continue to use the amount calculated under the ASC 
standard ratesetting methodology for procedures assigned payment 
indicators ``A2'' and ``G2''.
    We proposed to calculate payment rates for office-based procedures 
(payment indicators ``P2'', ``P3'', and ``R2'') and device-intensive 
procedures (payment indicator ``J8'') according to our established 
policies and, for device-intensive procedures, using our modified 
definition of device-intensive procedures, as discussed in section 
XII.C.1.b. of the proposed rule. Therefore, we proposed to update the 
payment amount for the service portion of the device-intensive 
procedures using the ASC standard rate setting methodology and the 
payment amount for the device portion based on the proposed CY 2019 
OPPS device offset percentages that have been calculated using the 
standard OPPS APC ratesetting methodology. Payment for office-based 
procedures would be at the lesser of the proposed CY 2019 MPFS 
nonfacility PE RVU-based amount or the proposed CY 2018 ASC payment 
amount calculated according to the ASC standard ratesetting 
methodology.
    As we did for CYs 2014 through 2018, for CY 2019, we proposed to 
continue our policy for device removal procedures, such that device 
removal procedures that are conditionally packaged in the OPPS (status 
indicators ``Q1'' and ``Q2'') would be assigned the current ASC payment 
indicators associated with these procedures and would continue to be 
paid separately under the ASC payment system.
    Comment: One commenter recommended that CMS change CPT code 0356T 
(Insertion of drug delivery implant into tear ducts) from payment 
indicator ``N1'' to ``R2.''
    Response: We note that, in the CY 2019 OPPS/ASC proposed rule, we

[[Page 59064]]

proposed to assign CPT code 0356T a status indicator of ``Q1'' under 
the OPPS. As stated in the CY 2019 OPPS/ASC proposed rule (83 FR 37163 
through 37164), HCPCS codes that are conditionally packaged under the 
OPPS (status indicators ``Q1'' and ``Q2'') and are not a device removal 
procedure are always packaged (payment indicator ``N1'') under the ASC 
payment system. Therefore, we are finalizing our proposal to assign 
payment indicator ``N1'' to CPT code 0356T under the ASC payment system 
for CY 2019.
    Comment: Several commenters disagreed with the proposed CY 2019 ASC 
payment rates for the surgical procedures described by the following 
CPT/HCPCS codes:
     CPT code 22513 (Injection of bone cement into body of 
middle spine bone accessed through the skin using imaging guidance);
     CPT code 22514 (Injection of bone cement into body of 
lower spine bone accessed through the skin using imaging guidance);
     CPT code 43210 (Diagnostic examination of esophagus, 
stomach, and/or upper small bowel with repair of muscle at esophagus 
and stomach using an endoscope);
     CPT code 62264 (Injection or mechanical removal of spinal 
canal scar tissue, percutaneous procedure, accessed through the skin, 
multiple sessions in 1 day);
     CPT code 62321 (Injection of substance into spinal canal 
of upper or middle back using imaging guidance);
     CPT code 62323 (Injection of substance into spinal canal 
of lower back or sacrum using imaging guidance);
     CPT code 62380 (Decompression of spinal cord and/or nerve 
root in lower back using endoscope);
     CPT code 63650 (Implantation of spinal neurostimulator 
electrodes, accessed through the skin);
     CPT code 63685 (Insertion of spinal neurostimulator pulse 
generator or receiver); and
     HCPCS code C9749 (Repair of nasal vestibular lateral wall 
stenosis with implant(s)).
    Some commenters noted that payment rates for some of these 
procedures are lower than their payment levels from several years ago. 
Other commenters suggested that the cost of the procedure significantly 
exceeds Medicare's payment and questioned the validity of some of the 
hospital cost data on which the ASC payment rates were based.
    Response: We are required by law to review and update the data on 
which we establish payment rates on an annual basis. The ASC payment is 
dependent upon the APC assignment for the procedure. Based on our 
analysis of the latest hospital outpatient and ASC claims data used for 
this final rule with comment period, we are updating ASC payment rates 
for CY 2019 using the established rate calculation methodologies under 
Sec.  416.171 of the regulations and using our finalized modified 
definition of device-intensive procedures, as discussed in section 
XII.C.1.b. of this final rule with comment period. We do not generally 
make additional payment adjustments to specific procedures. As such, we 
are finalizing the APC assignment and payment indicators for CPT codes 
22513, 22514, 43210, 62264, 62321, 62323, 62380, 63650, 63685, and 
C9749.
    Comment: One commenter recommended that the ASC payment system 
allow procedures conditionally packaged under the OPPS (status 
indicator ``Q1'' and ``Q2'') to be paid separately under the ASC 
payment system when they are performed with another procedure. The 
commenters also suggest that certain conditionally packaged codes are 
performed without another major procedure more than half of the time.
    Response: Under the OPPS, a conditionally packaged code describes a 
HCPCS code where the payment is packaged when it is provided with a 
significant procedure but is separately paid when the service appears 
on the claim without a significant procedure. Because ASC services 
always include a surgical procedure, HCPCS codes that are conditionally 
packaged under the OPPS, and which are not device removal procedures, 
are always packaged (payment indicator ``N1'') under the ASC payment 
system, no matter how frequently they are billed without a significant 
procedure under the OPPS. Therefore, we are not accepting this 
recommendation.
    Comment: One commenter recommended that CMS eliminate the 
prohibition against billing for services using an unlisted CPT surgical 
procedure code.
    Response: Under 42 CFR 416.166(c)(7), covered surgical procedures 
do not include procedures that can only be reported using a CPT 
unlisted surgical procedure code. Therefore, such procedures are not 
payable under the ASC payment system. As discussed in the August 2, 
2008 final rule (72 FR 42484 through 42486), it is not possible to know 
what specific procedure would be represented by an unlisted code. CMS 
is required to evaluate each surgical procedure for potential safety 
risk and the expected need for overnight monitoring and to exclude such 
procedures from ASC payment. It is not possible to evaluate procedures 
that would be reported by unlisted CPT codes according to these 
criteria. Therefore, we are not accepting this recommendation.
    After consideration of the public comments we received, we are 
finalizing our proposed policies, without modification, to calculate 
the CY 2019 payment rates for ASC covered surgical procedures according 
to our established methodologies using the modified definition of 
device-intensive procedures. For those covered office-based surgical 
procedures where the payment rate is the lower of the final rates under 
the ASC standard ratesetting methodology and the PFS nonfacility PE 
RVU-based amount, the final payment indicators and rates set forth in 
this final rule with comment period are based on a comparison using the 
PFS PE RVUs and the conversion factor effective January 1, 2019. For a 
discussion of the PFS rates, we refer readers to the CY 2019 PFS final 
rule with comment period.
2. Payment for Covered Ancillary Services
a. Background
    Our payment policies under the ASC payment system for covered 
ancillary services vary according to the particular type of service and 
its payment policy under the OPPS. Our overall policy provides separate 
ASC payment for certain ancillary items and services integrally related 
to the provision of ASC covered surgical procedures that are paid 
separately under the OPPS and provides packaged ASC payment for other 
ancillary items and services that are packaged or conditionally 
packaged (status indicators ``N'', ``Q1'', and ``Q2'') under the OPPS. 
In the CY 2013 OPPS/ASC rulemaking (77 FR 45169 and 77 FR 68457 through 
68458), we further clarified our policy regarding the payment indicator 
assignment of codes that are conditionally packaged in the OPPS (status 
indicators ``Q1'' and ``Q2''). Under the OPPS, a conditionally packaged 
code describes a HCPCS code where the payment is packaged when it is 
provided with a significant procedure but is separately paid when the 
service appears on the claim without a significant procedure. Because 
ASC services always include a surgical procedure, HCPCS codes that are 
conditionally packaged under the OPPS are generally packaged (payment 
indictor ``N1'') under the ASC payment system (except for device 
removal codes, as discussed in section IV. of the proposed rule). Thus, 
our policy

[[Page 59065]]

generally aligns ASC payment bundles with those under the OPPS (72 FR 
42495). In all cases, in order for those ancillary services also to be 
paid, ancillary items and services must be provided integral to the 
performance of ASC covered surgical procedures for which the ASC bills 
Medicare.
    Our ASC payment policies generally provide separate payment for 
drugs and biologicals that are separately paid under the OPPS at the 
OPPS rates. We generally pay for separately payable radiology services 
at the lower of the PFS nonfacility PE RVU-based (or technical 
component) amount or the rate calculated according to the ASC standard 
ratesetting methodology (72 FR 42497). However, as finalized in the CY 
2011 OPPS/ASC final rule with comment period (75 FR 72050), payment 
indicators for all nuclear medicine procedures (defined as CPT codes in 
the range of 78000 through 78999) that are designated as radiology 
services that are paid separately when provided integral to a surgical 
procedure on the ASC list are set to ``Z2'' so that payment is made 
based on the ASC standard ratesetting methodology rather than the MPFS 
nonfacility PE RVU amount (``Z3''), regardless of which is lower. 42 
CFR 416.171(d)(1).
    Similarly, we also finalized our policy to set the payment 
indicator to ``Z2'' for radiology services that use contrast agents so 
that payment for these procedures will be based on the OPPS relative 
payment weight using the ASC standard ratesetting methodology and, 
therefore, will include the cost for the contrast agent. 42 CFR 
416.171(d)(2).
    ASC payment policy for brachytherapy sources mirrors the payment 
policy under the OPPS. ASCs are paid for brachytherapy sources provided 
integral to ASC covered surgical procedures at prospective rates 
adopted under the OPPS or, if OPPS rates are unavailable, at 
contractor-priced rates (72 FR 42499). Since December 31, 2009, ASCs 
have been paid for brachytherapy sources provided integral to ASC 
covered surgical procedures at prospective rates adopted under the 
OPPS.
    Our ASC policies also provide separate payment for: (1) Certain 
items and services that CMS designates as contractor-priced, including, 
but not limited to, the procurement of corneal tissue; and (2) certain 
implantable items that have pass-through payment status under the OPPS. 
These categories do not have prospectively established ASC payment 
rates according to ASC payment system policies (72 FR 42502 and 42508 
through 42509; 42 CFR 416.164(b)). Under the ASC payment system, we 
have designated corneal tissue acquisition and hepatitis B vaccines as 
contractor-priced. Corneal tissue acquisition is contractor-priced 
based on the invoiced costs for acquiring the corneal tissue for 
transplantation. Hepatitis B vaccines are contractor-priced based on 
invoiced costs for the vaccine.
    Devices that are eligible for pass-through payment under the OPPS 
are separately paid under the ASC payment system and are contractor-
priced. Under the revised ASC payment system (72 FR 42502), payment for 
the surgical procedure associated with the pass-through device is made 
according to our standard methodology for the ASC payment system, based 
on only the service (non-device) portion of the procedure's OPPS 
relative payment weight if the APC weight for the procedure includes 
other packaged device costs. We also refer to this methodology as 
applying a ``device offset'' to the ASC payment for the associated 
surgical procedure. This ensures that duplicate payment is not provided 
for any portion of an implanted device with OPPS pass-through payment 
status.
    In the CY 2015 OPPS/ASC final rule with comment period (79 FR 66933 
through 66934), we finalized that, beginning in CY 2015, certain 
diagnostic tests within the medicine range of CPT codes for which 
separate payment is allowed under the OPPS are covered ancillary 
services when they are integral to an ASC covered surgical procedure. 
We finalized that diagnostic tests within the medicine range of CPT 
codes include all Category I CPT codes in the medicine range 
established by CPT, from 90000 to 99999, and Category III CPT codes and 
Level II HCPCS codes that describe diagnostic tests that crosswalk or 
are clinically similar to procedures in the medicine range established 
by CPT. In the CY 2015 OPPS/ASC final rule with comment period, we also 
finalized our policy to pay for these tests at the lower of the PFS 
nonfacility PE RVU-based (or technical component) amount or the rate 
calculated according to the ASC standard ratesetting methodology (79 FR 
66933 through 66934). We finalized that the diagnostic tests for which 
the payment is based on the ASC standard ratesetting methodology be 
assigned to payment indicator ``Z2'' and revised the definition of 
payment indicator ``Z2'' to include a reference to diagnostic services 
and those for which the payment is based on the PFS nonfacility PE RVU-
based amount be assigned payment indicator ``Z3,'' and revised the 
definition of payment indicator ``Z3'' to include a reference to 
diagnostic services.
b. Payment for Covered Ancillary Services for CY 2019
    In the CY 2019 OPPS/ASC proposed rule (83 FR 37164 through 37165), 
for CY 2019 and subsequent years, we proposed to update the ASC payment 
rates and to make changes to ASC payment indicators, as necessary, to 
maintain consistency between the OPPS and ASC payment system regarding 
the packaged or separately payable status of services and the proposed 
CY 2019 OPPS and ASC payment rates and subsequent year payment rates. 
We also proposed to continue to set the CY 2019 ASC payment rates and 
subsequent year payment rates for brachytherapy sources and separately 
payable drugs and biologicals equal to the OPPS payment rates for CY 
2019 and subsequent year payment rates.
    Covered ancillary services and their proposed payment indicators 
for CY 2019 were listed in Addendum BB to the proposed rule (which is 
available via the internet on the CMS website). For those covered 
ancillary services where the payment rate is the lower of the proposed 
rates under the ASC standard rate setting methodology and the PFS 
proposed rates, the proposed payment indicators and rates set forth in 
the proposed rule are based on a comparison using the proposed PFS 
rates effective January 1, 2019. For a discussion of the PFS rates, we 
refer readers to the CY 2019 PFS proposed rule that is available on the 
CMS website at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/PhysicianFeeSched/PFS-Federal-Regulation-Notices.html.
    Comment: Commenters recommended that CMS pay separately for 
Cysview[supreg], HCPCS code C9275 (hexaminolevulinate HCl), similar to 
the proposal to pay separately for Exparel. Commenters also recommended 
that CMS use its equitable payment adjustment authority under section 
1833(t)(2)(E) of the Act to provide a drug ``add-on'' payment for 
certain procedures.
    Response: As discussed in the CY 2017 OPPS/ASC final rule with 
comment period (81 FR 79668), we continue to believe that 
Cysview[supreg] is a drug that functions as a supply in a diagnostic 
test or procedure and therefore is packaged with payment for the 
surgical procedure. In the CY 2019 OPPS/ASC proposed rule, we did not 
propose to make any changes to the ``drugs that function as a supply in 
a diagnostic test or procedure'' packaging

[[Page 59066]]

policy or propose any drug ``add-on'' policies. Therefore, we are not 
accepting the commenters' recommendation.
    Comment: One commenter recommended that CMS develop a policy that 
pays separately for drugs that are administered at the time of cataract 
surgery, but are not integral or necessary to the cataract procedure, 
and have an FDA-approved indication to treat/prevent postoperative 
issues.
    Response: We appreciate the commenter's recommendation. We refer 
readers to section II.A.3. of this final rule with comment period for 
details related to the packaging policy for drugs that function as a 
supply in a surgical procedure or diagnostic test. While we did not 
propose such a change in the CY 2019 OPPS/ASC proposed rule, we will 
consider this recommendation in future rulemaking.
3. CY 2019 ASC Packaging Policy for Non-Opioid Pain Management 
Treatments
    In the CY 2018 OPPS/ASC proposed rule (82 FR 33588), within the 
framework of existing packaging categories, such as drugs that function 
as supplies in a surgical procedure or diagnostic test or procedure, we 
requested stakeholder feedback on common clinical scenarios involving 
currently packaged items and services described by HCPCS codes that 
stakeholders believe should not be packaged under the OPPS. We also 
expressed interest in stakeholder feedback on common clinical scenarios 
involving separately payable HCPCS codes for which payment would be 
most appropriately packaged under the OPPS. Commenters expressed a 
variety of views on packaging under the OPPS. In the CY 2018 OPPS/ASC 
final rule with comment period, we summarized the comments received in 
response to our request (82 FR 59255). The comments ranged from 
requests to unpackage most items and services that are either 
conditionally or unconditionally packaged under the OPPS, including 
drugs and devices, to specific requests for separate payment for a 
specific drug or device. We stated in the CY 2018 OPPS/ASC final rule 
with comment period that CMS would continue to explore and evaluate 
packaging policies under the OPPS and consider these policies in future 
rulemaking.
    In addition to stakeholder feedback regarding OPPS packaging 
policies, the President's Commission on Combating Drug Addiction and 
the Opioid Crisis (the Commission) recently recommended that CMS 
examine payment policies for certain drugs that function as a supply, 
specifically non-opioid pain management treatments. The Commission was 
established in 2017 to study ways to combat and treat drug abuse, 
addiction, and the opioid crisis. The Commission's report \87\ included 
a recommendation for CMS to ``review and modify ratesetting policies 
that discourage the use of non-opioid treatments for pain, such as 
certain bundled payments that make alternative treatment options cost 
prohibitive for hospitals and doctors, particularly those options for 
treating immediate postsurgical pain. . . .'' \88\ With respect to the 
packaging policy, the Commission's report states that ``the current CMS 
payment policy for `supplies' related to surgical procedures creates 
unintended incentives to prescribe opioid medications to patients for 
postsurgical pain instead of administering non-opioid pain medications. 
Under current policies, CMS provides one all-inclusive bundled payment 
to hospitals for all `surgical supplies,' which includes hospital-
administered drug products intended to manage patients' postsurgical 
pain. This policy results in the hospitals receiving the same fixed fee 
from Medicare whether the surgeon administers a non-opioid medication 
or not.'' \89\ HHS also presented an Opioid Strategy in April 2017 \90\ 
that aims in part to support cutting-edge research and advance the 
practice of pain management. On October 26, 2017, the opioid crisis was 
declared a national public health emergency under Federal law \91\ and 
this determination was renewed on April 20, 2018.\92\
---------------------------------------------------------------------------

    \87\ President's Commission on Combating Drug Addiction and the 
Opioid Crisis, Report (2017). Available at: https://www.whitehouse.gov/sites/whitehouse.gov/files/images/Final_Report_Draft_11-1-2017.pdf.
    \88\ Ibid, at page 57, Recommendation 19.
    \89\ Ibid.
    \90\ Available at: https://www.hhs.gov/about/leadership/secretary/speeches/2017-speeches/secretary-price-announces-hhs-strategy-for-fighting-opioid-crisis/.
    \91\ Available at: https://www.hhs.gov/about/news/2017/10/26/hhs-acting-secretary-declares-public-health-emergency-address-national-opioid-crisis.html.
    \92\ Available at: https://www.phe.gov/emergency/news/healthactions/phe/Pages/default.aspx.
---------------------------------------------------------------------------

    As discussed in the CY 2019 OPPS/ASC proposed rule (83 FR 37067 
through 37071), in response to stakeholder comments on the CY 2018 
OPPS/ASC proposed rule and in light of the recommendations regarding 
payment policies for certain drugs, we recently evaluated the impact of 
our packaging policy for drugs that function as a supply when used in a 
surgical procedure on the utilization of these drugs in both the 
hospital outpatient department and the ASC setting. Currently, as noted 
above, drugs that function as a supply are packaged under the OPPS and 
the ASC payment system, regardless of the costs of the drugs. The costs 
associated with packaged drugs that function as a supply are included 
in the ratesetting methodology for the surgical procedures with which 
they are billed and the payment rate for the associated procedure 
reflects the costs of the packaged drugs and other packaged items and 
services to the extent they are billed with the procedure. In our 
evaluation, we used currently available data to analyze the utilization 
patterns associated with specific drugs that function as a supply over 
a 5-year time period (CYs 2013 through 2017) to determine whether this 
packaging policy has reduced the use of these drugs. If the packaging 
policy discouraged the use of drugs that function as a supply or 
impeded access to these products, we would expect to see a significant 
decline in utilization of these drugs over time, although we note that 
a decline in utilization could also reflect other factors, such as the 
availability of alternative products. We did not observe significant 
declines in the total number of units used in the hospital outpatient 
department for a majority of the drugs included in our analysis.
    In fact, under the OPPS, we observed the opposite effect for 
several drugs that function as a supply, including Exparel (HCPCS code 
C9290). Exparel is a liposome injection of bupivacaine, an amide local 
anesthetic, indicated for single-dose infiltration into the surgical 
site to produce postsurgical analgesia. In 2011, Exparel was approved 
by the FDA for administration into the postsurgical site to provide 
postsurgical analgesia.\93\ Exparel had pass-through payment status 
from CYs 2012 through 2014 and was separately paid under both the OPPS 
and the ASC payment system during this 3-year period. Beginning in CY 
2015, Exparel was packaged as a surgical supply under both the OPPS and 
the ASC payment system. Exparel is currently the only non-opioid pain 
management drug that is packaged as a drug that functions as a supply 
when used in a surgical procedure under the OPPS and the ASC payment 
system.
---------------------------------------------------------------------------

    \93\ Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022496s000lbl.pdf.
---------------------------------------------------------------------------

    From CYs 2013 through 2017, there was an overall increase in the 
OPPS Medicare utilization of Exparel of approximately 229 percent (from 
2.3 million units to 7.7 million units) during this 5-year time period. 
The total number of claims reporting Exparel

[[Page 59067]]

increased by 222 percent (from 10,609 claims to 34,183 claims) over 
this time period. This increase in utilization continued, even after 
the 3-year drug pass-through payment period ended for this product in 
2014, with 18 percent overall growth in the total number of units used 
from CYs 2015 through 2017 (from 6.5 million units to 7.7 million 
units). The number of claims reporting Exparel increased by 21 percent 
during this time period (from 28,166 claims to 34,183 claims).
    Thus, we have not found evidence to support the notion that the 
OPPS packaging policy has had an unintended consequence of discouraging 
the use of non-opioid treatment for postsurgical pain management in the 
hospital outpatient department. Therefore, based on this data analysis, 
we stated in the CY 2019 OPPS/ASC proposed rule that we did not believe 
that changes were necessary under the OPPS for the packaged drug policy 
for drugs that function as a surgical supply when used in a surgical 
procedure in this setting at this time.
    In terms of Exparel in particular, we have received several 
requests to pay separately for the drug rather than packaging payment 
for it as a surgical supply. In the CY 2015 OPPS/ASC final rule with 
comment period (79 FR 66874 and 66875), in response to comments from 
stakeholders requesting separate payment for Exparel, we stated that we 
considered Exparel to be a drug that functions as a surgical supply 
because it is indicated for the alleviation of postoperative pain. We 
also stated that we consider all items related to the surgical outcome 
and provided during the hospital stay in which the surgery is 
performed, including postsurgical pain management drugs, to be part of 
the surgery for purposes of our drug and biological surgical supply 
packaging policy. In the CY 2018 OPPS/ASC final rule with comment 
period (82 FR 59345), we reiterated our position with regard to payment 
for Exparel, stating that we believed that payment for this drug is 
appropriately packaged with the primary surgical procedure. In 
addition, we have reviewed recently available literature with respect 
to Exparel, including a briefing document \94\ submitted for the FDA 
Advisory Committee Meeting held February 14-15, 2018, by the 
manufacturer of Exparel that notes that ``Bupivacaine, the active 
pharmaceutical ingredient in Exparel, is a local anesthetic that has 
been used for infiltration/field block and peripheral nerve block for 
decades'' and that ``since its approval, Exparel has been used 
extensively, with an estimated 3.5 million patient exposures in the 
US.'' \95\ On April 6, 2018, the FDA approved Exparel's new indication 
for use as an interscalene brachial plexus nerve block to produce 
postsurgical regional analgesia.\96\ Therefore, we also stated in the 
CY 2019 OPPS/ASC proposed rule that, based on our review of currently 
available OPPS Medicare claims data and public information from the 
manufacturer of the drug, we did not believe that the OPPS packaging 
policy had discouraged the use of Exparel for either of the drug's 
indications. Accordingly, we continue to believe it is appropriate to 
package payment for Exparel as we do with other postsurgical pain 
management drugs when it is furnished in a hospital outpatient 
department. However, we invited public comments on whether separate 
payment would nonetheless further incentivize appropriate use of 
Exparel in the hospital outpatient setting and peer-reviewed evidence 
that such increased utilization would lead to a decrease in opioid use 
and addiction among Medicare beneficiaries.
---------------------------------------------------------------------------

    \94\ Food and Drug Administration, Meeting of the Anesthetic and 
Analgesic Drug Products Advisory Committee Briefing Document (2018). 
Available at: https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AnestheticAndAnalgesicDrugProductsAdvisoryCommittee/UCM596314.pdf.
    \95\ Ibid, page 9.
    \96\ Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022496s009lbledt.pdf.
---------------------------------------------------------------------------

    Comment: Several commenters requested that CMS pay separately for 
Exparel in the hospital outpatient setting. Some of these commenters 
noted that Exparel is used more frequently in this setting and the use 
of non-opioid pain management treatments should also be encouraged in 
the hospital outpatient department (HOPD). One commenter stated that 
since drug became packaged in 2015, utilization of the drug in the HOPD 
has remained flat while the opioid crisis has continued to worsen. The 
commenter suggested that to address the opioid crisis among Medicare 
beneficiaries, CMS should promote ``increased penetration of non-opioid 
therapies in the HOPD setting--or in other words, higher rates of usage 
of non-opioid treatments for the same number of surgical procedures.''
    Response: This comment and other comments specific to packaging 
under the OPPS payment system are addressed in section II.A.3.b. of 
this final rule with comment period.
    We also stated in the proposed rule that, although we found 
increases in utilization for Exparel when it is paid under the OPPS, we 
did notice different effects on Exparel utilization when examining the 
effects of our packaging policy under the ASC payment system. In 
particular, during the same 5-year period of CYs 2013 through 2017, the 
total number of units of Exparel used in the ASC setting decreased by 
25 percent (from 98,160 total units to 73,595 total units) and the 
total number of claims reporting Exparel decreased by 16 percent (from 
527 claims to 441 claims). In the ASC setting, after the pass-through 
payment period ended for Exparel at the end of CY 2014, the total 
number of units of Exparel used decreased by 70 percent (from 244,757 
units to 73,595 units) between CYs 2015 and 2017. The total number of 
claims reporting Exparel also decreased during this time period by 62 
percent (from 1,190 claims to 441 claims). However, there was an 
increase of 238 percent (from 98,160 total units to 331,348 total 
units) in the total number of units of Exparel used in the ASC setting 
during the time period of CYs 2013 and 2014 when the drug received 
pass-through payments, indicating that the payment rate of ASP+6 
percent for Exparel may have an impact on its usage in the ASC setting. 
The total number of claims reporting Exparel also increased during this 
time period from 527 total claims to 1,540 total claims, an increase of 
192 percent.
    While several variables may contribute to this difference between 
utilization and claims reporting in the hospital outpatient department 
and the ASC setting, one potential explanation is that, in comparison 
to hospital outpatient departments, ASCs tend to provide specialized 
care and a more limited range of services. Also, ASCs are paid, in 
aggregate, approximately 55 percent of the OPPS rate. Therefore, 
fluctuations in payment rates for specific services may impact these 
providers more acutely than hospital outpatient departments, and 
therefore, ASCs may be less likely to choose to furnish non-opioid 
postsurgical pain management treatments, which are typically more 
expensive than opioids, as a result. Another possible contributing 
factor is that ASCs do not typically report packaged items and services 
and, accordingly, our analysis may be undercounting the number of 
Exparel units utilized in the ASC setting.
    In light of the results of our evaluation of packaging policies 
under the OPPS and the ASC payment system, which showed decreased 
utilization for certain drugs that function as a supply in the ASC 
setting in comparison to the hospital outpatient department setting, as 
well as the Commission's recommendation to examine payment

[[Page 59068]]

policies for non-opioid pain management drugs that function as a 
supply, we stated in the proposed rule that we believe a change in how 
we pay for non-opioid pain management drugs that function as surgical 
supplies may be warranted. In particular, we believe it may be 
appropriate to pay separately for evidence-based non-opioid pain 
management drugs that function as a supply in a surgical procedure in 
the ASC setting to address the decreased utilization of these drugs and 
to encourage use of these types of drugs rather than prescription 
opioids. Therefore, we proposed in section XII.D.3. of the CY 2019 
OPPS/ASC proposed rule (83 FR 37068 through 37071) to unpackage and pay 
separately at ASP+6 percent for the cost of non-opioid pain management 
drugs that function as surgical supplies when they are furnished in the 
ASC setting for CY 2019.
    We have stated previously (82 FR 59250) that our packaging policies 
are designed to support our strategic goal of using larger payment 
bundles in the OPPS to maximize hospitals' incentives to provide care 
in the most efficient manner. The packaging policies established under 
the OPPS also typically apply when services are provided in the ASC 
setting, and the policies have the same strategic goals in both 
settings. While the CY 2019 proposal is a departure from our current 
ASC packaging policy for drugs (specifically, non-opioid pain 
management drugs) that function as a supply when used in a surgical 
procedure, we stated in the proposed rule we believe that the proposed 
change will incentivize the use of non-opioid pain management drugs and 
is responsive to the Commission's recommendation to examine payment 
policies for non-opioid pain management drugs that function as a 
supply, with the overall goal of combating the current opioid addiction 
crisis. As previously noted, a discussion of the CY 2019 proposal for 
payment of non-opioid pain management drugs in the ASC setting was 
presented in further detail in the proposed rule, and we include a 
further discussion of the final policy for CY 2019 below. However, we 
also stated in the CY 2019 OPPS/ASC proposed rule that we were 
interested in peer-reviewed evidence that demonstrates that non-opioid 
alternatives, such as Exparel, in the outpatient setting actually do 
lead to a decrease in prescription opioid use and addiction and invited 
public comments containing evidence that demonstrate whether and how 
such non-opioid alternatives affect prescription opioid use during or 
after an outpatient visit or procedure.
    As noted above, for CY 2019, we proposed to pay separately at 
average sales price (ASP)+6 percent for non-opioid pain management 
drugs that function as a supply when used in a surgical procedure when 
the procedure is performed in the ASC setting. As described in section 
V.A.1. of the proposed rule, section 1847A of the Act establishes the 
ASP methodology, which is used for payment for drugs and biologicals 
described in section 1842(o)(1)(C) of the Act furnished on or after 
January 1, 2005. The ASP methodology, as applied under the OPPS, uses 
several sources of data as a basis for payment, including the ASP, the 
wholesale acquisition cost (WAC), and the average wholesale price (AWP) 
(82 FR 59337). As noted in section V.B.2.b. of the proposed rule, since 
CY 2013, our policy has been to pay for separately payable drugs and 
biologicals at ASP+6 percent in accordance with section 
1833(t)(14)(A)(iii)(II) of the Act (the statutory default) (82 FR 
59350).
    In the proposed rule (83 FR 37167), we did not propose a change to 
the packaging policy under the OPPS for CY 2019. However, we proposed 
to pay separately at ASP+6 percent for non-opioid pain management drugs 
that function as a supply when used in a surgical procedure when the 
procedure is performed in the ASC setting for CY 2019. Because the ASC 
payment rate also includes packaged payment for non-opioid pain 
management drugs, we intend to remove the packaged costs attributable 
to non-opioid pain management drugs--at this time, only Exparel 
qualifies--from the applicable OPPS rates prior to establishing the ASC 
rates in order to prevent potential overpayment of these procedures 
when separate payment is provided in the ASC setting.
    Of the drugs that are currently packaged in the ASC setting, this 
policy would apply to Exparel. Exparel is the only non-opioid pain 
management drug that functions as a supply when used in a surgical 
procedure that is covered under Medicare Part B. While there are other 
non-opioid pain management drugs available that are also administered 
post-surgically, such as non-steroidal anti-inflammatory drugs 
(``NSAIDs''), Exparel is the currently the only drug used in the ASC 
setting that is both covered under Medicare Part B and policy packaged 
as a drug that functions as a supply in a surgical procedure. To the 
extent that other non-opioid drugs that function as surgical supplies 
come onto the U.S. market, we proposed that this policy would apply to 
them as well in CY 2019.
    This proposal was also presented in section II.A.3.b. of the 
proposed rule for the OPPS. We proposed several conforming changes to 
the ASC regulation to implement this proposal. Specifically, at 42 CFR 
416.164(a)(4), we proposed a change to exclude non-opioid pain 
management drugs that function as a supply when used in a surgical 
procedure from our policy to package drugs and biologicals for which 
separate payment is not allowed under the OPPS into the ASC payment for 
a covered surgical procedure. Similarly, we proposed to add 42 CFR 
416.164(b)(6) to include non-opioid pain management drugs that function 
as a supply when used in a surgical procedure as a covered ancillary 
service. Finally, we proposed a conforming change to 42 CFR 
416.171(b)(1) to exclude non-opioid pain management drugs that function 
as a supply when used in a surgical procedure from our policy to pay 
for ASC covered ancillary services an amount derived from the payment 
rate for the equivalent item or service set under the OPPS.
    Comment: Several commenters supported the proposal to unpackage and 
pay separately at ASP+6 percent for the cost of non-opioid pain 
management drugs that function as a supply in the ASC setting, such as 
Exparel, for CY 2019. These commenters believed that packaged payment 
for non-opioid alternatives presents a barrier to care and that 
separate payment for non-opioid pain management drugs would be an 
appropriate response to the opioid drug abuse epidemic.
    Other commenters, including MedPAC, did not support this proposal 
and stated that the policy was counter to the OPPS packaging policies 
created to encourage efficiencies and could set a precedent for 
unpackaging services. One commenter stated that Exparel is more costly, 
but not more effective than bupivacaine, a less costly non-opioid 
alternative. Other commenters expressed concerns that the proposal may 
have the unintended consequence of limiting access to opioid 
prescriptions for beneficiaries for whom an opioid prescription would 
be appropriate. The commenters noted that some non-opioid pain 
management treatments may pose other risks for patients and patient 
safety.
    Response: We appreciate the commenters' input. We continue to 
believe that, under current circumstances, it is appropriate to pay 
separately for non-opioid pain management drugs that function as a 
supply in a surgical procedure in the

[[Page 59069]]

ASC setting where there is evidence that their use leads to decreased 
opioid use and/or addiction among Medicare beneficiaries following an 
outpatient visit or procedure. We believe this policy will encourage 
use of these types of drugs rather than prescription opioids. With 
regard to the comments that paying separately for these drugs could set 
a precedent for unpackaging other services, while we acknowledge that 
this policy is a departure from the current ASC packaging policy for 
drugs that function as a supply, we also believe that the limited scope 
of this policy, in terms of both the services included (evidence-based 
non-opioid pain management drugs) and the setting (ASCs) is 
sufficiently narrow and will not set an unwarranted precedent for the 
unpackaging of other OPPS or ASC services. We also do not believe that 
this policy will limit access to opioid prescriptions for beneficiaries 
for whom an opioid prescription would be appropriate. Exparel and other 
non-opioid pain management drugs packaged under the drugs that function 
as a supply policy are used to treat acute post-surgical pain and 
paying separately for these drugs under the ASC payment system will not 
prevent physicians from prescribing opioids for treating pain when 
appropriate. Also, we have a longstanding recognition that the decision 
on how to best treat a patient is a complex medical judgment made by 
the physician based on each individual beneficiary's unique clinical 
circumstances. With regard to concerns that some non-opioid pain 
management treatments pose other risks for patients and patient safety, 
the commenter did not identify any specific non-opioid pain management 
treatments in its comment. Exparel, the only drug to which the proposed 
policy applies, is currently being safely used in both the OPPS and ASC 
settings. This comment is also presented in section II.A.3.b of this 
final rule with comment period.
    In addition, as noted in section XII.D.3. of the proposed rule, we 
sought comments on whether the proposed policy would decrease the dose, 
duration, and/or number of opioid prescriptions beneficiaries receive 
during and following an outpatient visit or procedure (especially for 
beneficiaries at high-risk for opioid addiction) as well as whether 
there are other non-opioid pain management alternatives that would have 
similar effects and may warrant separate payment. For example, we 
stated we were interested in identifying whether single post-surgical 
analgesic injections, such as Exparel, or other non-opioid drugs or 
devices that are used during an outpatient visit or procedure are 
associated with decreased opioid prescriptions and/or reduced cases of 
associated opioid addiction following such an outpatient visit or 
procedure. We also requested comments that provide evidence (such as 
published peer-reviewed literature) we could use to determine whether 
these products help to deter or avoid prescription opioid use and 
addiction as well as evidence that the current packaged payment for 
such non-opioid alternatives presents a barrier to access to care and, 
therefore, warrants separate payment under either or both the OPPS and 
the ASC payment system. We stated that any evidence demonstrating the 
reduction or avoidance of prescription opioids would be the criteria we 
use to determine whether separate payment is warranted for CY 2019. We 
also stated that, should evidence change over time, we would consider 
whether a reexamination of any policy adopted in the final rule would 
be necessary.
    Comment: With regard to whether the proposed policy would decrease 
the dose, duration, and/or number of opioid prescriptions beneficiaries 
receive during and following an outpatient visit or procedure and 
supportive evidence of these reductions, a commenter submitted studies 
that claimed that the use of Exparel by Medicare patients undergoing 
total knee replacement procedures reduced prescription opioid 
consumption by 90 percent compared to the control group measured at 48 
hours post-surgery.\97\ The commenter submitted additional studies 
claiming statistically significant reductions in opioid use with the 
use of Exparel for various surgeries including laparotomy, shoulder 
replacement, and breast reconstruction.
---------------------------------------------------------------------------

    \97\ Michael A. Mont et al., Local Infiltration Analgesia With 
Liposomal Bupivacaine Improves Pain Scores and Reduces Opioid Use 
After Total Knee Arthroplasty: Results of a Randomized Controlled 
Trial. J. of Arthroplasty (2018).
---------------------------------------------------------------------------

    Several commenters identified other non-opioid pain management 
drugs that they believe decrease the dose, duration, and/or number of 
opioid prescriptions beneficiaries receive during and following an 
outpatient visit or procedure (especially for beneficiaries at high-
risk for opioid addiction) and may warrant separate payment for CY 
2019. Several commenters submitted supporting studies which claimed 
that a non-opioid intrathecal infusion drug indicated for the 
management of severe chronic pain reduced opioid use in patients with 
chronic pain.
    Other commenters representing hospitals, hospital associations, and 
clinical specialty organizations requested separate payment for IV 
acetaminophen, IV ibuprofen, and epidural steroid injections. In 
addition, one commenter, the manufacturers of a non-opioid analgesic 
containing bupivacaine hcl, but not currently approved by FDA, 
requested clarification regarding whether the proposal would also apply 
to this drug once it receives FDA approval. Several commenters 
requested separate payment for a drug which treats post-operative pain 
after cataract surgery, currently has drug pass-through status, and 
therefore is not packaged under the OPPS or ASC. The commenters 
requested that CMS explicitly state this drug will also be paid for 
separately in the ASC setting after pass-through status ends for the 
drug in 2020. Lastly, one commenter requested that a diagnostic drug 
that is not a non-opioid receive separate payment.
    Response: We appreciate these comments. After reviewing the studies 
provided by the commenters, we continue to believe the separate payment 
is appropriate for Exparel in the ASC setting. At this time, we have 
not found compelling evidence for other non-opioid pain management 
drugs described above to warrant separate payment at this time. Also, 
with regard to the requests for CMS to confirm that the proposed policy 
would also apply in the future to certain non-opioid pain management 
drugs, we reiterate that the proposed policy is for CY 2019 and is 
applicable to non-opioid pain management drugs that that are currently 
packaged under the policy for drugs that function as a surgical supply 
when used in the ASC setting, which currently is only Exparel. To the 
extent that other non-opioid pain management drugs that function as a 
surgical supply become available in the U.S. market in CY 2019, this 
policy would also apply to those drugs.
    As noted above, we stated in the proposed rule that we were 
interested in comments regarding other non-opioid treatments besides 
Exparel that might be affected by OPPS and ASC packaging policies, 
including alternative, non-opioid pain treatments, such as devices or 
therapy services that are not currently separable payable. We stated 
that we were specifically interested in comments regarding whether CMS 
should consider separate payment for items and services for which 
payment is currently packaged under the OPPS and the ASC payment system 
that are effective non-opioid alternatives as well as evidence that 
demonstrates such items and services lead to a decrease in prescription 
opioid use and/or

[[Page 59070]]

addiction during or after an outpatient visit or procedure in order to 
determine whether separate payment may be warranted. As previously 
stated, we intended to examine the evidence submitted to determine 
whether to adopt a final policy in this final rule with comment period 
that incentivizes use of non-opioid alternative items and services that 
have evidence to demonstrate an associated decrease in prescription 
opioid use and/or addiction following an outpatient visit or procedure. 
Some examples of evidence that may be relevant could include an 
indication on the product's FDA label or studies published in peer-
reviewed literature that such product aids in the management of acute 
or chronic pain and is an evidence-based non-opioid alternative for 
acute and/or chronic pain management. We indicated in the proposed rule 
that we also were interested in evidence relating to products that have 
shown clinical improvement over other alternatives, such as a device 
that has been shown to provide a substantial clinical benefit over the 
standard of care for pain management. We stated this could include, for 
example, spinal cord stimulators used to treat chronic pain such as the 
devices described by HCPCS codes C1822 (Generator, neurostimulator 
(implantable), high frequency, with rechargeable battery and charging 
system), C1820 (Generator, neurostimulator (implantable), with 
rechargeable battery and charging system), and C1767 (Generator, 
neurostimulator (implantable), nonrechargeable) which are primarily 
assigned to APCs 5463 and 5464 (Levels 3 and 4 Neurostimulator and 
Related Procedures) with proposed CY 2019 payment rates of $18,718 and 
$27,662, respectively, that have received pass-through payment status 
as well as other similar devices.
    Currently, all devices are packaged under the OPPS and the ASC 
payment system unless they have pass-through payment status. However, 
we stated in the proposed rule that, in light of the Commission's 
recommendation to review and modify ratesetting policies that 
discourage the use of non-opioid treatments for pain, we were 
interested in comments from stakeholders regarding whether, similar to 
the goals of the proposed payment policy for non-opioid pain management 
drugs that function as a supply when used in a surgical procedure, a 
policy of providing separate payment (rather than packaged payment) for 
these products, indefinitely or for a specified period of time, would 
also incentivize the use of alternative non-opioid pain management 
treatments and improve access to non-opioid alternatives, particularly 
for innovative and low-volume items and services.
    We also stated that we were interested in comments regarding 
whether we should provide separate payment for non-opioid pain 
management treatments or products using a mechanism such as an 
equitable payment adjustment under our authority at section 
1833(t)(2)(E) of the Act, which states that the Secretary shall 
establish, in a budget neutral manner, other adjustments as determined 
to be necessary to ensure equitable payments. For example, we stated in 
the proposed rule that we were considering whether an equitable payment 
adjustment in the form of an add-on payment for APCs that use a non-
opioid pain management drug, device, or service would be appropriate. 
We indicated that, to the extent that commenters provided evidence to 
support this approach, we would consider adopting a final policy in 
this final rule with comment period, which could include regulatory 
changes that would allow for an exception to the packaging of certain 
nonpass-through devices that represent non-opioid alternatives for 
acute or chronic pain that have evidence to demonstrate that their use 
leads to a decrease in opioid prescriptions and/or addictions during or 
after an outpatient visit or procedure to effectuate such change.
    Comment: Several commenters stated that separate payment for spinal 
cord stimulators (SCS) was also warranted because these devices provide 
an alternative treatment option to opioids for patients with chronic, 
leg or back pain. One commenter provided supporting studies which 
claimed that patients treated with their device reported a 
statistically significant average decrease in opioid use compared to 
the control group.\98\ This commenter also submitted data that showed a 
decline in the mean daily dosage of opioid medication taken and that 
fewer patients were relying on opioids at all to manage their pain when 
they used the manufacturer's device.\99\ Another commenter stated that 
there are few peer-reviewed studies that evaluate opioid elimination 
and/or reduction following SCS and that there is a need for more 
population based research with opioid reduction or elimination as a 
study endpoint. However, this commenter believed that current studies 
suggest that opioid use may be reduced following SCS therapy.
---------------------------------------------------------------------------

    \98\ Kapural L, Yu C, Doust MW, Gliner BE, Vallejo R, Sitzman 
BT, Amirdelfan K, Morgan DM, Brown LL, Yearwood TL, Bundschu R, 
Burton AW, Yang T, Benyamin R, Burgher AH. Novel 10-kHz high-
frequency therapy (HF10 therapy) is superior to traditional low-
frequency spinal cord stimulation for the treatment of chronic back 
and leg pain: The SENZA-RCT randomized controlled trial, 
ANESTHESIOLOGY. 2015 Oct;123(4):851-60.
    \99\ Al-Kaisy A, Van Buyten JP, Smet I, Palmisani S, Pang D, 
Smith T. Sustained effectiveness of 10 kHz high-frequency spinal 
cord stimulation for patients with chronic, low back pain: 24-month 
results of a prospective multicenter study. PAIN MED. 2014 Mar; 
15(3):347-54.
---------------------------------------------------------------------------

    Other commenters requested separate payments for various non-opioid 
pain management treatments such as: Continuous nerve blocks (including 
a disposable elastomeric pump that delivers non-opioid local anesthetic 
to a surgical site or nerve); cooled thermal radiofrequency ablation 
for non-surgical, chronic nerve pain; and physical therapy services. 
These commenters also stated that while ``certainly not a solution to 
the opioid epidemic, unpackaging appropriate non-opioid therapies, like 
Exparel, is a low-cost tactic that could change long-standing practice 
patterns without major negative consequences.'' One commenter suggested 
that Medicare consider separate payment for Polar ice devices for post-
operative pain relief after knee procedures. The commenter also noted 
that therapeutic massage, topically applied THC oil, acupuncture, and 
dry needling procedures are very effective therapies for relief of both 
post-operative pain and long-term and chronic pain.
    Commenters suggested various mechanisms through which separate 
payment or a higher paying APC assignment for the primary service could 
be made. Commenters offered reports, studies and anecdotal evidence to 
support why the items or services about which the commenters believed 
offered alternatives to or reduction of the need for opioid 
prescriptions.
    Response: We appreciate the thoughtful response to our solicitation 
for comments on this topic. We plan to take these suggestions into 
consideration for future rulemaking. We agree that providing incentives 
to avoid and/or reduce opioid prescriptions may be one of several 
strategies for addressing the opioid epidemic. To the extent that the 
items and services mentioned by the commenters are effective 
alternatives to opioid prescriptions, we encourage providers to use 
them when medically necessary. We note that some of the items and 
services mentioned by commenters are not covered by Medicare and we do 
not intend to establish payment for noncovered items and services. We 
look forward to working with stakeholders as we further consider 
suggested refinements to the OPPS and the ASC

[[Page 59071]]

payment system that will encourage use of medically necessary items and 
services that have demonstrated efficacy in decreasing opioid 
prescriptions and/or addictions during or after an outpatient visit or 
procedure.
    Comment: One commenter suggested that CMS provide separate payment 
for HCPCS code A4306 (Disposable drug delivery system, flow rate of 
less than 50 ml per hour) in the hospital outpatient department and the 
ASC settings following a post-surgery procedure. This commenter 
explained that if a patient needs additional pain relief three to five 
days post-surgery, a facility cannot receive payment for providing a 
replacement disposable drug delivery system HCPCS code A4306 unless the 
entire continuous nerve block procedure is performed. This commenter 
believed that CMS should allow for HCPCS code A4306 to be dispensed to 
the patient as long as the patient is in pain, the pump is empty, and 
the delivery catheters are still in place. The commenter believed that 
the ASC payment system should incentivize the continued use of non-
opioid alternatives when needed. Several commenters stated that CMS 
should use an equitable payment adjustment under its authority at 
section 1833(t)(2)(E) of the Act to establish add-on payments for 
packaged devices used as non-opioid alternatives.
    Response: We appreciate the commenters' suggestions. We acknowledge 
that use of these items may help in the reduction of opioid use post 
operatively. However, we note that packaged payment of such item does 
not prevent the use of these items. We remind readers that payment for 
packaged items is included in the payment for the primary service. We 
share the commenter's concern about the need to reduce opioid use and 
will take the commenter's suggestion into consideration for future 
rulemaking. After reviewing the non-opioid pain management alternatives 
suggested by the commenters as well as the studies and other data 
provided to support the request for separate payment, we have not 
determined that separate payment is warranted at this time for any of 
the non-opioid pain management alternatives discussed above.
    We also invited comments on whether a reorganization of the APC 
structure for procedures involving non-opioid products or establishing 
more granular APC groupings for specific procedure and device 
combinations to ensure that the payment rate for such services is 
aligned with the resources associated with procedures involving 
specific devices would better achieve our goal of incentivizing 
increased use of non-opioid alternatives, with the aim of reducing 
opioid use and subsequent addiction. For example, we stated we would 
consider finalizing a policy to establish new APCs for procedures 
involving non-opioid pain management packaged items or services if such 
APCs would better recognize the resources involved in furnishing such 
items and services and decrease or eliminate the need for prescription 
opioids. In addition, given the general desire to encourage provider 
efficiency through creating larger bundles of care and packaging items 
and services that are integral, ancillary, supportive, dependent, or 
adjunctive to a primary service, we also invited comments on how such 
alternative payment structures would continue to balance the goals of 
incentivizing provider efficiencies with encouraging the use of non-
opioid alternatives to pain management.
    Furthermore, because patients may receive opioid prescriptions 
following receipt of a non-opioid drug or implantation of a device, we 
stated that we were interested in identifying any cost implications for 
the patient and the Medicare program caused by this potential change in 
policy. We also stated that the implications of incentivizing use of 
non-opioid pain management drugs available for postsurgical acute pain 
relief during or after an outpatient visit or procedure are of 
interest. The goal is to encourage appropriate use of such non-opioid 
alternatives. As previously stated, this comment solicitation is also 
discussed in section XII.D.3. of this final rule with comment period.
    Comment: One commenter suggested that CMS restructure the two-level 
Nerve Procedure APCs (5431 and 5432) to provide more payment 
granularity for the procedures included in the APCs by creating a third 
level.
    Response: We refer readers to section III.D.6. of this final rule 
with comment period for a discussion of this comment. We believe that 
the current two-level APCs for the Nerve Procedures provide an 
appropriate distinction between the resource costs at each level and 
provide clinical homogeneity. We will continue to review this APC 
structure, to determine if additional granularity is necessary for this 
APC family in future rulemaking. In addition, we believe that more 
analysis of such groupings is necessary before adopting such change.
    In addition, we invited the public to submit ideas on regulatory, 
subregulatory, policy, practice, and procedural changes to help prevent 
opioid use disorders and improve access to treatment under the Medicare 
program. We stated that we were interested in identifying barriers that 
may inhibit access to non-opioid alternatives for pain treatment and 
management or access to opioid use disorder treatment, including those 
barriers related to payment methodologies or coverage. In addition, 
consistent with our ``Patients Over Paperwork'' Initiative, we stated 
that we were interested in suggestions to improve existing requirements 
in order to more effectively address the opioid epidemic.
    Comment: Several commenters offered views regarding payment 
barriers that may inhibit access to non-opioid pain management 
treatments which have been previously discussed throughout this 
section. With regard to barriers related to payment methodologies or 
coverage, some commenters suggested that CMS support multi-modal pain 
management and enhanced recovery after surgery (ERAS) and encourage 
patient access to certified registered nurse anesthetist (CRNA) pain 
management. One commenter also suggested that CMS reduce cost sharing 
and eliminate the need for prior authorization for non-opioid pain 
management strategies.
    Response: We appreciate the various, insightful comments received 
from stakeholders regarding barriers that may inhibit access to non-
opioid alternatives for pain treatment and management in order to more 
effectively address the opioid epidemic. Many of these comments have 
been previously addressed throughout this section.
    After consideration of the public comments that we received, we are 
finalizing the policy to unpackage and pay separately at ASP+6 percent 
for the cost of non-opioid pain management drugs that function as 
surgical supplies when they are furnished in the ASC setting for CY 
2019 as proposed. We also are finalizing our conforming changes to the 
ASC regulation as proposed. Specifically, we are finalizing our 
proposed conforming changes to 42 CFR 416.164(a)(4) to exclude non-
opioid pain management drugs that function as a supply when used in a 
surgical procedure from our policy to package payment for drugs and 
biologicals for which separate payment is not allowed under the OPPS 
into the ASC payment for the covered surgical procedure. We also are 
adding a new paragraph (6) to 42 CFR 416.164(b) to include non-opioid 
pain management drugs that function as a supply when used in a surgical 
procedure as covered ancillary services that are integral to a covered 
surgical procedure. Finally, we are

[[Page 59072]]

finalizing our proposed change to 42 CFR 416.171(b)(1) to exclude non-
opioid pain management drugs that function as a supply when used in a 
surgical procedure from our policy to pay for ASC covered ancillary 
services an amount derived from the payment rate for the equivalent 
item or service set under the OPPS.
    We will continue to analyze this issue on access to non-opioid 
alternatives in the OPPS and ASC settings as we implement section 6082 
of the Substance Use--Disorder Prevention that Promotes Opioid Recovery 
and Treatment for Patients and Communities Act (Pub. L. 115-271) 
enacted on October 24, 2018. This policy is also discussed in section 
II.A.3.b. of this final rule with comment period.

E. New Technology Intraocular Lenses (NTIOLs)

    New Technology Intraocular Lenses (NTIOLs) are intraocular lenses 
that replace a patient's natural lens that has been removed in cataract 
surgery and that also meet the requirements listed in 42 CFR 416.195.
    1. NTIOL Application CycleOur process for reviewing applications to 
establish new classes of NTIOLs is as follows:
     Applicants submit their NTIOL requests for review to CMS 
by the annual deadline. For a request to be considered complete, we 
require submission of the information that is found in the guidance 
document entitled ``Application Process and Information Requirements 
for Requests for a New Class of New Technology Intraocular Lenses 
(NTIOLs) or Inclusion of an IOL in an Existing NTIOL Class'' posted on 
the CMS website at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/ASCPayment/NTIOLs.html.
     We announce annually, in the proposed rule updating the 
ASC and OPPS payment rates for the following calendar year, a list of 
all requests to establish new NTIOL classes accepted for review during 
the calendar year in which the proposal is published. In accordance 
with section 141(b)(3) of Public Law 103-432 and our regulations at 42 
CFR 416.185(b), the deadline for receipt of public comments is 30 days 
following publication of the list of requests in the proposed rule.
     In the final rule updating the ASC and OPPS payment rates 
for the following calendar year, we--
    ++ Provide a list of determinations made as a result of our review 
of all new NTIOL class requests and public comments;
    ++ When a new NTIOL class is created, identify the predominant 
characteristic of NTIOLs in that class that sets them apart from other 
IOLs (including those previously approved as members of other expired 
or active NTIOL classes) and that is associated with an improved 
clinical outcome.
    ++ Set the date of implementation of a payment adjustment in the 
case of approval of an IOL as a member of a new NTIOL class 
prospectively as of 30 days after publication of the ASC payment update 
final rule, consistent with the statutory requirement.
    ++ Announce the deadline for submitting requests for review of an 
application for a new NTIOL class for the following calendar year.
2. Requests To Establish New NTIOL Classes for CY 2019
    We did not receive any requests for review to establish a new NTIOL 
class for CY 2019 by March 1, 2018, the due date published in the CY 
2018 OPPS/ASC final rule with comment period (82 FR 59416).
3. Payment Adjustment
    The current payment adjustment for a 5-year period from the 
implementation date of a new NTIOL class is $50 per lens. Since 
implementation of the process for adjustment of payment amounts for 
NTIOLs in 1999, we have not revised the payment adjustment amount, and 
we are not proposing to revise the payment adjustment amount for CY 
2019.
4. Announcement of CY 2020 Deadline for Submitting Requests for CMS 
Review of Applications for a New Class of NTIOLs
    In accordance with Sec.  416.185(a) of our regulations, CMS 
announces that in order to be considered for payment effective 
beginning in CY 2020, requests for review of applications for a new 
class of new technology IOLs must be received at CMS by 5:00 p.m. EST, 
on March 1, 2019. Send requests to ASC/NTIOL, Division of Outpatient 
Care, Mailstop C4-05-17, Centers for Medicare and Medicaid Services, 
7500 Security Boulevard, Baltimore, MD 21244-1850. To be considered, 
requests for NTIOL reviews must include the information requested on 
the CMS website at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/ASCPayment/NTIOLs.html.

F. ASC Payment and Comment Indicators

1. Background
    In addition to the payment indicators that we introduced in the 
August 2, 2007 final rule, we created final comment indicators for the 
ASC payment system in the CY 2008 OPPS/ASC final rule with comment 
period (72 FR 66855). We created Addendum DD1 to define ASC payment 
indicators that we use in Addenda AA and BB to provide payment 
information regarding covered surgical procedures and covered ancillary 
services, respectively, under the revised ASC payment system. The ASC 
payment indicators in Addendum DD1 are intended to capture policy-
relevant characteristics of HCPCS codes that may receive packaged or 
separate payment in ASCs, such as whether they were on the ASC CPL 
prior to CY 2008; payment designation, such as device-intensive or 
office-based, and the corresponding ASC payment methodology; and their 
classification as separately payable ancillary services, including 
radiology services, brachytherapy sources, OPPS pass-through devices, 
corneal tissue acquisition services, drugs or biologicals, or NTIOLs.
    We also created Addendum DD2 that lists the ASC comment indicators. 
The ASC comment indicators used in Addenda AA and BB to the proposed 
rules and final rules with comment period serve to identify, for the 
revised ASC payment system, the status of a specific HCPCS code and its 
payment indicator with respect to the timeframe when comments will be 
accepted. The comment indicator ``NP'' is used in the OPPS/ASC proposed 
rule to indicate new codes for the next calendar year for which the 
interim payment indicator assigned is subject to comment. The comment 
indicator ``NP'' also is assigned to existing codes with substantial 
revisions to their descriptors, such that we consider them to be 
describing new services, as discussed in the CY 2010 OPPS/ASC final 
rule with comment period (74 FR 60622). In the CY 2017 OPPS/ASC final 
rule with comment period, we responded to public comments and finalized 
the ASC treatment of all codes that were labeled with comment indicator 
``NP'' in Addenda AA and BB to the CY 2016 OPPS/ASC final rule with 
comment period (80 FR 70497).
    The ``CH'' comment indicator is used in Addenda AA and BB to the 
proposed rule (which are available via the internet on the CMS website) 
to indicate that the payment indicator assignment has changed for an 
active HCPCS code in the current year and the next calendar year, for 
example if an active HCPCS code is newly recognized as payable in ASCs; 
or an active HCPCS code is discontinued at the end of the current 
calendar year. The ``CH'' comment

[[Page 59073]]

indicators that are published in the final rule with comment period are 
provided to alert readers that a change has been made from one calendar 
year to the next, but do not indicate that the change is subject to 
comment.
    In the CY 2017 OPPS/ASC final rule with comment period (81 FR 79748 
through 79749), for CY 2017 and subsequent years, we finalized our 
policy to continue using the current comment indicators of ``NP'' and 
``CH''.
2. ASC Payment and Comment Indicators
    In the CY 2019 OPPS/ASC proposed rule, for CY 2019, there were 
proposed new and revised Category I and III CPT codes as well as new 
and revised Level II HCPCS codes. Therefore, proposed Category I and 
III CPT codes that are new and revised for CY 2018 and any new and 
existing Level II HCPCS codes with substantial revisions to the code 
descriptors for CY 2019 compared to the CY 2018 descriptors that were 
included in ASC Addenda AA and BB to the proposed rule are labeled with 
proposed comment indicator ``NP'' to indicate that these CPT and Level 
II HCPCS codes are open for comment as part of the proposed rule. 
Proposed comment indicator ``NP'' means a new code for the next 
calendar year or an existing code with substantial revision to its code 
descriptor in the next calendar year, as compared to current calendar 
year; and denotes that comments will be accepted on the proposed ASC 
payment indicator for the new code.
    In the proposed rule, we stated that we would respond to public 
comments on ASC payment and comment indicators and finalize their ASC 
assignment in this CY 2019 OPPS/ASC final rule with comment period. We 
refer readers to Addenda DD1 and DD2 to the proposed rule (which are 
available via the internet on the CMS website) for the complete list of 
ASC payment and comment indicators proposed for the CY 2019 update.
    We did not receive any public comments on the ASC payment and 
comment indicators. Therefore, we are finalizing their use as proposed 
without modification. Addenda DD1 and DD2 to this final rule with 
comment period (which are available via the internet on the CMS 
website) contain the complete list of ASC payment and comment 
indicators for the CY 2019 update.

G. Calculation of the ASC Payment Rates and the ASC Conversion Factor

1. Background
    In the August 2, 2007 final rule (72 FR 42493), we established our 
policy to base ASC relative payment weights and payment rates under the 
revised ASC payment system on APC groups and the OPPS relative payment 
weights. Consistent with that policy and the requirement at section 
1833(i)(2)(D)(ii) of the Act that the revised payment system be 
implemented so that it would be budget neutral, the initial ASC 
conversion factor (CY 2008) was calculated so that estimated total 
Medicare payments under the revised ASC payment system in the first 
year would be budget neutral to estimated total Medicare payments under 
the prior (CY 2007) ASC payment system (the ASC conversion factor is 
multiplied by the relative payment weights calculated for many ASC 
services in order to establish payment rates). That is, application of 
the ASC conversion factor was designed to result in aggregate Medicare 
expenditures under the revised ASC payment system in CY 2008 being 
equal to aggregate Medicare expenditures that would have occurred in CY 
2008 in the absence of the revised system, taking into consideration 
the cap on ASC payments in CY 2007, as required under section 
1833(i)(2)(E) of the Act (72 FR 42522). We adopted a policy to make the 
system budget neutral in subsequent calendar years (72 FR 42532 through 
42533; 42 CFR 416.171(e)).
    We note that we consider the term ``expenditures'' in the context 
of the budget neutrality requirement under section 1833(i)(2)(D)(ii) of 
the Act to mean expenditures from the Medicare Part B Trust Fund. We do 
not consider expenditures to include beneficiary coinsurance and 
copayments. This distinction was important for the CY 2008 ASC budget 
neutrality model that considered payments across the OPPS, ASC, and 
MPFS payment systems. However, because coinsurance is almost always 20 
percent for ASC services, this interpretation of expenditures has 
minimal impact for subsequent budget neutrality adjustments calculated 
within the revised ASC payment system.
    In the CY 2008 OPPS/ASC final rule with comment period (72 FR 66857 
through 66858), we set out a step-by-step illustration of the final 
budget neutrality adjustment calculation based on the methodology 
finalized in the August 2, 2007 final rule (72 FR 42521 through 42531) 
and as applied to updated data available for the CY 2008 OPPS/ASC final 
rule with comment period. The application of that methodology to the 
data available for the CY 2008 OPPS/ASC final rule with comment period 
resulted in a budget neutrality adjustment of 0.65.
    For CY 2008, we adopted the OPPS relative payment weights as the 
ASC relative payment weights for most services and, consistent with the 
final policy, we calculated the CY 2008 ASC payment rates by 
multiplying the ASC relative payment weights by the final CY 2008 ASC 
conversion factor of $41.401. For covered office-based surgical 
procedures, covered ancillary radiology services (excluding covered 
ancillary radiology services involving certain nuclear medicine 
procedures or involving the use of contrast agents, as discussed in 
section XII.D.2. of this final rule with comment period), and certain 
diagnostic tests within the medicine range that are covered ancillary 
services, the established policy is to set the payment rate at the 
lower of the MPFS unadjusted nonfacility PE RVU-based amount or the 
amount calculated using the ASC standard ratesetting methodology. 
Further, as discussed in the CY 2008 OPPS/ASC final rule with comment 
period (72 FR 66841 through 66843), we also adopted alternative 
ratesetting methodologies for specific types of services (for example, 
device-intensive procedures).
    As discussed in the August 2, 2007 final rule (72 FR 42517 through 
42518) and as codified at Sec.  416.172(c) of the regulations, the 
revised ASC payment system accounts for geographic wage variation when 
calculating individual ASC payments by applying the pre-floor and pre-
reclassified IPPS hospital wage indexes to the labor-related share, 
which is 50 percent of the ASC payment amount based on a GAO report of 
ASC costs using 2004 survey data. Beginning in CY 2008, CMS accounted 
for geographic wage variation in labor costs when calculating 
individual ASC payments by applying the pre-floor and pre-reclassified 
hospital wage index values that CMS calculates for payment under the 
IPPS, using updated Core Based Statistical Areas (CBSAs) issued by OMB 
in June 2003.
    The reclassification provision in section 1886(d)(10) of the Act is 
specific to hospitals. We believe that using the most recently 
available pre-floor and pre-reclassified IPPS hospital wage indexes 
results in the most appropriate adjustment to the labor portion of ASC 
costs. We continue to believe that the unadjusted hospital wage 
indexes, which are updated yearly and are used by many other Medicare 
payment systems, appropriately account for geographic variation in 
labor costs for ASCs. Therefore, the wage index for an ASC is the pre-
floor and pre-reclassified hospital wage index under the IPPS of the 
CBSA that maps to the CBSA where the ASC is located.

[[Page 59074]]

    On February 28, 2013, OMB issued OMB Bulletin No. 13-01, which 
provides the delineations of all Metropolitan Statistical Areas, 
Metropolitan Divisions, Micropolitan Statistical Areas, Combined 
Statistical Areas, and New England City and Town Areas in the United 
States and Puerto Rico based on the standards published on June 28, 
2010 in the Federal Register (75 FR 37246 through 37252) and 2010 
Census Bureau data. (A copy of this bulletin may be obtained at: 
https://www.whitehouse.gov/sites/whitehouse.gov/files/omb/bulletins/2013/b13-01.pdf.) In the FY 2015 IPPS/LTCH PPS final rule (79 FR 49951 
through 49963), we implemented the use of the CBSA delineations issued 
by OMB in OMB Bulletin 13-01 for the IPPS hospital wage index beginning 
in FY 2015. In the CY 2015 OPPS/ASC final rule with comment period (79 
FR 66937), we finalized a 1-year transition policy that we applied in 
CY 2015 for all ASCs that experienced any decrease in their actual wage 
index exclusively due to the implementation of the new OMB 
delineations. This transition does not apply in CY 2019.
    Generally, OMB issues major revisions to statistical areas every 10 
years, based on the results of the decennial census. However, OMB 
occasionally issues minor updates and revisions to statistical areas in 
the years between the decennial censuses. On July 15, 2015, OMB issued 
OMB Bulletin No. 15-01, which provides updates to and supersedes OMB 
Bulletin No. 13-01 that was issued on February 28, 2013. The attachment 
to OMB Bulletin No. 15-01 provides detailed information on the update 
to statistical areas since February 28, 2013. The updates provided in 
OMB Bulletin No. 15-01 are based on the application of the 2010 
Standards for Delineating Metropolitan and Micropolitan Statistical 
Areas to Census Bureau population estimates for July 1, 2012 and July 
1, 2013. The complete list of statistical areas incorporating these 
changes is provided in the attachment to OMB Bulletin No. 15-01. 
According to OMB, ``[t]his bulletin establishes revised delineations 
for the Nation's Metropolitan Statistical Areas, Micropolitan 
Statistical Areas, and Combined Statistical Areas. The bulletin also 
provides delineations of Metropolitan Divisions as well as delineations 
of New England City and Town Areas.'' (A copy of this bulletin may be 
obtained at: https://www.whitehouse.gov/sites/whitehouse.gov/files/omb/bulletins/2015/15-01.pdf.)
    OMB Bulletin No. 15-01 made changes that are relevant to the IPPS 
and ASC wage index. We refer readers to the CY 2017 OPPS/ASC final rule 
with comment period (81 FR 79750) for a discussion of these changes and 
our implementation of these revisions.
    In OMB Bulletin No. 17-01, OMB announced that one Micropolitan 
Statistical Area now qualifies as a Metropolitan Statistical Area. The 
new urban CBSA is as follows:
     Twin Falls, Idaho (CBSA 46300). This CBSA is comprised of 
the principal city of Twin Falls, Idaho in Jerome County, Idaho and 
Twin Falls County, Idaho.
    The OMB bulletin is available at: https://www.whitehouse.gov/sites/whitehouse.gov/files/omb/bulletins/2017/b-17-01.pdf. We note that we 
did not have sufficient time to include this change in the computation 
of the proposed FY 2019 IPPS wage index. We stated that this new CBSA 
may affect the budget neutrality factors and wage indexes, depending on 
the impact of the overall payments of ASCs located in this new CBSA. In 
the CY 2019 OPPS/ASC proposed rule (83 FR 37075), we provided an 
estimate (shown below) of this new area's wage index based on the 
average hourly wages for new CBSA 46300 and the national average hourly 
wages from the wage data for the proposed FY 2019 wage index (described 
in section III.B. of the preamble of the FY 2019 IPPS/LTCH PPS proposed 
rule). Currently, provider 130002 is the only hospital located in Twin 
Falls County, Idaho, and there are no hospitals located in Jerome 
County, Idaho. Thus, the proposed wage index for CBSA 46300 was 
calculated using the average hourly wage data for one provider 
(provider 130002).
[GRAPHIC] [TIFF OMITTED] TR21NO18.099

    Other than the previously described wage index, for CY 2019, the 
final CY 2019 ASC wage indexes fully reflect the OMB labor market area 
delineations (including the revisions to the OMB labor market 
delineations discussed above, as set forth in OMB Bulletin Nos. 15-01 
and 17-01).
    We note that, in certain instances, there might be urban or rural 
areas for which there is no IPPS hospital that has wage index data that 
could be used to set the wage index for that area. For these areas, our 
policy has been to use the average of the wage indexes for CBSAs (or 
metropolitan divisions as applicable) that are contiguous to the area 
that has no wage index (where ``contiguous'' is defined as sharing a 
border). For example, for CY 2014, we applied a proxy wage index based 
on this methodology to ASCs located in CBSA 25980 (Hinesville-Fort 
Stewart, GA) and CBSA 08 (Rural Delaware).
    When all of the areas contiguous to the urban CBSA of interest are 
rural and there is no IPPS hospital that has wage index data that could 
be used to set the wage index for that area, we determine the ASC wage 
index by calculating the average of all wage indexes for urban areas in 
the State (75 FR 72058 through 72059). (In other situations, where 
there are no IPPS hospitals located in a relevant labor market area, we 
continue our current policy of calculating an urban or rural area's 
wage index by calculating the average of the wage indexes for CBSAs (or 
metropolitan

[[Page 59075]]

divisions where applicable) that are contiguous to the area with no 
wage index.)
2. Calculation of the ASC Payment Rates
a. Updating the ASC Relative Payment Weights for CY 2019 and Future 
Years
    We update the ASC relative payment weights each year using the 
national OPPS relative payment weights (and PFS nonfacility PE RVU-
based amounts, as applicable) for that same calendar year and uniformly 
scale the ASC relative payment weights for each update year to make 
them budget neutral (72 FR 42533). In the CY 2019 OPPS/ASC proposed 
rule (83 FR 37171), consistent with our established policy, we proposed 
to scale the CY 2019 relative payment weights for ASCs according to the 
following method. Holding ASC utilization, the ASC conversion factor, 
and the mix of services constant from CY 2017, we proposed to compare 
the total payment using the CY 2018 ASC relative payment weights with 
the total payment using the CY 2019 ASC relative payment weights to 
take into account the changes in the OPPS relative payment weights 
between CY 2018 and CY 2019. We proposed to use the ratio of CY 2018 to 
CY 2019 total payments (the weight scalar) to scale the ASC relative 
payment weights for CY 2019. The proposed CY 2019 ASC weight scalar was 
0.8854 and scaling would apply to the ASC relative payment weights of 
the covered surgical procedures, covered ancillary radiology services, 
and certain diagnostic tests within the medicine range of CPT codes, 
which are covered ancillary services for which the ASC payment rates 
are based on OPPS relative payment weights.
    Scaling would not apply in the case of ASC payment for separately 
payable covered ancillary services that have a predetermined national 
payment amount (that is, their national ASC payment amounts are not 
based on OPPS relative payment weights), such as drugs and biologicals 
that are separately paid or services that are contractor-priced or paid 
at reasonable cost in ASCs. Any service with a predetermined national 
payment amount would be included in the ASC budget neutrality 
comparison, but scaling of the ASC relative payment weights would not 
apply to those services. The ASC payment weights for those services 
without predetermined national payment amounts (that is, those services 
with national payment amounts that would be based on OPPS relative 
payment weights) would be scaled to eliminate any difference in the 
total payment between the current year and the update year.
    For any given year's ratesetting, we typically use the most recent 
full calendar year of claims data to model budget neutrality 
adjustments. At the time of the proposed rule, we had available 98 
percent of CY 2017 ASC claims data.
    To create an analytic file to support calculation of the weight 
scalar and budget neutrality adjustment for the wage index (discussed 
below), we summarized available CY 2017 ASC claims by ASC and by HCPCS 
code. We used the National Provider Identifier for the purpose of 
identifying unique ASCs within the CY 2017 claims data. We used the 
supplier zip code reported on the claim to associate State, county, and 
CBSA with each ASC. This file, available to the public as a supporting 
data file for the proposed rule, is posted on the CMS website at: 
https://www.cms.gov/Research-Statistics-Data-and-Systems/Files-for-Order/LimitedDataSets/ASCPaymentSystem.html.
b. Updating the ASC Conversion Factor
    Under the OPPS, we typically apply a budget neutrality adjustment 
for provider level changes, most notably a change in the wage index 
values for the upcoming year, to the conversion factor. Consistent with 
our final ASC payment policy, for the CY 2017 ASC payment system and 
subsequent years, in the CY 2017 OPPS/ASC final rule with comment 
period (81 FR 79751 through 79753), we finalized our policy to 
calculate and apply a budget neutrality adjustment to the ASC 
conversion factor for supplier level changes in wage index values for 
the upcoming year, just as the OPPS wage index budget neutrality 
adjustment is calculated and applied to the OPPS conversion factor. For 
CY 2019, we calculated the proposed adjustment for the ASC payment 
system by using the most recent CY 2017 claims data available and 
estimating the difference in total payment that would be created by 
introducing the proposed CY 2019 ASC wage indexes. Specifically, 
holding CY 2017 ASC utilization, service-mix, and the proposed CY 2019 
national payment rates after application of the weight scalar constant, 
we calculated the total adjusted payment using the CY 2018 ASC wage 
indexes (which would fully reflect the new OMB delineations) and the 
total adjusted payment using the proposed CY 2019 ASC wage indexes. We 
used the 50-percent labor-related share for both total adjusted payment 
calculations. We then compared the total adjusted payment calculated 
with the CY 2018 ASC wage indexes to the total adjusted payment 
calculated with the proposed CY 2019 ASC wage indexes and applied the 
resulting ratio of 1.0003 (the proposed CY 2019 ASC wage index budget 
neutrality adjustment) to the CY 2018 ASC conversion factor to 
calculate the proposed CY 2019 ASC conversion factor.
    Section 1833(i)(2)(C)(i) of the Act requires that, if the Secretary 
has not updated amounts established under the revised ASC payment 
system in a calendar year, the payment amounts shall be increased by 
the percentage increase in the Consumer Price Index for all urban 
consumers (CPI-U), U.S. city average, as estimated by the Secretary for 
the 12-month period ending with the midpoint of the year involved. The 
statute does not mandate the adoption of any particular update 
mechanism, but it requires the payment amounts to be increased by the 
CPI-U in the absence of any update. Because the Secretary updates the 
ASC payment amounts annually, we adopted a policy, which we codified at 
42 CFR 416.171(a)(2)(ii)), to update the ASC conversion factor using 
the CPI-U for CY 2010 and subsequent calendar years.
    In the CY 2018 OPPS/ASC rulemaking (82 FR 33668 through 33670; 
59422 through 59424), we solicited and discussed comments regarding our 
current policy, codified at 42 CFR 416.171(a)(2)(ii), to update the ASC 
conversion factor using the CPI-U for CY 2010 and subsequent calendar 
years. In the CY 2018 OPPS/ASC final rule with comment period, we noted 
that in 2008 facilities paid under the ASC payment system received 
approximately 65 percent of the payment that hospitals paid under the 
OPPS received for an average service. The differential between ASC 
facility payment and OPPS provider payment has continued to increase 
since 2008, and by 2017, facilities paid under the ASC payment system 
received approximately 56 percent of the payment that hospitals paid 
under the OPPS received for an average service. At the same time, 
indicators of ASC payment adequacy, such as capacity and supply of 
providers and providers' access to capital, suggest that Medicare 
beneficiaries have adequate access to ASC services.\100\
---------------------------------------------------------------------------

    \100\ MedPAC. Report to the Congress: March 2018.
---------------------------------------------------------------------------

    The Administration recognizes the value that ASCs may bring to the 
Medicare Program that results in the delivery of efficient, high-
quality care to beneficiaries at a lower cost. The Administration is 
promoting greater

[[Page 59076]]

price transparency across all of Medicare's payment systems. Both 
beneficiaries and the Medicare Program benefit from reduced 
expenditures when a beneficiary's clinical needs allow for a procedure 
to be performed in lower cost settings, such as ASCs relative to 
hospital outpatient departments.\101\
---------------------------------------------------------------------------

    \101\ Medicare Beneficiaries Could Save Billions if CMS Reduces 
Hospital Outpatient Department Payment Rates for Ambulatory Surgical 
Center-Approved Procedures to Ambulatory Surgical Center Payment 
Rates, Department of Health and Human Services, Office of Inspector 
General, April 2014.
---------------------------------------------------------------------------

    As articulated in the FY 2019 President's Budget, the 
Administration supports payment reforms that base payment on patient 
characteristics rather than the site of care. To that end, we are 
exploring ways to align payments with the costs of care and to 
incentivize use of the most efficient and clinically appropriate sites 
of care including hospital outpatient departments, ASCs, and physician 
offices, to the extent feasible, in future rulemaking. In the near 
term, however, there is concern by some stakeholders that the 
differential between payment updates for HOPDs and ASCs is resulting in 
inefficient and unnecessary shifts of care to the hospital outpatient 
setting and away from ASCs. We are concerned about the potential 
unintended consequences of using the CPI-U to update payments for ASCs, 
such as consolidation of ASCs or fewer physician-owned ASCs, which may 
contribute to higher prices; stagnation in number of ASC facilities and 
number of multispecialty ASC facilities; and payments being misaligned 
with the cost of treatment for complex patients.
    We recognize prior public commenters' belief that ASCs may incur 
some of the same costs that hospitals incur, which may be better 
reflected in the hospital market basket update than the CPI-U. 
Nevertheless, we recognize also that ASCs are among the only health 
care facilities in Medicare that do not submit cost information and 
therefore their rates are not updated based on a related market basket. 
We do not believe that the ASC cost structure is identical to the 
hospital cost structure for a few reasons (these differences are 
illustrative and not exhaustive). First, the majority of ASCs are 
single specialty (61 percent based on 2016 data), whereas hospitals 
provide a wider variety of services, and also provide inpatient care 
and room and board. Second, the vast majority of ASCs are for-profit 
and located in urban areas, whereas hospital ownership is varied and 
hospitals are located in more geographically diverse locations. Third, 
compliance with certain laws, such as the Emergency Medical Treatment 
and Labor Act (EMTALA), apply to hospitals and do not apply to ASCs. 
These differences illustrate why there is reason to believe there is a 
measure of misalignment between the HOPD and ASC cost structure, and 
should be considered when assessing the suitability of using the 
hospital market basket as a better proxy for ASC costs than the CPI-U.
    According to commenters on the CY 2018 OPPS/ASC proposed rule, only 
8.5 percent of the CPI-U inputs are related to health care, and even 
those inputs are based on a consumer's experience purchasing health 
care items, rather than a provider's experience purchasing the items 
necessary to furnish a health care service, and do not measure whether 
a facility's costs increase, such as the cost of purchasing supplies 
and equipment or personnel labor costs.
    We also acknowledge prior public commenters' concern that the 
disparity in payments between the OPPS and the ASC payment system may 
reduce the migration of services from the HOPD setting to the less 
costly ASC setting. For example, one study looked at the impact of the 
difference in facility fees paid to ASCs versus hospital outpatient 
departments on ASC growth using a fixed effects model.\102\ The study 
found results indicating that, as ASC payments increase, patients are 
more likely to undergo outpatient procedures in an ASC than they are in 
a hospital. Another study found that the opening of an ASC in a 
hospital service area resulted in a decline in hospital-based 
outpatient surgery without increasing mortality or admission.\103\ In 
markets where facilities opened, procedure growth at ASCs was greater 
than the decline in outpatient surgery use at their respective 
hospitals.
---------------------------------------------------------------------------

    \102\ Munnich EL, Parente ST. Returns to Specialization: 
Evidence from the Outpatient Surgery Market. Journal of Health 
Economics,Volume 57, January 2018.
    \103\ Hollenbeck BK, Dunn RL, et. al. Ambulatory Surgery Centers 
and Their Intended Effects on Outpatient Surgery. HSR: Health 
Services Research. 50:5. October 2015.
---------------------------------------------------------------------------

    If a migration of services from the hospital setting to ASCs 
occurred, it may potentially yield savings to the Medicare program and 
beneficiaries if the savings from the migration of services net of any 
increases in total volume of services does not exceed the cost of a 
higher rate update factor. ASC payment rates would still generally be 
significantly less than under the OPPS.
    To the extent that it is clinically appropriate for a beneficiary 
to receive services in a lower cost setting, we believe it would be 
appropriate to continue to develop payment incentives and remove 
payment disincentives to facilitate this choice. While there are 
several factors that contribute to the divergence in payment between 
the two systems (which were identified in the comment solicitation on 
ASC payment reform in the CY 2018 OPPS/ASC rulemaking), such as 
different distribution of costs between hospitals and ASCs and 
different ratesetting methodologies between the OPPS and the ASC 
payment system, we believe that an alternative update factor could 
stabilize the differential between the OPPS payment and the ASC 
payment, to the extent that the CPI-U has been lower than the hospital 
market basket, and encourage the migration of services to lower cost 
settings as clinically appropriate (82 FR 59422 through 59424). In 
addition, we note that there are many services that can safely be 
performed in either the hospital setting or the ASC setting and a 
common rate update factor recognizes that the two provider types often 
compete for the same patients though patient acuity is likely higher in 
hospitals.
    Therefore, we believe providing ASCs with the same rate update 
mechanism as hospitals could encourage the migration of services from 
the hospital setting to the ASC setting and increase the presence of 
ASCs in health care markets or geographic areas where previously there 
were none or few, thus promoting better beneficiary access to care. 
However, because physicians have a financial interest in ASCs, higher 
payments could also lead to greater utilization of services.\104\ At 
the same time, we are cognizant of concerns that Medicare does not 
currently collect cost data from ASCs, which makes it difficult to 
assess payment adequacy in the same way that it is assessed for 
hospitals, to validate alignment between ASC and hospital cost 
structure, or to establish an ASC-specific market basket. Accordingly, 
until we have information on the ASC cost structure, we would like to 
balance our desire to promote migration of services away from the HOPD 
to ASCs where clinically appropriate with our desire to minimize 
increases in beneficiary out-of-pocket costs. In the CY 2019 OPPS/ASC 
proposed rule (83 FR 37173 through 37175), therefore, as described in 
more specific detail below, we proposed to apply a hospital market 
basket update to

[[Page 59077]]

ASCs for an interim period of 5 years but sought comments on ASC costs 
to assess whether the hospital market basket is an appropriate proxy 
for ASC costs. We noted that the hospital market basket is collected 
under OMB Control No. 0938-0050 and the information collected through 
hospital cost reports is used, in part, to inform the calculation of 
the hospital market basket.
---------------------------------------------------------------------------

    \104\ Munnich EL, Parente ST. Returns to Specialization: 
Evidence from the Outpatient Surgery Market. Journal of Health 
Economics, Volume 57, January 2018.
---------------------------------------------------------------------------

    We proposed that the hospital market basket update applied to ASC 
payment rates would be derived using the same hospital inpatient market 
basket percentage increase that we proposed to use to derive the OPD 
fee increase factor as described in section II.B. of the CY 2019 OPPS/
ASC proposed rule and would be adjusted for multifactor productivity. 
We proposed this payment update methodology for a 5-year period, during 
which we proposed to assess whether there is a migration of procedures 
from the hospital setting to the ASC setting as a result of the use of 
a hospital market basket update, as well as whether there are any 
unintended consequences (for example, an unnecessary increase in the 
overall volume of services or beneficiaries' out-of-pocket costs). We 
believed that 5 years would be an appropriate number of years to assess 
changes in the migration of services, as it should provide us enough 
time to confirm that trends in the data are consistent over time. In 
the proposed rule, we welcomed comment on whether implementing the 
hospital market basket update for a different number of years might be 
more appropriate.
    In the proposed rule, we stated that we were interested in 
commenter feedback on additional ways we can evaluate the impacts of 
this payment change over the 5-year period. For example, we welcomed 
input on how we should delineate between changes in the volume of a 
particular service due to the higher update, versus changes in the 
volume of a service due to changes in enrollment, patient acuity, or 
utilization, and what would be an appropriate interval to measure such 
migration of services.
    During this 5-year period, we intend to assess the feasibility of 
collaborating with stakeholders to collect ASC cost data in a minimally 
burdensome manner and could propose a plan to collect such information. 
As previously mentioned, in response to the comment solicitation in the 
CY 2018 OPPS/ASC proposed rule, stakeholders indicated a willingness to 
work with CMS to collect cost information in the least burdensome 
manner (82 FR 59422 through 59424).
    Therefore, for CY 2019 through 2023, in response to stakeholder 
concerns described in the CY 2018 OPPS/ASC final rule with comment 
period (82 FR 59420 through 59421) that ASCs may incur some of the same 
costs that hospitals incur and that are better reflected in the 
hospital market basket update than the CPI-U, and including the concern 
that the payment differentials between the different settings of care 
due to the use of the CPI-U may stagnate the migration of services from 
hospitals to the ASC setting, even though those services can be safely 
performed in ASCs, we proposed to update ASC payment rates using the 
hospital market basket and to revise our regulations under 42 CFR 
416.171(a)(2), which address the annual update to the ASC conversion 
factor, to reflect this proposal. In addition, we requested comments 
and evidence to assess whether the hospital market basket is an 
appropriate proxy for ASC costs. Under this proposal, for CY 2019, we 
proposed to use the FY 2019 hospital market basket update as published 
in the FY 2019 IPPS/LTCH PPS proposed rule (83 FR 20381). This proposed 
update to ASC payment rates was derived using the same hospital 
inpatient market basket percentage increase that we proposed to use to 
derive the OPD fee increase factor as described in section II.B. of the 
CY 2019 OPPS/ASC proposed rule. We also sought comments on an 
alternative proposal to maintain using the CPI-U for the annual ASC 
payment update while collecting evidence to justify a different payment 
update, or adopting the new proposed payment update based on the 
hospital market basket permanently. We requested comments on what type 
of evidence should be used to justify a different payment update and 
how CMS should go about collecting that information in the least 
burdensome way possible.
    Section 1833(t)(3)(G)(v) of the Act applies an additional 
adjustment of 0.75 for CY 2019 to hospitals. We noted that such 
adjustment was authorized by the Affordable Care Act and that, while 
the Affordable Care Act authorized a productivity adjustment for ASCs 
(as it did for hospitals), it expressly did not authorize the 
``additional adjustment'' that was mandated for hospitals. The 
additional adjustment is separate and distinct from the productivity 
adjustment that already applies to both hospitals and ASCs and there 
does not appear to be a correlation between the productivity adjustment 
and the additional adjustment. Further, application of the additional 
adjustment may be contrary to the goals we have articulated that led us 
to propose to apply the hospital market basket to the ASC payment 
system in the first place; that is, we believe that proposing to apply 
the hospital market basket to ASC rates may encourage the migration of 
services from the hospital setting to the ASC setting. However, if we 
had proposed to apply the additional adjustment, the ASC rate update 
would have been 1.25 percent, instead of the proposed 2.0 percent. The 
1.25 percent was lower than applying the CPI-U rate update factor, 
which at the time of the CY 2019 OPPS/ASC proposed rule would have been 
1.3 percent for CY 2019. This lower update would appear contrary to the 
goals set forth earlier in this section. However, we sought comment on 
whether applying this additional adjustment may nonetheless be 
appropriate.
    While we expect this policy will increase spending, by both the 
government and beneficiaries, relative to the current update factor 
over the 5-year period, as previously stated, we also believe that the 
proposal could encourage the migration of services that are currently 
performed in the hospital outpatient setting to the ASC setting, which 
could result in savings to beneficiaries and the Medicare program. We 
believe that it is important to maximize patient choice to obtain 
services at a lower cost to the extent feasible. We believe also that 
without cost data from ASCs to examine their cost structure and 
adequacy of payment, we lack key data that may help inform the 
development of payment policies that are based on patients' clinical 
needs rather than the site of care.
    In the proposed rule, we stated that, if, after review of all 
comments and all available evidence, we chose to finalize this 
proposal, we would continue to monitor site-of-service shifts for the 
duration of this policy to determine if services move safely to lower 
cost settings and to explore collecting additional data that may help 
inform further development of the ASC payment system. We proposed to 
continue to use the adjusted hospital market basket update through CY 
2023 (for 5 years total). We proposed that we intend to reassess 
whether application of the hospital market basket update to ASC rates 
has provided more patient choice to obtain services at a lower cost 
beginning with the CY 2024 rulemaking period, or sooner if appropriate.
    Section 3401(k) of the Affordable Care Act amended section 
1833(i)(2)(D) of the Act by adding a new clause (v), which requires 
that any annual update under the ASC payment system for the year,

[[Page 59078]]

after application of clause (iv), shall be reduced by the productivity 
adjustment described in section 1886(b)(3)(B)(xi)(II) of the Act, 
effective with the calendar year beginning January 1, 2011. The statute 
defines the productivity adjustment to be equal to the 10-year moving 
average of changes in annual economy-wide private nonfarm business 
multifactor productivity (MFP) (as projected by the Secretary for the 
10-year period ending with the applicable fiscal year, year, cost 
reporting period, or other annual period) (the ``MFP adjustment''). 
Clause (iv) of section 1833(i)(2)(D) of the Act authorizes the 
Secretary to provide for a reduction in any annual update for failure 
to report on quality measures. Clause (v) of section 1833(i)(2)(D) of 
the Act states that application of the MFP adjustment to the ASC 
payment system may result in the update to the ASC payment system being 
less than zero for a year and may result in payment rates under the ASC 
payment system for a year being less than such payment rates for the 
preceding year.
    In the CY 2012 OPPS/ASC final rule with comment period (76 FR 
74516), we finalized a policy that ASCs begin submitting data on 
quality measures for services beginning on October 1, 2012 for the CY 
2014 payment determination under the ASC Quality Reporting (ASCQR) 
Program. In the CY 2013 OPPS/ASC final rule with comment period (77 FR 
68499 through 68500), we finalized a methodology to calculate reduced 
national unadjusted payment rates using the ASCQR Program reduced 
update conversion factor that would apply to ASCs that fail to meet 
their quality reporting requirements for the CY 2014 payment 
determination and subsequent years. The application of the 2.0 
percentage point reduction to the annual update factor, which we 
proposed to be the hospital market basket update, may result in the 
update to the ASC payment system being less than zero for a year for 
ASCs that fail to meet the ASCQR Program requirements. We amended 
Sec. Sec.  416.160(a)(1) and 416.171 to reflect these policies.
    In prior years, in accordance with section 1833(i)(2)(C)(i) of the 
Act, before applying the MFP adjustment, the Secretary first determined 
the ``percentage increase'' in the CPI-U, which we interpreted cannot 
be a negative percentage. Thus, in the instance where the percentage 
change in the CPI-U for a year was negative, we would hold the CPI-U 
update factor for the ASC payment system to zero (75 FR 72062). 
Consistent with past practice, in the instance where the percentage 
change in the hospital market basket for a year is negative, we 
proposed to hold the hospital market basket update factor for the ASC 
payment system to zero. For the CY 2014 payment determination and 
subsequent years, under section 1833(i)(2)(D)(iv) of the Act, we would 
reduce the annual update by 2.0 percentage points for an ASC that fails 
to submit quality information under the policies established by the 
Secretary in accordance with section 1833(i)(7) of the Act. Section 
1833(i)(2)(D)(v) of the Act, as added by section 3401(k) of the 
Affordable Care Act, requires that the Secretary reduce the annual 
update factor, after application of any quality reporting reduction, by 
the MFP adjustment, and states that application of the MFP adjustment 
to the annual update factor after application of any quality reporting 
reduction may result in the update being less than zero for a year. If 
the application of the MFP adjustment to the annual update factor after 
application of any quality reporting reduction would result in an MFP-
adjusted update factor that is less than zero, the resulting update to 
the ASC payment rates would be negative and payments would decrease 
relative to the prior year. We refer readers to the CY 2011 OPPS/ASC 
final rule with comment period (75 FR 72062 through 72064) for examples 
of how the MFP adjustment is applied to the ASC payment system.
    For the CY 2019 OPPS/ASC proposed rule, the hospital market basket 
update for CY 2019 was projected to be 2.8 percent, as published in the 
FY 2019 IPPS/LTCH PPS proposed rule (83 FR 20381), based on IHS Global 
Inc.'s (IGI's) 2017 fourth quarter forecast with historical data 
through the third quarter of 2017. For this final rule with comment 
period, as published in the FY 2019 IPPS/LTCH PPS final rule (83 FR 
41395), based on IGI's 2018 second quarter forecast with historical 
data through the first quarter of 2018, the hospital market basket 
update for CY 2019 is 2.9 percent.
    We finalized the methodology for calculating the MFP adjustment in 
the CY 2011 PFS final rule with comment period (75 FR 73394 through 
73396) and revised it in the CY 2012 PFS final rule with comment period 
(76 FR 73300 through 73301) and the CY 2016 OPPS/ASC final rule with 
comment period (80 FR 70500 through 70501). For the CY 2019 OPPS/ASC 
proposed rule, the proposed MFP adjustment for CY 2019 was projected to 
be 0.8 percentage point, as published in the FY 2019 IPPS/LTCH PPS 
proposed rule (83 FR 20382) based on IGI's 2017 fourth quarter 
forecast. For this final rule with comment period, as published in the 
FY 2019 IPPS/LTCH PPS final rule (83 FR 41395) based on IGI's 2018 
second quarter forecast, the final MFP adjustment for CY 2019 is 0.8 
percentage point.
    We note that the update factor for CY 2019 under the current 
policy, which is to increase the payment amounts by the percentage 
increase in the CPI-U, U.S. city average, as estimated by the Secretary 
for the 12-month period ending with the midpoint of the year involved, 
is currently projected to be 2.6 percent (based on IGI's third quarter 
2018 forecast). The MFP adjustment that aligns with this payment update 
under current policy (ending with the midpoint of the year involved) is 
0.8 percentage point, resulting in an update amount under the current 
policy of 1.8 percent (CPI-U of 2.6 percent less MFP adjustment of 0.8 
percentage point).
    For CY 2019, we proposed to utilize the hospital market basket 
update of 2.8 percent minus the MFP adjustment of 0.8 percentage point, 
resulting in an MFP-adjusted hospital market basket update factor of 
2.0 percent for ASCs meeting the quality reporting requirements. 
Therefore, we proposed to apply a 2.0 percent MFP-adjusted hospital 
market basket update factor to the CY 2018 ASC conversion factor for 
ASCs meeting the quality reporting requirements to determine the CY 
2019 ASC payment amounts. The ASCQR Program affected payment rates 
beginning in CY 2014 and, under this program, there is a 2.0 percentage 
point reduction to the update factor for ASCs that fail to meet the 
ASCQR Program requirements. We proposed to utilize the hospital market 
basket update of 2.8 percent reduced by 2.0 percentage points for ASCs 
that do not meet the quality reporting requirements and then subtract 
the 0.8 percentage point MFP adjustment. Therefore, we proposed to 
apply a 0.0 percent MFP-adjusted hospital market basket update factor 
to the CY 2018 ASC conversion factor for ASCs not meeting the quality 
reporting requirements. We also proposed that if more recent data were 
subsequently available (for example, a more recent estimate of the 
hospital market basket update and MFP), we would use such data, if 
appropriate, to determine the CY 2019 ASC update for the final rule 
with comment period.
    For CY 2019, we proposed to adjust the CY 2018 ASC conversion 
factor ($45.575) by the proposed wage index budget neutrality factor of 
1.0003 in addition to the MFP-adjusted hospital market basket update 
factor of 2.0 percent discussed above, which resulted in a proposed CY 
2019 ASC conversion

[[Page 59079]]

factor of $46.500 for ASCs meeting the quality reporting requirements. 
For ASCs not meeting the quality reporting requirements, we proposed to 
adjust the CY 2018 ASC conversion factor ($45.575) by the proposed wage 
index budget neutrality factor of 1.0003 in addition to the quality 
reporting/MFP-adjusted hospital market basket update factor of 0.0 
percent discussed above, which resulted in a proposed CY 2019 ASC 
conversion factor of $45.589.
    Comment: The majority of commenters supported the proposal to 
update ASC payment rates using the hospital market basket update. A 
number of commenters suggested that the CPI-U is not a suitable 
inflation index to update ASC payments because it does not accurately 
represent the costs of ASCs or health care facilities, broadly. One 
commenter noted that only 8 percent of the CPI-U index is comprised of 
health care-related items and no other Medicare payment system utilizes 
the CPI-U as a provider inflation-metric as many payment systems for 
other providers utilize a provider-specific market basket index. The 
commenter also noted that, while the hospital market basket update is 
the most appropriate update factor to apply to ASC payment system 
rates, alternative update factors (for example, the Medicare Economic 
Index) would have been preferable to the CPI-U.
    Other commenters in support of the proposal suggested that ASCs may 
incur some of the same costs that hospitals incur. In addition, 
commenters suggested that utilizing the hospital market basket update 
as the update mechanism would promote site neutrality and help restore 
relativity of average ASC payment rates to average HOPD payment rates. 
Some commenters recommended that CMS establish the hospital market 
basket update permanently as the ASC rate update mechanism rather than 
on an interim basis over 5 years.
    Commenters also supported the proposal to not apply the additional 
adjustment of 0.75 percentage points that applies to hospitals under 
section 1833(t)(3)(G)(v) of the Act.
    However, some commenters, including MedPAC, disagreed with the 
proposal and recommended collecting cost data from ASCs to inform an 
ASC-specific market basket index for updating payment rates under the 
ASC payment system. MedPAC noted that ASCs are fully capable of 
submitting cost report data, similar to other providers, such as ESRD 
facilities, hospices, and home health agencies. In addition, MedPAC 
suggested that, to minimize burden on ASCs and CMS, CMS could require 
all ASCs to submit streamlined cost reports or require a random sample 
of ASCs to submit cost data.
    Response: We appreciate the commenters' support. We recognize the 
commenters' belief that ASCs may incur some of the same costs that 
hospitals incur, which may be better reflected in the hospital market 
basket update than the CPI-U. We also are aware that only a relatively 
small percentage of the CPI-U inputs are related to health care, and 
even those inputs are based on a consumer's experience purchasing 
health care items, rather than a provider's experience purchasing the 
items necessary to furnish a health care service, and do not directly 
relate to a facility's costs, such as the cost of purchasing supplies 
and equipment or labor costs. We also acknowledge commenters' concern 
that the disparity in payments between the OPPS and the ASC payment 
system may reduce the migration of services from the HOPD setting to 
the less costly ASC setting. We believe providing ASCs with the same 
rate update mechanism as hospitals could encourage the migration of 
services from the hospital setting to the ASC setting and increase the 
presence of ASCs in health care markets or geographic areas where 
previously there were none or few, thus promoting better beneficiary 
access to care. We believe that it is important to encourage such 
migration of services and that this policy would give physicians and 
patients greater choice in selecting the best care setting.
    In addition, we acknowledge commenters recommendations regarding 
the collection of ASC cost data to inform an ASC-specific market basket 
index for updating payment rates under the ASC payment system. We 
appreciate these comments and will take these comments into 
consideration in future policy development.
    Comment: Many commenters recommended that CMS discontinue 
``rescaling'' the ASC relative weights and, instead, apply the OPPS 
relative weights as developed under the standard ratesetting 
methodology. The commenters argued that the weight scalar distorts ASC 
payments and further increases the payment differential between HOPDs 
and ASCs.
    Response: We note that applying the weight scalar in calculation of 
ASC payment rates, which for this final rule with comment period is 
0.8792, ensures that the ASC payment system remains budget neutral. For 
a detailed discussion on why we apply a budget neutrality adjustment to 
the ASC ratesetting methodology, we refer readers to the August 2, 2008 
final rule (72 FR 42531 through 42533).
    After consideration of the public comments we received, we are 
finalizing our proposal to apply the hospital market basket update to 
ASC payment system rates for an interim period of 5 years (CY 2019 
through CY 2023), during which we will assess whether there is a 
migration of the performance of procedures from the hospital setting to 
the ASC setting as a result of the use of a hospital market basket 
update, as well as whether there are any unintended consequences, such 
as less than expected migration of the performance of procedures from 
the hospital setting to the ASC setting. In addition, we are finalizing 
our proposal to revise our regulations under 42 CFR 416.171(a)(2), 
which address the annual update to the ASC conversion factor.
    Therefore, as proposed, to determine the CY 2019 ASC update for 
this final rule with comment period, we are incorporating a more recent 
estimate of the hospital market basket update and the MFP adjustment. 
For this CY 2019 OPPS/ASC final rule with comment period, as published 
in the FY 2019 IPPS/LTCH PPS final rule (83 FR 41395), based on IGI's 
2018 second quarter forecast with historical data through the first 
quarter of 2018, the MFP-adjusted hospital market basket update for CY 
2019 is 2.1 percent (that is, the hospital market basket increase of 
2.9 percent minus the MFP adjustment of 0.8 percentage point). 
Therefore, we are finalizing the application of a 2.1 percent MFP-
adjusted hospital market basket update factor to the CY 2018 ASC 
conversion factor for ASCs meeting the quality reporting requirements 
to determine the CY 2019 ASC payment amounts. The ASCQR Program 
affected payment rates beginning in CY 2014 and, under this program, 
there is a 2.0 percentage point reduction to the update factor for ASCs 
that fail to meet the ASCQR Program requirements. We are finalizing to 
utilize the hospital market basket update of 2.9 percent reduced by 2.0 
percentage points for ASCs that do not meet the quality reporting 
requirements and then subtract the 0.8 percentage point MFP adjustment. 
Therefore, we are applying a 0.1 percent MFP-adjusted hospital market 
basket update factor to the CY 2018 ASC conversion factor for ASCs not 
meeting the quality reporting requirements.
    For CY 2019, we are adjusting the CY 2018 ASC conversion factor 
($45.575) by the proposed wage index budget neutrality factor of 1.0004 
in addition to the MFP-adjusted hospital market basket update factor of 
2.1 percent

[[Page 59080]]

discussed above, which results in a CY 2019 ASC conversion factor of 
$46.551 for ASCs meeting the quality reporting requirements. For ASCs 
not meeting the quality reporting requirements, we are adjusting the CY 
2018 ASC conversion factor ($45.575) by the proposed wage index budget 
neutrality factor of 1.0004 in addition to the quality reporting/MFP-
adjusted hospital market basket update factor of 0.1 percent discussed 
above, which results in a CY 2019 ASC conversion factor of $45.639.
3. Display of CY 2019 ASC Payment Rates
    Addenda AA and BB to this final rule with comment period (which are 
available on the CMS website) display the final updated ASC payment 
rates for CY 2019 for covered surgical procedures and covered ancillary 
services, respectively. For those covered surgical procedures and 
covered ancillary services where the payment rate is the lower of the 
final rates under the ASC standard ratesetting methodology and the MPFS 
final rates, the final payment indicators and rates set forth in this 
final rule with comment period are based on a comparison using the 
final PFS rates that will be effective January 1, 2019. For a 
discussion of the PFS rates, we refer readers to the CY 2019 PFS final 
rule with comment period.
    The final payment rates included in these addenda reflect the full 
ASC payment update and not the reduced payment update used to calculate 
payment rates for ASCs not meeting the quality reporting requirements 
under the ASCQR Program. These addenda contain several types of 
information related to the final CY 2019 payment rates. Specifically, 
in Addendum AA, a ``Y'' in the column titled ``To be Subject to 
Multiple Procedure Discounting'' indicates that the surgical procedure 
would be subject to the multiple procedure payment reduction policy. As 
discussed in the CY 2008 OPPS/ASC final rule with comment period (72 FR 
66829 through 66830), most covered surgical procedures are subject to a 
50-percent reduction in the ASC payment for the lower-paying procedure 
when more than one procedure is performed in a single operative 
session.
    Display of the comment indicator ``CH'' in the column titled 
``Comment Indicator'' indicates a change in payment policy for the item 
or service, including identifying discontinued HCPCS codes, designating 
items or services newly payable under the ASC payment system, and 
identifying items or services with changes in the ASC payment indicator 
for CY 2018. Display of the comment indicator ``NI'' in the column 
titled ``Comment Indicator'' indicates that the code is new (or 
substantially revised) and that comments will be accepted on the 
interim payment indicator for the new code. Display of the comment 
indicator ``NP'' in the column titled ``Comment Indicator'' indicates 
that the code is new (or substantially revised) and that comments will 
be accepted on the ASC payment indicator for the new code.
    The values displayed in the column titled ``Final CY 2019 Payment 
Weight'' are the final relative payment weights for each of the listed 
services for CY 2019. The final relative payment weights for all 
covered surgical procedures and covered ancillary services where the 
ASC payment rates are based on OPPS relative payment weights were 
scaled for budget neutrality. Therefore, scaling was not applied to the 
device portion of the device-intensive procedures, services that are 
paid at the MPFS nonfacility PE RVU-based amount, separately payable 
covered ancillary services that have a predetermined national payment 
amount, such as drugs and biologicals and brachytherapy sources that 
are separately paid under the OPPS, or services that are contractor-
priced or paid at reasonable cost in ASCs.
    To derive the final CY 2019 payment rate displayed in the ``Final 
CY 2019 Payment Rate'' column, each ASC payment weight in the ``Final 
CY 2019 Payment Weight'' column was multiplied by the final CY 2019 
conversion factor of $46.551. The final conversion factor includes a 
budget neutrality adjustment for changes in the wage index values and 
the annual update factor as reduced by the productivity adjustment (as 
discussed in section XII.G.2.b. of this final rule with comment 
period).
    In Addendum BB, there are no relative payment weights displayed in 
the ``Final CY 2019 Payment Weight'' column for items and services with 
predetermined national payment amounts, such as separately payable 
drugs and biologicals. The ``Final CY 2019 Payment'' column displays 
the final CY 2019 national unadjusted ASC payment rates for all items 
and services. The final CY 2019 ASC payment rates listed in Addendum BB 
for separately payable drugs and biologicals are based on ASP data used 
for payment in physicians' offices in October 2018.
    Addendum EE provides the HCPCS codes and short descriptors for 
surgical procedures that are to be excluded from payment in ASCs for CY 
2019.

XIII. Requirements for the Hospital Outpatient Quality Reporting (OQR) 
Program

A. Background

1. Overview
    CMS seeks to promote higher quality and more efficient healthcare 
for Medicare beneficiaries. Consistent with these goals, CMS has 
implemented quality reporting programs for multiple care settings 
including the quality reporting program for hospital outpatient care, 
known as the Hospital Outpatient Quality Reporting (OQR) Program, 
formerly known as the Hospital Outpatient Quality Data Reporting 
Program (HOP QDRP). The Hospital OQR Program is generally aligned with 
the quality reporting program for hospital inpatient services known as 
the Hospital Inpatient Quality Reporting (IQR) Program (formerly known 
as the Reporting Hospital Quality Data for Annual Payment Update 
(RHQDAPU) Program). In addition to the Hospital IQR and Hospital OQR 
Programs, CMS has implemented quality reporting programs as well as 
value-based purchasing programs for other care settings.
    We refer readers to section I.A.2. of this final rule with comment 
period where we discuss our new Meaningful Measures Initiative and our 
approach in evaluating quality program measures.
2. Statutory History of the Hospital OQR Program
    We refer readers to the CY 2011 OPPS/ASC final rule with comment 
period (75 FR 72064 through 72065) for a detailed discussion of the 
statutory history of the Hospital OQR Program.
3. Regulatory History of the Hospital OQR Program
    We refer readers to the CY 2008 through 2018 OPPS/ASC final rules 
with comment period (72 FR 66860 through 66875; 73 FR 68758 through 
68779; 74 FR 60629 through 60656; 75 FR 72064 through 72110; 76 FR 
74451 through 74492; 77 FR 68467 through 68492; 78 FR 75090 through 
75120; 79 FR 66940 through 66966; 80 FR 70502 through 70526; and 81 FR 
79753 through 79797; 82 FR 59424 through 59445). We have also codified 
certain requirements under the Hospital OQR Program at 42 CFR 419.46.
4. Meaningful Measures Initiative
    In the CY 2019 OPPS/ASC proposed rule, we proposed a number of new 
policies for the Hospital OQR Program (83 FR 37179). We developed these 
proposals after conducting an overall review of the program under our 
new

[[Page 59081]]

Meaningful Measures Initiative, which is discussed in more detail in 
section I.A.2. of this final rule with comment period. The proposals 
reflect our efforts to ensure that the Hospital OQR Program measure set 
continues to promote improved health outcomes for our beneficiaries 
while minimizing costs, which can consist of several different types of 
costs including, but not limited to: (1) Facility information 
collection burden and related cost and burden associated with the 
submitting/reporting of quality measures to CMS; (2) the facility cost 
associated with complying with other quality programmatic requirements; 
(3) the facility cost associated with participating in multiple quality 
programs, and tracking multiple similar or duplicative measures within 
or across those programs; (4) the CMS cost associated with the program 
oversight of the measure, including measure maintenance and public 
display; and (5) the facility cost associated with compliance with 
other federal and/or State regulations (if applicable). These proposals 
also reflect our efforts to improve the usefulness of the data that we 
publicly report in the Hospital OQR Program. Our goal is to improve the 
usefulness and usability of CMS quality program data by streamlining 
how facilities are reporting and accessing data, while maintaining or 
improving consumer understanding of the data publicly reported on a 
Compare website. We believe this framework will allow hospitals and 
patients to continue to obtain meaningful information about HOPD 
performance and incentivize quality improvement while also streamlining 
the measure sets to reduce duplicative measures and program complexity 
so that the costs to hospitals associated with participating in this 
program do not outweigh the benefits of improving beneficiary care.

B. Hospital OQR Program Quality Measures

1. Considerations in the Selection of Hospital OQR Program Quality 
Measures
    We refer readers to the CY 2012 OPPS/ASC final rule with comment 
period (76 FR 74458 through 74460) for a detailed discussion of the 
priorities we consider for the Hospital OQR Program quality measure 
selection. In the CY 2019 OPPS/ASC proposed rule (83 FR 37176) we did 
not propose any changes to these policies.
2. Accounting for Social Risk Factors in the Hospital OQR Program
    In the CY 2018 OPPS/ASC final rule with comment period (82 FR 59425 
through 59427), we discussed the importance of improving beneficiary 
outcomes including reducing health disparities. We also discussed our 
commitment to ensuring that medically complex patients, as well as 
those with social risk factors, receive excellent care. We discussed 
how studies show that social risk factors, such as being near or below 
the poverty level as determined by HHS, belonging to a racial or ethnic 
minority group, or living with a disability, can be associated with 
poor health outcomes and how some of this disparity is related to the 
quality of health care.\105\ Among our core objectives, we aim to 
improve health outcomes, attain health equity for all beneficiaries, 
and ensure that complex patients as well as those with social risk 
factors receive excellent care. Within this context, reports by the 
Office of the Assistant Secretary for Planning and Evaluation (ASPE) 
and the National Academy of Medicine have examined the influence of 
social risk factors in CMS value-based purchasing programs.\106\ As we 
noted in the CY 2018 OPPS/ASC final rule with comment period (82 FR 
59425), ASPE's report to Congress found that, in the context of value-
based purchasing programs, dual eligibility was the most powerful 
predictor of poor health care outcomes among those social risk factors 
that they examined and tested. In addition, as we noted in the CY 2018 
OPPS/ASC final rule with comment period (82 FR 59425), the National 
Quality Forum (NQF) undertook a 2-year trial period in which certain 
new measures and measures undergoing maintenance review have been 
assessed to determine if risk adjustment for social risk factors is 
appropriate for these measures.\107\ The trial period ended in April 
2017 and a final report is available at: https://www.qualityforum.org/SES_Trial_Period.aspx. The trial concluded that ``measures with a 
conceptual basis for adjustment generally did not demonstrate an 
empirical relationship'' between social risk factors and the outcomes 
measured. This discrepancy may be explained in part by the methods used 
for adjustment and the limited availability of robust data on social 
risk factors. NQF has extended the socioeconomic status (SES) 
trial,\108\ allowing further examination of social risk factors in 
outcome measures.
---------------------------------------------------------------------------

    \105\ See, for example United States Department of Health and 
Human Services. ``Healthy People 2020: Disparities. 2014.'' 
Available at: https://www.healthypeople.gov/2020/about/foundation-health-measures/Disparities; or National Academies of Sciences, 
Engineering, and Medicine. Accounting for Social Risk Factors in 
Medicare Payment: Identifying Social Risk Factors. Washington, DC: 
National Academies of Sciences, Engineering, and Medicine 2016.
    \106\ Department of Health and Human Services Office of the 
Assistant Secretary for Planning and Evaluation (ASPE), ``Report to 
Congress: Social Risk Factors and Performance Under Medicare's 
Value-Based Purchasing Programs.'' December 2016. Available at: 
https://aspe.hhs.gov/pdf-report/report-congress-social-risk-factors-and-performance-under-medicares-value-based-purchasing-programs.
    \107\ National Quality Forum. Final Report-Disparities Project. 
September 2017. Available at: https://www.qualityforum.org/SES_Trial_Period.aspx.
    \108\ National Quality Forum. Health Equity Program: Social Risk 
Initiative 2.0. 2017. Available at: https://www.qualityforum.org/WorkArea/linkit.aspx?LinkIdentifier=id&ItemID=86357.
---------------------------------------------------------------------------

    In the FY 2018 and CY 2018 proposed rules for our quality reporting 
and value-based purchasing programs, we solicited feedback on which 
social risk factors provide the most valuable information to 
stakeholders and the methodology for illuminating differences in 
outcomes rates among patient groups within a hospital or facility that 
would also allow for a comparison of those differences, or disparities, 
across facilities. Feedback we received through our quality reporting 
programs included encouraging CMS to explore whether factors that could 
be used to stratify or risk adjust the measures (beyond dual 
eligibility); considering the full range of differences in patients' 
backgrounds that might affect outcomes; exploring risk adjustment 
approaches; and offering careful consideration of what type of 
information display would be most useful to the public. We also sought 
public comment on confidential reporting and future public reporting of 
some of our measures stratified by patient dual eligibility. In 
general, commenters noted that stratified measures could serve as tools 
for hospitals to identify gaps in outcomes for different groups of 
patients, improve the quality of health care for all patients, and 
empower beneficiaries and other consumers to make informed decisions 
about health care. Commenters encouraged us to stratify measures by 
other social risk factors such as age, income, and educational 
attainment. With regard to value-based purchasing programs, commenters 
also cautioned to balance fair and equitable payment while avoiding 
payment penalties that mask health disparities or discourage the 
provision of care to more medically complex patients. Commenters also 
noted that value-based purchasing program measure selection, domain

[[Page 59082]]

weighting, performance scoring, and payment methodology must account 
for social risk.
    As a next step, CMS is considering options to reduce health 
disparities among patient groups within and across health care settings 
by increasing the transparency of disparities as shown by quality 
measures. We also are considering how this work applies to other CMS 
quality programs in the future. We refer readers to the FY 2018 IPPS/
LTCH PPS final rule (82 FR 38403 through 38409) for more details, where 
we discuss the potential stratification of certain Hospital IQR Program 
outcome measures. Furthermore, we continue to consider options to 
address equity and disparities in our value-based purchasing programs.
    We plan to continue working with ASPE, the public, and other key 
stakeholders on this important issue to identify policy solutions that 
achieve the goals of attaining health equity for all beneficiaries and 
minimizing unintended consequences.
    While we did not specifically request comment on social risk 
factors in the CY 2019 proposed rule, we received several comments with 
respect to social risk factors. We thank commenters for sharing their 
views and their willingness to support the efforts of CMS and NQF on 
this important issue. We take this feedback seriously and will continue 
to review social risk factors on an on-going and continuous basis. In 
addition, we both welcome and appreciate stakeholder feedback as we 
continue our work on these issues.
3. Retention of Hospital OQR Program Measures Adopted in Previous 
Payment Determinations
    We previously adopted a policy to retain measures from a previous 
year's Hospital OQR Program measure set for subsequent years' measure 
sets in the CY 2013 OPPS/ASC final rule with comment period (77 FR 
68471). Thus, quality measures adopted in a previous year's rulemaking 
are retained in the Hospital OQR Program for use in subsequent years 
unless otherwise specified. We refer readers to that final rule with 
comment period for more information. In the CY 2019 OPPS/ASC proposed 
rule (83 FR 37177), we did not propose any changes to our retention 
policy; however, we proposed to codify this policy at 42 CFR 
419.46(h)(1).
    We did not receive any public comments and are finalizing our 
proposal to codify at 42 CFR 419.46(h)(1) our policy to retain measures 
from a previous year's Hospital OQR Program measure set for subsequent 
years' measure sets as proposed.
4. Removal of Quality Measures From the Hospital OQR Program Measure 
Set
    In the CY 2010 OPPS/ASC final rule with comment period (74 FR 
60315), we finalized a process to use the regular rulemaking process to 
remove a measure for circumstances for which we do not believe that 
continued use of a measure raises specific patient safety 
concerns.\109\ In the CY 2019 OPPS/ASC proposed rule (83 FR 37177), we 
did not propose any changes to this policy; however, we proposed to 
codify this policy at 42 CFR 419.46(h)(3). We refer readers to section 
XIII.B.4.a. of this final rule with comment period for more details.
---------------------------------------------------------------------------

    \109\ We initially referred to this process as ``retirement'' of 
a measure in the 2010 OPPS/ASC proposed rule, but later changed it 
to ``removal'' during final rulemaking.
---------------------------------------------------------------------------

    We did not receive any public comments and are finalizing our 
proposal to codify at 42 CFR 419.46(h)(3) our policy to use the regular 
rulemaking process to remove a measure for circumstances for which we 
do not believe that continued use of a measure raises specific patient 
safety concerns as proposed.
a. Considerations in Removing Quality Measures From the Hospital OQR 
Program
(1) Immediate Removal
    In the CY 2010 OPPS/ASC final rule with comment period (74 FR 60634 
through 60635), we finalized a process for immediate retirement, which 
we later termed ``removal,'' of Hospital OQR Program measures, based on 
evidence that the continued use of the measure as specified raise 
patient safety concerns.\110\ In the CY 2019 OPPS/ASC proposed rule (83 
FR 37177), we did not propose any changes to our policy to immediately 
remove measures as a result of patient safety concerns; however, we 
proposed to codify that policy at 42 CFR 419.46(h)(2).
---------------------------------------------------------------------------

    \110\ We refer readers to the CY 2013 OPPS/ASC final rule with 
comment period (77 FR 68472 through 68473) for a discussion of our 
reasons for changing the term ``retirement'' to ``removal'' in the 
Hospital OQR Program.
---------------------------------------------------------------------------

    We did not receive any public comments and are finalizing our 
proposal to codify at 42 CFR 419.46(h)(2) our policy to immediately 
remove measures as a result of patient safety concerns as proposed.
(2) Consideration Factors for Removing Measures
    In the CY 2013 OPPS/ASC final rule with comment period, we 
finalized a set of factors \111\ for determining whether to remove 
measures from the Hospital OQR Program (77 FR 68472 through 68473). 
These factors are:
---------------------------------------------------------------------------

    \111\ We note that we previously referred to these factors as 
``criteria'' (for example, 77 FR 68472 through 68473); we now use 
the term ``factors'' in order to align the Hospital OQR Program 
terminology with the terminology we use in other CMS quality 
reporting and pay-for-performance (value-based purchasing) programs.
---------------------------------------------------------------------------

     Factor 1. Measure performance among hospitals is so high 
and unvarying that meaningful distinctions and improvements in 
performance can no longer be made (``topped out'' measures).
     Factor 2. Performance or improvement on a measure does not 
result in better patient outcomes.
     Factor 3. A measure does not align with current clinical 
guidelines or practice.
     Factor 4. The availability of a more broadly applicable 
(across settings, populations, or conditions) measure for the topic.
     Factor 5. The availability of a measure that is more 
proximal in time to desired patient outcomes for the particular topic.
     Factor 6. The availability of a measure that is more 
strongly associated with desired patient outcomes for the particular 
topic.
     Factor 7. Collection or public reporting of a measure 
leads to negative unintended consequences such as patient harm.
    In addition, we refer readers to the CY 2015 OPPS/ASC final rule 
with comment period where we finalized the criteria for determining 
when a measure is ``topped-out'' (79 FR 66769). In that final rule with 
comment period, we finalized two criteria for determining when a 
measure is ``topped out'' under the Hospital OQR Program: (1) When 
there is statistically indistinguishable performance at the 75th and 
90th percentiles of national facility performance; and (2) when the 
measure's truncated coefficient of variation (TCOV) is less than or 
equal to 0.10 (79 FR 66942).
    The benefits of removing a measure from the Hospital OQR Program 
are assessed on a case-by-case basis (79 FR 66941 through 66942). In 
the proposed rule, we noted that, under this case-by-case approach, a 
measure will not be removed solely on the basis of meeting any specific 
factor. We also noted that in the CY 2015 OPPS/ASC final rule with 
comment period (79 FR 66967), a similar measure removal policy was 
finalized for the ASCQR Program.
    In the CY 2019 OPPS/ASC proposed rule (83 FR 37177 through 37178), 
we

[[Page 59083]]

proposed to: (1) Update measure removal Factor 7; (2) add a new removal 
Factor 8; and (3) codify our measure removal policies and factors at 42 
CFR 419.46(h) effective upon finalization of the CY 2019 OPPS/ASC final 
rule and for subsequent years. We also provided clarification of our 
``topped-out'' criteria.
(3) Update To Measure Removal Factor 7
    As shown above, Factor 7 under the Hospital OQR Program states, 
``collection or public reporting of a measure leads to negative 
unintended consequences such as patient harm.'' In contrast, under the 
ASCQR Program, Factor 7 reads as follows, ``collection or public 
reporting of a measure leads to negative unintended consequences other 
than patient harm'' (79 FR 66967). We believe the wording in the ASCQR 
Program is more appropriate because measures causing patient harm would 
be removed from the program immediately, outside of rulemaking, in 
accordance with our previously finalized policy to immediately remove 
measures as a result of patient safety concerns (74 FR 60634 and 
discussed above). Therefore, in the proposed rule, we proposed to 
change measure removal Factor 7 in the Hospital OQR Program to 
``collection or public reporting of a measure leads to negative 
unintended consequences other than patient harm'' such that it aligns 
with measure removal Factor 7 in the ASCQR Program.
    Comment: Several commenters supported CMS' proposal to update 
measure removal Factor 7 to read, ``collection or public reporting of a 
measure leads to negative unintended consequences other than patient 
harm'' to align with the ASCQR Program.
    Response: We thank the commenters for their support.
    After consideration of the public comments we received, we are 
finalizing our proposal as proposed to revise measure removal Factor 7 
to read, ``collection or public reporting of a measure leads to 
negative unintended consequences other than patient harm.''
(4) New Measure Removal Factor 8
    In the CY 2019 OPPS/ASC proposed rule (83 FR 37178 through 37179), 
we proposed to adopt an additional factor to consider when evaluating 
measures for removal from the Hospital OQR Program measure set:
     Factor 8. The costs associated with a measure outweigh the 
benefit of its continued use in the program.
    As we discuss in section I.A.2. of the proposed rule and this final 
rule with comment period with respect to our new Meaningful Measures 
Initiative, we are engaging in efforts to ensure that the Hospital OQR 
Program measure set continues to promote improved health outcomes for 
beneficiaries while minimizing the overall costs associated with the 
program. We believe these costs are multifaceted and include not only 
the burden associated with reporting, but also the costs associated 
with implementing and maintaining the program. We have identified 
several different types of costs, including, but not limited to: (1) 
Facility information collection burden and related costs and burden 
associated with the submission/reporting of quality measures to CMS; 
(2) the facility cost associated with complying with other programmatic 
requirements; (3) the facility cost associated with participating in 
multiple quality programs and tracking multiple similar or duplicative 
measures within or across those programs; (4) the CMS cost associated 
with the program oversight of the measure including measure maintenance 
and public display; and (5) the facility cost associated with 
compliance with other Federal and State regulations (if applicable). 
For example, it may be needlessly costly and/or of limited benefit to 
retain or maintain a measure which our analyses show no longer 
meaningfully supports program objectives (for example, informing 
beneficiary choice or payment scoring). It may also be costly for 
health care providers to track confidential feedback, preview reports, 
and publicly reported information on a measure where we use the measure 
in more than one program. CMS may also have to expend unnecessary 
resources to maintain the specifications for the measure, as well as 
the tools needed to collect, validate, analyze, and publicly report the 
measure data. Furthermore, beneficiaries may find it confusing to see 
public reporting on the same measure in different programs.
    In weighing the costs against the benefits, we evaluate the 
benefits of the measure, but, we assess the benefits through the 
framework of our Meaningful Measures Initiative, as we discussed in 
section I.A.2. of the proposed rule and this final rule with comment 
period. One key aspect of patient benefits is assessing the improved 
beneficiary health outcomes if a measure is retained in our measure 
set. We believe that these benefits are multifaceted and are 
illustrated through the Meaningful Measures framework's 6 domains and 
19 areas. For example, we assessed the Healthcare Worker Influenza 
Vaccination and patient Influenza Vaccination measures categorized in 
the Quality Priority ``Promote Effective Prevention and Treatment of 
Chronic Disease'' in the meaningful measure area of ``Preventive Care'' 
across multiple CMS programs, and considered: Patient outcomes, such as 
mortality and hospitalizations associated with influenza; CMS measure 
performance in a program; and other available and reported influenza 
process measures, such as population influenza vaccination coverage.
    When these costs outweigh the evidence supporting the benefits to 
patients with the continued use of a measure in the Hospital OQR 
Program, we believe it may be appropriate to remove the measure from 
the program. Although we recognize that one of the main goals of the 
Hospital OQR Program is to improve beneficiary outcomes by 
incentivizing health care facilities to focus on specific care issues 
and making public data related to those issues, we also recognize that 
those goals can have limited utility where, for example, the publicly 
reported data (including percentage payment adjustment data) is of 
limited use because it cannot be easily interpreted by beneficiaries, 
and used to inform their choice of facility. In these cases, removing 
the measure from the Hospital OQR Program may better accommodate the 
costs of program administration and compliance without sacrificing 
improved health outcomes and beneficiary choice.
    We proposed that we would remove measures based on this factor 
assessing costs versus benefits on a case-by-case basis. We might, for 
example, decide to retain a measure that is burdensome for health care 
facilities to report if we conclude that the benefit to beneficiaries 
justifies the reporting burden. Our goal is to move the program forward 
in the least burdensome manner possible, while maintaining a 
parsimonious set of meaningful quality measures and continuing to 
incentivize improvement in the quality of care provided to patients.
    We refer readers to section XIII.B.4.b. of the proposed rule (83 FR 
37179 through 37186), where we proposed to remove two measures based on 
this proposed measure removal factor. In the proposed rule, we noted 
that we also proposed this same removal factor for the ASCQR Program in 
section XIV.B.3.b. of the proposed rule (83 FR 37195 through 37196), as 
well as for other quality reporting and value-based purchasing programs 
for FY 2019 including: The Hospital Value-Based Purchasing (VBP) 
Program (83 FR 20409), the Hospital IQR Program (83 FR 20472); the PPS-
exempt Cancer

[[Page 59084]]

Hospital Quality Reporting (PCHQR) Program (83 FR 20501 through 20502); 
the Long-Term Care Hospital Quality Reporting Program (LTCH QRP) (83 FR 
20512); the Hospice Quality Reporting Program (HQRP) (83 FR 20956); the 
Inpatient Rehabilitation Facility Quality Reporting Program (IRF QRP) 
(83 FR 21000); the Skilled Nursing Facility Quality Reporting Program 
(SNF QRP) (83 FR 21082); and the Inpatient Psychiatric Facilities 
Quality Reporting (IPFQR) Program (83 FR 21118).
    We invited public comment on our proposal to adopt an additional 
measure removal Factor 8, the costs associated with a measure outweigh 
the benefit of its continued use in the program, beginning with the 
effective date of the CY 2019 OPPS/ASC final rule with comment period 
and for subsequent years.
    Comment: Several commenters supported CMS' proposal to adopt an 
additional measure removal Factor 8, the costs associated with a 
measure outweigh the benefit of its continued use in the program. A few 
commenters noted that this removal factor will help CMS to remove 
unnecessary cost and burden from the Hospital OQR Program and allow 
providers of care to focus on improving quality through innovation. 
Commenters also praised CMS for aligning this and other removal factors 
across quality reporting programs.
    Response: We thank the commenters for their support.
    Comment: A few commenters opposed CMS' proposal to add a new 
measure removal Factor 8. A few commenters requested clarification on 
the types of costs that CMS will consider and requested transparency in 
the process of evaluation in the costs and benefits of measures. One 
commenter expressed concern that the costs described under measure 
removal Factor 8 are not defined. One commenter noted that there are 
costs associated with changing measures to facilities, providers, and 
measure developers. Another commenter expressed concern that CMS may 
deem a measure too costly to implement, while providers and patients 
may continue to find it meaningful. Commenters also recommended direct 
and indirect costs that CMS may consider in evaluating measures under 
measure removal Factor 8. These costs included those associated with: 
(1) Measures that require data collection from multiple data sources, 
rather than just one; (2) contracting with vendors; (3) tracking 
performance and investing in resources for quality improvement. One 
commenter stated it opposed the new factor unless costs and benefits 
are defined as only costs and benefits to beneficiaries and the public.
    Response: As noted in the proposed rule (83 FR 37176), we have 
defined costs, for the purpose of evaluating measures under proposed 
measure removal Factor 8, as including but not limited to: (1) Facility 
information collection burden and related costs and burden associated 
with the submission/reporting of quality measures to CMS; (2) the 
facility cost associated with complying with other programmatic 
requirements; (3) the facility cost associated with participating in 
multiple quality programs, and tracking multiple similar or duplicative 
measures within or across those programs; (4) the CMS cost associated 
with the program oversight of the measure including measure maintenance 
and public display; and (5) the facility cost associated with 
compliance with other federal and/or State regulations (if applicable). 
This was not intended to be a complete list of the potential factors to 
consider in evaluating measures. In addition, as we apply this measure 
removal factor in future rulemaking, we will describe our rationale for 
the removal of a measure and will include the costs and benefits we 
considered.
    We thank commenters for their suggestions regarding additional 
costs to consider. We will use this feedback as well as input from all 
stakeholders as we apply measure removal Factor 8 in future rulemaking.
    We believe that various stakeholders may have different 
perspectives on how to define costs as well as benefits. Because of 
these challenges, we intend to evaluate each measure on a case-by-case 
basis, while considering input from a variety of stakeholders, 
including, but not limited to: Patients, caregivers, patient and family 
advocates, providers, provider associations, healthcare researchers, 
healthcare purchasers, data vendors, and other stakeholders with 
insight into the direct and indirect benefits and costs (financial and 
otherwise) of maintaining any specific measure in the Hospital OQR 
Program. However, we also believe that while a measure's use in the 
Hospital OQR Program may benefit many entities, the primary benefit is 
to patients and their caregivers through incentivizing high-quality 
care and providing publicly reported data regarding the quality of care 
available. We note that we intend to assess the costs and benefits to 
program stakeholders, including but not limited to, those listed above. 
Therefore, we intend to consider the benefits, especially those to 
patients and their families, when evaluating measures under this 
measure removal factor. As noted above, we have offered a definition of 
costs. However, this was not intended to be a complete list of the 
potential factors to consider in evaluating measures and we intend to 
consider the additional examples of cost described in public comment, 
including the costs and benefits to beneficiaries and the public, as 
recommended by some commenters.
    Comment: A few commenters recommended that CMS seek input from 
hospitals, physicians, and other stakeholders when evaluating the costs 
and benefits of quality reporting.
    Response: We thank the commenters for their feedback and note that 
we will consider stakeholder input when evaluating both the costs of 
quality reporting as well as the benefits of collecting and reporting 
quality data. As stated above, we intend to evaluate costs and benefits 
for each measure on a case-by-case basis, while considering input from 
a variety of stakeholders, including, but not limited to: Patients, 
caregivers, patient and family advocates, providers, provider 
associations, healthcare researchers, healthcare purchasers, data 
vendors, and other stakeholders with insight into the direct and 
indirect benefits and costs (financial and otherwise) of maintaining 
any specific measure in the Hospital OQR Program.
    Comment: A few commenters recommended that CMS consider measure 
sets as a whole as well as the consistency of quality reporting program 
measure sets. One commenter recommended that when a measure is removed 
under Factor 8 that it should be replaced by a measure that is easier 
to implement and aimed at improving care within the same measure domain 
to avoid gaps in the measure set. A commenter further recommended that 
measure sets should include actionable process measures that contribute 
to the outcomes being measured.
    Response: We intend to continue to develop a robust measure set for 
the Hospital OQR Program and appreciate the commenters' feedback. We 
intend to consider the measure set as a whole, the types of measures in 
the measure set, and the consistency throughout quality reporting 
programs when assessing whether the costs outweigh the benefits of a 
measure's continued use in the Hospital OQR Program. We continually 
seek ways to improve the Hospital OQR Program measure set, including 
through identification of more efficient means of capturing data. 
Retaining a strong measure set that addresses critical quality issues 
is one benefit that we would consider in evaluating whether a

[[Page 59085]]

measure should be potentially removed from the Hospital OQR Program 
measure set. In addition, we note that in this final rule with comment 
period, we are not finalizing our proposals to remove two measures 
under Factor 8: OP-29: Endoscopy/Polyp Surveillance: Appropriate 
Follow-up Interval for Normal Colonoscopy in Average Risk Patients, and 
OP-31: Cataracts--Improvement in Patient's Visual Function within 90 
Days Following Cataract Surgery. This is discussed in more detail 
further below.
    After consideration of the public comments we received, we are 
finalizing our proposal to adopt measure removal Factor 8, the costs 
associated with a measure outweigh the benefit of its continued use in 
the program, for the Hospital OQR Program beginning with the effective 
date of this CY 2019 OPPS/ASC final rule with comment period, as 
proposed.
    As a result of the finalization of our proposals to update measure 
removal Factor 7 and add new removal Factor 8 as proposed, the new 
measure removal factors list for the Hospital OQR Program consists of 
the following:
     Factor 1. Measure performance among hospitals is so high 
and unvarying that meaningful distinctions and improvements in 
performance can no longer be made (``topped out'' measures).
     Factor 2. Performance or improvement on a measure does not 
result in better patient outcomes.
     Factor 3. A measure does not align with current clinical 
guidelines or practice.
     Factor 4. The availability of a more broadly applicable 
(across settings, populations, or conditions) measure for the topic.
     Factor 5. The availability of a measure that is more 
proximal in time to desired patient outcomes for the particular topic.
     Factor 6. The availability of a measure that is more 
strongly associated with desired patient outcomes for the particular 
topic.
     Factor 7. Collection or public reporting of a measure 
leads to negative unintended consequences other than patient harm.
     Factor 8. The costs associated with a measure outweigh the 
benefit of its continued use in the program.
(5) Codification at 42 CFR 419.46(h)(2) and (3)
    In the CY 2019 OPPS/ASC proposed rule (83 FR 37179), we proposed to 
codify our measure removal policies, including proposals made in the 
proposed rule, if finalized, at 42 CFR 419.46(h)(2) and (3).
    We did not receive any public comments and are finalizing our 
proposal to codify our measure removal policies, at 42 CFR 419.46(h)(2) 
and (3) as proposed.
(6) Clarification of Removal Factor 1: ``Topped-Out'' Measures
    As noted above, we refer readers to the CY 2015 OPPS/ASC final rule 
with comment period (79 FR 66769), where we finalized the criteria for 
determining when a measure is ``topped-out.'' In that final rule with 
comment period, we finalized two criteria for determining when a 
measure is ``topped out'' under the Hospital OQR Program: (1) When 
there is statistically indistinguishable performance at the 75th and 
90th percentiles of national facility performance; and (2) when the 
measure's truncated coefficient of variation (TCOV) is less than or 
equal to 0.10 (79 FR 66942).
    In the CY 2019 OPPS/ASC proposed rule (83 FR 37179), we clarified 
our process for calculating the truncated coefficient of variation 
(TCOV), particularly for two of the measures (OP-11 and OP-14) proposed 
for removal from the Hospital OQR Program. In accordance with our 
finalized methodology (79 FR 66942), we determine the truncated 
coefficient of variation (TCOV) by calculating the truncated standard 
deviation (SD) divided by the truncated mean. As discussed above, our 
finalized removal criteria state that to be considered ``topped-out,'' 
a measure must have a truncated TCOV of less than 0.10. We utilize the 
TCOV because it is generally a good measure of variability and provides 
a relative methodology for comparing different types of measures.
    Unlike the majority of the measures, for which a higher rate 
(indicating a higher proportion of a desired event) is the preferred 
outcome, some measures--in particular, OP-11 and OP-14--assess the rate 
of rare, undesired events for which a lower rate is preferred. For 
example, OP-11 assesses the use of both a contrast and non-contrast CT 
Thorax study at the same time, which is not recommended, as no clinical 
guidelines or peer-reviewed literature supports such CT Thorax 
``combined studies.'' However, when determining the TCOV for a measure 
assessing rare, undesired events, the mean--or average rate of event 
occurrence--is very low, and the result is a TCOV that increases 
rapidly and approaches infinity as the proportion of rare events 
declines.\112\ In the proposed rule, we noted that the SD, the 
variability statistic, is the same in magnitude for measures assessing 
rare and non-rare events.
---------------------------------------------------------------------------

    \112\ Rose-Hulman Institute of Technology. Denominator 
approaching zero. Available at: https://www.rose-hulman.edu/media/89584/lclimitsguide.pdf.
---------------------------------------------------------------------------

    In the proposed rule, we proposed to remove two measures that 
assess the rate of rare, undesired events for which a lower rate is 
preferred--OP-11 and OP-14--and refer readers to section 
XIII.B.4.b.(2)(c) of the proposed rule and this final rule with comment 
period, where these proposals are discussed in detail. Because by 
design these measures have maintained very low rates of rare, undesired 
events (indicating the preferred outcomes), we utilized the mean of 
non-adverse events in our calculation of the TCOV. For example, for OP-
11, to calculate the TCOV, we divide the SD by the average rate of 
patients not receiving both contrast and non-contrast abdominal CT (1.0 
minus the rate of patients receiving both), rather than the rate of 
those receiving both types of CT. Utilizing this methodology results in 
a TCOV that is comparable to that calculated for other measures and 
allows us to assess rare-event measures by still generally using our 
previously finalized topped-out criteria.
b. Removal of Quality Measures From the Hospital OQR Program Measure 
Set
    In the CY 2019 OPPS/ASC proposed rule (83 FR 37179 through 37186), 
we proposed to remove a total of 10 measures from the Hospital OQR 
Program measure set across the CY 2020 and CY 2021 payment 
determinations. Specifically, beginning with the CY 2020 payment 
determination, we proposed to remove (1) OP-27: Influenza Vaccination 
Coverage Among Healthcare Personnel (NQF #0431); and beginning with the 
CY 2021 payment determination, we proposed to remove--(2) OP-5: Median 
Time to ECG (NQF #0289); (3) OP 31: Cataracts--Improvement in Patient's 
Visual Function within 90 Days Following Cataract Surgery (NQF #1536); 
(4) OP-29: Endoscopy/Polyp Surveillance: Appropriate Follow-up Interval 
for Normal Colonoscopy in Average Risk Patients (NQF #0658); (5) OP-30: 
Endoscopy/Polyp Surveillance: Colonoscopy Interval for Patients with a 
History of Adenomatous Polyps--Avoidance of Inappropriate Use (NQF 
#0659); (6) OP-9: Mammography Follow-up Rates (no NQF number); (7) OP-
11: Thorax Computed Tomography

[[Page 59086]]

(CT)--Use of Contrast Material (NQF #0513); (8) OP-12: The Ability for 
Providers with HIT (Health Information Technology) to Receive 
Laboratory Data Electronically Directly into Their Qualified/Certified 
EHR System as Discrete Searchable Data (NQF endorsement removed); (9) 
OP-14: Simultaneous Use of Brain Computed Tomography (CT) and Sinus CT 
(no NQF number); and (10) OP-17: Tracking Clinical Results between 
Visits (NQF endorsement removed). We proposed to remove these measures 
under the following removal factors: Proposed measure removal Factor 8, 
the costs associated with a measure outweigh the benefit of its 
continued use in the program; measure removal Factor 3, a measure does 
not align with current clinical guidelines or practice; measure removal 
Factor 1, measure performance among hospitals is so high and unvarying 
that meaningful distinctions and improvements in performance can no 
longer be made (``topped-out'' measures); and measure removal Factor 2, 
performance or improvement on a measure does not result in better 
patient outcomes.
    These proposed measure-specific removals are discussed in detail 
further below. We also received several general comments regarding 
these proposals as a whole and are discussing those first.
    Comment: Many commenters supported CMS' proposals to remove 10 
measures from the Hospital OQR Program measure set. Some noted that the 
proposals will reduce burden, simplify hospital reporting, and reduce 
duplication. Several commenters suggested that CMS remove all 10 
measures beginning with CY 2020, rather than delaying removal of nine 
measures until CY 2021. Commenters agreed with CMS' rationale for 
removals and noted that topped-out or not beneficial measures should be 
removed as soon as possible.
    Response: We thank the commenters for their support. Data 
collection and reporting for the CY 2020 payment determination has 
already begun for all nine of the measures proposed for removal. 
Specifically, as finalized in the CY 2016 OPPS/ASC final rule with 
comment period (80 FR 70519 through 70520), data collection began with 
Q2, (April 1) of 2018. Thus, by the effective date of this final rule 
with comment period, hospitals will have already reported almost three 
quarters of data for these measures. In consideration of hospitals' 
efforts already exerted, we are finalizing removal of these measures 
starting with the next proximate payment determination.
    Comment: One commenter opposed all of CMS' proposals to remove 
measures from the Hospital OQR Program, citing its belief that 
consumers should be offered more quality information, rather than less, 
that can be used in selecting facilities. Another commenter recommended 
that CMS maintain the existing measure set and, instead of removing 
measures, work to reduce provider burden through alignment across 
programs.
    Response: We thank the commenters for their feedback and note our 
agreement that consumers should be provided with as much valuable 
quality information as possible. As described in the proposed rule, we 
proposed to remove these measures because the costs associated with a 
measure outweigh the benefit of its continued use in the program; the 
measure does not align with current clinical guidelines or practice, 
measure performance among hospitals is so high and unvarying that 
meaningful distinctions and improvements in performance can no longer 
be made (``topped-out'' measures); or because performance or 
improvement on a measure does not result in better patient outcomes. We 
have identified these and other measure removal factors specifically to 
ensure that the data provided to consumers is meaningful and valuable. 
We do not believe it is beneficial to maintain program measures 
indefinitely. However, we agree that burden should be reduced through 
program alignment and will continue to seek opportunities to do this. 
In the CY 2019 OPPS/ASC proposed rule, we proposed several policies to 
align with the ASCQR Program, including updating our measure removal 
factors and removing OP-27 and ASC-8, OP-29 and ASC-9, OP-30 and ASC-
10, and OP-31 and ASC-11, and we are finalizing several of these 
aligned proposals in this final rule with comment period.
    Comment: One commenter recommended that CMS consider the impact of 
the proposed removal of OP-5, OP-14, OP-27, OP-29, and OP-30 on the 
Hospital Compare overall hospital ratings.
    Response: Although these measure removals will reduce the number of 
outpatient measures in the Hospital Overall Star Ratings, a 
representative measure set remains and includes OP-32: 7-day visit rate 
after colonoscopy, OP-4: Aspirin on arrival, OP-22: Patient Left 
Without Being Seen, OP-23: Head CT or MRI Scan Results for Acute 
Ischemic Stroke or Hemorrhagic Stroke Patients who Received Head CT or 
MRI Scan Interpretation Within 45 minutes of ED Arrival, OP-33: 
External Beam Radiotherapy for Bone Metastases, OP-3: Median Time to 
Transfer to Another Facility for Acute Coronary Intervention, and OP-
18: Median Time from Emergency Department (ED) Arrival to ED Departure 
for Discharged ED Patients. Additional measures, including surgery and 
chemotherapy measures, may be considered for adoption in future years. 
(We refer readers to our web page at: https://www.medicare.gov/hospitalcompare/About/Hospital-overall-ratings.html for a discussion of 
Hospital Compare overall hospital ratings.)
(1) Measure Removal for the CY 2020 Payment Determination and 
Subsequent Years--Removal of OP-27: Influenza Vaccination Coverage 
Among Healthcare Personnel (NQF #0431)
    For the CY 2020 payment determination and subsequent years, we 
proposed to remove one NHSN measure under proposed measure removal 
Factor 8, the costs associated with this measure outweigh the benefit 
of its continued use in the program.
    We refer readers to the CY 2014 OPPS/ASC final rule with comment 
period (78 FR 75099), where we adopted OP-27: Influenza Vaccination 
Coverage Among Healthcare Personnel (NQF #0431), beginning with the CY 
2016 payment determination and for subsequent years. This process-of-
care measure, also a National Healthcare Safety Network (NHSN) measure, 
assesses the percentage of healthcare personnel who have been immunized 
for influenza during the flu season. We initially adopted this measure 
based on our recognition that influenza immunization is an important 
public health issue and vital component to preventing healthcare 
associated infections. We believe that the measure addresses this 
public health concern by assessing influenza vaccination in the HOPD 
among health care personnel (HCP), who can serve as vectors for 
influenza transmission.
    In the proposed rule, we proposed to remove OP-27, beginning with 
the CY 2020 payment determination under our proposed measure removal 
Factor 8 because we have concluded that the costs associated with this 
measure outweigh the benefit of its continued use in the program.
    The information collection burden for the Influenza Vaccination 
Coverage Among Healthcare Personnel measure is less than for measures 
that require chart-abstraction of patient data because influenza 
vaccination among healthcare personnel can be calculated through review 
of records maintained in

[[Page 59087]]

administrative systems and because facilities have fewer healthcare 
personnel than patients. As such, OP-27 does not require review of as 
many records. However, this measure does still pose information 
collection burden on facilities due to the requirement to identify 
personnel who have been vaccinated against influenza and for those not 
vaccinated, the reason why.
    Furthermore, as we stated in section XIII.B.4.a. of the proposed 
rule and this final rule with comment period, costs are multi-faceted 
and include not only the burden associated with reporting, but also the 
costs associated with implementing and maintaining the program. For 
example, it may be costly for health care providers to maintain general 
administrative knowledge to report these measures. In addition, CMS 
must expend resources in maintaining information collection systems, 
analyzing reported data, and providing public reporting of the 
collected information.
    In our analysis of the Hospital OQR Program measure set, we 
recognized that some facilities face challenges with respect to the 
administrative requirements of the NHSN in their reporting of the 
Influenza Vaccination Coverage Among Healthcare Personnel measure. 
These administrative requirements (which are unique to NHSN) include 
annually completing NHSN system user authentication. Enrolling in NHSN 
is a five-step process that the Centers for Disease Control and 
Prevention (CDC) estimates takes an average of 263 minutes per 
facility.\113\
---------------------------------------------------------------------------

    \113\ CDC, National Healthcare Safety Network (NHSN). Five-Step 
Enrollment for Acute Care Hospitals/Facilities. Available at: 
https://www.cdc.gov/nhsn/acute-care-hospital/enroll.html (the 
estimates for time to complete are 2 hours 45 minutes for step 1, 10 
minutes for step 2, 16 minutes for step 3a, 35 minutes for step 3b, 
32 minutes for step 4, and 5 minutes for step 5; totaling 263 
minutes).
---------------------------------------------------------------------------

    Furthermore, submission via NHSN requires the system security 
administrator of participating facilities to re-consent electronically, 
ensure that contact information is kept current, ensure that the 
hospital has an active facility administrator account, keep Secure 
Access Management Service (SAMS) credentials active by logging in 
approximately every two months and changing their password, create a 
monthly reporting plan, and ensure the facility's CCN information is 
up-to-date. Unlike acute care hospital which participate in other 
quality programs, such as the Hospital IQR and HAC Reduction Programs, 
HOPDs are only required to participate in NHSN to submit data for this 
one measure.
    In our assessment, we also considered that the vast majority (99.7 
percent) of Hospital OQR Program eligible hospitals already report this 
measure in the Hospital IQR Program for workers providing any services 
to inpatient care. The Hospital IQR Program measure includes the vast 
majority of all hospital personnel since many workers in outpatient 
departments provide services to both inpatient and outpatient 
departments (adopted at 76 FR 51631 through 51633). These workers 
include most emergency department clinicians, specialists such as 
pharmacists and imaging professionals, and custodians and other support 
staff working across the hospital.
    We continue to believe that the OP-27: Influenza Vaccination 
Coverage Among Healthcare Personnel (NQF #0431) measure provides the 
benefit of protecting patients against influenza. However, we believe 
that these benefits are offset by other efforts to reduce influenza 
infection among patients, such as numerous healthcare employer 
requirements for health care personnel to be vaccinated against 
influenza.^{114 115} We also expect that a portion of MIPS-
eligible clinicians nationwide will report on the Preventive Care and 
Screening: Influenza Immunization measure through the Quality Payment 
Program (QPP).\116\ Although MIPS-eligible clinicians may voluntarily 
select measures from a list of options, HOPD providers that are MIPS-
eligible will have the opportunity to continue collecting information 
for the measure. We remain responsive to the public health concern of 
influenza infection within the Medicare FFS population by collecting 
data on rates of influenza immunization among patients.\117\ Thus, the 
public health concern of influenza immunization is addressed via these 
other efforts to track influenza vaccination. The availability of this 
measure in another CMS program demonstrates CMS' continued commitment 
to this measure area. In addition, as we discussed in section 
XIII.B.4.a of the proposed rule, where we proposed to adopt measure 
removal Factor 8, beneficiaries may find it confusing to see public 
reporting on the same measure in different programs.
---------------------------------------------------------------------------

    \114\ CDC, Influenza Vaccination Information for Health Care 
Workers. Available at: https://www.cdc.gov/flu/healthcareworkers.htm.
    \115\ CDC Influenza Vaccination Coverage Among Health Care 
Personnel--United States, 2013-14 Influenza Season. Available at: 
https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6337a1.htm.
    \116\ QPP 2017 Measures Selection: Influenza. Retrieved from: 
https://qpp.cms.gov/mips/quality-measures.
    \117\ Ibid.
---------------------------------------------------------------------------

    We wish to minimize the level of cost of our programs for 
participating facilities, as discussed under the Meaningful Measures 
Initiative, described in section I.A.2. of the proposed rule and this 
final rule with comment period. In our assessment of the Hospital OQR 
Program measure set, we prioritized measures that align with this 
Initiative's framework as the most important to the Hospital OQR 
Program's population. Our assessment concluded that while the OP-27 
measure continues to provide benefits, these benefits are diminished by 
other factors and are outweighed by the costs and burdens of reporting 
this chart-abstracted measure.
    For these reasons, we proposed to remove OP-27: NHSN Influenza 
Vaccination Coverage among Healthcare Personnel (NQF #0431) from the 
Hospital OQR Program beginning with the CY 2020 payment determination 
and for subsequent years. In the proposed rule, we noted that if 
proposed measure removal Factor 8 is not finalized, removal of this 
measure would also not be finalized. We also noted that a similar 
measure was also proposed for removal from the ASCQR Program in section 
XIV.B.3.c. of the proposed rule and the IPFQR Program in the FY 2019 
IPF PPS proposed rule (83 FR 21104).
    Comment: Several commenters supported CMS' proposal to remove OP-27 
from the Hospital OQR Program measure set, and noted that the proposal 
will reduce burden and costs to hospitals and that levels of 
vaccination of health care employees is already very high.
    Response: We thank the commenters for their support regarding the 
burden associated with the OP-27 measure.
    Comment: Several commenters opposed CMS' proposal to remove OP-27 
from the Hospital OQR Program. A few commenters expressed concern that 
influenza is a critical public health issue and that influenza 
vaccination coverage of healthcare workers helps create a safe 
environment for patients, visitors, and employees. A few commenters 
expressed concern that removal of OP-27 would result in lower 
vaccination rates among healthcare workers. A few commenters noted that 
the Medicare population may be more susceptible to vaccine preventable 
illnesses such as influenza.
    Response: We thank these commenters for their input. We agree that 
influenza vaccination for both patients and healthcare personnel is 
important in the outpatient hospital setting, as well as other 
healthcare

[[Page 59088]]

settings, and we believe that these two activities are both intended to 
address the public health concern of reducing influenza infection.
    However, while we agree that Medicare beneficiaries may have 
additional risk of contracting influenza, as noted in our proposal, we 
believe the effects of removing this measure from the Hospital OQR 
Program are mitigated as the issue is addressed by other initiatives 
such as State laws[thinsp]and employer programs that require influenza 
vaccination of healthcare workers. Because of this, we do not believe 
that retaining this measure would result in lower rates of vaccination 
coverage among healthcare personnel. Further, we have retained the 
measure in the Hospital IQR Program (83 FR 41579), thus requiring 
reporting in the short-term, acute care hospital setting. In addition, 
we believe that the burden of this measure on hospitals outweighs the 
limited benefit of addressing this topic again under the Hospital OQR 
Program in addition to the many other vaccination initiatives.
    Comment: A few commenters stated that OP-27 plays a critical role 
in the CMS Quality Strategy and the National Quality Strategy in terms 
of immunization efforts. A few commenters suggested that removal of the 
measure would create greater inconsistency across quality reporting 
programs.
    Response: We agree that influenza is a critical public health issue 
that is part of the CMS Quality Strategy and the National Quality 
Strategy. Through our Meaningful Measures Initiative, it is our goal to 
ensure that we are addressing high-impact measure areas that safeguard 
public health while minimizing the level of burden for providers and 
suppliers. We continue to believe in the importance of influenza 
vaccination coverage for health care workers, particularly in acute 
care settings, and have retained this measure in the Hospital IQR 
Program (83 FR 41579) in order to address this concern.
    As we noted above, the burden of reporting this measure is greater 
for outpatient hospitals compared to the relative burden for hospitals 
participating in the Hospital IQR and HAC Reduction Programs. The 
entire burden of registering for and maintaining access to the CDC's 
NHSN system is due to this one measure; whereas hospitals paid under 
IPPS, participating in the Hospital IQR Program, the HAC Reduction 
Program and the Hospital VBP Program, for example, must register and 
maintain NHSN access for several healthcare safety measures, not just 
one. However, we note that, beyond the Hospital OQR Program, HOPDs may 
independently choose to voluntarily report data to NHSN on vaccination 
rates using the NHSN Healthcare Personnel Safety Component.
    Comment: One commenter stated that the cost associated with 
mitigating an influenza outbreak outweighs the cost of retaining OP-27 
in the Hospital OQR Program.
    Response: As we noted above, we have retained the measure in the 
Hospital IQR Program (83 FR 41579) in order to address concerns about 
influenza as a public health issue. In addition, as noted above, we 
believe the effects of removing this measure from the Hospital OQR 
Program are mitigated as the topic is addressed by other initiatives 
such as State laws[thinsp]and employer programs that require influenza 
vaccination of healthcare workers.\118\ \119\ As a result, we do not 
believe removing this measure from the Hospital OQR Program will result 
in lower rates of vaccination coverage among healthcare personnel in 
the HOPD setting or increase the risk of an outbreak.
---------------------------------------------------------------------------

    \118\ CDC. Influenza Vaccination Information for Health Care 
Workers. Available at: https://www.cdc.gov/flu/healthcareworkers.htm.
    \119\ CDC Influenza Vaccination Coverage Among Health Care 
Personnel--United States, 2013-14 Influenza Season. Available at: 
https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6337a1.htm.
---------------------------------------------------------------------------

    After consideration of the public comments we received, we are 
finalizing our proposal, as proposed, to remove OP-27: NHSN Influenza 
Vaccination Coverage among Healthcare Personnel (NQF #0431) from the 
Hospital OQR Program beginning with the CY 2020 payment determination 
and for subsequent years.
(2) Measure Removals for the CY 2021 Payment Determination and 
Subsequent Years
    In the CY 2019 OPPS/ASC proposed rule (83 FR 37181 through 37186), 
for the CY 2021 payment determination and subsequent years, we proposed 
to remove: Four measures under proposed measure removal Factor 8; one 
measure under measure removal Factor 3; two measures under removal 
Factor 1; and two measures under measure removal Factor 2.
(a) Measure Removals Under Finalized Removal Factor 8: OP-5, OP-29, OP-
30, and OP-31
    In the proposed rule, we proposed to remove four measures under 
measure removal Factor 8, which is being finalized in this final rule 
with comment period, for the CY 2021 payment determination and 
subsequent years: OP-5, OP-29, OP-30, and OP-31. In the proposed rule, 
we noted that if proposed measure removal Factor 8 was not finalized, 
removal of these measures would also not be finalized.
    The proposals are discussed in more detail below. In the proposed 
rule, we noted that in crafting our proposals, we considered removing 
these measures beginning with the CY 2020 payment determination, but we 
decided on proposing to delay removal until the CY 2021 payment 
determination to be sensitive to facilities' planning and operational 
procedures given that data collection for this measure begins during CY 
2018 for the CY 2020 payment determination.
 Removal of OP-5: Median Time to ECG (NQF #0289)
    We refer readers to the CY 2008 OPPS/ASC final rule with comment 
period (72 FR 66865) where we adopted OP-5: Median Time to ECG (NQF 
#0289) beginning with the CY 2009 payment determination.\120\ This 
chart-abstracted measure assesses the median number of minutes before 
outpatients with heart attack (or chest pain that suggests a possible 
heart attack) received an electrocardiograph (ECG) test to help 
diagnose heart attack.
---------------------------------------------------------------------------

    \120\ This measure was formerly called ``ED-AMI-4--Median Time 
to Electrocardiogram (ECG)'' in the cited Federal Register.
---------------------------------------------------------------------------

    We proposed to remove the OP-5 measure beginning with the CY 2021 
payment determination under our proposed measure removal Factor 8, the 
costs associated with the measure outweigh the benefit of its continued 
use in the program. As noted above, OP-5 is a chart-abstracted measure, 
which can be potentially more challenging for facilities to report than 
claims-based or structural measures. Chart-abstraction requires 
facilities to select a sample population, access historical records 
from several clinical data quarters past, and interpret that patient 
data. This process is typically more time and resource-consuming than 
for other measure types. As described in section I.A.2. of the proposed 
rule and this final rule with comment period, our Meaningful Measures 
Initiative is intended to reduce costs and minimize burden, and we 
believe that removing this chart-abstracted measure from the Hospital 
OQR Program would reduce program complexity.
    However, we do not believe the use of chart-abstracted measure data 
alone is sufficient justification for removal of a measure under 
proposed measure

[[Page 59089]]

removal Factor 8. The costs of collection and submission of chart-
abstracted measure data is burdensome for facilities, especially when 
taking into consideration that, although this measure is not topped-
out, we have come to the conclusion that the benefit of this measure is 
limited. Based on our analysis of data submitted by 1,995 hospitals 
from Quarter 3 in 2016 through Quarter 2 in 2017 the variation in 
average measure performance between hospitals is minimal, with a 
difference in median time to ECG of less than two minutes between the 
75th and 90th percentile hospitals. Furthermore, the difference between 
the 25th and 75th percentile, distinguishing between high and low 
performers, is only 5.5 minutes. Given clinical guidelines recommend 
that ECG be obtained within 10 minutes of arrival to the emergency 
department (ED), we do not believe this difference is clinically 
significant and further indicates that variations are not sufficiently 
large to inform beneficiary decision-making to justify the costs of 
collecting the data.\121\ These data are demonstrated in the table 
below.
---------------------------------------------------------------------------

    \121\ Diercks et al. 2006. Door-to-ECG time in patients with 
chest pain presenting to the ED. AJEM.
[GRAPHIC] [TIFF OMITTED] TR21NO18.100

    We believe that the minimal variation in hospital performance does 
not help beneficiaries to make informed care decisions, since 
distinguishing meaningful differences in hospital performance on this 
measure is difficult. As such, the measure benefit is limited, and no 
longer meaningfully supports program objectives of informing 
beneficiary choice.
    Thus, we believe that costs and burdens to both facilities and CMS 
such as program oversight, measure maintenance, and public display, 
associated with keeping this measure in the program outweigh the 
limited benefit associated with the measure's continued use. Therefore, 
we proposed to remove OP-5: Median Time to ECG from the Hospital OQR 
Program beginning with the CY 2021 payment determination and for 
subsequent years.
    Comment: Many commenters supported CMS' proposal to remove OP-5. 
One commenter stated that the burden of collecting data for this chart-
abstraction measure exceeds the value. Many other commenters praised 
CMS' measure removals in general due to the resulting burden reduction.
    Response: We thank the commenters for their support.
    Comment: A few commenters recommended retaining OP-5. One commenter 
noted that ECG findings are important in managing acute coronary 
symptoms and affect patient morbidity. This commenter also noted that 
it is not overly burdensome to report the measure. Another commenter 
recommended that the measure be retained and revised so that patients 
admitted for observation or inpatient care are included.
    Response: We thank commenters for this feedback. We agree that ECG 
findings are important, but our assessment indicates that there is 
minimal variation in hospital performance on this measure, and 
therefore, the opportunity to improve the management and patient 
morbidity associated with acute coronary symptoms is severely limited. 
In addition, we disagree that the measure is not burdensome to report 
overall, as it requires chart-abstraction. Many commenters supported 
removal and cited burden reduction as a benefit of this proposal. As a 
result, we believe it is appropriate to remove this measure and we do 
not intend to retain or revise it.
    After consideration of the public comments we received, we are 
finalizing our proposal, as proposed, to remove OP-5: Median Time to 
ECG from the Hospital OQR Program beginning with the CY 2021 payment 
determination and for subsequent years.
 Proposal To Remove OP-29: Endoscopy/Polyp Surveillance: 
Appropriate Follow-Up Interval for Normal Colonoscopy in Average Risk 
Patients
    We refer readers to the CY 2014 OPPS/ASC final rule with comment 
period (78 FR 75099 through 75100) where we adopted OP-29: Endoscopy/
Polyp Surveillance: Appropriate Follow-up Interval for Normal 
Colonoscopy in Average Risk Patients (NQF #0659) beginning with the CY 
2016 payment determination. This chart-abstracted process measure 
assesses the ``[p]ercentage of patients aged 50 years and older 
receiving a screening colonoscopy without biopsy or polypectomy who had 
a recommended follow-up interval of at least 10 years for repeat 
colonoscopy documented in their colonoscopy report.'' (78 FR 75099). 
This measure aims to assess whether average risk patients with normal 
colonoscopies receive a recommendation to receive a repeat colonoscopy 
in an interval that is less than the recommended amount of 10 years.
    In the proposed rule, we proposed to remove OP-29: Endoscopy/Polyp 
Surveillance Follow-up Interval for Normal Colonoscopy in Average Risk 
Patients beginning with the CY 2021 payment determination and for 
subsequent years under our proposed measure removal Factor 8, the costs 
associated with a measure outweigh the benefit of its continued use in 
the program. We adopted OP-29: Endoscopy/Polyp Surveillance Follow-up 
Interval for Normal Colonoscopy in Average Risk Patients in the CY 2014 
OPPS/ASC final rule with comment period (78 FR 75099 through 75100) 
noting that performing colonoscopy too frequently increases patients' 
exposure to procedural harm. However, we noted concern in the proposed 
rule that the costs of this measure outweigh the benefit of its 
continued use in the program.
    Chart-abstraction requires facilities to select a sample 
population, access historical records from several current and historic 
clinical data quarters, and

[[Page 59090]]

interpret that patient data. This process is typically more time and 
resource-consuming than for other measure types. In addition to 
submission of manually chart-abstracted data, we take all burden and 
costs into account when evaluating a measure. We noted in the proposed 
rule that removing OP-29 would reduce the burden and cost to facilities 
associated with collection of information and reporting on their 
performance associated with the measure.
    However, we also acknowledged that we do not believe the use of 
chart-abstracted measure data alone is sufficient justification for 
removal of a measure under proposed measure removal Factor 8. The costs 
of collection and submission of chart-abstracted measure data is 
burdensome for facilities especially when taking into consideration the 
availability of other CMS quality measures that are relevant in the 
clinical condition and highly correlated in performance across 
measures. In the proposed rule, we noted another colonoscopy-related 
measure required in the Hospital OQR Program, OP-32: Facility 7-Day 
Risk-Standardized Hospital Visit Rate after Outpatient Colonoscopy (NQF 
#2539), which measures all-cause, unplanned hospital visits 
(admissions, observation stays, and emergency department visits) within 
7 days of an outpatient colonoscopy procedure (79 FR 66949). This 
claims-based outcomes measure does not require chart-abstraction, and 
similarly contributes data on quality of care related to colonoscopy 
procedures, although the measure does not specifically track processes 
such as follow-up intervals. When we adopted OP-32, we believed this 
measure would reduce adverse patient outcomes associated with 
preparation for colonoscopy, the procedure itself, and follow-up care 
by capturing and making more visible to facilities and patients all 
unplanned hospital visits following the procedure (79 FR 66949). 
Furthermore, in the proposed rule, we noted our belief that the 
potential benefits of keeping OP-29 in the program are mitigated by the 
existence of the same measure (Appropriate Follow-up Interval for 
Normal Colonoscopy in Average Risk Patients) \122\ for 
gastroenterologists in the Merit-Based Incentive Payment System (MIPS) 
for the 2019 performance period in the QPP (82 FR 30292). Thus, we 
noted that the issue of preventing harm to patients from colonoscopy 
procedures that are performed too frequently is adequately addressed 
through MIPS in the QPP, because we expect a portion of MIPS-eligible 
clinicians reporting on the measure nationwide to provide meaningful 
data to CMS. In the proposed rule, we noted that although MIPS-eligible 
clinicians may voluntarily select measures from a list of options, HOPD 
providers that are MIPS-eligible will have the opportunity to continue 
collecting information for the measure without being penalized if they 
determine there is value for various quality improvement efforts.\123\ 
The availability of this measure in another CMS program demonstrates 
CMS' continued commitment to this measure area.
---------------------------------------------------------------------------

    \122\ QPP Measure Selection: Appropriate Follow-up Interval for 
Normal Colonoscopy in Average Risk Patients. Available at: https://qpp.cms.gov/mips/quality-measures.
    \123\ CMS finalized that services furnished by an eligible 
clinician that are payable under the ASC, HHA, Hospice, or HOPD 
methodology will not be subject to the MIPS payments adjustments, 
but eligible clinicians payable under those methodologies may have 
the option to still voluntarily report on applicable measures and 
the data reported will not be used to determine future eligibility 
(82 FR 53586).
---------------------------------------------------------------------------

    Furthermore, we seek to align our quality reporting work with the 
Patients Over Paperwork and the Meaningful Measures Initiatives 
described in section I.A.2. of the proposed rule and this final rule 
with comment period. The purpose of this effort is to hold providers 
accountable for only the measures that are most important to patients 
and clinicians and those that are focused on patient outcomes in 
particular, because outcome measures evaluate the actual results of 
care. As described in section I.A.2. of the proposed rule and this 
final rule with comment period, our Meaningful Measures Initiative is 
intended to reduce costs and minimize burden, and we believe that 
removing this chart-abstracted measure from the Hospital OQR Program 
would reduce program complexity. In addition, as we discussed in 
section XIV.B.3.b. of the proposed rule, where we proposed to adopt 
measure removal Factor 8, we noted that beneficiaries may find it 
confusing to see public reporting on the same measure in different 
programs.
    Therefore, due to the combination of factors of the costs of 
collecting data for this chart-abstracted measure, the preference for 
an outcomes measure in the Hospital OQR Program that provides valuable 
data for the same procedure, and the existence of the same measure in 
another CMS program, we noted in the proposed rule that the burdens and 
costs associated with this measure outweigh the limited benefit to 
beneficiaries. As a result, we proposed to remove OP-29: Endoscopy/
Polyp Surveillance Follow-up Interval for Normal Colonoscopy in Average 
Risk Patients beginning with the CY 2021 payment determination and for 
subsequent years. In the proposed rule, we noted that we also proposed 
to remove a similar measure in the ASCQR Program in section XIV.B.3.c. 
of the proposed rule.
    Comment: Several commenters opposed CMS' proposal to remove OP-29 
from the Hospital OQR Program. A few commenters expressed concern that 
physicians may not follow the recommended guidelines for colonoscopy 
screenings and noted that there is a potential for patient harm from 
unnecessary colonoscopy screenings that pose significant costs. One 
commenter believed that solely retaining the measure in MIPS is 
insufficient because the measure is voluntary in that program. A few 
commenters stated that OP-29 and OP-32 assess distinct and different 
aspects of colonoscopies, because OP-32 focuses on coordination and 
does not evaluate the interval between colonoscopies or the appropriate 
use of care. One commenter noted that OP-29 and OP-32 fall into 
different Meaningful Measures categories, Preventable Healthcare Harm 
and Admissions and Readmissions, respectively. Some commenters 
recommended retaining OP-29 to achieve a holistic approach to measuring 
the quality of care in this clinical area. One commenter asserted that 
OP-29 is not overly burdensome to collect and report. Some commenters 
disagreed with CMS' assessment that the costs of the measure outweigh 
the benefits.
    Response: Although MIPS-eligible clinicians may voluntarily select 
measures from a list of options, in crafting our proposal, we believed 
that MIPS reporting would mitigate the impact of removing this measure 
and provide some meaningful data in this clinical area. After 
considering the commenters' views, however, we acknowledge that 
although a similar measure is available in the QPP, OP-29 provides 
valuable information to beneficiaries specifically about the outpatient 
hospital setting, where high volumes of colonoscopies are performed. We 
agree that adherence to clinical guidelines for colonoscopy screening 
intervals is an important issue due to many studies that document 
inappropriate use.^{124 125 126} One study

[[Page 59091]]

showed high rates of inappropriate colonoscopies performed in older 
adult populations: 10 percent in adults aged 70-75, 39 percent in 
adults aged 76-85, and 25 percent in adults aged >=86.\127\ Thus, we 
believe that OP-29 is a critical measure for the Hospital OQR Program 
because there is demonstrated substantial overuse of surveillance 
colonoscopies among low-risk patients,\128\ with research showing that 
colonoscopies are often recommended at shorter intervals than are 
advised by guidelines among patients with normal colonoscopy 
results.\129\ We believe it is especially important to assess this 
topic due to the high-volume of these procedures that occur in the 
outpatient setting.
---------------------------------------------------------------------------

    \124\ Sheffield et al. 2013. Potentially Inappropriate Screening 
Colonoscopy in Medicare Patients: Variation by Provider and 
Geographic Region. JAMA Intern Med.
    \125\ Schoen R. E., Pinsky P. F., Weissfeld J. L., et al. 
Utilization of surveillance colonoscopy in community practice. 
Gastroenterology. 2010;138(1):73-81. doi: 10.1053/
j.gastro.2009.09.062.
    \126\ Krist, AH, Jones, RM, Woolf, SH et al. Timing of Repeat 
Colonoscopy: Disparity Between Guidelines and Endoscopists' 
Recommendation. American Journal of Preventive Medicine. 2007.
    \127\ Sheffield et al. 2013. Potentially Inappropriate Screening 
Colonoscopy in Medicare Patients: Variation by Provider and 
Geographic Region. JAMA Intern Med.
    \128\ Schoen R. E., Pinsky P. F., Weissfeld J. L., et al. 
Utilization of surveillance colonoscopy in community practice. 
Gastroenterology. 2010;138(1):73-81. doi: 10.1053/
j.gastro.2009.09.062.
    \129\ Krist, AH, Jones, RM, Woolf, SH et al. Timing of Repeat 
Colonoscopy: Disparity Between Guidelines and Endoscopists' 
Recommendation. American Journal of Preventive Medicine. 2007.
---------------------------------------------------------------------------

    Furthermore, while OP-29 and OP-32 assess the topic of 
colonoscopies generally, we acknowledge that they assess distinct 
clinical areas. OP-32 tracks adverse patient outcomes that result in 
unplanned hospital visits, whereas, OP-29 provides information about 
colonoscopies occurring at inappropriate intervals that may increase 
costs to beneficiaries and to CMS, a priority of our Meaningful 
Measures Initiative. While OP-32 provides vital data about patient 
outcomes after colonoscopies, OP-29 focuses on adherence to guideline 
recommendations for screening colonoscopy follow-up intervals, as noted 
by NQF's evaluation report.\130\
---------------------------------------------------------------------------

    \130\ NQF #0658 Endoscopy/Polyp Surveillance: Appropriate 
follow-up interval for normal colonoscopy in average risk patients, 
Date Submitted: Jul 09, 2012 National Quality Form, Stage 1 Concept 
Submission and Evaluation Worksheet 1.0.
---------------------------------------------------------------------------

    Despite the costs and burdens of chart-abstraction or the presence 
of other measures assessing a similar clinical topic, after considering 
incoming comments and reevaluating our data, we now believe OP-29 is a 
more critical measure for the Hospital OQR Program than initially 
perceived in the proposed rule. Specifically, as discussed above, upon 
reviewing the measure set as a whole, we now believe that OP-29 
assesses a distinct clinical area not addressed by OP-32. Further, 
although we noted that OP-29 requires the burden of chart-abstraction 
to report, we believe this measure is significantly less burdensome 
than OP-30 due to the significant burden of obtaining patient histories 
required for that measure. We also appreciate commenters' feedback that 
OP-29 is not overly burdensome to report. Because this measure tracks 
the number of patients who had a recommended follow-up interval of at 
least 10 years for repeat colonoscopy documented in their colonoscopy 
report, we believe it provides important information to beneficiaries 
on the avoidance of inappropriate endoscopies/colonoscopies. OP-29 
evaluates overutilization that can lead to the overuse of resources and 
unnecessary risks to beneficiaries from possible procedural 
complications and harms.
    Accordingly, after considering the public comments we received and 
upon further review of the benefits of the measure, we no longer 
believe that the costs associated with this measure outweigh the 
benefit of its continued use in the Hospital OQR Program.
    In section I.A.2. of the proposed and this final rule with comment 
period, we describe our Meaningful Measures Initiative that is intended 
to reduce costs and minimize burden. We believe that while removing 
this chart-abstracted measure from the Hospital OQR Program would 
reduce program complexity, retaining it provides pertinent information 
about colonoscopies occurring at inappropriate intervals that may 
contribute to increased costs to beneficiaries and to CMS, a priority 
of our Meaningful Measures Initiative. Therefore, we are not finalizing 
our proposal to remove this measure. We believe retaining this measure 
is responsive to those comments as it is a valuable process measure and 
assesses a distinct clinical area.
    Comment: A few commenters stated that OP-29 should be retained to 
promote program alignment across outpatient settings and allow for 
comparisons between facility types.
    Response: We have considered program alignment by adding and 
removing measures in tandem for the ASCQR and Hospital OQR Programs, 
such as ASC-9/OP-29: Endoscopy/Polyp Surveillance: Appropriate Follow-
up Interval for Normal Colonoscopy in Average Risk Patients. As noted 
above, we adopted OP-29 into the Hospital OQR Program because we 
believe it is important for HOPDs to be active partners in avoiding 
inappropriate use and ensuring that beneficiaries at their facilities 
are referred for follow-up care at appropriate intervals in alignment 
with current guidelines. As stated above, we are not finalizing our 
proposal to remove OP-29. We are similarly retaining the corresponding 
measure (ASC-9) in the ASCQR Program in section XIV.B.3.c. of this 
final rule with comment period.
    Comment: One commenter did not support CMS' proposal to remove OP-
29 because it is included in the Core Quality Measures Collaborative 
(CQMC) Gastroenterology Core Set and is widely used in the private 
sector.
    Response: The CMS CQMC identifies core sets of quality measures 
that payers have committed to using for reporting as soon as 
feasible.\131\ The guiding principles used by the Collaborative in 
developing the core measure sets are that they be meaningful to 
patients, consumers, and physicians, while reducing variability in 
measure selection, collection burden, and cost. Its goal is to 
establish broadly agreed upon core measure sets that could be 
harmonized across both commercial and government payers.\132\ We agree 
that the inclusion of OP-29 in the CQMC Gastroenterology Core Set 
speaks to its clinical value. However, although we are retaining OP-29 
for the reasons described in this section, we note that the inclusion 
of measures in the CQMC Core Sets does not necessitate retention in the 
Hospital OQR Program.
---------------------------------------------------------------------------

    \131\ Core Measures. Retrieved from: https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/QualityMeasures/Core-Measures.html.
    \132\ Ibid.
---------------------------------------------------------------------------

    Comment: One commenter recommended that CMS retain the measure and 
explore how to automate tracking of the information to reduce the 
resource-intensive use of chart-abstracted data.
    Response: We thank the commenter for the suggestion regarding 
automated data submission and will take this into consideration for the 
future. As discussed in section I.A.2 of this final rule with comment 
period, our Meaningful Measures Initiative prioritizes the least 
burdensome measure sets for our quality reporting programs, and we will 
continue to evaluate the Hospital OQR Program measure set through this 
framework. We continually seek opportunities to reduce

[[Page 59092]]

the reporting burden of our programs but note that collecting data for 
OP-29 still currently requires chart-abstraction.
    Comment: Many commenters supported CMS' proposal to remove OP-29, 
noting that the proposal reduces burden and duplication between 
programs. A few commenters noted that the measure was developed to 
assess provider, rather than facility-level, performance.
    Response: We thank the commenters for their support. As noted in 
our proposal above, this same measure is available through MIPS in the 
QPP and, although MIPS-eligible clinicians may voluntarily select 
measures from a list of options, we expect a portion of MIPS-eligible 
clinicians reporting on the measure nationwide to provide meaningful 
data to CMS about avoiding inappropriate use. While this measure was 
initially developed at the physician level, it has been field-tested in 
the HOPD facility setting by the measure stewards (78 FR 75099). 
Further, we believe it is important for HOPDs to be active partners in 
avoiding inappropriate use and ensuring that patients at their 
facilities are referred for follow-up care at appropriate intervals in 
alignment with current guidelines. In addition, after considering the 
public comments we received and upon further review of the benefits of 
the measure, we no longer believe that the costs associated with this 
measure outweigh the benefit of its continued use in the program as 
this measure assesses a unique and clinically important topic area not 
covered otherwise addressed by the Hospital OQR Program measure set.
    After consideration of the public comments we received, we are not 
finalizing our proposal to remove OP-29: Endoscopy/Polyp Surveillance: 
Appropriate Follow-up Interval for Normal Colonoscopy in Average Risk 
Patients from the Hospital OQR Program beginning with the CY 2021 
payment determination and for subsequent years. This measure will 
remain in the program under our measure retention policies, unless we 
take future action under our measure removal policies. We note that we 
also are not finalizing our proposal to remove ASC-9 under the ASCQR 
Program, and we refer readers to section XIV.B.3.c. of this final rule 
with comment period for more information.
 Removal of OP-30: Endoscopy/Polyp Surveillance: Colonoscopy 
Interval for Patients With a History of Adenomatous Polyps--Avoidance 
of Inappropriate Use
    We refer readers to CY 2014 OPPS/ASC final rule with comment period 
(78 FR 75102) where we adopted OP-30: Endoscopy/Polyp Surveillance: 
Colonoscopy Interval for Patients with a History of Adenomatous Polyps-
Avoidance of Inappropriate Use (NQF #0659) beginning with the CY 2016 
payment determination. This chart-abstracted process measure assesses 
the percentage of patients aged 18 years and older receiving a 
surveillance colonoscopy, with a history of a prior colonic polyp in 
previous colonoscopy findings, who had a follow-up interval of three or 
more years since their last colonoscopy documented in the colonoscopy 
report.
    In the proposed rule, we proposed to remove OP-30: Endoscopy/Polyp 
Surveillance: Colonoscopy Interval for Patients with a History of 
Adenomatous Polyps-Avoidance of Inappropriate Use beginning with the CY 
2021 payment determination and for subsequent years under our proposed 
measure removal Factor 8, the costs associated with a measure outweigh 
the benefit of its continued use in the program.
    We adopted OP-30: Endoscopy/Polyp Surveillance: Colonoscopy 
Interval for Patients with a History of Adenomatous Polyps-Avoidance of 
Inappropriate Use in the CY 2014 OPPS/ASC final rule with comment 
period (78 FR 75102) noting that colonoscopy screening for high risk 
patients is recommended based on risk factors and one such factor is a 
history of adenomatous polyps. The frequency of colonoscopy screening 
varies depending on the size and amount of polyps found, with the 
general recommendation of a 3-year follow-up. We stated that this 
measure is appropriate for the measurement of quality of care furnished 
by hospital outpatient departments because colonoscopy screening is 
commonly performed in these settings (78 FR 75102). However, we now 
believe that the costs of this measure outweigh the benefit of its 
continued use in the program.
    Chart-abstraction requires facilities to select a sample 
population, access historical records from several clinical data 
quarters past, and interpret that patient data. This process is 
typically more time and resource-consuming than for other measure 
types. In addition to submission of manually chart-abstracted data, we 
take all burden and costs into account when evaluating a measure. 
Removing OP-30 would reduce the burden and cost to facilities 
associated with collection of information and reviewing their data and 
performance associated with the measure.
    However, we do not believe the use of chart-abstracted measure data 
alone is sufficient justification for removal of a measure under 
proposed measure removal Factor 8. The costs of collection and 
submission of chart-abstracted measure data is burdensome for 
facilities especially when taking into consideration the availability 
of other CMS quality measures. Another colonoscopy-related measure 
required in the Hospital OQR Program, OP-32: Facility 7-Day Risk-
Standardized Hospital Visit Rate after Outpatient Colonoscopy (NQF 
#2539) measures all-cause, unplanned hospital visits (admissions, 
observation stays, and emergency department visits) within 7 days of an 
outpatient colonoscopy procedure (79 FR 66949). This claims-based 
outcome measure does not require chart-abstraction, and similarly 
contributes data on quality of care related to colonoscopy procedures, 
although the measure does not specifically track processes such as 
follow-up intervals. When we adopted OP-32, we believed this measure 
would reduce adverse patient outcomes associated with preparation for 
colonoscopy, the procedure itself, and follow-up care by capturing and 
making more visible to facilities and patients all unplanned hospital 
visits following the procedure (79 FR 66949). Furthermore, the 
potential benefits of keeping OP-30 in the program are mitigated by the 
existence of the same measure for gastroenterologists in the Merit-
Based Incentive Payment System (MIPS) for the 2019 performance period 
in the QPP (82 FR 30292). Thus, we believe the issue of preventing harm 
to patients from colonoscopy procedures that are performed too 
frequently is adequately addressed through MIPS in the QPP because we 
expect a portion of MIPS-eligible clinicians reporting on the measure 
nationwide to provide meaningful data to CMS. Although MIPS-eligible 
clinicians may voluntarily select measures from a list of options, HOPD 
providers that are MIPS-eligible will have the opportunity to continue 
collecting information for the measure without being penalized if they 
determine there is value for various quality improvement efforts.\133\ 
The availability of this measure in another CMS program demonstrates 
CMS' continued commitment to this measure area.
---------------------------------------------------------------------------

    \133\ CMS finalized that services furnished by an eligible 
clinician that are payable under the ASC, HHA, Hospice, or HOPD 
methodology will not be subject to the MIPS payments adjustments, 
but eligible clinicians payable under those methodologies may have 
the option to still voluntarily report on applicable measures and 
the data reported will not be used to determine future eligibility 
(82 FR 53586).
---------------------------------------------------------------------------

    Furthermore, we seek to align our quality reporting work with the 
Patients

[[Page 59093]]

Over Paperwork and the Meaningful Measures Initiatives described in 
section I.A.2. of the proposed rule and this final rule with comment 
period. The purpose of this effort is to hold providers accountable for 
only the measures that are most important to patients and clinicians 
and those that are focused on patient outcomes in particular, because 
outcome measures evaluate the actual results of care. As described in 
section I.A.2. of the proposed rule and this final rule with comment 
period, our Meaningful Measures Initiative is intended to reduce costs 
and minimize burden, and we believe that removing this chart-abstracted 
measure from the Hospital OQR Program would reduce program complexity. 
In addition, as we discussed in section XIII.B.4.a. of the proposed 
rule, where we proposed to adopt measure removal Factor 8, 
beneficiaries may find it confusing to see public reporting on the same 
measure in different programs.
    Therefore, due to the combination of factors of the costs of 
collecting data for this chart-abstracted measure, the preference for 
an outcomes measure in OQR that provides valuable data for the same 
procedure, and the existence of the same measure in the MIPS program, 
we believe that the burdens and costs associated with manual chart 
abstraction outweigh the limited benefit to beneficiaries of receiving 
this information. As a result, we proposed to remove OP-30: Endoscopy/
Polyp Surveillance: Colonoscopy Interval for Patients with a History of 
Adenomatous Polyps-Avoidance of Inappropriate Use beginning with the CY 
2021 payment determination and for subsequent years. In the proposed 
rule, we noted that we also proposed to remove a similar measure in the 
ASCQR Program in section XIV.B.3.c. of the proposed rule.
    Comment: Many commenters supported CMS' proposal to remove OP-30. A 
few commenters noted that the measure is burdensome and costly to 
report, in part due to the volume of cases that must be reviewed to 
identify patients that meet the inclusion and exclusion criteria. Some 
commenters agreed that the cost of the measure outweighs the benefits 
due to data collection challenges that are specific to OP-30, due to 
the extensive patient histories required and because data may need to 
be obtained from different settings.
    Response: We thank the commenters for their support. In addition to 
the burden of chart-abstraction, we agree with the commenter that 
pointed out the unique burden of OP-30, which requires that facilities 
conduct extensive patient histories and contact other facilities in 
order to obtain documentation of a history of adenomatous polyps.\134\ 
Thus, the costs and burdens are higher for this measure than for the 
other colonoscopy measure considered for removal, OP-29, which requires 
less information from patients and does not require historical 
documentation. We thank the commenter for its feedback on the burden 
associated with identifying patients meeting the inclusion and 
exclusion criteria for this measure. We are finalizing our proposal to 
remove OP-30.
---------------------------------------------------------------------------

    \134\ OP-30 Measure Information Form. Available at: https://www.qualitynet.org/dcs/ContentServer?c=Page&pagename=QnetPublic%2FPage%2FSpecsManualTemplate&cid=1228776612884.
---------------------------------------------------------------------------

    Comment: One commenter noted that the measure specifications for 
OP-30 will be updated soon and recommended that CMS retain the measure 
until new guidelines are available. A few commenters disagreed with 
CMS' assessment that the cost of the measure outweighs the benefit, and 
one commenter recommended that CMS try to automate tracking of data 
needed for the measure to reduce its burden.
    Response: We understand that the measure steward is planning to 
update OP-30; however, because these updates will not eliminate the 
need to collect patient histories, we do not believe such updates will 
lessen burden. Due to the burden of data collection for this measure, 
which includes taking extensive patient histories, we believe the costs 
outweigh the benefits and, therefore, we do not believe it is 
appropriate to retain the measure. We thank the commenter for the 
suggestion regarding automated data submission and will take this into 
consideration for the future. As discussed in section I.A.2 of this 
final rule with comment period, our Meaningful Measures Initiative 
prioritizes burden reduction in our quality reporting programs, and we 
will continue to evaluate the Hospital OQR Program measure set through 
this framework. We continually seek opportunities to reduce the 
reporting burden of our programs, but note that currently, collecting 
data for OP-30 still requires chart-abstraction.
    Comment: Several commenters noted that OP-30 was developed and 
tested as a provider-level measure and they did not believe it is 
appropriate for the hospital setting. One commenter stated that this 
measure is already being reported through the MIPS (formerly PQRS) and 
that MIPS is the appropriate program because OP-30 is a provider-level 
measure. Another commenter stated that duplicate reporting in CMS' 
quality reporting programs has caused unnecessary provider burden 
without adding new information to the pool of quality data available to 
the public. Another commenter noted that relying on MIPS reporting of 
this measure is inadequate, as MIPS is a voluntary measure in that 
program.
    Response: We adopted OP-30 into the Hospital OQR Program because we 
believe it is important for HOPDs to be active partners in avoiding 
inappropriate use and ensuring that beneficiaries at their facilities 
are referred for follow-up care at appropriate intervals in alignment 
with current guidelines. And, while this measure was initially 
developed at the physician level, it has been field-tested in the HOPD 
facility setting by the measure stewards (78 FR 75099). As noted in our 
proposal, this same measure is available through MIPS in the QPP and, 
although MIPS-eligible clinicians may voluntarily select measures from 
a list of options, we expect a portion of MIPS-eligible clinicians 
reporting on the measure nationwide to provide meaningful data to CMS 
about avoiding inappropriate use.
    A primary goal of our Meaningful Measures Initiative is to reduce 
provider burden through the deduplication of measures across quality 
reporting programs. As discussed above, after considering comments and 
revaluating our measure sets as a whole, we are not finalizing our 
proposal to remove OP-29 in order to retain a measure assessing 
inappropriate use of endoscopies/colonoscopies in the Hospital OQR 
Program. We believe there may be a measurement gap if both OP-29 and 
OP-30 are removed and because of the unique burden associated with OP-
30, we are finalizing its removal while retaining OP-29. Removing OP-30 
while retaining OP-29 best enables us to assess this important clinical 
area while ensuring that the costs of measure do not outweigh the 
benefits. Thus, due in part to the duplication of this measure through 
MIPS in the QPP and the additional burden to hospitals of obtaining 
patient records, we are finalizing our proposal to remove OP-30 from 
the Hospital OQR Program measure set beginning with the CY 2021 payment 
determination, as proposed.
    Comment: A few commenters opposed CMS' proposal to remove OP-30 
from the Hospital OQR Program. One commenter noted that OP-30 is a cost 
measure and helps avoid inappropriate use or missed opportunities to 
screen patients that could result in significant harm to beneficiaries. 
One commenter

[[Page 59094]]

expressed concern that physicians may not follow the recommended 
guidelines for colonoscopy screenings and noted that there is a 
potential for patient harm from unnecessary colonoscopy screenings that 
poses significant costs.
    Response: We agree that adherence to clinical guidelines for 
colonoscopy screening intervals is an important issue. Measuring the 
inappropriate use of colonoscopy screenings is critical to preventing 
the waste of resources and potential patient harm. In part for this 
reason, we are retaining OP-29 in the Hospital OQR Program measure set 
and will continue to require reporting on appropriate follow-up 
intervals for normal risk patients. We believe that retaining OP-29 in 
the Hospital OQR Program enables us to address concerns regarding 
patient harm from unnecessary colonoscopy screenings. Further, due to 
the unique documentation burden specifically for OP-30, we believe it 
adds undue burden especially in comparison to OP-29. After considering 
stakeholder comments, reevaluating our measure sets as a whole, and 
balancing the clinical value of measures with the costs, we believe it 
is appropriate to retain OP-29 while finalizing our proposal to remove 
OP-30.
    Comment: One commenter did not support CMS' proposal to remove OP-
30 because it is included in the CQMC Gastroenterology Core Set and is 
widely used in the private sector.
    Response: The CMS CQMC Gastroenterology Core Set is a set of 
measures identified as being meaningful to patients, consumers, and 
physicians, while reducing variability in measure selection, collection 
burden, and cost and is intended for use by payers who are part of the 
CQMC.\135\ Because of this, we believe beneficiaries will continue to 
receive this data to help them make health care decisions. We agree 
that this measure is valuable to many stakeholders and support its 
continued reporting through other quality reporting programs and in the 
private sector. However, due to the measure's requirement to obtain 
historical patient records, we believe that this measure adds undue 
burden to HOPDs. In addition, we note that the inclusion of measures in 
the CQMC Core Sets does not necessitate retention in the Hospital OQR 
Program.
---------------------------------------------------------------------------

    \135\ Core Measures. Retrieved from: https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/QualityMeasures/Core-Measures.html.
---------------------------------------------------------------------------

    Comment: A few commenters stated that OP-30 and OP-32 assess 
distinct different aspects of colonoscopies, because OP-32 focuses on 
care coordination and does not evaluate the interval between 
colonoscopies or the appropriate use of care. One commenter noted that 
OP-30 and OP-32 fall into different Meaningful Measures categories, 
Preventable Healthcare Harm and Admissions and Readmissions, 
respectively.
    Response: We thank the commenters for their feedback. We agree that 
OP-30 and OP-32 assess distinct clinical areas but do assess the topic 
of colonoscopies generally. While OP-32 tracks adverse patient outcomes 
that result in unplanned hospital visits, OP-30 provides information 
about colonoscopies occurring at inappropriate intervals for 
beneficiaries that may contribute to increased costs to beneficiaries 
and to CMS, a priority of our Meaningful Measures Initiative. However, 
we believe OP-30 should be removed because it is uniquely burdensome, 
as described in a previous response. After considering stakeholder 
comments, reevaluating our measure sets as a whole, and balancing the 
clinical value of measures with the costs, we believe it is appropriate 
to remove OP-30. We note that our retention of OP-29 allows us to 
continue to address inappropriate use of colonoscopy screening.
    After consideration of the public comments we received, we are 
finalizing our proposal to remove OP-30: Endoscopy/Polyp Surveillance: 
Colonoscopy Interval for Patients with a History of Adenomatous Polyps-
Avoidance of Inappropriate Use beginning with the CY 2021 payment 
determination and for subsequent years. We refer readers to section 
XIV.B.3.c. of this final rule with comment period where we are removing 
a similar measure from the ASCQR Program.
 Proposal To Remove OP-31: Cataracts--Improvement in Patient's 
Visual Function Within 90 Days Following Cataract Surgery
    We refer readers to the CY 2014 OPPS/ASC final rule with comment 
period (78 FR 75103) where we adopted OP-31: Cataracts: Improvement in 
Patient's Visual Function within 90 Days Following Cataract Surgery 
(NQF #1536) beginning with the CY 2016 payment determination and 
subsequent years. This measure assesses the rate of patients 18 years 
and older (with a diagnosis of uncomplicated cataract) in a sample who 
had improvement in visual function achieved within 90 days following 
cataract surgery based on completing both a pre-operative and post-
operative visual function survey.
    Since the adoption of this measure, we came to believe that it can 
be operationally difficult for facilities to collect and report the 
measure (79 FR 66947). Specifically, we were concerned that the results 
of the survey used to assess the pre-operative and post-operative 
visual function of the patient may not be shared across clinicians and 
facilities, making it difficult for facilities to have knowledge of the 
visual function of the patient before and after surgery (79 FR 66947). 
We were also concerned about the surveys used to assess visual 
function; the measure allows for the use of any validated survey and 
results may be inconsistent should clinicians use different surveys (79 
FR 66947). Therefore, on December 31, 2013, we issued guidance stating 
that we would delay data collection for OP-31 for 3 months (data 
collection would commence with April 1, 2014 encounters) for the CY 
2016 payment determination (https://www.qualitynet.org/dcs/ContentServer?c=Page&pagename=QnetPublic%2FPage%2FQnetTier3&cid=1228772854917). We issued additional guidance on April 2, 2014, stating that we 
would further delay the implementation of OP-31 for an additional nine 
months, until January 1, 2015 for the CY 2016 payment determination, 
due to continued concerns (https://www.qualitynet.org/dcs/ContentServer?c=Page&pagename=QnetPublic%2FPage%2FQnetTier3&cid=1228773786593). As a result of these concerns, in the CY 2015 OPPS/ASC final 
rule with comment period (79 FR 66948), we finalized our proposal to 
allow voluntary data collection and reporting of this measure beginning 
with the CY 2017 payment determination and for subsequent years.
    In the proposed rule, we proposed to remove OP-31: Cataracts: 
Improvement in Patient's Visual Function within 90 Days Following 
Cataract Surgery beginning with the CY 2021 and for subsequent years 
under our proposed measure removal Factor 8, the costs associated with 
the measure outweigh the benefit of its continued use in the program. 
We originally adopted OP-31 because we believe facilities should be a 
partner in care with physicians and other clinicians using their 
facility and that this measure would provide an opportunity to do so 
(79 FR 66947). However, in light of the history of complications and 
upon reviewing this measure within our Meaningful Measures framework, 
we have concluded that it is overly burdensome for facilities to report 
this measure due

[[Page 59095]]

to the difficulty of tracking care that occurs outside of the HOPD 
setting.
    In order to report on this measure to CMS, a facility would need to 
obtain the visual function assessment results from the appropriate 
ophthalmologist and ensure that the assessment utilized is validated 
for the population for which it is being used. If the assessment is not 
able to be used or is not available, the facility would then need to 
administer the survey directly and ensure that the same visual function 
assessment tool is utilized preoperatively and postoperatively. There 
is no simple, preexisting means for information sharing between 
ophthalmologists and facilities, so a facility would need to obtain 
assessment results from each individual patient's ophthalmologist both 
preoperatively and postoperatively. The high administrative costs of 
the technical tracking of this information presents an undue cost, and 
also burden associated with submission and reporting of OP-31 to CMS, 
especially for small facilities with limited staffing capacity.
    Furthermore, this measure currently provides limited benefits. 
Since making the measure voluntary, only 59 \136\ facilities have 
reported this measure to CMS, compared to approximately 4,798 total 
facilities for all other measures, resulting in only 1.2 percent of 
facilities reporting. Consequently, we have been unable to uniformly 
offer pertinent information to beneficiaries on how the measure 
assesses facility performance. This reinforces comments made in the CY 
2015 OPPS/ASC final rule with comment period in which commenters 
expressed concern that the incomplete display of data associated with 
voluntary reporting is confusing and not meaningful to beneficiaries 
and other consumers (79 FR 66947). Furthermore, commenters feared that 
the display of data from some hospitals, but not others, would lead 
some patients to conclude that some hospitals are more committed to 
improving cataract surgery. As described in section I.A.2. of the 
proposed rule and this final rule with comment period, we strive to 
ensure that beneficiaries are empowered to make decisions about their 
health care using information from data-driven insights. Because of the 
lack of sufficient data, this measure may be difficult for 
beneficiaries to interpret or use to aid in their choice of where to 
obtain care; thus, the benefits of this measure are limited.
---------------------------------------------------------------------------

    \136\ OQR Hospital Compare. Available at: https://data.medicare.gov/Hospital-Compare/Timely-and-Effective-Care-Hospital/yv7e-xc69.
---------------------------------------------------------------------------

    Thus, we stated that we believed the high technical and 
administrative costs of this measure, coupled with the high technical 
and administrative burden, outweigh the limited benefit associated with 
the measure's continued use in the Hospital OQR Program. As discussed 
in section I.A.2. of the proposed rule and this final rule with comment 
period, above, our Meaningful Measures Initiative is intended to reduce 
costs and minimize burden. We believed that removing this measure from 
the Hospital OQR Program will reduce program burden, costs, and 
complexity. Therefore, we proposed to remove OP-31: Cataracts: 
Improvement in Patient's Visual Function within 90 Days Following 
Cataract Surgery beginning with the CY 2021 payment determination and 
for subsequent years. In the proposed rule, we noted that we also 
proposed to remove a similar measure under the ASCQR Program in section 
XIV.B.3.c. of the proposed rule.
    Comment: A few commenters opposed all of CMS' proposals to remove 
measures, including OP-31.
    Response: In response to these comments requesting that measures, 
including OP-31, be retained, we reevaluated our measures and data. We 
found that a core group of facilities (between 52 and 66 for the CY 
2017 through CY 2019 payment determinations) reported on this voluntary 
measure. Although only a subset of hospitals voluntarily report data 
for this measure, we believe this measure is considered very meaningful 
by those that do report; a subset of reporting hospitals report 
consistently (11 hospitals submitted consistently for the CY 2017 
through CY 2019 payment determinations). Because this subset of 
hospitals has consistently reported this measure we are able to make 
the data publicly available year after year--in this case, for the CYs 
2017, 2018, and 2019 payment determinations.\137\ We believe providing 
data on this voluntary measure is still helpful for the public because 
it shows how a HOPD performs over time and in comparison to other HOPDs 
even if compared to a small group of HOPDs.
---------------------------------------------------------------------------

    \137\ Hospital Compare: https://www.medicare.gov/hospitalcompare/Data/Data-Updated.html.
---------------------------------------------------------------------------

    Furthermore, this is the only measure in the Hospital OQR Program 
measure set that deals with cataract surgery, which is commonly 
performed in the HOPD setting. If it is removed, the program will have 
a gap in coverage for this clinical area. As a result, we now believe 
that this measure maintains coverage in an important clinical area in 
the Hospital OQR Program and meaningful information can be provided to 
consumers regarding those facilities. In addition, when this measure 
was made voluntary in the CY 2015 OPPS/ASC final rule with comment 
period (79 FR 66947 through 66948), commenters expressed support, 
indicating that some stakeholders value the measure.
    Furthermore, we have reassessed our evaluation that the costs of 
this measure outweigh the benefits. Due to the voluntary nature of the 
measure, we believe that it is inherently not more burdensome than 
valuable. Because hospitals are not required to submit data, those that 
do not have the capacity to report, do not have to, thus creating no 
extra burden. Those that do report, do so voluntarily and have 
continued to report over the years--specifically since the CY 2015 
reporting period--despite any burdens. Because of this, we believe the 
measure is meaningful to the core group of facilities that do 
consistently report.
    After consideration of public comments and reassessing our 
analysis, we are not finalizing our proposal to remove OP-31: 
Cataracts: Improvement in Patient's Visual Function within 90 Days 
Following Cataract Surgery from the Hospital OQR Program beginning with 
the CY 2021 payment determination and for subsequent years. This 
measure will remain in the program under our measure retention 
policies, unless we take future action under our measure removal 
policies.
    Comment: Many commenters supported CMS' proposal to remove OP-31. A 
few commenters noted that data collection for this measure is difficult 
as it requires following up with clinical settings outside of the 
hospital. Another commenter supported removal and noted that the 
measure is meant for physician level-use, rather than facility-level 
reporting. One commenter questioned the validity of the measure and 
noted that it allows providers to use different surveys to collect 
measure information.
    Response: We thank the commenters for their support. As noted in 
the proposed rule, we agree that data collection for this measure may 
be difficult, and as a result in the CY 2015 OPPS/ASC final rule with 
comment period (79 FR 66948), we finalized our proposal to allow 
voluntary data collection and reporting of this measure beginning with 
the CY 2017 payment determination and for subsequent years. While this 
measure was initially developed at the physician level, it has been 
field-tested in the HOPD facility setting by the measure stewards (78 
FR 75099).

[[Page 59096]]

    In addition, we believe it is important for HOPDs to be active 
partners in care with physicians and other clinicians using their 
facility and this measure is an opportunity for hospitals to 
demonstrate this capability if they choose to report data. Further, as 
noted above, we no longer believe that the costs of this measure 
outweigh the benefits, as the measure is meaningful to the core group 
of outpatient hospitals that do consistently report and can provide 
valuable data to consumers on those specific facilities. While data 
collection for this measure can be difficult, those facilities that 
choose to report do so because they have systems in place to data from 
ophthalmologists' medical records. We agree that as a voluntary 
measure, only a subset of hospitals report on the measure, but note it 
is a meaningful measure to beneficiaries given that our analyses show 
that a consistent group of facilities report data on this measure. So, 
while data is not available for all facilities, the data that is 
available is meaningful. In addition, this measure has been 
appropriately validated for the population for which it being used, 
even acknowledging that various survey methods can be used.\138\
---------------------------------------------------------------------------

    \138\ NQF Measure Evaluation available at: https://www.qualityforum.org/WorkArea/linkit.aspx?LinkIdentifier=id&ItemID=68317.
---------------------------------------------------------------------------

    This same measure is available through MIPS in the QPP and, 
although MIPS-eligible clinicians may voluntarily select measures from 
a list of options, we expect a portion of MIPS-eligible clinicians 
reporting on the measure nationwide to provide meaningful data to CMS 
about this important outcome for beneficiaries.
    After consideration of the public comments we received and 
reassessing our analysis, we are not finalizing our proposal to remove 
OP-31: Cataracts: Improvement in Patient's Visual Function within 90 
Days Following Cataract Surgery beginning with the CY 2021 payment 
determination and for subsequent years. We are also retaining a similar 
measure in the ASCQR Program (ASC-11: Cataracts: Improvement in 
Patient's Visual Function within 90 Days Following Cataract Surgery) in 
section XIV.B.3.b. of this final rule with comment period.
(b) Measure Removal Under Removal Factor 3: OP-9: Mammography Follow-Up 
Rates
    We refer readers to the CY 2009 OPPS/ASC final rule with comment 
period (73 FR 68766) where we adopted OP-9: Mammography Follow-up Rates 
beginning with the CY 2010 payment determination. This claims-based 
measure assesses the percentage of patients with mammography screening 
studies that are followed by a diagnostic mammography, ultrasound, or 
MRI of the breast in an outpatient or office setting within 45 days. In 
the proposed rule (83 FR 37184 through 37185), we proposed to remove 
this measure under measure removal Factor 3, a measure does not align 
with current clinical guidelines or practice.
    An examination of the measure specifications \139\ shows that 
recent changes in clinical practice are not incorporated into the 
measure calculation. Since development of this measure in 2008, 
advancements in imaging technology and clinical practice for 
mammography warrant updating the measure's specifications to align with 
current clinical practice guidelines and peer-reviewed literature. 
Specifically, findings from the annual Literature Reviews and 
Environmental Scans conducted by the measure developer suggest that 
there is additional clinical benefit in performing adjuvant digital 
breast tomosynthesis (DBT) concomitant with full-field digital 
mammography (FFDM) or conventional mammography (currently included in 
the measure denominator), especially in women with dense breast 
tissue.\140\ \141\ \142\ In addition, in 2016, the American College of 
Radiology (ACR) updated its Breast Cancer Screening Appropriateness 
Criteria[supreg] to include DBT.\143\ The ACR notes that DBT can better 
detect potential false-positive findings without the need for recall. 
Furthermore, the cancer detection rate is increased with use of DBT 
compared with traditional mammography alone.\144\ A 2014 study 
published in the Journal of the American College of Radiology assessed 
the utilization of DBT among physician members of the Society of Breast 
Imaging and found that 30 percent of respondents reported using DBT 
concurrent with traditional mammography.\145\ With the update of the 
ACR clinical practice guidelines (that is, the Breast Cancer Screening 
Appropriateness Criteria[supreg]) to include DBT, use of this 
technology is expected to increase.
---------------------------------------------------------------------------

    \139\ Hospital Outpatient Quality Reporting Specifications 
Manual. Version 11.0a. Available at: https://www.qualitynet.org/dcs/ContentServer?c=Page&pagename=QnetPublic%2FPage%2FSpecsManualTemplate&cid=1228776146046.
    \140\ Bernardi, D., Macaskill, P., Pellegrini, M., Valentini, 
M., Fanto, C., Ostillio, L., Houssami, N. (2016). Breast cancer 
screening with tomosynthesis (3D mammography) with acquired or 
synthetic 2D mammography compared with 2D mammography alone (STORM-
2): a population-based prospective study. Lancet Oncol, 17(8), 1105-
1113. doi: 10.1016/s1470-2045(16)30101-2.
    \141\ Bian, T., Lin, Q., Cui, C., Li, L., Qi, C., Fei, J., & Su, 
X. (2016). Digital Breast Tomosynthesis: A New Diagnostic Method for 
Mass-Like Lesions in Dense Breasts. Breast J, 22(5), 535-540. doi: 
10.1111/tbj.12622.
    \142\ Pozz, A., Corte, A. D., Lakis, M. A., & Jeong, H. (2016). 
Digital Breast Tomosynthesis in Addition to Conventional 
2DMammography Reduces Recall Rates and is Cost Effective. Asian Pac 
J Cancer Prev, 17(7), 3521-3526.
    \143\ Mainiero MB, Bailey L, D'Orsi C, Green ED, Holbrook AI, 
Lee SJ, Lourenco AP, Moy L, Sepulveda KA, Slanetz PJ, Trikha S, 
Yepes MM, Newell MS, Expert Panel on Breast Imaging. ACR 
Appropriateness Criteria[supreg] breast cancer screening. Reston 
(VA): American College of Radiology (ACR); 2016. 7 p.
    \144\ Ibid.
    \145\ Hardesty LA, Kreidler SM, Glueck DH. Digital breast 
tomosynthesis utilization in the United States: a survey of 
physician members of the Society of Breast Imaging. Journal of the 
American College of Radiology. 2014. 11(6): 594-599.
---------------------------------------------------------------------------

    As currently specified, the measure does not adequately capture 
this shift in clinical practice. Thus, we believe this measure as 
specified does not align with current clinical guidelines or practice, 
and we proposed to remove OP-9: Mammography Follow-up Rates from the 
program for the CY 2021 payment determination and subsequent years. We 
intend to investigate respecification of this measure and consider it 
for adoption to the program through future rulemaking. Specifically, we 
will consider ways to capture a broader, more comprehensive spectrum of 
mammography services including adding diagnostic digital breast 
tomosynthesis. In the proposed rule, we noted that, in crafting our 
proposal, we considered removing this measure beginning with the CY 
2020 payment determination, but decided on proposing to delay removal 
until the CY 2021 payment determination and subsequent years to be 
sensitive to facilities' planning and operational procedures given that 
data collection for this measure begins during CY 2018 for the CY 2020 
payment determination.
    Comment: Many commenters supported CMS' proposal to remove OP-9 
from the Hospital OQR Program measure set and noted that the measure 
does not align with clinical guidelines. One commenter noted that the 
measure is meant for physician-level use, rather than facility-level 
reporting.
    Response: We thank the commenters for their support. We note that 
while the measure was developed for physician-level use, as we stated 
when adopting the measure, it has been tested and was determined to be 
appropriate for the Hospital OQR Program by the consensus-based 
development process that meets the statutory requirement for adoption 
of a measure (73 FR 68765).

[[Page 59097]]

    After consideration of the public comments we received, we are 
finalizing our proposal, as proposed, to remove OP-9: Mammography 
Follow-up Rates from the program for the CY 2021 payment determination 
and subsequent years.
(c) Measure Removals Under Removal Factor 1: OP-11 and OP-14
    In the proposed rule (83 FR 37185 through 37186), for the CY 2021 
payment determination and subsequent years, we proposed to remove OP-11 
and OP-14 under removal Factor 1, measure performance among providers 
is so high and unvarying that meaningful distinctions and improvements 
in performance can no longer be made. The Hospital OQR Program 
previously finalized two criteria for determining when a measure is 
``topped-out'': (1) When there is statistically indistinguishable 
performance at the 75th and 90th percentiles of national facility 
performance; and (2) when the measure's truncated coefficient of 
variation is less than or equal to 0.10 (79 FR 66968 through 66969). We 
refer readers to section XIII.B.4.a.(6) of the proposed rule, where we 
clarified and discussed how we calculate the TCOV for measures that 
assess the rate of rare, undesired events for which a lower rate is 
preferred such as OP-11 and OP-14.
    For each of these measures, we believe that removal from the 
Hospital OQR Program measure set is appropriate as there is little room 
for improvement. In addition, as discussed in section I.A.2. of the 
proposed rule and this final rule with comment period, our Meaningful 
Measures Initiative is intended to reduce costs and minimize burden. We 
believe that removing these measures from the Hospital OQR Program will 
reduce program burden, costs, and complexity. As such, we believe the 
burden associated with reporting these measures outweighs the benefits 
of keeping them in the Hospital OQR Program.
    Each measure is discussed in more detail below. In the proposed 
rule, we also noted that in crafting our proposals, we considered 
removing these measures beginning with the CY 2020 payment 
determination but decided on proposing to delay removal until the CY 
2021 payment determination and subsequent years to be sensitive to 
providers' planning and operational procedures given that data 
collection for the measures begins during CY 2018 for the CY 2020 
payment determination.
 Removal of OP-11: Thorax CT Use of Contrast Material
    We refer readers to the CY 2009 OPPS/ASC final rule with comment 
period (73 FR 68766) where we adopted OP-11: Thorax CT Use of Contrast 
Material (NQF #0513) beginning with the CY 2010 payment determination. 
This claims-based measure assesses the percentage of thorax studies 
that are performed with and without contrast out of all thorax studies 
performed.
    Based on our analysis of Hospital OQR Program measure data, we have 
determined that this measure meets our measure removal Factor 1. These 
analyses are captured in the table below.
[GRAPHIC] [TIFF OMITTED] TR21NO18.101

    As displayed in the table above, there is a statistically 
indistinguishable difference in hospital performance between the 75th 
and 90th percentiles, and the truncated coefficient of variation has 
been below 0.10 since 2012.
 Removal of OP-14: Simultaneous Use of Brain Computed 
Tomography (CT) and Sinus CT
    We refer readers to the CY 2010 OPPS/ASC final rule with comment 
period (75 FR 72082) where we adopted OP-14: Simultaneous Use of Brain 
Computed Tomography (CT) and Sinus CT beginning with the CY 2012 
payment determination and for subsequent years. This claims-based 
measure assesses the extent to which patients with a headache who have 
a brain CT also have a sinus CT performed on the same date at the same 
facility.
    Based on our analysis of Hospital OQR Program measure data, we have 
determined that this measure meets our measure removal Factor 1. These 
analyses are captured in the table below.

[[Page 59098]]

[GRAPHIC] [TIFF OMITTED] TR21NO18.102

    As displayed in the table above, there is a statistically 
indistinguishable difference in hospital performance between the 75th 
and 90th percentiles, and the truncated coefficient of variation has 
been below 0.10 since 2012.
    Therefore, we invited public comment on our proposals to remove: 
(1) OP-11: Thorax CT Use of Contrast Material, and (2) OP-14: 
Simultaneous Use of Brain Computed Tomography (CT) and Sinus CT measure 
for the CY 2021 payment determination and subsequent years as discussed 
above.
    Comment: Many commenters supported CMS' proposals to remove OP-11 
and OP-14, noting agreement that the proposals will reduce burden and 
that the measures have limited use for quality improvement.
    Response: We thank the commenters for their support. We agree that 
these topped-out measures have limited value.
    Comment: A few commenters opposed CMS' proposals to remove OP-11 
and OP-14. One commenter expressed concern that measures should not be 
removed from the program based solely on topped-out status. This 
commenter recommended that CMS ensure the measure is topped-out for a 
number of years, evaluate whether there are unintended consequences of 
removal, and continue monitoring performance on topped-out safety 
measures. Another commenter expressed concern that variation in measure 
performance exists between high and low performing States.
    Response: We thank the commenters for their feedback and note that 
we would consider re-proposing these measures for the Hospital OQR 
Program in the future if data and research indicate that performance in 
this area has declined, thus mitigating any potential unintended 
consequences of measure removal. In the meantime, however, we believe 
it is appropriate to remove these topped-out measures from the Hospital 
OQR Program, as we believe these measures have limited ability to 
encourage quality improvement or provide beneficiaries with information 
on differences in quality across hospitals.
    We have previously finalized our policy to consider measures for 
removal if they meet topped-out status (79 FR 66769) and accordingly, 
we disagree with commenters that topped-out status is not sufficient 
grounds for measure removal. In addition, ``topped-out'' status is only 
one of many factors we consider in removing measures. We consider the 
removal of each topped-out measure on a case-by-case basis, as 
appropriate, and determine whether a clinical or other quality 
improvement need for the measure justifies the retention of a topped-
out measure that otherwise meets our criteria. We also note that the 
measures have been topped-out for four years. However, if it becomes 
evident that performance on this measure topic declines over time, we 
will consider re-introducing this or similar measures and will do so 
through the rulemaking process. While slight variation may exist in 
measure performance, our analyses demonstrate that this variation is 
statistically indistinguishable.
    The Hospital OQR Program has finalized the ``topped-out'' 
methodology to evaluate variation in performance among HOPDs (79 FR 
66769), in line with other quality reporting and value-based purchasing 
programs including the ASCQR (79 FR 66968), Hospital IQR (80 FR 49641 
through 49643), Hospital VBP (79 FR 50055), IPFQR (82 FR 38463 through 
38465), and PCHQR (81 FR 57182 through 57183) Programs. Our topped-out 
methodology does not evaluate variation at the State level, but rather 
at the level of individual ASCs. Our analyses demonstrate that the 
variation in performance among HOPDs for these measures is 
statistically indistinguishable. As shown in the tables above, 
hospitals performing at the 90th vs. 75th percentile have a rate of 
98.5 percent as compared to a rate of 97.4 percent for OP-11 and a rate 
of 98.8 percent vs. 98.5 percent for OP-14.
    After consideration of the public comments we received, we are 
finalizing our proposals, as proposed, to remove: (1) OP-11: Thorax CT 
Use of Contrast Material, and (2) OP-14: Simultaneous Use of Brain 
Computed Tomography (CT) and Sinus CT measure for the CY 2021 payment 
determination and subsequent years.
(d) Measure Removals Under Measure Removal Factor 2: OP-12 and OP-17
    In the proposed rule (83 FR 37186), for the CY 2021 payment 
determination and subsequent years, we proposed to remove two measures 
under our measure removal Factor 2, performance or improvement on a 
measure does not result in better patient outcomes: OP-12 and OP-17. 
The proposals are discussed in more detail below. As discussed in 
section I.A.2. of the proposed rule and this final rule with comment 
period, our Meaningful Measures Initiative is intended to reduce costs 
and minimize burden. We believe that removing these measures from the 
Hospital OQR Program will reduce program burden, costs, and complexity. 
In addition, we noted that in crafting our proposals, we considered 
removing these measures beginning with the CY 2020 payment 
determination but decided on proposing to delay removal until the CY 
2021 payment determination to be sensitive to facilities' planning and 
operational procedures given that data collection for this measure 
begins during CY 2018 for the CY 2020 payment determination.
 Removal of OP-12: The Ability for Providers With HIT To 
Receive Laboratory Data Electronically Directly Into Their Qualified/
Certified EHR System as Discrete Searchable Data
    We refer readers to CY 2011 OPPS/ASC final rule with comment period 
(75 FR 72076) where we adopted OP-12: The Ability for Providers with 
HIT to Receive Laboratory Data Electronically Directly into Their 
Qualified/Certified EHR System as Discrete Searchable Data

[[Page 59099]]

beginning with the CY 2012 payment determination. This web-based 
measure assesses the extent to which a provider uses an Office of the 
National Coordinator for Health Information Technology (ONC) certified 
electronic health record (EHR) system that incorporates an electronic 
data interchange with one or more laboratories allowing for direct 
electronic transmission of laboratory data in the EHR as discrete 
searchable data elements. In the proposed rule, we proposed to remove 
OP-12 beginning with the CY 2021 payment determination and for 
subsequent years under our measure removal Factor 2, performance or 
improvement on a measure does not result in better patient outcomes.
    OP-12 is a process measure that tracks the transmittal of data but 
does not directly assess quality or patient outcomes. In the CY 2011 
OPPS/ASC final rule with comment period (75 FR 72075), commenters 
expressed concern that the measure only assesses HIT functionality and 
does not assess the quality of care provided. As discussed in section 
I.A.2. of the proposed rule and this final rule with comment period, 
one of the goals of our Meaningful Measures Initiative is to reduce 
burden associated with payment policy, quality measures, documentation 
requirements, conditions of participation, and health information 
technology. As also discussed in section I.A.2. of the proposed rule 
and this final rule with comment period, one of the goals of our 
Meaningful Measures Initiative is to utilize measures that are 
``outcome-based where possible.'' We do not believe OP-12 adds to these 
goals. In fact, we believe that provider performance in the measure is 
not an indicator for patient outcomes and continued collection provides 
little benefit.
    Therefore, we proposed to remove OP-12 from the Hospital OQR 
Program beginning with the CY 2021 payment determination and for 
subsequent years.
    Comment: Many commenters supported CMS' proposal to remove OP-12. 
One commenter noted that the measure does not directly assess quality 
of care or patient outcomes.
    Response: We thank the commenters for their support.
    Comment: A few commenters opposed CMS' proposal to remove OP-12. 
One commenter requested that CMS revise the measure so that it assesses 
quality of care in addition to HIT functionality. Another commenter 
recognized the value of removing OP-12 from the program but recommended 
that CMS continue to promote interoperability in the outpatient 
hospital setting.
    Response: We thank the commenters for their feedback. We note that 
as a structural measure, OP-12 is limited to evaluating whether or not 
a provider uses an ONC-certified EHR system, and does not provide data 
on patient outcomes. We agree that a measure assessing the impact of 
EHR use on quality would be valuable and we intend to identify and 
consider other measures that assess interoperability and care quality 
for future inclusion in the program as appropriate measures become 
available. Due to this measure's limitations as a structural measure, 
we do not believe it is possible to revise the measure in order to 
assess patient outcomes or quality of care directly. Due to the 
limitations of OP-12, we believe it is appropriate to remove this 
measure from the Hospital OQR Program.
    After consideration of the public comments we received, we are 
finalizing our proposal, as proposed, to remove OP-12 beginning with 
the CY 2021 payment determination and for subsequent years.
 Removal of OP-17: Tracking Clinical Results Between Visits
    We refer readers to CY 2011 OPPS/ASC final rule with comment period 
(75 FR 72085) where we adopted OP-17: Tracking Clinical Results between 
Visits beginning with the CY 2013 payment determination. This web-based 
measure assesses the extent to which a provider uses a certified/
qualified EHR system to track pending laboratory tests, diagnostic 
studies (including common preventive screenings), or patient referrals. 
In the proposed rule, we proposed to remove OP-17 beginning with the CY 
2021 payment determination and for subsequent years under our measure 
removal Factor 2, performance or improvement on a measure does not 
result in better patient outcomes.
    OP-17 is a process measure that tabulates only the ability for 
transmittal of data but does not directly assess quality or patient 
outcomes. In the CY 2011 OPPS/ASC final rule with comment period (75 FR 
72075), commenters expressed concern that the measure only assesses HIT 
functionality and does not assess the quality of care provided. As 
discussed in section I.A.2. of the proposed rule and this final rule 
with comment period, one of the goals of our Meaningful Measures 
Initiative is to reduce burden associated with payment policy, quality 
measures, documentation requirements, conditions of participation, and 
health information technology. As also discussed in section I.A.2. of 
the proposed rule and this final rule with comment period, one of the 
goals of our Meaningful Measures Initiative is to utilize measures that 
``outcome-based where possible.'' We do not believe OP-17 supports this 
goal. In fact, we believe that provider performance in the measure does 
not improve patient outcomes and continued collection provides little 
benefit. Therefore, we proposed to remove OP-17 from the Hospital OQR 
Program beginning with the CY 2021 payment determination and for 
subsequent years.
    Comment: Many commenters supported CMS' proposal to remove OP-17. A 
few commenters noted that the measure does not directly assess quality 
of care or patient outcomes.
    Response: We thank the commenters for their support.
    Comment: A few commenters opposed CMS' proposal to remove OP-17. 
One commenter noted that the ability to transfer electronic records can 
hasten diagnosis and treatment and reduce service duplication. Another 
commenter recognized the value of removing OP-17 from the ASCQR 
Program, but recommended that CMS continue to promote interoperability 
in the outpatient hospital setting.
    Response: We thank the commenters for their feedback. We note that 
as a structural measure, OP-17 is limited to evaluating whether or not 
a provider uses an ONC certified EHR system to track laboratory tests, 
diagnostic studies, or patient referrals but does not provide 
information of the impact on outcomes such as diagnosis and treatment. 
We intend to identify and consider other measures that assess 
interoperability and care quality for future inclusion in the program 
as appropriate measures become available. Due to the limitation of OP-
17 as a structural measure, we do not believe it is possible to revise 
it to assess patient outcomes or quality of care directly. Due to the 
limitations of OP-17, we believe it is appropriate to remove this 
measure from the Hospital OQR Program.
    After consideration of the public comments we received, we are 
finalizing our proposal, as proposed, to remove OP-17 beginning with 
the CY 2021 payment determination and for subsequent years.
5. Summary of Hospital OQR Program Measure Sets for the CY 2020 and CY 
2021 Payment Determinations
    In the proposed rule, we did not propose any new measures for the 
Hospital OQR Program. We refer readers to the CY 2018 OPPS/ASC final 
rule

[[Page 59100]]

with comment period (82 FR 59434 through 59435) for the previously 
finalized measure set for the CY 2020 payment determination and 
subsequent years.
    The tables below summarize the Hospital OQR Program measure sets as 
finalized in this final rule with comment period for the CY 2020 and 
2021 payment determinations and subsequent years (including previously 
adopted measures and excluding measures removed in this final rule with 
comment period).
BILLING CODE 4120-01-P
[GRAPHIC] [TIFF OMITTED] TR21NO18.103


[[Page 59101]]


[GRAPHIC] [TIFF OMITTED] TR21NO18.104


[[Page 59102]]


[GRAPHIC] [TIFF OMITTED] TR21NO18.105

BILLING CODE 4120-01-C
6. Hospital OQR Program Measures and Topics for Future Consideration
    In the CY 2019 OPPS/ASC proposed rule (83 FR 37188), we requested 
public comment on future measure topics for the Hospital OQR Program. 
We seek to develop a comprehensive set of quality measures to be 
available for widespread use for informed decision-making and quality 
improvement in the hospital outpatient setting. The current measure set 
for the Hospital OQR Program includes measures that assess process of 
care, imaging efficiency patterns, care transitions, ED throughput 
efficiency, Health Information Technology (health IT) use, care 
coordination, and patient safety. Measures are of various types, 
including those of process, structure, outcome, and efficiency. Through 
future rulemaking, we intend to propose new measures that help us 
further our goal of achieving better health care and improved health 
for Medicare beneficiaries who receive health care in hospital 
outpatient settings, while

[[Page 59103]]

aligning quality measures across the Medicare program to the extent 
possible.
    We are moving towards greater use of outcome measures and away from 
use of clinical process measures across our Medicare quality reporting 
and value-based purchasing programs. We invited public comments on 
possible measure topics for future consideration in the Hospital OQR 
Program. We specifically requested comment on any outcome measures that 
would be useful to add to as well as any process measures that should 
be eliminated from the Hospital OQR Program.
    Comment: Several commenters recommended measure topics for future 
consideration in the Hospital OQR Program. Commenters' recommendations 
included: (1) Antibiotic-use related measures to assess inappropriate 
prescribing; (2) a focus on clinical and population based outcome 
measures; (3) cancer care measures including two measures related to 
referral to radiation therapy for both post-breast conserving surgery 
(NQF 0219) and post-mastectomy (MASTRT); (4) psychiatric care and 
behavioral health measures; (5) measures identified as meaningful to 
providers as well patients and their families; (6) rural health 
measures; (7) measures assessing access to care; (8) measures assessing 
substance abuse; (9) management of chronic conditions; (10) measures 
that promote advance care planning and shared-decision making; (11) 
surgical site infections (SSIs) and medication safety measures such as 
the Ambulatory Breast Procedure Surgical Site Infection (SSI) Outcome 
Measure (NQF #3025) measure; (12) measures using the same unit of 
analysis that allow comparison between hospitals and ASCs; and, (13) 
adult immunization measures. Several commenters also supported outcome 
measures but noted the value of process measures for addressing topics 
where there is insufficient evidence or standardized data to assess an 
outcome. One commenter also recommended that CMS consider the 
recommendations of the 2018 National Quality Forum (NQF) Report titled, 
``A Core Set of Rural-Relevant Measures and Measuring and Improving 
Access to Care: 2018 Recommendations from the MAP Rural Health 
Workgroup.'' Another commenter encouraged CMS to recognize composite 
measures, especially for surgical care, that span across phases of 
care.
    Response: We thank the commenters for their recommendations and 
suggestions and agree that there are additional high priority topic 
measurement areas that may be appropriate for the Hospital OQR Program. 
We will consider the suggested topic areas for future rulemaking and 
intend to work with stakeholders as we continue to develop the Hospital 
OQR Program measure set. We thank the commenters for their views and 
will consider them as we develop future Hospital OQR Program measures 
and topics.
7. Maintenance of Technical Specifications for Quality Measures
    CMS maintains technical specifications for previously adopted 
Hospital OQR Program measures. These specifications are updated as we 
modify the Hospital OQR Program measure set. The manuals that contain 
specifications for the previously adopted measures can be found on the 
QualityNet website at: https://www.qualitynet.org/dcs/ContentServer?c=Page&pagename=QnetPublic%2FPage%2FQnetTier2&cid=1196289981244. In the proposed rule, we proposed to change the frequency of the 
Hospital OQR Program Specifications Manual release beginning with CY 
2019 and for subsequent years and we refer readers to section XIII.D.2. 
of the proposed rule and this final rule with comment period for more 
details.
8. Public Display of Quality Measures
    We refer readers to the CY 2014 and CY 2017 OPPS/ASC final rules 
with comment period (78 FR 75092 and 81 FR 79791 respectively) for our 
previously finalized policies regarding public display of quality 
measures. In the CY 2019 OPPS/ASC proposed rule (83 FR 37188), we did 
not propose any changes to our previously finalized public display 
policies.

C. Administrative Requirements

1. QualityNet Account and Security Administrator
    The previously finalized QualityNet security administrator 
requirements, including setting up a QualityNet account and the 
associated timelines, are described in the CY 2014 OPPS/ASC final rule 
with comment period (78 FR 75108 through 75109). In that final rule 
with comment period, we codified these procedural requirements at 42 
CFR 419.46(a). In the CY 2019 OPPS/ASC proposed rule (83 FR 37188), we 
did not propose any changes to our requirements for the QualityNet 
account and security administrator.
2. Requirements Regarding Participation Status
    In the CY 2019 OPPS/ASC proposed rule (83 FR 37188), we proposed to 
update our requirements related to the Notice of Participation (NOP) 
form.
a. Background
    We refer readers to the CY 2014 OPPS/ASC final rule with comment 
period (78 FR 75108 through 75109) and the CY 2016 OPPS/ASC final rule 
with comment period (80 FR 70519) for requirements for participation 
and withdrawal from the Hospital OQR Program. We also codified these 
procedural requirements at 42 CFR 419.46(a) and (b).
b. Removal of the Notice of Participation (NOP) Form Requirement
    We finalized in the CY 2014 OPPS/ASC final rule with comment period 
(78 FR 75108 through 75109) that participation in the Hospital OQR 
Program requires that hospitals must: (1) Register on the QualityNet 
website before beginning to report data; (2) identify and register a 
QualityNet security administrator; and (3) complete and submit an 
online participation form, the Notice of Participation (NOP) form, 
available at the QualityNet website if this form has not been 
previously completed, if a hospital has previously withdrawn, or if the 
hospital acquires a new CMS Certification Number (CCN). In addition, in 
the CY 2014 OPPS/ASC final rule with comment period (78 FR 75108 
through 75109), we finalized the requirement that that hospitals must 
submit the NOP according to the below deadlines. These requirements are 
also codified at 42 CFR 419.46(a).
     If a hospital has a Medicare acceptance date before 
January 1 of the year prior to the affected annual payment update, the 
hospital must complete and submit to CMS a completed Hospital OQR 
Notice of Participation Form by July 31 of the calendar year prior to 
the affected annual payment update.
     If a hospital has a Medicare acceptance date on or after 
January 1 of the year prior to the affected annual payment update, the 
hospital must submit a completed participation form no later than 180 
days from the date identified as its Medicare acceptance date.
    In the proposed rule (83 FR 37188), beginning with the CY 2018 
reporting period/CY 2020 payment determination, we proposed to remove 
submission of the NOP form as a requirement for the Hospital OQR 
Program. After reevaluating program requirements, we have concluded 
that this form does not provide CMS with any unique information, and as 
such, we believe it is unnecessarily burdensome for

[[Page 59104]]

hospitals to complete and submit. In place of the NOP form, we proposed 
that submission of any Hospital OQR Program data would indicate a 
hospital's status as a participant in the program. This includes 
submitting just one data element. That is, hospitals would no longer be 
required to submit the NOP form as was previously required. Instead, 
hospitals would need to do the following to be a participant in the 
Hospital OQR Program: (1) Register on the QualityNet website before 
beginning to report data; (2) identify and register a QualityNet 
security administrator; and (3) submit data. We also proposed to update 
42 CFR 419.46(a) to reflect these changes.
    Comment: A few commenters supported CMS' proposal to remove the NOP 
as a requirement for the Hospital OQR Program.
    Response: We thank the commenters for their support.
    After consideration of the public comments we received, we are 
finalizing our proposals, as proposed, to no longer require hospitals 
to submit the NOP form, and update 42 CFR 419.46(a) to reflect these 
changes.

D. Form, Manner, and Timing of Data Submitted for the Hospital OQR 
Program

1. Hospital OQR Program Annual Payment Determinations
    In the CY 2014 OPPS/ASC final rule with comment period (78 FR 75110 
through 75111) and the CY 2016 OPPS/ASC final rule with comment period 
(80 FR 70519 through 70520), we specified our data submission 
deadlines. We also codified our submission requirements at 42 CFR 
419.46(c).
    We refer readers to the CY 2016 OPPS/ASC final rule with comment 
period (80 FR 70519 through 70520), where we finalized our proposal to 
shift the quarters upon which the Hospital OQR Program payment 
determinations are based, beginning with the CY 2018 payment 
determination. The finalized deadlines for the CY 2020 payment 
determination and subsequent years are illustrated in the table below.
[GRAPHIC] [TIFF OMITTED] TR21NO18.106

    In the CY 2018 OPPS/ASC final rule with comment period, we 
finalized a policy to align the initial data submission timeline for 
all hospitals that did not participate in the previous year's Hospital 
OQR Program and made conforming revisions at 42 CFR 419.46(c)(3). In 
the CY 2019 OPPS/ASC proposed rule (83 FR 37188 through 37189), we did 
not propose any changes to these policies.
2. Change to the Frequency of Hospital Outpatient Quality Reporting 
Specifications Manual Release Beginning With CY 2019 and for Subsequent 
Years
    In the CY 2019 OPPS/ASC proposed rule (83 FR 37189), we proposed to 
change the frequency of the Hospital Outpatient Quality Reporting 
Specifications Manual release beginning with CY 2019 and for subsequent 
years. In the CY 2009 OPPS/ASC final rule with comment period (73 FR 
68766 through 68767), we established a subregulatory process for making 
updates to the measures we have adopted for the Hospital OQR Program. 
As stated in CY 2014 OPPS/ASC final rule with comment period (78 FR 
75091), we believe that a measure can be updated through this 
subregulatory process provided it is a nonsubstantive change. We expect 
to continue to make the determination of what constitutes a substantive 
versus a nonsubstantive change on a case-by-case basis. Examples of 
nonsubstantive changes to measures might include updated diagnosis or 
procedure codes, medication updates for categories of medications, 
broadening of age ranges, and exclusions for a measure (such as the 
addition of a hospice exclusion to the 30-day mortality measures). We 
believe that nonsubstantive changes may include updates to measures 
based upon changes to guidelines upon which the measures are based.
    For a history of our policies regarding maintenance of technical 
specifications for quality measures, we refer readers to the CY 2010 
OPPS/ASC final rule with comment period (74 FR 60631), the CY 2011 
OPPS/ASC final rule with comment period (75 FR 72069), and the CY 2013 
OPPS/ASC final rule with comment period (77 FR 68469 through 68470). In 
the proposed rule, we noted that we will continue to use rulemaking to 
adopt substantive updates to measures we have adopted for the Hospital 
OQR Program. We believe that this policy adequately balances our need 
to incorporate nonsubstantive updates to Hospital OQR Program measures 
in the most expeditious manner possible, while preserving the public's 
ability to comment on updates that so fundamentally change an endorsed 
measure that it is no longer the same measure that we originally 
adopted. We also noted that the NQF process incorporates an opportunity 
for public comment and engagement in the measure maintenance process.
    As stated in CY 2014 OPPS/ASC final rule with comment period (78 FR 
75091), under current policy, technical specifications for the Hospital 
OQR Program measures are listed in the Hospital Outpatient Quality 
Reporting Specifications Manual, which is posted on the CMS QualityNet 
website at: https://www.qualitynet.org/dcs/ContentServer?c=Page&pagename=QnetPublic%2FPage%2FSpecsManualTemplate&cid=1228772438492. We maintain the technical specifications for the 
measures by updating this Hospital Outpatient Quality Reporting 
Specifications Manual and including detailed instructions and 
calculation algorithms. In some cases where the specifications are 
available elsewhere, we may include links to websites hosting technical 
specifications. These resources are for hospitals to use when

[[Page 59105]]

collecting and submitting data on required measures. We revise the 
Hospital Outpatient Quality Reporting Specifications Manual so that it 
clearly identifies the updates and provide links to where additional 
information on the updates can be found. We provide sufficient lead 
time for facilities to implement the changes where changes to the data 
collection systems would be necessary. We generally release the 
Hospital Outpatient Quality Reporting Specifications Manual every six 
months and release addenda as necessary. This release schedule provides 
at least three months of advance notice for nonsubstantive changes such 
as changes to ICD-10, CPT, NUBC, and HCPCS codes, and at least six 
months of advance notice for changes to data elements that would 
require significant systems changes (78 FR 75091).
    However, we believe that unnecessarily releasing two manuals a year 
has the potential to cause confusion for Hospital OQR Program 
participants. Therefore, in the proposed rule, we proposed to update 
the frequency with which we release Hospital Outpatient Quality 
Reporting Specifications Manuals, such that instead of every 6 months, 
we would release Specifications Manuals every six to 12 months 
beginning with CY 2019 and for subsequent years. Under this proposal, 
we would release a Hospital Outpatient Quality Reporting Specifications 
Manual (Specifications Manual) one to two times per calendar year, 
depending on the need for an updated release and consideration of our 
policy to provide at least six months' notice for substantive changes.
    Comment: Several commenters supported CMS' proposal to release the 
Specifications Manual less frequently than every six months. However, a 
few commenters noted that ad hoc timing for release of the 
Specifications Manual may be confusing and recommended that CMS release 
the Specifications Manual once annually. One commenter requested that 
CMS notify hospitals and vendors about whether or not there will be an 
update on a 6-month schedule, even if the Specifications Manual is only 
released every 12 months.
    Response: We thank the commenters for their support. We clarify 
that under our proposal, we would release a full manual once or twice a 
year, depending on need, as well as any addenda as necessary. Addenda 
would include discrete updates and do not constitute full manual 
releases. We acknowledge that ad hoc specifications manual releases 
could be confusing. After considering public comments and in an effort 
to provide greater consistency, we are modifying our proposal that we 
would release a Hospital Outpatient Quality Reporting Specifications 
Manual one to two times per calendar year; instead, we are finalizing 
that we will release a full manual once every 12 months and release any 
addenda as necessary. This reduces manual releases from one to two 
times per year as proposed, to consistently only once a year. 
Specifications manuals and addenda will be provided via QualityNet.
    After consideration of the public comments we received, we are 
finalizing a modification of our proposal, beginning with CY 2019 and 
for subsequent years, to release Specifications Manuals every six to 12 
months, such that we will instead release a manual once every 12 months 
and release addenda as necessary.
3. Requirements for Chart-Abstracted Measures Where Patient-Level Data 
Are Submitted Directly to CMS for the CY 2020 Payment Determination and 
Subsequent Years
    We refer readers to the CY 2013 OPPS/ASC final rule with comment 
period (77 FR 68481 through 68484) for a discussion of the form, 
manner, and timing for data submission requirements of chart-abstracted 
measures for the CY 2014 payment determination and subsequent years. In 
the CY 2019 OPPS/ASC proposed rule (83 FR 37189), we did not propose 
any changes to our policies regarding the submission of chart-
abstracted measure data where patient-level data are submitted directly 
to CMS.
    We note that, in section XIII.B.4.b.(2)(a) of this final rule with 
comment period, we are finalizing our proposal to remove OP-5: Median 
Time to ECG for the CY 2021 payment determination and subsequent years. 
Therefore, the following previously finalized Hospital OQR Program 
chart-abstracted measures will require patient-level data to be 
submitted for the CY 2021 payment determination and subsequent years:
     OP-2: Fibrinolytic Therapy Received Within 30 Minutes of 
ED Arrival (NQF #0288);
     OP-3: Median Time to Transfer to Another Facility for 
Acute Coronary Intervention (NQF #0290);
     OP-18: Median Time from ED Arrival to ED Departure for 
Discharged ED Patients (NQF #0496); and
     OP-23: Head CT Scan Results for Acute Ischemic Stroke or 
Hemorrhagic Stroke Patients who Received Head CT Scan Interpretation 
Within 45 Minutes of ED Arrival (NQF #0661).
4. Claims-Based Measure Data Requirements for the CY 2020 Payment 
Determination and Subsequent Years
    In the CY 2019 OPPS/ASC proposed rule (83 FR 37189 through 37191), 
we proposed to extend the reporting period \146\ for OP-32: Facility 7-
Day Risk-Standardized Hospital Visit Rate after Outpatient Colonoscopy.
---------------------------------------------------------------------------

    \146\ We note that we previously referred to these reporting 
periods as ``collection periods'' (for example, 82 FR 59440); we now 
use the term ``reporting period'' in order to align the Hospital OQR 
Program terminology with the terminology we use in other CMS quality 
reporting and pay for performance (value-based purchasing) programs.
---------------------------------------------------------------------------

a. General
    We refer readers to the CY 2014 OPPS/ASC final rule with comment 
period (78 FR 75111 through 75112) for a discussion of the general 
claims-based measure data submission requirements for the CY 2015 
payment determination and subsequent years. In the proposed rule, we 
did not propose changes to our general requirements for claims-based 
measure data but refer readers to the section below for discussion 
regarding our proposal specific to OP-32.
    We note that, in section XIII.B.4.b. of the proposed rule, we 
proposed to remove OP-9: Mammography Follow-up Rates, OP-11: Thorax CT 
Use of Contrast Material, and OP-14: Simultaneous Use of Brain Computed 
Tomography (CT) and Sinus CT for the CY 2021 payment determination and 
subsequent years. As discussed in section XIII.B.4.b. of this final 
rule with comment period, we are finalizing the removals of all of 
these measures as proposed. Accordingly, the following previously 
finalized Hospital OQR Program claims-based measures will be required 
for the CY 2021 payment determination and subsequent years:
     OP-8: MRI Lumbar Spine for Low Back Pain (NQF #0514);
     OP-10: Abdomen CT--Use of Contrast Material;
     OP-13: Cardiac Imaging for Preoperative Risk Assessment 
for Non-Cardiac, Low Risk Surgery (NQF #0669);
     OP-32: Facility 7-Day Risk-Standardized Hospital Visit 
Rate after Outpatient Colonoscopy (NQF #2539);
     OP-35: Admissions and Emergency Department Visits for 
Patients Receiving Outpatient Chemotherapy; and
     OP-36: Hospital Visits after Hospital Outpatient Surgery 
(NQF #2687).

[[Page 59106]]

b. Extension of the Reporting Period for OP-32: Facility 7-Day Risk-
Standardized Hospital Visit Rate After Outpatient Colonoscopy
    In the CY 2015 OPPS/ASC final rule with comment period (79 FR 
66949), we finalized the adoption of OP-32: Facility 7-Day Risk-
Standardized Hospital Visit Rate after Outpatient Colonoscopy into the 
Hospital OQR Program for the CY 2018 payment determination and 
subsequent years, with public display to begin on or after December 1, 
2017. This measure is calculated with data obtained from paid Medicare 
FFS claims (79 FR 66950). For this reason, facilities are not required 
to submit any additional information. In that final rule with comment 
period, we also finalized the reporting period for measure calculation 
as claims data from two calendar years prior to the payment 
determination year. Specifically, for the CY 2018 payment 
determination, we stated we would use paid Medicare FFS claims from 
January 1, 2016 to December 31, 2016 to calculate measure results (79 
FR 66955). We finalized a 1-year reporting period, as it adequately 
balanced competing interests of measure reliability and timeliness for 
payment determination purposes and explained that we would continue to 
assess this during the dry run (79 FR 66955).
    We noted we would complete a dry run of the measure in 2015 using 
three or four years of data, and, from the results of this dry run, we 
would review the appropriate volume cutoff for facilities to ensure 
statistical reliability in reporting the measure score (79 FR 66953). 
Our analyses of the 2015 dry run using data from July 2011 through June 
2014 showed that a reporting period of one year had moderate to high 
reliability for measure calculation. Specifically, using data from July 
2013 through June 2014, we calculated facility-level reliability 
estimates as the ratio of true variance to observed variance.\147\ 
Consistent with the original measure specifications as described in the 
2014 technical report,\148\ this calculation was performed combining 
the measure results for HOPDs and ASCs. We found that for a facility 
with median case size, the reliability estimate was high (over 0.90), 
but the minimum reliability estimate for facilities with 30 cases (the 
minimum case size chosen for public reporting) was only moderate (that 
is, between 0.40 and 0.60).\149\
---------------------------------------------------------------------------

    \147\ Snijders TA, Bosker RJ. Multilevel Analysis: An 
introduction to basic and advanced multilevel modeling. SAGE 
Publications. 2000. London.
    \148\ Additional methodology details and information obtained 
from public comments for measure development are available at: 
https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/HospitalQualityInits/Measure-Methodology.html under 
``Hospital Outpatient Colonoscopy.''
    \149\ Landis JR, Koch GG. The Measurement of Observer Agreement 
for Categorical Data. Biometrics. 1977;33(1):159-174.
---------------------------------------------------------------------------

    However, after the 2015 dry run, CMS calculated the HOPD and ASC 
scores separately to compare similar types of providers to each other. 
During subsequent analysis of the 1-year period July 2013 through June 
2014, we confirmed that a 1-year reporting period with separate 
calculations for HOPDs and ASCs was sufficient but did result in lower 
reliability and decreased precision compared to these measures 
calculated from longer reporting periods (two or three years). Based on 
analyses conducted using data from July 2013 through June 2014 (1-year 
reporting period) and 2017 measure specifications,\150\ we found that 
the median facility-level reliability was 0.74 for ASCs and 0.51 for 
HOPDs. Using a 2-year reporting period (data from July 2012-June 2014), 
we found that median facility-level reliability was 0.81 for ASCs and 
0.67 for HOPDs. When the reporting period was extended to three years 
(using data from July 2011 through June 2014), we found that median 
facility-level reliability was higher for both ASCs and HOPDs: 0.87 for 
ASCs and 0.75 for HOPDs. These results indicate that a larger portion 
of the included facilities have scores measured with higher reliability 
when three years of data are used rather than one year of data.
---------------------------------------------------------------------------

    \150\ Current and past measure specifications are available at: 
https://www.qualitynet.org/dcs/ContentServer?c=Page&pagename=QnetPublic%2FPage%2FQnetTier3&cid=1228775214597.
---------------------------------------------------------------------------

    Using three years of data, compared to just one year, is estimated 
to increase the number of HOPDs with eligible cases for OP-32 by 5 
percent, adding approximately 235 additional facilities to the measure 
calculation. Facilities reporting the measure would increase their 
sample sizes and, in turn, increase the precision and reliability of 
their measure scores. Thus, we believe extending the reporting period 
to three years from one year for purposes of increasing reliability 
would be beneficial for providing better information to beneficiaries 
regarding the quality of care associated with low-risk outpatient 
colonoscopy procedures. In crafting our proposal, we considered 
extending the reporting period to two years beginning with the CY 2020 
payment determinations and subsequent years, but decided on proposing 
three years instead, because a higher level of reliability is achieved 
with a 3-year reporting period compared to two years.
    Therefore, we proposed to change the reporting period for OP-32: 
Facility 7-Day Risk-Standardized Hospital Visit Rate after Outpatient 
Colonoscopy from one year to three years beginning with the CY 2020 
payment determination (which would use claims data from January 1, 2016 
through December 31, 2018) and for subsequent years. Under this 
proposal, the annual reporting requirements for facilities would not 
change, because this is a claims-based measure. However, with a 3-year 
reporting period, the most current year of data would be supplemented 
by the addition of two prior years. For example, for the CY 2020 
payment determination, we would use a reporting period of CY 2018 data 
plus 2 prior years of data (CYs 2016 and 2017). In the proposed rule, 
we noted that since implementation of this measure began with the CY 
2018 payment determination, we have already used paid Medicare fee-for-
service claims from January 1, 2016 to December 31, 2016 to calculate 
measure scores, which have been previously previewed by facilities and 
publicly displayed. In crafting our proposal, we also considered 
timeliness related to payment determinations and public display. 
Because we would utilize data already collected to supplement current 
data, our proposal to use three years of data would not disrupt payment 
determinations or public display. We refer readers to the table below 
for example reporting periods and public display dates corresponding to 
the CY 2020, CY 2021, and CY 2022 payment determinations:

[[Page 59107]]

[GRAPHIC] [TIFF OMITTED] TR21NO18.107

    We refer readers to section XIV.D.4.b. of the proposed rule, where 
we discussed a similar proposal under the ASCQR Program.
    Comment: Several commenters supported CMS' proposal to extend the 
reporting period for OP-32. A few commenters supported a 3-year 
reporting period, noting that the extension will mirror the Alternative 
Payment Model (APM) being presented by ACEP to the Payment Model 
Technical Advisory Committee (PTAC) and urged CMS to seek stakeholder 
feedback on developing a methodology and releasing a methodology report 
for public review and comment.
    Response: We thank the commenters for their support for extending 
the reporting period for OP-32. Regarding the request to release a 
methodology report, we note that a methodology already exists. We 
publish annual updates and measures specifications reports, which is a 
description of the measure updates and measure results from 
reevaluation and includes detailed measure specifications.\151\ This 
report describes the measure methodology for a given reporting period. 
We encourage stakeholders to submit comments on the measure's 
methodology via the Outpatient and ASC Question and Answer tool, 
https://cms-ocsq.custhelp.com/.
---------------------------------------------------------------------------

    \151\ Measure Methodology. Colonoscopy measure. Available at: 
https://www.qualitynet.org/dcs/ContentServer?c=Page&pagename=QnetPublic%2FPage%2FQnetTier3&cid=1228775197506.
---------------------------------------------------------------------------

    Comment: One commenter supported a 2-year reporting period, 
specifically stating that the priority should be giving beneficiaries 
critical information they can use today; two years of data typically 
yields the best mix of reliability and predicting performance today; 
the larger increase in reliability occurs between one and two years; 
and the face validity for the measure is poor when using three years of 
data.
    Response: A 3-year reporting period substantially improves the 
reliability of the measure, as described above. Using a 1-year 
reporting period, we found that the median facility-level reliability 
was 0.74 for ASCs and 0.51 for HOPDs, and for a 2-year reporting period 
0.81 for ASCs and 0.67 for HOPDS. However, the median facility-level 
reliability was highest for both ASCs and HOPDs using a 3-year 
reporting period: 0.87 for ASCs and 0.75 for HOPDs. In addition, we 
note that using a 3-year reporting period does not affect the 
timeliness of our ability to report on this measure, as the data being 
used have already been collected. Specifically, we note that the most 
current year of data would be supplemented by the addition of two prior 
years. For example, for the CY 2020 payment determination, we would use 
a reporting period of CY 2018 data plus two prior years of data (CYs 
2016 and 2017).
    Comment: A few commenters did not support CMS' proposal to extend 
the reporting period for OP-32, and stated that the five percent 
increase in the number of HOPDs with eligible cases given the extension 
in the reporting period is not substantial enough, given that a 3-year 
reporting period makes the data impractical and meaningless to inform 
quality improvement efforts and may not reflect system improvements put 
in place at later dates to comply with new measures.
    Response: While extending the measure to include three years of 
data does increase the number of facilities that can be reported on, 
the main intent of increasing the reporting period to three years is to 
increase measure reliability, as described above.
    Comment: One commenter provided general feedback on the measure not 
specifically related to the proposed extension of the reporting period 
for OP-32. This commenter suggested the measure methodology be updated 
to exclude diagnosis codes and/or procedures that are obviously 
indicative of an unforeseen and/or unrelated event.
    Response: We measure all-cause hospital visits to encourage OPDs 
and ASCs to minimize all types of risks that may lead to the need for a 
hospital visit after a colonoscopy. Measuring only hospital visits that 
are potentially related to a colonoscopy, such as gastrointestinal 
bleeding, would limit the measure's impact on quality improvement 
efforts. Measuring all-cause patient outcomes encourages facilities to 
minimize the risk of a broad range of outcomes, including the risk of 
dehydration, pain, dizziness, and urinary retention. These are common 
problems that may be related or unrelated to a recent colonoscopy. We 
have structured the measure so that OPDs and ASCs that most effectively 
minimize patient risk of these outcomes will perform better.
    After consideration of the public comments we received, we are 
finalizing our proposal, as proposed, to change the reporting period 
for OP-32: Facility 7-Day Risk-Standardized Hospital Visit Rate after 
Outpatient Colonoscopy from one year to three years beginning with the 
CY 2020 payment determination and for subsequent years. We refer 
readers to section XIV.D.4.b. of this final rule with comment period, 
where we are finalizing a similar policy under the ASCQR Program.
5. Data Submission Requirements for the OP-37a-e: Outpatient and 
Ambulatory Surgery Consumer Assessment of Healthcare Providers and 
Systems (OAS CAHPS) Survey-Based Measures for the CY 2020 Payment 
Determination and Subsequent Years
    We refer readers to the CY 2017 OPPS/ASC final rule with comment 
period (81 FR 79792 through 79794) for a discussion of the previously 
finalized requirements related to survey administration and vendors for 
the OAS CAHPS Survey-based measures. In addition, we refer readers to 
the CY 2018 OPPS/ASC final rule with comment period (82 FR 59432 
through 59433), where we finalized a policy to delay implementation of 
the OP-37a-e OAS CAHPS Survey-based measures beginning with the CY 2020 
payment determination (2018 reporting period) until further action in 
future rulemaking. In the CY 2019 OPPS/ASC proposed rule (83 FR 37191), 
we did not propose any changes to the previously finalized requirements 
related to survey administration and vendors for the OAS CAHPS Survey-
based measures.
6. Data Submission Requirements for Previously Finalized Measures for 
Data Submitted via a Web-Based Tool for the CY 2020 Payment 
Determination and Subsequent Years
    We refer readers to the CY 2014 OPPS/ASC final rule with comment

[[Page 59108]]

period (78 FR 75112 through 75115) and the CY 2016 OPPS/ASC final rule 
with comment period (80 FR 70521) and the CMS QualityNet website 
(https://www.qualitynet.org/dcs/ContentServer?c=Page&pagename=QnetPublic%2FPage%2FQnetTier2&cid=1205442125082) for a discussion of the requirements for measure data submitted 
via the CMS QualityNet website for the CY 2017 payment determination 
and subsequent years. In addition, we refer readers to the CY 2014 
OPPS/ASC final rule with comment period (78 FR 75097 through 75100) for 
a discussion of the requirements for measure data submitted via the CDC 
NHSN website. In the CY 2019 OPPS/ASC proposed rule (83 FR 37191), we 
did not propose any changes to our policies regarding the submission of 
measure data submitted via a web-based tool.
    We note that, in section XIII.B.4.b.(1) of the proposed rule, we 
proposed to remove of OP-27: Influenza Vaccination Coverage Among 
Healthcare Personnel beginning with the CY 2020 payment determination 
and for subsequent years. Because we are finalizing this removal as 
proposed, for the CY 2020 payment determination, the following web-
based quality measures will be required:
     OP-12: The Ability for Providers with HIT to Receive 
Laboratory Data Electronically Directly into their ONC-Certified EHR 
System as Discrete Searchable Data (via CMS' QualityNet website);
     OP-17: Tracking Clinical Results between Visits (NQF 
#0491) (via CMS' QualityNet website);
     OP-22: Left Without Being Seen (NQF #0499) (via CMS' 
QualityNet website);
     OP-29: Appropriate Follow-up Interval for Normal 
Colonoscopy in Average Risk Patients (NQF #0658) (via CMS' QualityNet 
website);
     OP-30: Colonoscopy Interval for Patients with a History of 
Adenomatous Polyps--Avoidance of Inappropriate Use (NQF #0659) (via 
CMS' QualityNet website);
     OP-31: Cataracts: Improvement in Patient's Visual Function 
within 90 Days Following Cataract Surgery (NQF #1536) (via CMS' 
QualityNet website); and
     OP-33: External Beam Radiotherapy (EBRT) for Bone 
Metastases (NQF #1822) (via CMS' QualityNet website).
    Furthermore, we note that in section XIII.B.4.b.(2) of the proposed 
rule, for the CY 2021 payment determination and subsequent years, we 
proposed to remove: OP-12: The Ability for Providers with HIT to 
Receive Laboratory Data Electronically Directly into Their Qualified/
Certified EHR System as Discrete Searchable Data; OP-17: Tracking 
Clinical Results between Visits; OP-29: Endoscopy/Polyp Surveillance: 
Appropriate Follow-up Interval for Normal Colonoscopy in Average Risk 
Patients; OP-30: Endoscopy/Polyp Surveillance: Colonoscopy Interval for 
Patients with a History of Adenomatous Polyps-Avoidance of 
Inappropriate Use; and OP-31: Cataracts: Improvement in Patient's 
Visual Function within 90 Days Following Cataract Surgery beginning 
with the CY 2021 payment determination and for subsequent years. In 
section XIII.B.4.b.(2) of this final rule with comment period, we are 
finalizing the removal of OP-30 as proposed. However, as discussed in 
section XIII.B.4.b.(2)(a) of this final rule with comment period, we 
are not finalizing the removal of OP-29 or OP-31. Accordingly, the 
following web-based quality measures will require data to be submitted 
via a web-based tool for the CY 2021 payment determination and 
subsequent years:
     OP-22: Left Without Being Seen (NQF #0499) (via CMS' 
QualityNet website);
     OP-29: Endoscopy/Polyp Surveillance: Appropriate Follow-up 
Interval for Normal Colonoscopy in Average Risk Patients (NQF #0658) 
(via CMS' QualityNet website);
     OP-31: Cataracts: Improvement in Patient's Visual Function 
within 90 Days Following Cataract Surgery (NQF #1536) (via CMS' 
QualityNet website); and
     OP-33: External Beam Radiotherapy (EBRT) for Bone 
Metastases (NQF #1822) (via CMS' QualityNet website).
7. Population and Sampling Data Requirements for the CY 2020 Payment 
Determination and Subsequent Years
    We refer readers to the CY 2011 OPPS/ASC final rule with comment 
period (75 FR 72100 through 72103) and the CY 2012 OPPS/ASC final rule 
with comment period (76 FR 74482 through 74483) for discussions of our 
population and sampling requirements. In the CY 2019 OPPS/ASC proposed 
rule (83 FR 37191), we did not propose any changes to our population 
and sampling requirements for chart-abstracted measures.
8. Hospital OQR Program Validation Requirements
    We refer readers to the CY 2013 OPPS/ASC final rule with comment 
period (77 FR 68484 through 68487), the CY 2015 OPPS/ASC final rule 
with comment period (79 FR 66964 through 66965), the CY 2016 OPPS/ASC 
final rule with comment period (80 FR 70524), and the CY 2018 OPPS/ASC 
final rule with comment period (82 FR 59441 through 59443), and 42 CFR 
419.46(e) for our policies regarding validation. In the CY 2019 OPPS/
ASC proposed rule (83 FR 37191 through 37192), we did not propose any 
changes to these policies.
9. Extraordinary Circumstances Exception (ECE) Process for the CY 2020 
Payment Determination and Subsequent Years
    We refer readers to the CY 2013 OPPS/ASC final rule with comment 
period (77 FR 68489), the CY 2014 OPPS/ASC final rule with comment 
period (78 FR 75119 through 75120), the CY 2015 OPPS/ASC final rule 
with comment period (79 FR 66966), the CY 2016 OPPS/ASC final rule with 
comment period (80 FR 70524), the CY 2017 OPPS/ASC final rule with 
comment period (81 FR 79795), the CY 2018 OPPS/ASC final rule with 
comment period (82 FR 59444), and 42 CFR 419.46(d) for a complete 
discussion of our extraordinary circumstances exception (ECE) process 
under the Hospital OQR Program. In the CY 2019 OPPS/ASC proposed rule 
(83 FR 37192), we did not propose any changes to our ECE policy.
10. Hospital OQR Program Reconsideration and Appeals Procedures for the 
CY 2020 Payment Determination and Subsequent Years
    We refer readers to the CY 2013 OPPS/ASC final rule with comment 
period (77 FR 68487 through 68489), the CY 2014 OPPS/ASC final rule 
with comment period (78 FR 75118 through 75119), the CY 2016 OPPS/ASC 
final rule with comment period (80 FR 70524), the CY 2017 OPPS/ASC 
final rule with comment period (81 FR 79795), and 42 CFR 419.46(f) for 
our reconsideration and appeals procedures. In the CY 2019 OPPS/ASC 
proposed rule (83 FR 37192), we did not propose any changes to our 
reconsideration and appeals procedures.

E. Payment Reduction for Hospitals That Fail To Meet the Hospital OQR 
Program Requirements for the CY 2019 Payment Determination

1. Background
    Section 1833(t)(17) of the Act, which applies to subsection (d) 
hospitals (as defined under section 1886(d)(1)(B) of the Act), states 
that hospitals that fail to report data required to be submitted on 
measures selected by the Secretary, in

[[Page 59109]]

the form and manner, and at a time, specified by the Secretary will 
incur a 2.0 percentage point reduction to their Outpatient Department 
(OPD) fee schedule increase factor; that is, the annual payment update 
factor. Section 1833(t)(17)(A)(ii) of the Act specifies that any 
reduction applies only to the payment year involved and will not be 
taken into account in computing the applicable OPD fee schedule 
increase factor for a subsequent year.
    The application of a reduced OPD fee schedule increase factor 
results in reduced national unadjusted payment rates that apply to 
certain outpatient items and services provided by hospitals that are 
required to report outpatient quality data in order to receive the full 
payment update factor and that fail to meet the Hospital OQR Program 
requirements. Hospitals that meet the reporting requirements receive 
the full OPPS payment update without the reduction. For a more detailed 
discussion of how this payment reduction was initially implemented, we 
refer readers to the CY 2009 OPPS/ASC final rule with comment period 
(73 FR 68769 through 68772).
    The national unadjusted payment rates for many services paid under 
the OPPS equal the product of the OPPS conversion factor and the scaled 
relative payment weight for the APC to which the service is assigned. 
The OPPS conversion factor, which is updated annually by the OPD fee 
schedule increase factor, is used to calculate the OPPS payment rate 
for services with the following status indicators (listed in Addendum B 
to this final rule with comment period, which is available via the 
internet on the CMS website): ``J1'', ``J2'', ``P'', ``Q1'', ``Q2'', 
``Q3'', ``R'', ``S'', ``T'', ``V'', or ``U''. In the CY 2017 OPPS/ASC 
final rule with comment period (81 FR 79796), we clarified that the 
reporting ratio does not apply to codes with status indicator ``Q4'' 
because services and procedures coded with status indicator ``Q4'' are 
either packaged or paid through the Clinical Laboratory Fee Schedule 
and are never paid separately through the OPPS. Payment for all 
services assigned to these status indicators will be subject to the 
reduction of the national unadjusted payment rates for hospitals that 
fail to meet Hospital OQR Program requirements, with the exception of 
services assigned to New Technology APCs with assigned status indicator 
``S'' or ```T''. We refer readers to the CY 2009 OPPS/ASC final rule 
with comment period (73 FR 68770 through 68771) for a discussion of 
this policy.
    The OPD fee schedule increase factor is an input into the OPPS 
conversion factor, which is used to calculate OPPS payment rates. To 
reduce the OPD fee schedule increase factor for hospitals that fail to 
meet reporting requirements, we calculate two conversion factors--a 
full market basket conversion factor (that is, the full conversion 
factor), and a reduced market basket conversion factor (that is, the 
reduced conversion factor). We then calculate a reduction ratio by 
dividing the reduced conversion factor by the full conversion factor. 
We refer to this reduction ratio as the ``reporting ratio'' to indicate 
that it applies to payment for hospitals that fail to meet their 
reporting requirements. Applying this reporting ratio to the OPPS 
payment amounts results in reduced national unadjusted payment rates 
that are mathematically equivalent to the reduced national unadjusted 
payment rates that would result if we multiplied the scaled OPPS 
relative payment weights by the reduced conversion factor. For example, 
to determine the reduced national unadjusted payment rates that applied 
to hospitals that failed to meet their quality reporting requirements 
for the CY 2010 OPPS, we multiplied the final full national unadjusted 
payment rate found in Addendum B of the CY 2010 OPPS/ASC final rule 
with comment period by the CY 2010 OPPS final reporting ratio of 0.980 
(74 FR 60642).
    In the CY 2009 OPPS/ASC final rule with comment period (73 FR 68771 
through 68772), we established a policy that the Medicare beneficiary's 
minimum unadjusted copayment and national unadjusted copayment for a 
service to which a reduced national unadjusted payment rate applies 
would each equal the product of the reporting ratio and the national 
unadjusted copayment or the minimum unadjusted copayment, as 
applicable, for the service. Under this policy, we apply the reporting 
ratio to both the minimum unadjusted copayment and national unadjusted 
copayment for services provided by hospitals that receive the payment 
reduction for failure to meet the Hospital OQR Program reporting 
requirements. This application of the reporting ratio to the national 
unadjusted and minimum unadjusted copayments is calculated according to 
Sec.  419.41 of our regulations, prior to any adjustment for a 
hospital's failure to meet the quality reporting standards according to 
Sec.  419.43(h). Beneficiaries and secondary payers thereby share in 
the reduction of payments to these hospitals.
    In the CY 2009 OPPS/ASC final rule with comment period (73 FR 
68772), we established the policy that all other applicable adjustments 
to the OPPS national unadjusted payment rates apply when the OPD fee 
schedule increase factor is reduced for hospitals that fail to meet the 
requirements of the Hospital OQR Program. For example, the following 
standard adjustments apply to the reduced national unadjusted payment 
rates: The wage index adjustment; the multiple procedure adjustment; 
the interrupted procedure adjustment; the rural sole community hospital 
adjustment; and the adjustment for devices furnished with full or 
partial credit or without cost. Similarly, OPPS outlier payments made 
for high cost and complex procedures will continue to be made when 
outlier criteria are met. For hospitals that fail to meet the quality 
data reporting requirements, the hospitals' costs are compared to the 
reduced payments for purposes of outlier eligibility and payment 
calculation. We established this policy in the OPPS beginning in the CY 
2010 OPPS/ASC final rule with comment period (74 FR 60642). For a 
complete discussion of the OPPS outlier calculation and eligibility 
criteria, we refer readers to section II.G. of this final rule with 
comment period.
2. Reporting Ratio Application and Associated Adjustment Policy for CY 
2019
    In the CY 2019 OPPS/ASC proposed rule (83 FR 37193), we proposed to 
continue our established policy of applying the reduction of the OPD 
fee schedule increase factor through the use of a reporting ratio for 
those hospitals that fail to meet the Hospital OQR Program requirements 
for the full CY 2019 annual payment update factor. For the CY 2019 
OPPS, the proposed reporting ratio was 0.980, calculated by dividing 
the proposed reduced conversion factor of 77.955 by the proposed full 
conversion factor of 79.546. We proposed to continue to apply the 
reporting ratio to all services calculated using the OPPS conversion 
factor. For the CY 2019 OPPS, we proposed to apply the reporting ratio, 
when applicable, to all HCPCS codes to which we have proposed status 
indicator assignments of ``J1'', ``J2'', ``P'', ``Q1'', ``Q2'', ``Q3'', 
``R'', ``S'', ``T'', ``V'', and ``U'' (other than new technology APCs 
to which we have proposed status indicator assignment of ``S'' and 
``T''). We proposed to continue to exclude services paid under New 
Technology APCs. We proposed to continue to apply the reporting ratio 
to the national unadjusted payment rates and the minimum unadjusted and 
national unadjusted copayment rates of all applicable services for 
those hospitals that fail to meet the Hospital OQR

[[Page 59110]]

Program reporting requirements. We also proposed to continue to apply 
all other applicable standard adjustments to the OPPS national 
unadjusted payment rates for hospitals that fail to meet the 
requirements of the Hospital OQR Program. Similarly, we proposed to 
continue to calculate OPPS outlier eligibility and outlier payment 
based on the reduced payment rates for those hospitals that fail to 
meet the reporting requirements.
    We did not receive any public comments on these proposals. For the 
CY 2019 OPPS, the final reporting ratio is 0.980, calculated by 
dividing the final reduced conversion factor of 77.900 by the final 
full conversion factor of 79.490. We also are finalizing the remainder 
of our proposals regarding the payment reduction for hospitals that 
fail to meet the Hospital OQR Program requirements for CY 2019 payment 
determination without modification.

XIV. Requirements for the Ambulatory Surgical Center Quality Reporting 
(ASCQR) Program

A. Background

1. Overview
    We refer readers to section XIII.A.1. of the proposed rule for a 
general overview of our quality reporting programs and to section 
I.A.2. of the proposed rule and this final rule with comment period for 
a discussion of our new Meaningful Measures Initiative.
2. Statutory History of the ASCQR Program
    We refer readers to section XIV.K.1. of the CY 2012 OPPS/ASC final 
rule with comment period (76 FR 74492 through 74494) for a detailed 
discussion of the statutory history of the ASCQR Program.
3. Regulatory History of the ASCQR Program
    We seek to promote higher quality and more efficient health care 
for beneficiaries. This effort is supported by the adoption of widely-
agreed-upon quality measures. We have worked with relevant stakeholders 
to define measures of quality in almost every healthcare setting and 
currently measure some aspect of care for almost all Medicare 
beneficiaries. These measures assess structural aspects of care, 
clinical processes, patient experiences with care, and outcomes. We 
have implemented quality measure reporting programs for multiple 
settings of care. To measure the quality of ASC services and to make 
such information publicly available, we implemented the ASCQR Program. 
We refer readers to section XV.A.3. of the CY 2014 OPPS/ASC final rule 
with comment period (78 FR 75122), section XIV. of the CY 2015 OPPS/ASC 
final rule with comment period (79 FR 66966 through 66987), section 
XIV. of the CY 2016 OPPS/ASC final rule with comment period (80 FR 
70526 through 70538), section XIV. of the CY 2017 OPPS/ASC final rule 
with comment period (81 FR 79797 through 79826) and section XIV. of the 
CY 2018 OPPS/ASC final rule with comment period (82 FR 59445 through 
59476) for an overview of the regulatory history of the ASCQR Program.
4. Meaningful Measures Initiative
    In the proposed rule, we proposed a number of new policies for the 
ASCQR Program. We developed these proposals after conducting an overall 
review of the Program under our new Meaningful Measures Initiative, 
which is discussed in more detail in section I.A.2. of the proposed 
rule and this final rule with comment period. The proposals reflected 
our efforts to ensure that the ASCQR Program measure set continues to 
promote improved health outcomes for our beneficiaries while minimizing 
costs, which can consist of several different types of costs, 
including, but not limited to: (1) Facility information collection 
burden and related cost and burden associated with the submitting/
reporting of quality measures to CMS; (2) the facility cost associated 
with complying with other quality programmatic requirements; (3) the 
facility cost associated with participating in multiple quality 
programs, and tracking multiple similar or duplicative measures within 
or across those programs; (4) the CMS cost associated with the program 
oversight of the measure, including measure maintenance and public 
display; and (5) the facility cost associated with compliance with 
other federal and/or State regulations (if applicable). These proposals 
also reflected our efforts to improve the usefulness of the data that 
we publicly report in the ASCQR Program. Our goal is to improve the 
usefulness and usability of CMS quality program data by streamlining 
how facilities are reporting and accessing data, while maintaining or 
improving consumer understanding of the data publicly reported on a 
Compare website. We believe this framework will allow ASCs and patients 
to continue to obtain meaningful information about ASC performance and 
incentivize quality improvement while also streamlining the measure 
sets to reduce duplicative measures and program complexity so that the 
costs to ASCs associated with participating in this program do not 
outweigh the benefits of improving beneficiary care.

B. ASCQR Program Quality Measures

1. Considerations in the Selection of ASCQR Program Quality Measures
    We refer readers to the CY 2013 OPPS/ASC final rule with comment 
period (77 FR 68493 through 68494) for a detailed discussion of the 
priorities we consider for ASCQR Program quality measure selection. In 
the CY 2019 OPPS/ASC proposed rule (83 FR 37193), we did not propose 
any changes to these policies.
2. Accounting for Social Risk Factors in the ASCQR Program
    In the CY 2018 OPPS/ASC final rule with comment period (82 FR 59445 
through 59447), we discussed the importance of improving beneficiary 
outcomes including reducing health disparities. We also discussed our 
commitment to ensuring that medically complex patients, as well as 
those with social risk factors, receive excellent care. We discussed 
how studies show that social risk factors, such as being near or below 
the poverty level as determined by HHS, belonging to a racial or ethnic 
minority group, or living with a disability, can be associated with 
poor health outcomes and how some of this disparity is related to the 
quality of health care.\152\ Among our core objectives, we aim to 
improve health outcomes, attain health equity for all beneficiaries, 
and ensure that complex patients as well as those with social risk 
factors receive excellent care. Within this context, reports by the 
Office of the Assistant Secretary for Planning and Evaluation (ASPE) 
and the National Academy of Medicine have examined the influence of 
social risk factors in CMS value-based purchasing programs.\153\ As we 
noted in the CY 2018 OPPS/ASC final rule with comment period (82 FR 
59445 through 59447), ASPE's report to Congress found that, in the 
context of value-based

[[Page 59111]]

purchasing programs, dual eligibility was the most powerful predictor 
of poor health care outcomes among those social risk factors that they 
examined and tested. In addition, as we noted in the CY 2018 OPPS/ASC 
final rule with comment period (82 FR 59446), the National Quality 
Forum (NQF) undertook a 2-year trial period in which certain new 
measures and measures undergoing maintenance review have been assessed 
to determine if risk adjustment for social risk factors is appropriate 
for these measures.\154\ The trial period ended in April 2017 and a 
final report is available at: https://www.qualityforum.org/SES_Trial_Period.aspx. The trial concluded that ``measures with a 
conceptual basis for adjustment generally did not demonstrate an 
empirical relationship'' between social risk factors and the outcomes 
measured. This discrepancy may be explained in part by the methods used 
for adjustment and the limited availability of robust data on social 
risk factors. NQF is now undertaking an extension of the socioeconomic 
status (SES) trial,\155\ allowing further examination of social risk 
factors in outcome measures.
---------------------------------------------------------------------------

    \152\ See, for example, United States Department of Health and 
Human Services. ``Healthy People 2020: Disparities. 2014.'' 
Available at: https://www.healthypeople.gov/2020/about/foundation-health-measures/Disparities; or National Academies of Sciences, 
Engineering, and Medicine. Accounting for Social Risk Factors in 
Medicare Payment: Identifying Social Risk Factors. Washington, DC: 
National Academies of Sciences, Engineering, and Medicine 2016.
    \153\ Department of Health and Human Services Office of the 
Assistant Secretary for Planning and Evaluation (ASPE), ``Report to 
Congress: Social Risk Factors and Performance Under Medicare's 
Value-Based Purchasing Programs.'' December 2016. Available at: 
https://aspe.hhs.gov/pdf-report/report-congress-social-risk-factors-and-performance-under-medicares-value-based-purchasing-programs.
    \154\ National Quality Forum. Final Report-Disparities Project. 
September 2017. Available at: https://www.qualityforum.org/SES_Trial_Period.aspx.
    \155\ National Quality Forum. Health Equity Program: Social Risk 
Initiative 2.0. 2017. Available at: https://www.qualityforum.org/WorkArea/linkit.aspx?LinkIdentifier=id&ItemID=86357.
---------------------------------------------------------------------------

    In the FY 2018 and CY 2018 proposed rules for our quality reporting 
and value-based purchasing programs, we solicited feedback on which 
social risk factors provide the most valuable information to 
stakeholders and the methodology for illuminating differences in 
outcomes rates among patient groups within a hospital or facility that 
would also allow for a comparison of those differences, or disparities, 
across facilities. Feedback we received through our quality reporting 
programs included encouraging CMS to explore whether factors that could 
be used to stratify or risk adjust the measures (beyond dual 
eligibility); considering the full range of differences in patients' 
backgrounds that might affect outcomes; exploring risk adjustment 
approaches; and offering careful consideration of what type of 
information display would be most useful to the public. We also sought 
public comment on confidential reporting and future public reporting of 
some of our measures stratified by patient dual eligibility. In 
general, commenters noted that stratified measures could serve as tools 
for facilities to identify gaps in outcomes for different groups of 
patients, improve the quality of health care for all patients, and 
empower beneficiaries and other consumers to make informed decisions 
about health care. Commenters encouraged us to stratify measures by 
other social risk factors such as age, income, and educational 
attainment. With regard to value-based purchasing programs, commenters 
also cautioned to balance fair and equitable payment while avoiding 
payment penalties that mask health disparities or discourage the 
provision of care to more medically complex patients. Commenters also 
noted that value-based payment program measure selection, domain 
weighting, performance scoring, and payment methodology must account 
for social risk.
    As a next step, CMS is considering options to reduce health 
disparities among patient groups within and across healthcare settings 
by increasing the transparency of disparities as shown by quality 
measures. We also are considering how this work applies to other CMS 
quality programs in the future. We refer readers to the FY 2018 IPPS/
LTCH PPS final rule (82 FR 38403 through 38409) for more details, where 
we discuss the potential stratification of certain Hospital Inpatient 
Quality Reporting Program outcome measures. Furthermore, we continue to 
consider options to address equity and disparities in our value-based 
purchasing programs.
    We plan to continue working with ASPE, the public, and other key 
stakeholders on this important issue to identify policy solutions that 
achieve the goals of attaining health equity for all beneficiaries and 
minimizing unintended consequences.
3. Policies for Retention and Removal of Quality Measures From the 
ASCQR Program
a. Retention of Previously Adopted ASCQR Program Measures
    We previously adopted a policy that quality measures adopted for an 
ASCQR Program measure set for a previous payment determination year be 
retained in the ASCQR Program for measure sets for subsequent payment 
determination years, except when they are removed, suspended, or 
replaced as indicated (76 FR 74494 and 74504; 77 FR 68494 through 
68495; 78 FR 75122; and 79 FR 66967 through 66969). In the CY 2019 
OPPS/ASC proposed rule (83 FR 37194), we did not propose any changes to 
this policy.
b. Removal Factors for ASCQR Program Measures
(1) Previously Finalized Policy
    We refer readers to the CY 2015 OPPS/ASC final rule with comment 
period (79 FR 66967 through 66969) and 42 CFR 416.320 for a detailed 
discussion of the process for removing adopted measures from the ASCQR 
Program. In the CY 2015 OPPS/ASC final rule with comment period (79 FR 
66967 through 66969), we finalized the ASCQR Program measure removal 
factors \156\ for determining whether to remove ASCQR Program measures 
as follows:
---------------------------------------------------------------------------

    \156\ We note that we previously referred to these factors as 
``criteria'' (for example, 82 FR 59474 through 59475); we now use 
the term ``factors'' in order to align the ASCQR Program terminology 
with the terminology we use in other CMS quality reporting and pay 
for performance (value-based purchasing) programs.
---------------------------------------------------------------------------

     Factor 1. Measure performance among ASCs is so high and 
unvarying that meaningful distinctions and improvements in performance 
can no longer be made (``topped-out'' measures).
     Factor 2. Availability of alternative measures with a 
stronger relationship to patient outcomes.
     Factor 3. A measure does not align with current clinical 
guidelines or practice.
     Factor 4. The availability of a more broadly applicable 
(across settings, populations, or conditions) measure for the topic.
     Factor 5. The availability of a measure that is more 
proximal in time to desired patient outcomes for the particular topic.
     Factor 6. The availability of a measure that is more 
strongly associated with desired patient outcomes for the particular 
topic.
     Factor 7. Collection or public reporting of a measure 
leads to negative unintended consequences other than patient harm.
    In that final rule with comment period, we stated that the benefits 
of removing a measure from the ASCQR Program will be assessed on a 
case-by-case basis (79 FR 66969). Under this case-by-case approach, a 
measure will not be removed solely on the basis of meeting any specific 
factor. We noted that in the CY 2013 OPPS/ASC final rule with comment 
period (77 FR 68472 through 68473), similar measure removal factors 
were finalized for the Hospital OQR Program.
    In the CY 2019 OPPS/ASC proposed rule (83 FR 37194 through 37197), 
we proposed to: (1) Remove one factor; (2) add two new measure removal 
factors,

[[Page 59112]]

and (3) update 42 CFR 416.320(c) to better reflect our measure removal 
policies. We also made one clarification to measure removal Factor 1. 
These items are discussed in detail below.
(2) Removal of Factor 2
    In the CY 2019 OPPS/ASC proposed rule (83 FR 37195), we proposed to 
remove the ASCQR Program's measure removal Factor 2, availability of 
alternative measures with a stronger relationship to patient outcomes. 
We received comments in the CY 2015 OPPS/ASC final rule with comment 
period (79 FR 66967) remarking on the duplicative nature of the ASCQR 
Program's measure removal Factor 2, availability of alternative 
measures with a stronger relationship to patient outcomes, with measure 
removal Factor 6, the availability of a measure that is more strongly 
associated with desired patient outcomes for the particular topic. In 
that final rule with comment period, we stated that ``criterion (2) 
applies when there is more than one alternative measure with a stronger 
relationship to patient outcomes that is available, and criterion (6) 
applies where there is only one measure that is strongly and 
specifically associated with desired patient outcomes for the 
particular topic that is available'' (79 FR 66967). Since reevaluating 
those comments, we have now come to agree that ASCQR measure removal 
Factor 2 is repetitive with Factor 6. Therefore, we proposed to remove 
Factor 2, ``availability of alternative measures with a stronger 
relationship to patient outcomes,'' beginning with the effective date 
of the CY 2019 OPPS/ASC final rule with comment period. We invited 
public comment on our proposal as discussed above.
    Comment: One commenter supported CMS' proposal to remove measure 
removal Factor 2, noting its repetitive nature with removal Factor 6.
    Response: We thank the commenter for its support.
    After consideration of the public comments we received, we are 
finalizing our proposal to remove measure removal Factor 2, 
``availability of alternative measures with a stronger relationship to 
patient outcomes,'' from the ASCQR Program beginning with the effective 
date of this CY 2019 OPPS/ASC final rule with comment period, as 
proposed.
(3) Addition of Two New Measure Removal Factors
(a) Measure Removal Factor 2
    We want the ASCQR Program measure removal factors to be fully 
aligned with the Hospital OQR Program to provide consistency across 
these two outpatient setting quality reporting programs. We believe it 
is important to evaluate the appropriateness of measures across 
programs using similar standards. In evaluating the two programs' 
removal factors, we became aware that the Hospital OQR Program includes 
one factor not currently in the ASCQR Program. The Hospital OQR 
Program's second measure removal factor specifies ``performance or 
improvement on a measure does not result in better patient outcomes'' 
(75 FR 50185).
    Therefore, in the CY 2019 OPPS/ASC proposed rule (83 FR 37195), we 
proposed to add ``performance or improvement on a measure does not 
result in better patient outcomes'' as the new removal Factor 2 for the 
ASCQR Program (replacing the previously adopted factor removed above). 
We believe that this factor is applicable in evaluating the ASCQR 
Program quality measures for removal because we have found it useful 
for evaluating measures in the Hospital OQR Program, which also 
evaluates the outpatient setting. In the proposed rule, we also noted 
that this proposed factor is already included in the Hospital IQR (80 
FR 49641 through 49642), the PCHQR (82 FR 38411), the LTCH QRP (77 FR 
53614 through 53615), and the IPFQR (82 FR 38463) Programs. We proposed 
to add a new removal factor to the ASCQR Program: ``performance or 
improvement on a measure does not result in better patient outcomes'' 
beginning with the effective date of the CY 2019 OPPS/ASC final rule 
with comment period. We invited public comments on our proposal, as 
discussed above.
    Comment: A few commenters supported CMS' proposal to add a new 
measure removal Factor 2, noting it would align the ASCQR and Hospital 
OQR Programs and provide consistency for evaluating measures across 
quality reporting programs.
    Response: We thank the commenters for their support.
    After consideration of the public comments we received, we are 
finalizing our proposal to add a new removal factor to the ASCQR 
Program, ``performance or improvement on a measure does not result in 
better patient outcomes'' beginning with the effective date of the CY 
2019 OPPS/ASC final rule with comment period, as proposed.
(b) New Measure Removal Factor 8
    In the CY 2019 OPPS/ASC proposed rule (83 FR 37195), we proposed to 
adopt an additional factor to consider when evaluating measures for 
removal from the ASCQR Program measure set:
     Factor 8. The costs associated with a measure outweigh the 
benefit of its continued use in the program.
    As we discuss in section I.A.2. of the proposed rule and this final 
rule with comment period with respect to our new Meaningful Measures 
Initiative, we are engaging in efforts to ensure that the ASCQR Program 
measure set continues to promote improved health outcomes for 
beneficiaries while minimizing the overall costs associated with the 
program. We believe these costs are multifaceted and include not only 
the burden associated with reporting, but also the costs associated 
with implementing and maintaining the program. We have identified 
several different types of costs, including, but not limited to: (1) 
Facility information collection burden and related costs and burden 
associated with the submission/reporting of quality measures to CMS; 
(2) the facility cost associated with complying with other programmatic 
requirements; (3) the facility cost associated with participating in 
multiple quality programs, and tracking multiple similar or duplicative 
measures within or across those programs; (4) the CMS cost associated 
with the program oversight of the measure including measure maintenance 
and public display; and (5) the facility cost associated with 
compliance with other federal and/or State regulations (if applicable). 
For example, it may be needlessly costly and/or of limited benefit to 
retain or maintain a measure which our analyses show no longer 
meaningfully supports program objectives (for example, informing 
beneficiary choice or payment scoring). It may also be costly for ASCs 
to track confidential feedback, preview reports, and publicly reported 
information on a measure where we use the measure in more than one 
program. CMS may also have to expend unnecessary resources to maintain 
the specifications for the measure, as well as the tools needed to 
collect, validate, analyze, and publicly report the measure data. 
Furthermore, beneficiaries may find it confusing to see public 
reporting on the same measure in different programs.
    In weighing the costs against the benefits, we evaluate the 
benefits of the measure as a whole, but in particular, we assess the 
benefits through the framework of our Meaningful Measures Initiative, 
as we discussed in section I.A.2. of the proposed rule and this final 
rule with comment period. One key aspect of patient benefits is 
assessing the improved beneficiary health

[[Page 59113]]

outcomes if a measure is retained in our measure set. We believe that 
these benefits are multifaceted and are illustrated through the 
Meaningful Measures framework's 6 domains and 19 areas. For example, we 
assessed the Healthcare Worker Influenza Vaccination and patient 
Influenza Vaccination measures categorized in the Quality Priority 
``Promote Effective Prevention and Treatment of Chronic Disease'' in 
the meaningful measure area of ``Preventive Care'' across multiple CMS 
programs, and considered: Patient outcomes, such as mortality and 
hospitalizations associated with influenza; CMS measure performance in 
a program; and other available and reported influenza process measures, 
such as population influenza vaccination coverage.
    When these costs outweigh the evidence supporting the benefits to 
patients with the continued use of a measure in the ASCQR Program, we 
believe it may be appropriate to remove the measure from the Program. 
Although we recognize that one of the main goals of the ASCQR Program 
is to improve beneficiary outcomes by incentivizing health care 
facilities to focus on specific care issues and making public data 
related to those issues, we also recognize that those goals can have 
limited utility where, for example, the publicly reported data 
(including percentage payment adjustment data) is of limited use 
because it cannot be easily interpreted by beneficiaries and used to 
inform their choice of facility. In these cases, removing the measure 
from the ASCQR Program may better accommodate the costs of program 
administration and compliance without sacrificing improved health 
outcomes and beneficiary choice.
    We proposed that we would remove measures based on this factor 
assessing costs versus benefits on a case-by-case basis. We might, for 
example, decide to retain a measure that is burdensome for ASCs to 
report if we conclude that the benefit to beneficiaries justifies the 
reporting burden. Our goal is to move the program forward in the least 
burdensome manner possible, while maintaining a parsimonious set of 
meaningful quality measures and continuing to incentivize improvement 
in the quality of care provided to patients.
    We invited public comment on our proposal to adopt an additional 
measure removal Factor 8, the costs associated with a measure outweigh 
the benefit of its continued use in the program, beginning with the 
effective date of the CY 2019 OPPS/ASC final rule with comment period 
and for subsequent years.
    We referred readers to section XIV.B.3.c. of the proposed rule, 
where we proposed to remove four measures based on this proposed 
measure removal factor. We noted that we had also proposed this same 
measure removal factor for the Hospital OQR Program in section 
XIII.B.4.a.(4) of the proposed rule, as well as for other quality 
reporting and value-based purchasing programs for FY 2019 including: 
the Hospital VBP Program (83 FR 41442), the Hospital IQR Program (83 FR 
41544); the PCHQR Program (83 FR 41609 through 41610); the LTCH QRP (83 
FR 41625 through 41627); the HQRP (83 FR 41625 through 41627); the IRF 
QRP (83 FR 38556 through 38557); the SNF QRP (83 FR 39267 through 
39269); and the IPFQR Program (83 FR 38591 through 38593).
    Comment: Several commenters supported CMS' proposal to add measure 
removal Factor 8, and noted that it will allow CMS to reduce cost and 
burden, promote alignment of measure removal criteria across quality 
reporting programs and the Meaningful Measures Initiative, and allow 
providers to focus on improving care.
    Response: We thank the commenters for their support.
    Comment: A few commenters opposed CMS' proposal to add measure 
removal Factor 8. A few commenters requested clarification on the types 
of costs that CMS will consider and requested transparency in the 
process of evaluation in the costs and benefits of measures. One 
commenter expressed concern that the costs described under measure 
removal Factor 8 are not defined. One commenter noted the costs with 
changing measures to facilities, providers, and measure developers. 
Another commenter expressed concern that CMS may deem a measure too 
costly to implement, while providers and patients may continue to find 
it meaningful. Commenters also recommended direct and indirect costs 
that CMS may consider in evaluating measures under measure removal 
Factor 8. These costs included those associated with: (1) Measures that 
require data collection from multiple data sources, rather than just 
one; (2) contracting with vendors; (3) tracking performance and 
investing in resources for quality improvement. One commenter stated it 
would oppose the new factor unless costs and benefits are defined as 
only costs and benefits to beneficiaries and the public.
    Response: As noted in the proposed rule (83 FR 37193), we have 
defined costs, for the purpose of evaluating measures under measure 
removal Factor 8, as including, but not limited to: (1) Facility 
information collection burden and related costs and burden associated 
with the submission/reporting of quality measures to CMS; (2) the 
facility cost associated with complying with other programmatic 
requirements; (3) the facility cost associated with participating in 
multiple quality programs, and tracking multiple similar or duplicative 
measures within or across those programs; (4) the CMS cost associated 
with the program oversight of the measure including measure maintenance 
and public display; and (5) the facility cost associated with 
compliance with other federal and/or State regulations (if applicable). 
This was not intended to be a complete list of the potential factors to 
consider in evaluating measures. In addition, as we apply this measure 
removal factor in future rulemaking, we will describe our rationale for 
the removal of a measure and will include the costs and benefits we 
considered.
    We thank commenters for their suggestions regarding additional 
costs to consider. We will use this feedback, as well as input from all 
stakeholders, as we apply measure removal Factor 8 in future 
rulemaking.
    With respect to the commenter that suggested that costs and 
benefits should be defined as only costs and benefits to beneficiaries 
and the public, we believe that various stakeholders may have different 
perspectives on how to define costs as well as benefits. Because of 
these challenges, we intend to evaluate costs and benefits for each 
measure on a case-by-case basis, while considering input from a variety 
of stakeholders, including, but not limited to: Patients, caregivers, 
patient and family advocates, providers, provider associations, 
healthcare researchers, healthcare purchasers, data vendors, and other 
stakeholders with insight into the direct and indirect benefits and 
costs (financial and otherwise) of maintaining any specific measure in 
the ASCQR Program. However, we believe that while a measure's use in 
the ASCQR Program may benefit many entities, the primary benefit is to 
patients and their caregivers through incentivizing high-quality care 
and providing publicly reported data regarding the quality of care 
available. We note that we intend to assess the costs and benefits to 
program stakeholders, including but not limited to, those listed in the 
proposed rule. Therefore, we intend to consider the benefits, 
especially those to patients and their families, when evaluating 
measures under this measure removal factor. As noted above, we have 
offered

[[Page 59114]]

a definition of costs. However, this was not intended to be a complete 
list of the potential factors to consider in evaluating measures and we 
intend to consider additional examples of cost described in public 
comment, including the costs and benefits to beneficiaries and the 
public, as recommended above.
    Comment: A few commenters recommended that CMS seek input from 
hospitals, physicians, and other stakeholders when evaluating the costs 
and benefits of quality reporting.
    Response: We thank the commenters for their feedback and note that 
we will consider stakeholder input when evaluating both the costs of 
quality reporting as well as the benefits of collecting and reporting 
quality data. As stated above, we intend to evaluate costs and benefits 
for each measure on a case-by-case basis, while considering input from 
a variety of stakeholders, including, but not limited to: patients, 
caregivers, patient and family advocates, providers, provider 
associations, healthcare researchers, healthcare purchasers, data 
vendors, and other stakeholders with insight into the direct and 
indirect benefits and costs (financial and otherwise) of maintaining 
any specific measure in the ASCQR Program.
    Comment: A few commenters recommended that CMS consider measure 
sets as a whole and the consistency of quality reporting program 
measure sets. Another commenter recommended that when a measure is 
removed under Factor 8 that it should be replaced by a measure that is 
easier to implement and aimed at improving care within the same measure 
domain to avoid gaps in the measure set. One commenter further 
recommended that measure sets should include actionable process 
measures that contribute to the outcomes being measured.
    Response: We intend to continue to develop a robust measure set for 
the ASCQR Program and appreciate the commenters' feedback. We consider 
the measure set as a whole, the types of measures in the measure set, 
and the consistency throughout quality reporting programs, among other 
things, when assessing measures in the ASCQR Program. We continually 
seek ways to improve the ASCQR Program measure set, including through 
identification of more efficient means of capturing data. Retaining a 
strong measure set that addresses critical quality issues is one 
benefit that we would consider in evaluating whether a measure should 
be potentially removed from the ASCQR Program measure set. In addition, 
we note that in this final rule with comment period, as discussed in 
more detail further below, we are not finalizing our proposals below to 
remove two measures (ASC-9 and ASC-11) under Factor 8 in part to 
maintain a more balanced and cohesive ASCQR Program measure set.
    After consideration of the public comments we received, we are 
finalizing our proposal to adopt measure removal Factor 8, the costs 
associated with a measure outweigh the benefit of its continued use in 
the program, for the ASCQR Program beginning with the effective date of 
this CY 2019 OPPS/ASC final rule with comment period, as proposed.
    As a result of the finalization of our proposals to remove one and 
add two new removal factors as proposed, the new measure removal 
factors list for the ASCQR Program consists of the following:
     Factor 1. Measure performance among ASCs is so high and 
unvarying that meaningful distinctions and improvements in performance 
can no longer be made (``topped-out'' measures).
     Factor 2. Performance or improvement on a measure does not 
result in better patient outcomes.
     Factor 3. A measure does not align with current clinical 
guidelines or practice.
     Factor 4. The availability of a more broadly applicable 
(across settings, populations, or conditions) measure for the topic.
     Factor 5. The availability of a measure that is more 
proximal in time to desired patient outcomes for the particular topic.
     Factor 6. The availability of a measure that is more 
strongly associated with desired patient outcomes for the particular 
topic.
     Factor 7. Collection or public reporting of a measure 
leads to negative unintended consequences other than patient harm.
     Factor 8. The costs associated with a measure outweigh the 
benefit of its continued use in the program.
(4) Revisions to 42 CFR 416.320(c)
    In the CY 2019 OPPS/ASC proposed rule (83 FR 37196), we proposed to 
revise 42 CFR 416.320(c) to better reflect our considerations for 
removing measures policy in light of the above proposals.
    We did not receive any comments on our proposal. Therefore, we are 
finalizing our proposal to revise 42 CFR 416.320(c), as proposed.
(5) Clarification for Removal Factor 1: ``Topped-Out'' Measures
    We refer readers to the CY 2015 OPPS/ASC final rule with comment 
period where we finalized the criteria for determining when a measure 
is ``topped-out'' (79 FR 66968). In that final rule with comment 
period, we finalized two criteria for determining when a measure is 
``topped-out'' under the ASCQR Program: (1) When there is statistically 
indistinguishable performance at the 75th and 90th percentiles of 
national facility performance; and (2) when the measure's truncated 
coefficient of variation (TCOV) is less than or equal to 0.10 (79 FR 
66968 through 66969).
    In the CY 2019 OPPS/ASC proposed rule (83 FR 37196), we did not 
propose any changes to this policy; however, we clarified our process 
for calculating the truncated coefficient of variation (TCOV) for four 
of the measures (ASC-1, ASC-2, ASC-3, and ASC-4) proposed for removal 
from the ASCQR Program. Utilizing our finalized methodology (79 FR 
66968), we determine the truncated coefficient of variation (TCOV) by 
calculating the truncated standard deviation (SD) divided by the 
truncated mean. As discussed above, our finalized removal criteria 
state that to be considered ``topped-out,'' a measure must have a TCOV 
of less than 0.10. We utilize the TCOV because it is generally a good 
measure of variability and provides a relative methodology for 
comparing different types of measures.
    Unlike the majority of our measures, for which a higher rate 
(indicating a higher proportion of a desired event) is the preferred 
outcome, some measures--in particular, ASC-1, ASC-2, ASC-3, and ASC-4--
assess the rate of rare, undesired events for which a lower rate is 
preferred. For example, ASC-1 assesses the occurrence of patient burns, 
a patient safety issue. However, when determining the TCOV for a 
measure assessing rare, undesired events, the mean, or average rate of 
event occurrence, is very low and the result is a TCOV that increases 
rapidly and approaches infinity as the proportion of rare events 
declines.\157\ We note that the SD, the variability statistic, is the 
same in magnitude for measures assessing rare and non-rare events.
---------------------------------------------------------------------------

    \157\ Rose-Hulman Institute of Technology. Denominator 
approaching zero. Retrieved from: https://www.rose-hulman.edu/media/89584/lclimitsguide.pdf.
---------------------------------------------------------------------------

    In the proposed rule, we proposed to remove a number of measures 
that assess the rate of rare, undesired events for which a lower rate 
is preferred--ASC-1, ASC-2, ASC-3, and ASC-4--and referred readers to 
section XIV.B.3.c. of the proposed rule where these proposed measure 
removals are discussed in detail. Because by design

[[Page 59115]]

these measures have maintained very low rates (indicating the preferred 
outcome), we utilized the mean of non-adverse events in our calculation 
of the TCOV. For example, for ASC-1, to calculate the TCOV we divide 
the SD by the average rate of patients not receiving burns (1 minus the 
rate of patients receiving burns) rather than the rate of patients 
receiving burns. Utilizing this methodology results in a TCOV that is 
comparable to that calculated for other measures and allows us to 
assess rare-event measures by still generally using our previously 
finalized topped-out criteria.
c. Removal of Quality Measures From the ASCQR Program Measure Set
    In the CY 2019 OPPS/ASC proposed rule (83 FR 37197 through 37202), 
we proposed to remove a total of eight measures from the ASCQR Program 
measure set across the CY 2020 and CY 2021 payment determinations. 
Specifically, beginning with the CY 2020 payment determination, we 
proposed to remove: (1) ASC-8: Influenza Vaccination Coverage Among 
Healthcare Personnel (NQF #0431); and beginning with the CY 2021 
payment determination, we proposed to remove: (2) ASC-1: Patient Burn 
(NQF #0263); (3) ASC-2: Patient Fall (NQF #0266); (4) ASC-3: Wrong 
Site, Wrong Side, Wrong Patient, Wrong Procedure, Wrong Implant (NQF 
#0267); (5) ASC-4: All-Cause Hospital Transfer/Admission (NQF #0265); 
(6) ASC-9: Endoscopy/Polyp Surveillance Follow-up Interval for Normal 
Colonoscopy in Average Risk Patients (NQF #0658); (7) ASC-10: 
Endoscopy/Polyp Surveillance: Colonoscopy Interval for Patients with a 
History of Adenomatous Polyps--Avoidance of Inappropriate Use (NQF 
#0659); and (8) ASC-11: Cataracts--Improvement in Patient's Visual 
Function within 90 Days Following Cataract Surgery (NQF #1536). We 
proposed to remove these measures under the following measure removal 
factors: Factor 1--measure performance among ASCs is so high and 
unvarying that meaningful distinctions and improvements in performance 
can no longer be made (``topped-out'' measures); and Factor 8--the 
costs associated with a measure outweigh the benefit of its continued 
use in the program.
    We are finalizing the removal of two measures out of the eight 
measure removals we proposed. The proposed measure-specific removals 
are discussed in detail further below. However, because we received 
several general comments regarding all eight proposals as a whole, we 
are discussing those first.
    Comment: Many commenters supported all of CMS' proposals to remove 
measures from the ASCQR Program measure set. Some of these commenters 
noted that the proposals will reduce burden, simplify facility 
reporting, and reduce duplication. One commenter suggested that CMS 
remove all eight measures beginning with CY 2020, rather than delaying 
removal of seven measures until CY 2021. Some commenters agreed with 
CMS' rationale for removals and noted that topped-out or not beneficial 
measures should be removed as soon as possible.
    Response: We thank the commenters for their support for our 
proposed measure removals. However, data collection and reporting for 
the CY 2020 payment determination already began in January 2018 for all 
eight of the measures proposed for removal. Thus, by the effective date 
of this final rule with comment period, facilities will have already 
collected 11 months of data for the CY 2020 payment determination. In 
consideration of facilities' efforts already exerted, we are finalizing 
removal of these measures starting with the next proximate payment 
determination.
    Comment: One commenter opposed CMS' proposal to remove measures 
from the ASCQR Program, citing its belief that consumers should be 
offered more quality information, rather than less, that can be used in 
selecting facilities. Another commenter recommended that CMS maintain 
the existing measure set and work to reduce provider burden through 
alignment across programs instead.
    Response: We thank the commenters for their feedback and note our 
agreement that consumers should be provided with as much valuable 
quality information as possible. As described in the proposed rule, we 
proposed to remove some measures because the costs associated with a 
measure outweigh the benefit of its continued use in the program and 
measure performance among facilities is so high and unvarying that 
meaningful distinctions and improvements in performance can no longer 
be made (``topped-out'' measures). We have identified these and other 
measure removal factors specifically to ensure that the data provided 
to consumers is meaningful and valuable. We do not believe it is 
beneficial to maintain program measures indefinitely. However, we agree 
that burden should be reduced through program alignment and will 
continue to seek opportunities to do this. In the proposed rule, we 
proposed several policies to align with the Hospital OQR Program 
including updating our measure removal factors and removing OP-27 and 
ASC-8, OP-29 and ASC-9, OP-30 and ASC-10, and OP-31 and ASC-11, and we 
are finalizing several of these aligned proposals in this final rule 
with comment period.
(1) Measure Removal for the CY 2020 Payment Determination and 
Subsequent Years--ASC-8: Influenza Vaccination Coverage Among 
Healthcare Personnel
    For the CY 2020 payment determination and subsequent years, we 
proposed to remove one NHSN measure under proposed measure removal 
Factor 8, the costs associated with this measure outweigh the benefit 
of its continued use in the program.
    We refer readers to the CY 2012 OPPS/ASC final rule with comment 
period (76 FR 74510), where we adopted ASC-8: Influenza Vaccination 
Coverage Among Healthcare Personnel (NQF #0431), beginning with the CY 
2016 payment determination and for subsequent years. This process of 
care measure, also a National Healthcare Safety Network (NHSN) measure, 
assesses the percentage of healthcare personnel who have been immunized 
for influenza during the flu season. We initially adopted this measure 
based on our recognition that influenza immunization is an important 
public health issue and vital component to preventing healthcare 
associated infections. We believe that the measure addresses this 
public health concern by assessing influenza vaccination in the ASC 
among healthcare personnel (HCP), who can serve as vectors for 
influenza transmission.
    In the proposed rule, we proposed to remove ASC-8: Influenza 
Vaccination Coverage Among Healthcare Personnel beginning with the CY 
2020 payment determination under proposed measure removal Factor 8, 
because we have concluded that the costs associated with this measure 
outweigh the benefit of its continued use in the program.
    The information collection burden for the Influenza Vaccination 
Coverage Among Healthcare Personnel measure is less than for measures 
that require chart abstraction of patient data because influenza 
vaccination among health care personnel can be calculated through 
review of records maintained in administrative systems and because 
facilities have fewer health care personnel than patients. As such, 
ASC-8 does not require review of as many records. However, this measure 
does still pose information collection burden on facilities due to the 
requirement to identify personnel who have been

[[Page 59116]]

vaccinated against influenza and for those not vaccinated, the reason 
why.
    Furthermore, as we stated in section XIV.B.3.b. of the proposed 
rule, costs are multifaceted and include not only the burden associated 
with reporting, but also the costs associated with implementing and 
maintaining the program. For example, it may be costly for health care 
providers to maintain general administrative knowledge to report these 
measures. In addition, CMS must expend resources in maintaining 
information collection systems, analyzing reported data, and providing 
public reporting of the collected information.
    In our analysis of the ASCQR Program measure set, we recognized 
that some ASCs face challenges with respect to the administrative 
requirements of the NHSN in their reporting of the Influenza 
Vaccination Coverage Among Healthcare Personnel measure. These 
administrative requirements (which are unique to NHSN) include annually 
completing NHSN system user authentication. Enrolling in NHSN is a 
five-step process that the CDC estimates takes an average of 263 
minutes per ASC.\158\ Furthermore, submission via NHSN requires the 
system security administrator of participating facilities to re-consent 
electronically, ensure that contact information is kept current, ensure 
that the ASC has an active facility administrator account, keep Secure 
Access Management Service (SAMS) credentials active by logging in 
approximately every two (2) months and changing their password, create 
a monthly reporting plan, and ensure the ASC's CCN information is up-
to-date.
---------------------------------------------------------------------------

    \158\ Available at: https://www.cdc.gov/nhsn/ambulatory-surgery/enroll.html (the estimates for time to complete are 2 hours 45 
minutes for step 1, 10 minutes for step 2, 16 minutes for step 3a, 
35 minutes for step 3b, 32 minutes for step 4, and 5 minutes for 
step 5; totaling 263 minutes).
---------------------------------------------------------------------------

    Unlike short-term acute care hospitals which participate in other 
quality programs, such as the Hospital IQR and HAC Reduction Programs, 
ASCs are only required to participate in NHSN to submit data for this 
one measure. This may unduly disadvantage smaller ASCs, specifically 
those that are not part of larger hospital systems, because these ASCs 
do not have NHSN access for other quality reporting or value-based 
payment programs. It is our goal to ensure that the ASCQR Program is 
equitable to all ASCs and this measure may disproportionately affect 
small, independent ASCs. Especially for these small, independent ASCs, 
the incremental costs of this measure, as compared to other measures in 
the ASCQR Program measure set, are significant because of the 
requirements imposed by NHSN participation.
    We continue to believe that the Influenza Vaccination Coverage 
Among Healthcare Personnel measure provides the benefit of protecting 
ASC patients against influenza. However, we believe that these benefits 
are offset by other efforts to reduce influenza infection among ASC 
patients, such as numerous healthcare employer requirements for 
healthcare personnel to be vaccinated against 
influenza.^{159 160} We also expect that a portion of MIPS-
eligible clinicians nationwide will report on the Preventive Care and 
Screening: Influenza Immunization measure (NQF #0041) through the 
Quality Payment Program (QPP).\161\ Although MIPS-eligible clinicians 
may voluntarily select measures from a list of options, ASC providers 
that are MIPS-eligible will have the opportunity to continue collecting 
information for the measure. CMS remains responsive to the public 
health concern of influenza infection within the Medicare FFS 
population by collecting data on rates of influenza immunization among 
patients.\162\ Thus, the public health concern is addressed via these 
other efforts to track influenza vaccination. The availability of this 
measure in another CMS program demonstrates CMS' continued commitment 
to this measure area. In addition, as we discussed in section 
XIV.B.3.b. of the proposed rule, where we proposed to adopt measure 
removal Factor 8, beneficiaries may find it confusing to see public 
reporting on the same measure in different programs.
---------------------------------------------------------------------------

    \159\ CDC, Influenza Vaccination Information for Health Care 
Workers. Available at: https://www.cdc.gov/flu/healthcareworkers.htm.
    \160\ CDC Influenza Vaccination Coverage Among Health Care 
Personnel--United States, 2013-14 Influenza Season. Available at: 
https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6337a1.htm.
    \161\ QPP 2017 Measures Selection: Influenza. Retrieved from: 
https://qpp.cms.gov/mips/quality-measures.
    \162\ Ibid.
---------------------------------------------------------------------------

    We wish to minimize the level of cost of our programs for 
participating facilities, as discussed under the Meaningful Measures 
Initiative described in section I.A.2. of the proposed rule and this 
final rule with comment period. In our assessment of the ASCQR Program 
measure set, we prioritized measures that align with this Framework as 
the most important to the ASC population. Our assessment concluded that 
while the Influenza Vaccination Coverage Among Healthcare Personnel 
measure continues to provide benefits, these benefits are diminished by 
other factors and are outweighed by the costs and burdens of reporting 
this measure.
    For these reasons, we proposed to remove ASC-8: Influenza 
Vaccination Coverage among Healthcare Personnel (NQF #0431) from the 
ASCQR Program beginning with the CY 2020 payment determination and for 
subsequent years because the costs associated with the measure outweigh 
the benefit of its continued use in the program. We noted that if 
proposed measure removal Factor 8 is not finalized, removal of this 
measure would also not be finalized. We also noted that a similar 
measure was also proposed for removal from the Hospital OQR Program in 
section XIII.B.4.b.(1) of the proposed rule and the IPFQR Program in 
the FY 2019 IPF PPS proposed rule (83 FR 21104). We invited public 
comments on our proposal to remove ASC-8: Influenza Vaccination 
Coverage Among Healthcare Personnel from the ASCQR Program beginning 
with the CY 2020 payment determination under measure removal Factor 8, 
because we have concluded that the costs associated with this measure 
outweigh the benefit of its continued use in the program, as discussed 
above.
    Comment: Many commenters supported all of CMS' proposals to remove 
measures from the ASCQR Program. Many commenters specifically supported 
CMS' proposal to remove ASC-8 because the costs of the measure outweigh 
its continued use in the ASCQR Program. One commenter remarked that 
while immunization is a critical component of preventing influenza 
transmission, that many employer-based programs and requirements 
already promote vaccination. Another commenter noted that many ASCs may 
fail to receive the APU due to failing to submit data related to ASC-8.
    Response: We thank the commenters for their support.
    Comment: A few commenters noted that the NHSN website is very 
burdensome and it is difficult for ASCs to keep their accounts active 
when it utilized only once per year. One commenter noted that keeping 
such accounts active may be particularly difficult for ASCs that are 
not part of a hospital system. A few commenters recommended that the 
measure could be redeveloped and submitted via QualityNet in the 
future.
    Response: We thank the commenters for their support and agree that 
ASCs face an undue burden from registering and maintaining access to 
the CDC's NHSN system for this one measure as compared to other quality 
reporting programs that require access for several

[[Page 59117]]

healthcare safety measures. We will continue to assess the ASCQR 
Program measure set and will consider future measures, including the 
potential for a re-developed measure submitted via QualityNet that 
addresses influenza vaccinations for health care workers, as part of 
our goal to maintain a robust measure set.
    Comment: One commenter stated that although the process to register 
on NHSN is tedious, that it is not impossible and that reporting on the 
site is easy. Another commenter noted that the burden to submit the 
measure via NHSN is minimal once the data is collected and that having 
ASCs participate in NHSN reporting will provide benefit as new measures 
are developed in partnership with the CDC.
    Response: We thank the commenters for their input. We remain 
concerned that the burden of reporting this measure is greater for ASCs 
compared to the relative burden for hospitals participating in the 
Hospital IQR and HAC Reduction Programs. The entire burden of 
registering for and maintaining access to the CDC's NHSN system for 
ASCs, especially independent or freestanding ASCs, is due to this one 
measure; whereas hospitals paid under the IPPS, participating in the 
Hospital IQR Program, the HAC Reduction Program and the Hospital VBP 
Program, for example, must register and maintain NHSN access for 
several healthcare safety measures, not just one. However, we note 
that, beyond the ASCQR Program, facilities may independently choose to 
voluntarily report data to NHSN on vaccination rates using the NHSN 
Healthcare Personnel Safety Component.
    Comment: Several commenters opposed CMS' proposal to remove ASC-8 
from the ASCQR Program. A few commenters expressed concern that 
influenza is a critical public health issue and that influenza 
vaccination coverage of healthcare workers helps create a safe 
environment for patients, visitors, and employees. A few commenters 
expressed concern that removal of ASC-8 would result in lower 
vaccination rates among healthcare workers. A few commenters noted that 
the Medicare population may be more susceptible to vaccine preventable 
illnesses such as influenza.
    Response: We agree that influenza vaccination for both patients and 
healthcare personnel is important in the ASC setting, as well as other 
healthcare settings, and we believe that these two activities are both 
intended to address the public health concern of reducing influenza 
infection.
    However, while we agree that Medicare beneficiaries may have 
additional risk of contracting influenza, as noted in our proposal, we 
believe the effects of removing this measure from the ASCQR Program are 
mitigated as the issue is addressed in other initiatives such as State 
laws[thinsp]and employer programs that require influenza vaccination of 
healthcare workers.^{163 164} Because of this, we do not 
believe that retaining this measure would result in lower rates of 
vaccination coverage among healthcare personnel. Further, we have 
retained the measure in the Hospital IQR Program (83 FR 41579), thus, 
requiring reporting in the short-term, acute care hospital setting. In 
addition, we believe that the burden of this measure on ASCs, 
especially independent or freestanding ASCs, outweighs the limited 
benefit of addressing this topic again under the ASCQR Program in 
addition to the many other vaccination initiatives.
---------------------------------------------------------------------------

    \163\ CDC. Influenza Vaccination Information for Health Care 
Workers. Available at: https://www.cdc.gov/flu/healthcareworkers.htm.
    \164\ CDC Influenza Vaccination Coverage Among Health Care 
Personnel--United States, 2013-14 Influenza Season. Available at: 
https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6337a1.htm.
---------------------------------------------------------------------------

    Comment: A few commenters stated that ASC-8 plays a critical role 
in the CMS Quality Strategy and the National Quality Strategy in terms 
of immunization efforts. A few commenters stated that removal of the 
measure would create greater inconsistency across quality reporting 
programs.
    Response: We agree that influenza is a critical public health issue 
that is part of the CMS Quality Strategy and the National Quality 
Strategy. Through our Meaningful Measures Initiative, it is our goal to 
ensure that we are addressing high-impact measure areas that safeguard 
public health while minimizing the level of burden for providers and 
suppliers. We continue to believe in the importance of influenza 
vaccination coverage for health care workers, particularly in acute 
care settings, and have retained this measure in the Hospital IQR 
Program (83 FR 41579) in order to address this concern.
    As we noted above, the burden of reporting this measure is greater 
for ASCs compared to the relative burden for hospitals participating in 
the Hospital IQR and HAC Reduction Programs. The entire burden of 
registering for and maintaining access to the CDC's NHSN system for 
ASCs, especially independent or freestanding ASCs, is due to this one 
measure; whereas, hospitals paid under the IPPS, participating in the 
Hospital IQR Program, the HAC Reduction Program, and the Hospital VBP 
Program, for example, must register and maintain NHSN access for 
several healthcare safety measures, not just one.
    Comment: One commenter stated that the cost associated with 
mitigating an influenza outbreak outweighs the cost of retaining ASC-8 
in the ASCQR Program.
    Response: As noted above, because this issue is addressed in other 
initiatives at the State-level and through employers, we do not believe 
it would result in lower rates of vaccination coverage among healthcare 
personnel in ASCs or increase the risk of an outbreak.
    After consideration of the public comments we received, we are 
finalizing our proposal to remove ASC-8: Influenza Vaccination Coverage 
Among Healthcare Personnel from the ASCQR Program beginning with the CY 
2020 payment determination, as proposed.
(2) Measure Removals for the CY 2021 Payment Determination and 
Subsequent Years
    For the CY 2021 payment determination and subsequent years, we 
proposed to remove: (1) Four claims-based measures under measure 
removal Factor 1, ``topped-out'' status; as well as (2) two chart-
abstracted measures and (3) one web-based tool measure under proposed 
measure removal Factor 8.
(a) Proposals To Remove Measures Under Removal Factor 1: ASC-1, ASC-2, 
ASC-3, and ASC-4
    In the proposed rule, beginning with the CY 2021 payment 
determination and subsequent years, we proposed to remove ASC-1, ASC-2, 
ASC-3, and ASC-4 under measure removal Factor 1, measure performance 
among ASCs is so high and unvarying that meaningful distinctions and 
improvements in performance can no longer be made. The ASCQR Program 
previously finalized two criteria for determining when a measure is 
``topped-out'': (1) When there is statistically indistinguishable 
performance at the 75th and 90th percentiles of national facility 
performance; and (2) when the measure's truncated coefficient of 
variation is less than or equal to 0.10 (79 FR 66968 through 66969). In 
the proposed rule, we referred readers to section XIV.B.3.b. of the 
proposed rule, where we clarified and discussed how we calculate the 
TCOV for measures that assess the rate of rare, undesired events for 
which a lower rate is preferred, such as ASC-1, ASC-2, ASC-3, and ASC-
4.

[[Page 59118]]

    For each of these measures, we stated that we believed that removal 
from the ASCQR Program measure set is appropriate as there is little 
room for improvement. In addition, removal would alleviate the 
maintenance costs and administrative burden to ASCs associated with 
retaining the measures. As such, we stated that we believed the burden 
associated with reporting these measures outweighs the benefits of 
keeping them in the program.
    We also note that in crafting our proposals, we considered removing 
these measures beginning with the CY 2020 payment determination, but 
opted to delay removal until the CY 2021 payment determination to be 
sensitive to facilities' planning and operational procedures given that 
data collection for the measures begins during CY 2018 for the CY 2020 
payment determination. Each measure is discussed in more detail further 
below. However, because we received several general comments regarding 
these proposals as a whole, we are discussing those first.
    Comment: Many commenters supported all of CMS' proposals to remove 
measures from the ASCQR Program. Several commenters specifically 
supported the removal of ASC-1, ASC-2, ASC-3, and ASC-4.
    Response: We thank the commenters for their support.
    Comment: Several commenters opposed CMS' proposals to remove ASC-1, 
ASC-2, ASC-3, and ASC-4, noting that although the measures are topped-
out, that these measures provide important data for facilities and 
patients. A few commenters noted that they measure rare events for 
which the occurrence should be zero and that the measures should not be 
eliminated in order to continue to prevent and detect these types of 
occurrences. One commenter stated that measures should not be removed 
from the program based solely on topped-out status. This commenter 
recommended that CMS ensure the measure is topped-out for a number of 
years, evaluate whether there are unintended consequences of removal, 
and continue monitoring performance on topped-out safety measures. 
Another commenter expressed concern that variation in measure 
performance exists between high and low performing States. Another 
commenter was concerned that if the measures are removed that there may 
be no other national-level data sources about the quality of care that 
is being provided in ASCs, and another added that private insurers have 
started using them as well. Another commenter believed that these 
measures are crucial because they are applicable to all ASCs and was 
concerned that there are no other measures in the ASCQR Program that 
are reported by all ASCs.
    Response: We thank the commenters for their feedback. The ASCQR 
Program finalized the ``topped-out'' methodology to evaluate variation 
in performance among ASCs (79 FR 66968) consistent with other quality 
reporting and value-based programs, including the Hospital OQR (79 FR 
66769), Hospital IQR (80 FR 49641 through 49643), Hospital VBP (79 FR 
50055), IPFQR (82 FR 38463 through 38465), and PCHQR (81 FR 57182 
through 57183) Programs. Our topped-out methodology does not evaluate 
variation at the State level, but rather at the level of individual 
ASCs. Our analyses demonstrate that the variation in performance among 
ASCs for these measures is statistically indistinguishable. As shown in 
the tables provided for each proposal, facilities have a rate of 100 
percent performance at both the 90th and 75th percentiles for the past 
five years of reporting.
    Due to public comments, we have reevaluated our data. In the 
proposed rule, we believed that the measures' performance among ASCs is 
so high and unvarying that meaningful distinctions and improvements in 
performance can no longer be made and that the measures met the 
criteria for being topped-out. However, we have reviewed many studies, 
in addition to the public comments we received, that show the 
importance of measuring and reporting the data for these measures, as 
discussed in each proposal below. Therefore, we have now come to 
believe that these measures may be more valuable to stakeholders than 
we initially perceived in the proposed rule. We agree that it is 
important to continue to monitor these types of events considering the 
potential negative impacts to patients' morbidity and mortality, in 
order to continue to prevent their occurrence and ensure that they 
remain rare. We acknowledge that these measures provide critical data 
to beneficiaries and further transparency for care provided in the ASC 
setting that would be useful in choosing an ASC for care, and that 
these measures are valuable to the ASC community. Despite little room 
for improvement, these measures provide beneficiaries and ASCs with 
vital information about patient burns, patient falls, wrong site, wrong 
side, wrong patient, wrong procedure, wrong implant events, and 
hospital transfers/admissions that take place in the ASC setting and we 
believe it would be prudent to keep them in the program at this time in 
order to continue to detect and prevent these events. Further, we 
acknowledge that having measures that apply to all ASCs provides 
beneficiaries with the most comprehensive patient safety data to use 
when making decisions about a site of care. ASC-1, ASC-2, ASC-3, and 
ASC-4 are measures for which all ASCs, regardless of specialty area, 
can submit data in contrast to other measures, such as ASC-14: 
Unplanned Anterior Vitrectomy, which would only apply to ASCs where 
specialty-specific procedures are performed, such as ophthalmology 
procedures in the case of ASC-14. Therefore, we are not finalizing our 
proposals to remove ASC-1, ASC-2, ASC-3, and ASC-4. These measures will 
remain in the program under our measure retention policies, unless we 
take future action under our measure removal policies.
    Comment: A few commenters who opposed the removal of these measures 
were also concerned about the data submitted for them. One commenter 
expressed concern that only 50 percent of claims are required to have 
QDCs and questioned how some ASCs are able to report that no errors 
occurred in their facilities. Another commenter was concerned about the 
proportion of ASCs that had missing data for these measures, noting 
that the missing data would affect their eligibility to receive the 
APU, but does not impact their status as a Medicare provider. Another 
commenter was concerned about under-reporting and recommended that CMS 
conduct data validation studies and empirical analyses of these 
measures, particularly for ASC-1, ASC-2, and ASC-3. This commenter also 
recommended that the denominator for ASC-1, ASC-2, and ASC-3 should 
only include cases that present risk for the adverse event as utilizing 
an amplified denominator would provide a false reading of lower rates. 
A few commenters who supported the removal of these measures suggested 
that the measures could be redeveloped and submitted via QualityNet in 
the future. One commenter suggested that revising the data submission 
method in this way could capture data from all payers. One commenter 
noted that ASC-1, ASC-2, and ASC-3 specifically should include all 
patients in the denominator. A few commenters who opposed CMS' 
proposals to remove the measures stated that the measures could be 
redeveloped for all payers and could be reported via QualityNet in 
order to further reduce burden and ensure data is posted publicly for 
accountability and for quality improvement. A few commenters 
recommended that the measures could be included as part of

[[Page 59119]]

a composite measure that encompasses the various phases of care.
    Response: The ASCQR Program is a quality reporting program for 
which ASCs must meet program requirements including the submission of 
quality measure data, else they are subject to a two percent reduction 
in their annual payment update. As a quality reporting program, the 
data collected is publicly reported in order to aide beneficiaries in 
choosing sites of care. Our regulations at 42 CFR part 416 detail the 
requirements that determine a facility's eligibility to participate as 
a Medicare supplier of ambulatory surgical services. We will continue 
to assess our measure set in light of stakeholder concerns and within 
the framework of our Meaningful Measures Initiative.
    Currently, ASCs are only able to report adverse events for Medicare 
fee-for-service beneficiaries and that adverse events that have 
occurred to patients with other payers are not reflected in the 
currently reported data. As such, it is possible for an ASC to report 
zero adverse events via the ASCQR Program because no adverse events 
occurred to Medicare FFS beneficiaries within the reporting period. In 
addition, we thank the commenters for their suggestions regarding 
redeveloping the measure to capture all payers and to submit via 
QualityNet to reduce burden. We note that because the data for these 
measures are currently collected via Medicare FFS claims, as specified 
in the Specifications Manual,\165\ we are unable to include data from 
other payers for which Medicare does not receive FFS claims.
---------------------------------------------------------------------------

    \165\ Ambulatory Surgical Center Quality Reporting 
Specifications Manual, v7.0a. Available at: https://www.qualitynet.org/dcs/ContentServer?c=Page&pagename=QnetPublic%2FPage%2FQnetTier2&cid=1228772475754.
---------------------------------------------------------------------------

    We thank the commenters for the feedback and note that we are also 
concerned about some of the data submitted for these measures. In the 
FY 2013 IPPS/LTCH PPS final rule (77 FR 53641), we finalized our policy 
that the minimum threshold for successful reporting be that at least 50 
percent of claims meeting measure specifications contain QDCs. At that 
time, we believed that 50 percent was a reasonable minimum threshold 
for the initial implementation years of the ASCQR Program, because ASCs 
were not yet familiar with how to report quality data under the ASCQR 
Program and because many ASCs are relatively small and may have needed 
more time to set up reporting systems. We stated in that final rule 
that we intended to propose to increase this percentage for subsequent 
years' payment determinations as ASCs become more familiar with 
reporting requirements for the ASCQR Program. We have assessed this 
reporting threshold annually and have found that over 78 percent of 
reporting ASCs report data for at least 90 percent of eligible claims. 
However, we believe that the current data submission method for these 
measures may impact the completeness and accuracy of the data due to 
the inability of ASCs to correct the QDC codes that are used to 
calculate these measures from Medicare FFS claims. Currently, a 
facility that identifies an erroneous or missing QDC code is unable to 
correct or add a QDC code if the claim has already been submitted to 
Medicare. We believe that revising the data submission method for the 
measures, such as via QualityNet, would address this issue and allow 
facilities to correct any data submissions errors, resulting in more 
complete and accurate data. Further, we will conduct additional 
empirical analyses to identify any other potential issues with the data 
submitted for these measures. We refer readers to section XIV.B.6. of 
this final rule with comment period, where we discuss public comments 
received about the potential future validation of ASCQR Program 
measures.
    We are committed to work with stakeholders to ensure the ASCQR 
Program measure set does not place an inappropriate amount of burden on 
facilities while addressing and providing information about these types 
of patient safety, adverse, rare events to patients and other 
consumers. As such, while we will retain ASC-1, ASC-2, ASC-3, and ASC-4 
in the program as discussed above, after considering public comments 
and reevaluating our concerns about data submission, we will also 
suspend their data collection beginning with the CY 2019 reporting 
period/CY 2021 payment determination until further action in rulemaking 
with the goal of updating the data submission method for the measures. 
In other words, starting with the CY 2021 payment determination, 
facilities would not be required to submit data for these four measures 
as part of ASCQR Program requirements although the measures would 
remain in the ASCQR Program measure set. As we develop future revisions 
for the data collected for these measures, we will take into 
consideration other data submission methods that may allow for the 
reporting of adverse events across payers and will consider commenters' 
feedback toward the future updates to the measures.
    Comment: A few commenters noted that it would be beneficial to also 
have these measures included in the Hospital OQR Program in order to 
provide patients with more meaningful data to compare sites of service.
    Response: We thank the commenters for their feedback. We will take 
this into consideration for the future.
    Comment: One commenter stated that the NQF endorsement of these 
measures was removed because they were allowed to lapse by the measure 
steward, not because they failed the endorsement maintenance process, 
and noted that the ASCQR Program did not provide this as a rationale 
for removing the measures. The commenter noted that all of these 
measures have ongoing support from the ASC community.
    Response: NQF endorsement, or lack thereof, does not automatically 
qualify or disqualify a measure for removal from the ASCQR Program. We 
thank the commenter for its comment as ASC stakeholder feedback is 
important, and we will weigh the benefits of support of the ASC 
community in our consideration of our proposals to ensuring that the 
ASCQR Program has a robust and responsive measure set.
 Proposal To Remove ASC-1: Patient Burn
    We refer readers to the CY 2012 OPPS/ASC final rule with comment 
period (76 FR 74497 through 74498) where we adopted ASC-1: Patient Burn 
beginning with the CY 2014 payment determination (NQF #0263). This 
claims-based outcome measure assesses the percentage of ASC admissions 
experiencing a burn prior to discharge.
    Based on our analysis of ASCQR Program measure data for CYs 2013 to 
2017 encounters, the ASC-1 measure meets our measure removal Factor 1. 
These analyses are captured in the table below.

[[Page 59120]]

[GRAPHIC] [TIFF OMITTED] TR21NO18.108

    As displayed in the analysis above, there is no distinguishable 
difference in ASC performance between the 75th and 90th percentiles, 
and the truncated coefficient of variation has been below 0.10 since 
2013. In the proposed rule, we also noted that NQF endorsement of this 
measure (NQF #0263) was removed on May 24, 2016.\166\
---------------------------------------------------------------------------

    \166\ National Quality Forum. Available at: https://www.qualityforum.org/QPS/0263.
---------------------------------------------------------------------------

    Comment: One commenter specifically opposed the removal of ASC-1, 
noting that it measures rare, isolated events and that it is valuable 
to monitor for consumers as a burn measure.
    Response: We thank the commenter for its feedback. While the 
measure is topped-out, we acknowledge that it is still valuable. In the 
CY 2012 OPPS/ASC final rule with comment period (76 FR 74497), we 
adopted this measure for ASCs because they serve surgical patients who 
may face the risk of burns during ambulatory surgical procedures and 
because we agree monitoring patient burns is valuable to patients and 
other stakeholders. Further, we have reviewed numerous studies 
demonstrating the high impact of monitoring patient burns due to the 
large number of surgeries performed in the outpatient setting,\167\ 
because patient burns are serious reportable events in healthcare,\168\ 
and because of patient burns are preventable.^{169 170} We note 
that we are not finalizing our proposal to remove ASC-1 as discussed in 
the section above.
---------------------------------------------------------------------------

    \167\ U.S. Department of Health and Human Services. Centers for 
Medicare & Medicaid Services. https://www.cms.gov/.
    \168\ National Quality Forum. Serious Reportable Events in 
Healthcare 2006 Update. Washington, DC: NQF, 2007.
    \169\ ECRI Institute. New clinical guide to surgical fire 
prevention. Health Devices 2009 Oct;38(10):314-32.
    \170\ National Fire Protection Association (NFPA). NFPA 99: 
Standard for health care facilities. Quincy (MA): NFPA; 2005.
---------------------------------------------------------------------------

 Proposal To Remove ASC-2: Patient Fall
    We refer readers to the CY 2012 OPPS/ASC final rule with comment 
period (76 FR 74498) where we adopted ASC-2: Patient Fall beginning 
with the CY 2014 payment determination. This NQF-endorsed (NQF #0266), 
claims-based measure assesses the percentage of ASC admissions 
experiencing a fall in the ASC.
    Based on our analysis of ASCQR Program measure data for CYs 2013 to 
2017 encounters, the ASC-2 measure meets our measure removal Factor 1. 
These analyses are captured in the table below.
[GRAPHIC] [TIFF OMITTED] TR21NO18.109

    As displayed in the analysis above, there is no distinguishable 
difference in ASC performance between the 75th and 90th percentiles and 
the truncated coefficient of variation has been below 0.10 since 2013.
    Comment: One commenter specifically opposed the removal of ASC-2, 
noting that ASC-2 measures rare, isolated events and that it is 
valuable to monitor for consumers as a patient fall measure.
    Response: We thank the commenter for its feedback. While the 
measure is topped-out, we acknowledge that it is still valuable. In the 
CY 2012 OPPS/ASC final rule with comment period (76 FR 74498), we 
adopted this measure for ASCs because falls, particularly in the 
elderly, can cause injury and loss of functional status, because the 
use of anxiolytics, sedatives, and anesthetic agents may put patients 
undergoing outpatient surgery at increased risk for falls, and because 
falls in healthcare settings can be prevented through the assessment of 
risk, care planning, and patient monitoring. Further, we have reviewed 
numerous studies demonstrating the high impact of monitoring patient 
burns due to the large number of surgeries performed in the outpatient 
setting,\171\ because patient falls are serious reportable events in 
healthcare,\172\ and because of patient falls are preventable.\173\ 
Because

[[Page 59121]]

of these concerns, we agree that monitoring patient falls is valuable 
to patients and other stakeholders. We note that we are not finalizing 
our proposal to remove ASC-2 as discussed in the previous section.
---------------------------------------------------------------------------

    \171\ U.S. Department of Health and Human Services. Centers for 
Medicare & Medicaid Services. https://www.cms.gov/.
    \172\ National Quality Forum. Serious Reportable Events in 
Healthcare--2006 Update: A Consensus Report. March 2007.
    \173\ Boushon B, Nielsen G, Quigley P, Rutherford P, Taylor J, 
Shannon D. Transforming Care at the Bedside How-to Guide: Reducing 
Patient Injuries from Falls. Cambridge, MA: Institute for Healthcare 
Improvement; 2008.
---------------------------------------------------------------------------

 Proposal To Remove ASC-3: Wrong Site, Wrong Side, Wrong 
Patient, Wrong Procedure, Wrong Implant
    We refer readers to the CY 2012 OPPS/ASC final rule with comment 
period (76 FR 74498 through 74499) where we adopted ASC-3: Wrong Site, 
Wrong Side, Wrong Patient, Wrong Procedure, Wrong Implant beginning 
with the CY 2014 payment determination (NQF #0267). This claims-based 
outcome measure assesses the percentage of ASC admissions experiencing 
a wrong site, wrong side, wrong patient, wrong procedure, or wrong 
implant.
    Based on our analysis of ASCQR Program measure data for CYs 2013 to 
2017 encounters, the ASC-3 measure meets our measure removal Factor 1. 
These analyses are captured in the table below.
[GRAPHIC] [TIFF OMITTED] TR21NO18.110

    As displayed in the analysis above, there is no distinguishable 
difference in ASC performance between the 75th and 90th percentiles and 
the truncated coefficient of variation has been below 0.10 since 2013. 
In the proposed rule, we also noted that NQF endorsement of this 
measure (NQF #0267) was removed on May 24, 2016.\174\
---------------------------------------------------------------------------

    \174\ National Quality Forum. Available at: https://www.qualityforum.org/QPS/0267.
---------------------------------------------------------------------------

    Comment: One commenter specifically opposed the removal of ASC-3, 
noting that although wrong site surgery is infrequent, it is an 
egregious error. The commenter was concerned that removing the measure 
would imply that it is no longer important to providers and also noted 
their belief that because ASCs tend to have more rapid patient turnover 
that may make them prone to ``never events'' such as wrong site 
surgeries.
    Response: We thank the commenter for its feedback. While the 
measure is topped-out, we acknowledge that it is still valuable. In the 
CY 2012 OPPS/ASC final rule with comment period (76 FR 74498 through 
74499), we adopted this measure for ASCs because surgeries and 
procedures performed on the wrong site/side, and wrong patient can 
result in significant impact on patients, including complications, 
serious disability or death. We also stated that while the prevalence 
of such serious errors may be rare, such events are considered serious 
reportable events. Further, we have reviewed numerous studies 
demonstrating the high impact of monitoring wrong site, wrong side, 
wrong patient, wrong procedure, wrong implant procedures and surgeries 
due to the large number of surgeries performed in the outpatient 
setting,\175\ because these types of errors are serious reportable 
events in healthcare,\176\ and because of these errors are 
preventable.^{177 178} Because of this, we agree that it is 
important to monitor this measure in ASCs, which perform a large volume 
of outpatient surgeries every year. We note that we are not finalizing 
our proposal to remove ASC-3 as discussed in the previous section.
---------------------------------------------------------------------------

    \175\ U.S. Department of Health and Human Services. Centers for 
Medicare & Medicaid Services. https://www.cms.gov/.
    \176\ National Quality Forum. Serious Reportable Events in 
Healthcare--2006 Update: A Consensus Report. March 2007.
    \177\ American College of Obstetricians and Gynecologists. ACOG 
committee opinion #464: patient safety in the surgical environment. 
Obstet Gynecol. 2010;116(3):786-790.
    \178\ Joint Commission. Ambulatory Health Care: 2019 National 
Patient Safety Goals available at https://www.jointcommission.org/ahc_2017_npsgs/.
---------------------------------------------------------------------------

 Proposal To Remove ASC-4: All-Cause Hospital Transfer/
Admission
    We refer readers to the CY 2012 OPPS/ASC final rule with comment 
period (76 FR 74499) where we adopted ASC-4: All-Cause Hospital 
Transfer/Admission beginning with the CY 2014 payment determination 
(NQF #0265). This claims-based outcome measure assesses the rate of ASC 
admissions requiring a hospital transfer or hospital admission upon 
discharge from the ASC.
    Based on our analysis of ASCQR Program measure data for CYs 2013 to 
2017 encounters, the ASC-4 measure meets our measure removal Factor 1. 
These analyses are captured in the table below.

[[Page 59122]]

[GRAPHIC] [TIFF OMITTED] TR21NO18.111

    As displayed in the analysis above, there is no distinguishable 
difference in ASC performance between the 75th and 90th percentiles and 
the truncated coefficient of variation has been below 0.10 since 2013. 
In the proposed rule, we also noted that NQF endorsement of this 
measure (NQF #0265) was removed on February 4, 2016.\179\
---------------------------------------------------------------------------

    \179\ National Quality Forum. Available at: https://www.qualityforum.org/QPS/0265.
---------------------------------------------------------------------------

    Comment: One commenter specifically supported the inclusion of ASC-
4 in the ASCQR Program, noting that it believed that the issues 
surrounding transfers to hospitals, although infrequent, are 
significant. The commenter noted that it believed that ASCs can only 
function safely if there is a hospital available to care for patients 
with unanticipated problems, noting that there can be an unclear and 
competitive relationship between the ASC and the hospital.
    Response: While the measure is topped-out, we acknowledge that it 
is still valuable. In the CY 2012 OPPS/ASC final rule with comment 
period (76 FR 74499), we adopted this measure for ASCs because the 
transfer or admission of a surgical patient from an outpatient setting 
to an acute care setting can be an indication of a complication, 
serious medical error, or other unplanned negative patient outcome. We 
also stated that while acute intervention may be necessary in these 
circumstances, a high rate of such incidents may indicate suboptimal 
practices or patient selection criteria. Further, we have reviewed 
numerous studies demonstrating the high impact of monitoring patient 
transfers and admissions due to the large number of surgeries performed 
in the outpatient setting,\180\ and because facilities can take steps 
to prevent and reduce these types of events.^{181 182 183} On 
this basis, we agree that the issue of patient transfers to hospitals 
within the ASC setting are significant adverse events to beneficiaries 
and ASC stakeholders, even if infrequent.
---------------------------------------------------------------------------

    \180\ U.S. Department of Health and Human Services. Centers for 
Medicare & Medicaid Services. https://www.cms.gov/.
    \181\ Coley KC, Williams BA, DaPos SV, Chen C, Smith RB. 
Retrospective evaluation of unanticipated admissions and 
readmissions after same day surgery and associated costs. J Clin 
Anesth. 2002 Aug; 14(5):349-53.
    \182\ Fortier J, Chung F, Su J. Unanticipated admission after 
ambulatory surgery--a prospective study. Can J Anaesth. 1998 
Jul;45(7):612-9.
    \183\ Junger A, Klasen J, Benson M, Sciuk G, Hartmann B, Sticher 
J, Hempelmann G. Factors determining length of stay of surgical day-
case patients. Eur J Anaesthesiol. 2001 May;18(5):314-21.
---------------------------------------------------------------------------

    Currently, 42 CFR 416.41(b)(3)(i) and (ii) requires ASCs to have a 
written transfer agreement with a hospital that meets certain Medicare 
requirements or ensure all physicians performing surgery in the ASC 
have admitting privileges in a hospital that meets certain Medicare 
requirements. A written transfer agreement and physician admitting 
privileges are intended to ensure there is a relationship between the 
ASC and local hospital that would serve the patient in the event of a 
medical emergency. We note that changes to these requirements were 
proposed in the Medicare and Medicaid Programs; Regulatory Provisions 
To Promote Program Efficiency, Transparency, and Burden Reduction 
proposed rule (83 FR 47686) due to the difficulty of obtaining these 
agreements.
    Over the past 5 years, we have heard from the largest ASC trade 
association and multiple ASCs that we need to address the widespread 
issue of the growing number of hospitals that are declining to work 
with ASCs (either by declining to sign a transfer agreement or by 
declining to allow admitting privileges to the hospital by physicians 
who work in ASCs) due to competition between hospital outpatient 
surgery departments and ASCs. We have continually worked with the ASCs 
and hospitals directly to resolve this requirement issue. However, we 
are aware that several facilities have not been able to reach a 
positive outcome.
    On September 20, 2018, we issued a proposed rule in the Federal 
Register titled ``Medicare and Medicaid Programs: Regulatory Provisions 
To Promote Program Efficiency, Transparency, and Burden Reduction'' (83 
FR 47686 through 47762). In that proposed rule (83 FR 47693 through 
47694), we discussed proposals regarding ASC transfer agreements and 
admitting privileges. We noted that we have seen no evidence of 
negative patient outcomes due to a lack of such transfer agreements and 
admitting privileges, and research reports published by the ASC Quality 
Collaborative indicate the national hospital transfer rate from an ASC 
to a hospital for care is about 1.25 per 1,000 ASC admissions (https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/ASC-Quality-Reporting/). As we also noted in that 
proposed rule, ASCs are already required to have personnel trained and 
available for emergency response when there is a patient in the ASC, 
and the ASC is expected to provide initial stabilizing treatment until 
the patient is transferred. Finally, we noted that the current 
requirement dates back to 1982, when ASCs were a newly emerging medical 
care option and there was reasonable concern as to needed emergency 
care being available. As we noted above, we are not finalizing our 
proposal to remove ASC-4 as discussed in the section above.
    Comment: One commenter was concerned that ASC-4 only includes data 
for Medicare patients and the potential for this to skew the data and 
misrepresent the facility's transfer rate, and recommended that CMS 
collect data for all cases regardless of payer type. The commenter was 
also concerned that by only reporting Medicare data for the measure, 
that it may create a disincentive for facilities to transfer a Medicare 
patient because it would raise their transfer rate.
    Another commenter recommended that CMS expand ASC-4 to include 
patients who visit a hospital for an inpatient admission or emergency 
department visit in the days following their ASC procedure.

[[Page 59123]]

    Response: We do not believe that the ASC-4 measure, as specified in 
the ASCQR Program Specifications Manual,\184\ would create a 
disincentive for facilities to transfer a Medicare patient to a 
hospital because both the denominator, and the numerator as noted by 
the commenter, is comprised of all Medicare FFS beneficiaries that have 
been admitted to the ASC. We also note, that because ASC-4 is a claims-
based measure, it is only able to assess transfer rates for Medicare 
FFS beneficiaries for which claims are received by CMS. We agree that 
measuring hospital visits after ASC procedures may be a valuable metric 
to Medicare beneficiaries and the public due to concerns about patient 
harm or complications. As such, we have already incorporated multiple 
measures assessing this area by adopting ASC-12: Facility 7-Day Risk-
Standardized Hospital Visit Rate after Outpatient Colonoscopy (79 FR 
66970), ASC-17: Hospital Visits After Orthopedic Ambulatory Surgical 
Center Procedures (82 FR 59454), and ASC-18: Hospital Visits After 
Urology Ambulatory Surgical Center Procedures (82 FR 59463) into the 
ASCQR Program measure set. We will continue to evaluate the ASCQR 
Program measure set to ensure it is robust and responsive to 
beneficiary needs and thank the commenter for the feedback. We note 
that we are not finalizing our proposal to remove ASC-4 as discussed in 
the previous section.
---------------------------------------------------------------------------

    \184\ Version 7.0a of the ASCQR Program Specifications Manual is 
available at: https://www.qualitynet.org/dcs/ContentServer?c=Page&pagename=QnetPublic%2FPage%2FSpecsManualTemplate&cid=1228776140694.
---------------------------------------------------------------------------

(b) Measure Removals Under Removal Factor 8: ASC-9, ASC-10, and ASC-11
    In the proposed rule, we proposed to remove three measures (ASC-9, 
ASC-10, and ASC-11) under proposed measure removal Factor 8, the costs 
associated with a measure outweigh the benefit of its continued use in 
the program, for the CY 2021 payment determination and subsequent 
years. In the proposed rule, we noted that if proposed measure removal 
Factor 8 is not finalized, removal of these measures would also not be 
finalized.
    The proposals are discussed in more detail below. We note that in 
crafting our proposals, we considered removing these measures beginning 
with the CY 2020 payment determination but opted to delay removal until 
the CY 2021 payment determination to be sensitive to facilities' 
planning and operational procedures given that data collection for 
these measures begins during CY 2018 for the CY 2020 payment 
determination.
 Proposal To Remove ASC-9: Endoscopy/Polyp Surveillance: 
Appropriate Follow-Up Interval for Normal Colonoscopy in Average Risk 
Patients
    We refer readers to the CY 2014 OPPS/ASC final rule with comment 
period (78 FR 75127 through 75128) where we adopted ASC-9: Endoscopy/
Polyp Surveillance: Appropriate Follow-up Interval for Normal 
Colonoscopy in Average Risk Patients (NQF #0659) beginning with the CY 
2016 payment determination. This chart-abstracted process measure 
assesses the ``[p]ercentage of patients aged 50 years and older 
receiving a screening colonoscopy without biopsy or polypectomy who had 
a recommended follow-up interval of at least ten (10) years for repeat 
colonoscopy documented in their colonoscopy report.'' (78 FR 75127). 
This measure aims to assess whether average risk patients with normal 
colonoscopies receive a recommendation to receive a repeat colonoscopy 
in an interval that is less than the recommended amount of ten (10) 
years.
    In the proposed rule, we proposed to remove ASC-9: Endoscopy/Polyp 
Surveillance Follow-up Interval for Normal Colonoscopy in Average Risk 
Patients beginning with the CY 2021 payment determination and for 
subsequent years under our measure removal Factor 8, the costs 
associated with a measure outweigh the benefit of its continued use in 
the program. We adopted ASC-9: Endoscopy/Polyp Surveillance Follow-up 
Interval for Normal Colonoscopy in Average Risk Patients in the CY 2014 
OPPS/ASC final rule with comment period (78 FR 75127 through 75128) 
noting that performing colonoscopy too frequently increases patients' 
exposure to procedural harm. However, we noted concern in the proposed 
rule that the costs of this measure outweigh the benefit of its 
continued use in the program.
    Chart-abstraction requires facilities to select a sample 
population, access historical records from several current and historic 
clinical data quarters and interpret that patient data. This process is 
typically more time and resource-consuming than for other measure 
types. In addition to submission of manually chart-abstracted data, we 
take all burden and costs into account when evaluating a measure. We 
noted in the proposed rule that removing ASC-9 would reduce the burden 
and cost to facilities associated with collection of information and 
reviewing their data and performance associated with the measure.
    However, we also acknowledged that we do not believe the use of 
chart-abstracted measure data alone is sufficient justification for 
removal of a measure under proposed measure removal Factor 8. The costs 
of collection and submission of chart-abstracted measure data is 
burdensome for facilities, especially when taking into consideration 
the availability of other CMS quality measures that are relevant in the 
clinical condition and highly correlated in performance across 
measures. In the proposed rule we noted another colonoscopy-related 
measure required in the ASCQR Program, ASC-12: Facility 7-Day Risk-
Standardized Hospital Visit Rate after Outpatient Colonoscopy (NQF 
#2539) which measures all-cause, unplanned hospital visits (admissions, 
observation stays, and emergency department visits) within seven (7) 
days of an outpatient colonoscopy procedure (79 FR 66970). This claims-
based outcome measure does not require chart-abstraction, and similarly 
contributes data on quality of care related to colonoscopy procedures, 
although the measure does not specifically track processes such as 
follow-up intervals. When we adopted ASC-12, we believed this measure 
would reduce adverse patient outcomes associated with preparation for 
colonoscopy, the procedure itself, and follow-up care by capturing and 
making more visible to facilities and patients all unplanned hospital 
visits following the procedure (79 FR 66970). Furthermore, in the 
proposed rule we noted our belief that the potential benefits of 
keeping ASC-9 in the program are mitigated by the existence of the same 
measure (Appropriate Follow-up Interval for Normal Colonoscopy in 
Average Risk Patients) \185\ for gastroenterologists in the Merit-Based 
Incentive Payment System (MIPS) for the 2019 performance period in the 
QPP (82 FR 30292). Thus, we noted that the issue of preventing harm to 
patients from colonoscopy procedures that are performed too frequently 
is adequately addressed through MIPS in the QPP, because we expect a 
portion of MIPS-eligible clinicians reporting on the measure nationwide 
to provide meaningful data to CMS. Although MIPS-eligible clinicians 
may voluntarily select measures from a list of options, ASC providers 
that are MIPS-eligible will

[[Page 59124]]

have the opportunity to continue collecting information for the measure 
without being penalized if they determine there is value for various 
quality improvement efforts.\186\ The availability of this measure in 
another CMS program demonstrates CMS' continued commitment to this 
measure area.
---------------------------------------------------------------------------

    \185\ QPP Measure Selection: Appropriate Follow-up Interval for 
Normal Colonoscopy in Average Risk Patients. Retrieved from: https://qpp.cms.gov/mips/quality-measures.
    \186\ CMS finalized that services furnished by an eligible 
clinician that are payable under the ASC, HHA, Hospice, or HOPD 
methodology will not be subject to the MIPS payments adjustments, 
but eligible clinicians payable under those methodologies may have 
the option to still voluntarily report on applicable measures and 
the data reported will not be used to determine future eligibility 
(82 FR 53586).
---------------------------------------------------------------------------

    Furthermore, we seek to align our quality reporting work with the 
Patients Over Paperwork and the Meaningful Measures Initiatives 
described in section I.A.2. of the proposed rule and this final rule 
with comment period. The purpose of this effort is to hold providers 
accountable for only the measures that are most important to patients 
and clinicians and those that are focused on patient outcomes in 
particular, because outcome measures evaluate the actual results of 
care. As described in section I.A.2. of the proposed rule and this 
final rule with comment period, our Meaningful Measures Initiative is 
intended to reduce costs and minimize burden, and we believe that 
removing this chart-abstracted measure from the ASCQR Program would 
reduce program complexity. In addition, as we discussed in section 
XIV.B.3.b. of the proposed rule, where we proposed to adopt measure 
removal Factor 8, we noted that beneficiaries may find it confusing to 
see public reporting on the same measure in different programs.
    Therefore, due to the combination of factors of the costs of 
collecting data for this chart-abstracted measure, the preference for 
an outcomes measure in the ASCQR Program that provides valuable data 
for the same procedure, and the existence of the same measure in 
another CMS program, we noted in the proposed rule that the burdens and 
costs associated with this measure outweigh the limited benefit to 
beneficiaries. As a result, we proposed to remove ASC-9: Endoscopy/
Polyp Surveillance: Appropriate Follow-up Interval for Normal 
Colonoscopy in Average Risk Patients beginning with the CY 2021 payment 
determination and for subsequent years. We note that the Hospital OQR 
Program proposed to remove a similar measure, OP-29: Endoscopy/Polyp 
Surveillance Follow-up Interval for Normal Colonoscopy in Average Risk 
Patients in section XIII.B.4.b. of the proposed rule.
    Comment: Several commenters opposed CMS' proposal to remove ASC-9 
from the ASCQR Program. A few commenters expressed concern that 
physicians may not follow the recommended guidelines for colonoscopy 
screenings and noted that there is a potential for patient harm from 
unnecessary colonoscopy screenings that pose significant costs. One 
commenter suggested that solely retaining the measure in MIPS is 
insufficient because the measure is voluntary in that program. A few 
commenters stated that ASC-9 and ASC-12 assess distinct and different 
aspects of colonoscopies, because ASC-12 focuses on coordination and 
does not evaluate the interval between colonoscopies or the appropriate 
use of care. One commenter noted that ASC-9 and ASC-12 fall into 
different Meaningful Measures categories, Preventable Healthcare Harm 
and Admissions and Readmissions, respectively. These commenters 
recommended retaining ASC-9 to achieve a holistic approach to measuring 
the quality of care in this clinical area. One commenter noted that 
ASC-9 is not overly burdensome to collect and report. Some commenters 
disagreed with CMS' assessment that the costs of the measure outweigh 
the benefit.
    Response: Although MIPS-eligible clinicians may voluntarily select 
measures from a list of options, we believe that MIPS reporting would 
provide some meaningful data in this clinical area. While we proposed 
to remove this measure because we believed the costs associated with a 
measure outweigh the benefit of its continued use in the program, after 
reviewing public comments, we reevaluated our data and analysis. We 
acknowledge that adherence to clinical guidelines for colonoscopy 
screening intervals is an important issue due to studies that document 
inappropriate use.¹⁸⁷ ¹⁸⁸ ¹⁸⁹ One 
study showed high rates of inappropriate colonoscopies performed in 
older adult populations: 10 percent in adults aged 70-75; 39 percent in 
adults aged 76-85; and 25 percent in adults aged >=86.\190\ We believe 
that ASC-9 is a critical measure for the ASCQR Program because there is 
demonstrated substantial overuse of surveillance colonoscopies among 
low-risk patients,\191\ with research showing that colonoscopies are 
often recommended at shorter intervals than are advised by guidelines 
among patients with normal colonoscopy results.\192\ We believe it is 
especially important to assess this topic due to the high-volume of 
these procedures that occur in the outpatient setting.
---------------------------------------------------------------------------

    \187\ Sheffield et al. 2013. Potentially Inappropriate Screening 
Colonoscopy in Medicare Patients: Variation by Provider and 
Geographic Region. JAMA Intern Med.
    \188\ Schoen R. E., Pinsky P. F., Weissfeld J. L., et al. 
Utilization of surveillance colonoscopy in community practice. 
Gastroenterology. 2010;138(1):73-81. doi: 10.1053/
j.gastro.2009.09.062.
    \189\ Krist, AH, Jones, RM, Woolf, SH et al. Timing of Repeat 
Colonoscopy: Disparity Between Guidelines and Endoscopists' 
Recommendation. American Journal of Preventive Medicine. 2007.
    \190\ Sheffield et al. 2013. Potentially Inappropriate Screening 
Colonoscopy in Medicare Patients: Variation by Provider and 
Geographic Region. JAMA Intern Med.
    \191\ Schoen R. E., Pinsky P. F., Weissfeld J. L., et al. 
Utilization of surveillance colonoscopy in community practice. 
Gastroenterology. 2010;138(1):73-81. doi: 10.1053/
j.gastro.2009.09.062.
    \192\ Krist, AH, Jones, RM, Woolf, SH et al. Timing of Repeat 
Colonoscopy: Disparity Between Guidelines and Endoscopists' 
Recommendation. American Journal of Preventive Medicine. 2007.
---------------------------------------------------------------------------

    Furthermore, while ASC-9 and ASC-12 assess the topic of 
colonoscopies generally, we acknowledge that they assess distinct 
clinical areas. ASC-12 tracks adverse patient outcomes that result in 
unplanned hospital visits; ASC-9 provides information about 
colonoscopies occurring at inappropriate intervals that may contribute 
to increased costs to beneficiaries and to CMS, a priority of our 
Meaningful Measures Initiative. While ASC-12 provides vital data about 
patient outcomes after colonoscopies, ASC-9 focuses on adherence to 
guideline recommendations for screening colonoscopy follow-up 
intervals, as noted by NQF's evaluation report.\193\ Upon reviewing the 
measure set as a whole, we now believe that ASC-9 assesses a distinct 
clinical area not addressed by ASC-12 and as a result, there may be a 
measurement gap if both ASC-9 and ASC-10 are removed. Further, although 
we noted that ASC-9 requires the burden of chart-abstraction to report, 
we believe it is significantly less burdensome than ASC-10 due to the 
significant burden of obtaining patient histories required for that 
measure. We also appreciate commenters' feedback that ASC-9 is not 
overly burdensome to report. Because this measure tracks the number of 
beneficiaries who had a recommended follow-up interval of at least 10 
years for repeat colonoscopy documented in their

[[Page 59125]]

colonoscopy report, we believe it provides important information to 
beneficiaries on the avoidance of inappropriate endoscopies/
colonoscopies. ASC-9 evaluates overutilization that can lead to the 
overuse of resources and unnecessary risks to beneficiaries from 
possible procedural complications and harms.
---------------------------------------------------------------------------

    \193\ NQF #0658 Endoscopy/Polyp Surveillance: Appropriate 
follow-up interval for normal colonoscopy in average risk patients, 
Date Submitted: Jul 09, 2012 National Quality Form, Stage 1 Concept 
Submission and Evaluation Worksheet 1.0.
---------------------------------------------------------------------------

    In section I.A.2. of the proposed rule and this final rule with 
comment period, we describe our Meaningful Measures Initiative that is 
intended to reduce costs and minimize burden. We believe that although 
removing this chart-abstracted measure from the ASCQR Program would 
reduce program complexity, retaining it provides pertinent information 
about colonoscopies occurring at inappropriate intervals that may 
contribute to increased costs to beneficiaries and to CMS, a priority 
of our Meaningful Measures Initiative.
    Despite the costs and burdens of chart-abstraction or the presence 
of other measures assessing a similar clinical topic, after considering 
incoming comments and reevaluating our data, we now believe ASC-9 is a 
more critical measure for the ASCQR Program than we initially perceived 
in the proposed rule. Accordingly, upon further review of the benefits 
of the measure, we no longer believe that the costs associated with 
this measure outweigh the benefit of its continued use in the program. 
Therefore, we are not finalizing our proposal to remove this measure. 
This measure will remain in the program under our measure retention 
policies, unless we take future action under our measure removal 
policies.
    Comment: A few commenters stated that CMS should retain ASC-9 in 
order to promote program alignment across outpatient settings and allow 
for comparisons between facility types.
    Response: We have considered program alignment by adding and 
removing measures in tandem for the ASCQR and Hospital OQR Programs so 
that measures may be compared across facility types, such as ASC-9/OP-
29: Endoscopy/Polyp Surveillance: Appropriate Follow-up Interval for 
Normal Colonoscopy in Average Risk Patients. As noted above, we adopted 
ASC-9 into the ASCQR Program because we believe it is important for 
ASCs to be active partners in avoiding inappropriate use and ensuring 
that beneficiaries at their facilities are referred for follow-up care 
at appropriate intervals in alignment with current guidelines. As 
stated above, we are not finalizing our proposal to remove ASC-9. We 
are similarly retaining the corresponding measure (OP-29) in the 
Hospital OQR Program in section XIII.B.4.b. of this final rule with 
comment period.
    Comment: One commenter did not support CMS' proposal to remove ASC-
9 because it is included in the CMS Core Quality Measures Collaborative 
(CQMC) Gastroenterology Core Set and is widely used in the private 
sector.
    Response: The CMS CQMC identifies core sets of quality measures 
that payers have committed to using for reporting as soon as 
feasible.\194\ The guiding principles used by the Collaborative in 
developing the core measure sets are that they be meaningful to 
patients, consumers, and physicians, while reducing variability in 
measure selection, collection burden, and cost. The goal is to 
establish broadly agreed upon core measure sets that could be 
harmonized across both commercial and government payers.\195\ We agree 
that the inclusion of ASC-9 in the CMS CQMC Gastroenterology Core Set 
speaks to its clinical value. However, although we are retaining ASC-9 
for the reasons discussed in this section, we note that the inclusion 
of measures in the CQMC Core Sets does not necessitate retention in the 
ASCQR Program.
---------------------------------------------------------------------------

    \194\ Core Measures. Retrieved from: https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/QualityMeasures/Core-Measures.html.
    \195\ Ibid.
---------------------------------------------------------------------------

    Comment: One commenter recommended that CMS retain ASC-9 and 
explore how to automate tracking of the information to reduce the 
resource-intensive use of chart-abstracted data. Another commenter 
recommended that CMS retain the measure because it could be useful for 
validation, as it is a chart-abstracted measure.
    Response: We thank the commenter for the suggestion regarding 
automated data submission and will take this into consideration for the 
future. As discussed in section I.A.2 of this final rule with comment 
period, our Meaningful Measures Initiative prioritizes burden reduction 
in our quality reporting programs, and we will continue to evaluate the 
ASCQR Program measure set through this framework. We continually seek 
opportunities to reduce the reporting burden of our programs, but note 
that collecting data for ASC-9 still currently requires chart-
abstraction.
    In section XIV.B.6. of this final rule with comment period, we 
discuss public comments we received on the possible future validation 
of ASCQR Program measures and will include this comment in our 
consideration of that request for information. As discussed in detail 
above, after consideration of the public comments we received, we are 
not finalizing our proposal to remove ASC-9.
    Comment: Many commenters supported all of CMS' proposals to remove 
measures from the ASCQR Program. Several commenters specifically 
supported CMS' proposal to remove ASC-9 from the ASCQR Program, noting 
that it was developed and tested as a provider-level measure and they 
did not believe it is appropriate for the ASC setting. A few commenters 
further stated that this measure is already being reported through the 
MIPS (formerly PQRS) and that MIPS is the appropriate program because 
ASC-9 is a provider-level measure.
    Response: We thank the commenters for their support. As noted in 
our proposal, this same measure is available through MIPS in the QPP 
and, although MIPS-eligible clinicians may voluntarily select measures 
from a list of options, we expect a portion of MIPS-eligible clinicians 
reporting on the measure nationwide to provide meaningful data to CMS 
about avoiding inappropriate use. In addition, as noted when we adopted 
this measure (78 FR 75125), it was specified for the ASC setting and 
field tested at the ASC facility setting level by the measure steward. 
Further, we believe it is important for ASCs to be active partners in 
avoiding inappropriate use and ensuring that patients at their 
facilities are referred for follow-up care at appropriate intervals in 
alignment with current guidelines. In addition, after considering the 
public comments we received and upon further review of the benefits of 
the measure, we no longer believe that the costs associated with this 
measure outweigh the benefit of its continued use in the program as 
this measure assesses a unique and clinically important topic area not 
covered otherwise addressed by the ASCQR Program measure set.
    After consideration of the comments we received, we are not 
finalizing our proposal to remove ASC-9: Endoscopy/Polyp Surveillance: 
Appropriate Follow-up Interval for Normal Colonoscopy in Average Risk 
Patients from the ASCQR Program beginning with the CY 2021 payment 
determination and for subsequent years. This measure will remain in the 
program under our measure retention policies, unless we take future 
action under our measure removal policies. We note that we are also not 
finalizing our proposal to remove OP-29 under the Hospital OQR Program, 
and we refer readers to section XIII.B.4.b. of this final

[[Page 59126]]

rule with comment period for more information.
 Removal of ASC-10: Endoscopy/Polyp Surveillance: Colonoscopy 
Interval for Patients With a History of Adenomatous Polyps--Avoidance 
of Inappropriate Use
    We refer readers to CY 2014 OPPS/ASC final rule with comment period 
(78 FR 75128) where we adopted ASC-10: Endoscopy/Polyp Surveillance: 
Colonoscopy Interval for Patients with a History of Adenomatous 
Polyps--Avoidance of Inappropriate Use (NQF #0659) beginning with the 
CY 2016 payment determination. This chart-abstracted process measure 
assesses the percentage of patients aged 18 years and older receiving a 
surveillance colonoscopy, with a history of a prior colonic polyp in 
previous colonoscopy findings, who had a follow-up interval of 3 or 
more years since their last colonoscopy documented in the colonoscopy 
report.
    In the proposed rule, we proposed to remove ASC-10: Endoscopy/Polyp 
Surveillance: Colonoscopy Interval for Patients with a History of 
Adenomatous Polyps--Avoidance of Inappropriate Use beginning with the 
CY 2021 payment determination and for subsequent years under our 
proposed measure removal Factor 8, the costs associated with a measure 
outweigh the benefit of its continued use in the program.
    We adopted ASC-10: Endoscopy/Polyp Surveillance: Colonoscopy 
Interval for Patients with a History of Adenomatous Polyps--Avoidance 
of Inappropriate Use in the CY 2014 OPPS/ASC final rule with comment 
period (78 FR 75128) noting that colonoscopy screening for high risk 
patients is recommended based on risk factors, and one such factor is a 
history of adenomatous polyps. The frequency of colonoscopy screening 
varies depending on the size and amount of polyps found, with the 
general recommendation of a 3-year follow-up. We stated that this 
measure is appropriate for the measurement of quality of care furnished 
by ASCs, because colonoscopy screening is commonly performed in these 
settings (78 FR 75128). However, we now believe that the costs of this 
measure outweigh the benefit of its continued use in the program.
    Chart-abstraction requires facilities to select a sample 
population, access historical records from several clinical data 
quarters past, and interpret that patient data. This process is 
typically more time and resource-consuming than for other measure 
types. In addition to submission of manually chart-abstracted data, we 
take all burden and costs into account when evaluating a measure. 
Removing ASC-10 would reduce the burden and cost to facilities 
associated with collection of information and reporting on their 
performance associated with the measure.
    However, we do not believe the use of chart-abstracted measure data 
alone is sufficient justification for removal of a measure under 
proposed measure removal Factor 8. The costs of collection and 
submission of chart-abstracted measure data is burdensome for 
facilities especially when taking into consideration the availability 
of other CMS quality measures. Another colonoscopy-related measure 
required in the ASCQR Program, ASC-12: Facility 7-Day Risk-Standardized 
Hospital Visit Rate after Outpatient Colonoscopy (NQF #2539) measures 
all-cause, unplanned hospital visits (admissions, observation stays, 
and emergency department visits) within seven (7) days of an outpatient 
colonoscopy procedure (79 FR 66970). This claims-based outcome measure 
does not require chart-abstraction, and similarly contributes data on 
quality of care related to colonoscopy procedures, although the measure 
does not specifically track processes such as follow-up intervals. When 
we adopted ASC-12, we believed this measure would reduce adverse 
patient outcomes associated with preparation for colonoscopy, the 
procedure itself, and follow-up care by capturing and making more 
visible to facilities and patients all unplanned hospital visits 
following the procedure (79 FR 66970). Furthermore, the potential 
benefits of keeping ASC-10 in the ASCQR Program are mitigated by the 
existence of the same measure (Colonoscopy Interval for Patients with a 
History of Adenomatous Polyps-Avoidance of Inappropriate Use) \196\ for 
gastroenterologists in the Merit-Based Incentive Payment System (MIPS) 
for the 2019 performance period in the QPP (82 FR 30292). Thus, we 
believe the issue of preventing harm to patients from colonoscopy 
procedures that are performed too frequently is adequately addressed 
through MIPS in the QPP, because we expect a portion of MIPS-eligible 
clinicians reporting on the measure nationwide to provide meaningful 
data to CMS. Although MIPS-eligible clinicians may voluntarily select 
measures from a list of options, ASC providers that are MIPS-eligible 
will have the opportunity to continue collecting information for the 
measure without being penalized if they determine there is value for 
various quality improvement efforts.\197\ The availability of this 
measure in another CMS program demonstrates CMS' continued commitment 
to this measure area.
---------------------------------------------------------------------------

    \196\ QPP Measure Selection: Colonoscopy Interval for Patients 
with a History of Adenomatous Polyps--Avoidance of Inappropriate 
Use. Retrieved from: https://qpp.cms.gov/mips/quality-measures.
    \197\ CMS finalized that services furnished by an eligible 
clinician that are payable under the ASC, HHA, Hospice, or HOPD 
methodology will not be subject to the MIPS payments adjustments, 
but eligible clinicians payable under those methodologies may have 
the option to still voluntarily report on applicable measures and 
the data reported will not be used to determine future eligibility 
(82 FR 53586).
---------------------------------------------------------------------------

    Furthermore, we seek to align our quality reporting work with the 
Patients Over Paperwork and the Meaningful Measures Initiatives 
described in section I.A.2. of the proposed rule and this final rule 
with comment period. The purpose of this effort is to hold providers 
accountable for only the measures that are most important to patients 
and clinicians and that are focused on patient outcomes in particular, 
because outcome measures evaluate the actual results of care. As 
described in section I.A.2. of the proposed rule and this final rule 
with comment period, our Meaningful Measures Initiative is intended to 
reduce costs and minimize burden, and we believe that removing this 
chart-abstracted measure from the ASCQR Program would reduce program 
complexity. In addition, as we discussed in section XIV.B.3.b. of the 
proposed rule, where we proposed to adopt measure removal Factor 8, 
beneficiaries may find it confusing to see public reporting on the same 
measure in different programs.
    Therefore, due to the combination of factors of the costs of 
collecting data for this chart-abstracted measure, the preference for 
an outcomes measure in the ASCQR Program that provides valuable data 
for the same procedure, and the existence of the same measure in the 
MIPS program, we believe that the burdens and costs associated with 
manual chart abstraction outweigh the limited benefit to beneficiaries 
of receiving this information. As a result, we proposed to remove ASC-
10: Endoscopy/Polyp Surveillance: Colonoscopy Interval for Patients 
with a History of Adenomatous Polyps--Avoidance of Inappropriate Use 
from the ASCQR Program beginning with the CY 2021 payment determination 
and for subsequent years. We note that we proposed to remove a similar 
measure from the Hospital OQR Program in section XIII.B.4.b. of the 
proposed rule.

[[Page 59127]]

    Comment: Many commenters supported all of CMS' proposals to remove 
measures from the ASCQR Program. Several commenters specifically 
supported CMS' proposal to remove ASC-10 from the ASCQR Program because 
the costs outweigh the benefits of retaining it in the ASCQR Program. 
One commenter noted that unless the reporting facility was the site of 
the patient's previous procedure, the reporting facility would not have 
the data necessary from their medical records and would need to obtain 
it from other providers, including the date of the procedure, and the 
number types, and locations of any polyps found. One commenter 
recommended that CMS remove ASC-10 beginning with the CY 2020 payment 
determination, so that facilities may shift resources dedicated to 
operationalizing the measure sooner.
    Response: We thank the commenters for their support. In addition to 
the burden of chart-abstraction, we acknowledge the unique burden of 
ASC-10, which requires that facilities conduct extensive patient 
histories and contact other facilities in order to obtain documentation 
of a history of adenomatous polyps.\198\ Thus, the costs and burdens 
are higher for this measure than for the other coloscopy measure 
considered for removal, ASC-9, which requires less information from 
patients and does not require historical documentation.
---------------------------------------------------------------------------

    \198\ ASC-10 Measure Information Form. Available at: https://www.qualitynet.org/dcs/ContentServer?c=Page&pagename=QnetPublic%2FPage%2FSpecsManualTemplate&cid=1228776607946.
---------------------------------------------------------------------------

    Comment: Several commenters noted that ASC-10 was developed and 
tested as a provider-level measure and they do not believe it is 
appropriate for the ASC setting. One commenter stated that this measure 
is already being reported through the MIPS (formerly PQRS) and that 
MIPS is the appropriate program because ASC-10 is a provider-level 
measure. Another commenter stated that duplicate reporting in CMS' 
quality reporting programs has caused unnecessary provider burden 
without adding new information to the pool of quality data available to 
the public.
    Response: We adopted ASC-10 into the ASCQR Program because we 
believe it is important for ASCs to be active partners in avoiding 
inappropriate use and ensuring that beneficiaries at their ASCs are 
referred for follow-up care at appropriate intervals in alignment with 
current guidelines. In addition, as noted when we adopted this measure 
(78 FR 75125), it was specified for the ASC setting and field tested at 
the ASC setting level by the measure steward. As noted in our proposal, 
this same measure is available through MIPS in the QPP and, although 
MIPS-eligible clinicians may voluntarily select measures from a list of 
options, we expect a portion of MIPS-eligible clinicians reporting on 
the measure nationwide to provide meaningful data to CMS about avoiding 
inappropriate use.
    As discussed above, we are retaining ASC-9 in order to retain a 
measure assessing inappropriate use of endoscopies/colonoscopies in the 
ASCQR Program. After reconsideration, we believe there may be a 
measurement gap if both ASC-9 and ASC-10 are removed and because of the 
unique burden associated with ASC-10, we are finalizing our removal of 
this measure but retaining ASC-9. A primary goal of our Meaningful 
Measures Initiative is to reduce provider burden through the 
deduplication of measures across quality reporting programs. Thus, due 
in part to the duplication of this measure through MIPS in the QPP and 
the additional burden to ASCs of obtaining patient records, we believe 
ASC-10 is the more appropriate measure to be removed from the ASCQR 
Program measure set. Removing ASC-10 while retaining ASC-9 best enables 
us to assess this important clinical area while ensuring that the costs 
of measure do not outweigh the benefits.
    Comment: A few commenters opposed CMS' proposal to remove ASC-10 
from the ASCQR Program. One commenter noted that ASC-10 is a cost 
measure and helps avoid inappropriate use or missed opportunities to 
screen patients that could result in significant harm to beneficiaries. 
One commenter expressed concern that physicians may not follow the 
recommended guidelines for colonoscopy screenings and noted that there 
is a potential for patient harm from unnecessary colonoscopy screenings 
that poses significant costs.
    Response: We agree that adherence to clinical guidelines for 
colonoscopy screening intervals is an important issue. Measuring the 
inappropriate use of colonoscopy screenings is critical to preventing 
the waste of resources and potential patient harm. In part for this 
reason, we are retaining ASC-9 in the ASCQR Program measure set and 
will continue to require reporting on appropriate follow-up intervals 
for normal risk patients. We believe that retaining ASC-9 in the ASCQR 
Program enables us to address concerns regarding patient harm from 
unnecessary colonoscopy screenings.
    Further, due to the unique documentation burden specifically for 
ASC-10, we believe it adds undue burden to ASCs, particularly small 
ASCs and those that do not have EHRs and is more burdensome than ASC-9. 
After review of public comments we received, we reevaluated our data 
and our measure set as a whole. To balance the clinical value of 
measures with the costs, we believe it is appropriate to retain ASC-9 
while finalizing our proposal to remove ASC-10.
    Comment: One commenter did not support CMS' proposal to remove ASC-
10 because it is included in the CMS CQMC Gastroenterology Core Set and 
is widely used in the private sector.
    Response: The CMS CQMC Gastroenterology Core Set is a set of 
measures identified as being meaningful to patients, consumers, and 
physicians, while reducing variability in measure selection, collection 
burden, and cost and is intended for use by payers who are part of the 
CQMC.\199\ Because of this, we believe beneficiaries will continue to 
receive this data to help them make health care decisions. We agree 
that this measure is valuable to many stakeholders and support its 
continued reporting through other quality reporting programs and in the 
private sector. However, due to the measure's requirement to obtain 
historical patient records, we believe that this measure adds undue 
burden to ASCs, particularly small ASCs and those that do not have 
EHRs. In addition, we note that the inclusion of measures in the CQMC 
Core Sets does not necessitate retention in the ASCQR Program.
---------------------------------------------------------------------------

    \199\ Core Measures. Retrieved from: https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/QualityMeasures/Core-Measures.html.
---------------------------------------------------------------------------

    Comment: A few commenters stated that ASC-10 and ASC-12 assess 
distinct different aspects of colonoscopies, because ASC-12 focuses on 
care coordination and does not evaluate the interval between 
colonoscopies or the appropriate use of care. One commenter notes that 
ASC-10 and ASC-12 fall into different Meaningful Measures categories, 
Preventable Healthcare Harm and Admissions and Readmissions, 
respectively.
    Response: We thank the commenters for their feedback. We agree that 
ASC-10 and ASC-12 assess distinct clinical areas, but do assess the 
topic of colonoscopies generally. While ASC-12 tracks adverse patient 
outcomes that result in unplanned hospital visits, ASC-10 provides 
information about colonoscopies occurring at inappropriate intervals 
for beneficiaries that may contribute to increased costs to 
beneficiaries and to CMS, a priority of

[[Page 59128]]

our Meaningful Measures Initiative. However, we believe ASC-10 should 
be removed because it is uniquely burdensome, as described above, and 
because our retention of ASC-9 allows us to continue to address 
inappropriate use of colonoscopy screening.
    After consideration of the public comments we received, we are 
finalizing our proposal to remove ASC-10: Endoscopy/Polyp Surveillance: 
Colonoscopy Interval for Patients with a History of Adenomatous 
Polyps--Avoidance of Inappropriate Use from the ASCQR Program beginning 
with the CY 2021 payment determination and for subsequent years, as 
proposed. We refer readers to section XIII.B.4.b. of this final rule 
with comment period where we are removing a similar measure from the 
Hospital OQR Program.
 Proposal To Remove ASC-11: Cataracts: Improvement in Patient's 
Visual Function Within 90 Days Following Cataract Surgery
    We refer readers to the CY 2014 OPPS/ASC final rule with comment 
period (78 FR 75129) where we adopted ASC-11: Cataracts: Improvement in 
Patient's Visual Function within 90 Days Following Cataract Surgery 
(NQF #1536) beginning with the CY 2016 payment determination. This 
measure assesses the rate of patients 18 years and older (with a 
diagnosis of uncomplicated cataract) in a sample who had improvement in 
visual function achieved within 90 days following cataract surgery 
based on completing both a preoperative and postoperative visual 
function survey.
    Since the adoption of this measure, we came to believe that it can 
be operationally difficult for ASCs to collect and report the measure 
(79 FR 66984). Specifically, we were concerned that the results of the 
survey used to assess the preoperative and post-operative visual 
function of the patient may not be shared across clinicians and 
facilities, making it difficult for ASCs to have knowledge of the 
visual function of the patient before and after surgery (79 FR 66984). 
We were also concerned about the surveys used to assess visual 
function; the measure allows for the use of any validated survey and 
results may be inconsistent should clinicians use different surveys (79 
FR 66984). Therefore, on December 31, 2013, we issued guidance stating 
that we would delay data collection for ASC-11 for three (3) months 
(data collection would commence with April 1, 2014 encounters) for the 
CY 2016 payment determination (https://www.qualitynet.org/dcs/ContentServer?c=Page&pagename=QnetPublic%2FPage%2FQnetTier3&cid=1228772879036). We issued additional guidance on April 2, 2014, stating that we 
would further delay the implementation of ASC-11 for an additional 9 
months, until January 1, 2015 for the CY 2016 payment determination, 
due to continued concerns (https://www.qualitynet.org/dcs/ContentServer?c=Page&pagename=QnetPublic%2FPage%2FQnetTier3&cid=1228773811586). As a result of these concerns, in the CY 2015 OPPS/ASC final 
rule with comment period (79 FR 66984 through 66985), we finalized our 
proposal to allow voluntary data collection and reporting of this 
measure beginning with the CY 2017 payment determination and for 
subsequent years.
    In the proposed rule, we proposed to remove ASC-11: Cataracts: 
Improvement in Patient's Visual Function within 90 Days Following 
Cataract Surgery from the ASCQR Program beginning with the CY 2021 
payment determination under proposed measure removal Factor 8, the 
costs associated with the measure outweigh the benefit of its continued 
use in the program. We originally adopted ASC-11 because we believe 
ASCs should be a partner in care with physicians and other clinicians 
using their facility and that this measure would provide an opportunity 
to do so (79 FR 66984). However, in light of the history of 
complications and upon reviewing this measure within our Meaningful 
Measures framework, we have concluded that it is overly burdensome for 
ASCs to report this measure due to the difficulty of tracking care that 
occurs outside of the ASC setting.
    In order to report on this measure to CMS, a facility would need to 
obtain the visual function assessment results from the appropriate 
ophthalmologist and ensure that the assessment utilized is validated 
for the population for which it is being used. If the assessment is not 
able to be used or is not available, the ASC would then need to 
administer the survey directly and ensure that the same visual function 
assessment tool is utilized preoperatively and postoperatively. There 
is no simple, preexisting means for information sharing between 
ophthalmologists and ASCs, so an ASC would need to obtain assessment 
results from each individual patient's ophthalmologist both 
preoperatively and postoperatively. The high administrative costs of 
the technical tracking of this information presents an undue cost, and 
also burden associated with submission and reporting of ASC-11 to CMS, 
especially for small ASCs with limited staffing capacity.
    Furthermore, this measure currently provides limited benefits. 
Since making the measure voluntary, only 118 ASCs have reported this 
measure to CMS, compared to approximately 5,121 total ASCs for all 
other measures, resulting in only 2.3 percent of ASC reporting.\200\ 
Consequently, we have been unable to uniformly offer pertinent 
information to beneficiaries on how the measure assesses ASC 
performance. This reinforces comments made in the CY 2015 OPPS/ASC 
final rule with comment period, in which commenters expressed concern 
that the voluntary reporting of this measure would result in incomplete 
data that may be confusing to beneficiaries and other consumers (79 FR 
66984). As we state in section I.A.2. of the proposed rule and this 
final rule with comment period, we strive to ensure that beneficiaries 
are empowered to make decisions about their healthcare using 
information from data-driven insights. Because of the lack of 
sufficient data, this measure may be difficult for beneficiaries to 
interpret or use to aid in their choice of where to obtain care; thus, 
the benefits of this measure are limited.
---------------------------------------------------------------------------

    \200\ ASCQR Compare Data. Available at: https://data.medicare.gov/Hospital-Compare/Ambulatory-Surgical-Quality-Measures-Facility/4jcv-atw7/data.
---------------------------------------------------------------------------

    Therefore, we stated that we believed the high technical and 
administrative costs of this measure outweigh the limited benefit 
associated with its continued use in the ASCQR Program. As discussed in 
section I.A.2. of the proposed rule and this final rule with comment 
period, our Meaningful Measures Initiative is intended to reduce costs 
and minimize burden. We believed that removing this measure from the 
ASCQR Program will reduce program burden, costs, and complexity. As a 
result, we proposed to remove ASC-11 beginning with the CY 2021 payment 
determination and for subsequent years. We also proposed to remove a 
similar measure under the Hospital OQR Program in section XIII.B.4.b. 
of the proposed rule.
    Comment: A few commenters opposed all of CMS' proposals to remove 
measures, including ASC-11.
    Response: In response to the commenters who requested that 
measures, including ASC-11, be retained, we reevaluated our measures 
and data. We found that a core group of ASCs (between 107 and 137 for 
each year between the CY 2017 through CY 2019 payment determinations) 
report on this voluntary measure. Although only a subset of ASCs 
voluntarily report this measure, we believe it is considered

[[Page 59129]]

very meaningful by those ASCs that do report because these facilities 
do so consistently (38 ASCs submitted consistently for the CY 2017 
through CY 2019 payment determinations). Because this subset of ASCs 
has consistently reported this measure we are able to make the data 
publicly available year after year--in this case, for the CYs 2017, 
2018, and 2019 payment determinations.\201\ We think providing data on 
this voluntary measure is still helpful for the public because it shows 
how an ASC performs over time and in comparison to other ASCs even if 
compared to a small group of ASCs.
---------------------------------------------------------------------------

    \201\ Hospital Compare ASCQR: https://www.medicare.gov/hospitalcompare/asc-ascqr.html.
---------------------------------------------------------------------------

    Furthermore, this is the only measure in the ASCQR Program measure 
set that deals with cataract surgery, which is commonly performed in 
the ASC setting. If it is removed, the program will have a gap in 
coverage for this clinical area. As a result, we now believe that 
meaningful information can be provided to consumers regarding those 
facilities. In addition, when this measure was made voluntary in the CY 
2015 OPPS/ASC final rule with comment period (79 FR 66984) commenters 
stated that the measure would promote and improve care coordination 
among providers.
    Furthermore, we have reassessed our evaluation that the costs of 
this measure outweigh the benefits. Due to the voluntary nature of the 
measure, we believe that it is inherently not more burdensome than 
valuable. Because ASCs are not required to submit data, those that do 
not have the capacity to report, do not have to, thus creating no extra 
burden. Those that do report, do so voluntarily and have continued to 
report over the years--specifically since the CY 2015 reporting 
period--despite any burdens. Because of this, we believe the measure is 
meaningful to the core group of facilities that do consistently report.
    Therefore, we are not finalizing our proposal to remove ASC-11: 
Cataracts: Improvement in Patient's Visual Function within 90 Days 
Following Cataract Surgery from the ASCQR Program beginning with the CY 
2021 payment determination and for subsequent years. This measure will 
remain in the program under our measure retention policies, unless we 
take future action under our measure removal policies.
    Comment: Many commenters supported all of CMS' proposals to remove 
measures from the ASCQR Program. Several commenters specifically 
supported CMS' proposal to remove ASC-11 and agreed with CMS' 
assessment that the costs of this measure outweigh the benefit of 
retaining it in the ASCQR Program. One commenter remarked that the lack 
of consistent data and the difficulty of abstracting the data from 
ophthalmologists' medical records posed a significant and unacceptable 
data collection burden for the measure. One commenter recommended that 
CMS remove ASC-11 beginning with the CY 2020 payment determination, so 
that ASCs may shift resources dedicated to operationalizing the measure 
sooner.
    Response: We thank the commenters for their support. As noted in 
the proposed rule, we agree that data collection for this measure may 
be difficult, and as a result in the CY 2015 OPPS/ASC final rule with 
comment period (79 FR 66984 through 66985), we finalized our proposal 
to allow voluntary data collection and reporting of this measure 
beginning with the CY 2017 payment determination and for subsequent 
years. However, we believe ASCs should be a partner in care with 
physicians and other clinicians using their facility and this measure 
is an opportunity for hospitals to demonstrate this capability if they 
choose to report it. In addition, as noted above, we no longer believe 
that the costs of this measure outweigh the benefits, as the measure is 
meaningful. Further, while data collection for this measure can be 
difficult, those facilities that choose to report do so year after year 
despite any burdens.
    Comment: Several commenters noted that the measure was endorsed by 
the NQF as a physician-level, rather than facility-level, measure and 
that therefore it was never intended for the ASC setting. A few 
commenters noted that the measure is included in the MIPS (former PQRS 
Program) as a clinician-level measure and is therefore redundant in the 
ASC setting. One commenter noted that as a voluntary measure, ASC-11 
did not have widespread participation and therefore had minimal impact 
on the care of patients.
    Response: As we noted when we adopted this measure (78 FR 75125), 
it was specified for the ASC setting and field tested at the ASC 
facility setting level by the measure steward. We believe it is 
important for ASCs to be active partners in ensuring improvement in 
patients' visual function following cataract surgeries. As commenters 
correctly noted, this same measure is available through MIPS in the QPP 
and, although MIPS-eligible clinicians may voluntarily select measures 
from a list of options, and we expect a portion of MIPS-eligible 
clinicians reporting on the measure nationwide to provide meaningful 
data to CMS about this important outcome for beneficiaries. We agree 
that as a voluntary measure that only a subset of ASCs participating in 
the ASCQR Program reported on the measure, but note it is a meaningful 
measure to beneficiaries given that our analyses show that a consistent 
group of facilities report data on this measure. So, while data is not 
available for all facilities, the data that is available is meaningful.
    After consideration of the public comments we received, we are not 
finalizing our proposal to remove ASC-11: Cataracts: Improvement in 
Patient's Visual Function within 90 Days Following Cataract Surgery 
from the ASCQR Program beginning with the CY 2021 payment determination 
and for subsequent years. We also note that we are retaining a similar 
measure under the Hospital OQR Program, OP-31: Cataracts: Improvement 
in Patient's Visual Function within 90 Days Following Cataract Surgery 
in section XIII.B.4.b.(2)(a) of this final rule with comment period.
4. ASCQR Program Quality Measures Adopted in Previous Rulemaking
    We refer readers to the CY 2018 OPPS/ASC final rule with comment 
period (82 FR 59470) for the previously finalized ASCQR Program measure 
set for the CY 2020 payment determination and subsequent years.
5. Summary of ASCQR Program Quality Measure Sets Finalized for the CY 
2020, CY 2021, and CY 2022 Payment Determinations
    In the CY 2019 OPPS/ASC proposed rule, we did not propose any new 
measures for the ASCQR Program. The tables below summarize the ASCQR 
Program measure sets as finalized in this final rule with comment 
period for the CY 2020, 2021, and 2022 payment determinations 
(including previously adopted measures and measures finalized for 
removal in this final rule with comment period). We note that the 
tables reflect that we are finalizing our proposal to change the 
reporting period for one previously adopted measure, ASC-12, and we 
refer readers to section

[[Page 59130]]

XIV.D.4.b. of this final rule with comment period for details.
BILLING CODE 4120-01-P
[GRAPHIC] [TIFF OMITTED] TR21NO18.112



[[Page 59131]]

[GRAPHIC] [TIFF OMITTED] TR21NO18.113



[[Page 59132]]

[GRAPHIC] [TIFF OMITTED] TR21NO18.114

BILLING CODE 4120-01-C
6. ASCQR Program Measures and Topics for Future Consideration: Possible 
Future Validation of ASCQR Program Measures
    In the CY 2019 OPPS/ASC proposed rule (83 FR 37204), we requested 
public comment on the possible future validation of ASCQR Program 
measures. There is currently no validation of ASCQR measure data, and 
we believe ASCs may benefit from the opportunity to better understand 
their data and examine potential discrepancies. We believe the ASCQR 
Program may similarly benefit from the opportunity to produce a more 
reliable estimate of whether an ASC's submitted data have been 
abstracted correctly and provide more statistically reliable estimates 
of the quality of care delivered in each selected ASC as well as at the 
national level. We believe the Hospital OQR Program validation policy 
could be a good model for the ASCQR Program and are requesting comment 
on the validation methodology and identifying one measure with which to 
start.
    The Hospital OQR Program requires validation of its chart-
abstracted measures. We refer readers to the CY 2013 OPPS/ASC final 
rule with comment period (77 FR 68484 through 68487) and the CY 2015 
OPPS/ASC final rule with comment period (79 FR 66964 through 66965) for 
a discussion of finalized policies regarding Hospital OQR Program 
validation requirements, which are also codified at 42 CFR 419.46(e). 
Under the Hospital OQR Program, CMS selects a random sample of 450 
hospitals and an additional 50 hospitals based on the following 
criteria: (1) The hospital failing of the validation requirement that 
applies to the previous year's payment determination; or (2) the 
hospital having an outlier value for a measure based on data that it 
submits. An ``outlier value'' is defined as a measure value that is 
greater than 5 standard deviations from the mean of the measure values 
for other hospitals, and indicates a poor score. Then, CMS or its 
contractor provides written requests to the randomly selected hospitals 
by requesting

[[Page 59133]]

supporting medical record documentation used for purposes of data 
submission under the program. The hospital must submit the supporting 
medical record documentation within 45 days of the date written in the 
request. A hospital meets the validation requirement with respect to a 
calendar year if it achieves at least a 75 percent reliability score, 
as determined by CMS.
    Specifically, for the ASCQR Program, we are interested in the 
validation of chart-abstracted measures. We believe it would be 
beneficial to start with validation of just one measure, such as ASC-
13: Normothermia Outcome, prior to expanding to more measures. ASC-13: 
Normothermia Outcome was finalized in the 2017 OPPS/ASC final rule with 
comment period (81 FR 79798 through 79801) and assesses the percentage 
of patients having surgical procedures under general or neuraxial 
anesthesia of 60 minutes or more in duration who are normothermic 
within 15 minutes of arrival in the post-anesthesia care unit. We also 
considered starting with ASC-14: Unplanned Anterior Vitrectomy instead, 
which was finalized in the 2017 OPPS/ASC final rule with comment period 
(81 FR 79801 through 79803) and assesses the percentage of cataract 
surgery patients who have an unplanned anterior vitrectomy. However, we 
believe ASC-13 would be the most feasible measure for validation 
because it assesses surgical cases and would have a larger population 
of cases from which to sample. ASC-14, which assesses rare, unplanned 
events that are less common, would have a smaller population of cases 
from which to sample.
    Therefore, we invited public comment on the possible future 
validation of ASCQR Program measures. We specifically request comment 
on whether Hospital OQR Program's validation policies could be an 
appropriate model for the ASCQR Program, the possible ASC sample size, 
sampling methodology, number of cases to sample, validation score 
methodology, and reduced annual payment updates for facilities that do 
not pass validation requirements. We also requested comment on possibly 
starting with only one measure, specifically ASC-13, before expanding 
to more measures.
    Comment: A few commenters supported the possible validation of 
ASCQR Program data through a program similar to Hospital OQR Program 
validation. These commenters noted that this would further align the 
programs and provide accountability for the accuracy of reporting.
    Response: We thank the commenters for their support.
    Comment: One commenter opposed validation of ASCQR Program 
measures, citing the cost and burden to providers and CMS. This 
commenter recommended that CMS instead invest in ways to receive 
timelier and meaningful data related to patient quality and safety. One 
commenter was concerned about the burden to ASCs of the validation 
process due to the low level of EHR adoption among ASCs as compared to 
hospital outpatient departments, noting that the majority of ASCs may 
need to submit paper records.
    Response: We thank the commenters for their feedback regarding 
additional program impact of validation for the ASCQR Program. As noted 
above, we will take facility burden into consideration regarding the 
selection of measures for the potential future validation of ASCQR 
Program measures.
    Comment: One commenter was concerned that setting the sample size 
of ASCs at or around 500, comparable to Hospital OQR Program, would 
represent a significantly larger percentage of ASCs reporting chart-
abstracted measures under the ASCQR Program than under the Hospital OQR 
Program. The commenter recommended that a smaller number of ASCs be 
selected for validation, perhaps based on the percentage of HOPDs 
selected for validation under the Hospital OQR Program. Another 
commenter stated that a similar random sample to the Hospital OQR 
Program (450 ASCs) could be utilized, as well as an additional number 
of ASC's with outlier values. One commenter was concerned about ASCs 
that fail to record adverse events and recommended that CMS develop 
additional sampling criteria based on selecting ASCs that have a ``good 
score'' outlier rate.
    Response: We thank the commenters for their suggestions regarding 
sampling for any validation scheme considered for the ASCQR Program and 
will take these into consideration as we move forward.
    Comment: A few commenters supported beginning validation with only 
one measure, with one noting it would allow participants time to 
understand the program and its implications for payment. Some 
commenters supported using ASC-13 as an initial measure for validation 
within the ASCQR Program, with a few commenters noting it is an 
important and prescient measure for outpatient settings.
    Response: We thank the commenters for their feedback supporting 
validation for the ASCQR Program and the possible use of ASC-13 for 
this purpose. We agree that it is most feasible to begin potential 
future validation of measures in the ASCQR Program with a single 
measure.
    Comment: A few commenters expressed concern about using ASC-13 as 
an initial measure for validation within the ASCQR Program. One 
commenter noted their belief that ASC-13 is not indicative of care at 
an ASC. Another commenter expressed concern that ASC-13 is reported as 
a sample with an aggregated-web based metric and that patient-level 
information is not submitted by ASCs. One commenter was concerned about 
incongruent definitions of normothermia among quality reporting 
programs and recommended that if discrepancies are found during the 
validation process that anesthesia professionals be held harmless. 
Another commenter stated that ASC-14 would be a better initial measure 
for validation, noting that cases requiring general or neuraxial 
anesthesia are less common than cataract surgery and would likely have 
a smaller population of cases from which to sample.
    Response: We thank the commenters for their feedback and will 
further examine ASC-13 and ASC-14 case volumes, appropriate methods of 
validation of aggregated web-based metrics, and normothermia 
definitions among quality reporting programs.
    Comment: A commenter noted that not all ASCs report data for ASC-13 
and ASC-14 due to not performing cases involving general/neuraxial 
anesthesia of 60 minutes or more in duration (ASC-13) and/or cataract 
surgery (ASC-14), and noted their concern that ASCs that do report 
these measure would bear more burden and be required to meet a higher 
threshold for retaining their APU. The commenter recommended only 
selecting measures for validation that are applicable to all ASCs. 
Another commenter recommended that all measures should be validated, 
with the prioritization for ASC-1, ASC-2, and ASC-3 in order to study 
closely the occurrence of adverse events. A commenter recommended that 
the ASCQR Program implement validation only when more manually 
abstracted measures are added to the program, noting that implementing 
a validation process for a small number of measures is burdensome and 
may yield only limited value to CMS.
    Response: We thank the commenters for their feedback regarding 
alternate measures to consider for validation under the ASCQR Program. 
We agree that the percentage of ASCs actually reporting on a measure is 
an important

[[Page 59134]]

consideration in choosing measures for validation. We will investigate 
the feasibility of validating ASC-1, ASC-2, and ASC-3. We will further 
assess the potential burden impact of the potential future validation 
of any ASCQR Program measures. We note that one of the goals of our 
Meaningful Measures Initiative is to move the ASCQR Program forward in 
the least burdensome manner possible, while maintaining a parsimonious 
set of meaningful quality measures.
    Comment: One commenter was concerned that ASCs submit aggregated 
web-based data on an annual basis and that sampling is allowed for the 
submission of ASC-13 data without patient identifying information. The 
commenter recommended that CMS consider selection bias if ASC-13 data 
is validated.
    Response: We thank the commenter for its feedback and agree that 
there is a potential for selection bias if the aggregated web-based 
data for ASC-13 is validated. We will take this potential for selection 
bias into consideration as we craft future policy.
    We thank the commenters for their views and will take them into 
consideration as we determine future policy regarding validation in the 
ASCQR Program.
7. Maintenance of Technical Specifications for Quality Measures
    We refer readers to the CY 2012 OPPS/ASC final rule with comment 
period (76 FR 74513 through 74514), where we finalized our proposal to 
follow the same process for updating the ASCQR Program measures that we 
adopted for the Hospital OQR Program measures, including the 
subregulatory process for updating adopted measures. In the CY 2013 
OPPS/ASC final rule with comment period (77 FR 68496 through 68497), 
the CY 2014 OPPS/ASC final rule (78 FR 75131), and the CY 2015 OPPS/ASC 
final rule with comment period (79 FR 66981), we provided additional 
clarification regarding the ASCQR Program policy in the context of the 
previously finalized Hospital OQR Program policy, including the 
processes for addressing nonsubstantive and substantive changes to 
adopted measures. In the CY 2016 OPPS/ASC final rule with comment 
period (80 FR 70531), we provided clarification regarding our decision 
to not display the technical specifications for the ASCQR Program on 
the CMS website, but stated that we will continue to display the 
technical specifications for the ASCQR Program on the QualityNet 
website. In addition, our policies regarding the maintenance of 
technical specifications for the ASCQR Program are codified at 42 CFR 
416.325. In the CY 2019 OPPS/ASC proposed rule (83 FR 37204), we did 
not propose any changes to our policies regarding the maintenance of 
technical specifications for the ASCQR Program.
8. Public Reporting of ASCQR Program Data
    In the CY 2012 OPPS/ASC final rule with comment period (76 FR 74514 
through 74515), we finalized a policy to make data that an ASC 
submitted for the ASCQR Program publicly available on a CMS website 
after providing an ASC an opportunity to review the data to be made 
public. In the CY 2016 OPPS/ASC final rule with comment period (80 FR 
70531 through 70533), we finalized our policy to publicly display data 
by the National Provider Identifier (NPI) when the data are submitted 
by the NPI and to publicly display data by the CCN when the data are 
submitted by the CCN. In addition, we codified our policies regarding 
the public reporting of ASCQR Program data at 42 CFR 416.315 (80 FR 
70533). In the CY 2017 OPPS/ASC final rule with comment period (81 FR 
79819 through 79820), we formalized our current public display 
practices regarding timing of public display and the preview period by 
finalizing our proposals to: Publicly display data on the Hospital 
Compare website, or other CMS website as soon as practicable after 
measure data have been submitted to CMS; to generally provide ASCs with 
approximately 30 days to review their data before publicly reporting 
the data; and to announce the timeframes for each preview period 
starting with the CY 2018 payment determination on a CMS website and/or 
on our applicable listservs. In the CY 2018 OPPS/ASC final rule with 
comment period (82 FR 59455 through 59470), we discussed specific 
public reporting policies associated with two measures beginning with 
the CY 2022 payment determination: ASC-17: Hospital Visits after 
Orthopedic Ambulatory Surgical Center Procedures, and ASC-18: Hospital 
Visits after Urology Ambulatory Surgical Center Procedures.
    In the CY 2019 OPPS/ASC proposed rule (83 FR 37204 through 37205), 
we did not propose any changes to our public reporting policies.

C. Administrative Requirements

1. Requirements Regarding QualityNet Account and Security Administrator
    We refer readers to the CY 2014 OPPS/ASC final rule with comment 
period (78 FR 75132 through 75133) for a detailed discussion of the 
QualityNet security administrator requirements, including setting up a 
QualityNet account, and the associated timelines, for the CY 2014 
payment determination and subsequent years. In the CY 2016 OPPS/ASC 
final rule with comment period (80 FR 70533), we codified the 
administrative requirements regarding maintenance of a QualityNet 
account and security administrator for the ASCQR Program at 42 CFR 
416.310(c)(1)(i). In the CY 2018 OPPS/ASC final rule (82 FR 59473), we 
finalized expanded submission via the CMS online tool to also allow for 
batch data submission and made corresponding changes to the 42 CFR 
416.310(c)(1)(i). In the CY 2019 OPPS/ASC proposed rule (83 FR 37205), 
we did not propose any changes to these policies.
2. Requirements Regarding Participation Status
    We refer readers to the CY 2014 OPPS/ASC final rule with comment 
period (78 FR 75133 through 75135) for a complete discussion of the 
participation status requirements for the CY 2014 payment determination 
and subsequent years. In the CY 2016 OPPS/ASC final rule with comment 
period (80 FR 70533 and 70534), we codified these requirements 
regarding participation status for the ASCQR Program at 42 CFR 416.305. 
In the CY 2019 OPPS/ASC proposed rule (83 FR 37205), we did not propose 
any changes to these policies.

D. Form, Manner, and Timing of Data Submitted for the ASCQR Program

1. Requirements Regarding Data Processing and Collection Periods for 
Claims-Based Measures Using Quality Data Codes (QDCs)
    We refer readers to the CY 2014 OPPS/ASC final rule with comment 
period (78 FR 75135) for a complete summary of the data processing and 
collection periods for the claims-based measures using QDCs for the CY 
2014 payment determination and subsequent years. In the CY 2016 OPPS/
ASC final rule with comment period (80 FR 70534), we codified the 
requirements regarding data processing and collection periods for 
claims-based measures using QDCs for the ASCQR Program at 42 CFR 
416.310(a)(1) and (2).
    In the CY 2019 OPPS/ASC proposed rule (83 FR 37205), we did not 
propose any changes to these requirements. However, in the proposed 
rule we noted that in section XIV.B.3.c. of the proposed rule, 
beginning with the CY 2021 payment determination and for subsequent 
years, we proposed to

[[Page 59135]]

remove all four claims-based measures currently using QDCs:
     ASC-1: Patient Burn;
     ASC-2: Patient Fall;
     ASC-3: Wrong Site, Wrong Side, Wrong Patient, Wrong 
Procedure, Wrong Implant; and
     ASC-4: Hospital Transfer/Admission.
    We are not finalizing our proposals to remove ASC-1, ASC-2, ASC-3, 
and ASC-4, as described further in section XIV.B.3.c.(2)(a) of this 
final rule with comment period, and are instead retaining the measures 
in the ASCQR Program and suspending their data collection beginning 
with the CY 2019 reporting period/CY 2021 payment determination until 
further action in rulemaking with the goal of updating the measures. 
However, we did not propose any changes to our requirements regarding 
data processing and collection periods for these types of measures. 
These requirements will apply to any future claims-based measures using 
QDCs adopted in the program.
2. Minimum Threshold, Minimum Case Volume, and Data Completeness for 
Claims-Based Measures Using QDCs
    We refer readers to the CY 2018 OPPS/ASC final rule with comment 
period (82 FR 59472) (and the previous rulemakings cited therein), as 
well as 42 CFR 416.310(a)(3) and 42 CFR 416.305(c) for our policies 
about minimum threshold, minimum case volume, and data completeness for 
claims-based measures using QDCs. In the CY 2019 OPPS/ASC proposed rule 
(83 FR 37205), we did not propose any changes to these policies.
3. Requirements for Data Submitted via an Online Data Submission Tool
    We refer readers to the CY 2018 OPPS/ASC final rule with comment 
period (82 FR 59472) (and the previous rulemakings cited therein) and 
42 CFR 416.310(c) for our previously finalized policies for data 
submitted via an online data submission tool. For more information on 
data submission using QualityNet, we refer readers to: https://
www.qualitynet.org/dcs/
ContentServer?c=Page&pagename=QnetPublic%2&FPage%2FQnetTier2&cid=122
8773314768.
a. Requirements for Data Submitted via a Non-CMS Online Data Submission 
Tool
    We refer readers to the CY 2014 OPPS/ASC final rule with comment 
period (78 FR 75139 through 75140) and the CY 2015 OPPS/ASC final rule 
with comment period (79 FR 66985 through 66986) for our requirements 
regarding data submitted via a non-CMS online data submission tool 
(that is, the CDC NHSN website). We codified our existing policies 
regarding the data collection time periods for measures involving 
online data submission and the deadline for data submission via a non-
CMS online data submission tool at 42 CFR 416.310(c)(2).
    Currently, we only have one measure (ASC-8: Influenza Vaccination 
Coverage among Healthcare Personnel) that is submitted via a non-CMS 
online data submission tool. In the proposed rule, we noted that we 
proposed this measure for removal for the CY 2020 payment determination 
and subsequent years in section XIV.B.3.c. of the proposed rule. 
Because we are finalizing the removal of ASC-8 as proposed, no measures 
submitted via a non-CMS online data submission tool will remain in the 
ASCQR Program beginning with the CY 2020 payment determination. 
However, we did not propose any changes to our non-CMS online data 
submission tool reporting requirements; these requirements would apply 
to any future non-CMS online data submission tool measures adopted in 
the program.
b. Requirements for Data Submitted via a CMS Online Data Submission 
Tool
    We refer readers to the CY 2018 OPPS/ASC final rule with comment 
period (82 FR 59473) (and the previous rulemakings cited therein) and 
42 CFR 416.310(c)(1) for our requirements regarding data submitted via 
a CMS online data submission tool. We are currently using the 
QualityNet website as our CMS online data submission tool: https://www.qualitynet.org/dcs/ContentServer?c=Page&pagename=QnetPublic%2FPage%2FQnetHomepage&cid=1120143435383. We note that in the CY 2018 OPPS/ASC final rule with comment 
period (82 FR 59473), we finalized expanded submission via the CMS 
online tool to also allow for batch data submission and made 
corresponding changes to the 42 CFR 416.310(c)(1)(i).
    In the CY 2019 OPPS/ASC proposed rule (83 FR 37205 through 37206), 
we did not propose any changes to this policy. However, in the proposed 
rule we noted that in sections XIV.B.3.c. of the proposed rule, we 
proposed to remove three measures collected via a CMS online data 
submission tool--ASC-9: Endoscopy/Polyp Surveillance: Appropriate 
Follow-Up Interval for Normal Colonoscopy in Average Risk Patients, 
ASC-10: Endoscopy/Polyp Surveillance: Colonoscopy Interval for Patients 
with a History of Adenomatous Polyps--Avoidance of Inappropriate Use, 
and ASC-11: Cataracts: Improvement in Patients' Visual Function within 
90 Days Following Cataract Surgery \202\ beginning with the CY 2021 
payment determination. Because we are finalizing ASC-10 for removal as 
proposed and are not finalizing our proposals to remove ASC-9 and ASC-
11 in the ASCQR Program measure set (these measures will remain in the 
program), the following measures will require data to be submitted via 
a CMS online data submission tool for the CY 2021 payment determination 
and subsequent years:
---------------------------------------------------------------------------

    \202\ We note that the ASC-11 measure is voluntarily collected 
effective beginning with the CY 2017 payment determination, as set 
forth in section XIV.E.3.c. of the CY 2015 OPPS/ASC final rule with 
comment period (79 FR 66984 through 66985).

 ASC-9: Endoscopy/Polyp Surveillance: Appropriate Follow-Up 
Interval for Normal Colonoscopy in Average Risk Patients
 ASC-11: Cataracts: Improvement in Patients' Visual Function 
within 90 Days Following Cataract Surgery
 ASC-13: Normothermia Outcome
 ASC-14: Unplanned Anterior Vitrectomy
4. Requirements for Non-QDC Based, Claims-Based Measure Data
    In the CY 2019 OPPS/ASC proposed rule (83 FR 37206 through 37207), 
we did not propose any changes to our requirements for non-QDC based, 
claims-based measures. However, in the proposed rule we proposed to 
change the reporting period for the previously adopted measure, ASC-12: 
Facility 7-Day Risk-Standardized Hospital Visit Rate after Outpatient 
Colonoscopy. This proposal is discussed in more detail further below.
a. General
    We refer readers to the CY 2015 OPPS/ASC final rule with comment 
period (79 FR 66985) and the CY 2016 OPPS/ASC final rule with comment 
period (80 FR 70536) for our previously adopted policies regarding data 
processing and reporting periods for claims-based measures for the CY 
2018 payment determination and subsequent years. In addition, in the CY 
2016 OPPS/ASC final rule with comment period (80 FR 70536), we codified 
these policies at 42 CFR 416.310(b). In the proposed rule, we did not 
propose any changes to these policies. We note that the non-QDC, 
claims-based measures in the program are as follows:

 CY 2020 payment determination and subsequent years: ASC 12: 
Facility 7-Day Risk Standardized Hospital Visit Rate after Outpatient 
Colonoscopy (79 FR 66970 through 66978)

[[Page 59136]]

 CY 2022 payment determination and subsequent years:
 ASC-17: Hospital Visits after Orthopedic Ambulatory 
Surgical Center Procedures (82 FR 59455 through 59470)
 ASC-18: Hospital Visits after Urology Ambulatory 
Surgical Center Procedures (82 FR 59455 through 59470)
b. Extension of the Reporting Period for ASC-12: Facility Seven-Day 
Risk-Standardized Hospital Visit Rate After Outpatient Colonoscopy
    In the CY 2015 OPPS/ASC final rule with comment period (79 FR 66970 
through 66978), we finalized the adoption of ASC-12: Facility 7-Day 
Risk-Standardized Hospital Visit Rate after Outpatient Colonoscopy into 
the ASCQR Program for the CY 2018 payment determination and subsequent 
years, with public display to begin on or after December 1, 2017. This 
measure is calculated with data obtained from paid Medicare FFS claims 
(79 FR 66978). For this reason, facilities are not required to submit 
any additional information. In that final rule with comment period, we 
also finalized the reporting period for measure calculation as claims 
data from two calendar years prior to the payment determination year. 
Specifically, for the CY 2018 payment determination, we stated we would 
use paid Medicare FFS claims from January 1, 2016 to December 31, 2016 
to calculate measure results (79 FR 66985). We finalized a 1-year 
reporting period as it adequately balanced competing interests of 
measure reliability and timeliness for payment determination purposes, 
and explained that we would continue to assess this during the dry run 
(79 FR 66973).
    We noted we would complete a dry run of the measure in 2015 using 
three or four years of data, and, from the results of this dry run, we 
would review the appropriate volume cutoff for facilities to ensure 
statistical reliability in reporting the measure score (79 FR 66974). 
Our analyses of the 2015 dry run using data from July 2011 through June 
2014 showed that a reporting period of one year had moderate to high 
reliability for measure calculation. Specifically, using data from July 
2013 through June 2014, we calculated facility-level reliability 
estimates as the ratio of true variance to observed variance.\203\ 
Consistent with the original measure specifications as described in the 
2014 technical report,\204\ this calculation was performed combining 
the measure results for HOPDs and ASCs. We found that for a facility 
with median case size, the reliability estimate was high (over 0.90), 
but the minimum reliability estimate for facilities with 30 cases (the 
minimum case size chosen for public reporting) was only moderate (that 
is, between 0.40 and 0.60).\205\
---------------------------------------------------------------------------

    \203\ Snijders TA, Bosker RJ. Multilevel Analysis: An 
introduction to basic and advanced multilevel modeling. SAGE 
Publications. 2000. London.
    \204\ Additional methodology details and information obtained 
from public comments for measure development are available at: 
https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/HospitalQualityInits/Measure-Methodology.html under 
``Hospital Outpatient Colonoscopy.''
    \205\ Landis JR, Koch GG. The Measurement of Observer Agreement 
for Categorical Data. Biometrics. 1977;33(1):159-174.
---------------------------------------------------------------------------

    However, after the 2015 dry run, CMS calculated the HOPD and ASC 
scores separately to compare similar types of facilities to each other. 
During subsequent analysis of the 1-year reporting period of July 2013 
through June 2014, we confirmed that a 1-year reporting period with 
separate calculations for HOPDs and ASCs was sufficient, but did result 
in lower reliability and decreased precision, compared to results 
calculated with longer reporting periods (two or three years). Based on 
analyses conducted using data from July 2013 through June 2014 (1-year 
reporting period) and 2017 measure specifications,\206\ we found that 
the median facility-level reliability was 0.74 for ASCs and 0.51 for 
HOPDs. Using a 2-year reporting period (data from July 2012-June 2014), 
we found that median facility-level reliability was 0.81 for ASCs and 
0.67 for HOPDs. When the reporting period was extended to three years 
(using data from July 2011 through June 2014), we found that median 
facility-level reliability was higher for both ASCs and HOPDs: 0.87 for 
ASCs and 0.75 for HOPDs. These results indicate that a larger portion 
of the included facilities have scores measured with higher reliability 
when three years of data are used rather than one year of data.
---------------------------------------------------------------------------

    \206\ Current and past measure specifications are available at: 
https://www.qualitynet.org/dcs/ContentServer?c=Page&pagename=QnetPublic%2FPage%2FQnetTier3&cid=1228775214597.
---------------------------------------------------------------------------

    Using three years of data, compared to just one year, is estimated 
to increase the number of ASCs with eligible cases for ASC-12 by 10 
percent, adding approximately 235 additional ASCs to the measure 
calculation. ASCs reporting the measure would increase their sample 
sizes and, in turn, increase the precision and reliability of their 
measure scores. Thus, we believe extending the reporting period to 
three years from one year for purposes of increasing reliability would 
be beneficial for providing better information to beneficiaries 
regarding the quality of care associated with low-risk outpatient 
colonoscopy procedures. In crafting our proposal, we considered 
extending the reporting period to two years beginning with the CY 2020 
payment determinations and subsequent years, but decided on proposing 
three years instead, because a higher level of reliability is achieved 
with a 3-year reporting period compared to two years.
    Therefore, in the CY 2019 OPPS/ASC proposed rule (83 FR 37206 
through 37207), we proposed to change the reporting period for ASC-12: 
Facility 7-Day Risk-Standardized Hospital Visit Rate after Outpatient 
Colonoscopy from one year to three years beginning with the CY 2020 
payment determination (which would use claims data from January 1, 2016 
through December 31, 2018) and for subsequent years. Under this 
proposal, the annual reporting requirements for ASCs would not change 
because this is a claims-based measure. However, with a 3-year 
reporting period, the most current year of data would be supplemented 
by the addition of two prior years. For example, for the CY 2020 
payment determination, we would use a reporting period of CY 2018 data 
plus two prior years of data (CYs 2016 and 2017). In the proposed rule, 
we noted that since implementation of this measure began with the CY 
2018 payment determination, we have already used paid Medicare FFS 
claims from January 1, 2016 to December 31, 2016 to calculate the 
measure scores, which have been previously previewed by ASCs and 
publicly displayed. In crafting our proposal, we also considered 
timeliness related to payment determinations and public display. 
Because we would utilize data already collected to supplement current 
data, our proposal to use three years of data would not disrupt payment 
determinations or public display. We refer readers to the table below 
for example reporting periods and public display dates corresponding to 
the CY 2020, CY 2021, and CY 2022 payment determinations:

[[Page 59137]]

[GRAPHIC] [TIFF OMITTED] TR21NO18.115

    We refer readers to section XIII.D.4.b. of the proposed rule, where 
we discussed a similar proposal under the Hospital OQR Program.
    Comment: Several commenters supported the proposed extension of the 
reporting period for ASC-12: Facility 7-Day Risk-Standardized Hospital 
Visit Rate after Outpatient Colonoscopy. A few commenters supported a 
3-year reporting period, noting that the reliability of measure data 
intended for public reporting and accountability is important and urged 
CMS to seek stakeholder feedback on developing a methodology and 
release a methodology report for public review and comment.
    Response: We thank the commenters for their support for extending 
the reporting period for ASC-12. Regarding the request to release a 
methodology report, we publish an annual update and measures 
specifications report, which is a description of the measure updates 
and measure results from reevaluation and includes detailed measure 
specifications.\207\ This report describes the measure methodology for 
a given reporting period. CMS encourages stakeholders to submit 
comments on the measure's methodology via the Outpatient and ASC 
Question and Answer tool, https://cms-ocsq.custhelp.com/.
---------------------------------------------------------------------------

    \207\ Measure Methodology. Colonoscopy measure. Available at: 
https://www.qualitynet.org/dcs/ContentServer?c=Page&pagename=QnetPublic%2FPage%2FQnetTier3&cid=1228775197506.
---------------------------------------------------------------------------

    Comment: One commenter stated that in order to make the measure 
data as reliable as possible, CMS should increase the minimum case 
volume threshold from less than thirty cases to less than one hundred 
cases.
    Response: While it is true that a higher minimum case count would 
result in a higher minimum reliability, we must balance the goal of 
adequate reliability with the goal of providing measure performance 
information on as many facilities as possible. The minimum case count 
of 30 was set during the dry run of the measure and resulted in a 
minimum reliability estimate that was ``moderate'' for those facilities 
meeting the requirement. While the measure now calculates score for 
ASCs and OPDs separately, increasing the number years used for the 
measure should increase reliability for facilities meeting this minimum 
case count. We must balance the goal of adequate reliability with the 
goal of providing timely measure information that can inform quality 
improvement efforts. A 3-year reporting period improves the reliability 
of the measure and increases the number of facilities that meet the 
minimum case count.
    Comment: A few commenters supported a 2-year reporting period, 
stating that priority interest should be giving beneficiaries critical 
information they can use today and two years of data typically yields 
the best mix of reliability and predicting performance today.
    Response: We chose to propose a 3-year reporting period for the 
colonoscopy measure because using three years of data would increase 
the number of facilities meeting minimum case count requirements and 
increase the overall reliability of each facility measure score by 
increasing sample sizes. We balance the goal of adequate reliability 
with the goal of providing timely measure information that can inform 
quality improvement efforts. A 3-year reporting period substantially 
improves the reliability of the measure, as described above. Using a 1-
year reporting period, we found that the median facility-level 
reliability was 0.74 for ASCs and 0.51 for HOPDs, and for a 2-year 
reporting period 0.81 for ASCs and 0.67 for HOPDS. However, the median 
facility-level reliability was highest for both ASCs and HOPDs using a 
3-year reporting period: 0.87 for ASCs and 0.75 for HOPDs. In addition, 
we note that using a 3-year reporting period does not affect the 
timeliness of our ability to report on this measure, as the data being 
used has already been collected. Specifically, we note that the most 
current year of data would be supplemented by the addition of two prior 
years. For example, for the CY 2020 payment determination, we would use 
a reporting period of CY 2018 data plus two prior years of data (CYs 
2016 and 2017).
    Comment: Several commenters provided general feedback on the 
measure. A few noted that the data reported for the two measures (ASC-
12 and OP-32) reflects fundamental claim and billing policy 
differences--such as the CMS three-day payment window--between the two 
settings (ASCs and HOPDs) that preclude valid comparisons, and the two 
measures should be clearly distinguished. A few commenters noted that 
the all-cause ED visit outcome is too broad and is not giving any 
specific information about the quality of care given at an endoscopy 
center, and that the measure does not help the consumer make 
distinctions among ASCs.
    Response: We thank commenters for their feedback on the measure. 
The commenter is correct that there are differences between the ASC and 
HOPD colonoscopy measures (ASC-12 and OP-32) that specifically relate 
to billing differences between the two settings. For example, for 
outpatient (HOPD) colonoscopies that occur in the three calendar days 
preceding the date of a beneficiary's inpatient admission, the facility 
claim is bundled with the inpatient claim, and therefore would not be 
identified using only outpatient facility claims. Therefore, for OP-32, 
cases subject to the 3-day payment window are identified with a 
matching algorithm that uses inpatient and physician (Medicare Part B) 
claims to attribute the colonoscopy procedure to the appropriate 
outpatient facility (HOPD).²⁰⁸ ²⁰⁹ We also 
calculate the measure scores separately for ASCs and HOPDs; HOPDs are 
only compared to other HOPDs, and ASCs to other ASCs, therefore the 
difference in methodology does not affect the overall evaluation of 
ASCs or HOPDs within each measure's calculation. Furthermore, we note 
that ASC-12 and OP-32 performance data are presented separately on 
Hospital Compare. In the future, we intend to update publicly available 
resource materials to clarify that ASC-12 and OP-32 are calculated 
separately using

[[Page 59138]]

different benchmarks and should not be compared.
---------------------------------------------------------------------------

    \208\ Ranasinghe I, Parzynski C, Searfoss S, et al. Facility 7-
Day Risk-Standardized Hospital Visit Rate after Outpatient 
Colonoscopy: A Quality Measure for Profiling Facility Performance 
Using Claims Data. 2014; https://www.qualitynet.org/dcs/ContentServer?c=Page&pagename=QnetPublic%2FPage%2FQnetTier3&cid=1228775197506. Accessed October 22, 2018.
    \209\ Version 7.0a of the ASCQR Program Specifications Manual is 
available at: https://www.qualitynet.org/dcs/ContentServer?c=Page&pagename=QnetPublic%2Page%2FSpecsManualTemplate&cid=1228776140694.
---------------------------------------------------------------------------

    In addition, we measure all-cause hospital visits (including 
Emergency department visits) to encourage OPDs and ASCs to minimize all 
types of risks that may lead to hospital visits after a colonoscopy. 
Measuring only hospital visits that are narrow procedural complications 
of colonoscopy, such as gastrointestinal bleeding, would limit the 
measure's impact on quality improvement efforts and miss events such as 
dehydration, pain, dizziness, and urinary retention that are often 
related to the colonoscopy or the preparation for the colonoscopy and 
present to the ED. From the patient's perspective, these events reflect 
the quality of care for the full episode of care. Measuring all-cause 
patient outcomes encourages facilities and their clinicians minimizes 
the risk of a broad range of outcomes. We have structured the measure 
so that OPDs and ASCs that most effectively minimize patient risk of 
these outcomes will perform better.
    While we employ a conservative approach to categorizing facility 
performance relative to the national rate, the distribution of measure 
scores for both ASC-12 and OP-32 demonstrate meaningful variation. This 
variation provides valuable information to facilities about their 
performance and the possibility for reducing complications following 
low risk colonoscopies. Using claims from January 1, 2016 through 
December 31, 2016, we characterize the degree of variability by 
calculating the median odds ratio (MOR). The median odds ratio 
represents the median increase in odds of a hospital visit if a 
procedure on a single patient was performed at a higher risk facility 
compared to a lower risk facility. Both median odds ratios indicate the 
impact of quality on the outcome rate is substantial at both ASCs and 
HOPDs.
     For HOPDs, a value of 1.23 indicates that a patient has a 
23 percent increase in the odds of a hospital visit if the same 
procedure was performed at higher risk HOPD compared to a lower risk 
HOPD.
     For ASCs, a value of 1.19 indicates that a patient has a 
19 percent increase in the odds of a hospital visit if the same 
procedure was performed at higher risk ASC compared to a lower risk 
ASC.
    After consideration of the public comments we received, we are 
finalizing our proposal to change the reporting period for ASC-12: 
Facility 7-Day Risk-Standardized Hospital Visit Rate after Outpatient 
Colonoscopy from one year to three years beginning with the CY 2020 
payment determination and for subsequent years, as proposed. We refer 
readers to section XIII.D.4.b. of this final rule with comment period, 
where we are finalizing a similar policy under the Hospital OQR 
Program.
5. Requirements for Data Submission for ASC-15a-e: Outpatient and 
Ambulatory Surgery Consumer Assessment of Healthcare Providers and 
Systems (OAS CAHPS) Survey-Based Measures
    We refer readers to the CY 2017 OPPS/ASC final rule with comment 
period (81 FR 79822 through 79824) for our previously finalized 
policies regarding survey administration and vendor requirements for 
the CY 2020 payment determination and subsequent years. In addition, we 
codified these policies at 42 CFR 416.310(e). However, in the CY 2018 
OPPS/ASC final rule with comment period (82 FR 59450 through 59451), we 
delayed implementation of the ASC-15a-e: OAS CAHPS Survey-based 
measures beginning with the CY 2020 payment determination (CY 2018 data 
submission) until further action in future rulemaking, and we refer 
readers to that discussion for more details. In the CY 2019 OPPS/ASC 
proposed rule (83 FR 37207), we did not propose any changes to this 
policy.
6. Extraordinary Circumstances Exception (ECE) Process for the CY 2020 
Payment Determination and Subsequent Years
    We refer readers to the CY 2018 OPPS/ASC final rule with comment 
period (82 FR 59474 through 59475) (and the previous rulemakings cited 
therein) and 42 CFR 416.310(d) for the ASCQR Program's policies for 
extraordinary circumstance exceptions (ECE) requests.
    In the CY 2018 OPPS/ASC final rule with comment period (82 FR 59474 
through 59475), we: (1) Changed the name of this policy from 
``extraordinary circumstances extensions or exemption'' to 
``extraordinary circumstances exceptions'' for the ASCQR Program, 
beginning January 1, 2018; and (2) revised 42 CFR 416.310(d) of our 
regulations to reflect this change. We also clarified that we will 
strive to complete our review of each request within 90 days of 
receipt. In the CY 2019 OPPS/ASC proposed rule (83 FR 37207), we did 
not propose any changes to these policies.
7. ASCQR Program Reconsideration Procedures
    We refer readers to the CY 2016 OPPS/ASC final rule with comment 
period (82 FR 59475) (and the previous rulemakings cited therein) and 
42 CFR 416.330 for the ASCQR Program's reconsideration policy. In the 
CY 2019 OPPS/ASC proposed rule (83 FR 37207), we did not propose any 
changes to this policy.

E. Payment Reduction for ASCs That Fail To Meet the ASCQR Program 
Requirements

1. Statutory Background
    We refer readers to section XVI.D.1. of the CY 2013 OPPS/ASC final 
rule with comment period (77 FR 68499) for a detailed discussion of the 
statutory background regarding payment reductions for ASCs that fail to 
meet the ASCQR Program requirements.
2. Policy Regarding Reduction to the ASC Payment Rates for ASCs That 
Fail To Meet the ASCQR Program Requirements for a Payment Determination 
Year
    The national unadjusted payment rates for many services paid under 
the ASC payment system equal the product of the ASC conversion factor 
and the scaled relative payment weight for the APC to which the service 
is assigned. For CY 2019, the ASC conversion factor we are finalizing 
is equal to the conversion factor calculated for the previous year 
updated by the multifactor productivity (MFP)-adjusted hospital market 
basket update factor. The MFP adjustment is set forth in section 
1833(i)(2)(D)(v) of the Act. The MFP-adjusted hospital market basket 
update is the annual update for the ASC payment system for an interim 
5-year period (CY 2019 through CY 2023). As discussed in the CY 2011 
OPPS/ASC final rule with comment period (75 FR 72062), if the CPI-U 
update factor is a negative number, the CPI-U update factor would be 
held to zero. In the CY 2019 OPPS/ASC proposed rule (83 FR 37207), 
consistent with past practice, in the event the percentage change in 
the hospital market basket for a year is negative, we proposed to hold 
the hospital market basket update factor for the ASC payment system to 
zero. Under the ASCQR Program in accordance with section 1833(i)(7)(A) 
of the Act and as discussed in the CY 2013 OPPS/ASC final rule with 
comment period (77 FR 68499), any annual increase shall be reduced by 
2.0 percentage points for ASCs that fail to meet the reporting 
requirements of the ASCQR Program. This reduction applied beginning 
with the CY 2014 payment rates (77 FR 68500). For a complete discussion 
of the calculation of the ASC conversion factor and our proposal to 
update the ASC payment rates using the inpatient hospital market basket 
update for CYs

[[Page 59139]]

2019 through 2023, we refer readers to section XII.G. of this final 
rule with comment period.
    In the CY 2013 OPPS/ASC final rule with comment period (77 FR 68499 
through 68500), in order to implement the requirement to reduce the 
annual update for ASCs that fail to meet the ASCQR Program 
requirements, we finalized our proposal that we would calculate two 
conversion factors: A full update conversion factor and an ASCQR 
Program reduced update conversion factor. We finalized our proposal to 
calculate the reduced national unadjusted payment rates using the ASCQR 
Program reduced update conversion factor that would apply to ASCs that 
fail to meet their quality reporting requirements for that calendar 
year payment determination. We finalized our proposal that application 
of the 2.0 percentage point reduction to the annual update may result 
in the update to the ASC payment system being less than zero prior to 
the application of the MFP adjustment.
    The ASC conversion factor is used to calculate the ASC payment rate 
for services with the following payment indicators (listed in Addenda 
AA and BB to the proposed rule, which are available via the internet on 
the CMS website): ``A2'', ``G2'', ``P2'', ``R2'' and ``Z2'', as well as 
the service portion of device-intensive procedures identified by ``J8'' 
(77 FR 68500). We finalized our proposal that payment for all services 
assigned the payment indicators listed above would be subject to the 
reduction of the national unadjusted payment rates for applicable ASCs 
using the ASCQR Program reduced update conversion factor (77 FR 68500).
    The conversion factor is not used to calculate the ASC payment 
rates for separately payable services that are assigned status 
indicators other than payment indicators ``A2'', ``G2'', ``J8'', 
``P2'', ``R2'' and ``Z2.'' These services include separately payable 
drugs and biologicals, pass-through devices that are contractor-priced, 
brachytherapy sources that are paid based on the OPPS payment rates, 
and certain office-based procedures, radiology services and diagnostic 
tests where payment is based on the PFS nonfacility PE RVU-based 
amount, and a few other specific services that receive cost-based 
payment (77 FR 68500). As a result, we also finalized our proposal that 
the ASC payment rates for these services would not be reduced for 
failure to meet the ASCQR Program requirements because the payment 
rates for these services are not calculated using the ASC conversion 
factor and, therefore, not affected by reductions to the annual update 
(77 FR 68500).
    Office-based surgical procedures (generally those performed more 
than 50 percent of the time in physicians' offices) and separately paid 
radiology services (excluding covered ancillary radiology services 
involving certain nuclear medicine procedures or involving the use of 
contrast agents) are paid at the lesser of the PFS nonfacility PE RVU-
based amounts or the amount calculated under the standard ASC 
ratesetting methodology. Similarly, in section XII.D.2.b. of the CY 
2015 OPPS/ASC final rule with comment period (79 FR 66933 through 
66934), we finalized our proposal that payment for certain diagnostic 
test codes within the medical range of CPT codes for which separate 
payment is allowed under the OPPS and when they are integral to covered 
ASC surgical procedures will be at the lower of the PFS nonfacility PE 
RVU-based (or technical component) amount or the rate calculated 
according to the standard ASC ratesetting methodology. In the CY 2013 
OPPS/ASC final rule with comment period (77 FR 68500), we finalized our 
proposal that the standard ASC ratesetting methodology for this type of 
comparison would use the ASC conversion factor that has been calculated 
using the full ASC update adjusted for productivity. This is necessary 
so that the resulting ASC payment indicator, based on the comparison, 
assigned to these procedures or services is consistent for each HCPCS 
code, regardless of whether payment is based on the full update 
conversion factor or the reduced update conversion factor.
    For ASCs that receive the reduced ASC payment for failure to meet 
the ASCQR Program requirements, we believe that it is both equitable 
and appropriate that a reduction in the payment for a service should 
result in proportionately reduced coinsurance liability for 
beneficiaries (77 FR 68500). Therefore, in the CY 2013 OPPS/ASC final 
rule with comment period (77 FR 68500), we finalized our proposal that 
the Medicare beneficiary's national unadjusted coinsurance for a 
service to which a reduced national unadjusted payment rate applies 
will be based on the reduced national unadjusted payment rate.
    In that final rule with comment period, we finalized our proposal 
that all other applicable adjustments to the ASC national unadjusted 
payment rates would apply in those cases when the annual update is 
reduced for ASCs that fail to meet the requirements of the ASCQR 
Program (77 FR 68500). For example, the following standard adjustments 
would apply to the reduced national unadjusted payment rates: The wage 
index adjustment; the multiple procedure adjustment; the interrupted 
procedure adjustment; and the adjustment for devices furnished with 
full or partial credit or without cost (77 FR 68500). We believe that 
these adjustments continue to be equally applicable to payment for ASCs 
that do not meet the ASCQR Program requirements (77 FR 68500).
    In the CY 2015, CY 2016, CY 2017, and CY 2018 OPPS/ASC final rules 
with comment period (79 FR 66981 through 66982; 80 FR 70537 through 
70538; 81 FR 79825 through 79826; and 82 FR 59475 through 59476, 
respectively), we did not make any other changes to these policies. We 
did not propose any changes to these existing policies for CY 2019 in 
the CY 2019 OPPS/ASC proposed rule (83 FR 37207 through 37208).
    We did not receive any public comments on our proposal that, in the 
event the percentage change in the hospital market basket for a year is 
negative, we would hold the hospital market basket update factor for 
the ASC payment system to zero. We also did not receive any public 
comments on our existing policies for all other applicable adjustments 
to the ASC national unadjusted payment rates discussed earlier. 
Therefore, we are finalizing our proposal without modification and 
continuing the existing policies for CY 2019.

XV. Comments Received in Response To Requests for Information (RFIs) 
Included in the CY 2019 OPPS/ASC Proposed Rule

    In the CY 2019 OPPS/ASC proposed rule (83 FR 37208 through 37217), 
we included three requests for information (RFIs). We stated in the 
proposed rule that the RFIs were issued solely for information and 
planning purposes; none of the RFIs constituted a Request for Proposal 
(RFP), application, proposal abstract, or quotation. In addition, we 
stated that the RFIs did not commit the U.S. Government to contract for 
any supplies or services or make a grant award. Further, we stated that 
CMS was not seeking proposals through these RFIs and would not accept 
unsolicited proposals. Responders were advised that the U.S. Government 
will not pay for any information or administrative costs incurred in 
response to these RFIs; all costs associated with responding to these 
RFIs would be solely at the interested party's expense. In addition, we 
stated in the proposed rule that failing to respond to either RFI would 
not

[[Page 59140]]

preclude participation in any future procurement, if conducted. We also 
stated that it is the responsibility of the potential responders to 
monitor each RFI announcement for additional information pertaining to 
the request. We also noted that CMS would not respond to questions 
about the policy issues raised in these RFIs. In addition, we stated 
that CMS may or may not choose to contact individual responders, and 
that such communications would only serve to further clarify written 
responses. In the proposed rule, we stated that contractor support 
personnel may be used to review RFI responses. We also stated that 
responses to these RFIs were not offers and cannot be accepted by the 
U.S. Government to form a binding contract or issue a grant. We stated 
that information obtained as a result of these RFIs may be used by the 
U.S. Government for program planning on a non-attribution basis and 
that respondents should not include any information that might be 
considered proprietary or confidential. We stated that these RFIs 
should not be construed as a commitment or authorization to incur cost 
for which reimbursement would be required or sought. We also stated 
that all submissions become U.S. Government property and will not be 
returned. We posted the public comments that CMS received on the three 
RFIs as part of the posting of the public comments received on the CY 
2019 OPPS/ASC proposed rule on the website at: www.regulations.gov.

A. Comments Received in Response To Request for Information on 
Promoting Interoperability and Electronic Healthcare Information 
Exchange Through Possible Revisions to the CMS Patient Health and 
Safety Requirements for Hospitals and Other Medicare- and Medicaid-
Participating Providers and Suppliers

    In the CY 2019 OPPS/ASC proposed rule (83 FR 37209 through 37211), 
we included a Request for Information (RFI) related to promoting 
interoperability and electronic health care information exchange. We 
received over 60 timely pieces of correspondence on this RFI. We 
appreciate the input provided by commenters.

B. Comments Received in Response To Request for Information on Price 
Transparency: Improving Beneficiary Access to Provider and Supplier 
Charge Information

    In the CY 2019 OPPS/ASC proposed rule (83 FR 37211 and 37212), we 
included a Request for Information (RFI) related to improving 
beneficiary access to provider and supplier charge information as part 
of our price transparency initiatives. We received over 90 timely 
pieces of correspondence on this RFI. We appreciate the input provided 
by commenters.

C. Comments Received in Response To Request for Information on 
Leveraging the Authority for the Competitive Acquisition Program (CAP) 
for Part B Drugs and Biologicals for a Potential CMS Innovation Center 
Model

    In the CY 2019 OPPS/ASC proposed rule (83 FR 37212 through 37217), 
we included a Request for Information (RFI) related to leveraging the 
authority for the Competitive Acquisition Program (CAP) for Part B 
drugs and biologicals for a potential CMS Innovation Center Model. We 
received approximately 80 timely pieces of correspondence on this RFI. 
We appreciate the input provided by commenters.

XVI. Additional Hospital Inpatient Quality Reporting (IQR) Program 
Policies

A. Background

    We refer readers to the FY 2010 IPPS/LTCH PPS final rule (74 FR 
43860 through 43861) and the FY 2011 IPPS/LTCH PPS final rule (75 FR 
50180 through 50181) for detailed discussions of the history of the 
Hospital IQR Program, including the statutory history, and to the FY 
2015 IPPS/LTCH PPS final rule (79 FR 50217 through 50249), the FY 2016 
IPPS/LTCH PPS final rule (80 FR 49660 through 49692), the FY 2017 IPPS/
LTCH PPS final rule (81 FR 57148 through 57150), and the FY 2018 IPPS/
LTCH PPS final rule (82 FR 38323 through 38411) for the measures and 
program policies we have adopted for the Hospital IQR Program through 
the FY 2020 payment determination and subsequent years. In addition to 
the proposed and finalized policies discussed in this section, we also 
refer readers to the FY 2019 IPPS/LTCH PPS final rule (83 FR 41537 
through 41609) for a full discussion of the Hospital IQR Program and 
its policies.

B. Update to the HCAHPS Survey Measure (NQF #0166) for the FY 2021 
Payment Determination and Subsequent Years

1. Background of the HCAHPS Survey in the Hospital IQR Program
    As discussed in the CY 2019 OPPS/ASC proposed rule (83 FR 37218), 
CMS partnered with the Agency for Healthcare Research and Quality 
(AHRQ) to develop the Hospital Consumer Assessment of Healthcare 
Providers and Systems (HCAHPS) patient experience of care survey (NQF 
#0166) \210\ (hereinafter referred to as the HCAHPS Survey). We adopted 
the HCAHPS Survey in the Hospital IQR Program (at the time called the 
Reporting Hospital Quality Data Annual Payment Update Program, or 
RHQDAPU) in the CY 2007 OPPS final rule with comment period (71 FR 
68202 through 68204) beginning with the FY 2008 payment determination 
and for subsequent years. We refer readers to the FY 2010 IPPS/LTCH PPS 
final rule (74 FY 43882), the FY 2011 IPPS/LTCH PPS final rule (75 FR 
50220 through 50222), the FY 2012 IPPS/LTCH PPS final rule (76 FR 51641 
through 51643), the FY 2013 IPPS/LTCH PPS final rule (77 FR 53537 
through 53538), the FY 2014 IPPS/LTCH PPS final rule (78 FR 50819 
through 50820), and the FY 2018 IPPS/LTCH PPS final rule (82 FR 38328 
to 38342) for details on previously-adopted HCAHPS Survey requirements.
---------------------------------------------------------------------------

    \210\ The HCAHPS measure also includes the NQF-endorsed Care 
Transition Measure (CTM-3) (NQF #0228), which we added in the FY 
2013 IPPS/LTCH PPS final rule (77 FR 53513 through 53516). We added 
the Communication About Pain composite measure in the FY 2018 IPPS/
LTCH PPS final rule (38328 through 38342), and stated that we would 
seek NQF endorsement for this measure.
---------------------------------------------------------------------------

    The HCAHPS Survey (OMB control number 0938-0981) is the first 
national, standardized, publicly reported survey of patients' 
experience of hospital care and asks discharged patients 32 questions 
about their recent hospital stay. The HCAHPS Survey is administered to 
a random sample of adult patients who receive medical, surgical, or 
maternity care between 48 hours and 6 weeks (42 calendar days) after 
discharge and is not restricted to Medicare beneficiaries.\211\ 
Hospitals must survey patients throughout each month of the year.\212\ 
The HCAHPS Survey is available in official English, Spanish, Chinese, 
Russian, Vietnamese, and Portuguese versions. The HCAHPS Survey and its 
protocols for sampling, data collection and coding, and file submission 
can be found in the current HCAHPS Quality Assurance Guidelines, which 
is available on the official HCAHPS website at: https://www.hcahpsonline.org/en/quality-assurance/. AHRQ carried out a rigorous 
scientific process to develop and test the HCAHPS Survey instrument. 
This process entailed multiple steps, including: a public call for 
measures; literature reviews; cognitive interviews; consumer focus 
groups; multiple opportunities for additional stakeholder

[[Page 59141]]

input; a 3-State pilot test; small-scale field tests; and notice-and-
comment rulemaking. In May 2005, the HCAHPS Survey was first endorsed 
by the NQF.\213\
---------------------------------------------------------------------------

    \211\ We refer readers to the FY 2018 IPPS/LTCH PPS final rule 
(82 FR 38328 to 38342, 38398) and to the official HCAHPS website at: 
https://www.hcahpsonline.org for details on HCAHPS requirements.
    \212\ Ibid.
    \213\ Available at: https://www.qualityforum.org/Publications/2008/08/National_Voluntary_Consensus_Standards_for_Hospital_Care_2007__Performance_Measures.aspx.
---------------------------------------------------------------------------

    In the FY 2018 IPPS/LTCH PPS final rule (82 FR 38328 through 
38342), out of an abundance of caution, in the face of a nationwide 
epidemic of opioid overprescription, we finalized a refinement to the 
HCAHPS Survey measure as used in the Hospital IQR Program by removing 
the previously adopted pain management questions and incorporating new 
Communication About Pain questions beginning with patients discharged 
in January 2018, for the FY 2020 payment determination and subsequent 
years.\214\ These three survey questions within the HCAHPS Survey, 
collectively known as the Communication About Pain questions,\215\ 
address how providers communicate with patients about pain. These 
questions are as follows: \216\
---------------------------------------------------------------------------

    \214\ In the CY 2017 OPPS/ASC final rule with comment period (81 
FR 79855 through 79862), the Hospital VBP Program removed the Pain 
Management dimension of the HCAHPS Survey in the Patient and 
Caregiver-Centered Experience of Care/Care Coordination domain of 
the Hospital VBP Program beginning with the FY 2018 program year. 
Under the Hospital VBP Program, payment adjustments are tied to 
hospitals' performance on the measures that are used to calculate 
each hospital's Total Performance Score.
    \215\ Available at: https://hcahpsonline.org/en/survey-instruments/.
    \216\ We note that in the CY 2019 OPPS/ASC proposed rule, we 
inadvertently omitted the ``If No, Go to Question __'' phrase that 
accompanies the ``No'' response option for the first question. We 
have added the language above to reflect the full question.
---------------------------------------------------------------------------

     HP1: ``During this hospital stay, did you have any pain?''
    [square] Yes
    [square] No [rarr] If No, Go to Question __
     HP2: ``During this hospital stay, how often did hospital 
staff talk with you about how much pain you had?''
    [square] Never
    [square] Sometimes
    [square] Usually
    [square] Always
     HP3: ``During this hospital stay, how often did hospital 
staff talk with you about how to treat your pain?''
    [square] Never
    [square] Sometimes
    [square] Usually
    [square] Always
    In addition, we finalized public reporting on the Communication 
About Pain questions, such that hospital performance data on those 
questions would be publicly reported on the Hospital Compare website 
beginning October 2020, using CY 2019 data. We also stated that we 
would provide performance results based on CY 2018 data on the 
Communication About Pain questions to hospitals in confidential preview 
reports, upon the availability of four quarters of data, as early as 
July 2019. We believed implementing the Communication About Pain 
questions as soon as feasible was necessary to address any perceived 
conflict between appropriate management of opioid use and patient 
satisfaction by relieving any potential pressure physicians may feel to 
overprescribe opioids (82 FR 38333).
2. Updates to the HCAHPS Survey: Removal of Communication About Pain 
Questions
    As discussed in the CY 2019 OPPS/ASC proposed rule (83 FR 37218), 
since we finalized the Communication About Pain questions, we have 
received feedback that some stakeholders are concerned that, although 
the revised questions focus on communications with patients about their 
pain and treatment of that pain, rather than how well their pain was 
controlled, the questions still could potentially impose pressure on 
hospital staff to prescribe more opioids in order to achieve higher 
scores on the HCAHPS Survey. In addition, in its final report, the 
President's Commission on Combating Drug Addiction and the Opioid 
Crisis recommended removal of the HCAHPS Pain Management questions in 
order to ensure providers are not incentivized to offer opioids to 
raise their HCAHPS Survey score.\217\
---------------------------------------------------------------------------

    \217\ Available at: https://www.whitehouse.gov/sites/whitehouse.gov/files/images/Final_Report_Draft_11-15-2017.pdf.
---------------------------------------------------------------------------

    Other potential factors outside the control of CMS quality program 
requirements may contribute to the perception of a link between the 
Communication About Pain questions and opioid prescribing practices, 
including: misuse of the HCAHPS Survey (such as using it for outpatient 
emergency room care instead of inpatient care, or using it for 
determining individual physician performance); failure to recognize 
that the HCAHPS Survey excludes certain populations from the sampling 
frame (such as those with a primary substance use disorder diagnosis); 
and the addition of supplemental pain-related survey questions by the 
hospital that are not formally part of the HCAHPS Survey or otherwise 
required by CMS.
    Because some hospitals have identified patient experience of care 
as a potential source of competitive advantage, we have heard from 
stakeholders that some hospitals may be disaggregating their raw HCAHPS 
Survey data to compare, assess, and incentivize individual physicians, 
nurses, and other hospital staff. Some hospitals also may be using the 
HCAHPS Survey to assess their emergency and outpatient departments. To 
be clear, the HCAHPS Survey was never designed or intended to be used 
in these ways.\218\ In our HCAHPS Quality Assurance Guidelines,\219\ 
which sets forth current survey administration protocols, we strongly 
discourage the unofficial use of HCAHPS scores for comparisons within 
hospitals, such as for comparisons of particular wards, floors, and 
individual staff hospital members. The standardization of HCAHPS Survey 
administration and data collection methodologies is also emphasized 
during the required introductory and annual update trainings for 
hospitals/survey vendors.
---------------------------------------------------------------------------

    \218\ Tefera L, Lehrman WG, and Conway P. ``Measurement of the 
Patient Experience: Clarifying Facts, Myths, and Approaches.'' 
Journal of the American Medical Association. Available at: https://jama.jamanetwork.com/article.aspx?articleid=2503222.
    \219\ HCAHPS Quality Assurance Guidelines (v. 13.0), available 
at: https://www.hcahpsonline.org/en/quality-assurance/.
---------------------------------------------------------------------------

    As we stated in the CY 2019 OPPS/ASC proposed rule, we continue to 
believe that pain management is a critical part of routine patient care 
on which hospitals should focus and an important concern for patients, 
their families, and their caregivers. It is important to reiterate that 
the HCAHPS Survey does not specify any particular type of pain control 
method. The revised questions focus entirely on communication about 
pain with patients and do not refer to, recommend, or imply that any 
particular type of treatment is appropriate (82 FR 38333). In addition, 
appropriate pain management includes communication with patients about 
pain-related issues, setting expectations about pain, shared decision-
making, proper prescription practices, and alternative treatments for 
pain management.
    Although we are not aware of any scientific studies that support an 
association between scores on the prior or current iterations of the 
Communication About Pain questions and opioid prescribing practices, 
out of an abundance of caution and to avoid any potential unintended 
consequences, in the CY 2019 OPPS/ASC proposed rule (83 FR 37218), we 
proposed to update the HCAHPS Survey by removing the Communication 
About Pain questions effective with January

[[Page 59142]]

2022 discharges, for the FY 2024 payment determination and subsequent 
years. This proposal would reduce the overall length of the HCAHPS 
Survey from 32 to 29 questions, and the final four quarters of reported 
Communication About Pain data (comprising data from the first, second, 
third, and fourth quarters 2021) would be publicly reported on Hospital 
Compare in October 2022 and then subsequently discontinued. As stated 
above, in its final report, the President's Commission on Combating 
Drug Addiction and the Opioid Crisis recommended removal of the HCAHPS 
Pain Management Survey questions in order to ensure providers are not 
incentivized to offer opioids to raise their HCAHPS Survey score.\220\
---------------------------------------------------------------------------

    \220\ Final Report, The President's Commission on Combating Drug 
Addiction and the Opioid Crisis, available at: https://www.whitehouse.gov/sites/whitehouse.gov/files/images/Final_Report_Draft_11-15-2017.pdf.
---------------------------------------------------------------------------

    In proposing removal of the Communication About Pain questions, we 
did not propose to change how performance scores are calculated for the 
remaining questions on the HCAHPS Survey. The Hospital IQR Program is a 
quality data reporting program; payments to hospitals will not be 
affected so long as hospitals timely submit data on required measures 
and meet all other program requirements. We stated in the proposed rule 
that we would continue to use the remaining 29 questions of the HCAHPS 
Survey to assess patients' experience of care, and would continue to 
publicly report hospital scores on those questions in order to ensure 
patients and consumers have access to these data while making decisions 
about their care. Patients and providers can continue to review data 
from responses to the remaining 29 questions of the HCAHPS Survey on 
the Hospital Compare website.
    In crafting our proposal, we considered whether the Communication 
About Pain questions should be retained in both the HCAHPS Survey and 
the Hospital IQR Program but with a further delay in public reporting. 
For example, instead of public reporting starting in October 2020 as 
previously finalized, we could have proposed to delay public reporting 
of the Communication About Pain questions until October 2021. We stated 
we were interested in feedback on whether the Communication About Pain 
questions should be retained in both the HCAHPS Survey and the Hospital 
IQR Program but with a further delay in public reporting. Delay in 
public reporting would allow further time to engage a broad range of 
stakeholders and assess their feedback regarding use of the 
Communication About Pain questions in the HCAHPS Survey and the 
Hospital IQR Program and to assess the impact of the new Communication 
About Pain questions. However, we chose to propose to remove the 
Communication About Pain questions as discussed above instead, so 
providers would not perceive that there are incentives for prescribing 
opioids to increase HCAHPS Survey scores.
    In crafting our proposal, we also considered proposing earlier 
removal of the Communication About Pain questions from the HCAHPS 
Survey effective as early as January 2020 discharges, for the FY 2022 
payment determination and subsequent years. However, we stated that 
removing the questions effective with January 2020 discharges would not 
allow sufficient time to make necessary updates to the data collection 
tools, including the CMS data submission warehouse and associated 
reporting tools, as well as to update the HCAHPS Survey administration 
protocols and the survey tool itself. In addition, our proposal to make 
these updates effective later, with January 2022 discharges, would 
allow time to assess the potential impact of using the Communication 
About Pain questions while monitoring unintended consequences. It would 
also allow time for empirical testing for any potential effect the 
removal of the Communication About Pain questions might have on 
responses to the remaining non-pain related survey items.
    We invited public comment on our proposal as discussed above and 
whether the questions should be removed from the HCAHPS Survey and 
Hospital IQR Program. We stated that we were particularly interested in 
receiving feedback on any potential implications on patient care 
related to removing these questions. We also expressed interest in 
receiving feedback from stakeholders on: (1) The importance of 
receiving feedback from patients related to communication about pain 
management and the importance of publicly reporting this information 
for use both by patients in healthcare decision-making and by hospitals 
in focusing their quality improvement efforts; (2) additional analyses 
demonstrating a relationship between the use of pain questions in 
patient surveys and prescribing behavior, including unpublished data, 
if available; (3) input from clinicians and other providers concerning 
whether it would be valuable for CMS to issue guidance suggesting that 
hospitals do not administer any surveys with pain-related questions, 
including adding hospital-specific supplemental items to the HCAHPS 
Survey, as well as the potential implementation of a third party 
quality assurance program to assure that hospitals are not misusing 
survey data by creating pressure on individual clinicians to provide 
inappropriate clinical care; (4) information from clinicians and other 
providers concerning instances of hospital administrators using results 
from the HCAHPS Survey to compare individual clinician performance 
directly to other clinicians at the same facility or institution and 
examples where, as a result, clinicians have felt pressured to 
prescribe opioids inappropriately (in terms of either quantity or 
appropriateness for particular patients); (5) suggestions for other 
measures that would capture facets of pain management and related 
patient education, for instance, collecting data about a hospital's 
pain management plan, and provide that information back to consumers; 
and (6) how other measures could take into account provider-supplied 
information on appropriate pain management and whether patients are 
informed about the risks of opioid use and about non-opioid pain 
management alternatives.
    Comment: A number of commenters responded to CMS' request for 
feedback regarding potential misuse of the HCAHPS Survey and its impact 
on provider decision-making. Commenters indicated the Communication 
About Pain questions in the HCAHPS Survey unduly influence providers' 
decision-making by encouraging providers to focus on improving patient 
satisfaction scores regarding pain management. One commenter indicated 
this influence is significant enough to compel providers to prescribe 
opioids to patients showing signs of drug-seeking behavior. Other 
commenters expressed concern that some hospitals use disaggregated 
survey results to assess individual clinician performance, with some 
hospitals tying these disaggregated survey results to individual 
compensation.
    Response: We thank the commenters for their feedback. We also 
reiterate that the HCAHPS Survey was never intended to be used to 
assess the performance of individual clinicians or provider groups 
within a hospital. The HCAHPS Survey is designed to evaluate the 
performance of a hospital as a whole, not individuals or groups within 
the larger hospital setting; \221\ therefore,

[[Page 59143]]

its use for evaluating or incentivizing individual providers or groups 
within the hospital is contrary to the survey's design and policy aim.
---------------------------------------------------------------------------

    \221\ Tefera L, Lehrman WG, and Conway P. ``Measurement of the 
Patient Experience: Clarifying Facts, Myths, and Approaches.'' 
Journal of the American Medical Association. Available at: https://jama.jamanetwork.com/article.aspx?articleid=2503222.
---------------------------------------------------------------------------

    During annual survey vendor training for HCAHPS and in the HCAHPS 
Quality Assurance Guidelines, we clearly state the purpose and the 
proper use of HCAHPS data: Official HCAHPS Survey scores are published 
on the Hospital Compare website. CMS emphasizes that HCAHPS scores are 
designed and intended for use at the hospital level for the comparison 
of hospitals (designated by their CMS Certification Number) to each 
other. CMS does not review or endorse the use of HCAHPS scores for 
comparisons within hospitals, such as comparison of HCAHPS scores 
associated with a particular ward, floor, individual staff member, etc. 
to others. Such comparisons are unreliable unless adequate sample sizes 
are collected at the ward, floor, or individual staff member level. In 
addition, since HCAHPS questions inquire about broad categories of 
hospital staff (such as doctors in general and nurses in general rather 
than specific individuals), HCAHPS is not appropriate for comparing or 
assessing individual hospital staff members. Using HCAHPS scores to 
compare or assess individual staff members is inappropriate and is 
strongly discouraged by CMS.\222\
---------------------------------------------------------------------------

    \222\ HCAHPS Quality Assurance Guidelines, V13.0. pp. 23-24, 
available at: https://www.hcahpsonline.org/globalassets/hcahps/quality-assurance/2018_qag_v13.0.pdf.
---------------------------------------------------------------------------

    Comment: The majority of commenters supported CMS' proposal to 
remove the Communication About Pain questions from the HCAHPS Survey. A 
number of commenters who supported removal of the Communication About 
Pain questions also recommended CMS remove the questions earlier than 
proposed. Several commenters specifically recommended that CMS remove 
these questions immediately, asserting that the severity and urgency of 
the opioid crisis justifies immediate termination of the questions. One 
commenter recommended immediate removal of the Communication About Pain 
questions due to concerns that the subjective nature of the HCAHPS 
Survey, and the Communication About Pain questions, may not accurately 
represent hospital performance.
    Other commenters recommended that CMS remove the Communication 
About Pain questions as soon as feasible, with one commenter 
specifically recommending removal effective with January 2020 
discharges, due to the potential unintended consequences associated 
with continued use of the questions. These commenters further 
recommended that CMS first remove the Communication About Pain 
questions, then evaluate alternate methods of determining the impacts 
of removal and the value of collecting pain management data, rather 
than delaying removal in order to collect more data.
    Response: We thank the commenters for their feedback and their 
support of our proposal to remove the Communication About Pain 
questions from the HCAHPS Survey. We believe that removing the 
Communication About Pain questions from the HCAHPS Survey will address 
potential confusion about the appropriate use of the HCAHPS Survey, is 
responsive to concerns regarding the public health issues arising from 
the opioid epidemic, and addresses the recommendation of the 
President's Commission on Combating Drug Addiction and the Opioid 
Crisis.
    In addition, section 6104 of the Substance Use--Disorder Prevention 
that Promotes Opioid Recovery and Treatment for Patients and 
Communities Act (SUPPORT for Patients and Communities Act) (Pub. L. 
115-271) enacted on October 24, 2018, prohibits HCAHPS Surveys 
conducted on or after January 1, 2020 from including questions about 
communication by hospital staff with an individual about such 
individual's pain, unless such questions take into account, as 
applicable, whether an individual experiencing pain was informed about 
risks associated with the use of opioids and about non-opioid 
alternatives for the treatment of pain. Section 6104 of the SUPPORT for 
Patients and Communities Act also states that the Secretary shall not 
include any measures based on the pain communication questions on the 
HCAHPS Survey in 2018 or 2019 on the Hospital Compare website and in 
the Hospital Value-Based Purchasing (VBP) Program.
    We proposed to remove the Communication About Pain questions 
beginning with January 2022 discharges for the FY 2024 payment 
determination in an effort to avoid imposing undue burden on providers 
or their survey vendors to make necessary updates to surveys and data 
collection tools while also providing us additional time to assess the 
potential impact of using these questions in the HCAHPS Survey and the 
impact removal may have on responses to subsequent survey items (83 FR 
37218 through 38220). Based on the stakeholder comments supporting 
removal of these questions, particularly those who requested we remove 
them immediately or as soon as possible, we assessed the feasibility of 
removing the questions as soon as operationally possible.
    Upon further review of the operational timelines for making 
necessary updates to the HCAHPS Survey administration protocols, 
including conducting associated training of survey vendors and 
hospitals, and making updates to the CMS data submission warehouse and 
associated reporting tools, we found that it would be operationally 
feasible to remove the Communication About Pain questions earlier than 
we proposed. Furthermore, because the SUPPORT for Patients and 
Communities Act prohibits use of the Communication About Pain questions 
in HCAHPS Surveys conducted on or after January 1, 2020, it is 
appropriate to remove these questions from the HCAHPS Survey sooner 
than proposed--effective with October 2019 discharges, for the FY 2021 
payment determination and subsequent years. We also note that removing 
these questions effective with October 2019 discharges, for the FY 2021 
payment determination and subsequent years is responsive to commenters 
who recommended that we remove the Communication About Pain questions 
immediately or as soon as possible. Although we are removing the 
Communication About Pain questions, we will continue to consider the 
value of collecting data that relates to pain management. We will 
examine the effect of the absence of the Communication About Pain items 
on subsequent survey items once these items have been removed.
    Therefore, in response to stakeholder feedback, to comply with the 
requirements of the SUPPORT for Patients and Communities Act, and upon 
further review of the operational considerations involved in removing 
the Communication About Pain questions, we are finalizing a 
modification to our proposal and will remove the questions effective 
with October 2019 discharges, for the FY 2021 payment determination and 
subsequent years.
    Comment: A few commenters also recommended that CMS remove the 
Communication About Pain questions from public reporting. One commenter 
further recommended that CMS not publicly report performance data on 
the Communication About Pain questions until further research on the 
impact and utility of the questions is performed. Another commenter 
recommended that while the Communication About Pain questions remain in 
the HCAHPS Survey, CMS should remove them from

[[Page 59144]]

the scoring calculation to minimize potential adverse consequences.
    Response: We appreciate the commenters' feedback regarding public 
reporting of the Communication About Pain questions. Due in part to 
stakeholder input urging us to remove the Communication About Pain 
questions immediately or as soon as possible, as discussed above, we 
have assessed the operational considerations and are finalizing a 
modification to our proposal to remove the questions effective with 
October 2019 discharges, which is the earliest we can feasibility 
implement removal of the Communication About Pain questions.
    We are finalizing a modification of our public display proposal 
that we publicly reporting the Communication about Pain questions on 
Hospital Compare until October 2022 (comprising data from the first, 
second, third, and fourth quarters 2021) and then subsequently 
discontinue public reporting. Instead, we are finalizing that we will 
not publicly report data from the Communication about Pain questions at 
all because: We will no longer collect four quarters of CY 2019 
Communication About Pain questions data; stakeholders' recommendations 
that we not publicly report the Communication About Pain data at all in 
order to avoid exacerbating any possible link between these questions 
and inappropriate prescribing practices; and the requirements of the 
SUPPORT for Patients and Communities Act, which prohibit publicly 
reporting on Hospital Compare any measures based on the Communication 
About Pain questions appearing in the HCAHPS Survey in 2018 or 2019. 
Not publicly reporting the data collected from the Communication About 
Pain questions also aligns with our efforts to mitigate any potential 
tie between the Communication About Pain questions and inappropriate 
opioid prescribing practices.
    We note that in the FY 2018 IPPS/LTCH PPS final rule (82 FR 38342), 
we finalized a delay in public reporting, such that hospital 
performance data on the refined Communication About Pain composite 
measure questions would not be publicly reported on the Hospital 
Compare website until October of CY 2020, using CY 2019 data. We stated 
that we would provide performance results, based on CY 2018 data on the 
refined Communication About Pain composite measure questions to 
hospitals in confidential preview reports, upon the availability of 
four quarters of data. We stated that we anticipated that these 
confidential preview reports would be available as early as July 2019. 
The effect of the modified policy we are finalizing in this final rule 
with comment period is that Communication About Pain data from the 
final CY 2019 reporting period (which would consist of three quarters 
of data, 1st quarter through 3rd quarter 2019) will also not be 
publicly reported.
    However, we still plan to provide performance results based on 
these data to hospitals in confidential preview reports upon the 
availability of four quarters of CY 2018 data, as early as July 2019. 
Updated confidential reports will be provided on a quarterly basis with 
the availability of each new calendar quarter of data. The last 
confidential preview report containing the Communication About Pain 
questions data will reflect data from the fourth quarter of 2018 
(October 1, 2018) through the third quarter of 2019 (September 30, 
2019). We also note that the data collected from these questions will 
not be scored for purposes of CMS payments to hospitals, because the 
Hospital IQR Program is a pay-for-reporting, not pay-for-performance 
quality program and these questions are not part of the Hospital VBP 
Program.
    Comment: Many commenters supported CMS' proposal to remove the 
current Communication About Pain questions from the HCAHPS Survey 
beginning with January 2022 discharges for the FY 2024 payment 
determination and subsequent years. Many commenters supported removing 
the Communication About Pain questions based on concerns about 
unintended consequences of their continued use, specifically that the 
questions may incentivize or pressure clinicians into inappropriately 
prescribing opioids. Some commenters asserted that removing these 
questions from the HCAHPS Survey would allow providers to address 
patients' pain in a safer manner, avoid inadvertently fostering an 
environment that could potentially promote the inappropriate use of 
opioids, and change perceptions about pain management. One commenter 
noted the Communication About Pain questions may also disincentivize 
the use of alternative methods of pain management in an effort to 
address patients' pain in the most efficient manner (that is, 
prescription of opioids). Another commenter specifically cited 
agreement with the recommendation of the President's Commission on 
Combating Drug Addiction and the Opioid Crisis in supporting removal of 
the Communication About Pain questions.
    Several commenters supported removal of the Communication About 
Pain questions because the commenters' believe pain is subjective and 
is therefore, difficult to measure using a standardized set of survey 
questions. A number of other commenters supported removal of these 
questions due to their concern the questions correlate pain treatment 
with patient satisfaction, thereby creating unrealistic patient 
expectations regarding pain management. These commenters also expressed 
concern the questions contribute to an environment in which patients 
expect to be pain free, whereas the goal of pain therapy should be to 
appropriately manage, not eliminate, pain. One commenter specifically 
supported removal of these questions because the commenter believed the 
questions elevate pain too highly as a factor in patient satisfaction 
and, thereby, in hospital reimbursement. Another commenter supported 
removing the Communication About Pain questions because the commenter 
believed the approach to pain management is too complicated and unclear 
to be assessed using survey questions.
    Response: We thank the commenters for their support. We are not 
aware of any scientific studies that support an association between 
scores on the Communication About Pain questions and opioid prescribing 
practices. In addition, we continue to believe that many factors 
outside the control of our quality program requirements may contribute 
to the perception of a link between the Communication About Pain 
questions and opioid prescribing practices, that pain management is an 
appropriate part of routine care that hospitals should manage and that 
pain management is an important concern for patients, their families, 
and their caregivers. Furthermore, we continue to believe the HCAHPS 
Survey is a valid and reliable measure of hospital quality that 
encourages hospitals to assess and improve patient experience. However, 
we believe that removing the Communication About Pain questions from 
the HCAHPS Survey will address potential confusion about the 
appropriate use of the HCAHPS Survey, is responsive to concerns 
regarding the public health issues arising from the opioid epidemic, 
and addresses both the recommendation of the President's Commission on 
Combating Drug Addiction and the Opioid Crisis and the prohibitions in 
the SUPPORT for Patients and Communities Act.
    Comment: A few commenters encouraged CMS to remove the 
Communication About Pain questions from both payment programs (for 
example, the Hospital VBP Program) and public reporting programs (for

[[Page 59145]]

example, the Hospital IQR Program) given the concern about unintended 
consequences. One commenter stated that the Communication About Pain 
questions and related bonus payments led to an overuse of opioids and 
that removing the questions is important to addressing the current 
opioid crisis.
    Response: To be clear, the Communication About Pain questions in 
the HCAHPS Survey are only used in the Hospital IQR Program. While the 
Hospital VBP Program uses HCAHPS Survey data to score the Patient and 
Community Engagement domain, it does not include the Pain Management 
dimension of the HCAHPS Survey--the predecessor of the current 
Communication About Pain questions. This dimension was removed from the 
Hospital VBP Program in the CY 2017 OPPS/ASC final rule with comment 
period (81 FR 79855 through 79862) beginning with the FY 2018 program 
year. The Hospital VBP Program also does not use the current 
Communication About Pain questions. In addition, the Hospital IQR 
Program is a pay-for-reporting quality program, as opposed to a pay-
for-performance quality program, and does not award incentive payments 
of any kind, including based on performance.
    Comment: Several commenters acknowledged the lack of scientific 
evidence demonstrating an impact of the Communication About Pain 
questions on providers' prescribing practices, but supported removal of 
the questions out of an abundance of caution. One commenter noted that 
CMS programs can significantly influence trends in the opioid epidemic 
and agreed it was prudent, despite the lack of scientific evidence, to 
remove the Communication About Pain questions until a better 
understanding of the link between the questions and prescribing 
practices is reached. Another commenter acknowledged the value of 
patient satisfaction surveys but expressed concern about tying these 
surveys to publicly reported hospital ratings and accountability, and 
therefore, supported removal of the Communication About Pain questions 
from the HCAHPS Survey. Other commenters stated that the questions are 
only tenuously linked to improved quality of care, and that the 
questions are of limited value in their current state.
    Response: We thank the commenters for their support. As noted 
above, we are not aware of any scientific studies that support an 
association between scores on the Communication About Pain questions 
and opioid prescribing practices. However, we believe that removing 
these questions from the HCAHPS Survey will address potential confusion 
about the appropriate use of the HCAHPS Survey, and is responsive to 
concerns regarding the public health concerns about the opioid epidemic 
as well as the provisions of the SUPPORT for Patients and Communities 
Act.
    Comment: A few commenters supported removal of the Communication 
About Pain questions due to concerns regarding the wording and focus of 
the questions. One commenter expressed its belief the questions focus 
on the frequency of communication about pain management rather than the 
quality or impact of this communication on the patient's expectations 
and understanding about pain, while another commenter expressed concern 
that the questions fail to address population-specific challenges and 
variations in pain treatment regimens due to physician preference, 
patient behavior, or health care facility practices. A third commenter 
stated its belief the questions do not allow for a nuanced discussion 
of pain management and patient expectations. Another commenter asserted 
that the Communication About Pain questions create patient expectations 
that hospital personnel should always discuss pain and its treatment 
with patients, which the commenter believes can encourage inappropriate 
prescribing and unrealistic expectations. This commenter further 
asserted that the wording of the questions encourages providers to 
overemphasize pain when it may not be an issue for a particular 
patient.
    One commenter supported removal of the Communication About Pain 
questions to preserve the Survey's integrity. Another commenter 
supported removal of the Communication About Pain questions due to 
concerns that the subjective nature of the HCAHPS Survey, and the 
Communication About Pain questions, may not accurately represent 
hospital performance. A third commenter expressed concern that 
including any questions about pain might cause patients who were 
unhappy about their pain treatment to provide negative responses to 
other, unrelated questions.
    Response: We thank the commenters for their support of our proposal 
to remove the Communication About Pain questions from the HCAHPS 
Survey. We continue to believe the HCAHPS Survey as a whole, and the 
Communication About Pain questions, are valid and reliable measures of 
hospital quality that encourage hospitals to assess and improve patient 
experience. Further, we recognize that our programs may have an 
influence over trends in the opioid epidemic, which underscores our 
decision to remove the Communication About Pain questions from the 
HCAHPS Survey earlier than originally proposed. We believe that 
removing the Communication About Pain questions from the HCAHPS Survey 
out of an abundance of caution and to comply with the provisions of the 
SUPPORT for Patients and Communities Act will address potential 
confusion about the appropriate use of the HCAHPS Survey, and is 
responsive to concerns regarding the public health issues arising from 
the opioid epidemic.
    Comment: A few commenters also noted the lack of National Quality 
Forum (NQF) endorsement as a reason to remove the Communication About 
Pain questions from the HCAHPS Survey and recommended that regardless 
of whether the questions are removed, CMS should submit the 
Communication About Pain questions for NQF endorsement.
    Response: We note that, while the Hospital IQR Program is not 
statutorily limited to only using NQF-endorsed measures,\223\ we 
consider NQF endorsement status when evaluating measures for adoption 
into the measure set. While the Communication About Pain questions are 
not currently NQF endorsed, because we are removing the Communication 
About Pain questions from the HCAHPS Survey in the Hospital IQR 
Program, we do not believe it prudent to submit the questions for NQF 
endorsement at this time. However, we will take commenters' feedback 
and recommendations into account as we continue to assess whether and 
how the Hospital IQR Program should assess communications about pain 
management. We note, however, that the HCAHPS Survey, in its entirety, 
is in fact NQF-endorsed (NQF #0166).\224\
---------------------------------------------------------------------------

    \223\ Section 1886(b)(3)(B)(viii)(IX)(bb) of the Act.
    \224\ HCAHPS measure description and history, including NQF 
endorsement status, available at: https://www.qualityforum.org/QPS/0166/.
---------------------------------------------------------------------------

    Comment: A few commenters supported removal of the Communication 
About Pain questions because the commenters believe that it is 
inappropriate to tie pain management to hospital reimbursement. One 
commenter supported removal of the Communication About Pain questions 
because the commenter believed that incentivizing providers to base 
care on patient satisfaction increases healthcare costs. Another 
commenter expressed its belief that decreasing the incentive to 
prescribe opioids for pain management

[[Page 59146]]

could reduce healthcare costs because opioid use can lead to a cascade 
of negative health effects that can increase lengths of stay and 
healthcare costs. Other commenters supported removal of the 
Communication About Pain questions because they believe it will help to 
reduce administrative burden and costs associated with data collection 
and reporting.
    Response: As noted above, we continue to believe the HCAHPS Survey 
and Communication About Pain questions are reliable measures of 
hospital quality that encourage hospitals to assess and improve patient 
experience, and that pain management is a critical part of routine 
patient care on which hospitals should focus and an important concern 
for patients, their families, and their caregivers. We believe the 
HCAHPS Survey is appropriate for use in CMS quality programs for public 
display of quality measurement data and tying hospital performance to 
Medicare reimbursement. However, out of an abundance of caution, and in 
the face of a nationwide epidemic of opioid overprescription, we 
believe that removal of the Communication About Pain questions from the 
HCAHPS Survey is warranted in order to resolve any perceived conflict 
between appropriate management of opioid use and patient satisfaction. 
Moreover, the SUPPORT for Patients and Communities Act prohibits 
inclusion of the Communication About Pain questions in HCAHPS Surveys 
conducted on or after January 1, 2020.
    Comment: Many commenters did not support removal of the 
Communication About Pain questions based on concerns that removal of 
the questions may minimize the importance of appropriate communication 
about pain management in the hospital setting. Specifically, a number 
of commenters stated that pain management is a critical part of routine 
patient care on which hospitals should focus and an important concern 
for patients, their families, and their caregivers, and expressed 
concern that removing the Communication About Pain questions may result 
in potential negative consequences for both patients and providers. A 
few commenters expressed particular concern that removal of these 
questions could have a negative impact on the appropriate treatment of 
pain associated with complex chronic and end-of-life illnesses. Some of 
these commenters expressed concern that removing the Communication 
About Pain questions might lead hospitals and providers to place less 
importance on communicating with patients about their pain and pain 
management. One commenter also noted that The Joint Commission has 
included engaging patients in treatment decisions about their pain 
management as part of the pain assessment and management standards for 
2018 accreditation standards.\225\
---------------------------------------------------------------------------

    \225\ More information about The Joint Commission's new and 
revised pain assessment and management standards effective January 
1, 2018 is available at: https://www.jointcommission.org/joint_commission_enhances_pain_assessment_and_management_requirements_for_accredited_hospitals_/.
---------------------------------------------------------------------------

    Some commenters who did not support removal of the pain questions 
urged CMS not to overlook the need to measure and evaluate how patient 
care is delivered and the role of appropriate communication about pain 
management during a hospital stay, including legitimate pain management 
using opioids in addition to other pain management methods. Other 
commenters asserted that removal of the pain questions would be 
tantamount to CMS refusing to acknowledge, or avoiding, the legitimate 
pain management needs of patients.
    Response: We acknowledge commenters' concern that removal of the 
Communication About Pain questions may result in potential negative 
consequences for both patients and providers. We remain concerned, 
however, about the potential negative consequences resulting from 
retaining the Communication About Pain questions in the HCAHPS Survey, 
including confusion regarding the appropriate use of the questions. We 
believe these concerns, coupled with the severity and urgency of the 
nationwide opioid epidemic, warrant removing the Communication About 
Pain questions to relieve any potential pressure clinicians may feel to 
prescribe opioids in order to achieve higher scores on the HCAHPS 
Survey. By removing the Communication About Pain questions from the 
HCAHPS Survey, the Survey neither encourages nor discourages clinicians 
from communicating with their patients about their pain and how best to 
manage their pain as appropriate for the particular patient.
    In addition, we disagree with commenters' assertions that removal 
of the Communication About Pain questions might lead hospitals and 
providers to place less importance on communication with their patients 
about their pain and pain management, or might lead to a negative 
impact on appropriate pain treatment, including treatment for pain 
associated with complex chronic and end-of-life illnesses. As a number 
of commenters noted, pain management is an appropriate part of routine 
patient care upon which hospitals should focus and an important concern 
for patients, their families, and their caregivers, and we do not 
believe removal of the Communication About Pain questions will 
necessarily result in hospitals no longer focusing on maintaining a 
high level of performance. Rather, we remain confident that hospitals 
will continue to focus on appropriate pain management, including 
communicating with their patients about pain, as part of their 
commitment to the patient experience and ongoing quality improvement 
efforts. In addition, as one commenter noted, engaging patients in 
treatment decisions about their pain management is required under the 
enhanced pain assessment and management requirements, applicable to all 
Joint Commission-accredited hospitals, effective January 1, 2018.\226\
---------------------------------------------------------------------------

    \226\ Ibid. The enhanced standards require that the hospital 
involves patients in the pain management treatment planning process 
through the following: Developing realistic expectations and 
measurable goals that are understood by the patient for the degree, 
duration, and reduction of pain; discussing the objectives used to 
evaluate treatment progress (for example, relief of pain and 
improved physical and psychosocial function); and providing 
education on pain management, treatment options, and safe use of 
opioid and non-opioid medications when prescribed. The enhanced 
standards also require, among other things, the hospital to analyze 
data collected on pain assessment and pain management to identify 
areas that need change to increase safety and quality for patients.
---------------------------------------------------------------------------

    With respect to commenters' requests that we not overlook the need 
to measure and evaluate how patient care is delivered and the role of 
appropriate communication about pain management during a hospital stay, 
including legitimate pain management using opioids in addition to other 
pain management methods, we reiterate that we remain dedicated to 
improving the quality of care provided to patients, including patients' 
experience in receiving care, and continue to consider the appropriate 
management of pain and communication between patients and their 
providers regarding pain as important aspects of care quality. As 
previously stated, we believe that removing the Communication About 
Pain questions will relieve any potential undue pressure on clinicians 
to prescribe opioids in order to achieve high patient satisfaction 
scores. We also believe that removing any such potential pressure on 
clinicians to prescribe opioids will ensure that providers can use 
their best judgment regarding pain management methods most appropriate 
for their patients, which may include non-opioid

[[Page 59147]]

management methods. Moreover, the SUPPORT for Patients and Communities 
Act prohibits inclusion of the Communication About Pain questions in 
HCAHPS Surveys conducted on or after January 1, 2020.
    Finally, we disagree with commenters' assertion that removing the 
Communication About Pain questions is tantamount to CMS' refusal to 
acknowledge, or avoiding, the legitimate pain management needs of 
patients. In the CY 2019 OPPS/ASC proposed rule (83 FR 37220), we 
solicited feedback regarding suggestions for other measures that would 
capture facets of pain management and related patient education, for 
instance, for collecting data about a hospital's pain management plan 
and providing that information back to consumers, and how other 
measures could take into account provider-supplied information on 
appropriate pain management and whether patients are informed about the 
risks of opioid use and about non-opioid pain management alternatives. 
Numerous commenters responded to our requests for feedback, and we 
summarize these responses later in this discussion. We will take 
commenters' suggestions into consideration as we continue to consider 
how best to capture and assess facets of pain management through 
quality measurement.
    Comment: A number of commenters did not support removal of the 
Communication About Pain questions due to the lack of empirical 
evidence that the questions are influencing providers to prescribe 
opiates or demonstrating a link between patient experience scores and 
opiate prescribing. One commenter further asserted that the 
Communication About Pain survey questions do not put more pressure on 
providers to prescribe opioids, but rather encourage providers to 
communicate about and address pain using multiple treatment methods.
    Response: As previously stated, we are unaware of any empirical 
evidence demonstrating that failing to prescribe opioids lowers a 
hospital's HCAHPS Survey scores. While we intended for the 
Communication About Pain questions to encourage providers to 
communicate with patients about pain management-related issues, 
including non-opioid pain management therapies (82 FR 38330), out of an 
abundance of caution, and in the face of a nationwide epidemic of 
opioid overprescription, we believe that removal of the Communication 
About Pain questions is warranted in order to resolve any perceived 
conflict between appropriate management of opioid use and patient 
satisfaction. Moreover, because the SUPPORT for Patients and 
Communities Act prohibits the inclusion of such questions in HCAHPS 
Surveys conducted on or after January 1, 2020, removal of the 
Communication About Pain questions is required. We believe that 
removing these questions will resolve any potential confusion by 
ensuring providers can use their best judgment in appropriately 
managing patients' pain without any potential undue pressure stemming 
from fear of negative feedback on the HCAHPS Survey. We note that 
hospitals will continue to be required to administer the HCAHPS Survey 
comprised of the remaining 29 questions to eligible patients, and that 
hospital performance on HCAHPS Survey measures based on the remaining 
questions will continue to be publicly reported on Hospital Compare.
    Comment: Some commenters opposed removal of the Communication About 
Pain questions because hospitals rely on the data for quality and 
performance improvement purposes. A few commenters asserted historical 
HCAHPS Survey data is one of the most effective tools hospitals have to 
improve patient experience of care. Some commenters noted that 
hospitals rely on HCAHPS Survey data to inform their quality and 
performance improvement efforts, including data from the Communication 
About Pain questions to assess how well they are discussing pain and 
communicating issues about pain management to patients.
    A few commenters noted that removal of the questions would force 
hospitals to rely on their vendors for any pain communication composite 
calculations or benchmarks for internal assessment purposes, as opposed 
to the national and State averages provided by CMS under the HCAHPS 
Survey. These commenters recommended that CMS furnish providers with 
important care experience metrics by making current pain communication 
scores, along with national and State benchmarks, available through 
hospital preview reports, from October 2019 onward. Commenters further 
requested CMS include these scores in CMS data files for providers' 
benchmarking and analysis.
    Response: We appreciate commenters' feedback about their concerns, 
experiences using HCAHPS Survey data, and recommendations. We 
acknowledge that removal of the Communication About Pain questions will 
eliminate our ability to calculate State and national averages, but we 
believe the importance of removing any perceived pressure of opioid 
overprescribing justifies removal of the questions during the national 
opioid epidemic. Moreover, the SUPPORT for Patients and Communities Act 
prohibits inclusion of the Communication About Pain questions in HCAHPS 
Surveys conducted on or after January 1, 2020.
    As described above, we will provide each hospital with feedback on 
its own performance in confidential preview reports starting with four 
quarters of CY 2018 Communication About Pain question data, and then on 
a rolling four-quarter basis through the final quarter of CY 2019 
Communication About Pain question data (that is, the 3rd quarter of 
2019). These confidential reports will include State and national 
averages for the reporting periods when this measure is collected.
    Comment: A number of commenters recommended that CMS retain the 
Communication About Pain questions in order to further investigate the 
relationship between these questions and opiate prescribing patterns, 
asserting that continued data collection would enable CMS to make a 
data-driven decision to retain or remove the questions based on 
available evidence. A few commenters questioned removal of the 
Communication About Pain questions based on concerns that the 
Communication About Pain questions were only recently implemented in 
January 2018. These commenters recommended that CMS retain the 
Communication About Pain questions in order to engage a broad range of 
stakeholders and assess their feedback regarding the use and impact of 
the Communication About Pain questions on opioid prescribing practices, 
hospital quality improvement efforts, and patient care. Other 
commenters recommended convening Technical Expert Panels and a pilot 
study to better assess the implications of removing the pain questions 
on patient care before removing the Communication About Pain questions.
    Response: We thank commenters for their recommendations to postpone 
removal of the Communication About Pain questions until additional 
analyses can be performed. While we agree delaying removal of these 
questions would increase the amount of data available to potentially 
assess the questions' effect on physician prescription practices and 
the link between patient experience scores and opiate prescribing, we 
believe concerns regarding the potential negative consequences of 
retaining the questions and public health concerns about the opioid 
epidemic outweigh the benefits of additional data collection. We 
believe the importance of removing any

[[Page 59148]]

perceived pressure of opioid overprescribing justifies removal of the 
questions during the national opioid epidemic. Moreover, the SUPPORT 
for Patients and Communities Act prohibits inclusion of the 
Communication About Pain questions in HCAHPS Surveys conducted on or 
after January 1, 2020. For these reasons, as discussed above, we are 
finalizing a modification of our proposal and are removing the 
Communication About Pain questions beginning with October 2019 
discharges for the FY 2021 payment determination and subsequent years.
    Comment: Many commenters who did not support removal of the 
Communication About Pain questions due to the importance of capturing 
pain management experience data also recommended that CMS delay public 
reporting on the questions beyond October 2020 to allow further time 
for additional assessment of the questions. A number of these 
commenters recommended that CMS continue to test the questions and 
delay public reporting until the questions are valid, reliable, and do 
not pose a risk of unintended consequences. A few commenters also 
supported delaying public reporting based on their concerns about the 
absence of any evidence demonstrating a relationship between the use of 
the Communication About Pain questions and opioid prescribing behavior.
    Response: We thank commenters for their recommendations. We 
continue to believe the HCAHPS Survey as a whole, and the Communication 
About Pain questions, are valid and reliable measures of hospital 
quality that encourage hospitals to assess and improve patient 
experience. However, we believe that removing the Communication About 
Pain questions from the HCAHPS Survey during the national opioid 
epidemic will remove any perceived pressure of opioid overprescribing, 
and will address potential confusion about the appropriate use of the 
HCAHPS Survey. Therefore, as stated above, upon consideration of the 
comments received and public health concerns about the opioid epidemic, 
as well as to comply with the SUPPORT for Patients and Communities Act, 
we will not publicly report data collected from the Communication About 
Pain questions.
    Comment: A number of commenters responded to CMS' request for 
feedback in the proposed rule (83 FR 37220) regarding whether it would 
be valuable for CMS to issue guidance suggesting that hospitals do not 
administer any surveys with pain-related questions, including adding 
hospital-specific supplemental items to HCAHPS, as well as the 
potential implementation of a third party quality assurance program to 
assure that hospitals are not misusing survey data by creating pressure 
on individual clinicians to provide inappropriate clinical care. A few 
commenters recommended that CMS consider issuing guidance to providers 
and hospitals regarding appropriate use of the HCAHPS Survey, 
specifically against the disaggregation of HCAHPS Survey data. These 
commenters stated their belief that clearer survey use guidance would 
mitigate inappropriate use of survey results, such as using 
disaggregated data to assess providers' performance, to compare 
performance across providers or wards, and/or to influence provider 
performance by tying disaggregated survey results to individual 
clinician compensation. One commenter asserted that CMS guideline 
adherence works best when an HCAHPS Survey vendor provides hospitals 
and healthcare systems with clear communication and interpretation of 
those guidelines, and therefore recommended against implementation of 
an HCAHPS Survey-specific quality assurance program. This commenter 
recommended that CMS consider future implementation of a third-party 
quality assurance program for all CMS-mandated CAHPS surveys.
    Other commenters recommended against CMS disallowing administration 
of supplemental pain management related questions alongside the HCAHPS 
Survey. These commenters noted pain remains one of the most important 
aspects of a patient's experience of care, that hospitals rely on this 
survey-based information for research and evaluation regarding their 
quality and efficacy of care, and that disallowing these supplemental 
questions would effectively omit a critical care experience factor from 
hospitals' quality improvement efforts.
    Response: We thank the commenters for their feedback and will take 
these recommendations into consideration as we move forward with the 
HCAHPS Survey.
    Comment: A number of commenters responded to CMS' request for 
feedback regarding suggestions for other measures that would capture 
facets of pain management and related patient education, and that would 
provide that information back to consumers, as well as CMS' request for 
feedback regarding how other measures could take into account provider-
supplied information on appropriate pain management and whether 
patients are informed about the risks of opioid use and about non-
opioid pain management alternatives. Many commenters encouraged CMS to 
engage with stakeholders, including hospitals, clinicians, experts in 
pain management and palliative care, measure developers, researchers, 
the NQF, and the Measure Applications Partnership (MAP) to explore a 
range of approaches to assessing how healthcare systems and hospitals 
are addressing pain management, including further revisions to the pain 
questions in HCAHPS Survey and the use of other measurement methods, 
including pain assessments that are more sensitive to beneficiaries' 
needs.
    Several commenters recommended that CMS engage in further research 
on the current version of the Communication About Pain questions, 
including assessing the potential tie between the questions and opioid 
prescribing practices. A few commenters provided specific 
recommendations for improving pain management assessment within the 
HCAHPS Survey. Some commenters recommended that CMS revise the current 
pain management questions to focus more on alternative pain management 
methods, such as ice packs and over-the-counter pain medication, and to 
better assess whether the patient was given sufficient guidance on how 
to manage pain post-discharge. Another commenter recommended that CMS 
develop new pain management questions focused on pain management 
processes and evidence-based standards of care rather than patient-
reported outcomes. A third commenter recommended that CMS develop 
alternate questions assessing the role and behaviors of different 
clinicians in a patient's pain management because the commenter 
believed these alternatives are more objective than the current 
Communication About Pain questions and would provide a better picture 
of the assessment and treatment undertaken by the clinician for the 
patient's pain. Another commenter encouraged CMS to conduct additional 
research on pain-related survey questions and prescribing practices in 
emergency departments. One commenter recommended that CMS continue to 
collect the current Communication About Pain questions while evaluating 
potential new measures due to the importance of continuing to collect 
data on hospitals' communication about pain management as a critical 
component of patient experience and because more time is needed to 
collect feedback on potential alternatives.
    One commenter suggested CMS evaluate assessing communication about 
pain management within the context of specific care episodes because 
these

[[Page 59149]]

assessments could focus on the use of targeted pain management 
modalities, unlike the global HCAHPS Survey. This commenter further 
recommended that CMS focus on developing high-priority pain measures 
that can improve functional assessment scores with reduced opioid use. 
Another commenter recommended that CMS evaluate the use of patient-
reported outcome measures to assess pain management and communication 
about pain because the commenter believed these types of measures would 
provide hospitals with valuable experience of care data relative to the 
investment required to update infrastructure and workflow investment. A 
third commenter expressed support for development of meaningful 
measures of pain management but urged caution about the potential for 
measures to create undue barriers to access to appropriate pain 
medication for patients suffering from chronic pain and therefore 
recommended that CMS strive to make measures more sensitive to 
patients' disease state. Another commenter encouraged additional 
research and measure development specific to emergency department care 
and emergency nursing.
    Response: We appreciate the feedback from commenters and will take 
these comments into consideration as we continue to consider how best 
to capture and assess facets of pain management through quality 
measurement, including the role of appropriate communication about pain 
during a hospital stay, informing patients about the risks associated 
with the use of opioids, and educating patients on non-opioid 
alternative pain management methods. As stated above, we believe that 
removing the Communication About Pain questions from the HCAHPS Survey 
out of an abundance of caution during the national opioid epidemic will 
help to address any potential confusion about the appropriate use of 
the HCAHPS Survey by relieving any potential pressure or undue 
influence on clinicians' opioid prescribing practices.
    Comment: Some commenters recommended that CMS focus on mitigating 
any unintended consequences of pain management assessment before 
developing new measures, and further recommended against the adoption 
of measures that increase administrative burden and/or are not linked 
to improved outcomes. These commenters also recommended that CMS enable 
hospitals and physicians to monitor the administration of opioids and 
promote their evidence-based use through programs that are tailored to 
the needs of the hospital and its patient population. One commenter 
specifically recommended against development of pain management-
specific measures because the commenter believes a set of measures 
designed to be applied universally would downplay critical factors that 
are necessary to create individualized pain management plans. One 
commenter requested a model of the impact of the removal of the 
Communication About Pain questions on overall HCAHPS scores and urged 
CMS to carefully balance the need to remove the questions with the need 
to retain an important component of patient experience.
    Response: We appreciate the feedback from commenters and will take 
these comments into consideration as we continue to consider how best 
to capture and assess facets of pain management through quality 
measurement, including the role of appropriate communication about pain 
during a hospital stay, informing patients about the risks associated 
with the use of opioids, and educating patients on non-opioid 
alternative pain management methods. We will continue to consider 
unintended consequences of pain management assessment and we encourage 
hospitals to monitor the administration of opioids through programs 
that are tailored to the needs of the specific hospitals and patient 
populations. We do not anticipate that removing the Communication About 
Pain questions would impact the overall HCAHPS scores. We note that the 
data collected from the Communication About Pain questions will not be 
scored for purposes of CMS payments to hospitals, because the Hospital 
IQR Program is a pay-for-reporting not pay-for-performance quality 
program. Further, we note that the data from the Communication About 
Pain question will not be publicly reported. Our decision to remove the 
Communication About Pain questions from the HCAHPS Survey was based 
upon careful consideration of the importance of addressing patients' 
experience, stakeholder feedback, and the nationwide opioid epidemic.
    Comment: A few commenters recommended that instead of removing the 
Communication About Pain questions, CMS consider incentivizing 
alternative pain management methods. Specifically, one commenter 
recommended that CMS consider alternate ways to ensure adequate patient 
awareness of non-opioid alternative treatments because the commenter 
believed that in the future there will be more ways to treat chronic 
and acute pain. Another commenter expressed the belief that there is a 
need for additional funding or other incentives to increase research 
supporting evidence-based practices around effective pain assessment 
and intervention and to develop operational guidelines and clinical 
practice standards for use in hospitals. A few commenters who supported 
both the importance of assessing patient experience, as well as of 
avoiding incentivizing inappropriate opioid prescribing, urged CMS to 
ensure that CMS does not adopt policies that could impede access to 
medication for patients who legitimately need opioids.
    Response: We appreciate the feedback from commenters and will take 
these comments into consideration as we continue to consider how best 
to capture and assess facets of pain management through quality 
measurement, including the role of appropriate communication about pain 
during a hospital stay, informing patients about the risks associated 
with the use of opioids, and educating patients on non-opioid 
alternative pain management methods.
    After consideration of the public comments we received, and as 
required by the SUPPORT for Patients and Communities Act, we are 
finalizing a modified version of our proposals regarding removal of the 
Communication About Pain questions from the HCAHPS Survey in the 
Hospital IQR Program. Instead of removing the questions effective with 
January 2022 discharges, for the FY 2024 payment determination and 
subsequent years as proposed, we are finalizing removing them effective 
with October 2019 discharges, for the FY 2021 payment determination and 
subsequent years. In addition, instead of publicly reporting the data 
from October 2020 until October 2022 and then subsequently 
discontinuing public reporting as proposed, we are finalizing that we 
will not publicly report the data collected from the Communication 
About Pain questions at all.

XVII. Additional PPS-Exempt Cancer Hospital Quality Reporting (PCHQR) 
Program Policies

A. Background

    Section 1866(k)(1) of the Act requires that, for FY 2014 and each 
subsequent fiscal year, hospitals described in section 1886(d)(1)(B)(v) 
of the Act (referred to as ``PPS-Exempt Cancer Hospitals'' or ``PCHs'') 
submit data to the Secretary in accordance with section 1866(k)(2) of 
the Act with respect to such fiscal year.

[[Page 59150]]

    The PPS-Exempt Cancer Hospital Quality Reporting (PCHQR) Program 
strives to put patients first by ensuring they, along with their 
clinicians, are empowered to make decisions about their own health care 
using data-driven insights that are increasingly aligned with 
meaningful quality measures. To this end, we support technology that 
reduces burden and allows clinicians to focus on providing high quality 
health care to their patients. We also support innovative approaches to 
improve the quality, accessibility, and affordability of care, while 
paying particular attention to improving clinicians' and beneficiaries' 
experiences when participating in CMS programs. In combination with 
other efforts across the Department of Health and Human Services (HHS), 
we believe the PCHQR Program incentivizes PCHs to improve their health 
care quality and value, while giving patients the tools and information 
needed to make the best decisions.
    For additional background information, including previously 
finalized measures and other policies for the PCHQR Program, we refer 
readers to the following final rules: The FY 2013 IPPS/LTCH PPS final 
rule (77 FR 53556 through 53561); the FY 2014 IPPS/LTCH PPS final rule 
(78 FR 50838 through 50846); the FY 2015 IPPS/LTCH PPS final rule (79 
FR 50277 through 50288); the FY 2016 IPPS/LTCH PPS final rule (80 FR 
49713 through 49723); the FY 2017 IPPS/LTCH PPS final rule (81 FR 57182 
through 57193); the FY 2018 IPPS/LTCH PPS final rule (82 FR 38411 
through 38425); and the FY 2019 IPPS/LTCH PPS final rule (83 FR 41609 
through 41624).

B. Retention of Two Safety Measures in the PCHQR Program

    In the FY 2019 IPPS/LTCH PPS final rule (83 FR 41611 through 
41616), we finalized the removal of four previously finalized measures 
and finalized one new quality measure for the FY 2021 program year and 
subsequent years. We also discussed our proposal in the FY 2019 IPPS/
LTCH PPS proposed rule (83 FR 20503) to remove two National Healthcare 
Safety Network (NHSN) chart-abstracted measures from the PCHQR Program 
beginning with the FY 2021 program year under proposed removal Factor 
8, ``the costs associated with the measure outweigh the benefit of its 
continued use in the program.'' The measures we had proposed to remove 
under this removal factor are:
     NHSN Catheter-Associated Urinary Tract Infection (CAUTI) 
Outcome Measure (PCH-5/NQF #0138); and
     NHSN Central Line-Associated Bloodstream Infection 
(CLABSI) Outcome Measure (PCH-4/NQF #0139).
    We noted that we had first adopted the CAUTI and CLABSI measures 
for the FY 2014 program year in the FY 2013 IPPS/LTCH PPS final rule 
(77 FR 53557 through 53559), and we referred readers to that final rule 
for a detailed discussion of the measures. We also stated that we had 
proposed to remove these measures from the PCHQR Program based on our 
belief that removing these measures would reduce program costs and 
complexities associated with the use of these data by patients in 
decision-making. We also believed the costs, coupled with the high 
technical and administrative burden on PCHs associated with collecting 
and reporting this measure data, outweighed the benefits of the 
continued use of the CAUTI and CLABSI measures in the program. Further, 
we noted that it has become difficult to publicly report these measures 
due to the low volume of data produced and reported by the small number 
of facilities participating in the PCHQR Program and the corresponding 
lack of an appropriate methodology to publicly report these data.
    We stated in the FY 2019 IPPS/LTCH PPS final rule (83 FR 41613) 
that we had invited public comment on our proposals to remove the CAUTI 
and CLABSI measures from the PCHQR Program beginning with the FY 2021 
program year. We also stated that we would defer making a final 
decision on the removal or retention of the CAUTI and CLABSI measures 
from the PCHQR Program in order to conduct additional data analyses to 
assess measure performance based on new information provided by the CDC 
which was not available at the time we had proposed the removal of 
these measures. Lastly, we stated that we wished to evaluate those data 
for trends that link positive improvements (that is, a decrease in the 
reporting burden and/or cost, and/or demonstrated feasibility for 
public reporting) to these measures. We also noted that we would 
reconcile the public comments we received in future rulemaking.
    Comment: Many commenters supported the proposed removal of the 
CAUTI and CLABSI measures from the PCHQR Program. Commenters indicated 
that an appropriate statistical method to publicly report the data has 
not been identified and believed that these definitional and 
statistical issues may hamper the cancer hospitals' ability to identify 
opportunities for internal performance improvement activities related 
to these measures. Commenters also noted that the low number of PCHs, 
the heterogeneous makeup of the hospitals, and the nationwide 
dispersion of the sites make it difficult to provide meaningful 
comparisons for consumers. Commenters supported CMS' efforts in 
streamlining the PCHQR Program measure set, consistent with CMS' 
commitment to using a smaller set of more meaningful measures and 
reducing paperwork and reporting burden on providers. Nevertheless, 
given the potential negative impact of health-care acquired infections 
(HAIs) on patients, particularly for the cancer patient population, 
commenters encouraged the CDC and CMS to continue to work 
collaboratively with professional societies to standardize definitions, 
reporting, and sharing of data to foster performance improvement in 
these areas.
    Response: We thank the commenters for their support. We will 
continue to work collaboratively to standardize definitions, and to 
develop a sufficient reporting mechanism for quality metrics that 
assess the impact of HAIs on patients, particularly for the cancer 
patient population. However, for the reasons discussed in more detail 
below, we are not finalizing our proposals to remove the CAUTI and 
CLABSI measures from the PCHQR Program.
    Comment: Some commenters did not support the proposed removal of 
the CAUTI and CLABSI measures from the PCHQR Program, asserting that 
the application of proposed removal Factor 8 was inadequate for measure 
removal because consumers' needs have not been appropriately factored 
into the value assessment of the measures. Commenters specifically 
expressed concern that removing these measures might inappropriately 
deemphasize the importance of patient safety in quality care delivery. 
The commenters further questioned whether cost is the direct driving 
factor for the low volume of reporting on the CAUTI and CLABSI 
measures. Commenters also noted that because cancer hospitals will 
still be required to complete NHSN reporting for other measures, 
removal of the CAUTI and CLABSI measures would not necessarily lead to 
significant burden reduction. Lastly, commenters encouraged CMS to 
continue to work with the measures' developer to consider alternative 
methodologies for publicly reporting the measure data.
    Response: We thank the commenters for their feedback. We believe 
the primary benefit of a measure's use in the PCHQR Program is to 
empower consumers through incentivizing the provision of high quality 
care and providing publicly reported data

[[Page 59151]]

regarding the quality of care available for use in making decisions 
about their care. Therefore, we intend to consider the benefits, 
especially to patients and their families, when evaluating measures 
under measure removal Factor 8, which we finalized in the FY 2019 IPPS/
LTCH PPS final rule (83 FR 41609 through 41611). We emphasize that 
consumers' needs and interests are factored into the value assessment 
of measures prior to any proposal to remove a measure from the PCHQR 
Program, and further note that we regularly solicit consumer feedback 
on the PCHQR Program via public comment periods and education and 
outreach activities, and that this feedback informs our policy 
development efforts.
    At the time that we proposed to remove the CAUTI and CLABSI 
measures from the PCHQR Program, the available performance data did not 
enable us to assess PCH performance relative to oncology unit 
performance in other care settings. In addition, CDC's previous 
analytic work used to develop the rebaselined predictive models had 
demonstrated that PCH status was not a significant predictor for either 
CAUTIs or CLABSIs. Since that time, we have conducted our own updated 
analyses regarding the continued use of the CAUTI and CLABSI measures 
in the PCHQR Program using updated CDC data. Although CDC had 
previously believed that oncology unit locations, including those in 
PCHs, had a higher incidence of infections than other types of units in 
acute care hospitals, CDC now believes, after controlling for location 
type, that oncology unit locations in PCHs do not have a higher 
incidence of infection than oncology units within other acute care 
hospitals. CDC's updated analysis also produced a consistent finding 
that cancer hospital status was not a significant risk factor in any of 
the device-associated HAI risk models, including those used for CLABSI 
and CAUTI.\227\ We believe that these results indicate that reporting 
PCH CAUTI and CLABSI performance measure data is just as important as 
reporting acute care hospital CAUTI and CLABSI performance measure 
data.
---------------------------------------------------------------------------

    \227\ SIR Guide: August 2018 Update. Available at: https://www.cdc.gov/nhsn/pdfs/ps-analysis-resources/nhsn-sir-guide.pdf.
---------------------------------------------------------------------------

    We are aware that the CLABSI and CAUTI measures specifications were 
recently updated to use new standard infection ratio (SIR) calculations 
that can be applied to cancer hospitals, including PCHs. This SIR 
calculation method is different than the current CLABSI and CAUTI 
measure methodology, which provides raw location-stratified rates. We 
are also aware that there may be concern that the CAUTI and CLABSI data 
calculated under the current methodology may inaccurately appear to 
show lower performance among PCHs than the performance reported by 
acute care hospitals that are reporting CLABSI and CAUTI data under the 
newly updated methodology. We believe this recent update \228\ of the 
CAUTI and CLABSI measures addresses these concerns. Specifically, the 
updates include rates that are stratified by patient care locations 
within PCHs, and no predictive models or comparisons are used in these 
rate calculations. We intend to propose to adopt these updated versions 
of the CLABSI and CAUTI measures in future rulemaking but believe that, 
until that time, the importance of emphasizing patient safety in 
quality care delivery justifies retaining the current versions of the 
CLABSI and CAUTI measures in the PCHQR Program. Despite the fact that 
infection rates are not higher in the PCHs, we believe it is important 
to measure CLABSI and CAUTI in this setting. However, we will work 
closely with the CDC to assess the updated risk-adjusted versions of 
CAUTI and CLABSI, and evaluate the data provided in the form of SIRs 
for each PCH, for the purposes of future program implementation and 
public reporting.
---------------------------------------------------------------------------

    \228\ NHSN Patient Safety Component Manual: January 2018 Update. 
Available at: https://www.cdc.gov/nhsn/pdfs/pscmanual/pcsmanual_current.pdf.
---------------------------------------------------------------------------

    After consideration of the public comments we received, and 
consideration of the most recent information provided by the CDC, we 
are not finalizing our proposals to remove the Catheter-Associated 
Urinary Tract Infection (CAUTI) Outcome Measure (PCH-5/NQF #0138) and 
Central Line-Associated Bloodstream Infection (CLABSI) Outcome Measure 
(PCH-4/NQF #0139) from the PCHQR measures beginning with the FY 2021 
program year. We agree with the conclusions drawn from the CDC's data 
analyses, which demonstrate that reporting PCH CAUTI and CLABSI 
performance measure data is just as important as reporting acute care 
hospital CAUTI and CLABSI performance measure data. Further, we believe 
that these measures have the potential to provide beneficiaries with 
valuable information on PCH performance in avoiding hospital-acquired 
infections and improving patient safety. However, for the reasons 
discussed in section XVII.C.2. of this final rule with comment period, 
we are continuing to defer public reporting of these measure data.
    We believe this approach most effectively balances the needs of the 
PCHQR Program and the importance of collecting patient safety data 
while taking into consideration the impact on the 11 PCHs of reporting 
raw data to CMS. We hope to introduce the refined CAUTI and CLABSI 
measures with adequate risk adjustment into the PCHQR Program in the 
near future. We note any such change will be made via rulemaking, and 
that we will solicit input from the Measures Application Partnership 
(MAP) to garner multi-stakeholder input on the updated versions prior 
to proposing to adopt these refined measures.
    The table below summarizes the PCHQR Program measure set for the FY 
2021 program year:
BILLING CODE 4120-01-P

[[Page 59152]]

[GRAPHIC] [TIFF OMITTED] TR21NO18.116


[[Page 59153]]


[GRAPHIC] [TIFF OMITTED] TR21NO18.117

BILLING CODE 4120-01-C

C. Continued Deferment of Public Display of the NHSN Measures

1. Background
    Under section 1866(k)(4) of the Act, we are required to establish 
procedures for making the data submitted under the PCHQR Program 
available to the public. Such procedures must ensure that a PCH has the 
opportunity to review the data that are to be made public with respect 
to the PCH prior to such data being made public. Section 1866(k)(4) of 
the Act also provides that the Secretary must report quality measures 
of process, structure, outcome, patients' perspective on care, 
efficiency, and costs of care that relate to services furnished in such 
hospitals on the CMS website.
2. Deferment of Public Display of National Healthcare Safety Network 
(NHSN) Measures
    In the FY 2019 IPPS/LTCH PPS final rule (83 FR 41622), we indicated 
that all PCHs are reporting Colon and Abdominal Hysterectomy SSI, MRSA, 
CDI, and HCP data to the NHSN under the PCHQR Program. In 2016, the CDC 
announced that HAI data reported to NHSN for 2015 will be used as the 
new baseline, serving as a new ``reference point'' for comparing 
progress.\229\ The results of the rebaselining allow for year-to-year 
comparisons beginning with 2015 data; beginning with FY 2019, we will 
have more than 2 years of comparable data available for evaluation. We 
are currently still evaluating the data resulting from the rebaselining 
to properly assess trends.\230\ Therefore, in that final rule (83 FR 
41622), we finalized a modification of our proposal to delay public 
reporting of data for the SSI, MRSA, CDI, and HCP measures until CY 
2019. Based on stakeholder feedback, we finalized a policy to provide 
stakeholders with performance data as soon as practicable (that is, if 
useable data is available sooner than CY 2019, we will publicly report 
it on the Hospital Compare website via the next available Hospital 
Compare release).
---------------------------------------------------------------------------

    \229\ Centers for Disease Control and Prevention. ``Paving Path 
Forward: 2015 Rebase line.'' Available at: https://www.cdc.gov/nhsn/2015rebaseline/.
    \230\ Rebase line Timeline FAQ Document. Available at: https://www.cdc.gov/nhsn/pdfs/rebaseline/faq-timeline-rebaseline.pdf.
---------------------------------------------------------------------------

    As discussed above, we are not finalizing our proposal to remove 
the CAUTI and CLABSI measures. However, we will continue to defer 
public reporting for the CAUTI and CLABSI measures as indicated in the 
FY 2018 IPPS/LTCH PPS final rule (82 FR 38423). Based on our intent to 
propose to adopt the revised versions of the measures in the PCQHR 
Program in future rulemaking, we are continuing to evaluate the 
performance data for the updated versions of the CAUTI and CLABSI 
measures to draw conclusions about their statistical significance, in 
accordance with current risk adjustment methods defined by CDC. For 
these reasons, we are finalizing that we will provide stakeholders with 
performance data for the CAUTI and CLABSI measures as soon as 
practicable.
3. Update on Public Display of the Admissions and Emergency Department 
(ED) Visits for Patients Receiving Outpatient Chemotherapy Measure
    In the FY 2017 IPPS/LTCH PPS final rule (81 FR 57187 through 
57188), we stated that we would publicly report the risk-standardized 
admission rate (RSAR) and risk-standardized ED visit rate (RSEDR) for 
the Admissions and Emergency Department (ED) Visits for the Patients 
Receiving Outpatient Chemotherapy measure for all participating PCHs 
with 25 or more eligible patients per measurement period to maintain a 
reliability of at least 0.4 (as measured by the interclass correlation 
coefficient, (ICC)). We also noted that if a PCH did not meet the 25-
eligible patient threshold, we would include a footnote on the Hospital 
Compare website indicating that the number of cases is too small to 
reliably measure that PCH's rate, but that these patients and PCHs 
would still be included when calculating the national rates for both 
the RSAR and RSEDR. Lastly, we indicated that to prepare PCHs for 
public reporting, we would conduct a confidential national reporting 
(dry run) of measure results prior to public reporting.
    We recently completed the confidential national reporting (dry run) 
for this measure and are currently assessing the results to ensure data 
accuracy and completeness. We intend to propose a timeframe for public 
reporting of this measure in the FY 2020 IPPS/LTCH PPS proposed rule.
4. Summary of Public Display Requirements for the FY 2021 Program Year
    Our public display policies for the FY 2021 program year are shown 
in the following table:

[[Page 59154]]

[GRAPHIC] [TIFF OMITTED] TR21NO18.118

XVIII. Files Available to the Public via the Internet

    The Addenda to the OPPS/ASC proposed rules and the final rules with 
comment period are published and available via the internet on the CMS 
website. In the CY 2019 OPPS/ASC proposed rule (83 FR 37220), for CY 
2019, we proposed to change the format of the OPPS Addenda A, B, and C, 
by adding a column entitled ``Copayment Capped at the Inpatient 
Deductible of $1,364.00'' where we would flag, through use of an 
asterisk, those items and services with a copayment that is equal to or 
greater than the inpatient hospital deductible amount for any given 
year (the copayment amount for a procedure performed in a year cannot 
exceed the amount of the inpatient hospital deductible established 
under section 1813(b) of the Act for that year). We requested public 
comments on this proposed change to the OPPS Addenda A, B, and C for CY 
2019.
    We did not receive any public comments regarding the proposed CY 
2019 format changes for the OPPS Addenda A, B, and C. Therefore, for CY 
2019, we are finalizing our proposal to add an additional column 
entitled ``Copayment Capped at the Inpatient Deductible of $1,364.00'' 
where we flag, through use of an asterisk, those items and services 
with a copayment that is equal to or greater than the inpatient 
hospital deductible amount for any given year for which the copayment 
will be capped at the inpatient deductible amount.
    To view the Addenda to this final rule with comment period 
pertaining to CY 2019 payments under the OPPS, we refer readers to the 
CMS website at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/HospitalOutpatientPPS/Hospital-Outpatient-Regulations-and-Notices.html; select ``1695-FC'' from the list of regulations. All OPPS 
Addenda to this final rule with comment period are contained in the 
zipped folder entitled ``2019 OPPS 1695-FC Addenda'' at the bottom of 
the page. To view the Addenda to this final rule with comment period 
pertaining to CY 2019 payments under the ASC payment system, we refer 
readers to the CMS website at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/ASCPayment/ASC-Regulations-and-Notices.html; 
select ``1695-FC'' from the list of regulations. All ASC Addenda to 
this final rule with comment period are contained in the zipped folders 
entitled ``Addendum AA, BB, DD1, DD2, and EE.''

XIX. Collection of Information Requirements

A. Statutory Requirement for Solicitation of Comments

    Under the Paperwork Reduction Act of 1995, we are required to 
provide 60-day notice in the Federal Register and solicit public 
comment before a collection of information requirement is submitted to 
the Office of Management and Budget (OMB) for review and approval. In 
order to fairly evaluate whether an information collection should be 
approved by OMB, section 3506(c)(2)(A) of the Paperwork Reduction Act 
of 1995 requires that we solicit comment on the following issues:
     The need for the information collection and its usefulness 
in carrying out the proper functions of our agency.
     The accuracy of our estimate of the information collection 
burden.
     The quality, utility, and clarity of the information to be 
collected.

[[Page 59155]]

     Recommendations to minimize the information collection 
burden on the affected public, including automated collection 
techniques.
    In the CY 2019 OPPS/ASC proposed rule (83 FR 37720), we solicited 
public comment on each of these issues for the following sections of 
this document that contain information collection requirements (ICRs).

B. ICRs for the Hospital OQR Program

1. Background
    The Hospital OQR Program is generally aligned with the CMS quality 
reporting program for hospital inpatient services known as the Hospital 
IQR Program. We refer readers to the CY 2011 through CY 2018 OPPS/ASC 
final rules with comment periods (75 FR 72111 through 72114; 76 FR 
74549 through 74554; 77 FR 68527 through 68532; 78 FR 75170 through 
75172; 79 FR 67012 through 67015; 80 FR 70580 through 70582; 81 FR 
79862 through 79863; and 82 FR 59476 through 59479, respectively) for 
detailed discussions of Hospital OQR Program information collection 
requirements we have previously finalized. The information collection 
requirements associated with the Hospital OQR Program are currently 
approved under OMB control number 0938-1109. Below we discuss only the 
changes in burden that will result from the newly finalized policies in 
this final rule with comment period.
    In section XIII.B.4.b. of the proposed rule, we proposed to remove 
a total of 10 measures. Specifically, beginning with the CY 2020 
payment determination, we proposed to remove: (1) OP-27: Influenza 
Vaccination Coverage Among Healthcare Personnel; and beginning with the 
CY 2021 payment determination, we proposed to remove: (2) OP-5: Median 
Time to ECG; (3) OP-9: Mammography Follow-up Rates; (4) OP-11: Thorax 
CT Use of Contrast Material; (5) OP-12: The Ability for Providers with 
HIT to Receive Laboratory Data Electronically Directly into Their 
Qualified/Certified EHR System as Discrete Searchable Data; (6) OP-14: 
Simultaneous Use of Brain Computed Tomography (CT) and Sinus CT; (7) 
OP-17: Tracking Clinical Results between Visits; (8) OP-29: Endoscopy/
Polyp Surveillance: Appropriate Follow-up Interval for Normal 
Colonoscopy in Average Risk Patients; (9) OP-30: Endoscopy/Polyp 
Surveillance: Colonoscopy Interval for Patients with a History of 
Adenomatous Polyps--Avoidance of Inappropriate Use; and (10) OP-31: 
Cataracts--Improvement in Patient's Visual Function within 90 Days 
Following Cataract Surgery. However, after consideration of public 
comments we received, in this final rule with comment period we are not 
finalizing our proposals to remove two measures: OP-29: Endoscopy/Polyp 
Surveillance: Appropriate Follow-up Interval for Normal Colonoscopy in 
Average Risk Patients; and OP-31: Cataracts--Improvement in Patient's 
Visual Function within 90 Days Following Cataract Surgery beginning 
with the CY 2021 payment determination. The reduction in burden 
associated with our finalized policies is discussed below in sections 
XIX.B.3. and 4. of this final rule with comment period.
    In section XIII.D.2. of this final rule with comment period, we are 
finalizing our proposal to update the frequency with which we will 
release HOPD Specifications Manuals, with modification, such that 
instead of releasing the full manual once or twice a year, as proposed, 
we would release specifications manuals every 12 months beginning with 
CY 2019 and for subsequent years and release addenda (specific updates 
rather than full manual releases) as necessary. In section XIII.C.2. of 
this final rule with comment period, beginning with the CY 2020 payment 
determination, we are finalizing our proposal to remove the Notice of 
Participation (NOP) form as a requirement for the Hospital OQR Program 
and to update 42 CFR 419.46(a) to reflect these policies. As discussed 
below, we do not expect these finalized policies to affect our 
collection of information burden estimates.
2. Update to the Frequency of Releasing Hospital Outpatient Quality 
Reporting Specifications Manuals Beginning With CY 2019 and for 
Subsequent Years
    In section XIII.D.2. of this final rule with comment period, we are 
finalizing our proposal, with modification, to update the frequency 
with which we will release Hospital Outpatient Quality Reporting 
Specifications Manuals, with modification such that instead of 
releasing the full manual once or twice each year, as proposed, we will 
release the Specifications Manuals once every 12 months and release 
addenda as necessary, beginning with CY 2019 and for subsequent years. 
We anticipate that this change will reduce hospital confusion, as 
releasing fewer manuals per year reduces the need to review updates as 
frequently as was previously necessary. However, because this change 
does not affect Hospital OQR Program participation requirements or data 
reporting requirements, we do not expect a change in the information 
collection burden experienced by hospitals.
3. Estimated Burden of Hospital OQR Program Newly Finalized Policies 
for the CY 2020 Payment Determination and Subsequent Years
a. Removal of the Notice of Participation (NOP) Form Requirement
    In section XIII.C.2.b. of this final rule with comment period, 
beginning with the CY 2020 payment determination, we are finalizing our 
proposal to remove the NOP form as a requirement. As a result, to be a 
participant in the Hospital OQR Program, hospitals will need to: (1) 
Register on the QualityNet website; (2) identify and register a 
QualityNet security administrator, and (3) submit data. In addition, we 
are finalizing our proposal to update 42 CFR 419.46(a) to reflect these 
policies. We have previously estimated in the CY 2014 OPPS/ASC final 
rule with comment period (78 FR 75171) that the burden associated with 
administrative requirements including completing program requirements, 
system requirements, and managing facility operations is 42 hours per 
hospital or 138,600 hours across 3,300 hospitals. We believe that 
removal of the NOP requirement will reduce administrative burden 
experienced by hospitals by only a nominal amount, as it is not 
required every year, but only at the start of a hospital's 
participation. As a result, this finalized policy does not influence 
our information collection burden estimates.
b. Removal of OP-27 for the CY 2020 Payment Determination and 
Subsequent Years
    In section XIII.B.4.b. of this final rule with comment period, we 
are finalizing our proposal to remove the OP-27: Influenza Vaccination 
Coverage Among Healthcare Personnel (NQF #0431) measure beginning with 
the CY 2020 payment determination and for subsequent years. The burden 
associated with OP-27, a National Healthcare Safety Network (NHSN) 
measure, is accounted for under a separate information collection 
request, OMB control number 0920-0666. Because burden associated with 
submitting data for this measure is captured under a separate OMB 
control number, we are not providing an estimate of the information 
collection burden associated with this measure for the Hospital OQR 
Program.

[[Page 59156]]

4. Estimated Burden of Hospital OQR Program Newly Finalized Policies 
for the CY 2021 Payment Determination and Subsequent Years
a. Removal of Chart-Abstracted Measures for the CY 2021 Payment 
Determination and Subsequent Years
    In section XIII.B.4.b. of this final rule with comment period, we 
are finalizing our proposal to remove one chart-abstracted measure for 
the CY 2021 payment determination and subsequent years: OP-5: Median 
Time to ECG. With regard to chart-abstracted measures for which 
patient-level data is submitted directly to CMS, we have previously 
estimated it would take 2.9 minutes, or 0.049 hours, per measure to 
collect and submit the data for each submitted case (80 FR 70582). In 
addition, based on the most recent data, we estimate that 947 cases are 
reported per hospital for chart-abstracted measures. Therefore, we 
estimate that it will take approximately 46 hours (0.049 hours x 947 
cases) to collect and report data for each chart-abstracted measure. 
Accordingly, we believe that the removal of this chart-abstracted 
measure for the CY 2021 payment determination will reduce burden by 
151,800 hours (46 hours x 3,300 hospitals) and $5.6 million (151,800 
hours x $36.58 \231\).
---------------------------------------------------------------------------

    \231\ In the CY 2018 OPPS/ASC final rule with comment period (82 
FR 59477), we finalized an hourly labor cost to hospitals of $36.58 
and specified that this cost included both wage ($18.29) and 100 
percent overhead and fringe benefit costs (an additional $18.29). 
The estimate for this duty is available in the Bureau of Labor 
Statistics report on Occupation Employment and Wages for May 2016, 
29-2071 Medical Records and Health Information Technicians at: 
https://www.bls.gov/oes/2016/may/oes292071.htm.
---------------------------------------------------------------------------

b. Removal of Measures Submitted Via a Web-Based Tool for the CY 2021 
Payment Determination and Subsequent Years
    While we proposed to remove five measures submitted via a web-based 
tool beginning with the CY 2021 payment determination and for 
subsequent years, in section XIII.B.4.b. of this final rule with 
comment period, we are only finalizing our proposals to remove three 
measures: (1) OP-12: The Ability for Providers with HIT to Receive 
Laboratory Data Electronically Directly into Their Qualified/Certified 
EHR System as Discrete Searchable Data; (2) OP-17: Tracking Clinical 
Results between Visits; and (3) OP-30: Endoscopy/Polyp Surveillance: 
Colonoscopy Interval for Patients with a History of Adenomatous 
Polyps--Avoidance of Inappropriate Use. In section XIII.B.4.b. of this 
final rule with comment period, we are not finalizing our proposals to 
remove the following web-based measures for the CY 2021 payment 
determination and subsequent years: OP-29: Endoscopy/Polyp 
Surveillance: Appropriate Follow-up Interval for Normal Colonoscopy in 
Average Risk Patients; and OP-31: Cataracts--Improvement in Patient's 
Visual Function within 90 Days Following Cataract Surgery. Therefore, 
we are revising the initially estimated burden reduction from the CY 
2019 OPPS/ASC proposed rule.
    As we stated in the CY 2016 OPPS/ASC final rule with comment period 
(80 FR 70582), we estimate that hospitals spend approximately 10 
minutes, or 0.167 hours, per measure to report web-based measures. 
Accordingly, we believe that the removal of OP-12, OP-17, and OP-30 for 
the CY 2021 payment determination will reduce burden by 0.501 hours per 
hospital (3 measures x 0.167 hours per measure) and 1,653 hours (0.501 
hours x 3,300 hospitals) across 3,300 hospitals. In addition, we 
estimate that OP-30 requires 25 additional minutes (0.417 hours) per 
case per measure to chart-abstract and that hospitals would each 
abstract 384 cases per year for this measure. This number is based on 
previous analysis (78 FR 75171) where we estimated that each of the 
approximately 3,300 responding hospitals will have a case volume 
adequate to support quarterly sample sizes of 96 cases, for a total of 
384 cases (96 cases per quarter x 4 quarters) to be abstracted by each 
hospital annually. Therefore, we estimate an additional burden 
reduction of 528,422 hours (3,300 hospitals x 0.417 hours x 384 cases 
per measure) for all participating hospitals for OP-30. In total, we 
estimate a burden reduction of 530,075 hours (1,653 hours for web 
submission + 528,422 hours for chart-abstraction of OP-30) and $19.4 
million (530,075 hours x $36.58) due to the removal of three web-based 
measures from the Hospital OQR Program for the CY 2021 payment 
determination and for subsequent years.
c. Removal of Claims-Based Measures for the CY 2021 Payment 
Determination and Subsequent Years
    In section XIII.B.4.b. of this final rule with comment period, we 
are finalizing our proposals to remove three claims-based measures 
beginning with the CY 2021 payment determination: OP-9: Mammography 
Follow-up Rates; OP-11: Thorax CT Use of Contrast Material; and OP-14: 
Simultaneous Use of Brain Computed Tomography (CT) and Sinus CT. 
Claims-based measures are derived through analysis of administrative 
claims data and do not require additional effort or burden on 
hospitals. As a result, we do not expect these removals to affect 
collection of information burden for the CY 2021 payment determination.
    In total for the CY 2021 payment determination, we expect the 
information collection burden will be reduced by 151,800 hours due to 
the removal of one chart-abstracted measure, and 530,075 hours due to 
the removal of three measures submitted via a web-based tool. In total, 
we estimate an information collection burden reduction of 681,875 hours 
(151,800 hours for the removal of one chart-abstracted measure + 
530,075 hours for the removal of three web-based measures) and $24.9 
million (681,875 hours x $36.58) for the CY 2021 payment determination.

C. ICRs for the ASCQR Program

1. Background
    We refer readers to the CY 2012 OPPS/ASC final rule with comment 
period (76 FR 74554), the FY 2013 IPPS/LTCH PPS final rule (77 FR 
53672), and the CY 2013, CY 2014, CY 2015, CY 2016, CY 2017, and CY 
2018 OPPS/ASC final rules with comment period (77 FR 68532 through 
68533; 78 FR 75172 through 75174; 79 FR 67015 through 67016; 80 FR 
70582 through 70584; 81 FR 79863 through 79865; and 82 FR 59479 through 
59481, respectively) for detailed discussions of the ASCQR Program 
information collection requirements we have previously finalized. The 
information collection requirements associated with the ASCQR Program 
are currently approved under OMB control number 0938-1270. Below we 
discuss only the changes in burden that would result from the newly 
finalized provisions in this final rule with comment period.
    While we proposed to remove eight measures, in section XIV.B.3.c. 
of this final rule with comment period, we are only finalizing the 
removal of two measures: One measure beginning with the CY 2020 payment 
determination, ASC-8: Influenza Vaccination Coverage Among Healthcare 
Personnel, and one measure beginning with the CY 2021 payment 
determination: ASC-10: Endoscopy/Polyp Surveillance: Colonoscopy 
Interval for Patients with a History of Adenomatous Polyps--Avoidance 
of Inappropriate Use. We expect these finalized policies will reduce 
the overall burden of reporting data for the ASCQR Program, as 
discussed below. In section XIV.B.3.c. of this final rule with comment 
period, we are not finalizing our proposal to remove ASC-9: Endoscopy/
Polyp

[[Page 59157]]

Surveillance Follow-up Interval for Normal Colonoscopy in Average Risk 
Patients beginning with the CY 2021 payment determination and ASC-11: 
Cataracts: Improvement in Patient's Visual Function within 90 Days 
Following Cataract Surgery. In addition, we are not finalizing our 
proposals to remove ASC-1: Patient Burn; ASC-2: Patient Fall; ASC-3: 
Wrong Site, Wrong Side, Wrong Patient, Wrong Procedure, Wrong Implant; 
and ASC-4: All-Cause Hospital Transfer/Admission, but are instead 
retaining the measures in the ASCQR Program and suspending their data 
collection beginning with the CY 2019 reporting period/CY 2021 payment 
determination until further action in rulemaking with the goal of 
updating the measures.
2. Estimated Burden of ASCQR Program Newly Finalized Policy Beginning 
With CY 2020 Payment Determination and Subsequent Years: Removal of 
ASC-8
    In section XIV.B.3.c. of this final rule with comment period, we 
are finalizing the removal of one measure beginning with the CY 2020 
payment determination, ASC-8: Influenza Vaccination Coverage Among 
Healthcare Personnel. Data for ASC-8 are submitted via a non-CMS online 
data submission tool, to the NHSN. However, we note that the 
information collection burden associated with ASC-8, a NHSN measure, is 
accounted for under a separate information collection request, OMB 
control number 0920-0666. As such, we are not providing an estimate of 
the information collection burden associated with this measure under 
the ASCQR Program OMB control number.
3. Estimated Burden of ASCQR Program Newly Finalized Measure Removals 
for the CY 2021 Payment Determination
    While we proposed to remove seven measures beginning with the CY 
2021 payment determination, in section XIV.B.3.c. of this final rule 
with comment period, we are only finalizing our proposal to remove one 
measure: ASC-10: Endoscopy/Polyp Surveillance: Colonoscopy Interval for 
Patients with a History of Adenomatous Polyps--Avoidance of 
Inappropriate Use. In section XIV.B.3.c. of this final rule with 
comment period we are not finalizing our proposals to remove ASC-9: 
Endoscopy/Polyp Surveillance Follow-up Interval for Normal Colonoscopy 
in Average Risk Patients and ASC-11: Cataracts--Improvement in 
Patient's Visual Function within 90 Days Following Cataract Surgery. In 
addition, we are not finalizing our proposals to remove ASC-1: Patient 
Burn; ASC-2: Patient Fall; ASC-3: Wrong Site, Wrong Side, Wrong 
Patient, Wrong Procedure, Wrong Implant; and ASC-4: All-Cause Hospital 
Transfer/Admission, but are instead retaining the measures in the ASCQR 
Program and suspending their data collection beginning with the CY 2019 
reporting period/CY 2021 payment determination until further action in 
rulemaking with the goal of updating the measures. Therefore, we are 
revising the estimated information collection burden changes from the 
estimates included in the CY 2019 OPPS/ASC proposed rule (83 FR 37222).
a. Removal of One Chart-Abstracted Measure for the CY 2021 Payment 
Determination and Subsequent Years
    In section XIV.B.3.c. of this final rule with comment period, we 
are finalizing the removal of one chart-abstracted measure from the 
ASCQR Program measure set beginning with the CY 2021 payment 
determination: ASC-10: Endoscopy/Polyp Surveillance: Colonoscopy 
Interval for Patients with a History of Adenomatous Polyps--Avoidance 
of Inappropriate Use. We believe 3,937 ASCs will experience a reduction 
in information collection burden associated with our finalized policy 
to remove ASC-10 from the ASCQR Program measure set.
    In the CY 2017 OPPS/ASC final rule with comment period (81 FR 
79864), we finalized our estimates that each participating ASC would 
spend 0.25 hours (15 minutes) per case per measure per year to collect 
and submit the required data for ASC-10. We estimate that the average 
number of patients per ASC is 63 based on the historic average. In 
addition, we estimate the total annual information collection burden 
per ASC to be 15 hours and 45 minutes (15.75 hours) per measure (0.25 
hours x 63 cases). Therefore, for ASC-10, we estimate the total 
annualized information collection burden to be 62,008 hours (3,937 ASCs 
x 15.75 hours per ASC) and $2,268,244 (3,937 ASCs x 15.75 hours per ASC 
x $36.58 per hour \232\). Therefore, we estimate a total reduction in 
information collection burden of 62,008 hours and $2,268,244 as a 
result of our removal of ASC-10 from the ASCQR Program measure set for 
the CY 2021 payment determination. The reduction in information 
collection burden associated with these requirements is available for 
review and comment under OMB control number 0938-1270.
---------------------------------------------------------------------------

    \232\ In the CY 2018 OPPS/ASC final rule with comment period (82 
FR 59479 through 59480), we finalized an hourly labor cost to 
hospitals of $36.58 and specified that this cost included both wage 
and overhead and fringe benefit costs. The estimate for this duty is 
available in the Bureau of Labor Statistics report on Occupation 
Employment and Wages for May 2016, 29-2071 Medical Records and 
Health Information Technicians at: https://www.bls.gov/oes/2016/may/oes292071.htm.
---------------------------------------------------------------------------

D. ICRs for the Update to the HCAHPS Survey Measure in the Hospital IQR 
Program

    As described in section XVI. of this final rule with comment 
period, we are finalizing a modified version of our proposals regarding 
the Communication About Pain questions from the HCAHPS Survey in the 
Hospital IQR Program. Instead of removing the questions effective with 
January 2022 discharges, for the FY 2024 payment determination and 
subsequent years as proposed, we are finalizing to remove them 
effective with October 2019 discharges, for the FY 2021 payment 
determination and subsequent years. In addition, instead of publicly 
reporting the data in October 2022 and then subsequently discontinuing 
as proposed, we are finalizing that we will not publicly report the 
data collected from the Communication About Pain questions at all.
    While we anticipate that the removal of these questions will reduce 
the burden associated with reporting this measure, as further discussed 
below, the burden estimate for the Hospital IQR Program excludes the 
burden associated with the HCAHPS Survey measure, which is submitted 
under a separate information collection request and approved under OMB 
control number 0938-0981. For discussion of the burden estimate for the 
Hospital IQR Program under OMB control number 0938-1022, we refer 
readers to the FY 2019 IPPS/LTCH PPS final rule (83 FR 41689 through 
41694). For details on the burden estimate specifically for the HCAHPS 
Survey, including use of the Communication About Pain questions, we 
refer readers to the notice published in the Federal Register on 
Information Collection for the National Implementation of the Hospital 
CAHPS Survey (83 FR 21296 through 21297). We note that a revised 
information collection request under OMB control number 0938-0981 will 
be submitted to OMB based on the update to the HCAHPS Survey in 
accordance with this final rule with comment period.
    As noted above, the removal of the Communication About Pain 
questions does not change the estimated burden for the Hospital IQR 
Program under the program's OMB control number 0938-1022. However, we 
believe that overall cost and burden will change slightly for hospitals 
and HCAHPS Survey respondents. Under HCAHPS Survey

[[Page 59158]]

OMB control number 0938-0981, it is estimated that the average cost and 
hour burdens for hospitals are $4,000 and 1 hour per hospital for 
HCAHPS data collection activities. Because these estimates include 
administrative activities and overhead costs, we believe our removal of 
the Communication About Pain questions from the HCAHPS Survey will not 
reduce these estimates of hospital burden or will only nominally and 
temporarily increase the average cost and hour burdens associated with 
the removal of these questions from the survey, given the need to 
adjust the survey instrument and instructional materials and, 
therefore, marginally reduce the burden due to the shortening of the 
survey instrument.
    Under HCAHPS Survey OMB control number 0938-0981, the average time 
for a respondent to answer the 32 question survey is estimated at 8 
minutes, which we estimate to be 0.25 minutes per question (8 minutes/
32 questions = 0.25 minutes per question). In addition, under this OMB 
control number, the number of respondents is estimated at 3,104,200 
respondents. In this final rule with comment period, we are finalizing 
a modified version of our proposal to remove 3 questions, which we 
estimate would reduce the time burden by 0.75 minutes (0.25 minutes per 
question x 3 questions), or 0.0125 hours (0.75 minutes/60 minutes) per 
respondent. We anticipate a total hourly burden reduction for 
respondents of 38,803 hours (0.0125 hours x 3,104,200 respondents). 
Further, under OMB control number 0938-0981, the cost of respondent 
time is based on the average hourly earnings of $26.71 per hour, as 
reported by the U.S. Bureau of Labor Statistics final January 2018 
estimates available on the website at: https://www.bls.gov/eag/eag.us.htm.\233\ We anticipate a total cost reduction for respondents 
associated with the proposal to remove the three Communication About 
Pain questions of $1,036,428 (38,803 total hours x respondent earnings 
estimate of $26.71 per hour) for the FY 2021 payment determination.
---------------------------------------------------------------------------

    \233\ Average hourly earnings of $26.71 per hour based on the 
average hourly earnings of all employees on private non-farm 
payrolls, seasonally adjusted, per the U.S. Bureau of Labor 
Statistics.
---------------------------------------------------------------------------

E. ICRs for PPS-Exempt Cancer Hospital Quality Reporting (PCHQR) 
Program for the FY 2021 Program Year

    In the FY 2019 IPPS/LTCH PPS proposed rule (83 FR 20503), we 
proposed to remove two NHSN measures, Catheter-Associated Urinary Tract 
Infection (CAUTI) Outcome Measure (PCH-5/NQF #0138) and Central Line-
Associated Bloodstream Infection (CLABSI) Outcome Measure (PCH-4/NQF 
#0139), from the PCHQR Program beginning with the FY 2021 program year. 
In section VIII.B.3.b.(2) of the preamble of the FY 2019 IPPS/LTCH PPS 
final rule (83 FR 41613), we indicated that we would take final action 
regarding our proposals to remove the CAUTI and CLABSI measures in a 
future 2018 final rule. In section XVII. of this final rule with 
comment period, after consideration of the public comments received, 
and consideration of the most recent information provided by the CDC, 
we are not finalizing our proposals to remove the CAUTI and CLABSI 
measures. We note that this CDC information was not available at the 
time when we proposed the removal of these measures from the PCHQR 
Program.
    In the FY 2019 IPPS/LTCH PPS final rule (83 FR 41695) we reconciled 
the burden estimates associated with the NHSN measures (CLABSI, CAUTI, 
CDI, HCP, MRSA and Colon and Abdominal Hysterectomy SSI) included in 
the PCHQR Program, which were formerly accounted for under both the 
PCHQR Program's estimates OMB control number 0938-1175 and the CDC's 
estimates under OMB control number 0920-0666. Because the CDC maintains 
the NHSN system used to collect this data and captures the burden 
associated with this data collection under its estimates in OMB control 
number 0920-0666, we removed the duplicative burden estimate from the 
PCHQR Program's OMB Control Number, 0938-1175. As a result, there is no 
change in burden under the PCHQR Program associated with not finalizing 
removal of the CLABSI and CAUTI measures.
    In summary, our decisions not to remove the CAUTI and CLABSI 
measures in the PCHQR Program for FY 2021 program year and subsequent 
years does not change the information collection estimates for the 
PCHQR Program. We refer readers to section XIV.B.4 of the FY 2019 IPPS/
LTCH PPS final rule (83 FR 41694 through 41695) for more detail on the 
information collection calculations for the finalized policies in the 
PCHQR Program.

F. Total Reduction in Burden Hours and in Costs

    Below is a chart reflecting the total burden and associated costs 
for the provisions included in this final rule with comment period.

[[Page 59159]]

[GRAPHIC] [TIFF OMITTED] TR21NO18.119

XX. Response to Comments

    Because of the large number of public comments we normally receive 
on Federal Register documents, we are not able to acknowledge or 
respond to them individually. We will consider all comments we receive 
by the date and time specified in the DATES section of this final rule 
with comment period, and, when we proceed with a subsequent 
document(s), we will respond to those comments in the preamble to that 
document.

XXI. Economic Analyses

A. Statement of Need

    This final rule with comment period is necessary to make updates to 
the Medicare hospital OPPS rates. It is necessary to make changes to 
the payment policies and rates for outpatient services furnished by 
hospitals and CMHCs in CY 2019. We are required under section 
1833(t)(3)(C)(ii) of the Act to update annually the OPPS conversion 
factor used to determine the payment rates for APCs. We also are 
required under section 1833(t)(9)(A) of the Act to review, not less 
often than annually, and revise the groups, the relative payment 
weights, and the wage and other adjustments described in section 
1833(t)(2) of the Act. We must review the clinical integrity of payment 
groups and relative payment weights at least annually. We are revising 
the APC relative payment weights using claims data for services 
furnished on and after January 1, 2017, through and including December 
31, 2017, and processed through June 30, 2018, and updated cost report 
information.
    We note that we are finalizing our proposal to control unnecessary 
increases in the volume of covered outpatient department services by 
paying for clinic visits furnished at off-campus PBDs at an amount 
equal to the site-specific PFS payment rate for nonexcepted items and 
services furnished by a nonexcepted off-campus PBD (the PFS payment 
rate). The site-specific PFS payment rate for clinic visits furnished 
in excepted off-campus PBDs is the OPPS rate reduced to the amount paid 
for clinic visits furnished by nonexcepted off-campus PBDs under the 
PFS, which is 40 percent of the OPPS rate. We expect that, by removing 
the payment differential, we will control unnecessary volume increases 
both in terms of the number of covered outpatient services furnished 
and the costs of those services. We are implementing this policy with a 
2-year phase-in. In CY 2019, the payment reduction will be transitioned 
by applying 50 percent of the total reduction in payment that would 
apply if these off-campus PBDs were paid the site-specific PFS payment 
rate for the clinic visit service. In other words, these excepted off-
campus PBDs will be paid 70 percent of the OPPS rate for the clinic 
visit service in CY 2019. In CY 2020, we will complete the transition 
to paying the PFS-equivalent amount for clinic visits furnished in 
excepted off-campus PBDs. In other words, these excepted off-campus 
PBDs will be paid 40 percent of the OPPS rate for the clinic visit 
service in CY 2020.
    This final rule with comment period also is necessary to make 
updates to the ASC payment rates for CY 2019, enabling CMS to make 
changes to payment policies and payment rates for covered surgical 
procedures and covered ancillary services that are performed in an ASC 
in CY 2019. Because ASC payment rates are based on the OPPS relative 
payment weights for most of the procedures performed in ASCs, the ASC 
payment rates are updated annually to reflect annual changes to the 
OPPS relative payment weights. In addition, we are required under 
section 1833(i)(1) of the Act to review and update the list of surgical 
procedures that can be performed in an ASC, not less frequently than 
every 2 years.
    For CYs 2019 through 2023, we are finalizing our proposal to update 
the ASC payment system rates using the hospital market basket update 
instead of the CPI-U. We believe that this finalized proposal could 
stabilize the differential between OPPS payments and ASC payments, 
given that the CPI-U has been generally lower than the hospital market 
basket, and encourage the

[[Page 59160]]

migration of services to lower cost settings as clinically appropriate.

B. Overall Impact for Provisions of This Final Rule With Comment Period

    We have examined the impacts of this final rule with comment 
period, as required by Executive Order 12866 on Regulatory Planning and 
Review (September 30, 1993), Executive Order 13563 on Improving 
Regulation and Regulatory Review (January 18, 2011), the Regulatory 
Flexibility Act (RFA) (September 19, 1980, Pub. L. 96-354), section 
1102(b) of the Social Security Act, section 202 of the Unfunded 
Mandates Reform Act of 1995 (UMRA) (March 22, 1995, Pub. L. 104-4), 
Executive Order 13132 on Federalism (August 4, 1999), the Congressional 
Review Act (5 U.S.C. 804(2)), and Executive Order 13771 on Reducing 
Regulation and Controlling Regulatory Costs (January 30, 2017). This 
section of this final rule with comment period contains the impact and 
other economic analyses for the provisions we are finalizing for CY 
2019.
    Executive Orders 12866 and 13563 direct agencies to assess all 
costs and benefits of available regulatory alternatives and, if 
regulation is necessary, to select regulatory approaches that maximize 
net benefits (including potential economic, environmental, public 
health and safety effects, distributive impacts, and equity). Executive 
Order 13563 emphasizes the importance of quantifying both costs and 
benefits, of reducing costs, of harmonizing rules, and of promoting 
flexibility. This final rule with comment period has been designated as 
an economically significant rule under section 3(f)(1) of Executive 
Order 12866 and a major rule under the Congressional Review Act. 
Accordingly, this final rule with comment period has been reviewed by 
the Office of Management and Budget. We have prepared a regulatory 
impact analysis that, to the best of our ability, presents the costs 
and benefits of the provisions of this final rule with comment period. 
In the CY 2019 OPPS/ASC proposed rule (83 FR 37224), we solicited 
public comments on the regulatory impact analysis in the proposed rule, 
and we address any public comments we received in this final rule with 
comment period, as appropriate.
    We estimate that the total increase in Federal government 
expenditures under the OPPS for CY 2019, compared to CY 2018, due only 
to the changes to the OPPS in this final rule with comment period, will 
be approximately $440 million. Taking into account our estimated 
changes in enrollment, utilization, and case-mix for CY 2019, we 
estimate that the OPPS expenditures, including beneficiary cost-
sharing, for CY 2019 will be approximately $74.1 billion; approximately 
$5.8 billion higher than estimated OPPS expenditures in CY 2018. We 
note that these spending estimates include the final CY 2019 final 
policy to control for unnecessary increases in the volume of covered 
outpatient department services by paying for clinic visits furnished at 
excepted off-campus PBDs at a rate that will be 70 percent of the OPPS 
rate for a clinic visit service. Because the provisions of the OPPS are 
part of a final rule that is economically significant, as measured by 
the threshold of an additional $100 million in expenditures in 1 year, 
we have prepared this regulatory impact analysis that, to the best of 
our ability, presents its costs and benefits. Table 62 of this final 
rule with comment period displays the distributional impact of the CY 
2019 changes in OPPS payment to various groups of hospitals and for 
CMHCs.
    As noted in sections V.B.7. and X.C.2. of this final rule with 
comment period, we are finalizing our proposal for CY 2019 to pay for 
separately payable drugs and biological products that do not have pass-
through payment status and are not acquired under the 340B program at 
WAC+3 percent instead of WAC+6 percent, if ASP data are unavailable for 
payment purposes. If WAC data are not available for a drug or 
biological product, we will continue our policy to pay separately 
payable drugs and biological products at 95 percent of the AWP. Drugs 
and biologicals that are acquired under the 340B Program will continue 
to be paid at ASP minus 22.5 percent, WAC minus 22.5 percent, or 69.46 
percent of AWP, as applicable.
    We estimate that the update to the conversion factor and other 
adjustments (not including the effects of outlier payments, the pass-
through payment estimates, the application of the frontier State wage 
adjustment for CY 2019, and the finalized proposal to control for 
unnecessary increases in the volume of covered outpatient department 
services described in section X.B. of this final rule with comment 
period) will increase total OPPS payments by 1.3 percent in CY 2019. 
The changes to the APC relative payment weights, the changes to the 
wage indexes, the continuation of a payment adjustment for rural SCHs, 
including EACHs, and the payment adjustment for cancer hospitals will 
not increase OPPS payments because these changes to the OPPS are budget 
neutral. However, these updates will change the distribution of 
payments within the budget neutral system. We estimate that the total 
change in payments between CY 2018 and CY 2019, considering all budget 
neutral payment adjustments, changes in estimated total outlier 
payments, pass-through payments, the application of the frontier State 
wage adjustment, and the finalized proposal to control unnecessary 
increases in the volume of outpatient services as described in section 
X.B. of this final rule with comment period, in addition to the 
application of the OPD fee schedule increase factor after all 
adjustments required by sections 1833(t)(3)(F), 1833(t)(3)(G), and 
1833(t)(17) of the Act, will increase total estimated OPPS payments by 
0.6 percent.
    We estimate the total increase (from changes to the ASC provisions 
in this final rule with comment period as well as from enrollment, 
utilization, and case-mix changes) in Medicare expenditures (not 
including beneficiary cost-sharing) under the ASC payment system for CY 
2019 compared to CY 2018, to be approximately $200 million. Because the 
provisions for the ASC payment system are part of a final rule that is 
economically significant, as measured by the $100 million threshold, we 
have prepared a regulatory impact analysis of the changes to the ASC 
payment system that, to the best of our ability, presents the costs and 
benefits of this portion of this final rule with comment period. Tables 
63 and 64 of this final rule with comment period display the 
redistributive impact of the CY 2019 changes regarding ASC payments, 
grouped by specialty area and then grouped by procedures with the 
greatest ASC expenditures, respectively.

C. Detailed Economic Analyses

1. Estimated Effects of OPPS Changes in This Final Rule With Comment 
Period
a. Limitations of Our Analysis
    The distributional impacts presented here are the projected effects 
of the CY 2019 policy changes on various hospital groups. We post on 
the CMS website our hospital-specific estimated payments for CY 2019 
with the other supporting documentation for this final rule with 
comment period. To view the hospital-specific estimates, we refer 
readers to the CMS website at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/HospitalOutpatientPPS/. At the 
website, select ``regulations and notices'' from the left side of the 
page and then select ``CMS-1695-FC'' from the list of regulations and 
notices. The hospital-specific file layout and the

[[Page 59161]]

hospital-specific file are listed with the other supporting 
documentation for this final rule with comment period. We show 
hospital-specific data only for hospitals whose claims were used for 
modeling the impacts shown in Table 62 below. We do not show hospital-
specific impacts for hospitals whose claims we were unable to use. We 
refer readers to section II.A. of this final rule with comment period 
for a discussion of the hospitals whose claims we do not use for 
ratesetting and impact purposes.
    We estimate the effects of the individual policy changes by 
estimating payments per service, while holding all other payment 
policies constant. We use the best data available, but do not attempt 
to predict behavioral responses to our policy changes in order to 
isolate the effects associated with specific policies or updates, but 
any policy that changes payment could have a behavioral response. In 
addition, we have not made adjustments for future changes in variables, 
such as service volume, service-mix, or number of encounters.
b. Estimated Effects of the Finalized Proposal To Control for 
Unnecessary Increases in the Volume of Outpatient Services
    In section X.B. of this final rule with comment period, we discuss 
our CY 2019 finalized proposal to control for unnecessary increases in 
the volume of outpatient department services by paying for clinic 
visits furnished at an off-campus PBD at an amount equal to the site-
specific PFS payment rate for nonexcepted items and services furnished 
by a nonexcepted off-campus PBD (the PFS payment rate). Specifically, 
we are finalizing our proposal to pay for HCPCS code G0463 (Hospital 
outpatient clinic visit for assessment and management of a patient) 
when billed with modifier ``PO'' at an amount equal to the site-
specific PFS payment rate for nonexcepted items and services furnished 
by a nonexcepted off-campus PBD (the PFS payment rate), with a 2-year 
transition period. For a discussion of the PFS payment amount for 
outpatient clinic visits furnished at nonexcepted off-campus PBDs, we 
refer readers to the CY 2018 PFS final rule with comment period 
discussion (82 FR 53023 through 53024), as well as the CY 2019 PFS 
final rule.
    To develop an estimated impact of this policy, we began with CY 
2017 outpatient claims data used in ratesetting for the CY 2019 OPPS. 
We then flagged all claim lines for HCPCS code G0463 that contained 
modifier ``PO'' because the presence of this modifier indicates that 
such claims were billed for services furnished by an off-campus 
department of a hospital paid under the OPPS. Next, we excluded those 
that were billed as a component of C-APC 8011 (Comprehensive 
Observation Services) or packaged into another C-APC because in those 
instances OPPS payment is made for a broader package of services. We 
then simulated payment for the remaining claim lines as if they were 
paid at the PFS-equivalent rate. An estimate of the policy that 
includes the effects of estimated changes in enrollment, utilization, 
and case-mix based on the FY 2019 President's budget approximates the 
estimated decrease in total payment under the OPPS at $380 million, 
with Medicare OPPS payments decreasing by $300 million and beneficiary 
copayments decreasing by $80 million in CY 2019. This estimate is 
utilized for the accounting statement displayed in Table 65 of this 
final rule with comment period because the impact of this CY 2019 
policy, which is not budget neutral, is combined with the impact of the 
OPD update, which is also not budget neutral, to estimate changes in 
Medicare spending under the OPPS as a result of the changes in this 
final rule with comment period. The estimated decrease in payment due 
to this policy is not as great as in the proposed rule because we are 
proposing to transition the application of this policy over 2 years.
    We note that our estimates may differ from the actual effect of the 
policy due to offsetting factors, such as changes in provider behavior. 
We note that, by removing this payment differential that may influence 
site-of-service decision-making, we anticipate an associated decrease 
in the volume of clinic visits provided in the excepted off-campus PBD 
setting. In the proposed rule, we reminded readers that this estimate 
could change in this final rule with comment period based on a number 
of factors such as the availability of updated data, changes in the 
final payment policy, and/or the method of assessing the payment impact 
in the final rule with comment period. This estimate changed due to the 
final policy of establishing a 2-year phase-in. As discussed in more 
detail in section X.B. of the proposed rule, we sought public comment 
on both our proposed payment policy for clinic visits furnished at off-
campus PBDs as well as how to apply methods for controlling 
overutilization of services more broadly. We refer readers to section 
X.B. of this final rule with comment period for our discussion of the 
public comments we received.
c. Estimated Effects of Finalized Proposal To Apply the 340B Drug 
Payment Policy to Nonexcepted Off-Campus Departments of Hospitals
    In section X.C. of this final rule with comment period, we discuss 
the proposal we are finalizing to pay average sales price (ASP) minus 
22.5 percent under the PFS for separately payable 340B-acquired drugs 
furnished by nonexcepted, off-campus PBDs beginning in CY 2019. This is 
consistent with the payment methodology adopted in CY 2018 for 340B-
acquired drugs furnished in hospital departments paid under the OPPS.
    To develop an estimated impact of this finalized proposal, we began 
with CY 2017 outpatient claims data used in ratesetting for the CY 2019 
OPPS. We then flagged all claim lines that contained modifier ``PN'' 
because the presence of this modifier indicates that such claims were 
billed for services furnished by a nonexcepted off-campus department of 
a hospital paid under the PFS. We further subset this population by 
identifying 340B hospitals that billed for status indicator ``K'' drugs 
or biologicals (that is, nonpass-through, separately payable drugs) 
because such drugs may have been subject to the 340B discount. We found 
117 unique nonexcepted off-campus PBDs associated with 340B hospitals 
billed for status indicator ``K'' drugs. Their ``K'' billing represents 
approximately $183 million in Medicare payments (including beneficiary 
copayments) based on a payment rate of ASP+6 percent. Based on our 
adjustment, for CY 2019, we estimate that the Medicare Program and 
beneficiaries will save approximately $49.1 million, under the PFS. 
This estimate represents an upper bound of potential savings under the 
PFS for this policy change and does not include adjustments for 
beneficiary enrollment, case-mix, or potential offsetting behaviors. We 
noted in the proposed rule that the estimated effect of the proposed 
policy could change in this final rule with comment period based on a 
number of factors such as the availability of updated data, changes in 
the final payment policy, and/or the method of assessing the payment 
impact in the final rule.
d. Estimated Effects of OPPS Changes on Hospitals
    Table 62 below shows the estimated impact of this final rule with 
comment period on hospitals. Historically, the first line of the impact 
table, which estimates the change in payments to all

[[Page 59162]]

facilities, has always included cancer and children's hospitals, which 
are held harmless to their pre-BBA amount. We also include CMHCs in the 
first line that includes all providers. We include a second line for 
all hospitals, excluding permanently held harmless hospitals and CMHCs.
    We present separate impacts for CMHCs in Table 62, and we discuss 
them separately below, because CMHCs are paid only for partial 
hospitalization services under the OPPS and are a different provider 
type from hospitals. In CY 2019, we are paying CMHCs for partial 
hospitalization services under APC 5853 (Partial Hospitalization for 
CMHCs), and we are paying hospitals for partial hospitalization 
services under APC 5863 (Partial Hospitalization for Hospital-Based 
PHPs).
    The estimated increase in the total payments made under the OPPS is 
determined largely by the increase to the conversion factor under the 
statutory methodology. The distributional impacts presented do not 
include assumptions about changes in volume and service-mix. The 
conversion factor is updated annually by the OPD fee schedule increase 
factor, as discussed in detail in section II.B. of this final rule with 
comment period.
    Section 1833(t)(3)(C)(iv) of the Act provides that the OPD fee 
schedule increase factor is equal to the market basket percentage 
increase applicable under section 1886(b)(3)(B)(iii) of the Act, which 
we refer to as the IPPS market basket percentage increase. The IPPS 
market basket percentage increase for FY 2019 is 2.9 percent (83 FR 
41395). Section 1833(t)(3)(F)(i) of the Act reduces that 2.9 percent by 
the multifactor productivity adjustment described in section 
1886(b)(3)(B)(xi)(II) of the Act, which is 0.8 percentage point for FY 
2019 (which is also the MFP adjustment for FY 2019 in the FY 2019 IPPS/
LTCH PPS final rule (83 FR 41395)), and sections 1833(t)(3)(F)(ii) and 
1833(t)(3)(G)(v) of the Act further reduce the market basket percentage 
increase by 0.75 percentage point, resulting in the OPD fee schedule 
increase factor of 1.35 percent. We are using the OPD fee schedule 
increase factor of 1.35 percent in the calculation of the CY 2019 OPPS 
conversion factor. Section 10324 of the Affordable Care Act, as amended 
by HCERA, further authorized additional expenditures outside budget 
neutrality for hospitals in certain frontier States that have a wage 
index less than 1.0000. The amounts attributable to this frontier State 
wage index adjustment are incorporated in the CY 2019 estimates in 
Table 62 of this final rule with comment period.
    To illustrate the impact of the CY 2019 changes, our analysis 
begins with a baseline simulation model that uses the CY 2018 relative 
payment weights, the FY 2018 final IPPS wage indexes that include 
reclassifications, and the final CY 2018 conversion factor. Table 62 
shows the estimated redistribution of the increase or decrease in 
payments for CY 2019 over CY 2018 payments to hospitals and CMHCs as a 
result of the following factors: The impact of the APC reconfiguration 
and recalibration changes between CY 2018 and CY 2019 (Column 2); the 
wage indexes and the provider adjustments (Column 3); the combined 
impact of all of the changes described in the preceding columns plus 
the 1.35 percent OPD fee schedule increase factor update to the 
conversion factor (Column 4); the finalized off-campus PBD clinic 
visits payment policy (Column 5), and the estimated impact taking into 
account all payments for CY 2019 relative to all payments for CY 2018, 
including the impact of changes in estimated outlier payments, the 
frontier State wage adjustment, and changes to the pass-through payment 
estimate (Column 6).
    We did not model an explicit budget neutrality adjustment for the 
rural adjustment for SCHs because we are maintaining the current 
adjustment percentage for CY 2019. Because the updates to the 
conversion factor (including the update of the OPD fee schedule 
increase factor), the estimated cost of the rural adjustment, and the 
estimated cost of projected pass-through payment for CY 2019 are 
applied uniformly across services, observed redistributions of payments 
in the impact table for hospitals largely depend on the mix of services 
furnished by a hospital (for example, how the APCs for the hospital's 
most frequently furnished services will change), and the impact of the 
wage index changes on the hospital. However, total payments made under 
this system and the extent to which this final rule with comment period 
will redistribute money during implementation also will depend on 
changes in volume, practice patterns, and the mix of services billed 
between CY 2018 and CY 2019 by various groups of hospitals, which CMS 
cannot forecast.
    Overall, we estimate that the rates for CY 2019 will increase 
Medicare OPPS payments by an estimated 0.6 percent. Removing payments 
to cancer and children's hospitals because their payments are held 
harmless to the pre-OPPS ratio between payment and cost and removing 
payments to CMHCs results in an estimated 0.6 percent increase in 
Medicare payments to all other hospitals. These estimated payments will 
not significantly impact other providers.
Column 1: Total Number of Hospitals
    The first line in Column 1 in Table 62 shows the total number of 
facilities (3,840), including designated cancer and children's 
hospitals and CMHCs, for which we were able to use CY 2017 hospital 
outpatient and CMHC claims data to model CY 2018 and CY 2019 payments, 
by classes of hospitals, for CMHCs and for dedicated cancer hospitals. 
We excluded all hospitals and CMHCs for which we could not plausibly 
estimate CY 2018 or CY 2019 payment and entities that are not paid 
under the OPPS. The latter entities include CAHs, all-inclusive 
hospitals, and hospitals located in Guam, the U.S. Virgin Islands, 
Northern Mariana Islands, American Samoa, and the State of Maryland. 
This process is discussed in greater detail in section II.A. of this 
final rule with comment period. At this time, we are unable to 
calculate a DSH variable for hospitals that are not also paid under the 
IPPS because DSH payments are only made to hospitals paid under the 
IPPS. Hospitals for which we do not have a DSH variable are grouped 
separately and generally include freestanding psychiatric hospitals, 
rehabilitation hospitals, and long-term care hospitals. We show the 
total number of OPPS hospitals (3,727), excluding the hold-harmless 
cancer and children's hospitals and CMHCs, on the second line of the 
table. We excluded cancer and children's hospitals because section 
1833(t)(7)(D) of the Act permanently holds harmless cancer hospitals 
and children's hospitals to their ``pre-BBA amount'' as specified under 
the terms of the statute, and therefore, we removed them from our 
impact analyses. We show the isolated impact on the 46 CMHCs at the 
bottom of the impact table and discuss that impact separately below.
Column 2: APC Recalibration--All Changes
    Column 2 shows the estimated effect of APC recalibration. Column 2 
also reflects any changes in multiple procedure discount patterns or 
conditional packaging that occur as a result of the changes in the 
relative magnitude of payment weights. As a result of APC 
recalibration, we estimate that urban hospitals will experience no 
change, with the impact ranging from an increase of 0.4 percent to a 
decrease of 0.1 percent, depending on the number of beds. Rural 
hospitals will experience

[[Page 59163]]

an increase of 0.1 percent, with the impact ranging from a decrease of 
0.3 percent to an increase of 0.4 percent, depending on the number of 
beds. Major teaching hospitals will experience no change.
Column 3: Wage Indexes and the Effect of the Provider Adjustments
    Column 3 demonstrates the combined budget neutral impact of the APC 
recalibration; the updates for the wage indexes with the FY 2019 IPPS 
post-reclassification wage indexes; the rural adjustment; and the 
cancer hospital payment adjustment. We modeled the independent effect 
of the budget neutrality adjustments and the OPD fee schedule increase 
factor by using the relative payment weights and wage indexes for each 
year, and using a CY 2018 conversion factor that included the OPD fee 
schedule increase and a budget neutrality adjustment for differences in 
wage indexes.
    Column 3 reflects the independent effects of the updated wage 
indexes, including the application of budget neutrality for the rural 
floor policy on a nationwide basis. This column excludes the effects of 
the frontier State wage index adjustment, which is not budget neutral 
and is included in Column 6. We did not model a budget neutrality 
adjustment for the rural adjustment for SCHs because we are continuing 
the rural payment adjustment of 7.1 percent to rural SCHs for CY 2019, 
as described in section II.E. of this final rule with comment period. 
We also did not model a budget neutrality adjustment for the cancer 
hospital payment adjustment because we are using a payment-to-cost 
ratio target for the cancer hospital payment adjustment in CY 2019 of 
0.89, which is the same ratio that was reported for the CY 2018 OPPS/
ASC final rule with comment period (82 FR 59266). We note that, in 
accordance with section 16002 of the 21st Century Cures Act, we are 
applying a budget neutrality factor calculated as if the cancer 
hospital adjustment target payment-to-cost ratio was 0.89, not the 0.88 
target payment-to-cost ratio we are applying in section II.F. of this 
final rule with comment period.
    We modeled the independent effect of updating the wage indexes by 
varying only the wage indexes, holding APC relative payment weights, 
service-mix, and the rural adjustment constant and using the CY 2019 
scaled weights and a CY 2018 conversion factor that included a budget 
neutrality adjustment for the effect of the changes to the wage indexes 
between CY 2018 and CY 2019. The FY 2019 wage policy results in modest 
redistributions.
Column 4: All Budget Neutrality Changes Combined With the Market Basket 
Update
    Column 4 demonstrates the combined impact of all of the changes 
previously described and the update to the conversion factor of 1.35 
percent. Overall, these changes will increase payments to urban 
hospitals by 1.4 percent and to rural hospitals by 1.3 percent. Urban 
hospitals will receive an increase in line with the 1.4 percent overall 
increase for all facilities after the update is applied to the budget 
neutrality adjustments. The increase for classes of rural hospitals 
will be more variable with sole community hospitals receiving a 1.1 
percent increase and other rural hospitals receiving an increase of 1.6 
percent.
Column 5: Off-Campus PBD Visits Payment Policy
    Column 5 displays the estimated effect of our finalized CY 2019 
volume control method to pay for clinic visit HCPCS code G0463 
((Hospital outpatient clinic visit for assessment and management of a 
patient) when billed with modifier ``PO'' by an excepted off-campus PBD 
at a rate that will be 70 percent of the OPPS rate for a clinic visit 
service for CY 2019. We note that the numbers provided in this column 
isolate the estimated effect of this policy adjustment relative to the 
numerator of Column 4. Therefore, the numbers reported in Column 5 show 
how much of the difference between the estimates in Column 4 and the 
estimates in Column 6 are a result of the finalized off-campus PBD 
visits policy.
Column 6: All Changes for CY 2019
    Column 6 depicts the full impact of the CY 2019 policies on each 
hospital group by including the effect of all changes for CY 2019 and 
comparing them to all estimated payments in CY 2018. Column 6 shows the 
combined budget neutral effects of Columns 2 through 3; the OPD fee 
schedule increase; the effect of the finalized off-campus PBD visits 
policy, the impact of the frontier State wage index adjustment; the 
impact of estimated OPPS outlier payments, as discussed in section 
II.G. of this final rule with comment period; the change in the 
Hospital OQR Program payment reduction for the small number of 
hospitals in our impact model that failed to meet the reporting 
requirements (discussed in section XIII. of this final rule with 
comment period); and the difference in total OPPS payments dedicated to 
transitional pass-through payments.
    Of those hospitals that failed to meet the Hospital OQR Program 
reporting requirements for the full CY 2018 update (and assumed, for 
modeling purposes, to be the same number for CY 2019), we included 72 
hospitals in our model because they had both CY 2017 claims data and 
recent cost report data. We estimate that the cumulative effect of all 
changes for CY 2019 will increase payments to all facilities by 0.6 
percent for CY 2019. We modeled the independent effect of all changes 
in Column 6 using the final relative payment weights for CY 2018 and 
the relative payment weights for CY 2019. We used the final conversion 
factor for CY 2018 of $78.636 and the final CY 2019 conversion factor 
of $79.490 discussed in section II.B. of this final rule with comment 
period.
    Column 6 contains simulated outlier payments for each year. We used 
the 1-year charge inflation factor used in the FY 2019 IPPS/LTCH PPS 
final rule (83 FR 41722) of 4.3 percent (1.04338) to increase 
individual costs on the CY 2017 claims, and we used the most recent 
overall CCR in the October 2018 Outpatient Provider-Specific File 
(OPSF) to estimate outlier payments for CY 2018. Using the CY 2017 
claims and a 4.3 percent charge inflation factor, we currently estimate 
that outlier payments for CY 2018, using a multiple threshold of 1.75 
and a fixed-dollar threshold of $4,150, will be approximately 1.01 
percent of total payments. The estimated current outlier payments of 
1.01 percent are incorporated in the comparison in Column 6. We used 
the same set of claims and a charge inflation factor of 8.9 percent 
(1.08864) and the CCRs in the October 2018 OPSF, with an adjustment of 
0.981397, to reflect relative changes in cost and charge inflation 
between CY 2017 and CY 2019, to model the CY 2019 outliers at 1.0 
percent of estimated total payments using a multiple threshold of 1.75 
and a fixed-dollar threshold of $4,825. The charge inflation and CCR 
inflation factors are discussed in detail in the FY 2019 IPPS/LTCH PPS 
final rule (83 FR 41722).
    Overall, we estimate that facilities will experience an increase of 
0.6 percent under this final rule with comment period in CY 2019 
relative to total spending in CY 2018. This projected increase (shown 
in Column 6) of Table 62 reflects the 1.35 percent OPD fee schedule 
increase factor, minus 0.6 percent for the off-campus PBD visits 
policy, minus 0.10 percent for the change in the pass-through payment 
estimate between CY 2018 and CY 2019, plus a decrease of 0.01 percent 
for the difference in estimated outlier payments

[[Page 59164]]

between CY 2018 (1.01 percent) and CY 2019 (1.00 percent). We estimate 
that the combined effect of all changes for CY 2019 will increase 
payments to urban hospitals by 0.7 percent. Overall, we estimate that 
rural hospitals will experience a 0.5 percent increase as a result of 
the combined effects of all the changes for CY 2019.
    Among hospitals, by teaching status, we estimate that the impacts 
resulting from the combined effects of all changes will include an 
increase of 0.4 percent for major teaching hospitals and an increase of 
0.9 percent for nonteaching hospitals. Minor teaching hospitals will 
experience an estimated increase of 0.5 percent.
    In our analysis, we also have categorized hospitals by type of 
ownership. Based on this analysis, we estimate that voluntary hospitals 
will experience an increase of 0.6 percent, proprietary hospitals will 
experience an increase of 1.0 percent, and governmental hospitals will 
experience an increase of 0.5 percent.
BILLING CODE 4120-01-P

[[Page 59165]]

[GRAPHIC] [TIFF OMITTED] TR21NO18.120


[[Page 59166]]


[GRAPHIC] [TIFF OMITTED] TR21NO18.121


[[Page 59167]]


[GRAPHIC] [TIFF OMITTED] TR21NO18.122

BILLING CODE 4120-01-C
e. Estimated Effects of OPPS Changes on CMHCs
    The last line of Table 62 demonstrates the isolated impact on 
CMHCs, which furnish only partial hospitalization services under the 
OPPS. In CY 2018, CMHCs are paid under APC 5853 (Partial 
Hospitalization (3 or more services) for CMHCs). We modeled the impact 
of this APC policy assuming CMHCs will continue to provide the same 
number of days of PHP care as seen in the CY 2017 claims used for 
ratesetting in this final rule with comment period. We excluded days 
with 1 or 2 services because our policy only pays a per diem rate for 
partial hospitalization when 3 or more qualifying services are provided 
to the beneficiary. We estimate that CMHCs will experience an overall 
15.1 percent decrease in payments from CY 2018 (shown in Column 6). We 
note that this includes the trimming methodology described in section 
VIII.B. of this final rule with comment period.

[[Page 59168]]

    Column 3 shows that the estimated impact of adopting the FY 2019 
wage index values will result in an increase of 0.7 percent to CMHCs. 
Column 4 shows that combining this OPD fee schedule increase factor, 
along with changes in APC policy for CY 2019 and the FY 2019 wage index 
updates, will result in an estimated decrease of 15.0 percent. Column 5 
shows that the off-campus PBD clinic visits payment policy has no 
effect on CMHCs. Column 6 shows that adding the changes in outlier and 
pass-through payments will result in a total 15.1 percent decrease in 
payment for CMHCs. This reflects all changes to CMHCs for CY 2019.
f. Estimated Effect of OPPS Changes on Beneficiaries
    For services for which the beneficiary pays a copayment of 20 
percent of the payment rate, the beneficiary's payment will increase 
for services for which the OPPS payments will rise and will decrease 
for services for which the OPPS payments will fall. For further 
discussion on the calculation of the national unadjusted copayments and 
minimum unadjusted copayments, we refer readers to section II.I. of 
this final rule with comment period. In all cases, section 
1833(t)(8)(C)(i) of the Act limits beneficiary liability for copayment 
for a procedure performed in a year to the hospital inpatient 
deductible for the applicable year.
    We estimate that the aggregate beneficiary coinsurance percentage 
will be 18.5 percent for all services paid under the OPPS in CY 2019. 
The estimated aggregate beneficiary coinsurance reflects general system 
adjustments, including the CY 2019 comprehensive APC payment policy 
discussed in section II.A.2.b. of this final rule with comment period. 
The aggregate coinsurance percentage reflects changes that we have made 
for the CY 2019 OPPS. Total estimated copayments over total estimated 
payments results in 18.6 percent. Under the C-APC payment methodology, 
the copayment is based on the claim level for the C-APC rather than the 
service line level. Because outpatient copayment is capped at the 
inpatient deductible, this can lead to an aggregate cost-sharing below 
20 percent.
g. Estimated Effects of OPPS Changes on Other Providers
    The relative payment weights and payment amounts established under 
the OPPS affect the payments made to ASCs, as discussed in section XII. 
of this final rule with comment period. We do not anticipate that any 
types of providers or suppliers other than hospitals, CMHCs, and ASCs 
will be affected by the changes in this final rule with comment period. 
However, we are interested in exploring how these Medicare changes may 
affect others in the health care marketplace.
h. Estimated Effects of OPPS Changes on the Medicare and Medicaid 
Programs
    The effect on the Medicare program is expected to be an increase of 
$440 million in program payments for OPPS services furnished in CY 
2019. The effect on the Medicaid program is expected to be limited to 
copayments that Medicaid may make on behalf of Medicaid recipients who 
are also Medicare beneficiaries. We estimate that the changes in this 
final rule with comment period will increase these Medicaid beneficiary 
payments by approximately $35 million in CY 2019. Currently, there are 
approximately 10 million dual-eligible beneficiaries, which represents 
approximately one third of Part B FFS beneficiaries. The impact on 
Medicaid was determined by taking one-third of the beneficiary cost-
sharing impact. The national average split of Medicaid payments is 57 
percent Federal payments and 43 percent State payments. Therefore, for 
the estimated $35 million Medicaid increase, approximately $20 million 
would be from the Federal Government and $15 million would be from 
State government.
i. Alternative OPPS Policies Considered
    Alternatives to the OPPS changes we are making and the reasons for 
our selected alternatives are discussed throughout this final rule with 
comment period.
 Alternatives Considered for the Method to Control for 
Unnecessary Increases in the Volume of Outpatient Services
    We refer readers to section X.B. of this final rule with comment 
period for a discussion of our policy to use our authority under 
section 1833(t)(2)(F) of the Act to apply an amount equal to the site-
specific PFS payment rate for nonexcepted items and services furnished 
by a nonexcepted off-campus PBD for the clinic visit service, as 
described by HCPCS code G0463, when provided at an off-campus PBD 
excepted from section 1833(t)(21) of the Act. For 2019, we proposed to 
apply a PFS-equivalent payment rate for this service. However, after 
consideration of public comments received, we are phasing in the 
application of the reduction in payment for HCPCS code G0463 in this 
setting over 2 years. In CY 2019, the payment reduction will be 
transitioned by applying 50 percent of the total reduction in payment 
that would apply if these departments were paid the site-specific PFS 
rate for the clinic visit service. We also considered, but did not 
finalize, fully applying this payment reduction in CY 2019. Had we done 
so, total Medicare and beneficiary copayments in CY 2019 would have 
decreased by $750 million, compared to the decrease of $380 million as 
a result of the phase-in.
 Alternatives Considered for the Methodology for Assigning Skin 
Substitutes to High or Low Cost Groups
    We refer readers to section V.B.1.d. of this final rule with 
comment period for a discussion of our policy to assign any skin 
substitute product that was assigned to the high cost group in CY 2018 
to the high cost group in CY 2019, regardless of whether the product's 
mean unit cost (MUC) or the product's per day cost (PDC) exceeds or 
falls below the overall CY 2019 MUC or PDC threshold. We will continue 
to assign products that exceed either the overall CY 2019 MUC or PDC 
threshold to the high cost group. We also considered, but did not 
propose, reinstating our methodology from CY 2017 and assigning skin 
substitutes to the high cost group based on whether an individual 
product's MUC or PDC exceeded the overall CY 2019 MUC or PDC threshold 
based on calculations done for either the proposed rule or the final 
rule with comment period.
 Alternatives Considered for the Methodology for Payment for 
Non-Opioid Pain Management Treatments
    We refer readers to sections II.A.3.b. and XII.D.3. of the proposed 
rule and this final rule with comment period for a discussion of our 
change in the packaging policy for certain drugs when administered in 
the ASC setting and policy provide separate payment for non-opioid pain 
management drugs that function as a supply when used in a surgical 
procedure when the procedure is performed in an ASC. In those sections 
of the proposed rule, we also solicited comments on whether we should 
pay separately for other non-opioid treatments for pain under the OPPS 
and the ASC payment system. We discuss the comments we received in 
those sections of this final rule with comment period. In the proposed 
rule, we also considered and solicited comments on an alternative 
policy that would use our equitable adjustment authority under section 
1833(t)(2)(E) of the Act to establish an incentive payment for non-
opioid alternatives that would apply to drugs and devices under

[[Page 59169]]

the OPPS that are not currently separately paid, are supported by 
evidence that demonstrates such drugs and devices are effective at 
treating acute or chronic pain, and would result in decreased use of 
prescription opioid drugs and any associated opioid addiction, when 
furnished in the outpatient setting. We discuss the comments we 
received in those sections of this final rule with comment period.
2. Estimated Effects of CY 2019 ASC Payment System Changes in This 
Final Rule With Comment Period
    Most ASC payment rates are calculated by multiplying the ASC 
conversion factor by the ASC relative payment weight. As discussed 
fully in section XII. of this final rule with comment period, we are 
setting the CY 2019 ASC relative payment weights by scaling the CY 2019 
OPPS relative payment weights by the ASC scalar of 0.8792. The 
estimated effects of the updated relative payment weights on payment 
rates are varied and are reflected in the estimated payments displayed 
in Tables 63 and 64 below.
    Beginning in CY 2011, section 3401 of the Affordable Care Act 
requires that the annual update to the ASC payment system (which will 
be the hospital market basket for CY 2019) after application of any 
quality reporting reduction be reduced by a productivity adjustment. 
The Affordable Care Act defines the productivity adjustment to be equal 
to the 10-year moving average of changes in annual economy-wide private 
nonfarm business multifactor productivity (MFP) (as projected by the 
Secretary for the 10-year period, ending with the applicable fiscal 
year, year, cost reporting period, or other annual period). For ASCs 
that fail to meet their quality reporting requirements, the CY 2019 
payment determinations will be based on the application of a 2.0 
percentage point reduction to the annual update factor, which will be 
the hospital market basket for CY 2019. We calculated the CY 2019 ASC 
conversion factor by adjusting the CY 2018 ASC conversion factor by 
1.0004 to account for changes in the pre-floor and pre-reclassified 
hospital wage indexes between CY 2018 and CY 2019 and by applying the 
CY 2019 MFP-adjusted hospital market basket update factor of 2.1 
percent (hospital market basket update of 2.9 percent minus a projected 
productivity adjustment of 0.8 percentage point). The CY 2019 ASC 
conversion factor is $46.555 for ASCs that successfully meet the 
quality reporting requirements.
a. Limitations of Our Analysis
    Presented here are the projected effects of the changes for CY 2019 
on Medicare payment to ASCs. A key limitation of our analysis is our 
inability to predict changes in ASC service-mix between CY 2017 and CY 
2019 with precision. We believe the net effect on Medicare expenditures 
resulting from the CY 2019 changes will be small in the aggregate for 
all ASCs. However, such changes may have differential effects across 
surgical specialty groups, as ASCs continue to adjust to the payment 
rates based on the policies of the revised ASC payment system. We are 
unable to accurately project such changes at a disaggregated level. 
Clearly, individual ASCs will experience changes in payment that differ 
from the aggregated estimated impacts presented below.
b. Estimated Effects of ASC Payment System Policies on ASCs
    Some ASCs are multispecialty facilities that perform a wide range 
of surgical procedures from excision of lesions to hernia repair to 
cataract extraction; others focus on a single specialty and perform 
only a limited range of surgical procedures, such as eye, digestive 
system, or orthopedic procedures. The combined effect on an individual 
ASC of the update to the CY 2019 payments will depend on a number of 
factors, including, but not limited to, the mix of services the ASC 
provides, the volume of specific services provided by the ASC, the 
percentage of its patients who are Medicare beneficiaries, and the 
extent to which an ASC provides different services in the coming year. 
The following discussion presents tables that display estimates of the 
impact of the CY 2019 updates to the ASC payment system on Medicare 
payments to ASCs, assuming the same mix of services, as reflected in 
our CY 2017 claims data. Table 63 depicts the estimated aggregate 
percent change in payment by surgical specialty or ancillary items and 
services group by comparing estimated CY 2018 payments to estimated CY 
2019 payments, and Table 64 shows a comparison of estimated CY 2018 
payments to estimated CY 2019 payments for procedures that we estimate 
will receive the most Medicare payment in CY 2018.
    In Table 63, we have aggregated the surgical HCPCS codes by 
specialty group, grouped all HCPCS codes for covered ancillary items 
and services into a single group, and then estimated the effect on 
aggregated payment for surgical specialty and ancillary items and 
services groups. The groups are sorted for display in descending order 
by estimated Medicare program payment to ASCs. The following is an 
explanation of the information presented in Table 63.
     Column 1--Surgical Specialty or Ancillary Items and 
Services Group indicates the surgical specialty into which ASC 
procedures are grouped and the ancillary items and services group which 
includes all HCPCS codes for covered ancillary items and services. To 
group surgical procedures by surgical specialty, we used the CPT code 
range definitions and Level II HCPCS codes and Category III CPT codes, 
as appropriate, to account for all surgical procedures to which the 
Medicare program payments are attributed.
     Column 2--Estimated CY 2018 ASC Payments were calculated 
using CY 2017 ASC utilization data (the most recent full year of ASC 
utilization) and CY 2018 ASC payment rates. The surgical specialty and 
ancillary items and services groups are displayed in descending order 
based on estimated CY 2018 ASC payments.
     Column 3--Estimated CY 2019 Percent Change is the 
aggregate percentage increase or decrease in Medicare program payment 
to ASCs for each surgical specialty or ancillary items and services 
group that are attributable to updates to ASC payment rates for CY 2019 
compared to CY 2018.
    As shown in Table 63, for the six specialty groups that account for 
the most ASC utilization and spending, we estimate that the update to 
ASC payment rates for CY 2019 will result in a 1-percent decrease in 
aggregate payment amounts for eye and ocular adnexa procedures, a 3-
percent increase in aggregate payment amounts for nervous system 
procedures, 3-percent increase in aggregate payment amounts for 
digestive system procedures, a 3-percent increase in aggregate payment 
amounts for musculoskeletal system procedures, a 1-percent increase in 
aggregate payment amounts for genitourinary system procedures, and a 1-
percent decrease in aggregate payment amounts for integumentary system 
procedures. We note that these changes can be a result of different 
factors, including updated data, payment weight changes, and changes in 
policy. In general, spending in each of these categories of services is 
increasing due to the 2.1 percent payment rate update. After the 
payment rate update is accounted for, aggregate payment increases or 
decreases for a category of services can be higher or lower than a 2.1 
percent increase, depending on if payment weights in the OPPS APCs that 
correspond to the applicable services

[[Page 59170]]

increased or decreased or if the most recent data show an increase or a 
decrease in the volume of services performed in an ASC for a category. 
For example, we estimate a 1-percent decrease in aggregate eye and 
ocular adnexa procedure payments due to a reduction in hospital 
reported costs for the primary payment grouping for this category under 
the OPPS. This lowers the payment weights for eye and ocular adnexa 
procedure payments and, overall, offsets the 2.1 percent ASC rate 
update for these procedures. For estimated changes for selected 
procedures, we refer readers to Table 64 provided later in this 
section.
    Also displayed in Table 63 is a separate estimate of Medicare ASC 
payments for the group of separately payable covered ancillary items 
and services. The payment estimates for the covered surgical procedures 
include the costs of packaged ancillary items and services. We estimate 
that aggregate payments for these items and services will increase by 
79 percent for CY 2019. This is largely attributed to the introduction 
of utilization data for HCPCS code C9447 (Inj, phenylephrine 
ketorolac), Omidria[supreg], and HCPCS code Q4172 (Puraply or puraply 
am), a high-cost skin substitute. 
[GRAPHIC] [TIFF OMITTED] TR21NO18.123

    Table 64 below shows the estimated impact of the updates to the 
revised ASC payment system on aggregate ASC payments for selected 
surgical procedures during CY 2019. The table displays 30 of the 
procedures receiving the greatest estimated CY 2018 aggregate Medicare 
payments to ASCs. The HCPCS codes are sorted in descending order by 
estimated CY 2018 program payment.
     Column 1--CPT/HCPCS code.
     Column 2--Short Descriptor of the HCPCS code.
     Column 3--Estimated CY 2018 ASC Payments were calculated 
using CY 2017 ASC utilization (the most recent full year of ASC 
utilization) and the CY 2018 ASC payment rates. The estimated CY 2018 
payments are expressed in millions of dollars.
     Column 4--Estimated CY 2019 Percent Change reflects the 
percent differences between the estimated ASC payment for CY 2018 and 
the estimated payment for CY 2019 based on the update.
BILLING CODE 4120-01-P

[[Page 59171]]

[GRAPHIC] [TIFF OMITTED] TR21NO18.124

BILLING CODE 4120-01-C
c. Estimated Effects of ASC Payment System Policies on Beneficiaries
    We estimate that the CY 2019 update to the ASC payment system will 
be generally positive (that is, result in lower cost-sharing) for 
beneficiaries with respect to the new procedures we are adding to the 
ASC list of covered surgical procedures, the existing covered surgical 
procedures we reviewed as safe to perform in an ASC, and for those 
surgical procedures we are designating as office-based for CY 2019. For 
example, using 2017 utilization data and CY 2019 OPPS and ASC payment 
rates, we estimate that if 5 percent of

[[Page 59172]]

cardiac catheterization procedures migrate from the hospital outpatient 
setting to the ASC setting as a result of this policy, Medicare 
payments will be reduced by approximately $36 million in CY 2019 and 
total beneficiary copayments will decline by approximately $14 million 
in CY 2019. First, other than certain preventive services where 
coinsurance and the Part B deductible is waived to comply with sections 
1833(a)(1) and (b) of the Act, the ASC coinsurance rate for all 
procedures is 20 percent. This contrasts with procedures performed in 
HOPDs under the OPPS, where the beneficiary is responsible for 
copayments that range from 20 percent to 40 percent of the procedure 
payment (other than for certain preventive services), although the 
majority of HOPD procedures have a 20-percent copayment. Second, in 
almost all cases, the ASC payment rates under the ASC payment system 
are lower than payment rates for the same procedures under the OPPS. 
Therefore, the beneficiary coinsurance amount under the ASC payment 
system will almost always be less than the OPPS copayment amount for 
the same services. (The only exceptions will be if the ASC coinsurance 
amount exceeds the inpatient deductible. The statute requires that 
copayment amounts under the OPPS not exceed the inpatient deductible.) 
Beneficiary coinsurance for services migrating from physicians' offices 
to ASCs may decrease or increase under the revised ASC payment system, 
depending on the particular service and the relative payment amounts 
under the MPFS compared to the ASC. While the ASC payment system bases 
most of its payment rates on hospital cost data used to set OPPS 
relative payment weights, services that are performed a majority of the 
time in a physician office are generally paid the lesser of the ASC 
amount according to the standard ASC rate setting methodology or at the 
nonfacility practice expense based amount payable under the PFS. 
Because of this fact, we do not believe that the increase in ASC 
payment rates that will result from this policy will cause any 
significant migration of services from the physician office setting to 
the ASC setting. For those additional procedures that we are 
designating as office-based in CY 2019, the beneficiary coinsurance 
amount under the ASC payment system generally will be no greater than 
the beneficiary coinsurance under the PFS because the coinsurance under 
both payment systems generally is 20 percent (except for certain 
preventive services where the coinsurance is waived under both payment 
systems).
d. Alternative ASC Payment Policies Considered
    Alternatives to the ASC changes we are making and the reasons for 
our selected alternatives are discussed throughout this final rule with 
comment period.
 Alternatives Considered for the CY 2019 ASC Rate Update
    As discussed in section XII. of this final rule with comment 
period, for CY 2019 through CY 2023 (5 years total), in response to 
stakeholder concerns regarding the application of CPI-U to update ASC 
payment rates, we are updating ASC payment rates using the hospital 
market basket and revising our regulations under 42 CFR 416.171(a), 
which address the annual update to the ASC conversion factor, to 
reflect this policy.
    As an alternative proposal, we considered whether to continue 
applying the CPI-U as the update factor. If we were to update ASC 
payment rates for CY 2019 with an update factor based on CPI-U, the 
update would have been 1.8 percent (the 2.6 percentage point CPI-U less 
the 0.8 percentage point MFP adjustment). This update factor would have 
resulted in increased payments to ASCs in CY 2019 of approximately $60 
million, compared to the increased payments to ASCs in CY 2019 of 
approximately $80 million as a result of the 2.1 percent update based 
on the hospital market basket.
3. Accounting Statements and Tables
    As required by OMB Circular A-4 (available on the Office of 
Management and Budget website at: https://www.whitehouse.gov/omb/circulars_a004_a-4#a),we have prepared accounting statements to 
illustrate the impacts of the OPPS and ASC changes in this final rule 
with comment period. The first accounting statement, Table 65 below, 
illustrates the classification of expenditures for the CY 2019 
estimated hospital OPPS incurred benefit impacts associated with the CY 
2019 OPD fee schedule increase. This $440 million in additional 
Medicare spending estimate includes the $740 million in additional 
Medicare spending associated with updating the CY 2018 OPPS payment 
rates by the hospital market basket update for CY 2019, offset by the 
$300 million in Medicare savings associated with the finalized policy 
to pay for clinic visits furnished at off-campus PBDs at a PFS-
equivalent rate. In addition, we estimate that OPPS changes in this 
final rule with comment period will increase copayments that Medicaid 
may make on behalf of Medicaid recipients who are also Medicare 
beneficiaries by approximately $35 million in CY 2019. The second 
accounting statement, Table 66 below illustrates the classification of 
expenditures associated with the 2.1 percent CY 2019 update to the ASC 
payment system, based on the provisions of this final rule with comment 
period and the baseline spending estimates for ASCs. Both tables 
classify most estimated impacts as transfers.
BILLING CODE 4120-01-P
[GRAPHIC] [TIFF OMITTED] TR21NO18.125


[[Page 59173]]


[GRAPHIC] [TIFF OMITTED] TR21NO18.126

[GRAPHIC] [TIFF OMITTED] TR21NO18.127

BILLING CODE 4120-01-C
4. Effects of Changes in Requirements for the Hospital OQR Program
a. Background
    We refer readers to the CY 2018 OPPS/ASC final rule with comment 
period (82 FR 59492 through 59494), for the previously estimated 
effects of changes to the Hospital OQR Program for the CY 2018, CY 
2019, and CY 2020 payment determinations. Of the approximately 3,300 
hospitals that met eligibility requirements for the CY 2018 payment 
determination, we determined that 36 hospitals did not meet the 
requirements to receive the full OPD fee schedule increase factor. Many 
of these hospitals (18 of the 36), chose not to participate in the 
Hospital OQR Program for the CY 2018 payment determination. In the 
proposed rule, we did not propose to add any quality measures to the 
Hospital OQR Program measure set for the CY 2020 or CY 2021 payment 
determinations, and, in this final rule with comment period we are 
finalizing our proposals to remove eight measures from the program 
measure set; we are not finalizing our proposals to remove two 
measures, as discussed in section XIII.B.4.b. of this final rule with 
comment period. We do not believe that the finalized policies will 
increase the number of hospitals that do not receive a full annual 
payment update for the CY 2020 or CY 2021 payment determinations.
    In section XIII.B.4.b. of this final rule with comment period, we 
are finalizing our proposals to remove a total of eight measures. 
Specifically, beginning with the CY 2020 payment determination, we are 
finalizing the removal of: (1) OP-27: Influenza Vaccination Coverage 
Among Healthcare Personnel; and beginning with the CY 2021 payment 
determination, we are removing: (2) OP-5: Median Time to ECG; (3) OP-9: 
Mammography Follow-up Rates; (4) OP-11: Thorax CT Use of Contrast 
Material; (5) OP-12: The Ability for Providers with HIT to Receive 
Laboratory Data Electronically Directly into Their Qualified/Certified 
EHR System as Discrete Searchable Data; (6) OP-14: Simultaneous Use of 
Brain Computed Tomography (CT) and Sinus CT; (7) OP-17: Tracking 
Clinical Results between Visits; and (8) OP-30: Endoscopy/Polyp 
Surveillance: Colonoscopy Interval for Patients with a History of 
Adenomatous Polyps--Avoidance of Inappropriate Use. However, we are not 
finalizing our proposals to remove two measures: OP-29: Endoscopy/Polyp 
Surveillance: Appropriate Follow-up Interval for Normal Colonoscopy in 
Average Risk Patients; and OP-31: Cataracts--Improvement in Patient's 
Visual Function within 90 Days Following Cataract Surgery for the CY 
2021 payment determination and subsequent years. Therefore, we are 
revising the estimated burden changes found in the CY 2019 OPPS/ASC 
proposed rule (83 FR 37234 through 32736). The reduction in burden 
associated with our finalized policies is discussed below.
    In section XIII.B.4.a. of this final rule with comment period, 
beginning with the effective date of this CY 2019 OPPS/ASC final rule 
with comment period, we are updating one removal factor and adding one 
removal factor. We are also codifying our measure removal policies and 
factors at 42 CFR 419.46(h) effective upon finalization of this CY 2019 
OPPS/ASC final rule with comment period and for subsequent years. In 
addition, in section XIII.D.2. of this final rule with comment period, 
we are updating the frequency with which we will release Hospital 
Outpatient Quality Reporting Specifications Manuals, such that instead 
of releasing the full manual once or twice each year, as proposed, we 
will release the Specifications Manuals once every 12 months and 
release addenda as necessary, beginning with CY 2019 and for subsequent 
years. In section XIII.C.2. of this final rule with comment period, 
beginning with the CY 2020 payment determination, we are removing the 
Notice of Participation (NOP) form as a requirement for the Hospital 
OQR Program and updating 42 CFR 419.46(a)(3) to reflect this policy. 
Finally, in section XIII.D.4.b. of this final rule with comment period, 
we are changing the data reporting period for OP-32: Facility Seven-Day 
Risk-Standardized Hospital Visit Rate after Outpatient Colonoscopy from 
one year to three years beginning with the CY 2020 payment 
determination. As discussed below, we do not expect these policies to 
affect our burden estimates. However, as further explained in section 
XIX.B. of this final rule with comment period, we believe that there 
will be an overall decrease in the estimated information collection 
burden for hospitals due to the other finalized policies. We refer 
readers to section XIX.B. of this final rule with comment

[[Page 59174]]

period for a summary of our information collection burden estimate 
calculations. The effects of these proposals are discussed in more 
detail further below.
b. Estimated Effects of Hospital OQR Program Beginning With the 
Effective Date of This CY 2019 OPPS/ASC Final Rule With Comment Period
    In section XIII.B.4.a. of this final rule with comment period, we 
are: (1) Updating measure removal Factor 7; (2) adding one new removal 
factor; and (3) codifying our removal factors policy at 42 CFR 
419.46(h). We do not expect a change in the information collection 
burden or other costs experienced by hospitals because these changes do 
not affect Hospital OQR Program participation requirements or data 
reporting requirements.
c. Update to the Frequency of Releasing the Hospital Outpatient Quality 
Reporting Specifications Manual Beginning With CY 2019 and for 
Subsequent Years
    In section XIII.D.2. of this final rule with comment period, we are 
finalizing with modification our proposal to update the frequency with 
which we will release a Hospital Outpatient Quality Reporting 
Specifications Manual such that instead of releasing a full manual once 
or twice each year, as proposed, we will release the Specifications 
Manuals once every 12 months and release addenda as necessary, 
beginning with CY 2019 and for subsequent years. We anticipate that 
this change will reduce hospital confusion, as potentially releasing 
fewer manuals per year reduces the need to review updates as frequently 
as was previously necessary. However, because this change does not 
affect Hospital OQR Program participation requirements or data 
reporting requirements, we do not estimate a change in our calculation 
of the information collection burden experienced by hospitals.
d. Estimated Effects of Hospital OQR Program Finalized Proposals for 
the CY 2020 Payment Determination and Subsequent Years
(1) Removal of the Notice of Participation (NOP) Form Requirement
    In section XIII.C.2. of this final rule with comment period, 
beginning with the CY 2020 payment determination, we are removing the 
NOP form as a requirement. As a result, to be a participant in the 
Hospital OQR Program, hospitals will need to: (1) Register on the 
QualityNet website, (2) identify and register a QualityNet security 
administrator, and (3) submit data. In addition, we are updating 42 CFR 
419.46(a) to reflect these policies. We believe that the finalized 
policy to remove the NOP will reduce administrative burden experienced 
by hospitals by only a nominal amount. As a result, this finalized 
policy does not influence our information collection burden estimates. 
We refer readers to section XIX.B. of this final rule with comment 
period, where our burden calculations for the Hospital OQR Program are 
discussed in detail. In addition, we anticipate that this finalized 
proposal will reduce the possibility of hospitals failing to meet 
Hospital OQR Program requirements due to a failure to submit the NOP.
(2) Extension of the Reporting Period for OP-32: Facility 7-Day Risk-
Standardized Hospital Visit Rate After Outpatient Colonoscopy
    In section XIII.D.4.b. of this final rule with comment period, we 
are increasing the data reporting period for OP-32: Facility Seven-Day 
Risk-Standardized Hospital Visit Rate after Outpatient Colonoscopy from 
one year to three years beginning with the CY 2020 payment 
determination. We expect this policy to increase the reliability of OP-
32 data allowing better information to be publicly reported. However, 
the policy does not change our data reporting requirements, such that 
hospitals will be required to continue reporting claims data that are 
used to calculate this measure. Therefore, we do not expect a change in 
the information collection burden experienced by hospitals.
(3) Removal of OP-27 for the CY 2020 Payment Determination and 
Subsequent Years
    In section XIII.B.4.b. of this final rule with comment period, we 
are removing OP-27: Influenza Vaccination Coverage Among Healthcare 
Personnel (NQF #0431) beginning with the CY 2020 payment determination 
and for subsequent years. The burden associated with OP-27, a NHSN 
measure, is accounted for under a separate Paperwork Reduction Act 
Package, OMB control number 0920-0666. Because burden associated with 
submitting data for this measure is captured under a separate OMB 
control number, we are not providing an estimate of the information 
collection burden associated with this measure for the Hospital OQR 
Program. Aside from burden associated with information collection 
however, we also anticipate that hospitals will experience a general 
burden and cost reduction associated with this proposal stemming from 
no longer having to review and track program requirements associated 
with this measure.
e. Estimated Effects of Hospital OQR Program Proposals for the CY 2021 
Payment Determination and Subsequent Years
(1) Removal of Chart-Abstracted Measures for the CY 2021 Payment 
Determination and Subsequent Years
    In section XIII.B.4.b. of this final rule with comment period, we 
are removing OP-5: Median Time to ECG, a chart-abstracted measure, for 
the CY 2021 payment determination and subsequent years. We believe that 
the removal of this chart-abstracted measure for the CY 2021 payment 
determination will reduce collection of information burden by 151,800 
hours and $5.6 million (151,800 hours x $36.58), as discussed in 
section XIX.B. of this final rule with comment period. Aside from 
burden associated with information collection however, we also 
anticipate that hospitals will experience a general burden and cost 
reduction associated with this proposal stemming from no longer having 
to review and track program requirements associated with this measure.
(2) Removal of Measures Submitted via a Web-Based Tool for the CY 2021 
Payment Determination and Subsequent Years
    In section XIII.B.4.b. of this final rule with comment period, 
while we proposed to remove five measures, we are only finalizing the 
removal of three measures submitted via a web-based tool beginning with 
the CY 2021 payment determination and for subsequent years: OP-12: The 
Ability for Providers with HIT to Receive Laboratory Data 
Electronically Directly into Their Qualified/Certified EHR System as 
Discrete Searchable Data; OP-17: Tracking Clinical Results between 
Visits; and OP-30: Endoscopy/Polyp Surveillance: Colonoscopy Interval 
for Patients with a History of Adenomatous Polyps--Avoidance of 
Inappropriate Use. We are not finalizing the removal of OP-29: 
Endoscopy/Polyp Surveillance: Appropriate Follow-up Interval for Normal 
Colonoscopy in Average Risk Patients; and OP-31: Cataracts--Improvement 
in Patient's Visual Function within 90 Days Following Cataract Surgery. 
Therefore, we are revising the estimated burden changes found in the CY 
2019 OPPS/ASC proposed rule (83 FR 37234 through 32736). As discussed 
in section XIX.B. of this final rule with comment period, we anticipate 
a burden

[[Page 59175]]

reduction of 530,075 hours and $19.4 million associated with the 
removal of OP-12, OP-17, and OP-30 for the CY 2021 payment 
determination. Aside from burden associated with information collection 
however, we also anticipate that hospitals will experience a general 
burden and cost reduction associated with these measure removals 
stemming from no longer having to implement, review, track, and 
maintain program requirements associated with these measures.
(3) Removal of Claims-Based Measures for the CY 2021 Payment 
Determination and Subsequent Years
    In section XIII.B.4.b. of this final rule with comment period, we 
are removing three claims-based measures beginning with the CY 2021 
payment determination: OP-9: Mammography Follow-up Rates; OP-11: Thorax 
CT Use of Contrast Material; and OP-14: Simultaneous Use of Brain 
Computed Tomography (CT) and Sinus CT. These claims-based measures are 
calculated using only data already reported to the Medicare program for 
payment purposes, therefore, we do not believe removing these measures 
will affect the information collection burden on hospitals. 
Nonetheless, we anticipate that hospitals will experience a general 
burden reduction associated with these proposals stemming from no 
longer having to review and track various associated program 
requirements.
    In total for the CY 2021 payment determination, we expect 
information collection burden will be reduced by 151,800 hours due to 
our removal of one chart-abstracted measure, and 530,075 hours due to 
our removal of three measures submitted via a web-based tool. In total, 
we estimate an information collection burden reduction of 681,875 hours 
(151,800 hours for the removal of one chart-abstracted measure + 
530,075 hours for the removal of three web-based measures) and $24.9 
million (681,875 hours x $36.58) for the CY 2021 payment determination.
5. Effects of Requirements for the ASCQR Program
a. Background
    In section XIV. of this final rule with comment period, we discuss 
our adopted policies affecting the ASCQR Program. For the CY 2018 
payment determination, of the 6,683 ASCs that met eligibility 
requirements for the ASCQR Program, 233 ASCs did not meet the 
requirements to receive the full annual payment update. We note that, 
in the CY 2017 OPPS/ASC final rule with comment period (81 FR 79874), 
we used the CY 2016 payment determination numbers as a baseline, and 
estimated that approximately 200 ASCs will not receive the full annual 
payment update in CY 2019 due to failure to meet the ASCQR Program 
requirements (CY 2017 and CY 2018 payment determination information 
were not yet available). In the proposed rule, we did not propose to 
add any new quality measures to the ASCQR Program measure set for the 
CY 2020 payment determination and subsequent determinations, and we do 
not believe that the other measures we previously adopted will cause 
any additional ASCs to fail to meet the ASCQR Program requirements. 
Therefore, we do not believe that our finalized proposals will increase 
the number of ASCs that do not receive a full annual payment update for 
the CY 2020 payment determination. Below we discuss only the effects 
that will result from the newly finalized provisions in this final rule 
with comment period.
    In section XIV.B.3.c. of this final rule with comment period, we 
are removing one measure beginning with the CY 2020 payment 
determination (ASC-8: Influenza Vaccination Coverage Among Healthcare 
Personnel) and removing one measure beginning with the CY 2021 payment 
determination (ASC-10: Endoscopy/Polyp Surveillance: Colonoscopy 
Interval for Patients with a History of Adenomatous Polyps--Avoidance 
of Inappropriate Use). We expect these measure removals will reduce the 
overall burden of reporting data for the ASCQR Program, as discussed 
further below. In section XIV.B.3.c. of this final rule with comment 
period, we are not finalizing our proposals to remove ASC-9: Endoscopy/
Polyp Surveillance Follow-up Interval for Normal Colonoscopy in Average 
Risk Patients and ASC-11: Cataracts--Improvement in Patient's Visual 
Function within 90 Days Following Cataract Surgery. In addition, we are 
not finalizing our proposals to remove ASC-1: Patient Burn; ASC-2: 
Patient Fall; ASC-3: Wrong Site, Wrong Side, Wrong Patient, Wrong 
Procedure, Wrong Implant; and ASC-4: All-Cause Hospital Transfer/
Admission, but are instead retaining the measures in the ASCQR Program 
and suspending their data collection beginning with the CY 2019 
reporting period/CY 2021 payment determination until further action in 
rulemaking with the goal of updating the measures. Therefore, we are 
revising the estimated burden changes found in the CY 2019 OPPS/ASC 
proposed rule (83 FR 37236 through 32737).
    In sections XIV.B.3.b. and XIV.D.4.b. of this final rule with 
comment period, beginning with the effective date of this CY 2019 OPPS/
ASC final rule with comment period, we are finalizing our proposals to: 
(1) Remove one measure removal factor; (2) adding two new measure 
removal factors, and (3) update 42 CFR 416.320(c) to better reflect our 
measure removal policies; we are also: (4) Extend the reporting period 
for ASC-12: Facility Seven-Day Risk Standardized Hospital Visit Rate 
after Outpatient Colonoscopy from 1 to 3 years beginning with the CY 
2020 payment determination. As discussed below, we do not expect these 
policies will affect our burden estimates. However, as further 
explained in section XIX.C. of this final rule with comment period, we 
believe that there will be an overall decrease in the estimated 
information collection burden for ASCs due to the other finalized 
policies. We refer readers to section XIX.C. of this final rule with 
comment period for a summary of our information collection burden 
estimate calculations. The effects of these policies are discussed in 
more detail below.
b. Estimated Effects of ASCQR Program Newly Finalized Policies 
Beginning With the Effective Date of This CY 2019 OPPS/ASC Final Rule 
With Comment Period
    In section XIV.B.3.a. of this final rule with comment period, we 
are, beginning with the effective date of this CY 2019 OPPS/ASC final 
rule with comment period, removing one measure removal factor, adding 
two new measure removal factors, and updating 42 CFR 416.320(c) to 
better reflect our measure removal policies for the ASCQR Program. 
Because these changes do not affect ASCQR Program participation 
requirements or data reporting requirements, we do not expect these 
newly finalized policies to change the information collection burden or 
other costs experienced by ASCs.
c. Estimated Effects of ASCQR Program Newly Finalized Policies for the 
CY 2020 Payment Determination and Subsequent Years
(1) Extension of the Reporting Period for ASC-12: Facility 7-Day Risk-
Standardized Hospital Visit Rate After Outpatient Colonoscopy
    In section XIV.D.4.b. of this final rule with comment period, we 
are extending the data reporting period for ASC-12: Facility Seven-Day 
Risk-Standardized Hospital Visit Rate after Outpatient Colonoscopy from 
one year to three years beginning with the CY 2020 payment 
determination. We expect this newly finalized policy to increase the

[[Page 59176]]

reliability of ASC-12 data allowing better information to be publicly 
reported. However, the policy does not change our data reporting 
requirements, because ASC-12 is a claims-based measure that is 
calculated based on claims data that facilities already submit to CMS. 
Therefore, we do not expect a change in the information collection 
burden or other costs experienced by ASCs.
(2) Removal of ASC-8 for the CY 2020 Payment Determination and 
Subsequent Years
    In section XIV.B.3.c. of this final rule with comment period, we 
are removing one measure from the ASCQR Program measure set beginning 
with the CY 2020 payment determination, ASC-8: Influenza Vaccination 
Coverage Among Healthcare Personnel. As discussed in section XIX.C.3.b. 
of this final rule with comment period, the information collection 
burden associated with ASC-8, a NHSN measure, is accounted for under a 
separate information collection request, OMB control number 0920-0666. 
As such, we are not providing an estimate of the information collection 
burden associated with this measure under the ASCQR Program control 
number. Aside from burden associated with information collection 
however, we anticipate that facilities will experience a general burden 
and cost reduction associated with this proposal stemming from no 
longer having to review and track program requirements associated with 
this measure.
d. Estimated Effects of ASCQR Program Newly Finalized Policies for the 
CY 2021 Payment Determination and Subsequent Years: Removal of One 
Chart-Abstracted Measure for the CY 2021 Payment Determination and 
Subsequent Years
    In section XIV.B.3.c. of this final rule with comment period, we 
proposed to remove seven measures; we are finalizing the removal of 
only one measure from the ASCQR Program measure set beginning with the 
CY 2021 payment determination: ASC-10: Endoscopy/Polyp Surveillance: 
Colonoscopy Interval for Patients with a History of Adenomatous 
Polyps--Avoidance of Inappropriate Use. In section XIV.B.3.c. of this 
final rule with comment period we are not finalizing our proposal to 
remove ASC-9: Endoscopy/Polyp Surveillance Follow-up Interval for 
Normal Colonoscopy in Average Risk Patients and ASC-11: Cataracts--
Improvement in Patient's Visual Function within 90 Days Following 
Cataract Surgery. In addition, we are not finalizing our proposals to 
remove ASC-1: Patient Burn; ASC-2: Patient Fall; ASC-3: Wrong Site, 
Wrong Side, Wrong Patient, Wrong Procedure, Wrong Implant; and ASC-4: 
All Cause Hospital Transfer/Admission, but are instead retaining the 
measures in the ASCQR Program and suspending their data collection 
beginning with the CY 2019 reporting period/CY 2021 payment 
determination until further action in rulemaking with the goal of 
updating the measures. Therefore, we are revising the estimated burden 
changes found in the CY 2019 OPPS/ASC proposed rule (83 FR 37222).
    While we proposed to remove three chart-abstracted measures, in 
section XIV.B.3.c. of this final rule with comment period, we are 
finalizing the removal of only one chart-abstracted measure from the 
ASCQR Program measure set beginning with the CY 2021 payment 
determination: ASC-10: Endoscopy/Polyp Surveillance: Colonoscopy 
Interval for Patients with a History of Adenomatous Polyps--Avoidance 
of Inappropriate Use. We are not finalizing the removal of ASC-9: 
Endoscopy/Polyp Surveillance Follow-up Interval for Normal Colonoscopy 
in Average Risk Patients and ASC-11: Cataracts--Improvement in 
Patient's Visual Function within 90 Days Following Cataract Surgery. As 
discussed in section XIX.C.4.b. of this final rule with comment period, 
we believe the removal of ASC-10 will result in a burden reduction for 
ASCs. For ASC-10, we estimate the total annualized burden reduction to 
be 62,008 hours and $2,268,244 (3,937 ASCs x 15.75 hours x $36.58 per 
hour). Aside from burden associated with information collection 
however, we anticipate that facilities will experience a general burden 
and cost reduction associated with these removals stemming from no 
longer having to review and track program requirements associated with 
this measure.
    Therefore, as noted in section XIX.C.4. of this final rule with 
comment period, we believe the removal of a total of one measure (ASC-
10) from the ASCQR measure set for the CY 2021 payment determination 
will result in a total annual reduction in information collection 
burden of 62,008 hours and $2,268,244.

D. Effects of the Update to the HCAHPS Survey Measure in the Hospital 
IQR Program

    As discussed in section XVI. of this final rule with comment 
period, we are finalizing a modified version of our proposals regarding 
the Communication About Pain questions from the HCAHPS Survey in the 
Hospital IQR Program. Instead of removing the questions effective with 
January 2022 discharges, for the FY 2024 payment determination and 
subsequent years as proposed, we are finalizing to remove them 
effective with October 2019 discharges, for the FY 2021 payment 
determination and subsequent years. In addition, instead of publicly 
reporting the data in October 2022 and then subsequently discontinuing 
as proposed, we are finalizing that we will not publicly report the 
data collected from the Communication About Pain questions at all. We 
anticipate that the removal of these questions will result in only a 
nominal and temporary increase on the information collection burden on 
providers associated with adjusting the survey instrument and 
instructional materials, and a burden decrease for survey respondents. 
We note that the burden estimate for the Hospital IQR Program under the 
program's OMB control number 0938-1022 excludes the burden associated 
with the HCAHPS Survey measure, which is submitted under a separate 
information collection request and approved under OMB control number 
0938-0981. We address the anticipated information collection burden 
reduction in section XVIII.D. of this final rule with comment period.

E. Effects of Requirements for the PPS-Exempt Cancer Hospital Quality 
Reporting (PCHQR) Program

    As described in section XVII.B. of this final rule with comment 
period, we are not finalizing our proposals made in the FY 2019 IPPS/
LTCH PPS proposed rule (83 FR 20503) to remove two chart-abstracted, 
NHSN measures, the Catheter-Associated Urinary Tract Infection (CAUTI) 
Outcome Measure (PCH-5/NQF #0138) and the Central Line-Associated 
Bloodstream Infection (CLABSI) Outcome Measure (PCH-4/NQF #0139) from 
the PCHQR Program beginning with the FY 2021 program year.
    We estimate that not finalizing our proposals to remove the CAUTI 
and CLABSI measures will result in no changes to our previously 
finalized burden estimates under the PCHQR Program. We refer readers to 
section XIX.E. of this final rule with comment period for a discussion 
of the information collection estimates for the CAUTI and CLABSI 
measures. We refer readers to section XIV.B.4. of the preamble of the 
FY 2019 IPPS/LTCH PPS final rule (83 FR 41694 through 41695) and 
Appendix A, section I.L. of that final rule (83 FR 41772) for more 
detail regarding our previously finalized information collection and 
burden estimates under the PCHQR Program.

[[Page 59177]]

F. Regulatory Review Costs

    If regulations impose administrative costs on private entities, 
such as the time needed to read and interpret a rule, we should 
estimate the cost associated with regulatory review. Due to the 
uncertainty involved with accurately quantifying the number of entities 
that will review a rule, we assumed that the number of commenters on 
the CY 2019 OPPS/ASC proposed rule (2,994) will be the number of 
reviewers of this final rule with comment period. We acknowledge that 
this assumption may understate or overstate the costs of reviewing this 
final rule with comment period. It is possible that not all commenters 
will review this final rule with comment period in detail, and it is 
also possible that some reviewers will choose not to comment on this 
final rule with comment period. Nonetheless, we believe that the number 
of commenters on the CY 2019 OPPS/ASC proposed rule will be a fair 
estimate of the number of reviewers of this final rule with comment 
period. In the CY 2019 OPPS/ASC proposed rule (83 FR 37237), we 
welcomed any comments on the approach in estimating the number of 
entities that will review the proposed rule. We also recognize that 
different types of entities are, in many cases, affected by mutually 
exclusive sections of the proposed rule and this final rule with 
comment period, and, therefore, for the purposes of our estimate, we 
assumed that each reviewer reads approximately 50 percent of the rule. 
In the proposed rule, we sought public comments. We did not receive any 
public comments specific to our solicitation.
    Using the wage information from the BLS for medical and health 
service managers (Code 11-9111), we estimated that the cost of 
reviewing this rule is $107.38 per hour, including overhead and fringe 
benefits (https://www.bls.gov/oes/current/oes_nat.htm). Assuming an 
average reading speed, we estimate that it will take approximately 8 
hours for the staff to review half of this final rule with comment 
period. For each facility that reviewed this final rule with comment 
period, the estimated cost is $859.04 (8 hours x $107.38). Therefore, 
we estimated that the total cost of reviewing this final rule with 
comment period is $2,571,966 ($859.04 x 2,994 reviewers).

G. Regulatory Flexibility Act (RFA) Analysis

    The RFA requires agencies to analyze options for regulatory relief 
of small entities, if a rule has a significant impact on a substantial 
number of small entities. For purposes of the RFA, we estimate that 
most hospitals, ASCs and CMHCs are small entities as that term is used 
in the RFA. For purposes of the RFA, most hospitals are considered 
small businesses according to the Small Business Administration's size 
standards with total revenues of $38.5 million or less in any single 
year or by the hospital's not-for-profit status. Most ASCs and most 
CMHCs are considered small businesses with total revenues of $15 
million or less in any single year. For details, we refer readers to 
the Small Business Administration's ``Table of Size Standards'' at: 
https://www.sba.gov/content/table-small-business-size-standards.
    In addition, section 1102(b) of the Act requires us to prepare a 
regulatory impact analysis if a rule may have a significant impact on 
the operations of a substantial number of small rural hospitals. This 
analysis must conform to the provisions of section 603 of the RFA. For 
purposes of section 1102(b) of the Act, we define a small rural 
hospital as a hospital that is located outside of a metropolitan 
statistical area and has 100 or fewer beds. We estimate that this final 
rule with comment period will increase payments to small rural 
hospitals by less than 3 percent; therefore, it should not have a 
significant impact on approximately 616 small rural hospitals.
    The analysis above, together with the remainder of this preamble, 
provides a regulatory flexibility analysis and a regulatory impact 
analysis.

H. Unfunded Mandates Reform Act Analysis

    Section 202 of the Unfunded Mandates Reform Act of 1995 (UMRA) also 
requires that agencies assess anticipated costs and benefits before 
issuing any rule whose mandates require spending in any 1 year of $100 
million in 1995 dollars, updated annually for inflation. That threshold 
level is currently approximately $150 million. This final rule with 
comment period does not mandate any requirements for State, local, or 
tribal governments, or for the private sector.

I. Reducing Regulation and Controlling Regulatory Costs

    Executive Order 13771, titled Reducing Regulation and Controlling 
Regulatory Costs, was issued on January 30, 2017. It has been 
determined that this final rule with comment period, will be a 
deregulatory action for the purposes of Executive Order 13771. We 
estimate that this final rule with comment period will generate $22.52 
million in annualized cost savings at a 7-percent discount rate, 
discounted relative to 2016, over a perpetual time horizon.

J. Conclusion

    The changes we are making in this final rule with comment period 
will affect all classes of hospitals paid under the OPPS and will 
affect both CMHCs and ASCs. We estimate that most classes of hospitals 
paid under the OPPS will experience a modest increase or a minimal 
decrease in payment for services furnished under the OPPS in CY 2019. 
Table 62 demonstrates the estimated distributional impact of the OPPS 
budget neutrality requirements that will result in a 0.6 percent 
increase in payments for all services paid under the OPPS in CY 2019, 
after considering all of the changes to APC reconfiguration and 
recalibration, as well as the OPD fee schedule increase factor, wage 
index changes, including the frontier State wage index adjustment, 
estimated payment for outliers, the finalized off-campus provider-based 
department clinic visits payment policy, and changes to the pass-
through payment estimate. However, some classes of providers that are 
paid under the OPPS will experience more significant gains or losses in 
OPPS payments in CY 2019.
    The updates to the ASC payment system for CY 2019 will affect each 
of the approximately 5,500 ASCs currently approved for participation in 
the Medicare program. The effect on an individual ASC will depend on 
its mix of patients, the proportion of the ASC's patients who are 
Medicare beneficiaries, the degree to which the payments for the 
procedures offered by the ASC are changed under the ASC payment system, 
and the extent to which the ASC provides a different set of procedures 
in the coming year. Table 63 demonstrates the estimated distributional 
impact among ASC surgical specialties of the MFP-adjusted hospital 
market basket update factor of 2.1 percent for CY 2019.

XXII. Federalism Analysis

    Executive Order 13132 establishes certain requirements that an 
agency must meet when it promulgates a proposed rule (and subsequent 
final rule) that imposes substantial direct costs on State and local 
governments, preempts State law, or otherwise has Federalism 
implications. We have examined the OPPS and ASC provisions included in 
this final rule with comment period in accordance with Executive Order 
13132, Federalism, and have determined that they will not have a 
substantial direct effect on State, local or tribal governments, 
preempt State

[[Page 59178]]

law, or otherwise have a Federalism implication. As reflected in Table 
62 of this final rule with comment period, we estimate that OPPS 
payments to governmental hospitals (including State and local 
governmental hospitals) will increase by 0.5 percent under this final 
rule with comment period. While we do not know the number of ASCs or 
CMHCs with government ownership, we anticipate that it is small. The 
analyses we have provided in this section of this final rule with 
comment period, in conjunction with the remainder of this document, 
demonstrate that this final rule with comment period is consistent with 
the regulatory philosophy and principles identified in Executive Order 
12866, the RFA, and section 1102(b) of the Act.
    This final rule with comment period will affect payments to a 
substantial number of small rural hospitals and a small number of rural 
ASCs, as well as other classes of hospitals, CMHCs, and ASCs, and some 
effects may be significant.

List of Subjects

42 CFR Part 416

    Health facilities, Health professions, Medicare, Reporting and 
recordkeeping requirements.

42 CFR Part 419

    Hospitals, Medicare, Reporting and recordkeeping requirements.

    For reasons stated in the preamble of this document, the Centers 
for Medicare & Medicaid Services is amending 42 CFR chapter IV as set 
forth below:

PART 416--AMBULATORY SURGICAL SERVICES

0
1. The authority citation for part 416 is revised to read as follows:

    Authority: 42 U.S.C. 273, 1302, 1320b-8, and 1395hh.


0
2. Section 416.164 is amended--
0
a. By revising paragraph (a)(4);
0
b. In paragraph (b)(5), by removing the period and adding in its place 
``; and''; and
0
c. By adding paragraph (b)(6).
    The revision and addition read as follows:


Sec.  416.164  Scope of ASC services.

    (a) * * *
    (4) Drugs and biologicals for which separate payment is not allowed 
under the hospital outpatient prospective payment system (OPPS), with 
the exception of non-opioid pain management drugs that function as a 
supply when used in a surgical procedure;
* * * * *
    (b) * * *
    (6) Non-opioid pain management drugs that function as a supply when 
used in a surgical procedure.
* * * * *

0
3. Section 416.171 is amended by revising paragraphs (a)(2) and (b)(1) 
and (2) to read as follows:


Sec.  416.171  Determination of payment rates for ASC services.

    (a) * * *
    (2) Conversion factor for CY 2009 and subsequent calendar years. 
The conversion factor for a calendar year is equal to the conversion 
factor calculated for the previous year, updated as follows:
    (i) For CY 2009, the update is equal to zero percent.
    (ii) For CY 2010 through CY 2018, the update is the Consumer Price 
Index for All Urban Consumers (U.S. city average) as estimated by the 
Secretary for the 12-month period ending with the midpoint of the year 
involved.
    (iii) For CY 2019 through CY 2023, the update is the hospital 
inpatient market basket percentage increase applicable under section 
1886(b)(3)(B)(iii) of the Act.
    (iv) For CY 2024 and subsequent years, the update is the Consumer 
Price Index for All Urban Consumers (U.S. city average) as estimated by 
the Secretary for the 12-month period ending with the midpoint of the 
year involved.
    (v) For CY 2014 through CY 2018, the Consumer Price Index for All 
Urban Consumers update determined under paragraph (a)(2)(ii) of this 
section is reduced by 2.0 percentage points for an ASC that fails to 
meet the standards for reporting of ASC quality measures as established 
by the Secretary for the corresponding calendar year.
    (vi) For CY 2019 through CY 2023, the hospital inpatient market 
basket update determined under paragraph (a)(2)(iii) of this section is 
reduced by 2.0 percentage points for an ASC that fails to meet the 
standards for reporting of ASC quality measures as established by the 
Secretary for the corresponding calendar year.
    (vii) For CY 2024 and subsequent years, the Consumer Price Index 
for All Urban Consumers update determined under paragraph (a)(2)(iv) of 
this section is reduced by 2.0 percentage points for an ASC that fails 
to meet the standards for reporting of ASC quality measures as 
established by the Secretary for the corresponding calendar year.
    (viii)(A) For CY 2011 through CY 2018, the Consumer Price Index for 
All Urban Consumers determined under paragraph (a)(2)(ii) of this 
section, after application of any reduction under paragraph (a)(2)(iv) 
of this section, is reduced by the productivity adjustment described in 
section 1886(b)(3)(B)(xi)(II) of the Act.
    (B) For CY 2019 through CY 2023, the hospital inpatient market 
basket update determined under paragraph (a)(2)(iii) of this section, 
after application of any reduction under paragraph (a)(2)(vi) of this 
section, is reduced by the productivity adjustment described in section 
1886(b)(3)(B)(xi)(II) of the Act.
    (C) For CY 2024 and subsequent years, the Consumer Price Index for 
All Urban Consumers determined under paragraph (a)(2)(iv) of this 
section, after application of any reduction under paragraph (a)(2)(vii) 
of this section, is reduced by the productivity adjustment described in 
section 1886(b)(3)(B)(xi)(II) of the Act.
    (D) The application of the provisions of paragraph (a)(2)(viii)(A), 
(B), or (C) of this section may result in the update being less than 
zero percent for a year, and may result in payment rates for a year 
being less than the payment rates for the preceding year.
    (b) * * *
    (1) Covered ancillary services specified in Sec.  416.164(b), with 
the exception of radiology services and certain diagnostic tests as 
provided in Sec.  416.164(b)(5) and non-opioid pain management drugs 
that function as a supply when used in a surgical procedure as provided 
in Sec.  416.164(b)(6).
    (2) The device portion of device-intensive procedures, which are 
procedures that--
    (i) Involve implantable devices assigned a CPT or HCPCS code;
    (ii) Utilize devices (including single-use devices) that must be 
surgically inserted or implanted; and
    (iii) Have a HCPCS code-level device offset of greater than 30 
percent when calculated according to the standard OPPS ASC ratesetting 
methodology.
* * * * *

0
4. Section 416.320 is amended by revising paragraph (c) to read as 
follows:


Sec.  416.320  Retention and removal of quality measures under the 
ASCQR Program.

* * * * *
    (c) Removal of quality measures--(1) General rule for the removal 
of quality measures. Unless a measure raises specific safety concerns 
as set forth in paragraph (b) of this section, CMS will use the regular 
rulemaking process to remove, suspend, or replace quality measures in 
the ASCQR Program to allow for public comment.
    (2) Factors for consideration of removal of quality measures. CMS 
will

[[Page 59179]]

weigh whether to remove measures based on the following factors:
    (i) Factor 1. Measure performance among ASCs is so high and 
unvarying that meaningful distinctions and improvements in performance 
can no longer be made (topped-out measures);
    (ii) Factor 2. Performance or improvement on a measure does not 
result in better patient outcomes;
    (iii) Factor 3. A measure does not align with current clinical 
guidelines or practice;
    (iv) Factor 4. The availability of a more broadly applicable 
(across settings, populations, or conditions) measure for the topic;
    (v) Factor 5. The availability of a measure that is more proximal 
in time to desired patient outcomes for the particular topic;
    (vi) Factor 6. The availability of a measure that is more strongly 
associated with desired patient outcomes for the particular topic;
    (vii) Factor 7. Collection or public reporting of a measure leads 
to negative unintended consequences other than patient harm; and
    (viii) Factor 8. The costs associated with a measure outweigh the 
benefit of its continued use in the program.
    (3) Criteria to determine topped-out measures. For the purposes of 
the ASCQR Program, a measure is considered to be topped-out under 
paragraph (c)(2)(i) of this section when it meets both of the following 
criteria:
    (i) Statistically indistinguishable performance at the 75th and 
90th percentiles (defined as when the difference between the 75th and 
90th percentiles for an ASC's measure is within two times the standard 
error of the full data set); and
    (ii) A truncated coefficient of variation less than or equal to 
0.10.
    (4) Application of measure removal factors. The benefits of 
removing a measure from the ASCQR Program will be assessed on a case-
by-case basis. A measure will not be removed solely on the basis of 
meeting any specific factor or criterion.

PART 419--PROSPECTIVE PAYMENT SYSTEM FOR HOSPITAL OUTPATIENT 
DEPARTMENT SERVICES

0
5. The authority citation for part 419 is revised to read as follows:

    Authority:  42 U.S.C. 1302, 1395l(t), and 1395hh.


0
6. Section 419.32 is amended by adding paragraph (b)(1)(iv)(B)(10) to 
read as follows:


Sec.  419.32  Calculation of prospective payment rates for hospital 
outpatient services.

* * * * *
    (b) * * *
    (1) * * *
    (iv) * * *
    (B) * * *
    (10) For calendar year 2019, a multifactor productivity adjustment 
(as determined by CMS) and 0.75 percentage point.
* * * * *

0
7. Section 419.46 is amended by revising paragraphs (a)(1) through (3) 
and adding paragraph (h) to read as follows:


Sec.  419.46  Participation, data submission, and validation 
requirements under the Hospital Outpatient Quality Reporting (OQR) 
Program.

    (a) * * *
    (1) Register on the QualityNet website before beginning to report 
data;
    (2) Identify and register a QualityNet security administrator as 
part of the registration process under paragraph (a)(1) of this 
section; and
    (3) Submit at least one data element.
* * * * *
    (h) Retention and removal of quality measures under the Hospital 
OQR Program--(1) General rule for the retention of quality measures. 
Quality measures adopted for the Hospital OQR Program measure set for a 
previous payment determination year are retained for use in subsequent 
payment determination years, except when they are removed, suspended, 
or replaced as set forth in paragraphs (h)(2) and (3) of this section.
    (2) Immediate measure removal. For cases in which CMS believes that 
the continued use of a measure as specified raises patient safety 
concerns, CMS will immediately remove a quality measure from the 
Hospital OQR Program and will promptly notify hospitals and the public 
of the removal of the measure and the reasons for its removal through 
the Hospital OQR Program ListServ and the QualityNet website.
    (3) Measure removal, suspension, or replacement through the 
rulemaking process. Unless a measure raises specific safety concerns as 
set forth in paragraph (h)(2) of this section, CMS will use the regular 
rulemaking process to remove, suspend, or replace quality measures in 
the Hospital OQR Program to allow for public comment.
    (i) Factors for consideration of removal of quality measures. CMS 
will weigh whether to remove measures based on the following factors:
    (A) Factor 1. Measure performance among hospitals is so high and 
unvarying that meaningful distinctions and improvements in performance 
can no longer be made (``topped out'' measures);
    (B) Factor 2. Performance or improvement on a measure does not 
result in better patient outcomes;
    (C) Factor 3. A measure does not align with current clinical 
guidelines or practice;
    (D) Factor 4. The availability of a more broadly applicable (across 
settings, populations, or conditions) measure for the topic;
    (E) Factor 5. The availability of a measure that is more proximal 
in time to desired patient outcomes for the particular topic;
    (F) Factor 6. The availability of a measure that is more strongly 
associated with desired patient outcomes for the particular topic;
    (G) Factor 7. Collection or public reporting of a measure leads to 
negative unintended consequences other than patient harm; and
    (H) Factor 8. The costs associated with a measure outweigh the 
benefit of its continued use in the program.
    (ii) Criteria to determine topped-out measures. For the purposes of 
the Hospital OQR Program, a measure is considered to be topped-out 
under paragraph (h)(3)(i)(A) of this section when it meets both of the 
following criteria:
    (A) Statistically indistinguishable performance at the 75th and 
90th percentiles (defined as when the difference between the 75th and 
90th percentiles for a hospital's measure is within two times the 
standard error of the full data set); and
    (B) A truncated coefficient of variation less than or equal to 
0.10.
    (iii) Application of measure removal factors. The benefits of 
removing a measure from the Hospital OQR Program will be assessed on a 
case-by-case basis. Under this case-by-case approach, a measure will 
not be removed solely on the basis of meeting any specific factor.

    Dated: October 26, 2018.
Seema Verma,
Administrator, Centers for Medicare and Medicaid Services.
    Dated: October 29, 2018.
Alex M. Azar II,
Secretary, Department of Health and Human Services.
[FR Doc. 2018-24243 Filed 11-2-18; 8:45 am]
 BILLING CODE 4120-01-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.